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MINUTES OF THE 49th GENERAL ASSEMBLY OF THE EUROPE-
AN ASSOCIATION FOR THE STUDY OF DIABETES 
held in the Pi i Sunyer Hall, Fira de Barcelona, Barcelona, Spain on Thursday 26 September, 2013 at 18:30
Present: Dr. Andrew J.M. Boulton (President)
 Dr. Stefano Del Prato (Vice President)
 Dr. Bernard Thorens (Vice President)
 Dr. Michael Roden (Honorary Treasurer)
 Dr. Mark Walker (Honorary Secretary)
 Dr. Cees J. Tack (Chair, PGEC)
 Dr.Viktor Jörgens (Executive Director)
 Dr. Monika Grüsser (Vice Director)
 and 51 members
thanked all members of the EASD Office and the Execu-
tive Committee for their commitment and hard work.
b) Honorary Treasurer
i) Result of tax audit 2008-2010/actions to be taken
In autumn 2012 for the second time, a control of the EASD 
by the Inland Revenue took place. These controls will al-
ways occur every three years due to the large turnover 
of the Association. In August 2013, EASD received the 
draft conclusion of this tax control. The non-profit status 
of the EASD is beyond all question; the main issue is the 
question of the taxation of the income from industry ex-
hibition and symposia. EASD itself does not handle the 
industry exhibition and the symposia organized by third 
parties; these activities are taken care of by a professional 
congress organizer which is actually Interplan in Munich. 
In common with other medical associations in Germany, 
EASD has a contract, in our case with Interplan, giving 
them permission to organize these activities on their own 
responsibility without interfering with EASD concerning 
the organization and the fund raising. The basis of this col-
laboration is a loan contract and the income from such a 
loan contract is considered to be tax free. This legal and 
taxation construction is the basis of a healthy financial 
situation of German academic medical societies. The Düs-
seldorf tax authorities questioned this regulation and even 
asked their superiors for comments. In August 2013, they 
came up with the opinion that all incomes of EASD from 
these loan contracts, starting with 2008, are considered by 
the Inland Revenue as a taxable income. Taking into ac-
count corporation and local business tax, the result is that 
a total of Euro 5.4 million will likely have to be paid at 
the beginning of 2014. Following the advice of legal and 
The President, Dr. Boulton, welcomed everyone to the 
49th General Assembly. He asked those present to stand in 
memory of the following members, who had passed away: 
Drs. Georg Eisenbarth, John Hutton, Harry Keen, Carol 
Lurie, Irina G. Obrosova, Samuel Rahbar, Jean-Louis 
Richard, Richard Rubin and Patrick Vexiau.
1. MINUTES 48th GENERAL ASSEMBLY 2012
Since there were no comments, the minutes were unani-
mously approved and officially signed as a correct re-
cord.
 
2. REPORTS
a) President
The President’s report to the members on the activities 
of EASD was given in the President’s Address before the 
Minkowski Lecture. It is available under: http://www.eas-
dvirtualmeeting.org/resources/6926
The President announced the Claude Bernard Lecturer 
2014: Dr. Domenico Accili.
The President announced the Medical Devices in Diabe-
tology meeting on 26/27 February 2014. He said better 
post-marketing surveillance was required and the Swedish 
project of regulating pumps would be looked at.
The President expressed his thanks to all partners. Dr. 
Boulton reported that as expected the EASD Annual Meet-
ing in Barcelona was doing very well and the number of 
delegates attending had slightly increased. Dr. Boulton 
DOI 10.1007/s00125-014-3355-0
S 2 
1 C
taxation advisors, EASD will oppose this decision and will 
eventually go to court. Nevertheless, this amount will be 
paid in advance to avoid the potential addition of interest 
on this sum should we elect to await the outcome of our 
appeal and should this be negative. 
As we allowed for this potential outcome last year, no 
transfers have been carried forward from EASD to EFSD 
resulting in a reserve of Euro 5.2 million being kept on the 
accounts which is more than usual. Now EASD, following 
the income from the last Annual Meetings, will be able to 
cover the taxation imposed, but the Association will nev-
ertheless have a hard time to finance its activities in the 
first six months of 2014 until a substantial income from the 
Meeting in Vienna has occurred. 
The final decision regarding these matters will be made 
by the Düsseldorf Inland Revenue and their report could 
reach EASD at the beginning of 2014.
Following the advice from a specialist lawyer in Bonn, it 
was unanimously decided that when requested, the cur-
rent tax bill of Euro 5.4 million should be paid; after that, 
we will challenge the decision in court. It was also unan-
imously decided to seek further advice from the lawyer 
concerning the way forward.
Dr. Roden explained that with the possibility of this tax 
invoice in mind, EASD had made no financial transfer to 
EFSD in 2012, resulting in EASD having enough funds 
to pay the tax bill. However, this will necessitate making 
savings in the first half of 2014 until an income has been 
received from the Annual Meeting in Vienna. Such sav-
ings could include reducing the costs of the Annual Meet-
ing by no longer printing a Provisional Programme and no 
longer funding a Welcome and Farewell party. The deci-
sion had already been made to increase registration fees 
moderately.
Dr. Boulton thanked the Honorary Treasurer for his report 
and asked if there were any questions. Dr. Lenzen asked if 
there were any plans to relocate EASD. Dr. Boulton said 
that there were no relocation plans at that time.
c) Honorary Auditors
The President asked the Honorary Auditor, Dr. Peter Diem, 
for his report. Dr. Diem confirmed that the accounts had 
been checked carefully by Dr. Luis Gardete-Correia and 
were in perfect order. Dr. Boulton asked for the vote to 
accept the accounts. 
 
The Honorary Treasurer was unanimously discharged (35 
votes in favour and 6 abstentions).
 
d) Honorary Secretary
The Honorary Secretary reported that 2321 abstracts had 
been received for the Annual Meeting in Barcelona. Of 
these, 1360 were accepted: 264 oral presentations and 
1096 poster presentations. The main countries submitting 
abstracts are the United States, the United Kingdom, Japan 
and Germany. The palm questionnaire rating the 48th An-
nual meeting in Berlin gave excellent feedback on the ven-
ue facilities, the scientific programme, the Prize Lectures, 
the EASD symposia,  the oral presentations and abstracts, 
the poster presentations, the Industry symposia and the As-
sociations’ Village. The Rising Star Symposium continues 
to identify promising and innovative young researchers in 
Europe.
The Honorary Secretary concluded by reporting that the 
Programme Committee for 2014 had been appointed and 
had had its first meeting during the Annual Meeting in 
Barcelona. It would then meet in May 2014 to select the 
abstracts on an anonymous basis for the Annual Meeting 
in 2014.
Dr. Walker closed his report by thanking all those who had 
forwarded ideas for the scientific programme and all mem-
bers of the EASD staff, in particular Mrs. H. Goliberzuch 
and Mrs. M. Toledo, for their outstanding help and support 
with the organisation of the EASD Annual Meetings.
 
Dr. Boulton thanked Dr. Walker for his diligence and 
asked if there were any questions. There were no further 
comments.
 
e) Editor-in-Chief, Diabetologia
In the absence of Dr. Juleen Zierath, Editor-in-Chief, Dia-
betologia, the President reported the following informa-
tion:
The Committee on Publication Ethics had put together 
ethical guidelines for peer-reviewers. From July 2013, all 
papers returned for revision underwent plagiarism detec-
tion. Springer is as yet unable to check images for possible 
manipulation, but are aware such a service is of high prior-
ity for the journal. The Scientific Integrity Panel (SIP) set 
up a policy outlining what is expected of authors and how 
to deal with cases of misconduct which was published on 
the Diabetologia website in April 2013. Mr. Tony Kirby, a 
former press officer with the Lancet, has helped to publi-
cise papers by issuing press releases. 
In total, 1,990 articles were submitted to Diabetologia in 
2012 and 17% were published. The proportion of papers 
triaged increased to 63% in the first half of 2013. On aver-
age, papers are triaged in 3 days and peer-reviewed in 30 
days. 
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Dr. Boulton expressed his thanks to Dr. Zierath in her ab-
sence for her co-operation and hard work. Thanks were 
also expressed to the team in Bristol, especially to Dr. Judy 
Naylor, and the outgoing associate editors.
f) Chair, Postgraduate Education Committee
Dr. Tack reported on the courses that had taken place in 
2012 and 2013: Almaty/Kazakhstan, Lviv/Ukraine and 
Kazan/Russia. Dr. Tack said all courses in 2012 and 2013 
had been very successful and had attracted delegates from 
many of the countries neighbouring the one where the 
course was held. Dr. Tack said a course was being planned 
in Budapest/Hungary in November 2014 and additional 
courses will be agreed upon with the incoming PGEC 
Chair.
Dr. Boulton thanked Dr. Tack for his co-operation and 
commitment to postgraduate education.
 
g) Chair, Extra-European Postgraduate Activities
Dr. Czupryniak reported that a course had successfully 
been organised in Dubai/United Arab Emirates in 2012. 
In August 2013, a course was held in India when 4 cities 
(Chennai, Ahmedabad, Lucknow and Chandigarh) were 
visited. The main Extra-European course in collaboration 
with IDF and ADA in 2013 will take place in Sri Lanka in 
November. Also in November, another course will be held 
in the Gulf Region (Oman).
Dr. Czupryniak brought his report to an end by thanking 
Dr. Boulton for his support and the EASD team for their 
help in organising the courses.
Dr. Boulton thanked Dr. Czupryniak for his co-operation 
and hard work.
 
3. ELECTIONS
Honorary Secretary (2013-2016)
The election of Dr. Per-Henrik Groop was unanimously 
approved with 40 votes.  
Chair, PGEC (2013-2016)
The election of Dr. Leszek Czupryniak was unanimously 
approved with 41 votes and 1 abstention.  
Council Members (2014 - 2017)
The election of Drs. Bo Ahrén, Sehnaz Karadeniz, Michele 
Solimena, Nicholas Tentolouris was unanimously ap-
proved with 37 votes each and 4 abstentions.
Editor-in-Chief, Diabetologia (2013-2015) extension of 
office
The election of extension of office of Dr. Juleen Zierath 
was unanimously approved with 41 votes. 
4. STUDY GROUPS
i)  Non-Alcoholic Fatty Liver Disease (NAFLD) Study 
Group 
  The General Assembly was informed of the decision 
by the Executive Committee and Council to endorse 
the initiation of this EASD Study Group.
ii)  EASD Diabetes and Cancer Study Group
  The General Assembly was informed of the decision 
by the Executive Committee and Council to endorse 
the initiation of this EASD Study Group.
iii)  Gluco-Incretin Biology and Clinical Applications 
Study Group
  The General Assembly was informed of the decision 
by the Executive Committee and Council to endorse 
the initiation of this EASD Study Group.
iv) Metabolic Imaging Study Group 
  The General Assembly was informed of the decision 
by the Executive Committee and Council to endorse 
the initiation of this EASD Study Group.
5. HONORARY MEMBERSHIP
The nomination of Drs. Anthony Cerami, Willy Malaisse, 
John D. Ward was unanimously approved. Dr. Boulton 
thanked them for their outstanding contribution to diabe-
tes research.
6. ANY OTHER BUSINESS
Dr. Boulton reported that from January 2014 only an elec-
tronic version of the journal would be available for mem-
bers. He added that this was the correct way forward both 
economically and ecologically. He said this would not 
affect re-prints which would continue to be available. An 
email will be sent to all members informing them of this 
situation and a monthly email will be sent with the table of 
contents for each month’s journal.
The President thanked Dr. Walker, retiring Honorary Sec-
retary, and Dr. Cees Tack, retiring Chair of the PGEC, for 
their friendly collaboration and diligence during their term 
of office. He also expressed his sincere gratitude to the 
Local Organising Committee for their outstanding contri-
bution to the organisation of the 49th EASD Annual Meet-
ing.  He warmly thanked Dr. Jörgens, Dr. Grüsser and the 
EASD team in Düsseldorf for their dedicated work. 
 
Dr. Boulton brought the General Assembly to a close at 
19:25.
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Agenda for the 50th General Assembly
of the European Association for the Study of Diabetes
to be held in the Randle Hall at Messe Wien Exhibition & Congress Center, Vienna, Austria
on Tuesday, 16 September 2014 at 18:30
1. Minutes of the 49th General Assembly, Barcelona, Spain 2013
2. Reports
a) President Andrew J.M. Boulton 
i) Membership fees 2016
ii) Retirement Executive Director
b) Honorary Treasurer Michael Roden  
c) Honorary Auditors Peter Diem
 Luis M. Gardete-Correia
d) Honorary Secretary Per-Henrik Groop
e) Editor-in-Chief, Diabetologia Juleen Zierath
f) Chair, Postgraduate Education Committee Leszek Czupryniak
3. POSITIONS 
 To be elected for retiring member(s):
3.1 Elections 
a) President Extension of office (2014-2015) Andrew JM Boulton 
b) President (2015-2018) Andrew JM Boulton 
c) Vice President (2014-2017) Stefano Del Prato 
d) Honorary Treasurer Extension of office (2014-2016) Michael Roden 
d) Honorary Auditors (2014-2017) Peter Diem and Luis M. Gardete-Correia
e) Council Members (2015-2018) Henning Beck-Nielsen
 Svitlana Bolgarskaya
 Anna Novials 
 Raimund Weitgasser
4. Study Groups
a) Reactive Metabolites in Diabetes Study Group  
5. Honorary Membership
6. Any other business
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50th EASD Annual Meeting of the European Association for 
the Study of Diabetes
Vienna, Austria, 15 – 19 September 2014
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OP   19 Insulin: clinical decision making
OP   20 Novel compounds on the horizon
OP   21 Physiological adaptation to bariatric surgery
OP   22 Neuropathy: mechanisms and outcomes
OP   23 Novel regulators of insulin and glucagon secretion
OP   24 Genes and biomarkers for type 2 diabetes
OP   25 Novel insulin formulations and combinations
OP   26 Pregnancy and diabetes
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OP   45 Diabetic foot: mechanisms of wound healing
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 6 
1 C
PS   035  Mechanisms of insulin action in non-human  
models
PS   036 Mechanisms of insulin resistance in vivo
PS   037  Mechanisms of insulin action and inter-organ 
cross-talk
PS   038 Insulin resistance and adipose tissue
PS   039 Glucagon
PS   040 Exercise physiology I
PS   041 Exercise physiology II
PS   042 Consequences of hypoglycaemia
PS   043 Nocturnal and drug-induced hypoglycaemia
PS   044 Endocrine control of glucose tolerance
PS   045 Lipid metabolism in humans
PS   046 Brain and glucose metabolism
PS   047 Adipose tissue function in humans
PS   048 Brown, beige or brite?
PS   049 Animal models of obesity and type 2 diabetes
PS   050 Adipose tissue function: animal models
PS   051  The role of the liver in glucose and  
lipid metabolism
PS   052  Mitochondrial function, oxidative stress and  
glucose metabolism
PS   053  Metabolic effects of dietary composition,  
caloric restriction and bariatric surgery
PS   054 Inflammation and beta cell in type 2 diabetes
PS   055 Inflammation in adipose tissue and muscle
PS   056 Novel adipokines
PS   057 Nutrition and diet I
PS   058 Nutrition and diet II
PS   059 Metformin
PS   060 SGLT2 inhibitors: safety
PS   061 Insulin secretagogues
PS   062 SGLT2 inhibitors: non-glycaemic endpoints
PS   063 GLP-1 based therapies: efficacy I
PS   064 GLP-1 based therapies: efficacy II
PS   065 SGLT2 inhibitors: efficacy
PS   066 Novel therapies
PS   067 Non-glycaemic effects of DPP-4 inhibitors
PS   068 Incretin based therapies in special populations
PS   069 Safety of DPP-4 inhibitors
PS   070 Clinical studies with DPP-4 inhibitors
PS   071 Non-glycaemic endpoints
PS   072 Incretin based therapies basic: basic science
PS   073  Incretin based therapies: mechanistic /  
miscellaneous
PS   074 The potential future of insulin therapy
PS   075 Insulin treatment in the “real world”
PS   076 Glucose variability in insulin treatment
PS   077 Old and new insulin formulations
PS   078 Insulin immunogenicity and kinetics
PS   079 Insulin treatment and hypoglycaemic reactions
PS   080 Gastrointestinal liners and e-health opportunities
PS   081 Improvements in continuous glucose monitoring
PS   082  Improving insulin pump treatment and  
continuous glucose monitoring use
PS   083 On the way to optimise pump treatment
PS   084 Supporting tools for insulin treatment
PS   085 Psychological distress
PS   086 Psychology and quality of life
PS   087 Individual perception of diabetes
PS   088 Lifestyle and delivery of care
PS   089 Met and unmet needs in diabetes care
PS   090 Individualised care
PS   091 Tailored diabetes care
PS   092  Screening and risk factors for gestational  
diabetes mellitus
PS   093 Gestational diabetes mellitus management
PS   094  Pregnancy outcomes in gestational diabetes  
mellitus
PS   095 Postpartum outcomes
PS   096 Pregnancy in type 1 diabetes
PS   097 Neuropathy: biomarkers and mechanisms
PS   098 Mechanisms and outcomes of neuropathy
PS   099 Diabetic foot: prevention and treatment
PS   100 Management of foot ulcers
PS   101 Diabetic eye disease
PS   102 Mechanisms of microangiopathy: experimental
PS   103 Mechanisms of nephropathy: experimental
PS   104 Nephropathy: genes and mechanisms
PS   105 Diabetic nephropathy: clinical
PS   106 Clinical: hypertension in diabetes
PS   107 Predicting complications I
PS   108 Predicting complications II
PS   109 Predicting complications III
PS   110 Biomarkers and complications I
PS   111 Biomarkers and complications II
PS   112 Clinical observations in children
PS   113 Clinical observations in children and women
PS   114 Clinical observations in type 2 diabetes
PS   115 Liver
PS   116 Vascular calcification
PS   117 Vascular dysfunction
PS   118 Advanced glycation
PS   119 Metabolism and complications
PS   120 Animal models of complications I
PS   121 Animal models of complications II
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 7
1 C
OP 01 SGLT2 inhibitors:  
new outcome studies
1
Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as 
add-on to metformin in subjects with type 2 diabetes
S. Patel1, R. DeFronzo2, A. Lewin3, D. Liu4, R. Kaste4, H.J. Woerle5,  
U.C. Broedl5;  
1Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK, 2University of Texas 
Health Sciences, San Antonio, USA, 3National Research Institute,  
Los Angeles, USA, 4Boehringer Ingelheim Pharmaceuticals Inc.,  
Ridgefield, USA, 5Boehringer Ingelheim, Ingelheim, Germany.
Background and aims: A randomized, double-blind, parallel group Phase III 
study evaluated the efficacy and safety of fixed dose combinations (FDCs) of 
empagliflozin/linagliptin (EMPA/LINA) as add-on to metformin in subjects 
with type 2 diabetes (T2DM).
Materials and methods: Subjects were randomized to EMPA 25 mg/LINA 
5 mg (n=137), EMPA 10 mg/LINA 5 mg (n=136), EMPA 25 mg (n=141), 
EMPA 10 mg (n=140), or LINA 5 mg (n=132) as add-on to stable-dose met-
formin for 52 weeks. Primary analysis was at week 24. Exploratory endpoints 
at week 52 were changes from baseline in HbA1c, body weight, systolic and 
diastolic blood pressure (SBP and DBP), and percentage of subjects with 
baseline HbA1c ≥7% who reached HbA1c <7%. Efficacy was evaluated in 674 
subjects (mean [SD] age 56.2 [10.2] years; weight 86.2 [18.7] kg; BMI 31.0 
[5.5] kg/m2; HbA1c 7.98 [0.85] %).
Results: Compared with LINA 5 mg and their respective EMPA monothera-
pies, both EMPA/LINA FDCs led to significant reductions in HbA1c and 
higher percentages of subjects with HbA1c <7% at week 52 (Table). Com-
pared with LINA 5 mg, body weight was reduced with EMPA 25 mg/LINA 5 
mg (difference: -3.2 kg [95% CI 4.2, 2.2]; p<0.001) and EMPA 10 mg/LINA 
5 mg (difference: 2.8 kg [95% CI 3.8, 1.7]; p<0.05). The FDCs did not reduce 
body weight compared with their respective EMPA monotherapies. Changes 
from baseline in SBP and DBP were 0.3 mmHg and -0.6 mmHg, respectively, 
with LINA 5 mg. EMPA and FDCs reduced SBP from baseline by 2.8 to 3.6 
mmHg and DBP by 1.8 to 2.2 mmHg. Adverse events (AEs) were reported 
in 71.5%, 69.1%, 73.0%, 68.6% and 68.9% of subjects on EMPA 25 mg/LINA 
5 mg, EMPA 10 mg/LINA 5 mg, EMPA 25 mg, EMPA 10 mg and LINA 5 
mg, respectively, over 52 weeks. Confirmed hypoglycaemic AEs (glucose 
≤70 mg/dL and/or requiring assistance) were reported in 3.6%, 2.2%, 3.5%, 
1.4% and 2.3% of subjects on EMPA 25 mg/LINA 5 mg, EMPA 10 mg/LINA 
5 mg, EMPA 25 mg, EMPA 10 mg and LINA 5 mg, respectively; none re-
quired assistance. AEs consistent with urinary tract infection were reported 
in 10.2%, 9.6%, 13.5%, 11.4% and 15.2% of subjects on EMPA 25 mg/LINA 5 
mg, EMPA 10 mg/LINA 5 mg, EMPA 25 mg, EMPA 10 mg and LINA 5 mg, 
respectively, and AEs consistent with genital infection were reported in 2.2%, 
5.9%, 8.5%, 7.9% and 2.3% of subjects in these groups, respectively.
Conclusion: As add-on to stable-dose metformin in subjects with T2DM, 
FDCs of EMPA 25 mg/LINA 5 mg and EMPA 10 mg/LINA 5 mg for 52 weeks 
significantly reduced HbA1c compared with LINA 5 mg and compared with 
the respective EMPA monotherapies. The FDCs were well tolerated, with 
overall safety profiles similar to those known for the individual components.
Clinical Trial Registration Number: NCT01422876
Supported by: Boehringer Ingelheim and Eli Lilly
2
Empagliflozin compared with glimepiride as add-on to metformin  
for 2 years in patients with type 2 diabetes
M. Ridderstråle1, K.R. Andersen2, C. Zeller3, G. Kim4, H.J. Woerle4,  
U.C. Broedl4;  
1Steno Diabetes Center, Gentofte, Denmark, 2Boehringer Ingelheim  
Norway KS, Asker, Norway, 3Boehringer Ingelheim, Biberach,  
4Boehringer Ingelheim, Ingelheim, Germany.
Background and aims: We performed a Phase III trial, EMPA-REG H2H-
SUTM, to compare the efficacy and safety of empagliflozin (EMPA) and glime-
piride (GLIM) as add-on to metformin (MET) in patients with type 2 diabe-
tes (T2DM).
Materials and methods: Patients were randomized and treated double-blind 
with EMPA 25 mg (n=765) or GLIM 1-4 mg (n=780) for 104 weeks (mean 
[SD] age 55.9 [10.4] years; BMI 30.1 [5.3] kg/m2). The primary endpoint was 
change from baseline in HbA1c. Key secondary endpoints were change from 
baseline in weight, occurrence of confirmed hypoglycaemic adverse events 
(AEs; plasma glucose ≤70 mg/dL and/or requiring assistance) and changes 
from baseline in systolic and diastolic blood pressure (SBP and DBP).
Results: At week 104, EMPA significantly reduced HbA1c versus GLIM (Ta-
ble). Confirmed hypoglycaemic AEs were reported in 2.5% of patients on 
EMPA and 24.2% on GLIM (adjusted risk ratio: 0.102 [95% CI 0.065, 0.162]; 
p<0.001); no patients on EMPA and 2 on GLIM required assistance. EMPA 
significantly reduced weight and SBP versus GLIM (Table). At week 104, ad-
justed mean (SE) change from baseline in DBP was 1.8 (0.3) mmHg with 
EMPA compared with 0.9 (0.3) mmHg with GLIM (difference versus GLIM: 
-2.7 mmHg [95% CI 3.4, 1.9]; p<0.001). AEs were reported in 86.4% and 
86.3% of patients on EMPA and GLIM, respectively. AEs consistent with uri-
nary tract infection were reported in 13.7% and 13.1% of patients, and AEs 
consistent with genital infection were reported in 11.8% and 2.2% of patients, 
on EMPA and GLIM, respectively.
Conclusion: This large and long-term trial showed that EMPA 25 mg for 
104 weeks as add-on to MET was well tolerated and led to a greater HbA1c 
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reduction, weight loss and BP reduction with a low risk of hypoglycaemia 
compared with GLIM. 
Clinical Trial Registration Number: NCT01167881
Supported by: Boehringer Ingelheim and Eli Lilly
3
Energy balance following sodium-glucose co-transporter-2 (SGLT2) 
inhibition
G. Ferrannini1, T. Hach2, S. Crowe2, E. Ferrannini1;  
1University of Pisa, Italy, 2Boehringer Ingelheim, Ingelheim, Germany.
Background and aims: SGLT2 inhibitors lower glycaemia by inducing uri-
nary glucose excretion (UGE), with the attendant calorie loss. Evidence sug-
gests that the resulting weight loss (WL) is less than expected from UGE.
Materials and methods: To quantify this phenomenon we analysed data 
from 86 type 2 diabetic (T2D) patients (39 women, age = 58 ± 9 years, BMI = 
29.8 ± 4.5 kg/m2, HbA1c = 7.8 ± 0.8%, FPG = 169 ± 41 mg/dL, eGFR = 89 ± 19 
ml.min-1.1.73m2, µ ± SD), the per-protocol completers cohort of a clinical tri-
al who received empagliflozin (25 mg/day) for 90 weeks with frequent (n=11) 
assessments of body weight, eGFR, and FPG. Time-dependent glucose filtra-
tion was calculated as the product of eGFR and FPG, time-dependent UGE 
was estimated by assuming - from previous direct measurements - a quasi-
linear relationship between fractional UGE and glycaemia. The relation of 
calorie-to-weight changes was estimated using a mathematical model (http://
bwsimulator.niddk.nih.gov) that simulates the time-course of WL for a given 
change in calorie balance.
Results: At week 90, WL averaged -3.2 ± 4.2 kg (range -17.0 to +5.5); over 
90 weeks, UGE averaged 54 ± 15 g/day (fractional UGE = 45 ± 4%). The 
observed WL corresponded to a calorie deficit of -78 ± 103 kcal/day. On the 
other hand, the observed calorie loss (-217 ± 59 kcal/day) predicted a WL of 
-8.7 ± 2.4 kg (range -4.0 to -15.3 kg) over 90 weeks. Thus, patients lost only 38 
± 53% of the WL predicted by their glycosuria. As previous studies showed 
that empagliflozin does not affect either resting or meal-induced energy ex-
penditure, patients likely increased their energy intake (by an estimated +138 
± 116 kcal/day). This excess calorie intake was inversely related to baseline 
BMI (partial r=-0.33, p<0.01) and positively to baseline eGFR (partial r=0.30, 
p<0.01).
Conclusion: Chronic glycosuria elicits an adaptive increase in energy intake, 
particularly in leaner patients with preserved renal function. Combining 
SGLT2 inhibition with strategies to maintain energy intake or curb appetite 
is expected to be associated with major WL.
Clinical Trial Registration Number: NCT00881530
Supported by: Boehringer Ingelheim and Eli Lilly
4
Randomised, double-blind trial of dual add-on saxagliptin plus 
dapagliflozin vs saxagliptin or dapagliflozin add-on alone in poorly 
controlled type 2 diabetes on metformin 
L. Hansen1, P. Zee1, Y. Li2, W. Cook2, B. Hirshberg2, N. Iqbal1, J. Rosenstock3; 
1Bristol-Myers Squibb, Princeton, 2AstraZeneca, Wilmington,  
3Dallas Diabetes and Endocrine Center, USA.
Background and aims: SGLT2 and DPP-4 inhibitors have complementary 
mechanisms of action that can potentially improve glucose control with 
weight loss and a low risk of hypoglycaemia. We compared the efficacy and 
safety of dual add-on of saxagliptin (SAXA) and dapagliflozin (DAPA) with 
SAXA and DAPA alone in patients with type 2 diabetes mellitus (T2DM) 
poorly controlled with metformin.
Materials and methods: In this 24-week, multicenter, randomized, double-
blind, active-controlled trial, adults with T2DM and A1C ≥8.0% and ≤12.0%, 
received SAXA 5 mg and DAPA 10 mg once daily compared with SAXA and 
placebo (PBO) or DAPA and PBO on background of metformin XR ≥1500 
mg/d. The primary end point was the adjusted mean change in A1C from 
baseline to week 24. Safety and tolerability assessments included adverse 
events (AEs) and hypoglycaemia.
Results: A total of 534 patients were randomized. Mean ± SD A1C at baseline 
in SAXA+DAPA, SAXA+PBO, and DAPA+PBO groups was 8.9 ± 1.2%, 9.0 
± 1.1%, and 8.9 ± 1.2%, respectively. Adjusted mean reduction from baseline 
in A1C was -1.47% in SAXA+DAPA compared with -0.88% in SAXA+PBO 
(difference −0.59%; 95% CI [-0.81, -0.37]; P<0.0001) and -1.20% in 
DAPA+PBO (difference −0.27%; 95% CI [-0.48, -0.05]; P<0.02). The adjusted 
mean proportion of patients achieving A1C <7% was 41% in SAXA+DAPA 
compared with 18% in SAXA+PBO (difference of 23%; 95% CI [15, 32]) and 
22% in DAPA+PBO (difference of 19%; 95% CI [10, 28]). AEs occurred in 
48.6%, 52.8%, and 48.6% of patients in the SAXA+DAPA, SAXA+PBO, and 
DAPA+PBO groups, respectively. Urinary and genital infections occurred 
with the expected frequency previously reported. Incidence of hypoglycae-
mia was 1.1%, 0.6%, and 1.1%, respectively with no episodes of major hypo-
glycaemia.
Conclusion: This first report of triple therapy, adding a well-tolerated com-
bination of DPP-4 and SGLT2 inhibitors to background metformin therapy 
in patients with T2DM poorly controlled with metformin, demonstrated that 
the dual add-on combination of SAXA and DAPA had greater improvements 
in glucose control than each component alone. More than 40% of poorly con-
trolled T2DM patients receiving SAXA+DAPA achieved an A1C goal of <7%, 
with weight loss similar to DAPA alone and with very low hypoglycaemia 
risk.
Clinical Trial Registration Number: NCT01606007
Supported by: BMS and AstraZeneca
5
Long-term efficacy and safety of canagliflozin in older patients with type 
2 diabetes mellitus over 104 weeks
K. Stenlöf1, B. Bode2, S. Harris3, D. Sullivan4, A. Fung4, K. Usiskin4;  
1Clinical Trial Center, Sahlgrenska University Hospital, Gothenburg, 
Sweden, 2Atlanta Diabetes Associates, USA, 3University of Western Ontario, 
London, Canada, 4Janssen Research & Development, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-trans-
porter 2 (SGLT2) inhibitor developed for the treatment of type 2 diabetes 
mellitus (T2DM), lowers plasma glucose by increasing urinary glucose excre-
tion. This randomised, double-blind, Phase 3 study assessed the long-term 
efficacy and safety of CANA in older patients with T2DM over 104 weeks.
Materials and methods: Patients aged 55 to 80 years (N = 714) with T2DM 
inadequately controlled on a stable antihyperglycaemic agent (AHA) regimen 
received CANA 100 or 300 mg or placebo (PBO) during a 26-week core peri-
od followed by a 78-week extension (n = 624 [87%]). Efficacy endpoints were 
evaluated at 104 weeks and safety was assessed by adverse event (AE) reports.
Results: Mean baseline characteristics were similar across groups (age, 63.6 
years; HbA1c, 7.7%; fasting plasma glucose [FPG], 8.7 mmol/L; BMI, 31.6 kg/
m2; estimated glomerular filtration rate [eGFR], 77.5 mL/min/1.73 m2). At 
104 weeks, CANA 100 and 300 mg reduced HbA1c, FPG, body weight, and 
systolic blood pressure (BP), with small increases in high-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) com-
pared with PBO (Table). Over 104 weeks, overall AE rates were 88.0%, 89.8%, 
and 86.1% with CANA 100 and 300 mg and PBO, respectively; AE-related 
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discontinuation rates were 4.6%, 10.2%, and 6.8%, and serious AE rates were 
similar across groups. CANA 100 and 300 mg were associated with a higher 
incidence than PBO of urinary tract infections (14.5%, 16.5%, 10.1%) and 
genital mycotic infections in females (23.9%, 18.7%, 4.3%) and males (5.6%, 
10.9%, 1.4%). Incidences of osmotic diuresis-related AEs (eg, pollakiuria [in-
creased urine frequency] and thirst; 9.1%, 12.3%, 5.5%) and AEs related to re-
duced intravascular volume (eg, postural dizziness and orthostatic hypoten-
sion; 5.4%, 5.9%, 1.7%) were higher with CANA 100 and 300 mg than PBO, 
but these AEs led to few discontinuations. The incidence of documented hy-
poglycaemia (≤3.9 mmol/L) was modestly higher with CANA 100 and 300 
mg than PBO in patients on an AHA associated with hypoglycaemia (54.1%, 
61.0%, 48.9%) as well as those on an AHA not associated with hypoglycaemia 
(18.3%, 10.9%, 6.6%); severe hypoglycaemia rates were low across groups.
Conclusion: CANA 100 and 300 mg improved glycaemic control, reduced 
body weight and BP, and were generally well tolerated in older patients with 
T2DM over 104 weeks, consistent with 26-week results; the AE profile was 
consistent with that seen in a broad range of CANA-treated patients.
Clinical Trial Registration Number: NCT01106651
Supported by: Janssen Research & Development, LLC
6
Safety of dapagliflozin in patients with type 2 diabetes mellitus and 
hypertension inadequately controlled by a renin-angiotensin system 
blocker with/without a second agent
T.A. Mansfield1, M.A. Weber2, J.F. List1, A. Ptaszynska1;  
1Bristol-Myers Squibb, Princeton, 2SUNY Downstate College of Medicine, 
New York, USA.
Background and aims: Hypertension is common in patients with type 2 dia-
betes mellitus (T2DM) and is often treated with an ACE inhibitor (ACEi) or 
an angiotensin receptor blocker (ARB) plus other antihypertensive (AHT) 
agents if needed. Dapagliflozin inhibits renal glucose reabsorption causing 
glucosuria, weight loss, diuresis and decreased BP. Dapagliflozin significantly 
reduced HbA1c and seated and ambulatory systolic BP versus placebo in 
clinical studies of patients with T2DM and hypertension. Here we describe 
key safety data from these studies.
Materials and methods: In two, randomized, double-blind, 12-week studies, 
patients with T2DM and inadequate glycaemic control (HbA1c 7.0-10.5%) 
and BP (seated systolic BP / diastolic BP: 140-164 / 85-104 mmHg) receiving 
an ACEi or an ARB (Study 1) plus a 2nd AHT drug (Study 2) were rand-
omized to dapagliflozin 10 mg or placebo over 12 weeks. Preliminary efficacy 
results have been previously presented.
Results: In Study 1, 613 patients on an ACEi or ARB were randomized to 
treatment. In Study 2, 449 patients on an ACEi or ARB plus a 2nd AHT drug 
were randomized to treatment. In each study, similar proportions of dapagli-
flozin and placebo experienced adverse events (AEs), with few serious AEs 
reported. In Study 1 and 2, fewer dapagliflozin (1.0 and 0.4%, respectively) 
versus placebo (1.3 and 1.8%) patients withdrew due to an AE. Few hypo-
glycaemic events occurred (3.3 and 5.8% with dapagliflozin vs 1.3 and 2.7% 
with placebo), none of which led to discontinuation. No serious BP related 
safety issues were noted; one orthostatic hypotension AE occurred with da-
pagliflozin in Study 1. Serum uric acid decreased with dapagliflozin but there 
was no effect on serum sodium, potassium, or calcium, despite its diuretic 
effect (Table).
Conclusion: Dapagliflozin had a good safety profile over 12 weeks when used 
in combination with an ACEi or ARB ± 1AHT in patients with T2DM and 
inadequately controlled hypertension.
Clinical Trial Registration Number: NCT01137474, NCT01195662
Supported by: BMS/AstraZeneca
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Uric acid serum level affects serum level of cystatin C,  
independently of GFR, in patients with type 2 diabetes
F. Iliadis1, T. Didangelos1, A. Ntemka1, C. Margaritidis1, A. Zantidis1,  
E. Moralidis2, A. Makedou3, A. Gotzamani-Psarakou2, D. Grekas1,  
A. Hatzitolios1;  
1First Propedeutic Department of Internal Medicine, 2Laboratory of 
Nuclear Medicine, Medical School, 3Laboratory of Lipids, 2nd Paediatric 
Department, AXEPA Hospital, Aristotle University of Thessaloniki, Greece.
Background and aims: Cystatin C has been reported to be a reliable marker 
of GFR in both type1 and type 2 diabetic patients with mild-to-moderate 
CKD (stages 2-3). Recently, elevated serum level of cystatin C has also been 
identified as a significant prognostic indicator for the development of cardio-
vascular disease in people with diabetes. However, there are limited data on 
factors, other than GFR, that influence its serum concentration, especially 
in adult patients with type 2 diabetes. The aim of our study was to identify 
such factors.
Materials and methods: In this cross-sectional study, 560 consecutive type 
2 diabetic patients (252 men, 308 women), aged 65.0±10.0 years (mean±SD) 
were recruited from our outpatient diabetic clinic. All participants were Eu-
ropids. GFR was measured using 51Cr-EDTA (mGFR). Serum cystatin C was 
related to several clinical and biochemical parameters. Multivariate analysis 
was performed in order to identify factors independently associated with cys-
tatin C serum level beyond mGFR. SPSS 18.0 was used for statistical analysis. 
A value of p<0.01 was considered to indicate statistical significance.
Results: Cystatin C was significantly correlated with mGFR (r = -0.590; 
p<0.001), age (r =0.365; p<0.001), ACR-albumin creatinine ratio (r =0.159; 
p=0.001), uric acid (r =0.299; p<0.001), albumin (r = -0.206; p<0.001) and Hb 
(r = -0.230; p<0.001). There were no significant relationships between serum 
cystatin C levels and other variables (diabetes duration, sex, glucose-lowering 
therapy, BMI, fasting glucose, HbA1c, liver function tests, lipid profile, thy-
roid function tests, white blood cells, electrolytes and hsCRP). However, in 
standard multiple regression analysis, only mGFR (B= -0.008; p<0.001) and 
uric acid (B= 0.040; p=0.008) were independent predictors of cystatin C level.
Conclusion: In adult patients with type 2 diabetes, uric acid serum level 
seems to affect cystatin C serum level independently of GFR. Hence, uric 
acid level should be considered when cystatin C based equations for GFR 
estimation are used.
Clinical Trial Registration Number: NCT01215994
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Associations of serum bicarbonate with renal and cardiovascular 
outcome in patients with diabetic nephropathy
E. Schutte1, H.J. Lambers Heerspink2, H.L. Lutgers3, S.J.L. Bakker1,  
B.H.R. Wolffenbuttel3, K. Umanath4, D. de Zeeuw2, R.T. Gansevoort1;  
1Nephrology, 2Clinical Pharmacology, 3Endocrinology, UMC Groningen, 
Netherlands, 4Nephrology and Hypertension, Henry Ford Hospital, Detroit, 
USA.
Background and aims: Low serum bicarbonate, one of the metabolic com-
plications of impaired renal function, has been reported to be an independent 
predictor of renal function decline and mortality. To date, no study has inves-
tigated this association in patients with diabetic nephropathy (DN), whereas 
it has been suggested that acid-base balance is different in subjects with DM 
versus non-DM. We therefore investigated the association of serum bicarbo-
nate with renal and cardiovascular (CV) outcome in specifically type 2 DM 
patients with DN.
Materials and methods: Post-hoc analysis of the RENAAL and IDNT trials, 
both randomised controlled trials (RCTs) investigating the effect of angioten-
sin receptor blockers on renal and CV outcomes in patients with DN due to 
type 2 DM. DN was defined as urinary albumin-to-creatinine ratio (UACR) 
≥300 mg/g or proteinuria ≥900 mg/d. Serum bicarbonate was measured as 
total CO2. Linear regression analysis was used to examine baseline factors as-
sociated with serum bicarbonate concentration. In addition, Cox regression 
models were built to examine the longitudinal associations of serum bicarbo-
nate with renal outcomes (incidence of end-stage renal disease (ESRD), the 
combined endpoint ESRD or doubling of serum creatinine (DSCR)) and CV 
outcome (incidence of fatal/non-fatal stroke/myocardial infarction). Serum 
bicarbonate concentration was studied as continuous variable and stratified 
in quartiles to allow assessment of non-linear associations.
Results: We included 2628 patients (mean age 60 ± 7 (SD) years, 65% male, 
61% white) with mean estimated GFR (eGFR) 44 ± 16 mL/min/1.73m2 and 
median UACR of 1366 mg/g (interquartile range 682 - 2653). Mean serum bi-
carbonate level was 24.3 ± 3.7 mEq/L and 602 patients had serum bicarbonate 
levels <21 mEq/L. Multivariate linear regression analyses showed significant 
associations of serum bicarbonate with age, diuretic use, total cholesterol, 
potassium, chloride, phosphate and albuminuria (all p<0.05), and particu-
larly with eGFR (p<0.001). During follow-up for 2.8 ± 1.0 years, 948 (36%) 
patients developed ESRD, 731 (28%) ESRD or DSCR, and 457 (17%) a CV 
event. Cox regression analysis showed that serum bicarbonate had a negative 
association with incident ESRD (HR 0.91 (95% CI 0.90-0.93), P<0.001) and 
with the incidence of the combined endpoint of ESRD or DSCR (HR 0.94 
(0.92-0.96), P<0.001). These associations were independent of traditional 
risk factors for renal and CV disease, but lost significance when adjusting 
for baseline eGFR. Analysis of bicarbonate quartiles showed similar results 
for the lowest bicarbonate quartile (<21 mEq/L) versus the quartile with nor-
mal bicarbonate levels (24-26 mEq/L). No associations were found between 
serum bicarbonate and CV outcome in any model. Of note, in these RCTs no 
interaction was found between treatment allocation and bicarbonate versus 
any of the three outcomes.
Conclusion: In this cohort of type 2 DM patients with diabetic nephropathy, 
serum bicarbonate was not independently associated with renal or CV end-
points. This finding suggests that the predictive value of serum bicarbonate 
for adverse outcomes differs between diabetic and non-diabetic patients.
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Association between 3 biomarkers and kidney complications  
in type 2 diabetic patients
P. Saulnier1,2, E. Gand3, G. Velho4, K. Mohammedi4,5, P. Sosner6, P. Zaoui7, 
M. Fraty3, S. Ragot1, M. Marre4,5, R. Roussel4,5, S. Hadjadj8,9;  
1CIC1402 Inserm, CHU, Poitiers, 2INSERM, Cic1402, 3pole DUNE, CHU, 
Poitiers, 4U695, INSERM, Paris, 5Diabetology, Endocrinology and Nutrition, 
AP-HP, Paris, 6Cardiology, CHU, Poitiers, 7Nephrology, CHU, Grenoble, 
8Endocrinology, Diabetes, Metabolic diseases, CHU, Poitiers,  
9Cic1402, INSERM, Poitiers, France.
Background and aims: We aimed to explore the predictors of severe renal 
complications in type 2 diabetes in a multi-biomarker approach. Three pep-
tides recently reported as associated with cardiovascular or renal complica-
tions of diabetes in the literature were considered: the mid-regional part of 
pro-ADM (MR-proADM) which is a surrogate marker of adrenomedulin, ul-
trasensible copeptin (usCT-proAVP) which is a surrogate marker for arginine 
vasopressin release and soluble Tumor Necrosis Factor receptor 1 (sTNFr1) 
which is a marker of the TNF pathway.
Materials and methods: A total of 1,408 T2D patients without history of 
renal replacement and GFR>15ml/min at baseline were prospectively fol-
lowed in a mono-center hospital-based cohort in middle-western part of 
France. Median duration of follow up was 70 months (8,365 patient.years). 
The three peptides were measured on the same baseline plasma sample. Renal 
events were defined as sustained doubling of serum creatinine levels or renal 
replacement therapy during follow-up. Events were adjudicated by an inde-
pendent adjudication committee.
Results: During follow up 82 patients yielded a renal event (9.9 for 1,000 pa-
tient.years). The median (interquartile range) MR-proADM, usCT-proAVP 
and TNFR1s plasma concentrations were 0.73 (0.36) nmol/l, 6.57 (7.68) 
pmol/l and 1843 (770) pg/l respectively.
In univariate analysis, MR-proADM, usCT-proAVP and TNFR1s were sig-
nificantly associated with risk of renal event (p<0.0001 for all). Hazard ratio 
(HR) [95%CI] were 1.17 [1.15-1.20], 1.02 [1.02-1.03] and 1.11 [1.09-1.12] for 
an increase of 0.1 nmol/l MR-proADM, 1 pmol/l usCT-proAVP and 100 pg/l 
TNFR1s respectively. Kaplan Meier survival curves according to quartiles 
groups of biomarkers are presented in Figure. MR-proADM, usCT-proAVP 
and TNFR1s were significantly inter-correlated (Spearman test, all p<0.0001). 
When considering together all three biomarkers, only MR-proADM and 
TNFR1s remained significant predictors of renal event. After adjustment on 
age, sex and baseline eGFR, adjusted HR [95%CI] were 1.12 [1.07-1.17] and 
1.05 [1.02-1.07] for an increase of 0.1 nmol/l and 100 pg/l of MR-proADM 
and TNFR1s, respectively.
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Conclusion: High levels of MR-proADM and sTNFR1 were independently 
associated with an increased risk of renal event in patients with type 2 diabe-
tes. With this approach, usCT-proAVP did not carry additional information 
regarding of renal event when adjusting on these 2 biomarkers.
Supported by: PHRC2007
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Lipoprotein(a) predicts new onset of chronic kidney disease in patients 
with type 2 diabetes mellitus: a ten-year follow-up study
J.-S. Yun1, K.-H. Song1, Y.-M. Park2, S.-H. Ko1, Y.-B. Ahn1;  
1Internal Medicine, 2Preventive Medicine, The Catholic University of Korea, 
Seoul, Republic of Korea 
Background and aims: We investigated factors that might influence the de-
velopment of chronic kidney disease (CKD) in patients with type 2 diabetes.
Materials and methods: From January 2000 to December 2002, a total of 
1,367 patients with type 2 diabetes without CKD (estimated glomerular filtra-
tion rate [eGFR] ≥ 60 ml/min/1.73m2) were consecutively enrolled. Patients 
were divided into two groups according to their baseline serum Lp(a) levels 
(Lp(a) >30mg/dL vs Lp(a) ≤30mg/dL). The estimated GFR was measured an-
nually, and new onset CKD was defined as eGFR < 60 ml/min/1.73m2 using 
a Modification of the Diet in Renal Disease formula. We used a Cox propor-
tional hazard regression analysis to test associations between new onset CKD 
and potential explanatory variables.
Results: Of the 1,367 patients who were enrolled in this study, 904 (66.1%) 
completed the follow-up evaluation. The median follow-up time was 9.8 
years. The mean age was 56.0 ± 10.3 years, and the duration of diabetes was 
8.5 ± 6.9 years. The baseline eGFR was 98.3 ± 25.6 ml/min/1.73m2. During the 
follow-up period, 234 patients (25.9%) progressed to chronic kidney disease. 
The patients in the CKD group were older (P < 0.001), had hypertension (P < 
0.001), a longer duration of diabetes (P < 0.001), higher baseline A1C levels 
(Lp(a) >30mg/dL vs Lp(a) ≤30mg/dL: hazard ratio 3.4; 95% CI 2.50 - 4.54; P < 
0.001) after adjusting for sex, age, diabetic duration, mean A1C, albuminuria, 
treatment of insulin, ACE inhibitor/ARB and lipid lowering agents.
Conclusion: In conclusion, the development of CKD from normal renal 
function was independently associated with serum Lp(a) level in patients 
with type 2 diabetes.
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Lipidomic biomarkers associated with and predictive of rapid 
progression of renal disease in type 2 diabetes
M. Colombo1, H.C. Looker2, B. Farran2, F. Agakov3, P.E. Sanders4,  
M.S. Kuo4, M.K. Thomas4, P. McKeigue1, H.M. Colhoun5, on behalf of the 
SUMMIT Investigators;  
1Centre for Population Health Sciences, University of Edinburgh, UK, 
2Population Health Sciences, University of Dundee, UK, 3Pharmatics Ltd, 
Edinburgh, UK, 4Lilly Research Laboratories, Eli Lilly and Company, 
Indianapolis, USA, 5Population Health Sciences, University of Dundee, UK.
Background and aims: To identify lipidomic biomarkers associated with 
and/or predictive of rapid progression of nephropathy in subjects with type-2 
diabetes mellitus.
Materials and methods: 288 serum samples (134 cases and 154 controls) 
from the Genetics of Diabetes Audit and Research Tayside Study (Go-Darts) 
study were selected based on changes in eGFR following baseline sampling. 
All cases and controls had a baseline eGFR of 30-60ml/min with cases los-
ing >40% of baseline eGFR over a maximum follow-up of 3.5 years, whilst 
controls lost a maximum of 5% baseline eGFR after >3.5 years follow-up. 221 
lipid species, belonging to 9 lipid classes, were measured using a mass spec-
trometry platform. We assessed the association with the rapid eGFR loss with 
individual lipid species, the sum of the lipid class and ratios of individual li-
pids to the sum of lipid class, by univariate tests and using predictive selection 
models. We applied two complementary approaches to biomarker selection: 
forward selection using logistic regression, and sparse logistic regression with 
the L1 (LASSO) regularization penalty, with models adjusted for standard 
clinical covariates including age, sex, diabetes duration, baseline eGFR, al-
buminuria, HbA1c and use of ACE Inhibitors or ARBs. Model performance 
was assessed using Area Under the Receiver Operating Characteristic curve 
(AUROC) from cross-validated models.
Results: A model limited to clinical covariates only had an AUROC of 0.695. 
A class-by-class analysis of lipids reveals that the most predictive associations 
are with the Phosphatidylcholines lipids (PC) (AUROC = 0.739 with forward 
selection, 0.764 with LASSO-regularized selection). Other lipid classes which 
help improving predictions are Sphingomyelins (SPM) (AUROC = 0.724 and 
0.726). Among the Phosphatidylcholines PC26.6 was inversely associated 
with progression in univariate analysis (Odds Ratio 0.66, 95% Confidence 
Interval 0.49, 0.86, p<0.001).
Conclusion: Circulating serum phosphatidylcholines are associated with 
rapid eGFR loss in patients with diabetes and significantly improve its predic-
tion. The mechanism underlying association warrants further investigation.
Supported by: SUMMIT Consortium IMI-2008/115006
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Epidemiology of urinary tract infections in type 2 diabetes mellitus 
patients and associated healthcare cost
T. Wilke1, A. Groth2, B. Böttger2, S. Müller2, A. Fuchs3, S. Yu4, M. Botteman5, 
U. Maywald3;  
1Pharmerit / IPAM Wismar, 2IPAM Wismar, 3AOK Plus, Dresden, Germany, 
4Merck Sharp & Dohme Co., Whitehouse Station, USA,  
5Pharmerit International, Bethesda, USA.
Background and aims: Urinary tract infections (UTIs) are considered to be 
the most common bacterial infection in diabetes mellitus type 2 (T2DM) pa-
tients (pts). This study aims to assess the incidence of UTIs, identify predic-
tors of UTI event risk, and describe the associated treatment costs in T2DM 
pts.
Materials and methods: This was a retrospective database analysis of the 
German sickness fund covering Year 2010-12. Patient inclusion criteria were 
documented continuous insurance from 2010-12 and documented ≥1 inpa-
tient or ≥2 outpatient T2DM diagnoses. To be included as an UTI case, the 
UTI diagnoses had to be coded after a T2DM diagnosis. A UTI diagnosis was 
interpreted as incident if no prior UTI diagnosis was documented. If a prior 
UTI was documented, such a diagnosis was interpreted as recurrent only if it 
was not documented in the same or following quarter as the prior UTI AND 
documented by either a different physician and/or associated with antibiotics 
use. UTI event rates were calculated per 1,000-patient-years. Logistic regres-
sions were used to evaluate the association between pts characteristics and 
the risk of UTI within the whole sample and within a subsample of pts with 
available HbA1C/BMI data. Costs included UTI-related antibiotics use, out-
patient and inpatient treatment. Cost was analysed descriptively.
Results: There were 456,827 T2DM pts meeting the inclusion criteria. Me-
dian age was 75.5 years; 43.8% were male. In the first observation year (2010), 
60.8% of the prevalent T2DM pts received antidiabetic therapy (OAD: 76.1%; 
insulin: 40.5%). Average Charlson comorbidity index (CCI) was 7.29. In the 
observation period 2010-12, 89,024 pts (19.5%) had ≥1 UTI, and 28,393 pa-
tients (6.2%) with ≥2 UTI. The event rate was 120 cases/1,000 patient-years. 
An inpatient admission occurred in 3.7% of the observed UTI events. In the 
multivariate analysis, the following variables, among others, predicted the 
risk to experience ≥1 event (OR; all with p<0.001) in 2012: age 77-83 years 
and > 83 years vs. ≤62 years (1.46/1.58), female gender (1.66), previous UTI 
in 2010/11 (3.20), and other non-UTI infections in 2010/11 (1.74). Variables 
were mainly associated with the risk to experience ≥2 UTI in 2012: age 72-
77, 77-83 years and > 83 years vs. ≤62 years (1.38/1.51/1.65), female gender 
(1.32), previous UTI in 2010/11 (5.13), other non-UTI infections in 2010/11 
(1.63), and CCI>8 (1.67). In the subgroup with laboratory data available 
(217,022 pts), a higher UTI risk in 2012 was additionally associated with a 
mean HbA1C of 9.5-10.0/>10.0% vs. 7.0-7.5 in 2011 (1.31/1.33; p<0.001). 
The most commonly prescribed antibiotic for outpatients was ciprofloxacin 
(48.8%). Mean (SD), and median costs per UTI case were 193.28 € (802.85 
€) and 68.94 € respectively (inpatient: 50.5%; outpatient: 43.6%; medication/
other: 5.9%).
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Conclusion: Among a real-life T2DM cohort from 2010-12, UTI event risk 
was very high compared to previous studies which reported event rates 47-60 
cases/1,000 patient years. This may be due to the older and more comorbid 
sample which reflects a real life cohort of T2DM patients in Germany. Age, 
female gender, health status and previous infections are the greatest risk fac-
tors associated with the UTI event risk.
OP 03 Evolving tools in education
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Internet intervention designed to identify and reduce risk of  
diabetic driving mishaps, a randomised clinical trial
D.J. Cox1, L. Gonder-Frederick1, L.M. Ritterband1, B. Kovatchev1,  
K. Ingersoll1, H. Singh1, D. Ford1, K. Schmidt2, T. Banton1;  
1Psychiatry & Neurobehavioral Sciences,  
2Psychology, University of Virginia, Charlottesville, USA.
Background and aims: While driving mishaps are more common among 
those who have Type 1 Diabetes (T1D), in part due to extreme blood glucose 
(BG), this increased risk is believed to be restricted to a subgroup of drivers 
who are more vulnerable to moderate hypoglycaemia. We tested the hypothe-
ses that an interactive internet intervention, DiabetesDriving.com (DD.com), 
could: 1) identify high-risk drivers, and 2) aid high-risk drivers to diminish 
their risk by better anticipating, preventing, detecting, and treating extreme 
BG while driving.
Materials and methods: 1739 drivers with T1D from all 50 US states who 
registered for DD.com were screened for inclusion criteria, and for High or 
Low risk for future driving mishaps based on the Risk Assessment for Diabet-
ic Drivers (RADD). 379 High-Risk drivers were randomized to Routine Care 
(RC), DD.com, or DD.com + Motivational Interviews administered once 
before and once after DD.com. 122 Low Risk drivers were assigned to RC. 
DD.com was administered during months 1-2. During months 3-14, all par-
ticipants completed monthly on-line driving diaries in which the frequency 
of the following driving mishaps was reported: Severe hypoglycaemia while 
driving, Loss of vehicle control without hitting anything, Collisions, Being 
stopped by the police while driving, Automatic driving due to extreme BG, 
Unintentional stops while driving, and Requiring assistance from someone 
else while driving due to extreme BG.
Results: Analyses of partial data (4,036 diaries) indicate High-Risk RC driv-
ers reported more than twice as many driving mishaps/month than Low-Risk 
RC drivers (0.54 vs 0.21 mishaps/month, p<0.001). Both DD.com groups re-
ported similar numbers of mishaps/month (0.31 and 0.29), significantly fewer 
than for the High-Risk RC participants (p<0.001). DD.com participants who 
answered “yes” to the question, “Do you use continuous glucose monitor-
ing (CGM)?” reported a similar frequency of driving mishaps to those who 
said “no” (p=0.68), but this may be because the CGM users had significantly 
greater driving risk (RADD scores) than the non-CGM users (p=0.026).
Conclusion: Results indicate: 1) Diabetes-related driving mishaps are rela-
tively high frequency events for high-risk routine care individuals, 2) RADD 
can identify T1D drivers at-risk for future mishaps, 3) DD.com can reduce, 
and possibly prevent, future driving mishaps of T1D drivers at high risk for 
mishaps, and 4) the additional costs of MI cannot be justified in this particu-
lar situation.
Clinical Trial Registration Number: NCT01563887
Supported by: NIDDKD R01
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Effects of peer support in type 2 diabetes patients on diabetes related 
distress, self efficacy and well being: a randomised controlled trial
L. de Vries1, A.A. van der Heijden1, C.A. Baan2, J.M. Dekker1, M. Rijken3,  
G. Rutten4, G. Nijpels1;  
1The EMGO Institute for Health and Care Research, VU University Medical 
Center, Amsterdam, 2RIVM, Bilthoven, 3Nivel, Netherlands Institute  
for Health Services Research, Utrecht, 4UMCU, Utrecht, Netherlands.
Background and aims: Many type 2 diabetes mellitus patients face difficul-
ties self-managing their illness, which can lead to high levels of diabetes-re-
lated distress. Diabetes distress may be decreased by peer support, as peers 
understand and have dealt with similar problems, and can help motivate each 
other. However, a recent systematic review concluded that evidence of ben-
efits of peer support in patients with type 2 diabetes mellitus were inconsist-
ent. The primary aim of this study was to investigate the effectiveness of a 
group-based, peer support program on diabetes-related distress, well-being 
and diabetes-specific self-management in type 2 diabetes patients.
Materials and methods: A parallel group randomised controlled trial of a six 
session group-based peer support intervention, delivered by peer leaders and 
group psychotherapists, compared with one educational meeting on diabetes. 
Duration of the intervention was six months. Patients with a type 2 diabetes 
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duration of three years or more and between 50 and 70 years of age, recruited 
via their general practitioner, were randomised to receive the peer support 
intervention (n=101) or one educational meeting (n=132). Outcomes were 
measured one month before, and 6, and 12 months after baseline by means of 
self-reported questionnaires (PAID; WHO-5; diabetes specific CIDS). Base-
line characteristics between intervention and control group were compared 
and multilevel linear regression models were performed on complete cases to 
investigate the effect of the intervention on diabetes-related distress (n=118), 
psychological well-being (n=116) and diabetes-specific self-management 
(n=107) (Mlwin2.22). Unadjusted analysis as well as analysis adjusted for dif-
ferences in baseline characteristics are presented.
Results: Mean age of the study participants was 64 years (SD: 5) in both the 
control and intervention group. More men were randomised to the inter-
vention group (69.3%) and more participants were lower educated (60.4%). 
Other characteristics did not differ between the two groups at baseline. No 
effects were seen for diabetes-related distress or well-being. However, the in-
tervention group showed an increase in diabetes-specific self-management 
after 6 months of follow-up (β= 4.6; 95% CI: -5.4 to 14.6) and between base-
line and 12 months of follow-up (β= 5.1; 95% CI: 1.2 to 9.0). Adjustment 
for differences in sex and educational level between intervention and control 
group at baseline slightly increased the differences in effects after 6 months (β 
= 6.5; 95% CI: -2.8 to 15.7) and after 12 months (β=7.0; 95% CI:3.01 to 11.02).
Conclusion: Results of this study indicate that a group-based, peer support 
program had no effect on diabetes distress nor on well-being but a modest 
beneficial effect on diabetes-specific self-management in type 2 diabetes pa-
tients was seen, which sustained for at least six months after the last peer 
group session.
Clinical Trial Registration Number: NTR3474
Supported by: Dutch Diabetes Research Foundation
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The efficacy of a new education and treatment programme (PRIMAS) 
for people with type 1 diabetes in daily routine and RCT: a health care 
research trial
N. Hermanns, N. Bergis-Jurgan, D. Ehrmann, T. Haak;  
Research Institute of Diabetes Academy Mergentheim (FIDAM),  
Bad Mergentheim, Germany.
Background and aims: It´s a common result of health care research that ef-
ficacy of treatments assessed in randomized trials (RCT) is superior to ef-
ficacy of these treatments in routine care. We evaluated if a new education 
and teaching programme for type 1 diabetes patients (PRIMAS) had a similar 
efficacy in daily routine than in the RCT.
Materials and methods: In this health care research trial (HCRT) 255 people 
with type 1 diabetes from 42 diabetologists practices participated (age 43 ± 14 
yrs.; 54% male gender; diabetes duration 13 ± 12 years; HbA1c 8.1 ± 1.4%). 
Participants took part in the education and treatment programme (PRIMAS), 
which consisted of 12 lessons. The outcomes were assessed 6 months after 
the education programme was finished. In both trials HbA1c was assessed 
in a central laboratory. Patients also completed a Hypoglycaemia Aware-
ness Questionnaire, the Center of Epidemiological Studies-Depression Scale 
(CESD), the Diabetes Distress Scale (DDS), the Diabetes Self-efficacy Scale 
and the Empowerment Scale. Central outcomes were the difference in HbA1c 
reduction between the RCT and this health care research trial. Secondary 
outcomes were improvements of the hypoglycaemia awareness score, depres-
sive symptoms, diabetes related distress, self-efficacy and empowerment.
Results: HbA1c showed an equivalent improvement in RCT and HCRT 
(-0.36 ± 1.1 vs. -0.39 ±1.2 percentage points, Δ 0.03 95% CI -0.27 to 0.33 per-
centage points, p=.827). The confidence interval of HbA1c-differences was 
beneath the 0.4 % non-inferiority threshold as defined by the ADA. Similar 
results were obtained regarding the hypoglycaemia unawareness score (RCT 
-0.52 ± 1.42 vs. HCRT -0.36 ±1.36, p=.375), for depressive symptoms score 
(RCT -1.18 ± 7.93 vs. HCRT -1.85 ±8.49, p=.542), for diabetes distress score 
(RCT -0.32 ± 0.76 vs. HCRT -0.18 ±0.66, p=.180) for self-efficacy score (RCT 
+1.39 ± 3.56 vs. HCRT -1.11 ±5.88, p=.631) and for empowerment score 
(RCT +2.61 ± 5.93 vs. HCRT -2.34 ±7.01, p=.752).
Conclusion: The PRIMAS diabetes education and treatment programme had 
similar effects under routine care conditions than observed in a RCT. Thus, 
PRIMAS can contribute to an improvement of routine health care in people 
with type 1 diabetes.
Clinical Trial Registration Number: NCT01220557
Supported by: Berlin Chemie AG
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Effects of a patient-oriented decision aid for prioritising treatment goals 
in diabetes, a randomised controlled trial
P. Denig1,2, J. Schuling3,2, F.M. Haaijer-Ruskamp1,2, J. Voorham1,2;  
1Clinical Pharmacy and Pharmacology, University Medical Center 
Groningen, 2University of Groningen, 3General Practice, University Medical 
Center Groningen, Netherlands.
Background and aims: Decision aids (DA) can encourage patient-provider 
discussions about disease management by presenting available treatment op-
tions and expected outcomes for the individual patient. The newest genera-
tion DA for diabetes patients and providers prioritise between clinical do-
mains to guide treatment decisions. Our aim was to assess the effects of such 
a patient-oriented DA in comparison to usual care on shared goal-setting and 
treatment decisions.
Materials and methods: We conducted a randomised controlled trial includ-
ing 18 general practices in the north of the Netherlands. Four presentation 
formats of the DA were compared to usual care. Practices were randomly 
allocated to a computer-screen or printed version of the aid. Within each 
practice, patients were randomised to receiving either the short or extended 
version of the aid or usual care. Effects on patient empowerment for making 
shared decisions about treatment goals (primary outcome), smoking status, 
prescribing of glucose-regulating, blood pressure-regulating, lipid-regulating 
and albuminuria-regulating drugs (secondary outcomes) were tested in 
intention-to-treat and per-protocol analyses. Data were collected through 
structured questionnaires and automated data extraction from electronic 
health records in 6 months before and after the intervention.
Results: Of 665 eligible patients with type 2 diabetes being ≤65 years at time 
of diagnosis, 344 consented to participate; 225 were allocated to the interven-
tion groups and 119 to the usual care group. The mean empowerment score 
increased 0.1 on a 5-point scale in the overall intervention group. This effect 
was not significantly different from the control group in the intention-to-
treat analysis but was significant in the per-protocol analysis (n=103 patients, 
who received the DA as planned vs 119 control patients, p=0.031). Lipid-
regulating drug treatment was intensified in 24% of intervention and 11% of 
control patients with elevated cholesterol levels, which was a significant dif-
ference in the intention-to-treat (p=0.041) as well as the per-protocol analysis 
(p=0.038). No significant changes were seen for the other drug treatments or 
in smoking status.
Conclusion: Our study showed that a patient-oriented treatment DA can 
lead to improved drug treatment and has potential for increasing patient em-
powerment, provided it is used as intended. The effects of the DA may have 
been limited due to its single use within the setting of this randomised trial. 
Clinical Trial Registration Number: NTR1942
Supported by: ZonMW
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Health economic implications of education-based flexible insulin 
therapy versus conventional or technology-based approaches  
in type 1 diabetes
H. Zulewski1, M. Brändle2, A.-E. Minder1, B. Hunt3, W.J. Valentine3;  
1University Hospital Basel, 2Kantonsspital St. Gallen,  
3Ossian Health Economics and Communications, Basel, Switzerland.
Background and aims: To estimate the long-term clinical and cost outcomes 
associated with flexible intensive insulin therapy (FIT) in relation to stand-
ard management and a continuous subcutaneous insulin infusion with con-
tinuous glucose monitoring (CGM-CSII) for patients with type 1 diabetes in 
Switzerland.
Materials and methods: Evaluation of a long-term cost-effectiveness model 
with parameters estimated from three landmark type 1 diabetes trials: The 
Basel FIT study, STAR 3 and EDIC, with clinical outcomes extrapolated using 
the published and validated CORE Diabetes Model. Main outcome measures 
included life expectancy, quality-adjusted life expectancy, incidence of dia-
betes-related complications, direct costs, and incremental cost-effectiveness 
ratios (ICERs).
Results: FIT and CGM-CSII were associated with clinical benefits over 
standard management, improving life expectancy (14.43 years and 14.20 
years versus 14.07 years) and quality-adjusted life expectancy (10.14 quality-
adjusted life years [QALYs], and 9.97 QALYs versus 9.75 QALYs). Improve-
ments were driven by reduced incidences of diabetes-related complications 
and severe hypoglycaemic events, as a result of improved glycaemic control 
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over standard management. FIT was associated with reduced direct medical 
costs over standard management (CHF 186,373 versus CHF 192,588), and 
therefore was considered to dominate standard management. Costs were 
higher in the CGM-CSII (CHF 245,983) arm as a result of increased costs 
of CSII pumps and CGM consumables, with an ICER of CHF 248,602 per 
QALY gained versus standard management.
Conclusion: The education-based approach of FIT and the technology-based 
approach of CGM-CSII are both likely to produce improvements in clinical 
outcomes, but the high cost of CGM-CSII represents a barrier to its use, par-
ticularly compared to the cost savings associated with FIT. Investment of phy-
sician time in patient education may be more cost-effective than investment 
in CGM-CSII technology, in terms of optimizing management of patients 
with type 1 diabetes in Switzerland.
Supported by: Novo Nordisk
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Effects of multidisciplinary and structured education programme on 
glycaemic control during transition of young adults with type 1 diabetes
A. Da Porto, E. Tommasi, S. Cum, E. Del Forno, E. Caroli, E. Manca,  
A. Petrucco, R. Candido;  
Diabetes Unit, ASS 1 Triestina, Trieste, Italy.
Background and aims: The transition from pediatric to adult diabetes care 
represents a high risk period for a person with diabetes. Prior studies high-
light the risk of gaps in medical follow-up and adverse diabetes related out-
comes in emerging adults, including poor glycaemic control, appearance of 
long term diabetes complications and early mortality. Very little is known 
about the specific aspects of transitions process, in particular about the role of 
structured education during transition. Aim of our study was to evaluate the 
relationship between multidisciplinary structured education during transi-
tion and post-transition glycaemic control.
Materials and methods: We evaluated baseline clinical characteristics, gly-
caemic control, glycaemic variability, hypoglycaemia frequency and their 
variation one year after multidisciplinary structured education program 
in 55 young adults with type 1 diabetes who have done transition process. 
Data for Glycaemic variability (SD of average glucose) and hypoglycaemia 
frequency were obtained from the analysis of glycaemic samples from per-
sonal blood glucose meters during a period of 90 days. Multidisciplinary 
structured education was done at the first visit (and carried on during the 
following moths) by Diabetologist, Dietician and Nurse with particular atten-
tion to CHO counting, hypoglycaemia correction and modulation of insulin 
therapy during exercise. Every 2 months correct use of CHO count or adher-
ence to constant CHO diet were verified by dietician. Descriptive statistics 
were presented as means and SD or proportions. Chi square test was used 
to compare proportions. Multivariate logistic regression model was used to 
verify the association between correct management of CHO and glycaemic 
control at 1 year (variable included: age, sex, ∆ Hb1c ∆ glycaemic variability, 
∆ hypoglycaemic frequency).
Results: Average population age was 27,8±;10,1 years with mean diabetes du-
ration of 17,3±9,9 years. Average transition GAP from the last pediatric dia-
betes visit and first adult visit was 6, 24±9, 12 months. At the first visit to adult 
center mean Hba1c was 7, 9±1, 2% , on average worsen of 0,32 ±1,8% during 
transition GAP. Glycaemic variability was 83,1±23 mg/dl and hypoglycae-
mic frequency was 12,6 ±8,2%. Only 23,6% of patients correctly apply CHO 
counting and 11% employ constant CHO diet at baseline. Education was ac-
cepted by 85% of patients. One year later 34,6% of patients correctly apply 
CHO counting and 25,2% employ constant CHO diet (p 0.014 and 0,037 vs 
baseline). Hb1c and glycaemic variability decreased significantly from base-
line (-0,72±;0,65% p 0.009 and - 12% p 0,041 respectively) . Hypoglycaemia 
frequency decreased not significantly (-2% p 0,124). Correct CHO manage-
ment was associated to reduction of Hb1c (r 0,293 p 0,012) less glycaemic 
variability (r - 0,366 p =0,021) and lower hypoglycaemia frequency (r - 0,534 
p 0,032) after 12 months in univariate model but loose statistical relevance in 
multivariate one. Baseline Hb1ac was the only predictor of glycaemic control 
after 12 months of follow-up (R =0,0659 p 0,0001).
Conclusion: In our study sample age of transition and transition GAP was 
high, during transition GAP glycaemic control worsen. A multidisciplinary 
structured education during transition, if accepted by patient , lead to a bet-
ter CHO management that is associated to a better postransition glycaemic 
control.
OP 04 Brown adipose tissue
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Impaired brown adipose tissue fatty acid metabolism in obese subjects
T. Saari1, J. Raiko1, T. Niemi2, M. Taittonen3, J. Laine4, N. Savisto1,  
M. Haaparanta-Solin1, P. Nuutila1, K. Virtanen1;  
1Turku PET Centre, 2Department of Plastic and General Surgery, 
3Department of Anesthesiology, 4Department of Pathology,  
Turku University Hospital, Finland.
Background and aims: Brown adipose tissue (BAT) activation is commonly 
found during cold exposure: BAT glucose uptake and blood flow are in-
creased in cold conditions. Obese subjects have a blunted glucose metabolism 
in BAT. The role of fatty acid metabolism in BAT function is uncertain. The 
aim of this study was to quantify NEFA uptake using PET-CT in lean and 
obese subjects during cold exposure and in room temperature (RT), and to 
measure the differences in NEFA uptakes between lean and obese subjects.
Materials and methods: NEFA uptake was quantified in lean (n=12, 5F/7M, 
ages: 34.4±11.8 years, BMI: 24.1±1.4 kg/m2) and obese subjects (n=9, 4F/5M, 
ages: 45.7±5.8 years, BMI 32.6±4.4 kg/m2) using 18F-FTHA, a palmitate 
analog. Each subject was imaged twice, once at RT and once during cold ex-
posure. Cold exposure was started 2 hours before the imaging session. Tissue 
specific NEFA uptakes were calculated for supraclavicular adipose deposits, 
deltoid muscles and subcutaneous white adipose tissue (WAT). A biopsy was 
performed to confirm the existence of BAT in the supraclavicular area. Sub-
jects were grouped to BAT positive (BAT+) and BAT negative (BAT-) groups 
based on their biopsy result. Biopsy site was determined from CT images.
Results: Three lean subjects (2F/1M) had biopsy proven BAT. They had 7-fold 
higher NEFA uptake during cold compared to obese¬ subjects (5.56±1.15 vs. 
0.74±0.26 µmol/100g/min, P=0.01) and 4-fold compared to lean BAT- sub-
jects (1.43±1.00 µmol/100g/min, P=0.02 vs. BAT+). Cold exposure increased 
BAT NEFA uptake in BAT+ subjects 3-fold compared to RT (P=0.02). BAT+ 
subjects had higher BAT NEFA uptake in RT compared to obese subjects 
(1.69±0.57 vs. 0.57±0.55 µmol/100g/min, P=0.01). BAT FA uptake in cold 
was higher in lean BAT- subjects compared to all obese subjects (P=0.01). 
Lean and obese groups had similar muscle and WAT NEFA uptakes in cold 
and RT.
Conclusion: Cold stimulation increases NEFA uptake of BAT, but not skel-
etal muscles or WAT. All subjects who had functionally active BAT were lean, 
and all lean subjects had higher tissue activity during cold exposure in the 
supraclavicular area compared to the obese subjects. BAT+ subjects had in-
creased BAT NEFA uptake in RT. This would suggest that BAT takes in NEFA 
even without cold exposure. These results suggest that obese subjects have an 
impaired NEFA uptake in the supraclavicular area, typical BAT region.
Supported by: ACADFI, EU FP7 DIABAT, TDRF, FCF
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Cold exposure increases the oxygen uptake rate of brown adipose  
tissue in humans
M. U Din1, J. Raiko1, T. Saari1, T. Tolvanen1, V. Oikonen1, J. Teuho1,  
H. Sipilä1, N. Savisto1, P. Nuutila1,2, K.A. Virtanen1;  
1Turku PET Centre, Turku University Hospital and University of Turku, 
2Turku University Hospital, Department of Endocrinology, Finland.
Background and aims: Brown adipose tissue (BAT) activity has been sug-
gested to have direct relation with insulin sensitivity and inverse association 
with obesity. BAT is more active during cold environment as it produces heat 
by the oxidation of glucose and fatty acids, a phenomenon known as non-
shivering thermogenesis. Oxygen uptake rate can be a marker of BAT ther-
mogenic potential as an indicator of oxidative metabolism. In our present 
study we aimed to determine whether cold exposure increases the oxygen 
uptake rate in BAT and how much BAT oxygen uptake rate is associated with 
blood flow and NEFA uptake rate during cold.
Materials and methods: Healthy lean and obese study subjects (n = 8, age: 
34.5 ± 11.0 years, BMI range: 23.2 - 31.1 kg/m2) of both genders (3F/5M) 
were studied at two different scanning sessions, 1) at room temperature (RT) 
and 2) with acute cold exposure, using PET-CT. Radioactive oxygen [15O]O2, 
[15O]H2O and [
18F]FTHA were given for the measurements of oxygen uptake 
rate, blood flow and NEFA uptake rate of BAT, respectively. Indirect calorim-
etry was performed to assess the differences in whole body energy expendi-
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ture between RT and cold environment. Data was compared with two tailed 
T-test and correlation analysis were performed with Pearson’s correlations.
Results: Cold exposure increased oxygen uptake rate by 22.4 % (from 2.21 
± 0.68 to 2.85 ± 0.59 ml/100g/min, P = 0.001) in 16 BAT regions within 8 
subjects, while oxygen uptake tended to be higher during RT in deltoid mus-
cle (2.55 ± 1.52 vs. 3.13 ± 1.85 ml/100g/min, cold vs. RT, P = 0.06); however, 
no significant difference was found in white adipose tissue (1.76 ± 0.21 vs. 
1.78 ± 0.19 ml/100g/min, cold vs. RT, P = 0.76). Cold exposure also tended 
to increase whole body energy expenditure (from: 7.07 ± 1.10 to 8.24 ± 2.43 
MJ/24h, P = 0.09). During cold exposure, oxygen uptake rate correlated with 
blood flow (r = 0.51, P = 0.05) and NEFA uptake rate in BAT (r = 0.76, P = 
0.01, n = 5).
Conclusion: High oxygen demand during cold in brown adipose tissue is 
most likely due to increased oxidation of available substrates (either glucose 
or fatty acids) for thermogenesis. Positive correlation between NEFA and 
oxygen uptakes suggests that NEFAs that enter brown adipocytes during cold 
also undergo β-oxidation within mitochondria.
Supported by: Academy of Finland, EU FP7 DIABAT, The Diabetes Research 
Foundation, SKR
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Loss of sympathetic drive may explain loss of brown adipose tissue 
activity in elderly but not in obese males
L. Bähler, H.J. Verberne, W.M. Admiraal, M.R. Soeters, J.B.L. Hoekstra,  
F. Holleman;  
Academic Medical Center, Amsterdam, Netherlands.
Background and aims: Metabolically active brown adipose tissue (BAT) 
could facilitate weight loss by increasing energy expenditure. Cold is a potent 
stimulator of BAT, activating BAT primarily through the sympathetic nerv-
ous system (SNS). Old or obese individuals have less metabolic BAT activity 
than lean and young, but the role of the SNS in this decrease is unknown. We 
determined whether the lower metabolic BAT activity can be explained by a 
lower SNS response to cold.
Materials and methods: We studied 10 young obese (26 [21-31] years, BMI 
32 [31-39] kg/m2), 10 old lean (55 [51-60] years, BMI 23 [22-25] kg/m2) and 
14 young lean (26 [21-28] years, BMI 22 [21-23] kg/m2) males. Metabolic 
BAT activity was measured as maximal standardised uptake value and vol-
ume (SUVmax, SUVvol) on 18F-Fluorodeoxyglucose positron emission to-
mography CT (FDG). SNS activity was measured as semiquantative uptake 
values of 123I-metaiodobenzylguanidine (MIBG) on single photon emission 
computed tomography scans, with the mediastinum as reference region. 
Scans were made after an overnight fast and 2 hours of cold exposure.
Results: Metabolic BAT activity and volume were different between young vs 
old (median [IQR] SUVmax (g/L) 7.9[4.2-17.3] vs 3.0[0.0-4.2] p<0.05, SUV-
vol (cm3) 124.8[10.9-333.8] vs 4.3[0.0-12.3] p<0.05) but unexpectedly, not 
for lean vs obese (SUVmax (g/L) 7.9[4.2-17.3] vs 4.0[0.0-13.5] p=0.2, SUV-
vol (cm3) 124.8[10.9-333.8] vs 11.8[0.0-190.2] p=0.2). HOMA-IR differed 
between lean and obese (p<0.01) but not for young vs old. There was no cor-
relation between HOMA-IR and either SUVmax or SUVvol. There were no 
differences in the SNS activity in BAT between lean and obese males (p=0.2) 
but for young and old males this was borderline significant (p=0.06) We con-
firmed the strong positive correlation between BAT activity measured with 
FDG and MIBG in the whole group (spearman correlation ρ=0.76, p<0.01), 
which we previously showed.
Conclusion: We conclude that loss of sympathetic drive may explain the loss 
of BAT activity in elderly but not in obese males.
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Seasonal variation in temperature influences acute brown adipose tissue 
activation
J.W.T. Deelen, L. Bähler, J.B.L. Hoekstra, H. Verberne, F. Holleman;  
Academic Medical Center, Amsterdam, Netherlands.
Background and aims: Brown adipose tissue(BAT) has gained a lot of inter-
est because of its capacity to convert calories into heat. Retrospective data 
on diagnostic 18F-Fluorodeoxyglucose-(FDG)-Positron-Emission-Tomog-
raphy-(PET)-CT scans, in warm temperatures, show increased BAT activity 
during the winter months as compared to the summer months. Indeed, cold 
has been shown to be the strongest activator of BAT activity so far. Besides 
seasonal changes in BAT activity on diagnostic 18F-FDG-PET-CT scans, 
there is also an acute BAT activation after direct cold exposure. The mag-
nitude of this acute effect might still be influenced by seasonal temperatures 
through preconditioning of BAT. Indeed, frequent exposure to cold has been 
shown to increase BAT activity and volume. The aim of this study was to 
evaluate the seasonal effect of BAT in subjects exposed to acute cold.
Materials and methods: 18F-FDG-PET-CT scans of 63 consecutive subjects 
were included. These subjects participated in BAT research in the Academic 
Medical Center between January 2010 and December 2013. All subjects were 
cold exposed at 16-17 °C in an air cooled room, after an overnight fast. Tem-
perature data (24 hours, 1 week, 2 weeks and 4 weeks before the scan) were 
collected from the national weather institute. Correlations between BAT ac-
tivity (i.e. maximal and mean standardised uptake value(SUVmax and SU-
Vmean) and volume) and outdoor temperature (OT) were calculated by the 
Spearmans correlation coefficient.
Results: Forty-nine subjects were BAT positive. The BAT positive subjects 
were significantly younger (median age 25 IQR[21.1-29.4] vs 29.5 [23.5-51.8] 
years, p<0.05) and leaner (median BMI 22.6 [21.3-23.7] vs 26.2 [23.3-32.6] 
kg/m2, p<0.05) as compared to the BAT negative subjects. One week and 4 
weeks prior to the scan the OT was significantly lower in the BAT positive 
group compared to the BAT negative group: 10.0 °C ([4.6-16.4] vs 17.1 [9.1-
17.6] °C, p<0.01 ) and 10.6 °C ([7.7-16.3] vs 16.5 [10.3-17.0] °C, p<0.05). 
However, 24 hours and 2 weeks prior to the scan there were no significant 
differences in OT between the BAT positive and BAT negative subjects. There 
was a strong negative correlation for both the maximal BAT activity as well as 
BAT volume and outdoor temperature for all different time points (24 hours, 
1 week, 2 weeks and 4 weeks before the scan all p<0.01).
Conclusion: These data confirm the strong negative correlation between out-
side temperature and BAT activity and volume. In addition the data show that 
BAT activation by acute cold is largely influenced by outside temperatures. 
It seems therefore advisable to study BAT activity during periods of relative 
cold.
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Brown adipose tissue activity associates with insulin sensitivity and  
liver adiposity independently of visceral fat mass in healthy adults
J.R.H. Raiko1, T. Saari1, V. Saunavaara1, R. Parkkola2, P. Nuutila1,3,  
K. Virtanen1;  
1Turku PET Centre, University of Turku, 2Department of Radiology, 
Tampere University Hospital, 3Department of Endocrinology,  
Turku University Hospital, Finland.
Background and aims: Brown adipose tissue (BAT) activity associates with 
insulin sensitivity and inversely with obesity. However, it remains unclear if 
the association between BAT and insulin sensitivity is mediated by low intra-
abdominal adipose tissue mass and low liver adiposity in subjects with active 
BAT. In this study, we examined associations between BAT activity during 
cold exposure and glycaemic control, whole body insulin sensitivity, intra-
abdominal adipose tissue mass and liver adiposity.
Materials and methods: 22 healthy adult subjects (M/F: 8/14, 41.0 ± 8.3 
years, BMI 27.3 ± 5.3 kg/m2) underwent positron emission tomography with 
[15O]-H2O to measure BAT perfusion and [
18F]-FTHA to measure NEFA 
uptake in the supraclavicular BAT depot during cold exposure. Cold expo-
sure had started two hours prior to and continued during the PET imag-
ing. Whole body insulin sensitivity (hyperinsulinemic euglycemic clamp)
and HbA1c were measured. MRI imaging was used for the measurement of 
intra-abdominal adipose tissue volume and liver adiposity was adjusted with 
MR spectroscopy.
Results: Cold-induced NEFA uptake in BAT was 2.25±1.75 umol/100g/min 
and perfusion was 22.0±27.0 ml/100g/min. HbA1cwas 5.4±0.4%, M value was 
6.8±3.2 mg/kg/min, visceral adipose mass was 3.3±2.0 kg and liver fat con-
tent was 5.7±6.9%. NEFA uptake in BAT correlated with whole body insulin 
sensitivity (r = 0.50, P = 0.02), intra-abdominal fat mass (r = -0.43, P = 0.04) 
and liver adiposity (r = -0.47, P=0.04). Cold-induced BAT perfusion correlat-
ed with HbA1c (r = -0.57, P = 0.01). These associations (perfusion vs. HbA1c, 
and NEFA uptake vs. whole body insulin sensitivity) were independent of 
intra-abdominal fat volume or liver adiposity (P always < 0.05). Associations 
between NEFA uptake and liver adiposity were also independent of intra-
abdominal adipose tissue volume (P = 0.03).
Conclusion: These results show that cold-induced BAT activity is associated 
with glycaemic control and insulin sensitivity independently of visceral adi-
pose tissue mass and liver adiposity in health. Subjects with high BAT activ-
ity might have lower visceral fat mass due to increased energy expenditure. 
Additionally, BAT NEFA uptake might prevent fat accumulation in liver in 
visceral obesity. Although, liver fat content and visceral obesity correlate in-
versely with BAT activity, BAT may associate with insulin sensitivity via a 
separate mechanism. These may include yet unrecognized BAT-derived cy-
tokines affecting muscle metabolism.
Supported by: DIABAT, Acad. Finland
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Inorganic nitrate promotes the browning of white adipose tissue through 
the nitrate-nitrite-nitric oxide pathway
L.D. Roberts1, T. Ashmore2, A.O. Kotwica2, S.A. Murfitt3, B.O. Fernandez4, 
M. Feelisch4, A.J. Murray2, J.L. Griffin1;  
1Medical Research Council - Human Nutrition Research, University of 
Cambridge, 2Physiology, Development and Neuroscience, University of 
Cambridge, 3Biochemistry, University of Cambridge, 4Faculty of Medicine, 
Clinical & Experimental Sciences, University of Southampton, UK.
Background and aims: Inorganic nitrate is considered an oxidation end-
product of nitric oxide with little biological activity. However, recent studies 
demonstrate that dietary nitrate, largely derived from green leafy vegetables, 
modulates mitochondrial function in man and is effective in reversing fea-
tures of the metabolic syndrome in mice. The role of nitrate in white adipose 
tissue (WAT) function remains poorly characterized. The development of a 
brown-like phenotype in white adipocytes (“beige” or “brite” cells), a process 
known as “browning”, includes the induction of thermogenesis, the dissipa-
tion of chemical energy as heat. Activation of the browning response in WAT 
may represent a process underlying the altered systemic energy balance ob-
served with nitrate treatment.
Materials and methods: Wistar rats were treated with 0.35 mM, 0.7 mM 
or 1.4 mM sodium nitrate (NaNO3) in drinking water for 18 days (n = 6/
group). Nitrate induced browning of WAT was assessed using both RT qPCR 
and mass spectrometry based metabolomics. In vitro browning of primary 
adipocytes treated with 25 μM, 50 μM and 500 μM NaNO3 was analysed us-
ing respirometry, metabolomics, stable-isotope labelling techniques and RT 
qPCR. The mechanism of nitrate induced browning was defined in primary 
white adipocytes using pharmacological inhibitors of nitric oxide (NO), gua-
nylate cyclase and protein kinase G (PKG). The effect of hypoxia on nitrate 
induced browning of WAT was determined in vivo in Wistar rats and in vitro 
using primary adipocytes.
Results: Nitrate dose-dependently increased the expression of brown-adipo-
cyte specific genes in WAT of nitrate treated rats (UCP-1, CIDEA, PGC-1α, 
CYCS, CPT1, ACADvl, Two-way ANOVA, Control vs. 0.35 mM NaNO3 P ≤ 
0.01, Control vs. 0.7 mM NaNO3 P ≤ 0.0001, Control vs. 1.4 mM NaNO3 P 
≤ 0.001). Metabolomic analysis demonstrated that treatment with nitrate also 
decreased the total triacylglycerol content within WAT (0.95-fold, 0.35 mM 
NaNO3; 0.94-fold, 0.7 mM NaNO3; 0.98-fold, 1.4 mM NaNO3; ANOVA, 
Control vs. 0.35 mM P ≤ 0.01, Control vs. 0.7 mM P ≤ 0.01). These find-
ings were reproduced in vitro using primary white adipocytes treated with 
nitrate and analysed using RT qPCR, stable isotope labelling and metabo-
lomics, and were accompanied by an increase in oxygen consumption, as-
sessed by respirometry (Control 4.2 nmoles O2/min/106 cells, 50 μM NaNO3 
6.6 nmoles O2/min/106 cells, 500 μM NaNO3 7.7 nmoles O2/min/106 cells, 
ANOVA, P = 0.02)). Using pharmacological inhibitor assays in primary white 
adipocytes, nitrate was found to induce these phenotypic changes in WAT 
independently of NO synthase, through the recently identified xanthine oxi-
doreductase catalysed nitrate-nitrite-NO pathway and downstream cGMP/
PKG signalling. Furthermore, the nitrate induced browning of WAT, both in 
vitro and in vivo, was enhanced in hypoxia.
Conclusion: Since beige/brite cells exhibit anti-diabetic and anti-obesity ef-
fects and WAT from obese individuals is characterized by hypoxia, nitrate 
may be an effective means of targeting the induction of browning to white 
adipocytes located in obese and hypoxic adipose depots to treat the metabolic 
syndrome.
Supported by: MRC-HNR Elsie Widdowson Fellowship
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G1 lengthening promotes pancreatic progenitor cell differentiation  
in mouse embryonic development
N.A.J. Krentz, M. Tang, A. Watanabe, F.C. Lynn;  
University of British Columbia, Vancouver, Canada.
Background and aims: Cellular-based therapies for diabetes mellitus, such 
as the differentiation of human embryonic stem cells (hESCs), require an 
in-depth understanding of pancreatic development. During early pancreatic 
development, the Pdx1+Cpa1+ tip multipotent progenitor cells give rise to all 
three cell types of the pancreas, exocrine, endocrine and ductal cells, while 
the trunk Pdx1+Cpa1- cells give rise to endocrine or ductal cells only. The 
process that regulates the proliferation and differentiation of these progeni-
tors populations is not fully known. There is evidence during neurogenesis 
that the length of the G1 phase of the cell cycle can directly influence the 
differentiation of neural precursors. Thus, we hypothesize that the cell cycle 
length regulates pancreas organogenesis.
Materials and methods: Pregnant CD-1 mice (P12.5) were injected with the 
thymidine analog 5’Ethynyl-2’-deoxyuridine (EdU) every 1.5 hours starting 
at 9 am. Embryos were collected at evenly spaced intervals from 9:30 am to 
8 pm. The number of Pdx1+Cpa1+ and Pdx1+Cpa1- cells labelled with EdU 
was determined using immunofluorescence and confocal microscopy (n>4). 
The lengths of the G1, S and G2/M phases were determined mathematically 
from the length of time required to label all dividing cells, the number of cells 
labeled at time 0, and the proportion of dividing cells.
Results: We determined that the G1 length of multipotent progenitor cells 
at E12.5 was 3.6 hours while the bi-potent trunk cells had a G1 length of 5.8 
hours. We did not find any significant change in the lengths of either the S 
or G2/M phases of the cell cycle. Consistent with findings in neural develop-
ment, the difference in total cell cycle length of these two progenitor popu-
lations at E12.5 was largely due to a lengthening of the G1 phase. Intrigu-
ingly, the maximal proportion of EdU labeled cells or the growth fraction 
was significantly different (p<0.05; n=17) between multipotent and bi-potent 
progenitor cells with 90% and 66% EdU+, respectively. Preliminary data sug-
gests that the majority of non-dividing Pdx1+ cells are still located within 
the pancreatic epithelium, express other progenitor cell markers such as Sox9 
and Nkx6.1, and are Ki67+. These results suggest that there is a population 
of progenitor cells that are still in the cell cycle but are not dividing. As it has 
been previously shown that Ngn3 expression in endocrine progenitors in-
hibits proliferation by activation of Cdkn1a we also examined whether Ngn3 
cells are labelled with EdU. Consistent with these results, we did not find a 
meaningful population of Ngn3+EdU+ cells.
Conclusion: These results support the ‘cell cycle length hypothesis’ from neu-
rogenesis and suggest that G1 lengthening is important for pancreatic pro-
genitor cell differentiation. Understanding this process may give novel insight 
into pancreatic development and inform studies aiming to produce mature 
beta cells from hESCs for diabetes treatment.
Supported by: JDRF, SCN, CIHR
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Up-regulation of MafA drives embryonic progenitor-derived  
insulin-producing cells towards maturation and functional  
improvement both in vitro and in vivo
G. Li1, S. Shao1, J. Zhang1, W. Nishimura2, A. Sharma2, Y.-M. Bee3;  
1Clinical Research, Singapore General Hospital, Singapore, 2Joslin Diabetes 
Center, Boston, USA, 3Endocrinology, Singapore General Hospital, 
Singapore.
Background and aims: Shortage in pancreas donors has impeded trans-
plantation therapy for insulin-dependent diabetes. Our previous work has 
generated insulin-producing cells from mouse embryonic stem cells and 
embryos-derived progenitor cells, which could secret insulin upon glucose 
stimulation and correct hyperglycaemia after transplantation into diabetic 
animals. However, these cells failed to function completely alike the adult 
β-cells and revealed features of immaturity. It is known that MafA (v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog A) acts as a master 
transcription factor in regulating β-cell development and glucose responsive-
ness, but its expression is significantly lower in our insulin-producing cells. 
This study aimed to investigate if up-regulation of MafA could improve the 
function of these cells.
Materials and methods: MafA-expressing lentivirus was used to transduce 
mouse embryonic progenitor-derived insulin-producing (MEPI)-1 cells, fol-
lowed by evaluations of cell functions both in vitro and in vivo.
Results: MafA levels in MEPI-1 cells could be significantly elevated near to 
that in isolated adult islets by the lentivirus. Insulin production was augment-
ed by 50% and the expression of many genes (e.g. insulin, GLP-1 receptor, 
Glut2, glucokinase, Kir6.2 and Nkx6.1) important for β-cell development and 
function was significantly enhanced. These cells also exhibited higher extents 
of glucose metabolism, membrane potential depolarization and intracellular 
Ca2+ concentration rise, indicating more active signaling events upon glucose 
stimulation. Particularly, MafA up-regulation markedly improved glucose-
stimulated insulin secretion by reducing basal insulin release and shifting 
the dose-response curve of insulin secretion upon glucose stimulation more 
close to the physiological pattern. When transplanted into streptozotocin-
induced diabetic mice, MafA-upregulated MEPI-1 cells were able to correct 
hyperglycaemia for a longer term and reduce the hypoglycaemic incidences. 
In addition, MafA up-regulation slowed down MEPI-1 cell growth both in 
vitro and in vivo, and arrested the cells at G1 phase, which might be due to 
the observed elevation of expression of p27, an important cell cycle inhibitor.
Conclusion: Up-regulation of MafA levels in MEPI-1 cells enhances expres-
sion of the β-cell relevant gene profile, increases insulin biosynthesis, im-
proves stimulated insulin secretion by augmenting signaling cascade, slows 
cell growth, ameliorates their in vivo capability of correcting hyperglycaemia 
in diabetic animals. These findings indicate that MafA can promote matura-
tion of embryonic stem cell-derived insulin-producing cells, enabling them 
to achieve better correction of hyperglycaemia for treatment of type 1 dia-
betes.
Supported by: National Medical Research Council of Singapore
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Elucidating the role of Menin during islet cell development in the human 
foetal pancreas
J. Li1, J.L. Dubrick1, G.F. Fellows2, C.G. Goodyer3, R. Wang1;  
1Physiology & Pharmacology, Western University, 2Obstetrics and 
Gynaecology, Western University, London, 3Pediatrics, McGill University, 
Montreal, Canada.
Background and aims: The transcription factor, Menin, a tumour suppressor 
encoded by the Men1 gene, has recently been implicated as necessary for mu-
rine pancreatic development, suggesting a dual functionality: (1) to promote 
endocrine (including progenitor) differentiation via Ngn3 expression during 
development; and (2) to suppress proliferation and insulin hypersecretion in 
the adult pancreas. Most studies of Menin in the human have focused on its 
neoplastic role in the adult pancreas; however, knowledge of Menin’s function 
during human fetal pancreatic development is limited. In the present study, 
the expression pattern and functional role of Menin was examined in the 
early to mid-gestation human fetal endocrine pancreas.
Materials and methods: The presence of Menin in the human fetal (8-21 
weeks fetal age) pancreas was characterized by quantitative RT-PCR, west-
ern blotting and immunohistological approaches. Isolated human fetal islet-
epithelial cell clusters (15-18 weeks) were treated with either MEN1 siRNA or 
MEN1 overexpression vector.
Results: Immunostaining revealed strong nuclear Menin (nMenin) expres-
sion within pancreatic cells from 8 to 21 weeks of fetal age that paralleled 
Menin mRNA and protein expression patterns. nMenin+ cells co-localized 
with transcription factors (PDX-1, SOX9, NGN3) that are critical for main-
tenance of the progenitor pool and endocrine differentiation. A high propor-
tion of Ki67+ cells contained nMenin signals at 8-16 weeks but this decreased 
significantly at 18-21 weeks of development; the proliferative capacity of 
nMenin+ cells was reduced in parallel. Knockdown of MEN1 in human fetal 
islet-epithelial cells significantly increased apoptosis, reduced proliferation 
and decreased SOX9, NKX2.2 and NKX6.1 expression levels. Overexpression 
of MEN1 had opposite results: a significant increase in cell proliferation and 
insulin mRNA, suggesting that Menin plays a positive role in the developing 
human fetal pancreas.
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Conclusion: We have investigated the expression and potential function of 
MEN1 in the early to mid-gestation human fetal pancreas. Functional knock-
down and overexpression studies both suggest that Menin promotes human 
fetal pancreatic cell survival and proliferation, maintains the islet progenitor 
pool and regulates islet differentiation, very different from its anti-tumori-
genic role in the adult pancreas.
Supported by: CIHR
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SOX9 and WNT signalling during human foetal pancreatic development
R. Wang1, J.A. Belo1, J. Li1, G.F. Fellows2, C.G. Goodyer3;  
1Physiology & Pharmacology, Western University, 2Obstetrics and 
Gynaecology, Western University, London, 3Pediatrics, McGill University, 
Montreal, Canada.
Background and aims: Regulation of pancreatic progenitor proliferation 
and differentiation is crucial when generating an appropriate beta-cell mass. 
SOX9 is an important factor in pancreatic progenitor maintenance as well 
as endocrine differentiation; however, the signaling pathways that regulate 
expression of SOX9 remain unclear. A study of murine duodenal epithelium 
demonstrated that Wnt signaling regulated progenitor expansion and differ-
entiation in addition to Sox9 expression. In the present study, the co-locali-
zation and inter-relationship between SOX9 and Wnt/β-catenin factors and 
their targets in the developing human pancreas were examined.
Materials and methods: Human fetal pancreata (8-21 weeks fetal age) were 
examined for SOX9 and Wnt signaling molecules using immunofluores-
cence, western blot and qRT-PCR approaches. Isolated human fetal (18-21 
week) islet-epithelial cell clusters were also treated with or without recombi-
nant WNT3A in a dose- and time-dependent fashion. In addition, cells were 
treated with either a GSK3β inhibitor (1-Akp) or a Wnt signaling inhibitor 
(FZD8-CRD).
Results: Half of the SOX9+ cells expressed WNT3A at 8-12 weeks but the 
numbers decreased with age (p<0.05-0.01); in contrast, FZD and nβ-catenin 
expression in SOX9+ cells remained stable. The majority of insulin+ cells 
expressed WNT3A, FZD and nβ-catenin throughout this developmental 
period. To examine WNT signalling, isolated human fetal (18-21 week) islet-
epithelial cell clusters were treated with rWNT3A or vehicle. Cells treated 
with WNT3A showed a dose-related increase in nβ-catenin localization. In 
addition, a significant increase in SOX9 and ISL1 expression as well as the 
number of insulin+ cells was observed in the WNT3A treated group after 
48h of culture (p<0.01 vs. controls), but no significant effect on the glucagon+ 
cell number. Cell proliferation studies using Ki67 labeling showed a transient 
increase in cell proliferation at 4h of culture but no changes in proliferative 
capacity at 24 and 48h. Similar results were observed when the cells were 
treated with a GSK3β inhibitor. Furthermore, these effects of WNT3A on hu-
man islet-epithelial cell differentiation could be partially blocked by co-treat-
ment with FZD8-CRD, a Wnt signaling inhibitor, suggesting that WNT3A 
induces SOX9 expression and beta cell differentiation through both FZD and 
non-FZD pathways.
Conclusion: These data indicate an active role for WNT signalling during 
endocrine cell differentiation in the early to mid-gestation human fetal pan-
creas. SOX9+ progenitors express WNT3A, FZD and nβ-catenin, suggesting 
that the WNT pathway may be involved in maintenance and differentiation 
of these cells. The present data provide evidence for a role of Wnt/β-catenin 
and SOX9 in determination of insulin cells by regulating proliferation versus 
differentiation.
Supported by: CDA
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Changes in microRNAs profile underline the dedifferentiation process  
of in vitro cultured human pancreatic islet cells
G. Sebastiani1, G. Ventriglia1, L. Nigi1, M. Valentini1, L. Marselli2,  
P. Marchetti2, F. Dotta1;  
1University of Siena and Umberto di Mario Foundation,  
2University of Pisa, Italy.
Background and aims: Beta-cell dedifferentiation has recently been identi-
fied as a mechanism of beta-cell dysfunction both in type1 and type2 dia-
betes. Upon metabolic or inflammatory stress, beta-cells undergo a specific 
phenotypic re-arrangement which on one side protects them from apoptosis 
and, on the other, elicits functional impairment. Previously, we have set up 
a model of in vitro de-differentiation of human native islets (HI) that, when 
cultured in appropriate conditions, undergo an epithelial-mesenchymal like 
transition process (EMT), generating human pancreatic islet-derived mes-
enchymal cells (hPIDM). MicroRNAs (miRNAs) are smallRNAs, which 
regulate gene expression. MiRNAs have been demonstrated to control sev-
eral biological processes including stemness and cell differentiation. MiRNAs 
have also been proposed to contribute to the development of many disorders 
including diabetes. Here, we aimed at characterizing the miRNA expression 
profile during human pancreatic islet cell dedifferentiation process.
Materials and methods: Human native islets were collected from 3 multior-
gan donors and cultured for 15 days. De-differentiated proliferating hPIDM 
cells were collected and total RNA was extracted from human islets and from 
hPIDM cells. Expression of 768 miRNAs was evaluated using Taqman Hu-
man miRNAs panel A and B arrays. MiRNA prediction target analysis fol-
lowed by gene ontology classification was performed using Targetscan and 
DAVID 6.7. MiRNA target genes expression levels on 3 different human 
native islets preparations and 3 hPIDM cells samples were evaluated with 
Taqman plates by using Real Time PCR. Data and statistical analysis was per-
formed using expression suite software
Results: Among 768 miRNAs analyzed, 335 and 331 miRNAs were detect-
ed in HI and in hPIDM cells respectively. Following dedifferentiation, 110 
miRNAs resulted significantly decreased and 13 increased in hPIDM cells 
vs native human islets. Upregulated miRNAs included miR-100, miR-337-
3p, miR-214, miR-199a-3p and -5p, miR-137, miR-708, miR-99a and miR-
302s. To gain insights into the molecular pathways potentially regulated by 
these miRNAs, we looked at the predicted targets genes. Using Targetscan, 
we extrapolated a list of 196 genes predicted as targets of the 13 upregulated 
miRNAs. In order to classify the predicted genes we used the algorithm DA-
VID 6.7 which allowed us to perform a gene ontology analysis. We identified 
11 functional categories with a significant p-value. Among these categories, 
most genes belonged to cell-cell adhesion mechanisms and to differentiation 
process; By analyzing the expression levels of a selection of these predicted 
target genes in HI and hPIDM, we observed a major downregulation of 44 
genes during EMT, in line with the inverse expression levels of targeting miR-
NAs
Conclusion: We detected a specific miRNA signature of in-vitro dediffer-
entiated human pancreatic islet-derived mesenchymal cells. We specifically 
identified 13 miRNAs strongly upregulated during this process, which may 
indeed function as regulators of those genes controlling mesenchymal-like 
phenotype acquisition. Using a bioinformatic approach we uncovered a puta-
tive specific role for these miRNAs in exploiting several functions by regulat-
ing the expression of genes involved in cell-adhesion, cell-cell contact, mor-
phogenesis and in mesenchymal-like phenotype acquisition.
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Transcriptome profiling by RNAseq of single human islet cells reveals 
unique features of individual alpha and beta cells
M. Garieri, C. Borel, P. Ribaux, S.E. Antonarakis, E.T. Dermitzakis,  
P.A. Halban;  
Genetic Medicine and Development, University of Geneva, Switzerland.
Background and aims: Deep coverage RNA sequencing (RNAseq) allows 
for the detailed description of transcriptomes. Typically this is performed on 
pure or mixed cell populations and the data offer no insight into the tran-
scriptome signature or true identity of individual cells, or cell-to-cell vari-
ability in gene expression. To understand the unique features of individual 
human islet cells, we have now captured single cells and analysed them by 
RNAseq.
Materials and methods: Human islets isolated from 2 healthy donors (sam-
ples C1, C2) and 2 with type 2 diabetes (D1, D2) were dissociated (accutase) 
and single cells captured and processed in 96-well microfluidic plates (Flui-
digm C1 Single-Cell Auto Prep System). We RNA sequenced 288 single cells 
with Illumina HiSeq2000 (100 base pairs, paired-end reads), with an average 
of 36.6 million total reads. mRNA levels are expressed as Reads Per Kilobase 
per Million mapped (RPKM).
Results: After quality control, 275 cells were analysed. Of these, 123 were 
considered beta cells (defined as RPKM INS (insulin) >100, GCG (glucagon), 
PPY (pancreatic polypeptide) and SST (somatostatin) <100). The number 
of beta/total cells for each donor was: C1: 42/68; C2: 50/81; D1: 14/63; D2: 
17/63. In these cells, INS was highly expressed, but with considerable inter-
cellular variability (RPKM range for C1: 1040-52410; C2: 167-104500; D1: 
293-35930; D2: 316-22440). Interestingly, there was expression of GCG in 
all beta cells (range 1-75 RPKM), albeit at much lower levels than in the 48 
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captured alpha cells (RPKM GCG >100, INS, PPY and SST <100) with RPKM 
range C1: 68530-175400, C2: 36670-188100; D1: 110-90340; D2: 5752-59780. 
Similarly, there was low INS expression in all alpha cells (range 6-89 RPKM). 
Analysis of empty wells indicated that this low-grade expression was not due 
to contamination. There is considerable interest in islet cell plasticity, particu-
larly possible alpha-to-beta cell trans-differentiation. We identified a total of 
53 mixed phenotype “alpha-beta” cells (RPKM INS and GCG >100, PPY and 
SST <100) distributed as: C1: 6; C2: 10; D1: 25; D2: 12 cells, with INS 107-
70790 and GCG 115-136500 RPKM. The ratio INS/GCG also varied: 0.004-
119 (C1), 0.12-471 (C2), 0.009-222 (D1), 0.003-2.20 (D2). It has not yet been 
possible to determine whether the GLP-1 receptor (GLP1R) is expressed in 
human alpha as well as beta cells, yet this is of great clinical interest. Just 19 of 
the 123 beta cells expressed detectable levels of GLP1R (C1: 6/42 cells, 0.03-
79.4 RPKM; C2: 7/50, 0.03-14.5; D1: 3/14, 0.04-70.9; D2: 3/17, 0.03-0.49), 
whereas no alpha cells expressed any detectable GLP1R.
Conclusion: We have for the first time analysed gene expression in single hu-
man islet cells. There is remarkable intercellular variability in INS and GCG 
expression that may reflect beta and alpha cell functional heterogeneity. In-
triguingly, the regulation of expression of these two genes is not absolute, 
with low expression of INS in alpha and GCG in beta cells. There were several 
“alpha-beta” cells in all preparations, possibly representing cells in transition 
from one type to another. GLP1R was expressed in some but not all human 
beta cells, but was not detectable in any of the alpha cells. Inability to detect 
GLP1R expression could in theory be due to inadequate sequencing depth 
but in any event indicates extremely low levels of mRNA in all alpha and 
many beta cells that may not translate to physiologically meaningful protein 
levels.
OP 06 Novel mechanism of  
glucose tolerance
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Brain natriuretic peptide prevents diet-induced obesity and glucose 
intolerance in mice
M. Coue, P.-M. Badin, I.K. Vila, K. Louche, M.-A. Marques, D. Langin,  
C. Moro;  
Institute of Metabolic and Cardiovascular Diseases, Inserm UMR1048, 
Toulouse, France.
Background and aims: Growing evidences indicate that natriuretic peptides 
(NPs) and downstream cyclic GMP-dependent signaling play an important 
role in the regulation of energy metabolism. Recent studies have highlighted 
relationships between reduced circulating NPs levels, obesity and the risk of 
type 2 diabetes (T2D). The present work aimed to demonstrate the patho-
physiological link between NPs deficiency and metabolic disturbances in dif-
ferent mouse models of obesity and T2D.
Materials and methods: We first measured natriuretic peptides receptor 
(NPRA and NPRC) protein expression by western blot in genetic obese/dia-
betic mice (db/db versus db/+). We next investigated the effect of continuous 
delivery of Brain-NP (BNP) via intraperitoneal osmotic mini-pumps for 4 
weeks in db/db and high fat diet (60% kcal)-fed mice. Metabolic parameters 
such as body weight, body composition, insulin and glucose tolerance were 
examined.
Results: NPRA/NPRC protein ratio (NPs biologically active receptor/clear-
ance receptor) was dramatically down-regulated in skeletal muscles, liver 
and white and brown adipose tissue in db/db mice compared to db/+ mice 
(p=0.0001). More interesting, chronic BNP infusion improved glycaemic 
control reflected by reduced HbA1c (-15%, p=0.01) in db/db mice, and pre-
vented body weight gain (-45%, p=0.004) and improved glucose tolerance 
(p=0.02) in HFD-fed mice compared to saline-treated mice. This better meta-
bolic profile was accompanied by increased palmitate oxidation in skeletal 
muscle (p=0.04) and reduced lipotoxicity reflected by reduced intramyocellu-
lar content of C18-diacylglycerols (-15%, p=0.08) and total ceramides (-17%, 
p<0.05).
Conclusion: Collectively, our data indicate that obesity is associated with a 
reduced biological activity of NPs in several metabolic organs such as skeletal 
muscles that may contribute to the development of T2D. Increasing plasma 
NPs levels improves glycaemic control and glucose tolerance in obese/dia-
betic mice. Some of these beneficial effects may be driven by improved lipid 
oxidative capacity and reduced lipotoxic lipid pressure in skeletal muscle.
Supported by: ANR-12-JSV1-0010-01 and Société Francophone du Diabète
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Insulin is dispensable for the glucose lowering action of leptin in mice 
with streptozotocin-induced diabetes and congenital insulin deficiency
U.H. Neumann, H.C. Denroche, M. Mojibian, T.J. Kieffer;  
Cellular and Physiological Sciences, University of British Columbia, 
Vancouver, Canada.
Background and aims: It is widely believed that insulin is the only hormone 
capable of normalizing the catabolic consequences of type 1 diabetes. Howev-
er, it has been shown that the hormone leptin can reverse hyperglycaemia in 
streptozotocin (STZ)-induced diabetes in the absence of insulin therapy. All 
previous reports of leptin treatment in insulin deficient rodents used chemi-
cal or immune mediated β-cell destruction, where insulin depletion is incom-
plete. Since leptin enhances insulin sensitivity, we sought to definitively de-
termine whether leptin can reverse hyperglycaemia independently of insulin.
Materials and methods: To determine the effect of insulin receptor antago-
nism on leptin action, STZ-treated mice were implanted with a pump deliv-
ering either vehicle or 20 µg/day leptin or an insulin pellet to control fasting 
blood glucose. Fasted mice were administered an i.p. injection of vehicle or 
25 nmol/kg of the insulin receptor antagonist S961 alone (day 5) or preced-
ing an oral glucose gavage (day 7), and subsequent glucose homeostasis was 
assessed. In addition, we tested whether leptin treatment in mice with con-
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genital insulin deficiency could extend lifespan and reverse hyperglycaemia. 
Ins1-/-Ins2-/- (InsKO) mice were maintained on twice daily insulin injections 
until 14 days of age then transplanted with ~100-150 islets into the anterior 
chamber of the eye. At ~10 weeks of age InsKO mice were treated daily with 
an i.p. injection of 10 µg/day PEG-ylated leptin or vehicle and vehicle treated 
Ins1-/-Ins2+/- (Het) littermates were used as controls. On day 4 of treatment 
the transplanted eye was enucleated to render the mice entirely insulin defi-
cient. Survival, body weight, and fed and fasting blood glucose were assessed.
Results: In STZ-treated mice both leptin and insulin treatment reduced fast-
ing blood glucose by day 2 compared to vehicle treated controls (22.6±0.7 
mM STZ-vehicle, 10.8±2.0 mM STZ-leptin, 12.5±2.0 mM STZ-insulin). In-
jection of S961 increased blood glucose in the insulin treated mice after 2 
hours (17.9±4.5 mM STZ-insulin + S961, 4.8±0.5 mM STZ-insulin + vehi-
cle, P<0.05) however this dramatic elevation was not observed in the leptin 
treated group (7.7±2.7 mM STZ-leptin + S961, 4.7±1.1 mM STZ-leptin + 
vehicle). Similarly, after an oral glucose load the difference in area under the 
curve was substantially larger in the insulin treated mice (3592±206 STZ-
insulin + S961, 737±92 STZ-insulin + vehicle, P<0.05) than the leptin treated 
mice (2530±354 STZ-leptin + S961, 2042±337 STZ-leptin + vehicle). In our 
complementary model the majority of vehicle treated InsKO mice reached 
humane endpoint in less than 24 hours after ceasing insulin treatment; how-
ever, leptin treatment in InsKO mice prolonged survival for up to 3 weeks. 
On day 11 of leptin treatment fed blood glucose levels were dramatically el-
evated in leptin treated InsKO mice compared to Het controls (>33.3 mM 
vs 10.5±0.7 mM) yet upon 6 hour fasting leptin treated InsKO mice reached 
dangerously low blood glucose levels compared to Het controls (2.2±0.1 mM 
vs 4.0±0.3 mM, P<0.05), and hyperglycaemia rapidly returned upon 1 hour 
of re-feeding.
Conclusion: Insulin receptor antagonism and congenital insulin deficiency 
do not prevent leptin-mediated normalization of fasting glycaemia or surviv-
al, suggesting that leptin can act independently of insulin to improve diabetic 
symptoms in type 1 diabetes.
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Importance of ceramide transporter CERT in the development  
of muscle insulin resistance
R. Mahfouz1, D. Berkeš2, F. Foufelle1, P. Ferré1, E. Hajduch1;  
1INSERM, Paris, France,  
2Department of Organic Chemistry, Bratislava, Slovakia.
Background and aims: Accumulation of fatty acids (FA) in muscle cells, a 
situation that can be observed in obesity, is accompanied by a decrease of 
insulin sensitivity. FA are metabolized into a lipid derivative called ceramide 
and studies show that accumulation of ceramide in cells plays a central role in 
the development of muscle insulin resistance. In physiological condition, cer-
amide is produced at the endoplasmic reticulum (ER), and transported from 
the ER to the Golgi, where it is converted to sphingomyelin. The ceramide 
transporter CERT has been identified as a key factor for the ER-to-Golgi traf-
ficking of ceramide. We tested the hypothesis that a reduction of the activity/
expression of CERT could contribute to the accumulation of ceramide in the 
ER and in the development of insulin resistance in muscle cells.
Materials and methods: We quantified expression of CERT in various insu-
lin resistance models (i) in vitro in C2C12 and human myotubes treated with 
palmitate and in diabetic patient myotubes and (ii) in vivo in muscle from 
ob/ob mice as well as mice fed a high fat diet. To figure out whether CERT 
plays an important role in maintaining insulin sensitivity in muscle cells, we 
inhibited its expression using siRNA or a CERT chemical inhibitor (HPA-12).
Results: CERT protein expression was decreased in all insulin resistance 
models. We demonstrated that the decrease in CERT expression observed in 
the presence of FA excess was not related to the activation of ER stress, action 
of ceramide produced from palmitate itself or degradation via the protea-
some, but through caspase cleavage. In addition, we also showed a protein 
kinase D dependent hyperphosphorylation on serine residue of CERT in 
response to palmitate, indicating a decrease of its activity. We further con-
firmed the involvement of a reduction in CERT expression on insulin sensi-
tivity in muscle cells after either artificially inhibiting CERT expression with 
a siRNA or inhibiting its activity with the HPA-12 inhibitor. In opposite, in-
hibition of caspase activity prevented ceramide-induced insulin resistance in 
muscle cells.
Conclusion: Altogether, these results demonstrate the importance of a nor-
mal traffic of ceramide from the ER to the Golgi to preserve muscle cell insu-
lin sensitivity and the importance of CERT expression in this process.
Supported by: the SFD
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Myeloid Sirt1 regulation macrophage infiltration and insulin sensitivity 
in mice fed a high-fat diet
S. Ka1, M. Song1, E. Bae2, B. Park1;  
1Department of Biochemistry, Chonbuk National University, Jeonju, 
2College of Pharmacy, Woosuk University, Wanju, Republic of Korea 
Background and aims: Inflammation is an important factor in the devel-
opment of insulin resistance. Sirt1, a class 3 histone/protein deacetylase, 
has anti-inflammatory functions. Myeloid-specific Sirt1 deletion promotes 
macrophage infiltration into insulin-sensitive organs and aggravates tissue 
inflammation. In this study, we investigated how Sirt1 regulates macrophage 
locomotion in response to metabolic stresses.
Materials and methods: Myeloid-specific Sirt1-deleted mice (mS1KO) and 
wild type littermates were fed a 60% calorie high-fat diet (HFD) for 16 weeks. 
Tissue inflammation and metabolic phenotypes were compared. Bone mar-
row macrophages from wild type or mS1KO mice were used in in vitro chem-
otaxis assays and macrophage polarization studies.
Results: Sirt1 deletion did not alter body weight gain or food intake. How-
ever, mS1KO mice fed a HFD exhibited impaired glucose tolerance with re-
duced insulin secretion and insulin sensitivity. Consistent with these results, 
mS1KO pancreatic islets displayed decreased mass with profound apoptotic 
cell damage and increased macrophage infiltration and tissue inflammation. 
Liver and adipose tissue from mS1KO mice also showed greater accumula-
tion of macrophages and tissue inflammation. In vitro results showed that 
myeloid Sirt1 deletion stimulated proinflammatory M1-like macrophage po-
larization of bone marrow macrophages and augmented the migration poten-
tial of macrophages toward chemoattractants. The latter effect was mediated 
by increased expression and activation of nuclear factor κB/focal adhesion 
kinase and mitogen-activated protein kinase pathways.
Conclusion: Taken together, our results suggested that myeloid Sirt1 is cru-
cial for macrophage migration and the development of HFD-induced inflam-
mation and metabolic derangements.
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The effects of obesity and insulin resistance on serum NMR metabolic 
profile during an oral glucose tolerance test: a twin study
J. Rämö1, S. Kaye1, L.H. Bogl2, N. Matikainen3, A. Hakkarainen4,  
J. Lundbom4, N. Lundbom4, A. Rissanen5, J. Kaprio2,6, K. Pietiläinen1,6;  
1Research Programs Unit, Diabetes and Obesity, University of Helsinki, 
2Department of Public Health, Hjelt Institute, University of Helsinki, 
3Department of Endocrinology, Helsinki University Central Hospital, 
4Helsinki Medical Imaging Center, University of Helsinki,  
5Department of Psychiatry, Helsinki University Central Hospital,  
6FIMM, Institute for Molecular Medicine, Helsinki, Finland.
Background and aims: Untargeted metabolic profiling has shown that obe-
sity and insulin resistance (IR) are associated with differences in the levels 
of many circulating metabolites. Notably, the levels of low molecular weight 
metabolites (LMWMs) and fatty acids predict future risk of diabetes in 
healthy individuals. Recent studies have also revealed significant metabo-
lomic changes in response to an oral glucose tolerance test (OGTT). Obesity 
and IR are associated with the magnitudes of these changes, but their relative 
importances are unknown. In this study, we measured a novel panel of me-
tabolites, including lipoprotein fractions, during an OGTT in healthy young 
twins discordant for BMI, to control for genetic effects and to compare the 
effects of acquired obesity and IR on the dynamic metabolic profile.
Materials and methods: 31 rare MZ twin pairs discordant for obesity (With-
in-pair BMI difference BMI >3kg/m2), along with 119 MZ and DZ control 
pairs, were identified from cohorts of 22-32-year-old Finnish twins. Their se-
rum was analyzed with Nuclear Magnetic Resonance (NMR) at 4 timepoints 
(0/30/60/120min) during an OGTT. Based on a 50 percentile cut point for 
the difference of HOMA index within the discordant pairs, the twins were di-
vided into two groups, indicating whether or not the heavier twins’ acquired 
obesity was accompanied by IR. This allowed analyses of metabolite profiles 
during the OGTT in unhealthy and healthy obese co-twins as compared with 
their lean twin pair members.
Results: Glucose ingestion resulted in a significant alteration in the levels of 
12 out of 51 measured lipoprotein subclasses, 7 out of 24 lipids and 17 out of 
21 LMWMs (Multiple-corrected P<0.05). There was a late fall in VLDL tri-
glyceride content, most evident in larger fractions (-0.14 SD units, P=8.5e-12). 
The diameter of VLDL particles decreased (-0.34 SD units, P= 6.2e-06) and 
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that of LDL particles increased (0.12 SD units, P=0.008). Cholesterol content 
in very large HDL particles decreased (-0.36 SD units, P=3.12e-6) but rose 
in medium-sized particles (0.19 SD units, P=0.016). Healthy obese MZ co-
twins (without IR) had lower HDL cholesterol levels throughout the OGTT, 
especially in large HDL and HDL2 (P<3.8e-04). In contrast, unhealthy obese 
co-twins (with IR) showed changes in 32 out of 96 metabolites (corrected 
P<0.05), including lipoproteins, fatty acids and LMWMs. These include three 
recently discovered risk markers for all-cause mortality: α-acid glycoprotein, 
citrate and VLDL size.
Conclusion: Ingestion of pure glucose results in considerable change in the 
lipoprotein, lipid and LMWM profiles. Some lipoprotein changes can be ex-
plained by increased hepatic synthesis, but others may be indicative of novel 
actions of insulin. Acquired obesity primarily affects HDL composition, 
whereas an accompanied insulin resistance results in widespread changes in 
the metabolic profile both in the fasting state and during a glucose challenge.
Supported by: AOF, NNF, HUHRF, DRF, FFCR
OP 07 GLP-1 analogues:  
clinical efficacy
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Efficacy and safety of liraglutide vs placebo when added to basal insulin 
analogues in subjects with type 2 diabetes (LIRA-ADD2BASAL):  
a randomised, placebo-controlled trial 
J. Lahtela1, A. Ahmann2, H. Rodbard3, J. Rosenstock4, L. de Loredo5,  
K. Tornøe6, A. Boopalan7, M. Nauck8;  
1Tampere University Hospital, Finland, 2Oregon Health & Science 
University, Portland, USA, 3Endocrine and Metabolic Consultants, 
Rockville, USA, 4Dallas Diabetes and Endocrine Center, Dallas, USA, 
5Hospital Privado Centro Médico de Córdoba S.A., Cordoba, Argentina, 
6Novo Nordisk A/S, Søborg, Denmark, 7Novo Nordisk, Bangalore, India, 
8Diabeteszentrum, Bad Lauterberg, Germany.
Background and aims: This trial aimed to establish the superior efficacy 
and acceptable safety of liraglutide (LIRA) vs. placebo (PLAC) added to pre-
existing basal insulin analogue ± metformin in subjects with inadequately 
controlled type 2 diabetes.
Materials and methods: Subjects with type 2 diabetes, age 18-80 years, BMI 
20-45 kg/m2, HbA1c 7.0-10.0% and on stable insulin analogue dose ≥20 U/
day ± stable metformin ≥1500 mg/day were eligible for participation. In a 
multi-centre, multi-national, double-blind, parallel-group design, subjects 
were randomised 1:1 to receive once daily LIRA 1.8 mg or PLAC added to 
pre-existing treatment for 26 weeks. Following randomisation, insulin adjust-
ments above the pre-trial dose were not allowed. The primary endpoint was 
the change in HbA1c from baseline to Week 26.
Results: A total of 451 subjects were randomised (226 LIRA; 225 PLAC). 
All subjects but 1 (LIRA, not exposed) were included in the analysis. Mean 
baseline characteristics were similar between the two groups (LIRA;PLAC): 
HbA1c 8.2;8.3%, BMI 32.3;32.2 kg/m2, diabetes duration 12.1 years and in-
sulin dose 48.3;45.9 U (geometric mean 40.5 U for both groups). After 26 
weeks of treatment, subjects taking LIRA had a greater decrease in HbA1c 
from baseline than PLAC, and more LIRA subjects reached HbA1c <7.0% 
and HbA1c ≤6.5% using a lower mean estimated daily dose of basal insulin 
analogue compared to PLAC (35.8 U vs. 40.0 U; see Table). Subjects taking 
LIRA also achieved greater decreases from baseline in fasting plasma glucose 
(FPG), incremental post-prandial self-measured plasma glucose (SMPG), 
body weight, systolic blood pressure and lipids. Nausea and vomiting oc-
curred more frequently with LIRA than PLAC (22.2% vs. 3.1% and 8.9% vs. 
0.9%, respectively). Minor hypoglycaemia (plasma glucose <3.1 mmol/L) oc-
curred in 18.2% and 12.4% of LIRA and PLAC subjects, respectively. No se-
vere hypoglycaemic events (requiring assistance of another person to actively 
administer resuscitative actions) were reported during this trial.
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Conclusion: The addition of LIRA to basal insulin analogues ± metformin 
significantly improved glycaemic control, which can be attributed to the ef-
fect of LIRA on both FPG and post-prandial glucose levels. Additionally, 
LIRA induced greater weight loss and a reduction in systolic blood pressure 
and selected lipids compared to PLAC. Typical gastrointestinal symptoms 
and minor hypoglycaemia were more frequent with LIRA than PLAC. No 
severe hypoglycaemic events were reported during this trial.
Clinical Trial Registration Number: NCT01617434
Supported by: Novo Nordisk
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Efficacy and safety of once weekly dulaglutide vs insulin glargine in 
combination with metformin and glimepiride in type 2 diabetes patients 
(AWARD-2)
F. Giorgino1, M. Benroubi2, J.-H. Sun3, A.G. Zimmermann4, V. Pechtner5;  
1Endocrinology & Metabolic Diseases, University of Bari, Italy, 
2Evangelismos-Polyclinic, Athens, Greece, 3Chang Gung Memorial Hospital, 
Taoyuan Hsien, Taiwan, 4Eli Lilly and Company, Indianapolis, USA,  
5Eli Lilly and Company, Neuilly-Sur-Seine Cedex, France.
Background and aims: This Phase 3, 78-week, parallel-arm, open-label 
(double-blinded to dulaglutide [DU] doses) study compared two doses of the 
once weekly GLP-1 receptor agonist DU with insulin glargine titrated to fast-
ing glucose target, in patients with type 2 diabetes inadequately controlled 
with maximally tolerated doses of metformin and glimepiride. Metformin 
and glimepiride were to be continued throughout the study.
Materials and methods: Patients (N = 807; mean baseline characteristics: 
age 57 years; duration of diabetes 9.1 years; HbA1c 8.1%; body weight 86.3 
kg; BMI 31.6 kg/m2) were randomised (1:1:1) to once weekly DU 1.5 mg, 
DU 0.75 mg, or once daily insulin glargine. The primary objective was to 
demonstrate DU 1.5 mg was noninferior (margin 0.4%) to insulin glargine 
for HbA1c change from baseline at 52 weeks. Additional analyses were carried 
out at 52 and 78 weeks.
Results: At 52 weeks, DU 1.5 mg was superior and DU 0.75 mg was nonin-
ferior to insulin glargine on HbA1c change from baseline. The mean insulin 
glargine dose was 29.4 U. Body weight decreased with both DU doses and 
increased with insulin glargine. Over the 52-week period, the mean rate of 
documented symptomatic hypoglycaemia (≤3.9 mmol/L) was 2.0, 2.0, and 
3.3 events/patient/year for DU 1.5 mg, DU 0.75 mg, and insulin glargine, re-
spectively. At 78 weeks, HbA1c, body weight, and hypoglycaemia results were 
similar to 52 weeks, and the mean insulin glargine dose was 31.4 U. Through 
78 weeks, four events of severe hypoglycaemia occurred: 2 in patients treated 
with DU 1.5 mg and 2 in patients treated with insulin glargine. Nausea and 
diarrhoea were more common with DU 1.5 mg (15.4% and 10.6%) and DU 
0.75 mg (7.7% and 9.2%) versus insulin glargine (1.5% and 5.7%) through 
78 weeks.
Conclusion: DU 1.5 mg demonstrated superior and DU 0.75 mg noninferior 
glycaemic control compared with insulin glargine, and this was associated 
with weight loss, reduced incidence of hypoglycaemia, and an acceptable 
safety profile.
Clinical Trial Registration Number: NCT01075282
Supported by: Eli Lilly and Company
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Liraglutide 3.0 mg for weight management in obese/overweight adults 
with type 2 diabetes: SCALE diabetes 56-week randomised, double-blind, 
placebo-controlled trial
M.J. Davies1, R. Bergenstal2, B. Bode3, R. Kushner4, A. Lewin5, T.V. Skjøth6, 
C.B. Jensen6, R. DeFronzo7;  
1University Hospitals of Leicester, UK, 2Park Nicollet Institute, St Louis Park, 
USA, 3Atlanta Diabetes Associates, USA, 4Northwestern University, Chicago, 
USA, 5National Research Institute, Los Angeles, USA, 6Novo Nordisk A/S, 
Søborg, Denmark, 7Texas Diabetes Institute, San Antonio, USA.
Background and aims: Liraglutide at doses up to 1.8 mg is approved for the 
treatment of T2D. This study investigated the efficacy and safety of liraglutide 
3.0 mg and 1.8 mg, as adjunct to diet and exercise, for weight management in 
obese/overweight adults with T2D.
Materials and methods: In this 56-week, randomised, double-blind, place-
bo-controlled trial, adults with T2D (on diet and exercise alone or with 1-3 
oral antidiabetic drugs [OADs], HbA1c 7-10%, BMI ≥27.0 kg/m2) were ran-
domised 2:1:1 to receive liraglutide 3.0 mg, 1.8 mg or placebo. All subjects 
received diet (500 kcal/day deficit) and exercise instruction.
Results: 846 individuals were randomised: age 54.9 (18.0-82.0) years, 50% 
male, BMI 37.1 (27.0-67.6) kg/m2, HbA1c 7.9% (6.4-10.3%), fasting plasma 
glucose (FPG) 8.8 (4.2-17.3) mmol/l, T2D for 7.3 (0.2-36.5) years, 11.5% on 
diet and exercise, 57.3% on metformin only, 31.2% on combination OADs. 
Liraglutide 3.0 mg and 1.8 mg were superior to placebo, and 3.0 mg was 
superior to 1.8 mg on mean and categorical weight loss at week 56 (Table). 
Liraglutide 3.0 mg also achieved superior glycaemic control vs. placebo and 
liraglutide 1.8 mg (change in HbA1c and FPG, proportion reaching HbA1c 
≤6.5%, and [vs. placebo only] postprandial plasma glucose [PG] increment; 
Table). The safety profiles with liraglutide 3.0 mg and 1.8 mg were similar, 
although gastrointestinal disorders were more frequent with 3.0 mg (65% of 
individuals) than 1.8 mg (56%) and placebo (39%). No cases of pancreatitis 
were reported during the trial. An increase in mean serum lipase activity was 
seen with liraglutide 1.8 mg and 3.0 mg; the increase was not dose-dependent 
and few individuals (7.7% and 9.8% on liraglutide 1.8 mg and 3.0 mg, respec-
tively, vs. 6.3% on placebo) had levels ≥3 times the upper normal range at any 
time during treatment. Rates of documented symptomatic hypoglycaemia 
(PG <3.9 mmol/l) were 0.87, 0.95 and 0.31 events per patient year for liraglu-
tide 3.0 mg, 1.8 mg and placebo, respectively; in all groups, hypoglycaemia 
rates were greater for subjects on a sulphonylurea (SU) compared with those 
not on SU. Eight severe hypoglycaemic events were reported (5 events in 3 
subjects [0.7%] with liraglutide 3.0 mg; 3 events in 2 subjects [1.0%] with lira-
glutide 1.8 mg); all subjects affected were receiving background SU therapy.
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Conclusion: Liraglutide 3.0 mg, as adjunct to diet and exercise, was effica-
cious and well-tolerated for weight management over 56 weeks in obese/
overweight individuals with T2D.
Clinical Trial Registration Number: NCT01272232
Supported by: Novo Nordisk
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Efficacy and safety of once weekly dulaglutide versus once daily 
liraglutide in type 2 diabetes (AWARD6) 
S. Tofe Povedano1, K.M. Dungan2, T. Forst3, J.G. González González4,  
C. Atisso5, W. Sealls5, J.L. Fahrbach5;  
1Endocrinologia, Clinica Juaneda, Palma de Mallorca, Spain, 2The Ohio 
State University, Columbus, USA, 3Profil Mainz GmbH & Co. KG, Mainz, 
Germany, 4Universidad Autόnoma de Nuevo Leόn, Monterrey, Mexico,  
5Eli Lilly and Company, Indianapolis, USA.
Background and aims: This Phase 3, randomised, open-label, parallel-arm 
26-week (wk) study compared the efficacy and safety of once weekly dula-
glutide (DU) 1.5 mg, a long-acting GLP-1 receptor agonist, with once daily 
liraglutide (LIRA) 1.8 mg in metformin-treated (≥1500 mg) patients with 
type 2 diabetes.
Materials and methods: Patients (N=599; mean baseline age, 57 years; 
HbA1c, 8.1 %; weight 94.1 kg) were randomised to DU 1.5 mg or LIRA 1.8 
mg in a 1:1 ratio. The primary objective was HbA1c change from baseline at 
26 wks tested for noninferiority (margin 0.4%); DU 1.5 mg vs LIRA 1.8 mg.
Results: DU 1.5 mg was noninferior to LIRA 1.8 mg at 26 wks as measured 
by HbA1c change from baseline (between-group HbA1c change -0.06; 95% 
CI [-0.19, 0.07]) (Table 1). While both groups experienced significant weight 
reduction, LIRA-treated patients demonstrated a 0.71 kg greater weight re-
duction than DU-treated patients (p=0.01). The most common treatment-
emergent gastrointestinal adverse events for DU 1.5 mg and LIRA 1.8 mg, 
respectively, were nausea (20.4%, 18.0%), diarrhoea (12.0%, 12.0%), dyspep-
sia (8.0%, 6.0%), and vomiting (7.0%, 8.3%). Patients who discontinued study 
and/or study drug due to gastrointestinal adverse events were similar (DU 
1.5 mg [3.0%], LIRA 1.8 mg [4.3%]). Rates of hypoglycaemia (≤3.9 mmol/L 
± symptoms) were 0.34 events/pt/yr (DU 1.5 mg) and 0.52 (LIRA 1.8 mg) 
events/pt/yr. No severe hypoglycaemia was reported.
Conclusion: Once weekly DU 1.5 mg demonstrated noninferior glycaemic 
control compared to once daily LIRA 1.8 mg with a similar safety and toler-
ability profile.
Clinical Trial Registration Number: NCT01624259
Supported by: Eli Lilly and Company
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Harmony 1 year 3 Results: albiglutide vs placebo in patients with type 2 
diabetes mellitus not controlled on pioglitazone (pio) ± metformin (met)
C.M. Perkins1, B.W. Bode2, M.W. Stewart3, D.T. Cirkel4, F. Yang3, C.R. 
Perry3, P.D. Ambery5;  
1PPD, Morrisville, 2Atlanta Diabetes Associates, 3GlaxoSmithKline, King of 
Prussia, USA, 4GlaxoSmithKline, Stevenage, 5MedImmune, Cambridge, UK.
Background and aims: This 3 year (y), randomized, double-blind, placebo 
(Pbo) controlled study evaluated efficacy & safety of once weekly GLP-1 re-
ceptor agonist albiglutide 30 mg vs Pbo in patients (pts) inadequately con-
trolled (A1c 53-85.8 mmol/mol [7-10%]) on Pio ± Met.
Materials and methods: Pts could continue if hyperglycaemic rescue was 
needed. Primary endpoint (PE) was A1c change from baseline at week 52.
Results: Baseline demographics were similar between groups; mean A1c 65 
mmol/mol (8.1%); age 55 y; 80% on Pio + Met. PE showed Albi superior to 
Pbo (treatment difference: -8.2 mmol/mol [−0.75%], P<0.0001). Glycaemic 
reduction with Albi was maintained for 3 y: fewer Albi pts required rescue 
compared to Pbo pts: 45% vs 72%; P<0.0001. In pts completing 3 y of treat-
ment, A1c reduction was durable to wk 156 without rescue (n=54/26 for 
Albi/Pbo: -9.5 mmol/mol [-0.87%] Albi, -5.5 mmol/mol [-0.50%] Pbo) and 
with rescue n=89/83, -9.8 mmol/mol [-0.90%] Albi, -3.0 mmol/mol [-0.27%] 
Pbo). FPG changes were similar to A1c. Change in weight at 3 y was -0.16kg 
Albi and 1.50kg Pbo. Through wk 156, adverse events (% pts) of nausea and 
vomiting were low and comparable between Albi/Pbo (12.0%/11.9% and 
5.3%/4.0%) while diarrhea was higher with Albi (14.7% vs 10.6%). Injection 
site reactions were higher for Albi (18.0%) vs Pbo (8.6%). Incidence of pre-
rescue documented symptomatic (≤3.88 mmol/L [70 mg/dL]) and severe hy-
poglycaemia was low: 3.3%/1.3% for Albi and 2.0%/0% for Pbo.
Conclusion: Albi combination therapy resulted in durable glycaemic im-
provement with good tolerability.
Clinical Trial Registration Number: NCT00849056
Supported by: Research funded by GSK
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Better glycaemic control and less weight gain with once weekly 
dulaglutide vs bedtime insulin glargine, both combined with thrice  
daily lispro, in type 2 diabetes (AWARD-4)
J. Jendle1, L. Blonde2, J. Rosenstock3, V. Woo4, J. Gross5, H. Jiang6,  
Z. Milicevic7;  
1Endocrine and Diabetes Center, University of Orebro, Sweden, 2Ochsner 
Medical Center, New Orleans, 3Dallas Diabetes and Endocrine Center, 
Dallas, USA, 4University of Manitoba, Winnipeg, Canada, 5Federal 
University of Rio Grande do Sul, Porto Alegre, Brazil, 6Eli Lilly and 
Company, Indianapolis, USA, 7Eli Lilly and Company, Vienna, Austria.
Background and aims: This 52 week, parallel-arm, open-label, phase 3 study 
compared two doses of the once weekly GLP-1 receptor agonist dulaglutide 
(DU) versus bedtime insulin glargine, all combined with pre-meal insulin 
lispro with or without metformin, in patients with type 2 diabetes mellitus 
inadequately controlled on conventional insulin therapy. Insulin glargine and 
insulin lispro were titrated to attempt to reach glycaemic targets.
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Materials and methods: Patients (N = 884; mean baseline characteristics: 
age 59.4 years; duration of diabetes 12.7 years; HbA1c 8.5%; body weight 91.1 
kg; BMI 32.5 kg/m2; total daily insulin dose 56 U) were randomised (1:1:1) 
to once weekly DU 1.5 mg, DU 0.75 mg, or bedtime insulin glargine titrated-
to-target. The primary objective was to compare the change in HbA1c from 
baseline of DU 1.5 mg with insulin glargine at 26 weeks for noninferiority 
(margin 0.4%) and if met, then superiority was tested.
Results: At 26 and 52 weeks, both DU doses were statistically superior to 
insulin glargine for HbA1c change from baseline. Insulin glargine was associ-
ated with greater fasting serum glucose reduction compared with both DU 
doses. The mean prandial insulin doses at 26 weeks were 93 U for DU 1.5 
mg, 97 U for DU 0.75 mg, and 68 U for insulin glargine. The insulin glargine 
dose was 65 U. Similar insulin doses were observed at 52 weeks. Body weight 
decreased with DU 1.5 mg and increased with DU 0.75 mg and insulin glar-
gine at 52 weeks. The rate of documented symptomatic hypoglycaemia (≤3.9 
mmol/L) at 52 weeks was 31.0, 35.0,and 39.9 events/patient/year for DU 1.5 
mg, DU 0.75 mg, and insulin glargine, respectively. The number of severe 
hypoglycaemia events was 11 for DU 1.5 mg, 15 for DU 0.75 mg, and 22 for 
insulin glargine. Nausea, diarrhoea, and vomiting were more common with 
DU 1.5 mg (25.8%, 16.6%, and 12.2%, respectively) and DU 0.75 mg (17.7%, 
15.7%, and 10.6%) versus insulin glargine (3.4%, 6.1%, and 1.7%).
Conclusion: DU compared to insulin glargine, both combined with insu-
lin lispro, resulted in better glycaemic control, less body weight gain, no in-
creased risk of hypoglycaemia, and more common reporting of gastrointes-
tinal adverse events. 
Clinical Trial Registration Number: NCT01191268
Supported by: Eli Lilly and Company
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Does diabetes affect the efficacy of dual antiplatelet therapy in patients 
with acute coronary syndromes?
M. Samos1, L. Duraj2, M. Fedor2, F. Kovar1, P. Galajda1, J. Fedorova3,  
J. Stasko1, T. Bolek1, M. Mokan1, P. Kubisz1, M. Mokan1;  
1Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 
2Department of Hematology and Blood Transfusion, Jessenius Faculty of 
Medicine in Martin, Comenius University in Bratislava, 3HemoMedika, 
Center of Thrombosis and Hemostasis, Martin, Slovakia.
Background and aims: Diabetes is a strong, independent risk factor of acute 
coronary syndromes (ACS). Diabetes aggravates the course of ACS and in-
creases the risk of its complications. Recently, there is growing amount of 
data about failure in antiplatelet response, which is specifically associated 
with insulin resistance and diabetes. This incomplete antiplatelet response 
may contribute to a worse prognosis of ACS in diabetic patients. The aim of 
this study was to clarify the impact of presence of diabetes on the efficacy of 
dual antiplatelet therapy given in standard doses in patients with ACS.
Materials and methods: 82 patients with ACS (53 men, 29 women, mean age 
65 years) were enrolled in this preliminary prospective observational study. 
Patients were treated with aspirin loading dose (400 mg) and ADP recep-
tor antagonist loading dose: in 62 patients clopidogrel (600 mg) and in 20 
patients prasugrel (60 mg) was used. 21 patients had diabetes. Coronary an-
giography and percutaneous coronary intervention of culprit coronary lesion 
was subsequently performed. Light transmission aggregometry (LTA) with 
specific inducers and VASP phosphorylation assessment was chosen for anti-
platelet therapy efficacy testing. Samples were taken after first maintance dose 
administration (sample 1) and on 30th day from loading dose administration 
(sample2).
Results: Mean LTA measured platelet reactivity was 32.7±18.9% in sample1 
and 28.4±14.4% in sample2 respectively. No significant difference in antiplate-
let response on ADP receptor antagonist (ADP-RA) between diabetic and 
non-diabetic patients was found (sample1: 30.7±19.8% versus 33.5±18.8%; 
sample2: 28.4±12.1% versus 28.4±15.7%). Totally 38 non-responders on 
ADP-RA were identified; ADP-RA unresponsiveness was not associated with 
the presence of diabetes. Prasugrel therapy generally showed better plate-
let inhibition than clopidogrel administration (sample1: 22.8±13.7± versus 
35.8±19.3%, p<0.01; sample2: 20.0±9.9% versus 33.1±14.6%, p<0.05).
Conclusion: ADP-RA therapy unresponsiveness was frequently (46.3%) 
identified in ACS patients undergoing coronary angiography. However, dia-
betes was not connected with higher platelet reactivity or higher prevalence 
of ADP-RA non-response in this study. Prasugrel showed significantly better 
platelet inhibition than clopidogrel and thus prasugrel therapy should be pre-
ferred not only in diabetic ACS patients. Laboratory monitoring of antiplate-
let therapy efficacy may help identify patients with inadequate antiplatelet 
response.
Supported by: APVV, CEPV II, SSC 2012-2015, YHS
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Impact of diabetes mellitus on long-term prognosis in patients with 
ischaemic heart failure: a report from the Swedish Heart Failure Registry 
(S-HFR)
A. Norhammar1, I. Johansson1, M. Edner1, P. Näsman2, U. Dahlström3,4,  
L. Rydén1;  
1Cardiology Unit, Department of medicine Solna, Karolinska Institutet, 
Stockholm, 2Centre for Safety Research, KTH Royal Institute of Technology, 
Stockholm, 3Division of Cardiovascular Medicine, Department of Medicine 
and Health Sciences, Linköping University, 4Department of Cardiology 
UHL, County Council of Östergötland, Linköping, Sweden.
Background and aims: Patients with diabetes are at increased risk of devel-
oping heart failure. In an everyday life setting, we investigated the impact of 
diabetes on long-term prognosis in patients with heart failure of ischemic 
origin.
Materials and methods: Patients clinically judged to have ischemic heart 
failure, of whom 50% were previously revascularised with (n=5265) and 
without (n=12 408) type 2 diabetes, included in the Swedish Heart Failure 
Registry (S-HFR) 2003-2011 were followed for mortality until 30 September 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 25
1 C
2011 (median 22.5 months). Differences in background characteristics were 
adjusted for in a logistic regression model.
Results: Patients with diabetes were younger (75 vs. 77 years) and more often 
had preserved renal function (>60 ml/min; 44 vs. 38%), however hyperten-
sion was more common in those with diabetes (59 vs. 45%). EF did not dif-
fer, 17% in both groups had an EF ≥50%, however those with diabetes had 
more of severe heart failure symptoms (NYHA III-IV; 53 vs. 46%). Among 
those with diabetes, 88% received beta-blockade, 61% ACE inhibitors, 67% 
Statins and 71% Aspirin. Kaplan-Meyer curves of mortality are presented in 
Figure 1. The unadjusted and adjusted* ORs (95% CI) for mortality were 1.32 
(1.24-1.41) and 1.71 (1.56-1.86). In those revascularised (50%), unadjusted 
and adjusted* ORs for mortality were 1.52 (1.39-1.67) and 1.63 (1.45-1.84).
Conclusion: Diabetes is an independent predictor of long-term 
mortality in patients with ischemic heart failure. Revascularisa-
tion did not abolish the impact of diabetes. The use of anti-ischem-
ic secondary preventive treatment seemed somewhat low consid-
ering all patients were classified to have ischemic heart disease 
* Adjusted for gender, age, duration of heart failure, weight, blood pressure, 
hypertension, atrial fibrillation, pulmonary disease, EF class, revascularisa-
tion, eGFR class, Hb class and pharmacological treatment. Figure 1. Kaplan 
Meyer-curve showing long-term survival by diabetes (DM) in patients with 
ischemic heart failure. Odds ratio (OR), *=adjusted
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Impact of diabetes mellitus on long-term prognosis in patients with 
preserved heart failure: a report from the Swedish Heart Failure Registry 
(S-HFR)
I. Johansson1, M. Edner1, L. Rydén1, P. Näsman2, U. Dahlström3,4,  
A. Norhammar1;  
1Cardiology Unit, Department of medicine, Karolinska Institutet, Karolinska 
University Hospital Solna, Stockholm, 2Centre for Safety Research, KTH 
Royal Institute of Technology, Stockholm, 3Division of Cardiovascular 
Medicine, Department of Medicine and Health Sciences, Linköping 
University, Linköping, 4Department of Cardiology UHL, County Council of 
Östergötland, Linköping, Sweden.
Background and aims: Patients with diabetes are at increased risk for de-
veloping heart failure. We investigated the impact of diabetes on long-term 
prognosis in patients with heart failure and preserved left ventricular func-
tion from an everyday life perspective.
Materials and methods: Patients with EF ≥50%, with (n=1658) and without 
(n=5047) type 2 diabetes included in the Swedish Heart Failure Registry (S-
HFR) 2003-2011 were followed for mortality until 30 September 2011 (me-
dian 22.5 months). Differences in background characteristics were adjusted 
for in a logistic regression model.
Results: Patients with diabetes were younger (76 vs. 78 years), more often 
had known ischemic heart disease (47 vs. 36%), hypertension (68 vs. 52%), 
and more often had preserved renal function (eGFR > 60ml/min, 45 vs. 38%). 
NYHA classes III and IV were somewhat more common in those with diabe-
tes (44 vs. 39%). Kaplan-Meyer curves for mortality are presented in Figure 
1. The unadjusted and adjusted* ORs (95% CI) for mortality were 1.02 (0.92-
1.15) and 1.39 (1.20-1.61).
Conclusion: Our data support that diabetes is an independent predictor of 
mortality in patients with heart failure and preserved left ventricular func-
tion. As much as 50% of patients with preserved left ventricular function had 
reported ischemic heart disease, which questions the concept of a pure dia-
betic cardiomyopathy. * Adjusted for gender, age, duration of heart failure, 
weight, blood pressure (systolic and diastolic), ischemic heart disease, hyper-
tension, atrial fibrillation, pulmonary disease, revascularisation, eGFR class, 
Hb class, ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor 
antagonists, diuretics, digitalis, nitrates, statins and antithrombotic agents. 
Figure: Kaplan-Meier curve showing survival by diabetes in patients with 
heart failure and preserved ventricular function. Odds ratio (OR), *=adjusted
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Methylglyoxal-induced endothelial dysfunction has a role in the 
development of heart failure in a mouse model of type 1 diabetes
B. Vulesevic1, B. McNeill1, F. Giacco2, M. Brownlee2, R. Milne3,  
E. Suuronen1;  
1Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Canada, 
2Diabetes Research Center, Albert Einstein College of Medicine,  
Bronx, USA, 3Diabetes and Atherosclerosis Laboratory, University of  
Ottawa Heart Institute, Canada.
Background and aims: Diabetes mellitus increases the risk of heart failure 
independent of coronary artery disease or hypertension. Endothelial dys-
function (ED) and inflammation, both common in diabetes, are partly caused 
by the accumulation of methylglyoxal (MG), the primary substrate of the en-
zyme glyoxalase 1 (GLO1). We have generated transgenic mice that carry the 
human GLO1 transgene under the control of the preproendothelin promoter. 
Using this mouse model we examined if the over-expression of GLO1 could 
reduce MG-induced ED and prevent the development of heart failure caused 
by streptozotocin (STZ)-induced hyperglycaemia.
Materials and methods: GLO1 transgenic mice and their wildtype (WT) lit-
termates were treated with STZ (WT-diabetic and GLO1-diabetic mice) or 
vehicle (WT-control and GLO1-control mice). GLO1 activity was measured 
in endothelial cells (ECs) and cardiomyocytes isolated from the hearts. Eight 
weeks after STZ treatment, blood serum levels of the ED markers E-selectin, 
ICAM and VCAM were determined by ELISA. Heart function was assessed 
using echocardiography. Protein expression of the receptor for advanced gly-
cation end products (RAGE) and neurogulin in the heart was determined by 
western blot. Apoptosis, detected by TUNEL assay, and capillary numbers, 
expressed by number of CD31+ cells were determined by immunohisto-
chemistry. QPCR for the Bcl-2 pro-survival gene was done on ECs collected 
from the digested hearts.
Results: Increased GLO1 activity was confirmed to be 5.6-fold greater in aor-
tic endothelial cells (ECs) of GLO1-mice compared to their WT littermates. 
Also, the over-expression and increased activity of GLO1 in the heart was 
restricted to ECs, and not observed in cardiomyocytes. Eight weeks post-STZ 
elevated serum levels of all 3 ED markers was observed in WT-diabetic mice 
compared to all other groups (E-selectin ≥1.3-fold, VCAM ≥1.1-fold, and 
ICAM ≥6.7-fold; p≤0.04). RAGE levels were significantly higher in hearts of 
WT-diabetic mice compared to all other groups (≥1.8-fold, p≤0.03). The WT-
diabetic group had lower left ventricular ejection fraction (EF; 43.6%) and 
fractional shortening (FS; 28.6%), compared to the other 3 groups (≥67.5% 
(EF) and ≥42.7% (FS); p≤0.01). The number of CD31+ ECs in WT-diabet-
ic hearts was reduced by 46% compared to both non-diabetic groups and 
GLO1-diabetic mice (p=0.03). Apoptotic cells were more numerous in the 
hearts of WT-diabetic mice (0.44% of cells), compared to non-diabetic WT 
(0.03%) and GLO1-diabetic mice (0.07%; p≤0.04). The reduced number of 
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ECs seen in WT-diabetic mice may also be involved in the 3-fold reduction 
of neurogulin, an EC-produced protein that supports cardiomyocyte survival 
(p=0.04). The improved survival of ECs in GLO1-diabetic mice may be re-
lated to the preserved mRNA levels of Bcl-2, which can be modified by MG. 
Bcl-2 was down-regulated 2-fold in WT-diabetic ECs compared to the other 
groups (p=0.04).
Conclusion: Taken together, these results suggest that increased GLO1 activ-
ity in ECs reduced ED, cell death and inflammation, and preserved cardiac 
function, despite high blood glucose levels.
Supported by: Heart and Stroke
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A relationship of asymptomatic coronary artery disease and type 2 
diabetes in acute ischaemic stroke patients; cerebral angiography  
and coronary angiography study
H. Kwon, J. Lim, J. Shin, J. Son, S. Lee, S. Kim, S. Yoo;  
Division of Endocrinology and Metabolism, Department of Internal 
Medicine, The Catholic University of Korea, Bucheon, Republic of Korea 
Background and aims: Stroke and coronary artery disease (CAD) share sim-
ilar atherosclerosis risk factors such as smoking, hypertension, dyslipidaemia, 
and diabetes. CAD is considered the leading cause of mortality and morbidity 
in patients with ischemic stroke. However, data about the prevalence of CAD 
in the patients with acute ischemic stroke remains limited. Furthermore, 
characteristics of CAD in patients with diabetes are asymptomatic onset and 
multiple vessels involvement. But it remains unclear whether the impact of 
diabetes on CAD is different in ischemic stroke. The aim of this study was 
to determine the relation of type 2 diabetes and acute ischemic stroke to the 
presence and extent of asymptomatic CAD by coronary angiography.
Materials and methods: Acute ischemic stroke patients without known CAD 
were enrolled between October 2008 and September 2013 in our hospital. 
Patients with high Framingham Risk Score (FRS; a 10 year-risk of coronary 
heart disease ≥20%) underwent cerebral angiography and coronary angiog-
raphy at the same time. We analyzed the coronary angiography and other 
classic atherosclerosis risk factors in 187 patients retrospectively. The patients 
were divided into diabetes group and non-diabetes group, and the data was 
assessed according to the following classifications: (1) presence of coronary 
artery stenosis, (2) presence of significant stenosis (≥50%), (3) presence of 
multiple coronary artery stenosis (≥ 2 vessels), and (4) presence of significant 
multiple coronary artery stenosis (≥ 2 vessels). We calculated the prevalence 
of CAD with 95% confidence intervals. All data was analyzed after adjusting 
classic atherosclerosis risk factors such as age, sex, hypertension and history 
of past stroke. P value <0.05 was considered to be statistically significant.
Results: Mean age was 64.5 ±10.9 years and 126 patients (67.4%) were male. 
59 patients (M:F 35:24) had type 2 diabetes, 128 patients (M:F 91:37) had no 
history of diabetes. A total of 129 patients (69%; 48 with diabetes, 81 without 
diabetes) had hypertension (p-value< 0.008). Past stroke history was shown 
in 12 patients with diabetes, 15 patients without diabetes (p-value 0.15). The 
prevalence of coronary artery stenosis was 93% (n=55) in the diabetes group, 
82% (n=105) in the non-diabetes group (p-value 0.08). 31 patients (52.5%) 
had significant stenosis in the diabetes group, 49 patients (38.2%) had it in the 
non-diabetes group (p-value 0.019). Multiple coronary artery stenosis was 
shown in 42 patients (71%) with diabetes, 72 patients (56%) without diabe-
tes (p-value 0.04). The prevalence of significant multiple stenosis was 28.8% 
(n=17) in the diabetes group, 20.3% (n=26) in the non-diabetes group (p-
value 0.019). In the diabetes group, the patients had high FRS (40.9% ±8.59) 
and had a tendency of both intracranial and extracranial stenosis in cerebral 
angiography (n=29). The characteristics of coronary artery stenosis did not 
seem to correlate with the severity or location of cerebral artery stenosis.
Conclusion: This study shows that type 2 diabetes with acute ischemic stroke 
was strongly associated with asymptomatic and severe coronary artery dis-
ease. We suggest that assertive evaluation about asymptomatic CAD might be 
considered in type 2 diabetic patients with acute ischemic stroke.
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Cardiac 82Rb-PET/CT reveals microvascular dysfunction in 
asymptomatic patients with type 2 diabetes 
T.W. Hansen1, B.J. von Scholten1, P. Hasbak2, T.E. Christensen2,  
A.A. Ghotbi2, A. Kjaer2, P. Rossing1,3;  
1Steno Diabetes Center, Gentofte, 2Department of Clinical Physiology, 
Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, 
Copenhagen, 3University of, Copenhagen and Aarhus, Denmark.
Background and aims: Type 2 diabetes (T2DM) is commonly accompanied 
by asymptomatic coronary artery disease. Coronary flow reserve (CFR; CFR= 
stress divided by rest coronary blood flow) and coronary calcium score (CCS) 
represent different aspects of atherosclerosis. CFR is a measure of vasodila-
tor function and reflects physiologic changes of vascular smooth muscle as 
well as endothelial function and detects coronary microvascular dysfunction. 
CCS is an anatomic measure of atherosclerosis. Cardiac 82Rb positron emis-
sion tomography (PET)/computed tomography (CT) allows for simultaneous 
non-invasive assessment of both CFR and CCS. We aimed 1) to gain informa-
tion of the prevalence and predictors of reduced CFR and high levels of CCS 
in T2DM patients free of overt CV disease (with or without albuminuria) 
while comparing them to non-diabetic controls, and 2) to determine the as-
sociation between CFR and CCS.
Materials and methods: Cross-sectional study of 60 T2DM patients strati-
fied by normoalbuminuria (<30mg/24h) (n=30; age (mean ± SD) 60.9±10.1 
years; 40% women) and albuminuria (≥30mg/24h) (n=30; 65.6 ± 4.8 years; 
27% women) randomly selected from our outpatient clinic and 30 non-dia-
betic controls (59.8 ± 9.9 years; 40% women) undergoing quantitative rest 
and pharmacologic stress 82Rb PET/CT and comprehensive assessment of 
other cardiovascular risk factors.
Results: In controls, normoalbuminuric, and albuminuric patients the CFR 
was 3.0 ± 0.8, 2.6 ± 0.8, and 2.0 ± 0.5 (P <0.001); frequency of reduced CFR 
(<2.5) was 16.7, 40.0, and 83.3% (P<0.001); and CCS (median [IQR]) was 0 
[0-81], 36 [1-325], and 370 [152-1025] (P<0.001), respectively. After adjust-
ment for age, gender, body mass index, 24-h systolic blood pressure, heart 
rate, cholesterol, and smoking the level of CFR remained significant higher 
(P=0.023) and CCS significant lower (P=0.020) in normoalbuminuric vs. 
albuminuric patients. Moreover, the frequency of reduced CFR remained 
significant lower in normoalbuminuric vs. albuminuric patients (P=0.001) 
and in controls vs. albuminuric patients (P<0.001). The univariate associa-
tion between CFR and CCS was significant in control subjects (R2 =0.23; 
P=0.007), but not in normoalbuminuric or albuminuric patients (R2 ≤0.10; 
P≥0.09). Multivariate linear regression analysis (including variables as above 
and additionally urine albumin excretion (UAER) and HbA1c) was used to 
identify variables independently associated with CFR and CCS in the three 
groups. Lower CFR was significantly related to higher CCS, UAER, age, heart 
rate, lower HbA1c, and male gender (P≤0.047) in albuminuric patients; and 
to female gender (P=0.024) in normoalbuminuric patients. Higher CCS was 
significantly related to lower CFR and UAER (P≤0.048) in albuminuric pa-
tients; and to higher HbA1c in controls (P=0.033).
Conclusion: In T2DM patients free of overt cardiovascular disease the 
prevalence of coronary microvascular dysfunction was high, especially with 
concomitant albuminuria. This was not explained by elevated CCS (“athero-
sclerosis”) and prospective studies are needed to show the prognostic sig-
nificance.
Supported by: H-3-2013-015
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Validation of model to estimate risk of progression of diabetic 
retinopathy using screening and clinical data in 3 cohorts
I.M. Stratton1, S.J. Aldington1, R. Cragg2, T. Gazis3, G. Russell4, C. Connor5, 
S. Sivaprasad6, P.H. Scanlon1;  
1Gloucestershire Diabetic Retinopathy Research Group, Gloucestershire 
Hospitals, Cheltenham, 2Nottingham Diabetic Retinopathy Service, 
Nottingham University Hospitals NHS Trust, 3Diabetes and Endocrinology, 
Nottingham University Hospitals NHS Trust, 4Health Intelligence Ltd, 
Sandbach, 5Diabetic Eye Screening Programme for Lambeth, Southwark 
and Lewisham, Guy’s and St Thomas NHS Foundation Trust, London, 
6Ophthalmology, King’s College Hospital NHS Foundation Trust,  
London, UK.
Background and aims: Diabetic retinopathy (DR) is a microvascular compli-
cation of diabetes and can lead to vision loss and blindness. Annual screening 
with 2 field digital retinal imaging after mydriasis is recommended by the UK 
National Screening Committee. This is becoming difficult to achieve because 
of resource limitations and increasing numbers of people with diabetes. We 
have developed and validated a model to estimate risk of progression to sight 
threatening DR (STDR) using results from one screening episode, HbA1c 
in twelve months prior to screening and duration of diabetes in one Eng-
lish screening programme. We know that grading protocols differ between 
screening programmes and rates of DR are affected by duration of diabe-
tes, ethnicity, deprivation and diabetic control. Here we examine the perfor-
mance of the model in 3 more English programmes.
Materials and methods: Data were obtained from 3 English screening pro-
grammes and data for a subset of patients was extracted from primary care. 
Patients free of STDR were categorised into those with No DR, those with 
mild non proliferative DR (NPDR) in one eye and those with Mild NPDR in 
both eyes. Using the risk estimation algorithm the risk score in those free of 
STDR was estimated and progression to STDR in quintiles of risk obtained.
Results: The programmes had 8632, 1084 and 1377 people respectively. There 
were few non White Caucasian patients in the first 2 programmes but 30% of 
those in the third programme were of African or Afro-Caribbean ethnicity. 
Duration of diabetes was 6 (2 to 11) (median (25th to 75th centile)), 2.9 (0.6 
to 6.2) and 3.6 ( 1.4 to 6.8) years, HbA1c 56 (48 to 66), 53 (46 to 53) and 52 (45 
to 64), follow-up from date of index screening 2.9 (2.1 to 3.0), 4.2 (2.2 to 5.3) 
and 4.1 (2.1 to 6.9) years. In the first programme the rate of progression to 
STDR in the lowest risk quintile was 4.1 per 1000 patient years and in highest 
quintile 74.0 per 1000 patient years, in the second programme 2.4 and 79.2 
respectively and in the third programme 1.7 and 49.0 respectively. Area un-
der the ROC curve was 0.82, 0.87. and 0.77.
Conclusion: Within each of the three programmes examined the risk model 
discriminates well between those with very low and with high risk of progres-
sion to STDR. The algorithm would be suitable for calculation of personal-
ised screening intervals. Further validation in other screening programmes 
and ethnic groups is required.
Supported by: NIHR HTA
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Importance of using HbA1c data of total diabetes duration in studying 
the relation between HbA1c value and retinopathy in type 1 diabetes
A. Hirose1, S. Kitano1, Y. Uchigata2;  
1Diabetic Ophthalmology, Diabetes Center,  
2Diabetes Center, Tokyo Women’s Medical University, Japan.
Background and aims: Glycaemic memory, in which past glycaemia could 
affect future retinopathy, is a potential issue in studying the relation between 
glycosylated haemoglobin A1c (HbA1c) value and retinopathy. We have 
demonstrated that mean HbA1c value (mA1C) covering total diabetes du-
ration, which might reflect the full effect of glycaemic memory, could sub-
stantially predict retinopathy, but the longer the period without HbA1c data 
following diabetes onset in simulation, the less accurate the prediction in our 
type 1 diabetes mellitus (T1DM) patients. To confirm the importance of us-
ing HbA1c data of total diabetes duration, we examined the relation between 
mA1C and retinopathy in the public data of DCCT/Epidemiology of Diabe-
tes Interventions and Complications (EDIC) studies.
Materials and methods: From the primary prevention cohort, we included 
T1DM patients with the shortest diabetes duration (≤12 months) at DCCT 
baseline. We developed a window which we named ‘half-yearly visit (HYV)’ 
to calculate the mA1C and to determine the retinopathy steps of the final Ear-
ly Treatment Diabetic Retinopathy Study (ETDRS) severity scale for persons. 
HbA1c values of an even number of quarterly visits (QVs) were applied to 
those of HYVs: for example, the value of QV00 (DCCT baseline) to HYV00, 
QV02 to HYV01, and so on during DCCT. During EDIC, HbA1c values were 
applied to the corresponding HYVs according to their data collection dates 
from DCCT baseline: for example, 11.75≤X<12.25 years’ data to HYV24 (12 
years from DCCT baseline). Missing values were estimated by time-weighted 
averaging from the preceding and the succeeding HYV values. An mA1C at 
HYV24 (mA1C(HYV24)) was calculated by supposing that each patient had 
a diabetes duration of one year at HYV00 and had kept the same HbA1c value 
of HYV00 during that period. We also calculated simulated mA1C(24HYV)
s by masking HbA1c data for periods of 3, 6, and 9 years following diabetes 
onset, that is, by averaging HbA1c values from HYV05, HYV11, and HYV17 
to HYV24, respectively. Retinopathy was defined as positive if a patient’s ET-
DRS step was 4 or above at HYV24; otherwise it was considered negative. The 
Wilcoxon rank-sum test was performed. Two-sided P<0.05 was considered 
significant.
Results: Of the 55 cases who fulfilled the criteria, 40 cases (mean duration 
10.9, range 8-12 months) had retinopathy data at HYV24. The 40 values of 
mA1C(HYV24) were well-divided between the retinopathy-positive and 
-negative groups (P=0.0003). In simulated cases of mA1C(HYV24) masked 
during periods of 3, 6, and 9 years, the differences seemed to lessen gradually 
between the two groups (P=0.0009, 0.0145 and 0.180, respectively), and there 
was no significant difference in mA1C(HYV24) masked for 9 years. It seemed 
that the longer the period without HbA1c data following onset in simulation, 
the less difference between the two groups. This could be explained by the 
difference of the transitions of the mean HbA1c values in each HYV between 
the two groups over the course of 12 DCCT/EDIC years. In the earlier period 
(HYV01 to HYV18), these values were higher in the retinopathy-positive 
group (P<0.05 for each HYV), but gradually decreased until there was no 
significant difference between groups (HYV19 to HYV24).
Conclusion: It is important to consider using HbA1c data of total diabetes 
duration in studying the relation between HbA1c value and retinopathy in 
T1DM patients.
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Genetic variation of SLC19A3 is associated to diabetic retinopathy and 
nephropathy in type 1 diabetes
I. Toppila1, M. Porta2, N. Sandholm1, C. Forsblom1,3, L. Borio2, E. Beltramo2, 
K. Hietala1,4, M. Hosseini5,6, A.D. Paterson5, P.-H. Groop1,3;  
1Folkhälsan Research Center, Helsinki, Finland, 2Dept Medical Sciences, 
University of Turin, Italy, 3Div Nephrology, Dept Medicine, Helsinki 
University Central Hospital, Finland, 4Dept Ophthalmology, Helsinki 
University Central Hospital, Finland, 5Inst Medical Science, University of 
Toronto, Canada, 6Program in Genetics and Genome Biology, Hospital for 
Sick Children, Toronto, Canada.
Background and aims: Diabetes duration, glycaemic control and blood 
pressure control are the strongest known risk factors for the development 
of diabetic microangiopathy. Thiamine (Vitamin B1) regulates intracellu-
lar glucose management at different levels and has been shown to correct 
high glucose-induced abnormalities by reducing reactive oxygen species 
production. Thiamine and its derivative benfotiamin have also been shown 
to reduce progression of retinopathy and nephropathy in animals with ex-
perimental diabetes. According to our hypothesis, patients who are prone to 
develop diabetic retinopathy and/or nephropathy may have impaired ability 
to achieve sufficiently high intracellular thiamine levels. This might be par-
ticularly damaging in insulin independent tissues that are more exposed to 
hyperglycaemia because they cannot regulate glucose inflow, such as retinal 
capillary endothelium and pericytes, the neuroretina, renal podocytes and 
mesangium. The aim of this study was to test if mutations in thiamine trans-
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porters hTHTR1 and hTHTR2 (coded by SLC19A2 and SLC19A3, respective-
ly), and/or their transcription factors Sp1 and Sp2 (coded by SP1 and SP2), 
are associated with proliferative diabetic retinopathy (PDR) and/or diabetic 
nephropathy (DN).
Materials and methods: The patient population consisted of 1568 cases with 
PDR, and 217 controls with no/mild retinopathy from the Finnish Diabetic 
Nephropathy (FinnDiane) Study. PDR was defined as ETDRS-score of 53 
or worse or scattered laser treatment. Controls were required to have mini-
mal diabetes duration of 20 years, maximal ETDRS-score of 30 on altered 
ETDRS-scale (corresponding to mild retinopathy) and no laser treatment. 
We chose HapMapII imputed SNPs from all four candidate genes and 10kb 
up and downstream of them (n=134). Logistic regression adjusted for sex, 
age, diabetes duration, and first ten genetic principal components were used 
for statistical calculations. In addition, association was tested between patient 
groups with different states of DN, and intersection of classes with both se-
vere PDR and end-stage renal disease (ESRD) (n=369) vs. normo/microalbu-
minuric controls with no/mild retinopathy (n=190).
Results: Two SNPs, rs12694743 and rs6713116, showed association with 
PDR (rs12694743: OR = 1.91, CI95% = 1.62-2.19, P = 1.02×10-5; rs6713116: 
OR = 2.34, CI95% = 1.97-2.72, P = 9.10×10-6). Both SNPs are located in in-
tronic regions of SLC19A3. The signal was also noticeable in DN phenotypes, 
but was not significant after correcting for multiple testing. In analysis of in-
tersection of extreme phenotypes the signal was amplified (rs12694743: OR 
= 3.18, CI95% = 2.76-3.60, P = 7.51×10-8; rs6713116: OR = 3.87, CI95% = 
3.33-4.40, P = 7.49×10-7) providing proof of association not only with retin-
opathy, but both retinopathy and nephropathy. Replications in DCCT/EDIC 
and WESRD cohorts are ongoing.
Conclusion: The results of this study suggest that mutations in SLC19A3 may 
increase susceptibility to PDR and especially to the combined phenotype of 
PDR and ESRD.
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Microvesicles derived from mesenchymal stem cells in diabetic-like 
conditions increase permeability in a retinal blood-barrier model
A. Mazzeo, E. Beltramo, T. Lopatina, M. Porta;  
Dept of Medical Sciences, University of Turin, Italy.
Background and aims: Loss of pericytes in the early phases of diabetic retin-
opathy may disrupt their stable association with endothelial cells (EC), lead-
ing to EC proliferation and, eventually, angiogenesis. Microvesicles (MV) are 
small membrane particles derived from different cells which contain biologi-
cally active proteins and RNA and are known to promote phenotypic changes 
in target cells. MV derived from injured cells may induce dedifferentiation of 
pericytes, allowing their detachment from vessels. We have previously shown 
that MV derived from mesenchymal stem cells (MSC), but not from EC, 
induce pericyte detachment and that diabetic-like conditions (high glucose 
and hypoxia) play a synergistic role in this destabilizing influence. This study 
aimed at evaluating whether MV produced by MSC in hypoxia and/or high 
glucose are able to influence the retinal blood-barrier permeability and to 
explore the possible role of matrix metalloproteases (MMP) in MV-induced 
pericyte detachment.
Materials and methods: We used commercially available human microvas-
cular EC (HMEC) and MSC from bone marrow, while human retinal peri-
cytes (HRP) had been previously immortalized in our laboratory. A blood-
barrier model was established by seeding HMEC on the porous membrane 
of transwell inserts, letting them adhere for 24 hrs and then adding HRP into 
the same insert. MV were extracted from the supernatant of MSC cultured 
in 1) physiological conditions (NG) 2) hypoxia (hypo) 3) high glucose (HG) 
4) HG + hypo. These MV were subsequently added to the confluent HMEC/
HRP co-cultures. After 2 hrs of MV exposure, FITC was added into the up-
per chamber and fluorescence measured in the lower chamber of the inserts 
after another 30’, 1, 2, 3, 4 and 24h. MMP expression in both MV and super-
natants of HRP exposed to MV was evaluated by Zimography. Results were 
confirmed by pre-treatment of MV with batimastat, a MMP inhibitor, and 
subsequent exposure of HRP to them.
Results: Permeability of EC-HRP co-cultures was increased by exposure to 
MSC-derived MV obtained in all the above conditions, the highest percent-
age increase occurring after 6h of total exposure to MV (2h pre-treatment + 
4h FITC): NG-MV 134.42 ± 17.46% (p<0.05 vs control without MV), HG-
MV 128.07 ± 3.81% (p=0.000), NG+hypo-MV 119.87 ± 15.56% (p<0.05), 
HG+hypo-MV 134.60 ± 15.21% (p<0.05). MSC-derived MV expressed 
MMP-2 and MMP-9. The same MMPs were expressed by HRP following 24h 
exposure to MV, MMP-2 to a much higher degree. HRP number decreased 
after 4h incubation with untreated MV (75.81 ± 9.22%, p<0.05 vs control), 
while pre-incubation of MV with batimastat completely reverted their effect 
on pericyte detachment.
Conclusion: MSC-derived MV may play a role in vessel destabilization and 
increase of retinal blood-barrier permeability during the early stages of retin-
opathy. This effect may be mediated by increased MMP expression.
Supported by: EFSD/Novartis 
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Fenofibrate prevents the disruption of the outer blood retina barrier 
through downregulation of NF-κΒ activity
M. Garcia-Ramírez1,2, C. Hernández1,2, X. Palomer2,3,  
M. Vázquez-Carrera2,3, R. Simó1,2;  
1Diabetes and Metabolism Research Unit, Vall d´Hebron Research Institute. 
Universitat Autònoma de Barcelona, 2Centro de Investigación Biomédica 
en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 
Madrid, 3Department of Pharmacology and Therapeutic Chemistry and 
Institute of Biomedicine of the University of Barcelona (IBUB), Faculty of 
Pharmacy, University of Barcelona, Spain.
Background and aims: There is clinical evidence that fenofibrate, a PPARα 
agonist, arrests the progression of diabetic macular edema (DME). However, 
the underlying mechanisms of this beneficial effect remain to be elucidated. 
We previously reported that fenofibric acid (FA), the active metabolite of 
fenofibrate, prevents the disorganization of tight junction proteins and the 
hyperpermeability provoked by the diabetic milieu in the retinal pigment 
epithelium (RPE). The aim of the present study was to evaluate whether this 
effect is mediated by inhibiting the proinflammatory transcription factor NF-
κΒ, as well as the expression of several proinflammatory cytokines involved 
in the pathogenesis of DME.
Materials and methods: Human RPE were cultured under standard condi-
tions and under conditions leading to the disruption of the monolayer {IL-1β 
(10 ng/mL)}. The effect of FA, QNZ (a NF-κΒ inhibitor), WY14643 (a PPARα 
agonist), and MK-886 (a PPARα antagonist) in preventing the disruption 
of the monolayer was determined by dextran permeability and immuno-
histochemistry analyses. The effect of FA on NF-κΒ activity was assessed by 
EMSA and by NF-kB/p65 nuclear translocation analyses. The expression of 
cytokines (IL-6, IL-8, MCP-1) was measured by RT-PCR.
Results: FA prevented RPE monolayer disruption, and the consequent hyper-
permeability induced by IL-1β, through inhibition of NF-κΒ activity. This ef-
fect was due to PPARα activation and was associated with a significant down-
regulation of the expression of proinflammatory cytokines.
Conclusion: Our findings suggest that the anti-inflammatory effects of FA 
through inhibition of NF-κΒ activity play a key role in the beneficial effect of 
fenofibrate for treating DME.
Supported by: G. Catalunya 2009-SGR-739, Spain Ministerio SAF-2012-30708 
and CIBERDEM
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Diabetic macular oedema and diabetic retinopathy: treatment outcomes 
with aflibercept do not depend on systemic diabetes control
C. Metzig, for the VIVID-DME/VISTA-DME Study Investigators;  
Bayer HealthCare Pharmaceuticals, Berlin, Germany.
Background and aims: Diabetic macular edema (DME) is a major cause of 
vision loss in patients with diabetic retinopathy resulting from poorly con-
trolled diabetes mellitus. Vascular endothelial growth factor plays a key role 
in the pathogenesis of DME.
Materials and methods: Two similarly designed Phase 3 trials, VIVID-DME 
and VISTA-DME, evaluated the efficacy and safety of intravitreal aflibercept 
(IVT-AFL) injection for the treatment of DME. These trials randomised 872 
patients with DME 1:1:1 to receive either IVT-AFL 2 mg every 4 weeks plus 
sham laser (2q4), IVT-AFL 2 mg every 8 weeks following 5 initial monthly 
doses plus sham laser (2q8), or macular laser photocoagulation plus sham 
IVT treatment. The primary efficacy endpoint was the mean change in best-
corrected visual acuity (BCVA) from baseline at Week 52. An exploratory 
analysis examined BCVA and diabetic retinopathy severity score (DRSS) out-
comes in subgroups of patients in these studies with baseline haemoglobin 
A1c (HbA1c) levels ≤8% and >8%.
Results: Overall, 65% and 35% of patients had HbA1c ≤8% and >8% at base-
line, respectively. The mean change in BCVA from baseline to Week 52 in 
the 2q4 and 2q8 groups versus the laser group was +12.3 and +10.9 versus 
+1.1 letters (P<0.0001) in patients with baseline HbA1c ≤8%, and +10.4 and 
+10.3 versus -0.3 letters (P<0.0001) in patients with baseline HbA1c >8%, 
respectively. The proportion of patients in the 2q4 and 2q8 groups versus 
the laser group with ≥2-step improvement in DRSS score at Week 52 was 
34.7% and 29.8% versus 12.3% (P≤0.0001) in patients with baseline HbA1c 
≤8%, and 33.3% and 26.5% versus 11.4% (P<0.03) in patients with baseline 
HbA1c >8%, respectively. The overall incidence of ocular and nonocular ad-
verse events and serious adverse events, including the Anti-Platelet Trialists’ 
Collaboration-defined arterial thromboembolic events, was similar across 
treatment groups in the total patient population.
Conclusion: These findings suggest that the improvements achieved with 
IVT-AFL 2q4 and 2q8 over laser in vision and DRSS were robust and similar 
in patients with variable systemic disease control at baseline (HbA1c levels 
≤8% and >8%). Furthermore, the DRSS improvement indicates an effect of 
IVT-AFL not only on DME, but also on the underlying diabetic retinopathy.
Clinical Trial Registration Number: NCT01331681, NCT01363440
OP 10 Entero-pancreatic 
endocrinology
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Severely disrupted islet function in mice with global deletion of GLP-1 
and GIP receptors
B. Omar, B. Ahrén;  
Clinical Sciences, Lund University, Sweden.
Background and aims: The incretin hormones glucagon like peptide 1 (GLP-
1) and glucose dependent insulinotropic polypeptide (GIP) potentiate glu-
cose stimulated insulin secretion. Both incretin hormones promote prolifera-
tion of pancreatic beta cells and prevent beta cell apoptosis. Incretins have 
also long been known to mediate the majority of insulin secretion during a 
meal or oral glucose challenge, however a role for the endogenous and basal 
incretin hormones in the long term regulation of beta cell function has not 
been characterized. We have therefore evaluated the role of basal incretin 
hormones on islet function by using mice with targeted disruption of both 
incretin hormone receptors.
Materials and methods: Double incretin receptor knockout (DIRKO) mice 
with global deletion of both the GLP-1 receptor and GIP receptor genes were 
used to study the effect of chronic deficiency of incretin action on beta cell 
function ex vivo and in vivo. Ex vivo insulin secretion was determined in stat-
ic batch incubations of isolated islets from wild type and DIRKO mice with 
stimulatory glucose concentrations (16 mmol/l). In vivo insulin secretion was 
assessed by hyperglycaemic clamp in which, after a 20 minute baseline, mice 
were given a bolus injection of glucose (0.35mg/kg) together with infusion of 
30% glucose in saline and clamped at a target blood glucose concentration 
of 16.7 mmol/l. The steady state period was between 20 and 105 minutes. 
Plasma insulin was measured at multiple time points throughout the steady 
state period. Insulin sensitivity from the clamp was determined by the insulin 
sensitivity index, calculated as the mean glucose infusion rate during the last 
40 minutes of the steady state period divided by the mean plasma insulin 
concentration for the same period.
Results: Insulin secretion was markedly lower in islets from DIRKO mice 
compared to islets from wild type mice during static incubation of isolated 
islets with stimulatory glucose (16.7 mmol/l) (395 ± 80 vs 1171 ± 131 pmol/
islet/hour, p = 0.02). In order to specifically study beta cell function in vivo, 
hyperglycaemic clamp experiments were performed in which mice were 
clamped with a target blood glucose concentration of 16.7 mmol/l. This tar-
get was closely achieved in both wild-type and DIRKO mice (17.0 ± 0.3 vs 
17.1 ± 0.2 mmol/l). Insulin secretion during the hyperglycaemic clamp was 
severely impaired in DIRKO mice compared to control mice. The acute insu-
lin response (AIR) was blunted in DIRKO mice compared to controls (199 ± 
88 vs 540 ± 108 pmol/l, p = 0.005). The total area under the insulin secretion 
curve (AUC) during the steady state period was significantly lower in DIRKO 
mice compared to wild-type mice (25.5 ± 1.8 vs 37.0 ± 3.6 nmol/l*min, p = 
0.008). Insulin sensitivity, derived from clamp data, was not significantly dif-
ferent between wild-type and DIRKO mice (0.029±0.004 vs 0.036±0.005 mg 
glucose/kg/min/pmol insulin).
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Conclusion: Normal islet function is heavily dependent on both incretin 
hormones, whereas insulin sensitivity is not altered by genetic deletion of 
incretin hormone receptors
Supported by: LU, ALF/Region Skane
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GIP contributes to the protection from hypoglycaemia of DPP-4 
inhibition
S. Malmgren, B. Ahrén;  
Department of Clinical Sciences in Lund, Lund University, Sweden.
Background and aims: Intensive glucose lowering therapies in type 2 diabe-
tes (T2D) increases the risk of hypoglycaemia, which is associated with acute 
unpleasant consequences and increased long-term risk for cardiovascular 
diseases. A major defence mechanism to combat hypoglycaemia is glucagon 
counter-regulation; however, this mechanism is commonly compromised in 
persons with T2D. Therefore, there is a need to develop glucose-lowering ther-
apies which sustain the endogenous counter-regulations to hypoglycaemia. 
Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the regulatory inac-
tivation of the incretin hormones and is a glucose-lowering therapy in T2D 
with low risk for hypoglycaemia. We have previously shown that DPP-4 in-
hibition protects from insulin-induced hypoglycaemia in mice. The aim of 
the present study is to examine the mechanisms behind this protection and 
particularly the contribution of the incretin hormone glucose-dependent in-
sulinotropic polypeptide (GIP).
Materials and methods: Anesthetized C57BL/6 mice were infused with 15 
mU/kg/min of insulin and variable rates of glucose to target a steady state 
blood glucose of 2.5 mmol/L between minute 60 and 90 of the hyperinsuline-
mic hypoglycaemic clamp. To explore GIP in the endogenous defence against 
hypoglycaemia we performed hypoglycaemic clamps in GIPR -/- mice lack-
ing the GIP receptor (n=5) or wild type (wt) counterparts (n=7). To further 
explore the effect of GIP, wt mice were infused with synthetic GIP (50 pmol/
kg/min) during hypoglycaemic clamp (n=10). Glucose, insulin and glucagon 
levels were measured and glucose infusion rate (GIR) during the clamp was 
estimated. To explore the relationship of GIP expression to glucagon secre-
tion in humans, correlation analysis was performed in islet gene expression 
and secretion data from isolated human islets from 69 individuals. Values are 
presented as Mean±S.E and statistical significance assessed using Student’s 
t-test.
Results: GIPR -/- mice required increased GIR compared to matched wt ani-
mals to maintain blood glucose during the clamp (6.0±1.2 vs. 2.5±0.5 mg/kg/
min; p=0.03). Both wt and GIPR -/- mice had similar increases in endpoint 
glucagon after 90 minutes of clamp compared to baseline levels (2.3±0.5-
fold and 1.7±0.2-fold respectably; p=0.50). During GIP infusion, GIR was 
reduced to 4.2±0.9 compared to 6.9±0.8 mg/kg/min (p=0.040) in animals in-
fused with saline. This was accompanied by a tendency towards an increase in 
glucagon levels at 60 (11.5±2.0 vs 6.2±1.9 pg/mL; p=0.072) and 90 (17.5±4.0 
vs 8.6±2.1 pg/mL; p=0.062) minutes of the clamp. Clamp insulin levels did 
not differ between groups. In human islets, there was a significant positive 
correlation between GIP expression and glucagon secretion at 1 mM of glu-
cose (rho=0.345, p=0.004).
Conclusion: GIPR -/- mice were more sensitive to insulin-induced hypogly-
caemia while GIP infusion during clamp protects wt mice from hypogly-
caemia. Results from glucagon measurements suggests that GIP infusion 
protects from hypoglycaemia via increases in glucagon levels but also raise 
the possibility of glucagon independent mechanisms further explaining the 
protective mechanism of DPP-4 inhibition. Furthermore, the positive GIP 
expression correlation with increased glucagon secretion in human islets sug-
gests relevance in humans. Based on these findings we conclude that GIP is 
a protective factor from hypoglycaemia and suggest that it contributes to the 
low risk of hypoglycaemia that can be seen with diabetes treatment using 
DPP-4 inhibition, thus elevating GIP levels.
Supported by: Kungl. Fysiografiska Sällskapet i Lund
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Altered enteroendocrine expression of glucagon and somatostatin  
in the gut of patients with type 2 diabetes compared with healthy 
matched controls
T. Jorsal1,2, N.A. Rhee1,2, J. Pedersen1,2, S.L. Jepsen2, C.D. Wahlgren2,  
B. Mortensen1,2, P. Vilman3,4, H. Hassan3,4, J.W. Hendel3,4, S.S. Poulsen2,  
J.J. Holst2, T. Vilsbøll1, F.K. Knop1,2;  
1Diabetes Research Division, Department of Medicine, Gentofte Hospital, 
University of Copenhagen, Hellerup, 2Department of Biomedical Sciences, 
Faculty of Health and Medical Sciences, University of Copenhagen, 3Unit 
of Enteroscopy, Department of Medicine, Gentofte Hospital, University of 
Copenhagen, Hellerup, 4Endoscopy Unit, Department of Gastroenterology, 
Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Background and aims: Hormones secreted from enteroendocrine cells in the 
gut play a crucial role in regulation of whole-body glucose metabolism. Lit-
tle is known about the distribution of these enteroendocrine cells along the 
intestinal tract, and it is currently unknown whether the distribution and/
or phenotype of these cells is altered in type 2 diabetes (T2D). We aimed to 
evaluate the expression of products from enteroendocrine D, K and L cells, 
respectively, along the entire length of the small and large intestines in pa-
tients with T2D and in healthy control subjects
Materials and methods: We used double-balloon enteroscopy (DBE) to col-
lect mucosal gut biopsies. The study involved 12 subjects diagnosed with T2D 
and 12 age and BMI-matched non-diabetic controls. All subjects underwent 
anterograde and retrograde DBE. Biopsies were collected from every 30 cm 
from pylorus to the ileocecal valve and from 6 specific sites in colon. RNA was 
isolated and analysed for expression of glucagon (GCG), peptide YY (PYY), 
glucose-dependent insulinotropic polypeptide (GIP) and somatostatin (SST).
Results: Expression of markers for L cells (GCG, PYY) and K cells (GIP) 
showed significantly higher expression of L cell genes in the distal versus the 
proximal parts of the small intestine and significantly higher expression of the 
K cell marker (GIP) in the proximal part of the small intestine. Expression of 
the L cell marker (GCG) was significantly higher in the proximal small intes-
tine in subjects with T2D compared to healthy controls (337% (113%;1002%) 
p<0.05). Expression of the D cell marker (SST) was significantly lower in the 
distal part of the small intestine in T2D subjects compared with healthy con-
trols (21% (5%;27%) p<0.05).
Conclusion: Using DBE, we managed to collect biopsies along the entire 
length of the small and large intestines in patients with T2D and non-diabetic 
controls. Our results confirm the notion of higher expression of the L cell 
marker (GCG) distally, and higher expression of the K cell product (GIP) 
proximally in the small intestine. Importantly, we also show that intestinal ex-
pression of GCG and SST is altered in patients with T2D, a finding that might 
prove relevant in future prevention and treatment of the disease.
Supported by: Novo Nordisk Foundation
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Role of the somatostatin in the control of glucagon secretion by glucose 
and KATP channel blockers
A. Gómez-Ruiz, K.B. Lai, H.-Y. Chae, N. Antoine, P. Gilon;  
Pôle d’endocrinologie, diabète et nutrition, Université catholique de 
Louvain, Brussels, Belgium.
Background and aims: It is well established that glucose (G) inhibits gluca-
gon release by pancreatic α-cells. However, it has sometimes been reported 
that high concentrations of the sugar (>20mM) stimulate glucagon secretion. 
The mechanisms behind these effects are unknown. In particular, it is still 
unclear whether G controls glucagon release by modulating KATP channels of 
α- and non-α-cells within the islet and whether somatostatin (SST) released 
from δ-cells is involved in the control of glucagon release. In the present 
study, we evaluated the role of SST in the control of glucagon secretion by 
various G concentrations and KATP channel blockers.
Materials and methods: The effects of G and KATP channel modulators were 
tested on glucagon secretion of control islets and islets devoid of SST parac-
rine influence (islets pre-treated for 24h with 200ng/ml pertussis toxin (PTX) 
or from Sst-/- mice). Unless indicated, all the experiments were performed in 
the presence of a 6 mM mixture of amino acids (Mix AA: 2 mM alanine, 2 
mM glutamine and 2 mM arginine).
Results: The role of SST in the control of glucagon secretion by various G 
concentrations (0, 1, 2, 5, 7, 15 and 30 mM) was first evaluated in incubation 
experiments with control islets or islets preincubated with PTX to remove the 
paracrine influence of SST. In control islets, G dose-dependently inhibited 
glucagon secretion with a maximal effect obtained already at around 7 mM. 
In PTX-pre-treated islets, glucagon secretion was larger at all G concentra-
tions and the dose-response relationship for G-regulated glucagon secretion 
displayed a U-shape reflecting an inhibition of glucagon release at G concen-
trations up to 7 mM followed by a progressive decrease of the glucagonostatic 
effect at G concentrations >7 mM. Perifusion experiments with islets of Sst+/+ 
or Sst-/- mice confirmed these results. Thus increasing the G concentration of 
the medium from 1 to 7 or 30 mM equally inhibited glucagon release of Sst+/+ 
islets, whereas G7 inhibited glucagon release more potently than G30 in Sst-
/- islets. Moreover, increasing the G concentration of the perifusion medium 
from 7 to 30 mM did not affect glucagon release of Sst+/+ islets, whereas it stim-
ulated that of Sst-/- islets. These results suggest that SST is partially involved in 
the glucagonostatic effect of high G concentrations. We next studied the role 
of SST in the control of glucagon secretion by tolbutamide (Tolb, a KATP chan-
nel blocker). In Sst+/+ islet, Tolb (500 μM) did not affect glucagon release at 
G1 and slightly stimulated it at G7. By contrast, in Sst-/- islets, Tolb stimulated 
glucagon secretion both at G1 and G7. The glucagonotropic effect of Tolb in 
Sst-/- islets was much more evident in the absence of Mix AA. It is unrelated to 
Epac2 activation because a much lower concentration of Tolb (10 μM) and gli-
clazide (10 μM) which do not activate Epac2 also strongly stimulated glucagon 
release of Sst-/- islets perifused with G7 and without MixAA.
Conclusion: G dose-dependently inhibits glucagon release of control islets. 
This inhibition is independent of SST for intermediate G concentrations (0-7 
mM) but starts to involve SST for G concentrations > 7 mM. Pharmacological 
closure of KATP channels controls glucagon secretion by two mechanisms: a 
direct stimulation of α-cells (independent of Epac2 activation and observed 
in the absence of SST influence) and an indirect inhibition via SST released 
from δ-cells.
Supported by: FRSM, ARC and EFSD/Boehringer-Ingelheim 
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Effect of glucose and free fatty acid on PC1/3-PC2 expression  
in pancreatic alpha cell
V. Sancho Bornez, R. Lupi, V. Garau, S. Del Guerra, D. Lucchesi,  
A. Dardano, L. Giusti, R. Miccoli, G. Penno, S. Del Prato;  
Endocrinology and Metabolism, University of Pisa, Italy.
Background and aims: An intra-islet incretin system has been recently sug-
gested to operate through modulation of the expression and activity of pro-
convertase 1/3 and 2 (PC1/3, PC2) in pancreatic alpha-cell accounting for 
local release of GLP-1. Little is known, whether this alpha-cell activity can 
be affected by the metabolic alterations occurring in type 2 diabetes, such as 
hyperglycaemia, hyperlipidemia or hyperglucagonemia.
Materials and methods: AlphaTC1/6 cells from a mice pancreatic cell line 
were incubated in the presence of two glucose (G) concentration (5.5 and 
16.7 mM) for 16 h with or without free fatty acid (FA, 2:1 palmitate:oleate, 
0.5 mM), IL6 (200 ng/ml) or glucagon (GLU: 250 pg/ml). GLP-1 secretion 
was measured by ELISA and expression of PC1/3 and PC2 by RT-PCR and 
western blot; cell viability was determined by MTT method, Reactive Oxygen 
Species generation (ROS) by H2DCFDA fluorescence and apoptosis by An-
nexin staining and Propidium Iodine (PI) fluorescence.
Results: Upon 16.7G incubation, GLP-1 secretion (total and active) was sig-
nificantly increased (130±9% and 158±19%, respectively, p<0.04, all vs 5.5G) 
in parallel with a significant increment in PC1/3 expression (RNA: 1.37±0.06 
folds and protein: 138±10%, both p<0.02), a slight increase in cell viability 
(116±3%, p<0.001) and ROS generation (118±5%, p<0.001) and by a decre-
ment in PC2 expression (RNA: 0.51±0.06, p<0.05) with no change in cell ap-
optosis (105±4%). No change was observed upon incubation with mannitol. 
When cells were incubated at 5.5G + FA, also an increment in GLP-1 secre-
tion (173±21%, p<0.02) and PC1/3 expression was observed (RNA: 2.07±0.24 
folds, p<0.006) together an increment in ROS generation (132±8%, p<0.002), 
a decrement in cell viability (47±2%, p<0.001), and a modest increment in 
apoptosis (Annexin: 115±5%, p<0.03; PI: 109±5%). When incubated with 
16.7G + FA, the increment in GLP-1 secretion was reduced to basal (107±6% 
vs. 5.5G), accompanied by an increment in apoptosis (Annexin: 152±11%, 
p<0.001; PI: 142±9%, p<0.001) and ROS generation (139±9%, p<0.001). This 
was also observed with IL6 (GLP-1 secretion: 5.5G + IL6: 156±12% vs. 16.7G 
+ IL6: 111±25%; PC1/3: 5.5G + IL6: 2.78±1.04 vs 16.7G + IL6: 6.56±1.37), but 
in this case, no modification in ROS generation or apoptosis was observed 
when compared to 16.7G. The presence of GLU did not modify any of the 
parameters studied.
Conclusion: These data suggest that under hyperglycaemic, hyperlipidaemic 
or inflammatory conditions, alpha cells can increase expression PC1/3 and 
activate GLP-1 secretion, which may contribute protecting both alpha and 
beta-cells from glucose and lipotoxicity, while this effect seems to be lost in 
the presence of both pathophysiological conditions.
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Gp130 receptor signalling mediates alpha cell dysfunction in a rodent 
model of type 2 diabetes
S.Z.W. Chow1, M. Speck1, P. Yoganathan1, D. Nackiewicz1, A. Hansen2,  
M. Ladefoged2, B. Rabe3, S. Rose-John3, P.J. Voshol4, F.C. Lynn1,  
P.L. Herrera5, W. Muller6, H. Ellingsgaard7, J.A. Ehses1;  
1Surgery, University of British Columbia, Vancouver, Canada,  
2Novo Nordisk, Malov, Denmark, 3University of Kiel, Germany,  
4University of Cambridge, UK, 5University of Geneva, Switzerland, 
6University of Manchester, UK, 7University of Copenhagen, Denmark.
Background and aims: Dysregulated glucagon secretion accompanies islet 
inflammation in type 2 diabetes. We recently discovered that IL-6 stimulates 
glucagon secretion from human and rodent islets. IL-6 family cytokines re-
quire the gp130 receptor to signal. In this study we elucidated the effects of α 
cell gp130 receptor signaling on glycaemic control in type 2 diabetes.
Materials and methods: IL6 family cytokines were analyzed in islets in two 
rodent models of T2D. Gp130 receptor signalling was assessed in primary α 
cells. Furthermore, α cell specific gp130 knock out (αgp130KO) mice were 
generated and subjected to streptozotocin (STZ) alone, high fat diet (HFD) 
alone, and STZ plus HFD to study how α cell dysfunction contributes to gly-
caemic control. Glucose tolerance tests, insulin tolerance tests, and hyperin-
sulinemic-euglycemic clamps were performed to assess α cell function, β cell 
function, and insulin sensitivity.
Results: IL-6 family cytokines were elevated in islets in rodent models of 
this disease. Gp130 receptor activation induced STAT3 phosphorylation in 
primary α cells and stimulated glucagon secretion. αgp130KO mice showed 
no differences in glycaemic control, α cell function or α cell mass. However, 
when subjected to STZ alone αgp130KO mice showed improved glucose tol-
erance. Further, when subjected to STZ plus HFD to induce islet inflamma-
tion and pathophysiology modelling type 2 diabetes, αgp130KO mice had re-
duced fasting glycaemia, improved glucose tolerance, reduced fasting insulin, 
and improved α cell function despite decreased fasting GLP-1 levels. Hyper-
insulinemic-euglycemic clamps revealed no differences in insulin sensitivity.
Conclusion: We conclude that during T2D, activation of α cell gp130 recep-
tor signaling causes impaired α cell function, promoting hyperglycaemia. 
Despite decreased systemic GLP-1 levels in αgp130KO mice (likely due to 
receptor deletion in L cells), activation of α cell gp130 receptor signalling in a 
setting of reduced β cell mass and HFD-induced insulin resistance had detri-
mental effects on normal α cell function and glycaemic control. Antagonism 
of α cell gp130 receptor signaling may be useful for the treatment of T2D.
Supported by: CFRI, UBC, CIHR, CDA, UBC Transplantation Training Program
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Trajectories of glycaemic traits in south Asians and whites before 
diabetes diagnosis: a longitudinal analysis from the Whitehall II study
A.G. Tabák1,2, E.J. Brunner2, D.R. Witte3, K. Faerch4, D. Vistisen4,  
S. Ikehara5, M. Kivimaki2, A. Hulmán6;  
11st Department of Medicine, Semmelweis University, Faculty of Medicine, 
Budapest, Hungary, 2Department of Epidemiology and Public Health, 
University College London, UK, 3Centre de Recherche Public de la Santé, 
Strassen, Luxembourg, 4Steno Diabetes Center, Gentofte, Denmark,  
5Osaka University, Japan, 6University of Szeged, Hungary.
Background and aims: An increased risk of type 2 diabetes among south 
Asians compared to whites is well established. Most of the literature suggests 
that this is related to lower insulin sensitivity among south Asians however 
the role of insulin secretion is rarely assessed. Therefore, we aimed to inves-
tigate ethnic differences in trajectories of fasting (FPG) and 2-h post-load 
plasma glucose (2hPG), log-transformed homeostasis model assessment in-
sulin sensitivity (HOMA-S) and secretion (HOMA-B) prior to the diagnosis 
of type 2 diabetes.
Materials and methods: We analysed trajectories of glycaemic traits before 
the diagnosis of diabetes by fitting mixed-effects models to longitudinal data 
(with up to 4 repeat measures within individuals) from 101 south Asian and 
764 white participants of the Whitehall II study, who developed type 2 diabe-
tes during follow-up between 1992 and 2009.
Results: South Asians had an almost 4 times increased risk of incident di-
abetes compared to whites during follow-up (26.4% vs 10.2%, P < 0.001). 
According to age and sex-adjusted mixed-effects models, South Asians had 
a faster increasing FPG trajectory before diagnosis (slope difference: 0.34 
mmol/l per decade, 95% CI: 0.05, 0.64; P = 0.022) and 0.36 mmol/l (95% CI: 
0.10, 0.63; P = 0.007) higher FPG levels at diagnosis than whites. There were 
no differences in 2hPG trajectories between the two ethnic groups. South 
Asians had significantly lower HOMA-S already 15 years before diagnosis 
and the difference increased even further until diagnosis (difference at di-
agnosis: 0.30, 95% CI: 0.14, 0.46; P < 0.001). HOMA-B trajectories had dif-
ferent quadratic characteristics (P = 0.04 for ethnicity x time2 interaction). 
It increased in both ethnicities until 7 years before diagnosis however the 
increase was faster in whites, while it followed a similar decreasing trajectory 
thereafter until diagnosis. Differences in FPG and HOMA-B trajectories were 
robust to adjustment for measures of obesity and lifestyle measures.
Conclusion: Insulin sensitivity falls more rapidly among south Asians than 
whites. In contrast to whites, who could increase insulin secretion up to 7 
years before diagnosis, this compensatory mechanism is can be hardly seen in 
south Asians, hence a more rapidly increasing FPG trajectory develops prior 
to the diagnosis of diabetes. These findings extend our prior observation of 
inadequate β-cell compensation with aging in healthy south Asians.
Supported by: MRC, NHLBI, BHF, NIA
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Food sources of fat may clarify the earlier inconsistent role of dietary fat 
intake for incidence of type 2 diabetes
U. Ericson1, S. Hellstrand1, L. Brunkwall1, E. Sonestedt1, P. Wallström2,  
B. Gullberg2, E. Wirfält2, M. Orho-Melander1;  
1Department of Clinical sciences in Malmö, Diabetes and Cardiovascular 
disease, Genetic Epidemiology, Lund University Diabetes Center (LUDC), 
2Department of Clinical sciences in Malmö, Nutrition Epidemiology,  
Lund University, Malmö, Sweden.
Background and aims: Dietary fats could affect glucose metabolism and in-
sulin sensitivity and may thereby have a crucial role in the development of 
type 2 diabetes (T2D). Studies have indicated that replacing saturated fat with 
monounsaturated and polyunsaturated fats might be favorable in the preven-
tion of T2D. In line with this, plant sources of fat have been suggested to be 
a better choice compared with animal sources. Indeed, high intakes of red 
meat and meat products show positive associations with risk of T2D. Never-
theless, several epidemiological studies have indicated that a high intake of 
dairy products may be protective. Subsequently, the importance of dietary fat 
content and food sources of fat remains to be clarified. Our aim was to exam-
ine intakes of main dietary fat sources, classified according to fat content, in 
relation to incident T2D.
Materials and methods: In total 26 930 individuals (60% women), 45 -74 
years, from the population-based Malmö Diet and Cancer cohort, were 
included. Dietary data was collected with a modified diet history method. 
During 14 years follow-up, 2860 incident T2D cases were identified. Cox 
proportional hazards regression model was used to estimate hazard ratios 
(HR) of diabetes incidence in quintiles of energy adjusted dietary intakes. 
The multivariate model included adjustments for age, sex, season, diet assess-
ment method version, total energy intake, BMI, leisure time physical activity, 
smoking, alcohol consumption and education.
Results: High intake of high-fat dairy products was associated with lower in-
cidence of T2D (HR for the highest (median=8 portions/day) compared with 
the lowest (median=1 portion/day) intake quintile: 0.77; 95% CI: 0.68-0.87; P 
for trend <0.001). Concerning intakes of specific high-fat dairy foods, cream 
and high-fat fermented milk were inversely associated with risk of T2D 
(P<0.01). High intake of low-fat dairy products was associated with increased 
risk (P for trend=0.01), but this association disappeared after additional ad-
justment for protein intake (P for trend=0.37). High intakes of meat and meat 
products were, regardless of fat content associated with increased risk (HR: 
1.09; CI: 0.97-1.24; P for trend=0.04 and HR: 1.25; 95% CI: 1.11-1.41; P for 
trend <0.001, for high- and low-fat meat respectively)(median intakes in the 
highest quintiles=90, 80 g/day).
Conclusion: Our observations may contribute to clarifying previous find-
ings regarding dietary fats and their food sources in relation to T2D. The de-
creased risk at high intakes of high-fat dairy products, but not of low-fat dairy 
products, indicate that dairy fat, at least partly, explains observed protective 
associations between dairy intake and T2D. Meat intake was associated with 
increased risk independently of fat content.
Supported by: Swedish Research Council, Novo Nordisk Foundation, Swedish 
Diabetes Foundation
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Movement during sedentary time is associated with metabolic outcomes
J.D. van der Berg1, H. Bosma1, P. Caserotti2, G. Eiriksdottir3,  
N.Y. Arnardottir3,4, R.J. Brychta5, K.Y. Chen5, T. Sveinsson4, E. Johannsson6,  
L.J. Launer7, V. Gudnason3,8, P.V. Jonsson9,10, C.D.A. Stehouwer11,  
T.B. Harris7, A. Koster1;  
1Social Medicine/CAPHRI School for Public Health and Primary Care, 
Maastricht University, Netherlands, 2Institute of Sports Science and Clinical 
Biomechanics, University of Southern Denmark, Odense, Denmark, 
3Icelandic Heart Association, Kopavogur, 4Research Center of Movement 
Science, University of Iceland, Reykjavik, Iceland, 5Diabetes Endocrinology 
and Obesity Branch, National Institute of Diabetes and Digestive and 
Kidney Diseases, Bethesda, USA, 6Center for Sport and Health Sciences, 
Iceland University of Education, Laugarvatn, Iceland, 7Laboratory of 
Epidemiology and Population Sciences, Intramural Research Program, 
National Institute on Aging, Bethesda, USA, 8University of Iceland, 9Faculty 
of Medicine, University of Iceland, 10Department of Geriatrics, Landspitali 
National University Hospital, Reykjavik, Iceland, 11Department of Internal 
Medicine/Cardiovascular Research Institute Maastricht (CARIM), 
Maastricht University Medical Centre, Netherlands.
Background and aims: Studies have shown that more sedentary time is as-
sociated with adverse health effects including metabolic syndrome, type 2 
diabetes, cardiovascular diseases, and increased mortality risk. Next to total 
amount of sedentary time other aspects of sedentary behaviour, such as the 
pattern in which sedentary time is accumulated, have been associated with 
health outcomes. During sedentary time the degree of movement of the up-
per body can differ between individuals and this could be another relevant 
aspect of sedentary behaviour. Whether movement during sedentary time 
is meaningful for health outcomes is not clear and therefore this study aims 
to examine the association between movement during sedentary time and 
metabolic outcomes.
Materials and methods: 631 participants (aged 73-98 years) of the AGESII-
Reykjavik Study wore a triaxial accelerometer (ActiGraph GT3X) for 7 con-
secutive days. Movement during sedentary time was defined as any activity 
in the anteroposterior and/or mediolateral axes with an intensity ≥100 counts 
per minute (cpm), during sedentary time (<100 cpm in the vertical axis). 
Metabolic outcomes included body mass index (BMI), waist circumference 
(WC), levels of HDL-cholesterol (HDL), triglycerides (TG), fasting glucose 
(FG) and C-reactive protein (CRP).
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 33
1 C
Results: Linear regression analysis showed that compared with those who 
had the most minutes with movements during sedentary time, participants 
with fewer movement minutes (quartiles 3, 2, 1) had a higher BMI (B= 1.43; 
B= 1.97; B= 3.38; all p<0.05) and an up to 8.3 cm larger WC (B= 4.66; B= 
5.25; B= 8.30; all p<0.05) after adjusting for demographic and health factors, 
sedentary time, and MVPA. Fewer movement minutes were also associated 
with lower levels of HDL (Q3 B= -0.11; Q1 B= -0.13; all p<0.05) and higher 
TG levels (B= 1.10; B= 1.09; B= 1.10; all p<0.05, back transformed from log 
scale), but not with FG and CRP.
Conclusion: Movement during sedentary time was associated with meta-
bolic outcomes; an up to 3.4 kg/m2 higher BMI and 8.3 cm larger WC was 
seen in participants with less movement minutes. These findings suggest that 
movement during sedentary time could be a relevant aspect of sedentary be-
haviour.
Supported by: NIH contract N01-AG-12100 NIA Intramural Research Program
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Association of restrictive ventilatory dysfunction with development of 
prediabetes and type 2 diabetes in Koreans 
C.-H. Kim1, E.-H. Kim2, S.-J. Bae2, H.-K. Kim2;  
1Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, 
Kyeonggi-do, 2Health Promotion Center, Asan Medical Center, Seoul, 
Republic of Korea 
Background and aims: Accumulating evidence have suggested that reduced 
lung function, especially restrictive pattern, is associated with insulin resist-
ance and type 2 diabetes. However, the causal direction between reduced 
lung function and type 2 diabetes remains unclear and there is a paucity of 
longitudinal studies in Asian populations. We investigated whether restric-
tive ventilatory dysfunction is a predictor for development of prediabetes and 
type 2 diabetes in Koreans.
Materials and methods: We analyzed the clinical and laboratory data of 
17,144 Korean adults (age 20-79 years, 37.8% women) who underwent rou-
tine medical check-ups in 2008 (baseline) and again in 2012-13 (follow up) 
with a median 4.9-year (range 3.0-5.9 years) interval. Patients who had dia-
betes at baseline were excluded. Results of spirometry were categorized into 
three groups; normal (FEV1/FVC ≥0.70, FVC ≥80% predicted), obstructive 
ventilatory dysfunction (OVD; FEV1/FVC <0.70), and restrictive ventilatory 
dysfunction (RVD; FVC <80% predicted, FEV1/FVC ≥0.70). At baseline, 
1518 subjects (9.4%) had RVD and 770 (4.8%) had OVD. Prediabetes was 
defined as fasting plasma glucose 5.6-6.9 mmol/l or HbA1c 39-46 mmol/mol 
[5.7-6.4%].
Results: Subjects with RVD had higher age, body mass index (BMI), waist 
circumference, systolic and diastolic blood pressure, and fasting glucose level 
at baseline compared to those with normal ventilatory function. Among the 
16,195 participants who did not have diabetes at baseline, a total of 640 sub-
jects (4.0%) developed type 2 diabetes during the follow-up period. Com-
pared to subjects with normal ventilatory function, the subjects with RVD 
had a higher incidence of type 2 diabetes (3.7% vs. 6.3%, P<0.001) but sub-
jects with OVD did not (3.7% vs. 4.8%, P=0.119). On multiple logistic re-
gression analysis, the OR of type 2 diabetes in subjects with RVD was sig-
nificantly increased (1.47 [1.16-1.87], P=0.001) after adjusting for age, sex, 
exercise, drinking, smoking, and blood pressure. However, further adjust-
ment for BMI, waist circumference, and baseline glucose level attenuated 
the OR to become insignificant (1.17 [0.90-1.52], P=0.251). Since subjects 
with RVD already had higher prevalence of prediabetes at baseline, we con-
fined the analysis to subjects with normal fasting glucose and HbA1c levels 
at baseline. Among those 9461 participants, a total of 2288 subjects (24.2%) 
developed prediabetes and 37 (0.4%) developed type 2 diabetes during the 
follow-up. The OR of progression to prediabetes or diabetes in subjects with 
RVD was 1.30 (1.12-1.51, P=0.001) after controlling age, sex, exercise, drink-
ing, smoking, and blood pressure. The OR remained significantly increased 
after further adjustment for BMI, waist circumference, and baseline glucose 
level (1.26 [1.07-1.47], P=0.004).
Conclusion: Our results indicate that restrictive, but not obstructive, ventila-
tory dysfunction is independently associated with development of prediabe-
tes and may precede the development of type 2 diabetes.
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Lifestyle factors and genetic predisposition to obesity in people from 
Pakistan: the PROMIS study
S. Ahmad1, W. Zhao2, F. Renstrom1, A. Rasheed3, D. Rader2, P.W. Franks1,4,  
J. Danesh5, D. Saleheen2,3;  
1Genetic and Molecular Epidemiology (GAME) Unit, Department of 
Clinical Sciences Malmö, Lund University, Malmö, Sweden, 2Genetic and 
Molecular Epidemiology (GAME) Unit, Department of Clinical Sciences, 
Malmö, Sweden, Perelman School of Medicine at the University of 
Pennsylvania, Philadelphia, USA, 3Center for Non-Communicable Diseases 
Pakistan, Karachi, Pakistan, 4Department of Nutrition, Harvard School of 
Public Health, Boston, USA, 5Department of Public Health and Primary 
Care, University of Cambridge, UK.
Background and aims: Most complex trait genetics studies have focused 
on populations of European ancestry. However, conducting such studies in 
South Asians is important because their lifestyles are becoming increasingly 
westernized, their genetic architecture is somewhat distinct from Europe-
ans’, and the burden of complex diseases is growing rapidly. In 14,786 adults 
(N=7,354 with myocardial infarction (MI)) from the Pakistan Risk of Myo-
cardial Infarction Study (PROMIS) we tested if: a) 31 loci, established in Eu-
ropeans to predispose to higher BMI, also do so in Pakistanis, and b) physical 
activity, smoking and cooking oil type modify the effects of these loci.
Materials and methods: A genetic risk score (GRS) comprised of 31 BMI-
susceptibility loci was calculated by summing the BMI-associated alleles 
at each variant. Physical activity, smoking, and cooking oil type were as-
sessed using self-administered questionnaires. Generalized linear models 
and logistic regression were used to examine associations and interactions 
(SNP*lifestyle factor), with BMI as the outcome. Analyses were adjusted for 
age, age2, sex, MI (yes/no), and population substructure.
Results: In the total sample, each additional GRS risk allele was positively 
associated with BMI (0.07 (SE= 0.1) kg/m2/risk allele; P<0.0001). In inter-
action analyses, physical activity modified the effect of the GRS on BMI in 
the total sample (Pinteraction = 0.009); the BMI-raising allele was associated 
with 0.11 (SE= 0.02) kg/m2 higher BMI in inactivity participants (P<0.0001), 
whereas the GRS effect in moderately and in very physically active partici-
pants was 0.07 (SE= 0.01; P<0.0001), and 0.02 (SE= 0.03; P= 0.59) kg/m2 per 
allele respectively. Although the interaction effect estimates were essentially 
the same in cases and controls as in the full sample, the tests of interaction 
were not statistically significant by case/control strata (Pinteraction= 0.07 and 
0.08 respectively), possibly because of the smaller sample sizes (Fig. 1). In 
individual SNP analyses, the rs2815752 NEGR1 variant modified the associa-
tion of physical activity with BMI in the total sample (Pinteraction = 0.002), and 
in controls (Pinteraction= 0.035) and cases (Pinteraction = 0.035) separately.
Conclusion: Physical activity may modify the genetic predisposition to obe-
sity in Pakistanis, the latter observation being consistent with earlier reports 
in European ancestry populations.
Supported by: FIC, NHLBI, NINDS, WT,BHF, BUPA, DiaDexus, MRC, HLF, 
SSMF,LU , Novo NDK, VR
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Effect of lifestyle modification on the prevention of type 2 diabetes 
and impaired glucose tolerance in a young healthy urban South Asian 
population
J. Karalliedde1, M. Wijesuriya2, L. Vasantharajah2, M. Gulliford3,  
G. Viberti1, L. Gnudi3;  
1Diabetes, King’s College London, UK, 2Diabetes, Diabetes Association of 
Sri Lanka, Colombo, Sri Lanka, 3King’s College London, UK.
Background and aims: There is an increasing incidence of type 2 diabetes 
mellitus (T2DM) and related cardiovascular disease (CVD) in young South 
Asian subjects. Several studies have confirmed that lifestyle modification 
(LSM) is very effective in preventing T2DM in older subjects with impaired 
glucose tolerance (IGT). The effect of LSM on the prevention of cardio-meta-
bolic disease in young healthy urban South Asian subjects is unknown.
Materials and methods: A randomised controlled clinical trial to compare 
an intensive 3-monthly LSM (I-LSM) with a less-intensive 12 monthly LSM 
(LI-LSM) for a primary composite cardio-metabolic endpoint of new onset 
T2DM, IGT, impaired fasting glycaemia, hypertension, initiation of lipid low-
ering therapy and cardio-renal disease in subjects aged 5 to 40 years with 
at least 2 of the following risk factors: raised body mass index, raised waist 
circumference (WC), first degree family history of T2DM and physical inac-
tivity. A cluster sampling strategy was used to select a representative sample 
of healthy at risk subjects with two or more of the above risk factors. We ran-
domised 4606 subjects of whom 3,685 (48% males) qualified for analyses. The 
study was performed at a single centre in Colombo, Sri Lanka between 2010 
to 2013. Intervention: Each subject received LSM advice aimed at reducing 
weight, improving diet and increasing physical activity 3 monthly (I-LSM) or 
12 monthly (LI-LSM) for 4 years.
Results: There were no significant baseline differences in anthropometric, 
clinical and demographic measures between groups [I-LSM (n=1807, mean 
± SD age, 22.4±10 yrs.) and LI-LSM (n=1878 age, 22.4±9.8 yrs]. The cumula-
tive incidence of the primary end point after 4 years was n=270 in I-LSM vs. 
n=302 in LI-LSM, a 9% (95% CI 1.0% to 16%) relative risk reduction (RRR), 
which was independent of baseline age, gender, p=0.02. Similarly there was 
a significant 26% RRR (95% CI 2% to 44%) in new onset T2DM p=0.04, and 
18% RRR (95% CI 7% to 28%) in new onset IGT p=0.002. I-LSM did not sig-
nificantly reduce the other components of the primary composite endpoint.
Conclusion: Our results demonstrate for the first time that in a young healthy 
but at risk South Asian population intensive LSM significantly reduces the 
development of T2DM, IGT and a composite endpoint of cardio-metabolic 
disease. These results highlight the importance of intervening early with life-
style modification to prevent and reduce the burden of T2DM in young at 
risk subjects.
Clinical Trial Registration Number: SLCTR/2008/World Health Organization 
(WHO)
Supported by: BRIDGES grant from IDF and National Diabetes Centre Sri 
Lanka
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Exogenous and endogenous hydrogen sulfide protects the cardiomyocyte 
cell line H9c2 from methylglyoxal-mediated damage
T. Ghela1, J.G. Mabley2;  
1Brighton and Sussex Medical School,  
2School of Pharmacy & Biomolecular Sciences, University of Brighton, UK.
Background and aims: Methylglyoxal (MGO), a glycolysis derived reactive 
dicarbonyl compound, has been implicated as a meditator of diabetic car-
diovascular complications. MGO has already been shown to cause endothe-
lial cell dysfunction as well as cardiomyocyte contractile dysfunction via in-
creased cellular oxidative stress. Hydrogen sulfide is a gaseous transmitter 
found in the vasculature and synthesised from the amino acid L-cysteine. 
Hydrogen sulfide has been demonstrated to have a protective role in the vas-
culature acting as a vasodilator and protecting cells from increased oxida-
tive stress. Hydrogen sulfide has already been shown to protect endothelial 
cells from MGO-mediated damage. The aim of this study is to investigate 
whether hydrogen sulfide generated exogenously by a chemical donor or 
endogenously from L-cysteine is also able to protect cardiomyocytes from 
MGO-mediated dysfunction.
Materials and methods: The cardiomyocyte cell line H9c2 was exposed to 
increasing concentrations of MGO (0.1-1 mM) for 24h prior to measuring 
cell viability and apoptosis. In a second series of experiments H9c2 cells were 
exposed to MGO 0.6 and 0.8 mM in combination with 0.25 or 0.5 mM so-
dium hydrogen sulfide or L-cysteine. Cell viability was determined using the 
MTT assay and cell death by propidium iodide/Hoechst staining. Endoplas-
mic Reticulum (ER) stress by Western blotting for CHOP.
Results: Methylglyoxal dose-dependently reduced H9c2 cell viability. MGO 
0.6 and 0.8 mM reduced cell viability to 55±3% and 47±2% respectively, sodi-
um hydrogen sulfide protected against this loss of cell viability with 0.25 mM 
returning viability to 65±5% and 57±4% and 0.5 mM returning viability to 
70±4% and 63±3% respectively (p<0.05 vs. MGO alone). Similarly L-cysteine 
also protected against the MGO-mediated loss of cell viability with 0.25 mM 
returning viability to 79±5% and 61±3% and 0.5 mM returning viability to 
106±5% and 92±3% respectively (p<0.05 vs MGO alone). To determine if this 
protection by L-cysteine was mediated by endogenous synthesis of hydrogen 
sulfide we used an inhibitor of the synthesizing enzyme cystathionine-gam-
ma-lyase, DL-proparglycine (PAG) 10 mM, pretreating the cells for 2h prior 
to treatment with MGO and L-cysteine. In the absence of PAG 0.25 and 0.5 
mM L-cysteine protected against MGO 0.8 mM; increasing viability by 9±2% 
and 49±2% respectively but following PAG pretreatment this protection was 
reduced to -0.7±0.4% and 27±2% (p<0.05). MGO was found to increase ap-
optosis levels in H9c2 cells by a mechanism independent of ER stress. MGO 
also increases H9c2 cell necrosis levels. Again both sodium hydrogen sulfide 
and L-cysteine protected against this MGO-mediated increase in apoptosis 
and necrosis.
Conclusion: Hydrogen sulfide generated either directly from a chemical 
donor or indirectly from the endogenous substrate L-cysteine provided sig-
nificant protection against MGO-mediated decrease in H9c2 cell viability 
and increased necrosis and apoptosis. This data suggests that not only will 
hydrogen sulfide protect endothelial cells but will also directly protect car-
diomyocytes from methylglyoxal-mediated damage. These data suggest that 
hydrogen sulfide donors or therapies designed to increase endogenous pro-
duction of hydrogen sulfide may be useful in reducing diabetic cardiovascu-
lar complications.
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Metabolic modelling of methylglyoxal formation, metabolism and AGE 
formation in vascular endothelial cells in model hyperglycaemia in vitro
P.J. Thornalley, Z. Irshad, M. Xue, N. Rabbani;  
Warwick Medical School, Division of Metabolic and Vascular Health, 
University of Warwick, Coventry, UK.
Background and aims: Methylglyoxal (MG) is a reactive dicarbonyl, glucose-
derived metabolite and precursor of quantitatively major advanced glycation 
endproducts (AGEs). Increased MG-derived AGEs in vascular endothelial 
cells likely contributes to endothelial cell dysfunction and the development 
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of vascular complications of diabetes. Glyoxalase1 (Glo1) and glyoxalase 2 
(Glo2) of the cytoplasmic glyoxalase system metabolises MG and prevents 
AGE formation. The aim of this investigation was to produce a mathematical 
model of MG concentration and related AGE formation in human vascular 
endothelial cells in vitro from experimental measurements of glucose metab-
olism and activities of Glo1 and Glo2 in normal glucose concentration and 
also high glucose concentration to model hyperglycaemia. The model is then 
validated by experimental measurement of cellular MG and AGEs Exposure 
to increased AGEs may thereby by predicted for a given level of hyperglycae-
mia and the level of pharmacological induction of Glo1 induction required to 
prevent increased AGEs predicted.
Materials and methods: Human microvascular endothelial HMEC-1 cells 
were incubated in MCDB131 media with 10% serum containing low glu-
cose or high Glucose (5 mM, LG and 30 mM, HG, respectively) for 6 days 
at 37°C. Similar experiments were performed with human aortic endothelial 
cells (HAECs) in primary culture with 5 mM or 20 mM glucose. Rate of glu-
cose consumption, activities of Glo1 and glyoxalase 2, cellular and medium 
concentrations of MG, flux of MG (measured as the surrogate accumulation 
of D-lactate), D-lactate metabolism and cell protein content and flux of the 
major MG-derived AGE, hydroimidazolone MG-H1 were determined. Single 
and two compartment models of MG metabolism by the glyoxalase system 
and AGE formation were constructed using the COPASI programme.
Results: Incubation of HMEC-1 cells in HG produced a progressive decrease 
in Glo1 activity of 31% after 6 days. The rate of glucose metabolism was in-
creased 70% and the flux of formation of MG was increased 66%. A math-
ematical model taking into account flux of MG formation, reversible binding 
of MG to GSH and protein thiols, metabolism by Glo1 and rate of MG glyca-
tion predicted an increase in cellular MG concentration and related AGEs in 
HG 0f 134%. Experimental validation produced similar results: increased in 
MG content of cells (pmol/106 cells) of 114% (LG, 2.08 ± 1.15; HG, 4.76 ± 
0.38, P<0.02) and increased flux of formation of the major MG-derived AGE, 
MG-H1, of 102% in HG (P<0.05). Similar effects were found for HAECs. This 
can be corrected by a 3-fold induction of Glo1 expression which is achieved 
by small molecule Glo1 inducers.
Conclusion: MG-derived AGE formation in human vascular endothelial cells 
in vitro are increased in model hyperglycaemia by synergistic effects of in-
creased formation of MG from increased anaerobic glycolysis and decreased 
metabolism of MG by decreased Glo1 activity. Correction of increased MG 
and AGE formation in hyperglycaemia is likely within the pharmacological 
capability of Glo1 inducers currently under investigation.
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Intracellular accumulation of methylglyoxal alters the collagen 
expression profile of L6 myoblasts
B. Goldstein, Y. Mattern, D. Tschoepe, B. Stratmann;  
Diabetes Center, Heart und Diabetes Center NRW, Bad Oeynhausen, 
Germany.
Background and aims: We have previously shown that down-regulation of 
the Methylglyoxal (MG) detoxifying glyoxalase system by siRNA mediated 
knockdown of (GLO1) results in impaired endocytosis of the transmembrane 
GLUT4 transporter leading to a prolonged and exaggerated cellular glucose 
influx. The consequences of this finding were analysed with special focus on 
the expression of extracellular matrix components in ratL6 myoblasts stably 
overexpressing the GLUT4 transporter.
Materials and methods: Detection of proteins and mRNA expression levels 
were carried out by western blot and quantitative real time PCR (qRTPCR) 
analysis following intracellular accumulation of MG by siRNA mediated 
knockdown of Glo1 under hyperglycaemic conditions. MRNA levels and 
protein levels were determined 72 hrs after knockdown of Glo1. Normo- and 
hyperglycaemic controls were prepared following the same incubation time.
Results: The fibrillous collagens-1, -3, and -5 were significantly up-regulated 
on the mRNA-level (p<0.0005 vs. scrambled control), the increase in col-
lagen-1 expression was also demonstrated on the protein level (p<0.05 vs. 
scrambled control), whereas for collagen-5 the increased expression was not 
detected on the protein level. For collagen-4 an increased mRNA expression 
was already detected following hyperglycaemia (p<0.05 vs. normoglycae-
mia), which was more pronounced following Glo1 knockdown (p<0.0005 
vs. scrambled control). Regarding regulators of extracellular matrix turnover 
MMP-9 was significantly up-regulated (p<0.001 vs. scrambled control) on 
mRNA level, but not on protein level. A reduced expression of the cross-link-
ing enzyme PLOD2 (p<0.0005 vs. scrambled control) and a slightly but non-
significantly increased LEPREL2 were detected on protein level. DPSYL2, 
which is of influence in cytoskeletal remodeling, is up-regulated on mRNA 
and protein level (p<0.0005 vs. scrambled control, p<0.05 vs. hyperglycae-
mia, respectively).
Conclusion: The results of this experimental research further elucidate the 
effect of exaggerated glucose influx after MG induced prolonged GLUT4 
presence in the cell membrane on the cytoskeleton and extracellular matrix. 
The impact of expression of fibrillous and basal lamina associated collagens 
may account for the observations commonly detected in myofibrosis.
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Synergistic hepatotoxic effects with a combination of methylglyoxal and 
palmitic acid
T.L. Walter1, J.G. Mabley2;  
1Brighton and Sussex Medical School, 2School of Pharmacy & Biomolecular 
Sciences, University of Brighton, Brighton, UK.
Background and aims: Methylglyoxal (MGO), a glycolysis derived reactive 
dicarbonyl compound, has been implicated as a central mediator of diabetic 
complications. Recently diabetes has been found to be an independent risk 
factor for development of liver disease including non-alcoholic fatty liver dis-
ease (NAFLD). Hepatocyte exposure to MGO or the saturated fatty acid, pal-
mitic acid (PA) results in a loss of cell viability, increase in apoptosis and in-
creased inflammation as demonstrated by IL-8 release. The aim of this study 
was therefore to determine if a combination of methylglyoxal and palmitic 
acid can synergistically damage hepatocytes and increase inflammation.
Materials and methods: The human hepatocyte cell line, HepG2, was ex-
posed to MGO (0.6 mM) in combination with PA (3 or 10 µM) for 24h. Cell 
viability was determined using the MTT assay and cell death by propidium 
iodide/Hoechst staining. Inflammation was assessed by IL-8 release and En-
doplasmic Reticulum (ER) stress by Western blotting for CHOP.
Results: Hepatocytes exposed to a combination of MGO and PA had a lower 
cell viability and increased levels of apoptosis as compared to exposure to 
either component alone. Exposure to MGO 0.6 in combination with PA 3 
µM decreased cell viability to 78±3% as compared to 81±1% and 98±2% for 
MGO and PA alone (p<0.05), and also increased apoptosis from 0.3±0.05% 
to 2.3±0.2% as compared to 0.7±0.1% and 0.9±0.1% for MGO and PA alone 
(p<0.05). Exposure to MGO 0.6 in combination with PA 10 µM decreased cell 
viability to 74±1% as compared to 81±1% and 97±2% for MGO and PA alone 
(p<0.05), and also increased apoptosis to 3.9±0.1% as compared to 0.7±0.1% 
and 1.5±0.5% for MGO and PA alone (p<0.05). The increase in apoptosis 
may be accounted for by increased ER stress in response to the combination 
of MGO and PA as compared to that seen with PA alone. However, no such 
synergy was seen with inflammation only an additive effect was observed 
with IL-8 release increased by 49±13 and 46±8% with the combination of 
MGO 0.6 mM and PA 3 or 10 µM respectively. Whereas IL-8 increased by 
30±5% with MGO 0.6 mM and 13±6 and 8±7% for PA 3 and 10 µM when 
applied alone.
Conclusion: The synergistic effects of methylglyoxal and with relatively low 
physiological concentrations of palmitic acid on hepatocyte viability and ap-
optosis as well as the additive effects on inflammation may increase the risk of 
hepatotoxic effects being observed in diabetics. This may also account for the 
increased risk diabetics have of developing liver diseases such as NAFLD and 
strategies to not only lower saturated fatty acid levels but also methylglyoxal 
levels may prove effective in preventing these complications.
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The effect of hypertriglyceridaemia and metformin on reactive 
dicarbonyls in heart and kidney in a model of metabolic syndrome
H. Malinska, J. Trnovska, V. Škop, L. Kazdova;  
Center for Experimental Medicine, Institute for Clinical and Experimental 
Medicine, Prague 4, Czech Republic.
Background and aims: Biogenesis of reactive dicarbonyls is related to gly-
caemic and lipid status in diabetes and higher plasma levels of methylglyoxal 
are observed in diabetic patients. Excessive generation of dicarbonyls leads to 
production of advanced glycation end products (AGE), activates inflamma-
tory pathway, increases oxidative stress and can play a key role in the devel-
opment of diabetic vascular complications. Dicarbonyls determination could 
be early biomarker risk for these complications. Metformin, the most widely 
prescribed glucose- and lipid-lowering agent for treatment of type 2 diabetes, 
has also been proposed as a scavenger of methylglyoxal. However its effect on 
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individual dicarbonyls metabolism in tissue is not fully clarified. In our study 
we analyzed level of individual reactive dicarbonyls - methylglyoxal (MG), 
glyoxal (GL) and 3-deoxyglucosone (3-DG) in relation to lipid disorders and 
after metformin administration in non-obese rats with hereditary hypertri-
glyceridemia (HHTg rats).
Materials and methods: Adult Wistar rats (controls) and HHTg rats, which 
exhibit genetic fixed hypertriglyceridemia, tissue insulin resistance, impaired 
glucose tolerance, hyperinsulinemia and ectopic lipid accumulation, were fed 
a standard laboratory diet with or without metformin (300mg/kg b.wt.) for 
4 weeks. The concentration of dicarbonyls were determined by derivatisation 
with 1,2-diamino-4,5-dimethoxy-benzene and HPLC-method with fluores-
cence detection.
Results: Compared with controls, HHTg rats exhibited markedly elevated se-
rum levels of triacylglycerol (4.05±0.39 vs 1.88±0.23 mmol/l, p<0.001), FFA 
(0.97±0.19 vs 0.47±0.13 mmol/l, p<0.01) and hepatic triglycerides accumula-
tion (13.87±2.23 vs 4.32±0.70 μmol/g, p<0.001). In HHTg rats we observed 
markedly increased serum level of MG (p<0.01). Concentrations of individual 
reactive dicarbonyls in myocardium (MG: 14.99±0.78 vs 8.66±1.28 nmol/mg, 
p<0.001; GL: 3.53±0.51 vs 1.22±0.42 nmol/mg, p<0.01; 3-DG: 3.46±0.46 vs 
1.61±0.39 nmol/mg, p<0.01) and kidney cortex (MG: 6.14±0.59 vs 3.45±0.39 
nmol/mg, p<0.01) were significantly elevated in HHTg rats compared to 
controls. Metformin treatment was associated with significantly reduced 
level of reactive dicarbonyls in myocardium (MG: p<0.05, GL: p<0.05, 3-DG: 
p<0.01), when compared to untreated HHTg rats. There were no significant 
effects of metformin on dicarbonyls concentration in kidney cortex.
Conclusion: Results indicate that chronically elevated hypertriglyceridemia 
and FFA was associated with increased levels of methylglyoxal in serum and 
with markedly elevated reactive carbonyls in heart and kidney. Beneficial ef-
fect of metformin administration on reactive dicarbonyls in heart could con-
tribute to cardioprotective effect of metformin.
Supported by: grant IGA NT/14325-3
72
Association between decreased serum level of sRAGE, RAGE Gly82ser 
polymorphism and diabetic patients with mild cognitive impairment
P. Wang, R. Huang, W. Xia, H. Sun, R. Cai, S. Wang;  
Affiliated ZhongDa Hospital of Southeast University, Nanjing, China.
Background and aims: The incidence of mild cognitive impairment (MCI) 
is much higher in type 2 diabetes mellitus (T2DM). As the receptor for ad-
vanced glycation end products (AGEs ) and Aβ, RAGE was involved both 
in chronic complications of T2DM and Alzheimer’s disease. The aim of this 
study was to investigate the association of the serum level of sRAGE which 
acts as a decoy receptor of RAGE, the Gly82ser polymorphism in RAGE gene 
and T2DM with MCI.
Materials and methods: A total of 109 type 2 diabetic patients, 52 subjects 
met the MCI diagnostic criteria proposed by the MCI Working Group of 
the European Consortium on Alzheimer’s Disease, and 57 matched type 2 
diabetic patients, were enrolled into our study. Participants were evaluated 
using an extensive assessment of cognitive function, serum level of sRAGE 
was measured by enzyme-linked immunosorbent assay, and RAGE Gly82ser 
polymorphism was determined by PCR-RFLP.
Results: The serum level of sRAGE in the MCI patients with T2DM (me-
dian [interquartile range]= 0.86[0.42-1.20]ng/ml)was significantly lower 
those matched T2DM without MCI (0.86[0.42-1.20] ng/ml, p<0.001), even 
in the heterozygote group(0.87, 0.42ng/ml, p<0.001). It seems the 82S allele 
was associated with an elevated risk of MCI, the odds ratio (OR) of GS+SS is 
(1.476[0.680-3.202]), but without statistics significance because of the limita-
tion of population size.
Conclusion: T2DM with MCI showed a lower serum concentration of 
sRAGE, and sRAGE may be a potential marker and preventive measures for 
MCI, especially in T2DM patients. The RAGE gene Gly82ser polymorphism 
may play a role in MCI with T2DM, but still need more research with larger 
population size.
Supported by: ChiCTR-ONRC-13003095
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Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset 
of type 2 diabetes in overweight/obese adults: the SCALE obesity and 
prediabetes trial
X. Pi-Sunyer1, K. Fujioka2, C. le Roux3, A. Astrup4, F. Greenway5,  
A. Halpern6, M. Krempf7, D.C.W. Lau8, R. Violante Ortiz9, C.B. Jensen10,  
S.K. Lillleøre10, J.P.H. Wilding11;  
1Division of Endocrinology, Diabetes and Nutrition, St. Luke’s-Roosevelt 
Hospital Center, New York, USA, 2Scripps Clinic, La Jolla, USA, 3University 
College Dublin, Ireland, 4University of Copenhagen, Denmark, 5Louisiana 
State University, Baton Rouge, USA, 6University of São Paulo Medical 
School, Brazil, 7Université de Nantes, France, 8University of Calgary, 
Canada, 9Instituto Mexicano del Seguro Social, Ciudad Madero, Mexico, 
10Novo Nordisk A/S, Søborg, Denmark, 11University of Liverpool, UK.
Background and aims: This trial investigated the effects of liraglutide 3.0 
mg, as adjunct to diet and exercise, on weight loss, prediabetes prevalence 
and onset of T2D (ADA 2010) over 56 weeks. The effects of liraglutide 3.0 mg 
cessation were investigated in a subsequent 12 week re-randomised period.
Materials and methods: Adults (BMI ≥27 kg/m2 + ≥1 comorbidity or ≥30 
kg/m2) were advised on a 500 kcal/day deficit diet and exercise programme 
and randomised 2:1 to once daily sc liraglutide 3.0 mg (n=2487) or placebo 
(n=1244). Randomisation was stratified by prediabetes status (ADA 2010). 
At week 56, individuals without prediabetes on liraglutide 3.0 mg were re-
randomised 1:1 to liraglutide 3.0 mg or placebo (diet and exercise continued).
Results: Baseline characteristics: age 45.1 yr, 78.5% female, body weight 
106.2 kg, BMI 38.3 kg/m2, 61.2% with prediabetes. At week 56, individuals 
on liraglutide 3.0 had lost 8.0% weight compared to 2.6% with placebo (es-
timated treatment difference [ETD] -5.4%, p<0.0001, LSmeans, full analysis 
set-LOCF, ANCOVA). Liraglutide 3.0 mg improved fasting and post-load 
glycaemia compared to placebo (ETD FPG -0.38 mmol/L, PG [OGTT, area 
under curve] -2.02 h*mmol/L, HbA1c 0.23%-points; p<0.0001 for all). Of 
those with prediabetes at screening, more had reverted to normoglycaemia 
on liraglutide 3.0 mg (69.7%) vs placebo (32.1%) at week 56. Likewise, of 
those with normoglycaemia at screening, more had progressed to prediabetes 
on placebo (19.9%) vs liraglutide 3.0 mg (6.9%) at week 56 (Fig). Few indi-
viduals developed T2D during treatment, but significantly more on placebo 
than on liraglutide 3.0 mg developed T2D (n=14, 1.3 events/100 patient years 
of exposure [PYE] vs n=4, 0.2 events/100 PYE; p=0.0003). From week 56 to 
68, individuals re-randomised from liraglutide 3.0 mg to placebo regained 
more weight (2.9%) vs those staying on liraglutide 3.0 mg (0.7%) (ETD 2.2%, 
p<0.0001), and more individuals progressed to prediabetes on placebo (from 
8.0% to 22.4%, observed means) than on liraglutide 3.0 mg (from 9.1% to 
8.6%) (p<0.0001). None developed T2D.
Conclusion: Consistent with the effects on body weight and glycaemia, lira-
glutide 3.0 mg, as adjunct to diet and exercise, was superior to placebo in 
reducing the prevalence of prediabetes and T2D after 56 weeks. Continued 
treatment was required to sustain these effects.
Clinical Trial Registration Number: NCT01272219
Supported by: Novo Nordisk
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Effect of exenatide on postprandial cerebral and liver glucose 
metabolism: a double-blind randomised clinical trial
G. Daniele1, P. Iozzo2, M. Molina-Wilkins1, J. Lancaster1, D. Ciociaro2,  
C. Triplitt1, E. Cersosimo1, D. Tripathy1, P. Fox1, N. Musi1, R.A. DeFronzo1, 
A. Gastaldelli1,2;  
1University of Texas Health Science Center, San Antonio, USA,  
2Institute of Clinical Physiology, Pisa, Italy.
Background and aims: The main effect of GLP-1 receptor (GLP-1R) agonists 
is on insulin secretion. However, since GLP-1Rs have been found in the brain 
it has been hypothesized that GLP-1R agonists (GLP-1RA) could improve 
brain glucose metabolism. We have also shown that GLP-1Rs are present in 
human livers and that GLP-1 injection during pancreatic clamp can reduce 
hepatic glucose production. The aims of the study were to evaluate the effects 
of a single injection of GLP-1RA Exenatide (EX) on cerebral as well as hepatic 
and peripheral glucose metabolism.
Materials and methods: We studied 15 male subjects with increased post-
prandial glucose (n=12 IGT and n=3 newly diagnosed type 2 diabetics, 
age=56±8 y, BMI=29±1 kg/m2, HbA1c=5.7±0.1%). Each subject underwent 
2 oral glucose tests (OGTT 75 g), with double blind injection of EX (5 mcg) 
or placebo (PLC) 30 min before OGTT; 6,6-2H-glucose was infused for 4h 
(2h before and 2h during OGTT) and U-13C-glucose was added to oral glu-
cose to assess glucose absorption (RaOr), production (EGP), total rate of glu-
cose appearance (Ra) and disposal (Rd). Brain and liver glucose uptake were 
measured by PET following injection of 18FDG (5mCi) at t=0 and acquiring 
images 1h into the OGTT.
Results: EX delayed gastric emptying (RaOr-0-60min=12.1±3.2 vs. 34.5±3.1 
μmol/min⋅kg). Insulin response was lower in EX vs PLC (mean Insulin-
0-60min 17.5±3.2 vs. 24.7±3.8 mU/l) as a consequence of lower glucose 
excursion (mean glucose0-60min 107±6 vs. 138±8 mg/dl, all p<0.02). De-
spite whole body glucose Rd was comparable in EX and PLC (Rd-0-60min 
10.6±0.8 vs. 11.1±0.7 μmol/min⋅kg), in EX we observed lower liver uptake 
when corrected for glucose concentrations (0.17±0.02 vs. 0.25±0.04 μmol/
min⋅ml, p=0.047) but higher when expressed as percent of RaOr (p<0.005). 
Cerebral glucose metabolic rate (CMR) was increased after EX (0.18±0.01 vs. 
0.12±0.01 μmol/min⋅ml; p=0.02). Brain areas with the highest CMR were: 
Thalamus (0.23±0.02 μmol/min⋅ml), Occipital (0.24±0.02 μmol/min⋅ml) and 
Frontal lobes (0.19±0.02 μmol/min⋅ml), (all p<0.004). However, in the Hy-
pothalamus EX reduced the CMR from 0.13±0.02 to 0.09±0.01 μmol/min⋅ml 
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(p=0.003). Total glucose CMR was inversely correlated with RaOr (r=-0.63; 
p<0.0005).
Conclusion: EX increased CMR in multiple areas of the brain but reduced 
glucose uptake in the hypothalamus. Liver glucose uptake accounted for a 
higher percentage of RaOr in EX. These results implicates a role of both brain 
and liver in the regulation of glucose metabolism by EX.
Clinical Trial Registration Number: NCT01588418
Supported by: Amylin
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Impact of baseline gastric emptying on effects of lixisenatide and 
liraglutide in type 2 diabetes mellitus (T2DM) as add-on to insulin 
glargine
B.A. Menge1, C. Kapitza2, A. Hincelin-Méry3, C. Roy-Duval3, A. Delfolie3, 
H.-V. Coester4, T. Forst4, J.J. Meier1;  
1St Josef Hospital, Bochum, 2Profil Institute, Neuss, Germany,  
3Sanofi R&D, Chilly-Mazarin, France, 4Profil Institute, Mainz, Germany.
Background and aims: Lixisenatide (LIXI) and liraglutide (LIRA), both 
once-daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs), were 
administered as add-on to insulin glargine in patients with type 2 diabetes 
mellitus (T2DM) for 8 wks. Here we explore whether baseline (BL) gastric 
emptying (GE) is a potential factor influencing the efficacy of LIXI and LIRA.
Materials and methods: Patients were randomized 1:1:1 to once-daily s.c. 
LIXI 20 µg or LIRA 1.2 or 1.8 mg as add-on to insulin glargine for 8 wks. 
Patients fasted overnight for 10 h before a standardized 13C-labelled break-
fast on Days -4 and 55 (281 kcal; 16% protein, 62% fat, 24% carbohydrate 
including 91 mg 13C-octanoic acid mixed with egg). 13C-octanoic acid breath 
samples were collected 30 min before breakfast (just before GLP-1 RA ad-
ministration at Wk 8), every 15 min after breakfast for 2 h, then every 30 min 
for the next 3 h (total 15 samples). Breath samples were centrally analyzed 
for 13CO2 by isotope-selective non-dispersive infrared spectrometry. Time for 
retention of 13C to decline to 50% (t1/2) and time at which % of the 
13C dose 
excreted/unit time reached its peak (tlag) were assessed. All patients from the 
pharmacodynamic population were grouped into BL GE t1/2 tertiles (T) for 
analysis of 8-wk outcomes: T1 92-150 min, T2 151-170 min, T3 171-334 min. 
Statistical analyses were performed using a linear model (ANOVA) with Bon-
ferroni adjustment for tertile analyses.
Results: Mean (SD) BL t1/2 and tlag were 169.48 (41.07) and 113.46 (26.50) 
min for LIXI (n=46), 161.70 (23.40) and 111.23 (19.70) min for LIRA 1.2 mg 
(n=44) and 164.30 (27.13) and 109.61 (20.84) min for LIRA 1.8 mg (n=46). 
Least squares (LS) mean changes in GE t1/2 and tlag were 453.56 and 175.56 
min with LIXI (p<0.0001 for both vs BL), 175.31 and 70.10 min with LIRA 
1.2 mg, and 130.49 and 48.85 min with LIRA 1.8 mg (p<0.05 for all changes 
with LIRA vs BL). The study showed a significantly greater delay in GE with 
LIXI vs LIRA (p<0.0001) and significantly greater reductions in the AUC for 
postprandial glucose (AUC PPG)00:30-04:30 h with LIXI (p<0.0001). There were 
no significant differences in reductions in AUC PPG00:30-04:30 h and HbA1c by 
BL t1/2 tertile in the LIXI and LIRA groups (Table). Patients with faster BL GE 
experienced greater GE tlag delay with LIXI (LS mean tlag difference [SE] in T1 
vs T3: 165.33 [44.22] min; p=0.0009).
Conclusion: LIXI delayed GE significantly more than LIRA. BL GE t1/2 did 
not predict treatment response (AUC PPG00:30-04:30 h or HbA1c) with LIXI or 
LIRA. Delay in GE with LIXI was less pronounced in patients with slower 
BL GE, suggesting that risk of aggravating pre-existing GE disturbances with 
GLP-1 RAs is low.
Clinical Trial Registration Number: NCT01596504
Supported by: Sanofi
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Effect of liraglutide 3.0 mg cessation on efficacy and safety/tolerability 
after 56 weeks’ treatment in obese/overweight adults with type 2 diabetes: 
SCALE diabetes
R. DeFronzo1, R. Bergenstal2, B. Bode3, R. Kushner4, A. Lewin5, T.V. Skjøth6, 
C.B. Jensen6, M. Davies7;  
1Diabetes Division, Department of Medicine, University of Texas School  
of Medicine at San Antonio, 2Park Nicollet Institute, St Louis Park,  
3Atlanta Diabetes Associates, 4Northwestern University, Chicago,  
5National Research Institute, Los Angeles, USA, 6Novo Nordisk A/S,  
Søborg, Denmark, 7University of Leicester, UK.
Background and aims: This was a 56-wk randomised, double-blind, place-
bo-controlled trial to evaluate the effect of liraglutide on weight loss induc-
tion and maintenance and glycaemic control in overweight/obese subjects 
with T2D. Present data are from a 12-wk follow-up period, which assessed 
efficacy and safety after treatment cessation.
Materials and methods: Individuals were randomised 2:1:1 to liraglutide 3.0 
mg, 1.8 mg or placebo (PBO), as adjunct to diet and exercise (D&E) for 56 
wks. Those who completed 56 wks’ treatment entered the 12-wk off-treat-
ment follow-up; D&E continued until wk 68. With exception of pulse, lipase, 
data are LS means (ANCOVA).
Results: 846 individuals (age 54.9 years, weight 105.9 kg, BMI 37.1 
[27.0−67.6] kg/m2, HbA1c 7.9%, fasting plasma glucose (FPG) 8.8 mmol/l, 
7.3 years of T2D) were randomised. More individuals on liraglutide (3.0 mg: 
77%, 1.8 mg: 78%) vs PBO (66%) completed 56-wks’ treatment. After 56 wks, 
liraglutide 3.0 mg and 1.8 mg led to greater reductions in body weight than 
PBO (-5.93% and -4.58% vs -1.96%, respectively; both p<0.0001 vs PBO); 
weight loss was greater with 3.0 mg vs 1.8 mg (p=0.0024). FPG reductions 
at wk 56 were greater with liraglutide 3.0 mg and 1.8 mg vs PBO (-1.89 and 
-1.40 vs -0.12 mmol/l, respectively; both p<0.0001 vs PBO), and greater with 
3.0 mg vs 1.8 mg (p=0.0061). After liraglutide cessation weight re-gain was 
observed but weight loss from baseline (BL) to wk 68 remained greater with 
liraglutide 3.0 mg ( 4.66%) than PBO (-2.50%; p=0.0002). There was no sig-
nificant difference in weight loss between liraglutide 1.8 mg (-3.70%) and 
PBO, nor 3.0 mg and 1.8 mg from BL to wk 68 (Fig). FPG reverted toward 
PBO levels within 2 wks of treatment cessation; at wk 68, change in FPG 
from baseline was -0.21, -0.01 and -0.12 mmol/l for liraglutide 3.0 mg, 1.8 
mg and PBO, respectively (p=NS for all pairwise comparisons). Mean lipase 
activity increased from BL to wk 56 with liraglutide 3.0 mg and 1.8 mg vs 
PBO (+15.3, +16.6 vs +3.7 U/l, respectively); at wk 68, lipase activity was 
similar in all treatment groups. Mean pulse increased from BL to wk 56 with 
liraglutide (2.0 and 2.1 vs -1.4 beats/min for liraglutide 3.0 mg, 1.8 mg and 
PBO, respectively) but decreased after treatment cessation (change from BL 
to wk 68: -1.3, -0.5 and 0.4 beats/min for liraglutide 3.0 mg, 1.8 mg and PBO). 
No adverse effects of treatment cessation on safety or binge eating were noted.
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Conclusion: 12 wks after liraglutide cessation, the beneficial treatment effects 
on weight were reduced and effects on FPG were reversed, emphasising the 
need for continued treatment.
Clinical Trial Registration Number: NCT01272232
Supported by: Novo Nordisk
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DURATION-1 extension: efficacy and tolerability of exenatide once 
weekly over 6 years in patients with type 2 diabetes mellitus
E. Klein1, R.R. Henry2, J. Malloy3, P. Griffin3, M. Zhou4, N. Iqbal5;  
1West Olympia Internal Medicine, Olympia, 2Center for Metabolic Research, 
VA San Diego Healthcare System and University of California,  
3Bristol-Myers Squibb, San Diego, 4Bristol-Myers Squibb, Hopewell,  
5Bristol-Myers Squibb, Princeton, USA.
Background and aims: In a 30-week controlled, Phase III trial (DURA-
TION-1), exenatide once weekly (QW) exhibited greater reduction in HbA1c 
than exenatide twice daily (−1.9% vs −1.5%; P=0.002), with similar weight 
loss, in 295 intention to treat (ITT) patients with type 2 diabetes mellitus not 
controlled with diet and exercise, or single or combination oral glucose-low-
ering therapies. Here, we report data from patients who completed 6 years of 
treatment, the longest assessment of the efficacy and safety of a glucagon-like 
peptide-1 (GLP-1) receptor agonist to date.
Materials and methods: In the open-ended extension of DURATION-1, all 
patients received exenatide QW.
Results: In total, 127 patients (43%) completed 6 years of treatment; baseline 
characteristics of these patients were similar to the ITT population. In com-
pleters, baseline [mean ± SD] values were: HbA1c 8.2 ± 0.9%; fasting plasma 
glucose (FPG) 9.22 ± 2.26 mmol/L; weight 101 ± 17 kg; diabetes duration 7 ± 
6 years. Withdrawal from the extension was most often due to withdrawal of 
consent (23.4%), adverse events (AEs; 5.8%) or investigator decision (5.1%). 
Among 6 year completers, HbA1c improved significantly from baseline (least 
squared mean −1.6% [95% CIs −1.9, −1.4]), 45% achieved HbA1c <7.0%, 
and 32% achieved HbA1c ≤6.5%. Significant improvements in FPG (−1.58 
mmol/L [−2.13, −1.03]) and weight (−4.3 kg [−6.0, −2.6]) were observed, 
and improvements in cardiovascular markers were maintained over 6 years. 
Improvements in lipid levels were: total cholesterol (−0.28 mmol/L [−0.47, 
−0.09]); LDL cholesterol (−0.27 mmol/L [−0.42, −0.11]); HDL cholesterol 
(0.06 mmol/L [0.01, 0.12]); triglyceride (−0.67 mmol/L [−1.11, −0.24]). 
Overall, most improvements were generally observed at week 30 and main-
tained to 6 years. In the ITT population, nausea (mostly mild) was the most 
common AE with exenatide QW for week 0 to 30 (exposure-adjusted an-
nual event rate [events/year of patient exposure for each period] of 0.85) but 
decreased over time (to 0.08 from week 30 to 6 years), as did injection site 
pruritus (from 0.51 to 0.02) and injection site erythema (from 0.14 to 0.01). 
Treatment-emergent AEs leading to withdrawal from week 30 to 6 years were 
infrequent (6.6%). Most common AEs leading to withdrawal were nausea 
and type 2 diabetes mellitus progression (loss of glucose control) (n=2 each). 
Over 6 years, 2 pancreatitis (annual rate 0.002; 1 withdrawal), 1 pancreatic 
carcinoma (1 withdrawal), and 3 acute renal failure cases were reported. No 
major hypoglycaemia was reported. Most minor hypoglycaemia occurred 
with concomitant sulfonylurea use.
Conclusion: In the longest extension of a Phase III GLP-1 receptor agonist 
study reported to date, exenatide QW was associated with significant, sus-
tained improvements in glycaemic control and weight over 6 years in patients 
who continued therapy, with no unexpected safety findings.
Clinical Trial Registration Number: NCT00308139
Supported by: Bristol-Myers Squibb/AstraZeneca
78
One-year efficacy and safety of IDegLira in patients with type 2 diabetes
S.C.L. Gough1, J.B. Buse2, V.C. Woo3, H.W. Rodbard4, S. Linjawi5,  
P. Poulsen6, L. Korsholm6, B.W. Bode7;  
1University of Oxford, Oxford Centre for Diabetes, Endocrinology and 
Metabolism, UK, 2University of North Carolina School of Medicine, Chapel 
Hill, USA, 3University of Manitoba, Winnipeg, Canada, 4Endocrine and 
Metabolic Consultants, Rockville, USA, 5Coffs Endocrine & Diabetes 
Services, Coffs Harbour, Australia, 6Novo Nordisk A/S, Søborg, Denmark, 
7Atlanta Diabetes Associates, USA.
Background and aims: IDegLira, a combination of insulin degludec (IDeg) 
and liraglutide (Lira), provided the advantages and mitigated the main side 
effects of each of its components in a previous 26-week trial. This 26-week 
extension assessed whether these benefits were sustained up to 1 year of use.
Materials and methods: Patients with type 2 diabetes randomized to once-
daily IDegLira, IDeg or Lira (1.8 mg), plus metformin ± pioglitazone, contin-
ued their allotted treatment in the extension. IDegLira and IDeg were titrated 
to a FPG of 4-5 mmol/L (72-90 mg/dL).
Results: Of 1663 adults randomised in the main trial (mean age: 55 yr, BMI: 
31.2 kg/m2), 1311 (78.8%) entered the extension: 665 (79.7%) patients on 
IDegLira, 333 (80.4%) on IDeg and 313 (75.4%) on Lira. Mean HbA1c was re-
duced from baseline by 1.8% (IDegLira), 1.4% (IDeg) and 1.2% (Lira) to end 
of trial values of 6.4%, 6.9% and 7.1%, respectively; 78% of patients on IDeg-
Lira achieved an HbA1c of <7% vs. 63% for IDeg and 57% for Lira. Mean FPG 
was similar for IDegLira (5.7 mmol/L; 103 mg/dL) and IDeg (6.0 mmol/L; 
108 mg/dL) and higher for Lira (7.3 mmol/L; 132 mg/dL). At study end, daily 
insulin dose was 37% lower with IDegLira (39 U) vs. IDeg (62 U). IDegLira 
was associated with a mean weight reduction of 0.4 kg, and had a 37% lower 
rate of hypoglycaemia vs. IDeg. Fewer patients had gastrointestinal adverse 
events with IDegLira vs. Lira (nausea: 10.3% vs. 22.3%).
Conclusion: The improved glycaemic control and more favourable safety 
profile seen for IDegLira in the extension trial supports the sustainability of 
IDegLira over at least 1 year of treatment.
Clinical Trial Registration Number: NCT01336023
Supported by: Novo Nordisk
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Genetic risk score of 31 BMI loci and substantial weight change over  
a period of 50 years in the Malmö Diet and Cancer Study
G. Rukh1, U. Ericson1, G. Hindy1, O. Melander1, P. Nilsson2,  
M. Orho-Melander1;  
1Department of Clinical Sciences in Malmö, Lund University Diabetes 
Center (LUDC), 2Department of Internal Medicine, Skåne University 
Hospital, Lund University, Malmö, Sweden.
Background and aims: Body weight gain has increasingly become a public 
health threat worldwide as it is associated with many metabolic abnormalities 
conveying an increased morbidity and mortality. Our aim was to evaluate the 
contribution of genetic susceptibility defined as a genetic risk score (GRS) of 
31 BMI associated single nucleotide polymorphisms (SNPs) to BMI at young, 
middle-age and older age, and to substantial weight gain (SWG) covering 
a mean time period of over 50 years starting from age of 20 years in a large 
Swedish cohort.
Materials and methods: Totally, 22634 non-diabetic participants (62% fe-
males) from the population based Malmö Diet and Cancer Study (MDCS) 
with baseline examinations 1990-1996 (age 57±8y, BMI 26±4kg/m2) and who 
in a questionnaire reported weight at 20 years of age (BMI 21±3kg/m2) as well 
as if their weight after 20 years of age had been stable, unstable, increased or 
decreased. A random sample of the MDCS (N=6,103), who were alive and 
had not emigrated from Sweden (N=4,924) were invited to a follow-up (FU) 
re-examination 2007-2012. Of these, 3734 subjects attended and 2676 with 
information of self-reported BMI from 20y were included in this study (58% 
females, age 73±6y, BMI 26±4kg/m2, FU time from baseline 16.5±1.5y and 
from 20y of age 52.8±5.6y). SWG was defined as gaining (i) ≥10% of self-
reported weight at 20y until baseline, (ii) ≥10% of baseline weight until FU 
and (iii) ≥10% of self-reported weight at 20y until FU. A weighted GRS based 
on 31 GWAS identified BMI susceptibility loci was created. Linear regression 
was used to analyze the associated effect sizes (β) per increasing quintile of 
GRS on BMI at 20 years of age, at baseline and at the end of FU. Further, we 
used logistic regression to analyze the risk (OR) per GRS quintile for belong-
ing to the self-reported unstable weight group (23.7% of all individuals), and 
for SWG from 20 years age to baseline and to FU, and from baseline to FU. All 
analyses were adjusted for age, sex and FU time when applicable.
Results: The GRS associated with higher BMI at all ages and with highest ef-
fect size at middle-age; 20y (β 0.03±0.01, p=2.0x10-37), baseline (β 0.23±0.02, 
p=1.8x10-34) and FU (β 0.20±0.06, p=0.003). The GRS associated with 10% 
increased risk per GRS quintile for having unstable weight from 20y to base-
line (OR 1.10 [1.07-1.13], p=1.1x10-9) and with 4% increased risk of SWG 
(OR 1.04 [1.02-1.07], p=0.002) from 20y to baseline. The risk increase was 
42% for unstable weight reporters (p=4.1x10-7) and 15% for SWG (p=0.016) 
for individuals in the highest GRS quintile compared to lowest. In contrast 
to this, the GRS did not associate with SWG from 20y to end of FU (OR 
0.97 [0.90-1.05], p= 0.47) and it associated with 10% decreased risk of SWG 
from baseline to FU (OR 0.90 [0.84-0.97]; p=0.004) and 26% decreased risk 
comparing highest to lowest quintiles of GRS (OR 0.74 [0.55-1.01]; p=0.061).
Conclusion: Our data suggest that BMI GRS associates with BMI at all adult 
ages and with unstable weight and substantial weight gain until the later mid-
dle age. However, our results indicate inversed association with weight gain at 
older ages. Whether the latter can be explained by the BMI GRS accentuating 
the age related loss of muscle mass, other age related weight loss, age related 
effects on appetite regulation, or other reasons, needs to be investigated in 
future studies.
Supported by: VR, HLF, NNF, SDF, PF, KAWF, LF
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Effects of genetic and environmental influences on abdominal adipose 
tissue compartments and hepatic lipid accumulation:  
a classical twin study
A.L. Jermendy1, Z.D. Drobni1, T. Horvath1, C. Celeng1, A. Panajotu1,  
F.I. Suhai1, A.D. Tarnoki2, D.L. Tarnoki2, B. Merkely1, P. Maurovich-Horvat1, 
G. Jermendy3;  
1MTA-SE Lendulet Cardiovascular Imaging Research Group,  
2Semmelweis University Department of Radiology and Oncotherapy, 
3Bajcsy-Zsilinszky Hospital, Budapest, Hungary.
Background and aims: In patients with diabetes and/or obesity, accumu-
lation of abdominal adipose tissue and non-alcoholic fatty liver disease 
(NAFLD) are linked to increased cardiometabolic risk. Little is known about 
the genetic and environmental effects on the distribution of the abdominal 
adipose tissue compartments and hepatic lipid accumulation. The aim of the 
study was to assess the magnitude of genetic and environmental impact on 
the size of various abdominal adipose tissue compartments and the hepatic 
lipid accumulation within a cohort of healthy twin pairs.
Materials and methods: In this classical twin study, 136 adult twin subjects 
(58.8% women; age: 56.8±9.3 years, weight: 77.1±17.2 kg, BMI 27.3±4.9 kg/
m2 [x±SD], 37 monozygotic [MZ] and 31 dizygotic [DZ] pairs) were in-
volved. The twin pairs were investigated with a 256-slice CT-scanner. A 2 
mm thick axial slice was acquired at the level of L3-L4. Subsequently a 50 mm 
wide axial image slab was acquired below the diaphragm. For each patient 
CT-based measurement of waist circumference, subcutaneous adipose tis-
sue (SAT) and visceral adipose tissue (VAT) quantification were performed. 
Liver and spleen attenuation was determined by calculating the average of 
three 300 mm2 ROIs (regions of interest). Hepatic lipid accumulation was 
characterized by attenuation ratios (CTL/S) and ratio of ≤0.9 was assessed as 
sign of NAFLD. Concordance between MZ and DZ pairs was assessed by 
Pearson correlations. For assessing heritability of abdominal adipose tissue 
compartments and that of hepatic lipid accumulation, the structural equation 
(A-C-E) model was used.
Results: Comparing MZ to DZ twin pairs, no significant differences were 
found in age (55.9±9.7 vs. 58.2±8.8 years), in BMI (27.2±3.9 vs. 26.5±4.0 kg/
m2), in waist circumference (94.0±12.9 vs. 95.4±13.1 cm), in SAT (206.0±79.9 
vs. 200.9±83.1 cm2), in VAT (159.9±91.0 vs. 143.0±77.6 cm2), and in CTL/S 
ratio (1.1±0.2 vs 1.2±0.2); p>0.05 for all comparison. Strong correlations 
among BMI, SAT and VAT values were found in MZ twin pairs (r=0.63 [95% 
CI 0.34 - 0.84], r=0.74 [95% CI 0.54 - 0.90], r=0.60 [95% CI 0.34 - 0.79], re-
spectively) whereas these correlations were weak or absent in DZ twin pairs 
(r=0.08 [95% CI -0.43 - 0.43], r=0.35 [95% CI 0.00 - 0.64], r=0.20 [95% CI 
-0.16 - 0.51], respectively). As for hepatic lipid accumulation, correlations 
among CTL/S values were absent in both MZ pairs (r=0.30, 95% CI -0.16 - 
0.67) and DZ pairs (r=0.15, 95% CI -0.15 - 0.55). Using the structural equa-
tion (A-C-E) model, relatively strong heritability index was found regarding 
BMI (58%, 95% CI 18-85%), SAT (74%, 95% CI 43-93%) and VAT (59%, 95% 
CI 22-82%) whereas environmental influences predominated in hepatic lipid 
accumulation (additive genetic effect 30% [95% CI 0-75%], shared environ-
mental effect 1% [95% CI 0-41%], unique environmental effect 69% [95% CI 
32-100%).
Conclusion: Both BMI and abdominal adipose tissue compartments (SAT 
and VAT) have relatively strong heritability whereas hepatic lipid accumu-
lation (presence of NAFLD) is predominantly influenced by environmental 
factors.
Supported by: EFSD New Horizons
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Endogenous GLP-1 alters brain activations in response to  
visual food-cues in reward and satiety circuits in humans
J.S. ten Kulve1, R.G. Ijzerman1, L. van Bloemendaal1, F. Barkhof2,  
D.J. Veltman3, M. Diamant1;  
1Diabetes centre / Internal medicine, VU University Medical Centre, 
2Departement of Radiology, VU University Medical Centre, 3Departement 
of Psychiatry, VU University Medical Centre, Amsterdam, Netherlands.
Background and aims: The central nervous system (CNS) plays a major role 
in the regulation of feeding and maintenance of body weight. Food inges-
tion activates the secretion of gut-hormones, such as glucagon-like peptide-1 
(GLP-1). GLP-1 has been proposed to be involved in the CNS regulation of 
feeding, by relaying information about the nutritional status to the CNS. We 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 41
1 C
hypothesised that endogenous GLP-1 has effects on central reward and satiety 
circuits in overweight individuals with diabetes and healthy, lean individuals.
Materials and methods: We included overweight patients with type 2 diabe-
tes (T2DM) (n=20, mean ± SD age 59.3 ± 4.1 yrs, BMI 32.0 ± 4.7 kg/m2, 11 
males) and age matched healthy, lean controls (n=20, mean ± SD age 56.3 ± 
6.2 yrs, BMI 22.5 ± 1.7 kg/m2, 10 males). Using functional MRI (fMRI), we 
determined the effects of blocking endogenous GLP-1 on CNS responses to 
visual food-cues before and after a standardized liquid meal. To block the 
endogenous GLP-1 effects, intravenous administration of the GLP-1 recep-
tor antagonist exendin 9-39 (ex9-39) was used and compared to placebo in-
fusion. During the fMRI session, subjects were presented pictures of high 
calorie, low calorie and non-food objects. Imaging data were analysed using 
SPM8 and activation contrasts were computed (food vs. non-food).
Results: In the fasting state, obese T2DM patients versus lean individu-
als showed increased brain activation in response to food pictures within 
left amygdala, right orbitofrontal cortex and bilateral insula. The stand-
ardized meal reduced these hyperactivations in bilateral insula in patients 
with T2DM. Blocking endogenous GLP-1 with ex9-39 partly prevented this 
meal induced reduction in brain activations. In healthy lean individuals, the 
standardized meal also reduced activation in the insula in response to food 
pictures, however to a lesser extent and only in right insula. Blocking endog-
enous GLP-1 with ex9-39 did not prevent this meal induced reduction in 
brain activations.
Conclusion: Patients with T2DM showed increased brain activations in re-
sponse to food pictures in areas involved in reward and satiety while fasted. 
Intake of a meal reduced these brain responses and this effect was blunted 
with blockade of endogenous GLP-1. These effects could not be detected in 
healthy, lean individuals. The lower brain activation in response to food pic-
tures in healthy lean individuals at baseline, may have decreased the likeli-
hood to detect changes in these brain activation after a meal with or without 
blocking endogenous GLP-1. Our findings in patients with T2DM support 
the hypothesis that endogenous GLP-1 is involved in the regulation of central 
reward and satiety.
Clinical Trial Registration Number: NCT 01363609
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A high fat diet during pregnancy and lactation affects the metabolic fate 
of Gipr-/- mice via hypothalamic insulin signalling and  
DNA-methylation of lipid metabolism genes
F. Keyhani Nejad1,2, F. Isken1,2, M.A. Osterhoff1,2, B. Nitz3,4, T. Ludwig4,  
H. Grallert3,4, A.F.H. Pfeiffer1,2, M. Kruse1,2;  
1Department of Clinical Nutrition, German Institute of Human Nutrition, 
Nuthetal, 2Department for Endocrinology, Diabetes and Nutrition, Charité 
– University of Medicine, Berlin, 3Research Unit of Molecular Epidemiology, 
Helmholtz Zentrum München, German Research Center for Environmental 
Health, Neuherberg, 4Institute of Epidemiology II, Helmholtz Zentrum 
München, German Research Center for Environmental Health, Neuherberg, 
Germany.
Background and aims: Maternal high-fat (HF) feeding during intra-uterine 
(IU) and lactation (L) periods predisposes the offspring for obesity and im-
paired glucose homeostasis in mice. Inhibition of Glucose-dependent insu-
linotropic polypeptide (GIP) signaling in GIP receptor knockout mice (Gipr-
/-) leads to protection from HF induced obesity. We reported that Gipr-/- 
mice exposed to HF during IU/L were no longer protected from diet induced 
obesity and had a decreased glucose tolerance in adulthood. We hypothesized 
that the metabolic programming of IU/L HF consumption triggers hypotha-
lamic insulin resistance and promoter DNA methylation of key genes in fat 
metabolism and their subsequently altered gene expression in Gipr-/- mice.
Materials and methods: Female GIP receptor heterozygous (Gipr+/-) mice 
were fed either a HF (60% fat) or control (C, 10% fat) diet for 2 weeks prior to 
gestation and during IU/L. After weaning, male Gipr-/- and wild type (WT) 
offspring were kept on normal chow until the age of 25 weeks, after which 
all offspring were exposed to HF for the following 20 weeks. This resulted in 
Gipr-/- which were exposed to either a C (KO Ciu-HF) or a HF (KO HFiu-
HF) diet during IU/L and a HF later in adulthood. WT mice fed a control 
diet during IU/L and a HF in adulthood served as controls (WT Ciu-HF). 
A glucose tolerance test (GTT) was performed by i.p. injection of 2 g/kg BW 
glucose. At 45 weeks of age, body fat content, adipocyte size and genes in-
volved in hypothalamic insulin sensitivity and DNA-methylation of fatty acid 
oxidation genes in muscle were analyzed.
Results: Body fat content significantly increased in KO HFiu-HF com-
pared to KO Ciu-HF (22.6 ± 2.5 g vs. 19.5 ± 0.8 g, respectively; p<0.05). 
KO HFiu-HF showed significantly larger adipocytes compared to KO Ciu-
HF (p<0.005). KO HFiu-HF and WT Ciu-HF mice had significantly higher 
plasma glucose levels compared to KO Ciu-HF (AUC: 3,784.5±284.9 and 
3,836.9±180.2 vs. 2,829.5±256.3 mmol/l*min, respectively; all p<0.05). In KO 
Ciu-HF hypothalamic gene expression of PI3K subunit p85α was 22% down 
regulated compared to WT Ciu-HF mice (p<0.01) and back up regulated 
1.27 fold in KO HFiu-HF compared to KO Ciu-HF (p< 0.05). Expression 
levels of PPARα and CPT-1β, the key enzymes of fatty acid oxidation, were 
massively increased in KO Ciu-HF compared to WT Ciu-HF mice (2.45-fold 
for PPARα and 1.53-fold for CPT-1β, p<0.01), but then down regulated 41% 
for CPT-1β and 45.2% for PPARα in KO HFiu-HF compared to KO Ciu-HF 
(p<0.05) in muscle. One CpG-site of PPARα and three CpG-sites of CPT-1β 
showed hypomethylation in KO Ciu-HF compared to WT Ciu-HF and KO 
HFiu-HF. DNA-methylation was inversely correlated with gene expression.
Conclusion: Consuming a HF diet during IU/L leads to reduced central in-
sulin sensitivity and can change the offspring’s epigenetic marks resulting in 
decreased peripheral fatty acid oxidation, which reverses the protection of 
diet induced obesity in Gipr-/- mice.
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Weight loss normalises lowered mu-opioid receptor availability  
in the morbidly obese
H.K. Karlsson1, J.J. Tuulari1, L. Tuominen1,2, H. Honka1, J. Hirvonen1,3,  
P. Salminen4, P. Nuutila1,5, L. Nummenmaa1,6;  
1Turku PET Centre, 2Department of Psychiatry, Turku University Hospital, 
3Department of Radiology, Turku University Hospital, 4Department 
of Surgery, Turku University Hospital, 5Department of Endocrinology, 
Turku University Hospital, 6Department of Biomedical Engineering & 
Computational Science, Aalto University School of Science, Espoo, Finland.
Background and aims: Neurochemical pathways involved in overeating and 
obesity are poorly understood. Our previous positron emission tomography 
(PET) studies suggest that morbidly obese versus normal-weight human sub-
jects have lower mu-opioid receptor (MOR) availability but unaltered dopa-
mine D2 receptor (D2R) availability in the brain. Investigating the effects of 
weight loss could reveal whether altered receptor availability is a state or a 
trait of obesity.
Materials and methods: We recruited 21 morbidly obese women (mean 
BMI 41, mean age 42), with nine having type 2 diabetes (T2DM), eligible for 
bariatric surgery, and measured their brain D2R availability using PET with 
[11C]raclopride and MOR availability with [11C]carfentanil before and six 
months after the bariatric surgery. 14 non-obese age-matched healthy women 
(mean BMI 23, mean age 45) formed the control group. Receptor availability 
was assessed as the binding potential (BPND). Both ROI-based statistics and 
statistical parametric mapping were used to compare the parametric BPND 
maps within subjects (pre- vs. postoperative).
Results: Average weight loss after surgery was 25 kg. T2DM recovered in 
six subjects. Weight loss normalized lowered [11C]carfentanil BPND in the 
morbidly obese, with on average 31 % higher MOR binding in the postop-
erative scan (Figure 1). Significant changes were observed in several areas 
implicated in reward processing, including ventral striatum, dorsal caudate, 
insula, amygdala, thalamus and anterior cingulate cortex (ps < 0.005). How-
ever, weight loss did not influence [11C]raclopride binding in any brain re-
gion (Figure 1). Glycaemic status did not affect the receptor density before or 
after weight loss.
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Conclusion: Endogenous opioid system plays an important role in the 
pathophysiology of obesity while the role of dopaminergic pathways remains 
questionable. Because bariatric surgery and concomitant weight loss recov-
ers MOR availability, lowered MOR availability is a consequence of obesity 
and may mediate maintenance of excessive energy uptake. Understanding 
the opioidergic contribution to overeating is thus critical for developing new 
treatments for obesity.
Clinical Trial Registration Number: NCT00793143
Supported by: Academy of Finland, The Finnish Diabetes Research Foundation, 
CLIGS
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KBP-042 lowers body-weight and sustains weight-loss in  
high fat-diet rats
S.T. Hjuler, S. Gydesen, K.V. Andreassen, M.A. Karsdal, K. Henriksen;  
Diabetes group, Nordic Bioscience, Herlev, Denmark.
Background and aims: KBP-042 is a dual amylin- and calcitonin receptor 
agonist, with superior activity compared to salmon calcitonin. In this study 
we evaluated the long term potential of KBP-042 as a treatment against obe-
sity. We evaluated body weight, adiposity, glucose tolerance and insulin ac-
tion in a rat model of obesity.
Materials and methods: Male sprague-Dawley rats were fed a high fat-diet 
for ten weeks resulting in an obese and glucose intolerant phenotype. Based 
on body weight the rats were randomized into the treatment groups: Vehicle 
(saline), 0.625 µg/kg, 1.25 µg/kg, 2.5 µg/kg, 5.0 µg/kg, 10.0 µg/kg KBP-042 
s.c. once daily (n=10), as well as pair-fed controls for the two highest con-
centration groups (pair-fed 10 µg/kg and pair-fed 5 µg/kg) which were food 
restricted to match the food intake of the 10 µg/kg and 5 µg/kg groups.
Results: A dose-dependent and sustained weight-loss was obtained. For the 
KBP-042 10 µg/kg group the treatment resulted in a 4.7 % weight reduction 
(20 % vehicle-corrected), while only a transient change in food intake. Fur-
thermore, while the pair-fed groups did not lower body weight, they did not 
match the extent of their corresponding treatment group, +5.6 % and +7.1 % 
respectively (-5.6 % and -8.0 % vehicle-corrected). Adiposity was vastly im-
proved after treatment with KBP-042. The visceral fat depots were significant 
reduced (~40% perirenal AT: p<0.01 10 µg/kg vs. vehicle, ~33% epididymal 
AT p<0.05 10µg/kg vs. vehicle), and the subcutaneous inguinal AT was sig-
nificantly reduced (~35% p<0.05 10µg/kg vs. vehicle) all depots were lowered 
in a dose-dependent manner. For all the depots that we measured, we ob-
served no difference between the pair-fed groups and vehicle. The treatment 
groups showed improved glucose tolerance both in the oral glucose tolerance 
test (OGTT) (21 % p<0.001 vehicle vs. 10 µg/kg and 17 % p<0.001 vehicle 
vs. 5 µg/kg) and in the intravenous glucose tolerance test (IVGTT) (10 % 
p<0.02 vehicle vs. 10 µg/kg) without increasing insulin levels. Furthermore, 
the incretin GIP was significantly lowered after oral glucose load for the 2.5 
µg/kg, 5 µg/kg and 10 µg/kg groups (p<0.01 vs. vehicle) while there were no 
changes in the pair-fed groups.
Conclusion: In conclusion KBP-042 induced and sustained a significant and 
dose-dependent weight-loss, reduced adiposity and improved the glucose 
tolerance in high-fat diet rats, independent of calorie-restriction. This study 
demonstrates KBP-042 as a therapeutic agent against obesity in an interven-
tion model of obesity.
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Prevalence of nonalbuminuric chronic kidney disease (CKD)  
is increasing in patients with type 1 diabetes mellitus
E. Russo1, G. Penno1, M. Garofolo1, D. Lucchesi1, L. Pucci2,  
V. Sancho Bornez1, L. Giusti1, R. Bellante1, R. Russo2, R. Miccoli1,  
S. Del Prato1;  
1Endocrinology and Metabolism, University of Pisa,  
2Institute of Agricultural Biology and Biotechnology, CNR, Pisa, Italy.
Background and aims: According to traditional paradigms of diabetic ne-
phropathy, albuminuria precedes glomerular filtration rate (GFR) loss in the 
progression to CKD. However, even in type 1 DM (T1DM), recent findings 
(DCCT/EDIC) demonstrate that GFR loss may occur in normoalbuminuria. 
We compared prevalence of different CKD phenotypes in two cohorts of Ital-
ian T1DM subjects.
Materials and methods: The first cohort (C1) consisted of 777 T1DM re-
cruited 2001-2009 at our Metabolic Unit; the second cohort (C2) consisted 
of 936 T1DM belonging from the EURODIAB IDDM Complications Study 
(they attended 9 Italian centres in 1989-1991). Eligibility criteria were the 
same for both cohorts. However, C2 was stratified at enrollment by sex, age 
(15-29, 30-44, 45-59 yrs) and duration (1-7, 8-14, ≥15 yrs). Methods em-
ployed to assess diabetic complications were similar.
Results: Gender distribution (M/F: 52/48% vs 51/49%) and current smok-
ers (29.6% vs 30.4%) were similar. Due to inclusion criteria, C1 were older 
(40.2±11.7 vs 32.1±10.5) and had longer diabetes duration (19.4±12.2 vs 
14.4±9.0 years; both p<0.0001). C1 had higher BMI, sBP and hypertension rate 
(35.2% vs 21.9%), lower total- and LDL-C (higher rate of lipid-lowering treat-
ment: 12.9% vs 2.4%), higher HDL-C (p<0.0001 for all), with no differences 
in triglycerides. HbA1c was slightly lower in C1 (7.83±1.17 vs 8.08±1.79%, 
p=0.0008). C1 were more frequently on BP-lowering drugs (19.4% vs 9.4%) 
and RAS blockers (17.5% vs 6.7%, both p<0.0001). Prevalence of any retinop-
athy was similar (41.3% vs 41.2%), while proliferative retinopathy was more 
frequent in C1 (15.6% vs 8.8%, p<0.0001), with no difference in CV events 
(8.5% vs 9.9%). Albuminuria was more frequent in C2: rates of normo- (nA, 
ACR <30 mg/g), micro- (ACR 30-299) or macro- (ACR ≥300) were 91.6, 6.4 
and 1.9% in C1, and 79.2, 14.1 and 6.7% in C2 (p<0.0001). Stage 1 (≥90), 
2 (60-89) and ≥3 (<60 ml/min/1.73m2, MDRD) eGFR were 57.3, 39.0 and 
3.7% in C1, and 84.8, 13.2 and 1.9% in C2 (p<0.0001). In C1, 89.4% had no-
CKD; 6.8% stages 1-2 and 3.7% stages ≥3 CKD; in C2, 78.6, 19.5 and 1.9%, 
respectively (p<0.0001). The albuminuric (Alb+) and non-albuminuric (Alb-
) phenotypes were present in 41.4 and 58.6% of stages ≥3 in C1 vs 72.2 and 
27.8% in C2 (p<0.039). In both cohorts, nA was splitted in “normal albu-
minuria” (ACR <10 mg/g) and “low-microalbuminuria” (ACR 10-29 mg/g); 
stages 1-2 was stratified in 2a (75-89) and 2b (60-74 ml/min/1.73m2). Also 
in 2b eGFR, nA was common and more frequent in C1 than C2 (88.7% vs 
67.5%, p=0.006). Considering 2b and ≥3 CKD as a whole, nA was present in 
80% of C1 and 55% of C2 (p=0.001); “normal albuminuria” in 60 and 29%, 
respectively (p=0.0001).
Conclusion: Nonalbuminuric renal function impairment is detectable in a 
high proportion of T1DM. Thought several factors may contribute to explain 
the differences in the rate nonalbuminuric CKD phenotypes between the two 
cohorts, the possibility of really increasing incidence of the nonalbuminuric 
phenotypes, likely driven by improvements in care, cannot be roled-out.
Supported by: Regione Toscana - D55E11002680005
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Determinants of urinary albumin excretion within the normal range  
in patients with type 2 diabetes from the RIACE cohort 
G. Penno1, A. Solini1, Z. Giacomo2, E. Orsi3, C. Fondelli4, G. Zerbini5,  
R. Trevisan6, M. Vedovato7, F. Cavalot8, G. Gruden9, O. Lamacchia10,  
G. Pugliese11;  
1Department of Clinical and Experimental Medicine, University of Pisa, 
2Division of Endocrinology and Metabolic Diseases, University of Verona, 
3Diabetes Unit, Fondazione IRCCS Cà Granda - Ospedale Maggiore 
Policlinico, Milan, 4Diabetes Unit, University of Siena, 5Complications of 
Diabetes Unit, San Raffaele Scientific Institute, Milan, 6Endocrinology and 
Diabetes Unit, Ospedali Riuniti, Bergamo, 7Department of Clinical and 
Experimental Medicine, University of Padua, 8Department of Clinical and 
Biological Sciences, University of Turin, Orbassano, 9Department of Internal 
Medicine, University of Turin, 10Department of Medical Sciences, University 
of Foggia, 11Department of Clinical and Molecular Medicine, La Sapienza 
University, Rome, Italy.
Background and aims: Higher values of albumin excretion rate (AER) 
within the normoalbuminuric range are known to correlate with higher car-
diovascular disease (CVD) and renal risk. This cross-sectional analysis was 
aimed at assessing the determinants of AER in normoalbuminuric subjects 
with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events 
(RIACE) Italian Multicenter Study.
Materials and methods: The RIACE cohort consists of 15,773 patients, con-
secutively visiting 19 Diabetes Clinics throughout Italy in years 2007-2008. 
Exclusion criteria were dialysis or renal transplantation. AER was measured 
by immunonephelometry or immunoturbidimetry and eGFR was calculated 
by the MDRD study and the CKD-EPI equation. The 11,538 subjects with 
normoalbuminuria (73.2% of the entire cohort) were stratified in those with 
normal albuminuria (NA, AER<10 mg/24h; n=6,023, 52.2%) and low albu-
minuria (LA, AER=10-29 mg/24h, n=5,515, 47.8%).
Results: Compared with NA subjects, LA patients were more frequently 
males and former or current smokers, had longer diabetes duration, higher 
HbA1c, diastolic blood pressure, and, in men only, BMI waist circumference, 
triglycerides, and LDL-cholesterol (in men only), and higher prevalence of 
family history of hypertension, use of antihypertensive drugs and oral hypo-
glycaemic agents (OHAs) or insulin, hypertension, and the metabolic syn-
drome. Moreover, patients with LA had higher prevalence of: non-advanced 
(12.1% vs. 9.9%) and advanced (7.6% vs 6.5%) retinopathy (p<0.0001); any 
CVD (21.9% vs. 17.9%, p<0.0001); myocardial infarction (10.6% vs. 9.3%, 
p=0.019); and coronary (15.0% vs. 12.5%, p<0.0001 in males only) and 
peripheral (4.7% vs. 3.6%, p=0.003 in females only) artery disease. eGFR 
correlated significantly with AER (p<0.0001), though prevalence of LA in-
creased only from category 3b for eGFRMDRD and 3a for eGFRCKD-EPI. Lo-
gistic regression with backward variables selection showed an independent 
correlation of LA with age (OR=1.018), smoking status (former, OR=1.158; 
current, OR=1.234), HbA1c (OR=1.065), triglycerides (OR=1.001), dias-
tolic BP (OR=1.010), waist circumference (OR=1.004), use of RAS block-
ers (OR=1.081) or DHP Ca-channel blockers (OR=1.178), use of OHA 
(OR=1.324), OHA+insulin (OR=1.378), or insulin alone (OR=1.535), and 
family history of hypertension (OR=1.321).
Conclusion: Several factors that are potentially amenable of intervention are 
associated with an early increase of AER within the normoalbuminuric range 
in patients with type 2 diabetes from the RIACE cohort.
Clinical Trial Registration Number: NCT00715481
Supported by: Fo.Ri.SID, DEM, Eli-Lilly, Takeda, Chiesi, Boehringer-Ingelheim
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Kidney injury molecule - 1 is linked to the loss of kidney function and 
life span, in patients with type 1 diabetes
N.M. Panduru1,2, N. Sandholm2, C. Forsblom2, V. Harjutsalo2,3, A. Bierhaus4, 
M. Saraheimo5, P. Humpert6, P.-H. Groop5,2;  
12nd Clinical Department - Diabetes, Nutrition and Metabolic Diseases 
Chair, “Carol Davila” University of Medicine and Pharmacy, Bucharest, 
Romania, 2Folkhälsan Institute of Genetics, Folkhälsan Research Center, 
Helsinki, Finland, 3Diabetes Prevention Unit, National Institute for Health 
and Welfare, Helsinki, Finland, 4Department of Medicine I and Clinical 
Chemistry, University of Heidelberg, Germany, 5Division of Nephrology 
- Department of Medicine, Helsinki University Central Hospital, Finland, 
6Stoffwechselzentrum Rhein Pfalz, Mannheim, Germany.
Background and aims: We previously showed that kidney injury molecule 1 
(KIM-1) predicts progression to ESRD, but its relation with kidney function 
and mortality in patients with type 1 diabetes is not very clear. The aim of this 
study is to investigate if KIM-1 predicts and has a causal role in the loss of 
kidney function or life span by a Mendelian randomisation approach.
Materials and methods: We enrolled at baseline 1573 patients with type 1 
diabetes divided in three groups: 953 patients with normal AER, 269 patients 
with microalbuminuria and 350 patients with macroalbuminuria. KIM-1 was 
measured at baseline, by ELISA and normalized with urinary creatinine. Kid-
ney function was evaluated by estimated GFR acording to CKD-EPI formula. 
Life span was considered the vital time. The predictive value of KIM-1 for the 
loss of kidney function and life span was evaluated by linear regression. Mul-
tiple linear regression models estimated the observed effect (association) of 
KIM-1 on eGFR or life span. We assessed the causal effect of KIM-1 on eGFR 
and life span, by Instrumental variable analysis, using two stage least squares 
method (2SLS), with the top SNP associated with KIM-1 from our GWAS.
Results: In linear regression analysis KIM-1 predicted the loss of GFR in 
univariate analysis (β=-4.522; P<0.0001), but not when adjusted for albumin 
excretion rate (AER) (β=0.336; P=0.70). Also KIM-1 predicted the life span 
in univariate linear regression analysis (β=0.812; p=0.006), adjusted for AER 
(β=1.103; P<0.0001), but not eGFR (β=0.318; P=0.26). In our GWAS the sin-
gle nucleotide polymorphism - rs2036402 presented the strongest association 
with KIM-1 (p=3.54x10-38). The instrumental analysis (IV), showed that 
increased KIM-1 was associated with decreased eGFR, even after adjusting 
for AER (β=-5.981; P=0.021). Furthermore, the IV analysis showed that in-
creased KIM-1 was associated with life span even adjusted for AER (β=1.920; 
p=0.038), but not when ajusted for eGFR (β=1.167; p=0.19).
Conclusion: In summary, increased KIM-1 levels is associated with de-
creased eGFR in patients with type 1 diabetes. Furthermore KIM-1 is asso-
ciated with life span, in the same patients and this association seems to be 
mediated by eGFR.
Supported by: Folkhälsan Research Foundation, the Wilhelm and Else Stock-
mann Foundation.
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A novel podocyte gene, R3h domain containing-like inhibits non-
canonical TGF-beta signalling
T. Ishikawa1, M. Takemoto1, Y. Akimoto2, K. Yan3, S. Kenichi1, P. He1,  
R. Ishibashi1, Y. Maezawa1, C. Betsholtz4, K. Tryggvason5, K. Yokote1;  
1Department of Clinical Cell Biology and Medicine, Chiba University 
Graduate School of Medicine, 2Department of Anatomy, Kyorin University 
School of Medicine, Tokyo, 3Department of Pediatrics, Kyorin University 
School of Medicine, Chiba, Japan, 4Department Immunology,  
Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Sweden, 
5Diabetes Research, Duke-NUS, Singapore.
Background and aims: Diabetic nephropathy (DN) is a major microvascu-
lar complication of diabetes mellitus and is one of the most common causes 
of end-stage renal disease. However, the molecular mechanisms underlying 
DN remain largely unknown. We previously identified >300 glomerulus-en-
riched transcripts, including R3h domain containing-like (R3hdml), through 
large-scale sequencing and microarray profiling of the mouse glomerular 
transcriptome. Therefore, the aim of this study was to analyze both the in 
vivo and in vitro functions of R3hdml.
Materials and methods: R3hdml mRNA expression was examined in mice 
by non-radioactive in situ hybridization, and protein expression was evalu-
ated by immunohistochemistry (IHC) or western blot (WB) analysis. Cul-
tured murine podocytes, R3hdml knockout (R3hKO) podocytes, and human 
fibroblasts overexpressing R3hdml were used for in vitro analysis. The effects 
of transforming growth factor-β (TGF-β) on R3hdml expression and func-
tion were evaluated by real-time polymerase chain reaction and WB analy-
sis. R3hdml knockout mice were generated by homologous recombination. 
Diabetes was induced in mice by intraperitoneal injection of streptozotocin 
(STZ).
Results: Both R3hdml mRNA and protein were specifically expressed in glo-
merular podocytes. TGF-β has been reported to play a major role in DN. 
Therefore, we evaluated the effects of TGF-β on R3hdml expression and func-
tion. TGF-β can activate not only Smad-dependent pathways but also non-
Smad pathways, including the non-canonical p38 mitogen-activated protein 
kinase (MAPK) pathway. When human fibroblasts were treated with TGF-β, 
phosphorylation of p38 MAPK (pp38MAPK) increased by 2.26 ± 0.15-fold 
(mean ± SEM). On the other hand, TGF-β-induced pp38MAPK expression 
was significantly (54%) reduced in human fibroblasts overexpressing R3hdml. 
Smad phosphorylation was independent of R3hdml, indicating that R3hdml 
inhibited the non-Smad pathway but not the Smad-dependent pathway. 
Furthermore, TGF-β increased pp38MAPK by 2.35 ± 0.01-fold in primary 
cultured podocytes. TGF-β-induced pp38MAPK was significantly higher 
(2.03-fold) in R3hKO podocytes than in the wild-type(WT) controls. R3hKO 
mice showed aberrant podocyte structure and partial thickening of the glo-
merular basement membrane. Furthermore, IHC revealed that pp38MAPK 
was increased by 2.14 ± 0.490-fold in R3hKO glomeruli compared with the 
WT controls. R3hdml mRNA expression in the glomeruli was increased by 
2.7 ± 0.73-fold in the diabetic mice compared with the WT controls. Finally, 
we induced diabetes in both the WT and R3hKO mice by STZ injection and 
found that the prevalence of albuminuria was significantly increased in the 
diabetic and R3hKO mice compared with the diabetic WT controls.
Conclusion: We identified a novel podocyte-specific gene, R3hdml, which is 
regulated by TGF-β signaling. This gene product inhibits TGF-β-induced p38 
MAPK signaling. Our results suggest that podocyte-specific therapy presents 
a viable option to inhibit DN in the near future.
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ABCG8 polymorphisms and renal disease in type 2 diabetic patients
F. Fumeron1, A. Nicolas1, S. Fatima1, N. Munoz-Bellili1, P.-J. Saulnier2,  
S. Hadjadj2,3, G. Velho1, M. Marre1,4, R. Roussel1,4;  
1INSERM U1138, Centre de Recherche des Cordeliers, Paris, 2Université 
de Poitiers, UFR de Médecine et Pharmacie, Poitiers, 3INSERM, U1082, 
Poitiers, 4Department of Diabetology, Endocrinology and Nutrition, 
Assistance Publique Hôpitaux de Paris, Bichat Hospital, France.
Background and aims: The ATP-binding cassette transporters G5 and G8 
(ABCG5 and ABCG8) play an important role in the intestinal sterol absorp-
tion and biliary acid secretion. They are involved in the elimination of plant 
sterols. Polymorphisms of the genes coding for these transporters have been 
involved in absorption of sterols, cholesterol synthesis, gallstone disease, in-
sulin resistance and cardiovascular risk. Lipid metabolism and insulin resist-
ance are associated with diabetic nephropathy. The aim of our study was to 
assess the associations between two ABCG8 coding polymorphisms, T400K 
and D19H, and the incidence of renal events in type 2 diabetic subjects.
Materials and methods: First, participants were the 3,123 French type 2 dia-
betic subjects with micro- or macro-albuminuria from the genetic substudy 
of the DIABHYCAR trial. These participants had serum creatinine concen-
trations ≤150 μmol/l. The drug tested against placebo was low-dose ramipril 
(1.25 mg/day). The mean duration of follow-up was 4 years. Renal events 
were defined as a doubling of serum creatinine concentration or end-stage 
renal disease at follow-up. This trial showed no effect of the drug on the inci-
dence of renal events. We then used a second population (DIAB2NEPHRO-
GENE/SURDIAGENE study) of 2,452 patients with type 2 diabetes for the 
purpose of replication. Polymorphisms T400K and D19H were genotyped 
using Kaspar method. The genotyping success rate was > 98%.
Results: Seventy-five renal events (66 doublings of serum creatinine concen-
tration, and 9 cases of end-stage renal failure) occurred in genotyped patients 
during the study. The 400K allele was significantly associated with a higher 
risk of incident renal event: sex and age adjusted OR 1.66, 95%CI 1.15-2.39, 
P=0.007. This association was still significant after multiple additional adjust-
ments for values at baseline (BMI, blood lipids, estimated glomerular filtra-
tion rate, urinary albumin excretion): OR 1.57, 95%CI 1.07-2.31, P= 0.02. 
There was a trend toward an interaction with ramipril treatment (P interac-
tion= 0.06). The 400K allele was associated with a higher risk in the ramipril 
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treated group (OR 2.41, 95%CI 1.41-4.13, P<0.001) but not in the placebo 
group (OR 1.21, 95%CI 0.72-2.03). In the replication cohort, no association 
was found with the incidence of new renal events, but the 400K allele was 
associated with the prevalence of end stage renal disease at baseline (sex, age, 
BMI adjusted OR 1.77, 95%CI 1.01-3.10, P= 0.045). No significant associa-
tion was found between the D19H polymorphism and the risk of diabetic 
nephropathy.
Conclusion: A polymorphism of the sterol transporter ABCG8 has been as-
sociated with prevalence of end stage renal disease and with the incidence of 
new renal events in type 2 diabetic patients. These results described for the 
first time should be replicated.
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Genome-wide association studies of diabetic kidney disease
E. Ahlqvist1, H.A. Deshmukh2, N. Sandholm3,4, C. Ladenvall1,  
N. Van Zuydam5, M. Lajer6, L. Marcovecchio7, E. Rurali8, W.N. Rayner5;  
1Department of Clinical Sciences, Lund University, Malmö, Sweden, 
2Ninewells Hospital and Medical School, University of Dundee, UK, 
3Folkhälsan Research Center, Helsinki, Finland, 4Division of Nephrology, 
Helsinki University Central Hospital, Finland, 5Wellcome Trust Centre 
for Human Genetics, University of Oxford, UK, 6Steno Diabetes Center, 
Gentofte, Denmark, 7Department of Paediatrics, University of Cambridge, 
UK, 8Istituto di Ricerche Farmacologiche “Mario Negri”, IRCCS, Bergamo, 
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Background and aims: Diabetes mellitus is associated with devastating 
chronic complications including diabetic kidney disease (DKD), a leading 
cause of end-stage renal disease (ESRD). The risk of developing DKD is partly 
determined by genetic factors. In the SUMMIT consortium we performed 
meta-analysis of genome-wide association studies in European T1D and 
T2D patients to identify genetic determinants of DKD. The genetic variants 
regulating early stages of disease may differ from those that determine pro-
gression to severe disease. We therefore analyzed microalbuminuria (MiAU), 
reflecting early pathologic changes and endothelial dysfunction, and more 
severe DKD, i.e. macroalbuminuria (MaAU), chronic kidney disease (CKD) 
and ESRD, separately.
Materials and methods: DKD was defined as MiAU, MaAU or ESRD, whereas 
controls had normoalbuminuria and diabetes duration > 10 years. The study 
included four cohorts of T2D patients: GoDARTS (n=3240), SDR (n=1830), 
Steno (n=294) and MNI (n=353). We analyzed ~9.2 million single nucleotide 
polymorphisms (SNPs), imputed based on the 1000G (March 2012) refer-
ence panel, using logistic regression, adjusting for sex, age at onset and dura-
tion of diabetes, for five phenotypes: DKD, CKD, MiAU, MaAU+ESRD and 
ESRD. Meta-analyses were performed using a fixed effects model. We also 
performed joint analyses with four T1D studies analyzed using similar meth-
ods and phenotype definitions: FinnDiane (n=3415), Eurodiab (n=789), SDR 
(n=556) and Cambridge (n=396).
Results: In T2D, rs2206136 (OR=1.2, p=2.1x10-8) near PLCB4 was signifi-
cantly associated with CKD (3094 cases, 2906 controls). Nominal associa-
tions were also seen with DKD, MiAU and ESRD (p<0.01). The strongest 
associations for other phenotypes were rs183249293 (OR=0.42, p=2.4x10-7) 
for DKD (3345 cases, 2372 controls); rs2150814 (OR=0.8, p=8.1x10-8) 
near GABRR1 for MiAU (1989 cases, 2238 controls); rs76262407 (OR=5.5, 
p=1.1x10-7) for ESRD (371 cases, 4471 controls); and rs116354014 (OR=4.5, 
p=2.5x10-7) for MaAU+ESRD (1339 cases, 2372 controls). In the joint 
T1D+T2D meta-analysis rs2331712 near STXBP5L reached genome-wide 
significance (OR=1.4, p=1.9x10-8, 1184 cases, 8466 controls) for ESRD. The 
effect size was slightly higher in T2D (OR=1.8, p=4.1x10-6) compared to T1D 
(OR=1.3, p=0.0008). No association was seen with MiAU or CKD (p>0.1) 
suggesting an effect specifically on late stages of disease.
Conclusion: We have identified two new candidate loci for DKD situated 
near the PLCB4 (phospholipase C, beta 4) and STXBP5L (syntaxin binding 
protein 5-like) genes. PLCB4 has previously been shown to be differentially 
expressed in DKD, making it a strong candidate gene, possibly affecting dis-
ease risk via the DAG/PKC pathway.
Supported by: IMI, European Commission’s FP7 (the SUMMIT consortium, 
IMI-2008/115006)
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Low levels of C-peptide production protect from complications and 
improve HbA1c control in longstanding type 1 diabetes
D.L. Faustman1, P.E. Reinhold1, S.L. Washer1, E. Hsu1, M. Zhao1, D. Burger1, 
H. Zheng2;  
1Immunobiology Laboratory, Massachusetts General Hospital/Harvard 
Medical School, Charlestown, 2Biostatistics, Massachusetts General 
Hospital/Harvard Medical School, Charlestown, USA.
Background and aims: Low levels of C-peptide (2.5-50 pmol/L) are pro-
duced for decades after the onset of type I diabetes, but the clinical signifi-
cance is unknown. This study seeks to understand the clinical significance of 
extremely low levels (< 10 pmol/L) of C-peptide production.
Materials and methods: We evaluated the relationship between low levels 
of C-peptide and age of onset (n=1273), diabetes complications (n=324), 
HbA1c control (n=807), risk of hypoglycemia (n=331), and response to a 
mixed meal tolerance test (MMTT, n=9) in patients with longstanding type 
I diabetes. C-peptide samples were tested using a regular or ultrasensitive 
C-peptide ELISA kit. Hypoglycemia risk was determined using a validated 
survey. For the MMTT, each subject had three MMTT tests performed over 
a three-month period to understand biological variation in stimulated C-
peptide at low ranges of basal pancreas function.
Results: After adjusting for disease duration, we found that extremely low 
levels of C-peptide were associated with risk for diabetes-related complica-
tions (e.g., nephropathy, neuropathy, cardiovascular disease)(p=0.03) and 
poorer metabolic control captured by HbA1c (p=0.01). There was no asso-
ciation between C-peptide < 10 pmol/L and risk of hypoglycemia. Even at 
extremely low levels of C-peptide production, beta-islet cells responded to 
a glucose challenge from a MMTT by secreting insulin, indicating that pan-
creatic function is preserved, but patients with undetectable C-peptide (<1.5 
- 2.5 pmol/L) did not respond to the MMTT.
Conclusion: Extremely low levels of C-peptide appear to have clinical signifi-
cance and may be helpful in defining groups of long term diabetics who are at 
risk for complications or poor metabolic control.
Supported by: Iacocca Foundation
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Skin AGE fluorophore LW-1 predicts micro- and subclinical 
macrovascular complication progression in type 1 diabetes
V.M. Monnier1, W. Sun2, J.M. Lachin3, P.A. Cleary3, S. Genuth4,  
The DCCT/EDIC Research Group, D.R. Sell4;  
1Pathology & Biochemistry, Case Western Reserve Univ, Cleveland, 
2Biostatistic Center, George Washington University, Washington, 
3Biostatistics Center, George Washington University, Washington, 
4Pathology, Case Western Reserve Univ, Cleveland, USA.
Background and aims: Skin collagen Long Wave autofluorescence (LW) is 
widely used as a surrogate marker for the accumulation of advanced glyca-
tion end-products (AGE). We determined the relationship between LW-1, 
a novel fluorescent skin collagen marker of partially known structure, with 
glycaemia, other collagen AGEs and the severity of complications in biopsies 
obtained from 216 participants at closeout of the Diabetes Control and Com-
plications Trial (DCCT) study in 1993.
Materials and methods: Skin biopsy proteolytic digests were prepared as de-
scribed and LW-1 content was determined by fluorescence HPLC.
Results: LW-1 levels increased with age and diabetes duration and when cor-
rected for these parameters, they were significantly decreased with intensive 
vs, conventional diabetes therapy in both primary and secondary DCCT co-
horts (P less than 0.0001). They were associated with retinopathy progres-
sion (sustained greater than 3 microaneurysms ever in DCCT) and albumin 
excretion rate (AER closest to biopsy > 40 mg/24 hr) (P= 0.0038) which 
remained significant after adjustment for DCCT HbA1c. In EDIC, LW-1 
correlated with retinopathy progression at EDIC Year 13-16, intima media 
thickness(IMT) at Yr 6 (n=147, P=0.014) and left ventricular mass (EDIC 
Yr 14-16) adjusted for EDIC A1c (P=0.004). LW-1 correlated highly (P less 
than 0.0001) with collagen modifications in the order glucosepane > pento-
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 46 
1 C
sidine > pepsin insolubility > collagen fluorescence > MG-H1, and weaker 
with fructose-lysine (P = 0.0021), and explained almost 10% of the variability 
in DCCT HbA1c.
Conclusion: LW-1 is a novel robust marker which predicts progression of 
retinopathy and nephropathy and future progression of IMT and LVM in-
crease independently of the effects of HbA1c.
Supported by: NIH/NIDDK, JDRF
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Plasma levels of MMP-2, -3 and -10, and of TIMP-1 are associated with 
vascular complications in patients with type 1 diabetes: the EURODIAB 
prospective complications study
S.A. Peeters1,2, L. Engelen1,3, J. Buijs2, N. Chaturvedi4, J.H. Fuller5,  
C.G. Schalkwijk1,3, C.D.A. Stehouwer1,3;  
1Department of Internal Medicine, Maastricht University Medical 
Centre, Netherlands, 2Department of Internal Medicine, Atrium Medical 
Centre, Heerlen, Netherlands, 3CARIM School for Cardiovascular 
Diseases, Maastricht University Medical Centre, Netherlands, 4Institute of 
Cardiovascular Sciences, University College, London, UK, 5Department of 
Epidemiology and Public Health, University College, London, UK.
Background and aims: Extracellular matrix remodeling by matrix metallo-
proteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may 
lead to micro- and/or macrovascular complications in type 1 diabetes. Evi-
dence so far with regard to the associations between plasma MMPs and vas-
cular complications is contradictory, as both positive and null associations 
have been described in relatively small studies. Therefore we have investigat-
ed the associations between plasma MMP-1, -2, -3, -9 and -10, and TIMP-1 
on the one hand and cardiovascular disease (CVD) and microvascular com-
plications on the other in a cohort of type 1 diabetic patients, and the extent 
to which such associations may be explained (i.e. mediated) by low-grade 
inflammation (LGI) and/or endothelial dysfunction (ED), as estimated by 
plasma markers.
Materials and methods: The study included 493 type 1 diabetic patients 
(39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complica-
tions Study. We used linear regression analyses to investigate the differences 
in plasma levels of MMP-1, -2, -3, -9 and -10, and of TIMP-1 between pa-
tients with vs. without CVD, albuminuria (normo, micro and macro) and 
retinopathy (no, non-proliferative and proliferative). All analyses were ad-
justed for age, sex, duration of diabetes and Hba1c and additionally for other 
cardiovascular risk factors and other vascular complications, as appropriate. 
Standardized concentrations of plasma CRP, IL-6 and TNF-α were averaged 
to compose an LGI score and standardized concentrations of plasma sV-
CAM-1 and sE-selectin composed an ED score. These LGI and ED scores 
were then added to the fully adjusted model.
Results: Patients with CVD (n=118) had significantly higher levels of TIMP-
1 [β = 0.32 SD (95%CI 0.12; 0.52)] than those without CVD (n=375). Higher 
plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with 
increasing levels of albuminuria (p-trends were 0.034, 0.004, 0.004 and 0.001, 
respectively). The severity of retinopathy was significantly associated with 
higher levels of MMP-2 (p-trend=0.022). MMP-1, -3, -9 and -10, and TIMP-
1 were significantly and positively associated with the LGI score. MMP-2, 
MMP-10 and TIMP-1 were significantly and positively associated with the 
ED score. Nevertheless, the significant associations between plasma levels of 
MMPs and TIMP-1 on the one hand and CVD, albuminuria and retinopathy 
on the other were largely independent of LGI and ED.
Conclusion: In patients with type 1 diabetes, prevalent CVD, albuminuria 
and retinopathy were significantly associated with higher plasma levels of 
MMP-2, MMP-3, MMP-10 and TIMP-1, and these associations were largely 
independent of LGI and ED. Thus, these data support the hypothesis that 
extracellular matrix remodeling, by the action of MMPs and TIMP-1, is in-
volved in vascular complications in type 1 diabetes.
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Acute glucose and insulin changes during OGTT relate to LV-myocardial 
deformation changes, untwisting and coronary-flow-reserve through 
increased arterial stiffness
F. Kousathana1, I. Ikonomidis2, G. Pavlidis2, C. Koukoulis2, M. Varoudi2,  
G. Matsaggouras1, H. Triantafyllidi2, J. Lekakis2, G. Dimitriadis1,  
V.A. Lambadiari1;  
12nd Dept of Internal Medicine, Research Institute and Diabetes Center, 
Attikon University Hospital, 22nd Cardiology Dept, University of Athens, 
Attikon Hospital, Athens, Greece.
Background and aims: Insulin resistance is linked to endothelial dysfunc-
tion and increased arterial stiffness. Increased Arterial stiffness may impair 
LV function. We investigated whether first-degree relatives of diabetic pa-
tients have similarly impaired coronary microcirculation, LV-myocardial 
strain and twisting with diabetic patients, as assessed after an oral glucose 
tolerance test (OGTT).
Materials and methods: In 76 subjects without known diabetes a standard 
75-gr OGTT was performed. Glucose and insulin levels, pulse wave veloc-
ity (PWVa) and augmentation index (AI) (Arteriograph, Tensiomed) were 
measured at 0, 30, 60, 90 and 120 min after glucose load. At 0 and 120 min, we 
measured: a) E’ and A’ mitral annular velocities and their ratio E’/A’ using tis-
sue Doppler imaging, b) LV longitudinal (GLS-%), strain, systolic(LGSr) and 
diastolic strain rate (LGSrE), twisting (Tw -deg), peak twisting (Tw-deg/sec) 
velocity, and peak untwisting (unTw) velocity using speckle tracking echo-
cardiography and c) coronary flow reserve (CFR) of the LAD after adenosine 
infusion using Doppler echocardiography. We assessed insulin resistance us-
ing insulin sensitivity index (ISI) which includes both insulin and glucose 
levels at baseline and 120 min after OGTT.
Results: Of the 76 subjects, 36 who were first degree relatives of diabetics had 
normal OGTT (relatives), 20 had normal OGTT and no family history of dia-
betes (normals), and 20 had abnormal OGTT (diabetics). Age, sex and BMI 
were similar between subgroups (p=ns). Compared to normals, diabetics 
and relatives had both higher baseline PWVa (9.3±2 vs. 8.1±2 vs. 7.2±1.6 m/
sec,), AI (23±9 vs. 24±14, 18±15%,), insulin (median 14 vs. 15 vs. 10 μU/ml, 
p<0.09), and lower ISI (50± 24 vs. 73.±22 vs. 93±17), baseline E’/A’ (0.7±0.2 
vs. 0.98±0.2 vs 1.1±0.3,) LGSr (-0.95±0.1 vs. -0.94±0.1 vs. -1.1±15 l/sec,) LG-
SrE (0.98±0.1 vs. 1.±0.1 vs 1.3±15 l/sec, p<0.05 ) Tw (15±7 vs. 13±5 vs. 17±7) 
and unTw velocity (-95±31 vs. -94±40 vs. 116±36) and lower CFR (2.7±1.1 
vs. 2.6±0.9 vs. 3.0±0.6) (p<0.05 for all comparisons). Compared to baseline, 
insulin was increased at 120min, to 87μU/ml (521%) in diabetics, 59μU/ml 
(293%) in relatives and 29μU/ml (190%) in normals (p<0.05). PWVa was in-
creased at 120min to 8.9±2 m/s (10%) in relatives, was reduced to 6.8±2 m/s 
(6%) in normals and remained high (9.4±2m/s) in diabetics (p<0.05). Tw and 
unTw velocity at 120min, was increased to 17±7 (13%), and -105±31 (10%) 
in diabetics, to 15±5 (15%) and -105±40(10%) in relatives and was reduced 
to 13±7 (24%) and -87±30 (25%) in normals (p<0.05). CFR was decreased 
to 2.4±0.7 (14%) in diabetics, 2.3±0.7 (12%) in relatives and 2.8±0.9 (6%) in 
normals (p<0.05). ISI, insulin and glucose at 120 min were related with PWV, 
CFR, GLS, LGSr E ,Tw, Tw velocity unTw velocity and E’/A’ in both diabetics 
and relatives(p<0.05). At 0 and 120 min, PWV was related with the corre-
sponding LGSr E ,Tw, Tw velocity unTw velocity and E’/A’(p<0.05)
Conclusion: Acute hyperglycaemia and hyperinsulinemia post OGTT are 
related to abnormal LV-myocardial deformation, twisting and untwisting 
possibly through increases in arterial stiffness and impairment of coronary 
microcirculatory function in first degree relatives and diabetics
Supported by: Research Grant Authority Athens Kapodistrian University
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Vascular and cellular ageing in patients with type 2 diabetes mellitus
N.V. Brailova1,2, E. Dudinskaya1, O. Tkacheva1, S. Boytsov1, I. Strazhesko1, 
D. Akasheva1, M. Shestakova2,3, Y. Brailov3, M. Pokrovskaya1;  
1National Research Centre for Preventive Medicine,  
22National Research Center for Endocrinology,  
3Align Technology Inc., Moscow, Russian Federation.
Background and aims: It is known that glucose disturbances contribute to 
micro- and macrovascular complications and vascular aging. The length of 
telomere (TL) is considered as a biomarker for vascular and cellular aging. 
But the interrelation of vascular aging and cellular aging in type 2 diabetes 
mellitus (T2DM) and pathogenic mechanisms of this interrelation remains a 
challenge. The aim of our study was to determine mechanisms of TL shorten-
ing and vascular aging in patients with T2DM.
Materials and methods: The study group included 50 patients with T2DM 
in mean age 58.4±7.83 years and 156 healthy patients in mean age 57.04±7.7 
years. TL and telomerase activity (TA) was assessed by quantitative polymer-
ase chain reaction (PCR). Intima-media thickness (IMT) and plaque pres-
ence (PP) were determined by ultrasonography in both left and right carotid 
arteries. Arterial stiffness (AS) was appreciated by aortic pulse wave velocity 
(PWV) measuring by SphygmoCor (AtCor Medical). Endothelial dysfunc-
tion as assessed by flow-mediated endothelium-dependent dilation (FMV) in 
response to reactive hyperemia and endothelium-independent vasodilation 
in response to nitroglycerine (NDV). Oxidative stress was assessed by malon-
dialdehyde measuring, inflammation was estimated by interleukin-6 (IL-6), 
C-reactive protein (CRP), fibrinogen measuring.
Results: We found in group with T2DM compared with the control group of 
healthy patients a greater telomere shortening (9,57 vs 9,75, р=0,0051) and 
TA reduction (0,33 vs 0,49, р=0,0023). Vascular aging are more pronounced 
in patients with T2DM, than without diabetes: PWV СРПВ 12,3 m/s vs 
11,3 м/с (р=0,0032), IMT 0,93 mm vs 0,77 mm (р<0,0001), PP 2,02 vs 1,29 
(р=0,0026). Patients with T2DM have worse endothelial function: FMV 9 vs 
11 (р=0,0146), NDV 13 vs 16,5 (р=0,0001). With regard to lipid oxidation 
product and inflammatory markers we found significant differences: patients 
with T2DM have more increased malondialdehyde (0,08 vs 0,02,р=0,044), 
CRP (3,60 vs 2,35, р<0,0001), increased fibrinogen (0,30 vs 0,11, р=0,0007).
Conclusion: Vascular aging (AS, IMT increasing, subclinical atherosclero-
sis (PP), endothelial dysfunction) and cellular aging (TL, TA reduction) are 
more pronounced in patients with T2DM, than without diabetes. Patients 
with T2DM have more pronounced oxidative stress and chronic inflamma-
tion. Thus we can suppose that oxidative stress and chronic inflammation 
play principal role in TL shortening and vascular aging at macro, tissue and 
cell level.
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Arterial stiffness is not associated with skin microvascular function in 
individuals with or without type 2 diabetes: the Maastricht Study
T.T. van Sloten1, A.J.H. Houben1, D.M.J. Muris1, M.T. Schram1,  
P.C. Dagnelie2, C. van der Kallen1, N.C. Schaper1, S.J. Sep1, A. Koster3,  
A.D. Protogerou1, R.M.A. Henry1, C.D.A. Stehouwer1;  
1Medicine, Maastricht University Medical Centre,  
2Epidemiology, Maastricht University Medical Centre,  
3Social Medicine, Maastricht University Medical Centre, Netherlands.
Background and aims: Increased arterial stiffness leads to an increased 
pulsatile pressure load, which may damage the microcirculation. Individu-
als with type 2 diabetes (T2DM) may be particularly prone to the detrimen-
tal effects of this increased pressure load, because T2DM is associated with 
increased microvascular perfusion, allowing pulsatile pressure to penetrate 
deeply into the microcirculation. The skin enables the direct measurement of 
microcirculatory function both at rest and during provocative stimuli. Fur-
thermore, the cutaneous microcirculation is considered a representative vas-
cular bed to examine generalized microvascular phenomena. The aim of the 
present study was therefore to evaluate, in a large population-based cohort, 
the association between arterial stiffness and skin microvascular function. 
We additionally investigated whether any such association was stronger in 
individuals with as compared to those without T2DM.
Materials and methods: We used cross-sectional data of The Maastricht 
Study (for the present analysis: n=737; age 59.7 years; 45.2% women; 28.8% 
T2DM (by design)). The Maastricht Study is a population-based cohort study 
that focuses on the pathophysiology of T2DM. Arterial stiffness was deter-
mined via carotid-femoral pulse wave velocity (cfPWV, tonometry). In ad-
dition, finger skin capillaroscopy was used to determine capillary density at 
baseline and during post-occlusive hyperaemic response and venous conges-
tion. Laser Doppler flowmetry was used to assess skin microvascular flow-
motion.
Results: After adjustment for age and sex, both in individuals with and with-
out T2DM, cfPWV was not associated with baseline capillary density, hyper-
aemic capillary recruitment, or capillary density during venous congestion 
(Table, models 1). In addition, cfPWV was not associated with microvascular 
flowmotion (models 1). Further adjustment for potential confounders (mod-
els 2 and 3) did not materially change these results. There was no interaction 
with type 2 diabetes (P for interaction, all >.13).
Conclusion: In the present population-based cohort study, arterial stiffness 
was not associated with skin microvascular function. This suggests that in-
creased arterial stiffness does not lead to generalized microvascular dysfunc-
tion, irrespective of the presence of T2DM. 
Supported by: OP-ZUID, Province of Limburg, Weijerhorst, Pearl String initia-
tive, CARIM
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LKB1 and AMPK regulate Nptx2 expression and glutamate signalling in 
pancreatic beta cells
M.-S. Nguyen-Tu1, C. Kantor1, S. Sayers1, T.J. Pullen1, G. Sun1, M. Kone1,  
M. Ibberson2, J. Ferrer3, B. Thorens4, A. Swisa5, Y. Dor5, T. Hildebrandt6,  
I. Uphues6, G.A. Rutter1;  
1Section of Cell Biology, Department of Medicine, Imperial College London, 
UK, 2Swiss institute of Bioinformatics, University of Lausanne, Switzerland, 
3Endocrinology and Metabolic Medicine, Department of Medicine, 
Imperial College London, UK, 4Center for integrative Genomics, University 
of Lausanne, Switzerland, 5Hebrew University of Jerusalem, School of 
Medicine-IMRC, Israel, 6Boerhringer Ingelheim International GmbH, 
Ingelheim, Germany.
Background and aims: Inactivation in beta cells of the tumour suppressor 
Liver kinase B1 (LKB1/STK11) or the downstream enzyme AMP-activated 
protein kinase (AMPK) exerts dramatic effects on beta cell growth and in-
sulin secretion. Here, we used massive parallel sequencing (RNASeq), and 
subsequent functional analyses, to identify gene clusters which may mediate 
these effects.
Materials and methods: Mice null for LKB1 or both AMPK catalytic (α1, α2) 
subunits were generated by Ins1Cre-mediated (beta cell-selective) deletion 
of flox’d alleles. Islets were isolated from four 12 week old mice per geno-
type. After 24 h culture at 11 mM glucose RNA was extracted (RNAEasy) 
before deep sequencing (RNASeq) on a Hiseq 2000. Cytosolic free Ca2+ was 
measured using fura-2 using an Olympus IX81 microscope with microman-
ager-controlled data capture via an Andor Zyla cMOS camera. Immunohisto-
chemial analysis of pancreatic slices was performed using a rabbit anti-Nptx2 
antibody on a Zeiss-200M microscope (Zen software), and analysed using 
ImageJ. Insulin secretion was measured during static incubations (30 min) at 
3 or 16 mM glucose using radioimmunoassay.
Results: Amongst the mRNAs most strongly up-regulated by LKB1 deletion 
was a cluster involved with glutamate signalling, including Nptx2, encoding 
neuronal pentraxin 2 (11.2-fold, E-value <0.001), and dlgap2, encoding discs, 
large (Drosophila) homolog-associated protein 2 (11.9-fold, E<0.001). A sim-
ilar degree of up-regulation was observed after AMPK deletion (19.7-fold, 
E<0.01 and 4.7-fold, E<0.01, respectively). LKB1 deletion increased Nptx2 
immunoreactivity in islets by 6.0-fold, p<0.01. At 3 mM glucose, cytosolic 
calcium increases in response to the glutamate receptor agonist kainate were 
significantly increased by LKB1 deletion (area under the curve, 2.1-fold, 
p<0.05, amplitude 43 %, p<0.01), whilst insulin secretion was increased 2.2-
fold (p<0.05) at 3 but not 16 mM glucose.
Conclusion: LKB1regulates glutamate receptor signalling in beta cells by 
a mechanism likely to involve the up-regulation of Nptx2, a secreted pro-
tein which binds α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors, and by dlgap2, which interacts with PSD-95 (encoded by 
DLG4) and N-methyl-D-aspartate NMDA receptors. The actions of LKB1 are 
likely to involve the nutrient-sensitive protein kinase AMPK, and may thus 
provide a novel mechanism by which glucose or other secretagogues regulate 
insulin secretion or beta cell survival.
Supported by: EU-FP7(IMIDIA), The Wellcome Trust, Royal Society, 
MRC(UK), BBSRC(UK)
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The non-canonical NFκB pathway as a novel player in beta cell 
dysfunction in diabetes
E.K. Malle1, B.M. Tan1, S.N. Walters1, N.W. Zammit1, R. Brink1, J. Cantley2, 
S.T. Grey1;  
1Immunology, Garvan Institute of Medical Research, Sydney, Australia, 
2University of Oxford, UK.
Background and aims: We previously demonstrated that mice deficient for 
TRAF2 (βTRAF2) in their beta cells showed exacerbated glucose intolerance 
and an impaired first phase insulin secretion in a diet-induced obesity model. 
βTRAF2 islets also displayed dysregulated signaling as defined by hyperac-
tivation of the non-canonical NFκB signaling pathway. TRAF2 is an adap-
tor protein that functions by recruiting the E3 ubiquitin ligases BIRC2 and 
BIRC3 to the complex, which target the NFκB inducing kinase (NIK) for 
degradation thereby directly controlling the non-canonical NFκB pathway.
Materials and methods: To dissect out the function of this E3 ubiquitin li-
gase complex in islet biology in diabetes, we generated a beta cell specific 
BIRC2/3 knockout (βBIRC) mouse. Of note, a class of BIRC inhibitors, so-
called Smac mimetics, are in Phase I and II clinical trials as anti-cancer drugs. 
We hypothesized that genetic (βBIRC mice) or drug-based (Smac mimetic) 
deletion of BIRC would impair beta cell function.
Results: βBIRC mice showed increased glucose intolerance on a high-fat 
diet (45 kcal % fat) thus phenocopying βTRAF2. The common molecular de-
nominator that we found, was increased cell intrinsic NIK accumulation and 
processing of p100 to p52 in unstimulated βTRAF2 and βBIRC islets, indicat-
ing activation of the non-canonical NFκB pathway. Thus, disruption of the 
TRAF/BIRC E3 ligase complex derails control of non-canonical NFκB signal-
ing and thereby causes beta cell dysfunction. Next, we synthesized and puri-
fied the monovalent preclinical Smac-mimetic MV1. Treatment of C57BL/6 
islets with MV1 resulted in increased processing of p100 to p52 indicating ac-
tivation of the non-canonical NFκB pathway. We then transplanted a limited 
and defined number of vehicle-control and MV1-treated islets into syngeneic 
diabetic mice and performed an i.p.GTT at day 3 and 10 post transplant. Both 
control and MV1-treated islets established normoglycemia at postoperative 
day 1-2. At day 3, MV1-treated islets showed a severe decrease in glucose 
tolerance compared to vehicle-treated controls. However, at day 10 there was 
no difference to controls, indicating that the MV1 Smac mimetic causes a 
transient defect in beta cell function. This raises the question whether cancer 
patients receiving Smac mimetics should be monitored for changes in glucose 
tolerance. In all models, βTRAF2 mice, βBIRC mice and MV1-treated islets, 
the loss of beta cell function was independent of cell death, as they main-
tained their islet mass.
Conclusion: Mice lacking TRAF2 or BIRC2/3 in beta cells exhibit severe de-
fects in glucose homeostasis and insulin secretion in a diet-induced obesity 
model. At the molecular level this E3 ubiquitin ligase complex reigns in NIK 
activation as a non-canonical NFκB pathway trigger. Loss of this control cir-
cuit by either genetic deletion or treatment with an anti-cancer Smac mimetic 
drug precipitates a diabetes phenotype. These data define NIK activation and 
non-canonical NFκB as novel players in islet dysfunction, and commend 
them as potential drug targets in diabetes.
Supported by: NHMRC/JDRF Special Programs in T1D Grant to STG 
(#427695)
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Stimulation of insulin secretion by GPR75: identification of signalling 
pathways in rodent and human beta cells
Z. Hassan, B. Liu, S. Amisten, G.C. Huang, P.M. Jones, S.J. Persaud;  
Diabetes Research Group, Kings College London, UK.
Background and aims: GPR75 is an atypical chemokine receptor that is ac-
tivated by the pro-inflammatory chemokine ligand 5 (CCL5). We have previ-
ously demonstrated that GPR75 mRNA is highly expressed by mouse and 
human islets and it localises to β-cells, whereas the conventional CCL5-acti-
vated chemokine receptors CCR1, 3 and 5 are expressed at very low levels in 
islets. We have also shown that CCL5 elevates [Ca2+]i in β-cells and stimulates 
insulin secretion, but the downstream signalling cascades and involvement of 
GPR75 in the stimulatory effects of CCL5 are unknown. This study therefore 
determined the pathways downstream of CCL5 signalling in mouse and hu-
man islets and investigated whether GPR75 activation is required for CCL5-
induced insulin secretion.
Materials and methods: Changes in [Ca2+]i were measured by single cell 
microfluorimetry of Fura-2-loaded human islet cells, insulin secretion from 
isolated mouse and human islets was determined in static incubation experi-
ments and quantified by radioimmunoassay, and GPR75 was down-regulated 
by transient transfection with GPR75 siRNAs.
Results: Blockade of L-type Ca2+channels reduced CCL5-induced eleva-
tions in [Ca2+]i in human islets (10nM CCL5: 90±15% of ATP response; 
+10μM nifedipine: 14±6%, n=7-17, P<0.05), and opening of KATP channels 
was associated with a loss in CCL5 induced insulin secretion from mouse 
islets (2mM glucose: 0.19±0.02ng/islet/h; +25nM CCL5: 0.31±0.04, P<0.05; 
+25nM CCL5 +250µM diazoxide: 0.18±0.02, P>0.2 vs 2mM glucose). Inhibi-
tion of phospholipase C in human islets also abolished the secretory response 
to CCL5 (20mM glucose: 0.65±0.07ng/islet/h; +10nM CCL5: 1.22±0.25, 
P<0.05; +10nM CCL5 +10μM U73122: 0.44±0.07, P>0.2 vs 20mM glucose), 
as did depletion of typical isoforms of protein kinase C(PKC) by 24 hour 
exposure to 4βPMA (control: 196±26% of 20mM glucose response; PKC 
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depleted: 90±10%, n=7-8, P<0.01). Furthermore, inhibition of the calcium-
calmodulin-dependent protein kinase CAMK II diminished CCL5-induced 
insulin secretion from human islets (20mM glucose: 0.57±0.08ng/islet/h; 
+10nM CCL5:1.17±0.15, P<0.05; +10nM CCL5 +10μM KN62: 0.69±0.08, 
P>0.2 vs 20mM glucose). Exposure of β-cells to GPR75 siRNAs for 48 hours 
caused 39.6±1.4% reduction in GPR75 mRNA expression and this was ac-
companied by decreased insulin secretion in response to CCL5 (non-coding 
RNAs: 166±30% of 20mM glucose response; GPR75 siRNAs: 70±10%, n=6, 
P<0.05).
Conclusion: These data indicate that CCL5 activates β-cell GPR75 to stimu-
late insulin secretion from mouse and human islets, which is dependent on 
signal transduction cascades that include phospholipase C activation, calci-
um influx via L-type Ca2+ channels, and activation of the calcium-dependent 
protein kinases PKC and CaMK II. This novel role for CCL5 in improving 
β-cell function via GPR75 activation may provide a potential therapeutic tar-
get for improving insulin secretion in type 2 diabetes.
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Knockout of GPR55 impairs insulin secretion and reduces islet cell 
turnover
B. Liu1, S. Song1, D. Baker2, Z. Hassan1, R.L. Drynda1, J.E. Bowe1,  
P.M. Jones1, S.J. Persaud1;  
1Diabetes Research Group, King’s College London,  
2Blizard Institute, Queen Mary University of London, UK.
Background and aims: GPR55 is a G-protein coupled receptor (GPCR) 
whose activity is regulated by a range of synthetic and endogenous cannabi-
noids, and by lipid-derived ligands. We have previously reported that GPR55 
knockout (KO) mice are more susceptible to diet-induced obesity, and the 
aim of the current study was to investigate the effect of GPR55 deletion on 
islet function in vivo and in vitro following diet-induced obesity.
Materials and methods: GPR55 KO mice and age-matched WT mice were 
fed ad lib either standard chow (SC, fat: protein: carbohydrate: 14%:28%:58%) 
or a high fat diet (HFD, 55%:16%:29%) for 19 weeks. Glucose and insulin 
tolerance tests were performed following a single i.p. administration of glu-
cose (2g/kg body weight) or insulin (0.75U/kg body weight), and tail vein 
blood glucose concentrations were determined using a glucose meter. Islets 
isolated from WT and KO mice were lysed with acidiﬁed ethanol and insulin 
content was measured by radioimmunoassay. Dynamic insulin secretion was 
quantified by radioimmunoassay following perifusion of isolated islets. Islet 
caspase-3/7 activities were quantified using a luminescent assay following 
exposure to a cytokine cocktail (1U/µl IFNγ, 1U/µl TNFα, 0.05U/µl IL-1β). 
BrdU (1mg/ml) was delivered to mice in their drinking water for 7 days prior 
to sacrifice, and beta cell proliferation was determined by insulin and BrdU 
immunostaining.
Results: GPR55 KO mice fed a HFD for 19 weeks were glucose intoler-
ant (glucose at t=30, KO on SC: 20.8±1.3mM; KO on HFD: 28.1±1.1, n=6 
P<0.01) and insulin resistant (reduction in blood glucose following insulin 
injection, KO on SC: 1.1±0.1mM; KO on HFD: 0.3±0.4, n=6 P<0.05). Islets 
isolated from KO mice fed a HFD for 19 weeks showed a small reduction 
in basal insulin secretion at 2mM glucose (KO: 0.11±0.01pg/islet/min; WT: 
0.15±0.03, n=4 P<0.05) and glucose-stimulated insulin secretion was also 
impaired (peak responses to 20mM glucose, KO: 4.1±1.3pg/islet/min; WT: 
8.5±0.9; P<0.05). Islets from KO mice after maintenance for 19 weeks on SC 
showed increased cytokine-induced apoptosis (caspase 3/7 activities; lumi-
nescence, KO: 41,692±939; WT: 29,980±457; n=8 P<0.01) as did islets from 
KO mice fed on a HFD (KO: 55,093±2,740; WT: 38,599±564; n=8 P<0.01). In 
addition, while there was a 3.2±0.6-fold increase in beta cell BrdU incorpora-
tion in pancreases of WT mice fed a HFD this compensatory increase in beta 
cell proliferation in response to HFD was attenuated in KO mice (1.2±0.2-
fold increase in beta cell BrdU incorporation; n=12, P<0.05 vs WT). Con-
sistent with the reduced proliferation and increased apoptosis, islets isolated 
from HFD-fed KO mice had lower insulin content (KO: 134.8±2.3ng/islet; 
WT: 166.3±4.2; n=8 P<0.001).
Conclusion: GPR55 KO mice show impaired glucose handling under condi-
tions of diet-induced increased metabolic demand, which is associated with 
reduced insulin secretory capacity, increased islet cell apoptosis and insuf-
ficient compensatory increases in beta cell proliferation. These observations 
support GPR55 playing an important role in regulating islet function that 
could make it a suitable target for treating type 2 diabetes.
Supported by: Diabetes UK
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IDs are novel oxidative stress-responsive genes in beta cells that regulate 
redox status and survival through effects on mitochondria and the 
NFE2L2 pathway
M. Bensellam1, M. Montgomery2, J. Luzuriaga1, J. Chan1, D.R. Laybutt1;  
1Garvan Institute of Medical Research,  
2University of New South Wales, Sydney, Australia.
Background and aims: Oxidative stress is a central mechanism of beta-cell 
glucotoxicity, but the underlying signaling pathways are only partially under-
stood. Inhibitor of Differentiation (ID) proteins are transcriptional regulators 
induced by hyperglycaemia in islets, but the mechanisms involved and their 
role in beta-cells are not clear. Here we investigated: 1) whether oxidative 
stress regulates ID expression in beta-cells, and 2) the role of ID expression in 
beta-cell pathophysiology under conditions of oxidative stress.
Materials and methods: Fixed pancreata and isolated islets from diabetic 
db/db mice and their normoglycemic db/+ littermates were used to verify 
the expression of IDs and antioxidant genes. Insulin-secreting MIN6 beta-
cells and isolated islets from Id1 and Id3-KO mice were cultured for 0-48h 
in the presence or absence of H2O2 (100-300 µM) or ribose (5-50 mM) to 
induce oxidative stress. RNA interference was used to silence the expression 
of Id1 and/or Id3 in MIN6 cells. mRNA and protein levels were measured 
by real-time RT-PCR, western blot and immunocytochemistry. H2O2 levels 
were assessed by DCFDA probe, mitochondrial morphology by Mitotracker 
probe, oxygen consumption by Clark electrode and apoptosis by DNA frag-
mentation ELISA.
Results: ID1-4 expression was upregulated in the islets of diabetic db/db 
mice with parallel changes in the expression of multiple antioxidant genes. In 
MIN6 cells, ribose and H2O2 treatment increased the mRNA levels of Id1-4 
in a time- and concentration-dependent manner with parallel changes in the 
expression of antioxidant genes. Furthermore, immunostaining showed that 
ribose treatment increased ID1 and ID3 nuclear localisation. In ribose-treat-
ed cells, siRNA-mediated inhibition of Id1 and/or Id3 reduced the expression 
of multiple antioxidant genes, including heme oxygenase. Additive effects 
were observed when both isoforms were inhibited. Glutathione peroxidase 
activity was also reduced after Id1/3 knockdown. These effects were accom-
panied by ~2-fold increase in H2O2 levels (p<0.01), 18% reduction in oxygen 
consumption (p<0.01) and ~2-fold increase in beta-cell apoptosis (p<0.001). 
Furthermore, Id1/3 inhibition induced mitochondrial fragmentation similar 
to that observed in the presence of ribose. Similarly, ribose-induced apoptosis 
in islets was potentiated in Id1-KO islets and to a stronger extent in Id3-KO 
islets (1.6-fold; p<0.01). Finally, under oxidative stress, Id1/3 inhibition fur-
ther increased NFE2L2 nuclear localization but represses the expression of its 
interacting partners MafK and MafF.
Conclusion: We have identified IDs as a novel family of oxidative stress-re-
sponsive genes in beta-cells as well as an unexpected role for Id1 and Id3 in 
the modulation of redox status. Such modulation is likely to stem from the 
maintenance of an adequate mitochondrial adaptation and upholding of the 
expression of NFE2L2 interacting partners. The maintenance of an adequate 
mitochondrial-antioxidant response by Ids may promote beta-cell survival 
under conditions of oxidative stress.
Supported by: SFD (Paris, France) and NHMRC and ARC of Australia
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Optical interrogation of glucose-regulated beta cell connectivity
N.R. Johnston1, R.K. Mitchell1, J. Ferrer1, B. Thorens2, G.A. Rutter1,  
D.J. Hodson1;  
1Department of Medicine, Imperial College London, UK,  
2Center for Integrative Genomics, University of Lausanne, Switzerland.
Background and aims: The multicellular organization of beta cell dynam-
ics produces a gain-of-function in insulin release through the generation 
of rhythmic and synchronous activity patterns. Here, we describe an opti-
cal silencing strategy to allow the precise and specific interrogation of the 
functional wiring patterns which orchestrate and pace beta cell interactivity.
Materials and methods: Functional multicellular calcium (Ca2+) imaging 
(fMCI) was used in combination with online Monte Carlo-based correla-
tion analyses to construct the wiring patterns underlying cell-cell connec-
tivity and hormone release. Rapid Nipkow disk microscopy allowed video 
rate recording at speeds in excess of 5 Hz. Beta cell-specific expression of 
the light-activated inward chloride (Cl-) channel, halorhopsin, was directed 
by crossing the Ins1Cre deletor strain with animals engineered to express 
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eNpHR3.0-EYFP following excision of a loxP-flanked STOP cassette. To al-
low user-directed single cell silencing within the field of view, a diffraction-
limited 585nm laser was coupled via a fibre optic to a custom-manufactured 
dichroic array.
Results: Beta cells form a scale-free network which supports the synchro-
nous propagation of glucose-stimulated Ca2+ waves by efficiently connect-
ing distant regions of the intact islet (n = 12 recordings from 5 animals) 
(power law fit; R² = 0.7247). A typical feature of such a topology was the 
non-random appearance of superconnected hub cells whose firing activity 
repetitively preceded that of the remainder of the population. Online map-
ping of islet functional architecture using MATLAB routines coupled directly 
to the imaging setup revealed the presence of a statistically-stable hub cell 
population. Silencing of individual identified hubs using a pinpointing laser 
had catastrophic consequences for coordinated islet responses to glucose, and 
this could be reversed simply by ceasing illumination (11.5 ± 1.8 versus 3.1 ± 
0.8 % correlated cell pairs, laser OFF versus laser ON, respectively; P<0.01) 
(n = 8 recordings from 4 animals). By contrast, specific silencing of non-hub 
or follower cells was unable to significantly perturb islet dynamics (7.3 ± 1.8 
versus 9.9 ± 2.0 % correlated cell pairs, laser OFF versus laser ON, respec-
tively; P>0.05) (n = 7 recordings from 4 animals). Further supporting a role 
for distinct wiring patterns in glucose-regulated islet connectivity, low-grade 
cytokine (IL-1β and IL-6) treatment resulted in a dramatic and rapid collapse 
in correlated cell-cell activity due to impaired hub function (9.6 ± 0.9 versus 
5.1 ± 0.6 % correlated cell pairs, 0 versus 4 hrs cytokine exposure, respec-
tively; P< 0.01) (n = 7 recordings from 3 animals).
Conclusion: The intra-islet circuitry is dominated by superconnected hub 
cells which dictate population responses to glucose. Notably, these hubs are 
vulnerable to pro-inflammatory T2D insults and may contribute to the re-
duced functional beta cell mass that accompanies glucose intolerance.
Supported by: Diabetes UK, Wellcome Trust, MRC and the Royal Society.
OP 18 Novel genes for type 2 
diabetes and its complications
103
A common Greenlandic TBC1D4 variant confers muscle insulin 
resistance and type 2 diabetes
N. Grarup1, I. Moltke2, M.E. Jørgensen3, P. Bjerregaard4, J.T. Treebak1,  
T.S. Korneliussen5, M.A. Andersen1, T.S. Nielsen1, N.T. Krarup1,  
A. Linneberg6, J. Wang7, O. Pedersen1, R. Nielsen8, A. Albrechtsen9,  
T. Hansen1;  
1The Novo Nordisk Foundation Center for Basic Metabolic Research, 
University of Copenhagen, Denmark, 2Department of Human Genetics, 
University of Chicago, USA, 3Steno Diabetes Center, Gentofte, Denmark, 
4National Institute of Public Health, University of Southern Denmark, 
Copenhagen, Denmark, 5Centre for GeoGenetics, Natural History Museum 
of Denmark, University of Copenhagen, Denmark, 6Research Centre for 
Prevention and Health, Glostrup University Hospital, Glostrup, Denmark, 
7BGI-Shenzhen, China, 8Department of Integrative Biology, University 
of California, Berkeley, USA, 9The Bioinformatics Centre, Department of 
Biology, University of Copenhagen, Denmark.
Background and aims: Previous studies have shown that founder popula-
tions can be valuable for genetic association studies, because they have in-
creased levels of linkage disequilibrium and may harbor deleterious muta-
tions of higher frequency. The same can be argued for historically small and 
isolated populations. Motivated by this, and by the dramatically increased 
prevalence of type 2 diabetes in the small Greenlandic population, we per-
formed association mapping of four type 2 diabetes-related quantitative 
traits, plasma glucose and serum insulin levels at fasting and at two hours 
during an OGTT, in Greenlandic individuals without known diabetes.
Materials and methods: Discovery analyses were performed in up to 2,757 
participants of the Inuit Health in Transition cohort and replication in up to 
1,064 participants from the B99 cohort. Participants underwent an OGTT. 
Samples were genotyped by the Illumina CardioMetabochip. Association 
testing was done using a linear mixed model in GEMMA to control for ad-
mixture and relatedness. Exome sequencing of selected individuals was done 
by Agilent SureSelect capture and Illumina sequencing.
Results: Applying array-based genotyping and exome sequencing, we dis-
covered a nonsense variant in TBC1D4 with an allele frequency of 17% in 
the Greenlandic population. Under a recessive model, this variant strongly 
increases the levels of plasma glucose (β=3.8 mmol/L, P=2.5×10-35) and se-
rum insulin (β=165 pmol/L, P=1.5×10-20) two hours after an oral glucose 
load, while reducing fasting plasma glucose (β=-0.18 mmol/L, P=1.1×10-6) 
and fasting serum insulin (-8.3 pmol/L, P=0.0014). Even the heterozygous 
carriers have an increased 2 hour plasma glucose (β=0.43 mmol/L, P=5.3×10-
5). The same polymorphism was associated with an increased risk of type 
2 diabetes risk (OR 10.3, P=1.6×10-24). All findings were replicated in the 
B99 cohort. Analyses of muscle biopsies from mutation carriers showed de-
creased mRNA and protein expression of the long muscle-specific isoform 
of TBC1D4 and decreased muscle protein abundance of GLUT4 projecting a 
decreased insulin-stimulated glucose uptake in skeletal muscle.
Conclusion: We establish a single variant which imposes effect sizes several 
times larger than any findings of large-scale genome-wide association studies 
and accounts for more than 10% of all cases of type 2 diabetes in a popula-
tion. This finding constitutes further proof that it is valuable to conduct ge-
netic association studies outside the traditional setting of large homogeneous 
populations.
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Fine-mapping type 2 diabetes susceptibility loci with high-density 
imputation
A.P. Morris1,2, T.M. Teslovich3, T. Ferreira2, A. Mahajan2, Y. Lee3,  
N.W. Rayner2, R. Magi4, on behalf of the DIAGRAM Consortium;  
1Department of Biostatistics, University of Liverpool,  
2Wellcome Trust Centre for Human Genetics, University of Oxford, UK, 
3Department of Biostatistics, University of Michigan, Ann Arbor, USA, 
4Estonian Genome Centre, University of Tartu, Estonia.
Background and aims: Genome-wide association studies (GWAS) have been 
successful in identifying loci for type 2 diabetes (T2D). These loci are typi-
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cally characterised by common lead SNPs with association signals that extend 
over large genomic intervals. Consequently, there has been limited progress 
in localising causal variants for T2D and establishing the functional impact of 
these loci in the pathogenesis of the disease. We aimed to: (i) identify multiple 
signals of association with T2D in established loci; (ii) assess the evidence for 
association with low-frequency (LF) variants, minor allele frequency (MAF) 
<5%, in established loci; and (iii) localise the likely causal variant(s) for each 
association signal.
Materials and methods: We combined Metabochip and GWAS data from 
46,168 T2D cases and 172,714 controls of European ancestry, supplemented 
by imputation up to the 1000 Genomes Project reference panel (March 2012 
release), to facilitate fine-mapping of 39 established loci. We undertook ap-
proximate conditional analyses implemented in GCTA, using 3,298 cases and 
3,708 controls from GoDARTS as reference, to identify loci with multiple 
signals of association with T2D at “locus-wide” significance (p<10-5). We de-
fined “credible sets” of SNPs that account for 99% of the probability of includ-
ing the causal variant for each association signal.
Results: We identified five association signals mapping to the KCNQ1 lo-
cus, three at HNF1A, and two each at CDKN2A/B, DGKB, MC4R, GIPR 
and HNF4A. We highlighted LF associated variants mapping near HNF1A 
(rs1800574, MAF=2.2%, p=4.2×10-10), HNF4A (rs1800961, MAF=3.9%, 
p=1.4x10-9), and MC4R (rs17066842, MAF=4.8%, p=2.9x10-6), all independ-
ent (r2<0.05) of the common lead GWAS SNPs at these loci. The 99% credible 
set includes no more than ten variants at nine loci, with greatest refinement 
at MTNR1B (rs10830963 only), one signal at KCNQ1 (3 SNPs map to 197bp), 
and TCF7L2 (3 SNPs map to 4.3kb), and with both signals at CDKN2A/B 
each mapping to less than 1.5kb. The variants in the 99% credible sets at these 
nine “fine-mapped” loci are common (MAF≥5%) and predominantly non-
coding, with the exception of rs13266634 (R325W) at SLC30A8.
Conclusion: Our study has provided insight into the genetic architecture of 
T2D and has prioritised regions for follow-up with regulatory annotation 
that may aid characterisation of the functional role of these GWAS loci in the 
pathogenesis of the disease.
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Identification of protein-coding variants associated with risk of  
type 2 diabetes
A. Mahajan1, C. Fuchsberger2, J. Flannick3, M. Rivas1, P. Fontanillas3, 
A. Morris1, T. Teslovich2, M. McCarthy1,4, for T2D-GENES and GoT2D 
Consortia;  
1Wellcome Trust Centre for Human Genetics, University of Oxford, UK, 
2University of Michigan, Ann Arbor, 3Broad Institute, Cambridge, USA, 
4OCDEM, University of Oxford, UK.
Background and aims: Genome wide association studies (GWAS) have suc-
cessfully identified common [minor allele frequency (MAF) >5%] genetic 
variants contributing to risk of type 2 diabetes (T2D). However, the impact 
of low-frequency (LF; MAF 0.5-5%) and rare (MAF<0.5%) variants to dis-
ease susceptibility remains widely unexplored. We evaluated the role of this 
class of variation to T2D predisposition, focusing on coding variants as these 
are enriched for functional impact and allow more direct insight into disease 
biology.
Materials and methods: We analysed: (i) exome sequence data from 12,940 
individuals (6,504 T2D cases, 6,436 controls), ascertained from five major eth-
nic groups (European, South Asian, East Asian, Hispanic and African Ameri-
can); and (ii) exome-array data from additional 81,740 Europeans (29,569 
T2D cases, 52,171 controls). We first performed single-variant analyses within 
each ethnic group, and then combined ancestry-specific association summary 
statistics in a trans-ethnic meta-analysis using MANTRA. We defined exome-
wide significance by a log10 Bayes’ Factors (BF)>5. Conditional analysis was 
done to determine if coding variants drive the known common SNP GWAS 
signal, or represent statistically independent associations.
Results: In the combined analysis, 26 coding variants, mapping to 18 loci, 
were associated with T2D at exome-wide significance. All except two have 
MAF>5% in the ethnic group driving the association signal. Of these, seven 
variants at five loci (SLC30A8, MACF1, GCKR, PPARG, and KCNJ11-ABCC8) 
were confirmatory of previously-reported common coding variants driving 
GWAS signals. Of the remaining 19 T2D-associated coding variants, 13 also 
mapped to established GWAS loci but have not previously been reported to 
be causal. These included PAX4 R192H (rs2233580, log10BF>6.3), a signal 
driven exclusively by East Asians (odds ratio=1.79[1.59-1.99], MAF~10%). 
Reciprocal conditional analyses at these loci revealed the novel coding vari-
ants to be either independent of, or indistinguishable from previously report-
ed lead GWAS SNPs, and implicate several novel genes - including RREB1, 
THADA, and TM6SF2 - in T2D pathogenesis. The remaining six variants, 
mapping to three loci, were located entirely outside known GWAS regions. 
These include two variants in PAM (D563G, log10BF=9.96) and PPIP5K2 
(S1207G, log10BF=7.47), for which a T2D-association was recently described 
in the Icelandic population. Three further highly-correlated coding variants 
at MTMR3/ASCC2 were associated with T2D (Europeans specific signal). The 
MTMR3 variant (log10BF=6.46) has the strongest residual association signal 
after accounting for the other variants and represents the most plausible can-
didate at this novel locus. The last novel locus was FAM63A (log10BF=5.24) 
and signal was driven by a LF variant. The T2D risk-allele has a MAF of 1% 
in Europeans, and was otherwise only detected in South Asian sequence data 
(11 copies, p=0.02 for association).
Conclusion: Here we show that rare and LF coding variants of moderate to 
large effect are not major contributors to T2D risk. We identify 26 coding 
variants with exome-wide significant associations with T2D and highlight the 
promise of this approach to provide insight into the pathophysiology of the 
disease.
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Meta-analysis of birth weight genome-wide association studies identifies 
two novel loci extending links between early growth and adult metabolic 
diseases
M. Horikoshi1,2, M.N. Kooijman3, J.P. Bradfield4, D. Strachan5,  
N.V. Tejedor6, E. Kreiner-Møller7, P. Joshi8, V. Lindi9, N. Grarup10,  
S.F.A. Grant4, M.I. McCarthy1,2, I. Prokopenko11, R.M. Freathy12,  
A.P. Morris1,13, EGG Consortium;  
1Wellcome Trust Centre for Human Genetics, University of Oxford, 2Oxford 
Centre for Diabetes, Endocrinology & Metabolism, UK, 3Department of 
Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands, 4Center 
for Applied Genomics, The Children’s Hospital of Philadelphia, USA, 
5Population Health Research Institute, St George’s, University of London, 
UK, 6Center for Research in Environmental Epidemiology (CREAL), 
Barcelona, Spain, 7COPSAC, the Copenhagen Prospective Studies on 
Asthma in Childhood; Health Sciences, University of Copenhagen, 
Denmark, 8Centre for Population Health Sciences, University of Edinburgh, 
UK, 9Department of Physiology, Institute of Biomedicine, University of 
Eastern Finland, Kuopio, Finland, 10The Novo Nordisk Foundation, Center 
for Basic Metabolic Research, Faculty Of Medical and Health Sciences, 
University of Copenhagen, Denmark, 11Department of Genomics of 
Common Disease, Imperial College London, 12University of Exeter Medical 
School, 13Department of Biostatistics, University of Liverpool, UK.
Background and aims: Lower birth weight (BW) is associated with increased 
risk of future type 2 diabetes (T2D) and cardiovascular diseases. Based on 
HapMap 2 imputation, we previously reported 7 loci associated with BW, of 
which two (ADCY5 and CDKAL1) have been implicated in T2D and one 
(ADRB1) in hypertension. We have expanded this effort by increasing sample 
size and undertaking imputation up to 20.8M SNPs from the more dense 
1000 Genomes Project reference panels. With these data we aimed to 1) dis-
cover novel loci; 2) assess evidence of association with low-frequency variants 
(minor allele frequency <5%) of larger effect sizes; and 3) fine-map estab-
lished and novel loci by constructing credible sets of variants that are most 
likely to be causal on the basis of statistical evidence of association.
Materials and methods: For analysis, we considered 41,551 European sin-
gletons born at ≥37 weeks’ gestation with genome-wide association (GWA) 
and imputation data from 17 studies. Standardized sex-specific Z-scores of 
BW were tested for association with each SNP assuming an additive genetic 
model after adjustment for gestational week where available. Association 
summary statistics were combined across studies using inverse-variance 
fixed-effects meta-analysis.
Results: Two novel common variant loci were detected at genome-wide sig-
nificance: near MAFB (p=3.1x10-8) and at SREBF2 (p=3.9x10-9). MAFB has 
been implicated in hyperlipidemia and SREBF2 is involved in cholesterol 
biosynthesis. There was no evidence for low-frequency variants that explain 
common GWA signals. The 99% credible sets included fewer than 20 SNPs at 
4 loci. At ADRB1, the credible set included just 5 variants, including G389R. 
We will further refine the association signals by combining with GWA studies 
of non-European ancestry.
Conclusion: Collectively, 4 of the 9 known and novel loci provide genetic links 
between BW and adult metabolic phenotypes such as T2D, hypertension and 
hyperlipidemia, highlighting complex non-linear relationships between ge-
netic variation, early growth and later metabolic disease including T2D.
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Functional SNPs as focused gene probes: results from SUMMIT on 
diabetic nephropathy, coronary and lower extremity artery disease
D. Ziemek1, E. Fauman2, N.R. Van Zuydam3, N.W. Rayner3, C.L. Hyde2,  
N. Sandholm4, C. Forsblom4, E. Ahlquist5, C. Ladenvall5,  
SUMMIT Consortium;  
1Pfizer, Berlin, Germany, 2Pfizer, Cambridge, USA, 3OCDEM and WTCHG, 
University of Oxford, UK, 4FINNDIANE, Folkhalsan Institute of Genetics, 
University of Helsinki, Finland, 5Diabetes Center, Lund University, Sweden.
Background and aims: Diabetic nephropathy (DN), coronary (CAD) and 
lower extremity artery disease (LEAD) are devastating, but, at least partially, 
heritable complications of diabetes with a poorly understood mechanistic 
basis. To move towards more effective preventative and therapeutic strate-
gies, the SUMMIT consortium has conducted large-scale genome-wide as-
sociation studies. Despite large sample sizes for CAD (4009 cases and 7918 
controls), LEAD (2345 cases and 8706 controls), and specific sub-phenotype 
interrogation in DN (5908 cases and 4965 controls), only 3 genome wide sig-
nificant signals (p<5e-8) were detected. This might imply a highly polygenic 
architecture of the considered phenotypes or significant noise levels in the 
trait definitions. At the same time, repositories such as NHGRI’s GWAS cata-
log contain thousands of validated loci associated with a variety of traits. Each 
of these is likely tagging a functional alteration influencing a specific gene 
product. Focusing on these prior associations and their implicated genes can 
eliminate millions of non-functional SNPs to pinpoint variants associated 
with diabetic complications.
Materials and methods: We acquired all SNPs associated with any trait from 
NHGRI’s GWAS catalog as well as cis-expression QTLs from the GTEx pro-
ject. SNPs were pruned at a significance level of p<1e-5 and reduced to lead 
SNPs using a p-value-dependent distance cutoff. We mapped SNPs to proba-
ble causal genes using a novel LD and distance-based algorithm that has been 
validated to provide an F-measure of 73% on metabolite QTLs. This resulted 
in a total of 11,000 SNPs associated with over 2,000 phenotypes which map 
to 6,500 genes. As a measure of overall signal improvement, we compared 
QQ-plots before and after limiting analysis to gene probe SNPs based on a 
Wilcoxon rank-sum test of the truncated log p-values. Finally, we computed 
false discovery rate estimates for all SNPs in the full and the restricted set and 
report variants passing an FDR cutoff of 0.3 as candidates for specific signals 
discovered through the method.
Results: We obtained significant improvements for the QQ-plots on CAD, 
LEAD (with various stratifications) and eGFR traits (all p-values < 0.01). For 
instance, rs7173743 in the MORF4L1 gene is associated with CAD on the 
background of type 2 diabetes at a q-value of 0.07 in the focused set whereas 
it was insignificant (q-value = 1) in the full set. When combining SUMMIT 
CAD data with CARDIoGRAM data, this locus reaches genome-wide sig-
nificance. Other examples include rs13180 in the IREB2 gene for LEAD in 
smokers (q-value < 0.01) and rs13333226 in the UMOD gene (q-value < 0.08) 
for eGFR.
Conclusion: Overall we can implicate a number of plausible loci stemming 
from robust prior phenotype associations in traits studied by SUMMIT on 
the background of diabetes. We plan to explore these results on the basis of 
their associated genes in pathway-based analysis to derive mechanistic in-
sights for the traits under consideration in the SUMMIT consortium. This 
approach appears useful for finding novel associations for previously iden-
tified loci when the full GWAS lacks power to identify new loci achieving 
traditional genome-wide significance.
Supported by: SUMMIT Consortium IMI-2008/115006
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Genome-wide association study for diabetic retinopathy in Japanese 
patients with type 2 diabetes
M. Imamura1, A. Takahashi2, M. Kubo3, S. Maeda4;  
1Laboratory for Endocrinology, Metabolism and Kidney diseases, Center 
for Integrative Medical Sciences, 2Laboratory for Statistical Analysis, Center 
for Integrative Medical Sciences, 3Laboratory for Genotyping Development, 
Center for Integrative Medical Sciences, 4Laboratory for Endocrinology, 
Metabolism and Kidney Diseases, Riken, Center for Integrative Medical 
Sciences, Yokohama, Japan.
Background and aims: Diabetic retinopathy (DR) is one of the leading 
causes of blindness in Japanese adults. Several reports have shown familial 
aggregations of DR or advanced DR among patients with type 1 or type 2 dia-
betes, suggesting genetic susceptibility contributes to the development and/
or progression of DR. Although several candidate-genes have been shown 
to be associated with susceptibility to DR, namely genes encoding Angio-
tensin-I Converting Enzyme (ACE), Aldose reductase (AKR1B1), Vascular 
Endothelial Growth factor A(VEGFA) and Erythropoietin (EPO),the asso-
ciation of these genes with DR has not reached to genome-wide significance 
levels (p-value < 5.0×10-8) except rs1617640 in the EPO locus. Genome-wide 
association studies (GWAS) for advanced DR in European population have 
identified several suggestive loci with borderline association (p-value <1×10-
6), however the association of these loci with DR is still inconclusive. To iden-
tify novel genetic loci associated with the susceptibility to DR, we performed 
GWAS for DR in Japanese patients with type 2 diabetes.
Materials and methods: We divided Japanese patients with type 2 diabetes, 
registered in BioBank Japan, into 2 groups; 1) DR cases, defined as patients 
having any stages of DR, and 2) controls, who did not have any sign of DR 
and with long duration of diabetes (≥10 years) or with diabetic nephropathy. 
We examined 2 independent case-control groups (Study-1; 4,839 DR cases 
and 4,041 controls, Study-2; 693 DR cases and 1,524 controls) for ~7.5 mil-
lion single nucleotide polymorphisms (SNPs) from directly genotyped data 
(Study-1; Omni-express, Study-2; Illumina 610K) and genotype imputation 
using mini-MACH. Results of the 2 GWAS were combined with an inverse 
variance method in a fixed effect model.
Results: We identified 5 SNP loci associated with DR in Japanese patients 
with type 2 diabetes (rs8025089 on chromosome [Ch]15: p = 3.0 × 10-7, Odds 
ratio [OR] = 1.15, 95% confidence interval [CI], 1.09-1.22, rs12630354 on 
Ch3: p = 4.2 × 10-7, OR = 1.15, 95% CI, 1.09-1.22, rs2471299 on Ch7: p = 1.5 
× 10-6, OR = 1.14, 95% CI, 1.08-1.20, rs2517532 on Ch6: p = 3.9 × 10-6, OR = 
1.13, 95% CI, 1.08-1.19, rs4240499 on Ch10: p = 4.4 × 10-6, OR = 1.17, 95% 
CI, 1.10-1.26). A sub-group analysis, excluding patients with simple DR, has 
identified 3 loci associated with advanced DR (2,003 DR cases [Study-1] and 
368 DR cases [Study-2]) (p < 1 × 10-5). None of the association reached to 
genome-wide significance level (p < 5.0 × 10-8) in this study. Regarding previ-
ously reported DR susceptible loci (ACE, AKRB1, VEGFA and EPO), none of 
these loci was significantly associated with DR in the present study.
Conclusion: We have identified several candidate loci potentially contribut-
ing to DR susceptibility, although further studies are required to validate the 
association of these loci with DR.
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Clinical factors influencing the basal rate profile in subjects with  
type 1 diabetes treated with continuous subcutaneous insulin infusion 
(insulin pumps)
M. Kahle, U. Buss, A. Varnhorn, B. Nawrodt, M.A. Nauck;  
Diabeteszentrum Bad Lauterberg, Germany.
Background and aims: Defining an individually appropriate basal rate pro-
file in patients with type 1 diabetes requires knowledge about the general 
shape of such a profile, and needs to take into account patient factors with a 
significant influence on (a) the total dose of insulin administered as a basal 
rate and (b) the circadian variation in insulin needs. We assessed these influ-
ences based on a retrospective analysis of 339 patients, in whom the adequacy 
of basal rates was checked by means of a 24 h fasting period.
Materials and methods: Laboratory-based blood glucose profiles determined 
during regular day and night (eating meals) and during a 24 h fasting period 
(6 p.m. to 6 p.m.) and basal rate profiles corrected after the fasting period were 
entered into our database for 339 patients with type 1 diabetes during inpa-
tient treatment in a specialized diabetes centre (183 women, 156 men; age 41 
± 14 years, HbA1c 8.3 ± 1.6 %; BMI 26.1 ± 4.9 kg/m
2; diabetes duration 20 ± 
12 years; insulin dose 0.55 ± 0.20 IU/kg body weight per day). Patients were 
divided according to gender, or into tertiles of age, body-mass-index, and dia-
betes duration. A significant influence of the characteristic in question was as-
sessed by repeated-measures ANOVA on hourly basal rates and also expressed 
as a percentage of the overall 24 h basal rate for each individual hour.
Results: A 24 h fasting period resulted in relatively stable blood glucose val-
ues of 6.6 ± 2.8 mmol/L with 11.5 % of the values > 9.9 mmol/L and 11.3 % 
of the values < 3.7 mmol/L. Basal rates after correction for low or high blood 
glucose values during the fasting period showed typical circadian rhythms 
with “dawn-” and “dusk-” phenomena and a total (mean ± SD) basal rate 
of 21.5 ± 9.2 IU/day. There were significant differences due to gender (more 
prominent dawn phenomenon in males; p < 0.0001)), age (more prominent 
dawn phenomenon in younger subjects; p = 0.036), body mass index (higher 
overall basal rates in more obese subjects; p < 0.0001; with no influence on 
the circadian distribution p = 1.00), and diabetes duration (more prominent 
dawn phenomenon in those with shorter diabetes duration; p < 0.0001).
Conclusion: Our large database helps define basal rate profiles for subjects 
with type 1 diabetes treated with continuous subcutaneous insulin infusions. 
It also allows to take into account clinical characteristics of the patients with 
a significant influence on the basal rate profile (both total amount of insulin 
and circadian profile) to individually predict insulin requirements during in-
sulin pump treatment. Based on multivariate regression analysis, it may be 
possible to predict individual hourly basal rates with reasonable confidence 
intervals.
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Relationship of HbA1c with body weight change over 4 years from 
starting insulin therapy in people with type 2 diabetes: the CREDIT 
study
B. Balkau1, N. Freemantle2, F. Calvi-Gries3, V. Pilorget4, M. Vincent4,  
P. Home5;  
1INSERM, U1018, University Paris Sud 11, UMRS 1018, Villejuif, France, 
2University College London, UK, 3AtlanStat, Rezé, France,  
4Sanofi, Paris, France, 5Newcastle University, Newcastle upon Tyne, UK.
Background and aims: Insulin treatment is often delayed for people with 
type 2 diabetes; fear of weight gain and any consequences of glycaemic con-
trol can factor in that delay. Clinical trials provide some insight into this issue 
but have limited generalisability due to restrictions on participant selection 
and treatments used. Here, we examine the relationship between change in 
body weight and HbA1c over 4 years of insulin therapy in routine clinical 
practice.
Materials and methods: CREDIT was a noninterventional study of people 
with type 2 diabetes beginning insulin therapy in Europe, North America, 
and Asia. Physicians were free to choose and adapt treatments in accordance 
with usual practice; data were collected from physician records. Univariate 
and multivariable analyses were used to determine the relationship between 
change in body weight and HbA1c over 4 years.
Results: Determinants of HbA1c were studied in 1973 people with 4-year data 
from starting insulin; 47% were men, baseline mean age 61 ± 10 (SD) years, 
BMI 29.2 ± 6.1 kg/m², 10 ± 8 years of diabetes, HbA1c 9.5 ± 1.9 % (80 ± 
21 mmol/mol), 69% continuing oral glucose-lowering therapies. Half were 
started on basal insulin alone, 23% on premix insulin alone, and 15% on basal 
+ meal-time insulin; over all insulin regimens, starting insulin dose was 0.26 
± 0.18 U/kg. In the first year, HbA1c declined, then remained stable (Figure), 
with a decrease at year 4 of -2.0 ± 2.1 % (-22 ± 23 mmol/mol). Body weight 
increased an average of 1.9 ± 4.7 kg in the first year, but < 1.0 kg over the sub-
sequent 3 years; over the 4 years, weight increased by 2.6 ± 7.4 kg. Daily insu-
lin dose increased 0.15 ± 0.23 U/kg over the first year and by 0.27 ± 0.31 U/kg 
over the 4 years. This was accompanied by a change in insulin regimen from 
starting insulin to 4 years for 44% of population (30% on basal alone, 33% on 
basal + meal-time, and 25% on premix alone at year 4). After adjusting for 
region and centre, 4-year change in weight was predictive of HbA1c at year 4 
(P < 0.0001), but with a small effect size: a weight gain of 2.6 kg was associated 
with a 0.005 %-unit (0.05 mmol/mol) higher HbA1c at year 4. Other variables 
were associated with HbA1c at year 4: baseline HbA1c, BMI, age, and at 4 
years, insulin dose, number of oral glucose-lowering drugs and symptomatic 
hypoglycaemia. Taking these variables into account, weight change remained 
predictive of HbA1c at year 4 (P < 0.04). Symmetrically, the odds ratio (95% 
CI) for an HbA1c below 7.0 % vs. HbA1c ≥ 7.0 % at year 4 following a 1.0 kg 
increase in weight over the 4-year period, was 0.97 (0.96, 0.99; P = 0.0015 ), 
after adjusting for other predictive variables.
Conclusion: After 4 years of insulin treatment in people with type 2 diabe-
tes, weight gain was associated with minimally higher HbA1c values at year 
4. These results should allay fears of weight gain having a strong impact on 
glycaemic control. 
Supported by: Sanofi
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The INITIATOR study: real-world treatment patterns and outcomes in 
patients with type 2 diabetes initiating insulin glargine or liraglutide
P.A. Levin1, W. Wei2, E. Buysman3, S. Thayer3, L. Brekke3, W.H. Crown3,  
M. Grabner4, X. Ke4, R.A. Quimbo4, M.J. Cziraky4, W. Hu2, R. Cuddihy2,  
J.W. Chu5;  
1MODEL Clinical Research, Baltimore, 2Sanofi US, Bridgewater,  
3Optum, Eden Prairie, 4HealthCore, Wilmington,  
5Monterey Endocrine & Diabetes Institute, Monterey, USA.
Background and aims: Patients with type 2 diabetes mellitus (T2DM) not 
achieving glycaemic control on oral antidiabetic drugs (OADs) can initiate 
injectable therapy with insulin or a glucagon-like peptide-1 receptor agonist 
(GLP-1) analogue. As the first large real-world observational longitudinal 
study of T2DM patients Initiating New Injectable Treatment Introduced after 
Anti-diabetic Therapy with Oral-only Regimens (INITIATOR), this analysis 
aimed to provide a comprehensive understanding of patient characteristics, 
treatment patterns, and associated outcomes.
Materials and methods: T2DM patients from 2 of the largest US commer-
cial health insurers who were aged ≥ 18 years, previously on OADs only, and 
initiated either insulin glargine pen (GLA) or the GLP1 analogue liraglutide 
(LIRA) between April 1, 2010-March 31, 2012 were included. Patients had 
continuous healthcare coverage during the 6 months before (baseline [BL]), 
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and 12 months after initiation (follow-up). Health claims and medical chart 
data from eligible patients were extracted by OP and HC from their respec-
tive health plans. We compared differences in BL characteristics between 
treatment groups and 1-year follow-up measures to BL within each group. 
Treatment patterns, and clinical and economic outcomes at follow-up were 
assessed descriptively within each health plan.
Results: 4,490 patients were included (45.5% women; mean age 52.7 years; 
mean number of OADs 2). Significant BL differences existed: GLA patients 
had higher comorbidity burden, higher HbA1c, lower weight, and were less 
often women (Table). A total of 23.8% of LIRA patients had a HbA1c level of 
< 7.0% and 21.4% reported ‘improve weight control’ as a reason for initiation. 
At 1 year follow-up, overall treatment persistence was 64.0% for GLA and 
49.4% for LIRA patients; 3.5% of GLA patients were on twice-daily GLA. 
Both groups had significant HbA1c reductions. GLA patients had a slight 
weight gain whereas LIRA patients lost weight. Overall follow-up hypo-
glycaemia rates were 16% in GLA and 9% in LIRA patients; rates of severe 
hypoglycaemia were low. Compared with BL, LIRA patients had significant 
increases in total healthcare costs (OP and HC), in contrast to GLA patients 
who had fewer diabetes-related hospitalizations (OP only) and no increase 
in total healthcare costs. LIRA (OP and HC) and GLA patients (OP only) 
incurred higher diabetes drug costs.
Conclusion: These findings showed clinically relevant differences in BL 
characteristics and follow-up outcomes in T2DM patients initiating GLA or 
LIRA. This study highlights challenges in translating clinical trial findings 
into real-world settings, and in conducting comparative effectiveness studies 
where important BL group differences may exist.
Supported by: Sanofi US, Inc.
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Characteristics of patients with type 2 diabetes mellitus (T2DM)  
on basal insulin who do not achieve glycaemic goals
S. Brunton1, L. Blonde2, P. Chava2, R. Zhou3, J. Meyers4, K. Davis4,  
M. Dalal5, A. DiGenio6;  
1University of North Carolina, Chapel Hill,  
2Ochsner Medical Center, New Orleans, 3Medpace Inc., Cincinnati,  
4RTI Health Solutions, Research Triangle Park, 5Sanofi US, Inc., Bridgewater, 
6Isis Pharmaceuticals, Inc., Carlsbad, USA.
Background and aims: Despite the efficacy of basal insulin therapy in indi-
viduals with T2DM, a significant number of patients may not achieve gly-
caemic goals. Patients taking basal insulin who reach their fasting plasma 
glucose (FPG) goal but not their glycated haemoglobin A1c (HbA1c) target 
represent an important unmet T2DM management need. This study used 
both randomized clinical trial (RCT) and “real-world” data to compare the 
baseline characteristics of T2DM patients with HbA1c ≥ 7.0% achieving FPG 
levels < and ≥130 mg/dL.
Materials and methods: Characteristics, including age, gender, BMI, and 
weight, of patients on basal insulin who do or do not achieve HbA1c < 7.0% 
were analysed using 11 pooled RCTs assessing insulin glargine (6-months 
follow-up) and real-world data from the GE Centricity electronic medical 
records (EMR) database (6- and 12-months follow-up). Patients with HbA1c 
≥ 7.0% were stratified by FPG level (< 130 or ≥ 130 mg/dL).
Results: Patients with high HbA1c at follow-up also had high baseline HbA1c 
(HbA1c ≥ 7.0% vs < 7.0%: RCT, 9.1% vs 8.5%; EMR: 9.0% vs 8.1% [6-months 
follow-up] and 9.0% vs 8.0% [12-months follow-up]). About 50% of the RCT 
patients reached HbA1c goal vs < 30% of EMR patients. Of patients with 
HbA1c ≥ 7%, about 50% (RCT) and < 30% (EMR) achieved FPG < 130 mg/
dL. RCT patients tended to be younger, less obese, and weigh less vs EMR 
patients (mean: age 2-4 years younger; BMI ~3 kg/m2 less; and weight ~6 
kg less). Patients with HbA1c < 7.0% were somewhat older than those with 
HbA1c ≥ 7.0% (mean age in years for HbA1c < 7.0% vs ≥ 7.0%: RCT, 58.4 vs 
57.7; EMR, 62.3 vs 60.2 [6-months follow-up] and 62.7 vs 59.8 [12-months 
follow-up]). Little difference existed in gender distribution or mean BMI for 
patients with HbA1c < 7.0% versus HbA1c ≥ 7.0%. For both RCT and EMR 
patients with HbA1c ≥ 7.0%, those with FPG < 130 mg/dL were slightly older 
than those with FPG ≥ 130 mg/dL (mean age for FPG < 130 vs ≥ 130 mg/
dL: RCT, 58.7 vs 56.4 years; EMR, 62.3 vs 59.6 [6-months follow-up] and 
62.4 vs 59.0 [12-months follow-up]). Differences were also seen in baseline 
insulin usage in the RCT patients, with more patients with FPG ≥ 130 mg/
dL using a fast-acting insulin analogue (71.2% vs 28.9%). For both RCT and 
EMR patients, other demographic characteristics did not differ between the 
FPG groups.
Conclusion: We present differences in characteristics between patients on 
basal insulin who do or do not achieve HbA1c < 7.0%. Patients with a high-
er baseline HbA1c were less likely to achieve target HbA1c < 7.0% on basal 
insulin alone; more intensive treatment regimens may be required. A large 
proportion of the HbA1c > 7.0% patients were also above target for FPG at 
follow-up and would likely benefit from addition basal insulin titration. In 
patients achieving FPG < 130 mg/dL, despite above target HbA1c values, 
postprandial glucose (PPG) control could be used to help bring their HbA1c-
within recommended limits. Appropriate therapeutic choices for those not 
reaching HbA1c < 7.0% should be based on assessment of FPG and PPG, as 
well as of HbA1c. A better understanding of patient characteristics and factors 
involved in goal achievement might increase the numbers of patients reach-
ing targets and reduce the time they are exposed to hyperglycaemia and its 
adverse consequences.
Supported by: Sanofi US, Inc.
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People with type 2 diabetes with lower HbA1c using insulin experience 
fewer cardiovascular events and death: results from the CREDIT study
N. Freemantle1, N. Danchin2, F. Calvi-Gries3, M.-P. Dain4, M. Vincent4,  
P. Home5;  
1Department of Primary Care and Population Health, University College 
London, UK, 2Universite Paris 5, 3AtlanStat, Rezé, 4Sanofi, Paris, France, 
5Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, 
UK.
Background and aims: CREDIT (Cardiovascular Risk Evaluation in peo-
ple with Type 2 Diabetes on Insulin Therapy) was a noninterventional study 
designed to examine relationships between HbA1c and cardiovascular (CV) 
events in 2999 patients beginning insulin in real-world practice in Europe, 
North America, and Asia, with up to 54 months’ follow-up. The study did not 
impact normal practice, having no intervention or formal visits-instead, data 
were collected from physician reports.
Materials and methods: Primary outcome was the composite of nonfatal stroke 
or myocardial infarction (MI) or CV death. Events were blindly adjudicated by 
an endpoints committee. Relative hazard of CV events was described with Cox 
proportional hazards models, including patient risk factors, and updated mean 
HbA1c as a time-dependent covariate. Primary outcome components were de-
scribed separately. The relationship of severe and symptomatic hypoglycaemia 
(collected observationally for prior 6 months) to CV and all-cause mortality 
was examined by adding patient-level covariates to the Cox models.
Results: In total, 147 primary events were accrued during study follow-up. 
There were 60 CV deaths, 44 nonfatal MIs, and 57 nonfatal strokes, with 148 
all-cause deaths. There was a significant positive relationship between up-
dated mean HbA1c and primary outcome; hazard ratio (HR) 1.25 (95% CI: 
1.12-1.40; P<0.0001). CV death (HR 1.31 [1.10-1.57]; P=0.0027) and stroke 
(HR 1.36 [1.17-1.59]; P<0.0001) were both strongly associated with HbA1c, 
but MI was not (HR 1.05 [0.83-1.32]). One or more severe hypoglycaemic 
episodes affected 175 participants, while 1508 experienced ≥1 symptomatic 
hypoglycaemic event. We found no relationship between history of severe or 
symptomatic hypoglycaemic events and CV or all-cause death.
Conclusion: Thus, as measured in the CREDIT study, ongoing poorer glu-
cose control was associated with CV events; hypoglycaemia was not associ-
ated with CV or all-cause death.
Supported by: Sanofi
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Intensive versus conservative glucose control in patients undergoing 
coronary artery bypass graft surgery (GLUCO-CABG Trial)
D. Smiley1, S. Cardona1, F. Pasquel1, F. Farrokhi1, S. Jacobs1, L. Peng2,  
M. Halkos1, J.D. Puskas1, R.A. Guyton1, V. Thourani1, G.E. Umpierrez1;  
1Medicine-Division of Endocrinology, Emory University,  
2Biostatistics, Rollins School of Public Health, Atlanta, USA.
Background and aims: This randomized controlled trial aimed to determine 
whether intensive glucose control (intensive, BG target: 5.6-7.8 mmol/L) re-
duces perioperative complications compared to conservative glucose control 
(conservative, BG target: 7.8-10 mmol/L) in hyperglycaemic patients under-
going CABG.
Materials and methods: After ICU care, subjects were transitioned to the 
same treatment regimen targeting BG<7.8 mmol/L before meals during the 
hospital stay and 90 days post discharge. The primary outcome was differenc-
es in a composite score of hospital complications including mortality, wound 
infection, pneumonia, bacteremia, respiratory failure, acute renal failure, and 
major cardiovascular events.
Results: A total of 302 patients were randomized to intensive (n=151) or 
conservative (n=151) glucose control following a computerized insulin infu-
sion algorithm. The groups were well balanced. The mean ICU daily BG was 
7.3±0.78 mmol/L (IQR 6.9-7.7) in the intensive group and 8.6±1.1 mmol/L 
(IQR 7.9-9.1) in the conservative group (p=0.99), and the hospital length of 
stay was 11.4±11 vs. 9.5±6 days (p=0.13), respectively. In the ICU, a BG <3.9 
mmol/L occurred in 8% and 2% of the intensive and conservative groups 
(p=0.03), with no BG <2.2 mmol/L. After ICU care, there were no differ-
ences between intensive and conservative groups in mean daily BG (7.9±1.6 
mmol/L vs. 7.8 ±1.6 mmol/L), patients with hypoglycaemia (<2.2 mmol/L: 
1% vs. 3%, p=0.68), or hospital readmissions (18% vs. 20%, p=0.62).
Conclusion: In summary, intensive control targeting a BG of 5.6 -7.8 mmol/L 
in the ICU did not reduce perioperative complications, mortality or hospital 
length of stay compared to a less strict glucose target of 7.8-10 mmol/L in 
hyperglycaemic patients undergoing CABG surgery.
Clinical Trial Registration Number: NCT 01792830
Supported by: American Diabetes Association, Sanofi and Glytec
OP 20 Novel compounds  
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Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese 
patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial
I. Gantz1, T. Okamoto2, Y. Ito2, K. Okuyama2, S.S. Engel1;  
1Merck Sharp & Dohme Corp., Whitehouse Station, USA,  
2MSD K. K., Tokyo, Japan.
Background and aims: Omarigliptin (OMARI) is a potent, oral, once-weekly, 
dipeptidyl peptidase-4 (DPP-4) inhibitor in development for the treatment of 
type 2 diabetes mellitus. This is a randomized, double-blind, parallel-group, 
active and placebo-controlled study in monotherapy for Japanese patients 
with type 2 diabetes mellitus (T2DM) to assess the efficacy, safety, and toler-
ability of OMARI compared to placebo (PBO) and sitagliptin (SITA), a com-
monly used once-daily DPP-4 inhibitor.
Materials and methods: Patients either not on or on an oral antihypergly-
cemic agent (AHA) were eligible. After a diet/exercise run-in and, for pa-
tients on an AHA, a drug wash-off period, eligible patients (N = 414) were 
randomized (2:2:1) to OMARI 25 mg q.w., SITA 50 mg q.d. (recommended 
dose in Japan), or PBO for 24 weeks. The primary efficacy endpoint was the 
change in HbA1c from baseline at Week 24 with two co-primary hypotheses, 
superiority of OMARI to PBO and non-inferiority of OMARI to SITA based 
on the prespecified criterion of having an upper bound of the 95% confidence 
interval (CI) less than 0.3%.
Results: Treatment groups were well-balanced for baseline characteristics. 
At baseline, randomized patients had a mean HbA1c of 7.9, 8.0 and 8.1% 
in OMARI, SITA, and PBO group, respectively. Mean fasting plasma glu-
cose (FPG) was also similar between treatment groups with 9.0, 8.8, and 9.0 
mmol/L in OMARI, SITA and PBO group, respectively. At Week 24, OMARI 
significantly changed HbA1c by -0.80% from baseline relative to PBO (Ta-
ble). The change (least squares mean, 95% CI) relative to SITA was -0.02% 
(-0.15, 0.12) and met the prespecified non-inferiority criterion. FPG and 2hr 
post meal glucose were significantly reduced from baseline with OMARI and 
SITA relative to PBO. OMARI was well tolerated without symptomatic hypo-
glycaemia and was not associated with weight gain.
Conclusion: In monotherapy, treatment with once-weekly OMARI provided 
comparable efficacy to once-daily SITA and was generally well tolerated over 
24 weeks in patients with T2DM.
Clinical Trial Registration Number: NCT01703221
Supported by: MSD K. K.
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Postprandial effects of the phosphodiesterase-5 (PDE-5) inhibitor 
tadalafil in type 2 diabetes patients: a randomised controlled trial 
L. Sjogren, J. Olausson, L. Strindberg, R. Mobini, P. Fogelstrand,  
L. Mattsson Hultén, P.-A. Jansson;  
Molecular and Clinical Medicine, Medicine, Gothenburg, Sweden.
Background and aims: Type 2 diabetes (T2D) is characterised by post-
prandial hyperglycaemia and it is important to find better treatment for this 
metabolic aberration. One strategy may be to amplify NO signalling through 
PDE-5 inhibition which increases intracellular cyclic GMP levels. Previous 
data have shown that PDE-5 inhibition induced by tadalafil was able to im-
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prove markers of insulin sensitivity in T2D patients. Here, we investigated 
acute metabolic and vascular effects of tadalafil in T2D patients after a mixed 
meal.
Materials and methods: We performed a randomised, double blind, pla-
cebo controlled trial, in parallel groups. Twenty-six T2D patients (Age: 40-
70 (male) and 50-70 years (female); BMI: 27-40 kg/m2; HbA1c < 60 mmol/
mol) were enrolled and they received either 20 mg tadalafil (n=14) or pla-
cebo (n=12) 30 min prior to a mixed meal. To assess forearm glucose uptake 
(FGU) and muscle capillary recruitment (PSglu), intramuscular microdialy-
sis was combined with arterial and venous blood sampling, as well as plethys-
mography monitoring of forearm blood flow (FBF). Blood samples and tissue 
dialysates were repeatedly collected for 5 hours. We used an ANOVA and 
Mann-Whitney U-test for all statistical analyses. Furthermore, we performed 
an ad hoc analysis excluding patients on ACE-inhibitors because this family 
of drugs have known positive effects on glucose metabolism. Accordingly, 10 
patients in the tadalafil group and 9 patients in the placebo group were evalu-
ated in a subgroup analysis.
Results: The groups were comparable regarding gender, age, BMI and HbA1c. 
ITT analyses showed that T2D patients in the tadalafil group increased FBF 
(p < 0.05), whereas this was not observed in the placebo group. Moreover, 
incremental area under the curve (IAUC) for FGU and IAUC for PSglu dur-
ing 5 hrs after the meal were similar in the two groups. However, the ad hoc 
analysis showed a significant increase (p<0.05) for IAUC FGU as well as for 
IAUC PSglu (p<0.05) in T2D patients treated with tadalafil (n=10) compared 
with placebo (n=9). Finally, postprandial glucose and insulin concentrations 
were similar in the two groups.
Conclusion: In conclusion, our data suggest that tadalafil may induce posi-
tive metabolic and vascular effects in the postprandial state in type 2 diabetes 
patients.
Clinical Trial Registration Number: NCT01238224
Supported by: Eli Lilly AB
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A selective GPR40 (FFAR1) agonist provides immediate and durable 
glucose control in rodent models of type 2 diabetes
Y. Chen;  
Eli Lilly & Co, Indianapolis, USA.
Background and aims: LY2881835 (LY) is a high affinity, potent, and effica-
cious GPR40 agonist when examined in GPR40 receptor binding and cell-
based assays. In addition, a statistically significant (SS) increase in glucose-
dependent insulin secretion was seen when LY was examined in primary 
mouse, rat and human islets. The following studies were performed to 1) 
explore the in vivo selectivity of LY using wild type (WT), GPR40 KO-, and 
GPR120-KO mice plus 2) the glucose lowering properties of LY in rodent 
models of type 2 diabetes.
Materials and methods: Islets isolated from the WT, GPR40 KO- and 
GPR120-KO mice were treated with LY2881835. Insulin concentrations were 
measured after drug incubation for 90 min. LY2881835 was administered 
orally to the WT, GPR40 KO- and GPR120-KO mice. An OGTT was per-
formed 60 minutes following drug administration and immediately prior to 
administration of the oral glucose bolus. LY2881835 was administered orally 
once daily to DIO or Streptozotocin (STZ) -treated DIO mice for 14 days. 
OGTTs were performed on days 1, or 7 and 14 with the oral glucose bolus 
administered at 30 or 60 minutes following drug administration.
Results: A statistically significant (SS) increase in Insulin secre-
tion was seen when LY was tested in primary islets from WT and 
GPR120 KO mice; although, no insulin secretion was detected in pri-
mary islets from GPR40 KO mice. OGTTs performed in WT, GPR40- 
and GPR120-KO mice following oral administration of LY at 30 mg/kg dem-
onstrated SS reductions in glucose AUCs in WT and GPR120 KO mice but 
not in GPR40-KO mice when compared to controls. These findings demon-
strate that LY induces specific GPR40-mediated anti-diabetic activity when 
examined ex-vivo and in-vivo. To explore the activity and the durability of 
LY in a model of insulin resistance, LY was administered orally, at 30 mg/
kg to DIO mice (a model of Insulin resistance induced by a high fat/sucrose 
diet) for 14 days with OGTTs performed on days 1 and 14. SS reductions in 
glucose AUCs were seen on days 1 and 14. A similar study was performed 
in STZ-treated DIO mice to explore glucose control in a model of type 2 
diabetes. In this model, pancreatic insulin content was reduced ~80% due to 
STZ-treatment. Glucose AUCs were SS reduced during OGTTs performed 
on days 1, 7 and 14 compared to control mice.
Conclusion: These results demonstrate that LY functions as a GPR40-specific 
agonist mediating immediate and durable glucose control in rodent models 
of type 2 diabetes. The findings suggest that GPR40 agonism could benefit 
glucose control across the spectrum of type 2 diabetes phenotypes includ-
ing those patients with insulin resistance and substantially reduced beta-cell 
function.
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Pramlintide-insulin fixed-dose combination: a phase 1 dose ratio-finding 
study in patients with type 1 diabetes mellitus
T. de Bruin1, K. Yuen2, M.C. Riddle2, K. Herrmann3, P. Martin1,  
O. Kolterman4, P. Ohman5;  
1AstraZeneca, Wilmington, 2Oregon Health & Science University, Portland, 
3AstraZeneca, San Diego, 4Consultant, La Jolla, 5AstraZeneca, Gaithersburg, 
USA.
Background and aims: Patients with type 1 diabetes mellitus (T1DM) lack 
secretion of both insulin and amylin, which are normally co-secreted by 
β-cells; thus, replacing both hormones may provide therapeutic advantages 
in optimizing glycaemic control. In treating T1DM, fixed doses (e.g. 60 µg) 
of pramlintide (an analog of human amylin) are administered as adjunct to 
prandial insulin, irrespective of insulin dose. This phase 1 study adjusted the 
pramlintide dose relative to insulin and examined the effects of 3 dose ratios 
on postprandial glucose and glucagon for 3 hours after a standard breakfast 
(600 kcal, 55% carbohydrate, 15% protein, 30% fat) meal.
Materials and methods: Subjects in this single-blinded, 4-way, crossover 
study received regular insulin + placebo, pramlintide 6 µg/U + regular in-
sulin, 9 µg/U + regular insulin, and 12 µg/U + regular insulin in random or-
der, using a 30% reduction in usual preprandial insulin dose with an allowed 
maximum of 10U in all treatment groups before the test meal. Adverse events 
were identified on non-directed questioning, laboratory values, vital signs, 
and physical exam.
Results: Of 19 subjects randomized (mean [SD] age 46.2 [15.6] years, HbA1c 
7.75 [0.58] %, weight 81.5 [11.1] kg, BMI 26.4 [2.6] kg/m2), 17 completed all 
four treatments. Premeal fasting plasma glucose levels ranged from 7.7 (2.0) 
to 8.7 (2.0) mmol/L, and insulin doses from 5.1 (1.54) to 5.4 (1.28) U across 
all groups. Mean (SEM) postprandial incremental glucose AUC0-3h (mmol/
L•h) for the pramlintide 6, 9, and 12 µg/U + regular insulin groups were 456.6 
(102.7), 476.7 (103.5), and 321.3 (99.8), respectively, versus 1142.5 (99.7) for 
placebo. Postprandial incremental glucagon AUC0-3h (ng/L•h) for the pram-
lintide 6, 9, and 12 µg/U + regular insulin groups were 649.4 (342.5), 614.9 
(345.0), and 677.7 (333.8), respectively, versus 1503.0 (334.2) for placebo. 
All three pramlintide dose ratios lowered incremental glucose and glucagon 
AUC 58-72% and 55-59%, respectively, versus placebo. No treatment-related 
hypoglycaemia was reported. One subject reported nausea in all 3 pramlint-
ide dose ratios, and 1 reported abdominal pain and diarrhoea.
Conclusion: All three pramlintide dose ratios showed efficacy in lowering 
postprandial glucose and glucagon levels, and were generally well-tolerated.
Clinical Trial Registration Number: NCT01708044
Supported by: JDRF
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A novel chemically modified analogue of xenin-25 exhibits improved 
glucose-lowering and insulin-releasing actions 
V.A. Gault, C.M. Martin, V. Parthsarathy, N. Irwin;  
School of Biomedical Sciences, University of Ulster, Coleraine, UK.
Background and aims: Xenin-25 is a K-cell derived gut peptide that is co-
secreted with glucose-dependent insulinotropic polypeptide (GIP) following 
a meal. Recent studies have shown that xenin-25 improves glucose homeosta-
sis and possibly potentiates the biological action of GIP. However, like many 
regulatory gut peptides, xenin-25 is rapidly degraded by plasma enzymes 
following release into the circulation. The aim of the present study was to 
examine the biological actions of a novel analogue of xenin-25, chemically 
modified by substitution of naturally occurring Lys and Arg residues with 
Gln, namely xenin-25(Gln).
Materials and methods: Xenin-25 and xenin-25(Gln) were synthesised by 
Fmoc peptide chemistry, purified by rp-HPLC and characterised by MALDI-
ToF MS. Xenin-25 and xenin-25(Gln) were incubated with murine plasma in 
50 mmol/l TEA/HCl buffer (pH 7.8) at 37ºC for 0, 2, 8 and 24 hours and deg-
radation profiles analysed by rp-HPLC and MALDI-ToF MS. In vitro insulin-
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releasing properties of xenin-25(Gln) (10-12 to 10-6 mol/l) were determined in 
BRIN-BD11 cells (n=8; 20 min incubation) at 5.6 and 16.7 mmol/l glucose 
concentrations in the absence and presence of (d-Ala2)GIP. Acute effects of 
xenin-25(Gln) (25 nmol/kg bw; ip) on plasma glucose and Insulin concen-
trations were examined in NIH Swiss mice fed a high fat diet (45% fat, 35% 
carbohydrate and 20% protein) for 140 days prior to experiment. Persistent 
effects of xenin-25(Gln) on blood glucose concentrations were examined in 
lean C57Bl/6J mice.
Results: Xenin-25(Gln) was resistant to plasma-mediated degradation for up 
to 24 hours whereas native xenin-25 was sequentially degraded by murine 
plasma. In BRIN-BD11 cells, xenin-25(Gln) significantly stimulated (1.5 to 
2.9-fold; P < 0.05 to P < 0.001) Insulin secretion in a concentration-depend-
ent manner at both 5.6 and 16.7 mmol/l glucose. Moreover, xenin-25(Gln) 
significantly augmented (1.4 to 1.7-fold; P< 0.05 to P < 0.01) the insulinotrop-
ic response of (d-Ala2)GIP in vitro. Acute administration of xenin-25(Gln) to 
high fat fed mice significantly reduced plasma glucose concentrations com-
pared to glucose alone (56% reduction; P < 0.001) and xenin-25 (38% reduc-
tion; P < 0.05) treated mice. Correspondingly, the overall Insulin secretory 
response was significantly enhanced (3.4-fold increase; P < 0.05) in xenin-
25(Gln) treated mice compared to high fat fed mice administered glucose 
alone. Furthermore, xenin-25(Gln) elicited a protracted glucose-lowering ef-
fect (40% reduction; P <0.001) when administered 8 hours prior to a glucose 
load in C57Bl/6J mice.
Conclusion: In summary, xenin-25(Gln) represents a novel enzymatically 
stable analogue of xenin-25 with improved glucose-lowering and insulino-
tropic actions over the native peptide. As a result, xenin-25(Gln) can be posi-
tioned as a novel treatment of type 2 diabetes.
Supported by ERDF/INI
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Faster-acting insulin aspart improves postprandial glycaemia versus 
insulin aspart in patients with type 1 diabetes mellitus
T. Heise1, H. Haahr2, L. Jensen2, L. Erichsen2, M. Hompesch3;  
1Profil, Neuss, Germany, 2Novo Nordisk A/S, Søborg, Denmark,  
3Profil Institute for Clinical Research, Inc., Chula Vista, USA.
Background and aims: Faster-acting insulin aspart is insulin aspart (IAsp) 
in a new formulation containing two new excipients (nicotinamide and argi-
nine), which result in a faster initial absorption after s. c. injection.
Materials and methods: In total, 36 patients with type 1 diabetes mellitus 
(T1DM; mean ± standard deviation age: 38.6 ± 12.5 years; haemoglobin A1c: 
7.8 ± 0.81%) received a single dose (0.2 U/kg s. c.) of faster-acting insulin 
aspart formulation ‘B’ (FIA(B)) or IAsp immediately (≤2 minutes) before a 
standardised liquid meal test (600 kcal; 67% carbohydrates, 17% protein, 16% 
fat; to be consumed within 8 minutes) in a randomised, crossover design.
Results: Compared with IAsp, FIA(B) had a faster onset of appearance, i.e., 
time from trial drug administration until the first time serum insulin aspart 
concentration was >30 pmol/l (median difference [95% confidence interval 
(CI)]: -6.6 minutes [-8.0; -5.0]) and greater exposure during the first 2 hours 
with the largest difference in the first 15 minutes, whereas the overall phar-
macokinetic exposure was similar between the two insulins (mean ratio [95% 
CI] AUC0-15 minutes: 3.14 [2.59; 3.80]; AUC0-30 minutes: 1.93 [1.64; 2.26]); AUC0-1 
hour: 1.30 [1.15; 1.46]; AUC0-2 hours: 1.13 [1.03; 1.24]; AUC0-10 hours: 0.99 [0.93; 
1.06]). The faster absorption led to a greater reduction in postprandial blood 
glucose (BG) with FIA(B) versus IAsp, indicated by lower post-meal AUCBG 
over 2 and 6 hours (reduction by 26% and 33%, respectively; Figure), and 
by lower BG values 1 and 2 hours postprandially (mean difference [95% CI] 
BG1 hour: -1.24 mmol/l [-2.01; -0.46]; BG2 hours: -1.45 mmol/l [-2.49; -0.42]). 
No safety or tolerability issues were identified; in particular, no injection site 
reactions were observed.
Conclusion: FIA(B) was absorbed faster and had an increased early exposure 
than insulin aspart, leading to improved postprandial glycaemic control ver-
sus insulin aspart.
Clinical Trial Registration Number: NCT01121276
Supported by: Novo Nordisk
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Bariatric surgery improves whole body and femoral subcutaneous 
adipose tissue insulin sensitivity independently of whole body weight 
loss
L. Landini1,2, M. Bucci1, T. Pham1, J.C. Hannukainen1, P. Salminen3,  
P. Iozzo2, P. Nuutila1,4;  
1Turku PET Centre, University of Turku, Finland,  
2National Research Council, Pisa, Italy, 3Department of Surgery, 
4Department of Endocrinology, Turku University Hospital, Finland.
Background and aims: The effect of weight reduction by dietary treatment 
does not reverse adipose tissue insulin resistance, as opposed to skeletal mus-
cle in which it makes a big improvement. To the best of our knowledge, there 
is no evidence of how bariatric surgery modulates femoral adipose tissue 
glucose uptake. We examine how bariatric surgery modifies femoral adipose 
tissue glucose uptake both in fasting condition and during euglycemic hyper-
insulinemic clamp in severely obese patients and healthy lean subjects and 
we study if the changes in adipose tissue glucose uptake were related with the 
remission of diabetes.
Materials and methods: Femoral subcutaneous adipose tissue and muscle 
glucose uptake were studied with positron emission tomography using [18F]
fluorodeoxyglucose (Figure 1) during fasting and euglycemic hyperinsuline-
mic clamp in 25 morbidly obese patients (BMI of 43.2±3.6 kg/m2) before and 
six months after the bariatric surgery. Ten age-matched lean subjects (BMI: 
23.7±1.8 kg/m2) served as controls. All data are presented as mean ± SE.
Results: At baseline, nine patients had type 2 diabetes mellitus (T2DM) and 
seven had impaired fasting glucose (IFG) and/or impaired glucose tolerance 
(IGT). After surgery, remission of T2DM or IFG/IGT was observed in ten 
patients. Two patients dropped out from the study. At baseline, obese patients 
had impaired whole body (M value: 12.2±1.14 vs 40.3±3.00 µmol/(min*kg), 
p<0.001) and tissue specific (muscle 20.0±3.24 vs 68.4±8.24 µmol/(min*kg), 
p<0.001 and adipose tissue 5.8±0.54 vs 9.3±1.40, p<0.01) insulin sensitiv-
ity compared to controls. After the bariatric procedure, obese patients lost 
23±6% of body weight. M value and muscle and adipose tissue glucose uptake 
were increased by 106±80%, p<0.001; 166±173%, p<0.001; 77±129%, p=0.03, 
respectively. Furthermore, adipose tissue glucose uptake normalised after 
surgery. There were no differences in fasting adipose tissue glucose uptake 
before or after surgery in obese as compared to controls. Neither the changes 
in whole body nor the changes in tissue specific insulin sensitivity correlated 
with the change in weight loss. The remission of diabetes was positively cor-
related with the change produced by bariatric surgery on the effect of insulin 
on adipose tissue glucose uptake (Spearman´s correlation: R=0.54; p<0.05).
Conclusion: Bariatric surgery promotes the remission of T2DM and insulin 
resistance and this is connected with the improvement of insulin action on 
adipose tissue glucose uptake. Improved whole body and femoral subcuta-
neous adipose tissue insulin sensitivity do not relate with the whole body 
weight loss. Hence, insulin sensitivity may depend on the intrinsic action of 
the bariatric surgery.
Clinical Trial Registration Number: NCT00793143
Supported by: Academy of Finland, Sigrid-Juselius Foundation and HEPADIP 
EU FP6
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Meal protein uptake and systemic leucine kinetics after Roux-en-Y 
gastric bypass
K.N. Bojsen-Møller1,2, S.H. Jacobsen1,2, C. Dirksen1,2, N.B. Jorgensen1,2,  
J.E. Jensen1, V.B. Kristiansen3, J.J. Holst4,2, G. van Hall5, S. Madsbad1;  
1Department of Endocrinology, Hvidovre Hospital, 2Novo Nordisk 
Foundation Centre for Basic Metabolic Research, University of Copenhagen, 
3Department of Surgical Gastroenterology, Hvidovre Hospital, 4Department 
of Biomedical Sciences, University of Copenhagen, 5Clinical Metabolomics 
Core Facility, Rigshospitalet, Copenhagen, Denmark.
Background and aims: Gastric emptying and glucose absorption is acceler-
ated after Roux-en-Y gastric bypass (RYGB), but absorption kinetics of other 
nutrients are unknown. Exclusion of major parts of the stomach and delayed 
admixing of nutrients and pancreatic proteases could potentially impair pro-
tein digestion and absorption after surgery.
Materials and methods: Leucine kinetics was investigated after meal inges-
tion in 9 obese glucose tolerant subjects (BMI 39.2±1.8 kg/m2 (mean±sem), 
HbA1c 5.3±0.1%) before and 3 months after primary RYGB. Additionally, 
5 obese subjects (BMI 42.1±1.7 kg/m2, HbA1c 5.4±0.1%) who underwent 
conversion of gastric band to RYGB were studied with the band, after band 
removal and 3 months after conversion to RYGB. All received a 6 h primed-
continuous infusion of [3,3,3-2H3]-leucine combined with a 4 h meal test 
(200 mL, semi-liquid, 394 kcal, carbohydrate 50%, fat 35% and protein 15%) 
containing 15.2 g of casein intrinsically labeled with [1-13C]-leucine. Fat free 
mass (ffm) was assessed by whole body DEXA scan.
Results: Plasma leucine concentration was unchanged at fasting while the 
postprandial leucinemia increased (iAUC: pre 4.1±0.6, 3 mo 9.5±2.0 mmol/
L×min, p=0.03) but was shorter lasting after RYGB. Peak rate of appearance 
(Ra) of oral leucine increased (0.45 ± 0.04 vs 1.35 ± 0.22 µmol/kg ffm/min, 
p<0.01) and occurred earlier (173 ± 16 vs 65 ± 8 min, p<0.01) and oral recov-
ery increased over the 4 h measured (49±4% vs 70±4%, p<0.01). Peak rate of 
disappearance (Rd) of leucine increased after RYGB (1.9 ± 0.07 vs 2.9 ± 0.26 
µmol/kg ffm/min, p<0.01). Band removal did not change oral Ra (peak: 0.44 
± 0.06 vs 0.44 ± 0.07 µmol/kg ffm/min), oral recovery (38±4% vs 40±4%) 
or Rd of leucine (peak: 1.9 ± 0.2 vs 1.8 ± 0.1 µmol/kg ffm/min), but similar 
increases were seen after conversion to RYGB as after primary RYGB.
Conclusion: In conclusion, digestion and absorption of casein are dramati-
cally changed after RYGB from slow to fast, while protein kinetics is not al-
tered by the gastric band. Protein digestion and absorption thus seem to be 
accelerated rather than impaired after RYGB. Although the nutritional conse-
quences are unknown, fast absorption could change the nutritional anabolic 
effect of protein potentially favoring oxidation rather than protein synthesis. 
These findings may have implications for our recommendation of source, 
quantity and frequency of protein intake after RYGB.
 
Clinical Trial Registration Number: NCT01559792
Supported by: UNIK
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Beta cell function improvements in subjects with type 2 diabetes 1 year 
after biliopancreatic diversion
A.C.J. Vasques1, J.C. Pareja2, M.S. Oliveira2, F.S. Novaes2, M.M.O. Lima2, 
É.A. Chaim3, F. Piccinini4, C. Dalla Man4, C. Cobelli4, B. Geloneze2;  
1Laboratory of Investigation on Metabolism and Diabetes (LIMED), School 
of Applied Sciences, Limeira, 2Laboratory of Investigation on Metabolism 
and Diabetes (LIMED), Faculty of Internal Medicine, Campinas, 
3Department of Surgery, Faculty of Internal Medicine, Campinas, Brazil, 
4Department of Information Engineering, University of Padua, Italy.
Background and aims: Bariatric surgery is an alternative therapeutic ap-
proach for obese patients with poorly controlled type 2 diabetes (T2DM). 
To provide evidence for the underlying mechanisms associated with T2DM 
remission after biliopancreatic diversion (BPD), this study aimed to evaluate 
the long term effect of BPD on β-cell function parameters and insulin sensi-
tivity in grade I and II obese patients with T2DM.
Materials and methods: Sixty-eight women were divided into three groups: 
19 LeanNGT (BMI: 23±2 kg/m²), 18 ObeseNGT (BMI: 35±5 kg/m²) both 
with normal glucose tolerance (NGT), and 31 ObeseT2DM (BMI: 36±4 
kg/m²). Twenty ObeseT2DM women underwent BPD and were reassessed 
1 year after surgery. OGTTs and hyperglycaemic clamps were performed. 
Mathematical modeling, based on insulin and C-peptide serum levels, was 
used to analyze β-cell function, insulin sensitivity (ISoral and ISclamp) and 
delay time of β-cell response to a specific plasma glucose concentration. The 
basal (DIb), dynamic (DId), static (DIs) and total disposition indexes (DIoral 
and DIclamp) represents β-cell function adjusted to IS and were calculated by 
multiplying β-cell responsivity indices by IS.
Results: After BPD, BMI (pre: 36 ± 4 vs post: 28 ± 3 kg/m²), fasting glycae-
mia (pre: 133±38 vs post: 88 ± 13 mg/dl) and HbA1c levels (pre: 7.2 ± 1.3 vs 
post: 5.1 ± 0.9% were reduced (p < 0.001). At baseline, ISoral and ISclamp 
were reduced in the obese groups compared with the LeanNGT group (p < 
0.001). After BPD, IS indexes increased approximately 6-fold. ISoral became 
comparable to LeanNGT, and ISclamp became increased in comparison with 
the LeanNGT [29 (9-89) vs 15 (8-24) dl/kg/min per µU/ml, p < 0.01], respec-
tively. At baseline, the basal disposition index (DIbasal) was reduced in the 
ObeseT2DM [67 (44-145) dl/kg/min² per pmol/l] compared with the NGT 
groups [Lean: 258 (170-455) and Obese: 169 (119-326) dl/kg/min² per pmol/l; 
p < 0.001]. After surgery, the DIbasal increased 3-fold reaching similar levels 
to that of both NGT groups (p = 0.167). At baseline, the DId, DIs and DIoral 
derived from the OGTT were reduced in the ObeseTDM2 compared with 
both NGT groups (p < 0.001). After surgery, DId and DIoral were similar to 
ObeseNGT and remained reduced compared with the LeanNGT, while the 
DIs was restored to the levels of both NGT groups. In the clamp test, at base-
line, DId, DIs and DIclamp of the ObeseT2DM were similar to ObeseNGT 
and reduced compared with the LeanNGT (p < 0.05). After surgery, all of the 
DI were similar to LeanNGT levels and were increased compared with the 
ObeseNGT. The delay time, at baseline, was markedly increased in the Obe-
seT2DM compared with the NGT subjects in both dynamic tests (p < 0.001). 
After BPD, the delay time was decreased (Clamp: 100 (80-108) vs 29 (8-100) 
min.; OGTT: 15 (9-74) vs 9 (7-10) min.; p < 0.05) and reached similar levels 
to both NGT groups (p = 0.8).
Conclusion: In long term, the BPD resulted in positive physiological adapta-
tions in patients with grade I and II obesity and T2DM, with improvements 
in a wide range aspects of β-Cell function and IS which probably contributed 
to the improved glycaemic control.
Clinical Trial Registration Number: U1111-1137-0489
Supported by: FAPESP - Grants 2008/09451-7 and 2008/07312-0
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Restoration of beta cell function in severely obese type 2 diabetic 
patients after gastric bypass surgery is accompanied by improved insulin 
processing
E. Svehlikova1, A. Tuca1, V. Höller1, B. Obermayer-Pietsch1, O. Freisinger2,  
F. Tadler3, B. Ernst4, B. Wilms5, M. Thurnheer4, B. Schultes4, T.R. Pieber1;  
1Department of Internal Medicine, Division of Endocrinology and 
Metabolism, Medical University of Graz, 2Department of Surgery, Medical 
University of Graz, 3Department of Surgery, Krankenhaus der Elisabethinen, 
Graz, Austria, 4Interdisciplinary Obesity Center, eSwiss Medical & Surgical 
Center, St. Gallen, 5Exercise Physiology Lab, Institute of Human Movement 
Sciences, ETH Zurich, Switzerland.
Background and aims: Gastric bypass surgery improves glycaemic control, 
but the underlying mechanisms are incompletely understood. The aim of the 
study was to quantify changes in beta cell function and insulin sensitivity 
before, early and 1 year after gastric bypass in type 2 diabetic (DM) and non-
diabetic (ND) morbidly obese patients.
Materials and methods: Before, 8 to 21 days and 1 year after the surgery, 34 
T2DM (17 with diabetes duration ≥8 years) and 21 ND patients underwent 
an oral glucose tolerance test (OGTT) and a botnia clamp combining an in-
travenous glucose tolerance test (IVGTT) with a subsequent hyperinsulinae-
mic-euglycaemic clamp.
Results: In DM patients, glucose tolerance gradually improved after the sur-
gery, fasting insulin was decreased at 1 year (p<0.001). In the OGTT total 
insulin secretion (AUCCP/AUCGLU: time p<0.001; group p<0.001) as well as 
the early insulin response (time p<0.001; group p<0.001) displayed an early 
improvement in both groups followed by recline or constant values respec-
tively. DM patients did not reach non-diabetic values, but they showed an 
improved C-peptide secretion pattern with a shorter time to peak C-peptide 
(p<0.01) and reduced late hyperinsulinaemia in OGTT. Insulin response to 
the IVGTT (AIR) did not change early after the surgery, but declined at 1 
yr (time p<0.001; group p<0.001). On the contrary, proinsulin levels during 
OGTT successively declined after the surgery in both groups (peak proin-
sulin: time p<0.01). The proinsulin/C-peptide ratio decreased early postop-
eratively and remained comparable at 1 yr in both groups (time p<0.001). 
Having higher baseline values, DM group showed a greater reduction in 
proinsulin/C-peptide ratio compared to ND (time x group p<0.01). Insulin 
sensitivity displayed an early increase in DM patients reaching non-diabetic 
values at 1 yr and a later improvement in the ND group (Glucose disposal: 
time p<0.001; group p<0.001). The disposition index increased in DM pa-
tients but declined in ND group (time x group p<0.01; group p<0.001).
Conclusion: The progressive improvement of glucose metabolism in DM pa-
tients after gastric bypass surgery relies on both improved insulin sensitivity 
and beta-cell function that however does not normalize entirely. Importantly, 
our results on proinsulin levels provide the first and strong evidence of im-
proved insulin processing after gastric bypass, which may represent an im-
portant mechanism of the improvement of beta cell function in DM patients 
after the surgery.
Clinical Trial Registration Number: NCT 01271062
Supported by: EFSD/MSD 
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Mechanisms of post-prandial hypoglycaemia after Roux-en-Y gastric 
bypass (RYGB) and sleeve gastrectomy (LSG)
M. Nannipieri1, A. Belligoli2, A. Mari3, D. Moriconi1, S. Baldi4, D. Colligiani4, 
M. Anselmino5, M. Foletto6, E. Zabeo7, R. Vettor7, E. Ferrannini8;  
1Clinical and Experimental Medicine, University of Pisa, 2Medicine, 
University of Padua, 3Biomedical Engineering, CNR of Padua, 4Dpt Clinical 
and Experimental Medicine, University of Pisa, 5Azienda Ospedaliera 
Universitaria Pisana, 6Oncological, Surgical and Gastroenterological 
Sciences, University of Padua, 7Medicine, University of Padua, 8Dpt Clinical 
and Experimental Medicine, University of Pisa and CNR of Pisa, Italy.
Background and aims: Symptomatic hypoglycaemia (Hypo) is a well recog-
nised complication of RYGB surgery. Data on the development of postpran-
dial Hypo after LSG are scanty. We investigated the mechanisms of postpran-
dial Hypo in patients undergoing RYGB or LSG.
Materials and methods: 32 obese non-diabetic subjects treated with RYGB 
and 39 with LSG received a 3-h OGTT before and 12-18 months after sur-
gery. Hypo was defined as plasma glucose ≤2.7 mmol/L. Insulin sensitivity 
was assessed by OGIS index and ß-cell function by modelling analysis of the 
C-peptide response to glucose load.
Results: Postprandial Hypo occurred in 20 of 32 RYGB patients and in 13 of 
39 LSG patients. Age did not discriminate Hypo from non-Hypo (NH) sub-
jects. Presurgery BMI was lower in RYGB-Hypo than RYGB-NH (43.8±5.2 
vs 49.7±6.1 kg/m2, p=0.004), but not in in LSG-Hypo vs LSG-NH patients. 
Similarly, baseline insulin sensitivity was higher in RYGB-Hypo than RYGB-
NH (386±53 vs 325±44 ml.min-1.m-2, p=0.004), but was similar in LSG-
Hypo and LSG-NH subjects. After either operation, insulin sensitivity im-
proved (p<0.0001) to the same extent in Hypo and NH subjects. Pre-surgery 
fasting glycaemia was lower in both RYGB-Hypo and LSG-Hypo compared 
to the respective NH group (5.0±0.4 vs 5.7±0.9 mM, p<0.001, and 5±0.3 vs 
5.6±0.7 mM, p<0.02 in LSG). Similarly, before surgery mean OGTT glycae-
mia was lower in Hypo than NH subjects (6.9±0.9 vs 8.4±1.3 mM, p=0.001), 
as was the plasma glucose nadir (4.7±1.3 vs 6.4±1.6 mM, p=0.005) similarly 
in the two groups. Pre-surgery fasting plasma insulin and insulin secretion 
rate were similar at baseline in all four groups, and were similarly reduced 
after surgery (p<0.0001). In contrast, total insulin secretion was reduced in 
NH, but not in Hypo after either intervention (79 ± 23 vs 59 ± 27 and 71 ± 28 
vs 72 ± 30 nmol.m-2, p<0.01 for the timexgroup interaction). ß-cell glucose 
sensitivity was negatively correlated with glucose nadir values in both surger-
ies (p=0.02 in RYGB and p=0.0009 in LSG). Likewise, insulin sensitivity was 
inversely correlated with the glucose nadir (p<0.0001 in RYGB and p=0.009 
in LSG).
Conclusion: Baseline lower plasma glucose concentrations during an OGTT 
are associated with a higher risk of post-surgery reactive hypoglycaemia after 
both RYGB and LSG. Mechanistically, inherently higher insulin output and 
better ß-cell glucose sensitivity and peripheral insulin sensitivity are respon-
sible for postprandial Hypo in surgically weight-reduced patients.
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Inadequate eating behaviour and accelerated glucose appearance can 
be resolved by sensor-augmented nutrition training in patients with 
hypoglycaemias (NIPHS) after RYGB
K.G. Rett1, R. Weiner2, H. Schreiweis1, I. Skudelny1, D. Wagenknecht1,  
E. Fischer1, K. Krieger1, E. Weitz1, C. Stier2;  
1Endocrinology and Diabetes, Krankenhaus Sachsenhausen, 2Bariatric 
Surgery, Krankenhaus Sachsenhausen, Frankfurt am Main, Germany.
Background and aims: Gastric bypass (RYGB) has been said to promote pru-
dent eating by altering food preference and reducing intake of fat and sweet 
foods thereby contributing to the favourable effects on metabolic control and 
body weight. On the other hand, recent clinical and experimental data sug-
gest accelerated appearance of oral glucose due to the anatomic alterations 
and metabolic reprogramming of the Roux limb. We therefore assessed both 
eating behavior and glucose excursions in RYGB subjects with noninsulino-
ma pancreatogenous hypoglycaemia syndrome (NIPHS) - a condition with 
high glucose variability - under real life conditions.
Materials and methods: In 20 patients (18 f, 2 m) who had undergone RYGB 
for obesity (BMI 45,5+2,2 kg/m2; 80% type 2 diabetes) and in whom both 
NIPHS and inadequate postbariatric eating behavior had been diagnosed 
during a week of continuous glucose monitoring (CGM; Dexcom G4, low-
er alarm limit: 70 mg/dl) 6-18 months after the bariatric procedure (BMI 
36,7+2,7 kg/m2). It was our aim to modify eating behavior and dumping-like 
postprandial glucose excursions. During one week of sensor-augmented nu-
trition counseling, participants were asked to comply with defined nutrition 
targets (<30% fat/>40% carbohydrates/<20g sucrose/>25g fiber) and record 
nutrition and physical activity in detailed diaries.
Results: Daily energy intake (1409+135kcal; mean+SEM) was hypocaloric, 
whereas fat consumption exceeded general recommendations both in abso-
lute (64+7g) and relative terms (42% of daily energy intake). Carbohydrate 
ingestion was slightly too low both in absolute (131+15g) and relative terms 
(38% of daily energy intake), however 21% of the carbohydrates were con-
sumed as sucrose (28g). Protein intake (69+1g / 20% of daily energy intake) 
was rather low and fiber consumption(13+2g) definitely too low. In two fe-
male subjects, one with (DM+) and one without preoperative diabetes (DM-
), complete CGM-datasets before and after nutrition training have yet been 
compiled: Target adherence reduced glucose variability (STD) from 45 to 31 
(DM-) and from 24 to 16 (DM+), respectively; time spent in hypoglycae-
mia (IG<70 mg/dl) decreased from 11 to 8.4% (DM-) and from 29 to 2.6% 
(DM+) of the day, respectively; time spent in hyperglycaemia (IG>180 mg/
dl) decreased from 8.9 to 3.2% (DM-) and from 0.9 to 0% (DM+) of the day.
Conclusion: Inadequate postbariatric eating behavior was prevalent in 
symptomatic NIPHS subjects. In contrast to bariatric literature, sucrose and 
fat consumption were exceeding and fiber and complex carbohydrates fall-
ing short of prescribed and desirable amounts. Sensor augmented nutrition 
training focusing on strict adherence to adequate nutrition targets markedly 
reduced prandial glucose peaks, overall glucose variability and time spent 
<70 mg/dl in two preliminary cases. We challenge the idea of RYGB-induced 
prudent food preference. Sensor augmented nutrition training may help to 
avoid sweetened food as far as possible in order to balance accelerated glu-
cose appearance after RYGB.
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Diabetic neuropathy and urologic complications in men with  
type 1 diabetes in the DCCT/EDIC study
R. Pop-Busui1, B. Braffett2, J. Hotaling3, P. Cleary2, C. Martin1, R. Dunn4,  
H. Wessels5, A. Sarma4, DCCT/EDIC;  
1Department of Internal Medicine, University of Michigan Medical School, 
Ann Arbor, 2Department of Biostatistics, George Washington University, 
Rockville, 3Department of Urology, University of Utah, Salt Lake City, 
4Department of Urology, University of Michigan Medical School, Ann 
Arbor, 5Department of Urology, University of Washington, Seattle, USA.
Background and aims: Impaired genital sensory or motor function may 
promote sexual or urinary dysfunction, but data in persons with type 1 dia-
betes (T1D) are limited. We evaluated associations between diabetic periph-
eral neuropathy (DPN), erectile dysfunction (ED) and lower urinary tract 
symptoms (LUTS) in men with T1D participating in Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Intervention and Complica-
tions (DCCT/EDIC)
Materials and methods: DPN was evaluated with a composite of symptoms, 
neurological examination and nerve conduction studies (NCS) performed at 
baseline and biennially during DCCT, and at years 13/14 during EDIC. Con-
firmed DPN was defined as NCS abnormalities in ≥ 2 nerves and ≥ 2 posi-
tive responses among symptoms, sensory signs, or reflex changes. ED was 
assessed using the question from the International Index of Erectile Function 
“Over the past 4 weeks, how would you rate your confidence that you can get 
and keep erection?” at EDIC year 17. Answers “very low-low” were classified 
as ED. LUTS was assessed by the American Urological Association Symptom 
Index (AUASI). AUASI scores 0-7 were defined as no LUTS, and AUASI of 
8-35 as LUTS.
Results: ED and LUTS data were available from 635 men (mean age 52 years, 
mean duration 30 years, mean DCCT/EDIC A1c 7.9%). ED only was report-
ed by 193 (30%), LUTS only by 61 (10%) and both ED and LUTS by 97 (15%) 
men. Men with confirmed DPN at year 13/14 were more likely to report ED 
(41%), LUTS (31%) or both ED and LUTS (62%) at EDIC year 17 compared 
to those without ED or LUTS (22%) (p<0.0001 for all). In multivariable logis-
tic regression analysis adjusting for DCCT cohort assignment (Intensive vs. 
Conventional), DCCT/EDIC HbA1c, DCCT/EDIC systolic blood pressure, 
age, smoking and drinking status, men with confirmed DPN had 3.82 (95% 
CI 2.0-7.3) greater odds of having both ED and LUTS compared to those 
without DPN.
Conclusion: Men with T1D and DPN are more likely to report urologic com-
plications than men with no DPN. The temporal relationship between DPN 
and ED/LUTS in this cohort is under analysis.
Clinical Trial Registration Number: NCT00360815 , NCT00360893,
Supported by: NIH/NIDDK-5R01DK083927
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Erectile dysfunction and health-related quality of life in type 1 diabetes: 
longitudinal follow-up of the DCCT/EDIC cohort
A.M. Jacobson1, B.H. Braffett2, P.A. Cleary2, R.L. Dunn3, S. Holt4,  
M.L. Larkin5, H. Wessells4, A.V. Sarma3, DCCT/EDIC Research Group;  
1Diabetes, Obesity and Cardiometabolic Research Center, Winthrop-
University Hospital, Mineola, 2Biostatistics Center, George Washington 
University, Rockville, 3Urology, University of Michigan, Ann Arbor, 
4Urology, University of Washington, Seattle, 5Diabetes Research Center, 
Massachusetts General Hospital, Boston, USA.
Background and aims: No longitudinal studies have examined the effects of 
erectile dysfunction (ED) on health-related quality of life (HRQOL) among 
men with type 1 diabetes (T1DM). We used biomedical information gathered 
as part of the Diabetes Control and Complications Trial and its follow-up the 
Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) 
study to examine the relationship.
Materials and methods: Assessment of ED was made annually in EDIC 
through a question asking “Has the patient experienced impotence since 
the last completed annual visit?” The Diabetes Quality of Life Scale (DQOL) 
(higher score, better QOL; scale 0-100), was given biannually throughout 
EDIC follow-up. The cumulative effects of ED over the 17-year time-frame 
were examined by calculating the number of consecutive years of ED as of 
year 17. A multivariable regression model was built to estimate the associa-
tion between ED experience and having a low DQOL score (≤25th percentile; 
DQOL = 70). Analyses were adjusted for time-weighted DCCT/EDIC HbA1c 
levels.
Results: At EDIC baseline, the 693 male subjects with ED and QOL data 
were on average 35.6±6.7 years old with a mean BMI of 26.3±3.6 kg/m2, dia-
betes duration 13.3±4.8 years, and DCCT/EDIC time-weighted HbA1c of 
8.1±1.3%. Forty-one (6%) subjects reported ED at baseline (ED mean DQOL 
69.6±10.3 vs. No ED 76.9±9.2; p<0.0001) and 232 (37%) reported ED at 
EDIC year 17 (ED mean DQOL 72.6±11.2 vs. No ED 77.7±10.5; p<0.0001). 
Among the 652 men who reported no ED at baseline, 332 (51%) went on 
to develop ED; 262 (79%) of the incident cases were reported at 2 or more 
follow-up visits. The mean DQOL at year 17 decreased with the number of 
consecutive years of ED (mean DQOL score for no ED 77.7±10.5, 1 year of 
ED 75.3±13.4, 2 years of ED 71.9±9.5, 3 years of ED 73.1±8.6, and 4 or more 
years of ED 71.8±11.1; p<0.0001). The table shows the effect of consecutive 
years of ED as of year 17 on the odds of a low total DQOL score at year 17 
after adjusting for HbA1c. While HRQOL decreases initially with increased 
duration of ED, these effects start to diminish as the number of years with ED 
increases, suggesting some adaptation to the change in health state.
Conclusion: Development of ED is common in T1DM patients and is associ-
ated with decrease in health-related quality of life. The effects however are not 
cumulative as men may begin to cope with the change in health state. 
Clinical Trial Registration Number: NCT00360893
Supported by: U01DK094176 R01DK083927 U01DK094157
129
Diabetic peripheral neuropathy adversely affects balance during  
stair ascent and descent
S.J. Brown1, J.C. Handsaker1, F.L. Bowling2, C.N. Maganaris3,  
A.J.M. Boulton2, N.D. Reeves1;  
1Manchester Metropolitan University, 2University of Manchester,  
3Liverpool John Moores University, UK.
Background and aims: Patients with diabetic peripheral neuropathy (DPN) 
are known to display unsteadiness during walking and as a result be at in-
creased risk for falling. Whilst some studies have found increased postural 
sway during quiet standing and walking on level ground in patients with 
DPN, no data exist on objective measures of balance during stair walking. 
Walking on stairs is one of the most dangerous daily activities in terms of fall 
risk and this study investigated the underlying mechanisms of unsteadiness 
in patients with DPN during stair ascent and descent.
Materials and methods: Motion and force data were collected for 22 diabetes 
patients with DPN (PN; age: 57 ±9.3 years), 40 diabetes patients with no DPN 
(DM; 57 ±12.8 years), and 32 healthy controls (Ctrl; 50 ±19 years). Movement 
data was collected using a 10-camera 3D motion analysis system from reflec-
tive markers placed at anatomical locations on the body to calculate whole-
body centre-of-mass (CoM). The centre-of-pressure (CoP) under the feet was 
measured using 4 force platforms mounted into the middle of a 7-step stair-
case, which participants ascended and descended at least 3 times. Balance 
was quantified by assessing the separation between the centre-of-mass and 
centre-of-pressure (CoM-CoP separation) in the medial-lateral plane. This 
parameter was expressed in terms of maximum separation and the variation 
in separation (standard deviation within 3 trials). Results were analysed using 
analysis of variation with Tukey post-hoc tests.
Results: During stair ascent the PN group showed significantly higher maxi-
mum CoM-CoP separation (mean [SD] PN: 13 [2], DM: 10 [3], Ctrl: 10 [3] 
cm; p<0.01) and significantly increased variation in CoM-CoP separation 
(mean [SD] PN: 7 [1], DM: 5 [1], Ctrl: 6 [1] cm; p<0.05) compared to the Ctrl 
group. During stair descent the PN group again showed significantly higher 
maximum CoM-CoP separation (mean [SD] PN: 15 [3], DM: 13 [4], Ctrl: 12 
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[3] cm; p<0.05) and significantly increased variation in CoM-CoP separation 
(mean [SD] PN: 8 [1], DM: 7 [1], Ctrl: 7 [1] cm; p<0.01) compared to the Ctrl 
group. The PN group also displayed a significantly wider stance width com-
pared to the Ctrl group during stair descent only (mean [SD] PN: 17 [3], DM: 
15 [3], Ctrl: 15 [2] cm; p<0.05). No differences in any variable were observed 
in the DM group compared to the Ctrl group during stair ascent or descent.
Conclusion: Diabetes patients with peripheral neuropathy display greater 
extremes in magnitude of medial-lateral sway during stair ascent and descent 
as well as displaying higher variability during stair ascent and descent. This 
indicates that patients with DPN have difficulty regulating control of balance 
during this challenging task. A larger and more variable medial-lateral sway 
means that patients with DPN are more likely to lose control of balance and 
experience a fall during what is known to be an activity where the risk of falls 
is already very high (stair walking).
Supported by: EFSD
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Shear forces applied to the feet during walking act for a longer duration 
in patients with diabetic neuropathy
N.D. Reeves1, S.J. Brown1, J.C. Handsaker1, F.L. Bowling2, A.J.M. Boulton2;  
1School of Healthcare Science, Manchester Metropolitan University,  
2Faculty of Medical & Human Sciences, University of Manchester, UK.
Background and aims: High plantar shear pressures are believed to play an 
important role in the development of diabetic foot ulcers, despite little sup-
porting evidence. In-shoe plantar pressure systems can only measure vertical 
forces, whilst force platforms allow shear forces to be measured at the foot-
ground interface. We investigated whether shear forces at the foot-ground/
step interface are elevated in patients with diabetic peripheral neuropathy 
(DPN) during level ground and stair walking.
Materials and methods: Data are presented for 94 participants in three 
groups: patients with DPN (n=22), patients with diabetes but no neuropathy 
(DM; n=40) and non-diabetic controls (CTRL; n=32). As participants walked 
at a self-selected speed, ground reaction forces acting on the feet were meas-
ured from force platforms embedded into the floor (level walkway) and steps 
(staircase). Data were analysed using analysis of variance and post-hoc tests.
Results: Peak propulsive shear forces were no different (P>0.05) between 
groups during stair ascent, but were lower in the DPN compared to the CTRL 
group during stair descent. The anterior-posterior shear force-time integrals 
were however, higher in the DPN compared to the CTRL group during both 
stair ascent (DPN: 0.30, DM: 0.26, CTRL: 0.23 N·s/kg; P<0.01) and stair 
descent (DPN: 0.41, DM: 0.41, CTRL: 0.33 N·s/kg; P<0.01). During level 
ground walking, peak propulsive shear forces (DPN: 1.7, DM: 2.0, CTRL: 2.1 
N/kg; P<0.01) and anterior-posterior shear force-time integrals (DPN: 0.56, 
DM: 0.61, CTRL: 0.65 N·s/kg; P<0.05) were lower in the DPN compared to 
the CTRL group. During level ground and stair walking, the medio-lateral 
shear force-time integrals were significantly higher in the DPN compared to 
the CTRL group (P<0.01).
Conclusion: Our results highlight that shear ground reaction forces during 
level and particularly during stair walking, are applied on the feet of patients 
with diabetic neuropathy for longer. This longer application of shear forces to 
the feet may play an important role in the development of diabetic foot ulcers. 
Information on the specific area of the foot affected is not known from these 
measurements alone and warrants further investigation linked together with 
in-shoe plantar pressure measures.
Supported by: EFSD
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Increased default mode network functional connectivity in painful 
diabetic neuropathy
R. Gandhi1, S. Pallai1, I.D. Wilkinson2, S. Tesfaye1, D. Selvarajah3;  
1Academic Department of Diabetes and Endocrinology, Sheffield Teaching 
Hospital NHS Foundation Trust, 2Academic Department of Radiology, 
University of Sheffield, 3Department of Human Metabolism, University  
of Sheffield, UK.
Background and aims: Painful diabetic peripheral neuropathy (Painful-
DPN) is common and leads to considerable disability and a reduced quality 
of life. As there are no objective biomarkers of painful-DPN current treat-
ments are less than optimal. Recent imaging studies using resting-state func-
tional magnetic resonance imaging (rs-fMRI) have identified a network of 
brain structures that are active and connected during task-free paradigms, 
when the brain is at rest. This is called the default mode network (DMN). We 
therefore investigated the status of the DMN in painful DPN as a potential 
biomarker.
Materials and methods: 51 patients with type 1 diabetes (No DPN, n=17; 
Painful DPN, n=17 and healthy volunteers [HV], n=17) underwent detailed 
clinical and neurophysiological assessments. Rs-fMRI data were acquired at 
3T (Achieva, Philips Healthcare) Blood oxygen level-dependent susceptibil-
ity-weighted dynamic datasets (n=100) were acquired over 225asec whilst 
the subject fixated on a visual cross. Data analysis were performed using in-
dependent components Analysis (ICA) with the FSL Multivariate Explora-
tory Linear Optimized Decomposition into Independent Components (FSL-
MELODIC, FMRIB Oxford) tool and a previously validated dual-regression 
statistical approach.
Results: Patients with painful DPN had increased functional connectivity in 
the DMN areas including the cingulate gyrus, hippocampus, medial frontal 
cortex and precuneus, when compared to no DPN and HV subjects (TFCE, 
uncorrected p<0.001). There was no difference in DMN functional connec-
tivity between diabetic subjects with no DPN and HV.
Conclusion: This preliminary study suggests abnormal functional connectiv-
ity in patients with painful DPN. These findings demonstrate that chronic 
pain has a widespread impact on overall brain function in diabetes, and sug-
gest that disruptions of the DMN may underlie the cognitive and behavioral 
impairments accompanying chronic pain.
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Abnormal neural plasticity and cortical reorganisation in underlies  
the painful/painless leg
D. Selvarajah1, I.D. Wilkinson2, E. Bolan1, S. Tesfaye3;  
1Department of Human Metabolism, University of Sheffield, 2Academic 
Department of Radiology, University of Sheffield, 3Academic Department  
of Radiology, Sheffield Teaching Hospital NHS Foundation Trust, UK.
Background and aims: The clinical paradox of chronic painful neuropathic 
symptoms in patients with insensate feet (the so called ‘painless/painful leg’) 
is well recognised. Using recent advances in functional magnetic resonance 
imaging (fMRI) we sought to phenotype the pattern of brain activation in 
these patients with painful diabetic neuropathy (DN) to provide new insights 
into this poorly understood condition. In the present study, painful stimuli of 
the foot and thigh were examined in painful DN subjects with and without 
retained foot sensation using fMRI.
Materials and methods: 26 subjects (Painless DN, n=9; Painful DN sensate, 
n=9; Painful DN insensate, n=8) with Type 1 diabetes and 17 healthy volun-
teers underwent detailed clinical and neurophysiological assessments (vibra-
tion detection thresholds, sural, common peroneal and tibial nerve conduc-
tion studies using standard procedures). Painful neuropathic symptoms were 
assessed using the NTSS-6 questionnaire. All Painful DN subjects had severe 
neuropathic pain below the knees. Before fMRI heat pain was applied to the 
right anterior thigh (control region) and dorsum of the foot to establish a 
threshold of noxious thermal stimulation capable of eliciting a response of at 
least 7 on an 11 point Likert scale. Painful DN insensate patients were defined 
as those unable to perceive a noxious thermal stimulus applied to the foot 
at the maximum temperature setting (39.9oC). This was repeated inside the 
MR scanner (Acheiva 3T, Philips Healthcare) at the predetermined threshold 
alternating with a pain-free baseline condition in a pseudo-randomised box-
car design. Images were analysed using FSL (FEAT, FMRIB, Oxford).
Results: Thermal noxious stimulus delivered to the foot and thigh was associ-
ated with significantly increased neuronal response in both the sensory dis-
criminatory (left somatosensory cortex [stereotactic coordinates: -12,-44,78], 
left thalamus [-12,-12,4] and right midbrain [8,-18,-14]; corrected p<0.05) 
and emotional affective (bilateral insular cortex [-32,18,4 and 36,18,0]; cor-
rected p<0.05] and left anterior cingulated gyrus (0,28,20] ; corrected p<0.05) 
components of the pain matrix in Painful DN sensate subjects when com-
pared to Painful DN insensate and Painless DN groups. However, there was 
abnormal response to painful foot and thigh stimulation in the somatosen-
sory cortex that was shifted laterally to the region which generally dominates 
the upper limb (foot: -62,-6,26 and thigh: -60,-10,34; corrected p<0.05) in 
Painful DN insensate subjects compared with HV, Painful DN sensate and 
Painless DN subjects. There was also significantly increased ipsilateral so-
matosensory cortical (foot: 64,-6,14 and thigh: 68,-10,26; corrected p<0.05) 
activation in subjects with Painful DN insensate subjects compared to other 
study cohorts.
Conclusion: These results suggest a novel, dynamic reorganisation of the so-
matosensory (S1) representation in painful DN which explains why patients 
with insensate feet can have intolerable pain. A further understanding of the 
neural plasticity and cortical reorganisation in DN may lead to the develop-
ment of more effective compounds with fewer side effects.
Supported by: JDRF
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The mitochondrial transcription factor TFB2M plays a critical role  
in mitochondrial function and insulin secretion in pancreatic beta cells
L.M. Nicholas1, B. Valtat1, N.-G. Larsson2, M. Abels1, N. Wierup1,  
H. Mulder1;  
1Department of Clinical Sciences, Lund University, Malmo, Sweden,  
2Max Planck Institute for Biology of Ageing, Cologne, Germany.
Background and aims: Insulin release from pancreatic β-cells is controlled 
by mitochondrial metabolism via its key role in stimulation-secretion cou-
pling. Consequently, insulin secretion is critically dependent on mitochon-
drial (mt) DNA expression in these cells. Mitochondrial transcription factor 
B2 (TFB2M) has been newly identified to play a key role in mtDNA tran-
scription. Its exact role in mitochondrial metabolism in β-cells, however, 
remains unknown. This study, therefore, investigated the role of TFB2M in 
mitochondrial function and insulin secretion both in vitro and in vivo.
Materials and methods: RNAi was used to knockdown (KD) Tfb2m in 
INS-1 832/13 cells. Mice with β-cell specific knockout of Tfb2m were gen-
erated using the Cre-loxP system. Blood glucose and insulin concentra-
tions were measured weekly in non-fasted mice from 3 weeks of age. Mi-
tochondrial gene expression in cells and β-Tfb2m-/- islets was determined 
by RT-PCR. Oxygen consumption in INS-1 832/13 cells was assessed by 
Seahorse XF24. Mitochondrial function in 18 days β-Tfb2m-/- islets was in-
vestigated by using a dye reflecting mitochondrial membrane polarization 
(tetramethyl¬rhodamine methylester; TMRM). ATP production was deter-
mined by ATP-dependent luciferase activity in permeabilized cells. Insulin 
secretion from cells and isolated β-Tfb2m-/- islets from 18 and 35 days old 
mice was determined using radioimmunoassay upon stimulation with low 
and high glucose concentrations as well as mitochondrial fuels. β-cell mass 
was determined by immunofluorescence. Data were analysed using a 1-way 
ANOVA with repeated measures or a Mann Whitney test. A probability level 
of 5% was taken to be significant.
Results: Knockdown of Tfb2m in INS-1 832/13 cells resulted in decreased 
expression of a number of mitochondrial encoded genes including ATP syn-
thase protein 8, cyclooxygenase 1 and NADH dehydrogenase 1 (P<0.001) 
and 5 (P<0.01). These cells also had impaired basal and glucose-stimulated 
respiration, a reduction in ATP production and content (P<0.01). In line with 
these findings in vitro, β-Tfb2m-/- mice exhibited increased plasma glucose 
and decreased plasma insulin concentrations (P<0.01) after weaning, prior to 
the onset of diabetes. This could be attributed to impaired insulin secretion 
from pancreatic islets in response to glucose and mitochondrial fuel (P<0.05), 
which was present before and persisted after weaning. Furthermore, islets 
from pre-weaned β-Tfb2m-/- mice showed altered mitochondrial function 
upon glucose stimulation; the maximal decrease in TMRM fluorescence in-
tensity from baseline was reduced compared to controls (P<0.05). Loss of 
β-Tfb2m also resulted in decreased β-cell mass and β-cell area per pancreatic 
area (P<0.05) in these mice.
Conclusion: Loss of Tfb2m in pancreatic β-cells results in mitochondrial 
dysfunction and consequently impaired insulin secretion in response to met-
abolic stimuli. These changes precede the development of clinical indicators 
of type 2 diabetes (T2D). Taken together, these findings indicate that TFB2M 
may play a pathogenic and clinically important role in the development of 
T2D.
Supported by: Swedish Diabetes Foundation, Research Council and Region 
Skåne
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Roles of the type 2 diabetes-associated gene products Arap1 and StarD10 
in the control of insulin secretion
G.R.J. Carrat1, T.J. Pullen1, L. Marselli2, G. Meur1, P. Marchetti2,  
G.A. Rutter1;  
1Medicine, Imperial College London, UK, 2Department of Clinical  
and Experimental Medicine, University of Pisa, Italy.
Background and aims: Investigation of the function of genes identified by 
genome-wide association studies for Type 2 diabetes (T2D) may bring a bet-
ter understanding of disease aetiology and ultimately provide new therapeu-
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tic targets. Recently-identified common genetic variants in the ARAP1 locus 
affect fasting proinsulin levels (rs11603334) and glucose-induced insulin se-
cretion (rs1552224) in man. Here we investigate the roles of two genes impli-
cated at this locus: ARAP1 and STARD10.
Materials and methods: Arap1 and StarD10 expression was silenced by 
siRNA and proteins overexpressed via a coding plasmid transfected by Lipo-
fectamine 2000 (cell lines) or adenoviral infection (mouse and human islets). 
Total and secreted insulin were measured by radioimmunoassay.
Results: Expression quantitative trait loci (eQTL) analysis by qRT-PCR in 
human islets from 49 donors revealed increased expression of the short 
form of Arap1 (variant 1: Arap1v1) in the carriers of the risk variant at SNP 
rs1552224 (p<0.02). Association with StarD10 mRNA levels was not detect-
ed. Over-expression of the full-length variant of Arap1 (variant 3) in MIN6 
cells exerted no apparent effect on insulin secretion in response to either 
30mM glucose (control: 2.31 ± 0.28-fold; Arap1-V3: 2.22 ± 0.25-fold; NS) or 
30mM KCl (control: 4.24 ± 0.48; Arap1-V3: 4.13 ± 0.72; NS). However, over-
expression of Arap1v1, lacking an N-terminal inhibitory domain and thus 
predicted to be more active, tended to inhibit insulin secretion provoked by 
30 mM glucose (control: 4.01 ± 0.63-fold; Arap1-V1: 2.84 ± 0.53-fold; NS) or 
30mM KCl (control: 3.68 ± 0.28; Arap1-V1: 2.90 ± 0.32; p=0.083). Moreo-
ver, over-expression of Arap1v1 or StarD10 in human islets reduced insulin 
secretion provoked by 17 mM glucose (control: 33.39 ± 9.95-fold; Arap1V1: 
19.92 ± 3.11-fold, ; StarD10: 15.26 ± 1.11-fold) and by 30 mM KCl in the case 
of StarD10 (control: 38.39 ± 8.46-fold; Arap1V1: 35.22 ± 3.85-fold; StarD10: 
15.41 ± 2.04-fold). In addition, Arap1v1 overexpression strongly reduced the 
total insulin content of human (54.21 ± 0.04%; p<0.0001) and mouse (50.51 
± 0.03%; p<0.0001) islets. Forced over-expression of StarD10 in MIN6 cells 
decreased insulin secretion provoked by 30 (versus 3.0) mM glucose (con-
trol: 2.54 ± 0.21-fold; StarD10: 1.55 ± 0.10-fold; p<0.01) or 30mM KCl (con-
trol: 5.20 ± 0.35-fold, StarD10: 2.63 ± 0.14-fold; p<0.0001). Overexpression 
of StarD10 potentiated apoptosis induced by staurosporine (1µM) in mouse 
islets, assessed by TUNEL staining (control: 1.85 ± 0.23%; StarD10: 4.60 ± 
0.62%; p<0.0001). siRNA-mediated silencing of neither gene affected insulin 
content or secretion.
Conclusion: These data indicate that Arap1, whose expression is increased in 
the carriers of risk alleles at SNP rs1552224, affects islet insulin content and 
secretion and is thus likely to mediate the effects of these alleles on diabetes 
susceptibility. The demonstration that StarD10 over-expression also affects 
insulin secretion and beta cell survival suggests that changes in the latter gene 
product may also contribute. However, further eQTL studies will be required 
to test this hypothesis in larger cohorts.
Supported by: SFD, Wellcome Trust, MRC, IMIDIA, Royal Society
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Diazoxide as a tool to investigate metabolic amplification of insulin 
secretion: a reconsideration
N. Görgler, M. Willenborg, K. Schumacher, I. Rustenbeck;  
Institute of Pharmacology and Toxicology, University of Braunschweig, 
Germany.
Background and aims: Glucose-induced insulin secretion is mediated by 
a bifurcating pathway generating “triggering” and “amplifying” signals. The 
standard protocol to demonstrate the amplifying effect of glucose (and other 
nutrient secretagogues) is to depolarize the beta cells by raising the external 
K+ concentration while the KATP channels are clamped open by diazoxide 
to ensure the generation of the Nernst equilibrium. Any further increase in 
secretion which is caused by the addition of glucose is then believed to be 
mediated by the still incompletely understood amplifying pathway. Diazox-
ide, however, has been reported to have sites of action in addition to the KATP 
channel, which may complicate the interpretation of the observed effects.
Materials and methods: The membrane potential of primary mouse islet 
cells was measured by the patch clamp technique using the perforated patch 
configuration. The cytosolic Ca2+ concentration ([Ca2+]i) was measured with 
the Fura technique, the mitochondrial membrane potential with rhodamine 
123 and insulin granules were visualized by insulin-EGFP. Insulin secretion 
was quantified by batch perifusion of islets and ELISA of the fractionated ef-
flux. The adenine nucleotide content was measured by the luciferase method 
after static incubation.
Results: To depolarize the beta cell plasma membrane a K+ concentration was 
used (15 mM KCl) which mimicked the slow-wave depolarization by glucose 
(20 mV) and raised [Ca2+]i to levels comparable to those produced by 20 mM 
glucose. In the presence of a substimulatory glucose concentration 15 mM K+ 
produced only a modest transient increase of insulin secretion. When glucose 
was raised from 5 mM to 10 mM in the continuing presence of 15 mM K+ 
a marked increase of insulin secretion with a biphasic pattern resulted. The 
addition of 250 µM diazoxide diminished the secretion down to prestimu-
latory levels. The abolition of the glucose-stimulated secretion by diazoxide 
was unexpected since K+ still depolarized the beta cell plasma membrane (by 
18 ± 1 mV) and since the presence of 10 mM glucose was expected to ensure 
the generation of amplifying signals. Compared with the presence of 10 mM 
glucose plus 15 mM KCl the addition of diazoxide led to a slight decrease 
of the ATP/ADP ratio and an equally slight increase of the ATP/AMP ratio. 
Measuring [Ca2+]i using the same protocol showed that the level established 
by the combined action of 15 mM K+ and 10 mM glucose was moderately, but 
significantly diminished by diazoxide. Concomitantly diazoxide had a depo-
larizing effect on the mitochondria, which was also visible in the TIRF mode, 
showing that mitochondria co-exist with secretory granules in the immediate 
submembrane space.
Conclusion: Diazoxide does not only affect insulin secretion by the opening 
of KATP channels. The effect on mitochondrial function may interfere with 
the amplifying pathway of nutrient secretagogues, the existence of which is 
usually demonstrated by the use of diazoxide. The interference may not even 
require changes in the bulk cytosol, since mitochondria could be shown to 
exist in the immediate submembrane space close to secretory granules.
Supported by: DFG, DDG, DDS
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Elevated expression of CaV3.1 channels impairs glucose-stimulated 
insulin secretion through downregulation of the exocytotic machinery
J. Yu1, Y. Shi1, G. Yang1,2, L. Yu1, P.-O. Berggren1, S.-N. Yang1;  
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska 
Institutet, Stockholm, Sweden, 2Jilin Academy of Traditional Chinese 
Medicine, Changchun, China.
Background and aims: Pancreatic β cells are equipped with at least seven 
subtypes of voltage-gated calcium (CaV) channels, including CaV1.2, 
CaV1.3, CaV2.1, CaV2.2, CaV2.3, CaV3.1 and CaV3.2, to conduct L-, P/Q-, 
N-, R- and T-type CaV currents, respectively. These CaV channels are vital 
to the function and survival of β cells. CaV3 channel-mediated T-type Ca2+ 
currents have long been recorded in β cells from different species including 
human. Enhanced T-type Ca2+ currents are observed in type 2 diabetic Goto-
Kakizaki rat β cells and T-type Ca2+ currents, which are absent in normal 
mouse β cells, occur in nonobese diabetic mouse β cells. To date, it is not 
known whether the enhanced T-type Ca2+ currents and phenotypic switch 
of CaV3 channel expression in diabetic β cells are causes or consequences of 
the disease. The present work aimed at exploring the role of CaV3.1 channels 
in the pathogenesis of diabetes by elevating CaV3.1 channel expression in 
rat β cells.
Materials and methods: We employed multiple methods including con-
struction of adenoviral vectors (Ad) carrying either enhanced green fluores-
cent protein (EGFP) or EGFP-CaV3.1, patch-clamp analysis, confocal mi-
croscopy, immuneblot assay, islet perifusion and transplantation.
Results: The present work began with construction of Ad-EGFP-CaV3.1 
and Ad-EGFP. Subsequently, characterization of these constructs was per-
formed in COS-7 cells, rat islet cells and intact islets. Ad-EGFP-CaV3.1 and 
Ad-EGFP effectively transduced COS-7 cells and rat islet cells. Strong EGFP 
signals were detected in both Ad-EGFP-CaV3.1- and Ad-EGFP-transduced 
cells whereas typical unitary and whole-cell T-type Ca2+ currents were only 
observed in Ad-EGFP-CaV3.1-transduced cells. These data verify that Ad-
EGFP-CaV3.1 is expressed in COS-7 cells and rat islet cells resulting in en-
hanced T-type Ca2+ currents. Both Ad-EGFP-CaV3.1 and Ad-EGFP efficient-
ly infected islet cells throughout the intact islet. Ad-EGFP-CaV3.1-infected 
islets released less insulin during exposure to 2.8 mM glucose. Importantly 
these islets displayed impaired first phase but intact second phase insulin 
secretion when perifused with 16.7 mM glucose. These observations dem-
onstrate that elevated expression of CaV3.1 channels selectively impairs ba-
sal insulin release and first-phase glucose stimulated insulin secretion. More 
importantly, the relative abundance of synaptotagmin III, syntaxin 1A and 
SNAP-25 proteins in Ad-EGFP-CaV3.1-treated islets is lower than that in is-
lets infected with Ad-EGFP. These results reveal that elevated expression of 
CaV3.1 channels downregulates syntaxin 1A, SNAP-25 and synaptotagmin 
III, which are critical for glucose-stimulated insulin secretion. Most impor-
tantly, a significant normalization of hyperglycaemia occurred in streptozo-
tocin-induced diabetic rats transplanted with control islets or islets infected 
with Ad-EGFP into the anterior chamber of the eye, but not in those trans-
planted with islets transduced with Ad-EGFP-CaV3.1. These in vivo findings 
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indicate that elevated expression of CaV3.1 channels causes impaired glucose 
homeostasis.
Conclusion: Elevated expression of CaV3.1 channels impairs glucose-stimu-
lated insulin secretion through downregulation of the exocytotic machinery 
and plays an important role in the pathogenesis of diabetes.
Supported by: KI Stiftelser, SVLS
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NGF secretion from beta cells contributes to fine tuning  
of insulin secretion
A. Pingitore1, M.C. Caroleo2, E. Cione2, S. Persaud1;  
1Diabetes Research Group, Diabetes and Nutritional Sciences, King’s College 
London, UK, 2Pharmacy and NHS, University of Calabria, Rende, Italy.
Background and aims: Islet β-cells express a range of peptides such as nerve 
growth factor (NGF), which was originally identified as a signaling protein 
regulating neuronal survival. It is now recognised that NGF is a more com-
plex messenger involved in controlling a broad range of homeostatic respons-
es through binding to two trans-membrane receptors, trkA and p75NTR, 
both expressed in islets. The role of NGF in islet function has not been estab-
lished so we investigated whether β-cells possess an autocrine loop through 
which NGF release modulates insulin secretion.
Materials and methods: Studies were conducted with isolated mouse islets 
(MI) and human islets (HI), and with MIN6 pseudoislets (PI) that were gen-
erated by growing MIN6 β-cells on bacterial dishes for 10 days. NGF release 
from islets was determined by western blotting and quantified by ELISA, 
and insulin secretion was quantified by radioimmunoassay. The biological 
activity of β-cell-derived NGF was blocked via a NGF neutralising antibody 
(AbNGF) at 5µg/mL and trkA blockade was achieved with 5nM K252a. Im-
munoprecipitation studies were performed using INS-832/13 β-cells with 
an anti-RhoGDI antibody followed by electrophoresis and western blotting 
probing with anti- p75NTR.
Results: NGF expression and release from islets was identified by western 
blotting, and a sensitive ELISA indicated that NGF was secreted from MI 
in a glucose-dependent manner (2mM glucose: 17.8±6.1 pg/mL; 20mM 
glucose 56.7±2.8 pg/mL). Blockade of secreted NGF action in islets and PIs 
with AbNGF increased insulin output at 2mM glucose (MI 381.0±114.0%, 
p<0.001; HI 150.5±17.5%, p<0.05; PI 142.6±17.0%, p>0.2). In contrast, HI 
responded to K252a treatment at 2mM glucose with an elevation in insu-
lin secretion comparable to that seen with AbNGF blockade (133.7±16.2%, 
p<0.05), but trkA inhibition at 20mM glucose did not affect insulin release, 
suggesting that p75NTR is the receptor through which locally released NGF 
acts to inhibit GSIS from islets and pseudoislets. Consistent with this, over-
expression of p75NTR in β-cells significantly inhibited GSIS (by 48.5±2.5%). 
Furthermore, immunoprecipitation studies revealed that Rho-GDI was 
bound to β-cell p75NTR at 2mM glucose and the complex dissociated upon 
glucose stimulation. Impairment of NGF biological activity with AbNGF 
resulted in the inability of the p75NTR/Rho-GDI complex to dissociate in 
response to glucose. Most likely, this affects the correct cycling of Rho-GDI 
small GTPases, disturbing the control on granule secretion through the actin-
dependent cytoskeleton remodeling.
Conclusion: These observations support the presence of an autocrine NGF 
loop in islets, whose functions go beyond the canonical survival pathways: 
we propose that co-release of NGF with insulin following a glucose stimulus 
allows the fine tuning of the β-cell secretory response to prevent hyper-secre-
tion of insulin and potentially deleterious hypoglycaemia.
Supported by: EFSD 
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Alpha-cell functionality shows gender-specific adaptations face  
to a nutritional insult in Wistar rats
J. de Toro-Martin1, E. Fernandez-Millan2, E. Lizárraga-Mollinedo1,2,  
F. Escrivá1,2, C. Álvarez1,2;  
1Department of Biochemistry and Molecular Biology II,  
School of Pharmacy, UCM, 2Ciberdem, ISCIII, Madrid, Spain.
Background and aims: Nutritional rehabilitation after early food restriction 
has been extensively associated with the later appearance of metabolic distur-
bances, like type 2 diabetes, according to the thrifty phenotype hypothesis. 
This fact has been related with adaptations of beta-cell plasticity and func-
tion. Together with beta-cells, alpha-cells play a key role in the control of 
glucose homeostasis and abnormalities in alpha-cell functionality have been 
also reported in patients with type 2 diabetes. In the present study we aimed 
to analyse the adaptations of alpha-cells face to a nutritional rehabilitation 
and gender-specific differences were investigated.
Materials and methods: The experiments were carried out in male and fe-
male Wistar rats aged of 180 days, belonging to four diet groups: control (C), 
fed a standard chow diet, undernourished (U), fed 35% of the daily control 
food intake, control high-fat (CHF) and undernourished high-fat (UHF), 
both fed a HFD from weaning onwards. Immunohistochemical and mor-
phological analysis were performed to quantify alpha- and beta-cell mass, 
as well as the islet number and size. Functionality of alpha and beta cells was 
analysed in vitro by static incubation of isolated islets under different glucose 
concentrations (0.5, 3 and 17mM). Alpha-cell secretory capacity was studied 
by adding arginine (19mM) to the incubation buffer. Glucagon and insulin 
content were quantified in the isolated islets by RIA.
Results: Islets from HFD-fed rats showed increased size in both male and fe-
male rats, whereas islet density only increased in CHF female rats. Alpha-cell 
mass significantly increased in UHF rats, whereas no changes were observed 
in CHF rats. Both male and female CHF rats exhibited increased glucagon 
secretion under low glucose conditions (0.5mM) and a lack of suppression 
face to increasing glucose concentrations. Despite significantly increased islet 
glucagon content in both male and female UHF rats, gender-specific differ-
ences were observed regarding the islet functionality. While UHF male rats 
showed improved response to stimulating glucose concentrations, UHF fe-
male rats exhibited a nearly absence of alpha-cell response, similar to that 
shown by U rats. All populations showed increased glucagon secretion when 
analysed with 19mM arginine. However, UHF female islets showed the great-
er increase in glucagon secretion at 0.5mM (~4-fold) and a significant lack of 
suppression at 3mM (~3.6-fold). Despite the increased beta-cell mass shown 
by both CHF and UHF rats, a compromised beta-cell function was exhibited 
by these rats under stimulating glucose conditions (17mM), especially wors-
ened in UHF female rats, showing also decreased insulin content.
Conclusion: Since glucagon release by alpha-cells is mainly regulated by glu-
cose and a highly specific paracrine control, these results point to a defect 
in glucose sensitivity of alpha-cells after HFD, likely related to a deficient 
beta-cell-mediated paracrine control of glucagon. The worsening of these al-
terations in female rats evidences a gender-specific occurrence of impaired 
adaptations to a nutritional insult.
Supported by: MINECO (BFU2011/25420), CIBERDEM (ISCIII) and CAM 
(S2010/BMD-2423), Spain.
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A beta cell specific protein subnetwork significantly enriched for 
association with GLP-1 stimulated insulin secretion: a DIRECT study
V. Gudmundsdottir1, H.K. Pedersen1, L.M. ‘t Hart2, K. Banasik3,4,  
D. Boomsma5, E. de Geus5, M. Eekhoff6, M. Diamant6, M. McCarthy3,7,  
E. Pearson8, C. Workman1, R. Gupta1, S. Brunak1;  
1Technical University of Denmark, Kgs. Lyngby, Denmark,  
2Leiden University Medical Center, Netherlands, 3University of Oxford, UK, 
4University of Copenhagen, Denmark, 5VU University Amsterdam,  
6VU University Medical Center, Amsterdam, Netherlands, 7Oxford Centre 
for Diabetes, Endocrinology and Metabolism, 8University of Dundee, UK.
Background and aims: The heritability of insulin secretion response (ISR) 
during a modified hyperglycaemic clamp with glucose, glucagon-like pep-
tide-1 (GLP-1) and arginine stimulation has been shown to be considerable 
(h2=0.52 to 0.80) and it is of great interest to identify genetic variants in-
fluencing these responses. Evaluating ISR with a modified hyperglycaemic 
clamp is not feasible in larger cohorts of sizes preferred for genome-wide 
association studies (GWAS). When sample sizes are small, GWAS may be 
complemented with systems biology approaches to aid the prioritisation of 
genetic variants. Within the DIRECT consortium a GWAS was performed 
on GLP-1 stimulated ISR and here we aimed to use data integration to add 
biological context to the results and facilitate variant prioritisation.
Materials and methods: GLP-1 stimulated ISR was measured with a modi-
fied hyperglycaemic clamp in 130 twins and sibs from the Netherlands twin 
register. The cohort was genotyped using the Illumina HumanCore Exome 
BeadChip and association analysis was performed using the QTassoc soft-
ware and adjusted for age, sex, familial relationships and insulin sensitivity 
index. Gene-based P-values were mapped onto a β-cell specific protein-pro-
tein interaction (PPI) network, which was created by pruning high confi-
dence PPIs from InWeb 3.0 using published β-cell RNAseq data. Connected 
components in the network enriched for high scoring genes were identified 
with the Cytoscape plugin jActiveModules. The significance of the top-scor-
ing network was evaluated by converting the gene P-values to z-scores and 
estimating the probability of observing a combined z-score of same size or 
higher with 10,000 degree-preserved randomly sampled subnetworks from 
the β-cell PPI. Gene set enrichment analysis was performed on the top sub-
network using DAVID.
Results: None of the variants tested in the GWAS reached a genome-wide 
significance of P ≤ 5.0E-8. However, the top scoring subnetwork had a sig-
nificantly higher combined z-score than expected by random (P ≤ 1.0E-4). It 
contained 25 genes and was most strongly enriched for the Gene Ontology 
terms “plasma membrane part” (Padj = 2.2E-4), “cell junction” (Padj = 3.6E-
4) and “cell projection” (Padj = 4.9E-3). The subnetwork contained a number 
of genes known to affect β-cell mass and function (FOXO1), insulin secretion 
(WFS1, RYR2) or to be implicated in type 2 diabetes (MAGI2, CTNNA2 and 
PTPRD).
Conclusion: We have identified a β-cell PPI network enriched for genes with 
nominal associations with GLP-1 stimulated ISR, demonstrating how data 
integration can highlight biological mechanisms underlying a phenotype 
where GWAS results on their own may be insufficient. Furthermore, the net-
work can be used to prioritise genetic variants to take forward for replication 
in independent cohorts.
Supported by: EU IMI-DIRECT project
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FOXA2 bound sites are enriched for type 2 diabetes risk variants 
K.J. Gaulton1, A.P. Morris2, M.I. McCarthy1, the DIAGRAM consortium;  
1Wellcome Trust Centre for Human Genetics, Oxford, 2Department of 
Biostatistics, University of Liverpool, UK.
Background and aims: Risk variants for type 2 diabetes (T2D) are primarily 
non-coding and are enriched at regulatory features; however, specific causal 
variants and regulatory factors underlying risk variant activity are largely 
unknown. We aimed to integrate systematic regional genotyping data with 
genomic annotation to identify (i) regulatory factor binding sites broadly 
enriched for T2D risk and (ii) causal regulatory variants driving enriched 
signals.
Materials and methods: We used “credible sets” of SNPs that account for 
99% of the probability of including the causal variant for 39 T2D association 
signals identified in a study of 27,116 T2D cases and 57,574 controls (Me-
tabochip imputed up to 1000G). We then identified chromatin immunopre-
cipitation (ChIP) binding sites of 141 proteins obtained from ENCODE and 
several independent studies. Credible sets were tested for enrichment in the 
sum of posterior probabilities for variants overlapping binding sites for each 
factor pooled across all assayed cell types compared to variants in shuffled site 
locations (within 100kb). We performed enrichment tests both across all loci 
together and, for globally-enriched factors, at each locus individually.
Results: We identified significant enrichment for FOXA2 sites (assayed in 
pancreatic islets and HepG2 cells) across all risk loci (P=3x10-4). No other 
factor was significantly enriched. Among individual loci, there was nominally 
significant enrichment (P<.05) at 12 out of the 24 total loci containing at least 
one credible set variant overlapping a FOXA2 site. We identified candidate 
regulatory variants at 8 of these 12 loci using predictions of sequence motifs 
in FOXA2-bound sites. Further in silico and preliminary experimental study 
of allelic effects on protein binding suggests a subset are functional regula-
tory variants, including a variant with prior functional evidence (rs7903146 
at TCF7L2).
Conclusion: These results identify potential causal variants at a set of known 
T2D risk loci and suggest that altered FOXA2 binding may be a common 
functional avenue for many T2D risk variants.
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The terminal complement complex C5b-9, but not the anaphylatoxin 
C5a, is cross-sectionally associated with fatty liver disease:  
The CODAM study
M.M.J. van Greevenbroek1, M.F.J. Wilbrink1, E. Hertle1, N. Wlazlo2,  
C.J.H. van der Kallen1, E.J.M. Feskens3, C.G. Schalkwijk1, C.D.A. Stehouwer1; 
1Internal Medicine (UNS 50 box 14), Maastricht University,  
2Internal Medicine (UNS 50 box 14), Catharina Ziekenhuis, Eindhoven, 
3Human Nutrition, Wageningen University, Netherlands.
Background and aims: The etiological mechanisms that underlie human 
fatty liver disease are incompletely understood. We previously showed that 
certain aspects of complement activation -as reflected by systemic C3a lev-
els- were associated with human fatty liver disease. Objective: To investigate 
whether activation of the terminal complement pathway -as represented by 
C5a and soluble (s)C5b-9- was also associated with fatty liver disease.
Materials and methods: Plasma C5a and sC5b-9 were measured in a cross-
sectional evaluation of the Cohort on Diabetes and Atherosclerosis Maas-
tricht (CODAM,n=508, 61% men; 59±7 yrs). As markers of fatty liver dis-
ease we used liver fat content (eLF%), estimated using a validated predictive 
equation, as well as liver enzymes [alanine aminotransferase (ALT), aspar-
tate amino transferase (AST), and gamma-glutamyl transferase GGT)], that 
were compiled into a standardized (std) liver enzyme (LE) score. Multiple 
linear regression analyses were used to investigate associations between C5a 
and sC5b-9 and these fatty liver disease markers. Analyses were adjusted for 
age, sex, impaired glucose metabolism and type 2 diabetes mellitus, cardio-
vascular disease, smoking, alcohol consumption, kidney function, medica-
tion, physical activity, and waist circumference. We additionally investigated 
whether these associations, if present, were mediated (i.e. explained) by low-
grade inflammation (LGI). For this, 8 markers of LGI (TNF-α, CRP, IL6, IL8, 
serum amyloid A, ICAM1, ceruloplasmin and haptoglobin) were compiled 
into a std LGI score that was added to the fully adjusted regression models.
Results: In the fully adjusted regression models, std sC5b-9 was significantly 
associated with std eLF% (β=0.12 [95%CI: 0.05;0.18]) and with the std LE-
score (β=0.16 [95%CI: 0.09;0.24]). In contrast, C5a was not significantly asso-
ciated with either fatty liver disease marker. The association between sC5b-9 
and the markers of fatty liver disease was for a substantial part (20-30%), but 
not fully, explained by LGI. In the final, mediated, regression model, sC5b-9 
(β=0.08 [95%CI: 0.01;0.14], β=0.13 [95%CI: 0.05;0.21]) and the LGI score 
(β=0.14 [95%CI: 0.07;0.21], β=0.14 [95%CI: 0.06;0.23]) were both indepen-
dently associated with eLF% and the LE-score, respectively. Similar results 
were obtained when analyses were restricted to those who consumed no-to-
moderate amounts of alcohol (<30 g/d for men, <20g/d for women, n=400).
Conclusion: In the CODAM cohort, plasma levels of the anapylatoxin C5a 
appeared not to be associated with fatty liver disease. In contrast, a hallmark 
of full complement activation -i.e. formation of the (s)C5b-9 complex- was 
associated with human fatty liver disease, as represented by markers of he-
patic fat accumulation (eLF%) and hepatocellular injury (LE-score). These 
associations were only partly explained by LGI and therefore suggest a po-
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tential direct involvement of terminal complement activation in the aetiology 
of human fatty liver disease, which deserves further investigation aiming to 
unravel the potential mechanisms involved.
Supported by: NWO, DFN, NHS, CTMM-PREDICCt
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Novel metabolite models that distinguish impaired glucose tolerance 
(IGT) from normal glucose tolerance (NGT)
J.E. Cobb1, A. Eckhart1, K.-P. Adam1, R. Perichon1, J. Wulff1, M. Mitchell1,  
R. Elverson1, R. Wolfert1, K. Lawton1, E. Button1, Z. Li1, B. Carr2,  
M. Sinnott2, E. Ferrannini3;  
1Metabolon, Durham, USA, 2Vhi Healthcare, Dublin, Ireland,  
3University of Pisa, Italy.
Background and aims: Metabolomic profiling studies have identified a num-
ber of metabolites where fasting levels are associated with dysglycemia and 
type 2 diabetes. The aim of this study was to identify metabolites and metab-
olite-based models that distinguish IGT from NGT in non-diabetic subjects.
Materials and methods: Using the stable isotope dilution technique, quanti-
tative assays were developed for a set of 23 candidate biomarker metabolites 
previously linked to dysglycemia. This set included: α-hydroxybutyric acid 
(AHB), linoleoylglycerophosphocholine (LGPC), oleic acid, α-ketoglutaric 
acid, 2-aminoadipic acid, glycine, aromatic amino acids, and the 3 branched-
chain amino acids and several of their catabolites. These metabolites were 
measured in fasting plasma samples taken just prior to an OGTT from 1,679 
non-diabetic subjects: 979 from the RISC Study 3 year follow up (11.5% 
have IGT) and 679 subjects from the DMVhi cohort in the DEXLIFE project 
(11.8% have IGT).
Results: Random forest decision tree analysis using subject metabolite, an-
thropometric, and metabolic characteristic data were generated to rank vari-
ables for their ability to distinguish IGT from NGT. The top 4 were found to 
be AHB, fasting glucose, LGPC, and oleic acid in RISC and fasting glucose, 
age, LGPC, and AHB in DMVhi. Multivariate models for estimating risk of 
IGT were evaluated in both cohorts using AUCs calculated from the cor-
responding ROC curves. AUCs generally did not increase in models having 
more than 7 variables. A number of 7 variable, metabolite only models were 
developed that had AUCs >0.80. For example, in RISC, a model consisting of 
AHB, glucose, LGPC, oleic acid, glycine, creatine, and 2-oxoisoleucine had 
an AUC of 0.825. In contrast, a model consisting of age, sex, BMI, glucose, 
insulin and HDL had a significantly lower (p=0.0001) AUC of 0.731.
Conclusion: AHB and LGPC have been identified as metabolite markers of 
IGT and metabolite-based models may be useful for identifying IGT in non-
diabetic subjects
Supported by: DEXLIFE project (EU FP7 programme, Grant agreement no: 
279228)
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Causal effect of decreased LDL cholesterol and increased blood pressure 
on higher incidence of type 2 diabetes by Mendelian randomisation in 
the Malmö Diet and Cancer Study
G. Hindy, G. Rukh, P. Almgren, U. Ericson, O. Melander, M. Orho-Melander;  
Department of Clinical Sciences in Malmö, Lund University Diabetes 
Center, Skåne University Hospital, Lund University, Malmö, Sweden.
Background and aims: Obesity, dyslipidemia and hypertension associate 
with type 2 diabetes (T2D). However, the relationship between these traits 
and T2D may not be causal due to confounding and reverse causation. In 
the Mendelian randomization approach genetic variants are assumed to be 
randomly distributed, and can be used as instrumental variables to estimate 
causal relationships. The aim of this study was to investigate if BMI, systolic 
blood pressure (SBP) and lipid traits are causally associated with T2D in-
cidence by using genetic risk scores (GRSs) of single nucleotide polymor-
phisms (SNPs) identified in genome wide association studies (GWAS) for 
these traits as instrumental variables.
Materials and methods: In total, 27254 non-diabetic participants (61% fe-
males) from the population based Malmö Diet and Cancer Study (MDCS), 
collected at baseline during 1990-1996 (age 58±8 years, BMI 26±4 kg/m2), 
were genotyped for SNPs associating with BMI (N=31), high density lipopro-
tein cholesterol (HDLC, N=41), low density lipoprotein cholesterol (LDLC, 
N=32), triglycerides (TG, N=26) and SBP (N=29). Trait-specific weighted 
GRSs were created using PLINK software. During a mean follow-up time of 
15±4 years, 3248 incident T2D and 3977 cardiovascular disease (CVD) cases 
were identified. At baseline, BMI and SBP were measured for all individuals 
and fasting blood lipid levels were analyzed in a random sub-cohort (MDC-
CC) of 5284 individuals of which 781 developed T2D and 754 CVD. COX- 
regression was used to analyze the association between BMI, SBP, HDLC, 
LDLC and TG, and incidence of T2D per standard deviation (SD). For Men-
delian randomization, a two-stage least square regression method was used 
with the GRSs as instrumental variables. The predicted values for the first 
stage of regression of the lipid traits on their respective GRSs were estimated 
from MDC-CC for all MDCS. Adjustments were made for age, sex, lipid-
lowering and antihypertensive medication.
Results: As expected, baseline levels of higher BMI, SBP, LDLC and TG, and 
lower HDLC associated with higher incidence of T2D (HR 1.83 [1.78-1.88], 
P<0.00001; 1.34 [1.29-1.38], P=3×10-59; 1.17 [1.08-1.25], P=0.0004; 1.23 
[1.20-1.27], P=2×10-50 and 1.66 [1.51-1.82], P=4×10-27, respectively). The 
instrumental variable analysis revealed causal effect of increased BMI and 
SBP but decreased LDLC on higher incidence of T2D (HR 1.92 [1.30-2.83], 
P=0.001; 1.99 [1.14-3.48], P=0.02 and 1.14 [1.00-1.28], P=0.04, respectively). 
The instrumental variable analysis did not indicate causality between HDLC 
or TG and incidence of T2D (0.90 [0.78-1.03], P=0.13 and 1.07 [0.91-1.26], 
P=0.42, respectively). The instrumental variable analysis indicated a causal 
effect of increased SBP, LDLC and TG on higher incidence of CVD (HR 1.73 
[1.04-2.88], P=0.03; 1.21 [1.08-1.36], P=0.001 and 1.17 [1.01-1.36], P=0.04, 
respectively).
Conclusion: In this large prospective study the Mendelian randomization 
analysis indicated causal effects of increased BMI and SBP and decreased 
LDLC on higher incidence of T2D. Our results suggest opposite causal ef-
fects of LDLC on the risk of T2D and CVD, and raise the question about the 
potential deleterious effects of LDLC lowering agents on the risk of T2D. Fur-
ther, our study emphasizes the importance of weight loss and blood pressure 
control in prevention of T2D.
Supported by: VR, HLF, NNF, SDF, PF, KAWF, LF
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Genome wide meta-analysis highlights the role of genetic variation  
in RARRES2 in regulation of circulating serum chemerin 
J. Breitfeld1, M. Scholz2,3, C. Marzi4,5, H. Grallert4,5, C. Ladenvall6,  
K. Krause7, E. Laurila6, B. Isomaa8,9, L. Groop6, I. Prokopenko10,11,  
C. Gieger12, M. Blüher1,7, M. Stumvoll1,7, P. Kovacs1, A. Tönjes7;  
1IFB Adiposity Diseases, University of Leipzig, 2Institute of Medical 
Informatics, Statistics and Epidemiology, University of Leipzig, 3LIFE 
Research Center, University of Leipzig, 4Department of Molecular 
Epidemiology, Helmholtz Zentrum München, German Research Center 
for Environmental Health, Neuherberg, 5German Center for Diabetes 
Research (DZD), Neuherberg, Germany, 6Department of Clinical Sciences, 
Diabetes and Endocrinology, Lund University and Lund University Diabetes 
Centre, CRC at Skåne University Hospital, Malmö, Sweden, 7Department 
of Medicine, University of Leipzig, Germany, 8Folkhälsan Research Centre, 
University of Helsinki, Finland, 9Department of Social Services and Health 
Care, Jakobstad, Finland, 10Wellcome Trust Centre for Human Genetics, 
University of Oxford, UK, 11Department of Genomics of common diseases, 
Imperial College London, UK, 12Institute of Genetic Epidemiology, 
Helmholtz Zentrum München, German Research Center for Environmental 
Health, Neuherberg, Germany.
Background and aims: Chemerin is an adipokine proposed to link obesity 
and chronic inflammation of adipose tissue. Genetic factors determining 
chemerin release from adipose tissue are yet unknown.
Materials and methods: We conducted a meta-analysis of genome-wide as-
sociation studies GWAS for serum chemerin in three independent cohorts 
from Europe (Sorbs and KORA from Germany and PPP-Botnia study from 
Sweden; total N=2,791). Furthermore, we measured mRNA expression of 
genes within the associated loci in lymphocytes and adipose tissue by quanti-
tative RT-PCR and performed mRNA expression-genotype association stud-
ies.
Results: Heritability of circulating chemerin levels was 16.2%. Thirty one sin-
gle nucleotide polymorphisms (SNPs) at chromosome 7 within the RARRES-
LRRC61 locus reached genome-wide significance (p<10-7) in the meta-
analysis (strongest evidence for association at rs7806429 with p=7.8x10-14, 
beta=-0.067). All other SNPs within the cluster were in strong linkage dis-
equilibrium with rs7806429 (r2 >0.43 in the Sorbs). The results in the sub-
group analyses in males and females were consistent with the results in the 
total cohort. Although effect sizes for all genome-wide significant SNPs were 
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stronger in females than in males, no SNP gender interaction was observed. 
Furthermore, rs7806429 was associated with mRNA expression of RARRES2 
in visceral adipose tissue in women (p<0.05 after adjusting for age, sex and 
body mass index).
Conclusion: The present meta-analysis of GWAS combined with mRNA ex-
pression studies highlights the role of genetic variation in RARRES2 in the 
regulation of circulating chemerin concentrations.
Supported by: CRC 1052 (project C3)
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The effect of insulin degludec in combination with liraglutide and 
metformin in patients with type 2 diabetes requiring treatment 
intensification
V.R. Aroda1, T. Bailey2, B. Cariou3, S. Kumar4, L.A. Leiter5, P. Raskin6,  
J. Zacho7, M. Bandier7, A. Philis-Tsimikas8;  
1MedStar Health Research Institute, Hyattsville, 2AMCR Institute Inc., 
Escondido, USA, 3Department of Endocrinology, Nantes University 
Hospital, Nantes, France, 4WISDEM Centre, University Hospitals of 
Coventry and Warwickshire, Coventry, UK, 5St Michael’s Hospital, 
University of Toronto, Canada, 6University of Texas Southwestern Medical 
Center at Dallas, USA, 7Novo Nordisk A/S, Søborg, Denmark,  
8Scripps Whittier Diabetes Institute, San Diego, USA.
Background and aims: Several studies have evaluated the combination of 
a basal insulin and a glucagon-like peptide-1 (GLP-1) analogue in address-
ing the multiple concomitant defects in glucose homeostasis seen in type 2 
diabetes (T2D). The aim of this trial was to investigate the efficacy of insulin 
degludec (IDeg) compared with placebo in improving glucose control in pa-
tients with T2D, treated with liraglutide (lira) and metformin and qualifying 
for treatment intensification.
Materials and methods: In this 26-week, double-blind trial, patients with 
T2D who remained inadequately controlled (HbA1c 7-9%, inclusive) after a 
15-week run-in period with initiation and intensification of liraglutide to 1.8 
mg in combination with metformin (≥1500 mg) were randomised (1:1) to 
addition of once-daily IDeg (n=174) or placebo (n=172), with dosing of both 
IDeg and placebo based on titration guidelines (fasting plasma glucose [FPG] 
target 4.0-5.0 mmol/L).
Results: Patient characteristics were generally similar at randomisation: mean 
HbA1c was 7.5% (IDeg+lira) vs. 7.6% (placebo+lira), BMI 32.0 kg/m
2 vs. 32.4 
kg/m2, duration of diabetes 9.7 years vs. 9.3 years and FPG 8.7 mmol/L vs. 
9.1 mmol/L. At 26 weeks, IDeg+lira was superior to placebo+lira in improv-
ing glycaemic control in terms of HbA1c (estimated treatment difference 
[ETD]: -0.92% [-1.10; -0.75]95%CI, p<0.0001) with observed mean reductions 
of 1.04% and 0.16%, respectively. IDeg+lira was more effective in lowering 
FPG than placebo+lira, ETD -2.55 mmol/L [-3.07; -2.02]95%CI, p<0.0001 with 
observed mean reductions of 2.60 mmol/L and 0.28 mmol/L, respectively. 
At 26 weeks, IDeg dose was 51 U while placebo was titrated to a dose cor-
responding to 105 U. During lira run-in, mean body weight in those later 
randomised to trial treatment decreased from 95.4 kg to 92.3 kg. After 26 
weeks of treatment, patients randomised to IDeg+lira had gained on average 
2.0 kg, while patients randomised to placebo+lira had an additional weight 
reduction of 1.3 kg during treatment. Rates (episodes per exposure-year) of 
confirmed hypoglycaemia were low in both groups, higher with IDeg+lira 
than with placebo+lira (0.57 vs. 0.12), estimated treatment ratio: 4.67 [2.07; 
10.56]95%CI, p=0.0002. Rates of nocturnal confirmed hypoglycaemic episodes 
were low and similar for both groups (0.05 and 0.03, respectively, p=NS). 
There were no episodes of severe hypoglycaemia in either treatment arm. No 
safety issues were identified with IDeg+lira with respect to adverse events or 
standard safety parameters.
Conclusion: For patients with T2D treated with lira+metformin and qualify-
ing for treatment intensification, addition of IDeg compared with placebo 
significantly improved glycaemic control with low rates of overall hypogly-
caemia (higher with IDeg than placebo) and similar rates of nocturnal hypo-
glycaemia compared with placebo.
Clinical Trial Registration Number: NCT01664247
Supported by: Novo Nordisk
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Similar efficacy and safety with LY2963016 insulin glargine compared 
with insulin glargine in patients with type 1 diabetes mellitus:  
the ELEMENT 1 study
R.K. Pollom1, T. Blevins2, D. Dahl3, J. Rosenstock4, W.J. Huster1, L.L. Ilag1, 
M.J. Prince1;  
1Eli Lilly and Company, Indianapolis, 2Texas Diabetes & Endocrinology, 
Austin, USA, 3Gemeinschaftspraxis für Innere Medizin und Diabetologie, 
Hamburg, Germany, 4Dallas Diabetes and Endocrine Center, USA.
Background and aims: LY2963016 (LY IGlar) and insulin glargine (Sanofi-
Aventis; IGlar) are both insulin glargine products, with identical amino acid 
sequences. Even with identical primary structure, protein-based therapeutics 
manufactured by distinct processes must be shown to be clinically similar.
Materials and methods: A 52-week, Phase 3, randomized, open-label, par-
allel study, with a 24-week treatment period and a 28-week extension, was 
undertaken to compare the efficacy and safety of LY IGlar once daily (QD) 
vs IGlar QD in combination with pre-meal insulin lispro thrice daily in pa-
tients with T1DM (HbA1c ≤11.0 %). LY IGlar and IGlar were administered 
with prefilled pen injectors. The primary aim was to test the non-inferiority 
(0.3% margin) of LY IGlar to IGlar as measured by change in HbA1c, from 
baseline to 24 weeks. Testing for non-inferiority of IGlar to LY IGlar was 
also performed and pre-specified as a complementary hypothesis, which 
if met along with the primary aim, would demonstrate equivalent efficacy 
between LY IGlar and IGlar. Insulin doses were adjusted during the study 
to achieve glycemic targets (HbA1c <7%, fasting plasma-equivalent glucose 
≤ 6.0 mmol/L). Safety assessments included hypoglycaemia, adverse events 
(AEs) and antibody responses.
Results: Most patients (LY IGlar, 81.3%; IGlar 87.6%) were receiving IGlar 
prior to randomization. Both treatment groups had within-group statisti-
cally significant (p<.001) decreases in mean HbA1c values from baseline. The 
change in HbA1c from baseline with LY IGlar was non-inferior to IGlar (Ta-
ble). Non-inferiority of IGlar to LY IGlar was also demonstrated; thus, the 
criteria for equivalence in clinical efficacy between LY IGlar and IGlar were 
met. At 24 and 52 weeks, there were no treatment differences in secondary ef-
ficacy or safety outcomes including hypoglycaemia and treatment-emergent 
antibody response (Table). At 52 weeks, similar findings were seen between 
LY IGlar and IGlar in mean [SD] overall rates (events/patient/year) of noc-
turnal hypoglycaemia (LY IGlar, 16.1 [20.2]; IGlar, 17.3 [19.5], p=.250) and 
severe hypoglycaemia (LY IGlar, 0.1 [0.5]; IGlar, 0.1 [0.5], p=.826), and in 
mean [SD] weight gain (kg) (LY IGlar, 0.9 [3.3]; IGlar, 0.6 [3.7], p=.253). AE 
frequency was the same with LY IGlar (62%) and IGlar (62%) (p>.999).
Conclusion: LY IGlar compared with IGlar, used in combination with insu-
lin lispro, provided equivalent efficacy and a similar safety profile in patients 
with T1DM.
Clinical Trial Registration Number: NCT01421147
Supported by: Eli Lilly and Company
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Treatment intensification with IDegAsp BID vs IDeg OD plus IAsp in 
insulin-treated patients with type 2 diabetes: a randomised, controlled 
phase 3 trial
J.G. Cooper1, T.R. Pieber2, B. Cariou3, L. Endahl4, J. Zacho4, H.W. Rodbard5;  
1Stavanger University Hospital, Norway, 2Medical University of Graz, 
Austria, 3L’Institut du Thorax, Nantes University Hospital, France,  
4Novo Nordisk A/S, Søborg, Denmark, 5Endocrine and Metabolic 
Consultants, Rockville, USA.
Background and aims: This study compared the efficacy and safety of two 
regimens in the management of adults with TD2M previously treated with 
basal insulin and in need of insulin intensification to improve glycaemic con-
trol in the postprandial period: (1) IDegAsp (a fixed and soluble combination 
of 70% insulin degludec IDeg and 30% insulin aspart (IAsp), administered 
twice daily (BID), and (2) a basal-bolus regimen with once daily IDeg (OD) 
with IAsp 2-4 times daily.
Materials and methods: In this 26-week randomised multinational phase 3b 
trial, participants (mean: age 60 years, HbA1c 8.3%, duration of diabetes 13 
years) previously treated with a basal insulin (insulin glargine [64%]) were 
randomised (1:1) to IDegAsp BID (n=138) or IDeg OD plus IAsp 2-4 times 
daily (n=136). IDegAsp was administered with the two main meals of the day.
Results: HbA1c was reduced with IDegAsp BID and IDeg OD plus IAsp regi-
mens (to 7.0 and 6.8%, respectively; see Figure), with no significant difference 
between the two treatments. IDegAsp did not achieve non-inferiority, as the 
95% CI exceeded the pre-defined non-inferiority limit (Estimated Treatment 
Difference [ETD] 0.18, 95% CI -0.04; 0.41). A significantly lower total daily 
insulin dose of 1.11 U/kg for IDegAsp BID vs 1.34 U/kg for IDeg OD plus 
IAsp (estimated ratio 0.88, 95% CI 0.78; 1.00, p<0.05) was observed. Change 
in body weight (LOCF analysis) at end of trial was +2.75 kg and +3.76 kg 
for IDegAsp BID and IDeg OD plus IAsp (ETD -1.04, 95% CI -1.99; -0.10, 
p<0.05). Fewer confirmed hypoglycaemia episodes (self-reported plasma 
glucose <3.1 mmol/L) were reported for IDegAsp BID vs IDeg OD plus IAsp 
(11.6 vs 13.6 events/patient year exposure[Relative Rate (RR) 0.81, 95% CI 
0.61; 1.07, p=NS]). Frequency of nocturnal confirmed hypoglycaemia epi-
sodes (onset 00.01-05.59 h) was lower with IDegAsp BID vs IDeg OD plus 
IAsp (1.23 vs 1.55 events/patient year exposure, RR 0.80, 95% CI 0.50; 1.29, 
p=NS).
Conclusion: HbA1c was reduced with IDegAsp BID and IDeg OD plus IAsp, 
with no significant difference between the regimens. The 95% confidence 
interval for the HbA1c treatment difference did cross the pre-specified non-
inferiority margin for the primary analysis (however, all pre-specified sensi-
tivity analyses did achieve non-inferiority). IDegAsp BID was associated with 
significantly lower total daily insulin doses and less weight gain, with non-
significant lower rates of confirmed and nocturnal confirmed hypoglycaemia 
episodes compared with IDeg OD plus IAsp. Thus, IDegAsp BID offers the 
potential for a simple alternative to basal bolus treatment in patients who 
require intensification of basal insulin regimens, especially where adherence 
to more complex regimens may be challenging.
Clinical Trial Registration Number: NCT01713530
Supported by: Novo Nordisk A/S
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Glycaemic control and hypoglycaemia with new insulin glargine  
300 U/mL in people with type 1 diabetes (EDITION 4)
P.D. Home1, R.M. Bergenstal2, M.C. Riddle3, M. Ziemen4, M. Rojeski5,  
M. Espinasse6, G.B. Bolli7;  
1Newcastle University, Newcastle upon Tyne, UK, 2International Diabetes 
Center at Park Nicollet, Minneapolis, 3Oregon Health & Science University, 
Portland, USA, 4Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, 
Germany, 5Sanofi, Bridgewater, USA, 6Sanofi, Paris, France,  
7University of Perugia, Italy.
Background and aims: EDITION 4 studied the efficacy and safety of new 
insulin glargine (300 U/ml; Gla-300) compared with glargine 100 U/ml (Gla-
100) in people with type 1 diabetes mellitus.
Materials and methods: In this 6-month, multinational, multicentre, open-
label study, participants (n=549, BMI 27.6 kg/m2, diabetes duration 21.0 
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years, HbA1c 8.1 % [65 mmol/mol]) were randomised 1:1:1:1 to once-daily 
Gla-300 or Gla-100, morning or evening, while continuing mealtime insulin.
Results: Overall, Gla-300 was non-inferior to Gla-100 for HbA1c change from 
baseline (primary endpoint) (LS mean change [SE] −0.40 [0.05] % (−4.4 [0.6] 
mmol/mol) and −0.44 [0.05] % (−4.8 [0.6] mmol/mol); LS mean difference 
0.04 [95% CI: −0.10 to 0.19] % (0.4 [−1.1 to 2.1] mmol/mol)). Event rates of 
confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia at any time 
of day (24 h) were similar for the two groups, while nocturnal hypoglycaemia 
was lower in the Gla-300 group compared with the Gla-100 group during 
the first 8 weeks of the study (Table). Severe hypoglycaemia was observed in 
6.6% (Gla-300) and 9.5% (Gla-100) of participants. Neither glycaemic con-
trol nor hypoglycaemia differed between insulins or times for morning and 
evening injection groups. Total insulin dose increased to a somewhat greater 
extent for Gla-300 compared with Gla-100 (change from baseline +0.19 ver-
sus +0.10 U/kg). Weight gain was statistically significantly lower with Gla-
300 versus Gla-100 (LS mean difference −0.56 [95% CI: −1.09 to −0.03] kg, 
p=0.037). There was no difference in adverse events between the two groups.
Conclusion: In conclusion, new insulin glargine 300 U/ml provided compa-
rable glycaemic control versus glargine 100 U/ml, while nocturnal hypogly-
caemia was less frequent during the first 8 weeks of treatment.
Clinical Trial Registration Number: NCT01683266
Supported by: Sanofi
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Recombinant human hyaluronidase pretreatment of CSII cannula sites 
provides comparable glycaemic control with reduced hypoglycaemia  
in T1DM compared to usual CSII
J.S. Skyler1, B. Bode2, I.B. Hirsch3, J.B. Buse4, S.K. Garg5, D.E. Vaughn6,  
X.W. Wu6, D.B. Muchmore6;  
1University of Miami, 2Atlanta Diabetes Associates, 3University of 
Washington, Seattle, 4University of North Carolina, Chapel Hill, 5University 
of Colorado Denver, Aurora, 6Halozyme Therapeutics, Inc., San Diego, USA.
Background and aims: Recombinant human hyaluronidase (rHuPH20) is 
FDA-approved to increase dispersion and absorption of injected or infused 
drugs. In CSII, a single pretreatment of the cannula site with rHuPH20 ac-
celerates exposure to and action of bolus doses of rapid analogs for up to 3 
days of catheter use. This study was performed to characterize the clinical 
attributes of this treatment in an outpatient cohort of T1DM.
Materials and methods: 456 subjects with T1DM (age 48±13 years, BMI 
28.5±5.1, screening A1C 7.8±0.7) were randomized 3:1 to CSII with rHuPH20 
pretreatment or usual CSII for 6 months.
Results: A1C fell 0.14% from 7.69% with rHuPH20 and 0.18% from base-
line 7.70% for CSII alone. The primary endpoint of A1C noninferiority (0.4% 
margin) was achieved with a treatment difference of 0.05% (95% CI -0.08 to 
0.18) with similar % of subjects reaching A1C <7.0% (20.9% with rHuPH20 
and 17.5% for CSII alone, p=.45). Mean overall 90 min post-meal glucose 
excursion was 1.04 mmol/L with rHuPH20 and 1.09 mmol/L for CSII alone 
(p=.79). There were fewer hypoglycemic events (HEs) with rHuPH20 than 
for CSII alone. The protocol specified primary HE analysis was based on 
SMBG-based event rates after a month of active titration following rand-
omization; these data were derived from 261,341 individual SMBG readings. 
Hypoglycemia results are summarized in the table. Adverse event rates were 
generally comparable between treatments, although rHuPH20 pretreatment 
was associated with an increased incidence of infusion site pain (typically 
mild transient burning) from 6.2% to 14.9%.
Conclusion: We conclude that pretreatment of CSII cannulas with rHuPH20 
is well tolerated and results in similar glycemic control in T1DM with reduc-
tion of hypoglycaemia.
Clinical Trial Registration Number: NCT01848990
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A novel concentrated recombinant human insulin formulation with 
improved ultra-rapid action for continuous subcutaneous infusion 
therapy 
R. Pohl, B.R. Wilson, M. Li, M. Guinness, P. Reddy, K. O‘Brien, A. Krasner, 
E. De Souza;  
Biodel Inc, Danbury, USA.
Background and aims: BIOD-531, a U-400 formulation of recombinant 
human insulin, EDTA, citrate and MgSO4, is associated with an accelerated 
onset of action compared to Regular Human Insulin U-500 (U-500R) and In-
sulin Lispro Mix75/25, and has a basal duration profile in obese non-diabetic 
subjects and in diabetic swine. In order to assess the potential of BIOD-531 
for open and closed-loop continuous subcutaneous insulin infusion (CSII) 
therapy, we evaluated the pharmacokinetic (PK) and pharmacodynamic 
(PD) profiles of BIOD-531 vs. U-500R and Insulin Lispro U-100 (Humalog, 
IL) following pump bolus administration and compared it to the timing of 
subcutaneous (sc) injection in miniature diabetic swine.
Materials and methods: Test formulations consisting of IL, U-500R, BIOD-
531 or BIOD-530 (BIOD-531 without MgSO4) were administered using a 
crossover design by either Animas pump (Studies 1 and 2) or sc injection 
(Studies 3 and 4). On the morning of each study, miniature diabetic swine 
were given a sc dose (0.25 U/kg) of test formulation, followed by a meal. 
Blood glucose and plasma insulin were sampled from -30 to 480 min post 
dose. Plasma insulin was measured by an ELISA method and glucose con-
centration was determined by YSI. Data from each study were compared for 
significant differences from BIOD-531 using Students t-test.
Results: Key PK timing parameters (T50%max, Tmax and AUC0-20min) and on-
set of action PD parameter T-BG50%Minimum (time to 50% glucose nadir) are 
shown in Table below. BGMinimum is the lowest baseline subtracted glucose 
value or nadir. The rate of absorption and onset of action of BIOD-531 are not 
significantly different from IL and faster than U-500R following pump bolus 
and sc administration. In addition, the PK and PD profiles comparing BIOD-
531 vs. IL are similar following pump bolus or sc injection.
Conclusion: These data suggest the potential utility of BIOD-531 as CSII 
therapy for insulin resistant type 2 diabetes patients who require high doses 
of insulin. Furthermore, BIOD-531 may be useful to help conserve space in 
future Artificial Pancreas systems.
Supported by: NIH NIDDK R43DK096604
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Pregestational diabetes (type 1 and 2), gestational diabetes: data from  
the French population in 2011
C. Billionnet1, A. Weill1, P. Ricordeau1, F. Alla1, D. Mitanchez2,3,  
A. Hartemann4,3, S. Jacqueminet4;  
1Caisse Nationale de l’Assurance Maladie, 2Néonatalogie, Hôpital Armand 
Trousseau, 3Sorbonne Universités UPMC, 4Diabétologie, Institute of 
Cardiometabolism and Nutrition, Hôpital Pitié-Salpétrière, Paris, France.
Background and aims: Pregestational diabetes increases the risks of congen-
ital malformations and perinatal complications. The risks incurred by new-
born infants in the case of gestational diabetes (GD) are debated. There are 
no national data available in France except for data from multicenter cohorts. 
We evaluated the risks of complications according to the type of maternal 
diabetes from the French birth cohort in 2011.
Materials and methods: Data were obtained from the PMSI (French hos-
pital discharge database) and the SNIIRAM (French national health insur-
ance information system). All childbirths and terminations of pregnancy 
(TOP) after 22 weeks of gestation, due to medical reasons were selected. The 
mother’s diabetes was identified by an algorithm based on the consumption 
of antidiabetics and hospitalization diagnoses before and during pregnancy. 
An identifier in the PMSI links mothers and infants, thus enabling analyses of 
associations between the mother’s diabetes and outcome.
Results: 806 579 childbirths / TOP > 22 weeks were identified in the PMSI. 
The Mother - infant chaining was obtained for 474 614 births in public in-
stitutions. 1257 (0.16%) type 1 diabetes (T1D), 1896 (0.24%) type 2 diabetes 
(T2D) and 51 701 (6.4%) GD were identified, with a mean age respectively 
of 30.3, 33.3 and 32 years. In the case of T1D and T2D, the risks were respec-
tively increased for the following complications (OR adjusted on mother’s 
age [95%CI]): preterm birth (gestational age < 38 weeks) (6.6[5.9-7.4] and 
3.7[3.3-3.9]), caesarean section (4.3[3.8-4.8] and 2.9[2.7-3.2]), preeclampsia 
and eclampsia (6.7 [5.6-8.2] and 3.9 [3.2-4.7]), macrosomia (birth weight 
(BW) > 90th percentile) (7.0 [6.1-8.0] and 3.9 [3.4-4.4]) perinatal death (2.2 
[1.4-3.4] and 3.0 [2.2-4.1]), perinatal asphyxia (3.3 [2.2-5.1] and 2.5 [1.6-
3.7]), respiratory distress syndrome (OR adjusted on mother’s age and ges-
tational age): 2.6 [2.0-3.4] and 1.9 [1.5-2.5]), brachial plexus trauma and/or 
collarbone fractures in cases of vaginal delivery (8.5 [4.9-14.8] and 2.9 [1.5-
5.9]), cardiac malformations (4.4 [3.0-6.5] and 3.2 [2.2-4.7]). Data on mac-
rosomia are respectively for DT1 and DT2: BW > 4 kg 16.7% and 13.4%; BW 
> 90th percentile 42.5 % (n=354) and 30.4% (n=348). In the case of GD, the 
risk of certain outcomes was lower: prematurity (1.35 [1.32-1.38]), caesar-
ean section (1.46 [1.44-1.49]), preeclampsia and eclampsia (1.55 [1.46-1.65]), 
macrosomia (BW > 90th percentile) (1.7 [1.6-1.8]) respiratory distress syn-
drome (1.2 [1.1-1.3]). The risks were not increased for the others complica-
tions compared to the population without diabetes. Concerning macrosomia, 
9.0% of the newborn had a BW > 4 kg in GD, and 6.6% in the absence of 
diabetes. 15.7% of the newborn had a BW > 90th percentile in GD and 9.4% 
in the absence of diabetes.
Conclusion: The rate of perinatal complications remains high for both types 
of pregestational diabetes, especially T1D. The link between gestational dia-
betes and macrosomia is confirmed. Some complications associated with 
gestational diabetes are slightly increased (caesarean section, prematurity, 
eclampsia, respiratory distress syndrome), others are not (brachial plexus 
trauma and/or collarbone fractures, death, perinatal asphyxia).
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Maternity care at a superspecialised unit for women with type 1 diabetes 
results in pregnancy outcome comparable to background population
M. Landin-Olsson1, H. Strevens2, D. Ursing1;  
1Dept of Endocrinology, Skane University Hospital, 2Dept of Obstetrics and 
Gynaecology Lund, Skane University Hospital, Lund University, Sweden.
Background and aims: Pregnancies in women with Type 1 diabetes are more 
often complicated by preeclampsia, prematurity, caesarean section, malfor-
mation, macrosomia, stillbirth and postnatal hypoglycaemia in the infant. 
The rate of complications is mainly depending on the blood glucose regula-
tion. Our model for pregnant women with Type 1 is based on a specialised 
maternity unit including obstetrician, diabetologist, midwife and dietician. 
Women are required to take seven self monitored glucose measurements 
daily, all values are sent electronically to the hospital and followed up weekly 
by a phone call from a diabetologist. The insulin doses are adjusted frequently 
to optimize glucose levels. An extra ultrasound is done late in pregnancy and 
if growth is rapid there is a liberality to induce labour. This study is aimed 
to compare outcome of pregnancy in women with Type 1 diabetes with the 
Swedish background women and also to evaluate if higher insulin dose could 
further improve outcome.
Materials and methods: All consecutive pregnant women with Type 1 dia-
betes who delivered infants during 2000-2013 (n=266) at our hospital were 
compared to all women in Sweden who delivered infants during the same 
period. Data from background population was obtained from the Swedish 
Medical Birth Register, which has a very high rate of ascertainment. In the 
next step we compared outcome in pregnancies in Type 1 diabetic women 
who delivered in 2000-2006 (n=1418) with those who delivered in 2007-2013 
(n=148). For women in the later time period we tried to further increase in-
sulin doses to improve metabolic regulation.
Results: For women with Type 1 diabetes birth weight was only 59 g higher 
(3566 compared to 3507), despite a shorter gestational length (37.7 vs. 39.3 
weeks; p=0.001) and higher frequency of sectio (44% vs. 17%; p<0.001). The 
frequencies of preeclampsia, instrumental deliveries, postnatal hypoglycae-
mia, intensive care of infant, malformations and stillbirth were not signifi-
cantly different. Women with partus 2000-06 compared to 2007-13 had equal 
duration of diabetes (15.5 yrs; p=ns), weighted same (69.4 vs. 71.3 kg; p=ns), 
body length were same (167; p=ns), they gained equal in weight during preg-
nancy (14.7 vs. 15,2 kg; p=ns), had equal insulin dose at start (49.7 vs. 50.6 
IU; p=ns), same HbA1c at start (56 vs. 58 mmol/mol; p=) and gestational 
length was equal (264 vs. 265 days; p=ns). The women in the later group were 
treated with higher doses of insulin at the end of pregnancy (79.4 vs. 96.3 
IU; p=0.001), but despite this, HbA1c were lower in the first group (40 vs. 42 
mmol/mol; p=0.03) and birth weights did not differ (3619 vs. 3565 g; p=0.6). 
There were no differences in the frequencies of sectio (42% vs. 38%; p=ns), 
prematurity (19% vs. 22%; p=ns), malformations of all types (7.6% vs. 6.1%; 
p=ns), Apgar <7 at 5min (11.2 vs. 8.8%; p=ns), frequency of hypoglycaemia 
(24% vs. 19%; p=ns) or need of postnatal intensive care (47% vs. 35%; p=ns).
Conclusion: Pregnancy outcome in women with Type 1 diabetes was very 
close to results in the Swedish population. Further increase in insulin dose 
did not improve the results. This superspecialised maternity care for women 
with diabetes enables an almost normal outcome of pregnancy.
Supported by: Fundings from Region Skane, the Hospital fundings and ALF
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Screening for diabetic retinopathy in pregnancy
A.M. Egan1, L. McVicker1, L. Carmody1, B. Kirwin1, F. Harney2, F. Dunne1;  
1Galway Diabetes Research Centre, National University of Ireland Galway, 
2Department of Ophthalmology, University Hospital Galway, Ireland.
Background and aims: Pregnancy is associated with progression of diabetic 
retinopathy and therefore frequent retinal screening to allow prompt treat-
ment of disease is necessary. Our aims were to evaluate if our patients were 
receiving appropriate retinal screening during pregnancy and to assess the 
proportion who had progression of diabetic retinopathy. Additionally we 
wished to identify factors influencing screening and progression of retinopa-
thy in our cohort.
Materials and methods: We identified 341 women with pregestational dia-
betes from the Atlantic DIP database. This cohort comprised 233 (68%) with 
type 1 diabetes and 108 (32%) with type 2 diabetes. Screening was deemed 
appropriate if it occurred at least twice during pregnancy in separate trimes-
ters. Statistical analysis was performed using SPSS version 20.0 (IBM) . Hy-
pothesis testing was performed on the data of equal variance and normal 
distribution using an unpaired Student’s t test. A Chi-squared analysis was 
used to compare sample proportions. Binary logistic regression was used to 
evaluate factors associated with appropriate screening and progression of 
retinopathy.
Results: Appropriate screening took place in 191 (56%) pregnancies, more 
commonly in women with type 1 diabetes. Women who received ap-
propriate screening attended pre-pregnancy care (PPC) [56.5% versus 
22.7% (p<0.001)] and received folic acid [69.6% versus 53.3% (p=0.002)] 
more frequently than those who did not. Women who received appropri-
ate screening also had a longer duration of diabetes [11.3 ± 2.9 versus 9.3 
± 2.9 years (p=0.03)]. There was a significant difference in rates of ad-
equate screening across the five antenatal centres participating in the At-
lantic DIP study (21.6% - 71.4%, p<0.001). Modelling by logistic regression 
identified PPC as the only maternal factor significantly associated with re-
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ceiving appropriate screening [odds ratio 4.01; CI 2.38-6.75 (p<0.001)]. 
On evaluation of those patients who received appropriate screening (n=191), 
it was noted that 49 (26%) had retinopathy progression during pregnancy. 
Univariate analysis revealed that these women had on average, a longer dura-
tion of diabetes [14.4 ± 5.7 versus 10.0 ± 2.8 years (p=0.003)], a higher 1st tri-
mester HbA1c [7.7 ± 1.6 versus 7.1 ± 1.4% (p=0.02)], a larger drop in HbA1c 
between the 1st and 3rd trimesters of pregnancy [1.4 ± 1.3 versus 0.7 ± 0.9% 
(P=0.002)] and a higher systolic blood pressure at the booking visit [128.0 
± 17.6 versus 122.2 ± 13.2 mmHg (p=0.02)] compared to women with no 
progression. Logistic regression analysis of significant factors from univariate 
analysis, revealed decrease in HbA1c [odds ratio 2.09; CI 1.11; 3.92 (p=0.02)] 
and systolic blood pressure at booking[odds ratio 0.03; CI 1.03;1.06 (P=0.05)] 
as significant factors associated with retinopathy progression in pregnancy.
Conclusion: We demonstrate inadequate screening for diabetic retinopathy 
during pregnancy and significant variation across participating centres. Our 
study highlights the importance of participation in PPC as this is associated 
with appropriate screening in the ensuing pregnancy. As 26% of women con-
tinue to demonstrate progression of retinopathy during pregnancy, there is 
urgent need to ensure adherence to screening protocols. This is particularly 
important for women with larger reductions in HbA1c during pregnancy and 
higher systolic blood pressure at booking as these women are at greatest risk 
for progression.
Supported by: Health Research Board of Ireland
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Association of stillbirth with type 2 diabetes development and future 
cardiovascular events in women with and without gestational diabetes:  
a population-based cohort study
B. Pintaudi, G. Lucisano, A. D’Ettorre, G. Di Vieste, V. Lepore, M. Sacco,  
G. De Berardis, M. Scardapane, M.C. Rossi, F. Pellegrini, G. Tognoni,  
A. Nicolucci;  
Fondazione Mario Negri Sud, S. Maria Imbaro (CH), Italy.
Background and aims: Women with gestational diabetes mellitus (GDM) are 
at increased risk for the onset of type 2 diabetes (T2DM) and cardiovascular 
disease in the years following pregnancy. Aim of the study was to estimate the 
incidence of T2DM and cardiovascular events in women with previous GDM 
and in those with normal glucose tolerance in pregnancy and to evaluate the 
role of stillbirth in differentiating the risks.
Materials and methods: A population-based cohort study using adminis-
trative data of 12 local health authorities in Puglia, Italy, during the index 
period from January 1, 2002, to December 31, 2010 was conducted. From a 
population-based sample of 2.1 million women we identified those with a di-
agnosis of GDM during the index period and they were propensity-matched 
on a 1-to-3 basis with women without GDM or diabetes mellitus. Character-
istics that were matched were age, local health authority code, use of antihy-
pertensive and antithrombotic agents. Main outcome measures were T2DM 
development and hospitalizations for cardiovascular events occurring after a 
pregnancy complicated by GDM and ended at term or in miscarriage.
Results: There were 3851 women with GDM (mean age 37.1±5.9 years) 
and 11553 matched controls without GDM. During a median follow-up of 
5.4 years, the incidence rate of T2DM was of 2.1 per 1000 person-years in 
women without GDM, of 54.0 per 1000 person-years among women with 
GDM and pregnancy at term, and 115.0 per 1000 person-years among wom-
en with GDM and a pregnancy ended in stillbirth. The cumulative IRs of 
T2DM development showed that GDM increased the risk of T2DM by 21.7 
times, while GDM complicated by stillbirth increased the risk of T2DM by 
46.9 times as compared with women with a normal pregnancy. GDM and 
stillbirth during GDM were associated with a significantly higher risk of car-
diovascular events compared with normal pregnancy (IRR, 2.4;95% CI, 1.5 to 
3.8 and IRR, 16.7; 95% CI, 3.7 to 74.7, respectively).
Conclusion: Pregnancy complicated by GDM and ended in stillbirth repre-
sents a decisive factor in determining the development of T2DM and future 
cardiovascular events. For this reason these women deserve a careful follow-
up.
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Maternal obesity, glucose levels in early pregnancy, and gestational 
diabetes in association with cognitive and psychomotor development  
at 4 years of age
L. Chatzi1, V. Daraki1,2, V. Georgiou1, K. Koutra1, M. Kampouri1,  
A. Kyriklaki1, M. Karachaliou1, G. Chalkiadaki1, K. Sarri1, A. Pappas3,  
M. Vassilaki1, S. Papavasileiou2, M. Kogevinas4;  
1Department of Social Medicine, Heraklion, 2Clinic of Endocrinology 
Diabetes and Metabolic Diseases, University Hospital of Crete, Heraklion, 
3Diabetes Center, Venizelio Hospital, Heraklion, 4National School of Public 
Health, Athens, Greece.
Background and aims: Fetal life and early infancy are critical periods for 
brain development. An hyperglycaemic environment in utero may pro-
gramme biological regulatory mechanisms inducing delay in brain maturity 
and neurobehavioural abnormalities in offspring. Few studies have examined 
associations of maternal obesity and diabetes in pregnancy with offspring 
neurodevelopment, with conflicting results. The aim of this study was to as-
sess the associations of maternal glucose and insulin levels in early pregnancy, 
gestational diabetes (GDM), and pre-pregnancy body mass index (BMI) with 
offspring cognitive and psychomotor development at 4 years of age.
Materials and methods: The mother-child “Rhea” study in Crete is a pro-
spective cohort examining pregnant women (Greek and immigrants) resi-
dents at the prefecture of Heraklion that became pregnant during one year 
starting in February 2007. The present analysis includes seven hundred seven 
(707) mother-child pairs, after excluding twin pregnancies, and women with 
pre-gestational diabetes. Maternal fasting serum samples were collected at 
the time of the first major ultrasound (Mean: 12 weeks, SD: 1,5). Pregnant 
women were screened for GDM between 24 and 28 weeks of gestation, and 
GDM was defined by the criteria proposed by Carpenter and Coustan. Neu-
rodevelopment at 4 years was assessed by means of the McCarthy Scales of 
Children’s Abilities (MSCA). Multivariable linear regression models were 
used to estimate the effect of maternal glucose and insulin levels in early preg-
nancy, GDM, and pre-pregnancy BMI on neurodevelopmental scores at 4 
years of age after adjusting for maternal age, education, parity, child sex, birth 
weight, breastfeeding duration and quality of assessment.
Results: The percentage of overweight and obese mothers prior to gestation 
was 21% and 12.7% respectively, while 8% women developed GDM. Mater-
nal obesity prior to gestation was associated with reduced general cognitive 
(score reduction: -2.33; 95% CI: -4.57, -0.10), and perceptual development 
scores (score reduction: -2.87; 95% CI: -5.19, -0.55) at 4 years of age. There 
was also evidence of a dose-response relationship with continuous mater-
nal BMI. Stratified analysis by child sex showed a higher reduction in girls 
compared to boys (general cognitive score reduction: -4.00; 95% CI: -7.25, 
-0.75; perceptual score reduction: -3.42; 95% CI: -6.57, -0.27, p for interaction 
<0.01). Gestational diabetes, and maternal fasting glucose and insulin levels 
in early pregnancy were not associated with offspring neurodevelopmental 
outcomes after adjustment for potential confounders.
Conclusion: Maternal obesity prior to gestation may contribute to reduced 
child cognitive development at preschool age, while GDM was not found to 
be significantly associated with offspring neurodevelopment. Further follow 
up of this cohort will allow to determine whether these findings persist into 
later childhood development.
Supported by: NSRF 2007-2013 project, MIS 349580
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Gestational diabetes mellitus and risk for autism in offspring
A.H. Xiang1, X. Wang1, M.P. Martinez1, D. Getahun1, K.A. Page2,  
T.A. Buchanan2, E.S. Curry3, K.J. Coleman1;  
1Research & Evaluation, Kaiser Permanente Southern California, Pasadena, 
2Department of Medicine, Keck School of Medicine, Los Angeles, 
3Pediatrics, Kaiser Permanente Fontana Medical Center, Fontana, USA.
Background and aims: Pregnancies complicated by gestational diabetes mel-
litus (GDM) increase risks of perinatal morbidities and postnatal obesity and 
metabolic disorders in offspring. A few studies also suggest that maternal hy-
perglycaemia during pregnancy is associated with a high rate of inattention, 
developmental delays, and autism spectrum disorders (ASD) in offspring. 
The hypothesis is that hyperglycaemia may “disrupt” fetal brain development 
and maturation and lead to increased risks for offspring to develop neurobe-
havioral disorders in later life. We conducted a large population-based study 
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to assess the association between GDM exposure in-utero and development 
of ASD in offspring.
Materials and methods: This retrospective longitudinal cohort included 
children who were born as a singleton at 28-44 weeks gestation in hospitals 
from a large integrated health plan between January 1, 1995 and December 
31, 2009. Children were required to have the health plan membership by age 
1-2 years, when screening for developmental delays and ASD are initiated 
per the health plan guidelines. Children were prospectively followed from 
birth using electronic medical record until any one of following criteria was 
met: (1) a clinical diagnosis of ASD identified by ICD-9 codes 299.x, (2) 
>4-months of inactive health plan membership, (3) death from any cause, or 
(4) December 31, 2012. Children who were born to women with pre-existing 
diabetes were excluded. Survival analysis was used to estimate the incidence 
rate of ASD and Cox proportional hazard regression was used to estimate the 
relative risk (RR) of developing ASD associated with GDM.
Results: A total of 336,164 children (26,897 [8%] GDM exposed) met the 
cohort inclusion criteria with a median 5.5 years (range 1.0-18.0 years) of 
follow-up during which 4,526 children developed ASD. The incidence rate 
of ASD was 2.36/1000 per year (2.81/1000 for GDM and 2.32/1000 for non-
GDM group, respectively). In the unadjusted analysis, the incidence of ASD 
in the GDM exposed group was 20% higher than that in the GDM unexposed 
group (RR= 1.20, 95% CI: 1.08-1.32, p=0.0004). However, the RR was reduced 
to 1.06 (95% CI: 0.96-1.18, p=0.22) after adjustment for maternal age, parity, 
education, household income, race/ethnicity and child gender. The greatest 
reduction in the RR was due to the adjustment for maternal age (from 1.20 to 
1.09) as mothers who had GDM were on average 3.2 years older at delivery 
than mothers without GDM. Additional adjustment for child birth weight, 
gestational weeks at delivery and congenital abnormalities at birth, factors 
known to be associated with maternal hyperglycaemia, slightly reduced the 
RR association between GDM and ASD (to 1.04, p=0.46). Excluding children 
with congenital abnormalities at birth had no impact to the results. Analysis 
by ASD sub-type reached similar conclusions.
Conclusion: Data from a large multi-ethnic and population-based clinical 
care system did not support significant association between GDM exposure 
in-utero and risk of development of ASD in offspring. The slightly elevated 
risk for ASD in offspring exposed to GDM was largely due to older age of 
women with GDM.
OP 27 Protecting the periphery
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mRNA expression profiling in perivascular and subcutaneous adipose 
tissue of patients with carotid artery (ACI) stenosis
D. Schleinitz1, P. Büttner2, A. Körner3, B. Gutsmann1, M. Fasold4,  
M. Eszlinger5, S. Rohm6,7, O. Richter6,7, G. Aust6, P. Kovacs1;  
1IFB Adiposity Diseases, University of Leipzig, 2Cardiocenter Leipzig, Clinic 
for Internal Medicine and Cardiology, Department of Rhythmology R&L, 
University of Leipzig, 3Hospital for Children and Adolescents, University 
Hospital Leipzig, Center for Pediatric Research, University of Leipzig,  
4ecSeq Bioinformatics, 5Division of Endocrinology and Nephrology, 
University of Leipzig, 6Research Laboratories, Clinic for Visceral, 
Transplantation, Thoracic and Vascular Surgery, University of Leipzig,  
7Ev. Diakonissenkrankenhaus Leipzig, Clinic for Vascular Surgery,  
Center for Surgery, Leipzig, Germany.
Background and aims: There is growing evidence for a vasoregulatory and 
atherosclerosis-inducing role of local fat deposits around vessels. Secreted 
adipokines may contribute directly or indirectly to the regulation of vessel 
wall homeostasis. Investigating molecular mechanisms specific for perivas-
cular fat could therefore contribute to better understanding of its role in the 
pathophysiology of atherosclerosis and its sequelae such as stroke or myocar-
dial infarction. Aim of the study was to investigate gene expression profiles 
in paired human samples of subcutaneous (sc) and perivascular (pv) adipose 
tissue (AT) and to link it to clinical and anthropometric characteristics of 
carotid stenosis patients.
Materials and methods: A RNA/cDNA bank was established from paired sc 
(cervical) and pv (ACI) AT samples of patients who underwent carotid en-
darterectomy. Tissue specific marker genes (e.g. MYH2 for muscle, COMP for 
fibroblasts or GPM6A for nerve) have been measured to control for impuri-
ties of “non-adipocyte” cells. The expression median with appropriate ranges 
for every marker gene was set specifically for each fat depot. Sixty paired sam-
ples passed these criteria and were assayed on Illumina HT12 microarrays. P-
values for differential expression between AT depots and phenotypic groups 
(e.g. symptomatic vs. asymptomatic) were calculated using background-cor-
rected, quantile-normalized expression values and paired/standard t-test. To 
correct for multiple testing an experiment based genome wide significance 
level and FDR methodology were applied. Gene expression was correlated 
to anthropometric, metabolic and clinical parameters. Best hits underwent 
validation using TaqMan qPCR technology.
Results: We found 1100 genes with significant differential expression be-
tween sc and pc AT clearly distinguishing both AT types from each other. 
The top hits with >2 fold changes are represented by developmental genes like 
HOX genes, TBX15 or WNT5A but also genes found to be involved in athero-
sclerosis (CDKN2B, TRIB1) and coronary artery disease (PTGS2, CARD8). 
Intra-depot comparison of e.g. symptomatic vs. asymptomatic, lean vs. obese 
or diabetic vs. non-diabetic patients revealed genes with nominal differences 
in mRNA levels, which however, correlated with anthropometric and meta-
bolic parameters (BMI, triglycerides, cholesterol, percent stenosis).
Conclusion: Our data revealed fat depot-specific mRNA expression of devel-
opmental genes and genes associated with atherosclerosis or coronary artery 
disease, supporting the relevance of perivascular adipose tissue in the patho-
genesis of atherosclerosis.
Supported by: Junior Scientist Program, University Leipzig, Med. Faculty: 
formel.1
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rs196462, near SMOC2, is associated with lower extremity arterial 
disease in patients with diabetes
N.R. van Zuydam1, M. de Andrade2, E. Vlachopoulou3, V. Salomaa3,  
A. Paterson4, H. Colhoun5, I.J. Kullo2, GoLEAD, SUMMIT;  
1University of Oxford, UK, 2Division of Cardiovascular Diseases and the 
Gonda Vascular Center and Department of Health Sciences, The Mayo 
Clinic, Rochester, USA, 3National Institute for Health and Welfare, Helsinki, 
Finland, 4Hospital for Sick Kids and DCCT/EDIC, Toronto, Canada, 
5Medical Research Institute, University of Dundee, UK.
Background and aims: Lower extremity arterial disease (LEAD) is a com-
mon macrovascular complication of diabetes and the most common cause 
of amputations in patients with diabetes. LEAD in patients with diabetes is 
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often accompanied by dyslipidaemia, renal disease and neuropathy. Despite 
large sample sizes, previous GWA studies have identified 1 genome wide sig-
nificant (p<5e-8) signal near CHRNA3 and another highly significant signal 
(p<5e-7) in the 9p21 region. The lack of strong associations may be due to 
the highly polygenic architecture of LEAD, phenotypic heterogeneity or both. 
Based on the different risk factors contributing to LEAD in patients with and 
without diabetes we performed stratified analyses of LEAD in patients with 
and without diabetes and in smokers vs. non-smokers, irrespective of diabe-
tes status.
Materials and methods: We combined summary statistics in a fixed effects 
meta-analysis for 2,356,286 SNPs from 4,544 LEAD cases and 30,404 LEAD 
controls - of which 2,345 cases and 8,706 controls were patients with diabetes 
and 3,535 cases and 20,212 controls were smokers. We also performed an 
interaction analysis of allelic effects in patients with diabetes vs. individuals 
without diabetes and in smokers vs. non-smokers.
Results: Rs196462, near SMOC2, was associated with LEAD in patients with 
diabetes at genome wide significance (p<5e-8). Rs10743273, near PIK3C2G, 
was associated with LEAD in non-diabetic individuals and showed evi-
dence for interaction (OR=1.2, p=6.3E-4, phet=6.1e-4). Rs2451819 (OR=1.2, 
p=1.2e-5, phet=5.9e-4) near PIK3R1 and rs7084667 (OR=1.3, p=3.2E-5, 
phet=6.5e-4), near SFTPD were associated with LEAD in patients with dia-
betes and showed evidence for interaction. These genes play a role in insulin 
resistance, obesity and cardiovascular disease. The top SNP in smokers was 
rs1051730 (p=7.2E-7), near CHRNA3, that is established for LEAD and is as-
sociated with pack years. Rs2076156 (OR=2.4, p=1.1e-4, phet=3.5e-6), near 
BIK, rs12593396 (OR=1.46, p=4.2e-6, phet=1.3e-5), near ADAMTS7 and 
rs11214800 (OR=1.3,p=2.6e-4, phet=2.7e-5), near HRT3A were associated in 
LEAD in smokers and showed evidence for interaction with smoking status. 
The expression of BIK is directly affected by cigarette smoke, while SNPs near 
ADAMTS7 have been shown to interact with smoking status to affect blood 
pressure and SNPs in HRT3A have been associated with smoking quantity.
Conclusion: Diabetes and smoking are well established risk factors for LEAD 
and by stratifying analyses by these risk factors we have identified a signal 
near SMOC2 that appears to be specific to LEAD patients with diabetes. The 
interaction analysis also revealed interactions near genes that affect cardio-
metabolic traits. While signals in the smoking interaction analysis did not 
achieve
Supported by: The Wellcome Trust, IMI-SUMMIT, NHGR, NIH
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The association between diabetic peripheral neuropathy and peripheral 
artery disease
G.A. Nichols;  
Kaiser Permanente Center for Health Research, Portland, USA.
Background and aims: Diabetic peripheral neuropathy (DPN) and periph-
eral artery disease (PAD) are common complications that occur more fre-
quently in patients with type 2 diabetes than in the general population. Data 
on the association between these two conditions is surprisingly scant. We 
studied the association between DPN and PAD, including characteristics that 
were associated with each condition.
Materials and methods: We searched the electronic medical records of 
37,095 members of Kaiser Permanente Northwest who had type 2 diabetes 
identified prior to 2013 and had complete health plan eligibility in 2012 for 
physician-coded ICD-9-CM diagnoses of DPN or PAD in 2010-2012. We 
compared demographic (age, sex, diabetes duration) and clinical character-
istics (BMI, HbA1c, blood pressure, lipids, and presence of ischemic heart 
disease[IHD], chronic kidney disease [CKD] and heart failure [HF]) asso-
ciated with the presence of one or both of these conditions. To isolate the 
independent association between DPN and PAD, we constructed a multiple 
logistic regression model that controlled for risk factors for DPN and PAD.
Results: Of the 37,095 type 2 diabetes patients, 24% (n=9,044) had DPN 
without PAD, 3% (n=994) had PAD without DPN, 4% (n=1,592) had both 
DPN and PAD, and 69% (n=25,465) had neither condition. The table displays 
characteristics of patients with neither, both, or either DPN or PAD. Among 
the 29% of patients with DPN (n=10,636), 15% had PAD compared with 4% 
without DPN (p<0.001). Nearly two-thirds of patients with PAD also had 
DPN, while only about one-quarter of patients without PAD had DPN (62% 
vs. 26%, p<0.001). Characteristics of patients without PAD differed markedly 
depending on whether DPN was present. For example, mean age of patients 
with DPN but no PAD was 67.3 years, compare with 59.9 years among those 
without DPN or PAD (p<0.001), and those with DPN were two to three times 
more likely to have IHD, CKD or HF. However, characteristics including age, 
sex and presence of comorbidities were similar among patients with PAD 
regardless of the presence of DPN. After controlling for demographic and 
clinical characteristics, presence of DPN more than doubled the probability 
of having PAD (OR 2.32, 95% CI 2.08-2.60).
Conclusion: Our results demonstrate a strong association between DPN and 
PAD that remained even after controlling for a number of characteristics. 
Although our design did not evaluate the temporal relationship between 
these two conditions, older age and longer duration of diabetes among PAD 
patients suggests that DPN may often precede PAD. Research is needed to 
determine whether treating DPN can reduce the risk of PAD.
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Clinical and ultrasonographic results of endovascular therapy in  
diabetic patients with critical limb ischaemia 
O.N. Bondarenko, G.R. Galstyan, N.L. Ayubova, I.I. Sitkin, I.I. Dedov;  
Diabetic Foot Clinic, Endocrinology Research Center, Moscow,  
Russian Federation.
Background and aims: To evaluate arterial patency and clinical outcomes 
after percutaneous transluminal angioplasty (PTA) in diabetic patients with 
critical limb ischemia (CLI).
Materials and methods: From September 2010 to June 2013, a prospective 
single-center study was conducted involving 164 diabetic patients with CLI 
(76(46%)) men, mean age 64,1[54-68] years, mean HbA1c 7,9±1,4%, mean 
duration of diabetes 16,5[0,8-43] years, diabetes type 1/2 - 16/148) who un-
derwent PTA in 193 limbs. Myocardial infarction and stroke in anamnesis 
were in 25(15%) and 15(9%) patients, respectively. Chronic kidney disease 
(CKD) 3-4 stages was in 40(24%) patients, end-stage renal disease 16(10%). 
Diagnosis of CLI based on recommendation of TASC II. Patency of arteries 
of lower extremity was evaluated by duplex ultrasound (DU) during whole 
follow-up period. PTA in all patients was consider technically successful in 
restoring continuous arterial flow to the foot of at least one crural artery with-
out residual stenosis > 50%. Follow-up assessment during 3 years included 
clinical examination for wound healing (WH), limb salvage (LS) and com-
mon survival (CS).
Results: Peripheral arterial disease 4 category according Rutherford clas-
sification revealed in 29(15%), 5 category-in 103(53,4%), and 6 category in 
61(31,6%) patients. 0-1 the degree of tissue damage according Wagner clas-
sification identified in 29 (15%) cases, W 2 - 100 (51,8%) cases, W 3-4 - 64 
(33.2%) cases. Peripheral arterial disease 4-6 classes according Graziani clas-
sification was in 180 (93%) cases. Extensive tibial arterial calcification was in 
123(64%) cases, in patients with residual stenosis (> 50% remaining diam-
eter)-113 (89%). After PTA residual stenoses (>50%) in treated arteries were 
in 125(79,1%), thrombosis in the treated arteries - 9(5,7%), intimal dissection 
- 18(11,4%), incomplete stent disclosure - 3 (1,9%), incomplete capture stent 
area stenosis - 2(1,3%) and dislocation of the stent - 1(0,6%). Repeat PTA in 
the early period (30 days) was in 15 patients. Cumulative primary patency in 
the femoropopliteal segment was 55%, in tibial segment 25%; in patients with 
residual stenosis in treated arteries <50% -21%, with residual stenosis ≥50% - 
66% (Kaplan-Meier Estimates). Repeat PTA during follow-up was performed 
in 73(38%) cases generally, in patients with CKD 3-5 stages 18(45%). There 
were 10(5,2%) major amputations (log-rank, p<0,05), in patients with end-
stage renal disease 5(2,6%); LS rate was 94%, WH rate was 98% (log-rank, 
p<0,05); CS was 81% (log-rank, p<0,05).
Conclusion: CLI in diabetic patients is characterized by having severe mor-
phological lesions of the lower limb arteries, arterial calcification and soft 
tissue lesions. The high level of residual stenosis was revealed after PTA. Ex-
tremely low primary patency in diabetic patients with CLI mainly at the tibial 
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arteries is associated with chronic renal insufficiency and residual stenosis. 
Timely rеintervention in diabetic patients with recurrent CLI promotes op-
timal WH, LS and CS.
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Optimal blood pressure targets for prevention of peripheral artery 
disease in patients with type 2 diabetes and hypertension
A. Hishida1, M. Tochiya2, R. Koezuka2, Y. Oohata2, T. Tamanaha2,  
H. Makino2, I. Kishimoto2;  
National Cerebral and Cardiovascular Center, Suita, Japan
Background and aims: Peripheral artery disease (PAD) is one of the mac-
rovascular complications of diabetes, and often associated with considerable 
functional limitation. Although the benefits of reducing high blood pressure 
(BP) on the risks of cardiovascular disease and cerebral artery disease are well 
known, the optimal BP goal is not established. The guideline recommended 
BP target for patients with diabetes had recently been changed from <130/80 
mmHg to <140/80 mmHg, because there have been no clear evidence show-
ing that tight control (<130/80 mmHg) was associated with improved cardio-
vascular outcomes compared with <140/80 mmHg. However, previous stud-
ies did not address which goal is more appropriate for the reduction of PAD 
events. In this study, we retrospectively examined whether subjects with the 
tighter BP control were associated with better clinical outcomes with respect 
to PAD events in patients with type 2 diabetes mellitus and hypertension.
Materials and methods: Among 963 patients with type 2 diabetes and hy-
pertension, referred to our department between January 2000 and Decem-
ber 2012 (633 for men, mean age 66 years, HbA1c 8.7%, mean BP 137/74 
mmHg), subjects with baseline BP<140/80 mmHg were selected (n=513). 
Patients were categorized into two groups by their BP at baseline: Group 1, 
less than 130/80 mmHg and Group 2, 130/80 mmHg or higher. As a result, 
262 patients (51%) were categorized into Group 1 (33% for men, mean age 
66 years), and 251 patients (48%) into Group 2 (32% for men, mean age 66 
years). The effect of baseline BP category on the development of PAD event 
was analyzed at a mean follow-up of 4.5 ± 3.1 years. Multivariable Cox re-
gression models were performed to examine the independent association be-
tween baseline BP category and PAD events during follow-up. The PAD event 
was defined as angioplasty for PAD or ischemic ulcer requiring hospital care.
Results: Among all subjects, mean systolic and diastolic BP of Group 1 were 
116 ± 7.5 mmHg and 64.8 ± 7.2 mmHg respectively, whereas those of Group 
2 were 131.0 ± 14.2 mmHg and 74.5 ± 10.5 mmHg respectively. Between 
the two groups, there were no significant difference with respect to age, sex, 
smoking, HbA1c, eGFR, insulin use, previous stroke and previous myocar-
dial infraction. However the prevalence of PAD at baseline was significantly 
higher in Group 2 (8.8 % in Group 1 vs. 14.7 % in Group 2, p=0.04). During 
follow-up, 8 patients (1.6% of total population) were hospitalized for PAD 
events. Kaplan-Meier estimation showed that the risk of PAD hospitaliza-
tion was significantly higher in Group 2 (log-rank p=0.03). Cox regression 
analysis revealed that the association between baseline BP category and PAD 
events was significant after adjustment of age, sex, smoking, HbA1c, eGFR, 
insulin use, and previous stroke, myocardial infraction and PAD at baseline 
(p=0.04).
Conclusion: In patients with type 2 diabetes and hypertension, baseline 
BP<130/80 mmHg showed significantly lower risk of future PAD events than 
BP<140/80 mmHg. It is, therefore, suggested that tighter control of blood 
pressure could reduce the incidence of PAD events in patients with type2 
diabetes and hypertension.
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Beneficial effect of multifactorial intervention on the prognosis of 
patients with type 2 diabetes mellitus and critical limb ischaemia/
peripheral arterial disease
C. Hoebaus1, G. Schernthaner2, R. Koppensteiner1, G.-H. Schernthaner1;  
1Internal Medicine II, Medical University Vienna, 2Internal Medicine II, 
Rudolfstiftung Vienna, Austria.
Background and aims: The combination of critical limb ischemia/periph-
eral artery disease (PAD) and diabetes mellitus type 2 (T2DM) is known for 
poor survival. The last major publication on successful management of such 
a patient population reported a 50% mortality and 25% amputation rate af-
ter six years of follow up. We have analyzed whether more recent treatment 
advances of T2DM and PAD in the last five years have ameliorated those 
detrimental effects.
Materials and methods: In a prospective study we enrolled 366 patients 
(34% female) with PAD, 38% had T2DM, 33% impaired glucose tolerance 
(PRE) and 29% normal glucose tolerance (NGT). As expected the patient co-
hort had a high cardiovascular risk factor (CRF) burden: 92% hypertension, 
97% hyperlipidemia, 74% active or former smoker; Coronary heart disease 
(CHD) was known in 32% and carotid artery disease (CAD) in 39% of the 
patients. Within 6 months the target values of CRF control - LDL-Cholesterol 
<100 mg/dl, blood pressure (<140/80 mm Hg, HbA1c in DM <7.0%) were 
reached in 58%, 69% and 69%. Patients followed a strict control visit program 
in the center for 5 years.
Results: The overall survival of this cohort was 89.3% after 4.9 years. MACE 
(combination of death, non-fatal myocardial infarction or stroke) free sur-
vival was 84.3% and event free survival including interventional or surgi-
cal procedures due to critical limb ischemia/PAD was 68%. Patients with 
T2DM showed a survival of 87.8% compared to 89.3% PRE, and 95.2% NGT 
(p=0.161). MACE free survival was 81.3% for T2DM, 87.6% for PRE, and for 
92.4% NGT (p=0.059). Additionally, event free survival was 65.5% for T2D, 
71.9% for PRE, and 77.1% for NGT (p=0.155).
Conclusion: In summary, strict multifactorial management induced a dra-
matic reduction in the annual death rate (2.8 for patients with T2DM and 
PAD), MACE and amputation. Thus, management of such patients should be 
restricted to centralized centers to improve outcome for the patients.
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OP 28 Ectopic lipids and  
type 2 diabetes
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Effect of bariatric surgery on hepatic fatty acid uptake and blood flow
H.M. Immonen1, J.C. Hannukainen1, N. Kudomi2, R. Parkkola1,  
V. Saunavaara1, P. Iozzo3, P. Nuutila1;  
1Turku PET Centre, University of Turku, Finland, 2Faculty of Medicine, 
University of Kawaga, Japan, 3Institute of Biomedical Engineering,  
National Research Council, Padua, Italy.
Background and aims: Increased delivery of free fatty acids (FFAs) to the liv-
er plays a role in the pathogenesis of type 2 diabetes. Bariatric surgery is asso-
ciated with high rates of diabetes remission, but the underlying mechanisms 
are not fully elucidated. Liver fatty acid uptake is crucial in understanding the 
mechanism of postoperative metabolic changes. This study’s objective was 
to assess the surgery-induced changes in hepatic FFA uptake, together with 
quantification of hepatic perfusion and liver fat content (LFC).
Materials and methods: We measured hepatic FFA uptake, hepatic portal, 
and arterial perfusion with positron emission tomography using [18F]-
FTHA and [15-O]-H2O in 22 morbidly obese subjects before and 6 months 
after bariatric surgery and in 14 healthy lean volunteers. LFC was quantified 
by MRS and liver volume by MRI.
Results: Baseline: Plasma FFA concentration was elevated in the obese group 
compared to the lean control group (0.67 ± 0.22 vs. 0.48 ± 0.21 mmol/l, p 
= 0.02). Liver FFA uptake, when measured per depot or per unit mass, was 
higher in obese subjects compared to controls (depot: 254 ± 67 vs. 107 ± 
39 μmol/min, p < 0.001 and per unit mass: 14.4 ± 3.6 vs. 10.0 ± 3.7 μmol/
min/100 ml, p < 0.01, respectively). LFC in the obese group was significantly 
higher than in controls (5.7 ± 4.7 vs. 1.5 ± 1.5%, p < 0.01), and 9 of the obese 
patients had liver steatosis (LFC ≥ 5%). When obese subjects were divided 
into two groups, with LFC below (LFC-low) or above (LFC-high) the median 
of 4.4%, the LFC-high group had an increased FFA depot uptake compared to 
LFC-low group (p = 0.09). When patients were grouped according to diabetic 
status, no difference in FFA uptake was observed. In pooled data, FFA uptake 
correlated with intraperitoneal fat mass (r = 0.40, p = 0.02). Compared to 
controls, both portal and arterial blood flow were higher in the obese group 
(5.2 ± 2.1 vs. 3.6 ± 1.0 l/min, p = 0.01 and 0.34 ± 0.16 vs. 0.19 ± 0.10 l/min, p 
< 0.001, respectively). At 6 months after surgery: BMI decreased from 41 ± 
4kg/m2 to 32 ± 4kg/m2 (p < 0.001) and the remission of diabetes was observed 
in 8 out of 10 patients. Plasma FFA concentration was unchanged (p = NS vs. 
baseline). The liver depot uptake decreased by 15% (p = 0.02 vs. baseline), 
but remained twice as high compared to the control group (p < 0.001 vs. con-
trols). LFC was decreased by 69% (p = 0.001 vs. baseline) and was now similar 
to that of lean controls (p = NS vs. controls). None of the subjects had liver 
steatosis postoperatively. Portal blood flow decreased by 55% (p < 0.0001) 
and arterial flow by 76% (p < 0.0001), and both were reduced compared to 
levels measured in controls (p < 0.05 for both). Reduction in intraperitoneal 
fat mass was related to changes in LFC (r = 0.59, p = 0.02) and in portal blood 
flow (r = 0.69, p = 0.001). An association between the change in portal blood 
flow and improvement in insulin sensitivity index was observed (r = 0.52, p 
= 0.02).
Conclusion: Hepatic fatty acid uptake was decreased, but did not normalize 
to controls, when measured six months after bariatric surgery. After surgery, 
fatty acid uptake changes may contribute to the resolution of liver steatosis. 
Morbidly obese subjects showed increased portal vein flood flow, which re-
sulted in a higher supply of fatty acids for hepatic FFA uptake. Postoperatively 
blood flow decreased along with the reduction in visceral fat mass and im-
provement in insulin sensitivity.
Clinical Trial Registration Number: NCT01373892
Supported by: Academy of Finland, Sigrid Juselius Foundation, EUFP7 Hepadip
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High-fat diet increases autophagic flux in pancreatic beta cells in vivo
K.-Y. Chu, T.J. Biden;  
Garvan Institute, Darlinghurst, Australia.
Background and aims: Autophagy is an important cellular survival mecha-
nism that responds to changes in cellular nutrients, and potentially coun-
ter-regulates endoplasmic reticulum (ER) stress, previously implicated in 
lipotoxic beta-cell death. Because it is extremely difficult to measure true 
autophagic flux in vivo, it is still unclear how high-fat feeding or fatty acids 
regulate autophagy in pancreatic beta-cells. Here, we used both in vivo and 
in vitro models to study autophagic flux; and also investigated the upstream 
signaling pathways triggered by fatty acids.
Materials and methods: For unequivocal estimation of autophagic flux, 
GFP-LC3 mice were fed with chow or high-fat diet for 10 weeks and then, 
for 5 consecutive days before sacrifice, injected with 100mg/kg chloroquine 
to block clearance of autophagic markers. The pancreata and livers were col-
lected and fixed for cryosectioning. The beta-cells of the pancreatic sections 
were labeled with the insulin antibody, and the GFP-LC3 signaling analysed 
by fluorescence microscopy. Autophagic and ER stress markers were detected 
by western blot following acute (2h) treatment with chloroquine using both 
islets ex vivo from the high-fat fed mice, and mouse clonal MIN6 beta-cells 
treated with oleate and palmitate for 0-48h.
Results: Autophagic flux, assessed from the amount of GFP puncta, was in-
creased in pancreatic acinar tissue and beta-cells after high-fat feeding and 
chloroquine injection. In contrast, GFP signal in the liver was markedly at-
tenuated under identical conditions. LC3 levels in the isolated mouse islets 
were also increased by high-fat diet and further enhanced by chloroquine 
incubation ex vivo. ER stress, indicated by the markers CHOP and phospho-
eIf2α levels, in isolated islets was not augmented by high-fat feeding alone, 
but was induced by autophagic inhibition with chloroquine and further en-
hanced by high-fat feeding. This reveals a reciprocal relationship between ER 
stress and autophagy in beta-cells and suggests that autophagy is not solely 
secondary to ER stress in the context of lipotoxicity in vivo. In MIN6 cells, 
oleate increased LC3-II levels in both the presence and absence of chloro-
quine (indicative of enhanced flux and steady state autophagy respectively) 
whereas palmitate augmented the autophagic flux alone. ER stress was in-
creased by palmitate but not oleate, which concurs with the in vivo model 
that lipids/fatty acids could induce autophagy without the activation of ER 
stress. Nevertheless, neither fatty acid modulated classical mTOR signaling 
illustrated by the downstream phospho-4EBP levels.
Conclusion: Using GFP-LC3 mice with chloroquine injection we show for 
the first time that beta-cells have a very low basal autophagic flux but, in con-
trast to liver, this is increased by high-fat feeding. This appears to act as a 
protective mechanism prior to the activation of ER stress, and is triggered 
independently of the classical mTOR pathway.
Supported by: NHMRC
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Sphingosine kinase 1 promotes hepatic steatosis via up-regulation  
of PPARgamma
P. Xia1,2, J. Chen2, W. Wang1, G. McCaughan2, X. Gao1, M. Vadas2;  
1Endocrinology and Metabolism, Fudan University Zhongshan Hospital, 
Shanghai, China, 2Centenary Institute, the University of Sydney, Australia.
Background and aims: Sphingolipid metabolites have emerged playing key 
roles in the pathogenesis of metabolic diseases, including obesity, diabetes 
and nonalcoholic fatty liver disease (NAFLD). The current study aimed to ex-
plore the underlying mechanisms and discover a potentially druggable inter-
mediate in the steatotic pathways associated with sphingolipid metabolites.
Materials and methods: We utilized pharmaceutical inhibitors or genetic 
means to manipulate sphingosine kinase 1 (SphK1), one of the key enzymes 
that control sphingolipids metabolism. Both cellular and animal models were 
applied in the study investigating the role of SphK1 in hepatic lipid metabo-
lism and NAFLD development.
Results: A nearly 2-fold increase in the expression level of SphK1 was ob-
served in either cellular or animal models of NAFLD, without alterations in 
SphK2 (another isoenzyme of SphK), suggesting a specific link of SphK1 to 
NAFLD. Enforced overexpression of SphK1 significantly promoted lipid ac-
cumulation in mouse primary hepatocytes, whereas loss of SphK1 gene ex-
pression inhibited the process compared with the control hepatocytes (both 
p<0.01). Moreover, SphK1 deletion resulted in a significant amelioration 
in histological changes of steatosis, along with a 30% reduction in hepatic 
contents of triglycerides and cholesterols in diet-induced obese (DIO) mice 
(p<0.01). Analysis of fatty liver-related gene expression revealed a 40% re-
duction of transcriptional factor peroxisome proliferator-activated receptor 
γ (PPARγ) and its target genes in DIO SphK1-/- mice, in comparison with 
wild-type DIO mice (p<0.01). Accordingly, treatment with sphingosine-
1-phosphate (S1P) or overexpression of SphK1 increased PPARγ expression 
by 150% (p<0.01) in the lipid-laden hepatocytes. Furthermore, PPARγ inhi-
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bition by using its siRNA or antagonists markedly reduced SphK1-depentant 
hepatic lipid accumulation (all p<0.01).
Conclusion: SphK1 plays an important role in fatty liver development by 
promoting lipid accumulation and up-regulation of PPARγ in hepatocytes. 
The functional link between the SphK1 and PPARγ pathways in aggravating 
hepatic steatosis may reveal a new way to the management of NAFLD.
Supported by: NHMRC, Australia; Fudan, China
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Hypothalamic nitric oxide regulates insulin signalling and hepatic  
lipid metabolism
F.O. Martins1,2, S. Tovar3, J.G. Jones4,5, S. Perez-Sieira3,  
D. González-Touceda3, A. Natali6,7, C. Diéguez3, M.P. Macedo6,5;  
1Departamento de Fisiologia, Centro de Estudos de Doenças Crónicas 
(CEDOC), FCM, Universidade Nova de Lisboa, 2Centre for Neurosciences 
and Cell Biology, University of Coimbra, Portugal, 3Centro de Investigación 
de Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidad 
de Santiago de Compostela, Spain, 4Centre for Neurosciences and Cell 
Biology. University of Coimbra, 5Portuguese Diabetes Association 
(APDP-ERC), Lisbon, 6Departamento de Fisiologia, Centro de Estudos de 
Doenças Crónicas, New University of Lisbon, Portugal, 7Metabolism Unit, 
Department of Internal Medicine, University of Pisa, Italy.
Background and aims: Human studies demonstrated that NO is an impor-
tant regulator of insulin clearance. Whether the control of insulin clearance 
is solely dependent on hepatic mechanisms or also involves hypothalamic 
regulation is currently uncertain. Since hypothalamus is a critical regulator 
of energy metabolism and endocrine functions, we previously hypothesized 
that NO production by central/hypothalamic axis regulates insulin clear-
ance and therefore peripheral insulin bioavailability. We found a significant 
inverse correlation between NO production in the paraventricular nucleus 
(PVN) and systemic insulin clearance. However, the metabolic consequences 
of PVN NO-mediated regulation of insulin clearance remain unknown, so we 
hypothesized that in addition to insulin clearance, it also modulates hepatic 
glucose and lipid metabolism.
Materials and methods: Male Wistar rats underwent brain surgery using a 
stereotaxic apparatus for implantation of the double cannulas, for nucleus 
specific infusion in the PVN region. After the bregma localization the follow-
ing coordinates were used: AP: -1.8mm, Lat: +/- 0.4mm, DV: -8.0mm. Bolus 
infusion of 250ug/2uL of L-NAME (or 2uL of saline in the control animals) 
were performed in each side of the brain, once only in the day of the experi-
ment. An oral glucose tolerance test (OGTT) (2g/kg) was subsequently per-
formed. Liver was harvested and kept at -80º for protein extraction and analy-
sis of glucose and lipid metabolism-related enzymes by immunoblotting.
Results: We observed that PVN NO depletion led to changes in insulin sign-
aling as well as glucose and lipid metabolism. Regarding insulin signaling, 
IRS-1 and AKT expression as well as IRS-1 and AKT phosphorylation were 
decreased. In addition, expression of hepatic Glut 1, 2 and 4 were all signifi-
cantly decreased suggesting a reduced capacity for glucose uptake by the liver. 
Interestingly, depletion of PVN NO levels suppressed the lipogenic enzymes 
(ACC, FAS, ATP citrate lyase and pATP citrate lyase), which is consistent with 
the observed diminished hepatic non-esterified fatty acids (NEFA) content. 
Meanwhile, hepatic DGAT expression was increased, possibly in response to 
decreased NEFA. Hepatic TG levels were not diminished by PVN-NO deple-
tion possibly due to this compensatory DGAT upregulation.
Conclusion: These results support the hypothesis that increased PVN NO 
results in a decreased insulin clearance and a stimulation of de novo lipogen-
esis. This suggests that hypothalamic NO signaling has a role in regulating 
hepatic lipid metabolism.
Supported by: SFRH/BD/51194/2010; PTDC/DTP-EPI/0207/2012; PTDC/
BIM-MET/0486/2012
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MiR-494 is regulated by exercise in obese sedentary individuals with 
increased risk of type 2 diabetes and modulates skeletal muscle lipid 
metabolism in vitro
M. Balaz1, T. Kurdiova1, M. Vician2, O. Kyselovicova3, V. Belan4, I. Jelok5,  
C. Wolfrum6, J. Ukropec1, B. Ukropcova1;  
1Diabetes laboratory, Institute of Experimental Endocrinology,  
2Surgery Clinic, 3Faculty of Sport and Physical Education, 4Radiology Clinic, 
5National Institute of Cardiovascular Diseases, Bratislava, Slovakia, 6Institute 
of Food, Nutrition and Health, Schwerzenbach, Switzerland.
Background and aims: Exercise leads to activation of several signaling path-
ways which improve skeletal muscle lipid metabolism and insulin sensitivity. 
On the contrary, physical inactivity is associated with impaired lipid metabo-
lism and insulin resistance. We hypothesized that miR-494 might be involved 
in the response of skeletal muscle to both acute and regular exercise. The aim 
of our study was to investigate regulation of miR-494 in skeletal muscle of 
sedentary overweight to obese individuals (age 36.0 ± 1.7 yrs; BMI 31.6 ± 0.9 
kg.m-2; M/F, 8/7) with increased risk of T2D (prediabetics, n=10) who under-
went a 12-week endurance (n=8) or strength (n=7) training programme. A 
functional study examining the role of miR-494 in regulation of lipid metabo-
lism was performed in primary human myotubes.
Materials and methods: Biopsies of m. vastus lateralis were taken prior and 
after training. Effects of a single exercise bout were examined in a subpopula-
tion of 8 individuals (M/F, 4/4). All participants underwent complex meta-
bolic phenotyping, including an assessment of glucose tolerance (oGTT), 
subcutaneous and visceral adipose tissue content and distribution (MRI) and 
maximal aerobic capacity (bicycle ergometry). Total RNA, including miRNA, 
was isolated from skeletal muscle & serum and quantified with the aid of 
real-time PCR. In vitro functional studies were performed in primary human 
myotubes, transfected with miR-494 mimics, inhibitor or negative control.
Results: The 12-week training led to 19% increase of VO2 max (p<0.05), 
confirming the efficiency of training intervention. Expression of miR-494 in 
skeletal muscle was reduced by 28% (p<0.05) in response to 12-week train-
ing. However, no effect of an acute exercise bout on muscle miR-494 was 
observed in neither sedentary nor trained individuals. Interestingly, circulat-
ing levels of miR-494 were 2.6-fold higher (p<0.01) after 12-week training. 
Overexpression of miR-494, lowered expression of FoxJ3 (-48%, p<0.001), 
PGC1α (-33%, p<0.001), SIRT3 (-18%, p<0.001) and SIRT1 (-36%, p<0.001) 
and was associated with 22% reduction of mitochondrial content (p<0.05) 
and marked increase (3.6-fold, p<0.001) in triglyceride accumulation. Trans-
fection of miR-494 inhibitor significantly increased expression of PGC1α 
(+26%, p<0.001) and SIRT1 mRNA (+17%, p<0.01) and reduced lipid ac-
cumulation (-30%, p<0.01) in differentiated human myotubes. However, no 
effect of miR-494 inhibitor on mitochondrial content was observed.
Conclusion: Our results indicate that both skeletal muscle and circulating 
miR-494 levels are regulated by exercise training. In addition, our in vitro 
functional studies suggest that miR-494 might be involved in regulation of 
mitochondrial biogenesis and lipid storage/utilization capacity, likely by tar-
geting the PGC1α and SIRT1 pathways.
Clinical Trial Registration Number: ISRCTN95105191
Supported by: EFSD/Lilly 
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Fatty acid composition determines the acute effects of oral fat intake  
on insulin sensitivity and muscle mitochondrial function in humans
C. Koliaki1, K. Kaul1, A. Boenner1, P. Nowotny1, M. Esser1, K. Tinnes1,  
M. Roden1,2;  
1Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center 
for Diabetes Research, 2Department of Endocrinology and Diabetology, 
Heinrich Heine University, Düsseldorf, Germany.
Background and aims: Intravenous administration of fat, mainly consist-
ing of unsaturated lipids, promotes insulin resistance, which might relate to 
altered mitochondrial function. However, it remains unclear whether oral 
fat ingestion may also induce muscle and/or hepatic insulin resistance, and 
whether fatty acid composition might differently affect insulin sensitivity and 
skeletal muscle oxidative capacity. Thus, we examined in the present study the 
acute effects of an oral lipid challenge rich in either saturated or unsaturated 
lipids on insulin sensitivity and muscle mitochondrial respiration in healthy 
humans.
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Materials and methods: Ten healthy lean sedentary volunteers (age 25±1 
years, body mass index 24.8±0.3 kg/m2) were randomized in a cross-over 
manner to an oral lipid emulsion (50% fat) enriched in saturated fatty acids 
(SAFA: 92 g palm oil), omega-6 polyunsaturated fatty acids (PUFA: 92 g saf-
flower oil) and water as control (CON). Skeletal muscle biopsies were per-
formed before and 2.5 hours after interventions. Euglycemic-hyperinsuline-
mic clamps with infusion of deuterated glucose were initiated 6 hours after 
interventions to assess whole-body (M-value) and hepatic insulin sensitivity 
(insulin-mediated suppression of endogenous glucose production). High-
resolution respirometry was applied to assess ex-vivo muscle mitochondrial 
respiratory capacity.
Results: After both SAFA and PUFA, whole-body insulin sensitivity was 
lower compared to CON (CON: 7.3±0.8; PUFA: 5.8±0.8; SAFA: 4.3±0.5 
mg.kg-1.min-1, p<0.05), while hepatic insulin sensitivity remained unaltered 
(CON: 76±5; PUFA: 79±3; SAFA: 65±5%). SAFA led to greater whole-body 
insulin resistance than PUFA (p<0.05), and tended to reduce hepatic insu-
lin sensitivity to a greater extent (p=0.06). Plasma incretin levels rose after 
both interventions without affecting however serum glucose and insulin lev-
els. Although plasma free fatty acids (FFA) did not change upon SAFA or 
PUFA, the triglyceride enrichment of circulating plasma chylomicrons was 
markedly higher after both interventions (total AUC0-8h; CON: 84±13; PUFA: 
236±52; SAFA: 280±65 % hour, p<0.05). SAFA-induced insulin resistance as-
sociated with impaired suppression of lipolysis under insulin-stimulated con-
ditions, whereas PUFA-induced insulin resistance related to increased post-
intervention plasma FFA levels (p<0.05). ADP-stimulated respiration related 
to β-oxidation (malate, octanoylcarnitine, ADP) was lowered in muscle after 
PUFA intake (before: 22.4±2.2; after: 18.8±2.5 pmol.sec-1.mg-1, p<0.05), but 
was not altered after SAFA intake.
Conclusion: Oral intake of both saturated and unsaturated fat induces acute-
ly peripheral insulin resistance in healthy humans, which may be partly me-
diated by increased circulating triglyceride-rich chylomicrons contributing 
to muscle lipotoxicity. The underlying mechanisms are divergent depending 
on fatty acid composition, and may implicate adipose tissue insulin resistance 
in the case of saturated, and impaired skeletal muscle oxidative capacity due 
to FFA lipotoxicity in the case of unsaturated fat.
Clinical Trial Registration Number: NCT01736202
Supported by: DZD e.V., Helmholtz-Alliance ICEMED, EFSD 
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Mass sequencing of the faecal virome: a study in children with early 
onset of islet autoimmunity
L. Kramná1, K. Holková1, S. Oikarinen2, J.-P. Pursiheimo3, M. Knip4,  
O. Simell5, R. Veijola6, J. Ilonen7, H. Hyöty2, O. Cinek1;  
1Department of Peadiatrics, Charles University in Prague, Czech Republic, 
2Department of Virology, University of Tampere, 3Department of 
Medical Biochemistry and Genetics, University of Turku, 4Department 
of Paediatrics, University of Helsinki, 5Department of Paediatrics, Turku 
University Central Hospital, 6Department of Paediatrics, University of Oulu, 
7Department of Immunogenetics, University of Turku, Finland.
Background and aims: The search for an association between viruses and 
islet autoimmunity has been limited mostly to candidate virus genera and 
serotypes, whereas information has been very scarce about the whole virome 
(i.e. the complete “virus flora”). The next-generation sequencing technologies 
have offered a possibility to identify all prevalent viruses in a given sample. 
We used this technology to contrast the stool virome between children who 
developed very early islet autoimmunity with subsequent type 1 diabetes, and 
their matched peers in the Finnish prospective Diabetes Prediction and Pre-
vention (DIPP) birth cohort.
Materials and methods: We conducted a case-control study nested within 
the DIPP cohort; nineteen cases were selected among children with the earli-
est onset of islet autoimunity (mean age 15 months at first islet autoantibod-
ies). Control children without islet autoimmunity were matched 1:1 for gen-
der, time and place of birth and for the HLA risk. The virome was sequenced 
in available stool samples preceding the onset of autoimunity by 3, 6 and 9 
months. After mechanical enrichment of the virus fraction and nucleic acid 
extraction, we performed reverse transcription with tagged random prim-
ers, second strand synthesis, and partial amplification. Sequencing libraries 
were prepared using the Nextera XT protocol and sequenced on an Illumina 
MiSeq instrument. The resulting sequence reads were filtered, reduced in 
complexity using unbiased de-novo assembly, and analysed for human vi-
ruses using BLAST. Only indubitable virus infections with more than 5 reads 
were counted in the downstream analyses. The association was assessed using 
conditional logistic regression methods.
Results: The number of good quality sequence reads ranged from 200,000 to 
1.5 million per sample, most of which belonged to multiple bacteriophages 
and bacteria. At least one human virus was identified in 47% samples, with 
13% samples being simultaneously positive for more than one human virus. 
We most often observed parechoviruses (35%), bocaviruses (13%) and sapo-
viruses (11%), whereas enteroviruses and rhinoviruses were rare. The over-
all coverage of the viruses ranged from several thousand-fold in a massively 
replicating sapovirus to sparsely distributed numbers of reads. We noted a 
clustering of virus findings within the matching groups, indicating adequate 
matching strategies. No globally significant virus association with the develop-
ment of islet autoimmunity was observed at the genus level (all P values > 0.4).
Conclusion: This study shows a richness of human viruses previously not ap-
preciated in the stools of otherwise healthy Finnish children, and underlines 
the utility of massive parallel sequencing of the virome. Further extension of 
this pilot dataset will allow studies of individual virus subtypes and strains, 
and also of sequence contigs not matching currently known organisms.
Supported by: IGA NT11465-5
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Probiotic use in infancy and islet autoimmunity in the environmental 
determinants of diabetes in the young (TEDDY) study
U. Uusitalo1, X. Liu1, J. Yang1, C. Andren Aronsson2, K. Silvis3, S. Hummel4, 
M. Rewers5, W. Hagopian6, J.-X. She3, O. Simell7, A. Ziegler4, J. Krischer1, 
J.M. Norris8, S.M. Virtanen9, the TEDDY Study Group;  
1University of South Florida, Tampa, USA, 2Lund University, Malmo, 
Sweden, 3Medical College of Georgia, Atlanta, USA, 4Diabetes Research 
Institute, Munich, Germany, 5Barbara Davis Center for Childhood Diabetes, 
Aurora, 6Pacific Northwest Diabetes Research Institute, Seattle, USA, 
7University of Turku, Finland, 8Colorado School of Public Health, Aurora, 
USA, 9National Institute for Health and Welfare, Helsinki, Finland.
Background and aims: It is hypothesized that probiotics can prevent adverse 
immunological responses to environmental exposures by supporting the 
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healthy gut microbiota, and thus prevent the development to type 1 diabetes 
associated islet autoimmunity (IA) in young children. The aim of this study 
was to examine the association between early probiotic use and IA.
Materials and methods: The Environmental Determinants of Diabetes in the 
Young (TEDDY) study prospectively follows 8502 children with type 1 diabe-
tes (T1D) -associated HLA-DR-DQ alleles in Finland, Germany, Sweden and 
the US. Blood samples were collected every 3 months from birth to evaluate 
the primary outcome of IA, defined as appearance of one or more of the islet 
autoantibodies GADA, IAA, or IA-2A confirmed at two consecutive visits. 
The introduction of either probiotic supplement or infant formula containing 
probiotics was classified as: early introduction (at the age of <3 months), or 
late or no introduction (at the age of 3 months and later, or not introduced 
during the first 12 months). We applied time-to-event analysis to study the 
association between probiotic use and IA, stratifying by country and adjust-
ing for family T1D status, HLA type, sex, exclusive breastfeeding, and mode 
of delivery.
Results: Probiotic supplementation during the first 3 months either through 
dietary supplements and/or infant formula was most common in Finland 
(35.9%). In Germany 24.0%, in Sweden 11.6% and in the US 2.2% of children 
were given probiotics before the age of 3 months. Probiotic supplementation 
before 3 months of age was associated with a decreased risk of IA, compared 
with probiotic supplementation after 3 months or not at all (HR 0.62; 95% 
CI 0.45-0.84; p=0.0018). The country-specific hazard risk ratios for associa-
tions between the early probiotic supplementation and IA were: Finland 0.72 
(95% CI 0.49-1.07; p=0.10), Germany 0.65 (95% CI 0.26-2.55; p=0.37), Swe-
den 0.42 (95% CI 0.21-0.85; p=0.0165), and the US 0.62 (95% CI 0.15-2.50; 
p=0.50).
Conclusion: Early probiotic supplementation may reduce the risk of IA in 
children who are at elevated genetic risk of T1D.
Supported by: NIH, NIDDK, NIAID, NICHD, NIEHS, JDRF, CDC
171
Diabetic family history and beta cell autoimmunity in children with 
HLA-associated disease risk
H.T.A. Siljander1,2, R.-T. Salonsaari2, A. Hekkala3, S. Simell4, R. Veijola3,  
J. Ilonen5,6, O. Simell4, M. Knip1,2;  
1Children’s Hospital/ Scientific Laboratory, University of Helsinki and 
Helsinki University Central Hospital, 2Department of Pediatrics, Tampere 
University Hospital, 3Department of Pediatrics, Oulu University Hospital, 
4Department of Pediatrics, University of Turku, 5Immunogenetics 
Laboratory, University of Turku, 6Department of Clinical Microbiology, 
University of Eastern Finland, Kuopio, Finland.
Background and aims: We assessed the role of a positive family history for 
type 1 diabetes (T1D) in relation to beta-cell autoimmunity in children carry-
ing HLA-conferred disease risk, recruited from the general population.
Materials and methods: Children (n=7410, 52.7% males) with (n=189, 
2.6%) and without (n=7233) T1D-affected first degree relatives (FDRs) were 
recruited as newborn infants from the general population, based on HLA-
defined disease risk. They were observed for T1D-asssociated autoimmun-
ity and progression to T1D for 13.6 years (median; range 0.9-18.6 years). In 
1994-2002, the ICA assay was used for the primary autoantibody screening, 
after which IAA, GADA, and IA-2A were measured in seroconverted sub-
jects, but since 2003, all four autoantibodies have been analyzed from all 
samples available.
Results: Children with T1D-affected FDRs had a higher frequency of sero-
conversions and multipositivity, higher levels of IAA and GADA, and pro-
gressed more often to T1D than children with no affected FDRs. The age at 
diagnosis was similar regardless of family background. Compared to children 
with no affected FDRs, the highest T1D risk was associated with paternal 
T1D (OR=11.9; p<0.001), followed by maternal (OR=3.5; p<0.001) and sib-
ling-associated T1D (OR=3.4; p=0.083; sib vs. maternal T1D, p=NS). Chil-
dren with T1D-affected FDRs had higher frequency of the high risk HLA 
genotype (DQB1*02:0302; 30.2 vs. 21.0%, p=0.002) than those with no family 
history for T1D. In the analyses of T1D-free survival in subjects who had 
developed at least one T1D-associated autoantibody, the 10-year progression 
rate since seroconversion was 66.1% (CI 47.7-84.5%) in children with pater-
nal T1D, 37.7% (CI 12.8-62.6%) in children with maternal T1D, and 18.2% 
(CI 0-41.0%) in children with siblings affected by T1D (paternal vs. maternal, 
p=0.035), while the rate was 15.1% (12.9-17.2%) in children with no family 
history for T1D (paternal vs. no FDRs, p<0.001, and maternal vs. no FDRs, 
p=0.006). In the Cox regression analysis on seroconverted subjects, multi-
positivity (HR=7.2, CI 5.3-9.8), a positive family history for T1D (HR=2.0, CI 
1.3-3.1), high risk genotype (HR=1.8, CI 1.4-2.4), young age at seroconver-
sion (HR=0.7, CI 0.7-0.8), and higher levels of IAA (RU; HR=1.014, CI 1.007-
1.021), IA-2A (RU; HR=1.010, CI 1.004-1.017), and ICA (JDFU; HR=1.004, 
CI 1.002-1.006) remained independent predictors of T1D.
Conclusion: Children with T1D-affected family members carry a higher risk 
for the initiation of beta-cell autoimmunity than their peers with no family 
history for T1D, even among children with moderate to high HLA-associated 
disease risk. Paternal T1D is an indicator of high risk for progression towards 
T1D, although the association between the high-risk HLA genotype and pa-
ternal T1D may partly explain the higher proportion of T1D observed in the 
offspring of affected fathers.
Supported by: JDRF, ACADFI, S. Juselius Found., Univ. Hosp. of Finland
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A novel syndrome of early-onset type 1 diabetes and multi-organ 
autoimmunity caused by activating germline mutations in STAT3
S.E. Flanagan1, E. Haapaniemi2, M.A. Russell1, T.J. McDonald1, J. Barton3, 
N.P. Murphy4, M. Seppanen5, T. Milenkovic6, K. Heiskanen7, A. Lernmark8, 
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and Research Programs Unit, Molecular Neurology, University of Helsinki, 
Finland, 3Bristol Royal Hospital for Children, Bristol, UK, 4Children’s 
University Hospital, Dublin, Ireland, 5Helsinki University Central Hospital, 
Finland, 6Institute for Mother & Child Health Care of Serbia ‘Dr Vukan 
Cupic’, Belgrade, Serbia, 7Children’s Hospital, Helsinki University Central 
Hospital and University of Helsinki, Finland, 8Lund University/CRC, Skåne 
University Hospital SUS, Malmo, 9Karolinska Institutet, Huddinge, Sweden.
Background and aims: Type 1 diabetes (T1D) can be a feature of the mono-
genic polyautoimmune disorders, Immunodysregulation, Polyendocrinopa-
thy, Enteropathy X-linked syndrome (IPEX) and Autoimmune Polyendo-
crinopathy Syndrome 1 (APS1). In these conditions autoimmune disease 
presents very early and in IPEX syndrome T1D often occurs ≤3 months. 
Investigation of individuals with early onset T1D associated with multiple 
early-onset autoimmune features may therefore reveal novel monogenic 
causes of autoimmunity.
Materials and methods: We studied patients with early onset Type 1 diabetes 
(<12 months) and early-onset autoimmune disease (<5 years). Initial inves-
tigation was looking for a de novo mutation by sequencing the exome of an 
individual with early onset T1D, primary hypothyroidism and coeliac disease 
and the unaffected parents. This was followed by further testing of 24 indi-
viduals with ≥2 autoimmune disorders (diagnosed <5 years) and 64 subjects 
with isolated diabetes diagnosed <6months who are aged <5years.
Results: The only de novo coding pathogenic variant was, p.T716M, in 
STAT3 in the patient with T1D, primary hypothyroidism and coeliac dis-
ease. Sanger sequencing identified a further 4 patients (3 polyautoimmune 
disease, 1 PNDM) with de novo STAT3 mutations (p.K392R, p.N646K (x2), 
p.K658N) . All substitutions affect highly conserved residues and functional 
studies confirmed that all mutations increased STAT3 activity in vitro. Dia-
betes was present in 4/5 patients, presented early (2.5 [0-43] weeks (median 
[range])) and was insulin treated from diagnosis. Islet autoantibodies were 
detected in 3/4 patients supporting a diagnosis of autoimmune-mediated 
T1D. Additional autoimmune conditions included enteropathy, interstitial 
lung disease, juvenile-onset arthritis and primary hypothyroidism. Other 
common features were short stature (5/5 (<2SDS)) and eczema (4/5). The 
young age at presentation is consistent with STAT3 mutations causing ac-
celerated autoimmune disease.
Conclusion: We report germline activating STAT3 mutations are a novel 
cause of early onset polyautoimmunity in which T1D is a common feature. 
This result confirms the crucial role of STAT3 in the pathophysiology of T1D. 
Whilst monogenic polyautoimmune disease is rare, these conditions are im-
portant as they offer valuable insights into the biology of the immune system 
in T1D.
Supported by: SE and ATH are supported by Wellcome Trust Senior Investiga-
tor awards
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Family history of type 1 and type 2 diabetes and the risk of LADA-results 
from a population-based study of incident cases
S. Carlsson1, T. Andersson1, P.-O. Carlsson2, M. Dorkhan3, L. Groop3,  
J. Edwall Löfvenborg1, R. Hjort1, M. Martinell4, B. Rasouli1, P. Storm3,  
T. Tuomi5,6;  
1Division of epidemiology, Institute of Environmental Medicine, Stockholm, 
Sweden, 2Department of Medical Sciences, Uppsala, Sweden,  
3Department of Clinical Sciences, Clinical Research Centre, Malmö, 
4Department of Public Health and Caring Sciences, Uppsala, Sweden, 
5Division of Endocrinology, Helsinki, 6Research Program for Diabetes  
and Obesity, University of Helsinki, Finland.
Background and aims: LADA (latent autoimmune diabetes in adults) is sug-
gested to be genetic mix of type 1 and type 2 diabetes, linked to HLA-DQB1 
risk genotypes associated with autoimmunity as well as genes associated with 
type 2 diabetes, including TCF7L2 . Family history of diabetes (FHD) encom-
passes both genetic and shared environmental factors and is a strong predic-
tor of diabetes risk, although scarcely investigated in relation to LADA. Our 
aim was to investigate the risk of LADA in relation to family history of type 
1 and type 2 diabetes.
Materials and methods: We used data from a population based case-control 
study with incident cases of adult onset (≥35 years) diabetes, including 264 
cases of LADA (Glutamic acid decarboxylase antibodies (GADA) positive 
(>10 IU/mL) with c-peptide >0.3 nmol/l, 796 cases of type 2 diabetes (GADA 
negative), together with 1047 controls without diabetes, randomly selected 
from the population. Self-reported information on diabetes in first and sec-
ond degree relatives was collected and relatives with onset <40 years and in-
sulin treatment were classified as having type 1 diabetes (T1D) and otherwise 
as having type 2 diabetes (T2D). We estimated the odds ratio (OR) of LADA 
and T2D in relation to FHD, adjusted for age, sex and BMI.
Results: Family history of T1D (OR 6.2; 95% CI 1.8-20.8), and T2D (1.8; 95% 
CI 1.35-2.46) was associated with an increased risk of LADA and there were 
indications of a synergistically increased risk in those with a combination of 
T1D and T2D in the family (OR 9.39; 95% CI; 4.4-20.0). The association with 
FHD was even more pronounced for LADA with high GADA concentrations 
(>median); OR was estimated at 7.3 (95% CI 1.91-28.0) for FHD of T1D and 
at 12.4 (95% CI 5.5-27.9) for the combination of T1D and T2D in the family. 
No difference was seen for FHD of TD1 in female (OR 4.0; 95% CI 1.7-9.1) vs. 
male relatives (OR 4.4; 95% CI 1.9-10.2).The risk of T2D was associated with 
FHD of T2D (OR 2.9; 95% CI 2.3-3.6) but not FHD of T1D. In LADA pa-
tients, FHD of T1D vs T2D was associated with higher GADA (197.8 vs 139.5 
IU/mL, p=0.003) but lower c-peptide (0.55 vs 0.81 nmol/l, p=0.009) levels.
Conclusion: The current data add support to the view that LADA is an ad-
mixture of both T1D and T2D, also in terms of genetic risk.
Supported by: Swedish Medical Research Council, FORTE, AFA, ALF a
174
Low birth weight is associated with an increased risk of latent 
autoimmune diabetes in adults (LADA) and type 2 diabetes:  
results from ESTRID a Swedish case-control study
R. Hjort1, P.O. Carlsson2, M. Dorkhan3, L. Groop3, M. Martinell4,  
B. Rasouli1, T. Toumi5, S. Carlsson1;  
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Background and aims: A large body of research has recognized low birth 
weight as a risk factor for type 2 diabetes (T2D), hypothetically as an indica-
tor of poor nutrition of the fetus, leading to insulin resistance. Genetic factors 
have also been implicated, e.g. it has been suggested that effects of paternal 
diabetes may be mediated by effects on intrauterine environment, manifested 
in low birth weight of the offspring. In contrast a link between high birth 
weight and type 1 diabetes (T1D) has been documented. Our aim was to in-
vestigate, for the first time, the association between birth weight and LADA, 
a common diabetes form with features of both T1D and T2D.
Materials and methods: We used data from ESTRID (Epidemiological Study 
of Risk factors for LADA and type 2 Diabetes), a Swedish population-based 
study. Eligible for the analysis were 116 incident LADA cases (≥ age 35 and 
Glutamic Acid Decarboxylase Antibodies (GADA) positive (>10 IU/mL) 
with c-peptide >0.3 nmol/l), 298 incident T2D cases (≥ age 35 and GADA 
negative) and 521 disease-free controls randomly sampled from the popula-
tion. Information on birth weight and covariates was based on self-report. We 
present Odds Ratios (OR) and 95% Confidence Intervals (CI) calculated by 
logistic regression and adjusted for sex, age, current BMI (kg/m2) and family 
history of diabetes (FHD) in first and second degree relatives.
Results: Low birth weight was associated with an increased risk for LADA as 
well as T2D; OR per kilogram reduction was estimated at 1.40 (CI; 1.03-1.90) 
and 1.39 (CI; 1.07-1.81) respectively and OR for subjects weighing less than 3 
kg compared to more than 4 kg at birth was estimated at 2.06 (CI; 1.07-3.97) 
for LADA and 1.98 (CI; 1.16-3.40) for T2D. Further adjustments for educa-
tion, physical activity, smoking and alcohol did not affect these estimates. 
Indications of an excess risk was seen both in those with FHD (OR 1.24, CI; 
0.79-1.95) and without FHD (OR 1.59, CI; 1.04-2.43). A combination of low 
birth weight (<3 kg) and current obesity (BMI ≥30) further augmented the 
risk; OR 3.69, CI; 1.33-10.26 (LADA) and 14.72, CI; 6.44-33.62 (T2D).
Conclusion: Our results suggest that low birth may also be a risk factor for 
LADA of the same strength as for T2D. The association appeared to be in-
dependent of family history of diabetes, which provides some support for 
the hypothesis that environmental rather than genetic factors explain this 
link. The combination of low birth weight and adult obesity appears to be 
a particularly strong risk factor, this being in line with the thrifty phenotype 
hypothesis.
Supported by: VR, AFA, Swedish Diabetes Association
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A novel mitochondrial mechanism controlling insulin secretion  
in obesity
M. Liesa, S.B. Sereda, L. Stiles, L. Nocito, O.S. Shirihai;  
Boston University School of Medicine, USA.
Background and aims: Reactive oxygen species can increase or decrease in-
sulin secretion. However, it is unknown whether inhibiting an antioxidant 
system in islets can lead to improved insulin secretion without affecting their 
viability. Our goal is to identify whether modulating components related to 
heme metabolism, known to increase reactive oxygen species production but 
also antioxidant activity, can increase secretion without affecting viability. To 
this end, we studied the role of the mitochondrial transporter ATP-binding 
cassette B10 (ABCB10) regulating glucose stimulated insulin secretion in the 
context of diet-induced obesity, as ABCB10 is essential for proper heme me-
tabolism and protection from oxidative stress.
Materials and methods: Obesity in mice was induced by high fat diet feeding 
(45% Fat, Research Diets). Mice fed hypercaloric control diet (CD, calories 
matched with carbohydrates) or chow diet were used as controls. Glucose 
tolerance tests (1g/kg I.P.) after fasting were performed and both insulin 
(ELISA, ALPCO) and glucose (FreeLite glucometer) were measured. Stud-
ies were carried out along BU IACUC and “Principles of laboratory animal 
care” (NIH). Mouse models are whole body ABCB10 +/- mice (n=10 back-
crossed) and ABCB10-LoxP+/+ mice (pure) in C57Bl6J background. Islets 
were isolated 14-24 weeks after diet onset (weaning). Glucose stimulated in-
sulin secretion was performed in modified DMEM by incubating islets in 2.8 
mM glucose or 16.7 mM glucose for 30 minutes. Insulin in the media was 
measured by FRET (HTRF, CisBio). In the case of ABCB10-LoxP islets, they 
were transduced with Cre or Ds-Red control adenovirus at MOI 200 after 
isolation. Insulin was measured as in ABCB10 +/- islets. ABCB10 Real time 
PCR was performed using TaqMan probes.
Results: High fat diet and control diet feeding for 5 months had the expected 
effects increasing weight, fasting glucose and insulin levels, when compared 
to chow diet feeding. No significant differences in these parameters were de-
tected between wild type and ABCB10 +/- mice though. However, glucose 
tolerance tests showed that ABCB10 +/- mice were more tolerant than wild 
type mice and only after high fat diet feeding. This increase in glucose tol-
erance was associated with higher blood insulin levels in response to glu-
cose. In this regard, only high fat diet feeding resulted in ABCB10 +/- islets 
showing higher glucose stimulated insulin secretion when compared to wild 
type (40% increase). To address whether ABCB10 acutely regulated insulin 
secretion, we inactivated ABCB10 alleles after high fat diet feeding by Cre 
adenoviral expression in ABCB10 LoxP+/+ or LoxP+/- islets. Using this ap-
proach, we reduced ABCB10 expression by 80-90% and 40-50% respectively. 
We found that only after high fat feeding, glucose stimulated insulin secretion 
was increased in ABCB10 knock out (LoxP+/+ - Cre; ~30%) and in LoxP+/- 
Cre (~15%), when compared to respective DsRed transduced controls. This 
increase in insulin secretion was also present in ABCB10 knock out islets 
from chow diet mice just exposed for 24 hours to high glucose (20mM) and 
NEFA (palmitate 0.4 mM).
Conclusion: We report an unexpected role for the mitochondrial transporter 
ABCB10 regulating insulin secretion specifically in the context of high fat 
diet. We propose that lack of ABCB10 increases a reactive oxygen species-
related high fat specific signal in islets that stimulates insulin secretion. In 
all, ABCB10 modulation could be a potential approach to improve insulin 
secretion specifically in the context of obesity.
Supported by: Evans Center; BNORC-NIH/NIDDK 2P30DK046200
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Circulating irisin is up-regulated by insulin infusion in obese, but not 
in lean humans, and is inversely associated with insulin sensitivity and 
respiratory exchange ratio
M. Straczkowski1,2, A. Nikolajuk2, N. Matulewicz1, M. Stefanowicz1,  
M. Karczewska-Kupczewska1,3;  
1Department of Metabolic Diseases, Medical University of Bialystok, 
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Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 
3Department of Metabolic Diseases, Institute of Animal Reproduction and 
Food Research, Polish Academy of Sciences, Olsztyn, Poland.
Background and aims: Irisin is a recently discovered myokine, with the po-
tential to induce brown-fat-like development of white adipose tissue and to 
increase energy expenditure. In humans, data on the relationships of circulat-
ing irisin with insulin sensitivity and other metabolic parameters are incon-
sistent. The aim of the present study was to assess the associations of serum 
irisin with insulin sensitivity and substrate oxidation, as well as the effect of 
insulin infusion on circulating irisin.
Materials and methods: The study group consisted of 148 healthy subjects 
(115 males and 33 females, age between 18 and 35 years), 81 lean and 67 
overweight or obese. Euglycemic hyperinsulinemic clamp and indirect calo-
rimetry were performed. Serum irisin was measured in the baseline state and 
after the clamp.
Results: Baseline irisin was not different between lean and overweight/obese 
group (p=0.44). Insulin infusion resulted in an increase in serum irisin in 
overweight/obese (p=0.006), but not in the lean group (p=0.73). In conse-
quence, post-clamp irisin was higher in the overweight/obese (p=0.042). 
Baseline irisin was related to fasting NEFAs (r=0.26, p=0.008). Post-clamp 
irisin was positively related to BMI, waist circumference, triglycerides and 
resting energy expenditure (all p<0.05) and negatively to insulin sensitivity 
(r=-0.20, p=0.014) and respiratory exchange ratio, both at baseline (r=-0.21, 
p=0.046) and during the clamp (r=-0.34, p=0.001). Concordantly with the 
latter finding, we observed negative association of post-clamp irisin with glu-
cose oxidation (r=-0.26, p0=0.008) and positive with lipid oxidation (r=0.37, 
p<0.0001) during hyperinsulinemia.
Conclusion: Our data show that insulin increases circulating irisin, but this 
effect is dependent on the presence of overweight/obesity and may represent 
a compensatory response to increase lipid oxidation in these conditions.
Supported by: Grant UDA-POIG.01.03.01-00-128/08; from the Program In-
novative Economy
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Maternal BMI and exercise have interactive effects on brain’s white and 
grey matter composition in elderly women
M. Bucci1, J.J. Tuulari1, J. Raiko1, V. Huovinen1, H. Lipponen1, S. Koskinen1, 
S. Sandboge2, J. Eriksson2,3, P. Iozzo4, L. Nummenmaa1,5, P. Nuutila1;  
1Turku Pet Centre, University of Turku, 2Folkhälsan Research Centre, 
Helsinki, 3Department of General Practice and Primary Health Care, 
University of Helsinki, Finland, 4National Research Council, Pisa, Italy, 
5Department of Biomedical Engineering and Computational Science and 
Brain Research Unit, School of Science, Aalto University, Espoo, Finland.
Background and aims: Maternal obesity during pregnancy is a major health 
risk for the offspring and it may have a permanent effect on the offspring’s 
subsequent morbidity. Cardiovascular diseases and type 2 diabetes share 
common early life risk factors and start from early age. Frailty is considered a 
precursor of ageing. Exercise training programs promote beneficial effects on 
health and can be effective even in elderly subjects. Nevertheless, no data is 
available on brain morphometric changes in frail subjects, and the effects of 
exercise on brain tissue composition. The object of the study was to measure 
the possible differences in grey (GM) and white matter (WM) density be-
tween frail offspring of obese (OOM) and lean mothers (OLM). We hypothe-
sized that i) OOM have lower WM density compared to OLM and that ii) the 
OLM subjects will have higher capacity to increase WM density compared to 
OOM following the exercise intervention.
Materials and methods: 36 frail women aged 68-79 years were studied at 
baseline and 27 of them after four months of resistance exercise training. The 
participants were recruited from a large cohort from the Helsinki Birth Co-
hort Study (HBCS) according to the body mass index of their mothers when 
giving birth (16 from highest quartile and 20 from the two lowest quartiles). 
T1-weighted MRI images were segmented into GM and WM using SPM and 
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VBM8 toolbox, and compared using t tests. Data were thresholded at p < 
0.05, FDR corrected at cluster level.
Results: WM but not GM density was higher in OLM versus OOM glob-
ally in the brain. Exercise intervention increased WM density in both OLM 
and OOM subjects in the cerebellum. The intervention increased WM and 
decreased GM density in parietal superior regions in OLM and in cuneus 
and precuneus regions in OOM. When comparing OLM and OOM for the 
changes in WM density following intervention, cerebellum of the OLM 
showed higher increase of WM density compared to OOM (Figure 1).
Conclusion: Maternal BMI during pregnancy influences brain atrophy in 
their offspring, especially the white matter. We show that exercise has an im-
pact on brain morphology even in elderly women and in a brief time period. 
Being born to an obese mother compared to a lean or normal weight mother 
implies lower brain adaptability to exercise-induced changes in the WM den-
sity. These changes were more pronounced in the cerebellum region and this 
could have been caused by axon caliber and myelination increase in a similar 
way to what happens in subjects learning a new motor skill.
Clinical Trial Registration Number: NCT01931540
Supported by: DORIAN, EU FP7 Grant agreement N° 278603
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Plasma FGF21 is released from the splanchnic circulation in response to 
exercise and regulated by insulin and glucagon: a human study
P. Plomgaard1, J. Hansen1, J.O. Clemmesen2, N.H. Secher3, B.K. Pedersen4;  
1Department of Clinical Biochemistry, 2Department of Hepatology, 
Rigshospitalet, 3Department of Anaesthesiology, 4Center of Inflammation 
and Metabolism, Rigshospitalet, Copenhagen, Denmark.
Background and aims: FGF21 is a circulating protein that has beneficial 
metabolic effects. An increase in plasma FGF21 has been observed with fast-
ing and exercise; probably secreted from the liver. However the regulation of 
plasma FGF21 in normal physiology is not completely understood. Aims: 1) 
to demonstrate that FGF21 is released from the liver in response to an acute 
exercise bout. 2) to investigate if glucagon and/or insulin regulates plasma 
FGF21 levels.
Materials and methods: A: Ten healthy young males performed a 2 hour ex-
ercise bout, with a hepatic vein and arterial catheter allowing drawing blood 
repeatedly and simultaneously before, during and after a 2 hour bicycling 
exercise bout at 60% VO2max. Hepatic blood flow was determined by use of 
indocyanine green. B: Ten subjects underwent 4 trails resting in supine posi-
tion: 1) 1 hour of glucagon infusion 2) 1 hour of glucagon combined with a 
co-infusion of somatostatin 3) 1 hour of somatostatin infusion, 4) 1 hour of 
saline infusion (control). Blood samples were obtained every hour during the 
8 hour experimental day. Plasma insulin, glucagon and FGF21 was measured 
by immunoassays.
Results: The exercise study with the arterial-hepatic venous difference dem-
onstrated a higher level of insulin and glucagon in the hepatic vein compared 
to the artery. During the exercise bout a decrease in plasma insulin and an 
increase in plasma glucagon were observed, which normalised in the recov-
ery after the bicycling exercise. Plasma FGF21 gradually increased during the 
exercise bout to a 5-fold increase and rapidly returned to basal level into re-
covery. Calculating the arterial- hepatic vein differences revealed a net release 
of FGF21 at rest before the bicycling commenced. The secretion of FGF21 in-
creased gradually during the 2 hours of bicycling and returned to baseline in 
the recovery. The hepatic blood flow did not change during the experiment. 
In infusion study 1 (glucagon alone), plasma glucagon increased during the 
1 hour infusion followed by compensatory increase in plasma insulin. In trial 
2 (glucagon + somatostatin) glucagon increased similarly to trail 1, with no 
compensatory insulin increase. In trial 3 (somatostatin alone) both insulin 
and glucagon decreased, compared to trail 4 (saline), where no changes were 
observed. Interestingly, plasma FGF21 increased with a similar kinetics as 
observed with exercise, only when glucagon was infused and the compen-
satory insulin response was blocked by somatostatin. A delayed increase in 
plasma FGF21 was observed in trail 3 (somatostatin alone).
Conclusion: Here we present the first human data demonstrating by a direct 
measurement across the splanchnic organs that FGF21is released. The liver 
is the most likely organ to be responsible; however contributions from other 
organs as the spleen, intestines or pancreas cannot be excluded. Furthermore 
our data demonstrate that the splanchnic circulation releases exercise-in-
duced FGF21 in humans. Exercise increased plasma glucagon concomitantly 
with a decrease in insulin and simulating this condition in resting healthy 
men, increased plasma FGF21 with a similar kinetics as observed with ex-
ercise. These data add to the understanding of FGF21 in human physiology.
Supported by: Augustinus Fonden
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Selective expression of ROCK1 in the liver promotes insulin resistance 
and hepatic steatosis in diet-induced obese mice
I.S. Lima1,2, S.-H. Lee3, M. Chung1, M.J. Kim1, M.P. Macedo2,4, Y.B. Kim1;  
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Background and aims: In the European Union approximately 29 million 
people suffer from a chronic liver condition. The prevalence of non-alcoholic 
fatty liver disease (NAFLD) is 2-44% in the European population and 42.6-
69.5% in people with type 2 diabetes. Furthermore, over 50% of adults in the 
European Union are overweight or obese. Obesity is a risk factor for NAFLD 
and is strongly associated with insulin resistance. Our previous data showed 
that liver-specific deletion of Rho-kinase 1 (ROCK1) caused a significant im-
provement in insulin sensitivity and hepatosteatosis in obese mice induced 
by a high-fat diet. The current study was designed to further determine the 
physiological role of hepatic ROCK1 in regulating whole-body glucose and 
lipid metabolism.
Materials and methods: Mice expressing a constitutively active (CA) mutant 
of ROCK1 in liver were studied. These mice started a high-fat diet (HFD) at 
6 weeks of age for a period of 12 weeks. Insulin sensitivity and glucose toler-
ance were assessed and body weight and glucose levels were also monitored. 
Hepatic and serum content in triglycerides and cholesterol was determined. 
Hematoxylin and eosin stain (H&E stain) of liver sections from control and 
CA-ROCK1 mice was performed. Gene expression of key molecules involved 
in lipid metabolism was also determined for control and CA-ROCK1 mice.
Results: Liver-specific CA-ROCK1 mutant mice exhibited higher body 
weight 2 weeks after HFD feeding (21.6 ± 0.4 g N=10 vs. 23.6 ± 0.6 g N=10, p 
= 0.01) and this difference was increased by the period on HFD (33.8 ± 1.28 g 
N=10 vs. 39.4 ± 1.4 g N=10, p = 0.01). Blood glucose was also increased after 
4 weeks of HFD (148.0 ± 3.7 mg/dL N=10 vs. 165.4 ± 7.1 mg/dL N=10, p = 
0.05). These mice were insulin resistant, as revealed by the failure of blood 
glucose levels to decrease after in insulin injection (AUC 16058 ± 594.0 N=6 
vs. 20581 ± 1102 N=10, p = 0.01), but normal glucose tolerant. These ef-
fects were accompanied by hyperinsulinemia, increased hepatic triglycerides 
(430.2 ± 40.7 mg/dL N=9 vs. 674.1 ± 108.0 mg/dL N=8, p = 0.05) and serum 
cholesterol (94.2 ± 8.4 mg/dL N=10 vs. 131.4 ± 12.6 mg/dL N=9, p = 0.05) in 
the CA-ROCK1 mice. Histological analysis showed that hepatic steatosis by 
high-fat feeding was greatly increased in liver-specific CA-ROCK1 mutant 
mice compared with control mice. Moreover, activation of ROCK1 in liver 
caused an increase in gene expressions of key lipogenic enzymes, includ-
ing FAS (fatty acid synthase) and ACC (Acetyl-CoA carboxylase). However, 
overexpression of hepatic CA-ROCK1 had no effect on gene expression in-
volved in fatty acid oxidation and fatty acid uptake.
Conclusion: Our data demonstrate that activation of hepatic ROCK1 is suf-
ficient to cause insulin resistance and hepatic steatosis in diet-induced obese 
mice, suggesting an important role for hepatic ROCK1 in regulating fuel me-
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tabolism. Thus, hepatic ROCK1 could be a molecular target for the treatment 
of obesity and obesity-related metabolic disorders such as NAFLD.
Supported by: FCT SFRH/BD/71021/2010
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Prediabetes and type 2 diabetes are associated with increased content of 
dipeptide carnosine in human skeletal muscle
T. Kurdiova1, B. deCourten2, S. Vallova1, M. Balaz1, M. Vician3,  
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Background and aims: Carnosine (β-alanine L-histidine) is dipeptide com-
monly found in mammalian tissues and enriched in skeletal muscle. It has 
been shown to suppress many biochemical processes that accompany ageing 
and age related chronic diseases. Recent animal studies suggested the impor-
tance of carnosine supplementation for glycemic control and prevention of 
type 2 diabetes. Our aim was to analyze skeletal muscle carnosine content 
in middle aged (45.1±1.2 years) lean healthy ( BMI 24.5±0.4 kg.m-²), over-
weight/obese (BMI 29.3±0.8 kg.m-²), prediabetic (BMI 32.1±0.7 kg.m-²) and 
type 2 diabetic (BMI 30.7±0.9 kg.m-²) individuals (n=9/group).
Materials and methods: Metabolic phenotyping included euglycemic hy-
perinsulinemic clamp (insulin sensitivity), oral glucose tolerance test, MRI 
(abdominal adipose tissue content & distribution) and indirect calorimetry 
(resting energy expenditure). Physical activity was monitored with accel-
erometers and validated questionnaire. Samples of m.vastus lateralis were 
obtained by needle biopsy. Skeletal muscle carnosine content (HPLC) and 
serum CN1 carnosinase activity were determined. Mitochondrial biogenesis 
related genes as well as relative muscle mitochondrial content were assessed 
by qPCR.
Results: Skeletal muscle carnosine content progressively increased in pa-
tients with prediabetes (by 30%, NS) and type 2 diabetes (by 39%, p<0.05) as 
compared to lean individuals. It was positively associated with BMI (R=0.44, 
p=0.007), % body fat (R=0.35, p=0.037), abdominal subcutaneous adipose 
tissue content (R=0.38, p=0.024) as well as with atherogenic index (R=0.35, 
p=0.04), fasting and 2h glycaemia (R=0.39, p=0.02; R=0.55, p=0.002). Mus-
cle carnosine content was inversely associated with insulin sensitivity (R=-
0.42, p=0.006), percentage of high and moderate intensity ambulatory activ-
ity (R=-0.42, p=0.011) as well as with resting energy expenditure (R=-0.58, 
p<0.001). Associations of muscle carnosine with 2h glycaemia and resting 
energy expenditure were at least in part independent on BMI. Muscle car-
nosine levels were not related to mitochondrial content and Pgc1α and cy-
tochrome C mRNA. Serum CN1 carnosinase activity was not regulated in 
obesity and T2D.
Conclusion: We observed increased skeletal muscle carnosine content in pa-
tients with type 2 diabetes. This might represent a potential adaptive mecha-
nism counteracting disturbances related to diabetic status.
Clinical Trial Registration Number: NCT02011100
Supported by: VEGA 2/0192/14
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Effect of liraglutide 3.0/1.8 mg on body weight and cardiometabolic risk 
factors in overweight/obese adults with type 2 diabetes: SCALE diabetes 
randomised, double-blind, 56-week trial
B. Bode1, R. DeFronzo2, R. Bergenstal3, R. Kushner4, A. Lewin5, T.V. Skjøth6, 
C.B. Jensen6, M. Davies7;  
1Atlanta Diabetes Associates, Atlanta, 2Texas Diabetes Institute, San 
Antonio, 3Park Nicollet Institute, St Louis Park, 4Northwestern University, 
Chicago, 5National Research Institute, Los Angeles, USA,  
6Novo Nordisk A/S, Søborg, Denmark, 7University of Leicester, UK.
Background and aims: Obesity increases the risk of multiple comorbidities 
including type 2 diabetes mellitus (T2D) and cardiovascular (CV) disease. 
Weight loss of 5-10% can decrease the risk, but is difficult to achieve and 
maintain by lifestyle changes alone. Liraglutide at doses up to 1.8 mg is ap-
proved for treatment of T2D and is associated with weight loss in addition to 
glycaemic control. This study evaluated the effects of liraglutide (3.0 and 1.8 
mg) as adjunct to diet and exercise on weight loss (primary endpoint) and 
cardiometabolic risk factors (waist circumference, glycaemia, blood pressure 
[BP], pulse, fasting lipids, and CV biomarkers) in overweight/obese adults 
with T2D.
Materials and methods: Subjects were randomised 2:1:1 to liraglutide 3.0 
mg, 1.8 mg, or placebo for 56 weeks; all arms included a 500 kcal/day deficit 
diet and exercise.
Results: A total of 846 individuals (male 50%, mean age 54.9 years, BMI 
37.1 kg/m2 [27.0−67.6], HbA1c 7.9%, diabetes duration 7.3 years [0.2−36.5], 
11.5% on diet and exercise, 57.3% on metformin alone, and 31.2% on com-
bination OADs) were randomised into the trial. At week 56, least square (LS) 
mean weight loss was 5.9%, 4.6% and 2.0% for 3.0 mg, 1.8 mg, and placebo, 
respectively; 3.0 mg and 1.8 mg were superior to placebo (p<0.0001); 3.0 mg 
was superior to 1.8 mg (p=0.0024). Weight loss was accompanied by reduc-
tions in waist circumference of 6.0, 4.9, and 2.8 cm respectively; 3.0 mg and 
1.8 mg were superior to placebo (p≤0.0004); 3.0 mg was superior to 1.8 mg 
(p=0.0224). HbA1c decreased by 1.32%, 1.13% and 0.38% from baseline with 
3.0 mg, 1.8 mg, and placebo respectively (p<0.0001 vs. placebo; p=0.0125 for 
3.0 mg vs. 1.8 mg). At baseline, systolic (S) /diastolic (D) BP and lipids were 
well controlled. SBP reductions were 3.0, 3.1, and 0.4 mmHg from baseline 
(~130 mmHg) for the 3 arms respectively; greater with 3.0 mg and 1.8 mg 
(p<0.05 vs. placebo), with no significant differences between treatments 
in DBP at week 56. Similar LS mean pulse increases of 2.0 and 2.2 beats/
min occurred with liraglutide 3.0 and 1.8 mg vs. -1.5 beats/min for placebo 
(p<0.0001 vs. placebo) (observed means, LOCF: 2.0 and 2.1 vs. -1.4 beats/
min, respectively). Liraglutide 3.0 mg reduced total cholesterol, VLDL and 
triglycerides ( 4%, 13%, 14%, p<0.05) and increased HDL (+3%, p<0.05) vs. 
placebo whereas 1.8 mg had no effects. Liraglutide had no significant effects 
on LDL and FFA. Reductions in high-sensitivity C reactive protein occurred 
with liraglutide 3.0 and 1.8 mg (-27% and -25% vs. placebo, p≤0.0002). De-
creases in plasminogen activator inhibitor-1 (-24%, p=0.0004) and urinary 
albumin/creatinine ratio (-20%, p=0.0086) occurred only with liraglutide 3.0 
mg vs. placebo; No treatment effects on adiponectin occurred. Fibrinogen 
increased by 5% vs. placebo with 3.0 mg only (p=0.046).
Conclusion: After 56 weeks’ treatment, liraglutide 3.0 mg, as an adjunct to 
diet and exercise, caused significant weight loss that was associated with ad-
ditional benefits for multiple cardiometabolic risk factors compared to lira-
glutide 1.8 mg and placebo in overweight/obese adults with T2D.
Clinical Trial Registration Number: NCT01272232
Supported by: Novo Nordisk
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Efficacy and safety of liraglutide versus placebo in subjects with  
type 2 diabetes and moderate renal impairment (LIRA-RENAL):  
a randomised trial
G. Umpierrez1, S. Atkin2, S. Bain3, P. Rossing4, D. Scott5, M. Shamkhalova6, 
H. Bosch-Traberg7, A. Syrén7, M. Davies8;  
1Emory University School of Medicine, Atlanta, USA, 2Weill Cornell 
Medical College Qatar, Doha, Qatar, 3Abertawe Bro Morgannwg University 
NHS Trust, Swansea, UK, 4Diabetes, Steno Research Center, Gentofte, 
Denmark, 5Clinical Research Development Associates, Rosedale, USA, 
6Endocrinology Research Centre, Moscow, Russian Federation,  
7Novo Nordisk A/S, Søborg, Denmark, 8University of Leicester, UK.
Background and aims: Renal impairment in type 2 diabetes mellitus (T2DM) 
limits the available glucose lowering treatment options. The rationale for this 
trial was to establish the efficacy and safety of liraglutide 1.8 mg as add-on 
to existing glucose lowering drugs and/or insulin therapy in subjects with 
inadequately controlled T2DM and moderate renal impairment (estimated 
glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m2; MDRD).
Materials and methods: In this 26-week, double-blind, multicentre, mul-
tinational, parallel group trial, adults with T2DM and moderate renal im-
pairment, BMI of 20-45 kg/m2, HbA1c of 7.0-10.0% and on stable diabetes 
medication (unchanged medication and dose for ≥90 days prior to screening) 
were randomised 1:1 to receive either once-daily liraglutide 1.8 mg or pla-
cebo. Liraglutide was initiated at 0.6 mg/day and incremented by 0.6 mg/day 
on a weekly basis to the target dose of 1.8 mg/day. The primary endpoint was 
change in HbA1c from baseline (BL) to Week 26 (Table).
Results: 279 subjects were randomised (140 to liraglutide; 139 to placebo). 
All subjects, except for 2 in the placebo group, were exposed to trial medica-
tion and included in the analysis. Liraglutide 1.8 mg showed superior gly-
caemic control relative to placebo in subjects with moderate renal impair-
ment with a low risk of hypoglycaemia and reduced body weight (Table). 
The most common adverse events (AEs) were GI side effects (liraglutide 
35.7%, placebo 17.5%), mostly nausea and vomiting which resolved quickly. 
There was a higher incidence of AE leading to withdrawals in the liraglu-
tide group (13.6%), compared to placebo (2.9%). No deterioration in renal 
function was observed (eGFR change from BL: -1% liraglutide; +1% placebo 
p=0.36). There was an increase from baseline in amylase and lipase levels in 
the liraglutide group that was not seen in the placebo group. One subject with 
elevated lipase (>3x ULN) and amylase (>2x ULN) at baseline was diagnosed 
with chronic pancreatitis on Day 11 of treatment with liraglutide.
Conclusion: Liraglutide 1.8 mg showed superior HbA1c and weight reduc-
tion with no unexpected safety or tolerability issues including no worsening 
of renal function in subjects with moderate renal impairment over 26 weeks. 
The efficacy, low incidence of hypoglycaemia and safety of liraglutide in sub-
jects with T2DM and moderate renal impairment was demonstrated.
Clinical Trial Registration Number: NCT01620489
Supported by: Novo Nordisk
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Effect of saxagliptin on renal outcome
O. Mosenzon1, D.L. Bhatt2, L.E. Litwak3, M. Shestakova4, K.K. Ray5,  
G. Leibowitz1, B. Hirshberg6, C. Wei6, A. Parker7, N. Iqbal8, B.M. Scirica2, 
R.C.W. Ma9, I. Raz1;  
1The Diabetes Unit, Hadassah Hebrew University - Medical Center, 
Jerusalem, Israel, 2Brigham and Women’s Hospital, Harvard Medical School, 
Boston, USA, 3Hospital Italiano de Buenos Aires, Argentina, 4Endocrinology 
Research Center, Moscow, Russian Federation, 5St. Georges University of 
London, UK, 6AstraZeneca, Wilmington, 7AstraZeneca LP, Wilmington, 
8BMS, Princeton, USA, 9The Chinese University of Hong Kong, Hong Kong.
Background and aims: It was previously suggested that DPP-4 inhibitors 
may have a protective effect on diabetic kidney disease. Herein we studied 
the renal outcomes of 16,492 patients (pts) with type 2 diabetes, who were 
prospectively followed in the SAVOR TIMI 53 trial for a median of 2.1 years. 
Predefined renal outcomes (safety and efficacy) were: doubling of serum cre-
atinine, the composite of initiation of chronic dialysis, renal transplant or 
serum creatinine >6.0 mg/dl, reduction from baseline of albumin/creatinine 
ratio (ACR) and categorical changes in ACR.
Materials and methods: At baseline, pts were stratified into 3 groups accord-
ing to renal function: normal or mild renal dysfunction (RD) [eGFR >50 mL/
min; N=13,916], moderate RD [eGFR 30-50 mL/min; N=2,240], or severe RD 
[eGFR <30 mL/min; N=336). Baseline categorical ACR was normal (ACR<30 
mg/G) in 9,696 (58.8%) pts, microalbuminuria (ACR 30-300 mg/G) in 4,426 
(26.8%) pts and macroalbuminuria (ACR >300 mg/G) in 1,638 (9.9%) pts.
Results: Patients assigned to saxagliptin (SAXA) vs. placebo (PLB) were 
more likely to improve their categorical ACR (11% vs. 9% p<0.01) and less 
likely to worsen their categorical ACR (13% vs. 16% p<0.01). In patients with 
microalbuminuria at baseline, treatment with saxagliptin was associated with 
greater reversal to normoalbuminuria: at 1 year, 31.3% vs. 25.7%, respective-
ly (p<0.0001). These results were maintained for 2 years and at end of trial 
(EOT). At an “on treatment analysis”, the improvements in the SAXA group 
compared with the PLB group were observed in ACR and in all eGFR catego-
ries and at all time points (Table). Pearson correlation analysis showed that 
the change in albuminuria was independent of the change in HbA1c at 1 year, 
2 years, and EOT (Pearson coefficients: 0.015, 0.025, and 0.033, respectively). 
There were no differences in the other predefined renal outcomes between 
the SAXA and PLB groups: doubling of serum creatinine [153 (0.92%) vs. 147 
(0.89%), HR 1.04 (0.83-1.30)], the composite of initiation of chronic dialysis, 
renal transplant or serum creatinine>6.0 mg/dl [51 (0.31%) vs. 55 (0.33%), 
HR 0.90 (0.61-1.32)] or the composite end point of death and all of the above 
[573 (3.47%) vs. 525 (3.20%), HR 1.08 (0.96-1.22)].
Conclusion: In the SAVOR TIMI 53 trial, saxagliptin improved ACR and 
had a neutral effect on the other predefined renal outcomes. The beneficial 
effect of saxagliptin on albuminuria seems to be independent of its effect on 
glycaemia.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca/Bristol-Myers Squibb
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 85
1 C
184
Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and  
body weight in obese individuals with moderate or severe disease: 
SCALE sleep apnoea trial
A. Blackman1, G. Foster2, G. Zammit3, R. Rosenberg4, L. Aronne5,  
T. Wadden6, B. Claudius7, C.B. Jensen7, E. Mignot8;  
1Toronto Sleep Institute, MedSleep, Canada, 2School of Medicine, Temple 
University, Philadelphia, 3Clinilabs Sleep Disorders Institute, New York, 
4NeuroTrials Research, Atlanta, 5Weill Cornell Medical College, New York, 
6Perelman School of Medicine, University of Pennsylvania, Philadelphia,  
USA, 7Novo Nordisk A/S, Søborg, Denmark, 8School of Medicine, Stanford 
University, Palo Alto, USA.
Background and aims: Obesity is strongly associated with obstructive sleep 
apnoea (OSA) and weight loss has been shown to reduce disease severity. 
This randomised, double-blind, parallel-group trial compared the effects of 
liraglutide 3.0 mg to placebo, both as adjunct to diet (500 kcal/day deficit) 
and exercise, on OSA severity and body weight. The primary endpoint was 
change in apnoea-hypopnoea index (AHI, number of apnoea/hypopnoea 
events per hour of sleep) after 32 weeks (Table).
Materials and methods: Obese individuals without diabetes who had mod-
erate (AHI 15-29.9 events/h) or severe (AHI ≥30 events/h) OSA and were 
unwilling/unable to use continuous positive airway pressure therapy were 
randomised 1:1 to liraglutide 3.0 mg or placebo for 32 weeks. Of 359 ran-
domised individuals (mean baseline age 48.5 years, males 71.9%, AHI 49.2 
events/h, severe OSA 67.1%, body weight 117.6 kg, BMI 39.1 kg/m2, HbA1c 
5.7%), 276 (76.9%) completed the trial.
Results: After 32 weeks, the reduction in AHI was significantly greater with 
liraglutide 3.0 mg than with placebo (-12.2 vs. -6.1 events/h, p=0.0150) (Ta-
ble). Supporting the reduction in AHI, endpoints related to oxygen satura-
tion, polysomnographic measures of sleep quantity and efficiency, and qual-
ity of life also improved with liraglutide 3.0 mg, albeit statistically non-signifi-
cantly compared to placebo. Liraglutide 3.0 mg produced significantly greater 
mean percentage weight loss compared to placebo (-5.7 vs. -1.6%, p<0.0001) 
and enabled more individuals to reach ≥5% and >10% weight loss targets 
after 32 weeks. Post-hoc analysis showed a relationship between weight loss 
and change in AHI. In addition, there were significantly greater reductions 
in neck circumference, HbA1c and systolic blood pressure (SBP) with lira-
glutide 3.0 mg versus placebo. After 32 weeks, heart rate increased by about 
2 beats/min with liraglutide 3.0 mg compared to placebo. The safety profile 
of liraglutide 3.0 mg was generally consistent with that previously seen with 
liraglutide in type 2 diabetes. Nausea and diarrhoea were the most common 
adverse events with liraglutide 3.0 mg (27% and 17% of individuals, respec-
tively); most events were mild/moderate and transient.
Conclusion: As an adjunct to diet and exercise, liraglutide 3.0 mg was gener-
ally well tolerated and produced significantly greater reductions than placebo 
in AHI, body weight, SBP and HbA1c in obese individuals with moderate/
severe OSA. The results also indicate that weight loss improves OSA-related 
parameters.
Clinical Trial Registration Number: NCT01557166
Supported by: Novo Nordisk
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The incretin hormone GLP-1 is upregulated in critically ill ICU patients 
and regulates the metabolic response during acute inflammation:  
central role of IL-6
F. Kahles, C. Meyer, J. Möllmann, C. Lebherz, H.M. Findeisen, S. Diebold, 
A. Koch, F. Tacke, C. Trautwein, N. Marx, M. Lehrke;  
University Hospital Aachen, Germany.
Background and aims: Hypoglycemia predicts adverse outcome in critically 
ill patients including those with sepsis or myocardial infarction. The underly-
ing mechanism for inflammation-mediated hypoglycaemia are incompletely 
understood. Experimental data suggest that hyperinsulinemia might play a 
role here and that LPS induces insulin secretion in a glucose-dependent man-
ner. Since the incretin hormone Glucagon-like-peptide 1 (GLP-1) also causes 
insulin secretion, we speculated that GLP-1 may be of relevance for inflam-
mation dependent hypoglycaemia.
Materials and methods: C57BL/6J, IL6 knockout (KO) and IL1 receptor KO 
mice were given i.p. injections of saline or lipopolysaccharides (LPS) (100μg/
kg), IL1β, IL6 and TNFα (all 4 μg/kg), respectively (n=6-12/ group). A total 
of 155 critically ill patients (112 with sepsis, 43 without sepsis) were studied 
prospectively upon admission to the medical intensive care unit (ICU) and 
compared to 134 healthy controls.
Results: LPS upregulated GLP-1 secretion in C57BL/6J mice with a maximal 
3,4 fold increase (p<0,001) 120 minutes post LPS injection, which was paral-
leled by elevated insulin (p<0,001) and decreased glucose (p<0,001) levels. 
A similar increase of serum GLP-1 and insulin was found after IL1β or IL6 
administration. Studies in IL1-R-KO - and IL6 KO mice showed that LPS de-
pendent GLP-1 secretion was selectively dependent on IL6 but not on IL1 se-
cretion. Consistently IL6 (p<0,05) but not IL1β or LPS stimulated GLP-1 se-
cretion from intestinal L cells in vitro. To evaluate the functional relevance of 
GLP-1 for glucose metabolism we inhibited its degradation by administration 
of the DPP4 inhibitor sitagliptin (40mg/kg), which augmented LPS-induced 
insulin secretion and blood glucose lowering in mice. Conversely, injection 
of the GLP-1 receptor antagonist exendin 9-39 (100nM/kg) markedly blunted 
LPS-dependent increase of serum insulin and prevented endotoxic hypogly-
caemia. We next asked whether GLP-1 would also be upregulated in humans 
under inflammatory conditions. Indeed, critically ill patients admitted to the 
intensive care unit showed an 6.9 fold increase of total GLP-1 plasma levels in 
comparison to healthy controls (97.0 pM versus 13.9 pM; p<0.001). Among 
the ICU cohort higher GLP-1 plasma concentrations were found in patients 
presenting with sepsis (101.1 pM versus 67.5 pM in none septic patients) 
and more severe disease (109 pM in patients with Apache II > 10 versus 73,4 
pM in patients with Apache II < 10; p=0.002). GLP-1 levels were associated 
with IL6 concentrations (p<0.001) in the whole ICU cohort and with insulin 
(p<0,05) in none septic ICU patients.
Conclusion: GLP-1 provides a new metabolic cross talk between the gut and 
the immune system with LPS dependent hypoglycaemia being dependent on 
an inflammatory cascade including IL6, GLP-1 and insulin. GLP-1 plasma 
concentrations are elevated in critically ill patients, correlating with disease 
severity.
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Saxagliptin in patients with prior heart failure - observations from  
the SAVOR-TIMI 53 trial
B.M. Scirica1, E. Braunwald1, I. Raz2, O. Mosenzon2, A. Cahn2,  
J. Lopez-Sendon3, B. Hirshberg4, P.A. Pollack4, P. Steg5, A. Umez-Eronini1,  
K. Im1, D.L. Bhatt1;  
1Medicine, Brigham and Women’s Hospital, Boston, USA, 2Medicine, 
Hadassah Medical Center, Jerusalem, Israel, 3Hospital Universitario La Paz, 
Madrid, Spain, 4AstraZeneca, Wilmington, USA, 5Medicine, Département 
Hospitalo-Universitaire FIRE, INSERM U-1148, Université Paris-Diderot , 
and Hôpital Bichat, Paris, France.
Background and aims: Heart failure (HF) and T2DM frequently co-exist; 
however, there are limited data regarding the safety of a antihyperlycemic 
drugs in patients with T2DM and prior HF and thus clinical uncertainty over 
optimal glycemic control strategies.
Materials and methods: The SAVOR-TIMI 53 trial evaluated the safety and 
efficacy of saxagliptin vs. placebo in 16,492 patients with T2DM, at high risk 
of cardiovascular disease, of whom patients with HF at baseline were a pre-
specified sub-group. The 1° endpoint was CV death, MI, or ischemic stroke. 
The 2° endpoint included the 1° endpoint together with hospitalization for 
HF, unstable angina, or coronary revascularization. Median follow-up was 
2.1 years. The 1° and 2° endpoints were adjudicated by a blinded events com-
mittee.
Results: 2,105 patients (12.8%) reported prior HF at baseline. Patients with 
prior HF were older and more likely to have established CV disease and renal 
impairment, with no difference in duration of DM or HbA1c. More patients 
with prior HF were on ASA, statins, B-blockers, and insulin, but fewer on 
metformin or sulfonylurea. There was no difference in the duration of DM 
and only a small difference (0.1%) in baseline HbA1c. Patients with prior HF 
were at double the risk for all CV events compared to patients with no prior 
HF. (Table) The relative effect of saxagliptin versus placebo was similar in 
patients with and without prior HF for the 1° and 2° endpoints. The increased 
risk of hospitalization for heart failure with saxagliptin was also similar re-
gardless of prior HF, though the absolute risk difference with saxagliptin was 
greater in patients with prior HF. The incidence of hypoglycaemia, adverse 
events, and A1c reductions are presented in the Table.
Conclusion: Despite being at substantially increased risk of CV complica-
tions, saxagliptin neither increased nor decreased the risk of the 1° and 2° 
endpoints compared to placebo in patients with T2DM and prior HF. Simi-
larly, there was no relative differential in the increased risk of hospitalization 
for HF with saxagliptin, though the absolute risk was greater. These data pro-
vide important information regarding the safety and efficacy of an antihyper-
glycemic agent in a traditionally difficult to treat population. 
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca and Bristol-Myers Squib
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A randomised clinical trial on the efficacy of an adapted bowel 
preparation for diabetic patients undergoing a colonoscopy
J.A. Flores-Le Roux1, M.A. Alvarez2, J.J. Chillarón1, A. Seoane2,  
D. Benaiges1, L. Carot2, S. Bacchiddu2, J. Pedro-Botet1;  
1Endocrinology, 2Gastroenterology, Hospital del Mar, Barcelona, Spain.
Background and aims: Need for colonoscopy is common among diabetic 
patients because of the high prevalence of gastrointestinal symptoms but they 
are more likely to have inadequately cleansed bowels which leads to a re-
peat procedure that will increase patients’ exposure to unnecessary risk and 
costs. No studies have evaluated the importance of dietary recommendations 
before the procedure or the need for hypoglycaemic drug adjustments dur-
ing preparation. A specific bowel preparation for patients with diabetes with 
special attention to dietary recommendations and modification of hypoglyce-
mic medication could facilitate patient adherence and consequently improve 
bowel cleansing. We evaluated the efficacy and safety of an adapted protocol 
for colon cleansing in diabetic patients.
Materials and methods: Single-blind experimental design, 80 persons with 
diabetes who were scheduled for colonoscopies were randomly assigned to 
either the experimental diabetic colon preparation (DMe) or the standard co-
lon preparation (DMs). A group of 40 non-diabetic subjects was also includ-
ed (noDM). DMe patients were instructed to follow a specific low-residues 
diet, with special attention to carbohydrate intake, without liquid diet the day 
before colonoscopy, and to modify the doses of hypoglycaemic medication 
prior to the procedure. DMs subjects received the standard recommenda-
tions including general information on low-residues diet and liquid diet the 
day before the procedure with no counselling on hypoglycaemic medication 
adjustments. All patients received the same medication for bowel prepara-
tion. Endoscopists blinded to the type of preparation scored the type of re-
sidual stool and the percentage of bowel wall visualized for each segment of 
colon and for the overall examination using the Boston score. Hypoglycemic 
episodes during preparation were recorded.
Results: 73 diabetic patients were randomized: 37 in DMe group and 36 in 
the DMs group. 40 noDM subjects were also included. NoDM patients were 
younger (56±15 vs 68±10 years, p<0,001), less frequently male (55% vs 74%, 
p<0,001) and had a lower comorbidity index (1 vs 14, p=0,07) than diabetic 
subjects. Subjects in the DMe and DMs groups were comparable in all the an-
alyzed characteristics (table). Overall, the noDM group had a higher Boston 
score than diabetic subjects (8,3±1,5 vs 7±3,2, p=0,010). DMe patients had a 
higher Boston score than DMs (7,6±1,5 vs 6,4±2,8, p=0,02) a lower number 
of non-diagnostic colonoscopies (2,8% vs 19,4%, p=0,028) which was similar 
to that of noDM subjects (2,7%, p=0,93).
Conclusion: An adapted bowel preparation protocol for diabetic patients un-
dergoing a colonoscopy can achieve a better visualization of the colon wall, 
which in turn reduces the need for repeat procedures to a level equivalent to 
the general population.
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 87
1 C
188
Dissociation pattern in resting-state default mode network connectivity 
in type 2 diabetes patients
Y. Cui, Y. Jiao, S. Ju, G.-J. Teng;  
Radiology, Southeast University, Nanjing, China.
Background and aims: Type 2 diabetes mellitus (T2DM) has been shown to 
be associated with an increased risk of cognitive impairment. Patients with 
impaired cognition often show default-mode network (DMN) disruption. 
This study aimed to investigate the integrity of the DMN by using independ-
ent component analysis (ICA) methods in patients with T2DM and to cor-
relate the DMN functional connectivity (FC) changes with neurocognitive 
performance and clinical variables.
Materials and methods: The current study was approved by the local ethics 
committee and written informed consent was obtained from all participants. 
Twenty-nine T2DM patients and thirty well-matched healthy controls were 
included in the study and underwent resting-state functional MRI (rs-fMRI) 
in a 3 Tesla unit. All participants underwent a detailed battery of neuropsy-
chological tests. Clinical parameters such plasma glucose, HbA1c, insulin re-
sistance, BMI and cholesterol levels were also collected. A group ICA method 
was used to extract the DMN of all participants. Two components were 
identified to be related to two sub-networks of the DMN, including the ante-
rior and posterior parts of the DMN. Z-maps of the two sub-networks were 
compared between the two groups and correlated with the neurocognitive 
performance and clinical parameters by using Pearson correlation analysis.
Results: Patients with T2DM showed significantly increased frontal con-
nectivity around the medial prefrontal cortex (MPFC) in the anterior DMN 
(aDMN) and significantly decreased connectivity in the posterior cingulate 
cortex (PCC) and angular gyrus in the posterior DMN (pDMN) (Figure 1). 
The FC strength in aMDN was found to be negatively correlated with the 
score on complex-figure-test (r=-0.46) and positively correlated with the FPG 
(r=0.44). On the other hand, the FC strength in pDMN was negatively corre-
lated with the disease duration (r=-0.55) and the time spent on trail-making-
test (part B) (r=-0.68). These associations were independent of vascular risk 
factors and cerebral small vessel disease.
Conclusion: The current study demonstrated the dissociation between an-
terior and posterior DMN sub-networks in patients with T2DM. Our results 
highlight the important role of the DMN in the pathophysiology of T2DM-
related cognitive impairment and suggest that abnormal DMN activity may 
be a trait associated with T2DM patients.
Supported by: NSFC 81271739
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Disrupted circadian arousal patterns comorbid with diabetes
M. Kadono1, G. Hasegawa2, M. Fukui3, N. Nakamura3;  
1Internal Medicine, Ayabe City Hospital, 2Endcrinology and Metabolism, 
Kyoto Second Redcross Hospital, 3Endcrinology and Metabolism, Kyoto 
Prefectural University of Medicine, Japan.
Background and aims: Sleep-wake disturbances and disruptions of circadian 
rhythms are now recognized to be highly prevalent comorbidities in patients 
with medical illness. Likewise, it is supposed that circadian arousal rhythms 
were disrupted in parallel with metabolic and vascular vulnerability in dia-
betes. We aimed to explore disrupted circadian arousal patterns comorbid 
with diabetes.
Materials and methods: Ninety-one diabetic outpatients with BMI<25kg/
m2 in our diabetes clinic wore an actigraph for consecutive 7days (men:41, 
type1 diabetes:3, age:68.7±8.2 yrs). Patients with depression, dementia, liver 
cirrhosis, renal failure, blindness, and shift work were excluded. Activity re-
cording derived from an actigraph was aggregated in hourly bins counting 
the number of minutes containing any activity. Next, an average 24-hour 
arousal profile was calculated by averaging each corresponding hour of all 
recorded days. To determine several underlying circadian arousal patterns by 
the 24-hour arousal profiles, a principal component analysis was applied. The 
analysis identified three factors which explained 25.2%, 17.7 %, and 19.8% 
of the total variance. These components were interpreted as 1) a “Daytime 
Arousal” factor (DA) with positive loadings of hourly activity counts of 8:00 
a.m.-19:00, 2) a “Midnight Arousal” factor (MA), with positive loadings of 
0:00 a.m.-4:00 a.m.,and 3) a “Phase” factor (P), with positive loadings of 18:00 
- 0:00 a.m., and inverse loadings of 4:00 a.m-7:00 a.m.. In addition, a “Hyper-
arousal” (HA) factor, average total time spent awake per day, was calculated 
from total activity counts across a day. Last, the stepwise regression analysis 
was used to evaluate associations of diabetic clinical backgrounds with the 
circadian rhythms related measurements, DA, MA, HA and P.
Results: Higher age, higher BMI, higher cholesterol levels, insulin treatment 
were associated with lower levels of DA(p=0.04,0.03, 0.01 and 0.02,respec-
tively), while higher HbA1c and the presence of painful neuropathy was as-
sociated with higher DA (p=0.03 and 0.02). Male gender and higher levels 
of urinary albumin excretion were associated with higher MA(p=0.04 and 
0.03). Similarly to DA, lower age, lower BMI, higher HbA1c, no insulin treat-
ment, and painful neuropathy were associated with higher HA(p=0.05, 0.02, 
0.06 ,0.01, and 0.02). Furthermore, painful neuropathy and antilipids usage 
were independent predictors of delayed P (p=0.02 and 0.03), while cardiovas-
cular diseases and smoke were independent predictors of advanced P (p=0.04 
and 0.01).
Conclusion: Diabetic clinical backgrounds were associated with a variety of 
circadian arousal patterns and daily arousal levels. The current study suggests 
that high age, obesity, dyslipidemia, and insulin treatment in diabetes might 
reduce daily arousal levels with excessive daytime sleepiness, and that poorly 
controlled blood sugar and painful neuropathy in diabetes might be patho-
genically associated with sleep loss resulting from short sleep or insomnia 
which is a 24-hour disorder of hyperarousal. Furthermore, diabetic neuro-
vasculopathies may alter circadian arousal patterns by affecting the midnight 
arousal levels and circadian phase. These findings could provide a novel in-
sight helpful for interventions for various patterns of sleep/wake disorders 
comorbid with diabetes.
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Sleep stages and type 2 diabetes: characterisation of 
electroencephalography features
A. Lecube1, O. Mestres2, A. Ciudin3, C. Zafon4, G. Sampol2, O. Romero2,  
F. Rius5, C. Hernández3, A. Casteràs4, A. Caixàs6, R. Simó3;  
1Diabetes Research Unit Vall d’Hebron (Barcelona) and Endocrinology 
Department Arnau Vilanova, (Lleida), 2Sleep Unit, Pneumology 
Department Vall d’Hebron, Barcelona, 3Endocrinology Department, 
Diabetes Research Unit Vall d’Hebron, Barcelona, 4Endocrinology 
Department Vall d’Hebron, Barcelona, 5Endocrinology Department, 
Endocrinology Department Arnau Vilanova, Lleida, 6Endocrinology 
Department Parc Taulí, Sabadell, Spain.
Background and aims: There is growing evidence suggesting than type 2 
diabetes mellitus (T2DM) is an independent risk factor for severe nocturnal 
hypoxemia and sleep breathing disorders. However, it is unknown whether or 
not these sleep disturbances affect the structure of sleep.
Materials and methods: For this purpose we designed a case-control study 
between 28 patients with T2DM and 56 non-diabetic subjects, closely 
matched by age, gender, BMI, waist and neck circumferences, and smoking 
status. Subjects were also matched for their apnea-hypopnea index (IAH) 
[31.2 (1.0 to 106.3) vs 33.9 (1.2 to 109.1) events per hour, p=0.924]. The ex-
clusion criteria included chronic respiratory disease, neuromuscular and cer-
ebrovascular disease, alcohol abuse, use of sedatives, and pregnancy. Exami-
nation included a electroencephalography and respiratory polysomnography, 
as well as oxygen saturation measures and the degree of sleepiness using the 
Epworth Sleepiness Scale (ESS). Studies with less than 5 hours of correct sig-
nal recording were ruled out.
Results: No differences in the Rapid Eye Movement (REM) Sleep (13.5±8.2 
vs. 12.8±7.4 % of total time of sleep, p=0.689) nor in the Non-Rapid Eye 
Movement (NREM) Sleep stages (stage 1: 18.6±12.4 vs. 15.1±13.0 %TTS, 
p=0.243; satge 2: 58.1±14.0 vs. 59.3±12.5 %TTS, p=0.688; stage 3: 12.5±10.5 
vs. 12.3±10.2 %TTS, p=0.924; stage 4: 13.8±10.8 vs. 12.4±10.4 %TTS, 
p=0.594) were observed between subjects with and without T2DM. However, 
T2DM patients showed a higher number of microaurousals (or brief awaken-
ings) events than control subjects [34.1 (4.6 to 101.4) vs. 22.7 (1.3 to 93.1) 
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events per hour during the total time of sleep, p=0.023]. A significant posi-
tive correlation between microarousals and the AHI was detected (r=0.807, 
p<0.001). Finally, a stepwise regression analysis showed that both the AIH 
and the presence (or not) of T2DM (but not gender, age, BMI, neither neck 
circumference) independently predicted microarousals (R2=0.593).
Conclusion: T2DM adversely affects structure of sleep, becoming an inde-
pendent risk factor for higher rates of microarousals. As sleep fragmentation 
has been involved with increased levels of lipids and blood pressure, this in-
creased rate of microarousals may be implicated in the progression of cardio-
vascular disease in T2DM.
Supported by: ISCII FIS 12/00803, Fundación SEEN
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Diabetes is associated with increased prevalence of perinasal sinus 
diseases
Y. Kabeya, K. Kato, M. Okisugi, M. Tomita, T. Katsuki, Y. Oikawa,  
A. Shimada;  
Tokyo Saiseikai Central Hospital, Japan.
Background and aims: Past studies have reported that patients with diabetes 
are susceptible to respiratory tract infections. However, it remains unknown 
whether or not individuals with diabetes are more likely to have perinasal 
sinus diseases than those without. In the present study, we investigated the 
association between diabetes and perinasal sinus diseases in Japanese adults 
who underwent a health checkup.
Materials and methods: This was a cross-sectional study performed in the 
medical checkup unit of one general hospital in Japan. A total of 1,350 adults 
who underwent a medical checkup including a head MRI scan from January 
2007 to December 2011 were enrolled in the study. The participants were 
generally healthy and asymptomatic. Information on lifestyle was obtained 
by a questionnaire. Anthropometric data and blood samples were collected 
under a fasting condition. Diabetes was defined by any of the following crite-
ria: 1) self-reported diabetes or use of anti-diabetic medications based on the 
questionnaire, 2) fasting plasma glucose of ≥ 126 mg/dl, or 3) HbA1c of ≥ 6.5 
%. Perinasal sinus diseases were defined as partial or complete opacification 
of perinasal sinuses (including mucosal thickening and small polyps) detect-
ed by a head MRI scan. The prevalence of perinasal sinus diseases in adults 
with diabetes and those without was calculated, which was standardized to 
the 1985 model population of Japan. Multiple logistic regression analysis was 
performed to calculate the odds ratio of having perinasal sinus diseases in 
adults with diabetes in relation to those without. The model was adjusted for 
age, sex, body mass index, waist to hip ratio, smoking status, alcohol intake 
and white blood cell count. In addition, the dose-response relationship was 
examined between HbA1c levels and the presence of perinasal sinus diseases.
Results: Of the 1,350 adults (mean age, 62±10 years; 72% men), 220 diabetes 
cases were identified. Perinasal sinus diseases were diagnosed in 151 adults. 
The age-standardized prevalence of perinasal sinus diseases was 18.8% in 
adults with diabetes and 11.0% in those without, respectively. In the logistic 
regression analysis, a significant association was observed between diabetes 
and the presence of perinasal sinus diseases after adjustment for the con-
founders [odds ratio (OR) = 1.74, 95% CI = 1.12-2.71]. The odds of having 
perinasal sinus diseases increased with HbA1c levels. Compared with adults 
with HbA1c of <5.5%, those with HbA1c of 5.5-6.5% and ≥6.5% were more 
likely to have perinasal sinus diseases with ORs of 1.32 (95% CI=0.88-1.97) 
and 1.86 (95% CI=1.05-3.31), respectively (p for trend = 0.03).
Conclusion: The present study found that perinasal sinus diseases are more 
common in adults with diabetes than those without. The dose-response rela-
tionship between hyperglycaemia and the presence of perinasal sinus diseas-
es was also observed. The association was independent of known risk factors 
for perinasal sinus diseases. Although the clinical significance of the diseases 
detected by a head MRI scan remains undetermined, physicians should keep 
in mind the higher prevalence of perinasal sinus diseases among diabetic pa-
tients in daily practice.
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Hyponatraemia is associated with all-cause mortality in patients with 
type 2 diabetes (ZODIAC-46)
I.J. Riphagen1,2, S.J.J. Logtenberg1, K.H. Groenier3,4, K.J.J. van Hateren4,  
G. Navis1, I.P. Kema5, H.J.G. Bilo1,4, N. Kleefstra1,4, S.J.L. Bakker1,2;  
1Internal Medicine, UMCG, Groningen, 2Top Institute Food and Nutrition, 
Wageningen, 3General Practice, UMCG, Groningen, 4Diabetes Centre, Isala 
Clinics, Zwolle, 5Laboratory Medicine, UMCG, Groningen, Netherlands.
Background and aims: Hyponatremia (i.e. plasma sodium <135 mmol/L), 
the most prevalent electrolyte disorder in clinical practice, was found to be 
an independent predictor for all-cause mortality both in patients with heart 
failure and in the general population. Although hyponatremia appears more 
prevalent in diabetes, the association of hyponatremia with mortality in pa-
tients with type 2 diabetes is rarely studied. Our aim was to prospectively 
investigate whether plasma sodium is associated with cardiovascular (CV) 
and all-cause mortality in patients with type 2 diabetes.
Materials and methods: Patients with type 2 diabetes participating in the 
Zwolle Outpatient Project Integrating Available Care (ZODIAC) study were 
included. Cox regression analyses with restricted cubic splines were used to 
investigate the association of baseline plasma sodium with CV and all-cause 
mortality.
Results: We included 1,068 patients (45% male, age 67 ± 12 years). Mean 
plasma sodium concentration was 142.3 ± 3.0 mmol/L. In multivariable lin-
ear regression analyses, plasma sodium was associated with copeptin, a sur-
rogate marker for vasopressin, urinary albumin-to-creatinine ratio (ACR), 
HbA1c and gender. After median follow-up for 6.5 [interquartile range: 3.1-
10.2] years, 345 patients died (32%), with 145 deaths (14%) attributable to CV 
causes. A restricted cubic spline depicting the association of plasma sodium 
with all-cause mortality is shown in Figure 1. In univariable Cox regression 
analyses, plasma sodium levels <142 mmol/L were significantly associated 
with all-cause mortality (Hazard Ratio [HR] 0.90; p=0.003), but not with CV 
mortality (HR 0.90; p=0.07). After adjustment for age, sex, BMI, smoking, 
systolic blood pressure, total cholesterol-to-HDL ratio, duration of diabetes, 
HbA1c, use of antihypertensive medication including diuretics and RAAS 
inhibitors, history of CV diseases, serum creatinine, log ACR and copeptin, 
the associations of plasma sodium levels <142 mmol/L with all-cause mortal-
ity (HR 0.91; p=0.04) and CV mortality (HR 0.89; p=0.09) were essentially 
unchanged.
Conclusion: We found low plasma sodium levels to be independently as-
sociated with an increased risk for all-cause mortality in patients with type 
2 diabetes. Whether hyponatremia itself leads to poor outcome or that it is 
a marker for (unidentified) co-morbidity severity or use of specific medica-
tions remains to be elucidated.
Supported by: GSK
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Continuous intraperitoneal insulin infusion versus subcutaneous 
insulin for type 1 diabetes: a prospective, case-control trial proving non-
inferiority
H.J.G. Bilo1, P.R. van Dijk1, S.J.J. Logtenberg1, K.H. Groenier1, H. Feenstra2, 
R.O.B. Gans3, N. Kleefstra1;  
1Diabetes centre, Isala clincs, Zwolle, 2Internal Medicine, Diaconessenhuis, 
Meppel, 3Internal Medicine, University Medical Center Groningen, 
Netherlands.
Background and aims: Continuous intraperitoneal insulin infusion (CIPII) 
using an implantable pump is a last-resort treatment option for patients with 
type 1 diabetes mellitus (T1DM) who fail to reach acceptable glycaemic con-
trol with intensified subcutaneous (SC) insulin regimens. Aim of this study 
was to compare the effects of long-term CIPII with SC insulin therapy in 
T1DM.
Materials and methods: This is a 36 week, investigator initiated, prospec-
tive, open-label matched-control study. Patients were eligible if they had 
been treated with either CIPII or SC insulin for >4 years and had a HbA1c of 
≥53 mmol/mol. CIPII treated patients were matched to SC treated patients 
regarding age and gender. In order to account for inequality between treat-
ment groups, as CIPII treated patients are a selected group of patients in need 
of a last-resort treatment, the primary endpoint was not a superiority but a 
non-inferiority assessment of the difference in HbA1c between both groups. 
A non-inferiority margin of -5.5 mmol/mol was predefined. Secondary out-
comes were clinical and biochemical parameters, quality of life (SF-36 (scores 
0-100)) and treatment satisfaction (DTSQ (scores 0-36)). Analysis were per-
formed with ANCOVA, taking baseline differences into account.
Results: During study, one patient withdrew consent. Subsequently 183 pa-
tients, 36% male with a mean age of 50 years (SD 1) and diabetes duration 
of 26 years (SD 13), of which 39 were treated with CIPII and 144 with SC 
insulin therapy were analyzed. Age and gender were well matched. Results 
are presented in table 1. HbA1c remained stable within the CIPII group while 
it decreased with -1.0 mmol/mol (95%CI -1.9, -0.1) in the SC group. Using 
ANCOVA, the difference between treatment groups was -3.0 mmol/mol 
(95%CI -5.0, -1.0) and met the predefined non-inferiority criterion. Besides a 
difference in alanine aminotransferase (ALT) concentrations between groups 
of 3.6 U/L (95%CI 1.2, 6.0) being higher in the CIPII group, no other differ-
ences were found. At baseline and at the end of the trial, SF-36 scores were 
lower among CIPII treated patients as compared patients treated with SC in-
sulin. CIPII treated patients had lower SF-36 mental and physical component 
scores and higher treatment satisfaction as compared to patients treated with 
SC insulin at baseline and follow-up.
Conclusion: CIPII therapy is non-inferior to SC insulin therapy with respect 
to glycaemic control in the treatment of poorly controlled T1DM patients. 
Besides a lower ALT among SC treated patients, there are no differences in 
clinical and biochemical parameters. Despite a lower quality of life, treatment 
satisfaction is higher among CIPII treated patients. This study underlines the 
effectiveness of long-term CIPII therapy as last resort treatment in T1DM.
Clinical Trial Registration Number: NCT01621308
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Three to four weeks of overnight closed loop insulin delivery during free 
living: analysis of randomised crossover studies in adults and adolescents 
with type 1 diabetes
H. Thabit1, L. Leelarathna1, D. Elleri1, J.M. Allen1, A. Lubina-Solomon2,  
M. Stadler3, E. Walkinshaw2, A. Iqbal2, P. Choudhary3, M.E. Wilinska1,  
S.R. Heller2, S.A. Amiel3, M.L. Evans1, D.B. Dunger1, R. Hovorka1;  
1University of Cambridge, 2Academic Unit of Diabetes, Endocrinology and 
Metabolism, Department of Human Metabolism, University of Sheffield, 
3Diabetes Research Group, Kings College London, UK.
Background and aims: Results from single-night laboratory-based closed 
loop studies demonstrated improved overnight glucose control and reduced 
risk of hypoglycaemia in subjects with type 1 diabetes. Assessments outside 
hospital settings over longer periods in free living conditions are underway. 
We combined data collected during free-living unsupervised randomised 
open-label crossover studies comparing overnight closed loop and sensor 
augmented pump therapy.
Materials and methods: 40 participants with type 1 diabetes [24 adults re-
cruited at three centres and 16 adolescents recruited at one centre (age 43±12 
years, HbA1c 8.0±0.9%; mean±SD) (15.6±3.6 years, HbA1c 8.1±0.8%)] un-
derwent training on study devices followed by two periods of sensor aug-
mented pump therapy in combination with or without overnight closed-loop 
utilising a model predictive control algorithm to direct insulin delivery. The 
order of interventions was random; each period lasted four weeks in adults 
and three weeks in adolescents. Primary outcome was time when sensor glu-
cose was in the target range between 3.9 and 8.0mmol/l. All analyses were by 
intention to treat.
Results: Closed loop was started by participants on their own volition on 866 
nights (89%). The proportion of time when sensor glucose was in target range 
(3.9-8.0mmol/l) between midnight and 08:00 was increased by 18.5% during 
closed-loop compared to sensor augmented therapy (P<0.001; Table). Closed 
loop significantly reduced mean overnight glucose by 0.8mmol/l (P<0.001), 
with no difference in glycaemic variability as measured by the standard devia-
tion of sensor glucose. Time spent above target range was reduced (P=0.001) 
and so was time spent in hypoglycaemia below 3.9mmol/l (P=0.014) during 
closed loop. Lower mean overnight glucose during closed loop was brought 
about by increased overnight insulin delivery (P<0.001) without changing 
the total daily delivery (P=0.84).
Conclusion: Overnight closed loop at home in adults and adolescents with 
type 1 diabetes is feasible, demonstrating improvements in glucose control 
and reducing the risk of nocturnal hypoglycaemia. 
Clinical Trial Registration Number: NCT01440140 & NCT01221467
Supported by: DUK, JDRF
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Impact of real-time continuous glucose monitoring system usage on 
endothelial function in adolescents with type 1 diabetes
B. Głowińska-Olszewska, M. Jamiołkowksa, I. Jamiołkowska, W. Łuczyński, 
J. Tołwińska, A. Bossowski;  
Department of Pediatrics, Endocrinology, Diabetology with Cardiology 
Division, Medical University of Białystok, Poland.
Background and aims: Chronic hyperglycaemia and recently defined “glu-
cose variability” in the course of diabetes are established risk factors for car-
diovascular disease. Children with type 1 diabetes (T1DM) are the high - risk 
group of accelerated early atherosclerosis development. Real-time continu-
ous glucose monitoring system (RT-CGMS) provides with new possibilities 
for the detection of excessive glycaemic fluctuations and enables the patient 
to react quickly to decrease these adverse phenomena. The aim of the study 
was to assess the usefulness of RT-CGMS as an educational tool to find and 
reduce glycemic variability in order to improve the parameters of endothelial 
function in adolescents with T1DM.
Materials and methods: Forty T1DM patients aged mean 14.6 years, diabe-
tes duration: 7.4 years, mean HbA1c before the study: 9.35%, 19 boys and 21 
girls were recruited. The study was based on one month continuous glucose 
sensors use combined with education of the patients and caregivers. Several 
parameters of glycemic variability (mean glucose, SD for the mean glucose, 
AUC>140 mg/dl, AUC<70 mg/dl, minimal and maximal glucose level) were 
analysed during first and last sensor use, together with brachial artery flow 
mediated dilatation (FMD), as a parameter of endothelial function. HbA1c 
was measured before the study and after 3 months follow-up. Depending on 
the initial value of HbA1c the group was divided into well-controlled group 
(with HbA1c <7.5%, mean 7.25±0.19%) and poorly controlled group (with 
HbA1c>7.5%, mean 9.88±1.22%). Decrease of HbA1c by at least 0.5% after 
3-month follow-up was the criterion to divide the study group into improved 
vs. not improved. To determine the differences between the study groups 
for variables with normal distributions the t-Student test was applied. The 
t-Student test for paired variables was used to compare the variables within 
the respective groups at baseline and after one-month (glycaemic variabil-
ity parameters and FMD). To assess correlations between study parameters 
Pearson correlation coefficient was used.
Results: In the whole group FMD improvement was found (10.9% to 16.6%, 
p<0.005), together with significant decrease in all studied glycaemic variabili-
ty parameters. Significant HbA1c improvement was observed in 68% patients 
(27 children): 9.02% before vs. 8,04%, after study, P=0.001. In these patients 
compared to the group without improvement (10.0±1.7% vs. 10.4±1.4% af-
ter the study) we found greater increase of FMD (12% to 19%, P<0.005 vs. 
8.2% to 11.3%, P=0.08) and greater decrease of the mean glucose, SD for the 
mean glucose, AUC>140mg/dl and maximal glucose level. In group with ini-
tial HbA1c<7.5% we found greater improvement of FMD than in group with 
HbA1c >7.5% (16% to 28%, p<0.005 vs. 9.6 to 13.9%, P<0.005). Improvement 
of parameters of glycemic variability in group with HbA1c<7.5% was not so 
evident.
Conclusion: RT-CGMS can be considered as a new tool that allows to im-
prove endothelial function in type 1 adolescent diabetic patients by enabling 
the quick reaction to decrease glycemic variability parameters in short-time 
observation. Whether such approach might influence to reduce the risk of 
future cardiovascular disease remains to be elucidated.
Supported by: Medical University of Białystok
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Insulin pumps (CSII) and cardiovascular diseases and mortality in the 
Swedish national diabetes register
S. Gudbjörnsdottir1, B. Eliasson1, A.-M. Svensson2, T. Avdic1,  
M. Landin-Olsson3, J. Cederholm4;  
1University of Gothenburg, 2National Diabetes Register, Centre of registers, 
Gothenburg, 3University of Lund, 4Department of Public Health and Caring 
Sciences, Uppsala, Sweden.
Background and aims: Insulin pump treatment (CSII) is given for improved 
glycemic control and quality of life. However, studies on the effect of CSII on 
long-term risk for cardiovascular diseases (CVD) and mortality are lacking.
Materials and methods: Comparison between 2136 patients with type 1 dia-
betes with CSII and 13,028 patients with insulin injections, from the Swedish 
National Diabetes Register (NDR), followed for outcomes during mean 5.9 
years with 14,523 person-years.
Results: Baseline characteristics are given in the Table. Adjusted hazard ratios 
(95% confidence intervals) for fatal/nonfatal coronary heart disease and fatal/
nonfatal cardiovascular disease (heart disease or stroke) were 0.95 (0.90-0.99; 
p=0.02), and for all-cause mortality 0.95 (0.91-1.00; p=0.03), when adjust-
ing for age, sex, diabetes duration, baseline HbA1c, systolic blood pressure, 
smoker, BMI, total cholesterol, history of CVD or heart failure at Cox regres-
sion. Hazard ratio were similar in a sensitivity analysis adjusting by stratifica-
tion with a propensity score including these covariates and also HDL choles-
terol, cumulative albuminuria, creatinine, antihypertensive drugs, and lipid-
lowering drugs. P values for covariates between the groups after adjusting 
with the propensity score are given in the Table. Another sensitivity analysis 
in a subgroup with 15,164 patients with no history of CVD or heart failure 
also showed similar hazard ratios.
Conclusion: This large prospective observational study showed risk reduc-
tions of around 5% for cardiovascular diseases and mortality with CSII com-
pared to insulin injections in patients with type 1 diabetes followed for 6 
years.
Supported by: The Swedish Association of Local Authorities and Regions funds 
the NDR
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The long term effect of continuous subcutaneous insulin infusion  
on renal function in type 1 diabetic patients with microalbuminuria
R. Trevisan1, D. Bruttomesso2, G. Lepore1, S. Costa2, P. Fioretto3,  
M. Vedovato3, E. Zarra4, A. Corsi1, C. Scaranna1, U. Valentini4, A. Tiengo3;  
1Department of Medicine, AO Papa Giovanni XXIII, Bergamo, 2Department 
of Medicine, University of Padua, 3Department of Medicine, University of 
Padua, 4Department of Medicine, AO Spedali Civili, Brescia, Italy.
Background and aims: The purpose of the study was to investigate whether 
insulin pump therapy (CSII) was superior to multiple daily insulin injections 
(MDI) to prevent progression of albuminuria in patients with type 1 diabetes 
(T1DM).
Materials and methods: Case-control prospective study of 3 years duration. 
26 T1DM patients on CSII with AER of at least 20 μg/min were matched 
for age (40.3 ± 9.3 vs 42.2 ± 111 yrs), diabetes duration (27 ± 8 vs 24 ± 10 
yrs) BMI (24.4 ± 3 vs 24.7±4.2 kg/m2) and AER with 26 T1DM patients on 
MDI. Patients were in stable maximal RAAS blockade before entering the 
study. Before the study all patients received education in intensive diabetes 
treatment and self-care including carbohydrate counting. Patients return 
to the clinic every 6 months for measurement of AER, GFR (by ioexol e.v.), 
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urinary concentrations of 8-iso-PGF2alfa , HbA1c, 24hr blood pressure, 3 
days Continuous Glucose Monitoring sensor (CGM), self monitored blood 
glucose profiles.
Results: AER decreased slightly in MDI group from a median value of 65 μg/
min (31-100 IQR) to 55 (33-155) after 3 years of follow-up. AER decreased 
significantly (p<0.01) from 63 μg/min (37-154 IQR) to 18.3 (11-57) in CSII 
group. In particular only 3 patients on MDI regressed to normoalbuminuria 
at the end of follow-up, whereas 14 patients on CSII regressed to normoalbu-
minuria (p<0.001). GFR decline was faster in MDI group (-7.9±9.9 ml/min/
yr) than in CSII group (-3.1±3.3 ml/min/yr; p < 0,05). Urinary concentra-
tions of 8-iso-PGF2alfa were similar in the 2 groups and stable during the 
study. HbA1c was similar in MDI and CSII groups at entry into the study (8.5 
± 1.5% vs 8.2 ± 1.0% respectively). Despite the thigh follow-up, metabolic 
control did not improved in both groups during the study: HbA1c remained 
unchanged (HbA1c at the end of the study: 7.8 ± 1.25 % in MDI group vs 8.0 
± 1.3% in CSII group). All measures of glycaemic variability (Mean amplitude 
of glycaemic excursions [MAGE], Mean of daily differences [MODDs], Con-
tinuous overlapping net glycaemic action [CONGA], Low blood glucose in-
dex [LBGI]) were similar in the 2 groups throughout the study. Insulin daily 
dose was significantly higher in MDI than in CSII group both at entry (0.67 
± 0.39 vs 0.50 ± 0.11 U/Kg/day) and at the end of the study (0.67 ± 0.20 vs 
0.54 ± 0.12 U/Kg/day; p<0.01). 24-hour blood pressure was well controlled in 
both groups and stable throughout the study. Mean of standard deviation of 
individual 24-hour blood pressure values, as a measure of blood pressure var-
iability, were similar in both groups and stable during the follow-up period.
Conclusion: CSII, despite a similar blood glucose control, prevented the 
progression of albuminuria and the loss of GFR when compared to MDI in 
T1DM patients. The greater insulin requirement in patients on MDI suggests 
a condition of greater insulin resistance, a factor likely to contribute to the 
renal disease progression.
Supported by: EFSD 
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Effect of insulin pump treatment on albuminuria and kidney function in 
type 1 diabetes
S. Rosenlund1,2, T.W. Hansen1, S. Andersen2, P. Rossing1,3;  
1Steno Diabetes Center, Gentofte, 2Hilleroed Hospital,  
3University of Copenhagen, Denmark.
Background and aims: Treatment with continuous subcutaneous insulin 
infusion (CSII) may reduce urinary albumin excretion as compared to treat-
ment with multiple daily injections (MDI). We aimed to investigate the effect 
of 3 years CSII treatment on albuminuria, HbA1c, and kidney function com-
pared to MDI in a single centre clinical setting.
Materials and methods: Case-control study of all type 1 diabetes patients ini-
tiating CSII treatment from 2004-2010 at our outpatient clinic and followed 
for at least three years. We identified 193 patients and matched them (1:2) to 
386 patients treated with MDI in the same period. Matching was based on 
diabetes duration, gender, HbA1c and normo-, micro- or macroalbuminuria 
at baseline. Urinary albumin creatinine ratio (UACR) was measured yearly 
and annual change assessed from linear regression. Unpaired t-test and ad-
justed ANCOVA compared treatment groups.
Results: At baseline, both treatment groups included 39% men with diabetes 
duration of (mean ± SD) 23 ± 12 years and a frequency of normo-, micro 
and macroalbuminuria of 84%, 12% and 4% respectively. Patients were (CSII 
vs. MDI) 48 ± 12 vs. 44 ± 11 years old, HbA1c 68 ± 11 vs. 68 ± 10 mmol/
mol, eGFR 100 ± 23 vs. 101 ± 25 mL/min/1.73m2, UACR (median [IQR]) 9 
[6-19] vs. 9 [6-17] mg/g, and numbers on RAAS-treatment were 40 vs. 38%, 
(p>0.58 for all; except age; p<0.001). Annual change in UACR in CSII vs. 
MDI treated patients was (mean (CI95%)) -11.3 (-14.6; -8.0)% vs. -1.1 (-3.3; 
1.1)%, (p<0.001). This remained significant after adjustment for diabetes 
duration, age, gender and baseline values of eGFR, systolic blood pressure, 
HbA1c and RAAS-treatment (p<0.001). Adjustment for average follow up 
values instead of baseline values did not change the significance (p<0.001). 
The yearly change in eGFR was -1.9 ± 6.7 vs. -1.8 ± 4.4 mL/min/1.73 m2 
(p=0.73) and in HbA1c -1.2 ± 2.8 vs. 0.2 ± 2.3 mmol/mol (p<0.001). Number 
of patients starting RAAS-treatment during follow up was similar in CSII 
vs. MDI treated; 10.9 vs. 10.4 % (p=0.85). In multiple regression analysis, 
adjusted for baseline values, a larger decline in UACR was significantly as-
sociated to CSII treatment and higher UACR (p<0.001). After adjustment for 
follow up values, a larger decline in UACR was significantly associated to CSII 
treatment (p<0.001), lower average HbA1c (p=0.02) and stable RAAS-treat-
ment (p=0.04). In adjusted analyses restricted to patients on stable RAAS-
treatment during follow up (n=465) only CSII treatment was significantly 
associated to a larger decline in UACR (p<0.001).
Conclusion: In a case control study treatment with CSII over 3 years inde-
pendently reduced UACR and HbA1c compared to MDI. In these mostly 
normoalbuminuric patients, change in kidney function was small, and simi-
lar, in the groups. The reduced UACR was only partly explained by reduction 
in HbA1c and may in addition be due to less glycaemic variability. This can-
not be assessed from these data. The effect of CSII treatment on albuminuria 
needs investigation in randomized controlled trials.
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Specific overexpression of the calcium-sensor sorcin in pancreatic  
beta cells protects against ER-stress and diet-induced type 2 diabetes
A.P. Marmugi, G.A. Rutter, I. Leclerc;  
Medicine, Imperial College London, UK.
Background and aims: Pancreatic beta cells use electrical signals to couple 
changes in blood glucose concentration to insulin release via extracellular 
calcium (Ca2+) influx. Sorcin (SRI) is a Ca2+-binding protein whose overex-
pression in cardiomyocytes rescues the abnormal contractile function of the 
diabetic heart and plays a role in terminating Ca2+-induced Ca2+-release. We 
explored here the role of sorcin in regulating Ca2+ fluxes in pancreatic beta 
cells and its ability to protect against glucolipotoxicity in vivo.
Materials and methods: Two lines of transgenic mice were generated on a 
C56Bl/6 background permitting inducible overexpression of SRI cDNA with 
the TetOn-system specifically in beta cells. Animals bearing one (SRI-1) or 
ten (SRI-10) copies of the SRI transgene, and littermate controls (CTRL), 
were fed either a standard chow diet (SD) or a high fat diet (60% fat, HFD) 
and exposed to doxycycline in the drinking water (500mg/L) from 4 weeks 
onwards. Body weight measurements and fasting intraperitoneal glucose tol-
erance tests (1g/kg, IPGTT) were performed at regular intervals. Quantita-
tive RT-PCR and real-time calcium imaging with Fura-Red (excitation light 
at 420 and 480nm, 40x/1.4NA objective and a cMOS camera on board an 
Olympus IX-71 microscope) were performed on islets isolated from either 
transgenic animals or from wild-type mice transduced with adenoviruses 
overexpressing GFP-SRI or GFP.
Results: Glucose tolerance during IPGTTs worsened considerably in CTRL 
males under HFD (120 min glycaemias (mmol/L): 12.3 ± 0.9 at 8-week-old, 
22.1 ± 1.7 at 16-week-old, n=17) but not in CTRL males under SD (120 min 
glycaemia (mmol/L): 7.2 ± 0.2 at 8 weeks, 7.3 ± 0.5 at 16 weeks, n=10). Strik-
ingly, and despite having similar body weights, male SRI-1 mice on HFD dis-
played improved glucose tolerance at 16 weeks of age (areas under the curve 
(AUC; a.u.): 111.9 ± 8.8 for SRI-1, 136.2 ± 7.3 for CTRL, n=16, p<0.05). 
SRI-10 males on HFD already displayed improved glucose tolerance after 8 
weeks of age (AUC (a.u.): 73.0 ± 2.3 for SRI-10, 95.8 ± 5.3 for CTRL, n=22, 
p<0.001) and fasting glycaemia (0 min glycaemia (mmol/L): 8.7 ± 0.4 for SRI-
10, 10.9 ± 0.8 for CTRL, n=22, p<0.05). mRNA levels of genes involved in 
endoplasmic reticulum (ER) stress, including GRP78 (fold-change normal-
ised to beta-actin: 0.29 ± 0.13, n=11, p<0.05) and CHOP (0.16 ± 0.03, n=11, 
p<0.001), were reduced significantly in SRI-1 versus CTRL islets. Moreover, 
adenovirus-mediated SRI overexpression increased basal cytosolic Ca2+ levels 
in wild-type mouse islets (F420/480 ratio (a.u.): 1.0 ± 0.02 vs 0.74 ± 0.01, n=23 
clusters/group, p<0.001 vs GFP virus-infected islets) at low (3 mM) glucose 
and increased the peak amplitude of Ca2+ rises in response to high glucose (20 
mM; AUC (a.u.): 463.4 ± 14.9 vs 278.2 ± 6.0, n=23 clusters/group, p<0.001) 
or depolarisation with KCl (20 mM; AUC (a.u.): 157.8 ± 5.0 vs 89.3 ± 2.3, 
n=23 clusters/condition, p<0.001).
Conclusion: Our in vivo experiments reveal that targeted SRI overexpression 
preserves pancreatic beta cell function and whole body glucose homeostasis 
during high fat feeding. These actions involve the alleviation of ER stress and 
increases in intracellular Ca2+. Such alterations may avert apoptosis and loss 
of beta cell mass during type 2 diabetes.
Supported by: Diabetes UK, Wellcome Trust, BBSRC and MRC.
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Chaperones ameliorate beta cell dysfunction and amyloid formation 
associated with human islet amyloid polypeptide overexpression
J. Montane1,2, L. Cadavez1,2, C. Castaño1,2, A. Novials1,2;  
1Diabetes and Obesity Laboratory, Institut d’Investigacions Biomèdiques 
August Pi i Sunyer (IDIBAPS), 2Centro de Investigación Biomédica en 
Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 
Barcelona, Spain.
Background and aims: In type 2 diabetes and islet transplantation beta-cell 
dysfunction is thought to be due to several causes, one being the formation 
of toxic protein aggregates called islet amyloid, formed by accumulations 
of misfolded human islet amyloid polypeptide (hIAPP). The process of hI-
APP misfolding and aggregation is one of the factors that may perturb the 
endoplasmic reticulum (ER) homeostasis, leading to beta cell dysfunction 
and ultimately, cell death. Molecular chaperones have been described to be 
important for regulation of ER response to ER stress by stabilizing protein 
conformation and improving ER capacity. The aim of the present work is to 
determine whether chaperone treatment is able to counteract hIAPP-induced 
beta cell dysfunction and, ultimately, diminish amyloid formation and cell 
death in pancreatic islets.
Materials and methods: hIAPP Tg islets and INS1E cells, stably expressing 
hIAPP (hIAPP-INS1E) were cultured with 16mM or 25 mM glucose and 
400μM palmitic acid and treated with chemical chaperones taurine conju-
gated ursodeoxycholic (TUDCA) and phenyl butyric acid (PBA) or endoge-
nous chaperones BiP/GRP78 (BiP) or protein disulfide isomerase (PDI). Islet 
function was determined by glucose-stimulated insulin secretion and gene 
expression and protein levels of ER stress markers (CHOP, ATF3 and spliced 
XBP1) were analysed by real-time RT-PCR and Western blot. Wild type and 
hIAPP Tg islets were cultured for 7 days at 16mM glucose and treated with 
TUDCA or PBA. Amyloid formation was determined by ThioS staining.
Results: hIAPP-INS1E cells exposed to high glucose and palmitic acid 
showed an increase in ER stress when compared to INS1E cells expressing rat 
IAPP or INS1E control cells. Treatment with chaperones BiP, PDI, TUDCA or 
PBA alleviated ER stress and increased insulin secretion in hIAPP-expressing 
cells. Treatment of wild-type and hIAPP Tg islets with BiP, PDI, TUDCA and 
PBA increased insulin output in basal conditions after a glucose-stimulated 
insulin secretion. When hIAPP Tg islets were exposed to high glucose and 
palmitic acid, chaperone treatment was able to revert beta cell dysfunction 
by restoring insulin secretion. Moreover, when hIAPP Tg islets were cultured 
for 7 days at 16mM glucose, amyloid plaques were formed throughout the 
islet engaging 18.2±2.3% of the insulin positive area. TUDCA and PBA treat-
ment was able to diminish amyloid formation of hIAPP Tg islets to 5.3±0.9% 
and 1.2±0.4% respectively, indicating that chaperones may play an important 
role in preventing beta-cell dysfunction and amyloid formation associated 
to T2D.
Conclusion: Chaperones ameliorate induced ER stress, increase insulin se-
cretion and ultimately, diminish amyloid formation in a context of hIAPP 
overexpression. These innovative approaches could reveal new therapeutic 
targets and aid in the development and evaluation of strategies to diminish 
ER stress and limit the damaging amyloid observed in islets before transplant 
or in type 2 diabetic patients.
Supported by: FIS (PI08/0088 and PI1100679)
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Acidic, photo-activated nanoparticles restore autophagy in beta cells 
exposed to high nutrient environment
K. Trudeau1, S. Sereda1, A. Colby2, M. Grinstaff2, O. Shirihai1;  
1Boston University School of Medicine, 2Boston University, USA.
Background and aims: We have previously shown that chronic (>16 hour) 
exposure to fatty acids (palmitate and oleate) inhibit autophagic flux in the 
pancreatic beta-cell, leading to accumulation of autophagosomes and de-
creased autophagy-dependent turnover, resulting in beta-cell dysfunction. 
Further investigations determined that fatty acids induced lysosomal dys-
function, characterized by loss of lysosomal acidity, lysosomal swelling, and 
decreased activity of lysosomal pH-dependent proteases. In this study we 
tested the hypothesis that fatty acid-induced impairment of lysosomal acidi-
fication plays a central role in the arrest of autophagic turnover and impaired 
beta-cell glucose-stimulated insulin secretion. To address this hypothesis 
we developed lysosome-targeted nanoparticles (NPs) that release acid upon 
photo-activation.
Materials and methods: Acidic NPs were developed that expand in size after 
UV-light activation, exposing carboxylic acid residues in the polymer that 
mediate an acidifying effect. Rhodamine-labelled NPs were tested for uptake 
and localization into INS1 cells (beta-cell insulinoma line) using flow cytom-
etry and confocal imaging with LysoTracker dye. Efficacy of UV-activation 
and NP toxicity in INS1 cells were tested using propidium iodide staining and 
flow cytometry. Lysosensor Yellow/Blue dye and ratiometric imaging/analy-
sis was performed to determine if UV-activated NPs could affect lysosome 
acidity and size in INS1 cells exposed to 0.4mM palmitate for 18 hours. Also, 
p62 and LC3-II levels in INS1 cells were assessed by Western blot to test NP-
induced improvement of autophagic flux. Lastly, human islets were exposed 
to 2:1 oleate:palmitate for 4 days, and glucose-stimulated insulin secretion 
was analyzed to determine if UV-activated NPs could improve beta-cell func-
tion after fatty acid exposure.
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Results: The NPs were equilibrated in a dose-dependent manner in INS1 
and beta-cells within 1-2 hours and localized to lysosomes as assessed by co-
localization with LysoTracker staining. High concentration (250 µg/mL) of 
NPs induced significant cell death when UV-activated but was well-tolerated 
when not UV-activated, indicating successful activation of NPs in intact cells 
and allowing determination of a non-toxic treatment dose of 25 µg/mL NPs 
in cells. UV-activation of NPs in INS1 cells exposed for 18 hours to palmitate 
showed a significant rescue of lysosomal acidity and size compared to palmi-
tate treatment alone or palmitate co-treated with NPs that were never UV-ac-
tivated. Furthermore, palmitate-induced p62 and LC3-II accumulation were 
decreased following UV-activation of NPs, indicating downstream improve-
ment of autophagic flux. Finally, UV-activated NPs were able to partially re-
store fatty acid-induced decrease in glucose-stimulated insulin secretion in 
human islets, suggesting that rescuing lysosomal acidity and autophagic flux 
with acidic NPs can improve beta-cell function.
Conclusion: The capacity of acidic NPs to restore lysosomal acidity, mor-
phology and clearance supports an upstream role for impaired lysosomal 
dysfunction in the development of deregulated insulin secretion. Addition-
ally, acidic NPs may have therapeutic value in diseases where a cellular defect 
in lysosomal acidity inhibits autophagic flux, such as the fatty acid-induced 
arrest of autophagic flux in the pancreatic beta-cell.
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Reversible changes in pancreatic islet structure and function produced 
by elevated blood glucose
M.F. Brereton1, M. Iberl1, K. Shimomura1, Q. Zhang2, P. Proks1,  
A.A. Adriaenssens3, I.I. Spiliotis1, W. Dace1, K.K. Mattis1, F.M. Gribble3,  
F. Reimann3, A. Clark2, P. Rorsman2, F.M. Ashcroft1;  
1Department of Physiology, Anatomy and Genetics, University of Oxford,  
2Oxford Centre for Diabetes, Endocrinology and Metabolism, University 
of Oxford, 3Cambridge Institute For Medical Research, University of 
Cambridge, UK.
Background and aims: Hyperglycaemia is common to all forms of diabetes 
and results from impaired insulin secretion and aberrant glucagon secretion 
due to changes in pancreatic islet cell function and/or mass. The extent to 
which hyperglycaemia per se underlies these alterations remains poorly un-
derstood as previous studies have been restricted to in vitro culture systems, 
or animal models where diabetes is artificially induced by β-cell ablation and 
other confounding factors (e.g. obesity and insulin resistance) are common. 
We generated a mouse model in which diabetes could be rapidly and revers-
ibly switched on and off to study the effect of hyperglycaemia on pancreatic 
islet structure and function.
Materials and methods: An inducible human activating KATP channel muta-
tion was expressed in β-cells of adult mice. This inhibited insulin secretion 
and resulted in rapid onset of diabetes. Islet morphology, ultrastructure and 
electrophysiological characteristics were studied.
Results: 4-week exposure to hyperglycaemia was associated with a significant 
reduction in insulin-positive cells (% of islet area composed of insulin; con-
trol: 86.5+/-0.3% vs. diabetic 27.8+/-1.7%). This reflected a significant reduc-
tion in insulin mRNA and insulin protein levels in islets (P<0.05). Following 
exposure to chronic hyperglycaemia, islets became predominantly composed 
of glucagon-positive cells (control: 16.6+/-0.9% vs. diabetic 73.5+/-2.1%) 
consistent with increased glucagon mRNA and protein levels. These changes 
in insulin and glucagon expression did not reflect alterations in cell turnover 
(as assessed by Ki67 and apoptosis measurements). Instead, β-cell ultrastruc-
ture showed a striking reduction in insulin granule content. There was also 
a significant increase in dual insulin/glucagon-positive cells from 0.3+/-0.1% 
in control to 5.7+/-1.2% in diabetic islets (P<0.05). Lineage tracing showed 
these cells derived from β-cells and expressed β-cell transcription factors. 
Furthermore, they had functional β-cell, not α-cell, voltage-gated Na+ chan-
nels. Following 1 day or 4-weeks of diabetes, normoglycaemia was immedi-
ately restored (within 24h) by subcutaneous insulin or sulphonylurea therapy. 
Restoration of normoglycaemia with these anti-diabetic drugs prevented and 
fully reversed the changes in islet structure and function.
Conclusion: Chronic hyperglycaemia resulted in the partial loss of β-cell 
identity in a mouse model of β-cell dysfunction. Hyperglycaemia, rather than 
KATP channel activation, underlies these changes as they were all prevented, 
and even reversed by anti-diabetic drugs. This highlights the remarkable plas-
ticity of β-cells, and their ability to alter their gene expression, structure and 
function in response to changes in circulating glucose levels. These data sug-
gest that rapid implementation of good glucose homeostasis in diabetes can 
preserve β-cell structure and function, and even reverse established changes.
Supported by: Wellcome Trust, ERC, MRC
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Dual roles of a DPP-4 inhibitor on cytoprotection and proliferation of 
pancreatic beta cells in a mouse model of beta cell injury/regeneration
E. Mukai, A. Morita, A. Hiratsuka, T. Takatani, E.-Y. Lee, T. Miki;  
Department of Medical Physiology, Chiba University, Japan.
Background and aims: Dipeptidyl peptidase-4 inhibitors (DPP4i) increase 
pancreatic β-cell mass in mouse models of diabetes mellitus. However, it re-
mains unknown which of cytoprotection or proliferation of β-cells contrib-
utes to the increase by DPP4i. In this study, we analyzed these two events 
individually using a mouse model that sequentially exhibits β-cell injury and 
regeneration. 
Materials and methods: We generated transgenic mice expressing diphtheria 
toxin (DT) receptor (DTR) and a red fluorescent protein (tomato) specifically 
in β-cells (Rip-Cre;Rosa26iDTR/iTomato). To analyze cytoprotective effect of DP-
P4i, the mice were pre-administered with a DPP-4i MK-0626 (3mg/kg/day, 
mixed in a chow) and then were treated with DT (20 μg/kg, i.p.) for β-cell ab-
lation. Six days after β-cell ablation, pancreases were excised and subjected to 
morphological examination. To analyze pro-proliferative effect of MK-0626, 
we administrated the mice with MK-0626 for 14 days starting on the day of 
DT injection. To assess the effect of MK-0626 on β-cells through pathways 
other than potentiating Glucagon-like peptide (GLP)-1 signaling, the same 
experiments were also performed also with a GLP-1 analog liraglutide (100 
μg/kg, twice a day, s.c.). Molecular mechanism of β-cell protection was inves-
tigated using a β-cell line MIN6 cells expressing DTR. 
Results: DT injection to Rip-Cre;Rosa26iDTR/iTomato induced death in 96% of 
tomato-positive cells and a decrease in β-cell mass to ~30% at day 6 and then 
recovery of β-cell mass to ~50% at day 14. In Rip-Cre;Rosa26iDTR/iTomato, blood 
glucose levels were not increased after β-cell ablation by DT. As regards to 
cytoprotective effect of MK-0626, MK-0626 administration significantly in-
creased the number of surviving tomato-positive β-cell after DT ablation. 
Comparable cytoprotective effect was observed by liraglutide administra-
tion and there was no additive or synergistic effect by co-administration of 
MK-0626 and liraglutide. Mechanism of cytoprotection was evaluated by 
DT-induced cell death in MIN6 cells expressing DTR. Pretreatment of the 
cells with liraglutide significantly attenuated the decrease in cell viability by 
DT. Considering that caspase-3 activation was inhibited by liraglutide and 
that caspase-3 or -9 inhibitor attenuated DT-induced cell death, cytoprotec-
tive effect of GLP-1 is mediated by suppressing caspase-3 and -9 signaling. 
In addition, cytoprotective effect of liraglutide is significantly decreased by a 
PI3K inhibitor or a MEK inhibitor. As regards to β-cell proliferative effect of 
MK-0626, its administration significantly increased BrdU incorporation at 
14 days after DT ablation.
Conclusion: MK-0626 increased β-cell mass by both inhibition of cell death 
and augmentation of proliferation in our mice. The cytoprotective effect of 
MK-0626 is suggested to be mediated by increased GLP-1 through PI3K and 
MAPK signaling. 
Supported by: MSD company and JSPS KAKENHI
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RNA-sequencing identifies Nova1 as a major splicing regulator in 
pancreatic beta cells 
O. Villate1, J.-V. Turatsinze1, L.G. Mascali1, F.A. Grieco1, T.C. Nogueira1, 
D.A. Cunha1, M. Sammeth2, V.A. Salunkhe3, J.L.S. Esguerra3, L. Eliasson3,  
L. Marselli4, P. Marchetti4, D.L. Eizirik1;  
1Laboratory of Experimental Medicine and ULB Center for Diabetic 
Research, Université Libre de Bruxelles, Belgium, 2Laboratório Nacional 
de Computação Cientifica, Petropolis RJ, Brazil, 3Department of Clinical 
Sciences Malmö, Lund University, Lund University Diabetes Centre, Malmö, 
Sweden, 4Department of Endocrinology and Metabolism, University of Pisa, 
Italy.
Background and aims: Alternative splicing (AS) is a basic mechanism for the 
regulation of gene expression, affecting more than 90% of human genes. We 
have recently shown by exon array and RNA-sequencing that pancreatic beta 
cell exposure to the pro-inflammatory cytokines interleukin-1 beta (IL-1) + 
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interferon-gamma (IFN) modifies AS of >500 genes. Our recently published 
data indicate the presence of the Nova1 splicing factor in beta cells, but there 
is no information about its role on these cells. We have presently coupled 
specific knockdown (KD) of Nova1 with RNA sequencing to determine all 
splice variants and downstream pathways regulated by this protein in pan-
creatic beta cells.
Materials and methods: Nova1 expression was inhibited by 60% with the 
use of specific siRNAs. Three FACS-purified rat beta cell preparations (90-
95% pure) were RNA-sequenced under control conditions or after a 48-hour 
KD of Nova1. Samples were sequenced on an Illumina HiSeq 2000 sequencer 
and the data analysed using Tophat mapper and Flux Capacitor. The Cuf-
flinks software suite was used to identify potentially novel transcripts. Ex-
pression was considered changed if it fulfilled two criteria, namely p<0.05 
by the Benjamini-Hochberg-corrected Fisher testing and modified in the 
same direction in all samples. Beta cell function and viability was evaluated 
by glucose-induced insulin secretion, glucose oxidation and by the nuclear 
dyes Hoechst/PI.
Results: RNA-sequencing and the subsequent bioinformatics analysis identi-
fied 43,460 transcripts as expressed in primary beta cells, corresponding to 
18,257 genes. Nova1 KD modified expression of 18% of these genes and al-
tered the splicing of nearly 5000 transcripts. Pathway analysis indicated that 
these genes are involved in exocytosis, apoptosis, calcium signalling, splicing 
and transcription. Nova1 KD effects on splicing of key downstream genes 
such as Gabrg2 and Neurexin1 were confirmed by RT-PCR (n=5). In line 
with the observed pattern of gene expression, Nova1 silencing inhibited insu-
lin secretion and voltage dependent Ca2+ current by respectively 40±5% (n=5; 
P<0.05) and 35±10% (n=28-33; P<0.05) but did not affect glucose oxidation 
suggesting a main effect of exocytosis. Importantly, Nova1 silencing induced 
apoptosis via the intrinsic or mitochondrial pathway in INS-1E cells, FACS-
purified rat beta cells and human islet cells (increase in apoptosis of 6-20%; 
n=4-6; P<0.05), basally and after cytokine treatment.
Conclusion: The present data indicate that Nova1 has a major role in beta 
cell function, controlling the splicing and expression of key genes involved 
in gene transcription, insulin release and apoptosis. These findings identify 
a novel layer of regulation of beta cell function, namely AS controlled by key 
splice regulators.
Supported by: JDRF EU FP7 BetaBat Naimit
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Diabetes and ambulatory blood pressure monitoring: a cross-sectional 
analysis of 68045 hypertensive patients in Spain
O. Gonzalez Albarran1, M. Gorostidi2, J. Segura3, L. Ruilope3;  
1Endocrinology, Hospital Ramón y Cajal, Madrid,  
2Nephrology, Hospital Universitario de Asturias, Oviedo,  
3Nephrology, Hospital Doce Octubre, Madrid, Spain.
Background and aims: Hypertension affects the majority of patients with di-
abetes and constitutes a major risk factor for vascular complications. Ambu-
latory blood pressure monitoring (ABPM) provides a high-quality approach 
in estimating the true levels of blood pressure (BP).Several population- and 
patient-based studies have showed the benefits of ABPM in exploring the re-
lationship between BP and cardiovascular events. A series of reports dealing 
with diabetic patients have also shown a close correlation between ambula-
tory BP and diabetic complications. We aimed to assess such characteristics 
in comparison with non-diabetic hypertensives by using the Spanish Society 
of Hypertension ABPM Registry.
Materials and methods: We performed a cross-sectional analysis of a 68045 
patient database from the Spanish Society of Hypertension ABPM Registry, 
a nation-wide network of 41200 primary-care physicians performing ABPM 
under standardized conditions in daily practice. We identified 12 600 (18.5%) 
hypertensive patients with diabetes.
Results: When compared with patients without diabetes, diabetic hyperten-
sives exhibited higher systolic blood pressure (BP) levels in every ABPM pe-
riod (daytime 135.4 vs. 131.8, and night-time 126.0 vs. 121.0mmHg, P<0.001 
for both) despite they were receiving more antihypertensive drugs (mean 
number 1.71 vs. 1.23, Po0.001). Consequently, diabetic patients suffered from 
lack of control of BP more frequently than non-diabetic subjects particularly 
during the night (65.5% vs. 57.4%, Po0.001). Prevalence of a non-dipping 
BP profile (64.2% vs. 51.6%, Po0.001) was higher in diabetic patients. In the 
other hand, prevalence of ‘white-coat’ hypertension in diabetic patients was 
33.0%.
Conclusion: We conclude that there was a remarkably high prevalence of 
alterations in ABPM in patients with diabetes. Abnormalities in systolic BP, 
particularly during the night, and in circadian BP pattern could be linked 
with the excess of BP-related cardiovascular risk of diabetes. A wider use of 
ABPM in diabetic patients should be considered.
206
Achievement of individualised blood pressure targets in patients with 
hypertension and comorbid type 2 diabetes in a real world setting: results 
of the DIALOGUE registry
R.E. Schmieder1, D. Tschöpe2, C. Koch3, P. Bramlage4, T. Oarrak5, A.K. Gitt6; 
1Med. Klinik 4, Schwerpunkt Nephrologie / Hypertensiologie, 
Universitätsklinikum Erlangen, 2Herz- und Diabeteszentrum Nordrhein-
Westfalen, Bad Oeynhausen, 3Novartis Pharma GmbH, Nürnberg, 4Institut 
für Pharmakologie und Präventive Medizin, Mahlow, 5Stiftung „Institut für 
Herzinfarktforschung“, Ludwigshafen, 6Medizinische Klinik B, Herzzentrum 
Ludwigshafen, Germany.
Background and aims: There has been a recent appreciation of individu-
alized HbA1c treatment targets in patients with type-2 diabetes. Respec-
tive guidance for blood pressure Targets are inconsistent between different 
guidelines and decisions made should consider individual patient risk. To our 
knowledge there is neither clinical practice data on actually pursued blood 
pressure treatment targets nor on patient characteristics associated with ei-
ther strategy.
Materials and methods: DIALOGUE is a prospective, observational, multi-
center registry focusing on Treatment targets and their achievement in clini-
cal practice. Physicians were asked at baseline on blood pressure treatment 
targets pursued and compared to actual blood pressure levels values achieved 
at 6 months.
Results: A total of 8,601 patients were considered for the analysis. For 3,343 
of these (38.9%) a systolic blood pressure target of ≤130 mmHg (strict 
group), for 2,874 (33.4%) a target of >130 to ≤135 mmHg (medium) and 
for 2,384 (27.7%) a target of >135 to ≤140% (loose) was pursued. Patients 
in the strict target group were younger, had a shorter diabetes duration and 
less co-morbid disease (table). Overall 70.5% of those with a strict SBP target 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 95
1 C
also had a HbA1c target ≤6.5% and 40.7% of those with a loose SBP target 
also had loose HbA1c targets. At the 6 months follow-up the mean (±SD) 
SBP was 133.4±13.5 mmHg in the strict group (25% exceeding 140 mmHg), 
135.7±13.3 mmHg in the medium group (25% exceeding 140 mmHg)and 
139.0±15.0 in the loose group (25% exceeding 147 mmHg) (p<0.0001).
Conclusion: The data illustrate that systolic blood pressure targets chosen in 
patients with type-2 diabetes consider patient characteristics and overall co-
morbidity and are aligned with the corresponding HbAc1 treatment targets. 
The lesser morbid patient are, the stricter the treatment targets.
Supported by: Novartis 
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Considering individual variability in multiple risk markers in short-
term response to angiotensin-receptor-blockade improves renal risk 
prediction
H.J. Lambers Heerspink1, P. Rossing2, H.-H. Parving3, D. De Zeeuw1;  
1Clinical Pharmacology, University Medical Center Groningen, Netherlands, 
2Steno Diabetes Centre, Gentofte,  
3Medical Endocrinology, University of Copenhagen, Denmark.
Background and aims: The current use of Angiotensin-Receptor-Blockers 
(ARBs) is targeted towards blood pressure in order to ultimately decrease 
renal and cardiovascular (CV) risk. However, ARBs have multiple (off-target) 
effects that may potentiate or counteract the ultimate ARB effect on renal 
and CV outcomes. The extent to which the response in these off-target mark-
ers varies within an individual is unknown. We therefore investigated vari-
ability in the response to ARBs in different risk markers, the congruency in 
response between the markers within an individual, and the relation to hard 
renal outcomes.
Materials and methods: We used data from the RENAAL trial and assessed 
the change in the primary target systolic blood pressure (SBP), and the off-
targets, albuminuria, potassium, haemoglobin, cholesterol and uric acid after 
6 months of treatment with losartan. Response was defined as a change in 
expected direction whilst non-response was defined as no effect or change 
in opposite direction. Renal outcome was defined as end-stage renal disease 
(ESRD) or doubling of serum creatinine and ascertained during a median 
follow-up of 3 years. The improvement in predictive performance of renal 
outcomes for each individual after adding ARB induced changes in on-target 
and off-target risk markers to a renal risk score, consisting of age, gender, 
baseline eGFR, albuminuria, SBP, HbA1c, and haemoglobin, was assessed by 
C-statistic and relative integrated discrimination improvement (RIDI).
Results: We included 531 (71%) patients (age 60.0 years, 38% female) who 
had complete measurements at baseline and month 6. A response was ob-
served in SBP (61%), albuminuria (72%), potassium (66%), haemoglobin 
(72%), cholesterol (61%), and uric acid (47%). The proportion of individu-
als with off-target responses was similar among patients with SBP reduc-
tion compared to patients with SBP rise, suggesting that off-target responses 
were independent of SBP response. Moreover, correlations between SBP and 
off-target responses within an individual were weak (all r<0.2). Adding the 
individual responses in on-target and off-target risk markers to a renal risk 
score significantly improved renal risk stratification (increase in c-statistic 
from 0.81 to 0.85, p<0.001, and RIDI by 53.4%; p<0.001). Similar results were 
observed in two independent trials with irbesartan, the IDNT and IRMA-2 
trials.
Conclusion: The antihypertensive ARBs show multiple effects which vary 
between individuals and vary between parameters within an individual. In-
tegration of these short-term ARB induced responses of each individual in 
a multiple risk marker scores significantly improves renal risk prediction. 
These results highlight the importance of monitoring and targeting multiple 
renal risk markers in response to ARB therapy to optimize renal protection.
Clinical Trial Registration Number: NCT00308347
Supported by: HJ Lambers Heerspink is supported by the Netherlands Science 
Organisation
208
Distinct systolic blood pressure trajectories in type 2 diabetes patients. 
The Diabetes Care system cohort
I. Walraven, M.R. Mast, T. Hoekstra, A.P.D. Jansen, S.P. Rauh, F. Rutters, 
A.A.W. van der Heijden, P.J.M. Elders, A.C. Moll, B.C.P. Polak, J.M. Dekker, 
G. Nijpels;  
EMGO Institute for Health and Care research, VU University Medical 
Center, Amsterdam, Netherlands.
Background and aims: Observational studies showed that only 40 to 60% of 
type 2 diabetes mellitus (T2DM) patients within primary diabetes care reach 
the recommended systolic blood pressure (SBP) target of ≤ 140 mmHg. In 
order to eventually improve blood pressure (BP) management, the aim of this 
study was to identify subgroups of T2DM patients with distinct trajectories 
of SBP levels. Subgroup characteristics were determined and the prevalence 
of microvascular complications and all-cause mortality rates over time in the 
different subgroups was investigated.
Materials and methods: 5711 T2DM patients with at least two SBP follow-
up measurements were selected from a cohort of 9849 T2DM patients from 
the Diabetes Care system cohort in The Netherlands. The mean follow-up 
period was 5.7 years (range 2 - 9 years). Latent Class Growth Modelling was 
performed to identify subgroups of T2DM patients with distinct trajecto-
ries of SBP levels. Multinomial logistic regression analyses were conducted 
to determine subgroup characteristics. Associations of different subgroups 
with HbA1c level, retinopathy, microalbuminuria and medication use during 
follow-up were studied by constructing plots and by graphically comparing 
differences between classes.
Results: Four subgroups with distinct SBP trajectories were identified (Fig-
ure). The largest subgroup (85.6%) showed adequate SBP control (at or 
around 140 mmHg) over time. The second subgroup (5.6%) were hyperten-
sive in first few years, responded slowly to BP management and eventually 
reached SBP control. The third subgroup (3.4%) showed deteriorating hyper-
tension during the first four years, then showed insufficient response to BP 
management. The fourth subgroup (5.4%) showed deteriorating hyperten-
sion over time. Patients within subgroups 2-4, thus other than the adequate 
SBP control subgroup were significantly older, comprised more women, used 
more antihypertensive medication, had a higher prevalence of retinopathy 
and microalbuminuria and had higher all-cause mortality rates.
Conclusion: We identified four subgroups of T2DM patients with distinct 
SBP trajectories. More than 85% reached and maintained adequate SBP con-
trol. Subgroups with a more unfavourable course of SBP control also showed 
higher rates of retinopathy, microalbuminuria and all-cause mortality over 
time. This study identified important subgroups to target in order to improve 
BP management in T2DM patients.
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Relationships between the risk of cardiovascular events in type 2 diabetes 
and both visit-to-visit variability and time-to-effect in systolic blood 
pressure
T. Takao1, Y. Matsuyama2, H. Yanagisawa3, M. Kikuchi1, S. Kawazu1;  
1Division of Diabetes and Metabolism, The Institute for Adult Diseases, 
Asahi Life Foundation, Tokyo, 2Department of Biostatistics, School of 
Public Health, University of Tokyo, 3Department of Public Health and 
Environmental Medicine, The Jikei University School of Medicine, Tokyo, 
Japan.
Background and aims: Recent studies, mostly in treated hypertensive pa-
tients, found a visit-to-visit BP variability is a risk factor for cardiovascular 
diseases (CVD) and organ damage independently of the mean BP. However, 
reports in patients with diabetes remain limited. Lack of a BP legacy effect on 
cardiovascular events has been reported in type 2 diabetes. However, data on 
the effects of early lowering of BP are still scarce. This study aimed to deter-
mine whether systolic BP (SBP) variability is able to predict, independently of 
the mean SBP, the incidence of CVD events in patients with type 2 diabetes, 
and to analyze the time-to-effect relationship between SBP and the risk of 
these events.
Materials and methods: A total of 652 (538 men, 114 women) patients with 
type 2 diabetes who first visited our hospital between 1995 and 1996, with 
at least 1 hospital visit per year and no history of CVD, and undergone 4 or 
more SBP determinations, were retrospectively enrolled. Patients were fol-
lowed through June 2012. SD or CV was used as a measure of SBP variability. 
Risk of CVD events was evaluated by multivariate Cox proportional hazard 
models. SBP was analyzed as a mean value and a time-dependent covariate 
using the last observation carried forward or moving-mean during 1 year to 
17 years preceding the events. For all analyses, SAS (version 9.3) was used.
Results: The mean values at baseline were age 55.7 years, duration of dia-
betes 5.6 years, BMI 23.4 kg/m2, BP 133.7/77.9 mmHg, HbA1c 8.0%, Total-
cholesterol (TC) 209.3 mg/dl, and HDL-cholesterol (HDLC) 49.8 mg/dl. 275 
patients were current smokers. The median follow-up period from first visit 
was 11.5 years, and the total number of SBP measurements was 53,949 (per-
patient median: 78). By the end of follow-up, CVD events occurred in 71 
patients. Hazard ratios for the incidence of CVD unadjusted, adjusted for 
age and sex, and for age, sex, duration of diabetes, current smoker, mean SBP, 
mean HbA1c, mean TC/HDLC, mean BMI, and the number of SBP meas-
urements (ln-transformed), increased across tertiles of SD and CV of SBP 
(Table). The incidence of CVD was significantly associated with SBP during 
the preceding 2 to 8 years, with the highest significance during the preceding 
3 years, and borderline significance during the preceding 1 and the preceding 
9 to over 17 years.
Conclusion: Visit-to-visit SBP variability was able to independently predict 
CVD events in patients with type 2 diabetes. Increased SBP during the pre-
ceding 3 years resulted in the highest risk of CVD; therefore, to prevent CVD, 
SBP management should focus on stable and well-timed control.
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Re-evaluation of patients with type 2 diabetes from the RIACE cohort 
using the 8th Joint National Committee cut-offs for blood pressure
A. Solini1, G. Zoppini2, C. Fondelli3, E. Orsi4, M. Arosio5, R. Trevisan6,  
M. Vedovato7, F. Cavalot8, O. Lamacchia9, R. Buzzetti10, G. Penno1,  
G. Pugliese11;  
1Department of Clinical and Experimental Medicine, University of Pisa, 
2Division of Endocrinology and Metabolic Diseases, University of Verona, 
3Diabetes Unit, University of Siena, 4Diabetes Unit, Fondazione IRCCS 
Cà Granda - Ospedale Maggiore Policlinico, Milan, 5Endocrinology 
Unit, San Giuseppe Hospital, Milan, 6Endocrinology and Diabetes Unit, 
Ospedali Riuniti, Bergamo, 7Department of Clinical and Experimental 
Medicine, University of Padua, 8Department of Clinical and Biological 
Sciences, University of Turin, Orbassano, 9Department of Medical Sciences, 
University of Foggia, 10Department Experimental Medicine, La Sapienza 
University, Rome, 11Department of Clinical and Molecular Medicine,  
La Sapienza University, Rome, Italy.
Background and aims: The 8th Joint National Committee (JNC8) report has 
raised the recommended blood pressure (BP) threshold for drug therapy in 
diabetic subjects from 130/80 (JNC7) to 140/90 mmHg. This study was aimed 
at re-evaluating with the new BP cut-offs the prevalence of hypertension, an-
ti-hypertensive treatment, and achievement of target BP in patients with type 
2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) 
Italian Multicenter Study.
Materials and methods: The RIACE cohort consists of 15,773 patients, con-
secutively visiting 19 Diabetes Clinics throughout Italy in years 2007-2008. 
Exclusion criteria were dialysis or renal transplantation. BP was measured 
with a mercury sphygmomanometer on the right arm after at least 5 min 
of rest. Major acute cardiovascular disease (CVD) events were adjudicated 
based on hospital discharge records.
Results: Using the JNC7 BP targets, 6,854 patients (43.5%) had systolic BP 
<130 mmHg, 11,537 (73.1%) had diastolic BP <80 mmHg, and 6,276 (39.8%) 
met both targets. Using the JNC8 cut-offs, percentages were 66.6% for systolic 
BP (+23.1%), 94.2% for diastolic BP (+21.1%) and 65.7% for both (+25.9%). 
Change in percentage of subjects on-target rose from 21.1% to 24.3% for sys-
tolic BP and decreased from 25.0% to 16.4% for diastolic BP by age quartiles 
(p<0.001 for both). Based on JNC7 and JNC8 criteria, respectively, 2,228 and 
3,458 patients were normotensive (NT, 14.1% and 21.9%), 13,545 and 12,315 
hypertensive (HT, 85.9% and 78.1%), 11,150 and 11,150 treated HT (HT-tx, 
70.7% and 70.7%, i.e. 82.3% and 90.5% of HT), and 4,048 and 6,903 on-target 
HT-tx (HT-tx-target 25.7% and 43.8%, i.e. 36.3% and 61.9% of HT-tx). Then, 
the following six groups were compared: G1, NT by JNC7 (n. 2,228, 14.1%); 
G2, NT only by JNC8 (n. 1,230, 7.8%); G3, untreated HT (n. 1,165, 7.4%); 
G1-tx, on-target by JNC7 (n. 4,048, 25.7%), G2-tx, on-target only by JNC8 
(n. 2,855, 18.1%), G3-tx, not on-target (4,247, 26.9%). Prevalence values of 
any CVD and any coronary event were significantly higher in G1-tx (31.4% 
and 23.5%, respectively, p<0.001) than in G2-tx (27.6% and 19.6%) and G3-tx 
(26.3% and 16.1%), likely as an effect of reverse causality, i.e. a higher CVD 
risk prompted a stronger effort to reduce BP levels.
Conclusion: Achieving BP targets is easier with the JNC 8 criteria. However, 
it cannot be ruled out that a less aggressive approach might ultimately trans-
late into higher BP levels mainly in subjects at high CVD risk.
Clinical Trial Registration Number: NCT00715481
Supported by: Fo.Ri.SID, DEM, Eli-Lilly, Takeda, Chiesi, Boehringer-Ingelheim
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The regulation of Wnt signalling pathways by insulin and NEFAs  
in skeletal muscle and adipose tissue of healthy humans
M. Karczewska-Kupczewska1,2, A. Nikolajuk2, M. Stefanowicz1,  
N. Matulewicz1, M. Straczkowski1,2;  
1Department of Metabolic Diseases, Medical University of Bialystok, 
2Department of Prophylaxis of Metabolic Diseases, Institute of Animal 
Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, 
Poland.
Background and aims: The Wnt signaling plays an important role in em-
bryonic development, cell proliferation, cell cycle, differentiation, apoptosis 
and tissue homeostasis. The Wnt ligands bind to frizzled (Fzd) receptors and 
activate canonical (β-catenin dependent) and non-canonical (β-catenin in-
dependent) pathways. Dysregulation of Wnt signal transduction is associated 
with many pathophysiological states including metabolic disorders. The aim 
of the present study was to assess skeletal muscle and adipose tissue expres-
sion of genes associated with Wnt signaling pathways in young healthy popu-
lation, their regulation by hyperinsulinemia and serum NEFAs elevation and 
their relationship with insulin sensitivity.
Materials and methods: We studied 20 healthy male subjects (mean age 
25.20±3.15 years, mean BMI 26.47±4.64 kg/m2). The biopsies of vastus lat-
eralis muscle and subcutaneous adipose tissue were performed at baseline 
and after 6 hours of euglycemic hyperinsulinemic clamp with or without In-
tralipid/heparin infusion. The participants were divided into subgroups of 
high (high-IS) and low insulin sensitivity (low-IS).
Results: The muscle mRNA expression of β-catenin, Fzd coreceptor-LDL 
receptor-related protein 6 (Lrp6), Dishevelled 2 (Dsh2) and adipose tissue 
mRNA expression of Lrp6 were higher in low-IS, whereas adipose tissue mR-
NAof Dsh2 and glycogen synthase kinase 3β (GSK3β) were lower in low-IS 
(all p<0.05). Hyperinsulinemia resulted in a decrease in muscle and adipose 
tissue Lrp6, adipose tissue c-Myc and transcription factor 7 - like 2 (TCF7L2) 
expression and an increase in muscle and adipose tissue Dvl1/2/3 expres-
sion (all p<0.05). Intralipid/heparin infusion resulted in 4-fold increase in 
serum NEFAs (p<0.0001) and decrease in insulin sensitivity by approx. 40% 
(p<0.0001). Most of the described changes in Wnt signaling pathways disap-
peared after NEFAs elevation and adipose tissue c-Myc expression was even 
up-regulated by NEFAs (p=0.0005).
Conclusion: Our data indicate that Wnt canonical signaling is increased in 
insulin resistant subjects and insulin could inhibit β-catenin dependent path-
way and mediate switching between canonical and non-canonical pathways.
Supported by: Grant UDA-POIG.01.03.01-00-128/08; from the Program In-
novative Economy
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Ser312-phosphorylated fetuin-A: role in insulin action and insulin 
resistance
S.T. Mathews1, G. Ren1, X. He1, T. Kim1, C. Okerberg1, J. Papizan1,  
R. Bowers1, A. Mahurin1, F. Araya-Ramirez1, L. Littlefield1,2, P. Grandjean2,3;  
1Department of Nutrition, Auburn University,  
2Health and Human Performance, Baylor University, Waco,  
3Kinesiology, Auburn University, USA.
Background and aims: Fetuin-A, a hepatokine, inhibits insulin receptor ty-
rosine kinase and interferes with downstream insulin signaling, and glucose 
uptake. Elevated levels of fetuin-A has been shown to be correlated with in-
sulin resistance, obesity and type 2 diabetes. Fetuin-A exists in both phos-
phorylated and dephosphorylated forms in circulation. However, there are no 
reports on fetuin-A phosphorylation status in insulin resistant conditions or 
on its molecular characterization. The goal of this study was to characterize 
the role of fetuin-A phosphorylation on insulin signaling, and its association 
with obesity and insulin resistance.
Materials and methods: We generated Ser312Ala and Ser120Ala+Ser312Ala 
mutants to characterize effects of fetuin-A phosphorylation. Ser312-fetuin-A 
phosphorylation status was examined in diet-induced obese mice, ZDF rats, 
and obese individuals.
Results: While wild-type phosphorylated fetuin-A inhibited insulin sign-
aling (IR, AKT, and MAPK, GLUT4 translocation), glucose uptake, and 
glycogen synthesis, the single Ser312Ala-fetuin-A mutant and the double 
phospho-defective mutant (Ser312Ala+Ser120Ala) were without effect, in-
dicating that phosphorylation status of fetuin-A was critical to mediate its 
inhibitory effects on insulin action. We next examined phosphorylation sta-
tus of fetuin-A (Ser312) in animal models of obesity and insulin resistance. 
Serum Ser312phosphofetuin-A levels were significantly elevated in C57BL6 
diet-induced obese mice and 6 weeks-old ZDF rats, which was consistent 
with the observed hyperinsulinemia and increased HOMA-IR. Next, we ex-
amined total fetuin-A and Ser312-phosphorylated fetuin-A concentrations 
in 31 obese men and 11 age-matched normal weight individuals. While both 
serum fetuin-A and Ser312phosphofetuin-A levels were significantly elevated 
in obese individuals, only Ser312phosphofetuin-A was significantly correlat-
ed with serum insulin, HOMA, QUICKI and glucose-to-insulin ratio.
Conclusion: Our studies showing that that phosphorylation status of fetuin-
A is critical for its inhibitory effects on insulin action, and that serum Ser312-
phosphorylated fetuin-A concentrations are elevated in insulin resistant ani-
mals and humans, suggest that phosphorylated fetuin-A plays a key role in 
the modulation of insulin action.
Supported by: ADA, AAES
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Down-regulation of miR-22 and miR-26a independently induces insulin 
resistance in L6 myotubes
D.K. Andersen, B. Cobb, M.E. Cleasby;  
Royal Veterinary College, University of London, UK.
Background and aims: Insulin resistance (IR) in skeletal muscle invariably 
develops in advance of type 2 diabetes (T2D). MicroRNAs (miRNAs) are 
small non-coding RNAs that negatively regulate protein translation, via spe-
cific binding to the 3’UTRs of mRNAs. The involvement of miRNAs in nor-
mal and abnormal physiology is increasingly recognised. However, their role 
in the development of muscle IR is poorly characterised. We have previously 
shown the down-regulation of five miRNAs after 5 or 20 weeks of high-fat 
feeding of male Wistar rats: miR-22, miR-26a, miR-29a, miR-187 and miR-
126*. Here we interrogated miR-22 and miR-26a for roles in mediating mus-
cle insulin sensitivity.
Materials and methods: L6 myoblasts were cultured and differentiated into 
myotubes for study. Firstly, the effects of IR induced by long-term insulin 
treatment (HI, 10nM), palmitic acid (PA, 0.75mM), TNF-α (2ng/mL) or 
Dexamethasone (Dex, 2nM) on miRNA expression were investigated. Sub-
sequently, 100nM miR-22 or miR-26a miRNA inhibitor was transfected into 
myotubes on day 3 of differentiation and the effects on glucose uptake quanti-
fied using [H3]-2-deoxy-glucose tracer ± 100nM insulin. miRNA levels were 
quantified using probe-based Real-time PCR, normalising to small nucleolar 
RNA expression. TargetScan was used to predict targets of miR-22 that might 
impact upon insulin sensitivity and protein levels of these were quantified by 
western blotting. Data were analysed using Student’s paired t-test or Two-way 
ANOVA with Fisher’s LSD test post-hoc. Results are presented as percent-
ages of the control or basal treatment condition (n=3-4 independent experi-
ments).
Results: Interestingly, expression levels of both miR-22 and miR-26a in L6 
myotubes were reduced by HI (to 74%, p=0.047 and 68%, p=0.020 respec-
tively), but not by PA, TNF-α or Dex treatments, despite impairment in insu-
lin-stimulated glucose disposal. Specific miRNA inhibitor treatment reduced 
miR-22 and miR-26a expression to 45% p=0.0012 and 41% p=0.0002, respec-
tively. miR-22 inhibition abolished the effect of insulin to stimulate glucose 
uptake in L6 myotubes, reducing it from 144% of basal in control myotubes to 
98% in miR-22 silenced myotubes (Interaction p=0.04). miR-26a inhibition 
also abolished the effects of insulin stimulation on glucose uptake, although 
this was principally the result of a 29% increase in basal glucose disposal 
(Interaction p=0.0029). TargetScan-predicted targets of miR-22 included ca-
veolin-3, sirtuin-1, glucose transporter-1, phosphatase and tensin homolog 
(PTEN) and protein tyrosine phosphatase, non-receptor type 1. Western blot 
analysis to date of predicted targets has identified a trend towards increased 
caveolin-3 (160% p=0.11) after miR-22 silencing, but no effect on PTEN.
Conclusion: These data suggest that hyperinsulinaemia is the key component 
of the IR syndrome that drives down-regulation of the investigated miRNAs. 
Both miR-22 and miR-26a are shown to contribute to muscle IR through im-
pairment of insulin-stimulated glucose disposal. The mechanisms for the ef-
fects of miRNA inhibition are under investigation.
Supported by: Diabetes UK
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GLP-1 improves the reduction of glucose uptake through SIRT-1 in 
skeletal muscle cells under palmitate induced-insulin resistance
T. Kim1, J. Jeon2, E. Ha2, S.-E. Choi3, S.-Y. Ahn2, S. Han2, H. Kim2, D. Kim2, 
Y. Kang3, K.-W. Lee2;  
1Internal Medicine, Kwandong University, Gangneung,  
2Endocrinology and Metabolism, 3Institute of Medical Science,  
Ajou University School of Medicine, Suwon, Republic of Korea 
Background and aims: Insulin resistance is a major pathogenesis of type 2 
diabetes mellitus. Recently, the target molecules for diabetes treatment have 
been identified. Glucagon like peptide-1 (GLP-1) was developed as an anti-
diabetic agent and is known to have a potent glucose-dependent insulino-
tropic action on the pancreas as well as extrapancreatic actions. SIRT1, as an 
NAD-dependent deacetylase, has been demonstrated in the role of protecting 
ageing-related diseases and beneficial effects of metabolic homeostasis. We 
investigated whether the actions of GLP-1 were mediated by SIRT-1 activa-
tion in skeletal muscle cells under palmitate induced-insulin resistance.
Materials and methods: After confirming the action of GLP-1 to palmitate-
induced insulin resistance, we determined 2-[N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino]-2-deoxy-D-glucose (2-NDBG) uptake, GLUT4 mRNA, 
and the phosphorylation levels of protein related to insulin signal pathway 
(IRS-1, Akt) in human skeletal muscle myotubes (HSMM) exposed to pal-
mitate (200 μM, for 24 hours) and compared to those in HSMM exposed to 
palmitate and GLP-1 (200 nM) simultaneously. To elucidate whether SIRT-
1 contributed to GLP-1 action in the palmitate-induced insulin resistance, 
we compared the levels of proliferator-activated receptor-γ-co-activator 1α 
(PGC1α) deacetylation in HSMM exposed to palmitate and GLP-1 (200 ng/
ml) for 24 hours. Moreover, when exposed to SIRT1 inhibitor (EX527) in the 
same conditions, we demonstrated the changes of GLUT4 mRNA expression 
and insulin signaling.
Results: GLP-1 restored the reduction of glucose uptake, GLUT4 mRNA 
levels, and GLUT4 promoter activity by palmitate in human skeletal muscle 
myotubes. GLP-1 reduced acetylation of PGC1α in HSMMs over expressed 
PGC1α. This result suggested that GLP-1 activated a deacetylase, such as 
SIRT-1. SIRT1 inhibitor (EX527) suppressed GLUT4 mRNA expression 
by GLP-1 in HSMMs. SIRT1 inhibitor (EX527) prevented phosphoryla-
tion (IRS-1, Akt) of protein related to insulin signal pathways by GLP-1 in 
HSMMs. This suggested the expression of GLUT4 mRNA and the activation 
of insulin signaling by GLP-1 were associated with SIRT1.
Conclusion: Our data suggests GLP-1 improved palmitate-induced insulin 
resistance in HSMM by the activation of SIRT-1.
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Overexpression of the glucose transporter 1 in renal mesangial  
cells protects against cellular stress via Nrf2/NQO1
T. Fleming1, E. Schleicher2, H.-U. Häring2, P.P. Nawroth1;  
1Internal Medicine I and Clinical Chemistry, University of Heidelberg, 
Heidelberg, Germany,  
2Department of Internal Medicine, University of Tübingen, Germany.
Background and aims: Diabetic patients have been shown to be susceptible 
to the formation and accumulation of triose phosphates and the reactive me-
tabolite methylglyoxal (MG), formed by non-enzymatic degradation on these 
intermediates. These findings suggest that it is not the condition of hyper-
glycaemia, but how glucose is handled, which underlies the development of 
diabetic complications. In this project, this was addressed by characterizing 
rat mesangial cells which stably overexpress the glucose transporter-1 pro-
tein, the rate-limiting step for the movement of glucose into the cell. In such 
cells, glucose uptake and utilization is increased regardless of other regulator 
factors.
Materials and methods: The phenotype of rat mesangial cells over-express-
ing glucose transporter-1 (GLUT1) and the respective control cells, stably 
expressing lac operon (LacZ) were characterized with respect to growth and 
energy metabolism under basal condition (11mM glucose).
Results: It was found that despite a significantly higher glucose uptake, rat 
mesangial cells over-expressing glucose transporter-1 (GLUT1) had a re-
duced glycolytic rate. They also had reduced levels of metabolic cofactors 
and intermediates. They were also found to have significantly lower number 
of hyper-polarized mitochondria, suggestive of altered respiratory function. 
This was confirmed by the decreased rate of oxygen consumption. Mitochon-
drial superoxide production was shown to be decreased in the GLUT1 cells; 
however, generally oxidative stress within these cells was increased, sugges-
tive of increased cellular stress as a consequence of increased glucose uptake. 
Preliminary screening of antioxidant defence enzymes showed that NAD(P)
H dehydrogenase(quinone) 1 (NQO1), was significantly increased in terms 
of expression and activity as well as its regulator, Nrf2. The observed increase 
in antioxidant defences was confirmed by the increase in total antioxidant 
capacity, and increased tolerance to hydrogen peroxide and MG.
Conclusion: This data indicates that under conditions of high glucose uptake, 
antioxidant defences are increased to help protect the cell from the increased 
cellular stress The observed increases in defences system whilst protective are 
ultimately detrimental to the cell.
Supported by: DFG (BI-1281/3-1 & NA 138 /7-1), DZD/BMBF, Dietmar-
Hopp-Stiftung
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Extracellular vesicles released by hypoxic adipocytes impair insulin 
signalling and glucose uptake in adipocytes
S. Mora1, J. Mleczko1, J. Falcon-Perez2;  
1Cellular and Molecular Physiology, University of Liverpool, UK,  
2CIC BioGUNE, Bilbao, Spain.
Background and aims: Exosomes and microvesicles are extracellular vesicles 
(EVs) shed by many cell types that mediate cell to cell communication. EVs 
contain proteins and RNA species that modulate biochemical responses in 
target cells. Adipocytes have been shown to produce extracellular vesicles. 
During obesity adipocytes are subject to hypoxia. The aim of our study was 
to investigate whether EVs released by hypoxic adipocytes have autocrine ef-
fects in regulating insulin action and glucose uptake.
Materials and methods: We isolated EVs from the conditioned media of 
differentiated 3T3L1 adipocytes cultured under normoxia (control cells) or 
from cells exposed to hypoxia (1% O2) for 24hrs. EVs were purified from the 
culturing media using centrifugation techniques and characterized using bio-
physical and biochemical methods, including nanoparticle tracking analysis, 
cryoelectron microscopy, and immunoblotting techniques. EVs were then 
tested for their ability to modulate insulin action and insulin-stimulated glu-
cose uptake in 3T3L1 adipocytes. Independent sets of differentiated 3T3L1 
adipocytes were either left untreated or treated with EVs purified from con-
trol or hypoxic adipocytes for 24hr and subsequently their response to insulin 
stimulation was evaluated by western blotting and glucose uptake assays.
Results: We found that 3T3L1 adipocytes release EVs of heterogeneous sizes 
as determined by cryoelectron microscopy and nanoparticle tracking anal-
ysis. Hypoxia increased the release of EVs by adipocytes. Immunoblotting 
analysis showed that EV preparations were enriched in exosomal markers 
and markedly devoid of other organelle markers. Adipocytes treated with 
EVs obtained from hypoxic cells displayed a reduced insulin-mediated acti-
vation of glucose uptake compared to those left untreated or treated with EVs 
derived from control adipocytes. No differences in the expression levels of the 
glucose transporter Glut4 were observed in cells treated with EVs from hy-
poxic adipocytes compared to those left untreated or treated with EVs from 
control cells. However, cells treated with EVs released from hypoxic cells ex-
hibited reduced insulin-mediated activation of phosphatidylinositol 3-kinase 
as seen by a reduced phosphorylation of the downstream kinase AKT, with-
out alterations in the total AKT levels.
Conclusion: Our data suggest that EVs released by hypoxic adipocytes con-
tribute to insulin resistance, as they impair insulin signalling and glucose up-
take in adipose cells.
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Mechanism of increase in plasma intact GLP-1 by metformin in  
type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma 
DPP-4 activity?
T. Wu1, M.J. Bound1, C.F. Deacon2, K.L. Jones1, M. Horowitz1, C.K. Rayner1;  
1Discipline of Medicine, University of Adelaide, Australia,  
2Department of Biomedical Science, University of Copenhagen, Denmark.
Background and aims: Metformin increases plasma intact glucagon-like 
peptide-1 (GLP-1) concentrations. However, it remains uncertain whether 
this reflects an enhancement of GLP-1 secretion and/or a reduction in plasma 
dipeptidyl peptidase-4 (DPP-4) activity. We, therefore, evaluated the effects 
of metformin on plasma DPP-4 activity, and total and intact GLP-1 concen-
trations, before and during an intraduodenal (ID) glucose infusion in type 2 
diabetes.
Materials and methods: We retrospectively assayed plasma DPP-4 activity in 
12 Caucasian males with diet-controlled type 2 diabetes (HbA1c: 6.5 ± 0.1% 
(47.6 ± 1.4 mmol/mol); duration of known diabetes: 3.5 ± 0.9 years; age: 63.7 
± 1.9 years; BMI: 29.9 ± 1.2 kg/m2), treated with metformin 850 mg bd or pla-
cebo each for 7 days in a randomised crossover design, with 14 days ‘washout’ 
between. On days 5 or 8 of each treatment (6 patients each), subjects took 
their morning dose of metformin or placebo after an overnight fast, followed 
30 min later by an ID infusion of glucose (60 g over 120 min, ie. 2 kcal/min).
Results: Plasma fasting DPP-4 activity was less during metformin treatment 
than placebo (18.4 ± 1.6 vs. 20.5 ± 1.7 U/L, P = 0.014). During ID glucose 
infusion (t = 0-120 min), there was a slight reduction in plasma DPP-4 activ-
ity on both days (P < 0.001), without any difference between metformin and 
placebo. Both total and intact GLP-1 concentrations were greater after met-
formin than placebo (P = 0.014 and 0.006, respectively). During ID glucose 
infusion, the increment in intact GLP-1 (ie. difference in the areas under the 
curve (AUC)) after metformin versus placebo was directly related to the AUC 
for total GLP-1 (r = 0.61, P = 0.028), and tended to be inversely related to 
plasma DPP-4 activity (r = -0.48, P = 0.098).
Conclusion: The increase in plasma intact GLP-1 concentrations by met-
formin is, at least in part, attributable to stimulation of GLP-1 secretion - a 
reduction in soluble DPP-4 activity may also make a modest contribution.
Clinical Trial Registration Number: ACTRN12608000433303
Supported by: MSD funded investigator-initiated study
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Intestinal glucose uptake is modulated by metformin
J.B.L. Hoekstra, L. Bähler, K. Stroek, H. Verberne, F. Holleman;  
Academic Medical Center, Amsterdam, Netherlands.
Background and aims: Obesity is the result of an imbalance between en-
ergy intake and energy expenditure. Recently brown adipose tissue (BAT) 
has gained a lot of interest because of its capacity to convert calories into heat. 
BAT shows an intense 18F-Fluorodeoxyglucose-(FDG)-uptake on Positron-
Emission-Tomography-(PET)-CT scans. Physiological 18F-FDG accumula-
tion is also frequently observed in the intestine, however, the possibility of the 
intestine as an energy dissipating tissue has not yet been explored. Metformin 
is one of the few drugs in the treatment of diabetes mellitus(DM) that is as-
sociated with moderate weight loss. Interestingly, patients using metformin 
are known to have increased 18F-FDG-uptake in the colon. The aim of this 
study was to retrospectively assess determinants of 18F-FDG-uptake in the 
intestine in patients who underwent a primary diagnostic 18F-FDG-PET-CT 
scan.
Materials and methods: Consecutive 18F-FDG-PET-CT scans performed 
between January 1st and April 31st 2011 were analysed. 18F-FDG intestinal 
uptake was visually assessed using the 4-point scale described by Gontier et 
al. which uses liver uptake as a reference. (1; lower, 2; similar, 3; moderately 
higher than hepatic activity and 4; intense and diffuse uptake). Differences in 
continuous variables between the 4 grades were assessed using the Kruskal-
Wallis test. Differences in categorical variables between the 4 groups were 
assessed using the Fisher-Freeman-Halton exact test. All variables were used 
as covariate in a forward logistic regression model (e.g. grade 1 & 2 vs 3&4).
Results: Available for analysis were 270 18F-FDG-PET-CT scans of 270 pa-
tients. The majority of patients was female (51.9%) with a median age of 61 
[52-71] years, a BMI of 25.0[22.5-28.7] kg/m2. Approximately 20% of the 
subjects smoked (smoking >1 daily). Most patients had a grade 2 (44%) or 
grade 3 (39%) uptake of 18F-FDG in the intestines, far less subjects had a 
grade 1 (9%) or grade 4 (8%) uptake of 18F-FDG. There were no significant 
differences between the four grading groups with regard to age, sex, BMI or 
smoking status. Type 1 DM was observed in 2 % of the subjects and 37% of 
the patients had type 2 DM. Of the DM patients, 87.2% used insulin, 87.2% 
used metformin and 82.1% used sulfonylurea derivatives (SU). There was a 
positive trend over the 4 grades for the use of insulin, SU and metformin 
but also for diuretic use. The use of insulin (p<0.05), SU (p<0.001), met-
formin (p<0.001) and diuretics (p<0.05) was significantly higher in grade 
4 than grade 1. In a logistic regression analysis, use of metformin was the 
only significant predictor for high (e.g. grade 3 or 4 versus grade 1 or 2) 18F-
FDG-uptake in all segments of the intestine, with an odds ratio(OR) of 12.4 
(correlation coefficient(CC) 2.5, 95%CI 2.8-55.5). However, increased 18F-
FDG-uptake in the descendens alone was associated with both metformin 
with an OR of 17.0 (CC 2.8, 95%CI 5.1-57.4) and anti-inflammatory drugs 
with an OR of 3.6 (CC 1.2, 95%CI 1.1-11.9)
Conclusion: Metformin use is associated with increased intestinal 18F-FDG-
uptake, suggesting a potential role for increasing intestinal energy expendi-
ture.
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Metformin enhances intestinal glucose uptake in patients with  
type 2 diabetes
J.P. Koffert1, H. Honka1, K.A. Virtanen1, S. Kauhanen2, P. Iozzo3,  
R. Parkkola4, P. Nuutila1,5;  
1Turku PET Centre, 2Division of Digestive Surgery and Urology, Turku 
University Hospital, Finland, 3Institute of Clinical Physiology, National 
Research Council, Pisa, Italy, 4Department of Radiology, University of 
Tampere, 5Department of Endocrinology, Turku University Hospital, 
Finland.
Background and aims: The intestine is emerging as a key organ in the patho-
genesis of type 2 diabetes. This study’s objective was to determine the effects 
of metformin and rosiglitazone on intestinal glucose uptake in patients with 
type 2 diabetes.
Materials and methods: Forty-one patients with newly diagnosed type 2 
diabetes were randomized for treatment with metformin (1 g, b.i.d), rosigl-
itazone (4 mg, b.i.d), or placebo in a 26-week double-blind trial. Positron 
emission tomography (PET) is a key tool for the assessment of intestinal 
metabolism. Insulin stimulated glucose uptake in small intestine, caecum, 
and skeletal muscle was measured before and after treatment using [18F]-
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flurodeoxyglucose (FDG) PET during euglycemic hyperinsulinemic clamp. 
Magnetic resonance imaging (MRI) was used as an anatomical reference.
Results: Both active treatments improved glycemic control (p<0.01 vs. pla-
cebo). Rosiglitazone improved glucose uptake by 44% in the whole body 
(p<0.05) and by 38% in skeletal muscle (p<0.01, in both groups), while no 
changes were observed in the metformin group as previously reported (Dia-
betes 2002). In pooled data small bowel and caecal GU were associated with 
fGluc (r=-0.52, p=0.001; r=-0.43, p=0.01) and HbA1c (r=-0.40, p<0.02; r=-
0.46, p=0.005). Glucose uptake was increased 2-fold in the metformin group 
in small intestine (2.0 ± 0.7 vs. 4.3 ± 1.6 μmol [100 g](-1) min(-1), p<0.0001) 
and by 3.7-fold in caecum (1.6 ± 0.8 vs. 5.0 ± 1.9 μmol [100 g](-1) min(-1), 
p<0.0001). A significant but minor increase in the rosiglitazone group oc-
curred in the small intestine (2.3 ± 0.6 vs. 2.8 ± 0.8 μmol [100 g](-1) min(-1), 
p<0.03) and this increment was associated with M-value (r=0.67, p<0.02). No 
changes in intestinal glucose metabolism were observed in the placebo group.
Conclusion: This is study shows that metformin enhances glucose metabo-
lism both in the small intestine and the large intestine in patients with newly 
diagnosed type 2 diabetes. This effect is not related to enhanced insulin sen-
sitivity but associates with improved glycemic control.
Supported by: Academy of Finland, Finnish Diabetes Foundation, a grant of 
GlaxoSmithKline
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Tissue hypoxic condition, not metformin, induces lactic acidosis in 
patient type 2 diabetes
S. Hwang, E. Lee, Y.-H. Lee, B.-W. Lee, E. Kang, B. Cha, H. Lee;  
Internal Medicine, Yonsei University College of Medicine, Seoul,  
Republic of Korea 
Background and aims: Metformin is recommended as the first drug in type 
2 diabetic patients and has been shown to reduce diabetic-related complica-
tions and mortality. However, the use of metformin is limited by a concern 
of lactic acidosis (LA), especially in patients with renal failure. Therefore, we 
investigated the lactic acidosis and its relationship with metformin use in pa-
tients with type 2 diabetes.
Materials and methods: A total of 1,954 patients with type 2 diabetes were 
recruited from 2007 to 2011. They were analyzed according to the estimated 
glomerular filtration rate (eGFR) of 60 mL/min/1.72m2. LA was defined as 
serum lactate levels more than 5 mmol/l and arterial pH less than 7.35.
Results: According to the metformin use, there were no differences in serum 
lactate levels in patients with type 2 diabetes. In addition, serum lactate levels 
were not correlated with metformin dose (P = 0.350). These results were com-
parable in patients with eGFR < 60 mL/min/1.72m2. Overall, the prevalence 
of hyperlactinemia and LA were 18.8% and 3.0%, respectively. In subgroup 
analysis, they showed similar results regardless of metformin use. All patients 
with LA had at least one condition related to hypoxia or poor tissue perfusion 
such as myocardial infarction, septic shock, advanced cirrhosis and bleeding. 
On multiple regression analysis, metformin did not affect the development 
of lactic acidosis. Meanwhile, the tissue hypoxic condition was an independ-
ent risk factor for the development of lactic acidosis (odds ratio: 4.437, 95% 
confidence interval: 1.277-15.425).
Conclusion: In conclusion, tissue hypoxic condition was the one of the most 
attributable factors for the development of lactic acidosis in patients with type 
2 diabetes. The metformin use may not be the cause of lactic acidosis, but 
rather a coincidence in patients with type 2 diabetes.
OP 38 Novelties in risk prediction
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How can we best predict cardiovascular disease risk in type 1 diabetes?  
A comparison of risk equations
R. Saunders1, K. Boye2, J. Bae2, K. Norrbacka3, L. Timlin4, R. Pollock1,  
W. Valentine1;  
1Ossian Health Economics, Basel, Switzerland, 2Eli Lilly and Company, 
Indianapolis, USA, 3Eli Lilly and Company, Helsinki, Finland,  
4Eli Lilly and Company, Windlesham, UK.
Background and aims: Patients with type 1 diabetes (T1D) are at increased 
risk of developing cardiovascular disease (CVD) compared with the general 
population. In this study, the generalizability of CVD prediction models for 
patients with T1D, as well as a model averaging approach, is evaluated.
Materials and methods: Literature review identified two models of CVD risk 
and three clinical studies in patients with T1D that could be used to derive 
de novo formulae for estimating CVD risk. The five models of CVD were 
derived from the: EuroDiab study (EDS), FinnDiane Registry (FDR), Lung 
model (LM, based on Diabetes Control and Complications Trial [DCCT] 
data), Swedish National Diabetes Registry (SNDR), and Wisconsin Epide-
miologic Study of Diabetic Retinopathy study (WESDR). Two additional 
models were developed via model averaging. The first used the mean event 
probability over all models to define the patient’s risk of CVD. The second ap-
plied a weight, calculated as the sum of log ratios of six cohort characteristics, 
to each model. Prediction performance was evaluated between models and 
against first incident CVD in the DCCT, defined as myocardial infarction 
(MI), stroke or unstable angina. Two algorithms, FDR and LM, only estimat-
ed risk of MI and stroke. Goodness of fit was assessed using the Chi squared 
test. A successful prediction was defined as ≥ 60% likelihood (p ≥ 0.6) that 
the two distributions (model versus actual) were not significantly different.
Results: Comparing the predictive performance of the three models that es-
timated all three CVD endpoints, CVD events in the DCCT were success-
fully predicted by each model, although generally SNDR overestimated and 
EDS underestimated risk (Figure). WESDR (p = 0.99) most closely matched 
outcomes in the DCCT. Both model averaging approaches (unweighted and 
weighted) made successful predictions (both p = 0.99). Inter model compari-
son showed that no individual model could successfully predict outcomes in 
more than two of the other datasets. The unweighted model average did not 
aid prediction performance, however, the weighted model made successful 
predictions in all patient populations: SNDR (p = 0.99), EDS (p = 0.6), FDR 
(p = 0.6), WESDR (p = 0.99), LM (p = 0.99) and DCCT (p = 0.99).
Conclusion: A model averaging approach weighted to baseline patient char-
acteristics was the only model to provide a successful prediction in all six 
test cases. By evaluating multiple risk factors, model averaging may have ad-
vantages over traditional approaches to estimating CVD risk in patients with 
T1D.
Supported by: Eli Lilly and Company, USA
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Occurrence of clinical remission in adult-onset type 1 diabetes is 
associated with decreased risk of microvascular complications
P. Niedzwiecki, S. Pilacinski, A. Adamska, D. Zozulinska-Ziolkiewicz;  
Clinic of Internal Medicine and Diabetology, Poznan University of Medical 
Sciences, Poland.
Background and aims: Partial clinical remission is common in the initial 
course of type 1 diabetes. In this phase of disease substantial insulin secretion 
contributes to good metabolic control and low incidence of acute complica-
tions. The aim of the study was to determine the association between pres-
ence of partial remission and occurrence of chronic complications of type 1 
diabetes.
Materials and methods: 240 consecutive patients (77 women, 143 men), 
aged 26 (IQR: 22-31) hospitalized with newly diagnosed type 1 diabetes in 
the Department of Internal Medicine and Diabetology in 2004-2007 were 
asked to participate. Of these, 220 were included in the study. 133 of patients 
completed prospective follow-up. Finally, data of 81 patients (24 women, 57 
men), aged 33 (IQR 29-38) were included into endpoint analysis. Clinical 
remission was defined as time in which all of the following criteria were met: 
HbA1c below 6.5 % , dose of exogenous insulin below 0.3 U / kg body weight 
and serum C-peptide concentration above 0.5 ng / ml. Patients were divided 
into those who were in remission at any time during follow-up (remitters) 
and non-remitters. At 7 years of follow-up occurrence of chronic microvas-
cular complications of diabetes (retinopathy, diabetic kidney disease and 
neuropathy) was evaluated.
Results: In non-remitters group higher incidence of at least one microvascu-
lar complication (46.4 vs. 7.6 %, p < 0.0001), higher incidence of retinopathy 
(42.8 vs. 5.7 %, p < 0.0001), and neuropathy (21.4 vs 1.9 %, p = 0.006) was 
found. In univariate logistic regression, significant association was found 
between absence of remission and occurrence of at least one microvascular 
complication (OR: 10.6, 95% CI : 2.94-38.22, p = 0.002). In the Cox propor-
tional hazards regression model that included clinically significant param-
eters at diagnosis (presence of ketoacidosis, cigarette smoking and HbA1c 
value) as covariates, absence of remission was associated with occurrence of 
chronic complications of diabetes at 7 years [HR: 3.65 (95% CI 1.23-4.56), 
p=0.04].
Conclusion: Occurrence of clinical remission of diabetes is associated with 
reduced risk of chronic microvascular complications at 7-year follow-up.
Supported by: The Polish Diabetes Association
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Proinsulin in early atherosclerosis: causal factor or bystander?
R.J. Strawbridge1, A. Silveira1, P. Gustafsson1, K. Gertow1, D. Baldassarre2,3, 
F. Veglia3, S. Humphries4, U. de Faire5, E. Tremoli2,3, A. Hamsten1,  
the IMPROVE study group;  
1Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 
2Dipartimento di Scienze Farmacologiche e Biomolecolari, Universita di 
Milano, 3IRCCS Centro Cardiologico Monzino, Milan, Italy, 4Centre for 
Cardiovascular Genetics, University College London, UK, 5Department of 
Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Background and aims: Increased proinsulin levels (relative to insulin levels) 
have been demonstrated to predict future incidence of both Type 2 Diabetes 
(T2D) and cardiovascular disease (CVD), independently of classical risk fac-
tors, although the mechanisms of these relationships are poorly understood. 
A genome-wide association meta-analysis study conducted by the MAGIC 
consortium, and including this group, has identified a number of loci and 
genetic variants associated with increased circulating proinsulin levels. This 
project aims to determine whether proinsulin and/or proinsulin-associated 
pathways play a causal role in determining severity and rate of progression of 
early, subclinical atherosclerosis.
Materials and methods: The IMPROVE study (consisting of 3711 subjects, 
of whom 917 are T2D subjects) without clinical signs of CVD at enrolment, 
who have been carefully phenotyped and monitored with repeated state-
of-the-art high-resolution carotid ultrasound examinations. Biochemical 
phenotyping includes measurement (by Elisa) of circulating insulin and pro-
insulin levels. All subjects have been genotyped on the Illumina CardioMe-
tabo200K platform, providing good coverage of 5 of the 9 loci associated with 
proinsulin levels. Additional genotyping to cover the remaining 4 loci has 
been performed. Standard statistical methods and a Mendelian randomisa-
tion approach will be used to examine the influence and causality of proinsu-
lin on early atherosclerosis.
Results: Proinsulin levels demonstrated associations with progression of (but 
not baseline) carotid intima media thickness (cIMT). In contrast, proinsulin-
associated genetic variants influenced baseline but not progression cIMT 
measures, independently of established CVD risk factors and proinsulin lev-
els. Novel associations between a) novel genetic variants and proinsulin and 
b) proinsulin-associated SNPs and cIMT have been observed, however these 
require replication.
Conclusion: Proinsulin does not appear to be a causal factor in early sub-
clinical atheroscelerosis, however proinsulin-associated mechanisms are im-
plicated.
Supported by: the European Commission and the European Union Framework 
Programme 7
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Risk of cardiovascular disease events: the impact of diabetes  
and anti-diabetic drugs: a nested case-control study
M. Gejl1,2, J. Starup-Linde2, J. Scheel-Thomsen3, J. Rungby4, S. Gregersen2,  
P. Vestergaard5;  
1Department of Biomedicine – Pharmacology, Aarhus University, 
2Department of Endocrinology and Internal Medicine (MEA), Aarhus 
University Hospital, 3Department of Neurology, Aalborg University 
Hospital, Aalborg, 4Diabetes Research Division, Dept. of Medicine, 
Copenhagen University Hospital Gentofte, Copenhagen,  
5Department of Clinical Medicine and Endocrinology, Aalborg University 
Hospital, Denmark.
Background and aims: Diabetes Mellitus (DM) is associated with an in-
creased risk of cardiovascular disease. We investigated the effects of antidia-
betic drugs on the composite endpoint (CE) of ischemic heart disease, heart 
failure and stroke incidence in patients with DM.
Materials and methods: We conducted a nested case-control study. Cases 
were patients with type 1 or type 2 DM who subsequently suffered from CE; 
controls were DM patients with no history of CE after DM diagnosis. Using 
the Danish National Hospital Discharge Register, we included DM patients 
with information on date of DM diagnosis, date of CE, and comorbidities. 
From the Central Region of Jutland, Denmark, medication use and bio-
chemical parameters (LDL, HDL, total cholesterol, triglyceride, HbA1c, and 
creatinine) were collected. Logistic regression analyses were conducted. The 
analyses were mutually adjusted for comorbidities, pharmaceutical use, and 
the biochemical parameters.
Results: The data included 14,454 patients with DM who contributed a to-
tal of 115,225 person-years. 14.8 percent (2,257) suffered from a subsequent 
CE. CE prior to DM diagnosis (OR= 14.83, 95%CI: 12.63-17.41), atrial fi-
brillation (OR= 1.99, 95%CI: 1.57-2.51), and age at diabetes diagnosis (OR= 
1.01, 95%CI: 1.007-1.014) all significantly increased the risk of subsequent 
CE. Patients with type 2 DM had a higher risk compared to type 1 DM pa-
tients (OR= 3.05, 95%CI: 2.57-3.63). The diabetes complications retinopathy 
(OR= 1.70, 95%CI: 1.30-2.23), nephropathy (OR= 1.58, 95%CI: 1.28-1.95), 
neuropathy (OR= 1.99, 95%CI: 1.57-2.53) and peripheral artery disease 
(OR= 2.06, 95%CI: 1.68-2.56) increased the risk of CE so did male gender 
(OR= 1.12, 95%CI: 1.00-1.25), and hypertension (OR= 1.39, 95%CI: 1.20-
1.62). Treatment with statins reduced the risk of CE significantly (OR= 0.65, 
95%CI: 0.57-0.73) when looking at the DM group as a whole, when grouped 
only significant in subjects with type 2 DM (OR= 0.59, 95%CI: 0.51-0.67). 
Biguanides (OR= 0.54 95% CI; 0.44-0.67) and liraglutide (OR= 0.41 95% CI; 
0.32-0.52) (type 2 DM) both significantly decreased the risk of CE. DPP-4 
inhibitors and β-cell stimulating agents had a neutral effect. In the subgroup 
analysis, a total of 1,351 DM patients (10,229 person-years), had information 
on biochemical values and were included. 14.9 percent (201) suffered from 
a subsequent CE. When results were adjusted for biochemistry, liraglutide 
(OR= 0.25, 95%CI: 0.11-0.56) was the only antidiabetic drug that retained a 
significant reduction on the risk of CE.
Conclusion: We have shown an association between use of biguanides and 
liraglutide and a reduced risk of CE in patients with type 2 DM. The effect 
of liraglutide was not tied to patient biochemical values, e.g. cholesterol or 
glucose-control (HbA1c).
Supported by: Novo Nordisk 
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Activation of oestrogen receptor alpha in macrophages controls high-fat 
diet-induced inflammation of adipose tissue and prevents obesity and 
glucose intolerance
E. Riant1, S. Handgraaf1, A. Zakaroff1, D. Teixeira2, R. Burcelin1, J.-F. Arnal1, 
A. Bouloumié1, P. Gourdy1,3;  
1Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, 
Toulouse, France, 2Department of Biochemistry, Faculty of Medecine, Porto, 
Portugal, 3Diabetology Department, Toulouse, France.
Background and aims: Estrogens have been recognized as key regulators of 
body composition and glucose homeostasis. However, although both clinical 
and experimental data clearly evidenced the crucial role of estrogen receptor 
alpha (ERa), the mechanisms involved in the protective actions of estrogens 
against obesity and diabetes remain obscure. For instance, although estrogens 
are known to modulate inflammatory responses through ERa dependent ef-
fects, it is still uncertain wether specific actions of these sex steroid hormones 
on the stroma-vascular fraction (SVF) of adipose tissue could contribute to 
their benefits on body composition and glucose metabolism. In the present 
study, we aimed to determine 1) the influence of estrogens on the adaptation 
of SVF cells in response to a nutritional stress; 2) the contribution of ERa-
expressing myeloid cells to the prevention of obesity by estrogens.
Materials and methods: In a first set of experiment, 3 groups of C57Bl/6 
female mice were subjected to a chow or a high-fat (HFD) diet for 12 weeks: 
ovariectomized (estrogen deficiency), sham-operated (endogenous estro-
gens) and ovariectomized treated with 17b-estradiol (E2, 80µg/kg/d, sc). 
Weight gain, body composition and glucose tolerance were monitored and 
both isolated adipocytes and SVF from visceral adipose tissue (VAT) were 
analyzed by flow cytometry and RT-qPCR. Then, metabolic phenotype and 
SVF characteristics were studied in HFD-fed mice with specific invalidation 
of ERa in myeloid cells (ERa-LysM-Cre+ mice).
Results: Both endogenous estrogens and E2 administration prevented HFD-
induced obesity and glucose intolerance, as well as adipocyte hypertrophy. 
HFD increased the number of CD45- cells in VAT SVF, irrespective of es-
trogen status, but VAT infiltration by immune cells (CD45+) was strongly 
reduced by endogenous estrogens and E2, with a significant decrease in 
macrophage content (-65% CD45+/F4/80+ cells) and a predominance of 
M2 macrophages, as confirmed by mRNA analysis (+13-fold Ym1; -4.5-fold 
iNOS in E2-treated as compared to ovariectomized mice). VAT infiltration 
by B and TCD4+ and TCD8+ lymphocytes was also reduced by estrogens, 
but the pool of regulatory T cells was preserved. Demonstrating the role of 
ERa-LysM-Cre+ mice were characterized by a significant increase of HFD-
induced inflammation of VAT and developed exacerbated adiposity and glu-
cose intolerance.
Conclusion: These data demonstrate that estrogens limit HFD-induced in-
flammation of VAT and suggest that macrophages of the SVF largely con-
tribute to their protective action against obesity and though the activation 
of ERa.
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Heme oxygenase-1 drives metaflammation and insulin resistance in 
mouse and man
A. Jais1, E. Einwallner1, O. Sharif2, M. Bilban1, C. Duvigneau3, C. Lumeng4, 
W. Patsch5, O. Wagner1, J.A. Pospisilik6, H. Esterbauer1;  
1Department of Laboratory Medicine, Medical University of Vienna, 
2Dept. of Medicine 1, Laboratory of Infection Biology, Medical University 
of Vienna, 3Institute of Medical Biochemistry, University of Veterinary 
Medicine, Vienna, Austria, 4University of Michigan, Ann Arbor, USA, 
5Paracelsus Medical University, Salzburg, Austria, 6MPI for Max Planck 
Institute of Immunobiology and Epigenetics & Epigenetics, Freiburg, 
Germany.
Background and aims: Obesity and diabetes affect more than half a billion 
individuals worldwide. Interestingly, the two conditions do not always co-
incide and the molecular determinants of ‘healthy’ versus ‘unhealthy’ obe-
sity remain ill-defined. Chronic metabolic inflammation (metaflammation) 
is believed to be pivotal. Here, we tested a hypothesized anti-inflammatory 
role for heme oxygenase-1 (HO-1) in the development of human and mouse 
metabolic disease. Heme oxygenases catalyze the oxidative degradation of 
heme, a potentially harmful pro-oxidant, into biologically active products: 
biliverdin IXα, carbon monoxide(CO) and ferrous iron. In addition to its role 
in heme catabolism, HO-1 plays important roles in various pathophysiologi-
cal states associated with cellular stress.
Materials and methods: To address the metabolic role of HO-1 in vivo in 
macrophages, we have generated a myeloid-cell specific conditional HO-1 
knockout mouse model (‘MacHO’) and examined the role of HO-1 in the 
development of obesity-associated adipose tissue inflammation and insulin 
resistance. We fed either low-fat (10% calories derived from fat) or high-fat 
(60% of calories derived from fat) diets to male MacHO and littermate con-
trol mice for a total of 21 weeks.
Results: A significant difference in body-weight between the high fat diet 
groups was observed after 8 weeks of HFD feeding. Both insulin sensitivity 
and glucose tolerance were improved in MacHO mice fed the HFD compared 
with littermate control mice. Similarly, obese MacHO mice showed signifi-
cantly higher insulin sensitivity as measured by insulin tolerance test when 
compared to HFD-fed control-mice, whereas insulin sensitivity was com-
parable between both groups on control diet. Histological analysis of HFD 
WAT sections showed a higher density of smaller adipocytes and a signifi-
cant reduction in macrophage cell numbers, especially of the Cd11c+ pro-
inflammatory macrophage subpopulation. Furthermore, we found that mice 
lacking myeloid Hmox1 exhibited a strong reduction in hepatic accumula-
tion of triglycerides and cholesterol. Histological analysis showed decreased 
vacuole formation and a reduced number of lipid droplets, consistent with 
amelioration of hepatic steatosis. In line, in highly matched biopsies from 
‘healthy’ versus insulin resistant obese subjects we find HO-1 to be amongst 
the strongest positive predictors of metabolic disease in humans.
Conclusion: Intriguingly, cellular assays show that HO-1 is defining pre-
stimulation thresholds for inflammatory skewing and NF-kB amplification 
in macrophages. These findings identify HO-1 inhibition as a potential thera-
peutic strategy for metabolic disease.
Supported by: WWTF, MPG, ÖDG, FWF
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Adipose stem cells contribute to inflammation and insulin resistance 
through both TH-17 polarisation and increased pro-inflammatory 
cytokine secretion 
A. Eljaafari1,2, M. Robert1,3, B. Osta4, M. Chehimi1, C. Durand1, S. Chanon1, 
E. Lefai1, H. Vidal1, L. Pirola1;  
1Unité 1060-Carmen, INSERM, Pierre Benite, France, 2Recherche Clinique, 
Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, 
3Gastro-Enterology Surgery, 4Unité Immunogénomique et Inflammation, 
EA4130, Hopital E. Herriot, Lyon, France.
Background and aims: In obesity, white adipose tissue (WAT)-infiltrating 
immune cells induce a state of low grade inflammation. Among those cells, 
Th-17 cells have been identified as contributors of WAT inflammation. How-
ever, the mechanisms by which Th-17 are activated remain to be elucidated. 
Therefore, to gain further insight into the inflammatory processes taking 
place into WAT during obesity, we investigated whether adipose tissue-de-
rived stem cells (ASC) could promote Th-17 cell activation.
Materials and methods: Human ASC were isolated from the stromal vas-
cular fraction of residual WAT obtained during supra-mesocolic abdominal 
surgical procedures. Mononuclear cells (MNC) were prepared from blood 
donors, or from three surgical patients, as autologous controls. Co-cultures 
were performed with MNC and graded doses of ASC. Phyto-hemagglutinin 
A (PHA) was used for MNC stimulation. Cytokine secretion and mRNA 
expression were measured by ELISA and quantitative PCR, respectively. 
Binding of STAT3 and STAT5 on the IL-17 genomic locus was measured by 
chromatin immunoprecipitation (ChIP) in co-cultured cells. Finally, adi-
pogenesis was induced in the presence or absence of conditioning medium 
collected from ASC-MNC co-cultures. Insulin-sensitivity and adipocyte dif-
ferentiation were measured through AKT phosphorylation, and expression 
of mRNA markers, respectively.
Results: Co-cultures of ASC and PHA-activated MNC resulted in a dose-
dependent increase of IL-17A secretion (p<0.0001, at the highest ASC: MNC 
ratio, as compared with no ASC), and in an increase of IL-1b and IL-6 secre-
tion. In contrast, TNFa and IL-2 decreased (p=0.0003, and 0.0116, respec-
tively), suggesting polarization towards the Th-17 lineage, and reduction 
of the Th-1 cell subset. ASC induced an increase of STAT3 binding on the 
IL-17 locus, as measured by ChIP. Physical contact between ASC and MNC 
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played an important role in ASC-mediated enhancement of IL-17A produc-
tion, as co-cultures in transwell systems drastically decreased IL-17A produc-
tion (p<0.01). Finally, when conditioning medium of co-cultured cells was 
added to fresh ASC during their differentiation into adipocytes, a reduction 
in insulin-mediated AKT phosphorylation was observed, together with a po-
tent inhibition of adipogenesis, as assessed by decreased mRNA expression of 
FABP-4, adiponectin and PPARγ.
Conclusion: Our data demonstrate that in response to physical interaction 
between ASC and MNC, ASC mediate (i) polarization of T cells towards the 
Th-17 pathway, and (ii) enhancement of IL-1b and IL-6 secretion. Further-
more, such ASC-mediated cytokine secretion impairs ASC adipogenic capac-
ity and adipocyte insulin sensitivity. Thus, our data suggest that ASC from 
WAT might contribute to the initiation of low-grade chronic inflammation in 
obese patients through increased secretion of IL-17A and pro-inflammatory 
cytokines, which may in turn inhibit adipocyte differentiation.
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Interleukin-15 signalling promotes high fat diet-induced inflammation 
in the liver
S. Ilangumaran, Y. Cepero-Donates, G. Lacraz, M. Mayhue, S. Ramanathan; 
Pediatrics, Immunology division, Université de Sherbrooke, Canada.
Background and aims: Interleukin-15 (IL-15) is essential for the homeostasis 
of lymphoid cells particularly memory CD8 T cells and NK cells. These cells 
are abundant in the liver, and are implicated in obesity-associated pathogenic 
processes. Our recent findings show that IL-15 knockout mice are resistant 
to high fat diet-induced obesity. IL-15 is unique among the common gamma 
chain receptor family of cytokines in that it needs to be trans-presented by the 
IL-15 receptor alpha chain (IL-15Ra). The goal of this study is to characterize 
obesity-associated metabolic and cellular changes in the liver of mice lacking 
IL-15 or IL-15Ra.
Materials and methods: Wildtype, IL-15 knockout (IL15-KO) and IL-15Ra 
KO (IL15Ra-KO) mice in C57BL/6 genetic background were maintained on 
high fat diet (HFD) or normal control diet. After 16 weeks, liver mass, fat 
accumulation in the liver, serum lipid levels and gene expression in the liver 
were evaluated. Primary hepatocytes were stimulated with IL-15, and signal-
ling and gene expression were studied. Intrahepatic lymphocytes (IHL) were 
examined in WT, IL15-KO and IL15Ra-KO mice, as well as in hepatocyte-
specific IL15Ra-KO mice by flow cytometry.
Results: Diet-increase in liver weight and accumulation of lipids in the liver 
are prevented by IL-15 or IL-15Ra deficiency. IL-15 deficiency does not af-
fect diet-induced expression of enzymes involved in beta-oxidation of lipids 
in the liver. However, the liver tissues of IL15-KO and IL15Ra-KO mice 
showed decreased expression of TNFa and iNOS, chemokines CCl2, CCL5 
and CXCL10, and macrophage markers CD68 and F4/80. IL-15 stimulation 
induced chemokine gene expression in wildtype and IL15-KO hepatocytes, 
but not in IL15Ra-KO hepatocytes. High fat diet enhances the number of 
CD4, CD8, NK and NKT cells infiltrating the liver. The NK and NKT subsets 
in intrahepatic lymphocytes are severely reduced in mice lacking IL-15Ra.
Conclusion: High fat diet-induced lipid accumulation in the liver is medi-
ated, at least partly, by IL-15. High fat diet induces IL-15 gene expression 
in the liver and this is associated with increased inflammatory response. IL-
15 induces chemokine gene expression in hepatocytes that may account for 
increased intrahepatic lymphocytes. Overall, our findings support the idea 
that increased availability of IL-15 in obesity may stimulate hepatocytes to 
promote inflammation in the liver, leading to fatty liver disease.
Supported by: CIHR, CMDO
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Functional genomics identifies tnfaip3/A20 as a diabetes protective gene
N.W. Zammit1, E.K. Malle1, S.N. Walters1, C.C. Goodnow2, S.T. Grey1;  
1Garvan Institute, Darlinghurst, 2John Curtin School of Medical Research, 
Canberra, Australia.
Background and aims: Single-nucleotide polymorphisms (SNPs) within 
tnfaip3 (also known as A20) associate with susceptibility to type 1 diabe-
tes and complications in type 2 diabetes. How polymorphisms within the 
tnfaip3/A20 locus contribute to disease at the islet level is not understood.
Materials and methods: In a genome-wide N-ethyl-N-nitrosourea (ENU) 
mutagenesis screen of C57BL/6 mice we identified a mouse line harbour-
ing a non-synonymous amino-acid change, at an evolutionary conserved 
isoleucine. The T>A mutation substituted asparagine at residue 325 in place 
of isoleucine (A20I325N) that lies in a highly conserved beta-hairpin loop in 
A20s ovarian tumour (OTU) domain, away from the C103 catalytic residue. 
Despite the presence of increased circulating granulocytes and CD44high T-
cells, adult mice appear grossly normal and healthy; we therefore tested the 
effect of the mutation on islet biology.
Results: Here we demonstrate that pancreatic islets harbouring the A20I325N 
mutation to exhibit cell-intrinsic increased susceptibility to inflammatory 
triggers, with loss of metabolic function. When challenged with mild inflam-
matory stress by syngeneic transplantation of A20I325N islets into wildtype 
(WT) hosts, A20I325N islet grafts showed an abnormal production of inflam-
matory factors (e.g. CXCl10, CXCL1) with significant neutrophil infiltra-
tion. Furthermore, mutant islets exhibited severe glucose intolerance in an 
i.p.GTT, and an i.v.GTT revealed that beta-cell function was impaired. When 
directly challenged with an immunological insult in the form of allogeneic 
transplantation, A20I325N islets were hyper-inflammatory and more rapidly 
destroyed than WT allogeneic islets. Immunoblot analysis of cells harbor-
ing the A20I325N mutation show exaggerated poly-ubiquitination of RIP1 with 
exacerbated NF-κB and JNK/AP-1 signaling following TNF-stimulation. In-
vitro transfection studies using NF-κB and AP-1 luciferase reporter plasmids 
show WT A20 to inhibit luciferase production at the promoter level. Thus, 
A20 is critical for controlling NF-κB but also JNK activation; and loss of OTU 
function results in tissue hypersensitivity to inflammatory triggers and meta-
bolic impairment. Ectopic expression of WT A20 in A20I325N islets restored 
control of NF-κB and JNK/AP1 pathways and rescued A20I325N islets from 
hyper-inflammation. Whole body A20I325N mutant mice show normal glucose 
homeostasis, however, in a diet induced obesity model (45 kcal % fat), mice 
homozygous for the point mutation (A20I325N/I325N) develop more severe glu-
cose intolerance, compared to littermate controls and mice heterozygous for 
the point mutation (A20I325N/+). However, when A20I325N/+ mice are subjected 
to a low-dose lipopolysaccharide (LPS; i.p.) challenge, they also developed 
marked glucose intolerance compared to littermate WT controls. Further-
more, glucose intolerance was coupled with islet-specific immune infiltration 
of the pancreas.
Conclusion: These data identify A20 as a diabetes protective gene. A20 
negative feed-back on NF-κB and JNK/AP-1 pathways maintain islet inflam-
matory and metabolic homeostasis under vigorous inflammatory states. In 
contrast, functional impairment by SNPs can uncouple A20s protective effect 
and lead to diabetogenic outcomes.
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Anti-CD3 / anti-CXCL10 antibody combination therapy reverts  
type 1 diabetes in two mouse models
S. Lasch, P. Müller, M. Bayer, J.M. Pfeilschifter, E. Hintermann, U. Christen;  
Goethe University Hospital, Frankfurt am Main, Germany.
Background and aims: Therapy of type 1 diabetes (T1D) with anti-CD3 
monoclonal antibodies (a-CD3) results in a blockade of the autoimmune 
process in both animal models and patients with T1D patients. Treated pa-
tients show a reduced insulin need and elevated C-peptide levels. Unfortu-
nately, this effect is only temporal and patients revert within a few years to 
the status they had at the beginning of the therapy. In animal models several 
combination therapies using a-CD3 and treatments, such as rapamycin, nasal 
insulin, vitamin D, FTY 720, or Lactococcus lactis have been successful in 
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blocking T1D. We used a different approach and aimed at a blockade to cel-
lular re-entry into the islets of Langerhans after a-CD3 treatment by blocking 
the key chemokine CXCL10.
Materials and methods: We used the well-established RIP-LCMV-GP mouse 
model of T1D. As a target autoantigen in the β-cells, such mice express the 
glycoprotein (GP) of the lymphocytic choriomeningitis virus (LCMV) under 
control of the rat insulin promoter (RIP). RIP-LCMV-GP mice only develop 
T1D only after infection with LCMV. For the present study we used a com-
bination therapy (CT) and treated diabetic RIP-LCMV-GP mice first with 
a-CD3 (3 injections in 3 days) followed by administration of a neutralizing 
anti-CXCL10 monoclonal antibody (a-CXCL10) (8 injections over 3 weeks).
Results: The CT reverted T1D in RIP-LCMV-GP mice significantly (CT: 65% 
reversion; p=0,0078 / Control: 20% reversion). Thereby, the efficacy of the 
monotherapies was improved (a-CD3 alone: 47% reversion; p=0,1168 / a-
CXCL10 alone: 36% reversion; p=0,3735). Flow cytometry and histological 
experiments demonstrate a marked reduction of CD4 and CD8 T cells in 
the pancreas of mice treated with the CT compared to mono-therapies at 
day 31 after infection. Importantly, the presence of islet antigen (LCMV-GP)-
specific CD8 T cells was reduced dramatically. This effect is long-lasting since 
CT-treated islets show almost no infiltrates up to 181 days after infection. In 
order to confirm our data in a different model, we conducted a pilot study 
with NOD mice, in which CT cured 50% of diabetic mice whereas no mice 
show diabetes reversion with a-CD3 or without therapy.
Conclusion: In summary our data suggest that a combination therapy of an-
ti-CD3 and anti-CXCL10 antibodies results in a significant reduction of T1D 
in two independent mouse models. The neutralization of the key chemokine 
CXCL10 prevented a re-entry of aggressive T cells into the pancreas and 
thereby abrogated the destruction of beta-cells. Such a combination therapy 
might constitute a novel treatment for patients suffering from T1D.
Supported by: TRIP / Goethe University Hospital
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MiR-125a-5p is up-regulated in un-functional CD4+FOXP3+ T 
regulatory cells deriving from pancreatic lymph nodes of patients  
with type 1 diabetes and targets C-C chemokine receptor type 2
G. Ventriglia1, G. Sebastiani1, A. Stabilini2, F. Mancarella1, L. Nigi1,  
T. Brusko3, M. Battaglia2, F. Dotta1;  
1University of Siena and Umberto di Mario Foundation,  
2Diabetes Research Institute, San Raffaele Scientific Institute, Milano, Italy, 
3University of Florida, Gainesville, USA.
Background and aims: We previously showed that CD4+CD25brightCD127- 
T regulatory (Treg) cells deriving from pancreatic lymph node (PLN) of pa-
tients with type 1 diabetes (T1D) are epigenetically imprinted to be Treg, 
but for unknown reasons do not function as such in vitro. Importantly, this 
functional defect is present only in Treg cells residing in the PLN of T1D 
patients and not in those circulating in their peripheral blood (PB). Some 
microRNAs (miRNAs), an abundant class of small non-coding RNAs that 
regulate gene expression by affecting the degradation and translation of target 
mRNAs, are differentially expressed in Treg cells isolated from PLN as com-
pared to those isolated from PB of T1D patients. Among the differentially 
expressed miRNAs, we found that miR-125a-5p is specifically up-regulated 
in Treg cells isolated from PLN of T1D patients as compared to those isolated 
from PB of the same donors and to those isolated from non-diabetic donors. 
This differential expression was not identified in T conventional cells of T1D 
patients, uncovering both a cell (i.e., Treg cells) and a disease-specific (i.e., 
T1D) miRNA expression. Thus, we aimed at further investigating the role of 
miR-125a-5p in Treg cells.
Materials and methods: CD4+CD25brightCD127- Treg cells were FACS 
sorted from PLN and PB of patients with T1D and from non-diabetic donors. 
200 sorted cells were analyzed and miRNA expression was evaluated by RT-
PCR using Taqman miRNAs single assay. Data analysis was performed using 
2-ddCt method. Bioinformatic miRNAs target prediction was performed us-
ing Targetscan 6.2. Dual luciferase reporter assay was performed to experi-
mentally validate the predicted target gene. CCR2 expression was determined 
by flow cytometry.
Results: Computational target gene analysis of miR-125a-5p was performed. 
Target prediction analysis retrieved some potential interesting genes involved 
in Treg-cell biology, including: C-C chemokine receptor type 2 (CCR2), inter-
leukin 6 receptor (IL6R), interferon regulatory factor 4 (IRF4). Among these 
putative targets we focused on CCR2 to verify whether this chemokine recep-
tor is key in the observed Treg-cell dysfunction. Firstly, this prediction was 
validated by renilla luciferase assay: a decreased luciferase activity following 
miR-125a-5p overexpression was observed and this reduction was restored 
upon miRNA predicted target site mutations. Secondly, CCR2 expression on 
Treg cells was tested by flow cytometry and frequency of CCR2+ Treg cells 
was correlated with miR-125a-5p RT-PCR levels. Interestingly, lower expres-
sion of CCR2+ Treg cells correlated with higher expression of miR-125a-5p, 
suggesting an inverse correlation.
Conclusion: A disease- and tissue-specific miRNA, miR-125a-5p, has been 
identified in Treg cells isolated from PLN of patients with T1D. miR-125a-5p 
targets CCR2, thus leading to reduced CCR2 expression. Reduced expression 
of CCR2 may induce migration dysfunction in Treg cells residing in the PLN 
of T1D patients. Therefore these Treg cells could be unable to reach the target 
organ where they are supposed to control and possibly block the autoreactive 
immune response. Further in vitro and in vivo studies are ongoing to confirm 
this hypothesis.
Supported by: JDRFi nPOD Grant
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Cholecalciferol increases suppressor function in regulatory 
CD4+CD25+Foxp3+ T-cells from patients with new onset  
type 1 diabetes: a randomised controlled trial
G. Treiber1, B. Prietl1, E. Fröhlich-Reiterer2, E. Höller1, A. Ribitsch1,  
M. Fritsch3, B. Rami-Merhar3, C. Steigleder-Schweiger4, M. Borkenstein2, 
T.R. Pieber1;  
1Devision of Endocrinology and Metabolism, 2Department of Pediatrics 
and Adolescent Medicine, Medical University Graz, Austria, 3Department 
of Pediatrics, Medical University Vienna, 4Paracelsus Medical University, 
Salzburg, Austria.
Background and aims: Vitamin D has an important role in increasing the 
effects of innate immune processes while restraining the adaptive immune 
system, leading to improved outcomes in autoimmune diseases. Vitamin D 
deficiency is one environmental factor to influence the risk of type 1 diabetes 
(T1D) and in vitro data reinforce the role of vitamin D in the pathogenesis 
of T1D. In this study we evaluate the effects of Cholecalciferol on function of 
regulatory T-cells and residual b-cell function in patients with recent onset 
T1D.
Materials and methods: In this randomized, double-blinded, placebo con-
trolled trial thirty patients (age 15 [10-16], 77% male) with new-onset T1D 
were assigned to receive oral therapy of cholecalciferol (70IU/kg bodyweight/
day) or placebo for 12 months. Cellular frequencies were determined by 
FACS-analysis and functional tests were assessed with ex vivo suppression 
co-cultures. Mixed meal tolerance tests were performed to assess b- cell func-
tion.
Results: Suppressive capacity of regulatory T cells (Treg) increased with 
Cholecalciferol after 3, 6 and 12 month (p=0.0005) and delta suppression 
capacity between Cholecalciferol (28.1 [14.9 to 43.3]%) and placebo (-20.9 
[-30.1 to -11.3]%) was significant (p=0.002). Treg frequency did not dif-
fer after 12 month between the two groups (5.75±1.48% vs 5.38±1.73%, 
p=0.187). HbA1c and insulin dose were similar between the groups, fast-
ing C-peptide appeared to decrease slower (p=0.078) in the Cholecalciferol 
group (0.62±0.18 to 0.59±0.34 ng/ml) than in placebo group (0.65±0.27 to 
0.40±0.25 ng/ml). Serum calcium and parathormone stayed within the nor-
mal range.
Conclusion: Cholecalciferol, the inactive form of vitamin D used as adjunc-
tive immunomodulatory therapy with insulin is associated with an improve-
ment in suppressor function of regulatory T-cells in patients with new-onset 
T1D. Assessment of vitamin D status and a targeted supplementation may be 
indicated after the diagnosis of T1D.
Clinical Trial Registration Number: NCT01390480
Supported by: EFSD/MSD
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Novel epigenetic markers of type 2 diabetes in the liver
S. Cauchi1,2, R. Caiazzo2,3, B. Pichard1,2, A.-S. Régent1,2, M. Canouil1,2,  
S. Lobbens1,2, L. Yengo1,2, A. Leloire1,2, V. Raverdy2,3, O. Poulain-Godefroy1,2, 
F. Pattou2,3, P. Froguel1,2;  
1Genomics and Metabolic Diseases, UMR CNRS 8199, 2European Genomic 
Insitute for Diabetes (EGID), 3Inserm UMR 859, Lille, France.
Background and aims: The liver plays an important role in the regulation of 
glucose homeostasis. Epigenetic markers in this organ could contribute to the 
pathophysiology and heritability of type 2 diabetes (T2D). Our aims were to 
define DNA methylation patterns associated with T2D risk in the liver, cor-
relate these epigenetic factors with gene expression pathways and decipher 
intermediate metabolic traits.
Materials and methods: We analyzed the genome-wide methylation patterns 
in the liver tissue of 96 T2D cases and 96 matched normoglycemic controls 
using Infinium Human Methylation 450 BeadChips (Illumina). A beta-mix-
ture quantile normalization method was applied for correcting probe design 
bias. Genome-wide expression profiles were also assessed in a subset of 24 
T2D cases and 24 matched normoglycemic controls using HumanHT-12 v4 
Expression BeadChips (Illumina).
Results: We identified 158 sites differentially methylated between T2D cases 
and controls after Bonferroni correction for multiple comparisons (p<1.5 x 
10-7). Taken together, these sites tended to be hypomethylated in T2D cases 
compared to normoglycemic controls (p=1 x 10-7). Only two of these cytosine 
methylation marks were located near functionally relevant candidate genes 
differentially expressed between T2D cases and controls (p<4.2 x 10-4). Direct 
correlations between methylation levels and gene expressions were also ob-
served (p<1 x 10-3). Finally, associations with insulin resistance (p<3 x 10-3) 
and steatosis (p<3 x 10-5) were detected.
Conclusion: We identified the first epigenetic markers associated with T2D 
risk in the human liver tissue. DNA methylation information can be used 
to identify new pathways relevant to the pathophysiology of T2D and novel 
targets for disease prevention and treatment.
Supported by: Société Francophone du Diabète
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Identification of DNA methylation and mRNA expression changes 
associated with age in human pancreatic islets
K. Bacos1, P. Volkov1, T. Dayeh1, A.H. Olsson1,2, C. Ling1;  
1Clinical Sciences, Lund University, Malmö, Sweden, 2Endocrinology, 
Diabetes and Metabolism, Rigshospitalet, Copenhagen, Denmark.
Background and aims: Increased age is associated with a reduced capacity 
for insulin secretion and an increased risk of type 2 diabetes. Recent studies 
suggest that epigenetic modifications, such as DNA methylation, play a role 
in the development of type 2 diabetes. DNA methylation patterns has been 
shown to change significantly with age in tissues such as blood and muscle, 
but if this is the case also in human pancreatic islets has not yet been studied.
Materials and methods: Microarrays were used to analyse mRNA expression 
and DNA methylation in human islets from 87 non-diabetic donors with an 
age spanning between 26-74 years. A linear regression analysis was used to 
determine which methylation sites and probesets associate significantly with 
age.
Results: DNA methylation data of 482,889 sites remained after quality con-
trol and the methylation level of 322 of these where significantly associated 
with age after correction for multiple testing. These methylation sites corre-
spond to 214 individual genes, including loci previously associated with dia-
betes. Interestingly, all of the significant methylation sites showed increased 
DNA methylation with increasing age. Moreover, based on the annotation 
of the analyzed methylation sites, we found enrichment of significant sites 
on chromosomes 2 and 19 and in the following gene regions; TSS1500 (the 
region 1500 bases upstream of the transcription start site), TSS200 and the 
1st exon as well as in CpG islands. Seven genes exhibited significant asso-
ciations for both DNA methylation and mRNA expression with increased 
age. Of these, 5 showed an inverse relation, with increased methylation and 
reduced expression. These 5 genes encode for a ribosomal protein, a putative 
zinc finger transcription factor, a histone, a mitochondrial protein and a RNA 
methyl transferase protein, respectively.
Conclusion: Together, our study demonstrates that ageing is associated with 
differential DNA methylation in human pancreatic islets. These epigenetic 
modifications may contribute to altered gene expression, impaired insulin 
secretion and finally affect the risk for type 2 diabetes.
Supported by: Swedish Research Council, EFSD, Novo Nordisk Foundation, 
Exodiab, Söderberg, Påhlsson
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Spermatozoa from lean and obese human carry distinct epigenetic 
signatures
I. Donkin1, S. Versteyhe1, K. Qian1, L.R. Ingerslev1, F.R. Kantor1,  
M. Mechta1, N. Jørgensen2, J.R. Zierath1,3, R. Barrès1;  
1The Novo Nordisk Foundation Center for Basic Metabolic Research, 
Copenhagen University, Faculty of Health Sciences, 2Dpt of Growth and 
Reproduction, Rigshospitalet, Copenhagen, Denmark, 3Department of 
Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Background and aims: Obesity is associated with metabolic dysfunction and 
higher prevalence of related diseases such as Type 2 Diabetes. In humans, 
epidemiological evidence exists showing that paternal obesity can predispose 
offspring to obesity, regardless of the body mass index of the mother. Moreo-
ver, recent animal studies have shown that paternal nutritional status at time 
of mating can affect the metabolic health of the offspring, suggesting that 
spermatozoa carry environmental effects to the next generation. Here, we hy-
pothesize that spermatozoa from obese human present a specific epigenetic 
content that may predispose to metabolic dysfunction.
Materials and methods: Using deep-sequencing, we comprehensively pro-
filed small RNA content, DNA methylation and the histone retention profile 
of ultra pure motile spermatozoa fractions collected from 11 obese (BMI>30), 
insulin resistant, and 16 lean (BMI 20-25), normal glucose tolerant men in 
their reproductive age (20-40 y).
Results: Analysis revealed a subset of RNAs being differentially expressed 
in obesity, including known as well as new small RNA species. Notably, piR-
NA-associated genes were found to control epigenetic process and metabolic 
functions. We found regions differentially methylated in obesity. Interest-
ingly, around 25% were located in putative regulatory sites, and at close prox-
imity of genes involved in development and the regulation of metabolic pro-
cesses. Positioning of histones, on the contrary, was not affected by obesity.
Conclusion: Here we show that obesity is associated with an altered epige-
netic signature in spermatozoa. The identified differentially expressed RNA 
molecules and differentially methylated regions have the potential to alter 
gene expression in the developing embryo and participate in the predisposi-
tion of metabolic dysfunction and related comorbidities.
Clinical Trial Registration Number: H-1-2011-077
Supported by: NNFCBMR
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Variation in phenotype and DNA methylation is detectable in an 
observational cohort of young adult Bangladeshis exposed to famine 
during in utero and postnatal life
S. Finer1,2, S. Iqbal3, W.B. Ogunkolade2, C. Mathews2, R. Lowe2, M. Smart2, 
V.K. Rakyan2, D.S. Alam3, G.A. Hitman2;  
1Wellcome Trust-MRC Institute of Metabolic Science, University of 
Cambridge, 2Blizard Institute, Barts & the London, Queen Mary University 
of London, UK, 3ICDDR,B, Dhaka, Bangladesh.
Background and aims: Periconceptual, in utero and postnatal exposure to 
nutritional deficits may ‘programme’ cardiometabolic disease in later life. Re-
cent human studies suggest that epigenetic variation may be associated with 
periconceptual nutritional deficiency, but this has not been described with 
postnatal exposures or replicated across studies. Aim: 1. To identify whether 
Bangladeshi adults exposed to famine in utero and/or in postnatal life have 
a programmed phenotype 2. To detect DNA methylation variation in these 
offspring on a genome-wide scale and at previously described targets.
Materials and methods: A cross-sectional cohort of adults (27-32 years) exposed 
to severe famine during 1974-5 in Matlab, Bangladesh was studied in three groups: 
1. in utero exposed, 2. postnatal exposed, 3. Unexposed, 
Approach: • Clinical phenotype (n=219) • Whole blood DNA bisulphite con-
version (n=159) for (i) epigenome profiling via Illumina 450kMethylation 
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array, (ii) targeted pyrosequencing of published methylation variants: IGF2, 
PAX8, ZFYVE28, EXD3, BOLA3 • Validation using an external dataset 
Results: The in utero exposed group had an excess of underweight individu-
als (49%) compared to postnatal exposed (32%) or unexposed (30%); more 
postnatal exposed offspring (26%) were overweight compared to in utero 
exposed (13%) or unexposed (14%) (proportional odds model df=2, devi-
ance ratio 3.26, p=0.039). Of the underweight, in utero exposed had a higher 
mean glucose 120minutes post-glucose challenge (5.8mmol/l) compared 
to postnatal exposed or unexposed (both 4.8mmol/l) (ANOVA p<0.02). 
The Illumina 450k array identified differential methylation between the 3 
groups at 416 probes (ANOVA p ≤0.001) but these did not withstand correc-
tion for false discovery. Sixty-two regions showed methylation differences of 
≥5%; most (65%) were from the comparison of postnatal exposure to unex-
posed. KEGG pathway analysis suggested potential impact on pathways in-
volved in insulin signalling, axon guidance and ABC transporters. We found 
a 3-fold enrichment of published epigenomic variants in human islets in type 
2 diabetes in our dataset (p=0.01). Bisulphite-pyrosequencing and/or array 
data showed small (<7%) methylation differences at PAX8 and ZFYVE28, 
consistent with metastable epialleles in Gambian children exposed to vari-
able periconceptual nutrition. Small methylation differences (<4%) at IGF2 
were consistent with the published Dutch Winter Hunger studies but are of 
uncertain significance.
Conclusion: Our data identifies phenotypic evidence of developmental pro-
gramming of adult cardiometabolic disease from both in utero and postna-
tal famine exposure. We identify epigenetic differences in DNA methylation 
across multiple genomic regions, but larger studies are needed to control for 
false discovery. Via pathway analysis and comparison to external datasets, we 
suggest possible functional roles in insulin signaling and via pancreatic is-
let function. We replicate small quantitative differences in DNA methylation 
at targets previously associated with famine exposure. Future studies need 
larger sample sizes, longitudinal sampling and intervention to determine cau-
sality and potential reversibility.
Supported by: MRC CRTF
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New biomarkers of NAFLD: results from plasma metabolomic analysis
M. Gaggini1, C. Saponaro1, C. Rosso2, F. Carli1, E. Buzzigoli1, D. Ciociaro1, 
E. Bugianesi2, A. Gastaldelli1;  
1Cardiometabolic Risk Unit, Institute of Clinical Physiology, Pisa,  
2Medical Sciences, University of Turin, Italy.
Background and aims: Non Alcoholic Fatty Liver Disease ( NAFLD) is as-
sociated with both peripheral and hepatic insulin resistance and is an impor-
tant risk factor for both diabetes and cardiovascular disease. Metabolomic 
techniques aim to identify new biomarkers related to alteration in organ 
metabolism. We have performed metabolomic analysis of plasma samples of 
subjects with NAFLD to find possible markers of metabolic dysfunction and 
liver disease.
Materials and methods: We studied 54 subjects, 45 NAFLD with liver biopsy 
and 9 healthy control (CT) and measured plasma concentration profile of 
amino acids (AA) and fatty acid (FA) by GCMS. Data were correlated with 
indexes of insulin resistance (IR) measured by tracers, LFTs, NAS and fibrosis 
score, beta-hydroxybutyrate (BOH), ox-LDL, total antioxidative status (TAS), 
sRAGE, and adiponectin. We calculated: a) using tracer infusion, hepatic IR 
as endogenous glucose production x fasting insulin (H-IR=EGPxFPI), adi-
pose tissue insulin resistance (AT-IR) as fasting lipolysis x FPI; b) from fatty 
acid composition we calculated de novo lipogenesis index (DNL=16:0/18:2) 
and SCD1 activity as 16:1/16:0) from AA profile, the branched chain concen-
trations (BCAA) and the ratio of glutamate/(glycine +serine), that is as an 
index of glutathione biosynthesis (GSH_I).
Results: Subjects with NAFLD had increased H-IR (118±10 vs. 56±7) and 
AT-IR (34±3 vs. 13±2), GSH-I (0.73±0.06 vs 0.33±0.09), DNL (1.17±0.05 vs 
0.86±0.04) and SCD1 (0.10±0.01 vs 0.08±0.01) indices compared to controls. 
GSH-I, DNL and SCD1 were increased in proportion to the degree AT-IR 
(r=0.28; r=0.41; r=0.43) and also with the increase of H-IR(r=0.39; r=0.28; 
r=0.32). GSH_I was increased proportionally to the severity of fibrosis 
(r=0.36 per trend, p<0.0001), ln(cholesterol) (r=0.39) and negatively with 
ln(sRAGE) (r=0.30) but not with TG liver content nor with NAS score. TAS, 
ox-LDL and adiponectin. DNL was increased proportionally to circulating 
ln(TG) (r=0.53), fat in biopsy (r=0.45) and fibrosis (r=0.52).
Conclusion: Metabolomic analysis allowed the identification of indices 
(GSH-I, DNL and SCD1) associated with increased hepatic and adipose tis-
sue insulin resistance and severity of fatty liver disease.
Supported by: FP7 HEALTH-F2-2009-241762, FLIP
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Orphan nuclear receptor Nur77 mediates fasting-induced hepatic  
FGF21 expression
K.-H. Bae1, A.-K. Min1, M.-K. Kim2, E.-H. Kim3, E.-D. Jung4, M.-J. Kim5, 
K.-G. Park1;  
1Department of Endocrine and Metabolism of Internal medicine, 
Kyungpook National University School of Medicine, 2Department of 
Endocrine and Metabolism of Internal medicine, Keimyung University 
Dongsan Medical Center, 3Department of Endocrine and Metabolism 
of Internal medicine, Fatima Hospital, 4Department of Endocrine and 
Metabolism of Internal medicine, Daegu Catholic University Medical 
Center, 5Department of Endocrine and Metabolism of Internal medicine, 
Pooren Meerae Internal Medicine Clinic, Taegu, Republic of Korea 
Background and aims: The fasting-induced hepatic hormone, fibroblast 
growth factor 21 (FGF21), is an intriguing candidate for the treatment of 
metabolic syndromes. Although PPARalpha is known to play a major role in 
induction of hepatic FGF21 expression, other fasting-induced transcription 
factors in FGF21 expression has not be fully studied. In the present study, we 
investigated whether the fasting-induced activation of the transcription fac-
tors Nur77 increases hepatic FGF21.
Materials and methods: We examined the effects of glucagon/cAMP, a well-
known hormone induced by fasting, on hepatic Nur77 and FGF21 expression 
in vivo and in vitro. To elucidate the association between Nur77 and FGF21 
expression, we examined whether adenovirus-mediated over-expression of 
Nur77 (Ad-Nur77) increases FGF21 production and knockdown of Nur77 
with siRNA abolished forskolin-induced FGF21 expression. To further con-
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firm that Nur77 transcriptionally activates FGF21 expression, ChIP assay, 
EMSA and mutagenesis analysis were employed.
Results: We found that fasting induced hepatic Nur77 and FGF21 expres-
sion. Glucagon and forskolin increased Nur77 and FGF21 expression in vivo 
and in vitro, respectively. Ad-Nur77 increased FGF21 production in cultured 
hepatocytes. Hepatic overexpression of Nur77 via tail vein injection of Ad-
Nur77 increased FGF21 mRNA and protein levels. Moreover, siRNA-Nur77 
abolished the effect of forskolin on FGF21 expression. The results from ChIP 
assay, EMSA and mutagenesis analysis showed that Nur77 bound to puta-
tive NBRE of FGF21 promoter in cultured hepatocytes and fasting induced 
Nur77 binding to FGF21 promoter in vivo.
Conclusion: This study shows that Nur77 mediates fasting-induced hepatic 
FGF21 production. The present study suggests an alternative mechanism by 
which hepatic FGF21 transcription is mediated under fasting conditions.
Supported by: NRF-2012R1A2A1A03670452
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Overexpression JAZF1 protected ApoE-/- mice from atherosclerosis by 
inhibiting hepatic cholesterol synthesis
H. Wang1,2, L. Li1,2, P. Yan3, G. Yang3;  
1the Key Laboratory of Laboratory Medical Diagnostics in Ministry of 
Education, Chongqing, China, 2Department of Clinical Biochemistry, 
College of Laboratory Medicine, Chongqing Medical University, 
3Department of Endocrinology, the Second Affiliated Hospital, Chongqing 
Medical University, China.
Background and aims: Genome wide association studies have suggested 
an association of Juxtaposed with another zinc finger gene 1(JAZF1) with 
type2 diabetes mellitus(T2DM). As an inhibitor of the TAK1/TR4 signaling 
pathway, JAZF1 has been shown to be involved in gluconeogenesis, lipid me-
tabolism and insulin sensitivity. However, its role in insulin resistance and 
atherosclerosis in vivo remains unknown. The present study was designed 
to investigate in vivo the impact of JAZF1 on insulin resistance-associated 
dyslipidemia and atherosclerosis.
Materials and methods: We established Adenovirus-mediated JAZF1 over-
expression to characterize the role of JAZF1 in the regulation of lipid metabo-
lism and the development of atherosclerosis in normal chow- or high fat diet 
(HFD)-fed ApoE-/- mice .We use euglycaemic-hyperinsulinaemic clamping 
to examine Insulin sensitivity, Cholesterol de novo synthesis was measured by 
intraperitoneal acetate injection and atherosclerotic plaques were quantified 
by histological analysis ,A dual- luciferase reporter assay was used to assess 
the ability of JAZF1 to regulate HMGCR transcriptional activity, mRNA and 
protein expressions were measured by qRT-PCR and Western blot, respec-
tively.
Results: we showed that JAZF1 overexpression improved HFD-induced he-
patic insulin resistance in C57BL/6J mice. In HFD-fed ApoE-/- mice, JAZF1 
overexpression decreased serum cholesterol levels and hepatic cholesterol 
synthesis by inhibiting CREB dependent 3hydroxy3methylglutaryl coen-
zyme A reductase (HMGCR) promoter transcriptional activity and JAZF1 
overexpression had significantly reduced aortic and aortic sinus en face and 
cross- sectional plaque areas in HFD-fed ApoE-/- mice.
Conclusion: we report the first evidence that JAZF1 overexpression protect-
ed against development of atherosclerosis and insulin resistance induced by 
a HFD in apoE-/- mice and in C57BL/6J mice. Furthermore, we provide mo-
lecular explanation by which JAZF1 can regulate hepatic cholesterol synthe-
sis and HMGCR transcriptional activity via CREB -dependent mechanisms. 
Our data delineate that JAZF1 overexpression may represent a promising 
strategy for the treatment of insulin resistance-associated dyslipidemia and 
atherosclerosis.
Supported by: NNSFC (81270913,81300702,81300670)
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Defective autophagy results in reduced glycogen breakdown in the liver 
of IUGR newborn Wistar rats. Consequences for glucose homeostasis
E. Fernandez-Millan1, J. de Toro-Martin2, E. Lizarraga-Mollinedo1,2,  
F. Escriva1,2, C. Alvarez1,2;  
1CIBERDEM, ISCIII, 2Biochemistry and Molecular Biology II,  
School of Pharmacy, UCM, Madrid, Spain.
Background and aims: Glycogen autophagy is a highly regulated process 
that represents a mechanism of glucose homeostasis under conditions of de-
mand for the production of this sugar as in the liver of newborn animals. 
The abrupt interruption of the maternal glucose supply with birth, leads to 
the development of hypoglycaemia in the newborn. This promotes glucagon 
secretion and triggers the normal mechanisms for the newborn to adapt to 
the postnatal environment. Glucagon acts through the cAMP/protein Kinase 
A pathways and induces glycogen autophagy. We previously showed that in-
trauterine growth restriction (IUGR) induced massive glycogen accumula-
tion in the liver of fetuses and neonates. Interestingly, IUGR neonates were 
slightly hypoglycaemic and showed hypoglucagonaemia and glucagon resist-
ance but insulin hypersensitivity. In this study we set out to examine the au-
tophagic response in the liver of IUGR newborns and whether this process 
might be linked to the development of insulin resistance associated to IUGR.
Materials and methods: Newborn rats naturally delivered from pregnant 
females fed ad libitum or 65% food-restricted from the last third of gesta-
tion, were kept separated from their mothers and used 3 or 6h after birth. 
Liver glycogen content was quantified by a KOH-ethanol precipitation and 
acid hydrolysis method. The protein levels of the enzymes involved in glu-
cose metabolism, the markers of autophagy and ER stress were determined 
by western blot in hepatic homogenizes. Ultraestructural analysis of the neo-
natal liver was performed by electron microscopy.
Results: At birth (0h), liver glycogen values of control (C) and IUGR rats 
were 23.8 ± 3.2 and 57.4 ± 7.3 mg/g (p<0.01), respectively. In C rats, the 
amount of glycogen precipitously diminished at 3 and 6h of age whereas 
glycogen stores remained significantly elevated in restricted newborns. 
In agreement, glycogen synthase was found more active in IUGR group at 
both 3 and 6h after birth, the phosphorylated form of GSK3 increased and 
glycogen phosphorylase and PEPCK protein levels diminished (p<0.01). To 
address the implication of autophagy in the lack of glycogen mobilization 
in restricted newborns we measured autophagy markers at 3 and 6h after 
birth. C newborns fasted 6h, showed a marked induction of LC3B II conver-
sion. In contrast, IUGR newborns displayed defective autophagy at this time. 
Electron microscopic examination showed enhanced autophagic activity and 
consumption of liver glycogen stores from 3 to 6h after birth in C new-borns 
whereas in IUGR rats the formation of glycogen-containing vacuoles were 
rare and vast areas of cytoplasmic glycogen were observed at both 3 and 6 h of 
age. Alpha glucosidase enzyme levels increased at 6h of postnatal life in both 
groups of animals. When fed a high-fat diet during 22 weeks, C rats showed 
enhanced autophagic activity in liver however, IUGR rats maintained lower 
levels of Atg7 and LC3B II and developed insulin resistance, liver steatosis 
and ER stress.
Conclusion: We suggest that defective autophagy may lead to ineffective 
macromolecule turnover, such as glycogen or lipids in IUGR individuals and 
consequently compromise hepatic metabolic function favouring insulin re-
sistance development.
Supported by: MINECO (BFU2011/25420), CIBERDEM (ISCIII), CAM 
(S2010/BMD-2423)
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Benefits of a fixed-ratio formulation of once-daily insulin glargine/
lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately 
controlled on metformin
J. Rosenstock1, M. Diamant2, L. Silvestre3, E. Souhami3, T. Zhou4, V. Fonseca5;  
1Dallas Diabetes and Endocrine Center, USA, 2VU University Medical 
Center, Amsterdam, Netherlands, 3Sanofi, Paris, France,  
4Sanofi, Bridgewater, USA, 5Tulane University Health Sciences Center,  
New Orleans, USA.
Background and aims: LixiLan is a fixed-ratio formulation combining insu-
lin glargine (GLARG) with lixisenatide (Lixi) in a single pen device currently 
in development for the management of type 2 diabetes mellitus (T2DM). 
This randomized, open-label study assessed the efficacy and safety of Lixi-
Lan (GLARG 2 U / Lixi 1 µg) vs GLARG in insulin-naïve T2DM on top of 
metformin.
Materials and methods: Patients (mean baseline A1C 8.0%, BMI 32.1 kg/m
2, 
diabetes duration 6.7 yrs) were randomized to LixiLan (n=161) or GLARG 
(n=162) for 24 weeks. Primary objective was non-inferiority in A1C reduc-
tion; if non-inferiority met, statistical superiority was tested.
Results: At 24 weeks, mean A1c was reduced to 6.3% and 6.5% with Lixi-
Lan and GLARG respectively, establishing statistical superiority of LixiLan 
(LS mean difference: -0.17% [-0.312% to -0.037%; p=0.0130]), and 84% and 
78% achieved A1C <7%, respectively (Table). Despite substantial reductions 
of A1C, body weight was reduced with LixiLan (p<0.0001), with no increase 
in documented (≤70 mg/dL [3.9 mmol/L]) hypoglycaemic events (22% and 
23%, respectively) and no severe hypoglycaemia. Composite endpoints of 
A1C <7% with no weight gain, or no weight gain and no hypoglycaemia were 
achieved significantly more often with LixiLan. Incidence of nausea and 
vomiting was only 7.5% and 2.5%, respectively, with LixiLan.
Conclusion: LixiLan achieved robust A1C reductions to 6.3% with weight loss 
and no increased hypoglycaemia vs GLARG, with very low gastrointestinal 
adverse events in T2DM inadequately controlled on metformin.
Clinical Trial Registration Number: NCT01476475
Supported by: Sanofi
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Efficacy and tolerability of ITCA 650  
(continuous subcutaneous exenatide) in poorly controlled  
type 2 diabetes with baseline HbA1C >10%
R.R. Henry1, J. Rosenstock2, M.A. Baron3;  
1VA San Diego Healthcare System, La Jolla, 2Dallas Diabetes and Endocrine 
Center at Medical City, 3Intarcia Therapeutics, Boston, USA.
Background and aims: ITCA 650, the injection-free GLP-1 receptor agonist 
that provides continuous SC exenatide for up to 12 months from a single sub-
dermal placement, is undergoing extensive clinical evaluation in multiple 
Phase 3 double-blind studies. This report represents the first 6 month, open-
label experience with ITCA 650 mini-pumps from an ongoing multicenter 
study in subjects with type 2 diabetes who did not meet enrolment criteria for 
the double-blind placebo controlled trial because of A1C >10%.
Materials and methods: Entrance criteria for this open-label trial were: 
A1C >10% to ≤12%, age 18-80 years, BMI 25-45 kg/m2, and on stable (≥3 
months) diet and exercise and/or monotherapy or any combination of met-
formin, sulfonylurea, and thiazolidinedione. Treatment was initiated by 
placing a 3-month ITCA 650 mini-pump delivering 20 mcg/day, which was 
then replaced by a 6-month ITCA 650 mini-pump delivering 60 mcg/day for 
26 weeks. Pre-study oral antidiabetic agents (OADs) were maintained un-
changed for the 39 week of treatment. The primary endpoint was change in 
A1C from baseline to week 39.
Results: At the time of this initial interim analysis, 50, 39, and 25 of the 60 sub-
jects enrolled had completed 13, 19, and 26 weeks of treatment; respectively. 
Mean baseline characteristics for the entire cohort (n=60) were A1C 10.7%, 
age 52.1 yrs, BMI 32.1 kg/m2, duration of diabetes 8.9 yrs, OAD use 69%. 
Mean reductions of A1C at Weeks 13 (n=50), 19 (n=39), and 26 (n=25) were 
-2.5%, -2.9%, and -3.2%, respectively. A1C reductions ≥2% were achieved by 
78% of subjects who completed at least 13 weeks of treatment; 50% achieved 
>3% and 22% achieved ≥4% reductions. A1C targets of <7% were achieved in 
22% of subjects who had completed at least 13 weeks of treatment. Adverse 
events were consistent with previous trials with ITCA 650.
Conclusion: ITCA 650 has the potential to markedly improve glycemic con-
trol in patients with severe hyperglycaemia and longstanding diabetes.
Clinical Trial Registration Number: NCT01785771
Supported by: Intarcia Therapeutics
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IDegLira, a combination of insulin degludec and liraglutide,  
improves both pre- and postprandial plasma glucose in patients with 
type 2 diabetes
A. King1, A. Philis-Tsimikas2, I.H. Langbakke3, K. Kvist3, T. Vilsbøll4;  
1Diabetes Care Center, Salinas, 2Scripps Whittier Diabetes Institute,  
San Diego, USA, 3Novo Nordisk A/S, Søborg,  
4Gentofte Hospital, Hellerup, Denmark.
Background and aims: Pre- and postprandial glucose levels contribute im-
portantly to overall glycaemic control and consequently clinical outcomes. 
This analysis explored whether a novel combination of insulin degludec 
(IDeg) and liraglutide (Lira), IDegLira, enabled more patients to reach rec-
ommended pre- and postprandial target ranges, compared with administra-
tion of its individual components.
Materials and methods: In this post hoc analysis of two phase 3 trials: DUAL 
I (IDegLira vs. IDeg and Lira in patients uncontrolled on oral antidiabetic 
drugs [OADs]; 52 weeks) and DUAL II (IDegLira vs. IDeg in patients un-
controlled on basal insulin + OADs; 26 weeks), we investigated at end of 
trial (EOT) the proportion of patients with self-measured blood glucose 
(BG) values within the pre-prandial target range of ≥3.9 to ≤7.2 mmol/L and 
postprandial target of <9 mmol/L with IDegLira compared with IDeg or Lira 
alone. Postprandial BG values were assessed 90 minutes after breakfast, lunch 
and dinner. Preprandial BG was measured before breakfast, lunch, dinner 
and breakfast the following day. In addition, the full 9-point profile included 
measurements before bedtime and at 4am. Finally, we compared the propor-
tion of patients whose entire 9-point BG profile was between ≥3.9 and <9 
mmol/L with IDegLira and IDeg or Lira alone.
Results: At baseline, the proportion of patients with BG values within the 
target ranges was similar across treatments in the two trials. At EOT, the 
proportion of subjects with all three postprandial BG values <9 mmol/L was 
significantly higher for patients treated with IDegLira (DUAL I 51%; DUAL 
II 37%) than those treated with IDeg (DUAL I 38%; DUAL II 25%) or Lira 
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(36%). The likelihood of achieving all four pre-prandial BG values within 
the recommended range (≥3.9 to ≤7.2mmol/L) was significantly greater with 
IDegLira (DUAL I 48%; DUAL II 44%) compared with IDeg (DUAL I 41%; 
DUAL II 27%) or Lira (32%). At EOT, the proportion of patients with all 9 
BG values within the range ≥3.9 to <9 mmol/L was significantly higher for 
patients treated with IDegLira (DUAL I 39%; DUAL II 32%) than for patients 
treated with IDeg (DUAL I 28%; DUAL II 20%) or Lira (31%).
Conclusion: Treatment with IDegLira resulted in a greater likelihood of 
patients having both pre- and postprandial BG values within target ranges 
compared with either IDeg or Lira. Improved pre- and postprandial BG lev-
els suggest that the predictability of glycaemic control within one day is in-
creased with IDegLira.
Clinical Trial Registration Number: NCT01336023, NCT01392573
Supported by: Novo Nordisk
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DURATION-NEO-1: greater HbA1c reductions with exenatide 
suspension once weekly by autoinjector pen vs exenatide twice daily  
in inadequately controlled type 2 diabetes
C.H. Wysham1, J. Rosenstock2, J. Malloy3, M. Vetter4, Y. He4, P. Öhman5,  
N. Iqbal4;  
1Rockwood Clinic, Spokane, 2Dallas Diabetes and Endocrine Center  
at Medical City, 3Bristol-Myers Squibb, San Diego,  
4Bristol-Myers Squibb, Princeton, 5AstraZeneca, Gaithersburg, USA.
Background and aims: Once-weekly (QW) exenatide consistently improves 
glycaemic control and promotes weight loss in patients with type 2 diabetes 
mellitus (T2DM) but requires reconstitution and may be difficult to use for 
some patients. A QW suspension containing exenatide dispersed in micro-
spheres suspended in a triglyceride carrier, was developed to eliminate the 
need for reconstitution and allow delivery via a single-use autoinjector pen. 
This simplified approach may enhance adherence. An open-label, 28-week 
study compared exenatide suspension QW (ExSQW) to exenatide twice daily 
(ExBID) in patients with inadequately controlled T2DM.
Materials and methods: Patients treated with diet/exercise or combination 
of oral medications (metformin, sulfonylurea or pioglitazone) were rand-
omized (in a 3:2 ratio) to ExSQW 2 mg (n=229) or ExBID 10 mcg (n=148). 
The primary endpoint was change in HbA1c from baseline to Week 28 with 
ExSQW vs ExBID.
Results: Baseline characteristics were similar in both groups: mean±SD 
HbA1c of 8.48±1.03%, fasting plasma glucose (FPG) of 182±45 mg/dL 
(corresponding to 10.10±2.53 mmol/L), and body weight of 96.9±21.0 kg. 
Changes in HbA1c from baseline are shown in Figure 1; at Week 28, the re-
duction (least-squares [LS] mean±SE) in the ExSQW group was greater than 
in the ExBID group (-1.39±0.09 vs -1.02±0.11%; P=0.007). Achievement of 
HbA1c <7% was comparable in the ExSQW vs ExBID groups (49% vs 43%; 
P=0.225). Similar FPG reductions were observed in both groups as early as 
Week 2. By Week 28, FPG reductions reached -32.7±3.9 and -22.5±4.9 mg/
dL (corresponding to -1.81±0.22 and -1.25±0.27 mmol/L) for ExSQW and 
ExBID, respectively (P=0.166). Body weight decreased similarly in the Ex-
SQW (-1.49±0.28 kg) and ExBID (-1.89±0.36 kg) groups. Gastrointestinal 
(GI) adverse events (AEs) were less frequent in the ExSQW group than in 
the ExBID group (nausea: 9.6% vs 21.2%; diarrhea: 5.2% vs 11.6%; vomiting: 
3.5% vs 6.2%, respectively), but injection-site nodules occurred more often 
(12.7% vs 0.7%). No major hypoglycaemia was reported; minor hypogly-
caemia was infrequent, generally mild, and occurred primarily in patients 
with concomitant sulfonylurea use. The ExSQW and ExBID groups, respec-
tively, had low rates of serious AEs (2.6% and 4.8%) and withdrawals due to 
AEs (2.2% and 4.8%). The completion rate was slightly greater with ExSQW 
(86.0% vs 79.7%).
Conclusion: ExSQW with autoinjector delivery simplified treatment with 
robust glycaemic control, weight loss and less GI AEs, but more injection-site 
nodules, than ExBID.
Clinical Trial Registration Number: NCT01652716
Supported by: Bristol-Myers Squibb/AstraZeneca
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Cancer occurrence in type 1 diabetes patients: a 4-country study with 
8800 cancer cases in 3.7 mio person-years
B. Carstensen1, S. Friis2, J. Harding3, D.J. Magliano3, R. Sund4, I. Keskimäki5, 
R. Ljung6, A.-M. Svensson7, S. Wild8, S. Gudbjörnsdottir7;  
1Steno Diabetes Center, Gentofte, 2Danish Cancer Society, Copenhagen, 
Denmark, 3BakerIDI Heart and Diabetes Institute, Melbourne, Australia, 
4University of Helsinki, 5National Institute for Health and Welfare, Helsinki, 
Finland, 6Karolinska Insititutet, Institute of Environmental Medicine, 
Stockholm, 7University of Gothenburg, Sweden, 8University of Edinburgh, 
UK.
Background and aims: Diabetes (DM) patients carry an excess risk of can-
cer in the order of 20-25%; this is mainly derived from follow-up of type 
2 patients (T2D). The excess risk of cancer among type 1 (T1D) patients is 
described here as it is anticipated to be different from T2D patients.
Materials and methods: T1D patients from four countries with nation-wide 
diabetes registers: Australia (1997-2008), Denmark (1995{-2009), Finland 
(1972-2010), and Sweden (1987-2011) were followed for cancer occurrence. 
T1D was defined by diagnosis of DM before age 30. Cancer incidence rates 
were compared to population cancer incidence rates from national cancer 
registries. We used Poisson-models for rates, adjusting for age and date of 
follow-up, and date of birth. We estimated the overall rate ratio (RR) for all 
T1D patients and the effect of time since DM diagnosis.
Results: There were a total of 8,807 cancers among T1D patients during 3.7 
million person-years of follow-up with median age at cancer diagnosis 51.1 
(IQR: 43.5,59.5). Overall, we found an RR of any type of cancer of 1.00 (95% 
CI: 0.97-1.03) among men and 1.05 (95% CI: 1.02-1.08) among women. The 
highest RRs were found for colorectal cancer, (RR=1.13 (M), 1.14 (F)), liver 
cancer (RR=2.14 (M), 1.50 (F)), pancreas cancer (RR=1.74 (M), 1.31 (F)), 
endometrial cancer (RR=1.4 kidney cancer (RR=1.28 (M), 1.44 (F)), and thy-
roid cancer (RR=1.29 (M), 1.46 (F)), all significant. We found a strong effect 
of diabetes duration, with an RR of 2.5 during the first year, decreasing to 1.2 
(M) and 1.1 (F), after 2-5 years.
Conclusion: Some of the observed excess risk may be explained by risk fac-
tors for cancer being more frequent in T1D patients (obesity), however this 
effect is presumably smaller than in T2D patients, and hence consistent with 
the smaller excess risk. The long-term RR (>5 years of DM) is less than 1.2, 
which means that some small effect of exogenous insulin cannot be excluded, 
but the study is also consistent with an assumption of no such effect.
Supported by: EFSD 
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Time-varying incidence of cancer after incident type 2 diabetes: 
differences by obesity-versus non-obesity-related cancers
A. Renehan1, E. Badrick2, M. Sperrin2, M. Carr2, T. Moran3, I. Buchan2;  
1Institute of Cancer Sciences, University of Manchester,  
2Institute of Population Health, University of Manchester,  
3NHS, Northwest Cancer Intelligence Service, Manchester, UK.
Background and aims: People with Type 2 diabetes (T2D) are at increased 
incident risk of several cancer types, many of which are also causally linked 
with excess body weight. To explore these relationships further, we deter-
mined the incidence of cancer in people with incident T2D during different 
time windows following diabetes diagnosis, stratified as obesity- and non-
obesity-related cancers.
Materials and methods: We used the Salford Integrated record database linked 
with the Northwest cancer Intelligence service (UK) for data from 1995-2010. 
We identified incident cohorts with (N = 10,328) and without T2D, who were 
matched (1: 2) by age, sex and index year. Following exclusion of previous can-
cers, first site-specific cancers were identified prospectively in both cohorts. 
Obesity-related cancers were post-menopausal breast, colorectal, endometrial, 
kidney, gallbladder, pancreas, liver, and ovarian. Risk estimates were expressed 
as hazard ratios (HRs) and their 95% confidence intervals (CIs).
Results: Diabetic patients had a significantly higher BMI than matched con-
trols (mean 30.9 (SD6.7) vs 27.3 (SD5.4)), and were more likely to be ever 
smokers (60.0% vs 52.63%). Within 6 months following diabetes onset, par-
ticipants with T2D were at increased risk of obesity-related (HR 1.54, 95% CI: 
0.98, 2.40) but not non-obesity-related cancers. From 6 months to 10 years, 
risk associations for obesity- and non-obesity-related cancers remained close 
to null. After 10 years following diabetes onset, participants with T2D were 
at increased risk of non-obesity-related (HR 1.49, 95% CI: 1.13, 1.97) but not 
obesity-related cancers. These observations were robust to adjustment for 
smoking.
Conclusion: We confirmed that people with incident T2D are at increased 
risk of certain cancers; the risk for obesity-related cancers is particularly el-
evated near to the time of diabetes onset, and is likely to present detection 
time bias. Paradoxically, we noted elevated risk of non-obesity-related can-
cers among people with T2D with greater than 10 years disease duration, 
emphasizing the importance of assessing diabetes-cancer associations using 
time-varying approaches.
Supported by: EFSD
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Diabetes and cancer risk in a population-based study with 20 years of 
follow-up: the Rotterdam Study
K.M.J. De Bruijn1, R. Ruiter2, T.E. de Keyser2, A. Hofman2, B.H. Stricker2, 
C.H.J. van Eijck1;  
1Surgery, Erasmus University Medical Center, 2Epidemiology,  
Erasmus University Medical Center, Rotterdam, Netherlands.
Background and aims: Type 2 diabetes is associated with an increased risk 
of cancer. Most observational studies on this topic analyze diabetes as a di-
chotomous risk factor without adjusting for diabetes Duration before cancer 
occurrence. The objective of this study was to investigate the association be-
tween diabetes duration and cancer risk in more detail.
Materials and methods: In this prospective cohort study, incident diabetes 
was diagnosed on the basis of clinical information and use of glucose-lower-
ing medication. Details on incident cancers were obtained via general practi-
tioners and linkage to registers for pathology. Time-dependent Cox propor-
tional hazard models were used. Additionally, a five year latency period was 
taken into account.
Results: The study comprised 10,746 individuals. Diabetes was associated 
with an increased overall risk of incident cancers (HR 1.22, 95%CI 1.07-1.39). 
Distinguished by type of cancer, diabetes was associated with an increased risk 
of breast (HR 1.50, 95%CI 1.05-2.15) and pancreatic cancer (HR 2.93, 95% 
CI 1.75-4.89), but with a decreased risk of prostate cancer (HR 0.59, 95%CI 
0.38-0.93). As a diabetes diagnosis of less than three months before a cancer 
diagnosis was associated with strongly increased risks for all cancers (HR 3.30, 
95%CI 2.50-4.32) and pancreatic cancer (HR 28.74, 95%CI 6.32-130.58), at 
least a part of the association might be explained by detection bias or by pro-
topathic bias. After adjusting for a latency period of five years, the association 
regarding the decreased risk of prostate cancer remained statistically signifi-
cant, whereas the risk of rectal cancer increased (HR 2.26, 95%CI 1.04-4.95).
Conclusion: Although the magnitude of the association between diabetes 
and increased risk of cancer seems to be inflated by detection- or protopathic 
bias, an independent association remains. Future studies investigating this 
association should adjust for diabetes duration and a plausible etiological risk 
window.
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Cancer therapy alters whole body metabolism later in life: a potential 
role for epigenetic mechanisms
V. Nylander1, D. Simar2, M. Aznar3, L. Specht3, J.R. Zierath1, R. Barres1;  
1The Novo Nordisk Foundation Center for Basic Metabolic Research, 
University of Copenhagen, Denmark, 2School of Medical Sciences, 
University of New South Wales, Sydney, Australia, 3University of 
Copenhagen, Denmark.
Background and aims: Cancer survivors are at increased risk of acquiring 
metabolic dysfunction such as glucose intolerance and Type 2 Diabetes, years 
after end of cancer treatment. Epidemiological studies identified total body 
irradiation as the highest risk factor. Given the importance of muscle tissue in 
whole body glucose metabolism, we focused on skeletal muscle progenitors 
cells. We hypothesized that irradiation causes epigenetic changes in this cell type 
that could account for the delayed, deleterious effects on metabolic function. 
Aim: To determine if irradiation alters the DNA methylome of muscle pro-
genitor cells, leading to altered differentiation potential and metabolic dys-
function.
Materials and methods: Male C57Bl/6 mice were irradiated (IRR) or not 
(CTL) with one dose of total body irradiation (6 Gy). Mice were allowed to 
recover from acute irradiation effects for 5 weeks before randomisation into 
groups fed CHOW or high fat diet (HFD, 60 % energy intake from fat). Meta-
bolic characterization of mice was done by MR scan, glucose tolerance test 
and indirect calorimetry. Muscle progenitor cells were isolated by FACS sort-
ing to investigate for deficiencies in intracellular pathways controlling me-
tabolism or cell differentiation. In vitro experiments were performed using 
L6 rat myoblasts, which were irradiated with one dose of 1, 3 or 6 Gy. Cells 
were allowed to recover from irradiation for 4 weeks, before differentiation 
was induced and insulin signalling and DNA methylation was investigated. 
Statistical analysis used was one-way and two-way ANOVA for MR and body 
weight, and repeated measures analysis for indirect calorimetry data and glu-
cose tolerance tests.
Results: After recovery from irradiation, calorie intake, oxygen consumption 
and energy expenditure were similar in both groups. Prolonged HFD induced 
impaired glucose homeostasis in IRR-HFD, but not in IRR-CHOW. This was 
accompanied by increased fasting insulin levels in IRR-HFD (50%, p= 0.033), 
whereas fasting insulin was decreased in IRR-CHOW (20%, p= 0.022), as 
compared to respective controls. Muscle progenitor cells collected 17 weeks 
post irradiation and cultured in vitro exhibited decreased growth rate (30%, 
p=0.03) compared to cells collected from CTL animals. Muscle cells collected 
from IRR animals showed altered signalling pathways controlling cell divi-
sion and differentiation. Irradiation of rat muscle cell line phenocopied the 
impaired activation of signalling and exhibited an altered differentiation and 
DNA methylation profile.
Conclusion: Our study confirms that irradiation induces a long-term al-
teration of glucose metabolism and suggests that irradiation stably alters 
the epigenome and the differentiation potential of muscle progenitor cells. 
Irradiation-induced epigenetic modification could be a mechanism by which 
cancer survivors develop metabolic complications later in life.
Supported by: EFSD 
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Overexpression of cutaneous mitochondrial superoxide dismutase in 
recently diagnosed type 2 diabetic patients
D. Ziegler1,2, A. Strom1, S. Püttgen1, J. Brüggemann1, I. Ziegler1, B. Ringel1, 
M. Roden1,2, German Diabetes Study Group;  
1Institute for clinical Diabetology, German Diabetes Center at Heinrich 
Heine University, 2Department of Endocrinology and Diabetology, 
University Hospital, Düsseldorf, Germany.
Background and aims: Oxidative stress resulting from enhanced free-rad-
ical formation and immune-mediated processes has been implicated in the 
pathogenesis of diabetic neuropathy. Since manganese superoxide dismutase 
2 (SOD2) is responsible for superoxide detoxification in mitochondria, we 
hypothesized that cutaneous SOD2 could be overexpressed in recently diag-
nosed diabetes.
Materials and methods: We assessed skin biopsies and nerve function in 71 
participants of the German Diabetes Study (GDS) with recently diagnosed 
type 2 diabetes (age: 54.5±0.9 [SEM] years; male: 67.6%; BMI: 32.2±0.7 kg/
m², diabetes duration: 1.0±0.1 years; HbA1c: 6.5±0.1%) and 52 healthy con-
trol subjects (age: 55.2±1.2 years; male: 53.8%, 25.4±0.5 kg/m²). Intraepi-
dermal nerve fibre density (IENFD) was assessed by immunohistochemis-
try in 3-mm punch biopsies from the distal leg. Subepidermal SOD2 area 
was determined by immunofluorescence using a polyclonal SOD2 antibody. 
CD31 immunohistochemistry was used to quantify subepidermal endothe-
lial cell area. Peripheral nerve function was assessed by motor and sensory 
nerve conduction velocity (MNCV, SNCV), vibration perception thresholds 
(VPT), and thermal detection thresholds (TDT), while cardiac autonomic 
nerve function was assessed by heart rate variability (HRV) in the time and 
frequency domains. All comparisons were adjusted for sex, age, and BMI.
Results: IENFD was lower by 24% in diabetic subjects vs controls (6.9±0.3 
vs 9.1±0.4 fibres/mm; P<0.0001). Subepidermal SOD2 area was increased by 
60% in the diabetic group vs controls (0.24±0.02 vs 0.15±0.02%; P<0.0001). 
Subepidermal endothelial cell area did not differ between the diabetes group 
and controls (2.03±0.15 vs 1.89±0.13%), but was smaller by 28% in diabetic 
subjects with known diabetes duration ˃1 year compared to those who had 
diabetes for ≤1 year (1.64±0.16 vs 2.29±0.22%; P=0.047). Subepidermal en-
dothelial cell area declined (r=-0.33; P=0.02), whereas SOD2 area augmented 
with increasing diabetes duration (r=0.26; P=0.032). In the diabetes group, 
multivariate linear regression analyses revealed that subepidermal endothe-
lial cell area was associated with IENFD (ß=0.28; P=0.048), whilst SOD2 area 
was related to the low-frequency/high-frequency (LF/HF) ratio as an indica-
tor of sympathovagal balance (ß=0.384; P=0.001).
Conclusion: Patients with recently diagnosed type 2 diabetes show cutane-
ous SOD2 overexpression indicating enhanced local oxidative stress linked 
to cardiac sympathetic predominance as well as dermal microvascular altera-
tions related to epidermal nerve fibre loss and diabetes duration. Whether 
cutaneous SOD2 is an early marker to predict the development of diabetic 
peripheral and autonomic neuropathy remains to be determined in prospec-
tive studies.
Supported by: MIWF NRW, BMG, BMBF to DZD e.V.
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Wound healing rate is impaired by a glucose-induced overactive  
Delta4-Notch1 loop
X. Zheng1, V.G. Sunkari1, I.R. Botusan1,2, J. Grünler1, A.I. Catrina3,  
F. Radtke4, K. Brismar1, S.-B. Catrina1;  
1Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, Sweden, 2University of Medicine and Pharmacy “Carol Davila”, 
Bucharest, Romania, 3Department of Rheumatology, Karolinska Institutet, 
Stockholm, Sweden, 4Ecole Polytechnique Fédérale de Lausanne,  
Swiss Institute for Experimental Cancer Research, Switzerland.
Background and aims: Notch signaling is central for cell differentiation 
and angiogenesis. It is a cell-cell system composed of several Notch recep-
tors (Notch1-4) and their ligands (Jagged 1-2, delta 1, 3, 4). The signaling is 
activated after binding of the ligands to the receptor which is followed by pro-
teolytic cleavage of the receptor by γ-secretase complex with specific outcome 
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depending on the members of the Notch system involved. Diabetic wounds 
are characterized by impaired coordination of several cellular processes such 
as angiogenesis and cell differentiation. We have studied the potential role of 
Notch signaling in diabetic wound healing.
Materials and methods: Human dermal fibroblasts (HDF) and human der-
mal endothelial cells were used for in vitro studies and several animal models 
of diabetes (db/db mice and streptozotocin-induced diabetic mice) were used 
for in vivo studies. The functional consequence of the notch system modula-
tion was studied in vitro by assessment of the migration of HDF and by an-
giogenesis assay. Notch pathway inhibition was induced either by γ-secretase 
inhibitors or by specific siRNA silencing of the Notch receptors (1-4). Using 
cre-lox system we have generated mice that lack Notch 1 in the skin. Wound 
healing rate was evaluated both in db/db mice and in skin-specific Notch1 
knock-out mice in which diabetes was induced by streptozotocin.
Results: Notch signaling was activated in the skin of several animal models of 
diabetes and biopsies from patients with diabetic wounds. Hyperglycemia ac-
tivated Notch pathway and had repressive effect on fibroblasts migration and 
angiogenesis. Mechanistically, we found that hyperglycaemia enhances delta4 
expression in a Notch1-dependent manner and this positive delta4-Notch1 
feedback loop contributed to the impaired wound healing in diabetes. This 
was confirmed in vivo where inhibition of Notch signaling with γ-secretase 
inhibitors improved wound healing rate just in diabetic (db/db mice) but not 
in control non-diabetic animals. Using loss-of-function genetic approaches 
we demonstrated both at the cellular level (fibroblasts, endothelial cells) as 
well as in an animal model that the Notch1 activation was the key player of 
the repressive effects of Notch on wound healing in diabetes, which was con-
firmed in the biopsies from patients with diabetic foot ulcers.
Conclusion: Glucose activates a positive feedback loop (delta4-Notch1) that 
contributes to the deleterious wound healing in diabetes.
Supported by: VR, Family Erling-Persson Foundation, SLL, Tore Nilssons Foun-
dation
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SP regulates macrophage function in diabetic wound healing
E.C. Leal1,2, A. Tellechea1,2, S. Kuchibhotla2, M.E. Auster2, F.W. LoGerfo2,  
L. Pradhan-Nabzdyk2, E. Carvalho1, A. Veves2;  
1Center for Neurosciences and Cell Biology, Coimbra, Portugal, 2Beth Israel 
Deaconess Medical Center, Harvard Medical School, Boston, USA.
Background and aims: Chronic diabetic foot ulcerations develop in areas 
affected by diabetic neuropathy. As consequence, neuropeptides, such as sub-
stance P (SP), known to modulate inflammation, showed to be important 
in wound healing. However, little it is known about the effect of SP on mac-
rophages activation. We aimed to study the effect of SP on macrophage func-
tion in diabetic wound healing progression.
Materials and methods: We used wild type (WT) mice and two types of ge-
netically modified mice: one deficient of the NK1 receptor of SP (NK1RKO) 
and one deficient of the TAC1 gene that encodes for SP and other takinins 
(TAC1KO). Also, we treated the wound with SP or CJ012,255 (CJ), an in-
hibitor of SP receptor. Diabetes was induced by sreptozotocin intraperito-
neal injection, 50 mg/Kg, 5 days. The animals were kept 8 weeks diabetic 
prior wound healing experiment. M1 and M2 macrophages were identified 
by using immunohistochemistry at several phases of wound healing: baseline 
(Day-0), Day-3 and Day-10 post-wounding. MCP-1, IL-a and KC was quanti-
fied by q-RT-PCR.
Results: The M1/M2 ratio was increased at Day-0 in WT-diabetic mice and 
nondiabetic and diabetic NK1R and TAC1 mice when compared to WT-
nondiabetic mice. In WT-nondiabetic mice, the ratio increased at Day-3 but 
returned to normal levels by Day-10. In contrast, in WT-diabetic and non-
diabetic and diabetic NK1R and TAC1 mice at Day-0, Day-3 and Day-10, the 
M1/M2 ratio remains high, suggesting a persistent inflammation. At Day-10, 
the M1/M2 ratio was increased in CJ- treated WT-nondiabetic and WT-dia-
betic mice. In contrast, SP treatment reduced the diabetes-induced increase 
in M1/M2 ratio. Similar results were observed in the skin gene expression of 
the monocyte chemoattractant 1 (MCP-1) that recruits monocytes in areas of 
inflammation where they are converted to macrophages. At Day-0, MCP-1 
was increased in the TAC1KO mice. MCP-1 expression increased at Day-3 
in all non-diabetic and diabetic mice. At day-10, all mice groups had a de-
creased MCP-1 expression but, nonetheless, it was increased in WT-diabetic. 
SP treatment increased MCP-1 expression at Day-3 in both WT-nondiabetic 
and diabetic wounds. At Day-10, SP treatment reduced MCP-1 expression 
in both WT-nondiabetic and diabetic mice while CJ-treated mice had high-
er expression when compared to SP-treated mice. Moreover, diabetic mice 
showed an increase in IL-6 expression at baseline while SP induced a further 
increase in IL-6 gene expression in WT-nondiabetic mice at Day-3. NK1RKO 
and TAC1KO mice showed an increase in IL-6 expression at baseline. KC 
gene expression was also increased in WT diabetic mice at baseline and this 
increase persisted at Day-10. SP induced an acute increase at Day-3 that was 
followed by a reduction to normal levels at Day-10. NK1RKO and TAC1KO 
mice had also higher KC gene expression at baseline and NK1RKO mice 
showed a higher KC expression at Day-3.
Conclusion: In conclusion, the reduction in SP availability results in a pro-
inflammatory activation of skin macrophages before wounding. SP also plays 
a major role in shifting macrophages to the M2 activation promoting wound 
healing. Furthermore, SP induced an increase in the acute inflammatory 
phase of wound healing during the early stages of wound healing but con-
siderably reduces it in later stages, which is essential for a good skin repair.
Supported by: NIH 1R01NS066205, NIH 1R01DK076937, NIH 1R01NS046710, 
EFSD, FCT-PTDC/2010
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Living human keratinocytes as a therapeutic option to improve diabetic 
ulceration
D. Maucher, C. Schürmann, I. Goren, S. Frank;  
Pharmazentrum Frankfurt, Germany.
Background and aims: Diabetes-associated foot ulcerations (DFU) repre-
sent a serious clinical complication of wound healing. To date, pharmaco-
logical approaches to improve diabetic wound healing disorders still remain 
poor and limited. The lack of knowledge for underlying molecular and cel-
lular mechanisms of impaired wound healing particularly adds to this un-
satisfactory clinical condition. Here we used human keratinocytes (BAWD, 
bio-active wound dressing) as a dynamic approach to deliver a living source 
of multiple wound-induced mediators for treatment of highly disturbed heal-
ing conditions in severely diabetic mice.
Materials and methods: BAWD consists of human keratinocytes cell line 
(KCBl1). The cells were cultured on a hyaluronic acid matrix. The KCBl 1 cell 
line represents well-characterized, safe, and highly proliferative keratinocytes, 
which have been initially isolated from human foreskin. For wound healing 
studies, six full-thickness wounds (5 mm in diameter, 3-4mm apart) were 
made on the back of severely diabetic C57BL/6J-db/db mice. Upon injury, 
mice received a coverage of skin wounds using hyaluronic acid matrix alone 
(vehicle) or living keratinocytes (BAWD, therapeutic). Skin biopsy specimens 
were obtained from the animals at day 3, 7 and 10 after injury. Protein and 
RNA isolation was performed and wound biopsies were fixed for histology. 
The transcriptome of hyaluronic acid- and BAWD-covered wound tissue was 
analyzed by direct mRNA sequencing. Paraffin sections (4µm) were stained 
for collagen deposition (azan trichrome) or incubated using antisera against 
CD31, VEGF or myosin heavy chain 7.
Results: BAWD strongly improved diabetes-disturbed wound healing. 
BAWD-covered wounds showed a very robust formation of granulation tis-
sue in the presence of hyperglycaemia. New tissue was characterized by high 
expression levels of angiogenic VEGF. Induced expression of the endothelial 
marker Tie-2 and a high density of newly formed blood vessels defined newly 
formed tissue. Moreover, gene expression analyses of BAWD-improved 
wound tissue showed a keratinocyte-mediated induction of a large set of 
genes, which are known to be specifically involved in skeletal and heart mus-
cle development, differentiation and function. Improved wound tissue upon 
BAWD-treatment also showed combined expression levels of the mesenchy-
mal stem cell markers Sca-1 and CD29.
Conclusion: BAWD markedly improved wound healing in diabetic mice by 
accelerating the formation of new tissue at sites of diabetes-impaired wounds 
repair.
Supported by: GRK 1172
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Macro-encapsulated human embryonic stem cell-derived implants  
meet characteristics of clinical human islet cell grafts
E. Motté1, E. Szepessy1, K. Suenens1, G. Stangé1, M. Bomans2,  
D. Jacobs-Tulleneers-Thevissen1, Z. Ling1, E. Kroon3, D. Pipeleers1;  
1Diabetes Research Center, 2Beta-Cell nv, Jette, Belgium,  
3Viacyte Inc., San Diego, USA.
Background and aims: Shortage of good quality human pancreases for use 
in organ and islet cell transplantation has led to development of large-scale 
laboratory sources that generate insulin-producing implants. Pancreatic en-
docrine cells can be formed from human embryonic stem (huES) cells fol-
lowing in vitro derivation to pancreatic endoderm (PE) and further differen-
tiation in immune-incompetent mice. This study examines to which extent 
huES-generated implants meet characteristics of human islet cells as used in 
clinical transplantation.
Materials and methods: Free, alginate-micro- and Theracyte-macro-encap-
sulated huES-derived PE-grafts of similar size were implanted in mice with 
severe-combined-immune-deficiency. Their in vivo differentiation was com-
pared through plasma human C-peptide levels and cellular analysis of im-
plants at posttransplant week 20. Implants retrieved from Theracyte-macro-
devices were analyzed for glucose-regulated hormone synthesis and release. 
Data were compared with those collected for human islet cells.
Results: Endocrine enrichment was higher in encapsulated than free hu-ES-
implants or in clinical-grade human islet cell grafts, with enrichment in single 
hormone-positive alpha, beta and delta cells in macro-devices and alpha cells 
in microcapsules. Macro-huES-implants resulted in higher plasma human C-
peptide than free human islet cell transplants with similar cell number. They 
exhibited equally rapid insulin- and glucagon-secretory responses to increas-
ing and decreasing glucose concentrations during perifusion. Their insulin 
secretory amplitude to glucose was lower, in part attributable to a lower cellu-
lar hormone content; this was associated with lower glucose-induced insulin 
biosynthesis, but not with lower glucagon-induced stimulation of release.
Conclusion: Macro-encapsulated huES-derived implants can reach an endo-
crine composition and function with therapeutic potential. Their beta cells 
exhibit rapid glucose responsiveness with lower amplitude, compatible with 
an immature functional state. Comparative data with clinical-grade human 
islet cell grafts set references for further development and clinical translation.
Supported by: EC-FP7, JDRF encapsulation consortium, Flemish Government, 
FWO
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Impaired processing of human pro-islet amyloid polypeptide (proIAPP) 
promotes early islet graft failure
J.A. Courtade, P.C. Orban, C.B. Verchere;  
Pathology and Laboratory Medicine, The University of British Columbia, 
Vancouver, Canada.
Background and aims: Islet transplantation is a promising therapy for type 
1 diabetes. Long-term survival of islet grafts may be compromised not only 
by immune rejection but also other factors including the formation of islet 
amyloid from islet amyloid polypeptide (IAPP). IAPP aggregation has been 
linked to beta-cell dysfunction, apoptosis, and islet inflammation but the 
underlying mechanism of islet amyloid formation remains elusive. Elevated 
circulating proinsulin:insulin ratios have been detected in type 2 diabetes 
and in type 1 diabetic recipients of islet transplants. Processing of the IAPP 
precursor, proIAPP, may be similarly compromised in islet transplants and 
type 2 diabetes, since like proinsulin, proIAPP is processed by the beta cell 
prohormone convertases PC1/3 and PC2. We hypothesize that accumulation 
of proIAPP intermediates leads to amyloid formation and beta-cell dysfunc-
tion and assessed the impact of impaired proIAPP processing in transplanted 
islets.
Materials and methods: NOD.SCID mice (age 8-10 weeks) were made dia-
betic with streptozotocin and transplanted with islets from mice with beta-
cell expression of human proIAPP and lacking PC2 (hIAPPTg/0; PC2-/-) or 
controls (hIAPPTg/0;PC2+/-, hIAPP0/0;PC2-/-, hIAPP0/0;PC2+/-). Blood glucose 
was monitored weekly in recipients for 16 weeks or until graft failure (re-
turn of hyperglycaemia). Islet graft sections were stained for insulin, amyloid 
deposition (thioflavin S) and TUNEL positivity.
Results: Diabetes (blood glucose >16.9 mM) returned in almost all (90%) of 
recipients of hIAPPTg/0;PC2-/- islets within 16 weeks post-transplant, whereas 
recipients with normal human proIAPP processing (hIAPPTg/0;PC2+/-) re-
mained normoglycemic for the entire 16 weeks. Recipients of grafts express-
ing native rodent IAPP, with or without PC2, similarly maintained normogly-
cemia. Despite early graft failure in recipients of islets with impaired human 
proIAPP processing, beta-cell mass remained unchanged and amyloid depo-
sition was lower compared to human proIAPP-expressing mice with normal 
processing. Islet grafts had few TUNEL-positive beta cells and no difference 
in the number of TUNEL-positive cells among groups, suggesting that im-
paired human proIAPP processing compromises beta-cell function rather 
than promoting beta-cell apoptosis.
Conclusion: Impaired human proIAPP processing in islet transplants induc-
es early graft failure without affecting beta-cell mass or increasing amyloid 
formation. These data suggest that impaired proIAPP processing promotes 
dysglycemia, possibly via the formation of early (pro)IAPP aggregates that in-
duce beta-cell dysfunction. Our work implicates IAPP precursors as potential 
targets to prolong islet graft survival.
Supported by: CIHR Transplant Training Program
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In type 1 diabetic patients pancreas transplanted simultaneously  
with kidney preserves long-term kidney graft ultrastructure better  
than kidney transplantation alone
J.P.H. Lindahl1, F. Reinholt2, I.A. Eide1, A. Hartmann1, O. Øyen1,  
T. Jenssen1,3;  
1Department of Transplant Medicine, 2Department of Pathology,  
Oslo University Hospital, Norway, 3University of Tromsø, Norway.
Background and aims: In type 1 diabetic patients with end-stage renal dis-
ease (ESRD) we aimed to determine whether long-term normoglycaemia, as 
achieved by successful simultaneous pancreas and kidney (SPK) transplan-
tation, would preserve kidney graft structure, determined by morphometry 
and electron microscopy (EM), and function compared with live donor kid-
ney (LDK) transplantation alone.
Materials and methods: Estimated GFR (eGFR) was calculated in 25 recipi-
ents with SPK and 17 recipients with LDK in a stable phase 3 months after 
transplantation and annually during follow-up. Ultrasound guided kidney 
graft biopsies were obtained from all participants at follow-up. All biopsies 
were processed for light microscopy to measure glomerular volume, and EM 
to obtain data on glomerular basement membrane (GBM) width, mesangial 
fractional volume and podocyte coverage of the capillary basement mem-
brane.
Results: SPK and LDK recipients were similar in age and diabetes duration at 
engraftment. The median duration of follow-up was 10.1 years. HbA1c was 
5.6±0.4 % and 8.3±1.7 % in the SPK and LDK group, respectively (p<0.001). 
Compared with SPK recipients, patients who received LDK had significantly 
wider GBM (368.9±109.4 nm vs 281.0±56.7 nm; p=0.008) and increased me-
sangial fractional volume (23 (13, 59) % vs 16 (10, 41) %; p=0.006) at follow-
up. Podocyte coverage of the capillary basement membrane was equal in the 
SPK (88 (58, 100) %) and LDK (89 (57, 100) %) group (p=0.35). Glomeru-
lar volume tended to be higher in LDK (4.5 (2.2, 8.2) x 106 µm3) compared 
with SPK (3.2 (1.6, 12.9) x 106 µm3) recipients (p=0.10). In the SPK group the 
eGFR declined from 78.3±16.7 at transplantation to 67.3±23.7 ml/min/1.73 
m² at follow-up (-11.0±21.4 ml/min/1.73 m²), and the recipients of LDK de-
clined from 68.9±13.2 to 46.2±14.2 ml/min/1.73 m² (-22.7±15.2 ml/min/1.73 
m²), respectively (p=0.060).
Conclusion: In type 1 diabetic patients with long-term normoglycaemia af-
ter successful SPK transplantation kidney graft ultrastructure was better pre-
served compared with LDK.
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Coronary artery disease in type 1 diabetic patients long-term after 
simultaneous pancreas and kidney transplantation compared with 
kidney transplantation alone 
T. Jenssen1,2, J.P.H. Lindahl1, A. Hartmann1, K. Endresen3, A. Günther4;  
1Department of Transplant Medicine, Oslo University Hospital,  
2University of Tromsø, 3Department of Cardiology,  
4Department of Radiology, Oslo University Hospital, Norway.
Background and aims: Improved long-term glycaemic control protects 
against development of cardiovascular disease and death in type 1 diabetic 
patients. We aimed to determine whether long-term normoglycaemia, as 
achieved by successful pancreas and kidney transplantation (SPK), would 
change the development of coronary artery disease (CAD) compared with 
successful live donor kidney transplantation alone (LDK).
Materials and methods: Twenty type 1 diabetic patients who had received 
SPK grafts were compared with 11 recipients of LDK. All patients included 
underwent baseline (pre-transplant) and follow-up coronary angiography. 
Computed tomography (CT) examination was performed at follow-up to ob-
tain coronary artery calcium scoring (CACS). Logistic regression was used to 
evaluate association between CACS and CAD.
Results: Recipients of SPK grafts and LDK were similar in terms of age and 
diabetes duration at engraftment. The median duration of follow-up was 9.2 
years. HbA1C was 5.6±0.4 % and 8.4±2.0 % in the SPK and LDK group, re-
spectively (p<0.001). In the SPK group the eGFR declined from 81.6±14.8 at 
transplantation to 69.9±22.0 ml/min/1.73 m² at follow-up (-11.7±22.0 ml/
min/1.73 m²), and the recipients of LDK declined from 70.1±14.5 to 50.8±11.6 
ml/min/1.73 m² (-19.3±11.9 ml/min/1.73 m²), respectively (p=0.22). Coro-
nary angiography at baseline revealed that 11 out of 20 SPK recipients had 
CAD, defined as coronary luminal stenosis of 50 % or more in at least 1 vessel, 
compared with 1 out of 11 recipients in the LDK group (p=0.020). During 
follow-up there was no difference in patients with progression (defined as 
a new stenosis at or above 50 % in one or more vessels) of CAD between 
the SPK group (10 out 20 recipients) and the LDK group (5 out of 11 recipi-
ents; p=0.81). Median Agatston scores of coronary arteries with CT scan at 
follow-up were extremely high: 1625 (9, 7368) and 1391 (4, 5897) for the 
SPK and LDK group, respectively (p=0.92). There was, on the other hand, 
no significant association between high CACS and coronary artery lumen 
narrowing (≥50% diameter stenosis) in the SPK group (OR 1.001, CI 1.000, 
1.003; p=0.079) or in the LDK group (OR 1.000, CI 0.999, 1.001; p=0.61).
Conclusion: This study suggests that median 9 years of normoglycaemia, as 
achieved by successful SPK transplantation, is not sufficient to halt or reverse 
CAD in previously uraemic diabetic patients. Calcification of coronary arter-
ies is a prominent feature in this group of patients.
OP 47 Pharmacogenetics and 
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Modelling the rate of deterioration of diabetes in observational data:  
a DIRECT study
L.A. Donnelly1, K. Zhou1, C. Jennison2, E.R. Pearson1;  
1Division of Cardiovascular & Diabetes Medicine, University of Dundee, 
2Department of Mathematical Sciences, University of Bath, UK.
Background and aims: The rate at which diabetes progresses following diag-
nosis of type 2 diabetes(T2D) is highly variable between individuals. Outwith 
clinical trials of monotherapy such as ADOPT and UKPDS, it is challeng-
ing to model progression rates in the population of patients with diabetes 
due to the fact that underlying ‘diabetes severity’ reflects both drug treatment 
and HbA1C. The aim of this study was to combine these measures to derive a 
Diabetes Severity Score for each individual and then model the rate of pro-
gression.
Materials and methods: We utilised the electronic medical records from pa-
tients in the Genetics of Diabetes Audit and Research (GoDARTS) cohort, 
Tayside, Scotland. A Diabetes Severity Score was derived based on a patient’s 
observed HbA1C measures from diabetes diagnosis through to study end (de-
fined as earliest of insulin initiation, death or 31st July 2011). We expected 
patients to exhibit a steady progression and this would appear as a gradual 
increase in Diabetes Severity Score. We therefore fitted a linear model with 
a slope and intercept for each individual, an additional parameter for every 
drug combination, BMI category and an error term.
Results: 3533 patients were included in the analysis with a median follow up 
time of 7.5years and 17 HbA1C measures. Mean age at diagnosis was 63years 
and 56% were male. 12% patients progressed to insulin treatment over the 
follow-up period. The estimated effect on HbA1C of the diabetes drugs was in 
line with clinical trial data. For example Metformin lowered HbA1C in a dose 
dependent manner (-0.21%<500mg;-0.35% 500mg; -0.49% 850mg;-0.61% 
1G; -0.8%>1G) and sulphonylureas had a dose independent effect of -0.52%.
The median progression rate was an increase in 0.1% HbA1C per year. The 
top 25% of progressors had an increase >0.3% and the top 10% >0.6%. The 
lower 25% had little or no progression. When comparing the highest vs low-
est quartile, predictors of rapid progression at baseline were younger age at 
diagnosis (mean 58.2 vs 67years, p<0.0001); lower HDL (1.16 vs 1.24mmol/l, 
p<0.0001); higher triglycerides (2.71 vs 2.39mmol/l, p<0.0001); higher BMI 
(32.3 vs 31.3kg/m2,p=0.0002) and; higher HbA1C(8.02 vs 7.75%, p=0.0015). 
In addition 34.1% of the highest quartile progressed to insulin vs 1.6% in the 
lowest.
Conclusion: We have developed a novel approach to model diabetes progres-
sion in observational data across multiple drug combinations. The progres-
sion rates are similar to that described for monotherapy in ADOPT (0.14% 
HbA1C per year in metformin group); with progression faster in those with 
a more obese insulin resistant phenotype. This approach can be used to in-
vestigate biological determinants of progression as well as the impact of drug 
effects on progression rates. Gaining insight into why some patients progress 
rapidly and some do not will enable a more stratified approach to the man-
agement of T2D.
Supported by: IMI
258
HbA1c trajectories in type 2 diabetes patients: The Diabetes Care System 
cohort
G. Nijpels, I. Walraven, M.R. Mast, T. Hoekstra, A.P.D. Jansen,  
A.A.W. van der Heijden, S.P. Rauh, F. Rutters, E. van ‘t Riet, P.J.M. Elders, 
A.C. Moll, B.C.P. Polak, J.M. Dekker;  
EMGO Institute for Health and Care research, VU University Medical 
Center, Amsterdam, Netherlands.
Background and aims: The revised ADA/EASD guidelines for the manage-
ment of type 2 diabetes mellitus (T2DM) recommend HbA1c levels of ≤ 53 
mmol/mol. However, clinical characteristics of T2DM patients with glyce-
mic control trajectories that are distinct from achieving the recommended 
HbA1c target are inadequately studied. In order to eventually improve gly-
cemic control, the primary aim of this study was to determine subgroups of 
T2DM patients with distinct trajectories of HbA1c levels. Furthermore, sub-
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 115
1 C
group characteristics were determined and the prevalence of microvascular 
complications over time was investigated.
Materials and methods: 5423 T2DM patients with at least two HbA1c fol-
low-up measurements were selected out of 9849 T2DM patients from the 
primary Diabetes Care System cohort. The mean follow-up period was 5.7 
years (range 2 to 9 years). Latent Class Growth Modelling (LCGM) was per-
formed to identify subgroups of patients with distinct trajectories of HbA1c 
levels. Multinomial logistic regression analyses were conducted to determine 
subgroup characteristics. Associations of different subgroups with retinopa-
thy, microalbuminuria and medication use during follow-up were studied by 
constructing plots and by graphically comparing differences between sub-
groups.
Results: Four subgroups with distinct trajectories of HbA1c levels were 
identified (Figure). The first and largest subgroup (83%) maintained good 
glycemic control over time (HbA1c ≤ 53 mmol/mol), the second subgroup 
(8%) initially showed severe hyperglycaemia, but reached the recommended 
HbA1c target within 2 years. Patients within this subgroup had significantly 
higher baseline HbA1c levels but were otherwise similar to the good glycemic 
control subgroup. The third subgroup (5%) showed hyperglycaemia and a de-
layed response without reaching the recommended HbA1c target. The fourth 
subgroup (3.0%) showed deteriorating hyperglycaemia over time. Patients 
within the last two subgroups were significantly younger, had higher baseline 
HbA1c levels and had a longer diabetes duration at baseline. These subgroups 
also showed a higher prevalence of retinopathy and microalbuminuria com-
pared to the good glycemic control subgroup.
Conclusion: This is the first study identifying subgroups with distinct tra-
jectories of HbA1c levels in a T2DM cohort. More than 90% of the patients 
reached and maintained good glycemic control. Two subgroups showed a 
more unfavorable course of glycemic control. These T2DM patients were 
younger, had higher HbA1c levels and a longer diabetes duration at baseline.
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Statistical power enhancement in diabetic drug trial by selectively 
sampling participants from the tails of biomarker distributions: a 
DIRECT study
A. Ashfaq1, N.A. Pasdar1, A. Kurbasic1, D. Shungin1, E.R. Pearson2,  
P.W. Franks1;  
1Lund University Diabetes Research Centre, Department of Clinical 
Sciences, Lund University, Malmö, Sweden, 2Division of Cardiovascular & 
Diabetes Medicine Medical Research Institute, University of Dundee, UK.
Background and aims: Within the IMI DIRECT Study we are seeking to 
identify biomarkers that modify treatment response, primarily using obser-
vational studies to generate hypotheses that will be validated in clinical trials. 
Here, we compared statistical power to detect gene-metformin interactions in 
two types of trials: approach ‘A’ represents interactions evaluated in an exist-
ing clinical trial that involves randomly selected participants; approach ‘B’ 
involves selecting participants on the basis of discordant levels of genetic risk 
score (GRS) comprised of 20 variants that modify treatment effects (geno-
type-based recall: GBR).
Materials and methods: Model assumptions were based on published data 
from the Diabetes Prevention Program, a randomized controlled trial of met-
formin treatment vs. placebo. We simulated GRS-metformin interactions, as-
suming the 20 GRS variants convey comparable gene-metformin interaction 
effects to those reported for the MATE1 locus. The effects of the metformin 
and placebo interventions were estimated assuming randomised treatment 
allocation. To simulate approach ‘A’, participants were randomly sampled 
from a larger population-sampling frame (N=10,000-50,000), as might be 
the case in a conventional clinical trial. To simulate approach ‘B’, participants 
were purposefully sampled at random and from the upper tail of GRS distri-
bution from the same sampling frames. Time to diabetes event was calculated 
using the proportional hazards function. Sample size calculations were per-
formed using 1000 iterations per simulation in the R software package.
Results: Figure 1 shows representative results from these analyses: to obtain 
80% power to detect the specified gene x metformin interaction effect, the 
GBR approach would require 300-400 participants, whereas the random-
sampling approach would require roughly 800 participants for rare alleles 
(Fig. 1a). For common alleles a sample size of ~250 would suffice with the 
GBR approach compared with sample size of ~650 for the random sampling 
approach. Similarly, where interaction effects are smaller in magnitude, the 
difference in sample-size requirements for the random vs. the GBR sampling 
approach increases substantially. The size of the sampling-frame also affects 
power (Fig. 1b).
Conclusion: The GBR approach for validating observations of gene-drug 
interaction offers a potentially powerful alternative to conventional clinical 
trials, which is especially appealing when gene variants are rare and pheno-
typing is expensive.
Supported by: EC and EFPIA.
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Antidepressant medication use and trajectories of fasting plasma glucose 
and HbA1c levels: a 9-year longitudinal study of the DESIR cohort
M. Azevedo Da Silva, A. Dugravot, B. Balkau, A. Singh-Manoux, H. Nabi;  
CESP - U.1018, INSERM, Villejuif, France.
Background and aims: Some research has suggested that antidepressant 
medication use (AMU) may increase the type 2 diabetes (T2D) risk. However 
the causal mechanism of this association remains unclear. To study the bio-
logical plausibility of this relationship, we examined the association between 
AMU and changes in fasting plasma glucose (FPG) and in HbA1c levels over 
time.
Materials and methods: Participants were 4869 men (49.2%) and women, 
free of T2D and aged 30-65 years at baseline, followed for 9 years between 
1994 and 2005 in the French D.E.S.I.R. cohort study. AMU, FPG and HbA1c 
were assessed concurrently at 4 medical examinations in phases 1 (1994-
1996), 2 (1997-1999), 3 (2000-2002) and 4 (2003-2005). Linear mixed models 
were used to examine the longitudinal associations of AMU with FPG and 
HbA1c levels.
Results: FPG and HbA1c levels increased over follow-up. In model adjusted 
for sociodemographic characteristics, health-related behaviours, medical 
conditions and other medications, there was no difference in mean FPG and 
HbA1c levels (β=-0.001 p=0.974, β=0.012 p=0.662, respectively) among an-
tidepressant medication users and non-users at baseline (1994-1996). The 
interaction term between time and AMU, suggested no increase in FPG and 
HbA1c levels in antidepressant users comparatively to non-used over 9-year 
of follow-up (β=-0.004 p=0.535, β=-0.002 p=0.548 respectively). Similar pat-
terns of associations were observed when the type and the cumulative use of 
antidepressants over follow-up were considered.
Conclusion: Our results suggest that AMU is not associated with an increase 
in FPG and HbA1c levels over 9-year of follow-up. This suggests that the 
nature of the association between AMU and T2D risk, observed in previous 
studies, may not be causal.
Supported by: The Ministry of Research (France)
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Exogenous adiponectin administration through a subcutaneous 
minipump reverses high-fat diet-induced impairment of adipose tissue 
metabolism
P. Matafome1, T. Rodrigues1, A. Pereira1, L. Letra1, H. Azevedo2, A. Paixão1, 
M. Silvério1, A. Almeida2, C. Sena1, R. Seiça1;  
1Faculty of Medicine, University of Coimbra,  
2Hitag, Biocant, Cantanhede, Portugal.
Background and aims: Despite adiponectin administration is thought to be 
a future strategy to obese or type 2 diabetic patients, it still is a myth, due 
to its expensive costs and absence of studies demonstrating the effective-
ness of chronic exogenous adiponectin. Our aim was to develop a method 
to produce adiponectin for long-term adiponectin administration and test its 
usefulness in improving metabolic profile and adipose tissue metabolism in 
high-fat diet fed rats.
Materials and methods: Adiponectin (98 μg/day) was administered during 
28 days through a subcutaneous minipump with continued release to normal 
Wistar rats fed a high-fat diet. Several systemic markers of dysmetabolism 
and pathways of insulin signaling and lipid storage in epididymal and subcu-
taneous adipose tissue were assessed.
Results: Exogenous adiponectin was able to decrease body weight, fasting 
glycaemia, HbA1c and cholesterol levels (total and non-HDL). In adipose tis-
sue, adiponectin reverted high-fat diet-induced impairment of insulin sign-
aling and decreased IκBα and PPARγ levels, which were mainly observed in 
epididymal adipose tissue. High-fat fed rats showed little activation of lipoly-
sis during fasting in epididymal adipose tissue, despite no alterations were 
observed in the total amount of the protein. This was only partially reverted 
by adiponectin.
Conclusion: Long-term adiponectin administration through a subcutaneous 
minipump was able to improve pathways of insulin signaling and lipid stor-
age in adipose tissue after the consumption of a high-fat diet. Adiponectin 
was also able to improve the metabolic prolife, probably as a result of im-
proved adipose tissue metabolism.
Supported by: FCT
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Immuno-neutralisation of extra-cellular nicotinamide 
phosphoribosyltrasferase as a therapeutic strategy for treatment of type 
2 diabetes
P.W. Caton1, J. Kieswich2, M. Silvestre1, M.M. Yaqoob2;  
1Centre for Diabetes, Blizard Institute, Queen Mary London,  
2Translational Medicine and Therapeutics, William Harvey Research 
Institute, Queen Mary London, UK.
Background and aims: The protein extra-cellular nicotinamide phosphori-
bosyltransferase (eNAMPT; also termed visfatin/PBEF) is elevated in serum 
of type 2 diabetes (T2D) patients and raised eNAMPT levels are reported to 
strongly correlate with declining beta-cell function. Moreover, eNAMPT re-
portedly exerts pro-inflammatory effects suggesting a potential pathophysi-
ological role for eNAMPT in T2D. However, the precise functional relation-
ship between elevated serum eNAMPT and the pathophysiology of T2D has 
not been determined. Interestingly, eNAMPT exists in serum as a monomer 
and a dimer, suggesting a potential structure/function relationship, although 
the precise function and specific changes in each form in T2D have not been 
determined.
Materials and methods: To investigate the role of eNAMPT in T2D, C57Bl/6 
mice were fed a high-fat diet (HFD; 60% fat) for 10 weeks. In weeks 9 - 10, 
mice were administered polyclonal anti-NAMPT antibody (2.5 ug/ml; 2 dos-
es/week) or saline equivalent. After week 10, mice were fasted for 16 h prior 
to glucose tolerance testing (2 g/kg body weight glucose) or sacrificed in the 
fed state for tissue (islets, liver and white adipose tissue; qPCR and western 
blot) and serum analysis
Results: Serum eNAMPT monomer levels were elevated in HFD mice, whilst 
dimer levels were unchanged, as assessed by Native-PAGE immunoblot. 
Immuno-neutralization of eNAMPT corrected HFD-mediated fasting and 
fed hyperglycaemia, hyperinsulinemia and impaired glucose tolerance. These 
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effects were mediated through improvements in beta-cell health (increased 
ex vivo and in vivo islet glucose-stimulated insulin secretion and increased 
islet size) and correction of hepatic insulin resistance (reduced gluconeogen-
ic gene expression, increased insulin signalling). Consistent with a pro-in-
flammatory function of eNAMPT, improvements in glycaemia and beta-cell 
health following eNAMPT-immuno-neutralization were linked to lowering 
of HFD-mediated increases in gene expression of islet and white adipose tis-
sue pro-inflammatory cytokines, chemokines and immune cell markers, as 
well as decreased mRNA levels of islet pro-apoptotic markers.
Conclusion: Elevated serum eNAMPT monomer levels may contribute to 
pathophysiology of T2D, through pro-inflammatory effects. Moreover, selec-
tive neutralization or inhibition of eNAMPT monomer represents a potential 
therapeutic target for treatment of T2D.
Supported by: PWC is a recipient of an EFSD/Lilly Research Fellowship
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TLR4 inhibition blocks cytokine production and restores beta cell 
survival in human pancreatic islets
W. He1, C. Schuster-Klein2, B. Guardiola-Lemaître2, K. Maedler1;  
1Centre for Biomolecular Interactions, University of Bremen, Germany, 
2ADIR-Servier Group, Suresnes, France.
Background and aims: Inflammatory signals are strong mediators of meta-
bolic failure in fat, liver, brain, muscle as well as in pancreatic islets. Toll-like 
receptor-4 (TLR-4) signaling is one of the major pro-inflammatory pathways, 
whose ligands as well as downstream products, i.e. cytokines and chemokines, 
are increased systemically in patients with T2D as well as in at-risk individu-
als. TLR4 knockout mice are protected from the metabolic consequences of a 
high fat diet. In the present study we investigated the consequences of TLR4 
activation in human islets and whether pharmacological inhibition of TLR4 
restores beta-cell survival in a diabetogenic milieu.
Materials and methods: Isolated human islets were exposed to the TLR4 li-
gand Lipopolysaccharide (LPS) in the presence or absence of TLR4 receptor 
small molecule antagonist, TAK-242 (Resatorvid). The effect of TLR4 inhibi-
tion was compared with those achieved by the depletion of islet resident mac-
rophages by treatment of human islets with clodronate liposomes. Expression 
and secretion of pro-inflammatory cytokines/chemokines were evaluated by 
RT-PCR and ultrasensitive ELISA. TLR4 downstream signaling activation 
and apoptosis were analyzed by Western Blotting.
Results: Treatment of isolated human islets with LPS elevated mRNA levels of 
pro-inflammatory cytokines/chemokines, including IL-1alpha, IL-1beta, IL-
6, TNFalpha, CCL2 and IL-8. LPS induced IL-1beta secretion was confirmed 
by ELISA. TAK-242 completely blocked LPS-induced cytokine/chemokine 
expression and IL-1β secretion, while clodronate treatment only inhibited 
IL-1alpha/beta but not IL-6, IL-8, TNFalpha and CCL2 expression. TAK-242 
could completely antagonize the effects of LPS on TLR-4 downstream signal-
ing and apoptosis in human islets, it inhibited phosphorylation of inhibitor 
of nuclear factor kappa B alpha (IkBα) and c-Jun N-terminal kinase (JNK) as 
well as caspase-3 cleavage.
Conclusion: Our results show that TLR4 activation in human islets leads to 
islet inflammation and beta-cell apoptosis, which results in beta-cell failure, 
while the TLR4 inhibitor TAK-242 inhibits cytokine production and restores 
beta-cell survival.
Supported by: the European Research Council
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Intervention with Caspase-1 inhibitor attenuates the metabolic 
syndrome and prevents non alcoholic-steatohepatitis (NASH) in high fat 
diet-fed LDLR-/-.Leiden mice
P.Y. Wielinga, A.M. van den Hoek, K. Salic, W. Liang, T. Kooistra,  
R. Kleemann;  
Metabolic Health Research, Netherlands Organization for Applied Scientific 
Research (TNO), Leiden, Netherlands.
Background and aims: Non-alcoholic steatohepatitis (NASH) is a serious 
liver pathology which develops as a complication of the metabolic syndrome. 
Recently, the inflammasome was proposed to be involved in the development 
of NASH. Here we investigate whether a chemical inhibitor of caspase-1 in 
already manifest metabolic syndrome would prevent the development to 
NASH.
Materials and methods: Male LDLR-/-.Leiden mice were fed a high fat diet 
(HFD; group 1) or low fat diet (LFD; group 2) for 21 weeks. In a third group, 
intervention with caspase-1 inhibitor Ac-YVAD-CMK (40 mg/kg daily) was 
started after 9 weeks of HFD (manifest metabolic syndrome) and continued 
until 21 weeks.
Results: HFD treated mice developed obesity and insulin resistance after al-
ready 9 weeks of HFD feeding. Intervention with caspase-1 inhibitor attenu-
ated a further development of insulin resistance, and reduced body weight 
gain as well as adipose tissue inflammation compared to HFD. Histopatho-
logical analysis of the livers clearly demonstrated prevention of NASH de-
velopment with caspase-1 inhibitor : livers were less steatotic and neutrophil 
infiltration was diminished. Additionally, hepatic fibrosis quantified by sirius 
red staining and acta2 and col1a1 gene expression as observed in HFD treat-
ed mice, was completely prevented.
Conclusion: Intervention with a caspase-1 inhibitor in already established 
disease improved hallmarks of the metabolic syndrome and prevented the 
development of NASH. Our data further support the importance of cas-
pase-1/inflammasome in the development of NASH and demonstrate that 
therapeutic intervention in the already ongoing disease process is feasible.
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Family history of diabetes is a strong predictor of diabetes,  
hypertension and metabolic syndrome in Sri Lankan adults
P. Ranasinghe1, R. Jayawardena2, P. Katulanda3;  
1Department of Pharmacology, Faculty of Medicine, Colombo, Sri Lanka, 
2Institute of Health and Biomedical Innovation, Queensland University of 
Technology, Brisbane, Australia, 3Department of Clinical Medicine,  
Faculty of Medicine, Colombo, Sri Lanka.
Background and aims: Diabetes mellitus has become an important health 
concern in South Asia. Family history (FH) is a common non-modifiable risk 
factor for most of the chronic non-communicable diseases, as it is a collective 
reflection of the genetic susceptibility, shared environments and behaviors. 
Information on FH may serve as a unique and useful tool for public health 
and preventive medicine. The increased genetic predisposition amongst 
South Asians probably makes FH more important in risk assessment than in 
other ethnic groups. The present study aims to describe the influence of FH 
on diabetes prevalence and associated metabolic risk factors in a nationally-
representative sample of South Asian adults from Sri Lanka.
Materials and methods: A cross-sectional community based national survey 
was conducted in 7 of the 9 provinces in Sri Lanka. Five thousand adults were 
recruited for the study using a multi-stage stratified cluster sampling tech-
nique. An interviewer administered questionnaire was used to collect data, 
which included; age, gender, area of residence, ethnicity, level of education, 
household monthly income, duration of diabetes, FH, height, weight, waist 
circumference, hip circumference and blood pressure. FH was evaluated at 
three levels, a) parents, b) grandparents (paternal and maternal) and c) sib-
lings. Presence of diabetes in children was also evaluated. A binary-logistic 
regression analysis controlling for confounders (age, gender, body mass index 
and physical activity) was performed in all patients with ‘presence of diabetes’ 
as the dichotomous dependent variable and using FH in father, mother, ma-
ternal grandmother/grandfather, paternal grandmother/grandfather, siblings 
and children as binary independent variables. A p value <0.05 was considered 
significant.
Results: Sample size was 4485, mean age was 46.1±15.1 years and 39.5% were 
males. The crude prevalence of diabetes, hypertension and metabolic syn-
drome were 12.0%, 27.2% and 26.6% respectively. The overall prevalence of 
FH in the population was 25.5%. In all adults the prevalence of diabetes was 
significantly higher in patients with a FH (23.0%) than those without (8.2%)
(p<0.001). The prevalence of diabetes also increased with the number of af-
fected generations (one - 33.9%, two - 34.2% and three - 37.1%). Presence of 
a FH significantly increased the risk of diabetes (OR:3.35,95%CI:2.78-4.03), 
obesity (OR:2.45,95%CI:1.99-2.99), hypertension (OR:1.25,95%CI:1.08-1.45) 
and metabolic syndrome (OR:2.28,95%CI:1.97-2.63). In all adults presence of 
FH in father (OR:1.29,95%CI:1.02-1.63), mother (OR:1.23,95%CI:1.11-1.36), 
paternal grandfather (OR:1.27,95%CI:1.14-1.41), siblings 
(OR:4.18,95%CI:3.34-5.22) and children (OR:5.47,95%CI:2.93-10.19) all 
were associated with significantly increased risk of developing diabetes.
Conclusion: FH and diabetes had a graded association in the Sri Lankan 
population, as the prevalence increased with the increasing number of gen-
erations affected. FH of diabetes was also associated with the prevalence of 
obesity, metabolic syndrome and hypertension. Individuals with a FH of dia-
betes form an easily identifiable group who may benefit from targeted inter-
vention to prevent the development of diabetes and related metabolic disease.
Supported by: NSF Sri Lanka
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The FINDRISC scale substantially reduces its performance as a screening 
tool for diabetes if diagnosed by HbA1c instead of glucose
J.J. Cabre1,2, B. Costa1,2, F. Barrio1,2, J.L. Piñol1, R. Sagarra1, DE-PLAN-CAT;  
1Catalan Health Institute, Reus, 2Diabetes and Metabolism Area,  
IDIAP Jordi Gol, Spain.
Background and aims: Recently it has been suggested that progression to 
diabetes can be delayed by intensive interventions when applied to real-life 
primary health care of high-risk subjects identified first with the simple Finn-
ish Diabetes Risk Score (FINDRISC) tool. The aim of the study was to inves-
tigate differences in the performance of the FINDRISC as a screening tool for 
glucose abnormalities after shifting from glucose-based diagnostic criteria to 
the proposed new hemoglobin (Hb)A1c-based criteria.
Materials and methods: A cross-sectional primary-care study was conduct-
ed as the first part of an active real-life lifestyle intervention to prevent type 
2 diabetes within a high-risk Spanish Mediterranean population. Individu-
als without diabetes aged 45-75 years (n = 3,120) were screened using the 
FINDRISC. Where feasible, a subsequent 2-hour oral glucose tolerance test 
and HbA1c test were also carried out (n = 1,712). The performance of the 
risk score was calculated by applying the area under the curve (AUC) for 
the receiver operating characteristic, using three sets of criteria (2-hour glu-
cose, fasting glucose, HbA1c) and three diagnostic categories (normal, pre-
diabetes, diabetes).
Results: Defining diabetes by a single HbA1c measurement resulted in a sig-
nificantly lower diabetes prevalence (3.6%) compared with diabetes defined 
by 2-hour plasma glucose (9.2%), but was not significantly lower than that 
obtained using fasting plasma glucose (3.1%). The FINDRISC at a cut-off of 
14 had a reasonably high ability to predict diabetes using the diagnostic cri-
teria of 2-hour or fasting glucose (AUC = 0.71) or all glucose abnormalities 
(AUC = 0.67 and 0.69, respectively). When HbA1c was used as the primary 
diagnostic criterion, the AUC for diabetes detection dropped to 0.67 (5.6% 
reduction in comparison with either 2-hour or fasting glucose) and fell to 
0.55 for detection of all glucose abnormalities (17.9% and 20.3% reduction, 
respectively), with a relevant decrease in sensitivity of the risk score.
Conclusion: A shift from glucose-based diagnosis to HbA1c-based diagnosis 
substantially reduces the ability of the FINDRISC to screen for glucose ab-
normalities when applied in this real-life primary-care preventive strategy. 
As far as we know, this is the first estimate of a possible loss of performance 
of the FINDRISC questionnaire if there is a widespread use of these new 
proposed HbA1c-based diagnostic criteria, at least as a screening tool in the 
context of a program aimed at preventing diabetes.
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Value of the FINDRISK questionnaire to identify prediabetes and 
undetected type 2 diabetes
T.G. Dzebisashvili;  
Endocrinology, Moscow Regional Research Clinical Institute named by 
M.F.Vladimirskiy, Moscow, Russian Federation.
Background and aims: The prevalence rate of Type 2 diabetes mellitus (T2D) 
has been increasing worldwide. The associated cardiovascular risk factors are 
connected with the development of micro- and macrovascular complications 
in the course of the disease and sometimes even before the diagnosis of dia-
betes. T2D is preceded by a pre-diabetic state with impaired fasting glucose 
(IFG), impaired glucose tolerance (IGT) and, in many cases, the metabolic 
syndrome. In this state, which may last for many years, several studies have 
shown that diabetes can be prevented. Identification of subjects with predia-
betes is therefore of great importance, so that preventive action aimed at re-
ducing their risk of T2D and cardiovascular disease (CVD) can be offered. 
Due to cost-effectiveness, screening should primarily be implemented in sub-
jects at high risk to abnormal glucose tolerance (AGT=IFG/IGT/T2D). Aim 
is to evaluate the FINDRISK questionnaire as a screening tool for diabetes 
and prediabetes in a Russian population. In addition, we analysed the asso-
ciation between FINDRISK and CVD risk factor levels.
Materials and methods: In a population-based screening for AGT, a total 
of 1366 adults were invited. Full data with risk score estimate and glucose 
tolerance status were available for 560 subjects without known diabetes. AGT 
was diagnosed using standard OGTT according to WHO 1999/2006 criteria. 
Body mass index (BMI), waist circumference (WC), hypertension, blood li-
pids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) 
were determined. To assess performance of the risk score with respect to T2D 
and AGT, the area under the receiver operating characteristic curve (AUC), 
sensitivity, specificity, positive and negative predictive values were calculated.
Results: The prevalence of screen-detected T2D was 6.1%, whereas 36.1% 
were classified as having AGT. There was a marked increase in the prevalence 
of T2D and AGT with increasing value of the risk score. With risk score > 
10, the positive predictive values (PPV) for T2D and AGT were 11% and 
48%, respectively. Corresponding prevalence were 15% and 59% at higher 
level > 15. The AUC for T2D was 0.766, p < 0.001, whereas for AGT the area 
under the curve was 0.663, p < 0.001. Using the optimal cut-off value of 10 
with the largest area under the curve to identify previously undiagnosed pa-
tients with T2D, AGT resulted in a sensitivity of 91%, 67% and specificity of 
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52%, 59%. To achieve this, only 50% of the total population would need to be 
screened. Increasing the cutoff value of the score to 15 changed the sensitivity 
to 38%, 25% and specificity to 86%, 90% respectively. Apart from total cho-
lesterol and LDL cholesterol, several risk factors for cardiovascular disease: 
age (p < 0.001), BMI (p < 0.001), WC (p < 0.001), systolic and diastolic blood 
pressure (p < 0.001), fasting and 2h plasma glucose (p < 0.001), triglycerides 
(p = 0.016), HDL cholesterol (p = 0.003) had a direct association with the 
FINDRISK values.
Conclusion: FINDRISC proved to be simple and effective test to screen sub-
jects at high risk for T2D. With the optimal cut-off level, the FINDRISC iden-
tified 91% undetected T2D and 67% AGT with relatively high PPV 48% for 
AGT, but only 11% of PPV for new T2D.
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Trends in leisure time physical activity in Danish adults with diabetes
S. Molsted1, N.F. Johnsen2, O. Snorgaard3;  
1Department of Cardiology, Nephrology & Endocrinology, Nordsjællands 
Hospital, Hillerød, 2National Institute of Public Health, University of 
Southern Denmark, 3Department of Endocrinology, Hvidovre Hospital, 
Copenhagen, Denmark.
Background and aims: During the last decades there has been an increased 
focus on physical activity and exercise training in treatment of diabetes. The 
primary aim of this study was to compare leisure time physical activity (PA) 
reported in 2000, 2005 and 2010 by Danish subjects with diabetes. Further-
more, we analysed the subjects’ smoking, alcohol consumption, and body 
mass index (BMI).
Materials and methods: Data comprised level of leisure time PA in four 
categories: physical inactivity, moderate activity, medium activity, and high 
activity; smoking; alcohol consumption; and BMI provided by The Danish 
Health and Morbidity Surveys, nationwide surveys (n=~15,000) from the 
general population. Subjects older than 45 years at the time of the surveys 
were included from cross-sectional analyses from 2000, 2005 and 2010.
Results: The diabetes prevalence was 4.5% (n=386) in 2000, 6.0% (n=489) 
in 2005, and 7.5% (n=622) in 2010. In subjects with diabetes, percentages 
of inactive women decreased from 42.2% to 21.8% (p<0.001) and inactive 
men from 32.2% to 20.9% (p=0.01), with elevated prevalence in the three as-
cending levels of PA (moderate, medium, or high active) from 2000 to 2010. 
Prevalence of daily smokers was reduced from 29.3% to 20.1% (p=0.002). 
Subjects who exceeded a recommended maximum of alcohol consumption 
were increased from 6.5% to 14.0% (p=0.001). The BMI increased from 27.3 
± 4.7 to 28.6 ± 5.5 kg.m-2 in diabetes subjects (p=0.001). In subjects with-
out diabetes, the prevalence of physical inactivity decreased in women from 
20.9% to 11.9% (p<0.001) and men from 17.5% to 11.4% (p<0.001). The PA 
level was reduced in subjects with diabetes compared with subjects without 
diabetes throughout the study.
Conclusion: The percentage of physically inactive Danish subjects older than 
45 years with diabetes decreased from 2000 to 2010 with corresponding in-
creases of percentages of subjects with moderate, medium, and high levels 
of PA. The trends of increased level of PA and decreased smoking may have 
impact on cardiovascular risk and positively affect the declining relative mor-
tality among Danish patients with diabetes as shown in previous studies. On 
the other hand, elevated alcohol intake and increased BMI may increase the 
cardiovascular risk. Even though the PA level was elevated among subjects 
with diabetes, it remained reduced compared with the reported level of PA 
among subjects without diabetes.
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Effect of high intensity interval training on physical fitness, metabolic 
flexibility and insulin sensitivity
P. Calders, M. Bekaert, J. Ruige;  
University of Ghent, Belgium.
Background and aims: The purpose of this study was to evaluate the effect of 
high intensity interval training on antropometric parameters, physical fitness, 
metabolic flexibility and insulin sensitivity in participants with overweight or 
obesity compared to continuous aerobic training with the same total volume.
Materials and methods: 16 male participants with overweight or obesity (age 
range: 42 - 57, body mass index: 28 - 36) were randomized in two experi-
mental groups, high intensity interval training (n=8) and continuous aerobic 
training (n=8). Participants were excluded if they had diabetes, severe mus-
culoskeletal, cardiovascular and respiratory problems. High intensity interval 
training was composed of three blocks of 10 minutes at ventilatory threshold 
(blocks 1 and 3: 10 sprint bouts of 15 seconds, followed by 45 seconds rela-
tive rest; block 2: continuous training) twice a week for 15 weeks. Continu-
ous aerobic training was composed of three blocks of 10 minutes continuous 
training. After 5 weeks, intensity was increased to 110% of ventilatory thresh-
old. Before and after the training period, body composition, physical fitness 
(expressed as peakVO2 and anaerobic threshold (AT)), metabolic flexibility 
(expressed as resting respiratory exchange ratio(rRER)) and insulin sensitiv-
ity by oral glucose tolerance test were evaluated. The OGTT-composite score 
was calculated as (10,000/square root of [fasting glucose x fasting insulin] x 
[mean glucose x mean insulin during OGTT]). Significance level was cal-
culated based on non-parametric Kruskal-Wallis test with post hoc Mann-
Whitney U-test and set at P<0,05.
Results: High intensity interval training showed a significant positive evo-
lution (P<0,01) compared to continuous aerobic training for peak VO2 
(+18%), peak Wattage (+14%), ATVO2 (+14%) and ATWattage (+21%) in-
dicating an increased aerobic capacity. After 10 weeks, there was a significant 
decrease (P<0,05) of rRER (interval: pre: 0,85; post: 0,79; continuous: pre: 
0,87; post 0,86), indicating a better metabolic flexibility and a significant in-
crease (P<0,01) of the OGTTcomposite score (interval pre: 1,67; post: 2,96; 
continuous pre: 2,21; post: 2,33), indicating an increased insulin sensitivity.
Conclusion: In this study we could observe that high intensity interval train-
ing has stronger beneficial effects on body composition, physical fitness, 
metabolic flexibility and insulin sensitivity compared to continuous aerobic 
training with the same total volume.
Supported by: BOF University of Ghent
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A priori defined diet quality indexes and risk of type 2 diabetes mellitus: 
the multiethnic cohort 
S. Jacobs1, C.J. Boushey2, Y. Morimoto2, L.R. Wilkens2, L. Le Marchand2,  
J. Kröger1, M.B. Schulze1, L.N. Kolonel2, G. Maskarinec2;  
1German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, 
Germany, 2University of Hawaii Cancer Center, Honolulu, USA.
Background and aims: Dietary patterns have been associated with diabetes 
incidence; however, little is known about the impact of ethnicity on this as-
sociation. Our aim was to assess the association between predefined dietary 
indexes and risk of type 2 diabetes (T2D) among white, Japanese American, 
and Native Hawaiian men and women in the Hawaii component of the Mul-
tiethnic Cohort (MEC).
Materials and methods: After excluding participants with prevalent diabetes 
or missing values on covariates we used data from 41,918 men (5,791 incident 
cases) and 47,267 women (5,426 incident cases). Habitual dietary intake was 
assessed at baseline with a food frequency questionnaire designed for use in 
the relevant ethnic populations. Sex- and ethnic-specific hazard ratios and 
95% confidence intervals were calculated using adjusted Cox models for four 
dietary indexes, the Healthy Eating Index-2010 (HEI-2010), the alternative 
HEI-2010 (AHEI-2010), the alternate Mediterranean diet score (aMed), and 
the Dietary Approaches to Stop Hypertension (DASH).
Results: We observed strong inverse associations of adherence to the DASH 
index and T2D risk in white men and women, as well as Japanese American 
women and Native Hawaiian men, with respective risk reductions of 37, 31, 
19 and 21% comparing the categories of highest to lowest adherence to in-
dex (score point ranges in both sexes: 28-39 to 9-19). A higher adherence to 
AHEI-2010 was related with lower T2D risk in white men and women with 
a 26 and 22% lower risk comparing the categories of highest to lowest adher-
ence to index (score point ranges, men: 73-101 to 25-56, women: 47-100 to 
30-58), whereas higher adherence to aMed was associated with a 28% lower 
risk of T2D in white men only comparing the categories of highest to lowest 
adherence to index (score point ranges: 7-9 to 0-2). Neither the AHEI-2010 
nor the aMed were related to T2D risk in other ethnic groups than whites. 
Adherence to HEI-2010 was not associated with T2D risk.
Conclusion: In this large multiethnic cohort, the DASH, the AHEI-2010, and 
the aMed indexes performed well in whites, whereas only the DASH index 
was associated with a reduction in T2D risk in Japanese American women 
and Native Hawaiian men. Given the possible ethnic differences, further 
studies are warranted that focus on dietary indexes and their performance in 
multiethnic and minority populations.
Supported by: R21 DK073816 NCI grant R37CA54281 UM1CA164973 DAMD 
17-94-T-4184
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Sex-specific differences in prevention of type 2 diabetes mellitus:  
a systematic review and meta-analysis
J. Harreiter1, A. Glechner2, G. Gartlehner2,3, A. Kautzky1, S. Rohleder1,  
M. Van Noord2, A. Kaminski-Hartenthaler2, J. Tuomilehto4,5,  
A. Kautzky-Willer1;  
1Department of Medicine III, Divison of Endocrinology & Metabolism, 
Gender Medicine Unit, Medical University Vienna, 2Department for 
Evidence-based Medicine and Clinical Epidemiology, Danube University, 
Krems, Austria, 3Research Triangle Institute (RTI) International, North 
Carolina, USA, 4Diabetes Prevention Unit, National Institute for Health 
and Welfare, Helsinki, Finland, 5King Abdulaziz University, Jeddah, Saudi 
Arabia.
Background and aims: Type 2 diabetes mellitus (T2DM) is becoming an 
increasing challenge worldwide. Lifestyle interventions and several glucose 
lowering medications have been proved to be effective in preventing the 
progression to T2DM in people with prediabetes. The ADA/EASD position 
statement 2012 claims a patient centred approach, in which sex and gender 
aspects are relevant aspects. Sex-specific differences of the efficacy and safety 
of diabetes prevention strategies have not been studied so far.
Materials and methods: A systematic search of PubMed, Cochrane, Embase, 
CINAHL Web of Science, and reference lists of review articles from 1980 to 
June 2013 was performed. Literature was dually reviewed and risk of bias was 
rated for each study. Only randomised controlled trials with at least 1-year 
follow-up that compared active lifestyle interventions with usual care and 
pharmacotherapy trials with glucose lowering drugs that compared active 
treatment with placebo were included. Random effects meta-analysis of out-
comes of interest was performed.
Results: We identified 2548 relevant abstracts; 309 full-text articles were re-
trieved for further examination. Eighteen RCTs (44articles) met the eligibility 
criteria. Only 3 published sex-specific results; of 9 RCT´s unpublished sex-
specific data was supplied upon request. A similar efficacy of risk or harms 
of lifestyle interventions and pharmacological therapies between men and 
women was found. Lifestyle interventions reduced the risk to develop T2DM 
in prediabetic people in both sexes. After 1 year lifestyle intervention group 
had a lower risk than patients in control group (RR:0.60; 95% CI:0.35-1.05; 
4RCTs,888patients). A 37% lower risk of progressing to T2DM for pre-dia-
betic people receiving an average of 3 years of lifestyle intervention compared 
with those under usual care (RR:0.63; 95 CI:0.51-0.79; 5RCTs,1555patients) 
was found. Similar preventive effects of lifestyle interventions were found in 
men and women after 1 and 3 years. (p=0.61, p= 0.20). Only few studies pro-
vided sex-stratified results of pharmacological therapies in T2DM preven-
tion. Long-term evidence on potential sex differences of diabetes-associated 
comorbidity and mortality is missing.
Conclusion: The evidence indicates that intensified lifestyle intervention in 
structured programs is equally effective in both sexes. Therefore individually 
designed interventions to increase physical activity and healthy nutrition by 
behavioral modification for effective diabetes prevention should be offered 
for both sexes. More studies to reveal sex and gender-specific differences are 
necessary to follow a more patient centred approach.
Clinical Trial Registration Number: PROSPERO 2012:CRD42012003102
Supported by: BGM 12013
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Beneficial effect of pitavastatin on the incidence of diabetes in women 
was not associated with age: sub-analysis of J-PREDICT
T. Shiba1, K. Sakamoto1, C. Ito2, T. Yamazaki3, J. Kishimoto4, M. Noda5,  
Y. Terauchi6, M. Odawara7, H. Kitazato8, K. Maemura9, K. Tobe10,  
Y. Iwamoto11, Y. Akanuma12, T. Kadowaki13, the J-PREDICT study 
investigators;  
1Toho University, Tokyo, 2Grand Tower Medical Court, Hiroshima,  
3The University of Tokyo Hospital, 4Kyushu University Hospital, Fukuoka, 
5National Center for Global Health and Medicine, Tokyo, 6Yokohama 
City University Graduate School of Medicine, Kanagawa, 7Tokyo Medical 
University, 8Omori Red Cross Hospital, Tokyo, 9Nagasaki University 
Graduate School of Biomedical Sciences, Nagasaki, 10University of Toyama, 
11Tokyo Women‘s Medical University, 12The Institute for Adult Diseases, 
Asahi Life Foundation, Tokyo, 13The University of Tokyo, Japan.
Background and aims: Diabetes mellitus (DM) increases the risk of coro-
nary heart disease (CHD) far more in women than men. If statin therapy 
can prevent or delay the development of diabetes, it is helpful for prevent-
ing CHD, especially in women. Thus, we conducted a sex-specific analysis 
in J-PREDICT comparing the effect of pitavastatin (PIT) on the incidence of 
diabetes in woman versus men.
Materials and methods: J-PREDICT study was a prospective randomized, 
open-label, blinded-endpoint trial evaluating the effect of PIT on the inci-
dence of diabetes (n=1,269; 635 Control [lifestyle modification alone], 634 
PIT [PIT 1-2 mg + lifestyle modification]) in Japanese subjects with impaired 
glucose tolerance (IGT). The primary outcome was incidence of DM defined 
as 2-h plasma glucose of ≥200 mg/dl or fasting plasma glucose of ≥126 mg/dl 
measured at least once in 75g OGTT performed every six months. This study 
was performed based on the full analysis set (total, n=1090; men, n=683; 
women, n=407).
Results: Women were older than men and lower in body mass index. Women 
and men had similar levels of glycemic and insulin-related parameters. The 
incidence of diabetes in women was lower by 32% (HR, 0.68; 95%CI, 0.49-
0.93; p=0.02) in the PIT group compared with control group, but not sig-
nificantly different between the group in men (HR, 0.97; 95%CI, 0.78-1.21; 
p=0.78). The analyses using stratified log-lank test and Cox proportional haz-
ard model also brought a positive PIT effect only in women. Trends towards 
higher incidence of diabetes with increasing age were observed only in men. 
The beneficial effect of PIT was most in a group of 55 to 64 years in both 
genders, and only significant in women (p=0.02). Thus, incidence of diabetes 
in women was not associated with age (<55 years: HR, 0.64; 95%CI, 0.35-
1.18; 55-64 years: HR, 0.55; 95%CI, 0.33-0.92; ≥65 years: HR, 0.87; 95%CI, 
0.50-1.52). As for lipid parameters, PIT significantly reduced LDL cholesterol 
compared with control in men and women, but HDL cholesterol was signifi-
cantly increased only in men.
Conclusion: PIT reduced the incidence of diabetes in women with IGT. This 
beneficial effect in women was not associated with age. PIT treatment may be 
effective even in women with moderate or low risk of CHD.
Clinical Trial Registration Number: NCT00301392
Supported by: The Waksman Foundation of Japan Inc./ Kowa Pharmaceutical 
Co. Ltd.
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Can delaying the onset of type 2 diabetes be cost-effective?
A.M. Gray1, J. Leal1, O. Rivero-Arias1, S.D. Reed2, Y. Li2, K.A. Schulman2, 
R.M. Califf2, R.R. Holman3;  
1Nuffield Department of Population Health, University of Oxford, UK, 
2Duke Clinical Research Institute, Duke University, Durham, USA,  
3Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), 
University of Oxford, UK.
Background and aims: Type 2 diabetes is a 21st century epidemic, but life-
style and some pharmaceutical interventions can delay its onset in at-risk 
subjects. We evaluated what effects a delay in diabetes onset by a hypothetical 
intervention could have on quality-adjusted survival and lifetime complica-
tion costs in UK and US healthcare settings, and likely cost-effectiveness at 
different intervention costs.
Materials and methods: We used data representing the characteristics of 
3,058 NAVIGATOR trial subjects at the time they progressed from impaired 
glucose tolerance to new-onset diabetes, and simulated their remaining life-
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time clinical outcomes using the UKPDS Outcomes Model. Multiple simula-
tions examined the impact of a hypothetical intervention that delayed diabe-
tes onset by 1, 3, 5 or 7 years on costs and (quality-adjusted) life expectancy. 
For simplicity, we assumed that all patients would experience the same period 
of delay regardless of their characteristics or previous medical history. All 
future costs and effects were discounted at 3.5% (UK) and 3.0% (US).
Results: Subjects were mean (1SD) age 66.3 (6.9) years, HbA1c 43 (7) mmol/
mol, body mass index 31.5 (5.7) kg/m2, and 51% were male. The longer dia-
betes onset was delayed the greater was the increase in life expectancy and 
quality-adjusted life years (QALYs) and the decrease in the costs of diabetic 
complications. When diabetes onset was delayed by 7 years, undiscounted 
life expectancy measured from the simulation baseline increased from 13.8 
to 15.4 years; discounted QALYs increased from 7.6 (US 8.0) to 8.4 (US 8.8) 
years, with a corresponding decrease in the discounted costs of complications 
from £16,741 (US $140,967) to £16,377 (US $140,369). Assuming an annual 
cost for the hypothetical intervention of £1,000 (US $1,600), the estimated 
cost per QALY gained when onset was delayed by one year was £7,240 (US 
$11,546), falling to £6,909 (US $10,251) when onset was delayed by 7 years. 
If the annual cost for the hypothetical intervention was £3,000 (US $4,800), 
the estimated cost per QALY gained when onset was delayed by one year 
was £22,691 (US $34,870), falling to £21,302 (US $32,239) when onset was 
delayed by 7 years.
Conclusion: In our analysis, interventions that can delay the onset of dia-
betes substantially increased remaining life expectancy and quality-adjusted 
survival and slightly reduced remaining lifetime complication costs. At an-
nual costs of between £1,000 and £3,000 (US $1,600 and $4,800), the hypo-
thetical intervention yielded a cost per QALY gained that remained broadly 
within the ranges considered cost-effective in the UK and US. Further work 
is required to explore heterogeneity in the patient population and parameter 
uncertainty in the modelling. Developing such interventions continues to be 
a high priority, especially given the continued growth in the global popula-
tion with type 2 diabetes.
Supported by: Novartis
PS 002 Aetiological epidemiological 
studies of type 2 diabetes
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Blood glucose levels at baseline and incidence of type 2 diabetes:  
a prospective cohort study of 0.5 million adults in the China Kadoorie 
Biobank
H. Du1, L. Li2,3, I. Millwood1, F. Bragg1, L. Yang1, Y. Chen1, Y. Guo2, Z. Bian2, 
J. Chen4, R. Collins1, R. Peto1, Z. Chen1;  
1CTSU, University of Oxford, UK, 2Chinese Academy of Medical Sciences, 
3School of Public Health, Peking University, 4China National Center for 
Food Safety Risk Assessment, Beijing, China.
Background and aims: Random blood glucose (RBG) levels may be used 
to screen for diabetes, however the predictive value of RBG levels within the 
normoglycemic range on future diabetes risk has not been well studied, par-
ticularly among Chinese population.
Materials and methods: The study population includes 496,720 individuals 
enrolled into the China Kadoorie Biobank between 2004-8 from 10 diverse 
localities across China without prior physician diagnosed diabetes. At base-
line, RBG was measured by venous blood spot test and those with RBG ≥ 
11.1 mmol/L and those fasting blood glucose ≥ 7.0 mmol/L were identified 
as newly detected diabetes (2.8%) and excluded from the current analysis. 
Data on type 2 diabetes incidence was collected through electronic linkage 
with mortality and morbidity registries as well as with the national health 
insurance system. RBG was related to incidence of type 2 diabetes using Cox 
proportional Hazard models, with adjustment for potential confounders.
Results: The overall mean age of participants (n=474,423) was 51 years, mean 
BMI was 23.6 kg/m2, and mean RBG was 5.7 mmol/L. During the 7-year 
follow-up, 4194 incident cases of type 2 diabetes were identified. A dose-re-
sponse relationship was observed between baseline RBG and risk of diabetes. 
Compared to those with RBG < 6.0 mmol/L, those with 6.0 ≤ RBG < 6.9 
mmol/L had a diabetes hazard ratio (HR) 2.8 (95% CI: 2.7-2.9), those with 
7.0 ≤ RBG < 7.8 mmol/L had HR 3.8 (3.5-4.1) and those with RBG ≥ 7.8 (i.e. 
pre-diabetes) had HR 6.8 (6.3-7.4). The association of RBG with diabetes risk 
was slightly stronger in women than in men, and in younger than in older 
people. Stratifying the analyses by hours since last meal (< 2 hours, 2-4 hours, 
4-6 hours, or ≥ 6 hours) revealed a stronger association among those who had 
fasted for a longer period (HR of RGB ≥ 7.8 mmol/L 12.0 [5.3-27.2].
Conclusion: In this group of adult Chinese, higher RBG levels, even those 
within the normoglycemic range, constitute an independent risk factor for 
type 2 diabetes. Such levels should probably be taken into account in identify-
ing people at increased risk for diabetes.
Supported by: Wellcome Trust; MRC; British Heart Foundation; Cancer Re-
search UK; ChinaTRD
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Stressful life events and the metabolic syndrome: the Hoorn Study 
F. Rutters1, S. Pilz2, A.D. Koopman1, S.P. Rauh1, S.J. Te Velde1,  
C.D.A. Stehouwer3, P. Elders4, G. Nijpels4, J.M. Dekker1;  
1Department of Epidemiology and Biostatistics, VUmc, Amsterdam, 
Netherlands, 2Department of Internal Medicine, Medical University of 
Graz, Austria, 3Maastricht University Medical Centre, Department of 
Internal Medicine, Netherlands, 4Department of General Practice, VUmc, 
Amsterdam, Netherlands.
Background and aims: The amount of psychosocial stress may play a role in 
the development of the Metabolic Syndrome. The aim of our current study 
was to evaluate whether in a population-based cohort of older men and 
women the number of stressful life events is associated with the Metabolic 
Syndrome incidence, and whether any such relationship is mediated by be-
havioural factors.
Materials and methods: The association between the number of stressful 
life events experienced at baseline and Metabolic Syndrome incidence after 6 
years of follow up, was assessed in the Hoorn study. Subjects with the Meta-
bolic Syndrome at baseline, defined according to the Adult Treatment Panel 
III (NCEP), were excluded.
Results: We included 1099 participants (47% male; age 60.1±7 years). During 
6.5 years of follow-up, 238 subjects (21.7%) developed the Metabolic Syn-
drome. Using logistic regression, a positive association was observed between 
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Metabolic Syndrome incidence at follow-up and the number of stressful life 
events [OR 1.11 (1-1.25)]. However, we also observed effect modification for 
education level (P value interaction, p=0.01). In the low-education group, 
the model adjusted for age and sex showed a significant association between 
Metabolic Syndrome incidence and the amount of stressful life events [OR 
1.20 (1.03-1.39)]. No such significant association was observed in the middle/
high-education group [OR 1.05 (0.83-1.24)]. Additionally, a chi-square anal-
ysis showed a linear-by-linear association between the number of Metabolic 
Syndrome abnormalities and the amount of stressful life events (p<0.01) in 
the low educated group. Finally, we observed that smoking, high alcohol in-
take and low physical activity did not mediate the association between stress-
ful life events and Metabolic Syndrome incidence.
Conclusion: Experiencing more stressful life events is associated with a sig-
nificantly increased risk for developing metabolic syndrome in an elderly 
population-based cohort, especially in persons with a low education level.
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Circulating fractalkine levels predict the development of the metabolic 
syndrome
Y. Xueyao, S. Zhang, D. Yu, Q. Pan, X. Dong, J. Zhou, H. Li;  
Department of Endocrinology, the Afﬁliated Sir Run Run Shaw Hospital, 
Hangzhou, China.
Background and aims: The fractalkine/CX3CR1 axis plays an important role 
in regulating glucose and lipid metabolism. However, the role of fractalkine 
in metabolic disorders remains to be fully elucidated.
Materials and methods: We selected 887 Chinese (40-65 years old) at base-
line, with a subgroup of 459 participants examined again 2 years later. The 
relationship of serum fractalkine levels with the metabolic syndrome (Mets) 
and its components was investigated.
Results: At baseline, participants with MetS had a higher fractalkine con-
centrations than their counterparts without MetS (P<0.001). At the 2-year 
follow-up, participants in the highest quartile of baseline fractalkine exhib-
ited higher values for body mass index, waist circumference, waist-to-hip 
ratio, body fat percentage, blood pressure, glucose, insulin, total cholesterol, 
triglycerides (TG), homeostasis model assessment of insulin resistance (HO-
MA-IR), and lower value for high density lipoprotein- cholesterol (HDL-c) 
(all P<0.05). Among 390 participants without MetS at baseline, 45 developed 
it at year 2. Even after multiple adjustments for visceral adipose tissue area, 
HOMA-IR, C-reactive protein (CRP) or TG and HDL-c, baseline fractalkine 
predicted the development of MetS (OR=7.18, 95%CI: 2.28-18.59).
Conclusion: Circulating fractalkine predicts the development of the MetS 
independently of central obesity, CRP, insulin resistance and dyslipidemia.
Supported by: 2009C03010-4
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Influence of serum osteocalcin and liver fat content on glucose 
metabolism in a middle-aged and elderly Chinese population
M. Xia, H.-D. Lin, H.-M. Yan, H. Bian, X.-X. Chang, X. Gao;  
Endocrinology, Zhongshan Hospital, Shanghai, China.
Background and aims: The interaction among adipose tissue, liver and bone 
has been disclosed. Dysregulation of this network promotes the development 
of metabolic diseases, including diabetes. We aimed to investigate the rela-
tionship of serum osteocalcin (OCN) secreted by osteoblasts, liver fat content 
(LFC) and glucose metabolism in a middle-aged and elderly Chinese com-
munity population.
Materials and methods: A cross-sectional study was performed on 3782 
eligible participants from Shanghai Changfeng Community Study. LFC was 
measured via a newly-established ultrasound quantitative method. One-way 
ANOVA and multivariate linear regression analysis were carried out to deter-
mine the independent and joint association of OCN and LFC with glucose 
metabolism status.
Results: Decreased serum OCN was associated with higher body weight, 
waist circumference, diastolic blood pressure, serum triglyceride, fasting 
and postprandial blood glucose, fasting insulin and insulin resistance level 
(represented by HOMA-IR) as well as higher LFC (all P<0.05). There was a 
synergistic increase seen in serum fasting blood glucose, postprandial glu-
cose, insulin and HOMA-IR level in individuals with both increased LFC and 
decreased serum OCN (Figure 1). Multivariate regression analysis showed 
that both OCN and LFC were independently associated with FBG (std 
β=-0.122,P<0.001 and std β=0.110, P<0.001), PBG (std β=-0.074, P<0.001 
and std β=0.147, P<0.001) and HOMA-IR (std β=-0.053, P<0.001 and std 
β=0.169, P<0.001).
Conclusion: Our results suggest that both liver and bone contribute to the 
development of diabetes and serum OCN and LFC may have a synergistic 
effect on human glucose metabolism.
Supported by: Major State Basic Research Development Program of China; 
NSFC
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Cardio-metabolic parameters in non-diabetic patients with chronic 
kidney disease
M. Mota1, S. Popa1, M. Adina2, E. Mota3;  
1Diabetes, Nutrition & Metabolic Diseases, University of Medicine  
and Pharmacy, 2Diabetes, Nutrition & Metabolic Diseases,  
Clinical Emergency Hospital, 3Nephrology, University of Medicine  
and Pharmacy, Craiova, Romania.
Background and aims: The nature of the relationship of obesity and insu-
linresistance (IR) with adverse clinical outcomes in chronic kidney disease 
(CKD) is unclear. The aim of the study was to assess association of cardio-
metabolic parameters with estimated glomerular filtration rate (eGFR) in 
CKD and non-CKD non-diabetic subjects.
Materials and methods: We performed a cross-sectional analysis in a ran-
dom sample of 1391 non-diabetic subjects, aged 20-79 years, derived from 
PREDATORR study. CKD was defined as eGFR <60 ml/min/1.73m2 or uri-
nary albumin to creatinine ratio ≥30mg/g. The analysed cardio-metabolic 
parameters were: waist circumference (WC), waist to height ratio (WHtR), 
body mass index (BMI), body adiposity index (BAI), visceral adiposity index 
(VAI), glycemia, insulinemia, HOMA-IR, uric acid, lipid profile, systolic and 
diastolic blood pressure (SBP, DBP).
Results: The prevalence of CKD was 7.5%, majority of CKD patients being in 
the age group 60-79 years. Frequent cardio-metabolic comorbidities, in sub-
jects with CKD, were dyslipidemia (90%), abdominal obesity (89.4%), obesity 
(84.6%), hypertension (87.5%), prediabetes (52.9%), hyperuricemia (52.9%), 
IR (43.3%). Obesity, IR and dyslipidemia were prevalent in the young sub-
jects, while abdominal obesity, prediabetes, hypertension and hyperuricemia 
were prevalent in elderly people. Among the cardio-metabolic comorbidities 
associated with presence of CKD found to be statistically significant were obe-
sity, abdominal obesity hyperuricemia, prediabetes, hypertension (p<0.001 
for all), IR (p=0.002) and dyslipidemia (p=0.006). Young subjects with CKD 
had significantly higher WC (99.7±11 vs 88.3±17; p<0.001), WHtR (0.6±0.08 
vs 0.5±0.08; p=0.004), BMI (34.2±7.2 vs 25.3±5.1; p<0.001), BAI (35.6±10.5 
vs 27.3±5.8; p=0.01), VAI (2.5±1.7 vs 1.7±1.5; p=0.02), glycemia (81.9±10 
vs 74.6±10.4; p=0.04), insulinemia (17±9.9 vs 10.3±8.8; p=0.005), HOMA-
IR (3.5±2.4 vs 1.6±1.1; p=0.003) and uric acid (6.1±1.4 vs 4.7±1.4; p=0.006), 
compared to non-CKD young subjects. Elderly CKD subjects had only high-
er HbA1c (5.7±0.4 vs 5.5±0.3; p<0.001), insulinemia (12.8±7.4 vs 11±9.1; 
p=0.001), HOMA-IR (2.7±2 vs 2.4±2; p=0.003) and uric acid (6.3±1.7 vs 
5.4±2.3; p<0.001) compared to non-CKD elderly subjects. In CKD subjects 
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eGFR was negative correlated with age (r=-0.3; p<0.001), uric acid (r=-0.3; 
p=0.002) and positive correlated with WC (r=0.2; p=0.02), WHtR (r=0.2; 
p=0.03), BMI (r=0.2; p=0.01). Multiple linear regression indicated that age 
and uric acid were negatively associated with eGFR, while WHtR was posi-
tive predictor. In non-CKD subjects a negative correlation occurred between 
eGFR and age and, also, all cardio-metabolic parameters (WC, WHtR, BMI, 
VAI, BAI, glycemia, HbA1c, HOMA-IR, triglycerides, total and LDL choles-
terol, uric acid, SBP, DBP). Multiple linear regression indicated that only age, 
uric acid, SBP and HbA1c were negatively associated with eGFR.
Conclusion: This study proposed a synergistic association between cardio-
metabolic syndrome components and the presence of CKD. Obesity param-
eters were associated with CKD in young subjects, while HOMA-IR and uric 
acid were associated with CKD independently of age. WHtR and uric acid 
may be important pathogenic factors in non-diabetic CKD patients.
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Associations of sleep duration and sleep efficiency with glucose tolerance 
and beta cell function in Hong Kong Chinese children and adolescents
L. Xu1, Y.-K. Wing2, K.-C. Chow3, K. Cheung1, R. Ma1,4, W.-Y. So1,  
J.C.N. Chan1,4, A.M. Li5, A.P.S. Kong1,4;  
1Medicine and Therapeutics, 2Psychiatry,  
3The Nethersole School of Nursing, 4Li Ka Shing Institute of Health Sciences, 
5Paediatrics, The Chinese University of Hong Kong, Hong Kong.
Background and aims: Increasing evidence suggest a role of sleep duration 
on metabolic dysregulation and dysglycemia in adults. We aimed to examine 
the associations of sleep duration and sleep efficiency with glucose metabo-
lism in Hong Kong Chinese children and adolescents.
Materials and methods: Children and adolescents of Chinese ethnicity aged 
6-18 years were identified from a population-recruited, territory-wide survey. 
All subjects completed 3-day sleep diary and 3-day actigraphy for the assess-
ments of subjective and objective sleep duration and sleep efficiency. Oral 
glucose tolerance test (OGTT) and insulin assays were performed. Glucose 
tolerance, insulin sensitivity, and pancreatic β-cell function were assessed by 
2-hour plasma glucose level, Matsuda index (ISOGTT), and insulin secretion-
sensitivity index-2 (ISSI-2), respectively. Subjects with moderate-to-severe 
obstructive sleep apnea (OSA) as determined by an obstructive apnea hypo-
nea index (OAHI) > 5/hour in an overnight polysomnography were excluded 
from analyses. Multiple linear regression analyses were performed to explore 
the associations between sleep and glucose metabolism parameters. Variables 
with skewed distribution were log-transformed before entering into analyses.
Results: A total of 131 children and adolescents were studied. Among them, 
13 had moderate-to-severe OSA, leaving 118 subjects eligible for the pre-
sent analysis (mean age ± SD: 13.1 ± 3.3 years; male: 44.9%). After adjust-
ment for gender, Tanner stage, BMI z-score, and OAHI, sleep duration and 
sleep efficiency measured by actigraphy were negatively associated with log-
transformed 2-hour plasma glucose levels (β ± se: -0.042 ± 0.022, p = 0.054 
and -0.009 ± 0.004, p = 0.033, respectively) and positively associated with 
log-transformed ISSI-2 (β ± se: 0.102 ± 0.049, p = 0.038 and 0.023 ± 0.009, 
p = 0.014, respectively). There were no significant associations of log-trans-
formed ISOGTT (p > 0.20) with sleep duration and sleep efficiency as meas-
ured by actigraphy. Moreover, no associations were found between subjective 
sleep duration and sleep efficiency as measured by sleep diary and all glucose 
metabolism parameters as mentioned above (p > 0.20) (Table 1).
Conclusion: Short sleep duration and low sleep efficiency as measured by 
actigraphy are independent risk factors for worse glucose tolerance and β-cell 
function in children and adolescents.
Supported by: RGC of Hong Kong SAR (Project no. CUHK 4465/06M)
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Glycated albumin is a useful indicator for screening impending diabetes 
and predicting beta cell dysfunction in the pre-diabetic condition 
S.M. Hong1, S.Y. Rhee1, J. Kim2, Y.C. Hwang1, C.H. Jung3, K.J. Kim4,  
W.S. Jeon5, S.M. Jin6, B.W. Lee4, J.T. Woo1;  
1Department of Endocrinology and Metabolism, Kyung Hee University 
School of Medicine, 2Department of Internal Medicine, Dongsuwon 
General Hospital, 3Department of Internal Medicine, Asan Medical Center, 
University of Ulsan College of Medicine, 4Department of Internal Medicine, 
Severance Hospital, University of Yonsei College of Medicine, 5Department 
of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan 
University School of Medicine, 6Department of Internal Medicine, Samsung 
Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Republic of Korea.
Background and aims: Pre-diabetes is known as a pre-clinical stage of in-
creased risk for overt diabetes mellitus (DM) and cardiovascular disease. 
Because glycated albumin (GA) has been suggested to have more potential 
for assessing insulin secretory dysfunction and glycemic fluctuation than 
HbA1c, we studied the clinical significance of GA in this stage.
Materials and methods: We enrolled the 1379 anti-diabetic drug naïve 
subjects in retrospective, multi-center, cross-sectional manner. According 
to the 75-g OGTT, the subjects were classified as normal glucose tolerance 
(NGT), isolated IFG (i-IFG), isolated IGT (i-IGT), combined glucose intoler-
ance (CGI) and DM subgroup. We analyzed clinical characteristics of these 5 
groups including GA, insulin sensitivity (HOMA2%S), and insulin secretion 
(HOMA2%B) index.
Results: Mean GA was 11.6±1.4, 12.3±1.8, 12.3±1.9, 13.0±1.9, 18.8±7.9 
in NGT (n=295, 21.4%), i-IFG (n=257, 18.6%), i-IGT (n=103, 7.4%), CGI 
(n=257, 18.6%), and DM (n=466, 34%) subgroup. After adjusting covariates, 
adjusted mean of GA was 12.2±0.1, 12.2±0.2, 13.1±0.1 in i-IFG, i-IGT, and 
CGI subgroup (p<0.001), and significantly higher in CGI group by post-hoc 
analysis. Adjusted mean of HbA1c was also significant, but not distinguished 
differences among these subgroups. Moreover, correlation coefficient be-
tween HOMA2%B and GA (r=-0.393, p<0.001), and HOMA2%S and GA 
(r=0.258, p<0.001) was significantly higher than correlation with HbA1c. 
And these results were consistent after adjusting covariates.
Conclusion: We suggest that GA could be a better indicator for screening 
impending diabetes and assessing beta cell dysfunction in the subjects of pre-
diabetic period.
Supported by: Ministry of Health and Welfare (A102065)
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A population approach to modelling the oral glucose tolerance test in 
normal and impaired glucose tolerant states
M.J. Theodorakis, G.P. Chrousos;  
Endocrinology, Metabolism and Diabetes Unit, University of Athens, Greece.
Background and aims: The conventional approach to analyzing oral glucose 
tolerance testing (OGTT) data requires model identification in each individ-
ual separately (standard two stage), ignoring knowledge about the population 
as a whole. However, the OGTT is sparsely sampled and individual estimates 
are often not resolvable from the available data.
Materials and methods: We applied a population approach, nonlinear mixed 
effects modeling, to plasma glucose, insulin and C-peptide data obtained 
from a 120-minute OGTT undertaken by 106 subjects forming five groups 
with varying glucose tolerance. This method provides estimates of popula-
tion means, variances and covariances of model parameters, empirical Bayes 
estimates of individual parameter values and measures of intra-individual 
(within-subject) and inter-individual (between-subject) variability. The lat-
est version of the oral glucose minimal model was used to evaluate insulin 
sensitivity and a combined model approach was used to assess β-cell secre-
tion. These models allowed for the reconstruction of insulin secretion and 
glucose absorption profiles and gave population indexes of insulin sensitivity 
(SI=6.51±;1.20×10
-4 min-1•µU-1•ml), fractional hepatic extraction of insulin 
(F=0.522×0.291) and fractional insulin clearance (ki = 0.258×0.151 min
-1).
Results: Individuals with type 2 diabetes (T2DM) had significantly higher 
HOMA-IR, HbA1c and triglyceride levels compared to subjects with normal 
glucose tolerance (NGT). They also had increased fasting plasma insulin lev-
els, significantly reduced insulinogenic index from 0 to 20 minutes after oral 
glucose, and increased fasting glucagon levels compared to NGT subjects. 
All had similar fasting plasma biochemical values and were without medical 
histories of gastroparesis, kidney disease or microvascular disease. The popu-
lation model, including data from all groups of individuals, was implemented 
in NONMEM. When empirical post hoc Bayes estimates obtained from the 
population approach were used to determine individually predicted values, 
these points collapsed to the line of unity, showing no systematic deviations 
from the observed data. NGT subjects were found to have the highest median 
values for SI, as well as the most variability. Mean estimates and standard er-
rors for SI (104min
-1•µU-1•ml) in the different groups were: Group 1 (normal 
fasting and 2-hr plasma glucose; 17.7±;1.8), Group 2 (normal fasting / im-
paired 2-hr plasma glucose; 9.95±;2.0), Group 3 (impaired fasting and 2-hr 
plasma glucose; 5.67±;1.0), Group 4 (normal fasting / diabetic 2-hr plasma 
glucose; 3.82±;1.1) and Group 5 (diabetic fasting and 2-hr plasma glucose; 
9.39±;3.8). Individual insulin secretion profiles were also reconstructed from 
empirical Bayes estimates.
Conclusion: Whereas the traditional approach to parameter estimation 
failed to recover estimates in more than one third of the population, the pop-
ulation approach provided individual estimates in all subjects. Examination 
of the empirical Bayes estimates showed that individual parameter estimates 
were able to differentiate well between individuals at glucose tolerant states 
ranging from euglycemia to overt type 2 diabetes. Our findings suggest popu-
lation analysis is a powerful tool to obtain accurate assessments of indexes of 
insulin sensitivity and β-cell function from the OGTT, especially in epide-
miological studies with large numbers of sparsely sampled subjects.
Supported by: Kapodistrias Award, University of Athens
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Family history is not associated with lifestyle, clinical, or anthropometric 
factors in newly diagnosed type 2 diabetes mellitus patients:  
the DD2 study
E. Svensson1, K. Berensci1, S. Sander1, A. Mor1, J. Rungby2, J.S. Nielsen3,  
S. Friborg4, I. Brandslund5, J.S. Christiansen6, A. Vaag7, H. Beck-Nielsen3, 
H.T. Sørensen1, R.W. Thomsen1;  
1Department of Clinical Epidemiology, 2Department of Pharmacolgy, 
Aarhus University, 3Diabetes Research Centre, Department of 
Endocrinology, Odense University Hospital, 4Department of Endocrinology, 
Odense University Hospital, 5Department of Biochemistry, Lillebaelt 
Hospital, Vejle, 6Department of Internal Medicine and Endocrinology, 
Aarhus University Hospital, 7Department of Endocrinology, Rigshospitalet 
and University of Copenhagen, Denmark.
Background and aims: A positive family history of type 2 diabetes mellitus 
(T2D) increases the risk for developing T2D approximately two-fold, likely 
due to both genetic and lifestyle factors. It is unknown how having a fam-
ily history of T2D is related to demographic, clinical-, lifestyle and anthro-
pometric factors at T2D debut, thus we aimed to examine this in a cross-
sectional study.
Materials and methods: All participants in the Danish Centre for Strategic 
Research in Type 2 Diabetes (DD2) cohort responded to a questionnaire, in 
which detailed family history of diabetes (grandparents, parents, siblings and 
children) was assessed. We examined the prevalence and relative risk, and 
corresponding 95% confidence interval (CI) of having one first-degree rela-
tive vs no first-degree relative with history of T2D according to different de-
mographic, lifestyle, clinical and anthropometric factors at T2D debut.
Results: Of 2,718 T2D patients, 1,191 (44%) had one or more first-degree 
family relatives with diabetes, including 377 (14%) with two or more first-
degree relatives. Of the patients with positive family history, 20% had affected 
mothers, while 17% had affected fathers. Among the newly diagnosed T2D 
patients, a family history of T2D was to a lesser extent seen in men compared 
with women (adjusted relative risk (aRR) 0.84, 95% CI 0.78-0.90). Individuals 
aged less than 40 years at their T2D debut were more likely to have a family 
history of diabetes as compared with patients aged more than or equal to 60 
years at T2D debut (aRR 1.34, 95% CI 0.94-1.91). In contrast, family history 
of T2D was evenly distributed according to presence or absence of central 
obesity, large weight gain since age 20, physical activity, alcohol consumption 
and Charlson comorbidity score.
Conclusion: Almost half (44%) of newly diagnosed T2D patients have a first 
degree family relative with diabetes. Our results confirm that T2D heredity 
is stronger on the maternal side. Having a family history of diabetes is thus 
associated with female gender and younger age at T2D debut, whereas fam-
ily history does not appear to be associated with presence of comorbidity or 
specific lifestyle-, clinical- and anthropometric factors at debut.
Supported by: Danish Agency for Science, Danish Health and Medicines Au-
thority, DDA
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Determinants of skin autofluorescence in the general population and in 
type 2 diabetes
B.H.R. Wolffenbuttel1, R. Graaff1, H.L. Lutgers1, K. Eny2, A.D. Paterson2, 
S.N. Slagter1, J.V. van Vliet-Ostaptchouk1, M.M. van der Klauw1;  
1Endocrinology, University Medical Center Groningen, Netherlands, 
2Program in Genetics & Genomic Biology, Hospital for Sick Children, 
Toronto, Canada.
Background and aims: Skin autofluorescence (SAF) is a non-invasive mark-
er of advanced glycation end products and is associated with long-term dia-
betes complications and cardiovascular morbidity and death. SAF increases 
with age, and is higher among individuals with diabetes.
Materials and methods: We assessed the determinants of SAF in people with 
and without type 2 diabetes (T2DM) in the LifeLines Cohort study, a ran-
dom population-based sample of inhabitants of three Northern provinces of 
the Netherlands. For this cross-sectional analysis, we included subjects 18-
90 years of age, who had both genetic data available and SAF measurement 
collected between January 2008 and March 2011. We excluded subjects who 
were known to have type 1 diabetes and those with serum creatinine >140 
mcmol/l , leaving 9025 individuals (of whom n=314, 3.5% with T2DM) for 
analysis. Skin autofluorescence (SAF) was measured non-invasively with the 
AGE Reader.
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Results: Mean (±SD) age was 49 (±11) yrs for the non-diabetic participants 
and 59 (±11) yrs for the T2DM group, while mean SAF was 2.04 (±0.44) 
arbitrary units (AU) vs 2.45±0.59 AU. Linear regression showed that age, sex, 
body mass index, HbA1c, glomerular filtration rate (GFR), smoking, and a 
genetic polymorphism of N-acetyltransferase 2 (NAT2) significantly influ-
enced SAF in the general population (all p<0.001) and type 2 diabetic subjects 
(all p<0.009). In addition, total cholesterol was an independent predictor of 
SAF in diabetes. Finally, the effect size of sex, HbA1c, smoking and NAT2 
were larger in subjects with T2DM than in the general population (Table).
Conclusion: We conclude that SAF is influenced by several clinically sig-
nificant parameters, and some of them bear a more significant influence in 
T2DM. These factors should be taken into account when using SAF as a pre-
dictor of cardiovascular and diabetes-related complications. The large effect 
of smoking in T2DM supports increasing our efforts to promote smoking 
cessation in those individuals.
PS 003 Type 1 diabetes: 
epidemiology
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Environmental pollutants and the risk of type 1 diabetes
O. Vaarala1, H. Salo1, J. Koponen2, M. Knip3, H. Kiviranta2;  
1Department of Vaccinations and Immune Protection, National Institute 
for Health and Welfare, Helsinki, 2Department of Environmental Health, 
National Institute for Health and Welfare, Kuopio, 3Children‘s Hospital, 
University of Helsinki, Finland.
Background and aims: Environmental pollutants have been associated with 
immune aberrancies, but their role as a risk factor of type 1 diabetes is not 
known. We explored the association of the plasma levels of environmental 
pollutants and later development of type 1 diabetes associated beta-cell au-
toantibodies in children at genetic risk of type 1 diabetes.
Materials and methods: We analyzed the plasma levels of 13 persistent or-
ganic pollutants (POP) and 13 perfluorinated compounds (PFC) in a series of 
cord blood samples and plasma samples taken at the age of 12 months from 
children at genetic risk of type 1 diabetes who participated in the FINDIA pi-
lot study and were monitored for the appearance of type 1 diabetes associated 
autoantibodies. Plasma samples were pretreated with dispersive solid phase 
extraction. The PFCs and POPs were extracted with methanolic ammonium 
acetate and dichloromethane:hexane (1:4), respectively. The sample volume 
used for the analysis ranged from 25 μL to 200 μL. Instrumental analysis was 
performed with the LCMS/MS (PFAAs) and GC-MS/MS (POPs).
Results: The levels of 13 POPs or 13 PFCs did not differ in cord blood sam-
ples or plasma samples taken at the age of 12 months between the children 
who developed autoantibodies and children who remained autoantibody 
negative during the follow-up over the first 6 years of life. No association of 
environmental pollutants with the development of clinical type 1 diabetes 
was observed. Increased levels of both POPs and PFCs were associated with 
breast-feeding.
Conclusion: Our results do not suggest that early exposure to POPs or PFCs 
during pregnancy or early infancy is a risk factor for the later development of 
beta-cell autoimmunity and type 1 diabetes.
Clinical Trial Registration Number: NCT01055080
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Enteroviral infection in human type 1 diabetes: correlative evidence from 
multiple tissue sources in nPOD samples
S.J. Richardson1, T. Rodriguez-Calvo2, M. Oikarinen3, J.E. Laiho3,  
I. Kusmartseva4, M. Campbell-Thompson4, nPOD-V Consortium, A. Baj5,  
A. Toniolo5, M. von Herrath2, H. Hyoty3, N.G. Morgan1;  
1University of Exeter Medical School, UK, 2La Jolla Institute for Allergy and 
Immunology, USA, 3University of Tampere, Finland, 4University of Florida, 
Gainesville, USA, 5Università dell‘Insubria, Varese, Italy.
Background and aims: Considerable evidence has accumulated to support 
the hypothesis that type 1 diabetes (T1D) is associated with an enteroviral 
infection. Much of this depends on the analysis of viral infection in blood 
samples but definitive proof that this is also associated with the presence of 
enterovirus within the organs of affected individuals is still lacking. The pur-
pose of this study was to undertake the first fully coordinated analysis of mul-
tiple tissues available within the JDRF’s network of pancreatic organ donors 
with diabetes (nPOD) collection. These tissues were analysed using different 
methods, in multiple collaborating laboratories, to assess the correlation of 
potential indices of enteroviral infection.
Materials and methods: Tissue samples (pancreas/ spleen/ PBMCs) from 
controls, T1D and autoantibody positive (AAb+) cases were prepared by the 
nPOD Pathology Core and distributed in a blinded manner to each labora-
tory. Samples were immunostained for enteroviral capsid protein VP1 and 
class I MHC [using IHC in FFPE sections and IF in frozen sections] and 
probed by in situ hybridisation for enteroviral genome. Enterovirus sequence 
analysis was attempted in extracts prepared from frozen spleen and PBMCs 
in a selection of the cases.
Results: Expression of enteroviral capsid protein, VP1, and hyper-expression 
of class I MHC were detected consistently in the islets of Langerhans of pa-
tients with T1D while VP1 was also detected in the spleens. Immunoposi-
tivity was remarkably concordant between the different laboratories, despite 
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the different methodologies employed. Tissues from a total of 101 cases were 
then examined and scored for several indices of viral infection including VP1 
immunopositivity, class I MHC hyperexpression, positive in situ hybridisa-
tion signals and the presence of viral sequences. Among 28 controls, a total of 
54 indices of viral infection were assessed independently and 7 were reported 
as positive (13%). In 52 type 1 diabetes cases (including those with residual 
insulin-containing islets and those without) 99 indices were scored and 51 
were positive (51.5%). Among 21 autoantibody positive cases, 43 indices were 
assessed and 16 were positive (37.2%). PCR amplification and nucleic acid 
sequencing analysis of RNA extracted from cultured spleen cells or PBMCs 
revealed the presence of several enterovirus serotypes and the positivity cor-
related with VP1 staining in sections of tissue from the same samples.
Conclusion: The results support the conclusion that enteroviral infection oc-
curs at much higher frequency in T1D pancreas than in controls. Virus can 
be found both in blood samples and in other tissues (e.g. pancreas, spleen). 
Similar evidence of persisting virus was also found in AAb+ cases, supporting 
the hypothesis that enteroviruses may play a role early in the development 
of T1D.
Supported by: EU Framework 7 (PEVNET); JDRF nPOD-V
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Increased antibodies against other autoimmune diseases in first degree 
relatives of patients with type 1 diabetes
M. Szelachowska, K. Siewko, A. Zielinska, R. Maciulewski,  
A. Poplawska-Kita, D. Lipinska, M. Gorska;  
Department of Endocrinology, Diabetology and Internal Medicine, Medical 
University, Bialystok, Poland.
Background and aims: It is well known that T1D is associated with other 
autoimmune diseases. The aim of this study was to compare the prevalence 
of various auto-antibodies in first-degree relatives of patients with T1D and 
healthy individuals with negative family history of diabetes.
Materials and methods: The group studied consisted of 90 relatives and 
60 healthy individuals. Serum concentrations of antibodies to anti-21-hy-
droxylase (21-OH-Abs), anti-gastric parietal cell antibodies (GPC-Abs), 
anti-thyroglobulin antibodies (TG-Abs), anti-thyroid peroxidase antibodies 
(TPO-Abs) and anti-TSH receptor antibodies (TSHR-Abs) were measured by 
commercial radioimmunoassay.
Results: Positive antibodies against pancreatic islet antigens were found in 
34.4% of the relatives (IAA in 23.3%, GADA in 16.7% and IA-2A in 2.2%) 
and in none of the controls. Other antibodies (mainly TPO-Abs, TSHR-Abs 
and GPC-Abs) were detected in 40% of all relatives and in 93.5% of these with 
positive anti-islet antibodies. Median levels of 21-OH-Abs, GPC-Abs, TPO-
Abs and TSHR-Abs were significantly higher in the relatives, in particular 
these with positive anti-islet antibodies, as compared with the group of rela-
tives with no anti-islet antibodies and the controls. A positive correlation be-
tween IAA and TPO-Abs levels was noted in the whole group of relatives, as 
well as in a subgroup with anti-islet antibodies (r=0.549, p<0.05 and r=0.567, 
p<0.05, respectively).
Conclusion: Our results demonstrated for the first time significantly higher 
prevalence of anti-thyroid antibodies and anti-gastric parietal cell antibod-
ies in the first degree relatives of T1D patients, in particular in these with 
positive anti-islet antibodies. The finding suggest that these subjects may be at 
higher risk of developing not only type 1 diabetes, but also other autoimmune 
disorders and should be routinely screen especially for autoimmune thyroid 
disease and auto-immune gastritis.
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Prevalence of diabetes autoantibodies in Chinese adult patients with type 
1 diabetes mellitus and its relation with beta cell function
L. Liu, H. Deng, J. Yan, H. Ai, J. Lv, S. Lin, Y. Zhang, X. Zheng, D. Yang,  
B. Yao, J. Weng;  
Department of Endocrinology, The Third Affiliated Hospital,  
Sun Yat-Sen University, Guangzhou, China.
Background and aims: There are limited data on the frequency of beta-
cell autoantibodies in Chinese adult patients with type 1 diabetes mellitus 
(T1DM). Our study aimed to explore the prevalence of diabetes autoantibod-
ies (DAs) and its relation with beta-cell function in a cohort of adult patients 
with T1DM in Guangdong Province, China.
Materials and methods: Data were derived from Guangdong T1DM Trans-
lational Medicine Study. A total of 1070 patients with T1DM (488 males and 
582 females) who were ≥18 years of age and had DAs measurements avail-
able were included in this analyses. The median age was 31.7 years old and 
duration was 4.14 years. Autoantibodies (GADA, IA2A and ZnT8A) were 
measured by radioligand assay confirmed by Diabetes Antibody Standardiza-
tion Program. Fasting C-peptide (FCP) and postprandial C-peptide 2 hours 
(PCP2h) were measured centrally by standard methods.
Results: 548(51.2%) subjects were positive for at least one antibody and 
47(4.4%) subjects were positive for three antibodies. Among the subjects 
with single positive antibody, 324(89.3%), 37(10.2%) and 2(0.5%) partici-
pants were positive for GADA, IA-2A and ZnT8A, respectively. Detailed data 
were shown in Figure 1. DA-positive participants were younger at diagnosis 
(median: 25.8 vs. 27.2 years), more likely to be female, with lower BMI at 
diagnosis (median: 18.34 vs. 19.49 kg/m2), lower FCP levels (median: 0.12 
vs. 0.17 ng/ml) and PCP2h levels (median: 0.13 vs. 0.22 ng/ml) and higher 
HbA1c levels (median: 8.8% vs. 8.4%), compared with those who were DA 
negative (P<0.05 for each). A correlation was found between the number of 
positive antibodies and disease duration (rs=0.064, P=0.04) and FCP concen-
tration (rs=-0.149, P=0.00). As the increasing of disease duration, a tendency 
could be also observed that the rate of decline of FCP could be faster in the 
DA-positive group (Figure 2).
Conclusion: Our data showed the prevalence of diabetes autoantibodies in 
Chinese adult patients with T1DM was lower than the countries with high 
incidence of T1DM.The characteristics of DA-positive participants could 
suggest a more aggressive clinical status. There might be a more progressive 
decline in beta-cell function on account of diabetes autoantibodies.
Supported by: Sun Yat-Sen University Clinical Research 5010 Program 
(2007030)
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Relationship between glycaemic variability, functional beta cell mass and 
glucose disposal rate in (pre)type 1 diabetes
A. Van Dalem1, S. Demeester1, E.V. Balti1, K. Decochez1,2, I. Weets1,3,  
E. Vandemeulebroucke1,2, E. Coudenys1, P. Gillard1,4, C. De Block5, J. Ruige6, 
B. Keymeulen1,2, D.G. Pipeleers1, F.K. Gorus1,3, Belgian Diabetes Registry;  
1Diabetes Research Center, Brussels, 2Departement of Diabetology, 
University Hospital Brussels, 3Departement of Clinical Chemistry and 
Radio-immunology, University Hospital Brussels, 4Departement of 
Endocrinology, University Hospital Leuven, 5University Hospital Antwerp, 
6Departement of Endocrinology, University Hospital Ghent, Belgium.
Background and aims: Novel beta cell therapies in (pre)type 1 diabetes (T1D) 
aim to preserve or restore a functional beta cell mass (FBM) that avoids large 
glycemic excursions. In order to define therapeutic target populations, we ex-
amine which functional reserve is needed to curb glycemic variability (GV). 
As a first step we investigated cross-sectionally the correlation between GV 
(assessed by continuous glucose monitoring [CGM] and self-monitoring-of-
blood-glucose [SMBG]) and measures of FBM and of insulin resistance.
Materials and methods: The study was conducted in 9 recent-onset T1D pa-
tients (13-36 years; n=3 in remission defined as insulin dose <0.5 U.kg-1.day-1) 
and in 21 persistently autoantibody-positive first-degree relatives (autoAb+ 
FDR) with overall 50% 5-year disease risk (12-41 years; n=4 with impaired 
glucose tolerance [IGT] at baseline). All underwent CGM (iPro2, Medtronic) 
for 5 days followed by hyperglycemic clamp test (10.0 mmol/l). FBM was 
calculated as AUC C-peptide release between min120-150, and glucose dis-
posal rate (M) as average glucose infusion rate between min120-150 minus a 
space correction. We derived 90 different GV parameters from CGM meas-
urements using the GlyVarT 1.0 program (Medtronic) and 4 GV parameters 
from SMBG data (Contour Link, Bayer).
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Results: Overall, GV parameters (CGM: interquartile rangeday, SDday and 
%glycemiaday >7.7 mmol/l; SMBG: SDday and rangeday) were inversely cor-
related with FBM (r=-0.6 to -0.7, p≤0.001). All patients except 1 in remis-
sion and 4/21 FDR had a FBM ≤percentile 10 (P10) of healthy controls; 2 
of these 4 FDR developed T1D within 9 months. Among the 17 FDR with 
FBM >P10, 2 exhibited elevated GV parameters. A stronger correlation was 
found between GV parameters and M values (r=-0.8, p<0.001). Most patients 
(except 2 in remission) had M values ≤P10 of healthy controls, vs 0/21 FDR. 
Of the 7/21 FDR with M ≤P33 of controls, all had (n=4 including 1 with 
preT1D) or developed IGT (n=2) or T1D (n=1) within 4-10 months vs only 
1/14 FDR with higher M; their GV parameters were also higher (p=0.007 to 
0.053 vs FDR with M >P33). In autoAb+ FDR, M ≤P33 of controls detected 
presence or development of dysglycemia within 1 year with 88% sensitivity 
and 93% specificity. Especially when considering multiple parameters, CGM 
was more sensitive than SMBG in detecting individuals who later developed 
IGT or T1D.
Conclusion: In autoAb+ FDR low glucose disposal rate, also reflecting insulin 
resistance, outperforms FBM in diagnosing or predicting dysglycemia and is 
closely related to elevated CGM parameters. GV could provide non-invasive 
outcome measures in clinical trials.
Supported by: JDRF (USA), EU FP-7 (Brussels), FWO (Brussels)
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Baseline and five year treatment characteristics of adult onset  
type 1 diabetes
D. Hesse, A.A. Nielsen, M. Ridderstråle;  
Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Much less is known about adult onset type 1 diabetes 
(AOT1D) than childhood or adolescent onset T1D. We sought to character-
ize the initial five years of treatment of AOT1D.
Materials and methods: Subjects with AOT1D between 2001 and 2012 were 
identified in the electronic medical records of our diabetes center. Baseline 
demographics and diabetes related parameters for up to five years after on-
set were registered. Patients with latent autoimmune diabetes of the adult 
(LADA) were not included. Data are shown as mean ± standard deviation. 
Non-parametric tests were used throughout and a p-value <0.05 was consid-
ered statistically significant.
Results: 487 patients with AOT1D were identified (men/women 61/39%), 
age at onset 35.2±13.6 years. 383 patients were followed for as long as possible 
for up to five years for this study. Patients leaving the center, some of which 
returned, were also accounted for. GAD antibody status was available in 335 
subjects (standard onset test since 2005-08-01). 274 patients were GAD posi-
tive and 61 GAD negative (82/18%). IFCC HbA1c at onset was 97±30 mmol/
mol (n=487). At the five year follow-up HbA1c had decreased from 97±30 to 
69±18 mmol/mol (Kruskal Wallis [KW] p<0.0001; Figure 1). Patients with 
an HbA1c <53 mmol/mol after 5 years (17%; 31 out of 178 subjects with 
5 year data: 45±4 vs. 71±16 mmol/mol; p<0.0001) were already showing a 
significantly lower HbA1c by the second quarter after diagnosis (45±7 vs. 
53±12 mmol/mol; p<0.005). There was no difference in HbA1c between 
these groups at diagnosis (100±20 vs. 97±31 mmol/mol; ns), nor concerning 
other diabetes related variables. Apart from HbA1c, the only other five-year 
outcome that was different between the groups was a lower total insulin dose 
in the group <53 mmol/mol (36±22 vs. 52±23 IU; p=0.0001). The likelihood 
of having a five year HbA1c <53 mmol/mol was four times higher in sub-
jects who reached an HbA1c <53 mmol/mol within the first six months of 
treatment compared to those who did not (odds ratio 4.2 [1.4-13.0] 95%CI; 
p=0.01). Over the five years, there were significant but modest increases in 
blood pressure, HDL-cholesterol, and BMI, and a significant decrease in tri-
glycerides (KW p<0.0001 for all), with no change in LDL-cholesterol; most 
changes occurring during the first two years. By contrast, there was a gradual 
increase in total insulin dose (KW p<0.0001). Only 14 patients were trans-
ferred from multiple daily injections to continuous subcutaneous insulin in-
jection during the five first years of treatment.
Conclusion: Tight glycemic control in subjects with AOT1D can be main-
tained over time. Already within half a year from the onset/diagnosis it may 
be possible to predict the long term sustainability of the glycemic treatment 
by looking at the HbA1c level. The lack of other predictive variables for long 
term prognosis, as well as the lack of indicators for the need of alternative 
strategies, is striking and motivates further research into this large group of 
patients, including comparisons with patients with childhood- and adoles-
cent onset T1D.
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After diagnosis diabetes research support system-2 (ADDRESS-2): 
clinical presentation of type 1 diabetes in the beginning of the 21st 
century in a multi-ethnic UK cohort
V. Bravis1, A. Kaur1, H. Walkey1, I. Godsland1, C. Dayan2, M. Peakman3,  
P. Bingley4, N. Oliver1, D.G. Johnston1;  
1Department of Endocrinology, Diabetes and Metabolism,  
Imperial College, London, 2Cardiff University School of Medicine, 
3Department of Immunology, King‘s College, London,  
4Diabetes and Metabolism, University of Bristol, UK.
Background and aims: Type 1 diabetes (T1D) most commonly presents with 
the classical triad of polyuria, polydipsia and weight loss but duration and 
pattern of symptoms may vary. The reported frequency of diabetic ketoaci-
dosis (DKA) at presentation of T1D is 10 to 80% That has changed little over 
the last decades in the developing and the developed world. The purpose of 
our study was to determine the frequency of DKA at presentation of T1D, in 
a multi-ethnic UK cohort of patients and study their clinical characteristics.
Materials and methods: The ADDRESS-2 cohort comprises people with in-
cident T1D, and includes clinical and demographic features and, in many, 
islet-specific antibodies. From 01.09.11 to 31.12.13, children over 5 and 
adults under 60 years with T1D were recruited to ADDRESS-2 from 134 UK 
recruiting sites, within 6 months of diagnosis.
Results: 1,440 patients were recruited (1,264 white; 65% male; 55% chil-
dren; mean age 20.1y, SD 12.95; median age 15y, IQR 10-28). At presentation 
96.6% described osmotic symptoms, 85.8% weight loss and 84.7% fatigue. 
Subjects presented with none (0.6%), one (5.6%), two (20.2.%) or all three 
symptoms (73.8%). 43.7% presented with DKA. Symptom duration ranged 
from under 2 weeks to over 12 months (median 3w, IQR 2-6). There was no 
association between symptom type and age, gender or ethnicity. Symptom 
duration increased significantly with increasing age (p<0.01), female gender 
(p<0.01) and Black ethnicity (p=0.02). There was no significant difference 
in age between those presenting with or without DKA (DKA: median 15.5y, 
IQR 11-28; non-DKA: median 15y, IQR 10-28). Gender and ethnicity were 
not significantly different between those presenting with DKA and those 
without. 92% of those presenting with DKA suffered weight loss, 90% fatigue 
and 97% osmotic symptoms. Weight loss and fatigue were significantly more 
frequent with DKA (p<0.01) but osmotic symptoms occurred at comparable 
frequency (p=0.11). Increasing number of symptoms was significantly asso-
ciated with DKA presentation (p<0.01). Mean symptom duration in those 
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with DKA (5.1 weeks, SD 6.2) and those without (6.5 weeks, SD 18.8) was 
comparable (p=0.42). Positive autoantibody (AAb) status was not associated 
with symptom type, number or duration or DKA at presentation. GAD AAb 
titre had no effect on frequency of presentation with DKA. 8.2% of those pre-
senting with DKA had at least one other autoimmune condition versus 4.5% 
of those with no DKA (p<0.01). There was no overall significant difference in 
weight, height, BMI or birth weight between those with DKA or not. Family 
history of diabetes did not correlate with symptoms but paternal diabetes was 
significantly more frequent in the non-DKA population (p=0.01).
Conclusion: Our study offers important insight into clinical and anthropo-
metric characteristics of patients presenting with T1D in a modern multi-
Ethnic European country. The duration of symptoms is typically short and 
increases with age, female gender and Black ethnicity. Weight loss, fatigue 
and co-existing autoimmune disease are commoner in those with DKA. The 
frequency of DKA at presentation of T1D remains very high, suggesting that 
T1D remains a public-health issue.
Clinical Trial Registration Number: 10/H0505/85
Supported by: Diabetes UK & Juvenile Diabetes Research Foundation
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Serum bilirubin is inversely related to both HbA1c and complications in 
people with type 1 diabetes
P. Mansell, C. Chee, T. Gazis;  
Diabetes and Endocrinology, Nottingham University Hospitals, UK.
Background and aims: There is evidence of an inverse correlation between 
HbA1c and serum bilirubin in people with type 2 diabetes and in healthy 
populations in the Far East. We have investigated this further in a UK popula-
tion with type 1 diabetes, and also whether there is any association between 
bilirubin and microvascular complications.
Materials and methods: Data were extracted from the Nottingham Univer-
sity Hospitals diabetes register and pathology databases and the Nottingham 
retinopathy screening database. Of 2067 adults registered with type 1 diabe-
tes, we excluded those with renal failure, pregnancy or a recent diagnosis of 
diabetes.
Results: 1595 people (77% of those eligible) had HbA1c and serum bilirubin 
levels within a 15 month window. Mean (standard deviation) age was 45 (15) 
years with duration of diabetes 22 (13) years. There was an inverse relation-
ship between HbA1c and bilirubin (R= -0.15, P<0.001) which persisted in 
a stepwise linear regression model including also sex, age and duration of 
diabetes. Mean HbA1c in the group with the lowest quintile of bilirubin was 
76 (19) mmol/mol compared with 66 (16) mmol/mol in the highest quintile. 
The results were not significantly altered by excluding those with a serum 
bilirubin above the reference range. The group with the lowest quintile of 
bilirubin concentration had a higher prevalence of microalbuminuria (27.7 
vs 14.2%, P<0.001) and of retinopathy (29.0 vs 17.7%, P=0.011), compared 
with the remainder of the cohort.
Conclusion: There is a significant inverse correlation between HbA1c and 
bilirubin in people with type 1 diabetes in a UK population. Microvascular 
complications were more prevalent in those with a low bilirubin concentra-
tion, suggesting the inverse association with HbA1c is not solely a biochemi-
cal artefact.
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LDL-cholesterol is not a good marker of cardiovascular risk in type 
1 diabetes: observational study in 30,778 patients: a report from the 
national diabetes register in Sweden
C. Hero1, A.-M. Svensson2, P. Gidlund2, B. Eliasson1, K. Eeg-Olofsson1;  
1Department of Medicine, 2Region Västra Götaland, Swedish National 
Diabetes Register, Gothenburg, Sweden.
Background and aims: Patients with type 1 diabetes (T1D) are at high risk of 
cardiovascular disease (CVD). High LDL-cholesterol (LDL) is an important 
risk factor in general population and in type 2 diabetes. Less is known in 
T1D. The aim of this study was to assess LDL and total-cholesterol to HDL-
cholesterol ratio (Chol/HDL) as predictors of CVD in T1D and to evaluate 
the risk at different levels of LDL.
Materials and methods: 30,778 T1D patients, age 18-79 years, were included 
2003-2006 and followed for mean 6.8 years. Mean age 46 years, diabetes du-
ration 21 years, HbA1c 8% (NGSP), LDL 2.7 mmol/L and Chol/HDL 3.2. 
10% had a history of CVD. 26.6% (n= 8172) were treated with lipid-lowering 
medication, they were older, had longer diabetes duration and 24% had pre-
vious CVD.
Results: There were 13.8 CVD events/1000 person years (py) in patients 
without and 51.7 events/1000 py in patients with lipid-lowering medication. 
Cox regression analyses were performed with LDL and Chol/HDL as predic-
tors and fatal/nonfatal CVD as outcome, adjusted for other CVD risk fac-
tors. Adjusted hazard ratios (HR) per 1 mmol/L increase in LDL for CVD 
were 1.03 (95% CI 0.99-1.08) in all, 1.05 (1.00-1.14) in those without and 1.04 
(0.98-1.1) in those with treatment. All HR were non-significant. Adjusted HR 
per 1 unit increase in Chol/HDL for CVD were 1.08 (1.05-1.12) in all, 1.11 
(1.05-1.16) in patients without and 1.08 (1.03-1.13) in patients with lipid-
lowering medication. All p-values < 0.01. We also assessed risk of CVD with 
octiles of LDL, octile 4 as reference (LDL 2.5-2.7). Compared to reference 
only patients without lipid-lowering treatment, in the highest octile (LDL > 
3.6 mmol/L) had significant higher risk HR 1.25 (1.02-1.52).
Conclusion: In our study LDL was not a significant predictor of CVD in T1D 
apart from in patients in the highest octile not treated with lipid-lowering 
medication. The ratio of Chol/HDL was a significant predictor for CVD in 
all groups. The ratio of chol/HDL seems to be a more reliable marker for risk.
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Women from South Asia, Middle East and Africa at increased risk of 
postpartum weight retention and type 2 diabetes:  
a multi-ethnic population based cohort study in Oslo, Norway
C.W. Waage1,2, R.S. Falk3, C. Sommer1,4, K. Mørkrid1,2, K.R. Richardsen5,6,  
A. Bærug7, N. Shakeel2, K.I. Birkeland1,4, A.K. Jenum2,6;  
1Department of Endocrinology, Morbid Obesity and Preventive Medicine, 
Oslo University Hospital, 2Institute of Health and Society, Department of 
General Practice, Faculty of Medicine, University of Oslo, 3Department of 
Biostatistics, Epidemiology and Health economics, Oslo University Hospital, 
4Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 
5Norwegian Resource Centre for Womens Health, Department for Womens 
and Childrens Health, Oslo University Hospital, 6Faculty of Health Sciences, 
Oslo and Akershus University College of Applied Sciences, 7Norwegian 
Resource Centre for Breastfeeding, Oslo University Hospital, Norway.
Background and aims: Pregnancy has been considered a critical period for 
development of overweight and its complications including type 2 diabetes, 
both in the mother and through diverse mechanisms including epigenetic 
modifications, also in her child. Immigrant women of Asian and African 
origin living in Europe are at higher risk for obesity, type 2 diabetes and car-
diovascular diseases than the native European population. Women with ges-
tational weight gain above recommended levels from American Institute of 
Medicine are at increased risk of postpartum weight retention and thereby of 
later obesity and related co-morbidities. The aim of the study was to explore 
ethnic differences in postpartum weight retention three months postpartum 
in a population-based, multi-ethnic study of pregnant women.
Materials and methods: A multi-ethnic population based cohort study from 
Oslo, Norway of 823 healthy pregnant women, 59 % with ethnic minority 
background, included from 2008-2010. A total of 642 (78% of 823) were fol-
lowed till three months postpartum. A multiple linear regression analyses 
were performed to model the relationship between postpartum weight reten-
tion and ethnicity.
Results: Unadjusted mean postpartum weight retention was 2.3 kg (95% con-
fidence interval 1.7-2.9) for women from Western Europe and ranged from 
3.7-6.3 kg among ethnic minority groups. The proportion of women in the 
highest quintile (postpartum weight retention 8.5-24.4 kg) differed by eth-
nicity; 12% among Western European, 9% among East Asians, 25% among 
South Asians, 28% among Middle Eastern, 29% among East European and 
41% among African women (p<0.001 for all versus Western Europeans, ex-
cept for East Asians and Eastern Europeans). Postpartum weight retention 
as percentage increase of pre-pregnant body weight was 3.3% among West-
ern Europeans, 6.5% among East Asians, 7.6% among Middle Eastern, 8.0% 
among Eastern Europeans, 8.4% among South Asians and 9.3% among wom-
en from Africa. After adjustments for age, gestational weight gain, parity and 
education, women from South Asia retained 2.8 kg (95% confidence interval 
1.9-3.6), Middle East 2.0 kg (95% confidence interval 1.0-3.0) and women 
from Africa 4.4 kg (95% confidence interval 3.1-5.8) more than Western Eu-
ropeans (p<0.001).
Conclusion: Significantly more women from South Asia, Middle East and 
Africa had postpartum weight retention in the highest quintile compared to 
Western European women.
Clinical Trial Registration Number: 2009/617
Supported by: HSØ
294
The ‚obesity paradox‘ and mortality in adults with type 2 diabetes: 
explained by collider biases
E.L. Badrick1, M. Sperrin1, M. Carr1, T. Moran2, I. Buchan1, A. Renehan3;  
1Institute of Population Health, University of Manchester,  
2NHS, Northwest Cancer Intelligence Service,  
3Institute of Cancer Sciences, University of Manchester, UK.
Background and aims: Among adults with type 2 diabetes (T2D), being 
overweight or obese near the time of diagnosis is associated with reduced risk 
of mortality compared with normal-weight patients - the ‘obesity paradox’. 
We tested the hypothesis that the strengthening of the negative association 
between smoking and BMI induced by the conditioning on the disease state, 
T2D, explains the obesity paradox.
Materials and methods: We developed the logic of collider bias as it pertains 
to the association between smoking and body mass index (BMI) in 10761 
patients with T2D from the Salford Integrated Records database (Manchester, 
UK). We related peri-diagnosis BMI (within a year of diagnosis) and mortal-
ity using flexible parametric survival analyses with age (35 to 85 years) as the 
timescale, adjusting for sex and stratified by smoking, with BMI 25 to <30 kg/
m2 as a referent group.
Results: There were 1247 deaths during a mean period of 8.57 years of follow-
up. A U-shaped association was observed across BMI categories (18.5 to 25.9, 
25.0 to 29.9 [reference], 30.0 to 35.4, 35.0 to 39.9, and ≥40.0) for all-cause 
mortality (hazard ratio plus 95% confidence interval [CI], 1.22 (1.05-1.42); 
1.00; 0.97 (0.84-1.13); 1.33 (1.09-1.62); 2.02 (1.59-2.56) respectively). The 
U-shaped relationship was retained in ever-smokers, but in never smokers, 
increased risk of mortality was only seen in Obese II-III groups (2.43 CI 1.68-
3.50). The U-shaped relation was noted in younger but not older 10-year age 
bands. Associations remain after excluding patients who died or were cen-
sored within 2-years of diabetes diagnosis, suggesting reverse causality was 
not a major confounder.
Conclusion: We confirmed that, among adult patients with incident T2D, 
being normal weight or obese II/III is associated with higher mortality com-
pared with overweight and obese I categories, but these observations were 
explained by collider biases due to associations of age and smoking with mor-
tality in the diseased population. Weight loss interventions to reduce mortal-
ity in patients with T2D merits future research.
Supported by: EFSD
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Impact of visceral fat on skeletal muscle mass in a prospective cohort 
study: the Korean Sarcopenic Obesity Study (KSOS)
H. Hong1, T. Kim2, J. Ryu1, S. Kim1, J. Yu1, N. Kim1, J. Ahn1, H. Yoo1,  
H. Kim1, J. Seo1, S. Kim1, N. Kim1, S. Baik1, D. Choi1, K. Choi1;  
1Division of Endocrinology and Metabolism, Korea University College of 
Medicine, 2Department of Internal Medicine, Cardiovascular and Metabolic 
Disease Center, College of Medicine, Inje University, Busan, Republic of 
Korea.
Background and aims: To investigate whether visceral obesity promotes a 
decrease in skeletal muscle mass and vice versa.
Materials and methods: We observed changes in anthropometric and body 
composition data during a follow-up period of 27.6 ± 2.8 months in 379 Ko-
rean men and women (mean age 51.9 ± 14.6 years) from the Korean Sarco-
penic Obesity Study (KSOS), an ongoing observational prospective cohort 
study.
Results: Appendicular skeletal muscle mass (ASM) and total skeletal mus-
cle mass were calculated using dual-energy X-ray absorptiometry, and vis-
ceral fat area (VFA) was measured using computed tomography at baseline 
and follow-up examination along with the various kinds of confounding or 
possible mediating factors. Both ASM and total skeletal muscle mass signifi-
cantly decreased, whereas trunk and total fat mass increased in both men 
and women despite no significant change in weight and body mass index. 
Correlation analysis adjusting for age and gender revealed that baseline VFA 
was negatively correlated with changes in ASM (P = 0.001). However, base-
line ASM was not significantly associated with changes in VFA (P = 0.135). 
In particular, women with visceral obesity at baseline had a greater decrease 
in ASM than those without visceral obesity (P = 0.001). In multiple linear 
regression analysis, baseline VFA was an independent negative predictor of 
the changes in ASM after adjusting for confounding factors including age, 
gender, life style parameters, insulin resistance, high sensitivity C-reactive 
protein and vitamin D levels (P = 0.001), whereas the association between 
baseline ASM and changes in VFA was not statistically significant (P = 0.142).
Conclusion: This longitudinal study showed that visceral obesity was associ-
ated with future loss of skeletal muscle mass in Korean adults. These results 
may provide novel insight into sarcopenic obesity in an aging society.
Clinical Trial Registration Number: NCT01594710
Supported by: NRF of Korea
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Visceral fat is associated with hyperglycaemia after renal transplantation
M. von Düring1, T. Jenssen1,2, J. Bollerslev3, K. Godang3, A. Aasberg4,  
A. Hartmann1;  
1Department of Organ Transplantation, Section of Nephrology, University 
of Oslo, Rikshospitalet, 2Institute of Clinical Medicine, Faculty of Health 
Science, University of Tromsø, 3Section of Specialized Endocrinology, 
4Department of Pharmaceutical Biosciences, School of Pharmacy, University 
of Oslo, Rikshospitalet, Norway.
Background and aims: Hyperglycaemia and new onset diabetes after trans-
plantation (NODAT) are common complications in renal transplant recipi-
ents and are associated with impaired long-term survival. Studies in the non-
transplant population suggest that visceral fat facilitates development of type 
2 diabetes. The role of visceral fat for development of NODAT is not known. 
The aim in this study was to elucidate this relationship between visceral fat 
content and hyperglycaemia in renal transplant patients.
Materials and methods: We studied 159 renal transplant patients without 
a prior diagnosis of diabetes. All of them underwent oral glucose-tolerance 
tests (OGTTs) in a stable phase 10 weeks after transplantation. Visceral fat 
content was analyzed by a newly validated software (CoreScan) applied after 
total body composition DXA-scans using Lunar Prodigy, software version 
14.10.
Results: The amount of visceral fat (median 1.0 kg, interquartile range = IQR 
0.4 - 1.9 kg) was highest in patients with NODAT (median 2.2 kg, IQR 1.2-
2.7). There was a significant difference in the amount of visceral fat between 
the categories of glucose tolerance; NODAT, impaired glucose tolerance (me-
dian 1.2 kg), impaired fasting glucose (median 1.0 kg) and normal glucose 
tolerance (median 0.8 kg) (Kruskal-Wallis ANOVA, p = 0.003). The percent-
age visceral fat of the total fat mass was 97% higher in patients with NODAT 
(median 7.7%, IQR 6.0-8.6%) compared with NGT patients (median 3.9%, 
IQR 2.0-5.8%) (p < 0.001). Percentage visceral fat of total fat mass was also 
a better predictor of both fasting (fPG, R2 = 0.116, p < 0.001) and 2-hour 
plasma glucose (2hPG, R2 = 0.082, p < 0.001), compared to total body fat per 
se or BMI in a multiple regression analysis.
Conclusion: Visceral fat is adversely associated with glucose metabolism in 
renal transplant recipients. Whether reduction of visceral fat mass may pre-
vent development of NODAT needs further studies.
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Increased risk for diabetes development in non-diabetic Korean subjects 
with hypertriglyceridaemic waist phenotype
E.-J. Rhee, M. Lee, H. Park, W. Jeon, S. Park, C.-Y. Park, W.-Y. Lee,  
K.-W. Oh, S.-W. Park;  
Endocrinology, Department of Endocrinology and Metabolism, Kangbuk 
Samsung Hospital, Sungkyunkwan University, Seoul, Republic of Korea.
Background and aims: Hypertriglyceridemic waist (HTGW) phenotype is a 
simple and inexpensive screening parameter to identify people at increased 
risk for cardiovascular disease. We evaluated whether the HTGW phenotype 
predicts diabetes in Korean urban adults.
Materials and methods: 2,900 non-diabetic subjects (mean age 44.3 years) 
including 2078 male (71.7%) and 822 female (28.3%), who did annual medi-
cal check-up in a university hospital for four consecutive years were recruited. 
The subjects were divided into four groups according to the baseline serum 
triglyceride (TG) and waist circumference (WC); normal WC-normal TG 
(NWNT), normal WC-high TG (NWHT), high WC-normal TG (HWNT), 
high WC-high TG (HWHT). High serum TG was defined as TG≥150 mg/
dL and high WC was defined as WC≥90 cm for men and ≥85cm for women. 
New cases of diabetes were determined according to the self-questionnaire 
of the participants and fasting plasma≥126 mg/dL. Cox proportional hazard 
model analysis was used to assess the cumulative incidence of diabetes ac-
cording to baseline HTGW phenotypes.
Results: 101 (3.5%) new diabetes cases were diagnosed during four years of 
follow-up period. The subjects in HWHT group had the highest incidence 
of diabetes (8.3%) compared with the NWNT group (2.2%). The adjusted 
hazard ratio (aHR) for developing diabetes in the presence of HWHT phe-
notype at baseline was 4.11 (95% confidence interval [CI] = 2.40-7.06) after 
adjusting for age, and 2.44 (95% CI = 1.38-4.33) after adjusting for age, sex, 
total cholesterol and systolic pressure, when NWNT group was considered as 
the reference group.
Conclusion: This study demonstrated that HWHT showed the highest risk 
for diabetes development during four years of follow-up period. Recognizing 
HWHT type would be useful to identify individuals at high-risk of diabe-
tes and, which is of great significance in reducing the incidence of diabetes 
among Korean urban adults.
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Metabolically healthy obesity, presence or absence of fatty liver,  
and risk of type 2 diabetes in Japanese individuals
Y. Heianza1,2, Y. Arase2, K. Fujihara1, S. Hsieh2, K. Saito1,2, O. Hanyu1,  
S. Kodama1,2, S. Hara2, H. Sone1,2;  
1Department of Internal Medicine, Niigata University Faculty of Medicine, 
2Health Management Center, Toranomon Hospital, Tokyo, Japan.
Background and aims: Whether a “metabolically healthy obese (MHO) phe-
notype” that does not include typical obesity-related metabolic abnormali-
ties is really a benign or malignant state has not been elucidated in terms of 
predicting the progression to type 2 diabetes. We investigated whether the 
MHO phenotype was associated with an increased risk of the development of 
diabetes. If so, we aimed to determine what factors could explain this finding.
Materials and methods: Studied were 8090 Japanese individuals without dia-
betes (diabetes indicated by the ADA criteria). Metabolic health status was 
assessed by common clinical markers: blood pressure, triglycerides, HDL-
cholesterol, and fasting glucose concentrations. Cut-off value for obesity (O) 
or normal weight (NW) was a BMI of 25.0 kg/m2. Participants were catego-
rized at the baseline examination into 4 phenotypes: 1) metabolically healthy 
and normal weight (MHNW), 2) metabolically healthy and overweight or 
obese (MHO), 3) metabolically abnormal and normal weight (MANW), or 
4) metabolically abnormal and overweight or obese (MAO).
Results: The 5-year incidence rate of diabetes was 1.2% (n=58/4749) 
in MHNW individuals, 2.8% (n=20/719) in MHO individuals, 6.0% 
(n=102/1709) in MANW individuals, and 10.3% (n=94/913) in MAO indi-
viduals. Although the MHO individuals had no or 1 metabolic factor, 47.8% 
had ultrasonographic fatty liver (FL). The MHO group had a significantly 
increased risk of diabetes compared to the MHNW group (multivariate-ad-
justed OR, 2.23 (95% CI 1.33, 3.75)), but this risk was attenuated after adjust-
ment for FL. We then assessed the combined effect of obese phenotypes and 
FL on the development of diabetes. MHNW/non-FL group had the lowest 
incidence rate of diabetes (0.9%), and MHO/non-FL group also had a simi-
larly low incidence rate of diabetes (1.1%). On the other hand, the MHO/FL 
group had an elevated incidence rate (4.7%). Incidence rate of diabetes was 
markedly high at 8.5% in the MANW/FL group and 12.6% in the MAO/FL 
group. Compared to the MHNW/non-FL group, the risk of diabetes in the 
MHO/non-FL group was not significantly elevated (OR 1.01 (0.35, 2.88)). 
However, the MHO/FL and MHNW/FL groups had similarly elevated risks 
of diabetes (OR 4.09 (95% CI 2.20, 7.60) and 3.16 (1.78, 5.62), respectively). 
A prediction model with age, sex, and obese phenotypes had an area under 
the ROC curve (AUCROC) of 0.754 for the development of diabetes. The 
AUCROC was slightly but significantly (p <0.001) improved when we added 
the assessment of FL into the model, with an area under the ROC curve of 
0.778. The net reclassification improvement was 8.8% (95% CI 1.7% to 15.8%) 
by introducing the assessment of fatty liver in the prediction model.
Conclusion: Our results showed that individuals with MHO as defined in 
this study had a significantly higher risk of the development of diabetes 
compared to MHNW individuals without consideration of the presence of 
ectopic fat in the liver. However, at baseline almost half of MHO individu-
als had an accumulation of fat in liver as assessed by ultrasonography, and 
this observation partially explained the increased risk of diabetes among the 
MHO individuals. The presence of FL should be evaluated to assess whether 
an individual was actually in a metabolically benign state in predicting the 
development of diabetes.
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Presence and severity of obstructive sleep apnoea is independently 
associated with glycometabolic abnormalities in obese non-diabetic 
subjects
A. Cignarelli1, S. Perrini1, A. Ciavarella1, S. Kounaki1, V. Quaranta2,  
M. Barbaro1, A. Di Trani1, V. Falcone2, A. Natalicchio1, L. Laviola1, O. Resta2, 
F. Giorgino1;  
1Endocrinology & Metabolic Diseases,  
2Respiratory Diseases, University of Bari, Italy.
Background and aims: Obstructive sleep apnea (OSA) is a common under-
diagnosed condition in the obese population, and has been associated with 
worse glycemic control in individuals with type 2 diabetes. The relationship 
between OSA and glycometabolic parameters was investigated in obese non-
diabetic individuals.
Materials and methods: Ninety-one obese subjects (57% male, mean age 
45.3 ± 12 yrs, mean BMI 42.1 ± 9 kg/m2) underwent polysomnography and a 
2-h oral glucose tolerance test (OGTT).
Results: OSA was identified in 64% of subjects (73% in male, 41% in female, 
p=0.032 χ2). Obese subjects with OSA showed higher A1c (5.8% vs 5.5%, 
p=0.009), plasma glucose at 120 min during OGTT (PPG120) (133 mg/dl 
vs 102 mg/dl, p=0.001), triglyceride (140 mg/dl vs 117 mg/dl, p=0.045) and 
uric acid (5.8 mg/dl vs 4.9 mg/dl, p=0.035) levels than obese subjects without 
OSA. A1c levels and PPG12O were found to be significantly correlated with 
raised apnea-hypopnea index (AHI) (p=0.007 and p=0.004, respectively), 
oxygen desaturation index (p=0.002 and p=0.04, respectively), and percent 
of sleep time with oxyhaemoglobin saturation at <90% (ST90) (p=0.002 
and p=0.004, respectively). Furthermore, increasing quartiles of ST90 and 
AHI were associated with increasing levels of A1c and PPG120 (p=0.015 
and p=0.003, respectively, for ST90; and p=0.035 and p=0.014, respectively, 
for AHI). Multiple regression analysis showed that ST90 was the strongest 
independent determinant of A1c, after controlling for sex, age, BMI, waist 
circumference, CRP, HOMA-IR (β=0.442, p=0.007). Similarly, AHI persisted 
as an independent determinant of A1c (β=0.414, p=0.005). Both ST90 and 
AHI persisted as determinants of PPG120, albeit not significantly (β=0.377, 
p=0.095; and β=0.358, p=0.119, respectively).
Conclusion: OSA acts as an independent factor exacerbating the metabolic 
risk attributed to obesity. Recognition and treatment of OSA may decrease 
the progression toward type 2 diabetes in obese subjects.
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Retrospective analysis of fatty liver markers for incident diabetes: 
comparison between people with lower alcohol intake and higher alcohol 
intake
S. Katoh1, M. Kaji1, M. Zeniya1, Y. Sakamoto1, K. Utsunomiya2;  
1Harumi Triton Clinic, 2Department of Internal Medicine, Jikei University 
School of Medicine, Tokyo, Japan.
Background and aims: Although fatty liver is a risk factor for incident dia-
betes, markers of fatty liver for incident diabetes have yet to be sufficiently 
investigated. We retrospectively analyzed fatty liver markers including serum 
cholinesterase (ChE) for incident diabetes and compared them between peo-
ple with lower alcohol intake and higher alcohol intake in accordance with 
cut-off point for non-alcoholic fatty liver disease (ethanol intake 140g/week).
Materials and methods: Study periods I and II were defined as January 2007 
to May 2009 and June 2009 to December 2011, respectively. A total of 2084 
people (1389 men, 695 women; mean age: 46 years) who underwent an an-
nual medical check-up including blood sampling after an overnight fast in 
Periods I and II were recruited. They were accumulated as representatives 
of the diurnal regional population. We excluded people positive for hepatitis 
B virus antigen and hepatitis C virus antibody as well as those with diabe-
tes in Period I. Others were divided into lower alcohol intake (LAI) group 
(ethanol intake ≤ 140g/week, n=1515) or higher alcohol intake group (HAI) 
group (ethanol intake > 140g/week, n=448). In this study, diabetes was diag-
nosed by prescription of antidiabetic agents, fasting plasma glucose (FPG) ≥ 
6.8mmol/l, HbA1c (NGSP) ≥ 6.5% and/or a past history of diabetes in those 
not yet treated with antidiabetic agents. Fatty Liver Ultrasonography scores 
(FLUS) were also assigned as follows: 2 points, subjects with moderate or 
severe fatty liver; 1 point, those with mild fatty liver; 0 points, those with 
normal liver. Regression coefficient (B) was calculated using logistic regres-
sion analysis.
Results: The mean observation period was 2.23 years, with 27 LAI subjects 
and 15 HAI subjects with newly developed diabetes from Periods I to II. The 
remaining 1488 LAI subjects and 433 HAI subjects were nondiabetic. In lo-
gistic regression analysis, alanine aminotransferase (ALT) was independently 
and significantly (B=0.025, p=0.017) associated with incident diabetes as 
well as age (B=0.065, p=0.008), BMI (B=0.264, p=0.050), waist circumfer-
ence (WC) (B= - 0.120, p=0.036), fasting plasma glucose (FPG) (B=0.116, 
p<0.001) in Period I in the LAI group. Systolic and diastolic BP, Gamma-GTP, 
ChE, FLUS, triglyceride and HDL cholesterol were not associated. In receiver 
operating characteristic (ROC) analysis, the specific cut-off point in ALT in 
Period I for detecting incident diabetes was 24U/l (AUC 0.73, p<0.001, sen-
sitivity 70%, specificity 70%) in the LAI group. In the HAI group, ChE was 
independently and significantly (B=0.013, p=0.009) associated with incident 
diabetes as well as HDL cholesterol (B= - 0.069, p=0.046) and FPG (B=0.315, 
p<0.001) in Period I. ALT, age, BMI, WC, systolic and diastolic BP, Gamma-
GTP, FLUS and triglyceride were not associated. In ROC analysis, the specific 
cut-off point in ChE in Period I for incident diabetes was 372U/l (AUC 0.72, 
p<0.005, sensitivity 78.6%, specificity 64.8%) in the HAI group.
Conclusion: Although FPG was a powerful predictor for incident diabetes, 
ALT and ChE also independently affected incident diabetes in LAI group and 
HAI group, respectively. The ALT and ChE would be useful fatty liver mark-
ers for incident diabetes in non-alcoholic fatty liver disease and alcoholic 
fatty liver disease, respectively.
Clinical Trial Registration Number: 20-130 5420
Supported by: KAKENHI 22590609
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One normal range for HbA1c in every age? The effect of aging on HbA1c 
in the people without diabetes
J. Roth1, N. Müller1, C. Kloos1, U.A. Müller1, G. Wolf2;  
1Department of Internal Medicine III, Department Endocrinology and 
Metabolic Disorders, 2Department of Internal Medicine III, Jena, Germany.
Background and aims: Goals for HbA1c in National Guidelines and the cut-
off value for diagnosis of diabetes are not adjusted for age yet. The Framing-
ham Offspring Study and the National Health and Nutrition Examination 
Survey 2001-2004 showed a 0.6% increase of HbA1c for non diabetic people 
over the age of 70 compared to people below the age of 40 years. We evaluated 
this question in a German population.
Materials and methods: We analyzed the data from 10163 visits of 3861 
patients without diabetes (age 44.7y; 18-93y; 72.6% women; BMI 28,0±6,5 
kg/m²) which had parallel HbA1c and blood glucose measurements and in-
formation about drug treatment. The HbA1c values were divided in 3 age 
groups (<40y [n=3583]; >=40 < 70y [n=5454]; >70y [n=1126]). Patients with 
gestational diabetes mellitus, documented use of systemic glucocorticoids or 
HbA1c >= 6.5% were excluded. A glucose tolerance test was not performed. 
Data were drawn from the electronic patients record (EMIL®) of our uni-
versity outpatient department for endocrinology and metabolic disorders 
between 10/1992 and 01/2014. HbA1c was DCCT adjusted (mean normal 
range of healthy people 5.05%).
Results: The mean HbA1c (95. percentile) for the groups of age was: <40years 
5.0±0.36% (5.6%), >=40 < 70 years 5.3±0.38% (5.9%), >=70 years 5.4±0.37% 
(6.0%). The differences between <40 years vs. 40-70 years, <40 y vs. >70 y 
(p<0.001) and 40-70 y vs. >70 y (p<0.001) were significant. The mean blood 
glucose (non fasting) was <40y 4.5±0.6; 5.2± 1.1 mmol/l; >=40 < 70y 5.0±0.74; 
5.3±1.0 mmol/l and >=70y 5.1±0.85; 5.5±1.1 mmol/l. The differences < 40 vs. 
40-70y (p< 0.001) und >70y (p< 0.001); and 40-70y vs. >70y (p< 0.001) were 
also significant.
Conclusion: HbA1c increases significantly with the age of people without 
diabetes. The use of different cut-off values for the diagnosis of diabetes ac-
cording to age should be considered. Also HbA1c goals for old people with 
diabetes should consider the age dependend increase of HbA1c.
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The association of smoking cessation with HbA1c control of diabetes 
mellitus: a THIN database study
L. Nichols1, R. Ryan1, A. Farley2, A. Roalfe1, M. Mohammed3, L. Szatkowski4, 
T. Coleman4, R. Morris5, A. Farmer6, P. Aveyard6, D. Lycett7;  
1Primary Care Clinical Sciences, University of Birmingham,  
2Public Health, Epidemiology and Biostatistics, University of Birmingham, 
3University of Bradford, , 4University of Nottingham, 5University College 
London, 6University of Oxford, 7Coventry University, UK.
Background and aims: Smoking increases the risk of developing type 2 
diabetes mellitus. However several large observational studies have found 
during the first 3-5 years following smoking cessation the risk of developing 
diabetes is significantly greater than in continuing smokers; an association 
largely explained by weight gain. This increase in risk is temporary and after 
10-12 years the risk is equivalent to never-smokers. There is also prelimi-
nary evidence from small cohort studies, in those who already have diabetes 
that control deteriorates during the first year after smoking cessation before 
it improves. Our objective was to examine whether an association between 
smoking cessation and diabetes control exists in a large representative sample 
of the UK population. If deterioration in diabetes control around the time 
of smoking cessation does occur, this may have implications for enhanced 
diabetic care at that time.
Materials and methods: A retrospective cohort study (01/01/2005 - 
31/12/2010) was assembled using The Health Improvement Network (THIN) 
database. Inclusion criteria were: patients aged over 18, registered with their 
practice for at least one year on 01/01/2005, diagnosed with type 2 diabe-
tes mellitus and whose last recorded smoking status prior to 01/01/2005 was 
current smoker. An adjusted multilevel regression model was developed to 
investigate the association between change in HbA1c and stopping smoking.
Results: There were 10,692 adults with type 2 diabetes who were current 
smokers as at 01/01/2005. Of these, 3,131 (29%) quit smoking and remained 
abstinent for one year or longer. After adjustment for potential confounders, 
patients who quit smoking had an average increase in HbA1c after quitting of 
2.3mmol/l (95% CI 1.91 to 2.77, p<0.001). HbA1c did decrease as abstinence 
continued although the modelled trajectory showed this did not return to the 
levels seen in continuing smokers until 3 years after quitting. This increase in 
HbA1c was not mediated by weight change after quitting smoking.
Conclusion: Smoking cessation is associated with deterioration in glycaemic 
control in people with type 2 diabetes that persists for three years and appears 
not to be caused by weight gain. The rise in HbA1c is minor for each patient 
and clinician but will substantially increase microvascular complications in 
the whole population, which could be prevented by prompt action to improve 
glycaemic control on cessation. While we used an algorithm to help minimise 
the inaccuracies of recording smoking status within the THIN database and 
adjusted for missing data using imputation, our data is nonetheless limited by 
the accuracy of the information available within the THIN database. How-
ever, it provides the largest study so far on this phenomenon and confirms 
for the first time preliminary evidence of an association between quitting and 
worsening glycaemic control. It highlights the need for proactive review of 
glycaemic control and the need for prompt adjustment of medication in peo-
ple with diabetes following smoking cessation.
Supported by: NIHR SPCR
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How useful is HbA1c for diagnosis of diabetes in acute medical 
admissions?
K.T. O‘Brien1, A. Liew1, F.M. Ali1, D. Quinlan1, R.A. Round2, I.M. Stratton3, 
P.G. Nightingale4, S.E. Manley2, G.A. Roberts1;  
1Endocrinology and Diabetes Research Group, Waterford Institute 
of Technology, Ireland, 2Clinical Biochemistry, University Hospitals 
Birmingham NHS Foundation Trust, Birmingham, 3Gloucester Diabetic 
Retinopathy Research Group, Gloucestershire Hospitals NHS Foundation 
Trust, Cheltenham, 4Wellcome Trust Clinical Research Facility, University 
Hospitals Birmingham NHS Foundation Trust, UK.
Background and aims: The detection of hyperglycaemia is important in 
acutely ill patients who may present with either undiagnosed diabetes, symp-
toms or complications of diabetes, or stress hyperglycaemia; all indicating 
worse outcomes.
Materials and methods: Over a 2 year period, 2061 (14%) patients were ad-
mitted to hospital by one consultant physician out of a total of 14432 patients. 
OGTT was performed in 390 (19%) patients during their admission because 
of suspected symptoms or complications of diabetes. IFCC-calibrated HbA1c 
was measured by Menarini HA8160 IE HPLC in 148 (38%) of these patients 
and also 22 (1%) patients diagnosed with diabetes at admission.
Results: The acutely ill patients diagnosed with diabetes immediately were 
white Caucasian, >18 years old, aged (median IQ range) 36(26 to 61) years, 
55% male with admission plasma glucose (PG mmol/L) 19.3(11.8 to 27.4). 
Fasting PG on OGTT in those with possible symptoms or complications of 
diabetes, aged 70(59 to 79) years, 63% male with admission PG 6.4(5.6 to 7.4), 
was 5.2(4.8 to 5.7). This was similar to fasting PG on OGTT of 5.2(4.8 to 5.9) 
in 108 white Caucasian, primary care patients, aged 54(46 to 61) years, who 
were at increased diabetes risk, p=0.65. As expected, 2hPG at 9.0(7.3 to 11.4) 
was higher in acutely ill patients than GP patients, 5.5(4.4 to 7.5), p<0.001. 
HbA1c (%/mmol/mol) was highest in those diagnosed immediately on ad-
mission at 10.2(7.4 to 13.3)/88(57 to 122), p<0.001, and similar in the other 
groups of patients i.e. 5.7(5.3 to 6.0)/39(34 to 42) in admissions and 5.7(5.4 to 
6.1)/39(36 to 43) in GP patients, p =1.00. At OGTT, 15/148 (10%) were diag-
nosed with diabetes on HbA1c with 14/15 (93%) confirmed on OGTT. More 
patients, 48/148 (32%), were diagnosed with diabetes on OGTT than HbA1c.
Conclusion: HbA1c could play a diagnostic role in acute medicine as outlined 
in the ADA 2014 Clinical Practice Recommendations which are based on 
expert opinion and for which more evidence is requested. Those with very 
high HbA1c will possibly have been diabetic for some time before admission.
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Achievement of individualised HbA1c treatment targets in patients  
with type 2 diabetes and comorbid hypertension in a real world setting: 
results of the DIALOGUE registry
D. Tschöpe1, R.E. Schmieder2, C. Koch3, P. Bramlage4, T. Ouarrak5,  
A.K. Gitt6;  
1Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen,  
2Med. Klinik 4, Schwerpunkt Nephrologie / Hypertensiologie, 
Universitätsklinikum Erlangen, 3Novartis Pharma GmbH, Nürnberg,  
4Institut für Pharmakologie und präventive Medizin, Mahlow,  
5Stiftung „Institut für Herzinfarktforschung“, Ludwigshafen,  
6Medizinische Klinik B, Herzzentrum Ludwigshafen, Germany.
Background and aims: The recent EASD consensus statement has re-focused 
on individualized HbA1c Treatment targets in the care of patients with type-2 
diabetes mellitus. There are, however, neither clinical practice data on actu-
ally pursued treatment targets nor on patient characteristics associated with 
either strict or loose treatment targets.
Materials and methods: DIALOGUE is a prospective, observational, multi-
center registry focusing on treatment targets and their achievement in clini-
cal practice. Physicians were asked at baseline on HbA1c treatment targets 
pursued and compared to actual HbA1c values achieved at 6 months.
Results: A total of 8,636 patients were included. For 3,371 of these (39.0%) 
an HbA1c target of ≤6.5% (strict group), for 3,647 (42.2%) a target of >6.5 
to ≤7.0% (medium) and for 1,618 (18.7%) a target of >7.0 to ≤7.5% (loose) 
was pursued. Patients in the strict target group were younger, had lower fast-
ing and postprandial blood glucose values, shorter diabetes duration and less 
co-morbid disease at baseline than the other groups (table). At the 6 months 
follow-up the mean (±SD) HbA1c achieved in the strict group was 6.8±0.9% 
with 25% of patients exceeding 7.1%. Corresponding values for the medium 
and loose target group were 7.2±0.9 (25% >7.6%) and 7.7±1.2 (25% >8.3%), 
respectively (p<0.0001). There was a higher rate of long-acting insulin use 
(15.7%) in the loose target group than in the strict and medium group (8.2 
vs. 14.5%) (p<0.0001).
Conclusion: The data illustrate a differentiated selection of HbA1c treatment 
targets in patients with type-2 diabetes in Germany. Patients with strict tar-
gets typically are younger, have lower blood glucose values and less comor-
bidity, while loose targets are sought in those with existing complications.
Supported by: Novartis 
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Achievement of personalised HbA1c targets in patients with  
type 2 diabetes from the RIACE cohort
G. Pugliese1, E. Bonora2, E. Orsi3, C. Fondelli4, R. Trevisan5, M. Vedovato6, 
F. Cavalot7, L. Laviola8, M.G. Baroni9, S. Morano10, A. Solini11, G. Penno11;  
1Department of Clinical and Molecular Medicine, La Sapienza University, 
Rome, 2Division of Endocrinology and Metabolic Diseases, University of 
Verona, 3Diabetes Unit, Fondazione IRCCS Cà Granda - Ospedale Maggiore 
Policlinico, Milan, 4Diabetes Unit, University of Siena, 5Endocrinology 
and Diabetes Unit, Ospedali Riuniti, Bergamo, 6Department of Clinical 
and Experimental Medicine, University of Padua, 7Department of Clinical 
and Biological Sciences, University of Turin, Orbassano, 8Department of 
Emergency and Organ Transplantation, University of Bari, 9Department 
Experimental Medicine, La Sapienza University, Rome, 10Department of 
Experimental Medicine, La Sapienza University, Rome, 11Department of 
Clinical and Experimental Medicine, University of Pisa, Italy.
Background and aims: Though the HbA1c goal has been set at 7%, the use 
of personalized targets is currently recommended by several guidelines. This 
study was aimed at assessing the percentage of subjects with type 2 diabe-
tes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian 
Multicenter Study who reach individualized HbA1c goals.
Materials and methods: The RIACE cohort consists of 15,773 patients, con-
secutively visiting 19 Diabetes Clinics throughout Italy in years 2007-2008. 
Exclusion criteria were dialysis or renal transplantation. HbA1c was meas-
ured by HPLC using DCCT-aligned methods. Starting from a baseline HbA1c 
goal of <6.5%, the target has been arbitrarily increased by 0.5% according to 
the presence of each of the following criteria: age >70 years; disease duration 
>10 years; advanced complications; and co-morbidities. As a consequence, 5 
HbA1c targets were identified ranging from <6.5% to >8.5%.
Results: Mean HbA1c was 7.55±1.51% (median 7.30%, IQR 6.51-8.28%). 
The overall prevalence of subjects with HbA1c <7.0% was 40.9% (n=6,453), 
higher in men than in women (43.2% vs. 37.9%; p<0.0001). The 7.0% goal 
was reached by 71.0% of patients not taking any medication, 42.1% of those 
on oral hypoglycaemic agents (OHA), 17.4% of those on OHA+insulin and 
24.6% of those on insulin alone (p<0.0001), with a similar trend between 
genders. In the RIACE cohort, 5,512 subjects (34.9%) were >70 years old, 
7,931 (50.3%) had diabetes duration >10 years, 4,819 (30.6%) had ≥1 ad-
vanced complication and 2,803 (17.8%), had ≥1 severe co-morbidity. 
Moreover, 4,110 (G0, 26.1%), 4,914 (G1, 31.2%), 4,444 (G2, 28.2%), 1,957 
(G3, 12.4%), and 348 (G4, 2.2%) met 0, 1, 2, 3, and 4 of the above criteria, 
respectively. The prevalence of subjects meeting personalized goals were: 
G0 (goal <6.5%) 34.3%; G1 (<7.0%) 41.8%; G2 (<7.5%) 50.2%; G3 (<8.0%) 
59.9%; and G4 (<8.5%) 73.8% (p<0.0001); in men: G0 36.1%, G1 43.5%, G2 
51.5%, G3 63.5%; and G4 77.5% (p<0.0001); in women G0 32.0%, G1 39.5%, 
G2 48.3%, G3 55.1%; and G4 68.7% (p<0.0001). The overall prevalence of 
subjects meeting personalized targets was 45.2% (47.2% in men vs. 42.8% in 
women, p<0.0001). After excluding subjects with HbA1c <6.5% from G2-G4, 
the percentage of those on-target was era 37.6% (38.9% in men vs. 36.1% in 
women, p<0,0001).
Conclusion: Personalizing HbA1c goals increases the prevalence of subjects 
on-target, especially among those with more advanced disease. However, 
more than 50% of patients, and particularly 2/3 of those with short-duration, 
uncomplicated disease, do not meet the recommended HbA1c targets.
Clinical Trial Registration Number: NCT00715481
Supported by: Fo.Ri.SID, DEM, Eli-Lilly, Takeda, Chiesi, Boehringer-Ingelheim
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Determinants of glycaemic control: a nationwide longitudinal study  
of 131935 newly diagnosed cases of type 2 diabetes
A. Rawshani1, A.-M. Svensson1, B. Eliasson1, B. Zethelius2, A. Rosengren1,  
S. Gudbjörnsdottir1;  
1Clinical and Molecular Medicine, Inst of Medicine, Gothenburg,  
2Clinical Medicine, Inst of Medicine, Uppsala, Sweden.
Background and aims: Studies on glycemic (HbA1c) control have been com-
promised by small samples, short follow up, lack of data or unequal access to 
health care. We used the Swedish National Diabetes Register (2002-2011) to 
include 131935 newly diagnosed (within one year) cases of type 2 diabetes. 
We studied glycemic control and the effect of known and suspected determi-
nants of glycemic control. Due to knowledge gaps, emphasis was on ethnicity, 
income and education.
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Materials and methods: We assessed sex, age, BMI, duration of diabetes, 
education, income, ethnicity, physical activity, glucose-lowering treatment, 
previous cardiovascular disease, risk factors and statin treatment. We report 
(1) baseline characteristics; (2) progress of glycemic control from disease on-
set to end of follow up (up to 10 years); (3) linear mixed models to determine 
the effect of the above mentioned covariates on HbA1c (mmol/mol) and time 
duration until HbA1c started to increase (‚turn point‘); (4) logistic regression 
was used to study the probability of achieving glycemic control (<53 mmol/
mol) the 2nd year. Sensitivity analyses were performed.
Results: Phenotype at diagnosis varied markedly by ethnicity; e.g age differed 
up to 16 years (High-income Europe versus Sub-Saharan Africa) and BMI up 
to 4 kg/m2 (High-income Europe versus South Asia). Glycemic control varied 
strikingly by ethnicity (figure I) and socioeconomic status. Non-Western eth-
nicities displayed considerably higher HbA1c levels throughout follow-up. 
Overall, HbA1c levels started to increase after 2.9 (95% CI 2.8, 3.0) years but 
non-Western groups experienced the turn point up to 1 year earlier (figure I). 
Target level of HbA1c was out of reach for non-Western ethnicities. Kaplan-
Meier graphs revealed that this was not due to late initiation of pharmacolog-
ic treatment; paradoxically, non-Western ethnicities received pharmacologic 
treatment earlier. Linear models enhanced the ethnic differences in HbA1c. 
Interestingly, we found a strong interaction between ethnicity and type of 
glucose-lowering treatment (not detailed here). Sub-Saharan Africa, South 
& East Asia and the Middle East & North Africa displayed poorest control; 
generally 3-6 mmol/mol higher than high-income Europe. Higher income, 
but not education, was associated with lower HbA1c levels. Statin use was 
consistently associated with lower HbA1c (range 0.2-1.0 mmol/mol, depend-
ing on model). Logistic regression showed that income, education and, par-
ticularly, ethnicity are strongly associated with probability of not achieving 
glycemic control; e.g odds ratio for South Asians was 1.7 (95% CI, 1.5, 1.9), 
compared to individuals from high-income Europe.
Conclusion: Ethnicity is a strong determinant of glycemic control. Several 
non-Western populations should be targeted for interventions.
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Trends in diabetes, obesity, hypertension over twelve years in Turkey: 
rate of increase in diabetes is higher than the rate of increase in obesity
I. Satman1, N. Dinccag1, S. Kalaca2, K. Karsidag1, T. Yilmaz1, B. Omer3,  
Y. Tutuncu1, S. Celik1, J. Tuomilehto4,5, The TURDEP Study Group;  
1Endocrinology and Metabolism, Istanbul University, 2Public Health, 
Marmara University, 3Biochemistry, Istanbul University, Turkey, 4South 
Ostrobothnia Central Hospital, Seinajoki, Finland, 5Centre for Vascular 
Prevention, Danube University, Krems, Austria.
Background and aims: According to the sixth edition of Diabetes Atlas, 
highest prevalence of diabetes in Europe is in Turkey. We aimed to investigate 
the reasons of this epidemic by comparing 12-year trends in prevalence of 
diabetes, IGT, obesity, abdominal obesity and hypertension in two popula-
tion-based surveys in Turkey.
Materials and methods: TURDEP-I (1998) and TURDEP-II (2010) have 
been conducted in the same 540 centers twelve years apart in Turkey. Both 
surveys covered randomized people 20 years and over; TURDEP-I (n=24,714; 
55.2% women) and TURDEP-II (n=25,120; 63% women). Diabetes has been 
defined as previously known diabetes plus new diabetes based on OGTT 
2-hPG ≥200 mg/dL.
Results: Between the two surveys the mean age of the population increased 
by 4 years in men and women in average. The rates of increase in diabetes, 
IGT, obesity and abdominal obesity in men were higher in women (diabetes: 
1.2 vs. 0.9 fold, IGT: 2.5 vs. 2.2 fold, obesity: 1.0 vs. 0.4 fold, abdominal obesi-
ty: 1.0 vs. 0.3 fold; p<0.001). Hypertension increased by 9% in men while de-
creased by 12% in women (see Figure). Absolute change in the prevalence of 
diabetes is correlated to the absolute change in both general (r=0.74, p<0.001) 
and abdominal obesity (r=0.54, p=0.004) but not to hypertension. The cor-
relation does not change when the two populations are controlled for sex and 
age (general obesity: r=0.65, p=0.001, abdominal obesity: r=0.71, p<0.001).
Conclusion: Diabetes increased in epidemic proportion over the recent 12-
year period in Turkey. Although the contributions from aging of the popula-
tion and obesity are remarkable, these factors could not explain the whole 
problem; other lifestyle factors (such as change in nutrition and physical 
activity habits) should be examined in detail to find the causes of diabetes 
epidemic in Turkey.
Supported by: TUBITAK, SEMT, Istanbul University
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Epidemiology of hyperglycaemia in pregnancy and gestational diabetes 
in the World Health Organisation European region
U. Linnenkamp1, L. Makaroff1, L. Guariguata1, J. Beagley1, D. Whiting2, 
N.H. Cho3;  
1International Diabetes Federation, Brussels, Belgium, 2Directorate of 
Public Health, Medway Council, Chatham, UK, 3Department in Preventive 
Medicine, Ajou University School of Medicine, Suwon, Republic of Korea.
Background and aims: Hyperglycaemia is one of the most prevalent meta-
bolic disorders that occur during pregnancy. The International Diabetes Fed-
eration (IDF) has developed a methodology for generating estimates of the 
prevalence of hyperglycaemia in pregnancy (HIP), including gestational dia-
betes, among women of childbearing age (20-49 years). The IDF defines HIP 
to include both hyperglycaemia first detected in pregnancy (HFDP) as well as 
previously known diabetes. The IDF uses the WHO definition of people with 
HFDP to include people with gestational diabetes (GDM) and also those first 
diagnosed with diabetes in pregnancy (DIP).
Materials and methods: PubMed and cited literature were reviewed, to iden-
tify studies reporting prevalence of HIP. A simple scoring system was devel-
oped to characterise studies. Age-specific prevalence data from studies were 
entered to produce estimates for five-year age groups using logistic regression 
to smooth curves, with age as the independent variable. Adjustments were 
then made to align with recently published diagnostic criteria as defined by 
the WHO for hyperglycaemia first detected in pregnancy
Results: We have previously presented an analysis of the global burden of 
HIP and we now present a more detailed analysis of the HIP burden in the 
WHO-EUR-Region. After scoring and exclusion requirements, 13 studies 
were selected representing 11 countries (Belgium, France, Hungary, Ireland, 
Israel, Netherlands, Norway, Poland, Spain, Turkey and United Kingdom). 
The majority of studies (85%) were conducted in high income countries, only 
two were conducted in upper middle income countries and no studies were 
available for lower middle and low income countries within the Region. 54% 
of the selected studies were conducted in a single hospital, 31% were con-
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ducted in a locally representative sample leaving only a study from Hungary 
as being regionally representative and a study from Turkey being nationally 
representative. It is estimated that in 2013 of a predicted 10.7 million live 
births to women aged 20 - 49 years 15.2 % were affected by HIP. Thus, within 
the Region, 1.7 Million live births were affected by HIP. While the highest 
prevalence of HIP is found in pregnant women >40 years of age, the largest 
numbers of cases occur in women aged 25 - 35. Within the countries esti-
mated age-standardised prevalence of HIP ranged from 5.0% of all live births 
affected in Belgium up to 32.1% of all live births affected in Spain.
Conclusion: Prevalence estimates of HIP are sensitive to the data from which 
they are derived. Within the WHO-EUR-Region there is a lack of nationally 
representative studies on the prevalence of HIP, especially in lower middle 
income countries and low income countries. More data are needed, in par-
ticular from low income countries, to strengthen the methodology. These are 
the first estimates of HIP in the WHO - EUR Region and conform to the new 
WHO recommendations regarding diagnosis. They indicate the importance 
of this issue from a public health and maternal and child health perspective.
Supported by: Lilly Diabetes, Merck and Co, Novo Nordisk A/S, Pfizer, Sanofi 
Diabetes
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Prevalence of metabolic syndrome and cardiometabolic risk factors in 
patients with long-duration psychotic illnesses
D. Hopkins1, P. Gardner-Sood2, J. Lally2, D. Stahl3, K. Greenwood2,  
Z. Atakan2, S. Smith2, R. Ohlsen2, K. Ismail4, R. Murray2, F. Gaughran5;  
1Dept of Diabetic Medicine, King‘s College Hospital NHS Foundation Trust, 
2Institute of Psychiatry, King‘s College London, 3Dept of Biostatistics, King‘s 
College London, 4Diabetes & Psychiatry Research Group, King‘s College 
London, 5National Psychosis Service, South London and Maudsley NHS 
Foundation Trust, London, UK.
Background and aims: Patients with severe mental illness have significantly 
reduced life expectancy with increased cardiovascular events and a high 
prevalence of diabetes. As a preliminary step to testing interventions to try 
and improve physical health outcomes in patients with established psychosis 
we have conducted this study to determine the prevalence of the component 
risk factors that comprise the metabolic syndrome in a large cohort of estab-
lished patients.
Materials and methods: Cross-sectional study of 450 patients with estab-
lished (multi-episode) psychosis recruited at five centres in the United King-
dom. Anthropometric measures (height, weight and waist circumference), 
and blood pressure were recorded for all subjects. In addition blood samples 
for HbA1c, fasting glucose and lipid profile were obtained from 296 subjects.
Results: Mean age of the participants was 43.6 years (SD=10.1) and mean du-
ration of psychotic illness was 15.7 years (SD=10.3). 57% of participants were 
male. 55% percent (n=238) were Caucasian and 33% (n=146) were of Black 
African or Black Caribbean ethnicity. 50% of participants were obese (body 
mass index, BMI>30) 44% were prescribed dibenzodiazepine antipsychotic 
medication (clozapine and olanzapine). There was no association between 
dibenzodiazepine use and BMI. Of the 296 participants with complete data 
57 % fulfilled the International Diabetes Federation (IDF) criteria for diag-
nosis of the metabolic syndrome. Prevalence of central obesity was very high 
with 82%, of participants exceeding IDF cut-off values for waist circumfer-
ence. In addition, 54% had blood pressure above 130/85, 57% triglyceride 
above 1.7 mmol/l and 53% had HDL cholesterol below the IDF cut-off values 
of under 1.03 or 1.29 mmol/l for men and women respectively. 31% had fast-
ing dysglycaemia (fasting glucose of 5.6 mmol/l or greater) including 26% 
fulfilling criteria for a diagnosis of diabetes.
Conclusion: These data demonstrate a high prevalence of metabolic syn-
drome and dysglycaemia in a relatively young population with longstanding 
psychosis and the presence of multiple adverse cardiometabolic risk factors 
that could be ameliorated to improve cardiovascular outcomes. The preva-
lence of central obesity is considerably greater than that of obesity diagnosed 
by BMI indicating a need for waist measurement to predict risk in this popu-
lation.
Supported by: National Institute of Health Research, U.K.
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Prevalence of undetected thyroid disorders in subjects with diabetes in 
South India: a cohort analysis 
G. Krishnan, A. Shankar, S. Jothydev, J. Kesavadev;  
Jothydev‘s Diabetes and Research Center, Trivandrum, India.
Background and aims: Thyroid function test is not a part of routine diabetes 
practice in India, due to the extra cost involved and the lack of time for the 
physician to convince the patient on the requirement of an extra expensive 
investigation. Many a time, symptoms of hypothyroidism in diabetes patients 
are mistaken for hypoglycaemia and associated metabolic syndrome and 
hence goes grossly undetected.
Materials and methods: We screened T2DM patients, presenting at our 
comprehensive diabetes speciality clinic for the first time, to evaluate the 
prevalence of thyroid disorders. Screening was done during the past 5 years, 
using the ‚sensitive TSH test‘ in Cobas E411 Elecsys. Patients with undetect-
ed hypothyroidism reported mood changes, anxiety, anger, memory loss etc. 
which were corrected with thyroid supplementation.
Results: During selection of 7402 consecutive T2DM subjects aged ≥ 21yrs 
(62.48% male), 5.83% self reported hypothyroidism; 29.67% showed abnor-
mal TSH values, comprising of 10.42% with TSH values suggestive of sub-
clinical hypothyroidism((3.04-10 μIU/mL); 17.09% overt hypothyroidism 
(>10 μIU/mL) and 2.16% with low TSH values suggestive of hyperthyroid-
ism((<0.05 μIU/mL). Abnormal TSH values showed significant association 
with female sex and >60yrs age group; whereas distribution of other sub-
groups were not statistically significantly different. Among females, 9.09% 
had mildly increased TSH levels (3.04-10μIU/mL), 22.14% had high TSH 
levels (>10μIU/mL) and 1.45% had low TSH levels (<0.05 μIU/mL). Over-
all, subjects with newly detected hypothyroidism showed a trend of higher 
BMI (1.7 kg/m2) compared to others, but this was not statistically significant 
(p>0.05). The level of diabetes control was possibly confounded by treatment 
received and HbA1c did not significantly differ among hyperthyroid, euthy-
roid & sub-clinically hypothyroid patients (mean HbA1c=8.9%).
Conclusion: Considering the negligible extra cost of 1.26Euros for 90 tablets 
(presuming an average 50mcg/day dosage) of thyroid supplementation, dia-
betes patients will tremendously benefit from early detection of thyroid dis-
orders. The very high prevalence of hypothyroidism in diabetes, significantly 
higher than in the general population, makes it imperative to include TSH 
test in routine diabetes evaluation in developing countries like India.
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Prediabetes is associated with early changes in microcirculation
V.M. Shyshko1, T.V. Mokhort1, N.L. Tsapaeva2, E.E. Konstantinova3;  
1Endocrinology, 2Inner Disease #3, Belarussian State Medical University, 
3Institute of Heat and Mass Exchange, National Academy of Science, Minsk, 
Belarus.
Background and aims: Microangiopathy in patients with type 2 diabetes 
(T2D) results from previous microcirculation abnormalities (e.g. increased 
permeability, disturbance of intracapillary pressure and blood flow). Hyper-
glycemia as well as hesitance of glucose level in patients with prediabetes (im-
paired glucose tolerance and impaired fasting glucose) have negative impact 
on microvessel status. The aim of the study was to investigate microcircula-
tion in patients with prediabetes.
Materials and methods: We included 131 patients with average age 49,03 ± 
8,76 years. Patients were divided into 2 groups: group 1 - 37 patients with pre-
diabetes, group 2 - 35 patients with type 2 diabetes (with duration of disease 
no longer as 5 years and treated with oral blood glucose lowering drug) and 
group 3 - 59 almost healthy person. Microcirculation was measured by com-
puter based conjunctival biomicroscopy (Malaja et al.), results were evaluated 
by the set of criteria for quantitative evaluation of conjunctival microcircula-
tion: FC (number of active capillary tubes), AVA (arteriovenous anastomo-
sis), Mean (vascular tortuosity), Sl (sludge), Mtr (microthrombosis). Severity 
of each criteria was scored and more sever changes had higher degree.
Results: Microcirculation abnormalities were revealed in patients with predi-
abetes: we registered statistically significant decrease of active capillary tubes 
(FC) (3,0[2,0;3,0]vs2,0[2,0;3,0] in control group) (Р1-3<0,025), increased 
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number of AVA (2,0 [2,0; 4,0]vs2,0 [2,0; 2,0] in control group) (Р1-3<0,025) 
and Mtr (1,0[1,0;2,0]vs0,0[0,0;1,0] in control group) (Р1-3<0,001). Hence in 
patients with prediabetes we observed hypoperfusion and microthrombosis 
that predispose vascular wall to atherosclerosis. We registered more signifi-
cant changes in patients with T2D compared to patients with prediabetes and 
control group. Patients with T2D had more significant Mean (1,0[1,0;2,0]) 
compared to group 1 and 3 (1,0[1,0;1,0]) (Р1-2 <0,05 and Р2-3< 0,001 cor-
respondingly), erythrocyte properties are also changed that is presented in 
sludge formation (2,0[2,0;4,0]vs2,0[2,0;2,0] in groups 1,3) (Р1-2 <0,05, Р2-
3<0,001 correspondingly). Consequently microcirculation abnormalities in 
patients with prediabetes and T2D consist in changes as in vessel wall so and 
in intravessel homeostasis.
Conclusion: Analysis of microcirculation demonstrate presence of changes 
in microvessel system during early disturbance of glucose metabolism (that is 
in prediabetes). T2D is associated with more significant changes in microcir-
culation. Damage of microvessel is one of the factors that leads to endothelial 
dysfunction and atherosclerosis.
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Impact of glucose metabolism across the life course on retinal 
microvasculature architecture: the young Finns study
R. Tapp1, M. Hussain1, N. Hutri-Kähönen2, T. Lehtimäki2, A. Metha1,  
M. Kähönen2, O. raitakari3;  
1The University of Melbourne, Australia, 2University of Tampere and 
Tampere University Hospital, 3University of Turku and Turku University 
Hospital, Finland.
Background and aims: Studies in healthy adults and children indicate that 
retinal venular abnormalities are unrelated to arteriolar changes, and may be 
influenced by obesity, increased inflammation and glucose metabolism. Lim-
ited research has been conducted across the life course. We hypothesized that 
fasting plasma glucose (FPG) in late childhood/adolescence and change in 
FPG from late childhood/adolescence to mid adulthood would be associated 
with adverse changes in retinal microvascular architecture.
Materials and methods: The Cardiovascular Risk in Young Finns Study in-
cluded children aged 3 to 18 years, from five Finnish University cities, with 
participants chosen randomly from the national population registrar from 
those areas. Complete data were available for 1054 participants with a gesta-
tion ≥37 weeks. Retinal microvascular measures included retinal arteriolar 
and venular diameters.
Results: The mean age of the participants was 41 years (range 34 - 49 years) at 
the time of retinal photography. Regression analysis showed a strong positive 
association between change in FPG from late childhood/adolescence to mid 
adulthood with venular diameter (regression coefficient (β) 0.207; p<0.031) 
and no association with late childhood/adolescence or adult FPG (β -0.092; 
p=0.391 and 0.131; p=0.168 respectively), adjusted for age and sex. No asso-
ciation was evident between FPG and arteriolar diameter.
Conclusion: This is the first study to assess the impact of glucose metabolism 
across the life course on retinal microvascular architecture. Retinal arterioles 
and venules are differentially associated with FPG. Change in FPG from late 
childhood/adolescence to mid adulthood may adversely affect the microcir-
culation, with important implications for cardiovascular risk.
Supported by: Academy of Finland
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Serum high-sensitivity C-reactive protein levels are associated with high 
risk of development of diabetic nephropathy among Japanese type 2 
diabetes patients
T. Mashitani1, Y. Hayashino2, S. Tsujii2, H. Ishii1, Diabetes Distress and Care 
Registry at Tenri (DDCRT) Study Group;  
1Nara Medical University, Kashihara, 2Department of Endocrinology,  
Tenri Hospital, Japan.
Background and aims: Diabetic nephropathy is a common complication of 
diabetes and the leading cause of end-stage renal disease in developed coun-
tries. An understanding of the clinical characteristics and risk factors associ-
ated with diabetic nephropathy is useful for establishing effective therapeutic 
strategies to prevent the progression of diabetic nephropathy. Many cross-
sectional studies revealed that the C-reactive protein (CRP) levels were high 
in patients with diabetic nephropathy. Only one previous study reported that 
baseline C-reactive protein (CRP) levels were associated with a subsequent 
increment of urinary albumin excretion in patients with type 2 diabetes, but 
this study did not examine that either of progression or development of dia-
betic nephropathy was associated with high levels of CRP. The present study 
assessed the prospective association between baseline serum high-sensitivity 
CRP (hs-CRP) concentration and the subsequent risk of the development or 
progression of diabetic nephropathy among Japanese type 2 diabetes patients.
Materials and methods: Longitudinal data were obtained from 2,256 pa-
tients with type 2 diabetes registered in a Japanese diabetes registry. To assess 
the independent associations between serum hs-CRP quartiles at baseline, 
and either the development or progression of diabetic nephropathy at 1-year 
follow-up, we used the Cox proportional hazards model adjusted for poten-
tial confounders.
Results: Mean patient ages, BMI and HbA1c levels were 66.2 years, 24.6 kg/
m2 and 7.5%, respectively. Firstly, we examined the association between base-
line hs-CRP levels and subsequent risk of the development of diabetic ne-
phropathy. Over the median follow-up of 0.93 years, we observed 199 cases 
who developed diabetic nephropathy (incidence ratio = 156.4/1000 person-
years [95%CI, 137.0 to 177.6]). Baseline serum hs-CRP levels were signifi-
cantly associated with the urinary albumin-creatinine ratio (UACR) at base-
line (p < 0.001). Multivariable adjusted hazards ratios for progression from 
normoalbuminuria to microalbuminuria were 1.25 (95% CI, 0.74 to 2.1), 1.47 
(95% CI, 1.06 to 2.05; p = 0.022) and 1.31 (95% CI, 1.03 to 1.66; p = 0.025), 
respectively, for the 2nd, 3rd and 4th quartile of serum hs-CRP levels, show-
ing a statistically significant linear trend across categories (p = 0.001). Next, 
we examined the association between baseline hs-CRP levels and subsequent 
risk of progression of diabetic nephropathy. Over the median follow-up of 
0.94 years, we observed 109 cases whose diabetic nephropathy progressed 
(incidence ratio = 101.0/1000 person-years [95%CI, 83.7 to 120.6], Table 2). 
We did not observe a significant association between hs-CRP levels and sub-
sequent risk of diabetic nephropathy (p for trend = 0.514).
Conclusion: We observed a significant association between serum hs-CRP 
levels and baseline UACR levels. Serum hs-CRP levels were associated with 
the subsequent risk of developing, not progressing, diabetic nephropathy in 
type 2 diabetes patients independent of possible confounders. Serum hs-CRP 
may be useful for predicting patients’ risk of developing diabetic nephropa-
thy.
Supported by: Manpei Suzuki Diabetes Foundation and JSPS KAKENHI 
(Grant Number 25460641)
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Decrease in the incidence of renal placement therapy for diabetes 
mellitus in the Netherlands
S.T. Houweling1,2, P.R. van Dijk3, A. Kramer4, S.J.J. Logtenberg3,5,  
A.J. Hoitsma6, N. Kleefstra3,1, K.J. Jager4, H.J.G. Bilo3;  
1Medical Research Group Langerhans, 2Diabetes Centre, 3Diabetes centre, 
Zwolle, 4Department of Medical Informatics, ERA-EDTA Registry, 
Amsterdam, 5Department of Internal Medicine, University Medical Center 
Groningen, 6RENINE Registry, Leiden, Netherlands.
Background and aims: Diabetes mellitus (DM) is considered the main cause 
of end stage renal disease (ESRD) in many countries. In general, its frequency 
is estimated to be about 40% of ESRD and would be expected to rise in paral-
lel with the prevalence of DM. Aim of the present study was to investigate 
trends in incidence and prevalence of DM as cause of renal replacement ther-
apy (RRT) for ESRD in the Netherlands in the period 2000-2012.
Materials and methods: Using the RENINE-database, a countrywide and 
100% registration of subjects on RRT, the incidence and prevalence of all 
Dutch individuals initiating RRT having DM as primary diagnosis were ob-
tained. The age- and gender adjusted incidence and prevalence were calcu-
lated. Trends in time were analysed with Joinpoint regression.
Results: The prevalence of DM in the Dutch general population (GP) in-
creased from approximately 500.000 in 2000 to 893.000 in 2011. The number 
of individuals who started DM related RRT remained stable: 17.4 per million 
population (pmp) in 2000 and 19.1 pmp in 2012 with an annual percentage 
change (APC) of 0.8% (95% confidence interval (CI) -0.4;2.0). However, for 
RRT due to T1DM the incidence decreased from 7.3 pmp in 2000 to 3.5 pmp 
in 2012 with an APC of -4.8% (95%CI -6.5;-3.1). For T2DM it increased from 
10.1 pmp in 2000 to 15.6 pmp in 2012 with an APC 3.1% (95%CI 1.3;4.8). 
The incidence of RRT due to unknown or missing causes of renal failure in-
creased from 21.2 pmp to 28.5 pmp. The prevalence of RRT for DM increased 
at a lower rate after 2009: APC 1.0% (95%CI -0.4;2.5) versus 5.8% (95%CI 
5.6;6.1). Compared to a non-DM reference population, patients on RRT due 
to T1DM and T2DM had an increased mortality, age and gender adjusted 
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hazard ratios: 1.8 (95%CI 1.7;2.0) and 1.4 (95%CI 1.3 - 1.4). Compared to the 
period of 2000-2004, patients initiating RRT in 2005-2009 had a lower mor-
tality, age and gender adjusted hazard ratios: 0.8 (95%CI 0.7;0.8).
Conclusion: The incidence of RRT for DM is stable over the last decade re-
flecting a decrease for T1DM and an increase for T2DM. Taken together with 
a steady increase in prevalence of DM in the GP this may suggest that physi-
cians may be more successful in the prevention of diabetes related ESRD
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Cardiovascular events and all-cause mortality: associations with renal 
function in patients with type 2 diabetes
L.A. García Rodríguez1, L. Cea Soriano1, S. Johansson2, B. Stefansson2;  
1Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, 
Spain, 2AstraZeneca R&D, Mölnda l, Sweden.
Background and aims: Diabetes and chronic kidney disease are independ-
ent predictors of mortality and cardiovascular (CV) events. The aims of this 
study were to quantify the risk of death and CV events associated with esti-
mated glomerular filtration rate (eGFR) and to identify other potential risk 
factors in patients with type 2 diabetes.
Materials and methods: In this retrospective study, data were collected from 
The Health Improvement Network, a UK primary care database. From a co-
hort of patients aged 20-90 years with type 2 diabetes, 57 946 individuals 
were identified who had a valid serum creatinine measurement recorded in 
2000-2005. Patients were followed up from their start date (date of first ever 
valid recorded creatinine measurement) until they met one of the following 
endpoints in three separate analyses: myocardial infarction (MI), ischaemic 
stroke or transient ischaemic attack (IS/TIA), or death; patients were cen-
sored when they reached 90 years of age or the end of the study (31 December 
2010). Individuals with a record of haemodialysis or renal transplant before 
their start date were excluded or censored during follow-up. Incidence rates 
for death, MI and IS/TIA were calculated overall and by eGFR subgroup at 
baseline (15-29, 30-44, 45-59 and ≥ 60 mL/min). Cox regression models ad-
justed for potential confounding factors were used to estimate hazard ratios 
(HRs) and their corresponding 95% confidence intervals (CIs) for death, MI 
and IS/TIA according to sex, age, eGFR category and duration of diabetes.
Results: Median follow-up times were 6.80, 6.64 and 6.56 years for death, MI, 
and IS/TIA, respectively. Overall incidence rates for death, MI and IS/TIA 
were 43.65, 9.26 and 10.39 cases per 1000 person-years, respectively. Inci-
dence rates were highest for patients with the lowest eGFRs (15-29 mL/min): 
210.01, 31.65 and 32.48 cases per 1000 person-years for death, MI and IS/
TIA, respectively. For patients with an eGFR ≥ 60 mL/min, the corresponding 
incidence rates were 31.99, 7.44 and 8.65 cases per 1000 person-years. A low 
eGFR (15-29 mL/min) was associated with an increased risk of death (HR: 
4.00; 95% CI: 3.69-4.33), MI (HR: 3.29; 95% CI: 2.68-4.04) and IS/TIA (HR: 
2.47; 95% CI: 2.01-3.03) relative to eGFR ≥ 60 mL/min (Table). The risk of 
death, MI and IS/TIA significantly increased with age: HRs for patients aged 
75 years or older relative to patients aged 20-49 years were 12.14 (95% CI: 
10.79-13.67), 3.33 (95% CI: 1.79-3.98) and 6.64 (95% CI: 5.44-8.11), respec-
tively. Longer duration of diabetes was associated with an increased risk of 
death or experiencing a CV event: HRs for patients who had had diabetes for 
more than 15 years relative to those who had had diabetes for less than a year 
were 1.74 (95% CI: 1.59-1.90) for death, 1.87 (95% CI: 1.54-2.26) for MI and 
1.64 (95% CI: 1.36-1.98) for IS/TIA.
Conclusion: In patients with type 2 diabetes, the risks of death, MI and IS/
TIA increased with age, duration of diabetes and decreasing eGFRs.
Supported by: AstraZeneca
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Factors associated with cognitive impairment in patients with newly 
diagnosed type 2 diabetes: a cross-sectional study
C.D. Moulton1, S.A. Amiel2, R. Stewart1, K. Ismail1;  
1Institute of Psychiatry, 2Department of Diabetes and Nutritional Sciences, 
King‘s College London, UK.
Background and aims: Type 2 diabetes (T2DM) is a major risk factor for 
cognitive impairment (CI) and the pandemic of T2DM is expected to in-
crease the global dementia burden. The factors associated with CI in T2DM 
are poorly understood. A limitation of previous cohorts examining CI in 
T2DM is the variable and long duration of T2DM among participants, which 
increases the risk of effects being obscured by differential survival and dia-
betes complications. By analysing a population with newly diagnosed T2DM, 
we aimed to identify modifiable factors for cognitive decline at an earlier 
stage in the natural history of T2DM. Our primary hypothesis was that mark-
ers of glucose dysregulation would be associated with cognitive impairment 
and secondary hypotheses were that i) depression, ii) black or South Asian 
ethnicity and iii) body mass index (BMI) would be independently associated 
with CI in T2DM.
Materials and methods: We performed a cross-sectional analysis of baseline 
measures from the South London Diabetes (SOUL-D) cohort, a population-
based multi-ethnic study of individuals diagnosed with T2DM in the last 6 
months. We assessed CI using the 13-item Telephone Interview for Cognitive 
Status (TICS-M), which has a range of scores from 0-39. We defined CI as the 
lowest 10% of scores and the remainder as controls. We performed univariate 
and multivariate analyses of the association between CI and 1) markers of 
glucose dysregulation (HbA1c, fasting glucose, micro/macrovascular com-
plications); 2) sociodemographic factors (age, gender, ethnicity); 3) vascular 
risk factors (BMI, hypertension, hyperlipidaemia, smoking) and 4) depres-
sion (PHQ-9 score >12). We used Student’s t-test for continuous data and χ2 
tests for categorical data and logistic regression to control for key confound-
ing variables, including premorbid intelligence estimated by National Adult 
Reading Test (NART) score.
Results: In the preliminary analyses, of 1791 patients recruited, 1680 (93.8%) 
had a complete TICS-M assessment. Average diabetes duration was 4.6 (SD 
2.2) months. Cognitive impairment was defined as TICS-M score <17. In uni-
variate analyses, there were no differences in HbA1c, (p=0.22), fasting glu-
cose (p=0.96), microvascular complications (p=0.31), macrovascular com-
plications (p=0.41), depression (p=0.52), BMI (p=0.2), smoking (p=0.13), 
hyperlipidaemia (p=0.21) and hypertension (p=0.70) between patients with 
CI and controls. Patients with CI were older (p<0.001), more likely to be fe-
male (p<0.001), of black or South Asian/other ethnicity (p<0.05) and had 
lower scores on NART (p<0.0001). In multivariate analyses including age, 
gender, ethnicity, HbA1c, BMI and NART as covariates, the effects of age, 
ethnicity and NART remained significant but the effect of gender (p=0.12) 
was attenuated.
Conclusion: Although poor glycaemic control and depression are known 
risk factors for CI in established T2DM, this was not seen at diagnosis. In-
stead, older age, black or South Asian ethnicity and poorer NART scores were 
associated with CI at diagnosis of T2DM, though the latter two associations 
may partly reflect poorer literacy levels. Overall cognitive scores were lower 
than studies in non-diabetic populations. Our results suggest that at the time 
of T2DM diagnosis there may be a window of opportunity to identify patients 
at higher risk of CI.
Supported by: NIHR
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Risk factors for atrial fibrillation in type 2 diabetes. Report from the 
Swedish National Diabetes Register: NDR
B. Zethelius1, S. Gudbjörnsdottir2, B. Eliasson2, K. Eeg-Olofsson2,  
A.-M. Svensson2, J. Cederholm3;  
1Dept. of Public Health and Caring Sciences/Geriatrics, Uppsala University, 
2Dept. of Medicine, Sahlgrenska University Hospital, Gothenburgh 
University, 3Dept. of Public Health and Caring Sciences/Family Medicine 
and Preventive Medicine, Uppsala University, Sweden.
Background and aims: Atrial fibrillation (AF) is more frequent in patients 
with type 2 diabetes than in the general population. Further, AF has been 
shown to have a strong impact on risk for cardiovascular complications and 
mortality in patients with type 2 diabetes, who generally have elevated risks of 
cardiovascular complications, i.e. at least twice as common as in those with-
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out diabetes. The aim was to investigate which factors that contributes to the 
risk of AF in type 2 diabetes using national register data from Sweden.
Materials and methods: Observational cohort study of 64,864 patients with 
type 2 diabetes, aged 30-79 years, without AF at baseline. A history of car-
diovascular disease (CVD) was present in 16.9% and 3.6% had a history of 
congestive heart failure (CHF). Patients were, followed-up for development 
of AF (n=2,719) during 4.2 years from 2003 to 2009. A subgroup of 52,939 
patients without history of CVD or CHF at baseline was also analysed.
Results: At multivariate logistic regression, odds ratios (OR) of AF were 
4.49 for a baseline history of CHF and 7.98 for in-study developed CHF. 
Similarly for a history of CVD, the OR was 1.28 and for in-study developed 
myocardial infarction an OR of 1.37. Cardiovascular risk factors associated 
with risk for AF were hypertension (OR, 1.42), cumulative microalbumi-
nuria (OR, 1.24), obesity (OR, 1.31) and ORs for each decade of increas-
ing age was 1.93, and 1.43 for male gender, with all predictors p<0.001. 
Among patients without history of CVD or CHF at baseline, significant pre-
dictors were similarly for in-study developed CHF (OR, 10.2), hypertension 
(OR, 1.52), cumulative albuminuria (OR, 1.25), obesity (OR, 1.34) and ORs 
for each decade of increasing age was 1.93, and 1.48 for male gender, with all 
predictors p<0.002. In multivariable models, the following factors were not 
significantly (p>0.05) related to AF as the outcome: HbA1c, blood lipids and 
smoking status. Population Attributable Risk Percent (PARp: percent cases 
reduced if predictors could be eliminated) for AF was with hypertension 27%, 
in-study CHF 25% and previous history of CHF 8%, cumulative microalbu-
minuria 7% and for obesity 11%.
Conclusion: Except for CHF, hypertension, albuminuria and obesity account 
for large portions of PAR for AF in type 2 diabetes. The study underlies the 
contribution of CHF, hypertension and microalbuminuria to AF develop-
ment, factors that are shown to be modified by pharmacological treatment in-
cluding ACE-inhibition. Further, obesity also contributes to AF and life style 
measures aiming at weight reduction if obese may have benefits for reduction 
of AF incidence. Intervention studies on AF-prevention are warranted.
Supported by: The Swedish Association of Local Authorities and Regions funds 
the NDR.
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Risk of acute myocardial infarction in 121289 patients with  
type 2 diabetes: emphasis on socioeconomic status and ethnicity
A.-M. Svensson, A. Rawshani, A. Rosengren, S. Gudbjörnsdottir;  
Clinical and Molecular Medicine, Inst of Medicine, Gothenburg, Sweden.
Background and aims: Little is known about ethnicity and the risk of coro-
nary heart disease (CHD) and acute myocardial infarction (AMI) in diabetes. 
We examined the relationship between ethnicity and CHD death or hospitali-
zation for AMI in patients with type 2 diabetes.
Materials and methods: Patients included in the Swedish National Diabetes 
Register (2002-2006) were followed until a diagnosis of AMI or CHD death, 
death (other causes) or December 31 2011, through the nationwide Inpatient 
Registry and National Death Registry. All individuals (15.5% foreign-born) 
had equal access to low-cost health care. The study population included indi-
viduals from all the world‘s continents. Detailed data on income and educa-
tion was retrieved from the Swedish National Board of Health and Welfare. 
Incidence rates for AMI/CHD death were estimated by Poisson regression. 
Relative risk was estimated by Cox regressions adjusted for ethnicity, income, 
education, lipids, sex, age, blood pressure, smoking, kidney function, body 
mass index, physical activity, chronic obstructive pulmonary disease and 
cardioprotective drugs. Model fitting proceeded conventionally and, where 
appropriate, covariates were time dependent.
Results: In 121289 patients with type 2 diabetes, 12861 (10.6 %) had an 
event (mean follow-up 6.1 years). Incidence rates (figure) varied strikingly 
by ethnicity. Non-Western groups, particularly Sub-Saharan Africa and Latin 
America displayed particularly high figures. Adjusted hazard ratios for AMI/
CHD death by ethnicity was: High-income Europe, North America, 1.10 
(0.97-1.25); Low-income Europe, 1.19 (1.03-1.37); Latin America & Caribbe-
an, 1.30 (0.90-1.88); Middle East & North Africa, 1.37 (1.16-1.62); Sub-Saha-
ran Africa, 1.15 (0.95-1.40) and South & East Asia 1.10 (0.95-1.34), compared 
with Nordic countries. While education had no effect on the hazard, income 
was strongly associated with the risk of AMI/CHD death. Belonging to the 
lowest income quintile was associated with a hazard ratio of 2.25 (2.15-2.39), 
compared to the highest quintile. Among traditional risk factors, the hazard 
ratios for chronic obstructive pulmonary disease and low kidney function 
were surprisingly high.
Conclusion: Ethnic disparities in risk of AMI/CHD death could be explained 
by modifiable risk factors.
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Neighbourhood deprivation and inequities in mortality among patients 
with diabetes mellitus: a multilevel study
A. Chaikiat, X. Li, K. Sundquist;  
Center for Primary Health Care Research, IKVM, Malmo, Sweden.
Background and aims: Individuals with diabetes mellitus (DM) have higher 
risk of premature mortality and different mortality patterns, compared to 
individuals without DM. In this large-scale study, our aim was to examine 
if mortality (all cause and the five most common causes of death among in-
dividuals with DM in Sweden) vary by neighborhood-level deprivation after 
taking sociodemographic factors and comorbidities into account.
Materials and methods: The Swedish nationwide prescription register was 
used to identify 367 477 patients with DM who were followed for the out-
come variable mortality in order to test whether neighborhood-level dep-
rivation was significantly associated with mortality after adjusting for the 
following covariates: age, gender, marital status, family income, educational 
attainment, country of origin, mobility, urban/rural status and comorbidities.
Results: Multilevel logistic regression models were used in the statistical anal-
yses. The odds ratio (OR) for mortality increased with increasing deprivation. 
The OR in high deprivation neighborhoods was 1.13 (95% CI 1.08-1.18). The 
five most common causes of death in the study population were coronary 
heart disease (CHD), stroke, psychiatric disorders, cancer and type 2 DM. 
For CHD and psychiatric disorders the ORs increased by increasing neigh-
borhood deprivation and reached 1.37 (95% CI 1.26-1.48) and 1.29 (95% CI 
1.04-1.61), respectively, in high deprivation neighborhoods. The correspond-
ing OR for mortality from type 2 DM was 1.24 (95% CI 1.11-1.40).
Conclusion: This study shows that neighborhood-level deprivation is an im-
portant factor for mortality among patients with DM. Future research should 
examine possible pathways between neighborhood deprivation and mortality 
in order to reduce inequities in mortality among patients with DM.
Supported by: The Swedish Research Council
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Temporal trends in use of evidence-based treatments and risk factor 
control: a decade of nationwide monitoring
B. Eliasson1, A. Rawshani1, A.-M. Svensson1, N. Ekström1, B. Zethelius1,  
S. Gudbjörnsdottir2;  
1Clinical and Molecular Medicine, Inst of Medicine, 2Clinical Medicine,  
Inst of Medicine, Uppsala, Sweden.
Background and aims: Glucose-lowering therapy with metformin is a cor-
nerstone of diabetes treatment. Guidelines recommend instituting metform-
in at the time type 2 diabetes is diagnosed. Likewise, the primary preventive 
effects of statins in individuals with type 2 diabetes has been recognized for 
almost a decade. Little is known about the pace of adoption of these evidence-
based medications. We examined this in a nationwide prospective study 
spanning over a decade.
Materials and methods: We used the Swedish National Diabetes Register to 
include 131935 newly diagnosed (within one year) cases of type 2 diabetes 
during 2002 to 2011. The study population was divided in ten cohorts cor-
responding to the year of diagnosis. To study trends in use of oral glucose-
lowering drugs we included individuals who were treated with diet and 
lifestyle modifications at baseline. Patients were followed until initiation of 
oral glucose-lowering therapy or appropriate censoring. HbA1c was followed 
annually for each cohort. Trends in statin therapy was studied in therapy na-
ive patients who did not experience any cardiovascular event throughout the 
study. Lipid markers were followed annually for each cohort. Time to event 
(instituting therapy) was analysed by means of Kaplan-Meier method.
Results: We included 58407 patients treated with diet and lifestyle modifica-
tions. We observed a striking pattern (figure I) towards earlier initiation of 
glucose-lowering drugs since 2002. Median time to drug in 2002 was 1730 
(95% CI 1636, 1801) days compared to 471 (95% CI 420, 518) days in 2011. 
However, HbA1c levels displayed a different trend; Hba1c (at the same dura-
tion of diabetes) declined steadily from 2002 to 2007, whereafter levels in-
creased. Considering statin therapy, we note the same pattern as with glu-
cose-lowering drugs. Median time to therapy decreased from 2450 (95% CI 
2360, 2530) days in 2002 to 650 (95% CI 580, 730) days in 2011. Interestingly, 
the curve for 2011 leveled off and crossed the curve for 2010. LDL-cholesterol 
displayed a pattern similar to HbA1c - an initial decline from 2002 to 2007 
and thereafter a steady increase. Post hoc analysis of trends in body mass 
index (BMI) and physical activity sought to find an explanation for these 
trends; we noted that BMI at baseline and each point thereafter has increased 
annually since 2002.
Conclusion: We document a striking improvement in time to instituting oral 
glucose-lowering drugs. We also note that use of statins in primary preven-
tion has accelerated in parallell. However, neither HbA1c nor lipid levels re-
flected these trends. 
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Prescribing patterns of antidiabetic drugs within the first year following 
diagnosis of type 2 diabetes: results from the DD2 study
A. Mor1, K. Berencsi1, E. Svensson1, J. Rungby2,3, J.S. Nielsen4, S. Friborg5,  
I. Brandslund6, J.S. Christiansen7, A. Vaag8, H. Beck-Nielsen4,  
H.T. Sørensen1, R.W. Thomsen1;  
1Clinical Epidemiology, Aarhus University Hospital, 2Pharmacology, 
Aarhus University Hospital, 3Endocrinology, Gentofte University Hospital, 
Copenhagen, 4Diabetes Research Centre, Endocrinology, 5Endocrinology, 
Odense University Hospital, 6Biochemistry, Lillebaelt Hospital, Vejle, 
7Internal Medicine and Endocrinology, Aarhus University Hospital, 
8Endocrinology, Rigshospital, Copenhagen, Denmark.
Background and aims: Real-world data are sparse on prescribing patterns 
of antidiabetic drugs in cases of newly diagnosed type 2 diabetes mellitus 
(T2DM) and on patient characteristics that may predict type of early phar-
macotherapy.
Materials and methods: We studied 1,317 newly diagnosed T2DM patients 
enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes 
(DD2) cohort from outpatient hospital clinics and general practice, with at 
least one year of follow-up. We described the number and type of antidiabetic 
drugs prescribed in the first year after T2DM diagnosis. Using Poisson regres-
sion, we calculated risk ratios (RRs) of treatment with different antidiabetic 
drugs associated with baseline patient characteristics.
Results: Of the 1,317 newly diagnosed T2DM patients, 198 (15%) did not use 
any antidiabetic drugs within the first year post-diagnosis, 867 (66%) used 
only one drug, 197 (15%) used two drugs, and 55 (4%) used three or more 
drugs. Figure 1 demonstrates the ranking of individual types of antidiabetic 
drugs used by our 1,317 T2DM patients. The likelihood of receiving combi-
nation therapy with two or more drugs in the first year post-diagnosis was 
substantially higher in T2DM patients aged =3) were at higher likelihood 
of receiving combination therapy (30%; RR = 1.54, 95% CI: 1.05-2.26) than 
T2DM patients with no comorbidity (19%). Weight gain > 30 kg since 20 
years of age and lack of regular physical exercise also increased the likelihood 
of receiving combination therapy during the first year post-diagnosis (RR = 
1.42, 95% CI: 1.14-1.78 and RR = 1.42, 95% CI: 1.11-1.82, respectively). High-
er likelihood of receiving combination therapy also was observed in T2DM 
patients with fasting blood glucose > 7 mmol/L at diagnosis (RR = 3.37, 95% 
CI: 2.43-4.68), HbA1c >=7.5 (RR = 3.85, 95% CI: 3.00-4.94), and C-peptide < 
300 pmol/L (RR = 1.78, 95% CI: 1.15-2.76).
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Conclusion: Within the first year after T2DM diagnosis, 85% of the patients 
are treated with antidiabetic drugs, most commonly metformin (79%), an 
incretin (14%), or insulin (8%). Poor glycemic control and low C-peptide at 
T2DM diagnosis are predictors of combination therapy at one year. Other 
important predictors are young age, comorbidity, obesity, and lack of exer-
cise.
Supported by: DAS, DHMA, DDA, Novo Nordisk A/S
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Factors associated with adherence to oral antihyperglycaemic 
monotherapy in patients with type 2 diabetes in the UK
K. Tunceli, C. Zhao, K. Iglay, K.G. Brodovicz, C.M. Alexander, L. Radican;  
Merck & Co., Inc., Whitehouse Station, USA.
Background and aims: Suboptimal medication adherence is a critical factor 
contributing to poor glycemic control and an increased risk of complications 
in patients with type 2 diabetes (T2DM). The current retrospective database 
analysis aims to estimate adherence to oral antihyperglycemic monotherapy 
(OAM) for T2DM patients in the UK and describe factors associated with 
adherence in these patients.
Materials and methods: Patients with a physician prescription for metform-
in, sulfonylurea (SU), thiazolidinedione (TZD) or dipeptidyl peptidase-4 in-
hibitor (DPP-4i) as monotherapy between January 1, 2009 to June 30, 2012 
(index period) were selected from the IMS Disease Analyser-Mediplus UK 
database. Patients were required to have a diagnosis of T2DM, be ≥18 years 
old at the time of diagnosis, and have medical records available in the da-
tabase for 1 year before and after the index date. Patients were excluded if 
they had at least one diagnosis of type 1 diabetes mellitus, their dosing regi-
men (once daily or twice daily) could not be determined at the index date, 
they switched between once- and twice-daily dosing regimens during the 
12-month post-index period, or they violated the monotherapy requirement 
during the 12-month post-index period. Adherence was assessed using the 
proportion of days covered (PDC) defined as total days medications sup-
plied divided by days in follow-up period. Logistic regression was used to 
assess factors (age, gender, previous treatment status [new to or previously on 
OAM], dosing regimen [once- or twice-daily], and number of concomitant 
medications) associated with whether or not a patient is adherent (yes: PDC 
≥80%, no: PDC <80%).
Results: Eligible patients (N=6276; 57% men) had a mean age of 64.4 years 
(51.5% ≥65 years), 17.1% were on a once-daily regimen, and 58.1% were 
on ≥3 concomitant medications. Overall, 60.1% of patients were adherent 
to OAM. The figure shows the results from the logistic regression analysis 
examining factors associated with being adherent to OAM. Patients younger 
than 45 years old and those 45 to <65 years old were 46% and 19% less likely 
to be adherent, respectively, compared to those 65 years and older. Compared 
to those taking 3 or more concomitant medications, those on no concomitant 
medications or 1-2 concomitant medications were 30% and 14% less likely 
to be adherent, respectively. Gender, dosing regimen and previous treatment 
status were not significantly associated with adherence in the regression 
model.
Conclusion: Medication adherence was shown to be suboptimal in this co-
hort of patients with T2DM in the UK. Younger age and use of fewer con-
comitant medications were factors associated with poor medication adher-
ence in this study. 
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Clinical characteristics, comorbidities, and treatment patterns among 
patients with new-onset type 2 diabetes in a large integrated health 
system
K.M. Pantalone1, T.M. Hobbs2, B.J. Wells1, S.X. Kong2, M.W. Kattan1,  
J. Bouchard2, C. Yu1, B. Sakurada2, A. Milinovich1, W. Weng2, J. Bauman1, 
R.S. Zimmerman1;  
1Cleveland Clinic, 2Novo Nordisk, Plainsboro, USA.
Background and aims: The incidence of type 2 diabetes (T2D) has steadily 
increased over the past few decades. In the United States approximately 1.9 
million people ages 20 years or older were newly diagnosed with diabetes in 
2010 alone. Despite this increase, there are limited real-world data describing 
the clinical characteristics, comorbidities, and treatment patterns of patients 
with new-onset T2D. The objective of this research was to assess the profiles 
and treatment patterns of patients with new-onset T2D in a large integrated 
health system.
Materials and methods: An enterprise-wide electronic health record system 
(EHR) at a large U.S. academic health center was used to conduct a cross-
sectional analysis of 26909 patients with new-onset T2D diagnosed between 
2008 and 2012. Patients with T2D were identified using a validated algo-
rithm to classify T2D subjects based on a combination of clinical diagnoses, 
medications, and laboratory results. Patients with new-onset diabetes were 
isolated by requiring at least 2 office encounters at the institution with a pri-
mary care provider and/or endocrinologist prior to the diagnosis of T2D. The 
population was divided into five strata based on the year in which the new-
onset diagnosis of T2D occurred: 2008, 2009, 2010, 2011, and 2012. Comor-
bidities, glycemic control, and active prescriptions were assessed at 1 year 
after diagnosis.
Results: The population was 51.1% female and 73.5% White. A total of 4150 
(15.4%), 4500 (16.7%), 5372 (20.0%), 6301 (23.4%) and 6586 (24.5%) patients 
were included in each of the incidence year stratum, respectively. The mean 
ages (years) for patients at the time of diagnosis across the incidence year 
strata were 62.3, 61.2, 60.8, 61.0, and 60.8, respectively. The prevalence of 
hypertension (HTN) within 1 year of new-onset T2D was 80%. The percent-
ages of patients with active prescriptions for 2 or more classes of anti-diabetic 
agents at 1 year after diagnosis were 32.3, 32.6, 28.4, 29.5, and 31%, respec-
tively. The selection of anti-diabetic therapy was rather consistent among the 
new-onset T2D patients from 2008-2012, with the only exception being a 
steady decline in the use of thiazolidinediones mirrored by a concordant rise 
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in the use of dipetidyl peptidase-4 (DPP-4) inhibitors. Interestingly, within 
each incidence year strata, 52.1, 47.0, 48.3, 54.2, and 55.7% of patients did not 
have an HbA1c measurement recorded in the lab section of the EHR within 
the 1st year of diagnosis. Among patients with available HbA1c values, the 
percentages of patients with inadequate glycemic control (HbA1c>8%) at 1 
year were 25.1%, 24.4%, 22.2%, 25.9%, and 28%, respectively.
Conclusion: A high prevalence of HTN was observed among this population 
of patients with new-onset T2D. Nearly 1/3 of the new-onset T2D patients 
were receiving 2 or more classes of anti-diabetic agents at 1 year after di-
agnosis. The use of thiazolidinediones in patients with new-onset T2D has 
decreased, whereas the use of DPP-4 inhibitors has increased. Of note, the 
use of sulfonylureas has not decreased, despite the availability of several new 
agents. Approximately 1/2 of new-onset T2D patients did not have an HbA1c 
value recorded in the lab section of the EHR within the 1st year of diagnosis.
Supported by: Novo Nordisk
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Burden of baseline comorbidities in patients with type 2 diabetes 
initiating various classes of antidiabetic agents - an analysis of a large  
US claims database
T.M. Rehman1, S. Colilla2, T. Kou3, J. Wood3;  
1Global Pharmacovigilance and Epidemiology, Bristol Myers Squibb, 
Wallingford, 2GHEOR CORDS, Bristol Myers Squibb,  
3Global Pharmacovigilance and Epidemiology, Bristol Myers Squibb, 
Pennington, USA.
Background and aims: Channeling bias is a concern when designing obser-
vational comparative studies including users of different drug classes for the 
management of Type 2 Diabetes Mellitus (T2DM). Characterizing the differ-
ences in patient baseline characteristics across comparator drug classes will 
aid in the evaluation of channeling bias. This study described patient demo-
graphic and clinical characteristics among US patients with T2DM initiating 
a new class of antidiabetic drug in 2012.
Materials and methods: US adult patients with T2DM who initiated a new 
class of antidiabetic drug during the first six months of 2012 (N=183,692) 
were identified in the Truven MarketScan Commercial Claims and Encoun-
ters database. The date of first new class of oral or injectable antidiabetic drug 
during the study period was defined as the index date. Patient’s baseline char-
acteristics were identified in the 12 months prior to the index date. Comor-
bidities were based on ICD-9-CM diagnostic codes and NDC codes used for 
prescriptions.
Results: We identified 183,692 patients with majority (40%) initiating bi-
guanides. Similar mean age was seen in all of the drug classes except GLP-
1 RA users who were younger. Contrary to other classes, GLP-1 RA users 
were predominantly female. Over 50% of new users had hyperlipidemia and 
hypertension at baseline with the prevalence being highest in DPP-4i and 
GLP-1 RA users. A diagnosis of obesity was most notable in GLP-1 RA users. 
History of heart failure was highest in insulin users. Although rare, history 
of acute and chronic pancreatitis was lowest in GLP-1 RA and DPP-4i users. 
Compared to biguanide users, more concomitant use of lipid lowering medi-
cations was observed in users of all other classes.
Conclusion: Differences were observed in the burden of comorbidities 
across different antidiabetic drug classes initiated which suggests a degree of 
channeling bias. Careful consideration and accounting of these factors dur-
ing analysis is needed when conducting comparative observational studies 
among patients treated for Type 2 diabetes.
Supported by: Bristol-Myers Squibb
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Hospitalisation frequency for hypoglycaemia and emergency calls  
in type 2 diabetes mellitus patients exposed to vildagliptin vs  
insulin-secretagogues in the French Health Insurance database
B. Detournay1, S. Dejager2, J. Robert1;  
1Cemka-Eval, Bourg-la Reine,  
2Novartis Pharma SAS, Rueil Malmaison, France.
Background and aims: To compare the frequency of severe hypoglycaemic 
episodes leading to hospitalization and of emergency calls for any cause in 
patients exposed to the DPP-4 inhibitor vildagliptin vs those exposed to in-
sulin secretagogues (IS; sulphonylurea or glinide).
Materials and methods: Retrospective data were extracted from the EGB 
(Echantillon Généraliste des Bénéficiaires) database: a data resource com-
prising a sample of ~1% of all patients registered in the French National 
Health Insurance system (≈600,000 patients). Type 2 diabetes mellitus pa-
tients exposed to regimens comprising either vildagliptin (excluding treat-
ment with IS, insulin or another incretin therapy) or IS (excluding treatment 
with insulin and any incretin therapy) between 2009 and 2012 were selected. 
Hospitalizations related to hypoglycaemia during the exposure periods were 
identified in both cohorts. Two comparative analyses adjusting for key co-
variates within the model (subjects matched for age, gender, socioeconomic 
status, drug exposure duration), or with multivariate logistic regression, were 
performed.
Results: 1,440 patients were exposed to vildagliptin and 10,019 to IS. Pa-
tients in the IS cohort were older than in the vildagliptin cohort (mean 67.3 
(SD: 12.8) years old vs. 63.5 (SD: 11.9), p<0.0001) and had a longer exposure 
duration over the study period (vildagliptin has been marketed since Sep-
tember 2009 in France). During the observation period, no patient from the 
vildagliptin cohort (0.0%) was hospitalized for hypoglycaemia vs 130 (1.30%) 
with IS (138 hospitalizations) (p<0.0005). The rough hospitalization rates for 
hypoglycaemia were 0 in the vildagliptin cohort vs 5.6 hospitalization/1000 
patient-years [95% CI: 4.7; 6.6] in the IS cohort (p=0.02). 60 patients in the 
vildagliptin cohort (4.2%) vs 2,144 patients (21.4%) in the IS cohort visited 
the emergency department (p<0.0001), but with no significant difference be-
tween the 2 cohorts regarding the rates of all emergency calls/1000 patient-
years (p=0.5). After adjustment, rates of hospitalization and of all emergency 
calls were significantly lower with vildagliptin vs IS (Table). Consistent results 
were found when considering treatment initiations only, in the IS cohort. 
Due to limitations in the availability of some data in the database, adjust-
ments did not consider HbA1c levels or other potential confounding factors.
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Conclusion: There was a significantly lower frequency of hospitalization for 
severe hypoglycaemia and of all emergency calls in patients exposed to vilda-
gliptin vs IS. These real-life data should be taken into consideration in the 
benefit/risk evaluation of the drugs.
Supported by: Novartis SAS
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Predicting glycaemic changes in the non-diabetic general population:  
a DIRECT study
A.D.M. Koopman, S.P. Rauh, the DIRECT Consortium;  
Department of Epidemiology and Biostatistics, EMGO Institute for Health 
and Care Research, Amsterdam, Netherlands.
Background and aims: Recently, glycated haemoglobin (HbA1c) levels have 
been introduced as a diagnostic criterion for type 2 diabetes. Our study eval-
uates whether in addition to baseline HbA1c levels, non-invasive measures 
can be used to predict changes in HbA1c levels during 6 years follow-up.
Materials and methods: Data from 2,887 initially non-diabetic subjects 
(based on ADA 2011 criteria) from 3 population-based cohorts (Hoorn 
Study, Inter99, KORA S4) were used to develop sex-specific linear regres-
sion models predicting change in HbA1c levels during follow-up. By using 
change in HbA1c levels, lab differences were avoided. To minimize overfit-
ting of the model, we performed internal validation using bootstrapping 
techniques. Calibration was assessed with calibration graphs. Discriminative 
performance was assessed with classification tables, dichotomizing HbA1c 
levels (≥ 5.7% vs < 5.7%).
Results: At baseline, mean HbA1c level was 5.6%. During a mean follow-
up of 6 years (SD: 0.7 years), median change in HbA1c levels was +0.02%. 
HbA1c levels increased in 51% of the subjects, 2.3% of the subjects developed 
HbA1c levels ≥6.5%. After backward selection, next to baseline HbA1c levels, 
for men: age, waist circumference, smoking, and parental history of diabe-
tes were retained in the prediction model (explained variance (R2): 33%); 
and for women: BMI and waist circumference (R2: 23%). Calibration plots 
showed good agreement between predicted and observed HbA1c levels at 
follow-up. With respect to discrimination, our model classified 75% of the 
subjects correctly as having high/low HbA1c levels.
Conclusion: In the non-diabetic population, non-invasive predictors can be 
used next to baseline HbA1c levels to predict change in HbA1c levels during 
6 years follow-up. This model can be used in clinical practice to determine 
which patients are at high risk of glycaemic deterioration. High-risk patients 
can then be monitored more regularly than low-risk patients and targeted 
preventive interventions can be initiated.
Supported by: IMI Joint Undertaking
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Factors associated with weight gain and hypoglycaemia and the 
impact upon hospitalisation in type 2 diabetes patients managed with 
metformin plus sulfonylurea
J. Gordon1, P. McEwan1,2, M. Evans3, J. Puelles4;  
1Health Economics and Outcomes Research Ltd, Monmouth, 2Swansea 
University Centre for Health Economics, 3Cardiff and Vale University 
Health Board, 4Takeda Global Research and Development, London, UK.
Background and aims: The importance of avoiding complications that de-
crease quality of life and consume healthcare resources in people with type 
2 diabetes is well understood. However, the relationship between resource 
utilisation and patient phenotype is less well researched. The objective of this 
study was to assess factors associated with weight gain and the occurrence of 
hypoglycaemia in type 2 diabetes (T2DM) patients managed with metformin 
plus sulfonylurea (M+S), and any associated impact upon hospital resource 
utilisation.
Materials and methods: The study was a retrospective cohort study using the 
UK Clinical Practice Research Datalink (CPRD) and the Hospital Episode 
Statistics (HES) database. The cohort analysed were those with T2DM treated 
with M+S for at least 3 months during the period 1/1/2001 to 31/12/2011; 
patients with a diagnosis of malignant disease were excluded. The association 
between phenotypic factors at baseline (therapy escalation from metformin 
to M+S) and weight gain (defined as > 2kg weight change over 12 months) 
and primary care recorded hypoglycaemia (>=1 episode) over 12 months fol-
lowing therapy escalation was assessed using logistic regression. Hospitalisa-
tion associated with increasing body mass index (BMI) and hypoglycaemia 
was also assessed. Analysis was undertaken using R version 2.12.2
Results: A total of 11,071 patients met the study inclusion/exclusion criteria 
with mean age at baseline of 60.7 (SD=11.4) years, 39% female, 5.4 (SD=4.0) 
years duration of diabetes, HbA1c 8.7% (SD=1.6), weight 92.2 kg (SD=19.6) 
and BMI 32.2kg/m2 (SD=6.1). Weight gain (1=weight gain; 0 otherwise) was 
observed in 28.35% (n=3,139) and was significantly associated with baseline 
age (OR=0.99 for one-year increase in age, p<0.01), female gender (OR=0.87, 
p<0.05) and baseline weight (OR=1.003 for 1 kg increase in weight, p<0.05) 
and HbA1c (OR=1.06 for 1% increase in HbA1c, p=1 episode; 0 otherwise) 
occurred in 1.3% (n=142) of patients and was associated with duration of dia-
betes (OR=1.04 for one-year increase in duration, p<0.05), baseline HbA1c 
(OR=0.86 for 1% increase in HbA1c, p<0.05) and prior complications status 
(OR=1.92, p<0.05). Hospitalisation occurred in 10% of patients (n=1,125) 
and was significantly associated with BMI (OR=1.02 for 1 kg/m2 increase in 
BMI, p<0.01) but not hypoglycaemia. The mean number of hospital admis-
sions over the follow-up period was 1.7, 1.8, 1.9 and 3.1 in those with BMIs at 
the time of admission in the normal, overweight, obese and morbidly obese 
categories respectively.
Conclusion: This real-world observational analysis suggests there are identi-
fiable phenotypic characteristics predictive of weight gain, and there are iden-
tifiable phenotypic characteristics predictive of hypoglycaemia. This study 
also shows a general relationship between increasing BMI and hospitalisa-
tion, most notably in the comparison of normal vs morbidly obese subjects, 
that may not be adequately captured in widely used vascular risk equations 
such as UKPDS in which BMI has minimal influence on risk. Consequently 
the value of diabetes management strategies that minimise weight gain may 
be underestimated.
Supported by: TGRD (Europe) Ltd
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Analysis on incidence of new-onset diabetes mellitus after renal 
transplantation in different eras
M. Yu1, C. Lv1, M. Chen1, M. Xu2, Y. Zhang1, S. He1, M. Xue1, J. Gao3,  
X. Gao1, T. Zhu2;  
1Endocrinology, 2Urology, 3Evidence Base Medicine Center,  
Zhongshan Hospital affiliated to Fudan University, Shanghai, China
Background and aims: To retrospectively evaluate the long-term fluctuation 
of fasting plasma glucose (FPG) after renal transplantation, in order to ex-
plore the incidence of new-onset diabetes mellitus after transplantation (NO-
DAT) in different eras.
Materials and methods: We retrospectively evaluated 709 patients receiving 
kidney transplantation at our center between 1 January, 1993 and 31 Decem-
ber, 2008. After excluding patients with uncompleted data, graft failure or 
death within 1 year after transplantation, multi-organ transplant recipients, 
transplant more than once or previously known diabetes, 428 patients were 
analyzed. The incidence of new-onset diabetes mellitus after renal transplan-
tation was analyzed according to FPG in different eras. Immunosuppressive 
treatment after transplantation might be cyclosporine-A,(CSA)+ mycophe-
nolate mofetil(MMF)(or Azathioprine (AZA)) + glucocorticoid or tacroli-
mus (FK506)+MMF(or AZA)+ glucocorticoid. We use AZA for anti-prolif-
erative drug before 1997 and MMF after that. We started using FK506 in 1999 
and in some patients using CD25 monoclonal antibody for immunosuppres-
sion induction since 2001. Patients were divided into three groups 1993-1996, 
1997-2000, 2001-2008 according to different immunosuppressive treatment, 
and the incidence of NODAT was compared between different eras.
Results: Of the 428 Patients, 87 developed NODAT (20.3%) during a mean 
follow-up of 6 years. According to the different immunosuppressive treat-
ment in the different eras, patients were divided into three groups 1993-
1996, 1997-2000, 2001-2008, of which the incidence of NODAT was 18.42%, 
17.46% and 21.11% respectively. There was no difference in the incidence of 
NODAT among three transplantation eras.
Conclusion: The incidence of NODAT was 20.3% in patients surviving for 
more than 1 year during a mean follow-up of 6 years at Zhongshan Hospital. 
There was no difference in the incidence of NODAT among three transplan-
tation eras.
PS 008 Type 1 diabetes:  
genes and biomarkers
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Primary autoantigen specific genetic traits in the pathogenesis of  
type 1 diabetes
J. Lempainen1,2, A.-P. Laine1, A. Hammais1, J. Toppari2, R. Veijola3,  
O. Simell2, M. Knip4,5, J. Ilonen1,6;  
1Immunogenetics Laboratory, University of Turku, 2Department of 
Pediatrics, University of Turku and Turku University Hospital, 3Department 
of Pediatrics, University of Oulu and Oulu University Hospital, 4Children’s 
Hospital, University of Helsinki and Helsinki University Central Hospital, 
5Department of Pediatrics, Tampere University Hospital, 6Department of 
Clinical Microbiology, University of Eastern Finland, Kuopio, Finland.
Background and aims: Natural history studies on type 1 diabetes (T1D) as-
sociated autoimmunity provide an opportunity to identify detailed mecha-
nisms of autoantigen specific genetic traits of diseases pathogenesis. We hy-
pothetized that if the effect of a specific T1D-risk associated genetic marker 
is related to the triggering autoantigen of beta-cell destruction, the effect of 
the single variant should be dependent on the first appearing autoantigen-
specific autoantibody.
Materials and methods: The study subjects were participants in the prospec-
tive DIPP study and carried T1D-risk associated HLA class II genotypes. 
From the DIPP study cohort, we were able to identify 170 subjects with IAA 
as the first biochemical autoantibody and selected 325 autoantibody nega-
tive controls matched for gender, date of birth and study center. Similarly we 
identified 151 subjects with GADA as the first biochemical autoantibody and 
285 autoantibody negative controls for them. Forty-three single nucleotide 
polymorphisms (SNPs) associated with T1D risk were genotyped using the 
Sequenom platform. Differences in effect of various SNPs on the develop-
ment of autoantibodies and further progresssion to clinical T1D were tested 
among subjects with IAA or GADA as the first biochemically-defined au-
toantibody. Cox regression analysis was performed to test the effect of the 
gene markers on the T1D pathogenesis.
Results: The effect of INS rs689, IKZF4 rs1701704 and ERBB3 rs2292239 
polymorphisms differed significantly between subjects with IAA or GADA 
as the first biochemical autoantibody. INS SNP strongly affected the devel-
opment of clinical T1D and, in particular, the appearance of beta-cell hu-
moral autoimmunity among the group with IAA as the first autoantibody 
(p=0.0054 and 0.0024, respectively) whereas no effect of the INS SNP on the 
T1D pathogenesis in the GADA group could be observed. In contrast, IKZF4 
and ERBB3 SNPs were associated with the development of T1D in the GADA 
group (p=0.0022 and 0.0064, respectively) and, the two polymorphisms af-
fected the progression rate of beta-cell destruction after the appearance of au-
toimmunity in the GADA group (p=0.0025 and 0.0024, respectively) whereas 
no effect of these SNPs on the appearance of T1D or the progression rate of 
beta-cell destruction could be observed in the IAA group.
Conclusion: The first appearing autoantibody specific approach revealed two 
genetic pathways dependent on the primary autoantigen. The effect of INS 
gene SNP on the pathogenesis of T1D was restricted to subjects with IAA as 
the first autoantibody whereas the SNPs in the IKZF4-ERBB3 locus increased 
the T1D risk and, more specifically, the progression rate of beta-cell destruc-
tion among subjects with GADA as the first autoantibody.
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Concentrations of soluble receptor for AGEs decline at seroconversion in 
children with preclinical type 1 diabetes but not in autoantibody positive 
non-progressors
K.M. Salonen1, S.J. Ryhänen1, J.M. Forbes2, T. Härkönen1, J. Ilonen3,  
O. Simell4, R. Veijola5, P.-H. Groop6, M. Knip1,7;  
1Children´s Hospital, University of Helsinki, Finland, 2Mater Research UQ 
at TRI, University of Queensland, Brisbane, Australia, 3Immunogenetics 
Laboratory, 4Department of Paediatrics, University of Turku, 5Department 
of Paediatrics, University of Oulu, , 6Folkhälsan Institute of Genetics, 
Folkhälsan Research Center, Helsinki, 7Department of Pediatrics, Tampere 
University Hospital, Finland.
Background and aims: Our previous studies suggest that concentrations of 
soluble receptor for advanced glycation end products (sRAGE) might play a 
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role in the process leading to type 1 diabetes. We set out to define the changes 
in sRAGE in prediabetic and autoantibody positive children.
Materials and methods: We analyzed serum concentrations of sRAGE from 
samples of 168 children who progressed to type 1 diabetes and 43 children 
who became positive for at least 2 diabetes associated autoantibodies during 
prospective observation, but have not progressed to diabetes. We analyzed 
the sRAGE concentration before seroconversion, in the first autoantibody 
positive sample, and annually after that until the diagnosis of type 1 diabetes 
or end of follow up.
Results: The children who progressed to clinical type 1 diabetes were young-
er at seroconversion and at end of follow up than the non-progressors [2.04 
(± 1.5) years vs. 3.04 (± 1.5) years, p<0.001, and 5.91 (± 3.06) years vs. 9.67 
(± 2.62) years, respectively (Mann-Whitney U-test)]. The progressors had 
similar or higher sRAGE than the non-progressors before seroconversion 
(p=NS) but subsequently lower levels [1183 (±445) pg/ml vs. 1286 (±490) 
pg/ml, p<0.001 (t-test)]. The progressors had in the sample taken before se-
roconversion higher concentrations of sRAGE than in subsequent samples 
[mean sRAGE 1372 (± 573) pg/ml vs. 1183 (± 445) pg/ml, p<0.001 (t-test)]. 
The difference remained significant even after adjusting for sampling age 
[p<0.001 (linear regression)]. Concentrations of sRAGE were similar before 
and after seroconversion in the non-progressors [mean sRAGE 1290 (± 562) 
pg/ml vs. 1286 (± 490) pg/ml, p=NS (t-test)]. There was a correlation between 
age and sRAGE concentrations among the non-progressors [r 0.13, p=0.008 
(Spearman´s rho)] but not in the children who eventually presented with 
type 1 diabetes. After seroconversion there was no significant variation in the 
sRAGE concentrations in the two groups.
Conclusion: Children who later develop type 1 diabetes have higher sRAGE 
concentrations before seroconversion than after the initiation of beta-cell au-
toimmunity. Our study suggests that non-progressors with persistent positiv-
ity to islet cell autoantibodies do not experience a similar decrease in sRAGE. 
As AGEs have been shown to be detrimental to beta cells, the drop in circu-
lating sRAGE seen in temporal association with seroconversion may reflect 
failing protective mechanims in the progressors.
Supported by: JDFR, Novo Nordisk Foundation and Finnish National CLIGS
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High risk vs low risk nondiabetic first degree relatives of patients with 
type 1 diabetes: differences in CXCR3+, CCR4+, CD25high T memory 
cells and chemokine levels
T. Milicic1, A. Jotic1, I. Markovic2, K. Lalic1, L. Lukic1, N. Rajkovic1,  
M. Macesic1, J. Seferovic1, J. Stanarcic1, N. Lalic1;  
1Clinic for Endocrinology, 2Institute for Biochemistry, Faculty of Medicine, 
University of Belgrade, Serbia.
Background and aims: Previously was suggested the prominent role of the 
chemokine receptors CXCR3 and CCR4, associated with Th1 and Th2 memo-
ry cell subsets respectively, together with impairments in T regulatory (T reg) 
subset, in animal models of the initial phase of Type 1 diabetes (T1D). How-
ever, the relevance of the changes in CXCR3+ (Th1 associated), CCR4+ (Th2 
associated) and CD25high subsets (T reg associated) of the T memory cells as 
well as in chemokine/cytokine levels, interferon-γ inducibile chemokine (IP-
10) (Th1 associated), thymus-and activation-regulated chemokine (TARC) 
(Th2 associated) and transforming growth factor β (TGFβ) (Treg associated), 
for risk for T1D development, has not yet been clarified. Therefore, the aim of 
this study was to analyze (a) the percentage of CXCR3+, CCR4+, CD25high 
subsets of T memory cells and (b) chemokine/cytokine levels IP-10, TARC 
and TGFβ, in peripheral blood of two groups, the high risk and the low risk 
group, of nondiabetic first-degree relatives (FDRs) of patients with T1D as 
well as in the group of healthy unrelated controls. The difference between 
the two groups of FDRs was based on presence/ absence of glutamic acid 
decarboxylase (GADA) and tyrosine phosphatase insulinoma antigen-2 (IA-
2) antibodies. Thus, in the study we included 17 high-risk nondiabetic FDRs 
(GADA+, IA-2+) (group A) and 34 low-risk nondiabetic FDRs (GADA-
IA-2-) (group B) and 18 healthy unrelated controls (group C).
Materials and methods: T1D and glucose intolerance were excluded in the 
study by using WHO criteria. GADA and IA-2 levels were determined by 
ELISA. The percentages of CXCR3+, CCR4+ and CD25high T memory cell 
subsets were analyzed in peripheral blood by using four-color immunofluo-
rescence staining and flowcytometry. IP-10, TARC and TGFβ were deter-
mined by ELISA.
Results: When the percentage of CXCR3+ T memory cells was analyzed, it 
was found to be higher in group A vs groups B and C (A: 64.98±5.19 vs B: 
42.13±11.11; C: 53.09±6.29 %, A vs B: p<0.001; A vs C: p<0.01). In contrast, 
the percentage of CCR4+ T memory cells was significantly lower in group A 
vs groups B and C (A: 29.46±2.83 vs B 41.90±8.58; C: 40.90±7.24% p<0.001). 
Simultaneously, the percentage of CD25high T memory cells was signifi-
cantly lower in group A vs groups B and C (A: 0.13±0.05 vs B: 0.26±0.10 ; 
C: 0.26±0.06%, p<0.001). On the other hand, IP-10 and TARC levels were 
significantly higher in group A vs B and C (A: 160.12±73.40; 438.83±120.62, 
B: 105.39±71.30; 312.04±151.14, C: 85.24±19.82; 236.88±89.19 pg/ml, re-
specitevely; A vs B p<0.05, A vs C p<0.01), while there was no difference in 
TGFβ levels in groups A, B and C (A: 8883.17±3105.96, B: 7981.04±3889.51, 
C: 10064.44±681.99 pg/ml; A vs B vs C, p=NS).
Conclusion: Our results have demonstrated that high risk FDRs, showed 
higher levels of CXCR3+ T memory cells and IP-10, both associated with 
increased Th1 response, together with lower levels of CCR4+ T memory 
cells expressing Th2 response and CD25high T reg cells subsets, and without 
impairments in TGFβ level. The results imply that the risk for developing 
T1D might be associated with the dominant influence of Th1 autoimmune 
response, together with diminished Th2 autoimmune response, while Treg 
response in high risk FDRs was impaired but still functionally preserved.
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Differential apoptosis in lymphocytes of patients with type 1 diabetes 
associated with relative expression of microRNA-146a
F. Pérez-Bravo1, G. Mancilla1, D. García-Días1, E. Codner2;  
1Nutrition, University of Chile, 2IDIMI, University of Chile, Santiago, Chile.
Background and aims: It is well established that type 1 diabetes (T1D) is 
an autoimmune disease. Controversial data exists regarding the differential 
control of the immune system in T1D patients compared to unaffected in-
dividuals. MicroRNAs (miRNAs) are involved in the control of gene expres-
sion (by negative regulation of gene expression at post-transcriptional level, 
by mediating translational repression or degradation of the mRNA targets). 
Their potential role in T cell activation and autoimmunity is controversial. we 
aim to elucidate relationship miR-146a in cell survival
Materials and methods: We investigated the expression profile of miRNAs 
in polymorphonuclear cells (PBMC) samples of 5 T1D patients (12-17 years 
old) and 5 healthy controls by means of qPCR. Cells were cultured in 96-well 
plates in RPMI-1640 with 10% FBS at 37 ° C with 5% CO2. The activation was 
performed using anti-CD3 1ug/ml for 8 hours. RNA extraction and cDNA 
were performed by standard techniques. miR-146, miR-155, miR-182 and 
rnU6. Real-time PCR expression on time zero and after 8 h of culture was 
measured. Additionally we quantified baseline lymphocyte apoptosis by flow 
cytometry using Annexin V.
Results: The comparison between diabetics and controls both in basal condi-
tions and activation showed only miR146a statistically significant differences 
(p <0.0016), miR155 (p = 0.14) and miR182 (p = 0.95). In relation to apop-
tosis, DM1 patients showed a lower rate of apoptosis (1.82%) and statistically 
different when compared with control subjects (7.49%), p = 0.0286. Finally, 
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the correlation between the percentage of apoptosis and expression of mi-
R146a was r = 0.786 (p <0.0279)
Conclusion: Our results indicate that the low expression of miR-146a may be 
associated with a decreased rate of cell apoptosis. Thus the activation window 
would be higher in these patients. Previous studies have shown that mol-
ecules such as IRAK and TRAF6 are targets of miR-146a, which work in a 
negative feedback system for activation of NF-kB molecule that influences 
the rate of cell survival through the cell cycle progression
Supported by: Fondecyt 1130240
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Rapid assays for detection of type 1 diabetes-associated autoantibodies in 
organ donors
T. Härkönen1,2, M. Kararic1,2, H. Hyöty3,4, M. Knip1,2;  
1Children‘s Hospital, University of Helsinki and Helsinki University Central 
Hospital, Finland, 2Diabetes and Obesity Research Program, University 
of Helsinki, 3Department of Virology, School of Medicine, University of 
Tampere, 4Department of Clinical Microbiology, Center for Laboratory 
Medicine, Tampere, Finland.
Background and aims: Diabetes-associated autoantibodies are essential in 
the prediction of type 1 diabetes and in the classification of diabetes. Au-
toantibodies are also used to identify autoantibody-positive organ donors in 
large international studies (e.g. nPOD and PEVNET) which aim at uncover-
ing pathogenic changes in pancreas and related organs in order to understand 
the mechanisms of beta-cell destruction. The current study set out to develop 
rapid assays for autoantibodies to glutamic acid decarboxylase 65 (GADA), 
islet antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) by modifications of 
both our in-house radiobindingimmuno assay (RBA) and a commercial ELI-
SA (RSR Limited, United Kingdom).
Materials and methods: We have analyzed 100 diabetic children and non-
diabetic siblings for IA-2A and GADA both with conventional and rapid 
assays. The RBA was modified into a rapid assay by incubating the labeled 
antigens and serum for one hour at RT instead of overnight at 4 °C. Immune 
complexes were bound to Protein-A Sepharose at 4 ºC for one hour. The rapid 
assays were further optimized by incubating serum and labeled antigen for 
45 min at RT and immune complexes precipitated for 30 min at 4 ºC. Fur-
ther, antigen labels were made ready, standards and controls were pipetted 
on plates beforehand and all were kept at -80 ºC. The RSR ELISAs were first 
performed according to the manufacturer’s instructions. Then assays were 
modified by shortening the incubation times to 20 minutes and all incuba-
tions performed at RT. Six sera from the Finnish Pediatric Diabetes Register 
with varying autoantibody levels were selected and analyzed both with RIA 
and ELISA several times in different incubation conditions. For correlation 
analyses we also analyzed 17 diabetic and 20 non-diabetic siblings.
Results: The six sera from the Pediatric Diabetes register showed strong con-
sistence for medium titers and negative responses, but RBA results close to 
cut-off values showed some discrepancies. ELISA results were more consist-
ent. The analysis showed a strong correlation between the conventional and 
rapid RBA assays (r=0.92 for IA-2A and r=0.89 for GADA) with 1 hour incu-
bations, (r=0.912 for IA-2A, r=0.941 for GADA and r=0.862 for Znt8A) with 
45 min incubation and 30 min precipitation. ELISAs performed according 
to the manufacture’s instructions and with the rapid assays correlated well 
(r=0.96 for IA-2A, r=0.98 for GADA and r=0.87 for ZnT8A).
Conclusion: Our results indicate, that all three (IA-2A, GADA and ZnT8A) 
RSR ELISA assays can be accomplished within 1 hour 45 minutes and the 
results correlate well with results obtained according to the manufacture’s in-
structions. All three RBA assays can be performed in 2 hours 15 minutes and 
the results obtained correlate well with conventional in-house assays and are 
in good concordance with the ELISA results.
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Combined appearance of autoantibodies against GAD, IA-2, insulin and 
ZnT8 in the islet autoantibody standardisation program 2013 proficiency 
workshop
M. Schlosser1, V. Lampasona2, A.J.K. Williams3, P.W. Mueller4,  
D.L. Pittman5, W.E. Winter5, B. Akolkar6, P. Achenbach7;  
1Department of Medical Biochemistry and Molecular Biology, University 
Medical Center Greifswald, Karlsburg, Germany, 2Center of Genomics, 
Bioinformatics and Biostatistics, Milan, Italy, 3Clinical Science at North 
Bristol, University of Bristol, UK, 4National Diabetes Laboratory, Centers 
for Disease Control and Prevention, Atlanta, 5Department of Pathology, 
University of Florida, Karlsburg, 6Division of Diabetes, Endocrinology and 
Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney 
Diseases, Bethesda, USA, 7Institute of Diabetes Research, Helmholtz Center 
Munich, Germany.
Background and aims: The Islet Autoantibody Standardization Program 
(IASP), a continuation of the Diabetes Antibody Standardization Program 
(DASP) of the Immunology of Diabetes Society, set up to evaluate and im-
prove assays for type 1 diabetes (T1D)-associated autoantibodies (AAb). The 
IASP 2013 workshop aimed to assess the sensitivity/specificity and concord-
ance of assays measuring AAb to GAD (GADA), IA-2 (IA-2A), insulin (IAA), 
and zinc transporter 8 (ZnT8A) in laboratories throughout the world. We 
assessed the combined detection of these four AAb in IASP serum samples 
considering differences in assay performance.
Materials and methods: Coded sera from 50 patients with newly diagnosed 
T1D and 90 healthy controls were analyzed in laboratories by 33 GADA as-
says, 31 IA-2A assays, 18 IAA assays and 21 ZnT8A assays. Sera were cat-
egorized according to the number of laboratories calling them positive using 
local assay thresholds, and further stratified between patients and controls by 
the number of positive AAb. Category 1 (C1) included sera that were found 
AAb positive by at least 90% of assays. Category 2 (C2) included C1-sera 
plus additional sera that were found AAb positive by at least 50% of assays. 
Category 3 (C3) included C2-sera plus sera that were found AAb positive by 
at least 25% of assays.
Results: Of 50 patient sera, 39 (78%) were included in C1, 42 (84%) in C2 and 
45 (90%) in C3. None of the 90 control sera were included in C1 (0%), while 
1 (1%) and 6 (7%) control sera were included in C2 and C3 respectively. The 
number of multiple AAb positive patient sera increased from 27 (54%) in C1, 
to 37 (74%) in C2, and 39 (78%) in C3 (p=0.04). One control serum in C2 was 
positive for multiple AAb. For all AAb specificities, C1-sera had significantly 
higher antibody titres than C2-sera (p<0.0001). Among the 45 AAb positive 
patient sera in C3, 18 (39%) had all four AAb, and another 13 (26%) had three 
positive AAb. The most frequently AAb combination was GADA plus IA-2A 
plus ZnT8A and positivity for all four AAb. Among single AAb positive sera, 
GADA were most frequently detected in controls (n=3).
Conclusion: We conclude that in the IASP 2013 proficiency workshop, labo-
ratories with sensitive assays for GADA, IA-2A, IAA, and ZnT8A could de-
tect AAb in almost all sera from newly diagnosed T1D patients, with multiple 
AAb in up to 90% of patient sera. Moreover, in these assays the number of 
patients with single AAb was reduced. AAb assays may infrequently de-
tect positive signals against single but usually not multiple antigens in sera 
from controls. Thus the detection of different AAb is related to AAb level in 
both, patients and controls, and therefore dependent on assay sensitivity and 
threshold.
Supported by: NIDDK and IDS
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Gadolinium chelate (Gd-DO3A-GAD), new contrast agent for non-
invasive quantification of beta cell mass
K. Louchami1,2, S. Liang2, A. Rzajeva3, M. Aswendt4, A. Sener1,  
U. Himmelreich2;  
1Laboratory of EXperimental Hormonology, Université Libre de Bruxelles, 
2Biomedical MRI Unit/MoSAIC, Dept. Imaging & Pathology, KU Leuven, 
3Laboratory of Hormonology, Université Libre de Bruxelles, Belgium, 4Max 
Planck Institute for Neurological Research, Cologne, Germany.
Background and aims: The non-invasive imaging and quantification of pan-
creatic islet is considered a high-priority field of diabetes investigation. This 
work deals with the use of Gd-DO3A-GAD as new contrast agent in the per-
spective of pancreatic islets non-invasive imaging. The paramagnetic agent 
consists of Gd-DO3A as the Gd(III) chelate backbone. In its inactive state, 
long hydrocarbon side chains are anchored to one N atom of the Gd(III) 
chelate with glutamate moieties as head groups, which can enter the Gd(III) 
coordination sphere, thus limiting the water access to the paramagnetic core. 
Upon decarboxylation of the glutamate moieties due to the GAD (Glutamate 
decarboxylase) activity, there is an increase in the hydration sphere of the 
Gd(III) ion, leading to an increased T1 relaxivity. The present work, aims 
to perform the Glutamic acid decarboxylase characterization, the effect of 
Gd-DO3A on the insulin secretion evoked by D-glucose and the potential 
toxicity.
Materials and methods: The wistar rat pancreatic islets were obtained using 
the collagenase digestion method. Glutamate decarboxylase activity (14CO2 
production) was performed using the 14C-L-glutamic acid as substrate. The 
insulin secretion was measured by RIA (Radio Immuno-Assay) method. MRI 
experiments were performed using 9.4T Biospec small animal MRI system 
(Bruker, Ettlingen, Germany). Each phantom contains six tubes filled with 
2% agarose in H2O. Standard Bruker T1_map_RAREVTR sequence is used. 
(TE = 12.7ms, FOV= 5cm*5cm, Matrix size = 128*128).
Results: The Glutamate decarboxylase activity (14CO2 production) was 
measured using the 14C-L-glutamic acid as substrate in the pancreas ho-
mogenates from normal vs diabetes (Sreptozotocine) wistar rats demonstrate 
that the enzyme activity was 4 times fold higher in the normal animals. The 
time related L-glutamate decarboxylase activity in rat islets and brain ho-
mogenates after 120 min incubation reached respectively 45pmol/mg wet 
weight and 14pmol/1000islets. The present results demonstrate that the Gd-
DO3A (50mM) fails to modulate the insulin secretion evoked by D-glucose 
at low (2.8 mM) or high (16.7 mM) of the hexose. Last, the Pancreatic is-
lets (500), pancreatic islet cells (10.6) and INS1E (10.6) cells were incubated 
during 3hours in the presence of Gd-DO3A (50mM), phantom contains six 
tubes filled with 2% agarose in H2O were prepared, and the MRI experiments 
performed using 9.4T Biospec small animal MRI system (Bruker, Ettlingen, 
Germany). The results show clearly that Gd-DO3A (inactive state) was acti-
vated probably due to GAD which catalyzes the conversion of glutamate into 
the major inhibitory neuron transmitter GABA.
Conclusion: L-glutamate decarboxylase enzyme, which catalyzes the conver-
sion of glutamate seems also catalyze the Gd-DO3A. The enzyme activity is 
highest in the control than diabetic animals. Last, the Gd-DO3A-GAD fails 
to modulate the insulin secretion and didn’t show any toxicity. The present re-
sults support the idea that Gd-DO3A-GAD could be used as a contrast agent 
for non-invasive quantification of beta cell mass.
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How to survive type 1 diabetes - the prolong study
V. Lyssenko1,2, C. Møller1, P. Storm2, W. Poon2, P. Vikman2, L. Groop2,  
P. Rossing1, M. Eliasson3, B. Eliasson4, K. Brismar5, P.M. Nilsson2;  
1Steno Diabetes Center A/S, Gentofte, Denmark,  
2Clinical Sciences, Lund University, Malmö, 3Department of Public Health 
and Clinical Medicine, Umeå University, 4University of Gothenburg, 
5Karolinska Institutet, Stockholm, Sweden.
Background and aims: To successfully prevent and treat diabetes complica-
tions, identification of protective mechanisms is required for a better mecha-
nistic understanding of how the disease develops. PROLONG (PROtective 
Genes in Diabetic Complications and LONGevity) is a cross-sectional study 
of selected type 1 diabetic patients in Sweden and Denmark. The aim is to 
identify genetic markers, biomarkers and lifestyle factors, associated with 
protection from micro- or macrovascular diabetic complications in patients 
with long-standing type 1 diabetes.
Materials and methods: Patients with long diabetes duration (more than 30 
years) with no major diabetic complications (i.e. nephropathy, proliferative 
retinopathy or laser treatment, neuropathy, myocardial infarction, stroke). 
As a comparator group we ascertain patients with early development of dia-
betic complications within 5-20 years of diabetes duration from the same 
geographical regions. DNA exome sequencing performed using Infinium 
HumanOmniExpressExome v1.1 DNA Analysis Kit. RNA sequencing per-
formed using Illumina TruSeq Stranded mRNA Kit.
Results: Presently, 246 patients with type 1 diabetes are enrolled in the 
PROLONG study in Sweden (M/F %, 44/56, mean±SD, duration 38±12 
yrs, HbA1c IFCC 64±14 mmol/mol). Based on hospital records at a diabe-
tes centre in Denmark, we identified ~500 patients (M/F% 49/51, duration 
40±9 yrs, HbA1c IFCC 54±10 mmol/mol) without major diabetic complica-
tions and 225 (M/F%, 50/50, duration 15±4 yrs, HbA1c 71.4±16.8 mmol/
mol) who developed either macro-, or microvascular complications. Cur-
rently, the first DNA exome (n=96) and RNA sequencing analyses (n=96) 
have been completed on the Swedish PROLONG part. In line with previous 
observations in the Golden Years Project (UK), we observed that patients 
with long-standing diabetes without complications have higher HDL choles-
terol (1.87±0.56 vs 1.40±0.45 mmol/l, p=1.8×10-3) and lower triglycerides 
0.78±0.39 vs 1.12±0.46 mmol/l, p=2.9×10-3), and lower heart rate (74.4±10.5 
vs. 83.2±14.7, p=0.001). Notably, we saw no differences in the levels of C-
peptide (p=0.66), systolic (130±17 vs 130±22, p=0.86) or diastolic (89±9 vs. 
92±11, p=0.18) blood pressure between individuals with or without com-
plications. Furthermore, our preliminary analyses of the whole blood RNA 
expression pattern using Gorilla pathway analyses illustrated that sterol me-
tabolism (DHCR24, SQLE, CYP51A1, HMGCS1, MSMO1 genes, etc) (cho-
lesterol and sterol biosynthetic processes, p=9.9×10-7 and p=2.2×10-6; cho-
lesterol and sterol metabolic processes, p=2.4×10-5 and p=4.6×10-5) was the 
top pathway associated with freedom from diabetic complications.
Conclusion: Our preliminary cross-sectional data suggest that patients with 
longstanding diabetes but free of major diabetic complications are charac-
terised by a favourable lipid profile. Analyses are ongoing to verify, as well 
as dissect, the specific genomic markers that significantly differ in the sterol 
metabolism linked to this unique phenotype.
Supported by: Vetenskapsrådet, Novonordisk, Crafoord, HLF, Påhlsson
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Interleukin-15 and interleukin-6 concentrations in autoimmune diabetes 
K. Siewko, R. Maciulewski, A. Zielinska, A. Poplawska-Kita, D. Lipinska,  
M. Gorska, M. Szelachowska;  
Department of Endocrinology, Diabetology and Internal Medicine,  
Medical University, Bialystok, Poland.
Background and aims: Interleukin-15 and -6 (IL-15, IL-6) play a role in an 
inflammation, autoimmune, infectious and cancerous processes. Their in-
creased concentrations were observed in psoriasis, asthma, multiple sclero-
sis and type 2 diabetes. However, the role of IL-15 and IL-6 in autoimmune 
diabetes pathogenesis is still unknown. The aim of our study was to evaluate 
of relationship between IL-15, IL-6 and CRP concentrations in persons with 
newly diagnosis of autoimmune diabetes in compariosn to the first degree 
relatives of autoimmne diabetes and healthy controls.
Materials and methods: The group studied consisted of 54 persons with 
newly diagnosis of autoimmune diabetes (28 with Latent Autoimmune Dia-
betes in Adults (LADA) and 26 with type 1 diabetes (DM1)) and 70 healthy 
first degree relatives of patients with autoimmune diabetes and 60 healthy 
controls. GADA, IAA, IA-2A concentrations were measured by radioim-
munoassays method. IL-15, IL-6 concentrations by ELISA method and CRP 
concentration by immunoturbidimetric method.
Results: We found significantly higher concentrations of IL-15 and CRP in 
the whole diabetes group in comparison to the group of relatives (p<0.001, 
respectively) and controls (p<0,001, respectively) and between relatives 
group and control group (p<0.001, respectively). IL-6 concentration was sig-
nificantly higher in group of diabetes in comparison to the group of relatives 
and controls (p<0.001, respectively). We observed significantly lower IL-6 
concentrations in relatives compared to the controls (p<0.001). In group of 
LADA and DM1 we found significantly higher IL-15 concentration in com-
parison to the group of relatives and controls (p<0.001, respectively). IL-15 
was significantly higher in LADA compared to DM1 (p<0.001). We also ob-
served significantly lower IL-6 concentration in relatives group in compari-
son to LADA and DM1 group (p=0.002, p<0.001). 31 relatives (44.3%) had 
positive concentration at least of one of the antibodies (Ab) against pancreatic 
islet. Relatives with Ab characterized significantly lower IL-6 concentration 
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compared to the relatives without Ab, control group and group of patients 
with LADA and DM1 (p<0.001, respectively). IL-15 and CRP were signifi-
cantly higher in the group of relatives with Ab in comparison to the group 
of relatives without Ab and control group (p<0.001, respectively). In DM1 
and LADA groups we observed positive correlation between IL-15 and CRP 
(r=0.22, p<0.01; r=0.25, p<0.03).
Conclusion: Significantly higher IL-15, IL-6 and CRP concentrations in the 
whole group of diabetes and in the subgroup of LADA and DM1 in com-
parison to the relatives and controls can prove increase risk of cardiovascular 
disease in the patients of newly diagnosis of autoimmune diabetes. However 
lower IL-6 concentration in the group of healthy relatives, especially with 
positive autoantibodies relatives can be marker delaying development of 
diabetes. IL-15 and IL-6 can be a good markers of risk of development au-
toimmune diabetes and IL-15 can be especially sensitivity marker for LADA 
diabetes.
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Beta cell autoantibody positivity is not useful to delineate type 1 diabetes 
in Southeast Asians
S. Rama Chandran, Y.M. Bee, S.Y. Goh, D.S.L. Gardner;  
Endocrinology, Singapore General Hospital, Singapore.
Background and aims: There is a high prevalence of diabetes (DM) (11.3%) 
in Singapore. The estimated fourfold rise in DM prevalence in youth spells a 
grave outlook for the future burden of DM. Young onset diabetes presents a 
wide spectrum of aetiologies: type 1 and 2 diabetes (T1D & T2D), less well-
defined subtypes e.g. latent autoimmune diabetes of adults (LADA) and mo-
nogenic DM. Each subtype portends a unique clinical course, optimum treat-
ment modality and risk of transmission. In Asians, delineating these subtypes 
is challenging; the lower prevalence of β cell autoantibodies (Abs), lower age 
and lower BMI at onset of T2D compared to Caucasians increases this diffi-
culty. Previous studies may not have assessed Abs to more recently discovered 
antigens e.g. Zinc Transporter 8 (ZnT8). Aims: 1. To describe the prevalence 
of β cell and thyroid Abs in a cohort with young onset DM (<45 years). 2. To 
look at the performance of β cell Abs in distinguishing between DM subtypes 
in a group of South-East Asian (SEA) patients.
Materials and methods: n=50 (29F, 21M). SEA patients with young onset 
DM were recruited. Age at onset of DM, and BMI were recorded. Glutamic 
acid decarboxylase (GAD), ZnT8 and thyroid peroxidase (TPO) Abs were 
measured (IASP certified assays). Due to previous reports of low β cell Ab 
positivity in Asian T1D patients, this was not used as a criterion to classify 
DM subtype. Instead, patients were classified as having T2D if they were on 
oral anti-diabetic drugs (OAD) for at least 1 year before commencing insulin, 
were insulin independent or had no episodes of diabetes ketoacidosis (DKA), 
suggesting continued endogenous insulin production. The rest were classified 
as having T1D.
Results: The group was made up of 7 Malay (14%), 3 Indian (6%), and 40 
Chinese (80%) patients. Based on the criteria above, 16 (32%) were classified 
as T1D, 34 (68%) as T2D. T2D patients had a higher BMI (mean 27.4 + 5.1 
vs 23.0 + 3.5, p=0.003) and were older at DM onset (mean 26.0 +9.7 vs 17.3 
+7.3, p=0.003). There was no significant difference in glycaemic control (T1D 
vs T2D : HbA1c 72 vs 76 mmol/mol). 6 of 16 (37.5%) T1D were positive for β 
cell Abs. Surprisingly, 5 of 34 (14.7%) T2D patients were positive for β cell Abs. 
3 of these 5 were overweight/obese (BMI 26-32.1 kg/m2) by Asian standards. 
1 of the 2 remaining β cell Ab positive T2D patients has maintained excellent 
glycaemic control (HbA1c 31 mmol/mol) on just one OAD without insulin 
since diagnosis 3 years ago. TPO positivity was equivalent between T2D and 
T1D (20.6% vs 18.8%). In total, β cell Abs was positive in 11 (22% of cohort). 
GAD Ab positivity (n=10, 20%) was more common; n=4 (8%) had raised 
ZnT8 Ab, 1 of whom was GAD Ab negative. There were no significant differ-
ences in BMI or age of DM onset between Ab positive or negative patients. 4 
had a previous episode of DKA, just 1 of these had positive β cell Abs.
Conclusion: 1. In our cohort of SEA patients, a significant proportion has 
young onset non-insulin dependent DM. They are currently classified as hav-
ing T2D, but may harbour rare variants of monogenic DM, and should be 
assessed further. 2. β cell Ab positivity was found in a significant propor-
tion of T2D patients and its prevalence was low in T1D patients; it did not 
associate with insulin dependence, and did not delineate between clinically 
determined T1D and T2D. 3. Incorporating ZnT8 Ab to GAD Ab measure-
ment did not offer much higher detection rates for β cell Ab positivity. This 
also further implies that autoimmunity may not be the major driving factor 
for β cell loss in Asian T1D patients.
Supported by: SingHealth Foundation Research Grant
PS 009 Old genes, new phenotypes
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Genetic variation related to tolbutamide and GLP-1 stimulated insulin 
secretion converges functionally in protein network space:  
a DIRECT study
H.K. Pedersen1, V. Gudmundsdottir1, A. Jonsson2, L.M. ‘t Hart3,  
K. Banasik4,2, D. Boomsma5, M.M.W. Eekhoff6, T. Hansen2, O.B. Pedersen2, 
M. McCarthy4,7, E. Pearson8, C. Workman1, R. Gupta1, S. Brunak1;  
1Technical University of Denmark, Kgs Lyngby, 2University of Copenhagen, 
Denmark, 3Leiden University Medical Center, Netherlands, 4University of 
Oxford, UK, 5VU University, 6VU University Medical Center, Amsterdam, 
Netherlands, 7Oxford Centre for Diabetes, Endocrinology and Metabolism, 
8University of Dundee, UK.
Background and aims: Most proteins do not perform their biological func-
tion in isolation but rather in conjunction with other proteins in cellular ma-
chines or via interactions in metabolic or signaling pathways. This notion 
gives rise to genetic heterogeneity; the idea that genetic variants in different 
genes might cause identical or similar phenotypes, possibly by converging 
in pathway or network space. In this study we apply a systems biology data 
integration approach to investigate whether genetic variation related to tol-
butamide or glucagon-like peptide-1 (GLP-1) stimulated insulin secretion 
response (ISR) functionally converges in protein network space.
Materials and methods: Genetic variations related to GLP-1 and tolbuta-
mide ISR were identified in two genome-wide association studies (GWAS) in 
the DIRECT consortium; one on 130 individuals who underwent a modified 
hyperglycemic clamp with GLP-1 infusion, and one on 700 non-diabetic in-
dividuals who underwent a tolbutamide-modified IVGTT. Both GWAS were 
adjusted for age, sex, familial relationships and insulin sensitivity. GWAS 
p-values were collapsed to gene-associated p-values using MAGENTA and 
subsequently converted to z-scores. As tissue-specific protein-protein in-
teraction (PPI) networks have previously been shown to outperform global 
networks in disease-gene prioritisation, a β-cell specific PPI network was 
created by pruning high confidence PPIs from InWeb 3.0 using published 
β-cell specific RNAseq data. Strongly connected components in the β-cell 
specific network were identified by ClusterONE. The degree of functional 
convergence of drug-response implicated genetic variation was assessed by a 
complex-based z-score, calculated by summing gene z-scores for all proteins 
in the complex for both drugs. The likelihood of observing a similar degree of 
functional convergence by chance was estimated by calculating the combined 
z-score for 10,000 degree preserving sets of random proteins.
Results: The systems biology approach integrating GWAS-data with a β-cell 
specific PPI network identified a connected component consisting of 34 
proteins, which was significantly enriched for high-scoring genes associated 
with GLP-1- or tolbutamide ISR at p ≤ 1.0e-4. This highly connected pro-
tein complex primarily consisted of guanine nucleotide binding proteins and 
members of the potassium inwardly-rectifying channel, both of which have 
previously been linked to beta-cell function. This result cannot be explained 
by high overlap between genes associated with tolbutamide- or GLP-1 ISR, 
as only two genes where among the top 100 genes for both gene-lists (RAB-
3GAP1 and MYH13).
Conclusion: We have shown that even though the 100 top-scoring genes re-
lated to tolbutamide- and GLP-1 stimulated ISR show limited direct overlap, 
a subset of those converges in a protein complex with a plausible and interest-
ing biological role in insulin secretion.
Supported by: EU IMI-DIRECT project
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Intermediary diabetes mellitus (IDM): a new pathology between 
boundaries
C. Ionescu-Tirgoviste1, P. Gagniuc2, C. Guja1;  
1Diabetes, Nutrition and Metabolic Diseases, „Carol Davila“ University of 
Medicine and Pharmacy,  
2Institute of Genetics, University of Bucharest, Romania.
Background and aims: It is estimated that more than 30% of patients di-
agnosed with non-obesity-related type 2 diabetes may actually have what 
provisionally has been Latent Autoimmune Diabetes of Adults (LADA). Our 
study attempted to clarify the existence of this phenotype by using a new 
method for analyzing the promoters of genes associated with diabetes. Our 
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data shows that gene expression profiles could be the most important lead for 
detecting the primary cause of diabetes.
Materials and methods: In order to perform a generic analysis on gene ex-
pression profiles, we have used a total of 32 promoters of genes associated 
with classical T1D and T2D phenotypes. In order to measure the structural 
features of promoter sequences, we have used our original method of analysis 
based on DNA patterns (BMC Genomics 2012, 13:512). Thus, these DNA 
patterns can identify the transcription factors shared by genes associated 
with one or more phenotypes. Among the analyzed promoters of genes as-
sociated with classical T1D, we mention the HLA-DQA1, HLA-DQB1, 
HLA-DRB1, HLA-DPB1, PTPN22, TLR7, CTLA4, GSDMB, STAT4, IL7R, 
C1QTNF6, CD55, CTSH, ERBB3 and INS gene promoters and for T2D the 
CAMK1D, DUSP9, HHEX, IRS1, MADD, NOTCH2, TP53INP1, VPS13C, 
WFS1, ZFAND6, HMGA2, PPARG, CDKN2AIP, PROX1 and TCF7L2 gene 
promoters (Figure A-C). In order to show the general relationship between 
the three phenotypes, a second distribution was made by using the center of 
weight of the patterns (Figure D-F).
Results: The promoters of genes associated with the two main phenotypes 
of diabetes contain different DNA patterns. T1D promoters exhibit image-
based patterns which show that they are a part of a special class of promoters 
called „AT-based“ (Figure A). The promoters of genes associated with T2D 
exhibit patterns that show they are a part of a special class of promoters called 
„CG-based“ (Figure B). This separation of classes shows that genes associ-
ated with these two phenotypes rarely share transcription factors, therefore 
these genes can not be coexpressed. The third type of pattern is presented by 
a number of genes such as CD55, C1QTNF6, INS, ERBB3, HMGA2, CTSH, 
SLC30A8, CDKN2AIP, PROX1, PPARG, TCF7L2 which suggest a new phe-
notype, an Intermediary Diabetes Mellitus (IDM), (Figure C). The shape of 
these patterns indicate that genes associated with IDM can use transcription 
factors from both phenotypes, further indicating that IDM may contain the 
driver genes for triggering T1D and T2D.
Conclusion: Our current data showed that some promoters of genes associ-
ated with the two main phenotypes of diabetes seem to be associated to a 
third intermediary phenotype (IDM). These new data highlights the hetero-
geneity of different clinical phenotypes of diabetes.
Supported by: CNCS-UEFISCDI Nr. PN-II-ID-PCE-2011-3-0429
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A common variant downstream of PCSK2 is associated with reduced 
tolbutamide stimulated insulin release: a DIRECT study
A. Jonsson1, K. Banasik1,2, A.P. Gjesing1, A. Mahajan2, N. Robertson2,3,  
L.M. ‚t Hart4, E. Pearson5, M. McCarthy2,3, O. Pedersen1, T. Hansen1;  
1The Novo Nordisk Foundation Center for Basic Metabolic Research, 
University of Copenhagen, Denmark, 2Wellcome Trust Centre for Human 
Genetics, University of Oxford, 3Oxford Centre for Diabetes, Endocrinology 
and Metabolism, 4Department of Molecular Cell Biology, Leiden University 
Medical Center, Netherlands, 5Division of Cardiovascular and Diabetes 
Medicine, Medical Research Institute, University of Dundee, UK.
Background and aims: We have previously shown that there is a high herit-
ability of insulin secretion in response to a tolbutamide injection. The aim of 
this study was to perform a genome-wide association study to identify gene 
variants associating with tolbutamide stimulated insulin release.
Materials and methods: A total of 700 non-diabetic individuals, from two 
different cohorts, one family-based and one population-based, underwent 
a tolbutamide-modified frequently sampled IVGTT during which glucose 
was injected at 0 min and tolbutamide at 20 min. Measurements of plasma 
glucose, serum insulin and serum C-peptide were taken at 12 time points 
from fasting to 180 min and insulin secretion rate (ISR) and acute insulin 
response (AIR) were calculated. Genotyping was performed using the Illu-
mina HumanCoreExome BeadChip. Association analyses adjusted for age, 
sex and BMI or age, sex and insulin sensitivity (Si) and separated by cohort 
were performed with EMMAX using the statistical package EPACTS, in or-
der to handle relatedness in the samples. The results were then meta-analyzed 
using the GWAMA software.
Results: The strongest signal for reduced tolbutamide stimulated insulin re-
lease was seen downstream of the PCSK2 gene (AIR BMI adjusted: β=-0.216, 
P=1.6×10-6, AIR Si adjusted: β=-0.134, P=4.2×10-4), which has previously 
been associated with reduced glucose stimulated insulin secretion in humans.
Conclusion: Here we show that the PCSK2 locus, not only associates with 
reduced glucose stimulated insulin secretion as described previously, but also 
shows a strong signal for reduced tolbutamide stimulated insulin release. 
The signal is however not genome-wide significant and further replication is 
needed to confirm the association.
Supported by: EU IMI-DIRECT project
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Exome variation affects metformin treatment response
N. van Leeuwen1, G. Nijpels2, J.M. Dekker2, L.M. ‚t Hart1;  
1Molecular Cell Biology, Leiden University Medical Center,  
2EMGO Institute for Health and Care Research,  
VU University Medical Center, Amsterdam, Netherlands.
Background and aims: Metformin is the first line treatment for type 2 diabe-
tes. However the glycaemic response to metformin is highly variable between 
individuals. A recent study showed that the heritability of the absolute re-
duction in HbA1c was 34% and chromosome-wise heritability estimates sug-
gested that individual genetic variants scattered across the genome account 
for the effect. The aim of our study was the identification of genetic factors 
that influence treatment response to metformin. This will help to optimize 
and personalize treatment in the future and it will give further insight into 
the working mechanism. In this study we focused on genetic variation in the 
exome, the part of the genome that is translated into protein because genetic 
variation in this region has a large a priori chance of being causal.
Materials and methods: Genetic variation was measured in 800 patients on 
metformin therapy from the Diabetes Care System (n>8000), a large longi-
tudinal cohort of Dutch type 2 diabetic patients, using the Illumina Exome 
chip. Twenty-five percent of the patients on metformin therapy did not reach 
the treatment target of an HbA1c ≤53 mmol/l (7%) within one year after 
initiation of therapy and we assessed if this treatment failure was associated 
with genetic variation using logistic regression. In addition we assessed the 
association with the absolute change in HbA1c after one year of treatment 
using linear regression. In both analyses baseline HbA1c, age, BMI, eGFR, 
and sex, metformin dose and metformin dual/mono therapy were included 
as covariates.
Results: Several genetic variants affected the response to metformin treat-
ment in type 2 diabetes patients. The ten most significant gene variants gave 
a 1.7 to 8.5 fold reduced chance of reaching the treatment goal, an HbA1c 
level below 53 mmol/mol and the reduction in HbA1c ranged from 2 to 8 
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mmol/mol per risk allele (p 6.10-6 to 3.10-4). Most of these variants were 
low frequency variants and several were predicted to be damaging by SIFT/
Polyphen2. However, due to the low frequency and power, replication in ad-
ditional cohorts is necessary to reach genome wide significance. This replica-
tion is currently performed.
Conclusion: In this study we have identified a number of gene variants with 
relatively low frequency but a large effect on the metformin treatment re-
sponse suggesting clinical usefulness in personalizing type 2 diabetes treat-
ment. Furthermore, it identifies novel pathways modulating metformin re-
sponse. However, replication in additional patients and cohorts is needed 
before definitive conclusions can be drawn.
Supported by: ZonMW, Priority Medicines Elderly program (project nr. 
113102006)
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Insulin signalling genes exert a combined effect on all-cause mortality
C. Menzaghi1, A. Fontana2, M. Copetti2, S. Rizza3, B. Spoto4, G. Tripepi4,  
A. Marucci1, A. Testa4, F. Mallamaci4, S. De Cosmo5, S. Bacci5, M. Federici3, 
C. Zoccali4, V. Trischitta1;  
1Research Unit of Diabetes and Endocrine Diseases, IRCCS, San Giovanni 
Rotondo, 2Unit of Biostatistics, IRCCS, San Giovanni Rotondo, 3University 
of Rome Tor Vergata, 4Research Unit of Clinical Epidemiology and 
Physiopathology of Renal Disease and Hypertension, CNR-IBIM, Reggio 
Calabria, 5Unit of Endocrinology, IRCCS, San Giovanni Rotondo, Italy.
Background and aims: Type 2 diabetes (T2D) and cardiovascular (CV) dis-
ease are major factors increasing all-cause mortality. Both clinical entities rec-
ognize a common soil represented by insulin resistance (IR), which by itself 
also predicts all-cause mortality. IR is, at least partly, genetically determined. 
Thus, it is concievable that genetic factors, which modulate IR, play also a 
role in modulating T2D, CV desease and all-cause mortality. In fact, we have 
previously reported the combined effect of single nucleotide polymorphisms 
(SNPs) perturbing insulin signaling (ENPP1 K121Q, rs1044498; IRS1 G972R, 
rs1801278; TRIB3 Q84R, rs2295490) on IR and, as a likely consequence, T2D 
and major CV events. Based on these encouraging results, we investigated 
whether a combined effect of these 3 SNPs affects also all-cause mortality.
Materials and methods: We first studied a sample comprising 742 patients 
(i.e. discovery sample; 238 deaths/3,520 person-years; py). Replication was 
assessed in a second sample of 725 diabetic patients (i.e. replication sample; 
129 deaths/5,495 py).
Results: In the discovery sample, weighted genetic risk score (GRS), based on 
each SNP’s effect size, was associated with all-cause mortality (HR=1.12, 95% 
CI=1.03-1.23). After stratification according to low or high genetic load (GL) 
(i.e. 0-1 or > 2 risk alleles), patients with high GL (n=123) were at increased 
risk of all-cause mortality (HR=1.36, 95% CI=1.00-1.86), as compared to 
those with low GL (n=619). In the replication sample, HR (95% CI) for all-
cause mortality was 1.06 (0.94-1.19) for GRS and 1.58 (1.06-2.35) for GL. 
In a pooled analysis (1,467 individuals; 367 deaths) both GRS and GL were 
associated with all-cause mortality HRs (95% CI)=1.11 (1.01-1.22) and 1.41 
(1.10-1.80), respectively.
Conclusion: Our finding indicates that functional non-synonymous variants 
affecting insulin signaling exert a joint effect on all-cause mortality and is 
consistent with a pathogenic role of IR on life expectancy.
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Dissecting the genetic architecture of loci with established effects on 
multiple cardiometabolic phenotypes and type 2 diabetes
L. Marullo1, T.O. Kilpeläinen2, B.K. Cornes3, J. Dupuis4, C. Scapoli1,  
R.J.F. Loos5, J.B. Meigs3, A.P. Morris6, I. Prokopenko7, on behalf of the  
XC-Pleiotropy Group;  
1Department of Life Sciences and Biotechnology, Genetic Section, 
University of Ferrara, Italy, 2The Novo Nordisk Foundation Center for 
Basic Metabolic Research, University of Copenhagen, Denmark, 3General 
Medicine Division, Massachusetts General Hospital, Boston, 4Department of 
Biostatistics, Boston University School of Public Health, 5The Icahn School 
of Medicine at Mount Sinai, New York, USA, 6Department of Biostatistics, 
University of Liverpool, 7Department of Genomics of Common Disease, 
Imperial College London, UK.
Background and aims: Genome-wide association studies (GWAS) have 
identified hundreds of loci associated with Type 2 Diabetes (T2D) or other 
cardiometabolic phenotypes, many of which overlap or map to the same 
genomic interval. Variants associated with multiple phenotypes, such as 
T2D, fasting insulin, triglycerides, HDL-cholesterol and body fat percentage 
influencing variants at IRS1, can provide insight into biology of correlated 
cardiometabolic phenotypes. However, the genetic architecture of these loci 
is frequently complex and needs further investigation.
Materials and methods: To disentangle association patterns of 630 associ-
ated SNPs (Dec 2012) from GWAS meta-analyses in Europeans for 19 quan-
titative phenotypes, T2D and hypertension, we defined sets of adjacent vari-
ants located less than 500kb apart and harboring 446 associated SNPs within 
151 genomic regions (range=2-8 SNPs/region). We undertook approximate 
conditional analyses (ApCA) implemented in the GCTA tool to examine 
whether associations with multiple phenotypes within each region could be 
explained by LD.
Results: Across the 151 regions, we observed 14 (10%) loci in which the 
same SNP was associated with multiple phenotypes. Associations in 11 of 
these 14 loci were with epidemiologically highly correlated traits. Through 
ApCA, we identified 41 (27%) regions with multiple associated variants that 
underlie the same association signals, thus suggesting multi-phenotype ef-
fects. For 19 (13%) regions, the association with one phenotype partially ex-
plained the effect on another. Within 45 (30%) regions, multiple signals were 
explained by multiple non-related variants, whereas the remaining 32 (21%) 
regions showed complex architecture. Of the 44 regions associated with T2D, 
15 contained the same association signal for other cardiometabolic pheno-
types. Within 12 regions, including ANKRD55, SPRY2, DUSP8, PEPD and 
HNF4A, association with other phenotypes were not related to T2D variants. 
For 13 regions we observed complex architecture, while for the remaining 4 
regions, the association with T2D partially explained the effect on another 
cardiometabolic phenotype.
Conclusion: Overall, a substantial number (87 or 58%) of cardiometabolic 
loci, of which 28 T2D loci, show potential pleiotropic effects on multiple 
phenotypes, which might contribute to their shared biology. Within other 
regions, distinct genetic effects or more complex architecture could underlie 
independent regulatory mechanisms.
Supported by: EFSD 
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Genetic risk factors for diabetic complications in patients with  
type 2 diabetes from Ukraine
S. Alkayyali1, W. Poon1, L. Cherviakova2, N. Khalimon2, P. Nilsson4,  
L. Groop1,5, T. Svietleisha6, T. Buldenko6, H. Vasylkova6, V. Lyssenko1,7;  
1Diabetes and Endocrinology, Lund University, Malmö, Sweden, 
2Chernihiv Regional Hospital, Ukraine, 4Clinical Science, Lund University, 
Malmö, Sweden, 5Institute for Molecular Medicine Finland FIMM, 
Helsinki, Finland, 6Public Health Authority of Chernihiv Regional Public 
Administration, Ukraine, 7Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Chronic hyperglycaemia is associated with increased 
risk of progression to macro (cardiovascular diseases) and microvascular 
complications (neuropathy, retinopathy and nephropathy). Recently, ge-
nome-wide association studies have identified a number of genetic loci for 
association with type 2 diabetes (T2D) and cardiometabolic traits. The ef-
fects of some of these genetic variants and the risk of diabetes progression to 
diabetes complications has been investigated in several populations, but has 
never been studied in Ukrainians, a population at high cardiovascular risk.
Materials and methods: We studied the association of a panel of 145 SNPs in 
loci previously reported to be associated with T2D/glycaemic traits (n=75), 
dyslipidemia (n=11), obesity (n=8), hypertension (n=13), cardiovascular 
diseases (CVD) (n=21) and microvascular complications (n=17) in ap-
proximately 3,500 subjects with T2D from the DOLCE study (M/F% 32/68, 
mean±SD, age-at-onset 53.5±10.6 years, BMI 31.4±5.6 kg/m2, diabetes dura-
tion 7.1±7.4 years) (Diagnostic optimization and treatment of diabetes and 
its complications in the Chernihiv region). Effects of genetic loci were studied 
using logistic regression adjusted for sex and age-at-onset for macrovascular 
complications, and sex and diabetes duration for microvascular complica-
tions. The analyses were performed using R software, and genotyping was 
performed using Mass ARRAY iPLEX (Sequenom, San Diego, CA).
Results: We have replicated previous associations of GIPR rs10423928 
(OR=1.29, P=0.005), WDR12 rs6725887 (OR=1.42, P=0.005) and MIA3 
rs17465637 (OR=1.24, P=0.04) with CVD. VEGF rs2010963 (OR=1.28, 
P=0.02) previously reported to be associated with diabetic retinopathy (DR), 
was in our study associated with diabetic nephropathy (DN). The risk C-allele 
in TMEM26 rs1530440 (hypertension locus) was associated with increased 
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CVD risk (OR=1.18, P=0.04) and DN/DR (OR=1.4, P=0.01), while other 
two hypertension loci ATXN2 rs653178 (OR=0.87, P=0.03) and CYP17A1 
rs11191548 (OR=0.75, P=0.03) with decreased CVD risk . Also, the ERBB4 
rs7588550 (DN locus) was associated with increased risk for CVD (OR=1.79, 
P=0.01), while CVD loci PHACTR1 rs12526453 (OR=1.8, P=0.016) and 
PITX2 rs6843082 (OR=1.25, P=0.04) with increased risk for DR and DN.
Conclusion: We have replicated the previous association in GIPR, WDR12 
and MIA3 for risk of CVD. Furthermore, we have demonstrated an associa-
tion between risk alleles for hypertension and T2D/glycaemic traits loci and 
micro-/macrovascular complications. None of the studied BMI or dyslipi-
demia loci were significantly associated with complications in our study.
Supported by: Vetenskapsrådet, Novonordisk, Crafoord, HLF, Påhlsson.
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Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism 
(rs1799987) increases the risk of diabetic nephropathy in Asian type 2 
diabetic patients
Z. Zhang;  
Shandong Provincial Qianfoshan Hospital, Jinan, China.
Background and aims: To evaluate the association of CCR5/CCL5 variants 
with the risk of DN
Materials and methods: We conducted a systematic search of electronic da-
tabases (Pubmed , Embase and China National Knowledge Infrastructure) on 
three genetic variants (CCL5-403 G/A, CCL5-28 C/G, CCR5 59029G/A) and 
then 11 case-control studies involving 2512 DN cases and 2358 non DN con-
trol subjects were identified. The pooled odds ratio (OR) and 95% confidence 
interval (CI) were used to describe the strength of association with DN, the 
subgroup analysis was used to explore the heterogeneity bias among studies. 
Publication bias was tested by the Begg’s and Egger’s test.
Results: In the overall analysis, we found that CCR5 59029A-positive geno-
type (G/A or A/A) was an independent risk factor of DN (OR 1.69, 95% CI 
1.13-2.55). Subgroup analysis demonstrated that the risk of CCR5 59029A-
positive genotype was more significant among Asian patients with type 2 
diabetic nephropathy (OR 2.08, 95% CI 1.68-2.57), but was nonsignificant 
in Caucasians or type 1 diabetes nephropathy (OR 1.23, 95% CI 0.52-2.92 for 
Caucasians; OR 0.82, 95% CI 0.56-1.20 for type 1 diabetes nephropathy). In 
addition, CCR5 59029A-positive genotype was associated with increased risk 
of albuminuria (OR 1.68, 95% CI 1.15-2.44 for microalbuminuria; OR 2.53, 
95% CI 1.05-6.08 for macroalbuminuria). The CCL5 -403 G/A and CCL5-28 
C/G gene polymorphism was not significantly associated with the risk of DN 
(OR 1.00, 95% CI 0.82-1.21 for CCL5-403 G/A; OR 1.02, 95% CI 0.79-1.33 
for CCL5-28 C/G).
Conclusion: Our studies indicated that the CCR5 59029 A gene variant 
is a significant susceptibility factor for DN. Subtype of DM and ethnicity 
might contribute for the inconsistency present in studies. The CCL5 gene 
polymorphism(CCL5-403 G/A, CCL5-28 C/G ) might not be a risk factor 
for DN.
Supported by: CRD42014007495
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Indications for potential parent of origin effects within the FTO gene 
using long range phasing algorithms
X. Liu1,2, M. Scholz3,4, A. Tönjes5, M. Stumvoll1,5, P.F. Stadler2,6, Y. Böttcher1;  
1IFB AdiposityDiseases, 2Bioinformatics Group, Department of Computer 
Science, 3Institute for Medical Informatics, Statistics and Epidemiology, 
4LIFE Research Centre, 5Department of Medicine, University of Leipzig, 
Germany, 6Institute for Theoretical Chemistry, University of Vienna, 
Austria.
Background and aims: Genome-Wide Association Studies (GWAS) were 
successfully applied to discover associations with obesity. However, the 
GWAS design is based on unrelated individuals and clear inheritance infor-
mation of phases is limited. Taking into account parent of origin may provide 
further insights into the genetic mechanisms contributing to obesity. We hy-
pothesized there may be variants within the robustly replicated fat mass and 
obesity associated (FTO) gene that may confer different effect sizes for obesity 
depending on the transmission from father or mother.
Materials and methods: Genome-wide genotypes and pedigree information 
from the Sorbs population (N=525) were used. Phasing was done by applying 
long-range phasing and haplotype library imputation algorithm. Phased gen-
otypes among 525 individuals were generated by AlphaImpute. Subsequently, 
22 SNPs within FTO introns 1 to 3 were selected and parent of origin specific 
association analyses were performed using PLINK: (i) standard association 
test, (ii) considering paternal and (iii) maternal alleles.
Results: We identified several SNPs conferring different P values depending 
on parental origin. Among them, rs1861868, rs1121980 and rs9939973 (all 
intron 1) show significantly different effect estimates beta (Student´s t-Test; 
P<0.05). Of note, rs1121980 tags rs8050136 (r2=0.98) which was well repli-
cated to be strongly associated with BMI. 
Conclusion: Our results suggest that several FTO variants may underlie 
parent of origin effects modulating the risk of obesity. However, due to our 
limited sample size only large effects were detected. Further studies are war-
ranted to investigate FTO.
Supported by: DFG (BO 3147/4-1 to Y.B)
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PARP-1 inhibitor, Olaparib, increases GLP-1 secretion and promotes 
both insulin secretion and TCF7L2 gene expression
Q. Xia1, S. Lu1, B.T. Johnston1, S. McCormack2, S.F.A. Grant1,3;  
1Division of Human Gentics, 2Division of Endocrinology, The Children‘s 
Hospital of Philadelphia, , 3Department of Pediatrics, Perelman School of 
Medicine, University of Pennsylvania, Philadelphia, USA.
Background and aims: TCF7L2 is widely considered one of the most 
strongly type 2 diabetes (T2D) associated loci reported to date, but the patho-
physiologic mechanism by which variation within this gene modulates risk is 
poorly understood. We previously reported the specific protein factors that 
bind across the presumed causal variant at this locus, rs7903146, using oligo 
pulldown followed by mass spectrophotometry, with the most abundant of 
these being poly [ADP-ribose] polymerase type 1 (PARP-1) (Xia et al., 2014). 
PARP-1 has a potential role in the pathophysiology of diabetes, including 
evidence that PARP-1 knockout mice are protected from streptozotocin-
induced diabetes. Proteomic studies have suggested that PARP-1 is also a 
component of the TCF7L2/beta-catenin complex. One important potential 
regulatory target of TCF7L2 is the pro-glucagon gene, which encodes a pre-
cursor of glucagon as well as other factors important for glucose homeosta-
sis, including glucagon-like peptide-1 (GLP-1). We investigated if an existing 
PARP-1 inhibitor developed for oncologic indications, Olaparib, could have 
a GLP-1 agonist effect and thereby suggest regulation of PARP-1 mediated 
GLP-1 activity as one candidate mechanism for TCF7L2-related modulation 
of T2D risk.
Materials and methods: We used the human L-cell line, NCI-H716, for GLP-
1 secretion assessment. Cells were pre-treated with 10uM Olaparib and after 
48 hours the cells were transferred into PBS and incubated with or without 
16mM glucose for 30 minutes, after which the suspensions were collected 
for GLP-1 ELISA. Next, we tested the effect of Olaparib on L-cell mediated 
augmentation of insulin secretion. To do this, we collected the medium from 
the treated NCI-H716 cells and used it to culture the human beta cell line, 
EndoC-BH1, for 30 minutes, after which we measured insulin by ELISA. Fi-
nally, we used real-time PCR to compare relative expression of TCF7L2 in 
NCI-H716 L-cells in the presence and absence of Olaparib.
Results: Treating NCI-H716 cells with glucose increased the release of GLP-
1 into the medium as expected but, interestingly, Olaparib treatment also 
enhanced GLP-1 secretion significantly compared with the untreated group 
(51.1% average increase; P< 0.05). Furthermore, GLP-1 levels were further 
increased in the presence of the combination of glucose and Olaparib, com-
pared with glucose or Olaparib alone (26.0% and 29.4% average increase, re-
spectively; P<0.05).The medium collected from the NCI-H716 cells treated 
with 10uM Olaparib increased insulin secretion over basal levels in EndoC-
BH1 cells (15.2% average increase; P<0.05). We also observed that TCF7L2 
expression in HCI-H716 cells was highly statistically significantly increased 
(21.1% average increase; P<0.01) by Olaparib.
Conclusion: Our results show that inhibition of PARP-1 in NCI-H716 cells 
increases GLP-1 levels and augments glucose-stimulated insulin secretion 
in EndoC-BH1 cells. PARP-1 inhibition also increases TCF7L2 gene expres-
sion in the NCI-H716 cells. Taken together, these observations suggest that 
TCF7L2 modulates T2D risk through its regulation of PARP-1 related GLP-1 
activity. PARP-1 inhibition may represent an avenue for therapeutic interven-
tion for T2D.
Supported by: Pennsylvania Department of Health CURE award
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Defective glucose homeostasis in mice inactivated selectively for Tcf7l2 
in the adult beta cell with an Ins1-controlled Cre
G. da Silva Xavier1, A. Mondragon1, R. Mitchell1, D. Hodson1, J. Ferrer2,  
B. Thorens3, L. Chen4, J. Mcginty4, P. French4, G.A. Rutter1;  
1Cell Biology, 2Epigenomics and Disease, Imperial College, London, UK, 
3Center for Integrative Genomics, University of Lausanne, Switzerland, 
4Physics, Imperial College, London, UK.
Background and aims: Single nucleotide polymorphisms in the TCF7L2 
gene, including rs7903146, are associated with an elevated risk of type 2 dia-
betes in man. Previous studies of the effects of Tcf7l2 deletion in mice have 
provided conflicting results. In the present report we therefore inactivated 
Tcf7l2 specifically in pancreatic beta cells to investigate the cell-autonomous 
role for Tcf7l2 in these cells.
Materials and methods: To achieve highly selective deletion in the adult 
pancreatic beta cell, but not brain or other tissues, we crossed mice bear-
ing flox’d (exon 1) Tcf7l2 alleles to animals in which Cre recombinase was 
expressed from the Ins1 locus. Tcf7l2f/f::Ins1Cre+, and littermate control mice 
were maintained on a C57BL/6 background and on either a normal or a high 
fat (60%; HFD; age 8 - 20 weeks) diet (Research Diet, New Brunswick, NJ, 
USA). Glucose tolerance was assessed by oral and intraperitoneal administra-
tion (1 g/kg body weight) following a 16 h fast, and insulin secretion in vivo 
measured after intraperitoneal injection of glucose (3 g/kg). Insulin secretion 
in vitro was measured from groups of six islets by radioimmunoassay (Mil-
lipore). Quantitiative real-time PCR was performed on islet cDNA on a Fast 
7500 device (ABI) running 7500 software (ABI) and with powerSYBR rea-
gent (ABI). Changes in cytosolic calcium were assessed by Nipkow spinning 
disc confocal microscopy of whole islets loaded with fluo-2. Beta and alpha 
cell mass were assessed by optical projection tomography (19 μm resolution) 
of chemically-clarified pancreata double-stained for insulin and glucagon.
Results: Compared to littermate controls, Tcf7l2f/f::Ins1Cre+ mice displayed 
impaired intraperitoneal glucose tolerance by 16 weeks (increase in AUC of 
13.6 ± 2.8 %, n=6 mice per genotype, p<0.05), and impaired oral glucose 
tolerance (increase in AUC of 10.6 ± 1.3 %, n=6, p<0.05) from 8 weeks. Glu-
cose intolerance was thus apparent earlier than in mice deleted for Tcf7l2 
throughput the pancreas (Tcf7l2fl/fl::Pdx1.Cre+ mice; observed at 20 and 12 
weeks when glucose was administered by the intraperitoneal and oral route, 
respectively). Islets of Langerhans isolated from Tcf7l2f/f::Ins1Cre+ mice at 20 
weeks displayed impaired glucose (p<0.05) and GLP-1-(p<0.05) stimulated 
insulin secretion, and decreased insulin and GLP-1 receptor gene expres-
sion (p<0.01). Similarly, when maintained on a HFD, Tcf7l2f/f::Ins1Cre+ mice 
displayed impaired glucose tolerance, and lower plasma insulin following an 
intraperitoneal glucose tolerance test, than littermate controls, and impaired 
GLP-1 stimulated insulin secretion (p<0.01) and cytosolic calcium increases 
(p<0.03). 20 week-old Tcf7l2f/f::Ins1Cre+ mice that had been maintained on 
HFD for 12 weeks also displayed decreased (n=4, 31.7%, p<0.05) beta cell 
mass, but normal alpha cell mass, compared to littermate controls.
Conclusion: These findings provide further support for the view that type 
2 diabetes-associated Tcf7l2 variants ‎may exert their effects, at least in part, 
through cell autonomous actions on the beta cell. These include impairments 
in Ca2+ signalling, and expansion in response to insulin resistance.
Supported by: MRC, Wellcome Trust, Royal Society, Diabetes U.K.
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RNA editing - an emerging role in diabetes?
J. Sun, P. Spégel, H. Mulder;  
Department of Clinical Sciences, Lund University Diabetes Centre, Malmö, 
Sweden.
Background and aims: The genetic causes of T2D are still poorly understood. 
Previous studies have focused on discovery of genetic and epigenetic risk fac-
tors and gene-environment interactions. Less is known about post-transcrip-
tional regulation of these risk-genes, RNA editing, in particular, which can 
alter genomically encoded information. Recent studies have shown that RNA 
editing may modulate multiple cellular functions. It was estimated that A-to-I 
RNA editing occurs at over a hundred million genomic sites. Hence, it is nec-
essary to reveal the role of RNA editing events in the development of diabetes.
Materials and methods: To obtain putative A-to-I RNA editing events, we 
first built a prediction model based on the Darned database, containing a col-
lection of editing sites from published sequencing data. Next, prediction was 
performed on common variants in the gene body of 104 risk genes for type-
1 diabetes (T1D), type-2 diabetes (T2D), glucose traits and obesity. Finally, 
predicted sites of A-to-I RNA editing were checked in the DIAbetes Genetics 
Replication And Meta-analysis (DIAGRAM) consortium and an expression 
quantitative trait loci (eQTL) resource based on 5 311 human samples.
Results: A-to-I RNA editing events in Darned were mapped to 8 846 genes, 
including 46 genes related to diabetes, e.g., TCF7L2, FTO and ADCY5. GO 
enrichment analysis revealed that 1 540 out of these genes were enriched in 
metabolic processes (p = 1.2e-13). There are 141 042 common variants (dbSNP 
build 138) located in the gene body of 104 diabetes related genes. We de-
cided to keep only single nucleotide variants with reference/alternative allele 
as A/G, G/A, T/C and C/T. This resulted in 89 367 variants, out of which 25 
399 were predicted as putative A-to-I RNA editing sites, using 20 flanking nu-
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cleotides DNA sequences. Notably, 14 of these variants were found in risk loci 
for T1D, T2D, glucose traits and obesity (WFS1, CLEC16A, ZMIZ1, FUT2, 
CAPN10, TAGAP, KCNJ11, SH2B3, CTSH, HNF1B, PRKD2, SLC30A8 and 
KCNQ1), 2 197 were overlapped with DIAGRAM. The top nine loci (p < 
1.0e-30) were found located in TCF7L2, followed by six loci (p < 1.0e-13) in CD-
KAL1. However, most (81%) loci did not show associations with diabetes. 485 
putative sites of RNA editing were cis eQTL of 137 genes and 12 putative sites 
of RNA editing were trans eQTL of 51 genes (false-discovery rate of 0.50).
Conclusion: Our results suggest that RNA-DNA mismatches should be con-
sidered as an important factor in genetic studies of diabetes. The consequenc-
es of editing in risk alleles need to be further examined.
Supported by: Swedish Research Council and Regions Skåne ALF grants
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Global Long Interspersed Nucleotide Element 1 (LINE-1) DNA 
methylation in a longitudinal cohort of type 2 diabetes mellitus patients
N.S. Malipatil1, K. Siddals1, B. Fu2, M. Gibson3, R.P. Narayanan4,  
A.H. Heald5, R. Donn6;  
1Vascular Research Group, 2Centre for Biostatistics, Institute of Population 
Health, University of Manchester, 3Vascular Research Group, Salford 
Royal NHS Foundation Trust, Manchester, 4Department of Obesity and 
Endocrinology, University of Liverpool, 5Department of Medicine, Leighton 
Hospital, Crewe, 6Centre for Musculoskeletal Research, University of 
Manchester, UK.
Background and aims: Epigenetic mechanisms impact gene expression and 
could predispose individuals to a particular metabolic phenotype. Increased 
LINE-1 methylation has previously been associated with cardiovascular risk 
biomarkers in healthy individuals. Here we have investigated, for the first 
time, the relationship between global LINE-1 DNA methylation and cardio-
metabolic parameters in Type 2 Diabetes Mellitus (T2DM) patients. This has 
been conducted using a well characterised longitudinal cohort from Salford, 
UK.
Materials and methods: Global LINE-1 DNA methylation was quantified by 
pyrosequencing in blood-derived DNA samples from 445 Caucasian T2DM 
patients using PyroMark Q96 CpG LINE-1 (Qiagen). The cohort consisted of 
Males 267 and Females 178; mean age 59.4yrs (males 58.7 years, females 60.4 
years), with 7 years of longitudinal data. Global LINE-1 DNA methylation 
was analysed in relation to baseline anthropometric and biochemical meas-
urements and their average changes per year over follow up, using multiple 
linear regression models adjusted for age, body mass index (BMI) and strati-
fied by gender groups.
Results: Methylation at 4 CpG sites was quantified. The mean across the 4 
sites was 75.1% (95% Confidence Interval (CI) 74.83% - 75.33%). There were 
no statistically significant methylation differences by gender (males 75.2%, 
females 74.90% p=0.270) or by age (p=0.679). Linear regression showed no 
significant associations with LINE-1 DNA methylation in the total cohort 
with; BMI [normalised beta coefficient 2.76 (95% CI -13.91 - 19.44, p=0.745)], 
total cholesterol [-1.59 (95% CI -4.02 - 0.83, p=0.198)], triglycerides [-2.77 
(95% CI -6.76 - 1.22, p=0.173)], HDL-cholesterol [0.64 (95% CI -0.55 - 1.83), 
p=0.293] or LDL-cholesterol [-8.9 (95% CI -3.09 - 1.30, p=0.425)], or with 
systolic Blood Pressure (BP) [-22.51 (95% CI -66.75 - 21.28, p=-0.313)] or 
diastolic BP [-17.81 (95% CI -44.00 - 21.28, p=0.313)]. Furthermore, there 
was no association with glycated haemoglobin (Hba1C) [-1.35 (95% CI -5.69 
- 2.98, p=0.540)] at baseline or with average change per year in Hba1C over 
7 years follow up [-0.004 (95% CI -0.014 - 0.006, p=0.443)]; nor with levels 
of high sensitivity C-reactive protein (CRP) [13.57 (95% CI -21.36 - 48.52, 
p=0.445)]. However, stratification by gender revealed significant association 
of global LINE1 DNA methylation in women with LDL levels [-4.52 (95% 
CI -8.23 - 0.80, p=0.017)], with HDL: LDL cholesterol ratio [2.78 (95% CI 
1.02 - 4.53, p=0.002)] and a trend also towards hypomethylation with total 
cholesterol [-3.76 (95% CI -7.87 - 0.34, p=0.072)].
Conclusion: Our findings indicate a gender related difference in global 
LINE1 DNA methylation with specific blood metabolic parameters related to 
cardiovascular risk in type 2 diabetes mellitus.
Supported by: Hodginson Endowment Fund
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Altered DNA methylation and differential expression of genes 
influencing metabolism and inflammation in adipose tissue from 
subjects with type 2 diabetes
E. Nilsson1,2, P. Jansson3, A. Perfilyev1, M. Pedersen4, M.K. Svensson5,  
P. Poulsen6, R. Ribel-Madsen2, N.L. Pedersen7, P. Almgren8, J. Fadista8,  
T. Rönn1, B. Klarlund-Pedersen4, C. Scheele4, A. Vaag2, C. Ling1;  
1Epigenetics and Diabetes, Clinical Sciences, Malmö, Sweden, 2Diabetes 
and Metabolism, Department of Endocrinology, Copenhagen, Denmark, 
3Wallenberg laboratory, Gothenburg, Sweden, 4Infectious Diseases,  
The Centre of Inflammation and Metabolism and the Centre for Physical 
Activity Research, Copenhagen, Denmark, 5Sahlgrenska University 
Hospital, Institute of Medicine, Gothenburg, Sweden, 6Novo Nordisk 
A/S, Global Development, Bagsværd, Denmark, 7Karolinska institutet, 
Department of Medical Epidemiology and Biostatistics, Stockholm, 
8Diabetes and Endocrinology, Clinical Sciences, Malmö, Sweden.
Background and aims: Genetics, epigenetics and environment may together 
affect the susceptibility for type 2 diabetes (T2D). Our aim was to dissect 
molecular mechanisms underlying T2D using genome-wide expression and 
DNA methylation data in adipose tissue from monozygotic twin pairs dis-
cordant for T2D and independent case-control cohorts.
Materials and methods: Genome-wide DNA methylation and mRNA ex-
pression were analysed using the Infinium HumanMethylation450 BeadChip 
from Illumina and GeneChip® Human Gene 1.0 ST arrays from Affymetrix, 
respectively.
Results: In adipose tissue from discordant twin pairs, we found that de-
creased expression of genes involved in oxidative phosphorylation, carbohy-
drate-, amino acid- and lipid metabolism, and increased expression of genes 
involved in inflammation and glycan degradation accompany T2D. The most 
differentially expressed genes included ELOVL6, GYS2, FADS1, SPP1 (OPN), 
CCL18 and IL1RN. We replicated these results in adipose tissue from an in-
dependent case-control cohort. Several candidate genes for obesity and T2D 
(e.g. IRS1 and VEGFA) were differentially expressed in discordant twins. 
We found a heritable contribution to the genome-wide DNA methylation 
variability in twins. Differences in DNA methylation between monozygotic 
twin pairs discordant for T2D were subsequently modest. However, 15,627 
sites, representing 7,046 genes including candidate genes for T2D and obe-
sity showed differential DNA methylation in adipose tissue from unrelated 
subjects with T2D compared with controls. 1,410 of these sites did also show 
differential DNA methylation in the twins discordant for T2D. For the differ-
entially methylated sites, the heritability estimate was 0.28. We also identified 
copy number variants in monozygotic twin pairs discordant for T2D.
Conclusion: Taken together, subjects with T2D exhibit multiple transcrip-
tional and epigenetic changes in adipose tissue relevant to the development 
of the disease.
Supported by: The Swedish Research Council, ALF, EFSD/Lilly, Söderberg, 
Påhlsson, Novo Nordisk
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Diet-induced obesity alters methylation of HOX transcription factors  
in mouse visceral adipose tissue
L. Parrillo1, V. Costa2, R. Esposito2, G.A. Raciti1, G. Porciello1, C. Nigro1,  
P. Mirra1, A. Cozzolino1, C. Miele1, A. Ciccodicola2, F. Beguinot1;  
1DISMET & IEOS-CNR, Federico II University of Naples, 2IGB-CNR, Italy.
Background and aims: Exposure to high-fat regimens induces epigenetic 
modifications which might shape the obesity phenotype. Indeed, recent work 
has revealed altered DNA methylation at several obesity-related genes in 
response to high-fat diets. However, the detailed methylome profiles deter-
mined by high-fat exposure remain to be elucidated. In the present study, we 
have implemented an unbiased genome-wide analysis of DNA methylation 
changes secondary to diet-induced obesity.
Materials and methods: Male C57BL/6J mice were fed either high-fat (HFD) 
or regular chow diets (ND) for 5 months. Methylated DNA immunoprecipi-
tation combined with next generation sequencing (MeDIP-seq) were per-
formed on DNA extracted from the visceral epididymal fat (VF) of the ND- 
and the HFD-fed mice. RT-qPCR and MeDIP-qPCR were then performed on 
the VF of these mice.
Results: Mice fed HFD gained weight (difference with the ND-fed mice sig-
nificant at p<0.001) and developed a significant decrease in their glucose tol-
erance (GTT, p<0.01 vs. ND mice) and insulin sensitivity (ITT, p<0.001 vs 
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ND mice). MeDIP-seq analysis identified differentially methylated regions 
(DMRs) covering with sufficient depth almost the entire genome and showed 
that, in the HFD-fed mice, the number of hypermethylated DMRs was 
higher than that of hypomethylated DMRs. Most DMRs were located within 
gene bodies. Based on subsequent gene ontology analysis of the MeDIP-seq 
data, differentially methylated genes (DMGs) were identified in the HFD-
fed mice. Interestingly, a distinct set of genes belonging to the Homeobox 
(HOX) gene family was found to be epigenetically modulated by chronic 
exposure to HFD (Hoxa1, Hoxa3, Hoxa5, Hoxb3, Hoxb6, Hoxd1, Hoxa13). 
Hoxa5 was selected to validate the significance of this finding by measure-
ment of its promoter methylation status and its gene expression. Results of 
the MeDIP-qPCR analysis (p<0.05) of Hoxa5 were consistent with those gen-
erated by the MeDIP-Seq studies. In addition, the Hoxa5 mRNA expression 
levels were significantly decreased in the VF of the HFD- compared to those 
of ND-fed mice (p<0.05), revealing an inverse correlation with its methyla-
tion state. These changes were accompanied by increased methyltransferase 
Dnmt3a and methyl-CpG binding domain protein Mbd3 mRNA expression 
levels (p<0.05), suggesting that the increased methylation of several genomic 
regions in the HFD-fed mice is mediated, at least in part, by increased expres-
sion of Mbd3 and Dnmt3a.
Conclusion: Our study on a genome-wide scale indicates that, in the mouse 
model, diet-induced obesity is associated with DNA methylation changes in 
VF. DMRs are enriched in genes regulating transcription, including the HOX 
transcription factors. This further finding suggests that an alteration of the 
methylation state of some members of this gene family and their impaired 
transcription may represent a mechanism by which a chronic high-fat feed-
ing impacts on VF functions.
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Environmental exposures modulate Ankrd26 gene expression  
by inducing DNA methylation of its promoter 
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Background and aims: Obesity and Type 2 Diabetes (T2D) represent major 
public health problems, making the need of achieving a better understanding 
of the pathogenesis of these disorders a priority. Similar to genetic polymor-
phisms, epigenetic modifications may alter transcriptional activity, impact on 
obesity and T2D risk and explain, in part, predisposition for these diseases. 
Based on MeDIPseq data, we have identified the Ankyrin repeat domain 26 
(Ankrd26) gene as a target sensitive to environmental exposures. Previous 
work by us revealed that the Ankrd26 gene plays an important role in the 
control of food intake, fat mass and glucose tolerance in rodents. Indeed, 
mice with partial inactivation of this gene develop marked hyperphagia, se-
vere obesity and diabetes. We aimed to investigate whether obesity in vivo or 
elevated free fatty acids (FFAs) in vitro may impact on Ankrd26 gene tran-
scription by causing epigenetic modifications.
Materials and methods: Gene expression was evaluated by Real-time PCR 
analysis in the epididymal white adipose tissue (WAT), the tibialis skeletal 
muscle (SM) and liver (L) from diet-induced obese (DIO) C57Bl/6 mice and 
in 3T3-L1 adipocytes treated for 24, 48 and 96 hours with palmitate (PAL; 
0.25 mM) or oleate (OLE; 0.25 mM). DNA methylation of Ankrd26 promoter 
(CGI:from -726 to -226 bp) was investigated by MeDIP analysis in WAT from 
DIO mice and in PAL treated adipocytes.
Results: Ankrd26 mRNA expression is decreased in WAT and SM but not 
in L from DIO mice (WAT: C 0.509±0.011 AU vs. DIO 0.483±0.008 AU, 
p<0.001; SM: C 0.578±0.019 AU vs. DIO 0.558±0.011 AU, p<0.01; L: C 
0.492±0.023 AU vs. DIO 0.500±0.028 AU). In addition, PAL treatment for 
96 h induces a 20% decrease of Ankrd26 mRNA levels in mature adipocytes, 
as well (C 1.00±0.00 REU, PAL24h 0.95±0.09 REU, PAL48h 1.05±0.08 REU, 
PAL96h 0.82±0.04, p<0.001). No significant effects on Ankrd26 expression 
are observed when cells are treated with OLE. MeDIP analysis shows a 3-fold 
increased immunoprecipitation of a DNA fragment covering a portion of 
Ankrd26 CGI both in WAT from DIO mice and in PAL-treated adipocytes. 
Interestingly, PAL treatment induces a 20% increase of the de novo DNA me-
thyl transferase (DNMT) 3b mRNA expression (C 1.00±0.00 REU, PAL 96h 
1.19±0.03 REU, p<0.01).
Conclusion: Hyper-methylation of Ankrd26 promoter occurs both in vivo in 
WAT from DIO mice and in vitro in PAL-treated adipocytes, and is inversely 
correlated to its mRNA expression. This suggests that environmental expo-
sures impact Ankrd26 transcription by inducing epigenetic changes.
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DNA hyper-methylation of the zink transport (SLC30A8) gene  
is associated with type 2 diabetes in a Malay population
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Background and aims: The solute carrier family 30 member 8 (SLC30A8) 
gene codes for a zinc efflux transporter related to insulin secretion in pancre-
atic beta-cells. Recent genetic studies have demonstrated that the common al-
leles of single nucleotide polymorphisms (SNPs) including rs13266634 (C/T, 
Arg276Trp) and rs11558471 (A/G) in the SLC30A8 gene confer the risk sus-
ceptibility to type 2 diabetes (T2D). But the question regarding whether this 
gene has epigenetic effects in T2D is still remained.
Materials and methods: To address this question, we first replicated genetic 
association study of the SLC30A8 gene in 992 Malay subjects with normal 
glucose tolerance (NGT) and T2D. Genotyping experiments were conducted 
with TaqMan allelic discrimination. Analyses based upon genotypes and 
haplotypes constructed with these two SNPs rs13266634 and rs11558471 
provided compelling evidence of association with T2D in this Malay popula-
tion. We then performed DNA methylation analysis of four CpG sites in the 
SLC30A8 gene promoter with bisulfite pyrosequencing.
Results: The A allele of SNP rs11558471 (A/G) and the common haplotype 
C-A constructed by the major alleles of this polymorphism and rs13266634 
were found to be associated with T2D (P=0.002, OR=1.334, 95%CI=1.110-
1.602; P=0.008, OR=1.233, 95%CI=1.055-1.442). The averaged DNA meth-
ylation levels in the SLC30A8 gene promoter in the Malay cohort were high 
(~78.5%). DNA methylation levels in the SLC30A8 gene were increased in 
T2D patients compared with NGT subjects (79.9%, 95% CI=79.2-80.5% vs. 
77.1%, 95% CI=75.4-78.6%, P=0.001).
Conclusion: The present study demonstrates for the first time that DNA 
hyper-methylation of the SLC30A8 gene is associated with T2D in a Malay 
population and suggests that this gene has epigenetic effects in T2D.
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Visceral fat tissue content and HOMA-IR better predicts type 2 diabetes 
risk than genetic risk score based on 70 SNPs identified by GWAS for 
type 2 diabetes and/or obesity
E. Adamska1, A. Kretowski1,2, J. Goscik3, N. Wawrusiewicz-Kurylonek2,  
M. Paczkowska1, W. Bauer1,2, A. Citko1,2, M. Ciborowski1, D. Lipinska2,  
M. Gorska2;  
1Centre for Clinical Research, 2Department of Endocrinology, Diabetology 
and Internal Medicine, 3Centre for Experimental Medicine, Medical 
University of Bialystok, Poland.
Background and aims: The prevalence of obesity is growing rapidly effecting 
the large increase in type 2 diabetes (T2DM) incidence. To stop this epidemic 
trend it is important to find the method for early prediction of type 2 diabetes 
risk and motivation to begin an early lifestyle intervention. For the personal 
T2DM risk evaluation several factors, such as age, sex, ethnicity family his-
tory are well documented and the data concerning the role of genetic factors 
and gene-environment interaction has been recently accumulated. A precise 
interaction of these risk factors is, however, a complex process that varies 
both within and across populations. The aim of our study was to evaluate the 
role of clinical parameters and recently discovered genetic variants as a mark-
ers for type 2 diabetes for early prediction.
Materials and methods: Study group consisted of 945 Caucasian origin vol-
unteers without previously known disglycaemia collected between 2009 and 
2012 for the prospective 1000PLUS cohort study (463 women and 482 men, 
aged 18-65 years old, mean age 40.4±0.8 yrs). Among the study population 
634 subjects were overweight/obese and 311 people had BMI<25. In all sub-
jects demographic data, anthropometric measurements have been recorded; 
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blood samples at fasting for metabolic (glucose and insulin) and genetic 
analyses were collected. The oral glucose tolerance test (OGGT) have been 
performed and type 2 diabetes was diagnosed based on WHO criteria. Body 
composition: percentage of total body fat, visceral (VAT) and subcutaneous 
adipose tissue (SAT), VAT/SAT ratio were also analyzed by bio-impedance 
method. Genetic risk score (GRS) for each participant was calculated using 
previously identified 70 loci by weighting the number of risk alleles cor-
responding to a particular locus by its effect size (β-estimate) on diabetes 
risk and summing these values. The studied genotypes distributions were in 
Hardy-Weinberg equilibrium (p>0.05).
Results: In the logistic regression analysis the risk of type 2 diabetes develop-
ment was significantly associated with age [OR=1.2 (1.1-1.4), p=2.8x10-6], 
HOMA-IR [OR=1.9 (1.4-2.6), p=1.9x10-5], VAT/SAT ratio [OR=11.4 (2.0-
91.7), p=0.01] and GRS [OR=1.13 (1.05-1.2), p=2x10-5] but not with BMI 
and gender. When particular SNPs were introduced into the regression 
model instead of GRS the strongest association with type 2 diabetes risk 
was found for rs11558471 SLC30A8 (p=0.03), rs226000 PRRC2A (p=0.018), 
rs11708067ADCY5 (p=0.008), rs2844479 AIF1 (p=0.02), rs10938397 GN-
PDA2 (p=0.001), rs7647305 SFRS10 (p=0.01), rs174550 FAD1 (p=0.016), 
rs10946398 CDKAL1 (p<0.04), rs780094 GCKR (p=0.03), rs340874 PROX1 
(p=0.044) assuming the additive model.
Conclusion: We found that visceral fat tissue content and HOMA-IR better 
predict type 2 diabetes risk than the genetic risk score (based on 70 SNPs 
identified by GWAS for type 2 diabetes and/or obesity). However both of 
them, the clinical and genetic factors, allow for better individual prediction 
of type 2 diabetes.
Supported by: MNiSW 4774/B/P01/2009/37
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Mutation in APPL1 gene may contribute to familial diabetes mellitus
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Background and aims: Familial, apparently autosomal dominant, early-on-
set forms of diabetes mellitus of the adulthood that are negative for mutations 
in known MODY genes have been repeatedly described. Except that for their 
age of onset, these forms of diabetes resemble classical type 2 diabetes (T2D), 
thereby suggesting that they are due to mutations in genes modulating insu-
lin sensitivity and/or the fine tuning of insulin secretion rather than in genes 
playing a central role in insulin synthesis/ secretion, as is the case for MODY. 
The aim of this study was to identify genetic causes of these forms of diabetes.
Materials and methods: To accomplish this aim, whole exome sequencing 
was carried out in probands from 59 families from Italy and the US. New 
identified mutations were studied by transfection in HepG2 cells followed by 
evaluation of mRNA and protein expression levels along with insulin-stimu-
lated Akt2-ser473 and GSK3β-ser9 phosphorylation.
Results: Two mutations in the APPL1 gene (a L552X stop-codon and a D94N 
missense mutation), showing segregation with diabetes, were found in two 
different families. Neither mutation had been previously reported in publicly 
available databases. APPL1 binds to Akt2 and positively modulates insulin-
mediated Akt2 activation and downstream signaling, which is involved in 
both insulin action and secretion. Accordingly, APPL1 ablation causes in-
sulin resistance and impaired glucose homeostasis in mice. X552 totally 
abolished APPL1 protein (but not mRNA) expression, consistent with its be-
ing a stop-codon mutation. N94 APPL1 was expressed at the same level as 
WT APPL1; however, it caused significant reduction in the enhancement of 
insulin-stimulated of Akt2 and GSK3β phosphorylation observed after WT 
APPL1 transfection as compared to un-transfected cells, therefore behaving 
as a loss of function mutation. Both mutations were absent in 2970 T2D pa-
tients and in 1639 control subjects.
Conclusion: This is the first evidence of APPL1 mutations contributing to 
familial forms of diabetes mellitus of the adulthood and reaffirms the critical 
role of this gene in glucose homeostasis.
Supported by: Italian Society of Diabetology; NIH grant R01 DK55523
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Enhanced transcriptional activity of the K392R mutant form of STAT3 
found in a patient with early onset diabetes is not fully dependent on 
phosphorylation of Tyrosine-705
M.A. Russell1, S.E. Flanagan1, S. Ellard1, T. Otonkoski2, A.T. Hattersley1, 
N.G. Morgan1;  
1Institute of Biomedical and Clinical Science, University of Exeter Medical 
School, UK, 2Molecular Neurology and Biomedicum Stem Cell Centre, 
University of Helsinki, Finland.
Background and aims: We have recently reported a series of 4 novel activat-
ing germline mutations in STAT3 among patients exhibiting an early onset 
poly autoimmune syndrome including autoimmune diabetes. In the current 
study we have explored the molecular basis of the enhanced activity of one of 
these activating mutants, K392R.
Materials and methods: Wildtype (WT) and mutant (K392R) STAT3 were 
generated and transfected transiently into HEK293 cells. In addition, stable 
INS-1E cells were also created expressing these constructs under the control 
of a tetracycline inducible promoter. Transcriptional activity was assessed us-
ing a STAT3-responsive reporter construct while total and phosphorylated 
STAT3 were detected by Western blotting.
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Results: Transfection of WT and mutant (K392R) STAT3 into HEK293 cells 
resulted in equal levels of protein expression but differing levels of transcrip-
tional activation. Notably, the K392R mutant dramatically increased STAT3 
reporter activity relative to the WT (by 37.1±4.7 fold; p<0.01). Enhanced 
reporter activity was also observed in INS-1E cells expressing K392R al-
though the absolute increase was smaller than in HEK293 cells (4.0±0.4 fold; 
p<0.01). Classically, STAT3 activity is regulated mainly by phosphorylation at 
Tyr 705 but the extent of phosphorylation of this residue was only modestly 
increased in the mutant under unstimulated conditions (3.1±0.6 fold vs WT; 
p<0.05) despite its markedly enhanced transcriptional activity. Addition of 
IL-6 (20ng/ml) resulted in an increase in STAT3 activity in cells expressing 
either WT or K392R, although the increase was much greater for the mutant 
(a further 7.3±1.4 fold enhancement above that seen in WT cells stimulated 
with IL-6; p<0.05). IL-6 also further increased the extent of phosphoryla-
tion of Tyr 705 in both WT STAT3 and in the K392R mutant. The increased 
STAT3 activity of K392R was reduced, but not abolished, by pharmacological 
inhibition of the upstream kinase Jak which promotes phosphorylation of 
Tyr 705 (fold change from WT: K392R - 30.7±8.4, K392R + Jak inhibitor - 
6.0±0.8 p<0.05) suggesting that the enhanced activity is not dependent fully 
on Tyr 705 phosphorylation. To further assess the importance of this residue, 
Tyr 705 was replaced by phenylalanine (Y705F) to create a double mutant 
(K392R/Y705F). This was less active than K392R in reporter assays but, de-
spite the loss of Tyr 705, it still retained enhanced transcriptional activity in 
both the absence or presence of IL-6 (p<0.01).
Conclusion: The constitutively active K392R germline mutation of STAT3 
found in a patient with poly autoimmune syndrome and early onset diabe-
tes, induces a strong transcriptional activation which may contribute to the 
autoimmunity. The mechanism of activation is atypical and does not depend 
solely on increased phosphorylation of Tyr 705.
Supported by: EU Framework 7 (PEVNET)
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Background and aims: Mutations in the glucokinase (GCK) gene cause a 
spectrum of glycaemic disorders. Homozygous loss-of-function mutations 
are rare and cause permanent neonatal diabetes (GCK-PNDM) requiring 
lifelong insulin treatment. Heterozygous loss-of-function mutations cause 
mild fasting hyperglycaemia irrespective of mutation severity due to com-
pensation from the unaffected allele.
Materials and methods: We determined the relationship between in vitro 
mutation severity and clinical phenotype in a large international case series 
of patients with homozygous GCK mutations.
Results: Clinical characteristics for 30 patients with diabetes due to homozy-
gous GCK mutations (19 unique mutations, including 16 missense) were 
compiled and assigned a clinical severity grade (CSG) based on birth weight 
and age-at-diagnosis. The majority (28/30) of subjects were diagnosed by 9 
months of age, with the remaining two in adolescence. These are the first 
two cases of a homozygous GCK mutation diagnosed outside the neonatal 
period. Recombinant mutant GCK proteins were analysed for kinetic and 
thermostability characteristics and assigned a relative activity index (RAI) or 
relative stability index (RSI) value. Six of the 16 missense mutations exhibited 
severe kinetic defects (RAI≤0.01). There was no correlation between CSG 
and RAI (r2=0.02, p=0.65), indicating that kinetics alone did not explain the 
phenotype. Eighty percent of the remaining mutations showed reduced ther-
mostability, the exceptions being the two adolescent-onset mutations which 
exhibited increased thermostability. Comparison of CSG with RSI detected a 
highly significant correlation (r2=0.63, p=0.006).
Conclusion: Within the largest case series to date we demonstrate that ho-
mozygous GCK mutations can cause adolescent-onset diabetes. Protein in-
stability is the major determinant of mutation severity.
Supported by: Wellcome Trust / NIHR
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in HNF1 MODY and GCK MODY: results of a replication study
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Background and aims: Cystatin C is a marker of glomerular filtration rate 
(GFR). Its level is dependent on the concentration of CRP (C-Reactive Pro-
tein), which is decreased in diabetic patients with an HNF1A-MODY. We 
examined previously the cystatin C as a biomarker for the HNF1A-MODY 
with inconsistent results and showed that the cystatin C-based GFR estimate 
is higher than the creatinine-based one. Currently, we aimed to perform a 
replication study using a new cohort of HNF1A-MODY patients and, addi-
tionally, glucokinase (GCK) MODY subjects.
Materials and methods: The study included 63 patients with HNF1A-MODY, 
70 with GCK-MODY, 44 type 1 diabetes (T1DM), 47 type 2 diabetes (T2DM) 
patients and 61 subjects without diabetes. Creatinine was measured using 
Roche P800 analyzer (Roche Diagnostics, Burgess Hill, UK). The level of cys-
tatin C and CRP was determined using enzyme immunoassay. GFR was calcu-
lated from the following: the creatinine with the CKD - EPI formula, and from 
cystatin C with the 4-variable formula. Statistical analysis to determine the dif-
ference between two (t- student) and several groups (ANOVA with post-hoc 
tests) was used. If necessary, non-parametric tests were utilized as equivalents. 
Differences in the level of cystatin C between groups (GCK-MODY, HNF1A-
MODY, control, T2DM, T1DM) were adjusted for gender, age, BMI and 
estimated GFR (creatinine) and determined by analysis of covariance (AN-
COVA). Statistical analyzes were performed using STATISTICA software 10.0.
Results: Cystatin C level in post-hoc analysis (Scheffe test) was significantly 
lower (p<0.0001) in the control group (0,73 mg/l ±0,14), HNF1A-MODY 
(0,74 mg/l ±0,21) and GCK-MODY (0,71 mg/l ±0,15) when compared to 
patients with T1DM (0,90 mg/l ±0,15) and T2DM (0,96 mg/l ±0,24). The 
differences between the groups became borderline after adjustment for the 
gender, BMI, age and eGFR. Comparison of GFR estimated from the creati-
nine level (CKD-EPI) with GFR from cystatin C (CysC eGFR) has shown no 
difference inT2DM and control group (p=0.6938). T1DM patients had sig-
nificantly higher CKD-EPI than CysC eGFR (p=0.0002). An inverse relation-
ship was observed in MODY patients: CysC eGFR was significantly higher 
compared to the CKD-EPI in both GCK (p=0,031) and HNF1A (p=0,0143) 
MODY patients.
Conclusion: We confirmed that GFR value estimated from cystatin C level 
in MODY patients is significantly higher compared to GFR estimated from 
creatinine. Interestingly, a similar finding was identified in GCK-MODY. 
However, Cystatin C was not a good biomarker to differentiate between vari-
ous types of diabetes.
Supported by: ODW-5224/B/P01/2011/40
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Intima - media thickness and endothelial dysfunction in GCK  
and HNF1A MODY patients
G. Osmenda, M. Szopa, G. Wilk, B. Matejko, I. Solecka, T. Guzik,  
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Background and aims: Mutions in the GCK (glucokinase) gene are, along 
with the HNF1A gene mutations, the most frequent cause of MODY (matu-
rity onset diabetes of the young). Heterozygous loss-of-function GCK muta-
tions result in a mderate fasting hyperglycemia. The GCK-MODY patients 
are usually free from microvascular complications; however, little is known 
about atherosclerosis and intermediate related phenotypes. We aimed to 
examine intima-media thickness (IMT) and endothelial function in GCK-
MODY and HNF1A-MODY compared with controls.
Materials and methods: 66 GCK-MODY, 50 HNF1A-MODY patients and 54 
non-diabetic controls were examined. Carotid artery IMT and brachial artery 
FMD and NMD (nitroglycerin mediated dilatation) were assessed by ultra-
sonography. These parameters were compared with test for difference between 
two groups (t-test or U Mann Whitney test) or three groups (one way analysis 
of variance ANOVA or the Kruskal-Wallis test with post hoc test).
Results: The average maximum IMT was different among three groups - 
0.71±0.17 mm in GCK-MODY, 0.77±0.15 in HNF1A-MODY, and 0.71±0,15 
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in the controls (p=0.0041). In post hoc analysis maximum IMT for GCK-
MODY was statistically different from HNF1a MODY (p=0.0371) Mean IMT 
were as follow - 0.62±0.14 mm in GCK-MODY, 0.68±0.13 in HNF1A-MODY 
and 0.63±0.13 in controls (p=0.0077). Post hoc analysis showed a difference 
between GCK-MODY and NF1A-MODY (p=0.0108). The mean FMD% was 
11.0±4.5% in GCK-MODY, 10.1±4.9 in HNF1A-MODY and 13.9 ±4.8 in 
the controls (p=0.0001). The differences between CK-MODY and HNF1A-
MODY vs. controls were significant (p=0.0045, p=0.0001, espectively). ‚I was 
similar in all three groups - 24.1±4.5, 24.1±3.7 nd 24.2±3.6 in GCK-MODY, 
HNF1A-MODY and controls, respectively (p=0.7876). Patients were diag-
nosed with diabetes at similar age (GCK-MODY: 25.1±13.5 yrs vs. HNF1A-
MODY: 26.6±11.6, =0.4669). Glycemic control was similar in diabetic groups 
as in the GCK-MODY roup the mean HbA1c was 6.4%±0.7, while in HNF1A-
MODY patients it reached 6.7±1.4 (p=0.6936).
Conclusion: Both examined MODY grups showed evidence of early athero-
sclerosis or endothelial dysfunction. Mild hyperglycemia in the GCK-MODY 
seems to have a fragile impact on the ccurrence of intermediate atheroscle-
rotic phenotypes.
Supported by: ODW-5224/B/P01/2011/40
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Clinical features of MODY-HNF1a in children and adolescents  
with obesity
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Background and aims: to study clinical features of MODY-HNF1a in chil-
dren and adolescents with obesity.
Materials and methods: 18 patients who had heterozygous mutation in HN-
F1a gene were divided into 2 groups: group 1 - the patients with SDS BMI ≥ 
2 (n=6; 33.3%); group 2 - the patients with SDS BMI< 2 (n=12; 66.6%). We 
measured fasting and stimulated glucose, C-peptide, insulin levels (OGTT). 
The data is presented as medians (25; 75 percentile), Mann-Whitney U-test 
was used to compare medians.
Results: Age at diagnosis of diabetes: in group 1 was 10.4 years (9.5;14.4), in 
group 2 was 12.8 years (10.9;15.4), p<0,05. Diagnosis of diabetes in group 1: 
33.3% of patient were investigated due to suspected diabetes cases because 
of family history, 33.3% of patient were investigated due to obesity, 33.3% of 
patient had the clinical features of diabetes; diagnosis of diabetes in group 2: 
16.7% of patient were investigated due to suspected diabetes cases because of 
family history, 75% of cases were diagnosed occasionally, 8.3% of patient had 
the clinical features of diabetes. At the diagnosis HbA1c: in group 1 was 7.3% 
(6.8; 7.9); in group 2 was 6.5% (6.3; 8); (p>0.05). 100% patients in group 1 and 
91,6% patients in group 2 had family history of diabetes; one of the parents 
had insulin dependent diabetes mellitus (66.6% and 25%, respectively group 
1 and group 2), non insulin dependent diabetes mellitus (16.65% and 58.3%, 
respectively group 1 and group 2), gestational diabetes mellitus (16.65% and 
8.3%, respectively group 1 and group 2). Disease duration was 3 years (1.1; 
4.5), when diagnosis MODY- HNF1a was confirmed. We indentified the novel 
mutations: D45fs, V119G, R229X, S249Stop. The most common Pro291 fsin-
sC mutation was indentified in 5 cases (27.7%). Clinical data is presented in 
Table 1. Patients in group 1 had significantly higher HbA1c and fasting serum 
C-peptide. Two patients in group 1 were insulin resistant. Patients in groups 1 
and 2 were treated with sulfonylurea (50% of all patients) and metformin (50% 
and 8%, respectively). 42% patients in group 2 were treated with diet only.
Conclusion: MODY-HNF1a may be combined with obesity and in some 
cases with insulin resistance in children and adolescents. Obesity is a risk 
factor for early manifestation and more severe diabetes. Patients in group 1 
had higher C-peptide secretion. DNA testing of patient with mild diabetes, 
obesity and family history of diabetes could lead to diagnosis of new cases of 
MODY-HNF1a.
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Transcription activity testing can aid bioinformatics in ascribing 
pathogenicity to HNF1A variants identified by genomic sequencing  
in population-based cohorts
I. Aukrust1,2, L.A. Najmi1,3, J. Molnes1,4, J. Flannick4, N.P. Burtt4,  
A. Molven1,5, L. Groop6, D. Altshuler4, S. Johansson1, L. Bjørkhaug1,  
P.R. Njølstad1,7;  
1KG Jebsen Center for Diabetes Research, Dept of Clinical Science, 
University of Bergen, 2Dept of Biomedicine, University of Bergen, 3Center 
for Medical Genetics and Molecular Medicine, Haukeland University 
Hospital, Bergen, Norway, 4Program in Medical and Population Genetics, 
Broad Institute of Harvard and Massachusetts Institute of Technology 
(MIT), Cambridge, USA, 5Gade Laboratory for Pathology, Dept of Clinical 
Medicine, University of Bergen, Norway, 6Dept of Clinical Sciences, 
Diabetes and Endocrinology, Clinical Research Centre, Lund University, 
Malmö, Sweden, 7Dept of Pediatrics, Haukeland University Hospital, 
Bergen, Norway.
Background and aims: In a population sample of randomly selected indi-
viduals from 3 different cohorts, as much as 2% carry rare non-synonymous 
variants in 1 of 7 maturity-onset diabetes of the young (MODY) genes. Inter-
estingly, the majority of these individuals remain euglycemic through middle 
age. To evaluate their risk for T2D later in life, detailed analyses are required 
to determine the true pathogenic nature of these MODY gene variants, in ad-
dition to family pedigrees/phenotype analyses combined with bioinformatics 
in silico tools. Our aim is to test whether functional characterization of 25 rare 
variants (MAF<1%) in the hepatocyte nuclear factor 1 alpha (HNF1A) gene 
identified in randomly selected population cohorts, can aid bioinformatics to 
determine whether the variant is pathogenic or not.
Materials and methods: We classified the HNF1A variants into 5 groups: 1, 
not pathogenic; 2, likely not pathogenic; 3, uncertain; 4, likely pathogenic; 
5, definitely pathogenic, by the mutation analysis tools PolyPhen-2, AlignG-
VGD og SIFT. Transactivation (TA) of HNF-1A (wild-type and mutants) was 
measured by luciferase assays of transient transfected HeLa cells. Protein ex-
pression levels were confirmed by immunoblotting. Investigations of their 
DNA binding ability (by electrophoretic mobility shift assay) and subcellular 
localization are pending.
Results: Of 25 HNF1A variants, none were in class 5, 2 were in class 4, 14 in 
class 3 and 9 in class 2. Three variants had transcriptional activity of 0-40%, 
and all were associated with diabetes (two were in class 4). Four variants had 
transcriptional activity of 70-100%, all were class 2 or 3. Three of these were 
not associated with diabetes, while one was found both in diabetic and non-
diabetic individuals. Eighteen variants had transcriptional activity of 40-70%, 
6 were associated with diabetes, the others not.
Conclusion: Functional characterization by measurement of transcriptional 
activity for 25 HNF1A rare variants can supplement bioinformatics in ascrib-
ing pathogenicity, and seems to be most helpful for variants in class 3.
Supported by: KG Jebsen, Bergen University, Helse Vest, ERC, Swedish Research 
Foundation
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Endocytosis of secreted carboxyl-ester lipase protein in CEL-MODY,  
a syndrome of diabetes and pancreatic exocrine dysfunction
M. Dalva1,2, K. Fjeld1,2, J. Torsvik1, P.R. Njølstad1, B.B. Johannson1,2,  
A. Molven3,4;  
1KG Jebsen Center for Diabetes Research, Department of Clinical Science, 
University of Bergen, 2Center for Medical Genetics and Molecular 
Medicine, Haukeland University Hospital, 3Gade Laboratory for Pathology, 
Department of Clinical Medicine, University of Bergen, 4Department of 
Pathology, Haukeland University Hospital, Bergen, Norway.
Background and aims: The carboxyl-ester lipase (CEL) gene, encoding the 
pancreatic enzyme CEL, is highly expressed in the pancreatic acinar cells. A 
dominant-acting frame-shift mutation (c.1686delT) in the last exon of CEL 
causes CEL-MODY (MODY8), a disease characterized by diabetes and pan-
creatic exocrine dysfunction. The resulting mutant CEL protein (CEL-MUT) 
has an altered, repetitive C-terminus leading to a higher tendency to aggre-
gate and to undergo endocytosis as compared with the wild-type CEL protein 
(CEL-WT). We aimed to investigate the cellular reuptake of the mutant CEL 
protein and characterize its effect on cellular functions in acinar and β-cell 
models.
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Materials and methods: HEK 293 cells stably expressing CEL-MUT and 
CEL-WT proteins were used to produce conditioned medium for use in 
endocytosis studies in acinar cells (rat AR42J and mouse 266-6) and β-cell 
models (rat INS-1E and mouse MIN6). We employed immunofluorescence 
confocal microscopy and assays of cell viability and glucose-stimulated insu-
lin secretion.
Results: In stably transfected HEK293 cells, CEL-MUT was distributed in 
a cytoplasmic punctate pattern, whereas the CEL-WT predominantly local-
ized typically for secreted proteins in the Golgi compartments and the endo-
plasmic reticulum. When untransfected acinar cells and β-cells were grown 
in conditioned medium from CEL-expressing cells, an accumulation of the 
CEL-MUT protein was observed in punctate structures. Long-term incuba-
tion of acinar and β-cells in conditioned medium showed a tendency, how-
ever not significant, of lower viability in the presence of CEL-MUT compared 
with CEL-WT. Glucose-stimulated insulin secretion in MIN6 cells was not 
reduced in the presence of the mutant protein.
Conclusion: Our results suggest that CEL-MUT can be endocytosed both 
by acinar and β-cells. The endocytic process might represent a mechanism 
of protecting cells against the exposure to CEL aggregates by cell-mediated 
uptake and degradation of the potentially toxic protein. Furthermore, endo-
cytosis could be directly relevant for how the CEL-MUT causes disease af-
fecting both the exocrine and endocrine pancreas.
PS 012 Monogenic diabetes  
across the world
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Wolfram syndrome in the Japanese population: molecular analysis  
of the WFS1 gene and characterisation of clinical features
Y. Tanizawa, K. Matsunaga, K. Tanabe, on behalf of the Japan study group 
of Wolfram syndrome;  
Division of Endocrinology, Metabolism, Hematological Science and 
Therapeutics, Yamaguchi University, Graduate School of Medicine, Ube, 
Japan.
Background and aims: Wolfram syndrome (WFS) is a recessive neurologic 
and endocrinologic degenerative disorder, and is also known as DIDMOAD 
(Diabetes Insipidus, early-onset Diabetes Mellitus, progressive Optic Atrophy 
and Deafness) syndrome. Most affected individuals carry recessive mutations 
in the Wolfram syndrome 1 gene (WFS1). However, the phenotypic pleio-
morphism, rarity and molecular complexity of this disease complicate our 
efforts to understand WFS. To address this limitation, we aimed to describe 
complications and to elucidate the contributions of the WFS1 mutations to 
clinical manifestations in patients with WFS.
Materials and methods: The minimal ascertainment criterion for diagnos-
ing WFS was having both early onset diabetes mellitus (DM) and bilateral 
optic atrophy (OA). Genetic analysis for the WFS1 was performed by direct 
sequencing.
Results: Sixty-seven patients were identified nationally for a prevalence of 
one per 710,000, with 33 patients (49%) having all 4 components of DID-
MOAD. In 40 subjects who agreed to participate in this investigation from 
30 unrelated families, the earliest manifestation was DM at a median age of 
8.7 years, followed by OA at a median age of 15.8 years. However, either OA 
or DI was the first diagnosed feature in 6 subjects. In 10, features other than 
DM predated OA. Twenty-seven patients (67.5%) had a broad spectrum of 
recessive mutations in the WFS1. Two patients had mutations in only one 
allele. Eleven patients (27.5%) had intact WFS1 alleles. Ages at onset of both 
DM and OA in patients with recessive WFS1 mutations were indistinguish-
able from those in patients without WFS1 mutations. In the patients with 
predicted complete loss-of-function mutations, ages at the onsets of both 
DM and OA were significantly earlier than those in patients with predicted 
partial-loss-of function mutations.
Conclusion: This study emphasizes the clinical and genetic heterogeneity in 
patients with WFS. Genotype-phenotype correlations may exist in patients 
with the WFS1 mutations, as demonstrated by the disease onset.
Supported by: Grants from MHLW and MEXT of Japan
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Czech prediction programme for type 1 diabetes: additional source of 
MODY patients?
P. Dusatkova, L. Petruzelkova, S. Pruhova, J. Vcelakova, K. Stechova,  
O. Cinek, Z. Sumnik, J. Lebl, S. Kolouskova;  
Department of Pediatrics, 2nd Faculty of Medicine, Prague, Czech Republic.
Background and aims: Since 2001, we prospectively follow up first-degree 
relatives of patients with Type 1 Diabetes (T1D) in the Czech Prediction Pro-
gramme. Monogenic forms of diabetes, in particular Maturity-Onset Diabe-
tes of the Young (MODY), are estimated to be responsible for 1-2% of all 
patients with diabetes. However, the MODY occurence could be largely un-
derestimated because it bears several clinical features common to other types 
of diabetes. We aimed to search for families with MODY among participants 
of Prediction Programme for T1D having positive family history of diabetes.
Materials and methods: First-degree relatives of patients with T1D are in-
vestigated for HLA-DQ genotype and annualy screened for pancreatic au-
toantibodies (IA-2Ab, GADAb, IAA). Among 557 families included in the 
Prediction Programme for T1D, a positive family history of diabetes (at least 
2 affected family members) was reported in 53 families (9.5%). In these fami-
lies, one proband with diabetes was chosen for mutation screening of most 
prevalent MODY genes (GCK, HNF1A, HNF4A and INS) by direct Sanger 
sequencing.
Results: Of the 53 families with positive family history of diabetes in the 
Prediction Programme for T1D, 24 (45%) were genetically diagnosed with 
MODY. This makes up 4% of all the families from the Prediction Programme 
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for T1D. The most frequent mutations in our study were detected in the GCK 
(58%), followed by HNF1A (38%) and INS (4%) genes. The family-specific 
mutations were subsequently observed in 25/27 (93%) participants (first-de-
gree relatives of patients with T1D) studied in the Prediction Programme for 
T1D: they were asymptomatic with exception of two children with HNF1A-
MODY who presented osmotic symptoms (polyuria, polydipsia) during the 
follow up requiring insulin treatment which could be switched to administra-
tion of suplhonylurea derivates. Comparing MODY to non-MODY families 
with positive family history of diabetes, mothers of subjects in the Prediction 
Programme had more often diabetes than fathers and siblings (p<0.0001), 
the pancreatic islet autoantibodies were absent in all subjects with MODY 
(p=0.009) and the risk DQA1 and DQB1 alleles were less frequently seen 
in children from MODY families followed in the Prediction Programme 
(p=0.02).
Conclusion: This systematic search for MODY patients in the Prediction 
Programme for T1D has shown that monogenic diabetes accounts for a sub-
stantial number of cases with diabetes which could be higher than estimated 
previously. MODY should be considered in all families with history of diabe-
tes because they may benefit from the optimalization of the therapeutic op-
tions, prediction of disease prognosis and identification of diabetes risk in 
family members.
Supported by: Czech Ministry of Health (NT11402).
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MODY is uncommonly diagnosed in the South Asian ethnic group as a 
result of difficulty in differentiating young-onset type 2 diabetes from 
MODY
S. Misra1, B. Shields2, K. Colclough3, D.G. Johnston1, N.S. Oliver1, S. Ellard3, 
A.T. Hattersley2;  
1Diabetes, Endocrinology & Meabolism, Imperial College London,  
2NIHR Exeter Clinical Research Facility, University of Exeter,  
3Molecular Genetics, Royal Devon & Exeter NHS Foundation Trust, 
UK.
Background and aims: Maturity onset diabetes of the young (MODY) has 
been extensively described in white-European (WE) populations, however 
comparatively few cases have been found in other ethnic groups. It is unclear 
if this reflects a genuinely lower prevalence of MODY in other ethnic groups 
or a disparity in testing-rates. We examined South Asian (SA) referrals for 
MODY testing in the UK.
Materials and methods: A retrospective cross-sectional analysis of UK pa-
tients referred for MODY genetic testing was undertaken (HNF1A, HNF4A 
and GCK). Ethnic origin, results of genetic analyses and clinical and bio-
chemical characteristics were examined on all referrals, and sub-analysed by 
mutation result.
Results: 26 SA and 836 WE patients had mutations in one of the common 
MODY genes (HNF1A, HNF4A and GCK). This low SA prevalence of ge-
netically confirmed MODY did not reflect a low referral rate, as 207 of 3491 
(5.9%) referrals were SA, matching UK census data (5.3% population). How-
ever the mutation detection rate in the SA group was half that seen in the 
3284 WE referrals (12.6% vs 25.5%, p<0.001). To analyse why the mutation 
detection rate was lower, we compared the clinical phenotype of SA and WE 
patients who a) had a genetic diagnosis of MODY and b) in whom a MODY 
mutation was not detected. a) Mutation phenotypes were similar between 
ethnic groups; SA HNF1A patients had similar age at diagnosis (18.0 vs 15 
years, p=0.072), proportions of parental diabetes (100% vs 87.8%, p=0.244) 
and non-insulin requirement (80 vs 66.5%, p=0.30) to WE HNF1A patients. 
SA GCK patients were younger at diagnosis (12 vs. 19.5 years, p=0.008), with 
similar proportions of parental diabetes (85.6 vs. 74.5%, p=0.303) and non-
insulin requirement (100 vs. 90.6%, p=0.344) to WE patients. b) Phenotypes 
in those tested for MODY in whom no mutation was found differed markedly 
between ethnic groups; SA subjects were younger at diagnosis (20 vs 25years, 
p<0.001), with similar BMI (25.0 vs 25.2, p=0.198), were more likely to have 
an affected parent (77.3% vs 57.5%, p<0.001) and to be non-insulin treated 
(62% vs 52.1%,p=0.007) when compared to WE patients. The strongest pre-
dictors of MODY mutations in SA people were younger age at diagnosis (14.5 
vs. 20 years, p=0.001) and lower BMI (20.0 vs 25.0 kg/m2, p<0.001) when 
compared to SA people without mutations.
Conclusion: The reduced prevalence of molecular genetically diagnosed 
MODY in SA people results from a lower mutation detection rate, rather than 
a reduced referral rate. The low detection rate in the SA group reflects the 
higher prevalence of early-onset, non-insulin requiring, familial diabetes that 
does not result from MODY mutations. Differentiating MODY from young-
onset type 2 diabetes in people of SA origin is challenging, and further work 
is required to develop ethnic specific targeted referral criteria.
Supported by: DRWF
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Genetic testing for monogenic diabetes using targeted next-generation 
sequencing in the MODY registry cohort of Poland
A. Ludwig-Galezowska, M. Szopa, J. Machlowska, J. Skupien, P. Radkowski, 
T. Klupa, T. Koblik, B. Zapala, T. Staszel, B. Kiec-Wilk, I. Wybranska,  
P. Wolkow, M.T. Malecki;  
Jagiellonian University Medical College, Krakow, Poland.
Background and aims: Specific molecular diagnosis of monogenic dia-
betes mellitus is important for individualized patient care. When results of 
standard Sanger sequencing in selected genes are negative, Next Generation 
Sequencing-based exome - sequencing (NGS), might provide additional di-
agnostic potential. NGS enables the simultaneous analysis of multiple genes 
in a single test. Our aim was to assess the feasibility of using NGS for a detec-
tion of mutations in a set of earlier described monogenic diabetes genes in a 
group of patients from the Polish Registry of MODY.
Materials and methods: We selected 29 genes (GCK, HNF1A, HNF4A, HN-
F1B, NEUROD1, INS, CEL, PDX1, PAX4, BLK, KLF11, KCNJ11, ABCC8, 
PTFA1A, NEUROG3, RFX6, EIF2AK3, FOXP3, GLIS3, SLC19A2, SLC2A2, 
IER31P, ZFP57, WFS1, GATA6, GATA4, LMNA, PPARG) in which muta-
tions have been reported to cause MODY, neonatal diabetes, maternally 
inherited diabetes and deafness (MIDD) or familial partial lipodystrophy 
(FPLD). The Illumina MiSeq platform was used for sequencing. An exon-
capture assay was designed to include coding regions and splice sites, and it 
was based on the assay designed by the Exeter group. A total of 41 patients 
were selected from our cohort of suspected MODY. Sequence data were ana-
lysed for the presence of base substitutions, small insertions or deletions (in-
dels) and exonic deletions or duplications.
Results: Sequencing results were generated for all 41 patients. In two positive 
controls, we detected previously identified HNF1A and GCK mutation. We 
detected 2 known HNF1A gene mutation and 1 known GCK gene mutation 
(missed in Sanger sequencing) in patients previously examined with nega-
tive results towards HNF1A and GCK MODY, respectively. In the other 24 
patients previously negatively tested for HNF1A or GCK MODY we found 
high or moderate impact mutations in GCK (4), HNF4A (2), ABCC8 (2), 
HNF1A (1), NEUROD1 (1), ZFP57 (1), WFS1 (1), and GATA6 (1) gene. We 
also included 12 patients with no prior genetic testing. In this subgroup we 
identified known mutations in HNF1A (3), GCK (3), ZFP57 (1) and LMNA 
(1) gene. Currently, we are in the process of verification the sequence differ-
ences and their segregation in families by the Sanger sequencing.
Conclusion: Our pilot experiments using NGS for monogenic diabetes 
screening in the MODY cohort confirmed that its use is feasible in routine 
genetic testing. The screening should include patients in whom MODY is 
suspected and in whom earlier Sanger-based screening for MODY generated 
negative results.
Supported by: 0545/IP1/2011/71
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DNA testing of MIDD in patients with clinical suspicion on MODY or 
MIDD in Slovakia
J. Stanik1,2, M. Skopkova2, I. Masindova2, L. Valentinova2, M. Huckova2,3,  
L. Varga2,4, D. Danis2, M. Profant4, I. Klimes2, D. Gasperikova2,5;  
1Firts Department of Pediatrics, Medical Faculty at Comenius University, 
2DIABGENE & Diabetes Laboratory, Institute of Experimental 
Endocrinology, SAS, 3Center for Molecular Medicine, SAS, 4Department 
of Otorhinolaryngology - Head and Neck Surgery, Medical Faculty at 
Comenius University, 5Center for Molecular Medicine SAS, Bratislava, 
Slovakia.
Background and aims: Diabetes and deafness - the leading clinical features 
of MIDD (Maternally Inherited Diabetes and Deafness) arise from mutations 
in mtDNA, most often m.3243A>G. This mutation leads to different clinical 
symptoms according to heteroplasmy levels in different tissues. Usually, the 
first presentation of MIDD is a sensorineural hearing loss emerging in ado-
lescence; the diabetes mostly develops between 20th-40th year of life. More 
severe clinical presentation of the mutation is the MELAS syndrome (Mi-
tochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like epi-
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 159
1 C
sodes). The aim of our study was to search for m.3243A>G mutation among 
patients sent for MIDD or MODY testing, who lack mutations in the most 
common MODY genes (i.e. GCK, HNF1A or HNF4A).
Materials and methods: Unrelated probands from 257 families fulfilling at 
least one of the following criteria, i.e. matrilinear inheritance, diabetes plus 
hearing impairment, diabetes development after 20th year of life, or progres-
sive hearing loss, were tested for m.3243A>G mutation by the RFLP and/or 
Real-Time PCR. The heteroplasmy was evaluated for peripheral blood and/
or buccal mucosa. DNA testing was also extended to the family members of 
probands carrying the mutation.
Results: The m.3243A>G mutation was found in 18 patients from 8 fami-
lies (3%). Probands´ phenotypes varied from diabetes as the sole symptom 
to a complex picture of the MELAS syndrome (in one proband). Diabetes 
or impaired glucose tolerance developed all of the probands (diabetes onset 
ranged from 21 to 52 years), but only 3 of 10 relatives with the mutation. 
Five probands (62.5%), and 4 (40%) of the relatives with the mutation had 
hearing impairement. The heteroplasmy was higher in buccal swab samples 
compared to the peripheral blood (27.9±18.6% versus 12.7±17.3%). In one 
case, the heteroplasmy was detected in the buccal DNA only, while the blood 
DNA samples were repeatedly negative.
Conclusion: Among 257 probands with the clinical suspicion on MIDD or 
MODY, 8 (3%) had the m.3243A>G mutation of the mitochondrial DNA. At 
the time of testing, only 5 (62.5%) of the probands were diagnosed with typi-
cal combination of symptoms, i.e. diabetes and hearing loss. Therefore, DNA 
testing for MIDD seems to be reasonable also in diabetes patients without 
hearing impairement, particularly using DNA from the buccal mucosa.
Supported by: APVV 0187-12, “Transendogen” (ITMS 26240220051)
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Using targeted sequencing to investigate the prevalence of monogenic 
diabetes in the Norwegian childhood diabetes registry
B.B. Johansson1,2, H.U. Irgens1,3, J. Molnes1,2, O. Søvik1,3, S. Levy4,  
D.E. Undlien5, T. Skrivarhaug6, G. Joner6,7, A. Molven1,8, S. Johansson1,2,  
P.R. Njølstad1,3;  
1Department of Clinical Science, University of Bergen, 2Center for Medical 
Genetics and Molecular Medicine, Haukeland University Hospital, 
3Department of Paediatrics, Haukeland University Hospital, Norway, 
4Hudson Alpha Institute for Biotechnology, Huntsville, USA, 5University 
of Oslo, 6Department of Paediatrics, Oslo University Hospital, 7Institute of 
Health and Society, University of Oslo, 8Gade Institute, University of Bergen, 
Norway.
Background and aims: Type 1 diabetes is a heterogenous group of diabe-
tes. Since about 10-15 % lack detectable levels of diabetes associated auto-
antibodies at diagnosis, we hypothesized that many of these may have a mo-
nogenic form of diabetes. We therefore set out to systematically screen all 
auto-antibody negative patients in the Norwegian Childhood Diabetes Reg-
istry for 13 genes known to cause monogenic diabetes. The aim of this study 
was to estimate the prevalence of common forms of monogenic diabetes in 
childhood diabetes and assess the usefulness of large scale gene sequencing in 
routine clinical care of young onset diabetes.
Materials and methods: The Norwegian Childhood Diabetes Registry includes 
95% of all children with newly diagnosed diabetes from 2002. By 22.01.2014, 
the registry included 3578 children with clinical data regarding onset of dia-
betes, family history and treatment, as well as serum and DNA samples. In 
this study, we selected 478 cases that were negative for GAD and IA-2 autoan-
tibodies, as well as and 478 GAD and IA-2 antibody-positive individuals as 
controls. The samples were screened by TruSeq Custom Amplicon targeted 
sequencing method, focusing on 13 monogenic diabetes genes (HNF1A, HN-
F4A, GCK, NEUROD1, ABCC8, KCNJ11, HNF1B, INS, PDX1, KLF11, PAX4, 
BLK, CEL). The amplicons targeted the protein coding regions with flanking 
intronic sequences, UTRs and some selected regions; HNF4A (c.-192), INS 
intron (c.188-31) and GCK (c.-71). To test the sensitivity of the assay, we test-
ed 22 controls with known mutations in the selected target genes. We identi-
fied all these mutations. Sequencing was performed on a Miseq. All newly 
identified mutations were confirmed by Sanger sequencing. We used stand-
ard bioinformatics tools to assess the pathogenicity of the variants identified.
Results: As a first test, we screened 74 antibody negative cases that were C-
peptide positive (C-peptide>200 pmol/l at diagnosis) to increase the likeli-
hood of finding possible MODY. In the screened material we found 39 ex-
onic and splice variants whereof twelve of the patients (16%) had a likely 
pathogenic mutation in HNF1A or GCK. There were no false positive vari-
ants reported by the assay. Mean exonic coverage was estimated to 505X and 
94% of target exons were covered at 20X. We are currently in the process of 
analyzing the remaining samples.
Conclusion: In this preliminary study where we use targeted sequencing to 
investigate the prevalence of monogenic diabetes in the Norwegian Child-
hood Diabetes Registry we observe that 16% of the GAD- and IA-2-antibody 
negative patients harbor a likely pathogenic mutation. This panel-sequencing 
assay provides a specific and sensitive method for simultaneous analysis of 13 
genes associated with monogenic diabetes.
Supported by: Norwegian Diabetes Association
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Clinical features of MODY2 in children and adolescents in Russian 
Federation
L. Zilberman1, E. Sechko1, V. Peterkova1, T. Kuraeva1, O. Ivanova2;  
1Children, 2Laboratory Immunology, FGBU Endocrinology Research 
Centre, Moscow, Russian Federation.
Background and aims: Maturity-onset diabetes of the young, type 2 
(MODY2) is is a monogenic disease caused by mutations in the glucokinase 
gene (GCK). Aim: To determine the prevalence of GCK gene mutations and 
to delineate the clinical phenotype of identified GCK mutation carriers in 
monogenic diabetes patients in Russia.
Materials and methods: We included 96 patients with suspected MODY. All 
patients were screened for HNF1A and GCK mutations by direct sequencing.
Results: Mutations in the GCK were found in 46 patients (48 %), and HNF1A 
mutation - in 18 patients (19%), 32 patients (33%) were negative for MODY2 
and MODY3. The age at diagnosis was 10.4 yrs (7;14). 11% of patients were 
investigated because of clinical manifestations, 66% were diagnosed occa-
sionally, 23% were screened because of family history. Duration of the disease 
was 1.3 (0.6;2.3). BMI was in normal range in 95.6% of the patients (17.0 
(15.8;18.5)).BMI was increased to 28.8 (SDS BMI +3.2) in only one 8-year-
old girl.HbA1c at the time of diagnosis was 6.6% (6.4;6.8).autoantibodies 
(ICA, GAD, IAA) were negative in all patients. GTT: Glu (mmol/L)0`-6,6 
(5,9; 7), 1-h -11,15 (9,2; 12,78), 2-h -9,15 (8,475; 10,35).Seven patients (15%) 
aged 11.8-13.2 yrs with normal BMI were found to be insulin-resistant (Insu-
lin at baseline was 14.2 U/l(11.0;15.2), HOMA>3.5). Three patients requested 
insulin therapy (6.5%), and three other patients received sulfonylureas. 87% 
(40 patients) were able to maintain normal blood glucose levels with a diet 
and physical exercise only.
Conclusion: MODY3 is seemed to be less prevalent than MODY2 in Russian 
population. Most of the patients have asymptomatic disease and have been 
revealed occasionally in our study by impaired fasting glucose and slightly 
elevated HbA1c. Treatment for the majority of MODY2 children can be re-
stricted by diet and physical exercise.
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The length of the deletion in the region 17q contributes to the individual 
variability of the phenotype of patients with renal cysts and diabetes 
syndrome (RCAD, HNF1B-MODY)
S. Pruhova1, P. Dusatkova1, M. Malina1, Z. Slamova2, K. Blahova1,  
R. Kotalova1, J. Dusek1, J. Lebl1, T. Seeman1, O. Cinek1;  
1Department of Pediatrics, 2Department of Biology and Medical Genetics, 
2nd Faculty of Medicine, Charles University in Prague and University 
Hospital Motol, Czech Republic.
Background and aims: The renal cysts and diabetes (RCAD) syndrome 
caused by defects in a gene for hepatocyte nuclear factor 1 beta (HNF1B) 
is characterized by broad spectrum of clinical features. While heterozygous 
point mutations detectable by Sanger sequencing are relatively rare, we fo-
cused on gross deletions of the HNF1B gene that are determined by MLPA 
(Multiplex Ligation Probe-dependent Amplification). Rather importantly, 
the deletions most often extend beyond the single HNF1B gene, thus more 
deleted genes may participate in the clinical picture. Objective and hypoth-
eses. We compared the clinical phenotype of patients carrying the gross dele-
tions whose extent was precisely determined by array comparative genomic 
hybridisation (aCGH), and point mutations in the HNF1B gene.
Materials and methods: In thirteen patients (6 males, median age 15.5 years) 
carrying the HNF1B gene deletion was performed aCGH on CytoChip Oligo 
8x60K. The clinical data were compared with 5 patients (1 male, median age 
15.5 years) having point mutations in HNF1B.
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Results: The average length of heterozygous deletion was 1.69 Mb. The long-
est deletion reached 2.5 Mb affecting 47 genes and the shortest deletion found 
in three patients was 1.4 Mb long and deleted 16 genes. All patients lost also 
LHX1 gene encoding transcription factor important for the development of 
the renal and urogenital system. Compared to other deletion carriers, pa-
tients having longest deletions (2.5 and 2.1 Mb) manifested renal dysfunction 
at older age (10 and 30 years) with milder changes of the kidney structure 
(isolated cysts and functional changes only) and both presented diabetes as 
a first clinical feature of RCAD. Patients with shorter deletion manifested re-
nal changes (polycystosis) prenatally and are mostly without diabetes so far. 
Comparing deletion and point mutation carriers, prenatal ultrasound kidney 
changes were found in 10/13 and 4/5 patients, respectively. Diabetes mani-
fested at the median age of 17 years in 5/13 and 2/5 patients. Hypomagnesae-
mia was present in 11/13 and 2/5 patients.
Conclusion: Regardless to the length of the deletion in the region 17q, the 
dominating clinical phenotype of the patients is similar compared to the pa-
tients having point mutation in the HNF1B gene. However, the length of the 
deletion can contribute to the individual variability in the age of manifesta-
tion and other variability of the phenotype.
Supported by: Czech Ministry of Health NT 11402 and NT 1145
PS 013 Islet gene expression in  
type 2 diabetes
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Beta cell function, more than beta cell area, affects plasma glucose levels 
and influences the progression of type 2 diabetes in humans
M. Suleiman, F. Olimpico, M. Bugliani, F. Syed, M. Occhipinti, F. Scatena,  
F. Filipponi, D. Focosi, U. Boggi, P. Marchetti, L. Marselli;  
Department of Clinical and Experimental Medicine, Islet Cell Laboratory, 
University of Pisa, Italy.
Background and aims: Type 2 diabetes (T2D) is characterized by reduced 
beta cell functional mass. However, the direct relationships between beta cell 
amount or function with in vivo blood glucose levels and disease progression 
are unclear.
Materials and methods: Pancreases were obtained from 388 non-diabetic 
(ND) donors [age: 60±17 years, BMI: 25.2±3.8 kg/m2, mean glycemia (MG) 
in intensive care unit: 154±45 mg/dl] and 68 T2D subjects [(age: 71±8 years, 
BMI: 26.9±4.0 kg/m2, MG: 218±72 mg/dl, diabetes duration (DD): 9±7 
years)]. Pancreatic insulin area (PIA) was assessed by immunocytochemis-
try; islets (HI) were isolated and ex-vivo insulin release (IR) was evaluated in 
response to 3.3 and 16.7 mM glucose (G).
Results: PIA was lower in T2D than ND subjects (0.51±0.20 vs 0.84±0.42%, 
p<0.001). IR (μU/islet/min) in response to 3.3 mM G (0.031±0.010 vs 
0.036±0.015, p=0.004) and 16.7 mM G (0.050±0.030 vs 0.104±0.077, 
p<0.001) was also reduced in T2D islets, which was confirmed by calcula-
tion of stimulation index (SI, 1.6±0.7 vs 2.8±1.7, p<0.001). MG was not cor-
related with PIA (p=0.30), but it was inversely correlated with IR at 16.7 mM 
G (p=0.002) and SI (p=0.001). Anti-diabetic therapy consisted of diet alone 
(D) in 3 subjects, metformin (M) in 15, sulfonylurea alone or in combination 
with metformin in 25, insulin associated with oral agents in 6, insulin alone 
(I) in 9. Unsurprisingly, progression of therapeutic treatment was correlated 
with DD (p<0.001). There was no significant correlation between PIA and 
DD or pharmacological therapy. However, lower glucose stimulated IR was 
associated with progressively more intense diabetes therapy (p<0.001). Cor-
relations were validated by multivariate analysis, and comparisons between 
therapeutic groups confirmed differences in terms of DD (from 6±3 yrs in 
D+M to 17±10 yrs in I), IR in response to 16.7 mM G (from 0.069±0.043 to 
0.29±0.01 μU/islet/min) and SI (from 2.1±0.7 to 1.1±0.1) (p<0.01).
Conclusion: These results suggest that beta cell function, more than beta cell 
amount, affects plasma glucose levels and progression of T2D in humans; if 
so, improving beta cell function is a primary goal in T2D therapy.
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Uncovering conserved beta cell transcriptome of type 2 diabetes  
by meta-analysis of microarray data
E.-G. Hong1, J. Ohn1, H.-S. Kwon2, B.-Y. Cha2;  
1Internal Medicine, Hallym University, Chuncheon, 2Internal Medicine,  
The Catholic University of Korea, Seoul, Republic of Korea.
Background and aims: Pancreatic beta cell dysfunction is an early manifesta-
tion during progression to diabetes. Transcriptional profiling studies of beta 
cells from subjects with diabetes have revealed various genes or pathways of 
beta cell dysfunction. We aimed to uncover conserved beta cell transcrip-
tional signature in diabetes by meta-analyzing microarray datasets and find 
regulators.
Materials and methods: Microarray data of three independent transcrip-
tional profiling studies of beta cells from diabetes patients (GEO IDs: 
GSE20966, GSE25724, and GSE38642) were obtained from the public micro-
array database, Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/). Gene Set Enrichment Analysis (GSEA) was performed for 10,294 
curated mSigDB gene sets (http://www.broadinstitute.org/gsea/msigdb) in 
each microarray dataset and Enrichment Scores (ES) were calculated. As a 
measure of consistently altered expression, meta-Enrichment Score (Meta-
ES) is defined as the sum of Enrichment Scores in three datasets. Gene sets 
with significantly high absolute meta-ES values (P < 0.01) are extracted. Next, 
we constructed the network of the significantly and consistently altered gene 
sets and regulators at the hub of the gene set network were assumed to be the 
key regulators of beta cell transcriptome of diabetes.
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Results: 461 out of 10,294 mSigDB gene sets were significantly and consist-
ently altered across datasets (P value of meta-ES <0.01). In gene set network, 
cytokine metabolism and immunologic response pathways were up-regulat-
ed, while beta cell differentiation, energy metabolism, and microtubule asso-
ciated gene sets were down-regulated in all three datasets. Analysis of the net-
work topology of transcription factor target gene sets and biological pathway/
gene ontology gene sets suggests that HIF1A, aryl hydrocarbon receptor, and 
Nuclear Factor Y may be core regulators that account for the repressed beta 
cell development and metabolism of diabetes patients exposed to chronic 
metabolic and inflammatory stress (see attached figure).
Conclusion: Integrative meta-analysis of heterogeneous transcriptional pro-
filing studies of beta cells from diabetes patients proposes that HIF1A, aryl 
hydrocarbon receptor, and Nuclear Factor Y may be candidate regulators of 
impaired beta cell development and function in patients with type 2 diabetes. 
375
Serotonin receptors HTR1D and HTR2A are differentially expressed in 
human type 2 diabetes islet donors and regulate insulin secretion in vitro 
in human islets and INS (832/13) cells
H. Bennet1, A. Balhuizen1, A. Medina Benavente1, M. Dekker Nitert2,  
S. Essén3, P. Spégel4, P. Storm5, U. Krus6, N. Wierup7, M. Fex1;  
1Diabetes and Celiac Disease, Lund University, Malmö, Sweden, 2University 
of Queensland, Herston, Australia, 3Department of Chemistry, Lund 
University, 4Molecular Metabolism, Lund University, 5Diabetes and 
Endocrinology, Lund University, 6Islet Patophysiology, Lund University, 
7Neruoendocrine Cell Biology, Lund University, Malmö, Sweden.
Background and aims: Regulation of overall glucose homeostasis is achieved 
by an intricate interplay between metabolic and nervous input to the pan-
creatic alpha and beta cells. Failure of adequate signals to the beta cells may 
results in overt type 2 diabetes (T2D). Intra islet paracrine and autocrine cir-
cuits of the monoamine 5-hydroxy trymptamine (5-HT) is stored within the 
islets and can potentially regulate glucose stimulated insulin release (GSIS). 
Discrepancies in results of the effects of 5-HT on insulin release in in vitro 
and in vivo and lack of studies in human islets demand further investiga-
tion of the islet 5-HT systems. Moreover, diabetogenic effects of atypical an-
tipsychotics and antidepressants that specifically targets these systems urges 
increased under¬standing of effects directly on the islets. Therefore, in this 
study we aimed to perform a complete transcriptional mapping of 5-HT 
receptors, investigate differentially expressed receptors in non diabetic and 
T2D human islet donors, and to study the role for these receptors in insulin 
secretion.
Materials and methods: Islet donors were obtained from the Nordic Net-
work of Clinical transplantation in Uppsala, Sweden. RNA sequencing data 
of 131 islet donors (114 control donors and 17 T2D donors) were used. Vali-
dation of RNA sequencing data for receptors was performed by quantitative 
(Q) PCR (Applied Biosystems). One hour batch secretion experiments were 
performed using secretion assay buffer (2.8 mmol/l glucose, 114 mmol/l 
NaCl, 4.7 mmol/l KCl, 1.2 mmol/l KH2PO4, 1.16 mmol/l MgSO4, 25.5 
mmol/l NaHCO3, 20 mmol/l Hepes, 2.5 mmol/l CaCl2, and 0.2% BSA), with 
or without addition of agonists and antagonists. Localization for receptors 
and amine was performed by immunohistochemistry in sections of human 
pancreas.
Results: We detected the expression of fifteen 5-HT receptors in human is-
lets, as well as all enzymes involved in the biosynthesis of 5-HT (TPH1, TPH2 
and DDC). Searching for differential receptor expression between non-dia-
betic and T2D islet donors, expression for HTR1D and HTR2A was found 
to be increased in T2D islets (p=0.0043= and p=0.0041). Batch incubations 
with human islets revealed that agonist for 5-HT1d (PNU142633) decrease 
GSIS while an agonist for 5-HT2a (TCB-2) potentiated GSIS. Conversely, an 
antagonist for 5-HT2a (EMV) decreased GSIS and an antagonist for 5-HT1d 
(LY3107609) increased GSIS. Immunohistochemistry localized 5-HT1d and 
5-HT2a receptors and 5-HT to both human beta and alpha cells.
Conclusion: Our findings support a role for 5-HT in control of human islet 
hormone secretion, perhaps in a paracrine and autocrine fashion as we show 
that 5-HT is present in both human alpha and beta cells. Moreover, expres-
sion of HTR1D and HTR2A is changed in T2D islets, suggesting a role for 
these receptor in the pathophysiology of type 2 diabetes.
Supported by: Swedish Research Council, The Påhlsson and Crafoord founda-
tions,
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Effects of steroid treatment on beta cell mass in Japanese individuals 
with or without diabetes
S. Sato1, Y. Saisho1, J. Inaishi1, K. Kou1, T. Yamada2, H. Itoh1;  
1Department of Internal Medicine, 2Department of Pathology, Keio 
University School of Medicine, Tokyo, Japan.
Background and aims: Steroid is widely used anti-inflammatory agent. Ster-
oid treatment promotes hepatic and peripheral insulin resistance and, in ro-
dent studies, increases beta cell mass (BCM). Recently we have reported that 
there was no increase in BCM in Japanese obese individuals compared with 
lean subjects. Therefore in this study, we aimed to clarify the effects of steroid 
treatment on BCM in Japanese individuals with or without diabetes.
Materials and methods: We obtained the human pancreas at autopsy from 
26 non-diabetic individuals (NGT; control) and 26 steroid-treated non-dia-
betic individuals (SNGT) (age 63 ± 8 (mean ± S.D) vs. 60 ± 11 years, HbA1c 
5.5 ± 0.6 vs. 5.3 ± 0.6%, respectively). We also obtained the pancreas from 23 
steroid-treated individuals with diabetes (SDM) and 25 individuals with type 
2 diabetes (DM2) (age 65 ± 8 vs. 66 ± 8 years, HbA1c 7.1 ± 1.0 vs. 7.5 ± 1.2%). 
To be included, cases were required to have 1) had a full autopsy within 24 h 
of death, 2) pancreas tissue stored with adequate size and quality. Cases were 
excluded if pancreas tissue showed autolysis or any abnormal change such 
as pancreatitis. Pancreatic sections were stained for insulin or glucagon, and 
fractional beta (%BCA) or alpha cell area (%ACA) was measured.
Results: There was no significant difference in %BCA between SNGT and 
NGT (1.21 ± 0.59 vs. 1.66 ± 1.05%, P = 0.29). In SNGT group, there was no 
significant correlation between %BCA and duration of steroid treatment (r 
= 0.404, P = 0.06), or total steroid dose (r = 0.354, P = 0.15). %BCA in DM2 
was significantly decreased compared with NGT (0.92 ± 0.63%, P = 0.004), 
however there was no significant difference in %BCA between SDM and 
DM2 (0.99 ± 0.56%, P = 0.54). There was no correlation between %BCA and 
duration of steroid treatment (r = 0.065, P = 0.77) or total steroid dose (r = 
0.077, P = 0.75) in SDM. When the SDM group were divided into two groups 
according to the presence (SDM-DM2, n = 13) or absence (SDM-NGT, n = 
10) of type 2 diabetes, %BCA in SDM-NGT was significantly greater than 
that in SDM-DM2 (1.34 ± 0.53% vs. 0.72 ± 0.43%, P = 0.01) and comparable 
to that in NGT (P = 0.55). Although there was a significant negative correla-
tion between %BCA and HbA1c in NGT plus DM2 group (r = -0.451, P = 
0.004), this correlation was not observed in steroid-treated subjects (SNGT 
plus SDM groups) (r = -0.266, P = 0.08).
Conclusion: There was no increase in BCM in steroid-treated Japanese in-
dividuals with or without diabetes, suggesting that steroid treatment does 
not affect BCM in Japanese. No significant decrease in BCM in patients with 
steroid-induced diabetes suggests that the glucose intolerance in these sub-
jects is mainly due to the presence of insulin resistance rather than the deficit 
of beta cell. Since we were not able to observe a significant increase in BCM 
in the presence of obesity or steroid use in Japanese, these findings suggest 
that the increase in BCM in the face of insulin resistance is extremely limited 
in Japanese.
Supported by: NMTR, DSHF, JDF
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Dephosphorylation and nuclear translocation of the CREB-regulated 
transcription co-activator 1 (CRTC1) elevates miR-212 and miR-132 
expression in insulin secreting cells
H.A. Malm1, C. Berggreen2, M. Orho-Melander1, L. Eliasson1,  
O. Göransson2, I.G. Mollet1;  
1Dept Clinical Sciences in Malmö, Lund University Diabetes Centre, Malmö, 
2Dept of Experimental Medical Sciences, Lund University, Lund University 
Diabetes Center, Sweden.
Background and aims: We have previously demonstrated miR-212 and miR-
132 to be upregulated in diabetic GK rat islets. Others have demonstrated 
cAMP-responsive element binding protein (CREB) to bind CRE-sites on the 
miR-212/132 promotor. Here we aim to investigate mechanisms underlying 
cAMP-mediated transcriptional regulation of the miR-212/132 cluster in in-
sulin secreting cells.
Materials and methods: INS-1 832/13 cells were cultured for 0.5, 2, 6 and 
24h in various glucose concentrations and in the absence or presence of for-
skolin/IBMX or GLP-1 (2h). In addition, cells were transfected with siRNA 
against all three isoforms of CRTC or salt inducible kinases (SIKs) or with 
mature miR-212 and miR-132. Relative expression of miRNA and mRNA 
was determined by qPCR; Insulin secretion at 2.8 and 16.7 mM glucose was 
analyzed using RIA; protein expression and phosphorylation was evaluated 
with western blot analysis (WB) and CRTC1 translocation with confocal mi-
croscopy.
Results: Expression of both miRNAs was increased after 2h in forskolin/
IBMX (3-4-fold, p<0.01) and increased further at 6h. CREB was phosphoryl-
ated and CRTC1 was dephosphorylated (p<0.001) after 30 min incubation 
with forskolin/IBMX. In addition, SIK2 was phosphorylated on Ser358 after 
forskolin/IBMX treatment (p<0.001). In the presence of forskolin/IBMX, ex-
pression of miR-212 and miR-132 (p<0.05,) and insulin release at 16.7 mM 
glucose (p<0.01, 50%) were decreased in CRTC1 silenced cells. Expression 
of CRTC1 mRNA was reduced in cells overexpressing miR-212 and miR-132 
(p<0.05), suggesting a feedback control system. Confocal imaging revealed 
an accumulation of CRTC1 in INS-1 832/13 nuclei in forskolin/IBMX-incu-
bated cells (p<0.05). Finally, expression of miR-132 was elevated in cells incu-
bated with 10 (p<0.05) and 100 nM (p<0.01) GLP-1, respectively and expres-
sion of miR-212 was elevated in cells incubated with 100 nM GLP-1 (p<0.05).
Conclusion: We have demonstrated that the incretin GLP-1 is an activator of 
miR-212 and miR-132 expression. Furthermore, our data suggest that miR-
212 and miR-132 are regulated by cAMP in INS-1 832/13 cells, and that this 
is in part mediated through CRTC1 presumably acting together with CREB. 
We are currently further addressing the potential role of SIK isoforms as up-
stream regulators of the CRTC1/miR-212/132 pathway.
Supported by: Swedish RC, Diabetic Wellness, Swedish Diabetes Association, 
LUDC, EXODIAB
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Pdx1 coordinately cooperates with USF transcription factors to regulate 
expression of Alx3 in pancreatic beta cells
A. Fernández-Pérez, M. Vallejo;  
Instituto de Investigaciones Biomedicas Alberto Sols, CSIC/UAM and 
CIBERDEM, Madrid, Spain.
Background and aims: Alx3 is emerging as an important transcription factor 
for the control of glucose and metabolic homeostasis. Alx3 deficiency in mice 
results in age-dependent pancreatic islet cell apoptosis. As a consequence, be-
ta-cell mass and insulin content is reduced, and islet size is decreased. These 
mice exhibit elevated fasting blood glucose levels, impaired glucose tolerance, 
and insulin resistance that becomes evident as they age. These findings, to-
gether with its involvement in the regulation of the insulin gene, indicate that 
Alx3 is important for pancreatic islet function. For this reason, we embarked 
in a series of studies aimed to investigate the transcriptional mechanisms that 
promote Alx3 expression in pancreatic islet cells. We have previously report-
ed that the transcription factors USF1 and USF2 bind to different E-box ele-
ments in the promoter of Alx3 to regulate basal expression in mesenchymal 
and pancreatic cells. In the present study, we aimed to identify additional 
transcription factors involved in Alx3 expression in beta cells.
Materials and methods: Putative regulatory elements were identified by 
analysis of the promoter in silico. Binding of nuclear proteins from isolated 
mouse islets or from MIN6 cells was investigated by chromatin immunopre-
cipitation and electrophoretic mobility shift assays. To assess the role of spe-
cific transcription factors on the expression of Alx3 we used siRNA. Expres-
sion of Alx3 was assessed by quantitative RT-PCR. Luciferase reporter genes 
were used to test for promoter activity in transfected cells.
Results: The functional importance of USF1 and USF2 in the regulation of 
the endogenous Alx3 gene was confirmed in MIN6 cells by silencing their ex-
pression using siRNA. We found that silencing USF1 and USF2 concomitant-
ly decreased Alx3 expression by approximately 50%. In silico analysis of the 
Alx3 promoter led to the identification of the conserved sequence TTAAT-
GA, a potential binding site for the pancreatic transcription factor Pdx1. Mu-
tation of this site resulted in decreased promoter activity in transfected MIN6 
cells, and diminished Pdx1-dependent transactivation in Hela cells. ChIP as-
says using chromatin from isolated mouse islets, and EMSA using nuclear 
extracts from MIN6 cells confirmed binding of Pdx1 to the Alx3 promoter. 
In addition, silencing Pdx1 expression by siRNA resulted in decreased Alx3 
expression in MIN6 cells. Interestingly, mutations of the USF transcription 
factor-binding E-boxes almost completely inhibited Pdx1-dependent trans-
activation of the Alx3 promoter. A similar effect was observed when Pdx1 
was cotransfected with a dominant negative inhibitor of USF transcription 
factors. Finally, coexpression of USF1, USF2 and Pdx1 resulted in enhanced 
Alx3 promoter activity.
Conclusion: Expression of Alx3 in pancreatic islet cells is regulated by Pdx1. 
USF1 and USF2 transcription factors enhance Pdx1 transcriptional transac-
tivation from binding sites located on at least three different E-boxes. These 
data indicate that Pdx1, USF1 and USF2 coordinately interact to maintain 
Alx3 gene expression in pancreatic islet beta cells.
Supported by: MINECO (BFU2011-24245) and CIBERDEM
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Islet insulin resistance promotes local apolipoprotein CIII production 
and beta cell failure
K. Åvall1, Y. Ali1, L. Selander1, S.K. Nilsson2, R.M. Crooke3, M.J. Graham3, 
P.-O. Berggren1, L. Juntti-Berggren1;  
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska 
Institutet, Stockholm, 2Department of Medical Biosciences, Umeå 
University, Sweden, 3ISIS Pharmaceuticals, Carlsbad, USA.
Background and aims: The progression of type-2 diabetes (T2D) occurs in 
phases. The initial phase is characterized by peripheral tissue insulin resist-
ance with a β-cell compensatory response of increasing mass and insulin 
secretion. With prolonged hyperinsulinemia the β-cells start to fail, causing 
defects in insulin secretion and eventually increased β-cell apoptosis. Expres-
sion of apolipoprotein CIII (apoCIII) is increased under conditions of insulin 
resistance and recently it has been shown that hyperglycemia induces apoCIII 
transcription. The aim of the present study was to test the hypothesis that islet 
insulin resistance leads to local production of apoCIII and consequent β-cell 
failure in T2D.
Materials and methods: RNA was isolated and the expression of genes was 
measured by real-time quantitative PCR in islets from ob/ob and ob/lean 
mice at different ages. ApoCIII was lowered in vivo and in vitro by antisense 
treatment. Islets from ob/ob, C57Bl/6 and apoCIII-/- mice were transplanted 
into the anterior chamber of the eye (ACE) of ob/ob or C57Bl/6 mice. Chang-
es in [Ca2+]i were measured in islets microdissected out from the ACE and 
the effect of five months high fat diet (HFD) was studied longitudinally by in 
vivo imaging.
Results: ApoCIII was produced locally in the islets and there was a three-fold 
increase in islets from 12-weeks old diabetic ob/ob mice compared to ob/
lean mice. Lowering of apoCIII with antisense in vivo led to reduced body 
weight and improved glucose tolerance. Lowering apoCIII in vitro in iso-
lated islets resulted in normalized Ca2+-handling and decreased caspase 3/7 
activity, as a measure of apoptosis. ApoCIII-/- islets transplanted into ob/ob 
mice with high systemic apoCIII levels showed normal Ca2+-responses, com-
pared to transplanted ob/ob islets with increased endogenous apoCIII levels. 
Transplantation of islets from C57Bl/6 mice into the ACE of one eye of HFD 
fed mice showed an increased size compared to apoCIII-/- islets transplanted 
into the other eye of the same mouse.
Conclusion: Insulin resistance in the pancreatic islet leads to local expres-
sion of apoCIII and compromised β-cell function and survival that can be 
restored/prevented by reducing the lipoprotein in vivo. Hence, under condi-
tions of islet insulin resistance locally produced apoCIII is an important dia-
betogenic factor and may constitute a novel target for the treatment of T2D.
Supported by: Swedish Diabetes Assiciation, VR, Novo Nordisk, Erling.Persson 
foundation,
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Intracellular cholesterol transporters, islet dysfunction and insulin 
secretion in type 2 diabetes mellitus
J.B. Pinto;  
Biological and Biomedical Sciences, Glasgow Caledonian University, UK.
Background and aims: Elevated intracellular cholesterol levels prevent glu-
cose stimulated insulin secretion from pancreatic beta cells, by impairing 
iCa2+ elevation and its signaling, and hindering PiP2 hydrolysis, affecting ac-
tin dynamics and plasma membrane potential. Conversely, cholesterol deple-
tion restores exocytosis of insulin granules in sterol-loaded cells. Mechanisms 
that improve the efficiency of intracellular cholesterol transport may there-
fore prove valuable therapeutically. Cholesterol-binding members of the ster-
oidogenic acute regulatory protein domain (StarD) family of lipid trafficking 
proteins (STARTs) are known to modulate lipid homeostasis in a number of 
differing cell types, including macrophages, keratinocytes and hepatocytes; 
however, despite their potential therapeutic utility, little is known about the 
expression or function of StarD proteins, or their ligands, in beta-cells, or 
their relationship with insulin secretion. Our aims were to (i) investigate the 
expression of StarD cholesterol trafficking proteins, in BRIN-BD11 insu-
linoma cells, following manipulation of cellular cholesterol levels, and (ii) to 
explore the role of endosomal cholesterol transfer protein, StarD3, in choles-
terol homeostasis and insulin secretion.
Materials and methods: Methodologies included radioisotopic labelling of 
cellular lipid pools, colorimetric assays for lipid mass, Q-PCR, immunoblot-
ting and ELISA.
Results: Treatment with methyl beta-cyclodextrin (MCD; 1-10mmol l-1; 1h) 
efficiently removed cholesterol from BRIN-BD11 cells, dramatically increas-
ing endogenous cholesterol biosynthesis, while cholesterol lipid complex 
(CLC 1:200) induced significant increases in cholesterol mass (p<0.01), with-
out perturbing cholesterol biosynthesis. Secretion of insulin was modulated 
by cellular cholesterol content, exhibiting a biphasic response following MCD 
treatment, which was reflected in the expression of StarD3 protein, which 
increased at concentrations from 0.1 to 3mM MCD, but declined markedly at 
10mM MCD. Sterol loading of cells also increased the expression of StarD3, 
compared with control cells, while StarD1 levels were too low in BRIN-BD11 
cells for detection by immunoblotting. Levels of StarD4 protein showed a 
trend towards repression in cells treated with CLC, while StarD5 did not ap-
pear significantly altered under the conditions tested here.
Conclusion: The results suggest a possible relationship between StarD3 
expression and insulin secretion, which are now being explored using the 
StarD3 ligand, lutein, and genetic manipulation of this protein, establishing 
the importance of targeting StarD proteins as tools to improve insulin secre-
tion in beta cells.
Supported by: Rosetrees Fund
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Low calorie sweeteners do not stimulate insulin secretion in human 
pancreatic beta cells
F. Bonnet1, R. Scharfmann2, E. Lepicard3, P. Czernichow4, G. Friedlander2;  
1Dept. of Endocrinology-Diabetology, University Hospital, Rennes, 
2Faculté Necker, INSERM U845, Paris, 3Institute of European Expertise in 
Physiology (IEEP), Paris, 4Pépinière d’Entreprises Institut du Cerveau et de 
la Moelle, Endocells, Paris, France.
Background and aims: High obesity and diabetes rates highlight the need for 
individuals to balance calories consumed with calories burned through daily 
activities and exercise. Low calorie sweeteners can be a helpful tool to reduce 
energy intake and body weight in the context of a reduced-calorie diet, by 
offering an alternative to caloric sweeteners. However, it has been suggested 
that sweeteners can stimulate insulin secretion, increase sugar intestinal ab-
sorption and increase appetite, leading to hyperglycemia and weight gain. 
Our aims were firstly, to determine whether low calorie sweeteners modify 
insulin secretion, and secondly, to determine whether or not they stimulate 
glucose absorption by intestinal cells.
Materials and methods: Insulin secretion was investigated using a unique 
in vitro model of human pancreatic beta cells (EndoC betaH1). Low calorie 
sweeteners effects were investigated in the presence of basal (low, 2.8 mM) or 
high (11 mM) concentrations of glucose. Various low calorie sweeteners con-
centrations were tested including concentrations observed in commercially 
available soft drinks (1 mM). Glucose transport assays were performed using 
0.1 mM or 1 mM of deoxyDglucose, a non-metabolized radiolabelled glucose 
analogue GLUT2-specific, in CACO2 cells or beta pancreatic cells.
Results: Aspartame, acesulfame K (both at 0.1, 1 mM and 10mM) and blend 
of these two low calorie sweeteners (0.1/0.1mM, 1/1mM) did not induce in-
sulin secretion in human pancreatic beta cells. This was observed not only 
in the presence of low but also of high concentrations of glucose, showing 
no potentiation of glucose effect upon human pancreatic beta cells. Moreo-
ver, both low calorie sweeteners did not increase human pancreatic beta cells 
proliferation or survival. A rise in insulin secretion was observed only in 
the presence of a very high dose of 50mM of acesulfame K and the 20mM 
aspartame/50mM acesulfame K blend. Glucose uptake in both pancreatic 
and intestinal cells was not modified by aspartame, acesulfame K or blends 
of these two low calorie sweeteners up to 10mM. At higher non physiological 
doses (10 mM or 20mM), only aspartame reduced GLUT2-mediated glucose 
uptake in pancreatic beta cells (p<0.01 for both doses of deoxy-D-glucose) 
and CACO2 cells (0.1 mM deoxy-D-glucose: p=0.002; 1 mM deoxy-D-
glucose p=0.0007). Finally both low calorie sweeteners and the blend of low 
calorie sweeteners had no effect on GLUT2 expression.
Conclusion: At concentrations similar to those observed in commercially 
available soft drinks containing low-calorie sweeteners i.e. between 0.1 and 
1 mM, aspartame and acesulfame K affect neither insulin secretion nor pan-
creatic beta cells survival and proliferation. In addition, both sweeteners alter 
neither glucose transport nor glucose transporters expression in both pancre-
atic and intestinal cells.
Supported by: The Coca-Cola Company
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The pocket protein family involved in beta cell replication during 
pregnancy
Y. Xu1, L. Gao1, H. Zhang1, M. Woo2, X. Wu1;  
1First Affiliated Hospital with Nanjing Medical University, China,  
2Institute of Medical Science, University of Toronto, Canada.
Background and aims: The pocket protein family consists of retinoblastoma 
protein (Rb), p107 and p130, which can repress E2F-mediated gene tran-
scription, recruit chromatin remodeling enzymes, and undergo phosphoryla-
tion by cyclin-dependent kinases, comprising the central regulatory check-
point that controls the mammalian G1/S-phase cell cycle transition. In spite 
of the sequence similarity within the DNA binding domain, they play distinct 
roles in the regulation of cell cycle progression. Islet beta cell replication is 
the main source for beta cell mass expansion during pregnancy. Activation 
of prolactin receptor signaling plays a key role in this process. Whether the 
pocket protein family is critical for beta cell replication during pregnancy is 
unclear. The present study is to investigate the change of Rb, p107 and p130 
during pregnancy and its related mechanism in prolactin-mediated beta-cell 
replication.
Materials and methods: Pancreatic islets of C57BL/6 mice were isolated 
and purified by collagenase digestion at non-pregnant (NP), pregnant day 
10.5 (P10.5), P14.5, P18.5 and after parturition day 4 (AP4), AP8. The gene 
and protein expression of Rb, p107, p130 and E2F1~5 were detected by real-
time quantitative PCR and Western blotting methods. Rb and phosphor-Rb 
expression of islets were detected by immunofluorescence. INS-1 cells were 
transfected with siRNA mediated by liposome to knockdown Rb expression, 
and detected the change of cell cycle with prolactin stimulation by flow cy-
tometry. INS-1 cells were cultured with inhibitors of AKT, Stat5, ERK, JNK 
and Pim respectively with prolactin stimulation to observe the change of Rb/
E2F1 expression.
Results: During pregnancy, Rb, p107 and E2F1~3 gradually increased and re-
turned back to NP level after parturition, with peak of Rb, phosphor-Rb and 
E2F1 at P14.5, p107 and E2F2 at AP4, E2F3 at P18.5 (p<0.05). p130, E2F4~5 
reduced gradually during pregnancy, reached the bottom at p14.5~p18.5, 
then gradually returned back after parturition (P<0.05). Double staining of 
Rb and phosphor-Rb with insulin or glucagon respectively indicated that 
total Rb located in cytoplasm while phosphor-Rb located in nucleus. Rb 
and phosphor-Rb protein were expressed at NP, but strongly upregulated at 
P14.5 (P<0.05) and returned back to NP level after parturition. The mRNA 
and protein level of Rb, p107 and E2F1 in INS-1 cells increased significantly 
(P<0.05) while p130 decreased significantly (P<0.05) after prolactin stimula-
tion. Rb knockdown in INS-1 cells by siRNA markedly increased prolactin-
induced INS-1 cell proliferation with promoted G1/S-phase cell cycle transi-
tion (P<0.01). With the inhibitor of Stat5 and Pim respectively to block the 
signaling pathways, the protein expression of Rb and E2F1 were significantly 
decreased in prolactin-stimulated INS-1 cells (p<0.05). While inhibition of 
AKT, ERK and JNK signaling pathways did not influence Rb and E2F1 ex-
pression.
Conclusion: The expression of pocket protein family is dynamic changed 
during pregnancy. Rb is essential for G1/S-phase cell cycle transition in prol-
actin-induced INS-1 cell proliferation, which is the downstream of Stat5 and 
Pim pathway with prolactin receptor activation.
Supported by: NSFC (81070621/81261120566)
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Survivin mediated prolactin-induced INS-1 cell proliferation through 
both PI3K/AKT and STAT5 pathway
L. Gao1, Y. Xu1, X. Wang1, H. Zhang1, M. Woo2, X. Wu1;  
1Endocrinology, First Affiliated Hospital with Nanjing Medical University, 
China, 2Institute of Medical Science, University of Toronto, Canada.
Background and aims: Maternal pancreatic beta-cell mass increases dramat-
ically during pregnancy both in rodents and humans to meet the increased 
physiological demands. This process is mainly due to beta-cell proliferation 
induced by activation of prolactin receptor signaling. Our previous data 
showed that Survivin was dynamic expressed in the pancreatic beta cells 
during pregnancy. Islet beta-cell specific Survivin deletion mice displayed 
glucose intolerance during pregnancy with the defection in beta-cell pro-
liferation and beta-cell mass expansion. However, the relationship between 
Survivin and the multiple putative signaling pathways downstream of the 
prolactin receptor is unknown. This study was designed to explore the func-
tion of Survivin in prolactin-mediated beta-cell proliferation.
Materials and methods: INS-1 cells were cultured with prolactin simula-
tion. Cell proliferation was detected by cell cycle analysis by flow cytometry. 
The gene and protein expression of IRS2/PI3K/AKT, Jak2/Stat5 and Foxm1/
Survivin were detected by real time quantitative PCR and Western blotting 
methods. INS-1 cells were transfected with siRNA mediated by liposome to 
knockdown Survivin expression, and detected the change of cell cycle with 
prolactin stimulation. INS-1 cells were cultured with inhibitors of AKT and 
Stat5 respectively with prolactin stimulation to observe the change of Foxm1/
Survivin expression.
Results: Cell cycle analysis showed that the proliferation of INS-1 cells in-
creased significantly with prolactin stimulation (P<0.01). The mRNA ex-
pression of IRS2/PI3K/AKT, Jak2/Stat5 and Foxm1/Survivin were markedly 
upregulated (P<0.05). The protein expression of pAKT, pStat5 and Survivin 
were elevated at the same time (P<0.05). However, Survivin knockdown in 
INS-1 cells by siRNA markedly blocked prolactin-induced INS-1 cell prolif-
eration with delayed S phase in cell cycle (P<0.01). With the inhibitor of AKT 
and Stat5 respectively to block the signaling pathways, the protein expression 
of Foxm1 and Survivin were significantly decreased in prolactin-stimulated 
INS-1 cells (P<0.05).
Conclusion: Survivin is crucial for prolactin-induced INS-1 cell prolifera-
tion. Foxm1/Survivin is the common downstream of both PI3K/AKT and 
STAT5 pathway with prolactin receptor activation.
Supported by: NSFC
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The non-canonical Wnt ligand, Wnt4, is highly expressed in pancreatic 
beta cells and its expression is negatively correlated with cell growth
H.J. Welters, A. Henderson, A. Bowen;  
Institute of Biomedical and Clinical Science, University of Exeter Medical 
School, UK.
Background and aims: We have previously published data showing that in 
beta-cells most Wnt ligands are either not present or expressed at very low 
levels. The exception to this is Wnt4 which is expressed at levels 10 fold higher 
than any other Wnt ligand. Wnt4 has been suggested to have a negative ef-
fect on beta-cell biology, with the levels in islets increased in rodent models 
of insulin resistance. The aim of this study is to investigate the regulation of 
Wnt4 expression in beta-cells and the impact of Wnt4 on beta-cell growth.
Materials and methods: mRNA and protein expression levels were measured 
by qRT-PCR and western blotting.
Results: We investigated Wnt4 mRNA expression in mouse organs and found 
that islets expressed Wnt4 at 10 fold higher levels than kidney, liver, muscle 
or brain (Wnt4 mRNA expression relative to housekeeping genes; kidney: 
0.01±0.004, liver: 0.01±0.003, brain: 0.02±0.002, muscle: 0.02±0.009 and 
islets: 0.25±0.018, (mean±sem)), suggesting an important role for Wnt4 in 
islet cells. We used the rodent beta-cell line, INS-1 to investigate regulation of 
Wnt4 expression. In agreement with islet data, we found that INS-1 cells ex-
pressed high levels of Wnt4 mRNA and protein. To determine whether a dia-
betogenic environment altered Wnt4 expression, we treated INS-1 cells with 
high glucose (Wnt4 mRNA expression normalised to housekeeping genes 
and expressed relative to 5.5mM glucose; 5.5mM glucose: 1±0.07, 16.7mM 
glucose: 1.07±0.13, (mean±sem) n=3) or 0.25 and 0.5mM palmitate (Wnt4 
mRNA expression normalised to housekeeping genes and expressed relative 
to control; control: 1.0±0.06, 0.25mM palmitate: 1.1±0.1, 0.5mM palmitate: 
0.94±0.06, (mean±sem) n=3) for 24hrs. However none of these treatments 
altered Wnt4 mRNA expression. We did though find that as cell confluence 
increased (with an associated decrease in cell proliferation) levels of Wnt4 
mRNA increased (Fig 1). In contrast the levels of the proposed Wnt4 recep-
tor, Fzd6, remained unchanged (Fig 1). In addition levels of Wnt4 mRNA 
decreased upon 6hr treatment with the growth stimulating protein, HGF 
(Wnt4 mRNA expression normalised to housekeeping genes and expressed 
relative to control; control: 1±0.08, 10ng/ml HGF: 0.47±0.07, (mean±sem) 
n=3, p<0.01), suggesting a negative correlation between Wnt4 expression and 
beta-cell proliferation. In agreement with this we find that treatment of INS-
1 cells with Wnt4 is able to inhibit cell growth stimulated by the canonical 
Wnt ligand, Wnt3a (% change in cell growth over 72hrs compared to control; 
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10ng/ml Wnt3a: 114.8±1.03% (p<0.0001), 10ng/ml Wnt4: 97.1±1.04%, 10ng/
ml Wnt3a+10ng/ml Wnt4: 97.3±0.97% (mean±sem), n=4).
Conclusion: Our data suggests that Wnt4 may act as a negative regulator 
of canonical Wnt signalling in beta-cells, leading to inhibition of beta-cell 
proliferation.
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Pancreatic cell fate decisions after beta cell specific insulin gene knockout 
in adult mice: a new model of acute beta cell ‚dedifferentiation‘
M. Szabat1, M.M. Page1, Y. Fan2, M. Trucco2, J.D. Johnson1;  
1Cellular and Physiological Sciences, Diabetes Research Group, University 
of British Columbia, Vancouver, Canada, 2Division of Immunogenetics, 
Children‘s Hospital of Pittsburgh, USA.
Background and aims: Pancreatic beta cell de-differentiation, including the 
loss of key regulatory gene networks, as well as the loss of insulin production 
and storage, has been associated with both type 1 and type 2 diabetes. Stud-
ies using mouse models of toxin-induced beta cell destruction have reported 
beta cell regeneration via beta cell proliferation or trans-differentiation of 
other cell types (such as alpha cells) leading to reversal of diabetes. Our aims 
were to define the potentially cell-autonomous role(s) insulin has in control-
ling beta cell fate, including differentiation/dedifferentiation, trans-differen-
tiation, proliferation and apoptosis.
Materials and methods: We developed an inducible beta cell-specific insulin 
gene knockout model containing four engineered alleles, Pdx1-CreERT/-
:mTmG+/-:Ins1-/-:Ins2f/f. Cre-positive and Cre-negative littermates injected 
with vehicle or tamoxifen, respectively, were used as controls. Animals (6-8 
weeks) were monitored for fasting blood glucose and plasma insulin levels 
for a 5 week or 6 day period. Pancreatic sections were used for immunohisto-
chemical analysis for beta cell specific markers and markers for proliferation 
and apoptosis. Isolated islets were also harvested for RNA sequencing and 
qPCR.
Results: Tamoxifen-induced insulin gene deletion in pancreatic beta cells 
led to overt diabetes, marked by severe fasting hyperglycemia within 14 ± 
4 days in male mice (fasting blood glucose 29.6 ± 0.55 versus 8.7 ± 0.22mM 
at 5 weeks, p<0.05), with females having a delayed response (fasting blood 
glucose 17.6 ± 2.3 versus 8.13 ± 0.41mM at 5 weeks, p<0.05). Body weights 
remained stable throughout the study period in both sexes. The observed 
sex difference in diabetes incidence could be accounted for by differences in 
insulin sensitivity. As expected, plasma insulin levels were also significantly 
decreased to 38 ± 2.7% (p<0.05) of pre-tamoxifen levels in diabetic male 
mice. A significant reduction in insulin positive beta cell number/area was 
evident when comparing diabetic mice to non-diabetic animals. Prior to and 
after reaching hyperglycemia, immunohistochemical analysis of pancreatic 
sections did not reveal obvious signs of widespread trans-differentiation. Pre-
liminary data also showed a 1.83 fold increase in beta cell proliferation in 
Cre-positive animals 6 days after tamoxifen treatment.
Conclusion: As expected, the loss of insulin gene expression in adult animals 
leads to diabetes. This study sheds light onto the fate of individual beta cells 
when they lose their ability to express insulin, and reveals the cell fate deci-
sions of other pancreatic cell types when insulin secretory function in the ma-
jority of beta cells is lost, in a model that does not induce massive cell killing. 
These results increase our understanding of the role of insulin in the main-
tenance of beta cell differentiation and maturity in the adult state, as well as 
its possible contribution to beta cell death and dedifferentiation in diabetes.
Supported by: JDRF
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Reconstruction of alpha-, beta-, and delta-cells into islet architecture 
upregulates Pdx1 expression through Akt/FoxO1 regulatory pathway
W. Jeon, K.-M. Lee, J.-H. Kim, S.-K. Choi;  
DGIST, Daegu, Republic of Korea.
Background and aims: Islet transplantation has shown promise for treating 
insulin-dependent diabetes mellitus. However, the execution of this therapy 
relies largely on the availability of pancreatic tissue, and thus preparation of 
transplantable islets from cultured pancreatic cells is in high demand. To the 
best of our knowledge, in vitro reconstitution of pancreatic islet from na-
tive alpha-, beta-, and delta-cells has not been reported. We have previously 
generated a bioactive matrix named REP composed elastin-derived domains 
and integrin-binding Arg-Gly-Asp ligands. Using this matrix, we have very 
recently constructed islet-like architectures from the mixed culture of alpha-, 
beta-, and delta-cells from native islets and cell lines. This study aimed to 
investigate the signaling cascade and regulatory mechanism that promoted 
the islet cell survival and expression of islet-specific genes during islet re-
construction.
Materials and methods: Islets were isolated from 6-month aged rats and 
disintegrated into single cell population of alpha-, beta-, and delta-cells by 
trypsin treatment. Wells in a 24-well plate were treated with 200 μl of 1 μM 
REP matrix and incubated at 37 oC for 1 h. After protein precipitation, su-
pernatant PBS solution was pipetted out carefully, and alpha-, beta-, and 
delta-cells were seeded and cultured for 7 days. On day 1, 3, 5, and 7, the 
reorganization of islet architecture and mRNA expression were monitored 
by immunofluorescence microscopy and qRT-PCR, respectively. The protein 
content and phosphorylation ratio were quantified by Western blot analysis.
Results: Our data showed that both the mRNA and protein abundances of E-
cadherin and connexin-36 were much higher in the reconstructed islet than 
those in the conventional monolayer culture. The inhibition of E-cadherin 
or connexin-36 expression by siRNA severely limited islet reconstitution, 
suggesting the involvement of these cell adhesion molecules. Reconstructed 
islet exhibited higher basal insulin secretory activity, and under glucose-
stimulated condition (25 mM glucose) reconstituted islet showed greater 
glucose-stimulated insulin secretion than the cells in the monolayer culture. 
Importantly, the mRNA levels of islet-specific genes such as neuroD (Beta2), 
slc2a2 (Glut2), ins1, ins2, and pdx1 were significantly increased during islet 
reorganization. In addition, expression of proliferating cell nuclear antigen 
(PCNA) was greatly upregulated. Furthermore, Akt phosphorylation was 
also significantly elevated during islet reconstruction. FoxO transcription 
factors play a crucial role in the regulation of differentiation, proliferation, 
and survival of pancreatic islet cells. To analyze Akt/FoxO1 regulatory path-
way, we inhibited Akt activity during islet reconstitution. The inhibition of 
Akt by siRNA or MK2206 decreased both the FoxO1 phosphorylation and 
PCNA and Pdx1 mRNA expression. The inhibition of FoxO1 by AS1842856 
caused upregulation of PCAN and Pdx1 mRNA expression and subsequent 
increase in their protein content. The activation of Akt accompanied by the 
FoxO1 phosphorylation and cytoplasmic retention of FoxO1, resulting in in-
activation of transcriptional repression of Pdx1 gene expression.
Conclusion: We conclude that during islet reconstruction, Akt promotes is-
let cell survival and islet-specific gene expression through FoxO1 regulation.
Supported by: DGIST grants (Project No. 14-NB-01 and 14-BD-06)
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Beta cell mass expansion is impaired in aged rats exposed to 90% 
pancreatectomy and gastrin treatment
N. Tellez1, Y. Martí1, M. Vilaseca1, A. Pla1, E. Montanya1,2;  
1Diabetes, Nutrition and Endocrine diseases, CIBERDEM-IDIBELL-
University of Barcelona, 2Hospital Universitari de Bellvitge, Barcelona, 
Spain.
Background and aims: Aging is a non-modifiable risk factor for the develop-
ment of diabetes. The contribution of impaired beta cell regeneration to this 
increased risk remains unknown. In young rats, 90%-pancreatectomy (Px) 
results in β-cell mass regeneration which is further enhanced with gastrin 
treatment. The aim of our study was to investigate the β-cell regeneration 
potential of aged rats using the 90%-Px model and gastrin treatment.
Materials and methods: 1 and 12 month-old Wistar rats underwent 90%-Px 
and were treated from the day of surgery with [15leu] gastrin-17 (150μg/kg • 
12h, Px+G, n=21) or with vehicle (Px+V; n=21). A group of sham-operated 
rats treated with vehicle was included for each age group (S+V; n=18). Pan-
creatic remnants were harvested on days 3 and 14 after surgery for morpho-
metric, immunohistochemical and gene expression analysis.
Results: Young Px rats showed increased β-cell mass that was further in-
creased with gastrin treatment. Gene expression and nuclear immunolo-
calization of nkx6.1 in ductal cells, and the percentage of extra-islet β-cells 
(indirect markers of β-cell neogenesis) were also increased in gastrin- treated 
young Px rats. β-cell apoptosis was similar among groups, and β-cell replica-
tion and size were similarly increased in gastrin and vehicle-treated young Px 
rats. In aged rats, β-cell mass was not increased in any of the Px groups, de-
spite the increased β-cell replication and individual β-cell size. Gene expres-
sion and nuclear immunolocalization of nkx6.1 in ductal cells, and the per-
centage of extra-islet β-cells were not increased in aged gastrin- or vehicle-
treated Px rats. The dedifferentiation-related transcription factors Neurog3 
and Sox9 were significantly upregulated in islet β-cells from aged Px rats.
Conclusion: The potential for compensatory β-cell hyperplasia and hyper-
trophy is retained in aged rats. In contrast, impaired β-cell neogenesis along 
with beta cell dedifferentiation may contribute to the limited beta cell regen-
eration in aged rats.
Supported by: ACD, SED, CIBERDEM which is a project of ISCIII
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Cell surface marker expression and colony formation in islet-depleted 
pancreatic digests
P. Augstein1,2, E. Bandala-Sanchez2, G. Naselli2, T. Loudovaris3, L. Lee2,  
A. Neale2, P. Campbell3, W.J. Hawthorne4, P. Heinke1, I. Banakh2,  
L.C. Harrison2;  
1Institute of Diabetes, Karlsburg, Germany, 2The Walter and Eliza Hall 
Institute for Medical Research, Parkville, 3St. Vincent’s Institute of Medical 
Research, Fitzroy, 4Westmead Hospital, University of Sydney, Australia.
Background and aims: Stem cells (SCs) are characterized by self-renewal ca-
pacity and pluripotency. Hematopoietic SCs (HSC) are identified by a com-
bination of markers and functional assays. In the adult human pancreas, the 
existence of SCs is debated. To identify putative stem cells, we screened islet-
depleted pancreas digests, a by-product of the islet isolation procedure, for 
expression of surface markers and epithelial colony-forming potential (CFP).
Materials and methods: Islet-depleted pancreas digests from 18 cadaveric 
organ donors were stained with antibodies to hematopoietic, mesenchymal 
(MSC) and epithelial stem cell (EpSC) markers. Cells in the ‘side population’ 
(SP) were identified by Hoechst 33342 dye efflux in a BD-LSR-II-W flow cy-
tometer. EpCam, CD133, Hpd1 and Hoechst 33342 alone or in combination 
were used to separate populations in a FACSAria-C sorter. CFP was evaluated 
in a 2D assay. Data are presented as mean ± SEM.
Results: Very few cells expressed HSC markers (CD45 2.7 ± 0.8 %, CD117 1.2 
± 0.6 %, CD31 10.8 ± 0.8 %, CD56 2.8 ± 1.0 %). The MSC marker CD29 was 
detected on a majority of cells (97.1 ± 1.0 %), whereas the other MSC mark-
ers CD44 (46.4 ± 7.8 %), CD34 (34.1 ± 10.8 %), CD90 (17.2 ± 4.5 %), CD105 
(36.1 ± 11.1) and CD73 (27.6 ± 5.3 %) were expressed on fewer cells. Certain 
EpSC markers, EpCam (75.3 ± 3.9 %) and CD49f (60.9 ± 7.1 %), were ex-
pressed by a majority of cells whereas others, CD133 (44.6 ± 7.5 %) and CD26 
(20.5 ± 3.6 %), were expressed by fewer cells. The CFP of pancreas digest cells 
was however significantly enriched by selection for CD133highSP cells, such 
that CD133highSP > SP > CD133high > CD133low. The majority of CD133high 
(61.4 ± 6.3 %) and SP (58.32 ± 6.97 %) cells expressed the ductal marker 
CA19-9. In the human pancreas, ductal cells express CD133 and comprise a 
2-fold increased proportion (3.1 vs. 7.5 %) of the SP.
Conclusion: We identified two markers for the isolation of colony-forming 
cells. Our findings suggest that ductal cells that efflux Hoechst 33342 and 
express CD133high are a reservoir of stem cells in the adult human pancreas.
Supported by: JDRF, EFSD, NHMRC
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Highly-efficient MSCs fusion with beta cells results in beta cell-like 
phenotype
Z. Azizi1,2, F. Paroni1, C. Lange2, A.R. Zander2, C. Westenfelder3,  
K. Maedler1;  
1Center for Biomoleculare interactions, Unversity of Bremen, 2Center of 
Bone Marrow Transplantation, Universitätsklinikum Hamburg-Eppendorf, 
Germany, 3Departments of Medicine and Physiology, University of Utah and 
George E Wahlen Veterans Affairs Medical Centers, Salt Lake City, USA.
Background and aims: Mesenchymal stromal cells (MSC) have anti-inflam-
matory, anti-apoptotic and immunosuppressive effects and they are a potent 
source for cell therapy. Cell fusion enables rapid generation of functional new 
reprogrammed cells. In this study, we aimed to establish a fusion protocol of 
bone marrow derived human MSCs with the rat β-cell line (INS1-E) as well 
as isolated human pancreatic islets in order to generate functional insulin 
producing β-MSCs as a cell-based treatment for diabetes.
Materials and methods: Human MSCs were isolated from bone marrow 
and characterized by colony forming units in culture and flow cytometry 
for expression of CD73, CD105 and CD90 as well as lack of CD45, CD34 
and MHCII. Multipotency was tested by differentiation into the adipogenic 
and osteogenic lineages. To induce cell fusion, eGFP transfected MSCs with 
puromycin as selection marker were cultured with either mCherry-INS1E 
or human dispersed isolated islets and treated with phytohemagglutinin and 
Polyethylene glycol (PEG).
Results: Of the whole cell population, 44 ± 10% polykaryons were identi-
fied based on polyploidy flow cytometry at 2 days after fusion. 29± 6% of all 
MSCs were identified as β-MSC heterokaryons based on double positivity 
for mCherry and eGFP. Six days after fusion and four days after puromycin 
selection, the β-cell transcription factors Nkx6.1, MafA and PDX1 and im-
portant genes for regulating β-cell function insulin, GLUT2 and GCK and 
insulin content were increased in the β-MSCs from fused human dispersed 
islets/MSCs as well as INS-1E/MSCs compared to non-fused controls after 
puromycin selection. Insulin positive β-MSCs also expressed nuclear PDX1.
Conclusion: Our results show an efficient established protocol for fusion of 
human MSCs and β-cells, which resulted in a β-cell like phenotype; this could 
be a novel tool for cell-based therapies of diabetes.
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A novel and reliable protocol for human embryonic stem cell 
differentiation into the definitive endoderm based on dispersed single 
cells
U. Diekmann, S. Lenzen, O. Naujok;  
Institute of Clinical Biochemistry, Hannover Medical School, Germany.
Background and aims: The differentiation of embryonic stem (ES) cells into 
organs derived from the endoderm germ layer, such as liver or pancreas re-
quire as initial step the formation of the definitive endoderm (DE). Human 
ES cell differentiation is usually initiated from colonies, which is the routinely 
used cell culture procedure. However, differences in colony size, colony num-
ber and the potentially altered sensitivity of these cells to media supplements 
render colonies into a suboptimal starting material. The aim of this study was 
the development of a reliable and highly efficient protocol for the differentia-
tion of human ES cells into the DE lineage from dispersed single cells and 
their further differentiation into the pancreatic lineage.
Materials and methods: Three different human ES cell lines were passaged 
as dispersed single cells and defined cell numbers were subjected to differen-
tiation. Different protocols for the DE induction were tested by combining 
various concentrations of Wnt3a, CHIR-99021 and Activin A for four days. 
The expression of the marker genes T, GSC, MIXL1, SOX17 and FOXA2 was 
analyzed by qPCR, flow cytometry, and immunofluorescent staining (IF). 
Furthermore, differentiation of these DE cells into the pancreatic lineage with 
FGF10, retinoic acid, dorsomorphine plus SB-431542 was performed. PDX1- 
and NGN3-positive cells were quantified by IF.
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Results: Differentiation with CHIR-99021 and Activin A for the first 24 h and 
a subsequent treatment with Activin A alone resulted in the highest num-
bers of DE committed cells from all three tested cell lines. The expression 
of the marker genes SOX17 and FOXA2 were significantly increased under 
these conditions compared to random differentiated cells and to a classical 
DE differentiation protocol used as positive control. The quantification by IF 
and flow cytometry of DE committed cells revealed efficiencies ranging from 
~70% (Hues4 and HES3) up to >80% (Hues8), a more than 2-fold increase 
compared to the reference protocol (~33-40%). The ES cells proliferated un-
der this condition resulting in a more than 5-fold increased cell number after 
four days of differentiation. In addition, the dispersed single cells differenti-
ated into DE were able to further differentiate into PDX1-positive progeni-
tors (~40% after 10 days) and subsequently into NGN3-positive endocrine 
precursor cells (~10% after 14 days). High expression levels for the marker 
genes FOXA2, HNF6, MNX1 (HB9), NKX2.2, NKX6.1 and NGN3 in a man-
ner similar to the in vivo pancreatic development were detected proofing the 
maturation of the pancreatic precursor cells.
Conclusion: This novel protocol was able to differentiate three human ES 
cell lines in a highly efficient manner into the DE. Therefore only low initial 
cell numbers and reduced concentrations of expensive growth factors were 
required without growth limitations. In addition, these cells were able to dif-
ferentiate further into the pancreatic lineage and endocrine progenitor cells.
Supported by: REBIRTH Cluster of Excellence (DFG))
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Isolation and characterisation of embryo stem cell-like cells in adult 
human pancreas
S. Lee1,2, S. Jeong2, H. Park2, S.-C. Kim1;  
1Surgery, 2Asan Institute for Life Science, Asan Medical Center, Seoul, 
Republic of Korea.
Background and aims: Within recent years, stem/progenitor cells research 
has become a very important part of regeneration or differentiation into in-
sulin-producing cells. However, the stem/progenitor cells are extremely rare 
attendance and expressing location and moment of these stem cells are not 
clearly demonstrated in adult human pancreatic tissue. Therefore we have 
identified undifferentiated embryo stem cell-like cells expression in adult hu-
man pancreas and isolated for characterization.
Materials and methods: Enriched human exocrine cells are obtained after 
COBE purification of islet isolation. For islet-depleted pancreatic exocrine 
cells culture, endocrine cells were sorted out with microbead conjugated PSA-
NCAM antibody using magnetic-activated cell sorting (MACS) and purified 
CA19-9 positive pancreatic ductal cells or non-purified cells were cultured 
for 6 days. We observed morphology changes and RNA expression pattern of 
embryo stem cell markers. To identification of stem cells present location, we 
SSEA-4 positive cell selected from enriched exocrine cell fraction.
Results: Non-purified crud duct cells attached easily and epithelial-like cells 
extended grow up quickly from primary attached cells but purified ductal 
cells were showed insufficient growth. Expression of classic stem cell mark-
ers: Oct4, c-Myc, Klf4, Nanog, Sox2 and SSEA-4 mRNAs was found in crude 
duct and purified duct cell fraction. However, these stem cell markers was not 
detected or weakly expressed in PSA-NCAM negative and CA19-9 negative 
cell fraction. Classic stem cell mRNA markers were only expressed in SSEA-4 
positive cells and SSEA-4 positive cells were detected in pancreatic duct cell 
by immunocytochemistry.
Conclusion: We characterized and isolated of SSEA-4 positive embryo stem 
cell-like cells in adult human pancreatic duct and hypothesize that these cells 
differentiate to insulin- producing cells in adult human pancreas.
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Expression of insulin genes in foetal liver
S. Takasawa1, S. Murakami-Kawaguchi2, K. Nata3, A. Itaya-Hironaka1,  
S. Sakuramoto-Tsuchida1, A. Yamauchi1, H. Ota1, M. Takeda1, C. Tsuchida1, 
H. Tsujinaka1, T. Fujimura1, H. Okamoto4;  
1Biochemistry, Nara Medical University, Kashihara, 2Internal Medicine, 
Murakami Shinmachi Hospital, Aomori, 3Medical Biochemistry, Iwate 
Medical University School of Pharmacy, Yahaba, 4Tohoku University, 
Sendai, Japan.
Background and aims: Pancreatic beta cells are the major source of insulin 
in adult mammals. The cells have a limited capacity for regeneration and the 
destruction causes type 1 diabetes. Recently, a possible permanent cure for 
diabetes has been explored by using several different approaches, one of them 
being the transdifferentiation of nonpancreatic cells to insulin-producing 
cells. Hepatocytes seem to be an ideal target for the production of insulin, 
because both the liver and ventral pancreas appear to arise from the same cell 
population located within the embryonic endoderm during embryogenesis. 
Despite the similarity in development of these two cell types, the expression 
of the insulin gene in fetal liver has remained elusive because of its pancreatic 
beta cell-specific expression in adult animals. In the present study, we dem-
onstrate insulin mRNA and immunoreactive cells for insulin in fetal liver and 
the promoter activity for insulin in fetal hepatocytes.
Materials and methods: Timed pregnant ICR mice were obtained from Ja-
pan SLC. On embryonic days 13.5 (E13.5), E16.5 and E18.5, livers were dis-
sected. The livers of newborn mice were dissected at Day0. Livers from adults 
were dissected from 14-week-old female mice. Gene expression was analyzed 
by RT-PCR. Immunohistochemical analysis was carried out using antibod-
ies against insulin, proinsulin, processed insulin, glucagon, somatostatin, and 
pancreatic polypeptide. Promoter activity of mouse Ins1 (-703~+14) and Ins2 
(-830~+14) was measured using primary cultured fetal hepatocytes by lucif-
erase assay. Electrophoretic mobility shift assay was carried out using whole-
cell extracts of fetal liver. Human fetal (22-40 weeks) and adult liver RNAs, 
purchased from Clontech, were also analyzed by RT-PCR.
Results: The expression of insulin and transcription factors for insulin is in-
vestigated in mouse fetal liver. We detected mRNAs for Ins1 and Ins2 and 
proinsulin- and mature insulin-positive cells in mouse fetal liver by RT-PCR 
and immunohistochemistry. Glucagon, somatostatin and pancreatic poly-
peptide were not expressed throughout development. Mouse Ins2 and Ins1 
promoters were transiently activated in mouse fetal hepatocytes of E13.5 and 
E16.5, respectively. Pancreatic and duodenal homeobox 1 (Pdx1) mRNA was 
not expressed during development of the liver. In contrast, mRNAs and pro-
teins of neurogenic differentiation (NeuroD)/beta cell E-box transactivator 
2 (Beta2) and v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(MafA) were almost simultaneously expressed with insulin genes in the liver. 
Ins2 and Ins1 promoters were activated in hepatoma cells by the transfection 
of the expression vector for NeuroD/Beta2 alone and by the combination of 
NeuroD/Beta2 and MafA, respectively. In addition, we also analyzed human 
fetal and adult liver RNAs and found that mRNAs for insulin, NeuroD/Beta2, 
and MafA were expressed in human fetal liver.
Conclusion: These results indicate that the expression of NeuroD/Beta2 and 
MafA is linked temporally with the transcription of insulin gene in fetal liver 
and suggest the potential usage of fetal hepatocytes to make insulin-produc-
ing cells by introducing/inducing transcription factors.
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MICU2: a modulator of stimulus-secretion-coupling in INS-1 832 cells
A. Bagge1, L. Andersson1, P. Spégel1, B. Valtat1, V.K. Mootha2, H. Mulder1;  
1Unit of Molecular Metabolism, Lund University Diabetes Center, Malmö, 
Sweden, 2Broad Institute, Cambridge, USA.
Background and aims: In β-cells, glucose-stimulated insulin secretion 
(GSIS) is tightly coupled to the metabolism of glucose, which ultimately trig-
gers a rise in cytosolic calcium (Ca2+) levels activating the exocytotic machin-
ery. Ca2+ is also involved in activation of the more sustained second-phase 
of insulin secretion. However, the mechanism is less clear. The regulated 
mitochondrial Ca2+m-influx during metabolic activation is critical for GSIS 
but the function of Ca2+m is still not fully understood. Mcu and Micu1 are 
subunits of the Mitochondrial Calcium Uniporter complex (MCU-complex) 
and have been shown to be important for ATP synthesis and GSIS. Micu2 was 
recently identified in mouse liver as a part of the MCU-complex functioning 
as a gate-keeper for Ca2+m-uptake, similar to Micu1. Our preliminary data 
show that an expression quantitative trait locus (eQTL) associated with the 
MICU2 gene is correlated with β-cell function (HOMA-β) and fasting glu-
cose in humans. The aim of this study was to investigate the role of Micu2 in 
GSIS and mitochondrial function in the clonal beta-cell line INS-1 832/13.
Materials and methods: Micu2 was silenced for 72 h by siRNA in INS-1 
832/13 cells, and insulin secretion was determined by radioimmunoassay, 
ATP content by luciferase-dependent luminescence, and lactate release as 
wells as NADH/NAD+-ratio by colorimetric assays. Glucose utilization was 
measured as 3H2O after stimulation with 5-
3H-labeled glucose, seahorse 
XF24 was used to measure respiration and metabolite profiling was done by 
GC/MS.
Results: KD of Micu2 in INS-1 832/13 cells resulted in a 33% (N=3, p<0.001), 
37% (N=3, p<0.01) and 33% (N=3, p<0.05) reduction in insulin secretion 
compared to control cells at 2.8 mM and 16.7 mM glucose and 10 mM glycer-
aldehyde, respectively. No alteration in insulin secretion was observed when 
cells were stimulated by pyruvate or leucine/glutamine. Respiration rate was 
similarly decreased in Micu2 KD cells at 2.8 mM and 16.7 mM glucose com-
pared to control cells, while pyruvate-stimulated respiration was unaltered. 
Interestingly, KD of Micu2 abolished glucose-stimulated spare respiratory 
capacity by decreasing the maximal respiration rate by 44% (N=3, p<0.01); 
this was not observed during pyruvate-fueled respiration. KD of Micu2 af-
fected neither total cellular ATP content nor lactate secretion while glucose 
utilization was decreased. A 3.5-fold increase in the glucose-induced rise in 
NADH/NAD+-ratio was observed in Micu2 KD cells compared to control 
cells. Metabolite profiling showed a 4-fold (N=3, p<0.05) decrease in gluta-
mate/aspartate ratio upon Micu2 KD.
Conclusion: MICU2, a subunit of the MCU complex, modulated NADH/
NAD+-shuttle activity rather than dehydrogenase activities in the TCA-cycle 
since insulin secretion and respiration were decreased only when shuttle-
dependent fuels were used. This is corroborated by decreased glucose uti-
lization, unaltered total ATP content and lactate release as well as increased 
NADH/NAD+-ratio upon Micu2 KD. The decreased glutamate/aspartate-ra-
tio observed points to a perturbation in the malate-aspartate shuttle. Wheth-
er Micu2 acts exclusively in Ca2+ activation of the malate-aspartate shuttle 
or physically interacts with parts of the malate-aspartate shuttle altering its 
activity directly remains to be resolved.
Supported by: Hjelt Diabetes Foundation
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Trans-mitochondrial 13C-flux analysis supports an important role for 
non-oxidative metabolism in insulin secretion from human islets
R.G. Kibbey, T.C. Alves, R.L. Pongratz, O. Yarborough, G.W. Cline,  
G. Mason;  
Internal Medicine/Endocrinology, Yale University School of Medicine,  
New Haven, USA.
Background and aims: Non-oxidative mitochondrial metabolism has previ-
ously been implicated glucose-stimulated insulin secretion (GSIS). In par-
ticular, pyruvate carboxylase (PC) and mitochondrial PEPCK (PEPCK-M) 
have been strongly associated with GSIS. Recent reports suggested that in 
contrast to rodent islets, human islets have relatively little PC flux. The po-
sitional flux of [U-13C6]glucose carbons through each reaction provides im-
portant information regarding its relevance to the GSIS without perturbing 
normal metabolism. Current NMR-based methods are limited by sensitivity 
and cannot resolve the different anaplerotic fluxes.
Materials and methods: A novel quantitative LC/MS-based technique was 
developed to track 13C-labeled substrates and directly measure positional 
step-wise metabolic fluxes in INS-1 cells and human islets. Metabolic flux 
analysis was performed under metabolic steady-state but isotopic non-
steady-state conditions. Absolute flux was calculated with the program 
CWAVE using differential equations to model mass and isotope balance.
Results: Metabolism included oxidative (glycolysis, pyruvate dehydrogenase 
(PDH) and TCA cycle) and non-oxidative (PC, malic enzyme (ME) and PEP-
CK-M) reactions. There was significant isotope dilution between sequential 
steps in glycolysis and TCA consistent with very active metabolic cycling. 
Similar to oxygen consumption, TCA cycle flux increased incrementally 
with glucose (1.27±0.02, 2.31±0.06, and 5.02±0.1 fold, P <0.001, going from 
2.5 to 5 to 7 to 9 mM glucose) while the contribution of PDH to the TCA 
cycle (~90%) remained flat. PC flux was nearly evenly divided between ME 
and PEPCK-M flux, though remarkably, glucose carbons flowed exclusively 
through PEPCK-M and not ME. PC flux increased with glucose starting at 
2% to more than 50% the rate of the TCA cycle (fold increases of 3.73±0.36, 
9.89±0.52, and 28.91±2.2 above background, P<0.001 ) and closely correlated 
with insulin secretion. PEPCK-M flux increased linearly with insulin secre-
tion. Similar rates of PC relative to PDH fluxes were observed in islets from 
human donors.
Conclusion: This technique has broad applicability to the study of intracel-
lular metabolism in normal and diabetic human islets as well as other tissues. 
Quantification of discrete trans-mitochondrial fluxes beta-cells supports a 
very significant contribution of non-oxidative metabolism to the mechanism 
of insulin secretion.
Supported by: NIH R01-DK092606
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Mechanisms underlying translocation of the cAMP effector protein 
Epac2 to the beta cell plasma membrane
I. Alenkvist, A. Tengholm;  
Department of Medical Cell Biology, Uppsala, Sweden.
Background and aims: The second messenger cAMP promotes insulin se-
cretion by amplifying Ca2+-dependent exocytosis in pancreatic β-cells. Pro-
tein kinase A and Epac2, a guanine nucleotide exchange factor for the Rap 
family of small GTPases, mediate the effects of cAMP. Epac2 translocates 
to the β-cell plasma membrane in response to glucose and cAMP-elevating 
agents, but it is not known how the membrane interaction is mediated. Previ-
ous studies have shown involvement of the Ras-association domain close to 
the catalytic domain of the protein. The aim of the present study was to eluci-
date how different domains in the regulatory region contribute to membrane 
localization of Epac2 in β-cells.
Materials and methods: MIN6 β-cells were co-transfected with wildtype 
and mutant versions of Epac2 tagged with the fluorescent proteins GFP and 
mCherry. Time-lapse total internal reflection fluorescence microscopy was 
used to monitor association of the reporter proteins with the plasma mem-
brane in single intact or α-toxin-permeabilized cells.
Results: Addition of cAMP to permeabilized β-cells evoked concentration-
dependent translocation of Epac2 to the plasma membrane with half-maxi-
mal and maximal translocation at 30 µM and >100 µM, respectively. Whereas 
point mutation of the low-affinity cAMP-binding site (G114E) did not af-
fect cAMP-induced Epac2 translocation, removal of the entire low-affinity 
cAMP-binding domain (CNB1) reduced the maximal translocation ampli-
tude to 45% of control but increased the cAMP sensitivity (half-maximal 
translocation at 5.6 µM). After removal of the DEP domain, a protein module 
often involved in membrane anchoring, the cAMP-induced translocation was 
reduced by more than 90%. Epac2 translocation was also investigated in in-
tact cells stimulated with 100 µM of the phosphodiesterase inhibitor IBMX 
or by increase of the glucose concentration from 3 to 11 mM. Both stimuli 
triggered pronounced translocation of wildtype Epac2 to the plasma mem-
brane. The IBMX-induced translocation after DEP removal was lower (58%) 
while that of the CNB1 deletion mutant was significantly higher (145%) than 
control. In contrast, the glucose-induced Epac2 translocation was unaffected 
by either of the CNB1 or DEP deletions.
Conclusion: cAMP-induced translocation of Epac2 to the plasma mem-
brane involves multiple domains of the protein, including the DEP- and the 
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low-affinity cAMP-binding domains. The latter domain is not required for 
translocation, but it extends the range of effective cAMP concentrations and 
increases the magnitude of the translocation response. Glucose-stimulated 
Epac2 translocation in β-cells involves additional signals than cAMP eleva-
tion alone.
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Does increased mitochondrial pool improves beta cell function? 
Trying to create super beta cells with PGC-1a mediated mitochondrial 
biogenesis
A. Besseiche1, G. Guillemain1, E. Ramond1, J.-P. Riveline2, P. Ferré1,  
J.-F. Gautier2, B. Bréant3, B. Blondeau4;  
1Inserm-CRC, 2Hopital Lariboisière, 3Inserm, 4UPMC-CRC, Paris, France.
Background and aims: Understanding diabetes and try to cure it requires 
defining the regulators of pancreatic beta-cell function. Because beta cells 
rely on their cellular metabolism, mitochondrial activity and energy produc-
tion to secrete insulin properly, we tested the idea that augmenting mito-
chondrias in beta cells might improve their insulin secretion capacity, thus 
generating super beta cells that would be adapted to situations of increased 
insulin demand. To this aim, we overexpressed in beta cells the transcrip-
tional coregulator PGC-1α, a potent inducer of mitochondrial biogenesis, 
and studied both in vivo and in vitro the consequences on insulin secretion.
Materials and methods: To carry the study, we used two models of PGC-1α 
overexpression in beta cells: first Min6 cells overexpressing PGC-1α with an 
adenovirus and second, transgenic mice with a specific PGC-1α overexpres-
sion in mice using the Tetracycline inducible system. We measured insulin 
secretion in response to glucose, glucose tolerance in mice, mitochondrial 
function (cellular respiration, ATP turnover and reactive oxygen species - 
ROS - production) and assessed the beta-cell energy status by measuring the 
phosphorylation of the AMP-Kinase.
Results: In Min6 cells, PGC-1α overexpression increases mitochondrial 
biogenesis and β-cell respiration but paradoxically, does not increase ATP 
turnover. PGC-1α overexpression increases ROS production and leads to 
the activation of AMPK, suggesting both an oxidative and energetic stress 
in these cells. Instead of being improved, insulin secretion in response to 
glucose was blunted when PGC-1α is overexpressed. Interestingly, rescu-
ing insulin secretion was achieved using a powerful antioxidant (Tempol) 
to prevent ROS production or using compound C-induced, an inhibitor of 
AMP-kinase activation. Similar results were obtained on isolated islets from 
PGC-1α overexpressing mice: increased ROS production, activated AMPK 
and blunted insulin secretion.
Conclusion: In beta cells, increasing mitochondria with the use of PGC-
1α overexpression induces both an oxidative stress and an energetic stress. 
Therefore, strategies to increase insulin function through increased mito-
chondrial function may not be efficient. Specific mechanisms underlying 
these defects still need to be identified. In contrast with other metabolic tis-
sues, increased mitochondrial pool using PGC-1α is not beneficial for insulin 
production by beta cells.
Supported by: SFD and INSERM
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Mitochondrial coupling efficiency is swiftly increased by hyperoxia 
reciprocally to effects by hypoxia
I. Hals1, S. Bruerberg1, V. Grill1,2;  
1Inst of Cancer Researsch and Molecular Medicine, NTNU, Faculty of 
Medicine, 2Department of Endocrinology, St Olav‘s Hospital, Trondheim 
University Hospital, Trondheim, Norway.
Background and aims: Previous exposure to hyperoxia was recently shown 
to negatively affect beta cell function and viability. These findings are impor-
tant in the context of possible damage to beta cells during hyperoxic treat-
ment in humans, such as in preterm babies, and therefore prompt further 
studies. The early time course of effects of hyperoxia has not been clarified 
and may provide information on mechanisms. Accordingly, here we tested 
for acute effects of hyperoxia on mitochondrial function
Materials and methods: INS-1 derived 832/13 cells were cultured in RPMI 
medium, usually together with 11 mM glucose. For some experiments INS-
1 cells overexpressing uncoupling protein 2 (UCP-2) were used. Oxygen 
consumption was measured in intact cells by high-resolution respirometry 
(OROBOROS) before and after sequential administration of oligomycin 
(which blocks the production of ATP by ATP synthase), FCCP (which induc-
es respiration that maximises oxidative capacity), rotenone and lastly antimy-
cin. Elevated oxygen concentration (400 µM) was achieved in one chamber, 
the other containing normal levels of oxygen (200 µM).
Results: The presence of hyperoxia decreased the inhibitory effect by oli-
gomycin when the inhibitor was added 15-20 min after the introduction 
of hyperoxia. The ratio of oligomycin uninhibited respiration in relation to 
FCCP-induced respiration was increased by 59.4% (from 0.32 ± 0.02 (n = 6) 
at normoxia to 0.51 ± 0.02 (n = 20) at hyerpoxia, p < 0.0003). Similar effects of 
hyperoxia were seen in INS-1 cells overexpressing UCP-2. The glucose con-
centration ( 5.5 or 11 mM) during respirometry did not modify the uncou-
pling effect of hyperoxia. Opposite effects (decreased ratio oligomycin/FCCP 
respiration) was seen in cells pre-exposed for 8 h to hypoxia (0.3% oxygen) 
(0.29 ± 0.01 vs. 0.26 ± 0.02, n = 5, p< 0.05).
Conclusion: 1) Beta cell mitochondria swiftly adapt to hyperoxia by increas-
ing un-coupling 2) This effect is not mediated by UCP2, 3) The effect is re-
ciprocal to that exerted by previous hypoxia. Altogether our findings demon-
strate swift and relevant adaptability of beta cell mitochondria to differences 
in the oxygen environment, a feature that should, in the short term at least, 
promote their survival.
Supported by: Liaison Committee between RHA and NTNU, the Norwegian 
Diabetes Association
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Inhibition of the malate-aspartate shuttle abolishes glucagon secretion 
without affecting insulin secretion from mouse pancreatic islets
L.E. Andersson1, J. Stamenkovic1, A. Bagge1, V.V. Sharoyko1,  
C.B. Wollheim2,3, H. Mulder1, P. Spégel1;  
1Lund University Diabetes Center, Unit of Molecular Metabolism 
Department of Clinical SciencesLund University, 2Department of Clinical 
Sciences, Lund University Diabetes Center, Lund University, Malmö, 
Sweden, 3Department of Cell Physiology and Metabolism, University 
Medical Centre, Geneva, Switzerland.
Background and aims: Altered secretion of both insulin and glucagon has 
been implicated in the pathogenesis of Type 2 diabetes (T2D). The main fo-
cus of research has been on understanding the impaired insulin secretion 
from the pancreatic ß-cells, leaving the mechanisms controlling glucagon 
secretion from the pancreatic α-cells largely unresolved.
Materials and methods: The α-cell line, αTC1-6, and ß-cell line, INS-1 
832/13 were stimulated with glucose, in presence or absence of phenylsuc-
cinate, and pyruvate after which hormone secretion, metabolite levels, glu-
cose utilization, respiration and lactate release were assayed. Key experiments 
were replicated in isolated mouse islets.
Results: INS-1 832/13 and αTC1-6 cells respectively secreted insulin and 
glucagon dose dependently in response to glucose. Glycolytic metabolism 
was similar in the two cell lines; tricarboxylic acid (TCA)-cycle metabolism, 
respiration and ATP-production were less glucose-responsive in αTC1-6 
cells. Hence, a tight coupling of glycolytic and mitochondrial metabolism 
was observed only in INS-1 832/13 cells. Inhibition of the malate-aspartate 
shuttle, using phenyl succinate, impacted glucose-provoked ATP production 
and glucagon secretion from αTC1-6, but not INS-1 832/13 cells. Blocking 
the malate-aspartate shuttle increased levels of glycerol-3-phosphate only in 
the INS-1 832/13 cells. Accordingly, expression of components of the glyc-
erolphosphate shuttle relative to expression of the malate-aspartate shuttle 
was found to be lower in αTC1-6 cells. These results were confirmed in pri-
mary mouse islets, where phenyl succinate abrogated secretion of glucagon 
but not insulin.
Conclusion: Our data suggest that the glycerolphosphate shuttle augments 
the malate-aspartate shuttle in the ß-cell but not so in the α-cell. A suppressed 
activity of the glycerolphosphate shuttle in the α-cell prevents the α-cell from 
maintaining a high rate of glycolysis and glucagon secretion at high glucose 
levels. Importantly, pyruvate- and lactate-provoked glucagon secretion re-
mains unaffected since they are independent of mitochondrial shuttle ac-
tivity. Consequently, secretion of glucagon becomes more sensitive to fuels 
available during physical exercise.
Supported by: Novo Nordisk Foundation
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Shared and unique motifs of nutrient sensing in GLP-1 (GLUTag)  
and insulin (INS-1 832/13) secreting cells
P. Spégel1, L. Shcherbina2, L. Andersson1, C. Wollheim3, N. Wierup2,  
H. Mulder1;  
1Unit for Molecular Metabolism, 2Unit of Neuroendocrine Cell Biology, 
3Lund University Diabetes Centre, Malmö, Sweden.
Background and aims: Glucagon-like peptide-1 (GLP-1), secreted from 
intestinal L-cells, promotes beta-cell proliferation and enhances glucose-
stimulated insulin secretion. Despite this important role for GLP-1, much 
less is known about stimulus-secretion coupling in the L-cell as opposed to 
the beta-cell. GLP-1 secretion from L-cells has been suggested to be mainly 
regulated by nutrient up-take rather than metabolism of such fuels. However, 
it has also been shown that a, as of yet, unknown metabolic signal may po-
tentiate secretion of the hormone. We hypothesized that levels of a potential 
coupling factor of GLP-1 secretion should rise in nutrient stimulated L-cells 
in parallel to increased hormone secretion.
Materials and methods: GLUTag and INS-1 832/13 cells were stimulated 
with a range of different secretagogues in presence and absence of various 
pharmacological inhibitors. Nutrient-provoked hormone secretion was as-
sessed, in addition to profiling of alterations in metabolite levels by gas chro-
matography/mass spectrometry.
Results: Both glucose and glutamine stimulated TCA-cycle metabolism (3-
9-fold, p<0.05) and provoked GLP-1 (1.3-fold, p<0.001, glucose; 1.7-fold, 
p<0.001, glutamine) secretion from GLUTag cells; only glucose evoked se-
cretion of insulin (5-fold, p<0.001) from INS-1 832/13-cells. Both stimuli 
resulted in a rise in intracellular glutamate levels in GLUTag (5-fold, p<0.001, 
glucose; 1.7-fold, p<0.001, glutamine) and INS-1 832/13 (1.3-fold, p<0.01, 
glucose; 30-fold, p<0.001, glutamine). Addition of leucine, activating glu-
tamate dehydrogenase, did not affect GLP-1 secretion from GLUTag cells 
while robustly releasing insulin from INS-1 832/13 cells (5.2-fold, p<0.05). 
The membrane permeable glutamate analogue dimethyl-glutamate yielded 
similar levels of GLP-1 secretion (1.6-fold, p<0.001) and intracellular gluta-
mate levels (23-fold, p<0.05) as glutamine in the GLUTag cells. Addition of 
leucine did not affect dimethyl-glutamate stimulated GLP-1 secretion, but 
yielded similar levels of insulin secretion (5-fold, p<0.05) from INS-1 832/13 
cells as the combination of glutamine and leucine. The membrane permeable 
pyruvate analogue methyl-pyruvate provoked neither GLP-1 secretion nor el-
evated glutamate levels in GLUTag cells, despite a strong effect on TCA-cycle 
metabolism (5-15-fold, p<0.05). The same compound elicited a significant 
increase in TCA-cycle metabolism (4-16-fold, p<0.01) and insulin secretion 
(3-fold, p<0.01) similar to pyruvate in the monocarboxylate transporter-1 ex-
pressing INS-1 832/13 cells; glutamate levels were unaltered. Inhibition of the 
oxoglutarate transporter with phenyl-succinate affected neither GLP-1 secre-
tion nor glutamate levels in GLUTag cells, but decreased insulin secretion 
(-34%, p<0.05) and glutamate levels (-25%, p<0.05) in INS-1 832/13 cells.
Conclusion: Our findings show that metabolic coupling differs between 
L- and the beta-cells. Specifically, involvement and activity of glutamate de-
hydrogenase, mitochondrial metabolism and shuttles differed. Importantly, 
non-electrogenic elevation of glutamate is a signal for GLP-1 secretion, sug-
gesting that glutamate may be a coupling factor in both glucose- and glu-
tamine-stimulated GLP-1 secretion.
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Regulation of Glucose-Stimulated Insulin Secretion (GSIS) by  
miR-130a/b and miR-152 via pyruvate dehydrogenase E1 component, 
alpha subunit PDHA1
J.K. Ofori, V.A. Salunkhe, A. Bagge, A. Wendt, H. Mulder, L. Eliasson,  
J.L.S. Esguerra;  
Dept. of Clinical Sciences, Lund University Diabetes Centre, Malmö, 
Sweden.
Background and aims: MicroRNAs (miRNAs) are small RNAs that regulate 
genes at the post-transcription level and have been implicated in beta cell 
dysfunction. We have previously identified miR-130a/b and miR-152 to be 
up-regulated in the pancreatic islets of the non-obese type-2 diabetes (T2D) 
rat model Goto-Kakizaki (GK). Here we aim to investigate the contribution 
of these miRNAs in glucose-stimulated insulin secretion (GSIS) and to dis-
sect their molecular functions using insulin-secreting cells.
Materials and methods: We cultured the “glucose-responsive”, INS-1 832/13 
and “glucose-unresponsive”, INS-1 832/2 cells at low (2.8 mM) and high (16.7-
mM) glucose concentrations for 1h. The expression levels of miR-130a/b and 
miR-152 were measured by qPCR. MiRNAs were over-expressed by trans-
fecting mature miRNA sequences of miR-130a/b and miR-152. The effect on 
targets predicted by TargetScan was evaluated both on mRNA (qPCR) and 
protein levels (western blot). GSIS assays (at 2.8 mM and 16.7 mM glucose) 
were performed and the released insulin was measured using radioimmu-
noassay. Oxygen consumption rates were measured using extracellular flux 
analyzer, XF24 (Seahorse Bioscience).
Results: Similar to previous findings in GK islets, we found upregulation 
of miR-130a/b and miR-152 in the glucose-unresponsive INS-1 832/2 cells 
compared to INS-1 832/13 cells. At high glucose concentrations, the expres-
sion of the miR-130a, miR-130b and miR-152 decreased in INS-1 832/13 by 
80 % (n=3, p< 0.05), 75% (n=3, p< 0.001) and 60% (n=3; p< 0.05) respectively 
but not in INS-1 832/2. Perturbing the miRNA levels in INS-1 832/13 cells by 
over-expression of mature miR-130a and miR-152 resulted in reduced insulin 
secretion by 30% at 16.7 mM glucose (n=3; p < 0.01) and insulin content by 
70% (n=3; p< 0.05). We also observed decreased oxygen consumption rate 
after miR-130b over-expression. The putative target of the miRNAs, pyruvate 
dehydrogenase E1 component, alpha subunit (PDHA1) was reduced by 40% 
at both mRNA (n=3, p< 0.05) and protein level (n=3; p< 0.05) upon miRNA 
overexpression. Finally we showed that PDHA1 knock-down by siRNA re-
duced glucose-stimulated insulin secretion by 40% (n=3; p< 0.05).
Conclusion: We utilized clonal beta cells with disparate GSIS phenotypes to 
study the contribution of miRNAs in the beta cells. Perturbing the levels of 
miR-130a/b and miR-152 in the glucose-responsive cell line resulted in de-
fective beta cell phenotype such as reduced insulin secretion, reduced insulin 
content and decreased oxygen consumption rate. Consequently, deregulation 
of downstream miRNA targets, such as the PDHA1, a component of pyruvate 
dehydrogenase complex responsible for metabolic coupling in insulin beta 
cells, potentially contributes in beta cell dysfunction.
Supported by: Swedish RC, Diabetic Wellness, Diabetesfonden, Albert P. Foun-
dation, LUDC.
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Differential action of GLP-1 and GIP on human pancreatic islet function 
and viability
Y. De Marinis, P. Storm, J. Fadista, L. Groop;  
Dept of Clincal Sciences Malmö, Sweden.
Background and aims: Gastric inhibitory peptide (GIP) and glucagon-like 
peptide 1 (GLP-1) have been studied intensively in various animal models. 
Physiological studies of these incretins in human pancreatic islets are still 
lacking. Here, we have assessed the direct effects of GIP and GLP-1 on islets 
from non-diabetic and diabetic adult human donors.
Materials and methods: We investigated how the incretins affect glucose in-
duced human islet cell activity by MTS assay. Insulin section from islets of 
61 human donors was measured at 1 and 16.7 mM glucose. To varify various 
gene expression, RNA-sequencing was performed on human islets.
Results: When challenged by high glucose (20 mM, 72 hr), the number of 
metabolically active human islet cells decreased (60% decrease vs. 5.5 mM 
glucose, p<0.001), which can be partially rescued by GLP-1 analogue ex-
endin-4 (40% decrease vs. 5.5 mM glucose, p<0.001), and completely re-
versed by GIP. In islets from diabetic donors, there was a significant decrease 
in numbers of metabolically active cells, and further reduced at high glucose 
(60% decrease, p<0.001). GIP completely reversed the effect of high glu-
cose on reducing the number of metabolically active cells, while exendin-4 
showed no effect. Next, we measured effect of the incretins on insulin secre-
tion in islets from 61 donors at basal glucose (1 mM) and glucose stimulated 
insulin secretion (GSIS, 16.7 mM). The donors could be subdivided into two 
groups based on their response to glucose and incretins. In group 1 (37 do-
nors), islets showed low basal (0.12±0.01 ng/islet/hr) and GSIS (0.44±0.03 
ng/islet/hr) and responded well to GLP-1 (55% increase, p<0.01), but not to 
GIP. Group 2 (24 donors) showed high basal (0.47±0.05 ng/islet/hr) and GSIS 
(1.59±0.14 ng/islet/hr), had no further stimulatory effect of GLP-1 or GIP 
on GSIS. RNA-sequencing on islets showed that group 1 has higher mRNA 
expression of glucose transporter 1 gene (SLC2A1,5.5%, p<0.05) and lower 
expression of glucose transporter 2 gene (SLC2A2, 26.7%, p<0.01) compared 
to group 2.
Conclusion: In conclusion, this work provides a first description of incre-
tin effects in human pancreatic islets. We also showed that islet preparations 
from cadaver donors display different responses to glucose and incretins.
Supported by: ERC; Swedish VR
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Isolation of target genes of liraglutide, a GLP-1 receptor agonist,  
in pancreatic islets by using nano-LC-MS/MS system
E. Yoshida, J. Shirakawa, A. Kimura, H. Hirano, Y. Terauchi;  
Yokohama City University, Japan.
Background and aims: Activation of GLP-1 receptor potentiates insulin se-
cretion and beta cell proliferation in endocrine pancreas. However, the pre-
cise mechanisms by which GLP-1 receptor agonist regulate signaling path-
way involving insulin secretion and beta cell proliferation remain elusive. In 
the present work, we performed quantitative comparative proteome analysis 
of liraglutide-treated mouse islets by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) to identify novel target genes of GLP-1 receptor 
activation.
Materials and methods: Isolated islets from 8 to 10-week old C57BL/6 male 
mice were incubated at 5.6 mM glucose in the presence or absence of liraglu-
tide at a concentration of 1000 nM. More than 50 islets were lysed with urea, 
digested with trypsin, and desalted. The extracts were subjected to nano-LC-
MS/MS analysis by using LTQ Orbitrap Velos. The data were analyzed using 
Progenesis LC-MS software and Databases for Annotation, Visualization and 
Integrated Discovery (DAVID) software.
Results: We first confirmed that the treatment of liraglutide significantly 
increased proliferative BrdU-incorporated cells in isolated islets compared 
with vehicle control (p < 0.05). A total of 26225 proteins were identified from 
1 µg of protein extracts in islets by LC-MS/MS. Among them, the expres-
sion levels of 1012 proteins were increased, and those of 809 proteins were 
decreased in the presence of liraglutide. Analysis based on Gone Ontology 
(GO) categories revealed that genes up-regulated by liraglutide were linked 
to the biological processes of translation, vesicle-mediated transport, glyco-
lysis, and glucose metabolic process (enrichment score ≧ 1.3). There were 19 
proteins whose expressions were significantly elevated more than 2-fold by 
the treatment with liraglutide (anova p < 0.05), including such as Carboxy-
peptidase A1, Proteindisulfide-isomerase A2 (Pdia2), Glycerol-3-phosphate 
dehydrogenase 1-like protein, and Lithostathine-1 (Reg1). We here focused 
on Pdia2 and Reg1, since Pdia2 is supposed to play a role as a molecular chap-
erone and Reg1 is suggested to be involved in β cell regeneration or growth. 
We analyzed mRNA expression of Pdia2 and Reg1 in islets at the concen-
tration of 5.6 mM glucose, liraglutide-treated islets showed modestly higher 
expression than islets of vehicle control (1.28 fold and 1.39 fold, respectively). 
The mRNA expression levels of these proteins were enhanced in the presence 
of 11.1 mM glucose (Pdia2: 7.8-fold, p=0.058 and Reg1: 9.4-fold, p=0.061). 
Whereas there were 12 proteins that were decreased less than 0.5-fold by 
liraglutide, Caveolin-1, a protein which is the principal structural protein of 
caveolae membranes, only showed significant decrease by the treatment with 
liraglutide (anova p < 0.05).
Conclusion: These results suggested that liraglutide stimulated islet cell pro-
liferation and altered the expression levels of proteins such as Pdia2, Reg1 and 
Caveolin-1 in vitro. Pdia2 and Reg1 are suggested to be involved in prolifera-
tion and regeneration of β cells. Caveolin-1 is reportedly related to the regu-
lation of exocytosis and insulin receptor-mediated signaling. GO analysis 
showed that the target molecules of liraglutide were related to the functions 
involved in glucose metabolism, and the glucose signal in islets potentiated 
the expression of Pdia2 and Reg1 induced by liraglutide. In conclusion, Pdia2 
and Reg1 are novel targets of liraglutide and may be involved in the prolifera-
tion signal in islets.
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Dipeptidyl peptidase 4 is expressed in pancreatic islets in a species 
specific manner, and its activity is increased by high glucose in isolated 
mouse islets
L. Liehua1, B. Omar2, B. Ahrén2;  
1Endocrinology Department, The First Affiliated Hospital of Sun Yat-sen 
University, Guangzhou, China, 2Department of Clinical Science, Lund 
University, Sweden.
Background and aims: Functional glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic peptide were both discovered in pancre-
atic α cells recently, indicating a local incretin system within islets. However, 
whether dipeptidyl peptidase-4 (DPP-4), an indispensable part of the system, 
is expressed in islets and therefore may be involved in the local regulation of 
islet function remains uncertain. This study examined the islet distribution 
of DPP-4 in different species, as well as the possible regulating factors of its 
activity.
Materials and methods: Co-locolization of DPP-4 and insulin or glucagon 
was examined with immunofluorescent staining in pancreatic sections of 
humans, pigs, C57BL/6 mice and Sprague Dawley rats. Isolated islets from 
wild type mice were cultured in different conditions for 72 hours in RPMI 
medium (with 0.1% bovine serum albumin, 100U/ml penicillin and 100μg/
ml streptomycin) with the medium changed every day. DPP-4 activity of the 
islets was then measured using Gly-Pro-pNitroaniline as the substrate, and 
Nitroaniline as the standard. The examined conditions included different lev-
els of glucose and 5.6mmol/L glucose plus 10nmol/L insulin or 100nmmol/L 
GLP-1. DPP-4 activity was also analyzed in islets from GLP-1 receptor knock-
out mice (GLPR-/-) and double incretin receptor knockout mice (DIRKO).
Results: DPP-4 fluorescent signals were readily observed in islets of all spe-
cies. A pronounced species difference was observed, however. In human and 
pig islets, DPP-4 was expressed exclusively in α cells, with nearly no expres-
sion in β cells. In contrast, in mouse or rat islets, DPP-4 was expressed in a 
β cell dominant manner although low degree of expression was discovered 
in α cells (fig.1). DPP-4 activity in isolated mouse islets was gradually in-
creased by high glucose overtime, and the differences between 5.6 mmol/L 
group (3.6±1.2 pmol/min/islet) and the high glucose groups was statisti-
cally significant after 72 hours of culture (6.3±1.1,6.7±2.5, and 7.3±1.5 pmol/
min/islet for 11.1, 16.7,and 33.3mmol/L, respectively, P <0.05 vs. 5.6mmol/L 
for all groups, n=5). There was no significant effect of 10nmol/L insulin or 
100nmol/L GLP-1 on DPP-4 activity compared with control (5.3±1.5, 4.9±1.0 
and 5.7±1.1 pmol/min/islet respectively, P=0.72 n=3 ). Lack of impact of 
GLP-1 on intraislet DPP-4 activity was further confirmed by the result that 
DPP-4 activity was similar in wild type mice, GLPR-/- mice and DIRKO mice 
(6.5±2.1, 6.9±1.6 and 6.5±0.7 pmol/min/islet respectively, P=0.96, n=3).
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Conclusion: Active DPP-4 is expressed in islets in a species-specific manner. 
Local DPP-4 activity is directly increased by high glucose per se rather than 
via insulin or GLP-1 indirectly. The underlying regulatory mechanism of of 
DPP-4 activity and its clinical implications, as well as the importance of the 
species difference, remain to be further investigated.
Supported by: National Key Clinical Specialties of China.
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Defective compensatory insulin secretion causes HFD-induced glucose 
intolerance in mice with point mutation in free fatty acid receptor 1
G. Kaiser1,2, S. Sabrautzki3,4, F. Gerst1,2, G. Przemeck4,3, H.-U. Häring1,2,  
M. Hrabĕ de Angelis3,4, S. Ullrich1,2;  
1Institute for Diabetes Research and Metabolic Diseases (IDM) of the 
Helmholtz Center Munich, German Center for Diabetes Research (DZD 
e.V.), Tübingen, 2Internal Medicine IV, Endocrinology, Diabetology, 
Angiology, Nephrology und Clinical Chemistry, University Hospital 
Tübingen, 3German Center for Diabetes Research (DZD e.V.), Germany, 
4Institute of Experimental Genetics, Helmholtz Zentrum München, German 
Research Center for Environmental Health, Munich, Germany.
Background and aims: The fatty acid receptor 1 (FFAR1/GPR40) mediates 
the fatty acid-dependent augmentation of glucose-induced insulin secretion 
(GIIS) in pancreatic beta-cells. This feature led to the generation of specific 
FFAR1-agonists for the treatment of hyperglycemia. Intriguingly, Ffar1-
/- mice were protected against liver steatosis, suggesting that antagonists of 
FFAR1 could have beneficial effects on metabolism. To further understand 
the impact of FFAR1 on the regulation of glucose homeostasis and insulin 
disposal, mice carrying point mutations in Ffar1 were generated.
Materials and methods: 16,800 archived sperm samples were screened for 
N-ethyl-N-nitrosourea-induced point mutations in Ffar1. Mice were gener-
ated on C3HeB/FeJ background using three different sperm samples, each 
carrying one missense mutation in Ffar1. Heterozygous and wild-type lit-
termates were fed chow (CD) or high fat diet (HFD) for 8 weeks. Thereafter, 
glucose tolerance and insulin sensitivity as well as total pancreatic insulin 
content were assessed. Insulin secretion was measured in isolated islets of 
homozygous mice.
Results: Three mice strains, two with single point mutations in the extracel-
lular (T146S and R258W) and one in the intracellular domain (L106P) of the 
receptor showed normal development, behavior and growth. HFD-induced 
insulin resistance and male mice deviated from normal glucose tolerance, 
although the pancreatic insulin content was almost doubled in all the mice 
regardless of genotype. Most interestingly, heterozygous mice carrying the 
T146S-mutation in FFAR1 developed significant glucose intolerance de-
spite the adaptive increase in insulin production. Isolated islets from T146S 
homozygous animals showed impaired insulin secretion in response to the 
FFAR1 agonist TUG-469.
Conclusion: Proper activation of FFAR1 is necessary for insulin hyperse-
cretion in the insulin resistant state, in order to protect from HFD-induced 
glucose intolerance, but FFAR1 receptor signaling may not contribute to the 
adaptive increase in pancreatic insulin synthesis.
Supported by: BMBF to DZD e.V.
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Stimulation of free fatty acid receptor 1 reduces thioredoxin interacting 
protein and exhibits anti-apoptotic properties in insulin secreting cells
M. Panse1, G. Kaiser1,2, F. Gerst1,2, H.-U. Haering1,2, S. Ullrich1;  
1Internal Medicine IV, University Hospital Tübingen, 2Institute for Diabetes 
Research and Metabolic Diseases of the Hemholtz Center Munich at the 
Eberhard-Karls-University of Tübingen (IDM), Germany.
Background and aims: Multiple observations suggest that glucose-de-
pendent stimulation of thioredoxin interacting protein (TxNIP) expression 
contributes to glucotoxicity. TxNIP inhibits thioredoxin thereby increasing 
the mitochondrial oxidative stress. Glucose upregulates TxNIP through a 
ChREBP-dependent transcriptional activation. ChREBP is negatively regu-
lated by FOXO1. Palmitic acid activates FOXO1 through PKCδ and is known 
to downregulate TxNIP, inspite of inducing apoptosis under glucolipotoxic 
conditions. Since palmitic acid also acts as a ligand for Free fatty acid receptor 
1 (FFAR1), TxNIP downregulation could occur via metabolism or receptor 
activation. Recently we observed that FFAR1 agonists exhibit anti-apoptotic 
properties under glucolipotoxic conditions. Present study investigates the 
underlying mechanism of the putative protective effects of FFAR1 agonists.
Materials and methods: Human islets received from the European Centers 
of Islet Transplantation, mouse islets isolated from C57BL/6 and Ffar1-/- mice 
and INS-1E cells were treated either with palmitic acid (50-600 µmol/l) or the 
FFAR1 agonist and antagonist (TUG-469 and TUG 761 respectively, 0.1-10 
µmol/l). Changes in expression were analysed by qRT-PCR and western blot. 
Protein expression was downregulated by siRNA techniques.
Results: In human and mouse islets, as well as INS-1E cells, palmitic acid 
(600 µmol/l) reduced TxNIP mRNA by more than 50% under 11 mmol/l glu-
cose. This effect was also observed in Ffar1-/- mouse islets. Downregulation 
of PKCδ reversed the effect of palmitic acid on TxNIP, while, INS-1E cells 
overexpressing PKCδ and displaying high levels of nuclear FOXO1, had ex-
tremely low levels of TxNIP. In INS-1E cells, FFAR1 agonist (3-10 µmol/l) re-
duced TxNIP by more than 60% whereas the antagonist (10 µmol/l) doubled 
it. In contrast to palmitic acid, the FFAR1 agonist (10 µmol/l) downregulated 
TxNIP in a FFAR1 dependent manner. However, downregulation of either 
PKCδ or FOXO1 could not reverse the effects of the ligands.
Conclusion: The observations suggest that inhibition of TxNIP could be me-
diated by two distinct pathways: one pathway involves PKCδ dependent nu-
clear accumulation of FOXO1, stimulated by high concentrations of palmitic 
acid, while the other involves FFAR1 and does not seem to involve PKCδ and 
FOXO1, however, it may contribute to the anti-apoptotic property of FFAR1.
Supported by: GRK1302
406
Expression and function of an omega-3 fatty acid receptor GPR120 in 
Islets of Langerhans
M. Dogan, S.J. Persaud, P.M. Jones;  
Diabetes Research Group, Division of Diabetes and Nutritional Sciences, 
King‘s College London, UK.
Background and aims: GPR120 and GPR40 are both activated by medium 
and long chain fatty acids, although they share only 10% amino acid homol-
ogy. Several previous studies have demonstrated important effects on islet 
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function of GPR40 activation, but much less are known about the expres-
sion and function of GPR120 in islets, although it has been implicated in 
other metabolic processes. The current study investigated the expression of 
GPR120 in mouse and human islets, and measured the effects of a GPR120 
agonist on islet function.
Materials and methods: Expression of GPR40 and GPR120 mRNAs was as-
sessed by quantitative RT-PCR. Fluorescence immunohistochemistry was 
performed to localise GPR120 protein expression in mouse and human pan-
creas. Insulin, glucagon and somatostatin secretion were quantified by radio-
immunoassay. Caspase 3/7 activities were measured to determine apoptotic 
responses to a mixed cytokine challenge (50 U/ml IL-1β, 1000 U/ml TNF-α, 
1000 U/ml INF-γ).
Results: Both human and mouse islets expressed GPR120 mRNA, which 
was 6 times higher than GPR40 mRNA expression in mouse islets (data 
are expressed relative to β-actin mRNA levels; GPR120: 0.4±0.08; GPR40: 
0.07±0.01; n=6; *p<0.05). In mouse islets co-localisation of GPR120 immu-
noreactivity was detected in both insulin-expressing β-cells and glucagon 
expressing α-cells, but not with somatostatin expressing δ-cells. In contrast, 
GPR120 immunoreactivity co-localized only with β-cells in human islets. 
Cytokine-induced apoptosis was significantly reduced in the presence of a se-
lective GPR120 agonist, GAIII (luminescence: control: 50,525±2,473 100nM 
GAIII: 43,755±2,054 1µM: 35,491±2,828 10µM: 38,966±2,519; n=8, P<0.01). 
GAIII had no effect on basal (2mM glucose) insulin secretion but induced a 
significant potentiation of glucose-stimulated insulin secretion from mouse 
islets (20 mM glucose: 2.02±0.7; +1µM GAIII: 4.18±1.22ng/islet/30min; n=8, 
P<0.05). In contrast, GAIII (1µM) had no effect on basal or stimulated gluca-
gon and somatostatin secretion (p>0.2). Perifusion experiments using mouse 
islets confirmed GAIII enhanced glucose-induced (20mM) insulin secretion 
and that this effect was sustainable for the duration of exposure to GAIII. 
The effects of GAIII to stimulate insulin secretion were reduced in the pres-
ence of a PLC inhibitor, U-73122, but not by the PKC inhibitor Go6976 (peak 
stimulation: 1μM GAIII: 203±42% of 20mM glucose alone; 1μM GAIII+1μM 
Go6976: 218±5 (p>0.2); 1μM GAIII+1μM U-73122: 109±5% (p<0.01): n=3).
Conclusion: The medium and long chain free fatty acid receptors GPR120 
and GPR40 are expressed in both mouse and human islets. GPR120 expres-
sion was identified in β-cells and α-cells in mouse islets, but only in β-cells 
in human islets. GPR120 activation by GAIII induced a sustained potentia-
tion of glucose-induced insulin release, but had no effect on basal insulin 
release, nor on basal or stimulated glucagon and somatostatin secretion. Fur-
thermore, GAIII protected mouse islets against cytokine-induced apoptosis. 
These observations indicate that GPR120 is expressed by islets where it may 
offer a therapeutic target for regulating insulin secretion and islet cell apop-
tosis.
Supported by: Turkish Ministry of National Education
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Expression of GPR56 and collagen III in islets: a role in modulating 
insulin secretion
O.E. Olaniru, P.M. Jones, S.J. Persaud;  
Division of Diabetes and Nutritional Sciences, School of Medicine,  
King‘s College London, UK.
Background and aims: GPR56 is a member of the adhesion class of G-pro-
tein coupled receptors (GPCRs) and we have identified that it is one of the 
most highly expressed GPCRs in human islets. Collagen III is its primary 
agonist in the developing brain where it is found to play a significant role 
in formation of the cortex, and CD81, a scaffolding protein, couples GPR56 
with Gq to form a stable complex in the brain. GPR56 has been associated 
with inhibition of apoptosis in leukaemia cells. The role of GPR56 in islets 
is not known, so the aim of this study was to investigate its expression and 
function in islets.
Materials and methods: GPR56, collagen III and CD81 expression were in-
vestigated in mouse and human islets by RT-PCR, Western blotting and im-
munohistochemistry. Insulin secretion was quantified by radioimmunoassay 
after acute (1 hour) or chronic (3 days) exposure to collagen III. Islet insulin 
content after chronic exposure was assayed by acid ethanol extraction. Apop-
tosis induced by exposure of mouse islets to a cytokine cocktail was quanti-
fied by the Caspase-Glo luminescence assay.
Results: GPR56 and CD81 mRNAs were detected by RT-PCR in MIN6 
β-cells and in mouse and human islets, while mRNA encoding collagen III 
was detected in islets but not in MIN6 β-cells. Islet GPR56 expression was 
confirmed by detection of a 65kDa immunoreactive protein and immuno-
histochemistry revealed that collagen III was present in islet capillaries but 
not in endocrine cells. Isolated mouse islets exposed to collagen III for 1 hour 
showed significant reduction in insulin secretion at 2mM glucose (0.41±0.06 
ng/islet/h, + 100nM collagen III: 0.11±0.02, n=6, P<0.01) and 20mM glucose-
induced insulin secretion was also inhibited (4.05±0.74, + 100nM collagen 
III: 1.64±0.32, n=6, P<0.01). Conversely, islets incubated with 100nM colla-
gen III for 3 days exhibited enhanced insulin secretion at both basal and stim-
ulatory glucose concentrations (2mM glucose: 0.26±0.04, +100nM collagen 
III: 0.83±0.18; 20mM glucose: 6.33±0.63, +100nM collagen III: 13.30±1.18: 
n=6-8, P<0.01). There was no effect of 3 days exposure of islets to collagen III 
on insulin content (P>0.2). Measurements of caspase 3/7 activities indicated 
that collagen III did not provide protection against apoptosis, either basally 
(luminescence units: 14,307±1,830; + 100nM collagen III: 10,410±1,577, 
n=8, P>0.1), nor in response to exposure to a cytokine cocktail (lumines-
cence units: 46,746±2,038; +100nM collagen III: 53,452±2,671, n=8, P>0.2).
Conclusion: GPR56 is expressed by mouse and human islets and collagen III 
is localised to islet blood vessels, suggesting that GPR56 may be regulated in 
a paracrine manner by local interaction with its activating ligand. Exogenous 
collagen III does not significantly affect islet apoptosis, but prolonged treat-
ment with collagen III enhances insulin output. Given the proximity of col-
lagen III to islets in the pancreas it is likely that the chronic stimulatory effects 
are physiologically relevant and GPR56 may be a mechanism through which 
the islet vasculature can regulate β-cell function.
Supported by: UK government through Commonwealth Scholarship
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The mitogenic effect of Gas6 on pancreatic beta cells is mediated via the 
receptor tyrosine kinase Axl
T.N. Haase1, A. Gustafsson2, A. Nalla1, L. Ringholm3, P. Damm3,  
E.R. Mathiesen3, B. Dahlbäck2, N. Billestrup1, J.H. Nielsen1;  
1Department of Biomedical Sciences, University of Copenhagen, Denmark, 
2Wallenberg Laboratory, Skåne University Hospital, Malmö, Sweden, 
3Departments of Endocrinology and Obstetrics, University of Copenhagen, 
Denmark.
Background and aims: The pancreatic β-cell mass adapts through life to cope 
with changing metabolic requirements. Thus, the β-cell mass expands in situ-
ations with increased insulin requirements such as the perinatal period and 
during pregnancy. Growth arrest specific protein 6 (Gas6) is a ligand for the 
TAM family of receptor tyrosine kinases, comprising Tyro3, Axl and Mer, 
with the highest affinity for Axl. We have shown that Gas6 induces prolifera-
tion of β-cells in perinatal rats in an age-dependent manner and that β-cells 
express Axl. Whether the mitogenic effect of Gas6 on β-cells is mediated via 
Axl is unknown. Besides, Gas6 could potentially affect the β-cell mass in 
other situations in life where the β-cell mass expands. The aims of the cur-
rent study were to 1) identify if Gas6 induce β-cell proliferation via Gas6-Axl 
signaling, 2) identify the cell signaling pathway involved, and 3) determine 
if plasma levels of Gas6 and sAxl (a soluble form of Axl) is regulated in the 
third trimester of pregnancy where an expansion of the β-cell mass occurs.
Materials and methods: The effect of BGB324 (small molecule inhibitor of 
Axl) on Gas6-induced β-cell proliferation and cell signaling, studied with 
a phospho-kinase array and western blotting with specific antibodies, was 
examined in INS1E cells and primary islets of Langerhans isolated from 
neonatal rats. Blood samples for measurement of Gas6, sAxl, leptin, adipsin 
and TNF-α were previously collected from healthy pregnant women (n=23), 
recruited at the start of pregnancy, at median 14 (range 12-16, n=9), 27 (25-
29, n=9) and 33 weeks (31-35, n=23) of pregnancy. Thirteen healthy women 
served as a non-pregnant control group.
Results: Gas6 increased proliferation of INS1E cells and neonatal rat β-cells 
25% and 60% (p<0.05), respectively, and this effect was blunted by BGB324. 
After 30 min. stimulation Gas6 induced a transient increase in phosphoryla-
tion of Akt protein (pS473) in neonatal islets, but not in INS1E cells. The rise 
in p-Akt was blunted by BGB324. There was no difference in plasma levels of 
Gas6 (p=0.76) or sAxl (p=0.90) at 14, 27 or 33 gestational weeks or compared 
to non-pregnant women. In the third trimester (33 weeks) sAxl plasma levels 
correlated positively with plasma leptin (R2=0.37; p=0.035) and plasma adip-
sin (R2=0.39; p=0.031) and tended to correlate inversely with plasma TNF-α 
(R2=0.30; p=0.064).
Conclusion: The mitogenic effect of Gas6 on pancreatic β-cells is medi-
ated via Gas6-Axl signaling. The PI3K/Akt pathway is possibly involved in 
this response. The plasma levels of Gas6 and sAxl are not changed through 
pregnancy or compared to non-pregnant women, suggesting that circulatory 
Gas6/sAxl is not involved in the expansion of the β-cell mass in pregnancy. 
However, the positive correlations of sAxl with leptin and adipsin and nega-
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tive correlation with TNF-α, associated with adipose tissue mass, insulin re-
sistance, and inflammation, could reflect a beneficial anti-inflammatory role 
of sAxl. Gas6/Axl has been reported to repress TNF-α expression in various 
cell types including β-cells. Further studies are needed to understand the bio-
logical importance of the correlations.
Supported by: BerGenBio AS, Novo Nordisk Foundation, Danish Council f. 
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Persephin: a new player in beta cell proliferation
A.J. Ineson1, A. Clarke1, W. Vernon2, D.M. Smith3, N.G. Morgan1,  
M. Sorhede-Winzell3, H.J. Welters1;  
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School, 2Astra Zeneca, Macclesfield, UK, 3Astra Zeneca, Molndal, Sweden.
Background and aims: Defects in beta cell proliferation and survival are 
known to contribute to the development of Type 2 diabetes. Previously glial 
cell line derived neurotrophic factor (GDNF) has been shown to improve 
beta cell proliferation and survival. GDNF is a member of the GDNF family 
ligands (GFLs) which also includes artemin, neurturin and persephin. These 
molecules are all potent neurotrophic factors which preferentially signal via 
GDNF family receptor α 1-4 (GFRα1-4) respectively. Pancreatic beta cells 
share a range of properties with neurons, such as expression of glutamate 
receptors and maintenance of membrane electrical properties which are criti-
cal for the development of action potentials involved in the release of insu-
lin. Expression of GDNF family receptors extends these similarities. Indeed, 
GFLs are essential for the appropriate innervation of the developing pancreas, 
these nerves are associated with Schwann cells which are known to release 
GFLs. Currently the effects of GFLs on pancreatic beta cells are unknown 
and we aim to elucidate their role using the murine beta cell line, MIN6c4, 
as a model.
Materials and methods: Quantitative RT-PCR and western blotting were 
used to measure mRNA and protein expression respectively. Click- iTTM EdU 
kit was used to assess cell proliferation. Trypan blue was used to assess cell 
viability.
Results: Expression of GFRα1-4 mRNA was detected in MIN6c4 cells, mouse 
islets and human islets (n=3, except human islets where n=2). GFRα4 dis-
played at least 10 fold lower expression than all other receptors (Table 1). 
However protein expression of these receptors did not correlate with the 
mRNA levels. In MIN6c4 cell lysates both GFRα1 and GFRα4 protein was 
detected, but the truncated form (isoform 2) of GFRα2 was more abundantly 
expressed than the complete receptor and GFRα3 was undetected. Following 
16hr serum starvation, MIN6c4 cells were incubated for 6 hrs with 100ng/
ml of each GFL. Both GDNF and persephin significantly increased prolifera-
tion, whereas neurturin and artemin had no effect (fold increase compared 
to untreated (mean ± sem); GDNF: 1.8 ± 0.21, p<0.01, persephin: 1.6 ± 0.17 
p<0.05, neurturin: 1.2 ± 0.16 and artemin: 1.2 ± 0.14. One way ANOVA, post 
hoc Dunnett‘s test). In contrast after 1hr pretreatment with 100ng/ml of each 
GFL followed by 24 hr incubation with 0.5mmol/l palmitate to induce cell 
death, no protective effects were observed.
Conclusion: The lack of protein expression of GFRα2 and GFRα3 in MIN6c4 
cells supports the lack of proliferative effects observed after treatment with 
their respective ligands artemin and neurturin. However the expression of 
GFRα4 protein, despite low levels of mRNA expression, correlates with the 
ability of persephin to promote proliferation and suggests that, in addition 
to GDNF, another member of this family, is able to promote beta cell growth, 
thus identifying an additional potential therapeutic target.
Supported by: BBSRC / Astra Zeneca
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Overexpression of angiotensin II type 2 receptor gene induces cell 
apoptosis and dysfunction of insulin secretion in rat insulinoma  
(INS-1) cells
M. Liu1, D.Q. Jing1, S.N. Yin1, Y. Liu2, Y. Wang3;  
1Endocrinology, The First Affiliated Hospital of Chinese PLA General 
Hospital, 2Geriatric Endocrinology, Chinese PLA General Hospital, 
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Background and aims: AngiotensinII (AngII) exerts its effects by activating 
its receptors, primarily type 1 (AT1R) and type 2 receptor (AT2R), however 
there is little known about the effects of AT2R on the function of pancreatic 
islet beta cells.
Materials and methods: To identify the precise role of AT2R in pancreatic 
islet beta cell, INS-1 cells were transfected with a recombinant adenoviral 
vector expressing AT2R (Ad-G-AT2R-EGFP). After transfection, the cell ap-
optosis was detected by Annexin V and Hoechst staining; cell viability was 
determined by MTT assay and crystal violet staining; glucose-stimulated in-
sulin secretion (GSIS) and genes expression of components of classic GSIS 
pathway and the apoptotic pathway were examined.
Results: We found that AT2R overexpression alone induced cell apoptosis 
and suppressed cell viability in a dose- and time-dependent manner. These 
effects did not require exogenous AngII. Meanwhile, increased expression of 
AT2R was associated with decreased GSIS, and downregulation of insulin, 
pancreatic and duodenal homeobox (PDX)-1, glucose transporter (GLUT) 
2 and glucokinase (GCK) mRNA expression in a dose-dependent manner. 
Moreover, overexpression of AT2R markedly increased cleaved caspase-3, 
caspase-8, and caspase-9 protein expression, but decreased Bcl-2, phosphor-
Akt, and phospho-ERK protein expression. AT2R-induced cell apoptosis 
could be blocked by the caspase inhibitor Z-VAD-FMK.
Conclusion: These findings suggest that AT2R overexpression trigger INS-1 
cells apoptosis and dysfunction of insulin secretion, which may be meditated 
via cell death signaling pathway that is dependent on activation of caspase 
family.
Supported by: NSFC Research Programme
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Expression of the chemokine receptors CXCR6 and CX3CR1  
on CD8+ T cells in diabetic RIP-LCMV mice
P. Müller1, S. Lasch1, M. Bayer1, J.M. Pfeilschifter1, A. Ludwig2,  
E. Hintermann1, P. Gutwein1, U. Christen1;  
1Goethe University Hospital Frankfurt,  
2RWTH Aachen University, Germany.
Background and aims: In Type 1 Diabetes (T1D) self-destructing lympho-
cytes are attracted to the islets of Langerhans by proinflammatory chemokines. 
The IFNγ inducible transmembrane chemokines CXCL16 and CX3CL1 with 
their receptors CXCR6 and CX3CR1 and their sheddase ADAM 10 could be 
novel targets for T1D therapy. Here we investigated the expression of, and 
ADAM10 during the pathogenesis of T1D in a mouse model.
Materials and methods: We used the well-established RIP-LCMV model 
of T1D. As a target autoantigen in the β-cells, RIP-LCMV mice express the 
glycoprotein (GP) or the nucleoprotein (NP) of the lymphocytic choriomen-
ingitis virus (LCMV) under control of the rat insulin promoter (RIP). RIP-
LCMV-GP mice develop T1D within two to three weeks after infection with 
LCMV, RIP-LCMV-NP mice within one to six months after infection. In 
order to evaluate the influence of CXCL16/CXCR6 and CX3CL1/CX3CR1, 
RIP-LCMV mice were crossed to either CXCR6 or CX3CR1-deficient mice.
Results: Analysis of pancreas lysates from RIP-LCMV-GP mice collected 
at different times after infection revealed an upregulation of CXCL16 and 
CX3CL1 in a time dependent manner after infection with LCMV. There is a 
strong increase of CXCL16 and CX3CL1 production during the acute phase 
of infection until day 14. Thereafter in the chronic phase of the autoimmune 
destruction of the beta-cells the chemokine production is decreased com-
pared to the peak at day 14, but remains elevated throughout the observation 
time. Histologic studies of pancreata from RIP-LCMV-GP mice collected 
at the same times after LCMV infection revealed an enhanced CX3CL1/
CX3CR1 expression. In particular, CX3CR1 was predominantly found in in-
filtrates of CD4 and CD8 T cells. Stimulation of lymphocytes from different 
organs (spleen, pancreatic lymph nodes, and pancreas) with immunodomi-
nant LCMV-peptides followed by intracellular staining of IFNγ to determine 
autoantigen-specific T-cells revealed a time dependent expression of CX3CR1 
on autoantigen-specific CD8 T-cells. Importantly, CX3CR1 was expressed in 
a significantly higher frequency in pancreatic lymph nodes and spleen on 
specific CD8 T-cells, but was equally expressed in the pancreas. These data 
indicate a selective disappearance of specific CX3CR1+ T cells after encoun-
ter of their target autoantigens in the pancreas. The peak of CX3CR1+ anti-
gen-specific T-cells from pancreatic lymph nodes to pancreas is delayed for 
two days indicating a migration of autoaggressive T-cells into the pancreas. 
Preliminary, incidence studies of RIP-LCMV-GP/NP x CXCR6GFP/GFP mice 
showed a significant reduction of T1D development in both models com-
pared with RIP-LCMV.
Conclusion: In summary our data demonstrate that both CXCL16 and CX-
3CL1 are expressed after LCMV infection and remain elevated in the pancreas 
during the autoimmune destruction of beta-cells. However further analyses 
suggest that both the CX3CL1/CX3CR1 and the CXCL16/CXCR6 axis might 
be important for islet infiltration by antigen-specific T cells and subsequently 
the development of T1D.
Supported by: TRIP / Goethe University Hospital
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Commensal bacteria-LPS translocation does not promote the breakdown 
of T cell tolerance and autoimmune diabetes
G. Espinosa Carrasco, M. Villard, P. Plence, J. Hernandez;  
Inserm U844, Université de Montpellier 1, France.
Background and aims: Type 1 diabetes results as a failure of the mechanisms 
that maintain immune tolerance. Genetic and environmental factors con-
tribute to render potentially autoreactive T cells into pathogenic effectors. 
Both, CD8+ and CD4+ T cells override tolerance and cooperate to progres-
sively destroy the beta cells of the pancreas. Interestingly, it has recently been 
shown that commensal bacteria can shape and induce anit-self T cell re-
sponses. These observations suggest that bacterial products may promote the 
breakdown of T cell tolerance. Here we have addressed whether the systemic 
translocation of LPS from commensal bacteria promotes the breakdown of 
peripheral T cell tolerance to pancreatic antigens.
Materials and methods: To address this question, we have utilized transgenic 
mice that express a well-characterized model antigen, influenza HA, in the 
beta cells of the pancreas. These mice are profoundly tolerant of the HA an-
tigen in both the CD8+ and the CD4+ T cell compartments. Mild irradiation 
promotes the breakdown of T cell tolerance and the onset of autoimmune 
diabetes. One of the effects of irradiation is the systemic translocation of LPS 
from commensal bacteria. To assess whether bacterial LPS is responsible for 
the breakdown of tolerance observed we have treated mice with a cocktail of 
antibiotics in the drinking water in order to prevent translocation.
Results: Our results demonstrated that antibiotic treatment can efficiently 
prevent the systemic translocation of LPS induced by irradiation. Surpris-
ingly, the absence of LPS translocation did not prevent the onset of autoim-
mune diabetes in transgenic mice. Beta cell-specifc CD8+ T cells proliferated 
extensively in response to self-antigen cross-presentation in the draining 
lymph nodes of the pancreas, differentiated into effector cells and infiltrated 
the islets of Langerhans inducing disease in both antibiotic treated mice and 
controls. Analyses of the CD11c+ antigen presenting cells demonstrated that 
irradiation induces their activation as measured by the enhanced expression 
of CD80, CD86, CD70, CD40 and MHC II. However, antibiotic treatment 
did not completely reverse this activation in all the dendritic cell subsets ana-
lyzed.
Conclusion: Our results indicate that commensal bacteria LPS translocation 
is not sufficient to promote the breakdown of CD8+ T cell peripheral toler-
ance and the onset of autoimmune diabetes.
Supported by: LNCC
413
Predictive value of decision-tree analysis of blood gene expression 
profiles for islet infiltration in the LEW.1AR1-iddm rat model  
of type 1 diabetes
T. Schoeppe1, H. Weiss1, R. Schmidt2, M. Tiedge1;  
1IBIO, 2IBIMA, University of Rostock, Germany.
Background and aims: The LEW.1AR1-iddm rat is an animal model of spon-
taneous autoimmune diabetes. Islet infiltration occurs within a narrow time 
range between 40 and 60 days after birth resulting in progressive beta cell 
destruction and overt diabetes. It was the aim of this study to generate a pre-
diction model (decision-tree) for islet infiltration that based on gene expres-
sion profiles of peripheral blood mononuclear cells (PBMC) of prediabetic 
normoglycaemic LEW.1AR1-iddm rats.
Materials and methods: Normoglycaemic LEW.1AR1-iddm and LEW.1AR1 
control rats were killed at the age of 40 - 60 days. Serial pancreatic sections 
were stained with Haematoxylin-Eosin (HE) to document the state of islet 
infiltration. RNA was isolated from purified PBMCs for PCR-Array analy-
sis and RT-PCR. Gene expression data of proinflammatory cytokines, anti-
inflammatory cytokines and T-cell markers were analyzed by WEKA data 
mining tool using C4.5 algorithm to generate a decision-tree to predict islet 
infiltration.
Results: At the stage of organ preparation all rats were normoglyceamic 
(blood glucose level 5 - 7.5 mmol/l) and were discriminated by the status of 
infiltration (uninfiltrated, infiltrated). The gene expression profile of PBMCs 
followed a two-peak model with high expression of chemokines at day 40, 
60 and downregulation at day 50. The cytokine- and chemokine genes Ccl2, 
Cxcl11, Ccl21, Il-18, TNF (2.1-2,7fold), Cxcl1, Cxcl2, Cxcl3 (3.6-5.4fold) and 
Ccl7, Ccl24 (6.9-8.8fold) were upregulated at day 40 in rats with islet infiltra-
tion and facilitate recruitment of immune cells to the pancreas. A downregu-
lation of cytokine- and chemokine genes was observed for C4b, Ccl1, Ccl17, 
Ccl24, Ccr2, IL-1a, IL-1b, IL-6, IL-6r, IL-9, Tlr4, Tlr7 and TNF in combination 
with upregulated genes Cxcl2, Cxcl3 and IL-22 at day 50 in rats with pro-
gressive islet infiltration. Upregulation was also detected for C4b, Ccl1, Ccl2, 
Ccl21, Ccl22, IL-18 (2.3-5.3fold) and was accompanied by strong expression 
of Cxcl1 (33.8fold), Cxcl3, Cxcl2 (10.2-11.7fold), Ccl7 (49.7fold) and Ccl24 
(129.2fold) in infiltrated animals and highlight a significant inflammation 
state in the blood. Decision tree analysis showed specific combinations of 
genes with predictive character at different time points of islet infiltration. At 
the early stage of islet infiltration (d40) IL-1β proved to be the most predic-
tive marker of islet infiltration. At d45 IL-1β and TNF-α were characteristic 
for islet infiltration while with progression of islet infiltration and beta cell 
destruction the regulatory genes CTLA4 and CD25 (d50), NRP1 and IL-1β 
(d55) and IL-10 (d60) gained decisive power.
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Conclusion: The process of islet infiltration is mirrored by a two peak model 
of proinflammatory and antiinflammatory chemokines/cytokines expression 
in PBMCs. A proinflammatory gene expression profile has predictive power 
for the early period of islet infiltration while anti-inflammatory/regulatory 
genes dominate the progressive period of islet infiltration. In the late period 
of islet infiltration before onset of manifest hyperglycaemia proinflammtory 
genes showed a second peak. Thus, in risk patients the gene expression pro-
files in PBMCs could be an attractive strategy to monitor the state of islet 
autoimmunity in combination with the titer of autoantibodies.
Supported by: EFSD/GSK
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A LADA subform in the LEW.1AR1-iddm rat, a model for human  
type 1 diabetes 
A. Jörns, S. Lenzen;  
Institute of Clinical Biochemistry, Hannover Medical School, Hannover, 
Germany.
Background and aims: The LEW.1AR1-idddm rat as an animal model of hu-
man type 1 diabetes was characterized during diabetes development by an 
immune cell infiltrate of CD4 and CD8 T cells as well as CD68 macrophages 
with proinflammatory cytokine expression in pancreatic islets leading to ap-
optotic beta cell loss. In this rat model a late onset and slowly developing 
subform of diabetes could be distinguished from the early and quickly pro-
gressing one.
Materials and methods: Twice before and immediately after diabetes mani-
festation pancreatic tissue was analyzed, obtained from the rats by sequential 
biopsies and of the residual organ. The analyses were performed by immuno-
histochemistry and in situ RT-PCR for the immune cell composition and the 
cytokine pattern of the infiltrate including proliferation and apoptosis rate of 
the pancreatic beta cells in comparison with the normoglycaemic controls.
Results: The pancreatic islets from normoglycaemic LEW.1AR1-idddm rats 
showed no signs of immune cell infiltration and cytokine expression. Diabe-
tes manifestation took place between day 55 and day 65 for the early develop-
ing subform. In this fulminant subform the immune cell infiltrate was equally 
composed of CD8 T cells and CD68 macrophages started 3 to 5 days before 
diabetes manifestation. Immediately after infiltrating the islets the immune 
cells expressed the proinflammatory cytokines, IL-1β and TNF-α. Ultrastruc-
turally confirmed apoptotic beta cell death showed an apoptosis rate between 
1.7-3.7 % in the TUNEL assay whereas the proliferation rate of beta cells 
ranged from 0.7-2.5 %, as identified by double immunofluorescence staining 
of Ki67 and insulin. Diabetes manifestation occurring after day 80 showed 
a prolonged infiltration process of more than 10 days before disease onset. 
The immune cell infiltrate composition comprised 2/3 CD68 macrophages 
and only 1/3 CD8 T cells. These infiltrating islets strongly expressed the 
chemokine Ccl2 especially attracting macrophages into the islets in contrast 
to islets from the fulminant subform. The proinflammatory cytokine expres-
sion pattern showed a strong expression of IL-1β before diabetes manifesta-
tion and later on after onset concomitant with the expression of TNF-α. The 
apoptosis rate was lower than in the fulminant subform with values between 
0.8-2.0 % whereas the proliferation rate of beta cells ranged from 0.9-3.2 %.
Conclusion: Heterogeneities in the LEW.1AR1-idddm rat colony were ob-
served during diabetes development. Animals with a later onset of diabetes 
showed a milder diabetes form with a high number of surviving beta cells. 
This subform of the LEW.1AR1-idddm rats starting later than day 80 with an 
infiltration dominated by macrophages and a slower beta cell loss resembles 
very well the LADA (Latent Autoimmune Diabetes in Adults) subform in hu-
man adults developing autoimmune diabetes at an age >35 years. The lower 
frequency of T cells and the lower expression level of TNF-α in the immune 
cell infiltrate opens the perspective to develop specific immunomodulatory 
treatments for the LADA type of autoimmune diabetes.
Supported by: DFG (JO 395/2-1) and EU (NAIMIT)
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Aberrant hypothalamic expression of the master clock gene Per1 at 
diabetes onset in non-obese diabetic mice 
V. Burkart1, A. Reinbeck1,2, M. Ingenwerth3, A. Stahr3, H.-J. Partke1,  
C. von Gall3, M. Roden1,4;  
1Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, 
2Kidney Diseases Research, Bayer Pharma AG, Wuppertal, 3Institute for 
Anatomy II, Heinrich-Heine-University Düsseldorf, 4Department of 
Endocrinology and Diabetology, University Clinics Düsseldorf, Germany.
Background and aims: Fundamental metabolic and immunological pro-
cesses follow a circadian periodicity, which is under control of an endoge-
nous rhythm generator in the hypothalamic suprachiasmatic nucleus (SCN). 
Previous studies demonstrated disturbed rhythmicity of energy metabolism 
and physical activity in newly diabetic non-obese diabetic (NOD) mice. We 
therefore hypothesized that the pathogenesis of insulin-deficient diabetes in 
NOD mice is associated with disturbed expression of the period circadian 
clock protein homolog 1 (Per1), a master regulator of circadian rhythmicity 
in the hypothalamus.
Materials and methods: Female C57BL6 mice and prediabetic (normoglyce-
mic) NOD mice (70-80 days old) as well as newly diabetic (< 5 d) NOD mice 
were kept at a 12-h light / 12-h dark cycle. The physical activity (registered as 
“counts”) and the respiratory exchange rate (RER) of the animals were moni-
tored in an automated modular system for comprehensive metabolic pheno-
typing. Immunohistochemistry of the SCN was performed to quantify the 
expression of the master clock gene Per1 and of the transcription factor cFos, 
which reflects general cerebral activity.
Results: C57BL6 mice as well as non-diabetic and newly diabetic NOD mice 
showed comparable low physical activity during light phases whereas dur-
ing dark phases diabetic NOD mice showed a two-fold lower activity than 
C57BL6 and non-diabetic NOD mice (p < 0.05). The altered pattern of physi-
cal activity of diabetic NOD mice was associated with a constantly decreased 
RER in the light (0.82 ± 0.01) and dark phases (0.83 ± 0.01) when compared 
to non-diabetic NOD mice (RER light phase: 0.88 ± 0.01 (p < 0.001); RER 
dark phase: 0.95 ± 0.01 (p < 0.001)). In non-diabetic NOD mice, hypotha-
lamic expression of Per1 was high (Per1 positive cell nuclei in SCN: 126 ± 19) 
at Zeitgeber (ZT) 14 (2 h after light-on). However, at ZT02 (2 h after light-off) 
the Per1 expression in these animals did not show the expected reduction 
that is observed in C57BL6 mice (26 ± 11) but remained elevated (108 ± 14) 
(p < 0.01). In NOD mice, the high levels and the lack of circadian rhythmicity 
of Per1 expression persisted after the onset of diabetes (ZT14: 121 ± 23, ZT02: 
97 ± 19). Higher Per1 expression in NOD mice was associated with a loss of 
the periodicity of their hypothalamic cFos expression after diabetes onset.
Conclusion: In conclusion, the finding of an aberrant hypothalamic expres-
sion of the master clock gene Per1 in prediabetic NOD mice points to a role of 
disturbed circadian rhythmicity during the development of insulin-deficient 
diabetes in this model of type 1 diabetes.
Supported by: German Center for Diabetes Research
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Targeted deletion of SIRT6 in pancreatic beta cells leads to glucose 
intolerance
M. Song1, S. Ka1, E. Bae2, B. Park1;  
1Biochemistry, Chonbuk National University, Jeonju,  
2Pharmacy, Woosuk University, Wanju, Republic of Korea.
Background and aims: Sirtuin 6 (SIRT6) has emerged as a key regulator of 
glucose and fatty acid metabolism in liver and adipose tissues. However, the 
role of SIRT6 in pancreatic beta-cells has not reported. In this study, we ex-
amined the physiological role of SIRT6 in pancreatic beta-cell function and 
systemic glucose homeostasis.
Materials and methods: A Cre-LoxP system was used to generate beta-cell-
specific SIRT6 knockout (BS6KO) mice. Metabolic and histological analyses 
were carried out in BS6KO mice as well as littermate controls after normal 
chow diet (NCD) or high fat diet (HFD) for 16 weeks. Additionally, isolated 
islets from BS6KO mice were used to investigate the effect of SIRT6 deletion 
on insulin secretion and beta-cell viability.
Results: While their fasting glucose and body weight were comparable with 
wild-type mice on NCD, BS6KO mice fed the HFD induced more weight gain 
and exhibited hyperglycemia in both nonfasting and 16-h fasting conditions. 
Oral glucose tolerance test revealed that BS6KO mice had severe glucose in-
tolerance, which was paralleled by a reduction in insulin-immunoreactive 
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pancreatic beta-cell mass. Mimicking this, islets from BS6KO mice exhibited 
profound defects in the glucose-stimulated insulin secretion. On the con-
trary, normal islets transduced with SIRT6 adenovirus were resistant against 
cytokine- and lipo-toxicity.
Conclusion: In addition to being essential for maintaining glucose homeo-
stasis, SIRT6 is involved in beta-cell function by protecting beta-cells against 
exogenous insults and thereby maintaining insulin secreting capacity.
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Glycogen over-accumulation in beta cells affects insulin secretion and 
glucose homeostasis
J. Mir1,2, R. Gasa2, J. Duran1, R. Gomis2, J.J. Guinovart1;  
1Institute for Research in Biomedicine, 2Institut d‘Investigacions 
Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Background and aims: The presence of detectable amounts of glycogen in 
β-cells of diabetic patients has led to the notion that excessive glycogen ac-
cumulation is involved in glucotoxicity and β-cell dysfunction. However, the 
causal contribution of β-cell glycogen to the pathophysiology of diabetes re-
mains elusive. The regulatory subunit Protein targeting to glycogen (PTG) 
induces the dephosphorylation of glycogen synthase, resulting in a hyper-
activation of this enzyme and enhanced glycogen buildup. In this study, to 
directly investigate the effect of increased glycogen storage in β-cells on glu-
cose homeostasis and β-cell function, we have generated a transgenic mouse 
model over-expressing PTG in these cells.
Materials and methods: Mice over-expressing PTG in β-cells (βPTG) were 
generated by crossing conditional PTG transgenic mice with RIPCre mice. 
RIPCre littermates were used as controls (Ctrl) in all experiments. Glucose 
homeostasis was measured by intraperitoneal glucose tolerance test (IP-
GTT) and insulin sensitivity test (ITT). Pancreatic insulin positive area was 
measured by morphometry. Glycogen was detected by PAS staining and by 
enzymatic methods after precipitation in 66% ethanol and digestion with 
α-amyloglucosidase. Insulin secretion was measured by static incubation of 
isolated islets and quantified by ELISA.
Results: βPTG mice were born at expected ratios and showed no differences 
in growth and body weight. PAS staining revealed heterogeneous glycogen 
accumulation in β-cells. βPTG mice exhibited a mild impairment in glucose 
tolerance (AUC βPTG vs Ctrl: 665 ± 65 vs 429 ± 56, p<0.05) and normal 
peripheral insulin sensitivity. Random plasma glucose levels were indistin-
guishable from controls but fasting glycaemia was significantly lower (βPTG 
vs Ctrl: 45 ± 1.3 mg/dl vs 55 ± 2 mg/dl, p<0.05). Correlating with their mild 
glucose intolerance, morphometric analysis revealed a 33% reduction in pan-
creatic insulin positive area in adult βPTG mice relative to controls (βPTG 
vs Ctrl: 0.36 ± 0.01% vs 0.54 ± 0.04%, p<0.01). To address an additional ef-
fect of accumulated glycogen on insulin secretion, islets were isolated from 
βPTG and controls. Insulin content per islet was similar between βPTG and 
controls: 500 ± 49 ng vs 470 ± 35 ng, NS). Islets isolated from fed ad libitum 
βPTG mice contained 5-fold more glycogen than controls (βPTG vs Ctrl: 5.5 
± 0.4 ng/islet vs 1.1 ± 0.3 ng/islet, p<0.001) but, after an overnight fasting, 
glycogen was depleted to undetectable levels in both groups. Strikingly, βPTG 
islets from fed mice exhibited enhanced glucose-induced insulin secretion 
(percentage of release relative to insulin content at 16.7mM glucose, βPTG vs 
Ctrl: 1.2 ± 0.15% vs 0.68 ± 0.11%, p<0.05). This improvement was lost after 
fasting (βPTG vs Ctrl: 0.57 ± 0.12% vs 0.58 ± 0.11%, NS), suggesting that 
increased glycogen levels in fed βPTG islets were the reason for the enhanced 
glucose-induced insulin secretion.
Conclusion: Our results support the idea that high glycogen levels may con-
tribute to β-cell loss. Intriguingly, our findings also show that glycogen plays 
a beneficial role for glucose-induced insulin secretion. These contradictory 
effects of increased glycogen storage on β-cell physiology expose the pos-
sibility that the accumulation of glycogen has a time and/or dose dependent 
influence on these cells. Further investigations will be needed to define the 
precise mechanisms and progression of such events.
Supported by: EFSD/Novo Nordisk
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Reduction in pancreatic beta cell mass caused by enhanced expression of 
Cdkn1c via interaction between C/EBPβ and epigenetic control
Y. Ihara1, S.-I. Asahara2, H. Inoue1, K. Teruyama1, T. Matsuda2, S. Seino2,  
Y. Kido1;  
1Department of Biophysics,  
2Kobe University Graduate School of Medicine, Japan.
Background and aims: The relationship between pancreatic β-cell mass and 
the onset and progression of type 2 diabetes mellitus has received a lot of 
attention in recent years. Our research focused on the Cdkn1c gene, which 
codes for a cell cycle inhibitor, because it is involved in the regulation of pan-
creatic β-cell mass. The Cdkn1c gene is an imprinting gene whose expression 
is controlled by the non-coding RNA Kcnq1ot1. We found that when the ex-
pression of Kcnq1ot1 decreased, epigenetic alterations induced an increase in 
the expression of Cdkn1c, which, in turn, led to a decrease in the pancreatic 
β-cell mass. We have already reported that the transcription factor C/EBPβ 
accumulates in the pancreatic β-cells of high fat-fed mice. It has been report-
ed that a binding motif of C/EBPβ is present in the Cdkn1c promoter. On 
the basis of these findings, we hypothesize that the accumulation of C/EBPβ 
in pancreatic β-cells with reduced expression of Kcnq1ot1 causes further en-
hancement of Cdkn1c expression and promotes pancreatic β-cell failure.
Materials and methods: C/EBPβ was overexpressed in MIN6 cells treated 
with an inhibitor of epigenetic modification. In addition, Kcnq1ot1-trun-
cated C/EBPβ-overexpressing mice (KT mice) were produced by cross-
breeding Kcnq1ot1-truncated mice with pancreatic β cell-specific C/EBPβ-
overexpressing mice.
Results: The findings showed that the expression of Cdkn1c in MIN6 cells 
was not influenced by the expression level of C/EBPβ, however, it was en-
hanced by treatment with an inhibitor of epigenetic modification, and was 
further enhanced by C/EBPβ overexpression. Studies using chromatin im-
munoprecipitation (ChIP) assays have shown that the binding between C/
EBPβ and the Cdkn1c promoter was significantly enhanced during treatment 
with the inhibitor than under normal conditions. In vivo studies have shown 
that compared to C/EBPβ-overexpressing mice and wild-type mice, KT mice 
show significantly higher blood glucose levels, smaller pancreatic β-cell mass, 
and enhanced expression of Cdkn1c in the pancreatic islets.
Conclusion: The findings suggest that the introduction of epigenetic modifi-
cations into MIN6 cells or pancreatic β-cells may lead to enhanced binding of 
C/EBPβ to the Cdkn1c promoter, then an increase in the expression levels of 
Cdkn1c, and a decrease in pancreatic β-cell mass.
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Tbc1d1 knockout increases glucose-stimulated insulin secretion from 
isolated mouse pancreatic islets
T. Stermann1, F. Neumann2, S. Osthold1, A. Pujol3, F. Bosch3, M. Kragl4,5,  
E. Lammert4,5, A. Chadt1, H. Al-Hasani1;  
1Institute for Clinical Biochemistry and Pathobiochemistry, German 
Diabetes Center, Düsseldorf, 2German Institute for Human Nutrition, 
Potsdam-Rehbruecke, Nuthetal, Germany, 3Center of Animal Biotechnology 
and Gene Therapy, Barcelona, Spain, 4Institute for Beta Cell Biology, 
German Diabetes Center, 5Institute for Metabolic Physiology, Düsseldorf, 
Germany.
Background and aims: The GTPase-activating protein TBC1D1 is known to 
play a crucial role in the translocation process of GLUT4 storage vesicles in 
skeletal muscle. Previous studies showed the expression of TBC1D1 in the 
pancreas, while the physiological functions and the differential expression 
within the pancreas are unknown. In our project we investigate the role of 
TBC1D1 in mouse pancreatic islets of C57BL/6J mice with β-cell specific 
overexpression of Tbc1d1 and with a global knockout for Tbc1d1. 
Materials and methods: To investigate the role of TBC1D1 in isolated mouse 
pancreatic islets we measured changes in glucose-stimulated insulin secre-
tion (GSIS), palmitate uptake as well as protein and gene expression. Statistics 
are calculated by two-tailed, unpaired student‘s t-test.
Results: In Western blots TBC1D1 was highly enriched in the pancreatic 
islets. It could not be detected in Tbc1d1-deficient islets. Isolated islets of 
Tbc1d1-deficient mice showed a significant increase in GSIS (1012,06 % ± 
137,65 % vs. 1593,36 % ± 229,47 %, n=7, p=0.03). In contrast, isolated is-
lets which overexpress Tbc1d1 did not show any changes in insulin secretion 
(625,87 % ± 147,68 % vs. 597,10 % ± 164,93 %, n=7, p=0.67). In addition, 14C-
palmitate uptake in isolated islets from Tbc1d1-deficient mice (n=6) and cul-
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tivated MIN6 cells after Tbc1d1 knockdown (n=5) was significantly increased 
compared to respective controls (0,9 ± 0,038 fmol x min-1 x islet-1 vs. 1,28 ± 
0,069 fmol x min-1 x islet-1, p<0.05 and 0,994 ± 0,039 pmol x min-1 x mg-1 
protein vs. 1,251 ± 0,057 pmol x min-1 x mg-1 protein, p<0.01, respectively). 
Gene expression analysis of Tbc1d1 knockout islets revealed the significant 
up-regulation of Tbc1d4 and fatty acid receptors Ffar3, Gpr119 and Gpr120 
(n=8), genes responsible for cellular lipid sensing.
Conclusion: We showed the enriched expression of TBC1D1 in mouse 
pancreatic islets compared to the exocrine tissue. The significant increase in 
glucose-stimulated insulin secretion of Tbc1d1-deficient islets demonstrates 
a stimulatory effect of Tbc1d1-deficiency. The increased 14C-palmitate uptake 
in Tbc1d1-deficient islets might indicate a function for TBC1D1 in the regu-
lation of lipid metabolism, presumbly by regulating expression, transport or 
activity of fatty acid receptors and transporters. In a physiological context 
we assume that Tbc1d1-deficiency beneficially compensates for insulin resist-
ance and has a protective effect on lipid overload.
Supported by: vivid Research Training Group
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Glucose-induced ATP generation in alpha and beta cells matches the 
control ranges for glucagon and insulin release
J. Li, Q. Yu, A. Tengholm, E. Gylfe;  
Medical Cell Biology, Uppsala, Sweden.
Background and aims: ATP is a crucial signal in glucose-stimulated insulin 
secretion, coupling metabolism to depolarization by blocking ATP-sensitive 
K+ channels. ATP has been attributed various roles also in models of glucose-
regulated glucagon release, but consensus about mechanisms is still lacking. 
The aim of the present study was to clarify whether glucose-induced ATP 
generation in α-cells differs from that in β-cells in a manner consistent with 
a role in signal transduction of glucagon secretion. Since Ca2+ is a major trig-
ger of islet hormone secretion we also determined the relationship between 
Ca2+ and ATP.
Materials and methods: Islets from transgenic GLU-RFP mice, expressing 
red fluorescent protein (RFP) in the α-cells, or from normal C57BL/6 mice 
were transduced with adenovirus expressing the ATP biosensor Perceval. To-
tal internal reflection fluorescence (TIRF) microscopy was used to monitor 
the sub-plasma membrane ATP concentration ([ATP]pm) in superficial islet 
cells. [Ca2+]pm was recorded simultaneously using the indicators Fluo-4 or 
Fura Red. The identity of islet cells were determined by immunostaining and/
or cell-characteristic [Ca2+]pm responses.
Results: Elevating the glucose concentration from 3 to 20 mM induced 
β-cell-typical responses with slow [ATP]pm oscillations that were synchro-
nized among RFP-negative cells in the islets from GLU-RFP mice. However, 
the RFP-positive α-cells showed erratic reactions indicative of molecular 
interference between Perceval and RFP. We therefore analyzed [ATP]pm in 
normal mouse islets, identifying α- and β-cells by cell-characteristic [Ca2+]pm 
responses to low and high glucose as well as to glutamate. Glucose elevation 
from 1 to 5 mM, which inhibits glucagon release, induced small increases in 
average [ATP]pm in both α- (6 ± 2% increase of Perceval fluorescence) and 
β-cells (9 ± 1%). Subsequent elevation to 20 mM glucose, which stimulates 
insulin secretion, resulted in a much less pronounced increase of [ATP]pm in 
α- than in β-cells (12 ± 3% versus 49 ± 2% above the initial baseline). How-
ever, the α-cell response was left-shifted since [ATP]pm at 5 mM glucose was 
45% of that at 20 mM as compared to 19% in the β-cells. At 3 mM glucose 
[ATP]pm was stable in β-cells but showed irregular oscillations in α-cells that 
were antiparallel to oscillations of [Ca2+]pm. At 20 mM both α- and β-cells 
showed [ATP]pm oscillations that were antiparallel to those of [Ca
2+]pm.
Conclusion: [ATP]pm shows a left-shifted glucose dependence in α-cells as 
compared to β-cells, consistent with ATP involvement in glucose-inhibited 
glucagon release. [Ca2+]pm oscillations in both cell types are antiparallel to 
those of [ATP]pm probably reflecting energy-requiring Ca
2+ transport.
421
Biphasic nature of glucose-induced insulin secretion is independent on 
energy metabolism
A.I. Tarasov, J. Galvanovskis, F. Leenders, P. Rorsman;  
OCDEM, Oxford, UK.
Background and aims: Insulin secretion in vivo is biphasic but the underly-
ing mechanisms remain enigmatic. Many intracellular processes have been 
reported to follow an oscillatory/biphasic pattern and have thereby been im-
plicated as regulators of insulin release kinetics. In particular, the sustained 
second phase of insulin secretion has been suggested to be driven by beta-cell 
energy metabolism. However the efforts to dissect the relationship between 
the oxidative metabolism and insulin secretion have been hampered by the 
lack of reliable technology for analysing both processes in real-time.
Materials and methods: We resolved the two phases of insulin secretion in 
intact mouse islets using high-resolution 3-D multiphoton confocal imag-
ing with polar tracers. Cytosolic ATP/ADP ratio (using a recombinant probe 
Perceval) or Ca2+ levels ([Ca2+]i, using trappable dyes) were recorded in paral-
lel with secretion to correlate energy metabolism and intracellular signalling 
events to insulin granule exocytosis.
Results: Exocytosis in pancreatic beta-cells was triggered by the glucose-
induced elevation of cytosolic ATP and Ca2+ influx into the cytosol. Insulin 
secretion correlated strongly with changes in [Ca2+]i but showed little cor-
relation with bi-phasic kinetics of ATP increases. Other substrates of oxida-
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tive metabolism affecting cytosolic ATP/ADP levels, such as amino acids or 
methyl succinate, had no effect on the second phase of secretion. At the same 
time, changes in [Ca2+]i show a strong temporal correlation with exocytosis. 
The effects of [Ca2+]i on insulin exocytosis were potentiated by agents produc-
ing an elevation of intracellular cAMP (like GLP-1).
Conclusion: These findings illustrate the power of on-line high-resolution 
monitoring of multiple parameters in living systems. Our data suggest a hier-
archy of intracellular signalling events in the control of insulin secretion. We 
propose that insulin release kinetics is principally determined by variations of 
signalling events (including [Ca2+]i) rather than energy metabolism. The lat-
ter is likely to play the triggering role but the temporal fine-tuning is exerted 
via more distal events.
Supported by: Wellcome Trust Programme Grant (PR), OxBRC Fellowship 
(AIT)
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Identification of Rab27a-GAP-interacting proteins and its functional 
analysis in pancreatic beta cells
M. Yamaoka1, T. Ando1, M. Okamoto1, T. Terabayashi1, K. Matsunaga2,  
R. Ishizaki2, T. Izumi2, I. Niki1, T. Ishizaki1, T. Kimura1;  
1Pharmacology, Oita University, Faculty of Medicine, Yufu, 2Laboratory 
of Molecular Endocrinology and Metabolism, Department of Molecular 
Medicine, Institute for Molecular and Cellular Regulation, Gunma 
University, Maebashi, Japan.
Background and aims: Membrane trafficking is crucial for the regulation of 
the size of the readily releasable pool of insulin granules and for the recovery 
of insulin secretory membranes. Rab27a, which is a member of the Rab fam-
ily, have been considered to control of pre-exocytosis in pancreatic-beta cells 
through its GTP-dependent effectors. In contrast, the GDP-bound form has 
been regarded as an inactive form, because the functional binding partner 
of this form has not been identified. We previously identified coronin 3 as 
a novel GDP-dependent effector of Rab27a in pancreatic beta-cells. Moreo-
ver, we found that the insulin secretagogue glucose caused a shift from the 
GTP- to GDP-bound Rab27a via Rab27a-GAP, resulting in the regulation 
of endocytosis of insulin secretory membranes. Taken together, GTP- and 
GDP-bound Rab27a regulates insulin secretion at the pre-exocytotic and the 
endocytotic stages, respectively. In the present study, we investigated the un-
derlying mechanisms by which Rab27a-GAP controls endocytosis of insulin 
secretory membranes in pancreatic beta-cells.
Materials and methods: Affinity column chromatography was performed to 
identify Rab27a-GAP interacting proteins. Extracts from the insulin-secret-
ing beta-cell line, MIN6, were loaded onto glutathione-sepharose 4B beads 
coated with GST-Rab27a-GAP. The proteins bound to the columns were 
eluted and were analyzed by peptide mass fingerprinting. For binding assay, 
immunoprecipitation analysis was performed using COS7-cells expressing 
Rab27a-GAP. For the observation of the intracellular localization of Rab27a-
GAP and Arf6-GEF, MIN6-cells were analyzed with a TIRF microscopy sys-
tem or a confocal laser microscopy system.
Results: We identified Arf6-GEF as a Rab27a-GAP interacting protein. 
Arf6-GEF is a guanine nucleotide exchange factor that converts Arf6 from 
the GDP- to the GTP-bound form, resulting in the regulation of endocyto-
sis through clathrin-coated vesicle formation. We found that Rab27a-GAP 
directly interacted with Arf6-GEF. The C-terminal region of Rab27a-GAP 
bound the PH domain of Arf6-GEF. Glucose stimulation induced the redis-
tribution of both Rab27a-GAP and Arf6-GEF to the vicinity of the plasma 
membrane. Silencing of Arf6-GEF inhibited the glucose-induced redistribu-
tion of Rab27a-GAP. In contrast, the redistribution of Rab27a-GAP did not 
occur in Arf6-GEF-silencing cells.
Conclusion: These results indicate that Arf6-GEF is required for the glucose-
induced redistribution of Rab27a-GAP. We previously reported that GDP-
bound Rab27a regulates the retrograde transport of the internalized secre-
tory membrane, the stage after the GTP-bound Arf6-dependent formation of 
clathrin-coated vesicles. We therefore propose a model where Rab27a-GAP is 
involved in both Rab27a and Arf6 signaling and plays a pivotal role in mem-
brane trafficking for insulin secretion.
Supported by: Gunma Univ. (11028)
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Temperature-dependent effects of high glucose and potassium 
depolarisation on insulin granule mobility and exocytosis  
in insulin-secreting MIN6 cells
K. Schumacher1, M. Matz2, K. Baumann2, I. Rustenbeck1;  
1Institute of Pharmacology and Toxicology, 2Institute of Medicinal and 
Pharmaceutical Chemistry, University of Braunschweig, Germany.
Background and aims: It is widely assumed that the first phase of glucose-
induced insulin secretion can be mimicked by K+ depolarization. We found, 
however, that the insulinotropic efficacy was differently affected by lowering 
the temperature. We thus compared parameters of insulin granule mobility 
and secretion during glucose stimulation and K+ depolarization at different 
temperatures.
Materials and methods: Insulin granules were labeled by transient transfec-
tion with insulin-EGFP and the granules present in the submembrane space 
were imaged by TIRF microscopy. Single MIN6 cells were continuously peri-
fused with oxygenated HEPES-buffered Krebs-Ringer medium containing 
the respective stimuli at 37 °C, 32 °C, and 22 °C. The image files (1 sequence 
= 200 images) were evaluated by an in-house written program. The insulin 
secretion of MIN6 pseudo-islets was measured by perifusion with ELISA of 
the fractionated efflux.
Results: At 37 °C stimulation of the perifused MIN6 pseudo-islets with 30 
mM glucose and, after a wash-out period of 10 minutes, 40 mM K+ increased 
insulin secretion. K+ was about twofold more effective than glucose. At 32 °C, 
K+ was even more effective than at 37 °C, and was markedly but only tran-
siently effective at 22 °C. Relative to K+, glucose lost efficacy at 32 °C and was 
virtually ineffective at 22 °C. When the stimuli were applied in the reversed 
sequence K+ was of unchanged efficacy, but glucose was almost ineffective at 
all temperatures. The same experimental protocol was used to measure the 
mobility of insulin granules in the submembrane space of perifused single 
MIN6 cells. Under control conditions (3 mM glucose, 37 °C), the mean num-
ber of submembrane granules was 357 ± 37 per cell footprint at the beginning 
of image acquisition. 33.5 ± 1.4 % of these remained visible throughout the 
sequence (long-term residents). Newly arrived granules made up 8.9 ± 0.6 % 
per image, equivalent to about 32 granules. The number of departing granules 
closely mirrored that of arriving granules (mobility in the z-dimension). The 
short-term residents (present for ≤ 1 s) amounted to 82.2 ± 0.9 % of the total 
number of granules (7547 ± 928) in a sequence. At all temperatures stimula-
tion with glucose and K+ led to an increase in the number of arriving and 
departing granules, independent of the sequence of exposure. Consequently, 
the total number of granules per sequence was increased during phases of 
stimulation. The caging diameter (mobility in the x/y-dimension) in contrast, 
decreased during glucose- and K+-stimulation at 37 °C, but not at 32°C and 
22°C. The number of the long-term resident granules was similar for all three 
temperatures at basal glucose and when 40 mM K+ was applied first. How-
ever, when 30 mM glucose was applied first the number remained stable at 
37°C in contrast to a steady decline at 32°C and 22°C.
Conclusion: At all temperatures, glucose and K+ depolarization enhance the 
granule turnover in the submembrane space. This characteristic fits to K+-
induced secretion, whereas the temperature-dependency of the caging diam-
eter and of the long-term resident granules reflects the secretion pattern of 
the glucose stimulus when it is applied first. Additionally, glucose-induced 
secretion is associated with limited lateral mobility and/or longer presence of 
the granules at the plasma membrane.
Supported by: DFG, DDG, DDS
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CaMKII-mediated metabolis memory of pancreatic beta cells controls 
insulin secretion and is inhibited by palmitate
G.J. Santos1,2, S.M. Ferreira1, F. Ortis1, L.F. Rezende1, A.C. Dias1,  
E.M. Carneiro1, K.H. Kaestner2, A.C. Boschero1, T.R. Nardeli1;  
1Department of Anatomy, Cell Biology and Physiology and Biophysics, State 
University of Campinas, Brazil, 2Department of Surgery and Institute for 
Diabetes, Obesity and Metabolism, University of Pennsilvanya, Philadelphia, 
USA.
Background and aims: Ca2+/calmodulin-dependent protein kinase II (CaM-
KII) functions both in regulation of insulin secretion and neurotransmitter 
release through common downstream mediators. Memory is the ability to 
acquire, to store and to evocate any kind of information. In CNS, the process 
behind this phenomenon in the Long-Term Potentiation (LTP) and is known 
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that it requires Ca2+ to occur. In additional, CaMKII is necessary to store 
information during LTP. In pancreatic ß-cells, CaMKII plays pivotal role 
during GSIS process. Palmitate is a Saturated-fatty-acid-induced important 
for beta cell metabolism, especially during DM2 onset. It is well known that 
palmitate inhibits glucose-induced CaMKII phosphorylation and potentiates 
GSIS. Therefore, we investigates that pancreatic ß-cells acquire and store the 
information as a form of “metabolic memory”, just as neurons store cognitive 
information, and, that palmitate inhibits this process.
Materials and methods: To test this hypothesis, we developed a novel par-
adigm of pulsed exposure of mice and human ß-cells to intervals of high 
glucose, followed by a 24-hour consolidation period to eliminate any acute 
metabolic effects. After this period, we analyzed insulin secretion (by RIA), 
protein expression (by Western blot), response to a glucose-ramp and the 
glucose-induced Ca2+ influx.
Results: Strikingly, ß-cells exposed to this high-glucose pulse paradigm ex-
hibited significantly stronger insulin secretion. This metabolic memory was 
entirely dependent on CaMKII and was inhibited by Palmitate. We also ob-
served, in pulse group, an increase in Ca2+ influx induced by glucose. In ad-
ditional, metabolic memory was reflected on the protein level by increased 
expression of proteins involved in GSIS and Ca2+-dependent vesicle secre-
tion, such as GCK, Cav1.2, SNAP25, pCaMKII and pSynapsin. Finally, we 
observed in human islet elevated levels of the key ß cell transcription factor 
MAFA.
Conclusion: In summary, like neurons, human and mouse ß-cells are able to 
acquire and retrieve information in a process dependent on CaMKII that is 
inhibited by Palmitate.
Supported by: NIH, FAPESP and CNPq
425
Islet microcapillary endothelial cells secrete an attenuating factor  
of insulin secretion
S. Sasson1, B. Daniel1, A. Livne1, K. Nurit2, G. Cohen1;  
1Pharmacology, 2Medicine, Hadassah- Hebrew University School of 
Medicine, Jerusalem, Israel.
Background and aims: Paracrine interactions and chemotactic signals ex-
changed within islet of Langerhans’ endothelium and the endocrine cells 
have been proven critical for the development and organization of functional 
islet units. Moreover, autocrine and paracrine signals within the microen-
vironment of the islets can also modulate β-cell glucose-stimulated insulin 
secretion (GSIS). For instance, it has been shown that several extra-cellular 
matrix components, derived from islets’ microcapillary endothelium (IME), 
regulate β-cell spreading and amplify insulin secretion. We aimed at investi-
gating whether IME secrete other soluble factors that affect β-cell function 
and viability.
Materials and methods: Conventional conditioned-medium (CM) from 
IME (the MS-1 cell line and primary cultures of endothelia cells from rat 
islets) were prepared to study contact-independent IME-β-cell interactions. 
Standard GSIS assay in the absence or presence of insulin secretagogues was 
employed. In addition, cell viability assays (cell count, MTT assay and an-
nexin/PI flow cytometry) and size-based fractionation of the CM were per-
formed.
Results: Our data show that IME-derived CM contained soluble factor(s) 
that markedly attenuated GSIS from both INS-1E β-cell line and freshly iso-
lated rat islets. Fractionation of the CM indicated that the active factor was 
a high molecular weight protein. This factor reduced GSIS without changing 
the rate of insulin biosynthesis, cell viability and cellular ATP content. Using 
the insulin secretagogues IBMX, KCl, tolbutamide and L-arginine, we found 
that only the second phase of insulin secretion was markedly reduced by the 
CM. This was accompanied with a significant decrease in cellular cAMP level 
following glucose stimulation. Furthermore, mass spectrometric analysis of 
several high molecular weight proteins in the active CM fraction are cur-
rently being analysed to identify the active attenuating factors of GSIS.
Conclusion: These findings support the hypothesis that a paracrine interac-
tion between IME and β-cells modulates glucose-dependent insulin release 
and may contributes to maintaining glucose homeostasis.
Supported by: David R. Bloom Center for Pharmacy and the Dr. Adolf and 
Klara Brettler Centre
426
Glucose-stimulated insulin secretion is reduced after treatment  
with rosuvastatin calcium
V.A. Salunkhe, O. Elvstam, J.L.S. Esguerra, L. Eliasson, J. Vikman,  
A. Wendt;  
Diabetes Centre, Islet Cell Exocytosis, Clinical Research Centre, Lund 
University, Malmö, Sweden.
Background and aims: Statins are a family of drugs widely used to reduce the 
risk of cardiovascular disease by lowering the cholesterol levels. Rosuvastatin 
calcium (RS) is one of these highly prescribed statins and there are studies 
suggesting increased risk of diabetes for subjects on RS therapy. Whether RS 
influences insulin secretion from the beta-cell is yet to be established, but 
our group has previously shown that insulin secretion is highly sensitive to 
changes in plasma membrane cholesterol. Here, we aim to investigate the ef-
fects of RS on insulin secretion, exocytosis and Ca2+ influx through voltage-
dependent Ca2+ channels in pancreatic beta-cells.
Materials and methods: The study was performed in INS-1 832/13 cells. 
These cells were treated with different concentrations of RS (20 nM, 200 nM, 
2 μM and 20 μM) for various time spans (24/48 hour (h) and 1/2 month). 
Insulin secretion at 2.8 and 16.7 mM glucose (G) was measured by radio-
immunoassay. Exocytosis was detected as changes in membrane capacitance 
evoked by a train of 10 depolarizations from -70 mV to 0 mV using whole-
cell patch-clamp configuration.
Results: First we studied influence on glucose-stimulated insulin secretion 
(GSIS) in INS-1 832/13 cells treated with above mentioned concentrations of 
RS for 48 h. In cells treated with 200 nM, 2 μM and 20 μM RS insulin secre-
tion at 16.7 mM G was significantly reduced (26%, 35% and 29% reduction; 
p<0.05; p<0.01 and p<0.001 vs control, respectively; n=3-4). Moreover, in 
cells treated with 2 μM and 20 μM RS insulin secretion at 2.8 mM G increased 
significantly (67% and 165% increase; p<0.05 and p<0.01 respectively) and 
there was a significant reduction in total protein content (25% and 50% re-
duction, p<0.05 and p<0.001 respectively) compared to control. The lowest 
concentration of RS tested had no effect on insulin secretion at 2.8 and 16.7 
mM G. We then studied exocytosis in INS-1 832/13 cells treated for 24-48 h 
with the RS concentrations mentioned above. There was no significant dif-
ference in exocytosis in cells treated with the lower concentrations of RS as 
compared to control. However, in cells treated with 20 µM RS exocytosis and 
voltage-dependent Ca2+ current evoked by the first depolarization were sig-
nificantly reduced (34% and 41% reduction, p<0.05 and p<0.05 vs control, 
respectively; n=29-30). Hence, it is tempting to speculate that RS at 20 µM 
reduces exocytosis by altering properties of the voltage-dependent Ca2+ chan-
nels. In order to examine long term effects INS-1 832/13 cells were treated 
with 20 nM RS for 1 and 2 month. Subsequently, insulin secretion assay was 
performed but no significant change in insulin secretion was observed com-
pared to control at this low concentration.
Conclusion: We conclude that RS, dose dependently reduces GSIS in INS-
1 832/13 cells within 48 h. Thus, our data suggest that RS treatment might 
impair insulin secretion. Future experiments in in vivo and primary cells will 
further clarify if this indeed is the case.
Supported by: Swedish RC, Diabetic Wellness, Diabetesfonden, Albert P. Foun-
dation, EXODIAB
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Improvement of glucose-stimulated insulin secretion by heparan sulfate 
proteoglycan syndecan-4 overexpression in mouse pancreatic beta cell 
line
I. Takahashi, S. Takahashi, Y. Soma, H. Kato, C. Tega, H. Kinoshita, K. Nata; 
Dept. of Med. Biochem., Iwate med. Univ. Sch. of Pharm., Shiwa-gun, Japan.
Background and aims: Heparan sulfate proteoglycans (HSPGs) are com-
posed of a core protein to which extracellular glycosaminoglycan chains are 
attached. Syndecan-4 (Sdc4), one of the major heparan sulfate (HS)-contain-
ing core protein, is distributed on the cell surface, where it interacts with vari-
ous proteins, including growth factors, morphogens and extracellular matrix 
components to regulate their signaling. We recently found that HS is local-
ized exclusively around beta-cells in the islets of adult mice and is required for 
islet morphogenesis, beta-cell proliferation and insulin secretion. Further-
more, we found that the 3-O-sulfate groups of HS and Sdc4 are necessary for 
maintaining normal glucose-stimulated insulin secretion (GSIS), confirmed 
these results with RNA interference experiments. In this study, we attempted 
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to overexpress the core protein Sdc4 and to clarify the contribution of Sdc4 
to beta-cell function.
Materials and methods: Subcloning of MIN6 cells, mouse pancreatic beta-
cell line, was performed by the limiting dilution method. The cells were then 
screened and selected by an index of GSIS, KCl-induced insulin secretion, HS 
expression and mRNA expression of Sdc4. A stable transformant expressing 
the mouse Sdc4 was established by transfecting pCMV-mSDC4 and selected 
with hygromycin B. The stable transformant expressing the highest level of 
Sdc4 mRNA (by quantitative RT-PCR analysis) was used for further experi-
mentation. GSIS activity was measured with a basal (2.8 mM) or stimulatory 
(11.2 or 25 mM) glucose concentrations.
Results: MIN6 cells were subcloned, and 30 clones were obtained. Two 
sublines were selected for this study, designated T3 and T16. T3 cells ex-
hibit GSIS in a concentration-dependent manner, whereas T16 cells re-
spond poorly to glucose. In the presence of KCl, T16 cells secreted al-
most the same amount of insulin as T3. Next, the expression of HS in 
these subclones was analyzed by western blot analysis. Immunoblot with 
anti-HS antibody showed a single band of 35 kDa, consistent with the re-
ported size of the Sdc4, was detected in T3 cells. On the other hand, HS 
was not detected in T16 cells. In addition, the mRNA of Sdc4 was de-
tected in T3 cells by RT-PCR analysis, while not detected in T16 cells. 
In Sdc4 overexpressed T16 (T16/mSdc4) cells, insulin secretory response 
exhibited 3.1-fold (p<0.0001) as glucose was increased from 2.8 to 25 mM; 
while, non-transfected (control) T16 cells exhibited 1.3-fold. Moreover, in 
Sdc4 overexpressed T3 (T3/mSdc4) cells, insulin secretory response exhibit-
ed 22.1-fold (p<0.0001) as glucose was increased from 2.8 to 11.2 mM; while, 
control T3 cells exhibited 2.7-fold (p<0.005).
Conclusion: Our data indicate that HSPG Sdc4 plays important role(s) in the 
glucose-stimulated insulin secretory response. However, there exists the dif-
ference in glucose responsiveness between T16/mSdc4 and T3/mSdc4 cells 
compared with control cells. These results indicate that it is necessary to con-
sider the effect of HS chains covalently attached to the Sdc4 in addition to the 
overexpressed Sdc4.
PS 019 Cytokine-induced beta  
cell death
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A combined „omics“ approach identifies NMI as a novel cytokine-
induced regulator of IRE1α and JNK in pancreatic beta cells
F. Brozzi1, S. Gerlo2,3, F.A. Grieco1, S. Lievens2,3, C. Gysemans4, L. Marselli5, 
P. Marchetti5, C. Mathieu4, J. Tavernier2,3, D.L. Eizirik1;  
1Laboratory of Experimental Medicine and ULB Centre for Diabetes 
Research, Université Libre de Bruxelles, 2Department of Medical Protein 
Research, VIB, Gent, 3Department of Biochemistry, Ghent University, 
4Laboratory of Clinical and Experimental Endocrinology, KU Leuven, 
Belgium, 5Department of Clinical and Experimental Medicine, Islet Cell 
Laboratory, University of Pisa, Italy.
Background and aims: Type 1 diabetes (T1D) is an autoimmune disease with 
a strong inflammatory component. The cytokines interleukin-1β (IL-1) and 
interferon-γ (IFN) induce endoplasmic reticulum stress and the unfolded 
protein response (UPR) and contribute to beta cell apoptosis in T1D. IRE1α, 
one of the UPR mediators, triggers insulin degradation and inflammation in 
beta cells and is critical for the transition from “physiological” to “pathologi-
cal” UPR. The mechanisms regulating cytokine-induced IRE1α activation in 
beta cells remain to be clarified. To identify novel cytokine-induced regula-
tors of IRE1α we presently combined MAPPIT (MAmmalian Protein-Protein 
Interaction Trap)-based IRE1α interactome with functional genomics analy-
sis of beta cells exposed to IL-1 + IFN.
Materials and methods: By using ArrayMAPPIT, which identifies proteins 
that bind to the cytoplasmic domain of IRE1α, we identified 31 putative 
IRE1α-interacting proteins. These results were compared against our mi-
croarray and RNA sequencing data from INS-1E cells, FACS-purified rat 
beta cells and human islet cells exposed to IL-1 + IFN to identify IRE1α-
interacting proteins whose expression is modified by cytokines. Among the 
top 5 candidates, N-myc interactor (NMI) was chosen as the most promising 
cytokine-regulated IRE1α-interacting protein. RNA interference was used to 
knockdown (KD) NMI in rat pancreatic beta cells and human islets and his-
tological studies were done in pancreatic sections from non-obese diabetic 
(NOD) mice.
Results: Binary MAPPIT and immunoprecipitation confirmed NMI-IRE1α 
interaction in rodent beta cells. NMI interacted with IRE1α WT as well as 
with the kinase-defective K599A mutant IRE1α, indicating that NMI-IRE1α 
interaction is independent of IRE1α activation. An increased expression of 
NMI was detected in islets from NOD mice with insulitis, and in rodent or 
human beta cells exposed in vitro to IL-1 + IFN (between 3-10 fold increase; 
p<0.05 and p<0.01; n=3-5). NMI KD increased by 50% JNK phosphorylation 
(p<0.001; n=4), and increased cytokine-induced apoptosis by >10% (p<0.05; 
n=4-7) in rodent and human pancreatic beta cells after 24-48 h. Mechanistic 
studies demonstrated that NMI negatively modulates IRE1α-dependent ac-
tivation of JNK via the IRE1α/ TRAF2/ MKK7 pathway. Indeed, double KD 
of NMI with IRE1α, TRAF2 or MKK7 significantly (p<0.05-p<0.001; n=4) 
reverted the effects of NMI KD on JNK activation and/or apoptosis.
Conclusion: By using a combined omics approach, we identified NMI in-
duction as a novel negative feedback mechanism that decreases IRE1α-
dependent activation of JNK and apoptosis in cytokine-exposed beta cells.
Supported by: European Union (Naimit and BetaBat projects), JDRF
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LATS2 controls beta cell apoptosis by regulating the MOB1-Praja2 axis
T. Yuan1, J. Kerr-Conte2, A. Ardestani1;  
1Center for Biomolecular Interactions, Bremen, Germany,  
2Thérapie Cellulaire du Diabète, Lille, France.
Background and aims: Apoptosis is the hallmark of loss of insulin-produc-
ing β-cells in both type of diabetes. We have recently identified Mammalian 
Sterile 20-like kinase 1 (MST1) as a key regulator of β-cell death and dysfunc-
tion in diabetes. On search for endogenous down-stream molecule(s) that 
mediate MST1 activation, we detected expression of the Large tumor sup-
pressor 2 (LATS2) in β-cells whose activation was found under diabetic con-
ditions. LATS2 is a serine threonine kinase and direct down-stream substrate 
of MST1, which plays an important role in regulating cell proliferation and 
apoptosis. So far, the role of LATS2 in the β-cell; whether LATS2 is activated 
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in diabetes and whether such activation triggers β-cell death, are not known 
and is investigated in this study.
Materials and methods: Isolated human islets and the rat β-cell line INS1 
were exposed to a diabetic milieu (IL-1beta/IFNgamma or increased glucose 
concentration (22.2 mM)). Bcl-xL, MOB1 (LATS2-associated protein), Ring-
E3 lygase Praja2 (MOB1 negative regulator) and β-cell apoptosis (Caspase 3 
& PARP cleavage) were analyzed by Western blotting. Praja2 and Bcl-xL ex-
pression were also analyzed by real-time PCR. LATS2 was overexpressed by 
plasmid transfection, LATS2 inactivation was performed by overexpressing 
dominant-negative LATS2 (dn-LATS2) or specific siRNA to LATS2. Bcl-xL 
turnover was performed in HEK 293 cells overexpressing Bcl-xL and LATS2. 
Results: LATS2 was activated in human islets and INS1 cells exposed to IL-
1beta/IFNgamma or increased glucose concentrations. This correlated with 
MOB1 up-regulation, decreased Praja2 expression and increased β-cell apop-
tosis. Overexpression of LATS2 itself increased MOB1 levels and β-cell apop-
tosis in INS1 cells and human islets indicating that LATS2 alone is sufficient 
to promote β-cell death. MOB1 interacts with and activates LATS2 kinase 
activity. Interestingly, MOB1 co-precipitation with LATS2 was increased in 
the presence the diabetic milieu compared to untreated INS1 cells suggesting 
that MOB1 is essential for the higher LATS2 activity under diabetic condi-
tions. LATS2 overexpression in INS1 cells as well as in Bcl-xL -overexpressing 
HEK293 cells decreased mitochondrial anti-apoptotic protein Bcl-xL without 
changes in Bcl-xL mRNA levels; this suggested that the decrease in Bcl-xL 
expression occurred at a post transcriptional level and mediated the pro-ap-
optotic function of LATS2. Reciprocally, inhibition of endogenous LATS2 ac-
tivity by siRNA knockdown or overexpression of dominant negative LATS2 
protects β-cells from gluco- and cytokine-induced apoptosis demonstrated 
by decreased caspase-3- and PARP-cleavage as well as increased Bcl-xL levels. 
LATS2 knockdown down-regulated MOB1 and restored Praja2 levels under 
diabetic conditions in INS1 cells indicating a major role of MOB1 and Praja2 
in the mechanism of stress-induced β-cell apoptosis. Our results indicate that 
LATS2, MOB1 and Praja2 regulate each other and may be a component of the 
previously uncharacterized stress-sensitive apoptotic pathway. Under normal 
conditions, Praja2 promoted cell survival by degrading MOB1 and then in-
hibiting LATS2 action, but prolonged diabetogenic stress decreased Praja2 
expression, which allowed higher MOB1 levels and pro-apoptotic LATS2 
signaling.
Conclusion: Our results show that LATS2 plays an important role in β-cell 
apoptosis and its inhibition may provide a new strategy to restore β-cell sur-
vival in diabetes.
Supported by: ERC
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Identification of the ubiquitin ligase SCF(FBW7) as a novel regulator of 
the NF-κB pathway in pancreatic beta cells
K. Meyerovich1, M. Fukaya1, L.F. Terra2, D.L. Eizirik1, A.K. Cardozo1;  
1Université Libre de Bruxelles, Belgium,  
2Universidade de São Paulo, Brazil.
Background and aims: Activation of the transcription factor NF-κB by pro-
inflammatory cytokines contributes to β-cell demise in animal models of 
type 1 diabetes (T1D). Thus, understanding on how NF-κB is activated, is 
crucial to prevent β-cell death. SCF(FBW7) is an ubiquitin ligase with three 
isoforms, localised in the nucleolus, nucleus, and cytosol. It has been previ-
ously reported that FBW7 positively contributes to NF-κB activity in cancer-
ous cells. The aim of this study was to evaluate whether FBW7 modulates 
NF-κB activation and survival of pancreatic β-cells.
Materials and methods: Specific siRNAs were used to downregulate FBW7 
and βTrCP expression. Overexpression of FBW7 was carried out with plas-
mid encoding FBW7. Cell viability was assessed by the DNA-binding dyes 
Propidium Iodide and Hoechst 33342. NF-κB activity was measured using 
a luciferase reporter assay. mRNA expression of NF-κB-dependent genes, 
FBW7 and βTrCP was quantified by qPCR, while the proteins regulating NF-
κB activation were analysed by Western blot.
Results: IL-1β+INF-γ decreased FBW7 mRNA expression in primary rat 
β-cells by 45%. Knockdown of FBW7 by siRNA (FBW7) significantly in-
creased IL-1β+IFN-γ-mediated NF-κB activation in INS-1E cells, primary 
beta cells as well as in human β-cell line as measured by a luciferase reporter 
promoter. This was accompanied by increased expression of the NF-κB tar-
get genes Rantes and CCL19. There was also a two-fold induction of nitric 
oxide production (p<0.001) in INS-1E cells. Conversely, overexpression of 
FBW7 significantly decreased cytokine-induced NF-κB activation. The ef-
fects of FBW7 on NF-κB activation were independent of IκB-α degradation, 
as it knockdown did not modify the pattern of IL-1β+IFN-γ-mediated IκB-α 
degradation. On another hand, knockdown of FBW7 lead to accumulation 
of NFκB2 precursor p100 and increased levels of its cleaved form p52 in the 
nuclear fraction of INS-1E cells after 4H. Induction of NF-κB activity was 
reverted by a double knockdown approach of FBW7 and βTrCP, an E3 ligase, 
which was shown to be responsible for the proteosomal cleavage of p100 to 
p52. In line with these data, FBW7 knockdown potentiated the pro-apoptotic 
effects of IL-1β+IFN-γ in INS-1E cells (2-fold increase vs control siRNA, 
p<0.001), FACS purified rat β-cells (1.9-fold increase vs control siRNA, 
p<0.001) and human β-cell line.
Conclusion: These observations suggest that the E3 ligase FBW7 possesses 
an anti-apoptotic function in β-cells through regulation of the non-canonical 
NF-κB pathway. Moreover, it unveils the involvement of this pathway in IL-
1β+IFN-γ -induced NF-κB activation.
Supported by JDRF, FNRS-Belgium
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Fractalkine (CX3CL1), a new factor protectiong beta cells against TNF-
alpha
K. Bouzakri, S. Rutti, C. Arous, R. Dusaulcy, P.A. Halban;  
Department of Genetic Medicine and Development, CMU, Geneva, 
Switzerland.
Background and aims: We have previously shown the existence of a muscle-
pancreas intercommunication axis in which fractalkine (CX3CL1), a CX3C 
chemokine produced by skeletal muscle cells, could be implicated. It has re-
cently been shown that the fractalkine system modulates murine beta-cell 
function, and CX3CL1 expression is known to be regulated by TNFα, a cy-
tokine that impacts negatively on beta cell function. However, the impact 
of CX3CL1 on islets and sorted beta-cells exposed to TNFα remains to be 
explored.
Materials and methods: Human islets and sorted beta and non-beta cells 
were used to measure CX3CL1 and CX3CR1 mRNA expression by RNAseq. 
Glucose induced insulin secretion (GSIS: 1h; 16.7 mmol/l glucose) was meas-
ured using human islets following exposure to CX3CL1 (1-50 ng/ml) for 24h 
or rat beta cells exposed to 10 and 25ng/ml CX3CL1 for 48h alone or with 
20 ng/ml TNFα for the last 24h. Rat beta-cell apoptosis (TUNEL) and prolif-
eration (BrdU incorporation) were measured after 24h exposure to CX3CL1 
(1 to 50 ng/ml) alone, or to CX3CL1 (20 ng/ml) for 48h with addition of 
cytomix (20 ng/ml TNFα, IL-1β, INFγ) for the last 24h. Insulin signaling was 
analyzed by western blot in sorted rat beta-cells exposed to CX3CL1 (25ng/
ml) for 48h with TNFα (20ng/ml) added for the last 24h. Data are mean±SE 
(5 independent experiments).
Results: CX3CL1 and CX3CR1 are both expressed in human islets: CX3CL1 
is principally expressed by non-beta cells while its receptor is more expressed 
in beta-cells, as confirmed by immunofluorescence. Treatment with CX3CL1 
for 24h had no significant impact on human islet and rat sorted beta cell GSIS 
or insulin content, or on rat beta-cell proliferation and apoptosis. However, in 
rat sorted beta cells CX3CL1 completely blocked the adverse effect of TNFα 
on GSIS (control: 2.64±0.22% content/h; TNFα: 1.46±0.11%*; TNFα + 10 
ng/ml CX3CL1: 3.19±0.12%**; TNFα + 25 ng/ml CX3CL1: 2.62±0.31%**; 
*p<0.05 vs. control; ** p<0.05 vs. TNFα alone) as well as partially protecting 
against the effects of cytomix on apoptosis (control: 0.14±0.06% TUNEL-
positive beta-cells; cytomix: 0.59±0.22%*; cytomix + 25 ng/ml CX3CL1: 
0.26±0.08%*,+; *p<0.05 vs. control; +p<0.05 vs. cytomix alone). Furthermore, 
CX3CL1 (25ng/ml) treatment of sorted rat beta-cells prevented the reduc-
tion in IRS2 protein levels and in glucose-induced phosphorylation of Akt 
and AS160 normally evoked by TNFα. Such treatment with CX3CL1 also 
prevented TNFα-induced phosphorylation of mTOR and NFκB, without any 
impact on TNFα-induced basal ERK-1/2 phosphorylation. Finally, mTOR 
protein expression was reduced in cells pretreated with CX3CL1 and exposed 
to TNFα.
Conclusion: We demonstrate for the first time that CX3CL1 protects beta-
cells from the adverse effects of TNFα on their function, likely by restoring 
phosphorylation of key proteins in the insulin signalling pathway. We further 
demonstrate that CX3CL1 protects rat beta-cells from cytomix-induced ap-
optosis. Our data suggest that CX3CL1 might be an important target to mod-
ulate the negative effects on beta-cells induced by inflammation in Diabetes
Supported by: FNRS
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IL-13 improves beta cell survival and protects against IL-1beta-induced 
beta cell death
S. Rutti1, G. Ruozi2, L. Braga2, V. Jimenez3, A. Casellas3, C. Mallol3,  
E. Casana3, F. Bosch3, M. Giacca2, P. Halban1;  
1Genetic Medicine and Development, University of Geneva, Switzerland, 
2Molecular Medicine Laboratory, International Centre for Genetic 
Engineering and Biothechnology, Trieste, Italy, 3School of Veterinary 
Medicine, Universitat autonoma de Barcelona, Spain.
Background and aims: IL-13 is a cytokine classically produced by anti-in-
flammatory T-helper-2 lymphocytes. Interestingly, IL-13 is decreased in the 
circulation of type 2 diabetic patients and has recently been shown to impact 
positively on liver and skeletal muscle. Although IL-13 can impact positively 
on transformed beta-cell lines, its impact and mode of action on primary hu-
man or rodent beta-cell function and survival remain to be explored.
Materials and methods: Human and rat dispersed islet cells and sorted beta-
cells were maintained in culture for 48 h in the presence of IL-13 (1 to 50 
ng/ml) alone or in combination with IL-1β (20 ng/ml). Insulin secretion in 
response to glucose (1h; 16.7 mmol/l) was measured by radioimmunoassay, 
proliferation by incorporation of BrdU over 48 h, cell death by TUNEL and 
protein expression/phosphorylation by western blot. Results are presented as 
mean±SE, n=3-5 independent experiments with statistical significance of dif-
ferences assessed by Student’s t test or ANOVA with Bonferroni post hoc test.
Results: IL-13 did not affect human or rat beta-cell basal or glucose-stim-
ulated insulin secretion, or rat beta-cell proliferation. IL-13 (10 ng/ml) de-
creased basal cell death in human (IL-13: 0.6±0.2% TUNEL+ cells vs. con-
trol: 1.1±0.3%; p<0.05) and rat beta-cells (IL-13: 0.02±0.01% TUNEL+ cells 
vs. control: 0.12±0.03%; p<0.05) and protected sorted rat beta-cells against 
IL-1β induced apoptosis (normalized to control: IL-1β: 2.6±0.4, p<0.05 vs. 
control; IL-13 + IL-1β: 1.16±0.3%, p<0.05 vs. IL-1β ). However, IL-13 was 
unable to protect beta-cells from IL-1β impaired glucose stimulated insulin 
secretion. IL-13 (10 ng/ml) induced phosphorylation of Akt in rat primary 
beta-cells after 60 min (99±41% increase; p<0.05) and increased IRS2 protein 
expression after 48 h (68±18% increase; p<0.05) without changing protein 
levels of Akt isoforms.
Conclusion: We show for the first time that IL-13 improves survival of pri-
mary beta-cells and protects against IL-1β induced beta-cell death, without 
affecting proliferation or insulin secretion. These effects may be mediated 
through the IRS2/Akt signalling cascade. In addition to any beneficial effects 
on insulin target tissues, these data suggest that IL-13 may be useful for treat-
ment of type 2 diabetes by preserving beta-cell mass or slowing its rate of 
decline.
Supported by: JDRF
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The role of sphingosine-1-phosphate-lyase in insulin-secreting cells
C. Hahn, M. Kaminski, S. Lenzen, E. Gurgul-Convey;  
Hannover Medical School, Germany.
Background and aims: Type 1 diabetes is an autoimmune disease with a 
strong inflammatory component. The sphingolipid metabolism and sphingo-
sine-1-phosphate (S1P) play an important regulatory role in the development 
of several inflammatory disorders. S1P-lyase (SPL) cleaves irreversibly S1P in 
the last step of the sphingolipid catabolism. S1P was associated with protec-
tion against cytokine-mediated toxicity in insulin-secreting cells. However, 
the role of SPL in insulin-secreting cells remains unknown.
Materials and methods: Insulin-secreting INS1E cells were transfected with 
the pcDNA3.1 SPL vector or with siRNA against SPL. Cells were treated with 
glucose (3, 10, 30 mM) and/or cytokines (IL-1ß 600 U /ml or with a cytokine 
mix: IL-1ß 60 U/ml, TNFα 185 U/ml and IFNγ 14 U/ml). After a 24 h incu-
bation, gene expression (qRT-PCR), caspase-3 activation (Caspase-Glo 3/7 
kit), ROS production (DCFDA oxidation assay), ATP (ATPlite luminescence 
assay) and glucose-stimulated insulin secretion (RIA) were determined.
Results: The measurement of SPL expression in several rat tissues and 
INS1E cells revealed a moderate SPL expression level in INS1E cells com-
pared to different rat tissues. Cytokines induced caspase-3 activation in 
INS1E-control cells (IL-1ß 150% vs. cytokine mix 195%). This deleterious 
effect was significantly reduced by SPL-overexpression (IL-1ß 118% vs. cy-
tokine mix 126%) and significantly enhanced by SPL-suppression (IL-1ß 
302% vs. cytokine mix 292%). The protective effect of SPL-overexpression 
was associated with a reduced cytokine-induced ROS formation (INS1E-
control cells, IL-1ß 167%, cytokine mix 212%; INS1E-SPL cells, IL-1ß 132%, 
cytokine mix 144%). SPL-suppression increased cytokine-mediated ROS 
production (IL-1ß 252%, cytokine mix 290%). Interestingly, SPL-overex-
pression had a potentiating effect on glucose-stimulated insulin secretion 
(GSIS) (INS1E-control cells, 3 mM Glc 0.078, 10 mM Glc 0.206, 30 mM Glc 
0.192; INS1E-SPL cells, 3 mM Glc 0.085, 10 mM Glc 0.450, 30 mM Glc 0.403 
ng/µg DNA/h). The suppression of SPL weakened the stimulatory effect of 
glucose on insulin secretion (3 mM Glc 0.063, 10 mM Glc 0.071, 30 mM 
Glc 0.088 ng/µg DNA/h). Upon exposure to cytokines a significant 5-7 fold 
decrease in the amount of secreted insulin was observed in INS1E-control 
cells. The cytokine-mediated inhibition of glucose-induced insulin secretion 
was reduced by SPL-overexpression and potentiated by SPL-suppression. 
The effect of SPL on GSIS correlated with parallel changes in ATP content 
(INS1E-control cells, IL-1ß 85%, cytokine mix 63%; INS1E-SPL cells, IL-1ß 
93%, cytokine mix 87%; INS1E-siRNA-SPL, IL-1ß 71%, cytokine mix 49%, 
vs. 100% of untreated cells).
Conclusion: This study demonstrates that SPL plays an important role in the 
regulation of beta cell function and the cytokine toxicity to insulin-secreting 
cells. It seems that the concentration of intracellular S1P, controlled by SPL, 
must be tightly regulated to maintain the proper beta cell function and to 
prevent cytokine-mediated toxicity.
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Unique effects of acute exposure to low concentrations of IL-1beta on 
primary beta cell function and gene expression
C. Arous, P. Ferreira, E. Dermitzakis, P. Halban;  
Dept. of Genetic Medecine and Development, University Medical Center, 
University of Geneva, Switzerland.
Background and aims: The cytokine IL-1beta is thought to contribute to the 
low-grade systemic and islet inflammation leading to insulin secretion de-
fects in type 2 diabetes. Indeed, longterm exposure (>24 h) of beta cells to 
very high concentrations (20 ng/mL) of IL-1beta results in modulation of 
gene expression by NFκB, impaired function and ultimately cell death. Inter-
estingly, IL-1beta can also exert beneficial effects on beta cells following ex-
posure for >24 h to low concentrations of IL-1beta, with improved insulin se-
cretion, increased proliferation and decreased apoptosis but the mechanisms 
are less well understood. We have observed previously that shorter exposure 
(2 h) to low (0.1 ng/mL) but not high (20 ng/mL) concentrations of IL-1beta 
enhances glucose-stimulated insulin secretion through focal adhesion and 
actin remodeling. We now study the mechanism of this beneficial action of 
IL-1beta on beta cell function.
Materials and methods: Rat primary beta cells or human islets established in 
monolayer on extracellular matrix were incubated for 1 h at 2.8 mmol/L fol-
lowed by 1 h at 16.7 mmol/L glucose in the continued presence (or not, con-
trol) of 0.1 ng/mL or 20 ng/mL rat or human IL-1beta respectively. Insulin 
secretion was measured by radioimmunoassay. To inhibit transcription, rat 
beta cells were pre-treated 1 h with actinomycin D (0.1 µg/mL). NFκB (p65) 
was localized by immunofluorescence. RNA was extracted and sequenced by 
Illumina HiSeq to an average depth of 20M reads. Statistical analyses were 
performed in R and differential gene expression with DESeq2. Data are 
mean±SE ≥ 3 independent observations.
Results: Glucose-stimulated insulin secretion (GSIS), but not basal secretion, 
of rat primary beta cells and human islets, was increased by 56.5 ± 17.4% 
(p=0.032) and 74.9 ± 20.5% (p=0.021) respectively by 0.1 ng/mL IL-1beta 
whereas 20 ng/mL was without effect. NFκB was translocated rapidly to the 
nucleus during exposure of rat beta cells to 0.1 ng/mL IL-1beta and blockade 
of NFκB activation by Bay 11-7082 (5 µmol/L) prevented IL-1beta enhance-
ment of GSIS. Furthermore, 0.1 ng/mL IL-1beta had no impact on GSIS in 
the presence of actinomycin D. Taken together these data suggested that IL-
1beta enhanced GSIS through modulation of gene expression by NFκB. Tran-
scriptome analysis by RNA-seq revealed 928 genes differentially expressed 
by the low dose and 1738 by the high dose of IL-1beta with 55 up-regulated 
and 88 down-regulated uniquely by 0.1 ng/mL IL-1beta (p< 0.001). Of these 
genes modulated uniquely by low dose IL-1beta, 6.99% were classed as vesicle 
and secretory granule components, 13.3% are involved in the regulation of 
the transcription. The expression of one gene of particular interest for beta 
cell function, SIRT1, was increased from 8.52 ± 0.35 to 10.28 ± 0.54 RPKM 
(p=0.016) by 2 h exposure to 0.1 ng/mL IL.1beta with no significant change 
with 20 ng/mL.
Conclusion: Acute exposure of beta cells to 0.1 ng/ml IL-1beta can act rap-
idly and positively on insulin secretion through the regulation of gene tran-
scription. Results obtained with RNA sequencing analysis revealed changes 
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in gene expression profiles elicited uniquely by acute exposure to low but 
not high concentrations of IL-1beta and that could drive improved beta cell 
function.
Supported by: FNSNF
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The hepatokine fetuin-A triggers inflammation without inducing cell 
death but improves cAMP-dependent insulin secretion of pancreatic 
islets
F. Gerst1,2, G. Kaiser1,2, N. Stefan1,2, H.-U. Häring1,2, S. Ullrich1,2;  
1Internal Medicine IV, University Hospital Tübingen, 2Institute for Diabetes 
Research and Metabolic Deseases of the Helmholtz Center Munich at the 
Eberhard-Karl-University of Tübingen, Germany.
Background and aims: Nonalcoholic fatty liver displays an altered secretion 
of hepatokines. Previously, we found that increased plasma levels of the hepa-
tokine fetuin-A strongly predict the incidence of type 2 diabetes in humans. 
As mechanisms of action, fetuin-A directly inhibits insulin receptor signaling 
and augments inflammation by interacting with fatty acids to activate TLR4. 
In addition, we found a negative relationship of fetuin-A levels with adjusted 
insulin secretion only in subjects with impaired glucose tolerance. The pre-
sent study aims to examine the impact of fetuin-A on fatty acid-induced ef-
fects in pancreatic beta-cells.
Materials and methods: Human islets received from the European Centers 
of Islet Transplantation (ECIT) and mouse islets were cultured in medium 
supplemented with human fetuin-A or serum albumin as control (0.6 mg/
ml each) for 48h. Due to the low concentration of albumin palmitic acid was 
used at a concentration of 60 µmol/l, which does not induce metabolic stress. 
Changes in gene expression were analyzed by microarray and qRT-PCR. Ap-
optosis was estimated by TUNEL staining. Insulin secretion was evaluated 
after static incubation by radioimmunoassay.
Results: In agreement with previous observations in other cell types, fetuin-
A increased 2-fold the mRNA levels of IL1ß, IL33, IL24 and IL17RB in hu-
man islets. The stimulation of cytokine production depended on the activa-
tion of TLR2/4, as fetuin-A elevated the mRNA amount of IL1ß and MCP-1 
in WT, but not in TLR2/4 KO islets. On the contrary, palmitic acid neither 
stimulated nor augmented the fetuin-A-mediated cytokines production. Sur-
prisingly, in spite of increasing the cytokine levels, fetuin-A failed to induce 
apoptosis and, moreover, significantly inhibited palmitic acid-induced cell 
death. In addition, chronic exposure to fetuin-A did not affect glucose and 
palmitic acid stimulated insulin secretion but it selectively and specifically 
improved forskolin and exendin-4 stimulation of secretion.
Conclusion: These results suggest that fetuin-A stimulates cytokine produc-
tion in a TLR-dependent manner. However, it exerts rather beneficial effects 
on beta cell function, as it does not induce apoptosis and improves cAMP-
amplified insulin secretion.
Supported by: DZD e.V.
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The promoters of genes may be the closest link between type 1 diabetes 
and other autoimmune diseases
C. Guja1, P. Gagniuc2, C. Ionescu-Tirgoviste1;  
1Diabetes, Nutrition and Metabolic Diseases, „Carol Davila“ University of 
Medicine and Pharmacy Bucharest, 2Institute of Genetics, University of 
Bucharest, Romania.
Background and aims: Type 1 diabetes (T1D) is a T-cell mediated autoim-
mune disease that selectively targets pancreatic beta cells. T1D is thought to 
arise from the progressive loss of beta cells occurring over months upto years. 
Despite extensive genetic studies in T1D, rarely analyzes were performed 
with respect to promoters of genes associated with autoimmunity and T1D.
Materials and methods: For our study we chose a set of representative genes 
for several diabetes phenotypes. We analyzed the promoters of genes asso-
ciated with T1D, including HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-
DPB1, PTPN22, TLR7, CTLA4, GSDMB, STAT4, IL7R, C1QTNF6, CD55, 
CTSH, ERBB3 and INS and with T2D, including CAMK1D, DUSP9, HHEX, 
IRS1, MADD, NOTCH2, TP53INP1, VPS13C, WFS1, ZFAND6, HMGA2, 
PPARG, CDKN2AIP, PROX1 and TCF7L2. In order to detect a possible re-
lationship between T1D and other autoimmune diseases, we analyzed the 
promoters of genes associated with more than only one autoimmune disease, 
including RGS1, IL10, AFF3, IL21, INS, KIF3A, GPR183, GSDMB, ORM-
DL3, PTPN2, FUT2, TLR7, PTPN22, CTLA4, CD55 and STAT4. The DNA 
pattern” methodology that we have used, determines the coexpression rela-
tionships between genes. Thus, in the resulting distribution, the overlapping 
positions (or close positions) of promoters of these genes indicate that those 
promoters use transcription factors in common.
Results: Our distribution shows that there is a common denominator be-
tween promoters of genes involved in autoimmunity. Both the promoters 
of T1D genes and those associated with other autoimmune diseases occupy 
the same overlapping positions in our distribution. The figure (Figure A) 
below shows the general distribution of different phenotypes, namely T1D 
(in blue), T2D (in red), genes associated with both phenotypes (included in 
,,Intermediary Diabetes Mellitus” - IDM phneotype) in green and promot-
ers of genes associated with autoimmunity (in brown). In a general distribu-
tion of the average positions of gene promoters for each phenotype (Figure 
B), the close functional relationship between T1D and autoimmune diseases 
gene promoters is becoming increasingly clear. The clustering of these genes, 
very close to each other, suggests that transcription factors involved in their 
expression may be part of the triggering mechanism of anti beta cell auto-
immunity. The close distribution of the promoters of genes associated with 
the analyzed phenotypes represents a functional correlation, in the sense that 
these genes are more likely to be co- expressed.
Conclusion: Promoters of genes associated with T1D and with other autoim-
mune diseases share one common factor in causing T1D, namely the tran-
scription factors involved in long term gene expression. The wide distribution 
between promoters of genes associated with T1D and T2D strongly suggests 
that these two phenotypes are not using transcription factors in common.
Clinical Trial Registration Number: CNCS-UEFISCDI Nr. PN-II-ID-
PCE-2011-3-0429
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A novel autoantibody detected in patients with fulminant type 1 diabetes
F. Haseda1, A. Imagawa2, H. Nishikawa3, S. Mitsui1, C. Tsutsumi1,  
R. Fujisawa1, H. Sano1, Y. Murase-Mishiba1, J. Terasaki1, S. Sakaguchi3,  
T. Hanafusa1;  
1Department of Internal Medicine (I), Osaka Medical College, Takatsuki, 
2Department of Metabolic Medicine, Graduate School of Medicine, 
3Experimental Immunology, Immunology Frontier Research Center, Osaka 
University, Suita, Japan.
Background and aims: Fulminant type 1 diabetes (FT1D) is a subtype of 
type 1 diabetes characterized by complete insulin deficiency resulting from 
the destruction of pancreatic beta cells even at the disease onset. Massive 
cellular infiltration of T-cells and macrophages has been detected in islets 
and exocrine pancreas, suggesting that immune disorder might contribute 
to the development of FT1D. However, islet-related autoantibodies, such as 
GAD Ab or IA-2 Ab, were usually negative, indicating that we have no useful 
biomarker to diagnose FT1D. Therefore, we performed serological antibody 
analysis cyclopedically to discover a novel diagnostic marker of FT1D.
Materials and methods: First, we analyzed a total of 6 serum samples from 
3 patients with FT1D (1 sample in acute and 1 in chronic phases from each 
patient) on over 9000 human protein arrays (Invitrogen ProtoArrayR Human 
Protein Microarray v5.0) by fluorescence. Second, titres of the antibody were 
measured in sera from 20 patients with FT1D (both in acute and chronic 
phases), 32 patients with type 1A diabetes (T1AD), 30 patients with type 2 
diabetes (T2D), 22 patients with autoimmune thyroid disease (AITD) and 30 
healthy control subjects (HC) using ELISA assay. Duration of FT1D in acute 
and chronic phase was 8.1 ± 6.3 (mean ± SD, day) and 24.2 ± 9.1, respectively.
Results: By serological antibody analysis of over 9000 antibodies, we detected 
8 antibodies which showed high signals from all 3 patients with FT1D in 
acute phase (acute/chronic phase ratio>1.4). We focused on one novel anti-
body that has not yet been reported in any conditions and measured its titre 
by ELISA assay. Titres of the antibody were 0.1071 ± 0.0374 (mean ± SD, 
arbitrary unit) in FT1D patients (acute phase), 0.0823 ± 0.0182 in FT1D pa-
tients (chronic phase), 0.0771 ± 0.0171 in T1AD patients, 0.0710 ± 0.0171 in 
T2D patients, 0.0701 ± 0.0116 in AITD patients and 0.0641 ± 0.0078 in HC. 
Significantly high titre of the antibody was detected in sera from FT1D pa-
tients in acute phase (versus T1AD patients; P=0.0002, versus T2D patients; 
P<0.0001, versus AITD patients; P<0.0001, versus HC; P<0.0001), and also in 
sera from FT1D patients in chronic phase (versus T1AD patients; P=0.0188, 
versus T2D patients; P=0.0093, versus AITD patients; P=0.0229, versus HC; 
P=0.0027). Titres of the antibody were higher from FT1D patients in acute 
phase than those in chronic phase (P=0.0023, paired t-test). There was no 
significant correlation between the titres of the antibody and age, gender, 
HbA1c, plasma glucose and GAD or IA-2 antibody level in all diabetic pa-
tients.
Conclusion: We detected one novel antibody whose titre was high in sera 
from patients with FT1D both in acute and chronic phases. This antibody 
might become a diagnostic marker of FT1D.
Supported by: Novo Nordisk Insulin Study
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Inflammatory profile in patients with type 1 diabetes: exploring a hidden 
side of type 1 diabetes
M.S. Ruiz de Adana1,2, E. Rubio-Martín1,2, N. Colomo1,2, M. Carreira3,  
M.T. Anarte3, E. Maymó-Masip4,2, M. Rodríguez-Chacón4,2,  
G. Rojo-Martínez1,2;  
1Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, 
2CIBERDEM, Barcelona, 3Departamento de Personalidad, Evaluación y 
Tratamiento Psicológico, Facultad de Psicología. Universidad de Málaga, 
4Research Unit, Hospital Universitari Joan XXIII, Tarragona, Spain.
Background and aims: The aims of this study are to compare inflamma-
tory markers (IL-6, TNFα, high sensitivity C reactive protein -hsCRP-, TNF-
like weak inducer of apoptosis -sTWEAK-, and scavenger receptor CD163 
-sCD163-) between 158 T1DM patients and 638 healthy subjects and to eval-
uate if there are differences in these inflammatory markers in subjects with 
T1DM according to glycaemic control measured by HbA1c levels, to the type 
of insulin regimen (multiple daily injections [MDI] vs. continuous subcuta-
neous insulin infusion [CSII]), the presence of microvascular complications, 
the quality of life, the distress, and the symptoms of depression.
Materials and methods: Cross-sectional study which involved 158 patients 
with T1DM attending our diabetes unit. Additionally, 638 healthy subjects 
from the di@bet.es study (a cross sectional study comprising a representative 
sample of the Spanish adult population) and the Pizarra study (a population 
based cohort study undertaken in Pizarra, Spain) with similar age, sex dis-
tribution and BMI than the study patients were selected. Sociodemographic, 
clinical and biochemical data (HbA1c and lipid profile) were recorded. Qual-
ity of life was evaluated by the Diabetes Quality of Life questionnaire (DQoL), 
distress was assessed by the Diabetes Distress Scale (DDS), and symptoms of 
depression was evaluated by the Beck Depression Inventory (BDI). Inflam-
matory markers including IL-6, hs-CRP, TNFα, sTWEAK and sCD163 were 
measured.
Results: a) T1DM patients vs. healthy subjects. Patients with T1DM had low-
er sTWEAK levels (806±1312 vs. 1040±1212 pg/mL, p=0.0001) and higher 
IL-6 levels (2.6±3.0 vs. 1.7±2.6 pg/mL, p=0.001) and hsCRP levels (3.4±6.3 vs. 
3.0±5.2 mg/L, p=0.001) than healthy subjects with similar age, sex and BMI. 
No significant differences were found in TNFα and sCD163 levels. b) T1DM 
patients. Patients with T1DM had significantly higher IL-6 levels if they 
were treated with MDI vs. CSII (2.9±3.3 vs. 1.5±1.4 pg/mL, p=0.017), had 
microvascular complications (3.8±3.5 vs. 2.2±2.8 pg/mL, p=0.006) and had 
symptoms of depression (3.5±3.7 vs. 2.2±2.6 pg/mL, p=0.023). If we compare 
patients treated with CSII with those receiving MDI, the former ones had sig-
nificantly lower HbA1c levels (7.5±0.9 vs. 7.9±1.3%, p=0.04), lower score in 
BDI (7.5±8.8 vs. 12.2±12.2, p=0.008), DDS (1.5±0.8 vs. 1.9±1.0, p=0.05) and 
DQoL (83.4±19.0 vs. 90.8±22.0, p=0.03), lower IL-6 levels and higher TNFα 
levels (4.6±8.5 vs. 1.5±0.82 pg/mL, p=0.001), adjusted for age, sex and BMI.
Conclusion: Patients with T1DM had a different inflammatory pattern than 
their healthy counterparts. IL-6 levels were increased in patients with T1DM 
receiving MDI insulin regimen, with microvascular complications, and with 
symptoms of depression.
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Circulating immune mediators are closely linked in the early course of 
adult onset type 1 diabetes
H.F. Fleiner1, M. Radtke1, L. Ryan2, T. Moen3, V. Grill1;  
1Department of Cancer Research and Molecular Medicine, 2Centre of 
Molecular Inflammation Research, Department of Cancer Research and 
Molecular Medicine, 3Department of Laboratory Medicine, Norwegian 
University of Science and Technology, Trondheim, Norway.
Background and aims: Relationships between circulating immune media-
tors (cytokines, chemokines and growth factors) and a beta cell destructive 
autoimmune process are poorly elucidated in adult-onset type 1 diabetes. We 
measured serum levels of immune mediators in such patients with newly di-
agnosed disease during the course of ongoing deterioration of insulin secre-
tion.
Materials and methods: Levels of 27 immune mediators were measured in 
34 GADA (glutamic acid decarboxylase antibodies) positive type 1 diabetic 
patients, aged 27.4 ± 1.2 years at a mean of 7 weeks after diagnosis (designat-
ed 0 month) and 6 months later. Endogenous insulin secretion was assessed 
by C-peptide glucagon stimulation tests at 0, 6 and 12 months. Supplemen-
tary data were obtained in 9 GADA positive type 1 diabetic subjects and in 43 
non-diabetic age and sex matched subjects. Results were analyzed with and 
without adjustment for body weight (BMI).
Results: Mean levels of stimulated C-peptide had declined by 10% after 6 
months and by 28% after 12 months. This decline was not reflected by levels 
of immune mediators which displayed large inter- but small intra-individual 
differences with only minor changes observed between measurements at 0 
and at 6 months (ρ-values for correlations ranging from 0.000 to 0.005). Lev-
els of the majority of immune mediators were strongly and positively corre-
lated to each other in the diabetic subjects. However, such correlations were 
also found in the non-diabetic subjects and data did not suggest any network 
of immune mediators specific for the diabetic subjects. Body weight (BMI) 
was positively associated with levels of IL-1 ra, IL-2, IL-4, IL-6, IL-17, Basic 
FGF, GCSF, IFN gamma and MIP-1 alpha. When adjusted for BMI, levels at 
0 month for Basic FGF and MIP-1 alpha were inversely associated with the 
percentage decline in stimulated C-peptide from 0 to 12 months (nominally 
ρ<0.05).
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 186 
1 C
Conclusion: 1) There are close associations between different immune me-
diators 2) These associations are not specific for autoimmune diabetes 3) BMI 
is a major confounder 4) The associations of beta cell decline to individual 
immune mediators need confirmation in further studies.
Clinical Trial Registration Number: NCT00131755
Supported by: Research Council of Norway, Norwegian Diabetes Assoc. and 
St.Olavs Hospital
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Relationship between autoantibodies combination, metabolic syndrome 
and its components in autoimmune diabetes in adults
T. Bulum, K. Blaslov, J. Knežević-Ćuća, L. Duvnjak;  
Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, 
University Hospital Merkur, Zagreb, Croatia.
Background and aims: Although clinical presentation of latent autoimmune 
diabetes in adults (LADA) at diagnosis frequently features clinical traits of 
type 2 diabetes mellitus (T2DM), it is the autoimmune process that drives 
LADA patients through slower beta-cells destruction and insulin depend-
ency within few years. Majority of LADA patients has pronounced positivity 
for glutamic acid decarboxylase enzyme antibodies (GAD-Ab) frequently ac-
companied by moderate levels of circulating autoantibodies to islet cell cy-
toplasmic antigens (ICA-Ab). Positivity for tyrosine phosphatase-like trans-
membrane glycoprotein (IA2-Ab) has also been reported but to a lesser ex-
tent. While simultaneous positivity for ICA-Ab, and GAD-Ab with eventual 
presence and of IA2-Ab indicate patients with insulin deficiency and typical 
type 1 LADA phenotype, GAD antibody positivity, even in higher titers, rep-
resent a marker for slower progressing LADA. The role of IA2Ab positivity 
in LADA phenotypisation is poorly understood and controversial. The aim of 
our study was to establish a possible association between autoimmune profile 
of patients regarding double or triple antibody positivity and LADA pheno-
type in the context of metabolic syndrome (MS) prevalence, individual com-
ponents of metabolic syndrome and chronic diabetic complications.
Materials and methods: This cross-sectional study population comprised 
69 islet cell antibody positive patients coming for their comprehensive an-
nual review. Rate of positivity was calculated by determining end-point titres 
of samples that were converted to the units of Juvenile Diabetes Foundation 
(JDF-U) by comparison with a standard curve of end-point titer of standard 
sera. The threshold of detection was >5 JDF units. GAD and IA2-Abs were 
detected with an enzyme-linked immunosorbent assay (Euroimmun AG, 
Luebeck, Germany) and the results were expressed in arbitrary units. The 
cut-off limit was 10 U/ml for GAD Abs and 15 U/ml for IA2-Abs. MS was 
defined according to the International Diabetes Federation definition, arte-
rial hypertension (AH) was considered as blood pressure > 130/85 mmHg 
or the use of antihypertensive drugs. Patients were divided into three groups: 
Gad Ab only positive (n=28), GAD Ab+ICA Ab positive (n=26) and GAD 
Ab+ICA Ab+IA2 Ab positive (n=15).
Results: Twenty five (36.2%) patients were male, mean age approximately 51 
years with disease duration 8 years. The lowest value of waist circumference 
(80 vs 82 vs 89.5 cm), MS (1 vs 11 vs 15) and AH (1 vs 11 vs 16) prevalence 
was found in the group positive for all three antibodies compared the oth-
ers two groups. In the multinominal multivariate logistic regression model 
higher waist circumference (OR 0.931 (0.869-0.988)), MS prevalence (OR 
0.062 ( 0.007-0.537)) and AH prevalence (OR 0.065 (0.007-0.577)) were neg-
atively associated with triple Ab positivity compared to single Ab positivity, 
and compared to double Ab positive group with ORs as follows: 0.940 (0.877-
0.990), 0.097 (0.011-0.855), and 0.099 (0.011-0.879).
Conclusion: Our results highlight the importance of the inverse association 
of simultaneous Abs positivity for ICA, GAD and IA2 with the presence of 
MS and its components in LADA patients. This inverse relationship might 
implicate the presence of LADA patients’ phenotype closer to type 1 diabetes.
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Autoimmune gastrointestinal markers in patients with type 1 diabetes
O. Derevyanko, T. Nikonova, N. Dalantaeva, O. Ivanova, O. Smirnova;  
Endocrinology Research Centre, Moscow, Russian Federation.
Background and aims: In patients with type 1 diabetes the prevalence of 
other autoimmune diseases is 3 to 5 fold higher than in non-diabetic pa-
tients. Gastrointestinal autoimmune diseases are generally asymptomatic up 
to an advanced stage when they become major causes of mortality if not di-
agnosed and treated on time. The presence of immunological markers may 
be indicative of gastrointestinal autoimmune diseases even in a clinically 
asymptomatic case. The aim of our study was to investigate the frequency of 
specific autoantibodies occurrence in patients with T1 DM, to clarify the role 
of polyautoimmunity in the appearance of autoantibodies and the associa-
tion of autoantibody titer with clinical features of accompaning autoimmune 
diseases.
Materials and methods: 84 patients with T1DM and 21 healthy subjects 
(control group) were included in the study. T1DM patients were divided into 
two groups. The first group included 58 patients with T1DM only. The second 
group consisted of 26 patients with T1DM and another autoimmune disease 
(thyroid, celiac and Addison‘s disease, rheumatoid arthritis, vitiligo, myas-
thenia gravis). Anti-gastric parietal cells antibodies (AGPA) - markers of au-
toimmune gastritis, antinuclear antibodies (ANA), and anti-smooth muscle 
antibodies (ASMA) -markers of autoimmune hepatitis, antimitochondrial 
antibodies (AMA) - primary biliary cirrhosis marker were detected by using 
indirect immunofluorescence antibody test. All subjects were tested for ICA, 
GADA, IA-2A, C-peptide, HbA1c. Gastroscopy and ultrasound liver exami-
nation were performed to every patient.
Results: Significant difference was observed in frequency of ANA, AGPA, 
ASMA occurrence between the study groups and control group, p<0,05 (table 
1). Significantly higher appearance of ANA was observed in patients of the 
2nd group compared to the 1st group (p=0,007). 50% of patients with gastritis 
confirmed by gastroscopy had AGPA. 13% of patients with ultrasound signs 
of hepatic abnormalities were positive to ANA, 14% - to ASMA, 21% - to 
AMA compared to 28% (p=0,39), 38% (p=0,15) and 19% (p=0,86) of patients 
with normal hepatic features respectively.
Conclusion: Our study showed a high frequency AGPA, ANA, ASMA, AMA 
occurrence in patients with T1 DM. This data indicates the increased risk of 
gastric and hepatic autoimmune diseases in T1DM patients. Only ANA had 
significantly higher appearance in patients with several autoimmune diseas-
es. This might be due to the fact that ANA is a less specific autoantibody and 
can cause less specific autoimmunity against several organs. Other antibodies 
were observed with the same frequency in both study groups (p<0,05) but 
ANA, AGPA, ASMA had significantly higher appearance in patients with dia-
betes compared to the control group. These findings provide a rationale for 
screening, early diagnosis and treatment of additional autoimmune diseases 
in T1DM patients.
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Leukocyte profiles differ between type 1 and type 2 diabetes and are 
associated with metabolic phenotypes. Results from the German diabetes 
study (GDS)
B. Menart1,2, N.C. Schloot1, R. Ruetter1,2, B. Nowotny1,2, J. Rosenbauer3,2,  
C. Koliaki1,2, S. Kahl1,2, M.-C. Simon1,2, J. Szendroedi1,2, M. Roden1,2,4,  
for the GDS group;  
1Heinrich-Heine University, Institute for Clinical Diabetology,  
2German Center for Diabetes Research, 3Heinrich-Heine University, 
Institute for Biometrics and Epidemiology, 4Department of Endocrinology 
and Diabetology, Düsseldorf, Germany.
Background and aims: Altered immune reactivity precedes and accompa-
nies type 1 and type 2 diabetes. We hypothesized that the metabolic pheno-
type relates to the systemic cellular immune status.
Materials and methods: A total of 194 metabolically well controlled patients 
with type 1 diabetes (n=62, mean diabetes duration: 1.29 years) or type 2 dia-
betes (n=132, 1.98 years) and 60 normoglycemic persons underwent blood 
sampling for automated white blood cell counting (WBC) and flow cytom-
etry. Whole body insulin sensitvity was measured with hyperinsulinemic-
euglycemic clamp tests. Analysis of covariance was performed to compare 
groups and Spearman´s non-parametric correlations and partial correlations 
adjusted for age, sex, and BMI were estimated.
Results: Patients with type 2 diabetes had higher WBC counts than controls 
(P<0.001) along with higher percentage of T-cells (P=0.038), activated T 
helper (Th)- (P<0.001) and cytotoxic T (Tc)-cells (P<0.001), but lower pro-
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portions of natural killer (NK) cells (P<0.05). In type 1 diabetes, percentage 
of activated Th- (P<0.001) and Tc-cells (P=0.006) were also higher compared 
to controls, whereas the ratio of regulatory T (Treg)-cells to activated Th-cells 
was lower suggesting diminished regulatory capacity. Parameters of glyce-
mic control (HbA1c,blood glucose) related positively to Treg-cells only in 
type 2 diabetes (P<0.05). Upon age-, sex-, and body mass-adjustments, insu-
lin sensitivity correlated positively with monocytes (r=0.469, P<0.01), while 
circulating lipids correlated positively with T-cell subsets in type 1 diabetes 
(r=0.281, P<0.05).
Conclusion: Immune cell phenotypes showed distinct frequencies of occur-
rence in both diabetes types, and associate with insulin sensitivity, glycemia 
and lipidemia.
Clinical Trial Registration Number: NCT01055093
Supported by: DZD e.V.
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Insulin-induced level of TNF-alpha: the early marker of type 1 diabetes 
mellitus
E. Repina1, E. Stepanova2, M. Shestakova1, I. Dedov1;  
1Endocrinology Research Centre, 2Russian Medical Academy of 
Postgraduate Education, Moscow, Russian Federation.
Background and aims: To investigate an influence of monoclonal activator 
- insulin upon cytokine-producing function of peripheral blood cells in the 
patients with type 1 and 2 diabetes mellitus.
Materials and methods: 25 type 1 diabetes mellitus patients and 9 patients 
with type 2 diabetes mellitus were examined. As a control we examined 10 
healthy persons. Mononuclear leukocytes were isolated by centrifugation in 
the ficoll-verographin density gradient. The cells thus obtained were resus-
pended in the complete nutritient medium reducing their concentration to 
2,0x10^6/ml. Phytohemagglutinin (PHA-P, Sigma) (10 mcg/ml) and insulin 
(insulin human, Sigma) (10 mcg/ml) were added to the samples to stimu-
late mononuclear leukocytes; cell suspensions were further incubated for 36 
hours. Initial, PHA-induced and insulin-induced levels of interleukin-1 (IL-
1), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, gamma interferon (IFN-γ) and tumor 
necrosis factor alpha (TNF-α) in supernatants of cell cultures were measured 
by solid phase immunoassay at 450 nm. Results were compared with clinical 
characteristics of the patients. There were 8 males and 17 females in the group 
1 and 2 males and 7 females in the group 2. Median age, diabetes mellitus 
duration, HbA1c in the group 1 and 2 were respectively 32 years, 17 years, 
8,3 % and 63 years, 12 years, 9,1 %. Intensities of microvascular complication 
(diabetic retinopathy and diabetic nephropathy) were higher in the group 1. 
8 patients (32%) from group 1 had diabetic retinopathy on the last stage and 
only 1 patient (11%) from the group 2 had diabetic retinopathy on the same 
stage. Only 1 patient (11%) from the group 2 had diabetic nephropathy on 
microalbuminuria stage and 7 patients from the group 1 (28%) had diabetic 
nephropathy on proteinuria stage and on the stage of renal failor.
Results: For estimation of immune response intensity we used for the first 
time the index of autoimmune inflammation (IAI) - correlation of insulin-
induced and basal production of TNF-α. The T-cell response on insulin was 
absent in control group and in patients with type 2 diabetes mellitus. Only 
one patient with type 2 diabetes mellitus had IAI more than 1. It was the 
basis for a change the diagnosis from type 2 diabetes to type 1 diabetes mel-
litus. Our patients with type 1 diabetes mellitus had IAI from 3,09 till 19,23. 
It correlated with the stage and intensities of microvascular complications 
(diabetic retinopathy and diabetic nephropathy) of these patients.
Conclusion: The TNF-α production ratio of insulin-stimulated versus rest-
ing cells may be used as a reliable early marker of autoimmune versions of 
diabetes mellitus, marker of autoimmune process activity in pancreatic tissue 
and disease severity in type 1 diabetic patients.
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Regulatory T cell dysfunction in type 1 diabetes
A. Zóka1, A. Somogyi1, G. Barna2, Á. Oláh1, Z. Al-Aissa1, O. Hadarits3,  
G. Firneisz1;  
12nd Department of Internal Medicine, 21st Department of Pathology 
and Experimental Cancer Research, 31st Department of Obstetrics and 
Gynecology, Semmelweis University, Budapest, Hungary.
Background and aims: Type 1 diabetes mellitus (T1DM) develops as a result 
of the autoimmune damage of pancreatic ß-cells. Regulatory T-cells (Treg) 
have a crucial role in limiting the naturally occuring autoreactivity. Foxp3 is a 
master regulator transcription factor of Treg differentiation. Active Treg cells 
express high levels of IL-2 receptor α-chain (CD25) and CTLA4 (Cytotoxic 
T-Lymphocyte Antigen 4). The aim of our study was to clarify certain details 
of the immunological dysregulation and Treg dysfunction.
Materials and methods: Fourty patients with T1DM (M/F= 19/21; 
33.7±10.04 years) and fourty age-matched non-diabetic control subjects (M/
F=16/24; 32.97±11.63 years;) were involved. The mean disease duration was 
15.76(±7.23) years. Fasting, EDTA-anticoagulated blood samples were col-
lected. CD3, CD4, CD8, and CD25 surface proteins, intracellular CTLA4 and 
intranuclear Foxp3 were stained with specific fluorescent antibodies. A Beck-
man Coulter Navios flow cytometer and Kaluza software were used for quan-
titative analysis. Fluorescence intensity was described as median fluorescence 
intensity (MFI). Shapiro-Wilks normality test, Mann-Whitney-U-test, T-test 
and the Statsoft Statistica software were used.
Results: The proportion of Foxp3+ cells among CD4+ lymphocytes was 
not different in T1DM patients and control subjects. The proportion of 
CD25+ cells among CD4+Foxp3+ lymphocytes was lower in T1DM pa-
tients (72.89±7.74% vs. 63.23±12%, p<0.0001). CD25 and CTLA4 expression 
(MFI) of T-lymphocytes was significantly lower in T1DM patients (CD25: 
0.2±0.21 vs. 0.38±0.33, p<0.01; CTLA4: 1.02±0.45 vs. 1.3±0.48, p<0.05). Posi-
tive correlation was observed between the CD25 and the CTLA4 expression 
of T-lymphocytes (p<0.0001; r=0.57).
Conclusion: Although the CD4+Foxp3+ Treg cell population was not quan-
titatively different, the higher proportion of CD4+Foxp3+CD25- cells and 
lower CTLA4 expression in T-lymphocytes may reflect an increased propor-
tion of the inactive Treg cell subpopulation. This might contribute to the im-
paired immune regulation. To overcome the impaired Treg cell activation in 
T1DM might be an attractive therapeutic approach in the future.
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111In-exendin uptake in the pancreas correlates with the beta cell mass 
but not with the alpha cell mass
M. Brom, C. Frielink, L. Joosten, M. Gotthardt;  
Department of Radiology and Nuclear Medicine, Radboud University 
Medical Center, Nijmegen, Netherlands.
Background and aims: A method to non-invasively determine the beta cell 
mass in vivo would enable us to study the pathophysiology of diabetes and is 
still a major unmet need. Targeting of the GLP-1R with 111In-labeled exendin 
is an attractive approach for determination of the beta cell mass and preclini-
cal studies as well as a proof-of-concept study in type 1 diabetic patients and 
healthy subjects showed a direct correlation of beta cell mass and radiotracer 
uptake. Despite these highly promising initial results, the influence of alpha 
cells on the uptake of the radiotracer remains a matter of debate. In this study 
we examined the specificity of 111In-exendin in a rat model for beta cell loss by 
comparing the uptake of the tracer with the beta and alpha cell mass.
Materials and methods: Brown Norway rats were treated with 45 or 60 mg/
kg alloxan (n=4 per group) in order to destroy the beta cells and 4 rats were 
injected with vehicle as a control. One week after injection of alloxan, 15 MBq 
111In-exendin (corresponding to 0.1 µg exendin) was injected and the pan-
creas was dissected 1 h after injection of 111In-exendin. The radioactivity con-
centration was measured in a gamma counter and the beta cell and alpha cell 
mass were determined by morphometric analysis after immunohistochemi-
cal staining for insulin and glucagon, respectively.
Results: The uptake of 111In-exendin (percentage of the injected dose) showed 
a strong positive linear correlation with the beta cell mass (Pearson r = 0.90). 
The absolute alpha cell mass was similar in healthy rats (2.2 ± 0.4 mg) and 
rats treated with 45 or 60 mg/kg alloxan (2.3 ± 0.3 mg and 1.8 ± 0.3 mg, 
respectively) and there was no significant correlation between the alpha cell 
mass and the uptake of 111In-exendin (Pearson r = 0.31). The total mass of the 
endocrine pancreas was reduced in the alloxan treated rats (8.5 ± 1.9 mg, 5.5 
± 1.7 mg, and 2.8 ±0.8 mg for healthy, 45 and 60 mg/kg alloxan, respectively) 
and percentage of glucagon positive cells of the total endocrine mass was in-
creased after alloxan treatment (26% ± 4%, 43% ± 8%, and 69% ±21% alpha 
cells of the total endocrine mass for healthy, 45 and 60 mg/kg alloxan, respec-
tively). The uptake of 111In-exendin showed a negative linear correlation with 
the alpha cell fraction (calculated by dividing the alpha cell mass by the total 
endocrine mass, Pearson r = -0.81).
Conclusion: The uptake of 111In-exendin correlated with the beta cell mass, 
but not with the alpha cell mass. Together with the increased relative alpha 
cell mass and the negative linear correlation between the 111In-exendin up-
take and alpha cell fraction, these data clearly indicate towards specificity of 
111In-exendin to beta cells and that the influence of the alpha cells on 111In-
exendin uptake is negligible.
Supported by: NIH 1R01 AG 030328-01 and EC (FP7/2007-2013), BetaImage, 
grant n° 222980
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Towards clinical PET imaging of pancreatic beta cells with [18F]exendin-4
K. Mikkola1, C.-B. Yim1, P. Lehtiniemi1, V.-V. Elomaa1, T. Ishizu1,  
J. Rajander2, O. Solin1,2, P. Nuutila1;  
1Turku PET Centre, University of Turku and Turku University Central 
Hospital, 2Accelerator Laboratory, Åbo Akademi University, Turku, Finland.
Background and aims: [18F]exendin-4 is a radioligand specific for the gluca-
gon like peptide-1 receptor (GLP-1R) abundantly expressed in beta cells. 
Quantitative non-invasive PET (positron emission tomography) imaging of 
pancreatic beta cells would serve as a valuable diagnostic tool and provide 
means to monitor therapeutic interventions. Several exendin based tracers 
have been intensively explored for beta cell imaging. The obstacle with these 
has been high uptake in the kidneys. The aim of this study is to develop a 
novel [18F]exendin-4 tracer for clinical imaging of beta cells with PET.
Materials and methods: Biodistribution and kinetics of [18F]exendin-4 was 
evaluated in Sprague-Dawley rats (N=3-9 per time point) weighing 250−300 
g. After intravenous injection of [18F]exendin-4 (19 ± 3 MBq/kg, mass 0.3 ± 
0.2 nmol/kg) rats were sacrificed at 15 min, 30 min, 1 h, 2 h, 4 h or 6 h. The 
organ-specific radioactivity was reported as a percentage of the injected dose 
per gram of tissue (%ID/g). The GLP-1R specificity was assessed using cold 
exendin-3 (N=1). Intrapancreatic distribution of radioactivity was assessed 
using autoradiography. Islet labelling was verified by immunohistochemis-
try and islet-to-exocrine tissue ratios were analysed. Radioactive metabolites 
were determined by HPLC. For PET scans, rats were imaged up to six hours 
(dynamic 0-1 h, static 3.5-4 h and static 5.30-6 h) using Inveon Multimodal-
ity PET/CT.
Results: Radioactivity was nearly constant in the pancreas over the course of 
the study (0.18 ± 0.03 %ID/g at 1 h and 0.08 ± 0.03 %ID/g at 6 h p.i., Fig. 1A). 
Blocking studies indicated GLP-1R specific uptake in the islets. Autoradiog-
raphy analysis of pancreatic sections showed that the islet-to-exocrine tissue 
ratio was 78 ± 29 at 1 h p.i. The amount of unchanged tracer in plasma was 
28.3 ± 3.5 % at 1 h p.i. In line with other exendin based tracers, [18F]exendin-4 
uptake by kidneys was high at 1 hour time point (16.7 ± 3.0 %ID/g), but 
thereafter its clearance was fast and retention decreased (1.5 ± 0.4 %ID/g, at 6 
h p.i., Fig. 1B). After 6 h PET imaging, the highest tracer uptake was found in 
kidney, lung and stomach wall. Radioactivity in bone was low, indicating low 
defluorination of the tracer.
Conclusion: In conclusion, we found a specific and sustained uptake of [18F]
exendin-4 in the pancreatic islets and high renal clearance of the tracer. These 
indications are promising for the development of novel [18F]exendin-4 to-
wards clinical imaging of beta cells. Currently we are investigating [18F]ex-
endin-4 biodistribution and pancreatic uptake in larger animals. Figure 1. 
Biodistribution of [18F]exendin-4 radioactivity in rat at various time points 
after tracer injection.
Supported by: Finnish Centre of Excellence and EC 7th framework programme 
BetaImage
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111In-exendin imaging in patients with type 1 diabetes and healthy 
controls
W. Woliner - van der Weg1, M. Brom1, M. Béhe2, C.J.J. Tack3,  
O.C. Boerman1, M.J.R. Janssen1, M. Gotthardt1;  
1Radiology and Nuclear Medicine, Radboud University Medical 
Center, Nijmegen, Netherlands, 2Paul Scherrer institute, Center for 
Radiopharmaceutical Sciences, Villingen-PSI, Switzerland, 3Internal 
Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Background and aims: Currently the beta cell mass (BCM) can, in contrast to 
beta cell function, not be measured non-invasively. A non-invasive test would 
help to increase our knowledge about changes in beta cell mass during the 
development and treatment of diabetes. Preclinical studies showed that the 
pancreatic uptake of 111In-labeled exendin, which targets to the glucagon-like 
peptide-1 (GLP-1) receptor, directly correlates with BCM. As a first step into 
clinical use of 111In- exendin imaging for beta cell quantification, we acquired 
and analyzed single photon emission computed tomography (SPECT) images 
after 111In-exendin administration in T1D patients and healthy subjects.
Materials and methods: Patients with long standing T1D (BMI below 27, age 
21-60 yr, minimal 5 year duration of T1D) and healthy controls (normal glu-
cose tolerance measured by OGTT, matched for age, gender and BMI) were 
eligible for the study. Four, 24 and 48 hours after i.v. injection of 150 MBq 
111In-Exendin-4, SPECT images were acquired for quantitative assessment of 
the uptake into the pancreatic beta cells. The pancreas volume was measured 
by CT. Uptake calculation was based on the counts within two spherical vol-
umes of interest (VOIs) placed in the head and corpus region, multiplied by 
the pancreas volume. Counts were corrected for administered activity and 
time after injection, leading to the pancreatic uptake in counts per MBq (c/
MBq).
Results: To date, 10 T1D patients and 8 healthy volunteers were included. The 
T1D patients showed an average uptake of 451 c/MBq in the whole pancreas 
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(SD 426 c/MBq). The average uptake of the healthy controls was more than 
two and a half times higher; 1258 c/MBq per pancreas (SD 645 c/MBq). Both 
groups showed large interindividual differences: the uptake in T1D patients 
ranges from 81 to 1445 c/MBq per pancreas and in the healthy subjects from 
264 to 1998 c/MBq per pancreas.(See figure 1) Also the concentration of 
111In-Exendin in the pancreas (not corrected for pancreas size) is more than 
two times lower in the group with T1D. The images and subsequent quantita-
tive analysis show that the 111In retention in the pancreas remains stable for at 
least 4 to 48 hours after injection in the pancreas.
Conclusion: This clinical study indicates that 111In-Exendin imaging with 
SPECT could indeed be the first technology to enable non-invasive beta cell 
quantification. In line with literature, it visualizes considerable interindivid-
ual differences in both groups and shows a, in general, much lower uptake of 
111In-Exendin in T1D patients than in healthy volunteers. Therefore it could 
be a valuable tool for further elucidating the complex pathofysiology in dia-
betes.
Clinical Trial Registration Number: NCT01825148
Supported by: NIH 1R01 AG 030328-01 and EC (FP7/2007-2013), BetaImage, 
grant n° 222980
448
Glucagon and mixed-meal tests to estimate beta cell and incretin 
functions in normals: relevance for studies in type 1 diabetes
C. Guglielmi1, L. Valente1, S. Fallucca1, S. Angeletti1, S. Briganti1,  
M. De Pascalis1, J.M. Lachin2, P. Pozzilli1;  
1University Campus Bio Medico, Roma, Italy,  
2The George Washington University, Rockville, USA.
Background and aims: Measurement of C-peptide after the administration 
of different stimuli is the only instrument able to directly measure in vivo beta 
cell function and it is used as primary enpoint in several immunointervention 
trials. The two tests currently used are Glucagon Stimulation Test (GST) and 
Mixed Meal Tolerance Test (MMTT).
Materials and methods: We carried out a study in 10 healthy subjects (25-
40 yrs) to evaluate beta cell function, Gastric Inhibitory Peptide (GIP) and 
Glucagon Like Peptide 1 (GLP1) which may affect C-peptide response to the 
two tests. GST and MMTT were carried out one week apart according to 
standard tests.
Results: At the end of GST (20 min) stimulated C-peptide showed a mean 
increase from baseline of 147.1% while at the end of MMTT (120 min), the 
mean increase of C-peptide was equal to 99.8% (Δincrease= 47.2%) while 
Max C-peptide reached during MMTT was greater than that gained dur-
ing GST (C-pept maxMMTT=2.3nmol/L vs C-pep maxGST=1.9nmol/L). 
A positive and linear correlation was found between the incremental AUC 
(iAUC) C-peptide in GST and iAUC C-peptide in MMTT (r=0.61, p=0.05). 
These data show that the two tests can be considered equivalent in assessing 
beta cell function although there are differences: in MMTT, but not in GST, 
the incretin response affects C-peptide levels. A positive and linear correla-
tion between GIP and C-peptide levels was found during MMTT (r=0.92, 
p=0.008) and a positive and exponential correlation was found between GIP 
and insulin during MMTT (R2=0.82). This was not the case with GST. No 
correlation was found between GLP-1 and C-peptide levels during MMTT 
and between GIP or GLP1 levels and C-peptide during GST.
Conclusion: Although the two stimulation tests may produce a similar re-
sponse in C-peptide, they diverge in that the beta cell response to GST test is 
independent of the incretin axis whereas this is not the case with MMTT. This 
result indicates the two tests differ in their mechanisms of action of stimulat-
ing C-peptide secretion.
449
Functioning beta cells in type 1 diabetes may not be as low as it is 
presumed
G. Tamer1, B. Dogan2, I. Ocakoglu3, O. Kostek4, I. Kartal1, G. Sagun4,  
M. Adas5, I. Tamer6, H.H. Mutlu2, A. Orhun3;  
1Division of Endocrinology and Metabolism, Department of Internal 
Medicine, 2Department of Family Medicine, 3Department of Biochemistry, 
4Department of Internal Medicine, Medeniyet University, Goztepe Training 
and Research Hospital, 5Division of Endocrinology and Metabolism, 
Department of Internal Medicine, OkmeydanıTraining and Research 
Hospital, 6Department of Family Medicine, Dr Lutfi Kirdar Kartal Training 
and Research Hospital, Istanbul, Turkey.
Background and aims: Enhancing endogenous insulin production in type 1 
diabetic patients(T1DP) can improve glycemic control and decrease compli-
cations and rates of mortality. However, it can be succesfull even if sufficient 
β-cell function is present. We aimed to evaluate the extent of β-cell function 
by determining fasting levels of C-peptide and those after meal stimulus.
Materials and methods: Sixtythree T1DP were enrolled. Ethics comittee of 
our hospital approved the study protocol, which was in accordance with the 
Helsinki Declaration. Fasting C-peptide levels of all participants and stimu-
lated (at 90 th minute post mixed meal) C-peptide levels of 54 were measured 
by using an electrochemiluminescence assay. Two categorizations were done 
using fasting (the first categorization ) and at 90th minute post mixed meal 
test (the second categorization) of C-peptide levels. For the first categoriza-
tion; the groups were classified as follows: patients with undetectable ≤0.1 ng/
mL (group 1); with minimal 0.1-0.8 ng/ml (group 2); and with sustained ≥0.8 
ng/mL(group 3) C-peptide levels. For the second categorization, groups were 
as follows: patients with undetectable ≤0.1 ng/mL (group 1); with minimal 
0.1-0.8 ng/ml (group 2); and with sustained ≥0.8 ng/mL (group 3) C-peptide 
levels which increased at the 90th minute after the meal ≥150% of fasting C-
peptide level.
Results: For the first category; 25.4%, 49.2%, 25.4% of T1DP were in group 
1, group 2 and group 3, respectively. For the second category; 22.2% of T1DP 
were in group 1, 24.1% of them in group 2 and 53.7 % of them in group 3. 
For the first categorization 74% and for the second categorization 77.8% of 
T1DP had detectable C-peptide levels. More than 50% of T1DP had a re-
sponse to meal stimulus with C-peptide levels ≥0.8 ng/mL which increased 
up to ≥150% of fasting C-peptide levels like non-diabetics.
Conclusion: The finding that presence of insulin secretion which increases 
after meals, suggests the possibility of undergoing β-cell regeneration within 
many T1DP.
450
Residual beta cell function in long-standing childhood onset type 1 
diabetes
P.J. Bingley1, R.J. Aitken1, I.V. Wilson1, A.E. Long1, A.J.K. Williams1,  
T. McDonald2, S. Wong3, A.T. Hattersley2, K.M. Gillespie1;  
1School of Clinical Sciences, University of Bristol, 2University of Exeter 
Medical School, 3Institute of Molecular and Experimental Medicine,  
Cardiff University School of Medicine, UK.
Background and aims: Some people with type 1 diabetes have functioning 
beta cells years after diagnosis, but the reason is unclear. We aimed to de-
termine the frequency of residual C-peptide secretion in people with long-
standing type 1 diabetes recruited to the Bart’s-Oxford study at diagnosis and 
relate this to current and baseline islet autoantibodies.
Materials and methods: We measured two-hour post-meal urine C-
peptide:creatinine ratio (UCPCR) and autoantibodies to glutamate decar-
boxylase (GADA) and islet antigen-2 (IA2A) in samples collected from 140 
patients (median age at diagnosis 11.9 years, 50% male) a median of 22 years 
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(range 12.2-28 years) after diagnosis. Baseline status for GADA, IA2A and 
zinc transporter 8 autoantibodies was determined in samples collected within 
24 months of diagnosis (median 33 days). UCPCR thresholds equivalent to 
mixed meal-stimulated serum C-peptide ≥0.2 nmol/L and ≥0.03nmol/L were 
used to define ‘preserved’ and ‘minimal’ endogenous insulin secretion. HLA 
class II genotype was established by PCR-SSP. Associations were examined by 
chi-squared and non-parametric testing.
Results: Of the 140 patients, 23 (16.4%) still had detectable endogenous in-
sulin secretion; seven (5.0%) ‘preserved’ and 16 (11.4%) ‘minimal’. 62% of 
participants had at least one antibody in current samples; 29% were GADA+ 
and 50% IA2A+. Persistent C-peptide secretion was inversely related to age 
at diagnosis (p=0.0009), and no one diagnosed before age 10 had ‚preserved‘ 
secretion. UCPCR was independent of diabetes duration and baseline or 
current autoantibody status. Of 7 individuals with ‘preserved’ endogenous 
insulin secretion, 6 had GADA at diagnosis with at least one diabetes risk-
associated HLA class II haplotype.
Conclusion: A subset of patients with proven autoimmune-mediated type 
1 diabetes has endogenous insulin secretion many years after diagnosis, but 
this is rarely found in individuals diagnosed in early childhood. Ongoing 
islet autoimmunity is also common. We hypothesise that, while aggressive 
early onset autoimmunity results in complete beta cell destruction, the less 
aggressive autoimmune process associated with later onset type 1 diabetes 
allows residual beta cells to provide a focus for persistent function as a result 
of regulated autoimmunity and/or beta cell renewal.
Supported by: JDRF and Diabetes UK
451
High GADA titer significantly increases the risk of insulin requirement 
in LADA: a 7-year follow-up (NIRAD Study 7)
S. Zampetti1, G. Campagna1, C. Tiberti1, M. Songini3, M. Arpi4,  
G. De Simone5, E. Cossu6, L. Cocco7, G. Leto2, E. Bosi8, F. Giorgino9,  
M. Spoletini2, R. Buzzetti2, NIRAD Study Group;  
1Sapienza University, Rome, 3San Michele Hospital, Cagliari, 4Catania 
University, 5ASL Napoli, 6University of Cagliari, 7Cardarelli Hospital, 
Campobasso, 8San Raffaele Institute, Milan, 9University of Bari, Italy.
Background and aims: The aim of the study was to determine whether glu-
tamic acid decarboxylase antibody (GADA) titer and other clinical param-
eters could define the risk of progression to insulin therapy in LADA patients 
during a 7-years follow-up.
Materials and methods: N= 222 LADA and n=430 type 2 diabetes subjects 
were followed for 7-years from the time of GADA screening to evaluate their 
progression towards insulin therapy. Kaplan-Meier curves and multivariate 
logistic regression analysis were performed to identify markers able to influ-
ence this progression.
Results: During the follow-up, drop out was 4% in both groups. N=119 
(56.1%) out of n=212 LADA and n=86 (20.9%) out of n=412 type 2 diabe-
tes required insulin. Kaplan-Meier plots showed that 74/104 (71.1%) of high 
GADA titer required insulin compared to 45/108 (41.6%) of low GADA titer 
and to 86/412 (20.9%) of type 2 diabetes (p<0.0001 for both). BMI≤25 kg/
m2 and positivity to IA-2IC and ZnT8 were also markers of faster progres-
sion (p<0.0001 for both). The proportion of LADA requiring insulin was 
significantly higher in the group of subjects treated also with sulfonylurea 
in the first year from diagnosis than in those treated with diet and/or insulin 
sensitizers (p<0.001). Multivariate analysis confirmed that presence of high 
GADA titer was a significant predictor of insulin (p<0.0001, OR=6.95).
Conclusion: High GADA titer, BMI≤ 25, ZnT8 and IA2IC positivity and sul-
fonylurea, in the first year from diagnosis, significantly increase the progres-
sion towards insulin requirement in LADA.
452
Pre-existing insulin autoantibodies predict efficacy of otelixizumab in 
preserving residual beta cell function in recent-onset type 1 diabetes
S. Demeester1, B. Keymeulen1, L. Kaufman1, A. Van Dalem1, E.V. Balti1,  
U. Van de Velde1, P. Goubert1, K. Verhaeghen1, H.W. Davidson2,  
J.M. Wenzlau2, I. Weets1, D.G. Pipeleers1, F.K. Gorus1;  
1Diabetes Research Center, Brussel, Belgium,  
2Barbara Davis Center for Childhood Diabetes, Aurora, USA.
Background and aims: Immune interventions have shown partial and tran-
sient efficacy in preserving beta cell function in recent-onset type 1 diabe-
tes. Future trials would benefit from biomarkers that predict therapeutic 
response, particularly when targeting subclinical disease. (Auto)antibodies 
against insulin (I(A)A), GAD (GADA), IA-2 (IA-2A) and ZnT8 (ZnT8A) 
were measured from this perspective during a randomized placebo-con-
trolled anti-CD3-study (otelixizumab, GSK).
Materials and methods: Eighty recent-onset type 1 diabetic patients (n=40 
otelixizumab, n=40 placebo) were included and levels of autoantibodies 
and stimulated C peptide release were measured at baseline (median dura-
tion of insulin treatment: 7 days) and every 6 months until 18 months after 
randomisation. I(A)A, GADA, IA-2A and ZnT8A levels were determined by 
liquid-phase radio binding assays, C-peptide release was measured during 
hyperglycaemic glucose-clamp.
Results: At baseline and during follow-up, levels of GADA, IA-2A and Zn-
T8A were not significantly different between treatment arms. Compared to 
placebo treated patients, anti-CD3-treated participants experienced a less 
pronounced insulin-induced rise in I(A)A, but only in initially IAA+ partici-
pants with relatively preserved beta cell function at baseline and concomi-
tantly lower insulin needs. Univariate analysis identified IAA level at screen-
ing as well as C-peptide release at entry as predictors of anti-CD3 efficacy in 
terms of the preservation of beta cell function, but in multivariate analysis 
only IAA was retained (p=0.026).
Conclusion: Pre-existing insulin autoantibodies represent an independent 
marker for the therapeutic response of recent-onset type 1 patients to anti-
CD3 treatment. Future immune intervention trials in (pre)type 1 diabetes 
should consider both presence of IAA and relatively preserved functional 
beta cell mass as inclusion criteria.
Clinical Trial Registration Number: NCT00627146
Supported by: JDRF (USA), EU FP-7 (Brussels), FWO (Brussels), NIH (USA)
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Evaluation of DiaPep277® treatment in type 1 diabetes by integrated 
analysis
D. Elias1, A. Avron1, M. Tamir1, R. Eren1, D. Peled1, S. Dagan1, I. Raz2,  
P. Pozzilli3, T. Linn4, F. Bonnici5, DIA-AID 1 Study Group;  
1Andromeda Biotech Ltd., Yavne, Israel, 2Diabetes Unit, Hadassah 
University Hospital, Jerusalem, Israel, 3Endocrinology & Metabolic 
Diseases, University Campus Bio-Medico, Rome, Italy,  
4University Hospital Giessen, Germany, 5UCT Private Academic Hospital, 
Cape Town, South Africa.
Background and aims: Novel interventions evaluated in newly diagnosed 
type 1 diabetes (T1D) focus on preservation of beta cell function, glycemic 
control and insulin requirement. Primary study outcome is assessed by sepa-
rate evaluation of each parameter, but the clinical benefit lies in the overall 
combined effect. Study DIA-AID 1 showed that treatment with DiaPep277® 
over 2 years resulted in a significantly better preservation of C-peptide and 
better glycemic control, in adult subjects newly diagnosed with T1D. The 
purpose of this analysis was to compare the effect of DiaPep277® to Placebo 
in populations of “Responder” and “Non-Responder” patients.
Materials and methods: The “Responder” profile was determined 
based on the following combined criteria: • Preservation of at least 
80% of baseline stimulated and fasting C-peptide • HbA1c <8% 
• Insulin dose ≤0.5IU/kg and no increase from baseline Data were analyzed 
using the SAS® version 9.1 (SAS Institute, Cary North Carolina). The Chi-
square test was applied for analyzing the difference in proportion of respond-
ers and in other categorical parameters between the active and placebo 
groups. The two-sample T-test was applied for analyzing the difference in 
quantitative parameters between the active and placebo groups.
Results: Of the ITT population (N=457), 70% had full data (N=325) and 
could be profiled. In the DiaPep277® arm 53% met the criteria for “Respond-
er.” They presented at baseline with lower %HbA1c (p<0.0001) and also with 
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a higher age (p<0.0001). In the Placebo arm, the 27% who met the criteria for 
“Responder” due to spontaneous good diabetes control, presented with sig-
nificantly higher fasting and stimulated C-peptide levels (p<0.05) and lower 
%HbA1c (p<0.0001) at baseline. This increase of the “Responder” frequency 
from 27% in Placebo to 53% in DiaPep277® treated (P<0.0001) is a major 
clinical benefit, as it represents a doubling in subjects whose overall deterio-
ration is slowed by DiaPep277® treatment. Other baseline parameters showed 
no difference between “Responders” and “Non-Responders:” BMI, number 
of autoantibodies, gender, time from diagnosis, insulin dose and HLA.
Conclusion: This analysis identifies a quarter of subjects newly diagnosed 
with T1D as “Spontaneous Responders” whose presence in intervention stud-
ies adds to the variability of outcome. Still, on this background, half of adult 
patients treated for 2 years with DiaPep277® show a significant beneficial 
response when considering the integrated parameters of metabolic control.
Clinical Trial Registration Number: NCT00615264
PS 022 Beta cell ER stress  
and apoptosis
454
Cross-interaction between C/EBPbeta and AMPK determines  
the pancreatic beta cell mass
Y. Mieda1, T. Matsuda2, T. Kawamoto1, E. Suzuki2, S.-I. Asahara2, A. Kanno2, 
M. Koyanagi2, Y. Kido1;  
1Division of Medical Chemistry, Department of Biophysics, Kobe 
University Graduate School of Health Sciences, 2Division of Diabetes 
and Endocrinology, Department of Internal Medicine, Kobe University 
Graduate School of Medicine, Japan.
Background and aims: Accumulation of C/EBPβ plays an important role in 
pancreatic β-cell failure caused by endoplasmic reticulum (ER) stress. Pan-
creatic β cell mass increases when gene modification or DPP-4 inhibitors are 
used to reduce expression of C/EBPβ accumulated in type 2 diabetes model 
mice or pancreatic β-cell specific C/EBPβ transgenic mice. We, therefore, 
aimed to elucidate the control mechanism of C/EBPβ expression.
Materials and methods: MIN6 cells were loaded with AICAR, metformin, 
and Extendin-4 to assess the relationship between AMPK activity and C/
EBPβ expression levels. The effect of C/EBPβ phosphorylation on expression 
levels was also investigated. Further, vildagliptin and metformin were admin-
istered to pancreatic β cell specific C/EBPβ transgenic (TG) mice to investi-
gate the relationship between C/EBPβ expression levels and AMPK activity 
in the pancreatic islets.
Results: In the pancreatic β-cells, ER stress causes enhanced expression and 
accumulation of C/EBPβ. The accumulated C/EBPβ was shown to inhibit 
AMPK activity by lowering the AMP/ATP ratio. C/EBPβ expression levels 
were, however, inhibited when AMPK was activated, and enhanced when 
AMPK was inactivated. In other words, AMPK activity and C/EBPβ expres-
sion levels were negatively correlated. Some of these effects are thought to 
involve T188 phosphorylation of C/EBPβ. In other words, the decreased 
AMPK was thought to increase C/EBPβ expression by raising the stability of 
C/EBPβ as a protein via enhanced T188 phosphorylation of C/EBPβ. In the 
pancreatic islets of the TG mice, increased C/EBPβ expression was accompa-
nied by decreased AMPK activity. When the DPP-4 inhibitor vildagliptin was 
administered to the TG mice, the pancreatic islets exhibited improved AMPK 
activity accompanied by inhibited C/EBPβ expression. Moreover, with con-
comitant administration of vildagliptin and metformin, the pancreatic islets 
exhibited even greater activation of AMPK accompanied by even greater in-
hibition of C/EBPβ expression compared to vildagliptin alone. As a result, 
glucose tolerance was even further improved.
Conclusion: When pancreatic β cells are loaded with ER stress, enhanced C/
EBPβ expression and decreased AMPK activity are thought to act synergis-
tically to bring about pancreatic β cell failure. T188 phosphorylation of C/
EBPβ also played an important in control of C/EBPβ expression by AMPK 
or ER stress. An increase in the pancreatic β cell mass and inhibition of C/
EBPβ expression by vildagliptin was accompanied by activation of AMPK. 
Combining vildagliptin and metformin exhibited even greater AMPK acti-
vation accompanied by an increase in pancreatic β cell mass and inhibition 
of C/EBPβ expression, compared to vildagliptin alone. This suggests that 
decreased AMPK activity and enhanced C/EBPβ expression form a vicious 
cycle to bring about pancreatic β cell failure.
Supported by: Novartis
455
Enhancing peroxiredoxin 4 expression improves insulin biosynthesis and 
glucose-induced insulin secretion in insulin-producing INS-1E cells
I. Mehmeti, S. Lortz, M. Elsner, S. Lenzen;  
Institute of Clinical Biochemistry, Hannover Medical School, Germany.
Background and aims: Oxidative protein folding is crucial for the structural 
stability and proper function of most secretory proteins and polypeptide hor-
mones such as insulin. This process takes place in the endoplasmic reticu-
lum (ER) and is accomplished by protein disulfide isomerase (PDI) and ER 
oxidoreductin 1β (ERO-1β), generating stoichiometric amounts of hydrogen 
peroxide (H2O2) as byproduct. During insulin resistance in the pre-diabetic 
state, increased insulin biosynthesis can overwhelm the ER antioxidative 
and folding capacity, causing an imbalance in the ER redox homeostasis and 
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oxidative stress. Peroxiredoxin 4 (Prdx4), an ER-specific antioxidative per-
oxidase can utilize luminal H2O2 as driving force for reoxidizing PDI family 
members, thus efficiently contributing to disulfide bond formation. Therefore 
the aim of this study was to examine the functional significance of Prdx4 on 
β-cell function with emphasis on insulin content and secretion during stimu-
lation with nutrient secretagogues.
Materials and methods: The ER-specific Prdx4 was specifically overex-
pressed in insulin-producing INS-1E cells. The Prdx4 overexpression was 
verified by Western blot, while its antioxidative effect was assessed by DCF 
in the presence of 5 mM dithiothreitol (DTT). Insulin content and secre-
tion were determined by RIA and proinsulin transcription by qRT-PCR after 
stimulation with glucose (3, 10, 30 mM) and a combination of leucine (10 
mM) plus glutamine (2 mM).
Results: Immunoblotting revealed that INS-1E cells stably transduced with 
a lentiviral construct carrying Prdx4 exhibited a significant increase in the 
Prdx4 expression compared to control cells. Exposure of control cells to DTT 
resulted in a significant generation of reactive oxygen species (ROS), whereas 
Prdx4 overexpression completely prevented the DTT-mediated ROS gen-
eration. Overexpression of Prdx4 led to an improved insulin secretion after 
stimulation with 10 and 30 mM glucose compared to control cells, while the 
basal insulin secretion at 3 mM glucose was not affected. An augmented insu-
lin secretion could also be observed in Prdx4 overexpressing cells incubated 
with leucine plus glutamine. In addition, Prdx4 overexpressing cells exhibited 
an enhanced proinsulin mRNA transcription and insulin content when com-
pared to control cells.
Conclusion: These data strongly suggest that enhancing ER-specific perox-
iredoxin 4 expression in glucose-responsive insulin-secreting INS-1E cells 
significantly metabolized the DTT- mediated H2O2 generation within the 
ER and improved the glucose-induced insulin-secretion, which was accom-
panied by the enhancing proinsulin gene transcription and insulin content. 
This beta cell beneficial effect was also observed upon stimulation with leu-
cine, another nutrient insulin secretagogue, indicating that the effect is not 
restricted to glucose. Thus, Prdx4 improves the ER folding capacity and could 
contribute to the preservation of beta cell function under conditions of high 
insulin requirement.
456
Targeted overexpression of glycosylation-negative catalase mutations in 
the endoplasmic reticulum of insulin-producing cells
S. Lortz, I. Mehmeti, S. Lenzen;  
Institute of Clinical Biochemistry, Hannover Medical School, Germany.
Background and aims: In reaction to peripheral insulin resistance in type 
2 diabetes mellitus, β-cells show initially an increased insulin secretion. Es-
calated insulin biosynthesis and secretion require an enhanced capacity for 
protein folding and disulfide bond formation, resulting in an increased pro-
duction of H2O2 in the endoplasmic reticulum (ER). A direct quantification 
is not possible due to the oxidative environment in the ER and catalase over-
expression for compensating an elevated H2O2 production failed due to N-
glycosylation of the catalase protein. Therefore, a glycosylation-negative ER-
targeted catalase variant, designed by mutagenesis, should be overexpressed 
to reduce the H2O2 concentration in the ER of insulin-secreting cells and to 
proof its potential impact on insulin secretion and ER stress.
Materials and methods: The two potential N-glycosylation sites of the hu-
man catalase protein were eliminated by PCR-mediated mutagenesis. The 
generated catalase variants were peroxisomally overexpressed to confirm 
that catalase enzyme activity was unaffected by the mutations, before the ER-
specific expression was carried out in RINm5F and INS-1E cells. Catalase 
functionality in the ER and prevention of N-glycosylation was examined by 
enzyme activity measurement, incubation with H2O2 and Western blot analy-
sis. Glucose-induced insulin secretion was quantified by RIA and typical ER 
stress markers were quantified by qRT-PCR analysis.
Results: Despite of the mutation of the N-glycosylation motives at aspara-
gine-244 and -439, catalase activity was not affected by both single mutants 
(N244: 938±114, N439: 972±101, untransfected: 16±4 U/µg protein). After 
overexpression of both variants in the ER only the ER-catalase-N244 showed 
enzyme activity and lack of glycosylation, whereas ER-catalase-N439 was still 
glycosylated and only a slightly elevated catalase activity could be detected 
(N244: 935±51, N439: 74±10 U/µg protein). Quantification of catalase en-
zyme activity of the double mutant N244/439 after peroxisomal and ER-tar-
geted overexpression revealed lower catalase activity in both compartments 
compared with N244 (peroxisome: 278 ± 17, ER: 168 ± 12 U/µg protein). 
Measurement of glucose-induced insulin secretion and of ER stress-induced 
genes showed no significant changes compared with untransfected control 
cells.
Conclusion: With the overexpression of ER-catalase-N244 a highly effective 
H2O2 inactivation within the ER could be achieved for the first time. Double 
mutation of both N-glycosylation motives N-244 and -439 was associated 
with partial loss of function, possibly due to the destruction of the three-
dimensional enzyme structure. Since catalase has a high H2O2 inactivation 
capacity and is not involved in the protein folding process, the enzyme is an 
ideal tool for the investigation of insulin biosynthesis-associated oxidative ER 
stress, postulated for type 2 diabetes, or oxidative stress induced by misfolded 
protein aggregation in the ER. However, increased H2O2 inactivation through 
overexpression of ER-Catalase-N244 had no influence on insulin biosynthe-
sis and the ER-stress response.
457
ATF6β regulates the Wfs1 gene and has a cell survival role in the ER 
stress response in pancreatic beta cells
A. Volchuk, T. Odisho, L. Zhang;  
Cellular & Molecular Biology, Toronto General Research Institute, Canada.
Background and aims: Endoplasmic reticulum (ER) stress has been impli-
cated in the development of pancreatic β-cell dysfunction and death resulting 
in type 2 diabetes. The Unfolded Protein Response (UPR) is the cellular sys-
tem that responds to ER stress and consists of three main ER stress sensors, 
PERK, IRE1 and ATF6. Activating transcription factor 6 (ATF6) is an essen-
tial component of the UPR in cells undergoing ER stress that consists of two 
distinct genes, ATF6α and ATF6β. The ATF6β isoform has been less studied 
and its role in the UPR in β-cells is unclear.
Materials and methods: Rodent islets and insulinoma cell lines were used to 
examine ATF6β function. Microarray and qPCR validation was employed to 
identify ATF6β target genes and siRNA knock-down and adenoviral overex-
pression was used to assess the role of ATF6β in ER stress-induced apoptosis.
Results: ATF6β mRNA and protein were detected in pancreatic β-cell lines 
and rodent and human islets and the protein was proteolyzed to the nuclear 
active form (ATF6βp60) in response to pharmacological ER stress. Knock-
down of ATF6β using siRNA in INS-1 832/13 insulinoma cells did not af-
fect mRNA induction of several major ER stress response genes in response 
to tunicamycin-induced ER stress, suggesting ATF6β is not essential for the 
basic UPR. Expressing active ATF6βp60 and ATF6αp50 followed by micro-
array analysis revealed that ATF6β and ATF6α regulate similar UPR genes, 
including chaperones and ERAD components, although some genes such as 
Wfs1 are ATF6β-specific. Interestingly, knockdown of ATF6β increased the 
susceptibility of INS-1 832/13 β-cells to apoptosis under both control and 
ER stress conditions, while overexpression of active ATF6βp60 reduced ap-
optosis.
Conclusion: ATF6β is not essential for induction of major ER stress response 
genes, but is required to maintain cell survival in β-cells undergoing chronic 
ER stress. The ATF6β pro-survival role may relate to induction of genes that 
promote cell survival such as Wfs1.
Supported by: CIHR
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The novel translation initiation factor, eIF2A, is up-regulated by 
endoplasmic reticulum stress and protects beta cells from apoptosis
E. Panzhinskiy1, F. Taghizadeh1, K.-Y. Chu1, Y. Yang1, E. Jan2, J.D. Johnson1;  
1Cellular and Physiological Sciences,  
2Biochemistry, University of British Columbia, Vancouver, Canada.
Background and aims: Endoplasmic reticulum (ER) stress is an important 
mediator of pancreatic beta cell loss in diabetes. Recent reports have associat-
ed inhibition of protein synthesis by the ER stress-induced unfolded protein 
response (UPR) with apoptosis. ER-stress associated translation reprogram-
ming increase translation of stress-response mRNAs, but the signaling path-
ways that modulate this process in beta cells are not well studied. Recently, 
the novel translation initiation factors eIF2A and eIF2D have been implicated 
in the translation of specific mRNAs under stress conditions in other systems. 
We investigated the role of eIF2A and eIF2D in the regulation of UPR gene 
expression and ER-stress-induced apoptosis in beta cells.
Materials and methods: Thapsigargin (Tg, 1 μmol/l), palmitate (PA, 0.5 
mmol/l in BSA) were used to induce ER stress in primary mouse islets and 
mouse insulinoma cells (MIN6). Real-time RT-PCR, Western Blot and im-
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munocytochemistry were used to assess gene expression. Apoptosis was as-
sessed by flow cytometry of propidium iodide (PI) stained cells. Differences 
between means were considered statistically significant when p was < 0.05.
Results: We found that eIF2A and eIF2D were expressed in mouse islets at 
both mRNA and protein levels. We compared eIF2A protein expression levels 
between different mouse tissues (heart, brain, liver, muscle, spleen, pancreatic 
islets) and found that they were highest in the pancreatic islets. eIF2D protein 
levels did not significantly differ between islets and other tissues. Fluorescent 
microscopy revealed that eIF2A and eIF2D were mainly localized in the cy-
toplasm of primary beta cells. Using MIN6 cells, we found gradual induction 
of eIF2A protein expression over the time course of Tg-induced ER stress, 
with the maximal fold increase of 1.78 ± 0.18 (n = 4) after 24 h, which coin-
cided with activation of pro-apoptotic markers C/EBP homologous protein 
(CHOP, 137 ± 24 fold, n = 4) and cleaved caspase-3 (234 ± 11 fold, n = 4). We 
also observed a 1.66 ± 0.17 fold increase (n = 4) in eIF2D protein levels after 
6 h of Tg-treatment that coincided with maximum Activating Transcription 
Factor-4 protein levels (8.7 ± 1.3 fold increase, n = 4). However, the effect 
was transient and after 24 h of Tg treatment, eIF2D protein levels were not 
different from the basal level. Treatment of MIN6 cells with PA for 24 h also 
significantly increased protein levels of eIF2A (2.1 ± 0.5 fold, n = 3) with no 
significant differences in eIF2D levels observed. Isolated mouse islets treated 
with either Tg or PA for 24 h showed elevated levels of eIF2A protein (by 
1.35 ± 0.5 and 1.43 ± 0.2 fold respectively, n = 3) when compared to basal 
conditions, but not eIF2D. Importantly, we demonstrated that overexpression 
of recombinant eIF2A (10-fold) in MIN6 cells reduced thapsigargin-induced 
apoptosis by 51 ± 15% (n = 3). We found that decreased death of beta cells 
overexpressing eIF2A after 24 h of thapsigargin treatment was accompanied 
by decreased expression of UPR pro-apoptotic marker CHOP by 45 ± 13% 
(n = 3).
Conclusion: We conclude that eIF2A and eIF2D are expressed and differ-
entially regulated over the course of UPR in beta cells. Also we identified a 
novel protective role for eIF2A in the context of ER-stressed beta cells via the 
inhibition of CHOP. Thus, eIF2A may potentially serve as a new therapeutic 
target in diabetes.
Supported by: CDA
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The balance between adaptive and apoptotic unfolded protein responses 
regulates beta cell death through JNK, XBP1 and CHOP
J.Y. Chan, J. Luzuriaga, D.R. Laybutt;  
Garvan Institute of Medical Research, Sydney, Australia.
Background and aims: The loss of β-cell mass due to increased apoptosis 
is critical in both type 1 and type 2 diabetes. Pro-inflammatory cytokines 
and saturated fatty acids are potential mediators of β-cell apoptosis, although 
the mechanisms are poorly understood. Endoplasmic reticulum (ER) stress 
is present in β-cells in both type 1 and type 2 diabetes. ER stress is resolved 
through adaptive actions of the unfolded protein response (UPR). However, 
β-cells are prone to failure of the adaptive UPR with consequent activation of 
pro-apoptotic UPR, but the mechanisms are unclear. Here, we investigated 
the role of key ER stress-responsive transcription factors, XBP1 and CHOP, 
in the UPR induced by cytokines (IL-1β, TNF-α and IFN-γ) or the saturated 
fatty acid, palmitate. We also examined the influence of Jun N-terminal ki-
nase (JNK) activity in the UPR and the significance of these responses in 
β-cell survival.
Materials and methods: MIN6 β-cells and mouse islets were exposed for 24-
48 h to the combination of pro-inflammatory cytokines, IL-1β (100 U/ml), 
TNF-α (100 U/ml), IFN-γ (250 U/ml) or the saturated fatty acid, palmitate 
(0.4 mM coupled to 0.92% BSA). siRNA was used to silence XBP1 and CHOP 
in MIN6 cells. IRE1/XBP1 inhibitor (4μ8c - 30 μM) was used in mouse is-
lets. SP600125 (20 μM) was used to inhibit JNK activity. β-cell death was 
measured using a cell death detection ELISA. Gene and protein expression 
changes were assessed by real-time PCR and Western blot.
Results: In MIN6 cells, exposure to cytokines or palmitate resulted in in-
creased cell death and ER stress, which featured marked increases in pro-
apoptotic UPR markers, CHOP, Atf3 and Trib3. siRNA-mediated inhibition 
of XBP1 reduced the expression of adaptive UPR markers, including ER 
chaperones and foldases (BiP, Grp94, Fkbp11, Erp72, Edem1) and potenti-
ated cytokine- and palmitate-induced apoptosis (p<0.001). The enhancement 
of apoptosis was prevented by concomitant siRNA-mediated reduction of 
CHOP (p<0.001). IRE1/XBP1 inhibition by 4μ8c also increased cytokine- 
and palmitate-induced apoptosis in mouse islets. These findings suggest that 
XBP1-mediated maintenance of the adaptive UPR inhibits CHOP-dependent 
apoptosis following chronic cytokine and palmitate exposure in β-cells. Cy-
tokine exposure also increased levels of phosphorylated JNK. JNK inhibition 
by SP600125 prevented the inhibitory effects of cytokines on XBP1 and adap-
tive UPR gene expression, lowered pro-apoptotic UPR gene expression, and 
protected β-cells from cytokine-induced cell death (p<0.001).
Conclusion: These data suggest that JNK activity regulates the balance of the 
UPR in β-cells under conditions of ER stress; JNK activation inhibits XBP1-
mediated UPR adaptation and promotes apoptotic UPR in β-cells. The dif-
ferential regulation of adaptive and apoptotic UPR by JNK activation may 
provide a mechanism for the propensity of β-cells to apoptosis rather than ER 
stress adaptation in type 1 and type 2 diabetes.
Supported by: NHMRC of Australia
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Chronic ethanol consumption inhibits Glucokinase transcriptional 
activity through ATF3/PDX-1/HDAC1 axis and triggers metabolic 
syndrome in vivo
W.-H. Kim, J.-Y. Kim, K.-J. Park, D.-Y. Lee, G.-H. Kim, Y.-J. Lee;  
Korea National Institute of Health, Cheongwon-gun, Chungbuk,  
Republic of Korea.
Background and aims: Chronic ethanol consumption induces pancreatic 
β-cell dysfunction through glucokinase (GCK) nitration and downregula-
tion, leading to impaired glucose tolerance and insulin resistance; but the 
underlying mechanism remain largely unknown.
Materials and methods: To this, the 6-week male C57BL/6J mice were fed 
with 5% ethanol-containing liquid diet for 8 weeks and examined the effects 
of in vivo ATF3 silencing on GCK downregulation and metabolic alterations 
in ethanol-fed mice.
Results: Here, we demonstrate that GCK gene expression and promoter 
activity in pancreatic β-cells were suppressed by chronic ethanol exposure 
in vivo and in vitro; whereas expression of activating transcription factor 3 
(ATF3) and its binding to the putative ATF/CREB site on GCK promoter 
were upregulated. Furthermore, in vitro ethanol-induced ATF3 inhibited the 
positive effect of PDX-1 on GCK transcriptional regulation, enhanced re-
cruitment of HDAC1/2 and histone H3 deacetylation, and subsequently aug-
mented the interaction of HDAC1/PDX-1 on the GCK promoter, which were 
diminished by ATF3 siRNA. Corroboratory, in vivo ATF3-silencing reversed 
ethanol-mediated GCK downregulation and β-cell dysfunction, followed by 
the amelioration of impaired glucose tolerance and insulin resistance. ATF3 
association with T2D with alcohol consumption was supported by the iden-
tification of a novel non-coding variant, rs6670133, in the ATF3 gene after 
adjusting for age, sex, and alcohol consumption in Korean T2D population 
(P = 0.041).
Conclusion: We identified ethanol-induced ATF3 fosters β-cell dysfunction 
via GCK downregulation and that its loss ameliorates metabolic syndromes 
and could be a potential therapeutic target in treating T2D.
Supported by: KNIH 2011-NG64001-00
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Antiapopototic HSPB1 mediates prolactin-induced cytoprotective effects 
on beta cells
R.A.M. Wailemann1,2, L.F. Terra1, T.C. Oliveira1, A.F. Santos1,  
M.C. Sogayar1,3, L. Labriola1;  
1Biochemistry, Chemistry Institute, 2School of Arts, Science and Humanities 
(EACH), 3Cell and Molecular Therapy Center (NUCEL/NETCEM), 
University of São Paulo, Brazil.
Background and aims: Transplantation of isolated pancreatic islets is an al-
ternative for treatment of type 1 Diabetes; which is limited by the shortage of 
organ donors. Ex-vivo expansion of islet cell cultures appears as an attractive 
strategy; however, the islet fate in culture is determined, at least in part, by the 
balance between pro- and anti-apoptotic mediators.We have shown that re-
combinant human prolactin (rhPRL) inhibits beta-cell apoptosis. Moreover, 
we have recently reported PRL-induced up-regulation of the anti-apoptotic 
HSPB1 in human islets. Since the function of HSPB1 in beta-cells has not 
been directly studied, we set out to explore the role of HSPB1 in prolactin-
induced beta-cell cytoprotection.
Materials and methods: We used primary cultures of human pancreatic is-
lets and parental and HSPB1 knocked-down Min6 cells. Apoptosis was evalu-
ated by DNA fragmentation and quantified by flow cytometry. Protein levels 
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of the Bcl-2 gene family members, caspase-9, HSTF1, P38, pP38, STAT-1 and 
pSTAT-1were assessed by Western blotting. Caspase 3 and 8 activities were 
studied by fluorimetric assays.
Results: Our data showed that upon cytokines and rhPRL treatment, the pro-
portion of fragmented nuclei was increased in HSPB1 silenced cells (p<0.05) 
when compared to control cells. In addition, the inhibition of cytokine-in-
duced capase-3 and caspase-8 activities as well as Bcl-2/Bax ratio and cas-
pase-9 protein levels mediated by rhPRL in wild type cells was significantly 
reverted in knocked-down cells (p<0.05). Moreover, the kinetics of HSP-
B1and HSTF1 expression levels were studied in primary cultures of human 
pancreatic islets which were serum starved and treated with rhPRL for short 
periods of time (from 10 min to 2h). The results showed that while HSTF1 
presented a significant increase (p<0.01) in protein expression level after 10 
min of rhPRL treatment, HSPB1 reached its maximum expression level upon 
2h of hormonal treatment. Additionally, a significant (p<0.05) increase in 
STAT1 phosphorylation levels was detected after 10min of rhPRL treatment 
reaching the highest peak upon 30 min (p<0.001) of hormonal treatment.
Conclusion: Therefore, we demonstrated a key role for HSPB1 in rhPRL-
induced cytoprotective effects, since the lack of this protein completely abol-
ished the beneficial effects induced by PRL on beta-cell death. Moreover, 
we provided for the first time, evidence for the co-regulation of HSPB1 and 
HSTF1 induced by rhPRL in human pancreatic cells which could be medi-
ated by activated STAT1. Collectively, our results point to a promising target 
which could lead to the mitigation of beta-cell death through the up-regu-
lation of an endogenous protective pathway which is not dependent on the 
modulation of the immune system.
Supported by: FAPESP, CNPq, CAPES, FINEP, BNDES, MCT, MS-DECIT, 
PRP-USP
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Modulation of glutamate signalling in human islets of Langerhans  
under hyperglycaemia
C. Perego1, S. Moretti1, E.S. Di Cairano1, F. Daniele1, F. Bertuzzi2,  
A. Davalli3, F. Folli4;  
1DiSFB Dept of Pharmacological and Biomolecular Sciences, University 
of Milano, 2Niguarda Cà Granda Hospital, 3Dept. of Internal Medicine, 
Diabetes & Endocrinology Unit, Ospedale San Raffaele, Milano, Italy,  
4Dept. of Medicine Diabetes Division, University of Texas Health Science 
Center, San Antonio, USA.
Background and aims: Increasing evidence suggests that the excitatory 
neurotransmitter L-glutamate functions as a paracrine/autocrine signal in 
human islet of Langerhans. L-glutamate is released by α-cells together with 
glucagon and modulates hormone secretion by acting on specific glutamate 
receptors. When present at elevated concentrations, it may induce beta-cell 
death through oxidative stress. Its interstitial concentration is regulated by 
glutamate transporters of the SLC1A family which are expressed on the plas-
ma membrane of endocrine cells. Their functional activity is essential for islet 
function as shown by the fact that their pharmacological inhibition increases 
glutamate concentration in the islets and causes beta-cell death. Aim of this 
study was to verify whether chronic hyperglycaemia may modulate the gluta-
mate signalling system in human islets of Langerhans.
Materials and methods: Human islets were incubated under chronic (3 
days) hyperglycaemia (16.7 mmol/l glucose) or normoglycemia (5.5 mmoll 
glucose), and the expression and function of plasma membrane glutamate 
transporters and intracellular signalling proteins were studied by quantitative 
PCR analysis, western blotting, immunofluorescence,[3H]-Glutamate uptake 
and Ca2+-imaging experiments.
Results: Quantitative PCR analysis revealed a 40±3% reduction in the total 
ASCT2/SLC1A5 expression after incubation in chronic hyperglycaemia. No 
changes in the total GLT1/SLC1A2 mRNA and protein expression in human 
islets were detected. Immunofluorescence experiments performed on human 
islets exposed to hyperglycaemia revealed GLT1 relocalization into intracel-
lular vesicular compartments of beta-cells. Because of this relocalization, the 
GLT1-mediated surface activity measured by [3H]D-glutamate uptake was 
inhibited by 31±5% relative to normoglycemic conditions (p<0.05; n=4 in 
triplicate). Chronic hyperglycaemia induced a downregulation of the PI3K/
Akt pathway in human beta-cells, suggesting a possible involvement of this 
pathway in the modulation of GLT-1 trafficking (35±3 % downregulation of 
P-Akt expression, n=5 islet preparations). In line with this possibility, PI3K 
inhibition with 100 µM LY293 caused the GLT1 relocalization in intracel-
lular compartments, and a 75±8% downregulation of its activity, relative to 
control conditions (p<0.001; n=2 different islet isolations, in quadruplicate). 
Chronic treatment with 10 µM ceftriaxone, a drug capable to upregulate 
GLT1 expression, significantly prevented hyperglycaemia-induced apopotsis 
in human islets (65±12% reduction of apoptosis. P<0.001; n=2 preparations, 
in quadruplicate).
Conclusion: Our data indicate that glutamate signalling in human islet is al-
tered in hyperglycaemia and this may further contribute to beta-cell death. 
Targeting glutamate signalling system components may be a promising ap-
proach to prevent beta-cell death and to control glucose homeostasis in dia-
betes.
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Inhibition of de novo lipogenesis by lysosomal acid lipase in beta cells 
helps counter-regulate insulin secretion
G.L. Pearson1, P.J. Meikle2, N. Mellett2, H. Du3, T.J. Biden1;  
1Garvan Institute of Medical Research, Darlinghurst, 2Baker IDI, Melbourne, 
Australia, 3School of Medicine, Indiana University, Indianapolis, USA.
Background and aims: Endogenous lipolysis is hypothesised to contribute 
to the amplification phase of glucose-stimulated insulin secretion (GSIS) in 
pancreatic β-cells, mediated acutely by neutral lipases. Recent work shows 
that lysosomal acid lipase (LAL), an acidic lipase responsible for the break-
down of lipid delivered to the lysosome, is a negative regulator of GSIS. How-
ever, the exact mechanism of action of LAL and its role in whole body glucose 
homeostasis are unclear. Our current aims were to: (1) investigate glucose 
homeostasis in global LAL knock-out (KO) mice and (2) further characterise 
its mechanism of action.
Materials and methods: Wild-type (WT) and LAL KO mice were subjected 
to intraperitoneal glucose-tolerance tests (i.p. GTT). GSIS was measured by 
insulin RIA in islets isolated from WT and LAL KO mice. After 24 h LAL in-
hibition with Lalistat (5μmol/l) in MIN6 cells, gene expression was analysed 
by RT-PCR and lipid mass was assessed using mass spectrometry.
Results: LAL KO mice had significantly lower glucose excursions during an 
i.p.GTT compared to WT mice (AUC mean±SEM: WT 1514.3±104.8 n=10; 
LAL KO 1087.0±95.2 n=7; P<0.05 two-way ANOVA). This was most notable 
30 min after the glucose bolus, and coincided with significantly higher insulin 
levels throughout the i.p.GTT (insulin AUC mean±SEM: WT 18.6±0.9 n=10; 
LAL KO 44.3±4.3 n=7; P<0.001 two-way ANOVA). To delineate a β-cell spe-
cific effect of LAL deletion, islets were assessed for GSIS ex vivo. Islets from 
LAL KO mice had increased GSIS at 20mmol/l glucose compared to WT 
islets (pg insulin/islet/h±SEM, n=5: WT 516.3±69.1; LAL KO 872.5±108.8; 
P<0.05 paired t-test). Together these data confirm that LAL has a physi-
ological role in β-cell function and acts to inhibit insulin secretion in vivo. 
In mechanistic studies we determined that LAL inhibition in MIN6 cells 
enhanced expression of genes associated with de novo lipogenesis (Dgat1, 
Gpam), as well as the lipase Lipe. The cholesterol transporter Abca1 was sig-
nificantly downregulated. These data indicate that inhibition of LAL upregu-
lates de novo lipogenesis, which acts to increase lipid signals that enhance 
GSIS. Consistent with this, mass spectrometry revealed that disaturated dia-
clyglycerol mass was increased 3-fold after acute 20mmol/l glucose stimula-
tion (n=4, p<0.05 unpaired t-test), and with LAL inhibition this was further 
potentiated 1.5-fold (n=4, p<0.01 paired t-test).
Conclusion: Our data further elaborate the importance of neutral lipid 
turnover in β-cell function, highlighting the key role of LAL in whole body 
glucose homeostasis and insulin secretion. In addition to its known role in 
regulating lipophagy, our data suggests that LAL mediated lipid breakdown 
also inhibits insulin secretion by downregulating de novo lipogenesis. It is 
likely that LAL plays a key role in limiting insulin secretion during starvation.
Supported by: NHMRC PhD scholarship and NHMRC project grants
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Involvement of actin cytoskeleton in free fatty acid-induced beta cell 
death
A. Natalicchio, R. Labarbuta, F. Tortosa, G. Biondi, N. Marrano,  
A. Leonardini, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino;  
Endocrinology & Metabolic Diseases, University of Bari, Italy.
Background and aims: The role of actin cytoskeleton in regulation of pan-
creatic beta-cell survival has not been investigated. In this study, actin cy-
toskeleton remodeling was examined in the context of beta-cell apoptosis 
induced by free fatty acids (FFA).
Materials and methods: Studies were carried out in human pancreatic in-
sulin-releasing 1.1B4 cells treated with 0.2 mM palmitate up to 24 h with or 
without pretreatment with 0.01 μM cytochalasin D (CD) for 2 h or 25 nM 
jasplakinolide for 2 h. Actin cytoskeleton was visualized by immunofluores-
cence techniques. Expression and activation levels of the proteins under in-
vestigation were evaluated by immunoblotting techniques. Cell apoptosis was 
detected by measurements of cytosolic release of oligosomes (ELISA assay).
Results: Exposure of human 1.1B4 pancreatic beta-cells to 0.2 mM palmitate 
resulted in a 10- to-14-fold increase in cell apoptosis (p<0.05). The organiza-
tion of actin filaments was then examined in 1.1B4 beta-cells following expo-
sure to palmitate. Palmitate induced a typical peripheral distribution of actin 
filaments consistent with their mechanical supporting function for shrinking 
of apoptotic cells. Treatment of beta-cells with cytochalasin D (CD) (0.01 μM, 
2 h) led to collapse of the filamentous actin structures and a more rounded 
cell shape, and inhibited the effect of palmitate on apoptosis (p<0.05). To fur-
ther investigate the role of actin cytoskeleton in palmitate-induced apoptosis, 
1.1B4 beta-cells were treated with jasplakinolide, a potent inducer of actin 
polymerization. Jasplakinolide (25 nM, 2 h) led to the formation of relatively 
fine stress fibers and large aggregations of actin filaments, and enhanced pal-
mitate-induced apoptosis (p<0.05). In addition, palmitate-induced phospho-
rylation of the pro-apoptotic stress kinases JNK and p38 MAPK was reduced 
(by 45% and 90%) or increased (by 47% and 35%) after treatment with CD or 
jasplakinolide, respectively (p<0.05). Finally, palmitate induced a decrease in 
Akt phosphorylation, and this was prevented by CD (p<0.05); preincubation 
of beta-cells with the PI 3-kinase inhibitor LY294002 abrogated the ability of 
CD to restore Akt phosphorylation and to inhibit palmitate-induced apop-
tosis (p<0.05).
Conclusion: In conclusion, disruption and stabilization of actin cytoskeleton 
inhibit and enhance, respectively, FFA-induced beta-cell death. The essential 
role of actin cytoskeleton in FFA-induced apoptosis is coupled with activa-
tion of the pro-apoptotic JNK and p38 MAPK and inhibition of the anti-
apoptotic Akt kinase.
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Gluco-lipotoxicity inhibits ceramide transport between endoplasmic 
reticulum and Golgi apparatus in pancreatic beta cells
J. Veret1, E. Gjoni2, A. Cinque2, N. Coant1, N. Islam3, C. Ng3, C. Magnan1,  
L. Riboni2, P. Viani2, P. Giussani2, H. Le Stunff1;  
1UMR CNRS 8251, Unité Biologie Fonctionnelle et Adaptative, Paris, France, 
2Department of Medical Biotechnology and Translational Medicine, Milano, 
Italy, 3School of Biology and Environmental Science, Dublin, Ireland.
Background and aims: In type 2 diabetes (TD2) the chronic adverse effects 
of fatty acids (FA) on beta cell function and viability have been correlated 
to hyperglycaemia. Gluco-lipotoxicity refers to the combined, deleterious ef-
fects of elevated glucose and fatty acid levels on pancreatic beta-cell func-
tion and survival. Gluco-lipotoxicity caused beta-cell apoptosis and may thus 
contribute to progressive beta-cell loss in TD2. The molecular pathways and 
regulators involved in the detrimental effects of chronic exposure to FA, in 
particular palmitate, include the de novo synthesis of ceramide (Cer) in the 
endoplasmic reticulum (ER). However, increasing Cer levels in ER can also 
be due to a reduction of Cer utilization for complex sphingolipids synthesis. 
Therefore, we studied the effect of gluco-lipotoxicity on Cer metabolism in 
beta cells and its impact on beta-cell apoptosis.
Materials and methods: INS-1 cells were cultured with 0.4 mM palmitate 
and 5 or 30 mM of glucose. INS-1 cell apoptosis was determined by caspase 
3/7 activity assay. Sphingolipid metabolites were analyzed by liquid chroma-
tography-mass spectrometry. Metabolism of Cer was measured in INS-1 beta 
cells with [3H]sphingosine, a precursor of sphingolipid biosynthesis. Trans-
port of C5-Bodipy-ceramides between ER and Golgi apparatus was analysed 
by fluorescence confocal microscopy. Down-regulation of Cer transporter 
CERT was made by specific siRNA.
Results: Both nutrients taken separately did not induce INS-1 cell death, 
whereas the combined treatment with palmitate and glucose resulted in an 
extensive beta cell apoptosis and this was associated to a significant increase 
of Cer levels. The presence of fumonisin-B1, an inhibitor of Cer biosynthe-
sis, partially reversed the apoptosis induced by the combined treatment with 
palmitate and glucose. Metabolic studies using [3H]sphingosine as precursor 
of sphingolipid biosynthesis show that treatment with palmitate results in a 
small but significant increase of [3H]Cer associated to a decrease of [3H]
sphingomyelin (SM) at 5 mM glucose. Inhibition of Cer utilization for SM 
biosynthesis was significantly potentiated by the presence of 30 mM glucose. 
Lipidomic analysis showed that gluco-lipotoxicity inhibited biosynthesis of 
complex sphingolipids. Fluorescence microscopy studies using C5-Bodipy-
Cer show that at high gluco-lipotoxicity reduces the fluorescence accumula-
tion in the perinuclear region representative of the Golgi apparatus. Inter-
estingly, this was associated with an inhibition of the Cer transporter CERT 
function. Inhibition of CERT was mediated by a decrease of its expression 
and an increase of its phosphorylation status. Finally, selective silencing of 
CERT expression increased INS-1 cell apoptosis induced by palmitate.
Conclusion: Altogether these data suggest that gluco-lipotoxicity increased 
Cer accumulation in the ER through also through a decreased utilization of 
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newly synthesized Cer for SM biosynthesis. Moreover, these results support 
a role of Cer transport between ER and Golgi apparatus in the regulation of 
beta cell death induced by gluco-lipotoxicity.
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Palmitate and glucose induce autophagy in INS(832/13) cells
A.S. Medina, H. Bennet, M. Fex;  
Diabetes and Celiac Disease, Lund University, Malmö, Sweden.
Background and aims: Autophagy is an important biological process by 
which proteins and organelles are sequestered in autophagosomal membrane 
vesicles and delivered to the lysosome for degradation. Eukaryotic cells can 
degrade long-lived proteins and intracellular organelles through macro-
autophagy, for instance during periods of an increased energy demand. In 
addition, autophagy may function as a first line cellular defense to protect 
cells against various stressors and pathogens. The ATG genes, are crucial in 
regulating the formation of autophagy membranes, and dysfunctional regula-
tion/expression of these may be involved in disease processes. The role of au-
tophagy and/or regulation of ATG genes in type 2 diabetes are incompletely 
understood, although some evidence points to the involvement of autophagy 
in this disease. Therefore, the aim of this study was to investigate the exact 
cellular stressors that induce autophagy and ATG gene expression in beta 
cells in-vitro.
Materials and methods: The INS(832/13) beta cell line was cultured in com-
bination with 30mM glucose, 0.5mM palmitate, or a combination of both, 
cytokines, LPS and tamoxifen (as a positive control) and untreated cells as 
a negative control. Incubations were performed for 6, 12, 24, and 48 hours 
to investigate the degree of autophagy visualized by fluorescent LC3B stain-
ing and confocal microscopy. Quantitative (Q)-PCR for ATG genes was per-
formed in cells treated under each condition and insulin secretion analysis 
were performed following standard protocols.
Results: LC3B expression was used as the classical readout for autophagy. 
A preliminary time-course experiment evaluating INS(832/13) cells after 6, 
12, 24, and 48 hours exposure to 30mM glucose and 0.5mM palmitate and 
a combination of both (glucolipotoxicity) indicated that autophagy response 
was maximal between 12 and 24 hours, and more prominent in cells treated 
with palmitate alone as compared to glucose treatment alone. The combina-
tion of both glucose and palmitate did not induce more autophagy than pal-
mitate treatment, which was evaluated by counting the LCB3 positive dots in 
each sample. The LC3B dot-like structures appear in the cytoplasm and peri-
nuclear region and were more evident in all treated groups when compared 
to non-treated cells. An increase in expression was observed for ATG5, and 
ATG12 after 24 h incubation with palmitate. Insulin secretion was measured 
in cells treated in these conditions and preliminary data suggest a decreased 
in response to treatment with both palmitate and glucose. This indicates that 
the autophagic response induced by glucolipotoxicity inhibits insulin release, 
perhaps by mechanism relating to changes in autophagic response.
Conclusion: Our findings in vitro in INS(832/13) beta cells indicate that 
increased palmitate levels represent a powerful activator for the autophagy 
process which is coupled to an increase of specific ATG genes, necessary for 
the formation of the autophagosome. These changes are accompanied by a 
reduction in glucose stimulated insulin release.
Supported by: The Childhood Diabetes Foundation, Swedish Research Council
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L-type voltage-gated calcium channels mediate sensitivity to 
glucolipotoxicity in beta cells via activation of nuclear receptors Nr4a 
and inhibition of autophagy
P.J. Buda1, E. Zhang1, J. Esguerra2, E. Renstrom1;  
1Islets pathophysiology,  
2Islet cells exocytosis, Lund University, Malmö, Sweden.
Background and aims: Glucolipotoxicity is considered a major factor driving 
the gradual demise of pancreatic beta-cells mass in type 2-diabetes. Coun-
teracting this, autophagy allows cells to survive under adverse conditions. 
Recent reports underscore the protective role of autophagy in animal models 
exposed to free-fatty acids and high concentrations of glucose. However, little 
is known about the involvement of autophagy in diabetes progression and 
its regulation in pancreatic B-cells is poorly understood. Under high glucose 
and palmitate conditions voltage-gated calcium channels (VGCC) become 
activated and in turn stimulate extracellular calcium-dependent gene expres-
sion. In this study we investigated which VGCC-activated genes are essen-
tial for autophagy regulation and whether deliberate tuning of expression of 
these genes under glucolipotoxic conditions could improve beta-cell viability 
through the activation of autophagy.
Materials and methods: Genes activated by VGCC were revealed by use of 
affymetrix microarray performed on INS-1 cells after stimulation with 70mM 
potassium chloride. Amongst them autophagy related genes were identified 
based on the literature studies. Expression of these genes was measured by 
quantitative PCR and western blot. Their relation to the type of VGCC was 
obtained owing to specific VGCC inhibitors. Autophagy was assessed by use 
of western blot where the ratio of LC3B II over I form was calculated, and as 
well as by use of confocal microscopy on INS-1 cells wherein the number of 
LC3B-GFP puncta was counted. Apoptosis was measured by use of both flow 
cytometry (the number of AnnexinV and ViaProbe positive cells) and ELISA 
assay measuring enrichment of nucleosomes in cytosol.
Results: Affymetrix microarray revealed that activation of VGCC with 70mM 
potassium chloride upregulated autophagy related nuclear receptors Nr4a: 
NUR77 and NOR-1. Quantitative PCR showed 10-times increase of NUR77 
and NOR-1 genes under high potassium conditions. At the same time acti-
vation of VGCC inhibited autophagy, which was indicated by 20% decrease 
in LC3B II/I ratio and 50% decrease in the number of LC3B-GFP puncta in 
beta-cells. This coincided with 50% reduction of AMPK phosporylation - the 
main autophagy activator. Inhibition of VGCC-activated NUR77 and NOR-
1 expression by isradipine or downregulation of both genes with siRNA re-
stored AMPK activity and ablated inhibitory effect of high potassium on au-
tophagy. 25 mM glucose with 0,5 mM palmitate inhibited autophagy which 
was indicated by 70% decrease in LC3B-GFP puncta and increased 10 times 
the number of AnnexinV and ViaProbe positive cells as compared to low glu-
cose conditions. Isradipine or autophagy inducing rapamycin reduced apop-
tosis by 20% under glucolipotoxic conditions. Finally, cells depleted of both 
NUR77 and NOR-1 gained 25% improvement in cell viability at the presence 
of high glucose and palmitate.
Conclusion: Our study shows that inhibition of autophagy by L-type VGCC 
makes beta-cells more vulnerable to apoptosis under glucolipotoxic condi-
tions. Beneficial for cell viability activation of autophagy can be obtained 
by inhibition of L-type calcium currents as it prevents induction of anti-au-
tophagic - NUR77 and NOR-1.
Supported by: SRC
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Lipotoxicity alters the genome-wide epigenetic pattern in human 
pancreatic islets
C.A. Ling1, E. Hall1, P. Volkov1, T. Dayeh1, K. Bacos1, T. Rönn1,  
M. Dekker Nitert2;  
1Clinical Sciences, Lund University, Malmö, Sweden,  
2The University of Queensland, Brisbane, Australia.
Background and aims: Circulating levels of free fatty acids are often in-
creased in subjects with type 2 diabetes (T2D). Long-term exposure to lipids 
has harmful effects on islet function and insulin secretion. Epigenetic modi-
fications such as DNA methylation may contribute to T2D. However, there 
is limited information on whether fatty acids alter the epigenetic pattern in 
human pancreatic islets. Our aim was therefore to analyse the genome-wide 
DNA methylation pattern in human pancreatic islets exposed to palmitate 
for 48 hours and relate methylation to gene expression and insulin secretion 
in the islets.
Materials and methods: mRNA expression and DNA methylation were ana-
lysed genome-wide in human islets using microarrays.
Results: Palmitate treatment for 48 hours decreased glucose-stimulated insu-
lin secretion but did not affect apoptosis in the human islets. We found 1860 
genes with differential expression in palmitate-treated human islets. These 
include candidate genes for T2D such as GLIS3, HNF1B and SLC30A8. Ad-
ditionally, palmitate altered the expression of genes in glycolysis/gluconeo-
genesis, pyruvate metabolism, fatty acid metabolism, glutathione metabolism 
in human islets. The global DNA methylation level and DNA methylation 
levels of CpG island shelves and shores, 5’UTR, 3’UTR and gene body regions 
were altered in human islets exposed to palmitate. Moreover, 290 genes with 
differential expression had a corresponding change in DNA methylation e.g. 
several candidate genes for T2D. Importantly, 67 of these genes were also 
associated with BMI and 37 were differentially expressed in islets from T2D 
patients.
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Conclusion: We demonstrate that lipotoxicity gives rise to epigenetic modi-
fications as well as transcriptional changes in human pancreatic islets. These 
changes may contribute to impaired insulin secretion and T2D.
Supported by: Swedish Research council, ALF, Påhlsson, Novo Nordisk founda-
tion
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EPA and DHA protect pancreatic islets against palmitate toxicity
C.F. Lucena, L.P. Roma, K. Veras, M. Graciano, A.R. Carpinelli;  
Physiology and Biophysics, University of São Paulo, Brazil.
Background and aims: In previous studies, we have shown that fish oil 
supplementation improve the antioxidant defense in pancreatic islets from 
healthy rats. To test whether these effects were due to ω-3 fatty acids present 
in high concentrations in the supplemented diet, we decided to test whether 
EPA and DHA have the same effects in vitro and protect pancreatic beta cells 
from palmitate toxicity.
Materials and methods: Pancreatic islets were obtained by collagenase diges-
tion and cultured with RPMI 1640 medium containing 10mM glucose, 10% 
FBS, penicillin and streptomycin. After overnight culture, islets were divided 
in four groups: control (vehicle ethanol), ω-3 fatty acids (50μM EPA + 50μM 
DHA), 100 µM Palmitate (P), Pω3 (50 μM EPA + 50 μM DHA + 100µM 
palmitate). Islet cell death, glucose stimulated insulin secretion (GSIS) and 
superoxide (ROS) content (cytosolic and mitochondrial) were analyzed after 
48 h culture. Some of the experiments were performed using dispersed cells. 
Briefly, after 48 h culture, islets were dispersed into small cell clusters using 
trypsin and gentle pipetting in a Ca2+-free medium. Cells were then analyzed 
by flow cytometry.
Results: 48h culture in the presence of P increased beta cell ROS production 
and apoptosis and impaired GSIS. Under these conditions, EPA+DHA trig-
gered a parallel ~60-65 % reduction in ROS production and beta-cell apopto-
sis induced by P, and induced significant protection against the impairment 
in GSIS (~1,28ng insulin in P vs ~1,60ng insulin in Pω3, per islets/hour). 
The reduction in insulin secretion was not due to decreased insulin content. 
When dispersed cells were analyzed by flow cytometry, there was no differ-
ence in mitochondrial ROS production (mitosox probe). On the other hand, 
ROS production was increased with P and reduced to control levels when P 
cells were cultured in the presence of EPA and DHA, confirming the results 
obtained with whole islets using confocal microscopy. Apoptosis was also in-
creased in P vs control and the addition of ω-3 is not significantly different 
from control.
Conclusion: Our results show that EPA+DHA protect pancreatic islets from 
alterations induced by palmitate, i.e. increased superoxide production, de-
creased viability and beta cell function. The effects may result from decreased 
cytosolic superoxide production, which in turn can lead to increased viability 
and beta cell function. As we previously reported, in vivo ω-3 supplementa-
tion decrease protein levels of NAD(P)H oxidase subunits and consequently 
superoxide production in pancreatic islets. Considering that in vitro effects 
do not involve mitochondrial superoxide production, we can speculate that 
this protection might involve downregulation of NAD(P)H oxidase. How-
ever, further experiments are needed to elucidate the mechanisms involved 
in the protection of ω3 fatty acids against palmitate toxicity.
Supported by: Fapesp, CNPq, Capes
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Different regulation of beta cell proliferation induced by short-term and 
long-term high-fat diet loading
A. Nakamura1, N. Kitao1, H. Nomoto1, H. Miyoshi1, Y. Terauchi2,  
T. Atsumi1;  
1Division of Immunology and Metabolism, Hokkaido University, Sapporo, 
2Yokohama City University, Japan.
Background and aims: Evidence has mounted that insufficient adaptation 
of beta cell mass is symptomatic of type 2 diabetes. Because the adaptation 
mechanism of beta cell mass in response to insulin resistance is not fully un-
derstood, elucidating this mechanism is absolutely required for developing 
strategies of diabetes treatment. Previously, we demonstrated that insulin 
receptor substrate-2 (Irs2) is critically required for beta cell proliferation to 
occur in response to high-fat (HF) diet-induced insulin resistance. Recently, 
it was reported that beta cell proliferation began within the first 7 days of 
HF diet loading. However, it is unclear whether Irs2 is required for beta cell 
proliferation induced by short-term HF diet loading. Here, we investigated 
the effect of short-term HF diet loading on the regulation of beta cell pro-
liferation.
Materials and methods: Eight-week-old C57bl/6J mice were given free ac-
cess to either standard chow (SC) or a HF diet. After 7 days on the above 
diets, we investigated body weight, blood glucose, visceral fat weight, liver 
weight and pancreatic weight in these mice. Also, insulin tolerance test and 
immunohistochemical analysis to assess beta cell proliferation and mass were 
performed. Furthermore, we evaluated the changes in expression levels of 
genes involved in beta cell proliferation and function in islets isolated from 
these mice.
Results: Body weight and fed blood glucose levels were significantly higher 
in the mice on the HF diet than those in the mice fed SC. Although visceral 
fat weight were significantly higher in the mice on the HF diet than those in 
the mice fed SC, there were no differences in liver weight or pancreatic weight 
between the two groups. The glucose-lowering effect of insulin in the mice on 
the HF diet was equivalent to that in the mice fed SC on day 6. Immunohisto-
chemical analysis revealed that there was a significant increase in stimulated 
the BrdU incorporation rate in the mice on the HF diet in comparison with 
the mice fed SC on day 7, although there was no difference in the area of 
the beta cells relative to that of the whole pancreatic tissues between the two 
groups. Real-time quantitative PCR showed that Ki67 and Cyclin A2 mRNA 
were significantly increased in the mice on the HF diet in comparison with 
the mice fed SC. However, no increase in the expression levels of Irs2 or genes 
involved in beta cell function, such as pancreatic and duodenal homeobox-1, 
glucokinase, insulin-1, or insulin-2 were noted in the mice on the HF diet as 
compared with that in the mice fed SC.
Conclusion: Beta cell proliferation was induced by HF diet loading only for 
7 days without up-regulation of Irs2. Our results suggest different regulation 
of beta cell proliferation induced by short-term and long-term high-fat diet 
loading.
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Metabolic and pancreatic effects of transplantation of mesenchymal stem 
cells in a model of insulin resistance and type 2 diabetes
A.M.O. Leal1, P.G. Bueno2, G.D. Pisani2, J.U. Yaochite3, K.F. Malmegrin3,  
L. Avó1;  
1Medicine, 2Physiology, Federal University of São Carlos,  
3University of São Paulo, Ribeirão Preto, Brazil.
Background and aims: Type 2 Diabetes Mellitus (DM2) is associated with 
insulin resistance and dysfunction of pancreatic β cells. The regenerative cel-
lular therapy, in particular with multi/pluripotent cells has been investigated 
as a potential therapeutic strategy for DM2. Among them, mesenchymal 
stem cells (MSCs) due to its immuno regulatory role are important thera-
peutic candidates. The purpose of this study was to investigate the effects of 
multiple infusions of MSCs on glucose homeostasis and morphometry of the 
pancreatic islets in high fat diet-induced diabetes in Swiss mice.
Materials and methods: Swiss mice were fed a standard diet or a high fat diet 
for eight weeks. The animals were then divided into 3 groups: non-diabetic 
group (fed a standard diet), untreated diabetic group and MSCs transplanted 
group. The transplanted mice received 4 intraperitoneal infusions of MSCs 
cells (5-8 x 106 MSCs resuspended in buffer). Diabetic untreated animals re-
ceived only buffer injection and non-diabetic group did not receive injections. 
Fasting plasma glucose (FPG) was determined weekly and glucose (GTT) 
and insulin (ITT) tolerance tests were performed at 1, 2, 3, and 4 months after 
the infusions of MSCs. Four months after infusion of the MSCs, the animals 
were decapitated and pancreas and serum were collected for analysis.
Results: The MSCs transplanted animals were classified as responder (FPG 
< 180mg/dL) or non-responder (FPG > 180mg/dL). According to this cri-
terion, 72.2 % and 27.8 % of MSCs transplanted animals were classified as 
responders and non-responders, respectively. Fasting glycemia decreased 
significantly (p<0.05) in responders mice seven weeks after the infusion of 
MSCs compared to the untreated diabetic group. Four months after MSCs, 
GTT and ITT areas under the curve (AUC) decreased significantly (p<0.05) 
in responders mice compared to untreated diabetic mice. Serum insulin 
concentration was significantly higher in untreated diabetic animals than 
in non-diabetic animals (p<0.05) and was not different in responders and 
non-responders transplanted mice. Total islet area and volume of β cells 
were not different among the groups. However, the volume of α cells was sig-
nificantly (p<0.05) lower in untreated diabetic animals and responders mice 
compared to non-diabetic and non-responders mice, respectively. Apoptosis 
of islet cells was significantly (p<0.05) bigger in untreated diabetic animals 
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than in non-diabetic mice, and significantly lower in responders mice than 
in untreated diabetic and non-responders animals. Islet cell proliferation was 
significantly (p<0.05) lower in untreated diabetic animals than in non-dia-
betic mice. However, islet cell proliferation was not different in transplanted 
animals compared to non-diabetic and untreated diabetic animals. There 
was a positive correlation between apoptosis of islet cells and fasting glyce-
mia (r=0.56; p=0.002) and AUC of GTT (r=0.59; p=0.001) and ITT (r=0.42; 
p=0.03), and a negative correlation of proliferation of islet cells and fasting 
glycemia (r=0.39; p=0.03).
Conclusion: The results indicate that multiple infusions of MSCs decrease 
glucose intolerance and apoptosis in pancreatic islets and increase insulin 
sensitivity in high fat diet-induced diabetic mice.
Supported by: FAPESP 2010/50407-1
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Absence of CXCL10 prolongs islet graft survival in an autoimmune 
transplantation setting
C. Bender, S. Christen, J. Pfeilschifter, E. Hintermann, U. Christen;  
Pharmazentrum Frankfurt, Goethe University Hospital, Germany.
Background and aims: Type 1 diabetes (T1D) results from the autoimmune 
destruction of insulin-producing beta-cells in the pancreas. The chemokine 
CXCL10 seems to play an important role in the recruitment of autoaggres-
sive lymphocytes to the islets of Langerhans. Since transplantation of isolated 
islets is a promising therapy of T1D, but has been hampered by the fact that 
islet grafts get rejected even in presence of an immunosuppressive regimen, 
we intended to investigate a possible influence of CXCL10 on the islet rejec-
tion process.
Materials and methods: We used three different transplantation settings, 
including syngeneic, allogeneic and autoimmune transplantations. For the 
syngeneic and allogeneic transplantation we used streptozotocin-treated 
diabetic recipients (C57Bl/6 or FVB background). In order to investigate the 
autoimmune rejection we used diabetic RIP-LCMV-GP mice as recipients. 
The RIP-LCMV-GP mice express the glycoprotein (GP) of the lymphocytic 
choriomeningitis virus (LCMV) under control of the rat insulin promoter 
(RIP) specifically in the beta-cell of the pancreatic islets of Langerhans. One 
of the advantages of the RIP-LCMV-GP model is the uses of a well-defined 
target autoantigen which allows a precise observation and quantification of 
the destructive immune response resulting in the islet graft rejection. Pan-
creatic islets were isolated from either C57Bl/6 and CXCL10-deficient mice 
(syngeneic and allogeneic settings) or RIP-LCMV-GP and RIP-LCMV-GP x 
CXCL10-deficient mice (autoimmune setting) and were transplanted under 
the left kidney capsule of diabetic recipient mice.
Results: CXCL10 was expressed by islet grafts early after transplantation. 
However, no significant differences in the survival of wildtype or CXCL10-
deficent islets have been observed in the syngeneic (C57Bl/6 islets into 
C57Bl/6 recipients) and allogeneic (C57Bl/6 islets into FVB recipients) set-
tings. In contrast, autoimmune (RIP-LCMV-GP islets into RIP-LCMV-GP 
mice) transplantations demonstrated a marked prolongation of islet graft 
survival in the absence of CXCL10 in the transplanted islets. Insulin produc-
tion was intact for more than 100 days post-transplantation in non-rejected 
islet graft.
Conclusion: Consequently, CXCL10 might play a role in islet graft rejection 
in an autoimmune transplantation setting, and might be a potential therapeu-
tic target to prolong islet graft survival.
Supported by: Goethe University Hospital Frankfurt
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Improved revascularization of islet graft by angiogenic monocyte 
subpopulation derived from spheroid culture of bone marrow 
mononuclear cells 
S.-M. Jin, B. Oh, S.-H. Oh, S. Oh, K. Hur, M.-S. Lee, M.-K. Lee, J. Kim;  
Samsung Medical Center, Seoul, Republic of Korea.
Background and aims: Spheroid culture method is an effective strategy for 
the ex vivo expansion of autologous therapeutic cell population. We investi-
gated if co-transplantation of spheroids (BM-spheroid) formed by 3D culture 
of bone marrow-derived mononuclear cells (BM-MNCs) could improve the 
revascularization and organization of islet grafts.
Materials and methods: Angiogenic capacity of the spheres formed by sphe-
roid culture of BM-MNCs (BM-spheres) for 3 to 5 days was assessed by in 
vitro and in vivo models. A syngeneic marginal mass renal subcapsular islet 
transplantation model was used to determine the post-transplant outcome 
of co-transplanted BM-spheres and islets. Using green fluorescent protein 
transgenic (GFP-Tg) mice, the role of BM-spheroid and donor/recipient en-
dothelial cells in revascularization was assessed by immunohistochemistry.
Results: The main cellular component of BM-spheres were CXCR4+CD14+ 
myeloid cells. BM-sphere showed a superior angiogenic capacity over the 
fresh BM-MNCs and remnant non-spheroid BM-MNCs after spheroid cul-
ture. Co-transplantation with BM-spheres improved the outcome of syn-
geneic islet transplantation in terms of glucose tolerance, diabetes reversal 
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rate, plasma insulin levels, and fraction of endocrine cells and proliferating 
β-cells in graft immunohistochemistry. Co-transplantation with BM-spheres 
increased the vessel density derived from the donors and recipients.
Conclusion: Co-transplantation of islets and angiogenic myeloid cells de-
rived from the BM-spheroid improved the outcome of marginal mass islet 
transplantation by facilitation of revascularization.
Supported by: NRF 2011-0023257 
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First evaluation of a closed, continuous media renewal system for human 
islets of Langerhans
M. Ståhle1, A. Friberg1, S. Ingvast1, O. Korsgren1, A. Lams2, B. Delorme2;  
1Clinical Immunology, Immunology, Genetics and Pathology, Uppsala, 
Sweden, 2Macopharma, Lille, France.
Background and aims: Many clinical islet centres have adopted a short stor-
age period for islets prior to transplantation. A storage period provides time 
for quality assessment of islets, recipient matching, transport of islets and 
patients to transplant centre and initiation of immunosuppressive protocols. 
There are, however, risks for loss of islet tissue and contamination during 
the storage period. To reduce contamination risks and improve handling and 
storage conditions, the present study presents the first evaluation data from of 
a new closed PReservation ISlet system (called PRISM) specifically developed 
for islet storage with regulated continuous media renewal.
Materials and methods: At the end of the isolation process, purified islets 
were split and stored either in single transfer packs for platelets (Fenwal, Swe-
den) as control or in the new V1.4 PRISM automate (Macopharma, France) 
for 4-5 days. Islets were both kept in CMRL-1066 supplemented with 10 mM 
HEPES, 10 mM nicotinamid, 2 mM L-glutamine, 50 µg/mL gentamicin, 5 
mM sodium pyruvate, 20 µg/mL ciprofloxacin and 10% blood group-com-
patible human serum. After a first over night storage at 37°C, the temperature 
was lowered to 25°C for the rest of the study period. Culture media exchanges 
were either performed manually for islets in the platelet bags or automatically 
using the PRISM automate. Islet quality assessments were performed at day 
1 and last day (4 or 5) and included glucose-stimulated insulin release, intra-
cellular insulin content, ADP/ATP ratio, cytokine expression and recovery.
Results: No differences were found between islets kept in the PRISM auto-
mate compared to islets kept in single transfer packs for platelets regarding 
stimulated insulin release, intracellular insulin content, ADP/ATP ratio or 
expression of MCP-1, tissue factor, IL-6 or IL-8.
Conclusion: The closed, automatic media renewal PRISM technology seems 
to preserve functional integrity of clinical grade human islets kept in stor-
age as well as standard clinical practice. It presents an attractive method for 
standardization and automation of islet storage.
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Feasibility of islet magnetic resonance imaging using ferumoxytol in 
intraportal islet transplantation
J. Kim, S.-M. Jin, M.-K. Lee, M.-S. Lee, K. Hur, J. Jun;  
Samsung Medical Center, Seoul, Republic of Korea.
Background and aims: There is a clinical need for an alternative labeling 
agent for magnetic resonance imaging (MRI) in cell therapy including is-
let transplantation, because superparamagnetic iron oxide (SPIO) has been 
withdrawn from the market. We aimed to evaluate the feasibility of islet mag-
netic resonance imaging using ferumoxytol, which is a clinically available ul-
trasmall superparamagnetic iron oxide (uSPIO) as an iron supplement drug.
Materials and methods: We compared islet function and viability of control 
islets and islets labeled with ferumoxytol. In vitro efficacy of ferumoxytol la-
beling was assessed with prussian blue stain, electron microscopy and ex vivo 
MRI of labeled islets. In vivo efficacy of labeling was assessed in both renal 
subcapsular and intraportal islet transplantation models.
Results: Labeling with ferumoxytol up to 800μg/mL did not compromise the 
viability and glucose-stimulated insulin secretion of labeled islets. Prussian 
blue stain of labeled islets showed internalized ferumoxytol particles. Ex vivo 
magnetic resonance imaging of islets labeled with ferumoxytol (up to 800μg/
mL) for 48hr revealed visible hypointense spots representing labeled islets. 
In syngeneic renal subcapsular islet transplantation model, islet MRI at 14 
days-post-transplantation (DPTs) showed visible hypointense spots repre-
senting islet graft. In islet MRI at 7 and 14 days after syngeneic intraportal 
islet transplantation, there was a difference in the total area of hypointense 
spots between recipients with normoglycemia and hyperglycemia at 28 DPTs.
Conclusion: Islet MRI using ferumoxytol was feasible in terms of in vitro and 
in vivo efficacy and safety. Labeling islet with ferumoxytol could be a useful 
option for estimation of islet mass in clinical islet transplantation.
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Outcomes for adults with type 1 diabetes referred with severe 
hypoglycaemia and/or referred for islet transplantation to a specialist 
hypoglycaemia service
M.L. Byrne1, P. Srinivasan2, N.D. Heaton2, D. Hopkins3, S.A. Amiel1,  
P. Choudhary1;  
1Diabetes Research Group, 2Institute of Liver Studies,  
3Department of Diabetes, King‘s College Hospital, London, UK.
Background and aims: Severe hypoglycaemia (SH) and fear of hypoglycae-
mia remain major barriers to achieving good diabetes control. In adults with 
type 1 diabetes (T1D), structured education in flexible insulin therapy (e.g. 
DAFNE, Dose Adjustment For Normal Eating) reduces SH by 65%, and tech-
nology (insulin pump therapy and sensors) 4-fold. For persistent SH, despite 
optimised medical therapy, islet cell transplantation is indicated, reducing SH 
from 20.0 [7.0-50.0] to 0.3 [0.0-1.6] episodes per patient/year. We examined 
outcomes for patients referred to a diabetes centre with an islet transplant 
unit for islet transplantation and/or problematic hypoglycaemia.
Materials and methods: Retrospective case note audit of all people with T1D 
referred to islet transplant unit for islet transplantation and/or with prob-
lematic hypoglycaemia between 2009 and 2012 [n=82]. 45 met criteria for 
islet cell transplantation having >1 SH in previous year. Optimal outcome 
was defined as ≤1 severe hypoglycaemic episode over the past 12 months as 
documented at most recent visit.
Results: The cohort was 55.6% male, mean (±SD) age 44.8 (±11.7) years, 
BMI 25.2 (±3.6) kg/m2 and duration of diabetes 28.1 (±13.4) years. HbA1c 
at index visit was 8.5% (±1.8), median [IQR] frequency of severe hypogly-
caemia was 6.0 [2.0-21.5] per patient/year and 84.4% had impaired aware-
ness of hypoglycaemia. 84.4% were referred from secondary diabetes ser-
vices, 13.3% had completed DAFNE and 31.1% were using insulin pumps. 
Nine patients (20.0%) had initial assessment only (3 died, 2 did not attend 
follow up and 4 were referred back to local team with a new management 
plan). Follow up of the remaining 36 had a median duration of 28.5 [17.8-
42.5] months, during which SH fell from 6.0 [2.0-24.0] to 0.0 [0.0-3.0] events 
per patient/year; p<0.0001, without deterioration in HbA1c [8.3% to 8.1% 
[67.2mmol/mol vs. 65.0mmol/mol]; p=0.239]. 26 out of 36 remained on 
medical therapy (11 had dose adjustment alone; 11 completed DAFNE; 10 
converted to pump; 3 used sensors). 17 out of 26 achieved optimisation (13=0 
SH and 4=1 SH) with a SH reduction from 2.0 [1.5-9.0] to 0.0 [0.0-0.5] epi-
sodes per patient/year; p<0.0001, again without detrimental effect on HbA1c 
[8.1% to 7.7% [65mmol/mol vs. 60.7mmol/mol; p=0.072]. 9 out of 26 were 
not resolved but SH fell from 7.0 [4.8-40.5] to 4.0 [2.5-6.3] episodes per pa-
tient/year; p=0.058. The remaining 10 patients were listed for transplanta-
tion. 80% had completed DAFNE, 100% converted to insulin pump therapy 
and 70% used sensors. There was a trend to higher baseline SH rate in the 
group needing transplantation [2.0 [1.5-9.0] (optimised) vs. 7.0 [4.8-40.5] 
(improved) vs. 8.0 [5.3-106.0] (transplantation); p=0.060]. Overall, 47.2% of 
patients were resolved; 25.0% improved and 27.8% required transplantation.
Conclusion: The majority of patients presenting with problematic severe hy-
poglycaemia can be improved with appropriately supported non-transplant 
therapeutic options, around half achieving complete resolution. Despite op-
timised therapy, a third will require transplantation. Provision of expertise in 
hypoglycaemia management is essential to give people with T1D and SH ap-
propriate options and focus limited transplant resources on the most needy.
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Meal tests to assess beta cell function and mass in islet-transplanted 
patients
J.-F.R. Brun1, L. Bories2, T. Berney3, J. Mercier1, P.-Y. Benhamou4,  
A. Wojtusciszyn2;  
1INSERM U1046, Equipe d‘Explorations Métaboliques, 2INSERM U1001, 
Department of Endocrinology, Diabetes, and Nutrition, Montpellier, France, 
3Department of Surgery, Cell Isolation and Transplant Center, Geneva, 
Switzerland, 4Inserm, U1055, Grenoble, France.
Background and aims: Current model-derived calculations of insulin secre-
tion based on C-peptide kinetics during a meal test allow to measure the two 
phases of insulin secretion. The second phase expressed as a β-cell glucose 
sensitivity (BCS) has been shown to be a strong predictor of diabetes pro-
gression, and recent studies also suggest that it is closely related to the size 
of pancreatic beta-cell mass. Since beta-cell mass is a critical factor for the 
outcome of pancreatic islet transplantation, we measured these parameters 
in transplanted patients in order to see whether they were related to glucose 
tolerance.
Materials and methods: We performed 13 standardized breakfast tests (76 g 
of carbohydrates) in 7 patients treated with islet transplantation (5 F /2 M, age 
32-60 yr; weight: 51,3-72,8kg, time after transplantation 3-44 months) and 
compared them to 103 non-diabetic controls (C). Calculation of insulin sen-
sitivity (Caumo‘s oral minimal model) and insulin secretion rate (ISR) (Van 
Cauter‘s model), with calculation of beta-cell sensitivity to glucose (BCS) and 
insulin secretion parameters given by the classical models of Breda and of 
Mari were done with the results of the tests.
Results: According to fasting glycemia and glycemia at 2 hours, breakfast 
tests showed 6 normoglycemic profiles (NP) and 7 diabetic profiles (DP). NP 
patients had significant lower HbA1c (5,9% VS 7,1%; p < 0,001) and were 
insulin-independent compared to DP who all resumed insulin. No differ-
ences were observed between groups regarding time after transplantation. 
Comparison of NP and DP with C showed that total ISR was higher in C than 
in the two groups of transplanted patients : 110,98±4,11 pMol/m² in C vs 
61,17±9,75 (p<0,005) in NP and 26,88±7,78 in DP (p<0.02 compared to NP). 
Maximal insulin secretion exhibited the same trend: C : 777,27±31,51 pMol/
min/m² > NP 421,24±72,76 > DP 181,80±52,25 (C vs NP p<0.01; NP vs DP 
p<0.02). The most significant difference was found with beta-cell sensitivity 
C : 126,90±5,94 pMol/min/mmol/m² > NP 61,53±11,73 > DP 12,89±3,72 (C 
vs NP p<0.005; NP vs DP p<0.01). First phase index calculated according to 
Breda‘s model was also lower in DP vs NP (p<0,001). Insulin sensitivity did 
not differ among the 3 groups.
Conclusion: These results show that insulin secretion remains lower than 
normal in islet-transplanted patients if they have normal glucose tolerance, 
and is even lowered if they are still diabetic. BCS values are extremely low 
when islet-transplanted patients are diabetic and remain lower than normal 
(in the range observed in type-2 diabetics) when they have a normal glucose 
tolerance. This quantitative evaluation of insulin secretion is thus likely to 
be useful for the follow up of islet transplantation, even if its prognostic rel-
evance remains to be studied.
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Actual 10 year pancreas transplant alone (PTA) results in a single centre 
experience
M. Occhipinti, F. Vistoli, M. Barsotti, W. Baronti, L. Rondinini, G. Amorese, 
U. Boggi, P. Marchetti;  
Department of Clinical and Experimental Medicine, University of Pisa, Italy.
Background and aims: PTA for the treatment of selected type 1 diabetic pa-
tients is receiving increasing attention. However, information on PTA long-
term outcome is still limited . Aim of this study was to investigate the results 
of PTA performed in our center after 10 yrs of follow-up.
Materials and methods: From December 2000 to December 2003, 34 type 
1 diabetic patients (age: 37±9 yrs; 17 males/17 females; BMI: 23.5±3.3 kg/
m2, duration of diabetes: 23.6±10.1 yrs, insulin requirement: 47±10 UI/day) 
underwent PTA with the portal-enteric drainage approach. Immunosup-
pression consisted of basiliximab and high dose steroids as induction, and 
mycophenolate mophetil, tacrolimus and low dose steroid as maintenance 
treatment. Actual patient and pancreas (insulin-independence) survival, bio-
chemical parameters and indexes of cardiovascular status were analyzed at 10 
yrs after transplantation.
Results: Ten-year patient survival was 97% (33/34 patients; 1 death with 
functioning graft occurred at 5 yr post-transplant due to stroke), and death 
censored pancreas survival was 63.6%. Failures were due to acute rejection (2 
cases) and chronic rejection (10 cases). Patients with functioning grafts were 
normoglycemic in the absence of exogenous insulin therapy (fasting plasma 
glucose: 96±19 vs 230±108 mg/dl, HbA1c: 5.8±0.6 vs 8.3±1.8%, both p<0.001 
vs pre-transplantation values), with sustained endogenous insulin secre-
tion (C-peptide levels: 2.8±1.5 vs 0.1±0.1 ng/ml, p<0.001).Total cholesterol 
(157±40 vs 193±31 mg/dl, p<0.001) and LDL cholesterol (95±36 vs 128±36 
mg/dl, p<0.001) were lower after PTA, with no significant changes in statin 
therapy. Blood pressure values resulted similar before as after transplanta-
tion (systolic: 126±12 vs 125±17 mmHg; diastolic: 74±10 vs 78±10 mmHg), 
with unchanged anti-hypertensive therapy. Estimated glomerular filtration 
rate (EPI-MDRD) decreased at a rate of 1.7±2.1 ml/min/yr, and albumin ex-
cretion rate was lower after PTA (0.17±0.24 vs 1.6±2.9 g/24h, p<0.05). Left 
ventricular ejection fraction increased after transplantation from 54.1±4.3 to 
58.9±2.7% (p<0.01).
Conclusion: In this single centre experience, PTA successfully and safely al-
lowed long-term (10-yr) actual patient survival and insulin-independence, 
and associated with improvement of several biochemical and clinical param-
eters.
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Diabetic neuropathy in pancreas and kidney transplant recipients: 
follow-up after 8 years of normoglycaemia
P. Boucek1, T. Havrdova1, L. Voska1, A. Lodererova1, H. Vondrova2,  
R. Krejci2, F. Saudek1, K. Lipar1, C. Sommer3;  
1Institute for Clinical and Experimental Medicine, 2Thomayer Hospital, 
Prague, Czech Republic, 3University of Würzburg, Germany.
Background and aims: Very advanced forms of diabetic peripheral neu-
ropathy are generally present in pancreas/kidney transplant candidates. We 
present long-term follow-up data on the effect of normoglycemia after a si-
multaneous pancreas/kidney transplantation (SPK) on epidermal nerve fibre 
(ENF) density and neurological function in type 1 diabetic (DM) recipients.
Materials and methods: Lower thigh 3-mm skin biopsies with ENF counts 
(indirect immunofluorescence method), autonomic function (AFT) and 
quantitative sensory testing (QST) and electrophysiological examinations 
were performed at time of and at 8 years post-SPK in 12 Type 1 DM patients 
(mean±SD age 44±10; pre-transplant DM duration 28±9 years). Cardiovas-
cular autonomic reflex tests included heart rate variation with deep breathing 
(I-E), Valsalva ratio (VR) and heart rate (30:15) and systolic blood pressure 
(Δ sBP) responses to standing. Vibration perception thresholds (VPT; bio-
thesiometer) were used for quantitative sensory testing. Electrophysiology 
data analyzed were sensory (median and sural) and motor (median, tibial 
and peroneal) nerve conduction velocities (NCV) and peak action potential 
amplitudes. ENF counts, AFT and QST were also performed in 14 sex- and 
age-matched healthy controls(C). The Mann-Whitney U test and Wilcoxon 
test were used for statistical analysis.
Results: At follow-up, SPK recipients were insulin-independent with excel-
lent glycemic control (HbA1c 37±3 mmol/mol) and kidney graft function (S-
creatinine 102±2 μmol/L; eGFR 61±17 ml/min). However, the severe ENF 
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depletion present at baseline (SPK vs. C: 0.8±1.3 vs. 11.4±4.2 ENF/mm skin 
surface; p<0.001) was not improved at follow-up (1.4±4.7 ENF/mm; p>0.05 
vs. baseline) with total ENF absence in 11 biopsies. Similarly, all AFT and 
QST results were clearly abnomal in SPK recipients in comparison with C 
and no amelioration occurred after long-term normoglycemia. Although 
some improvement was seen at follow-up in several electrophysiological pa-
rameters, statistical significance for the SPK group as a whole was achieved 
in median motor NCV only (median; interquartile range, pre- vs. post-SPK: 
47.5; 43.0 to 50.0 vs. 51.4; 50.9 to 55.3 m/s; p=0.004).
Conclusion: Lower limb epidermal nerve fibre depletion and neurological 
function tests - except for median motor nerve conduction velocity - were 
not significantly improved following establishment of long-term normogly-
cemia in pancreas/kidney transplant recipients. These results confirm the 
poor reversibility of advanced structural and functional changes in diabetic 
peripheral neuropathy.
Supported by: NT13014-4 grant of the IGA MZ CR agency
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Effect of simultaneous kidney-pancreas transplantation in patients with 
type 1 diabetes to stabilise / progression of complications
M. Shamkhalova1, A. Glazunova1, M. Biragova1, S. Gracheva1,  
M. Shestakova1, Y. Moysyuk2, A. Pinchuk3, I. Dmitriev3, S. Arzumanov4;  
1Diabetic Nephropathy, National Research Centre for Endocrinology, 
2Transptantation of liver and kidney, Academician V.I. Shumakov Federal 
Research Center of Transplantology and artificial organs, 3Transptantation 
of the pancreas and kidney, Scientific-Research Institute of Emergency Care. 
N.a. N.V. Sklifosofskiy, 4Kidney transplantation and vascular surgery in 
urology and hemodialysis, Federal Research Centre of Urology, the Ministry 
of Health of Russia, Moscow, Russian Federation.
Background and aims: To evaluate the effect of successfully simultaneous 
kidney- pancreas transplantation (SPK) in patients with type 1 diabetes mel-
litus (T1DM) to stabilize/progression of complications.
Materials and methods: The study included 8 patients on standard immuno-
suppressive triple therapy. The average duration of T1DM 25 years [20,5;25], 
the duration of diabetic nephropathy (DN) - 7,96 лет[6,8;9,0]. All patients (3 
men and 5 women) remained in the study for at least months [12;25,5] after 
the transplantation.
Results: The mean level of HbA1c in the group before the study was 8,65 % 
[8,4;9,1], then decreased to individualising glycemic targets - 5.75% [5,55;6.0] 
after SPK. According to a continuous glucose monitoring system using 
«iPRO2» marked euglycemia during the day (glycemia 3,9-8,9 mmol/l - 89 
%, to lower than 3.9 mmol / l - 11% , higher than 8,9 mmol/l - 0 % of the 
time of day). The examination determined normoalbuminuria, GFR 80,125 
[71;90,5]. All patients had normal levels of hemoglobin 120,125 [112,5;130,0], 
parathormone 64,94[61,37;67,5], phosphorus 1,2 [1,05;1,4], blood pressure 
110[110,0;111,5]. The progression of initial proliferative diabetic retinopathy 
(DR) in the post-transplantation period was observed in 37.5 % of patients, 
followed by performing a vitrectomy and additional sessions laser panretinal 
photocoagulation. At 87.5% (7 people) identified nonstenotic atherosclero-
sis of the lower extremities, 1 patient - significant stenosis of the popliteal, 
posterior tibial artery to the right, requiring holding endovascular balloon 
angioplasty and stenting. In 75 % (6 people) developed ulcerative defects in 
the lower limbs and 4 people observed the progression of the chronic stage 
of osteoarthropathy.
Conclusion: In addition to the recovery of renal function and euglycemia 
in patients with T1DM undergoing SPK, noted the progression of DR and 
diabetic foot syndrome, which bear witness to the genesis of multivariate dia-
betic complications requiring verification and timely therapy.
PS 025 Hypoglycaemia rates and 
their economic burden
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Self-reported hypoglycaemia: a global study of 24 countries  
with 27,585 insulin-treated patients with diabetes: the HAT study
K. Khunti1, S. Alsifri2, R. Aronson3, M. Cigrovski Berković4,  
C. Enters-Weijnen5, T. Forsén6, G. Galstyan7, P. Geelhoed-Duijvestijn8,  
M. Goldfracht9, R. Kapur10, N. Lalic11, B. Ludvik12, E. Moberg13,  
U. Pedersen-Bjergaard14, A. Ramachandran15;  
1University of Leicester, UK, 2Alhada Armed Forces Hospital, Taif, Saudi 
Arabia, 3LMC Diabetes & Endocrinology, Toronto, Canada, 4University 
Hospital Centre Sestre milosrdnice, Zagreb, Croatia, 5Julius Clinical and 
Julius Center, UMC Utrecht, Netherlands, 6University of Helsinki, Finland, 
7Endocrine and Metabolic Consultants, Moscow, Russian Federation, 
8Medical Centre Haaglanden, The Hague, Netherlands, 9Clalit Health 
Services, Haifa, Israel, 10Novo Nordisk A/S, Søborg, Denmark, 11Faculty of 
Medicine University of Belgrade, Serbia, 12Medical University of Vienna, 
Austria, 13Department of Medicine, Karolinska Institutet, Stockholm, 
Sweden, 14Nordsjællands University Hospital Hillerød, Denmark,  
15India Diabetes Research Foundation and Dr. A. Ramachandran‘s Diabetes 
Hospitals, Chennai, India.
Background and aims: Hypoglycaemia is an important concern for patients 
with diabetes and physicians when setting glycaemic targets. The Hypogly-
caemia Assessment Tool (HAT) study, the largest and most comprehensive 
of its kind, assessed self-reported hypoglycaemia and associated predictive 
factors in a global population of patients with insulin-treated diabetes.
Materials and methods: HAT was a non-interventional, multicentre, 
6-month retrospective and 1-month prospective study of hypoglycaemic 
events in 24 countries using self-assessment questionnaires and patient dia-
ries (for 28 days) in people aged ≥18 years with type 1 (T1D) or type 2 (T2D) 
diabetes using insulin for ≥12 months attending routine clinics. Associations 
between predictive factors and hypoglycaemia were examined using negative 
binomial regression models adjusted for period and country.
Results: 27,585 patients completed the study (Table 1). 83.4% of patients 
with T1D and 50.8% of patients with T2D experienced ≥1 hypoglycaemic 
event in the 4 weeks before baseline (51.5 and 16.5 events per patient year). 
Higher (p<0.001) incidence rates were reported in the 4 weeks after baseline 
(73.3 [T1D] and 19.3 [T2D] events per patient year). A greater percentage 
of patients with T1D vs T2D reported any (83.0 vs 46.5%), nocturnal (40.6 
vs 15.9%) or severe (14.4 vs 8.9) hypoglycaemia in the prospective period. A 
weak correlation was seen (irrespective of diabetes type) between incidence 
of any hypoglycaemia and duration of diabetes (incidence rate ratio 1.01, 95% 
CI 1.01; 1.02) or duration of insulin therapy (1.04, 95% CI 1.03; 1.04).
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Conclusion: In this large, multinational population of patients with T1D or 
insulin-treated T2D, rates of overall, nocturnal and severe hypoglycaemia 
were higher than previously reported. An increased incidence of overall hy-
poglycaemia in the prospective study indicated significant under-reporting 
of hypoglycaemia.
Clinical Trial Registration Number: NCT01696266
Supported by: Novo Nordisk A/S
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Hypoglycaemia study questionnaire in patients with diabetes
R. Tahhan;  
Endocrinology, Al-Zahra Hospital, Dubai, United Arab Emirates.
Background and aims: To identify the frequency of self-reporting Moder-
ate and severe hypoglycemia hypo and its relation to demographic, clinical 
variables, fear of hypoglycemia FoH and mood among adults with diabetes in 
outpatients clinics in United Arab Emirates.
Materials and methods: The study adapted hypoglycemia patient question-
naire by ADA/Endocrine society 2013 workshop on hypo. After obtaining 
approval of hospital ethical committee, patient verbal consent, adults‘ pa-
tients with diabetes attending the clinics were encouraged to participate. 
FoH was assessed by Hypoglycemia fear survey HFS-II. WHO-5 survey is 
conducted for mood assessment when total HFS-II score ≥9. Hypoglycemia 
incidence was grouped according to its impact on patient‘s function into two 
groups; mild / no hypo and moderate/severe hypo group. Analysis was done 
using SPSS 21 for windows. Comparison between quantitative variables used 
student T-test or ANOVA when applicable and Chi-square test for qualitative 
variables.
Results: Total study sample is 104 patients with diabetes, mainly DM2 92.3% 
96/104.59.6 %( 42) females and 40.2% (62) males. Mean age, BMI, diabe-
tes duration and HbA1c; 45.88±9.6, 30.88±6.04, 7.68±5.89, and 7.60±1.33 
respectively. 56.7% reported mild/no hypo 59/104 versus 43.3 % (45) mod/
severe hypo. Diabetes duration increased the incidence of moderate/severe 
hypo; 6.41±5.71 (59) vs 9.36±5.75 (45) for no/mild hypo and mod/severe 
hypo respectively p= 0.002 but not for the other variables; age, HbA1c, BMI, 
RBG. Total HFS-II and its sub-scale worry and behavior scores were signifi-
cantly higher among those subjects reporting mod/severe hypo; 26.47±22.7, 
16.86±15.1, 9.35±9.44 respectively vs 9.83±11.57, 6.19±7.66, 3.64±6.77 for 
with mild/no hypo group P<0.001. Median score for total HFS-II in the sam-
ple is 10. An analysis using the cutoff more than 10 versus ≤ 10 was statisti-
cally significant in differentiating mod/severe hypo group from no/mild hypo 
34.9% vs 72.2% p= 0.001. In the subgroups of female gender versus male, the 
mean and median for the HFS worry subscale score was higher in the female 
subgroup compared to the male group;16.25±14.40,13 and 8.61±11.54,4.5 
p=0.005 respectively. The latter reflects a higher fear of hypo among females 
in the sample. A higher score but not significant in WHO-5 survey reflects a 
better mood among mild/no hypo 99.94±5.11 compared to mod/severe hypo 
group 59.87±16.8 (p= 0.092). Driving and diabetes; 31.7% and 6.1% of ques-
tionnaire respondents are checking their B.G sometimes and always before 
driving while they are on anti-hyperglycemic medications. 50% of insulin us-
ers are not doing so at all and 44.4% and 5.65% reported performing blood 
glucose checking sometimes and always before their journey. 15.1% 13/104 
reported hypo while driving in the last one year.
Conclusion: The ADA/Endocrine society hypoglycemia questionnaire is a 
useful tool for self-reporting hypoglycemia. FoH is significant among pa-
tients with moderate/severe hypo and can be effectively highlighted by HFS-
II. More educational efforts are needed to ensure safe driving in patients with 
diabetes in UAE.
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Effect of gender on hypoglycaemia rates and perception: analysis from 
the SAVOR-TIMI 53 trial
A. Smahelova1, W.H.H. Sheu2, A. Cahn3, D.L. Bhatt4, O. Mosenzon3,  
G. Jermendy5, J.B.L. Hoekstra6, J. Lopez-Sendon7, B. Hirshberg8, C. Stahre9, 
C. Wei10, W. Jia11, B.M. Scirica4, I. Raz12;  
1Department of 3 Internal Gerontometabolic Clinic, Charles University 
in Prague, Czech Republic, 2Department of Internal Medicine, Taichung 
Veterans General Hospital, Division of Endocrinology and Metabolism, 
Taichung, Taiwan, 3The Diabetes Unit, Hadassah Hebrew University 
- Medical Center, Jerusalem, Israel, 4Brigham and Women‘s Hospital, 
Harvard Medical School, Boston, USA, 5The Diabetes Unit, Bajcsy-
Zsilinszky Hospital, Budapest, Hungary, 6Dept of Internal Medicine, AMC, 
Amsterdam, Netherlands, 7Cardiology Department, Hospital Universitario 
La Paz, Madrid, Spain, 8AstraZeneca, Wilmington, USA, 9AstraZeneca, 
MÖLNDAL, Sweden, 10The Diabetes Unit, AstraZeneca, Wilmington, 
USA, 11Department of Endocrinology and Metabolism, Shanghai Jiao Tong 
University Affiliated Sixth People‘s Hospital, Shanghai, China, 12Diabetes 
Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Background and aims: Some studies suggest differences in gender should be 
considered when individualizing treatment for people with type 2 diabetes 
mellitus.
Materials and methods: We studied the effects of gender on the risk for hy-
poglycemia and its perception in the SAVOR-TIMI 53 trial, a randomized 
controlled trial in which 16,492 patients with type 2 diabetes mellitus were 
randomized to saxagliptin or placebo and were followed for a median of 2.1 
years. Patients were requested to record hypoglycemic episodes which were 
defined based on symptoms suggestive of hypoglycemia that recovered by 
carbohydrate ingestion and/or documentation of low blood glucose < 54 mg/
dl (minor) or the need for assistance from another person (major).
Results: A total of 11,037 (66.9%) males and 5,455 (33.1%) females were 
included in the trial. Hypoglycemic events were reported by 16.2% of men 
and 16.1% of women; however, the event rate was higher in men (4.1 vs. 3.6 
events/subject throughout follow up, p=0.002). Women were more likely 
than men to report clinical symptoms associated with hypoglycemia (83% vs. 
76% of events, p<0.01), to require intervention (64% vs. 55%, p<0.001) which 
was generally oral glucose, or to need assistance from another person (3.3% 
vs. 2.6%, p=0.05). Missing a meal was the most frequently identified trigger 
for hypoglycemia and was more common in women than in men (24% vs. 
16%, p<0.001). Finger stick glucose levels were reported in 83.0% and 81.5% 
of episodes by men and women respectively (p=0.6). Women reported hypo-
glycemic events at higher glucose levels than men. Glucose levels >=63mg% 
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were documented in 15% of hypoglycemic events reported by women and in 
11% of episodes reported by men (p<0.001). Low (<63mg/dl) blood glucose 
levels were reported in 72% of the hypoglycemic episodes in men and 67% 
in women (p=0.02).
Conclusion: These findings indicate significant gender differences in the per-
ception of hypoglycemia. The mechanisms and impact of these findings on 
diabetes management need further study.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca/Bristol-Myers Squibb
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Risk and protective factors for severe hypoglycaemia in patients with 
type 1 diabetes
T. Wohland1, T. Tiemann2, O.-M. Patzer3, J. Holstein4, P. Kovacs1,  
A. Holstein3;  
1IFB AdiposityDiseases Leipzig, University of Leipzig, Genetics of Obesity 
and Diabetes, 2Outpatient Diabetes Center, Rinteln, 3Lippe-Detmold 
Hospital, 1st Department of Medicine, 4Charité, University Medicine Berlin, 
Medical Department, Division of Nephrology and Internal Intensive Care 
Medicine, Germany.
Background and aims: Severe hypoglycaemia (SH) is associated with a criti-
cal prognosis. In addition to its acute life-threatening potential, SH may in-
crease cardiovascular and all-cause mortality irrespective of diabetes type. 
Therefore, preventing from SH is a crucial challenge which requires better 
understanding of the predisposing risk factors. Our aim was to characterize 
the clinical circumstances of SH in patients with type 1 diabetes (T1DM) in 
a German population under the conditions of real life and to evaluate cor-
responding risk factors.
Materials and methods: Prospective population-based, observational trial 
and case control study. All SH occuring between 2007 and 2013 in a large 
tertiary care hospital in the Lippe-Detmold area (200.000 inhabitants) were 
captured. The clinical characteristics of patients with T1DM and SH were 
compared with an unselected regional control group of 165 patients with 
T1DM who did not experience SH in the seven-year period. SH was defined 
as a symptomatic event requiring treatment with intravenous glucose or ad-
ministration of glucagon and being confirmed by a blood glucose measure-
ment of <50 mg/dl. Predictive factors for SH were analysed by a multivariate 
regression model.
Results: A total of 959 episodes of SH in 679 patients were registered: 37.1% 
of cases (356/959) were related to T1DM, 51.9% (498/959) to T2DM, 3% 
(29/959) to pancreoprivic diabetes and 7.9% (76/959) occurred in non-
diabetic individuals. The 356 cases of SH in T1DM (initial blood glucose 
31.6±10.7 mg/dl) comprised 189 subjects. 50.6% (180/356) of these hypo-
glycaemic episodes were related to only 29 patients who experienced ≥3 SH. 
Hypoglycaemic individuals with T1DM and the 165 subjects without SH had 
a similar mean age (48.0±19.0 vs. 47.5±17.4 years; n.s.), diabetes duration 
(24.7±15.5 vs. 23.8±15.2 years; n.s.) and comparable HbA1c values (7.5±1.3% 
vs. 7.7±1.4%; n.s.). Under regression analyses dementia (Odds Ratio and 
95% confidence interval; OR 12.93 [1.60;104.86]), living in care homes or 
care by home nursing services (OR 4.84 [1.33;17.63]), use of NPH as basal 
insulin supply (OR 3.05 [1.31;7.07]), treatment with ß-blockers (OR 2.19 
[1.20;4.00]), impaired awareness of hypoglycaemia (OR 2.16 [1.14;4.10]), hy-
perlipoproteinemia (OR 1.95 [1.09;3.48]) and extensive comorbidities (OR 
1.48 [1.25;1.75]) were significant risk factors for SH (all p<0.05). In contrast, 
use of short acting insulin analogues (OR 0.29 [0.17;0.49]), higher frequency 
of blood glucose self measurement (OR 0.43 [0.23;0.79]) and female sex (OR 
0.61 [0.39;0.96]) appeared to be protective against SH (all p<0.05).
Conclusion: Individuals with T1DM and SH clearly distinguish from those 
without SH as they are characterized by a cluster of risk factors and personal 
circumstances. At least, some of these predictive factors can be influenced by 
individualized therapies. In particular, the use of insulin analogues could be 
beneficial to prevent SH. The high proportion of patients with recurrent SH 
remains a therapeutic challenge.
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The influence of new European Union driver´s licence legislation on 
reporting of severe hypoglycaemia by patients with type 1 diabetes
R.M. Agesen1, L.A.H. Færch1, M.-L. Allingbjerg1, B. Thorsteinsson1,2,  
U. Pedersen-Bjergaard1,2;  
1Department of Cardiology, Nephrology, and Endocrinology, Nordsjællands 
University Hospital, Hillerød, 2Department of Clinical Medicine, Faculty of 
Health and Medical Sciences, Copenhagen, Denmark.
Background and aims: The risk of losing privileges such as driver´s licence 
may hamper reporting of severe hypoglycaemia by patients with type 1 dia-
betes and result in concealed severe hypoglycaemia. We tested the hypotheses 
that the implementation in Denmark of new stricter European Union (EU) 
legislation on driver´s licencing with the purpose to improve traffic safety 
in January 2012 has reduced the self-reported rate of severe hypoglycaemia 
in a routine clinical setting and that anonymous reporting results in higher 
event rates.
Materials and methods: A cohort of 309 patients with type 1 diabetes were 
recruited from our outpatient clinic. Numbers of severe hypoglycaemic 
events defined by need for treatment assistance from another person were 
retrieved from medical records in the years 2010 to 2012 and retrospectively 
reported in an anonymous questionnaire. Data from medical records in 2012 
were compared with those from 2010 and 2011 and with data from question-
naire.
Results: Reported rates of severe hypoglycaemia in the medical records were 
reduced by 55% in 2012 compared to the prior years (p=0.034). The fraction 
of subjects reporting recurrent episodes was grossly reduced from 5.6% to 
1.5% (p=0.014). Compared to reporting in the questionnaire the rate of se-
vere hypoglycaemia in 2012 was 70% lower (p<0.001).
Conclusion: Reporting of severe hypoglycaemia by patients with type 1 dia-
betes is significantly reduced following implementation of EU driver’s licens-
ing legislation, primarily due to a marked reduction in the fraction of subjects 
reporting recurrent episodes that according to the new regulations implies 
withdrawal of driver’s licensing. The growing burden of concealed severe 
hypoglycaemia may impair the safety of affected patients and unintendedly 
paradoxically reduce the general traffic safety.
Supported by: The Research Foundation of Nordsjællands University Hospital 
- Hillerød
486
Risk factors and economic burden of hypoglycaemia in patients with 
type 2 diabetes mellitus initiating basal insulin in a U.S. managed care 
system
C. Gerrits1, E. Chou1, H.-W. Chung2, H. Wang1, Q. Zhang1;  
1R&D, Sanofi, Bridgewater, 2TechData, King of Prussia, USA.
Background and aims: A retrospective study assessing risk factors of hypo-
glycemia and associated economic burden, in terms of healthcare utilisation 
and expenditures perspective, in adult patients with Type 2 Diabetes Mellitus 
initiating basal insulin on oral antidiabetic drug during 2006 to 2012 from a 
U.S. national claims database (Innovus LabRx).
Materials and methods: All patients had 24 months of continuous healthcare 
coverage with 12 months before (Baseline) and 12 months after (Follow-up) 
the initiation of basal insulin. Logistic regression was adapted to identify risk 
factors of hypoglycemia occurred at 1-year Follow-up, adjusting Baseline 
patient characteristics including age, gender, comorbidities, prescriptions, 
hypoglycemia status and healthcare utilisation. The economic burden of 
hypoglycemia was evaluated accounting for Baseline patient characteristics 
with a generalised liner model assuming gamma distribution with long link 
for healthcare costs. The subpopulation of patients without sulfonylurea or 
beta-blocker was also evaluated.
Results: While 6.8% (719/10,607) of the basal insulin initiator cohort (mean 
age 54 years, 44% females) had at least one medical claim for hypoglycemia, 
5.9% had hypoglycemia in patients who did not use sulfonylurea or beta-
blocker, and 9.8% in patients who were 65 years or older. Hypoglycemia was 
strongly associated with baseline hypoglycemia (Odds Ratio (OR)=5.78, 95% 
CI: 4.68-7.14) as well as baseline comorbidity (Charlson Comorbidity Index: 
3.4 for patients with hypoglycemia vs. 2.4 for patients without hypoglycemia), 
microvascular disorder (OR=1.36, 95% CI:1.12-1.66), macrovascular disor-
der (OR=1.33, 95% CI:1.09-1.62), pancreatitis (OR=1.62, 95% CI:1.06-2.47), 
foot exam (OR=2.93, 95% CI:2.28-3.76), and hospitalisation (OR=1.30, 95% 
CI:1.07-1.58) . During Follow-up, patients with hypoglycemia vs. those who 
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did not, incurred a total healthcare cost of $36,680 (95% CI: $34,245-$39,288) 
vs. $16,850 (95% CI: $16,549-$17,156), diabetes medical costs ($10,350 vs. 
$2,403; p<0.01), and total number of inpatient days (19.8 vs. 3.4; p<0.01). 
An average hypoglycemia related hospitalisation cost was $20,838. For every 
hypoglycemia episode avoided, an average Medical cost of $733 can be saved. 
A 10% risk reduction in hypoglycemia was associated with an annual Medical 
saving of $496.
Conclusion: Medically attended hypoglycemia was associated with and could 
be predicted by pre-existing comorbidity and result in increased healthcare 
utilisation and expenditures. An alternative basal insulin treatment with re-
duced risk of hypoglycemia can lessen economic burden.
Supported by: Sanofi
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Severe hypoglycaemia often results in hospital visits and ambulance calls 
regardless of insulin regimen
S.R. Heller1, B.M. Frier2, M.L. Hersløv3, J. Gundgaard4, S. Gough5;  
1Academic Unit of Diabetes, Endocrinology and Metabolism, University of 
Sheffield, 2The Queen’s Medical Research Institute, University of Edinburgh, 
UK, 3Medical & Science, Novo Nordisk A/S, 4Health Economics & HTA, 
Novo Nordisk A/S, Søborg, Denmark, 5NIHR Oxford Biomedical Research 
Centre, University of Oxford, UK.
Background and aims: Severe hypoglycaemia is a serious complication asso-
ciated with glucose-lowering treatment, in particular insulin and sulphony-
lureas, resulting in significant morbidity, and incurring considerable financial 
cost. Resource utilisation associated with severe hypoglycaemia was assessed 
across three insulin regimens: patients with type 2 diabetes (T2D) treated 
with basal insulin plus oral therapy (T2BOT), patients with T2D treated with 
multiple daily injections (T2MDI) and patients with type 1 diabetes (T1D) 
treated with basal-bolus insulin (T1BB) in a large clinical development pro-
gramme.
Materials and methods: Data relating to severe hypoglycaemic events (de-
fined as episode in which the patient required external assistance for recov-
ery) from the insulin degludec (IDeg) and insulin degludec/insulin aspart 
(IDegAsp) phase 3 programme (14 trials), which included the comparators 
insulin glargine (IGlar), biphasic insulin aspart (BIAsp), insulin detemir 
(IDet) and sitagliptin, were analysed using descriptive statistics. Mealtime 
insulin aspart (IAsp) was used in some regimens. This analysis used the clini-
cal trial serious adverse events records, which documented whether an am-
bulance/emergency response team, a hospital/emergency room visit for ≤24 
hours, or a hospital visit of >24 hours were required.
Results: In total, 536 severe hypoglycaemic events were analysed, of which 
157 (29.3%) required an ambulance/emergency team, 64 (11.9%) led to hos-
pital/emergency room attendance of ≤24 h and 36 (6.7%) required hospital 
admission (>24 h) (Table). Although the number of events were lower in 
patients with T2D compared with T1D, the proportion resulting in hospital 
treatment for ≤24 h were similar across treatment regimens, whereas a higher 
proportion (47.6%) in the T2BOT group required hospital treatment for >24 
h vs T1BB (5.0%) and T2MDI (5.3%). This resource utilisation and associated 
financial burden are significant: the UK tariffs for “Admitted Patient Care & 
Outpatient Procedures - Diabetes with Hypoglycaemic Disorders“ are £1,269 
for ≤69 years and £2,187 for ≥70 years, in addition to £235 for an ambu-
lance transfer. This yields an average cost per event across treatment regi-
mens of £305 ((11.9%+6.7%)*£1269+29.3%*£235) for patients ≤69 and £476 
((11.9%+6.7%)*£2187+29.3%*£235) for patients ≥70 years
Conclusion: This analysis suggests that severe hypoglycaemic events often 
result in emergency/ ambulance calls and treatment in hospital, and was ob-
served with all insulin regimens, incurring a substantial economic burden. 
Thus, preventative measures to reduce severe hypoglycaemia are likely to re-
duce this burden.
Supported by: Novo Nordisk
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Derivation and validation of a risk prediction tool for hypoglycaemia in 
hospitalised medical patients
B.R. Shah1,2, S. Walji3, A. Kiss2, J.E. James1, J.M. Lowe1,2;  
1Department of Medicine, University of Toronto,  
2Sunnybrook Research Institute, 3Department of Family and Community 
Medicine, University of Toronto, Canada.
Background and aims: There is no objective way of identifying, on admission 
to hospital, those patients with diabetes who are at risk for hypoglycaemia. At 
present, most admitted patients with diabetes have their blood glucose moni-
tored frequently but many never have glucose readings below an acceptable 
range. A method of identifying those at greatest risk of hypoglycaemia would 
lead to efficiencies in care delivery and improvements in quality of care and 
patient safety. The aim of this study was to develop and validate a tool using 
data available at the time of admission to predict the risk of hypoglycaemia 
during hospitalisation.
Materials and methods: A derivation cohort was identified of 300 random-
ly selected patients with diabetes admitted to a medical inpatient unit at a 
tertiary care teaching hospital in Toronto, Canada between November 2009 
and October 2010. All point-of-care glucose tests were collected, and hypo-
glycaemia was defined as any result during the hospitalisation ≤3.9 mmol/L. 
Pre-specified candidate variables were abstracted from hospital records for 
each patient. Multivariable logistic regression was used to identify the inde-
pendent predictors of hypoglycaemia using a backwards stepwise elimination 
method. The regression coefficients from the model were converted into an 
integer points score, and receiver operative characteristic curves were used to 
determine the threshold score that maximized sensitivity and specificity. The 
model was tested in a validation cohort of 300 randomly selected patients 
with the same inclusion criteria from a different Toronto tertiary care teach-
ing hospital. Discrimination of the model was assessed using the c-statistic, 
and calibration was assessed using the Hosmer-Lemeshow goodness-of-fit 
test.
Results: In the derivation cohort, 105 (35%) patients had hypoglycaemia 
during their hospitalisation. The predictor variables remaining after back-
wards elimination were sulfonylurea use, insulin use, beta-blocker use, al-
pha-blocker use, an emergency department visit for any reason in the prior 6 
months, fever and serum creatinine. The integer points scores derived from 
the model are shown in the Table. A summary score of ≥15 had a sensitivity of 
79% and a specificity of 55% for predicting hypoglycaemia. In the validation 
cohort, this model had a c-statistic of 0.703 and the Hosmer-Lemeshow test 
had a p value of 0.50.
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Conclusion: We have derived and validated an easy-to-use index that could 
be applied at the time of admission, which is moderately discriminative for 
predicting hypoglycaemia in hospitalised medical patients with diabetes.
Supported by: Sunnybrook AFP Innovation Fund
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The ‚Local Impact of Hypoglycaemia Tool (LIHT)‘ for estimating the 
economic impact of hypoglycaemic episodes in national, local and user-
defined populations
W.A. Parekh1, D. Ashley1, B. Chubb1, M. Evans2, H. Gillies3;  
1Health Economics & Outcomes Research, EU Market Access,  
Novo Nordisk Ltd, Crawley, 2Consultant Diabetologist, University Hospital, 
Llandough, Cardiff, 3Abacus International, Bicester, UK.
Background and aims: Insulin is the most efficacious glucose lowering ther-
apy for patients with diabetes, however, a common short-term adverse effect 
of insulin therapy is hypoglycaemia. Hypoglycaemia has a major impact on 
patients’ lives affecting employment, driving, relationships, travel, and leisure 
activities. Severe and non-severe hypoglycaemic episodes also represent a 
substantial and often under-estimated cost burden to the National Health 
Service (NHS) and society through increased treatment costs and reduced 
productivity. The purpose of the Local Impact of Hypoglycaemia Tool (LIHT) 
is to help clinicians and budget holders estimate the cost of hypoglycaemia in 
the UK and specifically in their locality at the Primary Care Organisation 
(PCO), General Practice (GP) or user defined population level.
Materials and methods: The LIHT is a versatile model which allows the 
incorporation of real-life local data. The user selects a region/population of 
interest and based on the epidemiology of diabetes in the UK the model es-
timates the number of insulin-treated adults with type 1 and type 2 diabe-
tes in that region. Using hypoglycaemia rates from the UK Hypoglycaemia 
Study Group (UKHSG) observational study, and the cost of a hypoglycae-
mic episode, the annual cost of severe and non-severe hypoglycaemic epi-
sodes in that population is estimated. The cost of a hypoglycaemic episode 
is dependent on the utilisation and unit costs of healthcare resources (blood 
glucose testing, glucose preparations, health care professional consultations, 
ambulance and hospital costs, derived from MIMS, Personal Social Services 
Research Unit (Health & Social Care) and NHS Tariff information), and is es-
timated to range from £1.67 to £2,195. In addition to the direct costs incurred 
by the NHS, indirect costs associated with lost productivity are estimated.
Results: The model highlights the cost burden of hypoglycaemia in the UK 
for insulin-treated adults with diabetes. On a national level, with a UK popu-
lation of almost 67 million people, the total cost of managing hypoglycaemic 
episodes in insulin-treated adults with diabetes is an estimated £363.6m per 
year (£235.6m for severe and £128m for non-severe episodes, respectively). 
In addition, hypoglycaemic episodes are associated with indirect and hidden 
costs, such as lost productivity and higher rates of falls and fractures. On a lo-
cal health economy level the model can provide estimations for each particu-
lar PCO within the UK. Using a hypothetical population of 100,000, the total 
cost of managing hypoglycaemic episodes is estimated to be £543,493 per 
year (£352,163 for severe and £191,330 for non-severe episodes, respectively).
Conclusion: This model highlights the substantial cost burden to the NHS 
of hypoglycaemia in insulin-treated adults and may aid clinicians and NHS 
budget holders with choices regarding insulin treatments. The model offers 
an opportunity to explore how reducing hypoglycaemia can improve the 
quality of diabetes care for patients and result in potential budget savings.
PS 026 Insulin secretion  
in animal models
490
Influence of fasting duration on glucose metabolism in C57BL/6J mice 
during intravenous glucose tolerance test
A.-H. Thorén Fischer, M. Abels, N. Wierup;  
Clinical Sciences in Malmö, Lund University, Neuroendocrine Cell Biology, 
Malmö, Sweden.
Background and aims: The intravenous glucose tolerance test (IvGTT) is 
commonly used to study insulin release and beta cell function in both hu-
mans and animal models. IvGTT is often preceded by a period of fasting and 
different laboratories use different protocols for this. Because the IvGTT is 
frequently used and a lot of conclusions are drawn from it, it is important to 
standardize the performance and use conditions that best reflect the situation 
aimed to study, e.g fasting or starvation. In this study we wanted to investigate 
how different fasting time affects insulin secretion and glucose elimination 
during IvGTT in mice. The time durations were chosen based upon com-
monly used fasting times to find a fasting duration that gave the strongest 
insulin response and glucose elimination.
Materials and methods: 20g C57BL/6J BomTac female mice (n=5 in each 
group) were fasted for different times (12 hour, 4 hour and 1 hour). The mice 
were anaesthetized with Hypnorm/Dormicum 30 minutes prior to the ex-
periment. A basal blood sample was taken from all the mice. Thereafter, glu-
cose (1 g/kg) was injected in a tail vein, and six following blood samples were 
taken at 1, 5, 10, 20, 50 and 75 minutes. All blood samples were taken from 
the retro orbital plexus. Glucose (colorimetric assay) and insulin (ELISA) 
were analyzed in plasma.
Results: The mice fasted for 12 hours had higher basal glucose levels, com-
pared with mice fasted for 1 and 4 hours (p<0.05). This group also had a 
decreased insulin response (acute insulin response (AIR), 2.5 vs. 6.6 and 6.7, 
p<0.001) after glucose administration, which resulted in a trend towards de-
creased glucose elimination (Kg, 1.9 vs. 2.8 and 2.7, p=0.06). When compar-
ing the groups fasted for 1 or 4 hours there was no difference in either glucose 
elimination or insulin response.
Conclusion: When planning in vivo experiment with mice it is important 
to know how they respond to different treatments such as fasting duration. 
In this study we show that the fasting time chosen for an IvGTT in normal 
C57BL/6J mice strongly effect the results, both concerning insulin release 
and glucose elimination we aimed to optimize the IvGTT protocol with a 
fasting time that gave maximal insulin release and glucose elimination. Our 
data suggest that 1h fasting is optimal for this. However, 12h fasting should 
be avoided, since it affects insulin release and glucose elimination negatively, 
probably as a stress response to starvation.
Supported by: The Swedish Research Council
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Impact of glucose dosing regimens on evaluating glucose tolerance and 
beta cell function by intravenous glucose test in diet induced obese mice
G. Pacini1, B. Omar2, B. Ahrén2;  
1Metabolic Unit, ISIB-CNR, Padova, Italy,  
2Department of Medicine, Lund University, Sweden.
Background and aims: Metabolic studies require accurate measurements of 
islet function, in particular insulin secretion. An important aspect is the ad-
aptation of beta cell function to insulin resistance, which is best described by 
the disposition index, derived from analyzing insulin and glucose data from 
an intravenous glucose tolerance test (IVGTT). One caveat when calculating 
this index is that basing the glucose dose on the individual’s total body weight 
can result in large differences in the amount of glucose given to lean and 
obese individuals. In this study, we therefore evaluated alternative glucose 
dosing regimens for the determination of the impact of glucose dosing on 
measures of beta cell function in normal and diet induced obese (DIO) mice.
Materials and methods: The glucose dosing regimens used for the IVGTT 
were either 0.35 mg per kg total body weight (BW) or per kg lean BW or a 
fixed glucose dose based on the average BW for all experimental mice. A total 
of 84 IVGTT were performed in 28 six-week old female C57BL6/JBomTac 
mice, 14 fed with 10% fat (CD) and 14 with a high fat diet (60% fat, HFD) for 
eight weeks before glucose tolerance testing. Lean body mass was determined 
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by dual emission x-ray absorptiometry using a PIXImus imager. IVGTTs 
were performed on 5 hour fasted mice. After injecting glucose in a tail vein, 
samples were taken from a retrobulbar intraorbital capillary plexus at 1, 5, 10, 
20, 30 and 50 minutes for determination of insulin and glucose concentra-
tion. Glucose was dosed per total body mass (0.35g/kg), per lean body mass 
(0.35 g/lean kg) or equal for all animals (10 mg).
Results: Each regimen detected a similar decrease in insulin sensitivity in 
DIO mice. The different glucose dosing regimens gave, however, diverging 
results in regards to glucose elimination and the acute insulin response. Thus, 
the fixed dose regimen was the only that revealed impairment of glucose 
elimination in HFD (glucose elimination rate 1.4±0.2 vs. 2.4±0.2 %/min, 
P<0.01), whereas dosing according to total BW was the only regimen which 
showed significant increases in acute insulin response in HFD mice (peak 
insulin concentration 1246±230 vs. 480±160 pmol/l, P<0.01). The fixed dose 
glucose dosing regimen was the only one that revealed a significant decline in 
the disposition index value in HFD mice (0.7±0.1 vs. 1.1±0.1, P<0.05), which 
is characteristic of type 2 diabetes in humans.
Conclusion: Our results therefore show that using different glucose dosing 
regimens during IVGTT in DIO mice, it is possible to model different aspects 
of physiology which are similar to prediabetes and type 2 diabetes in humans, 
with the fixed dose regimen producing a phenotype that most closely resem-
bles human type 2 diabetes.
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Beta cell-specific over-expression of CART improves beta cell function 
in vivo
M. Abels, M. Riva, A.-H. Thorén Fischer, N. Wierup;  
Clinical Sciences in Malmö, Lund University, Neuroendocrine Cell Biology, 
Malmö, Sweden.
Background and aims: Cocaine- and amphetamine-regulated transcript 
(CART) is a regulator of islet hormone secretion, enhancing insulin secre-
tion and lowering glucagon secretion, thereby fine-tuning blood glucose 
levels. CART also protects beta cells against glucotoxicity-induced apopto-
sis in vitro. Furthermore, beta cell CART expression is regulated by glucose 
and CART is up-regulated in beta cells of type 2 diabetes (T2D) patients and 
rodent models of T2D. The aim of this study was to examine the impact of 
up-regulated beta cell CART on in vivo beta cell function and survival, both 
crucial components for retaining normal glucose homeostasis.
Materials and methods: We generated transgenic mice that express CART 
under the control of the PDX1 promotor, resulting in overexpression of 
CART specifically in the beta cells (CARTtg). Mice (4 month, 6 months, and 
10 months) were subjected to intravenous glucose tolerance test (IVGTT) to 
study insulin secretion in vivo. To study in vivo beta cell survival, mice were 
subjected to a multiple low dose streptozotocin (STZ)-treatment to induce 
diabetes, followed by weekly glucose monitoring and IVGTT 3 weeks after 
treatment.
Results: 4-6 months old CARTtg mice displayed normal in vivo insulin se-
cretion compared to wild type (WT) littermates. However, at the age of 10 
months CARTtg mice displayed increased insulin secretory capacity (acute 
insulin release, AIR) during an IVGTT compared to WT mice (WT: 3.3 vs. 
CARTtg: 6.3, p=0.02). This was paralleled by improved glucose elimination 
(Kg) (WT: 1.8 vs. CARTtg: 2.5, p=0.03). In STZ-treated mice blood glucose 
levels were elevated, compared to control mice already after 1 week (12.5mM 
vs. 7.9mM:, p<0.001). From 3 weeks after STZ-treatment CARTtg mice dis-
played lower glucose levels compared to WT mice (WT: 17.1mM vs. CARTtg: 
21.7mM, p<0.001) suggesting improved remaining insulin secretory capacity. 
This was confirmed by IVGTT showing that CARTtg mice secreted more in-
sulin throughout the glucose tolerance test (Insulin AUC WT: 48 vs. CARTtg: 
69.4, p=0.02), which resulted in lower glucose levels (AUC glucose 1-20 min, 
WT: 642 vs. CARTtg: 557, p<0.05).
Conclusion: Here we show that overexpression of CART in beta cells pro-
vokes improved insulin secretory capacity in vivo. Furthermore, we also show 
that increased beta cell CART restores insulin secretion and glucose homeo-
stasis after diabetes induction, probably as a result of enhanced beta cell sur-
vival. In view of that CART is up-regulated in islets of T2D patients; our data 
suggest that CART is up-regulated in T2D as a homeostatic response trying 
to overcome hyperglycemia
Supported by: EFSD/MSD, The Novo Nordisk Foundation, The Swedish Re-
search Council
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LKB1-dependent regulation of incretin actions in pancreatic beta cells  
by metformin and adiponectin
K. Shinmura1, T. Negoro2, Y. Nakano2, T. Hirano1;  
1Department of Medicine,Division of Diabetes,Metabolism and 
endocrinology, Showa University School of Medicine, 2Department of 
Pharmacogenomics, Showa University School of Pharmacy, Tokyo, Japan.
Background and aims: Metformin is widely used to treat DM and improves 
blood glucose concentration through activation of LKB1-AMPK pathway. On 
the other hand, incretins, GLP-1 and GIP, raise intracellular Ca2+ and cAMP 
concentration in pancreatic β-cells, resulting in insulin secretion. Incretin 
and metformin are concurrently used for the treatment of type 2 diabetes 
and so we examined the effect of metformin on insulin secretion by incretin. 
We also examined the effect of adiponectin, which physiologically activates 
LKB1-AMPK pathway. Furthermore, we analyzed whether LKB1 plays a key 
role for the regulation of Ca2+ and cAMP by metformin and adiponectin.
Materials and methods: Insulin secretion, cAMP production, and intracel-
lular Ca2+ concentration were analyzed using MIN6 cells by stimulating with 
GLP-1 or GIP. Amount of insulin secretion was measured with the Mouse 
Insulin ELISA KIT (TMB) (AKRIN-011T, Shibayagi, Gunma, Japan). For 
cAMP assay, MIN6 cells were transfected with pGloSensor™20F cAMP Plas-
mid by Neon™ Transfection System and cAMP production was measured 
by luminescence spectroscopy using GloSensorTM cAMP assay (Promega, 
USA) reagent. Intracellular Ca2+ concentration was measured by the Fura-2 
fluorescence-imaging analytic method using Meta Fulora video image ana-
lyzer. For the knock down analysis of LKB1, the gene-specific siRNA was 
transfected by Neon System.
Results: Under physiological glucose concentration (5.5mM) but not under 
high glucose concentration (16.7 mM), Ca2+ influx by GLP-1 or GIP stimu-
lation was inhibited by metformin and adiponectin resulting in decreased 
insulin secretion. Furthermore, metformin and adiponectin regulated cAMP 
response by incretins. Knock down of LKB1 by siRNAs abrogated the effects 
of metformin on the action of incretins under physiological glucose concen-
tration.
Conclusion: Metformin and adiponectin regulated both Ca2+ and cAMP re-
sponses raised by GIP and GLP-1 under physiological glucose concentration 
but not under high glucose condition. According to the knock down experi-
ments, LKB1 is involved in cAMP production and Ca2+ response promoted 
by metformin. Now we are investigating whether knock down of LKB1 can 
abrogate the same effect of adiponectin.
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Kinome-wide RNAi screen identifies regulators of insulin like peptide 
production in drosophila melanogaster
K. Hasygar1,2, V. Hietakangas1,2;  
1Department of Biosciences/Genetics, University of Helsinki,  
2Institute of Biotechnology, Helsinki, Finland.
Background and aims: Insulin/IGF pathway plays a critical role in adjust-
ing the growth, metabolism and lifespan of animals in response to nutri-
tion. Aberrations in the pathway are causal for human metabolic diseases, 
most notably diabetes. Insulin/IGF like signaling (IIS) is highly conserved 
in multicellular animals, making simple genetic model systems, like Dros-
ophila, useful in dissecting the genes involved in IIS. Aim of our project is 
to identify signaling pathways regulating production of insulin like peptides 
in Drosophila melanogaster. Drosophila melanogaster has eight insulin like 
peptides, four of which are secreted from fourteen median neurosecretory 
cells called insulin producing cells (IPCs). IPCs are considered to be Dros-
ophila counterparts of pancreatic beta cells. They regulate metabolic homeo-
stasis and growth of the organism. In this study, we have performed a focused 
tissue-specific in vivo RNAi screen to identify signaling pathways regulating 
insulin production in IPCs.
Materials and methods: dILP2-Gal4; UAS-GFP driver line was used for 
IPC specific knockdown of kinases. RNAi lines against kinases were ob-
tained from VDRC, Austria and Bloomington Stock Center, USA. qRT-PCR 
assays were used to measure mRNA levels of insulin like peptides and im-
munostainings using anti-dILP2 antibody were used to assess secretion of 
insulin like peptides.
Results: 231 protein kinases were screened of which twelve genes showed 
severe undergrowth phenotype upon knockdown. These hits were confirmed 
using at least two independent RNAi lines. These genes were analyzed for 
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their roles in IPC viability, insulin-like peptide (dILP) mRNA expression and 
dILP2 secretion. None of the kinases had an effect on the viability of IPCs. 
One of the kinases, Tousled-like kinase, showed significantly reduced dILP3 
expression. Further, knockdown of several identified genes like ADCK, 
PKC98E, Rio2, aPKC, CDK12 and Rio1 showed accumulation of dILP2 in 
IPCs, implying disturbed dILP2 secretion. One of the genes, aPKC, has pre-
viously been linked to insulin secretion in mammals, suggesting conserved 
function. The mechanisms of action of other genes which are not previously 
studied with respect to insulin signaling are being investigated.
Conclusion: In conclusion, we have identified twelve protein kinases, which 
regulate insulin production in Drosophila melanogaster. One of the genes, 
Tlk, regulates dILP3 transcription in IPCs. Further, ADCK, PKC98E, Rio2, 
aPKC, CDK12 and Rio1 play a role in secretion of insulin like peptide 2 from 
IPCs.
Supported by: ILS Doctoral Program, Sigrid Juselius Foundation.
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Antidiabetic effects of tigerinin-1R in mice chronically maintained  
on high fat diet 
Y.H.A. Abdel-Wahab, O.O. Ojo, D.K. Srinisavan, B.O. Owolabi, P.R. Flatt;  
School of Biomedical Sciences, University of Ulster, Coleraine, UK.
Background and aims: We previously reported in vitro and acute in vivo 
insulinotropic effects of tigerinin-1R (RVCSAIPLPICH.NH2), an amphib-
ian host defence peptide, isolated from the skin secretion of Hoplobatrachus 
rugulosus. The present study investigated plasma degradation and chronic 
metabolic effects of tigerinin-1R in Swiss NIH mice fed a high fat diet to 
induce obesity-diabetes.
Materials and methods: Proteolytic degradation of synthetic tigerinin-1R 
was investigated by reversed-phase HPLC and MALDI-TOF mass spectrom-
etry using GLP-1(7-36) as positive control. Changes in glycaemic responses 
and metabolic parameters were measured in mice with high fat diet-induced 
obesity-diabetes treated with twice-daily intraperitoneal injection of tigerin-
in-1R (75nmol/kgbw) for 15 days. Glucose concentrations were measured by 
glucose oxidase method using an Analox GM9 glucose analyser and insulin 
concentrations were measured by radioimmunoassay. Indirect calorimetry 
and body composition were measured by CLAMS and DEXA whole body 
scanning. Insulin secretory responses of islets isolated from treated and un-
treated mice were examined.
Results: Unlike GLP-1(7-36), tigerinin-1R was resistant to in vitro degrada-
tion by plasma enzymes. Twice-daily injection of tigerinin-1R (75nmol/kg 
bw) for 15 days had no significant effect on food intake or body weight. Non-
fasting glucose levels were significantly lowered (16%, P<0.05) and insulin 
levels were elevated (20%, P<0.05) compared to saline treated controls at the 
end of the treatment period. Glycaemic responses to oral and intraperitoneal 
glucose administration (180mmol/kg body weight) were improved by 26% 
(P<0.05) and 22% (P<0.05) respectively in mice treated with tigerinin-1R. 
Plasma insulin responses to glucose administration were also significantly 
enhanced by 40% (P<0.001, oral) and 41% (P<0.001, intraperitoneal). Treat-
ment with the peptide had no effect on insulin sensitivity but compared to 
saline treated controls significantly improved beta cell responses of isolated 
islets in response to GLP-1 (10-6M,1.9-fold, P<0.001), GIP (10-6M, 1.6-fold, 
P<0.05, alanine (10mM, 1.4-fold, P<0.001), L-arginine (10mM, 1.6-fold, 
P<0.05) and KCl (30mM, 2.0-fold). Oxygen consumption, CO2 production, 
respiratory exchange ratio, energy expenditure and body composition were 
not significantly altered by treatment with tigerinin-1R.
Conclusion: These observations provide the first evidence for the therapeutic 
potential of tigerinin-1R as a novel anti-diabetic agent.
Supported by: Diabetes UK
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Gamma-oryzanol, a unique component of brown rice, improves 
pancreatic islet function via inhibition of exaggerated dopamine receptor 
signalling
C. Kozuka1, S. Sunagawa1, R. Ueda1, M. Higa2, H. Tanaka3, C. Takayama4, 
M. Matsushita5, S. Oyadomari6, M. Shimabukuro7, H. Masuzaki1;  
1Division of Endocrinology, Diabetes and Metabolism, Hematology, 
Rheumatology, University of the Ryukyus, 2the Diabetes and Life-
style Related Disease Center, Tomishiro Central Hospital, 3Tanaka 
Clinic, 4Department of Molecular Anatomy, University of the Ryukyus, 
5Department of Molecular and Cellular Physiology, University of the 
Ryukyus, Okinawa, 6Institute for Genome Research, 7Graduate School of 
Health Biosciences, University of Tokushima, Japan.
Background and aims: We recently demonstrated that γ-oryzanol, a major 
bioactive component of brown rice, prevents obesity and type 2 diabetes. 
Gamma-oryzanol attenuated the preference for dietary fat through reduction 
of exaggerated endoplasmic reticulum (ER) stress in high fat diet (HFD)-
induced obese mice. We also found that γ-oryzanol improved HFD-induced 
glucose intolerance, but the underlying mechanism still remains unclear. On 
the other hand, previous studies showed that local dopamine D2 receptor 
(D2R) signaling prevents insulin secretion in islets. In this context, we tested 
the potential involvement of D2R signaling in γ-oryzanol-mediated glucose 
homeostasis in pancreatic islets.
Materials and methods: Gamma-oryzanol was delivered into the stomach 
of male C57BL/6J mice by a gavage needle and its effects on islets function 
were determined. Response of a series of drugs influencing D2R signaling 
and γ-oryzanol, and insulin secretion in pancreatic β-cell line, MIN6 cells 
and isolated islets was assessed.
Results: In islets from HFD-fed obese mice, D2R signaling was exagger-
ated in islets from mice fed HFD (e.g. D2R mRNA level; 2.0-fold increase vs. 
chow-fed mice, p < 0.05), where augmented ER stress coexisted (e.g. Chop 
mRNA level; 2.1-fold increase vs. chow-fed mice, p < 0.01). In pancreatic 
β-cell line, MIN6 cells and isolated islets, γ-oryzanol activated the cAMP/
cAMP-dependent protein kinase (PKA) pathway via inhibition of D2R sign-
aling, thereby enhancement of glucose-stimulated insulin secretion (GSIS) 
(insulin secretion, 25mM glucose; MIN6 cells, 1.3-fold, p < 0.05, islets, 2.2-
fold increase vs. vehicle-treated cells, p < 0.01). In contrast, exaggerated secre-
tion of insulin-counteracting hormone, glucagon was remarkably suppressed 
by γ-oryzanol both in vivo and in vitro. ER stress is linked to the regulation 
of pancreatic β-cell functions and the pathophysiology of type 2 diabetes. ER 
stress in β-cells leads to apoptosis and suppression of insulin biosynthesis. 
We also found that γ-oryzanol reduces ER stress in islets from HFD-fed mice 
(e.g. Chop mRNA level; 37 % reduction, p < 0.05). Moreover, in MIN6 cells 
treated with tunicamycin, an ER stress inducer, γ-oryzanol improved in insu-
lin secretion and prevented ER stress-induced apoptosis.
Conclusion: These data indicate that γ-oryzanol directly improves the 
survival and function of murine pancreatic islets. A series of the effects of 
γ-oryzanol on pancreatic islets may shed light on a novel, natural food-based 
medicine for type 2 diabetes in humans.
Supported by: the Japan Ministry of Education, JSPS Research Fellowship
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Activation of GPR120 by fatty acid agonists augments insulin release 
from pancreatic islets and improves glucose tolerance in mice
A.M. McKillop, B.M. Moran, Y.H.A. Abdel-Wahab, P.R. Flatt;  
School of Biomedical Sciences, University of Ulster, Coleraine, UK.
Background and aims: GPR120 is a rhodopsin-like GPCR that has a high 
affinity for long chain saturated fatty acids 14-18 carbons and unsaturated 
fatty acids 16-22 carbons. This aim of this study was to assess the potency and 
selectivity of various GPR120 agonists and determine the cellular localisation 
of GPR120 in clonal beta cells and pancreatic islets.
Materials and methods: Insulin secretion and alterations in intracellular 
Ca2+ and cAMP response to glucose and GPR120 agonists including endog-
enous agonists (ALA, EPA, DHA) and a synthetic analogue (GW-9508) were 
examined using clonal pancreatic BRIN-BD11 cells, mouse pancreatic islets 
and in-vivo studies using NIH Swiss mice. Cytotoxicity was assessed by LDH 
release. Cellular localisation of GPR120 was explored by double staining im-
munohistochemistry.
Results: The most potent and selective GPR120 agonist tested was ALA (EC50 
1.2x10-8 mol/l) at 10-8-10-4 mol/l with a 1.5- to 2.1-fold increase in insulin 
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release at 5.6mM glucose (p<0.001), with maximum stimulation of insulin 
secretion by 53% at 10-4 mol/l (p<0.001) in BRIN-BD11 cells. Stimulation 
of insulin secretion was observed with GW-9508 (6.4x10-8 mol/l; 47%), EPA 
(7.9x10-8 mol/l; 36%) and DHA (1.0x10-7 mol/l; 50%) at 5.6mM glucose. At 
stimulatory glucose concentrations, ALA was the most potent agonist tested 
(EC50 of 8.5x10
-8 mol/l) at 10-8-10-4 mol/l with a 1.2- to 1.6-fold increase in 
insulin release at 16.7mM glucose (p<0.05-p<0.001). DHA enhanced insu-
lin release at 10-7-10-4 mol/l by 1.3- to 1.7- fold (p<0.01-p<0.001) (EC50 of 
1.2x10-7 mol/l) while EPA augmented insulin secretion at 10-9-10-4 mol/l by 
1.2- to 1.6-fold (p<0.05-p<0.001) (EC50 of 1.7x10-5 mol/l). Synthetic agonist 
GW-9508 enhanced insulin secretion at 10-8-10-4 mol/l by 1.2- to 1.7-fold 
(p<0.05-p<0.001) (EC50 of 7.0x10
-7 mol/l). Results were corroborated by 
islet studies, with no evidence of cytotoxic effects. Dose-dependent insulin 
secretion by GPR120 agonists was glucose-sensitive and accompanied by el-
evations of intracellular Ca2+(p<0.05-p<0.001) and cAMP (p<0.05-p<0.01). 
Immunocytochemistry demonstrated GPR120 expression on BRIN-BD11 
cells and was confined to islet beta cells with no distribution on alpha cells. 
Administration of GPR120 agonists (0.1μmol/kg body weight) in glucose 
tolerance studies was tested in mice. Using AUC data, ALA (p<0.05), EPA 
(p<0.05) and GW-9508 (p<0.01) decreased the glycaemic excursion. Simi-
larly both EPA(p<0.05) and GW-9508 (p<0.01) enhanced insulin release by 
35-40% after 15 min while both small molecules stimulated insulin secretion 
by 33-41 after 30 min (p<0.01). All agonists tested with exception of DHA 
augmented glucose-induced insulin release (p<0.05-p<0.01) when compared 
to glucose alone.
Conclusion: GPR120 is expressed on pancreatic beta cells, and agonists at 
this receptor are potent insulin secretagogues, with therapeutic potential for 
type 2 diabetes.
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Chronic glucocorticoid treatment induced insulin resistance but 
improved glucose tolerance due to increased insulin secretion and beta 
cell neogenesis
H.T.T. Do1,2, A. Besseiche2,3, G. Dorothée1, B. Fève1,4, B. Blondeau3,2,  
M. Buyse1,4;  
1INSERM UMR_S938, 2Université Paris 06 Pierre et Marie Curie,  
3INSERM UMR_S1138, 4APHP Hôpital Saint-Antoine, Paris, France.
Background and aims: Cortisol and corticosterone, the physiological glu-
cocorticoids (GCs) in humans and rodents, respectively, have pleiotropic 
functions to modulate blood pressure, immune responses, and energy ho-
meostasis. GCs and synthetic GCs are commonly used for the treatment of 
inflammatory diseases but their adverse effects can overcome their benefit, 
restricting their long-term use. More specifically, GCs exert deleterious ef-
fects on glucose metabolism, leading to a wide range of alterations from insu-
lin resistance to complicated diabetes, but also induce weight gain associated 
with lipodystrophy.
Materials and methods: In this study, we investigated the effects of a long-
term GC exposure in C57/Bl6 male mice. Corticosterone (CORT) was given 
in drinking water (100 µg/mL) for 8 weeks. Glucose tolerance, insulin sen-
sitivity, gene expression in adipocytes and pancreatic islets and pancreatic 
morphometry were studied.
Results: Mice treated with GC had a significant weight gain (Δ = 7.1 g vs 3.0 
g, p < 0.001) with an accumulation of both brown (x3, p < 0.001) and white 
(x2, p < 0.01) adipose tissues, characterized by a visceral adipocyte hyper-
plasia and subcutaneous adipocyte hypertrophy. Surprisingly, GC treatment 
promoted macrophage infiltration (F4/80, CD68) (x5, p < 0.05) within all 
adipose tissues. Of note, a M1/inflammatory macrophage phenotype (MCP1, 
IL6, TNFα) was restricted to visceral adipose tissue compared to subcutane-
ous fat depot, suggesting a substantial damaging effect on insulin sensitiv-
ity. Accordingly, CORT treatment induced an insulin-resistance, as demon-
strated by insulin tolerance test and HOMA-IR (x10, p < 0.001) as well as an 
decreased glucose uptake into adipose tissue (-50%, p < 0.01). CORT mice 
exhibited also postprandial hyperglycaemia (following ad libitum nocturnal 
feeding) (259 mg/dL vs 140 mg/dL, p < 0.001) but this effect was lost in fasted 
condition due to a reduced hepatic gluconeogenesis measured by pyruvate 
tolerance test. Strickingly, following a 6-h-fasting, GC treatment resulted in 
an improved glucose tolerance (OGTT/IPGTT), due to increased plasma in-
sulin levels (x8, p < 0.001). Pancreatic analysis revealed a dramatic increase 
of β-cell fraction (4.3% vs 0.6%, p < 0.05) and β-cell mass (x7, p < 0.05) as-
sociated with improvement in insulin secretion capacity from isolated islets. 
Increased islets size was observed (x2, p < 0.05), due to β-cell proliferation. 
More suprisingly, a dramatic increased islet density was found (x4, p < 0.05), 
revealing β-cell neogenesis, a result confirmed by increased Ngn3 expression. 
Several other β-cell genes (Pdx1, Rfx6, Nkx 2.2, NeuroD, Ins) were up-regulat-
ed, pointing to a new insight into GC-induced β-cell adaptation.
Conclusion: In this study we demonstrated that GC could differentially act 
on various fat depots to promote metabolic alteration and evidenced a new 
function of GCs on β-cell neogenesis.
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Effects of caloric restriction and Ins1 gene dosage on glucose homeostasis 
in female mice
D.A. Dionne, N.M. Templeman, J.D. Johnson;  
Cellular and Physiological Sciences, University of British Columbia, 
Vancouver, Canada.
Background and aims: Therapeutic benefits of caloric restriction (CR) on 
clinical outcomes in treatment of neurodegenerative disease, cancer, cardio-
vascular disease, and diabetes have been proposed. Studies indicate the posi-
tive health outcomes produced by CR may involve cellular nutrient-sensing 
pathways including insulin/insulin-like growth factor 1 signalling. CR has 
been reported to have significant effects on glucose metabolism and body 
composition, lowering fasting blood glucose and insulin, as well as improving 
glucose tolerance and insulin sensitivity. However, it is not clear which, if any, 
of the effects of CR are due to the lowering of circulating insulin. To deter-
mine whether CR-improved glucose homeostasis is a function of circulating 
insulin-dependent mechanisms we performed a gene-dosage study with mice 
either wildtype or heterozygous at the insulin 1 gene locus, while lacking the 
insulin 2 gene entirely. We have previously shown that male Ins1+/-:Ins2-/- 
mice are protected from diet-induced obesity compared to Ins1+/+:Ins2-/- 
littermate controls. In the present study, using female mice of the same geno-
types, we compared how changes to caloric intake and insulin gene dosage 
affect circulating hormone levels, glucose homeostasis, energy expenditure, 
markers of healthy aging, and longevity.
Materials and methods: Female Ins1+/-:Ins2-/- mice and Ins1+/+:Ins2-/- lit-
termate controls were fed a chow diet ad libitum (AL) until 13 weeks of age, 
then half of the mice continued AL feeding, while the others were placed on a 
CR diet where they were fed 60% of what their genotype-matched littermate 
controls ate daily. All mice were singly housed and CR mice were fed at night. 
Body mass, insulin secretion, and blood glucose response to intraperitoneal 
injections of glucose or insulin were assessed over a 1-year period.
Results: With the onset of CR, body mass in both genotypes fell and reached 
a new equilibrium by 20 weeks of age. Until ~38 weeks of age, food intake of 
AL-fed and hence CR fed Ins1+/-Ins2-/- mice was modestly higher than that 
of Ins1+/+:Ins2-/-, leading to a small difference in mean body weight of CR 
mice that disappeared as food intake of the two genotypes converged. As ex-
pected, mice on CR had lower fasting and fed plasma glucose when compared 
to genotype controls (p<0.05). CR improved glucose tolerance in mice at 25 
and 51 weeks of age, irrespective of Ins1 gene dosage. All groups had com-
parable glucose-stimulated insulin levels at 27 and 53 weeks of age. However, 
we observed paradoxical effects of CR on insulin sensitivity. While the first 
30 minutes post-injection were similar across groups, CR mice of both geno-
types exhibited a rapid recovery to baseline glucose. Fasting insulin levels at 
53 weeks were also paradoxical, with Ins1 gene dosage having no effect in CR 
mice. In fact, CR Ins1+/-:Ins2-/- mice had significantly increased circulating 
insulin (p < 0.05) when compared to AL control. CR Ins1+/+:Ins2-/- mice ex-
hibited the expected reduction in circulating insulin compared to AL control 
(0.21 ± 0.08 versus 0.31 ± 0.07 ng/ml; p = 0.0575).
Conclusion: Our results suggest one Ins1 allele is able to produce equal 
amounts of insulin as two alleles, although if a stressor is applied, such as 
ageing, this may be abrogated. CR appears able to prevent this loss and cause 
a rapid blood glucose recovery after exogenous insulin in a manner not ob-
served in other studies.
Supported by: CIHR
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Across glucose tolerance spectrum, men display greater decreases in 
insulin secretion than women
S.S. Shankar1, R.H. Raymond2, D. Chen3, C. Cobelli4, C. Dalla Man4,  
D.S. Lee3, R.P. Robertson5, D. Stefanovski6, M.T. Vassileva7, D.A. Fryburg8, 
for the Beta Cell Team of FNIH Biomarkers Consortium;  
1Eli Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, 2RSquared 
Solutions, Skillman, 3Pfizer Pharmatherapeutics R & D, Cambridge, USA, 
4University of Padova, Italy, 5Pacific Northwest Diabetes Research Institute, 
Seattle, 6Cedars-Sinai Medical Center, Los Angeles, 7Foundation for the NIH 
Biomarkers Consortium, Bethesda, 8ROI BioPharma Consulting, East Lyme, 
USA.
Background and aims: Little is known about gender differences in insulin 
secretion (IS). As part of a project examining the utility of beta cell func-
tion tests, we studied effect of gender on IS response to the arginine (ARG) 
stimulation test (AST) and the mixed meal tolerance test (MMTT) in over-
night fasted, obese men (M) and women (W) with normal glucose tolerance 
(NGT), prediabetes (PDM) and type 2 diabetes (T2DM).
Materials and methods: For AST, acute IS (AIRarg) was measured over 5 
min at baseline glucose after an i.v. ARG bolus (5 gm over 30 sec). Immedi-
ately following these samples, a 60 min infusion (900 mg/min) of glucose was 
initiated; ARG was administered again after 50 min of the glucose infusion; IS 
samples were then repeated (AIRmax). All arg results are baseline-adjusted. 
For MMTT, IS (Φtot and DItot) were measured in response to a standardized 
450 kCal meal and estimated using minimal model.
Results: The table below summarizes the results. Within each gender sig-
nificant declines in insulin secretion were detected for all 4 parameters (NGT 
and PDM were largely similar v. T2DM). To compare the changes in insulin 
secretion of women to men across the glucose tolerance groups, an ANCOVA 
model was developed. Of covariates tested (BMI and age), only age was in-
cluded in the model as a significant covariate. ANCOVA showed that from 
NGT to T2DM, as seen in both the AST and MMTT, the decline in insulin 
secretion is greater in men than in women.
Conclusion: We conclude that 1) in a cross-sectional analysis of men and 
women with NGT, PDM, and T2DM, insulin secretion declines in both gen-
ders; 2) From NGT to T2DM, men show a greater decline than women in 2 
different tests of insulin secretion. These results may have implications for 
gender balance in study designs measuring insulin secretion.
Clinical Trial Registration Number: NCT01663207
Supported by: FNIH Biomarkers Consortium Sponsors
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Circulating non-esterified fatty acids (NEFA) do not associate with  
beta cell dysfunction: evidence from the RISC study
E. Rebelos1, A. Natali1, A. Mari1, B. Balkau2, A. Golay3, P. Piatti4, N. Lalic5, 
M. Laakso6, E. Ferrannini1;  
1Department of Clinical and Experimental Medicine, University of Pisa, 
Italy, 2INSERM U 258, Villejuif, France, 3Department of Clinical and 
Experimental Medicine, University Hospitals of Geneva and University 
of Geneva, Switzerland, 4Internal Medicine Department, Cardio-Diabetes 
Trials Unit, Scientific Institute San Raffaele, Milan, Italy, 5Faculty of 
Medicine, Clinic for Endocrinology, Diabetes and Metabolic Disease, 
University of Belgrade, Serbia, 6Department of Medicine, University of 
Eastern Finland, Kuopio University Hospital, Finland.
Background and aims: It is commonly held that chronically elevated NEFA 
levels adversely affects insulin secretion and insulin action (lipotoxicity). Al-
though the association between NEFA and insulin resistance is well estab-
lished, the effect of raised NEFA on ß-cell function has only been explored in 
small experimental protocols using acute elevations in NEFA. Our aim was to 
analyse the relationship between endogenous NEFA levels and insulin secre-
tion and ß-cell function both cross-sectionally and longitudinally.
Materials and methods: In 701 women and 566 men from the Relationship 
Between Insulin Sensitivity and Cardiovascular Disease (RISC) cohort (mean 
age 44 years, BMI range 17-44 kg/m2, 14% with impaired fasting glycaemia 
(IFG) and 9% with impaired glucose tolerance (IGT)) followed up for 3 years, 
we measured insulin sensitivity (by a euglycaemic insulin clamp) and ß-cell 
function (by modelling of the C-peptide response to oral glucose and as the 
acute insulin response (AIR) to intravenous glucose).
Results: At baseline, both fasting and insulin-suppressed NEFA were signifi-
cantly (p<0.0001) higher across glucose tolerance groups, while insulin sensi-
tivity was lower (p<0.0001), insulin output was higher (p<0.0001) and ß-cell 
glucose sensitivity and AIR were lower (both p<0.0001). By multiple logistic 
analyses adjusting for center, sex, age, BMI, WHR, and glucose tolerance, 
both fasting and insulin-suppressed NEFA were inversely related to insulin 
sensitivity (both p<0.0001). Furthermore, after also adjusting for insulin sen-
sitivity, insulin-suppressed NEFA were positively associated with total insulin 
output (p=0.0042). In contrast, in the same multivariate models neither fast-
ing nor insulin-suppressed NEFA were related to ß-cell glucose sensitivity or 
AIR. This result was confirmed when also accounting for insulin sensitivity 
or family history of diabetes. At follow up, glucose tolerance status worsened 
in 127 subjects. By multiple logistic regression, this change was predicted by 
male gender, higher age and higher waist-to-hip ratio, worse baseline glu-
cose tolerance, lower insulin sensitivity and ß-cell glucose sensitivity (area 
under ROC curve = 0.79). In this model, neither baseline fasting nor baseline 
insulin-suppressed NEFA were significant predictors of progression.
Conclusion: In the non-diabetic and prediabetic state, circulating endog-
enous NEFA are independently associated with impaired insulin sensitivity 
and enhanced insulin release but not with measures of ß-cell function, and 
do not predict deterioration of glucose tolerance. Thus, in the RISC cohort 
there is no evidence for ß-cell lipotoxicity of endogenous total NEFA con-
centrations.
Supported by: EU GRANT QLG1-CT-2001-01252
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Increment of serum C-peptide by glucagon test closely correlates with 
human beta cell mass
Y. Fujita1, J. Kozawa1, H. Iwahashi1, S. Yoneda1, S. Uno1, A. Yoshikawa1,  
H. Eguchi2, H. Nagano2, A. Imagawa1, I. Shimomura1;  
1Department of Metabolic Medicine,  
2Department of Gastroenterological Surgery, Osaka University, Suita, Japan.
Background and aims: Evaluation of beta-cell mass is important in clinical 
practice of diabetes. Our objective was to evaluate the relationships between 
human beta-cell mass and various clinical parameters, including insulin se-
cretory capacities.
Materials and methods: We conducted a study of pancreatic tissues obtained 
from 32 (19 males and 13 females) patients undergoing a pancreatectomy 
between 2008 and 2012 in the Department of Gastroenterological Surgery of 
our hospital, and who had not been treated with oral hypoglycaemic agents or 
insulin. They were classified into normal glucose tolerance (NGT, n=13), im-
paired glucose tolerance (IGT, n=9), and diabetes mellitus (DM, n=10). Their 
insulin secretory capacity was evaluated by homeostasis model assessment 
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of beta-cell function [HOMA-beta, fasting immunoreactive insulin (µIU/
ml) x 20 / (fasting plasma glucose (mmol/l)- 3.5)], C-peptide index [fasting 
C-peptide (nmol/l)/ fasting plasma glucose (mmol/l)], insulinogenic index 
[∆ serum insulin 0-30 min (pmol/l) / ∆ plasma glucose 0-30 min (mmol/l) 
in 75 g-OGTT] and ΔC-peptide by glucagon test [ΔC-peptide, increment of 
serum C-peptide (nmol/l) at 6 min after intravenous injection of 1-mg gluca-
gon]. Pancreatic samples were fixed in formaldehyde, embedded in paraffin 
for subsequent analysis and cut from these paraffin blocks into 5-μm thick 
sections. We used immunohistochemistry to determine pancreatic beta-cell 
area. The relative beta-cell area represented the proportion of insulin-positive 
cell area to whole pancreatic section (%).
Results: The mean of relative beta-cell area was 1.072±0.424, 0.998±0.419 
and 0.762±0.441%, in NGT, IGT and DM, respectively. ΔC-peptide (r=0.64, 
p=0.002), HOMA-beta (r=0.50, p=0.003) and C-peptide index (r=0.36, 
p=0.042) correlated significantly and positively with the relative beta-cell 
area. Insulinogenic index tended to correlate positively but not significantly 
with the relative beta-cell area (r=0.33, p=0.078). Among them, ΔC-peptide 
showed the closest association with the relative beta-cell area. Age tended 
to correlate negatively but not significantly with the relative beta-cell area 
(r=-0.33, p=0.066). Neither BMI nor HbA1c showed a significant correlation 
with the relative beta-cell area (r=0.26, p=0.147; r=-0.16, p=0.378, respec-
tively). Glucose levels at 0, 30, 60, 120 min in 75 g-oral glucose tolerance test 
(OGTT) tended to correlate negatively with the relative beta-cell area (r=-
0.26, p=0.145, r=-0.30, p=0.105, r=-0.31, p=0.087, r=-0.34, p=0.064, respec-
tively), while the area under the curve of plasma glucose level from 0 to 120 
min in 75 g-OGTT correlated significantly and negatively with the relative 
beta-cell area (r=-0.36, p=0.045).
Conclusion: ΔC-peptide by glucagon test, HOMA-beta, and CPI correlated 
closely with beta-cell area, and ΔC-peptide was the most valuable index for 
the prediction of beta-cell mass.
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Normal meal tolerance test is more valuable than glucagon stimulation 
test in type 2 diabetes
Y. Fujioka, T. Ohkura, K. Shoji, K. Sumi, H. Shiochi, N. Yamamoto,  
K. Matsuzawa, A. Murawaki, S. Izawa, H. Ohkura, M. Kato, S. Taniguchi,  
K. Yamamoto;  
Tottori University Faculty of Medicine, Yonago, Japan.
Background and aims: The glucagon stimulation test (GST) is a standard 
method of evaluating endogenous insulin secretion. However, the GST has 
adverse effects and takes effort. In contrast, the meal tolerance test (MTT) has 
no adverse effect and cheaper than GST. Moreover, to perform the MTT by 
normal meal is important to evaluate insulin secretion in real life. However, 
the MTT is affected by the glucotoxicity than GST in the hyperglycemic state. 
The aim of this study is to evaluate the properties of the glucagon stimulation 
test and normal meal tolerance test in type 2 diabetes patients.
Materials and methods: We enrolled 142 patients of type 2 diabetes (mean: 
age 61.0, M/F: 80/62, BMI 24.7, HbA1c 9.4) and performed the GST and the 
MTT. We performed the MTT by using a normal diabetes food of 30kcal/ day 
per ideal body weight, which contains 60% of carbohydrates, protein 20%, 
lipid 20%. In the MTT, patients continued oral hypoglycemic agents and in-
sulin treatment as usual. In the MTT, we measured plasma glucose (PG) and 
serum C-peptide immunoreactivity (CPR), and plasma insulin level before 
and 120minutes after meal load. We calculated increment of CPR (ΔCPR) by 
subtracting fasting CPR (FCPR) from 6 minutes after glucagon injection and 
120 minutes after meal load.
Results: The mean fasting PG (FPG) was 154 mg/dl, the mean FCPR was 2.2 
ng/ml, the mean GSTΔCPR was 2.0 ng/ml, and the mean MTTΔCPR was 
3.1 ng/ml. 104 patients represent higher ΔCPR in the MTT than the GST, 
and the mean MTTΔCPR was significantly higher than the mean GSTΔCPR 
(P<0.01). To exclude influence of antidiabetic drugs, we examined 42 subjects 
that did not use antidiabetic agents. The mean GSTΔCPR was 2.4 ng/ml, and 
the mean NMTTΔCPR was 4.3 ng/ml and the mean MTTΔCPR was signifi-
cantly higher than the mean GSTΔCPR (P<0.01). To consider influence of 
glucotoxicity to both test, we performed ROC analysis by FPG. The optimal 
cut point of the FPG was under 147 mg/dl to define the MTT superior to the 
GST (sensitivity 0.64, specificity 0.76, AUC 0.73).
Conclusion: The MTT could examine insulin secretion including incretin 
effect by the meal load, and it may be one of the reasons why the MTTΔCPR 
is higher than the GSTΔCPR. Therefore, the MTT could evaluate the endog-
enous insulin secretion ability more than the GST. However, the MTT is af-
fected by the glucotoxicity than the GST. We had better consider to perform 
the GST in the hyperglycemic state, especially FPG is 147mg/dl or more. We 
need to use the GST and the MTT properly by a level of the FPG. In conclu-
sion, the MTT is more valuable as an insulin secretion test in type 2 diabetes 
patients than the GST.
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Adaptation of beta cell response to carbohydrate loading: influence of 
insulin resistance
R. Bizzotto1, B.E. Hurwitz2,3, N. Schneiderman2,3, J.B. Marks4,  
A.J. Mendez2,4, A. Gonzalez2, N. Gonzalez2, M.M. Llabre2,3, E. Santini5,  
J.S. Skyler4, A. Mari1, E. Ferrannini5;  
1Institute of Biomedical Engineering, CNR, Padova, Italy, 2Behavioral 
Medicine Research Center, University of Miami, Miami, 3Department of 
Psychology, University of Miami, Coral Gables, 4Division of Endocrinology, 
Diabetes and Metabolism, Miller School of Medicine, University of Miami, 
Miami, USA, 5Department of Clinical & Experimental Medicine, University 
of Pisa, Italy.
Background and aims: To maintain euglycemia, the β-cell must cope with 
variable carbohydrate intake (ChI) and with insulin resistance. Aim of this 
study was to quantify how insulin secretion adapts to variable ChI in insulin 
sensitive (IS) and insulin resistant (IR) individuals.
Materials and methods: 143 nondiabetic subjects, aged 18-55 years were 
classified as IS (n=64) or IR (n=79) using the euglycemic clamp. On sequen-
tial days, subjects were given a meal every 3½ hours over a 14-hour period 
(4 meals/day), with standard (300 kcal) or double (600 kcal) ChI in random 
order. Serial measurements of glucose, insulin and C peptide were obtained. 
Model-based total insulin secretion, β-cell glucose sensitivity (slope of the 
glucose concentration-insulin secretion relationship), and potentiation (fold 
enhancement of glucose sensitivity from baseline) were calculated.
Results: Total insulin secretion increased from 300-kcal to 600-kcal ChI in 
both groups, and was higher in IR compared to IS (Table). β-cell glucose 
sensitivity followed a similar pattern. Potentiation was also increased with 
the ChI load, but in IR the increase was blunted. In IR, mean glucose levels 
and their increase from 300-kcal to 600-kcal ChI were higher than in IS. In 
multivariate regression, mean glucose was significantly positively related to 
ChI and negatively to insulin sensitivity, β-cell glucose sensitivity and poten-
tiation (r2 = 0.37, p<0.0001). In IR, the percentage of plasma glucose values 
≥11.1 mmol/L rose from 2.3% to 6% on doubling ChI, whereas it declined 
from 0.6% to 0.2% in the IS group.
Conclusion: Higher carbohydrate meal content elicited an insulin secretion 
response that was higher both in absolute terms and in relation to the glu-
cose levels; this response was enhanced in IR. However, the enhancement 
of potentiation from 300-kcal to 600-kcal ChI was impaired in IR subjects, 
in whom the up-regulation of β-cell glucose sensitivity compensation was 
insufficient to preserve glucose tolerance to the same extent as in IS subjects. 
Therefore, even in nondiabetic subjects insulin resistance is associated with a 
relative incompetence of β-cell function despite insulin hypersecretion.
Supported by: NIH-National Heart, Lung and Blood Institute grant HL081817
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Decrease in plasma mannose level after glucose load is associated with 
glucose tolerance: plasma mannose level as a putative indicator of 
glycogenolysis
S. Hirano1, K. Yoshimura1, H. Takata1, S. Ohmi1, T. Taguchi2, S. Yamada2,  
I. Miwa2, Y. Terada1, S. Fujimoto1;  
1Department of Endocrinology, Metabolism and Nephrology,  
Kochi University, Nankoku,  
2Department of Pathobiochemistry, Meijo University, Nagoya, Japan.
Background and aims: Mannose is a monosaccharide constituent of gly-
coproteins and glycolipids. Experiments in rats showed previously that the 
plasma mannose level decreases after glucose load which causes insulin se-
cretion in normal rats, but does not decrease in diabetic rats and that hepatic 
glycogenolysis is a source of this plasma mannose, but these results are not 
fully elucidated in human. Subjects with glucose intolerance have impaired 
secretion and sensitivity of insulin, which are the most important factors in 
suppression of glycogenolysis. To explore the possibility of the plasma man-
nose level as an indicator of glycogenolysis in human, the decrease in plasma 
mannose levels after glucose load in subjects with various degrees of glucose 
intolerance was examined and was analyzed to clarify association with clini-
cal factors.
Materials and methods: 75g OGTT was performed on Japanese subjects 
without diabetic medication from whom informed consent was obtained. 
Based on OGTT data, subjects were classified as normal (NGT), impaired 
glucose tolerance (IGT), and diabetes (DM) according to WHO criteria. In 
each group, 25 subjects were consecutively recruited [total 75 subjects, age: 
65±11 (mean±SD); male/female: 34/41; BMI: 24.9±3.8 (mean±SD)]. In-
sulinogenic index (IGI) as an index of insulin secretion and QUICKI and 
Matsuda index as indices of insulin sensitivity were calculated. Mannose was 
assayed using established method. Briefly, after labeling with 4-aminoben-
zoyl ethyl ester, the concentration of mannose was determined using HPLC. 
Glucose contained in samples was confirmed not to affect the assay. The study 
protocol was approved by the ethics committee of the institute.
Results: Plasma mean levels of glucose during 120 min (Gm) were signifi-
cantly different among groups [NGT: 138±20, n=25; IGT: 178±27, n=25; DM: 
226±24 mg/dl, n=25, (means±SD)], while mean IRI during 120 min (Im) did 
not significantly differ. Basal levels of mannose were similar among groups 
(NGT: 40.8±10.0; IGT: 43.7±11.2; DM: 45.0±12.0 μM). After glucose load, 
the plasma mannose level was decreased gradually and reached plateau at 
90 min in NGT, but was not decreased significantly in DM. Plasma changes 
of mannose during 120 min from base line (M120-M0) were significantly 
different among groups (NGT: -16.7±8.2; IGT: -9.0±9.8; DM: -1.4±9.3 μM, 
P<0.001 ANOVA). Simple regression analysis revealed that M120-M0 was not 
significantly associated with Im, but was significantly associated with IGI 
(R=-0.282, P=0.014), QUICKI (R=-0.237, P=0.041), Matsuda index (R=-
0.254, P=0.027), and Gm (R=0.544, P<0.001).
Conclusion: The plasma mannose level was decreased after glucose load in 
normal glucose tolerance, but was not decreased in diabetes. The decrease in 
plasma mannose level after glucose load was associated with glucose toler-
ance, represented by the mean glucose level after glucose load. Moreover, it 
was associated with indices of insulin secretion and insulin sensitivity. These 
results support the possibility of the plasma mannose level as an indicator of 
glycogenolysis in human.
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Analysis of pancreatic response after oral glucose tolerance test in adults 
with cystic fibrosis
I. Sánchez-López1, M.A. Sampedro-Núñez1, S. Campos1, A. Vicuña1,  
M. Zelada1, M.Á. Maillo1, A. Mossé1, A.M. Ramos-Leví1, R.M. Girón2,  
M. Marazuela1, A. Arranz1;  
1Endocrinology,  
2Pulmonary Medicine, Hospital Universitario de La Princesa, Madrid, Spain.
Background and aims: Abnormalities in carbohydrate metabolism are par-
ticularly relevant in adults with cystic fibrosis (CF) because of their high 
prevalence (about 75 percent), and impact on morbidity and mortality in 
these patients. Oral glucose tolerance test (OGTT) provides important infor-
mation about pancreatic secretion in these subjects. The aim of this study is 
to analyze baseline and pancreatic response along OGTT in adults with CF.
Materials and methods: Retrospective study based on the performance of 
OGTT in 37 adult patients with CF followed in our hospital. Glucose, C-
Peptide and insulin were measured at fasting and at 30, 60, 90 and 120 min-
utes after a 75 grams glucose load. According to the results, patients were 
classified into: normal glucose tolerance (NGT), impaired glucose tolerance 
(IGT), indeterminate glycemia (INDET) and cystic fibrosis-related diabetes 
(CFRD). The following insulin secretion indexes were determined: HOMA-
ß, insulinogenic index (II) and first phase-OGTT (F1OGTT). Areas under 
the curve (AUC) were calculated for each group, and variance for the differ-
ent variables was analyzed. Statistical analysis was performed using SPSS for 
Windows, version 15.0.
Results: 37 patients. OGTT Results: 35.1% NGT; 32.4% IGT; 13.5% INDET; 
18.9% CFRD. Significant differences (p < 0.05) between groups were obtained 
at all times of the glucose curve except at fasting, and at 120 minutes for the 
ratio glucose/insulin. A greater glucose AUC in CFRD patients and a greater 
overall insulin and C-Peptide secretion in NGT and INDET groups were ob-
served. In early stages of the OGTT, lower values of insulin and HOMA-ß, II 
and F1OGTT indexes were observed in INDET group (p < 0.05). However, 
from time 60 min onwards, an increased insulin response in INDET group 
was observed compared to the rest.
Conclusion: OGTT shows a progressive deterioration of insulin secretion 
in prediabetic states. INDET and IGT subjects have a failure of the early re-
sponse and a delayed pancreatic secretion as a preliminary step to the devel-
opment of CFRD.
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Relationship of whole-body fuel oxidative partitioning with insulin 
secretion and beta cell function in non-diabetic humans
J.E. Galgani1, M.L. Mizgier1, A. Mari2, E. Ravussin3;  
1Pontificia Universidad Catolica de Chile, Santiago, Chile,  
2Istituto di Ingegneria Biomedica, Padova, Italy,  
3Pennington Biomedical Research Center, Baton Rouge, USA.
Background and aims: It is commonly reported that whole-body insulin 
sensitivity is inversely related with glucose-stimulated insulin secretion. This 
finding suggests a putative crosstalk between peripheral organs and pancreas. 
Such organ crosstalk could be mediated by changes in glucose flux (i.e. up-
take, oxidation or storage) in insulin-sensitive tissues, which may lead to the 
release of a circulating factor driving insulin secretion. To gain insight on 
such a metabolic feedback loop, we related fasting, postprandial and 24-hour 
whole-body non-protein respiratory quotient (npRQ), an index of fuel oxi-
dative partitioning (i.e. carbohydrate relative to fat oxidation), with insulin 
secretion and beta cell function in non-diabetic individuals.
Materials and methods: Thirty non-diabetic participants (15/15 males/
females; 35±12 [SD] years old; 27±4 kg/m2) were studied over three days. 
On day 1, npRQ was determined under fasting and postprandial (75-gram 
oral glucose tolerance test, OGTT) conditions. On day 2, participants spent 
24 hours in a respiratory chamber while fed with a standard, isoenergetic 
mixed diet. On day 3, insulin sensitivity was assessed by a 2-hour euglycemic-
hyperinsulinemic clamp. Insulin secretion was estimated by deconvolution 
of serum C-peptide concentration (fasting and postprandial) or 24-hour 
urinary C-peptide excretion (corrected for energy intake). In addition, beta 
cell function parameters including rate sensitivity (indicative of first-phase 
glucose-induced insulin response) and glucose sensitivity (slope of the glu-
cose concentration vs. insulin secretion relationship) were calculated by 
mathematical modelling.
Results: Insulin secretion estimated over 24 hours from urinary C-peptide 
excretion was directly related with fasting (r=0.64; p<0.001) and glucose-
stimulated (r=0.66; p<0.001) insulin secretion. The classical inverse asso-
ciation between insulin sensitivity (by clamp) and insulin secretion was also 
confirmed over 24 hours (r=-0.62; p<0.01), in response to an OGTT (r=-0.50; 
p<0.01) and overnight fasting (r=-0.40; p<0.05). Interestingly, insulin secre-
tion (from urinary C-peptide excretion) was inversely correlated with 24-
hour npRQ (r=-0.61; p=0.001), even after controlling for insulin sensitivity 
and energy balance (r=-0.52; p=0.01). However, fasting or glucose-stimulated 
npRQ did not correlate with insulin secretion rate (from serum C-peptide). 
Fasting npRQ correlated directly with rate sensitivity (r=0.40; p<0.05), while 
the association with glucose sensitivity was borderline (r=0.34; p=0.08).
Conclusion: Fuel oxidative partitioning determined over a day appears to 
influence 24-hour insulin secretion, although such association did not hold 
when a shorter period was considered. In addition, the first-phase glucose-
induced insulin response (i.e. rate sensitivity) may be sensitive to the level 
of fasting fuel oxidative partitioning. These findings lend support to the hy-
pothesis that a crosstalk between peripheral tissues and pancreas plays a role 
on insulin secretion. Intervention studies targeting peripheral (e.g. skeletal 
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muscle) carbohydrate oxidation and its effect on insulin secretion deserve 
further research.
Supported by: CNRU P30 DK072476 & FONDECYT 1130217
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Role of parasympathetic activity in insulin secretion in metabolically 
healthy obese patients
C. Cussac-Pillegand, S. Chiheb, Y. Jaber, C. Cyrille, R. Duteil, E. Cosson,  
P. Valensi;  
AP-HP, Jean Verdier Hospital, Bondy, France.
Background and aims: Cardiac parasympathetic activity is often altered in 
obese non-diabetic patients, even in the metabolic healthy obese individuals. 
We here hypothesized that the persistance of a good parasympathetic activ-
ity could contribute to a better insulin secretion in the presence of insulin 
resistance.
Materials and methods: We recruited 47 obese patients (BMI 42.3±6.5 kg/
m², 35.5±12.7 years). Among them 31 with only one criterion of the meta-
bolic syndrome (fasting hyperglycemia in only one patient) in addition to 
a large waist circumference was considered as metabolically healthy. Car-
diac parasympathetic activity (HF-HR) and vascular sympathetic activity 
(LF-SBP) were evaluated by spectral analysis of heart rate (HR) and systolic 
blood pressure (SBP) variations (Finapres®), respectively. An oral glucose 
tolerance test was performed. Two indexes of insulin resistance (Matsuda 
and HOMA-IR), and composite indexes of insulin secretion (insulinogenic 
index=IGI=Δinsulinemia(T0-T30)/Δglycemia(T0-T30); and oral disposition 
index=ODI=IGI/insulinemia) were calculated.
Results: Patients with a lower parasympathetic activity (HF-HR<median 
value: 2.61) had a lower Matsuda index (p=0.012), and ODI (p<0.03), higher 
plasma glucose levels at 90 and 120 min after glucose challenge (pmedian val-
ue) while age and BMI were similar. In metabolically healthy patients, but not 
in patients with more metabolic criteria, the same results were found, notice-
ably with plasma glucose during OGTT (at 60, 90, 120, 150, 180 min; p=0.007 
to 0.058) and LF-SBP (p=0.006) higher in those with HF-HR<median, and a 
significant correlation of ODI with HF-HR (r=0.464, p=0.008).
Conclusion: These results strongly suggest that vagal activity contributes to 
enhance insulin secretion in insulin resistant obese individuals. In metaboli-
cally healthy obese patients, low vagal activity together with a predominant 
sympathetic activity is associated with a more marked insulin resistance and 
reduced compensatory insulin secretion, leading to glucose disorders.
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Impact of serum triglyceride and HDL-cholesterol levels on early-phase 
insulin secretion in prediabetic subjects
M. Shimodaira, T. Niwa, K. Nakajima, M. Kobayashi, N. Hanyu;  
Department of Internal Medicine, Iida Municipal Hospital, Japan.
Background and aims: β cell dysfunction plays a fundamental role in the 
onset and progression of type 2 diabetes (T2DM), and the loss of early-phase 
insulin secretion is thought to be an early marker of T2DM. Recent studies 
have shown that increased triglycerides (TG) and decreased HDL-cholesterol 
(HDL-C) levels are risks for the onset of T2DM. However, in subjects with 
prediabetes (impaired fasting glucose, impaired glucose tolerance and the 
two combined), the association between lipid profiles and insulin secretion 
has not been well studied. The aim of this study was to investigate the rela-
tionship between serum TG and HDL-C levels and early-phase insulin se-
cretion following a 75-g oral glucose tolerance test (OGTT) in prediabetic 
subjects.
Materials and methods: We evaluated 663 prediabetic subjects (322 males 
and 341 females; age, 52 ± 8 years; BMI, 23.8 ± 3.1) who were not taking 
lipid-lowering agents. Prediabetes was defined as fasting plasma glucose of 
5.6-6.9 mmol/L or 2h post-challenge plasma glucose of 7.8-11.0 mmol/L. 
Insulin secretion was estimated by the insulinogenic index (IGI) [Δinsulin/
Δglucose (30 min-0 min)] and disposition index (DI; IGI/HOMA-IR), which 
is an adjusted measure of β cell function that accounts for variations in insu-
lin sensitivity. The relationship between continuous variables was examined 
by Pearson’s linear regression analysis. A stepwise multiple linear regression 
analyses was performed to assess independent relationships between DI and 
the clinical variables including age, sex, BMI, blood pressure, uric acid, total 
cholesterol (TC), TG, HDL, LDL-cholesterol (LDL-C), HbA1c, eGFR and 
smoking status. Because of collinearity between TG and HDL-C, two regres-
sion models were performed, which took into account each of these variables.
Results: Pearson’s linear regression analysis revealed that IGI and DI were 
positively correlated with HDL-C levels (r = 0.264, P = 0.004 and r = 0.278, P 
= 0.002, respectively). Moreover, the indices were negatively correlated with 
the log-transformed TG (r = −0.190, P = 0.006 and r =−0.133, P = 0.004, 
respectively). However, TC and LDL-C were not associated with indices of 
insulin secretion. Multivariate linear regression analyses revealed that DI was 
independently and positively correlated with HDL-C (β = 0.149, P = 0.004) 
and negatively with log-transformed TG (β = −0.249, P = 0.004).
Conclusion: Our results provide evidence that, in prediabetic subjects, lower 
HDL-C and higher TG levels are associated with dysfunctional early-phase 
insulin secretion. Thus, more attention should be placed on serum HDL-C 
and TG levels in prediabetic subjects because of their potential progression 
to T2DM.
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Most people with long duration of type 1 diabetes are insulin 
microsecretors and produce their own endogenous insulin
T.J. McDonald1, R. Oram1, B. Shields1, E. Pearson2, A. Hattersley1;  
1University of Exeter Medical School,  
2University of Dundee, Medical Research Institute, UK.
Background and aims: Ultrasensitive assays that can detect C-peptide un-
der5 pmol/L allow detection of very low levels of c-peptide. We aimed to use 
urine c-peptide creatinine ratio (UCPCR) to assess endogenous insulin in a 
large cross-sectional population-based study of patients with Type 1 diabetes 
(T1D).
Materials and methods: We recruited 944 patients from primary and sec-
ondary care in 2 UK centres. All diagnosed under 30 years, duration >5 years, 
clinical diagnosis of T1D. Median(IQR) age of diagnosis 11(6-17)y, duration 
18(11-26)y, HbA1c 8.7(7.9-9.8)%, insulin dose 0.78(0.60-0.97)u/kg/24hr, and 
BMI 25.6(23.3-28.6)Kgm-2. All provided a home post-meal UCPCR.
Results: 81% (790/944) had detectable endogenous production (median(IQR) 
UCPCR 0.012 (0.004-0.038)nmol/mmol). Most had very low, historically un-
detectable, levels (492/944, 53%, UCPCR >0.001-0.03 nmol/mmol). 8% had 
C-peptide levels above the DCCT cut off of significant endogenous insulin. 
Absolute UCPCR levels fell with duration but the proportion with detectable 
UCPCR never fell below 73% (maximum duration 47 years).Age of diagnosis 
and duration independent predictors of C-peptide in multivariate modelling.
Conclusion: The majority of patients with long duration T1D are insulin 
microsecretors and have detectable urine c-peptide. Some rare individuals 
with T1D maintain higher levels of endogenous insulin for many years after 
diagnosis of diabetes. The fact that some beta cells remain in most with long-
standing T1D may reflect escape from immune attack, or beta cell regenera-
tion. Understanding this may lead to a better understanding of pathogenesis 
in T1D and open new possibilities for treatment.
Supported by: HICF
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Presence and titer of GAD antibodies are determinants of beta cell 
function in patients with newly diagnosed type 2 diabetes mellitus: 
further insights in the metabolic phenotype of LADA patients
M. Trombetta1, L. Boselli1, C. Brangani1, F. Zardi2, C. Negri3, V. Stoico3,  
E. Bonora1, R. Bonadonna4;  
1Medicine, University of Verona, 2Hospital of Bolzano, 3AOUI of Verona, 
4Medicine, University of Parma and AOUI of Parma, Italy.
Background and aims: Latent Autoimmune Diabetes in Adults (LADA) is 
a metabolic disorder at the crossroad between type 1 (T1DM) and type 2 
diabetes (T2DM). Aim of our study was to carefully assess beta cell function 
and insulin sensitivity in patients with LADA, in comparison to patients with 
either type 2 diabetes clinically undistinguishable from LADA or typical type 
2 diabetes.
Materials and methods: In 35 (M/F=19/16) patients (mean±SEM: age 
57.4±1.6 years, BMI 27.5±0.9 kg/m2) with newly diagnosed LADA were com-
pared to 35 patients with newly diagnosed T2DM matched for age, gender, 
BMI and HbA1c (LADA-like). The latter group was extracted from the data-
base of the Verona Newly Diagnosed Type 2 diabetes (VNDS; N=589 GADA-
negative patients) The rest of VNDS patients herein represent typical T2DM. 
LADA patients were further divided in two groups according to GADA levels 
(median 4 kU/L): low GAD-LADA (GADA below 4kU/L)and high GAD-
LADA (GADA above 4kU/L). In all patients we performed on separate days: 
1. prolonged (5-hours) frequently sampled OGTT to assess derivative control 
(DC) and proportional control (PC) of beta cell function by state of art math-
ematical modeling of glucose and C-peptide curves; 2. standard euglycemic 
insulin clamp to assess insulin sensitivity (SI).
Results: SI was not statistically different (p<0.12) in LADA-like and in 
LADA patients, but in the latter was higher (+28%) than in VNDS (812±66 
vs 635±16 µmol.min-1.m-2 BSA, respectively; p=0.01). The DC of beta cell 
function was impaired in LADA compared to LADA-like (p<0.01) and to 
VNDS (p<0.05). The PC in LADA was similar to LADA-like (p=0.42), but it 
was reduced when compared to VNDS (p<0.03). High GAD- and low GAD-
LADA had similar SI, but the former had worse PC of beta cell function than 
the latter (p<0.01).
Conclusion: Patients with newly diagnosed LADA display more severe de-
fects in beta cell function even when compared to LADA-like patients with 
newly diagnosed T2DM; furthermore, the higher the GADA titer, the worse 
is beta cell dysfunction. These data may be of help in optimizing metabolic 
therapy and in refining metabolic prognosis of these patients.
Clinical Trial Registration Number: NCT01526720
Supported by: EFSD/Novo Nordisk, MIUR
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Influence of the human herpes virus 8 infection on beta cell function and 
insulin sensitivity in ketosis prone diabetes
J.-L. Nguewa1, F. Agbalika2, B. Baz1, S. Chon1, P. Boudou3, J.-P. Riveline1,  
S.P. Choukem4, E. Sobngwi5, J.-F. Gautier1;  
1University Center for Diabetes and its Complications, Endocrinology 
and Diabetology Department, Lariboisiere Hospital, 2Department of 
Microbiology, 3Department of Hormonology and Biochemistry, St. Louis 
Hospital, Paris, France, 4Endocrinology and Diabetology Department, 
University of Buea, 5Endocrinology and Diabetology Department, Nationa 
Obesity Center, Yaounde, Cameroon.
Background and aims: Ketosis Prone diabetes (KPD), an atypical diabetes 
with ketosis at onset and absence of β-cell autoantibodies is characterized 
after the ketotic episode by long-term non-insulin dependence (remission) 
for a majority of patients. Human herpes virus 8 (HHV-8) infection has been 
associated with KPD in patients of sub-Sahara African origin. Our objec-
tive was to investigate whether HHV-8 infection impacts on insulin secretion 
and/or insulin sensitivity in KPD at different stages of the disease.
Materials and methods: We compared patients with (KPD+) and without 
(KPD-) HHV-8 infection in 3 different groups. In group 1, 11 KPD+ and 7 
KPD- in remission (HbA1c level <7.0% at least 3 months apart after with-
drawal of exogenous insulin treatment) underwent an OGTT, a glucose 
ramping + arginine test and a hyperinsulinemic euglycaemic clamp. Group 2 
consisted of 17 KPD+ and 11 KPD- explored one week after ketosis resolution 
by C-peptide measurement in response to IV glucagon (delta C-peptide) and 
by the short insulin tolerance test (ITT). In group 3, we enrolled 40 KPD+ 
and 59 KPD- hospitalized for treatment adjustment because of elevated A1c. 
All KPD underwent delta C-peptide at 2 different occasions (V1 and V2). 
V1 was made 3.1±2.5 [mean±SD] years after the diagnosis of diabetes and 
V2 conducted 3.6±5.4 years after V1. Detection of HHV-8 antibodies was 
performed using 3 techniques, one for detection of antibodies against lytic 
antigens, a second against latent nuclear antigens and the last detecting the 
HHV-8 capsid protein.
Results: In each group, KPD- and KPD+ were comparable in terms of age, 
age at diabetes diagnosis, duration of diabetes, duration of remission (group 
1), BMI and HbA1c (group 1, group 2). In group 1, the insulinogenic index 
and insulin secretion rates were higher in KPD+ compared to KPD-, whereas 
insulin secretion in response to arginine and insulin sensitivity were similar. 
In group 2, delta C-peptide was up to 3-fold higher in KPD+ compared to 
KPD- while the glucose disappearance rate KITT were similar between the 2 
groups. In group 3, A1c levels in KPD+ were lower than KPD- and delta C-
peptide was higher in KPD+ compared to KPD- at V1 and V2.
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Conclusion: In conclusion, either in remission, shortly after ketosis resolu-
tion or during long term follow-up, latent HHV-8 infection is associated with 
better insulin secretion in response to glucose in patients of sub-Saharan Af-
rican origin with KPD. Mechanisms by which latent HHV-8 infection impact 
on β-cell functions need to be unraveled.
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Correlation between the indices for glycaemic variability and 24-hour 
urinary C-peptide values in patients with type 1 diabetes mellitus as 
assessed by CGM
C. Seo, R. Nishimura, Y. Onda, D. Tsujino, K. Andou, K. Ustunomiya;  
Division of Diabetes, Metabolism and Endocrinology Department,  
The Jikei University School of Medicine, Tokyo, Japan.
Background and aims: Loss of pancreatic cell function, abnormal secretion 
of the counter-regulatory hormones, inappropriate treatment, insulin resist-
ance, malingering/manipulation, concomitant diseases such as infection and 
some other endocrine disease, and mental/somatic stress are reported to be 
among the factors that tend to make glycemic control difficult in patients 
with type 1 diabetes. First and foremost of these are, however, loss of pan-
creatic β cell function and abnormal secretion of the counter-regulatory hor-
mones. Therefore, stable glycemic control becomes progressively lost with the 
loss of pancreatic β cell function. While, generally, it often proves extremely 
difficult to achieve glycemic control in type 1 diabetes, not all patients with 
type 1 diabetes exhibit unstable diabetes and a subset of patients exhibit stable 
glycemic control. In the latter patients, pancreatic β cell function is shown to 
be preserved to a certain extent, thus contributing to their stable glycemic 
control. However, to date, there are very few studies in which residual pan-
creatic β cell function was examined for correlation with glycemic variation 
evaluated by using Continuous Glucose Monitoring(CGM) that allows glu-
cose levels to be measured on a continuous basis.
Materials and methods: Of all patients being treated with intensive insulin 
therapy (excluding Continuous Subcutaneous Insulin Infusion) and moni-
tored by CGM, a total of 59 patients with type 1 diabetes (males/females, 
20/39) with detectable urinary C-peptide immunoreactivity (U-CPR) from 
24-hour samples were included in the study. Values measured for continu-
ous 24 hours and free from measurement errors were used for current analy-
sis. U-CPR values were used as an index for insulin-secretory capacity and 
the SD of 24hour-glucose concentration was used as an index for stability 
of glycemic control. The subjects’ U-CPR values were examined for correla-
tion with their duration of disease, BMI, and HbA1c values, as well as the SD 
of their glucose concentration. Statistical analyses were performed by using 
SPSS 17.0. Spearmann’s rank sum correlation coefficients were used to test for 
correlation between the variables examined.
Results: All data are shown as median and interquartile range. The subjects’ 
median U-CPR value was 1.4 (0.9-6.9) μg/day, their median age 39 (32-58) 
years, duration of disease 11 (6-22) years, BMI 21.2 (19.4-23.2) kg/m2, HbA1c 
value 8.0 (7.1-9.4)% ,their total insulin dose 36 (28-48) units, and their basal 
insulin ratio(basal insulin dose/total insulin dose) 44.4 (37.5-54.3)%. A sig-
nificant negative correlation was noted between their U-CPR values and the 
SD of their glucose concentration (r = -0.305; P = 0.019) , as well as between 
their U-CPR values and their duration of disease (r = -0.353; P = 0.006),and 
between their U-CPR values and their basal insulin ratio (r = -0.268; P=0.040) 
. However, there was no significant correlation between their U-CPR values 
and their age, BMI, HbA1c values or total insulin units.
Conclusion: Our study demonstrated that the lower the U-CPR values in 
patients with type 1 diabetes, the greater their glycemic variability and that 
the longer their duration of disease, the lower the U-CPR values, suggesting 
that U-CPR assessment may have a key role in predicting glycemic variations 
in patients with type 1 diabetes.
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Factors affecting glycaemic variability in patients with type 2 diabetes
S.-Y. Yoo1, S.-A. Lee1, H.-J. Chin2, D.-H. Lee3, G. Koh1;  
1Department of Internal Medicine, Jeju National University Hospital, 
2Department of Internal Medicine, Hankook General Hospital, Jeju, 
3Department of Internal Medicine, Wonkwang University Hospital, 
Jeollabuk-do, Republic of Korea.
Background and aims: It is not widely known about factors determining glu-
cose fluctuations in diabetic patients. Also, the role of glycemic variability in 
the development of cardiovascular diseases remains controversial. We inves-
tigated the relationship between indices of glycemic variability, cardiovascu-
lar (CV) risk factors, and clinical and laboratory variables in type 2 diabetic 
patients.
Materials and methods: We enrolled 236 type 2 diabetic patients which per-
formed a 7-point SMBG more than once during each month for 3 consecu-
tive months. From their SMBG data, glycemic variability indices (standard 
deviation (SD) and M-value) were calculated monthly. HbA1c was measured 
on the last day of the third month. BMI, waist circumference (WC), blood 
pressures (BP), duration of diabetes, hsCRP, fibrinogen, ALT, GGT, creati-
nine, uric acid, total cholesterol, triglyeride (TG), HDL-C, LDL-C, urine 
albumin:creatinine ratio (UACR) and ankle-brachial pressure index (ABI) 
were assessed. Treatment stage of diabetes was defined based on the number 
of oral hypoglycemic agents and the administration of insulin. The 10-year 
risk for CVD was calculated using 2013 ACC/AHA Prevention Guidelines 
Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator.
Results: The SD was significantly correlated with duration of diabetes 
(r=0.291; p<0.001) and UACR (r=0.144; p=0.028), but not with BMI, WC, 
BP, hsCRP, fibrinogen, ALT, GGT, creatinine, uric acid, lipid profile and ABI. 
The M-value was correlated with duration of diabetes (r=0.301; p<0.001), 
UACR (r=0.210; p=0.001), BMI (r=0.129; p=0.049), WC (r=0.163; p=0.013) 
and TG (r=0.181; p=0.005), but not with other parameters. Using hierarchical 
regression analysis to adjust for HbA1c and other covariates, only diabetes 
duration remained independent correlate of the SD (β=0.200, p<0.01) and 
M-value (β=0.154; p<0.01). CV risk factors failed to maintain its independ-
ent association. The patients were divided into three groups according to 
diabetes treatment stage and 10-year ASCVD risk, respectively. SD and M-
value showed significant differences according to increasing treatment stage 
(pANOVA<0.001; pTREND<0.001 and pANOVA<0.001; pTREND<0.001, 
respectively), but not increasing 10-year ASCVD risk (pANOVA=0.707; 
pTREND=0.518 and pANOVA=0.472; pTREND=0.780, respectively).
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Conclusion: In this study, duration of diabetes rather than CV risk factors 
was an independent variable of indices of glycemic variability. And the in-
dices were positively correlated to treatment stage of diabetes more than 10-
year ASCVD risk. These findings suggest that glycemic variability is largely 
determined by β-cell function which deteriorates with increasing duration of 
diabetes, but not cardiovascular complication.
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Loss of glucose sensitivity and islet neogenesis predict the occurence of 
diabetes after acute beta cell reduction
A.V. Sun1, T. Mezza1, G. Sorice1, C. Conte1, C. Cefalo1, R.N. Kulkarni2,  
A. Mari3, A. Giaccari1;  
1Catholic University, Rome, Italy, 2Joslin Diabetes Center, Boston, USA, 
3CNR, Padova, Italy.
Background and aims: Progressive deterioration in β cell function and de-
crease in β cell mass represent the main mechanisms involved in type 2 dia-
betes. To investigate if the deterioration of the β cell function corresponds to 
a loss of β cell mass, we performed oral glucose tolerance tests (OGTT), hy-
perglycemic clamps (HC) and followed by arginine stimulation in 16 patients 
undergoing pancreatoduodenectomy (PD), pre- and post-surgery. To further 
explore whether Islet features could be justified by in vivo beta cell function, 
we explored neogenesis from duct cells, islet size and trans-differentiation of 
α cells to β cells.
Materials and methods: Based on post-surgery OGTT, subjects were divided 
into 3 groups of glucose tolerance: normal (NGT, n=5), impaired (IGT, n=4) 
or diabetes (DM, n=7) (8 F/8 M, 51±15 yrs.). To evaluate β cell function, β 
cell glucose sensitivity (GS) during HC was calculated as the ratio of insulin 
secretion and glucose increments. During surgery, pancreas samples were 
collected for IHC for glucagon, insulin and somatostatin+ cells to assess islet 
morphology. Ductal cells were stained by CK19.
Results: Before surgery, Arginine-stimulated Insulin Secretion (AIS) was 
similar across groups, whereas GS was lower in IGT and DM as compared 
with NGT subjects (62.9±23.1 and 45.5±11.2 vs 90.6±18.7 pmol•min-1•m-2, 
respectively). Following 50% PD, GS decreased in all patients (p<0.01 for all 
groups), but the reduction was greater in DM compared to IGT and NGT pa-
tients (ΔGS: NGT -0.20±0.19 vs. IGT -0.27±0.11 vs. DM 0.37±0.08; p<0.003). 
A similarly scaled reduction was observed in ΔAIS (NGT -0.38±0.13 vs. IGT 
-0.76±0.06 vs. DM -0.90±0.04; p<0.01) and in 2nd phase insulin secretion. 
IHC demonstrated an increase in islet size, insulin+ CK19+cells (p<0.05) and 
scattered islets (<8 cells) (p=0.01) in DM patients, as compared with NGT 
and IGT.
Conclusion: In this study, loss of GS was the most reliable parameter for 
predicting the appearance of diabetes after 50% PD. Increased islet size and 
neogenesis could be compensatory mechanisms to cope with reduced func-
tion (GS) and to preserve β cell mass, at least as estimated by AIS. However, 
increased islet size does not seem to be able to compensate for the loss of 
glucose sensitivity.
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Serum bilirubin concentrations are positively associated with serum 
C-peptide levels in patients with type 2 diabetes
J.-O. Chung, D.-H. Cho, D.-J. Chung, M.-Y. Chung;  
Chonnam National University Medical School, Gwangju, Republic of Korea.
Background and aims: Bilirubin, the natural end product of heme metabo-
lism, has been recognized as a potent endogenous antioxidant. Several clini-
cal studies have demonstrated the inverse correlation between serum biliru-
bin levels and the risk of diabetes. However, the relationship between serum 
bilirubin levels and serum C-peptide levels in patients with type 2 diabetes 
has not been fully understood. The aim of the study was to investigate the 
relationship between physiological serum total bilirubin concentrations and 
serum C-peptide levels in Korean patients with type 2 diabetes.
Materials and methods: A total of 588 patients with type 2 diabetes (M: 337, 
F: 251, mean age 56.4 ± 13.6 years) were investigated in this cross-sectional 
study. All patients were allowed to eat a standardized meal. Fasting C-peptide 
level, 2-hour postprandial C-peptide level, and ΔC-peptide (postprandial C-
peptide minus fasting C-peptide) level were measured in all patients.
Results: Fasting C-peptide level, postprandial C-peptide level, and ΔC-
peptide level tended to be higher in patients with increased bilirubin con-
centrations. Partial correlation analysis showed that serum bilirubin levels 
were significantly correlated with fasting C-peptide level (r=0.159, P < 0.001), 
postprandial C-peptide level (r=0.209, P < 0.001), and ΔC-peptide level 
(r=0.186, P < 0.001) after adjustment for other covariates. In the multivariate 
model, the association between serum bilirubin concentrations and serum 
C-peptide levels remained significant, after adjustment for confounding fac-
tors including age, gender, familial diabetes, hypertension, hyperlipidemia, 
body mass index, glycated hemoglobin, duration of diabetes, and associated 
liver function tests (fasting C-peptide level: β=0.083, P=0.041; postprandial 
C-peptide level: β=0.106, P=0.005; ΔC-peptide level: β=0.096, P=0.015, re-
spectively).
Conclusion: Serum bilirubin concentrations within the physiologic range 
were positively associated with serum C-peptide levels in patients with type 
2 diabetes.
 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 216 
1 C
517
Improved beta cell and disposition function leads to reduction in daily 
insulin dosage over time in patients with type 2 diabetes treated by long-
term CSII therapy
S. Choi1, E. Hong1, K.-J. Kim1, H. An1, Y. Noh2;  
1Endocrinology and Metabolism, 2Biochemistry, School of Medicine, 
Konkuk University, Seoul, Republic of Korea.
Background and aims: We observed the daily insulin dosage required to 
maintain normoglycemia decreased over time during long-term continu-
ous insulin infusion (CSII) therapy in patients with type 2 diabetes. To see if 
the decreased daily insulin dosage is related to changes in beta cell function 
and insulin resistance during CSII therapy, we examined changes in C-pepti-
dogenic Index (CI), Matzda Index (MI), and disposition Index (DI; product 
of CI and MI) for 1 year.
Materials and methods: Two hundred seventeen patients with type 2 dia-
betes (age, 59.1 ± 11.1 years; male, 113; female, 104; duration, 12.6 ± 10.2 
years; body mass index, 23.7 ±3.7 kg/m2; HbA1c 8.9 ± 2.1 %) were treated by 
CSII.Blood samplings were performed at baseline and 6 months and 1 year 
after CSII therapy (after overnight fasting and 2 hours after ingestion of 500 
kcal-mixed meal).
Results: After 1 year of CSII therapy, HbA1c decreased from 8.9 ± 2.1 to 7.3 
± 1.7 % (p < 0.001), serum C-peptide level increased from 4.8 ± 2.8 to 6.0 ± 
2.9 ng/ml (p < 0.001), and CI increased from 0.021 ± 0.018 to 0.029 ± 0.017 
(p < 0.001) at 2 hours after meal ingestion. DI increased from 0.060± 0.059 
to 0.069 ± 0.045 (p < 0.003). Daily insulin dosage decreased from 71.7 ± 34.4 
to 46.3 ± 31.1 IU/day (p<0.001). This decreased daily insulin dosage was as-
sociated with the increased value of CI, DI and MI significantly by multiple 
regression analysis (p < 0.05).
Conclusion: The resolution of glucotoxicity through long-term CSII therapy 
may contribute to restoration of beta cell function and disposition capability 
in type 2 diabetic patients.It is suggested that the daily insulin requirement 
decreased due to improved beta cell function and disposition capability dur-
ing long-term CSII therapy in type 2 diabetic patients.
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Synergistic beta cell effect of macronutrients in a mixed meal is 
preserved in drug-naïve subjects with type 2 diabetes
W. Alsalim1, L. Ohlsson1, B. Omar1, G. Pacini2, B. Ahrén1;  
1Dept of Clinical Sciences, Lund, Sweden,  
2Metabolic Unit ISIB, Padova, Italy.
Background and aims: The macronutrient composition of a meal is funda-
mental for glycemic control through their synergistic stimulation of insulin 
secretion in healthy subjects. Since the relevance of this synergistic effect for 
development of type 2 diabetes (T2D) is unknown, we have explored it in 
drug-naïve well-controlled subjects with T2D compared to age- and BMI-
matched healthy subjects.
Materials and methods: After an overnight fast, eighteen (13M,5F) well-con-
trolled drug-naive T2D subjects (mean age 64 yrs, BMI 27.2 kg/m2, HbA1c 
44 mmol/mol=6.0%) and eighteen (11M,7F) healthy subjects (mean age 63 
yrs, BMI 25.3 kg/m2) underwent four tests in random order ingesting either a 
liquid mixed meal (550kcal; 60% carbohydrate, 20% protein and 20% fat) or 
each of the individual macronutrients: glucose (83g=330kcal) protein (whey 
protein, 30g=110kcal) or fat (sunflower and rapeseed oil, 12g=110kcal); all 
tests 350ml; samples were taken for analysis of glucose, insulin and intact 
GLP-1 (iGLP-1); their Suprabasal (sb) and total (t) 120 min areas under the 
curve (AUC) were calculated. β-cell function estimated as insulinogenic in-
dex [IGI=sb AUCinsulin/sb AUCglucose] and oral glucose insulin sensitivity 
(OGIS) were calculated from the glucose and insulin concentration.
Results: In healthy subjects, mixed meal (which included all three macro-
nutrients) augmented insulin levels and β-cell function compared to glu-
cose alone which resulted in lower postchallenge glycemia (IGI 49±7.2 vs. 
33.8±5.5 pmol/mmol, p=0.0009): tAUCglucose: 776±36 vs 890±52 pmol/l 
min, p=0.009 with no significant difference in iGLP-1 levels (tAUCGLP-1 
802±118 vs 926±123 pmol/l min, p=0.5). T2D subjects showed exactly the 
same augmenting effects on β-cell function of mixed meal vs. glucose alone 
(IGI: 42.6±7 vs. 22.5±5.5 pmol/mmol p=0.007) and tAUCglucose: 1231±63vs 
1484±18.2 mmol/l min, p<0.0001 with, again, no significant difference in 
iGLP-1 levels (tAUCGLP-1 933.6±156vs 939±134 pmol/l min, p=0.9). In fact, 
the relative increase of IGI by mixed meal compared to glucose alone was well 
preserved in T2D (19.9±5.4 vs 15.8±3.4 pmol/mmol, p =0.5). OGIS was high-
er in healthy subjects than in T2D after both mixed meal (398±15,304±15 
ml/min/m2, p=0.0005) and glucose (407±14,324±12 ml/min/m2, p=0.003).
Conclusion: Adding protein and fat to glucose in a mixed meal results in 
increased insulin levels due to augmented β-cell function which prevents 
hyperglycemia when compared to ingestion of glucose alone. This syner-
gistic effect of protein and fat on β-cell function, being not associated with 
augmented iGLP-1 levels, is well preserved in early stages of T2D pinpoint-
ing that a synergistic macronutrient effect may attempt to rescue the failing 
β-cell response to glucose. The detailed mechanism of this synergy may offer 
a novel target to augment β-cell function after meal ingestion in early T2D
Clinical Trial Registration Number: NCT 01366794
Supported by: VR, Region Skane
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Impact of Roux-en-Y gastric bypass on distribution of enteroendocrine 
cells and their gene expression in obese patients with type 2 diabetes and 
non-diabetic controls
N.A. Rhee1, C.D. Wahlgren1, J. Pedersen2, E. Langholz3, E.P. Wandall3,  
S.U. Friis3, P. Vilmann4, S.J. Paulsen5, V.B. Kristiansen6, J. Jelsing5,  
S.S. Poulsen2, J.J. Holst2, T. Vilsbøll1, F.K. Knop1;  
1Department of Internal Medicine, Gentofte Hospital, Diabetes Research 
Division, Hellerup, 2Department of Biomedical Sciences, University of 
Copenhagen, 3Department of Medicine, Unit of Enteroscopy, University 
of Copenhagen, Hellerup, 4Gastrounit, Copenhagen University Hospital 
Herlev, 5Gubra Aps, Hørsholm, Denmark, 6Gastro Unit, Copenhagen 
University Hospital Hvidovre, Denmark.
Background and aims: RYGB is a weight-reducing surgical procedure, 
which changes macroscopic gut anatomy and the route of ingested nutrients 
and secretory products through the gastrointestinal tract, resulting in weight 
loss and improved glucose homeostasis in the majority of subjects. The aim 
of this study was to describe the impact of Roux-en-Y gastric bypass (RYGB) 
on the distribution of small intestinal enteroendocrine cells and the expres-
sion of their hormonal products in obese patients with type 2 diabetes and 
non-diabetic controls.
Materials and methods: Twelve obese subjects with type 2 diabetes and 11 
age and BMI matched controls underwent RYGB and enteroscopy at least 
4 months later. Mucosa biopsies from both procedures were immunohis-
tochemically stained for cholecystokinin (CCK), glucose-dependent insu-
linotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide 
YY (PYY) and gene expression analyses were performed looking at ghrelin 
(GHRL), CCK, secretin, GIP, GLP-1, PYY, neurotensin and farnesoid X re-
ceptor (FXR).
Results: Mean time (±SEM) of enteroscopy after RYGB was 10.4±0.8 months. 
Immunohistochemically there was an increase in the density of cells stain-
ing positive for CCK, GIP, GLP-1 and PYY (controls only) after vs. before 
RYGB. The gene expression of GHRL, secretin and GIP mRNA was down-
regulated after RYGB. CCK, PYY, neurotensin and FXR mRNA gene expres-
sion was unaltered after RYGB whereas GLP-1 mRNA was up-regulated in 
both groups.
Conclusion: Numerous alterations in the distribution of enteroendocrine 
cells and their expression of hormonal products is seen after RYGB. These 
changes may play an important role in the metabolic improvements seen after 
RYGB.
Supported by: Novo Nordisk Foundation
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Insulin-like peptide 5 is an orexigenic gastro-intestinal hormone secreted 
from colonic L-cells
F. Reimann1, H. Heffron2, P. Richards1, J. Powell2, M. Binda3, J. Doran2,  
Y. Toyoda2, J.D. Wade4, S. Aparicio5, M. Carlton2, A.P. Coll1, S. O‘Rahilly1, 
F.M. Gribble1, J. Grosse2;  
1University of Cambridge, 2Takeda, Cambridge, UK,  
3Frimorfo Ltd, Fribourg, Switzerland, 4University of Melbourne, Australia, 
5BCCAB, Vancouver, Canada.
Background and aims: Intestinal hormones secreted from enteroendocrine 
L-cells orchestrate the fate of ingested nutrients. Glucagon-like peptide-1 
(GLP-1) acts as an incretin, thus boosting postprandial insulin secretion, 
and both GLP-1 and peptideYY (PYY) inhibit further food intake. Using a 
transgenic mouse model fluorescently labelling proglucagon expressing cells, 
we identified insulin-like peptide-5 (Insl5) as another hormone expressed in 
colonic L-cells, and characterised its role in murine physiology.
Materials and methods: Expression of Insl5 was investigated by RT-PCR and 
immunohisto-chemistry. Plasma levels of Insl5 after fasting and re-feeding 
were assessed by ELISA (Kamiya). Wild-type and newly generated Insl5-re-
ceptor (relaxin/insulin-like family peptide receptor-4) knock-out (Rxfp4-/-) 
mice, accustomed to fasting and/or i.p. injections, were injected with Isnl5 
(either from Phoenix or chemically synthesised in Melbourne) or polyclonal 
Insl5 antibodies (Phoenix) and assessed for food intake. All animal studies 
were in accordance with the UK Home Office legislation and approved by the 
appropriate ethical committee.
Results: RT-PCR detected specific Insl5 expression in colonic, but not duo-
denal/jejunal L-cells and immunofluorescence microscopy confirmed co-ex-
pression with proglucagon in an overlapping set of vesicles. In spite of a previ-
ous report of reduced insulin responses in Insl5-/- mice, we failed to detect 
significant effects of Insl5 on insulin secretion from isolated islets, and Rxfp4-
/- mice did not exhibit impaired glucose tolerance. However, we observed 
that over-night fasted mice had elevated plasma Insl5 levels (4.2 ± 0.5 pg/ml) 
which fell after 10 hrs of re-feeding (2.7 ± 0.2 pg/ml, n = 10). This effect was 
pronounced in mice restricted to 60% caloric intake for 2 weeks ( 32.7 ± 6.4 
pg/ml fasting; 2. 5 ± 0.2 pg/ml 10 h refed, n=10) but blunted in mice receiving 
a 45% high-fat diet, consistent with the finding that colonic Insl5 mRNA ex-
pression was elevated in the calorie restricted group. Over-night fasted mice 
injected with Insl5 (0, 8, 40, 200 or 1000 ng/25g body weight) showed a dose 
dependent increase in food intake (225 ± 25 mg chow/20 min at the highest 
dose compared to 13 ± 12.5 mg chow/20 min in the placebo group). This 
effect was absent in Rxfp4-/- mice. Tail vein injection with polyclonal Insl5 
antibodies blunted re-feeding responses in fasted mice (5.8 ± 0.2 g cumula-
tive food intake/24 h at 100 μg Insl5-IgG/mouse compared to 7.1 ± 0.1 g after 
injection of an unspecific control IgG, n= 5 respectively) and this effect was 
also absent in Rxfp4-/- mice.
Conclusion: These results are consistent with Insl5 acting as an orexigenic 
peptide secreted from the distal intestine, joining the only other established 
orexigenic gut-peptide, ghrelin, which is secreted from the stomach. Co-
expression in a subset of anorexigenic peptide (GLP-1 and PYY) secreting 
L-cells is surprising and requires further investigations.
Supported by: Wellcome Trust, MRC and Takeda Cambridge
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Mechanism and physiological roles of glucose sensing in  
enteroendocrine cells
E. Lee, T. Miki;  
Department of Medical Physiology, Chiba University, Graduate School of 
Medicine, Japan.
Background and aims: Glucagon-like peptide 1 (GLP-1) is secreted from 
enteroendocrine L-cells in response to oral glucose ingestion and plays an 
important role in dampening the rise in postprandial blood glucose levels. 
However, the mechanism of glucose sensing in the L-cells and its physio-
logical consequence is not fully understood. In this study, the mechanism of 
glucose sensing in the L-cells and the physiological importance of luminal 
glucose sensing in the maintenance of glucose homeostasis was examined in 
mice in vivo.
Materials and methods: C57BL/6 mice were administrated with carbohy-
drates (glucose or maltose) together with or without an antagonist of SGLT1 
(phloridzin) or GLUT2 (phloretin) and the portal blood was collected and 
subjected to GLP-1 assay. The activation of enteroendocrine cells and neu-
rons in the brainstem was detected by immunostaining of phospho-CaMK2. 
In addition, glucose-induced suppression of gluconeogenesis was evaluated 
by both oral (p.o.) and intraperitoneal (i.p.) administration.
Results: Significant GLP-1 secretion was induced by intraduodenal glu-
cose administration at 5 min after infusion. The secretion was significantly 
blocked by co-administration of phloridzin but not by phloretin. I.p. glucose 
administration failed to trigger GLP-1 secretion. While plasma GLP-1 con-
centration was not increased at 30 min after oral glucose administration, it 
was significantly increased by oral maltose. Interestingly, GLP-1 secretion at 
30 min after maltose administration was not suppressed by phloridzin, sug-
gesting that glucose-sensing mechanism in L-cells differs between early and 
late phases after stimulation. Immunostaining of duodenum revealed that en-
teroendocrine cells and small numbers of nonepitherial cells in the villi were 
detected positive for phospho-CaMK2 at 5 min after intraduodenal glucose 
administration. Similarly, several cells in the medulla oblongata were shown 
to be activated by intraduodenal glucose administration. We also examined 
the gluconeogenesis and STAT3 phosphorylation in the liver in response to 
either p.o. or i.p. glucose administration. Interestingly, the suppression of glu-
coneogenesis and induction of STAT3 phosphorylation by p.o. administra-
tion was significantly potent than that by i.p administration.
Conclusion: Glucose sensing in L-cells is dependent on SGLT1-mediated 
signaling in the early phase but becomes independent in the late phase after 
luminal glucose stimulation. Our data suggested that glucose in the gut lu-
men first activates enteroendocrine cells and then the information is trans-
ferred to several nuclei in the brain stem, influencing the glucose metabolism 
in the liver.
Supported by: JSPS
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Free fatty acid receptor GPR120 is highly expressed in enteroendocrine  
K cells of upper small intestine and has a critical role in GIP secretion 
after fat ingestion
K. Iwasaki1, N. Harada1, K. Sasaki1, S. Yamane1, K. Iida2, K. Suzuki1,  
A. Hamasaki1, E. Joo1, D. Nasteska1, K. Shibue1, T. Harada1, A. Hirasawa2,  
N. Inagaki1;  
1Department of Diabetes, Endocrinology and Nutrition, Graduate School 
of Medicine, 2Department of Genomic Drug Discovery Science, Graduate 
School of Pharmaceutical Sciences, Kyoto University, Japan.
Background and aims: Gastric inhibitory polypeptide (GIP) is an incretin 
secreted from enteroendocrine K-cells in response to fat and glucose inges-
tion. Recently, free fatty acid receptor (FFAR) GPR120 was identified as a “li-
pid sensor” and was involved in GLP-1 secretion. However, GPR120 expres-
sion and role in K-cells remain unclear. In this study, we elucidated GPR120 
gene expression in K-cells using GIP-GFP knock-in (GIP-GFP) mice in 
which K-cells can be visualized by GFP fluorescence. Furthermore, we clari-
fied the effects of GPR120 on GIP secretion using GPR120-defficient mice 
(GPR120-/-) and GPR120 antagonist.
Materials and methods: The number of GFP-positive cells was measured by 
flow cytometry analysis and immunohistochemistry. GFP-positive cells and 
GFP-negative cells were collected as K-cells and non-K-cells, respectively, 
from GI tract of GIP-GFP mice by flow cytometer. GIP content in GFP-posi-
tive and GFP-negative cells were measured by ELISA. GIP mRNA and FFAR 
mRNA expressions (GPR40, GPR41, GPR43, GPR119, and GPR120) in GFP-
positive and GFP-negative cells were assessed by sq RT-PCR. Oral glucose 
tolerance tests (OGTTs) and lard tolerance tests (OLTTs) were performed 
using GPR120-/- mice and wild-type (WT) mice to evaluate total GIP secre-
tion. After oral or intravenous administration of GPR120 antagonist in C57/
BL6 mice, total GIP levels during OLTTs were measured.
Results: GFP-positive cells were observed in small intestine, but not in stom-
ach and colon. K-cell number and GIP content and mRNA expression in K-
cells were significantly higher in upper small intestine than those in lower 
small intestine. GPR120 mRNA was highly expressed in K-cells (but not in 
GFP-negative cells) of upper small intestine, while GPR40 mRNA and GPR41 
mRNA were highly expressed in K-cells (but not in GFP-negative cells) of 
lower small intestine. GPR120-/- mice had lower GIP secretion (75% reduc-
tion) during OLTT compared to WT mice, but not during OGTT. Oral ad-
ministration of GPR120 antagonist significantly attenuated lard oil-induced 
GIP secretion. On the other hand, intravenous administration of GPR120 
antagonist did not reduce GIP levels after lard oil ingestion.
Conclusion: We confirmed that GPR120 is substantially expressed in K cells 
of the upper small intestine. Our results using GPR120-/- mice and a GPR120 
antagonist demonstrate that GPR120 plays a critical role in lipid-induced GIP 
secretion from K-cells population located mainly in upper small intestine.
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CART is a regulator of GIP and GLP-1 expression and secretion in vitro
L. Shcherbina, N. Wierup;  
Lund University Diabetes Centre, Lund University, Malmö, Sweden.
Background and aims: Cocaine- and amphetamine-regulated transcript 
(CART) is a regulatory peptide that controls islet hormone secretion and 
beta-cell survival. We have recently shown that CART is expressed in hu-
man enteroendocrine cells, including L- and K-cells in the human duodenum 
and jejunum. Furthermore, we have shown that CART plasma levels increase 
after a meal in humans. In the present study we aimed to examine whether 
endogenous L- and K-cell CART regulates incretin hormone secretion and 
expression.
Materials and methods: CART gene expression was silenced using siRNA in 
GLUTag and STC-1 cells, used as L- and K-cell models respectively. Gene ex-
pression was assessed with qPCR, protein content and secretion with ELISA, 
and cell survival using WST-1 assay.
Results: CART silencing resulted in a 84.6±5.9% reduction in CART mRNA 
levels in GLUTag cells (p<0.001) and in a 58.5±8.1% reduction of CART 
mRNA in STC-1 cells (p<0.001). This was paralleled by increased incretin 
gene expression in both GLUTag and STC-1 cells. In GLUTag cells GLP-1 
mRNA expression was increased by 133.7±12.5% after CART silencing 
(p<0.001). This corresponded to 2.3±0.8 fold increase in GLP-1 (active) con-
tent (p<0.05). In STC-1 cells silencing of CART increased mRNA levels of 
both GLP-1 and GIP by 147± 7.1% and 125± 8% respectively (p<0.001). In 
addition, silencing of CART provoked increased GLP-1 (active) secretion in 
GLUTag cells stimulated with 2.8 mM glucose, 16.7 mM glucose and IBMX 
and 16.7 mM glucose (3.79±0.15, 3.78±0.32 and 4.45±0.32-fold respectively, 
p<0.001). Moreover, CART silencing provoked 1.71±0.39-fold (P<0.05) in-
creased cell survival in GLUTag cells.
Conclusion: We conclude that CART expressed in L-cells and K-cells acts as 
a regulator of incretin synthesis and secretion.
Supported by: Novo Nordisk Foundation, The Swedish Research Council, EFSD/
MSD
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In vivo beta cell glucose sensitivity regulates ex vivo islet size, 
transdifferentiation and GLP1 immunoreactivity in the alpha cells in 
humans
T. Mezza1, A.V. Sun1, C. Conte1, G. Sorice1, S. Moffa1, C. Cefalo1,  
R.N. Kulkarni2, A. Mari3, A. Giaccari1;  
1Catholic University, Rome, Italy, 2Joslin Diabetes Center, Boston, USA, 
3CNR, Padova, Italy.
Background and aims: Neogenesis from duct cells, increased islet size and 
trans-differentiation of α cells to β cells likely represent compensatory mecha-
nisms to cope with the increased insulin demand in insulin resistance states. 
Following pancreatoduodenectomy healthy patients displays an increase in 
GLP-1 secretion, the mechanism contributing to greater GLP-1 secretion is 
not fully understood and suggests either hypersecretion by existing intestinal 
L-cells and/or other potential sources of the incretin hormone. Among those, 
α cells are a potential source of the incretin hormone.
Materials and methods: To investigate the relation between in-vivo insulin 
secretion (IS), sensitivity and incretic effect with ex-vivo islet characteristics, 
18 non-diabetic patients (10 F/8 M, 51±15 yrs., BMI 27.9±5.3 kg/m2) sched-
uled for pancreatoduodenectomy underwent a 2-h hyperglycemic clamp, a 
mixed meal test and an hyperinsulinemic euglycemic clamp. β cell glucose 
sensitivity (GS) was calculated as the ratio of insulin secretion and glucose 
increments, both during the hyperglycemic clamp and mixed meal test. The 
incretin effect was estimated as the ratio of glucose sensitivity during the 
HC and MMT. Pancreas samples were collected during surgery for IHC for 
glucagon, insulin and GLP1+ cells to assess islet morphology. Neogenesis was 
evaluated by the quantification of scattered islets and ductal cells by CK19 
immunostaining and trans-differentiation of α to β cell was quantified by 
counting the % of insulin and glucagon double positive cells.
Results: When subjects were classified as insulin sensitive or resistant (using 
the median glucose uptake during the euglycemic clamp [4.9 mg•kg-1•min-2] 
as a cut-off), insulin resistant subjects displayed a significantly higher basal IS 
(IR 127±23.7 vs. IS 91.7±6.78 pmol•min-1•m-2, p=0.04), whereas GS during 
HC (IR 47.7±10.5 vs. IS 91.5±17.4 pmol•min-1•m-2•mM-1, p=0.03) was sig-
nificantly lower. Analysis of the entire group revealed an inverse correlation 
between islet size and GS (r= -0.49; p<0.05) and GU, and between GS and % 
of double+ cells (r=-0.72; p=0.03). No correlation was found between neo-
genesis markers and GS. Following the pancreaticoduodenectomy, the incre-
tin effect was significantly decreased in the insulin sensitive patients (Incretic 
effect before surgery 3.21±0.88 vs. after surgery 1.48±0.31, p=0.05), whearas 
no changes were observed in the insulinresistant subjects (Incretic effect be-
fore surgery 2.03±0.41 vs. after surgery 2.16±0.96, p=NS).
Conclusion: Our data suggest that insulin resistance determines alterations 
in islet morphology and β cell function, with a strict correlation between 
function and morphology. Impaired β cell GS might represent a major stimu-
lus for the induction of trans-differentiation of α to β cells and increased islet 
size. Further, relative compensation of incretic effect following PD may be 
driven by the increased α mass and the GLP1 immunoreactivity in the α cells 
observed in insulinresistance.
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 219
1 C
525
Effect of acute GIP- and GLP-1- infusion on circulating levels of pro-
atrial natriuretic peptide in subjects with different stages of glucose 
tolerance
N.N. Rudovich1, A. Sparwasser2, W. Doehner3, O. Pivovarova1, A. Arafat4, 
A. Bergmann5, M. Nauck6, A.F.H. Pfeiffer1;  
1Clinical Nutrition, DIFE Potsdam, Nuthetal, 2Thermo Fisher Scientific, 
B.R.A.H.M.S GmbH, Biotechnology Centre Hennigsdorf, 3Interdisciplinary 
stroke research, 4Campus Mitte, Charité University Medicine, 5Sphingotec 
GmbH, Biotechnology Centre Hennigsdorf, Berlin, 6Diabeteszentrum Bad 
Lauterberg, Germany.
Background and aims: Glucagon-like peptide-1 (GLP-1) receptor agonist 
acts antihypertensive via release of atrial natriuretic peptide in mice. Moreo-
ver, reduction of glycemic load by alpha-glucosidase inhibitors increase 
circulating levels of pro-atrial natriuretic peptide (proANP) suggesting an 
evidence of gut-heart axis also in humans. Whether GLP-1 and glucose-de-
pendent insulinotropic peptide (GIP) interact with NP system in humans is 
unknown.
Materials and methods: Twelve patients with type 2 diabetes (T2DM) (nine 
men and three women; 61 ± 10 years; BMI 30.0 ± 3.7 kg/m²; HbA(1c) 7.3 ± 
1.5%) were studied. In randomized order, intravenous infusions of GLP-1(7-
36)-amide (1.2 pmol • kg⁻¹ • min⁻¹), GIP (4 pmol • kg⁻¹ • min⁻¹), GLP-1 plus 
GIP, and placebo were administered over 360 min after an overnight fast (≥ 
1 day wash-out period between experiments). Additionally, effect of 240 min 
GIP-infusion (2 pmol • kg⁻¹ • min⁻¹) on proANP was studied in glucose-
tolerant male subjects (n=8). Plasma proANP concentrations were measured 
by an automated mid-region-directed proANP immunoassay.
Results: GLP-1 decreased proANP levels (mean± sem, 44.1 ± 3.1 vs. 34.2 
± 3.0 pmol/l; p < 0.05). During placebo, GIP and GIP + GLP-1 infusion no 
significant changes of circulating proANP were observed in T2DM subjects. 
In glucose tolerant subjects, proANP levels are decreased at the end of the ex-
periments with placebo and GIP (51.9 ± 6.5 vs. 40.0 ± 5.4 pmol/l in placebo, 
p < 0.05; 49.5 ± 6.3 vs. 40.8 ± 6.5 pmol/l in GIP-tests, p = 0.051).
Conclusion: As proANP concentration reflects ANP secretion, our data 
could not confirm interactions between two major incretins and ANP in hu-
mans.
Clinical Trial Registration Number: NCT00774488
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Novel GIP receptor-mediated bioassay more accurately reflects changes 
of GIP activity than traditional assays
T. Yanagimachi, Y. Fujita, Y. Takeda, J. Honjo, H. Kitsunai, H. Sakagami,  
Y. Takiyama, A. Abiko, Y. Makino, M. Haneda;  
Division of Metabolism and Biosystemic Science, Department of Internal 
Medicine, Asahikawa Medical University, Japan.
Background and aims: GIP and GLP-1 are incretins released from the gut 
rapidly inactivated by dipeptidyl peptidase-4 (DPP-4) after secretion into 
truncated forms that are no longer insulinotropic forms of incretins. Al-
though recently developed ELISA kits may be able to measure active incretins 
levels, it is unclear if the available assays detect totally biological active forms. 
Moreover, recent reports suggest GIP has a short-form isoform GIP (1-30) 
secreted from gut and pancreas, which may not be detectable by the available 
methods. Therefore, we determined active GIP and GLP-1 levels from human 
blood samples using novel cell-based, receptor-mediated bioassays.
Materials and methods: We utilized the cell lines stably co-transfected with 
human-form GIP or GLP-1 receptors and a cAMP-inducible luciferase ex-
pression construct for bioassays. We performed a 75 g OGTT in six non-
diabetic subjects and measured plasma total GIP (Millipore), total GLP-1 
(Millipore), insulin, C-peptide and glucagon levels by ELISA, active GIP and 
active GLP-1 levels by bioassays. Next, we performed another OGTT in iden-
tical subjects after administration of DPP-4 inhibitor (sitagliptin: 100 mg/
day) for three days. We measured plasma total/active GIP and GLP-1 levels 
as above. Additionally, we compared the efficacy of our GIP bioassay with 
that of a commercial active GIP ELISA kit (IBL, Japan) by measuring samples 
from identical subjects before and after sitagliptin administration.
Results: To evaluate the specificity of the bioassays, we confirmed their re-
sponsiveness with several synthetic incretin receptor agonists. In the GIP bio-
assay, GIP (1-42) and short-form GIP (1-30) almost equivalently increased 
luciferase activity in a concentration dependent manner. In the GLP-1 bio-
assay, exendin-4 produced almost comparable luciferase activity to GLP-1 
(7-36 amide) but liraglutide did less than GLP-1 (7-36 amide). In samples 
collected during on OGTT, total GIP levels rapidly increased from 0 min to 
15 min and gradually increased up to 120 min (68.8 ± 11.4 pmol/l). In con-
trast, active GIP levels peaked at 30 min (42.3 ± 4.3 pmol/l) and dropped at 
60 min. Notably, active GIP had a positive correlation with the insulin levels. 
Total GLP-1 levels increased to 30 min and remained at similar levels up to 
120 min (25.4 ± 2.7 pmol/l). In contrast, active GLP-1 levels reached a peak 
at 30 min and then dropped. Administration of a DPP-4 inhibitor to identi-
cal subjects induced 1.4-fold increase of active GLP-1 levels at 15 minutes 
after oral glucose load. Interestingly, active GIP measured by bioassay levels 
increased approximately by 20-fold after DPP-4 treatment. But total and ac-
tive GIP levels by ELISA were increased just 1.7 and 2.1-fold, respectively. 
Other DPP-4 inhibitors (linagliptin: 5 mg/day and vildagliptin: 100 mg/day) 
showed similar effect to sitagliptin. Then we investigated the discrepancy in 
measured active GIP levels between bioassay and ELISA. We first confirmed 
that Sitagliptin per se did not increase luciferase activity. The bioassay could 
detect short-form GIP (1-30), but total or active ELISA kits could not at all.
Conclusion: We propose that the bioassays more accurately reflect the con-
tribution of the incretins in the entero-insular axis and short-form GIP (1-30) 
may be more important than GIP (1-42) in DPP-4 inhibitor treatment.
Supported by: JDF
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Effects of a non-glucose food preload on oral glucose tolerance in 
subjects with impaired glucose tolerance and type 2 diabetes
D. Trico1,2, A. Tulipani1, S. Baldi1, C. Morgantini2,  
M.P. Macedo3, A. Mari4, E. Ferrannini1, A. Natali1;  
1Department of Clinical and Experimental Medicine, University of Pisa, 
2Scuola Superiore Sant‘Anna, Pisa,  
3Centro de Estudos de Doenças Crónicas, Universidade Novade Lisboa, 
4Institute of Biomedical Engineering,  
National Research Council, Padova, Italy.
Background and aims: Protein and fat ingestion delays gastric emptying and 
stimulates gut hormones release. Recent studies have suggested that these ef-
fects could be exploited to improve the plasma glucose excursions induced 
by carbohydrates in type 2 diabetic patients (T2D). The present study was 
designed to measure the impact of a small non-glucose food preload on the 
major components of glucose homeostasis in subjects with impaired glucose 
tolerance (IGT) and T2D and to test whether gut hormones participate in 
this response.
Materials and methods: Ten diet-controlled T2D patients (8 males, age 55±7 
years, BMI 28.7±4.7 kg/m2, HbA1c 48±2 mmol/l) and thirteen IGT subjects 
(7 males, age 47±5 years, BMI 26.3±1.6 kg/m2, HbA1c 38±1 mmol/l) were 
enrolled. On two separate days, after an overnight fast, they were randomised 
to a preload of either 500 ml of water (control) or Parmesan cheese (50 g) 
plus a boiled egg with 300 ml of water; 30 minutes later they underwent a 
standard 75 gr oral glucose tolerance test (OGTT). Arterialised timed blood 
samples were collected to measure plasma glucose, insulin, C-peptide, GLP-1 
and GIP. Two stable glucose tracers were administrated ([6,6-2H2]glucose and 
[U-13C]glucose, i.v. and per os respectively) to measure the rate of appear-
ance of ingested (RaO) and endogenous glucose and the glucose clearance. 
Three major components of β-cell function, namely glucose sensitivity (βGS), 
rate sensitivity (βRS) and potentiation (POT) were evaluated by modeling 
insulin secretion (estimated from C-peptide deconvolution) and plasma glu-
cose. Insulin sensitivity was estimated using the OGIS method.
Results: In T2D patients, the plasma glucose rise during the OGTT was 
significantly lower after the food preload than after water ingestion (iAUC 
-49.4±5.9%, p<0.0002). The food preload produced a delay in glucose ab-
sorption (RaO iAUC -27±12%, p<0.05), an enhancement of βGS (+102±31%, 
p<0.006), and an increase in GLP-1 (iAUC +176±49%, p<0.004) and GIP 
response (iAUC +74±31%, p<0.03), while insulin sensitivity, glucose clear-
ance, endogenous glucose production, βRS and POT were not affected. In 
IGT subjects, the effect of the food preload on glucose tolerance was less 
pronounced (iAUC -39±7%, p<0.0002) and explained by a significant im-
provement in POT (+43±17%, p<0.04) and a minor delay in glucose absorp-
tion (RaO iAUC -16±8%, p<0.01). While the GLP-1 response was similarly 
enhanced (iAUC +149±58%, p<0.002), GIP secretion in IGTs was stimulated 
to a greater extent (iAUC +179±49%, p<0.001). In the whole dataset, glucose 
tolerance improved in proportion to its baseline derangement and was not 
correlated to the changes in either GLP-1 or GIP.
Conclusion: A small non-glucose food preload significantly improves glu-
cose tolerance in diet-controlled T2D and IGT. This results from different 
combinations of delayed glucose absorption and improved β-cell function 
in the two study groups. Simple diet recommendations have the potential 
to control postprandial hyperglycaemia in T2D patients by engaging mech-
anisms, other than gut hormones, that appear to be preserved in the early 
stages of the disease.
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Relationship between meal induced glucagon-like peptide-1 response 
and metabolic syndrome prevalence in type 1 diabetic patients
L. Duvnjak, K. Blaslov, T. Bulum, J. Knežević-Ćuća;  
University hospital Merkur, Zagreb, Croatia.
Background and aims: Metabolic syndrome (MS) can be found in about 30-
40 % of type 1 diabetic (T1DM). While there is a growing body of evidence 
suggesting that meal induced glucagon-like peptide-1 (GLP-1) response in 
type 2 diabetic (T2DM) patients is diminished, GLP-1 secretion in T1DM 
and population with MS was not extensively studied. We aimed to analyse the 
relationship between fasting total GLP-1 level, meal induced GLP-1 response 
and MS prevalence in T1DM patients.
Materials and methods: A total of 77 T1DM patients (61% male, mean age 
46 years, median BMI 25 kg/m2, median diabetes duration of 21 years) were 
included. MS was diagnosed in 26 (33.76%) of them according to IDF (Inter-
national Diabetes Federation) definition (2009 year) including at least two of 
the following criteria: waist circumference >80 cm in female (94 in male) , 
triglycerides above 1.7 mmol/L or specific treatment, HDL cholesterol <1.03 
mmol/L in males and 130 or diastolic >85 mm Hg, or specific treatment, fast-
ing plasma glucose (FPG): > 5.6 mmol/L, or previously diagnosed T2DM. 
The control group included 10 normal glucose tolerance (NGT) subjects ad-
justed for age, gender and BMI. Circulating GLP-1 level was measured before 
and 30 min after a test meal. The test meal (324 (324-528) kcal) comprised 
about 20% fat, 60% carbohydrate, and 20% protein. Total GLP-1 level was 
measured by ELISA using ALPCO Diagnostics kit. The change between 
30 minutes postprandial and fasting GLP-1 concentration was calculated: 
ΔGLP-1=postprandial GLP-1-fasting GLP-1 concentration.
Results: T1DM patients showed significantly lower total fasting, postprandial 
and meal induced GLP-1 level compared to NGT group. Between T1DM pa-
tients significantly higher rise in circulating GLP-1 level was noticed in group 
without compared to those with MS (1.89±2.25 pmol/L vs 0.77±1.74 pmol/L, 
p=0.017). Between the T1DM without MS and NGT group a significant dif-
ference in total fasting GLP-1 (1.34±1.39, 2.99±1.34, p=0.003), postpran-
dial GLP-1 level (3.24±2.43, 5.18±2.85, p=0.017) and ΔGLP-1(1.89±2.25, 
2.17±1.66, p=0.032) was found. The difference in meal induced change be-
tween these two groups was not significant (p=0.487). In the multivariate 
logistic regression analysis, ΔGLP-1 concentration was significantly inversely 
associated with the presence of MS after adjustment for age, sex, duration of 
diabetes and calorie intake (0.704 (0.528-0.956)).
Conclusion: In T1DM patients higher meal induced GLP-1 response is in-
versely related to the presence of MS. The possible role of GLP-1 in the patho-
genesis of MS in T1DM needs to be further investigated.
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Intravenous arginine stimulates GLP-1 release across spectrum of 
glucose tolerance
H. Ruetten1, R.H. Raymond2, R.A. Calle3, C. Cao4, D.S. Lee3,  
R.P. Robertson5, S.S. Shankar6, M. Staten7, D. Stefanovski8, M.T. Vassileva9, 
A. Vella10, G.C. Weir11, D.A. Fryburg12, for the Beta Cell Team of FNIH 
Biomarkers Consortium;  
1Sanofi, Inc., Frankfurt am Main, Germany, 2RSquared Solutions, Skillman, 
3Pfizer Pharmatherapeutics R & D, Cambridge, 4Takeda, Inc., Chicago, 
5Pacific Northwest Diabetes Research Institute, Seattle, 6Eli Lilly, Inc, 
Indianapolis, 7NIDDK, National Institutes of Health, Bethesda, 8Cedars-
Sinai Medical Center, Los Angeles, 9Foundation for the NIH Biomarkers 
Consortium, Bethesda, 10Mayo Clinic, Rochester, 11Joslin Diabetes Center, 
Boston, 12ROI BioPharma Consulting, East Lyme, USA.
Background and aims: Meal-induced secretion of GLP-1 has been well-de-
scribed, yet limited data exist on i.v. secretagogues of GLP-1. As part of a se-
ries of experiments to characterize beta cell response to i.v. arginine (arg), we 
previously showed that insulin secretion (AIRarg) responses to arg differed 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 221
1 C
across glucose tolerance (GT) groups. In the same subjects we report total 
GLP-1 responses to i.v. arg in 53 obese subjects with normal glucose tolerance 
(NGT), prediabetes (PDM), and type 2 diabetes (T2DM).
Materials and methods: Following an overnight fast, samples were acquire 
for total GLP-1 pre- and for 10 min post an i.v. arg bolus (5 gm over 30 sec) at 
basal glucose. Pre-and post-arg GLP-1 samples were also acquired during the 
last 10 min of a 60 min glucose infusion (900 mg/min).
Results: The table summarizes results during basal glucose period; previously 
reported and baseline adjusted AIRarg insulin responses are also included. 
Pre-arg fasting GLP-1 differed across GT spectrum, highest in T2DM. ARG 
elicited GLP-1 secretion in all 3 GTs, with greater changes in PDM and T2DM 
than NGT (Delta GLP-1). Pre-arg GLP-1 did not correlate with AIRarg, 
whereas change in GLP-1 correlated with AIRarg for NGT and T2DM but not 
PDM in basal glucose state (NGT/T2DM: r= 0.52/0.49 P<0.02; PDM r=0.16 
NS). Similar responses observed during high glucose infusion (not shown).
Conclusion: We conclude that 1) i.v. arginine acutely stimulates GLP-1 secre-
tion irrespective of glucose tolerance status; 2) Pre-arginine GLP-1 was not 
associated with insulin secretory response, but GLP-1 secretion after arginine 
is positively associated with insulin secretion in NGT and T2DM.
Clinical Trial Registration Number: NCT01663207
Supported by: FNIH Biomarkers Consortium Sponsors
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Effects of region of small intestine exposed to glucose on incretin 
hormones, insulinaemia and glycaemia in healthy older subjects
R.S. Rigda1, T.J. Little1,2, L.G. Trahair1, K. Lange2, C. Feinle-Bisset1,2,  
C.K. Rayner1,2, M. Horowitz1,2, K.L. Jones1,2;  
1Medicine, University of Adelaide, 2NHMRC Centre of Research Excellence 
in Translating Nutritional Science to Good Health, Adelaide, Australia.
Background and aims: The release of incretin hormones is pivotal to post-
prandial glucose homeostasis. We have reported that the stimulation of 
glucagon-like peptide-1 (GLP-1), but not glucose-dependent insulinotropic 
peptide (GIP), is dependent on the length of small intestine exposed to glu-
cose, but the impact of the region of small intestine remains uncertain. The 
aims of this study were to determine the incretin, insulinaemic and glycaemic 
responses to intraduodenal (ID) glucose when the proximal small intestinal 
region (~60cm from the pylorus) is bypassed.
Materials and methods: Ten healthy older subjects (9M,1F; age 65-79yr) 
were studied on 2 separate occasions after an overnight fast, in random or-
der. On each occasion they were intubated with a custom-designed catheter 
incorporating an intraduodenal (ID) balloon to isolate proximal (<60cm 
from pylorus) small intestinal regions. Each subject then received ID glu-
cose (3kcal/min) into either a) both the proximal and distal regions “GPD”, 
or b) the distal region only “GD”) for 60min. On the GPD study day, glu-
cose was infused into the proximal region and aspirated every 10min, so that 
the amount of residual glucose to be infused into the distal region could be 
calculated. On the GD study day, 0.9% saline was infused concurrently into 
the proximal region. Blood glucose and plasma insulin, total GIP and GLP-1 
were measured between t=0-60min, and the insulin/glucose ratio at 60min 
calculated. Data were analysed using Student’s paired t-tests and expressed 
as mean ± SEM.
Results: There were rises in blood glucose and plasma insulin, GIP and 
GLP-1 on both days (P<0.01). When the responses to GD and GPD were 
compared there was no significant difference in blood glucose, or plasma in-
sulin, although mean values for blood glucose were less, and plasma insulin 
greater, with GD and the insulin/glucose ratio at 60min was greater with GD 
(11.8±2.3 vs 7.8±1.2, P<0.05). The stimulation of GIP was less (P<0.01), and 
that of GLP-1 greater (P<0.05), with GD.
Conclusion: We conclude that the effects of enteral glucose on GIP and GLP-
1 are dependent on the region of small intestine exposed with a consequent 
impact on insulinaemia.
Supported by: NHMRC
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Encapsulated glutamine significantly increases circulating 
concentrations of glucagon-like peptide-1 and insulin and increases meal 
size in healthy volunteers
C.L. Meek1, F. Reimann1, A.J. Park2, F.M. Gribble1;  
1University of Cambridge, 2Addenbrooke‘s Hospital, Cambridge, UK.
Background and aims: Type 2 diabetes (T2D) is now a major cause of death 
and disability worldwide. At present, bariatric surgery is the only treatment 
capable of inducing diabetes remission, possibly due to enhanced nutrient 
delivery to the distal gut, a phenomenon which is associated with marked 
increases in the secretion of gut hormones, such as glucagon-like peptide 
1 (GLP-1). However, the use of bariatric surgery is limited by expense and 
invasiveness and there is an urgent need to identify safe and affordable non-
surgical treatments which can promote similar effects. Previous work in vitro 
has identified that glutamine is a potent secretagogue of GLP-1. The aim of 
the current study was to identify if encapsulated glutamine can increase en-
dogenous secretion of GLP-1 in human volunteers using a delivery system 
which targets glutamine release to the ileum. A secondary aim was to assess 
the effect of the encapsulated glutamine on glucose tolerance and meal size.
Materials and methods: A randomized, double blind, placebo-controlled 
cross-over study was performed to assess the effects of a single dose of en-
capsulated glutamine (6g, 3.6g or placebo) on venous concentrations of total 
GLP-1 in fasting healthy volunteers. Glutamine was encapsulated by a com-
pany specialising in drug delivery. Each capsule was coated with Acryl-Eze 
to promote capsule release around the mid ileum. Capsules were made using 
GMP-grade materials and were tested for stability to determine the shelf life. 
The effects of capsule ingestion upon glucose tolerance and meal size were 
studied using a standard 75g oral glucose tolerance test and ad libitum meal 
respectively. The study received ethical approval from the local research eth-
ics committee and all participants gave written informed consent. Statistical 
analysis was performed using the paired t test.
Results: 29 participants were recruited in total (14 male, 15 female; age 22-
58 years, body mass index 18.5 - 31.8 kg/m2). Ingestion of 6g glutamine was 
associated with increased concentrations of GLP-1 after 90 minutes (n=10; 
3.6 pmol/l vs 2.2 pmol/l for placebo; p=0.006), increased concentrations of 
insulin after 90 minutes (n=10; 62.0 pmol/l vs 50.9 pmol/l; p=0.047) and in-
creased meal size at 120 minutes (n=10; 542g vs 481g eaten; p=0.008). No 
safety concerns were identified following the ingestion of encapsulated glu-
tamine.
Conclusion: A single oral dose of encapsulated glutamine is able to promote 
increased secretion of GLP-1 and is associated with increased insulin release. 
However, this promoted increased meal size, an undesirable effect, perhaps 
because the orexigenic effects of insulin release predominated over the ano-
rexigenic effects of GLP-1 release following administration of glutamine. In 
conclusion, GLP-1 release was promoted in vivo using a single dose of encap-
sulated glutamine but the effect size was small and was not associated with 
beneficial metabolic effects.
Clinical Trial Registration Number: ISRCTN10757078
Supported by: EU FP7 266408; Wellcome Trust; NIHR.
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Gallbladder emptying and single-dose metformin elicit robust and 
additive glucagon-like peptide-1 responses
U. Rohde1, D.P. Sonne1, M. Hansen1, A. Brønden1, M. Christensen1,  
J.F. Rehfeld2, J.J. Holst3, T. Vilsbøll1, F.K. Knop1;  
1Diabetes Research Division, Gentofte Hospital, Hellerup,  
2Department of Clinical Biochemistry, Rigshospitalet,  
3Department of Biomedical Sciences, Faculty of Health and Medical 
Sciences, University of Copenhagen, Denmark.
Background and aims: Preclinical studies suggest that gallbladder emptying 
and subsequent activation of the bile acid receptor TGR5 on enteroendocrine 
L cells leads to glucagon-like peptide-1 (GLP-1) secretion. Drugs affecting 
bile acid binding (colesevelam (COL)) or reabsorption (metformin (MET)) 
seem to increase postprandial GLP-1 secretion in humans. We hypothesised 
that gallbladder emptying stimulates human GLP-1 secretion and that COL 
and MET, respectively, would potentiate any GLP-1 secretion induced by 
gallbladder emptying.
Materials and methods: Ten subjects (age (mean±SD): 23.4±3.8 years; BMI: 
21.9±1.8 kg/m2; HbA1c: 5.1±0.3%) were studied on 6 randomised days. In a 
double-blind fashion the subjects received 1) COL (3.75 g); 2) MET (1.5 g); 
or 3) placebo (PLA) in 50 ml water admixed 1.5 g paracetamol (for evaluation 
of gastric emptying) administered via nasogastric tube, with a concomitant 
60-minute iv infusion of saline and cholecystokinin-8 (CCK), respectively. 
Blood was sampled for 4 hours for measurements of plasma GLP-1, glucose, 
insulin, C-peptide and glucagon. Gallbladder emptying was measured by ul-
trasound. Food intake was assessed at the end of each day.
Results: CCK infusion during PLA induced complete gallbladder emptying 
and a significant GLP-1 response (incremental AUC) compared to saline in-
fusion (392±173 (mean±SEM) vs. -277±94 pM×min, p=0.02). MET without 
CCK elicited a significant GLP-1 response (215±87 vs. -277±94 pM×min 
(saline+PLA), p=0.002), which was potentiated by CCK-induced gallblad-
der emptying (963±202 pM×min (CCK+MET), p=0.03). COL did not elicit 
significant GLP-1 responses. Plasma glucose was not affected by the interven-
tions, nor was insulin, C-peptide, glucagon or food intake.
Conclusion: CCK-induced gallbladder emptying and single dose metform-
in, respectively, elicit robust and additive GLP-1 responses in humans. We, 
therefore, speculate that metformins mode of action includes stimulation of 
GLP-1 secretion by both bile acid-dependent and independent mechanisms.
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Effect of the bile acid chenodeoxycholic acid and the bile acid sequestrant 
colesevelam on glucose metabolism in patients with type 2 diabetes and 
in healthy control subjects
M. Hansen1,2, M. Scheltema1,3, D.P. Sonne1,2, J.F. Rehfeld4, J.J. Holst2,5,  
T. Vilsbøll1, F.K. Knop1,2;  
1Department of Internal Medicine, Gentofte Hospital, Diabetes 
Research Division, Hellerup, 2University of Copenhagen, Department of 
Biomedical Sciences, Denmark, 3University of Amsterdam, Department of 
Endocrinology and Metabolism, Netherlands, 4Rigshospitalet, Department 
of Clinical Biochemistry, Copenhagen, 5University of Copenhagen, Novo 
Nordisk Foundation Center for Metabolic Research, Denmark.
Background and aims: In patients with type 2 diabetes, rectal administra-
tion of bile acids, and oral bile acid sequestrants lower plasma glucose (PG). 
We evaluated the effects of chenodeoxycholic acid (CDCA) and the bile acid 
sequestrant colesevelam (COL), delivered by intragastric tube, on glucagon-
like peptide-1 (GLP-1) (primary endpoint), PG, insulin, C-peptide, glucagon, 
cholecystokinin (CCK), gastric emptying, gallbladder volume, appetite and 
food intake, in a placebo-controlled, double-blinded study.
Materials and methods: On 4 separate days 10 patients with type 2 diabetes 
(age (mean±SD): 62±7 years, BMI: 28.9±2.3 kg/m2; HbA1c: 53±12 mmol/
mol) and 10 matched healthy control subjects (age: 61±10 years, BMI: 
28.2±3.2 kg/m2; HbA1c: 37±4 mmol/mol) received 1) CDCA (1.25 g); 2) 
COL (3.75 g), 3) CDCA+COL, or 4) placebo; suspended in 100 ml of water 
with 1.5 g paracetamol (for evaluation of gastric emptying). During 180 min 
blood was drawn, gallbladder volume was evaluated by ultrasound, and ap-
petite perception was evaluated by visual analogue scale. At the end of each 
day ad libitum food intake was evaluated.
Results: In both the patients with type 2 diabetes and the healthy subjects, 
CDCA elicited a significant increase in GLP-1 vs. COL, CDCA+COL and pla-
cebo (p<0.05). While none of the interventions changed PG, CDCA elicited 
a small but significant increase in C-peptide/PG ratio vs. COL, CDCA+COL 
and placebo in both groups. CDCA increased glucagon in both groups vs. 
COL, CDCA+COL and placebo. In the healthy control subjects, COL in-
creased CCK significantly vs. CDCA, CDCA+COL and placebo, but not in 
patients with type 2 diabetes. CDCA slowed gastric emptying in both groups. 
COL tended to decrease gallbladder volume, whereas CDCA increased gall-
bladder volume. The interventions did not affect appetite perception or food 
intake.
Conclusion: Intragastric administration of CDCA increased GLP-1, insulin 
(measured as C-peptide/PG ratio) and glucagon secretion, and slowed gastric 
emptying. We speculate that the GLP-1 and subsequent insulin secretion is 
mediated by bile acid-induced TGR5 activation on L cells. Bile acid seques-
tration does not appear to have an acute effect on GLP-1 secretion in humans.
Clinical Trial Registration Number: NCT01666223
534
Early improvements in glucose metabolism after Roux-en-Y gastric 
bypass surgery are not explained by increased total bile acids or 
fibroblast growth factor 19
N.B. Jørgensen1, C. Dirksen1, K.N. Bojsen-Møller1, V.B. Kristiansen2,  
B.S. Wulff3, J.J. Holst4, S. Madsbad1, T.R. Clausen3;  
1Dept. of Endocrinology, Hvidovre Hospital, 2Dept. of Surgery, Hvidovre 
Hospital, Køge, 3Diabetes and Obesity Biology, Novo Nordisk A/S, Måløv, 
4Dept. of Biomedical Sciences, University of Copenhagen, Denmark.
Background and aims: Bile acids and fibroblast growth factor 19 (FGF19) 
have been suggested as key mediators of the dramatic improvements in glu-
cose metabolism after Roux-en-Y gastric bypass (RYGB). The aim of this 
study is to describe fasting and postprandial total bile acid (TBA) and FGF19 
concentrations before and after RYGB and relate them to parameters of glu-
cose metabolism.
Materials and methods: In this prospective study, we enrolled 13 patients 
with type 2 diabetes (T2D) (BMI: 42.8 [95% c.i.: 40.1-45.7] kg/m2) and 12 
subjects with normal glucose tolerance (NGT) (BMI: 41.3[38.8-44.0] kg/m2). 
They were subjected to a 4-hour liquid meal test before, 1 week, 3 months 
and 1 year after RYGB. Blood was sampled for TBA and FGF19 as well as 
markers of glucose metabolism. Effects of time after surgery and group were 
analyzed by analysis of variance (ANOVA) in a linear mixed effects model us-
ing time from surgery and group (T2D or NGT) as fixed effects and subjects 
as random effect.
Results: Fasting TBA concentrations decreased 1 week after RYGB in NGT 
subjects but increased gradually thereafter in both groups with time from 
surgery (T2D: pre: 1.3 µmol/L [0.7-2.4], 1 week: 1.3 [0.7-2.3], 3 months: 1.5 
[0.8-2.6], 1 year: 3.3 [2.3-4.7]; NGT:1.6 [1.1-2.4], 0.8 [0.4-1.5], 2.3 [1.6-3.4], 
2.6 [1.8-3.7], ANOVA ptime<0.001). Fasting FGF19 concentrations were 
unchanged after RYGB (ptime=0.6). Postprandial TBA concentrations were 
unchanged in T2D patients and decreased in NGT subjects 1 week after 
RYGB but increased afterwards with time from surgery (AUC TBA: T2D: 
627 mmol x min/L [410-958], 481 [250-926], 1091 [829-1438], 1818 [1395-
2368], NGT: 639 [521-784], 402 [320-505], 1338 [1051-1703], 1497 [1218-
2368], ptime<0.001). Changes in AUC FGF19 followed the same pattern as 
AUC TBA (ptime<0.001). No significant group differences of fasting or post-
prandial TBA and FGF19 concentrations were found. HOMA-IR decreased, 
beta-cell function improved, and GLP-1 secretion greatly increased shortly 
(1 week) after RYGB.
Conclusion: The lack of change or even decline in TBA and FGF19 shortly 
after RYGB suggests that altered bile acid metabolism does not contribute 
to the acute improvements in glucose metabolism early after RYGB. Later 
changes may play a role on the longer term.
Clinical Trial Registration Number: NCT00810823
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Inhibition of GIP receptor signalling in adipose tissue reduces insulin 
resistance in high fat diet-induced obesity
E. Joo, N. Harada, T. Fukushima, A. Hamasaki, S. Yamane, K. Iwasaki,  
D. Nasteska, K. Shibue, T. Harada, K. Suzuki, N. Inagaki;  
Department of Diabetes, Endocrinology and Nutrition,  
Graduate School of Medicine, Kyoto University, Japan.
Background and aims: Gastric inhibitory polypeptide (GIP) is an incretin 
that potentiates insulin secretion. GIP receptor (GIPR) is expressed not only 
in β-cells, but in adipose tissue as well, and previous in vitro studies show that 
GIP directly induces energy accumulation into the adipose tissue. Therefore, 
GIP has a direct and indirect effect (via insulin) on induction of adiposity. 
However, the effect of direct GIP action on adiposity in vivo remains un-
clear. In this study, we generated adipose tissue-specific GIPR-deficient mice 
(GIPRfat-/-) and clarified the direct GIP action in adipose tissue in vivo.
Materials and methods: GIPRfat-/- were generated from floxed GIPR mice 
(Lox) and adipocyte protein 2 (aP2)-Cre transgenic mice (aP2). GIPRfat-/-, 
Lox, and aP2 were fed normal fat diet (NFD: 10% fat) or high fat diet (HFD: 
60% fat) and their body weight gain was measured. After 15 weeks of NFD 
or HFD feeding, oral glucose tolerance test (OGTT), insulin tolerance test 
(ITT), and histological analyses (liver and adipose tissue) were performed. 
Fat volume (CT scan), energy expenditure, activity count, and triglyceride 
(TG) content in liver were measured.
Results: In GIPRfat-/-, expression levels of GIPR mRNA were substantially 
lower in visceral and subcutaneous adipose tissue (90% reduction). Body 
weight gain, blood glucose levels, and insulin levels during OGTT did not 
differ among three types of mice under NFD condition. Under HFD condi-
tion, body weight gain was slightly lower in GIPRfat-/- compared to that of 
control mice (Lox and aP2). Fat volume and adipocyte size did not differ be-
tween HFD-fed GIPRfat-/- and control mice. OGTT data showed that insulin 
and glucose levels were significantly lower in HFD-fed GIPRfat-/- compared 
to control mice. HOMA-IR and ITT data showed that insulin resistance was 
reduced in HFD-fed GIPRfat-/-. Furthermore, fat content in liver was signifi-
cantly lower in HFD-fed GIPRfat-/- compared to control mice. Histological 
analysis showed that hepatic steatosis was reduced in HFD-fed GIPRfat-/-. 
There was no significant difference in energy expenditure and mouse activity 
among three types of mice under HFD feeding.
Conclusion: GIP receptor signaling in the adipose tissue plays an important 
role in HFD-induced insulin resistance without increase in fat mass in vivo.
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The long-acting analogue of short-form GIP does not induce obesity 
in normal mice but ameliorates chronic hyperglycaemia in low-dose 
streptozotocin-induced diabetic mice
Y. Fujita, T. Yanagimachi, K.K. Atageldieyeva, J. Honjo, Y. Takiyama,  
A. Abiko, Y. Makino, M. Haneda;  
Department of Internal Medicine, Asahikawa Medical University, Japan.
Background and aims: It is still ambiguous whether GIP can be beneficial 
as potential therapeutics in the diabetic state. However, we reported that a 
short-isoform GIP, GIP (1-30), which is released chiefly from pancreatic al-
pha cells, may function not only as glucose-dependent insulin release in a 
paracrine manner, but also as the fetal islet development. Again, it is previ-
ously reported that GIP (1-30) less potentiates fat accumulation in contrast to 
GIP (1-42) secreted from the gut. To investigate the possibility of short-form 
GIP, we tested the efficacy of a long-acting GIP (1-30) analogue in vivo and 
investigated whether the analogue can suppress the progression to hypergly-
cemia and improve glycaemia in low-dose streptozotocin (LD-STZ) mice.
Materials and methods: We synthesized dipeptidyl peptidase-4 (DPP-4) 
resistant GIP (1-30) analogue via modification of the second position ala-
nin and then attaching 40kDa polyethylene glycol (PEG) to the C-terminus. 
First, we administrated PEGylated (350-7000 pmol/body) or non-PEGylated 
GIP to the non-diabetic control mice by the subcutaneous single injection, 
and evaluated pharmacokinetics of the peptides from 60 min until day 7. 
To measure plasma GIP activity, we employed the novel receptor-mediated 
bioassay reflecting cAMP production in vitro. Then, we used non-diabetic 
and LD-STZ-induced diabetic mice, with or without administration of the 
PEGylated GIP analogue. We designated mice to four groups, non-STZ, 
STZ, non-STZ+GIP, STZ+GIP, respectively. We injected the PEGylated GIP 
analogue or vehicle subcutaneously every 3 days (initial dose 100 pmol/body 
and maintenance dose 70 pmol/body) and monitored body weight and non-
fasted blood glucose until day 30. We measured HbA1c levels and conducted 
intraperitoneal glucose tolerance tests (IPGTT) at the end. Finally, we evalu-
ated the islet morphology via double immunofluorescent staining with insu-
lin and glucagon.
Results: The single subcutaneous injection of PEGylated GIP analogue 
gradually increased GIP activity in plasma but maintained much longer (the 
approximate half-life was 48 hours), whilst the injection of non-PEGylated 
analogue rapidly increased the activity but vanished within 2 hours. The 
maximum-dose injection of PEGylated GIP still augmented to detect bio-
logical GIP activity until day 7. Persistent PEGylated GIP treatment neither 
induced obesity nor affected glycemic levels in non-STZ groups. In contrast, 
PEGylated GIP treatment significantly decreased non-fasted blood glucose 
levels, reduced HbA1c levels (STZ+GIP: 4.9±0.2% vs STZ: 5.7±0.4 %, p<0.05) 
and improved glucose excursion after IPGTT (STZ+GIP: 2465±114 vs STZ: 
2961±166 min x mmol/l, AUC glucose, p<0.01) in LD−STZ mice. GIP treat-
ment did not significantly increase insulin levels after IPGTT. However, GIP 
treatment ameliorated alpha cell expansion in the islets concomitant with 
suppressing elevated plasma glucagon levels observed in non-treated LD-
STZ mice (STZ).
Conclusion: Our results indicate that the PEGylated short-form GIP ana-
logue is possibly durable enough to suppress the progression to overt hyper-
glycemia with improving the islet function in LD-STZ-induced diabetic mice.
Supported by: JSPS JDF
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Neural mechanisms contribute to islet effects of both GLP-1 and GIP
L. Ahlkvist, B. Ahrén;  
Medicine, Clinical Sciences, Lund, Sweden.
Background and aims: After meal intake, the incretin hormones glucagon-
like peptide 1 (GLP-1) and glucose-dependent insulinotrophic peptide (GIP) 
mediate 50-70% of β-cell insulin secretion. The rapid inactivation of the in-
cretin hormones makes them very short-lived in the circulation which has 
questioned their role as circulatory hormones. Previous studies showing 
expression of GLP-1 receptors in vagal nerve cells and induction of electri-
cal impulses in both afferent and efferent vagal nerve fibers by GLP-1 have 
instead indicated that the incretin hormones work through vagal nerve fibers. 
Therefore, the aim of this project was to examine whether blocking muscarin-
ic receptors, i.e. the effector system of the cholinergic islet system, disrupts 
the insulinotropic effects of GLP-1 and GIP.
Materials and methods: Fasted anesthetized C57BL/6J female mice were 
given either saline or atropine methyl bromide (5 mg/kg) intraperitoneally 12 
minutes before intravenous glucose administration (0.35 g/kg), co-injected 
with GLP-1 or GIP (both at 3 nmol/kg) via the tail vein. Blood was collected 
from the retrobulbar, intraorbital capillary plexus before and at 1, 5, 10, 20, 
30 and 50 minutes after intravenous challenge for analysis of plasma glucose 
(glucose oxidase) and insulin (ELISA). Pancreatic islets were isolated by col-
lagenase digestion and incubated (1h) in 2.8 and 11.1 mM glucose, with or 
without the presence of atropine (100 μM), GLP-1 (100 nM), GIP (100 nM), 
atropine (100 μM)/GLP-1 (100 nM) or atropine (100 μM)/GIP (100 nM). The 
supernatant was analyzed for insulin.
Results: Atropine significantly reduced the insulin response to glucose + 
GLP-1 compared to saline (5 min: 1.2±0.2 vs. 2.5±0.4 nM, P<0.01). Similarly, 
atropine also reduced the insulin response to glucose + GIP (5 min: 1.6±0.3 
vs. 2.7±0.5 nM, P<0.05 and 10 min: 0.6±0.1 vs. 1.4±0.3 nM, P<0.05). Atro-
pine did not affect the insulin response to glucose alone. In contrast, during 
islet incubations atropine did not affect the insulin secretory responses to 
GLP-1 or GIP.
Conclusion: We show here that blocking of muscarinic signaling by atropine 
markedly suppresses the insulinotropic effect of both GLP-1 and GIP in vivo 
but not in isolated islets. Based on these results, together with the finding of 
incretin hormone receptors on vagal nerve fibers, we therefore suggest that 
neural mechanisms contribute to the islet effects of both GLP-1 and GIP. 
Since only low levels of circulating intact incretin hormones reach the islets, 
parasympathetic vagal regulation of insulin secretion may therefore be an im-
portant component of the incretin effect.
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Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart 
rate, mesenteric blood flow and glycaemic responses to intraduodenal 
glucose in older subjects
L.G. Trahair1,2, M. Horowitz1,2, T. Hausken3, C. Feinle-Bisset1,2,  
C.K. Rayner1,2, K.L. Jones1,2;  
1Discipline of Medicine, The University of Adelaide, 2NHMRC Centre of 
Research Excellence in Translating Nutritional Science to Good Health, 
The University of Adelaide, Australia, 3Section for Gastroenterology, 
Department of Clinical Medicine, University of Bergen, Norway.
Background and aims: A postprandial fall in blood pressure (BP) occurs 
frequently in healthy older subjects and type 2 patients, the magnitude of 
which is related to the rate of gastric emptying (GE) and rise in splanchnic 
blood flow. Postprandial hypotension (PPH) is now recognised as an impor-
tant clinical problem in these groups. In humans, exogenous glucagon-like 
peptide-1 (GLP-1) has been reported to increase BP in two studies, but not 
another, while clinical trials of GLP-1 agonists in type 2 diabetes and obe-
sity have reported a modest reduction in BP and a rise in heart rate (HR). 
Studies relating to the cardiovascular effects of GLP-1 and its agonists have 
not, however, discriminated between fasting, as opposed to postprandial, BP 
and HR. The aims of this study were to determine whether exogenous GLP-1 
modulates the effects of an intraduodenal (ID) glucose infusion on BP, HR 
and splanchnic blood flow in healthy older subjects.
Materials and methods: On two separate days, 10 healthy ‘older’ subjects 
(9M,1F; age 73 ± 2 yr) received an infusion of GLP-1 (0.9 pmol/kg/min IV), 
or saline for 90 min (t = -30 - 60 min) in random order. Between t = 0 - 60 
min, ID glucose was infused at 3 kcal/min. BP and HR were assessed with 
an automated device (Dinamap, GE Medical Systems), superior mesenteric 
artery (SMA) flow by Doppler ultrasonography and blood glucose and serum 
insulin were also measured. Results are shown (mean ± SEM).
Results: During the ‘fasting’ period (t = -30 - 0 min), GLP-1 had no effect on 
BP (P = 0.40) or HR (P = 0.59). In response to ID glucose (t = 0 - 60 min), 
systolic BP decreased (P < 0.001; Figure 1A), and both HR (P < 0.001; Figure 
1B) and SMA flow (P < 0.05; Figure 1C) increased, on both days. GLP-1 at-
tenuated the maximum fall in systolic BP (saline: -14 ± 3 vs. GLP-1: -9 ± 2 
mmHg; P < 0.05), tended to increase the maximum rise in HR (saline: 13 ± 
3 vs. GLP-1: 15 ± 3 BPM; P = 0.09) and increased the maximum rise in SMA 
flow (saline: 500 ± 52 vs. GLP-1: 837 ± 102 ml/min; P < 0.01). GLP-1 dimin-
ished the peak glycaemic response to ID glucose (saline: 10.3 ± 0.5 vs. GLP-1: 
9.3 ± 0.3 mmol/L; P < 0.05) and increased the AUC 0 - 60 min insulin/glucose 
ratio (saline: 3.5 ± 0.7 vs. GLP-1: 4.9 ± 0.9; P < 0.05).
Conclusion: In healthy older subjects, acute administration of GLP-1 at-
tenuates the hypotensive response to ID glucose, apparently independent of 
changes in HR, and potentiates the increase in SMA flow. Given that GLP-1 
also slows GE, a role in the management of PPH warrants evaluation.
Supported by: NHMRC #627189
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Impaired incretin effect and gastrointestinal-mediated glucose disposal 
in non-diabetic patients with cirrhosis
F.K. Knop1, L. Gluud2, A.E. Junker1, J.J. Holst3, T. Vilsbøll1;  
1Diabetes Research Division, Gentofte, 2Department of Gastroenterology, 
Hvidovre, 3Department of Biomedical Science, Copenhagen, Denmark.
Background and aims: Cirrhosis is often complicated by glucose intolerance, 
but the pathogenesis not yet completely understood. We evaluated the in-
cretin effect and gastrointestinal-mediated glucose disposal (GIGD) in non-
diabetic patients with biopsy-verified liver cirrhosis.
Materials and methods: Patients with compensated cirrhosis (Child Pugh A 
or B) and matched healthy controls underwent a 4h 50g-oral glucose toler-
ance test (OGTT) and an isoglycaemic intravenous glucose infusion (IIGI) 
on two separate days. We calculated the incretin effect [100% × (AUCC-
peptide, OGTT - AUCC-peptide,IIGI/AUCC-peptide,OGTT)], the GIGD 
[100% × (glucoseOGTT - glucoseIIGI/glucoseOGTT)] and insulin resistance 
(according to the homeostatic model assessment (HOMAIR)). Characteris-
tics of participants are summarised as median±interquartile range and com-
pared using non-parametric analyses.
Results: Ten patients (5 women) with cirrhosis (age: 54±15 years; BMI: 26±6 
kg/m2; fasting plasma glucose (FPG): 5.8±0.7 mM; HbA1c: 38±6 mmol/
mol (5.6±0.4%)) and 10 matched healthy controls (age: 58±17 years; BMI: 
29±1 kg/m2; FPG: 5.2±0.4 mM; HbA1c: 34±6 mmol/mol (5.5±0.2%)) were 
included. Patients with cirrhosis were more glucose intolerant (AUCOGTT: 
609±458 (cirrhosis) vs. 180±109 mM×min (controls), P<0.01) and insulin 
resistant (HOMAIR: 3.7±4.9 (cirrhosis) vs. 2.6±1.4 (controls), P<0.05) than 
controls. Isoglycaemia was achieved using 35±12 g of glucose in patients 
with cirrhosis and 24±10 g in healthy controls (P<0.01). Patients with cir-
rhosis had impaired incretin effect (35±44 (cirrhosis) vs. 55±30% (controls), 
P<0.01) and GIGD (30±23 (cirrhosis) vs. 52±20% (controls), P<0.01).
Conclusion: Non-diabetic patients with cirrhosis exhibit impaired incretin 
effect and GIGD, which may contribute to the glucose intolerance associated 
with cirrhosis.
Clinical Trial Registration Number: NCT01492283
Supported by: The Novo Nordisk Foundation
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Gastrointestinal-mediated glucose disposal in total pancreatectomised 
patients
A. Lund1,2, J.I. Bagger1,2, M. Christensen1,2, M. Grøndahl1,2, E.R. Mathiesen3, 
C.P. Hansen4, J. Storkholm4, S. Larsen1, J.J. Holst2, T. Vilsbøll1, F.K. Knop1,2;  
1Diabetes Research Center, Gentofte Hospital, 2Department of Biomedical 
Sciences, University of Copenhagen, 3Center for Pregnant Women with 
Diabetes, Department of Endocrinology, 4Department of Gastrointestinal 
Surgery, Rigshospitalet, Copenhagen, Denmark.
Background and aims: Gastrointestinal-mediated glucose-disposal (GIGD) 
after OGTT reflects the percentage of glucose disposal caused by the oral 
route of glucose administration. It accounts for as much as 70% in healthy 
subjects. Mediators of GIGD may include the incretin hormones, gut micro-
biota, first-pass hepatic uptake of glucose, and at present unknown factors. It 
is likely that incretin-mediated potentiation of pancreatic insulin secretion 
constitutes a major contributor to GIGD, but so far, it has not been possible 
to discriminate between pancreatic and extrapancreatic mechanisms under-
lying GIGD. We aimed to evaluate the impact of extrapancreatic effects on 
GIGD.
Materials and methods: Data from 7 total pancreatectomised patients (age: 
61±4 years; BMI: 22.3±1.4 kg/m2; HbA1c: 63±4 mmol/mol (mean±SEM)) 
and 8 healthy control subjects (age: 58±3 years; BMI 23.2±0.9 kg/m2; HbA1c: 
32±2 mmol/mol) were included in the present analysis. Participants were ex-
amined over two experimental days: a 75g-OGTT and a corresponding iso-
glycaemic i.v. glucose infusion (IIGI). Difference between administered glu-
cose during OGTT and IIGI within the group of pancreatectomised patients 
were used to evaluate the impact of extrapancreatic mechanisms on GIGD.
Results: In healthy control subjects, 27±2 g of glucose was infused intrave-
nously to copy the plasma glucose profile from the 75g-OGTT, resulting in 
a GIGD of 65±2%. In total pancreatectomised patients we used 76±3 g of 
glucose to copy the plasma glucose profile from the 75g-OGTT, resulting in a 
GIGD of -2±5% (i.e. that the pancreatectomised subjects disposed of i.v. and 
oral glucose similarly).
Conclusion: The low GIGD in pancreatectomised patients suggests that ex-
trapancreatic factors do not play a major role in GIGD. The need for a larger 
glucose load on the IIGI day could however point to the existence of gut-
derived factors (e.g. gut-derived glucagon) contributing to a worsening of 
oral glucose tolerance in pancreatectomised patients.
Clinical Trial Registration Number: NCT02006459
Supported by: EFSD/Novo Nordisk
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 225
1 C
541
Preserved incretin effect despite significant hyperinsulinaemia following 
glucose loading in South Asians, in comparison to Caucasians
R. Ahluwalia1, T.L. Vilsboll2, L. Ranganath1, J.J. Meier3, J. Vora1, F.K. Knop2;  
1The Royal Liverpool & Broadgreen University Hospitals NHS Trust, 
Liverpool, UK, 2Diabetes Research Division, Copenhagen University 
Hospital Gentofte, Denmark, 3Department of Medicine, St. Josef-Hospital, 
Ruhr-University, Bochum, Germany.
Background and aims: Circulating hyperinsulinaemia in normal glucose 
tolerant South Asians is reflective of underlying insulin resistance. Role of 
incretin hormones in this adaptive islet response in South Asians, remains 
to be explored. Our study aims to investigate the incretin effect in matched 
groups of South Asians and Caucasians.
Materials and methods: Ten South Asian subjects (age: 34±4 years 
(mean±SEM); BMI 24.5±1 kg/m2; fasting plasma glucose (FPG): 4.8±0.2 
mmol/l;) and twelve age and BMI-matched Caucasian subjects (age: 31±3 
years; BMI 24.6±1 kg/m2; FPG: 4.6±0.1 mmol/l,) with normal glucose toler-
ance were recruited. On two different days, subjects underwent a 4h 50g-
OGTT and an isoglycaemic i.v. glucose (20%) infusion (IGII), respectively, 
involving sampling of insulin, C-peptide, glucagon and incretin hormones. 
The incretin effect was measured using the following formula based on beta 
cell secretory responses (AUCs): 100x(AUCOGTT-AUCIGII)/AUCOGTT.
Results: Fasting insulin levels were higher in South Asians vs. Caucasians 
(12.0±1.6 vs. 8.0±0.8 mU/l, p=0.02). The oral glucose curves were replicated 
successfully during the IGII studies. The integrated insulin responses after 
OGTT and IIGI, respectively, were significantly higher in South Asians vs. 
Caucasians (OGTT: 10239±1683 vs. 5377±616 mU/l x min, p=0.008; IGII: 
5610±1347 vs. 2703±321 mU/l x min, p=0.03). Incretin effects were similar 
in the two groups (48±6 vs. 49±2%, p=0.8).
Conclusion: Our findings show preserved incretin effect despite insulin re-
sistance and hyperinsulinaemia in normal glucose tolerant South Asians.
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Difference in insulin responsiveness between meal- and glucagon-
loading test in Japanese type 2 diabetes
T. Kitamoto1,2, E. Nara2, Y. Matsuzawa2, J. Saito2, M. Omura2, T. Nishikawa2;  
1Clinical Cell Biology and Medicine, Chiba University,  
2Endocrinology and Diabetes Center, Yokohama Rosai Hospital, Japan.
Background and aims: Responsiveness of c-peptide (CPR) to mixed meal 
tolerance test (MT) is a useful marker to evaluate the insulin secretion ability 
such as postprandial responsiveness of insulin production in type 2 diabetes. 
On the other hand, the total capacity of endogenous insulin secretion can 
be examined by the response of CPR after glucagon loading test (GT). Basal 
ability of insulin production was reported to be relatively impaired in Japa-
nese type 2 diabetes, rather than Western patients, suggesting that incretin-
related agents can be much more effective for glycemic control in Japanese 
than Western patients. Then, we tried to compare the responsiveness of 
CPR to MT and GT in Japanese type 2 diabetes for clarifying effectiveness 
of incretin-based therapy, such as DPP4 inhibitor (DPP4i) or GLP-1 analog 
(GLP-1A).
Materials and methods: We enrolled 95 Japanese type 2 diabetes patients 
prescribed DPP4i or GLP-1A from 2011 to 2012. CPR response (⊿CPR) 
to MT and GT was analyzed. Then, we divided the patients into 2 groups; 
controlled patients who reached glycemic target (HbA1c<7.0%) and uncon-
trolled patients whose HbA1c was over 8.0% at 6 months after each treat-
ment. We compared the clinical characteristics and responsiveness of CPR to 
MT with those to GT.
Results: DPP4i and GLP-1A were individually used in 47 and 48 patients, 
respectively. CPR response to MT was significantly higher in 29 cases than 
7 uncontrolled patients among 47 patients treated with DPP4i (3.5±2.0 vs. 
1.9±1.3 (ng/ml); p=0.022). CPR response to GT was significantly higher in 
16 cases than 22 uncontrolled patients among 48 patients treated with GLP-
1A (2.1±0.8 vs. 1.3±0.8 (ng/ml); p=0.003). The ROC analysis in each group 
showed optimal cut off point of ⊿CPR by MT was under 2.0 ng/ml in cases 
showing HbA1c>8.0% in DPP4i-treated group, while in GLP-1A-treated 
group, that of ⊿CPR by GT was over 1.39 and under 1.26 ng/ml in cases 
showing HbA1c<7.0% and HbA1c>8.0%, respectively. Moreover, 86% of un-
controlled patients by DDP4i-treatment showed more than 1.39 in ⊿CPR in 
GT, suggesting that they can be successfully treated with GLP1-A.
Conclusion: The present study clearly demonstrated that the gut-mediated 
insulin secretion estimated by MT can predict the efficacy of DPP4i, while 
total capacity of cAMP-mediated insulin secretion examined by GT may pre-
dict usefulness of GLP-1A. We can, therefore, simply decide whether DPP4i 
or GLP-1A might be effective for controlling hyperglycemia in Japanese type 
2 diabetes by performing MT and GT.
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Glypican-4 is increased in human subjects with impaired glucose 
tolerance and decreased in patients with newly diagnosed type 2 diabetes
H. Wang1,2, L. Li1,2, K. Li3, G. Yang3;  
1College of Laboratory Medicine, 2Key Laboratory of Diagnostic Medicine 
(Ministry of Education), 3Department of Endocrinology and Department of 
Surgery, Chongqing Medical University, China.
Background and aims: Glypican-4(GPC-4), a membrane-bound hormone 
owing to a glycosyl-phosphatidylinositol (GPI) anchor, is synthesized and 
secreted by adipose tissues.GPC-4 differentially expressed in visceral and 
subcutaneous adipose tissue, and the expression in human white adipose 
tissue (WAT) was highly correlated with BMI and the WHR. However, no 
report has demonstrated the relationship of circulating levels of GPC-4 with 
impaired glucose tolerance (IGT) or T2DM in humans. The aim of the cur-
rent study is to investigate whether GPC-4 correlates with obesity and insulin 
resistance by cross-sectional and interventional studies on anthropometric, 
metabolic, and hormonal predictors of circulating GPC-4.
Materials and methods: Circulating GPC-4 was measured with ELISA in 
subjects with NGT, IGT, and nT2DM who are involved in the study from 
June 1, 2013 to November 10, 2013. EHC were performed in healthy and 
T2DM subjects. Plasma glucose was measured by the glucose oxidase 
method. HbA1c was measured by HPLC. Plasma insulin was measured by 
radioimmunoassay. Plasma FFA was measured with a commercial kit. To-
tal cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein 
cholesterol, and triglycerides were analyzed enzymatically using an autoana-
lyzer.Real-time RT-PCR and Western blotting were used to assess mRNA and 
protein expression of GPC-4.
Results: Circulating GPC-4 levels were significantly higher in IGT subjects 
and lower in nT2DM subjects compared to controls. Circulating GPC-4 was 
positively correlated with BMI, WHR, HOMA-IS and FAT%, while it was in-
versely correlated with FBG and HbA1c. Excluding diabetic subjects, increas-
ing GPC-4 levels were associated with HOMA-IR and M values(r = 0.247 and 
r = -0.491; both P<0.05). In T2DM patients, GPC-4 mRNA expression were 
significantly reduced by 35 % in muscle and 28 % in fat compared to normal 
controls (both P< 0.05). GPC-4 protein levels were significantly reduced by 
about 51 % in both muscle and fat relative to normal subjects (both P< 0.05). 
GPC-4 levels were significantly increased upon an oral glucose intake. The se-
cretion of GPC-4 exhibited a characteristic diurnal rhythm in humans, with a 
major rise occurring between afternoon and midnight.
Conclusion: The present study revealed a difference in GPC-4 levels in nor-
mal, IGT and nT2DM subjects as well as a significant association between cir-
culating GPC-4 levels and IGT or nT2DM and various anthropometric and 
metabolic parameters. Our results demonstrated for the first time that cir-
culating GPC-4 concentrations were increased in IGT subjects and reduced 
in nT2DM subjects. We have also demonstrated that GPC-4 was associated 
with some metabolic or obesity related parameters, and that GPC-4 was af-
fected by an oral glucose challenge. We also found evidence to suggest that 
the down-regulation of GPC-4 expression in muscle and adipose tissues may 
be responsible for the reduced circulating GPC-4 levels in T2DM patients. 
Thus, our data suggest that GPC-4 is likely to play a major role in the develop-
ment of obesity, insulin resistance, and T2DM in humans.
Clinical Trial Registration Number: ChiCTR-OCS-13003185
Supported by: National Natural Science Foundation of China (81100567, 
81300702, 81300670)
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Bombesin receptor subtype-3 (BRS-3) and its synthetic agonist: 
therapeutic tandem for obese/type 2 diabetic patients
N. González1, A. Martín-Duce2, F. Martínez-Arrieta3, I. Ramos-Álvarez4,  
Z. Moreno-Villegas4, S. Portal-Núñez5, R. Sanz5, J. Egido4;  
1IIS-Fundación Jiménez Díaz-CIBERDEM-UAM, 2Universidad de Alcalá, 
3Hospital Universitario Puerta de Hierro, 4IIS-Fundación Jiménez Díaz-
CIBERDEM, 5IIS-Fundación Jiménez Díaz, Madrid, Spain.
Background and aims: BRS-3 gene/protein expressions are lower than nor-
mal (N) in skeletal muscle from obese (OB) or type 2 diabetic (T2D) pa-
tients; moreover in myocytes from all three groups, insulin-mimetic effects 
of [D-Tyr6,β-Ala11,Phe13,Nle14]bombesin6-14 ―synthetic BRS-3 agonist―, 
have been reported (v.g.: kinase phosphorylation increases, glucose metabo-
lism improving). Also, our previous data related to BRS-3, in patients simul-
taneously diagnosed with obesity and type 2 diabetes (OB/T2D), pointed 
out its potential therapeutic interest, leading the current study in: A) pieces 
of skeletal muscle from OB/T2D ─BRS-3 expression─; B) primary cultured 
myocytes from OB/T2D patients, ─BRS-3 signalling pathways, by using 
[D-Tyr6,β-Ala11,Phe13,Nle14]bombesin6-14, and confirmed its effect on 
glucose transport (GT) and glycogen synthase a activity (GSa)─.
Materials and methods: 10 OB/T2D patients (3F/7M; age:49±3 yrs; glu-
cose:112±6 mg/dl; cholesterol:184±9 mg/dl; triglycerides:143±18 mg/dl; 
Dianben treatment) and 23 N subjects (19F/4M; age:50±3; glucose:96±2; cho-
lesterol:185±8; triglycerides:98±9) undergoing surgery, previous informed 
consent given, were included. BRS-3 gene expression -RT-PCR-, BRS-3 pro-
tein, PKB, p70s6K, p42/44MAPKs and p90RSK1 phosphorylation -Western 
Blot-, GT and GSa -glucose precursors-; insulin acted as positive control. 
ANOVA (Levene/Bonferroni test; using SPSS 21.000) was performed; p<0.05 
significant value.
Results: In OB/T2D muscle pieces, BRS-3 mRNA level (23.6±1.3 times 
down-regulated, p<0.0001; n=5) and protein values (49±7% of N, p<0.05; 
n=3) were lower compared to N. In primary cultured myocytes from 5 OB/
T2D, the phosphorylation basal values of all kinases were reduced (p<0.05), 
compared to normal state. BRS-3´s agonist at 10-11 up 10-8M, slightly in-
creased PKB phosphorylation (overallmean:126±2% control, p<0.02), being 
reduced compared to that exerted by insulin (10-9M:143±4%). At 10-10M 
ligand, p70s6K activation (136±10% control, p=0.035), and 10-9M insu-
lin (132±8%, p=0.037) were equal; no increments compared to basal were 
detected at higher agonist concentrations (10-9 up 10-8M; overallmean: 
109±4%). The ligand at 10-11M, induced maximal phosphorylation of 
MAPKs (p42:159±15% control; p44:166±11%; p<0.0001), and p90RSK1 in-
crease was showed at 10-11M compound (148±2%, p<0.0001), being at 10-10 
up 10-8M (overallmean:133±3%), identical to that detected at 10-9M insulin 
(133±4%). In OB/T2D myocytes, BRS-3-agonist stimulated GT, already de-
tected at 10-12M (133±9% control), maximal at 10-11M (160±9%, p<0.0001) 
and maintained up to 10-8M (overallmean: 153±7%, p<0.007); this action 
was lower to that detected at 10-8M insulin (202±9%, p=0.009). The effect 
of the agonist on GSa, achieved the maximum at 10-11M (165±16% control; 
p<0.0001), which was not different, from that obtained at higher concentra-
tions 10-10 up 10-8M (overallmean: 145±5%; p<0.008).
Conclusion: Taken together these results from samples, which combine two 
major metabolic diseases -obesity and type 2 diabetes-, confirm that BRS-3 
receptor and its agonist could be useful as a therapeutic tandem also for OB/
T2D patients. 
Supported by: ISCIII, FRP, FMM
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Insight into the molecular mechanism of action of BTI320, a non-
systemic novel drug to control serum glucose levels in individuals with 
diabetes
K. Mayo1, M.C. Miller2, Y. Bobruff3, P. Sheehan4, D. Platt4, C.G. Parkin5;  
1University of Minnesota Health Sciences Center, Minneapolis, 
2Department of Biochemistry, University of Minnesota Health Sciences 
Center, Minneapolis, 3Research, Boston Therapeutics, Manchester, 4Boston 
Therapeutics, Manchester, 5CGParkin Communications, Inc., Boulder City, 
USA.
Background and aims: Starch is an α(1⇒4)-linked polymer of glucose, which 
is enzymatically digested or hydrolyzed down to smaller polysaccharides (e.g. 
dextrin) and then onto smaller sugars like maltotriose and maltose, and even-
tually to glucose. The key enzymes responsible for the breakdown of starch 
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are generally called α-glycosidases, with α-amylase being primary among 
them. BTI320 is a novel, non-systemic therapy that safely reduces postpran-
dial glucose excursions with reduced side effects compared with acarbose. 
Acarbose is a natural microbial pseudo-tetrasaccharide that binds revers-
ibly and competitively to the oligosaccharide binding site of α-glucosidases. 
BTI320 is composed of non-glucose-containing polysaccharides. It is es-
sentially a composite of two modified galactomannans: GM-α (1⇒1) linked 
polymer; and GM-β (1⇒4) linked polymer. We believe that BTI320 functions 
by targeting several polysaccharide hydrolyzing enzymes and that the active 
ingredient is GM-α.
Materials and methods: The present study was focused on assessing the mo-
lecular mechanism of action of BTI320 in relationship to α-amylase. We used 
1H and 13C nuclear magnetic resonance (NMR) spectroscopy to investigate 
interactions between BTI320 components, GM-α and GM-β, and the enzyme 
α-amylase, as well as the effects that GM-α and GM-β have on the rates of 
amylase-mediated starch hydrolysis towards glucose. The amylose iodine as-
say was also used to assess starch hydrolysis. Results are compared with those 
on acarbose.
Results: Chemical shift changes in NMR spectra of α-amylase demonstrate 
that GM-α interacts with the enzyme, possibly at or near its active site; GM-β 
appears to have no effect on α-amylase. GM-α and GM-β both interact with 
starch and apparently change the amylose structure, thus affecting how am-
ylase hydrolyses the starch. Under certain conditions, the rate constants for 
starch (1 mg/ml) hydrolysis with α-amylase goes from 22.5 s-1 in the absence 
of GM-α to 2.7 s-1 in the presence of 4 mg/ml GM-α (p<0.005). The effect 
on the rate of starch hydrolysis with acarbose is similar, but at acarbose con-
centrations of about 100-fold less. In addition, comparison of NMR data on 
α-amylase with GM-α and acarbose suggest that GM-α binds at or near the 
same site on the enzyme as acarbose.
Conclusion: GM-α acts as an inhibitor, possibly competitive, of α-amylase 
function, and appears to be the active ingredient in BTI320. Our findings 
provide insight into how BTI320 may function in vivo and support the po-
tential viability of BTI320 as an alternative to acarbose therapy for glycemic 
control.
Supported by: Boston Therapeutics
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Different clinical responses to exenitide, insulin and pioglitazone are 
associated with TNF-857C/T ploymorphism in newly diagnosed  
type 2 diabetic patients
H. Xu1, W. Xu1, W. Ren1, Z. Chen1, F. Xu1, K. Zeng1, J. Weng1, X. Ma2;  
1The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 
2Weill Cornell Medical College, New York, USA.
Background and aims: TNF-α is one of the pivotal proinflammatory cy-
tokines contributing to insulin resistance. Yet the association of TNF-1031T/
C-863C/A-857C/T genotype with clinical efficacy of exenitide, insulin or 
pioglitazone in type 2 diabetes has not been explored.
Materials and methods: Newly diagnosed and drug-naïve type 2 diabetic 
patients with HbAlc between 7% and 10% were enrolled nationwide. All pa-
tients were randomly assigned to exenitide, insulin or pioglitazone group. 
TNF-1031T/C-863C/A-857C/T polymorphisms were obtained by genomic 
DNA sequencing. Clinical efficacy were evaluated by examining changes of 
HbAlc, both fasting and 2 hour postprandial plasma glucose, insulin levels, 
HOMA-B, HOMA-IR, lipid profiles after one year treatment with anti-hyper-
glycemic agents mentioned as above and were analyzed according to different 
genotype groups. Molecular mechanisms of TNF polymorphisms on tran-
scriptional regulation were investigated by constructing luciferase reporters 
carrying the corresponding single nuclear polymorphism followed by tran-
sient transfection in RAW264.7 cells and electrophoretic mobility shift assay.
Results: Ten different TNF-1031T/C-863C/A-857C/T genotypes were found 
in 382 enrolled patients. All baseline parameters were comparable among dif-
ferent TNF genotype groups. One year treatment of each agent effectively 
decreased HbAlc, fasting and 2 hour postprandial plasma glucose levels 
(P<0.05). Weight gain was observed by the end of insulin therapy in all geno-
type groups, which resulting an increase of HOMA-IR accordingly (P<0.05). 
However, exenitide and piolitazone reduced HOMA-IR significantly in pa-
tients with TNF-1031TT-863CC-857CC genotype (TCC)(before vs after: 
1.58±0.62 vs 1.22±1.10, 1.68±0.63 vs 0.97±1.02, respectively, P<0.05) . On the 
contrary, no statistically changes of HOMA-IR was induced in TNF-1031TT-
863CC-857CT genotype carriers (TCT) by the same medications (1.77±0.50 
vs 1.42±1.01, 1.49±0.78 vs 1.24±0.83). Exenitide induced a comparably dra-
matic weight loss as to 4.7% in TCC patients and 4.5% in TCT ones (both 
P<0.05), waist and hip circumferences decreased in the former (before vs 
after, 89.95±8.25 vs 87.35±9.00, 98.08±5.35 vs 95.35±6.68 cm, respectively, 
P<0.05) while not in the latter (before vs after, 87.72±16.14 vs 86.81±10.45, 
95.92±16.30 vs 96.00±7.06 cm, respectively). In vitro studies demonstrated 
that human TNF-857T-allele containing luciferase reporter exhibited over 2 
fold greater transcriptional activity than that of the -857C allele across all 
experimental conditions: unstimulated or stimulated with LPS, IFN-γ, or 
both. EMSA analyses with biotin-labeled -857C- or T-allele probes revealed 
differential nuclear DNA-binding activities that were stronger with the C al-
lele than the T allele, which transcriptional factor OCT1 could bind. And 
overexpression of OCT1 totoally diminished differences of luciferase activity 
between -857T-allele and -857C-allele.
Conclusion: TNF-857T showed an OCT1 mediated, constitutively up-regu-
lated transcriptional activities of TNF gene, which may restrain the effect of 
insulin resistance improvement of exenitide and pioglitazone in Chinese type 
2 diabetic patients.
Clinical Trial Registration Number: NCT01147627
Supported by: FRFCU
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The effect of atorvastatin vs pravastatin on glucose homeostasis in the 
Otsuka Long-Evans Tokushima Fatty (OLETF) rats
S. Moon1,2, E.-S. Kim1,3, J.-H. Lee1, S. Kim1, E.-Y. Mo1, J.-H. Han1,  
Y.-B. Ahn2, H.-S. Son3;  
1Division of Endocrinology and Metabolism, The Catholic University of 
Korea, Incheon, 2The Catholic University of Korea, Suwon,  
3The Catholic University of Korea, Uijeongbu, Republic of Korea.
Background and aims: New-onset diabetes has been observed in clinical tri-
als and meta-analyses involving statin therapy. Controversy exists regarding 
the effects of statin treatment on progressive insulin resistance. To investigate 
the effect of atorvastatin (AS) vs pravastatin (PS) on glucose homeostasis in 
the Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Materials and methods: Thirty OLETF rats of 10 weeks of age were random-
ly divided into 3 groups: untreated (n=10); AS-treated (n=10); PS-treated 
(n=10) rats. As normal control rats (n=10), Long-Evans Tokushima Otsuka 
(LETO) were used. OLETF rats were either untreated or treated with AS (100 
mg/kg per day) or PS (25 mg/kg per day) from 12 weeks of age for 24 weeks. 
We measured daily food intake, weekly body weight and casual blood glucose 
levels. At 20 and 36 weeks of age, an oral glucose tolerance test (OGTT) was 
performed from the tail vein after overnight fasting.
Results: Food intake and casual blood glucose levels did not show significant 
differences among OLETF rats during the periods of studies. However, com-
pared with untreated OLETF rats, body weight was decreased significantly 
at 31 to 35 weeks of age in PS-treated rats. Long-term treatment with statins, 
either from 12 or 36 weeks of age, mean fasting blood glucose, insulin, GIP 
and glucagon levels were not statistically different among OLETF rats. How-
ever, fasting GLP-1 level at 20 weeks and stimulated 30 min GLP-1 level at 
36 weeks were significantly low in statin treated OLETF rats compared with 
untreated OLETF rats (p<0.002), in addition, fasting C-peptide level at 36 
weeks was significantly decreased in PS-treated OLETF rats compared with 
untreated OLETF rats, p<0.023). Kitt, HOMA-IR and ß-cell mass at 20 or 36 
weeks of age were not significantly different between three treated OLETF 
rats compared with untreated OLETF rats.
Conclusion: The results suggest that long-term treatment with statin did not 
increased blood glucose levels, however, statin therapy might be associated 
with a decrease of GLP-1 levels over 20 weeks of age in statin treatment rat 
model of spontaneously developing type 2 DM. Taken together with previous 
reports, present study imply a role for affecting incretin physiology by statin.
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The identification of novel metabolites that track with improvements 
in glycaemia following a 12-week lifestyle intervention in high risk 
individuals
A. Kennedy1, J. Cobb2, G. O’Donoghue3, G. Anderson3, N. McCaffrey1,  
S. Cleary1, E. Durkan1, H. Kenny1, J. Monedero1, K.-P. Adam2, M. Sinnott4, 
B. Carr4, T. Thybo3, J. Nolan3, D. O’Gorman1;  
1Centre of Preventive Medicine and School of Health & Human 
Performance, Dublin City University, Ireland, 2Metabolon Inc, Durham, 
USA, 3Steno Diabetes Centre, Copenhagen, Denmark, 4Vhi Healthcare, 
Dublin, Ireland.
Background and aims: A number of studies have identifed fasting metabo-
lites associated with insulin resistance, dysglycemia and type 2 diabetes. It is 
not known if metabolites respond to lifestyle modifications that reduce the 
risk of type 2 diabetes. The purpose of this study was to identify metabolite 
biomarkers, linked to dysglycaemia, that track with improvements in plasma 
glucose following a lifestyle intervention in high risk individuals.
Materials and methods: As part of the DEXLIFE programme, individuals 
with a FINDRISC score >12 or impaired fasting/2-hr glucose volunteered 
to participate in a 12-week diet and exercise intervention (n=104). An oral 
glucose tolerance test, body composition assessment(DEXA)and maximal 
aerobic capacity were determined before and after the intervention. Using 
the stable isotope dilution technique, quantitative assays were developed for 
a set of 23 candidate biomarker metabolites previously linked to dysglycemia. 
This set included: α-hydroxybutyric acid (AHB), linoleoylglycerophospho-
choline (LGPC), oleic acid, α-ketoglutaric acid, 2-aminoadipic acid, glycine, 
aromatic amino acids, and the 3 branched-chain amino acids and several of 
their catabolites.
Results: After the 12-week intervention fasting levels of 12 of the 23 metab-
olites were significantly different (p10% (n=16) there was a significant de-
crease in plasma tyrosine, α-ketoglutarate and phenyalanine (p<0.05) as well 
as increased glycine and serine (p10% decrease in 2-hr glucose (n=35) was 
associated with significant decreases in branched-chain amino acid catabo-
lites 3-methyl-2-oxopentanoic acid, 3-methyl-2-oxo-butyric acid, 4-methyl-
2-oxopentanoic acid (p<0.05) in addition to insulin, α-ketoglutarate, tyrosine 
(p<0.05) and increased glycine (p<0.05). The fold change in body weight was 
positively associated with the fold change in phenylalanine, tyrosine, leucine, 
isoleucine, 3-methyl-2-oxopentanoic acid and insulin (p<0.05) and negative-
ly associated with glycine (p<0.05).
Conclusion: A subset of metabolites linked to dysglycaemia track with 
improvements in fasting and 2-hr glucose following a 12-week lifestyle in-
tervention in high risk individuals. These metabolites are sensitive to small 
changes in metabolic function and may be useful for monitoring diabetes 
prevention programmes.
Supported by: DEXLIFE project (EU FP7 programme, Grant agreement no: 
279228)
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Fasting and postprandial hyperglycaemia: their relative contributions to 
the overall hyperglycaemia and their determinants in Korean patients 
with type 2 diabetes
J. Kim1, S.-Y. Yoo1, S.-A. Lee1, D.-H. Lee2, H.-J. Chin3, G. Koh1;  
1Internal Medicine, Jeju National University Hospital,  
2Internal Medicine, Wonkwang University Hospital, Iksan,  
3Hankook General Hospital, Jeju, Republic of Korea.
Background and aims: Monnier et al. showed greater contributions of post-
prandial (PHG) and fasting (FHG) hyperglycemiae to overall hyperglycaemia 
at lower and higher HbA1c, respectively. However, it has never been studied 
in Korean diabetic patients. In addition, there have been few studies about 
determinant factors in postprandial and fasting glucose levels. Therefore, we 
assessed the relative contributions of PHG and FHG to the overall hypergly-
cemia and the influencing factors on PHG and FHG in Korean patients with 
type 2 diabetes.
Materials and methods: We enrolled 195 Korean type 2 diabetic patients 
which did not take insulin or α-glucosidase inhibitor. They performed a 
seven-point self-monitoring of blood glucose (7-point SMBG) more than 
once during each month for 3 consecutive months. Glucose area under the 
curve (AUC) above 100 mg/dL (5.5 mmol/L) was defined as AUC(total) to 
represent the overall hyperglycemia. The area under the curve above fasting 
glucose level was considered the postprandial hyperglycemia (AUC(PHG)). 
The fasting hyperglycemia (AUC(FHG)) was calculated as [(AUC(total) - 
AUC(PHG)]. The relative contributions of PHG and FHG to overall hyper-
glycaemia were respectively defined as the proportions of AUC(PHG) and 
AUC(FHG) to AUC(TOTAL).
Results: The relative contribution of PHG showed a significant difference 
and gradual decrement according to increasing quartiles of HbA1c (66.9±6.0, 
36.1±6.0, 40.3±3.2, 32.3±3.8%; P(ANOVA)<0.001, P(TREND)<0.001). And 
the contribution of FHG was increased progressively with increasing quar-
tiles of HbA1c (33.0±9.5, 63.8±6.0, 59.6±3.2, 67.6±3.8%; P(ANOVA)<0.001, 
P(TREND)<0.001). AUC(PHG) was positively correlated to age (r=0.191; 
p<0.01), systolic blood pressure (r=0.185; p<0.01), duration of diabetes age 
(r=0.185; p<0.01), C-peptide (r=0.198; p<0.01), HbA1c (r=0.282; p<0.01), 
and hsCRP (r=0.145; p<0.05). AUC(FHG) was positively correlated to body 
weight (r=0.190; p<0.01), waist circumference (r=0.185; p<0.01), C-peptide 
(r=0.217; p<0.01), HbA1c (r=0.658; p<0.01), alanine aminotransferase 
(r=0.228; p<0.01), and triglyceride (r=0.278; p<0.01) but negatively corre-
lated to age (r=-0.146; p<0.05). Using multiple linear regression to adjust 
for age, sex and other covariates, only age (β=0.181; p<0.05) and triglycer-
ide (β=0.150; p<0.01) remained significant variables of the AUC(PHG) and 
AUC(FHG), respectively.
Conclusion: In Korean type 2 diabetic patients, postprandial hyperglycemia 
predominantly contribute to overall hyperglycemia at lower HbA1c level, 
whereas fasting hyperglycemia is a predominant contributor to it at higher 
HbA1c level. And age and plasma triglyceride are independent predictors of 
postprandial and fasting hyperglycemiae, respectively.
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A putative role of P4 and E2 in the maternal late-onset glucose 
intolerance induced by gestational glucocorticoid excess
P.R.L. Gomes, S. Bordin;  
University of Sao Paulo, Brazil.
Background and aims: In order to guarantee a proper maternal glycaemic 
control, at the end of pregnancy the pancreatic islets undergo a transient 
morpho-functional remodelling. We have shown that pancreatic beta cell 
resetting involves the modulation of several intracellular pathways, most of 
them in a glucocorticoid (GC)-dependent manner. On the other hand, we 
have recently described that the excess of GC at the end of pregnancy re-
sults in a late-onset of glucose intolerance due to an impairment of GSIS. This 
phenomenon is correlated with an early up-regulation of miR-29 expression, 
a validated target of progesterone (P4). Of note, P4 was reported as a beta 
cell pro-apoptotic hormone, whereas estrogen (E2) abolishes the cytokine-
induced beta-cell death. Thus, we hypothesized that the functional resetting 
of the maternal pancreatic islets could depend on the proper E2 and P4 sig-
nalling. The aim of this work was to investigate the mechanisms involved in 
the late-onset maternal glucose intolerance induced by gestational GC excess, 
focusing on E2 and P4 signalling in pancreatic islets.
Materials and methods: Pregnant Wistar rats were treated with dexametha-
sone, 0.2 mg/kg daily in drinking water during the 14th to 19th day of preg-
nancy (P-DEX). Age-matched untreated pregnant rats (P) were used as con-
trols. At the 19th day of pregnancy, DEX-treated and untreated rats were eu-
thanized and pancreatic islets were isolated and used for western blot, qPCR 
analysis and GSIS; serum was used for P4 and E2 measurement. The Ethics 
Committee approved the study, and complies with the Brazilian Society of 
Laboratory Animal Science.
Results: P4 levels were significantly reduced in P-DEX compared to P rats 
(respectively 155.7±45.1 and 295.5±44.8 ng/ml; p<0.05), as well as the ex-
pression of progesterone receptor (PR) (0.2±0.1 times of P group; p<0.05). 
Neither E2 levels (55.6±22.6 and 41.4±20.8 pg/ml, respectively for P and P-
DEX rats) nor ERβ expression was altered by the treatment, but ERβ was 
increased (9.4±2.6 times higher than P islets; p<0.05). SGK1, a GC target that 
negatively regulates insulin secretion, was upregulated in islets from P-DEX 
rats (1.9±1.5 times of control values; p<0.05). In parallel, maximum insu-
lin response to glucose was lower than untreated P rats (0.6±0.2 times of P; 
p<0.05), but still responsive to glucose. In the presence of 2.8 mM glucose, in-
sulin secretion values were 0.53±0.06 ng/ml (0.48±0.04 ng/ml in virgin rats), 
and with 16.7 mM glucose the values reached 1.17±0.19 ng/ml (1.34±0.10 ng/
ml in virgin rats). The expression of inflammatory markers was also assessed. 
Compared to P islets, phospho-IKK/IKK ratio and NF-κB expression were 
reduced in P-DEX (respectively 0.7±0.1 and 0.3±0.1 times of P islets; p<0.05.
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Conclusion: The lower levels of P4 and PR in P-DEX islets is likely to be a 
factor involved in the previously described up-regulation of miR-29. The up-
regulation of ERβ induced by DEX treatment could be preserving the secre-
tory responsiveness to glucose. Finally, the down-regulation of inflammatory 
markers could disrupt beta cell resetting after parturition, thus reflecting in 
an inappropriate maternal glucose homeostasis.
Supported by: FAPESP, CNPq
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Determinants of insulin sensitivity in Middle Eastern immigrants and 
native Swedes
L. Bennet1, L. Groop2, P.W. Franks3;  
1Department of Clinical Sciences, Family Medicine, Lund University, 
2Department of Clinical Sciences, Lund University Diabetes Center, 
3Department of Clinical Sciences, Genetic and Molecular Epidemiology, 
Lund University, Malmö, Sweden.
Background and aims: Little is known about the metabolic, lifestyle and her-
itable risk factors that underlie the observation that type 2 diabetes (T2D) is 
highly prevalent amongst Middle Eastern immigrants to Northern Europe. 
Hence, in the current report from the MEDIM study (the impact of Migra-
tion and Ethnicity on Diabetes in Malmö), we aimed to (1) investigate insulin 
sensitivity and secretion (2) study risk factors associated with T2D and (3) 
investigate the contribution of metabolic-, demographic- and lifestyle-related 
risk factors for impaired insulin sensitivity index (ISI) in immigrants from 
Iraq, with comparisons to native Swedes.
Materials and methods: Population-based, cross-sectional study conducted 
2010-2012 including residents 30 to 75 years of age born in Iraq or Sweden, in 
whom 10-h fasting blood samples and oral glucose tolerance tests were per-
formed. Further, sociodemography, lifestyle behaviors and comorbidity were 
assessed by questionnaires. Insulin sensitivity and secretion were assessed by 
Matsuda indices. Outcomes were T2D and ISI. Associations were assessed by 
logistic- and linear regression analysis.
Results: In Iraqi (n=1398) compared to Swedish (n=757) participants, T2D 
was twice as prevalent (11.6 vs. 5.8%, p<0.001) and T2D onset occurred more 
than six years earlier. The prevalence of family history of T2D was twice as 
frequent in Iraqis compared with Swedes. ISI was generally lower in Iraqis as 
compared to Swedes (ISI 76.9 vs. 102.3, p<0.001 (mmol/L*mIE/L)-1. Although 
insulin secretion (CIR) was generally higher in Iraqis, insulin response 
relative to the degree of insulin resistance (DIo) was lower in Iraqis than in 
Swedes (12712.9 vs. 14659.2 mmol/L-1* mmol/L-1* mmol/L-1, p<0.001). Low-
er ISI and DIo in Iraqis than in Swedes were also observed in participants 
without T2D as well as in participants with normal waist circumference and/
or normal weight (BMI<25kg/m2). Further, Iraqis without T2D presented a 
less advantageous glucose and lipid profile, larger waist circumference and 
higher BMI compared to Swedes (Table 1). Irrespective of other traditional 
risk factors for T2D, ISI conveyed higher standardized odds of T2D in Iraqis 
than in Swedes; the difference between the magnitude of these relationships 
was confirmed by a statistically significant interaction between country of 
birth and ISI (Pintersensitivity=0.044). There was no interaction between country 
of birth and CIR. The crude difference in ISI according to ethnicity remained 
significant even when adjusting for metabolic-, anthropometric-, and lifestyle 
factors.
Conclusion: The key findings of this study are that there are ethnic differ-
ences in the relationship of insulin sensitivity with T2D; our study suggests 
that ethnic background modifies the effect of insulin sensitivity on the risk of 
T2D diabetes and further that the impaired insulin sensitivity in this Arabic 
population is only partly explained by excess waist circumference or other 
known risk factors for insulin sensitivity. We conclude that Middle Eastern 
immigrant populations are likely to benefit greatly from interventions fo-
cused on improving insulin sensitivity.
Supported by: Lund University, Swedish Society of Medicine, Swedish Research 
Council
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Effect of lowering plasma glucose and FFA concentrations on insulin 
sensitivity and beta cell function in T2DM individuals
M. Abdul-Ghani, A. Merovci, C. Solis, J. Xiong, G. Daniele,  
A. Chavez-Valazquez, D. Tripathy, R.A. DeFronzo;  
Medicine\Diabetes, University of Texas Health Science Center at San 
Antonio, USA.
Background and aims: Chronic elevation in plasma FFA (lipotoxicity) and 
plasma glucose (gluco-toxicity) concentrations have been shown to have 
detrimental effect on both core defects (insulin resistance and beta cell dys-
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function) in T2DM. We have shown that lowering plasma FFA and plasma 
glucose concentrations separately in T2DM individuals improves beta cell 
function and ameliorate insulin resistance. In the present study, we examined 
the effect of lowering both the plasma FFA and glucose concentrations on 
beta cell function and insulin sensitivity in T2DM individuals.
Materials and methods: 12 T2DM subjects (age=49 ±3, BMI=31.1± 1.8, 
HbA1c = 8.5 ± 0.3, diabetes duration = 8.5 ± 0.3 years) received treatment 
with dapagliflozin (10 mg/day) for 3 weeks and during the third week they 
also received acipimox (250 mg four times daily). 75 gram OGTT and eugly-
cemic insulin clamp were performed at baseline and at weeks 2 and 3.
Results: Compared to baseline, dapagliflozin lowered the fasting plasma 
glucose concentration at 2 weeks (181±9 to 146±9, p<0.01); the decrease in 
(FPG) was accompanied by significant increase in insulin-stimulated total 
glucose disposal (TGD) (4.16 ±0.71 to 5.15±0.73, p<0.05), and beta cell func-
tion. ∆C-pep/∆G[0-120]÷IR increased by 105% (p=0.003). At week 3, plasma 
FFA concentration was decreased by 28% compared to week 2 and this de-
crease was accompanied by a small, non-significant increase (by 9%) in insu-
lin-mediated TGD, beta cell function (∆C-pep/∆G[0-120]÷IR)÷IR increased 
further by 53% (0.15±0.03 to 0.23 ±0.04, p=0.02).
Conclusion: Simultaneously lowering the plasma glucose and FFA concen-
trations has an additive effect to improve beta cell function, but not to im-
prove insulin sensitivity.
Supported by: NIH
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Effects of a lifestyle intervention in a pre-diabetic mouse model: glucose 
homeostasis and pancreatic beta cell function and mass
A. Gonzalez-Franquesa1, L. Navarro-Martínez1, R. Fernández-Ruiz2,  
P.M. García-Rovés1,2;  
1Diabetes and Obesity Laboratory, IDIBAPS, 2CIBERDEM, Barcelona, 
Spain.
Background and aims: Pancreatic beta-cells play a major role in obesity-re-
lated type 2 diabetes (T2DM) aetiology. Thus, pancreatic beta-cell plasticity is 
defined as the ability of the cells to adapt their function and mass to the vari-
ations in insulin demand. It is already known that during pregnancy mouse 
pancreatic beta-cell mass increases but it is then rapidly reversed towards the 
end of the pregnancy. Although pancreatic beta-cell mass has been extensive-
ly studied, many considerations of its plasticity in different physiological and 
pathological situations remain still unknown. This study assesses the adapta-
tions that occur in pancreatic beta-cells before and after following a lifestyle 
intervention programme aimed to recover glucose homeostasis in an animal 
model of diet-induced obesity and pre-diabetes.
Materials and methods: C57BL/6J male mice were divided in three groups: 
a control group (Ctrl) (fed with chow standard diet), a pathological group 
(HFD) (fed for 16 weeks with 45% HFD, D12451 Open Source DietsTM) and 
an intervention group (Int) in which mice followed a lifestyle intervention 
after they have reached the pathological state. This lifestyle intervention con-
sisted on calorie restriction, modification of the 45% HFD with mono- and 
poly-unsaturated fatty acids and the replacement of sucrose by corn starch, 
and an exercise training programme for 5 weeks. Insulin tolerance test (ITT), 
glucose tolerance test (IGTT), body weight evolution, fat volume, tissue 
weights, inflammatory profile, and fasting insulin and leptin levels were as-
sessed for the three groups. Pancreases were excised for immunohistochem-
istry studies. Pancreatic islets were isolated for in vitro glucose-stimulated 
insulin secretion (GSIS).
Results: The mice in the HFD group were glucose intolerant and showed in-
sulin resistance when compared to their littermates, Ctrl group. Morevoer, 
those mice on the HFD group were significantly overweight, hyperglycemic, 
hyperinsulinemic, and hyperleptinemic after an overnight fasting. Morpho-
logical analyses of the pancreases showed that the HFD group mice had an 
increase in beta-cell mass with more and bigger pancreatic islets than the Ctrl 
littermate mice. Isolated islets from HFD mice showed an increase in in vitro 
GSIS when incubated in 16.7mM of glucose. The mice on the Int group were 
leaner, returning to the Ctrl group body, liver and pancreas weight values and 
reducing the increase in fat volume of the mice in the HFD group. Those mice 
showed a general improvement in glucose homeostasis. However, the mice 
on the Int group were still moderately hyperglycemic and hiperinsulinemic 
after overnight fasting. Morphometric analysis of the pancreas showed that 
insulin positive area remained unchanged with respect to the HFD group 
although a significant increment in the number of small islets was observed.
Conclusion: Our lifestyle intervention improved most of the deleterious ef-
fects that led to a diet-induced pre-diabetic state in the absence of significant 
effects on pancreatic beta cells.
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Plasma 26RFa is increased in diabetic patients: evidence for an 
involvement in glucose homeostasis
G. Prevost1,2, L. Jeandel2, A. Arabo2, H. Berrahmoune1, M. Mehio2,  
D. Alexandre2, Y. Anouar2, H. Lefebvre1,2, N. Chartrel2;  
1Endocrinology, Diabetes and Metabolic Diseases, CHU ROUEN, Rouen, 
2Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 
(U) 982, Neuronal and Neuroendocrine Differentiation and Communication 
Laboratory , Institute of Research and Innovation in Biomedicine, 
Normandie University, University of Rouen, Mont saint Aignan, France.
Background and aims: 26RFa is an orexigenic neuropeptide identified as the 
endogenous ligand of the human orphan receptor GPR103. Moreover, animal 
studies suggest that 26RFa is involved in the pathophysiology of obesity. The 
aim of this study was to investigate plasma 26RFa level in obese and diabetic 
patients, and to explore a possible link between 26RFa and glucose homeo-
stasis.
Materials and methods: Fasting plasma 26RFa was determined by using a 
specific radioimmunoassay in 161 subjects divided into 4 groups: controls, 
obese patients, obese type 2 diabetic patients and type 1 diabetic patients. 
Plasma 26RFa was also evaluated during a 180 min oral glucose tolerant test 
(OGTT) in 10 healthy controls. Immunohistochemical studies with anti-
26RFa and anti-GPR103 antibodies were performed on human pancreatic 
slices. Finally, 26RFa was injected in C57Bl mice during an intraperitoneal 
glucose tolerance test (IPGTT).
Results: Fasting plasma 26RFa was significantly increased in obese patients 
as compared to controls (352±47 vs 224±32 pg/ml; p<0.05), but even more in 
type 1 and type 2 diabetic patients (605±115 pg/ml and 677±99 pg/ml vs con-
trols; p<0.001). Plasma 26RFa was positively correlated with age and blood 
glucose, but not with the BMI. In multivariate linear analysis, the correla-
tion between fasting 26RFa level and blood glucose was independent from 
age. During the OGTT in controls, plasma 26RFa significantly increased at 
120 min after the oral glucose load (+57,3% ; p<0.05). Immunohistochemical 
studies revealed that 26RFa and its receptor were present in the beta pan-
creatic cells. Finally, intraperitoneal 26RFa injection during IPGTT was as-
sociated with a reduced glucose-induced hyperglycemia, and an increase of 
insulin secretion.
Conclusion: This study reports for the first time that plasma 26RFa is in-
creased in diabetic patients and is correlated to blood glucose. Moreover, ani-
mal studies suggest that the neuropeptide exerts its anti-hyperglycemic effect, 
at least in part, via an increase of insulin secretion.
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An unusual metabolic interplay: type 1 diabetes and glutaric aciduria 
type 1
A. Galderisi1, V. Moret1, L. Giordano2, A.B. Burlina2, C. Monciotti1;  
1Pediatric Diabetology Unit, 2Metabolic Unit, Department of Woman’s and 
Child’s Health, University of Padua, Italy.
Background and aims: Type 1 diabetes (T1D) metabolic balance is affected 
by several variables (foods, insuiln dose and daily-life activities of our pa-
tients). The management becomes more difficult if an extra factor affects the 
glucose homeostasis such as in the case we report: the concomitant occur-
rence of Glutaric aciduria type 1 (GA1, a rare organic aciduria) and Type 1 
diabetes in a young boy. Even if their coexistence may appear a pure coinci-
dental association, their interplay shows an unexpected phenotype.
Materials and methods: A 21 months boy, treated for T1D since the age of 
15 months (anti-GAD>2000kUI/L at onset), was referred to our attention 
from another center for the onset of GA1. Due to the severe neurological 
impairment, consequent on GA1 related basal ganglia damage, he required 
enteral nutrition via nasogastric tube, receiving an age adapted lysine free 
diet, arginine (100 mg/kg/die) and carnitine (160 mg/kg/die). Insulin therapy 
was adapted to this regimen. CGMS (Medtronic®Guardian RT) highlighted 
a marked tendency to hypoglycemic events (30% of daily values below the 
range (mean AUC<3.9mmol/L: 0,8) in the early morning hours (4-6am), 
poor controlled by our insulin adjustments. (fig.1;human insulin, blue ar-
rows; glargine, red arrow).
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Results: After 15 days from the beginning of diet and therapy for GA1 we ob-
served a drop of anti GAD to 233KUI/L and a marked reduction of hypogly-
cemias (mean AUC<3.9mmol/L: 0), with an increased insulin requirement.
Conclusion: Animal models of GA1 showed an impairment of gluconeogen-
esis, involving Krebs disfunction in liver and GAD enzyme in brain. To date 
it has never been confirmed in humans with GA1. This is the first CGMS data 
from a GA1 patient: the hypoglycemia during nocturnal starvation reflects 
this gluconeogenetic impairment. The reduction of hypoglycemic events, the 
drop of anti-GAD, with the beginning of GA1 therapy, supports the observa-
tion on animal models. We can suppose that the contemporary presence of 
anti-GAD and the deficit of Krebs in T1D, may exacerbate the hypoglycemic 
events of GA1 making them clinically relevant.
Supported by: Medtronic provided CGMS device.
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Higher mean glucose levels and glucose variability in non-diabetes 
sepsis/septic shock patients than in healthy subjects
A. Sriwijitkamol, N. Suwansaksri, L. Preechasuk, C. Permpikul,  
S. Vannasaeng;  
Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, 
Thailand.
Background and aims: Hyperglycemia is one of the factors linked to increase 
mortality in sepsis or septic shock patients. Retrospective study had shown 
that the glucose variability (GV) associated with increased mortality in these 
patients. Until now, data on GV in sepsis/septic shock patients are sparse. 
Moreover, there is no prospective study to demonstrate whether glucose vari-
ability in sepsis patients is different from healthy subjects. Therefore, the aims 
of this study were to compare glucose profiles including mean glucose lev-
els and glucose variability between sepsis patients and healthy subjects, and 
to study the correlation of glucose variability calculated from glucose level 
obtained from continuous glucose monitoring (CGM) and capillary plasma 
glucose (CPG).
Materials and methods: Sepsis patients (SEPSIS) who had no history of 
diabetes and hemoglobin A1c (A1C) < 6.5% were recruited. All subjects had 
72-hour continuous glucose monitor or CGM, using iPro 2 (Medtronic, US) 
within 12 hours after admission. 72-hour CGM was also applied to healthy 
subjects without diabetes to serve as a control group (CON). Capillary plas-
ma glucose (CPG) was obtained from both groups for 4 to 6 times per day 
during the study period 3. Glucose levels (GL) obtained from CGM and CPG 
during the 24-hour and 72-hour were used to calculate mean glucose level 
(MGL24h and MGL72h), and glucose variability including standard devia-
tion (SD24h and SD72h), coefficient of variation (CV24h and CV72h) and 
mean amplitude of glycemic excursion (MAGE24h and MAGE72h).
Results: This was a prospective study. Fourteen subjects with sepsis and ten 
healthy subjects were recruited. SEPSIS was older than CON whereas there 
was no difference in sex, BMI and A1C. Glucose profiles obtained from CGM 
and CPG demonstrated the similar results as shown in table. The MGL24h 
and MGL72h were significant higher in SEPSIS than CON. The GV during 
72-hour as demonstrated by SD72h, MAGE72h were also higher in SEPSIS 
than CON. The glucose profiles obtained form CGM and CPG in SEPSIS had 
a strong correlation.
Conclusion: Patients without diabetes who sepsis had elevated mean glucose 
levels at 24-hour and 72-hour and glucose variability at 72-hour as compared 
to healthy subjects. Therefore, the strategy aimed to target both mean glucose 
level and glucose variability might have benefit in non-diabetic patients with 
sepsis/septic shock. We also demonstrated that the use of 4 to 6 time points 
of capillary glucose levels to calculate the glucose profiles provided accurate 
data similar to those obtained from CGM in sepsis patients.
Supported by: Siriraj Grant for research development Faculty of Medicine 
Siriraj Hospital
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Effects of chronic variable stress and dietary fat on insulin sensitivity
S. Müller-Lühlhoff1, T. Jelenik2, S. Hartwig1, S. Lehr1, P. Nowotny2,  
M. Roden2,3, H. Al-Hasani1, T.R. Castañeda1;  
1Institute for Clinical Biochemistry and Pathobiochemistry, 2Institute for 
Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes 
Research, 3Department of Endocrinology and Diabetology, University 
Clinics Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Background and aims: Stress is a state of threat to homeostasis that may 
contribute to metabolic disorders such as visceral obesity and type 2 diabetes. 
However, there is a lack of studies analyzing the long-term consequences of 
chronic stress on insulin sensitivity and its relation to fat consumption. Our 
aim was to characterize how chronic variable stress (CVS) in relation to di-
etary fat affects insulin sensitivity in mice.
Materials and methods: Three-months old, body weight (BW)-matched 
male C57BL/6 mice were exposed to a random series of stressors for 15 days 
(CVS), the unstressed control mice were housed separately (Ctrl). Body com-
position was analyzed with NMR. After CVS, blood was collected (08:00-
12:00 am) for corticosterone and insulin analysis. Subsequently, mice were 
consuming a low- (Chow) or a high-fat diet (HFD) for three months and 
insulin sensitivity was measured in vivo with hyperinsulinemic-euglycemic 
clamps. Statistical differences were considered significant at p<0.05 (two-
tailed unpaired t-test).
Results: CVS mice (n=24) had lower BW (25.49±0.33 g, p<0.001) and lean 
mass (23.08±0.37 g, p<0.001) with no changes in fat mass (2.23±0.08 g) com-
pared to the Ctrl group (n=24), (28.32±0.36 g, 25.37±0.39 g, 2.25±0.09 g, 
respectively). Plasma levels of corticosterone were higher in the CVS group 
(n=22-24) (109.90±13.71 vs 60.37±7.55 ng/ml, p<0.01) as well as insulin 
levels (0.65±0.06 vs 0.47±0.03 ng/ml, p<0.01) compared to the Ctrl group 
(n=19-24). When fed Chow, the CVS group (n=10) showed a trend to lower 
basal endogenous glucose production (EGP) (20.01±1.12 vs 23.86±1.48 mg/
kg/min, p=0.055), while insulin-stimulated glucose disposal (Rd) in periph-
eral tissues was increased in CVS compared to Ctrl (363±29 vs 275±17 % of 
basal, p<0.05). On HFD, basal EGP was unchanged, while Rd (135±12 vs 
192±14 % of basal, p<0.01) was decreased with CVS. Suppression of EGP 
by insulin was unaffected by CVS. CVS-Chow mice showed lower plasma 
adiponectin (5.87±0.43 vs 11.29±1.39 µg/ml, p<0.01) and a trend towards 
lower resistin (0.13±0.005 vs 0.14±0.005 µg/ml, p=0.06) compared to Ctrl. 
CVS-HFD mice showed lower plasma adiponectin (7.99±0.89 vs 15.74±3.28 
µg/ml, p<0.05) and a trend towards higher resistin (0.17±0.02 vs 0.11±0.02 
µg/ml, p=0.06) compared to Ctrl.
Conclusion: When fat consumption is low, chronic stress improves insulin 
sensitivity through higher peripheral glucose disposal. On the contrary, HFD 
consumption exacerbates insulin resistance under these conditions. Changes 
in adipokine profiles could be a possible mechanism underlying the effects of 
CVS and dietary fat on peripheral insulin sensitivity.
Supported by: DDZ TFG 2012
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Oxygen restriction as challenge test reveals early diet-induced health 
effects
E.M. van Schothorst1, L. Duivenvoorde1, D. Derous1, I. van der Stelt1,  
J. Masania2, N. Rabbani2, P.J. Thornalley2, J. Keijer1;  
1Human and Animal Physiology, Wageningen University, Netherlands, 
2Clinical Sciences Research Laboratories, Warwick Medical School, 
Coventry, UK.
Background and aims: Challenge tests stress homeostasis and may reveal 
deviations in health that remain masked under unchallenged conditions. Ide-
ally, challenge tests are non-invasive and applicable in an early phase of a 
study. The response to oxygen restriction (OxR; mild normobaric 12% O2) 
measures the flexibility to adapt metabolism. Metabolic inflexibility is one of 
the hallmarks of the metabolic syndrome and underlying insulin resistance.
Materials and methods: Male C57BL/6JOlaHsd adult mice were fed a low-
fat (LF) or high-fat (HF) diet for only five days. Indirect calorimetry was used 
to assess the response to OxR. Serum markers, including protein glycation/
oxidation, and gene expression in liver and white adipose tissue (WAT) were 
analyzed.
Results: Although HF-fed mice had a significant higher body weight (BW) 
after five days of feeding, HF-fed and LF-fed mice did not differ in calori-
metric values under normal conditions nor in fasting state. Moreover, the 
subgroups of mice that were fasted and exposed to OxR during the last 6h 
showed no differences in BW (gain), nor in blood glucose levels. Exposure to 
OxR, however, revealed significant differences in substrate use with the HF-
fed mice showing higher fatty acid oxidation levels and oxygen consumption, 
while their activity was similar to LF-fed mice. Furthermore, hepatic and 
WAT transcript levels differed significantly between both groups indicating 
differences in their adaptation to OxR. Only HF-fed mice showed increased 
hepatic lactate/glucose metabolism upon OxR, while LF-fed mice showed 
an increased oxidative stress response in WAT (see Figure). The adaptation 
in HF-fed mice appeared to be dampened, associated with increased serum 
markers of protein glycation/oxidation, whereas these changes were absent 
in LF-fed mice.
Conclusion: An oxygen restriction challenge test is a promising new method 
to test food products on potential beneficial effects for metabolic health. Dif-
ferential metabolic adaptations upon OxR in hepatic lactate metabolism and 
stress response. Transcripts appeared up-regulated by OxR both in LF and 
HF (blue), only in HF (red), only in LF (green), or non-regulated (black). 
Lactate/Glucose metabolism (A) was analysed in liver, stress response mainly 
in WAT (B). Underlined transcripts denote up-regulation by HF vs LF under 
normoxia. Mod1 appeared down regulated by HF vs LF under normoxia. *: 
not determined.
Supported by: BIOCLAIMS
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A syndrome of hyperinsulinaemic reactive hypoglycaemia associated 
with mutations in the human insulin receptor gene: two cases report
Y. Kuroda1,2, H. Iwahashi1, I. Mineo3, K. Fukui1, A. Fukuhara1, R. Iwamoto1, 
A. Imagawa1, I. Shimomura1;  
1Department of Metabolic Medicine, Graduate School of Medicine, 
2Department of Endocrinology and Metabolism, Sumitomo Hospital, 
3Diabetes Center, Toyonaka Municipal Hospital, Osaka, Japan.
Background and aims: Hyperinsulinemic hypoglycaemia in adults is the 
most frequently caused insulinoma but some cases, especially reactive hypo-
glycaemia, remain unexplained. We have experienced two independent cases 
of hyperinsulinemic reactive hypoglycaemia with adolescence or adult onset 
and analysed their pathophysiology and insulin receptor (IR) genes including 
those of their relatives.
Materials and methods: Genomic DNA was extracted from the patient’s leu-
kocytes and the direct sequencing for all exons of IR gene was performed. In 
overexpression experiments, we used pCMV expression vector and HEK293 
cells, and the mutant IR described below was generated by PCR-based mu-
tagenesis.
Results: Case 1 was a 42-year-old man. He had experienced recurrent epi-
sodes of finger tremor and cold sweat that dispelled by drinking juice since 
he was about 30 years old. His body mass index was 20.7. Laboratory tests 
showed fasting plasma glucose (FPG) was 76 mg/dl, fasting immunoreactive 
insulin (F-IRI) was 19.0µU/ml, fasting C-peptide (F-CPR) was 1.37 ng/ml, 
and HbA1c was 5.0%. A 75g OGTT exhibited normal glucose tolerance pat-
tern and reactive hypoglycaemia at 3h. Case 2 was a 34-year-old man. Since he 
was fifteen years -old, he had experienced recurrent episodes of finger tremor 
and cold sweat that dispelled by drinking juice. Laboratory tests showed FPG 
was 104mg/dl, F-IRI was 71.7µU/ml, F-CPR was 3.1ng/ml, and HbA1c was 
6.7%. A 75g OGTT exhibited diabetic pattern and reactive hypoglycaemia at 
4h. In both cases, neither anti-insulin nor anti-IR antibody was observed. We 
found that the former case had a novel missense mutation (Arg229Cys) in 
both alleles of IR gene, and both his parents had the same mutation only in 
one allele but not hyperinsulinaemic reactive hypoglycaemia. Furthermore, 
we also found that the latter case had a novel nonsense mutation (Trp1273X) 
followed by a mutation (Gln1274Lys) in a single allele of IR gene and his 
nine-year old son had the same mutation in one allele and also hyperinsuli-
naemic reactive hypoglycaemia. Overexpression experiments of the mutant 
gene (Arg229Cys) in HEK293 cells revealed increase of proreceptor-mature 
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receptor ratio of IR protein and reduced Akt phospholylation by insulin stim-
ulation (at concentration of 0.1 or 1.0nM) compared to wild type.
Conclusion: In two cases of hyperinsulinaemic reactive hypoglycaemia, we 
found novel mutations in the IR gene considered to be linked to their hypo-
glycemia. We propose a disease entity of a syndrome of hyperinsulinaemic 
reactive hypoglycaemia associated with mutations in the human IR gene.
PS 034 Glucose uptake and  
glucose action
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APPL1 affects on glucose uptake induced by uniaxial stretch  
in C2C12 myotubes
T. Saito, Y. Shimoda, Y. Tagaya, E. Yamada, S. Okada, M. Yamada;  
Medicine and Molecular Science, Gunma University, Maebashi, Japan.
Background and aims: Adaptor protein, phosphotyrosine interaction, PH 
domain and leucine zipper containing 1 (APPL1) was identified as protein 
kinase B or Akt (PKB/Akt) binding protein. It has been reported that APPL1 
highly expresses in adipose and muscle tissues and has an important role 
in GLUT4 translocation in response to insulin and adiponectin via Akt or 
5’ adenosine monophosphate-activated protein kinase (AMPK) dependent 
pathway. We found that Akt and AMPK were activated in mouse derived 
muscle cell line, C2C12 cell, in response to uniaxial stretch stimulation. 
Therefore, this study aimed to investigate the function of APPL1 in C2C12 
myotubes on GLUT4 translocation mechanism stimulated by mechanical 
stretch.
Materials and methods: C2C12 myoblasts were grown on an elastic silicone 
chamber and promoted differentiation. Differentiated C2C12 myotubes were 
stimulated by cyclic uniaxial stretch (10% of initial length, 10 cycle/min) for 
5 hours. Plasmid DNA was transfected into C2C12 myoblasts by electropora-
tion. Glucose uptake was measured by enzymatic assay and the localization 
of APPL1 was examined by immunofluorescence. Compound C, an AMPK 
inhibitor, or protein kinase C (PKC) zeta pseudosubstrate, a PKC inhibitor, 
was administrated to block the activity of AMPK or PKC zeta pathway dur-
ing stretch.
Results: Stretch increased glucose uptake, Akt, AMPK, and PKC zeta phos-
phorylation without affecting protein expression of these proteins and 
GLUT4. APPL1 localized at perinuclear in basal condition and moved to 
plasma membrane after stretch stimulation. Stretch-induced glucose up-
take, AMPK, and PKC zeta phosphorylation were statistically increased by 
26%, 28%, and 30%, respectively, in APPL1 transfected cells compared to 
non-transfected. On the other hand, stretch-induced Akt activation was sup-
pressed by 30% in APPL1-overexressed cells. Although compound C didn’t 
affect on glucose uptake, PKC zeta pseudosubstrate suppressed glucose up-
take induced by APPL1 by 67% in stimulated condition.
Conclusion: These results suggest that APPL1 is regulated by stretch stimula-
tion and promote stretch induced glucose uptake in C2C12 myotubes mainly 
through PKC zeta dependent signaling pathway, but not AMPK dependent 
pathway.
Supported by: JSPS KAKENHI
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Acetic acid enhances glucose uptake and blood flow rates in the skeletal 
muscle in humans with impaired glucose tolerance
E. Petsiou1, P. Mitrou2, E. Papakonstantinou1, E. Maratou2, V. Lambadiari1,  
F. Spanoudi1, S.A. Raptis1,2, G. Dimitriadis1;  
12nd Department of Internal Medicine and Research Institute, Athens 
University Medical School, Attikon University Hospital,  
2Hellenic National Center for Research, Prevention and Treatment of 
Diabetes Mellitus and its Complications (H.N.D.C), Athens, Greece.
Background and aims: Previous studies support the antiglycaemic effect of 
vinegar. However, the effect of vinegar on endothelial function and muscle 
glucose metabolism has not been studied in humans. This cross-over study 
aims to investigate the effects of vinegar on plasma glucose, insulin and lipid 
levels, as well as blood flow and muscle glucose uptake in subjects with im-
paired glucose tolerance (IGT), using the arteriovenous difference technique.
Materials and methods: Eight subjects with IGT (age 46+4years, BMI 29+2), 
without any medication therapy, were randomised to consume vinegar (30ml 
vinegar containing 6% acetic acid, 20ml water) or placebo (50ml water) be-
fore a mixed meal (566kcal; 75g carbohydrates, 26g protein, 6g fat). Plasma 
samples were taken at 15-60min intervals for 300min from the radial artery 
and from a forearm vein for measurements of glucose, insulin, triglycerides, 
non-esterified fatty acids (NEFA) and glycerol. Muscle blood flow was meas-
ured with strain-gauge plethysmography. Glucose flux was calculated as the 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 234 
1 C
arteriovenous difference of glucose multiplied by the blood flow rates. The 
cross-over study was conducted 1 week later.
Results: Vinegar compared to placebo: 1) decreased arterial plasma insulin 
(8101+1410 vs 12008+1645mU/L*min, p=0.043) 2) increased forearm blood 
flow (404+97 vs 134+71 ml/min/100ml tissue*min, p=0.048) 3) increased 
muscle glucose uptake (933+74 vs 603+108μmol/100ml tissue, p=0.02) 4) de-
creased arterial plasma triglycerides (45+11 vs 86+10 nmol/L*min, p=0.036), 
without changing NEFA and glycerol.
Conclusion: In individuals with impaired glucose tolerance, vinegar addi-
tion to a mixed meal results in an enhancement of muscle blood flow rates, 
an improvement of glucose uptake by the forearm muscle and a reduction of 
postprandial hyperinsulinaemia and hypertriglyceridaemia. From this point 
of view vinegar may be considered beneficial for improving insulin resistance 
and metabolic abnormalities in the atherogenic prediabetic state.
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Disclosing acute caffeine action on insulin sensitivity: effects on skeletal 
muscle
M.J. Ribeiro1, J.F. Sacramento1, S. Yubero2, B.F. Melo1, A. Obeso2,  
C. Gonzalez2, M.P. Guarino1,3, S.V. Conde1;  
1CEDOC, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 
Portugal, 2Departamento de Bioquímica y Biología Molecular y Fisiología, 
Universidad de Valladolid, Facultad de Medicina. IBGM, CSIC. Ciber 
de Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, 
Valladolid, Spain, 3UIS-Unidade de Investigação em Saúde- Escola Superior 
de Saúde de Leiria- Instituto Politécnico de Leiria, Portugal.
Background and aims: Caffeine, a non-selective adenosine antagonist, is 
the behaviorally active substance most widely consumed in the world. When 
consumed regularly, this xanthine presents beneficial effects on type 2 diabe-
tes and metabolic syndrome. However, the sensitizer effect of chronic caffeine 
intake contrasts with acute caffeine administration that has been associated 
with an increase in insulin resistance (IR). The aim of this work was to in-
vestigate the effect of acute caffeine administration on insulin sensitivity and 
the involvement of adenosine receptors. Additionally, the mechanism behind 
caffeine-mediated effects in skeletal muscle was assessed.
Materials and methods: In vivo experiments were performed in Wistar rats 
of both sexes, aged 3 months (200-350g) anaesthetized with pentobarbitone 
(60mg/Kg). The effect of the acute administration of caffeine (0.001-5μM), 
DPCPX (A1 antagonist, 0.0005-5μM), SCH58261 (A2A antagonist, 0.0005-
5μM) and MRS1754 (A2B antagonist, 0.001-5μM) on insulin sensitivity was 
evaluated by means of an insulin tolerance test. Skeletal muscle Glut4 and 
AMPKα1 expression were quantified by Western-blot. The effect of A1 and 
A2B adenosine agonists on glucose uptake was evaluated. Sodium nitroprus-
siate (SNP, 10nM), a nitric oxide (NO) donor was used to evaluate the effect 
of NO on adenosine antagonism induced-IR.
Results: Acute caffeine decreased insulin sensitivity in a concentration de-
pendent manner (Emax=55.54 ± 5.37%, IC50=11.61nM), an effect that is 
mediated by A1 and A2B adenosine receptors. Additionally, in skeletal mus-
cle, acute caffeine administration did not modify AMPK expression, however 
it significantly decreased Glut4 by 23.23% and 31.81% (0.05 and 0.5μM of 
caffeine, respectively). We found that A1, but not A2B agonists significantly 
increased glucose uptake to 2.11±0.04 nmol.mg-1 tissue in skeletal muscle 
when compared to control (1.69±0.04nmol.mg-1tissue). SNP partially re-
versed DPCPX and MRS1754 induced-IR by 77.4 and 51.1%, respectively, 
when compared with the application of adenosine antagonists alone (KITT 
DPCPX=2.12±0.44%glucose.min-1; KITT MRS1754=2.16±0.08%glucose.
min-1).
Conclusion: Acute caffeine administration decreases insulin sensitivity in a 
concentration dependent manner being this effect mediated by A1 and A2B 
adenosine receptors. In skeletal muscle, the effect of caffeine on insulin sen-
sitivity involves a decrease in Glut4 expression and in insulin-dependent glu-
cose uptake that is mediated mainly by A1 adenosine receptors. Additionally, 
adenosine-mediated insulin sensitivity seems to involve NO production and 
its sensitizer actions.
Supported by: FCT: PTDC/SAU-ORG/111417/2009, BFU2012-37459 and 
CIBER CB06/06/005
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Glucose uptake independent of insulin action: role of S-nitrosilated 
insulin chains
J.M. Gaspar1,2, I.S. Lima1,2, J. Caldeira3, Y.-B. Kim2, M.P. Macedo1,4;  
1Chronic Disease Center (CEDOC), New Medical School,, Lisbon, 
Portugal, 2Division of Endocrinology, Diabetes and Metabolism, Beth Israel 
Deaconess Medical Center, Boston, USA, 3REQUIMTE, Faculty of Sciences 
and Technology, 4Portuguese Association of Diabetes and Education 
Research Center (APDP-ERC), Lisbon, Portugal.
Background and aims: Portal insulin is removed (50-70%) during first pass 
transit in the liver by a process called insulin clearance. Protein disulfide 
isomerase (PDI) mediates insulin clearance by reduction of insulin disulfide 
bonds, breaking it into A and B chains by a mechanism that requires glu-
tathione (GSH). Previously, we reported that A/B chains of insulin could 
be S-nitrosated (A-SNO and B-SNO) in vitro, forming nitrosothiols. After 
a meal, the increase of GSH levels together with the activation of parasym-
pathetic nervous system which leads to nitric oxide (NO) release results in 
an increase in peripheral insulin sensitivity. A concurrent increase in hepatic 
PDI activity cleaves and nitrosilates A and B chain of insulin (A-SNO e B-
SNO). Our hypothesis is that S-nitrosilated modified derivatives of insulin, 
A-SNO and B-SNO, produced during the insulin clearance process stimulates 
glucose uptake in skeletal muscle by a mechanism independent of the insulin 
signalling pathway.
Materials and methods: The presence of BSNO in the liver of Wistar rats 
was analyzed by immunoprecipitation of S-nitrosilation proteins following 
by western blot for B-chain. Physiological effects of S-nitrosilated modified 
derivatives of insulin were evaluated in differentiated skeletal muscle cells 
(L6-mycGLUT4 cells) and adipocytes (3T3-L1 cells). The cells were stimu-
lated with 100nM insulin, A-chain, B-chain, A-SNO and B-SNO to evalu-
ate glucose uptake using 3H-Glucose method. To analyse detailed signalling 
pathways activated by these insulin derivatives we performed cellular extracts 
and by western blotting technique we investigate the enrolled proteins.
Results: We detected the existence of BSNO in liver homogenates of rats and 
that BSNO levels were decreased (23% comparing with sham rats) in animals 
that were subjected to an hepatic denervation of parasympathetic nerves - 
NO pathway. We observed that A-SNO and B-SNO significantly stimulates 
glucose uptake in L6 muscle cells (159.8 ± 19.2% and 204.8 ± 30.2% to con-
trol, respectively), similar to insulin stimulus (203.1 ± 15.0). The stimulation 
of glucose uptake was mediated by the activation of AMPK pathway, detected 
by the increase in phosphorylation of Thr172 AMPK. We also observed that 
these insulin derivatives did not activate the canonical insulin pathway. In 
adipocytes we observed that A-chain and B-chain insulin derivatives increase 
glucose uptake (309.2 ± 83.2% and 319.0 ± 23.6% to control, respectively). 
In a lesser extent B-SNO also stimulates glucose uptake (193.6 ± 13.8% to 
control). In adipocytes these derivatives does not activate either the canonical 
insulin pathway or AMPK signaling pathway.
Conclusion: As a conclusion insulin clearance process can lead to the for-
mation of A/B chain and/or the respective S-nitrosilated derivatives. In 
adipocytes, mainly A-chain and B-chain stimulates glucose uptake. On the 
other hand when insulin derivatives are S-nitrosilated (A-SNO and B-SNO) 
they act on skeletal muscle promoting glucose uptake, through activation of 
AMPK signaling pathway.
Supported by: Albert Renold (EASD), EMBO, PTDC/DTP-EPI/0207/2102 
(FCT)
564
Treatment with small, subthyrotoxic doses of thyroxine can improve 
peripheral cellular glucose transport and insulin sensitivity in patients 
with type 2 diabetes
E. Maratou1, V. Lambadiari2, F. Spanoudi2, E. Vassilatou2, G. Matsagouras2, 
E. Hatziagelaki2, P. Mitrou1, S.A. Raptis1,2, G. Dimitriadis2;  
1Hellenic National Center for Research, Prevention and Treatment of 
Diabetes Mellitus and its Complications (HNDC), 22nd Department 
of Internal Medicine, Research Institute and Diabetes Center, Athens 
University, “Attikon” University Hospital, Athens, Greece.
Background and aims: Variation of plasma thyroid hormones’ levels influ-
ences insulin sensitivity and peripheral glucose disposal. Administration of 
high doses of thyroxine to healthy humans induces insulin resistance, where-
as moderate doses increase peripheral glucose disposal. We investigated the 
effect of the administration of small doses of thyroxine to healthy humans 
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and patients with type 2 diabetes on the insulin sensitivity indices, in vitro 
glucose uptake and GLUT4 recruitment in the plasma membrane of periph-
eral monocytes.
Materials and methods: Eleven healthy, euthyroid subjects (CON) with a 
micronodular texture of the thyroid gland, aged 40.8±2.7 yrs, BMI 26.6±0.83 
kg/m2 , T3 118.1±5 ng/dl (1.818±0.077 nmol/l), T4 7.1±0.3 μg/dl (91.377 
±3.861 nmol/l), TSH 1.235±0.109 μU/ml, and eleven treatment-naive sub-
jects with type 2 diabetes (DM) [aged 42.9±3.8 yrs, BMI 27.48±1.39 kg/m2 
, T3 119±5.7 ng/dl (1.832±0.087 nmol/l), T4 8,13±0.46 μg/dl (104.8±5.93 
nmol/l), TSH 1.51±0.14 μU/ml], were studied before and after administra-
tion of 50 μg of thyroxine once daily for 2 months. The study was approved 
by the hospital ethics committee, and subjects gave informed consent. A meal 
was given to the participants. Blood was drawn before the meal for the study 
of glucose uptake and GLUT4 abundance in peripheral monocytes and sev-
eral blood samples were drawn for 300min from a forearm deep vein and 
the radial artery for measurements of glucose, insulin and HOMA-IR and 
Matsuda indices. The insulin’s effect on GLUT4 translocation from cytoplas-
mic depots to plasma membrane was studied by stimulating monocytes with 
various concentrations of the hormone (0, 25, 50,100 and 200uU/ml). The 
increment of enrichment of plasma membrane to GLUT4 is represented as 
%increment from baseline (0mU/l) to maximal concentration (200mU/l). 
Plasma membrane GLUT4 abundance and glucose uptake (fluorescent ana-
logue 6-NBDG) were studied in isolated monocytes by flow cytometry.
Results: The area under the curve of the 6-NBDG uptake was significant-
ly higher in both CON (pre treatment 7392.7+577.4 vs. post treatment 
9383.8+460, P<0.05) and DM (pre treatment 5597+245 vs. post treatment 
8916+1009, P<0.05) after the administration of thyroxine. The abundance of 
plasma membrane GLUT4 increased after the treatment in both CON (pre 
treatment 29.6%+3.76 vs. post treatment 41.93%+3.72, P<0.05) and DM 
group (pre treatment 10.96%+2.25 vs. post treatment 34.44%+5.08, P<0.005). 
Glucose uptake and GLUT4 abundance in plasma membrane of monocytes 
improved, TSH levels reduced significantly post-treatment (P<0.0001). Glu-
cose, insulin levels and HbA1c reduced significantly in DM group. HOMA-
IR and Matsuda indices improved post-treatment.
Conclusion: Administration of small, subthyrotoxic doses of thyroxine to 
euthyroid diabetic patients and healthy individuals, can improve peripheral 
cellular glucose uptake and insulin sensitivity. This could be of therapeutic 
importance in insulin- resistant subjects.
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Administration of small doses of thyroxine to euthyroid type-2 diabetic 
patients increased insulin-stimulated peripheral glucose uptake and 
improved glucose tolerance
F. Spanoudi1, E. Maratou2, E. Vassilatou1, G. Matsagouras1, E. Hatziagelaki1, 
S.A. Raptis2,1, G. Dimitriadis1, V. Lambadiari1;  
12nd Department of Internal Medicine, Research Institute and Diabetes 
Center, Athens University, “Attikon” University Hospital,  
2Hellenic National Center for Research, Prevention and Treatment of 
Diabetes Mellitus and its Complications (HNDC), Athens, Greece.
Background and aims: Variation of plasma thyroid hormones’ levels influ-
ences insulin sensitivity and peripheral glucose disposal. Administration of 
high doses of thyroxine to healthy humans induces insulin resistance, where-
as moderate doses increase peripheral glucose disposal. We investigated the 
effect of the administration of small doses of thyroxine to healthy humans 
and patients with type 2 diabetes on postprandial forearm muscle glucose 
uptake, and insulin sensitivity indices.
Materials and methods: A meal was given to eleven healthy euthyroid sub-
jects (aged 40.8±2.7 yrs, BMI 26.6±0.83 kg/m2, T3 118.1±5 ng/dl (1.818±0.077 
nmol/l), T4 7.1±0.3 μg/dl (91.377 ±3.861 nmol/l), TSH 1.235 ±0.109 μU/ml ) 
and eleven treatment-naive patients with type 2 diabetes (aged 42.9±3.8 yrs, 
BMI 27.48±1.39 kg/m2, T3 119±5.7 ng/dl (1.832±0.087 nmol/l), T4 8,13±0.46 
μg/dl (104.8±5.93 nmol/l), TSH 1.51±97 0.14 μU/ml). Blood was drawn for 
300min from a forearm deep vein and the radial artery for measurements of 
glucose, insulin, and glucose uptake. Forearm blood flow (BF) was measured 
with strain-gauge-plethysmography. Forearm Glucose-uptake, HOMA-IR, 
hepatic-insulin-sensitivity-index and ISI-Index (0-120) were calculated. Af-
ter the first meal-tolerance-test, treatment with 50μg of thyroxine once daily 
was initiated for a 2-month period. Then a second identical test was repeated.
Results: TSH levels reduced significantly post-treatment (DM: 1.51±0.11 
vs. 0.79± 0.11 μU/ml, p<0.0001). Glucose, insulin levels and HbA1c re-
duced significantly in the diabetic group, (2867±117 vs. 2315±108 mMmin, 
p<0.0001), (30426±5041 vs. 18230±3495 mUmin, p<0.0001), (8.35±0.18% 
vs. 7.31±0.256%, p<0.0001), respectively. Peak-baseline BF and Glucose-
uptake (AUC0-300min) increased significantly (1.952±0.3 vs. 3.54±0.26 ml/
min per 100cc tissue, p=0.0009) and (556±71 vs. 973±81μmol per 100cc tis-
sue, p=0.0026), respectively. All insulin-sensitivity indices improved post-
treatment (ISI-HOMA: 0.207±0.024 vs. 0.44±0.027, p<0.0001), (Gutt-Index: 
34.3±2.43 vs. 54.7±5.3 mg.L2/mmol/mU/min). The patients’ weight was sta-
ble within the treatment period.
Conclusion: Administration of small, subthyrotoxic doses of thyroxine to 
euthyroid diabetic patients and healthy individuals, can improve peripheral 
glucose disposal and overall insulin sensitivity. The insulin sensitizing effect 
of thyroid hormone ‘’boosting’’ within normal levels, improved glycaemia 
and insulin sensitivity indices. This could be of therapeutic importance in 
insulin-resistant subjects.
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Testosterone improves glucose homeostasis by increasing glucose uptake 
and glycolysis in human liver cells
D.M. Kelly1, P.L. Harrison2, S. Akhtar1, H.T. Jones3;  
1Human Metabolism, University of Sheffield, ,  
2Biomedical Research Centre, Sheffield Hallam University,  
3Barnsley Hospital NHS Foundation Trust, Barnsley, UK.
Background and aims: Men with low testosterone levels are at an increased 
risk of developing type-2 diabetes (T2D). Restoring testosterone to within 
the normal range through replacement therapy (TRT) improves insulin re-
sistance and glycaemic control in hypogonadal men with T2D. The cellular 
mechanisms underlying these actions remain unknown but may be due, in 
part, to an effect on the liver as a major metabolic organ involved in glucose 
regulation. We have previously shown in testicular feminised mice, which 
have low testosterone levels and a non-functional androgen receptor (AR), 
that hepatic expression of glucose regulatory targets were significantly re-
duced and that TRT had a beneficial effect. Here we investigate the effect of 
testosterone on glucose homeostasis in human liver cells as a mechanism to 
improve glucose control and T2D.
Materials and methods: Glucose uptake was assessed using 2-NBDG, a fluo-
rescent glucose analogue, in HepG2 cells treated with either testosterone (1-
100nM) or vehicle control for 24h. Metformin was used as a positive control 
(5mM, 10mM). Flutamide was used to block AR actions. XF metabolic assays 
(Seahorse Bioscience) were performed to further assess cellular bioenergetics 
and mitochondrial function. Cells were analysed for mRNA and protein ex-
pression of targets of glucose regulation (Hexokinase 4, HK4; Phosphofruc-
tokinase, PFK; Mitogen-activated protein kinase kinase, MAP2K), by qPCR 
and western blotting.
Results: Glucose uptake was increased in testosterone treated cells at 10nM 
(117±3.8% of control, P≤0.05) and 100nM (117±4.3%, P≤0.05) concentra-
tions compared to control. This increase was similar to that of Metformin 
5mM (113±3.5%, P≥0.9) and 10mM (122±4.8, P≥0.9). Flutamide had no ef-
fect on testosterone action on glucose uptake. Extracellular acidification rate 
as an indicator of changes in the rate of glycolysis were marginally increased 
in testosterone treated cells. Similarly, oxygen consumption rate as a func-
tion of mitochondrial respiration was slightly but not significantly increased 
in testosterone treated cells. HK4 protein expression was increased in 10nM 
testosterone treated cells versus vehicle control (0.56±0.04 vs 0.24±0.11 ar-
bitrary densitometry units [ADU], P=0.08), and significantly at 100nM 
concentrations (0.68±0.25 vs 0.24±0.11 ADU, P≤0.05). No difference was 
observed between treated and untreated cells for PFK and LXR protein ex-
pression and for mRNA expression of all targets.
Conclusion: Testosterone increases glucose uptake in HepG2 cells as a mech-
anism to potentially improve hepatic glucose control. This action may be via 
increased hepatic glycolysis involving the upregulation of HK4 expression (a 
key regulatory enzyme in glycolysis) or increased mitochondrial respiration. 
This effect may also be, in part, AR-independent. Testosterone may improve 
T2D in men via actions on hepatic glucose regulation.
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Impaired hepatic insulin extraction in type 2 diabetes
F. Piccinini1, C. Dalla Man1, A. Vella2, C. Cobelli1;  
1Department of Information Engineering, University of Padova, Italy,  
2Mayo Clinic, Rochester, USA.
Background and aims: The evaluation of hepatic insulin extraction (HE) 
during a meal is fundamental for understanding the regulation of carbo-
hydrate metabolism in healthy (H), prediabetic (PD), and type 2 diabetic 
(T2DM) subjects. In this study we use a new physiologically-based math-
ematical model for estimating HE across the spectrum of glucose tolerance.
Materials and methods: To this purpose we studied 18 H (age=49.6±8.2 
yr, BMI=27.7±3.1 kg/m2), 35 PD (both impaired glucose tolerant and im-
paired fasting glucose; age=53.2±7.7 yr, BMI=30.1±5.0 kg/m2) and 22 T2DM 
subjects (age=53.9±6.9 yr, BMI=32.7±4.9 kg/m2). Each subject underwent 
a standard mixed meal (75 g glucose, 43% carbohydrate, 17% protein, 40% 
fat). Frequent plasma sampling was undertaken in all the subjects in order to 
measure plasma glucose, insulin and C-peptide concentrations. The model 
assumes that C-peptide kinetics is described by a two-compartment model, 
insulin kinetics by a three-compartment model, and insulin secretion is a sum 
of two components, i.e. one proportional to glucose rate of change and one 
proportional, with a constant delay, to glucose concentration. HE suppres-
sion is assumed to be linearly dependent on plasma glucose concentrations. 
Basal (HEb) and total (HEtot) HE indices can be derived from the model pa-
rameters, as well as a new index quantifying HE sensitivity to glucose (SG
HE).
Results: The model well fitted C-peptide and insulin data in all the subjects, 
also providing precise parameter estimates. Rank sum test showed that HEb 
and HEtot are significantly lower in T2DM than H subjects (HEb=49% vs. 
64%, p=0.01; HEtot=43% vs. 59%, p=0.04). Moreover, SG
HE is significantly 
lower in T2DM than PD (SG
HE=0.10 vs. 0.14 l/mmol, p=0.006) and H sub-
jects (SG
HE=0.10 vs. 0.13 l/mmol, p=0.02). Figure 1 shows the average HE 
profiles reconstructed by the model in the three groups: evidently the basal 
state is impaired in T2DM, as it is confirmed by the statistical test, moreover, 
in T2DM, the profile has a longer low phase, and recovers slower than H and 
PD subjects.
Conclusion: The new physiological model for the quantification of HE, ini-
tially developed in H subjects, has been successfully used both in PD and 
T2DM. This model allows the estimation of a new index measuring HE sen-
sitivity to glucose. This was significantly lower in T2DM compared to H and 
PD, likely due to an inability of plasma glucose to suppress HE.
Supported by: FIRB 2008, DK82396, DK78646
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The effect of glycaemic variability on expression of genes involved in the 
development of hyperglycaemia induced tissue damage
K. Kuricová1, L. Pácal1, V. Dvořáková1, J. Šoupal2, M. Prázný2, K. Kaňková1;  
1Department of Pathological Physiology, Masaryk University, Brno,  
223rd Department of Internal Medicine, Charles University, Prague,  
Czech Republic.
Background and aims: Large prospective studies provided evidence of rela-
tionship between long-term diabetes compensation expressed as HbA1c and 
the risk of diabetic complications. However, HbA1c and diabetes duration 
explain only small portion of complications risk. It is well known that pa-
tients with the same HbA1c differ in amplitudes and duration of glycaemic 
excursions. Therefore, short-term (i.e. during the day) glycaemic excursions, 
so called glycaemic variability (GV), are debated currently. Animal experi-
ments and in vitro studies showed that oscillating glucose may have more 
deleterious effect on cells due to higher production of superoxide than hyper-
glycaemia itself. Therefore, aim of our study was to evaluate the effect of GV 
on the expression of genes whose products are involved in the development 
of tissue damage in diabetes. We compared the effect of low and high GV 
of diabetics, GV of healthy subjects and chronic normo- and hyperglycae-
mia. Specifically, we detected gene expression of glyoxalase 1 (GLO1), heme 
oxygenase (HMOX), receptor for advanced glycation end-products (RAGE), 
p53, superoxide dismutase (SOD2), DJ-1 (an enzyme with glyoxalase activ-
ity), transketolase (TKT) and thiamine pyrophosphokinase (TPK1).
Materials and methods: Primary human umbilical vein endothelial cells 
(HUVEC) were cultured 24 hours in the following settings mimicking situa-
tion in humans (both diabetics and healthy) and in commonly used in vitro 
hyperglycaemia model: (A) high GV (standard deviation [SD] > 5), (B) low 
GV (SD < 3), (C) non-diabetics (SD = 1), (D) continuous normoglycaemia (5 
mmol/l) and (E) continuous hyperglycaemia (25 mmol/l). Based on real 24 
hours glycaemic curves from type 1 diabetics (3 patients with low GV and 3 
with high GV) and healthy subjects (2 curves) we created 24 hours profiles 
with medium change after 2 hours. After 24 hours cells were harvested and 
RNA isolated and reverse transcribed using commercial kits (Roche). Gene 
expression was determined using quantitative PCR with predesigned probes 
(TaqMan™ Assay) with β-actin as a reference gene.
Results: HMOX expression was significantly lower in both low and high GV 
compared to GV of healthy subjects (P = 0.04, Mann-Whitney test). Similar 
pattern was also found in four of the selected genes (p53, SOD2, GLO1, DJ-
1) although statistically not significant (all P > 0.05, Mann-Whitney test). 
Expression of all genes with exception of DJ-1 was significantly higher in 
continuous normoglycaemia when compared to low and high GV (all P < 
0.04, Mann-Whitney). Finally, no significant difference was found between 
continuous hyperglycemia and low and high GV (all P > 0.05).
Conclusion: Results of our pilot study indicate that the effect of either low or 
high GV on expression of selected genes involved in diabetes induced tissue 
damage does not significantly differ from the effect of continuous hypergly-
caemia.
Supported by: IGA MZ NT13198
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Beneficial roll of TAZ modulator, TM-25659, in obese and diabetic 
conditions
J.-G. Jeong1, J. Jeon1, E. Ha1, S.-E. Choi2, S.-A. Lee1, Y. Kang2, M. Bae3,  
J. Ahn3, H. Jeong4, E. Hwang4, S. Han1, D. Kim1, K.-W. Lee1;  
1Endocrinology and Metabolism, Ajou University School of Medicine, 
Suwon, 2Institute of Medical Science, Ajou University School of Medicine, 
Suwon, 3Korea Research Institute of Chemical Technology, University 
of Science & Technology, 4College of Pharmacy, Graduate School of 
Pharmaceutical Sciences, and Global Top5 Research Program,  
Ewha Womans University, Seoul, Republic of Korea.
Background and aims: The transcriptional co-activator with PDZ-binding 
motif (TAZ) inhibits adipocyte development by intervention with per-
oxisome proliferator-activated receptor (PPAR)-gamma. Recently, PPAR-
gamma has been implicated in muscle lipid accumulation. Therefore, we 
investigated the effects of TAZ modulator on skeletal muscle function in C2 
myotubes and in C57BL/6J mice. In a previous study, Jang et al identified 
2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2’-(1H-tetrazole-5-yl)-biphenyl-4-
ylmethyl]-3H-imidazo[4,5-b]pyridine] (TM-25659) as a TAZ modulator and 
was shown to decrease weight gain in a high fat diet-induced obese model.
Materials and methods: We measured insulin signaling and glucose uptake 
using immunoblotting and 2-NBDG uptake. To elucidate the preventing 
mechanism of TM-25659 on palmitate-induced C2 myotubes insulin signal-
ing, we performed real-time PCR with pro-inflammatory cytokines (TNF-
alpha, IL-1-beta, IL-6 and MCP-1) mRNA. Male C57BL/6J mice that were 
fed a HFD for 8 weeks were randomly assigned for an additional 6 weeks to 
3 groups: normal diet (ND), HFD, HFD+TM-25659. After treatment, oral 
glucose tolerance test (OGTT) and intraperitoneal insulin tolerance test (IP-
ITT) were performed to evaluate anti-diabetic effects. After sacrifice, tissue 
extracts of the soleus muscle were obtained for quantification of insulin sign-
aling through Akt phosphorylation proteins by immunoblotting.
Results: In our present study, we confirmed TM-25659 considerably in-
hibits palmitate-induced insulin resistance on C2 myotubes. Moreover, we 
showed that TM-25659 significantly suppresses high fat diet (HFD) induced 
insulin resistance in C57BL/6J mice skeletal muscle. Consequently, the TM-
25659-treated group showed improved HFD-reduced glucose tolerance, in-
creased insulin sensitivity, and increased AKT phosphorylation protein. Also, 
TM-25659 down-regulated expression of genes involved in pro-inflamma-
tion.
Conclusion: These results suggest TAZ modulator, TM-25659, play a ben-
eficial role in controlling insulin resistance in obese and diabetic conditions.
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Human skeletal muscle clock: implications in myokine secretion in 
physiology and pathophysiology
S. Skarupelova1, L. Perrin1, E. Lefai2, H. Vidal2, J. Philippe1, C. Dibner1;  
1Division of Endocrinology, Diabetes and Nutrition, Geneva University 
Hospital (HUG), Switzerland, 2Faculté de Médecine, INSERM, Lyon, France.
Background and aims: Circadian rhythms are present in many organisms 
of different complexity, representing an adaptation mechanism allowing 
adjustment of organism’s internal processes to the external world. In mam-
mals circadian system is organized in a hierarchical structure with a central 
pacemaker residing in hypothalamic suprachiasmatic nuclei that in its turn 
controls peripheral secondary clocks in organs including skeletal muscle. The 
aim of our study was to characterize molecular clock and its function in hu-
man primary skeletal muscle of healthy, overweight and obese subjects.
Materials and methods: Human primary myoblasts were derived from 
muscle biopsies of Musculus gluteus maximus. Bioluminescent reporters 
Bmal1-luciferase and Per2-luciferase were introduced by lentiviral transduc-
tion, and allowed visualization of the oscillatory profiles of Bmal1 and Per2 
continuously in living cells. For clock ablation myotubes were transfected 
with siRNA-targeting Clock. Secretory profiles of myokine IL6 (ELISA meas-
urements), assessed in parallel with bioluminescence profile recording, were 
compared in myotubes with functional and ablated clock.
Results: Our experiments revealed that fully differentiated in vitro synchro-
nized myotubes exhibited circadian rhythm with a period length of about 
24.6 hours. Oscillation period tended to be longer in case of overweight and 
obese subjects. Endogenous core clock transcripts as well as bioluminescent 
profiles showed sustained circadian expression pattern with pronounced am-
plitude. Around 90% of Clock knockdown significantly flattened oscillatory 
profile of Bmal1-luciferase reporter and amplitude of endogenous core clock 
transcripts. Our results revealed that the primary myotubes with intact clock 
secret IL6 in the circadian manner. Moreover, remarkable down regulation 
of IL6 secretion was observed upon clock ablation, meaning that the clock 
machinery might regulate IL6 secretion in human skeletal muscle.
Conclusion: Our data demonstrate that the human skeletal muscle exhibits 
pronounced circadian oscillations that impacts on the muscle IL6 secretory 
function. Moreover, changes in rhythmicity of circadian machinery in hu-
man skeletal muscle might be associated with metabolic disorders such as 
obesity.
Supported by: FN 3100A-146475
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Role of the RNA binding protein Sam68 in leptin and insulin signalling 
in granulosa cells
V. Sanchez-Margalet1, T. Vilariño-García1, A. Perez-Perez1,  
F. Sanchez-Jimenez1, V. Blasco2, N. Prados-Nodd2, M. Fernandez-Sanchez2;  
1Medical Biochemistry and Molecular Biology and Immunology,  
Virgen Macarena University Hospital,  
2Instituto Valenciano de Infertilidad, Seville, Spain.
Background and aims: Obesity is a medical problem not only because it 
is associated with type 2 diabetes and cardiovascular risk, but also because 
in reproductive-age women obesity is associated with polycystic ovary syn-
drome (PCOS), insulin resistance and decreased fertility. The RNA-binding 
protein Sam68 is expressed in granulosa cells and the knockout female mice 
are subfertile, with ovulation problems. Since we have previously found that 
Sam68 may be recruited to insulin and leptin receptors, we planned to study 
the participation of Sam68 in signaling and action of insulin and leptin re-
ceptors in granulosa cells. In addition, we aimed to study the expression of 
Sam68 in granulosa cells in response to leptin and insulin in vitro.
Materials and methods: Signaling was studied by immunoprecipitation and 
immunoblot of the phosphorylated proteins. The expression of Sam68 is in-
hibited by antisense strategy. The expression level of Sam68, and leptin and 
insulin receptors are quantified by qPCR and immunoblot.
Results: We have found that Sam68 is tyrosine phosphorylated by insulin or 
leptin stimulation in granulosa cells, recruiting Sam68 to signaling complexes 
and decreasing its RNA binding capacity. In addition, both insulin and leptin 
increase the expression of Sam68 in granulosa cells. Finally, full expression of 
Sam68 is required for the activation of PI3K and MAPK signaling pathways 
by insulin or leptin in granulosa cells.
Conclusion: Sam68 is recruited to leptin and insulin receptor signaling, its 
expression is induced by both hormones, and Sam68 is necessary for the full 
activation of insulin and leptin receptor signal transduction in granulosa 
cells. Sam68 may be a new important element in the ovarian insulin resist-
ance and the decreased fertility found in obese women.
Supported by: PI12/01172 ISCIII
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Insulin regulates glycogen synthesis in endometrial epithelial cells 
through an increase in glycogen synthase
G. Choe, C.A. Flannery, F. Saleh, H.S. Taylor;  
Obstetrics, Gynecology, & Reproductive Sciences, Yale School of Medicine, 
New Haven, USA.
Background and aims: Endometrial gland secretion of glucose, lipids, and 
protein supports blastocyst nutrition prior to establishment of placental 
circulation. The endometrial glands fill with glycogen during the secretory 
phase in preparation for implantation, and regulation of glycogen synthesis 
has been attributed to progesterone. However, we hypothesized that insulin 
regulates glycogen synthesis in endometrial epithelial cells as it does in tradi-
tional insulin targets such as liver and muscle.
Materials and methods: We isolated endometrial epithelial and stromal 
cells from eight healthy women, and treated the cells separately with insulin, 
medroxyprogesterone (MPA), or vehicle. After 48hours, the cells were lysed, 
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and glycogen was isolated and quantified. Total and phosphorylated glycogen 
synthase (GS) and glycogen synthase kinase 3α/β (GSK3α/β) were evaluated 
by western blot after a 30min or 48hr hormone stimulation. Endometrial tis-
sue from 45 women distributed across the menstrual cycle was assessed for 
insulin receptor β (IRβ) by PCR and IHC.
Results: We found that IRβ had higher expression during the secretory phase 
of the menstrual cycle, with an increase in expression in both epithelial and 
stromal cells between day 16 and 24 of the menstrual cycle. In vitro MPA 
increases IRβ expression over 25-fold in primary stromal cells (p<0.0001) 
and to a lesser extent in epithelial cells. Insulin induces a 4.5-fold increase in 
glycogen content in primary epithelial cells (p<0.01), whereas MPA did not 
directly alter glycogen content relative to vehicle. In stromal cells, neither in-
sulin nor MPA altered glycogen content. Insulin induced phosphorylation of 
GSK3α/β acutely, and a 3.6-fold increase in GS protein by 48 hours (p=0.005).
Conclusion: We demonstrate that progesterone regulates IRβ expression 
during the secretory phase, facilitating insulin action. Insulin, not progester-
one, directly regulates glycogen synthesis through an increase in GS as well 
as acute phosphorylation events. This mechanism is novel and distinct from 
insulin regulation of glycogen synthesis in the liver and muscle that is accom-
plished predominantly through acute phosphorylation events of GSK3α/β 
and GS. A lasting increase in GS in response to insulin enables endometrial 
epithelial cells to synthesize glycogen continuously, independent of short 
term nutrient flux. This distinct regulation of glycogen synthesis is a unique 
adaptation to allow glycogen accumulation in endometrium. These findings 
suggest that successful implantation requires insulin, and may explain why 
women with insulin resistance have lower implantation rates.
Supported by: NICHD K08 Career Award
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ECSCR negatively regulates insulin sensitivity via PTEN stabilisation in 
endothelial cells
M. Ohta1,2, T. Sugano2, N. Inoue1,2, M. Whelan1, J. Matsumoto1,2, K. Inoue2, 
K. Mizuno1,2, M. Aikawa1;  
1Center for Interdisciplinary Cardiovascular Sciences, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, USA,  
2Kowa company, Ltd, Tokyo, Japan.
Background and aims: Endothelial insulin resistance impairs insulin deliv-
ery into skeletal muscle, and insulin-dependent glucose disposal is reduced 
in obesity patients with type 2 diabetes mellitus (T2DM). Endothelial cell 
surface expressed chemotaxis and apoptosis regulator (ECSCR) is a cell-sur-
face protein selectively expressed on endothelial cells. Recent study revealed 
ECSCR is potentially therapeutic target for T2DM to enhance Akt/eNOS 
phosphorylation and improve insulin sensitivity in Ecscr-deficient mice. 
However, the underlying mechanism is still unknown. We investigated the 
mechanism how ECSCR negatively regulate insulin signaling using human 
umbilical vein endothelial cells (HUVECs) and mouse pancreatic endothelial 
cell line (MS1).
Materials and methods: HUVECs and MS1 were transfected with vector 
expressing FLAG-MYC-tagged ECSCR and the pCMV6 control vector for 
overexpression study. HUVECs were transfected with siRNA for ECSCR 
and scramble control sequence for knockdown study. Protein degradation 
activities of PTEN and PTP1B were evaluated on HUVECs with 10 μg/mL 
of cycloheximide. mRNA and Proteins from cells were collected for RT-PCR 
and western blot analysis. All results are representative of at least three inde-
pendent experiments.
Results: ECSCR overexpression on HUVECs and MS1 suppressed basal 
phosphorylation of Akt at Ser473. ECSCR knockdown on HUVECs increased 
phosphorylation of Akt at Ser473. ECSCR knockdown also significantly in-
creased genes expression of PTEN and PTP1B, which are negatively modu-
lating insulin signal on HUVECs. However, only PTEN protein amount in 
HUVECs was decreased. To identify the mechanism how ECSCR modulates 
insulin signaling, we evaluated the protein degradation activity of PTEN and 
PTP1B on HUVECs. ECSCR knockdown strongly enhanced the degradation 
of PTEN, but not PTP1B. Insulin stimulation accelerated PTEN degradation 
in HUVECs with ECSCR knockdown.
Conclusion: Taken together, our data proposed new mechanism that EC-
SCR selectively stabilize PTEN protein to prevent from protein degradation 
in HUVECs. ECSCR inhibition will be potentially new class of therapeutic 
target to improve endothelial insulin sensitivity in T2DM.
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Insulin resistance of pancreatic alpha cells with age under high fat diet 
in mice
S. Schinner, B. Funk;  
Endocrinology and Diabetes, University Hospital Düsseldorf, Germany.
Background and aims: Insulin and GLP-1 are strong inhibitors of glucagon 
release from pancreatic alpha-cells. Obesity causes insulin resistance of liver 
and skeletal muscle. However, it is not known if obesity causes insulin resist-
ance in alpha-cells. In addition, the effectiveness of GLP-1 in ameliorating 
glucose tolerance and suppressing glucagon in aged organisms is not well un-
derstood. Therefore, we investigated insulin responsiveness of alpha-cells in 
a mouse model of obesity and GLP-1 (exendin-4) responsiveness in wildtyp 
mice of different age
Materials and methods: Young (6 weeks) and old (8 months) C57BL6 wild-
type mice (n= 27) were fed with a high-fat-diet (HFD) (60% kcal of fat) over 
a period of 8 weeks to induce obesity and hyperinsulinaemia. Intraperito-
neal glucose-tolerance-tests (ipGTT) were performed and levels of glucose, 
insulin and glucagon were assessed. Lean mice fed a standard diet served as 
controls (n= 27). In addition, young (6 weeks) and old (8 months) C57BL6 
wild-type mice were treated with exendin-4 (10nM/ kg bodyweight; ip) over 
a period of 3 weeks followed by an ipGTT assessing glucose tolerance and 
glucagon secretion.
Results: Young as well as old mice gained approx. 40% of body weight af-
ter HFD compared to controls. In controls the blood glucose levels were 
335±66mg/dl in young and 275±72 mg/dl in old mice 30 min after glucose 
load with corresponding levels of insulin (360±60 vs. 470±120 ng/ml) and 
glucagon (26±5 vs. 39±11 pg/ml). In young mice on HFD the blood glucose 
levels were comparable with 335±68 mg/dl after 30 min. In contrast, old mice 
after HFD showed significantly increased glucose levels of 503±100 mg/dl 
at 30 min. Insulin levels increased 1,7fold (810±286) after 30 min. and 6fold 
(2.170±280 ng/ml) after 120 minutes. Of note, glucagon levels were not sup-
pressed (62±2 pg/ml after 30min and 45±4 pg/ml after 120min) despite the 
peaks in insulin release. In vitro experiments revealed that isolated islets from 
old animals after HFD showed no inhibition of glucagon release in response 
to insulin. Exendin-4 treatment improved glucose-tolerance in young and old 
mice at comparable levels (young: control 0 min blood glucose = 77±31, 30 
min = 328±41; exdn-4: 0 min = 100±26, 30 min = 163±14 mg/dl; old mice: 
control 0 min = 82±28, 30 min = 314±57; exdn-4 0 min = 95±21, 30 min = 
160±30 mg/dl). Interestingly, basal glucagon levels were higher in older mice 
than in young mice (56±8 vs. 44±6 pg/ml). The response in glucagon lev-
els was comparable between controls and exendin-4 treated animals (young: 
control 0 min = 44±6, 30 min = 29±9; exdn-4 0 min = 42±12, 30 min = 38±14 
pg/ml; old: control 0 min = 56±8, 30 min = 36±9; exdn-4 0 min = 57±10, 30 
min = 34±5 pg/ml.
Conclusion: Higher age predisposes to impaired glucose tolerance after 
high-fat-diet in this animal model. Furthermore, high levels of endogenous 
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insulin in old mice on HFD fail to suppress glucagon release, indicating in-
sulin resistance of glucagon producing alpha-cells. This was paralleled by in 
vitro findings with islets from old mice under HFD.
Supported by: Else Kröner-Fresenius-Stiftung
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Different proprotein convertases are involved in the maturation of the 
two insulin receptor isoforms
F. Peiretti, I. Kara, B. Bonardo;  
UMR1062, Inserm, Marseille, France.
Background and aims: The insulin receptor (IR) is expressed as two iso-
forms, IRA (exon 11-) and IRB (exon 11+), which originate from the alterna-
tive splicing of exon 11 and differ from 12 amino acids located at the carboxyl 
terminus of the extracellular a-subunit. The most significant difference be-
tween the two IR isoforms is that IRA is more responsive to activation by 
IGF2 than IRB. Thus, it is suggested that IRA and IRB are both responsible for 
metabolic effects (triggered by insulin) whereas, only IRA is responsible for 
the mitogenic/proliferate effects (triggered by IGF2). The two IR isoforms are 
matured in the Golgi apparatus by the proteolytic activity of the proprotein 
convertase furin. We analyzed if the absence or presence of exon 11 could 
affect the maturation of IR isoforms.
Materials and methods: IR isoforms were overexpressed in different cell 
lines. Proprotein convertases activity was modulated by pharmacological 
inhibition, specific knockdown and overexpression. IR maturation was ana-
lyzed by western blot.
Results: In furin-defective LoVo cells, IRB is more matured than IRA. In 
furin-expressing cells, both IR isoforms are equally matured and furin knock-
down is more efficient in reducing the maturation of IRA than that or IRB. 
The global inhibition of proprotein convertase activity abolishes the furin-
independent maturation of IRB, indicating the involvement of a propotein 
convertase other than furin in this maturation. We demonstrate that in the 
absence of furin activity the proforms of IR are exposed at the cell surface 
where IRB (but not IRA) is matured by PCSK6. This difference in the matu-
ration of IRA and IRB was used as an opportunity to modulate the balance 
metabolic/mitogenic signals emanating from IR. Furin inhibition reduces the 
signals triggered by IGF2 (emanating from IRA) without unduly affecting 
those triggered by insulin (emanating from IRB).
Conclusion: Our results are the first to reveal a difference in the maturation 
of IR isoforms. The maturation of IRA is almost strictly under the control of 
furin whereas that of IRB involves furin and PCSK6. Furin inhibition reduces 
the amount of mature IRA without drastically altering that of IRB, which 
reduces the signals triggered by IGF2 but not those triggered by insulin.
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FKBP5 gene polymorphisms and expression in human adipose tissue are 
associated with insulin resistance and type 2 diabetes
M.J. Pereira1, J. Palming2, M.K. Svensson2, M. Rizell3, J. Dalenbäck4,  
M. Hammar5, T. Fall1, C.O. Sidibeh1, P.-A. Svensson6, J.W. Eriksson1;  
1Department of Medical Sciences, Uppsala University,  
2Department of Molecular and Clinical Medicine, , 3Sahlgrenska University 
Hospital, Gothenburg, 4Frölunda Specialist Hospital, Gothenburg, 
5AstraZeneca R&D, Mölndal, Sweden, 6Department of Molecular and 
Clinical Medicine, University of Gothenburg, Sweden.
Background and aims: Central obesity is associated with a cluster of meta-
bolic alterations, which include insulin resistance (IR), dyslipidemia and 
cardiovascular disease. Glucocorticoid excess is associated with redistribu-
tion of fat from peripheral to central depots and with IR and development of 
diabetes. To identify potential novel mechanisms for IR we investigated dex-
amethasone-induced changes of gene expression in human adipose tissue.
Materials and methods: Subcutaneous and omental adipose tissue, obtained 
from 25 non-diabetic subjects (28-60 yrs; 20.7-30.6 kg/m2), was incubated 
without or with dexamethasone (0.003-3 μM) for 24 h. Gene expression was 
assessed by microarray and real time-PCR. Protein levels were assessed by 
immunoblotting.
Results: FKBP5 (FK506 binding protein 5) was one of the genes responding 
most to dexamethasone. Gene expression increased up to 7-fold in a dose-de-
pendent manner in both subcutaneous and omental fat depots (p<0.001). The 
protein coded by this gene, the FKBP51, is an immunophilin, which means 
that it plays a role in the immune system. FKBP5 mRNA is widely expressed 
in metabolically active tissues with the highest gene expression in muscle and 
adipose tissue. However, FKBP51 protein was about 10-fold higher in the 
omental than in the subcutaneous fat depot (p<0.05), whereas the mRNA 
levels were similar. 80-90% of the FKBP5 protein in adipose tissue could be 
attributed to the adipocytes, while the stromal vascular cells contribute to 
10-20% (p<0.05). FKBP5 gene expression in the subcutaneous fat depot was 
positively correlated with markers of IR including, HOMA-IR and subcuta-
neous adipocyte diameter (r=0.59, p<0.001; r=0.48, p<0.05, respectively). In 
addition, FKBP5 gene expression in omental adipose tissue was associated 
with reduced insulin effects on glucose uptake in subcutaneous and omental 
adipocytes (p<0.05). Interestingly, FKBP5 SNPs (e.g. rs2817056, rs2395635, 
rs1334894) were found to be significantly associated with type 2 diabetes and 
with 2-h OGTT glucose, HDL-cholesterol and triglycerides in publicly avail-
able datasets from large, population-based cohorts.
Conclusion: The FKBP5 gene is regulated by glucocorticoids in both subcu-
taneous and omental adipose tissue, and its expression in human adipose tis-
sue is correlated to markers of IR. In addition, SNPs in the FKBP5 region are 
associated with type 2 diabetes and diabetes-related traits. We hypothesize 
that FKBP5 is a mechanism linking alterations in nutrient metabolism with 
immune function, both following glucocorticoid excess and in other condi-
tions with IR. Further studies will address whether FKBP5 is causally linked 
to IR and whether the related mechanisms can provide novel pharmacologi-
cal targets for the treatment of IR.
Supported by: Univ Gothen/Sahlgrenska Univ H; AstraZeneca R&D; FCT-
Portuguese Foundation
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Local overexpression of urocortin 3 in skeletal muscle of rats activates 
AMPK and Akt pathways and enhances glucose disposal
M.E. Cleasby1, M.M. Roustit1, J.M. Vaughan2, P.M. Jamieson3;  
1Comparative Biomedical Sciences, Royal Veterinary College, London, 
UK, 2Laboratory of Neuronal Structure and Function, Salk Institute for 
Biological Studies, La Jolla, USA, 3Centre for Cardiovascular Science, 
Queen’s Medical Research Institute, Edinburgh, UK.
Background and aims: Insulin resistance (IR) in skeletal muscle is an impor-
tant component of both type 2 diabetes (T2D) and the syndrome of sarco-
paenic obesity, for which there are no effective therapies. Urocortins (Ucns), 
ligands for corticotropin releasing factor receptors, are well-established as 
neuropeptides but also have roles in metabolism in peripheral tissues. We 
showed recently that global overexpression (OE) of Ucn3 resulted in muscu-
lar hypertrophy and resistance to the adverse metabolic effects of a high fat 
diet. Here, we aimed to establish whether short-term local Ucn3 OE could 
improve glucose disposal and insulin sensitivity in skeletal muscle through a 
paracrine mechanism.
Materials and methods: Ucn3 was overexpressed in right tibialis cranialis 
and extensor digitorum longus muscles of rats by in vivo electrotransfer and 
the effects on muscle size, metabolism, gene expression and signalling were 
studied versus the contralateral control muscles (electroporated with empty 
vector) after one week.
Results: No increase in whole muscle mass was detected after one week, but 
Ucn3 OE muscles showed 19% larger muscle fibre diameter (p=0.030), per-
haps mediated through the associated increases in insulin-like growth fac-
tor-1 (IGF1) and IGF1 receptor mRNA and increased Ser256 phosphoryla-
tion of forkhead transcription factor (FOXO1). Glucose clearance into test 
muscles, measured using tritiated 2-deoxyglucose after an intraperitoneal 
glucose load, was increased by 23% (p=0.018) per unit mass, implying an 
insulin sensitising effect of Ucn3 OE on glucose disposal additional to the 
effect of hypertrophy alone to enhance total glucose uptake. This effect was 
associated with increased total glucose transporter protein levels (GLUT1: 
34% increase, p=0.026; GLUT4: 48% increase, p=0.0009) and activation of 
two key signalling pathways mediating glucose disposal, the phosphoinositol 
3-kinase/Akt (insulin signalling) and AMP-activated protein kinase (AMPK) 
pathways. Phosphorylation of insulin receptor substrate-1 (Tyr609), Akt 
(Ser473; by 72%, p=0.005), Akt substrate of 160kDa (Thr642), glycogen syn-
thase kinase-3β (Ser9), AMPK (Thr172; by 27%, p=0.024) and its substrate 
acetyl coA carboxylase (Ser79) were all significantly increased by Ucn3 OE.
Conclusion: Ucn3 OE enhances glucose disposal and insulin sensitivity in 
muscle by an autocrine/paracrine mechanism that is separate from its pro-
hypertrophic effects, implying that such a manipulation may have promise 
for treatment of IR syndromes including T2D and sarcopaenic obesity.
Supported by: Wellcome Trust
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Physical inactivity and high fat diet synergistically enhance the 
accumulation of intramyocellular diacylglycerol and induce insulin 
resistance in murine soleus muscle
S. Kakehi1, Y. Tamura2, S.-I. ikeda3, R. Kawamori3, H. Watada2;  
1Sportology Center, 2Metabolism and Endocrinology,  
3Sportology Center, Juntendo University, Tokyo, Japan.
Background and aims: Intramyocellular lipids (IMCL), especially intramy-
ocellular diacylglycerol (IMDG) has been reported as one of the causes of 
insulin resistance in skeletal muscle. It has been demonstrated that physical 
inactivity and high fat diet (HFD) increase IMCL levels and induce insulin 
resistance, respectively. However, the combined effect of these two factors on 
insulin resistance has not been clarified yet.
Materials and methods: To elucidate them, C57BL6J mice were randomly 
assigned to four groups; control group, 24h hind-limb cast immobilization 
(HCI) group, short-term (2wk) HFD group, and 24h HCI after 2wk HFD 
group. Then, we evaluated ex-vivo insulin-stimulated 2-deoxy glucose uptake 
(2DG-uptake), insulin signal and intracellular fat composition in skeletal 
muscle.
Results: Twenty four hours HCI significantly decreased insulin-stimulated 
2DG-uptake by 40%, while 2wk HFD did not alter 2DG-uptake. On the other 
hand, 24h HCI after 2wk HFD dramatically decreased insulin-stimulated 
2DG-uptake by 74%. In parallel with decreased insulin-stimulated 2DG-
uptake, we observed decreased insulin stimulated serine phosphorylation of 
Akt and tyrosine phosphorylation of insulin receptor substrate (IRS)-1 after 
24h HCI, which were more exacerbated in 24h HCI after 2wk HFD group, 
while only 2wk HFD did not change these phosphorylation states. Concern-
ing, it has been hypothesized that IMDG accumulation and PKC activation 
impairs insulin signal transduction. Consistent with this hypothesis, we 
found that 24h HCI increased IMDG in soleus by 192%, while the amount 
of intramyocellular triacylglycerol (IMTG) was not changed. In addition, 
whereas IMDG and IMTG were not changed by 2wk HFD feeding, 24h HCI 
after 2wk HFD dramatically increased IMDG and IMTG by 330% and 144%, 
respectively. In parallel with IMDG accumulation, we observed increased 
PKCε activity in 24h HCI group and 24h HCI after HFD group by 151% and 
210%, respectively. Associated with the IMDG accumulation, expression 
level of diacylglycerol acyltransferase (DGAT)-1, which converts diacylglyc-
erol to triacylglycerol, was decreased in both HCI group and HCI after 2wks 
HFD group. In addition, activity of Lipin1, which converts phosphatidic acid 
to diacylglycerol, was increased in 24h HCI group and 24h HCI after HFD 
group by 141% and 210%, respectively
Conclusion: These results suggested that physical inactivity and HFD syner-
gistically induce IMDG accumulation and insulin resistance in soleus mus-
cle. Increased Lipin1 activity and decreased DGAT-1 expression might be 
involved in the mechanism of IMDG accumulation after physical inactivity 
and HFD.
PS 036 Mechanisms of insulin 
resistance in vivo
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Impact of hepatic lipid accumulation and composition on glucose 
tolerance and insulin sensitivity: a longitudinal study in male and female 
mice
A.F. Soares1, H. Lei2, R. Gruetter1,2;  
1Laboratory of Functional and Metabolic Imaging, 2Biomedical Imaging 
Research Center, École Polytechique Fédérale de Lausanne, Switzerland.
Background and aims: Metabolic disruptions characterized by high hepatic 
lipid content (HLC) are associated with impairments in whole body glucose 
homeostasis. To gain insight on the role of hepatic lipids in the metabolic 
performance in the absence artificial metabolic stresses we measured non-
invasively and longitudinally the HLC and profile in mice during adult devel-
opment by Magnetic Resonance (MR) Spectroscopy in vivo. In parallel, mice 
were challenged with insulin and glucose tolerance tests.
Materials and methods: Male (N=10) and female (N=10) C57Bl/6J mice 
were studied at 3 (3Mo), 7 (7Mo) and 10 months (10Mo) of age. Mice were 
scanned in a 14.1 T magnet with a 1H quadrature surface coil over the abdo-
men. Localized 1H spectra were acquired from a 8 µl volume with stimulated 
echo acquisition mode sequence and the HLC expressed as the percent of to-
tal 1H MR signal, with corrections for spin-spin relaxation effects. Additional 
spectra were acquired from the same volume with suppression of the water 
signal to enable the detection and quantification of all the lipid protons. The 
lipid profile was characterized by the following indices: saturated component 
(SC); unsaturated fatty acyl chains (UFA); mean number of double bonds per 
fatty acyl chain (ndb/FA), mean number of poly-unsaturated double bonds 
per fatty acyl chain (PUdb/FA) and per UFA (PUdb/UFA); mean chain length 
(MCL). OGTTs (1.5 g/Kg) and i.p. insulin tolerance tests (ITTs) were per-
formed after a 6h-fast. Plasma insulin was determined by ELISA and insulin 
sensitivity estimated with the quantitative insulin check index (QUICKI) as 
the inverse of the log10 sum of fasting insulin (µIU/ml) and fasting glucose 
(mg/dl). Data are expressed as mean ± SEM. Statistical significance was ac-
cepted for a P < 0.05 (one-way ANOVA with Newman-Keuls post test) and 
correlations assessed by the Pearson r coefficient.
Results: In males, the HLC at 3Mo was 1.35 ± 0.15%, increasing to 3.06 ± 
0.38% at 7Mo, not different from 2.70 ± 0.31% at 10Mo. Females had higher 
HLC at 3Mo (2.63 ± 0.19%) but no further changes henceforward (2.31 ± 
0.20% at 7Mo; 2.36 ± 0.20% at10 Mo). In males, the SC and MCL of hepatic 
lipids increased with age, with a trend for decreased PUdb/FA and PUdb/
UFA with no changes in ndb/FA or UFA content. Females showed the same 
trends. Glycemia 3h-post ITT and 2h-post OGTT was lower in females, while 
QUICKI was higer. These scores were preserved until 10Mo in females. In 
males, glycemia 2-h post OGTT increased with age and the area above the 
curve (AAC) for the ITT decreased. In males, but not females, higher body 
weight correlated with hepatic lipid accumulation (r = 0.7); worse ITT scores 
correlated with higher body weight (r = -0.6) and HLC (r = -0.7) and lower 
Pudb/UFA (r = 0.5); worse OGTT scores correlated with higher HLC (r = 0.4).
Conclusion: In male mice, loss of insulin sensitivity correlated with weight 
gain, HL accumulation and lower poly-unsaturation. Glucose intolerance 
was specifically associated with HLC, suggesting a deleterious effect of lipids 
on the adaptation of hepatic metabolism to the fed state. This behaviour was 
not observed in females even if they showed similar HLC. In fact, the poly-
unsaturation of HL in females didn’t change with HLC, suggesting a positive 
effect of PUFA on preserving the hepatic metabolic performance.
Supported by: CIBM
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Liver specific G0/G1 switch gene 2 (G0S2) overexpression exacerbates 
hepatic insulin resistance by exacerbating hepatic steatosis but 
ameliorates hepatic fibrosis
Y. Sugaya, H. Satoh, T. Watanabe;  
Department of Nephrology, Hypertension, Diabetology, Endocrinology, and 
Metabolism, Fukushima Medical University, Japan.
Background and aims: Hepatic steatosis is strongly associated with insulin 
resistance. Recently it has been  reported that G0/G1 switch gene 2 (G0S2) 
inhibited the lipolysis activity of adipose triglyceride lipase. Moreover, we 
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confirmed that G0S2 protein content was increased in the livers of high fat 
diet (HFD) fed rats. However, the precise physiological role of hepatic G0S2 
is still unknown. In the current studies, we investigated the effect of hepatic 
G0S2 on insulin sensitivity in HFD-fed male Wistar rats by overexpressing 
G0S2 proteins using an adenovirus (Ad) encoding mouse G0S2.
Materials and methods: Male Wistar rats were fed with 60% HFD for a total 
of 4 weeks. After 3-week feeding, the rats were injected with control Ad-GFP 
or Ad-G0S2. On day 7 post injection, glucose tolerance test and euglycemic-
hyperinsulinemic clamp studies were performed after an 8-hour fast.
Results: There were no significant changes in the body weight and fasting 
Glucose levels between Ad-GFP and Ad-G0S2 rats. However, after the glu-
cose load, the glucose levels were significantly higher in the Ad-G0S2 rats at 
15 and 30 min. During the clamp studies, the glucose infusion rate required 
to maintain euglycemia was significantly decreased by 16% in Ad-G0S2 rats. 
Clamp hepatic glucose output was significantly increased by 31% in Ad-G0S2 
rats, but there was no significant changes in insulin-stimulated glucose dis-
posal rate between two groups. Furthermore, the Oil Red O staining revealed 
that overexpression of G0S2 significantly increased lipid accumulation in the 
liver. However, Masson trichrome staining revealed that overexpression of 
G0S2 significantly ameliorated fibrosis in the liver. Consistent with histologi-
cal data, expression of TGF-β and Smad2 were significantly decreased in the 
livers of Ad-G0S2 rats
Conclusion: Overexpression of hepatic G0S2 protein exacerbates hepatic 
insulin resistance by the exacerbation of hepatic steatosis but ameliorates he-
patic fibrosis.
581
Fasting and postprandial hepatic energy metabolism in insulin resistant 
states 
M.J. Fritsch1,2, C. Koliaki1, R. Livingstone1, E. Phielix1, A. Bierwagen1,  
M. Meisinger1, T. Jelenik1, J.-H. Hwang1, J. Szendroedi1,3, M. Roden1,3;  
1Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, 
Germany, 2Department of Pediatrics and Adolescent Medicine, Medical 
University of Vienna, Austria, 3Department of Endocrinology and 
Diabetology, Heinrich-Heine University, Germany.
Background and aims: Alterations of hepatic energy metabolism are dis-
cussed as a mechanism contributing to hepatic steatosis and insulin resist-
ance. However, it remains unclear whether meal ingestion differently affects 
hepatic energy metabolism in insulin sensitive and insulin resistant humans.
Materials and methods: Young lean insulin sensitive (body mass index; 
23.2±0.5 kg/m2), age-matched obese insulin resistant nondiabetic (OBE: 
34.3±0.5 kg/m2) and elderly type 2 diabetes patients (T2D: 32.0±0.8 kg/m2) 
were examined (n=10 per group). Hepatic phosphorous compounds and fat 
content were quantified in vivo with 31P/1H magnetic resonance spectroscopy 
before, 160 min and 240 min after ingestion of a high caloric mixed meal 
(652 kcal, 55% CHO, 15% protein, 30% fat). Whole body insulin sensitiv-
ity (M-value) was assessed with the hyperinsulinemic-euglycemic clamp and 
skeletal muscle oxidative capacity was assessed ex vivo with high-resolution 
respirometry applied in biopsy samples.
Results: OBE and T2D patients were similarly insulin resistant (M-value; 
OBE: 3.6±0.4 mg.kg-1.min-1; T2D: 2.5±0.7 mg.kg-1.min-1). OBE and T2D had 
14fold (p=0.01) and 20fold (p=0.002) higher hepatic fat contents than lean 
persons. Fasting hepatic inorganic phosphate (Pi) was 42% lower in OBE 
(p=0.002) and 32% lower T2D (p=0.02) than in lean persons and correlated 
positively with M-value (r=0.63, p=0.001). After meal ingestion, hepatic ATP 
and Pi increased by 27% (p=0.02) and 33% (p=0.05) only in OBE. Circulating 
lipid peroxides transiently increased by 24% (p<0.05) at 180 min after the 
meal only in T2D. In parallel, mitochondrial oxidative capacity was reduced 
(p=0.01) along with augmented lipid storage (p=0.02) in skeletal muscle of 
T2D.
Conclusion: Obese insulin resistant persons respond to meal ingestion with 
augmented hepatic energy metabolism, whereas diabetes patients exhibit an 
oxidative stress response. These data indicate that obesity-associated adap-
tation of hepatic mitochondrial function is absent with the onset of type 2 
diabetes.
Supported by: MIWF NRW, BMG, BMBF, DZD e.V, ICEMED
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Serum hepassocin contributes to insulin resistance in type 2 diabetes
C.-J. Chang1, H.-T. Wu1, H.-Y. Ou2, H.-C. Hung2, Y.-C. Yang1, J.-S. Wu1;  
1Department of Family Medicine, College of Medicine,  
2Department of Internal Medicine, College of Medicine,  
National Cheng Kung University and Hospital, Tainan, Taiwan.
Background and aims: Increased serum hepassocin concentrations were 
observed in patients with non-alcoholic fatty liver disease and diabetes. Al-
though the mechanisms that hepassocin induces hepatic steatosis were clari-
fied, the role that hepassocin plays in the development of insulin resistance 
and diabetes is still obscure.
Materials and methods: A total of 100 age- and sex-matched normal glu-
cose tolerance (NGT), and newly diagnosed diabetic (NDD) patients were 
included (n=50 in each group) for the measurement of serum hepassocin 
concentrations by enzyme-linked immunosorbent assay. Insulin sensitivities 
in animals were determined using glucose tolerance test, insulin tolerance 
test, and euglycemic hyperinsulinemic clamp, as well as insulin signaling. 
Manipulations of hepassocin expression were achieved by portal vein injec-
tion of lenti-viral vectors containing hepassocin or short hairpin ribonucleic 
acid targeted to hepassocin.
Results: We found that the serum concentrations of hepassocin were sig-
nificantly increased in patients with NDD (p<0.001) as compared with NGT 
subjects. Fasting plasma glucose (p<0.001), NDD vs. NGT (p<0.001) were 
significantly associated factors with serum hepassocin concentrations. Over-
expression of hepatic hepassocin, as well as injection of hepassocin recombi-
nant protein in mice increased fasting glucose levels, impaired glucose utility 
and induced insulin resistance. In addition, knockdown of hepatic hepas-
socin ameliorated insulin resistance in high fat diet-induced diabetic mice.
Conclusion: Hepassocin plays a role in the development of insulin resistance, 
and might be a novel therapeutic target for the treatment of diabetes.
Supported by: B-ER-101-363
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The vicious circle of prostaglandin- and cytokine-dependent hepatic 
insulin resistance: a key role of prostaglandin E2
J. Henkel, R.G. Camargo, N. Schanze, G.P. Püschel;  
Nutritional Biochemistry, University of Potsdam, Nuthetal, Germany.
Background and aims: Hepatic insulin resistance and the ensuing impair-
ment of hepatic glucose metabolism, which is a major contributor to hyper-
glycemia in metabolic syndrome and type II diabetes, are elicited by a variety 
of factors that act in parallel. In obesity, impaired fatty acid handling results 
in an activation of PKC isoforms. In addition, a low-grade inflammation pre-
vails. Both contribute to the development of insulin resistance. The impact of 
cytokines on the insulin signalling cascade is well established. By contrast, the 
role of small lipid mediators like prostaglandins, which are released from res-
ident liver macrophages and infiltrating immune cells in the course of inflam-
mation, is not well characterized. The current study addressed this question.
Materials and methods: Male C57BL/6 mice were fed a modified western 
diet containing 50% of calories from fat, 1,25% cholesterol and 0,5% sodium 
cholate as well as 15% fructose in drinking water versus chow and water for 
4 or 8 weeks. The human macrophage cell line U937, primary mouse and rat 
macrophages were incubated with LPS or PGE2. HepG2 cells or primary rat 
hepatocytes were pre incubated either with PGE2, IL 6, OSM or with condi-
tioned media of PGE2-stimulated macrophages and subsequently stimulated 
with insulin. Gene expression and activation of insulin- and cytokine signal-
ling were quantified by Western blot and quantitative RT PCR.
Results: Hepatic expression of key enzymes in prostaglandin E2 (PGE2) 
formation, namely cyclooxygenase 2 (COX2) and microsomal PGE2 syn-
thase 1 (mPGES1), was induced 2-4-fold in mice fed a modified western 
diet compared to controls suggesting an enhanced capacity of local PGE2 
formation in these mice. In rat hepatocytes PGE2 interrupted Akt-depend-
ent insulin signalling. It enhanced hepatic lipid accumulation by inhibiting 
mitochondrial fatty acid oxidation and VLDL formation. PGE2 acted by a 
distinct mechanism from cytokines, namely a sustained ERK1/2 activation, 
and synergistically with the cytokines interleukin-6 (IL-6) and oncostatin 
M (OSM), which attenuated insulin signalling by inducing SOCS3. In rat, 
mouse and human macrophages the release of these cytokines was stimu-
lated by PGE2. Cytokines and PGE2 induced the PGE2-generating enzymes 
COX2 and mPGES1. While PGE2 besides IL-6 and OSM enhanced IL-1β 
formation, TNFα expression remained unchanged or reduced. Conditioned 
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medium of murine or human macrophages treated with low doses of PGE2 
stimulated the phosphorylation of STAT3 and induced SOCS3 in rat and hu-
man hepatocytes, while insulin-dependent glucokinase induction in hepato-
cytes was attenuated. These effects were abolished after parallel treatment of 
macrophages with the COX2-inhibitor indomethacin or incubation with an 
OSM-neutralizing antibody. In summary, in addition to directly interrupting 
insulin signalling pathway in hepatocytes, PGE2 may further impair hepatic 
insulin sensitivity in an autocrine feed-forward vicious cycle by inducing cy-
tokines like OSM and its own synthesis in macrophages.
Conclusion: The study provides first evidence that in addition to established 
mechanisms prostaglandins have an impact on the development of hepatic 
insulin resistance. The enzymes involved in the prostaglandin synthesis and 
the receptors to which they bind on the different liver cell types might there-
fore be potential new drug targets for the treatment of hepatic insulin resist-
ance.
Supported by: DGE
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Mitochondrial respiration in skeletal muscle, liver and fat does not differ 
in morbidly obese patients with and without type 2 diabetes
M.T. Lund1,2, M. Hansen1, A. Floyd2, J.W. Helge1, F. Dela1;  
1Biomedical Sciences, University of Copenhagen,  
2Department of Surgery, Koege Hospital, Denmark.
Background and aims: After an oral glucose load the uptake in skeletal 
muscle and liver accounts for ~80-90% of the ingested glucose. In patients 
with type 2 diabetes the ability to take up glucose in both tissues are severely 
impaired leading to decreased whole body glucose uptake and prolonged hy-
perglycemia. It has been speculated that the impaired glucose uptake partly 
is the result of an underlying mitochondrial dysfunction limiting the abil-
ity to oxidize glucose and fat. We have now compared the maximal coupled 
mitochondrial respiration in morbidly obese patients with and without type 
2 diabetes by studying three different tissues (skeletal muscle, liver and fat) 
obtained from all patients.
Materials and methods: 16 morbidly obese patients (5M/11F; 7 with (T2D) 
and 9 (OB) without type 2 diabetes) reported to the lab twice 2 months prior 
to their scheduled Roux-En-Y gastric bypass operation. Body composition 
was assessed by a dual Energy X-ray Absorption scan and maximal oxygen 
uptake (VO2max) was measured during a graded bicycle test. On a sepa-
rate day skeletal muscle (m. vastus lateralis) and subcutaneous fat samples 
(abdomen) were acquired by a Bergstrom needle biopsy and subsequently 
a hyperinsulinaemic euglycemic clamp (80 mU/m2/min) was performed to 
measure whole body insulin mediated glucose uptake. Finally, a liver biopsy 
was obtained during the gastric bypass procedure. Prior to respiration analy-
sis the skeletal muscle fibers were split and permeabilized in Saponin (50µg/
ml) for 20 min. Liver and fat tissue were dissected in 2 x 2 mm tissue samples 
before transferred to the respirometer. 2 µl digitonin (2.5 mg/ml) were ini-
tially added to the respirometer to permeabilize the fat tissue. Substrates were 
added consecutively: Malate (2 mM (liver: 6 mM)) and glutamate (10 mM); 
ADP (5 mM (liver: 1 mM)) and magnesium (20 mM (liver: 4 mM)); octanoyl 
carnitine (1.5 mM); succinat (10 mM).
Results: Weight (133±6 vs. 122±9 kg), BMI (43±2 vs. 41±1 kg/m2), age (36±3 
vs. 40±6 years) and VO2max (20±1 vs. 23±2 ml/min/kg) were similar in OB 
and T2D, respectively. Whole body glucose uptake tended to be higher in OB 
compared to T2D (4.8±0.5 vs. 3.6±0.3 mg/min/kg, respectively, P = 0.05). 
Maximal coupled respiration in skeletal muscle, liver and fat tissue are shown 
in Figure 1.
Conclusion: The main finding in the current study was the similar maximal 
coupled respiration in tissue samples from two different groups of patients 
with 25% different insulin sensitivity. Differences in body weight, age or aero-
bic fitness are not confounding factors. Thus, the mitochondria in patients 
with type 2 diabetes are able to consume oxygen at similar rates as healthy 
obese patients and this speaks against an underlying mitochondrial dysfunc-
tion in insulin resistance. These data do not rule out that substrate sensitivity 
at physiological concentrations is altered in patients with type 2 diabetes.
Supported by: The Danish Council for Strategic Research
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Failure of the skeletal muscle to contribute to diurnal glucose 
homeostasis in type 2 diabetes
M.E.O. Macauley, F.E. Smith, P. Thelwall, R. Taylor;  
Institute of Cellular Medicine, Newcastle Magnetic Resonace Centre, 
Newcastle University, Newcastle upon Tyne, UK.
Background and aims: In health, food carbohydrate is stored as glycogen in 
skeletal muscle and liver, preventing a deleterious rise in osmotically active 
plasma glucose after eating. Glycogen concentrations increase sequentially 
after each meal to peak in the evening. Skeletal muscle accounts for the larger 
part of this diurnal buffering capacity. Approximately 30% of meal carbohy-
drate is stored in skeletal muscle compared with 20% in liver after a single 
meal. The effectiveness of this diurnal mechanism has not been previously 
studied in type 2 diabetes. We have quantified the changes in skeletal mus-
cle and liver glycogen concentration before and after 3 meals consumed at 4 
hours interval.
Materials and methods: We studied 40 (25M;15F) well controlled type 2 
diabetes subjects on metformin only (HbA1c 6.4±0.07% or 47±0.8 mmol/
mol) and 14 (8M;6F) glucose tolerant controls matched for age, weight and 
BMI.13C Magnetic resonance spectroscopy at 3.0- Tesla, was used to quantify 
calf muscle and liver glycogen concentration in the fasting state (0830h) and 
at 2000h after 3 defined meals (2700kcal(M) and 2200kcal(F); 60%carbohy-
drate, 20%protein, 20%fat).
Results: Mean fasting plasma glucose and insulin concentrations were high-
er in the type 2 diabetes group (7.7±0.2 vs. 5.1±0.1mmol/l; P<0.0001) and 
(13.8±1.2 vs. 7.9±0.9mU/L; P=0.01) respectively. HOMA-IR was higher in 
the type 2 diabetes group (5.0±0.4 vs. 1.9±0.2; P<0.0001). Plasma glucose 
concentration measured 4 hours after the last meal (2000h) was higher in 
the type 2 diabetes group compared to the control group (6.5±0.2 vs. 5.7± 
0.2mmol/l; P=0.03). Plasma glucagon concentration rose similarly in the 
type 2 diabetes and control groups (70.4±4.7 to 108.5±7.5ng/L; P<0.0001 and 
48.4±4.8 to 67.7±7.3ng/L; P=0.001). Muscle glycogen concentration increased 
by 17% in the control group (68.1±4.8 to 79.7±4.2mmol/l; P=0.006), and the 
change in diurnal muscle glycogen inversely correlated with HOMA-IR (r = 
-0.56; P=0.02). In contrast, there was no change in muscle glycogen in the 
type 2 diabetes group after day-long eating (68.3±2.6 to 67.1±2.0mmol/mol; 
P=0.62). Liver glycogen rose similarly in both normal control (325.9±25.0 
vs. 388.1±30.3mmol/L; P=0.005) and type 2 diabetes groups (296.1±16.0 to 
350.5 ± 6.7mmol/l; P<0.0001).
Conclusion: In type 2 diabetes, the major physiological mechanism for skel-
etal muscle postprandial glycogen storage is completely inactive. This is di-
rectly related to insulin resistance, although liver glycogen storage is normal. 
Even in early well-controlled type 2 diabetes, failure of the buffering capacity 
of muscle glycogen stores is a major contributing factor to post prandial hy-
perglycemia.
Supported by: NAG
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Skeletal muscle develops insulin resistance before subcutaneous adipose 
tissue. Study on obese post-menopausal women
A. Sultan1,2, O. Fabre3, C. Amouzou3, C. Breuker3,1, K. Lambert3, C. Fedou1, 
A. Dupuis1, J. Cristol1, F. Galtier4, A. Avignon1,3, J. Mercier3, C. Bisbal3;  
1CHU Lapeyronie, 2INSERM Unit 1046, 3INSERM Unit 1046,  
4CIC, Montpellier, France.
Background and aims: Obesity has deleterious effects on human health by 
enhancing the development of chronic diseases such as insulin resistance (IR) 
and type 2 diabetes (T2D). Nowadays, the hypothesis commonly admitted is 
that, during obesity, there is a hypertrophy and a hyperplasia of subcutaneous 
adipose tissue leading to its dysfunctions and increase lipolysis. Consequent-
ly to this adipose tissue dysfunctions, subcutaneous adipose tissue cannot 
expand more .Then free fatty acid (FFA) concentration increases in systemic 
circulation and lipids are ectopically stored in visceral adipose tissue, liver 
and skeletal muscle which affect importantly their function. Moreover, mac-
rophages infiltration of adipose tissue induces a local chronic low-grade in-
flammation which develops to become systemic. This inflammation impairs 
the insulin response of insulin sensitive tissues (muscle, liver and fat) leading 
to peripheral IR. However, some obese people (25-30%) do not develop IR, 
and are metabolically healthy. In order to identify the early mechanisms lead-
ing from obesity to IR, we conducted a translationnal study both at systemic 
and tissue levels
Materials and methods: 31 post-menopausal women 50-65 years old, with 
no personal or familial history of type 2 diabetes were involved in this study.: 
(i)10 were leans (BMI 30kg/m2) and insulin sensitive (HOMA-ir 3): OIR. 
Skeletal muscle and subcutaneous adipose tissue were obtained from biopsies 
respectively in the vatus lateralis and abdominal subcutaneous adipose tissue. 
We analyzed the insulin response, inflammatory state at systemic and tissues 
level, intramuscular fatty acid accumulation, angiogenesis and adipocytes 
size of subcutaneous adipose tissue. This protocol was approved by the local 
Ethic Committee (N°:2011.01.04, ANSM: B110204-20) and informed written 
consent was obtain from all participants.
Results: Ours results show a significant decrease in insulin sensitivity of OIR 
skeletal muscle compared to control (p=0.03) and OIS (p=0.04) skeletal mus-
cle while subcutaneous adipose tissue remain insulin sensitive in all three 
groups of volunteers. Further, there is an increase of fatty acid accumulation 
in type I muscular fiber of OIR compare to control (p=0.02). Histological 
analysis show that macrophages infiltration is low in OIR’s subcutaneous adi-
pose and absent from OIS and CT volunteer’s subcutaneous adipose tissue. 
Adipocytes size remains the same among three groups. However angiogen-
esis is significantly decreased in subcutaneous adipose tissue of OIR (p=0.02) 
and OIS (p=0.007) compared to control.
Conclusion: All these results suggest that skeletal muscle seem to be affected 
by IR before subcutaneous adipose tissue during IR development. The only 
one impairment which occurs in subcutaneous adipose tissue is the decrease 
in adipose tissue angiogenesis
Clinical Trial Registration Number: 2010-A01522-37
Supported by: CHU Montpellier/SFD
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Serum myostatin and insulin resistance in postmenopausal women
V. Avila-Rubio, C. Novo-Rodriguez, B. Garcia-Fontana, A. Garcia-Martin, 
R. Reyes-Garcia, S. Morales-Santana, M. Muñoz-Torres;  
Bone Metabolism Unit of Endocrinology division of University Hospital 
Cecilio, Granada, Spain.
Background and aims: Myostatin is a secreted growth factor expressed in 
skeletal muscle, which negatively regulates skeletal muscle mass. Recent ani-
mal studies suggest an additional role for myostatin in glucose metabolism. 
We evaluated the possible associations between circulating levels of myosta-
tin and glucose metabolism parameters in non obese women with postmeno-
pausal osteoporosis.
Materials and methods: Prospective study including 28 women with post-
menopausal osteoporosis, matched for age, BMI and bone mineral density 
(BMD), divided into two groups according to the antiosteoporotic drug: A) 
60 mg Denosumab subcutaneous semiannually (n = 17) and B) 20 μg Teri-
paratide subcutaneous daily (n = 11), both for 3 months. The monitoring 
was conducted by the Bone Metabolism Unit of our hospital. We performed 
fasting plasma determinations of myostatin, glucose, peptide C, insulin, insu-
lin resistance index (HOMA2-IR), insulin sensitivity (HOMA2-%S), insulin 
secretion (HOMA2-%β) and HbA1c at baseline and one week, one month 
and three months after treatment.
Results: Both groups were comparable at baseline in the analyzed param-
eters without significant differences between them. Serum myostatin levels 
remained unchanged regardless of treatment group. A global analysis of all 
determinations (108) shows a positive correlation between myostatin and 
peptide C (r = 0.231, p = 0.02), insulin (rs = 0.215, p = 0.02), HOMA2-IR (rs 
= 0.200, p = 0.04), HOMA2-%β (rs = 0.210, p = 0.03) and HbA1c (r = 0.209, 
p = 0.03) and an inverse correlation with HOMA2-%S (rs = -0197, p = 0.04). 
No correlations were observed between myostatin and other related carbohy-
drate metabolism parameters as undercarboxilated osteocalcin, osteocalcin, 
IGF-1, vitamin D and BMI.
Conclusion: The findings of the present study show significant association 
between circulating myostatin and insulin resistance in non obese women 
with postmenopausal osteoporosis. This study supports the idea that myosta-
tin may exert a negative effect on glucose metabolism acting as an independ-
ent mechanism in the pathogenesis of type 2 diabetes mellitus.
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 244 
1 C
PS 037 Mechanisms of insulin action 
and inter-organ cross-talk
588
Intracerebroventricular administration of vaspin triggers a brain-liver 
circuit to improve hepatic glucose homeostasis via the hepatic branch of 
the vagus
W. Zhu1,2, L. Li1,2, K. Li3, G. Yang3;  
1College of Laboratory Medicine, 2Key Laboratory of Diagnostic Medicine 
(Ministry of Education), 3Endocrinology, The Second Affiliated Hospital, 
Chongqing Medical University, China.
Background and aims: Visceral adipose tissue-derived serpin (vaspin) is a 
member serpin A12 of the serine protease inhibitor family, which plays an 
important role in the modulation of glucose metabolism and insulin sensitiv-
ity. More and more findings raise the possibility that, vaspin regulates glucose 
metabolism and energy balance through its act on the central (hypothalam-
ic) site. However, the regulatory role of vaspin in the brain in the control of 
liver glucose fluxes is unknown. In this study, we investigated the effects of 
vaspin signal conveyed by the hypothalamus on liver glucose fluxes in nor-
mal-chow-diet (NCD) or high fat diet(HFD)-fed male rats with or without 
hepatic branch vagotomy. We reported here a novel role of central vaspin in 
triggering a brain-liver molecular signaling pathway and neuronal network 
to control glucose production in vivo
Materials and methods: We established a model of central administration of 
vaspin. Hyperinsulinemic-euglycemic clamp and hepatic branch vagotomy 
were used to assess the effects of central vaspin on glucose metabolism and 
changes in liver and signaling pathway. [3-3H] glucose radioactivity was de-
termined by scintillation counter. mRNA and protein expressions were meas-
ured by qRT-PCR and Western blot, respectively.
Results: We showed that central infusion of vaspin in HFD-fed animals 
significantly increased glucose uptake in peripheral tissues and decreased 
HGP. These changes were accompanied by a significant decrease in the he-
patic glucose-6-phosphatase (G6Pase) and phosphoenolpyruate carboxyki-
nase (PEPCK) expression. In agreement with this, we also found that central 
vaspin in HFD rats activates the insulin receptor (InsR) →insulin receptor 
substrate-1(IRS-1) →Akt kinase (Akt) →forkhead box-containing protein of 
the O subfamily 1(FoxO1) signaling cascade in the liver leading to the in-
creased insulin sensitivity and improved glucose metabolism.
Conclusion: Our findings suggest that hypothalamus is a site of vaspin ac-
tion, where vaspin triggers a brain-liver circuit via the hepatic branch of the 
vagus nerve to inhibit glucose production and improve insulin resistance.
Supported by: National Natural Science Foundation of China (81100567, 
81300702, 81300670)
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Abnormal hepatic energy metabolism in type 1 diabetes associates with 
long-term metabolic control
S. Gancheva1, A. Bierwagen1, P. Begovatz1, J. Lundbom1, P. Nowotny1,  
G. Giani2, B. Hoffmann3, J. Szendroedi1,4, M. Roden1,4;  
1Institute for Clinical Diabetology, German Diabetes Center, 2Institute for 
Biometry and Epidemiology, German Diabetes Center, 3Leibniz Research 
Institute for Environmental Medicine, 4Department of Endocrinology and 
Diabetology, University Hospital Duesseldorf, Duesseldorf, Germany.
Background and aims: Insulin resistant patients with type 2 diabetes exhibit 
lower hepatic energy metabolism, which has been explained by increased 
lipid availability and/or impaired glycemic control. This study set out to ex-
amine the role of insulin resistance and glycemic control for hepatic energy 
metabolism in type 1 diabetes mellitus (T1D) patients with good glycemic 
control.
Materials and methods: Thirty-seven newly diagnosed T1D patients (age: 
34±9 years; body mass index (BMI): 24.4±3.3 kg/m²) with known diabetes du-
ration of less than one year underwent euglycemic-hyperinsulinemic clamps 
to assess whole-body (M-value) and hepatic insulin sensitivity (insulin-me-
diated percent suppression of endogenous glucose production). Hepatic fat 
content (HCL), ɣ-adenosine triphosphate (ɣATP) and inorganic phosphate 
(Pi) concentrations were quantified via magnetic resonance spectroscopy 
(31P/1H-MRS) on a 3-T clinical MR scanner (Philips, Best, The Netherlands). 
BMI- and age-matched healthy controls (CON; n=27, age: 38±9 years; BMI: 
24.4±3.4 kg/m²) were also studied with 31P/1H-MRS.
Results: Well-controlled T1D patients (HbA1c: 6.5±1.1%) presented high 
whole-body and moderate hepatic insulin sensitivity (7.8±2.9 mg*kg-1*min-1 
and 62±24%). HCL was comparable between T1D and CON (1.7±3.1% and 
1.9±3.9%). Hepatic ɣATP concentrations were 16% lower in T1D (2.22±0.54 
vs CON: 2.61±0.55 mmol/l, P<0.01), whereas Pi levels were not different 
between groups. Within the T1D group, hepatic ɣATP related negatively 
with HbA1c (r=-0.42, P=0.01), whereas Pi related negatively to BMI (r=-
0.39, P=0.02), waist circumference (r=-0.47, P=0.003) and HCL (r=-0.55, 
P<0.001). Neither hepatic ɣATP, nor Pi displayed correlations with whole-
body and hepatic insulin sensitivity.
Conclusion: Hepatic ɣATP is reduced in patients with T1D even in the ab-
sence of liver steatosis, and associates with measures of long-term glycemic 
control, but not with hepatic and peripheral insulin sensitivity.
Clinical Trial Registration Number: NCT01055093
Supported by: DZD e.V.
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Insulin resistance and beta cell function in nonalcoholic fatty liver 
disease (NAFLD)
K. Wyne1, Y.S. Shen2, L. Folb3, H.P. Monsour4;  
1HMH, 2UT Houston, 3Endocrinology, HMH,  
4Hepatology, HMH, Houston, USA.
Background and aims: The global epidemic of non-alcoholic fatty liver dis-
ease (NAFLD) has led to the recognition of associated complications that 
include diabetes and cardiovascular disease in addition to the liver failure 
and/or hepatocellular carcinoma related to the nonalcoholic steatohepatitis 
(NASH). The increased risk of cardiovascular disease suggests that NAFLD is 
the hepatic component of the Metabolic Syndrome. The goal of this study is 
to evaluate β‐cell function and insulin resistance in correlation to metabolic 
parameters in NAFLD/NASH patients to determine parameters to identify 
NAFLD patients at increased risk of diabetes.
Materials and methods: Charts were reviewed retrospectively from 200 con-
secutive patients in the Metabolic Liver Clinic. After excluding those with 
viral or autoimmune hepatitis, glucoregulatory status was assessed by A1c 
and by OGTT with glucose & insulin measured at 0, 30, 60, 90 & 120 min-
utes plus c-peptide & proinsulin measured at 0 & 30 minutes. Homeostatic 
model assessment (HOMA) of β-cell function and insulin resistance (IR) 
were calculated. Subjects treated with insulin were excluded from this part 
of the analysis. We assessed correlations with fasting insulin, proinsulin, fast-
ing c-peptide, insulin resistance as measured by HOMA-IR, pancreatic β‐cell 
function, as measured by HOMA‐β, BMI, lipids, liver enzymes and NASH 
FibroSURE®. Spearman correlation coefficient was used to measure the as-
sociation between metabolic parameters.
Results: After excluding diabetes (whether known or newly diagnosed; 
n=64) 58 patients were found to have NAFLD and prediabetes. In the subjects 
with prediabetes the following significant correlations were found: HOMA-
IR with BMI (p=0.022) but not A1c; fasting proinsulin with BMI (p=0.0081)
and A1c (p=0.04), fasting glucose (p=0.006) with HDL (p=0.0007); fasting 
C-peptide with BMI (p<0.02), HDL (p=0.01) and HOMA-IR (p=0.0018); and 
FibroSURE® Steatosis Score with BMI (p < 0.0001) and A1c (p<0.05). There 
was a significant negative correlation between HDL and fasting insulin level 
(p =0.0079). There was no correlation between c-peptide and FibroSURE® 
Steatosis Score. When evaluated by gender the majority of the significant cor-
relations remained present in men but not in women with the exception of 
BMI (p<0.05 in women) and A1c (p<0.05 in women).
Conclusion: The majority of the patients referred to the Metabolic Liver 
Clinic for evaluation of NAFLD were found to have either Type 2 Diabetes or 
prediabetes, most of which was nor previously diagnosed. Analysis of those 
with prediabetes found insulin resistance with elevated insulin, proinsulin 
and c-peptide levels suggesting that identification of the NAFLD had facili-
tated early diagnosis of prediabetes in these patients who still had significant 
beta-cell function. These data demonstrate that screening NAFLD patients is 
an opportunity to identify prediabetes at a stage when therapy has the poten-
tial to slow or prevent the progression to not only Type 2 Diabetes but also the 
cardiovascular disease that is significantly increased in this population. Stud-
ies are ongoing to identify medical strategies to improve the glucoregulatory 
status of these NAFLD patients with prediabetes.
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The association of serum fibroblast growth factor 21 with insulin 
secretory function and metabolic parameters in type 2 diabetes
M.-J. Kim1, M.-K. Kim2, I. Song2, H. Kim2, Y.-K. Choi3, K.-H. Bae3,  
K.-G. Park3, I.-K. Lee3, J.-E. Lee4, E. Jung5, E. Kim6;  
1Pooren Meerae Internal Medicine Clinic, 2Department of Internal 
Medicine, Keimyung University School of Medicine, 3Kyungpook National 
University School of Medicine, 4CHA Gumi Medical Center, 5Department of 
Internal Medicine, Catholic University of Daegu School of Medicine,  
6Daegu Fatima Hospital, Republic of Korea.
Background and aims: Fibroblast growth factor 21 (FGF21) is a cytokine 
produced by the liver, adipose tissue, skeletal muscle, and the pancreas. Re-
cently, FGF21 is suggested as a key metabolic regulator in glucose and lipid 
metabolism and its level in serum is higher in the patients with metabolic 
syndrome, type 2 diabetes and non-alcoholic steatohepatitis. On the other 
hand, diminished expression of FGF21 is shown in type 1 diabetes and la-
tent autoimmune diabetes in adult (LADA). Type 2 diabetes is a heterogenic 
disease entity and patients with type 2 diabetes have diverse insulin secre-
tory dysfunction. So, we investigated the association of serum FGF21 and 
insulin secretory function in patients who admitted our institute for poorly 
controlled blood glucose and needed insulin therapy.
Materials and methods: We recruited 154 patients (men 52; women 152) 
with type 2 diabetes who were not treat with insulin prior to informed con-
sent from January 2011 to July 2013, who admitted Keimyung University 
Dongsan Medical Center. We reviewed personal history including drug his-
tory, anthropometric parameters, other metabolic parameters, and measured 
serum adiponectin and FGF21.
Results: Mean age was 55.4±14.0 in men and 61.4±14.1 in women and body 
mass index was 24.2±4.7 kg/m2 in men and 25.0±4.2kg/m2 in women. There 
was no significant difference in hemoglobin A1c (10.4% in men; 10.3% in 
women). Fasting C-peptide, insulin and homeostasis model assessment of 
insulin secretion (HOMA-IS) were used as assessment of insulin secretory 
function. Serum FGF21 level shows correlations with HOMA-IS and fasting 
insulin in men, but not in women. In addition, serum FGF21 level shows 
correlations with serum triglyceride, insulin and homeostasis model assess-
ment of insulin resistance (HOMA-IR) in men, however, shows correlations 
with urine albumin/creatinine and HOMA-IR in women. As a result of multi-
variate linear regression analysis, only HOMA-IS has a significant correlation 
with serum FGF21 level. Serum adiponectin level shows negative correlations 
with duration of diabetes, BMI, total cholesterol and low density lipoprotein 
in men and shows negative correlation with BMI, waist circumference, total 
cholesterol and triglyceride, high density lipoprotein in women.
Conclusion: Consequently, this study exhibits a positive correlation of serum 
FGF21 level with an index of insulin secretory function in men with type 2 
DM and supports the result of another study with type 1 diabetes and LADA.
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Novel paracetamol glucuronide derivative for quantifying 
gluconeogenesis using the deuterated water method
J. Jones1,2, S. Kahl3,4, F. Carvalho1, C. Barosa1, M. Roden3,4;  
1Metabolic Control Croup, Center for Neurosciences, Coimbra, Portugal, 
2Portuguese Diabetes Association (APDP), Lisbon, Portugal,  
3Institute of Clincal Diabetology, Deutsches Diabetes-Zentrum, 
4Department of Endocrinology and Diabetology, Heinrich-Heine University, 
Düsseldorf, Germany.
Background and aims: In fasted humans, the analysis of plasma glucose 2H-
enrichment in position 5 relative to position 2 (H5/H2) following ingestion 
of deuterated water (2H2O) is widely used to measure the fractional contri-
bution of gluconeogenesis to endogenous glucose production (EGP). This 
information can be noninvasively obtained via urinary Paracetamol glucu-
ronide (PG): a product that is more stable and abundant compared to blood 
glucose. However, current methods for derivatizing urinary PG to a form that 
can be analyzed for positional 2H-enrichment by NMR or MS are laborious 
and ill-suited for high-throughput studies. We developed a novel procedure 
where urinary PG is derivatized to 5-O-acetyl monoacetone glucuronic lac-
tone (MAGLA). The chemical transformation and purification steps are ro-
bust and amenable to automation and parallel processing and yield resolved 
signals for H5/H2 analysis by 2H NMR (see Figure). We applied this proce-
dure to a study where 2H2O and Paracetamol were given to overnight fasted 
healthy subjects and compared H5/H2 of plasma glucose with that of urinary 
glucuronide.
Materials and methods: Eleven subjects were admitted to the clinical re-
search unit on the evening before the study and provided a standard supper at 
17.30. Each ingested 0.5 g 2H2O/kg body water in three equally divided doses 
at 20:00, 22:00, and 24:00. At 05:00 the following day, Paracetamol (0.5g) was 
given and a primed infusion of [6,6-2H2]glucose was initiated. Urine was 
sampled from 06:00-08:00 and blood was sampled at 07:40. Plasma glucose 
and urinary PG enrichments of positions 5 and 2 were measured by 2H NMR 
following their derivatization to monoacetone glucose and MAGLA, respec-
tively. The fractional gluconeogenic contributions to EGP were calculated 
from plasma glucose H5/H2. These were compared with estimates obtained 
from urinary glucuronide H5/H2.
Results: The overall yield of MAGLA from urinary glucuronide was 20-40% 
and the preparations gave well-resolved 2H NMR signals for quantifying H5/
H2. Analysis of MAGLA yielded identical estimates of fractional gluconeo-
genic contributions to EGP to that of plasma glucose (54 ± 2% versus 55 ± 
3%, respectively). Furthermore, a Bland-Altman analysis indicated agree-
ment at the 95% confidence level between the sets of plasma glucose and 
urinary MAGLA measurements.
Conclusion: The conversion of urinary Paracetamol glucuronide to MAGLA 
is a relatively simple and robust procedure for obtaining estimates of gluco-
neogenesis using 2H2O, or indeed any gluconeogenic tracer. For overnight-
fasted healthy subjects, 2H NMR analysis of MAGLA provides identical esti-
mates of fractional gluconeogenesis to that of plasma glucose.
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BTG2 regulates hepatic gluconeogenesis through Nur77 in diabetes
S.-S. Im1, Y.-D. Kim1, B.-C. Oh2, J.-H. Bae1, D.-K. Song1;  
1Physiology, Keimyung University School of Medicine, Deagu,  
2Lee Gil Ya Cancer and Diabetes Institute, Inchon, Republic of Korea.
Background and aims: Beta cell translocation gene 2 (BTG2) is a member 
of a family that is involved in cellular functions. Herein, we demonstrate that 
BTG2 regulates glucose homeostasis via up-regulation of Nur77 in diabetic 
mice.
Materials and methods: Diabetes was induced in wild-type (WT) and db/
db mice by i.p injections of streptozotocin (80 mg/kg body weight). GTT and 
ITT were performed with db/db mice. Mice were infected with adenoviral 
vector expressing Btg2(1×109 pfu) by tail vein injection. Gene expression and 
induction level were mseasured by qPCR and immunoblotting.
Results: Hepatic BTG2 gene expression was elevated by fasting and forsko-
lin. Overexpression of BTG2 increased the expression of hepatic gluconeo-
genic genes, glucose output, and subsequently impaired glucose and insulin 
tolerance. Up-regulation of the transcriptional activity of Nur77 and gluco-
neogenic genes, and glucose production by forskolin were observed by BTG2 
transduction, but not in BTG2 knockdown. BTG2-stimulated glucose pro-
duction and G6pc promoter activity was attenuated by dominant-negative 
Nur77, but not in Pck1 promoter. Chromatin immunoprecipitation assays 
showed that BTG2 induced Nur77 occupancy on the glucose-6-phosphatase 
gene promoter via a physical interaction. BTG2 gene expression was in-
creased in streptozotocin-treated and db/db mice. Finally, impairment of 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 246 
1 C
glucose homeostasis such as the increase of blood glucose, glucose intoler-
ance and insulin intolerance was elevated in diabetic mice, whereas this phe-
nomenon was abolished in knockdown of BTG2.
Conclusion: These data suggest that BTG2 participates in the regulation of 
hepatic glucose homeostasis, which involves that BTG2 might serve as a po-
tential therapeutic target for combating metabolic dysfunction.
Supported by: KHIDI (A120864) to SSI
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New diabetes drug targets from structural characterisation of liver 
glycogen
R.G. Gilbert1,2, M.A. Sullivan2,1, S.A. Aroney2, S. Li2, P.O. Powell2,  
F.J. Warren2;  
1Tongji School of Pharmacy, Huazhong University of Science and 
Technology, Wuhan, China, 2Centre for Nutrition and Food Science, 
University of Queensland, Brisbane, Australia.
Background and aims: Glycogen is a highly branched polymer of glucose, 
functioning as a blood-glucose buffer. It comprises relatively small beta par-
ticles, which may be joined as larger aggregate alpha particles. The molecular 
size distributions from size-exclusion chromatography of liver glycogen from 
non-diabetic and diabetic mice show that diabetic mice have impaired alpha 
particle formation in liver glycogen, with diabetic mice unable to form as 
many large glycogen particles as non-diabetic controls. There is also reason to 
believe that the degradation of larger particles back to glucose will be slower, 
and hence under better control, than smaller beta particles. Further analysis 
into the nature of “healthy” glycogen has provided evidence that these alpha 
particles are held together via an unknown glue that is most likely proteina-
ceous. This study probes the structure of glycogen alpha particles by ana-
lyzing their digestion during acid hydrolysis and by comparing the in vitro 
digestion rate of glycogen phosphorylase for glycogen of various sizes. This 
greater insight into the internal nature of alpha particles is an important step 
into finding potential drug targets that would allow diabetic sufferers to form 
these larger alpha particles and hence have better blood-sugar control.
Materials and methods: The digestion of glycogen by acid hydrolysis was 
investigated by analyzing the size distributions, obtained using size-exclusion 
chromatography, of pig-liver glycogen and phytoglycogen at various time 
points in a low-pH buffer. In addition, glycogen from the livers of wild-type 
mice were extracted and fractionated into different sizes using sucrose den-
sity centrifugation. The size distributions of these fractions were compared 
using size-exclusion chromatography. The in vitro kinetics of the initial rates 
of phosphorylase degradation were examined and compared for each frac-
tion using an assay that utilized the production of NADPH in the reaction 
mixture, which has an absorbance at 340 nm.
Results: The acid hydrolysis experiments show that the alpha particles in the 
liver glycogen degrade via a different mechanism to that of the smaller beta 
particles, indicating a different type of chemical bonding (most likely pro-
teinaceous). The in vitro kinetics analysis of glycogen phosphorylase on frac-
tionated glycogen showed that larger glycogen particles indeed had a lower 
initial rate of phosphorylase degradation.
Conclusion: The difference in kinetics of the acid hydrolysis of alpha and 
beta particles indicates that they have a different mechanism of biosynthesis. 
The hypothesis that larger glycogen alpha particles are more slowly degraded 
by glycogen phosphorylase, presumably due to a lower surface area to vol-
ume ratio, was supported by the present data. This shows that diabetic mice, 
which have been shown to lack the larger alpha particles, may be vulnerable 
to having a fast, uncontrolled release of glucose. Because alpha particles have 
been shown here to have a separate mechanism of formation to smaller beta 
particles, the activation of this process in diabetic sufferers is now a potential 
drug target.
595
Post-prandial and ChREBP mediated PANDER expression
W.A. Danse, M.N. Kuehl, A.C. Chechele, B.R. Burkhardt;  
Cell Biology, Microbiology and Molecular Biology, University of South 
Florida, Tampa, USA.
Background and aims: Pancreatic-Derived Factor (PANDER, FAM3B) is 
a novel endocrine pancreatic secreted protein mainly characterized from 
this tissue. PANDER regulates hepatic insulin sensitivity and overall glyce-
mic levels. However, recent research now suggests that PANDER is poten-
tially expressed within the liver as well. Our previous data have shown the 
PANDER promoter to be highly active and glucose-responsive in a murine 
liver-derived cell line. To further investigate the regulation and expression 
of hepatic derived PANDER, we examined hepatic PANDER levels in mice 
and characterized the minimal element of the PANDER promoter in a liver-
derived cell line.
Materials and methods: Western analysis was performed to evaluate the 
presence of PANDER protein within murine tissues. Promoter deletion 
analysis and co-transfection experiments were performed using PANDER 
promoter-luciferase constructs and ChREBP expression plasmids in a mu-
rine liver-derived cell line, BNL-CL2.
Results: Initial western analysis performed on 15 different murine-derived 
tissues revealed robust PANDER expression within the murine liver and to 
a lesser extent in the brain and ovary. Furthermore, hepatic PANDER lev-
els were measured in the fasted and fed state of our PANDER transgenic 
and control mice and revealed increased levels in the post-prandial state. 
The minimal element was identified between -293 to -3 bp of the hepatic 
transcriptional start site. The region between -193 to -93 bp of the TSS was 
demonstrated as being necessary for basal promoter activity. This region con-
tains three E-box elements which may serve as a binding site for the critical 
hepatic transcription factor carbohydrate responsive element binding protein 
(ChREBP). Co-transfection reporter studies revealed that PANDER promot-
er activity is significantly upregulated (p<0.05) in response to increased levels 
of ChREBP under both starved and elevated glucose conditions.
Conclusion: Our western analysis results confirm the presence of PANDER 
protein within murine liver tissue as well as the upregulation of PANDER 
protein in the fed state. This supports our previous finding that elevated glu-
cose levels result in increased PANDER promoter activity. In addition, we 
identified a minimal element within the PANDER promoter which contains a 
putative binding site for the glucose-responsive transcription factor ChREBP. 
Our co-transfection experiments suggest that ChREBP may play a role in me-
diating the glucose-responsiveness of the PANDER promoter within the liver, 
and indicates another mechanism for regulation of hepatic insulin signaling 
via PANDER.
596
Soluble RAGE is unlikely to induce type 2 diabetes by inducing insulin 
resistance or beta cell dysfunction
S.K. Biswas1, S. Mohtarin1, S.R. Mudi2, T. Anwar1, S.M.K. Alam1,  
M.I. Arslan1;  
1Department of Biochemistry, Bangabandhu Sheikh Mujib Medical 
University (BSMMU), 2Department of Biochemistry and Cell Biology, 
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine 
and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh.
Background and aims: Soluble receptor for advanced glycation end product 
(sRAGE) is considered as protective against diseases originating from RAGE 
activation. However, recent studies have suggested that sRAGE may be in-
volved in the pathogenesis diabetes mellitus. A declining level of sRAGE has 
been suspected to be a predictor of type 1 diabetes, and an independent asso-
ciation has been found between low levels of sRAGE and development of type 
2 diabetes. To further explore the involvement of sRAGE in the pathogenesis 
of type 2 diabetes, present study was designed to assess whether sRAGE level 
alters in prediabetic subjects and whether sRAGE level correlates with insulin 
resistance and beta cell function.
Materials and methods: A total of 128 subjects were recruited from those 
who came for diabetes screening at our medical university. Subjects were 
grouped as control (normoglycemic), pre-diabetic and diabetic based on their 
blood glucose (fasting and 2 hrs after 75 grams glucose load) and HbA1c lev-
els following ADA criteria. Subjects suffering from complications of diabetes 
mellitus, hypertension, chronic liver and kidney diseases, and regular drug 
users were excluded. Fasting serum sRAGE levels were measured by ELISA 
(R&D Systems), and insulin levels were measured by enzyme immunoassay 
technique (Abbott AxSym System). Insulin resistance (HOMA2-IR) and beta 
cell function (HOMA2-%B) were calculated using HOMA2 calculator. To 
achieve a normal distribution some values were appropriately transformed 
before statistical analysis in SPSS 17.0 software. A p value of <0.05 was con-
sidered statistically significant.
Results: Age (40.2±8.7 years) and sex (m=58, f=70) distribution of the study 
subjects were not different among control (n=30), pre-diabetic (n=42) and 
diabetic (n=56) groups. Fasting glucose and HbA1c levels were found sig-
nificantly (p<0.001) elevated in diabetic group compared to control and 
pre-diabetic groups. Fasting insulin levels were found similar among control 
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(11.8±6.8), pre-diabetic (14.2±8.7) and diabetic (13.8±11.0 µU/mL) groups. 
However, HOMA2-IR values [median (IQR)] were 1.37 (0.99-2.12) for con-
trol, 1.71 (1.27-2.60) for pre-diabetic and 1.95 (1.13-3.23) for diabetic groups 
(p<0.05); and HOMA2-%B values were 140% (99-198) for control, 132% 
(107-167) for pre-diabetic and 46% (24-89) for diabetic groups (p<0.001). 
However, serum sRAGE levels did not show any difference among control 
[626 (413-826) pg/mL], pre-diabetic [656 (463-968)] and diabetic [646(493-
817)] groups. More importantly, serum sRAGE level did not show any sig-
nificant correlation with HOMA2-IR, HOMA2-%B, fasting glucose, insulin 
and HbA1c levels in all subjects. Serum sRAGE level also did not show any 
correlation with the above parameters in diabetic patients or in pre-diabetic 
subjects.
Conclusion: Serum sRAGE level did not show any change in pre-diabetic 
subjects compared with control and diabetic subjects. Moreover, sRAGE level 
did not show any correlation with insulin resistance or beta cell function. 
These data therefore suggest that sRAGE is unlikely to induce type 2 diabetes 
by inducing insulin resistance or beta cell dysfunction.
Supported by: Conversion of BSMMU into Center of Excellence Project
PS 038 Insulin resistance  
and adipose tissue
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The effect of bariatric surgery on fat distribution and glucose uptake in 
abdominal and femoral regions in morbidly obese patients
P.Y. Dadson;  
Turku PET Center, Finland.
Background and aims: Bariatric surgery reduces weight and improves in-
sulin sensitivity. We investigated the effects of bariatric surgery on fat dis-
tribution and insulin-stimulated glucose uptake in fat tissue in abdominal 
and femoral regions in morbidly obese patients compared with non-obese 
healthy controls.
Materials and methods: Twenty five morbidly obese patients (age 46±9, 
body mass index 43.2±3.8 kg/m2) and 10 non-obese controls (age 47.3±6.0, 
BMI 23.6±1.9) were studied using positron emission tomography to assess 
glucose uptake in fat tissue in the abdomen and in femoral area during in-
sulin stimulation. Whole body magnetic resonance imaging was performed 
to measure abdominal and femoral fat content of obese and controls. Obese 
patients were studied before and six months after the surgery. The abdominal 
subcutaneous fat was divided into anterior and posterior regions. The pos-
terior region was further divided into deep and superficial layers using the 
presence of fascia. The visceral fat was divided into intraperitoneal and extra-
peritoneal regions using specific anatomical reference points. Subcutaneous 
fat mass was segmented 10 cm in the mid-section of the thigh.
Results: Total body fat (kg) in obese decreased after surgery, but re-
mained higher compared to non-obese controls (P < 0.001). Compared 
to baseline, obese subjects lost 39% fat mass in posterior deep, 32% in 
posterior superficial and 40% in total anterior region (p < 0.001). Sub-
cutaneous fat in the thigh decreased by 28% (P < 0.001). For visceral 
fat, intraperitoneal fat decreased by 44% while extraperitoneal fat by 
29% after surgery (P < 0.001). In spite of the decreases in abdominal fat 
masses, the waist to hip ratio did not change after surgery (P = 0.10). 
Whole body insulin sensitivity increased by 94% at follow up (P < 0.001). In-
sulin-stimulated glucose uptake in abdominal adipose in deep layer increased 
by 19% (P = 0.001), 49% in superficial (P = 0.01) and 28% in subcutaneous 
fat in the thigh (P = 0.03) after surgery. When the various insulin-stimulated 
glucose uptakes were expressed per kilogram of fat, there were no changes 
after surgery and the results were similar to the non-obese controls.
Conclusion: Over 30% of fat mass is lost 6 months after surgery from all 
abdominal fat depots and adipose tissue insulin sensitivity improves in line 
with lipolysis. Adipose tissue metabolism in different depots remained the 
same after surgery and was close to the healthy controls.
Clinical Trial Registration Number: NCT00793143
Supported by: Academy of Finland
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Impact of adiposity on glycaemic variability with type 2 diabetes 
T. Mayu, H. Makino, T. Tamanaha, Y. Ohata, R. Koezuka, A. Hishida,  
I. Kishimoto;  
Diabetes, National cerebral and Cardiovascular Center, Suita City, Japan.
Background and aims: High glycemic variability generates oxidative stress 
and contributes to the development of endothelial dysfunction and cardio-
vascular complications in patients with type 2 diabetes. However, the factors 
affecting glycemic variability have not been fully studied. In the present study, 
we examined the effect of body status, body composition and abdominal fat 
area on the parameters of glycemic variability determined by continuous 
blood glucose monitoring system (CGMS) in subjects with type 2 diabetes.
Materials and methods: Among patients referred to our department between 
August 2012 and February 2014, 41 patients with type 2 diabetes (mean age 
68.7 years; 70 % men; HbA1c 8.4 %; BMI 24.2; energy intake; 22-32 kcal/
ideal body weight (60 % carbohydrate)) who underwent CGMS were select-
ed. Their antihyperglycemic therapy consisted of oral hypoglycemic agents 
(n=31) and/or insulin (n=32) (None were diet alone). Based on CGMS data, 
we evaluated the following criteria for variability of glycemic control from 
data of the intermediate 48 hours (midnight to midnight): average glucose 
levels, standard deviation (SD) values, mean amplitude of glycemic excur-
sions (MAGE), percentage of time spent in hyperglycemia (> 140 mg/dL) and 
percentage of time spent in hypoglycemia (< 70 mg/dL). We investigated the 
effect of body status (body mass index (BMI)) for these glycemic variability 
indices. Furthermore, the impact of body composition (body fat mass (kg), 
skeletal muscle mass (kg); n=19) and of abdominal fat area (subcutaneous fat 
area (SFA, m2), visceral fat area (VFA, m2); n=31) on glycemic variability is 
also evaluated in the subgroup analyze.
Results: Among all participants, the mean ± SD of average glucose levels, 
SD of glucose variability and MAGE were 140 ± 27 mg/dl, 32 ± 13 mg/dl 
and 81 ± 28 mg/dl, respectively. When patients were divided into two cat-
egories by median (74 mg/dl) split of MAGE, higher MAGE category had 
a significantly lower BMI (p=0.004) than those with lower MAGE category. 
In univariate analysis, BMI was significantly negatively correlated with SD 
(p<0.001), MAGE (p=0.015) and percentage of time spent in hypoglycemia 
(p=0.005), whereas BMI was not related to average glucose levels or percent-
age of time spent in hyperglycemia. In multivariate analysis relationships 
between BMI and MAGE or SD remained significant after adjustment of 
age, gender, diabetes duration and HbA1c (R2=0.29 for the model includ-
ing MAGE and R2=0.41 for the model including SD), and no correlation was 
found with percentage of time spent in hypoglycemia. Among body composi-
tion, body fat mass was negatively correlated to SD with a statistical signifi-
cance (p=0.036), while no relationship was observed between skeletal muscle 
mass and SD (p=0.974). Multivariate analysis showed that body fat mass was 
significantly related to SD (R2=0.39) after adjustments of age and sex. Among 
abdominal fat area, both SFA and VFA were significantly negatively associ-
ated with MAGE (SFA; p=0.004, VFA; p=0.011) and SD (SFA; p=0.002, VFA; 
p=0.040). In multivariate analysis, SFA and VFA was significantly related to 
MAGE (SFA; R2=0.46, VFA; R2=0.50) and SD (SFA; R2=0.50, VFA; R2=0.57).
Conclusion: In patients with type 2 diabetes, adiposity is negatively corre-
lated with glycemic variability independent of age, sex, diabetes duration, 
HbA1c or skeletal muscle mass. Our data raise the possibility that low fat 
mass indicates the presence of insulin secretory disorder.
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Insulin resistance predicts cardiovascular morbidity in men without 
diabetes mellitus and this effect is modified by level of physical activity
C.A. Larsson1,2, M.I. Hellgren2, B. Daka2, P.-A. Jansson3, U. Lindblad2;  
1Department of Clinical Sciences, Malmö, Social Medicine and Global 
Health, Lund University, Malmoe, 2Department of Public Health and 
Community Medicine and Global Health/Primary Health Care, University 
of Gothenburg, 3The Wallenberg Laboratory, Department of Molecular and 
Clinical Medicine, University of Gothenburg, Sweden.
Background and aims: Type 2 diabetes, as well as different measures of in-
sulin resistance, has been shown to predict cardiovascular disease (CVD). 
Although type 2 diabetes is known to have a more adverse cardiovascular 
effect in women than in men, it is not clear whether the same is true for insu-
lin resistance. The potentially mediating effect of physical activity on the as-
sociation between insulin resistance and CVD is also yet to be fully explored. 
The aim of the present study was thus to assess how well insulin resistance 
predicts CVD in non-diabetic men and women, and to explore the influence 
of physical activity.
Materials and methods: In 2002-2005, 2816 randomly selected men and 
women in two municipalities in Sweden, aged 30-75 years, were examined 
for CVD risk factors (76% participation). Anthropometric measurements 
were conducted, blood pressure was measured, and a standard oral glucose 
tolerance test was performed. Questionnaires about lifestyle and physical ac-
tivity were also completed. For this prospective cohort study, 2563 subjects 
without diabetes and prior history of CVD were surveyed for first events of 
CVD through record-linkage with the National Swedish Inpatient and Mor-
tality registers. Insulin resistance was estimated by fasting concentrations of 
plasma insulin and by HOMA index for insulin resistance (HOMAir; fasting 
insulin × fasting glucose / 22.5). After controlling for proportionality, Cox 
proportional regression model was used to analyse the association between 
insulin resistance and CVD. Log transformation of Homa-ir was used in all 
analyses to induce normality.
Results: After a mean follow-up of 8 years, HOMAir was significantly as-
sociated with increased CVD morbidity in men (50 events) and women (26 
events) combined (HR 1.3, 95% CI 1.1-1.6). However, when stratified by gen-
der, HOMAir was predictive for CVD solely in men (HR 1.8, CI 1.3-2.4) and 
not in women (HR 1.1, CI 0.1-1.5). When stratifying also for high and low 
physical activity the predictive value of insulin resistance became stronger in 
sedentary men (HR 2.3, CI 1.5-3.4), whereas it abolished in men perform-
ing moderate to vigorous physical activity (HR 1.0, CI 0.1-1.6). These results 
remained when also adjusting for age, APOB/APOA1, BMI, hypertension, 
smoking, alcohol consumption, and education, despite that almost all such 
risk factors showed significantly more beneficial levels in participants report-
ing high levels of physical activity as compared to those reporting low levels. 
Furthermore, a three-way interaction analysis between sex, HOMAir, and 
physical activity, was highly significant (p=0.002). The CVD risk associated 
with fasting plasma insulin was similar to the risk of HOMAir.
Conclusion: Although men may be more vulnerable to insulin resistance 
than women, only physically inactive men seemed to be at increased CVD 
risk from insulin resistance in this study. These results emphasise the im-
portance of a high level of physical activity, as physical activity substantially 
increases insulin sensitivity and may also limit the negative cardiovascular 
effects of an increased insulin resistance in men.
Supported by: The VG Region, The Skaraborg Institut, VR
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Android and gynoid fat are independently associated with hepatic and 
whole-body insulin resistance in non-diabetic males from the Oxford 
Biobank
K.E. Pinnick1, K. Brismar2, F. Karpe1;  
1Oxford Centre for Diabetes, Endocrinology and Metabolism,  
University of Oxford, UK, 2Department of Molecular Medicine and Surgery, 
Karolinska Institutet, Stockholm, Sweden.
Background and aims: Upper- and lower-body fat depots exhibit opposing 
associations with insulin resistance and type 2 diabetes risk independent of 
overall obesity. Most associations have been detected using conventional an-
thropometrics, yet these measurements do not accurately quantify regional 
fat depots compared with techniques such as dual-energy X-ray absorpti-
ometry (DXA). In this study we aimed to investigate whether android and 
gynoid DXA-quantified fat depots are independently associated with hepatic 
and peripheral insulin resistance in a healthy, non-diabetic, adult cohort.
Materials and methods: Subjects (406 (M) males, 387 (F) females), aged 30-
50 years, were recruited from the Oxford Biobank. All subjects underwent 
detailed screening which included a fasting blood sample, anthropometric 
measurements and quantification of regional fat depots (% fat) by DXA. 
Plasma glucose was measured enzymatically. Plasma insulin and insulin-
like growth factor binding protein 1 (IGFBP1) were measured by radioim-
munoassay. Whole-body and hepatic insulin resistance were estimated using 
HOMA-IR and plasma IGFBP1, respectively. Spearman’s Rank (rs) and par-
tial correlation coefficients (r) are presented.
Results: In both sexes, HOMA-IR positively correlated with android (M: 
0.511, p=1.4x10-28; F: 0.501, p=4.9x10-26) and gynoid (M: 0.452, p=2.5x10-18; 
F: 0.317, p=1.6x10-10) % fat, whereas plasma IGFBP1 was inversely related to 
android (M: -0.612, p=3.2x10-43; F:-0.524, p=6.1x10-29) and gynoid (M: -0.443, 
p=4.7x10-21; F: -0.248, p=7.2x10-7) % fat. Partial correlation analysis identified 
a depot-specific relationship between % fat content and markers of insulin re-
sistance in males. After controlling for total fat mass, android % fat remained 
inversely associated with IGFBP1 (-0.223, p=5.7x10-6) while the association 
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with HOMA-IR was abolished (-0.077, p=0.121). Furthermore, when HO-
MA-IR was corrected for, the inverse association between android % fat and 
IGFBP1 was retained (-0.241, p=9.2x10-7). By contrast, gynoid % fat was in-
versely associated with HOMA-IR after controlling for total fat mass (-0.154, 
p=1.8x10-3) and the association with IGFBP1 was abolished (0.095, p=0.054). 
These findings could not be replicated using anthropometric measures of 
regional fat depots. For example, after adjusting for total fat mass, waist cir-
cumference was equally associated with HOMA-IR (0.116, p=1.9x10-2) and 
IGFBP1 (-0.113, p=2.3x10-2). In females, after controlling for total fat mass, 
android and gynoid % fat also displayed opposite directions of association 
with HOMA-IR (android: 0.124, p=1.4x10-2; gynoid: -0.197, p=9.0x10-5) and 
IGFBP1 (android: -0.145, p=4.2x10-3; gynoid: 0.161, p=1.4x10-3) however the 
strength of association was similar for both depots.
Conclusion: Our findings highlight the advantage of quantifying specific fat 
depots by DXA over anthropometric measures when assessing insulin resist-
ance. In males, hepatic insulin resistance (assessed by IGFBP1) was inde-
pendently associated with greater android fat content whereas whole-body 
insulin resistance (HOMA-IR) was associated with diminished gynoid fat 
content. These findings lend further support to the paradoxical relationship 
between diabetes risk and body fat distribution.
Supported by: NIHR Biomedical Research Centre
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A study of the mechanisms through which the biogenesis of adiponectin 
is regulated in white adipose tissue
L. Zhang1, M.M. Li1, M. Corcoran1, S. Zhang1, G.J.S. Cooper1,2;  
1School of Biological Sciences, University of Auckland, New Zealand, 
2Manchester Biomedical Research Centre, University of Manchester, UK.
Background and aims: Adiponectin is an adipose tissue-derived hormone 
with anti-diabetic, anti-atherogenic and anti-inflammatory functions. De-
fects in adiponectin multimerization are associated with decreased adiponec-
tin levels, obesity and insulin resistance. In this study, we investigated the en-
zyme systems responsible for adiponectin multimerization and production, 
and other factors also contributing to this process.
Materials and methods: OB mice (10- or 27-week) and age-matched C57 
controls were used in this study. Fully differentiated 3T3-L1 adipocytes were 
also used. Quantitative real time-PCR was performed to measure the mRNA 
expression levels of a number of genes in white lipid tissue (WAT) from mice 
and 3T3-L1 adipocytes. ELISA/western blots were used to measure the ex-
pression of relative protein levels. Statistical analysis was performed by t-test 
or analysis of variance (ANOVA) with appropriate post-hoc tests.
Results: In fully-differentiated 3T3-L1 adipocytes, we observed that de-
creased insulin signalling caused by blocking the insulin receptor (InsR) 
with a blocking anti-InsR antibody, increased extracellular adiponectin lev-
els, whereas coexisting hyperinsulinaemia counteracted this effect. Blocking 
the adenosine monophosphate-activated protein kinase (AMPK) pathway 
by using an inhibitor (compound C) significantly decreased extracellular 
adiponectin levels. Furthermore, we demonstrated the expression of ly-
syl hydroxylases (LHs), prolyl hydroxylases (PHs) and glycosyltransferase 
25-domain-containing proteins 1&2 (Glt25D1&2) in the WAT of mice. Ex-
pression of LH3 was markedly increased in the WAT of OB mice compared 
with controls. In differentiated 3T3-L1 adipocytes, non-specific inhibition of 
LHs and PHs by the hydroxylase inhibitor, dipyridyl markedly suppressed 
adiponectin production, particularly of the higher molecular-weight iso-
forms, but increased the low molecular-weight isoform. Specific inhibition 
of prolyl-4-hydroxylase (P4H) with ethyl-3,4-dihydroxybenzoate had effects 
comparable to dipyridyl: however, it had different effects on the intracellular 
composition of adiponectin isoforms. Specific inhibition of LHs with minoxi-
dil also suppressed adiponectin production, especially of the high molecular-
weight (HWM) isoform. In addition, transient gene knock-down of LH3 
(Plod3) suppressed adiponectin production, especially of the HMW isoform.
Conclusion: Our results indicate that: hyperinsulinaemia and decreased 
insulin signalling exert countervailing effects on adiponectin production; 
AMPK pathway signalling also regulates adiponectin production; both PHs 
and LHs are required for adiponectin production; and the hydroxylation/gly-
cosylation of lysyl residues and hydroxylation of prolyl residues are essential 
for formation and secretion of higher-order adiponectin isoforms.
Supported by: Health Research Council of New Zealand
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The plasma levels of adipokines and incretins in patients with 
Alzheimer’s disease
B. Bendlová1, J. Vcelak1, D. Vejrazkova1, P. Lukasova1, O. Bradnova1,  
K. Dvorakova1, G. Vacinova1, R. Rusina2, I. Holmerova3, M. Vankova1;  
1Molecular Endocrinology, Institute of Endocrinology,  
2Neurology, Thomayer Hospital,  
3Faculty of Humanities, Charles University, Prague, Czech Republic.
Background and aims: Alzheimer’s disease (AD) is linked to type 2 diabe-
tes (T2D). T2D is a risk factor for vascular dementia but also for a progres-
sive neuron damage, which is probably associated with insulin resistance in 
central nervous system. AD is therefore sometimes called “diabetes of the 
brain”. The aim of the study was to compare the plasma levels of adipokines, 
incretins and other biomarkers associated with T2D in AD patients and in 
non-diabetic subjects without pathological changes in the brain.
Materials and methods: The study included 38 females (19 age and BMI 
matched pairs AD patient and control; age 70±8 years and BMI 26±4 kg/m2) 
and 24 males (12 age and BMI matched pairs AD patient and control; age 
67±7 years and BMI 27±3 kg/m2) who underwent neuropsychological ex-
amination and magnetic resonance imaging of the brain. The characteristics 
of fasting glucose and lipid metabolism and parameters of body composition 
including body adiposity index (BAI) were determined. Multiplex methods 
for evaluation of fasting plasma biomarkers were used: Bio-Plex ProHuman 
Diabetes 10-Plex Assay - C-peptide, ghrelin, GIP, GLP-1, glucagon, insulin, 
leptin, total PAI-1, resistin, visfatin and Bio-Plex ProHuman Diabetes Adip-
sin and Adiponectin Assays (Bio-Rad). Statistical analyses were performed 
using NCSS 2004 software (ANOVA).
Results: Compared groups of AD patients and controls (men/women sepa-
ratelly) did not differ in either age, BMI, WHR, waist and abdomen circum-
ferences, body adiposity index (BAI) or insulin resistance (HOMAR). In 
women, AD patients had significantly higher levels of visfatin (p=0.0006), 
ghrelin (p=0.03), GLP-1 (p=0.006) and glucagon (p=0.00002) compared with 
control women. Similar results were found in men, they had higher levels of 
visfatin (p=0.02) and ghrelin (p=0.02) compared with control men, GLP-1 
and glucagon did not reach statistical significance.
Conclusion: Alzheimer´s disease is associated with increased levels of plas-
ma visfatin, ghrelin, GLP-1 and glucagon. Plasma visfatin is a pro-inflamma-
tory cytokine that increases risk of endothelial cell deterioration due to the 
inflammation and oxidative stress. Visfatin is a marker of ageing and age-de-
pendent diseases. Ghrelin, GLP-1 and glucagon are considered as neuropro-
tective hormones. Dysregulation of these hormones in AD could be caused 
by impaired secretion/degradation and/or resistance of the target tissues.
Supported by: IGA MH CZ NT/13543/4, NT/13544/4, MH CZ 00023761
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Anti-TNF therapy has a possible favorable effect on insulin sensitivity in 
non-diabetic, non-obese patients with inflammatory bowel disease
S.A. Paschou1, F. Kothonas2, A. Myroforidis2, V. Loi1, T. Terzi1,  
O. Karagianni1, A. Poulou2, K. Goumas2, A. Vryonidou1;  
1Department of Diabetes and Endocrinology, 2Department of 
Gastroenterology, Hellenic Red Cross Hospital, Athens, Greece.
Background and aims: Insulin resistance is very common in autoimmune 
systemic diseases and recently it was also found in children and adults with 
inflammatory bowel disease (IBD). Inflammation and insulin resistance are 
closely linked, and inflammatory cytokines such as tumor necrosis factor al-
pha (TNFa) may inhibit insulin signaling and promote insulin resistance. The 
aim of this study was to investigate the effect of anti-TNF therapy on glucose 
and lipid metabolism in non-diabetic, non-obese patients with IBD.
Materials and methods: We studied 41 patients with IBD (25M/16F, 36.4 
± 11 (19-64) years old, 28 with Crohn’s disease and 13 with ulcerative co-
litis), without known history of diabetes. Eighteen patients (9M/9F, 33.6 ± 
8.8 years) were on anti-TNF therapy for more than 1 year, while the other 
23 patients (16M/7F, 38.7 ± 12.5 years) were treated with azathioprine and 
mesalazine (Aza/Mes). Nine of the patients from the second group were then 
treated with anti-TNF and studied again 6 months after. Fasting glucose, in-
sulin, c-peptide, HbA1c, lipids, and CRP levels were determined and HOMA-
IR index was calculated, in all patients. Statistical analysis of the data was 
performed using SPSS 16.00.
Results: Three of the patients were diagnosed with overt diabetes and were 
excluded from the analysis. Patients from the two therapy groups were 
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matched for age (anti-TNF: 33.6 ± 8.8 years vs Aza/Mes: 38.7 ± 12.5 years, 
p>0.05) and BMI (anti-TNF: 23.3 ± 3.4 vs Aza/Mes: 23.1 ± 1.7, p>0.05), and 
were not obese. We did not find any statistical differences between the pa-
tients from the two therapy groups in the levels of fasting glucose (anti-TNF: 
88 ± 10.7 vs Aza/Mes: 93.4 ± 14.9 mg/dl, p>0.05), insulin (anti-TNF: 10.9 ± 
7.9 vs Aza/Mes: 12.1 ± 6.6 mIU/ml, p>0.05), c-peptide (anti-TNF: 1.9 ± 0.9 vs 
Aza/Mes: 2.2 ± 1.4 ng/ml, p>0.05), HbA1c (anti-TNF: 5.2 ± 0.3 vs Aza/Mes: 
5.3 ± 0.4 %, p>0.05), total cholesterol (anti-TNF: 168.6 ± 32.7 vs Aza/Mes: 
162.8 ± 34.3 mg/dl, p>0.05), HDL (anti-TNF: 57.5 ± 15.7 vs Aza/Mes: 53.8 ± 
20.3 mg/dl, p>0.05), LDL (anti-TNF: 95.8 ± 28.7 vs Aza/Mes: 90.7 ± 24.4 mg/
dl, p>0.05), triglycerides (anti-TNF: 75.8 ± 37.6 vs Aza/Mes: 90.8 ± 61.3 mg/
dl, p>0.05), CRP (anti-TNF: 3 ± 5.4 vs Aza/Mes: 4.9 ± 6.1, p>0.05) and in the 
HOMA-IR index (anti-TNF: 2.77 ± 2 vs Aza/Mes: 3.1 ± 1.9, p>0.05). In pa-
tients who were treated for 6 months with anti-TNF, a statistically significant 
decrease in insulin (before: 15.4 ± 5.8 vs after: 10.2 ± 2.7 mIU/ml, p=0.049) 
and c-peptide (before: 2.4 ± 1.2 vs after: 1.4 ± 0.4 ng/ml, p=0.038) levels as 
well as the HOMA-IR index (before: 4.1 ± 2.1 vs after: 2.3 ± 0.7, p=0.047) 
was observed, without any statistically significant changes in weight, BMI, 
glucose, HbA1c, lipids and CRP levels (in all comparisons p>0.05).
Conclusion: These preliminary data indicate that anti-TNF therapy may have 
a favorable effect on insulin sensitivity in non-diabetic, non-obese patients 
with inflammatory bowel disease.
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Dual character of osteoprotegerin as a metabolic biomarker in a healthy/
prediabetic population
B. Buday1, F.P. Pach2, B. Literati-Nagy1, Z. Vecsei1, M. Vitai1, L. Koranyi1;  
1Department of Metabolism, Drug Research Center, Balatonfured, 
2Department of Medical Informatics, Bay Zoltán Nonprofit Ltd. for Applied 
Research, Budapest, Hungary.
Background and aims: Osteoprotegerin (OPG) is a member of the tumor 
necrosis factor receptor superfamily involved in bone metabolism (OPG/
RANK/RANKL axis), cardiovascular (CV) system and the bone - energy ho-
meostasis. It protects against vascular calcification in animal models while its 
high level has been linked to diabetic complications, CV death, inflammation 
and poor glycemic control in humans. However some conflicting data show 
that in normal glucose tolerant (NGT) subjects, these connections do not 
exist or show opposite results. To clarify this issue and the possible sex differ-
ence we investigated the metabolic connections of OPG in a cohort of healthy 
or prediabetic male and female subjects.
Materials and methods: We included 155 males and 154 females (aged 
49.18± 9.43 vs.41.62±12.95 years) in our study. They were diagnosed as NGT 
or glucose intolerant (GI = IGT, IFG or drug naïve 2DM) by OGTT, with no 
known diabetic/CV complication. IVGTT and a hyperinsulinemic euglyce-
mic clamp were done to determine insulin secretion and sensitivity (IS=Mm 
muscle glucose uptake). Serum glucose, insulin, free fatty acid (FFA), adipo-
cytokines, bone markers, lipid subfractions (SF: small-dense (SD): LDL-3,4,5, 
large-buoyant (LB): LDL-1-2.), apoproteins, anthropometric data (body fat 
percent, abdominal circumference (AC)) were measured. Serum OPG levels 
were determined by Biomedica ELISA kits.
Results: OPG levels did not differ significantly between the NGT and GI 
groups in either gender. In both genders it showed a significant (p<0.05) posi-
tive association with TNF-alpha levels, as expected (R=+0.178 in males and 
+0.359 in females, both NGT and GI), which was independent of age, Hba1c 
and BMI. However in all males OPG has showed a significant negative corre-
lations with BMI, FFA, triglyceride, (R=-0.286, -0.325 and -0.266), and posi-
tive correlation with Mm and adiponectin (AN), (R=+0.176 and 0.224 respec-
tively), i.e. with improving metabolic state. The correlation with Mm ceased 
after correction with BMI but stayed significant with AN. In all females there 
was a significant (p<0.05) negative correlation between OPG and FFA levels 
(R=-0.359), similar to the male group. Although the percent of LDL-3,4,5 (SD 
SFs) significantly increased (R=+0.380, 0.386, 0.213) while that of the LDL-1 
(LB-SF) decreased (R=- 0.4469) with increasing OPG levels. These associa-
tions were not mediated by TNF-alpha because they stayed significant after 
data were adjusted with its levels. Feature selection analysis confirmed FFA 
and TNF-alpha in both genders as important determinants of OPG (mean 
Z=9.75 and 4.12 vs.10.16 and 3.68 respectively), while SD and LB-LDL SFs 
were also confirmed as important attributes in females (mean Z= 9.176 and 
2.851, respectively).
Conclusion: Our study confirmed a gender-specific, conflicting metabolic 
character of OPG: it predicted improving metabolic state in both genders 
which was more emphasized in males. Besides, in females it predicted an 
unfavourable lipid profile with increased SD and decreased LB-LDL SFs, in-
dependent of BMI or TNF-alpha levels. The nature and cause of this “dual” 
character of OPG has not been addressed before and needs some further pro-
spective investigations.
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Cannabinoid receptor type 1 expression in human adipose tissue is 
upregulated by glucocorticoids and is associated with insulin resistance
C.O. Sidibeh1, M.J. Pereira1, M. Hammar2, P. Katsogiannos1, M. Rizell3, 
M.K. Svensson4, J.W. Eriksson1;  
1Department of Medical Sciences, Uppsala University, 2AstraZeneca R&D, 
Mölndal, 3Department of Surgery, 4Department of Molecular and Clinical 
Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Background and aims: Glucocorticoids are often used for treatment of auto-
immune or inflammatory conditions, including in post-transplant patients to 
prevent graft rejection. Elevated plasma glucocorticoid levels, as in Cushing’s 
syndrome or during exogenous administration, are associated with a multi-
tude of adverse effects such as obesity, dyslipidemia and insulin resistance 
(IR) and can eventually trigger onset of type 2 diabetes (T2D). We aimed 
to investigate the glucocorticoid-induced IR mechanisms in order to find 
unique mechanisms that could provide potential pharmacological targets or 
biomarkers in insulin resistant conditions.
Materials and methods: Paired subcutaneous (sc) and omental (om) adipose 
tissue samples were collected from non-diabetic subjects undergoing elec-
tive surgery mainly for kidney donations (M/F 10/15, 28-60 yr, BMI 20.7- 
30.6 kg/m2). Fasting blood samples were collected for the analysis of plasma 
glucose, insulin and lipid levels. In addition, anthropometric measurements 
were obtained. Adipose tissue was incubated for 24 h in DMEM containing 
6 mM glucose and 10% fetal bovine serum in 37 °C, 5% CO2 with or without 
the synthetic glucocorticoid dexamethasone (Dex) at varying concentrations 
(0.003-3.0 µM). Following incubation, parts of the tissue were snap-frozen 
for gene expression (microarray analysis, n=4, with/without Dex; real time 
PCR, n=10). Moreover, adipocytes isolated with collagenase underwent glu-
cose uptake assays (n=12) with or without insulin-stimulation (1000 µU/ml).
Results: Through affymetrix mRNA microarray analysis, it was shown that 
cannabinoid receptor type 1 (CNR1) is one of the genes with the highest in-
crease in mRNA expression after incubation with a supra-physiological con-
centration (3 µM) of Dex in subcutaneous and omental adipose tissue (~11- 
and ~7-fold, respectively; p<0.05). The upregulation by Dex of CNR1 gene 
expression was further verified by real time PCR analysis (p<0.05) and shown 
to be dose-dependent (0.03-3 µM). Basal CNR1 gene expression in subcuta-
neous adipose tissue positively correlated with HOMA-IR (p<0.05, r=0.60), 
serum insulin (r=0.65, p<0.01) and BMI (r=0.56, p<0.05 ). In addition, CNR1 
expression in subcutaneous adipose tissue treated with dexamethasone nega-
tively correlated with basal and insulin-stimulated glucose uptake (r=-0.74, 
p<0.05 and r=-0.79, p<0.01). Furthermore, a negative correlation was seen 
between the Dex-induced increase in CNR1 gene expression and the basal 
and insulin-stimulated glucose uptake in the respective adipose tissue depots 
(sc basal and insulin: r=-0.80, p<0.01; om basal: r=-0.65, p<0.05; om insulin: 
r=-0.55, p=0.098).
Conclusion: Dexamethasone promotes gene expression of CNR1 in adipose 
tissue, and significant associations between CNR1 expression and measures 
of insulin resistance were found. This study gives further support to the con-
cept of a role of the peripheral endocannabinoid system in obesity and insu-
lin resistance, and peripheral CNR1 may thus be an attractive target for new 
anti-diabetic drugs.
Supported by: SDA, UU, AstraZeneca R&D
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Fasting hyperglucagonaemia in patients with non-alcoholic fatty liver 
disease with and without type 2 diabetes
A.E. Junker1, L. Gluud2, F.K. Knop1, J.J. Holst3, T. Vilsbøll1;  
1Diabetes Research Division, Hellerup, 2Department of Gastroenterology, 
Hvidovre, 3Department of Biomedical Science, Copenhagen, Denmark.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) and hy-
perglucagonemia seems to influence glucose metabolism and both features 
are associated with type 2 diabetes (T2D). We investigated glucagon respons-
es during oral and intravenous glucose administration in biopsy-verified 
NAFLD patients with and without T2D.
Materials and methods: We performed a 50 g-OGTT, and isoglycaemic 
intravenous glucose infusion (IIGI) in participants with I) normal glucose 
tolerance (NGT) and no NAFLD (N=10; age (median±interquartile range): 
58±17 years; BMI: 29±1 kg/m2: HbA1c: 34±6 mmol/mol (5.5±0.2%)), II) 
NGT+NAFLD (N=9; age: 54±22 years; BMI: 28±7 kg/m2: HbA1c: 33±4 mmol/
mol (5.2±0.3%)), III) T2D and no NAFLD (N=8; age: 59±18 years: BMI: 27±3 
kg/m2: HbA1c: 45±9 mmol/mol (6.2±1.1%)), or IV) T2D+NAFLD (N=8; age: 
65±3 years; BMI: 30±4 kg/m2; HbA1c: 53±19 mmol/mol (7.0±1.4%)).
Results: In all groups, isoglycaemia was achieved during oral and intrave-
nous glucose administrations. Fasting plasma glucagon was elevated in par-
ticipants with NAFLD and NGT (7.0±2.7 pM) and T2D (6.7±2.3 pM), com-
pared to participants without NAFLD and NGT (2.8±4.0 pM, P<0.001) or 
T2D (4.5±2.9 pM, P<0.05). Increased glucagon responses (ΔAUC0-50 min) 
during OGTT vs. IIGI were seen in both groups with T2D (no NAFLD: 40±78 
(OGTT) vs. -63±43 pM×50min (IIGI), P<0.05; NAFLD: 30±99 (OGTT) vs. 
-38±44 pM×50min (IIGI), P<0.05) whereas no differences in glucagon re-
sponses to OGTT and IIGI were seen in NGT subjects (no NAFLD: -20±26 
(OGTT) vs. -88±60 pM×50min (IIGI), P=NS; NAFLD: -40 ± 75 (OGTT) vs. 
-90±70 pM×50min (IIGI), P=NS).
Conclusion: Fasting hyperglucagonemia seems to be a pathophysiological 
trait of NAFLD independently of concomitant T2D. In contrast, patients with 
T2D have an inappropriate glucagon response to oral glucose independently 
of NAFLD.
Clinical Trial Registration Number: NCT01492283
Supported by: The Novo Nordisk Foundation
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High fasting glucagon-like peptide 2 levels potentiate greater glucagon 
response during OGTT in patients with type 2 diabetes risk factors and 
newly-diagnosed type 2 diabetes
E.A. Shestakova, A.V. Ilyin, M.V. Shestakova, I.I. Dedov;  
Endocrinology Research Centre, Moscow, Russian Federation.
Background and aims: The glucagonostatic action of glucagon-like pep-
tide-1 (GLP-1) is established, whereas the influence of glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) on 
glucagon secretion is not fully understood. The aim of the study was to in-
vestigate the contribution of GLP-1, GIP and GLP-2 to glucagon response 
during the OGTT in patients with type 2 diabetes (T2D) risk factors.
Materials and methods: 127 patients with T2D risk factors (mean BMI 
33,7±7,54 kg/m2, mean age 57,6±12,77 years) and without prior glucose-low-
ering therapy underwent 75 g OGTT. Plasma glucose levels, glucagon and 
total GLP-1, GIP and GLP-2 levels were estimated in fasting state, at 30 and 
120 minutes after glucose load and area under curve (AUC) for glucagon, 
GLP-1, GIP and GLP-2 response was measured.
Results: According to the OGTT results 28 subjects had normal glucose tol-
erance (NGT), 44 patients were either at impaired glucose tolerance (IGT) 
or impaired fasting glycemia (IFG) state and 55 had newly-diagnosed T2D. 
The stimulated glucagon secretion was supressed in NGT group, whereas 
paradoxical initial increase in glucagon levels was observed in IGT+IFG 
and T2D patients (p<0,05). Total GLP-1 AUC was higher in NGT subjects 
comparing to IGT+IFG or T2D patients (p<0,01). Total GIP AUC was also 
higher in NGT comparing to other two groups and total GLP-2 AUC was 
higher in T2D group vs NGT and IGT+IFG groups, but these results were 
nonsignificant. When all participants were divided into tertiles by baseline 
total GLP-1, GIP and GLP-2 levels statistically significant difference in gluca-
gon AUCs was reached only in patient groups divided by GLP-2 baseline lev-
els (0,008±0,064 ng/ml*min vs 0,117±0,061 ng/ml*min vs 0,638±0,065 ng/
ml*min in tertiles with minimum, mean and maximum total GLP-2 fasting 
level, p=0,0001). Glucagon AUC was also positively related to fasting total 
GLP-2 level (r = 0,61, р=0,0001) in Spearmen correlation analyses.
Conclusion: Positive correlation of total GLP-2 baseline levels and glucagon 
secretion rate suggests glucagonotropic properties for GLP-2. We conclude 
that glucagon stimulation by GLP-2 may play a role in the absence of gluca-
gon suppression in T2D patients.
Supported by: Novartis Pharma grant
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The impact of autonomic neuropathy and hypoglycaemia unawareness 
on amino acids stimulated glucagon response to hypoglycaemia in 
subjects with type 1 diabetes
F. Porcellati, P. Lucidi, P. Cioli, P. Candeloro, A. Marinelli Andreoli, G. Bolli, 
C.G. Fanelli;  
Internal Medicine, University of Perugia, Italy.
Background and aims: To examine the effects of autonomic neuropathy 
(AN) and hypoglycemia unawareness (HU) on amino acids (AA) stimulated 
response of glucagon to insulin-induced hypoglycemia (H)
Materials and methods: we studied 41 subjects with type 1 diabetes 
(mean±SD: age 32.5±7.5 yrs; BMI 22.7±1.5 kg/m2; A1C 7.3±0.7%, diabetes 
duration 15.5±9.6 yrs) who were divided in three groups: no complications 
(ANneg, HUneg, [group A, N=15]), ANpos (group B, N=13) and HUpos 
(group C, N=13). Subjects were studied on two different occasions during 
low dose i.v. insulin (0.3 mU/kg/min) and variable glucose infusions to in-
duce a slow hypoglycemia plateau (50 mg/dl) at 150 min maintained for 40 
minutes. Then euglycemia was re-instituted and maintained for 40 minutes, 
until the end of study. On both occasions, at time 30 min, subjects ingested 
either placebo (P) or an AA mixture (42 g).
Results: In all subjects plasma insulin and glucose concentrations during the 
studies were not different with P and AA (p>0.1). The amount of glucose 
infused during the clamp was higher in the P than in the AA study (p<0.02). 
Plasma glucagon responses did not increase during H with P in the three 
groups (p=0.254). In contrast, with AA, glucagon response increased in all 
groups (p<0.001 vs P), less in C (p<0.05 vs A and B) although this differ-
ence disappeared after adjusting for duration (p=0.052). The linear regres-
sion analysis indicated that there was a negative correlation between diabetes 
duration and glucagon response to H, both with P and AA. Plasma adrena-
line responses and maximal total symptom scores were not affected by AA as 
compared to P in all groups (p=0.621 and p=0.248, respectively).
Conclusion: AA can support responses of glucagon to hypoglycemia not 
only in non-complicated Type 1 diabetes, but also in conditions well known 
for risk of severe hypoglycemia, i.e. AN and HU. Duration of diabetes has a 
significant negative impact on the AA-stimulated responses of glucagon to 
hypoglycemia
Supported by: EFSD
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Glucose transporter SGLT2 inhibition triggers glucagon secretion in 
alpha cells
C. Bonner1, J. Kerr-Conte1, V. Gmyr1, G. Queniat1, E. Moerman1,  
J. Thevenet1, C. Beaucamps1, N. Delalleau1, W.J. Malaisse2, A. Sener2,  
B. Deprez1, A. Abderrahmani1, B. Staels1, F. Pattou1;  
1European Genomic Institute for Diabetes, Lille Cedex, France,  
2Université Libre de Bruxelles, Belgium.
Background and aims: Type 2 diabetes mellitus (T2D) is a metabolic disor-
der characterized by chronic hyperglycemia resulting from defects in insulin 
secretion, insulin action, and an increase in gluconeogenesis. The gliflozins 
are a new class of oral antidiabetic agents acting as inhibitors of the glucose 
cotransporter 2 (SGLT2). By preventing renal glucose reabsorption, SGLT2 
inhibition reduces the renal threshold for glucose, resulting in glycosuria. 
In diabetic patients, the decline in plasma glucose induced by gliflozins is, 
however, blunted by an increase in endogenous glucose production. Yet, the 
underlying mechanisms are not known. The aim of this study was to deter-
mine whether the paradoxical effect of glucagon increase in subjects with 
T2D might be related to a direct action on the endocrine pancreas.
Materials and methods: Human or mouse islets, alphaTC1.9 cells, human 
pancreatic grafts and liver from fasted mice were studied. SLC5A1/2 gene 
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expression was assessed by qPCR analysis and SGLT1/2 proteins by histology 
and ELISA. RNA interference or SGLT inhibitors such as phlorizin or dapa-
gliflozin was used to inhibit SGLT2 in alpha cells, human islets or healthy 
mice.
Results: Here, we demonstrate that SGLT1/2 proteins (encoded by the 
SLC5A1/2 genes) are specifically expressed in human pancreatic alpha 
cells. SLC5A2 gene expression is lower in islets isolated from T2D patients 
(*p<0.05) and decreases in normal human islets after transplantation in in-
sulin resistant immuno-deficient mice (*p<0.05). Lower SLC5A2 gene ex-
pression is accompanied by an increase of SLC5A1 (**p<0.01) and glucagon 
(GCG) gene expression (***p<0.001). siRNA knockdown of SGLT2 in alpha 
cells, or its inhibition with phlorizin or dapagliflozin stimulated GCG gene 
expression (***p<0.001) and glucagon secretion (*p<0.05). In healthy mice, 
dapagliflozin treatment elevated fasting plasma glucose levels (***p<0.001) 
and hepatic gluconeogenic gene expression (G6pase and Pepck) (*p<0.05).
Conclusion: Collectively, these results reveal that inhibition of SGLT2 activ-
ity induces glucagon secretion, identifying a hereto unknown role of glifloz-
ins as alpha cell secretagogues.
Clinical Trial Registration Number: NCT 01123i87
Supported by: INSERM, EGID, University of Lille 2, Conseil Régional Nord-Pas 
de Calais
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Paradoxical synchronisation of Ca2+ oscillations between alpha and beta 
cells within intact pancreatic islets
Q. Yu, J. Li, A. Tengholm, E. Gylfe;  
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Insulin and glucagon are secreted in anti-synchro-
nous pulses causing pronounced variations in the insulin/glucagon ratio that 
determines hepatic glucose production. The insulin pulses are generated by 
oscillations of the cytoplasmic Ca2+ concentration, which is regarded the 
main trigger of both insulin and glucagon release. To clarify how the gluca-
gon release pattern is generated it is important to understand the relationship 
between the cytoplasmic Ca2+ dynamics in α- and β-cells.
Materials and methods: Pancreatic islets were isolated from transgenic 
GLU-RFP mice expressing red fluorescent protein (RFP) in the α-cells. The 
Ca2+ concentration in the sub-plasma membrane space ([Ca2+]pm) of superfi-
cial islet cells was recorded with total internal reflection microscopy and the 
fluorescent indicator Fluo-4.
Results: Introduction of 1 mM glutamate in the presence of the hyperpolar-
izing agent diazoxide triggered a pronounced elevation of [Ca2+]pm in 84% of 
the RFP-positive cells but had no effect in the RFP-negative ones, suggesting 
that glutamate responses can be used as a complementary tool to distinguish 
α- from β-cells. At 3 mM glucose, α-cells showed pronounced, unsynchro-
nized [Ca2+]pm oscillations, whereas [Ca
2+]pm was low and stable in the β-cells. 
When the glucose concentration was increased to 20 mmol/l, β-cells showed 
an initial decrease of [Ca2+]pm followed by a protracted increase, succeeded 
by oscillations that were almost perfectly synchronized among neighbouring 
β-cells. The α-cell oscillations were often temporarily suppressed in parallel 
with the initial [Ca2+]pm increase in the β-cells. When subsequently recur-
ring, the α-cell oscillations tended to synchronize with those in the β-cells, a 
phenomenon consistently evident when averaging Fluo-4 fluorescence from 
several α-cells within an islet.
Conclusion: Pancreatic α- and β-cells show distinguishing [Ca2+]pm signaling 
patterns in low and high glucose and in response to glutamate. Synchroniza-
tion of [Ca2+]pm oscillations between α-cells and β-cells at 20 mM glucose 
surprisingly indicates that pulsatile glucagon release is not generated by α-cell 
oscillations of [Ca2+]pm unless Ca
2+ becomes an inhibitory messenger under 
these conditions.
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Possible contribution of taurine to distorted glucagon secretion in 
insulin deficiency: a metabolome analysis using a novel alpha cell model 
of type 1 diabetes
M. Bessho1, Y. Murase-Mishiba1, J. Terasaki1, A. Imagawa2, T. Hanafusa1;  
1The Department of Internal Medicine(I), Osaka Medical College, Takatsuki, 
Japan, 2The Department of Metabolic Medicine, Graduate School of 
Medicine, Osaka University, Suita, Japan.
Background and aims: Glycemic instability is a serious problem in patients 
with type 1 diabetes (T1D). We recently reported that glucagon secretory ca-
pacity is positively associated with the degree of glucose fluctuation in T1D 
patients whose endogenous insulin was completely depleted, suggesting that 
glycemic instability may be due in part to paradoxically incresed endogenous 
glucagon secretion. However, the intracellular metabolic mechanism(s) in-
volved in the aberrant glucagon response under the condition of insulin defi-
ciency has not yet been elucidated.
Materials and methods: We generated an αTC6 cell line with lentiviral 
shRNA-mediated stable knockdown of the insulin receptor (IRKD), i.e., an 
in vitro α-cell model for T1D. The glucagon secretion in response to vary-
ing glucose concentrations (1.5, 5.6 and 30 mM) was studied in both control 
and IRKD cells. To investigate the cellular metabolic changes in α-cells under 
pathophysiological conditions of T1D, a comprehensive intracellular me-
tabolomic analysis of the IRKD αTC6 cells (IRKD cells) was performed us-
ing capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). 
The various metabolites, which were identified as being significantly altered 
in the IRKD cells and could potentially affect the glucagon secretion, were 
chosen for further uptake and biosynthetic analyses.
Results: The IRKD cells tended to secrete less glucagon compared to the con-
trols at the 1.5 mM glucose concentration (p=0.13). On the other hand, the 
IRKD cells exhibited significantly higher glucagon secretion in response to 
the 30 mM glucose concentrations than controls (60.1±4.2 vs. 18.0±1.1 pg/μg 
protein, p<0.01). By metabolome analysis, the cellular contents of 33 metabo-
lites in the control and IRKD cells were significantly different, with p<0.05 
for at least two points at each concentration of glucose. Of these metabo-
lites, taurine was remarkably increased in the IRKD cells and was one of the 
most likely candidate metabolite stimulating glucagon secretion. The cellular 
uptake of [³H] taurine was increased time-dependently in IRKD cells com-
pared to control cells. The expression of cysteine sulfinic acid decarboxylase 
(casd), the rate-limiting enzyme required for taurine synthesis, was increased 
in IRKD cells compared to control cells (p<0.05). Supplementation of taurine 
(100 mM) to the culture medium enhanced the glucagon secretion in a con-
centration-dependent manner in the αTC6 cells. When the IRKD cells were 
treated with 30 mM glucose plus 10 mM taurine, the glucagon secretion was 
significantly augmented compared with that in vehicle-treated cells (63.3±2.5 
vs. 49.1±0.9 pg/μg protein, p<0.01).
Conclusion: Our study indicates that the metabolic alterations induced by 
IRKD in α-cells, especially the increase of taurine, may lead to a distorted 
glucagon response in IRKD cells, suggesting the importance of taurine in the 
paradoxical glucagon response and the resultant glucose instability in T1D.
Supported by: KAKENHI (JSPS)
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Expression and function of the atypical purinergic receptor GPR17 in 
endocrine pancreas
E.S. Di Cairano1, S. Moretti1, F. Daniele1, V. Meraviglia2, A. Ulivi2, P. Rosa2, 
F. Bertuzzi3, S. LaRosa4, F. Folli5, F.V. Sacchi1, C. Perego1;  
1DiSFB Dept of Pharmacological and Biomolecular Sciences, University of 
Milano, 2Institute of Neuroscience, CNR-Biometra, Milano, 3Niguarda Cà 
Granda Hospital, Milan, 4Dept of Pathology, Ospedale di Circolo, Varese, 
Italy, 5Dept. of Medicine Diabetes Division, University of Texas Health 
Science Center, San Antonio, USA.
Background and aims: Islets of Langerhans control glucose homeostasis and 
metabolism by sensing blood glucose and nutrients. Factors secreted within 
the islet create a parallel tuning, defined autocrine-paracrine signaling, that 
modulates hormone release and cell viability. Studying the molecular actors 
of this signaling and their physiological significance may help in understand-
ing diabetes pathogenesis thus providing novel therapeutic targets. G-protein 
coupled receptors (GPCRs) are expressed in islets of Langerhans, regulate 
hormone secretion and cell survival, and are emerging as new targets for 
type-2 diabetes therapies. In this work, we focused on the expression and 
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role of the atypical orphan receptor GPR17, which is activated by uracil nu-
cleotides and can be partially antagonized by ATP, a well known autocrine/
paracrine signal in islets. We first verified the GPR17 expression in endocrine 
cell lines and in human islets, and then we investigated its possible role in 
islet physiology
Materials and methods: The expression of GPR17 was analysed by RT-
PCR analysis, western blot and immunofluorescence techniques in cell lines 
(αTC3, βTC3, the δ cell line RIN14B), in human isolated islets of Langerhans, 
and human pancreatic sections. The possible involvement of GPR17 in the 
control of hormone release and cell proliferation/viability was studied in cell 
lines and in human isolated by means of ELISA assays.
Results: By means of RT-PCR, we detected GPR17 mRNA in human islets, 
in α and δ cell lines, but not in β cell lines (n=5). By means of western blot 
experiments, we confirmed GPR17 protein expression in α and δ cell lines 
and in human islets, where its abundance was upregulated by hyperglycemia 
(2.13+0.15 fold increase over normoglycemic conditions; p<0.05, n=4). To 
investigate the specific endocrine cells where GPR17 was expressed in vivo, 
we carried out double immunofluorescence and confocal analysis on human 
pancreas sections, using hormones as markers of the different cell popula-
tions. We confirmed the expression of GPR17 in a sub-population of δ cells 
but no expression was detected in β-cells, in physiological conditions. To un-
derstand the possible role of GPR17 in islet physiology we activated GPR17 
with its agonist UDP-glucose, and we measured its effect on cell viability and 
hormone release in cell lines and human isolated islets. 3-day incubation 
of αTC3 with 100 µM UDP-G caused a significant increase in cell viability, 
measured by MTT test (108±2.56% UDP-G vs ctr, p<0.005 T-Test; n= 10). A 
similar behavior was observed in human islets, where we found a reduction 
of apoptosis in presence of 100 µM UDP-G (38±7% UDP-G vs ctr). Prelimi-
nary data on hormone release in static conditions indicated that incubation 
of human islets with 100 µM UDP-G, caused a decrease in the glucagon and 
somatostatin release in normoglycemia (37±10% and 25±5%, respectively)
(Elisa assay, 2 islets preparations, duplicate)
Conclusion: We demonstrated for the first time that GPR17 is expressed and 
functional in human islets of Langerhans. Studies are in progress to better 
define its role in islet cell physiology and pathology.
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Elevation of cAMP promotes an Epac2 dependent, L-type Ca2+-channel 
coupled, Ca2+-induced Ca2+ release in mouse alpha cells
Q. Zhang1, A. Salehi2, R. Ramracheya1, P. Rorsman1;  
1OCDEM, Oxford, UK, 2Department of Clinical Science, UMAS,  
Division of Islet Cell Physiology, Lund, Sweden.
Background and aims: Glucagon is a potent glucose elevating hormone that 
is secreted from pancreatic α-cells in response to hypoglycaemia. Glucagon 
secretion in mouse islets is inhibited by elevation of glucose and strongly 
stimulated by adrenaline. Although glucose and adrenaline have differential 
effects on glucagon secretion, these two different factors exert similar effects 
on α-cell electrical activity. This indicates that the stimulatory effect of adren-
aline is exerted distal to the firing of action potentials, i.e. cell exocytosis. 
Cell exocytosis is Ca2+-dependent and relies on Ca2+ from the extracellular 
environment or released from intracellular Ca2+ stores (by a process namely 
Ca2+-induced Ca2+ release). cAMP is known to regulate several pathways in 
Ca2+ signaling via phosphorylation by protein kinase A (PKA) and/or Epac 
(exchange protein activated by cAMP). This study aims to address whether 
this amplifying pathway is governed by cAMP in pancreatic α-cells.
Materials and methods: Mouse pancreatic islets were acutely isolated by 
enzyme digestion. Hormone secretion was measured by batch incubation 
experiments. Ca2+ signal was ratiometrically monitored using indo-1. Cell 
exocytosis was measured using capacitance measurements. Membrane po-
tential was measured using intact mouse islets with perforated patch clamp-
ing technique under current clamp mode.
Results: Adrenaline (5 μM) stimulated glucagon secretion 2 fold, an effect 
that was also produced by 10μM of the adenylyl cyclase activator forskolin 
(n=8). Adrenaline-stimulated glucagon secretion can be reversed following 
application of the L-type Ca2+ channel blocker isradipine (2.5μM) or 100μM 
ryanodine (an intracellular Ca2+ releasing channel blocker). α-cell exocytosis 
evoked by 300ms depolarization (from -70mV to 0mV) was strongly stimu-
lated when 0.1mM cAMP was applied intracelluarly; from 37±9fF (n=16) 
to 233±32fF (n=17). This was accompanied by a marked increase in Ca2+ 
transients (AUC from 1.4±0.3 to 2.5±0.8, p<0.05). cAMP delayed the decay 
of depolarization evoked Ca2+ transients (time constant τ, from 0.6±0.1s to 
1.7±0.5s, p<0.05). Neither the amplitude, nor the decay of Ca2+ transient were 
reduced when the PKA inhibitor Rp-CAMPS or PKI were applied in the pres-
ence of cAMP. In α-cells from mice lacking Epac2 (Epac2-/- mice), the cAMP 
amplification of cell exocytosis was markedly reduced to an insignificant level 
(from 32±7fF to 53±12fF, n=16 for control and n=8 for cAMP, p=0.1). Fur-
thermore, cAMP did not produce a significant change in the kinetics of de-
polarization triggered Ca2+ transients in epac2-/- α-cells. Adrenaline exerted 
a weaker stimulatory effect on glucagon secretion in epac2-/- mouse islets (2 
fold compared to 5 fold in wildtype, n=8). The PKA inhibitor Rp-cAMPS 
partially reduced adrenaline stimulated glucagon secretion in wildtype islets, 
but completely abolished that in epac2-/-islets.
Conclusion: Adrenaline stimulates glucagon secretion in mouse islet α-cells 
via a cAMP /Epac2 dependent pathway. This effect is likely to be exerted dis-
tally to electrical activity by promoting L-type Ca2+ channel coupled Ca2+-
induced Ca2+ release from the endoplasmic reticulum via ryanodine receptor. 
This study provides a novel insight into the regulation of glucagon secretion 
by adrenaline and highlights the importance of appropriate neuronal control 
in preventing life-threatening episodes of hypoglycaemia in diabetes.
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Alpha cell derived glucagon-related peptides are required for normal 
beta cell function and glucose homeostasis
S. Xu1, E. Dror1, F. Schulze1, T. Nordmann1, S. Häuselmann1, F. Thorel2,  
P.L. Herrera2, M. Böni-Schnetzler1, M.Y. Donath1;  
1Endocrinology, Diabetes and Metabolism and Department of Biomedicine, 
University Hospital Basel and University of Basel,  
2Department of Genetic Medicine and Development, University of Geneva 
Medical Centre, Switzerland.
Background and aims: Recent data indicate that pancreatic alpha cell de-
rived glucagon-like peptide-1 (GLP-1) and glucagon contribute to beta cell 
function. We studied the importance of these locally acting hormones versus 
systemically derived insulin secretagogues on beta cell function and glucose 
homeostasis.
Materials and methods: Selective and massive alpha cell ablation was 
achieved by diphtheria toxin injection into mice with alpha cell specific ex-
pression of human diphtheria toxin receptor at the age of 5 weeks. In vivo in-
traperitoneal glucose tolerance tests, and in vitro glucose-stimulated insulin 
secretion assay on isolated islet were performed.
Results: In agreement with previously published data, we did not observe 
any difference in intraperitoneal glucose tolerance between alpha cell ablated 
mice and their littermate controls up to the age of 12 weeks. At the age of 28 
weeks, alpha cell ablated mice had impaired intraperitoneal glucose tolerance 
and lower insulin secretion compared to littermate controls despite similar 
baseline systemic active GLP-1 levels (3.6 ± 0.9 pg/ml in alpha cell ablated 
mice versus 3.0 ± 0.8 pg/ml in littermate controls). The ileum content of ac-
tive GLP-1 was compensatory increased by 32% (p = 0.06) in alpha cell ablat-
ed mice. Body weight was comparable in both groups. Both sitagliptin injec-
tion to stabilize systemic GLP-1 or glucagon injection prior to intraperitoneal 
glucose load restored glucose tolerance in alpha cell ablated mice. In isolated 
islets from alpha cell ablated mice, glucose-stimulated insulin secretion was 
reduced by 69% (p < 0.0001) compared to wildtype islets. Administration of 
exogenous GLP-1 or glucagon as well as the adenylyl cyclase activator forsko-
lin during high glucose stimulation fully restored insulin secretion in vitro.
Conclusion: Alpha cell derived GLP-1 and glucagon are required for normal 
glucose homeostasis and beta cell function in vivo. Further, these findings 
indicate that the presence of cyclic AMP mediated beta cell priming by local 
glucagon-related peptides is crucial for full glucose-stimulated insulin secre-
tion.
Supported by: SNSF MD PhD Fellowship
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Improvement in insulin sensitivity following exercise training is 
independent of mitochondrial changes in older adults
F. Amati1, C. Greggio1, N.T. Broskey1, W. Janssens1, A. Boss2, R. Kreis2,  
C. Boesch2;  
1University of Lausanne, 2University of Bern, Switzerland.
Background and aims: Previous studies reported lower skeletal muscle mi-
tochondrial oxidative capacity as one of the links between type 2 diabetes and 
aging. This gave rise to the interesting indication that mitochondrial deficien-
cy may be an important factor in the pathogenesis of insulin resistance. We 
have recently shown that exercise training improves mitochondrial content 
and function in older sedentary adults. The purpose of this study was to link 
these improvements with improvements in insulin sensitivity.
Materials and methods: Twenty sedentary older (age range 61 to 72) men 
and women (11M, 9F), with average BMI 28±4 kg/m2 and either impaired 
or normal glucose tolerance (11 IGT, 8 NGT), participated in a four months 
supervised endurance exercise intervention with a pre/post-intervention 
design. Investigations included glucose clamps to measure insulin sensitiv-
ity, dual X-ray absorptiometry for overall body composition, magnetic reso-
nance imaging for visceral adipose tissue (VAT) and graded exercise testing 
for maximal oxygen consumption (VO2max). Maximal ATP production ca-
pacity (ATPmax) was used as marker for mitochondrial function and was es-
timated by phosphocreatine recovery following exercise using 31P magnetic 
resonance spectroscopy. Vastus lateralis muscle biopsies specimen were used 
to measure mitochondrial content by electron microscopy and western blot-
ting. Transcription factors involved in mitochondrial biogenesis were meas-
ured in a subset of volunteers by quantitative RT-PCR.
Results: The following changes were observed with intervention (data are 
mean change±SEM): insulin sensitivity (glucose infusion rate, GIR) +41±6% 
(P<0.001), BMI -1.6±0.7% (P=0.02), body fatness -7.3±1.6% (P<0.001), 
VAT -6.3±2.8% (P=0.04), VO2max +11.7±3.5% (P<0.001), ATPmax 
+18.7±6.3% (P=0.02), mitochondrial volume density (MitoVd) +54.9±11.8% 
(P<0.001), PGC1α mRNA +84.5±36.3% (N=12, P<0.001) and TFAM mRNA 
+60.6±30.6% (N=6, P=0.04). Significant differences in these responses were 
not observed between IGT vs. NGT, neither between obese vs. lean vol-
unteers. Although GIR correlated with ATPmax and MitoVd at baseline 
(P<0.05), changes in insulin sensitivity were not associated to changes in AT-
Pmax nor MitoVd.
Conclusion: In this cohort of older subjects, four months of exercise inter-
vention significantly enhanced skeletal muscle mitochondrial content and 
function. Insulin sensitivity was markedly improved in the whole cohort, as 
well as in both IGT and NGT volunteers. Interestingly, the improvements in 
insulin sensitivity were not related to the increases of mitochondrial content 
or function. Although the existence of mitochondria dysfunction may wors-
en insulin resistance, the lack of relationship between improvements in both 
mitochondria and insulin sensitivity questions the function of mitochondria 
on insulin resistance. Further studies are needed to elucidate the debated 
pathogenic role of mitochondria in insulin resistance of aging. In other terms 
is mitochondrial dysfunction a cause or a consequence of insulin resistance?
Clinical Trial Registration Number: NCT01224886
Supported by: SNSF, BASPO, Leenaards Foundation
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Endurance exercise training reduces inflammation and apoptosis of the 
hypothalamic neurons in obese mice
R. Marinho1, L.P. de Moura1, B.A. Rodrigues2, L.S.S. Pauli2, J.D. Botezelli2, 
E.C.C. Ropelle2, A.R.S. Cintra2, A.S.R. da Silva3, C.T. de Souza4, D.E. Cintra2, 
E.R. Ropelle2, J.R. Pauli2;  
1Programa de Pós-Graduação Ciências da Motricidade, Universidade 
Estadual Paulista - UNESP, Rio Claro, 2Programa de Pós-Graduação 
Ciências da Nutrição, Esporte e Metabolismo, Faculdade de Ciências 
Aplicadas - Universidade Estadual de Campinas (FCA-UNICAMP), 
Limeira, 3Escola de Educação Física e Esporte de Ribeirão Preto (EEFERP), 
Universidade de São Paulo, Ribeirão Preto,  4Laboratório de Fisiologia 
e Bioquímica do Exercício, Universidade do Extremo Sul Catarinense - 
UNESC, Criciúma, Brazil.
Background and aims: Consumption of fat-rich diets blunts leptin and insu-
lin anorexigenic signaling in the hypothalamus by a mechanism dependent 
on the in situ activation of inflammation. Since inflammatory signal trans-
duction can lead to the activation of apoptotic signaling pathways, we evalu-
ated the effect of endurance exercise training on the reduction of apoptosis 
of hypothalamic cells.
Materials and methods: Swiss mice was divided into 6 groups (with 5-8 
each): Control Group 1 and 2 (C1 and C2): sedentary animals fed with bal-
anced diet for 8 or 16 weeks, respectively; Obese 1 and 2 (OB1 and OB2): 
sedentary animals fed with high-fat diet (HFD) for 8 or 16 weeks, respec-
tively; Trained obese 1 (OBT1): animals fed HFD for 8 weeks and submit-
ted to physical training protocol (PTP) during 8 weeks; Trained obese 2 
(OBT2): animals fed HDF for 16 weeks and submitted to PTP during the 
second half of the experiment (8 weeks). The exercise program consisted of 
treadmill running 1h, 5 days/week during 8 weeks at a speed equivalent to 
60% of maximum potency determined at the beginning of training period. 
For determination of food intake, mice were intraceroventricular treated with 
insulin or leptin. Twenty-four hours after the last bout exercise, the mice were 
submitted to an insulin tolerance test. Next, the hypothalamus was removed 
and Western blotting and immunoprecipitation were performed to analyze 
the expression and phosphorylation of IR, IRS-2, Akt, JAK, STAT3, Foxo1, 
JNK, IKK, Bax, Casp9, Casp8, FADD, APAF, PERK, eIF2α.
Results: PTP was effective in improving the IR/IRS-2/AKt and JAK2/STAT3 
signaling pathway in the hypothalamus and reduced food intake of obese 
animals. The HFD led to an increased hypothalamic expression of proteins 
involved in inflammatory signal transduction (pJNK and pIKK). In addition, 
proteins from apoptotic pathways were affected by HFD. Expression of Bax 
and the association of APAF1 with caspase-9, and the association of FADD 
with caspase-8 were increased in the hypothalamus of obese mice. Further 
evidence for apoptotic or harmful activity in the hypothalamus was shown by 
the increased expression of PARP1, and by the phosphorylation of proteins 
involved in endoplasmic reticulum stress, eIF2α and PERK. Oppositely, PTP 
was able to reduce inflammatory and apoptotic proteins in the hypothalamus 
of these animals. Interestingly, the results obtained were more pronounced in 
mice of OBT1 than OBT2. This shows that the effects of exercise were more 
effective when the inflammatory and apoptotic process were absent.
Conclusion: Our study provides substantial evidence that physical activity 
could help to reorganize the set point of nutritional balance and therefore 
aid in counteracting the energy imbalance induced by overnutrition through 
the anti-inflammatory and anti-apoptotic response in hypothalamic neurons.
Supported by: FAPESP 2010/12091-2 and 2012/01750-0
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The effect of chronic exercise training on exercise efficiency and fat 
oxidation in older previously sedentary adults
N.T. Broskey, E.-J. Fares, C. Greggio, F. Amati;  
University of Lausanne, Switzerland.
Background and aims: Chronic aerobic exercise has been shown to increase 
exercise efficiency, which allows us to spend less energy for a similar amount 
of work. Exercise efficiency can be expressed as gross efficiency, computed 
as mechanical power (wattage) over the metabolic rate (calories expended); 
thus, representing whole-body efficiency. Other efficiencies are also used 
such as delta efficiency, which is the change in power over the change in met-
abolic rate between different intensities of exercise. Furthermore, it is known 
that substrate usage during exercise also changes with chronic training to rely 
more on fat than carbohydrates for a given submaximal exercise intensity. All 
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of these training adaptations have not yet been explored in older subjects at 
risk for type 2 diabetes. The purpose of this study was to examine the changes 
in exercise efficiencies and exercise fat oxidation in older sedentary adults 
undergoing an exercise intervention and compare these values to athletes of 
the same age.
Materials and methods: In this pre/post intervention design, 11 sedentary 
obese (age 67.0±1.1) and 12 sedentary lean (age 64.6±1.0) men and wom-
an underwent four months of endurance exercise intervention. Volunteers 
trained 3 supervised sessions per week at 60-75% of their maximal heart rate. 
Fifteen athletes matched by age (age 68.5±1.5) were also used for comparison 
purposes. Peak oxygen consumption (VO2peak) was determined by a graded 
exercise testing (GXT). Gross efficiency (GE, %) and exercise fat oxidation 
(EFO, µmol/min) were determined during one-hour of submaximal (55% of 
VO2peak) cycle ergometry exercise in tightly controlled conditions (fasting 
and 72 hours from last exercise bout). Delta efficiency (DE, %) was calculated 
from the GXT. Leg mass, used to normalize efficiency data, was measured by 
dual X-ray absorptiometry. Statistical comparisons between groups at base-
line were done with ANOVA. Intervention effects were measured by Paired T 
Test. Results are presented in mean ± SEM.
Results: At baseline, athletes had a higher GE than lean sedentary, which had 
a higher GE than the obese sedentary (p<0.001). Both the obese and lean in-
creased their GE after four months of exercise training (respectively p=0.0012 
and p=0.001). DE followed the same pattern as GE at baseline (p<0.001). Also 
similar to GE, both obese and lean increased their DE following exercise in-
tervention (respectively p<0.001and p=0.001) EFO was the same between all 
three groups at baseline (p=0.35). EFO did not change in the lean sedentary 
group (p=0.47) after the intervention but did increase in the obese (p=0.01).
Conclusion: This data shows that older adults are able to respond to a mod-
erate intensity exercise training protocol in terms of improvements in GE 
and DE, as shown in younger and performance-oriented studies. Thus, they 
expend fewer calories for the same power output. These observations point to 
the fact that exercise routines need to be modified in order to elicit metabolic 
adaptations and keep optimal caloric expenditure also at an older age. Former 
studies show that training improves the reliance on fat. Surprisingly, in our 
cohort fat oxidation was not different between the three groups at baseline. 
The obese group was the only one to improve fat oxidation after four months 
of exercise training, which can be explained by changes in body composition.
Clinical Trial Registration Number: NCT01224886
Supported by: SNSF, BASPO
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Changes in muscle lipid stores after exercise training in subjects with 
prediabetes and healthy controls
K.I. Birkeland1,2, Y. Li3, S. Lee3, F. Norheim3, S. Pourteymour3, T. Storaas4,  
S. Davanger5, J. Jensen6, C.A. Drevon3, T. Holen3;  
1Dep. of Endocrinology, Oslo University Hospital, 2Institute of Clincial 
Medicine, University of Oslo, 3Dep. of Nutrition, University of Oslo, 4Dep. 
of Cardiovascular Radiology, Oslo University Hospital, 5Dep. of Anatomy, 
University of Oslo, 6Norwegian School of Sport Sciences, Norway.
Background and aims: There is an association between muscle lipid stores 
and insulin sensitivity, but the mechanism is unclear. We examined how ex-
ercise intervention influenced muscle lipid stores in sedentary normal-weight 
control subjects and overweight prediabetic subjects impaired fasting glucose 
or impaired Glucose tolerance.
Materials and methods: Ten sedentary male control subjects and eight 
sedentary male prediabetic subjects participated in 12 weeks supervised 
training. Insulin sensitivity (euglycaemic clamp) and VO2max were meas-
ured. Muscle lipid stores were quantified by magnetic resonance spectros-
copy (MRS), electron microscopy (EM) point counting, and direct EM lipid 
droplet measurements of subsarcolemmal (SS) and intermyofibrillar (IMF) 
regions, and indirectly, by deep sequencing and real-time PCR of mRNA of 
lipid droplet-associated proteins.
Results: Insulin sensitivity (+28% and +36%) and VO2max (+14% and 
+15%) increased significantly in both the prediabetic and the control groups 
after 12 weeks of training. Muscle lipid stores were reduced, as measured by 
MRS at baseline before and after the intervention, whereas EM point count-
ing showed no change in LD stores post-exercise, indicating a reduction in 
LD store utilization with lowered LD levels. Large scale EM quantification of 
the sub-sarcolemmal LD population demonstrated reductions in LD density 
and LD diameters. The SS LD diameters were reduced by 28% and 26%, and 
SS LD numbers were reduced by 37% and 43%, for the prediabetic and the 
control groups, respectively. Thus, lipid droplet volume in the SS LD popu-
lation was reduced by ~80%, in both prediabetics and normal weight con-
trols. Interestingly, the lipid droplet diameters (n = 10 958) distribution was 
skewed, with a lack of small diameter lipid droplets (smaller than ~200 nm), 
both in the SS and IMF regions.
Conclusion: We demonstrate reduced muscle lipid stores in the control and 
prediabetic groups, using MRS, but no corresponding differences post-exer-
cise, using EM point counting, suggesting reduced LD utilization with lower LD 
stores. A large-scale EM quantification of LD numbers and diameters showed 
a differential behavior of two populations of LD. The SS LD were reduced by 
~80% in both groups, whereas the intramyofibrillar population of LD did 
not show any consistent changes. The EM quantification provided a skewed 
distribution of lipid droplet size, with a lack of small (< 200 nm) diameter 
LDs both in the SS and IMF regions, before as well as after the intervention.
Supported by: Helse Sor-Ost
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The improvement in beta cell function after intense aerobic exercise is 
directly related to the increase in vitamin D levels
G.P. Sorice, S. Moffa, C. Conte, T. Mezza, A. Giaccari;  
Endocrinology, Catholic University, Rome, Italy.
Background and aims: Low concentrations of 25-hydroxy-vitamin D 
[25(OH)D], the best indicator of vitamin D status, have been associated 
with alterations in glucose tolerance, insulin sensitivity and β cell function. 
Few data are available on the effects of a single session of aerobic exercise 
on 25(OH)D levels and the possible correlation with insulin secretion and 
sensitivity
Materials and methods: We therefore recruited 20 young (25-31 years-old), 
healthy, normal weight volunteers, with a sedentary/moderate active lifestyle; 
OGTT was performed before and on the day-after a bout of aerobic exercise 
(a single workout of jogging or running for 30-40 minutes, or until exhaus-
tion). Insulin secretion and sensitivity were estimated using OGTT-derived 
indices. During exercise, all subjects wore a metabolic holter to assess energy 
expenditure.
Results: Based on the energy expenditure during work-out, subjects were 
divided (the median in the cohort [7 METs] was used as cut-off value) into: 
non-intense (<7 METs) or intense group (>7 METs). In both groups, a sig-
nificant improvement in insulin sensitivity (p<0.04 Quicki) was observed. 
After exercise, 25(OH)D levels increased in the intense group and decreased 
in the non-intense group (p=NS for both). Furthermore, 25(OH)D levels, as 
well as the disposition index, were significantly greater in the intense group 
after physical activity (p<0.02 and p <0.03, respectively), as compared with 
the non-intense group. The improvement in the disposition index was corre-
lated with the change from baseline in 25(OH)D in the intense group (r=0.4, 
p<0.05).
Conclusion: These data indicate that a single session of aerobic exercise 
might improve beta cell secretory performance and this improvement is 
closely related with the increase in the levels of 25(OH)D after strenuous 
physical activity.
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Metabolic effects of interval training exercise in patients with type 2 
diabetes
C.M.A. Cefalo1, C. Saponara2, C. Conte1, V.A. Sun1, G.P. Sorice1, T. Mezza1, 
C. Policola1, S. Moffa1, M. Broccatelli1, I. Romito1, A. Sgadari1, A. Giaccari1;  
1Catholic University of the Sacred Heart,  
2Centro Diabetologico ACISMOM Camillo Negro, Rome, Italy.
Background and aims: Major guidelines on the management of type 2 diabe-
tes mellitus (T2DM) recommend performing at least 150 min/week of mod-
erate-intensity aerobic physical activity. Nevertheless, the most effective type 
of exercise for glycaemic control has not been established. The aim of the pre-
sent study was to compare the effects of interval training exercise, which pairs 
high-intensity exercise phases with low-intensity exercise recovery phases, 
with those of a conventional, constant-load aerobic exercise on glycaemic 
control (HbA1c), lipid profile and body composition in patients with T2DM.
Materials and methods: Thirty sedentary patients (17/13 M/F; age 
[mean±SD] 63.0±8.0 yrs; BMI 29.0±3.9 kg/m2; HbA1c% [median (1°-3° 
quartile)] 6.6 (6.5-7.1) with a diagnosis of T2DM ≥5 years and treated with 
oral hypoglycaemic agents and/or basal insulin were randomized into 3 
groups: constant-load aerobic exercise (CL), interval training aerobic exer-
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cise (IT) for 10 weeks (a 2-week conditioning phase + 8-week exercise pro-
gramme, 3 times/week) or no activity (SED) for the same time period. Fasting 
plasma glucose, insulin, HbA1c, triglycerides (TG), total cholesterol, HDL 
and LDL cholesterol and body composition (DXA) were measured at base-
line and at study end.
Results: Baseline characteristics of the 3 groups were comparable. After 10 
weeks, there were no significant differences from baseline in HbA1c% [pre 
vs. post: 6.7 (6.5-7.1) vs. 6.6 (6.5-6.9); 6.6 (6.5-7.0) vs. 6.5 (6.5-6.6); 6.7 (6.1-
7.5) vs. 6.6 (6.4-7.2) in the CL, IT and SED groups, respectively; p for time 
and interaction=ns) or cholesterol levels. Significant improvements in fasting 
plasma glucose (p=0.03), TG (p=0.02) and insulin resistance estimated with 
the HOMA-IR index (p=0.04) were observed in the IT group only, despite 
similar and significant changes in total body composition in both exercise 
groups (fat mass: -4.3% and -4.9%, fat free mass +1.5% and +1.7% in the CL 
and IT groups, respectively; both p<0.05 vs. baseline; CL vs. IT: p=ns).
Conclusion: Interval training exercise might have specific effects on segmen-
tal body composition and/or lead to different adaptive changes in skeletal 
muscle as compared with constant load aerobic exercise. Such changes might 
be responsible for the observed benefits on fasting plasma glucose, TG and 
HOMA-IR. The lack of significant effects on HbA1c might be due to the good 
glycaemic control at baseline.
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Investigation of glycaemic control in elite and recreationally-active 
individuals with and without type 1 diabetes mellitus during multi-day 
ultra-distance exercise: 2014 mHealth grand tour
M.D. Campbell1, D.J. West1, P. Simpson2, M.I. Trenell3;  
1Department of Sport, Exercise and Rehabilitation, Northumbria University, 
Newcastle upon Tyne, UK, 2DexCom Inc, San Diego, USA, 3Institute of 
Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Background and aims: Despite improvements in cardiovascular health and 
wellbeing, fear of exercise-induced hypoglycaemia and a paucity of evidence-
based advice on how to manage diabetes during / after exercise remain 
significant barriers to exercise participation to people with Type 1 diabetes 
(T1DM). How professional athletes with T1DM manage their diabetes may 
provide an insight into optimising diabetes control around exercise. The pre-
sent study examined glucose control in elite and recreational cyclists with and 
without T1DM during participation in the 2014 mHealth grand tour cycle 
ride from Brussels to Barcelona (EASD).
Materials and methods: Interstitial glucose (IG) concentrations were cap-
tured using continuous glucose monitoring (Dexcom G4®, INC, CA, USA) 
over a period of six consecutive days during a long-distance, multi-stage en-
durance cycling event in three groups of individuals: 10 recreationally-active 
type 1 diabetes individuals (T1rec), 8 elite cyclists with T1DM (T1pro), and 
10 recreationally-active individuals without diabetes (CON). Each individ-
ual completed all 6 days of road cycling in full, covering a total distance of 
1044km (174km av/day). Data (mean±SD) were analysed using a one-way 
ANOVA and independent student t tests.
Results: There was no change in glycaemic control over the course of the 
six days in any group, with similar mean, mean peak and mean nadir IG 
during ride time, daytime and night time periods (p>0.05). During the ride, 
mean IG was significantly greater in T1rec and significantly lower in T1pro 
compared to CON (7.6±2.8 vs. 5.2±2.7 vs. 6.3±01.0 mmol.l-1; p<0.05). Dur-
ing the ride, time spent in hypo- and hyperglycaemia were similar between 
T1rec and T1pro (hypo: 209±49 vs. 207±57min; p=0.332; hyper 240±5 vs. 
244±10min; p>0.05). During recovery time before sleep T1pro displayed 
similar mean IG to CON (6.4±2.8 vs. 6.6±0.9 vs. mmol.l-1; p=0.553), which 
was significantly less than T1rec (9.3±1.7 mmol.l-1; p=0.013). Similar patterns 
were observed during sleep, whereby T1pro displayed similar mean IG to 
CON (T1pro 6.7±3.4, CON 6.1±0.9 mmol.l-1; p=0.412), which were both sig-
nificantly less than T1rec (8.7±2.6 mmol.l-1; p<0.05). However, more T1rec 
individuals experienced nocturnal hypoglycaemia compared to T1pro (T1rec 
66% vs. T1pro 13% patients) with more time spent hypoglycaemic (T1rec 
402±62, T1pro 223±51 minutes; p=0.018) and lower mean IG nadir under 
T1rec (T1rec 2.6±1.3, T1pro 4.3±2.5, CON 4.4±0.7 mmol.l-1; p<0.05) during 
this time.
Conclusion: Recreational cyclists with T1DM had higher IG levels during 
exercise, in recovery and during sleep, and experienced more hypoglycaemic 
events than elite athletes with T1DM. Elite athletes with T1DM displayed IG 
comparable to people without diabetes during exercise, in recovery and dur-
ing sleep. Glycaemic stability in elite athletes with T1DM provides a valuable 
insight to strategies that can be used to optimise glycaemic control during 
exercise in the wider T1DM patient population.
Supported by: DexCom, GSMA, Orange, McCann Health, ANT+, Sony Mobile
622
The effect of basal insulin dose reduction during exercise in adolescents 
with type 1 diabetes mellitus
J. Sendela, A. Szypowska, K. Piechowiak, K. Dzygalo, A. Kowalska;  
Pediatrics, Medical University of Warsaw, Poland.
Background and aims: Physical activity helps improve metabolic control and 
reduces insulin requirement in type 1 diabetic children (T1DM). There is no 
consensus regarding the guidelines for administration of insulin in patients 
treated with continuous subcutaneous insulin infusion during physical activ-
ity. The aim of the study was to assess the impact of basal insulin reduction 
on the risk of hypoglycemia in T1DM children treated with insulin pump.
Materials and methods: We performed a non-randomized, open-labeled, 
two-way crossover study. There were 50 patients included, 28 (58%) boys and 
22 (42%) girls, aged 14.5 ±2.3 years (range 10-18) with mean diabetes dura-
tion 7.1 ±3.1 years, mean HbA1c 8.89±1.4 % mean BMI 21,19 ± 3,4kg/m2 and 
mean basal insulin 36% of total insulin dose. Subjects were allocated to one 
of two groups regarding on basal rate reduction 90 minutes prior to physical 
activity (group A - 50% and group B - 0% of basal dose). Patients performed 
45 minutes exercise on the cycle ergometer during two subsequent days. Pri-
mary outcome was the number of hypoglycaemic episodes, defined as blood 
glucose level below 70 mg/dl. Blood glucose concentrations were recorded 
with a continuous glucose monitoring system and with multiple blood glu-
cose self-tests for 90 minutes prior to the study and 20, 45, 105 minutes after 
the beginning of the study. Other data were collected such as: height, weight, 
glycated haemoglobin, daily insulin dose.
Results: During the 45 minutes of exercise more hypoglycaemia episodes 
were noted in the group A (16%) than in the group B (4%), the difference 
was close to statistical significance p=0.051. Most hypoglycaemia episodes 
were noted in the 20th min. of the study. There was no statistically signifi-
cant difference in blood glucose levels between both groups in each time-
interval. Mean glycaemia in the group A vs. group B: at the start was 118 vs 
108 (p=0.148); 20 min 127 vs 106 ( p=0.012); 45 min 123 vs 116 ( p=0.115); 
60 min. after finishing the study 145 vs 129 ( p=0.144). There was no between 
groups difference in the number of subjects with hyperglycaemia defined as 
blood glucose >160mg/dl 60 min. after finishing the study, OR 0.5 95%CI 
[0.2 to 1.2]; p=0.186. We did not found any correlation between basal insulin 
calculated as percentage of total insulin dose and blood glucose level during 
the study.
Conclusion: During prolonged exercise basal insulin dose reduction by 50% 
compared to the total cessation of insulin infusion was associated with a 4 
fold higher risk of hypoglycemia. Therefore we recommend more than 50% 
reduction in basal rate during prolonged exercise. The degree of basal insulin 
reduction should be individually determined for each child.
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An acute bout of exercise is not able to lower liver fat content in 
overweight middle-aged men
B. Brouwers1, L. Bilet1, P.A. van Ewijk1, M.K.C. Hesselink2, M.E. Kooi3,  
P. Schrauwen1, V.B. Schrauwen-Hinderling3, NUTRIM, School of Nutrition, 
Toxicology and Metabolism;  
1Human Biology, 2Human Movement Sciences, 3Radiology, Maastricht 
University, Netherlands.
Background and aims: Elevated hepatic lipid content (IntraHepatic Lipid, 
IHL) markedly increases the risk of metabolic complications, including in-
sulin resistance and cardiovascular events. Although prolonged exercise 
training has been shown to lower IHL, it is unknown if acute exercise has 
the same effect. Next to IHL, hepatic ATP content may be related to insulin 
resistance and IHL. Therefore, we aimed to investigate if acute exercise leads 
to changes in IHL and if these changes are accompanied by changes in hepatic 
ATP content.
Materials and methods: IHL content was determined by proton magnetic 
resonance spectroscopy (MRS) at baseline, directly after 2h of exercise (50 % 
of the maximal output) and again 4h post-exercise and expressed as percent-
age of the water resonance. Hepatic ATP content was measured by phospho-
rus MRS at baseline and 4h post-exercise in 8 subjects and is given relative 
to the total phosphorus signal. Blood was sampled and substrate oxidation 
was measured by indirect calorimetry. Since exercise leads to an increase in 
plasma FFA that may affect liver fat content, subjects performed the study not 
only in the fasted condition, but also while ingesting glucose.
Results: Twenty-one overweight middle-aged men with a wide range of IHL, 
including nonalcoholic fatty liver disease (age 54.8±7.2 years, BMI 29.7±2.2 
kg/m²) participated in this study. IHL was unchanged directly after exercise 
(8.27±1.80 to 8.34±1.85 %). Similar effects were observed when exercising 
with glucose supplementation (IHL: 8.26±1.88 to 8.40±1.89 %). 4h after ex-
ercise, IHL was elevated compared to baseline in the fasted condition (from 
8.3±1.8 to 8.7±1.8 %; p=0.010), while it did not change when glucose was sup-
plemented (from 8.3±1.9 to 8.3±1.9 %; p=0.789). Hepatic ATP content tended 
to decrease post-recovery in the fasted condition compared to baseline values 
(0.164±0.009 vs. 0.146±0.009 γ-ATP/total phosporus; p=0.086), whereas it 
did not change when glucose supplementation was given (0.168±0.008 vs. 
0.163±0.005 γ-ATP/total phosporus; p=0.582). Plasma FFA concentrations 
increased with time during exercise and recovery in the fasted condition 
(p<0.0001), but this effect was blunted in the glucose-fed condition. Respira-
tory quotient was significantly higher at all time points, except for baseline, 
in the glucose-fed state compared to fasted (p<0.01). Plasma glucose con-
centrations were comparable at baseline in both conditions (GLU:5.26±0.11 
vs. FASTED:5.23±0.11 mmol/l), but increased after 2h of exercise and post-
recovery in the glucose-supplemented state compared to the fasted condition 
(7.12±0.31 vs. 5.01±0.12 mmol/l, 6.51±0.26 vs. 4.49±0.11 mmol/l; p<0.0001). 
Moreover, plasma glucose increased with time during exercise and recovery 
in the glucose-supplemented condition (p<0.0001).
Conclusion: This data shows that an acute bout of exercise is not able to 
lower IHL, neither in a fasted nor in a glucose-supplemented condition, in 
overweight middle-aged men with a wide range of liver fat content. These 
results are in contrast to previous results on prolonged exercise training and 
demonstrate that the long term effects of training cannot simply be explained 
by an additive effect of acute exercise bouts.
Clinical Trial Registration Number: NCT01177332
Supported by: Dutch Diabetes Foundation
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Carbohydrate doses before a 10 km competition in type 1 diabetes 
athletes
S. Murillo1, L. Brugnara1, E. del Campo2, I. Yagüe3, B. Dueñas4, A. Novials1;  
1CIBERDEM - IDIBAPS, Hospital Clínic, Barcelona,  
2Asociación de Diabéticos de Madrid, 3Hospital de Fuenlabrada,  
4Fundacion para la Diabetes, Madrid, Spain.
Background and aims: Clinical guidelines recommend increasing the intake 
of carbohydrates (CH) to maintain glycaemic levels and avoid hypoglycae-
mia during exercise in type 1 diabetes (T1D) patients. Previous data indicate 
that the amount of CH recommended is higher than those actually consumed 
by patients in competitions. The aim of this study was to identify the real 
consumption of CH during a 10Km competitive run and to compare these 
quantities with those recommended by current guidelines.
Materials and methods: Athletes with T1D, older than 18 years and treated 
with multiple insulin doses or an insulin pump participated in two different 
protocols. Protocol 1: Observational study including 31 athletes with T1D, 
collecting data of dietary records of CH intake before, during and after a 
10Km competitive run. Data obtained were compared with those of a control 
group of 127 athletes without diabetes. Protocol 2: Single blind randomized 
trial in athletes with T1D, testing two different doses of pre-exercise CH 
supplements: a recommended dose of 0.7g CH/bogy weight (n=10) and a 
real dose (obtained after analyses from protocol 1) of 0.35g CH/bogy weight 
(n=8). This supplement was taken in the form of an isotonic beverage with 
a concentration of 6.5g of sucrose per 100ml. Capillary blood glucose was 
self-determined in all cases, before taking the supplement and at the end of 
competition.
Results: In the observational study, baseline characteristics were similar in 
both groups of individuals (table 1). Athletes with T1D consumed a lower 
quantity of CH at breakfast on a typical day and during the meal <1 hour after 
the competition. We did not find significant differences between groups in 
CH intake at breakfast or in the supplement before the competition. In T1D 
athletes, this supplement prior to the competition contains 25.0±11.3g of CH 
(0.33g CH/body weight). In the randomized study, athletes consuming the 
dose of 0.7g CH/bogy weight increased glycaemic levels significantly, from 
144.3±88.6mg/dl starting to 211.1±100.1mg/dl (p<0.05) finishing the com-
petition, while athletes taking 0.35g CH/bogy weight maintained glycaemic 
levels, from 197.5 ±38.9mg/dl before to 162.5±56.8mg/dl (p=0.5) after the 
competition.
Conclusion: On competition day, athletes with T1D seem to increase CH 
intake prior to the competition, both at breakfast and just before exercise, 
consuming similar amounts to those athletes without diabetes. In both cases, 
athletes with and without diabetes consume quantities of CH smaller than 
those recommended. A pre-exercise supplement with moderate-carbohy-
drate content (0.35g CH/bogy weight) appears to induce a more stable gly-
caemic response in comparison with a supplement with high-carbohydrate 
content in this group of athletes.
Supported by: Fundación para la Diabetes and SED Lifestyle Group (Spain)
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Exercise induces an anti-inflammatory response and positive effects on 
the metabolic status in a Non-Obese Diabetic (NOD) mouse model
R. Codella1,2, G. Lanzoni3, A. Zoso3, A. Montesano1, I. Terruzzi4,  
A. Caumo1,2, L. Luzi1,2, L. Inverardi3;  
1Department of Biomedical Sciences for Health, Università degli Studi 
di Milano, 2Metabolism Research Centre, IRCCS Policlinico San Donato 
Milanese, Italy, 3Diabetes Research Institute, Miami, USA, 4San Raffaele 
Scientific Institute, Milan, Italy.
Background and aims: The Non-Obese Diabetic (NOD) mouse represents 
a well-established experimental model analogous to human type 1 diabetes 
mellitus (T1DM) as it is characterized by a progressive autoimmune destruc-
tion of pancreatic β-cells. NOD mouse might provide a useful model for the 
study of exercise in T1DM. Experiments were designed to investigate the im-
pact of moderate-intensity training on T1DM immune modulation.
Materials and methods: Under a chronic exercise regime, NOD mice (n=20; 
♀; 8-wk old) were trained on a treadmill for 12 weeks (12m/min for 30min, 
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5d/wk) while same number, age-matched, control animals were sedentary. 
Prior and upon completion of the training period, fed plasma glucose and 
immunological soluble factors were monitored.
Results: After 12 weeks of training, control mice were all diabetic (n=5) 
whereas only 2 out 5 mice on-exercise became diabetic. An exercise-induced 
weight loss (-9%, p<0.05) was detected in the trained mice with respect to 
the controls. As to the cytokines results, while control mice did not show 
any changes in the inflammatory factors at end of the training program with 
respect to baseline, we observed a slight but significant decrease of MIP-1β 
(-1%), IFN-γ (-2%), IL-10 (-2%), IL-2 (-1%) IL-13 (-2%), GM-CSF (-2%), 
and a substantial increase in G-CSF (+27%) in the trained animals compared 
to their pre-training values (p<0.05). Preliminary data from a morphometric 
analysis of pancreata indicated the presence of larger infiltrates along with 
increased α-cells areas in the control mice.
Conclusion: In summary, moderate-intensity exercise induced an anti-in-
flammatory effect in the trained mice paralleled by a greater amount of infil-
trates in the disease-related deterioration of the control mice. We speculate 
that exercise may exert a positive immunomodulation of systemic functions 
with respect to both T1DM and inflammation.
Supported by: IMMEEDIA 247472; INMARESS 256506
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Sesamin improves lowered exercise capacity and mitochondrial 
dysfunction in the skeletal muscle from high fat diet-induced diabetic 
mice
S. Takada1,2, S. Kinugawa1, D. Takemoto3, T. Kadoguchi1, T. Yokota1,  
S. Matsushima1, A. Fukushima1, Y. Masaki1, T. Furihata4, T. Suga5,  
W. Mizushima1, Y. Ono3, H. Shibata3, K. Okita6, H. Tsutsui1;  
1Department of Cardiovascular Medicine, Hokkaido University Graduate 
School of Medicine, Sapporo, 2Research Fellow of the Japan Society for the 
Promotion of Science, Tokyo, 3Institute for Health Care Science, Suntory 
Wellness Limited, Osaka, 4Department of Cardiovascular Medicine, 
Hokkaido University Graduate School of Medicine, Sapporo,  
5Faculty of Sport and Health Science, Ritsumeikan University, Sapporo, 
6Department of Sport Education, Hokusho University, Sapporo, Japan.
Background and aims: We previously reported that high fat diet (HFD)-
induced diabetic mice had the reduced exercise capacity and impaired mi-
tochondrial function in the skeletal muscle, which was due to NAD(P)H 
oxidase-induced oxidative stress. Sesamin is a natural ingredient included in 
sesame (Sesamum indicum) which is a traditional herbal medicine, and has 
multiple biological functions such as antioxidant activity. We hypothesized 
that sesamin could ameliorate the reduced exercise capacity in diabetic mice.
Materials and methods: C57BL/6J mice were fed on normal diet (ND) or 
HFD, and each group of mice was treated with or without sesamin (0.2%) 
in the diet for 8 weeks. Exercise capacity and mitochondrial function in the 
skeletal muscle were evaluated.
Results: HFD significantly increased adipose tissue weight and plasma glu-
cose compared to ND, and sesamin did not affect these parameters in either 
group (p>0.05). HFD significantly increased body weight and plasma insulin 
compared to ND (body weight; 43±1 vs 29±1 g, insulin; 2.0±0.3 vs 0.5±0.1 
ng/mL, p<0.05), and these gains were ameliorated in HFD+sesamin (body 
weight; 37±1 g, insulin; 0.8±0.2 ng/mL, p<0.05). The work and peak oxygen 
uptake determined by treadmill tests were significantly reduced in HFD com-
pared to ND (work; 14±1 vs 28±1 J, peak VO2; 109±4 vs 152±2 mL/kg/min, 
p<0.05), and these reductions were ameliorated in HFD+sesamin (work; 
20±1 J, peak VO2; 129±2 mL/kg/min, p<0.05). Citrate synthase (CS) activity 
was significantly decreased, and NAD(P)H oxidase activity and superoxide 
production by lucigenin chemiluminescence were significantly increased in 
isolated skeletal muscle from HFD compared to ND (CS activity; 31 ± 3 vs 
108 ± 6 nM/min/mg protein, NAD(P)H oxidase activity; 19 ± 1 vs 5 ± 1 RLU/
min/mg protein, superoxide anion; 55 ± 9 vs 15 ± 2 RLU/min/mg protein, 
p<0.05), which were also ameliorated by sesamin (CS activity; 70 ± 8 nM/
min/mg protein, NAD(P)H oxidase activity; 8 ± 1 RLU/min/mg protein, su-
peroxide anion; 18 ± 2 RLU/min/mg protein, p<0.05). Additionally, in vitro 
data showed that sesamin and its nomo-catechol metabolite significantly sup-
pressed angiotensin II-induced NAD(P)H oxidase activity in C2C12 myo-
tubes (p<0.05).
Conclusion: Sesamin ameliorated the reduced aerobic exercise capacity in 
HFD-induced diabetic mice via the improvement of impaired mitochondrial 
function and attenuation of oxidative stress in the skeletal muscle.
Supported by: Suntory Wellness Limited
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High intensity intermittent exercise reverses abnormal cardiac function 
in people with type 2 diabetes: an MRI/S study
S.A. Cassidy1, C. Thoma1, K. Hallsworth1, D.G. Jakovljevic1, J. Parikh2,  
K.G. Hollingsworth2, R. Taylor2, M.I. Trenell1;  
1Institute of Cellular Medicine, 2Newcastle Magnetic Resonance Centre, 
Newcastle University, Newcastle Upon Tyne, UK.
Background and aims: Cardiovascular disease is the leading cause of mor-
bidity and mortality in Type 2 diabetes. Despite the clear individual and so-
cietal burden of cardiovascular disease in Type 2 diabetes, evidence based 
therapies to improve cardiac function are limited. High intensity intermittent 
exercise is a time efficient strategy for cardiovascular training, but its direct 
effects on cardiac structure and function in people with Type 2 diabetes are 
unknown. This study investigated high intensity intermittent exercise as a po-
tential therapeutic tool to moderate cardiac risk in this patient group.
Materials and methods: Twenty-three patients with Type 2 diabetes (age 
60±9 years, BMI 31±5 kg/m2, HbA1c 55±8 mmol/mol) were randomised to 
12 weeks of high intensity intermittent exercise (treatment, n=12) or stand-
ard care (controls, n=11). High intensity intermittent exercise consisted of 5 
x 2min intervals at >80% heart rate max using cycle ergometry three times 
a week (guided by a podcast). Each week the duration of each exercise bout 
was increased. Cardiac structure, function and energetics were measured re-
spectively by 3.0 T magnetic resonance imaging, 2 dimensional tagging and 
phosphorus-31 spectroscopy. Liver fat was determined by 1H-magnetic reso-
nance spectroscopy.
Results: Compared to controls, high intensity intermittent exercise improved 
cardiac structure (Left ventricular Mass-104±17 to 116±20 vs. 107±25 to 
105±25g, p<0.05; End-diastolic blood volume-118±30 to 126±30 vs. 129±28 
to 122±28ml, p<0.05) and cardiac systolic function (stroke volume-76±16 to 
87±19 vs. 79±14 to 75±15ml, p<0.05; Left ventricular ejection fraction-65±8 
to 70±6 vs. 64±11 to 63±10%, p<0.05). Early diastolic filling rates increased 
(241±84 to 299±89 vs. 250±44 to 251±47ml/s, p<0.05) and peak torsion de-
creased (8.1±1.8 to 6.9±1.6 vs. 7.1±2.2 to 7.6±1.9°, p=0.05) in the treatment 
group compared to controls. There was no effect on cardiac metabolism de-
termined by magnetic resonance phosphorus-31 spectroscopy. High intensity 
intermittent exercise also delivered benefits to glucose control (HbA1c-55±11 
to 51±10 vs. 55±6 to 57±8 mmol/mol; p<0.05) and liver fat (7±7 to 4±4 vs. 
7±7 to 8±7%; p<0.05).
Conclusion: High intensity intermittent exercise has positive effects on car-
diac structure and function alongside benefits to glucose control and liver fat. 
Clinical care teams should consider high intensity intermittent exercise as a 
therapeutic strategy to moderate cardiac dysfunction in people with Type 2 
diabetes.
Clinical Trial Registration Number: ISRCTN78698481
Supported by: NIHR Biomedical Research Centre and RCUK Centre for Ageing 
and Vitality
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Physical activity patterns in a type 2 diabetes population. Relationship 
with cardiovascular risk factors, diabetes complications and co-
morbidities
N. Porta1, M. Villaró1, T. Mur2, A. Jaen3, Diabetes in primary care  
Study group MutuaTerrassa;  
1Primary Care, 2Primary Care Research,  
3MutuaTerrassa Fundation, Mutua Terrassa, Spain.
Background and aims: The aim of our study is to analyze the physical activ-
ity (PA) pattern and risk factors associated with sedentary T2DM population.
Materials and methods: Cross-sectional multicenter random study in pri-
mary care. Physical Activity (PA) was assessed by Short International PA 
Questionnaire with 4 categories: Low or Sedentary (<600MET/week), Mod-
erate-medium (600-1499) ,Moderate-High(1500-2999) and High(≥3000). 
We registered sociodemographic, anthropometrics data and cardiovascular 
(CV) risk factors, disease and risk scores. Yesavage and Mediterranean Diet 
test and DM complications and comorbidities were also compiled. Analytical 
data: HbA1c, lipid, renal profile and uricaemia. Bivariate and multivariate lo-
gistic regression (PA low versus moderate to high) analyses were performed.
Results: Of 447 patients, 57.9% were men. Mean age: 67.9±10.4; mean 
HbA1c: 7.1%±1.2%; 36.6% had overweight and 50.7% obesity I(BMI 30-34); 
28,6% and 20.8% had CV and Chronic Renal Disease (CRD), respectively. 
PA pattern was: 24.4% low, 28.3% moderate-medium, 21.7%moderate-high 
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and 25.6%high. Low PA was more frequent in: women, ≥75 years, smokers, 
hypertensive, patients with higher BMI and waist risk circumference, higher 
Stroke scores, CRD, depression, and elevated lipid profile. Independent risk 
factors associated with low PA in the multivariate analysis were (Odds ratios, 
CI 95%): Hypertension (3.1, 1.5-6.2), CRD (1.8, 1.04-3.2), depression (2.7, 
1.2-5.9), longer time of T2DM onset (1.04, 1.0-1.09), higher levels of triglyc-
erides (1.01, 1.0-1.01) and ldl (1.01, 1.0-1.02). By contrast, have a good con-
trol of glycaemia (0.5, 0.3-0.8), of blood pressure (0.4, 0.3-08) and of triglyc-
erides (0.4, 0.2-1.0) were protective factors for sedentary. Female had a higher 
risk for sedentary in the limit of the significance (OR: 1.5; CI95%: 0.9-2.5).
Conclusion: 24% of our T2DM population was sedentary. PA improves gly-
caemia control, lipid profile, CV risk factors and CRD, all of them very im-
portant to prevention of diabetes morbidity. Inactivity is also related with a 
risk of depression, probably associated to the quality of life.
Supported by: Mutua Terrassa Fundation
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Lowered muscle endurance in association with neuropathy in patients 
with type 2 diabetes
T. Gysel1, J. Ruige2, P. Boon2, D. Cambier1, P. Calders1;  
1Dept. of Rehabilitation Sciences and Physiotherapy,  
2Ghent University, Ghent, Belgium.
Background and aims: Type 2 diabetes is characterized by a reduced sensi-
tivity of the tissues to insulin (insulin resistance), and a reduced formation of 
insulin by the pancreas. This is often accompanied by damage to blood ves-
sels and nerves (neuropathy). The treatment of diabetes includes medication, 
nutritional advice and exercise therapy. Strength training has a positive effect 
on insulin resistance and muscle function. What kind of strength training is 
most optimal, remains unknown. To investigate this, first of all, it should be 
examined to what extent different types of strength (maximal-, explosive-, 
endurance,⋯) are influenced by the severity of diabetes, taking into account 
additional conditions, such as peripheral neuropathy. Since the negative in-
fluence of diabetes and neuropathy on maximal strength has already been 
investigated, the purpose of this study was to investigate the association be-
tween neuropathy and arm/leg muscle endurance.
Materials and methods: Data from an isokinetic dynamometer, a clinical 
neurological examination + quantitative sensory examination and nerve 
conduction studies were obtained in 35 type 2 diabetic men, with (n=24) and 
without neuropathy (n=11). Seven patients had small fiber sensory neuropa-
thy, 17 had sensorimotor neuropathy. All men performed 25 elbow- and 30 
knee maximal concentric contractions on an isokinetic dynamometer at a 
given angular velocity of 180°/sec. Elbow- and knee flexor fatigue was meas-
ured with the fatigue index, calculated as the ratio of the average peak torque 
of the last third to the average peak torque of the first third. A neuropathy 
rank sum score (NRSS) was calculated for each patient to quantify the pe-
ripheral nerve function, adding the rank scores for the Michigan Neuropathy 
Screening Instrument (MNSI) questionnaire, the neuropathy disability score 
(NDS), the vibration perception thresholds (VPT’s), the motor and sensory 
nerve conduction velocities (MNCV’s and SNCV’s), as well as the amplitudes 
of the compound muscle - and sensory nerve action potentials (CMAP’s and 
SNAP’s). The VPT’s were ranked on the basis of the sum of the two percen-
tiles obtained at right and left great toe. The EMG-parameters (MNCV & 
CMAP of peroneal, tibial and ulnar nerve, SNCV & SNAP of radial and sural 
nerve) were ranked for all nerves according to the calculated z-score. In order 
to calculate these z-scores, MNCV + CMAP and SNCV + SNAP were meas-
ured in 16 healthy subjects in an age-matched comparison group. Finally, the 
mean sum score for the conduction studies was used for the total rank sum 
score. If no action potential could be obtained, the highest rank score was 
given. A high NRSS thus reflected severe nerve dysfunction. To estimate the 
correlations between the neuropathy rank sum score and the fatigue indices, 
pearson correlation analysis was used.
Results: A significant negative correlation was indicated between the isoki-
netic fatigue index of knee flexors and the NRSS (r= -0.356 , p=0.036). For 
elbow flexors there was also a tendency towards a negative correlation with 
the NRSS (r= -0.318 , p=0.062).
Conclusion: This finding suggests that not only maximal strength, but also 
endurance in diabetic people with neuropathy is worse than in diabetics 
without neuropathy.
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Characteristics of patients with type 2 diabetes who achieved better 
glycaemic control through resistance training: a meta-analysis
H. Ishiguro1, S. Kodama2, S. Matsunaga3, C. Horikawa3, Y. Heianza3,  
N. Ohara4, T. Yamada3, A. Suzuki3, O. Hanyu3, H. Sone3;  
1Tsugawa Hospital, Niigata prefecture, 2MIto kyodo Hospital, Ibaraki 
prefecture, 3Niigata University Faculty of Medicine,  
4Nagaoka Red Cross Hospital, Niigata prefecture, Japan.
Background and aims: Recently, an increasing number of studies have sug-
gested that resistance training (RT) has been effective in improving glyce-
mic control (GC) in patients with type 2 diabetes (T2D). Our aim of this 
meta-analysis is to determine the antihyperglycemic effect of RT and analyze 
characteristics of patients for whom RT could be especially indicated for im-
provement in GC.
Materials and methods: Electronic-based literature search was conducted 
for intervention studies examining the metabolic effect of RT in T2D patients 
using MEDLINE and EMBASE. Studies were included if 1) both an RT-exer-
cise group and non-RT control group were examined and 2) the net change in 
hemoglobin A1C (A1C) (i.e., difference in mean change in A1C from before 
to after the study between RT and non-RT groups) and its corresponding 
standard error as a study weight could be estimated. We included studies that 
described other interventions such as aerobic training if those other interven-
tions were similar between the RT and non-RT groups.
Results: Twenty-seven studies were eligible. Net change in A1C (95% confi-
dence interval [CI]) was -0.3 [-0.46--0.14]%. A significantly larger reduction 
in A1C was observed in studies of subjects with the following characteristics: 
1) short duration of T2D (>= 6 years vs. <6 years, P=0.03), 2) women-domi-
nant (<50% vs. >=50% proportion of men, P=0.006) and 3) high A1C values 
at baseline (>=7.5% vs. <7.5%, P=0.006). There was a linear relationship be-
tween baseline body mass index and the net effect on A1C (R-squared=0.42, 
P<0.001), predicting that a 1 kg/m2 leaner subject would achieve a 0.09% 
larger reduction in A1C after RT (Figure). The training protocol such as in-
tensity, interval between sets, frequency, and intervention periods did not 
significantly modify study results.
Conclusion: This meta-analysis produced useful suggestions regarding the 
characteristics of patients with T2D for whom clinicians should especially 
prescribe RT to achieve improved GC.
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Severe hypoglycaemia requiring medical assistance in patients with 
diabetes is associated with simultaneous prolongation of QTc interval 
M. Mylona1, G. Anastasiadis2, K. Zerva2, V. Vasgiourakis2, C. Liaskos1,  
S. Liatis1;  
1Diabetes Center, First Department of Internal Medicine,  
2Department of Cardiology, Laiko Hospital, Athens, Greece.
Background and aims: It has been shown that hypoglycemia induces mul-
tiple pre-arrhythmic changes, mainly increase pre-existent QT prolongation, 
produce intracellular Ca2+ overload, and decrease serum K+. As a conse-
quence, hypoglycemia is considered a state that may lead to sudden death, 
as a result of cardiac arrhythmia. Few data, however, directly link episodes of 
severe hypoglycemia with pre-arrhythmic conditions, such as QT prolonga-
tion. Aim of the present study is to explore the association between severe hy-
poglycemic events requiring medical assistance and QT interval, in patients 
with diabetes.
Materials and methods: Eight hospitals (nine clinics), in five cities of Greece, 
participated in a 16-month prospective survey of documented iatrogenic hy-
poglycemia at the emergency departments (ED). According to the protocol, a 
12-lead ECG was obtained simultaneously or immediately after the manage-
ment of hypoglycemia and no later than 30 minutes after the administration 
of glucose. The ECGs obtained from hypoglycemic patients were compared 
to those from a control group consisted of patients with diabetes, matched 
for age and gender, visiting the outpatient diabetes clinics of the same hos-
pitals, during the same time period. QT and RR intervals were measured 
blindly by three independent cardiologists. QTc was calculated according to 
the Bazett formula: QTc = QT interval/square root of the R-R interval. QTc 
measurements of≥440msec were considered abnormally prolonged and those 
of≥500msec as highly prolonged. Patients receiving medications possibly af-
fecting the QTc interval and those with hypokalaemia (serum potassium < 
3.5mEq/l) were excluded from the analysis.
Results: During a median follow-up of 16 months, 295 episodes of iatrogenic 
hypoglycemia in 294 patients with diabetes were identified and 223 ECGs 
were obtained according to the pre-specified criteria. However, 46 ECGs were 
excluded from the analysis, due to the presence of the above mentioned cri-
teria. Finally, 177 ECGs from hypoglycemic patients were analyzed (mean 
age 72.7±15.7 years, 48.6% women, 9% with type 1 diabetes) and com-
pared to 91 age and gender matched controls. Mean QTc interval was sig-
nificantly prolonged in patients compared to controls (440.4±45.1 msec vs. 
413.9±32.5msec, p<0.001). In addition, a significantly higher proportion of 
hypoglycemic patients had an abnormally prolonged QTc (≥440msec ) com-
pared to controls (49.7% vs. 24.2%, p<0.001), while 14 hypoglycemic patients 
(7.9%) had a highly prolonged QTc (≥500msec) compared to none in controls
Conclusion: In patients with diabetes, severe iatrogenic hypoglycemia re-
quiring medical assistance is associated with a both statistically and clinically 
significant prolongation of QTc interval.
632
Facial skin temperature measured by infrared thermography during 
hypoglycaemia in patients with longstanding type 1 diabetes
A.-S. Sejling1,2, K.H.W. Lange1, C.S.S. Frandsen3, S.S. Diemar4,  
L. Tarnow1,5, J. Faber6, T.W. Kjær7, C.B. Juhl8,2, B. Thorsteinsson1,4,  
U. Pedersen-Bjergaard1,4;  
1Nordsjællands Hospital, Hillerød, 2Faculty of Health Sciences, University 
of Southern Denmark, Odense, 3Hvidovre Hosptial, 4Faculty of Health and 
Medical Sciences, University of Copenhagen, 5Aarhus University, 6Herlev 
Hospital, 7Roskilde Hospital, Roskilde, 8Sydvestjysk Sygehus, Esbjerg, 
Denmark.
Background and aims: Hypoglycaemia is associated with increased activ-
ity in the autonomic nervous system resulting in increased sweat production 
and changes in peripheral blood flow. Since peripheral blood flow influences 
overlying skin temperature (Ts), hypoglycaemia may cause changes in skin 
temperature. The aim of this study was to investigate changes in Ts during 
induced hypoglycaemia in patients with long standing type 1 diabetes. We 
hypothesized that hypoglycaemia results in decreased Ts.
Materials and methods: Twenty-four patients with type 1 diabetes partici-
pated in the study (14 men, age 54 ± 12 years (mean ± SD), duration of diabe-
tes 28 ± 11 years, HbA1c 8.0 ± 1.0 %). Fourteen patients had hypoglycaemia 
unawareness and 10 patients had normal hypoglycaemia awareness. The pa-
tients were studied during euglycaemia (5.4 ± 0.6 mmol/L) and hypoglycae-
mia (2.4 ± 0.2 mmol/L) by a hyperinsulinaemic glucose clamp technique. 
During each phase of one hour, Ts was measured by infrared thermographic 
imaging in two pre-defined facial areas of approximately 2 cm2 size on the 
forehead just above the bony nose and on the tip of the nose. Autonomic 
symptoms of hypoglycaemia were recorded and venous blood was sampled.
Results: During hypoglycaemia Ts decreased on the forehead (ΔTs = -0.86 ± 
0.99°C, p=0.001) and on the nose (ΔTs = -1.75 ± 2.1°C p=0.002). There was 
a difference in Ts changes on the forehead between the two groups (ΔTs = 
-1.4 ± 0.29°C in aware patients vs ΔTs = -0.4 ± 0.23°C in unaware patients, 
p=0.01) (Figure). Epinephrine concentrations increased during hypogly-
caemia compared to euglycaemia (0.49 ± 0.42 ng/mL vs 0.07 ± 0.05 ng/mL, 
p<0.001) with no significant difference in rise of epinephrine between aware 
and unaware patients (0.54 ± 0.52 ng/mL vs 0.34 ± 0.31 ng/mL, p=0.19). Au-
tonomic symptom scores increased during hypoglycaemia (10 ± 6 points vs 
5.5 ± 1.8 points, p=0.001). The aware group reported 2.5 times higher symp-
tom scores during hypoglycaemia than the unaware group (15 ± 5.9 points vs 
6.5 ± 2.6 points, p<0.01).
Conclusion: Hypoglycaemia-associated changes in facial skin temperature 
can be quantified by infrared thermography in patients with type 1 diabe-
tes. Patients with normal awareness had a larger Ts decrease on the forehead 
compared to patients with hypoglycaemia unawareness and more autonomic 
symptoms during hypoglycaemia despite no significant difference in blood 
epinephrine concentrations between the two groups.
Clinical Trial Registration Number: H-1-2011-024
Supported by: Nordsjællands Hospital Research Foundation
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Cardiac autonomic regulation during acute experimental hypoglycaemia 
in type 2 diabetes
E. Chow1, A. Bernjak2, P.J. Sheridan1, S.R. Heller2;  
1Cardiovascular Sciences, 2Human Metabolism, University of Sheffield, UK.
Background and aims: Hypoglycaemia is associated with increased cardio-
vascular mortality in trials of intensive therapy in type 2 diabetes. In recent 
clinical studies involving type 2 diabetes patients, we reported a higher in-
cidence of ventricular ectopics and bradyarrhythmias during spontaneous 
prolonged hypoglycaemia, which we attributed to differential changes in 
autonomic tone. In this study our aim was to examine changes in cardiac 
autonomic function in more detail during sustained experimental hypogly-
caemia.
Materials and methods: Twelve type 2 diabetes subjects with normal car-
diac autonomic function tests and eleven age, BMI-matched nondiabetic 
controls underwent paired hyperinsulinaemic clamps separated by 4 weeks. 
In the euglycaemic arm, glucose was maintained at 6.0mmol/L for 2h while 
during hypoglycaemia, glucose was lowered to 2.5mmol/L over 1 hour and 
maintained for a further hour. Heart rate (HR), blood pressure and heart rate 
variability (HRV) were assessed at 30 min intervals. Spectral power of HRV 
was calculated within low frequency (LF: 0.04-0.15Hz) and high frequency 
(HF: 0.15-0.4Hz) intervals.
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Results: In the diabetic group, HR increased maximally from 72±10 to 77±10 
bpm (p=0.04) after 30 minutes of hypoglycaemia (T90), but fell to 71±8 bpm 
despite maintained hypoglycaemia (T120)(see Fig). High frequency HRV de-
creased up to T90 (logHF 1.89±0.61 vs 1.61±0.63, p =0.02), indicating acute 
vagal withdrawal, but returned towards baseline at T120. There was a rise in 
normalised low frequency power indicating increased sympathetic contribu-
tion. In the control group, the maximal increase in HR occurred earlier at 
T60 during hypoglycaemia (from 62±9 to 66±13 bpm, p=0.04) but HR re-
mained elevated at 65±11 bpm after hypoglycaemia for 1 hour. HF power de-
creased from baseline (logHF 2.36±0.44 to 2.14±0.59, p=0.05) and remained 
unchanged despite continued hypoglycaemia, indicating inhibition of vagal 
tone throughout. No significant changes in HRV occurred in either group 
during euglycaemic clamps.
Conclusion: Cardiac autonomic regulation during hypoglycaemia appears 
time-dependent and differs between patients with type 2 diabetes and non-
diabetic individuals. In type 2 diabetes, the initial heart rate increment to 
hypoglycaemia is delayed. Following early vagal withdrawal, there is reactiva-
tion of vagal activity during more sustained hypoglycaemia which did not 
occur in nondiabetic individuals. These mechanisms may relate to autonomic 
dysfunction and could contribute to tachy- and bradyarrhythmias during 
clinical hypoglycaemic episodes.
Clinical Trial Registration Number: DRN686
Supported by: NIHR
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Survey of outpatients with type 2 diabetes among older adults in Japan
M. Fukuda, K. Doi, M. Sugawara, Y. Naka, K. Mochizuki;  
Japan Physicians Association, Tokyo, Japan.
Background and aims: The number of older adults with Type II diabetes 
(T2DM) is continuously increasing in Japan, and care needs to be provided 
according to the individual needs of these patients, which require more ur-
gent attention in Japan than in the West. Despite this situation, few studies 
have investigated the prevalence of hypoglycemia among older T2DM in Ja-
pan. This study describes the results of a survey conducted by the Japan Phy-
sicians Association (JPA) to elucidate the prevalence of hypoglycemia among 
older T2DM in Japan. The survey collected data on patient knowledge about 
hypoglycemic symptoms as well as their clinical background.
Materials and methods: A total of 15,892 older adults aged ≥65 years (8319 
men and 7516 women) who were undergoing regular outpatient treatment 
for their diabetic conditions were included in this study. The survey included 
questions pertaining to 28 items concerning hypoglycemic symptoms and 
age-related syndromes experienced in the last month. The JPA also collected 
patients’ medical records from their doctors.
Results: The average age of patients was 74.2 years (men, 73.6 years; wom-
en, 75.0 years), the mean disease duration was 12.8 years (men, 13.1 years; 
women, 12.5 years), and the mean body mass index (BMI) was 24.1 (men, 
24.0; women, 24.2). Medications used for diabetes treatment, including con-
comitant prescriptions, were as follows: DPP-4 inhibitors, 53.3%; SU, 39.4%; 
α-GI, 23.4%; metformin, 22.8%; pioglitazone, 14.0%; glinide, 4.4% and insu-
lin, 17%. Although the incidence of hypoglycemic symptoms as estimated by 
the doctors on the basis of their diagnoses in the previous month was 7.8%, 
the actual incidence indicated by the patient responses was 10.4%. The re-
sponses indicated that the incidence of hypoglycemia among patients treated 
with either SU or insulin was 20.9%, whereas that among patients treated 
without neither drugs was lower at 2.5%. Tiredness/feeling languid (32.8%), 
loss of balance/dizziness (32.4%), cold sweats (30.4%), and eye blink (24.8%) 
were the most frequently experienced hypoglycemic symptoms. Among the 
patients who used SU or insulin, 80.1% were aware of their hypoglycemic 
symptoms and 64.4% knew how to treat these symptoms. However, only 
38.1% patients who were aware of their hypoglycemia always carried some 
form of glucose with them.
Conclusion: The results of our survey indicated that the symptoms of hypo-
glycemia were atypical and vague in older T2DM patients, and the actual inci-
dence of hypoglycemia among the patients was considerably higher than that 
estimated by the doctors on the basis of their diagnoses. Although there was 
satisfactory awareness of hypoglycemia among the older adults, two-thirds 
of them did not always carry some form of glucose with them. Therefore, 
more careful treatment of T2DM and more positive measures to promote the 
awareness of hypoglycemia are required for older adults with T2DM.
635
Impaired awareness of hypoglycaemia in insulin-treated patients with 
type 2 diabetes mellitus
N. Sakane, K. Kotani, K. Tsuzaki, K. Takahashi, Y. Sano;  
Kyoto Medical Center, Japan.
Background and aims: Severe hypoglycemia (SH) is associated with a high-
er risk of cardiovascular disease-related mortality and mortality. Impaired 
awareness of hypoglycemia (IAH) in insulin-treated patients with type 2 dia-
betes mellitus (T2DM) has been reported to be associated with the presence 
of SH. However, little is known regarding the actual states of hypoglycemia, 
including IAH, in Japan. The aim of the study was therefore to survey the 
states of hypoglycemia and patient-physician communication among insu-
lin-treated patients with T2DM.
Materials and methods: A questionnaire survey on hypoglycemia and pa-
tient-physician communication was conducted in 331 patients with insulin-
treated T2DM patients at 16 hospitals and clinics. Inclusion criteria were: 1) 
over 20 years, 2) T2DM, 3) insulin treatment, 4) patients regularly attended 
the surveyed hospitals and clinics. Exclusion criteria were: 1) children and 
young patients under 20 years old, and 2) type 1 diabetes mellitus. Clinical 
data such as the insulin regimen and diabetic complications were collected 
from their physicians. Hypoglycemia was defined as blood sugar ≤50 mg/
dL (2.8 mmol/L) or symptoms of dizziness, blurry vision, confusion, and/or 
sweating that the patient was able to resolve without assistance. Similar symp-
toms that required external assistance were defined as SH. Favorable glyce-
mic control to prevent diabetic complications was defined as HbA1c<7% ac-
cording to “Kumamoto declaration 2013”. Patient-physician communication 
regarding hypoglycemia and strategies to avoid it was based on the answer 
categories “never” and “seldom” as poor commutation, and “sometimes” and 
“often” as favorable communication, in response to “how often do you talk 
about hypoglycemia and strategies to avoid it with your physician?”.
Results: The rate of IAH was 22.1%. There were no significant differences 
in clinical characteristics, such as the age, diabetes duration, prevalence of 
hypoglycemia, insulin regimen, and diabetic complications, between patients 
with and without IAH. The rates of alcohol drinking and smoking in males 
were significantly higher than in females (22.5 vs. 1.4%; p<0.01, and 30.9 vs. 
12.2%; P<0.01, respectively). A stepwise logistic regression analysis revealed 
that glycemic control at an HbA1c level <7.0% was a significant risk fac-
tor of IAH (odds ratio [OR]: 2.12; 95% confidence interval [CI]: 1.22-3.68; 
P=0.01), along with a male sex (OR: 1.89; 95% CI: 1.06-3.38; P=0.03) and a 
BMI level (OR: 0.89; 95% CI: 0.82-0.97; P=0.01). Concerning talking about 
hypoglycemia with physicians, patients with IAH showed a similar frequency 
of talking with physicians as patients without IAH (76.1 vs. 71.4%; P=0.44, 
respectively), while patients with SH communicated more frequently than 
those without SH (90.9 vs. 70.3%; P=0.01, respectively).
Conclusion: The current survey found that IAH was not uncommon among 
insulin-treated patients with T2DM in Japan. Aging, a lower BMI, and lower 
HbA1c levels were significantly correlated with IAH. The patients with SH 
talked less about hypoglycemia with their physicians. To improve the actual 
states of hypoglycemia, physicians should be conscious of the factors associ-
ated with IAH, and should talk more about hypoglycemia to insulin-treated 
patients with T2DM in Japan.
Supported by: National Hsopital Organization
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Hypoglycaemia unawareness in emerging adults transferred  
from a paediatric to an adult diabetes unit
M.C. Careaga1, M. Vidal1, M. Jansa1, C. Yoldi2, R. Cardona2, A. Gomez2,  
M. Gimenez1, E. Esmatjes1, I. Conget1;  
1Diabetes Unit. Endocrinology and Nutrition Department,  
Hospital Clinic and University of Barcelona,  
2Pediatric Endocrinology, Hospital Sant Joan de Deu, Barcelona, Spain.
Background and aims: Repeated hypoglycemia and the syndrome of hypo-
glycemia unawareness (HU) are major barriers to achieving normoglycemia 
over a lifetime of using intensive insulin therapy and thus precludes eugly-
cemia’s long-term benefits. Type 1 Diabetes (T1D) management in young 
patients is troublesome specially when they are transferred to adult Diabetes 
Units. The aim of our study was to evaluate the impact of the presence of 
HU on the results of a transition therapeutic education program (TEP) spe-
cifically addressed to the transfer T1D patients from a pediatric to an adult 
diabetes Unit.
Materials and methods: We included 56 patients with T1D (age 18.0 ± 0.3 
years, 26 girls, disease duration 8.0 ± 4.0 years, HbA1c 8.0 ± 1.2%) consec-
utively transferred (2009-2011). The TEP included a co-ordinated transfer 
between the Units, individual visits and group sessions. At baseline, we reg-
istered data on BMI, insulin dose, HbA1c and the frequency of hypoglyce-
mia. For evaluation of the quality of life (QoL) and knowledge in T1D man-
agement, self-report questionnaires were assessed. Mother tongue (spanish 
and catalan versions) validated Clarke’s test was used to evaluate HU.After 
12-months, all subjects were re-evaluated.
Results: Nine out of 56 patients had HU (16%). Age, gender, duration of dis-
ease, type of treatment, HbA1c, the different aspects of QoL and the degree 
of knowledge of the disease were not different in those subjects afected by 
HU in comparison to the unaffected group. Only the number of severe hypo-
glycemia episodes was significantly different between groups (0.33±0.50 vs. 
0.09±0.28, episodes-subject-year with and without HU respectively,p 5 non 
severe episodes/week was close to significantly different (66 vs 34 %, p=0.13). 
After 12 momths, in the group with HU, 4 patients improved awareness, there 
was a reduction in the number of non severe hypoglycemia episodes/ week , 
but this was not the case of severe episodes. The HbA1c was not significantly 
different between the two groups (8.2 ± 1.1 vs. 7.6 ± 0.9% with and without 
HU, respectively)
Conclusion: The presence of HU is far from uncommon when emerging 
adults with T1D are transferred from a pediatric to an adult diabetes unit. 
While the use of an specific TEP improves metabolic prognosis in the mid-
term, the reduction of hypoglycemia episodes, specially severe, remains an 
elusive issue
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Timing of hypoglycaemia is associated with increased mortality  
and length of stay among patients with diabetes admitted to internal 
medicine departments
J. Wainstein1, M. Boaz2,3, E. Leibovitz4,5;  
1Diabetes clinic, Wolfson Medical Center, 2Research and Epidemiology, 
Wolfson Medical Center, Holon, 3Epidemiology, Tel Aviv University,  
4Interal Medicine E, Wolfson Medical Center, Holon,  
5Sackler school of Medicine, Tel Aviv University, Israel.
Background and aims: Hypoglycemia among hospitalized patients with dia-
betes is associated with poor hospital prognosis. The aim of the study was to 
examine the effect of hypoglycemia timing on hospital prognosis
Materials and methods: In this retrospective analysis of electronic medical 
records, we included all 3941 patients with diabetes (Mean age 71.7±12.9 
years, 49.3% males) discharged from internal medicine departments during 
2009. All glucose measurements were computerized using an institutional 
glucometer. Patients were categorized into 3 groups according to hypogly-
cemia timing: Group1, no hypoglycemia, Group 2, hypoglycemia only upon 
admission and Group 3, hypoglycemia during hospital stay.
Results: Included in the analysis were 3413 (86.4%) patients with diabetes 
who had glucose measurements performed during hospitalization. A total 
of 157 patients (4.6%) had at least 1 hypoglycemia event during the hospital 
stay (42 patients upon admission and 115 patients during hospitalization). 
Patients in Group 3 had significantly increased in-hospital mortality and 
length of hospital stay (27.0%, 18.4±24.7 days), compared to Groups 1 (3.4% 
mortality, 5.1±8.8 hospital days) and Group 2 (4.7% f mortality, 3.2±3.3 hos-
pital days). Mortality rates were associated with the severity and number of 
hypoglycemia events. Patients in Group 3 had higher creatinine and lower 
albumin levels compared to Groups 1 and 2.
Conclusion: Hypoglycemia during hospitalization is associated with in-
creased rates of in-hospital mortality and prolonged hospital stay among 
diabetic patients admitted to internal medicine departments. Poor hospital 
outcome was associated with timing of hypoglycemia, as well as the number 
and severity of the events.
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Baseline insulin deficiency is associated with increased mortality  
and severe hypoglycaemia in the ACCORD study
E.R. Seaquist1, H. Chen2, M. Miller2, L. Chow1;  
1Medicine, University of Minnesota,  
2Biostatistics, Wake Forest School of Medicine, Winston Salem, USA.
Background and aims: Intensive glycemic control is associated with in-
creased mortality, but the role of hypoglycemia remains unclear. Hypogly-
cemia is associated with insulin deficiency. Whether insulin deficiency and/
or islet autoimmunity may affect mortality in patients with type 2 diabetes 
remains unknown. Using the ACCORD (Action to Control Cardiovascular 
Risk in Diabetes) cohort, we tested the hypothesis that baseline insulin de-
ficiency and islet autoimmunity in type 2 diabetes would be associated with 
severe hypoglycemia and mortality.
Materials and methods: A nested case-control study (86 cases, 344 controls) 
was used. A participant who died during ACCORD with at least 1 episode of 
severe hypoglycemia, defined as hypoglycemia requiring assistance, was clas-
sified as a case. Participants who did not die during ACCORD and did not 
have severe hypoglycemia were classified as controls. Each case was matched 
to 4 controls [age (+/- 5 yrs), BMI (+/- 2.5), glycemic intervention arm, race]. 
Insulin deficiency was defined as fasting C-peptide < 0.45 nmol/L. Islet auto-
immunity was determined by antibodies against glutamic acid decarboxylase 
(GAD), tyrosine phosphatase-related islet antigen 2 (IA-2A), insulin (IAA), 
and zinc transporter (Zn-T8). Conditional logistic regression was used.
Results: Death during ACCORD with at least 1 episode of severe hypoglyce-
mia was associated with baseline insulin deficiency (OR 4.8, 95% CI 2.1-11.1, 
p<0.01) and GAD antibodies (OR 2.3, 95% CI 1.1-5.1, p=0.04). These asso-
ciations remained after adjusting for age and BMI (insulin deficiency: OR 6.5, 
95% CI 2.6-16.4, p<0.01; GAD antibodies: OR 2.4, 95% CI 1.0-5.4, p=0.04). 
Other baseline antibodies (IA2, IAA, Zn-T8) had no association. GAD an-
tibodies were more common in insulin deficient (54.6%) than non-insulin 
deficient (4.9%) participants.
Conclusion: In patients with type 2 diabetes, insulin deficiency, possibly due 
to islet cell autoimmunity, is associated with death and a history of severe 
hypoglycemia. Whether treatments to preserve insulin secretion in type 2 
diabetes may reduce mortality remains an intriguing area for further study.
Clinical Trial Registration Number: NCT00000620
Supported by: NIDDK and NHLBI
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Is hypoglycaemia an increasing barrier to achieving HbA1c target for 
NPH insulin than insulin glargine?
Q. Zhang1, E. Chou1, H.-W. Chung2, H. Wang1;  
1R&D, Sanofi, Bridgewater, 2TechData, King of Prussia, USA.
Background and aims: Hypoglycemia is a common side effect of insulin 
therapy and may impede the outcomes of glycemic control. This study was 
to assess risk of hypoglycemia at each level of achieved A1C between patients 
initiating NPH insulin (NPH) and insulin glargine (GLA) as add-on to oral 
anti-diabetic drugs (OAD) from a US managed care database.
Materials and methods: Patients with T2DM who initiated NPH or GLA 
between January 2006 and December 2012 were identified from Clinformat-
ics™ DataMart Multiplan. All patients had a minimum of 1-year continuous 
health coverage prior to and after basal insulin initialization. Baseline comor-
bidity was measured by Charlson Comorbidity Index (CCI) with a higher 
number corresponding to increased burden of comorbidity. Number of hy-
poglycemic events was evaluated against achieved level of A1C and tested at 
each A1C level with adjustment of baseline patient characteristics.
Results: NPH (n=864) had mean age of 47 years with average baseline A1C of 
7.5% and CCI of 2.38 relative to GLA (n=10,843) with mean age of 55 years, 
baseline A1C of 8.6% and CCI of 2.55. Both groups had about 46% female. 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 263
1 C
During the year following basal insulin initiation, unadjusted achieved A1C 
decreased -1.0% from baseline in NPH and -1.2% in GLA. Mean number of 
hypoglycemic events in the year was 0.74 in NPH and 0.50 in GLA after ad-
justment of baseline characteristics. Overall, number of hypoglycemic events 
increased as achieved A1C during the year approached the target (≤7%) 
and remained higher in NPH relative to GLA (p<0.01). In particular when 
achieved A1C was at 7%, number of hypoglycemia events was estimated at 
29.1/100 patient-years in NPH and 16.3/100 patient-years in GLA (Fig 1).
Conclusion: Consistent with previous research, this study shows an elevated 
hypoglycemia risk in NPH relative to GLA in the US managed care database. 
Furthermore, the risk of hypoglycemia rises as A1C approaches 7%, suggest-
ing hypoglycemia as an increasing barrier for more intensive glycemic con-
trol in patients with T2DM initiating basal insulin from the clinical practice 
setting.
Supported by: Sanofi
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Is the fear of hypoglycaemia associated with glycaemic imbalance?
A. Avignon1, M. Lièvre2, A. Penfornis3, B. Cariou4, N. Jeandidier5,  
S. Lavigne6, L. Vaur7;  
1Montpellier University Hospital, 2Laennec University of Medicine, Lyon, 
3Besançon University Hospital, 4Nantes University Hospital, 5Strasbourg 
University Hospital, 6ITEC Services, Cenon, 7Novo Nordisk, Paris, France.
Background and aims: The fear of hypoglycemia in clinical practice is im-
portant, but few practical tools exist to evaluate it. The HFS-II (Hypoglyce-
mia Fear Survey-II) is a validated questionnaire measuring fear of the risk of 
hypoglycemia in patients with diabetes. It evaluates behaviors to avoid hypo-
glycemia and its consequences as well as degree of worry related to hypogly-
cemia. The objective of this analysis is to estimate the clinical correlations of 
a high HFS score (>+1SD) on high HbA1c value (>=7 %) and occurrence of 
severe hypoglycemia within 30 days.
Materials and methods: Data from 1927 French patients with insulin-treated 
diabetes (1008 patients with type 1 diabetes mellitus [T1DM] and 919 with 
type 2 diabetes mellitus [T2DM]) completing the HFS-II questionnaire in the 
DIALOG observational prospective study was used. The correlated factors 
were analyzed using a multivariate logistic regression model.
Results: Factors that were correlated to a HbA1c>=7 % were separately inves-
tigated in patients with T1DM and T2DM. For patients with T1DM, the main 
factors contributing to an HbA1c>=7 % were the HFS class >+1SD (odds 
ratio [OR] 3.5; 95 % confidence interval [95CI] 1.9-6.4) and the class between 
-1 and +1SD (OR 2.8; 95CI 1.7-4.7) versus the lowest class (<-1SD), as well as 
the insulin therapy duration >10 years (OR 1.8; 95CI 1.3-2.5). In patients with 
T2DM, the HFS score was no longer significant in the multivariate model. On 
the other hand, the main associated factors contributing to occurrence of a 
severe hypoglycemic event in both T1DM and T2DM patients were history 
of hypoglycemia (OR 3.8; 95CI 1.4-10.6), T1DM (OR 1.8; 95CI 1.3-2.5) and 
an HFS score >+1SD versus <-1SD (OR 7.1; 95CI 3.2-16.1) or between -1SD 
and +1SD versus <-1SD (OR 3.4; 95CI 1.6-7.5).
Conclusion: The fear of hypoglycemia is correlated with high HbA1c values 
in patients with T1DM and also with the occurrence of severe hypoglycemia 
in both T1DM and T2DM.
PS 043 Nocturnal and drug-induced 
hypoglycaemia
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Predisposing factors for hypoglycaemia: analysis from the SAVOR-TIMI 
53 trial
I. Raz1, A. Cahn1, B.M. Scirica2, K.K. Ray3, F. Goldberg Eliaschewitz4,  
R.G. Moses5, B. Hirshberg6, M. Sjöstrand7, N. Iqbal8, O. Mosenzon1,  
B.S. Lewis9, D.L. Bhatt2;  
1The Diabetes Unit, Hadassah Hebrew University - Medical Center, 
Jerusalem, Israel, 2Brigham and Women’s Hospital, Harvard Medical School, 
Boston, USA, 3St. Georges University of London, UK, 4Clinical Research 
Center, São Paulo, Brazil, 5Illawarra and Shoalhaven Local Health District, 
Wollongong West, Australia, 6AstraZeneca, Wilmington, USA,  
7Clinical Development, AstraZeneca R&D, Mölndal, Sweden,  
8BMS, Princeton, USA, 9Lady Davis Carmel Medical Center, Haifa, Israel.
Background and aims: Hypoglycemia is a significant barrier to treatment 
escalation by patients (pts) and physicians. Predisposing factors to hypogly-
cemia in the SAVOR TIMI 53 trial were studied.
Materials and methods: In the SAVOR TIMI 53 trial, 16,492 patients (pts) 
with type 2 diabetes (T2D) were randomized to receive either saxagliptin 
(SAXA) or placebo. Conventional therapy was adjusted by investigators to 
achieve HbA1c (A1c) target. Pts were followed for a median of 2.1 years. Pa-
tients were requested to record hypoglycemic episodes based on symptoms 
suggestive of hypoglycemia that recovered by carbohydrate ingestion and/
or documentation of low blood glucose < 54 mg/dl (minor) or the need for 
assistance from another person (major).
Results: 2,722 individuals (16.5% of trial participants) experienced at least 
one hypoglycemic episode and 312 (1.9%) experienced at least one major hy-
poglycemic episode. Hypoglycemic risk increased with age, disease duration, 
reduced GFR and increased albuminuria (p <0.01). Incidence of hypogly-
cemic events changed with baseline A1c: 12.8% at A1c <7%, 17.4% at A1c 
7-8%, 20.5% at A1c 8-9% and 16.3% at A1c>9%. Pts on sulfonylurea (SU), 
long acting insulin (glargine or detemir), intermediate acting insulin, or short 
acting insulin in different combinations experienced increased hypoglycemic 
rates (14.9%, 20.2%, 23.9% and 29.3% respectively). Pts assigned to SAXA 
vs. placebo reported more hypoglycemic events (17.6% vs. 15.4%, p<0.001), 
including major hypoglycemic events (2.1% vs. 1.7%, p=0.05). Hypoglycemia 
requiring hospitalization was similar between groups (0.6% vs. 0.5%, p=0.3). 
Higher rates of hypoglycemia in SAXA vs. placebo arm were observed in 
SU treated pts (alone or in combination with other oral anti diabetic drugs) 
(17.2% vs. 12.5%, p<0.001), but not in insulin treated pts (27.1% vs. 26.7%, 
p=0.8). Patients treated with SU and baseline A1c<7% in SAXA arm had in-
creased rates of major hypoglycemia (3.6% vs. 1.6%, p=0.02). Addition of 
SAXA vs. placebo to metformin alone, insulin alone or to SU in combination 
with insulin and/or metformin, resulted in more pts achieving A1c<7% at 1 
year without experiencing hypoglycemia (figure).
Conclusion: The SAVOR TIMI 53 trial enables us to characterize the main 
predictors for development of hypoglycemia in T2D pts at high cardiovascu-
lar risk. Adding SAXA to metformin alone, insulin alone or to SU in com-
bination, increases the likelihood of attaining a glycemic target of A1c<7% 
without excess hypoglycemic risk.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca/Bristol-Myers Squibb
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A simple algorithm to predict the risk of hypoglycaemia in case of 
physical activity (PA) in patients with type 1 diabetes under pump 
therapy
G. Charpentier1, J. Boudoux2, M.-H. Petit3, A. Doudi3,1, C. Simon4,  
A. Pochat3,5, H. Laroye3, N. Brunel2, S. Franc1;  
1CHSF, Corbeil, France, 2ENSIIE, 3CERITD, Evry, 4CHU of Lyon,  
5CHSF, Evry, France.
Background and aims: The aim of our study was to develop a model to pre-
dict the occurrence of hypoglycemic events from data of Continuous Moni-
toring Systems (CGMs), collected during physical activity (PA) sessions, in 
patients with type 1 diabetes (T1D), under pump therapy.
Materials and methods: Twenty adult patients with type 1 diabetes (11 
males, mean age 45.3±11.9 yrs, HbA1c 7.9±0.9%, VO2max 33±10 ml/kg/
min) performed 5 basal sessions (i.e. 3 hours after lunch) in a random order: 
4 PA sessions (30-min cycling sessions on a constant-power electronic cycle 
ergometer) at 2 levels of PA and with 2 kinds of adjustment of the basal rate 
(BR) of their pump (50% VO2max with a BR reduction of 50 or 80%, 75% 
VO2max with again a BR reduction of 80 or 100%) and 1 rest session. Patients 
wore a CGMs from the beginning of each session and until the next morning. 
Classification methods were used, based on the patients’ profile and the kind 
of sessions, to classify patients according to the occurrence or not of hypo-
glycemia. Several models of prediction were then elaborated. A number of 
explanatory variables had been previously selected and were used to compare 
the effectiveness of each model to predict the risk of hypoglycemia.
Results: From one model to another, variables that proved not to be essential 
or that were not available for the patient in a realistic context, were progres-
sively removed. Finally, we considered variables available during the first ten 
minutes of a PA: weight, age, gender, VO2max, BR reduction, glucose level at 
the beginning of PA, glycemic gradient during the first 10 min of PA. Among 
these variables, we used statistical model selection methods in order to select 
the most relevant variables for the prediction of hypoglycemic events which 
were weight, and glycemic gradient during the first 10 min of PA reported 
to the initial glucose level (GG10). The value of the Area Under the Curve 
(AUC) of the ROC curve based on these variables was 0.74 which means 
a rather acceptable prediction but that can still be improved. We used a lo-
gistic regression for modeling the probability p of occurrence of hypoglyce-
mic events and the estimated model is: logit(p) = -4.13 - 438.7 x GG10 + 0.5 
weight (kg), where logit(p)=log(p/(1-p)) is an increasing function of p. The 
model, based on these 3 variables easy to collect in clinical practice, provides 
a prediction rate exceeding 80% (concordance between the predicted and the 
actual situation) with less than 20% of mismatch data.
Conclusion: A simple model of prediction mainly based on the CGM gradi-
ent of the first 10 min of a 30-min physical activity session, allows to predict 
the occurrence of hypoglycemia with a relative good efficiency. This kind of 
model that we can imagine coupled with CGMs to predict the risk of hypo-
glycemic event in clinical practice, (open-loop system), may, in an improved 
version, reveal to be of particular interest in the development of closed-loop 
systems.
Clinical Trial Registration Number: NCT01277965
Supported by: EFSD, Medtronic
643
The early warning indicators for nocturnal hypoglycaemia  
in type 2 diabetes
Y. Wang, H. Su, Y.M. Xue;  
Department of Endocrine and Metabolism,  
The First People’s Hospital of Yunnan Province, Kunming City, China.
Background and aims: The existing research on hypoglycaemia is largely 
done in special environments such as use of a specific medicine or focus-
ing on a certain age period, its practicality in broad clinical contexts is thus 
limited. Moreover, most causes of hypoglycaemia like endogenous insulin 
inadequacy and the diabetic process cannot be altered. This study is to ex-
plore quantitative indicators warning of nocturnal hypoglycaemia by using 
Continuing Glucose Monitoring System (CGMS) on a large sample in rou-
tine clinical environments to seek some basis for preventing hypoglycaemia 
in clinics.
Materials and methods: First, 1147 patients (male 723 and female 424) of 
type 2 diabetes were sampled, whose ages being 59.21±11.31(14~91 years 
old) and Mean Blood Glucose (MBG) being 7.41±2.98 mmol/L. Those 
whose BGs turned stable after treatment, except those who took medicine 
like hypnotics or sedative before sleep, were monitored for 65 to 82 hours by 
CGMS.. Second, another 479 patients whose BG 3 hours after supper was ≤ 
4.7mmol/L were sampled and randomly divided into the intervention group 
and the non-intervention group, measures like insulin dosage reduction be-
fore sleep and/or eating some 50 to 100 grams of protein or carbonhydrate 
were adopted for the intervention group. Statistical analyses were made by 
correlation regression (with r below representing correlation coefficient), rel-
ative risk (RR) calculation and Chi-square test whereas comparison between 
the two groups was made by t test.
Results: The occurrence rate of hypoglycaemia, asymptomatic hypoglycae-
mia and nocturnal hypoglycaemia is respectively 37.23% or 427 cases,22.75% 
or 261 cases, and 18.31% or 210 cases. Among 965 person-times showing 
hypoglycaemia, 60.8% or 697 person-times were asymptomatic whereas 
49.2% or 470 person-times showed nocturnal hypoglycaemia. 1. MBGs are 
correlated negatively with incidence rates of hypoglycemia on an exponen-
tial curve (r=-0.995, Ye=102.550-0.139X)and negatively with incidence rates of 
nocturnal hypoglycaemia (r=-0.953, Ye=104.135-3.445lgX)and of asymptomatic 
hypoglycaemia(r=-0.963, P<0.01 Ye=103.663-2.718lgX)on a hyperbolic curve. 2. 
The risk occurrence of nocturnal hypoglycaemia during 22:00~2:00 is 1.72 
times that during 2:00~6:00 (RR=1.72,x2=31.667,P<0.01). 3. BGs 3 hours 
after supper are negatively correlated with incidence rates of nocturnal hy-
poglycaemia on an exponential curve (r=-0.955, Ye=103.450-2.627lgX), with the 
limit value of BGs 3 hours after supper for 50% of nocturnal hypoglycaemia 
incidence rates being 4.7mmol/L. 4. For the 479 patients, no significant dif-
ference is found between MBGs of the two groups (8.29±1.98 vs 8.53±2.24, 
t=1.182,P>0.05). The incidence rate of the intervention group is significantly 
reduced in contrast to that of the non-intervention group (9.67% vs 16.76%, 
X2=8.79,P<0.01), with RR=1.7, relative efficiency= 42.43%, X 2=6.16,P<0.05.
Conclusion: 1. Occurrence rates of nocturnal hypoglycaemia in routine clin-
ical environments are high. 2. 22:00~2:00 is the peak period when nocturnal 
hypoglycaemia occurs. 3. The BG 3 hours after supper being ≤4.7mmol/L can 
be used as a quantitative indicator warning of the occurrence of nocturnal 
hypoglycaemia. 4. The occurrence of hypoglycaemia in the non-intervention 
group was 1.7 times that in the intervention group; with interventions to pa-
tients whose BG 3 hours after supper were ≤4.7mmol/L, 40% of them were 
protected from nocturnal hypoglycaemia.
Supported by: CHINA2010NS007
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The impact of nocturnal hypoglycaemia on sleep in subjects  
with type 2 diabetes
S. Madsbad1, N.R. Jørgensen2, R. Rabøl3, P.-L. Chu4, K. Stender-Petersen3,  
P. Jennum5;  
1Department of Endocrinology, Hvidovre Hospital, 2Department of 
Diagnostics, Copenhagen University Hospital Glostrup, 3Novo Nordisk A/S, 
Søborg, Denmark, 4Novo Nordisk Inc., Plainsboro, USA, 5Danish Center for 
Sleep Medicine, Copenhagen University Hospital Glostrup, Denmark.
Background and aims: Nocturnal hypoglycaemia is a major barrier in 
achieving optimal glycaemic control in patients with diabetes. Knowledge 
about the consequences of nocturnal hypoglycaemia on sleep is limited. The 
aim of the present trial was to investigate the impact of nocturnal hypogly-
caemia on sleep pattern.
Materials and methods: In this randomised, single-blinded, two-period, 
cross-over trial, 26 subjects with type 2 diabetes attended two experimental 
night visits (one normoglycaemic and one hypoglycaemic) in randomised 
order to assess the impact of nocturnal hypoglycaemia on sleep (using poly-
somnography) and on hormonal responses. Plasma glucose (PG) levels were 
controlled on the experimental nights by hyperinsulinaemic glucose clamp-
ing. On the hypoglycaemic night, hypoglycaemia was induced when subjects 
had reached sleep stage N2 or deeper by turning off the glucose infusion (PG 
target: 2.7-2.8 mmol/L) for approximately 15 min, after which subjects were 
brought back to normoglycaemia. On the normoglycaemic night, PG was 
maintained at 5-7 mmol/L throughout the night.
Results: There was no difference between the hypoglycaemic night and the 
normoglycaemic night, in either the number of EEG-identified arousals or 
awakenings in the first 4 hours of sleep (0-4h after reaching sleep stage N2). 
During the last 4 hours (4-8h) and during the entire night (0-8h), the number 
of awakenings was significantly lower (p<0.05) on the hypoglycaemic night 
than on the normoglycaemic night (observed geometric means 4-8 h: 10 vs. 
14 awakenings and 0-8h: 25 vs. 30 awakenings). Total sleep time tended to be 
longer on the hypoglycaemic night (observed means: 366 vs. 349 min, p=NS). 
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Statistically significantly higher hormonal counter-regulatory responses 
(adrenaline, growth hormone and cortisol) to hypoglycaemia were observed 
as compared with normoglycaemic night.
Conclusion: Nocturnal hypoglycaemia in patients with type 2 diabetes 
caused a decrease in awakening response following the event. These find-
ings underscore the risks associated with nocturnal hypoglycaemia since 
these events potentially affect the subject’s ability to wake up and respond 
adequately to hypoglycaemia. 
Clinical Trial Registration Number: NCT01780272
Supported by: Novo Nordisk
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Impact of nocturnal hypoglycaemia on the risk of hypoglycaemia the 
next day
G. Reihill, L. Green, S.A. Amiel, P. Choudhary;  
Diabetes Research Group, King’s College London, UK.
Background and aims: In people with type 1 diabetes [T1D], nocturnal 
hypoglycaemia (NH) is reported to occur on about 30% of nights. Fear of 
[NH] can lead to suboptimal glucose control. Antecedent hypoglycaemia, 
including specifically at night, blunts symptomatic and hormonal responses 
to subsequent hypoglycaemia, which may lead to a vicious cycle of recurrent 
hypoglycaemia, ultimately in some patients leading to impaired awareness of 
hypoglycaemia [IAH]. We aimed to study the impact of biochemical NH on 
the risk of subsequent daytime hypoglycaemia [DH], and conversely also the 
impact of antecedent DH on the risk of subsequent NH in adults with T1D 
using continuous glucose monitoring [CGM].
Materials and methods: 172 consecutive CGM traces obtained using 
Medtronic iPRO2 met the following criteria: 48 hours of CGM data starting 
from midnight, ≥ 3 valid calibrations/24 hours, mean absolute error <18. Pa-
tient inclusion criteria included: clinical diagnosis of T1D and not pregnant. 
We defined moderate CGM hypoglycaemia as sensor glucose <3.9mM and 
severe CGM hypo as sensor glucose ≤2.2 mM for at least 20 minutes. Noctur-
nal was defined as 24:00-06:00 hrs.
Results: The cohort providing data was 40% male, mean age 44.75 (±14.54) 
yrs; duration of T1D 18.95 (±13.821) yrs, mean HbA1c 8.1% (±1.30) 
[65±10.2mmol/mol]. 29.8% used continuous subcutaneous insulin infu-
sion [CSII]; 41.0% had IAH. 20.9% of traces had at least one episode of NH 
<3.9mM and 4.7% had at least one episode of NH ≤2.2mM in the 48hrs. 
Risk of mild DH <3.9mM following NH <3.9mM was 48.7% compared to 
43% after no NH<3.9mM [χ² 0.537] giving a relative risk [RR] of 1.13 [95%CI 
0.77 -1.66; p=0.124]. However, 25% of those with severe NH ≤2.2mM had a 
subsequent DH ≤2.2mM, compared to 6.7% risk of severe DH ≤2.2mM after 
no NH ≤ 2.2mM [χ² 0.056] giving a RR of 3.72 [CI 0.99-14.08; p=0.052]. 
Conversely, risk of mild NH <3.9mM after DH <3.9mM was 30.3% vs. 12.5% 
if no DH <3.9mM [χ² 0.004] giving a relative risk of 2.42 [95%CI 1.29-4.54; 
p=0.006]. Risk of severe NH ≤2.2mM after DH 2.2 ≤mM was 6.6% vs. 1.8% 
if no DH [χ² 0.001] giving a RR of 7.34 [CI 1.97-27.33; p=0.003]. Frequency 
of mild NH <3.9 mM was significantly lower in CSII vs. MDI (10% vs. 25%, 
p= 0.047), with less time hypo [14 vs. 52 mins/night]; p= 0.035 mins]. There 
were no significant differences between number or duration of mild DH 
episodes between MDI and CSII, or in number or duration of severe DH 
or NH ≤2.2mM. Frequency of NH was not significantly different between 
normal awareness and IAH [NH <3.9mM 0.29 vs. 0.25 p=0.620; NH ≤2.2mM 
[0.05 vs. 0.06 p=0.824.]. Duration of NH was also not significantly different; 
NH<3.9mM [52 vs. 40 mins; p=0.504], NH≤2.2mM [5 vs. 5 mins; p=0.936].
Conclusion: Mild NH does not increase the risk of mild hypoglycaemia the 
following day, with a trend to increased risk of DH after more severe NH. 
However, both mild and severe DH significantly increases the risk of NH. 
The lack of difference in hypoglycaemia rate using CGM between those with 
impaired awareness and normal awareness needs further research. Our data 
also add to the body of evidence that CSII use is associated with significantly 
reduced frequency and duration of NH. Meanwhile, patients can be advised 
to reduce overnight insulin following episodes of daytime hypoglycaemia.
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Severe hypoglycemia during therapy with sulfonylurea in patients with 
type 2 diabetes (T2D) in Germany/Austria: event rate and identification 
of patients at risk
N. Schloot1,2, A. Haupt1, M. Schütt3, K. Badenhoop4, C. Nicolay5,  
M. Reaney6,7, K. Fink8, R. Holl8, for the German BMBF Competence  
Net Diabetes Mellitus;  
1Medical BU Diabetes, Lilly Deutschland GmbH, Bad Homburg, 2Institute 
for Clinical Diabetology, German Diabetes Center, Heinrich Heine 
University, Düsseldorf, 3Department of Internal Medicine 1, University of 
Lübeck, 4Internal Medicine 1, Division of Endocrinology and Metabolism, 
Goethe University Hospital, Frankfurt am Main, 5Lilly Deutschland GmbH, 
Bad Homburg, Germany, 6Lilly Research Centre, Earl Wood Manor, 
Windlesham, Surrey, 7eResearchTechnology Limited (ERT), Peterborough, 
UK, 8Institute for Epidemiology and Medical Biometry, Ulm University, 
Germany.
Background and aims: We investigated the rate of severe hypoglycemia and 
confounding factors in T2D patients treated with sulfonylurea (SU) in the 
German/Austrian DPV-Wiss-database cohort.
Materials and methods: Data from 29,485 SU-treated patients were analyzed 
(mean (SD) age 69.5(11.5) years, diabetes duration 9.7 (7.6) years, with/with-
out antidiabetic co-medication). Primary objective was to estimate the event 
rate of severe hypoglycemia (defined as requirement for help +/- coma, or 
emergency hospitalization due to hypoglycemia). Secondary objective was 
the identification of confounding risk factors for hypoglycemia through 
group comparison and hierarchical negative binomial regression.
Results: Severe hypoglycemic events were reported in 826 (2.8%) of all SU-
treated patients; n=531 (1.8%) suffered from coma, n=501 (1.7%) were hos-
pitalized at least once. Event rates/year [95%CI] were 0.039 [0.037;0.042], 
0.019 [0.018;0.021] and 0.016 [0.015;0.018]. Unadjusted severe hypoglycemia 
rates for different treatment groups were 0.074 (SU + insulin), 0.038 (SU + 
insulin + other oral antidiabetic agents [OaD]), 0.027 (SU + other OAD), 
0.042 (SU only). Patients with severe hypoglycemia were older (p<0.0001) 
and had longer diabetes duration (p=0.0195). In regression analysis, severe 
hypoglycemia was associated with lower HbA1c and with the frequency of 
mild hypoglycemic events (all p<0.0001). Lower eGFR was associated with 
an increased rate of severe hypoglycemia (>60ml/min: 3.9% of all patients 
with SU; 30-60ml/min: 4.8%; ≤30ml/min: 7.7%). Indirect measures of insulin 
resistance such as increased BMI, plasma triglycerides and participation in 
educational diabetes program were associated with less frequent severe hy-
poglycemia (all p≤0.0002).
Conclusion: Our analysis of real-life data showed a higher risk for severe 
hypoglycemia in older patients, in patients reporting more non-severe hy-
poglycemia and in patients with decreased eGFR, suggesting that treatment 
with SU in those patients should be considered with caution.
Supported by: Lilly Deutschland GmbH
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High prevalence of silent hypoglycaemic episodes among patients with 
well-controlled type 2 diabetes mellitus treated by sulfonylureas
G. Simonyi1, R. Gasparics1, Á. Hegedűs1, G. Csitári1, R. Kollár1, P. Kempler2;  
1Metabolic Center, St Imre Teaching Hospital, 21st Department of Internal 
Medicine, Semmelweis University, Budapest, Hungary.
Background and aims: Hypoglycaemia is a well known cardiovascular risk 
factor. The aim of this study was to determine the prevalence of silent hy-
poglycaemic episodes among patients with well-controlled type 2 diabetes 
treated with sulfonylurea.
Materials and methods: 10 type 2 diabetic patients (7 men, 3 women) with 
HbA1c ≤7% treated with sulfanylurea and/or metformin without symptoms 
of hypoglycaemia during the past two years were included in the study (mean 
age: 71±10, mean duration of diabetes mellitus 11±9 years, mean HbA1c: 
4.9±0.9%). A 120-h long (5 days) glucose monitoring was performed using 
a Continuous Glucose Monitor System (CGMS) device (Medtronic iPro2®). 
Moreover, patients were asked to record four self-monitored capillary blood 
glucose levels each day for calibration of the monitor and also to record meal 
times, exercise and symptoms of hypoglycaemias. According to EASD/ADA 
recommendation a glucose concentration of ≤3.9 mmol/l can be used as a 
cut-off value in the classification of hypoglycaemia. The number of hypogly-
caemic events ≤3.9 mmol/l and, additionally, the number of hypoglycaemic 
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events <3.1 mmol/l were determined. An event was defined as a glucose value 
that persisted for at least 15 minutes with or without symptoms.
Results: Ten patients were each monitored for an average of 5757.0±1192 
min. The mean interstitial glucose (IG) concentration was 6.10±0.56 mmol/l. 
The minimum IG was 2.2 mmol/l and maximal IG concentration was 13.3 
mmol/l. 7/10 patients had a total number of 30 silent hypoglycaemic episodes 
(interstitial glucose ≤3.9 mmol/l), mean: 4.6±2.6 episodes per patients. The 
total duration of these hypoglycemic episodes was 374.5±462.97 min. 5/10 
patients had hypoglycaemic episodes of interstitial glucose ≤3.1 mmol/l. The 
numbers of episodes were 2.0±0.7 per patient. The total number of episodes 
was 9. The total duration of hypoglycemic episodes with glucose values ≤3.1 
mmol/l was 96.0±156.55 min. No symptoms of hypoglycemia were recorded 
by any patient in their daily diaries. CGMS measurements were generally well 
tolerated.
Conclusion: Our data suggest that silent hypoglycemia is quite common in 
well-controlled patients with type 2 diabetes treated with a sulfonylurea with 
or without metformin. It should be noted that glycemic control of our pa-
tients was overly normal. Nonetheless, as a key finding, in our small cohort 
of patients all episodes of hypoglycaemia were silent. CGMS might serve as a 
useful clinical tool to discover silent hypoglycemia.
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In case of physical activity performed just after lunch, what is the best 
option to reduce the risk of hypoglycaemia in case of pump therapy: 
basal rate or bolus reduction?
S. Franc1, M.-H. Petit2, A. Daoudi2,1, A. Pochat2,1, C. Simon3, H. Laroye2,  
L. Boursiquot1, E. Pussard4, C. Petit2, P. Dupont1, F. Koukoui1,  
G. Charpentier1;  
1CHSF, Corbeil, 2CERITD, Evry, 3CHU of Lyon,  
4CHU of Bicêtre, Kremlin-Bicêtre, France.
Background and aims: In T1 diabetic subjects on pump therapy, there is no 
consensus regarding the adjustment of insulin doses in the event of physical 
activity (PA) just after a meal. The aim of our study was to determine what 
was the best attitude in such a situation between reducing the basal rate (BR) 
of the pump (BRR) or the prandial bolus (PBR) to limit the risk of hypogly-
cemia.
Materials and methods: 20 patients (11 men, BMI 24±5kg/m2, age 45±12 
yrs, HbA1c 7.9±0.7%, diabetes duration 17.6±10 yrs, on pump therapy for 5 
years, practicing 4.3 hrs/wk of PA) performed 2 physical activity sessions (30-
min cycling sessions) 90 min after lunch in a random order, at 50%VO2max, 
one with bolus reduction (PBR) of 30/50%, the other one with basal rate 
(BRR) reduction of 50/80% (during PA+2hrs). Blood glucose (BG) levels 
were measured during the exercise period and over the following 2hrs.Pa-
tients wore an iPro2 device from lunchtime until breakfast the next day. We 
focused on the occurrence of hypoglycemic events recorded on the CGM 
system.
Results: CGM level at lunchtime did not differ between both groups but was 
higher after lunch, in case of PBR vs BRR, as was glucose level just before 
exercising [221 ± 62 vs 171 ± 59 mg/dl]. The mean decrease in glucose value 
was similar in PBR vs BRR (BG = -71 vs -77 mg/dl, CGM = 42.1 vs 34.4). 
After the initial drop, the average glucose level remained stable during the 
afternoon, at a higher level in case of PBR vs BRR. Total glucose AUC and 
time spent in [70;180 mg/dl] did not significantly differ in both cases but less 
time was spent >180 mg/dL (p=0.057) in case of PBR compared to BRR. Only 
1 hypoglycemia occurred during PA (BRR). During the afternoon, there was 
a trend towards less hypoglycemic events in case of PBR vs BRR (3 events in 
3 patients vs 10 in 6, p=0.07) with a mean number of events 3.5 times lower 
(0.16 ± 0.37 vs 0.56 ± 0.92). There was no significant hyperglycemic rebound 
before dinner in both cases and no significant difference in the CGM level 
at bedtime (176 ±79 mg/dl vs 160±85, p=NS). The average glucose level re-
mained stable and at a similar level at night in both cases. There was no differ-
ence in the timing and in the level of nocturnal nadir between PBR and BRR 
[77 ± 35 vs 77 ± 34 mg/dL, p=NS]; no differences were observed in the total 
AUC, the time spent in or out the range [70;180] or [80;140]. At night, the 
number of hypoglycemic events did not differ in case of PBR vs BRR (7 events 
in 5 patients vs 10 events in 7 patients, p=0.39) and the mean number did not 
significantly differ (0.37 ± 0.68 vs 0.56 ± 0.86). There was no hyperglycemic 
rebound the next morning, even in case of hypoglycemia at night.
Conclusion: In case of PA 90 min after a meal, PBR led to a higher sustain-
able glucose level in the afternoon than in case of BRR, limiting therefore 
the risk of hypoglycemia. PBR can thus be considered as the security option 
while BRR would lead to a lower glucose level and potentially to an increased 
risk of hypoglycemia. However, in both cases the practice of PA will first lead 
to an initial drop in glucose level of around 70 mg/dL. If a BRR strategy is 
choosen, then the BRR should be anticipated at least 30 min earlier to limit 
the risk of hypoglycemia.
Clinical Trial Registration Number: NCT01277965
Supported by: EFSD, Medtronic
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Effects of automatic insulin pump interruption and bedtime glucose 
levels on nocturnal hypoglycaemic events in the ASPIRE In-Home Study
D. Klonoff1, A. Ahmann2, S. Garg3, R. Slover3, T. Bailey4, B. Bode5,  
J. Thrasher6, R. Brazg7, F. Schwartz8, M. Mao9, R. Weiss10, ASPIRE In-Home 
Study Group;  
1Mills-Peninsula Health Services, San Mateo, 2Oregon Health and Sciences 
University, Portland, 3University of Colorado Denver, Aurora, 4AMCR 
Institute, Inc., Escondido, 5Atlanta Diabetes Associates, 6Arkansas Diabetes 
and Endocrinology Center, Little Rock,  7Rainier Clinical Research Center, 
Renton, 8Ohio University, Athens, 9Medtronic Diabetes, Northridge, USA, 
10Human Metabolism and Nutrition, Hebrew University, Jerusalem, Israel.
Background and aims: The ASPIRE In-Home Study was designed to evalu-
ate the Threshold Suspend (TS) feature of sensor-augmented pump (SAP) 
therapy, which automatically interrupts insulin delivery at a pre-set sensor 
glucose (SG) threshold. We evaluated the risk of nocturnal hypoglycemia 
(NH) with regard to bedtime sensor glucose (SG) values and use of the TS 
feature.
Materials and methods: Nocturnal hypoglycemia (NH) was defined as an 
event lasting >20 min with SG values ≤65 mg/dL that started between 10:00 
PM and 8:00 AM. Subjects with type 1 diabetes with ≥2 NH episodes during a 
2-week run-in phase were eligible. A total of 247 patients were randomized to 
SAP therapy with the TS feature (TS group, n=121) or without the TS feature 
(Control group, n=126). During the 6-month study phase, each patient-night 
was classified according to the patient’s treatment group assignment and the 
10:00 PM (“bedtime”) SG value. Four categories of bedtime SG values were 
defined as <100 mg/dL, 100-150 mg/dL, 150-200 mg/dL, and >200 mg/dL. 
The percentage of nights with a NH event was calculated for the TS and Con-
trol groups within each bedtime SG value category.
Results: The figure shows the percentage of nights with a NH event according 
to treatment group and bedtime SG value, and the number of patient-nights 
in each SG category. Higher bedtime SG values tended to decrease the risk 
of NH in the Control group (p<0.001 for trend) and in the TS group (p=0.01 
for trend). Subjects in the TS group who had bedtime SG values <100mg/dL, 
100-150 mg/dL, or 150-200 mg/dL were significantly less likely to experi-
ence a hypoglycemic event later that night than subjects in the Control group 
with similar bedtime SG values (p<0.001 for bedtime SG values <150 mg/dL; 
p=0.02 for bedtime SG values 150-200 mg/dL). For bedtime SG values <100 
mg/dL, the TS group’s percentage of nights with a hypoglycemic event was 
31% less than in the Control group, and 25% less for bedtime SG values of 
100-150 mg/dL. When the bedtime SG value was >200 mg/dL, the difference 
between the groups was not significant.
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Conclusion: In subjects with type 1 diabetes and bedtime SG values <200 
mg/dL, use of the TS feature was associated with a lower risk of nocturnal 
hypoglycemic events.
Supported by: NCT01497938
PS 044 Endocrine control  
of glucose tolerance
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Association of low normal TSH levels and increment of TSH levels 
with the development of metabolic syndrome; a 6-year retrospective, 
longitudinal study
S. Oh, J. Jun, S.-M. Jin, M.-K. Lee, M.-S. Lee, J. Kim, K. Hur;  
Samsung Medical Center, Seoul, Republic of Korea.
Background and aims: Many cross-sectional studies have showed an in-
creased association with metabolic syndrome (MetS) in the subjects with 
higher TSH levels in subjects with euthyroid (0.3-6.5mU/l) and subclinical 
hypothyroid (6.5-10mU/l). However, little is known about the relationships 
between TSH levels and development of MetS in a longitudinal study. We in-
vestigated the associations of baseline TSH levels or increment of TSH levels 
with new-onset MetS in subjects with euthyroid and subclinical hypothyroid.
Materials and methods: We retrospectively analyzed the medical records of 
23717 subjects (13989 men and 9728 women, age 18 to 89 years) who un-
derwent health screening annually or biennially from 2006 to 2012 at our 
Medical Center (Seoul, Republic of Korea). After exclusion of the subjects 
with abnormal value of T4 or fT4 and subjects with MetS at baseline, we se-
lected 19823 subjects (13989 men and 9728 women). We divided the subjects 
into 3 groups by baseline TSH levels as follows; low-normal TSH group (0.3-
2.5mU/l), high-normal TSH group (2.5-6.5mU/l)and subclinical hypothy-
roid TSH group (6.5-10mU/l). We also divided the subjects into two groups 
by changing TSH levels from baseline to last visit (increasing TSH group; the 
ratio of last TSH/initial TSH ≥ 1, decreasing TSH group; the ratio of last TSH/
initial TSH < 1).
Results: By using a Cox proportional hazard models, the groups by baseline 
TSH level sand the groups by a change of TSH levels, were analyzed for time 
to the development of MetS after adjustment of age, smoking, body mass in-
dex, systolic and diastolic blood pressure, lipid profile, fasting blood glucose 
and hemoglobin A1c. Compared to high-normal TSH group and subclinical 
hypothyroid group, the prevalence of new-onset MetS was higher among sub-
jects with low-normal TSH group after adjustment (p<0.001) in men, but not 
women. Compared to decreasing TSH group, increasing TSH group had an 
increased hazard ratio of 1.26 (95% confidence interval, 1.19-1.35, p<0.001) 
in men and 1.23 (95% confidence interval, 1.09-1.37, p<0.001) in women.
Conclusion: In contrast to the cross section study, the low-normal TSH levels 
(0.3-2.5mU/l) may be a risk for development of MetS in men, and increment 
of TSH levels also could be a independent risk for new-onset MetS in men 
and women.
651
Glucose intolerance and diabetes in patients with new onset Graves’ 
hyperthyroidism
X. Li, Y. Ling, Z. Lu, X. Gao;  
Department of Endocrinology and Metalolism, Zhongshan Hospital,  
Fudan University, Shanghai, China.
Background and aims: Overt thyrotoxicosis is associated with reduced insu-
lin sensitivity (IS) and beta cell function, the prevalence and characteristics 
of diabetes and impaired glucose regulation (IGR) in patients with Graves’ 
hyperthyroidism is still unknown in Chinese. This study is to evaluate the 
glucose homeostasis in patients with Graves’ hyperthyroidism and the asso-
ciations with thyrotropin levels.
Materials and methods: From 2012 to 2014, a total of 278 patients with new 
onset Graves’ hyperthyroidism without anti-thyroid therapy were enrolled 
from the department of endocrinology of our university. The oral glucose 
tolerance test (OGTT) was performed to measure the levels of fasting and 
2-hour postprandial blood glucose (FBG and 2hPG) levels. In addition, the 
glycosylated hemoglobin (HbA1c) and thyroid hormones levels were also 
measured. Analyses were performed with SPSS software version 13.0.
Results: Among the 278 patients with Graves’ hyperthyroidism, 82 cases is 
male (29.5%), and 196 cases were female (70.5%), with an average age of 45.4 
years. There were 148 cases (53.2%) with normal glucose tolerance (NGT), 88 
cases (31.7%) with IGR and 42 cases (15.1%) with diabetes. The T3(P < 0.05) 
and FT3(P < 0.01)levels were significantly higher in patients with diabetes 
than with NGT, after adjusting for sex, age and BMI. By the tertile groups 
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of fT3, the levels of FBG(P<0.05),2hPG(P<0.01),HbA1c(P<0.05)in the 3rd 
tertile group were significantly higher than the 1st tertile group, after sex, 
age and BMI were adjusted. The levels of FBG(r=0.24,P=0.05)were positively 
correlated with serum fT3 levels,and 2hPG were positively correlated with 
serum T3,T4,FT3 levels(r=0.30,P=0.01; r=0.28,P =0.02; r=0.30,P =0.02, re-
spectively). Multivariate linear regression model showed that only BMI was 
independently associated with FBG, but BMI and fT3 were both indepen-
dently associated with 2hPG in these patients. Logistic regression model 
showed that BMI(OR=1.26, 95% CI 1.00-1.60,P=0.05),fT3(OR=1.53, 95% 
CI 1.06-2.21,P=0.03)were the independent risk factor of diabetes in patients 
with Graves’ hyperthyroidism.
Conclusion: The patients with Graves’ hyperthyroidism had a high percent-
age of abnormal glucose homeostasis, including IGR and diabetes. Thyroid 
hormone was closely related to glucose homeostasis, BMI and fT3 were the 
independent risk factor for 2hPG and diabetes in the patients with Graves’ 
hyperthyroidism.
652
Association between lower normal free thyroxine concentrations and 
obesity phenotype in healthy euthyroid subjects
E. Mo, E. Kim, J. Shin, S. Moon, J.-H. Han, Y.-B. Ahn, H.-S. Son;  
The Catholic University of Korea, Seoul, Republic of Korea.
Background and aims: We investigated whether thyroid function could 
identify obesity phenotype in euthyroid subjects.
Materials and methods: A cross-sectional analysis was performed among 
non-diabetic, euthyroid subjects. We stratified subjects into four groups by 
BMI and insulin resistance (IR), defined by a HOMA-IR in the top quartile.
Results: Of 6241 subjects, 33.8% were overweight or obese (OW/OB) and 
66.2% were normal weight (NW). Free thyroxine (FT4) levels were negatively 
associated with body mass index, waist circumference, triglyceride, c-reactive 
protein and HOMA-IR and positively with high-density lipoprotein choles-
terol in both genders. In multivariate regression analysis, FT4 level, a con-
tinuous measurement, was negatively correlated with HOMA-IR (β = - 0.155, 
P < 0.001 in men; β = - 0.175, P < 0.001 in women). After adjustment for age, 
sex, metabolic and life style factors, subjects in the lowest FT4 quartile had 
an odds ratio (OR) for IR of 1.99 (95% confidence interval1.61-2.46), as com-
pared to those in the highest quartile. The association between low FT4 and 
IR remained significant in both NW and OW/OB subgroups.
Conclusion: Low normal FT4 levels were independently related to IR in NW 
and OW/OB euthyroid subjects. Further studies are needed to investigate 
the mechanisms by which low FT4 levels are linked to high IR in euthyroid 
ranges.
653
Exogenous glucagon decreases IGF-I bioactivity in humans, 
independently of insulin levels, by modulating its binding proteins
Z. Sarem1,2, C. Bumke-Vogt2, B. Assefa1,3, M.O. Weickert4,5, A. Adamidou1, 
V. Bähr1, J. Frystyk6, M. Möhlig1, J. Spranger1,3, A.F.H. Pfeiffer1,2,  
A.M. Arafat1,2;  
1Department of Endocrinology, Diabetes and Nutrition, Charité-University 
Medicine Berlin, 2Department of Clinical Nutrition, German Institute 
of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, 3Department of 
Endocrinology, Diabetes and Nutrition at the Center for Cardiovascular 
Research (CCR), Charité-University Medicine Berlin, Germany, 
4Warwickshire Institute for the Study of Diabetes, Endocrinology and 
Metabolism, University Hospitals Coventry and Warwickshire NHS 
Trust, Coventry, 5Division of Metabolic & vascular Health, Warwick 
Medical School, University of Warwick, Coventry, UK, 6Medical Research 
Laboratory, Institute of Clinical Medicine, Faculty of Health, Aarhus 
University, Denmark.
Background and aims: The mechanisms underlying glucagon-induced 
growth hormone (GH) release are unclear. Our goal was to identify the role 
of glucagon-induced changes in IGF-I bioactivity as a possible mechanism, 
excluding changes in insulin as known major confounder.
Materials and methods: In our double-blind placebo-controlled study, we 
investigated changes in GH, IGF binding proteins (IGFBPs) and IGF-I bio-
activity, determined using the cell-based KIRA-method, after intramuscular 
glucagon administration in 13 patients with type-1 diabetes mellitus (T1DM; 
6 males; [BMI]: 24.8 ± 0.95 kg/m2), 11 obese participants (OP; 5/6; 34.4 ± 1.7 
kg/m2), and 13 healthy lean participants (LP; 6/7; 21.7 ± 0.6 kg/m2). In vitro, 
the impact of glucagon on forkhead box transcription factor O1 (FOXO1), 
an important modulator of IGFBP-1, was further investigated using human 
osteosarcoma cells (U-2OS) that were transfected with pEGFP-FOXO1 and 
visualized by fluorescence microscopy.
Results: Glucagon significantly decreased IGF-I bioactivity in all groups (P< 
0.01), despite unchanged total IGF-I and IGFBP-3 levels, whereas significant 
increases in IGFBP-1 and IGFBP-2 were observed (P< 0.01). In contrast to 
the transient increase in insulin levels in OP and LP, no change was observed 
in T1DM. As expected, glucagon induced a surge in GH in all subjects. In vit-
ro, significant nuclear FOXO1 translocation was induced dose-dependently 
by glucagon.
Conclusion: Glucagon decreased IGF-I bioactivity in humans independently 
of endogenous insulin levels, likely through modulation of IGFBP-1 and-2 
levels. The increased FOXO1 nuclear translocation may explain glucagon-
mediated up-regulation of IGFBP-1. The glucagon-induced reduction in 
IGF-I bioactivity may represent a novel mechanism, underlying the impact 
of glucagon on GH secretion.
Clinical Trial Registration Number: NCT00929812
Supported by: DFG GK1208
654
Elevated level of serum leptin is associated with reduced insulin 
secretion in Bangladeshi impaired fasting glucose subjects
M. Hasan, I.A. Hossain, L. Ali;  
Biochemistry and Cell Biology, Bangladesh University of Health Sciences 
(BUHS), Dhaka, Bangladesh.
Background and aims: Leptin is an important adipose tissue-derived hor-
mone that has been shown to be involved in pathophysiological mechanisms 
related to cardiovascular disease and diabetes. However, few studies have ex-
amined the association between serum leptin and reduced insulin secretion 
in IFG subjects. Therefore, we explored the association of serum leptin with 
beta cell dysfunction in IFG subjects.
Materials and methods: Under a cross-sectional analytical design a total of 
65 participants, aged 35-68 years consisting of 47.7% (n=31) IFG (21 male & 
10 female) and 52.3% (n=34) healthy Controls (19 male & 15 female) were 
recruited for the study. Each participant underwent an oral glucose tolerance 
test and completed a questionnaire. Anthropometric indices were recorded 
and serum samples were collected for measurement. Serum leptin and in-
sulin were measured by enzyme immunoassay. Insulin secretory function 
(HOMA%B) and insulin sensitivity (HOMA%S) were calculated from fast-
ing serum glucose and fasting serum insulin values by Homeostasis Model 
Assessment (HOMA) using HOMA-CIGMA software.
Results: Serum leptin levels [Median (range) 16.43 (2.66-42.17) vs. 6.39 
(3.03-29.54) (ng/ml), p<0.001] was significantly higher in IFG group com-
pared to the Control. HOMA%B [97 (51-163) vs. 142 (61-375), p<0.001] 
was significantly lower in IFG group compared the Control. On Pearson cor-
relation analysis leptin showed significant positive correlation with gender 
(r=0.417, p=0.019) and significant negative correlation with age (r=-0.545, 
p=0.002) and HOMA%B (r=-0.359, p=0.048) in IFG subjects. In multi-
ple linear regression analysis leptin showed significant positive association 
with gender (β=0.396, p<0.001) and IFG group (β=0.418, p-0.010) however 
it showed significant negative association with age (β=-0.157, p=0.022) and 
HOMA%B (β=-0.104, p=0.049) after adjusting the major confounders (BMI 
and HOMA-IR). In binary logistic regression analysis age, gender, leptin and 
HOMA%B are independent determinants of IFG [age OR (95% CI): 1.14 
(1.01-1.29), p=0.032, gender OR (95% CI): 0.061 (0.006-0.654), p=0.021, lep-
tin OR (95% CI): 1.33 (1.13-1.58), p=0.001 and HOMA%B OR (95% CI): 0.93 
(0.90-0.97), p=0.001] after adjustment of BMI.
Conclusion: Higher serum leptin levels are independently associated with 
insulin secretory dysfunction in IFG subjects. Thus, leptin may represent use-
ful biomarkers for predicting the onset of glucose intolerance in Bangladeshi 
adults.
Supported by: BUHS
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The relationship between vitamin D and hypogonadism in patients with 
type 2 diabetes mellitus
H. Dogan1, G. Sargin2, E. Harman3;  
1Department of Internal Medicine, Bozyaka Training and Research Hospital, 
Izmir, 2Department of Internal Medicine, Canakkale State Hospital, 
Canakkale, 3Division of Endocrinology and Metabolism, Yesilyurt Training 
and Research Hospital, Izmir, Turkey.
Background and aims: Association has been reported between abnormal 
glucose metabolism, serum vitamin D levels and gonadal dysfunction. 25 
(OH) D levels are lower in patients with Type 2 diabetic male patients com-
pared with non-diabetic male patients. Type 2 diabetic patients were sepa-
rated into three groups according to vitamin D levels (<20 ng / ml, 20-29.9 
ng / ml and ≥ 30 ng / ml) and the relationship between vitamin D levels 
and insulin, c-peptide, fasting blood glucose, postprandial blood glucose, 
HOMA-IR, HbA1c, body mass index, FSH, LH, total testosterone levels were 
investigated.
Materials and methods: Fasting and postprandial blood glucose values were 
analyzed by enzymatic colorimetric method with Roche cobas 8000 brand 
device. HbA1c levels were analyzed by HPLC affinity boranate method with 
Premier Hb9210 trinity BioTec. And, insulin, C-peptide, FSH, LH, total tes-
tosterone, vitamin D levels were determined by kemiluninessans method 
with Beckman Coulter DXi 800. Kruskal Wallis H and Mann Whitney U tests 
used for statistical analysis, and <0.05 was considered as statistically signifi-
cant.
Results: There is statistically significant difference between HbA1c groups 
and the distribution of BMI, HOMA-IR, vitamin D, fasting and postpran-
dial blood glucose, C-peptide values (p<0,05). Total testosterone levels were 
found statistical significantly lower in the patients with vitamin D level <20 
ng/ml than vitamin D level 20-29.9 ng/ml and ≥30 ng/ml) (Table 1)(p <0.05). 
There is positive correlation between the level of vitamin D and total testos-
terone, and negative correlation between the level of FSH, LH and total tes-
tosterone. Vitamin D values were statistical significantly lower in the patients 
with HbA1c ≥10% than HbA1c: <6.5%, 6.5-8% and 8-10% (p <0.05).
Conclusion: 25 (OH) D levels should be evaluated in the patients with type 2 
diabetes mellitus associated with hypogonadism. Also, it is emphasized pos-
sible detection of vitamin D deficiency and replacement simultaneously.
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Betatrophin, a novel potential biomarker of beta cell function in diabetes 
R. Lupi1, S. Del Guerra2, P. Ursoleo2, C. Bianchi1, S. Del Prato2;  
1Medical Area, 2Clinical and Experimental Medicine, Metabolic Unit,  
Pisa, Italy.
Background and aims: Betatrophin was recently described as a potent stim-
ulator of beta cell proliferation in mice. However, information is scanty with 
respect to the behavior of this hormone in metabolic disorders in human be-
ings. Therefore, we have measured serum betatrophin levels in non-diabetic 
(ND), type 1 (T1DM), transplanted T1DM (TX) and type 2 (T2DM) diabetic 
patients. Moreover, since betatrophin is located in the corresponding intron 
of DOCK6, we have explored associations with the DOCK6 single nucleotide 
polymorphisms rs1541922 (SNP, C/T).
Materials and methods: We recruited 18 ND (49±18 yrs; 8M/10F; BMI 
25.4±0.7 kg/m2), 17 T1DM (47±9 yrs; 7M/10F; BMI 24.2±1.4 kg/m2), 14 TX 
(44±3 yrs; 5M/9F; BMI 21.2±2.2 kg/m2) and 33 T2DM (63±15 yrs; 18M/15F; 
BMI 28.5±4.7 kg/m2). Betatrophin levels were determined by an ELISA tech-
nique, C-peptide by an IRMA method, and DOCK6 SNP was genotyped us-
ing TaqMan Allelic Discrimination Assays on DNA from circulating blood 
cells.
Results: In the population as a whole, betatrophin levels were inversely as-
sociated with age (p=0.0009, r=0.612), triglyceride (p=0.032, r=0.418) and 
total cholesterol (p=0.049, r=0.378) concentrations, while a direct correlation 
was apparent with HDL levels (p=0.0035, r=0.542). When T1DM subjects 
were excluded from the analysis, betatrophin correlated with C-peptide con-
centration (p=0.026, r=0.421). Betatrophin was significantly higher in T1DM 
(892.7±84.59 pg/ml) and significantly reduced in T2DM (153.54±21.32 pg/
ml) as compared to ND (440.7±46.46, pg/ml; all p<0.05, Bonferroni’s test). 
In TX, betatrophin concentration returned to levels similar to those of ND 
(533.65±44.03 pg/ml). In the whole study population CC, CT and TT geno-
type frequency was 0%, 53% and 47%, respectively. Interestingly, with the 
exception of T2DM, the presence of the C allele in single copy was associated 
with a marked increase in betatrophin concentration (ND TT=268.9±11.6 
and CT=386.15±47.13; T1DM TT=818.14±9.9 and CT=1043.33±89.33; TX 
TT=449.73±46.95 and CT=785.4±9.23; all p<0.05 or less).
Conclusion: The correlation between betatrophin levels and C-peptide 
concentrations, together with normalization of betatrophin in TX patients, 
supports a role of the hormone in the maintenance of beta-cell function. 
Whether betatrophin may provide a useful biomarker of beta cell function 
(or mass), however, will require further investigation. Also, a potential modu-
lating effect of DOCK6 genotype remains to be fully explored.
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Hypothalamic-pituitary-adrenal axis dysfunction in 
streptozotocin(STZ)-diabetic rats: effect of lipoic acid and α-tocopherol 
treatment
P. Arias1, E.M. Repetto2, A.L. Bonelli2, S. Rocío2, M.E. Mercau2,  
C.B. Cymeryng2;  
1Chair of Human Physiology, University of Rosario Medical School, 
2Department of Biochemistry, University of Buenos Aires Medical School-
CEFYBO-CONICET, Argentina.
Background and aims: Glucocorticoid release is involved in glucose coun-
terregulation, and a diminished or absent adrenocortical function renders 
non-diabetic as well as insulin-treated diabetic subjects prone to hypogly-
cemia. We previously demonstrated that STZ-diabetic rats show increased 
basal, but markedly reduced ACTH-stimulated corticosterone (CS) levels. 
Present experiments, performed in STZ-diabetic rats receiving lipoic acid 
(LA) or α-tocopherol (aT) treatment, were designed 1) to evaluate the effect 
of these treatments on oxidative stress parameters, on nitric oxide synthase 
(NOS) activity, and on steroidogenic function of the adrenal cortex of STZ-
treated rats, and 2) to test the hypothesis that STZ-induced oxidative stress 
might modify CS release by affecting pituitary ACTH secretion.
Materials and methods: Male Wistar rats (220-240g) were randomly as-
signed to the following groups: CON (control), STZ (2 injections of 40 mg/
kg STZ separated by 48 h), LA (90 mg/kg ip every 48 h), aT (200 mg/kg/d 
po), STZ-LA or STZ-aT. LA, aT or vehicle were initiated immediately after 
the confirmation of hyperglycemia. After 4 weeks, all animals were sacrificed. 
Oxidative stress parameters and NOS activity, as well as the expression levels 
of CYP11A1, a key steroidogenic enzyme, and of the ACTH receptor MC2R 
were evaluated by RT-qPCR in the adrenal cortex. Plasma ACTH and serum 
CS levels (basal and ACTH-stimulated) were measured by RIA. After nor-
mality testing a one-way ANOVA was used for statistical evaluation.
Results: STZ rats displayed elevated basal CS levels, and a diminished CS 
response to ACTH injection. Antioxidants decreased CS levels to those ob-
served in controls (CON: 7.3 ± 2.5*, STZ: 71.7 ± 9.2, STZ aT: 5.8 ± 3.4*, 
STZ-LA: 19.1 ± 5.5* ng/ml; *p<0.001 vs STZ), and restored the defective re-
sponse to ACTH. Lower basal ACTH levels were detected in STZ animals; 
neither LA nor aT had an impact on these changes. At the adrenal level, both 
drugs precluded the increase in TBARS and carbonyl content, and in the ex-
pression levels of catalase and heme oxygenase-1 detected in STZ rats. Both 
antioxidants also prevented the increase in NOS activity detected in diabetic 
animals (CON: 88.5 ± 0.5*, STZ: 216.7 ± 9.2, STZ-aT: 108.6 ± 7.4* and STZ-
LA: 117.4 ± 16.8* pmol/min/mg protein; *p<0.01 vs STZ), and corrected the 
down-regulation of MC2R expression observed in the STZ group. CYP11A1 
mRNA levels were not affected by any of these treatments.
Conclusion: Our results show that, in STZ-diabetic rats, generation of ox-
idative stress is associated with an increased activity of the adrenocortical 
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NO generating system, a known negative modulator of CS release. Systemic 
antioxidant treatment not only normalized oxidative stress parameters and 
NOS activity, but also corrected the observed effects of STZ-induced diabetes 
on CS levels. Compared to control animals, STZ-diabetic rats showed lower 
baseline circulating levels of ACTH, probably resulting from exaggerated ba-
sal CS output. Antioxidant therapy restored basal and ACTH-induced gluco-
corticoid release without modifying plasma ACTH levels, further supporting 
the role of local regulatory signals, such as NO, in the dysregulation of adre-
nal steroidogenesis observed in this animal model of diabetes.
Supported by: PICT 2008 N1034
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Progressive reduction in beta cell mitochondrial function leads to 
diabetes
S. Weksler-Zangen1, G. Aharon-Hananel1, A. Kogot-Levin1, A. Saada2,  
I. Raz1;  
1Department of Internal Medicine, Diabetes Unit,  
2Department of Human Genetics and Metabolic Diseases,  
Hadassah University Hospital, Jerusalem, Israel.
Background and aims: Pancreatic β-cells couple glucose stimulated insulin 
secretion (GSIS) with oxidative phosphorylation via the mitochondrial res-
piratory enzyme, cytochrome c oxidase (COX). Emerging evidence suggests 
interplay between mitochondrial dysfunction and the development of diabe-
tes. We investigated the relation between COX activity and GSIS in isolated 
pancreatic islets of Cohen diabetes sensitive rats and the role it plays in dia-
betes development
Materials and methods: Cohen diabetic sensitive and Cohen diabetic resist-
ant rats were maintained on a diabetogenic-diet for periods of 4, 11, 20 and 
30 days. Blood glucose and insulin concentrations were measured before and 
during OGTT performed at different time periods on the diabetogenic-diet. 
Islet-COX activity was determined spectrophotometrically and normalized 
to citrate-synthase (a ubiquitous mitochondrial matrix enzyme).
Results: Islets of normoglycemic Cohen diabetic sensitive rats had 50% of 
COX activity and GSIS compared to islets of Cohen diabetic resistant rats 
supporting the existence of a congenital COX impairment. Following expo-
sure to a diabetogenic-diet, Cohen diabetic sensitive rats exhibited a pro-
gressive increase in blood glucose levels and decrease in GSIS, developing 
overt hyperglycemia within 20 days. The decline in GSIS coincided with a 
significant decrease in islets-COX activity. The reduction in islet-COX activ-
ity positively correlated (R2 = 0.9317) with GSIS and inversely correlated (R2 
=0.760) with blood glucose levels. Cohen diabetic resistant rats maintained 
normoglycemia during the various time periods on diabetogenic-diet and ex-
hibited a partial reduction in GSIS after only 30 days. Islets of Cohen diabetic 
resistant rats retained more than 50% of their baseline islets-COX activity 
after 30 days on diabetogenic-diet while in Cohen diabetic sensitive rats less 
than 20% of islets-COX activity remained.
Conclusion: These results show a link between islets COX activity, reduced 
GSIS and the development of diabetes in the Cohen diabetes sensitive rats. 
On the diabetogenic-diet, COX activity in islets of normoglycemic-Cohen 
diabetes resistant rats was reduced by 50%, while in the hyperglycemic-Co-
hen diabetes sensitive rats the activity was below 20%. Thus, we suggest that 
COX activity needs to be above a certain threshold to sustain adequate β-cell 
function and prevent diabetes development.
Supported by: Lower Saxony, Hannover, Germany and Israeli Science founda-
tion
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Reduced mitochondrial biogenesis in skeletal muscle is associated with 
obese phenotype in androgen receptor deficient mice (ARKO)
K. Kajita1, T. Usui1, Y. Kitada1, K. Taguchi1, I. Mori1, T. Ikeda1, H. Okada1,  
H. Morita1, T. Sasaki2, T. Kitamura2, T. Sato2, T. Ishizuka1;  
1General Internal Medicine, Gifu University Graduate School of Medicine, 
2Institute for Molecular and Cellular Regulation, Gunma University, 
Maebashi, Japan.
Background and aims: Androgen, including dehydroepiandrosterone 
(DHEA) and testosterone, reduces adiposity, although the underlying mecha-
nisms are unknown. Here, we examined the effect of androgen on heat pro-
duction and mitochondrial biogenesis.
Materials and methods: C57/Black male mice at 8 w of age were fed CE2 
powder with (testosterone group) or without (control group) 0.4% testoster-
one ad libitum for 4wk. In addition, we assessed mitochondrial biogenesis in 
ARKO at 8wk and 24wk of age. ARKO was provided by Dr. Shigeaki Kato. O2 
consumption, CO2 production and locomotor activity were measured by in-
direct calorimetry. The expression levels of PGC1α, ATP5B and Cox4 protein 
were measured with western blot. The mRNA expression levels of PGC1α, , 
nuclear respiratory factor-1 (NRF-1), nuclear respiratory factor-1 (NRF-2), 
mitochondrial transcription factor A (Tfam) and cytochrome C,and mito-
chondrial DNA (mitDNA) were evaluated with real time PCR.
Results: Testosterone group exhibited weight reduction, decreased fat mass 
and elevated heat production without reduction of food consumption. Obese 
phenotype was prominent in ARKO at 24wk, but not 8wk, of age. Serum 
testosterone level was elevated up to approximately 12-fold, while it was 
decreased to 10.4% in ARKO. The expression level of PGC1α, ATP5B and 
Cox4 protein in skeletal muscle, but not those in brown adipose tissue (BAT) 
and liver, were elevated in testosterone group, compared with control group, 
whereas they were suppressed in ARKO at 24wk compared with wild type 
littermate. Amount of mitDNA and expression level of mRNA involved mi-
tochondrial biogenesis, such as PGC1α, NRF-1, NRF-2, and Tfam in skeletal 
muscle were increased in testosterone group. Expression levels of these genes 
were reduced in skeletal muscle isolated from ARKO at 24wk, however sig-
nificant reduction was not observed at 8wk, showing that late-onset obesity 
in ARKO is caused by decreased mitochondrial biogenesis in skeletal muscle. 
Treatment with 10 nM testosterone significantly increased mRNA levels of 
PGC1α, NRF-1, NRF-2, Tfam and cytochrome C in C2C12 myotubes, which 
was abolished by flutamide, an AR inhibitor.
Conclusion: These results demonstrate that the testosterone-induced in-
crease in energy expenditure is derived from elevated expression level of 
PGC1α, and subsequent mitochondrial biogenesis in skeletal muscle, but not 
BAT. Therefore, skeletal muscle is the major organ contributing to testoster-
one-induced weight reduction.
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Obese but healthy: Is it really possible?
E. Hamo-Tchatchouang, E. Cosson, S. Chiheb, C. Cussac-Pillegand,  
I. Banu, M. Nguyen, M. Nguyen, P. Valensi;  
AP-HP, Jean Verdier Hospital, Bondy, France.
Background and aims: Patients displaying the metabolically healthy but 
obese (MHO) phenotype have an intermediate cardio-metabolic prognosis 
as compared with normal weight healthy and metabolically unhealthy obese 
(MUO) patients. We aimed to evaluate the prevalence and characteristics of 
definite MHO individuals.
Materials and methods: Definite MHO phenotype was defined as having 
none of the International Diabetes Federation metabolic syndrome criteria 
but waist circumference criterion which is considered as non discrimina-
tory, in 1159 patients including 943 women admitted in stable conditions for 
obesity (body mass index (BMI) 38.4±6.3 kg/m2) without known diabetes. 
Patients were characterized for cardio-metabolic disorders.
Results: The 202 (17.4%) MHO individuals, younger and with lower BMI 
than the 957 MUO patients in the total cohort, were matched for gender, age 
and BMI with 404 MUO patients. In addition to the features of metabolic 
syndrome, the definite MHO patients as compared with the MUO ones were 
fewer with an homeostasis model assessment of insulin resistance index ≥ 3 
(23.6 versus 38.9%, p<0.001), with an abnormal oral glucose tolerance test 
(13.9 versus 23.9%, p<0.001), HbA1c ≥ 5.7% (43.9 versus 54.2%, p<0.05), 
pulse pressure ≥ 60 mmHg (p<0.001) but did not show significant differences 
for the prevalence of microalbuminuria (11.1 vs 12.3%), cardiac autonomic 
dysfunction (45.5 vs 35.3%) and fatty liver index ≥60 (5.6 vs 10.2%).
Conclusion: Our data do not support the characterization of MHO, even def-
inite, as really healthy, as many patients with this phenotype have abnormal 
cardio-vascular markers and glucose or liver abnormalities.
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Automated quantification of brown and white adipose tissue with x-ray 
computer tomography (CT) and 18F-deoxyglucose positron emission 
tomography (FDG/PET)
M.S. Buchsbaum1, A. DeCastro1, L. Morrow2, A. Krentz3, G. Peterson3,  
D. Laurent4, M. Hompesch3;  
1Psychiatry, University of California, 2Profil Institute for Clinical Research, 
3Profil Institute for Clinical Researcj, San Diego, USA,  
4Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background and aims: Brown and white, adipose tissue in the thorax dif-
fer in proportions, locations and their heat generating capability. This study 
uses voxel-by-voxel analysis of CT and coregistered FDG-PET to assess the 
volumes, activity, deposit size, and admixture of tissue type in supraclavicu-
lar, interscapular, and circumcarotid areas. This novel application of image 
analysis methods adapted from brain imaging is evaluated for reliability and 
similarity to imaging fat assessment
Materials and methods: We studied 12 insulin resistant subjects and 2 over-
weight healthy volunteers with FDG-PET/CT of the thorax to assess the glu-
cose metabolic rate (GMR in μmol glucose/100g/min and standard uptake 
value (SUV) of adipose tissue. Subjects were exposed to a 90-min period of 
cold (67F) and warm (73 F) temperature on separate days. FDG-PET images 
were coregistered to a 200 mA CT. Segmented CT masks of 7 Hounsfield unit 
(HU) bands: -160 to -140, -140 to -120, -120 to -100, -100 to -80, -80 to -60, 
-60 to -40, and -40 to -20 were evaluated and compared to muscle and skin 
HU values. CT images had contiguous voxels automatically clustered using 
Analysis of Functional NeuroImages (AFNI) and the series of narrow HU 
unit bands as the criterion. In the -140 to -80 range, the largest supraclavicu-
lar clusters were 10-20 cm3.
Results: Greater cold minus warm differences in adipose tissue GMR than in 
HU defined muscle or skin were confirmed (adipose 0.06>muscle). Signifi-
cant areas of thermogenesis in Hounsfield value defined tissue (-120 to -80) 
were located in 64% of subjects, a percentage similar to that obtained in visual 
inspection studies and a relatively broad band (-160 to -40) range of mean 
thermogenesis was observed. Significantly lower metabolic variation (voxel 
SD within the clusters) was found in supraclavicular clusters at -100 to -80 
HU units and a trend observed for the variation to be higher for the cold than 
warm condition, suggesting a mixture of thermogenic and nonthermogenic 
cells being present. Cluster size and thermogenicity were highly correlated 
(r=0.90 to .98, p<001) across the right and left thorax, consistent with reli-
ability of the voxel clustering approach.
Conclusion: Automated algorithms based on FDG-PET/CT appear valuable 
in the anatomical localization, quantification, and characterization of adipose 
tissue temperature sensitivity. CT/FDG-PET may prove sensitive enough to 
detect pharmacological therapeutic interventions on different adipose tissue 
components. This assay complements measurements of weight, BMI, blood 
insulin measurement and the glucose tolerance test, as well as the sophisti-
cated hyperinsulinemic euglycemic clamp. Fig.CT with CT-based supraclav-
icular clusters (right thorax cerise, left blue)
Supported by: Profil/Novartis
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Adipose tissue depot specific promoter methylation of TMEM18
K. Rohde1,2, M. Keller1, M. Klös1, D. Schleinitz1, A. Dietrich3, M.R. Schön4, 
D. Gärtner4, T. Lohmann5, M. Dreßler5, M. Stumvoll1,2, P. Kovacs1,  
M. Blüher2, Y. Böttcher1;  
1IFB Adiposity Diseases, 2Department of Medicine, 3Department of Surgery, 
University of Leipzig, 4Städtisches Klinikum Karlsruhe, Clinic of Visceral 
Surgery, 5Municipal Clinic Dresden-Neustadt, Germany.
Background and aims: Epigenetic processes such as dynamic promoter 
methylation may play a role in obesity, fat distribution and its accompanied 
metabolic alterations. TMEM18 is a candidate gene for BMI comprising the 
second largest effect size among all loci identified so far via GWAS. We hy-
pothesized that differential TMEM18 gene expression in visceral (VAT) and 
subcutaneous adipose tissue (SAT) may be a consequence of depot specific 
differential methylation at the TMEM18 promoter region. Differential meth-
ylation levels may confer fat depot specific correlations with measures of obe-
sity and fat distribution.
Materials and methods: (i) TMEM18 mRNA expression was measured in 
VAT and SAT from 500 subjects. (ii) We investigated 146 Caucasian individu-
als for differential methylation levels in VAT vs. SAT at three CpG sites. (iii) 
Subsequently, we tested for potential correlation of methylation levels with 
anthropometric and metabolic parameters.
Results: (i) In 500 individuals, we observed significantly decreased mRNA 
expression in SAT (paired t-test, P<0.0001) compared to VAT with strongest 
effects in obese subjects. (ii) We identified significantly higher methylation 
levels for the entire CpG locus in SAT (paired t-test, P=0.00015). In 146 in-
dividuals, we detected positive correlations between CpG methylation levels 
in SAT with parameters of obesity and fat distribution (e.g. BMI, r=0.173; 
P=0.036; visceral fat area, r=0.246; P=0.004) and with metabolic traits (P ≤ 
0.05). However, these correlations did not withstand adjustment for covari-
ates. (iii)
Conclusion: Our data suggest an adipose tissue depot specific TMEM18 
promoter methylation that may mediate inter-depot specific variance in 
TMEM18 mRNA expression.
Supported by: DDG, DDS Foundation, IFB AdiposityDiseases
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A highly potent and specific PPAR alpha agonist, K-877, improves lipid 
profiles and insulin sensitivity in dyslipidaemia subjects; an integrated 
analysis of 3 Phase 2/3 trials
E. Araki1, S. Ishibashi2, S. Yamashita3, H. Arai4, K. Yokote5, H. Suganami6,  
T. Kodama7;  
1Department of Metabolic Medicine, Kumamoto University Graduate 
School of Medicine, 2Division of Endocrinology and Metabolism, Jichi 
Medical University, Tochigi, 3Department of Cardiovascular Medicine, 
Osaka University Graduate School of Medicine, Suita, 4Department of 
Human Health Sciences, Kyoto University Graduate School of Medicine, 
5Department of Clinical Cell Biology and Medicine, Chiba University 
Graduate School of Medicine, 6Clinical Data Science Department, Kowa 
Company, Ltd., Tokyo, 7Laboratory for Systems Biology and Medicine,  
The University of Tokyo, Japan.
Background and aims: K-877 is a specific PPAR alpha agonist with a poten-
tially improved pharmacological profile with respect to efficacy and safety 
compared with other PPAR alpha agonists. In subjects with atherogenic dys-
lipidemia, insulin resistance often co-exist, and as such, the treatments which 
concurrently improve plasma lipoprotein profiles and insulin sensitivity are 
highly demanded. Therefore, this integrated analysis set out to assess retro-
spectively the effect of K-877 on efficacy, safety and measures of insulin resist-
ance over 12 weeks in 3 phase 2/3 trials.
Materials and methods: This is an integrated analysis of two Phase 2 tri-
als (one monotherapy trial and one add-on to stable pitavastatin 2 mg/day 
therapy) and one Phase 2/3 trial (monotherapy). All subjects had hypertri-
glyceridemia and low HDL-C and/or high non-HDL-C. All these were 12 
weeks, randomized, multicenter, double-blinded, placebo controlled trials. 
The efficacy and safety of K-877 0.05, 0.1, 0.2 and 0.4 mg/day (twice daily) 
were examined in all trials.
Results: A total of 676 subjects (K-877; 37, 0.05 mg/day; 127, 0.1 mg/day; 
215, 0.2 mg/day; 172, 0.4 mg/day: placebo; 125) were evaluated in this inte-
grated analysis. The subject baseline characteristics were comparable among 
all groups. From baseline to Week12, a significant reduction in TG and an 
increase in HDL-C were observed for K-877 groups (TG; -40.6 to -52.7%, 
HDL-C; +12.0 to +24.0%, p<0.001 for all). In K-877 groups, the effects on TG 
and HDL-C were similar regardless of baseline HOMA-IR. Favorable effects 
on insulin sensitivity were also observed dose-dependently in K-877 groups 
[fasting plasma glucose (FPG): K-877; +4.62 to -5.53 mg/dL, placebo;+2.95 
mg/dL, fasting plasma insulin(FPI): K-877; -0.87 to -3.36 µU/mL, placebo; 
-0.28 µU/mL, HOMA-IR: K-877; -0.35 to -1.23, placebo;+ 0.01]. The re-
duction of FPG, FPI and HOMA-IR was greater in the subjects with higher 
HOMA-IR. The incidence of all adverse drug reactions in K-877 groups 
were similar to placebo (placebo; 8.0%, 0.05mg/day; 5.4%, 0.1mg/day; 4.7%, 
0.2mg/day; 7.9%, 0.4mg/day; 8.1%). Similar results were observed in the in-
cidence of adverse events including abnormal liver function test, increased 
blood creatine phosphokinase and increased blood creatinine.
Conclusion: In an integrated analysis, K-877 improved lipid profiles and in-
sulin sensitivity without increasing adverse events. K-877 could be a promis-
ing therapy for atherogenic dyslipidemia. The mechanisms how K-877 im-
prove insulin sensitivity should need further investigation.
Clinical Trial Registration Number: JapicCTI-121837(ja), JapicCTI-
121764(ja), JapicCTI-121837(ja)
Supported by: Kowa Company, Ltd.
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Genomic profiling in plasma reveals the effect of a polyunsaturated fatty 
acid-enriched diet on common microRNAs
J.M. Mercader1, F.J. Ortega2, M.I. Cardona-Alvarado3,  
J.M. Moreno-Navarrete2, M. Moreno2, M. Sabater2, N. Fuentes-Batllevell2,  
W. Ricart2, E.L. Pérez-Luque3, J.M. Fernández-Real2;  
1Joint IRB-BSC program on Computational Biology, Barcelona, 
2Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut 
d’Investigació Biomédica de Girona (IdIBGi), Girona, Spain, 3Department 
of Medical Research, Division of Health Sciences, Leon Campus, Mexico.
Background and aims: Consumption of long-chain polyunsaturated fatty 
acids (PUFAs) of omega n-3 and n-6 series, which are abundant in seafood 
and nuts, ameliorate components of the metabolic syndrome, reducing LDL-
cholesterol. Mechanisms responsible for diet-induced LDL reduction are 
likely associated with nutrients provided by these aliments, targeting primary 
routes of LDL reduction and regulating enzymes involved in cholesterol syn-
thesis. Circulating microRNAs (miRNAs) have demonstrated to be valuable 
biomarkers of metabolic diseases. Here, we investigated whether a sustained 
nuts-enriched diet can lead to changes in circulating miRNAs in parallel to 
LDL-cholesterol reduction.
Materials and methods: The profile of 192 common miRNAs was assessed 
in plasma from 10 healthy women before and after an 8-week trial with a 
normocaloric diet enriched in PUFAs (30 g/day of almonds and walnuts). 
The most relevant miRNAs were validated in an extended sample of 30 par-
ticipants (8 men and 22 women).
Results: Concomitantly with decreased body mass index (-3.5%, p<0.0001), 
circulating LDL (-10%, p<0.001), and increased adiponectin (35%, p=0.017), 
circulating concentrations of several miRNAs were modified by treatment, 
including decreased miR 330-3p, miR-328 and miR-221, and increased miR-
769-5p, miR-18a, miR-130b, miR-192, miR-19b, and miR-486-5p (all p<0.05). 
Interestingly, miR-130b (r=0.7, p<0.0001), miR-221 (r=0.44, p=0.03), and 
miR-409 (r=0.6, p=0.001) variations correlated with changes in circulating 
C-reactive protein concentrations, while miR-328 (r=0.5, p=0.01) and miR-
125b (r=0.63, p=0.002) were associated with adiponectin. Noteworthy, diet-
induced changes in circulating miR-486-5p were also associated with dietary 
fatty acids intake (r=0.44, p=0.02), miR-221 variations were inversely associ-
ated with increased dietary omega n-3 (r=-0.5, p=0.01), and modifications 
on circulating miR-192 correlated with dietary omega n-6 (r=0.62, p=0.001).
Conclusion: This study provides the first evidence that circulating miRNAs 
may be modified by polyunsaturated fatty acid-enriched diet and reveals 
their potential relevance in this context.
Supported by: CIBERobn, ISCIII, ACD
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Lysophosphatidylcholines as regulators of gene expression in human 
skeletal muscle
C. Klingler1, M. Wolf1, J. Li2, S. Chen2, X. Zhao2, E. Schleicher3,4,  
H.-U. Häring3,4, G. Xu2, R. Lehmann3,4, C. Weigert3,4;  
1Department of Internal Medicine IV, University Tuebingen, Germany, 
2Dalian Institute of Chemical Physics, Dalian, China, 3German Center 
for Diabetes Research, Tuebingen, 4Institute for Diabetes Research and 
Metabolic Diseases of the Helmholtz Center Munich at the University of 
Tuebingen, Germany.
Background and aims: Lysophosphatidylcholines (LPC) circulating in the 
blood stream recently gained attention as biomarkers for insulin resistance 
and T2DM. It remains to be resolved whether LPC plasma concentrations 
can contribute to the development of insulin resistance. Skeletal muscle might 
represent not only a target for LPC but might be a source of circulating LPC.
Materials and methods: Human Myocytes from biopsies of healthy young 
volunteers were differentiated to myotubes in AlphaMEM with 2% FBS for 5 
days. Myotubes were stimulated for 24 h, 4 h, and 30 min with 13C-labelled 
palmitate (0.250 mM). Afterwards LPC biosynthesis and secretion was quan-
tified by isotope-based LPC profiling. Furthermore, myotubes were stimu-
lated with different concentrations of LPC C16:0 and LPC C18:1 followed 
by transcriptomics analysis, qPCR, siRNA-based knock-down und gel shift 
assays.
Results: In primary human myotubes stimulation with palmitate resulted in 
the synthesis of several LPC species leading to time-dependent intracellular 
accumulation of LPCs. Moreover newly synthesized LPCs were released into 
the extracellular compartment. After stimulation of myotubes with 10 µM 
LPC (16:0) or LPC (18:1) whole genome expression analysis revealed an ac-
tivation of PPARδ-regulated transcripts. qPCR confirmed the induction of 
the PPARδ target genes PDK4 and ANGPTL4 mRNA already at a LPC con-
centration of 1 µM. This induction was attenuated in the presence of siRNA 
against PPARδ. By gel shift assays we could demonstrate that LPCs regulate 
DNA binding activity of the PPARδ/RXRα complex in a dose-dependent 
manner.
Conclusion: Extracellular LPCs can activate PPARδ-dependent gene expres-
sion in human myotubes as direct ligands of this nuclear receptor. LPCs origi-
nating from muscle could act in a paracrine or endocrine fashion on lipid 
metabolism of different target tissues.
Supported by: DFG GRK 1302
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 273
1 C
666
Lower intensified target LDL-C level of statin therapy results in a higher 
risk of incident diabetes: a meta-analysis of randomised statin trials
R. Cai, Y. Yuan, Y. Zhou, W. Xia, P. Wang, H. Sun, Y. Yang, R. Huang,  
S. Wang;  
Affiliated Zhong Da Hospital of Southeast University, Nanjing, China.
Background and aims: A recent meta-analysis has reported that intensive-
dose statin drug increases the risk of incident diabetes. However, doubling of 
the statin dose generates only a further 6% decrease in low-density lipopro-
tein cholesterol (LDL-c) on average. This study aimed to determine whether 
statin therapy with lower intensive-target LDL-c level contributes to higher 
risk of new-onset diabetes.
Materials and methods: Medline, Embase, and the Cochrane Central Reg-
ister of Controlled Trials were searched for randomized controlled endpoint 
trials of statins conducted from 1966 to 2012. We included trials with more 
than 1000 participants who were followed up for at least 2 years. The included 
trials were stratified by the target LDL-c level. I² statistic was used to measure 
heterogeneity between trials. We further calculated risk estimates with ran-
dom-effect meta-analysis. Meta-regression was used to identify the potential 
risk factors of statin-induced diabetes.
Results: Fourteen trials with a total of 95 102 non-diabetic participants were 
included. The risks elevated by 33% [odds ratio (OR) = 1.33; 95% confidence 
interval (CI) 1.14-1.56; I² = 7.7%] and 16% (OR = 1.16; 95% CI 1.06-1.28; I² 
= 0.0%) when the intensified target LDL-c levels were ≤1.8 mmol/L and 1.8-
2.59 mmol/L, respectively. Incident diabetes did not increase when the target 
LDL-c level was ≥2.59 mmol/L. Apart from age, female, and baseline level of 
total cholesterol, meta-regression analysis showed that the target and base-
line levels of LDL-c and relative LDL-c reduction were predictors of statin-
induced diabetes.
Conclusion: A lower intensified target LDL-c level of statin therapy resulted 
in higher risk of incident diabetes. 
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Intensified LDL-C target of statin therapy and cancer risk:  
a meta-analysis
S. Haixia, Y. Yuan, P. Wang, Y. Zhou, R. Cai, W. Xia, Y. Yang, R. Huang,  
S. Wang;  
The Affiliated ZhongDa Hospital of Southeast University, Nanjing, China.
Background and aims: Statin therapy and cancer incidence have no rela-
tionship according to a recent system review and meta-analysis. However, 
whether an intensified low-density lipoprotein-cholesterol (LDL-c) target of 
statin therapy is associated with cancer incidence has been rarely reported.
Materials and methods: PUBMED, EMBASE, and Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) data as of July 2013 were searched for 
randomized controlled trials (RCTs) on statins. An intensified LDL-c target 
of <2.59 mmol/L (100 mg/dl) or a relative LDL-c reduction by at least 30% of 
the baseline was the primary criterion for all the trials that were included in 
the meta-analysis. The I² statistic was used to measure heterogeneity among 
the trials, and risk estimates were calculated for incident cancer with ran-
dom-effect meta-analysis.
Results: Eleven eligible studies were identified with 70,714 participants, 6,423 
of whom (3,231 were given statins and 3,192 were given control treatment) 
developed cancer during the follow-up period. The intensified LDL-c target 
of statin therapy showed no effect on cancer incidence (odds ratio [OR] 1.02, 
95% CI 0.94−1.11, I²=38.2%), including some common types of respiratory 
and gastrointestinal cancer. However, pravastatin seemed to promote can-
cer incidence (OR 1.26, 95% CI 1.04−1.53). Meta-regression analysis showed 
that neither the chemical properties nor the species of the statins accounted 
for the residual variation in risk.
Conclusion: The intensified LDL-c target of statin therapy has no effect on 
the overall incidence of cancer, including some common types of respiratory 
and gastrointestinal cancer. Thus, such an intensified statin therapy need not 
be changed among adult clinical patients.
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Age at menarche, glycaemic control, cardiovascular risk factors and 
chronic complications in women with type 1 diabetes: a nationwide 
survey in Brazil
M.B. Gomes1, C.A. Negrato2;  
1Internal Medicine, State University of Rio de Janeiro,  
2Internal Medicine, Associação Médica de Diabetes de Bauru, Brazil.
Background and aims: Puberty is an early life event that may have several 
relations to later life diseases risk and is an event that is usually well recalled 
by adult women being a reliable measure of pubertal initiation. Earlier age at 
menarche onset has been associated with several adverse outcomes, such as 
type 2 diabetes, obesity, cardiovascular diseases, metabolic syndrome and all 
causes mortality, showing that the timing of pubertal development may have 
lifelong effects on a woman’s health. So far many menstrual irregularities were 
described in women with type1 diabetes like early and delayed menarche tim-
ing, menstrual cycle irregularities and early menopause. In general a higher 
age at menarche is observed in women with type 1 diabetes in comparison 
to controls of the same population, but this difference is not significant. The 
influence of glycemic control upon age at menarche is still controversial. The 
aim of this study was to determine the relationship between age at menarche 
with glycemic control and cardiovascular risk factors in patients with type 1 
diabetes in Brazil.
Materials and methods: This was a multicenter cross-sectional study con-
ducted between December 2008 and December 2010 in 28 public clinics in 
20 cities from the four Brazilian geographic regions. Data were obtained from 
1,527 female patients, 59.3% Caucasians, aged 25.1 ± 10.6 years. The diabetes 
duration was 11.4 ± 8.1 years. Patient information (clinical factors and age at 
menarche) was obtained through a questionnaire and a chart review. Age at 
menarche was stratified in four classes: 8 to 11 (class 1, early menarche), 12 
(class 2), 13 (class 3) and 14-18 years (class 4, late menarche).
Results: The mean age at menarche was 12.7 ± 1.7 years (median 13.0 years) 
without difference between the geographical regions of the country, eco-
nomic status, level of care and ethnicity. Patients from class1 had greater 
BMI than patients from the other classes, p<0.001], and were more likely to 
be overweight or obese than patients from the other classes, [169 (31.5%) 
vs 152 (28.3%), vs 117 (21.8%) vs 99 (18.4%), p <0.001], respectively. BMI 
had an inverse correlation with age at menarche (r=-0.14, p <0.001). No sig-
nificant difference was observed among the four classes of age at menarche 
for blood pressure, lipid profile and diabetes-related chronic complications. 
More patients from class 1 were using metformin in comparison to patients 
from class 4, 13.8% vs 7.1 % ,p=0.002, respectively. Logistic regression analy-
sis showed that early age at menarche, [(8-11 years, (odds ratio (ORs) 1.77 
[1.30-2.41,p<0.001)] and duration of diabetes [ORs 1.01 (1.00-1.03), p=0.02], 
were related to greater risk of patients’ overweight or obesity and adherence 
to diet [ ORs 0.78 (0.60-0.93), p=0.01], physical activity [ORs 0.75 (0.94-
0.94),p=0.01 insulin dose (U/kg) (ORs 0.54 [0.59-0.90,p=0.001]) were related 
to lower risk for overweight or obesity.
Conclusion: Early menarche occurred in 23.4% of Brazilian female with type 
1 diabetes and was strongly associated with overweight or obesity in puber-
tal/adult life which could be minimized with lifestyle changes such as bet-
ter adherence to diet and physical activity. Further prospective studies must 
be addressed to establish the relationship between early menarche, glycemic 
control, cardiovascular risk factors and diabetes-related chronic complica-
tions.
Supported by: FAPERJ, CNPq, SBD, FIOCRUZ
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MAPK signalling is required for brain insulin to suppress lipolysis in 
rodents
T. Scherer1,2, E. Zielinski2, C. Lindtner2, J. O’Hare2, C. Buettner2;  
1Department of Medicine III, Medical University of Vienna, Austria, 
2Department of Medicine, Mount Sinai School of Medicine New York, USA.
Background and aims: Insulin is the major anti-lipolytic hormone and is se-
creted postprandially. We recently showed that brain insulin action is able to 
suppress lipolysis by reducing sympathetic nervous system outflow to white 
adipose tissue. However, the relative importance of brain insulin versus the 
well-characterized peripheral insulin effects in regulating whole body lipoly-
sis is unknown.
Materials and methods: Here, we studied the role of brain insulin versus pe-
ripheral insulin action using two inducible insulin receptor knock-out mouse 
models and their respective controls. The first model lacks the insulin recep-
tor (IR) in the whole body (IRdeltaWB), while the second model lacks the IR 
in all peripheral tissues (IRdeltaPER) except the brain. All mice were subject-
ed to 2-hour hyperinsulinemic euglycemic clamp studies with stable isotope 
glycerol tracer to assess whole body lipolysis. To further identify the signal 
transduction pathway mediating brain insulin’s effects on lipolysis, we co-in-
fused insulin with either the Pi3K inhibitor LY294002 or the MAPK inhibitor 
U0126 directly into the mediobasal hypothalamus (MBH) of male Sprague 
Dawley rats (n ≥ 4 per group) using stereotaxically implanted cannulae, and 
assessed lipolytic flux using the rate of appearance (Ra) of the glycerol tracer.
Results: Male IRdeltaPER knock-out mice subjected to a hyperinsulinemic 
clamp showed a comparable % suppression of Ra glycerol per unit of insulin 
(4.7 ± 1.7 vs. 6.0 ± 1.4 %; P=0.6) to littermate controls despite being extremely 
insulin resistant (glucose infusion rate 21 ± 5 vs. 97 ± 10 mg*kg-1*min-1; P 
= 0.001). In contrast, male IRdeltaWB knock-out mice were unable to ad-
equately suppress lipolytic flux (0.4 ± 0.2 vs. 6.9 ± 2.2 %, P=0.017) compared 
to control mice when exposed to high doses of insulin during a clamp. MBH 
insulin co-infusion with LY294002 suppressed Ra glycerol to a similar extent 
than MBH insulin alone (17 ± 2 vs.15 ± 6 vs. 32 ± 7 (controls) µmol*kg-
1*min-1; P=0.7 MBH LY+Insulin vs. MBH Insulin) in rats. However, the co-
infusion of the MAPK inhibitor U0126 blocked the ability of insulin to sup-
press lipolytic flux (60 ± 8 µmol*kg-1*min-1; P=0.006 vs. MBH LY+Insulin; 
P<0.001 vs. MBH Insulin).
Conclusion: Insulin suppresses lipolysis even after the complete loss of pe-
ripheral insulin receptors, provided that functional brain insulin receptors 
and an intact MAPK pathway are present. Conditions in which brain insulin 
signaling is impaired, such as high fat feeding and obesity, are likely to com-
promise the regulation of lipolysis and lead to uncontrolled free fatty acid flux 
promoting lipotoxicity.
Supported by: NIH Grants DK074873, DK083568 and DK082724, EFSD 
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Alteration of hypothalamic glucose sensing in high fat-high sucrose 
diet fed rats: early defects linked to mitochondrial dynamics and mROS 
signalling
L. Desmoulins1, S.C. Collins1, S. Grall1, C. Allard1, X. Fioramonti1,  
P.-Y. Risold2, L. Pénicaud1, C. Leloup1;  
1Centre des sciences du gout et de l’alimentation, CNRS UMR 6265 INRA 
UMR 1324 Université de Bourgogne, Dijon, 2Laboratoire d’Histologie,  
IFR 133, Faculté de Médecine et de Pharmacie, Besançon, France.
Background and aims: The hypothalamus participates in the control of en-
ergy homeostasis by detecting circulating nutrients, such as glucose. The me-
diobasal hypothalamus (MBH), in particular, senses hyperglycemia and initi-
ates physiological responses, e.g., insulin secretion (IS) via the autonomous 
(vagal) nervous system. We have recently demonstrated that glucose sens-
ing (GS) requires mitochondrial reactive oxygen species (mROS) signaling 
heavily dependant on mitochondrial fusion and fission (dynamics). Recently, 
genetic models have associated some of these dynamics within the MBH to 
their obesogenic susceptibility. Using a model that only presents a hypotha-
lamic GS defect, our objectives were thus to determine whether modulating 
the diet affects 1) mROS signaling, 2) mitochondrial fission and fusion, 3) 
respiratory function in the hypothalamus, and how early these defects could 
be detected during the progression to diabetes.
Materials and methods: Male Wistar rats were fed a High Fat-High Sucrose 
(HFHS) diet during 3 weeks and compared to control rats fed a normal chow. 
Circulating hormones and metabolites were evaluated as well as glucose toler-
ance. Hypothalamic glucose-induced IS was studied in response to a carotid 
glucose injection towards the brain without alteration in peripheral glycemia 
and compared to islet glucose-induced IS. Hypothalamic ROS production 
and mitochondrial dynamics (main actors: DRP1 (fission), MFN2(fusion)) 
were quantified. Efficiency of hypothalamic mitochondrial respiration was 
evaluated using oxygraphy, as well as the redox status (glutathion red/ox) of 
MBH explants.
Results: A 3 weeks HFHS diet did not significantly alter body weight, despite 
the caloric intake (STD=72.3±1,2kcal/j ; HFHS=83,9±1,8 kcal/j ; p<0,001) 
and the fat mass (STD=11,8±0,6% ; HFHS=15,1±0,8% ; p=0,007) being in-
creased compared to control rats. HFHS fed rats displayed a glucose intoler-
ance in the first 30 min, an increased fasting glycemia but no modification of 
fasting insulinemia. Hypothalamic GS induced IS was drastically decreased 
(delta insulin: STD=86,1±26,9µU/ml ; HFHS=26,9±11,4µU/ml ; p=0,017) 
while glucose stimulated IS in isolated islets was not different compared to 
controls. These defects correlate with a decrease of MBH ROS production 
(-33%). The fission protein DRP1 exhibited a decreased mitochondrial trans-
location in the MBH, and no change in MFN2 (fusion) content was observed 
while controls exhibit an increase. Finally, mitochondrial respiratory defi-
ciencies were present in HFHS fed rats.
Conclusion: A hypothalamic alteration of mitochondrial ROS signaling, fis-
sion and fusion, and respiration was present in rats exposed to a 3 weeks 
HFHS diet. Such hypothalamic GS defects are early events preceding those 
in islets. These results suggest that the glucose intolerance seen in the first 30 
min involved the hypothalamo-pancreatic axis rather than the islet GS (the 
vagal control being of particular importance for this first phase). In conclu-
sion, these early but drastic hypothalamic modifications could participate in 
a primary nervous defect of the control of insulin secretion, and finally, the 
etablishment of a diabetic phenotype.
Supported by: CNRS, INRA, Ub, NRJ fondation, PRESS BFC, Région Bour-
gogne
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Brain glutamate dehydrogenase (GDH) knockout mice display modified 
central glucose metabolism reshaping peripheral energy distribution
M. Karaca1, F. Frigerio1, S. Carrobio1, S. Migrenne2, D. Skytt3,  
J. Tamarit-Rodriguez4, H. Waagepetersen3, C. Magnan2, P. Maechler1;  
1Dpt of Cell Physiology and Metabolism, University of Geneva, Switzerland, 
2CNRS EAC 4413, BFA, University Paris Diderot, Paris, France,  
3Dpt of Pharmacology and Pharmacotherapy, University of Copenhagen, 
Denmark, 4Dpt of Biochemistry, Complutense University, Madrid, Spain.
Background and aims: Glucose is the prominent source of energy delivered 
to the central nervous system (CNS) by the periphery. However, within the 
brain, oxidative catabolism of the main neurotransmitter glutamate contrib-
utes to maintenance of energy homeostasis. Upon glutamatergic transmis-
sion, following its uptake by astrocytes, glutamate may be amidated to glu-
tamine and then recycled back to neurons. Alternatively, glutamate may be 
deaminated to alpha-ketoglutarate by the mitochondrial enzyme glutamate 
dehydrogenase (GDH, encoded by the Glud1 gene) before further oxidation 
in the TCA cycle, ultimately producing ATP. We generated brain-specific 
GDH knockout mice (CnsGlud1-/-) to question the importance of GDH as a 
key enzyme connecting glucose and glutamate metabolism within the CNS.
Materials and methods: Mitochondrial oxygen consumption and cytosolic 
ATP levels were measured in isolated brain tissues and primary astrocytes. 
Glucose uptake was estimated by incorporation of injected 2-deoxy-D-[14C]
glucose. Brain metabolites were measured by NMR in living animals other-
wise using commercial kits. Peripheral glucose homeostasis was assessed by 
ip glucose tolerance tests. Insulin resistance was assessed by hyperinsuline-
mic-euglycemic clamps.
Results: In CnsGlud1-/- brains lacking GDH, glutamate oxidation was re-
duced, resulting in elevated glutamate plus glutamine pool and impaired glu-
tamate-induced oxygen consumption and ATP generation in their astrocytes. 
CnsGlud1-/- mice compensated for the lack of glutamate usage by increas-
ing brain glucose consumption. This adaptive mechanism was uncovered by 
the observed lower central glucose concentrations (-47%, p<0.05), enhanced 
brain glucose uptake (+32%, p<0.05) and increased glucose-stimulated ATP 
generation in their astrocytes. Higher brain glucose consumption in Cns-
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Glud1-/- mice was confirmed by measurements of elevated incorporation 
of 13C from [U-13C]-glucose into those amino acids representative for oxi-
dative metabolism of glucose products in the TCA cycle (alanine, aspartate, 
glutamate). CnsGlud1-/- mice were glucose intolerant with normal insulin 
production. However, they displayed increased endogenous glucose produc-
tion and decreased muscle glucose uptake. Fat turnover was also modified 
with higher circulating triglycerides and ketone bodies. Furthermore, plasma 
concentrations of most amino acids were lower in CnsGlud1-/- mice in com-
parison with control mice, suggesting increased mobilization of metabolites 
in CnsGlud1-/- skeletal muscles for provision of brain-specific energy sub-
strates. Lower plasma pancreatic polypeptide and higher catecholamines 
levels highlighted repressed parasympathetic activity with a concomitant in-
crease in the sympathetic input favouring energy mobilization.
Conclusion: Brain-specific GDH deletion induced impairment of glutamate 
oxidation in the CNS leading to central hypoglycaemia; in turn mobilizing 
energy substrates from the periphery.
Supported by: Swiss National Foundation
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Acyl ghrelin acts in the brain to control liver function and peripheral 
glucose homeostasis
R. Stark1, A. Reichenbach1, S.H. Lockie1, C. Pracht2, Q. Wu3, A. Tups2,  
Z.B. Andrews1;  
1Physiology, Monash University, Melbourne, Australia, 2Animal Physiology, 
Philips University, Marburg, Germany, 3Traditional Chinese Medicine, 
Peking Union Medical College Hospital, Beijing, China.
Background and aims: The gut hormone, ghrelin, acts on neuropeptide Y 
neurons in the arcuate nucleus of the hypothalamus and stimulates food 
intake to control energy balance. However, recent evidence suggests that 
peripheral ghrelin regulates glucose metabolism. Here, we designed experi-
ments to examine how central acyl ghrelin infusion affects peripheral glucose 
metabolism under pairfed or ad libitum feeding conditions.
Materials and methods: Three groups of mice received either ICV infusion 
of aCSF, ghrelin and allowed to eat ad libitum (Gh-lib) or ghrelin and pairfed 
to the average of the aCSF group (Gh-pf). Mini pumps delivered acyl ghrelin 
at a dose of 0.25 µg/hour at 0.5 µl/hour for 7 days.
Results: There was no difference in daily fed blood glucose, insulin, glucagon, 
triglycerides or non-esterified fatty acids between the groups. Body weight 
gain and food intake was significantly higher in Gh-lib mice compared to 
aCSF and Gh-pf. However, both Gh-lib and Gh-pf groups exhibited heavier 
white adipose mass, independent of body weight and food intake. Gh-pf mice 
exhibited a state of negative energy balance, as hypothalamic NPY and AgRP 
mRNA expression was increased in Gh-pf mice relative to aCSF or Gh-lib. 
Gh-pf mice exhibited better glucose tolerance than aCSF or Gh-lib mice dur-
ing a GTT, although both Gh-lib and Gh-pf increased insulin release dur-
ing the GTT. Central acyl ghrelin infusion and pairfeeding also increased 
breakdown of liver glycogen and triglyceride, and regulated genes involved in 
hepatic lipid and glucose metabolism. Gh-pf mice had an increase in plasma 
blood glucose during a pyruvate tolerance test in relative to Gh-lib or aCSF 
mice. Our results suggest that under conditions of negative energy (Gh-pf 
mice) central acyl ghrelin engages a neural circuit that influences hepatic glu-
cose function.
Conclusion: Metabolic status affects the ability of central acyl ghrelin to reg-
ulate peripheral glucose homeostasis.
673
Increasing central exposure of an MC4 agonist potentiates food intake 
and body weight lowering transiently in lean mice
M. Fritsch Fredin1, A. Lindblom1, P.R. Ceuppens2, E. Lundborg3,  
M. Ahlqvist3, M.H. Larsson1;  
1Bioscience, CVMD, AstraZeneca R&D, Mölndal, Sweden,  
2Discovery Statistics, AstraZeneca, Alderley Park, UK, 3DMPK & 
Bioanalytical Chemistry, CVMD, AstraZeneca R&D, Mölndal, Sweden.
Background and aims: It is well known that Melanocortin-4 receptors 
(MC4r) are widely expressed inside (hypothalamus) and outside (circum-
ventricular organs, brain stem) the blood brain barrier (BBB) and that hy-
pothalamus play a central role in regulation of food intake (FI) and body 
weight (BW). Interestingly, MC4r agonistic peptides which do not penetrate 
the BBB, decrease FI and BW in rodents both after peripheral and central 
administration. This study investigated whether increased CNS penetration 
potentiates the effects on FI and BW lowering of an orally administered small 
molecule MC4 agonist, cpd X.
Materials and methods: Female wildtype (WT) and Mdr1a/b-Bcrp triple 
targeted mutation (KO) mice on FVB background were dosed orally twice 
daily for 10 days with vehicle, or cpd X at 0.5 μmol /kg (only KO) or 15 μmol 
/kg. Individual FI and BW were recorded daily, including 2 base line days, 
while plasma and brain PK profiling were performed after 1 and 10 days of 
dosing. Lean and diet induced obese (DIO) mice on C57Bl /6 background 
were dosed twice daily with either vehicle or 30 μmol /kg cpd X. Analysis 
of Covariance, and 5% significance level tests based on Student´s t-test were 
used for statistical validation (n=5-8).
Results: Cpd X dosed at 15 μmol /kg resulted in plasma exposure (AUC0-24h, 
day 1) of 5.7 and 3.3 h*μmol/L in KO and WT mice, respectively, while the 
unbound brain /plasma ratio was more than 40 times higher in KO compared 
to WT mice. Cpd X significantly reduced FI and BW over the first 24hr of 
treatment in WT FVB (15 μmol /kg; FI; -20.2 ± 6.9%, BW; -2.3 ± 1.2%) and 
KO mice (FI; 0.5 μmol /kg -21.7 ± 6.3% and 15 μmol /kg -48.5 ± 8.9%, BW; 
0.5 μmol /kg -0.9 ± 0.8% and 15 μmol /kg -5.1 ± 1.0%) relative to vehicle. The 
effect on FI was transient and returned towards vehicle levels after 48 hours 
especially in the KO mice. In contrast, BW lowering was sustained for the 
remainder of the study, especially for the WT, but also for the high dose KO 
mice. Cpd X (30 µmol /kg) reduced BW 10.3 ± 1.7%) in DIO mice but had no 
effect in lean C57Bl /6 mice after 10 days treatment.
Conclusion: Higher brain exposure of cpd X was associated with greater 
transient reductions in FI and BW over the first 24 hours only. The initial 
effects support the hypothesis that CNS penetration of MC4r agonists poten-
tiates FI/BW lowering. The lack of durable efficacy may be due to the FVB 
genetic background or the fact that the mice used were not obese. The latter 
is supported by the lack of BW reduction in lean versus DIO mice on C57Bl/6 
background. Thus, lean FVB mice are unlikely to be predictive for the long-
term effects on FI/ BW lowering in C57Bl/ 6 DIO mice.
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Lack of alpha-MSH in POMC neurons controls hepatic glucose 
production
M. Schneeberger1,2, A. Garcia1,3, D. Sebastian4,3, M. Imbernón5,6,  
C. Castaño1,3, Y. Esteban1,3, P. Garcia-Roves1,3, R. Gomis1,2, R. Nogueiras5,6,  
A. Zorzano4,3, M. Claret1,3;  
1Laboratory of Diabetes and Obesity, IDIBAPS, Barcelona,  
2Department of Endocrinology and Nutrition, Universitat de Barcelona, 
3CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CBIERDEM), 
Barcelona, 4Departament de Bioquimica i Biologia Molecular, IRB 
Barcelona, 5Departamento de Fisiología, Universidad de Santiago de 
Compostela, 6CIBER de la Obesidad y Nutrición (CIBERobn), Santiago de 
Compostela, Spain.
Background and aims: Anorexigenic proopiomelanocortin (POMC)-ex-
pressing neurons in the arcuate nucleus of the hypothalamus constitute a 
fundamental nexus in the neuronal hierarchy controlling whole-body energy 
balance. In particular, POMC neurons are able to sense and integrate a range 
of nutrient and hormonal cues informing about the energy status of the or-
ganism. Mitochondrial fusion, the merge of two mitochondria into one single 
compartment, is a key process implicated in mitochondria quality control 
and also in the bioenergetic adaptations to changes in environmental nutri-
ent availability. A key protein mediating this fusion processes is Mitofusin 2 
(Mfn2). We tested the hypothesis that Mfn2 in POMC neurons may be an 
important component of the sensing machinery implicated in the regulation 
of systemic glucose homeostasis.
Materials and methods: Mice lacking Mfn2 in POMC neurons (POMCM-
fn2KO) were generated and detailed phenotyping performed.
Results: Young 6-week old POMCMfn2KO mice showed unaltered body 
weight and adiposity when compared to control counterparts. However, they 
exhibited mild glucose intolerance and insulin resistance. In vivo glucose-
stimulated insulin release and pancreatic morphometric parameters were 
unaltered in POMCMfn2KO mice. Mutant mice showed increased glucose 
levels in response to pyruvate test and upregulation of key hepatic gluconeo-
genic genes, enzymatic activity and proteins, consistent with enhanced he-
patic glucose production (HGP). POMCMfn2KO mice also showed reduced 
insulin signaling in the liver indicating insulin resistance. These alterations 
were related to a dramatic reduction in alpha melanocyte stimulating hor-
mone (αMSH), the main anorexigenic peptide released by POMC neurons. 
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ICV αMSH administration was able to reverse most of the glucose metabo-
lism alterations observed in POMCMfn2KO mice.
Conclusion: Deletion of Mfn2 in POMC neurons leads to defective glucose 
homeostasis independent of alterations in body weight. Our data indicate 
that the underlying cause is reduced αMSH production that eventually leads 
to enhanced HGP.
Supported by: EFSD/Lilly, ISCIII, UB, RecerCaixa
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Impaired cognition coexists with hippocampal remodelling obstacles in 
LDL receptor knock-out mice
Y. Huang1, W.-Q. Xia2, S.-H. Wang2;  
1Endocrinology, Yancheng First Peoples’ Hospital,  
2Endocrinology, Zhongda Hospital of Southeast University, Nanjing, China.
Background and aims: Evidences from clinical studies support that the ab-
normal cholesterol metabolism in the brain lead to the progress of cognitive 
dysfunction. Low-density lipoprotein receptor (LDLR) is well known for its 
role in regulating brain cholesterol homeostasis. We investigated whether 
LDLR plays roles in cognition and the related potential mechanisms.
Materials and methods: Twelve-month-old Ldlr-/-mice (n =12) and wild-
type littermates C57BL/6J (n =14) maintained on a standard lab chow diet 
were subjected to the morris water maze test, sucrose consumption test, and 
open-field test when they were 4, 7, and 12 month-old, respectively. All ani-
mals were killed for the hippocampal remodeling studies, including the hip-
pocampal neural stem cells (NSCs) proliferation, survival and differentiation 
studies, as well as synapse and apoptosis studies one week after the comple-
tion of all behavioral tests.
Results: The plasma cholesterol concentrations of Ldlr-/- mice increased 
moderately than C57BL/6J (P<0.05). The results of behavioral tests revealed 
that Ldlr-/- mice displayed impaired spatial memory, increased anhedonia and 
hyperactivity (all P<0.05), with decreased hippocampal BrdU+ cells (P<0.01), 
BrdU+/NeuN+ and BrdU+ cells ratio (P<0.05), and reduced expression lev-
els of synaptophysin as well as number of synaptophysin-immunoreactive 
presynaptic boutons in the hippocampal CA1 and dentate gyrus areas (all 
P<0.05). Ultrastructural changes in DG area of the hippocampus were ob-
served by transmission electron microscopy. Furthermore, the apoptosis oc-
curred in the hippocampus of Ldlr-/- mice was discovered with the elevated 
Bax/Bcl-2 expression ratio at both mRNA and protein levels (P<0.05; P<0.01, 
respectively), and increased activated-caspase3 level (P<0.05).
Conclusion: Deteriorations of brain cholesterol homeostasis induced by 
LDLR deficiency contributes to impaired spatial cognition, increased anhe-
donia and hyperactivity, probably via its negative effects on hippocampal re-
modeling, including reduced hippocampal NSCs proliferation, survival and 
differentiation as well as increased hippocampal vulnerability to apoptosis 
and synapse deficits.
Supported by: the National Nature Science Foundation of China (81070638 and 
81070916)
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Poorly controlled cholesterol is associated with cognitive impairment in 
type 2 diabetic patients: a resting state fMRI study
S. Wang, W. Xia, P. Wang, Y. Yang;  
Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Background and aims: Debate remains on whether hypercholesteremia, 
which often exist in T2DM patients, is etiologically associated with cogni-
tive impairment or dementia. This study aims to investigate whether poor 
controlled cholesterol impaired functional connectivity among patients with 
type 2 diabetes mellitus (T2DM).
Materials and methods: We used resting-state functional magnetic reso-
nance imaging (fMRI) to investigate the functional connectivity of 25 T2DM 
patients with poor controlled cholesterol, 22 patients with target cholesterol 
and 26 well-matched healthy controls. Further correlation analysis was con-
ducted between functional connectivity and clinical data as well as neuropsy-
chological tests.
Results: The three groups did not statistically differ in age, sex, education lev-
el, BMI, blood pressure, fasting C-peptides, and triglyceride. Compared with 
target cholesterol patients, patients with poor controlled cholesterol had sig-
nificantly higher serum cholesterol levels, LDL, LDL/HDL index and worse 
performance in TMT-B (p < 0.05). Apart from these, no other significant 
differences were noted between the two groups. Disordered functional con-
nectivity of bilateral hippocampus-middle frontal gyrus (MFG) in the poor 
controlled group had been consistently shown when compared with the other 
two groups. Besides, the aberrant functional connectivity was associated with 
TMT-B scores as well as the LDL/HDL index in T2DM patients with poor 
controlled cholesterol.
Conclusion: T2DM patients with poor controlled cholesterol show impaired 
attention and executive function. Resting-state connectivity disturbance of 
the hippocampus-MFG may be involved in this process. Lowering the LDL/
HDL ratio might be taken precaution against cognitive decrements.
Clinical Trial Registration Number: ChiCTR-ONRC-13003095
Supported by: NSFC
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Impact of insulin resistance on memory performance, brain morphology 
and neurochemical profiles of the cortex and hippocampus
J.M.N. Duarte1, R. Gruetter1,2;  
1Laboratoire d’imagerie fonctionnelle et métabolique, Ecole Polytechnique 
Federale de Lausanne, 2Radiology, Universities of Lausanne and Geneva, 
Switzerland.
Background and aims: Insulin signalling is involved in metabolic regulation 
and synaptic plasticity in the central nervous system. Glucose neurotoxicity 
and reduced insulin signalling may impair brain structure and function lead-
ing to behavioural and cognitive alterations. In the present study we aimed 
at identifying brain metabolic modifications upon altered insulin signalling, 
underlying or leading to neurodegeneration and eventual structural and 
functional anomalies.
Materials and methods: Hippocampal-dependent memory of Wistar rats 
(n=12) and insulin-resistant Goto-Kakizaki rats (GK, n=8) was evaluated by 
measuring spontaneous alternation in a Y-maze at 2, 4 and 6 months of age. 
After behavioural testing at each age, magnetic resonance imaging (MRI) 
and spectroscopy (MRS) were performed under 2% isoflurane anaesthesia 
in oxygen gas, on a 14.1 T spectrometer using a home-built quadrature sur-
face coil. MRI was performed with fast-spin-echo imaging with 4 s repetition 
time (TR) and 52 ms echo time (TE) and images were analysed with ImageJ. 
MRS was performed in hippocampal and cortical areas using SPin ECho, 
full Intensity Acquired Localized spectroscopy with TE=2.8 ms and TR=4 s. 
Spectra were analysed with LCmodel to quantify 20 metabolites composing 
the neurochemical profile. A glucose tolerance test (GTT) was performed by 
glucose administration (i.p. 2 g/kg) after fasting 18 hours.
Results: Fasting glycaemia was 3.4±0.1 and 4.3±0.2 mmol/L, while serum 
insulin was 4.0±1.1 and 5.9±1.6 mU/L, for Wistar and GK rats respectively. 
This resulted in a fasting glucose to insulin ratio of 4.8±1.8 for Wistar and 
1.0±0.2 mol/U for GK rats, depicting a 79% reduction in insulin sensitiv-
ity. The GTT area under the curve was 11.6±1.7 and 42.3±3.4 mmol.h/L for 
Wistar and GK rats, respectively. At all tested ages, GK rats displayed im-
paired memory performance, as depicted by reduced Y-maze spontaneous 
alternation (-14% to -22% relative to controls, P<0.01). The brain of GK rats 
displayed smaller hippocampal volume (-18% to -20% of controls, P<0.001) 
and larger volume of lateral and third ventricles (+39% to +84% of controls, 
P<0.001). Interestingly, glucose intolerance correlated with hippocampal 
(r=-0.86, P<0.001) and ventricular (r=0.57, P<0.01) volumes. Hippocampal 
volume further correlated with memory performance (r=0.47, P<0.001). 
The neurochemical profiles were affected by insulin resistance. Most nota-
bly, in comparison to controls, GK rats displayed reduced glutamine (-14% 
to -24%, P<0.001) and choline (-13% to -21%, P<0.001) in both regions. 
In the hippocampus, GK rats had higher taurine (+8% to +16%, P<0.001) 
and ascorbate (+38% to 48%, P<0.001) and reduced alanine (-19% to -30%, 
P<0.01) concentrations relative to controls. Cortical aspartate content was 
lower in GK relative to controls (-14% to 29%, P<0.01). Memory perfor-
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mance was strongly correlated to hippocampal glutamine (r=0.62, P<0.001) 
and taurine (r=-0.526; P<0.001).
Conclusion: These data demonstrate that insulin-resistant GK rats are char-
acterised by brain structural deterioration and metabolic modifications. 
Some metabolites of the measured neurochemical profile were associated to 
memory performance and therefore constitute non-invasive biomarkers of 
brain dysfunction in diabetic encephalopathy.
Supported by: CIBM and FNS
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Weight loss following bariatric surgery recovers decreased brain volumes 
but not increased fatty acid metabolism in the morbidly obese:  
a combined PET and VBM study
J.J. Tuulari1, H.K. Karlsson1, H. Numminen1, H. Honka1, J. Hirvonen2,  
P. Salminen3, M. Soinio4, P. Nuutila1, L. Nummenmaa5;  
1PET Centre, Turku, 2Department of Radiology,, University of Turku, 
3Department of Digestive and Acute Surgery, University of Turku and Turku 
University Hospital, 4Department of Medicine, Turku University Hospital, 
5Department of Biomedical Engineering and Computational Science, School 
of Science, Aalto University, Espoo, Finland.
Background and aims: Obese individuals have widespread cortical and sub-
cortical atrophy in white (WM) and grey matter (GM). This may be due to 
metabolic changes that divert brain energy metabolism to abnormally high 
utilisation of glucose or fatty acids (FA) leading to increased oxidative stress 
and cellular damage. We studied the effects of weight loss due to bariatric 
surgery on brain FA uptake and GM / WM densities in obese subjects with 
and without type 2 diabetes. We hypothesized to find decrease of FA uptake 
and increase in WM and GM after the surgery.
Materials and methods: We studied 20 morbidly obese subjects before 
(meanBMI 41; SD 3,4) and six months after bariatric surgery (meanBMI 31,8; 
SD 4,2), and 13 age-matched healthy subjects (meanBMI 22,6; SD 2,8) with 
palmitate analoque [18F]-FTHA positron emission tomography. Brain fatty 
acid (FA) uptake was calculated using Gjedde-Patlak analysis. For the voxel-
based morphometric analysis the T1-weighted MRI images were segmented 
into WM and GM using the VBM8 toolbox. Group differences in FA, WM 
and GM images were compared using independent samples t test in SPM8. 
Voxelwise associations between FA uptake and WM and GM volumes were 
analysed using Pearson correlations.
Results: Preoperatively, brain FA uptake was higher in morbidly obese versus 
lean subjects across the whole brain (Figure 1A) and this was not influenced 
by weight loss following surgery. Preoperatively the morbidly obese subjects 
had globally lowered grey and white matter density and both recovered fol-
lowing the surgery (Figure 1B). White or grey matter volumes and FA uptake 
were not associated. The observed differences were independent of diabetic 
state of the participants.
Conclusion: We show here that fatty acid uptake is increased in morbid 
obesity and that the increase coincides, but is not associated, with adverse 
structural changes in white matter. Brain atrophy reversed already within 6 
months after bariatric surgery whereas no changes occur in brain FA uptake. 
This suggests that increased FA fluxes do not serve potential reversible causes 
of brain morphological changes in obesity and diabetes, but could be due to 
obesity related increased brain insulin sensitivity, which is normalized after 
bariatric surgery.
Clinical Trial Registration Number: SleevePET2 NCT01373892
Supported by: Academy of Finland, Sigrid Juselius Foundation, HEPADIP, 
EUFP7
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Obesity decreases the expression of sirtuin proteins in adipose tissue of 
monozygotic twins, independent of genetic factors
J.S. Jukarainen, S. Heinonen, M. Tummers, E. Rappou, J. Rämö,  
M. Mundiany, A. Hakkarainen, N. Lundbom, J. Kaprio, K. Pietiläinen;  
University of Helsinki, Finland.
Background and aims: Sirtuins 1 and 3 (SIRT1, 3) are reported to be down-
regulated in the subcutaneous adipose tissue (SAT) of obese individuals. 
Some studies associate human SAT SIRT1 and 3 expression with a favorable 
obesity phenotype. How much all of these associations reflect acquired obe-
sity or are confounded by genetics and other factors is unclear. The objec-
tive of this study was to assess the roles of SAT SIRT1, 3 and 5 expression in 
obesity, insulin resistance and inflammation, controlling for genetic and early 
environmental factors by studying monozygotic (MZ) twins.
Materials and methods: Global gene mRNA expression, body composition 
and insulin sensitivity were assessed with Affymetrix U133 Plus 2.0 arrays, 
magnetic resonance imaging (MRI), DEXA scans and 75g oral glucose tol-
erance tests (OGTT) in healthy MZ twin pairs (N = 40) of which 26 pairs 
were discordant for BMI (BMI difference > 3 kg/m2). For statistical analyses, 
Δ-variables depicting intrapair differences in different traits were calculated 
by subtracting the value of the leaner co-twin from the value of the heavier 
co-twin. These Δ-variables were used to control for genetic and early environ-
mental factors that the twins share.
Results: SIRT1, SIRT3 and SIRT5 were significantly downregulated in the 
SAT of heavier co-twins of BMI-discordant pairs. Out of adiposity variables, 
Δintra-abdominal fat volume was the best predictor of ΔSIRT1 expression 
(r = -0.81 P < 0.001). Where SIRT3 and 5 were correlated with adiposity in 
the individual level (r = -0.30 to -0.55, P < 0.007), these associations disap-
peared in the intrapair differences control setting (r = -0.01 to -0.25, P > 
0.114). ΔSIRT1 and 5 expression was associated with insulin sensitivity dur-
ing OGTT (r = -0.32 to -0.47, P < 0.047). ΔSIRT1 and 5 were significantly cor-
related with ΔCRP levels, ΔCD14 expression and various inflammatory gene 
expression pathways in SAT (r = -0.29 to -0.52, P < 0.042). Contrary to earlier 
research, ΔSIRT1 mRNA was not correlated with Δadiponectin mRNA (r = 
0.12, P = 0.469).
Conclusion: Adiposity (especially IA fat) was strongly related to SAT SIRT1 
independent of genetic or early environmental influences, whereas SIRT3 
and 5’s association with adiposity seems to be confounded by genetic or early 
environmental factors. SAT SIRT1 and 5 are negatively associated with in-
sulin resistance and adipose tissue inflammation, even after controlling for 
twin-shared factors.
Supported by: Academy of Finland (grants 266286, 272376), Novo Nordisk 
Foundation, Helsin
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Obesity is associated with lower expression of mitochondrial respiratory 
chain and mitoribosomal transcripts in adipose tissue in monozycotic 
twins
S. Heinonen1, J. Buzkova2, R. Kaksonen1, A. Hakkarainen3, J. Lundbom3, 
N. Lundbom3, J. Kaprio4,5, A. Rissanen1, A. Suomalainen2, K. Pietiläinen1, 
University of Helsinki;  
1Obesity Research Unit, Diabetes and Obesity Research Programs Unit, 
2Research Program of Molecular Neurology and Department of Neurology, 
3Helsinki Medical Imaging Center, 4FIMM, Institute for Molecular 
Medicine, 5Finnish Twin Cohort Study, Department of Public Health,  
Hjelt Institute, Helsinki, Finland.
Background and aims: Low mitochondrial number and activity are sug-
gested to be underlying factors in obesity and metabolic syndrome. However 
the functions of mitochondrial ribosomes, which are responsible for the syn-
thesis of respiratory chain proteins, in acquired obesity are largely unknown.
Materials and methods: Rare young adult MZ twin pairs discordant (n =26, 
ΔBMI > 3 kg/m2) and concordant for obesity (n=14, ΔBMI <3kg/m2) identi-
fied from ten full birth cohorts of 22-32-year-old Finnish twins were exam-
ined. Abdominal body fat distribution was measured by magnetic resonance 
(MR) imaging, liver fat content by MR spectroscopy and insulin sensitivity 
by the oral glucose tolerance test (OGTT). Mitochondrial ribosomal protein 
(MRP) expression (Affymetrix U133 Plus 2.0) and respiratory chain (RC) 
protein levels (Western) were quantified from subcutaneous adipose tissue 
biopsies.
Results: The obese (BMI 31.2±1.0kg/m2) and lean (25.3±0.9kg/m2) co-twins 
of the discordant pairs had a mean 18±0.5kg, p<0.001 difference in the body 
weight. The obese co-twins had significantly more subcutaneous (3810±420 
vs. 6360±540cm3, p<0.001), intra-abdominal (1640±250 vs. 790±180 cm3, 
p<0.001) and liver fat (4.5±0.9 vs. 1.1±0.3%, p<0.001), and were more insulin 
resistant (HOMA-index 2.1±0.3 vs. 1.1±0.1, p<0.01), (AUC insulin 130±25 
vs. 88±8, p=0.055), (Matsuda-index 5.9±0.7 vs. 8.6±0.9, p=0.02). They also 
had significantly lower expression levels of mitochondrial ribosome subu-
nits in the adipose tissue, both small (MRPS mean ± SE -0.31±0.1) and large 
(MRPL 0.26±0.1) than the lean co-twins (MRPS 0.03±0.09, p<0.001, MRPL= 
-0.04±0.1, p=0.0021). MRPS expression in individuals correlated negatively 
with HOMA-index (r=-0.45, p<0.001), AUC insulin during OGTT (r=-0.57, 
p<0.001), fasting triglycerides (r=-0.50, p<0.001), and positively with Matsu-
da-index (r=0.38, p=0.01) and adiponectin (r=0.53, p=0.02). Large subunits 
(MRPL) correlated with AUC insulin (r=-0.45, p<0.001), triglycerides (r=-
0.41, p<0.001) and adiponectin (r=0.43, p=0.04). The levels of RC complexes 
that are partly encoded by mitochondrial DNA were significantly reduced 
in the obese co-twins’ fat (RC/β-TUBULIN i.e. RC per cellular proteins: CI 
p=0.042, CIII p=0.015, CIV p=0.019, CV p=0.036) compared to the lean 
cotwin. The amount of CI (p=0.050), CIII (p=0.011) and CIV (p=0.037) were 
reduced also per mitochondria (RC/PORIN) in the obese co-twins. However, 
CII, which is encoded by nuclear DNA, was not different between the dis-
cordant co-twins. No differences were observed between the twins from the 
concordant pairs.
Conclusion: Mitochondrial ribosome protein expression and respiratory 
chain protein levels in adipose tissue are decreased in acquired obesity, to-
gether with a reduction in whole body insulin sensitivity. This suggests that 
down-regulation of mitochondrial biogenesis in adipose tissue plays a major 
role in the development of metabolic complications in obesity.
Supported by: Academy of Finland, Novo Nordisk, HUCH, Diabetes Research 
Foundation
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Knock down of hormone-sensitive lipase in human adipocytes improves 
glucose metabolism via induction of de novo lipogenesis
M. Houssier1, P. Morigny1, S. Caspar-Bauguil1,2, L. Onfroy3, D. Beuzelin1,  
A. Mairal1, C. Postic4,5, H. Guillou6, D. Langin1,2;  
1Laboratoire de recherche sur les obésités, INSERM U1048,  
2Centre Hospitalier Universitaire, 3Déterminants moléculaires et cliniques 
de l’activité sympathique et de l’architecture cardiaque, INSERM U1048, 
Toulouse, 4INSERM U1016, 5Endocrinologie Métabolisme et Cancer, 
Institut Cochin, Paris, 6Toxicologie alimentaire, INRA UR66, Toulouse, 
France.
Background and aims: We recently showed that partial inhibition of adipose 
tissue lipolysis improves glucose metabolism and insulin sensitivity in vivo. 
Adipose tissue de novo lipogenesis (DNL) has recently emerged as a deter-
minant element of whole body insulin sensitivity. DNL enzymes are under 
the control of the transcription factor carbohydrate-responsive element bind-
ing protein (ChREBP). Here, we aimed at understanding the specific role of 
de novo lipogenesis (DNL) in the improvement of human adipocyte glucose 
metabolism when hormone-sensitive lipase (HSL) expression is diminished.
Materials and methods: Human mesenchymal adipose-derived stem 
(hMADS) cells were differentiated into adipocytes during 14 days of culture, 
and then used for metabolic analysis. Knock down was achieved by micropo-
ration of small interfering RNA against HSL (siHSL), ChREBP (siChREBP), 
and as a control green fluorescent protein (siGFP). Gene expression was 
quantified by RT-qPCR. Radiolabelled 2-deoxy-glucose was used to measure 
glucose uptake. Glucose oxidation and DNL (glucose carbon incorporation 
into fatty acids) were evaluated using radiolabelled glucose. Analyses of fatty 
acid composition in triglycerides and phospholipids were performed using 
capillary gas chromatography. Cells membranes were separated in 12 differ-
ent fractions by sucrose gradient, and lipid raft composition was analyzed by 
Western blot. GM1 ganglioside was detected by Cholera toxin B.
Results: Compared to control, glucose transport and oxidation were increased 
in siHSL adipocytes. This improvement of glucose metabolism was accompa-
nied by an increase of DNL both at the levels of key enzymes gene expression 
and metabolic flux. Notably, there was a marked induction of ChREBPb in 
siHSL adipocytes. To establish the role of DNL in the improved glucose re-
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sponse, ChREBP expression was knocked down. Although siChREBP alone 
did not affect glucose metabolism, we observed a significant decreased glu-
cose transport, glucose oxidation and DNL in cells exposed to dual inhibi-
tion (siHSL/ChREBP) compared to simple inhibition (siLHS), suggesting an 
involvement of ChREBP in the effects mediated by HSL down regulation. 
Cellular lipidomic analyses demonstrated a clear qualitative change in fatty 
acid composition of phospholipids (PL) and triglycerides (TG) between the 
different siRNA conditions. The knock down of HSL led to an increase pro-
portion of oleate (in PL and TG), in parallel to a decreased proportion of pal-
mitoleate, while the knock down of ChREBP had the opposite. An intermedi-
ate profile was observed with dual inhibition (siHSL/ChREBP). These results 
could partly be explained by the changes in the expression of ELOVL6, an 
elongase responsible for the shift between C:16 to C:18 series. Interestingly, 
these changes in PL composition could contribute to the observed changes in 
lipid rafts associated to insulin signaling.
Conclusion: These data concur to a prominent role of DNL in the improved 
glucose metabolism observed when adipocyte HSL expression is diminished.
Supported by: ANR ObeLip
682
High fat diet induced adipose tissue inflammation by suppression of 
anti-inflammatory phospholipids
M.A. Osterhoff1,2, T. Frahnow1, A.-C. Seltmann1, A.S. Mosig3,4,  
K. Neunübel3, S. Sales5, J.L. Sampaio5, S. Hornemann1, M. Kruse1,  
A.F.H. Pfeiffer1,2;  
1Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, 
2Endocrinology, Diabetes and Nutrition, Charité - University Medicine, 
Berlin, 3Molecular Haemostaseology, Jena University Hospital,  
4Center for Sepsis Control and Care, Jena University Hospital, 5Max Planck 
Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Background and aims: Little is known about the interdependency of com-
plex gene-networks regulating the metabolism or signaling function of spe-
cific lipids in humans. Lipid metabolism and signaling might be either con-
trolled genetically or by environmental factors. The aim of the study was to 
correlate lipidomic and genomic data of human subjects to identify specific 
gene-modules responsible for the regulation or connected with the function 
of specific lipid metabolites.
Materials and methods: In the NUGAT-Study (NUtriGenomic Analysis in 
Twins) all subjects (monozygous and dizygous twins) first received a car-
bohydrate-rich low-fat diet for 6 weeks (Clinical Investigation Day 1, CID1 
thereafter), immediately followed by a high-fat diet for 1 week (CID2) and 
additional 5 weeks (CID3). At each CID periumbilical fat biopsies were taken 
for RNA isolation and Agilent 8x40K gene micro Arrays. Plasma was meas-
ured for lipid metabolites and cytokines (ELISA). Weighted gene Co-Expres-
sion Network Analysis (WGCNA) was used for identification of co-expressed 
gene-networks and their correlation with lipidome data. MetaCore was used 
to find potential roles of identified gene-sets.
Results: By analysis of the 5000 strongest regulated genes 10 gene-modules 
were identified whereof 1 revealed a high correlation (p<0.00001 to 0.0006) 
with CRP (r2=0.31), VEGF (r2=0.39), IL1ra (r2=0.35) and PP (r2=0.3). This 
gene-module contained genes which are known to play a role in processses 
like phosphatidylethanolamine acyl-chain remodelling, immune response, 
response to wounding, platelet activation and cytokine production. Fur-
thermore, the gene-module was highly associated (r2=-0.32, p<0.0004) with 
a lysophosphatidylethanolamine-metabolite (LPE), a phospholipid which 
has been previously suspected for its anti-inflammatory/anti-bacterial func-
tions. In almost all volunteers LPE decreased during the high-fat diet (mean: 
-0.50+/-0.70 mmol/L), as well as IL1ra, while CRP and VEGF increased. 
Interestingly,the concentration of VEGF was very similar in monozygous 
twins, the heratibility was calculated to approx. 90% during all CIDs.
Conclusion: While LPE and IL1ra, which is an anti-inflammatory cytokine, 
decrease during the high-fat diet, CRP and VEGF, which are markers for in-
flammation and migration of monocytes/macrophages, increase. Our data 
show for the first time in humans that high-fat diet induces inflammation 
by remodeling lipid biosynthetic pathways reducing anti-inflammatory and 
increasing inflammatory signaling. Specifically we identify downregulation 
of the anti-inflammatory phospholipid LPE as a mediator of inflammatory 
processes in the adipose tissue.
Clinical Trial Registration Number: NCT01631123
Supported by: BMBF, DZD
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Adipose tissue as an extrathyroidal source of TSHbeta
M. Moreno, J.M. Moreno-Navarrete, F. Ortega, G. Xifra, W. Ricart,  
J.M. Fernandez-Real;  
Department of Diabetes, Endocrinology and Nutrition, Hospital of Girona, 
Spain.
Background and aims: In addition to the pituitary-thyroid circuit, additional 
TSH-related circuits may be functioning in extrathyroidal sites, including the 
immune system as evidenced by the ability of immune cells to produce TSH. 
A splice variant of TSHβ has been identified in the pituitary gland, thyroid 
and peripheral blood leukocytes.
Materials and methods: Either total (t-) or variant (v-) TSHβ gene expres-
sion were studied in 40 visceral (VAT) and in 42 subcutaneous adipose tissue 
(SAT) samples. The expression pattern was also evaluated in adipose tissue 
fraction cells (mature adipocytes (MA) and stromal vascular fraction (SVF)) 
and during adipocyte differentiation.
Results: Either t- or v-TSHβ were consistently detected in adipose tissue. 
t- and v-TSHβ expression were similar in MAs and SVFs. In SAT, t-TSHβ 
decreased during adipocyte differentiation. Perilipin 1, perilipin 2 (ADRP), 
FSP27 and several lipolytic gene expression (ATGL and MGLL) were nega-
tively associated with t- and v-TSHβ in both SAT and VAT. Conversely, t- and 
v-TSHβ were positively associated with caveolin1 in SAT and VAT. Moreover 
t- and v-TSHβ from AT were positively associated with PGC1a and SIRT1 
gene expression. Both TSHβ isoforms in AT were associated with an adverse 
lipid profile.
Conclusion: Current results provide novel evidence of adipose tissue as an 
extrathyroidal source of TSHβ in association with genes implicated in lipid 
droplet formation and lipolysis.
684
Coxsackie and adenovirus receptor: novel depot-specific molecule in 
human adipose tissue?
G. Xifra1, M. Serrano1, M. Moreno1, J. Bassols2, J.M. Moreno-Navarrete1,  
F. Ortega1, W. Ricart1, J.M. Fernandez-Real1;  
1Department of Diabetes, Endocrinology and Nutrition,  
2Department of Pedriatics, Hospital of Girona, Spain.
Background and aims: The Coxsackie and Adenovirus receptor (CAR) plays 
a crucial role in both virus-related pathology and adenoviral gene therapy. 
Recent findings disclose important functional roles in immunity, inflamma-
tion, and tissue homeostasis.
Materials and methods: CAR gene expression was measured in two-hun-
dred human adipose tissue samples (91 visceral (VAT) and 109 subcutaneous 
adipose tissue (SAT)). CAR was also studied in human adipose tissue frac-
tions (mature adipocytes (MAs) and stromal vascular fraction (SVF)).
Results: CAR expression was 60-fold higher in VAT than in SAT (0.036 ± 
0.021 vs 0.0006 ± 0.0005, p<0.0001). In human adipose tissue fractions CAR 
gene expression in SVF was significantly higher than in MAs, either in SAT 
(0.0016 ± 0.0002 vs 0.00038 ± 0.00004; p=0.005) or in VAT (0.0654 ± 0.0043 
vs 0.0249 ± 0.0040, p=0.028). In SAT, CAR expression was higher in obese 
than in lean subjects (0.00068 ± 0.00060 vs 0.00048 ± 0.00036, p=0.019), 
whereas in VAT this pattern was only observed in men (0.043 ± 0.022 vs 0.017 
± 0.022, p=0.031). In SAT, CAR was positively associated with BMI (r=0.258; 
p=0.008), fat mass (r=0.288; p=0.003), and inversely with the expression of 
genes such a PPARg (r=-0.381; p=0.035), FAS (r=-0.333; p=0.011) and Srebp-
1c (r=-0.357; p =0.019). In VAT, CAR was also positively associated with BMI 
(r=0.460; p=0.036) only in men, whereas negatively with the expression of the 
lipogenic gene S14 (r=-0.260; p=0.019) and GLUT4 (r=-0.531; p= 0.001) and 
FABP5 (r=-0.350; p= 0.015).
Conclusion: The Coxsackie and Adenovirus receptor is detected in both adi-
pose tissue depots, being preferentially expressed by VAT and stromal vascu-
lar cells. CAR expression was increased in AT from obese subjects, mainly in 
SAT, in inverse association with different lipogenic genes.
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Human adipose tissue microvascular endothelial cells (MVEC) regulate 
both tissue lipid in-/efflux and adipose cell PPARγ activation
S. Gogg, U. Smith;  
Department of Molecular and Clinical Medicine, University of Gothenburg, 
Sweden.
Background and aims: Animal studies have shown that specific deletion of 
PAPRγ in endothelial cells (EC) leads to dyslipidemia and endothelial dys-
function. We have previously established a method to isolate and culture 
human primary MVEC from adipose tissue biopsies. We here asked if the 
MVEC and (pre)adipose cells cross-talk in the regulation of the bidirectional 
transport of fatty acids between the blood and the adipose cells. We also ex-
amined the putative cross-talk between MVEC and PPARγ activation in the 
adipocytes which, in turn, is required to store excess fat in the adipose cells
Materials and methods: MVEC were extracted from human subcutaneous 
adipose tissue biopsies using immunomagnetic separation with anti-CD31 
Dynabeads. Selected MVEC were cultured and expanded in EC growth me-
dium and the remaining preadipocytes in DMEM-F12 prior to differentia-
tion. Subsequently, these cells were co cultured. To promote lipid accumula-
tion, the MVEC were incubated with 300 µM oleic acid (OA) and/or 5µM 
Rosiglitazone (ROSI) for 48 h. Accumulated lipids in the cells were visual-
ized with the fluorescent long-chain fatty acid analogue BODIPY-500/506 C1 
C12 and microphotographs were taken with fluorescence or confocal micro-
scopes. PPARγ activation was identified with the cell-based PPARγ reporter 
assay-GeneBLAzer UAS-bla HEK 293Hcells.
Results: Both lipid transporters CD36 and FABP4 were highly expressed 
in MVEC and they were further markedly increased by the addition of the 
PPARγ agonist ROSI. Interestingly, a similar effect was seen by just add-
ing oleic acid (OA) which in turn, also increased PPARγ gene activation in 
MVEC and there was no additive effect of combining OA with ROSI. Fur-
thermore, the stimulatory effect of OA was significantly inhibited by the 
PPARγ inhibitor GW9662, indicating that OA directly activated PPARγ in 
MVEC. We also examined the cross-talk between MVEC and adipose cells 
in co-cultures and confirmed the presence of a regulated bidirectional lipid 
transport (flux and efflux) between these cells. We then investigated the effect 
of OA in cultured adipocytes and, in contrast to MVEC. OA did not directly 
increase CD36, FABP4 or PPARγ expression. However, in co-cultures, the 
addition of the MVEC insert increased the expression of both lipid transport-
ers as well as that of PPARγ suggesting that MVEC secreted a PPARγ agonist 
to which the adipocytes responded. To further verify this, we incubated the 
PPARγ reporter cells (reporter assay) with MVEC conditioned media or with 
equivalent naïve media. Indeed, PPARγ activation was significantly increased 
when the cells were incubated with MVEC conditioned media as compared 
with naïve media. This was consistent for both basal culture medium and was 
further increased by the OA-containing media.
Conclusion: These findings support the presence of an intimate cross-talk 
between adipose cells and MVEC in the regulation of the bidirectional trans-
port of fatty acids. Furthermore, we can here also show for the first time that 
MVEC secrete a PPARγ ligand targeting both the MVEC and the adipose 
cells and that this process is further increased in the MVEC by fatty acids.
686
The effect of 2 days very-low calorie diet on cytokines in adipose tissue 
and in plasma in obese women
M. Siklova, V. Mayerova, L. Rossmeislova, J. Kracmerova, E. Czudkova,  
V. Stich;  
Department of Sport Medicine, 3rd Faculty of Medicine, Charles University 
in Prague, Czech Republic.
Background and aims: A number of bioactive molecules produced by adi-
pose tissue (AT), such as cytokines, chemokines and acute phase proteins, 
have been suggested as a possible link between obesity and insulin resistance. 
It has been shown that circulating adipokines are elevated in obese and dia-
betic subjects. Very-low-calorie diets (VLCD) are used as dietary interven-
tion to achieve a rapid weight loss in obesity treatment and were shown to 
improve insulin sensitivity (IS) as soon as after 2days of intervention. The aim 
of our study was to investigate the response of pro- and anti-inflammatory 
cytokines in AT and plasma after 2 and 28 days of VLCD and its possible 
relationship to IS improvement.
Materials and methods: 16 obese pre-menopausal women (BMI 32.5 ± 
3.6 kg/m2) followed 800 kcal/d VLCD for 28 days. Anthropometric meas-
urements, blood sampling and biopsy of subcutaneous abdominal AT were 
performed before diet and at the day 2 and 28 of VLCD. To evaluate insu-
lin sensitivity, euglycemic-hyperinsulinemic clamp was performed at each 
phase and Homeostatic model assessment of insulin resistance (HOMA-IR) 
was calculated. IL-6, IL-1β, IL-8, IL-10, MCP-1, and TNFα, were analyzed in 
plasma and in conditioned media of AT explants using multiplex immunoas-
say at Luminex 100. AT mRNA expressions of cytokines and lipogenic genes 
DGAT2, SDC, and FASN were analyzed.
Results: At day 2 IS increased as evaluated by HOMA-IR but not by glu-
cose disposal rate. At day 28 both indices of IS increased. Fat mass was not 
changed at day 2, while it decreased at day 28 (38±8.5 kg vs. 32±7 kg). At 
day 2, levels of IL-1β, IL-6 and IL-10 were increased in plasma, while the 
secretion and mRNA expression of all cytokines in AT was unchanged. In 
contrast, at day 28, secretion and mRNA expression of all cytokines in AT 
was increased, while their plasma levels were not different from the pre-diet 
condition. Expression of lipogenic genes DGAT2, SCD and FASN decreased 
at day 2 (DGAT2, p=0.04; SCD, p=0.005; FASN, p=0.05) and their decrease 
was further enhanced at day 28 (p=0.001 for all genes).
Conclusion: Improvement of IS after 2days of VLCD was not associated with 
changes in expression and secretion of cytokines in AT. The concomitant in-
crease in plasma cytokines suggests a contribution of non-adipose tissues. 
The lipogenesis in AT was down-regulated at the early phase of the diet.
Supported by: IGA NT 14486, PRVOUK
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The number of microRNA target sites identifies those transcripts that 
will experience the most dramatic downregulation in adipose tissue from 
obese subjects after weight loss
F.J. Ortega1, J.M. Mercader2, J.M. Moreno-Navarrete1, L. Nonell3,  
E. Puigdecanet3, G. Xifra1, M. Sabater1, M. Moreno1,  
N. Fuentes-Batllevell1, D. Mayas4, N. Moreno-Castellanos5, W. Ricart1,  
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Background and aims: Bariatric surgery is an excellent therapeutic approach 
to elucidate the pathophysiology of obesity-associated metabolic distur-
bances. The identification of abnormal function and gene expression patterns 
regulated by multiple microRNAs (miRNAs) may be useful in this context. 
In this study we aimed to identify changes in the genome wide adipose tis-
sue (AT) transcriptome linked to the miRNA profile after surgery-induced 
weight loss.
Materials and methods: Whole genome and miRNA expression patterns 
were assessed in subcutaneous AT of 16 morbidly obese women before 
and after surgery-induced weight loss. Validation of both genome wide and 
miRNA microarrays was made by quantitative real-time PCR using both 
longitudinal and cross-sectional cohorts. Three alternative datasets were 
downloaded from public repositories and analyzed to check for reproduc-
ibility. Analyses in macrophages and differentiated human adipocytes were 
performed in vitro to try to comprehend the associations found in human AT.
Results: Five thousand and eighteen different probe sets identified significant 
variations in gene expression. Only 15 miRNAs differed in the comparison 
before-after surgery-induced weight loss. Functional analysis revealed sig-
nificant changes in cell cycle, development and proliferation, in lipid me-
tabolism, and the inflammatory response, as further confirmed by in vitro 
results. Interestingly, when transcriptomes were analyzed taking into account 
the presence of miRNA target sites, the mRNAs that experienced the most 
dramatic changes were precisely those with more miRNA target sites (p=10-
195), being significantly down-regulated after surgery-induced weight loss.
Conclusion: Current findings suggest that surgery-induced weight loss is as-
sociated with an improvement in post-transcriptional modulation by miR-
NAs, in parallel to changes in inflammatory status and lipid metabolism of 
obese AT.
Supported by: EFSD/Lilly, FIS 2011-00214, CIBERobn, ISCIII
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Relationship between muscle/adipose tissue morphology, insulin 
sensitivity and beta cell function in diabetic and nondiabetic obese 
patients: effects of bariatric surgery
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Background and aims: Obesity is associated with low-grade inflammation in 
adipose tissue (AT), high lipolytic activity, ectopic fat deposition and insulin-
resistance (IR). Bariatric surgery leads to major fat mass loss and improve-
ments in IR and ß-cell function (ß-GS). Aim of this study was to relate the 
improved metabolic status after Roux-en-Y gastric bypass (RYGB) to the 
morphological changes of subcutaneous (SAT) and visceral AT (VAT) and 
skeletal muscle.
Materials and methods: 14 non-diabetic (ND) and 14 type 2 diabetic (T2D) 
obese patients (BMI = 50 ± 2 and 52 ± 2 kg/m2) received a euglycaemic clamp 
study (to measure IR) with 2H5-glycerol infusion (to measure lipolysis) and 
a mixed meal test (to measure insulin secretion and ß-GS) before and one 
year after RYGB. During RYGB, VAT (omental), SAT and rectus abdominis 
samples were excised for light (LM) and electron microscopy (EM) analysis.
Results: Before surgery, both T2D and ND patients showed marked IR and 
enhanced lipolysis, T2D also had impaired ß-GS. On LM, perivascular and 
interfibrillar muscle fat content was similar in ND and T2D; intramyocel-
lular fat was more abundant in T2D than ND patients (1.0 [1.5] vs 0.1 [0.5] 
units, p=0.008). In SAT, adipocyte area and density of crown-like structures 
(CLS) were similarly increased in T2D and ND. In VAT, adipocyte area (5806 
[1793] vs 5056 [1320], p=0.01) and CLS density (3.60 [7.31] vs 0.00 [1.75], 
p=0.0002) were higher in T2D than ND. ß-GS was inversely related to VAT 
adipocyte area (r = -0.58, p=0.004) and CLS density (r = -0.50, p=0.02). On 
EM, SAT and VAT adipocytes showed necrotic material, fibrosis, thickened 
capillary basal membrane, degenerating adipocytes with thin cytoplasm with 
extrusion of free lipids in interstitium and small mitochondria. In T2D pa-
tients, VAT and SAT blood capillaries contained neutrophils. After RYGB 
(33% weight loss), IR and lipolysis were markedly improved, equally in ND 
and T2D (p<0.003 for all). In T2D, ß-GS was improved (p=0.04) but not 
normalized. By LM, in both ND and T2D fat deposits were reduced in all 
muscle locations (p<0.03) as were adipocyte area and CLS density in SAT 
(p<0.0001). By EM, SAT adipocytes were generally smaller, in advanced state 
of delipidation, with thicker cytoplasm rim and more mitochondria. In T2D, 
capillaries were free of neutrophils. In the whole dataset, SAT adipocyte area 
and CLS density were strongly related to BMI, IR and lipolysis (r2’s between 
0.40 and 0.81, all p<0.0001). ß-GS was related to SAT CLS density (r = 0.46, 
p=0.006) and intramyocellular fat (r = 0.53, p=0.001); the post-surgery in-
crease in ß-GS was related to the concomitant decrease in intramyocellular 
fat (r = -0.79, p=0.002).
Conclusion: In morbid obesity, fat accumulation results in adipocyte en-
largement, lipid extrusion, macrophage infiltration and cell necrosis. In both 
T2D and ND, these changes correlate with IR and lipolysis; in VAT, histol-
ogy is worse in T2D than ND and correlates with ß-cell dysfunction. After 
surgically-induced major weight loss, AT/muscle histology and IR improve in 
parallel; in T2D, however, ß-cell glucose sensitivity remains abnormal despite 
the restoration of tissue morphology, suggesting a different origin for ß-cell 
incompetence.
PS 048 Brown, beige or brite?
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Background and aims: Brown adipose tissue (BAT) has a vital function as 
organ of non-shivering thermogenesis in small mammals and neonates and 
may also be of relevance in adult humans. Besides the unique expression of 
uncoupling protein 1, BAT also differs from white adipose tissue (WAT) by 
containing more mitochondria and multilocular lipid droplets. To obtain a 
more detailed understanding of the differences between WAT and BAT on 
the level of lipid metabolism, we performed an extensive lipid profiling of 
BAT and two different WAT depots, gonadal (GAT) and subcutaneous adi-
pose tissue (SAT).
Materials and methods: Interscapular BAT, femerogluteal SAT and GAT 
were quickly dissected from 12 C57Bl/6N mice (6 female and 6 male, 11 
week-old) following anaesthesia and decapitation. For lipid extraction, 10 
mg of frozen fat were homogenized in 75% ethanol and further extracted 
with MTBE. Nontargeted lipidomics analysis was performed on a Waters 
ACQUITY UPLC system coupled with an ABI Sciex tripleTOFTM 5600 plus 
mass spectrometer. High resolution tandem MS was utilized to enhance lipid 
identification. All detected lipids were quantified by normalization to internal 
standards.
Results: In total, 329 lipid species from 15 classes, covering FFA, DG, 
TAG and several phospho- and sphingolipid classes, could quantita-
tively be detected. In addition, acyl (alkenyl, alkyl) chains could be as-
signed to all phospho- and sphingolipids. Overall, WAT contained sig-
nificantly more TAG while BAT contained more phospholipids and 
sphingomyelin. Interestingly, 6 of the 11 lipids (9 PE- and 2 PC-species) 
that showed the highest specificity for BAT contained docosahexaeno-
ic acid. The key differences between the two WAT depots were a higher 
amount of TAG and lower content of several phospholipid classes in GAT. 
Interestingly, multivariate PCA analysis led to a clear separation of BAT sam-
ples from female and male mice. By analysing the acyl chain composition of 
the lipids contributing most to this separation, a set of fatty acids including 
arachidonic and stearic acid was found to occur more frequently in females, 
while another set including linoleic and palmitic acid was higher in males. 
Despite the differences between female and male GAT that could be expected 
in the light of their different anatomical location (ovarial/epididymal), the 
lipid composition of GAT was less sex-specific than the one of BAT.
Conclusion: By MTBE-based extraction followed by high-resolution LC-
tandem-MS analysis, we were able to generate detailed lipid patterns of 
brown and two white adipose tissue depots of female and male mice. When 
comparing the lipid composition of the different depots, the key findings 
were, firstly, clear adipose type-specific differences between BAT and WAT, 
and, secondly, sex-specific differences in phospholipid composition which 
were most prominent for BAT. By obtaining the composition of all phospho- 
and sphingolipids, we could identify common FFA residues characterizing 
the most discriminant lipid species, a prerequisite to explain the metabolic 
processes underlying the depot- and sex-specific differences observed.
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Peri-droplet mitochondria in brown adipocytes form an exclusive 
subpopulation of mitochondria
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Background and aims: Mitochondria play essential roles in brown adipose 
tissue differentiation and function. We have recently shown that mitochon-
drial dynamics is a physiological regulator of adrenergically‐induced changes 
in energy expenditure. Moreover, we and others report that changes in mi-
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tochondrial architecture may represent adaptive changes to bioenergetics 
needs. Conditions requiring high mitochondrial ATP synthesis capacity and/
or efficiency are associated with mitochondrial elongation. Whereas condi-
tions of excess energy supply and low ATP demand acutely induce mitochon-
drial fragmentation. However it remains unclear if diversity in subcellular 
mitochondrial architecture may play a role in generating functional speciali-
zation of subpopulations of mitochondria within the cell. We rationalized 
that the brown adipocyte may shed light on this question as its mitochondria 
are required for various and competing tasks, such as lipogenesis and beta 
oxidation as well as ATP synthesis and uncoupling, raising the possibility that 
the brown adipocyte may harbor a diverse set of mitochondria which are 
structured to fit different functions.
Materials and methods: Brown pre-adipocytes were harvested from 3-week-
old male C57BL6/J mice and differentiated in culture. Mitochondrial mem-
brane potential, motility and morphology were measured using TMRE and 
PAGFP respectively with Zeiss LSM 710 confocal microscope. NADH au-
tofluorescent was used to measure the NADH content of the mitochondria.
Protein import and turnover were measured using MitoTimer probe.
Results: Mitochondria in brown adipocyte are divided to two different popu-
lations, mitochondria with submicron proximity to the lipid droplet or Peri-
droplet (PD) mitochondria, and mitochondria that are located at least 5μm 
away from the vicinity of a lipid droplet or Cytoplasmic (C)mitochondria. 
Photo-conversion of matrix targeted photoactivatable GFP shows that these 
two populations rarely mix and that mitochondria remain faithful to the li-
pid droplet they adhere to and do not share their matrix content with other 
mitochondria, nor do they switch their affiliation from one group to another. 
These studies also show that PD-mitochondria are more elongated while the 
C-mitochondria tend to be smaller in size suggesting a more coupled respira-
tory function and involvement in ATP synthesis. In addition, using TMRE, 
we found that PD-mitochondria in brown adipocytes but not in other lipid-
containing cells are in different energetic state than C-mitochondria. Ratio-
metric imaging of membrane potential and NADH/NAD ratio show that PD-
Mitochondria have higher NADH/NAD ratio and more polarized membrane 
potential. Protein import and turnover studies using MitoTimer also indicate 
that PD-mitochondria have a higher rate of protein import and biogenesis, in 
agreement with the hyperpolarized state. Altogether these observations sup-
port a hypothesis that PD-mitochondria have a higher TCA cycle activity.
Conclusion: These data suggests that peridroplet mitochondria represent a 
functionally exclusive subpopulation of mitochondria in terms of biogenesis 
and function. This may also demonstrate that the unique architectural char-
acteristics of cells in diverse bioenergetics states may apply subcellularily to 
a diverse set of mitochondria within the cell, fulfilling different metabolic 
functions.
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Background and aims: Inflammatory cytokines are implicated in the patho-
genesis of obesity. Interleukin-15 (IL-15) is an inflammatory cytokine secret-
ed by many cell types. IL-15 is also produced during physical exercise by skel-
etal muscle and has been reported to reduce weight gain in mice. Contrarily, 
our findings on IL-15 knockout (KO) mice indicate that IL-15 promotes obe-
sity. The aim of this study is to investigate the molecular and cellular mecha-
nisms underlying the pro-obesity role of IL-15 in adipose tissues.
Materials and methods: C57BL/6 wildtype and IL-15 KO mice were main-
tained on high fat diet (HFD) or normal control diet. After 16 weeks, body 
weight, adipose tissue and skeletal mass, serum lipid levels and gene expres-
sion in the adipose tissues were evaluated. Primary cultures of brown and 
white adipocytes were studied using the Seahorse cell metabolism analyzer to 
evaluate oxygen consumption rates. IL15 gene expression and the expression 
of inflammation markers were studied in visceral adipose tissues obtained 
from patients undergoing bariatric surgery.
Results: We show that IL-15 deficiency prevents diet-induced weight gain 
and accumulation of lipids in visceral and subcutaneous white adipose tis-
sues. Circulating levels of cholesterol and non-esterified fatty acids were el-
evated in wildtype mice but not in IL-15 KO mice. The adipose tissues of 
IL-15 KO mice showed decreased expression of pro-inflammatory cytokines, 
chemokines and macrophage markers CD68 and F4/80. Gene expression 
analysis also revealed elevated expression of genes associated with adaptive 
thermogenesis in the brown and subcutaneous adipose tissues of IL-15 KO 
mice. Accordingly, oxygen consumption was increased in the brown adi-
pocytes from IL-15 KO mice. Adipose tissues from obese diabetic patients 
showed a tendency towards increase in the expression of IL-15.
Conclusion: Our results clearly show that IL-15 plays a pathogenic role in 
obesity. High fat diet-induced IL-15 promotes accumulation of fat in the 
white adipose tissues by inhibiting lipid utilization via adaptive thermogen-
esis. IL-15 also promotes inflammation in adipose tissues that could sustain 
chronic inflammation leading to obesity-associated metabolic syndrome.
Supported by: CIHR, CMDO
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Effect of the n-3 LC-PUFA EPA on white-to-brown transition of primary 
human adipose-derived stem cells
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Background and aims: Promoting the induction of brite adipocytes and 
thereby increasing energy expenditure may protect against the development 
of obesity. We have recently shown that both bone morphogenetic protein 
(BMP)4 and BMP7 induce browning of primary human adipose-derived 
stem cells (hASCs). Long-chain polyunsaturated fatty acids (LC-PUFAs) 
and their metabolites are potential PPARγ ligands and chronic activation of 
PPARγ is known to promote browning of white adipocytes. Furthermore, 
dietary n-3 LC-PUFAs have been shown to increase oxidative metabolism 
in white adipose tissue (AT) as well as adaptive thermogenesis in brown AT, 
suggesting a possible role for n-3 LC-PUFAs in the white-to-brown transi-
tion. Therefore, we investigated the direct effects of the n-3 LC-PUFA eicosa-
pentaenoic acid (EPA) on browning of hASCs in comparison to oleic acid 
(OA) as non-essential fatty acid and BMP4.
Materials and methods: Primary hASCs were isolated from the subcuta-
neous depot of different donors and challenged with EPA (20µM) or OA 
(20µM) during adipocyte differentiation (12 days). Cells treated with the 
known inducer of browning BMP4 (50 ng/ml) served as a positive control. 
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After 12 days of differentiation, lipid accumulation was measured by Oil Red 
O staining and gene expression was assessed by qRT-PCR.
Results: Chronic treatment of hASCs with EPA but not OA increased lipid 
accumulation to similar extents as BMP4. The BMP4-mediated enhancement 
of PPARγ and C/EBPα expression was absent in OA-treated hASCs, while 
the n-3 PUFA EPA slightly increased the expression of PPARγ and C/EBPα. 
Neither EPA nor OA affected the expression of the white-specific marker 
Tcf21, which was significantly reduced by BMP4. Remarkably, UCP1 expres-
sion was strongly enhanced (7-fold) after EPA exposure, while OA did not 
induce UCP1 expression. This EPA-mediated effect on UCP1 expression was 
comparable to that of BMP4.
Conclusion: In conclusion, chronic exposure to physiological concentrations 
of the n-3 LC-PUFA EPA induces browning of hASCs derived from white 
AT, providing a potential mechanism for the beneficial effects of dietary n-3 
LC-PUFAs on metabolism. The non-essential fatty acid OA has no effect on 
white-to-brown transition. The underlying mechanisms of the effect of the 
essential n-3 fatty acid EPA on browning will be investigated in future studies.
Supported by: Mead Johnson Nutrition, FP7-EU Marie Curie-IEF (ADDIO-
PIEF-2012-328793)
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PPARγ and PPARα agonists induce white-to-brown conversion of human 
white adipocytes along with a metabolic shift from glucose to fatty acid 
oxidation
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Background and aims: Since it was demonstrated that adult humans possess 
active thermogenically-competent brown adipose tissue, fighting obesity and 
its complications through increasing adipose tissue expenditure has emerged 
as a putative strategy. “Browning” of white adipose tissue in rodents is sug-
gested to be protective against obesity-induced insulin resistance. However, 
the capacity of human white adipocytes to acquire a brown/beige/brite me-
tabolism has not yet been demonstrated. We aimed at identifying the molecu-
lar and metabolic changes associated with the white-to-brown conversion of 
human mesenchymal adipose-derived stem (hMADS) cells following treat-
ment by PPARγ (rosiglitazone, Rosi) or PPARα (GW7647, GW) agonists.
Materials and methods: hMADS cells were differentiated into white adipo-
cytes within 14 days. Thereafter, Rosi or GW were added for 4 additional 
days before molecular (microarrays, qPCR and Western blot) and metabolic 
measurements using radiolabelled tracers were carried out.
Results: Both PPARγ and PPARα agonists promoted browning of white 
hMADS adipocytes, as evidenced by higher expression of UCP1 mRNA 
(29-fold and 18-fold respectively, p<0.01) and protein (18-fold and 13-fold 
respectively, p<0.05), and of other brown or beige/brite adipocyte markers 
(CIDEA, PGC-1α, TBX1, p<0.05). Microarray analysis confirmed by qPCR 
experiments revealed that treatments stimulated both the fatty acid synthesis 
and oxidation pathways. Functional measurements were consistent with gene 
expression data, showing that Rosi and GW increased both fatty acid com-
plete oxidation (by 70% and 66% respectively, p<0.05) and fatty acid incorpo-
ration into triglycerides (by 30%, p<0.01 and p<0.05 respectively). The higher 
fatty acid metabolism was associated with a decrease of both glucose uptake 
(p<0.05 and p<0.01 with Rosi and GW, respectively) and oxidation (p<0.05 
with Rosi and GW). Those metabolic changes occurred without modification 
of triglyceride cellular content.
Conclusion: PPARγ and PPARα activation in differentiated human white 
adipocytes promotes browning associated with a metabolic shift from glu-
cose to fatty acid oxidation. This striking metabolic remodeling favoring fatty 
acid use relies on molecular mechanisms which require further investigation.
Supported by: ANR miRBAT, EU FP7 DIABAT
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EHMT1 and the stimulation with elevated catecholamines can reinduce 
the perirenal brown adipocytes possessing classical features in adult 
humans
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1Department of Molecular and Internal Medicine, Hiroshima University, 
2Hiroshima City Asa Hospital, Japan.
Background and aims: Obesity, cause of various metabolic diseases such 
as type 2 diabetes, results from a chronic imbalance between energy intake 
and expenditure. Brown adipose tissue (BAT) generates heat against cold and 
obesity. According to previous reports, the adrenergic stimulation activates 
the thermogenic program of brown adipocytes. In addition, we previously 
demonstrated that EHMT1 is an essential methyltransferase in the PRDM16 
complex and controls brown adipose cell fate. However, there is a current lack 
of studies in humans auguing the perirenal BAT and EHMT1.
Materials and methods: We collected adipose tissues from perirenal regions 
in adult patients with pheochromocytoma (n = 11) and those with non-
functioning adrenal tumor (n = 7). We performed gene expression analysis 
of perirenal BAT using quantitative RT-PCR and protein analysis by using 
western blotting for PRDM16, EHMT1 and UCP1. Morphoogical analyses 
were performed by H&E staining and immunohistochemistry.
Results: The expression of BAT associated markers including Ucp1 (p < 
0.029), Cidea (p < 0.0046), Elovl3 (p < 0.015) were significantly higher in pa-
tients with pheochromocytoma. Morphological analysis showed that brown 
adipocytes were more apparent in patients with pheochromocytoma. These 
adipose cells possessed the molecular signatures of murine classical brown 
adipocytes. Furthermore, the upregulation of not only PRDM16 but also 
EHMT1 accorded with the upregulation of BAT associated markers at both 
the mRNA and the protein levels.
Conclusion: We find that the stimulation with elevated catecholamines and 
both PRDM16 and EHMT1 can collaboratively reinduce the perirenal brown 
adipocytes in adult humans, and these cells have the molecular signatures of 
classical brown adipocytes.
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MSCA1 is a functional markers of human brite adipogenesis: deleterious 
effect of inflammation on brite adipogenesis
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Background and aims: Obesity in humans is associated with the accumula-
tion of immune cells in adipose tissue (AT), contributing to systemic low-
grade inflammation. The promotion of brite adipogenesis has been shown to 
ameliorate metabolic parameters in rodents. However, their origin remains 
to be characterized in humans. Since native CD45-/CD34+/CD31- cells have 
been previously described as human adipocyte progenitors, the present study 
aimed to identify the brite-competent progenitor cell subset in humans and 
to characterize a potential relationship between brite adipogenesis and obesi-
ty-associated inflammation.
Materials and methods: Subcutaneous AT were collected from patient un-
dergoing aesthetic surgery for fat removal (cohort1, n=55, BMI range 18.4 
to 45 Kg/m²). Subcutaneous and matched visceral AT were collected from 
obese women undergoing gastric bypass (cohort 2, n=65, BMI range 33.4 to 
62.8 Kg/m²). AT collection was approved by the local ethics committee and 
donors gave their informed consent. Using flow cytometry approaches with 
two additional cell surface markers, ie MSCA1, the tissue non-specific alka-
line phophatase, and CD271, a nerve growth factor receptor, we partitioned 
the AT CD45-/CD34+/CD31- cell population into 3 subsets. We established 
culture conditions to promote brite adipogenesis using short-term treatment 
with pharmacological inducers. We developed cell sorting approaches to se-
lectively isolate the progenitor cell subsets. Brite adipogenic potential was 
assessed by lipid accumulation, gene expression analyses and protein expres-
sion of UCP1.
Results: We demonstrated in vitro that brite adipogenesis led to an in-
crease of MSCA1 expression (4-fold increase, p<0.05) and MSCA1 alkaline 
phosphatase activity (4-fold increase, p<0.05) in human cells. Futhermore, 
MSCA1 alkaline phosphatase activity was closely associated to the expression 
of UCP1 and the inhibition of MSCA1 using pharmacological or gene silenc-
ing approaches reduced brite differentiation. We showed that human native 
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immunoselected MSCA1+ cells exhibited brite precursor characteristics: high 
mitochondrial content (2-fold more compared to other progenitor subsets, 
p<0.01), highest expression of the brite-related precursor genes TMEM26, 
CD137, CIDEA (2-fold, 3.5-fold and 4.5 fold more respectively compared to 
other progenitor subsets, p<0.05) and they were located predominantly in 
subcutaneous compared to matched visceral AT. Moreover human MSCA1+ 
cell subsets exibited brite adipogenic potential in vitro. Finally, using human 
cohorts, we provided evidences that MSCA1+ progenitor cells accumulated 
with obesity and insulin resistance in subcutaneous AT. Using in vitro ap-
proaches we demonstrated that immune cells in part through inflammatory 
cytokines impaired brite adipogenesis by modulating MSCA1 activity.
Conclusion: We demonstrated the existence of brite competent progenitor 
cells positive for MSCA1 in human subcutaneous AT. However, we high-
lighted an increase of the proportion of MSCA1+ brite precursor cells in the 
context of obesity and insulin resistance suggesting a blockade of the terminal 
differentiation. Such a mechanism could be triggered by immune cells accu-
mulation occuring with obesity.
Clinical Trial Registration Number: NCT01525472
Supported by: INSERM, Clarins Dermocosmetique, Midi-Pyrenées, Sanofi-
Aventis
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BMP7 is produced by a specific human adipose tissue progenitor cell 
subset and promotes human progenitor cell brite adipogenesis
N. Boulet1,2, D. Esteve1,2, A. Bouloumié1,2, J. Galitzky1,2;  
1INSERM U1048/I2MC, 2Paul Sabatier University, Toulouse, France.
Background and aims: Brite adipocytes share some common features with 
white and brown adipocytes. Adipogenesis leads to the formation of new 
adipocytes from the differentiation of progenitor cells. Human adipose tissue 
(AT) progenitor cells, characterized as CD45-/CD34+/CD31-, are a heteroge-
neous population composed of three distinct progenitor cell subsets. CD45-/
CD34+/CD31- progenitor cells have white and brown-like adipogenic poten-
tial under pharmacological PPARγ agonist treatment. However in humans, 
endogenous signals promoting brite adipogenesis are not clearly known. In 
mice, bone morphogenetic protein 7 (BMP7) induces brown adipogenesis. 
The present study was undertaken to characterize BMP7 relevance in human 
AT and its effects on brite adipogenesis of human native AT progenitor cells.
Materials and methods: Human abdominal subcutaneous AT were obtained 
from healthy women undergoing aesthetic surgery (body mass index (BMI) 
18.4 to 39 kg/m²). AT collection was approved by the local ethics committee 
and donors gave their informed consent. AT cell populations (adipocytes, 
endothelial cells, immune cells and progenitor cells) and the three progenitor 
cell subsets were isolated by immunoselection/depletion approaches. BMP7 
gene expression was determined by RT-qPCR analyses in the different AT 
cell populations and BMP7 protein was studied by western blot. BMP recep-
tor gene expressions were performed by RT-qPCR on isolated AT progenitor 
cells. BMP7 signaling pathway was studied by western blot. AT progenitor 
cells were treated (or not, control (ctl)) for 48 hours by BMP7 (50ng/ml) then 
cultured in basal adipogenic media (without PPARγ agonist) for 9 days. At 
day 9, adipogenesis was evaluated by lipid accumulation quantification, brite 
adipocyte-related gene expressions were performed by RT-qPCR and UCP1 
protein was detected by immunohistochemistry and western blotting.
Results: BMP7 gene expression was specifically found in a progenitor cell 
subset compared to adipocytes, endothelial cells and immune cells (n=6-10, 
p<0.001). BMP7 gene expression was positively correlated with BMI (n=24, 
r=0.59, p<0.01) as well as BMP7 pro-peptide (n=7). Human AT progenitor 
cells expressed BMP receptors ALK2, ALK3, BMPR2 and ACVR2, but not 
ALK6 (n=12). BMP7 stimulation induced phosphorylation of SMAD1/5/8 
complex and P38MAPK. Early BMP7 treatment on human AT progenitor 
cells increased lipid accumulation (2 fold increase vs ctl, n=7, p<0.01), in-
duced the expression of brite adipocyte-related genes (n=6, p<0.05) as well as 
UCP1 protein after 9 days (2 fold increase vs ctl, p<0.05).
Conclusion: Our study shows that human AT progenitor cells express BMP 
receptors and are responsive for BMP7 stimulation. Early BMP7 treatment 
induces brite adipogenesis on human AT progenitor cells. BMP7 is locally 
produced by a progenitor cell subset and its expression increases with obesity. 
These results show that human progenitor cells have a brite adipogenic po-
tential and that BMP7 could be an endogenous brite adipogenic inducer. As 
brite promotion in rodent has been shown to ameliorate metabolic disorders 
associated with obesity, local BMP7 might be useful to fight against obesity-
associated pathologies in human.
Supported by: INSERM, Paul Sabatier University, Région Midi-Pyrénées, Clar-
ins
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Brown adipose tissue activity and sirtuin1 expressions in human white 
adipose tissue during weight loss
E. Rappou1, S.J.S. Jukarainen1, M. Tummers1, S. Kaye1, K.A. Virtanen2,  
J. Kaprio3, A. Rissanen1, K.H. Pietiläinen1;  
1Obesity Research Unit, University of Helsinki, 2Turku University Central 
Hospital, Turku PET Center, Turku University Central Hospital,  
3Finnish Twin Cohort Study, Hjelt Institute, Helsinki, Finland.
Background and aims: Caloric restriction has been suggested to delay aging-
associated disease and extend lifespan through sirtuin proteins. Sirtuins are 
highly enriched in brown adipose tissue (BAT), but little is known about sir-
tuins in white adipose tissue (WAT), especially during weight loss. We aimed 
to study the expression levels of sirtuin1 (SIRT1) in WAT in obese adults 
during a 12-month weight loss intervention and to correlate these changes 
with changes in BAT activity.
Materials and methods: 19 obese volunteers (7 males, 12 females) with BMI 
ranges 29.1-39.0, aged 20-48 years participated in a 12-month weight loss 
program. 19 healthy lean subjects (7 males, 12 females) with BMI ranges 
20.9-24.2, aged 23.7-36.2 years were examined as controls for the obese sub-
jects. The control group was examined similarly as the obese group, how-
ever without PET scanning and the weight loss intervention. Total RNA was 
extracted from subcutaneous WAT biopsies, taken at 0, 5 and 12 months. 
The whole genome-scale expression profiles were analysed using Affymetrix 
U133 Plus 2.0 chips. Glucose uptake in BAT was measured in obese patients 
before and after 5 months, using positron emission tomography (PET).
Results: SIRT1 expression levels were significantly higher (p<0.001) in the 
control group than in obese subjects at the baseline. All obese subjects lost 
weight between baseline and 5 months (mean 11.6 ± SE 1.3 kg). After this, 
1/3 of the patients continued to lose weight (weight loss at 12 months 17.5 ± 
2.6 kg), while 2/3 of them maintained or slightly regained the weight (mean 
weight loss at 12 months 5.0 ± 1.2 kg). The expression levels of SIRT1 in WAT 
followed inversely the BMI trend. Between 0 and 5 months, SIRT1 increased 
15% (p=0.0022). In those with continuous weight loss, SIRT1 continued to 
increase at 12 months 6% (p=0.049), while among those with weight regain, 
SIRT1 reverted back to baseline levels. Also, in partial correlation analysis 
adjusted for sex and age, SIRT1 expression levels correlated negatively with 
body weight, BMI and liver fat (r=-0.68-0.60, all p<0.001), and positively 
with BAT mass (r=0.53, p=0.04) and BAT glucose uptake (r=0.38, p=0.13) 
and whole body insulin sensitivity (r=0.66, p=<0.0001) at the baseline of the 
study. After weight loss, increase in SIRT1 correlated significantly with an 
increase in BAT glucose uptake (r=0.68, p=0.004).
Conclusion: Downregulation of SIRT1 expression in WAT in obesity cor-
relates with higher liver fat and poorer whole body insulin sensitivity. SIRT1 
levels in WAT increase during weight loss, together with an activation of BAT 
glucose uptake. This suggests that activation of SIRT1 expression in human 
WAT is of therapeutic potential, possibly through induction of BAT-like fea-
tures in human WAT.
Clinical Trial Registration Number: NCT01312090
Supported by: A.K.A., N.N., K.H.P., K.H.P., S.K., A.R.
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Dopaminergic effects on brown adipose tissue
F. Holleman, L. Bähler, M.R. Soeters, J.B.L. Hoekstra, H.J. Verberne;  
Academic Medical Center, Amsterdam, Netherlands.
Background and aims: Bromocriptine is a centrally acting dopamine recep-
tor agonist that improves insulin sensitivity in obese subjects. Yet, no expla-
nation has been found for this effect of bromocriptine. Brown adipose tissue 
(BAT), a tissue that converts calories into heat, might be involved in this pro-
cess. Since the central sympathetic nervous system is the primary activator 
of BAT, we hypothesized that dopamine plays a role in the activation of BAT. 
Therefore, the aim of this study was to investigate the influence of bromocrip-
tine on BAT activity in lean, healthy males.
Materials and methods: We included 8 lean (BMI 23[21-25] kg/m2), healthy 
Caucasian males (20.9[19-23] years). All subjects were studied before and 
after using bromocriptine (1st week 1,25mg/day, 2nd week 2,5mg/day in the 
evening) in a climate room at 21°C after an overnight fast. On these 2 study 
visits we measured metabolic BAT activity, defined as maximal standardized 
uptake value (SUVmax), using 18F-Fluorodeoxyglucose Positron Emission 
Tomography CT scans. Furthermore we investigated glucose metabolism 
with a 7 point oral glucose tolerance test, energy expenditure (EE) using indi-
rect calorimetry, weight and body temperature. Subjects recorded their eating 
behavior in the 4 days before the study visits.
Results: The use of bromocriptine did not significantly alter metabolic BAT 
activity (SUVmax before 11.97[4.3-15.8]; after 10.3[2.7-18.2]), EE (before 
2103 Kcal/day [1340-2486]; after 1915 [1784-2437]), body temperature (be-
fore 36.0 °C [35.6-36.4]; after 36.2 [36.0-36.7]) or weight (80 kg[72.1-82.2]; 
after 80 [72.1-81.8]). Unexpectedly, subjects became significantly less insulin 
sensitive after bromocriptine use. The area under the curve for glucose in-
creased (before 652 [539-752]; after 857 [772-992] (p=0.02)). But the area 
under the curve for insulin also increased (before 27x103 [26x103-37x103]; 
after 44x103 [41x103-65x103] (p=0.03)). There were no changes in diet be-
tween the 2 measurements that could explain the change in insulin sensitivity.
Conclusion: We conclude that bromocriptine does not activate BAT and 
does not increase EE in lean, healthy males.
PS 049 Animal models of obesity 
and type 2 diabetes
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Taurine treatment prevents obesity and diabetes through normalisation 
in circadian rhythms
A.L. Castillo Figueroa1, H.A. Figueiredo1,2, S. Rebuffat1,2, R. Gomis1,2,  
E. Vieira1,2;  
1Diabetes and Obesity Laboratory, IDIBAPS,  
2CIBERDEM, Barcelona, Spain.
Background and aims: Obesity and type 2 diabetes are associated with dis-
ruption of circadian rhythms. It has been suggested that several nutrients are 
potential candidates to correct alterations in circadian rhythms and prevent 
these diseases. More over the aminoacid taurine has positive effects on meta-
bolic dysfunction in obesity and diabetes in animal models of high fat diet. 
However, there is no study whether taurine can regulate circadian rhythms 
in mice. Therefore, we aim to study whether long term taurine treatment can 
ameliorate disturbances in circadian rhythms caused by high fat diet feeding
Materials and methods: Male C57BL/6 mice were divided in 4 groups. Con-
trol (C): mice fed with chow and Control+ taurine (C+T): mice fed with chow 
and 2.0% (w:v) of taurine in the drinking water. Obesity and diabetes were 
induced by HFD 45% of fat, and HFD + taurine group (HFD+T) treated with 
2.0% (w:v) taurine in the drinking water. Glucose tolerance test and insu-
lin tolerant test were performed in the last week of intervention. After 10 
weeks of taurine treatment mice were sacrificed at different times of the day 
(6:00, 12:00, 18:00, 24:00). Plasma insulin levels were measured by ELISA. 
The expressions of clock genes in isolated pancreatic islets were measured 
by RT-PCR.
Results: Mice treated with HFD increased food intake (p<0.001) and insulin 
levels (p<0.05) during the day and night time compared to chow fed mice. 
HFD group increased body weight (p<0.01) and visceral fat (p<0.05). HFD 
group disrupted the circadian pattern of insulin and exhibited higher insu-
lin levels throughout the 24h. HFD+T treatment prevented the increase in 
food intake and plasma insulin during the day and night. HFD+T group had 
a decrease in body weight (p<0.02) and visceral fat (p<0.05). Taurine pre-
vents the impairment in glucose tolerance and prevents insulin resistance, 
decreased plasma insulin levels and restored the oscillatory pattern of insulin 
in mice treated with HFD. Expression of clock genes in isolated pancreatic 
islets was measured. Rev-erb alpha, Bmal1 and Per1 were downregulated by 
HFD and taurine prevents this effect normalizing the expression of Per 1 at 
18h (p<0.01).
Conclusion: Taurine can prevent disturbances of circadian rhythm in food 
intake and insulin that was disrupted by HFD, and improves glucose metabo-
lism in HFD treated mice. These results suggest that these benefitial effects of 
taurine could be a potential candidate to prevent obesity and diabetes.
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Effects of resveratrol in experimentally induced endotoxaemia in mice
M.K. Nøhr1,2, A. Dudele3, S. Lund1,2, S.B. Pedersen1,2;  
1Department of Clinical Medicine, 2Department of Endocrinology and 
Metabolism C, 3Department of Bioscience, Aarhus University, Denmark.
Background and aims: Obesity is rapidly increasing in prevalence worldwide 
followed by a number of comorbidities such as cardiovascular diseases and 
type 2 diabetes. Obesity is often characterized by a chronic low-grade inflam-
mation, which is believed to induce insulin resistance and ultimately diabe-
tes. The triggering factor of this inflammatory state is unknown but lipopoly-
saccharide (LPS) originating from the gut microbiota has been suggested as a 
possible explanation hereof. Resveratrol is a naturally occurring polyphenol 
found in especially red wine, which has potential anti-inflammatory and anti-
diabetic effects. RSV activates the intracellular deacetylase sirtuin-1 (SIRT1) 
and inhibits nuclear factor κB (NF-κB) mediated inflammation. SIRT1 acti-
vation has been shown to mimic many of the positive effects seen of calorie 
restriction on metabolism.
Materials and methods: C57BL/6 mice were surgically implanted with mini-
osmotic pumps subcutaneously infusing LPS (600μg/kg/day) or saline. The 
mice had free access to water and normal diet (CT) or a RSV-modified diet 
(4g/kg) for the duration of 30 days. Body weight and food consumption were 
measured weekly. Glucose metabolism was evaluated by oral and intraperito-
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neal glucose tolerance tests (OGTT/IPGTT). Also, tissue and blood samples 
were collected for biochemical analyses and gene expression data.
Results: LPS-infused mice had an increased daily food intake compared 
to controls (185.1 ± 3.0 vs. 170.5 ± 2.9 g/kg, P < 0.01), which was reversed 
by RSV (175.2 ± 2.2 g/kg, P < 0.05). Despite this, there were no differences 
in average body weight gain after 28 days of treatment between the groups. 
Fasting glucose was reduced by RSV after 28 days of treatment (7.7 ± 0.2 vs. 
8.9 ± 0.4 mM, P < 0.01). During an OGTT, LPS-treated mice had a reduced 
hyperglycemia 15 min after glucose administration compared to control 
animals (14.9 ± 0.6 vs. 17.5 ± 0.8 mM, P < 0.05). RSV had no effect on the 
glucose metabolism during OGTT. Neither RSV nor LPS had any significant 
effect on transcriptional expression of glucagon-like peptide-1 (GLP-1), pep-
tide YY (PYY), glucose-dependent insulinotropic peptide (GIP), neuroten-
sin, TNF-α, prohormone convertase 1/3 (PC1/3) or dipeptidyl peptidase-4 
(DPP4) in the ileum of the small intestine.
Conclusion: LPS-infusion for 28 days induced hyperphagia without affect-
ing the body weight. RSV reversed this LPS-induced hyperphagia. To our 
surprise, LPS-treated mice did not show a worsening in glucose clearance as 
has earlier been suggested. Actually, LPS-treated mice had a small reduction 
in hyperglycemia 15 min following oral glucose challenge.
Supported by: The A.P. Møller Foundation, The Danish Council for Strategic 
Research
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T-bet regulation of the gut microbiota impacts insulin sensitivity
E. Stolarczyk1, C. Bailey1, A.W. Walker2, N. Garrido-Mesa3, E. Marks3,  
J. Willis3, I. Jackson3, N. Powell3, J.B. Canavan3, G.M. Lord3, J.K. Howard1;  
1Division of Diabetes and Nutritional Sciences, King’s College London, 
2University of Aberdeen, 3Division of Transplantation Immunology and 
Mucosal Biology, King’s College London, UK.
Background and aims: The gut microbiota plays a role in energy harvest, 
storage, and expenditure. Its composition differs in lean and obese humans 
and animals and transfer of microbiota from conventionally-raised to germ-
free mice increases body fat content and insulin resistance. The immune sys-
tem has co-evolved with the gut microbiota. We have recently highlighted the 
role of the immune cell transcription factor T-bet as a metabolic regulator 
uncoupling adiposity from insulin resistance. We hypothesised that the en-
hanced insulin sensitivity of T-bet (Tbx21) deficient mice was associated with 
an altered gut microbiota composition.
Materials and methods: Microbiota composition of T-bet deficient and con-
trol wild-type (WT) mice was analysed by 16S-pyrrosequencing. Subsequent 
analyses of colonic metabolites (short chain fatty acids, SCFA) were assessed 
by gas chromatography-mass spectrometry. The impact of genotype on adi-
posity and glucose homeostasis was determined by glucose and insulin toler-
ance testing following microbiota transfer to antibiotic-treated mice.
Results: T-bet deficient mice showed a decrease in the Firmicutes and De-
ferribacteres phyla and a significant increase in the Bacteroidetes and TM7 
phyla compared to wild-type mice. Furthermore, they exhibited an increase 
in the proportion of Clostidium species together with an increase in butyrate 
production (217.6±30.6 vs 336.6±32.9 μg/g feces, WT vs T-bet-/-, p=0.02). 
Transfer of T-bet deficient microbiota to microbiota-depleted WT hosts im-
proved insulin sensitivity (256.6±7.2 vs 221.0±8.8, WT vs T-bet-/- area under 
the curve insulin tolerance test, p=0.02). This was accompanied by an in-
crease in SCFA production, especially butyrate (216.3±76.0 vs 1581.1±636.8 
μg/g feces, WT vs T-bet-/- microbiota, p=0.02).
Conclusion: Our results suggest that deficiency of the immune cell transcrip-
tion factor, T-bet is associated with an altered gut microbiota composition 
that can enhance systemic insulin sensitivity.
Supported by: MRC grant MR/K002996/1
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TIP27 increases insulin sensitivity through PI3-kinase/Akt pathway and 
regulates glucose homeostasis in mice
L. Yuan1,2, L. Li1,2, G. Yang3;  
1College of Laboratory Medicine, 2The Key Laboratory of Laboratory 
Medical Diagnostics in Ministry of Education,  
3Department of Endocrinology, The Second Affiliated Hospital,  
Chongqing Medical University, China.
Background and aims: TIP27 (Juxtaposed with another zinc finger protein1) 
is a 27kDa transcription factor containing three putative zinc finger motifs 
and its expression is associated with diabetes mellitus and prostate cancer. 
However, little is known about its role in regulation of metabolism. In this 
study, we investigated the effects of TIP27 overexpression on glucose homeo-
stasis and insulin signaling pathway in high fat diet (HFD)-fed TIP27 trans-
genic (Tg) mice and diabetic db/db mice.
Materials and methods: Mainly,we use TIP27-Tg mice as research object.
Also,we established a gain-of-function model of TIP27 in db/db mice using 
an adenoviru-mediated cDNA.Using these models,We assessed the effects 
of TIP27 overexpression in both TIP27-Tg mice and db/db mice on glu-
cose metabolism and changes in insulin sensitivity during glucose tolerance 
tests (GTT) and insulin tolerance tests (ITT).Hyperinsulinemic-euglycemic 
clamp experiments was performed in Tip27-Tg mice.Glucose rates of ap-
pearance (GRa) were determined with 3-[3H] glucose. Whole body GRa and 
glucose uptake (GRd) were calculated using the non-steady-state equation. 
mRNA and protein expressions were measured by qRT-PCR and Western 
blot, respectively.
Results: We showed that TIP27 overexpression in both TIP27-Tg mice and 
db/db mice led to reduced total cholesterol, fasting plasma insulin levels, 
enhanced glucose tolerance and Insulin sensitivity.Hyperinsulinemic-eugly-
cemic clamp experiments also demonstrated that TIP27 overexpression in 
TIP27-Tg mice enhanced insulin sensitivity. In addition, the expression levels 
of PEPCK and Glucose-6-phosphatase (G-6-Pase) mRNA as well as proteins 
were significantly decreased in TIP27-Tg mice, whereas the phosphorylations 
of insulin-receptor(IR), IRS-1, Adenosine Monophosphate Activated Protein 
Kinase(AMPK) and Akt were significantly increased in the insulin target 
tissues. Finally, inhibition of phosphatidylinositol 3-kinase(PI3-kinase)/Akt 
signaling by LY294002, a PI3-Kinase inhibitor, abolished the suppressive ef-
fect of TIP27 overexpression on PEPCK and G-6-Pase expression.
Conclusion: TIP27 plays an important role in glucose homeostasis by the 
regulation of hepatic glucose metabolism and insulin sensitivity and this 
regulation requires activation of the PI3-kinase/Akt pathway.
Supported by: National Natural Science Foundation of China 
(81270913,81300702, 81300670)
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LEOPARD syndrome-associated SHP2 mutation confers leanness and 
protection from diet-induced obesity
M. Tajan1,2, T. Cadoudal1,2, A. Batut2,1, S. Deleruyelle1,2, S. Le Gonidec1,2,  
C. Saint-Laurent1,2, M. Vomscheid1,2, K. Treguer1,2, A. Nédélec1,2,  
M.-A. Marques1,2, P. Raynal2, H. Cavé3, T. Edouard4, P. Valet1,2, A. Yart1,2;  
1Institute of Cardiovascular and Metabolic Diseases, U1048,  
2Paul Sabatier University, Toulouse, 3Robert Debré Hospital, Paris, 
4University Hospital Center, Toulouse, France.
Background and aims: LEOPARD syndrome (LS) is a rare autosomal domi-
nant disorder associating various developmental defects notably cardiopa-
thies, dysmorphism and short stature. It is mainly caused by mutations of 
the PTPN11 gene that catalytically inactivate the ubiquitous tyrosine phos-
phatase SHP2. SHP2 plays essential roles in transducing canonical signal-
ing pathways (PI3K, MAPK) in response to a wide range of growth factors 
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and hormones. Recent studies using targeted invalidation of SHP2 in vari-
ous tissues and organs pinpointed key roles for SHP2 in regulating energy 
metabolism. However, the metabolic outcomes of LS mutations have never 
been examined. Therefore, we aimed to evaluate the metabolic status associ-
ated with LS using an original LS mouse model expressing one of the most 
common LS-associated SHP2 mutations. Beyond LS pathophysiology, since 
this mutation results in systemic partial inhibition of SHP2, this study also 
allowed assessing its role in the regulation of whole body metabolism.
Materials and methods: We performed a comprehensive analysis of the met-
abolic impact of LS-associated SHP2 mutations, by combining an extensive 
metabolic exploration of LS mice and of their WT littermates (body com-
position, glucose/insulin tolerance, energy expenditure,⋯) with functional 
analysis in cellulo. Animals were handled in accordance with the principles 
and guidelines established by the local Ethics Committee.
Results: Our results reveal that LS mice gain less weight than their WT lit-
termates (p<0.01), which correlates with a strong reduction of adiposity (2/3 
less at 28 weeks of age, p<0.001) despite similar food intake between geno-
types. We provide evidences that LS mutant expression impairs adipogenesis 
and triggers energy expenditure (p<0.001), two features that can contribute 
to the reduced adiposity of LS mice. This lean phenotype is associated with 
improved glucose and insulin tolerances (p<0.05). Consistently, we show that 
expression of LS mutants in a cell line induces a hyperphosphorylation of 
both Akt and Erk1/2 upon insulin stimulation (p<0.05), suggesting enhanced 
insulin sensitivity. Interestingly, chronic treatment of LS mice with low doses 
of MEK inhibitor results in weight and adiposity gains (p<0.05). Moreover, 
LS mice appear to be resistant to high fat diet-induced obesity and protected 
from associated disorders as insulin resistance (HOMA-IR WT 10.31 ± 2.60 
vs LS: 1.25 ± 0.35, p<0.05) or ectopic triglycerides deposits in the liver (WT: 
140 ± 15 vs LS: 73 ± 18 mg/g liver, p<0.05) or the muscle (WT: 0.22 ± 0.02 vs 
LS: 0.15 ± 0.03 g/g prot, p<0.05). Importantly, preliminary data in a French 
cohort of LS patients show that most of them have lower-than-average body 
mass index, which is associated, for tested patients, with reduced adiposity.
Conclusion: Altogether, our study demonstrates, for the first time, that LS 
status is associated with a metabolic benefit in vivo. In a more general context, 
our findings also highlight a key role for SHP2 in the regulation of whole 
body energy homeostasis and suggest that partial SHP2 inactivation could 
be protective towards the development of obesity and associated disorders.
704
Transient reduction of hyperinsulinaemia in growing female  
Ins1-/-:Ins2+/- mice protects against diet-induced obesity throughout 
adulthood
N.M. Templeman, X. Hu, S.M. Clee, J.D. Johnson;  
Cellular and Physiological Sciences, University of British Columbia, 
Vancouver, Canada.
Background and aims: There is clinical and experimental evidence that hy-
perinsulinemia can precede and perhaps cause diet-induced obesity. We have 
reported that preventing lifelong hyperinsulinemia by reducing the dosage 
of Insulin 1 in Insulin 2 null male mice (Ins1+/-:Ins2-/-) blocks diet-induced 
obesity. However, this model did not address effects of the ancestral Ins2 
gene (analogous to human INSULIN), nor whether protection against obe-
sity would persist without sustained repression of hyperinsulinemia. In the 
present study, we examined effects of reducing the ancestral Ins2 gene, in the 
absence of rodent-specific Ins1. Temporary repression of hyperinsulinemia 
in high fat-fed Ins1-/-:Ins2+/- females allowed us to test the hypothesis that a 
transient reduction of insulin secretion in young mice can provide long-term 
protection against obesity.
Materials and methods: Female Ins1-/-:Ins2+/- mice and Ins1-/-:Ins2+/+ litter-
mate controls were put on a high fat diet (HFD) or chow diet at weaning 
(n = 31-34). Insulin secretion, body mass, and body composition (DEXA) 
were tracked for at least 1 year, in addition to parameters of metabolic health 
including blood glucose response to glucose or insulin injections and levels 
of several hormones.
Results: Female Ins1-/-:Ins2+/- mice had lower circulating insulin as early as 
eight weeks of age, compared to Ins1-/-:Ins2+/+ littermates (p < 0.05). At 27 
weeks, all HFD-fed females had elevated basal insulin levels, but this was re-
duced by nearly 50% in Ins1-/-:Ins2+/- females (Ins1-/-:Ins2+/+ 1.17 ± 0.23 ng/
mL; Ins1-/-:Ins2+/- 0.62 ± 0.14 ng/mL; p < 0.05). Of note, reduced circulating 
insulin in Ins1-/-:Ins2+/- mice did not elevate blood glucose. Attenuated hy-
perinsulinemia in HFD-fed Ins1-/-:Ins2+/- females corresponded with reduced 
weight gain and fat mass expansion, although this divergence could not be 
explained by differences in energy expenditure or food intake in 17 week-
old mice. Interestingly, while Ins1-/-:Ins2+/- females on a HFD reached an 
equivalent degree of hyperinsulinemia as HFD-fed Ins1-/-:Ins2+/+ littermates 
by one year (Ins1-/-:Ins2+/+ 1.24 ± 0.13 ng/mL; Ins1-/-:Ins2+/- 1.21 ± 0.23 ng/mL; 
p = 0.8), their body mass never matched the more obese Ins1-/-:Ins2+/+ mice 
(Ins1-/-:Ins2+/+ 36.4 ± 1.2 g; Ins1-/-:Ins2+/- 30.9 ± 0.9 ng/mL; p < 0.5). Unlike 
control Ins1-/-:Ins2+/+ females, 40 week-old HFD-fed Ins1-/-:Ins2+/- females did 
not have high leptin levels (Ins1-/-:Ins2+/+ 6.3 ± 2.2 ng/mL; Ins1-/-:Ins2+/- 1.1 
± 0.4 ng/mL; p < 0.5); other hormones such as gastric inhibitory polypeptide 
were similarly elevated in all HFD-fed mice. Reduced insulin sensitivity and 
a decline in glucose tolerance were evident in all HFD-fed mice by 52 weeks, 
despite decreased weight gain in Ins1-/-:Ins2+/- mice.
Conclusion: Our results demonstrate that elevated insulin levels in grow-
ing female mice are associated with increased body mass and fat mass, and 
the maintenance of obesity throughout life. Attenuation of hyperinsulinemia 
during the first six months of murine life provides a long-lasting protection 
from obesity. Importantly, this protection persists despite a late-onset emer-
gence of pronounced hyperinsulinemia in high fat-fed Ins1-/-:Ins2+/- female 
mice. These findings suggest that suppressing elevated insulin levels during 
the growth period of adolescence and young adulthood can have far-reaching 
consequences on the obese phenotype of fully grown adults.
Supported by: CIHR Operating Grant, NSERC Canada Graduate Scholarship
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Partial pancreatic Ins2 gene deletion reverses diet-induced obesity in 
adult male mice
M.M. Page1, M. Szabat1, Y. Fan2, M. Trucco2, J.D. Johnson1;  
1Department of Cellular and Physiological Sciences, University of British 
Columbia, Vancouver, Canada, 2Department of Pediatrics, University of 
Pittsburgh School of Medicine, USA.
Background and aims: Obesity is an epidemic affecting more than 500 mil-
lion people worldwide. Furthermore, it is an important risk factor to sev-
eral diseases, including heart disease, diabetes, stroke and cancer. Obesity is 
commonly associated with basal hyperinsulinemia and insulin resistance, but 
the cause and effect relationship between obesity, hyperinsulinemia, insulin 
resistance and type 2 diabetes remains to be fully elucidated. Some evidence 
suggests a causal role for hyperinsulinemia in obesity, independently of in-
sulin resistance. Drugs that block hyperinsulinemia have been reported to 
cause weight loss in humans, but this has remained controversial and it has 
been suggested that such drugs work independently of insulin. We have re-
cently reported that life-long suppression of basal hyperinsulinemia in male 
Ins1+/-:Ins2-/- mice resulted in protection from diet-induced obesity via 
mechanisms that included the reprogramming of white adipose tissue to ex-
press Ucp1. While these results provided the first evidence hyperinsulinemia 
can play a causal role in mammalian obesity, they were unable to distinguish 
between acute and chronic effects of insulin and therefore could not answer 
whether insulin reduction in adult, obese mice would result in weight loss. To 
address this critical therapeutic question, we developed a mouse model with 
acute 50% deletion of the insulin 2 gene.
Materials and methods: We generated an inducible, 50% beta-cell specific 
insulin gene knockout mouse model (Pdx1CreER:Ins1-/-:Ins2f/+) to test 
the hypothesis that diet-induced obesity can be lowered by simply reducing 
pancreatic insulin production, which would indicate that long-term devel-
opmental reprogramming of the insulin system is not required to protect 
mammals from obesity. Control chow (25% fat) and high fat (58% fat) diets 
were initiated in both female and male mice at 6 weeks of age. Following 12 
weeks on the respective diets, test and littermate control mice were injected 
with tamoxifen (or vehicle) resulting in the inducible loss of one Ins2 allele 
in test mice.
Results: High fat diet-induced obesity was observed by 12 weeks of diet when 
compared to littermate control mice fed a control chow diet, and was espe-
cially pronounced in males. Remarkably, inducible reduction of pancreatic 
insulin 2 gene dosage in tamoxifen-injected Pdx1CreER:Ins1-/-:Ins2f/+ male 
mice resulted in a 5% rapid weight loss to the levels seen in mice on control 
diets within 3 weeks. This effect was also only seen in mice fed a high fat diet 
as body mass did not differ between mice fed a chow diet following tamoxifen 
injection. The weight loss observed in the HFD male mice, which was due to 
reduced fat mass, was not a result of hyperglycaemia, as fasted blood glucose 
did not differ from control male mice on the HFD (control, 8.4±0.2; test, 
8.4±1.3, p=0.99). Gene expression patterns were assessed in multiple tissues 
to provide molecular clues to the rapid mechanisms of weight loss subsequent 
to the abrogation of diet-induced hyperinsulinemia. Energy expenditure and 
related parameters were assessed using metabolic cages.
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Conclusion: Together, these data provide the first evidence in any organism 
that obesity can be reversed by acutely reducing the production and circula-
tion of insulin. Our results have profound implications for nutritional guide-
lines and therapeutic efforts to combat obesity.
Supported by: CIHR
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BACE2 suppression ameliorates beta cell dysfunction induced by human 
islet amyloid polypeptide (IAPP) overexpression
G. Alcarraz-Vizán1,2, C. Castaño1,2, L. Cadavez1,2, M. Visa1,2, J. Montane1,2, 
J.M. Servitja1,2, A. Novials1,2;  
1Diabetes & Obesity Laboratory, IDIBAPS, 2CIBERDEM, Barcelona, Spain.
Background and aims: BACE2 (β-site APP-cleaving enzyme 2) is a 
β-protease that has been found in the brain, where it is thought to play a role 
in the development of Alzheimer’s disease (AD). It has also been localized in 
the pancreas, where it seems to play a physiological role since BACE2-defi-
cient mice elicit better glucose tolerance than control littermates. Amyloido-
genic diseases, including AD and type 2 diabetes (T2D), have been reported 
to share the accumulation of abnormally folded and insoluble proteins that 
interfere with cell function. In the case of T2D, amylin (IAPP) deposits have 
been shown to be a key feature of the disease. The aim of the present study 
was to investigate the effect of BACE2 modulation on β-cell alterations in-
duced by IAPP overexpression.
Materials and methods: Heterozygous-hIAPP mice, BACE2-KO mice and 
their respective controls were used to analyze their phenotype after 16 weeks 
with high-fat diet (HFD) feeding. Afterward, these two models were crossed 
in order to analyze the impact of BACE2 suppression on β-cell alterations 
observed in Tg-hIAPP mice. Insulin tolerance test (ITT) and glucose toler-
ance test (GTT) were performed to evaluate the metabolic phenotype, and 
the area under the curve (AUC) of the GTT was calculated as a measure of 
glucose homeostasis. The ability to secrete insulin in response to glucose 
(GSIS) was quantified with an ELISA kit. Proliferation was analyzed by Ki67 
immunostaining and β-cell mass by insulin immunostaining.
Results: The GTT of Tg-hIAPP mice after 16 weeks of regular chow diet re-
vealed glucose intolerance with respect to the wild type animals. These ani-
mals showed a 1.3-fold increase (p<0.05) in β-cell mass, however, the secreto-
ry response of insulin was reduced after the glucose challenge (25% decrease 
p<0.05, vs. control littermates). 16 weeks of HFD feeding induced insulin 
resistance and glucose intolerance, both in Tg-hIAPP and wild type animals. 
On the other hand, BACE2-KO mice showed better glucose homeostasis than 
their wild type counterparts, which correlates with a 50% enhancement of 
insulin secretory response to glucose injection (p<0.05) and an increase in 
β-cell mass and β-cell proliferation. Moreover, BACE2-KO mice fed with a 
HFD showed an 18% reduction in body weight (p<0.05) and better glucose 
homeostasis than wild type animals (28% decrease in AUC of GTT), indicat-
ing that deletion of BACE2 protects against HFD. The crossed animals (Tg-
hIAPPxBACE2-KO) presented a significant improvement in glucose toler-
ance as compared to Tg-hIAPP mice (18% decrease in AUC). This improve-
ment was due to an enhanced insulin secretory response to glucose load (15% 
increase vs. Tg-hIAPP mice, p<0.05), indicating a potential effect of BACE2 
deletion on β-cell function.
Conclusion: The inhibition of BACE2 compensates glucose tolerance defects 
induced by hIAPP overexpression in the β-cell. Thus, targeting BACE2 may 
represent a good therapeutic strategy to improve β-cell function in T2D.
Supported by: FIS (PI08/0088 and PI11/00679)
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Altered energy metabolism in vivo and in vitro with amyloid beta42 
administration
J.K. Czeczor, T. Connor, A.J. Genders, K. Walder, S.L. McGee;  
School of Medicine, Metabolic Research Unit, Waurn Ponds, Australia.
Background and aims: Amyloid β42 (Aβ42) is a peptide associated with the 
onset of Alzheimer’s Disease (AD) and impairment of neuronal metabolism. 
Aβ42 is also peripherally secreted and increased levels of circulating Aβ42 are 
found in obese and diabetic patients. It is unknown whether circulating Aβ42 
contributes to altered glucose metabolism or insulin action in Type 2 diabetes 
(T2D). The aim of our study was to determine whether administration of 
Aβ42 alters glucose metabolism of insulin sensitive cells in vitro, and whole 
body metabolism in vivo.
Materials and methods: Basal and insulin stimulated glucose uptake and 
glucose production was measured in 3T3-L1 adipocytes and FAO hepato-
cytes respectively after treatment with either monomeric (m)Aβ42 or ag-
gregated (a)Aβ42 at various concentrations (0, 100, 200, 300nM) for 48h; 
scrambled (scr)Aβ42 was used as control. For in vivo studies, 6 week old, male 
C57Bl/6J mice (n=10 per group) were injected i.p. with recombinant mAβ42 
or control scrAβ42 for five weeks (1µg/day). Bodyweight and composition, 
indirect calorimetry and glucose and insulin tolerance were measured before 
and after treatment to determine the effect of mAβ42 administration on these 
measures. The clearance rate of mAβ42 from plasma was determined from 
mice that had been treated for two weeks, with plasma samples collected at 
various time points before (0) and post i.p. injection (1, 15, 30, 60min, 2, 4, 8, 
24h) of mAβ42 and scrAβ42.
Results: Monomeric Aβ42 increased both basal (p<0.001) and insulin 
(p<0.01) suppressed glucose production at higher doses (200; 300nM) in 
FAO hepatocytes compared with respective controls, while aAβ42 had no ef-
fect. In 3T3-L1 adipocytes, mAβ42 as well as aAβ42 impaired basal (p<0.001) 
and insulin stimulated (p<0.01) glucose uptake at higher doses (200; 300nM) 
compared with respective controls. In vivo administration of mAβ42 in-
creased basal circulating levels of mAβ42 compared with scrAβ42 treated mice 
(3.4ng/µl vs 0.8ng/µl; p<0.05) and also total mAβ42 exposure over 24 hours in 
mAβ42 treated mice (p<0.05). Administration of mAβ42 had no effect on bod-
yweight, body composition or food intake compared with control mice and 
did not induce glucose or insulin intolerance. However, mAβ42 treated mice 
displayed increased fasting glucose compared with control mice. There was 
no change in oxygen consumption between the two treatments, but adminis-
tration of mAβ42 resulted in a decrease in RER compared with control mice.
Conclusion: Our in vitro data suggest that primarily mAβ42 impairs insulin 
dependent and independent glucose metabolism in multiple cell types. In 
contrast to recently published studies, our in vivo data show that treatment 
with physiological levels of mAβ42 had no impact on glucose or insulin toler-
ance, despite elevated fasting glucose levels and a substrate shift towards lipid 
oxidation compared with control animals. These data suggest that not only is 
Aβ42 involved in the pathology of AD, but that Aβ42 could also be involved 
in the dysregulation of metabolism in obesity and T2D via insulin dependent 
and/or independent mechanisms.
Supported by: National Health and Medical Research Council
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Transgenerational phenotypic changes in selectively bred mice for 
different susceptibilities to diet-induced glucose intolerance
M. Nagao, A. Asai, H. Sugihara, S. Oikawa;  
Department of Endocrinology, Diabetes and Metabolism, Graduate School 
of Medicine, Nippon Medical School, Tokyo, Japan.
Background and aims: Gene-environment interactions (GEI) play a crucial 
role in the development of type 2 diabetes. To establish novel rodent models 
that can mimic the GEI, we have performed a selective breeding of mice. In 
brief, using 3 inbred strains (C57BL/6, C3H, and AKR) as background, mice 
exhibiting superior and inferior glucose tolerance after high fat diet (HFD) 
feeding have been bred repetitively over 20 generations to establish 2 distinct 
mouse lines with different susceptibilities (resistant and prone) to HFD-in-
duced glucose intolerance, and designated SDG-R and SDG-P, respectively. 
Here, we analyzed transgenerational changes of metabolic phenotypes in the 
selective breeding of SDG-R and SDG-P to explore the hereditary predisposi-
tion to diet-induced glucose intolerance.
Materials and methods: All mice were fed with HFD (32% energy from fat) 
for 5 weeks (5-10 weeks of age) for the selective breeding of SDG-R and SDG-
P. During the 5-20th generations, HFD intake was monitored every week, 
body weight was measured at the end of HFD feeding, and OGTT (2 g glu-
cose/kg body weight) was performed within 1 week after the end of the HFD 
feeding period. In the OGTT, mice of both sexes showing lower and higher 
blood glucose levels at 120 min (BG120 min) were selected to breed the next 
generations of SDG-R and SDG-P, respectively.
Results: The selection index BG120 min was markedly increased as the gen-
erations proceeded in SDG-P mice of both sexes (male, p<0.0001; female, 
p<0.0001: Jonckheere-Terpstra trend test). Although BG120 min was also el-
evated slightly in SDG-R mice (m, p=0.0016; f, p=0.0091), distinct differences 
were seen in BG120 min between the 2 lines at the 20th generation [SDG-R vs. 
SDG-P (mean±SEM mmol/l, t-test): m, 5.60±0.23 vs. 19.9±1.13 (p<0.0001); 
f, 4.34±0.17 vs. 9.60±0.62 (p<0.0001)]. In addition, fasting blood glucose 
levels (FBG) were increased in SDG-P mice of both sexes (m, p<0.0001; f, 
p<0.0001), whereas it was not altered in male (p=0.553) and gradually de-
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creased in female (p<0.0001) SDG-R mice. Post-HFD body weight was in-
creased in SDG-P mice of both sexes (m, p<0.0001; f, p<0.0001) as the gener-
ations proceeded, whereas it was not altered in male (p=0.709) and decreased 
slightly in female (p=0.0006) SDG-R mice. Despite the increasing trend of 
body weight in SDG-P mice, HFD intake was not altered in male (p=0.084) 
and even decreased in female (p=0.0002) SDG-P mice. In SDG-R mice, HFD 
intake was significantly decreased in both sexes (m, p<0.0001; f, p<0.0001). 
Linear regression analysis revealed that differences in the average values of BG120 min, FBG, post-HFD body weight, and HFD intake between the 2 
lines became more evident as the generations proceeded.
Conclusion: Even though BG120 min was the sole criterion for the selective 
breeding, SDG-P mice became more susceptible to HFD-induced obesity as 
well as glucose intolerance. In SDG-P mice, despite the increasing trend in 
body weight, HFD intake was not increased as generations proceeded, sug-
gesting that SDG-P mice had acquired a “thrifty metabolism” through the 
selective breeding. On the other hand, SDG-R mice had reduced HFD intake 
as the generations proceeded, suggesting that SDG-R mice had adapted feed-
ing regulation to maintain glucose tolerance under HFD. These differences 
may determine the distinct susceptibilities to diet-induced metabolic impair-
ments in the 2 lines of mice.
Supported by: Japan Society for the Promotion of Science
PS 050 Adipose tissue function: 
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Adipose tissue mRNA expression of WHR-associated genes exhibit  
inter-depot variability and correlates with fat distribution
J. Krüger1, M. Prellberg1, B. Gutsmann1, D. Schleinitz1, J. Breitfeld1,  
M. Kern2, N. Klöting1, M. Blüher1,2, M. Stumvoll1,2, P. Kovacs1;  
1IFB Adiposity Diseases,  
2Department of Medicine, University of Leipzig, Germany.
Background and aims: Body fat distribution (FD) is one of the main pre-
dictors of obesity associated complications. There is good evidence that fat 
distribution is controlled by genetic factors. Genome-wide association stud-
ies revealed novel loci associated with waist to hip ratio (WHR). Here, we 
hypothesized that genes within these loci exhibit fat depot-specific mRNA 
expression, which correlates with obesity-related traits. Furthermore, we 
conducted expression quantitative trait loci (eQTL) analyses to test whether 
WHR-associated variants may affect the mRNA expression of the corre-
sponding genes in adipose tissue (AT).
Materials and methods: By using qRT-PCR, we measured mRNA levels of 
LYPLAL1, ADAMTS9, VEGFA, CPEB4, RSPO3, ITPR2, SSPN, LY86 in paired 
human samples of visceral and subcutaneous AT from 570 individuals with 
detailed metabolic testing. Previously reported single nucleotide polymor-
phisms (SNPs) associated with WHR were genotyped in all subjects for sub-
sequent eQTL analyses. Since one of the SNPs (rs6795735) maps within the 
ADAMTS9-Antisense RNA 2 (ADAMTS9-AS2), we measured also the mRNA 
expression of ADAMTS9-AS2.
Results: All tested genes exhibited significantly higher mRNA levels in vis-
ceral relative to subcutaneous AT. In addition, the mRNA levels correlated 
with WHR (ADAMTS9, VEGFA, SSPN, LY86), % body fat (ADAMTS9, VEG-
FA, CPEB4, LYPLAL1) and BMI (ADAMTS9, CPEB4). None of the SNPs was 
significantly associated with the mRNA levels or metabolic traits including 
WHR or BMI, which is likely to be attributed to the small sample size, and 
so lack of statistical power. However noteworthy, we observed a strong cor-
relation between the mRNA expression of ADAMTS9-AS2 and ADAMTS9, 
suggesting that the previously reported association of the WHR-associated 
SNP rs6795735 might be mediated by its effects on ADAMTS9-AS2.
Conclusion: Our data including the inter-depot variability of mRNA expres-
sion and its strong correlation with metabolic traits suggest a role of genes 
within the WHR-associated loci in the regulation of fat distribution. In par-
ticular ADAMTS9, VEGFA and CPEB4 are promising candidates for func-
tional analysis of their role in adipocyte biology. This work is currently going 
on.
Supported by: CRC 1052 “Obesity Mechanisms”
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GLP-1 receptor agonist-induced lipolysis in adipocyte is mediated  
by SIRT1
F. Xu, B. Lin, Z. Chen, Z. Li, H. Ai, H. Liang, H. Xu, J. Weng;  
Endocrinology, The Third Affiliated Hospital of Sun Yat-Sen University; 
Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, China.
Background and aims: Accumulated evidence suggests GLP-1 and its mi-
metics exert their beneficial effects in extra-pancreatic organs. Here, we 
found that GLP-1 receptor agonist exenatide might reduce visceral fat by 
increasing lipolysis in adipocytes, and we also explored the potential role of 
SIRT1 in this effect both in vivo and in vitro.
Materials and methods: In this study, 8 weeks male SIRT1 heterozygous 
knockout mice (SIRT1+/-) in C57BL/6J gene background and their wild type 
littermates (WT) were used. After 12 weeks chow diet feeding or high-fat 
diet (HFD) challenge, animals were randomly divided into the following 5 
groups: WT+chow diet, WT+HFD+saline, WT+HFD+exenatide, SIRT1+/-
+HFD+saline and SIRT1+/-+HFD+exenatide. Mice were treated with intra-
peritoneal injection of exenatide (24 nmol/kg) or normal saline control daily 
for another 8 weeks. Systemic evaluations were carried out including body 
weight, FBG, ip GTT, ip ITT, blood lipids profile, and weight of epididymal 
fat. Quantitive RT-PCR and western blot were used to detect mRNA and pro-
tein expression in epididymal fat, respectively. In differentiated 3T3-L1 adi-
pocytes, lentivirus vector expressing SIRT1 RNAi sequence was transfected 
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to knock down SIRT1, and transfected cells were then treated with exendin-4 
for 24 h.
Results: The animal study showed that both body weight and epididymal 
fat weight were sharply decreased after exenatide treatment compared with 
saline control in WT+HFD group. However, the decrease in SIRT1+/-+HFD 
group after exenatide treatment was much milder. While lipids profile showed 
the same change. Both RT-PCR and western blot results indicated that the ex-
pression of SIRT1 was up-regulated in WT+HFD group with exenatide treat-
ment as compared with saline control; however, no significant difference was 
observed in SIRT1+/-+HFD mice after exenatide treatment. In differentiated 
3T3-L1 adipocytes, exendin-4 up regulated SIRT1 and p-AMPK expression 
in a dose-depended way. Lipolytic related factors including p-ACC, ACC 
and ATGL were all induced by exendin-4. After knocking down SIRT1 with 
SIRT1 RNAi, these factors were down regulated dramatically even with ex-
endin-4 treatment.
Conclusion: Our data demonstrated that GLP-1 receptor agonist exenatide 
could reduce visceral fat by inducing lipolysis in adipocytes, and this effect is 
mediated by SIRT1 both in vivo and in vitro. It might be a new mechanism 
for GLP-1 and its mimetics in the role of losing weight.
Supported by: 973 project (2012CB517506)
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Activation of adipose tissue cannabinoid receptors 1 (CB1R) alters 
antilipolytic action of insulin and increases lipolysis in mice
P. Degrace, T. Muller, S. Troy-Fioramonti, L. Demizieux, J. Gresti,  
M. Bouam, B. Vergès;  
Equipe Physiopathologie des Dyslipidémies, UMR866 INSERM-Université 
de Bourgogne, Dijon, France.
Background and aims: Recent data indicate that activation of peripheral en-
docannabinoid system (ECS) in tissues such as liver, muscle or adipose tis-
sue may directly influence carbohydrate and lipid metabolism. The existence 
of cannabinoid receptors 1 (CB1R) and ECS enzymatic machinery has been 
demonstrated in mature adipocytes, nevertheless studies regarding their 
role in lipogenesis and lipolysis control are often conflicting. This study was 
designed to examine the consequence of ECS activation by anandamide on 
lipolysis activity and related regulation pathways.
Materials and methods: Lipolysis activity was estimated measuring for 45 
min plasma glycerol release in response to β3-adrenergic receptor agonist 
(BRL37344) in wild type, DIO or CB1R-/- mice after acute peripheral anan-
damide injection compared with vehicle. Additional in vitro experiments 
were conducted to test direct effects of anandamide on glycerol release and 
signaling pathways on adipose tissue explants exposed to various concentra-
tions of insulin and norepinephrine.
Results: While anandamide alone had no remarkable effects on basal lipoly-
sis, ECS activation potentiated the effect of BRL37344 on glycerol release in 
wild type mice. The effect of anandamide on stimulated lipolysis was strongly 
reduced in CB1R-/- while it was amplified in obese animals whose adipose 
tissue CB1R mRNA expression was much higher than in lean mice. In control 
mice, the stimulatory effect of BRL37344 on glycerol release was totally coun-
teracted by insulin injection (0,025UI/kg) while it was partially maintained 
in the presence of anandamide suggesting that ECS activation may be associ-
ated with an alteration of the inhibitory action of insulin on lipolysis. These 
findings were also observed in cultured explants exposed to anandamide in 
which inhibition of glycerol release by insulin was abrogated. Further, anan-
damide treatment increased protein levels of the active form of hormone-
sensitive lipase and reduced level of Akt and Pi3K phosphorylation compared 
to control in accordance with a decrease in the activity of insulin-dependent 
signaling cascade.
Conclusion: All together, these data showed that activation of ECS in adi-
pose tissue increases lipolysis by altering the antilipolytic action of insulin. 
This suggests that antagonism of CB1R may constitute a new strategy to limit 
ectopic fat deposition associated with obesity.
Supported by: SFD research grant
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Increased BMP4 improves insulin sensitivity and increases beige/brown 
adipogenesis in adult mice
J.M. Hoffmann1, J.R. Grünberg1, I. Elias2, F. Bosch2, A. Hammarstedt1,  
S. Hedjazifar1, U. Smith1;  
1Department of Molecular and Clinical Medicine/Diabetes, The Lundberg 
Laboratory for Diabetes Research, Gothenburg, Sweden,  
2Department of Biochemistry and Molecular Biology, CBATEG (Center of 
Animal Biotechnology and Gene Therapy), Barcelona, Spain.
Background and aims: Bone Morphogenic Proteins (BMPs) belong to the 
transforming growth factor beta superfamily and regulate a wide range of 
developmental and cellular processes. BMP4 has been shown to be critical for 
adipose precursor cell commitment and differentiation to the white adipose 
lineage. However, recent data also suggest a role of BMP4 in beige/brown adi-
pose cell differentiation. A previous study has examined the developmental 
effect of BMP4 in mice genetically engineered to overexpress BMP4 in the 
adipose tissue. However, to be a potential therapeutic target it is important to 
examine if BMP4 also is able to increase beige/brown adipogenesis in adult 
animals. This is further underscored by our recent findings that adipose pre-
cursor cells in obesity exhibit a resistance to the effects of BMP4. To examine 
the effect of BMP4, we injected adult mice with AAV8-BMP4 or AAV8-null 
virus vectors targeting the liver and, thus, increasing circulating BMP4 levels.
Materials and methods: Six weeks old male C57BL6/N mice received a retro-
orbital injection of AAV8 expressing BMP4 or control (null) virus. The mice 
were fed a high fat diet (HFD) for 16 weeks and they underwent ip GTT, ip 
ITT and DEXA. Adipose tissue and muscle were taken for gene and protein 
analyses and immunohistochemistry was performed on paraffin-embedded, 
formalin fixed tissue samples. All reported results are statistically significant. 
Statistical analyses were performed using Students t-test or Mann-Whitney 
non-parametric U-test.
Results: HFD-BMP4 mice gained less weight than the HFD-null mice in 
spite of having the same food intake. They also had reduced total adipose 
tissue mass and smaller adipose cells. Furthermore, they had an improved 
glucose tolerance and were more insulin-sensitive than the HFD-null mice. 
In addition to the reduced fat mass they also had increased lean body 
mass. Both gene and protein expression of beige/brown adipose markers 
(TMEM26, CD137 and UCP1) were increased in the subcutaneous adipose 
tissue. Markers of mitochondrial biogenesis, like PGC1α, were significantly 
increased in both skeletal muscles and the adipose tissue. Since obesity also 
has been shown to lead to increased adipose tissue fibrosis and BMP4 may 
exert an anti-fibrotic effect, we examined markers of this process. Interest-
ingly, both α-SMA and CTGF mRNA levels were significantly reduced in the 
obese BMP4 mice.
Conclusion: We here demonstrate that increased circulating levels of BMP4 
in obese and adult mice lead to clear positive phenotypic changes with re-
duced body fat, increased lean body mass together with increased insulin 
sensitivity and improved glucose tolerance. These effects are probably due 
to the marked induction of beige/brown adipose cells in the subcutaneous 
adipose tissue as well as increased mitochondrial biogenesis also seen in 
the skeletal muscles. BMP4 also reduced markers of adipose tissue fibrosis 
known to be increased in obesity.
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Glyoxalase-1 overexpression reduces body weight and adipokine 
expression, and improves insulin sensitivity in high-fat diet-induced 
obese mice
D. Maessen1, O. Brouwers1, T. Miyata2, C. Stehouwer1, C. Schalkwijk1;  
1Internal Medicine, Maastricht University Medical Centre, Netherlands, 
2Centre of Translational and Advanced Research, Tohoku University, Sendai, 
Japan.
Background and aims: The development of obesity, and especially the ex-
pansion of visceral adipose tissue (VAT), is associated with the development 
of inflammation and insulin resistance. We previously demonstrated an ac-
cumulation of advanced glycation endproducts (AGEs) in obese VAT, lead-
ing to dysregulated expression of adipokines. In addition, the increased AGE 
levels were associated with the development of insulin resistance. Based on 
previous work, we hypothesized that inhibition of the major AGE precur-
sor methylglyoxal (MGO) attenuates the impaired adipokine profile and im-
proves insulin sensitivity in obesity. Because MGO can be detoxified by the 
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glyoxalase-1 (GLO-1) enzyme, we used a GLO-1 overexpressing transgenic 
mouse model which was fed with a high-fat diet (HFD).
Materials and methods: After a run-in period of 4 weeks, both wild-type 
(WT) mice and GLO-1 transgenic mice (10 weeks old) were either fed with 
a low-fat diet (LFD, 10% kcal% fat) or a HFD (45% kcal% fat) for 15 weeks. 
In the last two weeks of the study we performed an intraperitoneal glucose 
tolerance test (ipGTT) and insulin tolerance test (ipITT). All mice were eu-
thanized after 15 weeks of LFD or HFD and multiple organs were collected 
for ex vivo examination.
Results: Endogenous GLO-1 mRNA levels of the VAT were significantly 
lower in WT mice of the HFD group compared to the WT mice of the LFD 
group (p<0.01). Activity of the GLO-1 enzyme was also reduced in the VAT 
of the HFD group (p<0.05). Bodyweight gain was significantly increased after 
15 weeks of HFD feeding compared to the LFD group (15.2 ± 4.7 vs 6.5 ± 2.2 
gram, respectively; p<0.001). Overexpression of GLO-1 in mice fed with the 
HFD inhibited the bodyweight gain significantly compared to the WT mice 
(10.5 ± 4.5 vs 15.2 ± 4.7 gram, respectively; p<0.05), despite equal calorie 
intake (13.1 ± 2.0 vs 12.3 ± 1.6 kcal/day, respectively; p=0.30). Furthermore, 
the VAT of the HFD group was characterized by a pro-inflammatory profile, 
as indicated by an upregulated mRNA expression of MCP-1, F4/80, MHC-II, 
CD11c and TNFα (all p<0.05). Overexpression of GLO-1 in the HFD mice 
attenuated these increases in mRNA levels. Finally, HFD-induced insulin re-
sistance was attenuated by GLO-1 overexpression, as assessed by the ipGTT 
(ptrend<0.001) and the ipITT (ptrend=0.08).
Conclusion: Our data demonstrate that overexpression of the GLO-1 en-
zyme is a potential mechanism to reduce body weight gain, carbonyl stress, 
adipose tissue inflammation and insulin resistance in HFD-associated obe-
sity. Modulating the GLO-1 pathway may be a novel approach to prevent 
obesity-associated complications.
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Deletion of inhibitory G proteins protects from obesity
V. Leiss1, A. Novakovic1, T. Sartorius2, J. Machann3, H.-U. Häring2,  
B. Nürnberg1;  
1Pharmacology and Toxicology, , 2Internal Medicine IV,  
3Experimental Radiology, University Hospital Tübingen, Germany.
Background and aims: Many hormones and other substances involved in 
the breakdown or storage of fatty acids signal via G protein coupled receptors 
(GPCRs). Upon binding of such ligands to the respective GPCRs the asso-
ciated heterotrimeric G proteins are activated causing a dissociation of Gα 
subunits from Gβγ dimers. The Gα subfamily of inhibitory G proteins (Gαi) 
shows a sequence identity of up to 95% among the three isoforms Gαi1, Gαi2, 
and Gαi3. Due to this high homology it has been suggested that Gαi proteins 
serve the same functions, i.e. they are activated by a similar set of GPCRs 
and signal to an overlapping set of effectors. Interestingly, recent publications 
describe more and more individual tissue- and cell-specific functions for the 
different isoforms. In this study we aim to clarify the specific roles of Gαi2 and 
Gαi3 proteins for body weight gain in mouse models on normal (ND) and 
high-fat diet (HFD) conditions.
Materials and methods: In Gαi2- and Gαi3-deficient mice we analysed in 
vitro differentiation of adipocytes isolated from 4-6-week-old mice and in 
vivo body composition of mice fed a ND or HFD for 14 weeks by magnetic 
resonance imaging (MRI).
Results: Gαi2 and Gαi3 are both expressed in white adipose tissue. Interest-
ingly, both Gαi2- and Gαi3-deficient mice show a lean phenotype on ND com-
pared to their respective littermates. However, time occurrence of the weight 
differences is detectable in a genotype-dependent manner. Gαi2-deficient 
mice weigh less already at weaning, whereas Gαi3-deficient mice showed ini-
tially no differences. Magnetic resonance imaging revealed that 18-week-old 
Gαi2-deficient mice had significantly lower amounts of subcutaneous and 
visceral adipose tissue mass. In contrast, in Gαi3-deficient mice a reduced 
fat mass determined by MRI was first observed in 36-week old mice, which 
gained statistical significance at 56-weeks of age. In addition, Gαi2- and Gαi2-
targeted mice were protected from remarkably weight gain on HFD. Since 
Gαi2-deficient mice have pronounced weight differences starting at an early 
stage, we analysed differentiation of white adipocytes in vitro. Significantly 
less Oil-red-O-positive Gαi2-deficient adipocytes were detectable, whereas 
Gαi3-deficient in vitro adipocyte differentiation was similar to wild-type cells.
Conclusion: We conclude that deletion of Gαi2 and Gαi3 protects from weight 
gain in an age-dependent manner and results in a leaner phenotype. Our data 
suggest specific and independent roles of both isoforms in the differentiation 
of white adipocytes as well as in the regulation of adipose tissue mass.
Supported by: the DFG 
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14-3-3ζ controls mitotic clonal expansion and adipocyte differentiation 
via p27Kip1
G.E. Lim1, T. Albrecht1, J. Lee1, C. Nislow2, J.D. Johnson1;  
1Cellular and Physiological Sciences, 2Pharmaceutical Sciences,  
University of British Columbia, Vancouver, Canada.
Background and aims: Obesity is a major risk factor for type 2 diabetes, but 
the molecular mechanisms underlying adipogenesis are not fully known. 
While undergoing mitotic clonal expansion, adipocytes acquire specific tran-
scriptional networks to drive differentiation. Proper localization of transcrip-
tional regulators depends on molecular adaptor proteins, such as those of the 
14-3-3 protein family. Previously, we identified essential roles of 14-3-3ζ in 
the regulation of adipogenesis in vitro and in vivo. Given its ability to regu-
late many transcription factors, we sought to examine the effects of 14-3-3ζ 
knockdown on the adipogenic transcriptome.
Materials and methods: 3T3-L1 cells were treated with insulin, IBMX, and 
dexamethasone for 0, 24, or 48 hours to induce differentiation. Cells were 
transfected with siRNA targeting 14-3-3ζ or a scrambled control (siCon). 
Libraries for RNA-Seq were analyzed with an Illumina Hi-Seq 2500 (20 mil-
lion paired-end reads per sample). Differentially expressed genes (p<0.001 
cut-off) were subjected to Gene-set enrichment analysis (GSEA; FDR<25%) 
to determine biological processes affected by differentiation or si14-3-3ζ. 
Flow-cytometry was used to quantify the proportion of cells at stages of the 
cell cycle. Adipocyte differentiation was assessed by Oil Red-O staining and 
immunoblotting for Pparγ.
Results: RNA sequencing revealed that >5000 genes were significantly al-
tered (p<0.001) during the first 48 hr of differentiation. Categorization of 
differentially expressed genes by GSEA showed negatively enriched gene 
sets (p<0.0001) that were related to the cell cycle, fat cell differentiation, and 
regulation of transcription in 14-3-3ζ-depleted cells. Induction of numer-
ous genes associated with the cell cycle (GO:000749) and mitotic cell cycle 
phase transition (GO:0044772), such as Cdc25a, Cdk6, and Cdkn1b, were 
significantly impaired following 14-3-3ζ knockdown. To further explore the 
effect of 14-3-3ζ on the cell cycle, si14-3-3ζ-transfected 3T3-L1 cells were in-
duced to differentiate and subjected to flow cytometry at 0, 24, and 48 hours. 
Knockdown of 14-3-3ζ prevented cells from entering S-phase (25% vs 8%, 
p<0.01). P27Kip1 (encoded by Cdkn1b) regulates G1-S transition, and de-
pletion of 14-3-3ζ promoted a 4-fold increase (p<0.05) in p27Kip1 in undif-
ferentiated cells. Differentiation caused a gradual decrease in p27Kip1 levels, 
but its expression remained elevated in si14-3-3ζ-transfected cells. To test if 
elevated p27Kip1 contributes to the defects in si14-3-3ζ-mediated cell cycle 
progression and differentiation, 3T3-L1 cells were co-transfected with siRNA 
against 14-3-3ζ and p27Kip1. No effects on adipogenesis were observed in 
siCon- or sip27Kip1-transfected cells; however, co-transfection of sip27Kip1 
into 14-3-3ζ-deficient cells restored adipogenesis.
Conclusion: Our results demonstrate a novel role for 14-3-3ζ in the cell cycle, 
as 14-3-3ζ negatively regulates p27Kip1 expression. Loss of 14-3-3ζ induces 
premature cell cycle arrest and ultimately blocks adipogenesis. Despite broad 
changes in global gene expression of pre-adipocytes, reductions in p27Kip1 
alone are sufficient to rescue the defect in differentiation in 14-3-3ζ deficient 
cells. These findings suggest that modulating 14-3-3ζ or p27Kip1 expression 
could represent novel therapeutic approaches for the treatment of obesity.
Supported by: JDRF, CDA
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Deleted in breast cancer 1 (DBC1) plays a bifunctional role in adipocyte 
differentiation and inflammation
J. Moreno-Navarrete, M. Moreno, M. Vidal, F. Ortega, M. Serrano, G. Xifra, 
W. Ricart, J.M. Fernandez-Real;  
Hospital of Girona, Spain.
Background and aims: Deleted in breast cancer 1 (DBC1) is a pleiotropic 
nuclear protein that interacts and modulates the activity of several molecules, 
including Sirt1, NF-κB and Rev-erbα, which exert important roles in adipo-
cyte differentiation. Here, we aimed to investigate the possible role of DBC1 
in adipose tissue physiology and in adipocyte differentiation.
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Materials and methods: In two independent cohorts [cohort 1, participants 
with different degree of obesity (n= 105) and cohort 2, morbidly obese par-
ticipants (n=47)], DBC1 gene expression was investigated in adipose tissue 
according to obesity and insulin resistance. DBC1 mRNA and protein levels 
during adipocyte differentiation and the effects of DBC1 knockdown (using 
Dbc1-targeted and control shRNA lentiviral particles) in the early stage of 
this process were also evaluated.
Results: DBC1 mRNA was detected at substantial levels in both visceral 
(VAT) and subcutaneous (SAT) adipose tissue (mainly in the adipocyte frac-
tion), decreased in obese subjects, and directly associated with the expression 
of lipogenic and lipolytic genes in two both independent cohorts. Strikingly, 
DBC1 was linked to TNF mRNA levels in obese and morbidly obese partici-
pants and the administration of macrophage conditioned medium resulted 
in increased DBC1 gene expression in adipocytes. In line with these find-
ings, in the early stages of adipocyte differentiation, Dbc1 knockdown led 
to decreased lipid accumulation and adipogenic gene expression in parallel 
to the increase of Sirt1 and AMPK activity. On the other hand, Dbc1 gene 
knockdown also led to a significant reduction in the expression of inflam-
matory genes (Tnf, Il6, Stamp2, Lbp and Mcp1) at the end of adipocyte dif-
ferentiation.
Conclusion: Altogether these findings suggest that DBC1 exerts a bifunc-
tional role in adipocyte physiology, being essential for adipocyte develop-
ment, but also involved in adipocyte inflammation in the late stage of adipo-
cyte differentiation.
Supported by: ISCIII
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Antenatal antipsychotic exposure induces multigenerational  
and sex-specific programming of body weight and diabetes susceptibility 
in adult mouse offspring
E. Courty1, P. Gobalakichenane1,2, M. Garcia1, T. Ledent1, D. Mitanchez2,  
M. Buyse1,2, B. Fève1,2;  
1INSERM U938, 2APHP, Paris, France.
Background and aims: Atypical antipsychotic medications have revolution-
ized the treatment of severe mental diseases, but their metabolic side effects 
have been pointed, including obesity and diabetes. Among them, Olanzapine 
use has been reported during pregnancy and breastfeeding, but so far no clin-
ical trials assessed the safety of in utero olanzapine exposure to fetuses and 
infants, or long term health outcome. In this study we analysed the transgen-
erational impact on metabolic homeostasis of mouse fetal antipsychotic ex-
posure throughout gestational period.
Materials and methods: At 7d gestation, pregnant F0 CD1 mice received 
olanzapine (olz4 or olz8: 4 or 8 mg/kg/d) or haloperidol (hld: 2 mg/kg/day) 
or vehicule (control) through mini-osmotic pump until they gave birth natu-
rally. F1 female offspring exposed in utero to olz (mat-olz) and hld (mat-hld) 
were bred to produce F2 offspring. Offsprings were weight every 3 days until 
the age of 3 weeks then weekly until 3 months of age. Glucose metabolism 
was investigated by insulin tolerance test (ITT), oral glucose tolerance test 
(OGTT) and plasma insulin measurement at the age of 3 months and 1 year 
for F1 offsprings, and at the age of 3 months for F2. Part of the F1 offspring 
cohort was sacrificed at 3 months and 1 year to analyse body and tissue com-
position and measure biochemichal and hormonal parameters.
Results: The litter size of F1 mice was not influenced by the maternal treat-
ment. However birth weight of mat-antipsychotic offspring groups of both 
sexes was significantly decreased compared to mat-control (p<0.01), sug-
gesting an antipsychotic-induced intrauterine growth retardation. Only few 
weeks after birth, the initial difference in weight between mat-hld, female 
mat-olz and control disappeared. However, decreased weight of male mat-olz 
persisted thoughout life (p<0.05). The results of OGTT and insulin measure-
ment performed at the age of 3 months on F1 offspring were not different 
between mat-olz, mat-hld and control both in males and females. However 
mat-olz offspring developed a significant insulinoresisitance compared to 
mat-ctrl. At the age of 1 year, a sexual dimorphism was observed. Concern-
ing F1 male mat-olz, no modification in glucose metabolism (OGTT, ITT) 
or in hormonal parameters (insulin, leptin, adiponectin) or body mass com-
position was observed despite persistent lower weight compared to control 
(p< 0.05). However at the same time, mat-olz female developed impaired 
glucose tolerance (olz 4 and olz 8 vs ctrl p<0.05), hyperinsulinemia (olz 8 vs 
ctrl p<0.05) associated with insulinoresistance (olz 4vs ctrl p<0.05). Besides, 
increased leptin and adiponectin plasma level associated with expanded sub-
cutaneous adipose depot and higher body weight were found in olz female 
offspring. Strikingly, for F2 olz-offspring , both male and female mice devel-
oped a marked glucose intolerance, hyperinsulinemia and insulinoresistance 
compared to F2 controls, with a female-specific increase body weight (olz 4 
vs ctrl p<0.05, olz 8 vs ctrl p<0.01).
Conclusion: These data suggest that in utero antipsychotic exposure is suf-
ficient to provoke sharp health outcomes in sex-specific manner, indicating 
varying developmental vulnerabilites between sexes towards metabolic dis-
eases. They also evidence the transgenerational programming of diabetes 
susceptibility in response to maternal antipsychotic treatment.
Supported by: SFE société Française d’endocrinologie
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PS 051 The role of the liver in 
glucose and lipid metabolism
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Fat accumulates preferentially in the right liver lobe in non-diabetic 
subjects: implications for the diagnosis of NAFLD
H. Bian1,2, A. Hakkarainen3, Y. Zhou2, N. Lundbom3, X. Gao1,  
H. Yki-Järvinen2;  
1Department of Endocrinology and Metabolism, Zhong Shan Hospital, 
Fudan University, Shanghai, China, 2Minerva Foundation Institute for 
Medical Research, Helsinki, 3Department of Radiology, Helsinki Medical 
Imaging Center, Helsinki University Central Hospital, Finland.
Background and aims: The right lobe of the liver preferentially receives 
blood flow from superior mesenteric vein, while the left lobe mainly drains 
the spleen. In obese subjects, the rate of visceral lipolysis is increased com-
pared to non-obese subjects and can account for up to 50% of free fatty acids 
(FFA) delivery to the liver. Many obese subjects accumulate fat in the liver 
due to non-alcoholic causes (NAFLD) and therefore possibly an increased 
flux of FFA from visceral fat to the superior mesenteric vein. Studies using 
Doppler ultrasonography in healthy volunteers have shown that in response 
to a meal, intrahepatic portal vein blood flow increases more in the right than 
the left lobe. FFA delivery from both the meal and from visceral lipolysis 
might preferentially increase liver fat content more in the right than the left 
lobe. Metabolic consequences of hepatic insulin resistance in NAFLD such 
as hyperinsulinemia and hypertriglyceridemia could therefore also be better 
correlated with fat in the right than the left lobe. We aim to examine the dis-
tribution of liver fat (LFAT) in non-diabetic subjects and to test whether the 
fat in the right as compared to the left lobe correlate better with components 
of the metabolic syndrome or not.
Materials and methods: We determined LFAT by 1H-MRS in the right lobe 
(LFAT%MRS), and by MRI (LFAT%MRI) in four regions of interest (ROIs 
1-4, ROI1-2 in the left and ROI 3-4 in the right lobe) in 97 carefully phe-
notyped non-diabetic subjects (age range 22-74 yrs, BMI 18-41 kg/m2) and 
compared the accuracy of LFATMRI in the different ROIs in diagnosing non-
alcoholic fatty liver disease (NAFLD) using areas under the receiver operator 
characteristic (AUROC) curves.
Results: 38% of the subjects had NAFLD (LFAT%MRS). LFAT%MRI in 
ROIs 1, 2, 3 and 4 averaged: 4.8±0.5%, 5.5±0.5%, 5.8±0.5% and 5.7±0.5%. 
The LFAT%MRI was significantly lower in ROI 1 than in ROI 2 , ROI 3 and 
ROI 4 . LFAT%MRI was significantly higher in the right (5.7±0.5%) than the 
left (5.1±0.4%) lobe (p<0.02). LFAT%MRI in ROI 3 showed excellent ac-
curacy in diagnosing NAFLD (AUROC = 0.936±0.023, p< 0.001, sensitiv-
ity 94.6%, specificity 83.3%). The AUROC for ROI 1 was good (AUROC = 
0.879±0.034, p< 0.001, sensitivity 70.3%, specificity 90.0%) but significantly 
lower than that of AUROC for ROI 3 (p<0.02). Likewise, the AUROC was 
significantly higher using LFAT%MRI in the right (AUROC = 0.934±0.025, 
p< 0.001, sensitivity 86.5%, specificity 90.0%) than in the left lobe (AUROC 
= 0.894±0.032, p< 0.001, sensitivity 73.0%, specificity 91.7%) lobe (p<0.05). 
The correlation coefficients between BMI, waist and hip circumference, body 
fat, intra-abdominal and subcutaneous fat, S-AST, S-ALT and LFAT%MRS 
were significantly higher than those between these metabolic features and 
LFAT%MRI in ROI 1. The correlation coefficient between HOMA-IR, S-AST, 
S-ALT and LFAT% MRI in ROI 2 was significantly lower than those between 
LFAT%MRS and these metabolic features The correlation coefficients be-
tween the metabolic parameters and LFAT%MRI in ROIs 3 and 4 did not 
differ from those relating the respective parameters and LFAT%MRS.
Conclusion: Measurement of fat in the right lobe provides a more accurate 
diagnosis of NAFLD than fat in the left lobe.
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Pivotal role of TNF-alpha in the development and progression  
of non-alcoholic fatty liver disease in a murine model
S. Kakino, T. Ohki, H. Nakayama, X. Yuan, S. Otabe, T. Hashinaga,  
N. Wada, Y. Kurita, K. Tanaka, K. Hara, E. Soejima, Y. Tajiri, K. Yamada;  
Endocrinology and Metabolism, Kurume University, Japan.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) repre-
sents the hepatic component of the metabolic syndrome, incorporating a 
wide spectrum of liver disease from simple steatosis to non-alcoholic stea-
tohepatitis (NASH) leading to cirrhosis and ultimately hepatocellular carci-
noma. However, mediators of this progression are incompletely understood. 
Previously we have reported that adipocyte-specific nSREBP-1c transgenic 
(Tg) mice spontaneously developed hepatic lesions similar to those of human 
NASH. nSREBP-1c Tg mice are insulin resistant and their circulating levels 
of TNF-alpha are significantly higher than wild-type mice. In this study we 
assessed the role of TNF-alpha in the progression of NAFLD.
Materials and methods: We established a Tnf(-/-) nSREBP-1c Tg mouse line 
on C57B/6 background. Liver sections were stained with hematoxylin and 
eosin or azocarmine and aniline blue (Azan). mRNA levels of acetyl-CoA 
carboxylase (Acc1), stearoyl-CoA desaturase-1 (Scd1), monocyte chemot-
actic protein-1 (Mcp1), transforming growth factor-beta (Tgfb1), collagen 
type I alpha 1 (Col1a1), and tissue inhibitor of metalloproteinase 1 (Timp1) 
were determined by quantitative reverse transcription PCR. TIMP1 protein 
levels were assessed by Western blotting and immunohistochemical staining. 
Primary hepatocytes isolated from Tnf(-/-) C57BL/6 mice were cultured in 
Williams’ medium E.
Results: All of 17 nSREBP-1c Tg mice had fatty liver at the age of 20 weeks. 
However, significant fat deposits were observed only in 5 of 20 age-matched 
Tnf(-/-) nSREBP-1c Tg mice (p<0.0001). When compared with nSREBP-1c 
Tg mice, the prevalence of liver fibrosis was low in Tnf(-/-) nSREBP-1c Tg 
mice (11/17 vs. 3/20, p=0.006). nSREBP-1c Tg mice showed higher expres-
sion of Acc1, Scd1, Mcp1, Tgfb1, Col1a1, and Timp1 in the liver than wild-
type C57BL/6 mice. The protein levels of Timp1 were also increased in the 
liver from nSREBP-1c Tg mice. The expression levels of the genes and the 
Timp1 protein levels were reduced in Tnf(-/-) nSREBP-1c Tg mice. Incuba-
tion with 10 ng/ml TNF-alpha up-regulated the Timp1 expression in primary 
cultured hepatocytes from Tnf(-/-) C57BL/6 mice.
Conclusion: These observations indicate that TNF-alpha is involved in the 
development of NAFLD through the induction of key enzymes of lipid me-
tabolism, ACC1 and SCD1. TNF-alpha was also associated with the increase 
of inflammatory cytokines, MCP1 and TGF-beta. Several studies have shown 
that TIMP1 is increased in liver fibrosis both in murine models and human 
samples, and promotes liver fibrosis development. Here we showed that 
Timp1 mRNA was decreased in the liver from Tnf(-/-) mice, and the sup-
plementation of TNF-alpha increased the expression of Timp1 in primary 
cultured Tnf(-/-) hepatocytes. Thus TNF-alpha may play a pivotal role in 
both the development of NAFLD and progression to NASH in insulin resist-
ant state.
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Proteomic analysis of livers from fat-fed mice deficient in either PKCδ 
or PKCε
B.M. Liao1, K. Raddatz2, C. Schmitz-Peiffer1;  
1Diabetes and Obesity Research Program, Garvan Institute of Medical 
Research, Sydney, Australia, 2Competence Centre Functional Genomics – 
Pathoproteomics, University of Greifswald, Germany.
Background and aims: The two isoforms of protein kinase C (PKC), PKCδ 
and PKCε, have been associated with insulin resistance in the liver, which is 
a characteristic of Type 2 diabetes. Our previous comparison between PKCδ 
knockout (KO) mice and PKCε KO mice revealed roles for both of the kinases 
in the generation of insulin resistance, yet opposing roles in hepatic triglyc-
eride accumulation. Therefore we aim to gain mechanistic insights into the 
roles of PKCs in the modulation of insulin action and lipid metabolism using 
a proteomics approach.
Materials and methods: We conducted an unbiased in vivo spike-in SILAC 
proteomic profiling of livers from one week high fat diet-fed PKC KO mice 
and their wild-type counterparts.
Results: A total of 3359 proteins and 3488 proteins were identified from 
the PKCδ KO and PKCε KO study groups respectively, and we showed 
that several enzymes of lipid metabolism were affected by the fat diet. In 
fat-fed mice, 23 proteins showed significant changes upon PKCδ dele-
tion while 19 proteins were affected by PKCε deletion. Notably, retinol 
pathway was significantly upregulated in fat-fed mice with either dele-
tion. The majority of the proteins affected in this pathway belonged to 
the Cyp450 family which is involved in the metabolism of all-trans reti-
noic acid (atRA). Thus it is possible that alterations in atRA or its de-
rivatives protect PKC KO mice from fat diet-induced insulin resistance. 
Furthermore, gene ontology (GO) analysis showed proteins involved in bi-
ological processes such as lipid biosynthesis and oxidation-reduction were 
enriched in the absence of either PKC isoform. However certain GO terms 
such as monosaccharide metabolism were enriched solely in PKCδ KO and 
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isoprenoid biosynthesis only in PKCε KO. Taken together, these further sug-
gest that PKCδ and PKCε exert partly overlapping and differential effects on 
liver metabolism in response to fat oversupply.
Conclusion: These studies therefore provide a detailed comparison of the ef-
fects of fat feeding and deletion of PKC isoforms at the protein level, which 
will aid further understanding of the function of these PKCs, given their as-
sociation with defective glucose homeostasis.
Supported by: NHMRC Australia
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The hepatokine betatrophin is increased in nonalcoholic fatty liver 
disease and may affect insulin secretion in prediabetes
A. Peter1, K. Kantartzis1, A. Königsrainer2, I. Königsrainer2, H. Staiger1,  
F. Machicao1, H.-U. Häring1, A. Fritsche1, N. Stefan1;  
1Department of Internal Medicine IV, Institute of Diabetes Research and 
Metabolic Diseases of the Helmholtz Center Munich at the University 
of Tübingen and German Center for Diabetes Research, University of 
Tübingen,  
2Department of General, Visceral and Transplant Surgery, Germany.
Background and aims: Animal data suggest that the liver-secreted protein 
betatrophin is elevated in insulin resistant states and improves glucose toler-
ance by expanding beta cell mass. We now investigated whether betatrophin 
is a hepatokine that may be increasingly produced in nonalcoholic fatty liver 
disease (NAFLD) and may affect insulin secretion in humans.
Materials and methods: In liver tissue samples from 92 donors the rela-
tionship of hepatic betatrophin mRNA expression with liver triglyceride 
(TG) content, and in a subgroup of 29 donors the relationship of betatro-
phin mRNA expression with circulating betatrophin was studied. The asso-
ciations of the cholesterol-regulating single nucleotide polymorphism (SNP) 
rs2278426 in the betatrophin-encoding gene DOCK6, with insulin secretion 
was studied in a cross-sectional study (N=2136) and during 9 month of a 
lifestyle intervention (N=344).
Results: Betatrophin mRNA expression correlated positively with liver TG 
content (r=0.31, p=0.0025). In addition, a positive relationship was found be-
tween betatrophin mRNA expression and betatrophin plasma levels (r=0.41, 
p=0.03). The minor T allele of the SNP rs2278426, that also associated with 
lower plasma cholesterol levels in the present study (p=0.002), associated 
with higher insulin secretion, adjusted for sex, age and insulin sensitivity, in 
subjects with prediabetes (N=701, p=0.044), but not in subjects with nor-
mal glucose regulation (N=1435, p=0.78). The minor T allele of the SNP 
rs2278426 also predicted a larger increase in adjusted insulin secretion dur-
ing the lifestyle intervention in subjects with prediabetes (p=0.01) and associ-
ated with higher arginine-stimulated insulin secretion (p=0.04) in 97 subjects 
during a hyperglycaemic clamp.
Conclusion: We provide novel information that the liver-secreted protein 
betatrophin is increasingly expressed in NAFLD and that it may not only be 
involved in cholesterol metabolism, but also in glucose metabolism in sub-
jects who are at increased risk for type 2 diabetes.
Supported by: BMBF German Center for Diabetes Research; DFG KFO 114 
and STE 1096/3-1
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Acute elevation of triglycerides and free fatty acids does not modulate 
plasma betatrophin levels in healthy individuals
D. Tripathy1,2, T. Arakawa1, A. Chavez-Velazquez1, Z. Perez-Cadena1,  
R. DeFronzo1;  
1Diabetes, Medicine, University of Texas Health Science Center,  
2Audie L Murphy Veterans Affair Hospital, San Antonio, USA.
Background and aims: Betatrophin (ANGPTL8) is a liver-derived protein, 
and its overexpression in liver has been shown to cause beta cell proliferation, 
increased insulin secretion and hypertriglyceridemia in mice. ANGPTL8 
knockout leads to marked reduction in postprandial triglyceride levels in 
mice. However, the relationships between plasma triglycerides, free fatty ac-
ids (FFA), and betatrophin have not been studied in humans.
Materials and methods: We examined the effect of acute elevation of plasma 
triglycerides and FFA on plasma betatrophin levels in 9 healthy NGT subjects 
(7 male/2 female, age = 42 ± 4 yrs, BMI = 26.3 ± 1.0 kg/m2, FPG = 90±3 mg/
dl, 2h PG = 135 ± 11 mg/dl), without family history of T2DM. Subjects re-
ceived on two different occasions either a lipid (intralipid 60 ml/h) or saline 
(0.9% NaCl 60 ml/h) infusion for 6 hours followed by euglycemic insulin 
clamp (80 mU/m2.min) for 2 hours. Plasma triglyceride, FFA, and betatro-
phin levels were measured at baseline, 6 hours, and 8 hours.
Results: Plasma triglyceride levels during the lipid infusion increased from 
187 ± 39 mg/dl at baseline to 455 ± 59 mg/dl at 6 hours and declined to 398 
± 62 mg/dl at 8 hours, and during the saline infusion decreased from 183 ± 
60 mg/dl to 129 ± 28 mg/dl at 6 hours and 106 ± 25 mg/dl at 8 hours. Plasma 
FFA levels during the lipid infusion increased from 370 ± 39 µM to 846 ± 68 
µM at 6 hours and declined to 496 ± 66 µM at 8 hours. Plasma FFA concen-
trations did not change during the saline infusion. Insulin-mediated glucose 
disposal (Rd) was reduced during the lipid versus saline infusion (9.08 ± 1.5 
vs 11.3 ± 1.4 mg/kgFFM.min, p = 0.02). Plasma betatrophin concentrations 
during the lipid infusion were 22 ± 15, 27 ± 16, and 27 ± 17 ng/ml at 0, 6, and 
8 hours, respectively (p=ns). The corresponding values of betatrophin during 
the saline infusion were 21 ± 6, 18 ± 6, and 24 ± 5 ng/ml, respectively. There 
was no relationship between plasma triglyceride, FFA, betatrophin concen-
trations, or insulin mediated whole body glucose disposal.
Conclusion: Short-term physiologic increase in plasma FFA, and triglycer-
ides induce insulin resistance in skeletal muscle, but does not affect plasma 
betatrophin levels in healthy subjects. The association between betatrophin 
and lipids reported in animals is not observed in humans.
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ZBTB20 regulates lipid metabolism
W. Zhang1, L. Zhou1, L. Li1, Y. Zhang1, X. Jiang1, R. Chen1, D. Zou2;  
1Department of Pathophysiology, Second Military Medical University, 
2Department of Endocrinology, Changhai Hospital, Shanghai, China.
Background and aims: We aims to investigate the potential role of novel zinc 
finger protein ZBTB20.
Materials and methods: We established liver-specific Zbtb20 knockout mice 
(LZB20KO) by Cre/LoxP, analyzed phenotypes, determined gene expression 
by RT-PCR and Western blot, and examined protein/DNA interaction by 
ChIP and reporter assay.
Results: Specific deletion of ZBTB20 in the liver resulted in a marked reduc-
tion in plasma lipid levels and hepatic triglyceride contents, and a significant 
improvement of high carbohydrate diet-induced hepatic steatosis and insu-
lin resistance. Hepatic lipogenesis was substantially impaired in the absence 
of ZBTB20, which was associated with decreased expression of ChREBP-α 
and its target genes critical for glycolysis and lipogenesis, and could in part 
be restored by overexpression of ChREBP-α. Furthermore, liver ZBTB20 ex-
pression was significantly increased in ob/ob mice. Strikingly, liver-specific 
deletion of ZBTB20 in ob/ob mice could dramatically suppress hepatic lipo-
genesis, and improve obesity-induced hyperglycemia, dyslipidemia, hepatic 
steatosis, and insulin resistance.
Conclusion: Together, these date indicate that liver ZBTB20 is essential for 
lipid etabolism and may serve as a therapeutic target for metabolic syndrome.
Supported by: National Natural Science Foundation of China
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The role of starvation-induced autophagy in gluconeogenesis and 
ketogenesis
M. Kondo, A. Takagi, S. Kume, S. Ugi, T. Uzu, H. Maegawa;  
Department of Medicine, Shiga University of Medical Science, Japan.
Background and aims: During starvation, fatty acids released from adipose 
tissue are mainly used for hepatic gluconeogenesis and ketogenesis to main-
tain systemic energy homeostasis in animals. Autophagy, a major intracel-
lular degradation system, is induced by starvation. Systemic autophagy-de-
ficient mice die in neonatal starvation period, suggesting that autophagy is a 
critical survival response against starvation. However, the exact role of star-
vation-induced autophagy in systemic energy homeostasis remains unclear.
Materials and methods: To determine the importance of autophagy in each 
organ, we examined starvation-induced gluconeogenesis and ketogenesis in 
liver specific Atg5 knockout mice (L-Atg5-/-), kidney proximal tubular epi-
thelial cells specific Atg5 knockout mice (K-Atg5-/-), and their control mice 
(Atg5lox/lox).
Results: Under ad-libitum feeding condition, there were no significant dif-
ferences in plasma ketone levels. But under 36-h fasting condition, increase 
in plasma ketone levels was impaired in L-Atg5-/- mice but not in K-Atg5-/- 
mice. The impairment of ketogenesis in L-Atg5-/- mice was incomplete. In 
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addition, the oil-red-O-stained lipid accumulation as a main source of ke-
togenesis and elevation of expression of HMG-CoA synthase, a rate-limiting 
enzyme of ketogenesis were observed in the kidney likely in the liver. We 
then hypothesized that the kidney compensated for the absence of ketone 
in L-Atg5-/- mice. To examine this hypothesis, we generated the mice lack-
ing Atg5 in both the liver and kidney. These mice showed further decline in 
plasma ketone concentrations compared to L-Atg5-/- mice during a 36-h fast. 
Starvation-induced lipid droplets formation was impaired in Atg5-deficient 
organs. No significant differences in blood glucose levels and the expression 
of some enzymes for gluconeogenesis were observed among each type of 
mice, even with starvation.
Conclusion: These results suggest that starvation-induced autophagy is es-
sential for ketogenesis relating with lipid accumulation from free fatty acid, 
and that the kidney potentially has a function to generate ketone bodies.
Supported by: KAKENHI Grants-in-Aid
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The Cohen diabetic rat: a matter of mitochondrial disorder?
A. Kogot-Levin1, C. Mantzur1, A. Saada2, I. Raz1, S. Weksler-Zangen1;  
1Department of Internal Medicine, Diabetes Unit,  
2Department of Human Genetics and Metabolic Diseases,  
Hadassah University Hospital, Jerusalem, Israel.
Background and aims: The Cohen diabetic rat model consists of two strains: 
the Cohen diabetic sensitive rat (CDs) developing hyperglycemia and de-
creased glucose stimulated insulin secretion (GSIS) on the diabetogenic-
high-sucrose diet (HSD) and the Cohen diabetic resistant rat (CDr) which 
remains normoglycemic on HSD. Although underlying mechanisms causing 
inhibited GSIS in CDs remains yet elusive, we recently showed reduced ac-
tivity of the mitochondrial respiratory-chain enzyme, cytochrome c oxidase 
(COX) and ATP content in islets of hyperglycemic-CDs, tightly linking in-
hibited GSIS to COX deficiency. We examined whether CDs has a ubiquitous 
COX deficiency, thus suggesting a model of mitochondrial disorder related 
diabetes.
Materials and methods: CDs and CDr males, eight weeks old were fed a 
regular-diet (RD) or a diabetogenic-diet containing 72% sucrose for 30 days. 
Activity of COX normalized to citrate-synthase (CS) was determined in pan-
creatic-islets, lymphocytes, pancreas, heart and liver homogenates spectro-
photometrically. Expression levels of COX subunits 1 & 2 (COX1 & COX2) 
and their chaperons Sco1, COX11 and COX17 were examined in RNA ex-
tracted from islets by qRT-PCR and expressed as a fold-change of the expres-
sion in CDr fed RD. Mitochondrial DNA (mtDNA) content was analyzed in 
DNA from islets by qRT-PCR. COX1 protein levels were determined in islets 
by Western-blot analysis.
Results: An initial significant decrease in COX activity was observed in islets, 
lymphocytes, pancreas, heart and liver of normoglycemic-CDs demonstrat-
ing 85, 40, 30, 40 and 30% respective reduction (p<0.01) compared to CDr 
fed RD. On the diabetogenic-HSD, COX activity was significantly (p<0.01) 
reduced in hyperglycemic-CDs and normoglycemic-CDr but the decrease in 
hyperglycemic-CDs was more evident. Activity of the ubiquitous mitochon-
drial matrix enzyme CS used as an estimation of mitochondrial content was 
not different between groups. Islets COX1 and COX2 expression levels were 
0.3-fold reduced in CDs fed RD, (p<0.01) and Sco1, COX11 and COX17, 
COX assembly proteins, were 0.5, 0.3 and 0.2 fold reduced respectively 
(p<0.01), compared to CDr. COX1 protein levels were also reduced in islets 
of CDs fed RD. mtDNA content was 0.5-fold decreased (p<0.01) in islets of 
CDs fed RD, compared to CDr.
Conclusion: We demonstrate a widespread impairment of COX activity in 
islets, lymphocytes, pancreas, heart and liver of the normoglycemic-CDs 
deteriorating furthermore on diabetogenic diet. The more prominent COX 
deficiency observed in islets presumably explains why the clinical outcome 
in CDs is mainly manifested as diabetes, while the phenotype is milder in 
the other tissues. Moreover, alterations in mitochondrial function are likely 
to have deleterious effects in cells that have a high energy requirement, such 
as the β-cell. These finding links COX deficiency and β-cell dysfunction and 
positions the Cohen diabetic rat as a good model to study mitochondrial 
disease-related diabetes.
Supported by: Lower Saxony, Hannover, Germany and Israeli Science Founda-
tion
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Weight loss in obese ob/ob mice improves mitochondrial dynamics in 
liver, muscle and adipose tissue
J. Schultz, S. Baltrusch;  
Institut of Medical Biochemistry and Molecular Biology, Rostock, Germany.
Background and aims: Mitochondrial dysfunction has been proposed to 
play an important role in the development of type 2 diabetes. Six proteins 
are currently known in mammals regulating the mitochondrial live cycle. 
The Mitofusin 1 and 2 (Mfn1/2) and the optic atrophy protein 1 (Opa1) are 
essential for mitochondrial fusion, whereas the fission protein 1 (Fis1), the 
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mitochondrial fission factor (Mff) and the dynamin related protein 1 (Drp1) 
control fission. Recent studies indicate that obesity deteriorates mitochondri-
al dynamics, and thus, mitochondrial function. In this study we investigated 
regulation of mitochondrial dynamics in liver, muscle and adipose tissue of 
ob/ob mice after calorie-restricted feeding compared to ad-libitum feeding.
Materials and methods: Three month old male obese ob/ob (B6.V-lebob/ob) 
mice were fed for twelve weeks with a calorie-restricted diet, whereas the con-
trol group had unrestricted access to feed. Age matched ob/+ (B6.V-lebob/+) 
mice served as lean controls. Finally mice were killed and tissues were ana-
lyzed for Mfn1/2, Opa1, Fis1, Mff and Drp1 expression by quantitative PCR 
analyses. Fis1 protein expression was investigated using western blot and im-
munofluorescence analyses. The mitochondrial network was visualized by 
Mito Tracker DeepRed staining and fat accumulation by Red Oil staining.
Results: At the age of three month ob/ob mice showed a significantly higher 
body weight than ob/+ mice (46±2 vs. 31±1 g). After twelve weeks of calorie-
restricted diet obese ob/ob mice showed a significantly lower body weight 
compared to ad-libitum feed mice (39±2 vs. 62±2 g). In addition a lower level 
of fat accumulation in liver and muscle was observed in ob/ob mice after 
calorie-restricted diet. Gene expression of all fusion and fission proteins was 
lower in liver, muscle and adipose tissue of ob/ob mice compared to lean con-
trol mice, indicating reduction of mitochondrial dynamics. Calorie-restricted 
diet resulted in ob/ob mice in a significantly higher expression of all genes 
involved in mitochondrial fission and fusion compared to ad-libitum feed-
ing. The strong increase of Fis1 expression in calorie-restricted feed ob/ob 
mice could be confirmed in liver, muscle and adipose tissue on the protein 
level. Obese ob/ob mice showed formation of mitochondrial cluster in liver 
and fatty tissue whereas a more homogenous network of mitochondria was 
observed in diet feed ob/ob mice.
Conclusion: We observed a correlation between reduced body weight and 
lower fat accumulation and improved mitochondrial dynamics in liver, mus-
cle and adipose tissue of ob/ob mice. Thus, a calorie-restricted diet has a ben-
eficial effect on mitochondrial morphology in obese subjects. Mitochondrial 
function in liver, muscle and adipose tissue is significant to maintain insulin 
sensitivity and glucose tolerance. Our study provides further evidence that 
obesity induced mitochondrial dysfunction contributes to the development 
of type 2 diabetes.
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An mtDNA mutation in the cytochrome c oxidase changes mitochondrial 
dynamics and favours development of type 2 diabetes mellitus
J. Niemann, C. Johne, J. Schultz, M. Tiedge, S. Baltrusch;  
Institute of Medical Biochemistry and Molecular Biology, University 
Rostock, Germany.
Background and aims: Mutations in the mitochondrial genome (mtDNA) 
affect subunits of respiratory chain complexes and can impair their func-
tion. It has been postulated that mtDNA mutations which accumulate with 
age contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). We 
have shown that the conplastic mouse strain C57BL/6NTac-mtNOD/AtJ 
(mtNOD) with a mtDNA point mutation in the subunit 3 of cytochrome c 
oxidase (OXPHOS complex IV) has a higher ROS production with age com-
pared to controls. In this study we investigated mitochondrial morphology 
and mitochondrial fission-fusion processes in hepatocytes of this conplastic 
mouse strain.
Materials and methods: Primary hepatocytes were isolated from 3, 6, 9 and 
12 month old mtNOD and C57BL/6NTac (control) mice. Hepatocytes were 
stained with MitoTrackerGreen. Thereafter mitochondrial morphology was 
investigated by fluorescence microscopy and the median mitochondrial elon-
gation level was calculated using AutoQuant software. Gene expression of the 
mitochondrial fusion proteins OPA1, MFN1 and MFN2 and of the fission 
proteins FIS1 and DNM1L was determined by quantitative PCR analyses.
Results: The median mitochondrial elongation level in 3 month old hepato-
cytes of mtNOD mice was significantly lower compared to control mice. The 
median mitochondrial elongation level decreased with age in hepatocytes of 
control mice. In contrast, an increase of the median mitochondrial elongation 
level was observed in hepatocytes of mtNOD mice. Gene expression of the 
mitofusin MFN1 and MFN2 declined during ageing in control mice, whereas 
the expression of both genes increased in mtNOD mice. At the age of 12 
month the expression was in mtNOD mice twice as high as in control mice. 
In addition, the expression of the fission protein DNM1L was significantly 
lower in 12 months old mtNOD compared to control mice.
Conclusion: The observed mitochondrial phenotype correlated with the 
gene expression profile of mitochondrial fission and fusion genes at the 
investigated points of age. Our results indicate that a mtDNA mutation in 
the cytochrome c oxidase triggers a higher mitochondrial elongation level 
of hepatocytes with age. This process could be mediated by an interaction 
between the higher ROS production and the up-regulation of MFN1 and 
MFN2 in aged mtNOD mice. Thus, the C57BL/6NTac-mtNOD/AtJ mouse 
strain represents an interesting model to study trigger effects of age depend-
ent mitochondrial phenotypes in the pathogenesis of T2DM.
Supported by: Federal Ministry of Education and Research (BMBF)
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Dual effect of Nd2 gene mutation in complex I of the respiratory chain: 
ROS generation and induction of mitoprotective effects in the course of 
ageing
M. Wietzke, E. Meyer, F. Koch, J. Niemann, H. Weiss, S. Baltrusch,  
M. Tiedge;  
Institute of Medical Biochemistry and Molecular Biology, Rostock, 
Germany.
Background and aims: The mitochondrial genome of the diabetes-resistant 
B6-mtALR mouse strain is characterized by a mt-DNA encoded Nd2 poly-
morphism in complex I of the respiratory chain. In metabolically active or-
gans such as the liver disorders of the mitochondrial electron transfer with 
increased ROS generation are linked to accelerated aging. It was the aim of 
the study to investigate the production of reactive oxygen species (ROS), the 
expression of antioxidant enzymes and the expression of the aging marker 
p53 in liver tissue of conplastic B6-mtALR mice compared to B6-mtAKR 
control strain.
Materials and methods: Conplastic B6-mtAKR (AKR) and B6-mtALR 
(ALR) mice were examined over a period of 2 years. AKR and ALR animals 
were killed and liver tissue was collected at the age of 3, 6, 9, 12, 18 and 24 
months. The gene expression of Nd2, Sod1, Sod2, catalase, UCP2, TFAM and 
mTOR was quantified by real-time RT-PCR and the p53 protein expression 
was quantified by of Western blot analyses. The measurement of mitochon-
drial ROS production in the liver was performed by fluorescence microscopy 
after injection of the ROS sensor Mitosox.
Results: The gene expression of mt-Nd2 in the ALR strain showed no differ-
ences compared to the control strain AKR. The ROS production in the liver 
at the ages of 6 and 12 months was significantly increased in AKR mice (2-
18-fold, p <0.05). Only at the age of 18 months ROS production in the liver of 
ALR animals was significantly increased by 100% (p <0.05). Furthermore, the 
AKR strain showed higher expression of cytoprotective genes SOD2, SOD1 
and catalase with advanced aging whereas for the ALR strain only at the time 
of impaired ROS generation an increased expression of UCP2 (3x, p <0.05) 
and catalase (2.7x, p <0.05) was detectable. The aging markers p53 showed a 
higher expression in the liver of AKR mice compared to the ALR strain with 
the mt-ND2 mutation (x3.5, P <0.01).
Conclusion: The mt-ND2 mutation in complex I of the respiratory chain fa-
vors the formation of reactive oxygen species in the liver. The potential of 
increased ROS generation does not accelerate the aging process if antioxidant 
and mitoprotective genes provide sufficient protection as a process of mito-
hormesis. Only at advanced age the decreased expression of mitochondrial 
protective structures cannot counteract negative ROS effects on organ func-
tion and aging.
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The role of p66Shc in the development of obesity and metabolic 
disorders: a translational study
S. Ciciliot1,2, M. Albiero2, N. Poncina1,2, L. Menegazzo1,2, M. Foletto3,  
D. Nitti3, M. Giorgio4, A. Avogaro1,2, G. Fadini1,2;  
1Department of Medicine, University of Padova, 2Venetian Institute of 
Molecular Medicine, Padova, 3Clinica Chirurgica I, University of Padova, 
4Department of Experimental Oncology, European Institute of Oncology, 
Milan, Italy.
Background and aims: p66Shc is a redox enzyme and adaptor protein, po-
tentially associated with lifespan determination. Multiple evidences indicate 
that p66shc plays a role in the cellular response triggered by oxidative stress 
and the development of chronic diabetic complications. There are prelimi-
nary and contradictory data on the role of p66Shc in the development of 
obesity and type 2 diabetes. In this translational study, the role of p66Shc 
was evaluated in obesity and metabolic syndrome, studying the expression 
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of p66Shc in human adipose tissue and the characteristics of visceral adipose 
(VAT) and subcutaneous adipose tissue (SAT) in p66Shc-/-Ob/Ob mice at 18 
and 30 weeks of age.
Materials and methods: 4 different mouse models were used: C57/BL6 wt 
mice, Ob/Ob mice, p66 -/- mice, p66 -/- Ob/Ob mice. 2 time points: 18 and 
30 weeks of age. Both visceral (VAT) and sub-cutaneous (SAT) white adipose 
tissue samples were analysed.
Results: p66Shc-/-Ob/Ob mice develop obesity, but at 30 weeks, their body 
weight was significantly lower than in Ob/Ob controls. The size of visceral 
adipocytes was reduced in p66Shc-/- mice at 18 weeks, but not significantly 
different compared to control Ob/Ob mice at 30 weeks. The number of apop-
totic cells in VAT was increased in Ob/Ob mice compared to wt, but signifi-
cantly reduced by p66Shc deletion. The number of macrophages in VAT was 
also reduced in p66Shc-/-Ob/Ob compared to Ob/Ob mice. Based on ITT 
and GTT, p66Shc-/-Ob/Ob mice at 18 weeks are less glucose intolerant and 
insulin resistant compared to Ob/Ob mice, but become insulin resistant at 30 
weeks of age. In a sample of 46 individuals undergoing bariatric surgery, the 
expression of p66Shc linearly correlates with BMI in VAT, but inversely cor-
relates in SAT, only in young subjects.
Conclusion: These data support the hypothesis that p66Shc modulates the 
processes occurring during the development of obesity and metabolic disor-
ders, affecting adipogenesis and inflammation of visceral adipose tissue. The 
role of p66Shc appears to be influenced by age, most likely in relation to the 
role of this protein during aging.
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Regulation of skeletal muscle lipolysis and oxidative metabolism  
by G0/G1 switch gene 2
C. Laurens, P.-M. Badin, K. Louche, D. Langin, V. Bourlier, C. Moro;  
Institute of Metabolic and Cardiovascular Diseases, Inserm UMR1048, 
Toulouse, France.
Background and aims: Intramyocellular triacylglycerol (IMTG) pool is an 
important energy source in skeletal muscle, especially during exercise. Recent 
data suggest that the adipose triglyceride lipase (ATGL) plays a key role in 
providing energy substrate from IMTG and perturbations of its expression/
activity are linked to altered energy metabolism in skeletal muscle. However, 
little is known about its regulation. The aim of this study was to investigate 
the role of the protein G0/G1 Switch Gene 2 (G0S2), recently described as an 
inhibitor of ATGL in white adipose tissue, in the regulation of lipolysis and 
oxidative metabolism in skeletal muscle.
Materials and methods: G0S2 was overexpressed and knockdowned in hu-
man primary myotubes obtained from rectus abdominis biopsies in healthy 
volunteers and transduced with adenoviruses and lentiviruses, respectively. 
ATGL activity, IMTG content, fatty acid mobilization and oxidation, glucose 
oxidation and glycogen synthesis were assessed by using radiolabeled sub-
strates. Metabolic studies were supplemented with the investigation of mito-
chondrial phenotype using fluorescent probes and RT-qPCR (for the analysis 
of key gene expression).
Results: Our results show that G0S2 is expressed in human myotubes and 
inhibits ATGL activity (-47% ; P<0.05). G0S2 downregulation induces a de-
crease in IMTG pool (-70% ; P<0.001) and an increase in fatty acid mobiliza-
tion (+500% ; P<0.001) and oxidation (+300% ; P<0.001). Glucose oxidation 
and glycogen synthesis are decreased (-35% and -63% respectively ; P<0.01). 
The increase of fatty acid flux goes along with an increase in mitochondrial 
mass (+67% ; P<0.001) and membrane potential (+108% ; P<0.01). These ef-
fects may be mediated by the activation of Peroxysome Proliferator Activated 
Receptor δ (PPARδ) target genes Perilipin 2, PPAR Gamma Coactivator 1α 
and Pyruvate Dehydrogenase Kinase 4 (+89%, +93%, and +295%, respectively 
; P<0.01). Opposite effects are observed when G0S2 is overexpressed.
Conclusion: Collectively, the data indicate that G0S2 plays an important role 
in the regulation of human skeletal muscle lipolysis and oxidative metabo-
lism, by modulating fatty acid flux and expression of PPARδ target genes.
Supported by: ANR-12-JSV1-0010-01 and Société Francophone du Diabète
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Role of L-Carnitine on skeletal muscle hypertrophy and mitochondrial 
function
L. Luzi1,2, A. Montesano1, P. Senesi1,2, I. Terruzzi3;  
1University of Milan, 2Metabolism Research Centre and Department of 
Endocrinology and Metabolic Diseases, San Donato Hospital and Scientific 
Institute, 3Div. Metabolic and Cardiovascular Sciences. Metabolism, 
Nutrigenomics and Cellular Differentiation, San Raffaele Scientific Institute, 
Milan, Italy.
Background and aims: Type 2 diabetes mellitus (T2DM) is a metabolic dis-
ease associated with hyperglycaemic condition due to impairments in insulin 
release and/or function. Insulin Resistance (IR) is defined as a reduced re-
sponse to insulin biological effects in target tissues, like skeletal muscle. There 
is evidence that mitochondrial dysfunction is associated with IR and T2DM. 
In particular, oxidative stress has an important role in the inhibition of mus-
cle metabolism: the progressive reduction in the number and efficiency of 
mithocondria has been proposed as a mechanism able to induce muscle atro-
phy in T2DM. L-Carnitine (CARN) is an essential nutrient and plays an im-
portant role in mitochondrial β-oxidation and in the ubiquitin-proteasome 
system regulation. Muscle cells are unable to synthesize CARN. As a dietary 
supplement to ameliorate pathological condition characterized by myofibrils 
degeneration or improve athletic performance, CARN has been studied for 
its potential to enhance β-oxidation. However, CARN effects on myogenesis, 
mitochondrial capacity and atrophy process are not completely elucidated. 
This study aims to investigate CARN action on skeletal muscle remodeling, 
in particular in differentiation and atrophy processes, in normal and insulin 
resistance conditions.
Materials and methods: We analyzed muscle cell differentiation and mor-
phological features in C2C12 myoblasts exposed to 5 mM CARN. To study 
the RAN dose-response relationship we treated neo myotubes with 1, 5 and 
25 mM CARN for 24 hours (h). 5 mM CARN turned out to be the dose 
able to stimulate morphological changes and hypertrophic process in neo-
formed myotubes. 5 mM CARN was added to C2C12 during skeletal muscle 
proliferation, differentiation and on neo formed myotubes assessing cellular 
insulin response, mitochondrial function, oxidative stress pathways and at-
rophy genesis.
Results: Our data showed that CARN positively regulate the kinetics of 
C2C12 cell growth curve, accelerate myotubes formation and induce mor-
phological changes indicating the start of hypertrophy process. In addition, 
CARN improved AKT phosphorylation and downstream cellular synthetic 
pathways. CARN positively regulated mitochondrial biogenesis whilst nega-
tively modulated the pathways related to oxidative stress/ROS productions 
(SOD modulation).
Conclusion: We provide an interesting novel mechanism of the potential 
therapeutic use of CARN to treat insulin resistance condition characterized 
by skeletal muscle morphological and functional impairment, mitochondrial 
dysfunction and oxidative stress production in atrophy process.
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Associations of dietary fibre intake and risk factors of the metabolic 
syndrome. The lipid and glucose under prospective surveillance (LUPS) 
study
J. Haas1, H. Pinnschmidt2, M. Toeller1, A. Partenheimer1, K. Wegscheider2, 
D. Mueller-Wieland1;  
1Department of General Internal Medicine and Institute for Diabetes 
Research, Asklepios Clinic St. Georg, Asklepios Medical School,  
Faculty of Medicine of Semmelweis Medical University,  
2Department of Medical Biometry and Epidemiology,  
University Medical Center, Hamburg, Germany.
Background and aims: The metabolic syndrome is classified by a clustering 
of metabolic and cardiovascular risk factors, in particular, elevated waist cir-
cumference, serum triglycerides, blood pressure, fasting glucose and reduced 
HDL-cholesterol. The exact etiology remains unclear, but it is known to be a 
complex interaction between genetic, metabolic, and environmental factors. 
Amongst exogenous factors nutrition has a central role in the development 
of the metabolic syndrome, and dietary fibre intake is supposed to be an im-
portant factor in this respect. Therefore we aimed to evaluate associations of 
dietary fibre intake and the prevalence of risk factors of the metabolic syn-
drome in the LUPS cohort.
Materials and methods: Baseline data from the prospective LUPS cohort 
(1887 healthy workers, 1274 men and 613 women, aged 25-60 years) were 
investigated for associations between dietary fibre intake and risk factors of 
the metabolic syndrome (classification criteria) using logistic regression and 
Jonckheere-Terpstra test. Fibre intake was assessed by a standardized semi-
quantitative food frequency questionnaire with 85 items covering typical 
food choices and portion sizes in Germany.
Results: Mean dietary fibre intake (g/1000 Kcal/day) was 11.9 (95% CI: 11.6; 
12.3) in women and 9.9 (95% CI: 9.7; 10.1) men. The highest prevalence of 
risk factors for the metabolic syndrome was seen for increased blood pressure 
in 70% of men and 40% of women. The prevalence of the other risk factors 
of the metabolic syndrome in the cohort decreased from elevated waist cir-
cumference (28%), high triglycerides (20%), reduced HDL-cholesterol (19%) 
to increased fasting blood glucose (10%). Only elevated waist circumference 
showed a higher prevalence in women (37%) than in men (25%). Significant 
negative associations were found between fibre intake and waist circumfer-
ence (-6,36 standardized JT-statistics with continuous variable, odds ratio 
0,952 for grouped variable; waist circumference for men ≥ 102 cm and ≥ 88 
cm for women) as well as for fibre intake and fasting triglyceride levels (-5,57 
standardized JT-statistics, odds ratio 0,927; triglycerides ≥ 150 mg/dl), while 
positive associations were seen between fibre intake and HDL-cholesterol 
(8,66 standardized JT-statistics, odds ratio 0,948 ; HDL-cholesterol < 40 mg/
dl for men and < 50 mg/dl for women) (all p<0.05), however no associations 
were observed between fibre intake, and elevated blood pressure (≥ 130/85 
mmHg) as well as fibre intake and increased fasting glucose (≥ 100 mg/dl) in 
the baseline investigation of the LUPS cohort.
Conclusion: Dietary fibre intake, in the range commonly consumed by 
healthy workers, was significantly related to important risk factors of the 
metabolic syndrome in the LUPS study. Higher fibre intake was associated 
with smaller waist, lower triglycerides and higher HDL-cholesterol.
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Dairy lipids, proteins, and abdominal obesity (DairyHealth):  
a 12-week, randomised, parallel-controlled, human intervention study
K. Hermansen, M. Bohl, S. Gregersen;  
Dept of Endocrinology and Metabolism, Aarhus University Hospital, 
Denmark.
Background and aims: Abdominal obesity is associated with increased risk 
of cardiovascular disease (CVD), type 2 diabetes, and overall mortality. Obe-
sity leads to exaggerated postprandial lipaemia (PPL), an independent risk 
factor for CVD. Food quality has been found to affect PPL. Milk protein, 
especially whey and milk fat naturally enriched with short- and medium-
chain saturated fatty acids (SMC-SFA) seem to possess health beneficial ef-
fects. However, long-term human intervention studies are lacking. The aim 
was to test if whey protein and milk fat enriched in SMC-SFA has beneficial 
and synergistic effects on the postprandial lipid responses.
Materials and methods: 12-week, randomized, double-blinded, human in-
tervention study. 63 subjects were randomized to one of four diets in a 2x2 
Latin square design. Participants consumed daily 60g milk protein (whey or 
casein) and 63g milk fat (two different SMC-SFA compositions) daily. Be-
fore and after the 12-week intervention a high-fat meal test (65 E% fat, 19 
E% carbohydrates, and 16 E% protein; 4,500 kJ) was performed and changes 
from baseline in postprandial triglyceride, ApoB-48 (reflecting chylomicrons 
of intestinal origin), free fatty acids (FFA), insulin, glucose and glucagon were 
measured. Two-way ANOVA analysis was used. Power calculation showed 
that we needed 13 in each group to detect a difference of 20% in triglyceride 
response (α = 0.05, β = 0.80).
Results: 52 subjects completed the study. Baseline characteristics were simi-
lar between the four groups. We found that the ApoB-48 response decreased 
significantly after whey compared to casein (P=0.025). We found no signifi-
cant differences in postprandial triglyceride, FFA, insulin, glucose or gluca-
gon responses to whey versus casein or to the two different SMC-SFA compo-
sitions. No interaction between protein and fat was observed.
Conclusion: 12-week intervention with whey supplementation resulted in 
a decreased postprandial chylomicron response in subjects with abdominal 
obesity. This opens for the development of whey enriched dairy products that 
may posses beneficial effects on the risk of CVD.
Clinical Trial Registration Number: NCT01472666
Supported by: DSF 0603-00419B, MFF, Arla Foods
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Lysophosholipids in human blood and their interaction with white 
adipose tissue under an isocaloric high-fat diet in the NUGAT-study
T. Frahnow1, M.A. Osterhoff1,2, A.C. Seltmann1, S. Hornemann1, M. Kruse1, 
S. Sales3, J.L. Sampaio3, A.F.H. Pfeiffer1,2;  
1Clinical Nutrition, German Insitute for Human Nutrition Potsdam-
Rehbrücke, Nuthetal, 2Charité – University of Medicine Berlin, 3Max Planck 
Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Background and aims: Diets high in saturated fats increase diabetes risk and 
fatty liver. Apart from the cholesterol metabolism their detailed effects on the 
lipidome are not well established which we therefore studied using cutting 
edge technology.
Materials and methods: In the NUGAT study (NUtriGenomic Analysis in 
Twins) we used a twin-design with 92 healthy participants and two isocaloric 
nutritional interventions to investigate the impact of a six-week carbohydrate 
rich, low fat followed by a six-week high fat low carbohydrate diet. Extensive 
characterization of the metabolic responses was performed after the low fat 
(LF) and after 1 (HF1) or 6 (HF6) weeks of high fat diet to evaluate rapid 
and long-term effects. Apart from other 145 lipids, 20 lysophospholipids were 
analyzed within and in connection with measured biomarkers of blood and 
white adipose tissue. The fold changes (FC) between two clinical investiga-
tion days were calculated and the Benjamini-Hochberg method (BH) was 
used to adjust the global significance level for multiple testing.
Results: Lysophosphatidylcholines (LPC) and -ethanolamines (LPE) showed 
an almost continuous decrease during the six weeks on high-fat diet (LPC: 
FCLF, HF6 ≈ 0.55 ; LPE : FCLF, HF6 ≈ 0.73), whereas other measured lipid classes 
reacted biphasically and more adaptively. Members of LPC as well as LPE 
were also highly connected within and between these two lipid classes, partly 
reflecting their known biosynthesis. The lysophospholipids were associ-
ated with biomarkers of signal transduction, apoptosis (i.e. SQSTM1/p62: τ 
≈ 0.36, pBH < 0.05) as well as members of inflammatory pathways and the 
immune system (i.e. TBX21: τ ≈ -0.41, pBH < 0.05). These associations were 
not only given for basal values but also for differences between the clinical 
investigation days. The gene expression of NFKBIA/IκBα, which decreased 
significantly during the study ( FCLF, HF6 ≈ 0.80), also showed high associa-
tions with the LPEs and LPCs (i.e.: τ ≈ 0.40, pBH < 0.001). However, TLR2 
and TLR4 were independent of the lysophospholipids (TLR2: pBH > 0.41 ; 
TLR4: pBH > 0.31).
Conclusion: Although extensive adaptation occurs in our healthy partici-
pants after 6 weeks on a high-fat diet, parts of the metabolism remain dis-
turbed. The decreasing lysophospholipids seem to accompany the activation 
of the immune system as well as higher inflammatory processes. Our analysis 
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shows novel pathways by which saturated fats increase inflammation inde-
pendent of the known TLR4-related mechanisms of inflammation.
Clinical Trial Registration Number: NCT01631123
Supported by: BMBF, DZD
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The effect of meal frequency on fatty acid composition in serum 
phospholipids in patients with type 2 diabetes
H. Kahleova1, H. Malinska1, L. Kazdova1, L. Belinova1, M. Hill2,  
T. Pelikanova1;  
1Diabetes Centre, Institute for Clinical and Experimental Medicine, 
2Institute of Endocrinology, Prague, Czech Republic.
Background and aims: Fatty acids are important cellular constituents that 
may affect many metabolic processes relevant for the development of diabetes 
and its complications. We demonstrated previously the superior effect of two 
meals a day, breakfast and lunch (B2) on body weight, hepatic fat content and 
insulin sensitivity compared to the same diet divided into six smaller meals 
a day (A6). The aim of this secondary analysis was to explore the effect of 
frequency of meals on the fatty acid composition of serum phospholipids in 
subjects with type 2 diabetes (T2D).
Materials and methods: In a randomised, crossover study, we assigned 54 
patients with T2D to follow two regimens of a hypocaloric diet (-500 kcal/
day), each for 12 weeks: six meals (A6), and two meals a day, breakfast and 
lunch (B2). The diet in both regimens had the same macronutrient and en-
ergy content. The procedures were performed at weeks 0, 12 and 24. The fatty 
acid composition of serum phospholipids was measured by gas liquid chro-
matography. Insulin sensitivity was derived as an oral glucose insulin sensi-
tivity (OGIS) index.
Results: Saturated fatty acids (mainly the myristic and palmitic acids) de-
creased (p<0.001) and n6 polyunsaturated fatty acids increased (p<0.001) 
in response to both regimens, more with B2 (p<0.001 for both). Monoun-
saturated fatty acids decreased (p<0.05) and n3 polyunsaturated fatty acids 
increased (p<0.001) in response to both regimens with no difference between 
the treatments. The increase in OGIS correlated positively with changes in 
proportion of linoleic acid in B2. This correlation remained significant even 
after adjustment for changes in BMI (r=+0.38; p=0.012).
Conclusion: We demonstrated that meal frequency affects fatty acid compo-
sition of serum phospholipids. We observed more marked positive effects of 
B2. The increase in linoleic acid could partly explain the insulin-sensitising 
effect of B2 in T2D.
Clinical Trial Registration Number: NCT01277471
Supported by: Grant IGA MZCR NT/14250-3, and Institutional Support 
MZCR 00023001
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Early undernutrition worsens the metabolic effects of high-lipid diets
E. Lizárraga-Mollinedo1,2, J. de Toro-Martín1, E. Fernández-Millán2,  
M. García-San Frutos3, T. Fernández-Agulló3, M. Ros3, C. Álvarez1,2,  
F. Escrivá1,2;  
1Bioquímica y Biología Molecular II. Facultad de Farmacia, UCM, 
2Ciberdem, ISCIII, 3Ciencias de la Salud, Universidad Rey Juan Carlos, 
Madrid, Spain.
Background and aims: Early undernutrition is associated with increased risk 
of diseases in adulthood. Interventions on nutrition of mothers and children 
have short-term benefits on health but growth-retarded offspring overfed un-
dergoes a rapid catch-up growth and become long-term heavier than normal. 
Paradoxically, the West’s obesity epidemic is spreading into developing coun-
tries in conjunction with a high prevalence of malnutrition. This raises the 
question whether previous undernutrition exacerbates the metabolic altera-
tions associated with calorie-dense foods. Published results are contradictory 
about. The aim of present study is: A) to investigate the impact of undernutri-
tion in hypothalamus; B) to explain how this condition worsens some altera-
tions associated with subsequent high-fat diets.
Materials and methods: Wistar rats were subjected to undernutrition from 
14th d of foetal life until 70 d (U). Control (C) animals were fed a stand-
ard chow ad libitum (3% fat). From 70 days (C70d, U70d) until 9 m, several 
groups were established: C70 was segregated into two groups, given the com-
mercial chow (C9m) or a cafeteria diet (C9mCaf) of high lipid concentration, 
but lower than used in most similar studies (13% fat). A group of undernour-
ished rats was kept under restriction (U9m), other was transferred to cafete-
ria diet (U9mCaf) and other was transferred to commercial chow (U9mC). 
Adiposity was calculated by RMI. Hypothalamic POMC and NPY mRNA, 
as well as hepatic MCP-1 mRNA, were quantified. Insulin sensitivity was as-
sessed by euglycemic clamp.
Results: Calorie intake of restricted rats under the high-fat diet exceeded 
that of controls, which was consistent with a reduced POMC protein and 
increased NPY expression. These alterations could derive from an impaired 
neonatal “leptin surge”. All rats feeding cafeteria diet weighed more than their 
matched standard chow animals. In controls, this implied a mild obesity, not 
found in the pre-restricted. The relative increase in visceral fat over previous 
content was higher in U9mCaf than in C9mCaf rats: 6-fold vs. 2-fold, respec-
tively. Insulin-resistance was established in both groups. Hyperlipidemia and 
triglyceride deposits were increased only in liver and muscle of U9mCaf rats, 
in which a marked increase of hepatic MCP-1 mRNA was also found.
Conclusion: Metabolic effects of a cafeteria diet are worsened by previous 
undernutrition, specifically: ectopic lipid storage and dislipemia. Also, in-
creased MCP-1 in liver suggests accumulation of inflammatory macrophages, 
as hepatic injury in chronic liver diseases. These results indicate that previous 
food restriction increases vulnerability to the harmful effects of fatty diets.
Supported by: MINECO (BFU 2011-25420), CAM (P2010/BMD-2423), 
CIBERDEM (ISCIII)
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Severe food restriction induces stress and adipose tissue inflammation, 
contributing to the promotion of insulin resistance
Y.-S. Lee, C. Lee, H.-S. Jun;  
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, 
Republic of Korea.
Background and aims: Accumulation of proinflammatory immune cells 
in adipose tissue contributes to the development of obesity-associated dis-
orders. To reduce of obesity, food restriction has been recommended as an 
effective therapeutic strategy for weight loss. Many studies have shown that 
food-intake schedule can alter biological rhythms. Here, we studied whether 
food restriction program induces stress and cause immune cells infiltration 
in adipose tissue, contributing to the insulin resistance.
Materials and methods: C57BL/6 mice were fed 60% high fat diet for 8 weeks 
and randomly divided into three groups: the control group was continuously 
fed 60% high fat diet (100%); the 50% food restriction groups were fed 50% 
of the mean amount of food consumed by the control mice, fed 50% once a 
day (FR1; 50%-1, 9:00 AM) or fed 25% twice a day (FR2; 25%-2, 9:00 AM, 
9:00 PM) for 3 days. Body weight was monitored and immune cell infiltration 
of epididymal adipose tissue was examined by hematoxylin and eosin stain-
ing. In addition, the expression of lipolysis or inflammatory related genes in 
adipose tissue was analyzed by qRT-PCR and the serum corticosterone levels 
were measured by ELISA. To investigate the association between stress hor-
mone and adipose tissue inflammation, high fat diet induced obese mice were 
treated with vehicle or corticosterone (15 ug/h via an osmotic minipump, 
subcutaneously) for 3 days, and the expression of lipolysis and inflammatory 
related genes was analyzed by qRT-PCR, blood glucose levels were measured, 
and insulin tolerance tests were performed.
Results: Body weight loss was induced in food restricted groups (FR1 and 
FR2 group) compared to control group, with further body weight loss in FR1 
group than FR2 group (P<0.05). The infiltrated adipose tissue immune cell 
population was increased in FR1 group but not in FR2 group compared with 
control group (P<0.05). The expression of MCP-1 and TLR-4 mRNA expres-
sion was increased in FR1 group but not in FR2 group compared with control 
mice (P<0.05). The expression of lipolysis related genes, adipose triglyceride 
lipase (ATGL), hormone sensitive lipase (HSL), and lipoprotein lipase (LPL) 
mRNA was increased in FR1 group compared with FR2 group (P<0.05). The 
serum corticosterone levels were significantly increased in both FR1 and FR2 
compared with control group (P<0.05), with much higher in FR1 group than 
FR2 group (P<0.05). After corticosterone infusion for 3 days, the expression 
of ATGL mRNA was increased in adipose tissue (P<0.01) and blood glucose 
levels was increased (P<0.01) and impaired insulin tolerance (P<0.001).
Conclusion: These results indicate that severe food restriction could induce 
stress, lipolysis, adipose tissue immune cell infiltration and inflammation, 
which in turn may influence insulin resistance.
Supported by: MSIFP
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The effects of bariatric surgery on pancreatic lipid metabolism in 
morbidly obese subjects
H. Honka1, J. Koffert1, J.C. Hannukainen1, J.J. Tuulari1, H.K. Karlsson1,  
V. Oikonen1, P. Salminen2, M. Soinio3, A. Mari4, P. Iozzo5, P. Nuutila1,3;  
1Turku PET Centre, University of Turku, 2Division of Digestive Surgery and 
Urology, Turku University Hospital, 3Department of Endocrinology, Turku 
University Hospital, Finland, 4Institute of Biomedical Engineering, National 
Research Council, Padua, 5Institute of Clinical Physiology, National 
Research Council, Pisa, Italy.
Background and aims: As a treatment modality for morbid obesity, bari-
atric surgery leads to a sustained weight loss and a high remission rate of 
type 2 diabetes. However, the exact mechanisms behind the improved glu-
cose tolerance are not fully elucidated. In the present study we investigated 
whether bariatric surgery is able to improve pancreatic lipid metabolism in 
obese subjects.
Materials and methods: Totally, 24 morbidly obese subjects (BMI 41±4.0 kg/
m2, age 42±9.5 years) eligible for bariatric surgery, of which ten had type 2 
diabetes, and 15 healthy age-matched subjects were recruited in the study. 
Pancreatic fatty acid (FA) uptake was measured at fasting state using PET/
CT and a palmitate analogue [18F]FTHA. Pancreatic total volume, and fat and 
parenchymal volumes were measured using a CT based approach as recently 
described. Oral glucose tolerance test (OGTT) was performed to quantitate 
glucose tolerance and empirical/model-derived β-cell function parameters. 
Obese subjects were studied preoperatively and six months after bariatric 
surgery procedure (either Roux-en-Y gastric bypass or sleeve gastrectomy).
Results: Before surgery, obese subjects had higher rate of pancreatic FA up-
take (1.4±0.6 versus 0.7±0.3 µmol/min, P < 0.001) and fat percent (19±22 
versus 4.0±4.0 %, P < 0.01), and had greater amount of ectopic fat (17±21 
versus 3.0±3.1 ml, P < 0.01) than healthy controls. After bariatric surgery, 
obese subjects lost 24% of their weight (P < 0.0001), but were still obese (BMI 
32±4.2 kg/m2). Fasting plasma glucose and HbA1c were lower (both by 12%, 
P < 0.0001), whereas no difference was found in plasma FFA levels (0.82±0.22 
versus 0.76±0.18 mmol/l, NS). In subjects with type 2 diabetes preoperatively, 
parameters of β-cell function (insulinogenic index, glucose sensitivity, rate 
sensitivity) were improved (all P < 0.02), and in eight out of ten diabetes 
was in remission. In the obese group, pancreatic FA uptake (1.4±0.6 versus 
1.0±0.4 µmol/min, P < 0.01), fat percent (19±22 versus 14±13 %, P < 0.01), 
and ectopic fat volume (17±21 versus 11±12 ml, P < 0.01) were decreased, 
whereas parenchymal volume was unchanged (79±29 versus 72±22 ml, NS) 
after operation. Diminishment of ectopic fat was independent of weight loss 
and FA uptake (NS). Decrease in total pancreatic volume was associated with 
improved glucose tolerance, as measured with mean glucose during OGTT (r 
= 0.59, P < 0.005), and insulinogenic index (r = -0.45, P = 0.04).
Conclusion: The present study shows that, pancreatic lipid accumulation in 
obesity is reversible and modified by bariatric surgery. The results of the study 
imply that decreased pancreatic FA metabolism and loss of ectopic fat play a 
role in the improved glucose tolerance seen after bariatric surgery.
Clinical Trial Registration Number: NCT01373892
Supported by: Academy of Finland, Finnish Cultural Foundation
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The metabolic signature of RYGB is similar to that of equivalent caloric 
restriction
I. Lingvay1, L. Golici1, M. Poduri1, L.K. Mitchell1, A. Coster2, T. Zhao3;  
1Endocrinology, 2Pharmacology, 3Molecular Genetics, University of Texas 
Southwestern Medical Center, Dallas, USA.
Background and aims: Diabetes improves or remits within days following 
gastric by-pass surgery. It is debated whether this dramatic effect is due to 
the strict caloric restrictions imposed in the peri-operative period or due to 
surgery-specific changes in metabolism.
Materials and methods: Ten patients with type 2 diabetes underwent a 
strictly-observed 9-day inpatient caloric restriction intervention. Following 
re-equilibration to baseline characteristics (average 3.3 months), they were 
readmitted for a second identical intervention (identical daily oral intake) 
during which they also underwent gastric bypass. All measurements (6-hrs 
Mixed Meal Challenge Test) were performed before and after each study peri-
od (total of four measurements/patient). This precise study design allowed us 
to separate the effects of diet (first period) from the effects of surgery (second 
period-first period) on the hormonal changes observed after surgery. Paired 
t-test was used to compare changes observed during each period.
Results: Patients were 54.1+/-8.7 years old, 3 males, 70% minorities, BMI 
50.8+/-9 kg/m2, with advanced diabetes (9.2+/-8 years duration, treated with 
1.5 oral agents, additionally 7 were also treated with insulin, median dose 
0.8 u/kg). There was comparable and significant improvement in glycaemia, 
insulin sensitivity and beta-cell function. The diet only period fared better 
in regards to changes in ghrelin, GIP, and hepatic glucose output. Surgery 
induced large increases in GLP-1 and PYY (figure).
Conclusion: The severe caloric restriction employed immediately post gas-
tric bypass surgery is primarily responsible for the rapid improvement in 
glycaemia. The increase in incretin hormones is specific to surgery, but does 
not seem to have a direct effect on glycaemia, insulin resistance, nor beta-
cell function. Their effect, if any, is likely mediated through central mecha-
nisms which control appetite and promote the long term adherence to such 
restricted caloric intake.
Clinical Trial Registration Number: NCT01153516
Supported by: NIH 3UL1RR024982-05S1, K23RR024470
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Immediate post-operative effects after a mixed-meal test and long-term 
effects on hormone expression in the alimentary limb in gastric-bypassed 
patients
A. Lindqvist1, J. Berggren2, B. Nergård3, L. Groop1, J. Hedenbro4,  
N. Wierup1;  
1Clinical Sciences, Malmö, 2Department of Surgery, Kalmar,  
3Aleris Obesity, Lund, 4Department of Surgery, Lund, Sweden.
Background and aims: Gastric bypass surgery (GBP) is the most effective 
treatment for morbid obesity. Also, GBP results in rapid improvement in gly-
caemia long before significant weight loss. In the present study we aimed to 
1) investigate the influence of pre-surgery caloric restriction with that of the 
immediate effect of GBP on glycemia and 2) assess long-term effects of GBP 
on gut hormone expression in the alimentary limb.
Materials and methods: Obese women (47±1 years) were subjected to a 
mixed meal test (MMT) four weeks before (MMT-4w), 4h before (MMT-
4h) and one day after (MMT+1d) Roux-en-Y gastric bypass surgery. MMT-
4w was performed before initiation of the low-calorie diet regimen and 
MMT+1d constituted the first meal the patients received after surgery. Blood 
was collected at -10, -5, 0, 5, 10, 15, 30, 60 and 90 minutes upon initiation 
of MMT-ingestion. Glucose, insulin, glucose-dependent insulinotropic pep-
tide (GIP) and active glucagon-like peptide 1 (GLP-1) were analyzed for the 
MMTs. In another study, female patients were recruited and biopsies from 
the alimentary limb were obtained during surgery and via gastroscopy 12 
months after GBP. Samples were analyzed for all major enteroendocrine cell 
populations using immunocytochemistry and morphometry.
Results: While there was difference in glucose levels between the vari-
ous MMTs, the insulin response was markedly increased immediately at 
MMT+1d, compared to both the MMT-4w and MMT-4h (2.4-fold and 2.8-
fold, respectively). Active GLP-1 levels were similar in all MMTs, whereas the 
GIP-response was higher at the MMT+1d, compared to MMT-4w and MMT-
4h (1.6-fold and 1.4-fold, respectively). The elevation in insulin and GIP re-
sulted in increased insulin AUC-to-GIP AUC-ratio (p<0.01). Also, an imme-
diate post-operative effect was observed on insulin AUC-to-glucose AUC ra-
tio (p<0.05). No differences were observed for any of the parameters analyzed 
when comparing MMT-4w and MMT-4h. One year after GBP, the alimentary 
limb of the patients displayed increased density of serotonin-immunoreactive 
(IR) cells (2.1-fold; p<0.05) and GLP-1-IR cells (3.6-fold; p<0.01), while there 
was no difference in villi length, density of ghrelin-IR cells, cholecystokinin-
IR cells, secretin-IR cells, neurotensin-IR cells or GIP-IR cells.
Conclusion: Our data suggest that pre-surgery caloric restriction has no ef-
fect on the parameters analyzed; rather the re-arrangement of the gastroin-
testinal tract elicits an immediate stimulatory effect on insulin and GIP levels 
in response to a meal test. Our data also suggest that with this experimental 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 301
1 C
design, GIP is a strong contributor to the enhanced insulin secretion. Fur-
thermore, we report for the first time the effects of GBP on expression of 
gut hormones in the alimentary limb one year after GBP. Our data showing 
that GLP-1 and serotonin immunoreactive cells are markedly increased in the 
alimentary limb 12 months after GBP provide anatomical prerequisites for 
sustained hormonal changes after GBP.
Supported by: ERC, VR, ALF
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Searching for biomarkers determining the early efficacy of bariatric 
surgery in the treatment of type 2 diabetes mellitus
M. Ciborowski1, P. Samczuk1, M. Luba2, A. Citko1, J. Godzien3,  
H. Razak Hady2, J. Dadan2, C. Barbas3, M. Gorska4, A. Kretowski4,1;  
1Clinical Research Centre, Medical University of Bialystok, 21st Clinical 
Department of General and Endocrine Surgery, Medical University of 
Bialystok, Poland, 3Center for Metabolomics and Bioanalysis (CEMBIO), 
Universidad CEU San Pablo, Madrid, Spain, 4Department of Endocrinology, 
Diabetology and Internal Medicine, Medical University of Bialystok, Poland.
Background and aims: Bariatric surgery is an effective treatment for obesity 
and in 80-90% of subjects with type 2 diabetes improves significantly glycae-
mic control, independently of weight loss. Recent studies suggest different 
mechanisms that affects metabolic changes after surgery: incl. alterations in 
gut hormones secretion (ex. GLP-1), neurohumoral pathways modulation, 
changes in bile acid concentrations in the blood and/or altered intestinal 
microbiota. The recovery rate of the T2DM is also related to the method of 
bariatric surgery with the higher T2DM remission rate observed for a Roux-
en-Y gastric bypass (RYBG) in comparison to a laparoscopic adjustable gas-
tric banding (LAGB). The aim of this study was to search for the preoperative 
and postoperative metabolic biomarkers, which could determine the efficacy 
of the bariatric surgery and predict an early remission failure in the treatment 
of T2DM.
Materials and methods: The study was performed in the group of 49 obese 
patients with T2DM, who underwent bariatric procedures (laparoscopic 
sleeve gastrectomy - LSG or Roux-Y gastric bypass - RYGB) and were evalu-
ated for an early remission failure (1 month after the surgery) of T2DM. The 
fasting serum samples were fingerprinted by LC-QTOF-MS and data were 
collected in ESI (+) mode (50-1,000 m/z). Chromatograms were aligned 
and quality assurance of obtained data was performed. Statistical analysis 
was conducted to compare patients before and one month after the surgery 
(paired t-test), and to compare (before the surgery) patients who recovered 
from T2DM in one month post-surgery with those who did not. Patients be-
fore the surgery were compared by use of t-test or Mann-Whitney test de-
pending on the normality of variables distribution. Identification of signifi-
cant features was performed based on custom library with accurate mass and 
retention time of more than 100 metabolites.
Results: We found that before bariatric surgery lower serum levels of lipid 
compounds (incl. lysophosphatidylcholines, phosphatidylethanolamines, 
sphingomielynes, ceramides) and lower vitamin D3 metabolites concentra-
tions significantly predicted an early T2DM remission failure (p<0.01 for all). 
One month after bariatric surgery, in all subjects with T2DM remission, the 
decrease in level of free lipids (p value <0.05-0.01), acylcarnitines (p value 
<0.04-0.008) and choline (p=0.0006) was observed. On the other hand, in 
subjects without early T2DM recovery, no significant changes in acylcarni-
tines level were found.
Conclusion: Current results indicate, that changes in lipid metabolites con-
tribute to the improvement of glycaemia and remission of the T2DM after 
bariatric surgery. The rate of regulation of fatty acid oxidation and mitochon-
drial function pathways may contribute to the time of the T2DM remission.
Supported by: 30/KNOW/2013
PS 054 Inflammation and beta cell in 
type 2 diabetes
742
IA-2(256-760), the only marker of islet autoimmunity that increases  
by increasing the degree of obesity in type 2 diabetes patients
C. Tiberti, M. Spoletini, G. Campagna, S. Zampetti, L. Marandola,  
R. Buzzetti, NIRAD Study Group;  
Sapienza University, Rome, Italy.
Background and aims: Approximately 5-6% of type 2 diabetes patients 
(T2DM), in Italian population, are positive for antibodies specific to type 1 
diabetes (T1DM), although the same antibodies present significant quantita-
tive difference compared to T1DM. Glutamic acid decarboxylase (GADAs) is 
the marker with the highest prevalence, however also protein tyrosine phos-
phatase (IA-2IC) antibodies were shown to be an important autoimmune 
marker frequently found in these patients. We have previously demonstrated 
an extreme heterogeneity of T2DM positive patients in terms of phenotype, 
specifically the BMI varies widely. In the light of these findings we aim to 
evaluate whether the type and frequency of beta-cell specific antibodies vary 
according to different degrees of BMI in T2DM positive patients.
Materials and methods: In n=1850 T2DM subjects recruited in central Italy 
from the Non Insulin Requiring Autoimmune Diabetes (NIRAD) study co-
hort of 5330, clinical and biochemical characteristics as well as the following 
antibodies were evaluated at recruitment: GADA, IA-2IC and IA-2256-760. 
All patients were subdivided into three groups according to BMI: BMI≤25, 
25<BMI<30, BMI≥30. The differences of mean values of GADA, IA-2256-760 
and IA-2IC between groups were evaluated through the Anova and Benja-
mini-Hochberg test. A p value <0.05 was considered statistically significant.
Results: Out of n= 1850 type 2 diabetes patients n=120 (6.5%) were posi-
tive for at least one of the following antibodies: GADA (4.1%), IA-2256-760 
(3.3%) or IA-2IC (1.1%). As we consider the n=120 T2DM antibody posi-
tive patients, GADA and IA-2 IC showed decreasing frequencies with the 
increase of BMI (p for trend 30 (80% of positive patients). Analyzing GADA, 
IA-2256-760 and IA-2IC titers in all T2DM subjects subdivided according to 
BMI, we observed a decreasing mean values of GADA and IA-2IC titers with 
the increase of BMI (p for trend<0.0001 and p for trend=0.02, respectively). 
The mean values of IA-2256-760 titer, instead, were similar between the three 
groups of BMI.
Conclusion: We conclude that the IA-2 (256-760) specifically identify auto-
immunity in obese T2DM.
743
Human adenovirus-36 is uncommon in type 2 diabetes and is associated 
with increased insulin sensitivity in adults in Sweden
A. Hilding1, M. Almgren2, R.L. Atkinson3, J. He3, K. Brismar1, M. Schalling1, 
C.-G. Östenson1, C. Lavebratt1;  
1Dept. of Molecular Medicine and Surgery, 2Dept. of Clinical Neuroscience, 
Karolinska Instititet, Stockholm, Sweden, 3Obetech Obesity Research 
Center, Virginia Commonwealth University, Richmond, USA.
Background and aims: Human adenovirus-36 (Adv36) increases adiposity, 
but also upregulates distal insulin signaling in vitro in human adipose and 
muscle tissue and in vivo in the rodent independent of adiposity. According-
ly, healthy adults and children with antibodies against Adv36 had increased 
insulin sensitivity and reduced hepatic lipid accumulation. We hypothesized 
that Adv36 infection would be less frequent in individuals with type 2 diabe-
tes or impaired glycemic control.
Materials and methods: Presence of antibodies against Adv36 was analyzed 
for association to type 2 diabetes or impaired glycemic control in a longitu-
dinal population-based sample of well-examined adults (n=1734). Indices of 
impaired glycemic control included oral glucose tolerance, and circulating 
fasting levels of glucose, insulin and insulin-like growth factor binding pro-
tein-1 (IGFBP-1).
Results: Adv36 seropositivity was more common in those with NGT (nor-
mal glucose tolerance) than in those with diabetes (females: OR=17.2, 95% 
CI=4.0-74.3, males: OR=3.5, 95% CI=1.8-6.7). Also, females with NGT 
had higher frequency of Adv36 seropositivity than females with prediabe-
tes (impaired glucose tolerance or impaired fasting glucose, OR=1.8, 95% 
CI=1.1-3.1). Within the female prediabetes group Adv36 seropositivity was 
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associated with higher insulin sensitivity reflected by reduced HOMA-IR and 
increased IGFBP-1.
Conclusion: Adv36 infection associated with lower occurrence of type 2 dia-
betes and better insulin sensitivity in adults, particularly among females.
Supported by: VINNOVA, Sw. Res. Council, FAS, Sw. Diab. Ass., E Persson 
Found., Obetech Res. Center
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AKT/JNK switch induces beta cell apoptosis as part of TLR3 signalling 
during Coxsackievirus infection
N. Busse1, F. Paroni1, E. Domsgen2, J. Kerr-Conte3, A. Dotzauer1,  
K. Maedler1;  
1Center for Biomelecular Interactions, University of Bremen, Germany, 
2Center for Infection Medicine, Karolinska Institutet, Stockholm, Sweden, 
3University of Lille, France.
Background and aims: Type 1 diabetes results from a sophisticated interplay 
between genetic factors, immune system and environmental factors. Among 
environmental factors, viruses, mainly enteroviruses such as members of the 
Coxsackie B virus family, have been suspected since long time to trigger dia-
betes. Intra-islet viral particles have been detected in pancreata from patients 
with T1DM and T2DM, and known to cause β-cell dysfunction in vitro, 
suggesting that a direct infection contributes to onset of diabetes. Nonethe-
less the mechanisms of a correlation between virus infection and diabetes 
progression are poorly understood. Clarification of the viral triggered β-cell 
dysfunction and apoptosis may provide an indication to develop preventive 
therapies. We previously identified Toll-like receptor 3 (TLR3) and Protein 
kinase R (PKR) as first defensive defensive line during coxsackie virus infec-
tion. In this study we asked the question of what is the contribution of PKR 
and TLR3 in β-cell apoptosis during CVB3 infection.
Materials and methods: Isolated human islets and CM cell line were infected 
with coxsakievirus serotype B3. Replication of CVB was confirmed by im-
munostaining of viral protein 1 (VP1) and titration of islet lysate. shRNA 
and siRNA were used to silence TLR3 and PKR in both human islets and 
CM cells. Plasmids encoding for TLR3 and TBK1 were used for overexpres-
sion experiments. Either dominant negative expression constructs or specific 
inhibitors were used to study the role of JNK and AKT in human islets. Islet 
protein expression and phosphorylation were analyzed by western blot. Bind-
ing of CVB ssRNA and dsRNA was investigated by immunoprecipitation-RT-
PCR coupled assays.
Results: A time course analysis of CVB3 infection for downstream signaling 
showed AKT activation at 1h post-infection, which lasts for several hours. 
AKT was down-regulated at 24h post infection, when activation of pJNK, 
Caspase-3 and VP1 appeared in human islets. A possible correlation between 
AKT activation and PKR/TLR3 signaling was investigated. Knock down of 
PKR resulted in increased virus infection (VP1), JNK phosphorylation and 
activation of caspase 3, while AKT phosphorylation was PKR-independent. 
Lack of TLR3 had a pro-survival effect in CVB3 infected human islets leading 
to a reduced reduced JNK phosphorylation, caspase activation and VP1 as 
well as TBK1 phosphorylation. In contrast, overexpression of TLR3 enhanced 
AKT activation together with VP1 induction. Overexpression of TLR3/TBK1 
further enhanced phosphorylation of AKT, viral replication and caspase ac-
tivation suggesting pivotal role of AKT, enhanced by TLR3. AKT inhibition 
reduced viral replication, activation of caspase 3 and phosphorylation of JNK. 
Overexpression of DN-JNK led to a decrease in apoptosis indicated by the 
decreased level of cleaved caspase 3 but not of VP1. Treatment of human is-
lets with the JNK inhibitor confirmed the protective effects of JNK inhibition.
Conclusion: In summary, our data show that CBV infections have a direct 
deleterious effect on β-cell survival, resulting from virus-induced apoptosis, 
and potentiated by the AKT/TLR3 signaling pathway. With our present data 
we provide novel targets towards protecting the β-cell during virus infection.
Supported by: JDRF
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DPP-4 inhibitors: anti-inflammatory effects on M1 activation
E. Derlindati, V. Curella, I. Zavaroni, R.C. Bonadonna;  
Clinical and Experimental Medicine, University of Parma, Italy.
Background and aims: Macrophages are a heterogeneous cell population 
which, in response to the cytokine milieu, differentiate in either classically 
activated macrophages (M1) or alternatively activated macrophages (M2). 
This plasticity is essential to regulate inflammation, immune response and 
tissue remodeling and it may be a novel therapeutic target in inflammatory-
based diseases such as atherosclerosis. Some recent evidence suggests that 
dipeptidyl peptidase 4 may play a role in in cardiovascular diseases and that 
its inhibition might be beneficial in curbing inflammation and atherogenesis. 
The aim of this study was to evaluate the anti-inflammatory effects of a DPP-4 
inhibitor on classical macrophage activation .
Materials and methods: Monocytes were isolated from healthy donors’ buffy 
coats. After differentiating into macrophages, cells were stimulated with IFNγ 
and LPS in order to induce M1 activation, in presence or in absence of 2µM of 
DPP-4 inhibitor (KR-62436, Sigma Aldrich) for 24 hours. The working con-
centration of DPP-4 inhibitor was selected after dose finding experiments. 
Resting macrophages (RM) -no added stimuli- were used as a control. The 
expression of DPP-4 was evaluated in each experimental conditions, both 
by real time PCR and cytofluorimetric assay. Key pro-inflammatory genes 
and chemokines (IL6, IL8, TNF-alpha, MCP-1, COX2, SOD2, SOCS1) were 
evaluated by real time PCR. Protein expression of IL-6 and TNF-alpha were 
evaluated by ELISA. Results were obtained by means of six biological repli-
cates. DPP-4 activity is presently being assessed.
Results: M1 macrophages showed a significant up-regulation of DPP-4 
mRNA compared to RM (p=0.015), which was unchanged by DPP-4 inhibi-
tion. These data were confirmed by cytofluorimetric analysis. M1 significant-
ly up-regulated also the expression of pro-inflammatory genes SOCS1, IL-6, 
COX2 (by one hundred-fold), IL8, TNF-alpha (by fifty-fold), and MCP1, 
SOD2 (by ten-fold) compared to RM (p<0.05 or less). The addition of DPP-
4 inhibitor significantly reduced the mRNA expression of IL-6, TNF-alpha, 
MCP1 and COX2 (p<0.05), restoring the same gene expression level as RM, 
except for COX2 that remained significantly higher (by five-fold, p<0.05). 
TNF-alpha and IL6 proteins resulted significantly up regulated in M1 com-
pared to RM (by forty five-fold and six-fold respectively, p<0.01) and de-
creased by DPP-4 inhibition (p <0.05) although remaining significantly high-
er compared to RM (by three-fold, p<0.05). DPP-4 activity is currently under 
investigation in order to assess its role, if any, in anti-inflammatory effects.
Conclusion: This study shows that DPP-4 is overexpressed in classical acti-
vated macrophages, setting the stage for an involvement of DPP-4 in inflam-
matory processes. DPP-4 inhibition induced a significant reduction of the 
principal pro-inflammatory genes and proteins, but without affecting DPP-4 
expression. These data suggest an anti-inflammatory effect of DPP-4 inhibi-
tors that might be beneficial in the treatment of inflammatory related disease.
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In the long run hyperbaric oxygen therapy attenuates pro-inflammatory 
processes in streptozotocin induced diabetes in rats
E.M. Horvath1, R. Benko1, V.A. Agoston2, K. Ihionvien1, M. Szabo1,  
N. Beres1, Z. Benko1, C. Repas1, B. Bakk-Nurdisány1, M. Szepes1, L. Kiss1,  
Z. Nagy2;  
1Institute of Human Physiology and Clinical Experimental Research, 
2Department of Cardiology, Laboratory of Cell Biology, Section of Vascular 
Neurology, Semmelweis University, Budapest, Hungary.
Background and aims: Hyperbaric oxygen therapy (HBOT) is frequently 
used in diabetic patients with ulcerated wounds; however its possible nega-
tive consequences raise questions. In our previous experiments we showed 
that weeks after HBOT cardiovascular functions of rats with streptozotocin 
induced diabetes were improved or unaltered. In the present study our aim 
was to examine the effect of HBOT on systemic oxidative-nitrative stress and 
cytokine production in the same setting.
Materials and methods: Wistar rats (15) weighing 300 g were administered 
with a single dose of 70 mg/kg streptozotocin to induce diabetes mellitus. 7 
diabetic and 8 controls underwent one-hour long hyperbaric oxygen treat-
ment (HBOT: 2.5 bar) 12 times (in 16 days). 6 controls and 8 diabetic rats re-
mained untreated. Two weeks after the completion of HBOT series, heparin-
ized blood plasma and lymphocyte samples were collected. Malonyl-dialde-
hyde assay (MDA) were performed on the plasma samples and nitrotyrosine 
immunostaining (NT) was done on lymphocyte smears. Altered cytokines 
were identified by Rat Cytokine Antibody Array (R&D). According to the 
results the following cytokines were selected for ELISA measurement: Cy-
tokine-induced neutrophil chemoattractant 1 (CINC-1), lipopolysaccharide 
induced CXC chemokine (LIX/CXCL-5), tissue inhibitor of metalloprotein-
ase 1 (TIMP-1). For data analysis Two Way ANOVA and Bonferroni’s post 
hoc test were implemented.
Results: Without HBOT plasma MDA levels were significantly higher in dia-
betic rats compared to control animals (9.03 μM [6.33, 12.69] vs. 21.56 μM 
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[7.63, 34.18], p≤0.01) , however this difference was abolished after HBOT 
(6.24 μM [5.08, 6.71] vs. 9.68 μM [6.47, 19.24], NS.). Leukocyte tyrosine 
nitration was elevated due to diabetes with (23.78±3.43% vs. 41.2±3.49%, 
p≤0.01) or without HBOT (20.44±4.08% vs. 38.1±4.12%, p≤0.01). The plas-
ma levels of pro-inflammatory cytokines were increased in untreated diabe-
tes (CINC-1: 69.1 ng/L [63.85, 74.63] vs. 137.1 ng/L [66.71, 343.8], p≤0.01; 
LIX: 282 ng/L [141.9, 382] vs. 430.8 ng/L [327, 604.4], p≤0.05), however due 
to HBOT this difference was ceased (CINC-1: 66.96 ng/L [61.3, 83.5] vs. 96.9 
ng/L [70.73, 147.5], NS.; LIX: 245.3 ng/L [172.6, 340.3] vs. 346.8 ng/L [276.9, 
774.6], NS.). The anti-inflammatory factor TIMP-1 was not altered by dia-
betes in the lack of HBOT (24.49 μg/L [21.48, 26.41] vs. 27.79 μg/L [22.18, 
29.73], NS.), on the other hand after HBOT the plasma level of TIMP-1 was 
significantly higher in diabetic animals (20.76 μg/L [18.43, 25.62] vs. 32.31 
μg/L [21.65, 38.43], p≤0.01).
Conclusion: According to our results two weeks after HBOT, the oxidative 
stress and pro-inflammatory cytokine production induced by experimental 
diabetes were abolished. Also the anti-inflammatory factor TIMP-1 is elevat-
ed as a response to HBOT in diabetic animals. On the other hand nitrative 
stress is not altered by the therapy. These findings suggest that HBOT is not 
just safe to use in diabetic patients, but may also have beneficial effect on their 
chronic subclinical inflammation.
Supported by: Bolyai János Research Fellowship of the Hungarian Academy of 
Sciences
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The anti-inflammatory protein NUPR1 (p8) generally enhances viability 
of pancreatic islets but does not prevent lipotoxicity
B. Mihic-Necic1, A.E. Mehana1,2, C. Liu1, L. Parsons1,3, J. Straetener1,  
J. Baumann1, N. Perakakis1, K. Laubner1, J. Seufert1, G. Päth1;  
1Department of Internal Medicine II, Division of Endocrinology and 
Diabetology, University Hospital of Freiburg, 2University of Freiburg, 
Faculty of Biology, Germany, 3School of Biosciences, Cardiff University, UK.
Background and aims: Type 2 diabetes is closely related to obesity. Accord-
ing to the so-called “nutrition overflow hypothesis”, type 2 diabetes results 
from nutrition-induced local tissue inflammation leading to insulin resist-
ance, insulin secretory dysfunction and finally pancreatic beta cell loss. Free 
fatty acids acting through toll-like receptors are key mediators of this lipotox-
ic inflammatory response. (1) We previously demonstrated that cocultured 
human bone marrow-derived mesenchymal stromal cells (hMSC-TERT) 
protect rat INS-1E beta cells from alloxan- and streptozotocin-induced in-
jury. (2) We further demonstrated that mice with beta cell-specific overex-
pression of the intracellular protein NUPR1 maintained insulin secretion 
and storage during high fat diet-induced local low grade inflammation and 
intense inflammatory stress by insulitis. Here, we investigated the anti-lipo-
toxic potential of (1) cocultured hMSC-TERT and (2) beta cell-specific Nupr1 
overexpression.
Materials and methods: For coculture, INS-1E were seeded in wells and 
hMSC-TERT were seeded in inserts with 1 µm pores to allow soluble factors 
but not cells to pass the membrane. Primary mouse islets were obtained from 
transgenic (Tg) mice with beta cell-specific Nupr1 overexpression under the 
control of the rat insulin gene 1 promoter (RIP1). Non-transgenic littermates 
served as WT controls. Lipotoxicity was induced by palmitate. Viability of 
cells and islets was measured by MTS assay.
Results: We first evaluated by kill curve experiments that 24 h exposure to 
0.13 mM palmitate inhibits the viability of INS-1E by 50%. Experiments were 
performed with 0.1 mM palmitate. (1) 24 h exposure to 0.1 mM palmitate 
reduced viability of INS-1E by 42%. Cocultured hMSC-TERT could not pre-
vent this loss of viability. (2) Tg islets with ectopic NUPR1 demonstrated 1.5-
fold enhanced viability compared to WT controls. However, ectopic NUPR1 
did not reduce lipotoxicity since 24 h exposure to 0.1 mM palmitate reduced 
viability by 50% in both WT and Tg islets.
Conclusion: Despite their protective effects in other experimental settings, 
cocultured hMSC-TERT and also ectopic Nupr1 did not prevent lipotoxicity. 
Ectopic NUPR1 overproduction generally enhances viability of Tg islets and 
thereby contributes to enhanced beta cell function during inflammatory tis-
sue stress in Tg mice compared to WT controls.
Supported by: BMBF, FNS
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Protection of pancreatic beta cells in vitro and in vivo by NUPR1 (p8) 
protein during inflammatory diabetogenic stresses
A.E. Mehana1,2, I. Pilz1, B. Dufner1, C. Jäger1, S. Sojka1, J. Baumann1, M. Alt1, 
C. Liu1, L. Parsons1,3, K. Laubner1, N. Perakakis1, G. Päth1, J. Seufert1;  
1Division of Endocrinology and Diabetology, Department of Internal 
Medicine II, University Hospital of Freiburg, 2University of Freiburg, Faculty 
of Biology, Germany, 3Cardiff University, School of Biosciences, UK.
Background and aims: Type 2 diabetes is closely associated with obesity. 
Chronically enhanced circulating free fatty acids activate toll-like receptors 
and induce local inflammation leading to insulin resistance, insulin secre-
tory dysfunction and finally pancreatic β-cell loss. However, many obese 
subjects do not develop diabetes. This observation suggests the existence of 
molecular defence systems that prevent β-cell degradation in non-susceptive 
individuals. Therefore, identification of molecular mechanisms that provide 
anti-inflammatory protection and control β-cell turnover are of key interest. 
The intracellular protein NUPR1 has been shown to reduce tissue damage 
during acute pancreatitis in Nupr1-/- mice. The protein is also expressed in 
the endocrine pancreas. To investigate its potential protective role and cel-
lular mechanisms in the under diabetogenic stress, we generated transgenic 
mice with β-cell-specific Nupr1 overexpression under the control of the RIP1 
promoter (Tg).
Materials and methods: We induced low-grade inflammation by feeding 
mice with high fat diet (HFD) and/or insulitis by multiple low dose STZ in-
jections. Glucose tolerance was evaluated by measuring non-fasting random 
blood glucose, intraperitoneal glucose tolerance test (ipGTT), intraperito-
neal insulin tolerance test (ipITT) and serum insulin levels (ELISA). β-cell 
mass was determined morphologically. Islet inflammation was quantified by 
numbers of infiltrating CD45+ lymphocytes and NF-kB activation (Western 
blot). Ex vivo isolated islets from untreated wild type (Wt) and Tg animals 
and from animals after 20 weeks of feeding with HFD were cultured for 16 
days without treatment and subsequently exposed for 24hrs to 10ng/ml IL-1β 
or 0.33mM STZ were evaluated by glucose stimulated insulin secretion and 
content (GSIS), cleaved PARP (Asp214) for apoptosis (ELISA) and BrdU for 
cell proliferation.
Results: Immunohistochemically, we observed an islet enriched expression 
of NUPR1 in non-Tg mice. In vivo, Tg mice displayed improved glucose tol-
erance, improved insulin secretion and increased β-cell mass during HFD 
and/or insulitis as compared to Wt controls. NUPR1-Tg islets also showed 
reduced lymphocyte infiltration and reduced NF-kB activation. Ex vivo, Tg 
islets displayed greatly reduced apoptosis while insulin secretion and content 
was significantly enhanced compared to Wt islets during 16 days of culture 
or in response to 24 h exposure to IL-1β or STZ. Further, Wt islets showed 
a massively reduced proliferation rate in response to diabetogenic injuries, 
whereas this was completely maintained in isolated NUPR1-Tg islets.
Conclusion: NUPR1 protein may be an important molecular mediator in 
the stress defence system of pancreatic β-cells. It exhibits potent protection of 
insulin biosynthesis, secretion and content during inflammatory pancreatic 
β-cell stress by reducing activation of NF-kB and apoptosis and enhancing 
proliferation capacity as a possible mechanism to compensate for the diabe-
togenic decrease in pancreatic β-cell mass.
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Siglec F knockout impairs glucose stimulated insulin secretion in 
isolated mouse islets
K. Stolz, G. Dharmadhikari, K. Maedler;  
Centre for Biomolecular Interactions, University of Bremen, Germany.
Background and aims: Type 1 diabetes mellitus (T1DM) and type 2 diabetes 
mellitus (T2DM) result from a decline in β-cell function and survival partly 
as a consequence of islet inflammation. The inflammatory signaling and the 
activation of immune cells are caused by secreted stimulators or via cell-cell 
interactions. A group of cell surface adhesion and signaling molecules, the 
Siglecs (sialic acid-binding immunoglobulin (Ig)-like lectins) mediate such 
interactions. In humans, Siglecs are differentially expressed in α-and β-cells 
and show protective effects on β-cell function and survival upon overexpres-
sion. In this study we investigated, if the knockout (KO) of the functionally 
relevant paralog Siglec F shows an effect on β-cell function in mice.
Materials and methods: To investigate the effect of the knockout isolated 
mouse islets were treated with diabetogenic conditions (2ng/ml IL-1β/1000 
U/ml IFN-γ or 22.2mM Glucose/0.5mM Palmitate) for 3 days and subjected 
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Glucose stimulated Insulin secretion. Expression studies were carried out by 
FACS analysis and quantitative RT-PCR. For depletion of infiltrated mac-
rophages isolated mouse islets were treated with Chlodronate containing 
liposomes for 48 hours.
Results: Knockout of Siglec F shows no effect under diabetogenic treatment, 
but significant lower Insulin release upon Glucose stimulation under control 
conditions (p<0.05 versus wildtype). FACS analysis of dispersed wild type 
(WT) mouse islets showed Siglec F expression only in a very small cell popu-
lation that did not occur in KO Islets. Quantitative RT-PCR demonstrated 
the low expression of mouse Siglecs in isolated Islets, which disappeared after 
depletion of macrophages with Chlodronate-liposomes. Chlodronate treated 
WT and KO islets show no difference in Glucose stimulated Insulin secretion.
Conclusion: Siglec F knockout islets show impaired Insulin secretion due to 
altered interaction with infiltrating macrophages.
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The role of S100A8 and S100A9 in inflammatory interaction between 
pancreatic islets and macrophages
H. Inoue, J. Shirakawa, K. Orime, Y. Togashi, K. Tajima, Y. Terauchi;  
Yokohama City University, Japan.
Background and aims: The numbers of macrophages in the pancreatic islets 
of type 2 diabetes patients were reportedly increased. Yet, the pathophysi-
ological significance of macrophages infiltration into islet is unclear. In this 
study, we focused on S100A8 and S100A9 (S100A8/A9) in islets induced by a 
combination of macrophage and free fatty acids. They are inflammatory pro-
teins mainly expressed in monocyte and neutrophil. To address the mecha-
nism of mutual interaction of islets with macrophage, we investigated the role 
of S100A8/A9 in this process.
Materials and methods: Isolated C57BL/6J mouse pancreatic islets were 
co-cultured with unstimulated peritoneal macrophages in the presence of 
lipopolysaccharide (LPS), palmitate, oleate, or adipocytes derived from 
epididymal fat, in vitro. To study the effect of S100A8/A9 on beta cell func-
tion, we examined glucose-stimulated insulin secretion in S100A8- and 
S100A9-adenoviral-overexpressed islets. Furthermore, we also analysed 
S100A8/A9 expressions in islets from obese diabetic db/db mice. To elucidate 
the effect of S100A8/A9 on macrophages, macrophages were stimulated with 
medium used for co-culturing islet and macrophages.
Results: In the presence of macrophages, the mRNA expressions of IL-1β, 
TNF-α, IL-6, CCL2, S100A8, and S100A9 in islets were increased (2.3-fold**, 
2.9-fold**, 7.3-fold**, 9.6-fold**, 13.3-fold** and 72.7-fold**). LPS enhanced 
the macrophages-induced expression of TNF-α, IL-6 and CCL2 in islets 
(1.7-fold*, 2.4-fold** and 2.3-fold**), whereas palmitate augmented the ex-
pression of S100A8 and S100A9 under the same conditions (4.8-fold** and 
3.6-fold**). Oleate didn’t affect those gene expression levels in islets. Nei-
ther LPS nor palmitate was sufficient to facilitate S100A8/A9 expressions 
in islets in the absence of macrophage. When islets were co-cultured with 
adipocytes, the expressions of IL-1β, TNF-α, IL-6 and CCL2, S100A8 and 
S100A9 in islets were tended to elevate. The induction of TNF-α, S100A8 
and S100A9 expressions by adipocytes in islets were up-regulated by the ad-
dition of macrophages (2.4-fold**, 2.3-fold** and 4.8-fold**). The expression 
levels of S100A8 and S100A9 were potentiated at high glucose concentration 
(22.2 mM) compared with those at low glucose concentration (5.6 mM) in 
the presence of palmitate (7.3-fold** and 4.6-fold**). Immunoblot and ELISA 
suggested S100A8/A9 were secreted from co-cultured islets to supernatant. 
Adenoviral-overexpression of S100A8/A9 in islets didn’t affect insulin secre-
tion. Immunohistochemical analysis indicated that only beta cells, but not al-
pha cells or acinar cells, expressed S100A8/A9 in pancreas. In islets from db/
db mice, the expression of IL-1β, TNF-α, IL-6, CCL2, S100A8, and S100A9 
in islets were higher than that in islets from db/+ mice (6.1-fold**, 2.6-fold**, 
19.4-fold**, 7.7-fold**, 18.2-fold* and 10.7-fold†, respectively). Culture su-
pernatant from islet, macrophage, and palmitate up-regulated the expression 
level of IL-6 in unstimulated peritoneal macrophages (2.3-fold**). (†p<0.1, 
*p<0.05, **p<0.01)
Conclusion: These results suggest that S100A8/A9 proteins in beta cells were 
enhanced by macrophages, free fatty acids and high glucose, like diabetic 
condition. Secreted S100A8/A9 were thought to trigger the inflammatory cy-
tokine expression in macrophages. Taken together, S100A8/A9 may mediate 
the inflammatory interaction between pancreatic islets and macrophages in 
the progression of diabetes.
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Angiotensin II causes pancreatic islet dysfunction and inflammation 
independently of vasoconstriction
C. Thienel1, N.S. Sauter1, K. Kampe2, E. Dror1, S. Xu1, K. Timper1,  
A.W. Jehle2, M. Böni-Schnetzler1, M.Y. Donath1;  
1Clinic of Endocrinology, Diabetes and Metabolism and Department of 
Biomedicine, University Hospital of Basel and University of Basel,  
2Division of Nephrology and Transplantation Immunology,  
University Hospital of Basel and University of Basel, Switzerland.
Background and aims: Pathological activation of the renin-angiotensin sys-
tem (RAS) is closely associated with the metabolic syndrome and new-onset 
of type 2 diabetes (T2D) can be delayed by RAS inhibition. In animal models 
of T2D RAS blockage enhances glycemic control and pancreatic islet func-
tion. The aim of this study was to investigate the effects of angiotensin II on 
islet function and underlying mechanisms, independently of its effects on 
blood pressure.
Materials and methods: For in vitro experiments, angiotensin II-treated hu-
man or mouse pancreatic islets and the rat beta-cell line INS-1E were used 
for glucose-stimulated insulin secretion assays, RNA extraction or protein 
measurements. In vivo studies were done with C57Bl/6J mice fed a high fat 
diet (HFD) for 12 weeks followed by implantation of angiotensin II-releasing 
osmotic pumps. Hydralazine was given in the drinking water to avoid vaso-
constriction. After 4 weeks, at the end of the study, intraperitoneal glucose 
or insulin tolerance tests were performed and heart blood and organs were 
taken for further analysis.
Results: Treatment of human islets with angiotensin II significantly increased 
the expression of the pro-inflammatory cytokines IL-1beta, IL-6 and the 
chemokine MCP-1, caused beta-cell apoptosis (increase 3.1-fold ± 1.34) and 
impaired glucose-stimulated insulin secretion (stimulatory index reduced 
by 23.7%, p < 0.005). The angiotensin II-induced upregulation of IL-6 was 
inhibited by an IKK-2 inhibitor and by the IL-1Receptor antagonist IL-1Ra. 
Similarly angiotensin II reduced the stimulatory index of glucose-stimulated 
insulin secretion in mouse islets (31.9% reduction) and INS-1E cells and up-
regulated IL-6 levels (1.49-fold ± 0.25). In vivo cotreatment with angiotensin 
II and hydralazine normalised the blood pressure. Glucose tolerance testing 
revealed impaired glucose homeostasis in angiotensin II- and hydralazine-
treated HFD mice compared to saline- or hydralazine-treated HFD mice. 
This was associated with impaired insulin secretion whereas insulin sensitiv-
ity was unchanged. Further, animals revealed increased circulating and islet-
derived IL-6 levels (2.28-fold increase vs. hydralazine group). Treatment with 
an anti-IL-1beta antibody rescued the phenotype of the angiotensin II- and 
hydralazine-treated mice by restoring glucose-stimulated insulin secretion 
along with a reduction of islet-associated immune cells.
Conclusion: We conclude that chronic local RAS activation leads to islet dys-
function in vitro and in vivo and independently of vasoconstriction. Further, 
the rescue with NFkB inhibition and IL-1 blockage suggests that inflamma-
tion promotes angiotensin II-mediated islet dysfunction.
Supported by: SNF
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Lycopene attenuates the inflammatory adipose tissue response to high fat 
feeding by regulating both macrophage recruitment and M1/M2 status
M. Nagashimada, Y. Ni, N. Nagata, L. Xu, F. Zhuge, S. Kaneko, T. Ota;  
Brain/Liver Interface Medicine Research Center, Kanazawa University, 
Japan.
Background and aims: Obesity activates the innate immune system with 
subsequent recruitment of immune cells such as macrophages and T cells, 
which contribute to the development of insulin resistance. In particular, adi-
pose tissue macrophages (ATM) recruitment and polarization are considered 
pivotal in obesity-induced inflammation and insulin resistance. However, 
promising treatment modalities targeting ATM for insulin resistance and 
type 2 diabetes remain limited. Here, we show that lycopene, an antioxidant 
carotenoid compound, ameliorates adipose tissue inflammation and whole-
body insulin resistance in high-fat diet (HFD)-induced obese (DIO) mice by 
regulating both macrophage recruitment and M1/M2 status.
Materials and methods: C57BL/6J mice were fed a HFD or a HFD contain-
ing lycopene (HFD+LY; 12 mg/kg body weight) for a total of 8 weeks. The 
histology of epididymal white adipose tissue (eWAT) and insulin sensitivity 
were examined. Next, we quantified immune cells in stromal vascular frac-
tion of eWAT, peripheral blood, and bone marrow by fluorescence-activated 
cell sorter (FACS).
Results: After 8 weeks of feeding, lycopene improved HFD-induced glucose 
intolerance, and hyperinsulinemia (HFD 4.0±0.2 vs HFD+LY 2.0±0.1 ng/ml, 
p < 0.01; fed state), and also enhanced insulin signaling assessed by IRβ and 
Akt phosphorylation in eWAT of DIO mice. HFD+LY mice had decreased 
macrophage infiltration and crown-like structure formation in eWAT com-
pared with HFD mice even though weight and adiposity were similar. In ad-
dition, lycopene administration decreased expression of mRNA for MCP-1 
by 50% and pro-inflammatory cytokines, such as TNFα and interleukin-1β, 
by 62% and 55%, respectively (all p < 0.01) in eWAT of DIO mice. DIO mice 
had 2.3-fold increase in the levels of thiobarbituric acid reactive substances 
(TBARS) in eWAT compared to wild type (WT) mice, whereas lycopene 
reduced lipid peroxidation by 50% (p < 0.01) in DIO mice. These findings 
were associated with reduction of ER stress (CHOP/GRP78), and attenu-
ation of JNK/p38MAPK and NF-kB activation in eWAT. To further assess 
the impact of lycopene on adipose tissue inflammation, FACS analysis was 
performed on stromal vascular cells isolated from eWAT. ATMs identi-
fied as CD45+CD11b+F4/80+cells were increased in DIO mice by 11.4-fold 
compared with WT mice. In addition to reduction of total ATM content, 
HFD+LY mice had 35% fewer CD11c+CD206-(M1) ATMs whereas 60% 
more CD11c-CD206+(M2) ATMs than HFD mice, resulting in predominance 
of M2 over M1 ATM population. However, the predominance of the Ly6C- 
over Ly6Chi monocyte population was not observed in both peripheral blood 
and bone marrow of HFD+LY mice. Moreover, the numbers of either CD3+, 
CD4+, or CD8+ T cells were decreased by 36%, 52%, or 38% respectively (all 
p<0.05) in eWAT of HFD+LY group compared with HFD mice. In parallel, 
lycopene (10-50 nM) suppressed LPS-induced M1 markers mRNA exp38s-
sion (TNFα, MCP-1, and RANTES) in Raw264.7 macrophage cells whereas 
it augmented IL-4-induced M2 markers mRNA expression (IL-10 and Arg1) 
in a dose-dependent manner.
Conclusion: Lycopene, a potent antioxidant, decreases ATM recruitment 
and causes a dynamic M2 dominant shift of ATM, and thereby attenuates 
obesity-induced inflammation and insulin resistance. Reduction of oxidative 
stress might be a relevant strategy to limit inflammatory adipose tissue re-
sponse and subsequent development of insulin resistance.
Supported by: MEXT and MAFF, Japan
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CD11c+ adipose tissue macrophages are bone marrow-derived 
proliferating cells with a mixed polarization phenotype that accumulate 
early in obesity
S.M.W. Wetzels1,2, E. Wijnands3,2, J.J.G. van Wegberg1,2, K.H. Gaens1,2,  
E.A.L. Biessen3,2, C.D.A. Stehouwer1,2, C.G. Schalkwijk1,2, K. Wouters1,2;  
1Department of Internal Medicine, 2Carim, 3Department of Pathology, 
Maastricht University Medical Centre, Netherlands.
Background and aims: Accumulation of pro-inflammatory (M1) mac-
rophages in adipose tissue (AT) is a key event in obesity. These adipose tis-
sue macrophages (ATMs) express CD11c (CD11c+), in contrast to resident 
CD11c- (M2) ATMs. ATMs have been shown to be capable of proliferating. 
However, the exact dynamics and relative contribution of recruitment and 
local proliferation is unknown. We aimed to identify the origin of CD11c+ 
ATMs and investigate the temporal dynamics of ATM accumulation.
Materials and methods: We created mice expressing CD45.2 on resident im-
mune cells and CD45.1 on bone marrow-derived immune cells by a bone 
marrow transplantation strategy. After 6 weeks recovery, the mice were given 
a control or high fat diet (HFD) for 10 days or 5 weeks. Stromal vascular frac-
tion (SVF) of epididymal AT was analysed and sorted with flow cytometry. 
qPCR was performed on sorted ATMs to measure proliferation and activa-
tion markers. Data were analysed using t-tests or 1-way ANOVA.
Results: In lean mice, virtually all CD11c+ ATMs were from donor origin, 
while 20% of the CD11c- ATMs remained from acceptor origin. Upon HFD, 
CD11c+ ATMs already increased after 10 days (14.84 ± 0.46 vs 12.22 ± 0.95% 
SVF, p<0.05) and further accumulated until 5 weeks (18.43 ± 0.93 vs 12.22 
± 0.95% SVF, p<0.001). CD11c- ATMs were only increased after 5 weeks 
of HFD (26.59 ± 0.88 vs 18.25 ± 1.28% SVF, p<0.001). In line, monocytes 
are also increased after 10 days of HFD (10.31 ± 0.88 vs 6.59 ± 0.55% SVF, 
p<0.001) and levels remain constant after 5 weeks. Flow cytometry showed 
that only CD45.1 cells were accumulated upon HFD (14.40 ± 0.44 vs 11.81 ± 
0.89% SVF, p<0.05) while resident CD45.2 cells were not affected. qPCR anal-
ysis of sorted ATMs revealed that M1 CD11c+ ATMs display high TNF and 
Arginase-1 expression while expression of Mannose Receptor and MCP1 was 
lower compared to the putative M2 CD11c- ATMs. Additionally, HFD only 
marginally affected gene expression of both M1 and M2 markers. Moreover, 
only CD11c+ ATMs displayed an increased expression of the proliferation 
marker Ki67 upon HFD compared CD11c- M2 ATMs.
Conclusion: Our data show that monocytes numbers and CD11c+ “M1”ATMs 
accumulate in the early phases of obesity suggesting that recruiting monocyte 
precursors of CD11c+ M1 ATMs from bone marrow is an early event in obe-
sity. Moreover, these ATMs have increased Ki67 expression suggesting that 
local proliferation of recruited cells contributes to accumulation in obese AT. 
Interestingly, ATM-subtypes have mixed M1/M2 profiles and obesity affects 
cell numbers rather than inflammatory phenotype.
Supported by: NWO Veni, FP7MCCIG
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Adipocyte hypertrophy, inflammation and fibrosis: early changes in 
subcutaneous adipose tissue in healthy, non-obese subjects predisposed 
to type 2 diabetes
A.M.J. Henninger, B. Eliasson, L.E. Jenndahl, A. Hammarstedt;  
Lundberg Laboratory for Diabetes Research, University of Gothenburg, 
Sweden.
Background and aims: Adipose tissue dysfunction is thought to be an im-
portant player in the development of type 2 diabetes. We investigated adipo-
cyte hypertrophy, impaired adipocyte differentiation, inflammation, remode-
ling and adipose tissue fibrosis in healthy, non-obese, genetically predisposed 
subjects compared with control subjects with no known genetic predisposi-
tion for type 2 diabetes.
Materials and methods: We recruited 17 healthy, non-obese first degree rela-
tives (FDR) of persons with type 2 diabetes and 17 control subjects. Groups 
were matched for gender and BMI. Glucose tolerance was determined by an 
OGTT and insulin sensitivity was calculated using HOMA-IR. Blood sam-
ples were collected and subcutaneous abdominal adipose tissue biopsies ob-
tained for gene expression analysis and adipocyte cell size measurement.
Results: In spite of similar age, gender, BMI or fat percent in the groups, FDR 
displayed higher waist/hip ratio, fasting serum insulin levels, HOMA-IR and 
serum triglycerides, as well as adipocyte hypertrophy (all p-values <0.05). 
Adipocyte hypertrophy in the FDR group, but not among the controls, was 
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associated with measures of impaired glucose metabolism. There was an in-
creased wnt-signaling activity in the subcutaneous adipose tissue of the FDR 
and the gene expression of CCND2, Tcf7L2 and FN1 were significantly up-
regulated. Cytokines involved in inflammation (TNFalpha, IL1beta and IL10) 
showed an increased expression in adipose tissue among the FDR, as well 
as markers of macrophage infiltration (CD68 and MCP1). There were also 
signs of adipose tissue remodeling (MMP2) and fibrosis (CTGF and ACTA2) 
among the FDR.
Conclusion: Genetic predisposition for type 2 diabetes is associated with im-
paired glucose metabolism and adipose tissue dysfunction, including inflam-
mation, differentiation and remodeling. Reduced ability to maintain adipose 
tissue functionality may be a major susceptibility factor for later development 
of type 2 diabetes.
Supported by: EFSD/Lilly, SFF, Novo Nordisk Foundation
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Evidence for the presence of the phagocytic machinery in adipose tissue
L. Boutens, J. van der Reest, A. Helmke, R. Stienstra;  
Wageningen University, Netherlands.
Background and aims: The chronic inflammatory state that develops in adi-
pose tissue (AT) during obesity is generally considered to promote insulin 
resistance (IR) and Type 2 Diabetes (DMII). Obese, inflamed AT is character-
ized by the presence of dead hypertrophic adipocytes surrounded by inflam-
matory macrophages, forming so-called Crown-like structures (CLS). Con-
trary, in lean AT hardly any dead adipocytes and inflammatory macrophages 
can be identified. Immunologically silent clearance of dead cells by mac-
rophages is known to be crucial for maintaining homeostasis in many tissues. 
The presence of CLS in obese, inflamed AT suggests that the clearance of dead 
adipocytes is disrupted during the development of obesity and might con-
tribute to AT inflammation. We therefore aim to unravel the metabolic and 
immunologic (dys)regulation within AT macrophages (ATM) related to their 
phagocytic trait, in order to find new leads for therapeutic targets and strate-
gies for obesity-induced AT inflammation and subsequent IR and DMII.
Materials and methods: In vivo, C57Bl/6 mice were fed a Low Fat diet (LFD) 
or a High fat diet (HFD) to promote IR and DMII. Phagocytosis was studied 
ex vivo using a co-culture system of labelled macrophages and dead adipo-
cytes followed by staining for lipids and subsequent analysis using Flow Cy-
tometry. The effect of AT-derived factors on the phenotype of the macrophag-
es was examined using a co-culture system with AT explants. Quantitative 
PCR, Western Blotting, ELISA and Microarray were used to determine the 
immunological and metabolic state of macrophages.
Results: Microarray analysis of AT depots isolated from mice on a LFD or 
HFD revealed differential regulation of multiple genes that are known to 
play crucial roles in phagocytosis (Mertk, Gas6, Mfge8, Lrp, Gulp1, Elmo1 
and Ucp2) upon the development of obesity, accompanied by changes in the 
expression of apoptosis- (Caspases, Bax) and inflammation-related (Il-1β, 
Nlrp3) genes. In vitro analysis demonstrated a profound increase in lipids 
in macrophages that were co-cultured with dead adipocytes (using Flow Cy-
tometry), suggestive of phagocytosis of adipocytes by macrophages. Upon 
the phagocytosis of dead adipocytes, genes involved in fatty acid oxidation 
(FAO; Pparα, Pgc1α) were higher expressed and the macrophages were 
skewed towards a predominant anti-inflammatory phenotype, marked by 
higher expression and secretion levels of IL-10 and decreased expression and 
secretion of TNFα. Interestingly, macrophages that were co-cultured with 
AT explants from lean mice had a twofold higher phagocytic capacity than 
macrophages that were cultured without AT explants. An increased expres-
sion of genes involved in phagocytosis (Mertk, Gas6, Ucp2) in these mac-
rophages was accompanied by higher expression levels of genes involved in 
FAO (Cpt1β, Acad, Pgc1β) and anti-inflammatory cytokines (IL-10); closely 
mimicking the phenotypic changes that were found in macrophages that have 
phagocytised dead adipocytes.
Conclusion: Our data suggest that the phagocytic machinery is present in 
AT and is differentially regulated in obese, inflamed AT. Interestingly, mac-
rophages are capable of phagocytising dead adipocytes ex vivo and their 
phagocytic capacity is enhanced by AT-derived factors.
Supported by: NWO Vidi (ZonMw)
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Local biocommunication between peripancreatic adipose tissue and 
pancreatic beta cell: characterisation of factors involved in beta cell 
dysfunction
E. Sidot, C. Guzman, M. Tournier, A.-D. Lajoix, S. Peraldi-Roux;  
EA 7288, Montpellier, France.
Background and aims: In metabolic syndrome, pancreatic beta-cell is able to 
compensate for the insulin resistance by increasing beta-cell mass and func-
tion which allows to maintain the normoglycaemia. During the transition 
from pre-diabetes/obesity to type 2 diabetes (T2D), beta-cell is subjected to 
metabolic and inflammatory stress, that gradually lead to secretory dysfunc-
tion. In obesity, factors secreted by visceral adipose tissue may influence beta-
cell mass and function. Moreover, increased visceral adiposity is associated to 
the development of peripancreatic adipose tissue (PPAT), which penetrates 
the pancreas and establishes direct contact with islets of Langerhans. Re-
buffat et al (Endocrinology, 2012) showed in a model of obesity and insulin 
resistance that factors secreted by the PPAT modulate the proliferation of 
beta-cells. This is in favor of a local biocommunication between PPAT and 
beta-cell. Our goal is to characterize the PPAT in terms of immune cells and 
inflammatory factors secreted during the onset of type 2 diabetes (T2D) and 
determine how these factors are able to influence beta-cell compensation and 
decompensation in response to insulin resistance and metabolic syndrome.
Materials and methods: Our study was performed in the Zucker fa/fa rats/
ZDF rats model of obesity and T2D. Three groups of animals were studied, 
pre-obese rats (6 weeks old) obese/pre-diabetic rats (10 weeks old) and dia-
betic rats (12 week olds). The presence of immune cells infiltrating the PPAT 
was investigated by immunohistochemistry using the macrophage marker 
ED1. The expression profile of peripancreatic fat-derived factors was ana-
lyzed by antibodyarray (Chemiarray, RD System) and proteomic technology. 
A comparison of each group of rats allowed us to identify modifications in 
adipose tissue-derived factors and to correlate these changes to the metabolic 
status of the animals.
Results: An increase in macrophages infiltrating the PPAT was observed in 
obese/pre-diabetic animals (10 weeks old). Using chemiarray technology, we 
observed changes in cytokines and chemokines profiles secreted by PPAT in 
the ZDF rat model. While in the early stages of the disease we observed an 
increase in pro-inflammatory cytokines and chemokines secreted by PPA 
(such as, CINC- 1, 2, 3, IL-1β, LIX, TIMP-1, and MIP- 1α), surprisingly and 
unexpectedly, the expression profile of these factors changed and their levels 
decreased, when animals become diabetic (12 weeks ZDF rats). Proteomic 
profile also varies during the onset of the disease.
Conclusion: Therefore, our results showed that in obese/pre-diabetes rats, 
PPAT adipose tissue expression of inflammatory cytokines and chemokines 
are modified and thus could (i) induce and perpetuate inflammation by at-
tracting immune cell in tissue and (ii) contribute to progressive beta-cell dys-
function occurring in T2D.
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The metabolic and anti-inflammatory effects of long-term resveratrol 
intake; a randomised clinical trial
T.N. Kjær, M.M. Poulsen, M.J. Ornstrup, J. Jørgensen, B. Richelsen,  
S.B. Pedersen;  
Aarhus University Hospital, Denmark.
Background and aims: Low-grade inflammation due to macrophage infiltra-
tion and hypoxia in adipose tissue (AT) is thought to be the link between 
obesity and the metabolic syndrome (MS). Resveratrol (RV) is a natural anti-
inflammatory compound found in e.g. grape-skin that reduces inflammation 
and normalizes both insulin sensitivity and lifespan of diet induced obese 
rodents. Sirt1 enzymes, thought to mediate the RV-effects in rodents, are pre-
sent in human AT. In vitro, RV stimulates human AT to increase lipolysis, 
reduce secretion of the macrophage-attracting MCP1 and reduce inflamma-
tion. Furthermore, hypoxia induced inflammation in AT is completely re-
verted when exposed to RSV. In clinical trials the effects of RV are inconclu-
sive. A previous short term cross over study has shown that RV lowered sys-
tolic blood pressure, hepatic liver fat, and plasma triglycerides, leptin, TNF-α, 
leukocytes, alanine transaminase (ALT) and HOMA index in healthy obese 
humans. However, we and others have not been able to verify these findings. 
We aim to investigate the anti-inflammatory effects of long term RV intake 
and it’s potential to ameliorate aspects of MS.
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Materials and methods: A placebo controlled double blind clinical trial. 76 
males with MS were randomized to treatment with high dose RV (HD) 500 
mg x 2 or low dose RV (LD) 75 mg x 2 daily or placebo (PL) for 4 months. Be-
fore and after treatment, biopsies from skeletal muscle, adipose tissues were 
obtained for analysis of gene expression. MR and DEXA-scans were used 
to quantify changes in body fat amount and body composition respectively. 
Clinical blood pressure (BP) measurement, blood tests and urine samples 
were obtained at day 0, 30, 60 and 120 to follow BP, inflammation, lipid pro-
file, liver function, insulin sensitivity (HOMA).
Results: 76 were randomized for the trial and 66 completed the four months 
of treatment. At baseline the subjects were well matched for BMI, age and 
waist circumference. However lean mass was significantly greater in LD com-
pared to HD (p=0.048) and systolic BP was significantly higher in the PL 
group compared to LD group (p=0.05). Plasma biochemistry: At baseline 
there was a positive correlation between severity of metabolic syndrome and 
IL-6 level (p<0.03). Metabolic effects: There were no significant effects of RV 
treatment on total cholesterol, high-density lipoprotein (HDL), triglyceride, 
ALT, insulin, glucose (or HOMA-IR). Anti-inflammatory effects: There were 
no changes in hs-CRP, IL-6, soluble urokinase-type plasminogen activator 
receptor (suPAR) in plasma, and there were no significant changes of IL-6 
and TNF-α gene expression in AT or muscle tissue between the groups. Body 
composition: There was no difference in BMI, total lean mass, total fat mass, 
total fat percentage, subcutaneous adipose tissue, visceral adipose tissue, liver 
fat or extra/intra myocellular lipid between the groups. BP was unchanged 
between the groups.
Conclusion: Increasing severity of metabolic syndrome is associated with 
higher IL-6 plasma levels. However, RV did not affect IL-6 levels. So neither 
long term HD or LD treatment affects low-grade inflammation, or param-
eters of the MS. RV does not change body composition or AT depot size ir-
respective of dose. We conclude that RV has no role in reducing low-grade 
inflammation as seen in MS and shows no promise in ameliorating any as-
pects of the MS.
Clinical Trial Registration Number: NCT01412645
Supported by: School of MM DK
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Elevated glucose concentrations induce Prep1 overexpression through 
epigenetic modifications
M. Ciccarelli1, V. Vastolo2, L. Albano1, A. Desiderio1, M. Lecce1,  
D. Conza1, G.L. Russo3, F. Beguinot1, P. Ungaro2;  
1DiSMeT, University of Naples Federico II, 2CNR-IEOS, Naples,  
3CNR-ISA, Avellino, Italy.
Background and aims: Changes in epigenetic regulation of gene expression 
represent potentially important pathogenic mechanisms behind complex 
diseases such as diabetes. High glucose concentrations that mimics diabetic 
conditions can induce in vivo chromatin remodeling and histone modifi-
cations to allow increased binding of key transcription factors, such as the 
nuclear factor κ-B (NF-κB), regulating inflammatory and diabetes-related 
genes. Prep1, a homeodomain transcription factor essential in embryonic de-
velopment, has a role in glucose and energy metabolism. Adult Prep1-hypo-
morphic mutant mice (Prep1i/i), which express 2 to 3% of Prep1 mRNA and 
up to 10% of the protein, exhibit enhanced sensitivity to insulin action and 
are protected from developing streptozotocin-induced diabetes. Consistent 
with these findings overexpression of the wild-type Prep1 cDNA in L6 cells 
determined a >70% inhibition of insulin-stimulated 2-DG uptake by these 
cells and a similar decline in the expression of GLUT4 protein and mRNA. 
However, how the environment affect Prep1 gene remains unknown. The aim 
of this study is to evaluate whether and how a diabetic condition such as 
high glucose can dysregulate Prep1 gene expression by inducing epigenetic 
changes through NF-κB recruitment to its promoter.
Materials and methods: We mimicked diabetic condition by culturing L6 
skeletal muscle cells in High Glucose (25 mM) relative to Normal glucose 
(5.5 mM). Prep1 and NF-κB expression were analyzed by Real-Time PCR 
and western blot analysis. Chromatin Immunoprecipitation assays have been 
performed to identify histone marks and histone-associated proteins.
Results: L6 cells cultured in HG for 72 hours show a significant increase of 
Prep1 mRNA and protein levels compared to NG cultured cells. Time couse 
experiments of HG showed an increase of Prep1 expression both at mRNA 
and protein levels yet at four hours of HG incubation with the maximum 
effect reached at 48 and 72 hours of high glucose incubation. This effect was 
specific to glucose since equimolar amounts of xylose (osmolarity control) 
and 2-DG had no effect. As expected Glut4 mRNA levels decreased in re-
sponse to HG. In parallel, HG incubation induced nuclear translocation and 
binding to Prep1 promoter of the transcription factor NF-κB p65 that in turn 
enhanced the binding of the histone methyltransferase SET7/9 and histone 
acetyl-transferase p300 to Prep1 promoter. This event coincided with an in-
crease in lysine 4 dimethylation and lysine 9 and 14 acetylation on histone H3 
(two marks of active transcription). Co-incubation of L6 cells with HG plus 
JSH-23, an NF-κB inhibitor, prevented HG-induced p65 binding, histone 
modifiers recruitment and histone modifications on Prep1 promoter and re-
stored HG-induced Prep1 overexpression.
Conclusion: Elevated glucose concentrations alter the epigenetic state of 
Prep1 gene resulting in an increase of its expression levels. These findings 
might have clinical relevance as preliminary evidence in our lab indicates 
that Prep1 gene is overexpressed in euglycemic offspring of type 2 diabetic 
patients, suggesting that Prep1 overexpression may provide an early contri-
bution to disease in these individuals. Clarify Prep1 epigenetic regulation can 
yeld new insights into the physiopatology of glucose homeostasis and un-
cover potential targets for diabetes treatment and prevention.
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Palmitate challenged muscle cells attract monocytes through  
TLR4-dependent release of ATP
N.J. Pillon1, Y.E. Li1, P.J. Bilan1, J.T. Brozinick2, A. Klip1;  
1Cell Biology Program, The Hospital for Sick Children, Toronto, Canada, 
2Eli Lilly and Company, Indianapolis, USA.
Background and aims: Obesity and type 2 diabetes are associated with 
chronic activation of the immune system, and insulin-resistance arises by 
both lipotoxicity and low-grade inflammation. In response to high fat diet, 
the fat tissue attracts immune cells that cause low, sustained inflammation re-
sponsible for making the body resistant to insulin. Although inflammation is 
clearly recognized in adipose tissue, recent studies show that high fat-feeding 
is also responsible for a significant increase in pro-inflammatory cytokine 
expression in muscle. Yet, it is unknown whether there is a cause-effect re-
lationship between muscle inflammation and whole body insulin resistance. 
Strikingly, muscle contains resident macrophages and we and others have re-
cently detected infiltrating pro-inflammatory macrophages in muscle from 
type 2 diabetic individuals or from high fat-fed mice. Beyond this, little is 
known about the interplay between immune and muscle cells in the context 
of hyperlipidic environment, and a key unresolved issue is whether and how 
muscle cells themselves are capable of attracting monocytes.
Materials and methods: Skeletal muscle is composed primarily of muscle 
fibers and satellite myoblasts, but also encompasses blood and lymph vessels, 
nerves and immune cells. As each of these cell types can potentially respond to 
a high fat environment in vivo, we chose a cell culture approach to investigate 
the specific crosstalk between muscle cells and macrophages in the context of 
fatty acid exposure. This strategy enables us to control individual variables, to 
determine vectorial communication, and to explore separately the responses 
of each cell type. Medium collected from L6 myotubes (conditioned media, 
CM) exposed to saturated or unsaturated fatty acids (palmitate vs palmi-
toleate) was tested for its ability to attract monocytes. Secreted factors in the 
CM and inflammatory pathway activation in myotubes were analyzed using 
western blot, qPCR, nucleotide degradation strategies and gene knockdown.
Results: CM from L6 myotubes treated with palmitate - but not palmitoleate 
- induced THP1 monocyte migration across transwells. Palmitate caused 
both myotube lipotoxicity and inflammation. Although ceramide levels rose, 
they were not required for monocyte chemoattraction. Palmitate activated 
the TLR4-NFκB pathway in myotubes and elevated cytokine expression, 
but the monocyte chemoattracting agent in CM was not a polypeptide. In-
stead, nucleotide degradation eliminated the chemoattracting properties of 
CM. Moreover, palmitate induced the expression and activity of pannexin-3 
channels in myotubes, mediated by TLR4-NFκB. Importantly, TLR4-NFκB 
inhibition or pannexin-3 knockdown in myotubes prevented monocyte che-
moattraction by CM.
Conclusion: These findings constitute proof of concept that high levels of sat-
urated fats may promote monocyte migration towards skeletal muscle in vivo, 
promoting the macrophage infiltration of this tissue that arises with fatty diets. 
They also predict that targeting chemokine production may be insufficient to 
reduce macrophage infiltration of muscle, as other factors such as nucleotides 
may significantly contribute to immune cell chemoattraction. Moreover, this 
study identifies pannexin-3 as an interesting target to taper the arrival and 
contribution of tissue inflammatory macrophages to metabolic disease.
Supported by: Canadian Diabetes Association and Canadian Institutes of 
Health Research
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Serum omentin is associated with lipid levels, but not with  
glucose tolerance and type 2: KORA F4 study
C. Herder1,2, M. Carstensen1,2, D.M. Ouwens3,4, B. Kowall5, A. Peters6,7,  
W. Rathmann5, M. Roden1,2, B. Thorand6,7;  
1Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, 
2German Center for Diabetes Research, Düsseldorf, 3Institute for Clinical 
Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, 
4Department of Endocrinology, Ghent University Hospital, Belgium, 
5Institute for Biometrics and Epidemiology, German Diabetes Center, 
Düsseldorf, 6Institute of Epidemiology II, Helmholtz Zentrum Muenchen, 
Neuherberg, 7German Center for Diabetes Research, Neuherberg, Germany.
Background and aims: Circulating omentin levels are positively correlated 
with adiponectin. Although several studies suggested that omentin - like 
adiponectin - may be inversely associated with obesity and insulin resistance 
(HOMA-IR), data from population-based studies are not available so far. 
Therefore, we investigated in the population-based KORA F4 survey from 
Augsburg/Germany (i) whether serum levels of omentin were associated with 
prediabetes, type 2 diabetes (T2D) and continuous T2D risk factors and (ii) 
whether associations between omentin, prediabetes, T2D and related risk 
factors were mediated by BMI.
Materials and methods: Serum levels of omentin were measured by ELISA 
in 1089 participants (48% male; age range 61-82 years; BMI 29±4 kg/m²; 
NGT: n=576, IFG: n=56, IGT: n=186, IFG/IGT: n=46; newly diagnosed T2D: 
n=66, known T2D: n=159). Associations between serum omentin, glucose 
tolerance and continuous risk factors of T2D were assessed using logistic and 
linear regression models, respectively.
Results: We found no inverse association between serum omentin and pre-
diabetes or diabetes (P>0.05 for unadjusted comparison of categories of glu-
cose tolerance) and no significant associations with glucose tolerance status 
after adjustment for age, sex, BMI, lifestyle factors, lipids, hypertension and 
history of myocardial infarction. After adjustment for multiple confound-
ers, serum levels of omentin were associated with blood lipids (HDL choles-
terol: β=0.04, P<0.001; ln(triglycerides): β=-0.04, P=0.02), but not with BMI 
(P=0.4), parameters of glucose metabolism (fasting and 2-hr glucose, fasting 
insulin, HOMA-IR, HbA1c; P between 0.1 and 1.0) and systolic or diastolic 
blood pressure (P=0.9 and 0.09, respectively). Associations between omentin 
and lipids were explained by adiponectin.
Conclusion: In conclusion, our data indicate that omentin is assocated with 
lipid levels, but does not represent a novel biomarker of prediabetes and T2D.
Supported by: DZD e.V., DFG (RA 459/3-1)
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The novel adipokine / hepatokine betatrophin is increased in women 
with gestational diabetes mellitus
T. Ebert1,2, U. Wurst1,2, M. Stumvoll1, A. Tönjes1,2, M. Fasshauer1,2,  
S. Kralisch1,2;  
1Department of Endocrinology and Nephrology, University of Leipzig,  
2IFB AdiposityDiseases, Leipzig University Medical Center, Germany.
Background and aims: Betatrophin has recently been introduced as a novel 
adipokine/ hepatokine which promotes pancreatic β cell proliferation and 
improves glucose tolerance in mouse models of insulin resistance. However, 
regulation of betatrophin in women gestational diabetes mellitus (GDM), as 
well as its association with markers of obesity, glucose and lipid metabolism, 
inflammation, and renal function, have not been elucidated.
Materials and methods: Circulating betatrophin was quantified in 74 women 
with GDM and 74 healthy, pregnant, age-, body mass index-, and gestational 
age-matched controls by enzyme-linked immunosorbent assay. In a subset 
of the study population comprising of 85 patients (41 previous controls, 44 
previous women with GDM), postpartum betatrophin levels were measured 
in a follow-up study.
Results: Median [interquartile range] serum betatrophin levels were higher 
in women with GDM (1.80 [0.53] µg/l) as compared to non-diabetic preg-
nant controls (1.58 [0.44] µg/l) (p = 0.003) during pregnancy. In multivariate 
analysis, GDM status was an independent and positive predictor of circulat-
ing betatrophin (p < 0.05). Furthermore, high density lipoprotein cholesterol 
and leptin were independently and positively associated with betatrophin (p 
< 0.05). Moreover, betatrophin levels were significantly higher during gesta-
tion (1.69 [0.53] µg/l) as compared to postpartum levels (1.55 [0.66] µg/l) (p 
= 0.029).
Conclusion: Circulating betatrophin is increased in women with GDM and 
remains a positive predictor of GDM status. Betatrophin levels during ges-
tation are significantly higher as compared to postpartum concentrations. 
Further studies need to elucidate the pathophysiological significance of beta-
trophin upregulation in GDM and during pregnancy.
Supported by: DFG; Federal Ministry of Education and Research, Germany; 
MSD grant
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Plasma chemerin is a strong and independent predictor of cardiovascular 
event risk
A. Leiherer1,2, A. Muendlein1, P. Rein3, K. Geiger1, P. Fraunberger4,  
H. Drexel3,5, A. Vonbank3, C.H. Saely3,2;  
1VIVIT Institute, Feldkirch, Austria, 2Private University of the Principality 
of Liechtenstein, Triesen, Liechtenstein, 3Academic Teaching Hospital 
Feldkirch, Austria, 4Medical Central Laborotary, Feldkirch, Austria,  
5Drexel University College of Medicine, Philadelphia, USA.
Background and aims: Associations of the adipokine chemerin with the 
metabolic syndrome (MetS) and with chronic kidney disease (CKD), two 
important indicators of increased cardiovascular event risk, have been de-
scribed. However, the power of chemerin to predict cardiovascular events has 
not been investigated so far and is addressed in the present study.
Materials and methods: We measured plasma chemerin in a high-risk co-
hort of 495 patients undergoing coronary angiography for the evaluation of 
suspected or established coronary artery disease (CAD) in which cardiovas-
cular events were prospectively recorded over 3.5±1.1 years. Significant base-
line CAD was diagnosed in the presence of coronary artery stenoses ≥50%.
Results: At baseline, plasma chemerin was significantly higher in patients 
with the MetS as defined by the current harmonized consensus definition 
(n=147) than in non-MetS subjects (201±71 ng/ml vs. 163±62 ng/ml p<0.001) 
and was inversely correlated with estimated glomerular filtration rate (eGFR; 
r=-0.33, p<0.001). During follow-up, chemerin significantly predicted car-
diovascular events (n=82) univariately, after adjustment for age, gender, BMI, 
and eGFR, and also after additional adjustment for the presence of significant 
baseline CAD, with standardized hazard ratios of 1.83 [1.19-2.83], p= 0.006; 
1.77 [1.12-2.80], p =0.015; and 1.69 [1.07-2.67], p=0.024, respectively.
Conclusion: From this first prospective evaluation of the cardiovascular 
event risk associated with chemerin we conclude that chemerin is strongly 
predictive of cardiovascular events independently from standard risk factors, 
from the MetS, and from the baseline presence of CAD.
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Secreted frizzled-related protein 4 is up-regulated in type 2 diabetes  
and interferes with hepatic insulin signalling
M. Bekaert1, P. Fahlbusch2, S. Colenbie1, T. Doktorova3,  
Y. Van Nieuwenhove4, T. Vanhaecke3, J.B. Ruige1, D.M. Ouwens1,2;  
1Endocrinology, Ghent University Hospital, Belgium, 2Institute for Clinical 
Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, 
Germany, 3Toxicology, Center for Pharmaceutical Research VUB, Brussels, 
4Abdominal surgery, Ghent University Hospital, Belgium.
Background and aims: Accumulating evidence implicates secreted regulators 
of the Wnt signaling pathway to metabolic control. For example, the inflam-
mation-induced up-regulation of the Wnt inhibitor secreted frizzled-related 
protein 4 (Sfrp4) associates with impaired glucose-induced insulin secretion 
in type 2 diabetes. Importantly, Sfrp4 is also expressed in adipose tissue. The 
current study investigated whether the expression of Sfrp4 in visceral adipose 
tissue is altered in morbid obesity and type 2 diabetes, and whether Sfrp4 af-
fects the expression of key rate-limiting gluconeogenic enzymes.
Materials and methods: Gene expression levels of Sfrp4 were determined 
by real-time PCR in subcutaneous and visceral adipose tissue biopsies from 
morbidly obese men (n=45, of which 20 had type 2 diabetes) and control men 
(n=22) undergoing abdominal surgery. The effects of recombinant Sfrp4 (100 
ng/ml) on the mRNA expression of phosphoenolpyruvate carboxykinase 
(PEPCK), glucose-6-phosphatase (G6P) and fructose-1,6-bisphosphatase 1 
(FBP1) were studied in the human hepatocyte cell line HepaRG after glucose 
starvation in the presence and absence of 100 nM insulin.
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Results: In visceral adipose tissue, expression of Sfrp4 was 2.3-fold higher in 
patients with type 2 diabetes either versus patients with morbid obesity only 
or controls (P<0.002). There were no differences in Sfrp4 expression among 
these groups in subcutaneous adipose tissue. In vitro, in the absence of insu-
lin, Sfrp4 reduced FBP1 expression by 33% (P<0.05), while having no effect 
on G6P- and PEPCK-levels in HepaRG cells. Insulin exposure reduced the 
expression of PEPCK, G6P and FBP1 by 2.1-, 2.8-, and 2.7-fold, respectively 
(all P<0.001). Exposing HepaRG cells to Sfrp4 further impaired the suppres-
sion of FBP1- and PEPCK-levels by insulin by 30% and 35%, respectively. In 
contrast, Sfrp4 did not affect the suppression of G6P levels by insulin. Howev-
er, Sfrp4 reduced the insulin-mediated phosphorylation of Akt- and FOXO1, 
which has been implicated in the suppression of PEPCK expression, by 25% 
and 35%, respectively (both P<0.05).
Conclusion: These data show that the expression of the Wnt regulator Sfrp4 
is selectively increased in visceral adipose tissue from patients with type 2 
diabetes. In vitro, Sfrp4 interferes with the suppression of the expression of 
rate-limiting regulators of hepatic gluconeogenesis by insulin.
Supported by: BOF Special Research Fund
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Wnt1 inducible signalling pathway protein 1 (WISP1) is a novel marker 
of obesity regulated by high fat diet
C. Tacke1,2, V. Murahovschi1,2, F. Keyhani-Nejad1,2, O. Pivovarova1,2,  
I. Ilkavets3, M. Kemper1,2, S. Hornemann1,2, R. Dmitrieva4, A. Conradi4,  
S. Dooley3, A.F.H. Pfeiffer1,2, N. Rudovich1,2;  
1German Institut for Nutrition Science, Nuthetal, 2Charité University 
Medicine, Berlin, 3University Medical Centre Mannheim, University of 
Heidelberg, Mannheim, Germany, 4Almazov Federal Medical Research 
Centre, Saint Petersburg, Russian Federation.
Background and aims: The Wnt signaling is involved in several processes 
such as proliferation, adhesion, apoptosis and differentiation. WISP1 (WNT1 
inducible signaling pathway protein 1) is a target protein of canonical Wnt 
signaling and it belongs to the secreted extracellular matrix associated pro-
teins of the CCN family. Recently, we showed that WISP1 expression is as-
sociated with signs of insulin resistance and low-grade inflammation in hu-
mans. We tested here the acute effect of insulin on WISP1 expression in vivo 
in subcutaneous adipose tissue (SAT). Additionally, the effect of high fat diet 
induced obesity on regulation of WISP1 gene expression in mice.
Materials and methods: Body weight matched, twelve-week-old male 
C57Bl/6J mice were kept on either a control diet D12450B (1) containing 
10kcal-%fat, 20kcal-% protein, 70 kcal-% carbohydrate, 3.85kcal/g or a high 
fat diet D12492; (2) containing 60kcal-% fat, 20 kcal-% protein, 20 kcal-
%carbohydrate, 5.24 kcal/g for 6 weeks. Body weight and composition was 
determined by magnetic resonance spectroscopy in conscious mice. Over-
night fasted mice were sacrificed and epididymal white adipose tissue, liver 
and gastrocnemius muscle tissue were collected. Human mesenchymal stem 
cells (n=3) were differentiated in vitro into adipocytes. Differentiated adipo-
cytes were incubated with 100nM insulin for 4h. Healthy, moderately obese 
male subjects (n=14) underwent one or three of the following procedures: 1) 
isotonic saline-infusion (n=11); 2) hyperinsulinemic-euglycemic clamp (EC) 
for 4 h with continuous infusion of 40•mU•m2 of the body surface•min-1 
human insulin at a steady state capillary plasma glucose concentration of 4,4 
mmol/l (80 mg/dl) (n=10); 3) hyperinsulinemic-hyperglycemic clamp (HC) 
for 4 h with continuous infusion of 40•mU•m2 of the body surface•min-1 
human insulin at a steady state capillary plasma glucose concentration of 7,8 
mmol/l (140 mg/dl) (n=8). Healthy, obese male subjects (n=10) underwent 
1) isotonic saline-infusion and 2) intralipid/heparin -infusion. SAT biopsies 
were obtained before and after infusion. WISP1 gene expression was meas-
ured in human differentiated adipocytes, human SAT, in mice in epididymal 
white adipose tissue, in liver and gastrocnemius muscle tissue.
Results: WISP1 gene expression increased in human differentiated adipo-
cytes after stimulation with 100nM insulin, but no significant difference was 
observed in SAT after HC and EC. The high fat diet-fed mice had increased 
body weight, fat mass and lean mass compared with control group and up-
regulated WISP1 expression in adipose and muscle tissues. We couldn’t ob-
serve any acute effect on WISP1 expression in human SAT after intralipid/
heparin -infusion.
Conclusion: Insulin increased WISP1 expression in vitro, but has no acute 
effect in overweight subjects in vivo. High-fat diet induced obesity increased 
WISP1 gene expression in mice, however intralipid infusion hasn´t any acute 
effect in overweight subjects in vivo.
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Wnt1 inducible signalling protein 1 (WISP1) is a novel adipokine linked 
to inflammation and insulin resistance in adipose tissue
V. Murahovschi1,2, O. Pivovarova1,2, I. Ilkavets3, R. Dmitrieva4, S. Döcke1,  
M. Kemper1, Ö. Gögebakan1,2, M. Osterhoff1,2, N. Klöting5, A. Conradi4,  
S. Dooley3, C. von Loeffelholz6,2, M. Blüher5, A.F.H. Pfeiffer1,2,  
N. Rudovich1,2;  
1German Institut for Nutrition Science, Nuthetal, 2Charité University 
Medicine, Berlin, 3University Medical Centre Mannheim, University of 
Heidelberg, Mannheim, Germany, 4Almazov Federal Medical Research 
Centre, Saint Petersburg, Russian Federation, 5University of Leipzig,  
6Jena University Hospital, Germany.
Background and aims: WISP1 (Wnt1 inducible signaling pathway protein 1) 
belongs to the secreted extracellular matrix associated proteins of the CCN 
family and is a target gene of canonical Wnt signaling pathway. Here we show 
that WISP1 is released from adipocytes and circulating WISP1 levels corre-
late with weight reduction and signs of insulin resistance.
Materials and methods: The mRNA expression of WISP1 was studied 1) 
in paired samples of visceral (VAT) and subcutaneous adipose tissue (SAT) 
from healthy glucose-tolerant subjects (n=75); 2) in paired VAT, SAT and 
liver tissue samples from subjects with/without NAFLD (n=47); 3) in over-
weight subjects underwent weight reduction by caloric restriction (n=49); 4) 
in SAT of overweight subjects (n=14) in the euglycemic-hyperinsulinemic 
(EC) and hyperglycemic-hyperinsulinemic (HC) clamp test; 5) in human 
mesenchymal stem cells (MSC) derived adipocytes and in human GM-mac-
rophages. WISP1 protein levels were measured in overweight subjects under-
went weight reduction and in cell culture medium adipocytes during differ-
entiation. Expression and release of TNFα, IL-6, IL-10, IL-1ß was measured 
in differentiated adipocytes and in GM-macrophages after stimulation with 
0,5µg/ml WISP1 for 24h. 3T3-L1 differentiated adipocytes were treated with 
100nmol/L insulin with/without LY294002 (25µM, preincubation 30 min) 
and with/without PD 098059 (30µM, preincubation 30 min) for 4h.
Results: WISP1 protein release and WISP1 expression increase in cell culture 
medium during adipocytes differentiation. Expression and release of IL-6, IL-
10, IL-1ß, TNFα in GM-makrophage was significantly enhanced after stim-
ulation with 0,5µg/ml WISP1 for 24h. WISP1 expression was increased in 
differentiated 3T3-L1 cells after stimulation with 100nM insulin for 4h. This 
effect was abolished by incubation with LY294002 and PD098059. In human 
studies: 1) we found a correlation between insulin sensitivity, macrophages 
infiltration, adiponectin levels and WISP1 gene expression in samples of VAT 
and SAT; 2) WISP1 expression is higher in (VAT) rather than in (SAT); 3) 
hepatic WISP1 expression has no association with ectopic fat accumulation 
in obesity; 4) weight reduction decreases WISP1 expression in SAT as well as 
circulating WISP1 levels in plasma.
Conclusion: Our data shows that WISP1 is a novel adipokine but no hepa-
tokine that is substantially overexpressed in visceral fat from obese subjects 
and reflects insulin resistance and adipose tissue inflammation. Weight 
changes regulate circulating WISP1 levels and WISP1 expression in adipose 
tissue. Therefore, we propose that WISP1 is a novel biomarker and a potential 
link between obesity and the metabolic syndrome.
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FABP5 is an essential modulator of fatty acid-induced GIP secretion in 
enteroendocrine K cells
K. Shibue1,2, S. Yamane1, N. Harada1, A. Hamasaki1, K. Suzuki1, E. Joo1,  
K. Iwasaki1, D. Nasteska1, T. Harada1, Y. Adachi3, Y. Owada4, R. Takayanagi2, 
N. Inagaki1;  
1Department of Diabetes, Endocrinology and Nutrition, Graduate School 
of Medicine, Kyoto University, 2Department of Medicine and Bioregulatory 
Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 
3Department of Anatomy, School of Medicine, University of Occupational 
and Environmental Health, Fukuoka, 4Department of Organ Anatomy, 
Yamaguchi University Graduate School of Medicine, Japan.
Background and aims: Fatty acid-binding protein 5 (FABP5) is a 15-kDa 
cytosolic-protein with high affinity to long chain fatty acids (LCFA). It has 
been known as an intracellular chaperon that transports LCFA into various 
organelles and has been reported to be involved in insulin resistance in white 
adipose tissue (WAT). Using microarray analysis, we demonstrated that 
FABP5 is expressed exclusively in murine enteroendocrine GIP-producing 
K-cells. We investigated the physiological function of FABP5 in K-cells.
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Materials and methods: Immunostaining for FABP5 and GIP was performed 
in murine samples of small intestine for confirmation of specific expression 
of FABP5 in K-cells. To evaluate the acute GIP secretory response in FABP5-
/- mice, lard (10ml/kg) and glucose were injected orally; plasma glucose and 
serum levels of GIP, GLP-1 and insulin were measured. Using K-cells isolated 
from newly-generated GIP-GFP knock-in hetero (GIPgfp/+)-FABP5+/+ and 
GIPgfp/+-FABP5-/- mice, quantitative real-time PCR (qPCR) for GIP expres-
sion and measurement of GIP content were performed to determine whether 
or not FABP5 is involved in GIP biosynthesis. To assess potential effects of 
FABP5-deficiency on body weight and composition, mice were fed a high fat 
diet (HFD) for 10 weeks. Whole body CT scans of HFD-fed wild-type (WT), 
FABP5-/-, GIPgfp/gfp-FABP5+/+ and GIPgfp/gfp-FABP5-/- mice were com-
pared. Using WAT taken from HFD-fed WT and FABP5-/-mice, mRNA ex-
pression levels of lipid metabolism-related genes were evaluated by qPCR.
Results: Immunostaining of intestinal mucosa showed that GIP-positive 
cells were totally merged with FABP5-positive cells and that 90% of FABP5-
positive cells were merged with GIP-positive cells. Although plasma GIP lev-
els after lard injection were significantly lower in FABP5-/-mice compared 
to those in WT mice, there were no significant differences in the results of 
OGTT. Plasma glucose, insulin and GLP-1 levels after both glucose and lard 
administration were similar in WT mice and FABP5-/- mice. There was no 
significant difference in GIP mRNA expression or GIP content in K-cells 
from GIPgfp/+-FABP5+/+ and GIPgfp/+-FABP5-/-mice. Under HFD feed-
ing conditions, FABP5-/- mice exhibited significantly decreased body weight 
gain compared to WT control, but there was no significant difference in body 
weight between GIPgfp/gfp-FABP5+/+ and GIPgfp/gfp -FABP5-/- mice, in 
which GIP expression is genetically deleted. Whole body CT scan showed 
that body fat mass was significantly reduced in FABP5-/- mice compared 
to that in WT mice and that body fat mass in GIPgfp/gfp -FABP5+/+ and 
GIPgfp/gfp -FABP5-/- mice was comparable. qPCR of WAT revealed no 
significant change in mRNA expression levels of hormone sensitive lipase, 
PPARδ, aP2 or GIP-receptor between HFD-fed WT and FABP5-/-mice.
Conclusion: Our results show that FABP5 is involved in fatty acid-induced 
acute GIP secretion and that it contributes to the development of HFD-in-
duced obesity in a GIP-dependent manner.
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NOV/CCN3: a new adipokine involved in obesity-associated insulin 
resistance?
B. Feve1, C. Martinerie1, M. Fesatidou1, P.-O. Marchal1, C. Kazazian1,  
M. Buyse1, H. Do Thi Tu1, B. Antoine1, T. Ladent1, M.-P. Garcia1, H. Koseki2, 
C. Chadjichristos3, R. Denis4, S. Luquet4;  
1Faculté de Médecine Pierre et Marie Curie, CDR St-Antoine UMR_S938 
INSERM/UPMC, Paris, France, 2Chiba University Graduate School of 
Medicine, Chiba, Japan, 3Hôpital Tenon, UMR_S 702 INSERM/UPMC, 
4Université Paris Diderot-Paris7, CNRS EAC 4413, Paris, France.
Background and aims: The pathophysiology of obesity is far to be elucidat-
ed. Identification of new adipokines represents a major challenge to decipher 
the mechanisms of adipose tissue development and metabolism. Our recent 
results suggest that NOV/CCN3, a multifunctional matricellular protein, is 
synthesized and secreted by adipose tissue, with plasma levels correlated with 
body mass index and fat mass, and down-regulated following bariatric sur-
gery (Pakradouni et al.). NOV has been involved previously in tissue repair, 
fibrotic and inflammatory diseases, and cancer. However, its role in adipose 
tissue and energy homeostasis remains unknown.
Materials and methods: The aim of our work was to investigate the meta-
bolic phenotype of NOV knockout mice fed a standard or high fat diet (HFD)
Results: Weight gain was similar between wild type (WT) and NOV-/- mice 
fed a chow diet. Strikingly, the weight of NOV-/- mice fed a HFD was mark-
edly lower than that of WT animals. This was related to a sharp decrease in 
fat mass, whereas lean mass was preserved. Accordingly, NOV-/- mice fed 
a HFD displayed an improved glucose tolerance and insulin sensitivity. No 
significant changes were detected for food intake, energy expenditure, or 
locomotor activity. Importantly, the absence of NOV was associated with a 
marked decrease in adipose tissue expression of several proinflammatory cy-
tokines and chemokines. Conversely, exposure of 3T3-L1 mature adipocytes 
to NOV led to an induction of these cyto-/chemokines.
Conclusion: Altogether, these results show that NOV is a new adipokine that 
could be involved in obesity-associated insulin resistance
Supported by: Ypsomed-SFD
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The mRNA expression and release of (pro)-inflammatory and angiogenic 
factors in perivascular fat cells is influenced by fetuin-A via different 
signalling pathways
D.I. Siegel-Axel1,2, S. Ullrich1,2, N. Stefan1,2, K. Rittig1, F. Gerst1,2,  
U. Schmidt1, B. Schreiner1, H.-E. Schaller3, H.-U. Haering1,2;  
1Department of Internal Medicine, Medical Clinic IV, Division of 
Endocrinology, Diabetology, Angiology, Nephrology and Clinical 
Chemistry, 2Institute for Diabetes Research and Metabolic Diseases 
of the Helmholtz Centre Munich at the University of Tuebingen and 
German Center for Diabetes Research 3Department of Plastic, Hand and 
Reconstructive Surgery, BG-Trauma-Center, Tuebingen, Germany.
Background and aims: Our previous in vitro and in vivo studies showed 
that fetuin-A exerts effects on perivascular fat cells (PVFC) and vascular 
cells which may influence cardiovascular diseases, predominantly effects on 
(pro)- inflammatory and angiogenic factors. Analysis of underlying pathways 
demonstrated that fetuin-A/palmitate (fet/palm) stimulates IL-6 and -8 ex-
pression via TLR4 receptor signalling. In contrast, the inhibition of the potent 
angiogenic protein HGF was mediated via the well known insulin-dependent 
receptor tyrosine kinase pathway. In order to elucidate pathways downstream 
TLR4 receptor activation, in this study fet/palm induced signalling pathways 
were studied in PVFC more detailed using several kinase inhibitors.
Materials and methods: PVFC were isolated from fat specimens around arm 
arteries of patients from our trauma center. Cells were treated with or with-
out the JNK inhibitor SP500125 (10 μmol/L), the p38MAPkinase inhibitor 
SB203580 (10 μmol/L), the MEK1/2 inhibitor PD98059 (10 μmol/L) and the 
NFκB inhibitor BAY11-7082 (1 μmol/L) 2 h prior to the addition of fet (600 
μmol/L) and palm (50 μmol/L). After 24 h protein release was quantitiated by 
ELISA technology and mRNA expression by realtime PCR.
Results: The expression of IL-8, IL-6 and MCP-1 was upregulated by fet and 
this effect was potentiated significantly by the addition of palm. Additional 
incubation with the NFκB inhibitor abrogated these effects significantly. JNK 
inhibition caused a partial blockade of the fet/palm induced stimulatory ef-
fects on interleukins whereas MEK1/2 and p38MAPkinase inhibition had 
only slight influence on the potent stimulatory effects of fet/palm. In contrast 
to the TLR4-mediated stimulatory effects on interleukins, the expression of 
the strong angiogenic factor HGF was potently inhibited by fet/palm and this 
effect could not be abrogated by the NFκB inhibitor and only partially by 
the other MAPkinase inhibitors. However, the angiogenic factor bFGF was 
not inhibited but slightly stimulated by fet/palm and this was predominantly 
influenced by the JNK inhibitor and slightly by NFκB inhibitor. Finally, fet/
palm exerted nearly no effects on the angiogenic factor VEGF.
Conclusion: Fet/palm caused strong stimulatory effects on (pro)inflamma-
tory proteins. However, the observed effects on several potent angiogenic 
factors were diverse: bFGF was stimulated slightly, VEGF remained nearly 
unchanged and HGF was even inhibited significantly. Treatment with sev-
eral signalling pathway inhibitors showed that fet acts via different pathways 
downstream TLR4 receptor activation, such as JNK or NFκB signalling but 
to a lesser extent on other MAPkinases, such as MEK1/2 and p38. Neverthe-
less, the diverse inhibitory effect of fet/palm on the potent angiogenic factor 
HGF seems to be mediated at least partially by another - TLR4-independent 
- pathway.
Supported by: German Federal Ministry of Education and Research to the DZD 
and REGINA
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NAMPT knockdown attenuates atherosclerosis by promoting 
macrophage reverse cholesterol transport
M. Li1,2, L. Li1,2, C. Wang3, G. Yang3;  
1College of Laboratory Medicine, Chongqing Medical University,  
2The Key Laboratory of Laboratory Medical Diagnostics in the Ministry of 
Education, 3Department of Endocrinology, the Second Affiliated Hospital, 
Chongqing Medical University, Chongqing, China.
Background and aims: Nicotinamide phosphoribosyltransferase (NAMPT), 
also known as visfatin, was claimed to be secreted predominantly from vis-
ceral adipose tissue and to exert insulin-like action. It has been reported that 
NAMPT induced the release of inflammatory cytokines, cholesterol accumu-
lation and the formation of macrophage foam cells in cultured cells. So there 
may be some association with atherosclerosis due to its role in inflammation 
and lipid accumulation. However, the impact of NAMPT on atherosclerosis 
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remained to be systematically investigated. To determine the role of NAMPT 
in the development of atherosclerosis, we have determined whether NAMPT 
knockdown can improve insulin resistance and formation of atherosclerotic 
lesions by using a loss-of-function approach (adenovirus-mediated RNAi) to 
inhibit NAMPT expression in the liver in C57BL/6J and apoE KO mice on 
a high fat diet. More importantly, we disscussed the molecular mechanisms 
of NAMPT-knockdown in the regulation of cholesterol metabolism and the 
development of atherosclerosis.
Materials and methods: In vivo, NAMPT-knockdown C57BL/6J and apoE 
KO mice by a adenovirus-mediated RNAi was used to assessed the effects 
of NAMPT knockdown on metabolic parameters on a standard chow diet 
or a high fat diet; Euglycemic- hyperinsulinemic clamps were performed to 
assess glucose kinetics by tracer dilution methodology. An in vivo reverse 
cholesterol transport (RCT) assay that traces 3H-cholesterol derived from 
macrophages loaded with cholesterol ex vivo was performed. In vitro, as-
says testing effects of Ad-GFP or Ad-shVisfatin treatment on cholesterol 
efflux from 3H-cholesterol-loaded RAW264.7 cells to lipoprotein acceptors 
was conducted. The expressions of hepatic genes related to cholesterol me-
tabolism were analyzed by qRT-PCR and western blots; MK886, a selective 
inhibitor of PPARα was used to analyze the mechanisms by which NAMPT 
knockdown leads to increased cholesterol efflux and RCT.
Results: HFD-fed C57BL/6J mice with reduced hepatic NAMPT content 
showed no alterations in all tested metabolic parameters, except for elevated 
HDL-C and slightly decreased LDL-C levels without statistical significance 
compared to littermates fed HFD ;However, plasma HDL-C levels in HFD-
fed ApoE KO mice treated with Ad-shNAMPT were significantly increased 
and hepatic TC contents were decreased compared to littermates fed HFD ; 
Analysis of lipoproteins by FPLC showed an increase in cholesterol content 
in the HDL fractions of Ad-shNAMPT-treated mice compared with control 
mice; RCT assay showed that higher HDL levels in response to NAMPT 
knockdown increased cholesterol transport from peripheral macrophages 
to the liver . In cultured RAW264.7 cells, HDL-mediated 3H-cholesterol ef-
flux was increased by NAMPT knockdown; NAMPT knockdown upregu-
lated mRNA and protein expression involved in cholesterol efflux and RCT; 
MK886 abolished NAMPT knockdown-induced ABCA1/G1 and LXRα ex-
pressions in Hepa1-6 and RAW264.7 cells.
Conclusion: NAMPT knockdown exerted antiatherogenic effects by pro-
moting cholesterol efflux and macrophage RCT through the PPARα- LXRα- 
ABCA1/G1pathway in vitro or in vivo.
Supported by: National Natural Science Foundation of China (81270913, 
81070640, 81100567)
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Dietary fat intake in low-carbohydrate diets and subsequent mortality 
and weight change in type 2 diabetes
J.W.J. Beulens1, M.J.E. Campmans-Kuijpers1, I. Sluijs1, U. Nöthlings2,  
H. Freisling3, K. Overvad4, H. Boeing5, A.M. May1, on behalf of the EPIC 
consortium;  
1Julius Center for Health Sciences and Primary Care, University Medical 
Center Utrecht, Netherlands, 2Department of Food Sciences and Nutrition, 
University of Bonn, Germany, 3International Agency for Research on Cancer 
(IARC-WHO), Lyon, France, 4Department of Epidemiology School of 
Public Health, Aarhus University, Denmark, 5Department of Epidemiology, 
German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany.
Background and aims: The replacement of carbohydrates with fat in a diet 
for type 2 diabetes patients is still debated. This study aimed to investigate 
the association between dietary carbohydrate intake and replacement with 
different types of fat with all-cause and cardiovascular (CVD) mortality risk 
and 5-year weight change in patients with type 2 diabetes.
Materials and methods: The study included 6,192 patients with type 2 dia-
betes from 15 cohorts of the European Prospective Investigation into Cancer 
and Nutrition (EPIC). Dietary intake was assessed at baseline with country-
specific food-frequency questionnaires. Cox regression was used to estimate 
whether replacement of carbohydrates with different types of fat was associ-
ated with cardiovascular mortality adjusted for diabetes risk factors and di-
etary factors. Linear regression was used for associations with weight change.
Results: After a mean follow-up of 9.2 y ±; SD 2.3 y, 791 (13%) participants 
had died, of which 268 (4%) due to CVD. The risk of all-cause mortality in-
creased when 10 gram or 5 energy % of carbohydrates was replaced by total 
fat (HR 1.07 [1.02-1.13]), or SFAs (HR 1.25 [1.11-1.40]) and decreased when 
replaced by MUFAs (HR 0.89 [0.77-1.02]). CVD mortality risk increased 
when carbohydrates were substituted with SFAs (HR 1.22 [1.00-1.49]) or 
PUFAs (HR 1.29 [1.02-1.63]). The 5-year weight change decreased when car-
bohydrates were substituted with total fat or MUFAs, and increased when 
substituted by SFAs. After adjusting for 5-year weight change, the associa-
tions for (CVD) mortality lost significance.
Conclusion: In diabetes patients, substitution of carbohydrates with total fat 
or SFAs increased mortality risk. Replacement of carbohydrates with MUFAs 
was associated with lower mortality risk and weight change. Dietary guide-
lines should focus on replacement of carbohydrates by fat-subtypes, espe-
cially replacement of SFAs by MUFAs seems beneficial.
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Differential acute postprandial effects to isocaloric meals with different 
macronutrient content in subjects with type 2 diabetes and healthy 
controls
L. Belinova1, H. Kahleova1, H. Malinska1, O. Topolcan2, J. Vrzalova2,  
O. Oliyarnyk1, L. Kazdova1, M. Hill3, T. Pelikanova1;  
1Department of Diabetes, Institute for Clinical and Experimental Medicine, 
Prague, 2University Hospital in Pilsen,  
3Institute of Endocrinology, Praha, Czech Republic.
Background and aims: Dietary guidelines for treatment of diabetes focus 
mainly on carbohydrate counting. Evidence suggests that postprandial meta-
bolic response is also modified by other macronutrient content of meals and 
their effect on various gastrointestinal hormone release. We aimed to investi-
gate the effects of two standardized isocaloric meals: a processed hamburger 
meat meal rich in protein and saturated fat (M-meal) and a vegetarian sand-
wich meal rich in carbohydrates (V-meal) in terms of postprandial glucose, 
lipids and insulin levels, gastrointestinal hormone (GIH) response and oxida-
tive stress markers.
Materials and methods: In a randomized crossover study, 50 patients with 
type 2 diabetes (T2D) and 50 healthy subjects underwent two 3-hour meal 
tolerance tests. For statistical analyses, repeated-measures ANOVA was used.
Results: The M-meal resulted in a higher postprandial increase in lipids in 
both groups (p<0.001) and persistent postprandial hyperinsulinemia in dia-
betics. The plasma glucose levels were significantly higher after the V-meal 
only at the peak level. The GIH concentrations were higher (glucose-depend-
ent insulinotropic peptide(GIP): p<0.001; peptide tyrosine-tyrosine (PYY): 
p<0.05; pancreatic polypeptide (PP): p<0.01) and the ghrelin concentration 
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was lower (p<0.05) after the M-meal in healthy subjects. In contrast, the GIH 
concentrations were significantly higher after the V-meal in T2D patients 
(glucagon-like peptide-1:p<0.001; GIP: p<0.001; PYY: p<0.05; PP: p<0.05). 
Compared with the V-meal, the M-meal was associated with a larger increase 
in lipoperoxidation in T2D patients (thiobarbituric acid reactive substances: 
p<0.05).
Conclusion: Our results suggest that the diet composition and the energy 
content, rather than the carbohydrate count, should be important considera-
tions for dietary management and demonstrate that differences in isocaloric 
meals composition led to differences in postprandial gastrointenstinal hor-
mone response and oxidative stress.
Clinical Trial Registration Number: NCT01572402
Supported by: NT 14250-3/2013
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Dietary protein intake in low-carb diets and subsequent weight change 
and mortality in type 2 diabetes
M.J.E. Campmans-Kuijpers1, I. Sluijs1, U. Noethlings2, H. Freisling3,  
K. Overvad4, E. Weiderpass5, G. Fagherazzi6, P.H.M. Peeters1, J.W.J. Beulens1; 
1Julius Center, University Medical Center Utrecht, Netherlands, 
2Department of Food Sciences and Nutrition, University of Bonn, Germany, 
3International Agency for Research on Cancer (IARC-WHO), Lyon, France, 
4Department of Epidemiology School of Public Health, Aarhus University, 
Denmark, 5Department of Community Medicine, Faculty of Health 
Sciences, University of Tromsø, Norway, 6Institut Gustacve-Roussy, Villejuif, 
France.
Background and aims: Dietary replacement of carbohydrates with protein 
for patients with type 2 diabetes is still debated. This study aimed to inves-
tigate the association between dietary carbohydrate intake and replacement 
with (animal and plant) protein, with 5-year weight change and all-cause and 
cardiovascular (CVD) mortality risk in patients with type 2 diabetes.
Materials and methods: The study included 6,192 patients with type 2 dia-
betes from 15 cohorts of the European Prospective Investigation into Can-
cer and Nutrition (EPIC). Usual dietary intake was assessed at baseline with 
country-specific food-frequency questionnaires. Different methods to adjust 
for energy intake were used.
Results: Annual weight-loss of participants was 0.17 (SD 1.24)kg. After a mean 
follow-up of 9.2 (SD 2.3)y, 791 (13%) participants had died, of which 268 (4%) 
due to CVD. Substitution of dietary carbohydrate intake with plant protein 
was associated with reduced risk of all-cause mortality (HR 0.71 [0.61-0.89]) 
and CVD mortality (HR 0.68 [0.53-0.89]). Substitution with total protein or 
animal protein was not associated with total or CVD mortality risk. Five-year 
weight change increased by substitution with total protein (ß 151 [39-262]
g) and animal protein (ß 156 [39-271]g), but not by substitution with plant 
protein (ß 279 [-102-660]g). Five-year waist circumference change was not as-
sociated with any substitution of carbohydrates with protein. After adjustment 
for 5-year weight change, the association with CVD mortality was attenuated 
and became non-significant, but remained the same for all-cause mortality.
Conclusion: In diabetes patients, replacement of dietary carbohydrates with 
total protein and animal protein was associated with weight gain, but not 
with total and CVD mortality risk. Substitution of carbohydrates with plant 
protein may reduce the risk of total and CVD mortality.
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Does excessive consumption of high fructose corn syryp, aspartame or 
rebaudioside A affect insulin sensitivity and regulatory genes in liver and 
muscles?
P.B. Jeppesen1, M. Elsøe1, C. Laustsen2;  
1Dept. of Clinical Medicine, Aarhus University Hospital, Aarhus Sygehus 
THG, 2Dept. of Clinical Medicine, The MR Research Centre,  
Aarhus University Hospital, Denmark.
Background and aims: Added sugar is believed to play a critical role in the 
epidemic of welfare diseases and in particular, fructose, has been shown to 
be directly diabetogenic. Furthermore, intake of the added sweetener high-
Fructose corn syrup (HFCS), consistently correlates with increased risk for 
developing lifestyle diseases. The little information regarding non-caloric 
sweeteners such as Rebaudioside A and Aspartame.The aim of this study is to 
investigate the effects of long-term high-fructose (HF) feeding on Develop-
ment of insulin resistance (IR), steatosis and dyslipidaemia in rats; and to 
examine the effects of intervention sweetener diets post the HF feeding e.g 
excessive daily intake of HFCS, Rebaudioside A and Aspartame.
Materials and methods: 48 healthy male Wistar rats were randomly assigned 
to four groups. One control group and three intervention groups received a 
diet of 60% fructose for 16 weeks. Post HF feeding the three groups instead 
received water sweetened with HFCS, Rebaudioside A or Aspartame for 8 
weeks. Development and progression of IR, steatosis, dyslipidaemia and hy-
pertension was monitored and tissues were analyzed after termination.
Results: The fructose diet led to a significant increase in insulin resistance, 
fasting levels of TG, total- and LDL-cholesterol. No differences in weight were 
observed. When compared with control group the daily intake of HFCS re-
sulted in large increases in fasting blood TG levels (0.71±0.04 vs 1.53±0.14 
mM; p<0.005 ); Total cholesterol (1.45±0.05 vs 1,87±0.12 mM; p< 0.05); de-
velopment of IR HOMA-IR:(55.55±10.69 vs 28.20±21.67; p< 0.01) and a 43 % 
increased storage of lipids in liver and muscle tissue (MR-scanning). Further-
more, HFCS markedly changes the gene expression profile of key regulatory 
genes as Srebf-1, FAS in the liver and FAS and GLUT 4 as well as PGC1A in 
muscle tissue. Rebaudioside A or Aspartame did not change any of the above 
shown data significantly when compared with control group.
Conclusion: HF feeding and excessive daily intake of HFCS had a negative 
physiological impact in this study. Switching to Rebaudioside A or aspartame 
reversed the hypercholesterolaemia induced fructose feeding and improved 
insulin sensitivity. Excessive HFCS-intake caused IR within 8 weeks and in-
creased lipid storage in liver and muscle tissue.
Supported by: 2012-15-2934-00200
774
A low-dose whey protein preload slows gastric emptying and improves 
post-prandial glycaemia in type 2 diabetes
L.E. Mignone, T. Wu, M.J. Bound, K.L. Jones, M. Horowitz, C.K. Rayner;  
Discipline of Medicine, University of Adelaide, Australia.
Background and aims: We previously reported that a 55g whey protein 
‘preload’, taken 30 minutes before a meal, reduced postprandial glycaemia in 
patients with type 2 diabetes, related in part to slowing of gastric emptying. 
A smaller preload that could be taken a lesser interval before the meal would 
be advantageous in terms of cost, reduction in additional energy intake, and 
compliance. We therefore evaluated the effects of a low-dose 20g whey pro-
tein preload, formulated with 5g guar, on post-prandial glycaemia and gastric 
emptying.
Materials and methods: Seven subjects with type 2 diabetes [4 males and 3 
females; age 64.6 ± 0.4 years; body mass index: 29.3 ± 2.0 kg/m2; HbA1c 6.8 
± 0.4% (50.4 ± 3.9 mmol/mol); duration of known diabetes 4.8 ± 0.8 years], 
managed by diet or metformin only, were each studied on 2 occasions in ran-
domised order. On each day, a 150 mL preload drink containing either 20 g 
whey plus 5 g guar, or similarly flavoured placebo, was consumed 15 minutes 
before a 13C-octanoic acid-labelled mashed potato meal. Gastric emptying 
(breath test) and blood glucose (glucometer) were evaluated. Data are means 
± SEM.
Results: The half-emptying time (T50) of the potato meal was greater (199.7 
±20.8 vs. 167.4 ± 16.0 min, P = 0.004) after the whey protein preload than 
placebo. Fasting blood glucose did not differ between the two study days, and 
was not altered by either preload prior to the meal (t = -15 to 0 min). After 
the meal (t = 0 to 240 min), blood glucose concentrations were lower after 
whey protein than placebo (P < 0.001 for treatment x time interaction, with 
significant differences at t = 30 and 90 min after the meal, P < 0.05 for each).
Conclusion: A low-dose whey protein preload can slow gastric emptying and 
improve postprandial glycaemic excursions in patients with type 2 diabetes 
who have relatively good glycaemic control. It may represent a promising nu-
tritional strategy to optimise postprandial glycaemia in this group.
Supported by: NHMRC
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 313
1 C
775
Two weeks of adaptation to a high-protein hypercaloric high-fat-diet 
changes the postprandial carbohydrate and fat response after a mixed 
meal
A. Rietman1, J. Schwarz1, E. Siebelink1, F.J. Kok1, D. Tomé2, M. Mensink1;  
1Human Nutrition, Wageningen University, Netherlands,  
2Nutrition Physiology and Ingestive Behavior, AgroParisTech, INRA, 
UMR914, Paris, France.
Background and aims: We and others previously showed changes in fasting 
lipid metabolism after adaptation to a high-protein diet. To further explore 
these changes we evaluated the effect of a two week short-term adaptation 
to a high protein diet on postprandial carbohydrate and lipid metabolism in 
healthy human subjects, by applying a meal challenge (MC).
Materials and methods: A randomized crossover trial with a parallel control 
group was performed. After a 2-week-run-in period, participants were as-
signed to either the control-diet for 4 weeks (CD-group; n=10; 27.8 En% fat; 
16.9 En% protein; 55.3 En% carbohydrates), or a hypercaloric high-fat diet 
(HD-group; n=17; + 2 MJ per day), with in random order two periods of 2 
weeks, with either a high protein (HP; 37.7 En% fat; 25.7 En% protein; 36.6 
En% carbohydrates) or a normal protein content (NP; 39.4 En% fat; 15.4 En% 
protein; 45.2 En% carbohydrates). The MC (Liquid meal, 40 En% fat; 15 En% 
protein and 45 En% carbohydrate) was performed after 2 weeks and 4 weeks 
of intervention. Blood samples were drawn regularly during 6 hours post-
prandial for metabolite analyses.
Results: No significant differences were observed between NP and HP in 
fasting glucose (5.04 ± 0.08 vs. 5.05 ± 0.09 mmol/L) and insulin (4.21 ± 0.62 
vs. 3.95 ± 0.63 µU/L) levels. However, during the MC, subjects who were 
adapted to the HP diet showed a significantly higher iAUC of glucose as 
compared to subjects adapted to the NP diet (NP: 377.4 ± 14.1 vs. HP: 408.2 
± 13.2 mmol/L*60min; p=0.03), without clear differences in insulin iAUC 
(NP: 2583.9 ± 383.7 vs. HP: 2984.8 ± 496.9 mU/L*60 min; p=0.38). Fasting 
triglyceride (TG) concentration tended to be lower on the HP compared to 
the NP condition (NP: 0.77 ± 0.05 vs. HP: 0.65 ± 0.03 mmol/L; p=0.07). Also 
during the MC subjects adapted to the HP diet showed a lower iAUC of TG 
as compared to subjects adapted to the NP diet (NP 67.1 ± 5.6 vs. HP 57.9 ± 
4.4 mmol/L*60min; p=0.11).
Conclusion: Adaptation to a high protein hypercaloric high-fat diet resulted 
in a decreased clearance of carbohydrates after the MC as indicated by the in-
creased glucose iAUC, without changes in plasma insulin response compared 
to adaptation to a normal protein hypercaloric high-fat diet. Additionally, 
adaptation to the HP diet was associated with an improved lipid metabolism, 
as indicated by a lower level of circulating TG in fasted state as well as during 
the MC. Additional metabolomics data are anticipated to be present at the 
time of the meeting.
Clinical Trial Registration Number: NCT01354626
Supported by: NZO
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Differential islet, incretin and glucose prandial responses after high 
caloric breakfast vs isocaloric dinner in type 2 diabetic patients 
D. Jakubowicz1, O. Froy2, Y. Bar-Dayan1, H. Rabinovitz2, Z. Landau1,  
J. Wainstein1;  
1Diabetes Unit, E.Wolfson Medical Center, Holon,  
2Institute of Biochemistry, Food Science and Nutrition, Rehovot, Israel.
Background and aims: It was shown in type 2 diabetic (T2D) individuals 
that a high-calorie (HC) that a diet with high-calorie (HC) breakfast (B) with 
reduced dinner (D), resulted in a significant decrease in HbA1c, and was 
more beneficial than isocaloric diet with HCD and reduced B in improving 
glucose, lipids and hunger scores. Whether it is related to a potential diurnal 
pattern of incretin secretion and β-cell responsiveness to incretins after Iso 
HCB vs HCD has however, not been studied in T2D. We assessed in T2D 
postprandial early AUC30, late AUC 60-180 and AUC180 min response for 
plasma insulin, glucose, intact (i) and total (t) glucagon-like peptide-1 (GLP-
1) and hunger scores after HCB vs isocaloric HCD
Materials and methods: In a randomized crossover design 18-T2D (8 
males), aged 57 ± 83 yrs; BMI: 28.11 ± 2.92 kg/m2; HbA1c: 7.55 ± 0.42%, un-
dergone HCB meal test on day with HCB diet: B: 700 kCal; % of CH: protein: 
fat: 50:30:20%; lunch (L) (500 kCal, 20:45:25%) and D (200 kCal, 13:40:47%). 
Another day HCD meal test was done on HCD diet: B :(200 kCal,13:40:47%), 
L:(500 kCal, 20:45: 25%) and D (700 kCal, 50:30:20%).
Results: Glucose peak was lower after HCB: 230 ± 24 vs. HCD: 285 ± 25 mg/
dl, (p<0.001). Similarly, AUC180 for glucose was reduced after HCB:31255 ± 
1375 vs HCD:40899 ± 3007 mg/dl*min, (p< 0.001). AUC 60-180 for late insu-
lin secretion was not different (p<0.11), in contrast AUC30 for early insulin re-
sponse was significantly greater (almost 2-fold) after HCB:526 ± 109 vs.HCD: 
247 ± 47 mIU/ml*min, (p< 0.001). Postprandial AUC180 response after HCB 
vs after HCD was higher by 29 ± 9.7% for tGLP-1 (p<0.001) and by 20.7 ± 7% 
for iGLP-1 (p<0.001) and reduced by 44.2 ± 11% for hunger scores (p < 0.001). 
AUC30 for tGLP-1 and iGLP-1 were strongly and positively associated with 
AUC30 early insulin response (r=0.32, p < 0.0001); whereas negatively associ-
ated with the postprandial AUC180 for plasma glucose (r= 0.18, p < 0.0001)
Conclusion: HCB induced more rapid early (30-min) insulin response as-
sociated with greater total and intact GLP-1, lower glucose excursion and 
greater hunger suppression. It suggests that high caloric intake in the break-
fast with reduced intake at dinner might be a beneficial alternative for the 
management of type 2 diabetes.
Clinical Trial Registration Number: NCT01977833
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The effects of a high egg diet in people with type 2 diabetes mellitus: a 
three-month randomised controlled trial
N.R. Fuller1, I.D. Caterson1, G. Denyer2,1, A. Sainsbury1, T.P. Markovic1;  
1Sydney Medical School,  
2Faculty of Sciences, The University of Sydney, Australia.
Background and aims: The effects of high egg consumption in people with 
Type 2 Diabetes Mellitus (T2DM) are controversial, due to many confound-
ing factors in previously published research. This randomised, controlled 
study aimed to determine whether a high egg diet (two eggs per day on six 
days per week) leads to improved lipid profiles (increased high density lipo-
protein cholesterol; HDL-C) in people with pre-diabetes or T2DM, compared 
to a low egg diet (less than two eggs per week).
Materials and methods: 140 subjects with pre-diabetes or T2DM were ran-
domised to either a low or high egg diet as part of a weight maintenance 
study. Subjects attended the clinic monthly and were given a written guide 
as to the specific types of foods and quantities that could be consumed, with 
particular emphasis on improving management of T2DM, and replacing 
foods containing saturated fats with foods containing monounsaturated fats 
and polyunsaturated fats. Outcome measures were collected at screening and 
three months.
Results: There was no significant difference in the change in HDL-C from 
screening to three months between the two groups; mean difference (95% 
confidence interval (CI)) for the high egg versus low egg group: +0.02 
mmol/L (-0.03, 0.08); P = 0.38. There was a within group trend towards an 
improvement in HDL-C in the high egg group: +0.034 mmol/L (95% CI: 
-0.003, 0.071); P=0.07. No between group differences were found at three 
months for total cholesterol, low density lipoprotein cholesterol, triglycer-
ides, or glycaemic control. Both groups were matched for protein intake, yet 
the high egg group reported less hunger and greater satiety post meal. Both 
diets were well accepted, with the high egg group reporting a significantly 
greater enjoyment of foods, less boredom, and more satisfaction with the diet.
Conclusion: Eggs do not have an adverse effect on lipid levels in those with 
T2DM and hence at high risk of cardiovascular outcomes. Moreover, it is as-
sociated with better appetite control. These findings suggest that a high egg 
diet can be included as part of the dietary management of T2DM.
Clinical Trial Registration Number: CTRN12612001266853
Supported by: Australian Egg Corporation
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Assessment of caffeine dose and time of administration required for 
resetting of insulin sensitivity in high-sucrose rats
J.F. Sacramento1, J.C. Coelho1, B.F. Melo1, M.P. Guarino1,2, S.V. Conde1;  
1CEDOC, Faculdade Ciências Médicas, Universidade Nova de Lisboa,  
2UIS-Unidade de Investigação em Saúde- Escola Superior de Saúde de 
Leiria- Instituto Politécnico de Leiria, Portugal.
Background and aims: Several epidemiological studies have described ben-
eficial effects of chronic coffee intake on type 2 diabetes and metabolic syn-
drome. Our group has previously shown that chronic caffeine intake (1g/L 
over 15 days) prevents the development of insulin resistance (IR) and hyper-
tension in diet-induced IR rats. The aim of this work was to investigate the 
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therapeutic dose of caffeine that restores insulin sensitivity and normalizes 
blood pressure in diet-induced IR rats. The time required for the reversion of 
IR was also evaluated.
Materials and methods: All experiments were performed in 8-13 weeks 
Wistar rats of both genders (250-450g). Two groups of rats were used: a high-
sucrose diet-group (HSu) and a control group. The HSu insulin-resistant 
model was obtained by submitting the animals to a 35% sucrose diet during 
28 days. A dose-response curve for chronic caffeine intake (0.25-1g/L) on 
insulin sensitivity was performed both in HSu and control groups. Caffeine 
was administered in drinking water after the first 28 days of control or HSu 
diet and maintained during 13 weeks. The insulin sensitivity was evaluated 
by an insulin tolerance test in conscious animals. Plasma glucose and insulin 
were monitored each 2 weeks. At the end of the experimental period, rats 
were anaesthetized with pentobarbitone (60mg/Kg) and blood pressure was 
measured in the femoral artery. Blood was collected by heart puncture and 
skeletal muscle collected for Glut4, Insulin receptor and AMPKα1 quantifica-
tion by Western-blot.
Results: Administration of HSu diet during 28 days decreased insulin sensi-
tivity to 2.81±0.29 %glucose/min (KITT control= 4.70±0.28 %glucose/min). 
Chronic administration of 0.5 and 1g/L of caffeine did not modify insulin 
sensitivity. In the HSu group, 3 weeks after chronic administration of 1g/L of 
caffeine, insulin sensitivity was restored (KITT =4.70±0.299 %glucose/min). 
The insulin sensitivity in this group was maintained during the following 
weeks. In the HSu rats submitted to chronic administration of 0.5g/L caffeine 
insulin sensitivity start to increase (30%) after 5 weeks of administration and 
it was completely restored after 9 weeks (KITT = 4.75±0.669 %glucose/min).
Conclusion: Chronic caffeine administration in all concentrations tested re-
stores insulin sensitivity. The period of time to restore insulin sensitivity is 
positively related with caffeine concentration.
Supported by: EXPL/NEU-SCC/2183/2013
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A fish-based diet intervention improves endothelial function in 
postmenopausal women with type 2 diabetes mellitus: a lipidomics 
approach to understand the mechanisms
K. Kondo1, K. Morino1, Y. Nishio2, M. Kondo1, K. Nakao1, F. Nakagawa3,  
A. Ishikado4, O. Sekine1, S. Ugi1, H. Maegawa1;  
1Department of Medicine, Shiga University of Medical Scienece, Otsu, 
2Department of Diabetes and Endocrine Medicine, Kagoshima University, 
3JCL Bioassay Corporation, Suita, 4R&D Department, Sunstar Inc, 
Takatsuki, Japan.
Background and aims: The beneficial effects of fish and n-3 polyunsaturated 
fatty acids (PUFA) consumption on atherosclerosis have been reported in nu-
merous epidemiological studies. However, to the best of our knowledge, the 
effects of a fish-based diet intervention on endothelial function have not been 
investigated. Therefore, we studied these effects in postmenopausal women 
with type 2 diabetes mellitus (T2DM).
Materials and methods: Twenty-three postmenopausal women with T2DM 
were assigned to two four-week periods of either a fish-based diet (n-3 PUFA 
⋯ 3.0 g/day) or a control diet in a randomized crossover design. Endothelial 
function was measured with reactive hyperemia using strain-gauge plethys-
mography and compared with the serum levels of fatty acids and their me-
tabolites. Endothelial function was determined with peak forearm blood flow 
(Peak), duration of reactive hyperemia (Duration) and flow debt repayment 
(FDR). Serum lipid compositions and eicosanoids were measured with tan-
dem mass spectrography (LCMS).
Results: A fish-based dietary intervention improved Peak by 63.7%, Dura-
tion by 27.9% and FDR by 70.7%, compared to the control diet. Serum n-3 
PUFA levels increased after the fish-based diet period and decreased after 
the control diet period, compared with the baseline period (1.49 vs. 0.97 vs. 
1.19 mmol/l, p < 0.0001). There was no correlation between serum n-3 PUFA 
levels and endothelial function. Eicosanoids were measured with LCMS and 
7 / 86 metabolites were significantly changed after a fish-based diet interven-
tion. Interestingly, the ratio of epoxyeicosatrienoic acid (EET, known as the 
vasodilator) / dihydroxyeicosatrienoic acid (the inactive metabolites of EET) 
was increased after a fish-based diet intervention.
Conclusion: A fish-based dietary intervention improves endothelial func-
tion in postmenopausal women with T2DM. The improvement of endothelial 
function was not associated with serum n-3 PUFA concentration. These data 
suggests that the vasoactive metabolites such as EET, may contribute to this 
phenomenon.
Clinical Trial Registration Number: UMIN000002277
PS 058 Nutrition and diet II
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Incretin hormones are released in healthy subjects by both diet oil and 
olive oil while short chain fatty acids have no effect on secretion
M.J. Mandøe1,2, K.B. Hansen3, B. Hartmann2, J.J. Holst2, H.S. Hansen4;  
1Department of Clinical Physiology and Nuclear Medicine, Glostrup 
Hospital, 2NNF Center for Basic Metabolic Research, Department 
of Biomedical Sciences, University of Copenhagen, 3Department of 
Endocrinology, Rigshospitalet, 4Department of Drug Design and 
Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Background and aims: Diet oil (1,3-di-butyryl-2-oleoyl-glycerol) consists of 
two short chain fatty acids and 2-oleoyl-glycerol (2-OG), the latter being a 
naturally occurring ligand for the G protein-coupled receptor GPR119. Intes-
tinal 2-OG causes release of the incretin hormone, glucagon-like peptide-1 
(GLP-1), in healthy subjects and diet oil does the same in patients with type 
2 diabetes. This study evaluated tributyrin, which in mouse studies may in-
crease GLP-1 release, and a new form of diet oil with medium chain fatty ac-
ids (1,3-di-octanoyl-2-oleoylglycerol or “C8-diet oil”) on GLP-1 and glucose-
dependent insulinotropic polypeptide (GIP) secretion. Octanoic acid may 
not significantly activate known fatty acid receptors.
Materials and methods: C8-diet oil, tributyrin, olive oil and carrot were ad-
ministered orally to 12 Caucasian healthy male subjects (age: 24±0.6 years 
(mean±SEM), body mass index: 22.±0.6 kg/m2; HbA1c: 30.45±0.67 mmol/
mol) in a randomised, single-blinded cross-over study. The subjects were giv-
en four meals on four different days: 200 g grated carrot + 6.53 g tributyrin; 
200 g grated carrot + 13.15 g diet oil; 200 g grated carrot + 19 g olive oil or 200 
g grated carrot. All lipids amounted to 0.0216 mol, and theoretically, the C8-
diet oil and olive oil regimens both result in formation of 0.0216 mol 2-OG 
during digestion. Primary outcomes were total GLP-1 and GIP in plasma.
Results: C8-diet oil and olive oil resulted in (p≤0.01) greater postprandial 
GLP-1 and GIP responses [GLP-1: incremental area under curve 583 and 538 
pmol/l×120 min, p=0.733; GIP: 1674 and 3293 pmol/l×120 min, p=0.002] 
compared to both tributyrin (GLP-1: 94 pmol/l×120 min and GIP: 403 pmol/
l×120 min) and the carrot meal (GLP-1: 126 pmol/l×120 min and GIP: 423 
pmol/l×120 min
Conclusion: C8-diet-oil and olive oil enhanced secretion of GLP-1 and GIP 
significantly compared to tributyrin and carbohydrate. Tributyrin had no ef-
fect. Olive oil liberates not only 2-OG but in addition 2 oleic acid molecules, 
which may also stimulate incretin secretion. However, the previous reported 
effect of diet oil and the present effect of C8-diet oil giving the same full GLP-
1 response as olive oil, suggests that it is mediated by 2-OG and not by fatty 
acids.
Supported by: The Lundbeckfoundation, The Augustinusfoundation and Fog’s 
Foundation
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Glucose spikes of eating vegetables before carbohydrates with snacks 
at mid-afternoon are lower than that of eating carbohydrates before 
vegetables without snacks
S. Imai1, M. Fukui2, N. Ozasa3, S. Kajiyama4,5;  
1Graduate School of Comprehensive Rehabilitation, Osaka Prefecture 
University, 2Graduate School of Medical Science, Kyoto Prefectural 
University of Medicine, 3Graduate School of Medicine, Kyoto University, 
4Kajiyama Clinic, Kyoto, 5Kyoto Prefectural University of Medicine, Japan.
Background and aims: Postprandial plasma glucose and glucose spikes are 
associated with cardiovascular diseases in patients with diabetes. An appro-
priate diet is needed to reduce postprandial hyperglycemia and minimize hy-
poglycemic events in addition to improving mean blood glucose. However, a 
compliance of diet in patients with diabetes is low, partly as a result of eating 
snacks. We evaluated whether eating order without snacks and with snacks 
at different time of the day could change the postprandial glucose values as-
sessed by continuous glucose monitoring system (CGMS) in Japanese pa-
tients with type 2 diabetes mellitus (T2DM).
Materials and methods: This was a randomized, controlled, four-treatment, 
crossover study. Thirteen patients with T2DM (69.1 ± 6.7 yrs, HbA1c 7.5 ± 
1.2%: mean ± SD) were assigned to use CGMS (Medtronic Minimed Gold) 
for 8 days (4-day each) either (1) eating vegetables first or (2) carbohydrates 
first and (3) eating vegetables first with additional snacks (biscuits 18 g, 75 
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kcal, carbohydrate 13.5 g, protein 1.2g, fat 1.8 g) at 12:30 and (4) 15:30. The 
test meals consist of rice/bread, meat/fish, 500 g of vegetables, and contain 21 
g of dietary fiber: the energy ratio was 60, 16, and 24% from carbohydrates, 
protein, and fat, respectively. First, at 12:00 of the 1st day, each participant 
wore a CGMS at the clinic, and consumed the test meals at 7:00, 12:00, and 
19:00 at home on the 2nd and the 3rd day, and at noon of the 4th day a CGMS 
was removed at the clinic. The patients consumed the first dish of vegetables 
for 5 min, then the main dishes for 5 min, and rice or bread for 5 min of the 
test meals or eating vice versa. Next, the patients ate vegetables before car-
bohydrates of the test meals at the same time and consumed snacks at 12:30 
and 15:30 on the 2nd and the 3rd day. The daily glucose parameters were 
compared between four treatments.
Results: Mean blood glucose increased 0.67 mmol/L by adding snacks. Eat-
ing vegetables before carbohydrates with snacks at 15:30 resulted in lower in-
cremental glucose peak (IGP) and incremental area under the glucose curve 
(IAUC) 0-3h of lunch and dinner compared with eating carbohydrates before 
vegetables without snacks (Figure).
Conclusion: Glucose spikes of eating vegetables before carbohydrates with 
snacks at mid-afternoon were significantly lower than that of eating carbohy-
drates before vegetables without snacks in patients with T2DM.
 
Clinical Trial Registration Number: UMIN-9465
Supported by: Japanese Ministry of ESC and Osaka Prefecture University
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Dietary carbohydrates predict maternal hyperinsulinaemia and cord 
blood visfatin levels in pregnancy compared to total daily caloric intake, 
fat and proteins
G. Valsamakis1, D. Papatheodorou1, Z. Papadimitriou1, G. Landis2,  
E. Kapantais3, A. Thomopoulos1, G. Mastorakos1;  
1Endocrine Unit, Aretaieion University Hospital,  
2Endocrine Unit, Evgenideion University Hospital,  
3Diabetes Obesity Metabolism, Metropolitan Hospital, Athens, Greece.
Background and aims: Maternal diet affects insulin resistance and fetal 
growth-metabolism during pregnancy. Hyperinsulinemia is a marker of in-
sulin resistance. There is still ongoing debate regarding the effect of maternal 
diet composition and caloric intake into maternal hyperinsulinemia and fetal 
metabolism. The effect of maternal dietary nutrients (carbohydrates, pro-
teins, fat) and total daily caloric intake into maternal hyperinsulinemia , fetal 
metabolism and birthweight was assessed during normal pregnancy
Materials and methods: A prospective, non interventional study, 50 preg-
nant non diabetic women (mean±SD) pre-pregnancy BMI 24.2±4 kg/m2 and 
age 29.3±4.3 years were randomly assessed with validated quantitative food 
frequency questionnaire and a 7 day dietary diary for nutrient and total daily 
caloric intake (kcals) during the second trimester (24th-26th week). A 75gr 
oral glucose tolerance test was performed and maternal glucose and insulin 
levels measured at 0,5,15,30,60,90,120 min. 3 cases diagnosed with gesta-
tional diabetes were removed from the study. The delta area under the curve 
(ΔAUCΙnsulin) for maternal hyperinsulinemia was calculated by trapezoidal 
rule. During delivery cord blood levels for visfatin, adiponectin, leptin, glu-
cose and insulin were measured. Birth weight was measured.
Results: Dietary analysis revealed a diet composition of 20% protein, 40%car-
dohydrates and 40% fat. Mean birthweight was 3132±125 gr. Mean weight 
gain was 16±3 kg. There was no association between mean maternal total 
caloric intake and dietary nutrients with birth weight or maternal weight. 
Carbohydrates and caloric intake were negatively and positively associated 
with cord blood visfatin (r=-0.91, p=0.002) (r=0.72, p=0.037) respectively. 
Backwards multiple regression analysis showed carbohydrates (p=0.015, 
beta=-1.28) being the best predictors of maternal ΔAUCΙnsulin of the second 
trimester and cord blood visfatin levels (p=0.009) compared to dietary fat, 
proteins and mean total daily caloric intake.
Conclusion: Maternal carbohydrate intake is the best predictor of hyperinsu-
linemia among protein, fat and total caloric daily intake. Furthermore carbo-
hydrate intake seems to affect the insulinomimetic secretion of adipocytokine 
visfatin of the fetus. Further studies need to assess the effect of maternal diet 
composition into fetal metabolism and growth.
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Vitamin D supplementation might increase the benefits of weight loss  
on insulin sensitivity in obese individuals with hypovitaminosis D
C. Conte, C.M.A. Cefalo, C. Policola, V.A. Sun, S. Moffa, G.P. Sorice,  
T. Mezza, A. Giaccari;  
Catholic University of the Sacred Heart, Rome, Italy.
Background and aims: Hypovitaminosis D is highly prevalent in the general 
population, and particularly among obese individuals. It has been suggested 
that, besides being associated with obesity, vitamin D insufficiency might 
have an independent role in the pathogenesis of insulin resistance. Healthy 
dietary habits and weight loss are the mainstay for the prevention of type 
2 diabetes mellitus in overweight/obese individuals. Vitamin D supplemen-
tation might increase the benefits of these lifestyle interventions. Here we 
present the preliminary results of a currently ongoing double blind, placebo 
controlled randomised study. The aim of the study is to assess whether vita-
min D supplementation in conjunction with a weight-loss dietary regimen 
has a greater impact on insulin sensitivity as compared to weight loss alone in 
obese subjects with hypovitaminosis D.
Materials and methods: 12 obese volunteers (8/4 F/M; mean age±SD: 
40.4±12.4 yrs; BMI: 38.3±6.3 kg/m2) with hypovitaminosis D [serum 25(OH)
D: 14.8±7.8 ng/ml] were enrolled in this study after providing signed in-
formed consent. Subjects were randomised (1:1) to hypocaloric diet + either 
oral cholecalciferol 25,000 I.U./week (VIT) or placebo (PLA) for 3 months. 
Anthropometric assessments, a standard 2-hr OGTT and a hyperinsulinae-
mic euglycaemic clamp (HEC) for the measurement of insulin sensitivity (M 
value) were performed at baseline and at study end.
Results: Baseline anthropometric characteristics, insulin sensitivity and 
25(OH)D levels were comparable in the two groups. After 3 months of hy-
pocaloric diet + cholecalciferol or placebo, body weight was significantly 
reduced in both groups (-6.3% and -9.3% for VIT and PLA, respectively; 
p<0.05 for both; p for interaction=0.195). 25(OH)D levels increased only in 
the VIT group (13.5±6.2 vs. 29.1±6.2 ng/ml; p=0.007), and did not change in 
the PLA group (16.2±9.5 vs. 16.1±5.3 ng/ml; p=ns; p for interaction=0.019). 
No significant differences from baseline were observed in glucose and insulin 
areas under the curve during the OGTT in either group. Insulin sensitivity, as 
assessed with the HEC, significantly improved only in the VIT group (M pre 
vs. post: 5.2±2.4 vs. 7.3±3.2 mg•kg-1•min-1, p=0.046 and 4.4±2.6 vs. 4.7±2.2 
mg•kg-1•min-1, p=0.84 for the VIT and PLA groups, respectively). However, 
the increase in insulin sensitivity in the VIT group did not reach statistical 
significance vs. the PLA group (p for interaction=0.161), possibly due to the 
relatively small number of subjects.
Conclusion: Vitamin D supplementation might potentiate the effects of 
weight loss on insulin sensitivity. Increasing the sample size could allow us to 
confirm these preliminary findings.
Clinical Trial Registration Number: NCT02020694
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Secondary metabolites from vintage vegetables improve the health status 
of patients with type 2 diabetes when compared to equivalent modern 
vegetables
A.C.S. Thorup1, H.L. Kristensen2, P.B. Jeppesen1;  
1Department of Endocrinology and Internal Medicine,  
Aarhus University Hospital,  
2Department of Food Science, Aarhus University, Aarslev, Denmark.
Background and aims: Vegetables are an important part of the human diet 
and a major source of biologically active substances called secondary me-
tabolites. These secondary metabolites contribute to the nutritional quality 
of food giving it a bitter and strong taste, but more importantly are their po-
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tential health promoting effects. Aim: To determine if a high dietary intake of 
bitter and strong tasting vegetables have a beneficial impact on insulin resist-
ance related to type 2 diabetes (T2D) when compared to equivalent intake of 
modern mild and sweet tasting vegetables.
Materials and methods: The study was a 3-month randomized controlled 
parallel intervention study involving 77 participants aged 35-70 years with 
T2D. The participants were randomized into 3 different diets; 1) consum-
ing daily 500 g of bitter and strong tasting (BST) vegetables 2) 500 g daily of 
sweet and mild tasting (SMT) vegetables and 3) normal diet (control). Both 
vegetable diets (group 1 and 2) consisted of root vegetables and cabbages, but 
the seeds for the vegetables in the BST group originate from the Nordic gene 
bank collection. Additionally the vegetables were ensured a bitter and strong 
taste through modulation of the agronomic and postharvest storage practice.
Results: Both diets high in vegetables did significantly reduce the partici-
pants BMI (p<0.0001), fasting plasma glucose (p<0.05), HbA1c (p<0.001), 
body fat composition (p<0.01), fasting insulin concentration (p<0.05) and 
HOMA-IR (p<0.05). Furthermore, in the BST group significant difference 
was also found regarding average blood pressure from 24-h measurements 
(p<0.05), iAUC from OGTT (insulin (p<0.05) and glucose (p<0.01)) and 
plasma lipids (p<0.05).
Conclusion: The study shows that the vegetable diet with a high level of 
secondary metabolites hence the bitter and strong taste, have higher health 
promoting effects when compared to an equivalent diet with modern mild 
and sweet tasting vegetables. The results can be used to develop new recom-
mendations to a healthier lifestyle and to prevent any further progression of 
these lifestyle diseases.
Clinical Trial Registration Number: NCT01397942
Supported by: The Danish Council for Strategic Research
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Evaluation of the daily nutrient intake and accuracy of meal 
carbohydrate content estimation by type 1 diabetic patients under CSII 
and MDI
C. Schmid1, C. Krauß1, C. Kröner1, P. Buchwald2, C. Haug1, G. Freckmann1;  
1Institut für Diabetes-Technologie Forschungs- und 
Entwicklungsgesellschaft GmbH an der Universität Ulm, 
2Endokrinologikum Ulm, Germany.
Background and aims: Nutrition therapy is a key component in the treat-
ment of people with diabetes. Carbohydrate counting is a prerequisite for 
making appropriate insulin therapy decisions even with the increasing use of 
automated bolus calculators. The goal of this study was to determine the total 
daily nutrient intake of carbohydrates (CHO), proteins (P) and fats (F) in 
conditions similar to real life. In addition, we evaluated the accuracy of meal 
carbohydrate estimation.
Materials and methods: Fifty type-1-diabetic patients, (26f, 24m, mean age 
46 years, range: 20 to 68 years, HbA1c 7.5%±1.1%, duration of diabetes 23±12 
years, BMI 26.7±4.1 kg/m2, insulin therapy: CSII 35, MDI 15) participated 
as inpatients in the study, which lasted for 8 days They managed their own 
therapy and selected their meals freely from an ample buffet of typical food 
choices. The entire food intake was documented during the study and full 
24h intake was available for four days. The weight of the food was determined 
by scale, and the intake of CHO, P, and F was calculated as percentage of 
total calories from the nutrition labelling of the package or a nutritional soft-
ware (DGE-PC vers. 2.9.1.007). Individual accuracy of CHO estimation was 
evaluated for a subgroup of 39 patients. They were asked to estimate the CHO 
content of each meal in their preferred carbohydrate estimation unit. Ratios 
between estimated and actual CHO content were calculated.
Results: The mean meal composition for breakfast was: 43% CHO - 16% P - 
41% F as percentage of total calories (570 kcal), for lunch: 37% CHO - 20% 
P - 43% F (760 kcal), for dinner: 36% CHO - 21% P - 43% F (697 kcal) and for 
the whole day: 39% CHO ranging from 24% to 49% (45-60% recommended), 
17% P ranging from 12% to 23% (10-20% recommended), 45% F ranging 
from 36% to 63% (25-35% recommended) (2208 kcal). When compared as 
percentage of the calculated CHO content, the mean estimates of the sub-
group of 39 patients were in total 92.9%±13.0% (median 92.4%, min. 60.3%, 
max. 128.8%), for breakfast 99.9%±16.9%, for lunch: 93.8%±16.1% and for 
dinner: 87.2%±12.9%.
Conclusion: Nutrient intake was different from current nutritional recom-
mendations of the EASD. Especially daily carbohydrate intake was lower 
and fat intake was higher than recommended. In previous studies we found 
a similar macronutrient distribution reflecting current eating patterns and 
personal preferences. Currently, the establishment of more individualized 
recommendations is discussed. In contrast to results of other studies, the 
type-1-diabetic patients in this study estimated the amount of carbohydrates 
in self-chosen meals accurately in conditions similar to real life. Most of these 
patients are very motivated and participate frequently in similar studies indi-
cating that regular training is helpful to keep nutritional education at a high 
level.
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The increment of postprandial energy expenditure is associated with 
body weight reduction by dietary intervention in type 2 diabetes
D. Sanoyama, M. Nagao, Y. Nakajima, H. Sugihara, S. Oikawa;  
Department of Endocrinology, Diabetes and Metabolism,  
Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Background and aims: Body weight change is determined by the balance 
between food intake and energy expenditure. Total energy expenditure is 
composed of basal metabolic rate (BMR), activity induced energy expendi-
ture (AEE), and diet-induced thermogenesis (DIT). Although dietary energy 
restriction is an essential approach for diabetes management, the degree of 
body weight reduction varies between individuals. To clarify the determi-
nants for the efficacy of dietary intervention in type 2 diabetes, we measured 
energy expenditure (EE) by indirect calorimeter during short-term hospi-
talization, and analyzed relationships between the EE and other metabolic 
parameters.
Materials and methods: A total of 63 subjects (21 females and 42 males) with 
type 2 diabetes admitted to our hospital for glycemic control were enrolled in 
this study. During the hospitalization (15.2 ± 2.4 days), the subjects received 
calorie-restricted diets (daily total energy intake was determined based on 
the recommendation of the Japan Diabetes Society; [height (m)]2 × 22 × 27.5 
kcal/day) with restricted exercise. Clinical measurements were carried out 
after an overnight fast on the 2nd day of admission. Body weight was checked 
again on discharge. EE was evaluated at fasting (0900 h, FEE) and postpran-
dial state (1500 h, PPEE) using an indirect calorimeter during the hospitaliza-
tion, and the increment of PPEE over FEE (ΔEE) was calculated. We analyzed 
correlations between the EE indices (FEE and ΔEE) and the clinical measure-
ments. All data are expressed as means ± SD. Mean values were compared us-
ing Student’s t test. Correlations between the EE indices and other continuous 
variables were examined by Pearson’s correlation analysis.
Results: Body weight was reduced from 67.2 ± 15.8 to 65.0 ± 15.3 kg (p < 
0.001) during the hospitalization. PPEE was significantly higher than FEE 
(0.989 ± 0.208 and 1.083 ± 0.208 kcal/min for FEE and PPEE, respectively; 
p < 0.001). ΔEE was 0.094 ± 0.142 kcal/min. FEE was significantly higher in 
male (P < 0.001) and positively correlated with height (r = 0.69, p < 0.001), 
initial body weight (r = 0.75, p < 0.001), body mass index (r = 0.53, p < 0.001), 
abdominal circumference (r = 0.52, p < 0.001), fasting serum C-peptide (r = 
0.26, p = 0.037) and urinary C-peptide (r = 0.41, p = 0.001), whereas inversely 
correlated with age (r = −0.41, p < 0.001). ΔEE showed a positive correlation 
with daily body weight reduction (r = 0.37, p = 0.003) and an inverse correla-
tion with age (r = −0.25, p = 0.047). Multiple regression analysis with adjust-
ment for covariates (age, gender, initial body weight, and HbA1c) revealed 
that ΔEE is a potential independent predictor for daily body weight reduction 
(β = 0.449, p = 0.038).
Conclusion: The positive correlations of FEE with anthropometric and insu-
lin secretion parameters suggest that FEE is related to insulin resistance. On 
the other hand, ΔEE showed a positive correlation with body weight reduc-
tion during the short-term dietary energy restriction. Under the sedentary 
lifestyle like hospitalization, since FEE is nearly equivalent to BMR, ΔEE is 
supposed to reflect predominantly DIT. Taken together, these results indicate 
that ΔEE, as a surrogate marker of DIT, may determine the efficacy of dietary 
intervention in type 2 diabetes.
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Relationships of serum 25-OH vitamin D and parathyroid hormone 
levels with all-cause mortality in type 2 diabetes
F.H. Nystrom1, P. Jennersjö1, H. Guldbrand1, S. Björne1, T. Länne1,  
M. Fredriksson2, C. Östgren1;  
1Department of Medical and Health Sciences, Faculty of Health Sciences, 
2Department of Clinical and Experimental Medicine, Faculty of Health 
Sciences, Linköping, Sweden.
Background and aims: New and clinically useful markers of risk are of es-
sence in high risk states such as Type 2 diabetes.
Materials and methods: We analyzed baseline data from 741 patients (489 
men and 252 women) who participated in “Cardiovascular Risk factors in 
Patients with Diabetes - a Prospective study in Primary care” (CARDIPP). 
Participants of this prospective observational study were between 55-66 
years old when recruited between the years 2005-2008 and they all had Type 
2 diabetes. 25-OH-vitamin D and parathyroid hormone levels (PTH) were 
analyzed using electrochemo-luminiscense on a Cobas® e602 unit (Roche Di-
agnostics Scandinavia AB, Bromma, Sweden). Carotid-femoral pulse wave 
velocity (PWV) was measured with applanation tonometry (SphygmoCor® 
system, AtCor Medical, Sydney, Australia) and intima-media thickness of the 
carotid arteries (IMT) was evaluated using B-mode ultrasound (ATL HDI 
5000, Bothell, WA, USA). The participants were followed for all-cause mor-
tality until December 31, 2012, using the Swedish Cause of Death Registry.
Results: There was a negative linear relationship between vitamin D levels 
with waist circumference (r = -0.147, p < 0.0001) in the total cohort. During 
the follow up period 24 men and 9 women died. When entering major risk 
factors in Cox regression vitamin D levels were negatively related to all-cause 
mortality in men, independently of age, PTH, HbA1c, waist circumference, 
mean 24-hour systolic ambulatory blood pressure (ABP) and apolipoprotein 
B levels (p= 0.049). This finding of increased mortality related to low levels of 
vitamin D in men was also statistically significant when PWV and IMT were 
added to the equations in men (p= 0.028 Hazard ratio of 0.97, CI from 0.95 to 
0.997 for each nmol/l of vitamin D). The figure below shows mortality in men 
of the lower and higher tertiles of vitamin D levels, respectively. In women, on 
the other hand, levels of PTH (p= 0.016 without PWV and IMT) were posi-
tively related with all-cause mortality when performing the corresponding 
analyses (p= 0.006 with PWV and IMT, Hazard ratio of 1.049, CI from 1.014 
to 1.085 for each ng/l of PTH) while vitamin D levels were without statistical 
significance in the models (p =0.9).
Conclusion: Our data show that information about the levels of serum vita-
min D in men and of PTH in women add prognostic information in terms 
of total-mortality that goes beyond traditional risk factors and that also adds 
information independently of the levels of systolic ABP, IMT and PWV.
Supported by: ALF, FORSS, HLF, VR
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Oral glucose has no effect on appetite and satiety sensations compared to 
isoglycaemic i.v. glucose in healthy subjects
M. Gyldenløve1, A.E. Junker2, L. Skov1, T. Vilsbøll2, F.K. Knop2;  
1Department of Dermato-Allergology,  
2Diabetes Research Division, Department of Medicine, Gentofte Hospital, 
University of Copenhagen, Hellerup, Denmark.
Background and aims: Oral glucose ingestion is thought to elicit release of 
satiety-promoting gastrointestinal (GI) hormones. However, the effect of glu-
cose stimulation of the GI tract on appetite per se has been difficult to separate 
from the satiety-inducing effect of elevated plasma glucose concentrations. 
We aimed to evaluate the GI-independent effect of glycaemic excursions fol-
lowing OGTT on appetite and satiety sensations in healthy volunteers.
Materials and methods: Hunger, satiety, fullness, prospective food consump-
tion, thirst, well-being, and nausea were assessed by 100-mm visual analogue 
scales in 20 healthy subjects (7 females; age (mean±SEM): 54±3 years; BMI: 
27.0±0.6 kg/m2; HbA1C 5.4±0.1%) every 20 minutes during a 3h 50g-OGTT 
and an isoglycaemic i.v. glucose infusion (IIGI), respectively. Overall appetite 
score (OAS) was calculated as (satiety + fullness + (100 - hunger) + (100 
- prospective food consumption)) / 4. Gastrointestinal-mediated glucose dis-
posal (GIGD) was calculated as the difference in glucose amounts used dur-
ing OGTT and IIGI related to the amount used during OGTT (GIGD = 100% 
× (glucoseOGTT - glucoseIIGI) / glucoseOGTT).
Results: Isoglycaemia during the oral and i.v. glucose stimuli was achieved 
in all subjects. As expected, glucose stimulation of the GI tract had a strong 
impact on glucose disposal from the blood reflected by a mean±SEM GIGD 
of 57±2%. No significant differences in baseline appetite and satiety sensa-
tions were observed between the two experimental days. Overall, appetite 
sensations increased whereas satiety sensations decreased during both glu-
cose stimuli. There were no significant differences in hunger, satiety, fullness, 
prospective food consumption, thirst, well-being, nausea or OAS.
Conclusion: Our findings show that glucose stimulation of the GI tract has 
little or no effect on appetite and satiety sensations independently of plasma 
glucose levels. This suggests that the collective effect of GI factors triggered 
by oral glucose is of minor importance for appetite and satiety sensations in 
healthy subjects.
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Effectiveness of add-on glucose-lowering drugs for early glycaemic 
control in users of metformin: population-based cohort study
R.W. Thomsen1, L.M. Baggesen1, L. Pedersen1, E.S. Buhl2, C.L. Haase2,  
E. Svensson1, M.L. Svendsen1, M. Søgaard1, H. Nørrelund1, S.P. Johnsen1;  
1Department of Clinical Epidemiology, Aarhus University Hospital,  
2Novo Nordisk Scandinavia AB, Copenhagen, Denmark.
Background and aims: We examined the association of different add-on 
glucose-lowering drugs with achieved quality of early glycaemic control in a 
large population-based cohort of incident metformin users.
Materials and methods: We included all individuals with a first-time pre-
scription for metformin in Northern Denmark between 2000 and 2012 who 
had their treatment intensified with another glucose-lowering drug within 
the first year. We obtained individual-level data on glycated hemoglobin 
(HbA1c) measurements, comorbidities, and medications from population-
based medical databases.
Results: We identified 25,631 T2D patients with a first metformin prescrip-
tion. Of these, 3,898 (15%) received an add-on glucose-lowering drug within 
the first year following metformin start, of which 3,089 had a baseline HbA1c 
measured before their add-on drug. A number of 1,888 patients (61%) re-
ceived a sulfonylurea (SU) add-on, 648 (21%) received a DPP4 inhibitor, 
132 (4%) a GLP-1 receptor analogue, 125 (4%) another oral hypoglycemic 
agent (OHA), and 296 (10%) started insulin in addition to metformin. Me-
dian patient age at time of add-on was 60 years, 59% were males, and the 
median HbA1c before add-on was 7.9% (inter quartile range 7.0-9.2%). Pa-
tients with SU add-on had a median age of 61 y, a median HbA1c of 7.8% at 
baseline, and 23% had hospital-diagnosed comorbidity. The corresponding 
values were similar for patients with DPP4 inhibitor add-on (59 y, 7.7%, and 
21%); for GLP-1 add-on (55 y, 8.0%, and 15%); and for other OHA add-on 
(59 y, 7.9%, and 18%). Insulin add-on patients tended to have worse glycae-
mic control and more comorbidity (56 y, 9.6%, and 29%). Within 3-6 months 
after add-on therapy start, 2,357 T2D patients (76%) had a control HbA1c 
measurement recorded. Overall, the median HbA1c dropped from 7.9% at 
baseline to 6.7%, corresponding to a reduction of 1.2 percentage points (pp). 
Absolute reductions were 1.2 pp (from 7.9 to 6.7) for sulfonylurea add-on, 
1.0 pp (7.7 to 6.7) for DPP4 inhibitors, 1.5 pp (8.0 to 6.5) for GLP-1 recep-
tor analogues, 1.1 pp (8.0 to 6.9) for other OGDs, and 2.7 pp (9.7 to 7.0) for 
insulin add-on. Overall, 61% of all metformin users who had add-on therapy 
attained an HbA1c target of <7% within 3-6 months, while 36% attained an 
HbA1c target of <6.5%. In the largest group with SU add-on, the proportions 
attaining an HbA1c target of <7% were 83%, 55%, and 45% for the 3 different 
baseline HbA1c levels displayed in Figure 1. In comparison, a target of <6.5% 
was attained by 56%, 27%, and 26%. Target attainments for other treatment 
groups are shown in Figure 1.
Conclusion: This study provides data on glycaemic control in real-world 
metformin users who are started with different add-on glucose-lowering 
drugs. Overall, more than one third did not attain an HbA1c target of <7% 
within 6 months, and close to two thirds did not attain a target of <6.5%. 
Supported by: Novo Nordisk 
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Cardiovascular safety of metformin and sulphonylureas in  
type 2 diabetes patients
S. Ioacara1,2, M. Roden3, C. Guja4,2, C. Ionescu-Tirgoviste4,2, A. Reghina1,2, 
O. Georgescu1, S. Fica1,2;  
1“Elias” University Emergency Hospital, 2“Carol Davila” University of 
Medicine and Pharmacy, Bucharest, Romania, 3Institute for Clinical 
Diabetology, German Diabetes Center, Düsseldorf, Germany,  
4“I. Pavel” Outpatient Clinic, Bucharest, Romania.
Background and aims: To investigate the impact of the exposure to the oral 
glucose lowering drugs (OGLD) metformin and sulphonylureas, on cardio-
vascular mortality in type 2 diabetes patients.
Materials and methods: All consecutive diabetes patients residing in a ma-
jor urban area were screened at their first diabetes outpatient visit between 
01/01/2001-12/31/2008 (n=79869). Baseline was defined at 6 months after 
screening (n=78714). Exclusion criteria at baseline were: insulin treat-
ment (n=15515), not on monotheraphy with metformin or sulphonylurea 
(n=32257), and age <40 or ≥65 years (n=14128). All 16814 patients (46.9% 
females) were followed-up until (i) death, based on death certificate and Na-
tional Institute of Statistics data, or (ii) first insulin exposure, or (iii) end of 
follow-up on 12/31/2011. Data on gender, age, time-dependent daily dose 
and number of concomitant OGLD were available. Time-dependent compet-
ing risk regression analysis, with daily updates of treatment modalities was 
performed. Simultaneous use of cumulative exposure and ever exposed term 
of the available treatment options, a “fixed” cohort, and cumulative exposure 
limited to that attained one year prior to death (reverse causation) completed 
the evaluation.
Results: Mean baseline age was 55±6 years, with a mean follow-up of 6.0±2.9 
years. During 101418 person-years exposure time, there were 968 car-
diovascular deaths (328 myocardial infarction; 223 stroke) and 889 deaths 
from other causes (competing events), with an overall mortality rate 183 per 
1000 person-years. Cumulative time exposure (one year increments) (sub)
hazards (SHR) for cardiovascular death showed: male gender 1.850 (95% CI 
1.618-2.115, p<0.001), age at baseline 1.083 (95% CI 1.070-1.096, p<0.001), 
metformin 0.979 (95% CI 0.975-0.983, p<0.001), glimepiride 0.975 (95% 
CI 0.968-0.983, p<0.001), gliclazide 0.978 (95% CI 0.973-0.984, p<0.001), 
glipizide 0.984 (95% CI 0.977-0.992, p<0.001), glibenclamide 0.985 (95% 
CI 0.979-0.991, p<0.001), repaglinide 0.982 (95% CI 0.970-0.995, p=0.005). 
There was no significant impact of pioglitazone, rosiglitazone, and concomi-
tant number of OGLD. Cumulative dose exposure (one gram increments) 
results were comparable, with the exception of repaglinide 0.450 (95% CI 
0.192-1.051, p=0.065) and pioglitazone 0.866 (95% CI 0.751-0.998, p=0.047). 
Similar results were obtained with myocardial infarction or stroke death 
as end-point. Future exposure to sulphonylureas in patients on metformin 
monotheraphy at baseline (n=7546) was associated with a decrease in car-
diovascular mortality. Patients originally on sulphonylurea (n=9268) and 
subsequently exposed to metformin did not experience significant changes 
in cardiovascular hazards (all SHR p values >0.05). Cumulative exposure lim-
ited to that attained one year prior to death and “fixed” cohort analysis did 
not affect the original results.
Conclusion: Exposure to oral glucose lowering drugs in type 2 diabetes pa-
tients originally on monotherapy with metformin or sulphonylurea is safe 
in terms of cardiovascular mortality. Subsequent exposure to metformin in 
patients treated with sulphonylurea at baseline was not associated with in-
creased cardiovascular mortality.
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Polymophism of OCT2 and MATE1 improve glucose-lowering effect of 
metformin via influencing its pharmacokinetics in Chinese  
type 2 diabetic patients
W.L. Hou1, D.D. Zhang1, W. Lu1, T.S. Zheng1, L.L. Wan2, Q. Li1, F. Liu1,  
W.P. Jia1;  
1Department of Endocrinology and Metabolism, Shanghai Clinical Medical 
Center of Diabetes, Shanghai Key Clinical Center of Metabolic Diseases, 
2Department of Pharmacy, Department of Pharmacy, Shanghai, China.
Background and aims: This study aims to investigate the potential impact 
of organic cation transporter 2 (OCT2) nucleotid polymorphism at site 808 
(G→T) and multidrug and toxin extrusion protein 1 (MATE1) on metformin 
pharmacokinetics and long-term antidiabetic effect.
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Materials and methods: A total of 220 newly diagnosed type 2 diabetes 
patients taking oral metformin were recruited, genotyped and divided into 
three groups by SLC22A2 genotypes (G/G, G/T, T/T), as well as three groups 
by SLC47A1 genotypes (G/G, G/A, A/A). Six to ten patients in each group 
were randomly selected and undertaken metformin pharmacokinetic study. 
A one-year follow up randomized cohort study was performed to clarify met-
formin pharmacodynamics.
Results: After one year, the falling range of HbA1c level was significantly 
greater in subjects with heterozygous variant genotype (GT and AA) than 
wild type homozygote (-1.28% in GT vs -1.01% in GG, -2.32% in AA vs 
-1.07% in GG, both P<0.05) after adjustment for baseline HbA1c levels in 
each group. There were also differences in pharmacokinetic parameters 
of metformin between reference and variant forms of OCT2 and MATE1. 
Multivariate analysis further revealed that OCT2 exon 808 polymorphism, 
SLC47A1 genotype and gender were independent influencing factors for 
urine excretion of metformin (P<0.05).
Conclusion: Except for gender, the glucose-lowering efficacy of metformin 
can be enhanced by SLC22A2 808 G>T variants and SLC47A1 rs2289669 
G>A variants through delaying its transportation and renal clearance in Chi-
nese type 2 diabetes populations.
Supported by: the National Natural Science Fund of China
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Long term effects of metformin on plasma concentrations of C-peptide 
in insulin-treated type 2 diabetes patients: a placebo controlled trial
W.M.C. Top1,2, A. Kooy1,2, P. Lehert3, C.D.A. Stehouwer4;  
1Internal Medicine, Bethesda Hospital Care Group Leveste Middenveld, 
Hoogeveen, 2Bethesda Diabetes Research Centre, Hoogeveen, Netherlands, 
3Statistical Department, Louvain University, Belgium,  
4Internal Medicine, Maastricht University Medical Centre, Netherlands.
Background and aims: Type 2 diabetes (T2D) is characterized by beta cell 
failure and varying degrees of insulin resistance, both being targets of treat-
ment. While metformin is known to improve insulin sensitivity, its effects on 
beta cell function are assumed to be neutral. Because beta cell mass decreases 
over time, improvement of beta cell function may be more difficult to obtain 
in advanced T2D. In this study, the effects of metformin on beta cell func-
tion were evaluated in patients with advanced, insulin-treated T2D during a 
follow-up of 4.3 years.
Materials and methods: To evaluate the effect of metformin on endogenous 
insulin secretion, we analysed the plasma concentrations of C peptide (im-
muno-assay) at baseline, after 4 months and yearly for 4 years in a placebo-
controlled, randomized trial in insulin-treated patients with T2D (N=390, 
mean age 61.3 years, mean diabetes duration 13.1 years, mean baseline 
HbA1c 7.9%, 54% men). A linear model was performed on logtransformed 
values because of a skewed distribution of the data, and with adjustment for 
baseline values.
Results: Unadjusted mean C-peptide levels decreased from 0.52(+/- 0.38) to 
0.47(+/- 0.34) nmol/l in the placebo group, and increased from 0.47(+/- 0.40) 
to 0.55(+/- 0.47) nmol/l in the metformin group. For the final visit, regression 
analysis showed a significant treatment effect (difference, 5.8% (95% CI, 1.0-
11.5), P=0.034). The summary mean in the placebo group was 0.52(+/- 0.35) 
and in the treatment group 0.53 (+/- 0.40) nmol/l. No statistically significant 
treatment effect was found on the summary mean (difference, 2.7% (95% CI, 
-0.5-5.9), P=0.101). As a measure for steady state beta cell function, we calcu-
lated the fasting C-peptide/fasting glucose index (C-peptide/glucose x 100). 
This ratio decreased from 5.4 (+/- 4.1) to 5.0 (+/- 3.9) in the placebo group, 
and increased from 4.9 (+/- 4.0) to 5.9 (+/- 4.7) in the metformin group. 
Regression analysis showed a significant treatment effect both for the final 
visit (difference 0.9 (95% CI, 0.2-1.6), P=0.010) and for the summary mean 
(difference 0.9 (95% CI, 0.5-1.4), P<0.001).The greater part of this effect (71% 
( 95% CI,44-86)) was not mediated by changes in HbA1c.
Conclusion: Our study shows that beta cell function in advanced T2D can 
be improved by the addition of metformin in insulin-treated patients. This 
improvement is only partially explained by a reduction in HbA1c. In insulin-
treated patients not treated with metformin a slight decrease in beta cell func-
tion was observed during a follow-up of 4.3 y.
Clinical Trial Registration Number: NCT00375388
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Glucose-lowering effect of metformin resides in the gut not the 
circulation. A 12-week placebo-controlled double-blind randomised trial
M. Fineman1, R.A. DeFronzo2, J. Rosenstock3, J. Buse4, T. Kim1, C. Burns1,  
S. Skare1, A. Baron1;  
1Elcelyx Therapeutics, San Diego, 2UT Health Science Center, San Antonio,  
3Dallas Diabetes and Endocrine Center,  
4UNC School of Medicine, Chapel Hill, USA.
Background and aims: Metformin delayed release (Met DR) is formulated to 
deliver Met directly to the lower bowel where absorption is poor, resulting in 
low plasma Met exposure. In previous studies, the same dose of Met DR and 
Met immediate release (IR) comparably lowered fasting (FPG) and postpran-
dial plasma glucose and augmented GLP-1 and PYY release but plasma Met 
was reduced by approximately 50% with Met DR compared to IR. Maintained 
glucose-lowering efficacy with reduced plasma exposure may allow for re-
moval of the renal impairment contraindication due to reduced Met plasma 
exposure and subsequent lower risk of Met-associated lactic acidosis.
Materials and methods: The randomized, blinded, 12-week study compared 
3 doses of Met DR (600, 800, 1000 mg) to placebo (PBO) in subjects with 
T2DM (n = approximately 40/group, mean age 52 years, mean BMI 33 kg/
m2), screening mean FPG 144 mg/dl, and mean A1C 7.2%. Subjects were 
on diet and exercise (11%) or washed off previous Met (89%, average dose 
~1400 mg) and/or DPP-4i for 2 weeks prior to randomization. Two open-
label groups of Met extended release (XR 1000, 2000 mg) were also included 
as a reference.
Results: FPG decreased within the first week of treatment in all groups and 
was stable after 4 weeks. The mean 4-12 week change in FPG from baseline 
was -13.5, -12.3 and -18.0 mg/dl for 600, 800 and 1000 mg Met DR, respec-
tively, vs. -1.2 mg/dl for PBO (all p<0.05, median change). The mean FPG for 
Met XR 1000 mg (-13.3 mg/dl, p<0.05 vs. PBO) was similar to 600/800 mg 
Met DR, despite 4-9 fold higher fasting Met plasma concentrations (515 vs. 
56 and 119 ng/ml, respectively). Met XR 2000 mg reduced FPG by 26.5 mg/
dl (p<0.05 vs PBO) with a fasting Met plasma concentration of 912 ng/ml. 
The similar glucose-lowering effect of 600 mg Met DR and 1000 mg Met XR 
represents an approximately 40% shift in the dose response for Met DR, con-
sistent with the gut being the primary site of metformin action. At Week 12, 
mean A1C rose by 0.45% for PBO, reflecting withdrawal of oral agents, and 
remained unchanged in the DR groups and 1000 mg Met XR. The mean A1C 
change was -0.21% for 2000 mg Met XR. GI tolerability was similar among 
all Met groups.
Conclusion: Maintenance of efficacy at lower doses and markedly reduced 
plasma Met exposure with gut restricted Met DR confirms that Met works 
chiefly in the gut. Importantly, Met DR could be useful to reduce risk of lactic 
acidosis in patients with renal impairment.
Clinical Trial Registration Number: NCT01819272
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Effects of metformin on fuel metabolism, energy expenditure and body 
composition in human subjects and rats
I. Tokubuchi1, Y. Tajiri1, S. Iwata1, K. Hara1, K. Yamada1, H. Mifune2;  
1Division of Endocrinology and Metabolism, 2Department of Animal 
Experiment, Kurume University School of Medicine, Japan.
Background and aims: Metformin is widely used to treat obese diabetics be-
cause of its beneficial effects on body weight, energy intake, and glucose reg-
ulation. Metformin phosphorylates AMP-activated protein kinase (AMPK) 
and exerts its effects on hyperglycemia and insulin resistance through a 
blockade of gluconeogenesis in the liver and an enhancement of fat oxida-
tion in the skeletal muscle. However, results regarding effects on energy ex-
penditure (EE), respiratory quotient (RQ) and body composition have been 
rather controversial. In the present study, we investigated this unsolved issue 
separately during either fasting or post-prandial state in both human subjects 
and rats.
Materials and methods: All data were expressed as means±S.D. In human 
study, metformin hydrochloride (1500 mg/day) was administered either 23 
healthy subjects (group C: 16 males, 26±3 years old, BMI 22.0±3.4) or 13 
type 2 diabetic patients (group DM: 7 males, 44±17 years old, BMI 30.9±6.2) 
for 2 weeks. Meal tolerance test (592 kcal, 75 g of carbohydrate, 28.5 g of 
fat) was performed in the morning before and after 2 weeks administration 
of metformin. Blood samples were collected before and 1, 2, 3 hours after 
the ingestion of meal, and plasma concentrations of glucose (G), triglyceride 
(TG), lactate (LA) and pyruvate (PA) were measured. Simultaneously expired 
gas analysis was performed for the measurements of EE and RQ. In animal 
study, male Sprague Dawley rats (13 weeks old) were fed 10 g of standard 
chow twice daily (at 8AM and 7PM), and drinking water either with or 
without metformin hydrochloride (2.5 mg/ml) was given for 2 weeks. At 15 
weeks old, EE and RQ were measured in a chamber equipped with expired 
gas analysis system, body compositions were measured by CT scan, then they 
were sacrificed in either fasting or post-prandial state and blood samples were 
collected.
Results: In human study, by the administration of metformin for 2 weeks sig-
nificant decreases of G (P<0.01) and TG (P<0.05) were observed at all points 
in DM and a significant decrease of G after 2 hours (P<0.01) in C compared 
to values before administration. In DM, LA and PA after meal ingestion were 
significantly (P<0.05) increased by metformin administration. Although EE 
did not change, RQ decreased before meal (C: 0.8±0.06→0.78±0.05, P<0.05; 
DM: 0.73±0.03→0.71±0.02, P<0.05) and conversely increased 2 hours after 
meal ingestion(C: 0.77±0.05→0.8±0.07, P<0.05; DM: 0.71±0.04→0.74±0.04, 
P<0.05). In animal study, LA and PA were significantly (P<0.05) increased 
in both fasting and post-prandial state by the treatment of metformin for 
2 weeks. RQ decreased during fasting state in metformin-treated rats com-
pared to control rats (0.8±0.02 vs. 0.82±0.03, P<0.05) in spite of comparable 
EEs in both groups. Total fat volume was significantly decreased by the treat-
ment of metformin (19.5±2.3 vs. 25.5±4.1%, P<0.05) while body weight did 
not differ between both groups.
Conclusion: Long-term administration of metformin brought about a shift 
of fuel resource, especially fat oxidation during fasting state was noted in 
both human and animal experiments. Concomitantly, a significant decrease 
of fat volume was noted in animal experiment in reflection of a dominant 
fat utilization. Precise molecular mechanisms for these beneficial effects of 
metformin are now under exploration.
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Metformin-associated prevention of weight gain in insulin-treated type 2 
diabetic patients cannot be explained by decreased energy intake
M. Out1,2, I. Miedema3, H.A. Jager-Wittenaar3, C.P. van der Schans3,  
W.P. Krijnen3, P. Lehert4, C.D.A. Stehouwer5, A. Kooy1,2;  
1Bethesda Hospital, 2Bethesda Diabetes Research Center, Hoogeveen, 
3Research and Innovation Group in Health Care and Nursing, Hanze 
University of Applied Sciences Groningen, Netherlands, 4Department 
of Statistics, Louvain Academy, Mons, Belgium, 5Maastricht University 
Medical Centre, Netherlands.
Background and aims: Metformin is known to prevent weight gain in pa-
tients with type 2 diabetes (T2D). However, the mechanisms involved are still 
unknown. Less energy intake, malabsorption and metabolic effects may play 
a role.
Materials and methods: We analysed energy intake in the HOME trial, a 
placebo-controlled, randomised trial (RCT) conducted in 3 hospitals in insu-
lin-treated T2D patients (N=390, mean age 61.3 years, mean diabetes dura-
tion 13.1 years, mean baseline HbA1c 7.9%, 54% men). Dietary intake was 
assessed at baseline, after 1 year and after 4 years by four trained registered 
dieticians. For dietary assessment, patients were asked about their intake 
during the preceding week according to the dietary history method. Mean 
energy intake per day (kcal) was calculated using food calculation software 
(Becel Institute Nutrition Software). All analyses were based on intention to 
treat. For statistical analysis, we used a general linear model (ANCOVA) and 
a Linear Mixed Model (LMM) to determine the robustness of our results.
Results: Dietary assessments were available from 2 hospitals, resulting in in-
clusion of 310 patients of the 390 patients randomised in the original study. 
Of the 310 participants, 179 completed (93 placebo and 86 metformin) all 
three dietary assessments. Body weight of the patients in the placebo group 
increased 4.9 kg (SD 4.9) in 4 years and increased significantly more than 
in the metformin group (+ 1.1 kg, SD 5.2; p≤0.001). Mean daily energy in-
take after 4 years decreased from 1649 (SD 419) to 1632 kcal (SD 453) in the 
placebo group and from 1613 (SD 426) to 1567 kcal (SD 419) in the met-
formin group. ANCOVA did not detect a significant difference after 4 years 
(-71.0 kcal/day in metformin compared to placebo; 95% CI -199.4 to +54.5, 
p=0.28). The outcome remained non-significant after additional adjustment 
for gender, age, duration of diabetes and smoking, and was confirmed by a 
LMM (F-value 1.803, df=415, p = 0.18). LMM failed to detect a significant ef-
fect of energy intake as explanation for the difference in weight gain between 
the groups (F-value 0.054, df=1, p = 0.82).
Conclusion: In this long-term RCT in T2D patients treated with insulin, 
metformin treatment was not associated with a change in energy intake as 
compared to placebo. Therefore, the prevention of weight gain by metformin 
could not be explained by a lower energy intake. Further research is needed 
to investigate whether other mechanisms like malabsorption, changes in in-
testinal glucose metabolism or effects through the GLP-1 system are involved 
in the favourable effect of metformin on weight development.
Clinical Trial Registration Number: NCT00375388
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Are sulfonylurea and insulin therapies associated with a larger risk of 
cancer than metformin therapy? A retrospective database analysis
B. Kowall1, K. Kostev2, W. Rathmann1;  
1German Diabetes Center, Düsseldorf, Germany,  
2IMS Health, Frankfurt am Main, Germany.
Background and aims: Several meta-analyses of observational studies sug-
gested that metformin use reduces, while sulfonylurea use increases cancer 
risk in type 2 diabetes. However, studies of the effects of drugs are prone to 
bias. Recently, Suissa (2012) claimed that 23 published observational studies 
on the effects of metformin on cancer incidence were afflicted with time re-
lated bias like immortal time bias, bias from time lag and latency. As the few 
RCTs published so far have failed to confirm the results of the observational 
studies, the reduced cancer risk in metformin users may be put into question. 
Our aim is to compare cancer incidence in users of sulfonylurea, insulin and 
other diabetes medication, respectively, with cancer incidence in metformin 
users, and to avoid time related biases.
Materials and methods: In a retrospective observational study, we used the 
German Disease Analyzer database which includes patient data from general 
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practices throughout Germany. Practices anonymously report all diagnoses 
(ICD-10), prescriptions (ATC), hospital admissions, and laboratory test re-
sults on an ongoing basis. The study sample included 22,556 patients who 
received a diagnosis of type 2 diabetes during the index period used for this 
study (January 2000 to December 2012), and who did not have cancer before 
diagnosis of diabetes. The outcome measure was cancer incidence (ICD-10: 
all, breast, colon, and prostate cancer). The median follow-up time was 4.8 
years. 1,446 (6.4%) patients developed cancer. In an intention-to-treat type 
analysis, patients with sulfonylurea (or insulin, or other antidiabetic medi-
cations) as their first diabetes medication were compared to patients with 
metformin as their first antidiabetic drug prescription. In a second type of 
analysis, patients with a monotherapy of sulfonylurea, insulin, or other medi-
cations, respectively, were compared to patients with a metformin monother-
apy. For these analyses, time 0 was the time one year (three years in a sensi-
tivity analysis) after the first prescription of the respective medication. Cox 
regression models were fitted, and hazard ratios (HR) and 95% confidence 
intervals (CI) were calculated to compare users of sulfonylurea, insulin, and 
other medications with users of metformin.
Results: Compared to patients with metformin as first diabetes medication, 
no increased risks of cancer of all sites were found in patients with other 
first diabetes medication. In models adjusted for age, sex, obesity, hyperten-
sion, hyperlipidemia, duration of diabetes, and Charlson comorbidity index, 
the corresponding HRs were 1.02 (95%-CI: 0.89 - 1.17) for sulfonylurea, 1.09 
(95%-CI: 0.86 - 1.37) for insulin, and 0.91 (95%-CI: 0.74 - 1.12) for other dia-
betes medication. In the analogous analyses for the comparison of monother-
apies, similar results were obtained. In additional analyses with a latency time 
of three years, and in analyses for some selected cancer sites (breast, colon, 
and prostate cancer), no decreased cancer risk was found in metformin users.
Conclusion: In a retrospective database analysis, taking into account po-
tential time related biases, no different cancer risk was found in metformin, 
sulfonylurea and insulin users. This finding is in line with few other observa-
tional studies using time-dependent analyses. To clarify the association be-
tween antidiabetic drug use and cancer risk, there is a strong need for further 
well-designed observational studies and RCTs.
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The suppression mechanism of metformin on the tumour death ratio 
accelerated by a high calorie diet in the RasH2 mouse: a model for 
evaluating tumour prevention or regression 
O. Shuichi;  
Department of Internal Medicine, Kurume University, Kurume, Japan.
Background and aims: The objective of the current study was to investigate 
whether Metformin intake changed the rate of tumor death under different 
diet conditions in the rasH2 transgenic mouse, a model for evaluating and 
designing tumor prevention or regression therapies.
Materials and methods: Male rasH2 transgenic mice at 8 weeks of age were 
divided into 2 groups (n=4 per group): one fed a high calorie diet of 592 
kcal/100 g and drinking water ad libitum; and the other fed the same high 
calorie diet with Metformin added to the drinking water from initiation until 
32 weeks. Metformin was administered at a small dose of 25 mg/kg body 
weight per day. Then all mice were sacrificed and examined under microar-
rays analysis (SurePrint G3 Mouse GE microarrays kit 8x60K, Agilient) and 
then quantitative PCR.
Results: Body weights of the rasH2 transgenic mice fed a high calorie diet 
with or without Metformin were almost the same from the age of 10 weeks 
until 32 weeks (76.5 ± 17.6 g vs. 76.5 ± 17.6 g). The human ras gene expres-
sion of liver, lung, kidney, spleen and visceral fat were not significantly dif-
ferent between the 2 groups. The lifespan of mice fed a high calorie diet with 
Metformin (n = 15; 75.3 ± 17.4 weeks) was longer than those fed a high calo-
rie diet without Metformin (p < 0.05), regardless of no differences in weekly 
body weights. However, At autopsy, multiple occurrences of tumors in the 
lung, liver, spleen, digestive organs and kidney were found in all groups and 
malignancy was considered as the cause of death.Based on the results of mi-
croarrays analysis, we identified that Ddit4 gene, which plays an important 
role in responses to cellular energy levels and cellular stress, including re-
sponses to hypoxia and DNA damage, was a possible cause for this phenom-
enon. Our quantitative PCR experiments showed that the Ddit4 gene expres-
sion of mice with Metformin significantly decreased compared with that of 
mice without Metformin in kidney (0.90 ± 0.38 vs. 1.91 ± 0.49, p=0.037, n=4, 
respectively). Other organs showed tendency to decrease (liver: 0.35 ± 0.14 
vs. 0.89 ± 0.14, p=0.09; lung: 1.43 ± 1.19 vs. 1.74 ± 2.89, p=0.64, n=4, respec-
tively).
Conclusion: Findings from the current study demonstrate that a constitu-
tional predisposition to tumor may be enhanced by diet, and that high inci-
dence of tumor death may be suppressed by a small dose of orally adminis-
tered Metformin acting on ameliorating genes, including Ddit4 gene, in mice 
fed a high calorie diet. We hope this Metformin research will act as a step-
ping stone for making an effective drug for the anti-cancer effects especially 
among diabetic patients.
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 322 
1 C
PS 060 SGLT2 inhibitors: safety
798
Long-term renal safety with dapagliflozin treatment 
A. Ptaszynska1, T. Mansfield1, E. Johnsson2, S. Parikh3, Y. Yavin1, J.F. List1;  
1Bristol-Myers Squibb, Princeton, USA, 2AstraZeneca, Mölndal, Sweden, 
3AstraZeneca, Wilmington, USA.
Background and aims: Dapagliflozin (DAPA) reduces hyperglycaemia by 
inhibiting renal glucose reabsorption. Because of this mechanism of action 
renal safety has been monitored closely throughout the DAPA clinical devel-
opment programme.
Materials and methods: Renal safety was assessed in data pooled from 13 
placebo (PBO)-controlled trials lasting up to 24 weeks (short-term [ST] data-
set), 9 PBO-controlled trials lasting up to 102 weeks (ST + long-term [LT] 
dataset), and from all 21 phase 2b/3 trials, including an active-controlled 
study up to 208 weeks (all Ph2b/3 dataset) in type 2 diabetes mellitus (T2DM) 
patients. Frequency of adverse events (AEs), serious AEs, and abnormal labo-
ratory tests were summarised.
Results: Among a total of 9339 patients in the all Ph2b/3 dataset, estimated 
glomerular filtration rate (eGFR) at baseline (BL) was ≥ 60 mL/min/1.73 m2 
in 8268 (88.5%) patients and ≥ 30 to < 60 mL/min/1.73 m2 in 1070 (11.5%) 
patients. With DAPA, in the ST+LT dataset, after a small initial decrease at 
week 1 (mean change from BL: -4.2 vs 0.5 mL/min/1.73 m2 [DAPA 10 mg vs 
PBO]) mean eGFR returned toward baseline by week 24 (mean change from 
BL: -1.4 vs -0.7 mL/min/1.73 m2 [DAPA 10 mg vs PBO]) and was stable to 
week 102. In the ST and ST+LT datasets, AEs related to renal function were 
more frequent with DAPA (Table); most were small, reversible changes in 
serum creatinine. In both PBO- and DAPA-treated subjects, these AEs oc-
curred > 10 times more frequently over 24 weeks, and 6-8 times more fre-
quently over 102 weeks, in subjects with eGFR ≥ 30 to < 60 mL/min/1.73 m2 
at BL (moderate renal impairment) compared with those with eGFR ≥ 60 
mL/min/1.73 m2 at BL (Table). Serious AEs (SAEs) related to renal function 
were balanced across treatments and were recorded in 0.15% of patients in 
both DAPA and control groups in the all Ph2b/3 dataset (DAPA, 9 of 5936; 
control, 5 of 3403) and there were no instances of acute tubular necrosis or 
acute nephritis. Marked laboratory abnormalities were uncommon and simi-
lar between groups; for example, serum creatinine ≥ 2.5 mg/dL was observed 
in 3 (0.2%) of both DAPA- and PBO-treated patients at week 102, but in no 
patient with eGFR ≥ 60 mL/min/1.73 m2 at BL. Shifts between categories of 
albuminuria (normal, micro, and macro) at week 24 in the ST dataset were 
similar for DAPA and PBO; overall, albuminuria did not worsen in either 
group. Renal safety data with DAPA were similar in a 4-year active-controlled 
trial (N=816).
Conclusion: Pooled data from 21 phase 2b/3 trials in T2DM patients, in-
cluding 13 ST and 9 LT studies, show that DAPA 10 mg is associated with 
a slight excess of renal AEs, mostly transient creatinine changes, but not of 
renal SAEs, compared with PBO. The difference is driven primarily by the 
subgroup of patients with eGFR ≥ 30-< 60 mL/min/1.73 m2 at BL. There is no 
indication of renal toxicity with DAPA. These data provide further evidence 
of a good renal safety profile for DAPA in the treatment of T2DM.
Clinical Trial Registration Number: NCT00660907
Supported by: AstraZeneca/BMS
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Efficacy and safety of canagliflozin (CANA) in patients with type 2 
diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney 
disease during treatment
R. Roussel1, D. de Zeeuw2, G. Law3, G. Meininger3;  
1Hôpital Bichat, Paris, France, 2University of Groningen, Netherlands, 
3Janssen Research & Development, LLC, Raritan, USA.
Background and aims: CANA, an SGLT2 inhibitor, has provided reductions 
in HbA1c, body weight (BW), and systolic blood pressure (SBP) across Phase 
3 studies of patients with T2DM. CANA was also associated with transient 
reductions in estimated glomerular filtration rate (eGFR) that stabilized or at-
tenuated over the treatment period. This analysis evaluated the impact of de-
creases in eGFR on the efficacy and safety of CANA in patients with T2DM.
Materials and methods: Changes from baseline in HbA1c, BW, and SBP 
were assessed in the subset of patients with eGFR ≥60 mL/min/1.73 m2 at 
baseline who had a reduction in eGFR to ≥45 and <60 mL/min/1.73 m2 at 
the last post-baseline time point based on pooled data from 6 randomised, 
double-blind, placebo (PBO)-controlled studies over 18 or 26 weeks (N = 
262/4,158; 6.3%). Safety analyses, including the incidence of adverse events 
(AEs), were conducted in those who had a reduction in eGFR from ≥60 mL/
min/1.73 m2 to ≥45 and <60 mL/min/1.73 m2 at the last time post-baseline 
in a broader pooled population from 8 randomised, double-blind, PBO- and 
active-controlled studies over 26 or 52 weeks (N = 664/9,439; 7.0%).
Results: Among patients who had a reduction in eGFR from ≥60 to ≥45 
and <60 mL/min/1.73 m2 (mean baseline eGFR 67.3 mL/min/1.73 m2), 
mean eGFR at the last post-baseline time point was 54.6, 54.8, and 55.9 mL/
min/1.73 m2 with CANA 100 and 300 mg and PBO (mean change from base-
line of -12.7, -12.6, and -11.5 mL/min/1.73 m2). In these patients, CANA 100 
and 300 mg provided PBO-subtracted reductions (95% confidence interval) 
in HbA1c (-0.56% [-0.84, -0.28] and -0.78% [-1.05, -0.51]), BW (-2.1% [-3.2, 
-1.0] and -2.6% [-3.6, -1.5]), and SBP (-6.2 mmHg [-11.1, -1.3] and -6.4 
mmHg [-11.0, -1.9]). Changes in HbA1c and BW in patients who had eGFR 
reductions were similar to those in the overall efficacy population; changes 
in SBP with CANA were greater in those with eGFR reductions compared 
with the overall population (Figure). eGFR reductions were reversible once 
patients discontinued CANA treatment. In the broad dataset used for safety 
analyses, the incidence of overall AEs in patients whose eGFR decreased to 
≥45 and <60 mL/min/1.73 m2 was 62.7%, 64.2%, and 58.6% with CANA 100 
and 300 mg and non-CANA; rates of AE-related discontinuations were 6.0%, 
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8.1%, and 6.4% and serious AEs were 12.4%, 10.0%, and 7.9%. The incidence 
of volume depletion-related AEs was 4.5%, 4.6%, and 2.0% with CANA 100 
and 300 mg and non-CANA; discontinuations and serious AEs related to vol-
ume depletion were infrequent across groups.
Conclusion: Among patients with T2DM with reductions from eGFR ≥60 
mL/min/1.73 m2 at baseline to eGFR ≥45 and <60 mL/min/1.73 m2 during 
treatment, CANA 100 and 300 mg provided reductions in HbA1c, BW, and 
SBP, consistent with the overall population. CANA was generally well toler-
ated, with a low incidence of volume depletion-related AEs across groups.
Supported by: Janssen Research & Development, LLC
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Diuresis-related safety and tolerability of dapagliflozin in  
type 2 diabetes mellitus over 24 weeks
E. Johnsson1, K.M. Johnsson1, T.A. Mansfield2, A. Apanovitch2, Y. Yavin2,  
A. Ptaszynska2, S.J. Parikh3, J.F. List2;  
1AstraZeneca, Mölndal, Sweden, 2Bristol-Myers Squibb, Princeton, USA, 
3AstraZeneca, Wilmington,  USA.
Background and aims: Dapagliflozin lowers blood glucose in Type 2 diabe-
tes mellitus by increasing urinary glucose excretion, which is accompanied 
by mild osmotic diuresis.
Materials and methods: This placebo-controlled short-term pool comprised 
13 double-blind core phase IIb/III studies of up to 24 weeks’ duration (dapa-
gliflozin 10 mg N=2360; placebo N=2295).
Results: The incidence of volume depletion events (events of hypotension, 
dehydration or hypovolaemia) was 1.1% with dapagliflozin and 0.7% with 
placebo. Most events were reported by investigators as being mild in intensity 
(0.7% and 0.4% respectively). Events in 3 dapagliflozin patients and 1 placebo 
patient were reported as severe by the investigator. Volume depletion events 
led to discontinuation in 2 dapagliflozin and 1 placebo recipient, and study 
drug interruption in 1 dapagliflozin and 0 placebo recipients. Events were 
slightly more frequent for both dapagliflozin and placebo in patients using 
antihypertensive therapies including diuretics, loop diuretics and angiotensin 
converting enzyme inhibitors/angiotensin II receptor blockers, in older pa-
tients and in patients with baseline estimated GFR ≥30-<60 mL/min/1.73m2 
(Table). Orthostatic hypotension was measured in 13.1% of dapagliflozin re-
cipients and 11.3% of placebo recipients, but reported as an adverse event in 
only 0.1% and 0.3%, respectively. Pollakiuria was reported in 2.1% and 0.7% 
of dapagliflozin and placebo recipients, respectively, and polyuria in 0.9% and 
0.2% of patients, respectively.
Conclusion: Volume depletion events and urinary volume events were 
slightly more common with dapagliflozin than placebo, predominantly in at-
risk subjects, but were mostly mild and did not lead to study discontinuation.
Clinical Trial Registration Number: NCT00263276; NCT00357370; 
NCT00528372; NCT00528879; NCT00683878; NCT00859898; NCT00680745; 
NCT00972244; NCT00673231; NCT00984867; NCT00855166; NCT01031680; 
NCT01042977
Supported by: BMS/AstraZeneca
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Empagliflozin, a selective SGLT2 inhibitor, ameliorated hyperglycaemia 
and insulin resistance, while preserving the integrity of pancreas and 
kidney in CRDH rats
F.M. Younis1, Z. Abassi2, E. Mayoux3, K.S. Hollander1, L. Rath-Wolfson4,  
T. Rosenthal1;  
1Physiology and Pharmacology Dept., Sackler School of Medicine,  
Tel Aviv University, 2Physiology and Biophysics, Ruth & Bruce Rappaport 
Faculty of Medicine, Haifa, Israel, 3Research Division, Boehringer Ingelheim 
Pharma GmbH & Co.KG, Biberach an der Riss, Germany,  
4Pathology, Hasharon Hospital, Tel Aviv, Israel.
Background and aims: Empagliflozin (EMPA), a selective sodium glucose 
cotransporter 2 inhibitor, in development for the treatment of diabetes, low-
ers blood glucose independently of ß-cell function and insulin resistance via 
urinary glucose excretion (UGE). The aim of this study was to evaluate its 
prophylactic effects on hyperglycemia and insulin resistance in diabetic hy-
pertensive rat model (CRDH rats).
Materials and methods: Cohen-Rosenthal diabetic hypertensive (CRDH) 
rats (n=36) were divided into 3 groups: sugar diet (SD) + EMPA (Empa), SD 
+ vehicle (Veh), regular chow + vehicle (Cont). Treatment + SD were intro-
duced concomitantly to animals 6-8 weeks old for 18 weeks. Treatment was 
added to drinking water and adjusted for drinking volume and body weight; 
daily dose of 10 mg/kg. Hyperglycemia and insulin were monitored and IP-
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GTT was performed at day 80 and 120 of treatment. Immunofluorescence 
analysis of nephrin in the renal cortex and H&E in the pancreas was per-
formed in the different experimental groups.
Results: Empa treatment enhanced significant (P<0.05) glucose excretion 
and associated urine volume as expected in comparison to control, reaching 
(>2000 vs. Veh <200 mg/dl, and 32.6 ± 3.9 vs. 15.1± 4.7ml P<0.01), respec-
tively. Post prandial and fasting hyperglycemia was significantly improved 
by Empa treatment, (P<0.05). Fasting insulin levels did not differ between 
groups however, a significant decrease (P<0.05) in obtained HOMA-IR was 
seen in the EMPA treated group vs. Veh and Cont groups. Empagliflozin re-
duced AUC of glucose during IPGTT at 80 and 120 days of treatment. At 
the end of treatment, EMPA preserved nephrin integrity in the kidney as-
sociated with a reduction of proteinuria but also prevented diabetes induced 
impairment of diaphragm structure. Pancreas H&E staining in empagliflozin 
treated group revealed an impressive decrease in fatty infiltration and atrophy 
in comparison to control.
Conclusion: In CRDH rat model, empagliflozin treatment was shown to re-
duce hyperglycemia, to improve insulin resistance and ameliorate diabetic 
induced kidney and pancreatic damage.
802
Long-term empagliflozin treatment preserves beta cell function in ageing 
ZDF rats
E. Pepin1, T. Sulpice1, M. Mark2, E. Mayoux2, T. Alquier1,3, V. Poitout1,3;  
1Betagenex Inc., Laval, Canada, 2Boehringer-Ingelheim, Biberach, Germany, 
3Montreal Diabetes Research Center, CRCHUM and Department of 
Medicine, Université de Montréal, Canada.
Background and aims: Type 2 diabetes (T2D) development is characterized 
by a progressive decline in β-cell function. Pharmacological interventions 
aimed at decreasing blood glucose levels by stimulating insulin secretion gen-
erally fail to prevent the decline of β-cell function and disease progression. 
With a mode of action independent of insulin secretion, SGLT2 inhibitors 
(SGLT2i) may interrupt the vicious cycle of β-cell exhaustion and delay or 
prevent the deterioration of β-cell function during the progression of T2D. 
The Zucker diabetic fatty (ZDF) rat is a preclinical T2D model exhibiting 
a rapid progression of the disease associated with early hyperinsulinemia 
followed by a decline in β-cell function leading to hypoinsulinemia and hy-
perglycaemia. We investigated whether empagliflozin, a potent and selective 
SGLT2i, could impact the disease progression of aging diabetic ZDF rats.
Materials and methods: 7-week-old ZDF rats were treated daily with empa-
gliflozin (10mg/kg per os) or vehicle for 6 or 14 weeks. Baseline values were 
established in 7-week-old untreated ZDF rats. Body weight, 2h-fasted gly-
caemia, insulinemia and HbA1c were measured at baseline and then weekly 
during the 6 or 14 weeks of treatment (treated rats). Hyperglycemic clamps 
were performed at baseline and after 5 and 13 weeks of treatment.
Results: Plasma glucose and HbA1c levels increased from 7.3 ± 0.2 mM 
(n=10) and 3.0 ± 0.0 % (n=10), respectively, to 27.8 ± 0.9 mM (n=9; p<0.001) 
and 10.7 ± 0.5 % (n=9; p<0.001) over the 14 weeks study duration in vehicle-
treated ZDF rats. In contrast, plasma glucose and HbA1c did not significant-
ly increase in empagliflozin-treated rats (blood glucose: 8.0 ± 0.3 mM at 14 
weeks vs. 7.0 ± 0.2 mM at 7 weeks, n=6, NS; HbA1c: 4.1 ± 0.2 % at 14 weeks 
vs. 3.0 ± 0.1 % at 7 weeks, n=6, NS). Insulin levels declined greatly in the 
vehicle-treated group from 229± 33 to 48 ± 4 uU/mL (n=6, p<0.001), while 
the decline was less pronounced in the empagliflozin group (from 237 ± 38 
to 116± 21 uU/mL, n=6, p<0.001). During hyperglycemic clamps after 14 
weeks treatment, plasma insulin levels (AUC) and maximal insulin release in 
response to arginine (AIRmax) were significantly higher in empagliflozin- vs. 
vehicle-treated groups (AUC: 174± 20 vs. 47 ± 4, n=4 and 5, p<0.001; AIR-
max: 130 ± 10 vs. 22 ± 4 ng/mL, n=4 and 5, p<0.001). Accordingly, C-peptide 
levels during the clamp were higher in empagliflozin-treated rats (5.6 ± 0.3 vs. 
2.7 ± 0.3 nmol/L, n=4 and 5, p<0.001).
Conclusion: Empagliflozin treatment delays the onset of hyperglycaemia in 
the aging ZDF rats by preserving insulin secretory capacity. This suggests that 
this new mode of action to decrease plasma glucose levels may prove benefi-
cial for T2D patients by preserving β-cell function during the progression of 
the disease.
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LX4211, a dual inhibitor of SGLT1/SGLT2, reduces postprandial glucose 
in patients with type 2 diabetes mellitus and moderate to severe renal 
impairment
P. Lapuerta, A. Sands, I. Ogbaa, P. Strumph, D. Powell, P. Banks,  
B. Zambrowicz;  
Lexicon Pharmaceuticals, Inc., The Woodlands, USA.
Background and aims: The prevalence of renal impairment (RI) in type 2 
diabetes mellitus (T2DM) is ≥20%. Since selective sodium-glucose co-trans-
porter 2 (SGLT2) inhibitors target only the kidney, they have reduced efficacy 
in T2DM patients with RI. Because LX4211 blocks both SGLT2-mediated 
renal glucose reabsorption and SGLT1-mediated gastrointestinal glucose ab-
sorption, it should benefit patients with T2DM and RI by significantly reduc-
ing postprandial glucose (PPG) levels.
Materials and methods: The primary objective was to evaluate the effect of 
LX4211 on 4-hour PPG AUC change from baseline to Day 7 in patients with 
T2DM and baseline renal function (eGFR) ≥15 and ≤59 mL/min/1.73 m2 
(calculated by MDRD). Patients (N=31) were randomly assigned to receive 
LX4211 (400 mg, n=16) or placebo (n=15) 15 minutes before a standard 
breakfast on 7 consecutive days. Glucose and GLP-1 were measured 15 min-
utes prior to breakfast and 1, 2, 2.5, 3, and 4 hours post breakfast at baseline 
and on Day 7.
Results: LX4211 significantly reduced mean PPG AUC(-15min - 4hr) by 169.3 
mg•hr/dL compared to placebo in all treated patients, p=0.003. In patients 
with baseline eGFR values <45 mL/min/1.73 m2, the LX4211-treated patients 
(N=5) had a 259.6 mg•hr/dL mean PPG reduction compared to the placebo 
patients (N=9), p=0.002. Compared to placebo, LX4211 also showed signifi-
cant elevations in the mean change in incremental AUC between baseline 
and Day 7 for total GLP-1 of 9.7 pmol•hr/L (p=0.017) and for active GLP-1 of 
4.7 pmol•hr/L (p=0.042) in all patients. There were no serious adverse events 
(SAEs) and no discontinuations due to AEs. There were 3 mild cases of hypo-
glycemia reported as treatment-emergent adverse events during the trial: 1 in 
the LX4211-treated patients and 2 in placebo patients.
Conclusion: These results indicate that LX4211 may enhance glycemic con-
trol in patients with moderate to severe RI.
Clinical Trial Registration Number: NCT01555008
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Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, does 
not increase risk of fractures
K.M. Johnsson1, A. Ptaszynska2, T.A. Mansfield2, A. Apanovitch2,  
E. Johnsson1, S.J. Parikh3, J.F. List2;  
1AstraZeneca, Mölndal, Sweden, 2Bristol-Myers Squibb, Princeton, 
3AstraZeneca, Wilmington, USA.
Background and aims: Observational studies have shown a higher risk of 
fractures in patients with type 2 diabetes mellitus (T2DM), and a higher inci-
dence of fractures versus comparator has been reported for the sodium-glu-
cose cotransporter-2 inhibitor (SGLT2) inhibitor canagliflozin. Dapagliflozin 
is a highly specific SGLT2 inhibitor improving glycaemic control in T2DM 
by reducing renal glucose reabsorption. Here we assess frequency of fractures 
across the dapagliflozin clinical trial programme.
Materials and methods: Data on fractures were pooled across 21 double-
blind, core phase IIb/III T2DM studies of up to 208 weeks’ duration (dapagli-
flozin N=5936; placebo N=3403). Long-term data from a placebo-controlled 
subset of this pool were also analyzed, overall and in the subgroups of pa-
tients at risk: with renal impairment (estimated GFR [eGFR] using modifica-
tion of diet in renal disease [MDRD] <60 mL/min/1.73m2), older patients, 
and women over 50 years old.
Results: Proportion of patients with fractures was numerically the same 
or lower in the dapagliflozin arms in all pools including patients at higher 
risk (Table). A dedicated study of patients with moderate renal impairment 
(eGFR by MDRD <60 mL/min/1.73m2) had an imbalance in fractures (8 in 
dapagliflozin 10 mg arm vs 0 in placebo arm). This was not confirmed in the 
pooled data set of patients with renal impairment.
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Conclusion: Consistent with the lack of effect on bone mineral density previ-
ously reported, in these pooled clinical data analyses dapagliflozin therapy 
was not associated with an increase in fractures overall or in subgroups at 
risk (i.e. older patients, postmenopausal women and patients with renal im-
pairment).
Clinical Trial Registration Number: 00263276, 00357370, 00528372, 00528879, 
00643851, 00663260, 00683878, 00736879, 00859898, 00976495, 00831779, 
01095653, 00660907, 00680745, 00972244, 00673231, 01294423, 00984867, 
00855166, 01031680, 01042977
Supported by: BMS/AstraZeneca
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Two-year efficacy and safety of dapagliflozin for patients with  
type 2 diabetes mellitus and a history of cardiovascular disease
I. Gause-Nilsson1, T.W. DeBruin2, J. Sugg2, S.J. Parikh2, E. Johnsson1,  
L.A. Leiter3;  
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca, Wilmington, USA, 
3University of Toronto, Canada.
Background and aims: Dapagliflozin (DAPA) is a selective sodium-glu-
cose co-transporter 2 inhibitor with glucuretic and osmotic diuretic effects. 
The benefit/risk profile of DAPA was evaluated in a double-blind, placebo 
(PBO)-controlled phase 3 study of patients (pts) with type 2 diabetes mellitus 
(T2DM) inadequately controlled on usual care and preexisting cardiovascu-
lar disease (CVD). Primary outcome results for 24 weeks (wks) plus a 28-wk 
extension were previously reported; here we report results for 104 wks.
Materials and methods: Pts (HbA1c 7%-10%) were randomised 1:1 to re-
ceive 10 mg/d DAPA or PBO for 24 weeks, followed by consecutive extension 
periods of 28 and 52 wks. Pts were stratified by age (< or ≥ 65 years [y]) and 
insulin (INS) use; INS doses were reduced by 25% at randomisation. Efficacy 
data for 104 wks (observed cases) are descriptive (mean [95% CI]); glycaemic 
end points exclude pts who received rescue therapy (DAPA, n=130 [27.5%]; 
PBO, n=245 [50.5%]).
Results: In the efficacy population (N=962), mean age was 64 y; 47% 
were ≥ 65 y. Mean T2DM duration was 13 y. CVD history was mainly 
CHD (76.5%); 93% of pts had a history of hypertension. Most pts re-
ported using 1 (45.4%) or 2 (34.7%) oral antihyperglycemic agents; 
60.5% of patients used INS, 20% as monotherapy. Of the 964 randomised 
pts, 157 (33.6%) and 162 (32.5%) in the DAPA and PBO groups, re-
spectively, were eligible to continue into the 52-week extension period. 
Over 104 wks DAPA maintained reductions vs PBO for HbA1c, body weight 
(BW), systolic blood pressure (SBP), and fasting plasma glucose (FPG) (Ta-
ble). Pts in the DAPA group showed a mean decrease of -8.7 IU/d in daily 
INS dose compared with PBO. A larger proportion of pts achieved a com-
bined reduction of HbA1c ≥ 0.5%, BW ≥ 3% and SBP ≥ 3 mm Hg with DAPA 
compared with PBO (4.2% vs 1.1%); proportions were lower in both groups 
compared with earlier time points. In the safety population (N=965), for 
DAPA vs (vs) PBO, ≥ 1 adverse event was observed in 77.0% vs 72.5% of 
pts, hypoglycaemic events in 30.7% (none major) vs 29.4% (2 major) of pts, 
and cardiac disorders in 10.0% vs 13.5% of pts, respectively. Events of genital 
infection were reported in 7.7% of DAPA vs 0.4% of PBO-treated pts; events 
of urinary tract infection were reported in 11.8% of DAPA vs 6.8% of PBO-
treated pts. For DAPA vs PBO, mean percent changes were 3.6 vs -2.0 mg/
dL in total cholesterol, 4.3 vs -1.3 mg/dL in HDL-C, and 5.5 vs -1.6 mg/dL in 
LDL-C, respectively.
Conclusion: When added to standard of care over 104 wks in older pts with 
advanced T2DM and preexisting CVD, DAPA treatment resulted in sus-
tained reductions in HbA1c, FPG, SBP, and BW. Safety and tolerability were 
similar to PBO, except for a small excess of genital and urinary infections.
Clinical Trial Registration Number: NCT01042977
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Safety and tolerability of empagliflozin (EMPA) in phase III trials and 
their extensions in patients with type 2 diabetes (T2DM)
M. Roden1, L. Merker2, A.V. Christiansen3, F. Roux4, S. Hantel5, A. Salsali6, 
G. Kim5, T. Meinicke5, S.S. Lund5, T. Hach5, H.J. Woerle5, U.C. Broedl5;  
1Institute for Clinical Diabetology, German Diabetes Center, Leibniz 
Center for Diabetes Research, Düsseldorf, 2Diabetes- und Nierenzentrum, 
Dormagen, Germany, 3Boehringer Ingelheim Danmark A/S, Copenhagen, 
Denmark, 4Boehringer Ingelheim France, Reims, France,  
5Boehringer Ingelheim, Ingelheim, Germany, 6Boehringer Ingelheim 
Pharmaceuticals Inc., Ridgefield, USA.
Background and aims: Four 24-week randomized, double-blind, Phase III 
trials assessed the efficacy and safety of EMPA vs placebo (PBO) as mono-
therapy, add-on to metformin, add-on to metformin plus sulphonylurea, and 
add-on to pioglitazone ± metformin in patients with T2DM. Patients had the 
option to continue in 52-week double-blind extension trials. We assessed the 
safety and tolerability of EMPA using pooled data from these trials.
Materials and methods: In every trial, patients received EMPA 10 mg, 
EMPA 25 mg, or PBO until the last patient who entered the extensions had 
been treated for 76 weeks. Data were pooled from 2477 patients (N=825 on 
PBO, N=830 on EMPA 10 mg, N=822 on EMPA 25 mg) of whom 68.6% were 
treated in the extensions. Adverse events (AEs) were assessed descriptively 
in patients who took ≥1 dose of study drug. AEs included confirmed hypo-
glycaemic AEs (plasma glucose ≤70mg/dl and/or requiring assistance), AEs 
consistent with urinary tract infection (UTI), genital infection and volume 
depletion, identified using prospectively defined searches of investigator-re-
ported AEs based on 77, 89 and 8 MedDRA preferred terms, respectively, and 
hepatic events identified from 4 Standardised MedDRA Queries.
Results: Total exposure was 1029, 1202 and 1162 patient-years in the PBO, 
EMPA 10 mg and EMPA 25 mg groups, respectively. The percentages of pa-
tients with any AE(s), with serious AE(s), and with AE(s) leading to treat-
ment discontinuation were similar in the PBO, EMPA 10 mg and EMPA 25 
mg groups (Table). Confirmed hypoglycaemic AEs were reported in slightly 
higher percentages of patients on EMPA 10 mg or EMPA 25 mg than PBO, 
but very few required assistance. Events consistent with UTI were reported by 
similar percentages of patients on PBO, EMPA 10 mg and EMPA 25 mg, and 
by more female than male patients. Events consistent with genital infection 
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were reported by a higher percentage of patients on EMPA than PBO, and 
by more female than male patients. AEs consistent with volume depletion 
were reported by 2 patients (0.2%) on PBO, 10 (1.2%) on EMPA 10 mg and 6 
(0.7%) on EMPA 25 mg. Bone fractures were reported by 21 patients (2.5%) 
on PBO, 16 (1.9%) on EMPA 10 mg and 10 (1.2%) on EMPA 25 mg. Hepatic 
events were reported by 28 patients (3.4%) on PBO, 15 (1.8%) on EMPA 10 
mg and 25 (3.0%) on EMPA 25 mg.
Conclusion: Based on assessment of AEs, EMPA 10 mg and EMPA 25 mg as 
monotherapy or add-on therapy for ≥76 weeks were well tolerated in patients 
with T2DM.
Clinical Trial Registration Number: NCT01289990
Supported by: Boehringer Ingelheim and Eli Lilly
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Reduced risk of hypoglycaemic events with dapagliflozin vs glipizide  
as add-on therapy in type 2 diabetes mellitus: 4-year data from a  
phase 3 study 
K. Rohwedder1, E. Johnsson2, S. Parikh3;  
1AstraZeneca, Wedel, Germany, 2AstraZeneca, Mölndal, Sweden, 
3AstraZeneca, Wilmington, USA.
Background and aims: Dapagliflozin (DAPA), a selective inhibitor of the 
sodium-glucose co-transporter 2, reduces plasma glucose by increasing renal 
glucose excretion. Its insulin-independent mechanism results in a low risk 
of hypoglycaemia in contrast to sulphonylureas. In a phase 3, randomised, 
double-blind trial of DAPA versus glipizide in combination with metformin 
(MET) in adults with type 2 diabetes mellitus inadequately controlled by 
MET alone (N=814), DAPA was associated with reduced hypoglycaemic 
events versus glipizide over 52 weeks. We now report the 4-year hypoglycae-
mia- and key safety-related data.
Materials and methods: The phase 3, randomised, double-blind trial of 
DAPA (≤ 10 mg/d) versus glipizide (≤ 20 mg/d) in combination with MET 
(median 2000 mg/d) was extended from 52 weeks to 4 years. DAPA and glip-
izide were down-titrated if medically indicated.
Results: At the start of the study, 406 patients were randomised to the DAPA 
arm and 408 patients to the glipizide arm. The 4-year study was completed 
by 161 patients in the DAPA arm and by 141 patients in the glipizide arm. 
Including data after rescue, the rate of hypoglycaemia was ~10-fold less with 
DAPA (Table). Most events were minor (capillary or plasma glucose < 3.5 
mmol/L [< 63 mg/dL]). The majority of hypoglycaemic events occurred dur-
ing the first year of treatment: in year 1, 3.4% versus 39.7%, year 2, 1.6% ver-
sus 23.6%, year 3, 1.5% versus 37.2%, and in year 4, 2.2% versus 28.4% in the 
DAPA and glipizide arms, respectively. Study medication was down-titrated 
in the DAPA arm only during year 1, and in only 2.7% of patients. In the 
glipizide arm, 15.8% of patients had a down-titration in year 1, 1.9% in year 
2, and 4.8% in years 3 and 4. Key adverse events are also shown in the Table. 
The effect of therapy on HbA1c attenuated over time in both arms, but DAPA 
showed more persistent benefits versus glipizide up to year 4 (Table).
Conclusion: Fewer patients experienced hypoglycaemic events over 4 years 
with DAPA than with glipizide as add-on therapy to MET. DAPA treatment 
in combination with MET was efficacious and well tolerated over a 4-year 
period.
Clinical Trial Registration Number: NCT00660907
Supported by: AstraZeneca/BMS
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Risk factors associated with treatment discontinuation and  
down-titration in type 2 diabetes patients treated with sulfonylureas
K. Iglay1, Y. Qiu1, C.-P. Fan2, Z. Li2, J. Tang2, P. Laires1;  
1Merck & Co., Inc., Whitehouse Station, 2Asclepius JT, New York, USA.
Background and aims: Sulfonylurea (SU) therapy can be discontinued or 
down-titrated for reasons such as hypoglycemia or weight gain. A retrospec-
tive cohort study using the MarketScan database was conducted to identify 
risk factors associated with therapy changes (ie, discontinuation or down-
titration).
Materials and methods: Patients (pts) were included when the following 
criteria were satisfied: first SU prescription (Rx) (index date) between 2009 
and 2011, ≥18 years of age on the index date, and ≥ 1 year continuous enroll-
ment pre- and post-index. Pts with type 1, gestational or secondary diabetes, 
insulin use before the index date, or ≥ 2 SUs on the index date were excluded. 
Therapy changes were determined during the 1 year post-index period. Dis-
continuation occurred when the gap between the end date of current SU fill 
and the start date of subsequent fill was ≥ 90 days apart. Down-titration oc-
curred when an SU fill had a lower equivalent dose than that on the index 
date. The Kaplan-Meier method was used to estimate 3- and 6-month therapy 
change rates. Cox regression was used to identify risk factors associated with 
therapy changes in hazard ratios (HRs).
Results: 104,082 pts were included, of which 55,233 (53.1%) experienced 
therapy changes in the 1-year post-index period. 3- and 6-month therapy 
change rates were 23.2% and 38.9%, respectively. Major risk factors associ-
ated with therapy changes were post-index hypoglycemic events (discon-
tinuation HR= 1.78 [1.68, 1.90], p<.01; down-titration HR=2.79 [2.40, 3.23], 
p<.01) and concomitant use of insulin (discontinuation HR= 1.48 [1.40, 
1.57], p<.01; down-titration HR=1.82 [1.56, 2.11], p<.01). Other risk factors 
include younger age, use of 2nd generation SUs, prior cardiovascular condi-
tions and liver disease.
Conclusion: More than half of type 2 diabetes pts who newly initiated SU 
therapy experienced discontinuation or down-titration within 1 year follow-
ing treatment initiation. Insulin use and hypoglycemic events elevated the 
risk of therapy changes.
809
Severe hypoglycaemia during treatment with sulphonylurea in patients 
with type 2 diabetes in the capital region of Copenhagen, Denmark
S. Pilemann-Lyberg1,2, B. Thorsteinsson3,4, O. Snorgaard5, M. Zander6,  
H. Vestergaard7,8, M.E. Røder9;  
1Department of Endocrinology, Gentofte Hospital, 2Diabetes complications 
research, Steno Diabetes Center, Gentofte, 32Department of Cardiology, 
Endocrinology and Nephrology, Nordsjællands Hospital, Hillerød, 
4University of Copenhagen, 5Department of Endocrinology, Hvidovre 
Hospital, 6Department of Endocrinology, Bispebjerg Hospital, 7Department 
of Endocrinology, Herlev Hospital, 8NNF-CBMR, Copenhagen, 
9Department of Medicin F, Gentofte Hospital, Denmark.
Background and aims: Sulphonylureas (SU) are still recommended as a well 
established second line treatment in current guidelines for type 2-diabetes 
(T2DM). 16.865 patients in the Capital Region of Copenhagen were given 
SU as part of their treatment of T2DM in 2010-2011. Hypoglycaemia is a 
well-known side-effect, however to what extent SUs are associated with hos-
pitalizations due to severe hypoglycaemic episodes, defined as episodes with 
a need for external assistance, less is known. The aim of the present study was 
to investigate the prevalence and characterize patients with type 2-diabetes 
treated with SU and hospitalized due to hypoglycaemia.
Materials and methods: All patients with ICD-10 diagnosis codes of hypo-
glycaemia and/or T2DM, in the hospital admittance register for a period of 
two years (2010-2011), were included. All hospitals in the Capital Region of 
Copenhagen were included. From the hospital records, patients who met 
the inclusion criteria were included in the analysis. Inclusion criteria were 
T2DM, hospitalization due to hypoglycemia and treatment with SU as mono-
therapy or in combination with other glucose-lowering drugs, excluding in-
sulin treatment.
Results: From the hospital admittance register we found 3.156 patients ad-
mitted to hospital with T2DM and/or hypoglycaemia. Of these, 163 patients 
fulfilled the inclusion criteria. The mean age was 76 (53-97) years and 54% 
were males. Nearly half of the patients were treated with SU monotherapy, 
45% were treated with SU and metformin and 6% with triple therapy. Among 
the patients, 74% were on glimepiride, 15% glibenclamide, 6% gliplizide and 
2% gliclazide treatment. Sixty percent of the patients had diabetic complica-
tions, including 19% with diabetic nephropathy. The major reason for the 
severe hypoglycaemic episodes was unchanged dose of SU despite of a signifi-
cant decline in food intake (57%). In 10% of the patients (over)use of other 
medications, such as benzodiazepine and opoid drugs were recorded. In 6% 
of the patients intoxication by alcohol was noted as reason. A concomitant in-
fection existed in 5%. In 22% of the patients more than one reason was listed, 
most common were unchanged dose of SU despite of a significant decline in 
food intake and concomitant infection. In 22%, the reason for hypoglycaemia 
was unknown.
Conclusion: In conclusion, the incidence of hospital admission-requiring 
severe hypoglycaemia in patients treated with SU seems relatively low (be-
low 1% of SU-treated patients). It was mainly older patients with diminished 
food intake, (over) use of alcohol or other medications, and with concomitant 
diabetic complications.
810
HNF1A and HNF4A mutations are associated with prolonged half-life of 
glibenclamide but not glipizide in human MODY subjects
J. Urbanova1,2, M. Anděl1,2;  
1Center for Research in Diabetes, Metabolism and Nutrition, 2nd 
Department of Internal Medicine, Prague, 2Third Faculty of Medicine, 
Charles University in Prague, Czech Republic.
Background and aims: Patients with Maturity Onset Diabetes of the Young 
(MODY), which is caused by mutations in the transcriptional factors HNF-
1α or HNF-4α, display a hypersensitivity to the hypoglycaemic effects of sul-
fonylurea derivatives. The transcriptional network, including HNF-1α and 
HNF-4α, synergistically up-regulates the transcriptional activity of human 
xenobiotic-inducible genes, such as CYP2C9, which ensures the biotransfor-
mation of sulfonylurea derivatives in the liver. We hypothesized that MODY-
associated HNF1A/HNF4A mutations induce the reduction of sulfonylurea 
derivatives clearance, thereby prolonging their action and promoting hyper-
sensitivity in affected patients.
Materials and methods: Single doses of 3mg glipizide and 5mg glibencla-
mide were administered sequentially to seven MODY subjects (six HNF1A-
MODY and one HNF4A-MODY) and six age- and BMI-matched individuals 
with the wild-type sequence of HNF1A/HNF4A exons. Pharmacokinetics 
(plasma concentration levels, Cmax, tmax, t1/2, AUC) and pharmacody-
namics parameters (glycaemia, C-peptide and insulin plasma levels) were 
followed for 24 hours after the drug administration. CYP2C9 genotype was 
tested in each subject.
Results: Following glipizide treatment, there were no significant decreases 
in any of the pharmacokinetic parameters as measured when comparing 
MODY and control subjects. In contrast, the responses to glibenclamide 
treatment displayed a prolonged t1/2 from 5.0±1.4h in control subjects to 
9.5±6.7h in HNF1A/HNF4A MODY subjects (p = 0.04). When focusing on 
pharmacodynamics, we observed a differential response in control subjects 
to the doses of glipizide and glibenclamide applied. However, this differential 
response was not achieved in MODY subjects, suggesting a partially different 
mechanism of action of glipizide and glibenclamide.
Conclusion: It was only prolonged half-life of glibenclamide, but not glip-
izide, which we observed in HNF1A/HNF4A MODY subjects compared to 
control subjects. Importantly, the response of individual MODY subject to 
glipizide or glibenclamide treatment was highly correlated with each other 
(but not in control subjects), thereby providing a novel platform for the ap-
plication of personalized medicine. Further research on the mutation-specific 
responses of HNF1A or HNF4A MODY subjects is needed.
Clinical Trial Registration Number: UNCE 204015 and PRVOUK P31/2012, 
NT13663-3/2012
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Impact of hypoglycaemic events and HbA1c level on SU discontinuation 
and down-titration 
Y. Qiu1, P. Laires1, C.-P. Fan2, Z. Li2, J. Tang2, K. Iglay1;  
1Merck & Co., Inc., Whitehouse Station, 2Asclepius JT, New York, USA.
Background and aims: A retrospective cohort study using GE Centricity 
electronic medical records (EMR) was conducted to assess the association 
of hypoglycemic events and HbA1c level with discontinuation and down-
titration of sulfonylureas (SUs) among patients with type 2 diabetes mellitus 
(DM).
Materials and methods: Patients with ≥12 months EMR activity before and 
after initial SU prescription (index date) in 2010 - 2012 were included. Pa-
tients were excluded if they had type 1, gestational or secondary DM, re-
ceived insulin before the index date, used ≥2 SUs on the index date, or had 
incomplete prescription data in 1 year post-index. Discontinuation occurred 
when consecutive SU prescriptions (Rx) were ≥90 days apart. Down-titration 
occurred when a subsequent SU Rx had a lower equivalent dose than the 
index dose. Post-index hypoglycemic events (identified using ICD-9 codes) 
occurred after the index date and before therapy changes or the end of the 
1 year post-index. Multivariate Cox regression was used to assess the asso-
ciation of post-treatment hypoglycemic events and HbA1c with discontinu-
ation/down-titration.
Results: 28,371 patients were included in the study, of which 13,459 (47.4%) 
were discontinuers, 717 (2.5%) down-titraters, and 14,195 (50.0%) continu-
ers. 0.6% of the continuers had hypoglycemic events in the 1 year post-in-
dex period, compared to 3.1% of down-titraters and 0.8% of discontinuers 
(p<0.01). Patients with hypoglycemic events were at higher risk for discon-
tinuation (HR = 1.82, [1.47, 2.23]; p<0.01) and down-titration (HR = 4.25, 
[1.92, 8.03]; p<0.01). Patients with higher post-index HbA1c levels or use of 
2nd generation SUs (vs. 3rd generation) were at higher risk of discontinuation 
(HR= 1.05 [1.04, 1.06], and HR= 1.19 [1.14, 1.24] respectively, both p<0.01).
Conclusion: Hypoglycemic events were a significant risk factor for SU dis-
continuation or down-titration. Higher HbA1c levels were significantly as-
sociated with SU discontinuation.
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Efficacy and safety of trelagliptin, a novel once-weekly oral DPP-4 
inhibitor: a phase 3, double-blind, non-inferiority study in Japanese  
type 2 diabetes mellitus patients
N. Inagaki1, H. Onouchi2, H. Sano2, S. Kuroda2, K. Kaku3;  
1Department of Diabetes, Endocrinology and Nutrition, Kyoto University 
Graduate School of Medicine, 2Pharmaceutical Development Division, 
Takeda Pharmaceutical Company Limited, Osaka,  
3Kawasaki Medical School, Okayama, Japan.
Background and aims: There are some options of oral hypoglycaemic agents 
for type 2 diabetes mellitus (T2DM). In patients with T2DM, improving 
adherence to medication is important in order to maintain favourable gly-
caemic control during long-term treatment and, thus prevent the onset or 
aggravation of complications. Trelagliptin is a novel dipeptidyl peptidase-4 
(DPP-4) inhibitor, which is currently under development as a once-weekly 
oral hypoglycaemic agent. A phase 1 single-dose study (3.125 mg to 800 mg) 
and a multiple-dose study (100 mg or 200 mg) in healthy adult subjects were 
completed, and a dose-dependent increase in pharmacokinetic parameter 
values was observed. Sustained Inhibition of DPP-4 activity up to 168 hours 
after administration was also observed. Furthermore, a phase 2 dose-rang-
ing study (12.5 mg to 200 mg; once-weekly for 12 weeks) in T2DM patients 
showed a statistically significant HbA1c reduction at all doses compared with 
placebo. Based on these results, a phase 3 study in T2DM patients was con-
ducted to evaluate the efficacy and safety of once-weekly trelagliptin treat-
ment compared with a daily DPP-4 inhibitor (alogliptin).
Materials and methods: This was a phase 3, multicentre, randomised, dou-
ble-blind, parallel-group, non-inferiority study to evaluate the efficacy and 
safety of trelagliptin 100 mg once-weekly for 24 weeks with alogliptin 25 mg 
daily as a comparator in Japanese T2DM patients with inadequate glycaemic 
control despite diet and/or exercise therapy. A placebo group was also set as 
a reference group. Patients were randomly assigned (allocation ratio 2:2:1) to 
receive either trelagliptin, alogliptin or placebo. The primary endpoint was 
the change from baseline in HbA1c at the end of the treatment period.
Results: A total of 243 patients were enrolled to receive trelagliptin (n=101), 
alogliptin (n=92), or placebo (n=50). Baseline characteristics were as fol-
lows: mean age (SD) of 58.9 (10.39) years, mean BMI of 24.96 (4.161) kg/m2 
and mean HbA1c of 7.78 (0.837) %. There was no major difference among 
the treatment groups. At the end of the treatment period, the least square 
mean difference (trelagliptin - alogliptin) of change from baseline in HbA1c 
was 0.11% (95% CI: -0.054 to 0.281). Non-inferiority of trelagliptin group 
to alogliptin Group was attained. Additionally, HbA1c was decreased sig-
nificantly in the trelagliptin and alogliptin groups compared to the placebo 
group at the end of the treatment period (p<0.0001). Inhibition rate of DPP-4 
activity was also measured, and trelagliptin group showed sustained inhibi-
tion of DPP-4 activity throughout the treatment period. The frequency of 
adverse events in the trelagliptin group was similar to those in alogliptin and 
placebo groups. No hypoglycaemia was reported in trelagliptin group. Once-
weekly treatment with trelagriptin was well tolerated and no major concern 
was seen.
Conclusion: In this study, once-weekly trelagliptin treatment was as effective 
as a daily DPP-4 inhibitor, alogliptin, and was well-tolerated over 24 weeks. It 
may provide a new treatment option for T2DM patients.
Clinical Trial Registration Number: NCT01632007
Supported by: Takeda Pharmaceutical Company Limited
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Cost-effectiveness of metformin plus vildagliptin versus metformin plus 
sulphonylurea for the treatment of type 2 diabetes patients in Portugal
D. Viriato1, F. Calado2, J.-B. Gruenberger2, S.H. Ong2, D. Carvalho3,  
J. Silva-Nunes4, S. Johal5, R. Viana1;  
1Novartis Farma SA, Porto Salvo, Portugal, 2Novartis Pharma AG, Basel, 
Switzerland, 3Faculty of Medicine, São João Hospital, Porto, 4Curry Cabral 
Hospital, Lisbon, Portugal, 5HERON Commercialization, London, UK.
Background and aims: The objective of the study is to evaluate the cost-ef-
fectiveness of vildagliptin plus metformin compared with generic sulphony-
lurea plus metformin in patients with type 2 diabetes mellitus, not controlled 
with metformin, from a Portuguese healthcare system perspective.
Materials and methods: A cost-effectiveness model was constructed using 
risk equations from the United Kingdom Prospective Diabetes Study Out-
comes Model with a 10,000-patient cohort and a lifetime horizon. The model 
predicted microvascular and macrovascular complications and mortality in 
yearly cycles. Patients, who entered the model as metformin monotherapy 
failures, were modelled as switching to alternative treatments (metformin 
plus basal-bolus insulin and subsequently metformin plus intensive insulin) 
using a threshold of glycated haemoglobin A1c >7.5% for inadequate gly-
caemic control. Baseline patient characteristics and clinical variables were 
derived from a Portuguese epidemiological study. Costs estimates were based 
on direct medical costs only. One-way and probabilistic sensitivity analyses 
were conducted to test the robustness of the model assumptions.
Results: Over a lifetime horizon, there were fewer non-fatal diabetes-related 
adverse events (AEs) in patients treated with metformin plus vildagliptin 
compared with patients treated with metformin plus sulphonylurea (6752 
versus 6815). Addition of vildagliptin compared with sulphonylurea led to 
increased drug acquisition costs counterbalanced with reduced costs of AEs, 
managing morbidities, and monitoring patients. Treatment with metformin 
plus vildagliptin yielded a mean per-patient gain of 0.1279 quality-adjusted 
life years (QALYs) and a mean per-patient increase in total cost of €1161, giv-
ing an incremental cost-effectiveness ratio (ICER) of €9072 per QALY. Uni-
variate analyses showed that ICER values were robust and ranged from €4195 
to €16,052 per QALY when different parameters were varied. The Probabil-
istic Sensitivity Analysis suggested that, for a willingness-to-pay threshold 
of €30,000 per QALY, treatment with metformin plus vildagliptin had a 79% 
probability of being cost-effective compared with metformin plus sulphony-
lurea.
Conclusion: Treatment with metformin plus vildagliptin compared with 
metformin plus sulphonylurea is expected to result in a lower incidence of 
diabetes-related AEs and to be a cost-effective treatment strategy.
Supported by: Novartis
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Predictors of glycaemic response to add-on therapy with  
a DPP-IV inhibitor: a retrospective cohort study using the primary care 
THIN database
J. Mamza1, R. Mehta2, R. Donnelly1, I. Idris1;  
1School of Medicine,  
2Trent Research Design Services, University of Nottingham, UK.
Background and aims: Apart from baseline HbA1c, little is known about 
clinical or biochemical factors that affect the magnitude of the glycaemic re-
sponse to a DPP-IV inhibitor when used in routine practice as part of com-
bination therapy in patients with type 2 diabetes. Similarly, there is limited 
information about the effectiveness of a DPP-IV inhibitor in different drug 
combinations. These subjects were investigated using a large UK Primary 
Care database.
Materials and methods: A cohort of 25,183 patients with type 2 diabetes, 
newly treated with a DPP-IV inhibitor between June 2007 and May 2013, 
was sourced from UK General Practices via the Health Initiative Network 
(THIN) database. The index date was defined as the date of initiation of DPP-
IV inhibitor therapy. Baseline clinical parameters of patients with suboptimal 
glucose control (HbA1c>6.5% or 48mmol/mol) 6 months or more after start-
ing a DPP-IV inhibitor in combination with other glucose-lowering therapy 
(n=17,697) were compared against 12-months follow-up data using multi-
variate logistic regression. Response to DPP-IV inhibitor therapy was defined 
as HbA1c <6.5% and/or >1% (13mmol/mol) reduction at 12 months. A com-
parative analysis of on-treatment effects of various combination regimens 
were examined using a propensity score matching technique. Associations 
were examined using t test and Chi squared test.
Results: Among patients whose glucose-lowering therapy was intensified by 
co-administration of a DPP-IV inhibitor, independent predictors of response 
were baseline HbA1c [1.57, 95%CI (1.53-1.61)], and use of metformin [1.31, 
95%CI (1.20-1.44)] and aspirin [1.14, 95%CI (1.06-1.23)]. The independ-
ent predictors of non-response included obesity [0.82, 95%CI (0.72-0.93)], 
previous hypoglycaemia events [0.84, 95%CI (0.77-0.93)], total cholesterol 
level [0.94, 95%CI (0.90-0.97)], concurrent use of lipid lowering drugs [0.88, 
95%CI (0.81-0.97)], and combination therapy involving metformin, sulpho-
nylurea and thiazolidinediones (TZDs) [0.80, 95%CI (0.70-0.91)]. Overall, 
intensification of therapy with the addition of a DPP-IV inhibitor resulted 
in significant reductions in HbA1c (0.5%, 6.5mmol/mol), body weight (1Kg) 
and total cholesterol 0.1mmol/L (p<0.001). Using propensity score analysis, 
the addition of a DPP-IV inhibitor to metformin monotherapy yielded a 5% 
greater glycaemic effect [1.05, 95%CI (1.02-1.07)] compared with other regi-
mens, while adding a DPP-IV inhibitor to Metformin+Sulphonylurea+TZD 
had a negative effect on glucose control [0.95, 95%CI (0.93-0.98)].
Conclusion: This large Primary Care database shows that in routine clini-
cal practice the glycaemic response to a DPP-IV inhibitor is greatest in pa-
tients concurrently receiving metformin and aspirin and those with higher 
baseline HbA1c. Lower responses were observed in those on triple therapy 
(Met+SU+TZD) and with previous hypoglycaemic events. Serum lipids and 
statin therapy may also influence the response to a DPP-IV inhibitor.
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Efficacy and safety of initial therapy with linagliptin and pioglitazone 
fixed-dose combinations versus monotherapy with pioglitazone or 
linagliptin
S. Weber-Born1, M. Nauck2, S. Patel3, M. Kobe4, R. Toorawa3, H.-J. Woerle1;  
1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim,  
2Diabetes Centre Bad Lauterberg, Harz, Germany,  
3Boehringer Ingelheim Ltd, Bracknell, UK,  
4Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA.
Background and aims: Targeting the core defects in type 2 diabetes (T2D) 
by combining oral antidiabetes drugs (OAD) with different mechanisms of 
action may produce additive improvements in glycaemic control. This study 
evaluated the efficacy and safety of fixed-dose combinations (FDC) of the 
DPP-4 inhibitor linagliptin (LINA) plus the thiazolidinedione pioglitazone 
(PIO) vs LINA or PIO monotherapy.
Materials and methods: This multicentre, double-blind, parallel group, 
phase 3 study randomised 936 T2D patients with insufficient glycaemic con-
trol to 1 of 7 treatment arms: LINA+PIO FDC (LINA5 mg plus PIO15, 30, or 
45 mg) or monotherapy with LINA5 mg or PIO15, 30, or 45 mg. An initial 
30-wk treatment (Part A) was followed by a 54-wk extension (Part B; 557 
patients) in which LINA+PIO FDC (LINA5 mg plus PIO30 or 45 mg) were 
further assessed vs LINA5 mg or PIO30 or 45 mg monotherapy. The primary 
endpoint was HbA1c change from baseline after 30 wks (FAS LOCF).
Results: At baseline, 54.8% were male, 85.1% were white, mean ± sd age was 
57 ± 11 yrs, and weight was 93.1 ± 19.5 kg. In the full analysis set (n=893), 
68.1% had T2D for ≤5 years, 33.9% received ≥1 prior OAD, and mean ± sd 
HbA1c was 8.1 ± 0.9%. The FDC arms had larger decreases from baseline 
after 30 wks in HbA1c than the respective monotherapies (Part A; Figure). At 
84 wks (Part B), mean ± sd change from baseline in HbA1c ranged from -0.61 
± 0.61% (LINA; n=12) to -1.30 ± 0.78% (LINA+PIO45 FDC; n=15). In pa-
tients with baseline HbA1c ≥7.0%, each FDC arm was more likely than LINA 
monotherapy to achieve HbA1c <7.0% at wk 30 (p<0.001); in the comparison 
vs PIO monotherapy, only LINA+PIO45 FDC was more likely than PIO45 to 
achieve HbA1c <7.0% (p=0.0254). Adjusted mean ± se changes from baseline 
after 30 wks in FPG ranged from -0.08 ± 0.19 mmol/l (LINA) to -1.95 ± 0.19 
mmol/l (LINA+PIO45 FDC). Adjusted mean ± se body weight changes were 
lower with LINA monotherapy (-0.62 ± 0.76 kg) and FDC (range: +0.63 ± 
0.70 kg to +1.50 ± 0.74 kg) than with PIO monotherapy (range: +1.53 ± 0.78 
kg to +3.24 ± 0.73 kg). In the safety analysis (up to 84 wks from Parts A and 
B combined), frequencies of overall AEs and serious AEs ranged from 65.7% 
(PIO30) to 74.6% (PIO45) and 3.6% (PIO45) to 11.3% (LINA+PIO30 FDC), 
respectively. Drug-related AEs ranged from 11.1% (LINA+PIO15/30 FDC) 
to 16.5% (LINA+PIO45 FDC). Predefined AEs of oedema ranged from 4.4% 
(LINA) to 12.8% (LINA+PIO45 FDC). One on-treatment fatality was report-
ed (PIO45). Frequency of investigator-reported hypoglycaemia was ≤1.5% 
per arm. One patient had severe hypoglycaemia (LINA+PIO15/30 FDC).
Conclusion: FDC therapy with LINA+PIO was well tolerated with no new 
safety concerns compared with the known safety profiles of the individual 
monotherapies and had possible additive effects on glycaemic control; in ad-
dition, LINA attenuated the weight gain effects of PIO.
Clinical Trial Registration Number: NCT01183013
Supported by: Boehringer Ingelheim
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Vildagliptin as add-on to insulin improves glycaemic control without 
increased risk of hypoglycaemia in Asian (predominantly Chinese) 
patients with type 2 diabetes mellitus
G. Ning1, W. Wang1, L. Li2, J. Ma3, X. Lv4, M. Yang5, W. Wang5,  
M. Woloschak6, V. Lukashevich6, W. Kothny7;  
1Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, 
2Shengjing Hospital of China Medical University, Shenyang, 3Nanjing First 
Hospital, 4General Hospital of Beijing Military Region, 5Beijing Novartis 
Pharma Co., Ltd., Shanghai, China, 6Novartis Pharmaceuticals Corporation, 
East Hanover, USA, 7Novartis Pharma AG, Basel, Switzerland.
Background and aims: There are limited data from randomized controlled 
trials evaluating the efficacy and safety of oral antidiabetic drugs in combina-
tion with insulin in Asian patients with T2DM, who may be at higher risk of 
hypoglycaemia due to lower weight and increased insulin sensitivity. Here 
we present the efficacy and safety of vildagliptin in combination with insulin 
with or without metformin from a dedicated Asian study in a predominantly 
Chinese population with T2DM.
Materials and methods: In this 24-week, multicentre, double-blind, place-
bo-controlled trial, patients with T2DM inadequately controlled (HbA1c 
7.5-11.0%) on stable therapy with long-acting, intermediate-acting or pre-
mixed insulin, with or without concomitant metformin were randomized to 
receive vildagliptin 50 mg bid (n=146) or placebo (n=147). The primary effi-
cacy endpoint was change in HbA1c from baseline to week 24. Key secondary 
endpoints included change in FPG and the proportion of patients achieving 
HbA1c <7.0%. Safety and tolerability were also assessed.
Results: Of the 293 randomized patients, 276 completed the study. The de-
mographic and baseline characteristics of patients were comparable between 
the groups. At baseline the mean age of patients was 58.1 years, mean T2DM 
duration was 11.3 years, mean FPG was 9.5 mmol/L, mean BMI was 26.1 kg/
m2 and mean HbA1c was 8.7%. At baseline, 71% of patients were on stable 
metformin therapy. The mean doses of insulin and metformin were 32.5 U/
day and 1587.7 mg/day, respectively. After 24 weeks vildagliptin showed a 
clinically relevant and statistically significant reduction in HbA1c vs. placebo 
(-1.1% vs. -0.4%, respectively; p<0.001). The decrease in FPG from baseline 
was numerically higher in the vildagliptin group than in the placebo group 
(-0.72 mmol/L vs. -0.28 mmol/L; p=0.250). The proportion of patients achiev-
ing HbA1c <7.0% was significantly higher in the vildagliptin group than in 
the placebo group (23.6% vs. 11.1%, p<0.005). The overall incidences of ad-
verse events were 43.8% vs. 46.3% and serious adverse events were 3.4% vs. 
6.8% in the vildagliptin and placebo groups, respectively. Hypoglycaemia was 
less frequent with vildagliptin (n=4, 2.7%) than with placebo (n=8, 5.4%); 
one patient in the placebo group reported a severe hypoglycaemic event. No 
deaths were reported during the study.
Conclusion: In Asian (predominantly Chinese) patients with T2DM inad-
equately controlled on insulin (with or without metformin), the addition of 
vildagliptin 50 mg bid significantly improved glycaemic control without an 
increased risk of hypoglycaemia. Vildagliptin is an attractive treatment for 
these patients.
Clinical Trial Registration Number: NCT01582230
Supported by: Novartis
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The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) 
as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) 
in the UK
G. Thompson1, M. Schroeder1, C. Neslusan2, M. Willis3, P. Johansen3,  
A. Teschemaker2;  
1Janssen UK, High Wycombe, UK, 2Janssen Global Services, LLC, Raritan, 
USA, 3The Swedish Institute for Health Economics, Lund, Sweden.
Background and aims: CANA is a novel treatment for T2DM that inhibits 
the sodium glucose co-transporter 2, a mechanism that is complementary 
to other anti-hyperglycemic drug classes, including insulin. In a previously 
reported analysis of a randomized, double-blind, active-controlled, Phase 
3 study in 756 subjects inadequately controlled on dual therapy with met-
formin (MET) and sulfonylureas (SU), CANA 300mg demonstrated statisti-
cal superiority compared to SITA 100mg in lowering HbA1C at 52 weeks 
(-1.03% [-11.3 mmol/mol] and -0.66% [-7.2 mmol/mol], respectively; least 
squares mean difference -0.37% [95% CI, -0.50 to -0.25] or -4.0 mmol/mol 
[-5.5 to -2.7]). CANA 300mg also significantly reduced systolic blood pres-
sure (SBP) and body weight (BW) versus SITA 100mg (SBP: -5.1 mmHg; 0.9 
mmHg), (BW: -2.5%; 0.3%). The objective of this study was to evaluate the 
long-term cost-effectiveness of using CANA 300mg versus SITA 100mg as an 
add-on therapy in patients inadequately controlled on a background of MET 
plus SU in the UK.
Materials and methods: Outcomes and costs associated with CANA 300mg 
versus SITA 100mg in triple therapy with background MET plus SU were 
simulated over 40 years using ECHO (Economic and Health Outcomes)-
T2DM, a validated micro-simulation model. Treatment effects (HbA1C, BW, 
SBP, LDL and HDL cholesterol) and incidence of adverse events (AEs) were 
sourced from the trial. Simulated treatment was intensified when HbA1C 
exceeded 7.5% by adding basal insulin, and subsequently prandial insulin. 
Costs and quality of life impacts associated with the development of mi-
cro- and macro-vascular events and AEs were adapted to the UK setting. In 
the base case, initial patient characteristics were sourced from the trial. In 
a second simulation, initial patient characteristics were based on a sample 
of patients with T2DM in the THIN (The Health Improvement Network) 
database, a large anonymised primary care electronic medical record data 
resource representative of UK population.
Results: In the base case simulation, use of CANA 300mg versus SITA 100mg 
as an add-on in patients inadequately controlled on MET plus SU increased 
Quality-Adjusted Life-Years (QALYs) (0.04). Total lifetime treatment costs 
for CANA 300mg were marginally higher (£671), yielding an incremental 
cost-effectiveness ratio (ICER) of £17,813. The scenario that used baseline 
patient characteristics from the UK THIN database also yielded an increase 
in QALYs (0.02), with a corresponding ICER of £17,968.
Conclusion: The magnitudes of the ICERs estimated in these simulations are 
below the current threshold used in the UK to assess whether an interven-
tion is cost-effective. As such, treating patients inadequately controlled on 
MET plus SU with CANA 300mg is likely to be a more efficient use of limited 
health care resources compared to using SITA 100mg.
Clinical Trial Registration Number: NCT01137812
Supported by: Janssen UK
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Effect of empagliflozin compared with glimepiride as add-on to 
metformin for 2 years on the amount and distribution of body fat in 
patients with type 2 diabetes
G. Kim1, M. Ridderstråle2, K.R. Andersen3, C. Zeller4, H.J. Woerle1,  
U.C. Broedl1;  
1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 
2Steno Diabetes Center, Gentofte, Denmark, 3Boehringer Ingelheim Norway 
KS, Asker, Norway, 4Boehringer Ingelheim Pharma GmbH & Co. KG, 
Biberach, Germany.
Background and aims: In a randomized, double-blind, Phase III trial in 
patients with type 2 diabetes (T2DM), the SGLT2 inhibitor empagliflozin 
(EMPA) 25 mg qd as add-on to metformin for 104 weeks led to significant 
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and sustained reductions in body weight compared with an increase in body 
weight with glimepiride (GLIM). Patients had the option to participate in a 
dedicated body composition sub-study in which we aimed to determine the 
effects of EMPA vs GLIM on the amount and distribution of body fat.
Materials and methods: Body composition was evaluated in 91 randomised 
patients in the sub-study. Using whole body dual energy X-ray absorptiom-
etry (DXA), changes from baseline to week 52 and week 104 in trunk fat, 
limb fat, total fat mass and fat-free mass were assessed in 62 patients (36 re-
ceiving EMPA and 26 receiving GLIM). Using magnetic resonance imaging 
(MRI), changes from baseline to week 52 and week 104 in abdominal vis-
ceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT) 
were assessed in 51 patients (29 receiving EMPA and 22 receiving GLIM). 
Changes from baseline were evaluated using mixed model repeated measures 
(MMRM) analyses.
Results: In the 91 patients evaluated in the sub-study, baseline mean [SD] age 
was 55.7 [10.4] years, weight was 85.1 [14.7] kg, BMI was 31.9 [4.9] kg/m2 and 
60% had BMI ≥30 kg/m2. EMPA significantly reduced trunk fat, limb fat and 
total fat mass vs GLIM at week 52 and week 104 (table). EMPA also signifi-
cantly reduced fat-free mass vs GLIM at week 52 but not at week 104 (table). 
Adjusted mean (SE) changes from baseline in abdominal VAT at week 52 
were -15.5 (5.2) cm2 with EMPA compared with +10.0 (6.1) cm2 with GLIM 
(p<0.01) and at week 104 were 16.0 (8.4) cm2 with EMPA compared with 
+17.7 (10.0) cm2 with GLIM (p<0.05). Adjusted mean (SE) changes from 
baseline in abdominal SAT at week 52 were 29.9 (7.3) cm2 with EMPA com-
pared with +25.8 (8.6) cm2 with GLIM (p<0.001) and at week 104 were 32.5 
(9.2) cm2 with EMPA compared with +34.4 (10.7) cm2 with GLIM (p<0.001).
Conclusion: When used as add-on to metformin, treatment with EMPA led 
to reductions in trunk fat, limb fat, abdominal VAT and SAT at week 52 and 
further reductions at week 104 compared with GLIM. Reductions in fat-free 
mass with EMPA vs GLIM were observed at week 52 but not at week 104.
Clinical Trial Registration Number: NCT01167881
Supported by: Boehringer Ingelheim and Eli Lilly
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Empagliflozin decreases inflammation and AGE/RAGE markers in the 
aortic vessel wall of a streptozotocin type 1 diabetic model
S. Steven1, M. Oelze1, S. Kröller-Schön1, P. Welschof1, Y. Mikhed1,  
S. Abgdauletova1, E. Schulz1, E. Mayoux2, T. Münzel1, A. Daiber1;  
1Department of Cardiology, 2nd Medical Clinic of the University Medical 
Center, Mainz, 2Boehringer Ingelheim Pharma GmbH & Co. KG, 
CardioMetabolic Diseases Research, Ingelheim, Germany.
Background and aims: Hyperglycemia and associated glucotoxicity is a ma-
jor cause of vascular complication in patients with Type 1 and Type 2 dia-
betes. Pharmacological interventions, aiming to decrease blood glucose via 
stimulation of glucose entry in the tissues appeared unsuccessful to decrease 
significantly the cardiovascular complications and associated mortality. 
SGLT2 inhibitors may interrupt the vicious cycle of maintaining glucotoxic-
ity within the tissue in particular in the vessel walls by excreting glucose out 
of the body rather than pushing it back into the tissue. Therefore we investi-
gated whether empagliflozin, a potent and selective SGLT2 inhibitor has the 
potential to decrease the inflammation and AGE/RAGE signalling in aortic 
vessel wall of streptozotocin (STZ) type 1 animal model.
Materials and methods: Type 1 diabetes in Wistar rats was induced by an 
intravenous injection of STZ (60mg/kg). One week after injection, empagli-
flozin was administered via drinking water at two doses (10mg/kg Lo dose, 
and 30mg/kg Hi dose) for 8 weeks. Two control groups were run in parallel, 
non-diabetic animals and diabetic animals treated with solvent in drinking 
water. At the end of treatment, animals were scarified and blood sample and 
aortic vessel wall collected for analysis. Glucose and methylgloxal (by HPLC) 
were determined in blood. In vessel wall, several markers of inflammatory 
pathway, AGE-positive protein, RAGE expression, were determined by quan-
titative rtPCR or western blot analysis.
Results: Plasmatic glucose and HbA1c were significantly decreasing in a dose 
dependant manner with empagliflozin treatments. The expression of the NA-
DPH oxidase isoforms Nox1 and Nox2 as well as the general stress response 
enzyme heme oxygenase-1 (HO-1) was increased in diabetes and significant-
ly reduced by SGLT2i therapy. Aortic RAGE expression and levels of AGE-
positive proteins was increased in the STZ group and normalized by SGLT2i 
therapy. In line with this, serum levels of the AGE precursor methylglyoxal 
were significantly increased in the STZ group and improved by SGLT2i ther-
apy. The inflammatory genes monocyte chemoattractant protein-1 (MCP-1, 
CCL-2), the monocyte/macrophage-specific protein CD68 and the cytokine 
interleukin-6 (IL-6) were up-regulated at the mRNA level in the aorta and 
significantly reduced by both SGLT2i doses. Likewise the immune-signaling 
proteins interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and the gen-
eral markers of inflammation, cyclooxygenase-2 (COX-2) or intercellular ad-
hesion molecule-1 (ICAM-1) were all up-regulated in STZ-treated rats and 
reduced by SGLT2i therapy.
Conclusion: These results show that the specific SGLT2 inhibitor, empagli-
flozin, by decreasing blood glucose via its excretion in urine is able to de-
crease several markers of oxidative stress, inflammation and AGE/RAGE 
signaling in aortic vessel wall of Type 1 diabetic animals. Therefore these re-
sults support the improvement of endothelial function that we have observed 
with empaglilozin in this model and are very promising in term of long term 
effects of empagliflozin on cardiovascular complications. Ongoing cardiovas-
cular trials in Type 2 diabetic population will address this question.
Supported by: Boehringer Ingelheim
820
Predicted temporal changes in energy intake and energy expenditure in 
subjects with type 2 diabetes treated with canagliflozin
D. Polidori1, A. Sanghvi2, R. Seeley3, K. Hall2;  
1Janssen Research & Development, LLC, San Diego,  
2National Institute of Diabetes and Digestive and Kidney Diseases,  
National Institutes of Health, Bethesda, 3University of Cincinnati, USA.
Background and aims: Canagliflozin (CANA), an SGLT2 inhibitor approved 
for the treatment of type 2 diabetes, reduces plasma glucose concentrations 
by increasing urinary glucose excretion (UGE), with sustained increases in 
UGE of ~80-120 g/day (~320-480 kcal/day) observed with CANA treatment. 
CANA treatment also induces weight loss, with body weight (BW) decreas-
ing for approximately 26 weeks before reaching a new, lower steady-state BW 
that is maintained with sustained CANA treatment. Data from animal studies 
and small short-term studies in humans suggest that energy intake (EI) is 
increased in response to SGLT2 inhibition. The aim of this analysis was to 
calculate the temporal changes in energy expenditure (EE) and EI that occur 
with CANA treatment.
Materials and methods: Data from a 52-week Phase 3 study comparing the 
efficacy of placebo (PBO), CANA 100 mg, and CANA 300 mg were used in 
the analysis (N = 371, mean (SD) baseline BW = 87 (21) kg, HbA1c = 7.8 
(0.8)%, 55% female). Following the 26-week core study period, PBO-treated 
subjects were switched to sitagliptin (SITA) 100 mg (which is BW neutral) for 
the remaining 26 weeks. BW was measured approximately every 6 weeks and 
treatment-induced UGE increases of 0, 80, and 90 g/day were assumed for 
PBO/SITA, CANA 100 mg, and CANA 300 mg, respectively, based on data 
from previous studies. A previously validated mathematical model was used 
to calculate the changes in EE and EI in each treatment group based on the 
measured BW and UGE data.
Results: CANA treatment dose-dependently reduced BW (Figure A), with 
mean (SE) reductions in BW of 0.9 (0.4)%, 3.3 (0.4)%, and 4.5 (0.3)% ob-
served at Week 52 for PBO/SITA, CANA 100 mg, and CANA 300 mg, respec-
tively (p <0.001 for both CANA doses vs. PBO/SITA). EI increased over time 
in CANA-treated subjects until approximately Week 26 when the sustained 
increase in daily EI nearly matched the daily caloric loss due to UGE (Figure 
B), thereby obtaining a new state of energy balance and a stable BW. Only 
small changes in EE were predicted, as the decrease in metabolic rate associ-
ated with weight-loss was nearly balanced by increased dietary thermogen-
esis arising from increased EI (Figure B).
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Conclusion: CANA treatment reduces BW due to UGE-associated caloric 
loss. The sustained UGE increase leads to a period of weight loss followed by 
a plateau in which a lower equilibrium BW is maintained. The plateau in BW 
is predicted to be due to sustained increases in EI that match the caloric loss 
to UGE, with only minimal changes in EE predicted.
Clinical Trial Registration Number: NCT01081834
Supported by: Janssen Research & Development, LLC
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The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic 
nephropathy in BTBR ob/ob type 2 diabetic mice with and without 
hypertension
F. Gembardt1, C. Bartaun1, N. Jarzebska1, E. Mayoux2, V.T. Todorov1,  
B. Hohenstein1, C. Hugo1;  
1Department of Internal Medicine III - Nephrology, University Hospital 
Carl Gustav Carus, Dresden, Germany, 2Boehringer Ingelheim Pharma 
GmbH & Co. KG, Biberach a. d. Riss, Germany.
Background and aims: Diabetic nephropathy is the leading cause of end-
stage renal disease in man in the western world. Recent development of so-
dium-glucose co-transporter 2 (SGLT2) inhibitors offers a new anti-diabetic 
therapy via enhanced glucose excretion. Whether this strategy exerts benefi-
cial effects on developing type 2 diabetic nephropathy is unclear. We investi-
gated the effects of the SGLT2 inhibitor empagliflozin in BTBR ob/ob mice, 
which spontaneously develop type 2 diabetic nephropathy.
Materials and methods: In a first experiment, BTBR ob/ob mice either re-
ceived a diet containing 300ppm empagliflozin or equicaloric placebo chow 
for 12 weeks. In a second experimental setting, BTBR ob/ob mice received an-
giotensin (Ang) II and were separated in the same 2 diet groups for 6 weeks. 
Urine, blood, and tissues were harvested and blood pressure was monitored 
by tail cuff measurements.
Results: In both experiments, empagliflozin treatment enhanced glucosu-
ria, (6,987±987µmol/mg Crea vs 2,182±972µmol/mg Crea; P<0.001; Ang 
II: 9,716±658µg/mg Crea vs 5,303±947µg/mg Crea; P<0.05) thereby low-
ering blood glucose (204±16 vs 402±27mg/dl P<0.001; Ang II: 170±20 vs 
410±39mg/dl P<0.01). While Ang II infusion induced profound hyperten-
sion (146±4 vs 84±1mmHg, P<0.0001), empagliflozin treatment had no sig-
nificant effect on blood pressure in normotensive or hypertensive mice (81±1 
vs 84±1mmHg; 139±6 vs 146±4mmHg). In both experiments, empagliflozin 
reduced albuminuria in diabetic mice (2,291±524vs 834±135µg/mg Crea, 
P<0.001; Ang II: 4,869±1776 vs 1,470±226µg/mg Crea, P<0.05). Empagliflo-
zin treatment did not affect matrix expansion as evaluated by immunohisto-
chemistry, while it decreased the diabetes-related glomerular hypertrophy in 
normotensive BTBR ob/ob mice (3,392±100.9 vs 3,646±59.8 µm2, P<0.05), 
but not in hypertensive mice (3,786±230.0 vs 3,877±88.6 µm2). After 6 weeks, 
diabetic BTBR ob/ob mice on the placebo diet showed a significant increased 
MCP-1 (~1.4-fold; P<0.05 vs WT), RANTES (~2.6-fold; P<0.05 vs WT), and 
IL-6 (~2.4-fold; P<0.05 vs WT) mRNA expression. While none of these in-
flammatory markers were significantly affected after 6 weeks of empagliflozin 
treatment, 12 weeks of empagliflozin treatment reduced renal mRNA expres-
sion of MCP-1 by ~75% (P<0.05 vs placebo), of RANTES by ~55% (P<0.05 vs 
placebo), and of IL-6 by 52% (P<0.05 vs placebo).
Conclusion: Taken together, our present results confirm that SGLT2 inhibi-
tion by empagliflozin is a good therapeutic option to lower blood glucose 
levels and improve albuminuria in a type 2 diabetes model without or with 
hypertension. Moreover, empagliflozin treatment differentially ameliorates 
markers of renal injury such as glomerular hypertrophy in murine diabetic 
nephropathy without hypertension. In conclusion these results support the 
concept of SGLT2 inhibition for the prevention of diabetic nephropathy.
Supported by: Boehringer Ingelheim Pharma GmbH & Co.KG
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Dapagliflozin lowers blood pressure in hypertensive and 
nonhypertensive patients with type 2 diabetes 
D. Sjöström1, P. Johansson1, A. Ptaszynska2, J. List2, E. Johnsson1;  
1AstraZeneca, Mölndal, Sweden, 2Bristol‐Myers Squibb, Princeton, USA.
Background and aims: Consistent with mild diuresis and weight loss, dapa-
gliflozin (DAPA), a highly selective sodium-glucose co-transporter 2 inhibi-
tor, also reduces BP in patients (pts) with type 2 diabetes mellitus (T2DM). 
High BP is associated with an increased risk of cardiovascular events and 
reducing BP has been shown to reduce this risk regardless of pretreatment BP. 
Therefore, it is of interest to investigate the ability of DAPA to safely reduce 
BP across different BP categories in the T2DM population. These analyses 
evaluated the effect of DAPA on BP in hypertensive (baseline [BL) systolic BP 
[SBP] > 140) and nonhypertensive (BL SBP ≤ 140) pts across the phase 2b/3 
clinical development programme.
Materials and methods: Safety data were pooled from 13 placebo (PBO)-
controlled studies in which pts with T2DM were randomised to DAPA 10 
mg/d (N=2360) or PBO (N=2295) for up to 24 weeks.
Results: At BL, 91.5% and 91.1% of the hypertensive pts were being treated 
with antihypertensive medications in the DAPA and PBO groups, respec-
tively, compared with 68.2% and 72.6% of the pts in the nonhypertensive 
group. In studies with 24 weeks of follow-up, treatment with DAPA resulted 
in mean PBO subtracted changes (95% CI) in SBP of -3.6 (-4.9 to -2.3) mm 
Hg in hypertensive, and -2.6 (-3.4 to -1.8) mm Hg in nonhypertensive pts 
(figure). The corresponding data for diastolic BP (DBP) were -1.2 (-2.0 to 
-0.4) mm Hg and -1.2 (-1.7 to -0.7) mm Hg, respectively. The difference from 
PBO in proportion of pts with any measured orthostatic reaction (defined 
as a decrease from supine to standing of > 20 mm Hg in SBP or > 10 mm 
Hg in DBP) over 24 weeks was similar in hypertensive (DAPA, 17.4%; PBO, 
15.5%), and nonhypertensive (DAPA, 11.4%; PBO, 9.6%) pts. At the 24-week 
visit there was no increase in the proportion of pts with measured orthostatic 
reactions in DAPA-treated vs PBO-treated pts in either hypertensive (6.1% 
vs 6.6%) or nonhypertensive (4.0% vs 4.2%) pts. Adverse events registered 
under the preferred term “orthostatic hypotension” were rare and none were 
classified as serious. The highest rate (0.4%) was registered in the nonhyper-
tensive PBO group. There was no clinically significant mean change in heart 
rate with DAPA in either hypertensive or nonhypertensive pts (-0.5 and 0.1 
beats/min, respectively). The proportion of pts on antihypertensive drugs was 
stable over the observation period (change ≤ 1%).
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Conclusion: DAPA 10 mg induces a modest BP reduction across BP cat-
egories and may thereby contribute to a reduced cardiovascular risk in hy-
pertensive as well as nonhypertensive T2DM pts. The potential of DAPA to 
reduce cardiovascular events is currently under investigation in a large-scale 
outcomes study, DECLARE.
Clinical Trial Registration Number: NCT00263276, NCT00357370, 
NCT00528372, NCT00528879, NCT00683878, NCT00859898, NCT00680745, 
NCT00972244, NCT00673231, NCT00984867, NCT00855166, NCT01031680, 
NCT01042977
Supported by: AstraZeneca and BMS
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Sodium glucose cotransporter 2 inhibition with empagliflozin reduces 
microalbuminuria in patients with type 2 diabetes 
D. Cherney1, M. von Eynatten2, S.S. Lund3, S. Kaspers3, S. Crowe3,  
H.J. Woerle3, T. Hach3;  
1Toronto General Hospital, University of Toronto, Canada,  
2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA,  
3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Background and aims: Empagliflozin (EMPA) is a sodium glucose cotrans-
porter 2 (SGLT2) inhibitor that lowers HbA1c, blood pressure (BP) and 
weight in patients with type 2 diabetes (T2D) and has similar potential in 
type 1 diabetes (T1D). It has also been shown that EMPA reduces renal hy-
perfiltration associated with T1D, suggesting a renoprotective reduction in 
intraglomerular pressure. Based on preclinical data, we hypothesised that 
the addition of EMPA to standard care, including stable doses of renin an-
giotensin system inhibitors (RASi), would reduce microalbuminuria versus 
placebo, consistent with attenuated renal injury.
Materials and methods: This post-hoc analysis assessed the effect of EMPA 
on urine albumin to creatinine ratio (UACR). Data were pooled from 458 
patients with T2D and pre-existing microalbuminuria (UACR 30-300 mg/g; 
mean [SD] estimated glomerular filtration rate [eGFR; modification of diet in 
renal disease] 87.9 [23.3] mL/min/1.73m2; mean [SD] age 56.7 [10.1] years) 
who had participated in 1 of 4 Phase III randomised placebo-controlled tri-
als. Changes in UACR were assessed in 438 patients who received EMPA 10 
mg (n=141), EMPA 25 mg (n=150) or placebo (n=147) for 24 weeks.
Results: After controlling for baseline log-transformed UACR, HbA1c, sys-
tolic BP, eGFR, region, trial and treatment, EMPA 10 mg and EMPA 25 mg 
significantly reduced UACR by 30% and 25%, respectively, compared with 
placebo at week 24 (Table; p<0.01).
Conclusion: EMPA 10 mg and EMPA 25 mg reduced microalbuminuria by 
a clinically meaningful amount when used as add-on to standard therapy in-
cluding stable RASi in patients with T2D. Prospective studies are needed to 
examine the potential renal protective effects of EMPA in patients with T1D 
and in patients with T2D.
Supported by: Boehringer Ingelheim and Eli Lilly
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Albuminuria, the sentinel marker of renal failure, is consistently 
decreased with empagliflozin in several preclinical models of diabetic 
nephropathy
M. Mark1, V. Vallon2, C. Hugo3, R.J. Roman4, E. Mayoux1;  
1Cardiometabolic, Boehringer-Ingelheim, Biberach, Germany, 2University of 
California, San Diego, USA, 3University Hospital CGC, Dresden, Germany, 
4University of Mississippi Medical Center, Jackson, USA.
Background and aims: Diabetic nephropathy (DN) is the leading cause of 
end-stage renal disease worldwide. The earliest clinical sign of diabetic ne-
phropathy is microalbuminuria. Moreover albuminuria is considered a pre-
dictive surrogate marker for cardiovascular and renal risk. Long term renal 
and/or cardiovascular protection with the emergent new class of anti-diabetic 
drugs, SGLT2 inhibitors, are not yet established. However we were interested 
to determine whether empagliflozin, a potent, selective sodium glucose co-
transporter 2 inhibitor, could impact the sentinel maker of renal disease albu-
minuria in different preclinical models of diabetic nephropathy.
Materials and methods: Type 1 diabetic Akita mice, hypertensive Type 2 
diabetic Dahl-STZ rats, normotensive and hypertensive (with angiotensin 
implant) BTBR ob/ob mice were treated for several weeks (9-15 weeks) with 
empagliflozin (10 to 30mg/kg). Dahl-rats, made hypertensive with 4% high 
salt diet and diabetic with a injection of 50mg/kg streptozotocin were also 
treated with an ACE inhibitor (lisonopril 10mg(kg) or empagliflozin (20mg/
kg) in drinking water or with the combination of both drugs. Blood and urine 
were collected to determine plasmatic glucose concentration and proteinuria 
respectively. Blood pressure (BP) was determined using the tail-cuff system.
Results: As expected, in all these different preclinical models empagliflozin 
was effective in lowering significantly blood glucose (-58% up to -100%: nor-
malization). A 76% blood pressure reduction was observed in Akita mice 
with empagliflozin while no effect on blood pressure was observed in nor-
motensive and hypertensive BTBR ob/ob mice. In hypertensive Dahl-STZ 
rat, either lisinopril or empagliflozin was able to reduce blood pressure while 
the combination induced a significant drop in blood pressure. Interestingly, 
proteinuria was significantly and consistently reduced by empagliflozin in 
diabetic mice (~ -60 %). In Dahl-STZ rat, lisonopril alone did not reduce 
proteinuria while empagliflozin decreased it by -28%. When used in com-
bination with lisinopril the effect of empagliflozin on proteinuria was even 
further pronounced (~-50%).
Conclusion: These results show that the specific SGLT2 inhibitor, empagli-
flozin, is able - on top of lowering blood glucose levels -to consistently de-
crease proteinuria, in several preclinical models of nephropathy independent 
of their origin as Type 1 or type 2 diabetes and also independent of their BP 
status. Whereas these are promising results hinting towards a renal benefit 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 334 
1 C
on the long term use of empagliflozin, it is premature to speculate about the 
clinical outcomes with empagliflozin. Studies are currently underway to ad-
dress this question.
825
Dapagliflozin lowered ambulatory BP in patients with type 2 diabetes 
mellitus and hypertension inadequately controlled by a renin-
angiotensin system blocker ± another agent
N. Iqbal1, M.A. Weber2, T.A. Mansfield1, J.F. List1, A. Ptaszynska3;  
1Global Clinical Research, Bristol-Myers Squibb, Princeton,  
2Department of Medicine, SUNY Downstate College of Medicine, New York, 
3Bristol-Myers Squibb, Princeton, USA.
Background and aims: Hypertension is common in patients with type 2 dia-
betes mellitus (T2DM) and treatment usually starts with an ACE inhibitor 
(ACEi) or an angiotensin receptor blocker (ARB), with other antihyperten-
sive (AHT) therapies added if required. Dapagliflozin reduces renal glucose 
reabsorption accompanied by weight reduction and a diuretic effect, both 
contributing to BP reduction. Here we assess the effects of dapagliflozin in 
two studies of patients with inadequately controlled T2DM and hyperten-
sion.
Materials and methods: Two randomized, double-blind studies assessed 
the effects of 12 weeks of dapagliflozin 10 mg or placebo on BP in patients 
with inadequately controlled T2DM (HbA1C 7.0-10.5%) and hypertension 
(seated systolic BP [SBP] / diastolic BP: 140-164 / 85-104 mmHg) despite 
receiving glucose-lowering drugs and an ACEi or ARB (Study 1) plus a 2nd 
AHT agent (Study 2). Preliminary results have been presented previously; 
here we describe ambulatory BP data.
Results: In Study 1, 613 patients on an ACEi or ARB were randomized to 
dapagliflozin or placebo. At Week 12, mean 24-hour ambulatory SBP was 2.9 
(SEM: 1.01) mmHg lower with dapagliflozin versus placebo (p=0.0043, Fig-
ure) and night-time SBP was reduced versus placebo (-2.34 [1.16] mmHg). In 
Study 2, 449 patients on an ACEi or ARB plus another AHT drug (thiazide/
thiazide-like diuretics in ~44% of patients, calcium channel blockers ~27%, 
beta blockers ~27%) were randomized to dapagliflozin or placebo. At Week 
12, mean 24-hour ambulatory SBP was lower with dapagliflozin versus pla-
cebo (-4.5 [1.37] mmHg, p=0.0012, Figure) and a reduction in night time SBP 
was also evident versus placebo (-3.9 [1.51] mmHg). Dapagliflozin was well 
tolerated and heart rate showed no significant change from baseline.
Conclusion: Dapagliflozin significantly reduced mean 24-hour ambulatory 
SBP versus placebo in patients with T2DM and hypertension in combination 
with an ACEi or ARB ± 1 AHT over 12 weeks.
Clinical Trial Registration Number: NCT01137474, NCT01195662
Supported by: BMS and AstraZeneca
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Impact of weight loss on weight-related quality of life (WRQL)  
and health satisfaction (HS): evidence from a head-to-head study of 
canagliflozin (CANA) vs sitagliptin (SITA)
S. Traina1, A. Slee2, C. Neslusan1;  
1Janssen Global Services, LLC, Raritan, 2Axio, Seattle, USA.
Background and aims: The positive health impacts of performing diabetes 
self-care (e.g., healthy food choices, increased physical activity, and medica-
tion taking) are not always apparent to a person with type 2 diabetes mellitus 
(T2DM); therefore, adherence can be difficult. People with T2DM are more 
likely to adhere to treatments that offer noticeable benefits, such as conveni-
ence, avoidance of hypoglycemic episodes, and weight loss vs. those that do 
not. Previous studies have demonstrated associations between WRQL and 
disease outcomes and between HS and performance of self-care behaviors. In 
this study, we explore the impact of the amount of weight loss demonstrated 
with CANA treatment on WRQL as measured by the Impact of Weight on 
Quality of Life (IWQOL-Lite) and physical HS (which includes satisfaction 
with weight, energy, appetite, sleep, physical activity, and general health) as 
measured by the Current Health Satisfaction Questionnaire (CHES-Q). In a 
previously reported study of CANA vs. SITA in dual therapy with metformin 
and background diet and exercise, CANA was associated with a mean weight 
loss of -2.1 kg to -2.5 kg vs. SITA after 52 weeks.
Materials and methods: In that study, the IWQOL-Lite and CHES-Q were 
administered at baseline and over time. Post hoc analyses were used to ex-
plore the strength of the relationship between weight change and improve-
ment in IWQOL-Lite total and physical HS scores. Empirical distributions of 
scores were examined to investigate floor and ceiling effects. The final analyti-
cal sample was limited to subjects with baseline scores that were not at the 
ceiling (e.g., allowing for improvement in score). Differences in least squares 
mean (LSM) change in weight by changes in IWQOL-lite and CHES-Q after 
52 weeks were compared using ANCOVA models adjusting for selected base-
line covariates (i.e., weight, age, and gender). Logistic regression, adjusted for 
the same covariates, was used to generate odds ratios (ORs) for score changes 
associated with weight change.
Results: Empirical distributions of change scores indicated that 29.1% of 
IWQOL-Lite and 5.4% of CHES-Q scores were at the ceiling at baseline; these 
scores did not decline over time and were thus excluded from the analyti-
cal sample. Subjects with improved IWQOL-Lite total and CHES-Q physical 
scores lost more weight than those with no score improvement (IWQOL-
Lite: -3.54 kg; 95% CI -4.07, -3.01 and -2.33 kg; 95% CI -2.78, -1.87, respec-
tively; LSM difference -1.21 kg; 95% CI -1.92, -0.51; CHES-Q: -3.50 kg; 95% 
CI -3.89, -3.12 and -1.86 kg; 95% CI -2.25, -1.47, respectively; LSM difference 
-1.65 kg; 95% CI -2.17, -1.12). Weight loss of 2 kg was associated with a 68% 
greater chance of IWQOL-Lite total score improvement (OR 1.68; 95% CI 
1.16, 2.42) and a 72% greater chance of CHES-Q physical domain score im-
provement (OR 1.72; 95% CI 1.28, 2.31).
Conclusion: Results suggest that the magnitude of weight loss shown in clini-
cal trials to be associated with CANA vs. SITA is noticeable by and important 
to people living with T2DM. Treatments providing adequate glycemic con-
trol that also offer a weight loss benefit are likely to improve WRQL and HS, 
and in turn, may support persistent and consistent performance of healthy 
behaviors.
Clinical Trial Registration Number: NCT01106677
Supported by: Janssen Research & Development, LLC
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The 2 week fasting glucose as a predictor of response to once weekly 
dulaglutide 1.5 mg
T. Forst1, S. Gough2, G. Grunberger3, V. Pechtner4, R. Shaginian5, H. Wang6, 
L. Fernandez6;  
1Profil Mainz, Germany, 2University of Oxford and Oxford University 
Hospitals NHS Trust, UK, 3Grunberger Diabetes Institute, Bloomfield Hills, 
USA, 4Lilly Diabetes, Eli Lilly and Company, Neuilly-Sur-Seine, France, 
5Lilly Diabetes, Eli Lilly and Company, Houten, Netherlands,  
6Lilly Diabetes, Indianapolis, USA.
Background and aims: The identification of patients most likely to respond 
to a specific treatment is important when attempting to individualize patient 
care. Predictors of treatment success for weekly GLP-1 receptor agonists 
are, to date, largely unknown. This analysis was therefore conducted to as-
sess whether laboratory fasting blood glucose (FBG) in patients with type 2 
diabetes mellitus (T2DM) measured early in treatment with the once weekly 
GLP-1 receptor agonist dulaglutide (DU) 1.5 mg predicts treatment response.
Materials and methods: Post hoc analyses were conducted separately for 2 
double-blind, randomized Phase 3 studies (AWARD-5, in combination with 
metformin, and AWARD-1, in combination with metformin and pioglita-
zone) in patients with T2DM assigned to once weekly DU 1.5 mg. Baseline 
tertile values from AWARD 5 were used to categorize FBG at baseline and 
weeks 2 and 8 as follows: Low (L, <7.9 mmol/l); Intermediate (I, ≥7.9 to <10.3 
mmol/l); and High (H, ≥10.3 mmol/l). Treatment response in AWARD-5 
was assessed at week 12 and 26 by the following composite efficacy endpoint 
(CEE): HbA1c <7.0% (53 mmol/mol) or HbA1c reduction from baseline 
>0.8% [if baseline HbA1c <8.0% (64 mmol/mol)]; >1.1% [if baseline A1c 
≥8.0% (64 mmol/mol) and <9.0% (75 mmol/mol)]; or >1.6% [if baseline 
HbA1c ≥9.0% (75 mmol/mol)]. The association between FBG categories and 
the CEE was analyzed using chi-square tests. The association between week 
2 FBG and HbA1c treatment response at weeks 13 and 26 was validated in 
AWARD-1 using the same FBG categorization and CEE definition.
Results: In AWARD-5, mean baseline HbA1c for DU 1.5 mg (N=304) was 
8.1% (65 mmol/mol). At baseline, mean FBG was 9.8 mmol/l and 33% 
(n=99), 32% (n=97), and 36% (n=108) of patients had FBG in the L, I, and 
H categories, respectively. After 2 weeks of treatment, mean FBG was 7.2 
mmol/l and 68% (n=208), 21% (n=64), and 11% (n=32) of patients had FBG 
in L, I, and H categories, respectively. At week 26, mean HbA1c was 6.9% 
(52 mmol/mol). There was a strong association between FBG at week 2 and 
achieving the CEE at week 26 (p<0.001). A significantly higher percentage of 
patients in FBG category L (83% [172/208]) at week 2 met the CEE at week 26 
compared to patients in FBG categories I (61% [39/64]), p<0.001, and H (34% 
[11/32]), p<0.001, at this time. CEE results at week 12 were consistent with 
those at week 26. Similar findings were seen using AWARD-1 data.
Conclusion: In patients treated with once weekly DU 1.5 mg in AWARD-5 
and AWARD-1, FBG values at week 2 were strongly associated with treat-
ment response at week 26 as measured by a CEE. The probability of achiev-
ing a treatment response at week 26 was greatest for patients in the lower 
FBG categories at week 2. FBG values at week 2 may be an early and useful 
measurement for predicting response to once weekly DU 1.5 mg treatment 
in patients with T2DM.
Supported by: Eli Lilly and Company
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Real-world comparative effectiveness of exenatide once weekly  
and liraglutide in patients with type 2 diabetes mellitus
W. Saunders1, H. Hiep Nguyen2, I. Kalsekar2;  
1Saunders Research, Charlotte, 2AstraZeneca, Fort Washington, USA.
Background and aims: Exenatide once weekly (EQW) and liraglutide once 
daily (LIRA), glucagon-like peptide-1 receptor agonists (GLP-1RAs), have 
demonstrated improvements in glycaemic outcomes in patients with type 
2 diabetes mellitus (T2DM) in randomized clinical trials. However, little is 
known about their real-world comparative effectiveness. This retrospective 
cohort study used the Quintiles Electronic Medical Record (EMR) database 
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to evaluate the 6-month change in HbA1c for patients initiating EQW or 
LIRA.
Materials and methods: Patients with T2DM prescribed EQW or LIRA be-
tween 01 February 2012 and 31 May 2013 were identified. Baseline HbA1c 
measures were from 75 days prior to 15 days after initiating EQW or LIRA, 
with follow-up measures documented at 6 months (± 45 days). Adjusted 
linear regression models compared the difference in mean HbA1c change. 
A priori defined sensitivity analyses were performed in the subgroup of pa-
tients with baseline HbA1c ≥7.0% and no prescription for insulin during the 
12-month pre-index period.
Results: For EQW and LIRA respecitvely, mean (SD) age of the main study 
cohort was 58.0 (11.0) and 58.1 (11.0) years, mean (SD) baseline HbA1c was 
8.3% (1.7) and 8.4% (1.6), and 48.1% and 54.1% of patients were women. In 
adjusted models, change in HbA1c did not differ between EQW and LIRA 
during 6 months of follow-up (Table). Results were consistent in the sub-
group analyses.
Conclusion: In a real-world setting, HbA1c similarly improved in patients 
initiating EQW or LIRA.
Supported by: Bristol-Myers Squibb/AstraZeneca
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Effectiveness of lixisenatide before breakfast or the main meal using 
CGM with AGP analysis
E. Strock1, R. Mazze1, M. Powers1, A. Monk1, S. Richter2, R. Bergenstal1,  
E. Souhami3, N. Demil3, B. Ahrén4;  
1International Diabetes Center, Minneapolis, 2Park Nicollet Institute, 
Minneapolis, USA, 3Sanofi, Paris, France, 4Lund University, Sweden.
Background and aims: Lixisenatide is a once-daily glucagon-like peptide-1 
receptor agonist that has been shown by 7-point self-monitoring blood glu-
cose to lower postprandial and fasting glycaemia. The aim of this study was 
to understand, in a subset of type 2 diabetes mellitus (T2DM) patients in a 
multicentre randomized trial, the change in diurnal glucose patterns using 
continuous glucose monitoring (CGM) prior to and during lixisenatide treat-
ment based on the time of administration: before breakfast (BK) or the main 
meal (MM) as defined by the patient.
Materials and methods: Blinded CGM was used 14 days before and during 
lixisenatide treatment (BK or MM). CGM data were analyzed using Ambu-
latory Glucose Profile (AGP) analysis to detect changes in diurnal glucose 
patterns.
Results: Sixty-nine patients completed (T2DM 7.8±4.9y; age 57.8±10.2y; 
53.6% female). AGP analysis showed significant reduction in 24h glu-
cose exposure (AUC) in both groups (BK: 4918.1±652.3 to 3681.2±699.6 
mg/dL*24h, p<0.0001; MM: 4127.9± 876.6 to 3880.9±1165.0 mg/dL*24h, 
p=0.0224). Reduction in hourly waking AUC was significant in both groups 
(BK: 181.1±28.1 to 157.2±29.5 mg/dL*h, p<0.0001, MM: 177.9±37.7 to 
165.6±48.2 mg/dL*h, p=0.0184). However, hourly sleeping AUC reduc-
tion was significant in the BK group (161.8±28.0 to 144.6±28.8 mg/dL*h, 
p<0.001) and not in the MM group (159.8±36.4 to 153.4±51.5, p=0.0942). 
Variability (IQR) improved in both groups, although was not significant. 
Subjects in both groups had less than 1% of time spent in hypoglycaemic 
range (<60mg/dL). HbA1c reduction was similar in both groups. Figure 1 
shows composite AGPs for each group.
Conclusion: In summary, lixisenatide before MM appears to benefit after-
noon and evening glucose exposure, while lixisenatide before BK appears to 
have a sustained improvement in the overall diurnal glucose patterns.
Clinical Trial Registration Number: NCT01517412
Supported by: Sanofi
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Harmony 2 year 3 Results: albiglutide monotherapy in drug naïve 
patients with type 2 diabetes mellitus
M.C. Carr1, M. Rendell2, R.A. Scott3, J. Ye4, M.W. Stewart1, M. Nauck5;  
1GlaxoSmithKline, King of Prussia, 2Creighton University Diabetes Center, 
Omaha, USA, 3GlaxoSmithKline, Uxbridge, UK, 4GlaxoSmithKline, 
Research Triangle Park, USA, 5Diabeteszentrum Bad Lauterberg, Germany.
Background and aims: This 3 year (y),double-blind, placebo (Pbo)-con-
trolled study examined efficacy/safety of albiglutide at 30mg (A30) and 50mg 
(A50) vs Pbo in patients with A1C (53-85.8 mmol/mol [7-10%]) on diet and 
exercise.
Materials and methods: Both Albi arms began A30 QW (A50 started at Wk 
12) and continued on randomized medication after hyperglycemic rescue. 
Primary endpoint (PE) was A1C change from baseline at Wk 52.
Results: Baseline characteristics were similar between arms; mean A1C 65 
mmol/mol (8.1%); age 53 y; diabetes duration 4 y. The PE reported previ-
ously showed Wk 52 A1C difference (Albi − Pbo) -9.2 mmol/mol (95% CI: 
-12.1, -6.3) [−0.84% (95% CI: -1.11, −0.58)] for A30 and -11.4 mmol/mol 
(95% CI: -14.3, -8.4) [−1.04% (95% CI: -1.31, −0.77)] for A50; both P<.0001. 
In pts completing 3y without rescue, A1C reduction was durable to Wk 156 
in both albi arms (-10.5 mmol/mol, SD 10.6 [-0.96%, SD 0.968], A30 (n=30), 
-11.7 mmol/mol, SD 9.7 [-1.07%, SD 0.887], A50 (n=32), -6.7 mmol/mol, SD 
7.0 [-0.61%, SD 0.644], Pbo (n=14), with generally greater reductions in the 
A50 arm. FPG (mmol/L [mg/dL]) decreased in a dose dependent manner 
in the albi arms, (-1.3, SD 1.77, A30; -1.8, SD 2.01, A50; -0.23, SD 0.81, Pbo 
[-23.6, SD 31.87, A30; -32.9, SD 36.14, A50; -4.3, SD 14.63, Pbo]) and was 
maintained to Wk 156. Modest weight loss (kg) occurred in all arms (-2.91 
Pbo,-1.32 A30, -2.24 A50). The probability of requiring rescue by Wk 156 
was 74% Pbo, 54% A30, and 42% A50. Metformin was the most common 
rescue medication. In pts completing 3y with rescue, A1C reduction was -7.5 
mmol/mol, SD 14.1 [-0.69%, SD 1.293], A30 (n=66), -9.3 mmol/mol, SD 9.3 
[-0.85%, SD 0.85], A50 (n=51), -9.0 mmol/mol, SD 14.4 [-0.82%, SD 1.319], 
Pbo (n=47), confounded by a higher use of rescue medication in the Pbo arm. 
On-therapy adverse event (AE) % was higher in the A30 and A50 arms than 
Pbo 89.1/89.9/83.1 but SAE % was similar 14.9/17.2/15.8. GI AEs for Pbo/
A30/A50 were: nausea 10/14/11; diarrhea 15/13/16; vomiting 1/4/4. Injec-
tion site reactions were higher for A30 and A50 vs Pbo 22/28/11. Pre-rescue 
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documented (≤3.88 mmol/L [70 mg/dL]) symptomatic hypoglycemia events 
were low: A30 2%, A50 1%, Pbo 3%; no severe events reported.
Conclusion: Albi monotherapy resulted in robust, durable A1C reduction 
through Wk 156 and was generally well tolerated.
Clinical Trial Registration Number: NCT00849017
Supported by: GSK
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Harmony 3 year 3 Results: albiglutide vs sitagliptin and glimepiride in 
patients with type 2 diabetes mellitus on metformin
J.E. Matthews1, B. Ahren2, J. Ye1, M.C. Carr3, M.W. Stewart3;  
1GlaxoSmithKline, Research Triangle Park, USA, 2Department of Clinical 
Sciences, Division of Medicine, Lund Universtiy, Sweden,  
3GlaxoSmithKline, King of Prussia, USA.
Background and aims: This 3-year (y), randomized (rzd), double-blind, pla-
cebo (Pbo) controlled, study examined albiglutide (Albi) 30mg vs placebo 
(Pbo), sitagliptin (Sita), or glimepiride (SU) in patients (pts) with T2DM 
(A1C 53-85.8 mmol/mol [7-10%]) on Metformin (Met).
Materials and methods: Pts meeting predefined hyperglycemia criteria 
qualified for blinded dose titration (SU 2-4mg, Albi 30-50mg). Pts received 
hyperglycemic rescue if prespecified rescue criteria were met & continued 
receiving rzd medication. Pts (%) who completed the 3y study (including res-
cue): Pbo 53, Sita 61, SU 60 & Albi 61.
Results: Primary endpoint at Wk 104 (baseline A1c 65 ± 8.7 mmol/mol [8.1 ± 
.8%]), Albi treatment difference was superior to Pbo (-9.9 mmol/mol [-.91%]; 
P <.0001), Sita (-3.8 mmol/mol [−.35%]; P = .0001) & SU (-3.0 mmol/mol 
[-.27%]; P = .003). At Wk 156, probability of rescue (%) was lower in Albi: 
Pbo 65.6 (P <.0001), Sita 47.8 (P = .0124), SU 44.3 (P = .1605), Albi 37.3. 
In pts completing 3y of treatment with & without rescue, durability of Albi 
was demonstrated with both A1c & FPG reduction from baseline. There was 
minimal change in weight at 3y (kg): Pbo -.41, Sita -.61, albi -1.0 & weight 
gain with SU +1.60. GI AEs (% pts) to Wk 156 with Pbo/Sita/SU/Albi were: 
nausea 13/7/8/12 & vomiting 1/5/4/7. Prerescue documented (≤3.88 mmol/L 
[70 mg/dL]) symptomatic hypoglycemic events (%) were Pbo 4.0, Sita 1.7, SU 
19.9, Albi 3.6; with 1 severe event (SU).
Conclusion: We conclude that Albi treatment, as add on to Met, was gener-
ally well tolerated with maintained glycemic control over a 3y study period.
Clinical Trial Registration Number: NCT00838903
Supported by: Research funded by GSK
832
Effectiveness of switching from a DPP-4 inhibitor to the human  
GLP-1 analogue liraglutide in patients with type 2 diabetes: data from 
the EVIDENCE study
S. Madani1, G. Charpentier2, L. Martinez3, E. Eschwège4, A. Penfornis5,  
P. Gourdy6, J.-F. Gautier7;  
1Novo Nordisk, Paris la Defense, 2Centre Hospitalier Sud Francilien, 
Corbeil, 3Université Pierre & Marie Curie, Paris, 4INSERM, Villejuif, 
5University of Franche-Comté, Besançon, 6Toulouse University Hospital, 
7Lariboisière Hospital, Paris, France.
Background and aims: We used data from a post-marketing study in France 
to assess the effectiveness of switching from a DPP-4 inhibitor (DPP-4i) to 
liraglutide in patients with type 2 diabetes.
Materials and methods: EVIDENCE is a multicentre, observational, post-
marketing outpatient study requested by the French National Health Author-
ity to evaluate the efficacy and safety of the human GLP-1 analogue liraglu-
tide. Its primary objective is to determine the percentage of patients still tak-
ing liraglutide and at HbA1c target (<7%) after 2 years. Statistical analyses: 
for quantitative variables a normality Kolmogorov-Smirnov test was used; 
comparisons of two dependent groups were performed using the Wilcoxon 
signed rank test; for paired qualitative variables the McNemar test was used.
Results: Data were collected from 3152 subjects of whom 1261 (40%) were 
receiving a DPP-4i prior to liraglutide initiation. A total of 1002 (32%) sub-
jects switched from a DPP-4i to liraglutide at the start of the study. Baseline 
characteristics of subjects who switched and were still on liraglutide treat-
ment at the end of the study are presented in Table 1. These subjects (n = 624) 
achieved significant reductions in mean HbA1c (-0.85%, p<0.0001), fasting 
plasma glucose (-0.28 g/l, p<0.0001) and body weight (-3.60 kg, p<0.0001). 
An increased percentage of subjects reached the HbA1c target of <7% after 
switching to liraglutide (31.7% at the end of the study vs. 9.7% at baseline; 
p<0.0001). Withdrawals (21.4% in overall study cohort) were mostly due to 
gastrointestinal disorders experienced at the start of the study.
Conclusion: Switching from a DPP-4i to liraglutide led to significant im-
provements in glycaemic control and body weight in this observational 
study. In a randomised controlled trial, switching from the DPP-4 inhibitor 
sitagliptin to liraglutide provided significant HbA1c (-0.5%; p<0.0001) and 
body weight reductions (-2.5 kg; p<0.0001). The greater reductions in HbA1c 
and body weight in this observational study versus the controlled setting of 
a clinical trial may reflect different baseline characteristics and concomitant 
diabetes medications. However, these data support the potential benefits of 
switching from a DPP-4i to a GLP-1 analogue, as previously observed in a 
randomised clinical trial.
Clinical Trial Registration Number: NCT01226966
Supported by: Novo Nordisk
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Safety and tolerability of liraglutide 3.0 mg in overweight and obese 
adults: the SCALE obesity and prediabetes randomised trial
C. le Roux1, D.C.W. Lau2, A. Astrup3, K. Fujioka4, F. Greenway5, A. Halpern6, 
M. Krempf7, R. Violante Ortiz8, J.P.H. Wilding9, C.B. Jensen10,  
C.B. Svendsen10, X. Pi-Sunyer11;  
1University College Dublin, Ireland, 2University of Calgary, Canada, 
3University of Copenhagen, Denmark, 4Scripps Clinic, La Jolla, 5Louisiana 
State University, Baton Rouge, USA, 6University of São Paulo Medical 
School, Brazil, 7Université de Nantes, France, 8Instituto Mexicano del Seguro 
Social, Ciudad Madero, Mexico, 9University of Liverpool, UK, 10Novo 
Nordisk A/S, Søborg, Denmark, 11Columbia University, New York, USA.
Background and aims: The primary objective of this trial was to investigate 
the efficacy of the GLP-1 receptor agonist (RA) liraglutide 3.0 mg, as adjunct 
to diet and exercise, for weight management. Key safety and tolerability data 
are presented.
Materials and methods: Individuals (BMI ≥27 kg/m2 with ≥1 comorbidity 
or ≥30 kg/m2) were advised on a 500 kcal/day deficit diet and exercise pro-
gramme and randomised 2:1 to once daily sc liraglutide 3.0 mg (n=2487) 
or placebo (n=1244). Certain event types (deaths, select CV disorders, pan-
creatitis, neoplasms, thyroid disorders requiring thyroidectomy) underwent 
blind independent assessment.
Results: Baseline characteristics: age 45.1 years, 78.5% female, body weight 
106.2 kg, BMI 38.3 kg/m2. Liraglutide 3.0 mg induced greater weight loss 
(primary endpoint; 8.0%) vs placebo (2.6%) after 56 weeks (estimated treat-
ment difference [ETD] -5.4%; p<0.0001). Consistent with the known effects 
of GLP-1RAs, the most common AEs with liraglutide 3.0 mg were mild/mod-
erate nausea and diarrhoea, mostly transient and with onset in weeks 1−4. 
AEs leading to withdrawal occurred in 9.9% of individuals on liraglutide 3.0 
mg, mostly in weeks 1-12 and due to GI AEs, vs 3.8% with placebo. Similar 
proportions reported serious AEs in both treatment groups (6.3% vs 5.0%). 
None occurred in ≥1% of individuals. 3 deaths occurred: liraglutide 3.0 mg 
(n=1) vs placebo (n=2) (1 CV-related death in each group). Liraglutide treat-
ment was not associated with increased risk of depression or suicidality. 
Gallbladder-related AEs were more common with liraglutide 3.0 mg vs pla-
cebo (2.5% vs 1.0%), due to more events of ‘cholelithiasis’ and ‘cholecystitis’. 
The frequency of pancreatitis was higher with liraglutide (0.3%) vs placebo 
(0.1%). 1 individual per group co-reported gallbladder-related AEs and pan-
creatitis. An increase in mean serum lipase activity was seen with liraglu-
tide, but few individuals (2.5% vs 1.1% with placebo) had levels ≥3 times 
the UNR. Most elevations were transient and not predictive of pancreatitis. 
Liraglutide reduced mean SBP and DBP vs placebo at week 56 (ETD -2.8 and 
-0.9 mmHg, p<0.001), but increased mean pulse (ETD 2.4 bpm, p<0.0001) 
and a persistent increase of >20 bpm at ≥2 consecutive visits occurred in 5.1% 
vs 1.4% of individuals, respectively. CV events were similar with liraglutide 
(8.7%) vs placebo (9.9%). There were no cases of medullary thyroid carcino-
ma or C-cell hyperplasia and liraglutide did not increase calcitonin. Injection 
site reaction rates were 22.4 and 14.9 events/100 patient years of exposure 
(PYE) with liraglutide and placebo, respectively, with similar allergic reaction 
rates between treatments (2.6 and 3.2 events/100 PYE).
Conclusion: The safety profile of liraglutide 3.0 mg was consistent overall 
with the known effects of a GLP-1RA. The clinical significance of the imbal-
ance in gallbladder and pancreatitis events is currently unknown.
Clinical Trial Registration Number: NCT01272219
Supported by: Novo Nordisk
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Efficacy and safety of liraglutide for perioperative blood sugar control in 
diabetic subjects within enhanced recovery after surgery protocols
K. Mori, Y. Sato, Y. Tahara, Y. Iwasaki, S. Kaneko;  
Division of Diabetes, Endocrinology and Lifestyle-Related Disease, 
Takatsuki Red Cross Hospital, Japan.
Background and aims: Enhanced recovery after surgery (ERAS) protocols 
are multimodal perioperative care pathways designed to achieve early recov-
ery after surgical procedures by maintaining preoperative organ function and 
reducing the profound stress response following surgery. The key principles 
of the ERAS protocol include perioperative nutritional management such as 
avoidance of perioperative fasting and carbohydrate loading up to 2 hours 
preoperatively. This perioperative nutritional management may result in 
blood sugar fluctuations in insulin-dependent diabetic patients. It has been 
controversial to employ glucagon-like peptide-1 receptor (GLP-1R) agonist 
therapy for perioperative glycemic control. To investigate the efficacy and 
safety of liraglutide, a GLP-1R agonist, for perioperative glycemic control of 
surgical patients within ERAS protocol, we performed a randomized pro-
spective study.
Materials and methods: Informed consents were obtained from 25 subjects 
with T2DM undergoing elective operations within ERAS protocol. Twelve 
subjects (male; 7, Age; 67.3±8.7 years old) were initiated with liraglutide, 
and 13 subjects (male; 6, Age; 67.1±9.3 years old) were administered insulin 
therapy before elective operations, e.g. orthopedic operations (23 cases) and 
urological surgery (2). In cases of hyperglycemia during perioperative pe-
riod, regular insulin was added. As GLP-1 decreases gastrointestinal motility, 
surgical cases with gastrointestinal tracts were excluded. Fluctuation in gly-
cemic level, hypoglycemic events, BMI change, doses of insulin administered 
if needed and perioperative complications were analyzed.
Results: Liraglutide was continued through the entire period of hospital stay 
including the operation day (day 0). The mean glucose levels of liraglutide 
or insulin therapy on day 0 and day 1 were 137.6±26.41, 138.2±33.1 and 
146.5±24.4, 187.1±35.6 mg/dl, respectively. The body weight of patients re-
ceiving liraglutide or insulin therapy before the operation decreased -4.7±1.0 
kg or -1.8±0.9 kg, respectively. Additional regular insulin was not needed ex-
cept in the case of 1 patients. There was an additional benefit of body weight 
loss enabling efficient rehabilitation. Hypoglycemic events, wound healing 
retardations, or other complications were not observed in patients receiving 
liraglutide.
Conclusion: Liraglutide provides an effective and optional way for perioper-
ative blood sugar control within ERAS protocols in patients with T2DM, es-
pecially those with limited exercise ability and those at risk of hypoglycemia.
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Novel combination of insulin degludec and liraglutide (IDegLira) is 
efficacious across the range of disease progression in type 2 diabetes
H.W. Rodbard1, J.B. Buse2, V.C. Woo3, T. Vilsbøll4, I. Langbakke5,  
L. Korsholm5, S. Gough6;  
1Endocrine and Metabolic Consultants, Rockville, 2University of North 
Carolina School of Medicine, Chapel Hill, USA, 3University of Manitoba, 
Winnipeg, Canada, 4University of Copenhagen, Hellerup, Denmark,  
5Novo Nordisk A/S, Søborg, Denmark, 6University of Oxford, UK.
Background and aims: This study explored whether a novel combination of 
insulin degludec (IDeg) and liraglutide (Lira), IDegLira, was consistently ef-
fective across three parameters of type 2 diabetes (T2D) progression: HbA1c, 
diabetes duration and dose of insulin.
Materials and methods: Mean HbA1c reductions of 1.8 and 1.9% were ob-
served with IDegLira in two Phase 3 trials: DUAL I (IDegLira versus IDeg 
and Lira 1.8 mg in patients uncontrolled on metformin ± thiazolidinedi-
one [TZD] for 52 weeks) and DUAL II (IDegLira versus IDeg [max 50 U] 
in patients uncontrolled on basal insulin + oral glucose lowering drugs for 
26 weeks), respectively. This post-hoc analysis investigated how the extent of 
progression of T2D at baseline, defined as baseline HbA1c category, insulin 
dose and diabetes duration, impacted the efficacy of IDegLira.
Results: In DUAL I, HbA1c reductions (1.1-2.5%) were significantly greater 
(p<0.01) with IDegLira versus IDeg or Lira in all four baseline HbA1c cat-
egories assessed (≤7.5%; >7.5% to ≤8.5%; 8.5 to ≤9.0% and >9.0%). HbA1c 
reductions were similar to those observed in DUAL II (0.9-2.5%) (Figure). 
In DUAL I, higher baseline HbA1c categories were associated with greater 
HbA1c reductions with IDegLira (p<0.0001). HbA1c reduction was inde-
pendent of diabetes duration. In DUAL II, pre-trial basal insulin dose (≤30 
U or >30 U) did not affect HbA1c reduction with IDegLira (1.9 vs 1.9%, esti-
mated treatment difference (ETD) 0.02, 95% CI -0.26 to 0.30, p=0.91). Those 
patients entering DUAL II on metformin (48%) achieved a greater HbA1c 
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reduction (2.1 vs 1.7%, ETD -0.44, 95% CI -0.71 to -0.16, p<0.01) than the 
remaining 52% who entered on metformin + sulphonylureas (SU) or glinides 
and then discontinued SU or glinide at randomisation.
Conclusion: HbA1c reductions with IDegLira were substantial for patients 
with all levels of baseline HbA1c and were independent of diabetes duration 
and prior insulin dose. Similar levels of glycaemic control can be obtained 
with IDegLira irrespective of stage of progression of T2D
.
Clinical Trial Registration Number: NCT01336023, NCT01392573
Supported by: Novo Nordisk
836
IDegLira, a combination of insulin degludec and liraglutide, enables 
patients with type 2 diabetes to reach target glycaemic control faster than 
its individual components alone
T. Vilsbøll1, J. Vora2, H. Jarlov3, K. Kvist3, L. Blonde4;  
1Internal Medicine F, Gentofte Hospital, Copenhagen, Denmark, 
2Department of Diabetes & Endocrinology, Royal Liverpool University 
Hospitals, UK, 3Novo Nordisk A/S, Søborg, Denmark,  
4Ochsner Medical Center, New Orleans, USA.
Background and aims: IDegLira is a novel combination of insulin degludec 
(IDeg) and liraglutide (Lira). The aim of this post hoc analysis was to investi-
gate the time to glycaemic control and to observe changes in body weight in 
response to IDegLira vs Lira or IDeg alone, in patients with type 2 diabetes 
(T2D).
Materials and methods: In two completed phase 3 trials: DUAL I (IDegLira 
vs IDeg and Lira in patients uncontrolled on oral antidiabetic drugs [OADs]; 
52 weeks) and DUAL II (IDegLira vs IDeg in patients uncontrolled on basal 
insulin + OADs; 26 weeks), a greater HbA1c reduction was observed with 
IDegLira compared with IDeg or Lira alone (DUAL I: IDegLira: -1.84%, 
IDeg: -1.40%, Lira: -1.21%; DUAL II: IDegLira: -1.90%, IDeg: -0.89%). In 
this analysis of both trials, we compared the proportion of patients achieving 
HbA1c (<7%) and fasting plasma glucose (FPG) (≤7.2 mmol/L) targets and 
mean change in body weight during the first 12 weeks of treatment. HbA1c 
was assessed after 8 and 12 weeks; FPG and weight were assessed at Weeks 
4, 8 & 12. All data were analysed using LOCF to account for missing data.
Results: At baseline, HbA1c was well matched across treatment arms in both 
trials. In DUAL I, the proportion of patients achieving HbA1c <7% at Week 8 
was significantly greater with IDegLira (57%) than with IDeg (38%) or Lira 
(47%). These differences in proportions were more pronounced at Week 12. 
In DUAL II, the proportion of patients at HbA1c target was significantly high-
er with IDegLira than with IDeg at Weeks 8 & 12. At baseline, the proportion 
of patients with FPG ≤7.2 mmol/L was similar in both trials. In DUAL I, 
the proportion of patients at target at Week 4 was significantly higher with 
IDegLira (76%) than with IDeg (62%) and Lira (62%); these differences per-
sisted at Weeks 8 & 12. In DUAL II, patients were also more likely to achieve 
FPG target at Weeks 4, 8 & 12. In DUAL I at Weeks 4, 8 & 12, treatment with 
IDegLira resulted in a significantly greater reduction in mean body weight 
compared with IDeg, which was associated with a small overall weight gain, 
but the weight loss with IDegLira was less than that achieved with Lira. In 
DUAL II, weight loss was greater with IDegLira vs IDeg at Weeks 4, 8 & 12.
Conclusion: Patients treated with IDegLira were more likely to achieve 
HbA1c and FPG targets earlier than with IDeg or Lira alone. IDegLira pro-
vided a favourable early change in weight when compared with IDeg alone, 
but less than with Lira alone. Treatment with IDegLira results in rapid and 
substantial improvement in glycaemic control with a beneficial weight profile 
as early as 4 weeks after initiation in both insulin-naïve and insulin-treated 
patients. Early improvement in achieving target glycaemia levels may have a 
positive impact on patients’ perception of their progress and on adherence 
to treatment.
Clinical Trial Registration Number: NCT01336023, NCT01392573
Supported by: Novo Nordisk
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Harmony 4: 3 year efficacy of albiglutide (albi) vs insulin glargine (glar) 
in patients with type 2 diabetes mellitus
P.N. Weissman1, M.W. Stewart2, D.T. Cirkel3, J. Ye4, P.D. Ambery5;  
1Endocrinology Associates, Miami, 2GlaxoSmithKline, King of Prussia, 
USA, 3GlaxoSmithKline, Stevenage, UK, 4GlaxoSmithKline, Research 
Triangle Park, USA, 5MedImmune, Cambridge, UK.
Background and aims: This 3 year (y) randomized, open label, Ph 3 study 
assessed efficacy and safety of Albi 30 mg once weekly vs Glar in T2DM pts 
uncontrolled (A1c 53.0-85.8 mmol/mol [7-10%]) on metformin (met) ± sul-
fonylurea (SU).
Materials and methods: Pts were treated to a target A1c ≤53.0 mmol/mol 
(7.0%) and FPG ≤5.6 mmol/L (100 mg/dL). If needed, pts could uptitrate Albi 
to 50 mg QW and Glar per prespecified criteria. Patients could continue if 
hyperglycemic rescue was required. Primary endpoint (PE) was change from 
baseline in A1c at wk 52 in Albi vs Glar.
Results: Baseline demographics were similar between groups; mean age 56 
y, A1c 67.2 mmol/mol (8.3%), 82% on met + SU. Treated N=504/241 (Albi/
Glar). A1c decreased in both groups and was maintained for 3 y. The PE 
showed non-inferiority between Albi and Glar at wk 52 with a treatment 
difference of 1.20 mmol/mol (95% CI: 0.44, 2.95) (0.11% [95% CI: -0.04%, 
0.27%]). At wk 156, a similar proportion of patients in each group required 
rescue: Albi 56.2%, Glar 48.0%, p=0.1515. In pts completing 3 y with and 
without rescue, A1c reduction was durable in both groups. Change in FPG 
favored Glar, whereas change in weight favored Albi. AEs through wk 156 for 
Albi/Glar were (% pts): nausea 13.3%/7.5%; diarrhea 10.9%/7.9%; vomiting 
5.4%/5.4%. Prerescue documented (≤3.9 mmol/L [70 mg/dL]) symptomatic 
and severe hypoglycemia events were less with Albi vs Glar (18.5%/0.6% vs 
30.3%/0.8%). Injection site reactions occurred in 17.5% of Albi and 10.0% 
of Glar pts.
Conclusion: Albi showed similar A1c improvement at wk 156 to Glar with 
modest weight loss and acceptable tolerability.
Clinical Trial Registration Number: NCT00838916
Supported by: GSK
838
Harmony 5 - year 3 Results: albiglutide vs placebo and vs pioglitazone in 
triple therapy (background metformin and glimepiride) in people with 
type 2 diabetes
P. Shamanna1, P. Home2, M.W. Stewart3, J.M. Mallory3, D.M. Miller3,  
C.R. Perry3, M.C. Carr3;  
1Bangalore Diabetes Centre, India, 2Newcastle University,  
Newcastle upon Tyne, UK, 3GlaxoSmithKline, King of Prussia, USA.
Background and aims: A 3-year, randomized, double-blind, multicenter 
study evaluated once weekly (QW) GLP-1 receptor agonist albiglutide (Albi) 
vs placebo (Pbo) and vs pioglitazone (Pio) in people with A1C 53-85.8 mmol/
mol [7.0-10.0 %] on background dual therapy of metformin and glimepiride.
Materials and methods: Uptitration of Albi 30 to 50 mg QW and Pio 30 to 45 
mg QD was allowed if needed. If hyperglycemic rescue was required, people 
remained in the study.
Results: Baseline characteristics were similar between groups. At Week 52 
(primary endpoint), Albi significantly decreased A1C vs Pbo but did not 
meet criteria for noninferiority vs Pio. Among people remaining in the study 
for 3-years (including those who received rescue medication), glycemic con-
trol was enhanced on Albi and Pio and maintained on Pbo (figure). Weight 
loss (kg) was observed on Albi and Pbo (-0.6 and -0.6), but weight increased 
on Pio (5.9 kg). Adverse events were higher on Albi than Pbo and Pio for 
injection site reactions (14.4%, 5.2%, 5.1% of participants, respectively), diar-
rhea (13.7%, 10.4%, 8.3%), and nausea (11.1%, 6.1%, 7.2%), but not vomiting 
(2.6%, 3.5%, 5.1%). The incidence of SAEs (14.4%, 18.3%, 17.3%) and AEs 
leading to withdrawal (8.1%, 10.4%, 10.5%) was lower on Albi than Pbo and 
Pio.
Conclusion: Albi in triple therapy gives effective glucose lowering to 3-years, 
was well tolerated, and was associated with less weight gain than Pio.
Clinical Trial Registration Number: NCT00839527
Supported by: Research funded by GSK
839
A network meta-analysis to compare once weekly dulaglutide versus 
other GLP-1 receptor agonists in patients with type 2 diabetes
A. Padhiar1, J.C. Thompson1, J.N. Eaton1, N.S. Hawkins1, K. Norrbacka2,  
M. Reaney2, R. Shaginian3, K.S. Boye4, N. Varol2;  
1ICON Health Economics, Oxford, 2Eli Lilly and Company,  
Windlesham, UK, 3Eli Lilly and Company, Houten, Netherlands,  
4Eli Lilly and Company, Indianapolis, USA.
Background and aims: A network meta-analysis (NMA) was performed to 
compare the efficacy of once weekly dulaglutide 1.5mg to other GLP-1 recep-
tor agonists (GLP1 RAs) licensed for use in the USA/Europe for the treat-
ment of hyperglycaemia in type 2 diabetes (T2D).
Materials and methods: A systematic review was conducted in CENTRAL, 
EMBASE, MEDLINE and recent conference proceedings from ADA, EASD, 
IDF-WDC, IDF-WPR and AASD (1990-Jan 2014) to identify randomised 
controlled trials of adults with T2D treated with liraglutide (1.2mg QD, 
1.8mg QD), exenatide (5μg BID, 10μg BID, 2mg QW), lixisenatide (20µg 
QD) and/or albiglutide (30mg QW, 50mg QW). The AWARD 1, 2, 5 and 6 
trials provided data for once weekly dulaglutide 1.5mg. The primary end-
point of the NMA was relative reduction in HbA1c. To adjust for potential 
heterogeneity, networks were stratified by background therapy: metformin 
monotherapy (add-on to MET) and metformin in combination with sulfony-
lurea (SU) and/or thiazolidinediones (TZD) (add-on to MET ± SU ± TZD). 
Networks were further stratified by study duration of 16-36 weeks and 37-56 
weeks to generate four networks. Baseline HbA1c was adjusted for using me-
ta-regression. The NMA was performed within a Bayesian framework; both 
fixed and random effects models were assessed.
Results: Baseline HbA1c adjusted results are presented as mean differences 
in HbA1c (%) change from baseline and 95% credible intervals (CrI) for once 
weekly dulaglutide 1.5mg versus other GLP1 RAs in Table 1. Random effects 
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models are presented where convergence was achieved; otherwise, fixed ef-
fects models are presented. The 37-56 weeks add-on to MET network was 
disconnected; therefore a NMA could not be conducted. In the 16-36 week 
network meta-analyses, once weekly dulaglutide 1.5mg showed improved 
control of HbA1c (%) compared to exenatide 5µg BID and lixisenatide 20µg 
QD as add-on to both MET and MET ± SU ± TZD, and exenatide 10µg BID 
as add-on to MET ± SU ± TZD only with statistically significant reductions 
from baseline. In the 37-56 week add-on to MET ± SU ± TZD NMA, once 
weekly dulaglutide 1.5mg showed a significant reduction in HbA1c (%) com-
pared to albiglutide 30mg QW and exenatide 10µg BID. A higher baseline 
HbA1c (%) was associated with greater reductions in HbA1c (%) but the effect 
was non-significant.
Conclusion: In the AWARD clinical trial program, once weekly dulaglutide 
1.5mg demonstrated significant improvements in HbA1c (%) reduction from 
baseline. In these NMAs, we have shown statistically significant improve-
ments in HbA1c (%) control with once weekly dulaglutide 1.5mg in seven 
comparisons. The results in the remaining comparisons were not statistically 
significant. Once weekly dulaglutide 1.5mg was not statistically significantly 
inferior to other GLP1 RAs in any of the comparisons.
Supported by: Eli Lilly and Company
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EVIDENCE 1
P. Gourdy1, A. Penfornis2, G. Charpentier3, S. Madani4, L. Martinez5,  
E. Eschwège6, J.-F. Gautier7;  
1Institut de Recherche sur les Maladies Métaboliques et Cardiovasculaires, 
Toulouse, France, 2University of Franche-Comté, Besançon,  
3Centre Hospitalier Sud Francilien, Corbeil, 4Novo Nordisk, Paris, 
5Université Pierre & Marie Curie, Paris, 6INSERM, Villejuif,  
7Lariboisière Hospital, Paris, France.
Background and aims: We report 2-year data on effectiveness and toler-
ability of the GLP-1 analogue liraglutide in the EVIDENCE observational, 
postmarketing study.
Materials and methods: EVIDENCE is a 2-year multicentre, observational, 
postmarketing outpatient study requested by the French National Health Au-
thority in order to evaluate the efficacy and safety of liraglutide in clinical 
practice. Diabetologists and general practitioners in France recruited patients 
starting treatment with liraglutide. Patients and physicians completed ques-
tionnaires at study entry, 3 months and 6 months, then at 6-month inter-
vals for a further 18 months. The primary objective was to determine the 
percentage of patients still taking liraglutide and at HbA1c target (<7%) af-
ter 2 years. We present here data on effectiveness as measured by change in 
the proportion of patients with HbA1c <7%, HbA1c, fasting plasma glucose 
and weight. Tolerability and persistence under treatment are also presented. 
The characteristics of included participants were described by the mean and 
standard deviation (mean±SD) for continuous measures, and frequency for 
categorical measures. The changes from baseline to the end of the study were 
compared by the McNemar test for proportion, and by the Wilcoxon test for 
continuous measures.
Results: Baseline data were collected from 3152 patients (53% male, age 
59±11 years, BMI 34±7 kg/m2, diabetes duration 10±6 years, HbA1c 
8.5±1.5%); 2029 patients (64.4%) were still taking liraglutide at the end of 
the study, beyond the initial objective of 1707. Most patients (n=2804, 90%) 
exceeded the ADA/EASD target with an HbA1c ≥7% at baseline. The pro-
portion of patients with HbA1c <7% was significantly higher after 2 years’ 
liraglutide treatment (n=759, 39.4%) vs. baseline (n=213, 11.0%; p<0.0001). 
Following 2 years of liraglutide treatment, significant reductions in HbA1c 
(-1.01±1.54%, p<0.0001), fasting plasma glucose (-0.32±0.63 g/l, p<0.0001) 
and body weight (-4.09±6.97 kg, p<0.0001) were observed from baseline. 
These data are from patients who had both baseline and 2-year data avail-
able and were still on liraglutide treatment at the end of the study (n=1928). 
GI disorders (nausea, vomiting, diarrhoea) were the most frequent adverse 
events, reported by 261 patients (8.7%) treated with liraglutide; they were also 
the most common reason for withdrawal.
Conclusion: These results show that the results obtained at 1 year were main-
tained at the end of the study. The effectiveness of liraglutide in real world 
clinical practice is similar to efficacy observed in randomised clinical trials 
(RCTs) (up to -1.5% HbA1c reductions and -3.24 kg weight loss). However, 
the absence of a control arm makes it difficult to evaluate if observed improve-
ments are attributable to liraglutide alone. The slightly lower mean HbA1c in 
this study may be due to differing treatment strategies: in RCTs, liraglutide 
was generally added on to existing therapy, whereas in EVIDENCE a third 
of patients switched from a DPP-4 inhibitor to liraglutide. The incidence of 
GI events was lower than that reported in RCTs (up to 26.5%). In summary, 
2-year results from the EVIDENCE study suggest that clinical trial data for 
liraglutide translate into therapeutic benefits in clinical practice.
Clinical Trial Registration Number: NCT01226966
Supported by: Novo Nordisk
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Lixisenatide is effective and well tolerated in patients with type 2 diabetes 
mellitus and renal impairment
M. Hanefeld1, A. Ambos2, J. Arteaga3, L.A. Leiter4, G. Marchesini5,  
E. Nikonova6, M. Shestakova7, W. Stager8, M. Tambascia9,  
R. Gómez Huelgas10;  
1Study Center Prof. Hanefeld, GWT-TUD GmbH, Dresden, Germany, 
2North Estonia Medical Center, Tallinn, Estonia, 3National University 
of Colombia School of Medicine, Bogotá D.C., Colombia, 4St. Michael’s 
Hospital, University of Toronto, Canada, 5University of Bologna, Italy, 
6Global Medical Affairs, Diabetes Division, Sanofi, Bridgewater, USA, 
7Endocrinology Research Center, Moscow, Russian Federation, 8Diabetes 
Division, Sanofi, Bridgewater, USA, 9University of Campinas, Brazil, 
10University Regional Hospital, Malaga, Spain.
Background and aims: This post hoc assessment evaluated the efficacy and 
safety of the once-daily prandial glucagon-like peptide-1 (GLP-1) receptor 
agonist (RA) lixisenatide in patients with type 2 diabetes mellitus and renal 
impairment.
Materials and methods: Patients from the modified intent-to-treat popu-
lations of nine GetGoal trials were categorized by baseline estimated GFR 
(eGFR) according to ADA 2013 categories of renal function at randomization 
(normal renal function, eGFR ≥90 ml/min; mild renal impairment [Stage II], 
eGFR 60-89 ml/min; moderate renal impairment [Stage III], eGFR 30-59 ml/
min). Meta-analyses were performed using effect estimates (placebo-adjusted 
mean difference or placebo-adjusted rate difference for lixisenatide-treated 
patients between baseline renal categories) and their standard errors, entered 
as generic inverse variances.
Results: Patient distribution across renal function categories was as follows: 
normal renal function, lixisenatide n=2081, placebo n=1158; mild renal im-
pairment, lixisenatide n=592, placebo n=404; moderate renal impairment, 
lixisenatide n=110, placebo n=62. HbA1c, 2h postprandial plasma glucose 
and fasting plasma glucose were reduced in lixisenatide-treated patients with 
normal and Stage I, II and III renal function. Meta-analyses showed no signif-
icant difference between normal renal function and mild or moderate renal 
impairment groups for clinical endpoints (Table). The most common adverse 
events in all groups were gastrointestinal (GI); mainly nausea and vomiting. 
There was 10% higher risk of nausea and vomiting between patients with nor-
mal renal function and those with mild renal impairment (placebo-adjusted 
rate difference p=0.003), but no significant difference between patients with 
mild and moderate renal impairment (p=0.92).
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Conclusion: This study shows that a difference in baseline renal status did 
not have an effect on efficacy outcomes in lixisenatide- vs placebo-treated 
patients, and a uniform placebo-adjusted effect of lixisenatide was observed 
across renal categories.
Supported by: Sanofi
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Predicting treatment success with exenatide twice daily (EBID) at 6 mo: 
Are baseline postprandial glucose excursions important? 
J. Shaw1, B. Gallwitz2, G. Schernthaner3, J. Han4, J. Malloy5;  
1Baker IDI Heart and Diabetes Institute, Melbourne, Australia,  
2Eberhand-Karls-University, Tubergen, Germany, 3Rudolfstiftung Hospital, 
Vienna, Austria, 4AstraZeneca, 5Bristol-Myers Squibb, San Diego, USA.
Background and aims: Information on predicting glycaemic treatment suc-
cess in patients (pts) before initiation of specific therapies, particularly GLP-
1 receptor agonists, is limited. As EBID effectively suppresses postprandial 
blood glucose (BG) through mechanisms including decreased gastric empty-
ing, we assessed whether a greater postprandial BG defect was predictive of 
treatment success for EBID and, conversely, whether a pt with a greater fast-
ing BG defect was less likely to achieve treatment success with EBID.
Materials and methods: A pooled dataset (24-30 wks) from 8 EBID stud-
ies that collected self-monitored BG data was used. Treatment success at 6 
mo was defined as HbA1c <7% or HbA1c decrease ≥1%. Logistic regression 
models were applied to analyze these binary outcomes, with baseline HbA1c, 
post-breakfast (postprandial) BG excursion and pre-breakfast (fasting) BG 
as independent variables. Odds ratios (ORs) were calculated for baseline 
HbA1c, post-breakfast BG excursion, and pre-breakfast BG.
Results: 1414 EBID pts were included; mean baseline HbA1c was 8.0%. Most 
pts (93%) received background therapy with ≥1 other agent. At endpoint, 
mean reduction in HbA1c was 1.0%; 58% of pts achieved HbA1c <7% and 
52% achieved HbA1c decrease ≥1% with EBID. Baseline HbA1c was the most 
significant baseline predictor of treatment success (P<0.0001). The likelihood 
of attaining treatment success for every 1% increase in baseline HbA1c giv-
en the same baseline pre-breakfast and post-breakfast BG depended on the 
definition of success (Table); pts close to 7% HbA1c at baseline were more 
likely to attain HbA1c <7% at endpoint, while pts further from 7% HbA1c 
at baseline were more likely to achieve HbA1c decrease ≥1% at endpoint. 
For pts with higher post-breakfast (post-prandial) BG treated with EBID, 
each 1.11 mmol/L increase was significantly associated with a 7.4% increased 
likelihood of achieving an HbA1c reduction ≥1% given comparable HbA1c 
and pre-breakfast BG. Baseline post-breakfast BG excursion did not predict 
achievement of HbA1c <7. Conversely, pts with an increased pre-breakfast 
(fasting) BG were significantly less likely to achieve either goal with EBID; 
ORs for HbA1c <7% or HbA1c reduction ≥1% decreased by 9 and 12%, re-
spectively, for each 1.11 mmol/L increase given comparable baseline HbA1c 
and post-breakfast glucose.
Conclusion: A greater postprandial BG defect was predictive of a greater 
likelihood of achieving an HbA1c reduction ≥1% but not HbA1c <7% with 
EBID and, conversely, a greater fasting BG defect was associated with less 
likelihood of achieving Hb1c <7% or an HbA1c reduction ≥1% among those 
treated with EBID. However, neither postprandial nor fasting BG defects 
at baseline predicted treatment success with EBID as effectively as baseline 
HbA1c.
Clinical Trial Registration Number: NCT00360334, NCT00359762, NCT00577824, 
NCT00082381, NCT00082407, NCT00381342, NCT00434954, NCT00375492
Supported by: Bristol-Myers Squibb/AstraZeneca
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Lixisenatide added to basal insulin reduces glycaemic variability in 
patients with type 2 diabetes mellitus
D. O‘Neal1, G. Umpierrez2, A. DiGenio3, R. Goldenberg4,  
E. Hernandez-Triana5, J. Lin6, C.-Y. Park7, E. Renard8, B. Kovatchev9;  
1University of Melbourne Dept of Medicine, St Vincent‘s Hospital, Australia, 
2Emory University School of Medicine, Atlanta, 3ISIS Pharmaceuticals, 
Carlsbad, USA, 4LMC Diabetes & Endocrinology, Thronhill, Canada, 
5Endocare Research Institute, Universidad del Rosario, Bogota, Colombia, 
6Novosys Health, Flemington, USA, 7Sungkyunkwan University School 
of Medicine, Seoul, Republic of Korea, 8Montpellier University Hospital, 
France, 9University of Virginia Health System, Charlottesville, USA.
Background and aims: This analysis evaluated the impact on glycaemic vari-
ability (GV) of lixisenatide (LIXI) vs placebo (PBO) as add-on to basal insu-
lin ± oral antidiabetes drugs (OADs) in patients with type 2 diabetes mellitus 
(T2DM).
Materials and methods: Patient-level data from GetGoal-L, GetGoal-Duo1, 
and GetGoal-L-Asia were pooled: standard deviation (SD); mean amplitude 
of glycaemic excursions (MAGE); mean absolute glucose (MAG); area under 
the curve-fasting glucose (AUC-F); and high and low blood glucose indi-
ces (HBGI/LBGI) were calculated. Changes in GV metrics over 24 weeks of 
treatment were compared. Relationships between baseline GV, patient char-
acteristics, and clinical outcomes were assessed.
Results: Data from 1,198 patients were analysed (665 LIXI and 533 PBO); 
47.9% of patients were men, mean age was 57.2 years, mean BMI 30.4 kg/m2, 
mean T2DM duration 11.7 years, and mean HbA1c 8.1%. GV significantly de-
creased at Week 24 with LIXI vs PBO, respectively: SD −8.28 vs −3.89 mg/dL 
(p = 0.003); MAG −6.80 vs −1.48 mg/dL (p < 0.001); MAGE −16.02 vs −7.02 
mg/dL (p = 0.003); HBGI −3.65 vs −0.88 (p < 0.001); and AUC-F −298.51 vs 
−15.49 mg/dL*h (p < 0.001). LBGI was unchanged 0.04 vs −0.03 (p = 0.277). 
Higher baseline GV correlated with older age, longer T2DM duration, lower 
BMI, higher baseline HbA1c, greater postprandial plasma glucose (PPG) re-
duction, and higher symptomatic hypoglycaemia rates (Table).
Conclusion: When added to basal insulin ± OADs, LIXI significantly re-
duced GV and PPG excursions vs PBO, without increased risk of hypoglycae-
mia (as shown by LBGI). This may have relevance in patients with advanced 
T2DM where GV is increased.
Supported by: Sanofi US, Inc.
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Sustained glycaemic control with exenatide once weekly versus insulin 
glargine: associations with baseline factors and early treatment response
M.E. Trautmann1, J. Malloy2, J. Han3;  
1Diabetes Research, Hamburg, Germany, 2Bristol-Myers Squibb, 
3AstraZeneca, San Diego, USA.
Background and aims: To assist decision making in type 2 diabetes mel-
litus therapy, this post hoc analysis explored the association between base-
line characteristics or early (≤12 week) treatment responses with sustained 
glycaemic control, comparing the glucagon-like peptide-1 receptor agonist 
exenatide once weekly (QW) with titrated insulin glargine (glargine).
Materials and methods: Three-year data were analysed from the open-label 
DURATION-3 study, in which patients received exenatide QW (N=233) or 
glargine (N=223) in addition to metformin alone or with a sulphonylurea. 
Loss of, or inability to achieve, HbA1c control was defined as HbA1c >7% at 
2 consecutive visits or HbA1c >9% at 1 visit after 26 weeks of treatment. Base-
line characteristics considered were: age, gender, body mass index, weight, 
background glucose-lowering medication, disease duration, creatinine clear-
ance, HbA1c, fasting serum glucose (FSG), Homeostasis Model Assessment 
(HOMA) -S (insulin sensitivity) and HOMA-B (β-cell function). Early treat-
ment responses considered were HbA1c, FSG and weight. Cox proportional 
hazard models were used to analyse the intention to treat (ITT) population 
and logistic regression was used to analyse the 3-year Completer population 
(exenatide QW, N=140; glargine, N=147).
Results: Of the ITT patients, 50% on exenatide QW versus 43% on glargine 
achieved the sustained glycaemic goal; of 3-year Completers, 43 versus 33% 
achieved the glycaemic goal. The median duration of HbA1c control was 25.0 
versus 16.7 months for exenatide QW versus glargine (ITT; Kaplan-Meier; 
P=0.03). The hazard ratio (glargine/exenatide; Cox model) of inability to 
achieve the glycaemic goal was 1.4 (P=0.006). In 3-year Completers (both 
treatments), stepwise logistic regression showed that only baseline HbA1c 
and HOMA-B were significantly associated with sustained glycaemic con-
trol. Regardless of therapy, every 1% higher baseline HbA1c (>7%) increased 
the risk of losing glycaemic control by 90% (P=0.0002); every 10% higher 
baseline HOMA-B decreased the risk of losing glycaemic control by 11% 
(P=0.0288). The rate of weight change in weeks 1-8 was the most relevant ear-
ly treatment response predictor of HbA1c control (P=0.0640). The medium 
slope of weight change was -0.0308 kg/day for exenatide QW (-0.86 kg in 4 
weeks) versus 0.0018 kg/day for glargine (0.05 kg in 4 weeks). The odds (glar-
gine/exenatide QW) of losing glycaemic control if the same weight change 
was seen in both groups was 1.2 (weight loss) and 1.1 (weight gain), indicat-
ing that glargine-treated patients were more likely to lose glycaemic control 
over time regardless of weight gain or loss. For a 1 kg decrease in weight over 
weeks 1-4 with exenatide QW, the odds of losing glycaemic control decreased 
by 30%; for a 1 kg increase in weight over weeks 1-4 with glargine, the odds 
increased by 29%.
Conclusion: Despite continued glargine titration, more patients achieved 
sustained glycaemic control with exenatide QW. Baseline HbA1c and HO-
MA-B significantly impacted the odds of sustained control. The analysis of 
early treatment responses from this study suggest that the rate of weight 
change following treatment initiation (weeks 1-8) may potentially predict the 
chance of patients achieving longer term sustained glycaemic control.
Clinical Trial Registration Number: NCT00641056
Supported by: Bristol-Myers Squibb/AstraZeneca
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Daily blood glucose variability with exenatide once weekly versus basal 
insulin in 3 randomised controlled trials 
J. Vora1, J. Malloy2, M. Zhou3, E. Hardy4, N. Iqbal5, M. Trautmann6;  
1Royal Liverpool University Hospital, UK, 2Bristol-Myers Squibb, San Diego, 
3Bristol-Myers Squibb, Hopewell, 4Astra Zeneca, Wilmington, 5Bristol-
Myers Squibb, Princeton, USA, 6Diabetes Research, Hamburg, Germany.
Background and aims: Glucose lowering therapy aims to improve overall 
glycaemic control in patients with type 2 diabetes mellitus. However, data 
on blood glucose variability with different treatments are scarce. Because ba-
sal insulin mainly affects fasting plasma glucose and exenatide once weekly 
(QW) controls both fasting plasma glucose and postprandial plasma glucose, 
we hypothesized that daily blood glucose variability would be improved more 
by exenatide QW than by titrated basal insulin in randomised controlled tri-
als.
Materials and methods: After 26 weeks, 7-point self-monitored blood glu-
cose profiles were assessed in 3 randomised controlled trials of exenatide 
QW: 2 versus insulin glargine (once daily at night) in global and Japanese 
populations; 1 versus insulin detemir (once daily at night [90%] or twice daily 
[10%]). All patients had failed ≥1 oral drug; Japanese patients discontinued 
sulfonylureas at randomisation. Outcomes assessed were mean amplitude 
of glucose excursion (MAGE; average daily mealtime glucose excursion), 
blood glucose range (average difference between maximum and minimum 
daily blood glucose) and blood glucose variability (average SD of daily blood 
glucose).
Results: In all 3 studies, HbA1c reductions were greater with exenatide QW 
than basal insulin (−1.5 vs −1.3% P<0.02; −1.1 vs −0.7%, P<0.001; −1.3 vs 
−0.9%, P<0.001, respectively). Baseline characteristics and laboratory results 
were well balanced across treatments within studies. Exenatide QW signifi-
cantly reduced different measures of blood glucose variability (including 
MAGE, range and variability) more than insulin glargine in both available 
studies (Table), demonstrating greater consistency in blood glucose over the 
day. A greater decrease in glucose variability was also observed for exenatide 
QW versus insulin detemir, although comparison between treatments was 
not statistically significant in this analysis. Basal insulin reduced pre-break-
fast (fasting) blood glucose from baseline more than exenatide QW (−2.54 to 
−3.41 vs −1.88 to −2.77 mmol/L; P<0.05) but the relative effect of exenatide 
QW increased through the day, with a greater reduction in blood glucose 
post-dinner versus basal insulin (−2.89 to −4.23 vs −1.84 to −2.54 mmol/L; 
P<0.05). The loss of control with basal insulin in the latter half of the day is 
consistent with its once daily kinetics.
Conclusion: Exenatide QW improved daily blood glucose variability more 
than insulin glargine, and lowered fasting blood glucose less - but post-din-
ner blood glucose more - than both basal insulins (glargine and detemir).
Clinical Trial Registration Number: NCT00641056, NCT01003184, 
NCT00935532
Supported by: Bristol-Myers Squibb/AstraZeneca
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Relationship between changes in postprandial glucagon, patient 
characteristics, and response to lixisenatide as add-on to oral 
antidiabetics
C.J. Bailey1, S.T. Azar2, L. Blonde3, D. Dicker4, M. Puig-Domingo5,  
F.G. Eliaschewitz6, E. Nikonova7, R. Roussel8, K. Sakaguchi9,  
L. Sauque-Reyna10, M. Nauck11;  
1School of Life and Health Sciences, Aston University, Birmingham, UK, 
2American University of Beirut Medical Center, Lebanon, 3Ochsner Medical 
Center, New Orleans, USA, 4Hasharon Hospital-Rabin Medical Center, 
Petach-Tikva, Israel, 5Universitat Autònoma de Barcelona, Badalona, Spain, 
6CPClin – Clinical Research Center, São Paulo, Brazil, 7Global Medical 
Affairs, Diabetes Division, Sanofi, Bridgewater, USA, 8Université Paris-
Diderot, France, 9Kobe University Graduate School of Medicine, Japan, 
10Instituto de Diabetes Obesidad y Nutricion S.C., Cuernavaca, Mexico, 
11Diabeteszentrum Bad Lauterberg, Germany.
Background and aims: Lixisenatide, a once-daily prandial glucagon-like 
peptide-1 receptor agonist, reduces postprandial (PP) glycaemic excursions 
and HbA1c. We report an exploratory analysis of the GetGoal-M and S trials 
in patients with type 2 diabetes mellitus (T2DM) with different changes in PP 
glucagon levels in response to lixisenatide treatment.
Materials and methods: Patients (n=423) were stratified by their change in 
2 hour PP glucagon level between baseline evaluation and Week 24 of treat-
ment with lixisenatide as add-on to oral antidiabetics (OADs) into groups 
of Greater Change (GC; n=213) or Smaller Change (SC; n=210) in plasma 
glucagon levels (median change -23.57 ng/L). ANOVA and Chi-squared tests 
were used for the comparison of continuous and categorical variables, respec-
tively. Baseline and endpoint continuous measurements in each group were 
compared using paired t-tests.
Results: Mean change from baseline in 2 hour PP glucagon levels for the 
GC vs SC groups was -47.19 vs -0.59 ng/L (p<0.0001), respectively. Patients 
in the GC group had a shorter mean duration of diabetes (7.3 vs 9.0 years; 
p=0.0036) and lesser OAD use (4.5 vs 5.7 years; p=0.0092) than those in 
the SC group. Patients in the GC group had a greater mean reduction in 
HbA1c (-1.10 vs -0.67%; p<0.0001), fasting plasma glucose (FPG; -25.20 vs 
-9.30 mg/dL [p<0.0001]), PP plasma glucose (PPG; -129.40 vs -78.22 mg/dL 
[p<0.0001]), and a greater drop in weight (-2.27 vs -1.17 kg; p=0.0002) and 
body mass index (-0.84 vs -0.44 kg/m2; p=0.0002) than those in the SC group. 
More patients in the GC group also achieved composite endpoints, including 
HbA1c <7% with no symptomatic hypoglycaemia and no weight gain (40.38 
vs 19.52%; p<0.0001), than in the SC group.
Conclusion: Greater reductions in PP glucagon associated with lixisenatide 
as add-on to OADs in patients with T2DM are also associated with greater 
reductions in HbA1c, FPG, PPG, and greater weight loss, highlighting the 
importance of glucagon suppression on therapeutic response.
Clinical Trial Registration Number: NCT00712673; NCT00713830
Supported by: Sanofi
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Glycaemic efficacy of canagliflozin by baseline HbA1c and known 
duration of type 2 diabetes mellitus
S. Cerdas1, L.A. Leiter2, L. Blonde3, J. Wilding4, C. Tong5, J. Yee5,  
G. Meininger5;  
1Hospital Cima, Centro de Investigacíon Clínica San Agustín, San José, 
Costa Rica, 2Keenan Research Centre in the Li Ka Shing Knowledge Institute 
of St. Michael’s Hospital, University of Toronto, Canada, 3Department of 
Endocrinology, Diabetes, and Metabolic Diseases, Ochsner Medical Center, 
New Orleans, USA, 4Department of Obesity and Endocrinology, University 
of Liverpool, UK, 5Janssen Research & Development, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA) is a sodium glucose co-trans-
porter 2 (SGLT2) inhibitor that has demonstrated glycaemic efficacy across a 
range of type 2 diabetes mellitus (T2DM) patient populations. This analysis 
evaluated the effects of CANA compared with placebo (PBO) on changes in 
HbA1c based on baseline HbA1c and duration of T2DM using pooled data 
from 4 clinical studies in patients with T2DM.
Materials and methods: Data were pooled from the 4 randomised, double-
blind, 26-week, PBO-controlled, Phase 3 studies that enrolled a general pop-
ulation of patients with T2DM (N = 2,313; mean age, 56.0 y; HbA1c, 8.0%; 
BMI, 32.1 kg/m2; SBP, 128.4 mmHg). Changes in HbA1c with CANA 100 
and 300 mg and PBO were evaluated at 26 weeks in subgroups by baseline 
HbA1c (<8.0%, 8.0%-<9.0%, and ≥9.0%) and T2DM duration (<5 y, 5-<10 
y, and ≥10 y).
Results: CANA 100 and 300 mg, respectively, were associated with progres-
sively greater PBO-subtracted reductions in HbA1c as baseline HbA1c in-
creased (<8.0%: -0.45% and -0.65%; 8.0%-<9.0%: -0.91% and -1.07%; ≥9.0%: 
-1.25% and -1.48%, Table). CANA 100 and 300 mg were associated with 
PBO-subtracted reductions in HbA1c in patients with T2DM <5 y duration 
(-0.70% and -0.96%, respectively) as well as those with 5-<10 y T2DM dura-
tion (-0.74% and -0.91%, respectively) and ≥10 y T2DM duration (-0.74% 
and -0.85%, respectively). Overall AE rates with CANA 100 and 300 mg and 
PBO were 60.1%, 59.2%, and 59.4%, respectively. CANA 100 and 300 mg 
were associated with a higher incidence of genital mycotic infections and 
osmotic diuresis-related AEs (eg, pollakiuria [increased urine frequency], 
thirst) compared with PBO; these AEs led to few discontinuations.
Conclusion: CANA provided glycaemic improvements in patients with 
T2DM regardless of baseline HbA1c or known duration of T2DM. Greater 
reductions in HbA1c with CANA were seen in patients with higher baseline 
HbA1c, similar to what has been observed with other antihyperglycaemic 
agents. Reductions in HbA1c were similar across all T2DM duration sub-
groups.
Supported by: Janssen Research & Development, LLC
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Durability of glycaemic response with dapagliflozin as add-on therapy 
in type 2 diabetes inadequately controlled with metformin; 4-year data 
versus glipizide
S. Del Prato1, M. Nauck2, K. Rohwedder3, E. Johnsson4, S. Parikh5;  
1University of Pisa, Italy, 2Diabetes Center, Bad Lauterberg,  
3AstraZeneca, Wedel, Germany, 4AstraZeneca, Mölndal, Sweden, 
5AstraZeneca, Wilmington, USA.
Background and aims: Dapagliflozin (DAPA), a selective inhibitor of the 
sodium-glucose co-transporter 2, reduces plasma glucose by increasing renal 
glucose excretion. Its insulin-independent mechanism results in a low risk of 
hypoglycaemia in contrast to sulphonylureas. In a phase 3 trial of DAPA (≤ 
10 mg/d) versus glipizide (≤ 20 mg/d) in patients (N=814) with type 2 dia-
betes mellitus inadequately controlled by metformin (MET) alone (median 
2000 mg/d), the change in HbA1c with DAPA was statistically noninferior 
to glipizide over 52 weeks. Further to these previously presented data on the 
primary end point we report the durability of glycaemic control over 4 years.
Materials and methods: The durability of glycaemic control was evaluated 
by calculating the coefficient of failure (CoF; the slope of the regression line 
vs time) for HbA1c and fasting plasma glucose (FPG) from 18 weeks (end 
of titration period) to 208 weeks. DAPA and glipizide were down-titrated if 
medically indicated. The CoF was determined for 3 groups: patients who had 
at least 3 postbaseline values from after week 18 to week 208 (full analysis 
set), all patients who completed 208 weeks of treatment (all completers), and 
patients who completed 208 weeks of treatment but who were not down-
titrated (completers not down-titrated). Patients who required rescue medi-
cation were excluded from the analyses.
Results: The CoF for DAPA was significantly lower compared with glipizide, 
irrespective of which glycaemic variable (HbA1c or FPG) or analysis set was 
employed (Table). For the full analysis set, the CoF for HbA1c showed a rise 
of 0.2%/year (95% CI, 0.1 to 0.3) with DAPA and a rise of 0.6%/year (95% CI, 
0.5 to 0.7) with glipizide. Corresponding values for FPG were 0.4 mmol/L/
year (95% CI, 0.2 to 0.5) for DAPA and 0.8 mmol/L/year (95% CI, 0.5 to 1.1) 
for glipizide. More patients treated with DAPA completed the 208-week study 
than patients treated with glipizide (161 vs 141, respectively). Fewer DAPA-
treated patients had their dose down-titrated (3 vs 42, respectively; Table). 
For all completers and for completers who were not down-titrated, the CoFs 
for HbA1c and FPG were significantly lower with DAPA compared with 
glipizide (Table). Thus, the higher rates of discontinuation or down-titration 
with glipizide did not account for the lower CoF with DAPA. Treatment with 
DAPA in combination with MET was well tolerated over the 208-week pe-
riod.
Conclusion: Glycaemic durability over a 4-year period was significantly bet-
ter with DAPA compared with glipizide as demonstrated by the CoF. DAPA 
in combination with MET was well tolerated.
Clinical Trial Registration Number: NCT00660907
Supported by: AstraZeneca / BMS
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Empagliflozin twice daily versus once daily as add-on to metformin in 
patients with type 2 diabetes
S. Ross1, C. Thamer2, J. Cescutti3, T. Meinicke4, H.J. Woerle4, U.C. Broedl4;  
1University of Calgary, LMC Endocrinology Centres, Canada,  
2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 
3Boehringer Ingelheim France S.A.S., Reims, France,  
4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Background and aims: A randomized, double-blind, placebo-controlled, 
parallel-group study compared the efficacy and safety of empagliflozin 
(EMPA) twice daily (bid) versus once daily (qd) regimens as add-on to met-
formin (MET) in patients with type 2 diabetes (T2DM).
Materials and methods: Patients (n=983) were randomised to EMPA 12.5 
mg bid (n=219), EMPA 25 mg qd (n=218), EMPA 5 mg bid (n=219), EMPA 
10 mg qd (n=220) or placebo (PBO; n=107) added on to stable dose MET bid 
(≥1500 mg/day) for 16 weeks. The primary endpoint was change from base-
line in HbA1c at week 16. The secondary endpoint was change from baseline 
in fasting plasma glucose (FPG) at week 16. Exploratory endpoints included 
changes from baseline in body weight, systolic and diastolic blood pressure 
(SBP and DBP) at week 16. The primary analysis was a test of non-inferiority 
of EMPA 12.5 mg bid versus EMPA 25 mg qd and of EMPA 5 mg bid versus 
EMPA 10 mg qd. The superiority of EMPA doses versus placebo was also test-
ed. Efficacy was evaluated in 965 patients (mean [SD] age 58.2 [10.3] years; 
weight 89.0 [18.5] kg; BMI 31.8 [5.2] kg/m2; HbA1c 7.77 [0.80] %).
Results: Reductions from baseline in HbA1c were non-inferior for EMPA 12.5 
mg bid versus 25 mg qd and for EMPA 5 mg bid versus 10 mg qd. Reductions 
from baseline in HbA1c were statistically significant with all EMPA doses 
compared with PBO. FPG changes with EMPA were consistent with HbA1c 
changes. EMPA qd and bid doses reduced body weight, SBP and DBP to a 
similar extent. Adverse events (AEs) were reported by 45.7%, 41.7%, 43.8%, 
50.0% and 47.7% of patients on EMPA 12.5 mg bid, EMPA 25 mg qd, EMPA 
5 mg bid, EMPA 10 mg qd and PBO, respectively. Confirmed hypoglycaemic 
AEs (<70 mg/dl and/or requiring assistance) were reported by 1 patient each 
on EMPA 25 mg qd, EMPA 5 mg bid, EMPA 10 mg qd and PBO, and were 
generally mild in intensity; none required assistance. AEs consistent with uri-
nary tract infection (UTI) were reported in 5.9%, 5.5%, 7.8%, 9.5% and 3.7% 
of patients on EMPA 12.5 mg bid, EMPA 25 mg qd, EMPA 5 mg bid, EMPA 
10 mg qd and PBO, respectively. AEs consistent with genital infection were 
reported in 4.1%, 4.1%, 3.7%, 3.2% and 2.8% of patients in these groups, and 
increased urination in 2.7%, 2.8%, 2.7%, 2.3% and 1.9% of patients in these 
groups, respectively. AEs consistent with volume depletion were reported in 
0.5% of patients on EMPA 12.5 mg bid, 0.9% on EMPA 10 mg qd and no 
patients in other groups.
Conclusion: As add-on to MET in patients with T2DM, HbA1c reductions 
with EMPA bid dose regimens were statistically non-inferior to those with 
EMPA qd dose regimens. All EMPA dose regimens led to significant reduc-
tions in HbA1c versus PBO and were well tolerated.
Clinical Trial Registration Number: NCT01649297
Supported by: Boehringer Ingelheim and Eli Lilly
 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 346 
1 C
850
Systematic review and network meta-analysis to compare dapagliflozin 
with other diabetes medications in combination with metformin for 
adults with type 2 diabetes
G. Wygant1, A.H. Barnett2, M.E. Orme3, P. Fenici4, R. Townsend5,  
M. Roudaut6;  
1Bristol-Myers Squibb, Princeton, USA, 2Diabetes Centre, Birmingham, 
3ICERA Consulting Ltd, Swindon, UK, 4Bristol-Myers Squibb (at the time 
of research), Paris, France, 5AstraZeneca (at the time of research), Brussels, 
Belgium, 6Bristol-Myers Squibb, Paris, France.
Background and aims: Effective management of type 2 diabetes mellitus 
(T2DM) and its complications is required in order to address the growing 
burden of the disease on healthcare resources. However, there are many fac-
tors to consider when assessing the suitability of available treatments. A net-
work meta-analysis (NMA) update was undertaken to evaluate the sodium 
glucose co-transporter-2 (SGLT-2) inhibitor, dapagliflozin, versus other dia-
betes medications as add-on to metformin. This update allowed inclusion of 
a new drug class (glucagon-like peptide-1 [GLP-1] analogues), a new time-
point (24-weeks) and covariate analysis.
Materials and methods: The systematic review identified recent randomised 
controlled trials (2011-July 2013) involving T2DM patients inadequately con-
trolled on metformin monotherapy. Comparators licensed in the EU includ-
ed dipeptidyl peptidase-4 inhibitors (DPP-4i), thiazolidinediones (TZDs), 
glucagon-like peptide-1 (GLP-1s) analogues, sulfonylureas (SUs) and dapa-
gliflozin. Bayesian NMA was conducted for outcomes at 24- and 52-weeks, 
and both fixed and random-effect models were explored. Covariate analyses 
were performed to assess confounding baseline parameters where feasible.
Results: Of 2247 articles retrieved, 16 were included in the review. Combined 
with 19 from the pre-2011 analysis, a total of 19 and 8 studies were included 
in the 24-week and 52-week basecase NMA, respectively. There were suffi-
cient data to analyse mean change in HbA1c, systolic blood pressure (SBP), 
change in weight, as well as the proportion of patients experiencing hypo-
glycaemia at both 24 and 52-weeks. There were no significant differences 
in change in HbA1c or SBP between dapagliflozin and the other classes of 
diabetes drugs as add-on to metformin at 24 or 52-weeks. Significant weight 
loss results were seen by 24-weeks for dapagliflozin compared to DPP-4i and 
TZD and at 52-weeks for dapagliflozin compared to SU, DPP-4i and TZD: 
-4.66 kg (-6.43, -2.90); -2.59 kg (-4.53, -0.66) and -4.76 kg (-7.28, -2.24) at 
52 weeks, respectively. Dapagliflozin resulted in a significantly lower risk of 
hypoglycaemia compared to SU (OR: 0.05 [0.01, 0.19]) over 52-weeks. Co-
variate analysis indicated that a higher HbA1c at baseline was predictive of a 
larger treatment effect.
Conclusion: This NMA update supports previous findings that effects on 
HbA1c are largely similar between drug classes. However, dapagliflozin 
compared with DPP-4i, TZDs and SUs offered superior weight control when 
added to metformin and was associated with a significantly reduced risk of 
hypoglycaemia in comparison to SUs. The wider evidence base compared to 
previous analysis increases the confidence in the results.
Supported by: BMS and AstraZeneca
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Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in 
drug-naïve subjects with type 2 diabetes
A. Lewin1, R. DeFronzo2, S. Patel3, D. Liu4, R. Kaste4, H.J. Woerle5,  
U.C. Broedl5;  
1National Research Institute, Los Angeles, 2University of Texas Health 
Sciences, San Antonio, USA, 3Boehringer Ingelheim Ltd., Bracknell, 
Berkshire, UK, 4Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, 
USA, 5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, 
Germany.
Background and aims: A randomized, double-blind, parallel group Phase 
III study evaluated the efficacy and safety of fixed dose combinations (FDCs) 
of empagliflozin/linagliptin (EMPA/LINA) in drug-naïve subjects with type 
2 diabetes (T2DM).
Materials and methods: Subjects were randomized to EMPA 25 mg/LINA 
5 mg (n=137), EMPA 10 mg/LINA 5 mg (n=136), EMPA 25 mg (n=135), 
EMPA 10 mg (n=134), or LINA 5 mg (n=135) for 52 weeks. Primary analysis 
was at week 24. Exploratory endpoints at week 52 were changes from baseline 
in HbA1c, body weight, systolic and diastolic blood pressure (SBP and DBP), 
and percentage of subjects with baseline HbA1c ≥7% who reached HbA1c 
<7%. Efficacy was evaluated in 667 subjects (mean [SD] age 54.6 [10.2] years; 
weight 87.9 [20.1] kg; BMI 31.6 [5.6] kg/m2; HbA1c 8.02 [0.96] %).
Results: Compared with LINA 5 mg, both FDCs led to significant reduc-
tions in HbA1c and higher percentages of subjects with HbA1c <7% at week 
52. EMPA 10 mg/LINA 5 mg led to significant reductions in HbA1c and a 
higher percentage of subjects with HbA1c <7% vs EMPA 10 mg. There were 
no significant differences in changes from baseline in HbA1c or percentages 
of subjects with HbA1c <7% with EMPA 25 mg/LINA 5 mg vs EMPA 25 
mg. Compared with LINA 5 mg, body weight was significantly reduced with 
EMPA 25 mg/LINA 5 mg (difference: -2.2 kg [95% CI 3.4, 1.0]; p<0.001) and 
EMPA 10 mg/LINA 5 mg (difference: 1.5 kg [95% CI -2.8, -0.3]; p<0.05). The 
FDCs did not reduce weight vs their respective EMPA monotherapies. There 
were no changes from baseline in SBP or DBP with LINA 5 mg but EMPA 
and FDCs reduced SBP from baseline by 2.1 to 2.5 mmHg and DBP by 0.2 
to 1.6 mmHg. Adverse events (AEs) were reported in 75.7%, 72.8%, 68.9%, 
81.5% and 71.9% of subjects on EMPA 25 mg/LINA 5 mg, EMPA 10 mg/
LINA 5 mg, EMPA 25 mg, EMPA 10 mg and LINA 5 mg, respectively, over 
52 weeks. Confirmed hypoglycemic AEs (glucose ≤70 mg/dL and/or requir-
ing assistance) were reported in 1 patient each on EMPA 25 mg and LINA 5 
mg and 4 subjects on EMPA 10 mg; none required assistance. AEs consistent 
with urinary tract infection were reported in 12.5%, 15.4%, 10.4%, 16.3% and 
10.4% of subjects on EMPA 25 mg/LINA 5 mg, EMPA 10 mg/LINA 5 mg, 
EMPA 25 mg, EMPA 10 mg and LINA 5 mg, respectively, and AEs consistent 
with genital infection were reported in 5.9%, 2.9%, 4.4%, 5.2% and 3.0% of 
subjects in these groups, respectively.
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Conclusion: In drug-naïve subjects with T2DM, FDCs of EMPA 25 mg/
LINA 5 mg and EMPA 10 mg/LINA 5 mg for 52 weeks significantly reduced 
HbA1c vs LINA 5 mg. HbA1c reductions were significantly greater with 
EMPA 10 mg/LINA 5 mg vs EMPA 10 mg, but not with EMPA 25 mg/LINA 
5 mg vs EMPA 25 mg. FDCs were well tolerated, with overall safety profiles 
similar to those known for the individual components.
Clinical Trial Registration Number: NCT01422876
Supported by: Boehringer Ingelheim and Eli Lilly
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Improvement in glycaemic control and reduction in body weight over 
52 weeks with dapagliflozin as add-on therapy to metformin plus 
sulphonylurea
S. Matthaei1, K. Bowering2, K. Rohwedder3, A. Grohl4, E. Johnsson5;  
1Diabetes-Zentrum Quakenbrück, Germany,  
2University of Alberta, Edmonton, Canada, 3AstraZeneca, Wedel,  
4Aptiv Solutions, Köln, Germany, 5AstraZeneca, Mölndal, Sweden.
Background and aims: Dapagliflozin (DAPA), a highly selective sodium-
glucose co-transporter 2 inhibitor, improves glycaemic control and promotes 
body weight loss in patients with type 2 diabetes mellitus (T2DM) as mono-
therapy or in combination with other antihyperglycaemic drugs. This phase 
3 study evaluated DAPA as an add-on therapy to metformin (MET) plus sul-
phonylurea (SU).
Materials and methods: Patients (men and women aged ≥ 18 years) with 
T2DM (HbA1c ≥ 7.0%-≤ 10.5% at randomisation) who were receiving a 
stable (≥ 8 weeks prior to enrolment) dose combination of MET (≥ 1500 
mg/d) and SU (maximum tolerated dose of at least half maximum dose) were 
eligible to participate. Patients were randomised to receive DAPA 10 mg or 
placebo (PBO) once daily for 52 weeks (24-week double-blind period and 
28-week extension).
Results: At week 52, HbA1c and fasting plasma glucose (FPG) improved with 
DAPA versus PBO (HbA1c -0.8% vs -0.1%; FPG -1.5 mmol/L [-27.6 mg/dL] 
vs 0.6 mmol/L [11.5 mg/dL]; Table). Over 52 weeks more patients achieved 
the American Diabetes Association recommended glycaemic goal of HbA1c 
< 7.0% with DAPA (27.3%) versus PBO (11.3%). Both body weight and sys-
tolic blood pressure were reduced with DAPA versus PBO. Total, low-density 
lipoprotein, and high-density lipoprotein cholesterol increased and triglycer-
ides decreased from baseline to week 52 with DAPA versus PBO. No patient 
discontinued as a result of a lack of glycaemic control and fewer patients on 
DAPA (10.1%) than on PBO (42.7%) were rescued for failing to reach glycae-
mic targets (week 4-16, FPG >13.2 mmol/L (240 mg/dL); week 16-24, FPG 
>11.1 mmol/L (200 mg/dL); week 24-52, HbA1c > 8.0%). In DAPA versus 
PBO groups the frequency of adverse events (AEs) was 69.7% versus 73.4%, 
respectively; serious AEs were 6.4% versus 7.3%, and hypoglycaemic events 
were 15.6% versus 8.3% (1 event of hypoglycaemia led to discontinuation in 
the DAPA treatment arm). Genital infections were reported by 10.1% versus 
0.9% of patients with DAPA versus PBO (women 14.3% vs 2.0%; men 4.3% vs 
0%). Urinary tract infections were reported by 10.1% versus 11.0% of patients 
with DAPA versus PBO (women 12.7% vs 22.4%; men 6.5% vs 1.7%).
Conclusion: DAPA 10 mg resulted in sustained glycaemic benefits and 
weight loss over the duration of this 52-week study in patients with T2DM 
and inadequate glycaemic control on a background combination of MET and 
SU.
Clinical Trial Registration Number: NCT01392677
Supported by: AZ/BMS
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Efficacy and safety of canagliflozin in patients with type 2 diabetes 
mellitus who were, or were not, on antihyperglycaemic agents at 
screening
G. González-Gálvez1, E. Jodar2, K. Kim3, M. Alba4, C. Tong4, G. Meininger4;  
1Instituto Jalisciense de Investigacion en Diabetes y Obesidad, Guadalajara, 
Mexico, 2Department of Endocrinology, Hospital Quiron, Madrid, Spain, 
3Department of Internal Medicine, Dongguk University Ilsan Hospital, 
Dongguk University School of Medicine, Goyang, Republic of Korea, 
4Janssen Research & Development, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-trans-
porter 2 (SGLT2) inhibitor, demonstrated glycaemic improvement and was 
generally well tolerated in a Phase 3 study of patients with type 2 diabetes 
mellitus (T2DM) inadequately controlled on diet and exercise. In that study, 
the efficacy and safety of CANA monotherapy compared with placebo (PBO) 
were evaluated in patients who were, or were not, on antihyperglycaemic 
agents (AHAs) at screening.
Materials and methods: In this randomised, double-blind, PBO-controlled 
study, patients with T2DM inadequately controlled with diet and exercise (N 
= 584; age, 55.4 y; HbA1c, 8.0%; fasting plasma glucose [FPG], 9.5 mmol/L; 
body mass index, 31.6 kg/m2) received CANA 100 or 300 mg or PBO once 
daily. Change in HbA1c from baseline to Week 26 was assessed in the overall 
modified intent-to-treat population and subsets of patients who were not on 
AHAs at screening (n = 303), or on AHAs (oral AHA monotherapy [except 
PPAR-γ agonists] or low-dose combination metformin + sulphonylurea) and 
entered the AHA washout period (n = 281).
Results: Patients on AHAs at screening had a higher baseline mean age and 
T2DM duration, lower mean estimated glomerular filtration rate (eGFR), 
and higher HbA1c and FPG. Relative to PBO, CANA 100 and 300 mg low-
ered HbA1c in patients not on AHAs (differences of -0.72% and -1.05%) and 
on AHAs at screening (differences of -1.11% and -1.29%; Figure) at Week 26; 
changes were similar to those in the overall population. The overall incidence 
of adverse events (AEs) was higher with CANA 100 and 300 mg than PBO 
in patients not on AHAs (59% and 52% vs 46%) and on AHAs at screening 
(62% and 68% vs 52%), but the incidence of serious AEs and AEs leading to 
discontinuation were low across groups in both subsets.
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Conclusion: CANA treatment lowered HbA1c and was generally well toler-
ated in patients with T2DM who were, or were not, on prior AHA therapy 
at screening.
Clinical Trial Registration Number: NCT01081834
Supported by: Janssen Research & Development, LLC
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Canagliflozin reduces both HbA1c and body weight in patients with type 
2 diabetes mellitus on background metformin
G. Langslet1, J.A. Davidson2, V. Valentine3, U. Vijapurkar4, W. Canovatchel4, 
G. Meininger4;  
1Lipid Clinic, Oslo University Hospital, Norway, 2Touchstone Diabetes 
Center, The University of Texas Southwestern Medical Center, Dallas, 
3Northside Family Medicine, Albuquerque,  
4Janssen Research & Development, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-trans-
porter 2 (SGLT2) inhibitor, is approved for the treatment of adults with type 
2 diabetes mellitus (T2DM). Reductions in HbA1c and body weight (BW) 
have been observed with CANA in 2 studies as add-on to metformin over 
52 weeks. This post hoc analysis describes the distribution of change from 
baseline in HbA1c and BW in these studies at Week 52.
Materials and methods: This analysis used data from 2 separate randomised, 
double-blind, active-controlled Phase 3 studies of CANA 100 and 300 mg 
versus either sitagliptin (SITA) 100 mg (Study 1: N = 1,284; HbA1c, 7.9%; 
BW, 87.2 kg) or glimepiride (GLIM; Study 2: N = 1,450; HbA1c, 7.8%; BW, 
86.6 kg). Study 1 included a treatment arm where patients received placebo 
during the 26-week core period and switched to SITA during the 26-week 
extension period (n = 183); this arm was excluded from the current analysis.
Results: In Study 1, least squares (LS) mean HbA1c changes from baseline 
were −0.73%, −0.88%, and −0.73%, and LS mean BW changes from baseline 
were −3.8%, −4.2%, and −1.3% with CANA 100 and 300 mg and SITA 100 
mg, respectively. In Study 2, LS mean HbA1c changes from baseline were 
−0.82%, −0.93%, and −0.81%, and LS mean BW changes from baseline were 
−4.2%, −4.7%, and 1.0% with CANA 100 and 300 mg and GLIM, respec-
tively. A greater proportion of patients had reductions in both HbA1c and 
BW with CANA 100 and 300 mg compared with SITA 100 mg (67.7%, 74.7%, 
and 50.6%, respectively) or GLIM (72.4%, 78.5%, and 26.8%, respectively; 
Figure). More patients had a decrease in HbA1c with either no change or an 
increase in BW with SITA or GLIM versus CANA 100 and 300 mg in both 
studies.
Conclusion: CANA provided reductions in both HbA1c and BW versus 
SITA 100 mg or GLIM in most patients with T2DM as add-on to metformin 
at 52 weeks.
Clinical Trial Registration Number: NCT01106677, NCT00968812
Supported by: Janssen Research & Development, LLC
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Glycaemic efficacy of canagliflozin is largely independent of baseline 
beta cell function or insulin sensitivity
D. Matthews1, B. Zinman2, C. Tong3, G. Meininger3, D. Polidori4;  
1The Oxford Centre for Diabetes, Endocrinology and Metabolism, UK, 
2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University 
of Toronto, Canada, 3Janssen Research & Development, LLC, Raritan, USA, 
4Janssen Research & Development, LLC, San Diego, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-trans-
porter 2 (SGLT2) inhibitor, lowers plasma glucose and HbA1c in patients 
with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excre-
tion. Because CANA’s mechanism of action is insulin-independent, it was 
hypothesised that the glycaemic efficacy of CANA would be independent of 
baseline beta-cell function (BCF) or insulin sensitivity (IS). This hypothesis 
was tested using data from 4 placebo (PBO)- and 2 active-controlled studies 
to measure BCF (HOMA-%B) and IS (HOMA2-%S).
Materials and methods: The first analysis pooled data from 26-week PBO-
controlled studies (N = 2,313; baseline HbA1c = 8.0%, HOMA2-%B = 49, 
HOMA2-%S = 60). Patients were divided into tertiles of HOMA2-%B or HO-
MA2-%S and, given the potential impact of baseline HbA1c, further divided 
based on baseline HbA1c (HbA1c <7.5%, 7.5% ≤ HbA1c <8.5%, HbA1c 
≥8.5%). Change in HbA1c from baseline with CANA 100 and 300 mg and 
PBO was evaluated for each subgroup. A second analysis included 52-week 
studies comparing CANA 300 mg with sitagliptin (SITA) 100 mg (N = 1,488; 
baseline HbA1c = 8.0, HOMA2-%B = 49, HOMA2-%S = 59). Patients were 
divided into the same HOMA2-%B, HOMA2-%S, and baseline HbA1c sub-
groups described in the first analysis.
Results: Overall, reductions in HbA1c from baseline were greater in patients 
with higher baseline HbA1c (Figures A and B). Within each baseline HbA1c 
range, the HbA1c decrease seen with CANA was generally similar across ter-
tiles of HOMA2-%B (as shown for the PBO-controlled studies in Figure A; 
similar results for CANA were also observed in the active-controlled stud-
ies) and HOMA2-%S (as shown for the active-controlled studies in Figure B; 
similar results for CANA were also observed in the PBO-controlled studies). 
Greater reductions in HbA1c were observed with CANA than with SITA, 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 349
1 C
with the biggest differences seen in patients with higher baseline HbA1c and 
in patients with lower HOMA2-%S (Figure B).
Conclusion: Consistent with expectations based on the insulin-independent 
mechanism of action of CANA, the glycaemic efficacy of CANA is largely 
independent of baseline measures of BCF or IS.
Supported by: Janssen Research & Development, LLC
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Effects of sodium glucose co-transporter 2 inhibitors in patients with 
type 2 diabetes: a systematic review with meta-analysis of randomised 
clinical trials 
H. Storgaard1, L.L. Gluud2, M. Christensen1,3, F. Knop1, T. Vilsbøll1;  
1Diabetes Research Division, Department of Medicine, Gentofte Hospital, 
University of Copenhagen, Hellerup, 2Gastrounit, Hvidovre Hospital, 
University of Copenhagen, 3Department of clinical pharmacology, 
Bispebjerg Hospital, University of Copenhagen, Denmark.
Background and aims: Several randomised clinical trials (RCTs) have as-
sessed the effects of sodium glucose co-transporter 2 inhibitors (SGLT-2i) for 
patients with type 2 diabetes. We performed a systematic review with meta-
analyses of RCTs on SGLT-2i for ≥12 weeks. The primary outcomes were 
changes in HbA1c, body weight and adverse events.
Materials and methods: Random effects meta-analysis was performed. Bias 
and heterogeneity were assessed in subgroup, sensitivity, regression and se-
quential analyses. We included 24 placebo-controlled RCTs on 12-102-week 
treatment with canagliflozin 300 mg (7 trials), dapagliflozin 10 mg (13 trials) 
or empagliflozin 25 mg (4 trials) and 7 trials with active controls.
Results: Random effects meta-analysis of 3,425 patients randomised to 
SGLT-2i and 3,234 patients randomised to placebo found that SGLT-2i re-
duced HbA1c (mean difference -0.71%; CI -0.80 to -0.63) and body weight 
(-2.0 kg; -2.2, -1.9). The analysis was stable to assessments of bias and the 
results were confirmed in sequential analyses. Beneficial effects in favour of 
SGLT2i on fasting plasma glucose (-1.6 mM; CI -1.9 to -1.4), systolic blood 
pressure: (-4.4 mmHg; -5.2 to -3.6) and diastolic blood pressure: (-1.6 mmHg; 
CI -2.1 to -1.1) were detected. Analyses on adverse events showed that 6% of 
patients randomised to SGLT-2i developed genital or urinary tract infections 
(relative risk 1.7; CI 1.4 to 2.1); number needed to harm 50).
Conclusion: We conclude that SGLT-2i have clinically relevant effects on 
glycaemic control and body weight and should be considered as second line 
treatment after metformin in obese patients with type 2 diabetes. The risk 
benefit balance may not be favourable in patients prone to genital or urinary 
tract infections.
PS 066 Novel therapies
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Pharmacokinetics of once weekly dulaglutide in patients with  
type 2 diabetes mellitus
A. de la Peña1, C. Loghin2, X. Cui3, X. Zhang1, J.S. Geiser1, J. Martin1,  
J.Y. Chien1;  
1Eli Lilly and Company, 2Clinical Pharmacology, Eli Lilly and Company, 
Indianapolis, 3inVentiv Health Clinical, Burlington, USA.
Background and aims: The aim of these analyses was to characterize the 
pharmacokinetics (PK) of once weekly dulaglutide in patients with type 2 
diabetes mellitus (T2DM).
Materials and methods: PK meta-analysis of Phase 1 data and population 
PK modeling of Phase 2 and Phase 3 studies were used in order to perform 
this characterization.
Results: The PK of dulaglutide was well described by a 2-compartment model 
with first-order absorption. After subcutaneous (SC) administration, dula-
glutide was slowly absorbed. Time to reach maximum concentration (Cmax) 
at steady state ranged from 24 to 72 hours (median = 48 hours); absolute 
bioavailability was 47% and half-life was 4.7 days. Steady state was achieved 
between 2 and 4 weeks of dosing. At steady state for dulaglutide 1.5 mg, the 
mean peak (Cmax) and total area under the concentration-time curve (AUC) 
exposures of dulaglutide were 114 ng/mL (range 56 to 231 ng/mL) and 14000 
ng·h/mL (range 6940 to 26000 ng·h/mL), respectively; the accumulation ratio 
was approximately 1.56. Intra-patient variability was <17% for both AUC and 
Cmax. Mean volume of distribution after intravenous administration was 5.32 
L, showing dulaglutide distributes primarily in the blood volume. Apparent 
clearance in patients with T2DM after multiple 1.5 mg dosing was 0.107 L/
hr. Body weight influenced dulaglutide PK, however weight explained <6% 
of the inter-patient variability. Effects of age, weight, sex, race and ethnic-
ity on dulaglutide PK were not clinically relevant and generally less than the 
inter-patient variability of dulaglutide exposure (AUC, Cmax) (≤35%). Injec-
tion site (abdomen, upper arm, thigh) had no statistically significant effect 
on exposure.
Conclusion: The PK of dulaglutide 1.5 mg supports once weekly administra-
tion in patients with T2DM. No dose adjustment is needed based on body 
weight, sex, age, race or ethnicity, or injection site.
858
A multicentric, double-blind, randomised-controlled trial (RCT) of 
carnitine orotate complex in diabetic patients with non-alcoholic fatty 
liver disease (NAFLD)
J. Bae1, W. Lee2, K. Yoon3, J. Park4, H. Son4, K. Han5, K. Lee6, J.-T. Woo4, 
M.-K. Lee7;  
1Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Samsung Changwon Hospital, 2Division of Endocrinology and 
Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital,  
3Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Kangnam St Mary‘s Hospital, 4Division of Endocrinology and 
Metabolism, Department of Internal Medicine, 5Division of Endocrinology 
and Metabolism, Department of Internal Medicine, Eulji Hospital, Seoul, 
6Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Suwon, 7Division of Endocrinology and Metabolism, Department 
of Internal Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Background and aims: We aimed to evaluate the effects of carnitine orotate 
complex (Godex®, 412mg/capsule, Celltrion Pharm, Seoul, Korea) on non-
alcoholic fatty liver disease in diabetic patients. In addition, we also evaluated 
whether carnitine orotate have effect on the glucose metabolism, particularly, 
in relation to improvement of hepatic steatosis.
Materials and methods: Seventy-eight outpatients with NAFLD, who were 
receiving medical treatment for type 2 diabetes, were randomly assigned to 
receive double-blind oral carnitine orotate 900mg (GODEX®) daily (n=39) or 
placebo (n=39) for 3 months. Hepatic steatosis was assessed by using hepatic 
computed tomography (CT) attenuation values (Hounsfield units) obtained 
by unenhanced low-dose CT at baseline and 3 months after initiation of treat-
ment. Also, biochemical marker for liver function and glycemic control were 
measured.
Results: There was no difference in the baseline mean liver attenuation be-
tween carnitine-treated and control groups. On the Hepatic CT analysis, 
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participants treated with carnitine orotate complex showed increase in mean 
liver attenuation values and liver attenuation index (LAI) after 12 weeks 
treatment(p<0.008 vs. placebo). Mean changes in LAI level from baseline at 
week 12 was 6.21±8.51 in carnitine orotate complex group (p<0.001) while 
it was 0.74±8.05 in placebo group (p=0.582). Both serum aspartate ami-
notransferase (P<0.001) and alanine aminotransferase (P<0.001) level were 
also reduced significantly in the carnitine-treated group. Those on treatment 
with carnitine showed improvement in HbA1c level with 0.33% decrease 
from baseline (P<0.007). When subjects were classified into tertiles by LAI 
changes from baseline at 12 weeks, participants in the highest tertile of LAI 
changes showed significant decrease in fasting glucose, HbA1c, and HOMA 
IR from baseline.
Conclusion: Three months of treatment with carnitine improved hepatic 
steatosis and liver enzymes levels in diabetic patients with NAFLD. Carni-
tine also improved glycemic control in relation to improvement of hepatic 
steatosis.
Clinical Trial Registration Number: KCT0000505
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Sulforaphane reduces hepatic glucose production in liver cells and 
improves glucose tolerance in diabetic animal models
A.S. Axelsson, Y. Tang, A.H. Rosengren;  
Department of Clinical Sciences, Lund University, Malmö, Sweden.
Background and aims: Novel means to treat type 2 diabetes are needed. 
One strategy for expanding the therapeutic options is drug repositioning, i.e. 
finding new indications for old drugs. The aim of this study was to employ 
a new method for drug repositioning combining gene network analysis of 
metabolic tissues and comprehensive public data on “drug signatures”. A drug 
signature denotes gene expression traits affected by a particular compound. 
Thus, we analysed gene co-expression networks in liver from different rodent 
models and identified a “disease signature” that predicts diabetes status. Next, 
we interrogated a library with >1000 drug signatures to identify drugs that 
can revert the aberrantly expressed genes in diabetes and improve metabolic 
control.
Materials and methods: A diabetes signature consisting of 50 genes was 
derived from rodent liver microarray data using co-expression analyses and 
causality tests. This signature was matched with publically available drug sig-
natures using Gene Set Enrichment Analysis. The findings were validated by 
oral and intraperitoneal (i.p.) glucose tolerance tests (GTT) in Wistar rats 
and C57Bl6 mice with diet-induced glucose intolerance, as well as in clonal 
H-4-II-E liver cells.
Results: We identified sulforaphane (SFN) as the top candidate compound. 
SFN is an isothiocyanate contained in cruciferous vegetables. It is known to 
induce an anti-oxidant response by nuclear translocation of NRF2 and has 
recently been suggested to have anti-cancer effects and improve diabetic 
complications. First, we incubated hepatic H-4-II-E cells with 10 micromol/l 
SFN for 28 h. This decreased basal glucose output by 49% (p=0.002). Pre-
incubation with palmitate (0.25 mmol/l) for 16 h elevated glucose output 
by 34% compared with non-treated control cells (p=0.006). Interestingly, 
SFN not only prevented the palmitate-induced increase of glucose produc-
tion but led to a net reduction of glucose output by 45% compared with the 
control cells (p=0.006). SFN also improved the insulin-mediated inhibition 
of glucose production in these cells (p=0.0003). Next, Wistar rats with diet-
induced insulin resistance were treated with 2.5 mg/kg SFN three times a 
week during 4 months, which improved insulin sensitivity as measured by 
an ip insulin tolerance test (AUC p=0.0038) and tended to decrease fasting 
glucose (p=0.055). Microarray analysis of liver from these rats revealed that 
a major fraction of the genes in the diabetic signature was reversed by SFN 
treatment (p<0.0001, Fisher’s exact test). Treatment of rats with higher doses 
of SFN (5 mg/kg daily) over shorter periods of time (2 weeks) improved glu-
cose tolerance assessed by an oral GTT (p=0.049 at 60 min; AUC=0.093). 
Furthermore, mice with diet-induced diabetes demonstrated improved fast-
ing glucose (p=0.044) and glucose tolerance measured by an i.p. GTT (AUC 
p=0.011) after 4-week treatment with 10 mg/kg SFN.
Conclusion: Through a new method for network-based drug repositioning 
we have identified SFN as a potential new anti-diabetic compound. Our re-
sults show that SFN improves diet-induced insulin resistance in vivo, reverses 
aberrantly expressed genes and reduces glucose output from H-4-II-E liver 
cells. The observed effects, in combination with the documented ability of 
SFN to protect tissues from diabetic complications and low toxicity, make 
SFN a promising new drug for future treatment of T2D.
Supported by: EFSD/Novo Nordisk, Swedish Research Council
860
Timed daily bromocriptine mesylate (BC) administration improves 
glucose disposal in a canine diet-induced model of impaired glucose 
tolerance
M.C. Moore, M. Smith, B. Farmer, A.D. Cherrington;  
Molecular Physiology & Biophysics, Vanderbilt University, Nashville, USA.
Background and aims: We previously showed that 4 wk of high-fat diet 
(HFD; 52% of energy) blunts net hepatic glucose (glc) uptake (NHGU) dur-
ing a hyperinsulinemic hyperglycemic (HIHG) clamp in dogs. Here we ex-
amined the impact of BC treatment upon glucose disposal during an OGTT 
and a HIHG clamp in HFD-fed dogs.
Materials and methods: After an initial OGTT (0.9 g/kg), 10 dogs began the 
HFD. After 4 wk of HFD, 5 dogs received subcutaneous BC injections (15 µg/
kg/d) and 5 (CTR) received vehicle for 26d (rx period) at the onset of loco-
motor activity, while continuing the HFD. Surgery for placement of hepatic 
balance catheters was performed ~16d before the end of rx. Dogs underwent 
OGTT2 ~5d before rx ended and a HIHG clamp (4xbasal insulin, 2xbasal 
glc) at the end of rx. During the 1st 90 min of the clamp (P1), glc was infused 
via peripheral vein; during the last 90 min (P2), glc was also infused via the 
hepatic portal vein at 22.2 µmol×kg-1×min-1.
Results: By 4 wk of HFD, dogs had gained 4±1 kg (mean±SEM); CTR and 
BC dogs lost 0.3±0.2 and 0.9±0.4 kg, respectively, during rx (P=0.4). In 
OGTT2 vs OGTT1, the deltaAUC0-120 min for glucose increased 58% (CTR) 
and 26% (BC; P<0.05 vs CTR), while that of insulin was increased 68% and 
95% (CTR vs BC; P=0.4). The C-peptide response increased nearly 2-fold 
in CTR (OGTT2 vs OGTT1; P<0.05) but did not change in BC, suggesting 
that BC might decrease insulin clearance. In the clamp studies, there were 
no significant group differences during the basal or P1 periods. Nonhepatic 
glucose uptake was greater in BC vs CTR during P2, and total body glucose 
disposal (GIR) showed a strong tendency to be enhanced in BC (Table 1). 
There was no significant correlation between plasma insulin concentrations 
and net hepatic or nonhepatic glucose uptake.
Conclusion: BC rx of HFD-fed dogs improves glucose tolerance and glucose 
disposal during a HIHG clamp primarily by enhancing nonhepatic glucose 
disposal.
Supported by: VeroScience
861
Prevention of diet-induced hepatic insulin resistance by antisense 
oligonucleotides targeted to mINDY
D. Pesta1, R. Perry1, D. Zhang1, M. Jurczak1, A. Birkenfeld1, S. Bhanot2,  
V. Samuel1, G. Shulman1;  
1Yale University, New Haven, 2Isis Pharmaceuticals, Inc, Carlsbad, USA.
Background and aims: INDY as part of the SLC13 protein family is a high-
affinity di- and tricarboxylate plasma membrane transporter involved in 
citrate import. In Drosophila, genetic deletion of INDY alters energy me-
tabolism and extends lifespan. Mice lacking INDY are protected from both 
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diet-induced and age-associated hepatic insulin resistance. Here, we exam-
ined the impact of selective hepatic knockdown of mammalian Indy protein 
(mINDY) expression using anti-sense oligonucleotides (ASOs).
Materials and methods: We studied the effect of mINDY knockdown on 
hepatic glucose metabolism in 4 week high fat fed rats (n=15 per group) as-
sessed by hyperinsulinemic-euglycemic (HEC) clamp studies.
Results: After 4 weeks of ASO treatment, mINDY mRNA expression was re-
duced by 91% (P<0.001) in the treatment group. The mINDY ASO treated 
rats showed a 34% reduction in fasting plasma insulin concentrations com-
pared to the control group (14.5 vs. 9.6 μU/ml, P<0.05) and was associated 
with ~30% reduction in basal rates of endogenous glucose production [5.9 ± 
0.6 vs. 8.4 ± 0.8 mg/(kg-min), Furthermore hepatic insulin responsiveness 
was increased in the mINDY ASO rats as reflected by increased suppression 
of hepatic glucose production during the HEC [19.7 vs. 61.6%, P<0.05].
Conclusion: Taken together these data suggest that hepatic mINDY may be 
a novel therapeutic target for the treatment of hepatic insulin resistance and 
type 2 diabetes.
Supported by: Austrian Science Fund (FWF), project number J 3267 and NIH 
grant R24
862
LX4211 improves glycaemic control in NOD mice with type 1 diabetes
D.R. Powell, D. Doree, S. Jeter-Jones, Z.-M. Ding, B. Zambrowicz, A. Sands;  
Lexicon Pharmaceuticals, Inc., The Woodlands, USA.
Background and aims: There is a need for oral agents that improve glycemic 
control without increasing hypoglycemia (hypoG) events in patients with 
type 1 diabetes (T1D). LX4211 is a compound that may meet this need, as it 
lowers blood glucose (G) by the dual insulin (Ins)-independent mechanisms 
of inhibiting intestinal sodium-glucose cotransporter (SGLT)1 to delay G ab-
sorption and inhibiting kidney SGLT2 to decrease G reabsorption. We tested 
if LX4211 can improve the poor glycemic control of NOD mice receiving low 
daily insulin doses for their T1D, and if LX4211 treatment of these mice is 
accompanied by a decrease in hypoG events.
Materials and methods: NOD mice receiving only 0.05 U Ins/day for their 
T1D served as a model of poor glycemic control, while NOD mice receiving 
0.2 U Ins/day for their T1D served as a model of improved glycemic control. 
T1D, defined as fed blood G > 300 mg/dL on 2 consecutive samples, was 
induced in 11 week old NOD mice using IP cyclophosphamide (200 mg/kg 
x2, separated by 2 weeks). Ins was delivered SC by Alzet pump (Model 1004, 
4 week duration). The day after pump implantation, mice received the first of 
22 once-daily oral doses of LX4211 or vehicle. Glycemic control was moni-
tored by measuring blood A1C (A1C Now+ kit) and fed blood G (ACCU-
CHEK Aviva glucometer). HypoG was defined as a fed blood G < 50 mg/dL.
Results: As is shown in the table below, 1) LX4211 significantly improved gly-
cemic control in NOD mice with poorly controlled T1D, as evidenced by the 
rapid and sustained lowering of blood G levels, and the delayed rise in A1c 
levels, in LX4211-treated mice receiving 0.05 U Ins/day; 2) the glycemic con-
trol of LX4211-treated mice receiving 0.05 U Ins/day was similar to that of 
vehicle-treated mice receiving 0.2U Ins/day; and 3) hypoG was less frequent 
in LX4211-treated mice receiving 0.05 U Ins/day than in vehicle-treated mice 
receiving 0.2 U Ins/day.
Conclusion: LX4211 significantly improved glycemic control in NOD mice 
with poorly controlled T1D, and this improvement was associated with a 
marked decrease in the frequency of hypoG events.
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Berberine increases serum osteocalcin levels and improves early phase 
of insulin secretion in non-alcoholic fatty liver disease patients with 
impaired glucose metabolism
H. Yan1, M. Xia1, X. Chang1, H. Bian1, L. Zhang1, H. Lin1, X. Yao2, S. Rao2, 
M. Zeng2, Y. Tu3, W. Jia3, W. Deng4, X. Gao1;  
1Department of Endocrinology and Metabolism, 2Department of Radiology, 
Zhongshan Hospital, Fudan University, Shanghai, China, 3Department of 
Endocrinology and Metabolism, The Sixth People‘s Hospital, Jiao Tong 
University, 4School of Public Health, Fudan University, Shanghai, China.
Background and aims: Inereasing evidences have shown that osteocalcin 
participate in the glycemic control and energy metabolism. Positive modula-
tion of serum osteocalcin concentrations could be valuable for the preven-
tion, delay and treatment of diabetes. Berberine is the active phytochemical 
that has potential to treat diabetes and diabetic complications. We aim to 
observe the effect of berberine on serum osteocalcin levels in patients with 
non-alcoholic fatty liver disease(NAFLD) and impaired glucose metabolism.
Materials and methods: We randomly assigned 124 adults with NAFLD and 
impaired glucose metabolism to 16 weeks of treatment with lifestyle inter-
vention (LSI) (a reduction of 500 kcal in daily intake and exercise) or ber-
berine (1.5g daily) plus LSI. Before and after treatment, we assessed serum 
glucose and lipid metabolism, insulin, osteocalcin levels, liver enzymes, and 
hepatic fat content by proton magnetic resonance spectroscopy.
Results: Berberine plus LSI treatment, as compared with LSI control, was 
associated with a significantly higher increasing in early phase insulin secre-
tion (ΔI30/ΔG30)[6.47±13.86 vs -0.06±10.56, p=0.011]and serum osteocal-
cin levels[4.54±4.55 vs 0.85±3.62 ug/L, p<0.001], and a significantly higher 
reduction in 2 hour blood glucose, HOMA-IR, total cholesterol, triglyceride, 
alanine aminotransferase, body weight, waist circumference and hepatic fat 
content(all p<0.05).Although these data had higher improvement in berber-
ine plus LSI than in LSI group, such as fasting glucose, 30 minute glucose, 
HbA1c, LDL-c, aspartate aminotransferase and glutamyltransferase, the 
differences of them were insignificant. Spearman‘s correlation analysis dem-
onstrated that the difference of osteocalcin before and after treatment was 
significantly positively associated with the difference of ΔI30/ΔG30, and neg-
atively associated with the differences of 30 minute blood glucose, HbA1c, 
total cholesterol, BMI, waist circumference, and hepatic fat content before 
and after treatment in the two groups. A stepwise multiple linear regression 
analysis demonstrated that the difference of osteocalcin was the only variable 
independently associated with the difference of ΔI30/ΔG30(p=0.045),the 
other variables excluded from the regression equation including differences 
of HbA1c, total cholesterol, triglyceride, HDL-c, LDL-c, BMI, waist circum-
ference, WHR, blood pressure and hepatic fat content. The incidence of ad-
verse events between groups were significantly different(p&lt0.001), with no 
serious adverse events occurred.
Conclusion: For NAFLD patients with abnormal glucose metabolism, Ber-
berine can increase serum osteocalcin levels, improve early phase insulin 
secretion and decrease 2 hour blood glucose. Elevated levels of osteocalcin 
may be one of the mechanisms of berberine improving glucose metabolism.
Clinical Trial Registration Number: NCT00633282
Supported by: NSFC
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Proteinuric nephropathy in acquired and congenital generalised 
lipodystrophy: baseline and after recombinant leptin therapy 
L. Major1, C. Musso2, E. Cochran3, M. Tonietti4, C. Mussin5, R. Brown3,  
L. Trifone4, F. Grabois4, E. Andres6, M. Ferraro6, P. Gorden3;  
1Nutrition, Hospital San Isidro, Buenos Aires, 2Endocrinology and 
Metabolsim, Hospital Milstein, Capital Federal, Argentina,  
3NIH, NIDDK, Bethesda, USA, 4Nutrition, Hospital Dr. R Gutierrez, 
5Nutrition, Hospital Cutral Co, Neuquen,  
6Nutrition, Hospital Dr P Elizalde, Buenos Aires, Argentina.
Background and aims: Lipodystrophies, acquired and congenital, are syn-
dromes characterized by absence of body fat, low levels of the adipocyte-derived 
hormone/cytokine leptin, severe hypertriglyceridemia, insulin resistance as-
sociated with diabetes, hepatomegaly and hepatic steatosis. Nephropathy has 
been previously reported but it is not a feature of the syndrome, but proteinu-
ria was common and very high in this group of young patients. Aim: Evaluate 
basal renal disease in patients with lipodystrophy and modifications 3 and 6 
months after r-metHuLeptin therapy.
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Materials and methods: We studied 6 patients with lypodystrophy, 4 gener-
alized (2 congenital generalized lypodystrophy CGL, and 2 acquired general-
ized lypodystrophy, AGL) and the other 2 with familial partial lypodystro-
phy (FPL). We determined basal, and after 3 and 6 month of leptin therapy: 
Creatinine, urea, microalbuminuria, proteinuria and % HbA1c. We evaluate 
which patients were on Angiotensin-converting enzyme (ACE) inhibitors 
therapy. In 2 of the 6 patients renal biopsy was done. We performed percuta-
neous renal biopsies in 2 patients.
Results: HbA1c and proteinuria improved after leptin therapy. Patient 2 
didn’t develop proteinuria. Four patients have proteinuria at baseline and af-
ter leptin improved significantly (patients 3, 5 and 6) or even turned negative 
(patient 1). Patients 1,3 and 5 were on enalapril. Renal Biopsy: patient 1 has 
diagnosis of mesangial proliferative glomeruloesclerosis and Patient 3 devel-
oped focal segmental glomeruloesclerosis (FSGS)
Conclusion: Renal function was evaluated in a group of patients with lipod-
ystrophy during the course of a therapeutic trial of recombinant human lep-
tin. It was describe that in some cases treated with recombinant human leptin 
there was an exacerbation of their underlying renal disease. In our patients 
we demonstrated efficacy of leptin to improved renal disease.
Clinical Trial Registration Number: NCT00025883
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Ranolazine induces skeletal muscle hypertrophy activating Ca2+/
calmodulin pathway
I. Terruzzi1, P. Senesi2,3, A. Montesano2, L. Luzi2,3;  
1Div. Metabolic and Cardiovascular Sciences. Metabolism, Nutrigenomics 
and Cellular Differentiation, San Raffaele Scientific Institute, 2Department of 
Biomedical Sciences for Health, University of Milan, 3Metabolism Research 
Centre and Department of Endocrinology and Metabolic Diseases, San 
Donato Hospital and Scientific Institute, Milan, Italy.
Background and aims: The underlying causes of type 2 diabetes are a com-
bination of a defect in insulin secretion from pancreatic β cells and an im-
pairment in insulin-mediated glucose disposal (insulin resistance) in insulin 
target tissues, such as skeletal muscle. Ranolazine (RAN) is a novel anti-is-
chemic and antianginal drug that reduces angina frequency in patients with 
chronic stable angina, a manifestation of coronary artery disease. RAN de-
creases myocardial ischemia by improving sodium-calcium homeostasis via 
inhibition of the late phase of the inward sodium current (late INa). Recently, 
RAN has been shown to lower haemoglobin A1c (HbA1c) in patients with 
diabetes mellitus. The mechanism by which RAN improves glycaemic control 
is unknown. Previous studies in isolated human and murine β cell showed 
that RAN preserves pancreatic cells mass and promotes glucose-stimulated 
insulin secretion. However, RAN hypoglycaemic mechanisms in skeletal 
muscle is jet not studied. Objective of the present study was to determine the 
effect of RAN on skeletal muscle metabolism and differentiation.
Materials and methods: We examined RAN action on skeletal muscle using 
C2C12 murine myoblastic cell. After treatment of C2C12 with 1, 10 or 25µM 
RAN for 24 hours to study the RAN dose-response relationship: 10µM RAN 
was considered the dose able to stimulate morphological changes and hyper-
trophic process in neo-formed myotubes. 10µM RAN was added to C2C12 
during proliferation, differentiation and neo formed myotubes to assess RAN 
possible interference in insulin pathway.
Results: RAN enhanced myoblasts proliferative capacity decreasing the ex-
pression of cell cycle inhibitors (p21 protein/cyclins). Interestingly, RAN did 
not modify p70S6 kinase activation showing it did not modulate the classic 
signaling pathways involved in cell growth. Western and Immunofluores-
cence studies revealed that during differentiation, RAN improved neo myo-
tubes formation, but did not stimulate kinases involved in skeletal muscle 
differentiation and glucose uptake (ERKs and AKT pathways). Neo formed 
myotubes analysis showed that RAN activated Ca2+/calmodulin dependent 
protein kinase (CaMKII), which plays an important role in GLUT4 upregula-
tion and in myotube differentiation, confirming that RAN improved skeletal 
muscle metabolism a without affecting p70S6 and ERKs pathway.
Conclusion: Taken together, our results demonstrate that RAN have a posi-
tive action on skeletal muscle cells differentiation and metabolism, activating 
not AKT insulin mediated pathway, but Ca2+/calmodulin signaling pathway. 
This finding provides interesting evidence on the innovative use of RAN in 
diabetic condition, not only to improve insulin secretion of β cell but also 
insulin sensitivity in skeletal muscle.
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Lipolytic and insulinotropic effects of HM12525A, a novel long-acting 
GLP-1/glucagon dual agonist
S. Jung1, Y. Park1, J. Kim1, J. Lee1, Y.-M. Lee1, Y. Kim1, J. Kang1,  
M. Trautmann2, M. Hompesch2, S. Kwon1;  
1Hanmi Parmaceutical, Seoul, Republic of Korea,  
2Profil Institute, Chula Vista, USA.
Background and aims: Oxyntomodulin, an alternative cleavage product of 
proglucagon, is a gut hormone which shows enhanced body weight loss and 
improved glycemic control by activating GLP-1 (GLP-1R) and glucagon re-
ceptor (GCGR), respectively. But its clinical application is limited due to a 
short half-life. We have developed the long acting GLP-1/glucagon dual ago-
nist, HM12525A, by conjugating a novel GLP-1/glucagon dual agonist with 
constant region of human immunoglobulin via non-peptidyl linker. In a pre-
vious study, we demonstrated that once weekly administration of HM12525A 
exerted potent body weight loss and improved glycemic control in obese 
and diabetic animal models. However, the underlying modes of action for 
HM12525A are still poorly defined. The aim of this study was to investigate 
the molecular basis for the beneficial effects of HM12525A in vitro and in 
vivo system.
Materials and methods: To evaluate the effect of HM12525A on lipid droplet 
formation, 3T3-L1 cells were incubated with HM12525A during adipogenic 
differentiation. After 10~14days, the cells were stained with Oil-red O to 
determine triglyceride content. Fully differentiated 3T3-L1 adipocytes were 
treated with HM12525A, and the phosphorylation of hormone-sensitive li-
pase (HSL) was evaluated through western blot analysis. To measure lipolytic 
activity, conditioned medium was collected following HM12525A treatment 
for 4hr, and the amount of glycerol was quantified. Serum concentration of 
insulin in normal mice during ipGTT was quantified to evaluate the insulino-
tropic and insulin sensitizing potency of HM12525A.
Results: Consistent with in vivo results in which HM12525A administra-
tion significantly reduced the fat mass of diet-induced obesity (DIO) mice, 
HM12525A inhibited the lipid droplet formation in 3T3-L1 adipcoytes in a 
dose-dependent manner. Of note, these inhibitory effects were partially re-
served by either GLP-1R or GCGR antagonist, suggesting that the dual ago-
nism of HM12525A synergistically exerts its lipolytic action. At the molecu-
lar level, phosphorylation of HSL, a key marker for the activation of lipolysis, 
and the following glycerol release were increased upon HM12525A treatment 
in 3T3-L1 adipocytes. As to the insulinotropic effects in pancreatic β-cells, 
HM12525A increased insulin secretion in RINm5F cells. In line with in vitro 
results, HM12525A administration significantly increased insulin secretion 
as well as insulin sensitivity, thereby attenuating the glucose excursion during 
ipGTT in normal mice.
Conclusion: Our results indicate that a well balanced dual agonism of 
HM12525A mediates synergistic effects on lipolysis of adipocytes. Moreover, 
HM12525A improves glucose tolerance by enhancing both insulin secretion 
and insulin sensitivity in β-cells and normal mice. Therefore, our results col-
lectively demonstrate that a novel GLP-1/glucagon dual agonist HM12525A 
mediated lypolytic and insulinotropic effects through which anti-obesity and 
anti-diabetic potentials were conferred.
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Renoprotective effect of gemigliptin, dipeptidyl peptidase 4 inhibitor, on 
streptozotocin-induced type 1 diabetic model
M.-K. Kim1, Y.-A. Jung1, G.-S. Jung2, Y.-K. Choi2, K.-H. Bae2, I.-K. Lee2,  
K.-G. Park2, J.-E. Lee3, E. Jung4, M.-J. Kim5, E. Kim6;  
1Department of Internal Medicine, Keimyung University School of 
Medicine, 2Department of Internal Medicine, Kyungpook National 
University School of Medicine, Daegu, 3Department of Internal Medicine, 
CHA Gumi Medical Center, Gumi, 4Department of Internal Medicine, 
Catholic University of Daegu School of Medicine, 5Pooren Meerae Internal 
Medicine Clinic, 6Department of Internal Medicine, Daegu Fatima Hospital, 
Republic of Korea.
Background and aims: Gemigliptin is a dipeptidyl peptidase 4 (DPP4) in-
hibitor, which is currently used in the treatment of patients with type 2 dia-
betes through augmentation of GLP-1 activity. In addition to GLP-1 activity, 
growing body of evidence shows that DPP4 play various roles in metabolism 
and inflammation through enzymatic activity and non-enzymatic activity. 
Some studies reported that DPP 4 activity increased in the urine and kidney 
of the diabetic patients and inhibition of DPP 4 activity attenuated diabetic 
neuropathy, retinopathy and renal ischemia-reperfusion injury. Therefore, 
the aim of this study was to determine whether gemigliptin has renoprotec-
tive effects on the kidney of streptozotocin (STZ)-induced type 1 diabetic 
mice model.
Materials and methods: Diabetes was induced by single intraperioneal in-
jectin of streptozotocin (150 mg/kg/body weight). Diabetic mice was treated 
without or with an oral dose of gemigliptin 300mg/kg/ day for 8 weeks. Re-
nal injury was observed by electron microscopy and light microscopy. We 
also measured serum glucose and urinary albumin excretion and evaluated 
fibrotic markers using immunohistochemical staining,qRT-PCR and western 
blot analysis.
Results: Blood glucose was significantly higher in diabetic mice than control 
mice, and gemigliptin did not reduce blood glucose levels of STZ-induced 
diabetic mice. Diabetic mice exhibited marked increased kidney/body weight 
ratio and urinary albumin excretion, but gemigliptin treatment significantly 
reduced kidney/body weight ratio and albuminuria. Moreover, gemigliptin 
treatment significantly reduced glomerular basement membrane thickness 
of kidney compared with STZ-induced diabetic mice. Histological examina-
tion showed renal fibrosis was induced by STZ, but gemigliptin treatment 
significantly attenuated STZ-induced renal fibrosis. In addition, immunhis-
tochemical staining showed decrease of type 1 collagen and fibronectin in 
the kidney of STZ-induced diabetic mice treated with gemigliptin. To test 
whether attenuation of renal fibrosis by gemigliptine is GLP-1 dependent, 
we examined the effects of gemigliptin on TGF-β-stimulated fibrotic gene 
expression in cultured renal cells. The results showed that gemigliptin-treated 
RMCs and NRK-52E cells showed markedly decrease in type 1 collagen and 
fibronectin expression through inhibition of smad3 activity.
Conclusion: In conclusion, our data showed that gemigliptin has renoprotec-
tive effect on diabetic nephropathy regardless of glucose lowering effect. The 
present study raises the possibility that gemigliptin could be used to prevent 
the progress of diabetic nephropathy including patients with type 1 diabetes.
868
Pituitary adenylate cyclase-activating polypeptide, a substrate of DPP-4, 
protects glomerular podocytes from inflammatory injuries
K. Sakamoto, M. Takemoto, K. Kuno, T. Ishikawa, P. He, R. Ishibashi,  
K. Kobayashi, H. Kawamura, H. Tokuyama, Y. Maezawa, K. Yokote;  
Department of Clinical Cell Biology and Medicine, Chiba University 
Graduate School of Medicine, Japan.
Background and aims: Diabetic nephropathy (DN) is a leading cause of 
end-stage kidney disease; however, to date, there are few available treatment 
options. Although the mechanisms of DN are not well understood, inflam-
mation plays a crucial role in the initiation and/or progression of DN. Di-
peptidyl peptidase-4 inhibitors (DPP4i) have recently been introduced for 
use as oral hypoglycemic agents. In addition to reducing blood glucose lev-
els, DPP4i have been found to possess pleiotropic actions, e.g. protecting the 
kidney from injuries. Although the mechanisms underlying the pleiotropic 
effects of DPP4i are not clear, it has been speculated that substrates, including 
incretins, which are stabilized by DPP4i may play a role in these effects. Pi-
tuitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide, 
which was originally isolated from the ovine hypothalamus and has diverse 
biological functions. PACAP is known to be one of the substrates of DPP4. 
Furthermore, in studies of kidney pathology, PACAP has been found to have 
renoprotective effects. However, the specific cell types within the kidney that 
are protected by PACAP have not yet been identified. In the present study, 
we investigated the effects of PACAP on kidney cells and the mechanisms by 
which PACAP decreases the expression of inflammatory cytokines.
Materials and methods: We used immunohistochemistry (IHC), western 
blotting (WB), and real-time polymerase chain reaction (RT-PCR) to evalu-
ate the expressions of PACAP receptors in kidney tissue, isolated glomeruli 
and cultured podocytes. Next, we evaluated if PACAP induces the phospho-
lylation of cAMP response element-binding protein (CREB) in cultured po-
docytes using WB. In addition, podocytes were stimulated with lipopolysac-
charide (LPS) and PACAP, and the effects of PACAP on the expression of 
inflammatory cytokines were examined using WB or RT-PCR. Activation of 
NF-κB and ERK were evaluated by nuclear localization of NF-κB and phos-
pholylaiton of ERK, respectively.
Results: We found that VPAC1, one of the PACAP receptors, is expressed 
in podocytes, a key player of glomerular filtration barrier. PACAP (10 nM) 
significantly increased the cellular contents of cAMP in cultured podocytes. 
In the presence of PACAP, CREB was increased by 1.9 ± 0.5 fold (mean ± 
SEM). In cultured podocytes, LPS increased the expression of interleukin-6 
(IL-6) and monocyte chemo-attractant protein-1 (MCP-1) by 4.2 ± 0.6 fold 
and 32.8 ± 3.3 fold, respectively. In the presence of PACAP, the increased 
expression of IL-6 and MCP-1 was significantly attenuated by 20% and 25%, 
respectively, through the protein kinase A signaling pathway. In the presence 
of LPS, NF-κB transnuclear localization and phosphorylation of ERK were 
significantly increased, and PACAP significantly reduced these increases by 
51% and 81%, respectively.
Conclusion: In the present study we demonstrated that PACAP has anti-
inflammatory effects on glomerular podocytes. To date, treatment options 
for DN are limited and PACAP may be useful in the prevention/attenuation 
of DN.
 
869
Effect of two years of sitagliptin treatment on renal function in elderly 
patients with type 2 diabetes mellitus
S. Kurioka;  
Komatsu Hospital, Neyagawa, Japan.
Background and aims: Many elderly patients with type 2 diabetes suffer 
from complications of chronic kidney disease and diabetic nephropathy. In 
this study, we examined the effect of a DPP-4 inhibitor, sitagliptin, on renal 
function in elderly patients with type 2 diabetes.
Materials and methods: A total of 70 patients aged ≥ 65 years with type 2 
diabetes mellitus, which included 42 males (60%), were examined. Patients 
had the following characteristics: age (mean ± SD) was 74 ± 5 years, BMI 24.5 
± 3.5 kg/m2, duration of diabetes 14 ± 10 years, HbA1c 8.3 ± 1.0%, serum 
creatinine 0.82 ± 0.27 mg/dl, eGFR 69.3 ± 23.9 ml/min/1.73m2, and an urine 
albumin-to-creatinine ratio (UACR) of 94.1 ± 172.0 mg/gCr. Patients had 
been treated with either 25 mg (n = 6 [9%]) or 50 mg (n = 64 [91%]) of sitag-
liptin over a two-year period. HbA1c, eGFR and UACR were assessed yearly. 
eGFR data had been collected 1 year before commencement of sitagliptin. Of 
the 70 patients, 22 (31%) had eGFR < 60ml/min/m2 and 28 (40%) had UACR 
> 30 mg/gCr. All endpoints were evaluated by ANOVA.
Results: HbA1c values before treatment, 1 year, and 2 years after sitagliptin 
treatment were 8.3, 7.5, and 7.3, respectively (before vs. after treatment, p 
< 0.0001). Gradually decreasing eGFR values were noted, as evidenced by 
values of 71.0, 69.3 (p < 0.05 when compared with eGFR 1 year before treat-
ment), 65.6 (p < 0.05 when compared with eGFR before treatment), and 63.0 
(p < 0.005 when compared with eGFR before treatment) at 1 year before 
treatment, before treatment, 1 year, and 2 years after treatment, respectively, 
while eGFR values were not decreased in patients with reduced renal func-
tion (eGFR < 60ml/min/m2), as evidenced by values of 52.5, 47.6 (p < 0.05 
when compared with eGFR 1 year before treatment), 47.8 (p = 0.88 when 
compared with eGFR before treatment), and 45.5 (p = 0.54 when compared 
with eGFR before treatment), respectively. UACR values were significantly 
decreased in patients with micro- or macroalbuminuria (UACR> 30 mg/
gCr), as evidenced by values of 207.3, 136.5 (p = 0.27 when compared with 
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UACR before treatment), and 106.6 (p < 0.05 when compared with UACR 
before treatment) before treatment, 1 year, and 2 years after treatment, re-
spectively.
Conclusion: Despite the gradual decline in eGFR values in patients with nor-
mal renal function, eGFR did not decrease in patients with reduced renal 
function. These findings suggest that sitagliptin exhibits a renal protective 
effect, and is effective in maintaining long-term glycemic control in elderly 
patients with type 2 diabetes.
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A DPP-4 inhibitor suppresses atherosclerotic lesions in the aorta and 
coronary arteries with decrease of macrophage infiltration in cholesterol-
fed rabbits
T. Hirano1,2, S. Yamashita2, M. Takahashi2, H. Hashimoto2, M. Goto2;  
1Diabetes, Metabolism, and Endocrinology, Showa University School of 
Medicine, Tokyo, Japan, 2Sanwa Kagaku Lab., Mie, Japan.
Background and aims: Several studies have demonstrated suppression of 
atherosclerosis by dipeptidyl peptidase-4 (DPP-4) inhibitors in hypercho-
lesterolemic mice. However, it remains unknown whether DPP-4 inhibitors 
might also exert anti-atherogenic effects in bigger animals. We examined the 
effect of anagliptin, a DPP-4 inhibitor, on the development of atherosclerosis 
in the aorta and coronary arteries in cholesterol-fed rabbits.
Materials and methods: Japanese white rabbits were fed either a normal 
diet or a diet containing 0.5% cholesterol. The cholesterol-fed rabbits were 
given drinking water not mixed (n = 18) or mixed with 3 mg/mL of ana-
gliptin (n = 16) for 12 weeks. The lipoprotein fractions were measured by 
high-performance liquid chromatography. The serum oxidative stress mark-
ers 8-hydroxy-2’-deoxyguanosine (OHdG) and malondealdehyde (MDA) 
were measured by ELISA and TBARS, respectively. Inflammatory cytokine 
gene expressions in the carotid artery were quantified by real time-qPCR. We 
measured the lesion area in the aorta and the coronary arteries in seven cross-
sections of the heart. Values were expressed as mean ± SE.
Results: Dietary cholesterol intake led to a marked increase of the serum 
total-cholesterol (TC) level (37.9 ± 3.9 vs. 0.59 ± 0.04 mmol/L), with the most 
striking increase seen in the VLDL fraction (30−80 nm) among the major 
lipoproteins. No significant changes of the body weight, water intake, HbA1c, 
serum lipids and lipoproteins, or glucose response to intravenous glucose 
loading were observed following the administration of anagliptin. The plas-
ma DPP-4 activity was suppressed by 86%, and the plasma active GLP-1 lev-
els doubled. Dietary cholesterol intake resulted in the development of severe 
atherosclerosis in the aorta, with a ratio of the lesion area to the total aortic 
surface areas of 22.0 ± 2.3%, and anagliptin treatment induced marked sup-
pression of the percent lesion area to 8.6 ± 2.1% (p < 0.001). Atherosclerotic 
lesions were also observed in the coronary arteries. The four major coronary 
arteries increased in area with cholesterol feeding (1.14 ± 0.12 vs. 0.81 ± 0.06 
mm2), while anagliptin treatment attenuated this change (0.87 ± 0.07 mm2). 
The intimal formation in the coronary arteries in the cholesterol-fed mice 
was attenuated by anagliptin treatment (0.04 ± 0.02 vs. 0.13 ± 0.05 mm2). 
The alpha-SMA-positive and macrophage-positive areas in the coronary ar-
teries were suppressed 54 and 78% respectively, by anagliptin treatment (p 
< 0.05). Notably, the ratio of the macrophage area to the plaque area was 
substantially decreased by 83%. The serum 8-OHdG and MDA showed no 
significant changes following the anagliptin treatment. However, the arterial 
gene expressions of the inflammatory cytokines TNF-alpha and interleukin-6 
were markedly reduced by approximately 90% (p < 0.001−0.05), and the ex-
pressions of macrophage chemoattractant protein-1and CD26 in the carotid 
arteries were partially reduced (by about 30%) following the anagliptin ad-
ministration.
Conclusion: Our study demonstrated for the first time that a DPP-4 inhibi-
tor suppressed the development of atherosclerosis in the aorta and coronary 
arteries in bigger animals than rodents, by inhibiting the inflammatory re-
sponses in the vessels.
Supported by: Sanwa Kagaku
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A DPP-4 inhibitor remarkably suppresses foam cell formation in 
peritoneal macrophages obtained from db/db diabetic mice, comparison 
with a SGLT2 inhibitor and pioglitazone
M. Terasaki, M. Nagashima, M. Hiromura, K. Notomi, T. Hirano;  
Department of Medicine, Showa University School of Medicine, Tokyo, 
Japan.
Background and aims: We reported that a dipeptidyl peptidase-4 inhibi-
tor (DPP-4i) confer an anti-atherosclerotic effect in diabetic apolipopro-
tein-E null mice with significant suppression of foam cell formation in 
macrophages(Mφ). However, it remains to be elucidated whether a DPP-4i 
exerts anti-atherogenic properties beyond glycaemic control. We evaluated 
the suppressive effect of DPP-4i on foam cell formation in Mφ obtained from 
db/db diabetic mice, and compared with other glucose-lowering agents, a 
sodium-glucose co-transporter (SGLT)2-inhibitor and pioglitazone.
Materials and methods: Male db/db mice at 9-week-old were fed normal diet 
containing none (n=23), alogliptin (0.02% w/w, n=12), pioglitazone (0.02%, 
n=12), or ipragliflozin (0.0014%, n=13) for 4 weeks. In subset of animals at 
age of 13 weeks, glucose (0.5g/kg body weight) was administrated orally, 
and bled 0, 15, 30, 60, and 120 min thereafter (OGTT). Peritoneal Mφ were 
obtained from mice at age of 13 weeks after the injection of thioglycollate. 
Foam cell formation was determined by the incorporation of [3H]-oleate into 
cholesteryl-oleate stimulated by oxidized-LDL in Mφ. CD36 and Acetyl-CoA 
acetyltransferase(ACAT)-1 gene expression was measured by RT-PCR.
Results: Food and water intakes were comparable among treated groups, 
whereas final body weight was increased in piogitazone group by 6% and 
decreased in ipragliflozin group by 5% compared with non-treated con-
trol group. Pioglitazone and ipragliflozin decreased fasting blood glu-
cose (FBG), HbA1c and glucose-AUC in OGTT compared with control 
group(FBG:6.1±0.4, 10.0±1.6, and 19.4±1.8mmol/l, HbA1c: 5.2±0.2, 5.7±0.3, 
and 8.4±0.2%, AUC: 790±280, 2123±260, 4183±293mmol/l×min, respec-
tively). Alogliptin group exhibited mild reductions of FBG, HbA1c, and AUC 
(16.0±1.3mmol/l, 7.0±0.4%, and 3413±463mmol/l×min). Despite mild ame-
lioration of glycemic control with alogliptin, the Mφ foam cell formation was 
36% decreased, which was comparable to those with pioglitazone or ipragli-
flozin (35 and 30%, respectively). Foam cell formation was critically regulated 
by glycemic control (HbA1c) in each group (r=0.70~0.94, p<0.02). The lin-
ear regression curves were similar between control and ipragliflozin groups. 
Alogliptin group distributed below the regression curves made by control 
and ipragliflozin groups, indicating that foam cell formation of alogliptin 
group is further suppressed than corresponded HbA1c. Gene expressions of 
CD36 and ACAT-1 were upregulated in db/db mice. Alogliptin treatment de-
creased gene expression of CD36 and ACAT-1.
Conclusion: A pioglitazone and a SGLT2-inihibitor both suppress foam 
cell formation in obese diabetic mice by substantial glucose-lowering effect, 
whereas DPP-4inhibitor remarkably suppresses foam cell formation despite 
mild amelioration of glycaemic control, suggesting a pleiotropic effect of 
DPP-4 inhibitor on atherogenesis beyond glucose.
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Increase in beta cell function and improvement in HOMA-2beta index 
induced by saxagliptin in patients with latent autoimmune diabetes in 
adults
R. Buzzetti1, P. Pozzilli2, R. Frederich3, N. Iqbal3, B. Hirshberg4;  
1Department of Experimental Medicine, Sapienza University of Rome, 
2Department of Endocrinology and Diabetology, Policlinico Universitario 
Campus Bio-Medico, Rome, Italy, 3Bristol-Myers Squibb, Princeton, 
4AstraZeneca, Wilmington, USA.
Background and aims: We used the presence of glutamic acid decarboxy-
lase antibodies (GADA) to identify patients with latent autoimmune diabetes 
of adults, a population which typically responds poorly to oral antidiabetic 
medications. We previously reported that saxagliptin (SAXA; 2.5, 5, and 
10 mg/d) was generally well tolerated and produced greater reductions vs 
placebo (PBO) in HbA1c and fasting and postprandial plasma glucose, with 
consistent treatment effects in GADA-positive and GADA-negative patients.
Materials and methods: In this analysis, we assessed the effects of SAXA 
on β-cell function (postprandial C-peptide AUC and HOMA-2β) in GADA-
positive (n=133) and GADA-negative (n=2576) patients from 5 placebo-
controlled clinical trials.
Results: There were little or no changes from baseline to week 24 in fast-
ing C-peptide concentrations across patient and treatment groups (Table). 
SAXA produced similar increases relative to PBO in C-peptide AUC and 
HOMA2-β% in GADA-positive and GADA-negative patients, with no evi-
dence of an interaction of GADA status on treatment effects, although the 
number of GADA-positive patients limits this interpretation.
Conclusion: These results suggest that SAXA improves β-cell function over 
24 weeks in patients with and without GADA at baseline.
Clinical Trial Registration Number: NCT00121641, NCT00316082, 
NCT00121667, NCT00295633, NCT00313313
Supported by: BMS and AZ
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Efficacy of DPP-4 inhibitors and their effect on blood cyclosporine levels 
in patients with post-transplantation diabetes 
E. Kang1, J. Bae1, Y. Lee1, C. Ahn1, B. Cha1, H. Lee1, K. Huh2, M. Kim2,  
Y. Kim2;  
1Internal Medicine, 2Transplantation Surgery, Yonsei University Health 
System, Seoul, Republic of Korea.
Background and aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been 
widely used in kidney-transplant patients with diabetes. However the efficacy 
and interactions with immunosuppressants according to individual DPP-4 
inhibitors are not widely studied. Therefore we tried to compare the glucose-
lowering efficacy of DPP-4 inhibitors in patients with post-transplantation 
diabetes and evaluate the drug interaction with immunosuppressant, cyclo-
sporine.
Materials and methods: A total of 91 renal allograft recipients with diabetes 
who began to take DPP-4 inhibitors after transplantation were enrolled. The 
glucose-lowering efficacy of three DPP-4 inhibitors, vildagliptin, sitagliptin, 
and linagliptin were compared using glycosylated hemoglobin (HbA1c) after 
treatment for three months. Changes in blood cyclosporine levels were also 
assessed in 48 patients treated with cyclosporine.
Results: There were no significant differences in HbA1c levels among vilda-
gliptin, sitagliptin, and linagliptin treatment (-0.29±1.71% vs. -0.40±1.87% 
vs. -0.82±1.32%, P=0.559). However, blood cyclosporine level was signifi-
cantly increased in the sitagliptin group, compared with vildagliptin and 
linagliptin group after three months of treatment (P=0.005). Difference in 
cyclosporine blood level was significant between vildagliptin group and sit-
agliptin group (P=0.004).
Conclusion: There were no significant difference in glucose-lowering efficacy 
among vildagliptin, sitagliptin, and linagliptin in kidney-transplant recipi-
ents with diabetes. However, drug interaction between cyclosporine was sig-
nificant in patients with sitagliptin treated group. Physicians should consider 
drug interaction when prescribing sitagliptin in kidney-transplant patients 
receiving cyclosporine as an immunosuppressant.
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A comparison of the effects of the DPP-4 inhibitor sitagliptin and the 
sulfonylurea glimepiride on metabolic parameters and endothelial 
function
H. Nomoto1, H. Miyoshi1, A. Nakamura1, T. Kondo1, N. Manda2,  
Y. Kurihara3, T. Atsumi1, S. Aoki4;  
1Medicine II (Immunology and Metabolism), Hokkaido University, 2Manda 
Memorial Hospital, 3Kurihara Clinic, Sapporo, 4Aoki Clinic, Sapporo, Japan.
Background and aims: DPP-4 inhibitors improve hyperglycemia in a glu-
cose-dependent manner, and have been reported to possess favorable effects 
on atherosclerosis in animal experiments. However, it has not been eluci-
dated whether DPP-4 inhibitors are able to improve endothelial function in 
patients with type 2 diabetes. Therefore, we investigated the efficacy of the 
DPP-4 inhibitor, Sitagliptin (Sita) on endothelial function and glycemic me-
tabolism compared with Glimepiride (Gli) therapy.
Materials and methods: This study was a multicenter, prospective, rand-
omized parallel-group comparison. Study inclusion criteria were current 
metformin treatment and inadequate glycemic control (HbA1c levels of 6.9% 
to 8.4%) with sufficient control of blood pressure and lipid profile. Patients 
who suffered severe atherosclerosis, liver damage and renal dysfunction were 
excluded. Flow mediated dilation (FMD), Endo PAT, a comprehensive panel 
of hemodynamic parameters (Task Force® Monitor), and serum metabolic 
markers were assessed before and after the 26 week treatment period. All 
FMD assessments were performed by the same individual in a quiet, tem-
perature-controlled setting. Patients were randomly assigned to once daily 
Sita (50mg) or Gli (0.5 to 2mg) therapy according to age, body mass index 
and baseline FMD values. Statistical analysis was performed using a Mann-
Whitney U test and a p value < 0.05 was considered significant.
Results: Forty-six men and thirty-three women aged 59.0 ± 10.4 years with 
HbA1c levels of 7.1 ± 0.4 % were enrolled. After 26 weeks, improvements 
in HbA1c levels were similar between the Sita and the Gli group (p = 0.48).
Contrary to expectations, the observed improvements in %FMD and Endo 
PAT were not statistically different between groups (%FMD; Sita 5.9 to 6.0 %, 
Gli 5.7 to 6.1 %, RHI; Sita 1.9 to 2.3, Gli 2.1 to 2.3). Plasma HDL-cholesterol, 
adiponectin and TNF-α levels were significantly improved in the Sita group 
(p < 0.05) and LDL-cholesterol also tended to be improved (p = 0.07). Blood 
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pressure, cardiac index, total peripheral resistance index and most other met-
abolic parameters were not different.
Conclusion: In type 2 diabetic patients without advanced atherosclerosis, 
changes in endothelial function were similar between Sita and Gli groups af-
ter 26 weeks. However, early Sita therapy was associated with more favorable 
effects on adipokine and lipid profiles compared with Gli therapy. Therefore, 
it is probable that over the long term these beneficial changes in glycemic and 
lipid control will aid in the prevention of atherosclerosis.
Clinical Trial Registration Number: UMIN000004955
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Co-administration of the DDP-4 inhibitor linagliptin and native GLP-1 
induce synergistic body weight loss and appetite suppression in DIO rats
M. Feigh1, H.B. Hansen1, G. Hansen1, S. Paulsen1, M. Mark2, N. Vrang1,  
T. Klein2;  
1Gubra, Hørsholm, Denmark, 2Boehringer Ingelheim, Biberach, Germany.
Background and aims: Linagliptin is a dipeptidyl peptidase (DPP)-4 in-
hibitor approved for the treatment of type 2 diabetes. DPP-4 inhibitors are 
weight-neutral, suggesting that elevation of endogenous incretin (GLP-1) 
levels is not sufficient to promote weight loss per se. However, it may be pos-
sible that long-term exogenous GLP-1 treatment in the context of concurrent 
DPP-IV inhibition may yield synergistic effects on appetite and body weight 
regulation. Hence, we evaluated the chronic metabolic effects of linagliptin 
and native GLP-1(7-36) co-administration in DIO rats.
Materials and methods: Male diet-induced obese (DIO) rats (n= 8-10 per 
group) were treated with either linagliptin (1.5 mg/kg, PO, BID; 0.5 mg/kg, 
SC, BID) or native GLP-1 (0.4 mg/kg, SC, BID) as monotherapy, and com-
pared to co-administration of linagliptin and GLP-1 for a total of 28 days. 
Body weight, food intake and body composition was measured. Also, fore-
brain preprodynorphin gene expression levels were analyzed to assess for po-
tential central effects on central endogenous opioidergic neurotransmission.
Results: In DIO rats, monotherapy with linagliptin did not significantly in-
fluence Food intake, body weight and adiposity during the study period. In 
contrast, combined linagliptin and GLP-1 treatment induced a reduction in 
food intake in conjunction with a pronounced body-weight (~8% compared 
with baseline) and whole-body fat mass (~20% vehicle-corrected) lowering 
effect at study end, which was superior to GLP-1 administration per se. No-
tably, the anorexigenic effect of linagliptin and GLP-1 co-administration was 
associated with a marked increase in chow preference at the expense of pal-
atable high-fat carbohydrate diet intake. Interestingly, combined linagliptin 
and GLP-1 treatment increased preprodynorphin mRNA levels in the cau-
date-putamen, an effect not obtained with administration of the compounds 
individually.
Conclusion: These data demonstrate that combined treatment with linaglip-
tin and GLP-1 synergistically reduces body weight in obese rats. This anti-
obesity effect is caused by appetite suppression and change in diet preference, 
presumably associated with increased dynorphin activity in dopaminergic 
forebrain regions involved in reward anticipation and habit learning. In con-
clusion, linagliptin and GLP-1 co-administration may therefore hold promise 
as a novel therapeutic principle for combined weight and diabetes manage-
ment in obese patients.
Supported by: Boehringer Ingelheim
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Effects of sitagliptin on body fat and intrahepatic lipid content in 
Japanese overweight patients with type 2 diabetes
Y. Nagai, H. Kato, Y. Sada, S. Asai, A. Ohta, Y. Tanaka;  
Metabolism and Endocrinology, Internal Medicine, St. Marianna University 
School of Medicine, Kawasaki, Japan.
Background and aims: Previous studies showed that human hepatocyte and 
adipocyte have the receptor of glucagon-like peptide-1 (GLP-1). Actually, 
GLP-1 analog, exendin-4 decreases intrahepatic lipid (IHL) and body fat in 
obese patients with type 2 diabetes. However, concrete changes of body fat 
and IHL by DPP-IV inhibitors were not fully evaluated. Thus, the aim of this 
study was to evaluate the effect of DPP-IV inhibitor, sitagliptin on body fat 
and IHL in overweight Japanese patients with type 2 diabetes.
Materials and methods: This was a prospective, 24-week, single center, open 
labeled comparison study. The subjects were 20 Japanese type 2 diabetic pa-
tients (male: 11, female: 9) with BMI>25 kg/m2. Nine of them were drug naïve 
and the remaining 11 received metformin. After a 4 to 8 weeks period of in-
structing lifestyle modification (28 kcal/kg of ideal body weight and 150 - 200 
kcal daily exercise), subjects were randomly assigned to receive sitagliptin 
25mg titrated up to 50 mg (S) or glimepiride 0.5 mg titrated up to 1 mg (G). 
At the baseline, week 12 and week 24 after starting each treatment, body fat 
and IHL at segment 6 of the liver were evaluated by dual energy X-ray ab-
sorptiometry (DEXA) and 1H-magnetic resonance spectroscopy (1H-MRS), 
respectively.
Results: Though HbA1c and GA levels were significantly decreased in both 
groups after 24 weeks (HbA1c; 7.3 ± 0.1 to 6.5 ± 0.1% (S) and 7.1 ± 0.2 to 6.6 
± 0.1%(G), GA; 18.2 ± 1.0 to 14.8 ± 1.0% (S) and 17.0 ± 0.5 to 15.7 ± 0.4% 
(G), all p<0.05 vs. baseline), no significant differences were observed between 
the two groups (p=0.15). The body fat was not altered in G, but significantly 
decreased by 1.2% in S (p<0.05 vs. base line). Reduction of IHL at week 24 
was -0.8 ± 11.4% (p=0.47 vs. baseline) in G and 16.8 ± 3.5% (p<0.01) in S. No 
severe hypoglycemia event occurred in both groups during the study period.
Conclusion: Our findings indicate that while sitagliptin and glimepiride 
achieve blood glucose control to the same degree, the effects on adiposity 
were different: sitagliptin might have a beneficial effect on body fat and IHL 
apart from glucose control. 
Clinical Trial Registration Number: UMIN000013356
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Efficacy and safety of saxagliptin in older participants in the SAVOR-
TIMI 53 trial
L.A. Leiter1, H. Teoh2, D.L. Bhatt3, O. Mosenzon4, B.M. Scirica3, P. Kumar5, 
A. Smahelova6, B. Hirshberg7, C. Stahre8, R. Frederich9, F. Bonnici10, I. Raz11;  
1Li Ka Shing Knowledge Institute and Keenan Research Centre for 
Biomedical Science, St. Michael‘s Hospital, University of Toronto,  
2St. Michael‘s Hospital, University of Toronto, Canada, 3Brigham and 
Women‘s Hospital, Harvard Medical School, Boston, USA, 4The Diabetes 
Unit, Hadassah Hebrew University - Medical Center, Jerusalem, Israel, 
5Bangalore Diabetes Hospital & Centre for Diabetes & Endocrine 
Care, Bangalore Diabetes Hospital, India, 6Department of Internal 
Gerontometabolic Clinic, Charles University in Prague, Hradec Kralove, 
Czech Republic, 7AstraZeneca, Wilmington, USA, 8AstraZeneca, 
MÖLNDAL, Sweden, 9Bristol-Myers Squibb, Princeton, USA,  
10UCT Private Academic Hospital, Cape Town, South Africa,  
11Hadassah Hebrew University - Medical Center, Jerusalem, Israel.
Background and aims: There are limited data from randomised clinical trials 
(RCT) on the efficacy and safety of antihyperglycaemic treatments in the el-
derly and very elderly despite the high prevalence of diabetes in these popula-
tions. The aim of this analysis was to examine the cardiovascular (CV) effects, 
glycaemic efficacy, and safety of saxagliptin (SAXA) in the elderly (≥65 years, 
N=8,561) and very elderly (≥75 years, N=2,330) participants in the SAVOR-
TIMI 53 trial.
Materials and methods: Individuals ≥40 years old (N=16,492) with HbA1c 
≥6.5% and ≤12.0% were randomised (1:1) to double-blind saxagliptin (5mg 
or 2.5mg OD) or placebo treatment for a median follow-up of 2.1 years.
Results: The exposure to study medication was similar in all age groups. The 
hazard ratio (HR) for SAXA vs. placebo for the primary CV endpoint (myo-
cardial infarction, ischemic stroke, CV death) was 0.92 for those ≥65 years 
vs. 1.15 for those <65 years (p=0.058), and 0.95 for those ≥75 years (nominal 
interaction p-value, 0.67). The HR for the secondary composite end point 
and total mortality in the elderly and very elderly was balanced and showed 
a similar pattern to that of the entire study population. There was no treat-
ment interaction based on age in terms of the risk of hospitalization for heart 
failure (p for interaction with age, 0.34), a component of the secondary end 
point, which showed an imbalance in the overall trial population. The dif-
ference in HbA1c associated with the use of SAXA was comparable (-0.33% 
vs. -0.36%) in those ≥ and <75 years with a baseline HbA1c of 7.6%. The in-
cidence of overall adverse events (AEs), serious AEs and discontinuations 
related to serious AEs was similar in the elderly, very elderly and the entire 
study population between SAXA and placebo.
Conclusion: The SAVOR-TIMI 53 trial provides efficacy and safety data from 
a RCT with a robust number of elderly and very elderly participants. The ef-
ficacy, CV safety, and overall safety of saxagliptin in this subset of patients are 
similar to those found in younger patients supporting the safety of SAXA in 
the older patient population.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca/Bristol-Myers Squibb
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Effects of baseline glycaemic HbA1c on CV outcomes and blood glucose 
control during the EXAMINE trial in patients with type 2 diabetes and 
recent acute coronary syndrome
W.B. White1, S.R. Heller2, R.M. Bergenstal3, C. Wilson4, R. Oh4;  
1Calhoun Cardiology Center, University of Connecticut School of Medicine, 
Farmington, USA, 2University of Sheffield, UK, 3International Diabetes 
Center, Park-Nicollet Clinic, Minneapolis, USA, 4Takeda Development 
Center Americas, Inc., Deerfield, USA.
Background and aims: EXAMINE was a randomized, double-blind cardio-
vascular (CV) outcomes safety trial in patients with diabetes and recent acute 
coronary syndromes (ACS) that showed similar rates of major adverse CV 
events (MACE) with the dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin 
compared with placebo. In this analysis, we investigated the effects of baseline 
HbA1c on MACE and the effect of alogliptin vs placebo on HbA1c according 
to baseline HbA1c levels.
Materials and methods: EXAMINE randomized 5380 patients in 49 coun-
tries with type 2 diabetes and an ACS within 15 to 90 days to alogliptin or 
placebo in addition to both evidence-based CV prophylaxis and treatment 
for type 2 diabetes according to regional guidelines. The median follow-up 
period in the trial was 18 months. Events were prospectively adjudicated by 
an independent, blinded committee (C5, Cleveland Clinic). The relationship 
between MACE and baseline HbA1c was analyzed using Cox proportional 
hazards models without adjustment for multiple comparisons.
Results: The HbA1c at the final visit was lower in the alogliptin arm vs place-
bo for each level of baseline HbA1c (Table). These changes occurred despite 
greater intensification of all additional medications in the placebo group. 
There was no systematic change in MACE rates according to baseline HbA1c 
(Table), p = 0.971 for interaction.
Conclusion: In patients with type 2 diabetes at high CV risk, there was no 
relationship between MACE and baseline HbA1c; the highest event rates 
were seen at an HbA1c of between 8 and 9%. Participants in the alogliptin 
arm achieved a lower HbA1c than those on placebo at all levels of baseline 
HbA1c. Of note, clinician investigators did not add sufficient additional ther-
apy in those taking placebo to match HbA1c levels by the end of this double-
blind randomized trial.
Clinical Trial Registration Number: NCT00968708
Supported by: Takeda Development Center Americas, Inc.
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Efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes 
and severe renal impairment
W. Kothny1, J. Foley2, A. Schweizer1, M.S. Rendell3, V. Lukashevich2;  
1Novartis Pharma AG, Basel, Switzerland,  
2Novartis Pharmaceuticals Corporation, East Hanover,  
3Creighton University School of Medicine, Omaha, USA.
Background and aims: There are limited clinical data comparing DPP-4 
inhibitors directly. Here we present the efficacy data from a 24-week study 
in patients with type 2 diabetes mellitus (T2DM) and severe renal impair-
ment (RI) comparing vildagliptin (VILDA) and sitagliptin (SITA). VILDA 
is mostly hydrolyzed to inactive metabolites; approximately 20% is excreted 
as unchanged drug. In patients with severe RI slower elimination effectively 
doubles the period of time that VILDA prevents GLP-1 and GIP degradation. 
Therefore, a 50 mg dose once daily provides full efficacy. SITA is essentially 
excreted unchanged by the kidney. In patients with severe RI, Cmax increas-
es four-fold, requiring dose reduction. Thus, the expected maximal effective 
dose and the dose mandated in the label in patients with severe RI is 50 mg qd 
for VILDA and 25 mg qd for SITA, which have been compared in this study.
Materials and methods: Patients with T2DM (N=148), drug-naive or 
on treatment (HbA1c 6.5%-10%), and severe RI [eGFR (MDRD) <30 ml/
min/1.73m²], including patients on haemodialysis (N=12), were randomized 
in this multicenter, double-blind, parallel-group study to receive VILDA 50 
mg qd (N=83) or SITA 25 mg qd (N=65) for 24 weeks in addition to their 
continued background antidiabetic therapy. Changes in HbA1c and fasting 
plasma glucose (FPG) from baseline to study endpoint were compared be-
tween treatments using an ANCOVA model. Hypoglycaemia was defined as 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 358 
1 C
symptoms suggestive of hypoglycaemia confirmed by a self-monitored blood 
glucose measurement of <3.1 mmol/l plasma glucose equivalent.
Results: Mean age of the randomized patients was 66.8 years, BMI 33.2 kg/
m² and T2DM duration 19.2 years; 80% of the patients were receiving insulin 
therapy alone or in combination with oral antidiabetic drugs. Mean eGFR 
was 19.7 and 20.4 ml/min/1.73m² in the VILDA and SITA groups, respec-
tively. At the end of treatment, mean HbA1c was reduced by 0.54% from a 
lower baseline of 7.52% with VILDA and by 0.56% from a baseline of 7.80% 
with SITA (p=NS between treatments). Twice as many patients in the VIL-
DA group achieved an HbA1c target ≤6.5% compared with SITA (29.0% vs 
14.3%, p=0.050). FPG was reduced by 0.47 mmol/l with VILDA compared to 
a slight increase of 0.16 mmol/l with SITA (between-group difference: -0.63 
mmol/l; p=0.185). While the incidence of hypoglycaemia was similar be-
tween treatments (15.7% vs 15.4%), adverse events likely related to hypogly-
caemia (hyperhidrosis, tremor, asthenia) as well as asymptomatic low blood 
glucose were markedly less frequent with VILDA than SITA (7.2% vs 13.8%; 
8.4% vs 16.9%; 6.0% vs 21.5%; and 4.9% vs 9.2%, respectively). Overall safety 
was similar between the two treatments.
Conclusion: In patients with T2DM and severe RI, VILDA and SITA pro-
duced similar and clinically relevant HbA1c reductions. However, more pa-
tients achieved an HbA1c goal ≤6.5% with VILDA compared to SITA which 
was not associated with an increase in confirmed (<3.1 mmol/l) hypoglycae-
mia. The lower levels of glycaemia achieved with VILDA may have been due 
to the lower rate of symptoms suggestive of hypoglycaemia which typically 
occur at plasma glucose >3.1 mmol/l, where glucagon counter-regulation 
is most important. This may be attributed to the previously described effect 
of VILDA to improve glucagon counter-regulation by maintaining meal-in-
duced increases in GIP during inter-meal periods.
Clinical Trial Registration Number: NCT00616811
Supported by: Novartis
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Pharmacokinetics of once weekly dulaglutide in special populations
C. Loghin1, A. de la Peña2, X. Cui3, X. Zhang2, J.S. Geiser2, J.Y. Chien2;  
1Clinical Pharmacology, Eli Lilly and Company, 2Eli Lilly and Company, 
Indianapolis, 3Biostatistics, inVentiv Health Clinical, Burlington, USA.
Background and aims: For use in a broad type 2 diabetes mellitus (T2DM) 
population, dulaglutide pharmacokinetics (PK) were characterized in sub-
jects with renal or hepatic impairment.
Materials and methods: Two separate open-label, single-dose studies as-
sessed dulaglutide 1.5 mg PK in subjects with hepatic (n=15) or renal impair-
ment (n=32), relative to healthy subjects (n=11 and 16, respectively). Both 
studies included mild, moderate and severe impairment; the renal study also 
included end stage renal disease.
Results: Dulaglutide exposure (area under concentration-time curve [AUC] 
and maximum concentration [Cmax]) was <30% higher in renal impairment 
groups versus controls. There was no relationship between PK parameters 
and renal function based on estimated glomerular filtration rate. In addition, 
there was no statistically significant linear relationship at the 5% significance 
level between exposure and creatinine clearance (CrCL). A statistically signif-
icant linear relationship was observed between CrCL and dulaglutide appar-
ent clearance (CL/F); however the relationship was weak based on its small 
slope (p=0.0133) and goodness of fit (r2=0.1315). Across all hepatic groups, 
impaired subjects had lower exposure compared to controls. There was no 
trend in exposure relative to degree of hepatic impairment, with the largest 
difference observed in subjects with moderate impairment (Cmax and AUC 
values approximately 70% and 67% of controls, respectively). No notable dif-
ferences in safety profiles were seen between subjects with hepatic or renal 
impairment and healthy subjects.
Conclusion: There were no clinically relevant effects of renal or hepatic im-
pairment on dulaglutide PK. Dulaglutide can be administered once weekly to 
patients with renal or hepatic impairment, without dose adjustment.
Clinical Trial Registration Number: NCT01253304
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Liraglutide 3.0 mg improves insulin secretion and action in overweight/
obese adults without type 2 diabetes: the SCALE obesity and prediabetes 
trial
D.C.W. Lau1, J.P.H. Wilding2, A. Astrup3, K. Fujioka4, F. Greenway5,  
A. Halpern6, M. Krempf7, C. le Roux8, R. Violante Ortiz9, R.V. Overgaard10, 
C.B. Jensen10, X. Pi-Sunyer11;  
1University of Calgary, Canada, 2University of Liverpool, UK, 3University of 
Copenhagen, Denmark, 4Scripps Clinic, La Jolla, 5Louisiana State University, 
Baton Rouge, USA, 6University of São Paulo Medical School, Brazil, 
7Université de Nantes, France, 8University College Dublin, Ireland, 9Instituto 
Mexicano del Seguro Social, Ciudad Madero, Mexico, 10Novo Nordisk A/S, 
Søborg, Denmark, 11Columbia University, New York, USA.
Background and aims: Obesity is commonly associated with impaired in-
sulin sensitivity and pancreatic beta-cell dysfunction; both implicated in the 
pathogenesis of type 2 diabetes (T2D). This trial investigated the effects of 
liraglutide 3.0 mg, as adjunct to diet and exercise, on weight loss (primary 
endpoint) and insulin secretion and action in overweight/obese individuals 
with and without prediabetes at screening.
Materials and methods: Adults (BMI ≥27 kg/m2 with ≥1 comorbidity or 
≥30 kg/m2) were advised on a 500 kcal/day deficit diet and exercise pro-
gramme and randomised 2:1 to once-daily s.c. liraglutide 3.0 mg or placebo. 
Randomisation was stratified by prediabetes status (ADA 2010) and BMI at 
screening. AUCs for glucose, insulin and C-peptide during a 75-g 120 min 
OGTT at week 0 and 56 were estimated (least square [LS] means, full analy-
sis set [FAS] with LOCF), as were indices of insulin secretion (IS, C-peptide 
deconvolution method), insulin sensitivity (SI, Matsuda index) and beta-cell 
function (disposition index [DI], IS*SI) (completers, exploratory analyses).
Results: Baseline characteristics: age 45.1 years, 79% female, weight 106.2 kg, 
BMI 38.3 kg/m2, 61.2% with prediabetes. At week 56, individuals on liraglu-
tide 3.0 mg (n=2437) had weight loss of 8.0% vs 2.6% with placebo (n=1225) 
(estimated treatment difference [ETD] -5.4%, p<0.0001, LSmeans, FAS with 
LOCF, ANCOVA). Fasting and post-load glycaemia was improved with lira-
glutide 3.0 mg, as both FPG and glucose AUC were lower with liraglutide 
3.0 mg vs placebo (ETD -0.38 mmol/L and -2.02 h*mmol/L, respectively; 
p<0.0001, ANCOVA). Post-load insulin and C-peptide were also improved 
with liraglutide 3.0 mg vs placebo (estimated treatment ratios 1.10 and 1.07, 
respectively; p<0.0001, ANCOVA on log scale). Improvements applied to in-
dividuals both with and without prediabetes, but glucose-lowering was most 
prominent in individuals with prediabetes (p<0.0001). Improved post-load 
glucose with liraglutide 3.0 mg vs placebo, was accompanied by increased 
IS (11% vs 1%), increased SI (21% vs 10%) and improved beta-cell function 
(35% vs 11%) (all p<0.0001, ANOVA). Similar effects were seen in individu-
als both with and without prediabetes.
Conclusion: Liraglutide 3.0 mg, as adjunct to diet and exercise, led to weight 
loss and improvements in insulin secretion and action, all of which likely 
explain the observed improvements in fasting and post-load glycaemia in 
overweight and obese individuals with and without prediabetes.
Clinical Trial Registration Number: NCT01272219
Supported by: Novo Nordisk
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Pharmacokinetics and tolerability of a single dose of semaglutide,  
a once-weekly human GLP-1 analogue, in subjects with and without 
renal impairment
T.C. Marbury1, A. Flint2, S. Segel2, M. Lindegaard2, K.C. Lasseter3;  
1Orlando Clinical Research Center, Orlando, USA, 2Novo Nordisk, Soborg, 
Denmark, 3Clinical Pharmacology of Miami, Inc., USA.
Background and aims: The pharmacokinetics and tolerability of semaglu-
tide, a once-weekly, human GLP-1 analogue in development for treatment of 
type 2 diabetes, were investigated in subjects with and without renal impair-
ment.
Materials and methods: Using the Cockcroft-Gault formula, 56 subjects 
were assigned to one of five renal function groups and received a single dose 
of 0.5 mg s. c. semaglutide. In the end-stage renal disease (ESRD) group, 
semaglutide was given 1-24 h after haemodialysis, with no haemodialysis 
for 48 h post dose. Semaglutide plasma concentration was assessed regularly 
up to 480 h (~20 days) post dose; the primary endpoint was area under the 
semaglutide time-concentration curve from time zero to infinity (AUC0-∞). 
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Secondary endpoints included other pharmacokinetic parameters (Cmax, tmax 
and t1/2), safety and tolerability of semaglutide.
Results: Exposure of semaglutide in subjects with mild or moderate renal 
impairment or ESRD was similar to that in subjects with normal renal func-
tion (Table). Subjects with severe renal impairment had a 22% higher ex-
posure of semaglutide than those with normal renal function and the 95% 
CI (1.02, 1.47) exceeded the ‘no effect’ limits (0.70, 1.43). One subject with 
severe renal impairment reported two major hypoglycaemic events. There 
were no appreciable changes in laboratory safety parameters or vital signs; 
no serious adverse events (AEs) were noted. One subject withdrew due to 
gastrointestinal AEs.
Conclusion: In three of four groups with renal impairment, there was no 
effect on semaglutide exposure. In the severe renal impairment group, sema-
glutide exposure was increased. Semaglutide was well tolerated. The long-
term effect of semaglutide on renal impairment will be investigated in future 
trials.
Clinical Trial Registration Number: NCT00833716
Supported by: Novo Nordisk
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VIRTUE study: effects of vildagliptin versus sulphonylureas as 
monotherapy or combined with metformin in Muslim patients with  
type 2 diabetes fasting during Ramadan
I. Shaltout1, F. Pathan2, R. Medlej3, M. Al-Arouj4, A.A.K. Hassoun5,  
M.S. Chawla6, D. Knap7, J.A. Vaz8;  
1Cairo University, Cairo, Egypt, 2BIRDEM Hospital, Dhaka, Bangladesh, 
3Chronic Care Center, Saint Joseph University, Beirut, Lebanon, 4Dasman 
Diabetes Institute, Dasman, Kuwait, 5Dubai Diabetes Center, United Arab 
Emirates, 6Lina Diabetes Care Center, Mumbai, India, 7Novartis Pharma 
AG, Basel, Switzerland, 8Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Background and aims: For Muslim patients with type 2 diabetes mellitus 
(T2DM), fasting during Ramadan can increase the risk of serious complica-
tions such as hypoglycaemia. This post-hoc analysis of the VIRTUE study 
assessed, in routine clinical practice, the effectiveness and safety of vildaglip-
tin relative to sulphonylureas (SUs) as monotherapy or when combined with 
metformin in Muslim patients with T2DM fasting during Ramadan.
Materials and methods: VIRTUE was a multicentre, prospective, 16-week, 
observational study conducted in the Middle East and Asia, and included 
adult Muslim patients with T2DM who were receiving vildagliptin or SUs 
(either as monotherapy or combined with metformin as per routine care) for 
≥4 weeks and <3 years prior to the start of fasting. The primary endpoint was 
the proportion of patients with ≥1 hypoglycaemic event (HE) during Rama-
dan. Secondary endpoints included change from baseline in HbA1c and body 
weight, and safety assessments.
Results: Overall, 145 patients received monotherapy (vildagliptin, N=62; SU, 
N=83) and 1,148 received dual therapy (vildagliptin + metformin, N=607; SU 
+ metformin, N=541). Fewer patients experienced ≥1 HE with vildagliptin 
compared with SUs, both as monotherapy and when combined with met-
formin, the latter achieving statistical significance (p<0.001; Table). No grade 
2 (severe) HEs were reported with vildagliptin therapy, compared with four 
patients receiving SU + metformin (p=0.048 vs vildagliptin + metformin). 
Pre- to post-Ramadan changes in HbA1c and body weight were also assessed 
in vildagliptin and SU treatment groups (Table). Vildagliptin therapy was 
generally well tolerated. The incidence of adverse events with vildagliptin 
compared with SUs was 9.7% vs 18.1%, respectively, for monotherapy and 
10.2% vs 23.5% for combination with metformin. The most common AEs 
were hypoglycaemia, pyrexia and nausea.
Conclusion: In this post-hoc analysis, fewer patients experienced HEs with 
vildagliptin compared with SUs; this achieved significance in patients receiv-
ing combination therapy with metformin. In addition, vildagliptin +/- met-
formin was associated with good glycaemic and weight control, and was well 
tolerated in this population. As such, vildagliptin may be a useful treatment 
option for patients with T2DM fasting during Ramadan.
Supported by: Novartis Pharma AG (including medical writing assistance)
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Enhanced glucose-lowering effect of dipeptidyl peptidase-4 inhibitor  
in subjects with type 2 diabetes who have a history of gastrectomy
Y. Wada1, Y. Hamamoto1, S. Honjo1, K. Fujimoto1, H. Tatsuoka1,  
A. Matsuoka1, H. Ikeda2, J. Fujikawa3, H. Koshiyama1;  
1Center for Diabetes and Endocrinology, The Tazuke Kofukai Foundation 
Medical Research Institute Kitano Hospital, 2Ikeda Hospital, Amagasaki, 
Japan, 3Laboratory Medicine, The Tazuke Kofukai Foundation Medical 
Research Institute Kitano Hospital, Osaka, Japan.
Background and aims: It has been reported that glucagon like peptide-1 
(GLP-1) exhibits its effects not only directly through its receptor on the target 
cell membrane but also via central nervous system. Hepatic branch vagotomy 
reportedly decreases insulin secretion in rodents. On the other hand, acceler-
ated gastric excretion in subjects with gastrectomy affects postprandial ab-
sorption of nutrients and secretion pattern of GLP-1 and glucose-dependent 
insulinotropic polypeptide (GIP). In this study, we investigated whether the 
effect of dipeptidyl peptidase-4 (DPP-4) inhibitor is different between the 
subjects with and without the history of gastrectomy.
Materials and methods: Among patients with type 2 diabetes who were pre-
scribed with DPP-4 inhibitor during 2010 to 2013 at our clinic, those who 
have the history of gastrectomy more than 6 months before (50±11.4 months) 
the administration of DPP-4 inhibitor were retrospectively identified from 
our database (gastrectomy group). Also, patients without the history of gas-
trectomy who were prescribed with DPP-4 inhibitor (n=20; male: n=13) were 
randomly selected as a control group. The HbA1c levels measured before and 
three and six months after DPP-4 inhibitor administration were evaluated. 
Each value is shown in mean ± SE.
Results: A total of 10 subjects (male: n=8) were identified to meet the condi-
tions (50mg of sitagliptin: n=6, 50mg of vildagliptin: n=4). Control group 
received 50mg of sitagliptin (n=18), 50mg of vildagliptin (n=1) and 5mg of 
linagliptin (n=1). The drugs used in combination were sulfonylureas (n=5), 
insulin (n=2), biganide (n=1), alfa-glucosidase inhibitor (n=1), glinide (n=1) 
in gastrectomy group, and sulfonylureas (n=11), insulin (n=4), biganides 
(n=5), and alfa-glucosidase inhibitor (n=1) in control group. Age (71.6±2.5 
vs 69.1±2.7 years; gastrectomy group vs control group, p=0.50), body mass 
index (22.5±1.1 vs 24.1±0.7 kg/m2; p=0.22) and HbA1c levels before DPP-4 
inhibitor administration (8.1±0.1 vs 7.9±0.1 %; p=0.18) were not different 
between two groups. DPP-4 inhibitor administration significantly decreased 
HbA1c levels in both groups by -1.11±0.20 % in gastrectomy group (p<0.01) 
and -0.88±0.11% in control group (p<0.01) at 3 months, and by -1.25±0.11 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 360 
1 C
% (p<0.01) and -0.82±0.12 % (p<0.01) at 6 months; however, gastrectomy 
group showed significantly greater reduction compared to control group at 
6 months (p=0.02).
Conclusion: Our results suggest that glucose-lowering effect of DPP-4 inhib-
itor is enhanced in the patients who have a history of gastrectomy. Although 
the study with larger number of subjects will be needed to confirm our re-
sults, it is conceivable that enhanced secretion of incretins after gastrectomy 
might have contributed to the results.
PS 069 Safety of DPP4 inhibitors
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Safety of linagliptin in 8778 patients with type 2 diabetes mellitus: 
pooled analysis of 23 placebo-controlled randomised clinical trials
G. Schernthaner1, K. Khunti2, S. Patel3, K. Cheng4, M. Mattheus4,  
H.-J. Woerle4;  
1Rudolfstiftung Hospital, Vienna, Austria,  
2University of Leicester, 3Boehringer Ingelheim Ltd, Bracknell, UK, 
4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Background and aims: Linagliptin is a DPP-4 inhibitor approved for the 
treatment of type 2 diabetes mellitus. A robust, global clinical trials program 
has investigated the efficacy and safety of linagliptin in adult patients. In these 
trials, linagliptin was given as monotherapy or as add-on to common an-
tidiabetes drugs, such as metformin, sulphonylureas, thiazolidinediones, or 
insulin. This pooled analysis was undertaken to assess the overall safety of 
linagliptin in a larger group of patients than would be available in a single 
randomised trial.
Materials and methods: Tolerability was evaluated by incidence and inten-
sity of adverse events (AEs), AEs of special interest (heart failure, pancrea-
titis, and pancreatic cancer), and incidence and intensity of hypoglycaemia. 
Data were analysed for 8778 patients (linagliptin, n=5488; placebo, n=3290) 
participating in 23 placebo-controlled randomised trials with durations ≤54 
weeks. Data were assessed descriptively.
Results: Total exposure was 2883.6 patient years (mean, 192 ± 127 days) and 
1957.8 patient years (mean, 217 ± 151 days) in the linagliptin and placebo 
groups, respectively. Linagliptin was well tolerated, with AEs occurring in 
a similar proportion of linagliptin and placebo patients (58.0% and 62.3%, 
respectively). Drug-related AEs were observed in 11.8% and 13.3% of pa-
tients, respectively. Heart failure was observed in 0.5% and 0.2% of patients, 
respectively. Pancreatitis was reported in 0.1% of both groups. One pancre-
atic carcinoma occurred in the linagliptin group. Investigator-defined hypo-
glycaemia occurred in 10.6% and 12.2% of linagliptin and placebo patients, 
respectively (linagliptin, n=5303; placebo, n=3084). Severe hypoglycaemia 
was experienced by 0.4% and 0.5% of patients, respectively. Most hypogly-
caemia occurred in trials allowing sulphonylureas or insulin as background 
medications.
Conclusion: These findings provide further evidence for the safety and toler-
ability of linagliptin in a broad range of patients.
Supported by: Boehringer Ingelheim Pharma GmbH & Co. KG
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Lower risk of hypoglycaemia with vildagliptin versus low dose 
glimepiride in relation to the HbA1c level
B. Ahrén1, A. Schweizer2, M. Dworak3, J.E. Foley4, S. Dejager5, G. Heimann2, 
M. Akacha2, Q. Shao4;  
1Lund University, Sweden, 2Novartis Pharma AG, Basel, Switzerland, 
3Novartis Pharma GmbH, Nürnberg, Germany, 4Novartis Pharmaceuticals 
Corporation, East Hanover, USA, 5Novartis Pharma SAS, Rueil Malmaison, 
France.
Background and aims: In a previously published study (mean HbA1c 7.3%; 
N=3118), vildagliptin (50 mg bid) showed a reduced risk of hypoglycae-
mia compared with glimepiride as add-on therapy to metformin after 52 
(1.7/16.2%) and 104 (2.3/18.2%) weeks at similar efficacy. Glimepiride (start-
ing dose 2 mg/day) could be titrated to a maximum dose of 6 mg/day. A 
limitation of the study was the perception that the hypoglycaemia difference 
was driven by high doses of glimepiride. It was therefore of interest to com-
pare the risk of confirmed hypoglycaemia with vildagliptin to the subgroup 
of glimepiride patients remaining on the dose of 2 mg/day throughout the 
study, in addition to all glimepiride patients.
Materials and methods: Comparisons were done by modeling risk as a func-
tion of time and last measured HbA1c using discrete event time modelling, 
with treatment, age and gender as additional covariates. Hypoglycaemia was 
defined as symptoms suggestive of low blood glucose confirmed by self-mon-
itored blood glucose measurement <3.1 mmol/l plasma glucose equivalent.
Results: The hypoglycaemia risk at week 18 was significantly lower with vild-
agliptin 50 mg bid compared to glimepiride 2 mg/day, with similar results un-
adjusted or adjusted for last HbA1c (adjusted HR = 0.05 [95% CI 0.03, 0.10]). 
The risk of hypoglycaemia was very low with vildagliptin over the full HbA1c 
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range while the risk with glimepiride 2 mg/day increased with lower HbA1c 
(Figure). The increase for lower levels of HbA1c was more pronounced in the 
glimepiride 2 mg/day subgroup than in the full set of patients treated with 
glimepiride (adjusted HR = 0.08 [95% CI 0.0, 0.15]).
Conclusion: Taken together, the data show a substantially lower risk of con-
firmed hypoglycaemia with vildagliptin compared to low dose (2 mg/day) 
glimepiride, and indicate that the previously reported results are not driven 
by high doses of glimepiride.
Supported by: Novartis
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Incidence of fractures in patients with type 2 diabetes in the SAVOR-
TIMI 53 trial
K. Strojek1, O. Mosenzon2, J. Davidson3, B.M. Scirica4, G. Leibowitz2,  
R.G. Bretzel5, J.E. Villena6, M. Alvarsson7, B. Hirshberg8, C. Stahre9,  
A. Parker10, D.L. Bhatt11, I. Raz12;  
1Department of Internal Diseases Diabetology and Cardiometabolic 
Diseases, Silesian Medical University Zabrze, Poland, 2The Diabetes Unit, 
Hadassah Hebrew University - Medical Center, Jerusalem, Israel, 3The 
University of Texas Southwestern Medical Center, Dallas, 4Brigham and 
Women‘s Hospital Harvard Medical School, Boston, USA, 5St. Josefs 
Hospital Balserische Stiftung, Giessen, Germany, 6Hospital Nacional 
Cayetano Heredia, Lima, Peru, 7Dept. of Endocrinology, Metabolism and 
Diabetes, Karolinska University Hospital, Stockholm, Sweden, 8AstraZeneca, 
Wilmington, USA, 9AstraZeneca, Mölndal, Sweden, 10The Diabetes Unit, 
AstraZeneca LP, Wilmington, USA, 11The Diabetes Unit, Brigham and 
Women‘s Hospital, Harvard Medical School, Boston, USA, 12Diabetes Unit, 
Hadassah Hebrew University - Medical Center, Jerusalem, Israel.
Background and aims: Patients with type 2 diabetes have an increased risk of 
bone fractures, the predisposing factors for which in diabetes are unknown. 
In the SAVOR-TIMI 53 trial, fractures were considered an adverse event of 
special interest (AESI) and information regarding fractures was actively col-
lected by the investigators.
Materials and methods: We compared the incidence of fractures among the 
8,280 patients who were assigned to treatment with saxagliptin to the inci-
dence in the 8,212 patients who were assigned to placebo.
Results: During the median follow-up of 2.1 years, 235 (2.8%) and 236 (2.9%) 
patients in the saxagliptin and placebo groups experienced a fracture; HR 
(95% CI) = 0.99 (0.83-1.19). The treatment exposure-adjusted rate of bone 
fracture (first event only) was 14 per 1000 patient-years of follow-up in both 
groups. Fracture risk was similar in patients treated with saxagliptin or pla-
cebo across different subgroups defined by race, cardiovascular risk, renal 
function and duration of diabetes. A multivariable analysis of the entire 
study population showed the risk of fracture was associated with older age 
(p=0.001), female gender (p<0.0001), longer diabetes duration (p<0.0001), 
elevated HbA1c (p=0.03) and treatment with TZDs (p=0.03). Fracture risk 
was not associated with body mass index, estimated glomerular filtration 
rate, or the use of other anti-diabetic drugs.
Conclusion: The SAVOR TIMI 53 trial provides important data regarding 
the risk of fractures in a large population of patients with type 2 diabetes. 
Treatment with saxagliptin was not associated with an increased risk of frac-
tures. The association between longer diabetes duration and poor glycemic 
control to increased risk of bone fracture is an intriguing finding.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca/Bristol-Myers Squibb
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Assessment of heart failure risk with vildagliptin in diabetic patients: 
pooled analysis of safety data from approximately 17,000 patients
M. Evans1, G. McInnes2, M. Stumvoll3, S. Del Prato4, A. Schweizer5,  
Q. Shao6, V. Lukashevich6, W. Kothny5;  
1University Hospital Llandough, Cardiff, UK, 2Institute of Cardiovascular 
& Medical Sciences University of Glasgow, UK, 3University of Leipzig, 
Germany, 4University of Pisa, Italy, 5Novartis Pharma AG, Basel, 
Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, USA.
Background and aims: Heart failure (HF) is an important and disabling 
complication of type 2 diabetes mellitus (T2DM). Two recently completed 
DPP4 inhibitor cardio-vascular (CV) outcome trials (SAVOR-TIMI-53 and 
EXAMINE) confirmed the overall CV safety of this class, but also triggered 
a discussion of a potential HF risk with these agents. We present a meta-
analysis of prospectively adjudicated HF events from the vildagliptin pooled 
database with approximately 17,000 patients.
Materials and methods: Data from 40 randomized, double blind, placebo 
or active-controlled Phase III vildagliptin studies of ≥12-week duration were 
pooled. Vildagliptin data on the approved doses of 50 mg qd or bid were 
considered and analysed consistent with FDA guidance on CV safety. Vilda-
gliptin was used as a monotherapy or in combination with other anti-diabetic 
drugs in a broad T2DM population including patients with HF NYHA Class 
I-III. All reported HF events were prospectively adjudicated by independ-
ent experts as either 1) HF requiring hospitalization or 2) new onset of HF. 
The Mantel-Haenszel (M-H) relative risk (RR) of confirmed HF events with 
vildagliptin vs. comparators (all non-vildagliptin treatments) was calculated.
Results: There were 9599 patients exposed to vildagliptin (9250 subject year 
exposure [SYE]) compared to 7847 exposed to comparators (7317 SYE). 
Baseline demographic and clinical characteristics were comparable between 
treatment groups. Over 40% of patients had 2 or more CV risk factors and 
approximately 18% had a previous history of cardio-cerebro-vascular disease. 
Confirmed HF events were reported in 41 (0.43%) patients on vildagliptin 
50 mg qd/bid dose and in 32 (0.45%) patients on comparators (Figure) with 
M-H RR of 1.08 (95% CI 0.68-1.70). No dose response was observed.
Conclusion: This analysis of prospectively adjudicated HF events from the 
large vildagliptin database indicated that vildagliptin is not associated with 
increased risk of HF in patients with T2DM relative to comparators.
Supported by: Novartis
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Safety profile of the DPP-4 inhibitors vildagliptin and sitagliptin in 
patients with type 2 diabetes and severe renal impairment
V. Lukashevich1, J. Foley1, A. Schweizer2, M.S. Rendell3, W. Kothny2;  
1Novartis Pharmaceuticals Corporation, East Hanover, USA,  
2Novartis Pharma AG, Basel, Switzerland,  
3Creighton University School of Medicine, Omaha, USA.
Background and aims: Therapeutic management of type 2 diabetes mellitus 
(T2DM) with declined kidney function is challenging especially in patients 
with severe renal impairment (RI). Since the actions of the incretin hormones 
GLP-1 and GIP are glucose-sensitive, hypoglycaemia secondary to increased 
drug exposure is unlikely to occur with DPP-4 inhibitors (DPP-4i), making 
this drug class very attractive in treating patients with RI. It has been sug-
gested that safety profiles of DPP-4i may differ in patients with RI, driven by 
whether or not unchanged drug or metabolites are renally excreted. Here we 
present a large pooled analysis of safety data for two different DPP-4i elimi-
nated via the kidney, vildagliptin (Vilda), which is primarily hydrolyzed, and 
sitagliptin (Sita), excreted as unchanged drug, from two studies in 368 pa-
tients with T2DM and severe RI.
Materials and methods: Data were pooled across two double-blind studies 
of similar design (a new study comparing Vilda and Sita at the doses rec-
ommended by label in severe RI and a previously reported study comparing 
Vilda and placebo [Pbo]). Patients with severe RI [eGFR (MDRD) <30 mL/
min/1.73m²], including patients on haemodialysis (N=16) were treated with 
Vilda 50 mg qd (N=206), Pbo (N=97) or Sita 25 mg qd (N=65) for 24 weeks. 
Absolute incidence rates were calculated for all adverse events (AEs), serious 
AEs (SAEs), discontinuation due to AEs, and deaths. Laboratory data were 
also analyzed.
Results: Mean age of the patients was 65.3 years, BMI 31.3 kg/m², HbA1c 
7.7% and T2DM duration 18.5 years; 81.3% of patients were treated with 
insulin as monotherapy or in combination with oral antidiabetics. The in-
cidence of AEs, SAEs, discontinuations due to AEs and deaths were overall 
comparable between Vilda, Sita and Pbo as shown in Table, which also pre-
sents the most commonly reported AEs. The incidence of cardiac events was 
also similar between treatments (12.6%, 15.4% and 12.4% with Vilda, Sita and 
Pbo, respectively). Hepatobiliary AEs were infrequent in all 3 groups (1.0%, 
1.5% and 0% of patients, respectively) as were persistent elevations ≥3xULN 
of hepatic enzymes alanine or aspartate aminotransferase (0.5%, 0% and 
1.1%, respectively). No cases of pancreatitis were reported in either group. 
There was no deterioration of renal function with Vilda or Sita compared 
with Pbo. While a limited number of patients with end stage renal disease on 
haemodialysis was included in the study (Vilda=8 and Sita=6), the safety data 
did not indicate that these patients were at increased risk compared to the 
population with severe RI.
Conclusion: Taken together, in a pooled analysis of patients with severe RI, 
Vilda and Sita had overall safety profiles comparable with Pbo, indicating that 
two different DPP-4i that are excreted via the kidney as unchanged drug or 
metabolites can be safely used in patients with T2DM and advanced RI at the 
doses recommended by the label.
Supported by: Novartis
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Cardiovascular safety of dipeptidyl peptidase-4 inhibitors in patients 
with type 2 diabetes: meta-analysis of randomised clinical trials
G. De Berardis1, F. Pellegrini1, M. Scardapane1, G. Lucisano1, L. Hazell2,  
M. Pladevall3, L. Scotti4, C. Varas-Lorenzo3, S. Perez-Gutthann3,  
M. Sturkenboom5, A. Nicolucci1;  
1Dept. Clinical Pharmacology and Epidemiology, Fondazione Mario Negri 
Sud, Santa Maria Imbaro, Italy, 2Drug Safety Research Unit, Southampton, 
UK, 3RTI Health Solutions, Barcelona, Spain, 4University Milano-Bicocca, 
Italy, 5Erasmus University Medical Center, Rotterdam, Netherlands.
Background and aims: In the framework of an EU funded study, the “Safety 
Evaluation of Adverse Reactions in Diabetes (SAFEGUARD) project”, a me-
ta-analysis of randomized clinical trials (RCTs) to assess the cardiovascular 
(CV) safety of dipeptidyl peptidase-4 inhibitors (DPP-4i) was performed.
Materials and methods: Trials were identified through searches of MED-
LINE, EMBASE and Cochrane databases (January 1966-September 2013) 
using standard search strategies. Reference lists of selected articles were also 
checked. Eligible studies included published RCTs that compared DPP-4i 
against placebo/no treatment, or another non-insulin blood glucose lowering 
agent in individuals with type 2 diabetes and reported major CV events (CV 
mortality, sudden death, myocardial infarction, stroke, or heart failure). Two 
reviewers independently assessed trials for inclusion and extracted data. Ef-
fect estimates were pooled using fixed or random effects meta-analysis based 
on exact bivariate non-linear mixed models. Results are reported as relative 
risks (RR) with 95% confidence intervals (CI).
Results: The electronic search identified 8,168 citations on all non-insulin 
blood glucose lowering agents, of which 334 were selected. Out of 140 RCTs 
on DPP-4i, 70 reported at least one CV event. When DPP-4i were compared 
with placebo/no treatment, no association was suggested with CV mortality 
(27 studies, 43,381 participants; RR=0.85; 0.71-1.02), sudden death (15 stud-
ies, 23,494 participants; RR=1.17; 0.90-1.51), myocardial infarction (20 stud-
ies, 27,553 participants; RR=0.95; 0.84-1.09), and ischemic stroke (15 studies, 
27,224 participants; RR=1.04; 0.84-1.29). There was an increase in the risk of 
heart failure in patients treated with DPP-4i compared to placebo (9 stud-
ies, 20,349 participants; RR=1.24, 1.03-1.49). For active comparator studies 
no association was found for CV mortality (24 studies, 22,064 participants; 
RR=0.92; 0.50-1.70), sudden death (8 studies, 7,130 participants; RR=0.83; 
0.23-3.00), myocardial infarction (12 studies, 5,453 participants; RR=0.70; 
0.34-1.43), or heart failure (6 studies, 6180 participants; RR=1.31; 0.50-3.43). 
DPP-4i reduced the risk of ischemic stroke when compared to active com-
parator (8 studies, 7,777 participants; RR=0.33; 0.14-0.79).
Conclusion: These results, based on publicly available data, suggest that 
DPP-4i did not influence the risk of CV mortality or other CV events in 
comparison with placebo/no treatment, except for an increased risk of heart 
failure. However, the results are driven by the findings from the “Saxagliptin 
Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mel-
litus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53” study and 
the finding needs to be confirmed by pooling these data with those of other 
ongoing studies specifically designed to assess the effect on CV end-points. 
Furthermore, DPP-4i showed a lower risk of ischemic stroke than active com-
parators. Additional trial data are required before definitively draw conclu-
sions on CV safety of DPP-4i.
Supported by: EC 7th Framework Programme (FP7/2007-2013 grant agree-
ment 282521–SAFEGUARD
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Cardiovascular safety of vildagliptin: an adjudicated meta-analysis  
of 40 studies
G. McInnes1, S. Del Prato2, M. Evans3, M. Stumvoll4, A. Schweizer5,  
V. Lukashevich6, Q. Shao6, W. Kothny5;  
1Institute of Cardiovascular & Medical Sciences University of Glasgow, UK, 
2University of Pisa, Italy, 3University Hospital, Llandough, Cardiff, UK, 
4University of Leipzig, Germany, 5Novartis Pharma AG, Basel, Switzerland, 
6Novartis Pharmaceuticals Corporation, East Hanover, USA.
Background and aims: Since the previous assessment of the cardiovascular 
(CV) safety profile of the DPP-4 inhibitor vildagliptin, a considerable number 
of additional studies have completed, including trials in high risk patients, 
such as with congestive heart failure or moderate/several renal impairment. 
It was therefore important to re-assess the CV safety of vildagliptin in this 
enlarged pool of studies.
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Materials and methods: Patient-level data were pooled from 40 double-
blind, controlled studies of vildagliptin, used either as monotherapy or com-
bination therapy, ranging in duration from 12 to ≥104 weeks. A retrospective 
meta-analysis of prospectively adjudicated CV events by a blinded independ-
ent expert committee was performed using Mantel-Haenszel risk ratios (RR) 
to compare the vildagliptin treatment group (approved doses of 50 mg bid 
and qd) to the comparators groups (placebo and active comparators).The pri-
mary endpoint was a major adverse CV events (MACE) composite of myo-
cardial infarction, stroke and CV death. Additional assessments included the 
individual components of the composite endpoint.
Results: Patients included in the pooled dataset [treated with vildagliptin 
(N=9599; 9250 subject year exposure [SYE]) or comparators (N=7847; 7317 
SYE)] had a mean age of ~57 years, slight male predominance (~55/45%), 
mean BMI of 30.5 kg/m2 (nearly 50% obese), mean HbA1c of 8.1%, and a 
mean T2DM duration of 5.6 years]; 46% of patients had dyslipidemia, 58% 
hypertension and 27% were 65 years or older. The incidences and risk ratios 
for the MACE composite endpoint as well as the individual components are 
shown in the Figure below. A MACE occurred in 111 (1.16%) patients receiv-
ing vildagliptin and 108 (1.52%) patients receiving comparators, the resulting 
RR being 0.86 (95% CI 0.66, 1.11), indicating no increased risk of MACE with 
vildagliptin. Similar risk ratios were also seen for each individual component 
of the composite endpoint (Figure).
Conclusion: This large meta-analysis demonstrates that vildagliptin is not 
associated with an increased risk for adjudicated MACE events relative to 
comparators, confirming the CV safety profile of the drug in a largely ex-
panded pooled population. 
Supported by: Novartis
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Lower respiratory tract infections and the use of dipeptidyl  
peptidase-4 inhibitors: a population-based matched cohort study
J.-L. Faillie1, L. Azoulay2, K. Filion2, V. Patenaude2, S. Suissa2, P. Ernst2;  
1Department of Medical Pharmacology, Montpellier University Hospital, 
France, 2Centre for Clinical Epidemiology, Lady Davis Institute, Montreal, 
QC, Canada.
Background and aims: It is hypothesized that dipeptidyl peptidase-4 (DPP-
4) inhibitors, also known as gliptins, may alter the immune response and play 
a role in the occurrence of infections. The aim of this study was to determine 
whether the use of DPP-4 inhibitors is associated with an increased risk of 
community-acquired lower respiratory tract infection, when compared to 
sulfonylureas.
Materials and methods: A population-based matched cohort study was con-
ducted among linkable patients with records in both the United Kingdom 
Clinical Practice Research Datalink (CPRD) and the Hospital Episodes Sta-
tistics (HES) database. Between January 1, 2007 and March 31, 2012, each 
new user of DPP-4 inhibitors was matched to two patients prescribed sulfo-
nylureas either in monotherapy or in combination, on three variables: age, 
duration of treated diabetes (defined as the time between a first ever non-
insulin prescription and cohort entry) and use of sulfonylurea in the prior 
year. Cox proportional hazards models were used to estimate hazard ratios 
(HRs) and 95% confidence intervals (CIs) of community-acquired lower res-
piratory tract infection, comparing DPP-4 inhibitors users to sulfonylurea 
users. In secondary analyses, types of DPP-4 inhibitors, and the outcome of 
hospitalization for community-acquired pneumonia were assessed. All mod-
els were adjusted for comorbidities and diabetes-related variables (such as 
hemoglobin A1c and previous use of anti-diabetic drugs).
Results: Overall, 6933 new users of DPP-4 inhibitors were compared to 
17,026 users of sulfonylureas. The crude incidence rates of community-ac-
quired lower respiratory tract infection was 8.44 per 100 person-years (95% 
CI: 7.71 - 9.23) for DPP-4 inhibitors users and 7.54 (95% CI: 7.21 - 7.89) for 
sulfonylurea users. Compared to sulfonylureas, the use of DPP-4 inhibitors 
was not associated with an increased risk of community-acquired lower res-
piratory tract infection and hospitalization for community-acquired pneu-
monia (0.90, 95% CI: 0.78 - 1.04 and 0.76, 95% CI: 0.44 - 1.31, respectively) 
(table 1). In the subgroup analysis by type of DPP-4 inhibitors, the risk of 
community-acquired lower respiratory tract infection ranged from a 17% de-
creased risk (HR: 0.83, 95% CI: 0.71 - 0.97) for sitagliptin, to a 31% increased 
risk for vildagliptin (HR: 1.31, 95% CI: 1.00 - 1.72).
Conclusion: Overall, the use of DPP-4 inhibitors as a class does not appear 
to be associated with an increased risk of community-acquired lower respira-
tory tract infections or hospitalization for community-acquired pneumonia. 
Additional research is needed to determine whether there is a within-class 
effect.
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Pregnancy outcomes after unintentional exposure to vildagliptin
C. McNeill1, C. Chu1, P.M. Paldánius2, W. Kothny2;  
1Novartis Pharmaceuticals Corporation, East Hanover, USA,  
2Novartis Pharma AG, Basel, Switzerland.
Background and aims: Type 2 diabetes mellitus (T2DM) is increasingly di-
agnosed in younger adults and as the population of women with diabetes 
becomes younger, T2DM and pregnancy increasingly co-exist. Pregnancies 
complicated by diabetes are associated with an increased risk of adverse 
outcomes such as preterm delivery, abortions, congenital abnormalities and 
neonatal mortality. However, data on outcomes in women exposed to newer 
oral anti-diabetes drugs (OADs), including vildagliptin, are limited. In the 
absence of adequate studies, most OADs carry warnings against use during 
pregnancy. Nevertheless, some use of these drugs occurs during pregnancy, 
either accidentally or intentionally. This analysis was performed to evaluate 
outcomes in pregnant women exposed to vildagliptin treatment.
Materials and methods: The Novartis Safety Database was searched to iden-
tify all known records (cut-off date: 30 September 2013) of exposure to vilda-
gliptin (± metformin) during pregnancy. The database includes clinical study 
and post-marketing surveillance reports, as well as spontaneous reports. 
Maternal outcomes (number of live births, pre-term deliveries, abortions or 
caesarean sections) and neonatal outcomes (number of congenital anomalies 
or deaths) were analysed and presented as descriptive data when available.
Results: A total of 32 pregnancies in 31 women with T2DM were identified 
from the database: 14 cases from controlled clinical trials, 15 spontaneous 
reports and 3 cases from post-marketing studies. The availability of demo-
graphic and baseline characteristics data was limited. The mean age was 33.9 
(range 19 - 44) years and 29.0% of women had a previous history of an abor-
tion (elective or spontaneous). Limited information was available on cumula-
tive vildagliptin dose or trimester(s) of exposure. 23 out of 32 pregnancies 
(71.9%) resulted in a live birth and more than half of all the pregnancies 
(n=18, 56.3%) had an unremarkable outcome of normal newborns without 
complications. Three (9.4%) pregnancies resulted in normal newborns with 
pregnancy complications (one case of gestational hypertension, haemorrhage 
during pregnancy and placenta previa) and two (6.3%) resulted in preterm 
deliveries. Four caesarean sections were reported (all live births), one in the 
preterm and three in term pregnancies. There were eight (24.9%) spontane-
ous or missed abortions, but their relationship to vildagliptin was unclear. 
Additionally one case of therapeutic abortion was reported. No congenital 
abnormalities or neonatal deaths were reported.
Conclusion: Although the numbers are low, this analysis provides pre-
liminary information on pregnancy outcomes in T2DM after exposure to 
vildagliptin. No prospective studies of vildagliptin have been performed in 
pregnant women with T2DM. As with most OADs, vildagliptin is also not 
recommended for use during pregnancy.
Supported by: Novartis Pharma AG
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Oral glucose lowering with linagliptin plus metformin is a viable initial 
treatment strategy in patients with newly diagnosed type 2 diabetes and 
marked hyperglycaemia
B. Gallwitz1, S.A. Ross2, A.E. Caballero3, S. Del Prato4,  
D. Lewis-D’Agostino5, Z. Bailes6, S. Thiemann7, S. Patel6, H.-J. Woerle7,  
M. von Eynatten5;  
1Dept. Medicine IV, Universitätsklinikum Tübingen, Germany, 2LMC 
Endocrinology Centres, University of Calgary, Canada, 3Joslin Diabetes 
Center and Harvard Medical School, Boston, USA, 4Department of 
Endocrinology and Metabolism, Section of Diabetes, University of Pisa, 
Italy, 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA, 
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GmbH & Co. KG, Ingelheim, Germany.
Background and aims: Newly diagnosed type 2 diabetes (T2D) patients 
commonly present with marked hyperglycaemia. This condition has rarely 
been studied for novel oral diabetes drugs and insulin is often proposed as 
the preferred starting therapy.
Materials and methods: We explored oral glucose-lowering combina-
tion therapy in newly diagnosed (≤12 months) T2D patients with marked 
hyperglycaemia (n=316) utilising prespecified exploratory subgroup 
analyses from a randomised double-blind study of initial combination of 
linagliptin+metformin versus linagliptin. Baseline mean±SD age and HbA1c 
was 48.8±11.0 years and 9.8±1.1%, respectively. The primary endpoint was 
HbA1c change from baseline to week 24.
Results: Mean±SE HbA1c reduction was -3.4±0.2% versus -2.5±0.2% with 
linagliptin+metformin and linagliptin, respectively, in patients with baseline 
HbA1c ≥9.5%, and -2.1±0.2% versus -1.4±0.2% in patients with baseline 
HbA1c <9.5%. Similar HbA1c reductions occurred in all subgroups of age, 
body-mass index (BMI), renal function, race, and ethnicity (table). Hypo-
glycaemia was rare (1.9% and 3.2% of patients, respectively) with no severe 
episodes.
Conclusion: In our analysis of newly diagnosed T2D patients presenting 
with marked hyperglycaemia, initial linagliptin+metformin elicited consist-
ent HbA1c reductions across different subgroups. Oral glucose-lowering 
combination therapy may be a viable initial alternative to insulin for effective 
treatment of these patients.
Clinical Trial Registration Number: NCT01512979
Supported by: Boehringer Ingelheim
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Vildagliptin versus insulin as add-on therapy to glimepiride in  
type 2 diabetes mellitus: results from a randomised controlled trial
H.-J. Strotmann1, D. Goetze2, C. Koch3, T. Forst4;  
1Hausarztpraxis, Neubukow, Germany, 2Internistische Facharztpraxis, 
Magdeburg, Germany, 3Novartis Pharma GmbH, Nuernberg, Germany, 
4Profil Mainz GmbH & Co. KG, Germany.
Background and aims: The study was designed to compare the effects of the 
dipetidyl-peptidase 4 (DPP-4) inhibitor vildagliptin and insulin, in addition 
to glimepiride, in patients with type 2 diabetes mellitus (T2DM) who do can-
not receive metformin.
Materials and methods: This was a multicenter, randomized, parallel-group 
controlled study to evaluate the occurrence of hypoglycemic events (HE) and 
treatment success on treatment with vildagliptin vs. NPH insulin, each in 
addition to background therapy with glimepiride. T2DM patients with in-
tolerance or contraindications to metformin therapy, and who did not have 
adequate glycemic control on their previous sulfonylurea monotherapy, 
were eligible for inclusion. Vildagliptin 50 mg once daily was compared in 
an open-label design with NPH insulin once daily, in an individually titrat-
ed dose, over 24 weeks. Primary efficacy endpoints were a combination of 
HbA1c target <7.0% without HE (<3.9mmol/L) and bodyweight gain (>3%), 
and rate of confirmed HEs. Secondary efficacy variables, amongst others, in-
cluded assessment of the Treatment Satisfaction Questionnaire for Medica-
tion (TSQM-9).
Results: 162 patients with T2DM and a mean age of 67.7 (SD 10.8) years 
were enrolled at 47 centers in Germany (83 patients in the vildagliptin group 
vs. 79 patients in the insulin group). Mean HbA1c at baseline was 7.6% (SD 
0.5; 7.61 ± 0.47% in the vildagliptin group, 7.67 ± 0.52% in the insulin group; 
p=0.510). After 24 weeks, 13.4% in the vildagliptin group and 29.1% in the 
insulin group had confirmed HEs, while 11.0% of patients in the vildagliptin 
group and 23.8% in the insulin group experienced a bodyweight gain >3%. 
48.8% patients in the vildagliptin group and 60.8% patients in the insulin 
group achieved the HbA1c target level of <7.0% at Week 24. Overall, the rate 
of patients fulfilling the combined criteria was similar in the two treatment 
groups: 35.4% in the vildagliptin group vs. 34.2% in the NPH insulin group 
achieved an HbA1c level of <7.0% without HEs and bodyweight gain >3% 
(OR=0.985, 95% CI for OR: [0.507; 1.915], p=0.9646). Patients` satisfaction 
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with medication, assessed as TSQM-9 scores for “convenience”, showed an 
increase from baseline to week 24 for the vildagliptin group and a decrease 
in the insulin group (9.6 ± 19.1 score points vs. -5.6 ± 22.0 score points; 
p<0.001). Scores for “effectiveness” and “global satisfaction” increased simi-
larly for both treatment groups.
Conclusion: In the treatment of T2DM in patients with insufficient glyce-
mic control on sulfonylurea monotherapy, addition of vildagliptin or insulin 
resulted in a similar number of patients reaching target HbA1c without HEs 
or bodyweight change >3%. That more patients achieved the HbA1c target 
of <7.0% with insulin treatment was expected because of individualized 
dose titration, but was associated with a doubling of confirmed HEs in this 
group. Vildagliptin was associated with greater convenience and treatment 
satisfaction scores compared with insulin. In these patients, the addition of 
vildagliptin to glimepiride could be considered as a treatment option prior to 
escalation to insulin treatment, with the advantages of a lower HE rate and 
greater patient convenience.
Clinical Trial Registration Number: NCT01649466
Supported by: Novartis Pharma GmbH, Germany
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Efficacy of vildagliptin and sitagliptin in reducing fasting plasma glucose 
in type 2 diabetes mellitus: results from a randomised controlled trial
R. Göke1, E.D. Dütting2;  
1Diabetologische Schwerpunktpraxis, Marburg,  
2Novartis Pharma GmbH, Nuremberg, Germany.
Background and aims: This study was designed to compare the effects of 
dipetidyl-peptidase 4 (DPP-4) inhibitors vildagliptin and sitagliptin, in ad-
dition to metformin, on fasting plasma glucose (FPG) levels in patients with 
type 2 diabetes mellitus (T2DM).
Materials and methods: This study applied a randomized cross-over, open-
label, active-controlled design to assess the FPG-lowering abilities of a sin-
gle pill combination (SPC) of vildagliptin and metformin (50/1000 mg bid) 
compared to sitagliptin/metformin SPC (50/1000 mg bid). Patients with type 
2 diabetes mellitus (T2DM) insufficiently controlled by stable metformin 
therapy (1000-2000 mg/day) were included. FPG was assessed twice, after 2 
weeks’ treatment with either medication: on day 14, and again on day 15 after 
a missed dose the previous evening.
Results: 99 patients with T2DM (35.4% female) and a mean age of 61.2 years 
(SD 10.1) were enrolled at 15 centers in Germany. Mean HbA1c on screening 
was 7.5 % (SD 0.68), and mean FPG was 164.3 mg/dL (SD 30.9). After 14 days 
of treatment, mean FPG was 137.8 mg/dL (SD 28.5) on vildagliptin and 140.1 
mg/dL (SD 26.5) on sitagliptin (p < 0.05, Wilcoxon). Change of FPG from 
baseline to day 14 was significantly greater under vildagliptin [-21.9 mg/dL 
(SD 27.0)] as compared to sitagliptin [-14.5 mg/dL (SD 23.0)] (p = 0.0196, 
Wilcoxon). After a missed evening dose, FPG increased slightly at day 15 in 
both treatment groups, with a greater increase on vildagliptin than sitagliptin 
treatment [day 15 FPG: 147.6 mg/dL (SD 29.2) vs. 143.4 mg/dL (SD 27.9), re-
spectively; p = 0.0473, Wilcoxon]. Adverse events were infrequent, and were 
mainly of mild or moderate intensity in both treatment groups.
Conclusion: Both DPP-4 inhibitors, given as SPC with metformin bid, low-
ered FPG after 14 days of treatment. Vildagliptin produced a significantly 
greater reduction in FPG versus baseline compared with sitagliptin, and this 
may have clinical relevance.
Clinical Trial Registration Number: NCT01398592
Supported by: Novartis Pharma GmbH, Germany
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Improvement in postprandial glucose after 2-year treatment  
with alogliptin in patients with type 2 diabetes inadequately controlled 
with metformin
J. Liu1, R. Oh1, C. Wilson1, R. Camisasca2;  
1Takeda Development Center Americas, Inc., Deerfield, USA,  
2Takeda Development Centre Europe, London, UK.
Background and aims: Increased postprandial glucose (PPG) contributes 
to hyperglycemia in patients with type 2 diabetes (T2D), and may be asso-
ciated with an increased risk of cardiovascular disease. Alogliptin (ALO) is 
an oral anti-diabetic agent that improves glycemic control by enhancing the 
incretin system in patients with T2D. Based on its mechanism of action, ALO 
may have a significant impact on PPG. The impact on PPG by ALO has only 
been demonstrated in a short-term (16-week) study. In a sub-population of a 
large 2-year, multicenter, double-blind, randomized clinical trial examining 
the durability of glycemic control of ALO compared to glipizide (GLIP), the 
long-term reduction in PPG by ALO was examined.
Materials and methods: A total of 2639 patients with T2D inadequately con-
trolled by metformin alone were randomized to ALO 12.5mg (A12.5), ALO 
25mg (A25) or GLIP (5mg titrating to 20mg) treatment groups. The primary 
endpoint was HbA1c reduction from baseline (BL) at 52 and 104 weeks. In 
study centers capable of measuring PPG, 2-hour PPG was measured after a 
standardized meal at BL, week 12, 26, 52, and 104 visits.
Results: A total of 1418 subjects had a BL PPG measurement. Mean 2-hour 
PPG levels were similar among treatment groups at BL: 207.5 mg/dL, 203.2 
mg/dL, and 197.3 mg/dL in the A12.5 (n=470), A25 (n=492), and glipizide 
(n=456) groups, respectively. Reduction of PPG occurred in all 3 groups at 
week 12 and lasted through week 104. At week 104, the LS mean reductions 
from BL in 2-hour PPG levels were significantly greater with A12.5 (n=230, 
-12.9 mg/dL; p=0.014) and A25 (n=257, -11.4 mg/dL; p=0.027) when com-
pared with GLIP (n=214, 0.9 mg/dL). The 2hour PPG excursion was deter-
mined by the 120-min glucose value minus the 0-min glucose value at that 
visit. At week 104, the LS mean changes from BL in PPG excursions were 6.4 
and -6.8 mg/dL in the A12.5 and A25 treatment groups, respectively, vs 2.8 
mg/dL in the GLIP treatment group; no statistically significant treatment-
group differences were observed.
Conclusion: In this study, ALO reduced PPG over the 2-year treatment pe-
riod, and this reduction appears to be more sustainable with ALO than that 
with GLIP.
Clinical Trial Registration Number: NCT00856284
Supported by: Takeda Development Center Americas, Inc.
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Assessing time to insulin use among type 2 diabetes patients treated with 
sitagliptin or sulfonylurea plus metformin dual therapy
S.E. Inzucchi1, Y. Qiu2, S. Rajpathak2, K.G. Brodovicz2, S.S. Engel2,  
P. Mavros2, L. Radican2, P. Brudi2, K. Tunceli2, C.-P.S. Fan3, Z. Li3, J. Tang3,  
L. Blonde4;  
1Yale University School of Medicine, New Haven, 2Merck Sharp & Dohme 
Corp, Whitehouse Station, 3AsclepiusJT LLC, New York, 4Ochsner Medical 
Center, New Orlean, USA.
Background and aims: In type 2 diabetes mellitus (T2DM), decline of β-cell 
function over time leads to the need for treatment intensification and eventu-
ally initiation of insulin therapy in many patients (pts). Sitagliptin (SITA) and 
sulfonylureas (SU) are commonly prescribed after metformin as dual therapy 
in T2DM. This study assessed the time to insulin initiation among pts treated 
with MET+SITA in comparison to those treated with MET+SU.
Materials and methods: This retrospective cohort study used a sample from 
the GE Centricity database. Included were pts with T2DM, ≥18 years (yrs), 
with continuous medical records. Index was the date of the 1st prescription 
of SITA or SU used as dual therapy with metformin for ≥90 days in 2006-13. 
SITA and SU users were matched 1:1 using propensity score (PSM). Differ-
ences in time to insulin use (from index date) between SITA and SU users 
were assessed using Kaplan-Meier (KM) curves and Cox regression. Con-
ditional logistic regression (CLR) examined the likelihood of insulin use in 
each of yrs 1-5 post index. Adjustments were made for baseline characteris-
tics. Subgroup analyses for baseline A1C< 9% or ≥9% were then conducted.
Results: PSM produced 3,862 matched pairs. The percent of pts progress-
ing to insulin by yrs 1-6 were 3.6, 8.4, 12.9, 17.7, 22.4, 26.6 for SITA and 4.1, 
9.4, 14.6, 21.0, 27.1, 34.1 for SU users, respectively. KM curves for SITA and 
SU users were significantly different (p=0.0034) indicating that SITA users 
progressed more slowly to insulin initiation than SU users. This remained sig-
nificant after adjusting for baseline characteristics (HR: 0.76, 95% CI: [0.464, 
0.897]). CLR analyses confirmed the robustness of the results (ORs: 0.77; 
0.79; 0.81; 0.57; 0.29; for yrs 1-5 respectively, p<.05 for Yr 4 and Yr 5). The 
SITA vs. SU comparison in pts with baseline A1C <9% and ≥9% produced 
hazard ratios of: 0.77, 95% CI: [0.621, 0.945], and 0.75, 95% CI: [0.490, 1.145], 
respectively.
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Conclusion: In this matched cohort study, pts with T2DM who started with 
MET+SITA dual therapy progressed to insulin therapy at a slower rate than 
those who started with MET+SU dual therapy.
Supported by: MSD
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Combination with linagliptin improves the tolerability of metformin in 
type 2 diabetic patients previously labelled as intolerant to metformin
G. Gusmão, M. Moureira, F. Sosa;  
Endocrinologia, Hospital Santa Helena, Jequié - Bahia, Brazil.
Background and aims: Metformin is the first-line drug for the treatment of 
type 2 diabetes but gastrointestinal intolerance to it is frequent. We sought to 
determine if patients withdrawn from metformin treatment due to intoler-
ance would be able to tolerate it when rechallenged, and if the addition of 
linagliptin would improve the probability of tolerating metformin.
Materials and methods: From the clinical records of our Diabetes Clinic, 
we identified type 2 diabetic patients aged 30 to 80 with HbA1c > 7% who 
had withdrawn from metformin due to gastrointestinal intolerance but had 
presented no serious adverse effects and had no significant renal insufficiency 
or other contraindications for metformin use, were not taking incretin-based 
therapy and were possible candidates for treatment with metformin and/or 
linagliptin. After at least 6 months from withdrawal, they were randomised to 
treatment with metformin alone (500 mg twice daily for 2 weeks, then 1000 
mg twice daily for 10 additional weeks if the previous dose was tolerated), or 
with metformin (same pattern) plus linagliptin 5 mg daily, in an open fash-
ion. Tolerance was assessed at weeks 2 and 12 by questionnaire performed by 
personnel blinded to the treatment status. Fasting glucose and HbA1c were 
measured at baseline and 12 weeks
Results: We found 84 consecutive patients who were offered to participate. 
25 declined, 30 received metformin plus linagliptin (ML) and 29 metformin 
alone (M). Their age was 63.2 ± 7.6 years, 56% were female; at baseline their 
fasting plasma glucose (FPG) was 9.2 ± 1.6 mmol/l and their HbA1c was 
8.2 ± 0.9%. There were no significant differences between the groups for any 
of these variables. In the M group, 8 patients (28%) tolerated the low-dose 
and 5 (17%) the full-dose metformin (odds/ratio 3.94; 95% CI 1.32-11.76, 
p=0.014). In the ML group, 18 patients (60%) tolerated the low-dose and 14 
(47%) the full-dose metformin (odds/ratio 4.20; 95% CI 1.26-13.96, p=0.019). 
By intention to treat, at week 12 the FPG in the M group was reduced by 1.1 
± 0.5 mmol/l and HbA1c was reduced by 0.2 ± 0.1%. In the ML group FPG 
was reduced by 2.7 ± 1.2 mmol/l and HbA1c was reduced by 0.9 ± 0.3% (both 
p <0.001 between groups, non-paired t-test). By protocol (patients that toler-
ated at least low-dose metformin), at week 12 the FPG in the M group was 
reduced by 2.5 ± 0.9 mmol/l and HbA1c was reduced by 0.5 ± 0.2%. In the 
ML group FPG was reduced by 3.2 ± 1.3 mmol/l (p=0.020) and HbA1c was 
reduced by 1.1 ± 0.4% (p <0.001). Apart from minor gastrointestinal distur-
bances, the patients did not report any side effects that could be attributed to 
the studied drugs.
Conclusion: A significant proportion of patients labelled as intolerant to 
metformin could be successfully rechallenged with it, although only a frac-
tion of them tolerated the full-dose treatment. The addition of linagliptin 
improved very significantly the probability of a successful rechallenge with 
metformin, resulting in a clear improvement in glycemic control, without ad-
ditional tolerability issues.
900
Real life effectiveness and safety of vildagliptin compared with other 
OADs in European type 2 diabetes mellitus patients: results from the 
EDGE study
P.M. Nilsson1, H. Brath2, A. Penfornis3, J.J. de Castro4, I. Conget5, R. Göke6, 
E. Pagkalos7, N.C. Schaper8, P. Geransar9, G. Bader10, P.M. Paldánius10,  
A.H. Barnett11, C. Mathieu12;  
1Skåne University Hospital, Malmö, Sweden, 2Health Center South, Vienna, 
Austria, 3Jean Minjoz Hospital, Besançon, France, 4Armed Forces University 
Hospital, Lisboa, Portugal, 5Hospital Clinic i Universitari, Barcelona, Spain, 
6University of Marburg, Germany, 7Private Hospital “Thermi”, Kalamaria 
Thessaloniki, Greece, 8University Hospital Maastricht, Netherlands, 
9Novartis Pharmaceuticals UK Ltd, Frimley/Camberley, UK,  
10Novartis Pharma AG, Basel, Switzerland, 11Heart of England NHS 
Foundation Trust and University of Birmingham, UK,  
12Catholic University of Leuven, Belgium.
Background and aims: Stepwise treatment intensification is necessary in 
type 2 diabetes mellitus (T2DM) due to progressive loss of β-cell function. 
European societies (ESC/EASD) provide algorithms for improving glycaemic 
and risk factor control with a holistic approach in the management of T2DM 
and cardiovascular disease; HbA1c goal of ≤7%, avoiding hypoglycaemia and 
individualising therapy and glycaemic targets. The purpose of the observa-
tional EDGE study was to prospectively evaluate the effectiveness and safety 
of vildagliptin vs other oral antidiabetes drugs (OADs) in T2DM patients 
inadequately controlled with monotherapy. Here, we present the post-hoc 
analysis results for the 12 participating European countries.
Materials and methods: Patients receiving physician-prescribed add-on 
OAD treatment were assigned to: (i) vildagliptin or (ii) other OADs (except 
other incretin-based therapies). The primary composite endpoint was the 
proportion of patients with HbA1c drop >0.3%, without peripheral oedema, 
hypoglycaemia, discontinuation due to a gastrointestinal event or weight gain 
≥5% at 1 year. A secondary composite endpoint was attainment of HbA1c 
<7.0% at 1 year without hypoglycaemia or weight gain ≥3%.
Results: In Europe, 23038 patients receiving mostly metformin monother-
apy were enrolled (total intention to treat: 22073; vildagliptin: 15582; other 
OADs: 6491). The mean baseline HbA1c was 7.9±1.3%, mean T2DM dura-
tion was 6.3±5.6 years and 52.0% were male. Prevalence of risk factors such 
as hypertension (68.5%) and lipid disorders (50.0%) was high. Micro- and 
macrovascular complications were present in 9.6% and 18.4% of patients. 
Reflecting real life setting, there was heterogeneity in patient characteristics 
among different countries and imbalances between treatment cohorts. Pa-
tients in the vildagliptin cohort were younger at baseline (61.8±11.0 years vs 
63.4±10.5 years) with slightly higher BMI (30.5±5.3 vs 29.9±4.9) while the 
cohorts had comparable mean baseline HbA1c (7.9±1.3% vs 7.8±1.2%). Both 
the primary (49.3% vs 46.5%; OR 1.11, 95% CI: 1.05; 1.18; p<0.001) and sec-
ondary (34.6% vs 28.5%; OR 1.32, 95% CI: 1.23; 1.42; p<0.001) composite 
endpoints were reached more often in patients receiving vildagliptin than 
other OADs. Between-country variability was substantial for both endpoints. 
The percentage of patients reporting adverse events was low and similar, 5.8% 
in each cohort. Also hypoglycaemia rates were low, 0.2% for vildagliptin vs 
0.8% for other OADs.
Conclusion: In addition to confirming the real world effectiveness and safety 
of vildagliptin, EDGE highlights the sustained need for improvement in ad-
herence to Europe-specific guidelines (ESC/EASD) for optimised manage-
ment of glycaemic targets.
Supported by: Novartis
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Duration of maintenance of dual therapy with metformin and sitagliptin 
in type 2 diabetes: the Odyssée observational study 
P. Valensi1, G. De Pouvourville2, N. Benard3, C. Chanut-Vogel3, C. Kempf4, 
C. Moisan3, J. Dallongeville5;  
1Department of Endocrinology Diabetology Nutrition-Jean Verdier 
Hospital, CRNH-IdF, CINFO, Bondy, 2ESSEC, Paris,  
3MSD, Courbevoie, 4CSD, PARIS, 5Institut Pasteur, Lille, France.
Background and aims: Sulfonylurea and DPP-4 inhibitors are usually pre-
scribed for T2DM patients in combination with metformin. Odyssée, a pro-
spective, real-world, observational study conducted in France in primary 
care practices, compared the duration of maintenance of treatment without 
modification (withdrawal, substitution, or add-on therapy) in T2DM patients 
in whom dual therapy with metformin + sitagliptin (MetSita) or metformin + 
sulfonylurea (MetSu) was initiated.
Materials and methods: Odyssée was a multicenter, longitudinal study. It 
was conducted in a randomly selected sample of general practitioners in 
France. Patients were not randomized and were followed for a period of up 
to three years. Treatments were prescribed at the discretion of the physician. 
Physicians were expected to include all patients who met the eligibility crite-
ria: Adult (aged ≥18 years) patients with type 2 diabetes who had initiated a 
de novo treatment with metformin and sitagliptin dual therapy or metformin 
and sulfonylurea dual therapy within the previous eight weeks were eligible 
for the study. Patient follow-up and changes to treatment were performed 
according to the physician’s clinical practice and were not specified in the 
study protocol.
Results: At baseline, differences between the two arms (MetSita [n = 1874] 
and MetSu [n = 733]) were modest (mean age: 62.4 vs 64.2 years, BMI: 30.3 vs 
29.6 kg/m2, diabetes duration: 6.4 vs 7 years, respectively). Mean HbA1c lev-
els were similar (7.5 vs 7.6%). The median treatment duration for patients in 
the MetSita group was longer than the MetSu group (median treatment dura-
tion 43.2 vs 20.2 months, respectively; between-group difference 23 months, 
log-rank p <0.0001). This difference persisted after adjustment for baseline 
differences and confounders using propensity score methods and applica-
tion of maximum bias statistical methodology for missing data (42.4 vs 20.2 
months). A similar reduction in HbA1c was noted in both arms (- 0.6%) and 
the incidence of hypoglycemia (prior to treatment modification) was lower 
in the MetSita arm than the MetSu arm (9.7% vs 21.0%). 130 (6.9%) and 58 
(7.9%) patients presented a total of 159 and 79 (AEs) during follow-up in the 
MetSita and MetSU group, respectively. According to the investigating physi-
cians, 60 AEs potentially related to treatment occurred in 52 (2.8%) patients 
in the MetSita group, and 24 AEs potentially related to treatment occurred in 
20 (2.7%) patients in the MetSU group.
Conclusion: Conducted under real-life conditions, the Odyssée study 
showed that combined therapy with MetSita is maintained without treat-
ment modification longer than combined therapy with MetSu. In addition, 
the study showed that the glycemic effect is similar, with a lower incidence of 
symptomatic hypoglycemia, with MetSita compared to MetSu.
Supported by: Merck Sharp & Dohme
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Efficacy and safety of a fixed-dose combination of vildagliptin and 
metformin (LMF237) in Japanese patients with type 2 diabetes
M. Yoshiki1, M. Odawara2, M. Sano1, I. Hamada1, V. Lukashevich3,  
W. Kothny4;  
1Novartis Pharma KK, Tokyo, 2Tokyo Medical University, Japan,  
3Novartis Pharmaceuticals Corporation, East Hanover, USA,  
4Novartis Pharma AG, Basel, Switzerland.
Background and aims: The use of DPP-4 inhibitor and metformin combina-
tion therapy has been increasing in Japanese patients with type 2 diabetes 
mellitus (T2DM), but no single-pill combination (SPC) of a DPP-4 inhibi-
tor and metformin is currently available in Japan. This clinical study aimed 
to evaluate the efficacy and safety of an SPC of vildagliptin and metformin 
(LMF237), in Japanese patients with T2DM inadequately treated with vilda-
gliptin monotherapy. There is limited data assessing the benefit of adding 
metformin at the doses used in Japan to a DPP-4 inhibitor.
Materials and methods: In a 14-week, multicenter, randomized, double-
blind, parallel-group, placebo-controlled study, 171 patients with T2DM 
were randomized to LMF237 bid (N=115) or placebo (vildagliptin mono-
therapy) (N=56) in a ratio of 2:1. In addition, patients in the LMF237 group 
were further randomized to receive either LMF237 (vildagliptin/metformin) 
50/250 mg bid (N=56) or 50/500 mg bid (N=59) in a 1:1 ratio. The primary 
efficacy variable included change from baseline to endpoint (Week 14 or final 
study visit) in HbA1c. The incidence of adverse events (AEs) during the treat-
ment period was also assessed.
Results: Treatment groups were well-balanced for baseline demographic and 
background characteristics. Patients had a mean age of 57.0 years (73.1% were 
<65 years old) and a mean T2DM duration of 7.0 years. A higher percent-
age of male patients (71.3%) was randomized compared to female patients 
(28.7%). Mean baseline values of HbA1c, FPG and BMI were 7.9%, 158.7 mg/
dL and 25.8 kg/m2, respectively. The change in mean HbA1c was −0.83% in 
the LMF237 group (both doses combined) and 0.14% in the placebo group. 
The between-group difference in HbA1c change (LMF237 - placebo) of 
−0.98% was clinically relevant and statistically significant (p<0.001) (Table). 
In addition, clinically and statistically significant reductions in HbA1c from 
baseline to endpoint were observed for the subgroups of patients receiving 
LMF237 50/250 mg bid or 50/500 mg bid (−0.61% and −1.04%, respectively; 
both p<0.001). The overall incidences of AEs were 43.5% in the LMF237 
(both doses combined) and 67.9% in the placebo. In the LMF237 subgroups, 
the incidence of AEs was similar (44.6% in 50/250 mg bid and 42.4% in 
50/500 mg bid). The incidences of serious AEs were low in both treatment 
groups (0.9% vs 3.6%, respectively). No deaths or hypoglycemic AEs were 
reported in either group.
Conclusion: Treatment with LMF237 (vildagliptin + metformin SPC) dem-
onstrated a significantly greater reduction in HbA1c compared to placebo 
(vildagliptin monotherapy), without an increase in hypoglycemia incidence, 
and was well-tolerated in Japanese patients with T2DM inadequately con-
trolled with vildagliptin alone. Thus, LMF237 is an attractive treatment op-
tion for Japanese patients with T2DM.
Clinical Trial Registration Number: NCT01811485
Supported by: Novartis Pharma KK
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Liraglutide 3.0 mg reduces body weight and improves cardiometabolic 
risk factors in overweight/obese adults: the SCALE obesity and 
prediabetes randomised trial
M. Krempf1, A. Astrup2, C. le Roux3, K. Fujioka4, F. Greenway5, A. Halpern6, 
D.C.W. Lau7, R. Violante Ortiz8, J.P.H. Wilding9, C.B. Jensen10,  
S.K. Lillleøre10, X. Pi-Sunyer11;  
1Clinique d‘endocrinologie, CHRU Nantes, France,  
2University of Copenhagen, Denmark, 3University College Dublin, Ireland, 
4Scripps Clinic, La Jolla, 5Louisiana State University, Baton Rouge, USA, 
6University of São Paulo Medical School, Brazil, 7University of Calgary, 
Canada, 8Instituto Mexicano del Seguro Social, Ciudad Madero, Mexico, 
9University of Liverpool, UK, 10Novo Nordisk A/S, Søborg, Denmark, 
11Columbia University, New York, USA.
Background and aims: A 5-10% weight loss has been shown to improve the 
multiple cardiometabolic comorbidities associated with chronic obesity. This 
phase 3 trial investigated the effects of liraglutide 3.0 mg, as adjunct to diet 
and exercise, on weight loss (primary endpoint) and cardiometabolic risk fac-
tors (waist circumference, BP, lipids and other biomarkers).
Materials and methods: Individuals (BMI ≥27 kg/m2 with ≥1 comorbidity 
or ≥30 kg/m2) were advised on a 500 kcal/day deficit diet and exercise pro-
gramme and randomised 2:1 to once-daily s.c. liraglutide 3.0 mg (n=2487) or 
placebo (n=1244). Randomisation was stratified by prediabetes status (ADA 
2010 criteria) and BMI. Data are shown for the full analysis set (exposed indi-
viduals with ≥1 post-baseline assessment) with LOCF. The trial has an ongo-
ing 2-year extension for participants with prediabetes.
Results: Baseline characteristics were: age 45.1 years, 78.5% female, body 
weight 106.2 kg, BMI 38.3 kg/m2, 61.2% with prediabetes. At week 56, in-
dividuals on liraglutide 3.0 mg achieved more weight loss (8.0%) than those 
on placebo (2.6%) (estimated treatment difference [ETD] -5.4% [95% CI 
5.8; -5.0]; p<0.0001) (Table). Weight loss was accompanied by reductions in 
waist circumference (ETD 4.2 [-4.7; -3.7] cm), systolic BP (ETD -2.8 [ 3.6; 
-2.1] mmHg) and diastolic BP (ETD 0.9 [-1.4; -0.4] mmHg) for liraglutide vs 
placebo (all p<0.001). Mean pulse was increased at week 56 with liraglutide 
3.0 mg vs placebo (ETD 2.4 [1.9; 3.0] bpm, p<0.0001). Improvements in all 
fasting lipids were seen with liraglutide 3.0 mg vs placebo. Improvements in 
hsCRP (% relative difference -30% [ 34; 26]), PAI-1 (-21% [-26; -17]) and 
adiponectin (+8% [5; 12]) (all p<0.0001) were also observed with liraglutide 
3.0 mg vs placebo. Liraglutide 3.0 mg reduced net use of anti-hypertensive 
(OR 1.7, p<0.0001) and lipid-lowering (OR 1.5, p=0.02) medications at week 
56 vs placebo, while maintaining greater beneficial effects on BP and lipids.
Conclusion: Weight loss with liraglutide 3.0 mg, as adjunct to diet and exer-
cise, produced improvements in a wide range of cardiometabolic risk factors, 
including inflammatory markers, in overweight or obese individuals, which 
if sustained in the long term may be associated with reduced cardiovascular 
events.
Clinical Trial Registration Number: NCT01272219
Supported by: Novo Nordisk
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Efficacy and safety of liraglutide 3.0 mg for weight management in 
overweight/obese adults: the SCALE obesity and prediabetes trial
K. Fujioka1, J.P.H. Wilding2, A. Astrup3, F. Greenway4, A. Halpern5,  
M. Krempf6, D.C.W. Lau7, C. le Roux8, R. Violante Ortiz9, C.B. Jensen10,  
S.K. Lillleøre10, X. Pi-Sunyer11;  
1Scripps Clinic, La Jolla, USA, 2University of Liverpool, UK, 3University of 
Copenhagen, Denmark, 4Louisiana State University, Baton Rouge, USA, 
5University of São Paulo Medical School, Brazil, 6Université de Nantes, 
France, 7University of Calgary, Canada, 8University College Dublin, Ireland, 
9Instituto Mexicano del Seguro Social, Ciudad Madero, Mexico, 10Novo 
Nordisk A/S, Søborg, Denmark, 11Columbia University, New York, USA.
Background and aims: Obesity is associated with prediabetes, which is a 
high risk factor for development of T2D. This trial investigated the effects of 
liraglutide 3.0 mg, as adjunct to diet and exercise, on weight loss (co-primary 
endpoints: mean change in body weight [BW] and proportions of individuals 
losing ≥5% and >10% of BW), safety and tolerability in overweight and obese 
adults without T2D over 56 weeks.
Materials and methods: Individuals (BMI ≥27 kg/m2 with ≥1 comorbidity 
or ≥30 kg/m2) were advised on a 500 kcal/day deficit diet and exercise pro-
gramme and randomised 2:1 to once daily sc liraglutide 3.0 mg (n=2487) or 
placebo (n=1244). Randomisation was stratified by prediabetes status (ADA 
2010 criteria) and BMI. Data are shown for FAS (exposed individuals with ≥1 
post-baseline assessment) with LOCF.
Results: Baseline characteristics: age 45.1±12.0 years, 78.5% female, BW 
106.2±21.4 kg, BMI 38.3 kg/m2, 61.2% with prediabetes) completed 56 weeks 
(71.9% on liraglutide 3.0 mg; 64.4% on placebo). At week 56, individuals on 
liraglutide 3.0 mg had lost 8.0% (8.4 kg) of BW vs 2.6% (2.8 kg) on placebo 
(estimated treatment difference [ETD] -5.4% [5.6 kg], p<0.0001, ANCOVA) 
(Fig). Proportion of individuals achieving a BW loss ≥5% was 64% with lira-
glutide 3.0 mg and 27% with placebo (estimated OR 4.8, p<0.0001, logistic 
regression). The proportion achieving BW loss >10% was 33% and 10%, re-
spectively (OR 4.3, p<0.0001). BW loss was independent of prediabetes status 
at screening (Fig). Consistent with BW loss, liraglutide 3.0 mg also reduced 
waist circumference (ETD −4.2 cm) and BMI (−2.0 kg/m2) (both p<0.0001 
vs placebo, ANCOVA), and improved glycaemia, blood pressure and lipids 
(not shown). The most common AEs with liraglutide 3.0 mg were nausea 
and diarrhoea, with onset in week 1−4. Most events were mild/moderate and 
transient. AE withdrawal was 9.9% with liraglutide 3.0 mg (mostly due to 
gastrointestinal AEs) and 3.8% with placebo. The incidences of gallbladder 
disorders and pancreatitis were low, although events were reported more 
frequently with liraglutide 3.0 mg (2.7 and 0.3 events/100 patient years of 
exposure [PYE], respectively) than with placebo (1.1 and 0.1 events/100 PYE, 
respectively). Two individuals (1 in each group) co-reported gallbladder-
related AEs and pancreatitis.
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Conclusion: Liraglutide 3.0 mg, as adjunct to diet and exercise, was superior 
to placebo on all co-primary endpoints and generally well tolerated.
Clinical Trial Registration Number: NCT01272219
Supported by: Novo Nordisk
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Liraglutide improves carotid intima-media thickness in patients with 
type 2 diabetes and non-alcoholic fatty liver disease: an 8-month 
prospective pilot study
R.V. Giglio, M. Rizzo, A.M. Patti, D. Nikolic, V. Di Bartolo, G. Castellino,  
G. Pecoraro, C. Rinaudo, F. Emanuele, A. Bonfiglio, M. Soresi, G. Montalto;  
Biomedical Department of Internal Medicine and Medical Specialties, 
University of Palermo, Italy.
Background and aims: It has been shown in the last years that GLP-1 ana-
logues, such as liraglutide, have several anti-atherogenic properties beyond 
their effects on glucose metabolism, including that on subclinical atheroscle-
rosis. Yet, the effects of liraglutide in subjects with non-alcoholic fatty liver 
disease (NAFLD) are largely unknown.
Materials and methods: We included in a 8-month prospective study 29 sub-
jects with type-2 diabetes and NAFLD (16 men and 13 women, mean age: 
61±10 years), who were matched for age and gender with another group of 
29 subjects with type-2 diabetes (T2DM) but without NAFLD (16 men and 
13 women, mean age: 61±8 years). The diagnosis of NAFLD was based on 
ultrasonographic and biochemical data. All subjects were naïve to incretin-
based therapies and treated with metformin only. Liraglutide was given, on 
top of meformin, at a dosage of 0.6 mg/day for two weeks, followed by a dose 
of 1.2 mg/day for the rest of the study. At baseline and every 4 months fasting 
plasma samples were taken for laboratory analyses and carotid-intima me-
dia thickness (IMT) was assessed by B-mode real-time ultrasound. Statistical 
analysis was performed by ANOVA and the Spearman correlation method.
Results: From baseline to 4 months and 8 months of liraglutide therapy 
we found significant reductions in HbA1c in both groups of patients (from 
8.9±1.5 to 6.6±1.2 to 6.5±1.1% in subjects with T2DM and NAFLD, and from 
8.7±0.6 to 7.1±1.1 to 6.9±0.9% in subjects with T2DM only, p<0.0001 for 
both groups). By contrast, no significant changes were found in body weight, 
waist circumference, body mass index as well as in plasma lipids for both 
groups of subjects; yet, it should be noted that some differences approached 
the statistical significance but probably did not reach it because of the small 
study groups. Carotid IMT significantly decreased only in the group of pa-
tients with T2DM and NAFLD (from 0.96±0.27 to 0.82±0.17 to 0.85±0.12 
mm, p=0.0325). Correlation analysis revealed that changes in carotid IMT 
after 8 months of therapy were not associated with changes in any other eval-
uated parameter, including fasting glicemia or HbA1c.
Conclusion: Liraglutide significantly reduced carotid IMT in patients with 
T2DM and NAFLD, and this beneficial effect was present beyond glycemic 
control. Yet, whether these findings may translate into a better cardio-meta-
bolic outcome is still unknown.
Clinical Trial Registration Number: NCT01715428
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The dynamic changes of diabetic maculopathy with intensification of 
glycaemic control with GLP-1 agonist therapy
L. Varadhan1, A. Machin1, T. Humphreys2, A.U. Nayak1, B. Jose1,  
A.B. Walker1, G.I. Varughese1;  
1Dept of Endocrinology and Diabetes, 2Dept of Ophthalmology,  
University Hospitals North Staffordshire NHS trust, Stoke on Trent, UK.
Background and aims: Transient worsening of diabetic retinopathy (DR) 
with rapid and significant improvement in glycaemic control with GLP-1 ag-
onist therapy has already been well documented. This phenomenon is more 
common with longer duration of diabetes and pre-existing DR with an inher-
ent risk of maculopathy. The aim of our study was to assess the incidence and 
outcomes of diabetic maculopathy with sustained GLP-1 therapy in type 2 
diabetes.
Materials and methods: A retrospective observational analysis was conduct-
ed on all patients who continued on GLP-1 therapy (Exenatide or Liraglutide) 
beyond 2 years. Retinal screening data at baseline(INITIAL), closest to the 
lowest HbA1c (INTERIM) and 2 years after initiation (FINAL) were derived 
from the regional DR screening database. Maculopathy was diagnosed based 
on referral criteria of UK National screening committee guidelines. HbA1c 
at baseline, lowest HbA1c achieved on treatment (within the first 12 months) 
and HbA1c at the latest DR screening were recorded.
Results: 125 patients were included in the analysis. Mean of various param-
eters were: Duration of diabetes 12.4 years (1-32); Baseline HbA1c 83mmol/
mol (45-132); reduction in HbA1c at INTERIM phase was -19 mmol/mol (0 
to -70); duration of follow up 933 days (407-1760); HbA1c at FINAL analysis 
73mmol/mol (30-143). 82 patients had HbA1c lesser than or equal to their 
INITIAL value, mean difference being -23 mmol/mol (0 to -68). 72 patients 
had DR at baseline of whom 49 showing evidence of maculopathy. 3 had 
resolution of maculopathy at INTERIM study (without Laser) and a further 
30 had resolution by the FINAL study (4 of them resolved likely with laser 
treatment). New onset of maculopathy was noted in 16 patients at INTERIM 
study. 9 of the 16 patients had no DR at INITIAL study and their duration of 
diabetes and reduction of HbA1c achieved at INTERIM study was similar 
to rest of the group. By the FINAL study, maculopathy had spontaneously 
resolved in 13 of the 16 without any Laser treatment. 9 of the 13 patients had 
sustained reduction in HbA1c [FINAL HbA1c still being lower than INITIAL 
HbA1c- mean -34mmol/mol (-3 to -68)]
Conclusion: Pre-existing maculopathy improves in a significant propor-
tion of patients with improvement in glycaemic control. Worsening of DR 
with intensification of diabetes control could lead to development of macu-
lopathy but sustained improvement of glycaemic control could potentially 
reverse this transient complication. Patients with pre-existing DR may be at 
higher risk of continued progression of maculopathy. The retinal screening 
programme should have provisions to monitor this paradoxical phenomenon 
and refer to ophthalmologist if required.
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Patient-reported outcomes with once weekly dulaglutide 1.5 mg versus 
once daily liraglutide 1.8 mg (AWARD-6)
K.S. Boye, M. Yu, K. Van Brunt, J.L. Fahrbach;  
Eli Lilly and Company, Indianapolis, USA.
Background and aims: Patient-reported outcomes (PRO) were exploratory 
objectives in AWARD-6, a noninferiority study designed to compare the ef-
ficacy and safety of once weekly dulaglutide (DU), a long-acting GLP-1 re-
ceptor agonist, to once daily liraglutide (LIRA) in metformin-treated patients 
with type 2 diabetes.
Materials and methods: This was a Phase 3, randomised, open-label, par-
allel-arm study where 599 patients received once weekly DU 1.5 mg or once 
daily LIRA 1.8 mg for 26 weeks. PRO measures for health status (EQ-5D), im-
pact of weight-related self-perception (IW-SP), and ability to perform physi-
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cal activities of daily living questionnaire (APPADL) were administered at 
baseline and 26 weeks. Analysis of covariance models were fitted with factors 
of pooled country, baseline score, HbA1c strata (≤8.5, >8.5) and treatment.
Results: DU 1.5 mg was noninferior to LIRA 1.8 mg in HbA1c change from 
baseline. Significant reductions in weight were observed with both DU 1.5 
mg and LIRA 1.8 mg (LS mean [SE]: -2.90 [0.22] and -3.61 [0.22] kg, re-
spectively; p=0.01 DU 1.5 mg vs LIRA 1.8 mg). Both groups had significant 
improvements from baseline in IW-SP, with no between-group differences. 
Only DU-treated patients had significant improvements from baseline in 
APPADL (p=0.014); between-group differences were not significant. Both 
groups had significant improvements from baseline in EQ-5D VAS with no 
between-group differences. In the EQ-5D UK population index score, pa-
tients treated with DU 1.5 mg had significant improvements from baseline 
(p=0.031), while there was no significant change with LIRA 1.8 mg and no 
significant between-group difference.
Conclusion: Both once weekly DU 1.5 mg- and once daily LIRA 1.8 mg-
treated patients experienced glycaemic and weight benefits. Significant im-
provements from baseline were observed in all PRO measures for DU 1.5 
mg; significant improvements were only observed in the EQ-5D VAS and 
IW-SP for LIRA 1.8 mg. There were no significant between-group differences 
observed in any PRO measures.
Clinical Trial Registration Number: NCT01624259
Supported by: Eli Lilly and Company
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Results of the albiglutide HARMONY program prospective major 
adverse cardiovascular event (MI, stroke, cardiovascular death, and 
unstable angina) meta-analysis
P.D. Ambery1, J. Donaldson2, J. Ye3, J. McMurray4;  
1MedImmune, Cambridge, 2GlaxoSmithKline, Uxbridge, UK, 
3GlaxoSmithKline, Research Triangle Park, USA,  
4University of Glasgow, UK.
Background and aims: In keeping with guidance issued by the FDA in 2008 
requiring demonstration of the cardiovascular (CV) safety of new glucose-
lowering agents for type 2 diabetes, GSK conducted a meta-analysis of CV 
events for albiglutide.
Materials and methods: Possible CV events were collected prospectively 
across 1 Phase II and 8 Phase III albiglutide studies for blinded adjudication 
by an independent Clinical Endpoint Committee. Subjects were randomized 
to albiglutide or to placebo or active comparators (sitagliptin, insulin lispro, 
insulin glargine, pioglitazone, liraglutide, and glimepiride). Five of the Phase 
III studies were up to 3 years in duration. There were 5107 subjects in the 
safety population of whom 2524 were exposed to albiglutide (4870 person-
yrs) and 2583 to comparators (5213 person-yrs).
Results: The primary endpoint was the first occurrence of MACE+ (MACE 
+ unstable angina) for albiglutide versus all comparators. MACE (CV death, 
non-fatal myocardial infarction, or non-fatal stroke) was a pre-defined sec-
ondary endpoint. Results are shown in the table.
Conclusion: Although the upper bound of the 95% CI for MACE+ events in 
this prospective adjudicated metaanalysis was below 1.8, because it is above 
1.3, a cardiovascular endpoint study is required for albiglutide. No difference 
was seen in heart failure events or all-cause mortality for albiglutide versus 
comparators in this meta-analysis.
Supported by: GSK
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Safety and efficacy of liraglutide in patients with type 2 diabetes and 
end-stage renal disease: an investigator-initiated, randomised, placebo-
controlled trial
T. Idorn1, F.K. Knop2,3, M.B. Jørgensen1, T. Jensen4, M. Resuli5,  
P.M. Hansen5, K.B. Christensen6, J.J. Holst3, M. Hornum1, B. Feldt-Rasmussen1;  
1Department of Nephrology, Copenhagen University Hospital, 2Diabetes 
Research Division, Department of Internal Medicine, Gentofte Hospital, 
Hellerup, 3Department of Biomedical Sciences, The NNF Center for Basic 
Metabolic Research, Faculty of Health Sciences, University of Copenhagen, 
4Department of Endocrinology, Copenhagen University Hospital, 
5Department of Internal Medicine, Hillerød Hospital, 6Department 
of Biostatistics, Institute of Public Health, University of Copenhagen, 
Denmark.
Background and aims: Diabetes is the leading cause of end-stage renal dis-
ease (ESRD), however, few antidiabetic agents are available to these patients. 
We evaluated safety and efficacy of liraglutide treatment in patients with type 
2 diabetes (T2D) and dialysis-dependent ESRD.
Materials and methods: 24 patients with T2D and ESRD and 23 patients 
with T2D and normal kidney function (71% and 74% treated with insulin, re-
spectively) were randomly allocated to 12 weeks of double-blinded liraglutide 
(titrated dose of 0.6 mg, 1.2 mg or 1.8 mg) or placebo treatment (1:1) injected 
subcutaneously once-daily. 20 participants (1:1) in each group completed the 
study period. Dose-corrected plasma trough liraglutide concentration was 
evaluated at the final trial visit as the primary outcome measure. Additional 
safety and efficacy parameters were assessed.
Results: Liraglutide-treated ESRD patients were titrated slower than liraglu-
tide-treated controls, but ended at comparable doses at 12 weeks (1.33±0.13 
and 1.26±0.06 mg/day, respectively; p=0.61). Dose-corrected plasma trough 
liraglutide concentrations at the final trial visit were increased by 49% (con-
fidence interval: 6-109%, p=0.02) in liraglutide-treated ESRD patients com-
pared with liraglutide-treated controls (plasma concentrations 11,975 [9,379-
15,289] and 8,057 [6,306-10,293] pmol/l/mg, respectively) (see Figure). Nau-
sea and vomiting were more frequent in liraglutide-treated ESRD patients 
compared with liraglutide-treated controls. Severe adverse events were more 
frequent in the ESRD group (n=7, including n=6 during liraglutide treat-
ment) compared with controls (n=1 during placebo treatment), although 
none were assessed to be related to the trial medication. Glycaemic control 
was improved in all treatment arms assessed by HbA1c and blood glucose 
measurements, and baseline insulin doses were significantly reduced in both 
liraglutide-treated groups (p<0.02).
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Conclusion: Liraglutide treatment appears to be applicable in patients with 
ESRD and T2D. Slower dose escalation and reduced treatment doses may be 
advisable.
Clinical Trial Registration Number: NCT01394341
Supported by: Novo Nordisk A/S
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Influence of liraglutide treatment in obstructive sleep apnoea in obese 
type 2 diabetes patients
C. Abreu1, F. Gómez-Peralta1, J. Castro1, E. Alcarria1, M. Cruz-Bravo1,  
M. Llorente1, C. Albornos1, C. Moreno1, M. Cepeda2, F. Almodóvar3;  
1Unidad de Endocrinología y Nutrición, Hospital General de Segovia, 
2Servicio de Medicina Interna, Hospital General de Segovia,  
3Unidad de Endocrinología y Nutrición, Hospital Universitario Fundación 
Alcorcón, Madrid, Spain.
Background and aims: Liraglutide, a long-acting human glucagon-like pep-
tide-1 analogue, is a novel class of type 2 diabetes mellitus (T2DM) treatment 
that exerts its glucose-lowering effect through different mechanisms that lead 
to clinically significant reductions in HbA1c and fasting and postprandial 
glucose levels with moderate weight loss. Concerns about the health impact 
of obstructive sleep apnoea (OSA) among obese patients with T2DM have 
been increasing. We aimed to evaluate the impact of liraglutide in the OSA 
symptoms-somnolence in obese T2DM patients.
Materials and methods: This was a retrospective observational, unicentric 
study conducted in obese (BMI ≥ 30kg/m2) T2DM subjects receiving treat-
ment with liraglutide for at least 3 months before study inclusion. Following 
routine clinical practice, data of the HbA1c, anthropometric measures, blood 
pressure, and the Epworth Sleepiness Scale (ESS) were collect at the study 
initiation (V1) and month 3 (V2).
Results: A total of 109 subjects were evaluated (mean age, 59.7±10.9 years; 
female, 51.4%). Significant differences between V1 and V2 were found 
in mean values of body weight (106.0±16.8Kg vs 102.3±15.8Kg; p<0.001), 
BMI (40.5±6.4 kg/m2 vs 39.0±5.9 kg/m2; p<0.001), waist circumference 
(124.7±13.5cm vs 121.4±12.3cm; p<0.001), HbA1c (8.2 ± 1.7% vs 7.4±1.6%; 
p<0.001), glycemia (188.4±48.7 mg/dL vs 164.6±44.8 mg/dL; p<0.001), fast 
glycemia (185.6±81.6 mg/dL vs 135.4±30.6 mg/dL; p<0.005), total choles-
terol (196.2±52.7mg/dL vs 173.1±30.2mg/dL; p<0.05) and ESS (5.7±4.7 vs 
4.2±3.5; p<0,005). A significant correlation was observed between baseline 
ESS score and HDL-cholesterol (r=-0.248; p<0.05), Tg/HDL ratio (r=+0.248; 
p<0.05), body weight (r=-0.215; p<0.05), and BMI (r=-0.225; p<0.05).
Conclusion: Our findings show that treatment with liraglutide significantly 
reduced the ESS score in obese T2DM patients. Besides this, an improvement 
in glycemic control, cholesterol and body weight was also achieved.
Supported by: FSEEN
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Time course and mechanisms of the antihypertensive and renal effects  
of liraglutide treatment
B. von Scholten1, M. Lajer1, J. Goetze2,3, F. Persson1, P. Rossing1,4;  
1Steno Diabetes Center, Gentofte, 2Rigshospitalet, Copenhagen,  
3Aarhus University, 4University of Copenhagen, Denmark.
Background and aims: Glucagon-like peptide-1 receptor agonist stud-
ies have revealed clinically significant reductions in systolic blood pressure 
(SBP). The aim was to investigate the time course of the anti-hypertensive 
effect of liraglutide treatment and potential mechanisms behind, in patients 
with type 2 diabetes.
Materials and methods: Open-label, single-centre trial; 31 patients with type 
2 diabetes and hypertension completed the study. All patients were treated 
with liraglutide up-escalated to maximum dose of 1.8 mg/d for 7 weeks, 
followed by a 21-day washout period. The primary outcome was change in 
24hour blood pressure.
Results: 24hour SBP increased by 10 mmHg on day 3 (p=0.008) and 7 
mmHg on day 7 (p=0.033, 0.6 mg/d). On day 29, (1.8 mg/d), 24hour SBP 
was 7 mmHg lower vs. baseline (p=0.106). Following the treatment period 
(day 49) and after washout (day 70), 24hour BP was equivalent to baseline. 
Secondarily, extracellular volume (ECV) was reduced by 2.0 L (CI= 1.0-3.1 
L, p=0.0005) and midregional-pro-atrial natriuretic peptide (MR-proANP) 
by 20% (CI= 12%-28%, p<0.0001. In addition, urinary albumin excretion 
declined 30% (CI=12%-44%, p=0.003), glomerular filtration rate (GFR) by 
11 mL/min/1.73m2 (CI=7.2-14.4 mL/min/1.73m2, p<0.0001), and fractional 
albumin excretion by 29% (CI=3%-48%, p=0.032).
Conclusion: Liraglutide treatment was associated with an initial increase in 
24hour SBP, followed by a 7 mmHg reduction after escalation to 1.8 mg/day. 
This effect subsided after 4 weeks of maximum dose. Reductions in ECV and 
MR-proANP may explain the antihypertensive potential. Liraglutide treat-
ment was associated with reversible reductions in albuminuria and GFR, 
which has to be confirmed in randomised blinded trials.
Clinical Trial Registration Number: NCT01499108
Supported by: Novo Nordisk
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Continuous exenatide infusion improved perioperative glucose control 
and reduced glycaemic variability in cardiac surgery patients:  
the EXECUTIVE trial
M. Haluzik1, M. Lips2, J. Drapalova1, M. Mraz1, M. Dobias2, P. Kopecky2,  
J. Lindner3, V. Burda4, D. Novak4, M. Diamant5, S. Svacina1;  
13rd Department of Medicine, Charles University, Prague, Czech Republic, 
2Department of Anaesthesiology, Resuscitation and Intensive Medicine, 
Charles University, Prague, Czech Republic, 32nd Surgical Dept. of 
Cardiovascular Surgery, Charles University, Prague, Czech Republic, 
4Department of Cybernetics, Czech Technical University, Prague, Czech 
Republic, 5Diabetes Centre, Vrije Universiteit University Medical Centre, 
Amsterdam, Netherlands.
Background and aims: Reduction of operation-related hyperglycaemia has 
been shown to improve postoperative outcomes, though this effect is often 
blunted by increased number of hypoglycaemic episodes. To intensify perio-
perative glucose control while minimizing the risk of hypoglycaemia we per-
formed a randomized control trial with the GLP-1 receptor agonist exenatide 
as add-on to standard perioperative insulin therapy in subjects undergoing 
elective cardiac surgery.
Materials and methods: Thirty eight subjects (63,2% diabetics) with de-
creased left ventricular systolic function (ejection fraction < 50%) scheduled 
for elective CABG (coronary artery by-pass grafting) were randomized to 
receive either exenatide or placebo in a continuous 72-hour i.v. infusion on 
top of standard perioperative insulin therapy. Parameters of glucose control 
and glycaemic variability together with indices of cardiac function assessed 
by transthoracic echocardiography, perioperative hemodynamic parameters, 
the need of antiarrhythmic treatment and inotropic drug dosage were col-
lected as primary endpoints.
Results: Compared to placebo group subjects receiving exenatide showed 
improved perioperative glucose control (average glycaemia 6.1 ± 2.5 vs. 6.8 ± 
2.8 mmol/l, p<0.001; time in target range of 4.5-6.5 mmol/l 55.0 ± 3.4 vs. 38.6 
± 3.3%, p=0.001; time above target range 39.7 ± 3.3 vs. 53.5 ± 3.6%, p<0.01) 
without an increased risk of hypoglycaemia (2 episodes of hypoglycaemia ≤ 
3.3 mmol/l in exenatide vs. 4 episodes in placebo group). Exenatide infusion 
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also reduced glycaemic variability (SD - standard deviation: 1.4 ± 0.5 vs. 2.0 
± 0.6, p<0.01; MAGE - mean amplitude of glycaemic excursions: 2.5 ± 1.1 
vs. 3.3 ± 0.9, p<0.01) and decreased the need of temporary pacing (16.7 vs. 
47.4% of subjects, p<0.05), while no significant difference in perioperative 
hemodynamics, postoperative echocardiographic parameters and inotropic 
medication dosage was found between the groups.
Conclusion: Perioperative administration of i.v. exenatide in subjects un-
dergoing elective CABG improved glucose control and decreased glycaemic 
variability without increasing the risk of hypoglycaemia. Except of decreased 
need of temporary pacing, exenatide did not significantly affect parameters 
of cardiac function.
Clinical Trial Registration Number: NCT01373216
Supported by: IIT from BMS and Astra Zeneca, RVO-VFN 64165 and 
SVV260019/2014
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GLP-1 reduces the activation of PI3K and MAPK pathways and of 
oxidative stress induced by Na-arachidonate in platelets
C. Barale, L. Mattiello, F. Cavalot, A. Guerrasio, I. Russo;  
Internal Medicine and Metabolic Disease Unit, Department of Clinical 
and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 
Orbassano, Italy.
Background and aims: Glucagon-like peptide-1 (GLP-1), exerts not only 
metabolic but also cardiovascular effects: its influence on platelets, however, 
is largely unknown. We previously showed that GLP-1 increases platelet sen-
sitivity to the anti-aggregating pathway nitric oxide/cGMP/cGMP-depend-
ent protein kinase (PKG). The GLP-1 influence on pro-aggregating pathways 
has not been investigated so far. Aim of this study is to verify the GLP-1 abil-
ity to interplay with arachidonic acid, a precursor of platelet activators which 
increases reactive oxygen species (ROS) production: in particular, we aimed 
at investigating whether the native GLP-1 (7-36), the truncated GLP-1(9-36), 
and the GLP-1 analogue liraglutide influence the arachidonic acid-induced 
activation of the signalling pathways PI3-Kinase (PI3K) and MAP-Kinase 
(MAPK) and of oxidative stress in platelets, and whether these putative GLP-
1 effects persist when PKG is inhibited.
Materials and methods: In washed platelets from 24 healthy subjects (M/F 
13/11; age 25.6±5.9 years, body mass index 22.5±2.4 kg/m2) we measured the 
influence of a 15 min pre-incubation with 100nmol/l GLP-1(7-36), or GLP-
1(9-36) or liraglutide on the effects of Na-arachidonate (NaA) (0.5 mmol/l) 
on: i) phosphorylation of Akt and Erk-1/2, molecules of the PI3K and MAPK 
pathways, respectively (Western Blot); ii) ROS production (DCF-DA assay). 
Experiments were repeated in the presence of the PKG inhibitor KT5823 (1 
micromol/l), the Erk-1/2 inhibitor U0126 (40 micromol/l) and the GLP-1 re-
ceptor (GLP-1R) antagonist exendin (9-39) (100 nmol/l).
Results: GLP-1 (7-36), GLP-1 (9-36) and liraglutide, similarly reduced 
platelet signalling induced by NaA. In particular: i) the fold increase on 
basal values of pAkt with NaA alone, NaA+GLP-1 (7-36), NaA+GLP-1 (9-
36) and NaA+liraglutide was 11.2±2.1, 3.1±0.8, 2.8±1.1, 2.8±1.3 respec-
tively (p<0.0001 vs NaA alone for all), ii) the fold increase on basal val-
ues of pErk1/2 with NaA alone, NaA+GLP-1 (7-36), NaA+GLP-1 (9-36) 
and NaA+liraglutide was 14.6±2.5, 3.9±1.0, 3.7±1.5, 4.0±1.9 respectively 
(p<0.0001 vs NaA alone for all); iii) in the presence of the PKG inhibitor 
KT5823 the inhibition of pAkt and pErk-1/2 exerted by GLP-1 (7-36), GLP-
1 (9-36) and liraglutide did not occur (p=ns vs NaA alone for all); iv) the 
fold increase on basal values of ROS with NaA alone, NaA+GLP-1 (7-36), 
NaA+GLP-1 (9-36) and NaA+liraglutide was 8.2±1.1, 5.6±2.0, 5.5±1.1, 
5.5±1.4 respectively (p=0.001-0.0005 vs NaA alone); v) the Erk-1/2 inhibi-
tor U0126 reduced the NaA-induced activation of ROS, its fold increase on 
basal values with NaA+U0126 being 4.2±1.0 (p<0.0005 vs NaA alone). Pre-
incubation with the GLP-1R antagonist exendin (9-39) did not modify the 
effects of all the incretin preparations on the NaA-induced activation of PI3K 
and MAPK pathways.
Conclusion: In human platelets, GLP-1 (7-36), GLP-1 (9-36) and liraglu-
tide, independently of GLP-1R, reduce the NaA-induced activation of PI3K 
and MAPK pathways and of oxidative stress. Because MAPK activation is 
involved in the NaA-induced increase of oxidative stress, the inhibiting ef-
fects of GLP-1 on MAPK activation can account for its ability to attenuate 
the NaA-induced increase of oxidative stress. Finally, the effects of GLP-1 on 
intraplatelet signalling do not occur when PKG is inhibited, further confirm-
ing the interplay of GLP-1 with PKG.
Supported by: a „PRIN“ grant of MIUR
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Effect of dipeptidyl peptidase-4 inhibitor sitagliptin  
on CD4+ T lymphocytes and monocytes in patients with type 2 diabetes 
A. Hattori1, H. Tokuyama1, F. Shimada2, M. Nieda3, Y. Maezawa1,  
K. Kobayashi1, H. Kawamura1, M. Takemoto1, K. Yokote1;  
1Clinical Cell Biology and Medicine, Chiba University Graduate School of 
Medicine, 2Diabetes and Metabolism, National Hospital Organization Chiba 
Medical Center, 3Japan Biotherapy Institute, Tokyo, Japan.
Background and aims: Dipeptidyl Peptidase-4 inhibitors (DPP-4i) are cur-
rently used widely because of their efficacy and relative low risk of side effects. 
However several adverse effects of DPP-4i have been reported, e.g. raising the 
risk of pancreatitis and autoimmune diseases. DPP-4 is identical to CD26, 
a molecule expressed on immune cells particularly activated helper T cell 
(CD4+T;Th), but the effect of DPP-4i on immune cells is still unclear. The 
aim of this study is to evaluate the effect of DPP-4i on human T lymphocytes, 
especially Th, and monocytes in vivo and ex vivo.
Materials and methods: Thirty-two Japanese patients with type 2 diabetes 
(19 male and 13 female, mean age 62.5 years, mean HbA1c 7.6%) taking Sitag-
liptin 50mg/day as the first or the additional medication were enrolled to the 
study. Blood sampling was performed before and 8 weeks after the treatment. 
Leukocyte counts were performed by automatic blood cell counter. Surface 
markers including CD26 and CD163 on lymphocytes and monocytes were 
measured by flow cytometer after purification of peripheral blood mononu-
clear cells. Ex vivo intracellular cytokine assay was performed to detect sub-
sets of Th: Th0, Th1 and Th2 . The concentration of soluble CD26 (=DPP-4), 
soluble CD163 (macrophage/monocyte activation marker), TNF-α (Th1 cy-
tokine) and IL-4 (Th2 cytokine) in patients’ serum were measured by ELISA.
Results: Cell numbers (T cell numbers/μL) and percentages of circulating 
T lymphocytes were significantly decreased (1252±77/μL vs 1131±78/μL, 
p=0.02 and 65.4±8.9% vs 62.2±11.3%, p=0.02) after the administration of 
DPP4i, although those of total lymphocytes did not changed. In the T lym-
phocyte subset, cell numbers and percentages of Th decreased significantly 
(853±316/μL vs 764±286/μL, P=0.01 and 44.8±8.3% vs 43.0±9.5%, p=0.04), 
but not Tc (CD8+T). Ex vivo assay showed the significant increase of Th1/2 
ratio (8.7±1.0 vs 10.7±1.5, p=0.03) but TNF-α and IL-4 concentrations did 
not change. The change of Th1/2 ratio in 8 weeks were more correlated to 
the change of Th2 (r=-0.90) than a change of Th1(r= 0.58). The number of 
CD26+Th cells and serum level of soluble CD26 did not show any significant 
change. The percentage of circulating CD163+ monocytes (as it is called M2 
phenotype monocyte) were significantly decreased (10.0±2.3% vs 2.7±0.5%, 
p=0.006) though total monocyte number did not. The concentration of solu-
ble CD163 was significantly decreased (623±57ng/mL vs 584±60ng/mL, 
p=0.008)
Conclusion: These findings suggest that DPP-4i possibly effect the balance 
of circulating T lymphocyte subset, particularly Th, and monocyte, but not 
effect Th1 and Th2 cytokines. These observation may indicate the direct effect 
of DPP-4 (CD26) inhibition on the differentiation from Th0 to Th2 rather 
than to Th1. On the other hand the decrease of soluble CD163 possibly re-
flects the suppression of macrophage/monocyte activation that could lead to 
improvement of chronic inflammation. Further detailed study is needed to 
clarify the effect of DPP-4i to human T lymphocytes and monocytes.
Supported by: Diabetes Masters Conference
 
915
A dipeptidyl peptidase-4 inhibitor directly suppresses inflammation and 
foam cell formation in monocytes/macrophages beyond incretins
K. Nohtomi, M. Terasaki, K. Kohashi, M. Hiromura, M. Nagashima,  
T. Hirano;  
Showa University School, Department of Medicine, Tokyo, Japan.
Background and aims: We reported that incretins (Glucagon-like peptide 
(GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP)) and a 
dipeptidyl peptidase-4 inhibitor (DPP-4i) confer an anti-atherosclerotic 
effect in apolipoprotein-E null mice. It remains unclear whether the anti-
atherogenesis of DPP-4i is wholly dependent on incretins or partly initiated 
via direct mechanisms independent of incretins. In this study we sought to 
elucidate the direct action of DPP-4i on anti-atherogenesis by examining the 
in vitro effect of incretins and DPP-4i on the expression of inflammatory cy-
tokines and foam cell formation in monocytes/macrophages.
Materials and methods: Mouse peritoneal macrophages were obtained from 
the ascites by injection of thioglycolate. Monocytes/macrophages were ob-
tained from human peripheral blood mononuclear cells through a CD14 
column. Foam cell formation was determined by the incorporation of [3H]-
oleate into cholesteryl-oleate stimulated by oxidized-LDL.
Results: Exendin (Ex)-4 (5nM) and GIP (1nM) elicited cyclic (c)AMP gen-
eration and suppressed the LPS-induced gene expression of inflammatory 
molecules such as Interleukin (IL)-1beta, IL-6, TNF-alpha, and nuclear fac-
tor-kappa B by 10~50% in U937 human monocytes. This suppressive effect, 
however, was attenuated by an inhibitor of adenylate cyclase and mimicked 
by 8-bromo-cAMP or forskolin. Teneligliptin (1-10 nM) substantially sup-
pressed the LPS-induced expression of inflammatory cytokines by 20~75% 
without affecting the cell viability or DNA synthesis.Similarly, treatments 
with antibody or small interfering RNA of CD26 suppressed the expression 
of inflammatory cytokines.Teneligliptin with DPP4-resistant incretins (Ex-
4 and DAla(2)GIP) additively suppressed the expression of these cytokines. 
Ex-4, GIP, and teneligliptin all suppressed LPS-induced extracellular signal-
regulated kinase (ERK) phosphorylation to the same extent. The suppres-
sion of p-ERK by incretins was cAMP-dependent, while the suppression by 
teneligliptin was not. Teneligliptin suppressed cell surface toll-like receptor 
(TLR)-4-and TLR-5-mediated cytokine production, but had no effect on the 
intracellular TRLs-induced cytokines. Ex-4 and GIP slightly suppressed foam 
cell formation in mouse peritoneal macrophages and human macrophages 
whereas teneligliptin did not. Foam cell formation was enhanced by 2-fold 
in peritoneal macrophages of diabetic mice (db/db) and in the macrophages 
of patients with poorly controlled type 2 diabetes. Ex-4, GIP, and teneliglip-
tin suppressed foam cell formation in the macrophages of diabetic mice and 
patients by 25-50%. The gene expressions of acyl-CoA cholesterol acyltrans-
ferase (ACAT)-1 and CD36 were up-regulated in diabetes, and incretins and 
teneligliptin attenuated the upregulation. CD26 mRNA and transcripts cord-
ed by exons 3-13 of the GLP-1 receptor and exons 1-14 of the GIP receptor 
were detectable in the monocytes/macrophages of mouse and human.
Conclusion: The present in vitro study suggests that DPP-4i suppresses in-
flammation partly via ERK inactivation and foam cell formation by down-
regulating CD36 and ACAT-1 in monocytes/macrophages. This suppressive 
effect appears to be Independent of incretin’s action via cAMP.
Supported by: Tanabe-Mitsubishi phama.co.
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Liraglutide associated reversal of obesity and age dependent cardiac 
fibrosis correlates with improved vascular reactivity and modulation of 
macrophage gene expression
A.E. Dear1, T. Gaspari2, I. Welungoda2, Y. Hu1, R.E. Widdop2,  
R.W. Simpson1;  
1Medicine, Monash University,  
2Pharmacology, Monash University, Melbourne, Australia.
Background and aims: Cardiac fibrosis observed in obesity and myocardial 
aging results from excessive deposition of extracellular matrix (ECM) com-
ponents, contributes to a detrimental increase in myocardial stiffness and is 
a major factor in the development of cardiac hypertrophy and the transition 
to heart failure. Excessive deposition of cardiac ECM is characterised by in-
creased macrophage infiltration, differentiation of fibroblasts to the secretory 
myofibroblast phenotype and enhanced deposition of type I and III collagens. 
Expression of the glucagon like peptide-1 receptor (GLP-1R) in cardiac cells 
together with cardioprotective effects of GLP-1 and GLP-1R agonists in in 
vivo studies suggests a possible role for GLP-1 and GLP-1R agonists in the 
modulation of cardiac fibrosis. Our current study aimed to determine the 
effect of the GLP-1R agonist liraglutide in obesity and age induced models of 
cardiac fibrosis and identify associated molecular mechanisms.
Materials and methods: In vivo experiments utilised 5 month old C57Bl/6J 
mice maintained on a high fat diet (HFD) for 16 weeks to evoke obesity in-
duced hypertension and cardiac fibrosis. 20 month old C57Bl/6J mice main-
tained on a normal chow diet were utilised as a model of aged induced car-
diac fibrosis. Treatment regimens for both obesity and age induced cardiac 
fibrosis consisted of liraglutide 300μg/kg s.c., twice daily for 4 weeks. In vitro 
studies utilised the murine macrophage cell line RAW264.7 stimulated with 
lipopolysaccharide (LPS) (100ng/ml) and treated with liraglutide (100nM), 
with or without the specific GLP-1R antagonist exendin-9 (100nM) for 48 
hours.
Results: Treatment of 5 month old C57Bl/6J mice with liraglutide prevented 
HFD-induced increase in blood pressure, reduced fat mass and importantly 
protected against increased interstitial cardiac fibrosis over vehicle treated 
animals (n=4, p<0.05). Studies comparing young 5 month old with 20 month 
old aged C57Bl/6J mice maintained on a normal chow diet demonstrated 
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liraglutide treatment significantly inhibited age associated cardiac fibrosis 
(n=4-6, p<0.05) and was associated with a reduction in body weight and im-
proved vascular reactivity. In vitro studies identified significant induction of 
the M2 anti-inflammatory gene IL-10 mRNA expression together with inhi-
bition of the M1 pro-inflammatory gene MCP-1 mRNA expression in liraglu-
tide treated RAW264.7 cells (n=3, p<0.05).
Conclusion: Taken together these observations identify a potential role for 
liraglutide in the prevention of obesity and age associated cardiac fibrosis and 
downstream effects of this condition including cardiac failure in a non-dia-
betic setting and posits components of a molecular mechanism responsible 
for these effects.
Supported by: Novo Nordisk Research Grant
917
The effect of liraglutide and ischaemic postconditioning on myocardial 
salvage after ischaemia-reperfusion injury in pigs
K. Ekström1, M. Dalsgaard1, K.K. Iversen1, U. Pedersen-Bjergaard1,  
N.G. Vejlstrup2, S.S. Diemar1, M. Idorn3, B. Thorsteinsson1, T. Engstrøm2;  
1Department of Cardiology, Nephrology and Endocrinology,  
Nordsjællands Hospital, 2Department of Cardiology, Rigshospitalet,  
3Center for Cancer Immune Therapy, Department of Hematology,  
Herlev Hospital, Copenhagen, Denmark.
Background and aims: Acute ST-segment elevation myocardial infarction 
(STEMI) is routinely treated by acute primary percutaneous coronary in-
tervention (pPCI) in Denmark. Despite timely reperfusion, this may itself 
damage the tissue (reperfusion injury). Conditioning with glucagon-like 
peptide-1 (GLP-1) analogues, used for treatment of type 2 diabetes, has 
been shown to reduce reperfusion injury. Gradual restoration of blood flow 
(ischemic postconditioning) provides protection of cardiac tissue follow-
ing acute myocardial infarction (MI). It has not yet been tested if combined 
postconditioning treatment with a GLP-1 analogue and ischemic postcondi-
tioning offers additive protective effect on the myocardium. We here present 
preliminary results.
Materials and methods: 58 non-diabetic female Danish Landrace pigs 
(60±10kg) were randomly assigned to four groups. MI was induced by occlu-
sion of the left anterior descending artery (LAD) for 45 minutes in all groups. 
Group 1 (n=14) was treated with i.v. liraglutide after 15 minutes of ischemia 
until reperfusion. Group 2 (n=17) received liraglutide treatment concomi-
tant with ischemic postconditioning, performed after 45 minutes of ischemia. 
Group 3 (n=15) was treated with ischemic postconditioning, and group 4 
(n=12) served as controls.
Results: No intergroup differences in relative infarct size were detected (over-
all mean 57 ± 3%; p=0.68). Overall mortality was 34% (CI: 25-41%) including 
26% post-intervention, with no intergroup differences (p=0.99). Occurrence 
of VF was 59% (CI: 25-80%) including 39% post-intervention with no inter-
group differences (p=0.65).
Conclusion: No cardioprotective effects of liraglutide, ischemic postcondi-
tioning or combined treatment were found. Thus, based on our preliminary 
data, we cannot support a class effect of GLP-1 analogues in cardioprotection. 
Neither an additive effect of additional treatment with ischemic postcondi-
tioning could be demonstrated.
Supported by: Nordsjællands Hospital
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Effects of liraglutide in an adolescent prediabetic transgenic pig model
E. Streckel1, C. Braun-Reichhart1, N. Herbach2, M. Dahlhoff3, B. Kessler1,  
A. Blutke2, A. Bähr1, N.B. Michaelsen4, N. Übel5, M. Eddicks5,  
M. Ritzmann5, B. Goeke6, R. Wanke2, E. Wolf1,3, S. Renner1;  
1Chair for Molecular Animal Breeding and Biotechnology, LMU Munich, 
2Institute of Veterinary Pathology, LMU Munich, 3Chair for Molecular 
Animal Breeding and Biotechnology, Gene Center, LMU Munich, Germany, 
4Research Bioanalysis, Måløv, Denmark, 5Clinic for Swine, LMU Munich, 
6Department of Internal Medicine II, University Hospital Grosshadern, 
Munich, Germany.
Background and aims: To evaluate the effect of the glucagon-like pep-
tide-1 receptor agonist liraglutide in adolescent transgenic pigs expressing 
a dominant-negative glucose-dependent insulinotropic polypeptide receptor 
(GIPRdn), with special emphasis to body weight, food intake, glycemic con-
trol, alpha- and beta-cell mass as well as proliferation in the exocrine pan-
creas.
Materials and methods: GIPRdn transgenic pigs (Trial 1: 2 months, un-
changed β-cell mass; Trial 2: 5 months, 35% reduced β-cell mass) were treated 
with 0.6 mg - 1.8 mg liraglutide or placebo subcutaneously once daily for 
90 days. Glucose tolerance was evaluated in a mixed meal oral test. Finally 
animals were subjected to necropsy and alpha- and beta-cell mass as well 
as beta-cell and acinus-cell proliferation were determined by quantitative-
stereological analyses.
Results: Liraglutide treatment led to marked and sustained reductions in 
body weight gain (30-40%) and food intake (20-50%) compared to placebo 
treatment, associated with reduced activation of the growth-related insulin 
signaling pathway in skeletal muscle. In the mixed meal test performed after 
the treatment period, liraglutide-treated animals exhibited only a moderate 
increase of blood glucose, probably due to the known effect of liraglutide on 
gastric emptying. Additionally, AUC insulin was significantly smaller in lira-
glutide- vs. placebo-treated animals. Further, liraglutide treatment reduced 
HOMA-IR and increased several insulin sensitivity indices. Absolute alpha- 
and beta-cell mass was reduced in liraglutide-treated pigs, but not when relat-
ed to body weight. Beta-cell proliferation was reduced in liraglutide-treated 
animals while acinus-cell proliferation in the exocrine pancreas did not differ 
between the two treatment groups.
Conclusion: The GIPRdn transgenic pig model recapitulates principle clini-
cal effects of liraglutide observed in type 2 diabetic humans. However, the 
reduction of body weight gain observed in adolescent pigs was much more 
dramatic than the weight reduction seen in adult patients; thus special care is 
warranted in prospective treatment trials involving adolescent patients. There 
was no evidence for an increasing effect of liraglutide on alpha- and beta-cell 
mass or a stimulating effect on beta-cell and acinus-cell proliferation.
Supported by: Leading-Edge Cluster m4 - Personalized Medicine and Targeted 
Therapy
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Exenatide stimulates leptin gene expression and attenuates lipid 
deposition in skeletal muscle
Z. Chen1, F. Xu1, H. Gu1, B. Lin1, K. Zeng1, H. Lu2, W. Shao2, H. Liang1,  
J. Yan1, I. George Fantus2, T. Jin2, J. Weng1;  
1The Third Affiliated Hospital of Sun Yat-sen Univeristy, Guangzhou, China, 
2Banting and Best Diabetes Centre, Toronto, Canada.
Background and aims: GLP-1-based drugs, such as exenatide, exert their 
beneficial effects on both pancreatic β-cells and extra-pancreatic organs. 
Here, we aim to assess the stimulation of exenatide on leptin gene expression 
in adipocytes and determine the effects of exenatide on ectopic lipid deposi-
tion in the skeletal muscle in two obese mouse models.
Materials and methods: High fat diet (HFD) fed C57BL/6 mice and db/db 
mice were treated with exenatide for 4 or 8wks. After treatment, serum lep-
tin level was measured by ELISA kit and lipid accumulation in skeletal mus-
cle was detected by oil red o staining. Key proteins involved in muscle lipid 
oxidation were determined by Western blotting. Rat primary adipocytes and 
differentiated 3T3-L1 adipocytes were treated with exendin-4 in vitro. Mean-
while, rat primary adipocytes were transfected with Leptin-LUC fusion gene 
plasmid by electroporation and LUC reporter activity was measured followed 
by exendin-4 treatment.
Results: Exendin-4 increased leptin mRNA levels in both rat primary adi-
pocytes and differentiated 3T3-L1 cells, and stimulated leptin gene promoter 
activity. This increase, however, was not observed in adipocytes from GLP-
1R-/- mice. In HFD fed C57BL/6 mice, exenatide administration for four 
wks resulted in a transient increase of serum leptin levels. In db/db mice, 
exenatide treatment for 8 wks resulted in increased serum leptin level, associ-
ated with increased leptin mRNA expression in epididymal adipocytes and 
reduced serum triglyceride and free fatty acid contents. In addition, exena-
tide administration attenuated lipid accumulation in skeletal muscle of db/db 
mice, along with elevated JAK2 and phosphorylated STAT3 levels, as well as 
increased expression fatty acid transport protein 1 (FATP1), lipid oxidation 
related protein CPT1, and lipolysis related protein LPL and ATGL.
Conclusion: This study revealed that adipocytes are among the targets of the 
incretin hormone GLP-1 and the therapeutic agent exenatide. Our observa-
tions support the notion that leptin reduces intramyocellular lipid through 
activating the short-form leptin receptors.
Supported by: National Natural Science Funds for Distinguished Young 
Scholar of China
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Effect of liraglutide on beta cell mass and function in alloxan diabetic 
mice
K. Tamura, K. Minami, H. Takahashi, M. Kudo, S. Seino;  
Kobe University Graduate School of Medicine, Japan.
Background and aims: Although GLP-1 receptor agonists have been shown 
to have beneficial effects on both beta-cell mass and function, the mechanism 
of the effect of the drugs on beta-cells is still unclear. The objective of this 
study is to characterize the effect of liraglutide, a long-acting GLP-1 analog, 
on beta-cell mass and function in alloxan-induced diabetic mice.
Materials and methods: We crossbred Ins2-CreER knock-in mice with 
R26R-YFP mice to generate Ins2-CreER/R26R-YFP double knock-in mice, 
in which the pancreatic beta-cells can be labeled specifically and perma-
nently upon injection of tamoxifen. These mice enabled us to discriminate 
beta-cell neogenesis from self-replication. Pancreatic beta-cells were labeled 
by 5 consecutive injections of tamoxifen (4 mg/head/injection) to male mice 
at 6 weeks of age. Ten days after the last injection, diabetes was induced by a 
single dose of alloxan (60 mg/kg, i.p.). On the following day, mice with blood 
glucose concentration above 300 mg/dl were used for the study. Liraglutide 
(200 µg/kg s.c.) or vehicle (saline) was administered once daily from the day 
following alloxan injection for 30 days. Food intake, body weight, blood glu-
cose levels, serum insulin levels and serum glucagon levels were measured. 
Beta-cell mass was estimated by immunofluorescent staining of pancreas sec-
tions. Proliferation rate was evaluated by Ki67 immunostaining and apopto-
sis rate was evaluated by TUNEL-method. To investigate beta-cell function, 
oral glucose tolerance test was performed.
Results: About 80% of beta-cells were destroyed by alloxan injection, lead-
ing to hypoinsulinemia and hyperglycemia in the mice. Liraglutide treat-
ment ameliorated hyperglycemia in alloxan-diabetic mice. We found that 
beta-cell mass in liraglutide-treated group was two-fold higher than that in 
vehicle group, which correlates with the increment of serum insulin levels. 
In liraglutide-treated group, proliferation rate was significantly higher and 
apoptosis rate was significantly lower than in vehicle-treated mice. To exam-
ine the effect of liraglutide on beta-cell neogenesis, we injected tamoxifen to 
the alloxan-treated Ins2-CreER/R26R-YFP mice. As a result, the percentage 
of YFP-labeled beta-cells was not changed significantly before and after lira-
glutide treatment, suggesting that the contribution of neogenesis is, if any, 
limited to the increment of beta cell mass by liraglutide treatment. Further-
more, oral glucose tolerance test showed that the insulin secretory response 
to glucose was recovered following 30 days liraglutide treatment, and that this 
effect was sustained two weeks after drug withdrawal.
Conclusion: Chronic treatment of alloxan-induced diabetic mice with lira-
glutide preserved beta-cell mass by increasing cell proliferation and decreas-
ing cell death. In addition, liraglutide treatment achieved sustained improve-
ment of insulin secretory function of pancreatic beta-cells.
Supported by: MEXT, JST, Novo Nordisk
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Peripheral glucagon-like peptide-1 receptor agonism decreases VLDL 
production and fasting dyslipidaemia in insulin resistance
J. Taher, C. Baker, C. Cuizon, M. Naples, S. Farr, K. Adeli;  
The Hospital for Sick Children, Toronto, Canada.
Background and aims: Glucagon-like peptide-1(GLP-1) is an incretin hor-
mone that stimulates pancreatic insulin release to reduce plasma glucose 
levels and thus acts as an important drug target in the treatment of type 2 
diabetes (T2D). While GLP-1 receptor (GLP-1R) agonism is known to en-
hance satiety and induce weight loss, our laboratory has also shown that GLP-
1 regulates lipoprotein metabolism by decreasing intestinal chylomicron 
production and may also play a similar role in the liver. Hepatic lipids are 
packaged with apolipoprotein B-100 (apoB100) into VLDL and secreted into 
the plasma. Dysregulation of VLDL production results in the fasting dyslipi-
demia that is observed in patients with T2D. In a similar way to intestinal me-
tabolism, we postulate that GLP-1R agonism regulates fasting dyslipidemia 
by decreasing VLDL production in insulin resistance. We further postulate 
that this occurs through either a peripheral or central pathway independent 
of changes in food consumption.
Materials and methods: Fructose-fed insulin resistant Syrian golden ham-
sters were given twice daily intraperitoneal (i.p) injections of the GLP-1R 
agonist exendin-4 (ex4; 20ug/kg) for 7 days and placed into metabolic cag-
es. Alternatively, fructose-fed hamsters received an intracerebroventricular 
(ICV) administration of ex4 (250ng) into the third ventricle of the brain for 
4 days. Plasma was subsequently collected over a 6 hour time course follow-
ing i.p poloxamer administration to prevent lipoprotein uptake. Livers were 
excised for PCR analysis.
Results: Peripheral ex4 prevented fructose-induced fasting hypertriglyc-
eridemia (vehicle(veh)=3.4 fold triglyceride (TG)increase; ex4=1.4 fold TG 
increase) and hypercholesterolemia (veh=1.3 fold increase; ex4=0.8 fold de-
crease). Ex4 also decreased VLDL-triglyceride( 1.28mmol/L vs 0.55mmol/L; 
p<0.01), -cholesterol (0.37mmol/L vs 0.16mmol/L; p<0.05) and -apoB100 
levels following poloxamer (veh=2.4 fold increase; ex4= 0.12 fold increase) 
indicating a decrease in VLDL production. Ex4 reduced food consumption 
by 4.3g/day (p<0.001) and body weight by 11g over 7 days(p<0.001) how-
ever pair-fed (PF) hamsters did not significantly differ in fasting lipid levels 
from vehicles fed ad libitum. Ex4 treated hamsters had decreased expression 
of hepatic mRNA markers for de novo lipogenesis including srebp-1c (1.96 
fold decrease; p<0.001). Ex.4 significantly reduced respiratory exchange ratio 
(veh=0.89; PF=0.90; ex.4=0.80; p<0.001) and CO2 production (veh=1355ml/
kg/hr; PF=1344ml/kg/hr; ex.4=1200ml/kg/hr; p<0.05) indicating a switch 
from carbohydrate to lipid metabolism as the main source of energy utiliza-
tion. When ex4 was administered by ICV, there was a similar decrease in 
body weight (10g; p<0.001) and food consumption (4g/day; p<0.05) however 
no changes in VLDL-TG, -cholesterol or apoB100 accumulation. This sug-
gests that while the effects of ex4 on satiety may be regulated centrally, the 
effects on VLDL production may be regulated peripherally.
Conclusion: Our studies suggest that GLP-1R agonism reduces fasting dys-
lipidemia in insulin resistance by decreasing VLDL production through a 
peripheral pathway. Additional studies are in progress to examine the in-
volvement of an afferent-efferent signalling pathway. Further experimental 
evidence to test this role can lead to identification of putative drug targets 
to fight the metabolic complications of the fasting dyslipidemia observed in 
T2D.
Supported by: HSFO, BBDC, OGS, Mitacs
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Near-normalisation of glycaemic control in patients with type 2 diabetes 
with a glucagon-like peptide-1 receptor agonist in combination with 
exercise
P.F. Mensberg1,2, S. Nyby1,2, P.G. Jørgensen3, H. Storgaard1, J. Sivertsen3,  
M.T. Jensen3, J.J. Holst4, B. Kiens2, E.A. Richter2, F.K. Knop1, T. Vilsbøll1;  
1Diabetes Research Center, Department of Medicine, Gentofte Hospital, 
Hellerup, 2Department of Nutrition, Exercise and Sports, Section of 
Molecular Physiology, Copenhagen, 3Department of Cardiology, Gentofte 
Hospital, Hellerup, 4Department of Biomedical Sciences, NNF center for 
Basic Metabolic Research, Copenhagen, Denmark.
Background and aims: Exercise and glucagon-like peptide-1 receptor ago-
nist (GLP-1RA) treatment, respectively, improve glycaemic control in pa-
tients with type 2 diabetes (T2D). We investigated the effects of exercise in 
combination with GLP-1RA treatment in patients with T2D.
Materials and methods: Thirty-three untrained obese patients with T2D 
were included in a randomised double-blinded placebo-controlled clinical 
trial (23 men, age: 56±10 years (mean±SD); weight 99±16 kg; BMI: 32±4 kg/
m2; fasting plasma glucose (FPG): 10.1±2.8 mmol/l; HbA1c: 65±14 mmol/
mol (8.1±1.3%)), treated with diet only (n=3) or metformin (n=30). Patients 
were randomised to liraglutide (titrated to 1.8 mg once-daily) and exercise 
or placebo and exercise during 16 weeks. Both groups had 3 60-minute su-
pervised training sessions per week; 2 spinning sessions and 1 session with 
resistance training.
Results: HbA1c, FPG and weight reductions were greater with liraglutide and 
exercise vs. placebo and exercise (Table 1). Both groups exhibited similar re-
duction in body fat mass and increase in maximal oxygen uptake. The most 
common adverse event was transient nausea (liraglutide: 24%, placebo: 6%).
Conclusion: Exercise alone for 16 weeks has no or little effect on glycaemic 
control and body weight, but combined with GLP-1RA treatment it can near-
normalise glycaemic control and cause robust weight loss in overweight, dys-
regulated patients with type 2 diabetes.
Clinical Trial Registration Number: NCT01455441
Supported by: Novo Nordisk A/S
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Transfer of liraglutide from blood to cerebrospinal fluid is limited and an 
unlikely contributor to body weight loss in patients with type 2 diabetes
M. Christensen1,2, A.H. Sparre-Ulrich1,3, B. Hartmann4, U. Grevstad5,  
M.M. Rosenkilde3, J.J. Holst4, T. Vilsbøll1, F.K. Knop1;  
1Diabetes Research Division, Department of Medicine, Gentofte Hospital, 
Hellerup, 2Department of Clinical Pharmacology, Bispebjerg Hospital, 
3Department of Neuroscience and Pharmacology, Faculty of Health and 
Medical Sciences, University of Copenhagen, 4NNF Center for Basic 
Metabolic Research, Department of Biomedical Sciences, Faculty of 
Health and Medical Sciences, University of Copenhagen, 5Department of 
Anesthesiology, Gentofte Hospital, Hellerup, Denmark.
Background and aims: The mechanisms by which subcutaneously adminis-
tered glucagon-like peptide-1 (GLP-1) receptor agonists confer weight loss in 
humans are incompletely understood. A centrally mediated effect by passage 
of the blood-brain barrier has been suggested from animal studies. There are 
no human data on blood-brain transfer of GLP-1 receptor agonists.
Materials and methods: We measured liraglutide in plasma and cerebro-
spinal fluid (CSF) obtained by lumbar puncture in 8 patients with type 2 
diabetes (male: 4/8, age: 63±2 years [mean±SEM], BMI: 30±1 kg/m2, Hba1c 
56±4 mmol/mol) treated with 1.8 mg liraglutide subcutaneously for at least 1 
month and with weight loss 8.4±0.4 kg in response to treatment. Liraglutide 
was measured with a radioimmunoassay (antibody no. 98302) specific for 
the intact N-terminus of the GLP-1 moiety of liraglutide. For validation of 
the CSF-assay, we obtained control CSF from subjects (n=9) not treated with 
liraglutide.
Results: Plasma-liraglutide was in the nanomolar range (31±4.4 nmol/L). 
When applying the assay to the CSF control samples, we measured a picomo-
lar baseline level of 17±1.2 pmol/L. Recovery of liraglutide added to CSF was 
100 % and sensitivity < 2 pmol/L. The non-corrected CSF-liraglutide concen-
trations in the liraglutide-treated patients were 23±1.8 pmol/L (comparison 
to untreated controls, Mann-Whitney test: P0.6).
Conclusion: Blood-brain barrier transport of liraglutide appears very limited 
and CSF-liraglutide does not seem to correlate with the plasma liraglutide 
concentrations or with clinical weight loss. Therefore, our results do not sup-
port that blood-to-CSF transfer is a significant contributor to the anorectic 
effects of GLP-1 receptor agonists.
924
Exenatide promotes hyperbolic-like specular changes in insulin 
sensitivity and beta cell function in non-human primates
F. Casiraghi1, A. Caumo1,2, S. Benedini1,2, L. Luzi1,2, F. Folli3;  
1I.R.C.C.S Policlinico San Donato, Milan, 2University of Milan, Italy, 
3UTHSCSA, San Antonio, USA.
Background and aims: The GLP-1 receptor agonist Exenatide (EXE) im-
proves glycemic control in type 2 diabetes mellitus (T2DM) by enhancing 
glucose-dependent insulin secretion, suppressing inappropriate glucagon 
secretion, slowing gastric emptying, and regulating appetite. However, the 
effects of continuous chronic EXE infusion on insulin sensitivity and β-cell 
function are not completely understood. We investigated the effect of con-
tinuous EXE infusion on a well characterized non-human primate (baboon) 
model of insulin resistance and T2DM.
Materials and methods: We examined the effect of a continuous IV Infu-
sion (via tether system) of: i) EXE (0.014 ug/kg.h, n=10) or ii) saline (SAL, 
n=10) on insulin sensitivity and β-cell function in non-diabetic baboons 
(NDB). At baseline, baboons received a two-step Hyperglycemic Clamp 
(+125 and +225 mg/dl) followed by an IV Arginine bolus (0.15 g/kg) 
(HC+A), with a total duration of 210 minutes. Immediately after HC+A, ba-
boons underwent a partial pancreatectomy (~30% total mass) and started 
EXE or SAL infusion for 13 weeks. At the end of treatment, EXE infusion 
was stopped for 72 hours before HC+A was repeated and remnant pan-
creas was collected after humane euthanasia, at necropsy. Insulin sensitiv-
ity was calculated by linear regression from the two-step dose-response 
relationship between the incremental (above baseline) glucose clearance and 
the incremental insulin concentration measured during the final 30 min of 
each step. Beta-cell function was calculated by linear regression from the 
two-step dose-response relationship between the incremental C-peptide con-
centration and the incremental glucose concentration measured during the 
final 30 min of each step.
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Results: We found a significant increase in insulin sensitivity (6.6±3.4 to 
11.2±5.5 104 ml/kg per μU/ml, p<0.05) and a significant decrease in beta cell 
function (4.6±1.9 to 3.1±1.7 102 ng/ml per mg/dl, p<0.05) in the EXE group. 
No significant changes were found in the saline group. When plotted on the 
insulin sensitivity vs. beta-cell function diagram (Figure 1), the changes in 
insulin sensitivity and beta-cell function induced by EXE (Basal vs. End of 
Study [EOS]) were reminiscent of the hyperbolic-like changes induced by 
aerobic exercise.
Conclusion: This study shows a significant increase of insulin sensitivity cou-
pled with a significant decrease in beta cell function, after chronic EXE infu-
sion. These results are similar to what has been observed in diabetic patients 
performing aerobic physical activity. Since baboon is good model to study 
human metabolic diseases, we speculate that a similar pattern of increased 
insulin sensitivity and decreased beta function can be reasonably expected in 
humans treated with exenatide.
Supported by: NIH grant RO1 0801148
925
Sitagliptin may improve insulin sensitivity through increases in serum 
osteocalcin and adiponectin concentrations in patients with  
type 2 diabetes
Y. Sakuma1, Y. Suzuki2, R. Iwai3, S. Fukushima4, J. Ogino4, S. Yoshida5,  
N. Hashimoto4;  
1Clinical Research Support Center, Asahi General Hospital, Asahi Chiba, 
2Diabetes and Metabolic disease, Asahi General Hospital, Tokyo Women’s 
Medical University, Asahi, Yachiyo, 3Clinical Laboratory, Asahi General 
Hospital, 4Diabetes, Endocrine and Metabolic disease, Tokyo Women’s 
Medical University, Yachiyo, 5Diabetes and Metabolic disease, Asahi General 
Hospital, Japan.
Background and aims: Recent reports have suggested that dipeptidyl pepti-
dase (DPP)-4 inhibitors improve insulin sensitivity in addition to their glu-
cose lowering effects in patients with type 2 diabetes. The underlying mecha-
nisms are not well known. There is growing evidence that osteocalcin, an 
osteoblast-secreted protein, can enhance insulin sensitivity and secretion in 
animal models. We aimed to evaluate the relationship between circulating 
undercarboxylated osteocalcin(unOC) and insulin sensitivity, especially se-
rum adiponectin concentration during sitagliptin add-on therapy in patients 
with type 2 diabetes.
Materials and methods: A total of 131 Japanese patients with type 2 diabetes 
were enrolled in the study with the informed consent: 73 males/58 females, 
age 61±12 years, estimated duration of the disease 11±7 years, body mass 
index 25.8±4.7 kg/m², and HbA1c 7.9±1.1 %. They were treated with 50 to 
100 mg of sitagliptin for 12 months in addition to the preceding anti-diabetic 
agents. We measured fasting glucose, fasting insulin, indexes of insulin sensi-
tivity (HOMA-IR and quantitative insulin sensitivity check index or QUICKI) 
and secretion capacity (HOMA-β and C-peptide index or CPI), and serum 
concentrations of unOC and adiponectin. Next we examined cross-sectional 
and longitudinal associations between serum unOC and adiponectin.
Results: Sitagliptin add-on therapy significantly improved parameters for 
glycaemic control (HbA1c: 7.9±1.1 vs. 7.5±1.0 %, p<0.0001) and insulin 
sensitivity(HOMA-IR:3.2±2.3, vs. 2.7±1.8, p<0.0005, QUICKI:0.336±0.035 
vs. 0.343±0.034, p<0.005). Serum unOC and adiponectin levels were sig-
nificantly increased (unOC: 2.22±1.11 vs. 2.48±1.38, p<0.05, adiponectin: 
8.67±5.65 vs. 11.22±8.58 μg/ml, p<0.0001). Increases in serum adiponectin 
were significantly associated with decreases in HOMA-IR (r=-0.228, p<0.05) 
and increases in QUICKI (r=0.222, p<0.05). Serum unOC concentrations 
were positively correlated with adiponectin concentrations after 12-month 
treatment with sitagliptin (r=0.333, p<0.001) although both parameters 
showed no association at baseline (r=0.103, p=0.2537).
Conclusion: Sitagliptin improved insulin sensitivity associated with in-
creases in concentrations of unOC and adiponectin, which suggests some 
potential roles of DPP-4 inhibitors through bone and fat tissues, described 
as endocrine organs important for the regulation of glucose homeostasis and 
energy expenditure.
926
Effect of lixisenatide vs liraglutide on glycaemic control, gastric 
emptying and safety parameters in optimised insulin glargine type 2 
diabetes mellitus ± metformin
J.J. Meier1, J. Rosenstock2, A. Hincelin-Mèry3, C. Roy-Duval3, A. Delfolie3, 
H.-V. Coester4, T. Forst5, C. Kapitza4;  
1St Josef Hospital, Ruhr-University Bochum, Germany,  
2Dallas Diabetes and Endocrine Center, USA, 3Sanofi R&D, Paris, France, 
4Profil Institute, Neuss, 5Profil Institute, Mainz, Germany.
Background and aims: The meal test-related pharmacodynamics and safety 
of lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily (QD) were 
compared in this 8-week, randomized, open-label, 3-arm parallel mechanis-
tic trial in patients with type 2 diabetes mellitus (T2DM) ± metformin after 
optimal insulin glargine titration.
Materials and methods: The primary endpoint was change from baseline 
in incremental area under the glucose curve for 4 hours after a standardized 
solid breakfast (AUC post-prandial plasma glucose [PPG]00:30-04:30 h).
Results: Lixisenatide reduced PPG AUC00:30−04:30 h (least squares [LS] mean 
± standard error] by -240.2 ± 20.0 h.mg/dL, which was significantly more 
than liraglutide 1.2 and 1.8 mg (-131.8 ± 20.2 and -157.1 ± 21.0 h.mg/dL, 
respectively; p<0.0001; Table). Lixisenatide delayed gastric emptying more 
than liraglutide 1.2 and 1.8 mg (p<0.0001; Table) as measured by a 13C octa-
noic acid breath test. A1C decreased significantly from baseline in all groups, 
with similar reductions with lixisenatide and liraglutide 1.2 mg and small 
but significantly greater reductions with liraglutide 1.8 mg (by -0.16%). Mean 
ambulatory monitored 24-h increase in heart rate was greater with liraglutide 
1.2 and 1.8 mg (by 6 beats/min) vs lixisenatide (p<0.0001). Symptomatic hy-
poglycaemia was slightly more frequent with lixisenatide and liraglutide had 
more gastrointestinal adverse events reported. There were greater increases in 
amylase and lipase levels with liraglutide vs lixisenatide (Table) and 1 patient 
in the liraglutide 1.8 mg group developed asymptomatic oedematous pan-
creatitis documented by MRI and lipase elevations.
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Conclusion: Lixisenatide and liraglutide + insulin glargine improved glycae-
mic control in T2DM ± metformin, albeit with differing gastric emptying 
mechanisms of action and safety/tolerability profiles.
Clinical Trial Registration Number: NCT01596504
Supported by: Sanofi
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The influence of DPP-4 inhibitors on fat metabolism in type 2 diabetes 
patients
A.S. Ametov, D.G. Gusenbekova;  
Department Endocriniligy and Diaetology RMAPO, Ministry of Health, 
Moscow, Russian Federation.
Background and aims: To evaluate the effect of sitagliptin in combination 
with metformin on glucose toxicity and lipotoxicity in patients with type 2 
diabetes and obesity.
Materials and methods: The study involved 82 patients (55 women, 27 men, 
mean age 56,1 ± 5,47 years) with obesity, lipid metabolism disorders, who 
have not reached target levels HbA1s (average HbA1c 8,3 ± 1,6%) after met-
formin and diet therapy. The first group of patients (42 patients) received 
co-formulated drug, consisting of sitagliptin 100mg and metformin 2g once 
a day; the second comparison group (40 patients) received metformin 1.5-2.0 
g/day. Dynamics of fasting glycemia, postprandial glycemia, glycated hemo-
globin, weight, BMI, WC, WHR, lipid profile (total cholesterol, triglycerides, 
LDL, HDL, apoβ protein), insulin, proinsulin, leptin, adiponectin, insulin 
resistance using the index HOMA IR and functional activity of β-cells (by 
HOMA-β index) was evaluated at baseline and at 6 months of therapy. In ad-
dition, MRI was performed to assess visceral fat in all the patients.
Results: At 6 months patients in both groups demonstrated significant posi-
tive changes in the levels of fasting glucose, postprandial glycemia and gly-
cosylated hemoglobin. In group I, HbA1 decreased from 8,3 ± 1,6% to 6,6 ± 
1,24% (p <0.01), in group II there was a decrease from 8,35 ± 1,75% to 7,62 
± 1.39% (p <0.01). FPG and late products of glycosylation levels in group I 
reduced on average by 2.67 and 3.3 mmol/L, correspondingly, in group II by 
2.1 and 1.8 mmol/l. No significant differences in the dynamics of total cho-
lesterol, HDL between the groups were found. LDL in group I lowered by 0.7 
mmol/l, in group II by 0.3 mmol/l (p <0.05); in group I, TG decreased by 1.33 
mmol/l. in group II by 0, 63 mmol/l (p <0.05); in group I IRI reduction was 
3.45 mcU/ml. in group II 1.63 mcU/ml (p = 0.05). Proinsulin level dropped 
down in group I by 2,93 ± 3,02, in group II by 1,26 ± 1,1, C-peptide level 
increased by 1,4 ± 1,6 ng/ml, in group II 0.16 ± 0,1 ng/ml, HOMA β grew up 
in group I by 23.4 standard units, in group II by 4.8 standard units (p <0.005). 
The ratio of proinsulin/insulin dropped down in group I by 0, 19 ± 0,7, in 
group II by 0,02 ± 0,2. There were no significant differences between the 
groups in the dynamics of HOMA IR and both groups demonstrated positive 
dynamics. Adiponectin levels were different between the groups, there was an 
increase by 1.9 ng/ml in group I, in group II by 0.49 ng/ml. (p <0.01). Leptin 
lowered by 7.37 ng/ml in group I, in group II by 1.21 ng/ml (p <0.01). Also 
groups showed dramatic difference in anthropometric parameters dynamics 
(p <0,001). Average weight loss was 4, 9 ± 3, 2 kg in group I, in group II 2,0 
± 0,94 kg correspondingly. BMI in group I decreased by 1,8 ± 1,3, in group II 
by 0,68 ± 0,3. WC shortened by 6,5 ± 4,7 sm in group I, in group II by 2,42 ± 
1,02 sm. WHR in group I decreased from 0,95 ± 0,06 sm to 0,91 ± 0,05 sm, 
in group II from 0,94 ± 0,03 sm to 0,93 ± 0,03 sm, respectively. Also MRI 
showed a significant reduction of visceral fat area by 20,6 ± 13,5 sm2 (7.5%) 
in group I, compared to group II with 5,7 ± 3,75 sm2 reduction(1.76%). P 
<0.01, while in the dynamics of the area of the subcutaneous fat there is no 
reliable dynamics between groups. Episodes of hypoglycemia have not been 
registered in any of the groups during the treatment.
Conclusion: The administration of sitagliptin and metformin decreased glu-
cose toxicity and lipotoxicity that generally led to the improvement of glyce-
mic control.
928
Feed-back suppression of meal-induced GLP-1 secretion: a randomised, 
prospective comparison of the DPP-4 inhibitors sitagliptin and 
vildagliptin
O. Baranov1, C.F. Deacon2, J.J. Holst2, U. Buss1, M.A. Nauck1;  
1Diabetes Centre, Bad Lauterberg im Harz, Germany,  
2Department of Biomedical Sciences, University of Copenhagen, Denmark.
Background and aims: DPP-4 inhibitors inhibit/delay proteolytic degrada-
tion of intact incretin hormones (GIP, GLP-1) and thereby stimulate insulin 
and suppress glucagon secretion. Higher intact GLP-1 increments with DPP-
4 inhibitors lead to feedback inhibition of (total) GLP-1 (L-cell-) secretion. In 
this respect, the present study wanted to compare the effects of vildagliptin 
and sitagliptin.
Materials and methods: 24 patients with type 2 diabetes (12 without diabetes 
medication, 12 on metformin monotherapy), including 10 women/14 men, age 
63 ± 3 years, BMI 30 ± 4 kg/m2, diabetes duration 5 ± 5 years, HbA1c 6.6 ± 0.7 
% participated, in randomized order, in treatment periods lasting 7-9 days on 
either vildagliptin (50 mg b.i.d. = 100 mg/d), sitagliptin (100 mg q.d. in those 
on diet, 50 mg b.i.d. in those on metformin treatment = 100 mg/d) or placebo 
(b.i.d). On the last day of the treatment period, participants underwent a mixed 
meal stimulation test after an overnight fast. Capillary blood was taken for glu-
cose measurements, venous blood samples were taken for the determination of 
serum insulin and C- peptide, and plasma GLP-1 and GIP (both intact and to-
tal concentrations), and glucagon. Statistics: ANCOVA for repeated measures.
Results: Both DPP-4-inhibitors significantly reduced the post-prandial in-
crements in plasma glucose. Intact GLP-1 and GIP concentrations were 
roughly doubled by both DPP -4 inhibitors. Total GLP-1 secretion reduced 
by 56 % with vildagliptin and by 33% with sitagliptin treatment (significant if 
compared to placebo, not between vildagliptin and sitagliptin). Glucagon was 
suppressed slightly more markedly with vildagliptin. Parameters of glycaemic 
control and insulin secretion did not differ much between vildagliptin and 
sitagliptin treatment.
Conclusion: Vildagliptin and sitagliptin affect the concentrations of incre-
tin hormones, glucose concentrations, insulin and glucagon secretion as ex-
pected, including a feedback inhibition of L-cell secretion induced by DPP-4 
inhibition, most likely mediated by elevated „intact“ GLP-1 concentrations. 
In this respect, and regarding more clinical parameters (glycaemic control, 
insulin secretion, glucagon suppression) at most minor differences were de-
scribed between vildagliptin and sitagliptin tratment, which most likely are 
without clinical significance.
Supported by: Novartis Pharma
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Effects of standard dose of vildagliptin vs sitagliptin on blood glucose 
fluctuations evaluated by long-term self-monitoring blood glucose 
(SMBG)
K. Kimachi, H. Miyoshi, N. Aikawa, H. Nomoto, H. Kameda, K. Cho,  
T. Kondo, T. Atsumi;  
Department of Medicine II (Immunology and Metabolism),  
Hokkaido University School of Medicine, Sapporo, Japan.
Background and aims: No previous studies have compared the DPP-4 inhib-
itors, vildagliptin and sitagliptin, in terms of fluctuations of daily blood glu-
cose profile by using long-term SMBG. The aim of this study was to evaluate 
the effects of switching from sitagliptin to vildagliptin, or from vildagliptin to 
sitagliptin on 12-week glucose fluctuations using SMBG in Japanese patients 
with type 2 diabetes.
Materials and methods: We conducted a multicenter, prospective, open-
label controlled trial with blinded endpoint analysis. Thirty-two patients with 
type2 diabetes mellitus had been treated by vildagliptin or sitagliptin in each 
standard use (vildagliptin 50mg twice daily or sitagliptin 50mg once daily), 
and were allocated to two groups who received vildagliptin during 12 weeks 
then switched to sitagliptin during 12 weeks, or vice versa. SMBG systems 
were distributed to all patients at the beginning and measurements of seven-
point SMBG (daily profile of blood glucose level of before and 2 hours af-
ter each meal, and at bedtime) during the trial were used to determine: 1) 
the mean amplitude of glycemic excursions (MAGE), 2) M-value, 3) mean 
(± standard deviation) blood glucose level, and 4) fasting and postprandial 
blood glucose level. Plasma glycosylated hemoglobin (HbA1c), glycoalbumin 
(GA), 1,5-anhydroglucitol (1,5AG), immunoreactive insulin (IRI), Proinsu-
lin/IRI ratio, C-peptide immunoreactivity (CPR) and glucagon levels were 
measured.
Results: The MAGE was significantly lower in patients taking vildagliptin 
than sitagliptin (61.9±27.3 vs. 72.9±38.4 mg/dL; p=0.04). In patients taking 
vildagliptin, the mean blood glucose level was significantly lower (151.0±31.6 
vs. 157.5±29.2 mg/dL; p=0.02), M-value was significantly lower (11.7±2.4 
vs. 14.5±2.5; p=0.01) and the blood glucose level after supper was signifi-
cantly lower (172.2±40.8 vs. 190.6±42.2 mg/dL; p=0.04). 1,5-anhydroglu-
citol (1,5AG) was significantly higher(1.40±2.67 vs. -0.90±1.59; p=0.003), 
and proinsulin/IRI ratio was significantly lower(-0.039±0.13 vs. 0.51±0.11; 
p=0.01). There were no significant differences in plasma HbA1c, GA, fasting 
CPR, or glucagon levels between patients taking vildagliptin and sitagliptin.
Conclusion: Vildagliptin was superior to reduce the fluctuations of daily 
blood glucose profile compared with sitagliptin in Japanese patients with 
type 2 diabetes.
Clinical Trial Registration Number: UMIN000005627
930
Factors associated with progression of type 2 diabetes and impact of 
treatment with saxagliptin in the SAVOR-TIMI 53 trial
G. Leibowitz1, O. Mosenzon1, D.L. Bhatt2, B. Hirshberg3, C. Wei3, A. Cahn1, 
G. Jermendy4, W.H.H. Sheu5, J. Lopez-Sendon6, A. Avogaro7, B.M. Scirica2, 
I. Raz1;  
1The Diabetes Unit, Hadassah Hebrew University - Medical Center, 
Jerusalem, Israel, 2Brigham and Women‘s Hospital, Harvard Medical 
School, Boston, 3AstraZeneca, Wilmington, USA, 4Bajcsy-Zsilinszky 
Hospital, Budapest, Hungary, 5Department of Internal Medicine, Division 
of Endocrinology and Metabolism, Taichung Veterans General Hospital, 
Taiwan, 6Cardiology Department, Hospital Universitario La Paz, Madrid, 
Spain, 7Dept. of Medicine, University of Padova, Italy.
Background and aims: In type 2 diabetes (T2D), glycemic control often 
deteriorates over time, requiring intensification of treatment. We aimed to 
identify factors associated with progression of diabetes and studied the im-
pact of saxagliptin, a DPP-4 inhibitor, on diabetes progression. In addition, 
we evaluated the effect of saxagliptin on beta cell function as reflected by a 
decline in HOMA2-β.
Materials and methods: We studied the association of clinical and biochemi-
cal parameters with diabetes progression in the SAVOR-TIMI 53 study, a ran-
domized clinical trial of 16,492 patients with T2D treated with saxagliptin vs. 
placebo added to current anti-diabetic medications for a median of 2.1 years. 
Diabetes progression was defined by 1) HbA1C increase ≥0.5%, 2) initiation 
of new anti-diabetic medications, 3) increase in oral medication dose or 4) 
≥25% increase in insulin dose for ≥3 months. HOMA2-β was measured at 
baseline and at year 2 in 4134 patients (25.1% of trial).
Results: Progression of diabetes during the study occurred in 54.7% of all 
subjects. Compared with placebo, treatment with saxagliptin decreased the 
risk of diabetes progression (OR 0.60; 95% CI 0.57-0.65; p<0.001). The occur-
rence of an HbA1C increase of ≥0.5%, initiation of insulin, and the increase 
in dose for an oral hypoglycemic medication or insulin was decreased by 
30%, 30% and 19% respectively in patients treated with saxagliptin compared 
with placebo. At 2 years, HOMA2-β was decreased by 7.6% with placebo, 
compared with 2.7% with saxagliptin (p=0.0004). A multivariate analysis 
that included baseline demographics, biochemical parameters, and medical 
treatments showed that older age, lower HDL, lower baseline HOMA2-β, and 
baseline sulfonylurea use were significantly associated with diabetes progres-
sion.
Conclusion: Saxagliptin decreased the progression of diabetes via improved 
glycemic indices and fewer concomitant anti-hyperglycemic agents com-
pared with placebo, which may be related to reduced natural decline in β-cell 
function.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca/Bristol-Myers Squibb
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IDegAsp provides superior FPG control and reduced hypoglycaemia 
vs BIAsp 30 in insulin-naive adults with type 2 diabetes: a randomised 
phase 3 trial
E. Franek1, M. Haluzík2, S. Canecki Varžić3, M. Sargin4, S. Macura5,  
J. Zacho5, J. Christiansen6;  
1Central Clinical Hospital MSWiA, Warsaw, Poland, 2General University 
Hospital and 1 Faculty of Medicine, Praha, Czech Republic, 3Clinical 
Hospital Center Osijek, Croatia, 4Kartal Training and Research Hospital, 
Istanbul, Turkey, 5Novo Nordisk A/S, Copenhagen, Denmark, 6Aarhus 
University Hospital, Denmark.
Background and aims: Insulin degludec/insulin aspart (IDegAsp) is a 
70%/30% combination of insulin degludec (IDeg) and insulin aspart (IAsp), 
providing both a basal insulin with an ultra-long duration of action and a 
rapid-acting bolus insulin in a single injection.The aim of this trial was to 
compare the efficacy and safety of IDegAsp and biphasic insulin aspart 30 
(BIAsp 30), each administered twice daily (BID) ± metformin in insulin-
naive adults with type 2 diabetes (T2DM).
Materials and methods: This was a 26-week randomised, open-label, mul-
tinational, treat-to-target trial. Subjects (mean: age 58.9 years, duration of 
diabetes 9.5 years, HbA1c 8.4%, FPG 10.2 mmol/L, BMI 31.2 kg/m
2) were 
randomised 1:1 to IDegAsp BID (n=197) or BIAsp 30 BID (n=197). Insulin 
was administered before breakfast and the main evening meal and titrated 
to a pre-breakfast and pre-main evening meal self-measured plasma glucose 
(SMPG) target of ≤5 mmol/L. Patient characteristics were similar in both 
treatment arms.
Results: IDegAsp was non-inferior to BIAsp 30 based on mean change in 
HbA1c from baseline (primary endpoint; estimated treatment difference 
[ETD] +0.02% [95% CI -0.12; 0.17]), end of treatment mean HbA1c was 49.0 
(6.6) and 48.0 (6.5) (mmol/mol [%]), respectively. IDegAsp was superior to 
BIAsp 30 in lowering FPG (ETD -1.0 mmol/L [95% CI -1.42; -0.59]; p<0.001). 
Mean daily insulin dose after 26 weeks was similar in both treatment arms. 
IDegAsp was associated with significantly lower rates of confirmed (plasma 
glucose (PG) <3.1 mmol/L or severe [requiring assistance]) and nocturnal 
confirmed (between 00.01-05.59 h) hypoglycaemia vs BIAsp 30 (Figure). 
Rates of severe hypoglycaemia were low in both treatment arms. Both treat-
ments were well tolerated and rates of adverse events were similar.
Conclusion: IDegAsp BID in insulin-naive adults with T2DM effectively 
improves HbA1c (non-inferior to BIAsp 30) and is superior to BIAsp 30 in 
lowering FPG. The significantly lower rates of confirmed and nocturnal con-
firmed hypoglycaemia for IDegAsp vs BIAsp 30 are consistent with previous 
findings, reflecting the more prolonged and stable glucose-lowering effect of 
the IDeg (basal) component in IDegAsp compared to the protaminated por-
tion of IAsp in BIAsp 30.
Clinical Trial Registration Number: NCT01513590
Supported by: Novo Nordisk A/S
932
Pharmacokinetic (PK) and pharmacodynamic (PD) properties of 
BioChaperone Combo (BC Combo), the first fixed combination of 
glargine and lispro, in type 1 diabetes (T1DM) 
U. Hoevelmann1, B. Alluis2, G. Meiffren2, A. Ranson2, O. Soula2, G. Soula2, 
R. Soula2, B. Kronshage1, L. Nosek1, S. Famulla1, T. Heise1;  
1Profil, Neuss, Germany, 2Adocia, Lyon, France.
Background and aims: BC Combo is a novel insulin formulation in a clear 
solution combining the two already licensed insulin analogues glargine and 
lispro (75/25) at neutral-pH using the BioChaperone technology.
Materials and methods: We investigated the pharmacodynamic and phar-
macokinetic properties in patients with T1DM (21 randomised (mean±SD 
age: 42.3±13.0 years; HbA1c: 7.8±0.6 %), 19 completers) receiving a single 
dose of 0.8 U/kg (s.c.) of BC Combo or Humalog Mix25 (MIX) under au-
tomated glucose clamp conditions (ClampArt®, target blood glucose (BG) 
100 mg/dL, duration 30 h post-dosing) in this double-blind, 2 way-crossover 
study.
Results: As visible from the mean glucose infusion rate (GIR) curves (Fig-
ure), BC Combo showed a faster onset of action (25±11 vs. 40±13 min, 
p=0.0017), an earlier Tmax (2.8±0.8 vs. 3.4±0.8 h, p=0.0145) and an improved 
glucose-lowering effect in the first two hours post-dosing (AUCGIR 0-2h 
504±210 vs. 325±183 mg/kg, p=0.0012), compared with MIX, likewise evi-
denced by a greater early appearance (AUCINS 0-1h 86±39 vs. 34±19 h*mU/L, 
p<0.0001). Minimal duration of action was achieved before 30 hours by less 
subjects on BC Combo than on MIX (2 vs 14, p=0.0002) indicating a longer 
duration of action (defined as the time after dosing at which the BG increases 
to > 118 mg/dL, Figure) for BC Combo (29.8±0.7 vs. 25.5±4.3 h). This also 
resulted in lower mean BG values in the last hour of the clamp (104.5±8.8 and 
137.8±35.7, p=0.0008). In addition, BC Combo showed a more pronounced 
late metabolic effect (AUCGIR 12-30h 1480±900 vs. 961±553 mg/kg, p=0.0257) 
which was in line with a higher late exposure (AUCINS 12-30h 563±409 vs. 
286±233 h*mU/L, p<0.0001) and a longer half-life (17.6±8.7 vs. 7.7±3.0 h, 
p<0.0001) supporting the use of BC Combo as a once daily injection. No 
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safety issues were identified. Both formulations were well tolerated and no 
injection site reactions occurred.
Conclusion: The PK and PD results of BC Combo showed a stronger pran-
dial effect with a faster onset and also a longer basal action for BC Combo 
indicating the potential of an improved metabolic control vs. MIX when used 
as once daily treatment.
Clinical Trial Registration Number: NCT01981031
933
Long-acting basal insulin (HM12470) offers once-weekly dosing 
potential with a favorable PK, PD and mitogenic profile
I. Choi1, S. Hwang1, J. Kim1, S. Jung1, D. Kim1, Y.-M. Lee1, Y. Kim1,  
M. Trautmann2, M. Hompesch2, J. Son1, S. Kwon1;  
1Hanmi Pharmaceutical Co., Ltd., Gyeonggi-do, Republic of Korea,  
2Profil Institute, Chula Vista, USA.
Background and aims: The novel long-acting basal insulin (HM12470) has 
been developed for once-weekly injection by conjugating an insulin analog 
with the constant region of a human immunoglobulin fragment via non-pep-
tidyl linker. This study investigated the in vitro properties, pharmacokinetics 
and pharmacodynamics of HM12470 in normal and diabetic animal models 
to evaluate the once-weekly dosing potential and the mitogenic potency.
Materials and methods: Pharmacokinetics of HM12470 was evaluated after 
subcutaneously administration to mice, rats, dogs, pigs, and monkeys. Based 
on these preclinical PK data, human plasma profile of HM12470 was predict-
ed for once-weekly dosing by the Wajima Css-MRT method. Blood glucose 
lowering was monitored in db/db mice after HM12470 was subcutaneously 
injected. In vitro analysis, the lipogenic potency in fully differentiated 3T3-
L1 adipocyte cells, and cell proliferative potency in MCF-7 and SaOs-2 cells 
were evaluated.
Results: In a pharmacokinetic study, subcutaneously injected HM12470 ex-
hibited a half life of ~ 43 hr in normal rats, while insulin degludec showed 2.9 
hr of half-life. The extended half-life was also confirmed in other species such 
as mice, dogs, pigs, and monkeys. The improved pharmacokinetic profile had 
contributed to prolonged glucose lowering efficacy in db/db mice. Based on 
the results from three different species (mice, rats, and dogs), human phar-
macokinetics was predicted that half-life time of HM12470 was expected to 
be ~132 hr and the peak-to-though ratio was to be 1.6 on once weekly dosing. 
In vitro mitogenic potency of HM12470 was assessed by using cell prolifera-
tion in MCF-7 and SaOs-2 cells. Compared to its lipogenic efficacy assessed 
in fully differentiated 3T3-L1 adipocyte cells, the mitogenic to lipogenic po-
tency ratio was significantly lower than that of human insulin.
Conclusion: HM12470 has a prolonged pharmacokinetic and pharmaco-
dynamic profile in animal studies, and the predicted half-life and peak-to-
trough ratio of HM12470 in human are promising once-weekly dosing po-
tential with flat exposure profile. Moreover, HM12470 is expected to have low 
mitogenic potency based on in vitro results.
934
The ultra-rapid biochaperone insulin lispro shows a faster onset of action 
and stronger early metabolic effect than insulin lispro alone
G. Andersen1, B. Alluis2, G. Meiffren2, A. Ranson2, O. Soula2, G. Soula2,  
R. Soula2, A. Fischer1, L. Nosek1, F. Schliess1, T. Heise1;  
1Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany,  
2Adocia, Lyon, France.
Background and aims: We investigated the pharmacodynamic characteris-
tics of BioChaperone insulin lispro (BC LIS), a novel insulin lispro formula-
tion with BioChaperone aimed at accelerating the absorption from the sub-
cutaneous tissue.
Materials and methods: In this double-blind, crossover study people with 
type 1 diabetes received 0.2 U/kg of BC LIS or insulin lispro (LIS) alone under 
automated glycaemic clamp conditions (ClampArt®, target blood glucose 100 
mg/dL, clamp duration 6h post-dosing).
Results: Thirty-seven patients were enrolled and 36 completed this study (age 
42.7±13.4 years (mean±SD), BMI 24.8±1.7 kg/m², HbA1c 7.6±0.6%). Mean 
glucose infusion rates (GIR) are given in the figure. Compared with LIS, BC 
LIS showed ultra-rapid properties with a faster onset of action (23.1±7.0 vs. 
34.4±15.3 min, p<0.0001), an earlier maximum effect (TGIR max 99±42 vs. 
133±45 min, p=0.0002) and a stronger early metabolic effect in the first hour 
(AUCGIR 0-1h 218±88 vs. 129±63 mg/kg, p<0.0001) and first 2 hours (AUCGIR 
0-2h 627±235 vs. 525±214 mg/kg, p=0.0041). Total (AUCGIR 0-6h 1409±494 vs. 
1434±506 mg/kg, p=0.72) and maximum metabolic effect (GIRmax 7.85±2.87 
vs. 7.96±2.81 mg/kg/min, p=0.76) were comparable. Both insulin formula-
tions were well tolerated.
Conclusion: BC LIS has the characteristics of an ultra-fast acting insulin with 
a faster onset of action, an earlier maximum action and stronger metabolic 
effect in the first 2 hours than insulin lispro alone. BC LIS therefore has the 
potential to provide excellent postprandial glycaemic control.
Supported by: 2013-003507-19
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935
Comparison of duration of action of 2 insulin glargine products, 
LY2963016 and insulin glargine, in subjects with type 1 diabetes mellitus
H. Linnebjerg1, T. Heise2, X. Zhang1, M.E. Seger1, D. Coutant1, L. Chua3,  
E. Lam3;  
1Eli Lilly and Company, Indianapolis, USA, 2Profil, Neuss, Germany,  
3Lilly-NUS Centre for Clinical Pharmacology, Singapore.
Background and aims: LY2963016 (LY IGlar) and insulin glargine (Sanofi-
Aventis; IGlar) are both insulin glargine products, with identical amino acid 
sequences. Even with identical amino acid sequences, proteinbased therapeu-
tics manufactured by distinct processes must be shown to be similar. This 
study compared the duration of action of LY IGlar and IGlar.
Materials and methods: This was a Phase 1, randomised, doubleblind, 2peri-
od, crossover, glucose clamp study. Fasted male subjects with type 1 diabetes 
mellitus received a single subcutaneous dose of 0.3 U/kg LY IGlar and IGlar 
on 1 occasion each. A minimum 7day washout separated doses. Pharmaco-
dynamic effects were assessed with a euglycaemic clamp (Biostator®, glucose 
target level 100 mg/dL [5.6 mmol/L]) lasting up to 42 hours postdose. Du-
ration of action was defined as the time post dosing at which the subject›s 
blood glucose level was consistently >150 mg/dL (8.3 mmol/L) without any 
glucose infusion.
Results: Twenty male subjects aged 2354 years with type 1 diabetes mellitus 
participated in this study. Based on timetoevent (survival) analysis, median 
duration of action was estimated to be 37.1 and 40.0 hours for LY IGlar and 
IGlar, respectively, while mean duration of action (standard error) was 23.8 
(3.8) and 25.5 (3.9) hours for LY IGlar and IGlar, respectively. In 14 of the 40 
clamps (7 LY IGlar, 7 IGlar), subjects’ duration of action exceeded the 42hour 
clamp period. The mean profiles of the pharmacodynamic variables (glucose 
infusion rate and blood glucose) were similar between treatments over the 
42hour clamps (see figure below). LY IGlar was well tolerated, with similar 
adverse event profiles observed following LY IGlar and IGlar dosing. No 
safety concerns from clinical laboratory, vital signs or ECG data were noted.
Conclusion: Similar pharmacodynamic effects and duration of action were 
demonstrated for LY IGlar and IGlar in this 42hour clamp study in subjects 
with type 1 diabetes mellitus.
Clinical Trial Registration Number: NCT01600950
Supported by: Eli Lilly and Company
936
Higher early insulin exposure and greater early glucose-lowering effect 
with faster-acting insulin aspart in patients with type 1 diabetes mellitus
H. Haahr1, U. Hövelmann2, L. Brøndsted1, C.L. Adrian1, L. Nosek2, T. Heise2; 
1Novo Nordisk A/S, Søborg, Denmark, 2Profil, Neuss, Germany.
Background and aims: Faster-acting insulin aspart (faster aspart) is insulin 
aspart (IAsp) in a new formulation containing two new excipients (nicoti-
namide and arginine), which result in a faster initial absorption after s. c. 
injection.
Materials and methods: In total, 52 patients with type 1 diabetes mellitus 
(mean ± standard deviation age: 40.3 ± 12.0 years; haemoglobin A1c: 7.3 ± 
0.7%) were randomised to a single dose (0.2 U/kg s. c.) of faster aspart or IAsp 
under glucose clamp conditions (Biostator; blood glucose target 100 mg/dl; 
clamp duration 12 hours post-dose) in a crossover design.
Results: Compared with IAsp, faster aspart had a faster onset of appearance, 
i.e., time from trial drug administration until the first time serum insulin as-
part concentrations reached the lower limit of quantification (mean difference 
[95% confidence interval (CI)]: -6.33 minutes [-7.30; -5.36]), earlier time to 
50% Cmax (median difference [95% CI]: -11.0 minutes [-13.5; -9.0]), earlier 
tmax (median difference [95% CI]: -7.5 minutes [-17.5; 0.0]), and greater early 
exposure up to 2 hours post-dose (e.g., 4.5-fold more insulin aspart in the cir-
culation in the first 15 minutes post-dose); total exposure was similar (Table). 
Faster aspart had an earlier and higher glucose-lowering effect (indicated by 
higher glucose infusion rates, GIR) in the first 2 hours post-injection versus 
IAsp (Table) and an earlier time to 50% GIRmax (mean difference [95% CI]: 
-7.81 minutes [-13.19; -2.44]). The maximum GIR and total glucose-lowering 
effect (Table) were similar between faster aspart and IAsp. No safety or toler-
ability issues were identified; in particular, no injection site reactions occurred.
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Conclusion: Faster onset and higher early exposure with faster-acting insulin 
aspart led to a greater early glucose-lowering effect, indicating that faster as-
part has the potential to improve postprandial glucose versus IAsp.
Clinical Trial Registration Number: NCT01618188
Supported by: Novo Nordisk
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Biphasic pharmacokinetic and pharmacodynamic profiles associated 
with concentrated insulin BIOD-531 show rapid onset and basal 
duration of action
L. Morrow1, M. Hompesch1, L. Canney2, P. Pichotta2, A. Krasner2,  
E. De Souza2;  
1Profil Institute for Clinical Research, Chula Vista,  
2Biodel Inc., Danbury, USA.
Background and aims: Formulations of human insulin and insulin analogs 
containing citrate and EDTA have been shown to be more rapidly absorbed 
than commercially available insulin products. The aim of this study was to 
compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of 
BIOD-531, a concentrated (400 U/ml or U-400) formulation of recombinant 
human insulin containing EDTA, citrate and MgSO4, to products marketed 
as combined prandial/basal insulins.
Materials and methods: A single-center, randomized, double-blind four-
period crossover study employing 24-hour euglycemic clamps, evaluating 
the PK and PD profiles of BIOD-531 at two doses (1 U/kg and 0.5 U/kg) vs. 
Humulin® R U-500 (1 U/kg, U-500R) and Humalog® Mix75/25™ (0.5 U/kg, 
HU 75/25) in obese non-diabetic subjects.
Results: Thirteen subjects (age 39.8 ± 13.5 yrs; weight 99.5 ± 12.6 kg) were 
randomized. BIOD-531 was associated with an increased rate of absorption 
vs. U-500R as measured by multiple PK parameters including a 92% shorter 
time to early ½ Tmax (11.0 ± 1.9 min) vs. U-500R(135.3 ± 34.9 min), a 43% 
shorter time to Tmax (223.8 ± 62.3 min) vs. U-500R (393.3 ± 58.3 min) and a 
765% increase in early insulin exposure as measured by AUCins0-30min (2966 
± 383 mU*min/L) vs. U-500R (343 ± 74 mU*min/L). BIOD-531 was associ-
ated with a more rapid glucose lowering effect as measured by multiple PD 
parameters including a 66% faster time to onset of action (7.2 ± 4.1 min) vs. 
U-500R (21.4 ± 6.7 min) and 169% increase in AUCGIR0-60min (108.5 ± 22.0 
mg/kg vs. U-500R (40.4 ± 10.0 mg/kg). These differences were all statistically 
significant. BIOD-531 was associated with an increased rate of absorption vs. 
HU 75/25 as measured by multiple PK parameters including a 66% shorter 
time to early ½ Tmax (16.4 ± 4.9 min) vs. HU 75/25 (47.9 ± 2.6 min), an 18% 
shorter time to Tmax (131.3 ± 43.4 min) vs. HU 75/25 (160.0 ± 11.9 min) and a 
917% increase in early insulin exposure as measured by AUCins0-30min (1200 ± 
141 min) vs. HU 75/25 (118 ± 22 mU*min/L). BIOD-531 was associated with 
a more rapid glucose lowering effect as measured by multiple PD parameters 
including a 59% faster time to onset of action (14.6 ± 6.0 min) vs. HU 75/25 
(35.9 ± 7.9 min) and 375% increase in AUCGIR0-60min (68.9 ± 13.4 mg/kg) vs. 
HU 75/25 (14.5 ± 4.7 mg/kg). With the exception of Tmax, these differences 
were all statistically significant. The duration of action of BIOD-531 is ap-
proximately 18 hours, shorter than that of either comparator. All study drugs 
were well tolerated.
Conclusion: BIOD-531 is associated with more rapid onset of action than 
either marketed prandial/basal insulin product suggesting that it may provide 
improved mealtime glucose control with low injection volumes. Further-
more, the duration of action of BIOD-531 is consistent with a basal insulin.
Supported by: NIDDK Award R43DK096604
938
Pharmacokinetics and elimination of basal insulin peglispro (BIL) versus 
PEG-only in rats following a single IV or SC dose
M. Knadler, J.A. Martin, B.B. Ellis, P.L. Brown-Augsburger, A.T. Murphy,  
V.J. Wroblewski;  
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA.
Background and aims: BIL (LY2605541) is a novel, 20-kDa PEGylated in-
sulin lispro that has a large hydrodynamic size. It has a prolonged duration 
of action which is related to a delay in insulin absorption and a reduction in 
clearance. The aim of this study was to examine the pharmacokinetics and 
elimination of BIL compared with 20-kDa PEG only in rats.
Materials and methods: Male Sprague Dawley rats were given a 0.5-mg/kg 
IV or 2-mg/kg SC dose of BIL with 14C-labeled 20-kDa PEG portions of BIL 
or 125I-labeled lispro portions of BIL. PEG only (
14C- 20-kDa PEG) was dosed 
at 10 mg/kg IV or SC. Blood for serum, urine, and feces were collected up 
to 336 h postdose. Samples were analyzed for 14C using liquid scintillation 
counting, for 125I using gamma counting, for BIL using ELISA, and for PEG-
related products using liquid chromatography/mass spectrometry (MS) or 
size-exclusion chromatography.
Results: AUCs for BIL were 41% and 16% of circulating 14C after IV and 
SC dosing, respectively. AUCs for BIL were 63% and 31% of circulating 125I 
for IV and SC dosing, respectively. After SC dosing, t½ of 14C was 4.4-fold 
longer than that of 125I. After IV dosing, BIL Cl was 2.4-fold faster than that 
of 14C radioequivalents and 1.6-fold faster than that of 125I radioequivalents 
indicating catabolism of BIL into products with longer half-lives. The t½ and 
Cl of 14C after PEG-only dosing were similar to those after BIL dosing. SC 
bioavailability of radiolabeled BIL was 23%−29%; absorption was ≥75%. The 
bioavailability of 20-kDa PEG-only was 78%. Excretion of radioactivity after 
IV or SC dosing of 14C-BILwas generally similar. In the BIL study, 14C was 
eliminated in urine and feces (urine:feces ratio, 0.9 for IV and 1.35 for SC). In 
the PEG-only study, most of the 14C was recovered in urine after IV or SC ad-
ministration. In the BIL study, ≥86% of 125I was eliminated in urine mainly as 
small peptides, amino acids or free 125I. After SC 14C-BIL dosing, a mean ±SD 
of 2.5% ± 0.66% of the dose was excreted intact in urine. Based on qualitative 
MS analyses, the main PEG-related product found in serum and urine after 
BIL dosing was 20-kDa PEG with lysine attached. After PEG-only dosing, 
the main urinary product appeared to be intact PEG based on size-exclusion 
chromatography.
Conclusion: These data suggest that elimination of BIL is via catabolism to 
smaller peptides and/or amino acids and PEG with lysine attached. BIL is 
cleared faster than the products from catabolism. After BIL dosing, the PEG 
portion is eliminated via biliary and renal routes; after PEG alone, most of the 
14C dose is eliminated renally. The PEG in BIL would only partially depend on 
renal function for elimination, unlike PEG-only. The protein attached to PEG 
may direct the elimination of PEG.
Supported by: Eli Lilly and Company
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Pump use is less frequent in minority youth: transatlantic analysis in 
three large registries representing Austria, Germany, England, Wales and 
the United States
B. Rami-Merhar1, D. Maahs2, J. Warner3, S. Hofer4, W. Tamborlane5,  
J. Hermann6, A. Icks7, D. Schatz8, N. Foster9, R.W. Holl6;  
1Medical University of Vienna, Austria, 2University of Colorado, Denver, 
USA, 3on behalf of the National Paediatric Diabetes Audit and the 
Royal College of Paediatrics and Child Health, Cardiff, UK, 4Medical 
University of Innsbruck, Austria, 5Yale School of Medicine, New Haven, 
USA, 6University of Ulm, 7Department of Public Health, Heinrich Heine 
University Düsseldorf, Germany, 8University of Florida College of Medicine, 
Gainesville, 9JAEB Center, Tampa, USA.
Background and aims: Use of insulin pumps has recently increased among 
children and adolescents with type-1 diabetes in many parts of the world. Pa-
tient and family preferences, beliefs and policies of healthcare professionals, 
expectations on metabolic goals, but also financial aspects / reimbursement 
by health insurance interact on the decision for or against CSII in individual 
patients. Each of these components depends on society and may be different 
for minority youth. Ideally, important treatment choices should be independ-
ent from the socio-economic background of a patient. The aim of this study 
was to evaluate this claim based on data from 3 large, multicenter registries.
Materials and methods: In total, 54,767 children and adolescents (<18 years) 
with T1D from the United States (T1D Exchange registry, n=13,966), Eng-
land and Wales (National Paediatric Diabetes Audit, n=14,539) and Austria 
/ Germany (DPV registry, n=26,262) with documented insulin therapy were 
available for analysis. Minority status was defined by ethnicity for UK and 
US, and by country of birth for Austria/Germany. Using a multivariable lo-
gistic regression model, the frequency of CSII was adjusted for differences in 
age, gender and diabetes duration among the 3 registries (SAS 9.4).
Results: Pump use differed among the 3 registries: 47.0 % in the US, 40.1 % 
in Austria/Germany and 13.9 % in the UK (p<0.001). After demographic ad-
justment, respective figures were 45.7 %, 40.5 % and 11.7 %. Despite different 
definitions, the percentage of minority youth was rather similar: 22.2 % in the 
US , 20.0 % in Austria/Germany and 23.8 % in the UK. In the whole cohort, 
22.4 % of minority children, compared to 34.7 % of non-minority children, 
used insulin pumps (OR 0.543 [0.517, 0.570, p<0.001]. This difference was 
detected in all 3 registries: US: 29.3 % versus 50.6 % on CSII, OR 0.403 [0.369 
- 0.441]; Austria/Germany: 30.9 % versus 41.9 %, OR 0.621 [0.580 - 0.664] 
and UK: 8.1 versus 14.8 % on CSII, OR 0.507 [0.446-0.577].
Conclusion: Even after taking differences among age, gender and duration 
of diabetes among the registries into account, the use of CSII in children and 
adolescents differs markedly between the US, central Europe and the UK, 3 
wealthy regions of the world. However, in all 3 registries, minority youth are 
significantly less likely to be treated with CSII. The reasons for this are likely 
to be complex, including health beliefs/acceptance of technology, patient se-
lection by treatment facilities, including potential language barriers relevant 
for (technical) patient education, which is more demanding for CSII therapy. 
In addition, financial aspects, such as differences in availability of health in-
surance or reimbursement of CSII therapy, may play a role. In order to pro-
vide access to modern diabetes therapy irrespective of social background, 
more research into barriers to CSII use for minority youth in different socie-
ties is required.
Supported by: Competence net Diabetes mellitus; HQIP; Helmsley trust
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Cardiovascular outcomes and their relationship to risk factors and 
baseline disease over 4 years when starting insulin in type 2 diabetes: the 
CREDIT study
W. Scherbaum1, N. Freemantle2, F. Calvi-Gries3, N. Danchin4, M. Vincent5, 
P. Home6;  
1Heinrich-Heine-University, University Hospital Düsseldorf, Germany, 
2University College London, UK, 3AtlanStat, Rezé, France, 4Université Paris 5, 
5Sanofi, Paris, France, 6Newcastle University, Newcastle upon Tyne, UK.
Background and aims: To evaluate the relationship between risk factors/dis-
ease at baseline and adverse cardiovascular (CV) outcomes over 4 years from 
starting insulin therapy in people with type 2 diabetes (T2DM) in routine 
clinical practice in Europe, Canada, and Japan.
Materials and methods: CREDIT (Cardiovascular Risk Evaluation in peo-
ple with Type 2 Diabetes on Insulin Therapy) was a noninterventional study 
of people with type 2 diabetes beginning insulin therapy in Europe, North 
America, and Asia. Data from people with T2DM starting any insulin were 
collected in 12 countries over 4 years (± 6 months). Candidate explanatory 
variable for MACE+ (defined in Table) were age, sex, BMI, previous diagnosis 
of high blood pressure (BP), family history of premature CV disease, level of 
physical activity, smoking status, macrovascular disease, microvascular dis-
ease, HbA1c when starting insulin, and number of noninsulin antidiabetic 
treatments, first insulin regimen, time from diagnosis of T2DM, insulin dose 
(U/kg), systolic BP, diastolic BP, heart rate, antihypertensive treatment, an-
tiplatelet/anticoagulant treatment, and statin/fibrate treatment. These vari-
ables were conditioned for multivariable survival analyses using a stepwise 
reduction process with forced inclusion of HbA1c. This enabled the estimate 
of the relationship between the variables and time to a composite of blindly 
adjudicated CV events.
Results: When starting insulin, participant characteristics (51% male) in-
cluded median age of 61 years, 9.3 % HbA1c (78 mmol/mol), and 9.0 years’ 
duration of diabetes. Survival models were based on 286 events in 2974 peo-
ple. First insulin regimen and starting HbA1c were not predictive factors. The 
final multivariable Cox model included, as independent factors for MACE+, 
male gender, longer duration of diabetes, prior or current macrovascular 
disease, use of antihypertensive or of antiplatelet/anticoagulant medications, 
and lack of physical activity (Table).
Conclusion: Strong relationships were found between baseline factors and 
CV outcomes in people with T2DM starting insulin, after accounting for 
a number of explanatory characteristics. Evidence of CV disease at start of 
therapy (identified as prior macrovascular disease or use of antihypertensive/
antiplatelet/anticoagulation therapy) was strongly predictive of a MACE+ 
event. Being physically active or being female was shown to have a strong 
protective effect for MACE+. 
Supported by: Sanofi
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Adherence to insulin treatment in insulin naive type 2 diabetic patients: 
results of telephonic intervention
D. Gogas Yavuz1, H. Bilen2, S. Sancak3, T. Galip4, Z. Hekimsoy5, I. Şahin6,  
M. Yılmaz7, H. Aydın8, A. Atmaca9, M. Sert10, P. Karakaya11, D. Arpacı12,  
A. Oğuz13, N. Guvener14, Dropout Study Group;  
1Endocrinology and Metabolism, Marmara University School of Medicine, 
Istanbul, 2Endocrinology and Metabolism, Ataturk University School 
of Medicine, Erzurum, 3Endocrinology and Metabolism, Fatih Sultan 
Mehmet EAH, Istanbul, 4Endocrinology and Metabolism, Sakarya 
Devlet Hastanesi, Sakarya, 5Endocrinology and Metabolism, Celal Bayar 
University Medical Faculty, Manisa, 6Endocrinology and Metabolism, Inonu 
University School of Medicine, Malatya, 7Endocrinology and Metabolism, 
Namık Kemal University Medical Faculty, Tekirdag, 8Endocrinology and 
Metabolism, Yeditepe University Medical School, Istanbul, 9Endocrinology 
and Metabolism, Ondokuzmayıs University Medical Faculty, Samsun, 
10Endocrinology and Metabolism, Cukurova University Medical School, 
Adana, 11Endocrinology and Metabolism, Bakırkoy EAH, 12Endocrinology 
and Metabolism, Sakarya Devlet Hastanesi, 13Endocrinology and 
Metabolism, Medeniyet University Medical Faculty, 14Endocrinology and 
Metabolism, Baskent University Medical Faculty, Istanbul, Turkey.
Background and aims: The aim of the present study was to assess the efficacy 
of telephone support on insulin treatment adherence in insulin naive type 
2 diabetic patients using different insulin treatment regimens (basal, basal-
bolus and premix ) in third care medical centers in Turkey
Materials and methods: In this 12 week-open label randomized multi-
center study A total of 1456 insulin naive type2 diabetic patients (mean 
age 56±12yrs, diabetes duration 6,0±6 yrs, 49.1% female) were recruited 
in 14 third care endocrine centers from different city’s in Turkey. Patients 
randomized to telephonic intervention (TI) (50.3%) and control group (C )
(%49.7). Primary outcome was medication adherence.
Results: At the end of the 12th week 83.2 % of TI group and %70.3 of the 
Control group were adherent to treatment (p<0,0001). According to insulin 
treatment regimens adherence rates were %76.9,%78.6,%74,1 for Basal-Bolus 
(BB), Premix and Basal regimens respectively and insulin regimens were 
not different in TI group. While patients on premixed insulin regimen were 
more compliant to insulin treatment compared to other regimens in control 
group (p<0.001). Non adherent subjects had shorter duration of diabetes and 
higher HbA1c levels compared to adherent subjects in the whole study group 
(p<0.01). Multivariate analysis indicate that illiterates, unwillingness to ther-
apy are the independent risk factors for decreased adherence to insulin thera-
py. Noncompliance rates for daily insulin injections were 27%,15%,15.8% for 
basal-bolus ,premixed and basal insulin regimens respectively and was higher 
in basal bolus group compare to other insulin regimens (p<0.0001) .Reported 
dropout causes of insulin therapy were depend on patients (56.8%) ,doctors 
(24.8%) and adverse effects of insulin (4.8%). Frequency of hypoglycemia 
(minor and major) were 30.5%, 34%, 11.2% for Basal-Bolus, Premixed and 
Basal regimens respectively (p<0.0001).
Conclusion: Telephonic intervention increases adherence and compliance to 
insulin treatment in insulin naive type 2 diabetic patients. Telephone com-
munication between diabetes management team and diabetic patients could 
be considered as a part of routine follow up procedure in diabetes treatment
942
Trajectories of HbA1c after initiation of insulin therapy in  
type 2 diabetes mellitus patients
R. Mast1, I. Walraven1, T. Hoekstra1, D. Jansen1, A.A.W. van der Heijden1, 
P.J.M. Elders1, R.J. Heine2, J.M. Dekker1, J.G. Hugtenburg1, G. Nijpels1;  
1EMGO Institute for Health and Care Research, VU University Medical 
Center, Amsterdam, Netherlands,  
2Eli Lilly and Company, Indianapolis, USA.
Background and aims: ADA/EASD guidelines for the management of type 
2 diabetes mellitus (T2DM) recommend HbA1c levels of ≤ 53 mmol/mol. 
About 25% of all T2DM patients initiate insulin to reach this target. How-
ever, trajectories of the HbA1c levels after initiation of insulin have never 
been described and not much is known about characteristics associated with 
reaching and sustaining the HbA1c target. The aim of the current study was 
to identify subgroups of T2DM patients with distinct HbA1c trajectories after 
the start of insulin treatment and factors associated with reaching and sus-
taining the target HbA1c level ( ≤ 53 mmol/mol).
Materials and methods: 798 T2DM patients from the Diabetes Care System 
(DCS) cohort of 9849 T2DM patients were included. Inclusion criteria: aged 
≥ 40 year, initiated insulin during follow up after reaching a HbA1c level of 
≥ 53 mmol/mol, with a follow up ≥ 2 years. Latent Class Growth Modelling 
(LCGM) was used to identify trajectories of HbA1c after the initiation of in-
sulin. Cox regression analyses were used to determine which characteristics 
were associated with reaching and sustaining target HbA1c ≤ 53 mmol/mol.
Results: Four classes of HbA1c development were identified (figure 1). In the 
first class (3.8%) an gradual increase in HbA1c over time was seen, the second 
class (3.3%) showed a decrease in HbA1c during follow-up. The third class 
(5.1%) showed a good response to insulin treatment. The fourth class (87.8%) 
consisted of T2DM patients with stable HbA1c levels around 58 mmol/mol. 
During a mean follow-up of 4.5 years (SD 3.0), 174 patients (21.8%) reached 
and sustained the HbA1c target of ≤ 53 mmol/mol. Higher HbA1c levels at 
time of insulin initiation (HR 0.80 (95% CI 0.68 to 0.92)) and advanced age at 
baseline (HR 1.03 (95% CI 1.02 to 1.05)) were associated with reaching and 
sustaining the HbA1c target of ≤ 53 mmol/mol.
Conclusion: Less than a quarter of the patients achieved and sustained 
HbA1c levels ≤ 53 mmol/mol after insulin initiation. Low HbA1c level at 
the start of insulin, and higher age were associated with reaching the HbA1c 
target. Initiating insulin earlier, i.e. at lower HbA1c levels in T2DM patients, 
may improve the likelihood of achieving and sustaining glycemic control.
943
Four-year analysis of insulin dose and hypoglycaemia in the real-world 
treatment of type 2 diabetes: results from the CREDIT study
M. Pfohl1, N. Freemantle2, F. Calvi-Gries3, M.-P. Dain4, M. Vincent4,  
P. Home5;  
1Evangelisches Bethesda-Krankenhaus zu Duisburg GmbH, Germany, 
2University College London, UK, 3AtlanStat, Rezé, 4Sanofi, Paris, France, 
5Newcastle University, Newcastle upon Tyne, UK.
Background and aims: CREDIT (Cardiovascular Risk Evaluation in Peo-
ple with Type 2 Diabetes on Insulin Therapy) was a noninterventional study 
of people starting insulin therapy in routine clinical practice in Europe, N. 
America, and Asia and followed for 4 years (n=2272 with 4-yr data).
Materials and methods: Baseline data were collected retrospectively to avoid 
influence on choice of insulin; data were extracted from regular clinical re-
cords. For this analysis, records of symptomatic and severe hypoglycaemia 
were extracted for the 6 months prior to the 1, 2, 3, and 4-year follow-up 
intervals.
Results: Total daily insulin dose increased 25.6% from year 1 to year 4 for all 
insulin regimens as taken at times of follow-up (Table). Overall, the percent-
age of patients reporting symptomatic hypoglycaemia was 18.5% at year 1 
and 16.6% at year 4; event rates were between 0.8 and 1.5 per person across 
years and insulin regimens. Prevalence of severe hypoglycaemia was < 3.5% 
for all insulins and years (except mealtime insulin alone at year 4); event rates 
ranged from 0.0 to 0.2 per person.
Conclusion: These CREDIT study results show that regardless of insulin reg-
imen utilised (whether maintained from start or changed), total daily insulin 
dose increases over time, while symptomatic and severe hypoglycaemia were 
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relatively unchanged. Increased hypoglycaemia on insulin does not appear 
to be a necessary consequence of increased need for exogenous insulin with 
time in routine care.
Supported by: Sanofi
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Insulin treatment across Europe: results from the GUIDANCE study
R.C. Vos, G.E.H. Rutten, GUIDANCE;  
Julius Center for Health Science and Primary Care, University Medical 
Center Utrecht, Netherlands.
Background and aims: Given the increasing prevalence of type 2 diabetes 
(T2DM), insulin treatment will be needed for a growing number of patients. 
Traditionally the conversion to insulin therapy has been managed in the sec-
ondary care setting, but more and more primary care physicians are involved 
in insulin therapy. We compared insulin treated patients across eight Euro-
pean countries, stratified to treatment setting.
Materials and methods: Data were available from the medical records 
of 1960 insulin treated T2DM patients of eight European countries, from 
mainly primary care (Belgium, France, Germany, Sweden, the Netherlands) 
and mainly secondary care (Italy, Ireland, the United Kingdom) countries. 
Patients from ‘mainly primary care’ and ‘mainly secondary care’ countries 
were compared for patients variables: age, sex, duration of diabetes, HbA1c, 
BMI, micro- and macro vascular complications, type of insulin treatment; 
and service variables: access of a nurse or a dietician, physician’s number of 
T2DM patients treated, and physician’s feelings about the diabetes guidelines. 
MLwiN for binomial multilevel analysis was used to analyse the relation of 
the patient and service variables with insulin treated patients from mainly 
primary and secondary care countries.
Results: Type of insulin treatment differed across European countries; insu-
lin treated patients from mainly secondary care countries used more often 
short acting analogues (OR 2.54, 95%CI 1.89-3.43) and less often either NPH 
(OR 0.45, 95%CI 0.28-0.73), long acting analogues (OR 0.50, 95%CI 0.36-
0.68) or short acting human insulin (OR 0.59, 95%CI 0.37-0.92) compared 
to those in mainly primary care countries. Further, insulin treated patients 
from the mainly secondary care countries showed higher HbA1c levels (OR 
1.49, 95%CI 1.34-1.66) and had more often access to a dietician (OR 2.54, 
95%CI 1.89-3.43), but were less likely to have macro vascular complications 
(OR 0.65, 95%CI 0.49-0.86). No clinical relevant differences were found for 
the other variables.
Conclusion: The results of this large European cross-sectional study show 
that T2DM patients on insulin and mostly treated in a primary care setting 
in five European countries did not differ from the same category of patients 
mainly treated in outpatient clinics or hospitals in three other countries, with 
the exception of type of insulin, HbA1c and the presence of macro vascular 
complications. The decision to treat a T2DM patient in primary or secondary 
care is likely not based on clinical arguments.
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Metabolic control in type 2 diabetic patients with convential or 
intensified insulin therapy: a retrospective single centre survey over a 
period of 22 years
G. Kramer, N. Kuniss, C. Kloos, N. Mueller, A. Saemann, G. Wolf,  
U.A. Mueller;  
Dept. Internal Medicine III, University Hospital Jena, Germany.
Background and aims: The 2012 EASD/ADA position statement on man-
agement of hyperglycaemia in type 2 diabetes recommends mealtime insulin, 
consisting of one to three injections, when basal insulin has been titrated to 
an acceptable fasting glucose but HbA1c remains above target. The progres-
sion from basal insulin to a twice daily pre-mixed insulin (CT) is regarded as 
a “less studied alternative”. Multiple insulin injection therapy (MIT) is regard-
ed to be more easily adaptable to the patients needs. Therefore it is supposed 
that MIT is associated with better metabolic control and less hypoglycaemia 
compared to CT in patients with diabetes type 2 (DM2).
Materials and methods: HbA1c, insulin dose, body weight and incidence of 
non severe and severe hypoglycaemia were analysed in respect to the strategy 
of insulin therapy applied (MIT or CT). 20943 visits of 1447 insulin treated 
people with DM2 in an university outpatient department for endocrinology 
and metabolic diseases from a period of 22 years (9.1.1990 to 20.9.2012) were 
included. Data were drawn from the electronic patient record EMIL©. Be-
cause the strategy of insulin therapy changed over the long period, we com-
pared visits with CT and visits with MIT. All visits with one or two insulin 
injections were classified as CT, visits with more than two injections as MIT. 
Visits with basal insulin only were not included. Non severe hypoglycaemia 
was defined as a condition with typical symptoms (e.g., sweating, feeling 
shaky, impaired concentration) which disappeared quickly after carbohydrate 
ingestion or a plasma glucose < 2.7 mmol/l with or without typical symp-
toms. Severe hypoglycaemia was defined as necessity of intravenous glucose 
injection. All patients participated in a structured education programme at 
least once. The normal range and mean value of HbA1c changed from 1999 
to 2012, therefore we adjusted HbA1c according the mean normal value of 
healthy people to the DCC trial (5.05 %).
Results: MIT was used in 13901 (66.4 %) of all 20943 visits. Compared to 
CT these patients were younger (62.0 ± 10.1 vs. 68.7 ± 9.9 years; p < 0.0001), 
time since diabetes diagnosis was longer (16.5 ± 8.7 vs. 15.8 ± 8.1 years; p < 
0.0001), had higher BMI (32.8 ± 6.1 vs. 30.9 ± 5.3 kg/m2; p < 0.0001), a higher 
daily insulin dose (76.4 ± 52.0 vs. 46.5 ± 26.9 IU/day; p < 0.0001), and lower 
HbA1c (7.7 ± 1.4 vs. 7.9 ± 1.4 %; p < 0.0001). In MIT more non severe hy-
poglycaemic incidences per week (0.3 ± 0.7 vs. 0.2 ± 0.8; p = 0.01) occurred, 
episodes of severe hypoglycaemia/last 12 months were rare and comparable 
(0.02/Patient/year) with both insulin therapy strategies. Multiple, linear re-
gression analysis showed that the only parameter associated with HbA1c was 
the insulin dose (β = 0.222, p < 0.001). Higher HbA1c is weakly associated 
with higher daily insulin dose, but not age (β = -0.019, p = 0.471), time since 
diabetes diagnosis (β = 0.060, p = 0.023) as well as incidence of non severe 
hypoglycaemia/week (β = 0.006, p = 0.797).
Conclusion: MIT and CT insulin therapy result in comparable metabolic 
control with HbA1c below 8 %. MIT is associated with higher BMI and 
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higher incidence of non severe hypoglycemia. People with DM2 should be 
actively involved in the decision which insulin therapy to choose considering 
the life style and convenience. Therapy strategies can be swopped if necessary.
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Less nocturnal hypoglycaemia and weight gain with new insulin glargine 
300 U/ml vs 100 U/ml: 1-year results in people with type 2 diabetes using 
basal insulin and OADs (EDITION 2)
H. Yki-Järvinen1, R.M. Bergenstal2, G.B. Bolli3, M. Ziemen4, M. Wardecki5, 
I. Muehlen-Bartmer4, M. Maroccia6, M.C. Riddle7;  
1University of Helsinki, Finland, 2International Diabetes Center at Park 
Nicollet, Minneapolis, USA, 3University of Perugia, Italy,  
4Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany,  
5Sanofi, Warsaw, Poland, 6Umanis, Levallois-Perret, France,  
7Oregon Health & Science University, Portland, USA.
Background and aims: EDITION 2 investigated glycaemic control and hy-
poglycaemia using new insulin glargine 300 U/ml (Gla-300) versus glargine 
100 U/ml (Gla-100) in people with type 2 diabetes mellitus on basal insulin 
plus OAD(s).
Materials and methods: In EDITION 2, 811 adults with type 2 diabetes 
mellitus and inadequate control of HbA1c were randomised to receive either 
Gla-300 or Gla-100 for 6 months. In this 6-month open-label extension, par-
ticipants continued to receive Gla-300 or Gla-100 once daily plus OADs; 315 
(78%) participants in the Gla-300 group and 314 (77%) participants in the 
Gla-100 group completed 12 months of treatment.
Results: Improved control of HbA1c was maintained at 12 months with each 
regimen. Over 12 months, per participant-year event rates of confirmed (≤3.9 
mmol/l [≤70 mg/dl]) or severe nocturnal hypoglycaemia were 37% lower 
with Gla-300 than Gla-100 (1.74 vs 2.77, RR: 0.63 [95% CI: 0.42 to 0.96]). 
Fewer participants experienced ≥1 confirmed (≤3.9 mmol/l [≤70 mg/dl]) or 
severe nocturnal hypoglycaemic event with Gla-300 than Gla-100 (RR: 0.84 
[95% CI: 0.71 to 0.99]). Severe hypoglycaemia at any time of day was infre-
quent, experienced by 7 participants in the Gla-300 group and 6 participants 
in the Gla-100 group. Body weight increase was observed in both groups, and 
was significantly less with Gla-300 than Gla-100 (LS mean [95% CI]: 0.42 
[0.04 to 0.80] versus 1.14 [0.76 to 1.52] kg, p=0.0091). No between-treatment 
differences in adverse events were seen.
Conclusion: Over 12 months of treatment, people with type 2 diabetes mel-
litus using Gla-300 and OADs had comparable glycaemic control, and experi-
enced fewer nocturnal hypoglycaemic events and less weight gain compared 
with those using Gla-100.
Clinical Trial Registration Number: NCT01499095
Supported by: Sanofi
PS 076 Glucose variability in insulin 
treatment
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New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in 
insulin-naïve people with type 2 diabetes mellitus (EDITION 3)
G.B. Bolli1, M.C. Riddle2, R.M. Bergenstal3, M. Ziemen4, K. Sestakauskas5, 
H. Goyeau6, P.D. Home7;  
1University of Perugia, Italy, 2Oregon Health & Science University, Portland, 
USA, 3International Diabetes Center at Park Nicollet, Minneapolis, USA, 
4Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany,  
5Sanofi, Chilly Mazarin, 6EXPERIS IT, Nanterre, France,  
7Newcastle University, Newcastle upon Tyne, UK.
Background and aims: EDITION 3 studied the efficacy and safety of new in-
sulin glargine 300 U/ml (Gla-300) vs glargine 100 U/ml (Gla-100) in people 
with type 2 diabetes mellitus uncontrolled on non-insulin therapy.
Materials and methods: In this 6-month, multicentre, open-label study, 
participants were randomised to once-daily Gla-300 or Gla-100 in the even-
ing while stopping sulfonylureas. Insulin was titrated seeking FPG 4.4-5.6 
mmol/l. The primary endpoint was HbA1c change to month 6. The main 
secondary endpoint was percentage of participants with ≥1 confirmed (≤3.9 
mmol/l [≤70 mg/dl]) or severe nocturnal (00:00-05:59 h) hypoglycaemic 
event from week 9 to month 6.
Results: In total, 878 participants were randomised (baseline characteristics: 
BMI 33.0 kg/m2; diabetes duration 9.8 years; HbA1c 8.5 % [70 mmol/mol]). 
HbA1c decreased similarly with both treatments. LS mean changes (SE) were 
−1.42 [0.05] % (−15.5 [0.5] mmol/mol) with Gla-300 and −1.46 (0.05) % 
(−16.0 [0.5] mmol/mol) with Gla-100, and LS mean difference (95% CI) was 
0.04 (−0.09 to 0.17) % (0.4 [−1.0 to 1.9] mmol/mol). The relative risk of expe-
riencing ≥1 confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe nocturnal hypo-
glycaemic event with Gla-300 vs Gla-100 was 0.76 (95% CI: 0.59 to 0.99) for 
the 6-month treatment period, 0.74 (0.48 to 1.13) for baseline to week 8, and 
0.89 (0.66 to 1.20) (p=0.45) for week 9 to month 6. Using a stricter thresh-
old of <3.0 mmol/l (<54 mg/dl), relative risks of experiencing ≥1 confirmed 
or severe nocturnal hypoglycaemia were 0.59 (0.33 to 1.06) for the entire 
6-month treatment period, 0.73 (0.30 to 1.79) for the first 8 weeks of treat-
ment, and 0.61 (0.31 to 1.21) for week 9 to month 6. Rates (per participant-
year) of confirmed (≤3.9 mmol/l) or severe events at any time of day (24 h) 
were lower with Gla-300 (rate ratio 0.75 [0.57 to 0.99]) over 6 months. Severe 
hypoglycaemia was infrequent (0.9% of participants experienced ≥1 event in 
both groups). Mean weight change was +0.4 (SD 3.8) kg with Gla-300 and 
+0.7 (3.8) kg with Gla-100. No differences in adverse events were seen.
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Conclusion: In insulin-naïve people with type 2 diabetes mellitus, new insu-
lin glargine 300 U/ml provides comparable effective glycaemic control, with 
less hypoglycaemia, compared with glargine 100 U/ml.
Clinical Trial Registration Number: NCT01676220
Supported by: Sanofi.
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Similar efficacy and safety with LY2963016 insulin glargine compared 
with insulin glargine in patients with type 2 diabetes mellitus:  
the ELEMENT 2 study 
P. Hollander1, J. Rosenstock2, A. Bhargava3, L.L. Ilag4, R.K. Pollom4,  
W.J. Huster4, M.J. Prince4;  
1Baylor Endocrine Center, Dallas, 2Dallas Diabetes and Endocrine Center, 
3Iowa Diabetes and Endocrinology Research Center, Des Moines,  
4Eli Lilly and Company, Indianapolis, USA.
Background and aims: LY2963016 (LY IGlar) and insulin glargine (Sanofi-
Aventis; IGlar) are both insulin glargine products, with identical amino acid 
sequences. Even with identical primary structure, protein-based therapeutics 
manufactured by distinct processes must be shown to be clinically similar.
Materials and methods: This was a 24-week, Phase 3, randomized, double-
blind, parallel study to compare the efficacy and safety of LY IGlar and IGlar. 
The primary objective was to test the non-inferiority (0.3% margin) of LY 
IGlar to IGlar as measured by change in HbA1c from baseline to 24 weeks in 
patients with T2DM on ≥2 oral antihyperglycaemic medications (OAMs). 
Testing for non-inferiority of IGlar to LY IGlar was also performed and 
pre-specified as a complementary hypothesis, which if met along with the 
primary aim, would demonstrate equivalent efficacy between LY IGlar and 
IGlar. Patients were insulin-naïve (HbA1c ≥7.0% to ≤11.0%) or previously on 
IGlar (HbA1c ≤11.0%). Insulin-naïve patients started on 10 U/day while those 
previously on IGlar started at an equivalent dose to their prestudy IGlar dose. 
Both groups followed a patient-driven titration algorithm until fasting blood 
glucose reached ≤5.6 mmol/L. For blinding purposes, patients randomized 
to treatment were provided syringes and insulin vials contained in a partial 
cover that concealed distinguishing differences in vial appearance.
Results: Both treatment groups had within-group similarly significant 
(p<.001) decreases in mean HbA1c values (~ -1.3% [Endpoint: LY IGlar, 
7.04%; IGlar, 6.99%]). Change in HbA1c from baseline with LY IGlar was 
non-inferior to IGlar (Table). Noninferiority of IGlar to LY IGlar was also 
demonstrated; thus, criteria for equivalence in clinical efficacy between LY 
IGlar and IGlar were met. There were no treatment differences in secondary 
efficacy or safety outcomes, including hypoglycaemia and treatment-emer-
gent antibody response, in the total population and in the insulin-naïve/pres-
tudy IGlar subgroups. The treatment groups had similar mean (SD) overall 
nocturnal hypoglycaemia rate (events/patient/year) (LY IGlar: 7.46 (11.73), 
IGlar: 8.08 (14.62), p=.686) and only 2 patients per group experienced severe 
hypoglycaemia. Adverse event frequencies (LY IGlar, 52%; IGlar, 48%; p=.31) 
were similar. No treatment differences were observed in mean (SD) weight 
change (kg) at endpoint, LY IGlar: 2.09 (3.80), IGlar: 2.33 (3.39), p=.334).
Conclusion: LY IGlar compared with IGlar in combination with OAMs pro-
vided equivalent efficacy and similar safety profiles in patients with T2DM.
Clinical Trial Registration Number: NCT01421459
Supported by: Eli Lilly and Company
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Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs 
evening injections in adults with type 1 diabetes mellitus measured with 
continuous glucose monitoring (CGM)
R.M. Bergenstal1, T.S. Bailey2, D. Rodbard3, M. Ziemen4, H. Guo5,  
I. Muehlen-Bartmer4, A.J. Ahmaan6;  
1International Diabetes Center at Park Nicollet, Minneapolis,  
2AMCR Institute, Escondido, Biomedical Informatics Consultants, Potomac, 
4Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany,  
5BDM Consulting Inc., Somerset,  
6Oregon Health and Science University, Portland, USA.
Background and aims: Previous euglycaemic clamp studies in type 1 diabe-
tes (T1DM) showed that insulin glargine 300 U/ml (Gla-300) provides evenly 
distributed 24-h coverage due to low fluctuation and high reproducibility in 
insulin glargine exposure. The primary objective of this exploratory study in 
T1DM was to compare the percentage of time in the glycaemic range of 4.4-
7.8 mmol/l, utilising CGM during Gla-300 vs insulin glargine 100 U/ml (Gla-
100) treatment. HbA1c, mean glucose level, glucose variability and incidence 
of hypoglycaemia were evaluated.
Materials and methods: In this multicentre, 16-week, open-label phase 2 
study, 59 adults with T1DM (mean age 44.2 y; DM duration 22.1 y; baseline 
HbA1c 7.46 %) were randomised (1:1) to Gla-300 or Gla-100 once daily, with 
crossover between morning and evening injections. CGM data were evalu-
ated during the last 2 weeks of each 8-week study period.
Results: HbA1c was similar for Gla-300 and Gla-100 (7.02 % vs 7.17 %) at 
week 16, and mean glucose (CGM sensor glucose [SG] from week 15-16) 
was similar for Gla-300 vs Gla-100 (9.2 mmol/l vs 9.4 mmol/l). The percent-
age of time SG was within the target range 4.4-7.8 mmol/l with Gla-300 and 
Gla-100 was 32% vs 31% (LS mean, difference [95% CI] 0.75 [−3.61 to 5.12] 
%, NS). Hypoglycaemia was lower for subjects receiving Gla-300 vs Gla-100 
using SG thresholds of 3.9, 3.3, 2.8, and 2.2 mmol/l. Hyperglycaemia above 
thresholds of 10.0, 13.9, and 22.2 mmol/l was also lower. Frequency (%) of 
SG values 13.9 mmol/l for people on Gla-300 vs Gla-100 was mean (SD) 4.7 
(3.3) vs 5.4 (4.3) and 12.7 (8.0) vs 16.4 (10.5), respectively. Mean 24-h glucose 
profiles, averaging SG during the last 2 weeks of each treatment period for all 
subjects on Gla-300 or Gla-100, showed less excursion on Gla-300 (Figure). 
When morning and evening injection periods were combined, all metrics 
for within-subject glycaemic variability were consistently lower with Gla-300: 
total standard deviation was lower by 7.4%, within day variability was lower 
by 5.4%, variability between daily means was lower by 14.3% and variability 
between days for the same time of day was lower by 7.2%.
Conclusion: In 59 adults with T1DM, Gla-300 injected either in the morning 
or the evening provided similar overall glucose control and percentage time 
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in target SG range (4.4-7.8 mmol/l) vs Gla-100, with less hypoglycaemia, a 
mean glucose profile for all subjects with less glucose excursion, and lower 
within- and between-day glucose variability.
Clinical Trial Registration Number: NCT01658579
Supported by: Sanofi
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Getting the time right: is there any relationship between insulin 
administration-to-meal ingestion time interval and blood glucose 
control in type 2 diabetes?
U. Bujacz-Jedrzejczak, J. Loba, L. Czupryniak;  
Medical University of Lodz, Poland.
Background and aims: Patients treated with short-acting or premixed 
analog insulins are advised to take them immediately before a meal while 
those treated with classic human insulin are instructed to take insulin 20-30 
minutes prior to a meal. The patients find the latter piece of advice difficult to 
comply with, and whether the compliance with recommended insulin dose-
to-meal time interval (I-to-M, in minutes) has any relevance to metabolic 
control is unknown. We conducted a prospective observational study aiming 
at assessing the relationship between glucose control and mean duration of 
I-to-M.
Materials and methods: The study group consisted of 90 type 2 diabetes 
patients (mean age 64±12 years, duration of diabetes 9.4±4.7 years, HbA1c 
7.5±1.5%, BMI 30.8±4.4 kg/m2), treated with insulin twice daily (before 
breakfast and evening meal), who were asked to record the actual hours of 
insulin injections and meal initiation for 30 consecutive days for I-to-M to 
be calculated. HbA1c was measured within 10 days after recordings were 
completed.
Results: There was no correlation between HbA1c and mean I-to-M in the 
whole study group. However, in the patients treated with analog insulins 
(n=51) there was a trend to positive correlation between HbA1c and mean 
I-to-M, while in those treated with human insulins (n=39) the trend was op-
posite (Fig. 1).
Conclusion: We conclude that compliance with the recommended pre-meal 
insulin dose timing might have some, albeit minor, impact on overall glucose 
control in type 2 diabetes.
951
The impact of pure protein load on glucose levels in type 1 diabetes 
patients treated with insulin pumps
T. Klupa1,2, T. Benbenek-Klupa3, B. Matejko1, S. Mrozińska1, M. Małecki1,2;  
1Department of Metabolic Diseases, Jagiellonian University, 2University 
Hospital, Krakow, Poland, 3DiabMed Enterprise, Kraków, Poland.
Background and aims: It is well recognized that the mealtime insulin re-
quirement in type 1 diabetes (T1DM) patients is driven mostly by carbohy-
drate content and controlling it may improve glucose levels. However, it is 
uncertain whether the calculation of other food components may optimize 
glycemic control. The aim of this study was to estimate the impact of pure 
protein load on glucose levels in T1DM patients treated with personal insulin 
pumps.
Materials and methods: We examined 10 T1DM patients (6 females, 
4 males, mean age - 32.3 years, mean T1DM duration - 11.7 years, mean 
HbA1c - 6.85%) treated with insulin pump (Medtronic Paradigm 722 or Veo) 
equipped with a continuous glucose monitoring system (CGMS) option. In 
phase I of the study, baseline insulin infusion was optimized to minimize dif-
ferences in fasting glucose levels to less than 30 mg/dL between any two time 
points between 9 am and 3 pm. The procedure of optimization was based on 
a retrospective analysis of CGMS records and included increasing or decreas-
ing the rate of basal insulin infusion two hours before the observed rise or 
fall in glucose level. Then, the new settings of the basal infusion rate were re-
checked with CGMS to meet the study criteria. In phase II, the patients were 
exposed to single, pure protein load (Protifar, Nutricia) at the dose of 0.3 g/kg 
(0.34 mL of Protifar/kg dissolved in 200 mL of water) of body weight admin-
istered at 9 a.m. Such a dose of protein is an equivalent of the usual protein 
portion in a medium-size meal, based on the dietary recommendations for 
patients with diabetes (15-20% of energy). The rate of basal insulin infusion 
during protein load was the same as defined initially in phase I, no modifica-
tions or extra insulin boluses were permitted. CGMS record was performed 
in both phases, during which the patients avoided physical activity. Glucose 
patterns were defined during 6 hours of phase I (fasting) and phase II (protein 
load).
Results: Mean baseline glucose level was 119.8 and 117.6 mg/dL for Phase I 
and Phase II, respectively (p=0.68). Mean maximal glucose level was 146.4 
and 145.2 mg/dL for Phase I and Phase II, respectively (p=0.85). Mean maxi-
mal glucose level increment was similar for the entire 6-hour lasting fasting 
and protein load test (26.6 mg/dL vs. 27.6 mg/dL, respectively, p=0.78). There 
was no difference between the change in baseline vs. 6th hour glucose levels 
for the fasting state vs. protein load test (12.5 mg/dL and 19 mg/dL, respec-
tively, p=0.04). The glucose variability assessed by CGMS-based standard de-
viation of mean glucose levels was 36.4 and 37.9 mg/dL for Phase I and Phase 
II, respectively (p=0.01).
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Conclusion: The administration of a pure protein load does not seem to have 
a clinically significant impact on glucose levels in T1DM patients treated with 
insulin pumps. Thus, we do not recommend protein content counting for 
glycemic control in this group of patients.
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Effects of insulin degludec and insulin glargine on day-to-day fasting 
blood glucose variability in patients with type 1 diabetes
T. Nakamura1, K. Sakaguchi1, A. So1, S. Nakajima2, M. Takabe2,  
H. Komada1, Y. Okuno1, Y. Hirota1, T. Nakamura2, K. Iida2, M. Kajikawa2,  
M. Nagata2, W. Ogawa1, S. Seino3;  
1Diabetes, Metabolism and Endocrinology, Kobe University Graduate 
School of Medicine, 2Best Basal Insulin Study Group, Kobe,  
3Molecular and Metabolic Medicine, Kobe University Graduate School of 
Medicine, Japan.
Background and aims: Insulin degludec (IDeg), a novel ultra-long acting 
insulin analogue, has been suggested to have a longer and flatter glucose-
lowering effect than insulin glargine (IGlar). It is thus possible that IDeg 
yields lower glycemic variability, in particular at fasting state. We have com-
pared the effects of IDeg and IGlar on day-to-day variability of fasting blood 
glucose (FBG) in type 1 diabetes subjects treated with basal-bolus insulin 
injections.
Materials and methods: This open-label, multicenter, randomized crossover 
trial investigated the effects of 4-week basal-bolus insulin treatment with ei-
ther IDeg or IGlar as a basal insulin. Patients who were found to satisfy the 
inclusion criteria were randomly allocated IGlar (first period) / IDeg (sec-
ond period) or IDeg (first period) / IGlar (second period) groups. The last 
week of each treatment period was the data-collecting phase during which 
the patients were directed to examine blood glucose level 7 times per day. 
The level of glycoalbumin was measured at the end of each treatment period. 
The primary end point was the standard deviation (SD) and the coefficient of 
variation (CV) of FBG during the last week of the treatment period. Second-
ary end points included the level of glycoalbumin, the dose of daily insulin, 
the intra-day variability of blood glucose level, and the frequency of severe 
hypoglycemia. Data are shown as means ± SD, and were statistically analyzed 
with the paired t-test.
Results: Thirty-six randomized subjects (17 in the IDeg/IGlar and 19 in the 
IGlar/IDeg groups) were recruited, and the data of 32 subjects who com-
pleted the trial were analyzed (age: 57.4 ± 13.9 years, BMI: 22.6 ± 3.2 kg/m2, 
HbA1c: 7.4 ± 0.8 %). The mean (139.5 ± 31.8 vs. 154.2 ± 37.2 mg/dL, P = 0.03) 
and the SD (46.9 ± 17.5 vs. 57.5 ± 24.6 mg/dL, P = 0.02) of FBG were smaller 
during the IDeg treatment period than those during the IGlar treatment pe-
riod whereas the CV was not different between the two periods (IDeg 34.3 
± 13.3 vs. IGlar 37.1 ± 13.0 mg/dL, P = 0.29). The level of glycoalbumin was 
similar in the two treatment periods (IDeg 21.5 ± 3.0 vs. IGlar 21.8 ± 3.6 mg/
dL, P = 0.39). The daily dose of basal insulin in the IDeg period was slightly 
but significantly smaller than that in the IGlar period (IDeg 11.0 ± 5.2 vs. 
IGlar 11.8 ± 5.6 units/day, P <0.01). The SD of the 7 measurements of blood 
glucose was similar in the two treatment periods (IDeg 56.4 ± 15.3 vs. IGlar 
61.0 ± 16.9 mg/dL, P = 0.19). No severe hypoglycemia was observed during 
the trial period.
Conclusion: In patients with type 1 diabetes, IDeg yielded lower FBG levels 
with lower day-to-day variability of FBG as compared to IGlar. IDeg is thus 
a useful option for the supplementation of basal insulin in type 1 diabetes.
Clinical Trial Registration Number: UMIN000009965
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Low within- and between-day variability in exposure to new insulin 
glargine 300 U/ml
R.H. Becker1, I. Nowotny1, L. Teichert1, K. Bergmann1, C. Kapitza2;  
1Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany,  
2Profil, Neuss, Germany.
Background and aims: Low fluctuation and high reproducibility in exposure 
are needed for effective and safe basal insulin use.
Materials and methods: Fifty people with type 1 diabetes mellitus underwent 
two 24-h euglycaemic clamps in steady state conditions after 6 QD adminis-
trations of 0.4 U.kg−1 in a double-blind, randomised, two-way crossover study 
demonstrating equivalence in bioavailability of new insulin glargine 300 
U.ml−1 (Gla-300) formulations (R, standard cartridge; T, vial formulation). 
Serum insulin (INS) concentration was analysed by radioimmunoassay.
Results: The INS-AUC point estimate of T/R was 1.00 (90% CI: 0.95 to 1.06). 
Due to low fluctuation in INS-concentration over time (Table), median cu-
mulative exposure (INS-AUCt/INS-AUC24) developed linearly over 24 h, and 
excursion (BDE = [Cmax − Cmin]/2) from the average concentration within 24 
h (CAVG = INS-AUC24/24) was only 3.3 µU.ml
−1. Within-day variability (fluc-
tuation; peak-to-trough ratio [PTR] = Cmax/Cmin) was <2. SWING ([Cmax − 
Cmin]/Cmin = PTR-1) and peak-to-trough fluctuation (PTF = [Cmax − Cmin]/
CAVG) were <1. Between-day variability (reproducibility; within-subject coef-
ficient of variation for exposure, CV% [INS-AUC]), was 17.4% (90% CI: 14.9 
to 21.1), at a between-subject CV% (INS-AUC) of 34.8% (90% CI: 28.8 to 
43.4).
Conclusion: Gla-300 appears suitable for safe, effective basal insulin use, 
providing evenly distributed 24-h coverage at a clinically relevant dose of 0.4 
U.kg−1 due to low fluctuation and high reproducibility in insulin glargine ex-
posure. 
Clinical Trial Registration Number: NCT01838083
Supported by: Sanofi.
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Simulating the glycaemic impact of meal insulin dose determinations 
using continuous glucose monitoring vs self-monitored blood glucose
D. Price1, S. Nandagopalan2;  
1Dexcom, Carlsbad, 2San Jose, USA.
Background and aims: Current continuous glucose monitoring (CGM) sys-
tems are labeled as adjunctive to self- monitored blood glucose (SMBG). The 
user guides provide instructions that diabetes management decisions should 
be based on blood glucose values. However, there are many anecdotes and 
emerging data that some CGM users make their dosing decisions based on 
the CGM data. This Monte Carlo simulation compares the impact of deter-
mining a pre-meal insulin dose using CGM and SMBG glucose on the fre-
quency of post-meal hypoglycemia (< 70 mg/dL, 3.8 mmol/L) and hypergly-
cemia (> 180 mg/dL, 10.0 mmol/L).
Materials and methods: The dose is calculated from pre-meal glucose and 
estimated carbohydrate (CHO) count and targets a post-meal glucose of 100 
mg/dL (5.6 mmol/L), allowing CGM users an adjustment based on the direc-
tion and rate of glucose change (ROC). The study quantifies the impact of 
this adjustment at different magnitudes of CHO counting errors and assumes 
correct dosing parameters. The evaluation is based on simulated patient data 
across ranges of pre-meal glucose (50 to 400 mg/dL, 2.8 to 28 mmol/L), ROC 
(-4 to 4 mg/dL/minute, -0.2 to 0.2 mmol/L/minute) and CHO (30 to 100 
grams). The dose and post-meal glucose are calculated using a simplified but 
realistic model and allows comparison of hypoglycemia and hyperglycemia 
frequencies for the two monitoring methods. The model considers the dif-
ferences in device accuracy and precision. However, it does not consider the 
impact of outlier glucose values (from either SMBG or CGM) or include the 
use of CGM alerts.
Results: Both methods perform similarly when ROC is close to 0. With 
CGM, the frequency of hypoglycemia and hyperglycemia changes little 
across the ROC range. At negative values of ROC, SMBG results in a higher 
frequency of hypoglycemia and a lower frequency of hyperglycemia, com-
pared to CGM. The opposite is true at positive ROC. As CHO error increases, 
so does the frequency of hyperglycemia and hypoglycemia, and the differ-
ences between dosing decisions using CGM and SMBG are minimized.
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Conclusion: Similar to carbohydrate counting errors, the direction and ROC 
at the time of the insulin dose can have major impacts on subsequent rates 
of hypoglycemia and hyperglycemia. Accordingly, in order to optimize glyce-
mic control, the direction and ROC should be considered when determining 
a meal insulin dose. This model suggests that using CGM data to determine a 
dose has glycemic advantages relative to using a static SMBG measurement.
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Least glucose variability is observed with the combination of a GLP-1 
agonist and basal insulin among four commonly used insulin regimens 
in type 2 diabetes (VARIATION study)
H.S. Bajaj1, R. Aronson2, C. Ye3, K. Venn2, A.L. Patrick2;  
1LMC Diabetes & Endocrinology, Brampton, 2LMC Diabetes & 
Endocrinology, Toronto, 3McMaster University, Hamilton, Canada.
Background and aims: The majority of insulin management trials to date 
have focused on HbA1c as the primary measure of glycemic control. Limited 
data pertaining to glucose variability with various insulin regimen exists in 
the literature. This cohort study compares glucose variability in patients with 
well-controlled type 2 diabetes (DM) among four commonly-used insulin 
regimen (A= basal insulin + oral drugs, B= basal insulin + GLP-1 agonist, C= 
pre-mix insulin and D= basal-bolus insulin).
Materials and methods: Eighty patients were recruited from five of our dia-
betes clinics in Ontario, Canada between November 2013 and March 2014. 
Study inclusion criteria were 1. type 2 DM; 2. age between 18 to 80 years; 3. 
BMI ≤ 45 kg/m2; 4. stable insulin regimen for a minimum of 6 months; 5.clin-
ically stable HbA1c value of ≤7.5% within 3 months before study enrolment. 
Participants were instructed to follow usual diet and exercise regimen dur-
ing the 6-day, masked Continuous Glucose Monitoring (CGM) period. Daily 
glucose standard deviation (SD) was chosen as the primary outcome for the 
study. Six patients were excluded from analysis (three for clinical instability; 
three for missed medication doses during 6-day CGM period).
Results: Key baseline clinical characteristics as well as CGM results are pre-
sented in Table 1. Each of the four study cohorts had an average HbA1c of 
7.0%. Statistically significant differences were observed on inter-cohort com-
parisons on Analysis of Covariance (ANCOVA) modeling - with the lowest 
SD observed in cohort B compared to cohorts C and D (1.8 mmol/L vs. 2.1 
and 2.2 mmol/L; p=0.05 and 0.01, respectively). SD of cohort B was also nu-
merically less compared to that for cohort A (2.0 mmol/L), however this did 
not reach statistical significance (p=0.15). Self- reported hypoglycemia epi-
sodes during the 6- day study period were highest among cohort D compared 
to the other three cohorts (p=0.01 vs. cohorts A & B; p=0.03 vs. cohort C). 
No other statistically significant differences were observed on inter-cohort 
comparisons for CGM measurements (frequency, duration and degree of hy-
poglycemia or hyperglycemia).
Conclusion: Among patients with Type 2 DM who have well-controlled 
HbA1c on insulin, least glucose variability is observed in the combination 
regimen using basal insulin with a GLP-1 agonist. This reduced glucose vari-
ability with GLP-1 agonists suggests their complementary glycemic action 
with basal insulin and is explained by known mechanisms of action for this 
incretin-based injectable medication class - with multi-pronged effects on 
both alpha and beta cells in the pancreas as well as appetite suppression.
956
Sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin 
(EMPA) in type 1 diabetes (T1D): impact on diurnal glycaemic patterns
B.A. Perkins1, D.Z. Cherney2, H. Partridge1, N. Soleymanlou3,  
H. Tschirhart1, B. Zinman1, R. Mazze4, N. Fagan5, S. Kaspers6, H.J. Woerle6, 
U.C. Broedl6, O. Johansen7;  
1Department of Medicine, Division of Endocrinology, University of Toronto, 
2Department of Medicine, Division of Nephrology, Toronto General 
Hospital, University of Toronto, 3Boehringer Ingelheim Canada Ltd./Ltée, 
Burlington, Canada, 4International Diabetes Center, Park Nicollet Institute, 
Minneapolis, 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA, 
6Boehringer Ingelheim, Ingelheim, Germany,  
7Boehringer Ingelheim Norway KS, Asker, Norway.
Background and aims: We recently reported improved glycemic control, de-
creased hypoglycemia incidence, and reduced insulin dose in T1D patients 
treated with open-label EMPA. To further characterize the effects, we ana-
lysed glucose patterns by continuous glucose monitoring (CGM).
Materials and methods: In this 8-week single-arm open-label pilot study of 
EMPA (NCT01392560), we compared ambulatory glucose profiles (AGP) 
during 2-week intervals in a placebo run-in, end-of-treatment, and post-
treatment period. Glucose exposure was measured by total area under the 
curve (AUCTOTAL in mg/dL∙h), AUCNIGHT (23:00 to 6:59h) and AUCDAY (7:00 
to 22:59h). Glucose Variability was represented by inter-quartile range and 
Glucose Stability by the average hourly absolute change (in mg/dL/hr) of all 
CGM readings in the 2-week periods.
Results: 40 patients aged 24±5 years, and A1c 8.0±0.9% completed the 
trial. 39 patients had data available for the analysis of the CGM endpoints. 
Though A1c decreased (8.0±0.9% to 7.6±0.9%, p<0.0001), AUCTOTAL de-
creased non-significantly from 153.7±25.4 to 149.0±30.2 mg/dL∙h (p=0.31) 
and increased post-treatment (164.1±29.5 mg/dL∙h, p=0.02 vs. baseline). The 
trend of decrease in AUCNIGHT (152.0±36.6 to 141.9±34.4 mg/dL∙h, p=0.13) 
exceeded AUCDAY (154.5±24.5 to 152.6±30.4 mg/dL∙h, p=0.65). Glucose 
Variability showed a decreasing trend (from 83.1±18.9 to 75.6±28.6 mg/dL, 
p=0.06) more than Glucose Stability (from 10.8±3.6 to 10.3±4.5 mg/dL/h, 
p=0.51), and subsequently levels increased relative to pre-treatment levels 
(89.3±19.3, p=0.04 and 11.8±3.7, p=0.08) when EMPA was discontinued. The 
on-treatment changes occurred despite basal insulin reduction (25.7±10.6 
to 19.5±7.9U, p<0.0001) without significant bolus reduction (29.0±15.8 to 
27.0±14.2U, p=0.19).
Conclusion: The improved A1c observed with EMPA was associated with 
a pattern of improved night-time glycemia more prominent than daytime.
Clinical Trial Registration Number: NCT01392560
Supported by: Boehringer Ingelheim
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A single dose pharmacokinetic study of basal insulin peglispro  
in subjects with hepatic impairment
S.L. Choi1, C. Loghin2, P. Garhyan3, M.P. Knadler3, E. Lam1, V. Sinha4,  
N. Porksen3, H. Linnebjerg3;  
1Eli Lilly-NUS Centre for Clinical Pharmacology, Singapore,  
2Clinical Pharmacology, Eli Lilly and Company, Indianapolis,  
3US Endocrinology/Diabetes Care, Eli Lilly and Company, Indianapolis, 
4Office of Clinical Pharmacology, Center for Drug Evaluation and Research, 
Silver Spring, USA.
Background and aims: Basal insulin peglispro (BIL; LY2605541) is being 
developed for the treatment of type 1 and type 2 diabetes mellitus (T2DM) 
as a once daily subcutaneous (SC) administration. BIL is a novel, PEGylated 
insulin lispro that has a large hydrodynamic size. It has prolonged duration 
of action which is related to a delay in insulin absorption and a reduction 
in clearance. The patient population may include those with hepatic impair-
ment, so the pharmacokinetics (PK) of BIL was assessed in subjects with 
varying degrees of hepatic impairment compared to healthy subjects with 
normal hepatic function.
Materials and methods: In this parallel-group, open-label study, 35 subjects 
received a single SC dose of 0.33 U/kg (0.075 mg/kg) BIL and blood samples 
for PK were taken up to 9 days postdose. BIL PK was determined using a spe-
cific, validated enzyme-linked immunosorbent assay method. PK parameters 
were calculated using noncompartmental analyses. The effect in subjects with 
hepatic impairment was compared to subjects with normal hepatic function 
using the ratio of least squares (LS) geometric means of primary PK param-
eters: area under the concentration time curve from zero to infinity (AUC[0-
∞]) and maximum observed drug concentration (Cmax). AUC(0-∞) and Cmax 
were log transformed and analyzed using an Analysis of Variance model with 
group as a factor.
Results: In total, 35 subjects were assessed (12 with normal hepatic func-
tion; 8 mild, 8 moderate, 7 severe hepatic impairment, based on the Child-
Pugh criteria). Subjects were nondiabetic, apart from one subject with T2DM 
(moderate hepatic impairment). Subjects were male (57%) and female (43%), 
41-69 years old, with mean body mass index (SD) 27.7 kg/m2 (4.52 kg/m2). 
Healthy subjects were matched to hepatically impaired subjects for age (±10 
years), weight (±10 kg), and gender. Ratios of the LS geometric means and 
90% confidence intervals (CIs) for AUC(0-∞) for mild, moderate, and severe 
hepatically impaired subjects to the healthy subjects were 0.789 (0.556, 1.12), 
0.744 (0.525, 1.06), and 0.782 (0.543, 1.12), respectively. Ratios (90% CIs) for 
Cmax were 0.728 (0.398, 1.33), 0.905 (0.495, 1.65), and 0.840 (0.448, 1.58), re-
spectively. Median time of Cmax and mean half-life were similar between the 
hepatically impaired subjects and healthy subjects. Healthy subjects reported 
7 treatment emergent adverse events (TEAEs) (5 of 12 subjects; 41.7%) and 
hepatically impaired subjects reported 7 TEAEs (1 TEAE reported by 1 of 8 
[12.5%] mild; 3 TEAEs reported by 2 of 8 [25.0%] moderate, and 3 TEAEs 
reported by 2 of 7 [28.6%] severe). The majority of TEAEs were mild in sever-
ity. TEAEs experienced by >1 subject included hypoglycemia, nausea, fatigue, 
and headache.
Conclusion: Single doses of BIL were well tolerated by hepatically impaired 
and healthy subjects in this study. A substantial overlap of AUC(0-∞) and 
Cmax was observed across all groups. Although the mean AUC(0-∞) and Cmax 
were lower in hepatically impaired subjects, the ratios between hepatically 
impaired and healthy subjects were not statistically different. Based on data 
from this study, requirement for dose adjustment of BIL in subjects with he-
patic impairment would not be anticipated.
Clinical Trial Registration Number: NCT01751399
Supported by: Eli Lilly and Company
 
958
Conventional insulin therapy (CT) vs multiple insulin injection (MIT)  
in type 2 diabetes: analysis of a quality assurance project (DPV)
C.S. Kloos1, G. Kramer1, U.A. Müller1, R. Schiel2, S. Hofer3, S. Merger4,  
W. Kerner5, R.W. Holl6;  
1Internal Medicine, Klinikum für Innere Medizin III, Jena,  
2Medigreif Inselklinik Heringsdorf, Germany, 3Medical University of 
Innsbruck, Austria, 4Pediatric Department, University Ulm,  
5Karlsburg Hospital, 6Institute for Epidemiology and Medical Biometry, 
Ulm, Germany.
Background and aims: People with type 2 diabetes and insulin therapy re-
ceive predominantly an intensive form of insulin treatment with multiple in-
sulin injections (MIT). Evidence from randomized studies for the superiority 
of MIT over CT in type 2 diabetes is lacking, but MIT produced increased 
weight gain, higher costs of therapy and more hypoglycaemic episodes. This 
survey provides data from a project of quality assurance in Germany and 
Austria (DPV) with documentation of insulin treatment in type 2 diabetes.
Materials and methods: Patients older than 18 years with type 2 diabetes and 
insulin treatment were extracted from the DPV database. CT was defined as 
2 insulin injection time-points per day, MIT as more than 2 insulin injection 
time-points per day. Patients with less than 2 daily insulin injection time-
points and patients with LADA (positive ß-cell antibodies) were excluded 
from the analysis. Patients with insulin therapy and Metformin as concomi-
tant therapy were included, but not evaluated separately.
Results: A total of 88 519 (CT 23 118 (26%); MIT 65 401 (74%)) patients were 
analysed. Patients with CT (44% male) compared to patients with MIT (53% 
male) were older (74.6 (10.2) vs. 66.7(12.0) years), had comparable time from 
diabetes diagnosis (13.0 (9.5) vs. 13.4 (9.8) years), lower BMI (29.1 (5.7) vs. 
31.7 (6.7)kg/m2), lower daily insulin dose (39.2 (20.2) vs. 65.3 (41.1) IE/day) 
and better HbA1c (7.81 (1.9) vs. 8.14 (2.0)%; p<0.001; normal mean 5.05%). 
Hypoglycaemic events (per patient/year) with need for help was comparable 
in both groups (1.02 (1.07) vs. 1.06 (1.24)), hypoglyceamia with coma was 
associated more often with CT (0.051 (0.43) vs. 0.038 (0.38)).
Conclusion: In a non randomized, multicentric, observational survey with 
data derived from clincial routine care, glycaemic control of people with CT 
was comparable to people with MIT. Patients with MIT were predominently 
male, younger, had higher BMI and needed more insulin. Hypoglycaemic 
episodes had a similar incidence compared to other studies in patients with 
insulin-treated type 2 diabetes.
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Preserved pharmacokinetic properties and distinct glycaemic effects of 
insulin degludec and liraglutide in IDegLira, a fixed ratio combination 
product
C. Kapitza1, B.W. Bode2, S.H. Ingwersen3, L.V. Jacobsen3, P. Poulsen3;  
1Profil Institut fuer Stoffwechselforschung GmbH, Neuss, Germany,  
2Atlanta Diabetes Associates, USA, 3Novo Nordisk A/S, Søborg, Denmark.
Background and aims: Insulin degludec/liraglutide (IDegLira) is a novel 
fixed ratio combination of insulin degludec (IDeg), a basal insulin with an 
ultra-long duration of action, and liraglutide (Lira), a once-daily glucagon-
like peptide-1 analogue. The pharmacokinetics (PK) and pharmacodynamics 
of IDegLira were compared with those of the mono-components in healthy 
volunteers and in subjects with type 2 diabetes.
Materials and methods: The relative bioavailability of IDegLira and its mo-
no-components were compared in a single-dose, randomised, double-blind, 
double-dummy four-period crossover clinical pharmacology study in 24 
healthy volunteers. Dose proportionality and covariate effects on exposure 
were evaluated in a population PK analysis of data from a randomised treat-
to-target phase 3 study (n=1549) in subjects with type 2 diabetes. The expo-
sure-response relationship for change from baseline in HbA1c of IDegLira 
relative to mono-components was also assessed using phase 3 data.
Results: The overall PK properties of IDeg and Lira were preserved for IDe-
gLira compared with IDeg or Lira when dosed separately. The IDeg exposure 
(area under the curve) was equivalent when dosed as IDegLira or IDeg alone. 
Lira AUC was lower when dosed as IDegLira but met the criterion for bio-
equivalence (90% CI within 0.8-1.25). Population PK analysis revealed no 
relevant deviations from dose proportionality for the components of IDeg-
Lira, and covariate effects on exposure (such as body weight) were consistent 
with previous results for IDeg and Lira. Glycaemic response to IDegLira was 
larger than that of IDeg or Lira alone, reflecting distinct glucose-lowering 
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effects of its mono-components throughout the dose/exposure range (see 
Figure).
Conclusion: The PK properties of IDeg and Lira are preserved in the IDegLi-
ra co-formulation; both mono-components contribute to glycaemic control 
across the recommended dose range.
Supported by: Novo Nordisk A/S
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Aspart pharmacokinetics in children with type 1 diabetes during closed 
loop insulin delivery: comparison between diluted (U20) and standard 
(U100) insulin strengths
Y. Ruan1, D. Elleri1, M. Tauschmann1, J.M. Allen1, M.E. Wilinska1,  
D.B. Dunger2, R. Hovorka1;  
1Wellcome Trust-MRC Institute of Metabolic Science, University of 
Cambridge, 2Department of Paediatrics, University of Cambridge, UK.
Background and aims: To compare pharmacokinetics of two different con-
centrations of insulin aspart in children aged 3 to 6 years with type 1 diabetes 
(T1D) during closed loop insulin delivery.
Materials and methods: Young children with T1D underwent an open-label, 
randomized, two-period crossover study involving two occasions in a clinical 
research facility, 2 to 6 weeks apart, from 17:00 day 1 to 8:00 day 2 with an 
evening meal consumed at 17:00. In random order, diluted (1:5 dilution with 
normal saline, 20 IU/ml) or standard strength (100 IU/ml) insulin aspart was 
administered via an insulin pump as a meal bolus and then overnight dur-
ing closed loop advised by a model predictive algorithm. Plasma insulin was 
measured every 30 to 60 min. A compartment model adopting Bayesian pa-
rameter estimation was used to measure time-to-peak of insulin concentra-
tion (tmax), insulin metabolic clearance rate (MCRI), and background insulin 
concentration (insc).
Results: Eleven children [6 male; age 5.07(range 3.75-6.96yrs); A1C 60(14)
mmol/mol; BMI sds 1.0(0.8); duration of diabetes 2.2(1.0)yrs; mean (SD); 
total daily dose 12.9(10.6,16.5)IU; fasting C-peptide 5(5,17.1)pmol/l; 
median(IQR)] participated in the study. Pharmacokinetic parameters (Table) 
were not different between the two aspart concentrations but tmax showed 
less inter-subject variability following administration of diluted aspart (SD 
8.7 vs. 14.4min; diluted vs. standard strength; P =0.047). insc but not the other 
parameters was positively correlated with total daily insulin dose (Spearman’s 
rs = 0.7; P =0.014) but not with fasting C-peptide (rs = -0.19; P = 0.39) sug-
gesting that it does not reflect residual insulin secretion.
Conclusion: Diluting insulin aspart does not change its pharmacokinetics, 
but may result in less variable absorption and could be used in young people 
with T1D undergoing closed loop insulin therapy.
Clinical Trial Registration Number: NCT01557634
Supported by: JDRF, Diabetes UK and EU FP7 SPIDIMAN project
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New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed 
dosing intervals in people with type 2 diabetes mellitus
N. Jeandidier1, M.C. Riddle2, G.B. Bolli3, P.D. Home4, R.M. Bergenstal5,  
M. Ziemen6, I. Muehlen-Bartmer6, M. Wardęcki7, L. Vinet8,  
H. Yki-Järvinen9;  
1University of Strasbourg, France, 2Oregon Health & Science University, 
Portland, USA, 3University of Perugia, Italy, 4Newcastle University, 
Newcastle Upon Tyne, UK, 5International Diabetes Center at Park Nicollet, 
Minneapolis, USA, 6Sanofi-Aventis Deutschland GmbH, Frankfurt am 
Main, Germany, 7Sanofi, Warsaw, Poland, 8EXPERIS IT, Nanterre, France, 
9University of Helsinki, Finland.
Background and aims: The smoother, more prolonged PK and PD profiles 
of new insulin glargine (300 U/ml; Gla-300) vs glargine 100 U/ml (Gla-100), 
with glycaemic control extending beyond 24 h, provide a rationale for flexible 
timing of daily injections depending on individual lifestyle. These 3-month 
sub-studies, of Gla-300 injected each evening, compared the efficacy and 
safety of using a fixed 24-h dosing interval with a flexible dosing regimen 
allowing between-injection intervals of 24 ± 3 h on at least 2 days each week.
Materials and methods: The background multicentre, 6-month, open-label 
studies compared Gla-300 vs Gla-100 in people with type 2 diabetes mellitus 
using basal + meal-time insulin (EDITION 1) or basal insulin + OADs (EDI-
TION 2). Participants (EDITION 1, N=109; EDITION 2, N=89) using Gla-
300 were randomised at month 6 to continue the fixed regimen or move to 
flexible intervals. Efficacy and safety were evaluated 3 months later (month 9).
Results: The frequency of maintaining a 24 ± 1 h interval between injections 
was ~88% with the fixed regimen and ~60% with the flexible regimen. HbA1c 
change (primary endpoint) was comparable in fixed vs flexible regimens (Ta-
ble). Percentages of participants with ≥1 hypoglycaemia at any time of day 
(24 h), or ≥1 nocturnal (00:00-05:59 h) hypoglycaemia, were also compara-
ble. Severe hypoglycaemia was experienced by only 1 participant, in the EDI-
TION 1 sub-study. There were no differences in adverse events.
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Conclusion: Occasional flexibility in timing of daily Gla-300 injections by ± 
3 h resulted in similar efficacy and safety compared with advising injections 
at a fixed time each day.
Clinical Trial Registration Number: NCT01499082, NCT01499095
Supported by: Sanofi.
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Unmet needs in HbA1c goal achievement (< 7.0%) by patients with 
type 2 diabetes mellitus treated with basal insulin: pooled randomised 
controlled trial data and real-world clinical practice data
P. Chava1, L. Blonde1, S. Brunton2, R. Zhou3, J. Meyers4, K. Davis4, M. Dalal5, 
A. DiGenio6;  
1Ochsner Medical Center, New Orleans,  
2University of North Carolina, Chapel Hill, 3Medpace Inc., Cincinnati,  
4RTI Health Solutions, Research Triangle Park, 5Sanofi US, Inc., Bridgewater, 
6Isis Pharmaceuticals, Inc., Carlsbad, USA.
Background and aims: Despite the efficacy of basal insulin therapy in pa-
tients with type 2 diabetes mellitus (T2DM), many patients do not reach 
glycaemic goals. Here we use both randomized clinical trial (RCT) data and 
“real-world” data from a retrospective study of electronic medical records 
(EMR) to assess the characteristics of T2DM patients who do not achieve 
target glycaemic control while on basal insulin (HbA1c ≥ 7.0%) in order to 
better understand the clinical characteristics of these patients.
Materials and methods: Patients with T2DM aged ≥ 18 years treated with 
basal insulin, but with HbA1c ≥ 7.0% were identified by analysing results from 
11 RCTs at 6 months after the index date, defined as date of first prescrip-
tion for basal insulin, and results from the GE Centricity EMR database at 
6-months and at 12-months follow-up after the index date. Patients were 
stratified based on fasting plasma glucose (FPG) levels (< 130 or ≥ 130 mg/
dL). Information on patient demographic and clinical characteristics were 
available from both sources of data.
Results: The table shows that in the RCTs around 52% achieved HbA1c < 
7.0% (recommended by the ADA for most diabetic patients). HbA1c < 7.0% 
was achieved by fewer patients (~27%) in the EMR database at both 6 and 12 
months. Among those with HbA1c ≥ 7.0%, 54.9% of RCT patients and 17.6% 
and 27.7% of EMR patients at 6 and 12 months, respectively, had FPG < 130 
mg/dL. About half of the RCT patients not achieving goal had a FPG ≥ 130 
mg/dL. This suggested that these patients needed further basal insulin titra-
tion, whereas patients at goal likely required postprandial glucose control. 
In the EMR cohort, > 70% of patients were likely to need additional basal 
insulin titration.
Conclusion: Failure to adequately titrate basal insulin is an unmet need in 
many T2DM patients, which is evident even in RCTs. When basal insulin is 
adequately titrated and FPG is controlled, additional postprandial treatment 
may be needed. Another important unmet need is understanding the causes 
of failure to achieve control of FPG with basal insulin.
Supported by: Sanofi US, Inc.
963
New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in 
a meta-analysis of phase 3a EDITION clinical trials in people with  
type 2 diabetes mellitus
R.A. Ritzel1, R. Roussel2, G.B. Bolli3, L. Vinet4, H. Yki-Järvinen5;  
1Klinikum Schwabing, Städtisches Klinikum München GmbH, Germany, 
2Assistance Publique Hôpitaux de Paris, Bichat Hospital, France,  
3University of Perugia, Italy, 4EXPERIS IT, Nanterre, France,  
5University of Helsinki, Finland.
Background and aims: The EDITION 1, 2 and 3 studies compared the effi-
cacy and safety of new insulin glargine 300 U/ml (Gla-300) with insulin glar-
gine 100 U/ml (Gla-100) in people with type 2 diabetes mellitus on basal and 
mealtime insulin, basal insulin and OADs, and no prior insulin, respectively. 
A meta-analysis of these studies was conducted to study efficacy and safety.
Materials and methods: Meta-analysis of these three studies enabled glycae-
mic control and hypoglycaemia to be examined over 6 months in a large, 
heterogeneous type 2 diabetes mellitus population (Gla-300, N=1247; Gla-
100, N=1249).
Results: Mean change in HbA1c was comparable for Gla-300 and Gla-100 (LS 
mean change [SE]: −1.02 [0.03] % for both groups). Gla-300 was associated 
with reduced risk of experiencing hypoglycaemia compared with Gla-100 
(nocturnal and at any time of day; Table). Nocturnal hypoglycaemic event 
rates were consistently lower with Gla-300 than Gla-100. Severe hypogly-
caemia was rare in both treatment groups (2.3% with Gla-300 vs 2.6% with 
Gla-100). Weight gain with Gla-300 and Gla-100 was slight (LS mean change 
[SE]: 0.49 [0.10] kg and 0.75 [0.10] kg, respectively), with a trend for less 
weight gain with Gla-300 (LS mean difference: −0.26 [95% CI: −0.52 to 0.01] 
kg, p=0.058).
Conclusion: Gla-300 provides comparable glycaemic control to Gla-100 in 
type 2 diabetes mellitus, with consistently less hypoglycaemia at any time of 
the day and less nocturnal hypoglycaemia.
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Clinical Trial Registration Number: NCT01499082/ NCT01499095/ 
NCT01676220
Supported by: Sanofi
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Long-term efficacy and safety of insulin degludec in combination with 
bolus insulin aspart in children and adolescents with type 1 diabetes
N. Thalange1, L.C. Deeb2, V. Iotova3, T. Kawamura4, G.J. Klingensmith5,  
A. Philotheou6, J. Silverstein7, S. Tumini8, A. Ocampo Francisco9,  
O. Kinduryte10, T. Danne11;  
1Norfolk & Norwich University Hospital, Norwich, UK, 2Larry Deeb PA, 
Tallahassee, USA, 3University Hospital Sveta Marina, Varna, Bulgaria, 
4Osaka City University, Japan, 5Barbara Davis Center for Childhood 
Diabetes, Aurora, USA, 6UCT Private Academic Hospital, Cape Town, 
South Africa, 7University of Florida, Gainesville, USA, 8Ospedale „SS.
Annunziata“, Chieti, Italy, 9Novo Nordisk A/S, Søborg, 10Novo Nordisk A/S, 
Bagsværd, Denmark, 11Children‘s Hospital auf der Bult, Hannover, Germany.
Background and aims: This 1:1 randomised controlled, open-label, treat-to-
target trial investigated the efficacy and safety of insulin degludec (IDeg) and 
insulin detemir (IDet), both in combination with bolus insulin aspart (IAsp) 
in children and adolescents with type 1 diabetes for 26 weeks (n=174 IDeg; 
176 IDet) followed by a 26-week extension (n=152 IDeg; 128 IDet).
Materials and methods: The trial included 85 children aged 1-5 years (IDeg: 
43), 138 children 6-11 years (IDeg: 70) and 127 adolescents 12-17 years (IDeg: 
61). Randomised subjects [baseline mean (SD) diabetes duration 4.0 (3.5) 
years, HbA1c 8.1 (1.1)%, fasting plasma glucose (FPG) 8.7 (5.1) mmol/L], re-
ceived IDeg once daily + IAsp or IDet once/twice daily +IAsp.
Results: Non-inferiority of IDeg vs. IDet at 26 weeks was confirmed for 
HbA1c (primary endpoint): estimated treatment difference (ETD) 0.15% 
[-0.03; 0.32]95% CI (non-inferiority margin: 0.4%, p<0.05). At 52 weeks, HbA1c 
was 7.9% with IDeg and 7.8% with IDet (NS), change in mean FPG was -1.29 
mmol/L with IDeg vs. +1.10 mmol/L with IDet (ETD -1.62 mmol/L [-2.84; 
-0.41], p<0.05) and mean basal insulin dose was 0.38 U/kg (IDeg) vs. 0.55 
U/kg (IDet). Rates of confirmed hypoglycaemia (i.e., severe [altered men-
tal status, cannot assist in own care, semiconscious/unconscious, or in coma 
± convulsions] and/or plasma glucose (PG) <3.1 mmol/L) were similar for 
IDeg and IDet at 52 weeks (57.7 vs. 54.1 events/exposure year, estimated rate 
ratio (ERR): 1.11 [0.89 ; 1.38], NS), as were rates of nocturnal (11 pm - 7 am) 
hypoglycaemia; (6.0 vs. 7.6 events/exposure year, ERR 0.99 [0.72 ; 1.34], NS). 
Incidence and rates of severe hypoglycaemia tended to be higher with IDeg 
than IDet: 17.8% vs. 13.7%; 0.51 vs. 0.33 events/exposure year (ERR 1.30 
[0.64; 2.64], NS). Rates of severe hypoglycaemia, including only episodes of 
semiconscious/unconsciousness and coma ± convulsions, were 0.09 and 0.14 
for IDeg and IDet, respectively (ERR 0.62 [0.24;1.60] NS, post-hoc analysis). 
The rate of hyperglycaemic episodes with ketosis (self-measured PG >14.0 
mmol/L with blood ketones >1.5 mmol/L) was significantly lower for IDeg 
vs. IDet (0.7 vs. 1.1 events/exposure year, treatment ratio 0.41 [0.22; 0.78], 
p<0.05). Weight SD scores increased with IDeg and remained unchanged 
with IDet (change: 0.11 vs. -0.06, ETD: 0.17 [0.10; 0.25], p<0.05). Adverse 
event profiles were similar for IDeg and IDet.
Conclusion: IDeg+IAsp effectively improved long-term glycaemic con-
trol at lower dose, achieving significantly greater reduction in FPG versus 
IDet+IAsp with similar rates of overall and nocturnal hypoglycaemia and 
significantly lower rates of hyperglycaemia with ketosis. Rates of severe hy-
poglycaemia tended to be higher with IDeg than IDet. Less weight gain was 
observed with IDet. No safety issues were identified with IDeg or IDet.
Clinical Trial Registration Number: NCT01513473
Supported by: Novo Nordisk
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Injection depth does not affect the pharmacokinetics or 
pharmacodynamics of insulin lispro in healthy obese or normal weight 
subjects
K. Yeo1, A. de la Peña2, E. Catton2, D.A. Ignaut2;  
1Lilly-NUS Centre for Clinical Pharmacology, Singapore,  
2Eli Lilly and Company, Indianapolis, USA.
Background and aims: An 8-mm needle length is commonly used world-
wide, and recent recommendations suggest that using shorter, 4-, 5-, or 6-mm 
needles may be optimal for most patients to avoid intramuscular injection 
and still maintain adequate glucose control. The goal of this analysis was to 
compare the pharmacokinetics (PK) and pharmacodynamics (PD) of insulin 
lispro after administration at a 5-mm injection depth or an 8-mm injection 
depth in 2 separate populations: normal weight (Study 1) or obese (Study 2).
Materials and methods: In both open-label, randomized, 2-period crosso-
ver euglycemic clamp studies, subjects received single doses of insulin lispro 
(0.25 U/kg) on 2 different occasions; PK and PD measures were collected 
under euglycemic conditions for up to approximately 6 hours post-dose.
Results: In Study 1, 16 healthy normal weight subjects (13 male; age 31±9 
years; BMI=23±2 kg/m2) were dosed at a 5-mm and an 8-mm injection depth 
on 2 separate occasions. In Study 2, 16 healthy obese subjects (11 male; mean 
age 41±11 years; BMI=34±3 kg/m2) were also dosed at a 5-mm and an 8-mm 
injection depth. In both studies, PK parameters [AUC(0-tlast), AUC(0-∞), 
and Cmax] and PD parameters (Gtot, Rmax) were log-transformed prior to 
analysis using a mixed effects model. The table shows PK and PD parameters 
for both studies.
Conclusion: There were no statistical differences in PK or PD of insulin lis-
pro following administration at the 5-mm injection depth or 8-mm injection 
depth in either study. Injection depths in the 5-8 mm range did not affect the 
PK or PD of insulin lispro in either normal weight or obese subjects. These 
observations are consistent with clinical data in pediatric, adult, and obese 
patients with type 1 and type 2 diabetes mellitus, where the 5-mm needle was 
found to be as efficacious and safe as an 8-mm needle.
966
Development of a clinical predictive score for requirement of 
hypoglycaemic agents for optimal control of blood glucose during 
glucocorticoid treatment
H. Morita1, M. Yamauchi1, I. Mori1, T. Ikeda1, Y. Kitada2, K. Taguchi3,  
K. Fujioka3, H. Okada4, T. Usui5, M. Kawashima1, K. Kajita1, T. Ishizuka3;  
1Department of General Internal Medicine, Gifu University Graduate 
School of Medicine, 2Department of General Internal Medicine, Hashima 
City Hospital, 3Department of General Internal Medicine, Gifu Municipal 
Hospital, 4Department of General Medicine, Gifu Prefectural Central 
Medical Center, 5Department of General Medicine, Japanese Red Cross Gifu 
Hospital, Japan.
Background and aims: Long-term glucocorticoid (GC) treatment may be 
necessary for patients with various autoimmune diseases. The highest dose of 
GC is usually administered at the Initiation of the therapy, which often causes 
hyperglycemia and needs hypoglycemic agents in some patients. The aim of 
the present study is to elucidate risk factors related to GC-induced hypergly-
cemia and to develop a simple method to predict in advance the requirement 
of hypoglycemic agents to achieve optimum control of blood glucose during 
GC treatment.
Materials and methods: We retrospectively evaluated 230 patients (57±19 
years, 57% of whom were women) with autoimmune diseases admitted be-
tween 2004 and 2013 in our department to develop a predictive scoring sys-
tem. Inclusion criteria indicated that the dosage of prednisolone treatment 
should be more than 5 mg/day for 4 weeks at least. Exclusion criteria included 
use of hypoglycemic agents before GC administration or concomitant use of 
anti-cancer drugs.
Results: Forty-three percent (Ninety-nine persons) of GC-administered pa-
tients required hypoglycemic agents (19% for oral hypoglycemic agents, 5% 
for a GLP-1 analog or 20% for insulin). A logistic regression analysis revealed 
that risk factors of requirement of hypoglycemic agents during GC adminis-
tration should be raised in accordance with age and fasting plasma glucose 
(FPG). A ROC analysis showed that cutoff values of age and FPG were 58 
years old and 101 mg/dl, respectively. We scored patient profiles as follows: 0 
point for FPG less than 101 mg/dl and age less than 58 years old, 1 point for 
FPG more than 101 mg/d and age more than 58 years old, respectively. Mean 
of the sum of the points was 1.27 for patients requiring hypoglycemic agents 
and 0.64 for others, respectively. The percentages of patients requiring hypo-
glycemic agents in the sum of each point were 17% (12 / 72) at 0 point , 45% 
(48 /106) at 1 point and 75% (39 /52) at 2 points, respectively. The sensitivity 
and specificity were 87.9% and 45.8%, respectively, when 1 point was defined 
as the cut-off value of the sum of the scores.
Conclusion: Use of a scoring system composed in accordance with age and 
FPG is a simple and effective way to predict the requirement of hypoglycemic 
agents for hyperglycemia in patients treated with GC.
967
Insulin antibodies are associated with lipoatrophy in adults with  
type 2 diabetes mellitus 
K. Takahashi, A. Hakozaki, M. Narazaki, N. Takebe, Y. Ishigaki;  
Department of Diabetes and Metabolism, Iwate Medical University, 
Morioka, Japan.
Background and aims: The clinical significance of insulin antibodies (IA) 
cannot be ignored, even after the introduction of either recombinant human 
or analog insulin. Previous studies suggest potential associations of IA with 
hypoglycemia and hyperglycemia, as well as skin reactions. Furthermore, 
in recent studies, elevated IA levels were independent risk factors for coro-
nary heart disease in insulin-treated elder adults, or for retinopathy in type 2 
diabetic subjects with insulin therapy. In the subjects under insulin therapy, 
lipodystrophy, i.e. lipohypertrophy and lipoatrophy, are common problems at 
frequently injected sites. We occasionally notice that some diabetic subjects 
developing lipodystrophy tend to show high levels of IA. Indeed, strong as-
sociation of lipodystrophy with IA has been reported in children and adoles-
cents with type 1 Diabetes.Herein, we endeavored to ascertain clinical and 
immunological factors that are associated with lipodystrophy in adults with 
type 2 diabetes.
Materials and methods: Subjects were inpatients of our University Hospital. 
The study groups consisted of 40 females and 42 males, of which mean age 
was 63± 12 years, duration of diabetes 15± 8.0 years, and HbA1c 9.0± 2.2%. 
After obtaining approval from the ethics committee of the University and 
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informed consent from all subjects, blood samples were collected. IA were 
measured by RIA kits of IA with reduced non-specific bindings (Yamasa Co, 
Tokyo, Japan.) Grading of lipodystrophy was applied as follows. Grade 0: 
no lipoatrophy or lipohypertrophy at any injection site, grade 1: moderate 
lipohypertrophy without increased palpable density of subcutaneous tissue, 
grade 2: severe hypertrophy with increased density of the injection site, and 
grade 3: lipoatrophy at anyinjection site. Statistical significance was analysed 
by the Mann-Whitney U test, c2 test, or multiple linear regression analyses.
Results: Thirty-eight out of 82 subjects (46.3%) receiving current or previ-
ous therapy with recombinant human or analogue insulin were IA positive 
(percent binding 9.6± 17%). We found lipoatrophy (grade 3) of at least one 
injection site in 3 subjects, severe lipohypertrophy (grade 2) in 8 and mod-
erate lipohypertrophy (grade 1) in 23 adults. No alteration (grade 0) was 
found in the remaining 48 subjects. Subjects with lipoatrophy displayed sig-
nificantly higher levels of percent binding with IA (66± 21%) than those with 
severe lipohypertrophy (8.0± 8.0%, P=0.03) or those without lipodystrophy 
(3.3± 6.3%, P=0.03). Multiple regression analyses revealed that lipoatrophy 
(β=0.78, t=7.99, P=0.000) and percent binding with IA (β=0.65, t=6.05, 
P=0.000, R=0.65) could significantly predict each other.
Conclusion: To our knowledge, this is the first report that showed strong re-
lationship between lipoatrophy and IA in subjects with type 2 diabetes under 
insulin therapy. However, it is the chicken or the egg with lipoatrophy and 
percent binding with IA. Further investigations should be needed to eluci-
date the pathological relationship between them. In conclusion, we propose 
that the emergence of IA and its concomitant adverse effects should be taken 
into account, when starting insulin therapy in subjects with type 2 diabetes 
mellitus.
968
The immunogenicity of originator insulin glargine: incidence and 
absence of clinical sequelae
A. Vlajnic1, L. Traylor2, J. Frimpter2, H. Khatami1, H. Schellekens3;  
1Sanofi, Bridgewater, 2Sanofi US, Inc., Bridgewater, USA,  
3Department of Pharmaceutical Sciences, Faculty of Sciences,  
Utrecht University, Netherlands.
Background and aims: The immunogenicity of various basal insulins ap-
pears to be variable, with no apparent clinical impact. This analysis assessed 
immunogenicity and its clinical relevance in trials of the originator insulin 
glargine (GLA) after > 10 years experience.
Materials and methods: This was a retrospective analysis of supporting data 
from published registration studies of GLA vs NPH insulin (NPH) in pa-
tients with type 1 diabetes mellitus (T1DM; n = 4) or type 2 diabetes mel-
litus (T2DM; n = 3). Assessments included: change in antibody (Ab) levels 
(%bound/total [%B/T]) against GLA (IGAb) and human insulin (HIAb); 
proportion of patients with predefined change in Ab levels (≥ 20 units from 
baseline); and possible Ab-associated clinical effects.
Results: In the T1DM studies, baseline IGAb and HIAb levels ranged from 
21.72-29.35 and 20.50-29.91 (%B/T), respectively. Significantly larger reduc-
tions in Ab levels from baseline were seen with GLA vs NPH in 2 studies for 
IGAb and HIAb (Table). The proportion of patients with predefined chang-
es in Ab levels was low in all studies and treatment groups with available 
data: GLA, IGAb increase 2.0‒14.5%, decrease 2.0‒4.3% and HIAb increase 
1.2‒8.3%, decrease 2.8‒4.3%; NPH, IGAb increase 0‒1.2%, decrease 0‒2.9% 
and HIAb increase 0‒0.8%, decrease 0‒2.7%. In most studies more GLA-
treated patients showed an increase in IGAb; however, one study showed a 
decrease (p = 0.0029). In the T2DM studies, baseline HIAb and IGAb lev-
els ranged from 9.86-17.97 and 6.83‒17.57 (%B/T), respectively. Ab level 
increases were less marked in GLA-treated patients (significant in 2 stud-
ies) (Table). More T2DM patients had predefined changes in Ab levels vs 
T1DM patients: GLA, IGAb increase 0.01‒3.1%, decrease 0‒6.2% and HIAb 
increase 0.01‒2.5%, decrease 0‒9.2%; NPH, IGAb increase 0.01‒13.3%, de-
crease 0‒2.8% and HIAb increase 0.01‒13.8%, decrease 0‒2.8%. Significantly 
more NPH-treated patients had predefined increases in IGAb and HIAb in 
Study 3002 (overall and insulin-naïve subgroup; all p < 0.0001). There was no 
evidence of insulin resistance, loss of glycaemic control, or increased hypo-
glycaemia associated with Ab level change in T1DM or T2DM patients. There 
was no association between changes in Ab levels and in HbA1c in any treat-
ment group; total insulin dose was unchanged or only slightly increased in a 
majority of T1DM patients. Two T2DM patients (1 GLA-treated and 1 NPH-
treated) had isolated dose increases; HbA1c decreased from baseline in both. 
No correlation was seen between changes in Ab levels and hypersensitivity.
Conclusion: Treatment with GLA is associated with generally low rates of Ab 
formation, without evidence of any clinical consequences. As some regula-
tory agencies require assessment of immunogenicity for biologics, including 
biosimilars, these data may provide a potential benchmark for consideration 
of emerging data from GLA biosimilar studies.
Supported by: Sanofi US, Inc.
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Evaluation of immunogenicity of LY2963016 insulin glargine compared 
with insulin glargine in patients with type 2 diabetes mellitus
L.L. Ilag, M.A. Deeg, W.J. Huster, T.M. Costigan, J.S. Zielonka, R.K. Pollom, 
M.J. Prince, R.J. Konrad;  
Eli Lilly and Company, Indianapolis, USA.
Background and aims: LY2963016 (LY IGlar) is an insulin glargine product, 
with an identical amino acid sequence to insulin glargine (Sanofi-Aventis; 
IGlar), which demonstrates similar pharmacokinetic and pharmacodynamic 
profiles and no clinically meaningful differences from IGlar in safety or ef-
ficacy in patients with type 2 diabetes mellitus (T2DM). When evaluating 
similar biological products, assessment of immunogenicity is important to 
examine potential differences between products in the incidence and severity 
of human immune responses and implications this might have for safety or 
efficacy.
Materials and methods: This was a 24-week, Phase 3, randomised, double-
blind, parallel study to compare the efficacy and safety of LY IGlar (N=376) 
and IGlar (N=380) in patients with T2DM on ≥2 oral antihyperglycaemic 
medications (OAMs). Patients were insulin-naïve (HbA1c ≥7.0% to ≤11.0%) 
or previously on IGlar (HbA1c ≤11.0%). Anti-insulin glargine antibodies (% 
binding) were measured for the overall 24-week treatment period. The rela-
tionships between anti-insulin glargine antibody levels or treatment emer-
gent antibody responses (TEAR) and selected efficacy and safety measures 
were evaluated using ANCOVA.
Results: Approximately 40% of patients (LY IGlar, 41%; IGlar, 38%) entered 
the study on IGlar and the remainder (LY IGlar, 59%; IGlar, 62%) were insu-
lin-naïve. Similar proportions of patients completed the 24-week treatment 
period (LY IGlar, 89%, IGlar 86%). As shown in Table 1, proportions (%) of 
patients with detectable antibodies at baseline and throughout the treatment 
period were similar for LY IGlar vs IGlar (p>.05). There were no differences 
in TEAR incidence between patients randomised to LY IGlar vs IGlar and 
clinical outcomes (HbA1c, basal insulin dose and total hypoglycaemia) were 
not affected by TEAR status (i.e., p>.05 for treatment-by-TEAR interaction 
for these outcomes) (Table 1). The incidence of treatment-emergent allergic 
events did not differ between LY IGlar and IGlar (p>.05) (Table 1). Clinical 
outcomes were also not affected by insulin antibody levels (p>.05).
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Conclusion: These clinical safety data demonstrate a highly similar immu-
nogenicity profile of LY IGlar to IGlar, with no effects of anti-insulin glargine 
antibodies on selected efficacy and safety outcomes in patients with T2DM.
Clinical Trial Registration Number: NCT01421459
Supported by: Eli Lilly and Company
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Demonstration of differential immune modulation by originator and 
biological copies of insulin glargine in an in vitro model of human 
immunity
E. Luna1, P. Agrawal1, R. Mehta1, C. Vernhes1, C. Denys2, H. Khatami3,  
A. Schmidt4, N. Tennagels4, D.R. Drake III1;  
1Sanofi Pasteur-Vaxdesign Campus, Orlando, USA, 2Sanofi, Paris, France, 
3Sanofi, Bridgewater, USA, 4Sanofi, Frankfurt am Main, Germany.
Background and aims: Because the manufacture of insulin analogs require 
sophisticated production and purification procedures, it is possible originator 
and biological copies of insulin might have varied immunogenicity profiles 
based on differences in the structure (protein aggregation, denaturation), pu-
rity (contamination with endotoxins or others), and/or other characteristics 
of these products. To date, few studies have addressed the specific pathways 
of potential immune modulation triggered by biological copies of insulin 
glargine
Materials and methods: Here, we used an in vitro model of immunity, 
termed the MIMIC® system, to study antigen presenting cell (APC) activation 
and cytokine secretion induced by a range of doses of originator and biologi-
cal copies of insulin glargine that are available in some countries
Results: By flow cytometric phenotype analysis, the originator and biological 
copy products triggered minimal changes in expression of activation markers 
on MIMIC® system-derived APCs. In contrast, some lots of the biological 
copies of insulin glargine, but not the originator product, were capable of 
inducing the secretion of some pro-inflammatory markers, such as IL-8, in 
the treated MIMIC® cultures. These immunogenicity differences appear to be 
due to the effect of the compounds on monocytic and/or lymphocytic popu-
lations in the in vitro human cell system. Of note, all insulin analogs included 
in this analysis were comparable in their insulin receptor activity in vitro and 
typically generated similar analytical profiles.
Conclusion: In contrast to the originator product, some of the biological 
copies of insulin glargine (variable by lot) triggered the induction of pro-
inflammatory cytokines in the MIMIC® system, which might indicate a dif-
ference in the biochemical composition of some of these insulin biological 
copies. While the mechanism and differences causing these effects is still un-
der investigation, and the potential clinical impact is unknown, the data pre-
sented here suggests there might be different immune modulation potentials 
between originator and copy insulin compounds. Further investigation of the 
potential clinical relevance and/or mechanisms regulating this response may 
be warranted.
Supported by: Sanofi/ Sanofi Pasteur.
971
Binding kinetics, internalisation and localisation of long-acting basal 
insulin peglispro (BIL) and insulin receptor in cells
V.V. Kiselyov, J.S. Moyers, C.B. Volk, J.X.C. Cao, G.Y. Wu, L. Ding,  
M.D. Michael;  
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA.
Background and aims: BIL (LY2605541) is a novel, PEGylated insulin lis-
pro that has a large hydrodynamic size. It has a prolonged duration of action 
which is related to a delay in insulin absorption and a reduction in clear-
ance. We compared the binding kinetics, intracellular localization, in vitro 
clearance, and effect on activation and localization of human insulin recep-
tor (hIR) of BIL with those of insulin lispro and biosynthetic human insulin 
(BHI).
Materials and methods: Cellular internalization and localization of BIL, 
BHI, insulin lispro, and tyrosine-phosphorylated hIR (hIR-pY) were ob-
served by immunofluorescent confocal imaging in U2OS cells that overex-
press hIR. Binding and kinetic properties of BIL and BHI were measured in 
IM9 cells using radio-ligand binding techniques. The in vitro clearances of 
BIL and BHI were studied in HEK cells overexpressing hIR.
Results: Co-localization studies using antibodies to insulin or PEG, and the 
early endosomal marker, EEA1, showed that the internalization and subcel-
lular localization pattern of BIL were similar to those of BHI and insulin lis-
pro; all were rapidly internalized and co-localized with EEA1. During ligand 
washout, concomitant loss of insulin, PEG methoxy group, and PEG polymer 
backbone immunostaining was observed for BIL similar to the loss of in-
sulin immunostaining observed for insulin lispro and BHI. Co-localization 
studies using an antibody to the lysosomal marker LAMP2 did not reveal 
evidence of lysosomal localization for insulin lispro, BHI, or BIL, using either 
insulin or PEG immunostaining reagents. In vitro clearance studies showed 
efficient insulin receptor-mediated-clearance of BHI and the insulin portion 
of BIL. In contrast, the concentration of PEG polymer backbone appeared to 
decrease significantly more slowly. This is consistent with a process whereby, 
upon internalization of BIL, the insulin moiety is degraded, whereas the PEG 
backbone is recycled out of cells, and is consistent with the above observa-
tion that no PEG was detected in lysosomes. BIL and BHI both induced 
rapid phosphorylation and internalization of hIR. Co-staining of hIR-pY 
and EEA1 showed that hIR promptly entered early endosomes after BIL and 
BHI treatment. Minimal lysosomal localization of hIR-pY was detected with 
either ligand. Ligand washout studies suggested a more rapid dephosphoryla-
tion of hIR-pY after treatment with BIL than with BHI. Whole cell binding 
analysis performed with IM9 cells also showed slightly faster hIR dissocia-
tion kinetics for BIL than for BHI. The pH dependence of the dissociation 
rate and the magnitude of accelerated dissociation from the receptor at high 
concentrations of BIL were similar to those of BHI. Affinity of BIL for hIR 
was ~20-fold lower than that of BHI.
Conclusion: The mechanism of insulin receptor activation by BIL is similar 
to that of BHI as evidenced by preservation of pH and ligand concentration 
dependences of the dissociation rate. The reduction of affinity to the insulin 
receptor is attributable mainly to a decrease in the association rate constant. 
The insulin and PEG moieties of BIL undergo a dynamic cellular process of 
rapid internalization and transport to early endosomes after stimulation of 
hIR-pY followed by loss of cellular immunostaining in a manner similar to 
those of insulin lispro and BHI suggestive of efficient transport of the PEG 
backbone out of cells.
Supported by: Eli Lilly and Company
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Pharmacological evaluation of once-weekly potentials by combination of 
long-acting insulin with long-acting exendin4 in an animal model
S. Kwon1, C. Lim1, Y. Park1, J. Kim1, S. Jung1, I. Choi1, S. Lee1, J. Kang1,  
M. Trautmann2, M. Hompesch2, Y. Kim1;  
1Hanmi Parmaceutical, Seoul, Republic of Korea,  
2Profil Institute, Chula Vista, USA.
Background and aims: Combination of basal insulin and GLP-1 receptor 
agonist could provide diabetic patients with improved efficacy and safety. 
However, the recently developed combination products require an once-
daily administration, which is still frequent and thus negatively affects treat-
ment adherence and efficacy. We have developed the novel long-acting basal 
insulin analog and exendin-4 analog, namely HM12470 (once-weekly regi-
men) and HM11260C (once-weekly or monthly regimen), respectively, using 
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LAPSCOVERY technology. Because of their prolonged and flatness phar-
macokinetic (PK) / pharmacodynamic (PD) properties, the combination of 
HM12470 and HM11260C could maximize the dosing convenience as well 
as the therapeutic advantages. The objective of this study was to evaluate the 
once-weekly potentials of HM12470 and HM11260C combination in animal 
model.
Materials and methods: Human PK profile of HM12470 was predicted 
based on PK results of three different animal species using Wajima Css-MRT 
method and compared with that of HM11260C in human. db/db mice were 
chronically administrated with HM12470 and/or HM11260C. To evaluate 
the glucose lowering efficacy, 4h fasting blood glucose (FBG) levels were 
measured every 3-4days. Body weight was determined every 2days for proper 
drug administration. At the end of study, HbA1c levels were determined. To 
evaluate the PK profiles of combination treatment, serum concentration of 
HM12470 and/or HM11260C were quantified after single administration of 
HM12470 and/or HM11260C in SD rats.
Results: The half-life of HM12470 in human was predicted as 132hr which 
was similar with HM11260C (140hr), suggesting their once-weekly com-
bination potentials. In db/db mice, once-weekly mimetic administration 
(Q2D) of HM12470 and HM11260C showed significantly reduced FBG lev-
els compared to that of individual compounds. Consistent with FBG con-
trol, HM12470 and HM11260C combination group had lower HbA1c level 
(6.8±0.8%) than HM12470 (9.0±0.6%) or HM11260C (8.0±1.7%) groups, 
indicating improved glycemic control by combination treatment. Moreover, 
this improved glycemic control was maintained even by reducing HM12470 
dose in combination treated group. Furthermore, combination treatment 
attenuated body weight gain observed in HM12470 only groups. As to the 
pharmacokinetic profiles, administration of HM12470 and HM11260C did 
not affect pharmacokinetic profiles of either individual compounds in SD 
rats, ruling out possible drug-drug interference.
Conclusion: Based on PK prediction results, HM12470 could be a best 
partner of HM11260C for the once-weekly combination therapy. Of note, 
combination of HM12470 and HM11260C not only improved glycemic 
control, but also controlled unwanted body weight gain by insulin drug in 
db/db mice. Given that there were no PK interference between HM12470 
and HM11260C, our results collectively demonstrate that combination of 
HM12470 and HM11260C provide optimal convenience as well as thera-
peutic advantages, shedding light on ideal therapy for the management of 
diabetic patients.
PS 079 Insulin treatment and 
hypoglycaemic reactions
973
Hypoglycaemia in people with type 2 diabetes achieving vs not achieving 
HbA1c target levels over 4 years in routine clinical practice:  
analysis of the CREDIT study
L. Blonde1, N. Freemantle2, F. Calvi-Gries3, M. Vincent4, P. Home5;  
1Ochsner Medical Center, New Orleans, USA, 2University College London, 
UK, 3AtlanStat, Rezé, France, 4Sanofi, Paris, France,  
5Newcastle University, Newcastle upon Tyne, UK.
Background and aims: To evaluate the incidence and rate of hypoglycaemia 
in people with type 2 diabetes achieving vs not achieving HbA1c < 7.0 % (53 
mmol/mol) over 4 years after starting insulin therapy in routine clinical prac-
tice in Europe, Canada, and Japan.
Materials and methods: CREDIT (Cardiovascular Risk Evaluation in people 
with Type 2 Diabetes on Insulin Therapy) was a noninterventional study de-
signed to examine the relationship between HbA1c and cardiovascular events 
and to provide insight into current, real-world practices of the use of insulin 
by 2999 people beginning insulin, with up to 54 months’ follow up (n = 2272 
with 4-year data). For this analysis, records of symptomatic, severe, and noc-
turnal symptomatic hypoglycaemia were collected for the 6 months prior to 
the 1, 2, 3, and 4-year follow-up intervals. Updated mean HbA1c was calcu-
lated as the average of normalized HbA1c measurements from 1 month after 
insulin initiation up to follow-up year values. Hypoglycaemia events were 
categorised by whether or not the person experiencing the event had updated 
mean HbA1c < 7.0 % or not at the follow-up visit closest to the event.
Results: Overall mean (SD) HbA1c declined from 80 (21) mmol/mol (9.5 
[2.0] %) when starting insulin to 60 (14) mmol/mol (7.6 [1.3] %) at 4 years 
(median 56 mmol/mol [7.3 %]). During the last 6 months of year 1, 2, 3, and 
4 follow-up, the proportion of people experiencing ≥ 1 hypoglycaemic event 
was higher for those who achieved target (range 17.7%-24.6%) than for those 
who did not (range: 15.8%-16.8%) (Table). This was also true for incidence 
rate of any documented symptomatic hypoglycaemia (1.18-1.40 vs 0.75-
0.96 events/person), and nocturnal symptomatic hypoglycaemia (0.14-0.24 
vs 0.12-0.20 events/person). The percentage of people who experienced ≥ 1 
severe hypoglycaemic event for the 4 half-yearly follow-up periods was also 
higher for those to target (range 3.0%-4.6%) than for those not (0.9%-1.6%). 
Mean rates of severe hypoglycaemia were 0.04-0.20 vs 0.02-0.04 events/per-
son, while severe nocturnal hypoglycaemia was 0.02-0.06 vs 0.00-0.01 events/
person.
Conclusion: People with type 2 diabetes starting insulin who achieve up-
dated mean target HbA1c levels in routine clinical practice do experience 
higher rates of symptomatic and nocturnal hypoglycaemia than those failing 
to achieve target HbA1c. However, the difference between groups in the per-
centage of individuals with hypoglycaemia seems to diminish over time, and 
rates for both groups are relatively modest. Moreover, the rate of severe hy-
poglycaemia is low and could not be distinguished by whether target HbA1c 
is achieved. Initiation of insulin in the CREDIT population was associated 
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with a significant improvement in glycaemia. These hypoglycaemia data are 
consistent with a positive benefit risk ratio for this therapeutic strategy.
Supported by: Sanofi
974
IDegAsp lowers the rate of hypoglycaemia vs biphasic insulin aspart 30 
in adults with type 2 diabetes achieving glycaemic target (HbA1c <7.0%): 
a meta-analysis
A. Vaag1, J.S. Christiansen2, L. Niskanen3, T. Johansen4, S. Rasmussen4,  
G. Fulcher5;  
1Rigshospitalet and Copenhagen University, 2Aarhus University Hospital, 
Denmark, 3Faculty of Health Sciences, University of Eastern Finland, 
Helsinki, Finland, 4Novo Nordisk A/S, Søborg, Denmark,  
5The University of Sydney, Australia.
Background and aims: Insulin degludec/insulin aspart (IDegAsp) is a solu-
ble co-formulation of 70% insulin degludec and 30% insulin aspart. The ob-
jective of this post-hoc meta-analysis was to compare hypoglycaemia rates 
for IDegAsp, vs. biphasic insulin aspart 30 (BIAsp 30) in adults with type 
2 diabetes (T2D) achieving the ADA/EASD target of HbA1c <7% at end of 
trial (EOT).
Materials and methods: This analysis included two 26-week trials (NN5401-
3592/97) comparing twice-daily IDegAsp vs BIAsp 30. HbA1c, fasting plasma 
glucose (FPG) and insulin dose were analysed using an ANCOVA model; 
episodes of hypoglycaemia were analysed using a negative binomial regres-
sion model. Confirmed hypoglycaemia was defined as self-reported PG <3.1 
mmol/L or severe (requiring third-party assistance); nocturnal confirmed 
hypoglycaemia had onset 00:01-05:59 am, inclusive.
Results: In total, 49.1% (426/868) of subjects achieved EOT HbA1c of <7% 
(IDegAsp: 49.2% [248/504]; BIAsp 30: 48.9% [178/364]) and were included 
in the meta-analysis. Treatment groups had similar EOT HbA1c levels (6.4% 
vs. 6.4%; estimated treatment difference [ETD]: 0.00% [-0.07; 0.07], p=0.996), 
whereas IDegAsp achieved a significantly greater reduction from baseline in 
FPG (-3.0 vs. -2.1 mmol/L; ETD: -1.1 mmol/L [-1.4; -0.9] p<0.0001). Mean 
daily insulin dose at EOT was significantly lower for IDegAsp than BIAsp 30 
(0.9 vs. 1.1 U/kg; estimated dose ratio: 0.77 [0.72; 0.84]; p<0.0001). IDegAsp 
was associated with a significantly lower rate of overall confirmed hypogly-
caemia (rate ratio [RR] IDegAsp/BIAsp 30: 0.70 [0.55; 0.90], p=0.0047) and a 
significantly lower rate of nocturnal hypoglycaemia than BIAsp 30 (RR: 0.34 
[0.22; 0.51], p<0.0001). Severe hypoglycaemia rates were low and similar be-
tween groups.
Conclusion: The significant difference vs. BIAsp 30 in overall and nocturnal 
confirmed hypoglycaemia in adults achieving target glycaemia (HbA1c <7%) 
support the flat and stable pharmacodynamic profile of the basal degludec 
component in IDegAsp.
Clinical Trial Registration Number: NCT01009580 / NCT01059812
Supported by: Novo Nordisk
975
New insulin glargine 300 U/mL: glycaemic control and hypoglycaemia in 
Japanese people with type 1 diabetes mellitus (EDITION JP 1)
M. Matsuhisa1, M. Koyama2, X. Cheng3, S. Shimizu4, T. Hirose5, on behalf of 
the EDITION JP 1 study group;  
1Diabetes Therapeutics and Research Center, The University of Tokushima, 
2Asia Pacific TSU, Sanofi Japan, Tokyo, Japan, 3Clinical Science & Operation, 
China R&D, Sanofi, Beijing, China, 4Biostatistics and Programming, Sanofi 
Japan, 5Division of Diabetes, Metabolism and Endocrinology, Department 
of Medicine, Toho University School of Medicine, Tokyo, Japan.
Background and aims: EDITION JP 1 studied the efficacy and safety of new 
insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in 
Japanese people with T1DM using basal plus mealtime insulin.
Materials and methods: In the 6-month, multicentre, open-label, phase 3 
trial, participants (n=243; mean age 45.2 years; T1DM duration 13.0 years; 
HbA1c 8.1 %) were randomised to once-daily Gla-300 or Gla-100 in combi-
nation with mealtime insulin. Basal insulin was titrated to target FPG 4.4-
7.2 mmol/L (80 to 130 mg/dL). Primary endpoint was HbA1c change from 
baseline to month 6.
Results: Similar HbA1c decreases were seen with both Gla-300 and Gla-100 
(LS mean [SE] −0.30 [0.06] % and −0.43 [0.06] %; LS mean difference 0.13 
[95% CI: −0.03 to 0.29] %). Fewer participants who received Gla-300 expe-
rienced confirmed or severe nocturnal hypoglycaemic events versus Gla-100 
over the 6-month study period, with the greatest difference observed during 
the first 8 weeks (Table). The rate of hypoglycaemic events per participant-
year at any time of the day (24 hours) was lower with Gla-300 than Gla-100. 
Severe hypoglycaemia was infrequent in either group. Comparable numbers 
of adverse events were recorded in each group.
Conclusion: In Japanese people with T1DM using basal and mealtime insu-
lin, Gla-300 provides comparable effective glycaemic control with less noc-
turnal hypoglycaemia, particularly in the first 8 weeks, and no increase in 
daytime hypoglycaemia versus Gla-100. 
Clinical Trial Registration Number: NCT01689129
Supported by: Sanofi
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Glycaemic control and hypoglycaemia in Japanese people with type 
2 diabetes mellitus receiving new insulin glargine 300 U/mL in 
combination with OADs (EDITION JP 2)
Y. Terauchi1, M. Koyama2, X. Cheng3, S. Shimizu4, T. Hirose5, on behalf of 
the EDITION JP 2 study group;  
1Department of Endocrinology and Metabolism, Yokohama City University 
Graduate School of Medicine, 2Asia Pacific TSU, Sanofi Japan, Tokyo, 
Japan, 3Clinical Science & Operation, China R&D, Sanofi, Beijing, China, 
4Biostatistics and Programming, Sanofi Japan, 5Division of Diabetes, 
Metabolism and Endocrinology, Department of Medicine, Toho University 
School of Medicine, Tokyo, Japan.
Background and aims: EDITION JP 2 studied the efficacy and safety of new 
insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in 
Japanese people with T2DM using basal insulin plus OAD(s).
Materials and methods: In this 6-month, multicentre, open-label, phase 3 
study, participants (n=241; mean age 60.8 years; mean BMI 25.3 kg/m2; mean 
duration of T2DM 14.0 years; mean HbA1c 8.0 %) were randomised to re-
ceive once-daily Gla-300 or Gla-100 plus OAD(s). Insulin was titrated to tar-
get FPG 4.4-5.6 mmol/L (80-100 mg/dL). The primary endpoint was HbA1c 
change from baseline to month 6.
Results: HbA1c decreased similarly in both groups (LS mean [SE] −0.45 
[0.06] % for Gla-300 and −0.55 [0.06] % for Gla-100; LS mean difference 
0.10 [95% CI: −0.08 to 0.27] %). Fewer participants experienced any hypo-
glycaemic events during 6 months with Gla-300 versus Gla-100. The number 
of participants with ≥1 confirmed (≤3.9 mmol/L) or severe hypoglycaemic 
event (24 h and nocturnal) was consistently lower with Gla-300 compared 
with Gla-100, and rate per participant-year was lower with Gla-300 versus 
Gla-100 (Table). Severe hypoglycaemia was infrequent in both groups. LS 
mean (SE) weight change was −0.62 (0.19) kg for Gla-300 and 0.37 (0.19) kg 
for Gla-100. Similar safety profiles were observed in both groups.
Conclusion: In Japanese people with T2DM using basal insulin plus OAD(s), 
Gla-300 provides comparable effective glycaemic control with fewer hypogly-
caemic events, particularly during the first 8 weeks.
Clinical Trial Registration Number: NCT01689142
Supported by: Sanofi
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The beneficial effect of insulin degludec on nocturnal hypoglycaemia and 
insulin dose in type 1 diabetic patients: a systematic review and meta-
analysis of randomised trials
K. Dzygalo1, D. Golicki2, A. Kowalska1, A. Szypowska1;  
1Department of Paediatrics, 2Department of Experimental and Clinical 
Pharmacology, Medical University of Warsaw, Poland.
Background and aims: Insulin degludec is a new-generation ultra-long act-
ing basal insulin which offers a significantly more predictable glucose-lower-
ing effect than other long-acting insulin analogues. To compare the effect of 
treatment with insulin degludec and long-acting insulin analogues glargine 
and detemir in type 1 diabetic (T1D) patients by means of a systematic review 
and meta-analysis.
Materials and methods: The following electronic databases were searched 
up to January 2014: MEDLINE, EMBASE, The Cochrane Library. Additional 
references were obtained from the reviewed articles. There were included 
randomized controlled trials of at least 12 weeks‘ duration with basal-bolus 
regimen therapies in T1D patients.
Results: Current analysis included 4 studies involving 1,846 T1D patients. 
The combined data from all trials showed a statistically significant reduction 
in the basal insulin dose (MD 0.042, 95% CI -0.067 to -0.018, p=0.001) and 
the total daily insulin dose (MD -0.072, 95% CI 0.016 to -0.027, p=0.002) 
in the degludec group compared to other long-acting analogues. There was 
also a significant reduction of nocturnal hypoglycemia in the degludec group 
compared to the controls (Rate Ratio 0.697, 95% CI 0.617 to 0.786, p=0.000). 
There were no differences between the groups in terms of HbA1c values, fast-
ing plasma glucose (FPG), adverse events.
Conclusion: Basal-bolus treatment with insulin degludec was superior to 
long-acting insulin analogues detemir and glargine in reducing the rate of 
nocturnal hypoglycemia. In comparison to other long-acting analogues, 
treatment with insulin degludec was safe, patients obtained similar metabolic 
control expressed by HbA1c and FPG levels with the added benefit of a re-
duced basal and total insulin dose.
978
Hypo-/hyperglycaemia alert based on online glucose prediction using a 
global model for type 1 diabetes
C. Yu1, C. Zhao1, Y. Fu2;  
1Control Science and Engineering, Zhejiang University, Hangzhou, China, 
2Control Science and Engineering, Becton Dickinson Technologies, 
Research Triangle Park, USA.
Background and aims: Avoiding hypo/hyperglycemia is a major challenge 
for diabetes mellitus. A timely alert of hypo/hyperglycemia episodes before 
they occur can allow enough time for the patient to take necessary actions to 
avoid hypo/hyperglycemia.
Materials and methods: A global model, which is developed based on one 
subject and then applied to new subjects without any customization, is used 
for early hypo/hyperglycemia alert based on online glucose prediction using 
clinical data provided by BD. Two autoregressive (AR) modeling methods are 
considered using standard least squares algebra: (i) global prediction model; 
(ii) subject-dependent model. Both are developed based on time-series glu-
cose data with 2 min as sampling interval. Also, to evaluate the role of high-
frequency glucose data, the glucose data are filtered by a first-order low-pass 
filter with 30min the as threshold. Online short-term glucose predictions are 
made for 15 subjects for alert of hyper/hypoglycemia based on filtered and 
non-filtered data.
Results: The results are summarized in Table 1 as evaluated by time lag which 
is the time difference between the predicted hyper/hypoglycemia and the 
measured event.
Conclusion: The results indicate that the accuracy of global model is compa-
rable to or even better than that of subject-dependent model for alert of hy-
per/hypoglycemia based on the index of time lag. However, the sensitivity for 
hypos using global model is lower than that using subject-dependent model. 
Also, the model developed based on filtered glucose data can get smaller time 
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lag of hyper/hypoglycemia alert than that based on raw glucose data since the 
high-frequency noises are removed after low-pass filtering.
Supported by: National Natural Science Foundation of China (No. 61273166)
979
Assessment of glycaemic control and risk of hypoglycaemia for two 
basal-bolus algorithms in hospitalised patients with diabetes mellitus 
type 2
J.K. Mader1, K.M. Neubauer1, L. Schaupp1, F. Aberer1, K. Donsa2,  
T. Augustin2, S. Spat2, B. Hoell2, P. Beck2, J. Plank1, T.R. Pieber1;  
1Internal Medicine / Endocrinology and Metabolism, Medical University of 
Graz, 2HEALTH, Joanneum Research GmbH, Graz, Austria.
Background and aims: Current guidelines recommend pre-meal blood glu-
cose (BG) levels of <7.8mmol/l in the hospital. The aim of this analysis was 
to compare two versions of a workflow-integrated algorithm for basal-bolus 
insulin therapy (REACTION algorithm) for glycaemic management in pa-
tients with diabetes mellitus type 2 (T2D) hospitalised at the general ward.
Materials and methods: For both algorithms BG measurements were per-
formed four times daily (pre-breakfast, pre-lunch, pre-dinner, bedtime); in-
sulin injections were given according to the algorithm. Advice for total daily 
dose (TDD) (50% basal insulin, 50% pre-meal bolus insulin) was generated 
once daily. In the initial algorithm bolus insulin dose was evenly distributed 
over the day; in the refined algorithm bolus insulin dose was redistributed 
whereas TDD and the 50:50 ratio remained unchanged.
Results: 52 (15 female, age 69±11 years, HbA1c 76±30mmol/mol, BMI 
30±6kg/m2, diabetes duration 14±11 years) and 95 (42 female, age 68±11 
years, HbA1c 65±21mmol/mol, BMI 31±7kg/m2, diabetes duration 15±11 
years) T2D patients were treated with the initial and the refined algorithm re-
spectively. Mean BG was 8.8±1.8mmol/l (initial algorithm) vs. 8.5±1.8mmol/l 
(refined algorithm). The overall risk of getting a hypoglycaemic episode (<3.9 
mmol/l) during the first 10 treatment days was 3% vs. 1.3% (initial vs. refined 
algorithm). There was no significant change in hypoglycaemia occurrence 
over the treatment time and no influence of time of day between groups. 
Mean TDD was 45±26U (basal: 22±18U, bolus: 24±16U) for the initial algo-
rithm and 47±26U (basal: 24±18U, bolus: 24±18U) for the refined algorithm.
Conclusion: The refined version of the REACTION algorithm could estab-
lish similar glycaemic control with reduced risk of hypoglycaemia. Insulin 
doses were comparable for the two versions of the algorithm. The REAC-
TION algorithm has the potential to improve glycaemic management in the 
hospital setting.
Clinical Trial Registration Number: NCT014072, NCT01932775, 
NCT01766752
Supported by: European Commission, Project REACTION (FP7 248590)
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Sustained glycaemic control and less hypoglycaemia with new insulin 
glargine 300 U/ml vs 100 U/ml: 1-year results in type 2 diabetes with 
basal and mealtime insulin (EDITION 1)
M.C. Riddle1, H. Yki-Järvinen2, G.B. Bolli3, M. Ziemen4,  
I. Muehlen-Bartmer4, S. Cissokho5, P.D. Home6;  
1Oregon Health & Science University, Portland, USA, 2University of 
Helsinki, Finland, 3University of Perugia, Italy, 4Sanofi-Aventis Deutschland 
GmbH, Frankfurt am Main, Germany, 5Keyrus Biopharma, Levallois-Perret, 
France, 6Newcastle University, Newcastle upon Tyne, UK.
Background and aims: EDITION 1 studied the efficacy and safety of new 
insulin glargine 300 U/ml (Gla-300) versus glargine 100 U/ml (Gla-100) in 
people with type 2 diabetes mellitus using basal plus mealtime insulin.
Materials and methods: In EDITION 1, 807 people with elevated HbA1c 
were randomised to titrate Gla-300 or Gla-100 once daily in the evening for 
6 months, continuing the mealtime insulin. In a 6-month open-label exten-
sion, participants continued Gla-300 or Gla-100; 89% and 88% completed 12 
months of treatment.
Results: Improved glycaemic control was maintained over 12 months in 
both groups (LS mean difference Gla-300 vs Gla-100: −0.17 [95% CI: −0.30 
to −0.05] % for HbA1c and −0.34 [95% CI: −0.69 to 0.01] mmol/l for FPG) 
(Figure). Basal insulin doses were higher with Gla-300 than Gla-100 after 12 
months (1.03 vs 0.90 U/kg). During the 12 months of treatment, a similar 
percentage of participants had ≥1 confirmed (≤3.9 mmol/l [≤70 mg/dl]) or 
severe hypoglycaemic event at any time of the day (85.9% with Gla-300 vs 
91.5% with Gla-100; RR 0.94 [95% CI: 0.89 to 0.99]). During the night this 
percentage was lower in Gla-300 (54.5% vs 64.7% in Gla-100; RR 0.84 [95% 
CI: 0.75 to 0.94]). Severe hypoglycaemia was reported by 6.7% of Gla-300- 
and 7.5% of Gla-100-treated participants. No between-treatment differences 
in adverse events were seen.
Conclusion: In conclusion, over 1 year of treatment in people with type 2 
diabetes mellitus using basal and mealtime insulin, Gla-300 provided sus-
tained glycaemic control with a lower incidence of hypoglycaemia compared 
with Gla-100.
Clinical Trial Registration Number: NCT01499082
Supported by: Sanofi
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Acute and sub-acute effects of the endobarrier on glucose homeostasis 
and appetite in obese uncontrolled type 2 diabetes mellitus patients
G. Segal-Lieberman1, A. Lang2, M. Lahav2, N. Lieberman3, A. Paster1,  
N. Konvalina1, H. Kanety1, R. Hemi1, O. Cohen1;  
1Institute of Endocrinology, Sheba Medical Center, Ramat-Gan,  
2Institute of Gastroenterology, Sheba Medical Center, Ramat-Gan, 
3Community Medical Devision, Clalit Medical Services, Tel-Aviv, Israel.
Background and aims: Diabetes is a prevalent metabolic disease accompa-
nied by an increased risk for cardiovascular disease as well as micro-vascular 
complications. To date, bariatric surgery has become one of the most effective 
means of providing durable, clinically-significant resolution of diabetes, with 
the majority of subjects with T2DM undergoing these procedures experienc-
ing a remission of their disease. One of the theories behind the early resolu-
tion of diabetes after the Roux-en-Y Gastric bypass operation claims that the 
mediating factor lies within the bypassing of the duodenum by the ingested 
food. The Endobarrier gastrointestinal liner system (by GI Dynamics®) is an 
endoscopically-delivered device that mimics gastric bypass surgery by shield-
ing the duodenum and upper jejunum from contact with chyme.
Materials and methods: An Endobarrier device was placed in the duode-
num via an endoscopic procedure in 33 uncontrolled diabetic obese subjects. 
Acute and sub-acute effects of the device on glucose homeostasis were evalu-
ated using a Continuous Glucose Monitoring (CGM) recording device for 
one week, as of two days prior to device implantation until four days after its 
removal. The effect of the device on appetite was evaluated using the 5-ques-
tion visual analog scale, where each question was given a score between 1-10.
Results: Our population included 17 females and 16 males with mean dia-
betes duration of 10.4 (SD±5.8) years, most were insulin treated. Baseline 
HbA1c level was of 9.3% (SD±1.0) and baseline body mass index was 38.0 
kg/m2 (SD±5.0). CGM data revealed a significant decrease in average daily 
glucose levels from 243.2 mg/dL (SD±63.4) one day before the procedure to 
227 mg/dL (SD±53.6) (p value = 0.002) on the day of the procedure, while the 
subjects were fasted most of the day. As of the first day after the procedure, 
despite the fact that eating was initiated, prandial medications were termi-
nated and basal insulin dose was lowered by 50%, the recorded glucose levels 
continued to decreased and reached a decrease of 30.3 mg/dL (SD±69.4) (p 
value= 0.048) vs. baseline on the last day of CGM recording. Whereas no 
significant change in the VAS score was recorded after one week, one month 
after the Endobarrier insertion, a significant change of 1.1 points (SD±1.7) 
(p value=0.003) vs. baseline was recorded suggesting a significant decrease 
in appetite one month after the procedure, despite a weight loss of 4.2 kg at 
this time-point.
Conclusion: Endobarrier therapy in advanced uncontrolled obese diabetic 
patients significantly improves their glucose homeostasis, as early as the first 
day after the procedure. This improvement becomes even more prominent 
as days go by and eating becomes more regular. Despite a substantial weight 
loss, appetite is significantly suppressed one month after the insertion of the 
device. EndoBarrier seems to have an early lowering effect on blood glucose 
as well as a suppressive effect on appetite, rendering it an attractive option for 
the care of „diabesity“ in this challenging population.
Clinical Trial Registration Number: NCT01718457
Supported by: IASD
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Effects of duodeno-jejunal bypass liner on bile acid homeostasis in 
patients with severe obesity
A.A. Young1, K.K. Brown1, J.D. Williams1, F. Pimentel2, A. Sharp2,  
P.P. Parra2, D. Turiel2, R. Munoz2, M. Arrese2, V. Irribarra2, J.F. Miguel2,  
L.M. Kaplan3, A. Levine4, D. Maggs5, A. Escalona2;  
1GlaxoSmithKline, Research Triangle Park, USA, 2Pontificia Universidad 
Católica de Chile, Santiago, Chile, 3Obesity, Metabolism & Nutrition 
Institute, Massachusetts General Hospital, Boston, 4Wyss Institute, Harvard 
University, Cambridge, 5GI Dynamics, Lexington, USA.
Background and aims: Endoscopic placement of a duodenojejunal bypass 
liner (DJBL) elicited a 16.1 ± 1.6% loss of body weight in 17 morbidly obese 
patients, and normalization of HbA1c (<6.3%) in 5/7 of the subset with type 2 
diabetes. DJBL excludes nutrient contact with the duodenal mucosa and thus 
mimics aspects of Roux-en-Y gastric bypass surgery. Biliary and pancreatic 
secretions pass outside the liner until they mix with chyme in the proximal 
jejunum. We examined the effects of DJBL on plasma concentrations of bile 
acids (BA) and other markers of BA metabolism.
Materials and methods: Plasma total BA concentration was measured en-
zymatically. Primary and secondary bile acids, their taurine and glycine con-
jugates, and 7a-hydroxy-cholest-4-ene-3-one (C4), an intermediate used as 
a correlate of BA synthetic rate, were determined by HPLC/MS in samples 
taken at fasting and over 3 hours after a standard (Ensure) test meal. Testing 
occurred before, 1, 12, 24, and 52 weeks after DJBL placement in severely 
obese patients (age 34.8±9.5 years; body mass index 42.6±5.2 kg/m2). FGF-
19, a feedback inhibitor of BA synthesis secreted from the ileum, was meas-
ured by ELISA.
Results: One week after DJBL placement, fasting and post-meal total BA 
concentrations, and C4 concentrations abruptly decreased; FGF-19 con-
centrations increased. Thereafter, fasting and post-meal total BAs increased 
(1.7-fold, 2.3-fold, respectively, from baseline; each P<0.05). Changes were 
associated with 10-fold (fasting) and 5-fold (post-meal) increases in unconju-
gated primary and, respectively, 25-fold and 5-fold increases in unconjugated 
secondary BAs. Conjugated BAs did not change. Aside from the transient 
perturbations at week 1, FGF-19 progressively declined. This was especially 
apparent in the post-meal samples (arrows). Aside from week 1, C4 was un-
changed.
Conclusion: Marked increase in circulating BAs with DJBL, attributable to 
unconjugated species, occurs without an apparent increase in BA synthetic 
rate (unchanged C4) but with a reduction in BA sensing in the ileum (re-
duced FGF-19). Possible mechanisms may include early bacterial deconjuga-
tion and passive absorption of secreted BAs. The contribution of these BA 
changes to the benefits of DJBL, and other procedures such as RYGBS, merits 
further study.
Clinical Trial Registration Number: NCT00985491
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Duodenal-jejunal bypass liner (DJBL) exerts prompt and robust 
metabolic changes in severely obese patients
R. Muñoz1, J. Miquel2, M. Arrese2, V. Irribarra3, F. Pimentel1, A. Sharp1,  
D. Turiel1, P. Pizarro Parra1, A. Young4, K.K. Brown4, D. Maggs6, A. Levine7, 
J. Cormier6, A. Escalona1;  
1Department of Digestive Surgery, 2Department of Gastroenterology, 
3Department of Nutrition, Diabetes and Metabolism, Pontificia Universidad 
Católica de Chile, Santiago, Chile, 4Enteroendocrine Discovery Performance 
Unit, GlaxoSmithKline, Research Triangle Park, 5GI Dynamics, Lexington, 
6Wyss Institute, Harvard University, Cambridge, USA.
Background and aims: The endoscopically placed duodenal-jejunal bypass 
liner (DJBL) prevents nutrient contact with the duodenal mucosa, thereby 
replicating elements of gastric bypass surgery, and eliciting robust weight loss 
and metabolic improvement in obese subjects with or without diabetes. We 
examined the time-dependent effects of DJBL on clinical, metabolic and hor-
monal measures out to 52 weeks in a cohort of severely obese subjects (n=17; 
age 34.8±9.5 years; body mass index 42.6±5.2 kg/m2, 77% female) some of 
whom had overt type 2 diabetes (DM subset n=7; A1C 7.07±1.48%).
Materials and methods: Clinical endpoints (A1C, body weight) and mixed 
meal (Ensure) challenge samples were collected at baseline and 1, 12, 24, and 
52 weeks for measurement of plasma glucose, FFA, triglycerides, c-peptide, 
glucagon, and GLP-1.
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Results: In the overall cohort, there was prompt and robust weight loss ob-
served that plateaued at 6-12 months (weight loss % at 52 weeks: overall 
-15.9%, non-DM -14.3%, DM -18.2%). A1C in the DM group decreased to 
6.24±1.18% at 52 weeks. Lowering of both fasting and post-prandial glucose 
(see figure) in the DM group was observed 1 week post implant and was 
maintained to 52 weeks. GLP-1 responses were augmented and triglycerides 
and FFAs suppressed during meal challenges from 12 to 52 weeks (P<0.05 
vs. baseline for AUC for all analytes). In addition, augmented c-peptide and 
suppressed glucagon was observed during meal challenge in the DM group 
(significant AUC changes observed 12 to 52 weeks).
Conclusion: The DJBL exerts prompt and robust effects on body weight and 
metabolic markers in obese subjects with or without dysglycemia. Enhanced 
incretin secretion and improved islet function may underlie some of the 
metabolic benefits. The unique combination of metabolic benefits following 
DJBL may offer an attractive alternative to pharmacological and surgical ap-
proaches.
Clinical Trial Registration Number: NCT00985491
Supported by: GI Dynamics funded clinical study
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The duodenal-jejunal bypass liner (DJBL) effect of regression from 
prediabetes
V. Irribarra1, A. Sharp2, D. Turiel2, P.P. Pizarro2, S. Guzman2, R. Muñoz2,  
F. Pimentel2, A. Escalona2;  
1Nutrition Diabetes and Metabolism, 2Digestive Surgery, Pontificia 
Universidad Catolica de Chile, Santiago, Chile.
Background and aims: The endoscopically delivered duodenal jejunal by-
pass liner (DJBL) has demonstrated clinically meaningful metabolic effects 
in obese individuals with type 2 diabetes (T“DM). Prediabetes is a high risk 
state for the development of T2DM. The aim of this study was to examine the 
DJBL effects on glycaemic control, β cell function and sensitivity to insulin in 
a group of severely obese subjects with prediabetes.
Materials and methods: DJBL was implanted for one year in 61 subjects with 
severe obesity (BMI ≥ 35 Kg/m2). Among these subjects, 18 were diagnosed 
with prediabetes. The included subjects were mostly females (mean± SD) age 
36.8 ± 6.6 years, BMI 39.6 ± 2.9 Kg/m2 and 17/18 were on metformin. Sub-
jects were followed monthly for weight, fasting glucose, insulin and Hb A1c. 
Insulin sensitivity and β cell function were estimated with HOMA calculator 
(www.dtu.ox.ac.uk/Homacalculator/index.php). Statistical analyses (ANO-
VA for repeated measures) were performed with Statistical Package for Social 
Sciences 17.0. A p-value of < 0.05 was considered significant.
Results: At implantation 17 out of 18 subjects were on anti diabetic medica-
tion that was withdrawn in 9/17 subjects, 8 subjects remained under met-
formin treatment. After implantation Hb A1c. decreased from 6.37 ± 0.82 % 
(baseline)to 5.9 ±0.56% at 4 weeks and remained below 6%. At 52 weeks was 
5.88 ± 0.52 (p<0.001) and fasting glucose decreased from 104 ± 18 mg/dL 
to 95.9 ± 14.8 mg/dL (NS). We observed an important change in insulin se-
cretion reflected as improvement of insulin resistance. HOMA-IR decreased 
progressively from 3.1 ± 1.0 to 1.7 ± 0.7 (p< 0.001) and β cell function im-
proved as insulin sensitivity increased from 37.5 ± 11.9 % to 75.3 ± 31.1 % 
(p< 0.001). At the end of the study 50% of subjects achieved Hb A1c < 5.7 %.
Conclusion: The DJBL improved glucose metabolism in this group of pre-
diabetic subjects, achieving normal glucose levels in half of them. The de-
crease of insulin resistance and recovery of beta cell function observed in 
these patients opens new possibilities in order to obtain a regression from 
prediabetes.
Clinical Trial Registration Number: NCT00985491
Supported by: GI Dynamics
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Acceptance of a truly non-invasive glucose monitoring device  
for home use
Y. Mayzel1, A. Gal1, I. Harman-Boehm2, A. Drexler3, E. Naidis1,  
N. Goldstein1, K. Horman1, S. Cohen1;  
1Integrity Applications, Ashkelon, 2Soroka University Medical Center,  
Beer-Sheva, Israel, 3David Geffen School of Medicine,  
University of California, Los Angeles, USA.
Background and aims: Adherence to self-monitoring of blood glucose 
(SMBG) holds a key role in achieving tight glycemic control in diabetic 
patients. The conventional blood glucose monitoring methods require per-
formance of invasive measurements, which involve pain and a rather com-
plex multi-step procedure. Thus, despite the clear advantages of conducting 
SMBG, invasive monitoring suffers from under-utilization. A Non-invasive 
(NI) glucose monitoring approach is expected to encourage frequent self-
monitoring, mainly due to a pain-free alternative. To further motivate uti-
lization, a NI device should be user friendly and simple-to-handle by a lay 
person in home use. GlucoTrack® is such a NI, CE Mark approved glucose 
monitoring device. The device suitability for home utilization was evaluated 
in regards to the impact of an unskilled user upon the device accuracy, ease 
and simplicity of use and general user satisfaction.
Materials and methods: Series of clinical trials were conducted by third 
party to assess usability, user satisfaction and possible user impact. All tri-
als began with individual calibration and brief training by a proficient team. 
Then, usability and general impression from the device were assessed based 
on feedback received from 72 educated (high-school and higher) users 
(Home group). 30 participants of the Home group used the device at home 
for 5-7 days after calibration. 42 other subjects of the Home group conducted 
the measurements by themselves for three more days simulating home alike 
environment. Then, user impact on the measurements’ accuracy was evalu-
ated by comparing performances when measurements were conducted by a 
proficient team (Clinic group, consisting of 135 subjects) with measurements 
conducted by the subjects themselves (42 of Home group subjects).
Results: Clarke Error Grid analysis shows 95.7% and 96.2% of the points in 
the clinically accepted A+B zones in the Clinic and Home groups, respec-
tively. Mean Absolute Relative Differences of 31.6% and 30.7% were observed 
in these groups, respectively. 86% of all subjects expressed willingness to use 
the device regularly. 78% were pleased with the device. GlucoTrack display 
appeared clear and understandable to 91% of Home users. The operation in-
structions were clear to 97% of high school graduated Home subjects and 
to 88% with higher education. 79% and 85% (high school and higher edu-
cated Home users, respectively) found measurement performance to be sim-
ple. 74% and 69% claimed the device is easy to use among high-school and 
higher-educated, respectively.
Conclusion: GlucoTrack performances show negligent dependence upon 
user skills, based on similar accuracy when used by proficient and new users. 
Using the device yields positive user feedback, high satisfaction of usability, 
ease of use and users‘ willingness to increase the frequency of SMBG. These 
advantages, along with its painless nature of measurements and long term 
cost-effectiveness of use, suggest GlucoTrack as a utilizable home-use device 
for enhanced SMBG.
Clinical Trial Registration Number: NCT00889668
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Improvement of metabolic control in type 1 diabetic children using ELKa 
toolset: a randomised controlled trial
A. Kowalska, K. Piechowiak, A. Szypowska;  
Department of Pediatrics, Medical University of Warsaw, Poland.
Background and aims: In intensive insulin therapy, prandial in-
sulin doses should be calculated before each meal with carbohy-
drate (CHO) and fat/protein (FP) exchange counting. Therefore 
food weighing and complicated calculations need to be performed. 
ELKa system is an advanced toolset which helps performing calculation 
of food exchanges. It consists of ELKa software including database of vari-
ous meals and nutrients and ELKaPlus digital kitchen scale. Among similar 
devices it is extraordinary due to opportunity of transmission weights in a 
real-time to a computer via USB port. After choosing the name of a particu-
lar product from the list, the program gives precise information about the 
amount of CHO and FP exchanges in a serving. It simplifies every-day cal-
culations and it increases the precision of results. A number of our patients 
use the system and it appears to be useful accessory, but no clinical trials were 
performed yet. The aim of this study was to investigate the benefit of using 
ELKa toolset in comparison with standard method of CHO and FP counting 
on metabolic control in type 1 diabetic children.
Materials and methods: A randomized 26-week clinical trial was conducted 
on 106 patients (64 girls, 42 boys) aged 11 ± 4.2 years (range 1.8 - 17.2 years), 
with mean BMI 19.6 ± 3.4 (range 14.5- 33.2), diabetes duration 5 ± 3.1 years 
(range 1 - 14.3 years), and HbA1c 7.5 ± 1% (range 5.1%- 10%). All patients 
were treated with insulin pumps. Patients were randomly assigned into two 
groups: the group A (n=53) using ELKa system for food exchange counting 
and the group B (n= 53) using standard method of food calculation. There 
were no significant differences between groups in mean baseline HbA1c lev-
els (group A: 7.6% ± 0.1; group B: 7.4% ± 0.1; p=0.395), BMI (A: 18.4; B: 
19.7; p= 0.165), duration of diabetes (A: 4.3 years; B: 4.6 years; p= 0.265) 
and insulin/kg/24h (A: 0.8; B: 0.8; p=0.099). Control group was slightly older 
(6.9 years ± 0.5 vs. 5.3 years ± 0.5; p=0.042). At follow-up visits after 3 and 6 
months, HbA1c, BMI, daily insulin dose and blood glucose values were as-
sessed. The group A also was asked about the frequency of using the toolset.
Results: 94 patients completed 26-week follow-up. There were no significant 
difference between groups with regard to HbA1c (group A - 7.4% ± 0.2, n=43 
vs. group B - 7.6% ± 0.1, n=51; p= 0.222). Patients who declared using the 
toolset everyday (86-100% of meals) or for the most part of the week (51- 85% 
of meals) had significantly lower HbA1c (6.9 ± 0.2, n=21) in comparison with 
the control group (7.6 ± 0.1, n=51; p=0.0005). Moreover subgroup of patients 
who used ELKa only for 50-85% meals also achieved better result in a glycated 
hemoglobin than control group (HbA1c 6.8% ± 0.2, n=14; p= 0.0009).
Conclusion: Our results confirm the beneficial effect of using ELKa system 
in day-to-day calculations of CHO and FP exchanges. Diabetic children who 
used the system for more than 50% meals achieved better metabolic control 
than children who performed food calculations without this tool.
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Role of mobile technology to improve diabetes care in adults with type 1 
diabetes: the REMOTE-T1D study
S.K. Garg1, W.R. Hiatt2, P.A. Gottlieb1, C.R. Beatson1, F. Flacke3, V.N. Shah1, 
J.K. Snell-Bergeon1;  
1Barbara Davis Center for Childhood Diabetes, University of Colorado 
Denver, 2CPC Clinical Research, University of Colorado Denver, Aurora, 
USA, 3Sanofi, Paris, France.
Background and aims: This study evaluated the role of mobile technology 
to improve diabetes care in adults with type 1 diabetes (REMOTE-T1D). We 
hypothesized that the use of mobile technology (iPhone plus iBGStar®) will 
result in improvement in Patient Reported Outcomes (PRO).
Materials and methods: This single-center, prospective, 6-month, open-
label, investigator-initiated pilot study enrolled 100 adult patients with type 1 
diabetes. Patients were randomized in a 1:1 fashion to an intervention group 
using self-monitoring of blood glucose (SMBG) with iBGStar vs. SMBG with 
Accu-Chek Nano® (control). All subjects wore a blinded, continuous glucose 
monitor (CGM) for four separate 7-day periods. Primary outcomes included 
PRO (hypoglycemia fear questionnaire) and the secondary outcomes includ-
ed glucose control parameters. Insulin doses, hypoglycemic episodes and 
self-monitored blood glucose (SMBG) measures were obtained at each visit. 
At the conclusion of the study, satisfaction with the device was ascertained.
Results: Baseline demographics and A1c values were similar between the two 
groups (mean SD ± A1c 7.7 ± 1.0 and 8.0 ± 0.9 in the control and iBGStar 
groups, respectively, p=0.15) . The Hypoglycemia Fear Scale improved com-
pared to baseline in both groups to a similar extent at 3 months (-4.5 ± 9.5 in 
the iBGStar group vs. -3.0 ± 8.4 in the control group, p=0.65 between groups) 
and the changes remained similar between groups at 6 months (-3.9 ± 12.5 in 
the control group vs. -1.4 ± 10.0 in the iBGStar group, p=0.31). There was a 
significant improvement in change of A1c in the iBGStar group at 6 months 
when compared to baseline or the control group (Figure). The percentage of 
time spent in hypoglycemia (less than 70 mg/dL) as assessed by CGM read-
ings was similar in the two groups throughout the study. There was a signifi-
cant increase in insulin dose at 3 months in the iBGStar group (7.7 ± 20.9 
units/day) but not in the control group (1.7 ± 18.3 units/day), with no differ-
ence in hypoglycemic episodes (21.5 ± 15.5 in the iBGStar group vs. 25.5 ± 
31 in the control group, p=0.48) throughout the study. The number of SMBG 
tests per day was similar at baseline (4.8 ± 1.1 in the iBGStar group and 5.2 ± 
1.1 in the control group, p=0.07) and decreased significantly from baseline in 
both groups at 6 months (-0.3 ± 0.09 in the iBGStar group vs. -0.4 ± 0.9 in the 
control group, p=0.48). At the exit interview, when asked whether they would 
prefer the iBGStar vs. their past SMBG device, 87.5% preferred the iBGStar.
Conclusion: We conclude that the use of iBGStar in this REMOTE-T1D 
study which allowed for easier communication of SMBG readings with the 
treating center by its email function, improved A1c at 6 months with no in-
creased risk of hypoglycemia or change in PRO. This device was well-received 
by patients.
Clinical Trial Registration Number: NCT1825382
Supported by: Sanofi
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Long-term tele-monitoring of patients with type 2 diabetes mellitus: 
results of the Greek pilot of the renewing health multicentre randomised 
control trial
G.E. Dafoulas1, A. Mavrodi2, P. Gkiata3, H. Giannakakos4, P. Stafylas5,  
M. Delizona6, V. Aletras2, P. Pechlivangolou7, K. Theodorou1, G. Koukoulis6, 
A. Bargiota6;  
1Faculty of Medicine,University of Thessaly, Larisa, 2Department of Business 
Administration, University of Macedonia, Thessaloniki, 3Intermunicipal 
Digital Community of Central Greece, Trikala, 45th Regional Health 
Authority of Thessaly and Sterea, Larisa, Greece, 5Health Information 
Management SA, Brussels, Belgium, 6Department of Endocrinology and 
Metabolic Diseases, Regional University Hospital, Larisa, Greece, 7Toronto 
Health Economics and Technology Assessment Collaborative, University of 
Toronto, Canada.
Background and aims: Evidence is required to assess the impact of long 
term telemedicine use in treatment of patients with type 2 diabetes mellitus 
(DMT2). The aim of the present study was to examine the impact of a long-
term telemonitoring program for patients with DMT2 on glycemic control, 
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health-related quality of life (HRQOL), physical activity and compliance with 
the mediterranean diet compared to usual care.
Materials and methods: In the Greek pilot of a prospective, randomized, 
single-blinded, multicenter, one year study 154 patients with DMT2 capable 
to use the telemonitoring device, with an HbA1c > 53 mmol/mol (7.0 % ac-
cording to NGSP) were studied after they were randomly assigned in the te-
lemonitoring group (IG), (N=74) and in the control group (CG), (N=80) and 
having signed the informed consent form. In the (IG) group patients‘ blood 
glucose profiles were collected weekly using a mobile phone health platform, 
for a period of one year. Allocated health professionals provided by phone the 
appropriate counseling on lifestyle and medication changes when required. 
Patients in (CG) group received usual care with face-to-face consultations. 
HRQOL was assessed using a generic (SF36v2) questionnaire and a disease-
specific questionnaire, the Problem Areas in Diabetes (PAID) scale. Physi-
cal activity was assessed using the self-administered short form instrument. 
International Physical Activity Questionnaire (IPAQ) and the compliance 
with the Mediterranean diet using the Mediterranean Diet Quality Index 
(KIDMED) adapted for Greek adults.
Results: The table shows the outcome of the variables studied in both groups. 
A greater reduction in HBA1C was observed in the IG compared to the CG at 
the end of the study. There was a statistically significant improvement in the 
generic HRQOL in the MCS, in the disease specific HRQOL and the physical 
activity in the IG compared with the CG, but there was no improvement in 
KIDMED in neither or the two groups.
Conclusion: Our preliminary results indicate that in patients with DMT2, 
home telemonitoring is more effective than usual care in improving glycemic 
control with concurrent improvement in patients quality of life and increase 
of their physical activity. However home telemonitoring does not seem capa-
ble to empower patients with DMT2 with to follow a healthier diet.
Clinical Trial Registration Number: NCT01498367
Supported by: ICT-PSP CIP EC, Greek Ministry of Health, Thessaly Prefecture
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Accuracy of Continuous Glucose Monitoring (CGM) under free-living 
conditions during three home closed loop studies
L. Leelarathna1, H. Thabit1, D. Elleri2, J.M. Allen1, A. Lubina-Solomon3,  
J.K. Mader4, C. Benesch5, M. Stadler6, T.R. Pieber4, S. Arnolds5, S.R. Heller3, 
S.A. Amiel6, D.B. Dunger2, M.L. Evans1, R. Hovorka1;  
1Institute of Metabolic Science, University of Cambridge, 2Department 
of Paediatrics, University of Cambridge, 3Academic Unit of Diabetes, 
Endocrinology and Metabolism, Department of Human Metabolism, 
University of Sheffield, UK, 4Division of Endocrinology and Metabolism, 
Department of Internal Medicine, Medical University of Graz, Austria, 
5Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany,  
6Diabetes Research Group, Kings College, London, UK.
Background and aims: Closed loop systems modulate insulin delivery based 
on glucose levels measured by commercial CGM devices. We evaluated the 
accuracy of Freestyle Navigator II CGM (Abbott Diabetes Care, CA, USA) 
against the capillary glucose measured by the in-built glucometer of Freestyle 
Navigator II CGM using Freestyle Lite glucose strips. Data collected dur-
ing three unsupervised randomised open-label crossover home closed-loop 
studies were pooled for the current analysis.
Materials and methods: Paired CGM and capillary glucose values (10,616 
pairs) were collected from 57 participants with type 1 diabetes [41 adults (age 
39±12 years, HbA1c 7.9±0.8%; mean±SD) recruited at five centres; 16 adoles-
cents (15.6±3.6 years, HbA1c 8.1±0.8%) recruited at one centre]. Participants 
were instructed to calibrate the sensor according to manufacturer instruc-
tions. Numerical accuracy was assessed by relative absolute difference (RAD) 
(|sensor - capillary| / capillary) x 100%) when capillary > 4.2 mM and by ab-
solute difference (AD) |sensor - capillary| when capillary ≤ 4.2 mM. Clinical 
accuracy was assessed by the Clarke error grid analysis.
Results: Total duration of sensor use for whole cohort was 2,002 days (48,052 
hours). The average number of capillary glucose values taken by adults and 
adolescents was 5.9 ± 2.0 and 4.3 ± 2.4 per day, respectively. Overall sensor 
accuracy for the entire capillary glucose range (1.1 to 27.8 mmol/L was good 
with a median (IQR) RAD of 10.2% (4.5 - 19.0). Sensor accuracy stratified 
according to capillary glucose levels is shown in Table. Lowest RAD was ob-
served in the hyperglycaemic range. Over 95% of pairs were in combined 
Clarke error grid zones A and B. Calculated per subject, median (IQR) RAD 
was 10.8% (8.7 -11.5). Ninety percent of participants had a median ARD < 
13.5%.
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Conclusion: In a cohort comprising 57 subjects with T1D aged 12 years and 
older, we observed high and consistent accuracy of FreeStyle Navigator II. 
Particularly at glucose levels above 10 mmol/l, this facilitates safe operation of 
closed loop as otherwise insulin over-delivery due to overestimated glucose 
levels could lead to hypoglycaemia. Our results support the use of Freestyle 
Navigator II in home closed loop studies and may contribute towards estab-
lishing performance criteria for CGM in home use.
Clinical Trial Registration Number: NCT01221467, NCT01440140 and 
NCT01666028
Supported by: JDRF, Diabetes UK and Seventh Framework Programme of the 
European Union
990
Comparison of paired and sensor-based glucose testing for meal bolus 
adjustment
G.A. Hayter, E.S. Budiman;  
Abbott Diabetes Care, Alameda, USA.
Background and aims: Meal boluses, whether based on carb counting or 
fixed bolus dosing, can benefit from periodic review of the post prandial glu-
cose response. For carb counting, this can mean adjusting the carb ratio. For 
fixed bolus, this can be used to directly increase or decrease the fixed amount. 
The post prandial glucose response can be characterized by the difference be-
tween the peak glucose in response to the meal and the glucose at meal start. 
Two glucose testing methods for measuring this difference are considered. 
The first approach relies on a pair of discrete strip tests, one at the meal start 
and one at some fixed time after meal start. This method is confounded by 
the fact that peak meal times vary widely. The second approach utilizes sensor 
data which is sampled periodically. The benefit of this method is that the peak 
time can be estimated which provides a better estimate of the glucose differ-
ence. The precision of both methods will be compared, taking into account 
measurement error.
Materials and methods: Sensor data from a feasibility study of a 14-day sen-
sor wear, comprising of 55 subjects with diabetes, is used. These data have a 1 
minute sample rate and will represent “truth” for this analysis. True meal start 
and peaks have been previously identified. Paired testing is simulated using 
the truth data, with the first reading at the true meal start and the second 
reading at a predetermined fixed time interval (e.g., 60 ,120 and 180 minutes). 
Sensor-based testing is simulated by decimating the truth data to longer sam-
pling intervals (e.g., 5, 10, 15 minutes) and a meal detection algorithm is ap-
plied to these decimated data to estimate meal start and peak times.
Results: The figure summarizes the median and inter-quartile-range (IQR) 
of the relative difference (RD) between the “true” glucose meal response and 
the results from the six methods. The three sensor-based testing methods 
are shown to have much better precision than the paired testing methods; 
IQR RD for the best paired testing (Paired 120) is about 46% compared to 
about 25% for all of the sensor-based testing methods, and paired testing has 
substantially more negative bias. The difference in precision between the two 
test methods is primarily attributed to the wide variation in glucose meal 
response from patient to patient; the sensor-based method estimates the peak 
time based on the data while the paired testing method assumes a fixed dura-
tion for the peak time. The figure also shows that performance for sensor-
based testing is similar for sample periods up to 15 minutes.
Conclusion: The sensor-based testing method offers a more consistent char-
acterization of meal response than the paired testing method, resulting in 
higher confidence that bolus adjustments can be made safely and effectively. 
The higher level of precision may allow dose titration that results in lower 
overall glucose levels with lower risk of hypoglycemia, but these results must 
be evaluated in prospective trials.
Supported by: Abbott Diabetes Care
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A cell-based hybrid biosensor for automatic real-time quality control of 
islets and sensing of insulin demand
F. Lebreton1, M. Raoux1, Y. Bornat2, J.-B. Floderer2, D. Bosco3, J. Gaitan1,  
P. Meda4, T. Berney3, B. Catargi1,5, S. Renaud2, J. Lang1;  
1Dépt. Sciences & Technologies, Université de Bordeaux, UMR CNRS 5248, 
Pessac, 2Institut Polytechnique de Bordeaux, UMR CNRS 5218, Talence, 
France, 3Dépt de Chirurgie, Hôpitaux Universitaires de Genève et Université 
de Genève, 4Dépt. Physiologie & Métabolisme, Université de Genève, 
Switzerland, 5Hôpital St André, CHU de Bordeaux, France.
Background and aims: Glucose sensors have achieved considerable progress 
in the treatment of diabetes but require complex algorithms to match the 
complexity of everyday life. In contrast, pancreatic islets have been shaped 
during 0.5 billion years of evolution to secrete insulin not only in response 
to glucose, but also to other nutrients and to modulate their functioning to 
take physiological conditions into account via hormone receptors. Islets may 
provide the optimal sensor that uses changes in electrical activity as the first 
integrative signals of regulation. We have set out to develop recording and 
real-time analysis of these signals (i) for long-term analysis in drug testing, 
(ii) to provide a device for pre-transplantation control of donor islets and (iii) 
to advance in the development of a novel sensor for insulin demand.
Materials and methods: Mouse and human islets were cultured on multi-
electrode arrays. Electrical activities received on each electrode were continu-
ously amplified and analogically filtered. Output signals were recorded for of-
fline analysis or digitally converted and processed (for up to 60 electrodes in 
parallel) in real time using integrated circuits that were specifically designed 
on a custom electronics board.
Results: An acquisition system of islet electrical activity has been designed 
to process 60 channels in real time. This portable and autonomous system 
measures islet signals of extremely low amplitude (microvolts). Digital filters 
embedded on integrated circuits perform signal frequency separation, as well 
as frequency and statistical computation on individual signals. Extracellular 
recordings of human and mouse islet cells reveal two distinct glucose-de-
pendent signals. According to pharmacology and experiments in Cx36-null 
mice, rapid action potentials (AP) are due to depolarization of single cells, 
whereas slower changes (slow waves, SW) result from coupling of multiple 
cells via gap junctions. In mouse islets, GLP-1 enhances SW frequencies at 
8.2 mM glucose with maximal effect at 50 pM. In islets perfused with glucose, 
first increasing the concentration in small 0.5 mM steps from 3 to 11 mM and 
then decreasing by the same steps, both APs and SWs displayed a maximal 
effect at 10 mM. An exquisite glucose-dependency was present with a hyster-
etic shape, characterized by a shift of the EC50 from 7.5 mM for the increasing 
phase of the glucose ramp to 8.5 mM glucose for the decreasing phase. Simi-
lar characteristics were observed in human islets. Moreover, our algorithms 
correctly blind ranked signals recorded at different glucose concentrations.
Conclusion: Glucose and GLP-1 signatures can be automatically computed 
from AP and SW signals. The islets provide natural integrated hysteretic 
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algorithms with rapid reaction to hyperglycemia and hormones as well as 
exquisite sensitivity to decreasing glucose levels, a safety latch against hypo-
glycemia. In the long-term, this system may also provide a unique biosensor 
for insulin demand.
Supported by: Région d’Aquitaine, ANR Emergence, French Min. of Research 
PhD scholarship
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Hurdles in bioelectronics sensors: how to guide cells toward electrodes?
E. Pedraza1, A. Karajić2, F. Lebreton1, M. Raoux1, J. Gaitan1, V. Ravaine2,  
A. Kuhn2, J. Lang1;  
1Dept. Sciences & Technologies, Université de Bordeaux, UMR CNRS 5248, 
2Université de Bordeaux, UMR CNRS 5255, Pessac, France.
Background and aims: We are exploiting the innate, multi-parametric sens-
ing ability of islets in order to develop a hybrid bioelectronics glucose sensor. 
In our sensor, multielectrode arrays (MEA) record the electrophysiological 
signal produced by beta cells in response to multiple environmental factors 
(glucose, lipids, hormones, etc.). Signal quality, and consequently overall sen-
sor performance, relies critically on close cell-electrode proximity. However, 
attempts to improve cell-electrode co-localization, via chemical/physical 
modification of electrodes or dielectrophoresis, lead to additional cell stress 
and convoluted setups. In contrast, we present here a non-invasive method of 
further exploiting the electrical properties of beta cells to guide them directly 
toward electrodes via simple electrophoresis.
Materials and methods: The electrophoretic motion of clonal beta cells 
(INS-1 832/13) (1E6 cells/mL) and murine islets (60 islets) in an electric field 
was investigated using a low conductivity, isotonic buffer (5 mM HEPES, 280 
mM mannitol, 5 mM glucose). The electric charge at the surface of the INS-1 
cells was measured in terms of their zeta potential using a Zetasizer Nano. 
Computational models describing the distribution of the electric field and 
predicting the path of cell motion were created to optimize electrode configu-
ration. INS-1 cells were subjected to an electric field for 10 min and subse-
quently assessed via proliferation assay (MTT) after 24 h, glucose stimulated 
response test after 48 h, and analysis of electrophysiological activity after 48 
h. Student‘s t-test was used in statistical analysis. Differences were considered 
significant (p<0.05).
Results: Application of a minimum uniform electric field succeeded in dis-
placing INS-1 cells and dissociated mouse islets (0.6 V/cm), as well as whole 
islets (10 V/cm), toward the positively charged electrode, suggesting that 
these cells possess a negative surface charge. This was confirmed by a zeta 
potential measurement of -27 ± 1.43 mV for INS-1 cells (n=9). Based on the 
results of the computational models, an electric field was generated in the 
MEA by applying an electric potential across neighboring electrodes in an 
alternating pattern. When 1.5 V was applied to the MEA, INS-1 cells and 
dissociated mouse islets mirrored the electrode pattern by repelling away 
from negatively charged electrodes and co-localizing directly over positively 
charged electrodes. Cells persisted in this pattern even after removal of the 
electric field. Subsequent assessment of viability, insulin secretion function, 
and electrophysiological activity revealed that cells were not functionally al-
tered by the process as compared to controls (n=3) (p>0.1).
Conclusion: Our findings demonstrate that INS-1 beta clonal cells and disso-
ciated mouse islets can be driven directly to target electrodes by applying an 
electric field. The positive results of the viability tests, insulin secretion tests, 
and electrical recordings demonstrate that this technique is not detrimental 
to the health and function of beta cells. Furthermore, its application can be 
extended to other cell types and other bioelectronics sensors. We are cur-
rently investigating how to adapt this technique to improve the manipulation 
of whole islets, a task which is complicated by their higher density compared 
to single cells.
Supported by: Excellence cluster Labex AMADEus
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Sensor and software use for improved glucose control in individuals with 
diabetes managed by multiple daily injections of insulin: the SIGN study 
R.A. Ajjan1, K. Abouglila2, S. Bellary3, A. Collier4, B. Franke5, E. Jude6,  
G. Rayman7, A. Robinson8, B. Singh9;  
1Molecular Vascular Medicine, Leeds University, 2County Durham & 
Darlington NHS Foundation Trust, Durham, 3Heart of England NHS Trust, 
Heartlands Hospital, Birmingham, 4University Hospital Ayr,  
5The Rotherham Hospital NHS Foundation Trust, Rotherham,  
6Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne,  
7Ipswich Hospital, 8Royal United Hospital, Bath,  
9Royal Wolverhampton Hospital NHS Trust, New Cross Hospital, UK.
Background and aims: Studies investigating the role of continuous glucose 
monitoring (CGM) to improve glycaemic control in type 1 and type 2 dia-
betes patients remain relatively scarce. Our study aims were to: 1) Assess 
whether subjects with type 1 (T1D) or type 2 diabetes (T2D) managed by 
multiple daily injection (MDI) of insulin could improve glycaemic control by 
understanding CGM data and reviewing ambulatory glucose profiles (AGP) 
with their clinician. 2) Identify device features and glucose profile character-
istics that enable improved clinical outcomes.
Materials and methods: A UK, multicentre (n=9), 100 day study recruit-
ed 105 MDI treated diabetes patients aged 18-82 years with HbA1c of 58-
108mmol/mol. Subjects were randomised to control or intervention group; 
the control group used a standard self-monitoring blood glucose device, 
FreeStyle Freedom Lite. The intervention group employed a FreeStyle Navi-
gator CGM and were asked to disable the glucose alarm function. At days 30 
and 45, subjects reviewed AGP and summary statistics with a clinician and 
completed a questionnaire at the end of the study. Post-hoc exploratory anal-
ysis evaluated the frequency of high glucose variability, defined to be, have at 
least one period of the day (by each patient’s typical meals and bedtimes) with 
the 50th - 10th percentiles > 4.72 mmol/L.
Results: In T1D intervention group (n=29), within group analysis showed 
significant reduction in hypoglycaemia (<3.9mmol/L) of 0.6±1.4hrs/day 
(mean±SD; p=0.0472) and a marginal decrease of 0.3±1.0hrs/day in time 
spent at <3.1mmol/L (p=0.0760), with no significant change in HbA1c (-3 ± 8 
mmol/mol; p= 0.58). In T2D intervention group (n=28), within group analy-
sis showed a significant increase in time within 3.9-10.0mmol/L of 1.4±3.5 
hrs/day (p=0.0427) associated with a reduction in HbA1c of 9±12 mmol/
mol (p=0.0002) without an increase in hypoglycaemia. Subjects agreed or 
strongly agreed with the statements: i) glucose profile was easy to understand 
[T1 (n=29) 93%, T2 (n=29) 93%], ii) need for management change was clear 
[T1 (n=30) 93%, T2 (n=28) 100%], iii) changes made after consultation with 
attending physician were helpful [T1 (n=30) 93%, T2 (n=29) 100%]. In the 
intervention group, incidence of high glucose variability was greater for T1 
than T2 patients at baseline [T1 19/25 (76%), T2 13/28 (46%), p=0.048], with 
no significant changes detected at trial end [T1 19/25 (76%); p=1.00 and T2 
10/28 (36%), p= 0.588].
Conclusion: T1D and T2D subjects were able to understand glucose data 
independently and in review with their clinician. Using FreeStyle Naviga-
tor CGM over three months T1D subjects showed significantly reduced 
time in hypoglycaemia. T2D subjects showed significantly increased time in 
3.9-10.0mmol/L and reduction in HbA1c without increasing hypoglycaemia. 
Further study is required to understand how to best manage glucose variabil-
ity to further improve glycaemic control.
Clinical Trial Registration Number: ADC PMR APO 12015
Supported by: Abbott Diabetes Care
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CGM is not a limiting factor in artificial pancreas systems
A. Balo1, K. Nakamura1, T. Bailey2, A. Chang3, M. Christiansen4, D. Price1;  
1Dexcom, Inc, San Diego, CA, USA, 2AMCR, Inc, Escondido, CA, USA, 
3John Muir Physician Network Clinical Research Center, Concord,  
4Diablo Clinical Research Inc., Walnut Creek, USA.
Background and aims: CGM used for AP systems requires low glucose ac-
curacy for safety, euglycemic and hyperglycemic accuracy to optimize insulin 
dosing determinations, and consistent performance across sensors and over 
time. A modified CGM designed specifically for the AP project was assessed 
in a clinical research study.
Materials and methods: The study enrolled 51 subjects from 3 US centers, 
86% with T1D. Subjects wore sensors for up to 7 days and used self-mon-
itored blood glucose to calibrate their CGM twice daily. Each subject was 
in-clinic for 12 hours on day 1, 4, or 7 to collect YSI reference venous glucose 
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every 15 minutes and capillary SMBG test every 30 minutes; glucose was ma-
nipulated to provide sufficient data in low and high glucose ranges.
Results: On average, the CGM provided glucose readings with a mean abso-
lute relative difference (MARD) of 9% relative to temporally-matched refer-
ence YSI compared to 5% of that for the SMBG meter. The CGM readings 
were highly correlated with YSI with correlation coefficient of 0.97 compar-
ing 0.99 of that for SMBG in the regression analyses. Using YSI reference, 
the CGM performed similarly as the SMBG meter. In particularly, for hypo-
glycemia (< 70 mg/dL , i.e.3.9mml/L), the mean absolute difference (MAD) 
was 6.4 mg/dL ( 0.36 mmol/L) for the CGM compared to 4.2 mg/dL i.e. 0.23 
mmol/L) for the SMBG; for hyperglycemia (> 180 mg/dL i.e.10 mmol/L), the 
MARD was 8% for the CGM compared to 5% for the meter. The Clarke Error 
Grid (CEG) showed that 92% of CGM-YSI matched pairs fall in the clinically 
accurate A zone with 7% in the B zone, 0.0% in the C zone, and 0.5% in D 
zone for CGM; and 98.5% of SMBG-YSI matched pairs fall in the A zone with 
1.1% in the B zone, 0.0% in the C zone, and 0.4% in the D zone.
Conclusion: The overall point accuracy, clinical accuracy,accuracy over the 
duration of wear, accuracy across the glycemic ranges, and reliability (98% of 
sensors lasted 7 days) were comparable to the SMBG meter. Accordingly, the 
CGM accuracy should not limit AP system development. Figure 1. Compari-
son of CGM-YSI vs. SMBG-YSI
Clinical Trial Registration Number: NCT02087995
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Glucose concentrations in blood and tissue: variable time lag
R. Chlup1,2, J. Krejci3, M. O´Connell4, B. Sebestova3, R. Plicka3, L. Brozova3, 
B. Doubravova3, H. Zalesakova2, J. Vojtek3, J. Bartek5;  
1Dept. of Physiology and IInd Dept. of Medicine, Palacký University and 
Teaching Hospital, Olomouc, Czech Republic, 2Institute of Gerontology 
and Geriatrics, Moravsky Beroun, 3BVT Technologies, a.s., Strazek, Czech 
Republic, 4Probe Scientific Ltd, Bedford, UK, 5Dept. of Medical Chemistry 
and Biochemistry, Palacký University Olomouc, Czech Republic.
Background and aims: Time constants dealing with carbohydrate metabo-
lism are hot topics of diabetes physiology. Current methods derive glucose 
concentrations from different tissues using subcutaneous and whole blood 
measures. The aim of this pilot study was to assess the time delay between 
glucose concetration in blood and tissue in the course of increase and de-
crease.
Materials and methods: Three healthy volunteers, 3 persons with type 1 dia-
betes (DM 1) and 4 persons with type 2 diabetes (DM 2) underwent concur-
rent glucose measurements using standard equipment (1) continuous glucose 
monitoring system (CGMS), namely, sensor Enlite, transmitter Minilink and 
monitor Guardian, Medtronic Minimed, CA, USA, calibrated by glucom-
eter Calla, Wellion, Austria, and (2) Beckman analyser to estimate venous 
plasma lglucose concentrations. Samples were taken in fasting state (just be-
fore drinking 300 ml tea with 50 g glucose) and then 4 times (hourly). This 
test was performed on 3 consecutive days. Carelink Personal and MS Excel 
were applied to plot the 4-hour evolution of glucose concentration obtained 
by CGMS and by Beckman, respectively. In each volunteer the time differ-
ence between ascending and descendig plots was estimated and averaged for 
healthy persons, for DM 1 and for DM 2, respectively.
Results: The results are summarized in the Table showing 1) the mean time 
delay of defined glucose concentrations between the methods, 2) the mean 
period of time from the start of consuption of glucose to the maximum dif-
ference betwen the rising glucose concentrations, 3) the mean period of time 
from the start of consumption of glucose to the maximum glucose concen-
tration, 4) the mean delay betwen the decreasing glucose oncentrations. The 
results are relevant to common practice.
Conclusion: In persons with diabetes glucose tolerance testing resulted in 
slower transport of glucose into subcutaneous tissue than in healthy subjects. 
The rate of change of glucose between blood and tissue varies, introducing er-
rors in CGMS readings when calibrations are made in non-steady state con-
ditions. CGMS can provide reliable plasma glucose concentrations but only 
if the system is calibrated during steady state. Hence, before each calibration 
an appropriate algorhithm to confirm the presence of a steady state should 
be applied.
Supported by: Palacky University Olomouc; Probe Scientific Ltd
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Glucose trend prediction in diabetic patients using Random Forests 
algorithm for analysis of CGM data
K. Tabakov1, N. Myakina2;  
1Department of Information Technology, Novosibirsk State University, 
Russian Federation, 2Laboratory of Endocrinology, Institute of Clinical and 
Experimental Lymphology, Novosibirsk, Russian Federation.
Background and aims: Avoiding both hypoglycemia and hyperglycemia is 
the critical difficulty in the management of diabetes because of the impact 
of multiple factors on glycemic trends. Despite this, the development of new 
approaches to analysis of data obtained in continuous glucose monitoring 
(CGM) provides an opportunity for prediction of glucose level without quan-
tifying of these factors. The aim of the study was to evaluate the possibility 
of using the Random Forest algorithm for glucose level prediction based on 
CGM data.
Materials and methods: Total 50 records of 48 h CGM obtained from pa-
tients with type 1 and type 2 diabetes mellitus were analyzed. Based on this 
dataset using Random Forests algorithm and R-STUDIO software a 50 lin-
ear regression models were created for each case individually. Programming 
the Random Forests module was performed using the author‘s modification 
of the algorithm of local search, which allows you to automatically find the 
optimal settings of the program for a particular purpose. Various predictive 
windows of 50-360 min were chosen to predict glucose trends in these diabe-
tes patients. The algorithm was trained individually for each case on a set of 
randomly selected segments of the CGM record that total was 50% of the en-
tire record. Subsequently, the algorithm was verified on the data not included 
in the training set. Model adequacy was evaluated by the difference between 
the predicted and actual value and also by the mean square error of all the 
predicted values at hypoglycemic and hyperglycemic ranges.
Results: Overall, a valid prediction has been provided at normal, hypoglyce-
mic and hyperglycemic ranges in 50-180 min predictive window: the mean 
squared prediction error was 8.1, 8.6 and 9.8, respectively (p=0.0001).
Conclusion: Random Forests algorithm can be successfully utilized to pre-
dict glucose levels in diabetic patients based the CGM data. At the predictive 
window of 50-120 min (an important period related to postprandial glyce-
mia) the model has a good predictive accuracy. Models like these could be 
employed in a semiclosed-loop device that can provide better glycemic con-
trol in diabetic patients.
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Time delay, reference measurement errors and number of reference 
measurements may strongly alter MARD values for CGM devices
H. Kirchsteiger1, G. Freckmann2, L. Heinemann3, V. Lodwig4,  
G. Schmelzeisen-Redeker4, M. Schoemaker4, L. del Re1;  
1Institute for Design and Control of Mechatronical Systems,  
Johannes Kepler University Linz, Austria,  
2Institute for Diabetes-Technology GmbH, Ulm, 3Science & Co, Düsseldorf, 
4Roche Diagnostics GmbH, Mannheim, Germany.
Background and aims: As a parameter describing the measurement quality 
of CGM systems most often the median (or mean) average relative deviation 
(MARD) is stated. For calculation of MARD paired CGM readings and re-
sults of reference blood glucose measurements are used. However, this com-
parison is affected by: a) measurements are made in different compartments 
(blood, interstitial fluid) which leads to a time-delay between the results; b) 
reference values are also affected by measurement errors; c) the selection and 
number of time points used for computation has an effect as well.
Materials and methods: In order to evaluate the effect of these factors we 
re-analyzed data from a clinical study in which the performance of 3 differ-
ent CGM systems (two of each kind, 6 in total) was evaluated in 12 patients 
with type 1 diabetes. We systematically varied the time delay between the 
two measurement methods to find the delay which results in the minimal 
MARD. The result was verified using a correlation based time delay analysis. 
We simulated measurement errors of the reference method and formulated 
an optimization problem, which gives as a solution the reference measure-
ment values inside the error bounds, which result in the minimal MARD 
values. We also systematically selected different time points of paired refer-
ence and CGM measurements which were excluded from the MARD com-
putation: a) repeatedly excluding the time-point which contributes the most 
to the MARD; b) repeatedly excluding the time-point which contributes the 
least to the MARD. This results in two functional dependencies of the MARD 
from the nr. of samples used with the actual MARD value being in between 
the extreme cases.
Results: MARD values decrease from originally 16.5%, 12.6%, and 16.7% for 
the CGM systems by 1.5%, 1.7%, and 2.5% when compensating for the ef-
fect of the time-delay. MARD values varied in the worst case in the range of 
11.0_21.8%, 6.9_16.3%, 10.7_21.6% when compensating for a 5% measure-
ment error of the reference method and the estimated time-delay. The MARD 
values varied even more with different selections of the time-points of paired 
measurements: Reducing the number of paired measurements by 50% can re-
sult in an improvement (= lower value) by nearly 50% of the original MARD 
value. However, selecting different time points can also result in an MARD 
value twice as high as the original value.
Conclusion: MARD is greatly affected by various factors. Following a rigor-
ous protocol that controls for certain factors that have an impact on MARD 
is crucial to enable uniform comparability among different clinical studies. 
POCT05-A guidelines should consider the effects discussed.
Supported by: Roche Diagnostics
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Using of RT-CGMS during perinatal period with special focus on 
newborn hypoglycaemia occurence: our ongoing experience
K. Stechova1, K. Chaloupek2, D. Bartaskova1, I. Spalova3, M. Cerny2;  
1Dpt.of Internal Medicine, 2NICU, Dpt.of Obstetrics and Gynaecology,  
3Dpt.of Obstetrics and Gynaecology, University Hospital Motol, Prague, 
Czech Republic.
Background and aims: In babies of diabetic mothers perinatal complications 
including hypoglycaemia are still seen more frequently than in newborns of 
healthy mothers. In our study by using real time continuous Glucose moni-
toring system (RT-CGMS) we monitor pregnant women prior the labour and 
we continue to monitor their newborns after the birth as well to be able to 
follow complex glycaemia changes which influence the child prior and after 
the birth and correlate them with the newborns´s clinical status including 
hypoglycaemia occurence.
Materials and methods: Newborns: We analysed by RT-CGMS 30 newborns 
of mothers suffering from pregestational diabetes, all mothers were treated by 
insulin. 23/30 of these children were born to type 1 diabetes (T1D) mothers, 
in 5/30 mothers were treated for T2D (type 2 diabetes) and in 2/30 cases the 
mother has MODY2 (maturity onset diabetes of the young). Median of gesta-
tion age in diabetes group was 37 weeks (range 31-38 weeks). Newborns were 
classified into four clinical status cathegories for further analysis. The first 
Enlite sensor was placed immediately after the birth (connected to Guardian 
real time device, Medtronic, Minneapolis, MN, USA). Eight term newborns 
born to healthy mothers were analysed as controls too. The median of moni-
toring in diabetes group was 5 days (range 3-8 days) and 4 days in controls 
(range 4-6 days). Mothers: in 9 T1D mothers their RT-CGMS records at least 
3 days prior the labour and during the labour were available for the analysis 
too. In mothers the same type of RT-CGMS device was used as in newborns.
Data were analysed by SPSS sw v.17. Notice - hypoglycaemia in newborns is 
considered as glycaemia ≤ 2,5 mmol/l.
Results: RT-CGMS revealed higher frequency of hypoglycaemia episodes in 
newborns of diabetic mothers (only 6/30 newborns of diabetic mothers were 
without any hypoglycaemia). These hypoglycamia episodes were present not 
only shortly after the birth but after 3rd monitoring day as well (p=0.01). In 
control newborns hypoglycaemia episodes were present too (4/8) but during 
the first 4 days of life only and were less frequent and shorter. In T1D group 
the occurrence and severity of hypoglycaemia were influenced by: the pres-
ence of macrosomia (p=0.022), length of the newborn (p=0.001), maternal 
HbA1c in 3rd trimester (p<0.001), maternal weight gain (p=0.02), maternal 
total insulin dose (p=0.001) and by maternal age (p=0.03). Of particular im-
portance to newborn´s clinical status and hypoglycamia occurence seems to 
be the difference between maternal glycaemia one hour prior the child´s birth 
and newborn´s glycaemia measured immediately after the birth (p<0.001). 
Hypoglycaemia events were always confirmed in the laboratory and in gen-
eral sensor readings correlated well with laboratory findings (r=0,82, p=0,01).
Conclusion: RT-CGMS can help not only to maintain maternal (near)nor-
moglycaemia but is useful in revealing postnatal hypoglycaemia in her child 
which together with an adequate treatment can improve adaptation of new-
borns born to diabetic mothers.
Supported by: NT/11407-5, 00064203
999
Efficacy and safety of insulin pump therapy in type 2 diabetes:  
the OpT2mise study
Y. Reznik1, O. Cohen2, R. Aronson3, S. Runzis4, J. Castaneda4, S. De Portu4, 
S. Lee5, I. Conget6;  
1Endocrinology and Diabetes Department, Caen, France, 2Institute of 
Endocrinology, Tel Hashomer, Israel, 3LMC Diabetes & Endocrinology, 
Toronto, Canada, 4Medtronic International Trading Sàrl, Tolochenaz, 
Switzerland, 5Medtronic Inc, Northridge, USA, 6Endocrinology and 
Nutrition Department, Barcelona, Spain.
Background and aims: Multiple daily injection (MDI) regimens may be of-
fered to patients with type 2 diabetes (T2D) not responding to basal insulin 
therapy but offer only marginally improved rates of success. Alternative ap-
proaches to insulin therapy have included continuous subcutaneous insulin 
infusion (CSII) which have been studied in prior randomized controlled 
studies in T2D patients but produced conflicting results. This study is the first 
large multicenter, randomized, controlled trial aiming to compare the effi-
cacy and safety of CSII vs MDI in insulin-using patients with T2D who failed 
to respond to a basal-bolus regimen after active insulin titration.
Materials and methods: Subjects with poor glycemic control (n=495) on 
multiple doses of insulin (MDI, basal-bolus using insulin analogs) were en-
rolled into a 9-week run-in period for insulin dose optimization (≥0.7 and 
≤1.8 U/kg/d). Subjects showing persistent hyperglycemia (HbA1c ≥8% and 
≤12%) at the end of this period were then randomly assigned to switch to 
CSII or to continue with MDI regimens for 6 months. Both arms underwent 
double-blinded continuous glucose monitoring (CGM) assessments at base-
line and 6 months. The primary endpoint was the between-group difference 
in mean change in HbA1c from baseline to 6 months.
Results: A total of 331 subjects were randomized (45.6% women, mean±SD 
age 56.0±9.6 yr, BMI 33.4±7.3 kg/m2, diabetes duration 15.1±8.0 yr, HbA1c 
9.0±0.8%). Subjects assigned to CSII achieved significantly greater HbA1c 
reduction than MDI arm (-1.1±1.2% vs. -0.4±1.1%, p<0.001), for a between-
group difference favoring the CSII arm of -0.7% (95% CI, -0.9 to -0.4). The 
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percentage of subjects achieving HbA1c <8.0% was 57% in CSII arm vs. 27% 
in MDI arm (OR=1.9, 95% CI 1.47 to 2.46, P<0.001) CGM analysis showed 
a significant reduction of duration of hyperglycemic events in the CSII arm 
compared to the MDI arm (- 225 min vs -56 min, p<0.001) while no differ-
ence in the time spent in hypoglycemia was observed between both arms. At 
the end of the study, total daily insulin dose was 20.4% lower in the CSII arm 
than in the MDI arm (97±56 U/d vs 122±68 U/d, p<0.001), and there was no 
significant between-arms difference in body weight change (CSII,+1.5±3.5 
kg vs MDI, +1.1±3.6 kg, p=0.215). No ketoacidosis occurred in either group, 
and one episode of severe hypoglycemia occurred in the MDI group.
Conclusion: The OpT2mise study demonstrates that CSII provides a sig-
nificant advantage in glycemic control over MDI in T2D patients who fail to 
achieve HbA1c target and therefore represents a new option for the treatment 
of T2D.
Clinical Trial Registration Number: NCT01182493
Supported by: Medtronic International Trading Sàrl
1000
Multi-centre closed-loop insulin delivery trial points to variability in 
keeping glycaemia in a pre-defined target range at the individual level
E.M. Renard1,2, H. Zisser3,4, B. Kovatchev5, C. Cobelli6, D. Bruttomesso6,  
R. Nimri7, B.A. Buckingham8, P. Chase9, F.J. Doyle III4, L. Magni10,  
P. Calhoun11, J. Lum11, Control to Range Study Group;  
1Department of Endocrinology, Diabetes, Nutrition, Montpellier University 
Hospital, 2Institute of Functional Genomics, University of Montpellier 1, 
France, 3Sansum Diabetes Research Institute, Santa Barbara, 4Chemical 
Engineering Department, University of California, Santa Barbara, 
5University of Virginia, Charlottesville, USA, 6University of Padova, Italy, 
7Schneider Children‘s Medical Center of Israel and Sackler Faculty of 
Medicine, Tel Aviv, Israel, 8Stanford University, Stanford, 9Barbara Davis 
Center for Childhood, Aurora, USA, 10University of Pavia, Italy, 11Jaeb 
Center for Health Research, Tampa, USA.
Background and aims: Closed-loop insulin delivery aims at keeping blood 
glucose close to normal in patients with Type 1 diabetes (T1D) based on con-
tinuous glucose monitoring (CGM) and insulin administration according to 
a control algorithm. The performance of a model predictive control (MPC) 
algorithm in reaching a predefined glucose target range in a large number of 
patients at the individual level was investigated.
Materials and methods: Fifty-three T1D patients (27 adults: 15M/12F, age: 
41+/-11, BMI: 24+/-3, HbA1c: 7.7+/-0.6%, T1D duration: 25+/-11 yrs; 26 
adolescents: 13M/13F, age: 15+/-1, BMI: 23+/-4, HbA1c: 8.1+/-0.9%, T1D 
duration: 8+/-3 yrs) underwent a 22-hour (9AM-7AM) closed-loop insulin 
delivery trial in 7 Clinical Research Centers. Each admission included 3 meals 
with normal announced bolus before each meal and no exercise. The closed-
loop system included the Dexcom Seven Plus CGM (San Diego, CA), the 
OmniPod insulin pump (Insulet Corp, Bedford, MA) and a laptop computer 
running an MPC algorithm. The inter-device communication was automated 
by the Artificial Pancreas Software. Control was evaluated for its ability to 
maintain glycemia in 71-180 mg/dl range from YSI-measured glucose every 
15 min for 90 min post-meal and every 30 min between meals and overnight.
Results: For adults, mean glucose was 159 mg/dl and the mean percentage 
in target range was 66% overall, 59% daytime, and 82% overnight. At least 
one YSI value was >300 mg/dl and at least one ≤60 mg/dl in 22% and 19% 
of admissions, respectively. For adolescents, mean glucose was 166 mg/dl 
and the mean percentage in target range was 62% overall, 53% daytime, and 
82% overnight. At least one YSI value was >300 mg/dl and at least one ≤60 
mg/dl in 32% and 20% of admissions, respectively. In 33 cases, out-of-range 
excursions included only post-meal hyperglycemia. In 18 cases, hypoglyce-
mia occurred as late post-meal events, following previous hyperglycemia in 
most cases. An alternative glycemic pattern, observed in 4 cases, included 
several hypoglycemic excursions during day and/or night without any post-
meal hyperglycemia. Individual patterns of out-of-range excursions under 
closed-loop could be related to inaccurate estimations of insulin sensitivity 
and CHO/insulin ratio from pre-investigational individual data in open-loop 
control conditions.
Conclusion: Our data analysis points to the inter-individual variability of 
closed-loop glucose control contrasting with overall acceptable performance. 
It supports the necessity of both closed-loop studies in large populations in-
cluding patients with various characteristics, and individualization of control 
algorithm parameters.
Clinical Trial Registration Number: NCT01271023
Supported by: JDRF
1001
The impact of exercise and reductions in insulin pump basal delivery 
implemented prior to exercise on circulating insulin levels in people with 
type 1 diabetes
S.A. McAuley1,2, J.C. Horsburgh2, G.M. Ward1,3, J.L. Gooley2,  
R.J. MacIsaac1,2, D.N. O‘Neal1,2;  
1Department of Endocrinology & Diabetes, St Vincent‘s Hospital, 
2Department of Medicine, University of Melbourne,  
3Department of Pathology, University of Melbourne, Australia.
Background and aims: Minimal data guides optimisation of insulin pump 
basal insulin infusion rate (BIIR) reductions prior to exercise. This study in-
vestigates the effect of a reduction in subcutaneous BIIR, and the effect of 
exercise itself, on circulating free insulin levels.
Materials and methods: In a two-stage randomised crossover study, 11 
adults with type 1 diabetes using insulin pump therapy were studied fasting 
following a night on a single BIIR (6M/5F, mean ± SD: age 43 ± 10 years, 
diabetes duration 22 ± 9 years, HbA1c 7.1 ± 0.5 %, BIIR per kg body weight 
0.011 ± 0.001 U/h/kg). Insulin, insulin pump and pump consumables were 
standardised. The exercise stage (ES) and non-exercise stage (NES) were in 
random order, separated by 1 to 6 weeks. In both stages, after 60 min of rest, 
BIIR was reduced by 50% for 210 min. Venous samples were collected at 15 
min intervals from 60 min pre- until 210 min post-BIIR reduction. During 
NES participants were observed at rest without exercise. During ES partici-
pants exercised for 30 min on a stationary bicycle (target workload 65-70% 
of age-predicted maximal heart rate) commencing 60 min post-BIIR reduc-
tion, then rested for 120 min. Plasma insulin was measured by RIA; plasma 
was pre-treated with polyethylene glycol to precipitate bound insulin when 
antibodies were present. Data are presented as mean ± SEM.
Results: Following the BIIR reduction in NES, free insulin levels reduced by 
5.3 ± 3.2 %, 16.2 ± 2.4 % and 16.4 ± 3.5 % from baseline at 1h, 2h and 3h, re-
spectively (baseline vs 1h p = 0.09; 1h vs 2h p < 0.001; 2h vs 3hr p = 0.81). The 
rate of insulin level decline post-BIIR reduction in NES did not correlate with 
baseline BIIR per kg body weight (r = 0.18, p = 0.59). Exercise for 30 min in-
creased free insulin levels by 0.8 ± 0.3 mU/l compared to rest (p = 0.02). Insu-
lin levels subsequently declined more rapidly over the first hour post-exercise 
compared to NES (-2.2 ± 0.4 mU/l vs -0.7 ± 0.2 mU/l; p = 0.006) [see figure].
Conclusion: The NES data demonstrate that when preparing for exercise, an 
interval of at least two hours is required after a 50% BIIR reduction to impact 
circulating free insulin levels. However, even by three hours post-reduction, 
insulin levels remain above 80% of baseline. Supplemental carbohydrate and/
or a greater reduction in insulin dosing may be required to avoid exercise-
induced hypoglycaemia. A transient increase in free insulin levels occurred 
during 30 min moderate-intensity exercise, consistent with initial enhanced 
absorption from the subcutaneous insulin depot due to increased blood flow 
during exercise. The subsequent more rapid decline in insulin levels over the 
first hour post-exercise could partly relate to this prior enhanced absorption. 
These findings may guide optimisation of BIIR reductions prior to exercise.
Clinical Trial Registration Number: ACTRN12613000581763
Supported by: ADS-Sanofi grant, Lynne Quayle Charitable Trust, sensors from 
Medtronic
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Factors associated with successful continuous subcutaneous insulin 
infusion therapy in type 2 diabetes patients - the OPT2MISE trial 
O. Cohen1, Y. Reznik2, I. Conget3, R. Aronson4, J. Castañeda5, S. Huang6,  
S. Lee6, J. Shin6, OpT2mise Study Group;  
1Ch. Sheba Medical Center., Tel-Hashomer, Israel, 2Centre Hospitalier 
Régional Universitaire de Caen Côte de Nacre, France, 3Endocrinology and 
Nutrition Department, University Hospital Clinic, Barcelona, Spain,  
4LMC Diabetes & Endocrinology, Toronto, Canada, 5Medtronic Bakken 
Research Center, Maastricht, Netherlands, 6Medtronic, Northridge, USA.
Background and aims: The recent randomized study OpT2mise, demon-
strated that insulin pump therapy (CSII) provided significant improvement 
in glycemic control, as compared with injection therapy (MDI) in type 2 dia-
betes (T2D). We aimed to assess the association between baseline or treat-
ment related factors with glycemic improvements seen in the CSII arm of 
the study.
Materials and methods: Sub-optimally controlled (HbA1c ≥ 8%) T2D sub-
jects, despite an MDI optimization period, were randomly assigned to CSII or 
continuing an MDI regimen. Simple and multiple linear regression analysis 
were performed to assess the association of A1c change at 6 months and fac-
tors such as age, gender, duration of diabetes, baseline A1c, BMI, treatment 
satisfaction score (DTSQs), total daily insulin dose, cognitive state score 
(MoCA) and glucose self-measurements (SMBG). Analyses were adjusted by 
baseline A1c.
Results: A total of 331 subjects were randomized (45.6% women, age 56.0±9.6 
yr, BMI 33.4±7.3 kg/m2, diabetes duration 15.1±8.0 yr, HbA1c 9.0±0.8%). Sub-
jects assigned to CSII achieved significantly greater A1c reduction (p<0.001) 
and more treatment satisfaction (p<0.001) than MDI arm. The effect of CSII 
and MDI in A1c change was dependent on baseline A1c (p<0.001). CSII was 
superior to MDI in the observed range of baseline A1c values and the advan-
tage of CSII over MDI increased with higher baseline A1c (between group 
difference= -0.4±0.9% for subjects with baseline A1c≤9.0% and -1.0±1.4% 
for subjects with baseline A1c>9.0%, p<0.01 in both cases). Older age, longer 
duration of diabetes, low cognitive score and low SMBG use did not diminish 
the effect. In the CSII arm only 6 month satisfaction and number of boluses 
were associated with A1c reduction (a 3 point higher DTSQs was associated 
with a reduction of -0.02% in A1c and one additional bolus was associated 
with a reduction of -0.2% in A1c, p<0.01).
Conclusion: CSII in sub-optimally controlled T2D patients was associated 
with greater improvement in A1c compared to MDI. Baseline A1c was a 
major predictor of glycemic response with improved CSII advantage over 
injection therapy for subjects with worst glycemic control. Further A1c im-
provement in CSII arm was associated with treatment satisfaction and num-
ber of boluses without increase in total daily dose. Although CSII treatment 
involves the use of advanced technology, patients who used lower frequency 
of SMBG, had lower cognitive state or older in age achieved comparable im-
provement in glycemic control with CSII.
Clinical Trial Registration Number: NCT01182493
Supported by: Medtronic Europe
1003
Effects of automatic insulin pump interruption on duration and weekly 
rate of nocturnal hypoglycaemic events in the ASPIRE In-Home Study
R. Weiss1, B. Bode2, T. Bailey3, F. Schwartz4, R. Brazg5, R. Bergenstal6,  
J. Thrasher7, R. Weinstock8, A. Ahmann9, D. Klonoff10, R. Slover11, S. Garg11, 
J. Welsh12, M. Mao12, ASPIRE In-Home Study Group;  
1Human Metabolism and Nutrition, Hebrew University, Jerusalem, Israel, 
2Atlanta Diabetes Asscociates, 3AMCR Institute, Escondido,  
4Ohio University, Athens, 5Rainier Institute of Clinical Research, Renton, 
6International Diabetes Center at Park Nicollet, Minneapolis, 7Arkansas 
Diabetes Clinic and Research Center, Little Rock, 8Joslin Diabetes Center, 
Syracuse, 9Oregon Health and Sciences University, Portland,  
10Diabetes Research Institute, Mills–Peninsula Health Services, San Mateo, 
11University of Colorado, Denver, 12Medtronic Inc, Northridge, USA.
Background and aims: The ASPIRE In‐Home Study was designed to evalu-
ate the Threshold Suspend (TS) feature of sensor‐augmented pump therapy, 
which automatically suspends insulin delivery at a pre‐set sensor glucose 
(SG) value. We evaluated the duration and weekly rate of nocturnal hypogly-
cemic (NH) events that occurred during the study
Materials and methods: An NH event was defined as lasting >20 min with 
SG values ≤65 mg/dL that started between 10PM and 8AM. Subjects with 
type 1 diabetes with ≥2 NH events during a run‐in phase were eligible. A 
total of 247 patients were randomized to SAP therapy with the TS feature 
(TS group, n=121) or without the TS feature (Control group, n=126). NH 
event durations throughout the 2‐week run‐in and 3‐month study phases 
were enumerated and categorized as lasting <2hours, 2‐4 hours, or >4 hours
Results: In panel A, 68% of NH events during the run‐in phase lasted <2 
h, 20% lasted 2‐4 h, and 13% lasted >4 h. During the study phase in the TS 
group, 79% of the NH events lasted <2 h and 3% lasted >4 h, while in the 
Control group, 64% lasted <2 h and 12% lasted >4 h; these between‐group 
differences were significant (p<0.001 for each) and reflect shorter NH events 
in the TS group. In Panel B, the rate of NH events per patient‐week was high-
er in the run‐in phase than in the study phase, regardless of treatment group. 
During the study phase, the rate of NH events was significantly lower in the 
TS group than in the Control group, regardless of event duration. Compared 
to the Control group, the rate of NH events lasting <2 h was reduced by 15% 
(p=0.02), the rate of NH events lasting 2‐4 h was reduced by 47% (p<0.001), 
and the rate of NH events lasting >4 h was reduced by 84% in the TS group 
(p<0.001). There was no severe hypoglycemia in the TS group and 4 events 
in the Control group.
Conclusion: In subjects with type 1 diabetes prone to hypoglycemia, use of 
TS was associated with favorable changes in the duration of NH events, with 
an increase in the proportion of short‐duration events and a corresponding 
decrease in the proportion of long‐duration events. Use of the TS feature was 
also associated with a reduction in the weekly rate of number of NH events, 
especially those lasting >4 h, suggesting a preventive effect and a reduction in 
the risk of progression to severe hypoglycemia.
Clinical Trial Registration Number: NCT01497938
Supported by: Medtronic Inc
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Glucose variability outcome for type 1 diabetic patients switching to 
CSII: improved complexity patterns beyond glucose dispersion reduction
M. Lytrivi, L. Crenier;  
Endocrinology, Erasme Hospital, Brussels, Belgium.
Background and aims: Standard Deviation (SD) and MAGE are commonly 
reported indices of glucose variability (GV). However, they represent meas-
ures of glucose dispersion rather than true quantifications of instability. These 
indices are also directly proportional to the mean, making them inappropri-
ate for comparisons of glucose profiles at different glucose levels. The aim of 
this work was therefore to study the evolution of GV in type 1 diabetic pa-
tients switching to continuous subcutaneous insulin infusion (CSII) in terms 
of both dispersion and complexity of the displayed patterns. For this purpose, 
we used metrics independent of the mean, as the Coefficient of Variation 
(CV), Approximate Entropy (ApEn) and the Detrended Fluctuation Analysis 
(DFA) method, which are, contrary to CV, sensitive to intrinsic complexity 
and self-similarities of glucose patterns rather than to value scattering.
Materials and methods: CV, ApEn (m=1,r=0.2xSD) and DFA-α were com-
puted from blinded Continuous Glucose Monitorings (CGMs) of 48h dura-
tion (iPro2 with Enlite® sensors, Medtronic MiniMed, Northridge, CA) ob-
tained from 20 adults with type 1 diabetes on MDI (baseline) and 6 months 
after initiation of CSII. Mean and SD of glucose, HbA1c, MAGE, the number 
of hypoglycemic episodes and time in hypoglycemia (TH) were also recorded.
Results: CV was reduced by 4.9 ± 9.7 (p=0.036) on CSII, while change in 
CV (ΔCV) was strongly correlated with baseline CV (Pearson’s r=-0.77, 
p<0.0001) but not with baseline HbA1c, glucose mean or SD. ApEn was found 
to increase on CSII (see panel A), indicating an increase in complexity of the 
glucose profiles. Although CV and ApEn were independent, changes in ApEn 
were inversely correlated with ΔCV (Spearman’s rho=-0.48, p<0.041), mean-
ing that larger CV reductions were concurrent with greater increases of ApEn 
(see panel B). ApEn was found to be inversely correlated with DFA-α (r=-
0.93, p<0.00001 on CSII) confirming that high ApEn glucose profiles obtain a 
DFA-α closer to 1 (DFA-α values ranged from 1.08 to 1.65 on CSII), meaning 
increased complexity with more self-similar structures and long-range cor-
relations as described in CGM profiles of healthy subjects. Additionally, SD, 
MAGE, mean glucose, HbA1c and TH (<50 mg/dl) were reduced by 17 ± 24 
mg/dl (p=0.004), 35 ± 52 mg/dl (p=0.008), 22 ± 40 mg/dl (p=0.022), 0.69 ± 
0.79% (p=0.001) and 0.77 ± 1.21 h/day (p=0.01), respectively.
Conclusion: CV on MDI predicts GV outcome on CSII. Patients with the 
highest baseline CV demonstrated the greatest reduction on CSII. In these re-
sponders, CSII increased also Approximate Entropy. This brings the glucose 
control closer to physiology, not only in terms of dispersion, but also in terms 
of the complexity exhibited in the glucose patterns. To our knowledge, this 
property of the CSII treatment had never been investigated.
PS 083 On the way to optimise pump 
treatment
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PaQ®, a simple 3-day basal/bolus insulin delivery device, may optimise 
insulin delivery in type 2 diabetes as determined by continuous glucose 
monitoring
R. Mazze1, E. Strock1, J. Mader2, L. Lilly3, F. Aberer2, T. Pieber2;  
1International Diabetes Center, Minneapolis, USA,  
2University of Graz, Austria, 3CeQur, Marlborough, USA.
Background and aims: PaQ (CeQur SA) is a simple patch-on device that 
provides set basal rates and bolus insulin on demand.
Materials and methods: A 6-week open-label single-arm study utilized 
blinded continuous glucose monitoring (CGM) to assess the effect of glyce-
mic control achieved with PaQ compared to multiple daily injections (MDI) 
of insulin. Twenty patients (age 59 ±5 y, T2D duration 15±7 y, A1C 7.7 ±0.7 
%), on a stable MDI regimen were enrolled and 18 completed. The study was 
comprised of three 2-week periods; baseline (MDI), transition to PaQ, and 
PaQ therapy. There was no attempt to treat to target. CGM data was ana-
lyzed by Ambulatory Glucose Profile (AGP) reporting system. AGP is used 
to graphically and statistically represent parameters of glycemic control for 
each period of CGM and treat data collected over a period of days as if it were 
measured on the same (modal) day.
Results: An overall trend toward improved glycemia was seen with an aver-
age reduction in glucose exposure from 4024 to 3834 mg/dL/24hrs (P=0.18) 
and improved glucose fluctuations from 10.9 to 9.7 mg/dL/hr (P=0.07) while 
participants used the same total daily dose of insulin during Baseline and 
PaQ treatment periods. Analysis of by-patient CGM modal days revealed that 
11 participants improved their glycemic control (see accompanying figure).
Conclusion: A larger study utilizing CGM is needed to further assess the 
insulin delivery potential of PaQ.
Clinical Trial Registration Number: NCT01535612
Supported by: CeQur
1006
Association of late eating habit and sleep duration with glycaemic 
control in adult type 1 diabetes patients treated with insulin pumps
B. Matejko1, B. Kieć-Wilk1,2, M. Małecki1,2, T. Klupa1,2;  
1Department of Metabolic Diseases, Jagiellonian University,  
2University Hospital, Krakow, Poland.
Background and aims: The most important benefit of continuous subcuta-
neous insulin infusion (CSII) is customized, flexible basal and bolus dosing to 
meet patients’ individual insulin requirements. This system of insulin deliv-
ery appears to offer not only improvement in metabolic control, but also in-
creased physiological and psychological wellbeing. However, concerns have 
also been raised that, by enabling more freedom, CSII could potentially give 
rise “unhealthy” behaviors, which in turn could lead to the deterioration of 
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metabolic control. The goal of this research was to examine if sleep duration 
and late eating habit in CSII treated T1DM patients were associated with gly-
cemic control as assessed by HbA1c level and mean self-monitoring blood 
glucose (SMBG) readings.
Materials and methods: We included 148 adult T1DM patients on insulin 
pump (100 females and 48 males) who filled a questionnaire concerning 
sleep duration (≤6h and >6h) and late eating (snacking after 10 p.m. - rarely, 
sometimes, often). Other sources of information about the patients includ-
ed available medical records together with the results of biochemical tests 
(HbA1c measured with high performance liquid chromatography method-
HPLC), memory read-outs from insulin pumps, data from blood glucose 
meters. Data from personal insulin pumps and blood glucose meters were 
downloaded regularly to the computer and analysed via CareLink Profes-
sional (Medtronic) and Accu Chek 360 (Roche) software. Tests for differences 
between the two groups, univariate correlations analysis, and multivariate re-
gression analysis were used.
Results: The patients‘ mean age was 26 yrs, mean T1DM duration 13.4 yrs, 
mean HbA1c level 7.2%, mean BMI 23.3 kg/m2, while mean nighttime sleep 
duration was 7.2 h. Short sleep duration (26.3% of patients) as compared to 
long sleep duration was associated with worse glycemic control - HbA1c: 7.6 
vs. 7.1%, p=0.0293; mean SMBG readings: 159 vs. 149 mg/dl, p=0.0491, re-
spectively. Additionally, in a univariate correlation analysis we found an as-
sociation between frequent late snacking (rarely: 54.1%, sometimes: 38.5%, 
often: 7.4%) and worse HbA1c level (r=0.19, p=0.0287) and SMBG readings 
(r=0.21, p=0.0135). In the multivariate regression analysis (dependent varia-
bles - age, T1DM duration, gender, BMI, sleep duration and frequency of late 
snacking), independent predictors for HbA1c were the patient‘s age (β=-0.34, 
p=0.0013), T1DM duration (β=0.21, p=0.0440) and sleep duration (β=-0.23, 
p=0.0061). The analyzed model was significant (p=0.0017). In the multivari-
ate regression analysis for mean SMBG readings, the same variables except 
for T1DM duration were significant
Conclusion: In summary, short sleep duration seems to be associated with 
poorer glycemic control in T1DM patients treated with CSII but late snack-
ing is not.
1007
Factors predictive of overnight closed loop performance during free 
living in children and adults with type 1 diabetes
M. Tauschmann1, H. Thabit1, L. Leelarathna1, D. Elleri1, J.M. Allen1,  
A. Lubina-Solomon2, M. Stadler3, E. Walkinshaw2, A. Iqbal2, P. Choudhary3, 
S.R. Heller2, S.A. Amiel3, M.L. Evans1, D.B. Dunger1, R. Hovorka1;  
1Wellcome Trust-MRC Institute of Metabolic Science, University of 
Cambridge, 2Academic Unit of Diabetes, Endocrinology and Metabolism, 
Department of Human Metabolism, University of Sheffield,  
3Diabetes Research Group, Kings College London, UK.
Background and aims: Overnight closed-loop (CL) insulin delivery is feasi-
ble, safe, and effective in the home setting but outcomes vary between indi-
viduals. Understanding the factors influencing the performance of overnight 
CL under free-living conditions may help target those likely to benefit most 
while improving the control algorithm.
Materials and methods: We combined data collected during two randomized 
home studies in 16 adolescents (age 15.6±3.6 years; mean±SD) and 24 adults 
(age 43.2±11.7) with type 1 diabetes on insulin pump therapy (pooled HbA1c 
8.0±0.8%; duration of diabetes 20.0±14.0 years, BMI 24.3±3.7 kg/m2, total 
daily insulin dose 46.2±17.3 U/day). Participants underwent, in random or-
der, two periods of sensor augmented insulin pump therapy (SAP) or SAP 
combined with overnight CL insulin delivery, each lasting three-weeks (ado-
lescents) or four-weeks (adults). Associations between baseline character-
istics (age, HbA1c, duration of diabetes, BMI, total daily insulin dose and 
gender) and the performance of overnight CL (time in target, mean glucose) 
were examined using correlation analysis (Spearman’s correlation coefficient, 
r).
Results: We analysed data on 866 CL nights at home. Lower baseline HbA1c 
(r= -0.43, p<0.01) was associated with lower mean glucose during CL, but not 
with greater time in the glucose target range (3.9 to 8.0 mmol/l). Longer dura-
tion of diabetes was inversely associated with time in target (r=-0.44, p<0.01). 
Other baseline characteristics such as gender, age, BMI, and total daily dose 
showed no association with either mean glucose or time in target. Baseline 
HbA1c (range 6.2-9.6%), age, duration of diabetes, and total daily dose were 
not associated with improvements (difference between conventional pump 
therapy and CL) in mean glucose or time in target during CL as compared to 
SAP treatment. Females showed a greater improvement in mean overnight 
glucose during CL than males (r=0.33, p=0.037).
Conclusion: In adolescents and adults with type 1 diabetes, the extent of 
glucose improvements during CL is seen irrespective of baseline HbA1c. 
Reasons for reduced efficacy in patients with longer duration of diabetes as 
well as gender-specific differences in improved mean glucose warrant further 
investigations.
Clinical Trial Registration Number: NCT01440140, NCT01221467
Supported by: JDRF, Diabetes UK, NIDDK, EC FP7, BRC NIHR
1008
High reported treatment satisfaction in people with type 1 diabetes 
switching to latest generation insulin pump regardless of previous 
therapy
K. Barnard1, M. de Lange2, M. Halbron3, B. Levy4, M. Lévy5,  
B. Lippmann-Grob6, K. Walshe7, R. Ziegler8;  
1Human Development and Health, University of Southampton, 
Southampton, UK, 2Groene Hart Hospital, Gouda, Netherlands, 
3Diabetology Department, AP-HP, Hôpital Pitié-Salpétrière, Paris, France, 
4LifeScan Inc., Pennsylvania, USA, 5Hôpital de Nanterre, France, 6Diabetes 
Klinik, Bad Mergentheim, Germany, 7Lagan Valley Hospital, Lisburn, UK, 
8Diabetes Clinic for Children and Adolescents, Muenster, Germany.
Background and aims: Literature is lacking on how people with type 1 diabe-
tes (T1D) cope with different insulin delivery therapies. CHOICE (Compar-
ing perception of insulin tHerapies for T1D patients with the aim tO Improve 
quality of CarE) is an ongoing, multicentre, multinational, prospective obser-
vational study designed to fill this knowledge gap. A key aim is to compare 
treatment satisfaction (TS) between insulin pump naïve (IPN) and insulin 
pump experienced (IPE) people, after switching to a latest generation insulin 
pump (LGIP).
Materials and methods: People with T1D from 5 EU countries were in-
cluded, comprising an IPN group and an IPE group. To optimise treatment 
homogeneity, only one LGIP (Animas Vibe) was used. An online participant 
survey including demographics, questions about LGIP use and the Insulin 
Treatment Satisfaction Questionnaire (ITSQ) was used to collect data. ITSQ 
is a psychometrically validated questionnaire available in different languages 
(including French and English), developed to evaluate TS with a range of 
insulin therapies, and provides a basis upon which new data are compared.
Results: Interim data (see table) are reported for participants (n=190; age 
range 12-79 years; disease duration 0-71 years) from 3 countries: France, the 
UK, and Ireland. There were no major cross-country differences between 
participants in gender, disease duration or previous treatment. French par-
ticipants were 5 years younger than those in the UK and Ireland. Participants 
aged 12-29 reported higher fasting glucoses and higher pump use prior to 
LGIP. There was no significant difference in ITSQ overall satisfaction score 
with Animas Vibe, between participants previously treated with an insulin 
pump versus participants previously treated with multiple daily insulin in-
jections. There was good internal consistency of the ITSQ Scale. The mean 
ITSQ-Sumscore (range 0-100) of 72.3 (SD 17.5) was similar to the 2004 con-
firmatory sample value (71.4; SD 16.5).
Conclusion: Data show that TS is very high in participants using an LGIP 
such as Animas Vibe regardless of previous insulin therapy. In this study, 
LGIP facilitated a good psychosocial functioning, important to optimal qual-
ity of life. Different people will use their insulin pump in different ways in the 
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context of their lived experience to support their own diabetes self-manage-
ment. This study is ongoing, and final data are pending.
Supported by: Animas Corp.
1009
OpT2mise study: the impact of insulin pump therapy on treatment 
satisfaction and resource utilisation in patients with type 2 diabetes
R. Aronson1, O. Cohen2, I. Conget3, S. de Portu4, A.-S. Racault4, J. Shin5,  
Y. Reznik6;  
1LMC Diabetes & Endocrinology, Toronto, Canada, 2Institute of 
Endocrinology, Ch. Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel, 
3Endocrinology & Nutrition Dept, Hospital Clínic i Universitari, Barcelona, 
Spain, 4Medtronic Int, Tolochenaz, Switzerland, 5Medtronic Inc, Northridge, 
USA, 6Endocrinology & Diabetes Dept, CHU Côte de Nacre, Caen, France.
Background and aims: Achieving glycemic outcomes in insulin-using type 
2 diabetes (T2D) patients often requires multiple daily injections (MDI) with 
basal and bolus insulin types. Insulin pump therapy (CSII) has recently been 
evaluated in T2D patients in a large prospective randomized controlled trial. 
Patient outcomes have been found to be positively associated with treatment 
satisfaction and safety, contributing to improved health and reduced health-
care costs. We assessed the effects of CSII on treatment satisfaction (TS) and 
on medical resource utilization, in suboptimally controlled T2D patients par-
ticipating in the OpT2mise study.
Materials and methods: T2D subjects, suboptimally controlled (HbA1c ≥ 
8%) despite an MDI optimization period, were randomly assigned to CSII or 
continuing MDI. The primary endpoint was the between-group difference in 
mean HbA1c change from baseline to 6 months. TS was measured by means 
of the Diabetes Treatment Satisfaction Questionnaire, status (DTSQs) and 
change (DTSQc). DTSQs questionnaires were collected at baseline and at 6 
months; DTSQc was completed at 6 months. Data on medical resource use 
including diabetes-related hospitalizations, insulin usage and number of glu-
cose testing strips were collected at each visit.
Results: 331 subjects were randomized (45.6% women, mean±SD age 
56.0±9.6 yr, BMI 33.4±7.3 kg/m2, diabetes duration 15.1±8.0 yr, HbA1c 
9.0±0.8%). Subjects assigned to CSII achieved significantly greater HbA1c 
reduction than MDI arm (-1.1±1.2% vs. -0.4±1.1%, p<0.001). DTSQs scores 
at baseline and at 6 months were available for 283 patients. Mean DTSQs 
score increased significantly in the CSII arm after 6 months, with no change 
in the MDI arm (difference between groups = 5.0, 95 % CI=3.39-6.62, P < 
0.001) with significant improvements in treatment convenience, flexibility, 
understanding of diabetes, willingness to recommend the treatment, satisfac-
tion to continue treatment, and perceived frequency of hyperglycemia (all P 
< 0.001). There was no difference in the perceived frequency of hypoglyce-
mia. Greater HbA1c decrease at 6 month was significantly associated with 
improved satisfaction, in the CSII arm only (P<0.05). Results were consistent 
in both DTSQs and DTSQc. Despite improved HbA1c outcome, mean total 
daily insulin dose (TDD) significantly declined from baseline to end of study 
in the CSII arm (112.1 ± 54 to 96.9 ± 55.8, P < 0.001). Mean TDD increased 
in the MDI arm over the same period (106.1 ± 49.2 to 121.7 ± 68.2, P< 0.05). 
Both groups had a statistically significant decline in daily strip use over the 
study. There was no significant difference in the number or length of stay of 
diabetes-related hospitalizations.
Conclusion: CSII therapy in suboptimally controlled T2D patients was as-
sociated with greater improvement in HbA1c at 6 months than patients 
continuing MDI therapy. In addition, CSII was associated with a significant 
increase in treatment satisfaction, with a significant reduction in total daily 
insulin usage. In T2D patients, suboptimally controlled with MDI therapy, 
CSII provides improved outcomes with greater treatment satisfaction.
Clinical Trial Registration Number: NCT01182493
Supported by: Medtronic International Trading Sàrl
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Insulin pump failures: a prospective study
A. Esvant1, I. Guilhem1, S. Breitel2, M. Cuggia3, A.-M. Leguerrier1,  
J.-Y. Poirier1;  
1Diabetes Department, University Hospital of Rennes,  
2AIR de Bretagne, Rennes, 3Pôle Pharmacologie et Investigation cliniques, 
unité „Fouille de données“, University Hospital of Rennes, France.
Background and aims: The rate of insulin pump failures in our centre had 
been evaluated by a prospective observational study published in 2009. Dur-
ing this six-year study (2001-2007), 36% of our pumps had broken down af-
ter a median time of 15 months. We had recorded substantial rates of severe 
pump failures with a complete failure in 44% of cases. The aim of this study 
was to update our data from 2008.
Materials and methods: This was a single-centre prospective observational 
study on 314 new pumps provided between 2008 and 2011 and maintained 
by the same institution. The pumps were used by adult type 1 diabetic pa-
tients treated in the Diabetes Department of a University Hospital in an 
ambulatory setting. There were 74 Animas®2020 and 240 Medtronic® in-
cluding 40% Paradigm®Veo pump, 45% Paradigm®522/722 and 15% Para-
digm®512-515/712-715. Pump failures were recorded until December 2013. 
We focussed on malfunctions directly related to the pump itself. Patients 
could not contact the manufacturer directly to exchange the pump. All pump 
failures were documented by a healthcare professional. We studied Kaplan-
Meier survival curves. Logrank test, Cox model, t-test and χ2 (or non-para-
metric tests when necessary) were used to compare the two brands. Statistical 
analyses were performed with the SPSS software (version 22; IBM, USA).
Results: The mean duration of pump use was 25±12 months (mean±SD) (CI 
95%: 24-27) and did not differ between the two brands (p NS). Malfunctions 
occurred in 220 pumps (70%). Median time of survival was 27 months (CI 
95%: 25-29). The rate of malfunction was 33 per 100 pump-years. We re-
corded 25 (11%) complete failures (pumps were immediately unusable), 16 
(7%) alarms, 79 (36%) mechanical malfunctions that required pump replace-
ment as recommended by the manufacturer, 94 (43%) minor defects. The 
cause of the defect could not be determined in 6 (3%) situations. Complete 
failures were mainly due to inoperative keypad (n=14); mechanical defects 
were mostly related to cracks in reservoir or battery compartment (n=60) and 
minor defects to screen display defects (n=48). Median time of survival in 
case of complete failure was 12 months (CI 95%: 9-16) versus 23 months (CI 
95%: 21-25) in case of others defects (p<0.001). Survival curves of Medtronic® 
and Animas® pumps did not differ. Duration of survival of Paradigm®Veo 
pumps was longer than that of Animas® pumps (HR=0.65, CI 95%: 0.45-0.94, 
p=0.023). However the proportion of severe pump failures (complete failures 
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and alarms) was higher with Paradigm®Veo pumps (33%) compared to Ani-
mas® pumps (12%) (p=0.007).
Conclusion: Pump malfunctions remain common with modern pumps. In 
this study, we reported less complete failures than in our previous study. This 
may reflect an improvement of the pumps. However, the current high rates 
of mechanical and minor defects suggest changes in our practice and may be 
explained by the greater attention paid by patients and healthcare profession-
als to pump defects. A multi-centre evaluation of pump failures is needed.
1011
A randomised three-period trial to compare the pharmacodynamics 
and pharmacokinetics of different glucagon dosages at different blood 
glucose levels
T. Jax1,2, H. Blauw3,4, J. DeVries4, T. Heise5, for the PCDIAB consortium;  
1Cardiometabolic Research, Profil Institut für Stoffwechselforschung GmbH, 
Neuss, 2Klinik für Kardiologie, Herzzentrum Wuppertal, Universität Witten/
Herdecke, Germany, 3Inreda Diabetic BV, Goor, Netherlands,  
4Academic Medical Centre at the University of Amsterdam, Netherlands, 
5Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany.
Background and aims: Bihormonal closed-loop systems deploy the admin-
istration of glucagon in case of imminent or actual hypoglycaemia. The ad-
ministration of glucagon in such a closed-loop system will not necessarily be 
limited to hypoglycaemia, but can also be done preemptively, trying to avoid 
hypoglycemia. Thus more information is needed about the pharmacody-
namic effects of small doses of glucagon at non-hypoglycaemic blood glucose 
(BG) levels. We evaluated the pharmacokinetics and pharmacodynamics of 
different dosages of s.c. glucagon at different BG levels.
Materials and methods: The study was conducted as an open, randomized 
3-period cross-over experiment in six otherwise healthy patients with T1DM. 
At each of the 3 periods, different BG levels were established in 4 consecutive 
steps (144, 108, 72, and 50.4 mg/dl) and glucagon was given s.c. at each BG 
level in a randomized sequence (A: 0.11 mg at first 3 BG levels and 1.00 mg at 
the fourth, B: 3 x 0.22 mg and 0.66 mg, C: 3 x 0.44 mg and 0.33 mg).
Results: Glucagon raised BG in a dose-dependent fashion at all BG levels. 
Mean glucose excursion ranged from 48.7 mg/dl to 111.0 mg/dl (Figure). 
The response after repeated dosing tended to decrease only with the 0.44 mg 
glucagon dose (mean glucose excursion from 97.3 mg/dl to 71.0 mg/dl), pos-
sibly due to hepatic glycogen depletion. Time till maximum glucose concen-
tration showed a dose dependency, with mean values increasing from 41.3 
min to 79.2 min. Maximum plasma glucagon concentration increased with 
increasing glucagon dosage and was reached after around 10-25 minutes. 
For the 0.11 mg glucagon dose, plasma glucagon concentration tended to in-
crease with decreasing baseline BG levels and in 3 patients no clear increase 
in glucagon concentration was seen at BG level of 144 mg/dl.
Conclusion: In conclusion, s.c. administered glucagon produces a predict-
able pharmacodynamic response at lower doses than the usual rescue dose 
and across a range of hypo- to hyperglycaemic BG levels. This supports the 
use of small glucagon doses in closed-loop systems to prevent impending 
hypoglycaemia. The results of this study can be used to further optimize the 
control algorithms of bihormonal closed-loop systems.
Supported by: PCDIAB, European Commission FP7 grant 305654
 
1012
The impact of insulin pump therapy on glycaemic profile of patients with 
type 2 diabetes: data from the OpT2mise study
I. Conget1, O. Cohen2, R. Aronson3, J. Castaneda4, R. Re4, J. Shin4, Y. Reznik5;  
1Diabetes Unit. Endocrinology Department, Hospital Clinic i Universitari, 
Barcelona, Spain, 2Institute of Endocrinology, Ch. Sheba Medical Center, 
Tel Hashomer, Israel, 3LMC Diabetes & Endocrinology, Toronto, Canada, 
4Medtronic, Northridge, USA, 5Endocrinology and Diabetes Department, 
Centre Hospitalier Régional Universitaire de Caen Côte de Nacre, Caen, 
France.
Background and aims: Previous studies did not conclusively demonstrated 
a benefit of continuous subcutaneous insulin infusion (CSII) in patients with 
Type 2 Diabetes (T2D) previously treated with basal-bolus multiple daily in-
jections (MDI). The OpT2mise study is a multicenter, randomized trial com-
paring CSII to MDI in a large cohort of T2D subjects suboptimally controlled 
despite MDI therapy. Aim: To further understand the mechanism underlying 
the differences between both types of therapies, a study on the glucose met-
rics, as a secondary endpoint, was performed.
Materials and methods: Subjects with poor glycemic control (n=495) on 
MDI were enrolled into a run-in period for insulin dose optimization (Total 
Daily Dose ≥ 0.7 and ≤ 1.8 U/kg/d). Those showing an HbA1c ≥8% and ≤12% 
were then randomly assigned to CSII or continuing on MDI for 6 months. 
Blinded Continuous Glucose Monitoring (CGM, iPro2, Medtronic) data was 
collected for a 6 day period before and 6 months after randomization and 
changes in glucose metrics were evaluated (Glucose exposure, Glucose Vari-
ability and Glucose Ranges).
Results: A total of 331 patients were randomized, aged 56.0±9.6, 45.6% 
women, BMI 33.4±7.3, diabetes duration 15.1±8.0 yr, and HbA1c 9.0±0.8%. 
CSII achieved significantly greater HbA1c reduction than MDI (- 1.1±1.2% 
vs. - 0.4±1.1%, p<0.001). Data on CGM were available for 290 patients (143 
and 147; 123 and 112 in the CSII and MDI arms at baseline and at 6 month, 
respectively). After 6 months, compared to MDI, 24h sensor glucose (SG) 
was reduced significantly more in CSII group (- 17.1 mg/dl, p<0.05), with less 
exposure to SG > 180 and SG > 250 mg/dl (-12.2%, p < 0.001 %, and -6.4%, 
p < 0.05), more time in target (70-180 mg/dl; 11.8 %, p < 0.001) and no dif-
ference in time exposure to SG < 70 mg/dl. Concerning glucose variability, 
there were no difference in 24h Standard Deviation (SD) SG, coefficient of 
variation (CV) or in mean amplitude of glucose excursions (MAGE).
Conclusion: In comparison with MDI, CSII treatment in suboptimally con-
trolled patients with T2D provides a significant improvement in glucose pro-
file with increased time spent in target, less exposure to hyperglycemia and 
without an increase in the risk of hypoglycemia.
Clinical Trial Registration Number: NCT01182493
Supported by: Medtronic Europe 
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1013
Impact of a built-in insulin calculator feature on diabetes control:  
pilot study
T. Haak1, M. Diamant2, T. Danne3, G. Freckmann4;  
1Research Institue of the Diabetes Academy Mergentheim (FIDAM), 
Bad Mergentheim, Germany, 2VU University Medical Centre, 
Amsterdam, Netherlands, 3Diabetes Zentrum fur Kinder and Jugendliche 
Kinderkrankenhaus auf der Bult, Hannover,  
4Institut fuer Diabetes-Technologie Forschungs- und 
Entwicklungsgesellschaft mbH an der Universitaet Ulm, Germany.
Background and aims: To evaluate the impact of the FreeStyle InsuLinx me-
ter with a built-in insulin bolus calculator on glycaemic control by observing 
time spent in euglycaemia (3.9 to 10.0mmol/L) in the assessment phase vs. 
the baseline phase for the intervention group (primary endpoint), and meas-
ures of glycaemic control from a continuous glucose monitor (e.g. time spent 
in hypoglycaemia, secondary endpoints). Additional secondary endpoints 
considered in the study were: total daily dose of insulin (TDD), Hypoglycae-
mia Fear Survey (HFS), Diabetes Distress Scale (DDS) and Diabetes Treat-
ment Satisfaction Questionnaire (DTSQ) results.
Materials and methods: The pilot study was a multicentre, randomised, two 
arm (control and intervention), parallel study conducted at 4 European study 
centres, with Type 1 diabetes subjects on Multiple Daily Injections (MDI, 3 or 
more per day) using U100 insulin (n=49). All subjects wore a masked Free-
Style Navigator Continuous Glucose Monitor (CGM) for 14 days (baseline 
phase) where upon randomisation, 33 entered the intervention group (one 
subject was excluded from analysis as their Navigator had alarms switched 
on for both CGM phases) and 16 the control group. The intervention group 
proceeded to use the InsuLinx meter with built-in insulin calculator in either 
Easy (n=7, fixed dose meal time insulin calculator) or Advanced mode (n=25, 
rapid acting Insulin calculator with carb counting) for 45 days, the control 
group used a FreeStyle Freedom Lite meter for 45 days. After this time both 
arms continued with their designated meter together with a masked CGM for 
14 days (assessment phase).
Results: When comparing baseline versus assessment phase in the inter-
vention group, no significant difference in time spent in euglycaemia (3.9 
to 10.0mmol/L) was found (primary endpoint). Study statistics found a de-
crease in the number of excursions per day <3.9mmol/L (-0.24, p<0.05) and 
on the DTSQ, the treatment satisfaction scale was significantly improved by 
2.0 points within the intervention group. When separated into InsuLinx easy 
mode vs. advanced mode, there was a significant reduction of the number of 
excursions per day <3.9mmol/L (-0.5, p<0.05) compared to baseline when 
the meter was used in easy mode. When comparing the intervention group 
versus the control group, the use of the InsuLinx meter in easy mode resulted 
in a significant reduction of time spent <3.9mmol/L (-1.1 hours/day from 
baseline of 2.2, p<0.05). The HFS found that using the InsuLinx meter in 
advanced mode, resulted in a significant reduction in the total worry score 
(by 3.9, p<0.05) compared to the control group. TDD of insulin increased 
significantly (p<0.05) for subjects in the intervention group compared to the 
control group.
Conclusion: The indications from this pilot study are that use of a meter with 
a built-in insulin calculator can lead to improvements in diabetes control, 
particularly in reducing the prevalence of hypoglycaemic events, can reduce 
worry of hypoglycaemia and improve treatment satisfaction. It is postulated 
that patients first try to avoid hypoglycaemia and next focus on reducing hy-
perglycaemia; hence the relatively short length of the study may have pre-
vented an increase in time in euglycaemia.
Clinical Trial Registration Number: ADC-PMR-INX-11012
Supported by: Abbott Diabetes Care
1014
Does frequent use of an automated bolus advisor improve glycaemic 
control in pediatric patients treated with insulin pump therapy?  
First results of the BABE study
R. Ziegler1, C. Rees2, N. Jacobs1, C.G. Parkin3, M.R. Lyden4, B. Petersen5,  
R.S. Wagner2;  
1Diabetes Clinic for Children and Adolescents, Muenster, Germany,  
2Roche Diagnostics, Indianapolis, 3CGParkin Communications, Inc., 
Boulder City, 4Biostat International, Tampa, USA,  
5Roche Diagnostics GmbH, Mannheim, Germany.
Background and aims: Studies have shown that use of an automated bolus 
advisor improves glycemic control in type 1 and insulin-treated type 2 dia-
betes; however, the relationship between frequency of bolus advisor use and 
glycemic improvement has not been well studied.
Materials and methods: The Bolus Advisor Benefit Evaluation (BABE) study 
was a single-center, retrospective cohort study that assessed the impact of 
frequent use of the Accu-Chek Aviva Combo system bolus advisor (BA) fea-
ture on glycemic control among pediatric type 1 diabetes patients on insulin 
pump treated at a pediatric diabetology clinic in Germany. Measurements 
of HbA1c, hypoglycemia (<60 mg/dL), therapy changes, mean blood glu-
cose and glycemic variability (SD) were assessed at baseline and after 3 and 6 
months of BA use. A total of 104 pediatric patients with mean (SD) baseline: 
HbA1c 8.0(1.6)%, age 12.7(4.9) years, diabetes duration 46.7(43.7) months, 
and 58.7% female were assessed. Baseline differences in HbA1c, diabetes du-
ration and age were accounted for by ANCOVA analyses.
Results: After 6 months of BA use, 71 patients reported high frequency (HF) 
of device use (≥50%) versus 33 patients who reported low frequency (LF) 
use (<50%) during the study period. Mean (SE) HbA1c among HF users was 
significantly lower than LF users: 7.5(0.1)% vs. 8.0(0.2)% (p=0.0252). There 
was with no between-group difference in the percentage of hypoglycemia 
values (<60 mg/dL) within 30 days prior to 6-month visit: 5.5 (4.5)% vs. 
5.9(5.8)%, p=0.6526. More HF than LF users received therapy changes during 
the 6-month period: 62(87.3%) vs. 22(66.7%), p=0.0174. HF users showed 
significantly lower mean blood glucose (164.4 [29.78] vs. 194.5 [38.70] mg/
dL, p<0.0001) and less glycemic variability as assessed by standard deviation 
(80.1 vs. 100.6, p=0.0001) than LF users.
Conclusion: Frequent use of an automated bolus advisor was associated with 
significant improvements in glycemic control and more therapy changes with 
no increase in hypoglycemia associated with BA use in pediatric patients 
treated with CSII therapy.
Supported by: Roche Diagnostics
1015
A new assessment tool to measure the ability of bolus calculation and 
carbohydrate estimation (SMART) in people with diabetes performing 
an intensive insulin therapy
D. Ehrmann1, N. Hermanns1, A. Reimer1, J. Weißmann2, T. Haak1,  
B. Kulzer1;  
1Research Institute of Diabetes Academy Mergentheim (FIDAM),  
Bad Mergentheim, 2Roche Diagnostics, Mannheim, Germany.
Background and aims: Intensive insulin therapy relies on correct prandial 
insulin dose adaptation dependent from current glucose level, amount of 
planned carbohydrate intake and the consideration of other situational fac-
tors like physical activity or circadian fluctuation of insulin sensitivity. People 
with diabetes and intensive insulin therapy should be able to estimate car-
bohydrates and calculate insulin bolus correctly, while regarding the factors 
mentioned above. An assessment tool for the measurement of the ability of 
carbohydrate estimation and bolus calculation is missing. The objective of 
this study was the development and psychometric evaluation of an assess-
ment tool for carbohydrate estimation and bolus calculation (“aSsessMent of 
the Ability of Bolus Calculation and CaRbohydrate esTimation” SMART). Of 
special interest were the associations of both abilities with glycaemic control.
Materials and methods: The SMART consisted of one scale for the assess-
ment of bolus calculation (BOLUS) with 10 items and a scale for carbohy-
drate estimation (CARB) with 12 items. People with type 1 or type 2 diabetes 
on an intensive insulin regimen were invited to participate. HbA1c and stored 
data of blood glucose meters were used to determine glycaemic control.
Results: 411 patients participated (age 42.9 ±15.7, 58% female, HbA1c 8.6 
±1.8%, 28% with CSII-treatment) and approx. 56,000 blood glucose meter 
readings could be obtained. The reliability of both scales was sufficient (Cron-
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bachs alpha for BOLUS r= 0.78 and the CARB r = 0.67). Better bolus calcula-
tion was associated with a higher level of education (r = 0.24, p<.05), lower 
HbA1c (r = -0.27, p<.05), lower mean blood glucose (r = -0.29, p<.05), and 
a lower standard deviation of blood glucose values (r = -0.43, p<.05). Better 
carbohydrate estimation was associated with a lower body mass index (r = 
-0.2, p<.05), lower mean blood glucose (r = -0.3, p<.05), a lower frequency of 
hyperglycaemia (r = -0.27, p<.05), and a higher frequency of euglycaemia (r 
= 0.26, p<.05). Patients with an insulin pump were better on both scales than 
patients with multiple daily insulin injections (BOLUS: 7.2 ± 2.4 vs. 6.4 ± 2.7, 
p<.01; CARB: 7.8 ± 2.1 vs. 7.1 ± 2.6, p<.01). Patients with previous diabetes 
education performed significantly better on both scales (BOLUS: 6.8 ± 2.5 vs. 
5.7 ± 2.8, p<.01; CARB: 7.4 ± 2.4 vs. 6.5 ± 2.6, p<.01).
Conclusion: SMART provides a reliable and valid assessment of the ability to 
estimate the correct amount of carbohydrates and to calculate the appropri-
ate prandial insulin dose. SMART is also sensitive to depict effects of diabe-
tes education and of CSII treatment in comparison to multiple daily insulin 
injections. In summary SMART can assist the identification of people with 
diabetes on an intensive insulin regimen, who are in need for improvements 
in carbohydrate estimation and/or calculation of prandial insulin dose.
Supported by: Roche Diagnostics
1016
A clinical evaluation of blood sampling practices in patients with 
diabetes: impact on fingerstick blood volume and pain
M. Grady1, M. Pineau2, M. Pynes2, L.B. Katz3, B. Ginsberg4;  
1Clinical Affairs, LifeScan Scotland Ltd, Inverness, UK, 2Clinical Research, 
Facet Technologies, Kennesaw, 3Clinical Affairs, LifeScan, Wayne,  
4Diabetes Consultants, Wyckoff, USA.
Background and aims: There is a perception that patients with diabetes 
struggle to produce sufficient blood to fill glucose test strips, including strips 
with 1µl fill requirements. The purpose of this study was to determine the 
volume of blood expressed when these patients perform routine fingersticks 
using their own lancing device and sampling technique, and to evaluate the 
relationship between blood volume and pain. In addition, a survey was used 
to explore patient perceptions and preferences regarding blood sampling.
Materials and methods: Each of the 64 subjects (type 1 or type 2 diabetes 
mellitus) performed 8 fingersticks using their own lancing device, preferred 
depth setting and lancing technique. Eight different commercially available 
lancing systems were used (8 subjects/system). Blood volume and perceived 
pain were recorded after each fingerstick. Subjects used the same depth set-
ting typically used at home to lance. In addition, they were instructed to 
express capillary blood from their fingertips using the same technique they 
typically use at home and consistent with their specific lancing device in-
structions.
Results: Average blood volume generated across all subjects was 3.1µl 
(SD=2.1µl, from 512 fingersticks) with 97% of subjects expressing an aver-
age of ≥1.0µl of blood. There was no significant contribution due to lancing 
system on individual or mean blood volume (F=1.623; p=0.15). There was 
no correlation between pain response and the volume of blood expressed 
(r=-0.054; p=0.67). Similarly, there was no statistically significant correlation 
(r=0.164; p=0.19) between lancing depth setting and the pain reported by the 
subject. Nearly all subjects agreed they could easily and comfortably obtain 
a 1µl blood sample, and most subjects actually preferred a larger drop size 
when doing blood glucose tests to ease sampling and avoid wasting strips.
Conclusion: These results provide evidence across 8 lancing systems that 
challenges the current perceptions that patients with diabetes struggle to pro-
duce sufficient blood samples to fill most test strips, including those with 1µl 
fill requirements, and that obtaining larger volumes of blood is more painful. 
These results are consistent with previous literature suggesting patients (1) 
derive no real benefits from test strips with very low blood sample volumes 
and (2) generally prefer a blood drop size that enables them to confidently 
fill their test strip.
Clinical Trial Registration Number: NCT01914302
1017
System accuracy evaluation of 10 SMBG systems with 3 lots each 
following ISO 15197:2013 against 2 different comparison methods
G. Freckmann, M. Link, A. Baumstark, C. Schmid, S. Pleus, C. Haug;  
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft 
mbH an der Universität Ulm, Germany.
Background and aims: High quality blood glucose (BG) monitoring systems 
are required for adequate self-monitoring of blood glucose (SMBG). The in-
ternational standard ISO 15197, which was revised in 2013, stipulates per-
formance requirements for SMBG systems. Prior to the revision, ISO 15197 
prescribed a system accuracy evaluation against the manufacturer’s measure-
ment method. This was changed so that any method traceable according to 
ISO 17511 may be used. In order to investigate possible effects on apparent 
SMBG system accuracy, 10 SMBG systems with 3 lots each were evaluated 
against 2 comparison methods.
Materials and methods: In this study, system accuracy of 10 SMBG systems 
was evaluated with 3 different reagent system lots each. Each lot was tested 
on 100 capillary blood samples from different subjects following investiga-
tional procedures of the international standard ISO 15197:2013. Compari-
son measurements were performed with the YSI 2300 STAT Plus™ glucose 
analyser (glucose oxidase method (GOD)) and the Cobas® c111 (hexokinase 
method (HK)). Both methods were traceable according to ISO 17511 as re-
quired by ISO 15197:2013. Compliance with accuracy criteria stipulated in 
ISO 15197:2013 was assessed for each reagent system lot by calculating the 
percentage of results within ±15% or within ±15 mg/dL of the comparison 
method results for BG concentrations above or below 100 mg/dL, respective-
ly, and by calculating the percentage of results within Consensus Error Grid 
zones A and B across all 3 lots of a system. Additionally, accuracy criteria of 
ISO 15197:2003 were applied by calculating the percentage of results within 
±20% or within 15 mg/dL of comparison method results above or below 75 
mg/dL, respectively.
Results: Seven of 10 systems (Accu-Chek® Performa; BGStar®; Contour® 
next USB; Contour® XT; FreeStyle InsuLinx; mylife™ Pura™; MyStar Extra®) 
fulfilled the minimum accuracy criteria of ISO 15197:2013 (at least 95% of 
results within ±15% or ±15 mg/dL of the comparison method results and 
at least 99% within Consensus Error Grid zones A and B) with all 3 tested 
reagent system lots, independent from the comparison method applied. In 
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the evaluation against the respective system’s manufacturer’s measurement 
method (GOD for 7 systems, HK for 3 systems), individual reagent system 
lots showed 90% to 100% of results within ±15% or ±15 mg/dL of the com-
parison method results, with 23 of 30 lots having at least 95% within these 
limits. When evaluated against the alternate comparison method, between 
83% and 100% of results were within these limits for individual lots and 25 of 
30 lots showed at least 95% within the limits. Eight of 10 systems fulfilled the 
minimum accuracy criteria of ISO 15197:2003 (at least 95% of results within 
±20% or ±15 mg/dL of the comparison method results) against the respective 
manufacturer’s measurement method. Individual lots showed between 94.5% 
and 100% of the results within these limits and 28 of 30 lots showed at least 
95% within these limits.
Conclusion: In this evaluation, 7 of 10 systems met the minimum system ac-
curacy criteria of ISO 15197:2013. Analysis of individual reagent system lots 
showed that specific evaluation results differed depending on the comparison 
method. These data suggest that the comparison method used in an evalua-
tion can have an influence on an SMBG system’s apparent system accuracy.
Investigator-initiated study supported by Sanofi
 
1018
Is fingerstick calibration beneficial for stable and consistent sensors?
E.S. Budiman;  
Abbott Diabetes Care, Alameda, USA.
Background and aims: Subcutaneously inserted glucose monitoring systems 
typically require fingerstick calibrations. Calibrations allow for sensor spe-
cific adjustment and can correct for any sensor drift over the wear duration. 
When sensors can be manufactured with a sufficiently low in-vitro lot sensi-
tivity CV and can remain stable in-vivo, fingerstick calibration may no longer 
be beneficial. Universal calibration provides a shared, one-time calibration 
factor for all sensors from the same lot. This analysis computes the expected 
average and expected 90th percentile sensor performance in fingerstick and 
universal calibration studies. Per-sensor mean absolute relative difference 
(MARD) distribution is used for the comparison.
Materials and methods: A total of 33 subjects with diabetes were enrolled to 
wear four sensors simultaneously. Sensors from a lot with low in-vitro sensi-
tivity CV (=2.9%) were used in the study. To examine the effect of fingerstick 
error, an emulator that allows raw sensor data from the actual clinical study to 
be recalibrated with any meter was used. No difference in per-sensor MARD 
distribution was observed when the same meter type from a different clinical 
study data was used for calibration (z-test p-value = 0.80). The fingerstick 
calibration study was repeated 1000 times using a simulated 15/15 error me-
ter (i.e. 95% of the values within 15 mg/dL below 100 mg/dL reference value, 
and within 15% at or above 100 mg/dL). The universal calibration study is 
also repeated 1000 times, each time randomly selecting 3 sensors and using 
the median of the per-sensor sensitivities to calibrate the rest.
Results: Each study generated a distribution of per-sensor MARD values. 
After repeating the study 1000 times, the range of average per-sensor MARD 
from the fingerstick calibration studies has a mean and standard deviation 
of 13.7% and 0.24%, respectively (Table 1). The table also shows the average 
from the 1000 universal calibration studies, as well as the 90th percentile of 
both studies. The per-sensor MARD distribution of the universal calibration 
studies, both in terms of the average and 90th percentile, is statistically better 
than that of the fingerstick calibration studies (p<0.0001).
Conclusion: Fingerstick calibration can be a necessary element to ensure 
good and consistent sensor performance. However, stable sensors with low 
in-vitro sensitivity variation do not appear to benefit from fingerstick calibra-
tion.
Supported by: Abbott Diabetes Care
 
1019
Standardised procedure for the assessment of new-to-market continuous 
glucose monitoring (CGM) systems (Space2)
J. Kropff1, D. Bruttomesso2, W. Doll3, A. Farret4, S. Galasso2, Y.M. Luijf1,  
J.K. Mader3, J. Place4, F. Boscari2, T.R. Pieber3, E. Renard4, J.H. DeVries1;  
1Department of Internal Medicine, Academic Medical Centre, Amsterdam, 
Netherlands, 2Department of Clinical and Experimental Medicine, 
University of Padova, Italy, 3Department of Internal Medicine, Medical 
University Graz, Austria, 4Department of Endocrinology, Montpellier 
University Hospital, France.
Background and aims: This study assessed the accuracy and reliability of the 
two most widely used continuous glucose monitoring (CGM) systems.
Materials and methods: We studied the G4 Platinum (DG4P) and Veo Enlite 
(ENL) CGMs, in 24 patients with type 1 diabetes. CGMs were tested during 
six day home use and a nested six hour clinical research center (CRC) visit. 
During the CRC visit, frequent venous blood glucose samples were used as 
reference while patients received a meal with an increased insulin bolus to in-
duce an aggravated postprandial glucose nadir. At home, patients performed 
at least six reference capillary blood measurements per day. Wilcoxon signed-
rank test was performed using all data points ≥15 min apart.
Results: Overall Mean Absolute Relative Difference (MARD) (SD) measured 
at the CRC was 13.6% (11.0) for DG4P and 16.6% (13.5) for ENL (p<0.0002, 
CI Δ=1.7-4.3%, n=530). Overall MARD assessed at home was 12.2% (12.0) 
for DG4P and 19.9% (20.5) for ENL (P<0.0001, CI Δ=5.8-8.7%, n=839). Dur-
ing the CRC visit, MARD in the hypoglycaemic range (≤ 70mgdL) was 17.6% 
(12.2) for DG4P and 24.6% (18.8) for ENL (p0.005, CI Δ=3.1-10.7%, n=117). 
Both sensors showed higher MARD during hypoglycemia compared to eu-
glycemia (70-180mgdL) (DG4P 17.6% vs. 13.0% and ENL 24.6% vs. 14.2%).
Conclusion: During circumstances of intended use, including both a CRC 
and home phase, the Veo Enlite sensor was noticeably less accurate than the 
G4 Platinum sensor. Both sensors showed lower accuracy in the hypoglycae-
mic range. DG4P was less affected by this negative effect of hypoglycemia on 
sensor accuracy than ENL.
Clinical Trial Registration Number: NCT01751932
Supported by: Dexcom, USA.
1020
How current continuous glucose monitoring (CGM) users translate 
CGM data into diabetes management: results of a survey
S.V. Edelman1, J.H. Pettus1, D.A. Price2;  
1University of California, 2Dexcom, San Diego, USA.
Background and aims: The use of real time (RT) CGM devices is becoming 
the standard of care for treating patients with type 1 diabetes (T1D) as several 
studies have shown that children and adults that regularly use CGM improve 
their glycemic control. However, the specific interventions that patients make 
on a day-to-day basis in response to the CGM information have not been 
determined. This study was conducted to learn more about current CGM 
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practices and assess how CGM users respond to their CGM information in 
a real-world setting.
Materials and methods: A 70 question clinical scenario-based survey was 
developed that probed 5 topics:subject characteristics and general CGM use, 
treating and preventing incidental and mealtime hypo- and hyperglycaemia 
and nocturnal issues. The survey was extensively beta-tested to make sure 
questions were clearly written and unambiguous. Clinicians that actively 
prescribe CGM from across the US were contacted and asked to recruit and 
provide a survey web link to regular Dexcom CGM users (>6 days a week on 
average) from their practice.
Results: 222 of 300 respondents had T1D and are analyzed in this abstract: 
mean age (46 ± 14 years), duration of T1D (22±14 years), self-reported HbA1c 
(6.9% ± 0.8%), 52% male, 75% used CSII and 25% MDI (75% had used CGM 
>1 year), education- 65% university graduates or had another advanced de-
gree. Key findings: The majority of the participants viewed the RT informa-
tion (51%) or hypo/hyper alarms (30%) as the most important information; 
only 3.6% of subjects thought the computer downloads analysis was most 
helpful. To prevent hypoglycemia, 70% of participants reported they would 
prophylactically consume carbohydrates in response to a displayed glucose 
of 120mg/dl with a decreasing trend (angled or downward rate of change 
arrow). 42% of respondents stated that at least one time in the last 6 months, 
their CGM device alerted somebody around them to respond to their hypo-
glycemia alarm when they themselves were unable to. 70% and 66% of par-
ticipants report waking up at night at least once per week in response to alerts 
for hypo- and hyperglycemia respectively. In a scenario-based question about 
response to a low alert waking them up at midnight, 50% of respondents 
stated they would treat the low glucose without confirming with their meter. 
65% of participants reported that since starting CGM, the number of bo-
luses they took per day had increased. Daytime and nighttime glucose targets 
commonly changed- 57% lowered their daytime glucose targets. Participants 
reported a mean increase in correction insulin dose (unrelated to a meal) for 
1 arrow up was 111%, a mean decrease in the correction dose for 1 arrow 
down was 41%, relative to the correction dose with a flat arrow. For a 50 gram 
glucose meal at euglycemia, the meal dose increased by 81% for 2 arrows up 
and decreased by 53% for 2 arrows down, relative to the meal dose with a flat 
arrow. Most (59%) participants also reported they adjusted the insulin timing 
in each of the scenarios, based on the direction and rate of change.
Conclusion: Patients use CGM data in many of their clinical decisions and 
for multiple aspects of their diabetes management. These changes contribute 
to safer diabetes management and improved outcomes. The adjustments re-
ported by patients in this survey to their mealtime and correctional insulin 
doses are much larger than current recommendations.
PS 085 Psychological distress
1021
Metabolic control in type 1 diabetic children with self report depression: 
3-year follow-up
B.M. Zdunczyk1, K. Dżygało2, K. Piechowiak3, A. Szypowska2;  
1Clinical Child and Adolescent, Clinical Hospital,  
2Department of Pediatrics, Clinical Hospital,  
3Department of Pediatrics, Clinical Hospital, Warsaw, Poland.
Background and aims: Many studies show there is a higher risk of depres-
sion in patients with diabetes than in healthy population. Depression has 
been associated with worse disease outcomes and readmissions in adults with 
diabetes. Less is known about the effect of depression on metabolic control 
and hospital admissions in children and adolescents with type 1 diabetes. The 
aim of this study was to examine if depression is associated with worse meta-
bolic control and repeat hospitalisations in children and adolescents with 
type 1 diabetes in 3-year follow-up.
Materials and methods: In years 2010-2012 we screened 477 children for 
depression: during the routine visit in the outpatient clinic 252 girls and 225 
boys, with diabetes duration > 1 year filled in Polish version of Children’s 
Depression Inventory by M. Kovac, a self-report questionnaire consisting of 
27 items. At the same time other data was collected: sex, age, diabetes dura-
tion, HbA1c, BMI, daily insulin dose. Medical parameters of 139 children (65 
boys, 74 girls, age 11,38 ±1,85 diabetes duration 4,53±3,05, ins/kg 0,81±0,20, 
BMI 19,18±0,2 , HbA1c 7,5±1,3 at baseline ), collected for 3 years were ana-
lysed.
Results: 5% (22/137 participants scored ≥ 13, indicating elevated depressive 
symptoms. There was no difference between children with CDI ≥ 13 and CDI 
< 13 in diabetes duration (p = 0.483) and age (p = 0.329). We found sig-
nificant relationship between scores in CDI and HbA1c in subsequent years 
of follow up: 2010 - r=0.1753 p=0,039, 2011 - r=0.1349 p=0,037 and 2013 - 
r=0.2629 p=0,0018 but not 2012 - r=0.1159 p=0,183. CDI scores were not as-
sociated with daily insulin dose for all years but the baseline (2010 r = 0.181, 
p = 0.033, 2011 r = 0.139 p= 0.125, 2012 r = 0.099, p= 0.273). We didn’t find 
the difference between participants with CDI ≥ 13 and CDI < 13 in HbA1c 
(p=0.573), daily insulin dose (p=0.113) or BMI (p= 0.541). At the same time 
children with CDI ≥ 13 had higher insulin dose/kg/d (p = 0.024). Surprising-
ly we didn’t find the difference between children with CDI ≥ 13 and CDI < 13 
in the number of hospitalisations (p=0.797) or psychological care (p = 0.064).
Conclusion: 15% participants show elevated depressive symptoms as as-
sessed with Children’s Depression Inventory at the baseline. Children and 
adolescents with higher scores on the CDI don’t differ from patients without 
depressive symptoms in age, BMI and daily insulin dose. Although depressive 
symptoms are associated with worse metabolic control children with higher 
scores in CDI achieve the same HbA1c level as their peers with lower CDI 
scores. This trend is seen for the whole period of follow-up. Our results show 
that depressive symptoms are not associated with higher use of hospital facili-
ties. Still it is necessary to pay attention to emotional wellbeing of children 
and adolescents with diabetes type 1 regardless of HbA1c.
1022
The assessment of factors related to depressive symptoms in adult 
patients with type 1 diabetes
A. Duda-Sobczak, D. Zozulinska-Ziolkiewicz, D. Pisarczyk-Wiza,  
B. Wierusz-Wysocka;  
Department of Internal Medicine and Diabetology,  
Poznan University of Medical Sciences, Poland.
Background and aims: Depressive disorders are more common among peo-
ple with diabetes compared with general population. The presence of depres-
sive symptoms may reduce motivation and the treatment adherence and in 
fact worsen the treatment outcomes. The aetiology of depression is complex 
and not only related to diagnosed chronic disease. The aim of this study was 
to assess factors related to depressive symptoms in adult patients with type 
1 diabetes.
Materials and methods: 304 subjects (164 women), aged 43 (33-52) years, 
type 1 diabetes duration 26 (33-31) years, HbA1C 7.8 (7.1-8.8)% were in-
cluded. Subjects diagnosed with chronic complications causing disability 
(blindness, end stage renal disease, painful peripheral neuropathy, limb am-
putation) were excluded to avoid the presumable impact of irreversible dis-
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ability on questionnaire answers. Depressive symptoms were assessed using 
Beck Depression Inventory (BDI). Additionally, Problem Areas in Diabetes 
Questionnaire (PAID), Multidimensional Fatigue Symptom Inventory-Short 
Form (MFSI-SF) were completed. Data on social, economic and lifestyle fac-
tors were collected. Metabolic control expressed by HbA1C and medical histo-
ry was assessed via medical chart review. The studied group was divided into 
two subgroups according to the presence or absence of depressive symptoms 
based on the BDI standard cut-offs.
Results: 41% of study participants presented any depressive symptoms. They 
were more frequent among women (p<0.0001), less educated, unemployed 
and not physically active participants (p=0.016, p=0.015, p=0.0014 respec-
tively). Fear of hypoglycemia and diagnosed chronic complications of dia-
betes appeared more frequently among patients exhibiting depressive symp-
toms (p=0.013, p=0.04 respectively). The intensity of depressive symptoms 
correlated with fatigue as well as with degree of coping with diabetes (r=0.56, 
p<0.0001; r=0.42, p<0.0001 respectively). No relation of metabolic control 
(HbA1C) with depressive symptoms was demonstrated.
Conclusion: In adult type 1 diabetic patients depressive symptoms are related 
not only to chronic disease, but also to sex, socioeconomic status and lifestyle. 
The results of this study may be useful in delineating the complex treatment 
plan including nonpharmacological and psychological interventions.
Supported by: Poznan University of Medical Sciences
1023
The effect of a diabetes-specific cognitive behavioural treatment 
programme (DIAMOS) for people with diabetes and subthreshold 
depression
B. Kulzer, A. Schmitt, A. Gahr, T. Haak, N. Hermanns;  
Research Institute of Diabetes Academy Mergentheim (FIDAM),  
Bad Mergentheim, Germany.
Background and aims: Subthreshold depression is one of the most frequent 
mental comorbidities in people with diabetes and is associated with a poorer 
long-term prognosis. Since specific intervention concepts are missing a new 
self-management oriented group programme (DIAMOS) was developed for 
this patient group and evaluated in a randomised trial.
Materials and methods: The active control group (CG) received diabetes ed-
ucation. DIAMOS consisted of cognitive behavioural interventions aiming at 
the reduction of diabetes distress. Patients completed several questionnaires 
at baseline and follow-up: The Center of Epidemiological Studies-Depression 
Scale (CES-D), the Patient Health Questionnaire (PHQ 9), the Problem Areas 
in Diabetes Questionnaire (PAID) and the Diabetes Distress Scale (DDS). 
Primary outcome was the reduction of depressive symptoms. Secondary out-
comes were diabetes distress, well-being, self-care behaviour, diabetes accept-
ance, diabetes treatment satisfaction, HbA1c and inflammatory markers. 214 
participants were randomised.
Results: Baseline characteristics (age 43.3 ±13.3 yrs., female gender 56.5%, 
diabetes duration 14.2 ±10.5 yrs., type 2 diabetes 34.1%, BMI 28.7 ±71 kg/m²) 
were comparable between both interventions groups except BMI and dia-
betes type. At 12-month follow-up there was a significant greater reduction 
of the CESD- and PHQ 9-scores in DIAMOS compared to the CG (Δ -3.7, 
95%-CI 0.57 to 6.85 p=.021 respectively Δ -1.49, 95%-CI 0.08 to 2.90; p=.039 
). The risk of incident major depression was reduced (OR 0.63, 95%-CI 0.42 
to 0.96, p=.028) Also PAID-scores (Δ -8.3 95%-CI 3.33 to 12.72, p=.001) and 
DDS-scores (Δ -0.22 95%-CI 0.02 to 0.42, p=.042) were significantly reduced. 
C-reactive protein was significantly more lowered (Δ -0.25 95%-CI 0.02 to 
0.48 p=.035). No effect of the intervention was observed in other inflamma-
tory markers (IL1RA, IL6 and adiponectin).
Conclusion: DIAMOS is more effective in lowering depressive symptoms 
and diabetes related distress in diabetic patients with subthreshold depres-
sion. DIAMOS also has a preventive effect regarding the incidence of major 
depression.
Clinical Trial Registration Number: NCT01009138
Supported by: the BMBF within the competence network Diabetes
1024
Non severe hypoglycaemia does not affect the prevalence of diabetes 
related stress
N. Kuniss, G. Kramer, N. Müller, C. Kloos, G. Wolf, U.A. Müller;  
Endocrinology, University Hospital Jena, Germany.
Background and aims: The occurrence of hypoglycaemia is supposed to be 
associated with lower quality of life in patients with type-2 diabetes. Further-
more hypoglycaemia is suspected to be a trigger for depression. We investi-
gated the association of hypoglycemic events with diabetes related stress in a 
large outpatient cohort with diabetes type 1 (DM1) and type 2 (DM2).
Materials and methods: In a cross-sectional study we assessed hypoglycae-
mia and diabetes related stress with the PAID questionnaire in 785 people 
with diabetes in an university outpatient department for metabolic diseases 
over a period of three months (1.11.2012 to 31.01.2013). A PAID score ≥40 
indicates a depressed mood. 193 people (24.6%) had DM1 (HbA1c 7.2%, 
age 54.5J, diabetes duration 22.3J, BMI 27.0kg/m2), 182 (23.2%) had DM2 
without insulin therapy (HbA1c 6.6%, age 63.5J, diabetes duration 8.6J, BMI 
31.1kg/m2) and 410 (52.2%) had DM2 with insulin therapy (HbA1c 7.1%, age 
68.0J, diabetes duration 18.6J, BMI 33.6kg/m2). Patients with and without hy-
poglycaemia were compared. Mild hypoglycaemia was defined as a condition 
with typical symptoms (e.g. sweating, impaired concentration) disappearing 
quickly after carbohydrate ingestion or plasma glucose <2.7 mmol/l with or 
without typical symptoms. Severe hypoglycaemia was diagnosed if intrave-
nous glucose injection or intramuscular glucagon injection was necessary. 
HbA1c was adjusted according to the mean normal value of healthy people 
in the DCC trial (5.05%).
Results: People with DM1 had 1.09 mild hypoglycaemia/week and 0.04 se-
vere hypoglycaemia/last 12 months. There were no significant differences in 
diabetes related stress comparing people with DM1 with (n=111) and without 
(n=82) mild hypoglycaemia (PAID score 19.0±14.6 vs. 16.5±14.6, p=0.284), 
as well as with (n=7) and without (n=186) severe hypoglycaemia (20.7±18.0 
vs. 18.1±15.8, p=0.666). The mean PAID score of both groups is well below 
the threshold for depressive mood (PAID score <40). The frequency of mild 
hypoglycaemia/week in people with DM2 without and with insulin therapy is 
low (without insulin 0.03, with insulin 0.1). People with DM2 treated without 
insulin with (n=4) and without (n=178) mild hypoglycaemia have no dif-
ferent PAID score (20.3±15.0 vs.15.5±14.5, p=0.515). People with DM2 on 
insulin with (n=33) and without (n=377) mild hypoglycaemia as well show 
no differences in the PAID score (16.7±11.2 vs. 16.9±14.8, p=0.945). Severe 
hypoglycaemia/last 12 months did not occur in people with DM2 in this 
study group.
Conclusion: In an outpatient setting neither in people with diabetes type-1 
nor type-2 mild and severe hypoglycaemia are associated with increased dia-
betes related stress or increased incidence of depressive mood.
 
1025
Psychosocial distress in a clinical setting: Is PAID 1 a valuable tool  
to disclose distress
K.E. Nielsen, M. Glindorf, H.U. Andersen;  
Steno Patient Care Center, Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Psychosocial problems are common among patients 
with diabetes and often not recognized and addressed in the relatively short 
and busy meeting with the health care professional in daily clinical setting. 
Problem Areas in Diabetes (PAID) 1 (question 12: ‘Worrying about the future 
and the possibility of serious complications’) has been identified as a one-
item screening tool, with high sensitivity and specificity for the recognition 
of diabetes-related emotional distress. In a specialized diabetes clinic we have 
in 2011 implemented PAID 1 at the biennial status examination performed 
by the diabetes nurse to evaluate whether this is a feasible screening tool in 
the daily clinical setting.
Materials and methods: 3274 patients, aged 54.7 ± 42.3 years, male 56.6 %, 
Type 1 diabetes 67 %, disease duration 22,8 (0-80) years, are included in this 
material. The result of the screening is registered in the Electronic Patient File 
from where data is worked up. PAID is a questionnaire for self-administra-
tion developed to explore and screening for diabetes-related emotional issues 
from the patient‘s perspective. The table is built on a 5 point Likert scale from 
a point „not a problem“ to the „serious problem“.
Results: 41 % type 1 and 36 % type 2 diabetes patients show significant dis-
tress (PAID 1 score >2), not dependent on diabetes duration, confirming data 
from previous PAID studies. No influence of gender was seen. A previous 
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study has found PAID score to be weakly related to Hba1c. In our study, 
PAID 1 score is also related to poor metabolic control, figure 1.
Conclusion: We conclude that PAID 1 is suitable as a rapid tool to disclose 
emotional distress in a busy clinical setting. PAID 1 has been easily imple-
mented by the nurses and it is found valuable as an opening question in the 
consultation in order to discuss emotional distress and worries related to 
diabetes treatment, complications and daily life. Next step will be to study 
change in PAID 1 over time and how we can manage further screening and 
treatment of emotional distress in a structured way.
1026
Associations between glycaemic control, depressed mood, clinical 
depression and diabetes distress
H. Ascher-Svanum1, D. Schuster1, H. Schmitt2, L. Marangell1, E. Dennehy1, 
A. Zagar1, D. Jiang1, D. Kendall1, J. Raskin3, R. Heine1;  
1Eli Lilly and Company, Indianapolis, USA, 2Lilly, Brussels, Belgium,  
3Lilly, Toronto, Canada.
Background and aims: Although depression has been associated with poor 
glycemic control in patients with type 2 diabetes (T2DM), the available data 
are inconsistent and both methodological approaches and data quality vary 
significantly across studies. Specifically, depression has been defined and 
measured in multiple ways, including identification of a clinical syndrome, 
use of a depression rating scale and as measured by distress linked to diabetes 
and its management. This exploratory, post hoc analysis assessed the associa-
tion between depression, evaluated by these 3 methods, and glycemic control 
over 2 years in patients withT2DM initiating insulin in a single treatment 
trial.
Materials and methods: We analyzed data from a 24-month, prospective, 
observational study that evaluated glycemic response in patients with T2DM 
who initiated insulin therapy (N=985) in 5 European countries. Secondary 
measures included patient-reported diagnosis of depression at baseline, se-
verity of depressed/anxious mood (EuroQol (EQ)-5D item) and diabetes-
related distress (Psychological Distress domain of the Diabetes Health Pro-
file, DHP-18). The latter two measures were assessed at baseline and 5 time 
points throughout the study. Glycemic control was measured by A1c at these 
same time points. Analyses employed t-tests to assess the unadjusted baseline 
difference in A1c between patients with and without the respective depres-
sion parameter. The potential effect of demographic and clinical confounding 
variables was controlled through a linear model structure.
Results: At baseline, A1c of patients with depressed mood (moderately or 
extremely depressed/anxious) was higher, but not statistically significantly 
different from patients without depressed mood (9.6% vs. 9.5%, respective-
ly, p=.303). However, patients with depressed mood had higher A1c values 
throughout the 24 months follow up (p<.001). Patients with clinical depres-
sion had a higher baseline A1c than patients without clinical depression 
(10.8% vs. 9.4%, respectively, p<.001) and higher A1c values during the first 
6 months (p<.010) following insulin initiation. Significant group differences 
were not observed at subsequent time points. Patients with high diabetes dis-
tress had higher A1c at baseline as compared to patients with low distress 
(9.9% vs. 9.4%, respectively, p<.001) and higher A1c values were observed 
in the high distress group throughout the 24 months follow up (p<.001). Re-
ported results are based on the unadjusted group comparisons.
Conclusion: In this exploratory, post hoc analysis we demonstrated consist-
ent and significant associations between poorer glycemic control and each of 
the 3 depression parameters: depressed mood, clinical depression and diabe-
tes distress. The associations with poorer A1c were observed concurrently at 
baseline for clinical depression and diabetes distress and longitudinally for 
all 3 depression parameters. Our findings support - in this patient group- 
the previously reported association between depression and diabetes control. 
However, this analysis was not designed to assess causality and will require 
replication. The similar, but not identical findings, of the 3 unique depres-
sion measures suggest that each tool may capture a different but interrelated 
condition that may require assessment and management to optimize glucose 
control in patients with T2DM.
Supported by: Eli Lilly and Company
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Association of the presence and severity of depression with demographic, 
socioeconomic, glycaemic and metabolic risk factors in type 2 diabetes
C. Verras, S. Vrakas, A. Angelidi, A. Foutris, A. Ganotopoulou, V. Katsouri, 
V. Liosi, C. Sagia, G. Cristofilidis, A. Dimitriadou, V. Fousteris, A. Melidonis; 
Diabetes Center, Tzanio General Hospital, Piraeus, Greece.
Background and aims: Depression is a serious mental disease quite preva-
lent. Surveys have shown a strong association between depression and diabe-
tes mellitus with poor outcomes in disease control. The purpose of this study 
is to explore possible correlations between demographic, socioeconomic and 
metabolic parameters with the presence and severity of depression in people 
with type 2 diabetes.
Materials and methods: 269 patients (132 males, aged 65 ± 10.2 years) with 
type 2 diabetes were included in the study. Information regarding demo-
graphic characteristics, socioeconomic status, anthropometric and metabolic 
parameters, glycemic control, type of antidiabetic treatment and the presence 
of complications of diabetes were collected from all patients. The question-
naire scale BDI-II is widely used for depression and consists of 21 questions 
each answer being scored on a scale value of 0 to 3. The total score ranges 
from 0 to 63. Higher total scores indicate more severe depressive symptoms. 
Statistical analysis was performed using STATA 9.0 software.
Results: Severity of depression showed a statistically significant relationship 
with the following parameters: age (Coefficient=-0.21, p<0.0001), living with 
their children (Coefficient=4.6, p=0.012), menopause (Coefficient=-10.3, 
p=0.039), bmi (Coefficient=0.53, p=0.001), HbA1c (Coefficient=1.68, 
p=0.002), oral hypoglycemic agents (Coefficient=-5.5, p=0.035) and insulin 
(Coefficient=5.5, p=0.006). On multivariate analysis, HbA1c showed signifi-
cant positive association with the severity of depression (Coefficient = 1.73, 
95% CI: 0.42 - 3.04, p = 0.010). Moreover, analysis regarding glycemic con-
trol revealed that participants with HbA1c < 7% had lower BDI-II score than 
those with HbA1c > 7% (p=0.023).
Conclusion: Higher HbA1c levels appear to act favorably to the presence and 
severity of depression. Furthermore, good glycemic control is inversely as-
sociated with depression in people with type 2 diabetes.
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Improvement in depressive symptoms is associated with reduced 
markers of inflammation and oxidative damage in type 2 diabetic 
patients 
M. Vucic Lovrencic1, M. Pibernik-Okanovic2, D. Ajdukovic2, M. Sekerija3, 
N. Hermanns4;  
1Merkur University Hospital, 2Merkur University Hospital, University Clinic 
for Diabetes, 3Croatian National Institute of Public Health, Zagreb, Croatia, 
4Forschungsinstitut Diabetes-Akademie Bad Mergentheim  
(FIDAM GmbH), Bad Mergentheim, Germany.
Background and aims: Processes of inflammation and oxidative damage in 
diabetic patients suffering from subsyndromal depression have not been suf-
ficiently clarified. This study was aimed at examining one-year changes in 
inflammatory and pro-oxidative biomarkers in patients treated for elevated 
depressive symptoms that did not reach criteria for clinical depression.
Materials and methods: A randomized controlled comparison of two behav-
ioural interventions for subsyndromal depression - six-week psychoeduca-
tion and physical exercise, and a control condition consisting of brief diabetes 
re-education - was performed in a sample of 209 type 2 diabetic patients with 
subsyndromal depression (aged 57±6 yrs, 54% female, with diabetes duration 
of 11±8 yrs, 32% insulin treated, with HbA1c of 7.3%±1.2 [56±12.3 mmol/
mol] and BMI of 30±5 kg/m2). Clinical depression was excluded by using a 
Structured Clinical Interview for the DSM-IV Axis I disorders. A level of 
depressive symptoms, endogenous inflammatory markers (leukocytes, CRP), 
indicators of antioxidant capacity (myeloperoxidase index [MPXI], plasma 
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uric acid), and markers of oxidative damage (sialic acid, urinary-8-OH-
deoxyguanosine [u-8-OH-dG]) were assessed at baseline, and after six-and 
twelve months. Repeated measures ANOVA’s were employed to determine 
within- and between-group differences in depressive symptoms and meas-
ured biomarkers at follow-ups.
Results: Participants in the psychoeducational, physical exercise and the 
control group improved equally in depressive symptoms from baseline to 
12-month follow-up (time versus time x group effect; F= 12.51 p<.0001 
η2=0.07 and F=0.609 p=0.656 η2=0.007, respectively). Total leukocytes sig-
nificantly decreased in all three groups (7.7±1.8 to 7.1±1.6 F=15.72 p<.0001 
η2=.119) as did sialic acid (2.1±0.3 to 1.8±0.3 F=135.67 p<.0001 η2=0.323) 
and u-8-OH-dG (1.1±0.5 to 0.99±0.5 F=10.66 p<.0001 η2=0.06). No with-
in- and between-group changes were observed with respect to CRP and 
MPXI. Uric acid increased significantly during one year in all three groups 
(295.1±84.9 to 315.8±84.4 F=12.53 p<.0001 η2=0.07), with time effects being 
greater in women in comparison with men (η2=0.13 versus η2=0.03).
Conclusion: Lowering depressive symptoms in subsyndromally depressed 
type 2 diabetic patients was found to be associated with long-term improve-
ments in biomarkers of inflammation and oxidative stress. Treatment of even 
mild depressive symptoms may have favourable clinical implications.
Clinical Trial Registration Number: ISRCTN05673017
Supported by: EFSD 
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Socioeconomic deprivation independently predicts symptomatic painful 
diabetic neuropathy in type 2 diabetes
S.G. Anderson1, R.P. Narayanan2, N.S. Malipatil3, H. Roberts4, G. Dunn5, 
A.H. Heald4,6;  
1Cardiovascular Sciences Research Group, University of Manchester, 
2Department of Obesity and Endocrinology, The University of Liverpool, 
3Vascular Research Group, The University of Manchester, 4Department 
of Medicine, Leighton Hospital, Crewe, 5Department of Podiatry, East 
Cheshire NHS Trust, Macclesfield, 6The school of Medicine and Manchester 
Academic Health Sciences Centre, The University of Manchester, UK.
Background and aims: Painful peripheral neuropathy in people with type 2 
diabetes is a disabling complication. We explored associations of this condi-
tion with socioeconomic deprivation in an area of the UK, Cheshire which 
has a wide variation in demographic profile.
Materials and methods: The Townsend index of socioeconomic deprivation 
was examined in the pseudonymised GP records of 15388 (44.1% female) 
individuals with type 2 diabetes in Cheshire UK, and related to prevalence 
of drug treated painful diabetic neuropathy. We also analysed prescription 
trends with respect to pharmacotherapy for neuropathy pain relief.
Results: Treatment for neuropathic pain was initiated in 3266 (21.2%) of 
patients. Those on treatment were older [68.2 (95% CI 67.8-68.7) vs 66.6 
(66.4-66.8) years] than those not on treatment. There was no difference in 
HbA1c (7%, 55 mmol/mol). The odds of having treated painful peripheral 
neuropathy increased by 3.8 % for each 5 years of increasing age of the pa-
tient odds ratio (OR) 1.05: 95% confidence interval (CI) 1.04-1.07; p<0.0001. 
There was a 3% increased chance for each unit increase in BMI OR 1.03: 
95% CI 1.02-1.03; p<0.0001, but no relation with HbA1C. (OR 1.0: 95% CI 
0.99-1.0; p=0.58). There were significant differences between the groups for 
the Townsend deprivation index, with a greater proportion (30.6% vs 22.8% 
of patients with treated neuropathic pain) having a score of ≥1 (Χ2=83.9, 
p<0.0001). Multivariate logistic regression analyses indicated that each unit 
increment in the Townsend index was associated with an 6% increased odds 
of requiring neuropathic pain treatment [odds ratio (95%CI) 1.06 (1.05-
1.08), p<0.0001] independent of five year age band, BMI, gender, systolic BP, 
eGFR , HbA1C and total cholesterol.
Conclusion: A higher level of socioeconomic deprivation seemingly may 
predispose to severe neuropathic pain in diabetes requiring pharmacological 
intervention. Targeted allocation of healthcare resources to this group may 
offer significant clinical benefits.
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Physicians’ challenges when discussing the type 2 diabetes diagnosis with 
patients: insights from a cross-national study (IntroDia™)
W.H. Polonsky1, A. Belton2, S. Down3, M. Capehorn4, V. Gamerman5,  
F. Nagel6, J. Lee6, D. Clark6, S. Edelman7;  
1Department of Psychiatry, University of California San Diego and 
Behavioral Diabetes Institute, San Diego, USA, 2International Diabetes 
Federation, Brussels, Belgium, and The Michener Institute for Applied 
Health Sciences, Toronto, Canada, 3Somerset Partnership NHS Foundation 
Trust, Bridgwater, 4National Obesity Forum and Clifton Medical Centre, 
Rotherham, UK, 5Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, 
USA, 6Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, 
Germany, 7Division of Endocrinology and Metabolism, University of 
California San Diego and Veterans Affairs Medical Center, San Diego, USA.
Background and aims: Physician communication at diagnosis of type 2 
diabetes (T2D) may impact patient self-care, quality of life, and outcomes. 
IntroDia™ is a survey of ~17000 T2D patients and physicians in 26 countries 
to investigate early physician-patient communication and its potential con-
sequences.
Materials and methods: As part of IntroDia™, we surveyed 6753 physicians 
from Asia, Europe, America, Africa, and Australia using an online survey 
that included a novel questionnaire of 12 challenges that physicians may en-
counter at T2D diagnosis, and the Jefferson Scale of Physician Empathy.
Results: Across countries, 76-100% of physicians (88% overall) agreed that 
conversations with patients at T2D diagnosis impact on patients’ disease ac-
ceptance and treatment adherence. 92% of physicians wanted tools to help 
patients sustain behavioural change. Using factor analysis, the 12 items re-
sulted in loading onto 2 factors (Table): Discouraged with Patients at Diag-
nosis (DPD; α = 0.87), comprising 8 related challenges, and Frustrated with 
Situation at Diagnosis (FSD; α = 0.72), comprising 4 challenges. Correlation 
between these 2 factors suggested related, but distinct, groups of challenges 
(r = 0.64, p < 0.0001). Factor scores varied globally (DPD highest in France; 
FSD in Japan). Upon adjusting for demographic/clinical practice variables, 
regression models showed a negative relationship between physician empa-
thy and perceived challenges for total score (all 12 items) as well as DPD and 
FSD (all p < 0.0001).
Conclusion: Many physicians, especially those scoring lower on empathy, 
report significant challenges and frustrations during conversations with 
patients at diagnosis of T2D. Most physicians wanted tools to help patients 
sustain behavioural change. Supporting use of empathy-related skills may 
contribute to better patient outcomes.
Supported by: Boehringer Ingelheim/Eli Lilly
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Health-related quality of life and the relation to metabolic syndrome, 
type 2 diabetes, degree of obesity and low-grade inflammation in obese 
individuals
S.N. Slagter, M.M. van der Klauw, J. van Vliet-Ostaptchouk, J.C. Keers,  
H.L. Lutgers, A.P. van Beek, B.H.R. Wolffenbuttel;  
Endocrinology, University Medical Center Groningen, Netherlands.
Background and aims: We assessed the differences in health-related quality 
of life (HRQL) in obese participants with and without metabolic syndrome 
(MetS) and type 2 diabetes (T2D), by degree of obesity and level of inflamma-
tion (high sensitive C-reactive protein (hsCRP)). HsCRP is related to Obesity, 
MetS and T2D.
Materials and methods: Participants were derived from the random pop-
ulation-based LifeLines study in the Netherlands. In total, 53,266 subjects 
(39,540 normal weight and 13,726 obese; BMI >30 kg/m2), aged 18-80 years, 
were included. Subjects with diabetes were those with known T2D or had a 
fasting blood glucose >7.0 mmol/L. HRQL was assessed with the Short Form-
36. Sex-corrected physical (PCS) and mental component score (MCS) were 
calculated. MetS was measured with the NCEP ATP III (2005). ANCOVA 
was used to compare the PCS and MCS score, with age as covariate. Clinically 
relevant differences in PCS and MCS were defined as a minimum difference 
score of respectively, 2 and 3 points between groups of patients. We defined 
a poor outcome on individual scales of the PCS and MCS as a score below 80 
points. Results on individual scales were stratified by gender.
Results: PCS and MCS: Compared to normal weight individuals, obese sub-
jects had a significantly lower PCS (ranging from 3.1-7.5 points difference), 
pending on their MetS and T2D status, degree of obesity and level of inflam-
mation. However, no clinically relevant changes were found for MCS. Obese 
subjects with MetS had a significant lower PCS (49.7 vs. 51.1) and MCS (50.4 
vs. 51.2) than obese subjects without MetS, however these differences were 
small. Having T2D only affected the PCS (50.7 vs. 47.5; p<0.001). Increasing 
BMI was associated with a worse score of both PCS and MCS. However, test 
for linearity was only significant for PCS (p<0.001). Subjects with elevated 
hsCRP had a lower PCS than those with normal hsCRP (test for linearity, 
p<0.001). Individual scales: Among obese males, MetS affected physical func-
tioning, role physical and general health within the physical health domain, 
compared to obese men without MetS (all p<0.01). Within the dimension 
mental health, only social functioning and role emotional was affected by 
MetS. In obese women all scales of the physical and mental health domain 
was affected by MetS. Higher BMI among the obese subjects, was associated 
with having a poor outcome on all scales (test for linearity, all p<0.01), ex-
cept for role emotional in men and mental health in women. Elevated hsCRP 
showed more affected scores on scales within the dimension of physical 
health, than within the dimension of mental health. A higher percentage of 
obese male and female subjects with T2D had a worse score on all scales of 
physical health compared to those without T2D. Only the score on social 
functioning was affected by T2D (p<0.01).
Conclusion: Obese individuals had a lower HRQL compared to normal 
weight individuals, even in the absence of MetS, T2D or inflammation. Hav-
ing T2D, a BMI ≥40 kg/m2 or hsCRP >10 mg/L was associated with clini-
cally relevant decreased physical health. MetS, T2D, increasing BMI and low-
grade inflammation were all associated with poorer outcome of scales in the 
domain of physical health rather than in the mental health domain.
1032
Day napping and risk of type 2 diabetes: a dose-response meta-analysis
T. Yamada, K. Hara, N. Shojima, H. Hosoe, T. Kadowaki;  
Department of Diabetes and Metabolic Diseases, University of Tokyo, Japan.
Background and aims: A nap is a short period of sleep, typically during day-
light hours, and the habit of napping is widely prevalent around the world. 
Daytime naps are usually brief, but can range from a few minutes to a few 
hours. The frequency varies from taking an occasional nap to planned rest 
periods several times daily for habitual nappers. Some individuals take a nap 
because they are excessively sleepy during the daytime as a result of a sleep 
disorder. We performed a meta-analysis of evidence on the association be-
tween napping and the risk of type 2 diabetes and attempted to quantify the 
potential dose-response relation.
Materials and methods: We searched Medline, the Cochrane Library, Web 
of Science, and Science Direct for articles published up to March 2014 using 
the keywords nap (siesta) and diabetes. We also searched the references of 
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the original studies that we identified. Observational studies reporting risk 
estimates for type 2 diabetes were assessed. To ascertain the validity of the 
eligible studies, the quality of each report was appraised with reference to the 
STROBE statement. In addition, the Newcastle-Ottawa Scale for assessing the 
quality of prospective cohort studies in meta-analyses was used to quantify 
the validity of each study. The adjusted relative risk and 95% confidence in-
terval were calculated with the random effect model. Dose-response relations 
were evaluated using data from different nap categories in each study. Two 
authors independently confirmed the eligibility of the studies and collated the 
data. Any discrepancies were resolved through discussion. Sex was employed 
as an independent category for comparison. Publication bias was evaluated 
by the funnel plot, Begg test, and Egger test.
Results: Among 1,035 potential studies, 225,717 Asian and Western subjects 
stratified into 5 categories were identified. The analyses performed in each 
study were well adjusted for several confounders for diabetes. Pooled analysis 
revealed that a longer nap time (≥60 min/day) significantly increased the risk 
of type 2 diabetes (relative risk 1.46 (1.23-1.74, p<0.001)), while shorter nap 
time (<60 min/day) did not (0.95 (0.75-1.21, p=0.68)). Meta-analysis showed 
a significant non-linear dose-response relation between nap time and the risk 
of diabetes (P for non-linearity<0.01) (Figure 1), with no effect of nap time up 
to about 40 minutes/day followed by a sharp increase in the risk of diabetes at 
longer times. Publication bias was not significant.
Conclusion: There was a J-curve relation between nap time and the risk of 
type 2 diabetes, with longer nap times being associated with an increased risk.
1033
Longterm impact of childhood onset type 1 diabetes: social insertion, 
quality of life, sexuality 
H. Mellerio1, S. Guilmin-Crépon1, P. Jacquin2, C. Alberti1,  
C. Levy-Marchal3;  
1Inserm, ECEVE U1123 et CIC-EC 1426, 2Assistance Publique-Hôpitaux de 
Paris, Hôpital R.Debré, Médecine de l‘adolescent,  
3Inserm, CIC-EC, CIC 1426, Paris, France.
Background and aims: Little is known about the long-term social outcome 
of diabetic children. This study aimed to describe socio-professional life, 
quality of life (QOL) and sexuality at adult age of children and adolescents 
with type 1 diabetes (T1D).
Materials and methods: Of 721 adults with childhood-onset T1D identi-
fied in the nationwide French Register of Incidence of Diabetes, 388 (53.8%; 
age=28.5±3.1 yrs; age at diagnosis of diabetes=11.5±2.5 yrs; duration of di-
abetes=17.0±2.7 yrs) responded to a questionnaire (198 items). Data were 
compared to French general population (FGP) using indirect standardized 
ratios (SIR) matched for age, gender, period +/- educational level and famil-
ial life, or Z-scores adjusted for age, gender and period. Linear regression 
was used to investigate correlates of Physical (PCS) and Mental (MCS) SF36 
Composite Scores.
Results: Educational level was similar to FGP (68.6%≥high school de-
gree; SIR=1.06(CI95%:0.93;1.20)), whereas school delay in first year of 
primary school was lower (5.3%, SIR=0.49(0.30;0.75)). Unemployment 
was increased in women (15.3%, SIR=1.50(1.0;2.1)) but not in men (8.6%, 
SIR=0.96(0.51;1.57)). Professional occupation and employment contract 
patterns were close to what was expected. Adults with T1D were less likely 
to be homeowner (25.7%, SIR=0.72(0.57;0.89)). Frequency of daily alcohol 
consumption was higher than in FGP (SIR: men=3.34(2.38;4.54); wom-
en=6.53(4.57;12.99)); 7.2% (12/166) of men consumed more than recom-
mended (2 glasses per day), 5.0% (11/220) of women (1 glass per day). Fa-
milial life pattern was not different from FGP and among those who planned 
to have children, 72.2% (125/173) had one or more biological child. Overall, 
7.1% were very dissatisfied with sexual life (SIR=1.90(1.18;2.75)). Sexual prob-
lems prevalence was higher in women (SIR: dysorgasmia=1.91(1.21;2.88); 
decrease/loss of desire=2.11(1.35;3.08)), but similar in men; Social discrimi-
nation was more frequent (SIR=5.64(4.64;6.62)). PCS and MCS were respec-
tively moderately (mean=52.0±7.5; mean Z-score=-0.2(CI95%:-0.3;-0.1)) 
and substantially altered (mean=42.1±12.4; mean Z-score=-0.7(-0.8;-0.6)). 
Fatigue and abandoning sport were associated with lower PCS and MCS; 
educational level and presence of diabetes complication were also predictive 
of worse PCS, and sexual dissatisfaction and negative feelings related to tran-
sition pediatric/adult care were predictive of lower MCS. Participants with 
at least one vascular complication (n=136) had preserved social outcomes 
but decreased PCS (mean=50.0±8.3; mean Z-score=-0.5(-0.7;-0.3)) and MCS 
(mean=40.3±12.3; mean Z-score=-0.9(-1.1;-0.7)).
Conclusion: Young adults with T1D have a satisfying social well-being but 
alteration of MCS, frequent dissatisfaction with sexuality and uncommon al-
cohol consumption suggest the high impact of disease on morale, especially 
in women. Improving the screening of sexual problems and alcohol con-
sumption, as well as optimize the psychological support of patients to cope 
with the T1D burden must be high priorities for health caregivers.
Supported by: Pfizer foundation for child and adolescent health
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Spectrum of diabetes research does not reflect patients‘ scientific 
preferences
S. Arnolds1, S. Heckermann1, P.T. Sawicki2;  
1Profil Institut für Stoffwechselforschung GmbH, Neuss,  
2Institute for Health Economics and Clinical Epidemiology,  
Medical Faculty of the University of Cologne, Germany.
Background and aims: Involvement of patients and their relatives in plan-
ning of research has been proposed to increase the patient orientated rel-
evance of scientific investigations. Here we compare the proportions of re-
search topics patients would like to see and the trend in the distribution of 
research categories of accepted EASD abstracts during the last four years.
Materials and methods: We evaluated the spectrum of diabetes research as 
published during the EASD meetings 2010 - 2013 and compared them with 
the results of a survey in 918 lay people (652 patients with diabetes, 205 rela-
tives, 61 others concerned) interested in diabetes research, who had described 
their research preferences in diabetes. To obtain a fairly unselected sample of 
an interested lay group a questionnaire was published in a popular weekly news 
magazine inviting patients with diabetes and their relatives to state which area 
of research was of top priority to them. Nine research categories had been de-
fined by consensus by four scientifically active diabetologists, and their com-
pleteness had been checked by testing whether all EASD abstracts published 
2008 were covered by a defined scientific field. For this 4-year evaluation two 
reviewers (SA and PTS) independently assigned each EASD abstract to one of 
the nine research categories and also classified them according to a commercial 
sponsorship as indicated in the abstract EASD booklet. The 4-year period was 
analyzed in terms of changes or trends observed in the proportions of EASD 
research topics and the results were compared with patients’ preferences.
Results: “Development, pathophysiology and prevention of diabetes” was 
the primary category of scientific interest for 25% of patients, 19% preferred 
“transplantation and cell therapy” and 16% “blood glucose measurement, 
devices and artificial pancreas”. During the 4 years of EASD abstract inves-
tigation 50% or more of total research activities was constantly dedicated to 
“development, pathophysiology and prevention of diabetes”, less than 2% to 
“transplantation and cell therapy” and 2.8% to 4.3% to “blood glucose meas-
urement, devices and artificial pancreas”. The average proportion of EASD 
research related to “blood-glucose lowering therapy without insulin” and 
“insulin therapy” more or less corresponded with the proportion of research 
patients would like to see (12.0% vs. 12.5%, and 6.9% vs. 4.7%, respectively). 
The majority of this research, however, was commercially funded. In total, 
non-commercial research was not closer correlated to patients’ preferences 
compared to commercial research.
Conclusion: The distribution of diabetes research topics over the last four 
years as measured by the distribution of accepted EASD abstracts does not re-
flect what patients with diabetes and their relatives want to have investigated. 
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Better patient involvement and a reassessment of non-commercial funding 
strategies might help create more valuable research at least from patients’ 
point of view.
1035
Glycaemic perception and other factors influencing adherence to self-
monitoring blood glucose in patients with type 1 or type 2 diabetes
M. Jansà Morató1, M. Vidal Flor1, M. Galindo Rubio2,  
M. Penalba Martínez3, L. Corredoira González4;  
1Servicio de Endocrinología y Nutrición, Unidad de Diabetes, Hospital 
Clínic i Provincial de Barcelona, 2Servicio de Endocrinología y Nutrición, 
Hospital Clínico de San Carlos de Madrid, 3Servicio de Endocrinología 
y Nutrición, Hospital Universitari i Politècnic La Fe de Valencia, 
4Departamento de Estadística, BioClever 2005 S.L., Barcelona, Spain.
Background and aims: Self-monitoring blood glucose is an important tool 
to achieve good glycemic control. However, many patients measure their glu-
cose concentrations less often than recommended. This study was conducted 
to assess the factors associated with adherence to self-monitoring blood glu-
cose in patients with diabetes mellitus treated with insulin.
Materials and methods: In this observational, prospective and multicenter 
study in patients with type 1 or type 2 diabetes treated with insulin as per 
usual clinical practice, socio-demographic and clinical characteristics were 
collected at the baseline visit. Glycemic perception was assessed through 4 
monthly telephone calls asking patients about their perceived glycemic levels 
and then comparing these perceptions with their real values from the glu-
cometer. A patient was considered adherent if the minimum number of glu-
cose measurements established by the Spanish Society of Diabetes was car-
ried out. To assess factors associated with adherence to self-monitoring blood 
glucose, a multivariate logistic regression were performed.
Results: A total of 2.700 patients were recruited, of whom 2.029 (75%) were 
considered valid for the analysis. With an age range of 18 to 80 years, the 
mean duration of the disease was 16.5±10.5 years and 30% of patients had 
type 1 diabetes. The majority of patients (81%) had an unsatisfactory glyce-
mic control (baseline HbA1c ≥7%), which was significantly associated with 
an incorrect glycemic perception. Only 17% of patients had a correct glyce-
mic perception. More than half of the patients (54%) were adherent to the 
self-monitoring according to the SED rules (95%CI: 52%, 56%), this being 
51% in patients with type 1 diabetes. In patients with an age range of 18 to 44 
years, the recommendation of >21 measurements/week (OR: 0.031; 95%CI: 
0.015, 0.062) and alcohol consumption (OR: 0.452; 95%CI: 0.254, 0.805) were 
associated to low adherence. In patients with an age range of 45 to 64 years, 
an increase in the number of insulin injections/day was associated to a high-
eradherence (OR: 1.296; 95%CI: 1.073, 1.566), while the recommendation 
of >21 measurements/week (OR: 0.070; 95%CI: 0.048, 0.104) and the belief 
that it was possible to know their glucose levels without the glucometer (OR: 
0.925; 95%CI: 0.877, 0.976) were associated to low adherence. In patients 
over 65 years, the recommendation of >21 measurements/week (OR: 0.112; 
95%CI: 0.076, 0.163), obtaining the test strips from the health centre vs from 
the pharmacy (OR: 0.554; 95%IC: 0.378, 0.812) and discouragement in cases 
of off-target HbA1c levels (OR: 0.488; 95%IC: 0.337, 0.706) were associated 
to low adherence.
Conclusion: Adherence to self-monitoring blood glucose in patients with 
diabetes varies depending on age and on being recommended >21 measure-
ments/week as a common factor associated with low adherence in all age 
groups. Other variables associated with poor adherence by age group are: al-
cohol intake in young patients, confidence in glycemic perception in middle 
age and lack of motivation for poor control in older people.
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The relation between illness perception, diabetes distress and depression 
in type 2 diabetes patients: pilot study in a Romanian sample
A.S. Mocan1,2, S.S. Iancu1, I.A. Vereşiu1, D.E. Dumitraş3, S. Puşcaşu2,  
C.M. Mureşanu2, A.G. Şerban2, L.A. Pop2, A.S. Băban2;  
1Diabetes, Nutrition and Metabolic Diseases Department, Emergency 
Clinical County Hospital, 2Psychology and Educational Sciences Faculty, 
Babes -Bolyai University, 3Department of Economic Sciences, University of 
Agricultural Science and Veterinary Medicine, Cluj-Napoca, Romania.
Background and aims: Depression has a major negative effect on diabetes 
outcome. Illness perception and diabetes distress may contribute to emotion-
al and somatic depressive symptoms. Our aim was to investigate the relation-
ship between illness perception, diabetes distress and depression.
Materials and methods: 204 type 2 diabetes patients were included in the 
study. Revised Illness Perception Questionnaire (IPQ-R) and Diabetes Dis-
tress Scale (DDS) were used to investigate illness burden. Beck Depression 
Inventory was used for depression. Linear regression analysis was used to 
evaluate the association between the five components of IPQ-R (illness 
identity, causes, timeline, consequences and cure-control), respectively four 
components of DDS (emotional burden, physician-related distress, regimen-
related distress and diabetes-related interpersonal distress) and emotional 
and somatic symptoms of depression.
Results: Mean age of the participants was 64.61 years (range 32-81 years) 
and the mean HbA1c 7.43% (SD=1.46%). Depressive symptoms were found 
in 43.1% of patients of them 22.1% had subclinical depression. In depressive 
group, HbA1c was associated with somatic depressive symptoms (r = .262, p 
< 0.05). Emotional diabetes distress was identified as a mediator between ill-
ness perception identity and somatic depression: first and second mediation 
linear regression R2 = .174, p < .005, R2 = .239, p< .005, Sobel test z-score = 
2.853, p= 0.0043. Emotional diabetes distress was also identified as a media-
tor between perception of illness consequences and somatic depression: first 
and second mediation linear regression R2 =. 172, p < .005, R2 = .217, p<. 
005, Sobel test z-score = 3.170, p= 0.0015. Finally emotional diabetes distress 
was identified as a mediator between emotional representation of illness and 
somatic depression: first and second mediation linear regression R2 =. 236, 
p < .005, second mediation linear regression R2 = .216, p<. 005, Sobel test 
z-score = 3.1621, p= 0.0015.
Conclusion: Diabetes distress represents a mediator between illness percep-
tion and depression symptoms. Diabetes symptoms, perception of the illness 
severity and feelings of diabetes’ complication inevitability having a signifi-
cant effect on the mental representation of future life with diabetes. In re-
turn diabetes patients tend to be irritable, restless, with insomnia and fatigue. 
The results are important for clinical practice and may help these patients 
with cognitive restructuring concerning both illness perception and diabetes 
impact. A possible explanation for these findings may be the emotional and 
cognitive dysfunctional coping strategies in these patients.
1037
Depression influences on cardiometabolic profile responses to a lifestyle 
intervention in at-risk Brazilians
A. Cezaretto1, M. Pakseresht2, F. Kolahdooz2, S. Sharma2,  
B. Almeida-Pititto1, C.R. Barros1, S.R.G. Ferreira1;  
1Nutrition, University of Sao Paulo, Brazil,  
2Endocrinology, University of Alberta, Edmonton, Canada.
Background and aims: Cardiometabolic diseases and depression are relevant 
public health problems that are commonly associated. Benefits of lifestyle in-
terventions on improving cardiometabolic profile are well documented. Low 
adherence to a healthy lifestyle may be partially explained by the association 
with psychological disorders, such as depression. Aims: To evaluate whether 
depression modifies the impact of a lifestyle intervention on cardiometabolic 
profile responses in an at-risk sample of the Brazilian population.
Materials and methods: 129 individuals at risk of cardiometabolic diseases 
recruited from Brazilian public health care services (66% women, 56.2±11.6 
yrs, BMI 30.3±5.4 kg/m²). Participants were allocated to one of two 18-month 
interventions on diet and physical activity. Socio-demographic and clinical 
data were obtained. Depressive symptoms were assessed by the Beck Depres-
sion Inventory and score ≥12 diagnosed depression. Changes in each of the 
five metabolic syndrome components (body adiposity: ≥5% decreased waist 
circumference and/or BMI; plasma glucose: ≥10% decreased fasting and/or 
post-load glycemia; blood pressure:≥ 10% decreased mean blood pressure; 
HDL-cholesterol: ≥10% increased HDL; and triglycerides: ≥10% decreased 
triglycerides) were used to define responses to the intervention and improve-
ment on cardiometabolic profile. Multiple logistic regression models were 
employed (by each gender) in order to analyze influence of depression in 
each of 6 cardiometabolic profile outcomes. All models were adjusted for age, 
physical activity and type of intervention. Inflammatory markers were added 
into the models as possible mediators of relationship between depression and 
cardiometabolic outcomes. Likelihood ratio test was employed to compare 
the results of a logistic regression model with interaction term and a logistic 
regression model without interaction term.
Results: Approximately 42% of individuals had depressive symptoms. De-
pressed participants had a higher BMI, cholesterol and diastolic blood pres-
sure, and had a lower level of the quality of life and physical activity compared 
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to non-depressed individuals. Depressed women after 18 months of interven-
tion were less likely to have an improvement in their plasma glucose (OR: 
0.32; 95%CI: 0.12; 0.87) and blood pressure (OR: 0.29; 95%CI: 0.10; 0.94) 
compared to non-depressed women. Depression had no effect on the impact 
of intervention on body adiposity and lipid profile. Inclusion of inflammatory 
markers into the models did not influence the association of depression and 
improvement in cardiometabolic profile. Comparing models including or not 
the interaction variable (depression*interdisciplinary intervention) no differ-
ence in results was found.
Conclusion: Depression at baseline of a lifestyle intervention may predict 
a lower chance of improving long-term cardiometabolic profile particular-
ly among women. This raises the necessity of increase health professionals 
awareness and public health policy makers’ attention to depressed people at 
high cardiometabolic risk. We suggest a focus on screening and management 
of depression as part of the intervention programs for lifestyle changes in 
at-risk individuals.
Clinical Trial Registration Number: RBR #65N292
Supported by: FAPESP
1038
The impact of hyperglycaemia and obesity on hospitalisation costs and 
clinical outcome in general surgery patients
L. Buehler1, M. Fayfman1, A.-S. Alexopoulos1, L. Zhao2, F. Farrokhi1,  
J. Weaver3, D. Smiley1, F. Pasquel1, G. Umpierrez1;  
1Medicine-Division of Endocrinology, Emory University,  
2Biostatistics, Rollins School of Public Health,  
3Information Technology, Emory University, Atlanta, USA.
Background and aims: The association between inpatient hyperglycemia 
and poor outcome in surgical patients is well established. It is not known if 
obesity increases rates of complications in surgical patients with and without 
hyperglycemia and diabetes.
Materials and methods: We analyzed the effects of obesity and hypergly-
cemia on hospitalization costs and clinical outcome in patients, with and 
without diabetes (DM), who underwent gastrointestinal, hepato-biliary and 
pancreatic surgery. Inpatient hyperglycemia was defined as BG ≥7.8 mmol/L. 
Overweight was defined by body mass index (BMI) between 25-30 kg/m2 and 
obesity as a BMI >30 kg/m2. Hospital cost was calculated using cost-charge 
ratios from Centers for Medicare & Medicaid Services. Hospital complica-
tions included a composite of major cardiovascular events, pneumonia, bac-
teremia, acute kidney injury, respiratory failure, and death.
Results: Among 2366 surgery patients, hyperglycemia was present in 1799 
patients (76%) of whom 506 (28%) had history of DM and 1293 (72%) had no 
DM before surgery. Compared to patients with normoglycemia, those with 
DM and non-DM with hyperglycemia had higher number of hospital com-
plications (5% vs. 21% vs. 20%, p<0.0001), longer hospital stay (5 days vs. 9 
days vs. 9 days, p<0.0001), more readmissions within 30 days (10% vs. 18% 
vs. 17%, p<0.0001), and higher hospitalization costs ($20,212 vs. $78,690 vs. 
$72,550, p<0.0001). Multivariate analysis adjusted for age, gender, BMI and 
type of surgery (laparotomy/open surgery) revealed that hyperglycemia in 
DM and non-DM patients was associated with a ~4-fold increased risk of 
complications compared to patients with normoglycemia [OR 4.4 (95% CI: 
2.8,7.0) and 4.0 (2.6,6.1)]. In contrast, compared to normal-weight subjects 
(BMI 18.5-25 kg/m2), the presence of overweight status and obesity was not 
associated with increased risk of complications (17.3% vs. 15.7% vs. 16.1%, 
p=0.77), or hospitalization costs ($58,313 vs. $58,173 vs. $66,644, p=0.41). 
Open surgery was associated with higher rates of complications (19.2% 
vs. 8.9%, p<0.0001) and higher hospitalization costs ($67,191 vs. $43,767, 
p<0.0001) compared to laparoscopic surgery; however, there were no dif-
ferences in mortality, hospitalization costs or type of surgery among normal 
weight, overweight and obese (all, p=NS).
Conclusion: Perioperative hyperglycemia but not increasing BMI, in patients 
with and without diabetes undergoing gastrointestinal surgery, was associ-
ated with a higher number of complications and hospitalization costs.
1039
Seasonal fluctuations in nutrition variability in Europe: are patients with 
symptoms of a metabolic syndrome different? 
A. Dzien1, C. Dzien-Bischinger1, C. Dzien1, H. Winner2, E. Theurl3;  
1Medical Center Hentschelhof, Innsbruck,  
2Department of Economics and Social Science, University of Salzburg, 
3Department of Public Economics, University of Innsbruck, Austria.
Background and aims: A lower nutrition variability seems to be related with 
an increased risk for metabolic and cardiovascular disorders. Seasonal chang-
es in the availability of certain food items might influence food variability 
also in the high income countries of central Europe. We were interested in 
the possible dependency of nutrition variability over 4 seasons in an Austrian 
population especially with respect to differences between healthy people and 
patients with symptoms of a metabolic syndrome, including type 2 diabetes, 
hypertension and obesity (Body mass index, BMI,≥30 kg/m2).
Materials and methods: For this purpose we have evaluated data from 3354 
individuals (mean age 45.5±18.9 years; mean BMI 24.3±4.4 kg/m2) attending 
a medical outdoor center in an urban area between January 2006 and May 
2013. Because of repeated controls during the evaluation period data from 
4457 observations in healthy people and 352 in the 85 patients with symp-
toms of a metabolic syndrome were available. To obtain information on their 
“normal” nutrition behaviour, patients were requested to complete a semi-
quantitative food frequency questionnaire including 51 different food items. 
Frequencies of consumption of food items were reported on a scale between 1 
(seldom or never) and 6 (more than once daily). Based on this sample, we de-
fined dietary diversity as the total number of different food items consumed 
during one week.
Results: Overall, nutrition variability was lower in patients with symptoms of 
a metabolic syndrome compared to the healthy control group. While nutri-
tion variability revealed no significant seasonal dependency in the healthy 
group, low variability values were found in patients with symptoms of a meta-
bolic syndrome during spring and fall.
Conclusion: The food variability seems to be lower in patients with a meta-
bolic syndrome compared to a healthy control group. Regarding a possible 
seasonal influence the food variability revealed a decrease in the fall period. 
This lower food variability could be due to strict dietary recommendations, 
but also to rigid food behaviour, which becomes obvious when fresh local 
fruit and vegetables are available in autumn. Dietary cancelling should in-
clude the recommendation for food variability.
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Somatic symptoms in Chinese patients with type 2 diabetes:  
frequency, risk factors, and the relation to quality of life
Y. Zhang1, A. Luk1, W. Yang2, W. Jia3, W. Li4, L. Ji5, X. Guo6, A. Kong1,  
R. Ozaki1, R. Yeung1, N. Sartorius7, Y.-K. Wing8, J. Weng9, J. Chan1,  
China Diabetes and Depression Study Group;  
1Department of Medicine and Therapeutics, The Chinese University of 
Hong Kong, Shatin, 2Department of Endocrinology, China-Japan Friendship 
Hospital, Beijing, 3Department of Endocrinology, Shanghai 6th Hospital, 
4Department of Endocrinology, Peking Union Medical College Hospital, 
Beijing, 5Department of Endocrinology, Peking University People‘s Hospital, 
6Department of Endocrinology, Peking University First Hospital, Beijing, 
China, 7Association for the Improvement of Mental Health Programmes, 
Geneva, Switzerland, 8Department of Psychiatry, The Chinese University of 
Hong Kong, 9Department of Endocrinology, The Third Affiliated Hospital, 
Sun Yat-sen University, Guangzhou, China.
Background and aims: Somatic symptoms are common in patients with 
chronic diseases which may reflect underlying emotional distress. We in-
vestigated the burden of somatic symptoms, risk factors and its associations 
with psychological health and quality of life in Chinese patients with type 2 
diabetes.
Materials and methods: 2401 patients aged 18-75 years attending hospital-
based clinics in 4 cities in China underwent detailed clinical-psychological 
assessment during a 12-month period in 2011-2012. Somatic symptom 
burden was measured using the 28-item Somatic Symptom Inventory (SSI); 
emotional distress was measured using the 21-item Depression, Anxiety 
Stress Scale (DASS); quality of life was measured using the Euroqol-5D.
Results: In this cross-sectional analysis, the mean (SD) age of the study co-
hort was 56.4 (10.6) years (46.6% women). Somatic symptoms were highly 
prevalent with a mean SSI score of 41.4 (15.1), and 14 of the 28 symptoms 
were reported by more than 30% of patients. Overall, 71.5% of patients re-
ported at least one pain symptom, and 51.9% reported at least one gastro-
intestinal symptom. The most frequent reported symptom was trouble with 
vision (55.9%), followed by joint pain (44.9%), fatigue (44.8%), and muscles 
soreness (42.7%). In multivariate linear regression, after controlling for study 
sites, somatic symptom severity (adjusted R2=0.483; P<0.001) was indepen-
dently associated with women (β=0.088, P<0.001), long duration of diabe-
tes (β=0.049, P=0.008), frequent hypoglycemia during the past 3 months 
(β=0.075, P<0.001), history of cardiovascular disease (β=0.045, P=0.006), 
sensory neuropathy (β=0.088, P<0.001), and emotional distress (β=0.623, 
P<0.001). Using stepwise linear regression, age (β=-0.053, P=0.026), women 
(β=-0.07, P=0.001), obesity (β=-0.066, P=0.002), frequent hypoglycemia in 
past 3 months (β=-0.063, P=0.003), sensory neuropathy (β=-0.049, P=0.025), 
and emotional distress (β=-0.216, P<0.001) were independently associated 
with poor quality of life. After inclusion of somatic symptom severity (β=-
0.257, P<0.001), sensory neuropathy became non-significant (β=-0.026, 
P=0.217).
Conclusion: Somatic symptom burden is high in Chinese patients with type 
2 diabetes which may reflect underlying emotional distress, suboptimal gly-
cemic control and sensory neuropathy.
Clinical Trial Registration Number: NCT01277432
Supported by: EFSD/CDS/Lilly, ADF and Liao Wun Yuk Diabetes Memorial 
Fund
1041
The Diabetes Self-Management Questionnaire (DSMQ) can detect 
inadequate self-care behaviour and help identify patients at risk of a 
negative diabetes prognosis
A. Schmitt, N. Hermanns, B. Kulzer, A. Reimer, S. Schall, T. Haak;  
Research Institute of the Diabetes Academy Mergentheim, German Diabetes 
Center Mergentheim, Bad Mergentheim, Germany.
Background and aims: Existing psychometric instruments to assess diabetes 
self-management often reveal weak or inconsistent associations with ‚hard 
data‘ such as medical outcomes and HbA1c. To fill this gap, the Diabetes Self-
Management Questionnaire (DSMQ) was developed, focussing on self-care 
activities which directly impact medical diabetes outcomes. This study evalu-
ates the questionnaire’s practical utility in detecting high-risk patients at a 
tertiary diabetes centre.
Materials and methods: 226 people with diabetes (age 43 ± 15 y.; 55% fe-
male; BMI 29 ± 7; 70% type 1 diabetes; illness duration 15 ± 10 y.; 92% treated 
with insulin; HbA1c 8.9 ± 1.6%) were assessed with the DSMQ and further 
questionnaires regarding diabetes acceptance (AADQ), coping with illness 
(FQCI), treatment satisfaction (DTSQ), diabetes distress (PAID), and depres-
sive symptoms (CES-D); additional data (demographic variables, self-mon-
itoring of blood glucose, HbA1c, and long-term complications) were gained 
from electronic patient records. People were then categorized by a median 
split of the DSMQ total score into groups performing ‘adequate’ (n = 107) 
versus ‘inadequate’ diabetes self-care (n = 119); the groups were compared 
regarding relevant outcomes using multivariate ANOVA (subsequently pre-
sented data are M ± SD, F statistic, and effect size Cohen’s d).
Results: After adjusting for sex, age, BMI, diabetes type, diabetes duration, 
and type of treatment, people performing ‘inadequate self-care’ compared to 
those with ‘adequate self-care’ showed stronger diabetes non-acceptance (31 
± 8 vs. 22 ± 6, F = 90.5, d = 1.24), less active coping with diabetes (2.7 ± 0.9 
vs. 3.4 ± 0.8, F = 18.1, d = 0.82), lower diabetes treatment satisfaction (20 ± 7 
vs. 24 ± 6, F = 21.3, d = 0.60), higher diabetes distress (43 ± 21 vs. 33 ± 19, F 
= 17.0, d = 0.85), and more depressive symptoms (24 ± 11 vs. 20 ± 11, F = 4.8, 
d = 0.36). Moreover, they performed fewer blood glucose self-tests (3.3 ± 3.5 
vs. 5.6 ± 2.4 times per day, F = 24.7, d = 0.74), consulted their diabetologist 
less often (1.9 ± 1.8 vs. 2.6 ± 2.3 times per half-year, F = 6.6, d = 0.34), had a 
higher HbA1c value (9.5 ± 1.5 vs. 8.2 ± 1.4%, F = 34.6, d = 0.87), and showed 
a higher prevalence of retinopathy (28% vs. 14%, F = 6.0, d = 0.35).
Conclusion: The DSMQ yields excellent distinction between people with 
diabetes performing adequate versus insufficient diabetes self-care, thus ena-
bling detection of people at high risk of a negative diabetes prognosis. The 
16-item questionnaire is an efficient tool which may be used for screening 
and diagnostic purposes or clinical diabetes research.
Clinical Trial Registration Number: NCT01812291
Supported by: ‘Competence Network for Diabetes mellitus’ (FKZ 01GI1107)
1042
What drives patients? A cross-sectional survey of the effects and fear 
of hypoglycaemia on individuals, workplace, and patients‘ continued 
eligibility to drive
M. Bagger1, M. Dømgaard1, N.A. Rhee2, C.M. Burton3, B. Thorsteinsson4;  
1Research & Knowledge, Danish Diabetes Association, Odense, 
2Clinical, Medical and Regulatory Affairs, Novo Nordisk Scandinavia 
AB, Copenhagen, 3Point Of Care Medical Consulting, Copenhagen, 
4Department of Cardiology, Nephrology and Endocrinology, Nordsjællands 
Hospital, Hillerød, Denmark.
Background and aims: The aim of this study was to investigate the effect 
of hypoglycaemia and fear of hypoglycaemia on the individual and society.
Materials and methods: An anonymous cross-sectional survey of Danish 
Diabetes Association members was conducted to investigate individual and 
societal consequences of hypoglycaemia.
Results: A total of 3,117 of 9,951 invited individuals with type 1 (32.2%) or 
type 2 diabetes (67.8%) completed the survey. The calculated incidence rates 
of self-reported severe hypoglycaemia was 2.9, 0.6 and 0.1 events per patient 
year (ppy) in patients with type 1 diabetes, Insulin using type 2 diabetes and 
non-insulin using type 2 diabetes, respectively; and incidence rates of self-re-
ported mild hypoglycaemia were 99.0, 23.2 and 10.9 events ppy, respectively. 
Self-care strategies to avoid hypoglycaemia include maintaining higher blood 
glucose levels (45.7%) and reducing physical activity (15.7%). Few people 
take sick leave as a result of hypoglycaemia, but prolonged mental recovery 
≥4 hours following an episode of mild or severe hypoglycaemia was reported 
by 8.7% and 31.0%, respectively. 9.3% of patients holding a valid driver li-
cense reported having 1 or more episodes of severe hypoglycaemia in the 
last year. Patients considering under-reporting of hypoglycaemia to maintain 
their driver license were more likely to have experienced severe hypoglycae-
mia (Odds Ratio [OR] 3.03, 95% CI 2.42-3.79, p<0.0001).
Conclusion: A high proportion of Insulin treated patients experience hypo-
glycaemia resulting in fear of hypoglycaemia and changes in self-care behav-
iour that may compromise glycaemic control. Many patients with a history 
of severe hypoglycaemia consider under-reporting hypoglycaemic events 
through concern over retaining their driver license.
Supported by: Novo Nordisk Scandinavia AB
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Perception of type 1 diabetes management by adolescents, parents and 
healthcare professionals: divergence of opinions influences metabolic 
and psychological outcomes
S. Schmit1, J. Jacobs1, J.-P. Bourguignon2, M. Fichelle3, S. Jellimann4,  
O. Ziegler5, C. De Beaufort3;  
1Centre for Health Studies, CRP-Sante, Luxembourg, 2Adolescent Health 
Centre, CHU de Liège, Belgium, 3Department of Paediatric Endocrinology 
and Diabetology, Centre Hospitalier de Luxembourg, Luxembourg,  
4Clinical Infantile and Genetic Medecine, CHRU de Nancy -  
Hôpital d‘Enfants, 5Department of Diabetology, Metabolic Diseases and 
Nutrition, CHRU de Nancy - Hôpital Brabois Adultes, France.
Background and aims: It is a major challenge for adolescents with type 1 
diabetes to manage their disease, due to physical changes and psychosocial 
factors that characterise this period of transition. Although parents play an 
important role in supporting their children, responsibility is shifting. This 
may enhance conflicts between parents and adolescents, creating an impor-
tant barrier to efficient metabolic control as well as to quality of life. Phy-
sicians and nurses represent another party supporting and influencing the 
youth’s self-management. This study aims at comparing the perception of 
these different parties of several aspects of diabetes management and at iden-
tifying the influence of the convergence or divergence of these opinions on 
metabolic outcomes and the youth’s well-being.
Materials and methods: Adolescents between 13 and 17 years visiting the 
outpatient clinic in 3 regions, as well as their parent(s), paediatric diabetolo-
gist and diabetes nurse filled out questionnaires containing questions on the 
adolescent’s metabolic targets, treatment, well-being, quality of life, self-
management and perception of self-management. Clinical data concerning 
blood glucose measurements, insulin regimen, episodes of severe hypogly-
caemia and diabetic ketoacidosis and Hb1Ac level were collected via a Clini-
cal Record Form. Answers of the 4 parties were compared to see whether 
convergent answers are related to metabolic control, well-being and quality 
of life. The study was approved by the three IRB’s and Informed consent was 
obtained from all participants.
Results: The sum of distances between answers of the 4 parties on HbA1c 
targets and on well-being was correlated to HbA1c outcomes (R = 0.448, p 
< 0.001; R = 0.232, p = 0.036). The sum of distances between opinions on 
HbA1c aims, on hyperglycaemia management and on fear from hypogly-
caemia were inversely correlated to the youth’s self-management score (R = 
-0.378, p < 0.001; R = -0.349; p = 0.001; R = -0.295, p = 0.003).
Conclusion: These results confirm the importance of harmony between the 
different protagonists of the youth’s type 1 diabetes management. The themes 
that seem to be most important are Hb1Ac targets, perception of the adoles-
cent’s well-being and perceptions of hyper- and hypoglycaemia management. 
Communication between protagonists proves to be extremely important in 
adolescent diabetes management, since the difficulty of this management 
may be related to the level of harmony between adolescents, parents and 
healthcare teams. These findings are an important element to be taken into 
account in the conception of patient education programmes.
Supported by: INTERREG IV A
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The impact of glycaemic variability on quality of life in adults with type 
1 diabetes
M. Reddy1, R. Agha-Jaffar1, P. Herrero2, P. Georgiou2, M. El-Sharkawy2,  
P. Pesl2, N. Jugnee1, H. Thomson1, C. Toumazou2, D. Johnston1, N. Oliver1;  
1Division of Diabetes, Endocrinology and Metabolism,  
2Centre for Bio-Inspired Technology, Institute of Biomedical Engineering, 
Imperial College London, UK.
Background and aims: We aimed to assess whether glycaemic variability 
(GV) has an impact on quality of life (QOL) in adults with established type 
1 diabetes mellitus (T1DM) on either multiple daily injections (MDI) of in-
sulin or continuous subcutaneous insulin infusion (CSII). There is evidence 
suggesting that GV reduces QOL in people with type 2 diabetes mellitus 
(T2DM), but this has not been fully explored in T1DM.
Materials and methods: Subjects wore a retrospective continuous glucose 
monitor (CGM) for 5-6 days and completed the diabetes quality of life ques-
tionnaire (DQOL). GV measures (SD, CONGA, LI, JINDEX, LBGI, HBGI, 
GRADE, MODD, MAGE, ADRR, MVALUE, MAG) were calculated using 
the EasyGV version 9.0 software. A linear regression analysis was then per-
formed to assess whether there was a correlation between GV and measures 
of QOL.
Results: 57 adult subjects with T1DM (51% male, 65% on CSII, 35% on MDI 
, mean (SD) age 41 (13) years, duration of diabetes 21 (12) years, HbA1c 7.9 
(1.1) %, body mass index 25.2 (4.0) kg/m2,) were included in the analysis. 
No significant associations between GV measures and DQOL scores (Table 
1) were demonstrated. The GV was significantly higher for those subjects on 
MDI compared to the CSII group (p-value <0.05 for all GV measures), but 
no significant difference in QOL between the two treatment modality groups 
was observed.
Conclusion: Treatment with CSII is associated with lower GV compared to 
MDI. Interestingly, the outcomes from our study suggest that increased gly-
caemic variability does not impact overall quality of life in adults with T1DM, 
irrespective of whether they are on MDI or CSII.
Supported by: Wellcome Trust
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The relationship between negative emotions and quality of life in high 
risk patients with type 2 diabetes in Hong Kong
Y. Junmei1, R. Yeung1,2, A. Luk1,3, R. Wong3, A. Kong1,3, R. Ozaki1,3,  
R.C.W. Ma1,3, W. So1,3, J.C.N. Chan1,2;  
1Department of Medicine and Therapeutics, Chinese University of Hong 
Kong, 2Asia Diabetes Foundation, Prince of Wales Hospital,  
3Diabetes and Endocrine Centre,, Prince of Wales Hospital, Hong Kong.
Background and aims: To measure the rate of negative emotions among 
Chinese type 2 diabetic patients with high cardio-metabolic risk, and the re-
lationship between negative emotions and quality of life in Chinese patients 
with type 2 diabetes in Hong Kong.
Materials and methods: A consecutive cohort of patients with type 2 dia-
betes, aged 18-75 years, referred to our hospital for comprehensive diabetes 
complication screening with high cardio-metabolic risk from 4 March to 
30 December 2013 were recruited. High cardio-metabolic risk was defined 
as poor glycemic control (HbA1c ≥8%), obesity (body mass index [BMI] ≥ 
27.5 kg/m2), central obesity (waist circumference ≥90cm in men or ≥80cm in 
women), and/or chronic kidney disease (GFR<60ml/min/1.73m2). Clinical 
characteristics, self-care behaviors, and psychological measures were docu-
mented. Specifically, three types of negative emotions (depression, anxiety, 
and stress) were measured by the 21- item Depression, Anxiety, and Stress 
Scale (DASS-21). Quality of life was assessed by the 5-item Euroqol for health 
related quality of life (EQ-5D) and the Brief version of World Health Organi-
zation Quality Of Life (WHOQOL-BREF).
Results: Among 370 eligible patients, 303(82%) completed the assessments 
and 10 patients were excluded because they failed to complete >20% of the 
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WHOQOL-BREF. Among the remaining 293 patients (age [mean±SD]: 
59.1±9.6 years, 52.2% male), 67% of patients had at least one negative emo-
tion, and 22% had significant levels of all three negative emotions. 50% of 
patients had moderate/ severe depressive symptoms, 43% had moderate/
severe anxiety symptoms, and 22% had moderate/severe levels of stress. 
Compared with patients with no/mild depression, patients who had moder-
ate/ severe depression were younger (57.7±9.4 vs 60.3±9.7 years, p=0.024), 
had shorter diabetes duration (10.8±7.6 vs 12.8±8.2 years, p=0.030), used 
less insulin (38.8% vs 50.3, p=0.049) and exercised less frequently (43.3% vs 
56%, p=0.030). They also had worse health related quality of life (EQ-5D: 
median[IQR] 0.85[0.75,1] vs 1[0.8,1] , p=0.004), worse quality of life in all 
4 domains of the WHOQOL-BREF: physical health (13.0±2.2 vs 15.3±2.1, 
p<0.001), psychological health (12.7±2.5 vs 14.6±2.5, p<0.001), social re-
lationships (13.2±2.7 vs 14.7±2.5, p<0.001), and environment (12.9±2.8 vs 
14.2±2.5, p<0.001). Similar results were found after stratifying patients by 
having anxiety or stress.
Conclusion: Patients with high cardio-metabolic risk were more likely to 
have significant levels of depressive and anxiety symptoms, and associated 
with worse health and non-health related quality of life.
Supported by: Merck Sharpe & Dohme
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Evaluation of cognitive functions and daily living activities of elderly 
diabetic patients under intensive insulin therapy
Ü. Karabulut1, O. Basat1, S. Uçak2;  
1Sisli Etfal Training and Research Hospital, Department of Family Medicine, 
2Umraniye Training and Research Hospital, Department of Internal 
Medicine, Istanbul, Turkey.
Background and aims: Elderly population is a sensitive group. Insulin thera-
py needs strict compliance because of severe complications due to treatment. 
Cognitive functions and functionality may have an effect on the outcomes in 
this group. Our aim was to evaluate the cognitive functions and daily living 
activities of elderly diabetic patients who are under the basal-bolus intensive 
insulin therapy regimen.Our aim was to evaluate the cognitive functions and 
daily living activities of elderly diabetic patients who are under the basal-
bolus intensive insulin therapy regimen.
Materials and methods: Our single centre, cross sectional study included 108 
patients admitted to our Family Medicine outpatient clinic between February-
June 2013, who are over 65 years of age and under intensive insulin therapy. 
Patients with established cognitive disorders, severe micro and macrovascular 
complications associated with diabetes mellitus were excluded from the study. 
Turkish validated versions of Mini Mental State Examination (MMSE) for 
cognitive functions, activities of daily living (ADL) and instrumental activities 
of daily living (IADL) scales were used to evaluate cognitive functions and 
daily living activities. MMSE score of ≤ 22 was considered as impaired cogni-
tive functions. IADL scores vary between 0 and 17, higher score means pa-
tients are less dependent on somebody. ADL scores vary between 0-27, higher 
score means patients are more dependent on somebody. Fasting glucose and 
HbA1c levels were measured and history of mild and severe hypoglycemia 
were recorded. For group comparisons chi square and Student’s T-tests were 
performed, p<0.05 was regarded as statistically significant.
Results: MMSE revealed 24 patients (22.2%) with impairment of cogni-
tive functions. Fasting plasma glucose levels were 184.96±76.92 and main 
HbA1c levels were 9.06±2.02% in patients with impaired cognitive functions 
and fasting plasma glucose levels were 177.98±58.0 and main HbA1c lev-
els were 8.64±1.33% in patients with normal cognitive functions (p>0.05). 
Number of severe hypoglycemic episodes was significantly higher in patients 
with impaired cognitive functions. 26.9% of patients with impaired cognitive 
functions reported at least one episode of severe hypoglycemia in the last 3 
months whereas only 6.1% of patients with normal cognitive functions re-
ported severe hypoglycemia. IADL and ADL scores of patients with impaired 
cognitive functions and normal cognitive functions were statistically signifi-
cant. (IADL scores 11.04±4.89 vs 15.30±2.53 and ADL scores 8.96±3.26 vs 
2.85±0.8, p: 0.000). Impaired cognitive functions were in relation with more 
hypoglycemic episodes and lower functionality.
Conclusion: Due to complexity of intensive insulin therapy regimen, cogni-
tive functions and functionality of elderly diabetics should be carefully exam-
ined before deciding on intensive insulin therapy. In addition to that elderly 
diabetics under intensive insulin therapy should be evaluated closely by the 
physician.
1047
Stress: an important comorbidity of the metabolic syndrome
M.M. Singh1, K. Usman1, A.K. Vaish1, A. Nischal2, W. Ali3;  
1Internal Medicine, King George‘s Medical University,  
2Psychiatry, King George‘s Medical University,  
3Pathology, King George‘s Medical University, Lucknow, India.
Background and aims: In has become increasingly evident that psychologi-
cal status affects all medical conditions, hence researchers have focused on 
these psychological status’ roles especially on non communicable disease 
with almost unknown origin. The relationship of psychological distress with 
chronic metabolic disease such as diabetes mellitus, insulin resistance and 
dyslipidemia has been established. There are some evidences that have shown 
relations of lower physical well being and social function as indicators of 
Quality of life to Metabolic Syndrome. With this background, the present 
study was undertaken to investigate association of depression, anxiety, psy-
chological distress and quality of life with metabolic syndrome in a sample 
of Indian population as a population with high prevalence of Metabolic 
Syndrome. Present study was undertaken with the aims of assessing levels 
of stress (Anxiety / Depressive symptoms)and Quality of Life in patients of 
Metabolic Syndrome and comparing it with healthy controls.
Materials and methods: A hospital based cross sectional case-control study 
was conducted in 200 patients attending medicine clinics and wards. They 
were analyzed separately as cases and controls based on the International 
Diabetes Federation Criteria for Metabolic Syndrome. Subjects who were a 
known case of any Psychiatric illness, having history of any major Psycho-
social stressor in the past three months, suffering from any major medical or 
surgical illness or those patients who were on medications affecting emotion 
and mood were excluded from the study. Levels of stress were assessed using: 
General Health Questionnaire - 12 items, Hospital Anxiety and Depression 
Scale, Hamilton Rating Scale for Depression and Hamilton Rating Scale for 
Anxiety. Quality of life was assessed using World Health Organization Qual-
ity of life - BREF Version. Levels of stress and Quality of life in cases were sub-
sequently compared with age, sex and social status matched healthy controls.
Results: A significant proportion of cases of metabolic syndrome reported 
psychological distress as evaluated by General Health Questionnaire. A sig-
nificant proportion of cases of metabolic syndrome suffer from anxiety and 
depressive disorder as evaluated by Hospital Anxiety Depression Scale. Se-
verity of anxiety as evaluated by Hamilton Anxiety Rating Scale is not as-
sociated with metabolic syndrome. Severity of depression as evaluated by 
Hamilton Depression Rating Scale is associated with metabolic syndrome. 
Cases of metabolic syndrome reported lower Quality of life scores thereby 
signifying poor quality of life in all the four domains as compared to con-
trols, viz., Domain 1 (Physical health), Domain 2 (Psychological), Domain 
3 (Social relationships) and Domain 4 (Environment) but the difference was 
statistically insignificant for the Domain 1.
Conclusion: This study proves the higher prevalence of depression as com-
pared to anxiety and impaired quality of life in cases of metabolic syndrome. 
Although it suggest that psychological stress may have a causal role in etiol-
ogy of metabolic syndrome yet there is a hen and egg dilemma that which 
comes first psychological stress or metabolic syndrome pointing out need for 
further studies to examine the effect of stress reduction techniques in reduc-
ing insulin resistance and improving the metabolic syndrome as a whole.
1048
Diabetes and work: a national register based cohort study on the 
potential influence of socioeconomic group, age, gender and ethnicity
K. Poulsen, B. Cleal, I. Willaing;  
Steno Center for Health Promotion, Steno Diabetes Center, Gentofte, 
Denmark.
Background and aims: In countries with ageing populations it is antici-
pated that people will have to remain active in the labour market for longer 
and thus retire later in life. It is important, therefore, to address potential 
problems that might accrue from this significant social change. A number 
of studies have previously shown the impact of diabetes mellitus on, sickness 
absence, presenteeism and disability retirement among the workforce, yet the 
extent to which diabetes mellitus impacts on the working age population and 
the nature of its distribution within this group has not been comprehensively 
delineated. The aim of this study was to examine the impact and demographic 
distribution of incident diabetes mellitus on the working age population.
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Materials and methods: The Danish National Diabetes Register was linked 
with socioeconomic and population registers covering the entire population. 
Twelve year diabetes incidence was analysed using multivariate Cox regres-
sion for 2,161,700 people aged 30-59 years at baseline.
Results: 93.2 % were of Danish origin, 3.6 % of non-Danish Western origin 
and 3.3 % of Non-western origin. 12 year incidence of diabetes was, respec-
tively, 5.8%, 7.9 % and 11.4 %. Occupational activity was stratified by five 
main socioeconomic categories which are derived from the International 
Standard for the Classification of Occupations: professionals, managers, tech-
nicians, workers skilled at basic level and unskilled workers. Professionals 
were used as reference. The results of the survival analysis are shown in the 
table with 99 % confidence intervals.
Conclusion: Diabetes incidence increases with age, male gender, occupations 
with low socioeconomic status and among people of Non-western origin. The 
results indicate that undifferentiated upward adjustment of the retirement 
age has the potential to cause a marked increase in employees with diabetes, 
especially among already vulnerable groups. The social and economic impli-
cations are unknown and need to be subject of future research.
1049
Relative rates of disability retirement among employees in Denmark with 
and without diabetes: a prospective analysis with 10 year follow-up
B. Cleal1, K. Poulsen1, H. Hannerz2, L. Andersen2;  
1Steno Health Promotion Center, Steno Diabetes Center, 2National Research 
Center for the Working Environment, Copenhagen, Denmark.
Background and aims: Work and the workplace have been allocated a piv-
otal role in the future of health promotion, with economic and social stability 
predicated, in many accounts, on the assumption that more people will be fit, 
able and willing to work for longer. In this light, it is important to determine 
what socio-demographic trends might challenge this vision of future pros-
perity. Our ambition in this study was to estimate the proportion of disability 
retirements, among employees with diabetes, which could be attributed to 
socioeconomic status. This perspective was considered important since both 
incident diabetes and work-disability are marked by a social gradient. Ob-
taining more detailed and nuanced information on the relationship between 
diabetes and disability retirement is, therefore, undertaken in order to inform 
efforts to reduce disability retirement among people with diabetes.
Materials and methods: Using four national population registries, includ-
ing the Danish National Diabetes Registry, we identified all employees in 
Denmark aged 20-59 years old at baseline (January 2001 ). These individuals 
were stratified according to their presence/absence in the diabetes registry 
and their socioeconomic status, and subsequently followed in our national 
registries until 31 December 2010.
Results: 29,210 people with diabetes and 1,950,962 people without diabetes 
were included in the analysis. The follow-up yielded 3,163 cases of disabil-
ity retirement among people with diabetes and 64,262 cases among people 
without diabetes. With Professionals without diabetes as reference, the results 
indicate heightened levels of risk according to both presence of diabetes and 
socioeconomic status. The compound risk of being a person with diabetes 
and working in an occupation identified as having low socioeconomic status 
is clearly revealed in the 11.62 rate ratio for people with diabetes in elemen-
tary occupations.
Conclusion: The results show liability for early retirement among people 
with diabetes is especially acute for employees in lower socio-economic 
groups.The relative risks revealed in our study are especially concerning for 
the fact that there is evidence to suggest levels of social inequality in prevalent 
T2DM are on the increase. If current trends continue, therefore, there will, 
both proportionally and numerically, be more individuals with diabetes with 
a relatively high risk of disability retirement. Targeting primary, secondary 
and tertiary prevention to the groups that need it most thus seems an essen-
tial strategy in attempts to prolong the working lives of individuals.
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Early evaluation of the ANAIS (Alimentación Normal Con Ajuste De 
Insulina) programme, a Spanish version of DAFNE
R. Sánchez Hernández1,2, Y. López Plasencia1,2, D. Alvarado Martel1,2,  
J. Rodríguez Cordero1, A. Jiménez Ortega1, A. Carrillo Domínguez1,  
F. Nóvoa Mogollón1,2, A. Wägner1,2;  
1Endocrinology and Nutrition, Hospital Insular de Gran Canaria,  
2Instituto Universitario de Investigaciones Biomédicas y Sanitarias. 
Universidad de Las Palmas de Gran Canaria, Spain.
Background and aims: The DAFNE (Dose adjustment for normal eating) 
programme promotes a flexible diet and has led to a reduction in clinical ad-
missions and improved quality of life (QoL) in type 1 diabetes (T1D). ANAIS 
is a translation and adaptation of DAFNE to Spanish cultural and dietary 
patterns. Our aim was to evaluate the programme, using both clinical and 
patient-centred variables.
Materials and methods: This randomized, controlled, parallel group trial in-
cluded patients with >2 years of T1D, age >18 years and HbA1c 7-12%. Par-
ticipants were randomized (2:1 ratio) to participate immediately in a 5-day 
outpatient course (immediate ANAIS) or to do so after one year (delayed 
ANAIS). The primary endpoint was glycaemic control (HbA1c), measured 3, 
6 and 12 months after the programme. We also evaluated the number of hy-
poglycemic episodes, weight, insulin dose, diabetes-related QoL (EsDQOL), 
treatment satisfaction (DTSQ), fear of hypoglycemia (MH-15), anxiety 
(STAI), depression (BDI), diet flexibility (open question) and achievement 
of self-defined goals (scale from -2 (much less than expected) to +2 (much 
more than expected)). Comparisons were made (Student‘s t, Wilcoxon‘s test 
and chi-square).
Results: So far, 80 patients (48 immediate ANAIS) have been included, 45% 
men, aged 34.6 (SD 11.35) years, diabetes duration 12.5 [range 3-47] years, 
with a BMI: 24.9 (3.9) kg/m2 and a daily insulin dose of 0.75 (0.24) UI/Kg. 
In the intervention group, there was a 0.2-0.3% non-significant reduction in 
HbA1c at 3,6 and 12, less hypoglycaemia at 6 months (2 [0-16] vs 1 [0-8]/
week, p=0.045), and a trend towards a reduction in long acting insulin dose 
at 12 months (31.08 UI (12.5) vs 28.92 UI (12.6), p=0.08). No changes in 
weight were seen. Quality of life improved at 3 (96.7+/-19.9 vs 82.4+/-22.4 
points, p<0.0005), 6 (87.1+/-22.7; p<0.0005) and 12 months (87.1+/-19.2; 
p=0.002). Treatment satisfaction increased at 3 (25.9+/-5.7 vs 28.2 (3.2) 
points, p=0.019), 6 (30.8 (4.6), p<0.0005) and 12 months 30.4 (7.7) p=0.024). 
Reduction in the fear of hypoglycaemia at 3 months (27.8 (9.3) vs 24.7 (8.5) 
p=0.045). Reduction in anxiety-trait at 1 year. No changes in depression. On 
average, the patients achieved their primary goal somewhat more than ex-
pected (1point [(-1)-+2]). Before ANAIS, 25.5% considered their diet to be 
restricted. At 3 months, no patient had that opinion. In the control group, 
there were no significant changes in HbA1c or hypoglycaemia, but a weight 
increase was observed (baseline BMI: 24.85 kg/m2 (4.57), 25.27 (4.69) at 3 
and 25.07 (4.05) at 6 months, p<=0.005) and total insulin dose increased 
at 12 months (0.80 UI/kg (0.27) vs 0.87 (0.3), p=0.039). QoL and fear for 
hypoglycaemia improved, but there was no change in treatment satisfaction 
or depression. Initially 38.7% considered their diet to be restricted and at 6 
months, 31.3% still thought so.
Conclusion: So far, after the inclusion of a half of the patients, ANAIS has led 
to positive results in hypoglycemic events, weight and insulin dose, as well as 
in several measures of patient satisfaction, anxiety and depression and self-
defined goal achievement.
Supported by: Spanish Diabetes Society (SED)
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A new metric for objective evaluation of daily glucose profiles to obtain 
personalised recommendations for an individually sufficient diabetes 
care 
E. Salzsieder1, P. Heinke1, L. Vogt2, P. Augstein1;  
1Institute of Diabetes, Karlsburg,  
2Diabetes Service Center Karlsburg, Germany.
Background and aims: Structured glucose monitoring (CGM or SMBG) is 
an indispensible precondition for sufficient diabetes care and management. 
However, an objective and practicable tool for objective evaluation of meas-
ured glucose profiles to draw helpful, therapeutically relevant conclusions 
from the measured glucose profiles is missing. It was the aim of our study 
to develop and to verify an objective evaluation tool for measured glucose 
profiles that might be able to bridge this existing gap in diabetes care and 
management.
Materials and methods: 1495 registered glucose profiles provided the data-
base for this study. First, a factor analysis was performed to identify factors 
with major impact on the measured profiles. For each factor one parameter 
was selected and used for the development of a metric which can be used for 
automated, i.e. objective evaluation of the measured glucose profiles on the 
one hand and which provides recommendations for an improved diabetes 
management on the other.
Results: This study resulted in a Q-Score, which can be used for objective 
evaluation of glucose profiles, for automated identifying of potentials of im-
provement, and for providing recommendations for applying these potentials 
in practical diabetes care by predicting the expected outcome. To verify the 
Q-Score two diabetes specialists (DS) diagnosed independently 729 glucose 
profiles. The results were analysed for the inter-individual variation. There 
was a high correlation between the Q-Score and the results of both DS. The 
Q-Score was then tested for categorisation of glucose profiles. 729 profiles 
were categorised by one DS in very good, good, satisfactory, borderline, and 
not satisfactory and compared with the result obtained from the evaluation 
by applying the Q-Score. The Q-Score was significantly correlated with the 
results obtained from the evaluation of the DS.
Conclusion: The Q-Score combines all essential quality parameters to de-
scribe glucose profiles in only one parameter. The Q-Score is independent 
of subjective opinions and can be used therefore for automated evaluation 
of glucose profiles and to draw conclusions to generate patient related help-
ful recommendations for improving personalized diabetes care and manage-
ment. The Q-Score has the high potential to become a practical tool in diabe-
tes diagnosis and therapy.
1052
An innovative use of the ambulatory glucose profile to reveal the 
glycaemic effect of food
L.K. Lyons, K.D. Kulkarni;  
Scientific Affairs, Abbott Diabetes Care, Alameda, USA.
Background and aims: The Ambulatory Glucose Profile (AGP) has been 
proposed as a standard reporting system for continuous glucose monitoring 
(CGM). The AGP reveals the progression from pre- to post-prandial peri-
ods, which may aid in refining nutrition & insulin therapy. Our aim was to 
explore the use of AGP to determine pre- and post-prandial identifiers and 
corresponding interventions.
Materials and methods: AGP reports were evaluated from an intervention 
group of 53 subjects in a prospective, 9-site, 100-day study in the UK. Subjects 
were 18-82 years old, with type 1 or 2 diabetes, had HbA1c of 7.5 - 12.0%, and 
were managed by multiple daily injections of insulin. CGM (alarms turned 
off) was used by the intervention group. AGP reports similar to Figure 1 were 
evaluated using >14 days of CGM data.
Results: Five key metrics were identified to aid in prandial assessment and 
decision making (Figure 1). 1) Target Range identifies whether the pre-pran-
dial and post-prandial median glucose levels are within target. If pre-prandial 
glucose is outside of target, consider assessing basal insulin and pre-prandial 
events or snacks; whereas, if the post-prandial glucose is outside target, con-
sider assessing carbohydrate (carb) portions, insulin to carb ratio, and insulin 
timing. 2) Post-Prandial Peak is the highest point on the median curve typi-
cally occurring 1-3 hours after the start of the meal. Peak times may differ 
depending on meal composition. Peak time can aid in planning the timing 
of prandial insulin. Ideally the insulin action peak should match the post-
prandial peak. 3) Prandial Glucose Change (pre-prandial - peak = change), 
reflects the balance of prandial insulin dose and carb. For excessive change, 
carbs may need to be decreased or the prandial insulin increased. 4) Duration 
of the Post-Prandial Curve is the amount of time after a meal to reach pre-
prandial glucose levels. Longer durations can indicate high fat or high protein 
meals, gastroparesis, or inadequate prandial insulin coverage. The amount 
and timing of prandial insulin can be adjusted to lessen the duration of post-
prandial rise. If post-prandial glucose does not return to baseline within the 
typical 3-5 hours and the next pre-prandial glucose starts at a higher level,an 
adjustment of basal and bolus insulin doses may be required. 5) Mealtime 
Glucose Variability is represented as the difference between the 25th-75th 
percentile curves or the interquartile range (IQR) after a meal. If carb type 
or amount varies on different days, the AGP may show greater variability or 
a wider IQR. Because AGP combines glucose profiles from multiple days, 
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evaluate the sources of variability such as food-insulin balance and the tim-
ing of meals across days. Decreasing variability or IQR may reduce the risk of 
hypo or hyperglycemia.
Conclusion: Analysis of AGP prandial periods can reveal the glycemic effect 
of food and insulin. AGPs can refine nutrition and insulin therapy relative 
to type and amount of carb, amount of dietary fat and protein, timing and 
amount of prandial insulin, and meal times.
Clinical Trial Registration Number: NCT01713348
Supported by: Abbott Diabetes Care
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Perioperative diabetes regulation and Protocol Compliance: the PC study
J. Hermanides1, J.A.W. Polderman1, F.A. de Groot1, F. Holleman2, B. Preckel1; 
1Anesthesiology,  
2Internal Medicine, Academic Medical Centre, Amsterdam, Netherlands.
Background and aims: Peri-operative diabetes regulation differs between 
hospitals. Compliance with regard to peri-operative glucose regulation pro-
tocols is notoriously low and evidence with regard to efficacy is lacking. 
There are, however, convincing studies demonstrating that improving post-
operative diabetes control decreases complications. We therefore investigated 
whether implementing a modified and stricter peri-operative diabetes proto-
col improved compliance and peri-operative glucose regulation.
Materials and methods: We performed a prospective observational cohort 
study from March 2013 through July 2013, comparing compliance and glu-
cose regulation following protocol A (conventional protocol) with protocol 
B (strict protocol). Protocol A prescribed a Glucose-Insulin-Potassium infu-
sion, with 8 IU of insulin. Protocol B prescribed a Glucose-Insulin infusion, 
with 1/8 IU of the normal daily insulin dose. A pre-defined treatment algo-
rithm to treat hyperglycaemia, glucose > 10 mmol/l, was added. In May 2013, 
we switched from protocol A to protocol B. Analyses were performed with 
the Mann Whitney U test and multivariate regression analyses.
Results: In total, 192 patients were included in protocol A and 183 in proto-
col B, mean age was 64 years and 54% was female, 10,4% of patients (n=20) 
had diabetes type 1, 86,5% (n=166) type 2, 3.1% (n=6) other. There were no 
differences between the patient characteristics in protocol A and B. The me-
dian compliance (IQR) was 67% (57-83) for Protocol A and 71% (57-83) for 
Protocol B, p=0.04. Differences between peri-operative glucose values are 
shown in graph 1. Adjusted for age, gender, ASA status, DM type, emergency 
procedures, fasting glucose and compliance, protocol B (red line) improved 
the proportion of patients that reached the target of < 10 mmol/l (OR 0.36, 
95% CI 0.19-0.70, p< 0.01) before discharge to the ward.
Conclusion: Implementing a stricter peri-operative diabetes protocol only 
slightly improved compliance, but significantly and relevantly improved post-
operative glucose control before discharge from the recovery.
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The burden of “serial non-adherence” in type 2 diabetic patients
C. Frois1, K. Dea1, D. Ling1, J. Dunn2, M. Baron3;  
1Analysis Group, Inc., Boston, 2VRx Pharmacy Services, Salt Lake City, 
3Intarcia Therapeutics, Inc., Boston, USA.
Background and aims: Although medication adherence is recognized as a 
key concern for the treatment of Type 2 diabetes patients, there has been 
limited assessment of the scope of “serial non-adherence,” i.e. non-adherence 
to current diabetes regimen following non-adherence to prior therapies 
(diabetes or non-diabetes related), its predictability, and impact on patient/
healthcare burden. The aim of this research was to characterize the health-
care burden associated with non-adherence with second-line anti-diabetic 
medication and to identify its key predictors, including the role of serial non-
adherence.
Materials and methods: A retrospective cohort study was conducted using 
the Truven Health MarketScan® US Commercial health insurance database 
for the period 2008-2012. Patients were identified as first-line metformin 
users by requiring no prior anti-diabetic drug history going back at least 
12-months before the date of the first metformin prescription. Patients in 
this group who subsequently initiated second-line (post-metformin) thera-
py were identified and selected for study. Diabetic regimen adherence was 
measured using the proportion of days covered (PDC), calculated as the total 
number of non-overlapping days of supply of any antidiabetic medication 
one year following the initiation of second-line therapy divided by 365 days. 
Adherence for selected non-diabetic medications, including lipid-lowering 
drugs and anti-hypertensives, was measured in a similar way during the base-
line period. Non-adherence was defined as PDC<80%. Logistic regression 
models were constructed to identify predictors of adherence to second-line 
anti-diabetic therapy.
Results: Among the 46,789 patients who initiated second-line anti-diabetic 
therapy with at least 12 months of follow-up, 58% were non-adherent to 
anti-diabetic therapy during the first year after initiating second-line ther-
apy. Among these patients, non-adherence to first-line metformin was very 
common (80% of patients) as was non-adherence to earlier non-diabetic 
medication (53% of those with non-diabetic prescriptions), with serial non-
adherence accounting for over a quarter of overall non-adherence. Regres-
sion analysis showed that serial non-adherence was associated with a 4.67 
times greater risk of non-adherence to second-line therapy (p<0.0001). Non-
adherent patients were significantly (20% and 53%) more likely than adher-
ent patients to experience any and severe hypoglycemia events, respectively 
(p<0.001 for both). After accounting for other confounding factors, non-
adherent patients had average annual medical costs $2,432 higher than ad-
herent patients, which included $1,678 higher annual inpatient costs during 
the first year following initiation of second-line therapy (p<0.0001 for both).
Conclusion: This study showed that more than half (58%) of patients initiat-
ing second-line anti-diabetic therapy are not adherent to therapy, with se-
rial non-adherence (i.e., non-adherence to earlier diabetic and non-diabetic 
therapy) associated with much greater risk of non-adherence (OR=4.67). 
Second-line non-adherence is associated with higher risk of hypoglycemia 
and with higher healthcare costs. Since prior non-adherence is observable 
and appears highly predictive of later non-adherence, intervention strategies 
that target serial non-adherence may be particularly effective in improving 
the care of these diabetes patients.
Supported by: Intarcia grant
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Do type 2 diabetes patients achieve therapeutic goals with medication 
adherence?
A.B. Garcia, E. Lopez Gonzalez, S. Milrad, A. Luongo, S. Houssay,  
M.L. Ruiz, FRADYC II Group;  
Hypertension Committee, Argentinean Diabetes Society, Buenos Aires, 
Argentina.
Background and aims: In developed countries, adherence to drug treatment 
in chronic diseases hovers around 50 %. Improving adherence is key to effec-
tively address the treatment of people with diabetes. Objectives: To determine 
the percentage of medication adherence and its relationship to the achieve-
ment of A1c, blood pressure and lipids goals in people with T2DM. To assess 
which factors are associated with lower medication adherence.
Materials and methods: A study was conducted in 31 medical centers spe-
cialized in diabetes in Argentina (12/ 2010- 05/2011), with a clinical and 
laboratory evaluation. The Morisky-Green test was used to assess adherence 
and WHO -5 for well-being and depression. Were taken as therapeutic targets 
A1c <7 % , blood pressure < 140/90 mmHg and LDLcolesterol < 100mg/dl. 
(ADA ). Statistics : Chi2, multiple logistic regression.
Results: 1,491 people were included; mean age 64.1 ± 11.3 years, duration of 
DM2 : 9.8 ± 7.8 years, 46.7 % female, BMI 31.4 ± 6. kg/m2 and A1C 7.2%± 
1.4. The mean WHO -5 test was 63.4 ± 22.1% with 39.2 % having values sug-
gestive of depression. Adherence criteria was observed in 55% of the People. 
Factors that correlated with lower adherence to drug treatment by multiple 
logistic regression were: age under 65 years ( OR: 1.36 , CI 1.08 to 1.72, p < 
0.009 ), symptoms of depression WHO - 5 (OR : 1.59 , CI :1,01 -2, 59, p <0.04 
), lower WHO -5 well-being (OR 1.02, CI :1,02 -104, p <0.04 ), sedentary life-
style (OR : 1.38 , CI 1.07 to 1.73, p < 0.01), fewer diabetologist visits in a year 
( OR: 1.37, CI 1.07 to 1.72 , p < 0.01) and not having health insurance (p < 
0.008 ) . In those who met adherence criteria 39.4% ( p < 0.001 ) achieved A1c 
< 7%, 69.4 % BP targets ( p < 0.048 ) and LDL- c 47.9 % ( p < 0.001 ); having 
25.6% achieved the three goals, 39.8 % two and 9.52% none.
Conclusion: In this sample of individuals with type 2 diabetes we found 
the frequency of medication adherence being 55 % and that 25.6 % of them 
achieved the three standard goals significantly. Predictors of lower adherence 
were age, symptoms of depression, lower welfare, sedentary lifestyle, diabe-
tologist number of visits / year and not having health insurance.
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Regular exercise improves metabolic control and reduces chronic 
complications in patients with type 2 diabetes
J. Tang1, X. Li2, Y. Yang1, L. Yuan3, J. Han1, C. Ju1, L. Shen4, Q. Lou5, F. Zhao6, 
Z. Sun1, X. Guo4;  
1Zhongda Hospital, Institute of Diabetes,Southeast University, Nanjing, 
2Institute of Public Health,Southeast University, Nanjing,  
3West China Hospital, Institute of Diabetes,Sichuan University, Chengdu, 
4Peking University First Hospital, Institute of Diabetes, Peking University, 
5Sir Run Run Shaw Hospital, Institute of Diabetes, Zhejiang,  
6China-Japan Friendship Hospital, Institute of Diabetes, Beijing, China.
Background and aims: To investigate the current situation of exercise in 
patients with type 2 diabetes and the effect of different levels of exercise on 
metabolic control and chronic complications.
Materials and methods: A total of 5961 patients with type 2 diabetes from 
50 centers in China were included in this nationwide, multicenter, cross-sec-
tional survey. Patients were divided into three groups according their compli-
ance to exercise: full, partial and poor compliance. Data were analyzed using 
analysis of variance and Chi-square methods.
Results: According to the questionnaire feedback, the patients (percent-
ages) of full, partial and poor compliance groups were 2096(35.17%), 
2398(40.23%) and 1466 (24.60%), respectively. There were significant dif-
ferences in glucose and lipid level among three groups. Fasting blood 
glucose (7.70±2.83 vs 8.17±2.91 vs 8.55±3.47, P<0.05), 2h postprandial 
blood glucose (10.80±4.23 vs 11.71±4.38 vs 12.16±4.75, P<0.05), HbA1c 
(7.96±2.12 vs 8.31±2.23 vs 8.70±2.32, P<0.05 ), total cholesterol (4.75±1.33 
vs 4.90±1.51 vs 4.82±1.36, P<0.05), triglycerides (1.90±1.60 vs 2.09±1.72 
vs 2.25±2.00,P<0.05), body mass index (24.12±3.73 vs 24.61±4.04 vs 
24.80±4.68, P<0.05), systolic blood pressure (129.26±16.32 vs 129.97±16.71 
vs 131.86±17.80, P<0.05), diastolic blood pressure (78.03±9.89 vs 79.24±10.38 
vs 79.83±10.81, P<0.05) of patients in the full compliance group were signifi-
cantly lower than those of partial and poor compliance group. The targeted 
rate of HbA1c (43.83% vs 27.98%, χ2=59.444, P<0.05) in the full compli-
ance group was higher than the poor compliance group. The morbidity of 
diabetic peripheral vascular disease (12.51% vs 15.96%,χ2=8.580,P<0.05), 
diabetic nephropathy (12.56% vs 18.69%,χ2=25.547,P<0.05), diabetic pe-
ripheral neuropathy (24,50% vs 29.33%,χ2=10.715,P<0.05), diabetic retin-
opathy (28.84% vs 33.63%,χ2=9.629,P<0.05) and diabetic foot (4.11% vs 
9.14%,χ2=47.724,P<0.05) of patients in the full compliance group were less 
than poor compliance group. For patients using insulin therapy, the incidence 
of hypoglycemia (45.25% vs 39.11%,χ2=9.549,P<0.05) in the full compliance 
group was higher than the poor compliance group.
Conclusion: Regular exercise can improve glycemic, lipids, blood pressure, 
weight control and reduce morbidity of diabetic complications of patients 
with type 2 diabetes.
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Pedometer-based walking intervention and resting blood pressure in 
type 2 diabetes: a meta-analysis of randomised controlled studies
X. Cai, S. Qiu, C. Ju, Z. Sun;  
Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, 
Medical School, Nanjing, China.
Background and aims: Pedometer-based walking intervention, which is as-
sociated with improved physical activity and reduced body weight, has be-
come popular among patients with type 2 diabetes (T2D). However, its ef-
fectiveness in resting blood pressure (systolic and diastolic) control has been 
poorly recorded. The aim of this meta-analysis of randomized controlled tri-
als (RCTs) was to evaluate the association of pedometer-based walking inter-
vention with resting blood pressure in T2D patients.
Materials and methods: PubMed, Web of Science and the Cochrane Library 
were searched from January 1994 to December 2013, using the following 
key words: pedomet*, acceleromet*, step counter, blood pressure, diabetes. 
RCTs in the English language were eligible for inclusion if they had utilized 
an intervention (lasting at least 8 weeks) using pedometer as a motivational 
tool to increase walking or walking speed in T2D patients, with more than 5 
participants and reported changes in resting blood pressure. The summary 
estimates were made by a random-effects model.
Results: Of the 179 articles retrieved, 10 RCTs were included. Pedometer-
based walking intervention was associated with a decreased resting systolic 
blood pressure by -1.13 mmHg (10 RCTs, 1020 participants; 95% confidence 
interval (CI): -2.79 to 0.52 mmHg), and a decreased resting diastolic blood 
pressure by -1.49 mmHg (9 RCTs, 928 participants; 95% confidence interval 
(CI): -4.04 to 1.05 mmHg) in T2D patients. However, both results were not 
statistically significant (P = 0.18 and P = 0.25, respectively). Univariate meta-
regression analyses showed that neither intervention duration nor diary use 
was associated with a significant changes in resting systolic blood pressure 
(P = 0.687 and P = 0.890, respectively) or diastolic blood pressure (P = 0.957 
and P = 0.131, respectively). No significant publication bias was detected by 
Begg‘s test or Egger‘s test in meta-analysis of resting systolic blood pressure 
(P = 0.371 and P = 0.218, respectively), or diastolic blood pressure (P = 0.917 
and P = 0.879, respectively).
Conclusion: Current evidence regarding the effects of pedometer-based 
walking intervention in decreasing resting blood pressure remains insuffi-
cient in T2D patients. More well designed RCTs with guidelines for reporting 
data and details about the anti-hypertensive drugs use are needed.
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Does clinical inertia vary by personalised HbA1c goal? A study of 
predictors and prevalence of clinical inertia in a US managed care setting
J. Lin1, S. Zhou2, W. Wei2, C. Pan3, M. Lingohr-Smith1, P. Levin4;  
1Novosys Health, Flemington, 2Sanofi US, Inc., Bridgewater, 3Pro-Unlimited, 
Inc., Boca Raton, 4Model Clinical Research, Baltimore, USA.
Background and aims: Clinical inertia (CI) in type 2 diabetes mellitus 
(T2DM) care is defined as a failure to intensify treatment in patients with 
inadequate glycaemic control. There is a gap in understanding patterns of 
CI, particularly when considering the recent move towards personalized gly-
caemic targets rather than the standardized HbA1c goal of < 7.0%. This study 
applied 3 different definitions of CI to a T2DM cohort from a large US man-
aged care database to investigate the prevalence and predictors of CI. The 3 
definitions of CI were based on different HbA1c goals: (1) HbA1c < 7.0%; (2) 
a modified target defined by Ismail-Beigi; and (3) Healthcare Effectiveness 
Data and Information Set (HEDIS) HbA1c targets.
Materials and methods: Eligible adult T2DM patients were identified from 
the Optum Impact National Managed Care Database™ (IHCIS) between 
January 1, 2008-December 31, 2012. The index date was defined as the date 
of the first above target HbA1c (the trigger HbA1c) during the study period. 
Patients were required to have continuous health plan coverage for 6 months 
prior to index (baseline period) and for 6 months after index (response pe-
riod). CI was defined as patients not receiving treatment intensification, de-
fined as adding another oral antidiabetes drug (OAD), or initiating insulin 
or a glucagon-like peptide-1 receptor agonist within the response period. 
Predictors of CI were identified from the baseline period and evaluated by 
multiple logistic regression.
Results: The prevalence of CI was the highest for Definition 1, although the 
differences between the definitions were not substantial; 72.8%, 70.4%, and 
70.6% for Definitions 1, 2, and 3, respectively. Common predictors of CI in-
cluded higher age, higher baseline OAD usage, and a more recent index year, 
indicating a higher risk of CI over time (Table). Patients at a lower risk of CI 
included those with certain comorbidities, increased baseline non-diabetes 
medication use, an endocrinologist visit, and a higher index HbA1c value. 
Differences between the predictors were also observed between the 3 defini-
tions. Patients with baseline neuropathy, retinopathy, and a Charlson Comor-
bidity Index of 2-3 were less likely to experience CI according to Definition 
1 only. Baseline myocardial infarction was identified as a predictor of CI for 
Definition 1 only.
Conclusion: These data suggest that the prevalence of CI in a US managed 
care setting was high and increased over the study period. The prevalence and 
predictors of CI were generally similar across all 3 study populations with 
different HbA1c targets; however, there were some significant differences, 
particularly in the comorbidity-related predictors identified for Definition 1. 
This study provides some insights into clinical patterns of CI that could aid 
targeting of relevant T2DM subpopulations for improvement.
Supported by: Sanofi U.S.
1059
Association of metabolic control and chronic complications with  
self-care behavior in Chinese type 2 diabetic patients: a nationwide, 
multi-centre, cross-sectional survey
Y. Yang1, Z. Sun1, X. Guo2, L. Yuan3;  
1Department of Endocrinology, Medical School, Zhongda Hospital, Institute 
of Diabetes, Southeast University, Nanjing, 2Department of Endocrinology, 
Peking University First Hospital, Beijing, 3Department of Endocrinology, 
Medical School, West China Hospital, Sichuan University, Chengdu, China.
Background and aims: The purpose of this survey was to study the associa-
tion of metabolic control and complications, with attitudes towards diabetes 
and self-care behavior in type 2 diabetic patients in China.
Materials and methods: Adults with type 2 diabetes from 50 medical cent-
ers across China covered 29 administrative divisions were eligible. The third 
version of the Diabetes Attitude Scale (DAS-3) and summary of Diabetes 
Self-Care Activities (SDSCA) were utilized to assess attitude towards diabe-
tes and self-care behavior, respectively. Adequate metabolic control (hemo-
globin A1c <7.0%, FPG<7.2 mmol/L, 2hPPG1.3 mmol/L in women, TC <4.5 
mmol/L, TG <1.7 mmol/L) was defined as standards of medical care from the 
2013 American Diabetes Association. The information of chronic complica-
tions was collected through primary interrogation and check.
Results: A total of 5961 respondents completed the questionnaires. As shown 
in table 1, patients with optimal glycemic control have higher scores of SDSCA 
in general diet (HbA1c, P<0.001, FPG, P<0.001), exercise (HbA1c, P<0.01), 
SMBG(HbA1c, P<0.001), and medication adherence(HbA1c, P<0.05, FPG, 
P<0.01, 2hPPG, P<0.001) than those with poor glycemic control. Patients 
with adequate lipid control have higher scores of SDSCA in general diet(TG, 
P<0.01), SMBG(TG, P<0.01, LDC, P<0.001, TC,P<0.05), and medication ad-
herence (HDL,P<0.001, TC, P<0.05). People with targeted BMI (BMI≤24kg/
m2) have higher scores of SDSCA in general diet (P<0.01), special diet 
(P<0.05), and but lower in medication adherence (P<0.001). However, there 
was no significant difference on scores of attitude towards diabetes between 
patients with optimal and poor metabolic control. On the other hand, the 
score of SDSCA in general diet(P<0.01), exercise(P<0.01), SMBG(P<0.01), 
and medication adherence(P<0.001) of patients without chronic complica-
tions including macroangiopathy, microangiopathy, neuropathy were signifi-
cantly higher than those of patients with chronic complications. Meanwhile, 
showed less positive attitude on psychosocial impact of diabetes(P<0.05).
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Conclusion: These data demonstrated that metabolic control and diabetic 
complications was directly associated with self-care behavior but not attitude. 
It suggests that the diabetes educators in China should pay more efforts on 
diabetes skill training towards self-care behavior for patients.
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Identifying consistent inconsistency in network meta-analyses: an 
illustration in type 2 diabetes
D.A. Scott, N. Hawkins;  
Health Economics & Epidemiology, ICON Clinical Research UK Ltd, 
Oxford, UK.
Background and aims: Network meta-analyses (NMA) combine direct and 
indirect evidence across a connected network of trial comparisons to provide 
estimates of comparative efficacy for multiple treatments. They have been em-
braced by reimbursement agencies and recommended by health technology 
assessment bodies. A key concern is the comparability of treatment effect es-
timates from different trials. Where there is both indirect and direct evidence 
for one or more comparisons (‘loops’ in the network) it is possible to evaluate 
empirically the ‘consistency’ of the network. Inconsistencies between direct 
and indirect estimates may be alleviated by adjusting for trial differences us-
ing regression analysis or by excluding studies. However, as the networks of 
trial evidence become more complex, and potentially include multiple ‘loops’ 
it becomes more difficult to interpret evidence regarding ‘inconsistency’.
Materials and methods: A variety of alternative methods have been pro-
posed to examine inconsistency including (i) node-splitting whereby the 
difference between the direct and indirect evidence is calculated (where pos-
sible) for each comparison in the network, (ii) comparisons of the NMA to 
an ‘inconsistency’ model where the effect estimates for each treatment com-
parison in the network is allowed to be independent, (iii) a method which 
looks at inconsistencies between alternative study designs, (iv) plotting re-
sidual deviance for individual trial arms within the NMA, and (v) plotting 
mixed predictive p-values against a uniform distribution. We compare the 
implementation and interpretation of these methods using a previously pub-
lished NMA in type 2 diabetes. In this analysis HbA1c was compared across 
six treatments (two GLP-1s at different administrations, placebo, and insulin 
glargine) in a network of 22 studies with multiple ‘loops’. As in the original 
study, a random effect model controlling for baseline HbA1c was performed.
Results: The methods agreed in showing the presence of inconsistency with 
the network. For example, the inconsistency model showed an improved fit 
(DIC -62.35) compared to the consistency model (DIC -60.25). The node 
splitting method identified two treatment arcs as being inconsistent, liraglu-
tide 1.8mg vs placebo and liraglutide 1.8mg vs exenatide QW. However, the 
methods varied in their ability to provide an overall ‘test’ of inconsistency 
across the network and their ability to identify which parts of the network 
contain inconsistencies. We highlight that none of the methods alone can 
identify individual studies as being the cause of inconsistencies and argue 
that we need to consider the whole structure of the network and the charac-
teristics of the studies (in terms of treatments, subjects, and design) within 
the network.
Conclusion: Meta-analysis and decision makers often seek similarity across 
the network. However, we argue that we may be more confident generalising 
from treatment effects estimated from a well-connected and heterogeneous 
network if the estimates within the network prove to be consistent.
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A patient centered approach on newly-arrived persons to a diabetes clinic
A.C. Paiva, M.J. Afonso, R.T. Ribeiro, L. Serrabulho, J. Susano, J.F. Raposo;  
APDP - Diabetes Portugal (Education and Research Centre - APDP/ERC), 
Lisbon, Portugal.
Background and aims: It‘s recognized that person-centred therapeutic edu-
cation and group education with active methodologies promote experiences 
sharing, conviviality and stimulates learning among participants. The clinic 
introduced two structured programs for self-management education (DSME) 
addressed to newly-arrived patients covering a wide range of Diabetes Care 
in an integrated way. It‘s a comprehensive program of patient-centred care 
designed to increase autonomy, promote better adherence to treatment, and 
thus better metabolic control. We aim to perceive the programme’s practical 
feasibility and people‘s adherence.
Materials and methods: Programme 1: lasts for 04:30h;-During this period 
the person performs several tests: blood samples, EKG and retinography. A 
nurse performs a foot screening with risk assessment and foot care education. 
Then the person participates in two group sessions: a session with nurse guid-
ance addressing pathophysiology of diabetes, relating the various important 
aspects in treatment and self-control, as well as doubts clarification and a final 
session about healthy eating, its importance for the metabolic control and 
lipid profile, and role of exercise in controlling diabetes (guided by a dieti-
cian/nutritionist). The average time between the program and the 1st medical 
consultation at the clinic is 4 weeks. Programme 2: lasts for 3 months, divided 
in three group education sessions before the diabetes individual medical con-
sultation (med). Sessions are guided by a facilitator using an IDF approved 
education tool, which provides an interactive verbal and visual learning expe-
rience, allowing groups engagement in an open and meaningful debate about 
diabetes. Sessions are divided by themes: the 1st (S1) leads to a reflection on 
their role in disease‘s self-management, the 2nd (S2)covers general concepts 
for healthy eating, and the 3rd (S3) is a physical activity session with a gym 
teacher. Patients are selected based on their age (50-80 y) and HbA1c(< 10%), 
they are invited to attend programme 1 or 2 according to their convenience.
Results: Programme 1: A sample of 300 people (February to September 2013) 
with 60.4±10.3 years of age, an initial mean HbA1c of 8.7±1.5% and BMI 
mean of 28,2±4,6kg/m2 were analysed. No consistent changes were observed 
in terms of BMI or HbA1c in this group between the session and the medi-
cal consultation. Programme 2: We analysed a sample of 231 people (same 
period of time), with 68.3±8.8 years of age and an initial mean HbA1c of 
9.1±0.7% and BMI mean of 35,3 ± 3,2 kg/m². The drop-out rate was 10,8% at 
session 2 and 82% at session 3. No consistent changes were observed in BMI 
between the various groups. In terms of HbA1c it was observed a tendency of 
decrease between S1 and medical consultation directly related to the number 
of sessions attended (∆A1c - Session 1: -0,27%; Session 2: -0,59 %; Session3: 
-0,85 %)
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Conclusion: It‘s well known that active methods are a fundamental tool 
in group training. Here, the consistent decrease in HbA1c (programme 2) 
achieved independently of weight loss, hints to the impact of sharing solu-
tions among peers by boosting diabetes acceptance, well-being and develop-
ment of autonomy with DSME. The longer duration of this program also ena-
bles a slower integration of knowledge and skills in the daily life. However, the 
high drop-out before the exercise session advises us to consider alterations on 
program implementation, further encouraging patients participation.
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Relation between quality of care indicators of diabetes and prediction of 
hospitalisation and mortality for heart failure
L. Policardo, G. Seghieri, P. Francesconi;  
Agenzia Regionale Sanità, Florence, Italy.
Background and aims: Heart failure (HF) is a major complication of diabetes 
especially as a consequence of ischemic heart disease. With the aim of evalu-
ating whether a panel of quality of care indicators, as suggested by current 
guidelines, are related to the risk of hospitalization or subsequent mortality 
for HF, this study has retrospectively followed up, along a period of eight 
years (from 2005 to 2012) a cohort of diabetic patients living in Tuscany, a 
region of centre of Italy.
Materials and methods: The database used for this investigation was ob-
tained from linking three datasets: the first concerning all hospital discharges 
with main diagnosis of heart failure (ICD-9-CM 402 to 428) from all Tuscan 
hospitals over the period 2005 to 2012, the second was the general population 
registry of all inhabitants of Tuscany and the third a dataset containing the 
registry of all known diabetic patients from Tuscany. This latter gave infor-
mation about whether patients did perform annual assessment of HbA1c, 
eye examination, serum lipids, creatinine and microalbuminuria. In addition, 
from this dataset it was possible to evaluate whether patients were given at 
least 2 annual drug prescription of ACE-inhibitors (ACEI), aspirin (ASA) or 
lipid-lowering drugs (LIPID).
Results: On a total of 95,205 diabetic patients (47,762 males and 47,443 fe-
males), followed up over eight years, we counted 4,494 hospitalizations for HF 
(2,131 in males and 2,363 in females). After using a Cox proportional hazard 
model, the hazard ratio (HR) of hospitalization for HF, adjusted for age and 
Charlson co-morbidity index was inversely related with the annul execution 
of HbA1c, microalbuminuria or of lipid profile both in men (HR:0.923;0.896-
0.952(95%CI), 0.972;0.949-0.995 and 0.895;0.870-0.920), and in women 
(HR.0.908;0.883-0.934, 0.968;0.945-0.991 and 0.900;0.878-0.923). The an-
nual evaluation of serum creatinine, was on the contrary a positive predic-
tor of risk (HR:1.306;1.260-1.353 in males and 1.359;1.315-1.405 in females). 
Annual eye examination was associated with a decrease in the risk of hospi-
talization for HF only among females (HR:0.957;0.937-0.977 among women 
and HR:0.986;0.964-1.008 among men). Finally, the composite indicator 
including the prescription for at least five years of ASA, ACEI and LIPID 
was significantly related with an augmented risk of HF-related hospitaliza-
tion in both males (HR:1.285;1.130-1.456) and females (HR: 1.192;1.028-
1.375). After HF hospitalizations 997 all-cause deaths were recorded and, by 
using a Cox model adjusting for age, sex and Charlson index, the survival 
after HF-hospitalization was significantly predicted by a low Charlson index 
(HR:0.928;0.864-0.996) and, again, by a lower number of annual evaluations 
of serum creatinine (0.935;0.886-0.985). No other indicator was significantly 
correlated with the prediction of post-hosptalization fatal events
Conclusion: In this cohort of Tuscan diabetic patients, over a eight-year pe-
riod the annual execution of HbA1c, microalbuminuria, lipid profile and eye 
examination were inversely related with the risk of hospitalization for HF. 
Prescription of ACEI, ASA and lipid-lowering drugs was, on the contrary, 
associated with a significant increase in predicted hospitalization risk. Finally, 
post-hospitalization mortality risk was predicted by a higher Charlson index 
and by a higher rate of annual serum creatinine evaluations.
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Quality of care in type 1 diabetes in Italy: focus on gender differences
V. Manicardi1, G.T. Russo2, E. Torlone3, M. Calabrese4, M.R. Cristofaro5, 
M.R. Improta6, P. Li Volsi7, A. Maffettone8, M.F. Mulas9, A. Napoli10,  
C. Suraci11, A. Ceriello12, G. Lucisano13, A. Nicolucci13, M.C. Rossi13;  
1Dept. of Int. Medicine, E.Franchini Hospital, Montecchio, Reggio Emilia, 
2University of Messina, 3University of Perugia, 4Hospital of Prato, 5Cardarelli 
Hospital, Campobasso, 6University of Naples, 7Hospital of Sacile (PN), Sacile 
(PN), 8Hospital Monaldi, Naples, 9Hospital Brotzu, 10Sapienza University, 
Roma, 11S.Pertini Hospital, Roma, Italy, 12Idibaps, Barcellona, Spain,  
13Mario Negri Sud, Santa Maria Imbaro (CH), Italy.
Background and aims: We evaluated the quality of care according to gen-
der in type 1 diabetes (T1D) in 300 diabetes outpatient clinics participating 
to “The Annali AMD” initiative. The Italian Association of Diabetologists 
(AMD) identified a set of quality indicators used for benchmarking activities 
since 2006, including process and intermediate outcome measures, as well as 
indicators of treatment intensity/appropriateness. A quality of care summary 
score (Q score), based on a combination of process and outcome indicators 
(range 0-40), was also calculated.
Materials and methods: We report here clinical data of 28,802 T1D patients 
(54.5% men; 45.5% women), collected during 2011 and extracted from elec-
tronic medical records.
Results: Both men and women received similar evaluation for process in-
dicators (HbA1c, Lipids, BP, microalbuminuria, foot and eye examination), 
whereas the outcome indicators and treatment intensity/appropriateness dif-
fered according to gender (Table). No gender differences as to age (F: 45±16 
years; M: 45±17) and diabetes duration (F: 19±13 years; M: 18±13) were 
noted. Men were more often smokers than women (31.8% vs. 22.7%) and 
showed a higher BMI (25±4 vs. 24±4 kg/m2), but F showed higher prevalence 
of BMI lt 18 or gt 35. T1D women showed poorer metabolic control and more 
often did not receive lipid-lowering agents in spite of high LDL-cholesterol 
levels than men, while men had poorer blood pressure control, and higher 
percentage of micro/macroalbuminuria. However, the overall quality of care, 
as estimated by Q score, was similar in both genders. Regarding the therapeu-
tic approach (MDI vs CSII), the percentage of women treated with CSII was 
higher than men (19,6% vs. 13.8%); women were slightly younger (42.2±16.9 
vs 45.1±16.9) for the same duration of disease (18.3±12.5 vs 18.1±13.2). A 
greater proportion of subjects treated with CSII reached the HbA1c level be-
low 7.0% but women experienced more difficulties in achieving the HbA1c 
goal even if treated with CSII (HbA1c &lt 7.0%: 25.1% F vs 31.2 % M ).
Conclusion: Despite a similar quality of care, T1D women still show a poor-
er metabolic control, with any type of treatment, and were less intensively 
treated for LDL-C, while men show a worse cardiovascular profile in terms of 
blood pressure, microalbuminuria, BMI and smoking habits.
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 438 
1 C
1064
A global study of unmet need for glycaemic control and predictor factors 
among patients with type 2 diabetes mellitus
D. Raccah1, E. Chou2, S. Colagiuri3, Z. Gaàl4, F. Lavalle5, A. Mkrtumyan6,  
E. Nikonova7, N. Tentolouris8, J. Vidal9, M. Davies10;  
1Department of Diabetology, University Hospital Sainte-Marguerite, 
Marseille, France, 2Sanofi R&D, Bridgewater, USA, 3Boden Institute, 
University of Sydney, 4Josa Andras Teaching Hospital Department of 
Medicine, Nyíregyháza, Hungary, 5Hospital Universitario, Facultad 
de Medicina UANL, Monterrey, Mexico, 6Moscow State Medical and 
Stomatological University named after Evdokimov, Moscow, Russian 
Federation, 7Global Medical Affairs, Diabetes Division, Sanofi, Bridgewater, 
USA, 8University of Athens Medical School, Greece, 9Endocrinology and 
Nutrition Department, Hospital Clinic, Barcelona, Spain,  
10Diabetes Research Centre, University of Leicester, UK.
Background and aims: Information on the efficacy of various treatments for 
type 2 diabetes mellitus (T2DM) in achieving glycaemic control is available 
globally from a number of different sources. This study utilized data from 
randomized controlled trials (RCTs), clinical trial registries (CTRs) and elec-
tronic medical records (EMRs) to identify unmet need for improved prandial 
glycaemic control in patients with T2DM following initiation of basal insulin 
therapy in Europe (EU), Asia Pacific (APAC), the US, and Latin America 
(LATAM).
Materials and methods: Different levels of evidence were used as available 
for each country/region, including RCTs (EU, LATAM, and APAC), CTRs 
(CREDIT 4-y, 9 countries mainly EU; ALOHA 0.5-y, Japan; Asia-FINE, 11 
Asian countries), and EMRs (Germany IMS-DA, UK THIN, and US GE). We 
evaluated hyperglycaemia status by categorizing as ‘well controlled’ (defined 
as endpoint fasting plasma glucose [FPG] at target [defined as FPG <130 or 
140 mg/dL; cut-off depending on country-specific recommendations] and 
HbA1c at target [defined as HbA1c <7%]), ‘residual hyperglycaemia’ (FPG at 
target but not HbA1c) or ‘uncontrolled’ (both FPG and HbA1c above target). 
Logistic regression analysis was used to identify predictor factors from the 
RCT dataset.
Results: Analysis of RCT data showed that ~43-54% of patients with T2DM 
globally had residual hyperglycaemia (Table), and rates across CTRs (CRED-
IT 31%, Asia-FINE 34.9%, and ALOHA 36%), and EMR (26% [Germany], 
36% [UK], and 25% [US]) datasets were similar. A comparison across the 
EU showed consistent residual hyperglycaemia between CTR and EMR data-
bases. Significant predictor factors were identified from RCT data, including 
baseline HbA1c (all countries/regions except Brazil), baseline FPG (UK and 
Japan), and duration of diabetes (Brazil).
Conclusion: The higher proportion of patients with residual hyperglycaemia 
in the RCTs may be due to the selected population in RCTs. However, ir-
respective of intrinsic source differences between the datasets, 25-54% of pa-
tients with T2DM globally had residual hyperglycaemia despite meeting FPG 
goals, indicating an unmet need for additional prandial glycaemic control.
Supported by: Sanofi
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Metabolic outcome data from a type 2 diabetes clinic in Denmark 
between 2001-2012
N. Safai, R.S. Terkildsen, U. Trustrup, M. Glindorf, M. Ridderstråle;  
Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Multifactorial interventions offered patients with 
type 2 diabetes (T2D), lead to substantial reduction in morbidity and mortal-
ity. Subsequent the Steno-2 study, a clinic providing referred T2D patients 
with dysregulated diabetes, complications or poor compliance, was opened 
at a specialized Diabetes Center (DC). Patients undergo a six to nine month 
treatment programme consisting of lifestyle education and motivation, and 
individually tailored pluri-farmacy targeting hyperglycaemia, hypertension, 
dyslipidaemia, and microalbuminuria. Our aim here was to find out the im-
pact of this programme on short term metabolic outcomes and compare at-
tainment of metabolic goals for patients in the general population to those 
of DC.
Materials and methods: Annual data from all patients with T2D referred to 
the type 2 clinic between Jan 1st 2001 and Jan 1st 2013 were extracted from the 
electronic medical records as part of quality of care assurance. In accordance 
with the national plan for diabetes care, the majority of patients (72%) were 
referred back to their general practitioner (GP) after being treated at the type 
2 clinic. The remainder was retained at DC due to their level of disease com-
plexity. Data up to nine months at type 2 clinic were followed. For compari-
son we used data from the Danish Adult Diabetes Database (DVDD) from 
2012. Non-parametric statistic analysis was used throughout.
Results: We included a total of 4.143 patients (male 59%), with 489 (12%) 
patients going through more than one treatment programme. Mean age was 
60 ± 12 years (mean ± SD) and mean duration of diabetes was 6.8 ± 6.6 years. 
DVDD contains data from 12.501 patients (male 56%) with T2D followed 
by GPs; mean age 68 ±11 years, and mean duration of diabetes 6.5 years. 
The mean HbA1c in patients with T2D followed by GPs was 48 mmol/mol 
(DCCT HbA1c 6.5%), while that of referred patients was 67±20 mmol/mol 
(8.3%) and decreased to 55±14 mmol/mol (7.2%) by the end of programme 
(p75 mmol/mol); 32% at baseline and 9% after completion of the programme. 
The well-regulated group (HbA1c <53 mmol/mol) increased from 25% to 
52% of all after 9 months (p<.0001). Mean body mass index (BMI) also de-
creased significantly, most notable from 2010; mean BMI from 31.3±6.5 kg/
m2 to 30.9±6.2 kg/m2. This decrease was most prominent in those who were 
obese (BMI >30 kg/m2) at baseline, as well as in females (p<0.0001 for both). 
Mean systolic and diastolic BP levels decreased from 143±21/82±12 mmHg at 
baseline to 137±19/80±10 mmHg (p<0.0001). The percentage of patients be-
low target pressure (<140/<90mmHg) went from 45% at baseline to 70% after 
the programme (Figure). LDL-cholesterol decreased from 2.6±1.0 mmol/L to 
2.2±0.9 mmol/L (p<0.0001); 52% of patients on target (LDL-cholesterol <2.6 
mmol/L) at baseline and 84% after finishing the programme.
Conclusion: Our data show that the patients referred from GPs to a special-
ized DC are of appropriate complexity or dysregulated and that their meta-
bolic control can be improved to near average GP level. 
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Trends over 8 years in quality of care provided by Italian diabetes clinics 
to elderly patients with type 2 diabetes
R. Candido1, M.C. Rossi2, M.A. Pellegrini3, G. Felace4, M. Boemi5,  
M. Scardapane2, A. Nicolucci2, P. Di Bartolo6, C. Giorda7;  
1Diabetic Centre, A.S.S. 1 Triestina, 2Department of Clinical Pharmacology 
and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), 
3Diabetes and Metabolism Unit, AOU Santa Maria della Misericordia, 
Udine, 4Diabetes and Metabolism Unit, O.C. di Spilimbergo, Spilimbergo 
(UD), 5Diabetes Unit, Department of Medicine, INRCA-IRCCS, Ancona, 
6Diabetes Unit, A.Usl della Romagna, Ravenna,  
7Diabetes and Metabolism Unit, ASL TO5, Chieri (TO), Italy.
Background and aims: The prevalence of diabetes in people over 75 years 
approaches 30%, while at least 25% of all patients attending Italian outpa-
tients diabetes clinics are older than 75 years. Clinicians who manage older 
people with diabetes require special skills to provide high-quality care. In the 
context of a continuous quality improvement initiative promoted in Italy by 
Associazione Medici Diabetologi (AMD Annals initiative), we evaluated the 
trends over 8 years in the quality of care provided by diabetes clinics to elderly 
patients (i.e. > 75 years).
Materials and methods: Overall, 300 diabetes clinics (about half of all clinics 
in Italy), all using electronic medical record systems, extracted data relative 
to the years 2004-2011 . The proportion of patients with at least one value 
registered during each year (process measures), the percentage of patients 
reaching specific favorable or unfavorable targets (intermediate outcome 
measures), and rates of use of drugs were evaluated. In addition, a quality of 
care summary score (Q score) was calculated. The Q score, ranging between 
0 and 40, is based on process and outcome indicators (HbA1c, blood pres-
sure, LDL-cholesterol, microalbuminuria) and is closely related to long-term 
outcomes in diabetic patients.
Results: Over the years, there was an increase in the percentage of patients 
aged > 75 years (19.9% in 2004 vs. 27.2% in 2011) and in the prevalence of 
male patients (42% in 2004 vs. 46% in 2011). As compared to 2004 we ob-
served after 8 years a slight increase in the mean age (79.9±3.8 vs. 80.5±4.1) 
and in the duration of diabetes (13.8±10.5 vs. 14.2±10.9). Table 1 shows qual-
ity of care indicators.
Conclusion: Care provided by diabetes clinics to elderly patients shows a 
significant improvement over the years. Elderly patients are more frequently 
monitored for blood pressure, lipid profile and microalbuminuria, show bet-
ter intermediate outcomes and are less often treated with sulphonylureas. In 
addition we observe a better global quality of care with a significant increase 
in the Q score through the years.
1067
Comparing the use of patient level data to an average patient profile 
within a type 2 diabetes simulation model
P. McEwan1,2, H. Bennett2, T. Ward2, K. Bergenheim3;  
1Swansea Centre for Health Economics, Cardiff, 2Health Economics and 
Outcomes Research Ltd, Monmouth, UK, 3Global Health Economics and 
Outcomes Research, AstraZeneca, Molndal, Sweden.
Background and aims: To accommodate patient heterogeneity and complex 
treatment pathways, type 2 diabetes models employ simulation techniques 
beyond the basic Markov process. Yet averages are commonly relied upon 
when defining patient populations and treatment effects; in turn clinicians 
may struggle to relate the results of such modelling to the full spectrum of 
patients they see in practice. This study investigates the value of fully model-
ling between patient variation by comparing patient and cohort level model 
inputs within a published simulation model, based on the UKPDS68 out-
comes equations.
Materials and methods: Anonymised UK patient data was obtained from 
The Health Improvement Network (THIN) describing 2,251 patients initi-
ating dual therapy. Simulations were initialised by applying either the aver-
age patient profile to the cohort, or by individually replicating each patient’s 
profile, followed by the collation of model outputs over all replications. The 
impact of utilising patient level baseline and treatment effect data was com-
pared to the average patient profile through evaluation of total costs, benefits 
and complication rates, predicted over a medium-term horizon of 20 years.
Results: On average patients were aged 63.36 (±11.14) at baseline, with the 
following risk factor profile; HbA1c 8.39 (±1.23) %, total cholesterol 4.18 
(±0.92) mmol/L, systolic blood pressure 135.07 (±14.76) mmHg and weight 
89.85 (±19.01) kg. The mean treatment effect on HbA1c was a reduction of 
1.01 (±1.23) %. Over 20 years, fewer macrovascular and microvascular events 
(-82/1,000 patients) and higher all-cause mortality (+17/1,000 patients) were 
predicted when using patient level data inputs compared to the average pa-
tient profile. Differences in the simulated frequency and timing of deaths 
were driven primarily by variation in baseline age and led to fewer estimat-
ed life-years (-0.66), quality adjusted life-years (QALYs) (-0.59) and costs 
(-£551) per patient. Patients estimated to have both lower costs and higher 
QALYs than those associated with the average patient profile were younger, 
with higher HbA1c and cholesterol and lower blood pressure at baseline.
Conclusion: Modelling results differ depending on the use of patient level or 
average cohort model inputs. Patient level data may provide insight into the 
type of patients in whom therapy is likely to be most beneficial. Furthermore, 
it enables the accurate simulation of correlations between patient characteris-
tics and treatment effect, which are rarely accounted for as part of a standard 
probabilistic sensitivity analysis.
Supported by: AstraZeneca, BMS
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Is there an evidence base for the clinical features used to differentiate 
type 1 from type 2 diabetes? A systematic review of the literature
B.M. Shields1, J.L. Peters2, C. Cooper2, J. Lowe2, B. Knight1, R. Powell3,  
C.J. Hyde2, A.T. Hattersley1;  
1NIHR Exeter Clinical Research Facility, University of Exeter Medical 
School, 2Peninsula Technology Assessment Group, University of Exeter 
Medical School, 3Research Design Service, Royal Devon and Exeter NHS 
Foundation Trust, Exeter, UK.
Background and aims: Clinicians predominantly use clinical features to dif-
ferentiate Type 1 from Type 2 diabetes but no guidelines quote an evidence 
base for which features are the most discriminatory. Whilst Type 1 patients 
are thinner, diagnosed younger, and rapidly go onto insulin, the best cut offs 
of these criteria are not provided. Misclassification of diabetes is widespread 
(7-15% of cases) and will result in patients receiving the wrong treatment. 
The key difference between Type 1 and Type 2, that determines treatment, 
is that patients with Type 1 diabetes develop absolute insulin deficiency. We 
aimed to systematically review the literature to identify which clinical criteria 
could be used to discriminate Type 1 and Type 2 diabetes, using insulin defi-
ciency as a gold standard.
Materials and methods: The search strategy took the form of: (terms for 
diabetes) AND (terms for C-Peptide). 14 databases including MEDLINE 
and EMBASE were searched. All diagnostic accuracy studies, published 
since 1979, using clinical criteria to predict insulin deficiency (defined by C-
peptide concentrations) were included. There was no restriction on race, age, 
language, or country of origin. Data synthesis was largely descriptive.
Results: 10,917 abstracts were screened, and 231 full texts reviewed. 10 ref-
erences were identified for final inclusion. Studies varied by age, race, year, 
and proportion of participants who were C-peptide negative, prohibiting for-
mal meta-analysis. Consistent predictors across studies were age at diagnosis 
(the most discriminatory feature; mean ranking of predictors by discrimi-
natory ability within studies=1.4), insulin treatment/time to insulin (mean 
rank=1.7), and BMI (mean rank=2.6). Discriminatory cutoffs were age at 
diagnosis 30-40 years, time to insulin 1-2 years, and BMI 27-28kg/m2 (>66% 
sensitivity and specificity for all). BMI added little over age at diagnosis and/
or time to insulin (<1% improvement in classification).
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 440 
1 C
Conclusion: Studies of the accuracy of clinical criteria to define Type 1 dia-
betes are surprisingly few given the importance for treatment of patients. De-
spite finding only 10 studies, and considerable heterogeneity between studies, 
age at diagnosis (35 years) and time to insulin treatment(1.5 years) were con-
sistently the most discriminatory. BMI, despite being widely used in clinical 
practice, adds little to these 2 criteria.
Supported by: NIHR
 
1069
Admission albumin levels are associated with increased risk for 
hypoglycaemia during hospitalisation as well as poor 1-year survival, 
among patients with diabetes mellitus
E. Leibovitz1,2, M. Boaz3,2, J. Wainstein4;  
1Interal Medicine E, Wolfson Medical Center, Holon,  
2Sackler school of Medicine, Tel Aviv University,  
3Research and Epidemiology, Wolfson Medical Center, Holon,  
4Diabetes clinic, Wolfson Medical Center, Holon, Israel.
Background and aims: Among non-critically ill patients, there are detrimen-
tal effects of hypoglycemia during hospital stay. Hospitalization-associated 
hypoglycemic events may occur in patients with diabetes mellitus that are 
prone to develop it. We studied the association between admission hypoal-
buminemia and the risk of hospitalization-associated hypoglycemia, among 
patients admitted to internal medicine departments.
Materials and methods: In this retrospective analysis of electronic medical 
records, we included all 2599 patients with diabetes mellitus and documented 
admission albumin levels (Mean age 71.7±13.0 years, 48.4% males, 65.9% of 
all patients with diabetes), admitted to internal medicine departments dur-
ing 2009. All glucose measurements were computerized using an institutional 
glucometer. Patients were categorized into 4 groups according to hospitali-
zation-associated hypoglycemia (yes/no) and admission alumin levels below 
3.5 g/dL (yes/no).
Results: Patients with hypo-albuminemia had higher rates of hypoglycemia 
and severe hypoglycemia during the admission despite similar HbA1c and 
average glucose control during the admission. Only creatinine (OR 1.237, 
95% CI 1.098-1.392, p<0.001) and albumin levels (OR 0.417, 95% CI 0.342-
0.509, p<0.001) affected the risk for hypoglycemia. In addition, Patients with 
hospitalization-associated hypoglycemia combined with admission hypoal-
buminemia had the lowest survival rates (hospital and 1-year), compared 
to the other groups (OR 7.419, 95% CI 5.255-10.473 respectively, p<0.001). 
Patients with hypoglycemia but with normal albumin levels had a similar 
survival curve compared to diabetes patients without hypoglycemia nor hy-
poalbuminemia.
Conclusion: Low albumin levels upon admission are associated with in-
creased risk for hypoglycemia during hospitalization. The occurrence of 
hypoglycemia among patients with low albumin levels is associated with 
reduced 1-year survival compared to both diabetes patients with hypoalbu-
minemic but without hypoglycemia, as well as diabetes patients without hy-
poglycemia and normal albumin levels.
1070
Real-world treatment switching patterns in patients (pts) with  
type 2 diabetes mellitus (T2DM) on basal insulin (INS)
J. Kapustin1, J.E. Anderson2, T. Reid3, A. Rhinehart4, S. Brunton5, J. Stewart6, 
W. Zhou6, T. Dex7, M. Kazemi7, A. Vlajnic7, M. Dalal7;  
1University of Maryland School of Nursing, Baltimore, 2The Frist Clilnic, 
Nashvill, , 3Mercy Diabetes Center, Janesville, 4Johnston Memorial Diabetes 
Care Center, Abingdon, 5Primary Care Education Consortium, Charlotte, 
USA, 6Sanofi Canada, Laval, Canada, 7Sanofi US, Bridgewater, USA.
Background and aims: Increasing treatment options have empowered but 
also complicated disease management. We explored transitions from INS to 
other therapies in a real-world setting.
Materials and methods: We analysed data from Diabetes FORWARD, a prac-
tice-based research network focused on T2DM pts and their providers across 
the US (September 2012-December 2013). Pts aged ≥ 18 years, diagnosed with 
T2DM and with a start date for INS ≤ 12 months (mo) before enrolment were 
eligible. Based on prescription data from electronic medical records, pts were 
stratified by treatment switches at 3, 6, and 9 mo as those who: remain on INS; 
switch to oral antidiabetes drugs (OADs); switch to a glucagon-like peptide-1 
receptor agonist (GLP-1) ± INS; or switch to other insulin (85-90% added 
prandial insulin to INS). As in any observational study, not all pts contributed 
data at each time point; therefore, 3, 6 and 9 mo groups were defined.
Results: 300 pts were eligible. At 3 mo, 81% of pts remained on INS, de-
creasing to 65% at 6 mo and 56% at 9 mo; proportions of pts switching to 
other therapies increased. At baseline (BL) there were no differences in age, 
gender, race/ethnicity, education level, or number of OADs between groups. 
Pts remaining on INS or switching to other insulin had more Medicare cov-
erage. In the GLP-1 group, more pts had private health insurance, although 
numbers are small (Table). At all time points, pts transitioning to OADs re-
ported worse general health than those remaining on INS; those transition-
ing to other insulin reported the worst general health (Table). There were no 
differences in BL HbA1c between groups, although BL HbA1c was numeri-
cally highest for pts switching to other insulin (Table). HbA1c decreased in all 
groups except for pts transitioning to other insulin which increased. Greatest 
reductions in HbA1c were seen in the OAD and GLP-1 groups (Table). Pts 
switching to GLP-1 or other insulin had higher BL weight; those in the 6 and 
9 mo OAD groups had the lowest weight. Greatest weight loss was observed 
in the GLP-1 group (data not shown).
Conclusion: Patterns observed here suggest that, in the practice setting, pts 
with T2DM transitioning from INS to OADs report worse health, have a 
lower weight, and relatively good glycaemic control. However, those tran-
sitioning to GLP-1 report good health, higher weight, and better glycaemic 
control. Pts transitioning to other insulin report poorer health, higher weight, 
and the worst glycaemic control. Medicare beneficiaries had the least access 
to GLP-1 suggesting insurance influences provider decisions. Other reasons 
for switching therapy may be intolerance to, or ineffectiveness of, previous 
therapy and disease progression.
Supported by: Sanofi US
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Overtreatment in elderly patients ≥75 years with type 2 diabetes and 
renal disease
A. Penfornis1, J.-F. Blickle2, B. Fiquet3, S. Dejager3;  
1Jean Minjoz Hospital, Besançon, 2Strasbourg University Hospital,  
3Novartis Pharma SAS, Rueil Malmaison, France.
Background and aims: Few data exist regarding management of patients 
(pts) with type 2 diabetes mellitus (T2DM) over 75 years (y), who frequently 
have renal impairment (RI). This real-life study aimed to assess the treatment 
of T2DM in elderly patients with chronic kidney disease (CKD), a uniquely 
fragile population that poses specific challenges.
Materials and methods: Observational cross-sectional study: 3704 pts with 
T2DM were recruited by 968 physicians in France. Data from 980 diabetic pts 
≥75 y with CKD are presented in this sub-analysis.
Results: Mean age was 81 y (range 75-101), 56% were male, with BMI 28.5 
kg/m², while mean estimated glomerular filtration rate (eGFR) was 43 mL/
min/1.73m². 20% of patients had severe RI (eGFR <30mL/min/1.73m²; mean 
22.5) and 71% had moderate RI (eGFR 30-60 mL/min/1.73m²; mean 43.7). 
38% had seen a nephrologist. Mean HbA1c was 7.4% (60% had HbA1c <7.5% 
and 36% <7%). They had long-standing T2DM (15.4 y), often complicated 
(macrovascular complications 49%, heart failure 20%, retinopathy 20%). 
Respectively, 96% and 78% had hypertension and dyslipidemia, almost all 
treated. They received a mean of 5.5 concomitant therapies for cardiovascular 
risk management. Antidiabetic therapy was oral-based for 51% of pts (40, 46 
and 13% as single, dual or triple-drug therapy) and insulin-based for 49% 
(combined with ≥1 oral antidiabetic [OAD] in 59%). Treatment included 
metformin (47%), SU (26%), glinide (19%), α-glucosidase inhibitor (6%), 
DPP-4 inhibitor (31%) or insulin (49%). The type of agents differed across 
renal function (RF) strata: there was less use of metformin (70, 49 and 29% 
of pts, respectively, in normal RF, moderate or severe RI), SU (28, 28 and 
19%) and DPP-4 inhibitors (38, 33 and 20%) and more use of glinides (11, 19 
and 22%) and insulin (37, 46 and 65%) with declining RF. Metformin daily 
dose remained high (mean 1.9 g/d; >2 g/d for 25%) across all degrees of RI. 
Metformin was stopped/reduced at the end of the visit in only 25% of the 
metformin-treated pts overall and 40% of those with severe RI. 60% (n=579) 
of these older pts with overt RI and multiple comorbidities (nearly half with 
macrovascular disease) had an HbA1c level <7.5% (mean 6.7%) while being 
still quite intensively treated (Figure). Only ¼ were receiving oral monother-
apy and 69% were receiving insulin secretagogues and/or insulin.
Conclusion: In clinical practice, most elderly T2DM pts with CKD appeared 
to be over-treated, putting them at high risk for severe hypoglycaemia. RI was 
insufficiently taken into account when adjusting anti-diabetics; at odds with 
current guidelines, 30% and 19% of elderly pts with severe RI were receiving 
metformin and SU, respectively.
Supported by: Novartis
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Patient-reported outcomes and costs associated with insulin and  
non-insulin therapies for type 2 diabetes in five European countries
S. Nuhoho1, J. Vietri2, G. Isherwood3, M. Worbes-Cerezo4;  
1Janssen-Cilag A/S, Birkerød, Denmark, 2Kantar Health, Milan, Italy, 
3Kantar Health, Epsom, 4Janssen Cilag Limited, High Wycombe, UK.
Background and aims: The progressive nature of type 2 diabetes (T2D) of-
ten requires escalation of therapy for glycemic control and to protect against 
complications, but the consequences of different management strategies on 
patient well-being are not well documented. This study was conducted to de-
scribe patient outcomes by medication regimen.
Materials and methods: Data came from the 2013 5EU National Health and 
Wellness Survey, representative of adults in France, Germany, Italy, Spain, 
and UK in terms of age and gender. Respondents were categorized into four 
groups by use of antihyperglycemic medications: 1 non-insulin medication, 2 
non-insulin medications, ≥3 non-insulin medications, and therapy including 
insulin. Outcome measures included the SF-36v2, Work Productivity & Ac-
tivity Impairment questionnaire, and 6-month self-reported healthcare use. 
Indirect costs were estimated using work impairment and wage statistics, and 
direct medical costs estimated using reported medical visits and unit costs. 
Groups were compared using ANOVA with pairwise t-tests and chi-square 
test for continuous and categorical variables, respectively.
Results: Of 2,894 respondents included in the final sample, 68% were male 
and 32% were employed. Respondents using insulin had the lowest average 
scores for mental health component summary (44.9) by ˃2 points, physical 
component summary (40.9) by 3.8 points, and SF-6D health utility (0.63) 
by 0.05 points. Twice as many respondents using insulin (24%) reported ≥2 
hypoglycemic events requiring assistance per year as non-insulin users (5.6-
11.9%). The average rating of activity impairment was 1.3 times as high in 
insulin users (46.5%) as in non-insulin users (32.0-34.2%), with similar in-
creases in ratings of work impairment among the employed subsample using 
insulin (32.4%) vs other employed respondents (21.3-24.9%). Healthcare use 
was most frequent in respondents using insulin, with a mean 11 total pro-
vider visits vs 8 during the same period for other groups. Emergency visits 
(mean 0.4) and hospitalizations (mean 0.3) were also most frequent among 
insulin users. Estimated annual indirect costs were higher in the insulin 
group than in non-insulin mono- and dual-therapy patients, while estimated 
direct costs were higher among insulin users than any other group (Table). 
All presented differences p<0.05.
Conclusion: T2D patients using insulin experience greater burden in health-
related quality of life, impairment to work and activities, and use more 
healthcare than patients managed without insulin. Therapies that delay insu-
lin initiation may potentially offer better quality of life and work productivity 
to patients and provide savings to the healthcare system, though confounds 
such as duration of diabetes may have affected results. Further research com-
paring insulin-based and non-insulin management strategies is required.
Supported by: Janssen Pharmaceutica NV
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Randomised trial of a type 2 diabetes community case worker 
intervention reduces hospitalisations and emergency visits over 3 years 
in a collaborative care model
R.O. Yeung1, Y. Zhang1, A.O. Luk1, Y. Cheung2, R. Ozaki1, H. Chung1,  
J.C.N. Chan1, W. So1;  
1Medicine, Chinese University of Hong Kong,  
2Ma On Shan Family Medicine Clinic, Hong Kong.
Background and aims: Collaborative care between family medicine doc-
tors and specialists with periodic review at a diabetes centre reduced major 
clinical outcomes and mortality compared to management by family doctors 
alone. Further, increased contact time with support staff who promoted self-
management and reduced negative emotions has improved metabolic control 
and reduced acute health care utilization. We hypothesized that provision of 
a community care worker (CCW) in the setting of collaborative care further 
improves metabolic control and reduces acute health utilization in patients 
with type 2 diabetes.
Materials and methods: In a collaborative care model, patients with type 
2 diabetes attending a community-based family medicine clinic underwent 
annual comprehensive assessment (CA) at a specialist diabetes centre for risk 
stratification with personalized report and decision support using the web-
based Joint Asia Diabetes Evaluation portal and were randomized to either 
additional support by a trained CCW (JADE+CCW) or JADE alone (JADE). 
Guided by the personalized report, the CCW counselled patients after the 
medical consultation to reinforce treatment adherence, self-care, and pro-
vide emotional support. Using intention-to-treat analysis, primary outcome 
was change in glycemic control after 3 years. Secondary outcomes included 
cardiometabolic control (changes in blood pressure and LDL-C), as well as 
acute health care utilization as measured by number of hospitalizations, total 
length of stay (TLOS), and number of emergency visits over 3 years. Meta-
bolic control was measured at CAs. Hong Kong’s public health care system 
services the majority of the population, so utilization measures were retrieved 
from the Health Authority database that captured all visits to public medical 
institutions within 3 years of enrolment. Negative binomial regression was 
used to ascertain the incident rate ratio (IRR) of hospitalization and emer-
gency visits between groups, as well as rate ratio (RR) of TLOS.
Results: Of 661 patients recruited, 332 were randomized to JADE and 329 
to JADE+CCW. At entry, 46% were male, with mean±SD age of 60.3±10.9 
years, diabetes duration of 6.8±6.0 years, and HbA1c of 6.8±1.1%. The me-
dian number of CAs was 4 in both groups over 3 years, and those in the in-
tervention group saw the CCW 12.2±4.3 times. After 3 years, HbA1c deterio-
rated in both groups (JADE 0.44% (95%CI 0.32- 0.55%) and 0.48% (95%CI 
0.37- 0.70) in JADE+CCW (P=0.635 between groups)), whereas LDL-C 
improved in both groups. Systolic blood pressure improved in JADE+CCW 
from baseline (133.1 to 129.5mmHg, P<0.001) but did not in JADE (131.8 to 
131.4mmHg P=0.406). In JADE, 44% had ≥ 1 hospitalization with a mean 
TLOS of 7.1±23.1 days and 50% had ≥1 emergency visit. The respective fig-
ures in JADE+CCW were 35%, 3.3±11.2 days and 43%. After adjusting for 
age, sex, diabetes duration, and risk level, the IRR (95% CI) in JADE+CCW 
was 0.77 (0.61-0.97) for hospitalization, 0.68(0.55-0.84) for emergency visits, 
and TLOS was 0.45(0.37-0.54) times as long compared to JADE.
Conclusion: The use of a trained CCW within a collaborative care setting 
reduced acute care utilization in patients with type 2 diabetes. These find-
ings highlight the importance of using knowledge transfer and team-based 
management to make quality diabetes care more accessible and sustainable.
Supported by: Asia Diabetes Foundation
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Tailored support for type 2 diabetes patients with a first acute coronary 
event after discharge from hospital: results of a RCT in primary care
M.J. Kasteleyn, R.C. Vos, G.E.H. Rutten, Diacourse Study Group;  
University Medical Center Utrecht (UMCU), Netherlands.
Background and aims: Type 2 diabetes mellitus (T2DM) patients with a re-
cent acute coronary event (ACE) might experience decreased quality of life 
and increased distress. The first period after discharge is a critical time. We 
aimed to evaluate the effectiveness of a tailored supportive intervention on 
diabetes related distress, psychological well-being and clinical variables in 
T2DM patients and a recent first ACE.
Materials and methods: In this randomised controlled trial, the interven-
tion group received a tailored supportive intervention based on the results 
of focus groups with patients and their partners. A diabetes nurse visited the 
T2DM patients at home within three weeks after discharge from hospital after 
a first ACE, and two weeks and two months later. From a list of ten topics, 
three were chosen by the patient and discussed with the patient and his/her 
partner, based on a protocol and with the use of a patient’s handbook with 
assignments and homework. The attention control group received a consul-
tation by telephone. Outcome variables were measured after discharge and 
five months later, using validated questionnaires: diabetes-related distress 
(PAID) well-being (WHO5), health status (EQ VAS), anxiety and depression 
(HADS). HbA1c, blood pressure and lipids were retrieved from the general 
practitioners’ medical records. Differences between groups in change over 
time were analysed according to the intention-to-treat principle, using AN-
COVA. The Holm-Bonferroni correction is used to adjust for multiplicity.
Results: Of the 201 randomised patients, 81 patients from the intervention 
group (age 65.8±9.3 yrs, 76.5% male) and 80 from the control group (age 
65.6±9.4 yrs, 75% male) completed both baseline and follow-up question-
naires. All patients experienced low distress after discharge from hospital 
(8.7±11.8), which did not increase during the five months after discharge. 
Low levels of anxiety (4.1±3.8) and depression (3.7±3.5) were experienced 
at baseline and did not increase after five months. Baseline well-being (In-
tervention group: 60.6±27.4; control group: 58.2±25.5) and health status (In-
tervention group:71.2±13.4 and control group: 68.8±16.2) were less favour-
able in both groups. A significant intervention effect was found for health 
status (effect size=0.35; p=0.007) and a trend was found for well-being (ef-
fect size=0.22; p=0.061). This corresponds to a small to moderate statistical 
and clinical difference in health status and in well-being between the two 
intervention and control group. From the patients in the intervention group 
(n=48) who received cardiac rehabilitation as well, 62% rated the interven-
tion as having added value. Especially the individualised and timely character 
of the intervention was appraised.
Conclusion: This tailored intervention significantly improved the health sta-
tus of T2DM patients shortly after discharge from hospital because of their 
first ACE. It did not influence the fortunately low levels of diabetes related 
distress, anxiety or depression in this group of patients.
Clinical Trial Registration Number: NCT01801631
Dutch Diabetes Research Foundation (no: 2009.70.)
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Improvements of diabetic control in a diabetes day clinic compared to 
the classic out-patient approach
V. Altabas, M. Strinović, J. Marinković, L. Ružman, G. Mirošević,  
M. Berković Cigrovski, D. Herman Mahečić, P. Šulentić, I. Kruljac,  
M. Vrkljan;  
Department of Endocrinology, Diabetes and Metabolic Diseases, UHC 
„Sestre milosrdnice“, Zagreb, Croatia.
Background and aims: Diabetic day clinics allow patient - focused, struc-
tured and extensive education, improving knowledge about the nature of dia-
betes, its complications, and therapy options. In a small group environment 
patients are able to ask questions, share their problems and hear other peo-
ple‘s experiences. More frequent and precise pharmacological interventions 
are an additional benefit of diabetic day clinics. With acquisition of knowl-
edge and skills necessary to control diabetes, a positive attitude of patients 
towards their illness developes, allowing better diabetes control on the long-
term. The aim of this research is to show the superiority of a combined struc-
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tured approach in diabetes day clinics in the treatment of adult patients with 
diabetes in comparison to periodical visits in out-patient clinics.
Materials and methods: A total of 280 adult diabetic patients participated in 
this study, 140 patients were treated in the diabetes day clinic, and 140 con-
trols were treated as out-patients. There was no significant difference between 
groups considering age, sex, diabetes type, and diabetes duration at study 
start. The study group underwent structured theoretical and practical edu-
cation about diabetic nutrition, weight control, physical activity, acute and 
chronic diabetic complications and pharmacological management. They re-
ceived psychological assistance, and training in specific skills in the diabetes 
day clinic. The control group received standard care in the out-patient clinic. 
Routine biochemistry relevant to glycemic control (e.g. fasting and postpran-
dial glycemia, HbA1c, lipidogram) was determined, and - if necessary - ther-
apy was adjusted in all patients. BMI and routine biochemistry were repeated 
after 3 months. Statistical analysis was performed by using Student’s t-test for 
numerical data, and chi-square test for qualitative data.
Results: In the study group, both fasting (10,68±3,89 vs. 8,34±2,49 mmol/L, 
p<0.0001)and postprandial blood glucose (12,79±4,97 vs. 10,70±4,43 
mmol/L, p<0.0001) were significantly improved during treatment in the 
diabetes day clinic, consecutively there was a statistical significant reduction 
in HbA1c at the first control visit performed after three months (9,08±2,33 
vs. 7,2±41,51%,p<0.0001), body mass index (30,33±5,80 vs. 30,11±5,33 kg/
m2,p=0,0029), and improved HDL cholesterol (1,21±0,36 vs. 1,33±0,36 
mmol/L, p=0,0003). In the control group, there was no statistical significant 
difference in controlled parameters noticed on control visits. Additionally, 
patients in the study group had significant lower values of fasting (8,34±2,49 
vs. 8,92±3,03 mmol/L, p=0,03), and a significant more profound drop in 
HbA1c levels (-1,84±0,15% vs. +0,09±0,25%, p<0,0001) in comparison to 
controls after three months of follow up.
Conclusion: Diabetic day clinic provide a superior way to intervene in gly-
cemic control, offering better chances for life style changes (reflected in a sig-
nificant weight loss) and a better glycemic control.
1076
Relation between perception of professional care provision and self-care 
activities in people with diabetes: Japanese DAWN2 subsample analysis
Y. Hayashino1, H. Ishii2;  
1Tenri Hospital, Nara, 2Nara Medical University, Kashihara, Japan.
Background and aims: It has not been studied whether the perception of 
people with diabetes (PWD) that they received care by a healthcare profes-
sional was associated with adherent self-care activities in PWD. The aim of 
this analysis was to investigate the association between the perception of 
PWD that they received diabetes care by a healthcare team and the diabetes 
self-care activities practiced by PWD and glycemic control using Japanese 
sub-sample data from the second Diabetes Attitudes, Wishes and Needs 
(DAWN2) study.
Materials and methods: The DAWN2 study was a multi-national ques-
tionnaire-based online survey of perceptions about healthcare provision for 
benchmarking and sharing of clinical practices to improve diabetes care in 17 
countries. In Japan, a total of 508 PWD participated in the survey. PWD were 
asked whether they experienced healthcare provision (measuring HbA1c, 
blood pressure, lipid profile, etc.) during the past 12 months. Diabetes self-
care activities were assessed using the Summary of Diabetes Self-Care Activi-
ties (SDSCA)-6 scores, representing the mean number of days that PWD per-
formed specific self-care activities in the past 7 days. Statistical comparison 
was performed using the Mann-Whitney U test.
Results: The mean age of PWD was 54 years, and 57.9% were male. The mean 
duration of diabetes was 12.4 years and the mean HbA1c was 6.8%. With 
regard to healthcare provision, 91.3% of PWD recognized that they were pro-
vided with “measuring HbA1c level,” and 71.9% of PWD recognized that they 
were provided with “measuring weight.” In contrast, “examining feet” (15.7%) 
and “asking if having been anxious or depressed” were not frequently recog-
nized (12.2%). PWD were more likely to practice “taking all diabetes medica-
tions exactly as previously agreed with a healthcare professional” (mean: 6.1 
days) and “eating healthily” (4.1 days), and were less likely to practice “testing 
blood sugar” (2.6 days) and “checking feet” (1.4 days). PWD who recognized 
that they were provided healthcare provision, such as “examining feet” and 
“asking about the amount of physical activity,” showed a significant difference 
in the days of practicing the related self-care activity compared to PWD who 
didn’t experience the healthcare provision. (“examining feet”: 2.0 days vs. 1.3 
days, “asking about the amount of physical activity”: 4.2 days vs. 2.5 days.) 
PWD who experienced “examining feet” also showed a significant difference 
in the days of practicing not only “checking feet” but also “eating healthily” 
and “testing blood sugar the number of times recommended by a health care 
provider” compared to those who didn’t. HbA1c was significantly lower in 
the group who practiced 5 days or more of the following self-care activities: 
“eating healthily” and “being physically active” compared with the group who 
practiced less than 5 days of those self-care activities.
Conclusion: The findings of this analysis suggest that PWD who reported 
to have received sufficient healthcare provision practiced certain self-care 
activities more often, and that certain diabetes care provisions may have a 
favorable effect on all-around self-care activities. PWD who practice self-care 
activities more often may achieve better HbA1c as a treatment outcome.
Supported by: Novo Nordisk A/S
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Shared decision making in type 2 diabetes using the Diabetes Medication 
choice Decision Aid: preliminary results from a cluster-randomised trial 
T. Karagiannis1, M.E. Branda2,3, A. Liakos1, E. Athanasiadou1, M. Mainou1, 
D.G. Goulis4, P. Boura1, V.M. Montori2,3, A. Tsapas1,5,  
the Diabetes Medication Choice Cards Trial in Greece study group;  
1Clinical Research and Evidence-Based Medicine Unit, Second Medical 
Department, Aristotle University, Thessaloniki, Greece, 2Knowledge and 
Evaluation Research Unit, Mayo Clinic, Rochester, 3Division of Health Care 
Policy and Research, Department of Health Sciences Research, Mayo Clinic, 
Rochester, USA, 4Unit of Reproductive Endocrinology, First Department 
of Obstetrics and Gynaecology, Aristotle University, Thessaloniki, Greece, 
5Harris Manchester College, University of Oxford, UK.
Background and aims: Patient involvement in healthcare decisions is advo-
cated in existing type 2 diabetes guidelines and can improve the quality of 
care. Decision aids (DAs) are tools that facilitate the shared decision making 
(SDM) process. In a cluster-randomised clinical trial we compared the ef-
ficacy of the Diabetes Medication Choice DA with usual care in patients with 
type 2 diabetes in Greece.
Materials and methods: Practices, matched by setting and level of care were 
randomly allocated to use of the DA or usual care to support decision making 
for choice of antidiabetic medications. Eligible patients required treatment 
intensification (HbA1c 7.5-10%) and had more than one available treatment 
options. The trial comprised an initial clinical encounter and two follow-up 
visits. Immediately after the initial encounter, we assessed the quality of the 
decision making process by a modified 13-item Decisional Conflict Scale, 
patient‘s knowledge about antidiabetic medications, and patient‘s and clini-
cian‘s satisfaction.
Results: We enrolled five practices (N=101) to the DA arm and four practices 
(N=103) to the usual care arm, between May 2013 and February 2014. Pa-
tients‘ baseline characteristics were equally balanced between the two arms. 
Patients in the decision aid arm had better (lower), albeit not significantly, 
scores in overall decisional conflict (mean difference 7.0; 95% CI -8.1 to 
22.2), and its subscales (Table). Knowledge transfer was high in both groups 
(mean difference 2.4%; 95% CI -16.0 to 20.7). Patients allocated to the DA 
and standard practice were equally satisfied. In most cases, physicians found 
the DA useful and reported that its use and integration in their clinical set-
ting was easy. They also appeared willing to use a similar DA for patients with 
other chronic conditions.
Conclusion: Our results are similar to findings from trials that assessed the 
Diabetes Medication choice DA in US. Promoting patient-centered care 
through a DA for type 2 diabetes in Greece was positively accepted by clini-
cians and patients. Further research is needed to determine the DA‘s impact 
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on care experience and patient-oriented outcomes on populations with dif-
ferent background sets of values and preferences.
Clinical Trial Registration Number: NCT01861756
Supported by: EFSD grant supported by AstraZeneca
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Group-based self-management support leads to more adequate exercise 
behaviour in recently diagnosed type 2 diabetes patients
A.L. van Puffelen1, M. Rijken1, G. Nijpels2, G.E.H. Rutten3, F.G. Schellevis1,2; 
1NIVEL, the Netherlands Institute for Health Services Research, Utrecht, 
2Department of General Practice & Elderly Care Medicine, EMGO Institute 
for Health and Care Research, VU University Medical Center, Amsterdam, 
3Julius Center for Health Sciences and Primary Care, UMC Utrecht, 
Netherlands.
Background and aims: Adequate self-care behaviours and lifestyle changes 
are considered essential, though challenging elements in the management 
of type 2 diabetes mellitus (T2DM). Previous research indicated that illness 
perceptions of patients and partners are important precursors for health be-
haviours. In addition, interventions based on the Common-Sense Model of 
Self-Regulation (CSM) seem effective in enhancing health outcomes in vari-
ous (chronic) conditions. We therefore developed a group-based self-man-
agement support programme for recently diagnosed T2DM patients (1-3 
years post-diagnosis) and their partners, based on the CSM. In this study, we 
want to investigate the short and long-term effectiveness of this new course 
on self-care behaviours in T2DM.
Materials and methods: Randomised controlled trial with a pre-test (T0), 
post-test (T1) design and follow-up after six months (T2). T2DM patients 
were selected on the basis of medical records of participating general practices 
in different regions in the Netherlands and, after informed consent, randomly 
allocated to the intervention (four course sessions) or attention control (sin-
gle information meeting) condition. Self-care was assessed with three items 
of the revised Summary of Diabetes Self-Care Activities (SDSCA) measure, 
assessing exercise, diet (both 0 - 7 days) and smoking (yes/no) during the 
past week. Exercise and diet were dichotomised into adequate (≥ 5 days) and 
non-adequate behaviours. Effectiveness on self-care was established by logis-
tic regression analyses adjusting for demographic characteristics (age, gender 
and educational level) and pre-test scores on self-care.
Results: A total of 167 patients participated in the study: 81 in the interven-
tion and 86 in the control condition. 146 patients returned the T1 question-
naire (drop-out rate 13%). Participating patients had an average age of 64 
years (SD = 10.10, 27 - 83 years) and 56% were male. At baseline, 43% of 
the patients reported adequate exercise, 77% adequate dietary and 82% non-
smoking behaviours. Preliminary results showed a significantly higher pro-
portion of self-reported exercise behaviours in the intervention group (47%) 
at T1 (OR = 2.42, CI = 1.07 - 5.50), compared to the control group (32%). 
No significant differences between the intervention and control group were 
found on (changes in) reported dietary (76% vs 72%) and non-smoking be-
haviours (87% vs 74%) at T1.
Conclusion: In the short term, a self-management support programme based 
on the CSM appears to be effective in enhancing adequate (self-reported) ex-
ercise behaviours in recently diagnosed T2DM patients. Results on long-term 
effectiveness of the course are currently investigated and will be presented 
during the conference.
Clinical Trial Registration Number: NTR3302
Supported by: Dutch Diabetes Research Foundation 2009.70
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Diabetes care process performance using the alphabet strategy compared 
to the national audit data: practice of evidence based medicine (POEM) 
2013
J.D. Lee1, P. Saravanan2, V. Patel3;  
1Diabetes Centre, George Eliot Hospital NHS Trust, Nuneaton,  
2Metabolic & Vascular Health, 3Education and Development,  
Warwick Medical School, Coventry, UK.
Background and aims: The Alphabet Strategy is a diabetes care checklist 
based on a mnemonic: A for advice with regard smoking cessation, ideal 
weight attainment, regular exercise; B for blood pressure; C for cholesterol 
profile and creatinine care; D for diabetes glycaemic control; E for yearly eye 
exam; F for regular year foot exam; and G for guardian drugs with regard to 
aspirin, ACE inhibitors, and statins. Such a management strategy has been 
demonstrated to be effective in ensuring performance of care processes and 
attainment of diabetes target parameters. We performed an audit of the notes 
of all patients with Type 2 diabetes attending the diabetes outpatient depart-
ment using the Alphabet Strategy as an audit template to determine adher-
ence to the checklist. We compared these results to the UK’s recently pub-
lished National Diabetes Audit 2011/12.
Materials and methods: The Diabetes Outpatient Clinic register was con-
sulted for the names of patients currently attending the department. Relevant 
demographic and diabetes data were extract from information attained at 
most recent clinic visit. Case notes, electronic letters and the computerised 
pathology reporting system were reviewed for outstanding care processes. 
Care performance within 15 months of the most recent clinic visit was reg-
istered as positive documentation. Data collection was performed over three 
months between October to end of December 2013. Statistical analysis was 
performed using chi-squared test.
Results: Data was available from 551 patients. Mean age of the whole cohort 
was 63 years. 18.7% of people were more than 74 years of age. Men com-
prised 59.2% of the study group, and as a group were of similar average age 
to females at 63 years. Compared to the NDA, POEM achieved better per-
formance of care processes except for annual foot exam. For target process 
achievement, POEM achieved better control in total cholesterol and target 
blood pressure, but fared worse in glycaemic control.
Conclusion: The use of the Alphabet Strategy continues to help achieve per-
formance of essential diabetes care processes.
1080
Cost-effectiveness of centralised and partly centralised care compared to 
usual care for patients with type 2 diabetes
A.A.W. van der Heijden1, T.L. Feenstra2, M.C. de Bruijne1, C.A. Baan3,  
G.A. Donker4, J.M. Dekker1, G. Nijpels1;  
1The EMGO Institute for Health and Care Research, VU University Medical 
Center, Amsterdam, 2UMC Groningen, 3RIVM, Bilthoven,  
4Nivel, Utrecht, Netherlands.
Background and aims: Due to an ever increasing number of type 2 diabetes 
patients, innovations to control the increasing health care use and costs are 
needed. Results of diabetes care programs on the costs or (cost-) effectiveness 
are heterogeneous. The aim of this study is to compare the cost-effectiveness 
of two diabetes care models with usual care for type 2 diabetes patients from 
the societal perspective.
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Materials and methods: An economic evaluation was performed alongside 
a clinical trial. In two distinct regions of the Netherlands, two diabetes care 
models were implemented with different levels of centralized organizational 
structures. One of them was centralized care (CC) with a central organization 
and coordination of the care between all care providers and the use of a cen-
tral database. Patients receive an annual extended diabetes assessment at the 
Diabetes Care Centre, in addition to the care by patients’ general practitioner 
(GP). GP’s receive feedback about their performance. Partly centralized care 
(PC) focuses on adherence to type 2 diabetes guidelines. An online clini-
cal database is used to monitor mean values of risk factors. All assessments 
were performed in patient’s GP practice. Usual care (UC) has a decentralized 
organisation structure and patients’ GP is responsible for the diabetes care. 
Clinical outcome measure was risk of a coronary heart disease (CHD) calcu-
lated with the UKDPS risk engine. Cost-effectiveness analysis was performed 
from the societal perspective comparing patients receiving CC (n=313), PC 
(n=293) and UC (n=485) during one year of follow-up. Missing costs and 
effects data were imputed using multiple imputation. Differences in costs, ef-
fects and cost-effectiveness between the diabetes care groups were analysed 
using bootstrapping techniques.
Results: Differences in changes in CHD risk over 12 months of follow-up 
between the three groups were statistically insignificant and clinically irrel-
evant. Compared to UC, health care costs during the follow-up period were 
lower in CC (-1300 (95% CI: -2300 to -570)) and PC (-960 (95% CI: -1890 to 
-100)). Costs from the societal perspective showed the same trend, although 
not statistically significant.
Conclusion: Clinical outcomes did not differ between the different care 
models. Lower health care costs were observed in (partly) centralized care 
compared to usual care, mainly due to substitution of secondary health care 
use by primary health care use. This suggests that centralizing the diabetes 
care results in equal outcomes at lower health care costs.
Clinical Trial Registration Number: ISRCTN66124817.
Supported by: ZonMw and Unive
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The effectiveness of the Diabetes Shared Care Program for  
diabetes-related avoidable hospitalisations in Taiwan: a nationwide 
population-based study
E. Kornelius1,2, C.-N. Huang1,2, J.-Y. Chiou3, Y.-S. Yang1,2, Y.-L. Lu1,2,  
C.-H. Peng4;  
1Department of Endocrinology and Metabolism, Chung Shan Medical 
University Hospital, Taichung, 2Institute of Medicine of Chung-Shan 
Medical University, 3School of Health Policy and Management,  
Institute of Medicine of Chung-Shan Medical University,  
4Institute of Biotechnology, HungKuang University, Taichung, Taiwan.
Background and aims: The Diabetes Shared Care Program was implemented 
in 2001 by Taiwan’s Ministry of Health and Welfare to improve the quality 
of diabetes care. The efficacy of this program is unknown and we aimed to 
evaluate whether Diabetes Shared Care Program participants had lower fre-
quency of avoidable hospitalizations in Taiwan.
Materials and methods: We collected nationally representative data from 
Taiwan’s National Health Insurance Research Database. The dataset com-
prised 120,000 patients who were newly diagnosed with type 2 diabetes in 
1999. The analysis included the patients‘ follow-up data until December 31, 
2011. We designed a case-control study consisting of patients with avoid-
able hospitalizations as cases and selected two age-, gender-, and avoidable 
hospitalization duration-matched controls by risk-set sampling. We further 
compared the hypoglycemia risk between Diabetes Shared Care Program 
participants and non-participants. We used the conditional logistic regres-
sion to estimate the crude and adjusted odds ratio (OR).
Results: A total of 2,377 avoidable hospitalizations cases and 4,754 matched-
controls were identified. After adjusting for potential confounders in the 
stratified analyses, Diabetes Shared Care Program participants had a signifi-
cantly lower frequency of all diabetes-related avoidable hospitalizations (OR, 
0.15; 95% CI 0.13-0.17). A similar trend was found for short-term complica-
tions (OR 0.13; 95% CI 0.08-0.20), long-term complications (OR 0.13; 95% 
CI 0.11-0.16), uncontrolled diabetes (OR 0.21; 95% CI 0.15-0.30), and lower-
extremity amputations (OR 0.06; 95% CI 0.03-0.13).
Conclusion: The Diabetes Shared Care Program decreased the frequency of 
all diabetes-related avoidable hospitalizations in Taiwan.
PS 092 Screening and risk factors  
for gestational diabetes mellitus
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Screening for gestational diabetes mellitus in resource constrained 
settings
V. Mohan1, R. Unnikrishnan1, B. Bhavadharini1, M. Mahalakshmi1,  
K. Maheswari1, G. Kalaiyarasi1, R. Uma2, R.M. Anjana1, M. Deepa1,  
B. Malanda3, A. Belton3, A. Kayal3;  
1Diabetology, Madras Diabetes Research Foundation & Dr. Mohan‘s 
Diabetes Specialities Centre, 2Gynaecology, Seethapathy Clinic, Chennai, 
India, 3International Diabetes Federation, Brussels, Belgium.
Background and aims: The International Association of Diabetes in Preg-
nancy Study Groups (IADPSG) criteria for screening for gestational diabetes 
mellitus (GDM) requires 3 venous samples drawn in the fasting state. This is 
difficult in resource-poor settings for two reasons: women find it difficult to 
come to the clinic in the fasting state and also obtaining three blood samples 
is difficult due to limited resources. We therefore assessed the usefulness of 
a non-fasting capillary blood glucose (CBG) as a preliminary screening test 
to reduce the number of women who would need to be referred for a definite 
diagnostic test done in the fasting state.
Materials and methods: Pregnant women (n=1031) attending antenatal clin-
ics in Tamil Nadu in Southern India underwent a CBG test 2 hours after a 75 
g glucose load administered irrespective of time of last meal (non-fasting). 
Participants were requested to come back within the next 2 to 3 days for a 
fasting OGTT, and both IADPSG and WHO (1999) criteria were used for 
diagnosis of GDM. The optimal sensitivity and specificity of the non-fasting 
2 hour CBG value to identify GDM diagnosed by IADPSG and the WHO 
(1999) criteria were determined.
Results: A non-fasting 2 hour CBG value of 126 mg/dl (6.9 mmol/l) had sen-
sitivity and specificity of 64.6% and 63% respectively to identify GDM diag-
nosed by IADPSG criteria, but 40% of all pregnant women would need to be 
referred for the fasting OGTT. For the WHO 1999 criteria, the CBG cutpoint 
of 144 mg% (7.9 mmol/l) had a sensitivity and specificity of 87.9% and 86.9% 
respectively and only 19.1% of the women would have to be referred for the 
fasting OGTT.
Conclusion: A 2 step screening procedure for GDM using a non-fasting 2 
hour CBG as the initial screening test and use of WHO (1999) criteria would 
help to minimize the number of women who would need to be referred for 
a diagnostic OGTT in the fasting state and thus make screening for GDM 
feasible in resource constrained countries.
Supported by: IDF, Abbott Fund
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Gestational diabetes: what is the impact of the adoption of the criteria of 
IADPSG?
M. Bachaoui1, K. Benharrat1, A. Rahou1, L. Benali1, A. Ouslim2, F. Ayad1,  
S. Aribi1, M. Belhadj1;  
1University Hospital Establishment (EHU), Internal Medecine-Diabetology, 
2University Hospital Center (CHU), Obstetrics and Gynecology, Oran, 
Algeria.
Background and aims: We have always performed a systematic screening for 
gestational diabetes (GDM). The recommendations made in 2010 by the In-
ternational Association of Diabetes and Pregnancy Study Groups (IADPSG) 
give the possibility for each country to choose whether the screening should 
be universal or selective on the basis of risk factors assessment (adjusted ac-
cording to the prevalence of diabetes in the population). We have chosen to 
continue systematic screening. The aim of our study was to assess the level of 
risk in our screened population, and the maternal-fetal morbidity associated 
with GDM depending on the presence or absence of risk factors
Materials and methods: We retrospectively analyzed the data of all pregnant 
women admitted in day-hospital in the service of our hospital between June 
1, 2010 and December 31, 2012 for screening for GDM. We conducted a sys-
tematic screening between 24 and 28 weeks of gestation by OGTT with 75 g 
glucose (IADPSG criteria). We evaluated the frequency of risk-factors: Age ≥ 
35 years, BMI ≥ 25 kg/m2, history of diabetes in first degree relatives, previ-
ous GDM or macrosomic child. We compared the incidence of maternal and 
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fetal complications between the group with risk-factors (RF +) and the group 
without risk-factors (RF -).
Results: Of 1680 women screened, 330 had a GDM, an estimated prevalence 
of 19.6%. Among them 52 (15.8%) showed no RF : average age 28.3 years, 
mean BMI 23.6 kg/m2 ; and 278 (84.2%) had at least one RF : 128 (46%) had 
age ≥ 35 years, 208 (74%) BMI ≥ 25 kg/m2, 139 (50%) a history of GDM, 70 
(25%) a history of macrosomia and 35 (12%), family history of diabetes. The 
maternal-fetal prognosis of the group without RF compared to the one with 
RF only differs in macrosomia: 7.3% vs 15.6% (p <0.05), preeclampsia 0% 
vs 6.2% (NS), preterm (<37 weeks) 16.6% vs 13.2% (NS), cesarean 32.2% vs 
37.6% (p = 0.44), insulin 63% vs 49% (p = 0.19).
Conclusion: Our population has a high prevalence of GDM. It is diagnosed 
in a non-negligible population without RF. There is no significant difference 
in the maternal-fetal morbidity between the groups with and without RF, so 
it seems appropriate to maintain a systematic screening.
1084
National guidelines for gestational diabetes mellitus (GDM) screening in 
Italy: application and effectiveness
E. Lacaria1, C. Lencioni2, M. Romano1, P. Lemmi2, M. Rossi1, L. Russo2,  
S. Del Prato1, A. Bertolotto1, G. Di Cianni2;  
1Department of Endocrinology and Metabolism, Section of Diabetes 
and Metabolic Diseases, University of Pisa, 2Department of Diabetes and 
Metabolic Diseases, Hospital of Livorno ASL 6, Italy.
Background and aims: Universal screening for GDM has been used in Italy 
for over 20 years; since 2012 the National Health Authority recommended 
GDM screening only for women with risk factors. According to these new 
Criteria, screening test (OGTT 75 g 2 hours) is recommended early in preg-
nancy (14-18 week) in women at high risk (HG: previous GDM; pre-preg-
nancy BMI ≥30 kg/m2, glucose value at 1st visit between 100-125 mg/d.) and 
later in pregnancy (24-28 week) in women at medium risk (MR: pre-preg-
nancy BMI ≥25 and <30 kg/m2, age ≥35 years, previous macrosomia; posi-
tive family history of diabetes), while women at low risk (LR: no risk factors) 
are excluded from screening. The aim of the present study was to evaluate 
whether the new national guidelines (NGL), are correctly applied and the 
effectiveness of GDM diagnosis according to risk factor profile.
Materials and methods: We collected a cohort of 2552 Caucasian pregnant 
women (age 33±5 years; family history of diabetes 18.2%; pre-pregnancy BMI 
22.8±4 kg/m2) consecutively screened for GDM according to NGL. For each 
category we recorded timing of screening test and prevalence of GDM. Final-
ly, we compared GDM prevalence in this cohort with that one recorded in a 
historical cohort (years 2001-2003) of 3950 women with universal screening, 
this population being comparable with the most recent one (age 31±5 yrs, 
family history of diabetes 18.1%; pre-pregancy BMI 22.5±3.7 kg/m2).
Results: Out of 98 LR women (3.8% of total), 2 (1.6%) underwent OGTT 
at early stage and the remaining 96 (98.4%) in the late period. MR women 
(n 2193) accounted for 86% and a late screening was performed in almost 
all cases (98.4%). The remaining 10.2% (n 261) included HR women who 
underwent early screening in only 7% of cases with 93% of them screened in 
the late period. GDM was diagnosed in 279 cases with a prevalence of 10.9%, 
i.e. 25.3% higher than previously reported in our population (8.7%; P=0.003). 
Based on risk factory categories, GDM prevalence increased from 4.7% in LR, 
to 13.7% in MR women, and 29.8% in HR.
Conclusion: Our data show that the NGL recommendations are still poorly 
applied. Contrary to what recommended only a minority of HR women per-
form the screening test early in pregnancy, in spite of a 30% prevalence of 
GDM. Action has to be taken to improve application of new recommenda-
tions.
1085
Experiences of the providing for pregnancies complicated with IADPSG 
criteria
A. Kun1, J. Tornoczky2, L. Muth3, Z. Kerenyi4,5, A.G. Tabak6,7;  
1Department Obstetrics and Gynecology, Tolna County Balassa Janos 
Hospital, Szekszard, Hungary, 2Diabetes Care Outpatient Unit,  
33rd Department Internal Medicine, Tolna County Balassa Janos Hospital, 
Szekszard, 4Diabetology, Tóth Ilona Health Service, 5National Centre for 
Diabetes Care, Semmelweis University, 61st. Department of Medicine, 
Semmelweis University, Budapest, Hungary, 7Department of Epidemiology 
and Public Health, University College London, UK.
Background and aims: Based on the results of the HAPO study IADPSG rec-
ommended in 2010 new criteria for diagnosing gestational diabetes (GDM). 
To our knowledge the new criteria might significantly increase prevalence 
of GDM. The aim of our study was to determine the result of the care of our 
IADPSG-GDM patients.
Materials and methods: Continuing the universal screening between 15th 
January 2009 and 15th March 2013 in the West Hungarian Region (Szek-
szárd district) a three-points 75 g OGTT (fasting, 60- and 120 min blood 
glucose values) were performed in 4658 pregnant women (age: 29.64±5.55 
yrs; mean±SD;). GDM was diagnosed using new IADPSG criteria, too.
Results: 388 (WHO, 9.08 %) and 699 (IADPSG, 15.00%) resp., GDM cases 
were found. Women in both GDM groups - compared to healthy counter-
parts - were older (31.40±5.19 vs. 29.51±5.47 yrs [WHO]; 31.14±5.13 vs. 
29.35±5.49 yrs [IADPSG];), had sygnificantly higher systolic blood pressure 
(121.38±9.66 vs. 119.17±9.33 mmHg; [WHO]; 121.62±9.61 vs. 118.92±9.26 
mmHg [IADPSG];). All-risk-scores of both GDM groups were significantly 
higher than that in the healthy women. According to both criteria 254 women 
had GDM. Using IADPSG criteria 104 WHO-GDM cases were lost, 435 new 
cases were found. There was no difference in the frequency of Caesarean sec-
tion between healthy women and both GDM groups. Analysing data of 4900 
newborn babies (71 twin pairs) no differences in the frequency of intrauter-
ine death and congenital malformations between any groups could be prov-
en. Babies born to IADPSG-GDM mothers had a bigger mean birth weight 
than newborn babies of healthy women (3413±548 vs. 3327±505 g) while 
no differences were found by babies of WHO-GDM mothers (3340±537 
vs.3340±511 g). The authors formed within IADPSG-GDM group treated 
/n:289/ (diet or diet and insulin) and untreated /n:409/ subgroup. The date 
in treated subgroup of IADPSG-GDM were: age: 32.02±4.76 yrs, weight gain: 
10.28±5.54 kg birth weight: 3331±531. vs. the date in untreated subgroup of 
IADPSG-GDM were: age: 30.52±5.30 yrs. weight gain: 13.18±5.43 kg birth 
weight: 3470±554 kg.
Conclusion: Analysing results of a universal screening using IADPSG cri-
teria frequency of GDM probably doubles. In IADPSG-GDM the adverses 
pregnancy outcomes be prevented by complexes pregnancy care.
1086
Age at menarche: a new risk factor for GDM?
E. Anastasiou, A. Papadimitriou, M. Zairi, A. Angelopoulou, V. Vasileiou, 
E. Zapanti, M. Alevizaki;  
Diabetes Center, 1st Endocrine Section, Alexandra Hospital, Athens, Greece.
Background and aims: Earlier age at menarche has been associated with in-
creased risk of type 2 diabetes (DM2) and obesity. As DM2 shares several 
common risk factors with Gestational Diabetes Mellitus (GDM), the aim of 
this study was to examine whether there is an association between age at me-
narche and GDM risk in a large cohort of pregnant women.
Materials and methods: Over a period of 10 years, at a tertiary hospital, 5390 
pregnant women without known DM underwent a 100g OGTT in the third 
trimester of pregnancy. For GDM diagnosis the Carpenter and Coustan cri-
teria were applied. Age, pre-pregnancy BMI, family history of DM2, parity, 
education status, smoking and age at menarche were recorded. For statistical 
analysis x2, t-test were used; odds ratios (OR-95%CI) were calculated and 
stepwise logistic regression model was applied.
Results: GDM (n=2452) women presented with lower age at menarche com-
pared to Normal (n=2938) pregnant women (12.9 ± 1.5 vs 13.1±1.6 years, 
p<0.001). Women with age at menarche equal to or more than 12 years were 
found to have a reduced risk of GDM (OR = 0.84 [95%CI = 0.76-0.94], com-
pared to those with age at menarche less than 12 years. They also had lower 
BMI (25.1 ± 5.0 vs 26.4 ± 5.9 kg/m2, p<0.001). Further the prevalence of obe-
sity (BMI>30 kg/m2) was significantly lower in this group (14.1% vs 21.7%, 
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p<0.001). The odds ratio for a woman with menarche age <12 years to be 
obese was 1.7 [95%CI=1.5-1.9]. Additionally, the presence of a family history 
(FH) of DM2 was associated with earlier age at menarche (12.7 ± 1.5 vs 13.2 
± 1.6 years, p<0.001). The OR for age at menarche <12 years to have FH of 
DM2 was 1.4 [95%CI = 1.2-1.5]. Subsequently, a stepwise logistic regression 
model was applied where GDM was a dependent variable, and independent 
predictors were: age at menarche <12y, age>25y, positive FH of DM2 and 
BMI>30 kg/m2. The age at menarche remained an independent predictor of 
GDM when age and FH of DM2 were included in the model, but lost its sig-
nificance when BMI was added in the model.
Conclusion: We showed that early age at menarche increases the risk of 
GDM, a finding which has not been reported. This association may be ex-
plained by the effect of obesity on both conditions, namely early menarche 
and GDM.
1087
Drinking alcohol before pregnancy induces the abnormal foetus 
development through oxidative stress-mediated metabolic disorders in 
maternal liver and pancreas 
D.-Y. Lee, Y.-J. Lee, J.-Y. Kim, E.-A. Jeong, K.-J. Park, G.-H. Kim,  
W.-H. Kim;  
Korea National Institute of Health, Cheongwon-gun, Chungbuk,  
Republic of Korea.
Background and aims: Alcohol drinking during pregnancy poses serious 
health risks to the unborn child such as prematurity, low or high birthweight, 
fetal death and fetal alcohol syndrome. However, the effects of maternal etha-
nol consumption before pregnancy on the abnormal development of fetus 
and the association with the impaired glucose tolerance of mother are not 
fully understood.
Materials and methods: To this, the 6-week C57BL/6J female mice were fed 
with 5% ethanol-containing liquid diet for 2 weeks before pregnancy and ex-
amined the effects of ethanol pre-exposure on fetal development during a 
subsequent pregnancy.
Results: Here, we found that pregnancy or fertility rates were decreased in 
ethanol-fed mice, correlated with the delaying of eye formation and the for-
mation of defective toe. Also, birth weight in postnatal 0 day (P0) of etha-
nol-fed mice was higher than those of pair-fed mice, but thereafter, in P14 
and P21, growth retardation appeared in the child of ethanol-fed mice. The 
macrosomia phenomenon in ethanol-fed mice is strongly associated with the 
dysregulation of glucose metabolism and triglyceride accumulation in ma-
ternal liver during the pregnancy. Gut-derived serotonin (GDS) as well as 
hepatic inflammatory chemokines and cytokines are also markedly increased 
in ethanol-fed mice, subsequently followed by the alteration of glucose me-
tabolism in the liver and pancreatic β-cells. Alcohol intake changed the ex-
pression of GDS-response receptors from Gs-GPCR to Gi or Gq-GPCR. The 
detrimental fetal development and impaired glucose metabolism by maternal 
pre-exposure to ethanol are strongly attenuated by the injection of 4-methyl-
prazol, an inhibitor of CYP2E1.
Conclusion: Taken together, our results suggest that ethanol consumption 
before pregnancy is a major causing factor for the detrimental fetus devel-
opment via maternal metabolic disorders, especially on the dysregulation of 
glucose or insulin metabolism in maternal liver and pancreatic β-cells.
Supported by: KNIH 2012-NG63002-00
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Adverse foetal outcomes in women at risk of gestational diabetes with 
normal OGTT: exploring the role of HbA1c in risk prediction
A.U. Nayak1, C.J. Duff2, R. Indusekhar1, L. Varadhan1;  
1Combined Antenatal Diabetes Clinic, 2Clinical Biochemistry, University 
Hospital of North Staffordshire NHS Trust, Stoke on Trent, UK.
Background and aims: Screening for gestational diabetes (GDM) is cur-
rently based on performing oral glucose tolerance test (OGTT) in pregnant 
women with various risk factors such as high body mass index, ethnicity and 
previous macrosomia. Women who get diagnosed with GDM with a positive 
OGTT benefit from targeted antenatal care towards improving pregnancy 
outcomes. However pregnancy outcomes in those women at high risk for 
GDM but normal glucose tolerance at screening are not well documented. 
The aim of our study was to compare the fetal complication profile in women 
confirmed to have gestational diabetes (GDM) with women at risk of GDM 
but normal OGTT and explore the potential utility of HbA1c in predicting 
such fetal outcomes.
Materials and methods: The records of 40,943 deliveries performed at the 
regional maternity hospital over a 7 year period (2006 - 2013) were identified 
and reviewed. Women with pre-existing diabetes (type 1 or type 2) were ex-
cluded (n=203, 0.5%). Based on active identification of risk factors for GDM, 
OGTT was performed at around 28 week gestation (n=8,542). HbA1c was 
performed simultaneously with the OGTT in line with the hospital policy. 
Women were categorized into (1) Low risk (i.e. those not screened for GDM 
with OGTT/HbA1c) (n=32,198), (2) High risk with negative OGTT and 
HbA1c <42 mmol/mol (n=7,420), (3) High risk with negative OGTT and 
HbA1c ≥ 42 mmol/mol (n=157) and (4) confirmed GDM (n=965).
Results: Women in high risk category with normal OGTT, especially those 
with HbA1c ≥ 42, had statistically significant (P<0.001) and worst fetal out-
comes (table 1). On logistic regression, the risk of fetal macrosomia was sig-
nificantly higher in category 2 [OR 1.95 (1.57-2.42), P<0.001] and category 3 
[OR 3.7 (1.53-9.35), P=0.004], whilst for women with GDM it was a similar 
risk to that for women in low risk category. The risk of preterm delivery and 
still birth was also significantly higher in category 3 [OR 1.63 (1.02-2.61), P 
=0.041 and OR 4.87 (1.78-13.29), P=0.002 respectively] compared to the low 
risk group. The GDM group interestingly fared very similar to the low risk 
group, which could be largely attributed to the active intervention and follow 
up provided once diagnoses is established.
Conclusion: Women with risk factors for GDM but a negative OGTT, appear 
to be a high risk cohort for adverse fetal outcomes especially fetal macroso-
mia. A small but significant sub-cohort of these high risk women (1.8%) with 
elevated HbA1c could be at a further risk of pre-term delivery and still birth. 
HbA1c could potentially help in risk stratification of high risk women with 
negative OGTT. Such women may need risk reduction intervention includ-
ing diet and life style measures in line with what is already offered for GDM.
1089
Beta cell death is not increased in pregnant women with gestational 
diabetes mellitus
E.M. Akirav, L.M. Kenna, M.S. Radin;  
Biomedical Research, Winthrop University Hospital, Mineola, USA.
Background and aims: Gestational diabetes mellitus (GDM) affects approxi-
mately 7% of all pregnancies in the United States. Although it is believed that 
insulin resistance and reduced β-cell function are the underlying causes of 
GDM development, changes in β-cell mass during GDM remain largely un-
known. We have previously developed a novel biomarker assay for the detec-
tion of β-cell death in type 1 diabetes by measuring the levels of β-cell derived 
demethylated insulin DNA in the blood. This study is designed to evaluate 
the levels of β-cell death in normal subjects and in patients with gestational 
diabetes mellitus.
Materials and methods: Serum samples from women with gestational diabe-
tes mellitus (GDM) were compared with samples from women with normal 
pregnancy (PRG), women at postpartum (PP), and non-pregnant (NP) wom-
en. Samples were analyzed for β-cell derived DNA as a biomarker of β-cell 
death. Postprandial glucose, insulin and c-peptide levels were also measured.
Results: Women with GDM showed higher glucose levels when compared 
with PRG (PRG=105.9±7.24 vs. GDM=201.7±6.96 mg/dL, p<0.0001). Sur-
prisingly, β-cell derived insulin DNA levels were lower in GDM when com-
pared with PRG and NP groups (Demethylation index: PRG=0.19±0.09, 
GDM=0.009±0.0009, PP=1.06±0.78, and NP=0.05±0.047; GDM vs. PRG 
p=0.0175 and GDM vs. NP p=0.0132). This decrease in β-cell death was 
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associated with reduced insulin (PRG=18.69±2.22, GDM=4.05±2.34, 
PP=8.11±3.56, and NP=3.78±2.04 μU/mL; ANOVA p=0.0005, PRG vs. 
GDM p=0.01, PRG vs. PP p=0.05, PRG vs. NP p=0.01) and c-peptide 
(PRG=3.36±0.64, GDM=0.24±0.10, PP=2.01±0.74, and NP=1.66±0.44 ng/
mL; ANOVA p=0.0042, PRG vs. GDM p=0.01) levels.
Conclusion: This study shows, for the first time, lower β-cell death in women 
with GDM, suggesting that β-cell death is not a main contributor to the de-
velopment of GDM.
1090
Genetic variants associated with type 2 diabetes and obesity better 
predict gestational diabetes than traditional risk factors
J. Hryniewicka1, M. Zbucka-Kretowska2, N. Wawrusiewicz-Kurylonek3,  
W. Bauer3,4, M. Szamatowicz1, B. Telejko3, M. Kuzmicki1, J. Szamatowicz1,  
M. Gorska3, A. Kretowski3,4;  
1Department of Gynecology,  
2Department of Reproduction and Gynecological Endocrinology,  
3Department of Endocrinology, Diabetology and Internal Medicine,  
4Centre for Clinical Research, Medical University of Bialystok, Poland.
Background and aims: There is increasing evidence that gestational diabetes 
(GDM) shares genetic risk with type 2 diabetes (T2DM) and that 50 % of 
women with prior GDM develop T2DM in the next few years. Recent meta-
analyses have shown that T2DM risk variants may be associated with GDM 
through different mechanisms, including impaired β-cell function (CD-
KAL1, IGF2BP2, KCNQ1, KCNJ11, MTNR1B), insulin resistance (TCF7L2), 
and abnormal glucose utilization (GCK). So, in the present study we evalu-
ated the risk of GDM development associated with genetic variants increas-
ing the susceptibility for obesity and T2DM.
Materials and methods: Four hundred and seventy four pregnant women, 
including 103 diagnosed as having GDM according to the JADPSG criteria 
and 371 controls with normal glucose tolerance, were genotyped for 65 SNPs, 
identified in genome wide-associated studies as risk variants for T2DM and 
obesity.
Results: On the basis of genotype case-control differences we found an as-
sociation between GDM and four obesity gene variants (BAT2 [rs2260000] 
- OR=2.07 [1.05-4.1], p=0.03; MTCH2 [rs10838738] - OR=1.97 [1.002-
3.88], p=0.045; FAIM2 [rs7138803] - OR=1.95 [1.15-3.34], p=0.012; CRY2 
[rs11605924] - OR=0.56 [0.34-0.92], p=0.021), and three T2DM risk variants 
(TCF7L2 [rs7901695] - OR=1.67 [1.16-2.4], p=0.03; SLC30A8 [rs11558471] - 
OR=1.67 [1.16-2.4], p=0.007; CDKAL1 [rs10946398] - OR=1.62 [1.02-2.56], 
p=0.036). In logistic regression model comprising all studied SNPs, adjusted 
for relevant clinical data, GDM was significantly predicted by BMI before 
index pregnancy (OR=1.15 [1.07-1.23], p=5.2x10-5) and 4 studied SNPs: 
CDKAL1 (rs10946398) - OR=1.67 (1.02-2.1), p=0.04; GCK (rs4607517) - 
OR=2.64 (1.31-5.3), p=0.007; ADRA2A (rs10885122) - OR=2.88 (1.36-6.1), 
p=0.003 and KCTD15 (rs29941) - OR=2.17 (1.2-3.9), p=0.007.
Conclusion: Our results suggest that genetic variants associated with T2DM 
and obesity better predict GDM than the patient’s age, the history of previous 
births and BMI before pregnancy. The mechanisms related to GDM risk seem 
complex and comprise the effect of numerous genes involved in insulin secre-
tion/function and glucose homeostasis.
Supported by: Grant No. N N407 141937 from the State Committee for Scien-
tific Research
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MTNR1B genetic variability is associated with gestational diabetes in 
Czech women
D. Vejrazkova1, P. Lukasova1, M. Vankova1, O. Bradnova1, J. Vcelak1,  
V. Cirmanova1, K. Andelova2, H. Krejci3, B. Bendlova1;  
1Institute of Endocrinology, 2Department of Mother and Child Care, 
3Department of Obstetrics and Gynecology, 1st Faculty of Medicine,  
Charles University and General University Hospital in Prague, Prague, 
Czech Republic.
Background and aims: The gene MTNR1B encodes a receptor for melatonin, 
the main regulator of sleep cycle and circadian rhythm. Melatonin receptors 
are expressed in the brain and also in human pancreatic β-cells. This find-
ing implies that genetic variants in the gene might affect glucose tolerance. 
Meta-analysis confirmed that rs10830963 shows the most robust association. 
The aim of our study was to assess and compare the SNP rs10830963 in the 
Czech GDM patients and in control normoglycemic women without history 
of GDM. We also aimed to study relations between the risk confering allele 
G of the SNP and biochemical as wel as anthropometric characteristics in 
both groups.
Materials and methods: Our cohort of subjects consisted of 880 women, 458 
of them were diagnosed with GDM (age 34,0±6,12 years; BMI 24,3±4,93 kg/
m2) and they met the 0.5-1.5 year interval after the childbirth. 422 were nor-
moglycemic control women without history of GDM (age 34,8±15,09 years; 
BMI 23,7±4,18 kg/m2). We evaluated broad biochemical (3-hour oGTT, lipid 
profile, thyroid and steroid hormones, liver enzymes) and anthropometric 
(BMI, WHR, waist circumference, fat distribution, total body fat content) 
parameters in all participants. We used the ABI TaqMan SNP Genotyping 
Assays to genotype for rs10830963. Statistical analysis was conducted using 
the NCSS 2004 software.
Results: In accordance with available literature data, the risk allele G was in 
our study significantly more frequent in the GDM group (38.3 % vs 29.4 % 
in controls, test power 0.96; OR 1.49 CI 95% [1.22; 1.82] pOR=0.0001). De-
spite of higher frequency, the G allele in the GDM group was not associated 
with any markers of glucose metabolism nor with anthropometric data. In 
contrast, controls showed significant association of the allele G with fasting 
plasma glucose (median 4.95 mmol/l in GG genotype vs. 4.60 mmol/l in CG 
as well as in CC genotypes; p=0.002 and p<0.001, resp.) and also with postch-
allenge levels of glycemia during the 30., 60., and 90. min. of the oGTT. Fast-
ing insulinemia was in controls similar across the genotypes, nevertheless, 
postchallenge insulin levels were higher in GG homozygotes compared with 
CC genotype in 90. and 180. min of oGTT, the same results were observed 
in C-peptide concentrations. Consequently, Cederholm index of insulin sen-
sitivity and HOMAF index were higher in CC homozygotes in comparison 
with risk GG genotype (p=0.02 and p=0.05, resp.).
Conclusion: Significantly higher frequency of the risk confering allele G in 
GDM group indicates that MTNR1B SNP rs10830963 is involved in gesta-
tional diabetes mellitus in Czech women. However, the association of the 
SNP with glucose metabolism, which is obvious in healthy control group of 
women, disappears completely in women of similar age and BMI who have 
experienced GDM.
Supported by: IGA MH CR NT/13544-4, IGA MH CR NT/13543-4, MH CR 
00023761
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Gestational diabetes mellitus and health care cost: short- and long-term 
association
A. Danyliv1,2, P. Gillespie1, C. O‘Neill1, F. Dunne2,3,  
ATLANTIC DIP (Diabetes in Pregnancy) Research Team;  
1School of Business and Economics, 2School of Medicine, Clinical Sciences 
Institute, 3Galway Diabetes Research Centre, National University of Ireland 
Galway, Ireland.
Background and aims: There is an extensive body of literature showing that 
gestational diabetes mellitus (GDM) diagnosed on WHO criteria is associ-
ated with maternal, ante- and neonatal complications. Yet, little is known 
about the health care cost associated with GDM beyond the period immedi-
ately after the delivery and maternity care cost associated with GDM on the 
International Association of Diabetes and Pregnancy Study Group (IADPSG) 
criteria. In this paper, we assess the association of the GDM diagnosis on the 
IADPSG criteria with the health resource utilization during maternity care 
and in longer term, two to five years after the index pregnancy.
Materials and methods: Maternity care utilization was measured for a sam-
ple of 658 women drawn from the Atlantic Diabetes in Pregnancy (ATLAN-
TIC DIP) collaborative network who have had pregnancy two to five years 
previously. Annual health care utilization two to five years after the index 
pregnancy was assessed for a sub-sample of 348 women who returned a 
follow-up questionnaire. Irish cost weights were applied to the health care 
resource utilization to assess the cost of care. The difference in resource utili-
zation and cost between women with GDM and normal glucose tolerance in 
the index pregnancy was assessed in a series of uni-variate and multivariate 
analyses.
Results: The independent effect of GDM is approximately additional € 817.6 
to the maternity cost and additional € 680.5 to the annual health care cost 
two to five years after the delivery. However, at the group/population level the 
effect might be higher due to inherent background differences of the women 
with GDM and NGT, especially worse body mass indicators. The excess in 
the maternity care cost is caused by higher likelihood of caesarean section 
and neonatal unit admissions in women with GDM. For the follow-up health 
care cost, most of the excess is related to higher chances of hospitalizations 
and outpatient unit visits not related directly to diabetes care. Diabetes care 
(diabetes nurse, dietitian, diabetes day centre, insulin and oral glucose agents, 
and blood sugar tests) constitutes smaller but still substantial part of the cost 
increase.
Conclusion: Thus, our results suggest that GDM on IADPSG criteria is as-
sociated with increased cost of maternity care and health care two to five 
years after the index pregnancy. This excess is not so much caused by the 
glucose tolerance treatment and monitoring routines as by more intensive use 
of hospital services, indicating worse health status of GDM women. Hence, 
this diagnosis objectively represents a serious condition altering health care 
cost around and beyond pregnancy. These findings provide information for 
further cost-effectiveness studies of the programs of GDM screening, treat-
ment and monitoring in Irish setting.
Supported by: HRB of Ireland, GA No. ICE/2011/3
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The effect of professional continuous glucose monitoring on glycaemic 
control and hypoglycaemia in insulin-requiring gestational diabetes 
mellitus
S.S. Paramasivam1, A.T.B. Tan1, S.P. Chan1, P.C. Tan2, S.Z. Omar2,  
J. Ratnasingam1, L. Ibrahim1, L.L. Lim1, R.A. Razak1, F.Z.M. Shah1,  
S.R. Vethakkan1;  
1Endocrinology, 2Obstetrics and Gynaecology, University of Malaya,  
Kuala Lumpur, Malaysia.
Background and aims: Reducing hyperglycemia in gestational diabetes 
mellitus(GDM)improves pregnancy outcomes and reduces perinatal morbid-
ity. Continuous Glucose Monitoring (CGM) is ideal for monitoring glucose 
levels where tight glycemic control without hypoglycaemia is required for a 
short period of time. While CGM is known to improve glycemic control/
pregnancy outcomes in women with pre-gestational diabetes the same has 
not been established in GDM. Aims: To determine if professional CGM im-
proves glycemic control with less hypoglycaemia in insulin-requiring GDM.
Materials and methods: In this prospective, open-label trial 24 women with 
insulin requiring GDM, gestation<28weeks, were randomized to 2 groups. 
Group 1(CGM) (n=11) underwent CGM using the iPro2 Enlite 6-day sensor 
at 28, 32 and 36 weeks gestation while Group 2( control) did not. All patients 
performed 7 point fingerstick glucose profiles 3x/week, recorded hypoglyce-
mic events( symptoms without glucose readings or fingerstick fasting glu-
cose<3.5/nonfasting glucose<4.0 mmol/L) and were reviewed at 1-2 weeks 
intervals. In group 1, both CGM and fingerstick data were used to manage 
diabetes while women in group 2 were managed based on fingerstick data 
alone. HbA1c was measured at weeks 28,33 and 37. Euglycemia on CGM was 
defined as 3.5-6.7mmol/L.
Results: There were no significant differences in mean age, prepregnan-
cy BMI, HbA1c and total insulin dose between groups at baseline. In the 
control group, mean HbA1c rose significantly from week 28( 5.31±0.52%) 
to 33(5.42±0.56%) to 37(5.6±0.63%), while HbA1c in the CGM group did 
not change significantly from week 28(5.06±0.3%) to 33(4.95±0.34%) and 
37(5.01±0.35%). HbA1c was significantly higher in controls compared with 
CGM at 33 and 37 weeks gestation. In the CGM group, 100% of patients at 37 
weeks had HbA1c<5.6% compared to only 46.2% in controls(p=0.006). There 
was also a significant difference in mean change in HbA1c from 28 weeks 
to 37 weeks between the 2 groups(CGM -0.05%, control +0.29%, p=0.017). 
Mean time spent in euglycemia in the CGM group increased from the 1st to 
the 3rd CGMS at week 28 and 36 respectively(79.18±10.01% to 85.00±7.69%, 
p=NS) and mean time spent in hyperglycemia decreased(18.82±10.73% to 
11.55±7.07%, p=NS). There was however an increase in mean time spent in 
hypoglycemia(2.00±2.83% to 3.45±3.78%, p=NS). 63.6% of patients in the 
CGM group(7/11) showed increased frequency of hypoglycemia from 28 
weeks to 37 weeks compared to 30.8%(4/13) in the control group. The CGM 
group showed a significant increase in mean total insulin dose at 37 weeks 
compared to controls(52.91±27.92 vs 33.92±14.98 units, p<0.05). Mean birth 
weight in the CGM group was lower compared to controls (2851.8±323.3 vs 
3065.8 ±464.0 g, p=NS).
Conclusion: Glycemic control in the women who underwent CGM was 
significantly better compared to women who received usual antenatal care 
based on fingerstick glucose alone. Use of CGM however, was associated with 
an increase in hypoglycemic events explained perhaps by the concomitant 
increase in total insulin received as a result of greater awareness of hypergly-
cemia by the managing team.
Supported by: ERG
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Gestational diabetes mellitus: the first prospective randomised study of 
metformine-glyburide vs insulin
J.-L. Ardilouze1,2, J. Ménard2, P. Perron1,2, G. Houde1,2, J.-M. Moutquin3,2, 
M.-F. Hivert1,4, J.-P. Baillargeon1,2;  
1Department of Medicine, 2Centre de Recherche du Centre Hospitalier 
Universitaire de Sherbrooke, 3Department of Obstetrics and Gynecology, 
University of Sherbrooke, Canada, 4Harvard Pilgrim Health Care Institute, 
Department of Population Medicine, Boston, USA.
Background and aims: Oral hypoglycemic agents (metformin - Met - and 
glyburide - Gly) have been used separately to treat gestational diabetes mel-
litus (GDM), with various failure rates imposing insulin therapy. Because 
GDM is mostly the consequence of insulin resistance and beta-cell deficiency, 
we reasoned that a combination of both drugs (Met-Gly) might efficiently 
treat women with GDM and may decrease the failure rate. For ethical and 
safety considerations, only half-maximal dosages were prescribed as per 
Health Canada suggestions. Here, we assessed maternal glycemic control 
(GC) and neonatal issues.
Materials and methods: We performed a randomized controlled study com-
paring a Met-Gly combination of half-maximal doses (Met 1250 mg/day, Gly 
10 mg/day, with an incremental increase in dosages) to intensive insulin ther-
apy (aspart/lispro and N/NPH) in women with GDM who did not achieve 
Canadian Diabetes Association treatment goals under diet (±exercise as in-
dicated) therapy (capillary fasting glucose value < 5.3 mmol/L and 2-hr post-
prandial glucose value < 6.7 mmol/L). GC was defined as the 2-week mean 
of capillary glucose values (fasting and 2 hours after each 3 meals) measured 
daily (mean of 14 values for each recording time point).
Results: Treatments started at 29.3±3.8/30.1±3.1 weeks of gestation, respec-
tively, in the Met-Gly (n=35) and the insulin (n=33) groups, while there 
was no difference between groups in age (31.1±4.7/30.7±4.4 yrs), weight 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 450 
1 C
(85.3±17.5/85.3±22.9 kg), BMI (32.0±5.4/32.2±7.2 kg/m2) and GC record-
ed during the previous 2 weeks: fasting glucose value was 5.3±0.7/5.3±0.6; 
postprandial glucose values were: 6.3±0.8/6.3±0.7, 6.6±0.8/6.4±0.6 and 
6.8±0.8/6.8±0.9 mmol/L, respectively post breakfast, lunch and supper. At 
delivery, in the Met-Gly group, 8 women were taking Met only (844±265 mg 
daily), 14 were taking Met (1179±153 mg) and Gly (3.9±1.9 mg), 10 were 
on Met-Gly+insulin (1333±250 mg, 8.6±2.2 mg and 12.7±9.9 units) and 3 
were on insulin alone. In the 13 women taking insulin (37%), injections were 
started 4.2±2.1 weeks after initiation of Met-Gly treatment. There was no dif-
ference in insulin doses between women taking insulin alone in the Met-Gly 
group and women in the insulin group: breakfast: 7.0±4.2/11.3±9.0, lunch: 
8.5±4.9/9.6±8.1, supper: 11.0±4.2/10.3±6.8, bedtime: 11.0±7.1/18.7±15.1 
units. During the 2 weeks prior to delivery, no difference was observed in 
GC between groups (fasting: 4.7±0.3/4.8±0.3; postprandial 5.8±0.4/5.9±0.5; 
5.8±0.5/5.9±0.5; 6.0±0.5/6.1±0.5 mmol/L). At delivery, we found no dif-
ference in the number of caesarean sections (9/8), neonatal’ birth weight 
(3360±389/3227±570 g), gestational age (38.7±1.1/38.4±1.5 weeks) or neo-
natal hypoglycemias (21/15).
Conclusion: Our data suggest that a majority of women with GDM could 
benefit from hypoglycemic agents: a combination of mild doses of Met-Gly 
successfully controlled GC in >60% women with GDM, with neonatal out-
comes that are comparable to those of neonates born to women with GDM 
on insulin therapy.
Clinical Trial Registration Number: NCT01215331
Supported by: FRQS
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Metformin in gestational diabetes and fasting glucose as a predictor of 
treatment failure
M.O. Khin1, S. Gates2, P. Saravanan1,3;  
1Division of Metabolic and Vascular Health, 2Clinical Trial Unit, Warwick 
Medical School, University of Warwick, Coventry, 3Department of Diabetes 
& Endocrinology, George Eliot Hospital, Nuneaton, UK.
Background and aims: Gestational Diabetes (GDM) is common and affects 
up to 18% of pregnancy. Proper glycaemic control is the key to the reduction 
of GDM-related maternal and neonatal morbidity and mortality. The current 
guidelines suggest insulin or metformin only after dietary failure. Almost 
half of metformin-treated GDM need supplementary insulin. Identifying 
the characteristics of women who fail metformin may help to define optimal 
therapeutic strategy in GDM.
Materials and methods: This was a historical cohort of GDM in a District 
General Hospital, UK between 2009 and 2012. GDM was diagnosed by 75 g 
OGTT test between 24-28 weeks of gestation with fasting level ≥6.1 mmol/l 
and/or 2-hour post-prandial(PP) level ≥ 7.8 mmol/l. Treatment targets were: 
pre-meals 4-5.5 and 1-hour post meals < 7.8 mmol/l. The treatment was es-
calated if 2-3 readings per week were above target. Daily metformin dose was 
500-2000 mg. Non-parametric tests were applied appropriately to compare 
the treatment groups. Logistic regression and receiver operator curve (ROC) 
were performed to identify the predictors of metformin failure.
Results: Of the 299 being diagnosed and treated, complete treatment data 
were available in 228. Out of 228, 31(14%) were diet(D) alone, 141(62%) 
were on metformin(M) and 46(15%) on insulin(I) until delivery. 10 stopped 
metformin for gastrointestinal intolerance and were excluded from analy-
sis. Compared to D group, despite older age(29 vs 32 years, p<0.05), great-
er BMI(27.45 vs 31.5, p<0.01), higher fasting(4.5 vs 4.9 mmol/l,p<0.01) & 
PP(8.1 vs 8.5 mmol/l, p<0.05) and earlier gestational age(GA) at OGTT 
(30+3vs 26+4 weeks, p<0.001) in M group, the outcomes(birth weight, Apgar 
scores at 1 and 5 minutes, caesarean section, shoulder dystocia and NICU ad-
mission rates) were similar, but borderline higher average HbA1c(5.35 vs 5.5 
%, p=0.05) and earlier GA at delivery (39 vs 38+2weeks, p<0.01) in M group. 
The maternal characters between M and I groups had no significant differ-
ence, and M group had lower average HbA1c (5.7 vs 5.5%, p<0.05) and all 
other outcomes were similar. 57% (80/141) of the metformin-treated GDM 
needed insulin. Both metformin success(M alone) and failure(M+I) groups 
had similar post-treatment HbA1c (5.45 vs 5.5%, p=0.38). The failure group 
had higher maternal age (30 vs 32 years, p<0.05) and fasting level at OGTT 
(4.6 vs 5.2 mmol/l, p<0.001) and lower GA at dietary failure (29+2 vs 27+6 
weeks, p<0.01). Metformin failure was predicted if fasting OGTT level > 4.8 
mmol/l (69%sensitivity, 63%specificity). If the fasting level of IADPSG (Inter-
national Association of Diabetes and Pregnancy Study Groups) criteria (≥5.1 
mmol/l) was used, the positive predictive value was 79%. Premature delivery 
(<37weeks) were higher in the failure group (OR 12.6; 95% CI 1.6, 99.8).
Conclusion: Metformin can be a better alternative than insulin for optimal 
glycaemic control in GDM. As metformin can benefit greater than diet alone, 
metformin should be initiated early at the diagnosis of GDM, based on fast-
ing glucose at diagnosis. It is also important to consider adding basal insulin 
at initiation of metformin or alternative treatment option for the GDM iden-
tified by IADPSG fasting criteria for optimal treatment strategy.
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Type 2 diabetes mellitus genetic risk variant T in TCF7L2 rs 7903146  
in women is associated with an increased probability of insulin therapy 
in gestational diabetes mellitus
L. Potasso1, N. Perakakis1, A. Lamprinou2, E. Polyzou3, D. Kassanos3,  
A. Peter2, R. Rasenack4, G. Päth1, J. Seufert1, K. Laubner1;  
1Internal medicine II, Uniklinik Freiburg, ,  
2Clin. medicine IV, Uniklinik Tübingen, Germany, 3Obstetrics and 
Gynaecology, University Hospital of Attikon, Athens, Greece,  
4Gynaecology and Obstetrics, Uniklinik Freiburg, Germany.
Background and aims: Single nucleotide polymorphisms (SNPs) within the 
transcription factor 7-like 2 (TCF7L2) gene are well known risk variants for 
type 2 diabetes mellitus (T2DM). The rs7903146 SNP is involved in glucose- 
and incretin-induced insulin secretion and in proinsulin conversion. The aim 
of this international multicentric analysis was to assess and compare the ef-
fect of the TCF7L2 rs7903146 T risk variant on the development and clinical 
course of gestational diabetes mellitus (GDM).
Materials and methods: We genotyped the C/T polymorphism of the TC-
F7L2 gene variant rs7903146 in 150 unrelated Caucasian women with a his-
tory of GDM and in 160 non-diabetic pregnant women as control. The enrol-
ment took place in Germany and in Greece. The prevalence of non-risk CC 
and risk TT alleles in the two groups was compared. Moreover, in the GDM 
group we evaluated the impact of the T risk allele on clinical sequelae and 
outcomes, defined as need for therapy with insulin and macrosomy of the 
offspring.
Results: The TT variant was associated with increased risk of GDM (p= 
0.021). Women carrying the T risk allele mutation had a lower BMI (mean 
24.86 kg/m² for TT vs 26.06 kg/m² for CC), and a higher probability of initia-
tion of insulin therapy, both in homozygotes (p = 0.02) and heterozygotes (p= 
0.001) for the mutation. No statistically significant effect of the T allele on the 
development of macrosomy was detected (p > 0.05).
Conclusion: The TT genotype of TCF7L2 rs7903146 is associated with an 
increased risk of GDM in Caucasian women. This confirms the hypothesis of 
a common genetic background between GDM and T2DM. Moreover, the T 
allele is associated with the necessity of therapy with insulin in GDM, both in 
homozygotes as well as in heterozygotes, independently from BMI. These re-
sults suggest an independent effect of the T risk allele on the severity of GDM.
1097
Blood pressure, microalbuminuria and weight gain in women with 
gestational diabetes
A. Galdon, O. Gonzalez Albarrán, A. Matei, M. Cano, S. Calvo;  
Endocrinology, Hospital Ramón y Cajal, Madrid, Spain.
Background and aims: Women with prior gestational diabetes mellitus 
(GDM) are at increased risk of developing type 2diabetes and associated vas-
culopathy. Moreover, more than 30% of the women have overweight or obe-
sity. The aim of the present work was to study the relationship between over-
weight/obesity and weight gain during the pregnancy and the development of 
hypertension in women with gestational Diabetes. Moreover, we studied the 
urinary albumin excretion and its possible relationship with blood pressure 
levels and the glucose abnormalities in women with GDM.
Materials and methods: We prospectively studied 422 women with GDM. 
We evaluated: glucose control (HbA1c/monthly, need of insulin therapy), 
BMI (before the pregnancy), Weight gain (according to IOM, 2009). Blood 
pressure was measured at each office visit. We defined hypertension when the 
confirmed blood pressure levels were SBP/DBP >=140/90 mmHg or antihy-
pertensive treatment. Microalbuminuria and glomerular filtration by MDRD 
were measured. We collected obstetric history, personal history of GDM and 
personal and family history of cardiovascular risk factors.
Results: The mean age was 33,45 ± 4,5 yrs.; 26,25% smoking, 15,6% history 
of dyslipemia, 30% had history of previous abortions, 62,34% of women had 
first-degree relatives with type 2 DM and 59,25% had family history of hy-
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pertension. 43 of the women with GDM (10,2%) presented hypertension 
during the pregnancy. The time of diagnosed of hypertension was 27 ± 4,2 
weeks. The prevalence of overweight /Obesity (estimated by BMI before preg-
nancy) was significant higher in the group of GDM women with hyperten-
sion (mean BMI=28,86±4,5 kg/m2) during the pregnancy as compared to the 
GDM women without hypertension(mean BMI= 28,86±4,5 kg/m2), 72% in 
the group with hypertension vs. 23% in the GDM women without hyper-
tension (p<0.005). The weight gain during the pregnancy was higher in the 
group of GDM women with hypertension (28% of them had an increase in 
their weight higher that the IOM recommendations, 2009), by contrast, only 
13% of GDM women without hypertension We found a significant relation-
ship between the levels of SBP/DBP and the levels of urinary albumin excre-
tion (r=0.42, p<0.05). Greater percentage of GDM women with hypertension 
needed insulin therapy for the glucose control as compared with GDM with-
out hypertension (p<0.05).
Conclusion: Women with GDM, the overweight/obesity before pregnancy 
and the increase in the weight during the pregnancy are related with the de-
velopment of hypertension.
1098
Hypertension in type 2 diabetic pregnancy: 24hr ambulatory blood 
pressure monitoring vs conventional office cuff measurement
G. Roma1, E.R.M. Belinfante2, O. Bitterman1, P. Chianello1, M. Framarino3, 
C. Giuliani1, V. Toscano1, H.L. Lutgers4, A. Napoli1;  
1Department of Clinical and Molecular Medicine, S. Andrea Hospital, 
Sapienza University, Rome, Italy, 2Rijksuniversiteit Groningen, UMCG, 
Netherlands, 3Department of Obstetrics and Gynecology, Sapienza 
University, Rome, Italy, 4Department of Endocrinology and Metabolism, 
University Medical Center Groningen, Netherlands.
Background and aims: There are only few data on hypertension in type 2 
diabetic pregnancy. Hypertension diagnosis is conventionally based on office 
conventional measurements. However, nowadays new technologies exist that 
give relevant additional information on blood pressure. Our primary aims 
were: 1) To determine the additional value of 24h-blood pressure monitoring 
(ABPM) in terms of hypertension prevalence and prediction of pregnancy 
outcome in comparison to conventional approach. 2) To characterize and 
model the blood pressure profiles of the type 2 diabetic women that devel-
oped hypertension during pregnancy.
Materials and methods: Retrospective study of 52 type 2 diabetic pregnant 
women, age 24-39yrs, diabetes duration of at least 1 year (on average 9.5yrs), 
and average pregestational BMI of 26.99kg/m2 were followed throughout 
entire pregnancy. Blood pressure (BP) was measured with both the conven-
tional method and 24h-ABPM. According to the guidelines, hypertension 
(conventional BP levels≥140/90mmHg) was classified as chronic, gestational, 
or preeclampsia. The 24h-ABPM (cut-offs 24hr≥130/80, daytime 135/85, 
night-time≥120/70mmHg) defined white-coat, sustained and masked hyper-
tension. Data were processed using the IBM program ‘SPSS 20’. X2, Fisher’s 
and Kruskal-Wallis test were performed when appropriate. P-values <0,05 
were considered significant.
Results: The two methods classified different patients as hypertensive. Con-
ventional method identified 13 (25%) women with hypertensive disorders 
(6 sustained + 7 white-coat hypertension). 24h-ABPM identified 17 women 
with hypertensive disorders (32.7%) (6 sustained + 11 masked hypertension). 
Six women were classified as hypertensive with both methods (sustained hy-
pertension). Thus 24h-ABPM hypothetically spared 7 subjects (white-coat) 
from unnecessarily intensive therapy. In the third trimester, short-term vari-
ability of both daytime (p<0.034) and 24h-measurements (p<0.001) of hy-
pertensive women were significantly higher than in normotensive women. 
First trimester 24h-ABPM curves of women who developed hypertension 
later in pregnancy were consistently higher compared to those who didn’t de-
velop hypertension. Hypertensive disorders did not alter maternal and fetal 
outcome(just one case with preeclampsia).
Conclusion: 24h-ABPM showed significantly more accuracy in diagnosing 
and predicting the onset of hypertension already since the first trimester in 
type 2 diabetic pregnancies. Moreover, it succeeded in identifying masked, 
sustained and white-coat hypertension over the conventional method, fun-
damentally improving the opportunity for appropriate treatment We would 
strongly suggest to use 24h-ABPM in the screening for hypertension in high 
risk groups such as type 2 diabetic pregnancies.
1099
Gestational diabetes and obstetric cholestasis: a 10 year retrospective 
cohort review of outcomes and predictors
J. Marathe1, W. Lim2, G.A. Dekker2,3, W.M. Hague3,4;  
1Division of Medicine, Queen Elizabeth Hospital, Woodville South, 
2Women‘s and Children‘s Division, Lyell McEwin Hospital, Elizabeth Vale, 
3Robinson Institute, University of Adelaide,  
4Women‘s and Children‘s Hospital, Adelaide, Australia.
Background and aims: Obstetric cholestasis (OC) is a gestational liver dis-
order of unclear aetiology, associated with increased perinatal morbidity and 
mortality. Recent reports have suggested a link between OC and gestational 
diabetes (GDM), which also carries increased perinatal risks. Only two series 
of patients have been published to date with little information on what may 
predict the development of GDM in OC patients, and no Australian data cur-
rently published. Our aims were to look at the diagnosis of GDM associated 
with OC, review the outcomes of cases associated with both, and to screen 
for predictors that may indicate patients to be at increased risk of developing 
GDM.
Materials and methods: A retrospective case review was conducted of all 
pregnancies associated with antenatally-diagnosed OC (diagnosed by serum 
bile acids (SBA) ≥10 μmol/L with associated pruritus) at two major hospi-
tals providing 80% of public antenatal care in South Australia, Australia be-
tween 2001 and 2010. All files were reviewed for severity of OC (severe = SBA 
≥40 μmol/L), fetal and maternal complications, presence of GDM (defined 
by Australian guidelines current at the time of pregnancy), and additional, 
including demographic, information deemed relevant. As an initial analysis 
binary predictors were analysed against the presence of GDM using the chi-
squared test, and then by multivariate analysis using logistic regression. P 
<0.05 was considered significant.
Results: 346 women were identified as being diagnosed with OC during 390 
individual pregnancies over the 10 year period; 47 pregnancies were also af-
fected by GDM (14% of total pregnancies affected by OC + GDM); 6 women 
had diabetes prior to pregnancy, and were excluded from subsequent analy-
sis. There were no fetal deaths in OC + GDM pregnancies, and 85% of deliv-
eries occurred at or after 36 weeks in this group (vs. 86% in OC only pregnan-
cies; P=0.8). Univariate analysis for predictors of GDM was conducted using 
the variables listed in the table; the only variables that remained significant 
in the multivariate analysis were [normal] Body Mass Index (BMI) (P=0.002) 
and not being on ursodeoxycholic acid (P=0.001).
Conclusion: The data supports the finding of an increased rate of GDM in 
pregnancies complicated by OC, at almost double the local rate when com-
pared with the general pregnant population. This is the largest identified co-
hort to date with both conditions, and is the first series to suggest that nor-
mal BMI and not being on ursodeoxycholic acid may decrease the risk of 
developing OC-associated GDM. Although it is reassuring that there were 
no deaths, there is still the potential for a complicated course, and further 
investigation with larger cohorts, and more variables as potential predictors 
should be investigated.
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Improved outcome of women with gestational diabetes mellitus
C. Nilsson1, D. Ursing2, H. Strevens3, M. Landin-Olsson2;  
1Department of Paediatrics, Institution of Clinical Science, Helsingborg, 
2Department of Endocrinology, 3Department of Obstetrics and 
Gynaecology, Institution of Clinical Science, Lund, Sweden.
Background and aims: The number of women with gestational diabetes mel-
litus (GDM) during pregnancy is increasing around the world, with a 10-
100% increase in some race/ethnicity groups. GDM affects 1-14% of all preg-
nant women and is more common in populations with high frequency of type 
2 diabetes. Among known risk factors for GDM is higher age, overweight, 
prior GDM and/or family history of diabetes. There are complications for the 
mother and child associated with GDM, both during and after pregnancy. 
With better maternity care and glucose control during pregnancy we expect 
improvement in outcome. The aim of this study was to compare pregnancy 
outcome of women with GDM 2013 against women with GDM 1995-1998.
Materials and methods: Since 1995 in our region in Sweden, all pregnant 
women are tested with a 2-hour oral glucose tolerance test (OGTT) consist-
ing of 75 g glucose in solution as a general screening for GDM in the 28th 
gestational week. The cut off value for GDM in Sweden is ≥10.0 mmol/l in 
capillary plasma glucose and is based on the European Association for the 
Study of Diabetes (EASD) recommendations. Women who receive a GDM 
diagnosis are transferred to our specialised maternity unit with a team of ob-
stetrician, diabetologist, midwife and dietician. In 2013, 115 women received 
GDM diagnosis and as comparisons we choose all women who had GDM 
during 1995-1998 (n=115) in our region. The women’s medical journals from 
their GDM pregnancy were studied retrospectively. Duplex pregnancies (n=2 
2013, n=3 1995-1998) as well as infants born before 37 weeks of gestation 
(n=10 2013, n=11 1995-1998) and after 41 weeks of gestation (n=0 2013, n=3 
1995-1998) were excluded from the analysis regarding the newborn.
Results: When comparing women who had GDM 2013 against women with 
GDM 1995-1998, there was no significant difference between the groups re-
garding age of the mother, ethnicity, family history of diabetes, gestational 
length, HbA1c, insulin treatment during pregnancy, height of the mother, 
length of the newborn and apgar score at 5 and 10 minutes of the newborn. 
However, first weight of the women during GDM pregnancy 2013 was sig-
nificantly higher than the weight of women with GDM 1995-1998, 71 kg (43-
119) (n=114) and 64 kg (43-133) (n=111; p=0.007) respectively. However, 
there was no significant difference in weight of the mother at delivery. For 
women with GDM 2013 weight at delivery was 80 kg (54-130) (n=49) and for 
women with GDM 1995-1998 weight at delivery was 78 kg (55-138) (n=77; 
p=NS). Birth weight of the child in GDM pregnancies 2013 was 3508 g ±487 
(n=81) and in GDM pregnancies 1995-1998 3741 g ±589 (n=94; p=0.005). 
The percent of caesarean delivery was 24% in the GDM pregnancies 2013 and 
17% in the GDM pregnancies 1995-1998 (p=0.04).
Conclusion: Even though women with GDM 2013 weigh more when they 
start the pregnancy there is no difference in weight at delivery compared to 
women with GDM 1995-1998. This is also reflected on the newborn, that 
2013 had significantly lower birth weight but with the same gestational length 
as 1995-1998. We believe that this is due to a more active and intense treat-
ment of women with GDM during pregnancy together with higher frequency 
of caesarean delivery. Prevention of large infants is crucial to avoid complica-
tions during delivery.
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Gestational diabetes: perinatal outcomes compared to background 
population and pregestational diabetes
J.C. Wiebe1,2, B. Vega Guedes3,2, A. López Alonso3, O. Ramírez García3,  
F. Cabrera Morales3, L. Valle Morales3, J.A. García Hernández3,2,  
A.M. Wägner1,2;  
1Endocrinology Dept, Complejo Hospitalario Universitario Insular-Materno 
Infantil de Gran Canaria, 2Instituto Universitario de Investigaciones 
Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, 
3Gynaecology and Obstetrics Dept., Complejo Hospitalario Universitario 
Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria, 
Spain.
Background and aims: Prevalence of gestational diabetes (GD) ranges be-
tween 5-14% and is associated with an increased risk of maternal and fetal 
complications. The aim of this study was to assess the prevalence of GD and 
its outcomes in our population and to compare perinatal results with those of 
the general population (GP) and pregestational diabetes (PD).
Materials and methods: All patients with GD (NDDG criteria) who deliv-
ered at our centre (reference for our region) between January 2011 and De-
cember 2012 were identified, and their records were reviewed and compared 
to those with pregestational diabetes and the background population. Statisti-
cal analysis was performed using Microsoft Excel and SPSS for Windows. For 
frequency comparisons between groups, chi-squared was used. A bilateral 
p<0.05 was considered significant.
Results: A total of 11480 deliveries were registered, 874 of whom (7.6%) had 
GD and 123 (1%) PD (44.6% type 1). Women with GD were more frequently 
above 35 than the GP (43.7% vs 28.9% p=0.004), similar to those with PD 
(41%), more frequently overweight/obese (BMI > 25 kg/m2) than the GP 
(62.6% vs 42.9% p<0.05), but similar to the PD (75% p= 0.15) and more often 
multiparous than the GP (68.4% vs 40.2 p<0.05) and PD (54.6 % p=0.04). 
There was a trend towards more induction of labour (42.3% vs 31.7% p 0.06) 
and cesarean sections (21.2% vs 14.8% p=0.07) in GD than in the GP, but 
less cesarean sections than in the PD (43.9 % p<0.05) and no differences in 
gestational age at delivery. No significant differences were found in perinatal 
mortality when compared to the GP (5.7 ‰ vs 3.8‰ p= 0.32) or the PD (8 
‰ p =0.7). Macrosomy (>4Kg) was more frequently seen in the GD than 
in the GP (10% VS 0.9% P < 0.05), but less than in the PD (26.7 % p <0.05). 
Shoulder dystocia occurred as often as in the GP (1% vs 0.73% p=0.75), but 
less than in the PD (6.5% p<0.05). No differences were found in Apgar scores 
or pH at birth. Admission to the Neonatal Unit was more frequent in the GD 
than the GP (19.4% vs 10.2% p= 0.004) and tended to be less than the PD 
(28.5% p = 0.08).
Conclusion: The prevalence of GD in our population is in the lower range of 
what has been described in other populations. Women with GD are at higher 
risk (age, obesity) and have worse perinatal results than the general popula-
tion, although better than women with PD.
Supported by: ISCIII PI11/02441
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Maternal and infant outcomes of women with milder degrees of GDM 
treated with diet only compared to women with normal glucose tolerance
O. Kgosidialwa, F. Dunne, A. Egan, L. Carmody, B. Kirwan;  
Galway University Hospital, Ireland.
Background and aims: The prevalence of GDM has increased worldwide in 
part as a result of increasing obesity rates but also as a result of the implemen-
tation of the new evidence based IADPSG criteria. GDM results in increased 
health care costs and efforts to reduce these costs without increasing adverse 
effects to mother and child need to be considered. Thus the aim of this study 
was to ascertain if any subset of milder degrees of GDM treated with diet 
only have comparable outcomes to those with NGT and thus may be suitable 
for ongoing management in a less intensive setting in primary or community 
care
Materials and methods: This observational retrospective cohort study car-
ried out a secondary analysis of the ATLANTIC DIP dataset. Two groups of 
women one with diet treated GDM and one with NGT were extracted from 
an anonymised dataset and compared. The impact of BMI in addition to a 
diagnosis of GDM was also analysed. The following maternal (caesarean sec-
tion, polyhydramnios, pre-eclampsia) and infant outcomes (LGA, admission 
to neonatal unit, hypoglycemia and congenital malformations) were exam-
ined. Pearson’s Chi squared test was used to ascertain statistical differences 
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between GDM and NGT. Logistic regression was used to model relationships 
between maternal and infant outcomes and BMI as a categorical variable 
(<25, 25-30, > 30) in the two groups.
Results: 5806 women were identified, 887 with GDM and 4919 with NGT. 
Baseline characteristics were similar between the groups. Women with GDM 
had a higher risk of polyhydramnios (OR= 3.06; 95% CI 1.72-5.44) and C-
section (OR=1.32; 95% CI 1.06-1.66) compared to women with NGT. A BMI 
>30 further increased the risk of C-section (OR =2.76 95% CI 2.20-3.46). 
C-section rate in women with BMI >30 was twice as common in GDM com-
pared to NGT women (60.3% vs 31.6%, P<0.05). Rates of PET were not in-
fluenced by GDM status but were increased with BMI >30 (OR=2.21 95% 
CI 1.55-3.16). Infants of mothers with GDM had a higher risk of hypogly-
cemia (OR 6.39 95%CI 3.34-12.3) and congenital malformations (OR= 1.77 
95%CI= 1.37-2.29) compared to infants of NGT mothers. BMI did not im-
pact on this any further. Rates of LGA were greatest with BMI > 30 (OR 1.76 
95% CI 1.44-2.16). Neonates of GDM mothers were twice likely to be admit-
ted to the neonatal unit compared to neonates of NGT mothers (18.5% vs 
9.1%, P<0.05).
Conclusion: Milder forms of GDM requiring dietary intervention only are 
associated with a higher risk of adverse maternal and infant morbidities 
when compared to women with NGT. These adverse events increase further 
in those with a BMI >30. Thus these women need to be monitored and treated 
in the high intensity multi disciplinary hospital environment and are not suit-
able for ongoing less intensive care in the primary care or community setting.
Supported by: HRB
1103
Analysis of pregnancy outcomes in gestational diabetes mellitus based on 
the new IADPSG criteria compared to the former criteria
M. Egloff1, K. Gariani1, S. Prati1, J. Philippe1, M. Boulvain2, F.R. Jornayvaz1;  
1Division of Endocrinology, Diabetology, Hypertension and Nutrition, 
2Division of Obstetrics, Geneva University Hospitals, Switzerland.
Background and aims: Results from the Hyperglycemia and Adverse Preg-
nancy Outcomes (HAPO) study led the International Association of Diabetes 
and Pregnancy Study Groups (IADPSG) to propose new diagnostic criteria 
for Gestational Diabetes Mellitus (GDM). The new IADPSG criteria have 
lower glucose concentration thresholds, with an increase in GDM prevalence 
as a consequence. In our institution, these criteria were implemented in Sep-
tember 2011. The aim of this study was to determine if the use of the new 
diagnostic criteria led to changes in the management and in the occurrence 
of pregnancy complications among women diagnosed with GDM compared 
to the old diagnostic criteria.
Materials and methods: We conducted a retrospective study of women with 
GDM followed at a single multidisciplinary university center. We included 
all consecutive women between July 2009 and December 2010 (group 1) di-
agnosed using the old criteria (O’Sullivan followed by a 100 g oral glucose 
tolerance test) and between January 2012 and April 2013 (group 2) using 
the revised criteria (IADPSG consensus, 75 g oral glucose tolerance test in 
the fasting state). All women were instructed to adapt their diet and record 
self-monitoring of blood glucose according to international guidelines. No 
oral antidiabetic drugs were used. Parameters assessed were: percentage of 
women requiring insulin therapy; and pregnancy complications: caesarean 
section, macrosomia (birth weight >90th percentile) and preeclampsia. Man-
agement guidelines have not been modified between the two periods.
Results: We included 286 women with GDM, 129 in group 1 and 157 in group 
2. Mean age was similar between groups (34.0±5.4 (group 1) versus 33.0±5.2 
(group 2) [years], P=0.12), as were BMI (25.2±5.3 versus 26.1±5.1 [kg/m2], 
P=0.17) and weight gain during pregnancy (13.3±5.7 versus 13.2±6.9 [kg], 
P=0.94). There was a trend - although not significant - towards a lower per-
centage of women requiring insulin therapy in group 2 (55.0% (group 1) ver-
sus 43.3% (group 2), P=0.06) However, we did not find a significant difference 
in the number of cesarean section (38.9% versus 43.1%, P=0.55), the number 
of babies born with macrosomia (37.6% versus 33.0%, P=0.74) and the occur-
rence of preeclampsia (1.6% versus 1.3%, P=1.0).
Conclusion: Our study indicates that, when using the new IADPSG criteria, 
we include women with a less severe GDM, as less women required insulin 
in addition to dietary advice. There was no significant difference in caesarean 
section, macrosomia and preeclampsia.
1104
Excessive weight gain and pregnancy outcomes in pregestational and 
gestational diabetes
J. Sastre1, F. Del Val1, C.M. Cortes1, A.M. Luque1, M. Olivar1, A. Marco1,  
V. Peña1, A. Pantoja2, M. Veganzones3, J. López1;  
1Endocrinology, 2Pediatrics,  
3Obstetrics, Complejo Hospitalario de Toledo, Spain.
Background and aims: Women with diabetes mellitus (DM) during preg-
nancy are at higher risk of adverse maternal and neonatal outcomes. Exces-
sive gestational weight gain (GWG) is a potential risk factor for these adverse 
results. In 2009 the Institute of Medicine (IOM) established recommenda-
tions for appropriate GWG in non-diabetic women. We try to examine if 
excessive GWG, using IOM recommendations, in pregnancies with pregesta-
tional diabetes mellitus (PGDM) or gestational diabetes(GDM) is associated 
with higher adverse pregnancy outcomes.
Materials and methods: We performed a retrospective study of 2773 single-
ton pregnancies in women with DM [[259 PGDM (176 type 1 DM, 83 type 
2 DM), 2514 GDM]. Maternal weight and body mass index (BMI) had been 
recorded pre-pregnancy and at the time of delivery. GWG was calculated and 
compared with IOM guidelines to assess if the upper limit per BMI category 
was breached. Examined maternal outcomes included pre-eclampsia, ges-
tational hypertension and cesarean delivery. Fetal outcomes included large 
for gestational age (LGA), macrosomia and neonatal morbidity. Multivariate 
analyses were performed and odds ratio calculated using a logistic regression 
analysis adjusted with age, parity, ethnicity, pre-pregnancy BMI, and neonatal 
sex.
Results: 1. Women with PGDM: 46,2% demonstrated excessive GWG. In the 
excessive GWG group a higher percentage were overweight (60,2%) or obese 
(56,2%, p< 0,01). There were no significant differences in GWG between type 
1 and type 2 DM. Excessive GWG was associated with higher odds for LGA 
(OR 2,5 , CI 1,4-4,7 p<0,01), macrosomia (OR 6,4 , CI 2,2-20 p<0,01) and 
cesarean delivery (OR 2,1, CI 1,1-3,9 p<0,05). 2. Women with GDM: 18,3% 
demonstrated excessive GWG. A higher percentage in the group with exces-
sive GWG were overweight (40,2%) or obese (35,2%, p< 0,01). Insulinization 
was more frequent in the excessive GWG group (43,0% vs 52,6%, p< 0,01). 
Excessive GWG was associated with higher odds for LGA (OR 2,3 , CI 1,7-3,1 
p<0,01), macrosomia (OR 2,2 , CI 1,5-3,3 p<0,01) and cesarean delivery (OR 
1,6, CI 1,3-2,0 p<0,05).
Conclusion: Excessive GWG confers an additional risk for LGA, macroso-
mia and cesarean delivery of both GDM and PGDM. Multidisciplinary life-
style intervention programs must be implemented to achieve weight control 
in all women with diabetes during pregnancy.
1105
Mental health in early pregnancy is associated with pregnancy outcome 
in women with pregestational diabetes
N.F. Callesen1,2, A.L. Secher1,2, P. Cramon2, L. Ringholm1,2, T. Watt2,  
P. Damm1,3, E.R. Mathiesen1,2;  
1Center for Pregnant Women with Diabetes, 2Department of Endocrinology, 
3Department of Obstetrics, Rigshospitalet, Copenhagen, Denmark.
Background and aims: This study aims to explore the role of early pregnancy 
locus of control, presence of anxiety and depression, and health-related qual-
ity of life for pregnancy outcomes in women with pregestational diabetes.
Materials and methods: A cohort of 148 pregnant women with diabetes (118 
type 1 diabetes and 30 type 2 diabetes), originating from a clinical trial cohort 
from 2009 to 2011, completed three internationally validated questionnaires; 
Multidimensional Health Locus of Control, Hospital Anxiety and Depression 
Scale and 36-Item Short-Form Health Survey - SF 36 at 8 weeks of gestation. 
Selected pregnancy outcomes were preterm delivery (<37 weeks) and neona-
tal overweight (large for gestational age, birth weight >90th percentile). Differ-
ences between groups were analysed by unpaired t-test. Three women giving 
birth to a small for gestational age infant were excluded from the analyses of 
the large for gestational age group vs. appropriate for gestational age group.
Results: Women with preterm delivery (n=28) had worse quality of life scores 
for the SF-36 Mental Component Summary (mean 42.8 (SD 13.1) vs. 48.8 
(9.7), p=0.03), SF-36 Emotional Role Limitations (58.3 (38.1) vs. 82.9 (31.3), 
p=0.0005) and SF-36 Mental Health (67.7 (20.4) vs. 75.2 (15.8), p=0.04) at 
8 weeks of gestation, compared to women delivering at term. Both women 
delivering preterm and women delivering at term had high levels of internal 
locus of control (30.4 (5.5) vs. 29.8 (4.9), maximum score 36, p=0.57), and 
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comparable lower levels of locus of control attributed to chance, doctors and 
other people. The level of anxiety and depression was generally low without 
any differences between the groups. As compared to women with appropri-
ate for gestational age infants (n=86), women with large for gestational age 
infants (n=59) had similar scores for locus of control, anxiety and depression, 
and health-related quality of life. High levels of internal locus of control were 
seen both in women with large for gestational age and appropriate for gesta-
tional age infants (30.0 (4.5) vs. 29.8 (5.3), p=0.85).
Conclusion: Women with pregestational diabetes who delivered preterm 
were characterised by worse mental quality of life in early pregnancy.
Supported by: EFSD / LifeScan
1106
Pregnancy outcome in depressive and GDM subjects in Bangladesh:  
a hospital based comparative study
K. Natasha;  
Community Medicine, Institute of Health and Society, Faculty of Medicine, 
Oslo, Norway.
Background and aims: In Bangladesh the prevalence rate of depression in 
adult population is only 4.6%. Gestational Diabetes Mellitus (GDM) is also 
alarming here but the actual prevalence rate of both diseases in pregnancy is 
still lacking, though they are common and result in serious consequences for 
mother and foetus. To our knowledge there has been little research address-
ing the association between them in pregnancy and the outcome. These data 
are deficient even in South Asia let alone Bangladesh. This study was the cor-
ollary part of one study (which tried to find out prevalence of depression and 
associated factors, among GDM subjects and to compare with Non GDM) to 
reveal the outcome of pregnancy with depression and GDM and compared.
Materials and methods: A total of 748 pregnant women participated in the 
study. They were followed up from their 1st visit (not included after 13th 
week) to 1st week after delivery for at least 3 checkups. Depressive symptoms 
was scored following MADRS scale (0-12=not, 13-19=mildly, 20-34 moder-
ately, 35-60=severely - depressed). Blood glucose was measured on every visit 
following WHO criteria; GDM was diagnosed within 24th to 28th weeks. 
Delivery procedure, Birth weight and APGAR score at 1st and 5th minute 
were assessed for the neonate.
Results: Prevalence of depression among pregnant women was 12.69%. The 
rate was higher in GDM ( n 366) subjects (21.73%) with mean age 28.34 years 
than NGDM (n 382) subjects (7.73%) with mean age 27.17 years. Over all 
mean depressive score was higher at 3 stages in GDM group. Rate of caesar-
ean section, number of live birth, and birth weight was higher but APGAR 
score at 2 stages were lower in GDM group. Mean age, Parity and birth weight 
of baby was higher but mean education years, mean APGAR scores of babies 
at both time period was lower in depressed groups (all 3 stages). Pregnant 
who were depressed specially in last trimester seem to have more rate of CS. 
Though gestational age at delivery did not vary much among the depressed 
and non depressed group. Chi square test and ’t tests’ proved there was signif-
icant association with depressive scores with gestational age and birth weight. 
Physical Exercise and Weight gain rate is under analysis
Conclusion: The important finding of this study was the elevated prevalence 
rate of depression in pregnancy which was greater than assumed. And preg-
nancy outcomes are strongly associated with GDM and Depression. Develop-
ing countries do not focus much on mental health but it is becoming ultimate 
necessity for future.
Supported by: Iver Helles Foundation, Norway
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Atlantic DIP: diabetes in pregnancy is the most significant risk factor for 
caesarean delivery
L. Carmody, A.M. Egan, O. Kgosidialwa, B. Kirwan, F. Dunne;  
Galway Diabetes Research Centre, National University of Ireland Galway, 
Ireland.
Background and aims: Diabetes mellitus (DM) is a common medical disor-
der of pregnancy. Caesarean delivery (CD) is associated with increased cost 
and maternal morbidity. Our aim was to determine the influence of DM on 
risk of CD in our cohort of patients enrolled in the Atlantic Diabetes in Preg-
nancy (DIP) study.
Materials and methods: Women with singleton pregnancies of 23 weeks or 
more estimated gestational age were identified and 6526 unique deliveries 
included. This included 4688 (71.8%) pregnancies with normal maternal glu-
cose tolerance (NGT), 282 (4.3%) with pregestational diabetes mellitus type 
1 and type 2 (PGDM) and 1556 (23.9%) with gestational diabetes mellitus 
(GDM). GDM was defined according to IADPSG criteria. Backwards step-
wise logistic regression was utilised to evaluate the independent influence 
of selected variables on CD risk including diabetes mellitus (DM), maternal 
smoking and obesity, nulliparity, hypertension, ethnicity and macrosomia.
Results: In total, 1968 (30.16%) pregnancies resulted in CD. In the setting 
of NGT pregnancies there were 1196 (25.51%) with CD, 181 (64.18%) with 
PGDM and 591 (37.98%) with GDM (p<0.001). Evaluating the group as a 
whole using regression models, the presence of DM (either pregestational or 
gestational) significantly increased the odds for CD (aOR 1.73, p<0.001, 95% 
CI 1.51-1.99). Maternal obesity was also noted to be a significant risk factor 
(aOR 1.72, p<0.001, CI 1.509-1.974). Other identified risks for CD in our 
cohort include foetal macrosomia (aOR 1.61, p=0.003, CI 1.18-2.2), hyper-
tension (aOR 1.66, p<0.001, CI 1.38-2.01), nulliparity (aOR 1.45, p<0.001, 
CI 1.27-1.65) and increasing maternal age (aOR 1.05, p<0.001, CI 1.04-1.06). 
When GDM was evaluated as an independent risk factor, it was also found 
to increase the odds for CD (aOR 1.36, p<0.001, CI 1.18-1.58) and analysing 
this subgroup of women (n=1556), persistent risk factors for CD include obe-
sity (aOR 1.99, p<0.001, CI 1.57-2.52) and maternal age (aOR 1.04, p=0.002, 
CI 1.01-1.07). In the setting of PGDM (n=181), this underlying diagnosis 
greatly increases the odds of CD (aOR 4.95, p<0.001, CI 3.75-6.52) and was 
the only independent risk identified within this group of women.
Conclusion: Despite significant advances in the management of patients with 
diabetes in pregnancy, DM remains the most significant, independent risk 
factor for the adverse outcome of CD. Future research should focus on meth-
ods of reducing this risk.
Supported by: Health Research Board of Ireland
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Evaluating haemoglobin A1c and metabolic syndrome versus oral glucose 
tolerance test in postpartum diabetes screening
M. Tome, M.J. Picon, J. Alcaide, I. Cornejo, M. Molina, F. Tinahones;  
University Hospital Virgen de la Victoria, Malaga, Spain.
Background and aims: Gestational diabetes mellitus(GDM) increases the 
risk of type 2 diabetes (DM-2). Guidelines of clinical practice recommend 
postpartum screening with oral glucose tolerance test (TTOG). Compliance 
rates of women performing this test are low because this is an uncomfortable 
test. We investigated the reliability of other postpartum screening test in or-
der to increase the compliance of women in postpartum.
Materials and methods: We evaluated 419 women with a history of GDM 
in postpartum screening using hemoglobin A1c (A1C), HDL cholesterol, 
triglycerides, blood pressure and waist circumference and compared them 
with TTOG one year after delivery. We classified these patients into normal 
or pathological carbohydrate metabolism according to TTOG, A1C (follow-
ing ADA criteria) and diagnostic criteria for the metabolic syndrome (MS) 
attending to ATPIII Expert Panel.
Results: Based on the TTOG 257 women (61,3%) had normal carbohydrate 
metabolism and 162 women (38,7%)had a pathological status: 69 (16,5%) im-
paired fasting glucose (IFG), 43 (10,3%) impaired glucose tolerance (IGT), 
30 (7,2%) IFG+IGT and 14 (4,7%) had diabetes. According to the A1C cri-
teria, 331 (77,9%) had normal carbohydrate metabolism and 84 (19,8%) had 
a pathological status: 82 (19,3%) prediabetes and 2 (0,5%) had diabetes. At-
tending to MS, 341 (80,2%) were normal and 64 (15,1%) had at least 3 diag-
nostic criteria for MS.
Conclusion: A1c and MS diagnostic criteria underestimate carbohydrate 
metabolism reassessment in women with a history of GDM compared to the 
gold standard TTOG.
1109
The role of HbA1c for detection of diabetes and abnormal glucose 
tolerance after pregnancy with gestational diabetes mellitus
R. Claesson, M. Ekelund, C. Ignell, K. Berntorp;  
Department of Clinical Sciences, Malmö, Lund University, Malmö,  
Sweden.
Background and aims: Recently, HbA1c has been proposed as a diagnostic 
tool to identify individuals with undiagnosed diabetes, or who are at risk of 
diabetes. Women with gestational diabetes mellitus (GDM) represent a high 
risk group for type 2 diabetes development. According to Swedish national 
guidelines life style intervention and follow-up of these women after preg-
nancy have high priority, but it is not made clear by which measures these 
women should be followed. The aim of the present study was to compare 
the performance of HbA1c with established glucose criteria during an oral 
glucose tolerance test (OGTT) and to assess HbA1c as a screening test for 
undiagnosed diabetes and pre-diabetes after pregnancy with GDM.
Materials and methods: Glucose homeostasis was reevaluated 1-5 years 
after delivery in 140 women with prior GDM by means of OGTTs and si-
multaneous HbA1c measurements. Glucose tolerance was defined according 
to World Health Organization criteria. HbA1c ≥48 mmol/mol was used for 
diabetes diagnosis and HbA1c 39-47 mmol/mol to define high risk women 
(pre-diabetes).
Results: Mean ± SD for age and body mass index of included women were 
35.4 ± 5.6 years and 26.6 ± 2.3 kg/m2, respectively. A median (interquartile 
range) of 26 (21-60) months had elapsed since their GDM pregnancy. Based 
on the OGTT 62 women (44%) had normal glucose tolerance, 50 (36%) pre-
diabetes, and 28 (20%) diabetes, as compared to 114 (81%), 21 (15%) and 5 
(4%), respectively, using HbA1c criteria. The agreement between diagnoses 
resulting from HbA1c and OGTT criteria was estimated by constructing cross 
tables and calculation of the κ coefficient (κ). The consistency in classifying 
diabetes versus non-diabetes was 82% (115/140) and κ 0.194, indicating poor 
agreement. The corresponding figures for the classification of any degree of 
abnormal glucose tolerance were 59% (82/140), κ 0.227. Combining HbA1c 
with fasting glucose criteria improved the agreement to fair (κ 0.596), but was 
no better than using the fasting glucose test alone (κ 0.599). The area under 
the receiver operating characteristic curve for HbA1c and fasting glucose to 
detect any degree of abnormal glucose tolerance was 0.708 and 0.834, respec-
tively. Diagnostic accuracy was assessed using sensitivity, specificity, positive 
predicted value (PPV) and negative predictive value (NPV). Proposed cut 
points of HbA1c had low sensitivity (30%) and modest NPV (52%) to de-
tect any degree of abnormal glucose tolerance, whereas specificity and PPV 
were high. The combined use of HbA1c and fasting glucose criteria improved 
the performance (sensitivity 67%, specificity 95%, PPV 95%, NPV 69%), but 
was similar to the use of the fasting glucose test alone. The latter identified 
63% (49/78) of the women with pre-diabetes or diabetes in the study cohort. 
However, combined with a lower cut point of HbA1c (≥31 mmol/mol), an 
additional 59 women were identified, among whom 36% had pre-diabetes or 
diabetes based on post glucose load hyperglycemia.
Conclusion: Proposed thresholds of HbA1c had low diagnostic sensitivity. 
Combined with a fasting glucose test the performance was no better than 
using a fasting glucose test alone. Considering that early detection of pre-di-
abetes is of outmost importance in these women to prevent the development 
of diabetes, combining a fasting glucose test with a lower cut point of HbA1c 
may be an alternate approach to select women for an OGTT to identify those 
with isolated post glucose load hyperglycemia.
1110
Glucose intolerance after a recent history of gestational diabetes
K. Benhalima1, L. Leuridan1, P. Calewaert1, R. Devlieger2, J. Verhaeghe2,  
C. Mathieu1;  
1Endocrinology, 2Obstetrics & Gynecology,  
University Hospital of Gasthuisberg, Leuven, Belgium.
Background and aims: The prevalence and the risk factors for glucose in-
tolerance in early postpartum remain unclear in different populations. Our 
aim was to evaluate the uptake of our current screening strategy postpartum, 
the prevalence and the risk factors for glucose intolerance in women with a 
recent history of gestational diabetes (GDM).
Materials and methods: Retrospective analysis of the medical files of our 
university hospital from 01-01-2010 till 31-12-2013 of women with a recent 
history of GDM diagnosed with the Carpenter & Coustan criteria. Since 2010 
all women with a history of GDM are advised to undergo a 75g oral glucose 
tolerance test (OGTT) between 6-24 weeks postpartum. Indices of insulin 
sensitivity (the Matsuda index and the reciprocal of the homeostasis mod-
el assessment of insulin resistance, 1/HOMA-IR) and an index of beta-cell 
function, the Insulin Secretion-Sensitivity Index-2 (ISSI-2) were calculated 
based on the OGTT during pregnancy and postpartum. Multivariable logis-
tic regression was used to adjust for confounders.
Results: Over a 4 year period, 231 women were identified with a recent his-
tory of GDM. Of all women, 21.4% (46) did not attend the scheduled post-
partum OGTT. Compared to women who received an OGTT postpartum, 
women who did not attend the postpartum OGTT smoked more often be-
fore pregnancy (10.9% vs 2.4%, p=0.021), had more often a previous history 
of GDM (21.7% vs 10.7%, p=0.042), less often breastfed (56.5% vs 75.7%, 
p=0.011) and had a lower insulin sensitivity based on the OGTT during 
pregnancy [the Matsuda index 2.2 (1.5-3.1) vs 2.8 (1.9-3.8), p=0.033 and 
1/HOMA-IR 0.015 (0.010-0.023) vs 0.020 (0.012-0.032), p=0.030]. Of all 
women (169) who received an OGTT postpartum, 40.8% (69) had predia-
betes (14.9% impaired fasting glucose, 32.5% impaired glucose tolerance and 
7.1% both impaired fasting and impaired Glucose tolerance) and 5.3% (9) 
had overt diabetes. Compared to women with a normal OGTT postpartum, 
women with prediabetes or diabetes were more often overweight (39.7% vs 
25.3%, p= 0.009) or obese at first prenatal visit (27.4% vs 19.5%, p=0.037), 
were more often multiparous (44.0% vs 26.6%, p=0.028), had a higher glu-
cose challenge test [168.0mg/dl (153.0-190.0) vs 159.0mg/dl (149.5-175.5), 
p=0.007], had an earlier diagnosis of GDM [gestational weeks 26.0 (25.0-
28.0) vs 27.0 (25.0-29.0), p=0.030], had an higher median fasting [94.5mg/
dl (84.2-101.7) vs 88.0mg/dl (81.0-99.0), p=0.006] and 2 hour glucose value 
during pregnancy [175.0mg/dl (162.0-198.0) vs 168.0mg/dl (158.0-181.0), 
p=0.003] and were more often treated with basal-bolus insulin injections 
(52.0% vs 17.4%, p=0.032). Women with glucose intolerance postpartum also 
had a lower beta-cell function and lower insulin sensitivity, remaining signifi-
cant after adjustment for age, BMI, ethnicity, breastfeeding, contraception, 
multiparity and corticoid treatment [ISSI-2 in pregnancy 1.5±0.5 vs 1.7 ±0.4, 
p=0.029; ISSI-2 postpartum 1.5 (1.2-1.9) vs 2.2 (1.8-2.6),p=0.020; Matsuda 
index postpartum 3.8 (2.6-6.2) vs 6.0 (4.3-8.8), p=0.021).
Conclusion: Glucose intolerance is frequent in early postpartum and these 
women have a lower beta-cell function and lower insulin sensitivity. One fifth 
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of women did not attend the scheduled OGTT postpartum and these women 
have an adverse risk profile compared to women who received the OGTT 
postpartum.
Supported by: Scholarship of FWO Vlaanderen for KB, CM and RD
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The risk of future glucose intolerance in women with history of 
gestational diabetes
O. Yilmaz1, N. Dinccag2, S. Celik2, S. Ozel3, C. Idiz2, F. Turker2, A.K. Uzum2, 
N. Gul2, G. Yenidunya2, I. Satman2;  
1Internal Medicine Department, 2Endocrinology and Metabolism Division, 
3Bioistatistics and Medical Informatics Department, Istanbul University, 
Turkey.
Background and aims: In women with gestational diabetes mellitus (GDM) 
abnormal glucose metabolism normalizes soon after delivery. However, the 
history of GDM predisposes to carbohydrate intolerance in the future. The 
aim of this study was to evaluate risk factors predicting to future development 
of diabetes mellitus (DM) in women with a history of GDM.
Materials and methods: 221 women with history of GDM were enrolled into 
the study. A 75 g OGTT was performed within 3 months following delivery 
(n=181) or 11±2 years after delivery(n=40) . Based on ADA criteria partici-
pants were classified into 3 groups as normal glucose tolerance; NGT (group 
1), IGT and/ or IFG ( group 2) and DM (group 3) We evaluated the relation-
ship between status of carbohydrate metabolism after delivery and possible 
risk factors such as: age-at- gestation; BMI; family history of DM; poor ob-
stetric history; gestational week, A1C and OGTT glucose levels at diagnosis 
of GDM; weight gain and insulin requirement during index pregnancy.
Results: As shown in the table below, 16.2 % of participants had any degree of 
glucose intolerance after delivery. Gestational age of women who progressed 
to prediabetes or diabetes was lower than the others. At diagnosis OGTT 
glucose levels were higher and family history and poor obstetric history was 
much more higher in group 2 and 3. Women who developed later carbohy-
drate intolerance had insulin requirement during pregnancy.
Conclusion: Age-at-gestation, having poor obstetric history, higher glucose 
levels (fasting, 1st, 2nd hr) at diagnosis of GDM and insulin requirement dur-
ing pregnancy are crucial predictors of development of glucose intolerance 
in the future. Those women required careful and more frequent follow-up 
after delivery.
1112
Biomarkers of endothelial dysfunction in relation to impaired 
carbohydrate metabolism early after pregnancy with gestational diabetes 
mellitus
C.S. Göbl1,2, L. Bozkurt3, T. Prikoszovich3, A. Tura4, G. Pacini4,  
A. Kautzky-Willer3;  
1Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-
Maternal Medicine, Medical University of Vienna, 2Department of Internal 
Medicine III, Division of Endocrinology and Metabolism, Gender Medicine 
Unit, Medical University of Vienna, 3Department of Internal Medicine 
III, Division of Endocrinology and Metabolism, Gender Medicine Unit, 
Medical University of Vienna, Austria, 4Institute of Biomedical Engineering, 
Metabolic Unit, National Research Council, Padova, Italy.
Background and aims: The diagnosis of gestational diabetes mellitus (GDM) 
implicates an increased risk for the later development of type 2 diabetes. It 
was previously shown that metabolic reassessment early after delivery identi-
fies females with particularly high risk. However, the relation to endothelial 
dysfunction, which might represent an early precursor of atherosclerosis and 
cardiovascular disease in females after pregnancy with GDM, is less well un-
derstood.
Materials and methods: 108 women with previous gestational diabetes 
(pGDM) and 40 controls were included 3-6 months after delivery and un-
derwent specific metabolic assessments including a frequently sampled in-
travenous glucose tolerance test (FSIGT) and an oral glucose tolerance test 
(OGTT) to derive parameters of insulin sensitivity and β-cell dysfunction in 
addition to dynamics of glucose, insulin, C-peptide, proinsulin and amylin. 
The area under the curve was calculated by the trapezoidal rule including 
measurements of fasting, as well as 30’, 60’, 90’ and 120’ post load concentra-
tions. OGTTs were repeated in females with pGDM over 10 years of follow-
up to identify subjects with diabetes manifestation. Circulating ICAM-1 
(intracellular-adhesion-molecule-1), VCAM-1 (vascular-cell-adhesion-mol-
ecule-1) and E-selectin, representing biomarkers of endothelial dysfunction 
were assessed at baseline and annually over five years after index pregnancy.
Results: Adhesion molecules and E-selectin were significantly related to in-
sulin sensitivity estimated from the FSIGT (SI-FSIGT): ICAM-1: r=-0.23, 
p=0.009; VCAM-1: r=-0.22, p=0.011; E-selectin: r=-0.21, p=0.018. Fractional 
polynomial regression models revealed further associations between ICAM-
1 and AUC-glucose (p=0.003), AUC-proinsulin (p=0.005) and AUC-amylin 
(p=0.017) as well as between E-selectin and AUC-glucose (p=0.013) and BMI 
(p=0.004) after adjustment for the degree of insulin resistance. Moreover, ad-
hesion molecules remained significantly elevated in pGDM subjects as com-
pared to the control group in a multivariable model including SI-FSIGT, age 
and BMI. 21% of females after pregnancy with GDM developed diabetes dur-
ing the follow-up period. Longitudinal analysis revealed significantly higher 
ICAM-1 and E-selectin levels in subjects with progression to overt diabetes.
Conclusion: Biomarkers of endothelial dysfunction are related to impaired 
carbohydrate metabolism in subjects with recent history of GDM. This ob-
servation might indicate the later development of overt cardiovascular dis-
orders in this specific risk collective. Follow-up examinations with clearly 
defined cardiovascular endpoints are recommended to perform an accurate 
risk stratification.
Supported by: Austrian Science Fund (P14515 MED) to AKW
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Non-alcoholic fatty liver disease is prevalent in non-diabetic women 
with previous gestational diabetes mellitus regardless of their glucose 
tolerance
S. Foghsgaard1,2, L. Vedtofte1, C. Andersen1, E.S. Andersen1, L.L. Gluud1,  
C. Strandberg3, T. Buhl4, E.R. Mathiesen5, P. Damm6, J.A. Svare7, F.K. Knop1, 
T. Vilsbøll1;  
1Diabetes Research Center, 2Department of Biomedical Sciences, Panum 
Institute, 3Department of Radiology, 4Department of Nuclear Medicine, 
Gentofte Hospital, University of Copenhagen, 5Center for Pregnant Women 
with Diabetes, Department of Endocrinology, 6Center for Pregnant Women 
with Diabetes, Department of Obstetrics, Rigshospitalet, University of 
Copenhagen, 7Department of Obstetrics and Gynaecology, Herlev Hospital; 
University of Copenhagen, Denmark.
Background and aims: Gestational diabetes mellitus (GDM) increases the 
risk of developing type 2 diabetes later in life. Furthermore, type 2 diabetes 
and obesity are associated with non-alcoholic fatty liver disease (NAFLD). 
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NAFLD is defined as a condition with excessive fat accumulation in the liver 
and absence of significant alcohol consumption. We examined glucose tol-
erance and fat distribution in obese, non-diabetic women with prior GDM.
Materials and methods: Based on a 75g-OGTT, non-diabetic women with 
previous GDM were classified as having normal glucose tolerance (NGT) or 
prediabetes (impaired fasting glucose and/or impaired glucose tolerance). 
Insulin resistance (IR) was assessed by HOMA-IR. All women underwent 
an ultrasound scan of the liver to detect fat accumulation, blood sampling, 
and a dual energy X-ray absorptiometry (DXA) scan. The android-to-gynoid 
fat-ratio and total visceral fat mass were calculated based on the DXA scan. A 
questionnaire was used to evaluate alcohol consumption habits.
Results: Women with previous GDM were included (n=70; age: 38±5 years 
(mean±SD); BMI: 31±5 kg/m2; HbA1c: 34±4 mmol/mol (5.4±0.4%); HO-
MA-IR: 1.2±0.6; duration since GDM: 5±2 years). Twenty four women had 
NGT (fasting plasma glucose (FPG) 5.4±0.3 mM; 2h-OGTT plasma glucose 
(PG): 6.7±1.4 mM) and 46 women had prediabetes (FPG 5.5±0.5 mM; 2h-
OGTT PG: 9.2±1.1 mM). NAFLD was diagnosed in 5 (21%) women with 
NGT and 15 (33%) with prediabetes). Glucose tolerance status (NGT or 
prediabetes) did not coincide with NAFLD (p=0.39). Multivariable logis-
tic regression analyses showed that NAFLD was positively associated with 
HOMA-IR (p=0.035), BMI (p=0.004), C-peptide (p=0.038), mass of vis-
ceral fat (p=0.004), the android-to-gynoid fat-ratio (p=0.027), and plasma 
levels of alanine aminotransferase (p=0.018) and aspartate aminotransferase 
(p=0.028).
Conclusion: NAFLD is prevalent in non-diabetic women with previous 
GDM regardless of their glucose tolerance status, but is associated with 
HOMA-IR, high BMI, high C-peptide levels, android fat distribution, and 
elevated plasma liver enzymes.
Clinical Trial Registration Number: EudraCT 2012-001371-37
Supported by: Unrestricted grant from Novo Nordisk as an IIS-protocol
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Incretin function in adult offspring of women with diabetes in pregnancy
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Copenhagen, 5Marie Krogh Center for Metabolic Research, Copenhagen, 
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Background and aims: Fetal exposure to maternal diabetes is associated with 
increased risk of pre-diabetes and type 2 diabetes (T2DM) in the offspring. 
The pathogenesis of T2DM seems to involve dysfunction of the incretin hor-
mones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide-1 (GLP-1), as well as hyperglucagonemia. Our aim was to inves-
tigate the levels of the incretin hormones GIP, GLP-1 and glucagon in adult 
offspring exposed to intrauterine hyperglycemia.
Materials and methods: A cohort of 587 Caucasian offspring, without 
known diabetes was followed up at the age of 18-27 years. We included two 
groups exposed to maternal diabetes in utero: offspring of women with gesta-
tional diabetes mellitus (O-GDM) or type 1 diabetes (O-T1DM). Two refer-
ence groups were included: offspring of women with risk factors for GDM, 
but normo-glycemia during pregnancy (O-NoGDM) and offspring from the 
background population (O-BP). The subjects underwent a 75-g oral glucose 
tolerance test (OGTT) with venous blood samples at 0, 30, 120 min.
Results: Significantly lower levels of GLP-1 in the fasting state was found in 
the 2 diabetes-exposed groups (O-GDM and O-T1DM) compared to O-BP 
(p=0.032 and 0.004 respectively). The levels of glucagon during OGTT 
(time=30 min.) showed a tendency towards higher level in O-GDM com-
pared to the unexposed groups (O-NoGDM and O-BP). No association be-
tween levels of GIP and exposure status was found.
Conclusion: Reduced levels of GLP-1 in the fasting state and increased levels 
of glucagon during OGTT may contribute to the increased risk of glucose 
intolerance among adult offspring born to women with diabetes during preg-
nancy.
PS 096 Pregnancy in type 1 diabetes
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Hyperglycaemia remains the major risk factor of major foetal 
complications in pregnant women with type 1 diabetes and good 
glycaemic control
J. Skupien, K. Cyganek, B. Katra, I. Janas, P. Witek, M.T. Malecki;  
Department of Metabolic Diseases, Jagiellonian University Medical College, 
Krakow, Poland.
Background and aims: In women with type 1 diabetes pregnancy is associ-
ated with increased risk of adverse outcomes. The aim of this study was to 
ascertain the association of glycemic control, estimated with HbA1c, with se-
lected serious adverse pregnancy outcomes, such as preterm labor, congenital 
malformations low birth weight and stillbirths in a group of pregnant women 
with very good metabolic control.
Materials and methods: The study cohort comprised 510 women with type 
1 diabetes. They received intensive diabetes management during the period 
of pregnancy in an academic outpatient reference center between 1998 and 
2012. We excluded multiple pregnancies (n=9), miscarriages (before 20th 
week of gestation, n=40), cases with missing outcomes and lost to follow-
up (n=6). Of the remaining 455, 183 women (40.2%) entered the intensive 
management program before conception (pregnancy planning). HbA1c was 
measured in 3 pregnancy trimesters, in a laboratory implementing internal 
and external quality assurance protocols, with an assay (high performance 
liquid chromatography) that was adjusted to DCCT standard.
Results: The median HbA1c in the 1
st, 2nd and 3rd trimester was 6.5%, 5.7% 
and 5.6%, respectively. Only 155 (34.1%) women in the 1st trimester, 44 
(9.7%) in 2nd and 39 (8.6%) in 3rd had HbA1c 7.0% or higher. In spite of that, 
we observed 70 (15.4%) preterm labors (two between 20th and 26th week of 
gestation). There were 34 (7.5%) cases of low birth weight (below 2500 g), 
10 of them occurred in term newborns. There were also 10 (2.2%) stillbirths 
and 28 (6.1%) congenital malformations in live births. Additional 4 cases of 
congenital malformations occurred in stillborn fetuses. The strongest predic-
tor of preterm delivery was the 3rd trimester HbA1c: relative odds of preterm 
delivery per 1% increase in HbA1c was 1.46, p=0.004. First and 2
nd trimester 
HbA1c had weaker impact: odds ratios were 1.20 (p=0.06) and 1.35 (p=0.01), 
respectively (both per 1% increase in HbA1c). Of note, 97% preterm labors 
took place after 26th week of gestation. Interestingly we did not observe sig-
nificant relationship between low birth weight and HbA1c, while the odds 
of this complication increased by 1.48 (p=0.02) per each additional 5 years 
of maternal age. The 1st trimester HbA1c (but not 2
nd or 3rd) was associated 
with the risk of stillbirths: relative odds per 1% increase of HbA1c was 1.70, 
p=0.005. Similarly, 1st trimester HbA1c, but not 2
nd or 3rd, was associated with 
the risk of congenital malformations (relative odds per 1% increase of HbA1c-
was 1.41, p=0.005). Although pregnancy planning resulted in 0.8% (6.8 vs. 
6.0%) reduction of median HbA1c in the 1
st trimester and 0.3% (5.8 vs. 5.5%) 
in the 3rd, it was not sufficient to significantly lower the risk of adverse out-
comes (odds ratio 0.80, p=0.35 for the composite outcome of preterm deliver-
ies, stillbirths and malformations).
Conclusion: Despite very good glycemic control the risk of the examined 
adverse outcomes of pregnancy in women with type 1 diabetes remains high. 
In this study preterm labors were associated predominantly with the 3rd tri-
mester HbA1c but less with earlier glycemic exposure. Hyperglycemia during 
the first trimester of pregnancy, the period of embryonic organogenesis, was 
associated with increased risk of congenital malformations and stillbirths. 
These results emphasize the need for maintaining normoglycemia through-
out the whole course of pregnancy.
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Fixed rate intravenous insulin infusion for euglycaemic diabetic 
ketoacidosis to a pregnant type 1 diabetic with good foetal outcome
K. Tofeec, L. Pichaipillai, C. Bond, S. Ramtoola, M. Littley;  
Diabetes and Endocrinology, Royal Blackburn Hospital, Lancashire, UK.
Background and aims: Diabetic Ketoacidosis (DKA) is a life threating condi-
tion during pregnancy. It carries high mortality (up to 30%) for both infant 
and mother. Ketosis has been implicated in foetal distress and causes adverse 
neurological outcome. During pregnancy, euglycemic diabetic ketoacidosis 
requires prompt recognition and treatment. The current national guideline 
in UK recommends using a fixed dose of insulin infusion (0.1units/kg/hr), 
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titration of fluids to keep this infusion continuously running and continu-
ation of long acting insulin during management of DKA. We report a case 
of euglycemic DKA in a pregnant Type 1 diabetic who received fixed rate 
insulin infusion with complete recovery.
Materials and methods: A 24 year old type 1 diabetic for 10 years attended 
the antenatal clinic in a District General Hospital for antenatal management 
of her 2nd pregnancy. Her antenatal period had been uneventful till 24 weeks, 
with a satisfactory diabetes control (HbA1c of 50 mmol/mol) on a basal bolus 
regimen. She presented to the antenatal clinic with history of nausea, recur-
rent vomiting, abdominal pain and headache for preceding 6 days. She had 
stopped taking her short acting insulin but continued with her basal insu-
lin. Clinically she was dehydrated. Investigations showed plasma glucose 6.5 
mmol/l and blood ketones 3.9. Venous blood gas showed acidity (PH) 7.21, 
bicarbonate 9 and lactate 0.9. Rest of the biochemical investigations were un-
remarkable. Cardiotocography for fetal monitoring was normal
Results: A diagnosis of euglycemic diabetic ketoacidosis was confirmed, 
fixed dose of intravenous insulin with dextrose infusion was initiated as per 
Joint British Diabetes Societies (JBDS) guidelines. She was transferred to 
HDU for close monitoring. No precipitating factors for DKA was found. She 
made an excellent recovery and discharged home in 2 days. She delivered by 
caesarean section at term with good foetal outcome.
Conclusion: Euglycemic DKA is poorly understood in non-specialist prac-
tice, but it is important to recognize the condition early. Poor oral intake due 
to vomiting and nausea as well as pregnancy were the only contributing fac-
tors in our case. Fixed rate intravenous insulin has been part of the DKA 
pathway (JBDS Guidelines) only recently along with bedside measurement of 
metabolic changes. The rationales for this recommendation are:faster resolu-
tion of ketosis with higher insulin and glucose concentrations thereby rapid 
recovery with reduction in the length of stay, and significant delay in the nor-
malisation of pH with a sliding scale protocol. Euglycemic DKA, although 
uncommon, still continues to be perceived in clinical practice.Type 1 diabetic 
patient presenting with nausea and vomiting and found to have a normal 
glucose may still have life-threatening ketoacidosis, and an evaluation of their 
acid/base status is still revealed.Identification of such presentation timely is 
crucial and also the need for early fixed rate intravenous insulin infusion 
along with dextrose which will prevent significant morbidity for both the 
mother and the foetus like in our case.
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Higher gestational weight gain is associated with increasing offspring 
birth weight independent of maternal glycaemic control in women with 
type 1 diabetes
E.R. Mathiesen1,2, A.L. Secher1,2, C.B. Parellada1,2, L. Ringholm1,2,  
B. Ásbjörnsdóttir1,2, P. Damm1,3;  
1Center for Pregnant Women with Diabetes, 2Department of Endocrinology, 
3Department of Obstetrics, Rigshospitalet, Copenhagen, Denmark.
Background and aims: To evaluate the association between gestational 
weight gain and offspring birth weight in singleton term pregnancies of 
women with type 1 diabetes.
Materials and methods: One-hundred-and-fifteen consecutive women re-
ferred <14 weeks were retrospectively classified as underweight (pre-preg-
nancy BMI <18.5 kg/m2, n=1), normal weight (18.5-25.0, n=65), overweight 
(25.0-29.9, n=39) or obese (≥30.0, n=10). Gestational weight gain was cat-
egorized as excessive, appropriate or insufficient according to the Institute of 
Medicine recommendations for each BMI class.
Results: HbA1c at 8 and 36 weeks was comparable between women with 
excessive (n=62), appropriate (n=37) and insufficient (n=16) gestational 
weight gain (median 6.7 (range 5.6-8.4) vs. 6.5 (5.4-8.3) vs. 6.6 (5.6-8.3) % 
(50 (38-68) vs. 48 (36-67) vs. 49 (38-67) mmol/mol), p=0.78, and 6.0 (5.1-6.9) 
vs. 6.0 (4.7-7.1) vs. 6.3 (5.1-7.0) % (42 (32-52) vs. 42 (28-54) vs. 45 (32-53) 
mmol/mol), p=0.40, respectively) and pre-pregnancy BMI was 25 (18-41) vs. 
24 (18-31) vs. 23 (20-30) kg/m2 (p=0.05). Offspring birth weight and birth 
weight z-score decreased across the groups (3,681 (2,374-4,500) vs. 3,395 
(2,910-4,322) vs. 3,295 (2,766-4,340) g, p=0.02, and 1.08 (-1.90-3.25) vs. 0.45 
(-0.83-3.18) vs. -0.02 (-1.51-2.96), p=0.009). In a multiple linear regression 
analysis, gestational weight gain (kg) was positively associated with offspring 
birth weight (g) (β=19, p=0.02) and birth weight z-score (β=0.06, p=0.008), 
when adjusted for pre-pregnancy BMI, HbA1c at 36 weeks, smoking, parity 
and ethnicity.
Conclusion: Higher gestational weight gain in women with type 1 diabetes 
was associated with increasing offspring birth weight independent of glycae-
mic control and pre-pregnancy BMI.
Supported by: EFSD / LifeScan
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Abnormal renin-angiotensin system in early pregnancy in a prospective 
cohort of women with type 1 diabetes
D. Fu1, J.Y. Yu1, A.J. Jenkins1,2, A.J. Nankervis3, K.F. Hanssen4,5,  
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Background and aims: The renin-angiotensin system plays an important 
role in regulation of blood pressure, and abnormalities predispose to cardio-
vascular disease. Preeclampsia (PE), a hypertensive disorder of pregnancy, is 
~4 fold more prevalent in women with diabetes, but underlying mechanism 
is not fully understood. In this prospective study of type 1 diabetic (T1DM) 
women, we aimed to determine whether plasma levels of angiotensin-con-
verting enzyme (ACE), angiotensinogen, and prorenin were altered early in 
pregnancy in women with subsequent PE, and whether they could serve as 
early markers for PE.
Materials and methods: Maternal plasma ACE, angiotensinogen and 
prorenin were measured longitudinally by ELISA at approximately 12, 22, 
and 32 weeks of pregnancy in 23 women with T1DM who subsequently 
developed PE (DMPE+), 24 diabetic women who did not have PE (DMPE-
), and 20 non-diabetic normotensive women (DM-PE-). The three subject 
groups were matched for age, diabetes duration, HbA1C, and parity, as ap-
propriate. Diabetic women were entirely complication-free before pregnancy. 
All study visits took place before the clinical onset of PE.
Results: Plasma concentrations of both ACE and prorenin were similar in 
the DMPE+ vs. DMPE- women at all three trimesters, but angiotensinongen 
was significantly lower in DMPE+ than DMPE- subjects at the 3rd trimester 
(P<0.01). Interestingly, all diabetic women, whether they subsequently devel-
oped PE or not, showed significantly higher levels of ACE and lower levels 
of angiotensinogen at the 1st trimester compared with non-diabetic controls 
(P<0.01), suggesting increased activity of the renin-angiotensin pathway.
Conclusion: Plasma levels of ACE, angiotensinongen, and prorenin can-
not be used for early prediction of PE in women with T1DM. However, the 
renin-angiotensin system appears to be abnormally active early in pregnancy 
in women with T1DM, creating ‘fertile soil’ for the subsequent development 
of PE.
Supported by: NIH grants M01-RR-1070 and M01 RR-14467
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Impact of parity on glycaemic control, cardiovascular risk factors and 
diabetes-related chronic complications: a multicentre study in Brazil
C.A. Negrato1, M.B. Gomes2;  
1Internal Medicine, Bauru‘s Diabetics Association, Bauru,  
2Diabetes Unit, State University of Rio de Janeiro, Brazil.
Background and aims: Pregnancy in women with preexisting diabetes can 
predispose these women to some diabetes-related chronic complications or 
accelerate the course of these complications if they are already present. The 
aim of this study was to determine the impact of parity on glycemic con-
trol, cardiovascular risk factors and diabetes-related chronic complications in 
women with type 1 diabetes in Brazil.
Materials and methods: This was a multicenter cross-sectional study con-
ducted between December 2008 and December 2010 in 28 public clinics in 
20 cities from the four Brazilian geographic regions. Data were obtained from 
1,532 female patients, 59.2% Caucasian, aged 25.2 ± 10.6 years. The diabetes 
mean duration was 11.5 ± 8.2 years. Patient information (clinical factors and 
number of pregnancies) were obtained through a questionnaire and a chart 
review. Number of pregnancies were stratified in five groups: group 0 (no 
pregnancy), group 1 (one pregnancy), group 2 (two pregnancies), group 3 
(three pregnancies) and group 4 (≥four pregnancies).
Results: The comparison between the patients stratified according to parity 
showed that patients from groups 0, 1 and 2 were younger than patients from 
group 4 (p<0.001). Patients from groups 0 and group 1, had been diagnosed 
with diabetes with lower age and had less mean diabetes duration than pa-
tients from the other groups (p<0.001). The age at menarche was not different 
between the four groups (p=0.3). Overweight or obesity was present in 538 
patients (35.1%). Patients from group 0 had lower BMI than patients from the 
other groups. A linear association was found between the frequency of over-
weight or obesity and parity (p=0.004). A difference between the five groups 
was observed for the mean of HbA1c without difference between-groups. A 
higher frequency of hypertension and higher levels of systolic and diastolic 
blood pressure were observed in group 4 in comparison to the other groups 
(p<0.01 for all comparisons). Metformin was used by 162 patients (10.6 %) 
and its use was related to parity (p=0.02). The number of pregnancies was 
related to the presence of diabetes-related chronic complications (micro and 
macrovascular). A lower frequency of non-proliferative and proliferative 
retinopathy and macrovascular complications was noted in patients from 
group 0 in comparison to the other groups (p<0.01). A tendency for an asso-
ciation between parity and nephropathy was also observed (p=0.056).
Conclusion: Parity in women with type 1 diabetes is strongly associated with 
the presence of cardiovascular risk factors and diabetes-related chronic com-
plications Further prospective studies must be addressed to establish the rela-
tionship between the impact of pregnancy upon starting and/or deteriorating 
cardiovascular risk factors and diabetes-related chronic complications.
Supported by: Farmanguinhos/Fundação Oswaldo C
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Association between breast-feeding duration with post-pregnancy 
glycaemic control and body weight in women with type 1 diabetes
M.T. Małecki1, B. Katra1, K. Cyganek1, P. Blizanowska2, B. Matejko1;  
1Department of Metabolic Diseases,  
2Department of Pharmacy, Jagiellonian University, Kraków, Poland.
Background and aims: In accordance with the new WHO guidelines, breast-
feeding (BF) is recommended until the sixth month of the baby’s life. Such 
model of feeding reduces the risk of digestive tract infections with infants and 
their susceptibility to illnesses. Apart from obvious benefits for the infant’s 
health, it has also beneficial effect on the mother’s health. BF may be more 
challenging in women with type 1 diabetes (T1DM) because of difficulties in 
maintaining their glycemic control. The frequency of long-term BF in T1DM 
women and its relationships with clinical course of T1DM is unknown.
Materials and methods: The aim of the study was assessment of frequency 
of long BF (defined as 6 months or longer) in T1DM women and its impact 
on post-pregnancy glycemic control as well as body weight. We collected data 
on BF from singleton pregnancies in 176 consecutive women with T1DM 
(mean age 27.8 yrs, mean BMI 23.3, mean T1DM duration 11.9) who were 
under our medical care between 1999-2012. They were contacted to complete 
a standard questionnaire on BF. Their medical records were available for the 
analysis. We divided all post-pregnancy follow-up data into three groups: 
within 6 months after delivery (period I), 6-12 months after delivery (period 
II), and more than 12 months (period III).
Results: The majority of T1DM women (n=110, 62,5%) breastfed for at least 
6 months. The clinical characteristics of long-term BF T1DM women vs. 
short-term BF T1DM women was as follow: mean age - 28.4 yrs. vs. 26.7 
(p=0.01), mean T1DM duration - 11.9 yrs. vs. ± 11.4 (p=0.64), mean BMI be-
fore pregnancy - 23.5 kg/m² vs. 23.6 (p=0.64), proportion of pregnancy plan-
ning - 68% vs. 56 (p=0.10). The HbA1c level in the long-term BF was lower at 
period II and III of the post-pregnancy follow-up (6.0% vs. 7.7% p=0.05; 6.9% 
vs. 7.9%; p=0.02, respectively). BMI did not differ between long-term BF and 
short-term BF group at any follow-up period.
Conclusion: Long-term BF seems to be associated with lower HbA1c, but not 
BMI, after the pregnancy. Type 1 diabetes and breast-feeding require a change 
in the habits and routines of everyday life. This results could be a better treat-
ment motivation in this group of patients.
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Presence of components of the metabolic syndrome in offspring of 
mothers with type 1 diabetes
Z. Vlachová1, B. Bytoft2, S. Knorr3, T.D. Clausen4, R. Beck-Jensen5,  
K. Højlund1, E.R. Mathiesen6, P. Ovesen7, H. Beck-Nielsen1, C.H. Gravholt3, 
P. Damm2, D.M. Jensen1;  
1Department of Endocrinology, Diabetes Research Center, Odense 
University Hospital, 2Department of Obstetrics, Center for Pregnant Women 
with Diabetes, Rigshospitalet, Copenhagen, 3Department of Endocrinology 
and Internal Medicine, Aarhus University Hospital, 4Department of 
Gynecology and Obstetrics, Hillerød Hospital, 5University Department of 
Growth and Reproduction, Rigshospitalet, 6Department of Endocrinology, 
Rigshospitalet, Copenhagen, 7Department of Gynecology and Obstetrics, 
Aarhus University Hospital, Denmark.
Background and aims: Some studies have shown that intrauterine expo-
sure to maternal type 1 diabetes (TIDM) may have long-term effects on the 
offspring including increased risk of obesity and type 2 diabetes. However, 
the knowledge of the long-term impact of various maternal glycaemic levels 
during pregnancy is scarce. We aimed to study body composition and other 
metabolic risk factors in offspring of T1DM mothers compared to offspring 
of non-diabetic mothers with specific focus on associations between mater-
nal glycaemic control during pregnancy and long-term outcomes of the off-
spring.
Materials and methods: During 1993 to 1999 pregnancies of women with 
T1DM in Denmark were prospectively reported to a central registry in the 
Danish Diabetes Association (n=1215). Maternal glycaemic status along with 
pregnancy outcome and complications were recorded. We invited 746 chil-
dren from these pregnancies to a follow-up examination. A group of control 
children matched with respect to date of birth, sex and postal code was iden-
tified from the National Central Person Registry. Anthropometric measure-
ments and blood sampling for metabolic characterization inclusive an oral 
glucose tolerance test were performed.
Results: We examined 277 children of women with T1DM (mean age 16.7 
(13.0 - 19.8 years)) and 304 control children (mean age 16.8 (13.5 - 20.4 
years)). Offspring of women with T1DM had significantly higher body mass 
index standard deviation score (BMI-sds) based on Danish reference curves 
for BMI adjusted for age and sex (ΔBMI-sds: 0.46 (95% CI; 0.27 - 0.65)), 
waist circumference (Δ: 3.6; 2.4 - 4.9 cm), waist-to-hip ratio (Δ: 0.009; 0.002 
- 0.016), fasting serum insulin (Δ: 6.9; 2.0 - 11.6 pmol/l) and 2 h serum insu-
lin (Δ: 43.5; 14.4 - 72.7 pmol/l) compared to control offspring. Furthermore 
we observed that offspring of T1DM mothers with peri-conceptional HbA1c 
levels above 8 % (63 mmol/mol) had higher BMI, waist circumference and 2 
h serum insulin than offspring of mothers whose peri-conceptional HbA1c 
was below 7 % (53 mmol/mol).
Conclusion: Offspring of mothers with T1DM have a more unfavourable 
metabolic profile than children of non-diabetic mothers. Our data indicate 
that maternal intrauterine hyperglycemia plays a significant role in this.
Clinical Trial Registration Number: NCT01559181
Supported by: EFSD/Novo Nordisk, The Danish Council for Independent Re-
search, Lundbeck
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Cardiovascular autonomic tone relation to obesity stage, metabolic 
syndrome, advanced glycation end products and other metabolic 
parameters in prediabetes
R. Dimova, T. Tankova, N. Chakarova, G. Grozeva, L. Dakovska;  
Medical University Sofia, Clinical Center of Endocrinology, Bulgaria.
Background and aims: The aim of the study was to assess cardiovascular 
autonomic function (CAF) at different stage of obesity and in the presence 
of metabolic syndrome (MetS), and its relation to metabolic parameters and 
advanced glycation end products (AGEs) in subjects with prediabetes - im-
paired fasting glucose (IFG) and impaired glucose tolerance (IGT).
Materials and methods: A total of 148 subjects - 91 females and 57 males 
(mean age 50.4±13.6years, mean BMI 32.4±8.8kg/m2) with prediabetes - 83 
with IFG, 29 with IGT and 36 with IFG+IGT, divided into 5 groups according 
to BMI: 15 normal weight, 43 overweight, 48 obesity class I, 25 class II, and 17 
class III, and into 2 groups according to the presence of MetS - 118 with MetS 
and 30 controls were enrolled. Glucose tolerance was studied during OGTT. 
Anthropometric indices, blood pressure and serum lipids were measured. 
AGEs were evaluated by skin autofluоrescence (AGE-Reader). Body compo-
sition was estimated by impedance analysis (InBody 720). CAF was assessed 
by ANX-3.0 using frequency-domain analysis during standard clinical tests 
- deep breathing, Valsalva and standing from a seated position.
Results: No statistically significant difference in CAF was established be-
tween the groups according to BMI and the presence of MetS, as well as be-
tween subgroups according to glucose intolerance. In subjects with prediabe-
tes sympathetic and parasympathetic tone at rest and during applied clinical 
tests showed negative correlation with visceral fat area, AGEs, and HbA1c 
and did not demonstrate significant correlation with BMI, waist circumfer-
ence, lipid profile and blood pressure.
Conclusion: Obesity stage and MetS are not associated with CAF deteriora-
tion in prediabetes on their own. Central obesity, HbA1c, and AGEs accu-
mulation appear to be the main determinants of autonomic imbalance and 
increase cardiovascular risk at the early stages of glucose intolerance.
Supported by: Medical University Sofia
1123
Decreased beta cell function is associated with cardiovascular autonomic 
neuropathy in newly diagnosed type 2 diabetic patients
X.b. Yang1, H.r. DENG1, W. Xu1, Y.h. Zhu1, S.d. Lin2, H.z. Yang3, D.h. Cai4, 
J.p. Weng1;  
1Third Affiliated Hospital of Sun Yat-sen University, Guangzhou,  
2First Affiliated Hospital of Shantou University Medical College, 
3Guangdong Provincial People’s Hospital, 4Zhujiang Hospital, Southern 
Medical University, Guangzhou, China.
Background and aims: Cardiovascular autonomic neuropathy (CAN) is 
closely associated with increased mortality in diabetic patients. Several risk 
factors of CAN have been clearly clarified. However, the impact of beta-cell 
function on CAN, especially in newly diagnosed type 2 diabetic patients, is 
still controversial. Therefore, this study aimed to investigate the association 
between beta-cell function and CAN in newly diagnosed type 2 diabetic pa-
tients.
Materials and methods: 90 newly diagnosed type 2 diabetic patients (68.9% 
male, mean age: 45 years old) were enrolled. Standard battery of Ewing tests, 
including Valsalva manoeuvre (Valsalva ratio), the deep breathing test of 
expiration-to-inspiration ratio and the lying to standing test among the heart 
rate tests, and the orthostatic hypotension test, were used to identify CAN. 
Based on the results from Ewing tests, subjects were then further divided 
into two groups: diabetic patients with CAN (CAN+ group) or without CAN 
(CAN- group). Fasting glucose, insulin and c-peptide were measured. HO-
MA-B and HOMA-IR were calculated.
Results: The positive rate of CAN in newly diagnosed type 2 diabetic pa-
tients was 22.2%. Compared with CAN- group (n=70), CAN+ group 
(n=20) had significantly lower fasting insulin, c-peptide and HOMA-B 
[median (interquartile range): 5.34(3.50~8.57)mu/L VS 8.75(4.92~13.87)
mu/L, P=0.045; 0.51(0.39~0.65)nmol/L VS 0.75(0.51~0.98)nmol/L, P=0.14; 
15.75(9.52~36.36) VS 32.28(18.67~61.04), P=0.012, respectively]. No sig-
nificant difference was observed in HOMA-IR between groups. Fasting c-
peptide was correlated with valsalva ratio(r=0.24, P= 0.043) and the lying 
to standing test (r=0.26, P=0.023). Logistic regression analysis revealed that 
HOMA-B was an independent protective factor of CAN in this population 
(OR: 0.97, 95%CI: 0.94~0.99, P=0.027).
Conclusion: Prevalence of cardiovascular autonomic nerve is high in newly 
diagnosed type 2 diabetic patients. Decreased beta-cell function is associated 
with CAN in this population.
Supported by: STPPGDP, China (2006A36001001)
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Autonomic dysfunction is associated with loss of postprandial glycaemic 
control in newly diagnosed type 2 diabetes patients
T.F. Dejgaard1, J. Fleischer2, S.L. Cichosz2, P. Hoeyem2, E. Laugesen2,  
P.L. Poulsen2, J.S. Christiansen2, L. Tarnow2,3, T.K. Hansen2;  
1Steno Diabetes Center, Gentofte, 2Institute of Clin. Medicine, Aarhus 
University and Dept. of Endocrinology and Internal Medicine, Aarhus 
University Hospital, 3Nordsjaellands Hospitaler, Hilleroed, Denmark.
Background and aims: Maintaining tight blood glucose control by minimiz-
ing the magnitude and frequency of glucose excursions and especially post-
prandial glucose control is essential in achieving an ideal glycaemic control. 
Glycaemic variability may play a significant role in the development of dia-
betic neuropathy e.g. through activated oxidative stress. The aim of the pre-
sent study was to investigate the association between autonomic dysfunction 
and postprandial glucose control in newly diagnosed type 2 diabetes patients.
Materials and methods: A total of 81 patients diagnosed within the last 5 
years with type 2 diabetes according to WHO-criteria were consecutively re-
cruited for this observational cohort study. All patients were equipped with a 
continuous glucose monitor (CGM) for three days and performed self-moni-
tored blood glucose measurements (SMBG) at least four times per day during 
this period. Afterwards they were all tested for cardiac autonomic neuropathy 
(CAN) using conventional cardiovascular reflex tests (response to standing, 
deep breathing and Valsalva manoeuvre) and divided according to the pres-
ence of CAN. Postprandial glucose measures were calculated using CGM for 
each group based on the time of SMBG before main meals.
Results: The cohort consisted of 38 women and 43 men with non-insulin-
treated type 2 diabetes, a mean age of 58 (±11) years, a BMI of 30 (±4), and 
an HbA1c of 6.6 (± 0.7) %. CAN was present in 22 subjects (9 women and 13 
men). The groups with and without CAN were similar with respect to blood 
pressure, HbA1c, cholesterol levels and had comparable smoking habits. The 
nocturnal glucose drop and dawn glucose levels were significantly higher in 
the group with CAN as compared with patients without CAN (7.4 versus 
6.5 mmol/L, P=0.017) and (7.9 versus 7.2 mmol/L, P=0.045). The breakfast 
premeal glucose was not different between patients with or without CAN, but 
peak glucose after breakfast was significantly higher in patients with CAN 
(11.4 versus 9.7 mmol/L, P=0.009), and the autonomic dysfunction group 
had significantly larger excursions 0.5-1.5 hour post meal (P<0.04, Figure 1). 
No difference in glucose was seen between groups at lunch or dinner. After 
adjusting for gender, age, systolic blood pressure, resting heart rate and BMI, 
the presence of CAN still had a significant influence on breakfast peak glu-
cose (P=0.005) and the postprandial breakfast glucose increase.
Conclusion: CAN is associated with loss of postprandial control in newly 
diagnosed type 2 diabetes patients. These findings emphasise the importance 
of screening for autonomic changes early in diabetes and the need for under-
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standing the complex interaction between postprandial glucose excursions 
and the development of autonomic neuropathy.
Clinical Trial Registration Number: NCT00674271
1125
Artery stiffness parameters in patients with cardiovascular autonomic 
neuropathy and type 2 diabetes mellitus
V.A. Serhiyenko, V.B. Segin, S. Ajmi, A.A. Serhiyenko;  
Endocrinology, National, Lviv, Ukraine.
Background and aims: Artery stiffness parameters are known as a poten-
tially applicable atherosclerotic risk marker and strongest predictors of car-
diovascular morbidity and mortality. This study was aimed to investigate the 
parameters of arterial stiffness in patients with type 2 diabetes mellitus (DM) 
and cardiovascular autonomic neuropathy (CAN).
Materials and methods: The study involved 65 patients with type 2 DM of 
age 54.7±3.8 years, median BMI 28.5±0.9 kg/m2 and HbA1c level 7.4±0.6%, 
among them 12 patients without cardiovascular diseases (CVD) and CAN, 14 
patients with mild, 18 - moderate and 21 severe CAN. Control - 12 healthy 
volunteers. The diagnosis of CAN was based on the results of 5 standard 
cardiovascular tests, 24-hour HRV. The 24-hour blood pressure profiles, 
aorta (AIxao) and brachial augmentation index (AIxbr), pulse wave veloc-
ity (PWV) and ambulatory arterial stiffness index (AASI) were assessed by 
TensioMedTM Arteriograph 24 (Hungary). Statistics: ANOVA.
Results: We found that development of mild CAN in patients with type 2 DM 
is associated with statistically significant increase of artery stiffness indices 
(AIxao +22.1%, AIxbr +41.9%, AASI +16.7%, p<0.05; PWV +13.5%, p<0.01) 
compared to patients without verified CVD and CAN. The average value of 
PWV was considered as high (10.1 m/sec). Among the patients of this group 
in 7.1% we observed the optimal value of AIxbr, in 50.0% - normal, 42.9% - 
elevated; in 42.9% - normal value of PWV and in 57.1% - elevated. The arteri-
al stiffness parameters in patients with moderate CAN exceed the physiologi-
cal values, in particular AIxao +26.2%, p<0.01; AIxbr +66.2%, p<0.001; PWV 
+24.7%, p<0.001; AASI +30.6%, p<0.01 compared to group without CVD 
and CAN. PWV was statistically significant higher compared to patients with 
mild CAN (+9.9%, p<0,05). The value of AIxbr was normal in 55.5%, elevated 
in 38.9%, pathological in 5.6%; PWV in 16.7% - normal, 50.0% - elevated and 
in 33,3% of cases pathological. The development of severe CAN was charac-
terized by elevated and pathological values of arterial stiffness parameters, in 
particular AIxao +37.8%, AIxbr +81.2%, PWV +37.1% and AASI +55.6%, 
p<0,001 compared to patients without CVD and CAN. The values of PWV 
and AASI were statistically significant higher compared to patients with mild 
(+20.8% and +33.3%, p<0,001) and moderate CAN (+9.9% and +19.2%, 
p<0,05), Among the patients of this group mostly elevated and pathological 
parameters were observed: in 42.9% - elevated parameters of AIxbr; in 23.8% 
-PWV; in 38.1% - pathological levels of AIxbr; 61.9% - PWV; normal value of 
PWV was observed in 14.3 % of patients, AIxbr in 19.0% (table).
Conclusion: The development and progression of CAN is associated by in-
creasing of artery stiffness parameters, in particular mild CAN by elevated 
PWV, moderate - by elevated and severe by elevated and pathological values 
of all investigated parameters. Non-invasive arteriography may be included 
in complex algorithm for CAN diagnosis and reduction of artery stiffness 
parameters should be one of the treatment goals.
1126
Low serum ficolin-3 levels indicate peripheral neuropathy in diabetic 
patients
X. Zhang, Y. Hu, J. Shen, F. Liu, W. Jia;  
Endocrinology & Metabolism, Shanghai Jiaotong University Affiliated Sixth 
People’s Hos, China.
Background and aims: Diabetic peripheral neuropathy(DPN) is one of the 
most common chronic complications of diabetes. The inflammatory mecha-
nisms involving complement activation has been shown to take part in the 
pathophysiology of DPN. Ficolin-3, a soluble molecule of the innate system, 
has a primary role in the activation of the lectin pathway in the complement 
system. In the present study we aimed to elucidate the possible connection 
between serum ficolin-3 levels and DPN in diabetes mellitus.
Materials and methods: Consecutive diabetic inpatients at the Shanghai 
Clinical Medical Center of Diabetes from January 2012 to December 2013 
were randomly recruited in this cross-sectional study. The demographic and 
clinical variables were obtained through a questionnaire. Serum ficolin-3 
concentration was measured with ELISA. DPN was diagnosed by abnormali-
ties in two or more of three major categories (positive symptoms, increased 
vibration perception threshold (VPT) values, and slowed nerve conducting 
velocities (NCVs)). Patients were divided into two groups including DPN 
and non-DPN group.
Results: A total of 466 patients (mean age, 57.98±11.09 years; male/female, 
256/210; mean diabetes duration, 9(4-15) years) were finally enrolled in this 
study. There was no difference in serum ficolin-3 levels in male and female 
patients[(25.00±11.52) vs (23.74±12.27)ng/mL, P=0.257)], also no dif-
ference was found in the prevalence of DPN in male and female patients. 
There were significantly difference in ficolin-3 levels among patients with-
out diabetic complications(n=156, (27.15±10.23)ng/ml), complicated with 
only DPN(n=40, (18.30±8.99)ng/ml), only diabetic nephropathy (n=25, 
(24.78±9.63)ng/ml) , as well as only diabetic retinopathy group(n=58, 
(25.27±10.26)ng/ml) (P<0.001). Serum ficolin-3 levels were lower in DPN 
patients compared with non-DPN patients(18.73±10.75 vs 26.69±10.68 ng/
mL, P<0.001). Ficolin-3 levels were negatively correlated to VPT(r=-0.158 
P=0.025). Partial spearman correlation analysis further indicated that fico-
lin-3 was still associated with VPT (r= -0.283 p=0.001) even after adjusted 
for age, diabetes duration, smoking, hypertension, alanine aminotransferase 
and Glomerular filtration rate. Logistic regression analysis of DPN showed 
that age (OR, 1.047; 95%CI (1.005-1.092); p=0.029), diabetes duration(OR, 
1.10; 95%CI 1.040-1.166; p=0.001), ficolin-3(OR, 0.939; 95%CI 0.910-0.970; 
p<0.001) were independent associated factors for DPN. The prevalence of 
DPN among ficolin-3 quartiles was compared too, and the results revealed 
that it’s elevated with the descending serum ficolin-3 concentrations. Par-
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ticipants in the lowest quartile of serum ficolin-3 had a significantly in-
crease risk of DPN compared with those belongs to the highest quartiles. 
Compared with Quartile1(referent), patients in Quartile2(OR, 2.76; 95%CI, 
1.56-4.88; P<0.001) ,Quartile 3(OR, 3.02 ; 95%CI,1.69-5.40; P<0.001) and 
Quartile4(OR, 6.84 ; 95%CI, 3.39-13.80; P<0.001) had higher risk of DPN.
Conclusion: Ficolin-3 levels decrease in diabetic patients with DPN, strongly 
inversely correlated with VPT. The risk of DPN increased with the decrease 
of serum ficolin-3 levels. Therefore, decreased ficolin-3 level may be a bio-
marker of DPN in diabetic population.
Supported by: grant (81270397) from the National Science Foundation Items 
of China
1127
High serum cystatin C indicates diabetic peripheral neuropathy in type 
2 diabetes
Y. Hu1, F. Liu1, J. Shen1, H. Zeng1, L. Li1, J. Zhao2, J. Zhao3, F. Lu1, W. Jia1;  
1Endocrinology & Metabolism, 2Vascular Surgery,  
3Interventional Radiology, Shanghai Jiaotong University Affiliated Sixth 
People’s Hospital, China.
Background and aims: Recent studies have shown that cystatin C is a pre-
dictor of mortality and cardiovascular diseases. We carried out this study to 
explore the relationship between serum cystatin C and diabetic peripheral 
neuropathy(DPN)
Materials and methods: Totally 937 diabetic patients were randomly en-
rolled in this cross-sectional study. The demographic and clinical variables 
were obtained through a questionnaire. Serum cystatin C concentration was 
measured with immunoturbidimetry. DPN was evaluated by neurological 
symptoms, neuro- thesiometer and electromyography.
Results: Serum cystatin C levels were higher in confirmed DPN pa-
tients[1.3(1.1-1.5)mg/L] compared with unconfirmed DPN[1.1(0.9-1.3)
mg/L, p<0.001] and non-DPN patients(1.0(0.9-1.3)mg/L, p<0.001). Spear-
man correlation analysis showed that confirmed DPN was positively re-
lated to age(r=0.196, p<0.001), diabetes duration(r=0.141, p<0.001), 
hypertension(r=0.128, p<0.001), CysC(r=0.154, p<0.001), Cr(r=0.066, 
p<0.05) and urinary albumin (r=0.144, p<0.001), and negatively related to 
GFR(r=-0.164, p<0.001). Patients were then divided into quartiles according 
to the serum CysC levels. Compared with cystatin C Quartile1(referent), the 
risk of confirmed DPN was significantly higher in Quartile2(OR, 1.753; 95%CI 
1.055-2.912; p<0.05), Quartile3(OR, 2.463; 95%CI 1.445-4.917; p<0.001) and 
Quartile4(OR, 5.867; 95%CI 2.075-16.589; p<0.001). Finally, receiver operat-
ing characteristic (ROC) analysis revealed that the optimal cutoff point of cys-
tatin C to predict DPN(OR, 2.380; 95%CI 1.577-3.592; p<0.0001) in diabetic 
patients without diabetic nephropathy was 1.25mg/L(AUC=0.704, 95 % CI 
0.645-0.763, Youden index=0.305, sensitivity: 61.8%, specificity: 68.6%).
Conclusion: Cystatin C levels are higher in diabetic patients with DPN, and 
high serum cystatin C may be a risk factor and potential biomarker for dia-
betic peripheral neuropathy.
Supported by: the National Natural Science Foundation of China 81270397& 
81170759
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GABA-dependent pain facilitation of spinal 5-HT3 receptor in diabetic 
neuropathic pain
C.S.C. Morgado1, M.A. Silva1, D.A. Martins2, I.F. Tavares1;  
1Department of Experimental Biology, 2Department of Experimental 
Biology, Faculty of Medicine of Porto, University of Porto, Portugal.
Background and aims: Diabetic neuropathic pain (DNP) is a frequente 
complication of diabetes, associated with increased morbidity and reduced 
quality of life. Impaired spinal pain inhibition is likely to contribute to DNP, 
namely the increased GABA content and the shift in its role from inhibitory 
to excitatory through its action on GABA A receptors (GABAAR). The acti-
vation of spinal 5-HT3 receptor (5-HT3R) is known to induce GABA release 
and its inhibition was shown to be anti-hyperalgesic in streptozotocin (STZ)-
diabetic rats. We hypothesised that the anti-hyperalgesic effect of 5-HT3R 
inhibition is mediated by counteracting the excitatory role of GABA through 
GABAAR at the spinal cord of STZ-diabetic rats. In this study we evaluated 
the effect of intrathecal administration of muscimol (GABAAR agonist) on 
the mechanical hyperalgesia reversal induced by 5-HT3R inhibition.
Materials and methods: Diabetes was induced in male Wistar rats by in-
traperitoneal injection of STZ solution (60 mg/Kg). Control animals re-
ceived only the vehicle. Blood glucose concentration was quantified in blood 
samples taken from the tail vein and only STZ-injected rats with glycaemia 
higher than 270 mg/dl were considered diabetic and included in the study. 
At 4 weeks post-injection, a catheter was implanted in the lumbar spinal 
cord subarachnoid space for drug administration. Mechanical nociception 
was evaluated by paw-pressure test in control and STZ-diabetic rats after in-
trathecal delivery of saline (STZ+saline; ctr+saline) or Y-25130 hydrochlo-
ride (Y-25130, 5-HT3R antagonist, 30 fmol, STZ+Y-25130; ctr+Y-25130). An 
additional group of STZ+saline and STZ+Y-25130 diabetic rats received in-
trathecal administrations of muscimol (0.3 ug) at 3,5h after saline or Y-25130 
infusions(STZ+saline+musc; STZ+Y-25130+musc) and the PPT were evalu-
ated 30 min after. Means were compared by ANOVA repeated measures 
or one-way ANOVA followed by Tukey post-hoc test and are presented as 
mean±SEM.
Results: The STZ-diabetic rats presented significantly increased blood glu-
cose levels and decreased body weights at 4 weeks after diabetes induction 
when compared with control rats. The STZ-diabetic rats developed mechani-
cal hyperalgesia as demonstrated by the significantly lower paw pressure 
threshold (PPT) when compared with control animals (STZ: 5.74 ± 0.71; con-
trol: 10.42± 0.20, p<0.001). Intrathecal delivery of Y-25130 in STZ-diabetic 
rats significantly increased the PPT, with a maximum peak effect at 4h post-
administration (STZ+saline: 6.10± 0.32; STZ+ Y-25130: 10.98± 0.74, p<0.01). 
The administration of muscimol 30 min before the peak maximum effect of 
Y-25130 abolished its anti-hyperalgesic effect in STZ-diabetic rats (PPT in 
STZ+Y-25130: 10.98± 0.74; STZ+Y-25130+Musc: 5.70±0.64, p<0.01).
Conclusion: These findings suggest that the activation of 5-HT3R at the spi-
nal cord of STZ-diabetic rats is likely to increase GABAergic neurotransmis-
sion. Considering the previously reported shift in the role of GABA, through 
the activation of GABAAR, in STZ-diabetic rats, this is likely to be facilitating 
pain spinal transmission. The use of 5-HT3R antagonists may then be con-
sidered as a promising pharmacological treatment in alleviating mechanical 
hyperalgesia induced by diabetes.
Supported by: EU Project REDDSTAR and SPD grant
1129
Glucosamine induced Schwann cell death and nerve conduction delay 
associated with activation of hexokinase
H. Mizukami1, S. Ogasawara1, K. Sango2, K. Tsuboi1, C.K. Sookja3,  
S. Yagihashi1;  
1Pathology and Molecular Medicine, Hirosaki University, Hirosaki, 
2Peripheral Nerve Research Laboratory, Tokyo Metropolitan Medical 
Research Institute, Setagaya, Japan, 3Department of Anatomy, University of 
Hong-Kong, China.
Background and aims: Glucosamine is one of the amino-sugars, widely sold 
on the market for relief of symptoms in patients with arthritis. In our previ-
ous studies, comprehensive metabolomics analysis enabled us to find accu-
mulation of glucosamine (GlcN) in the sciatic nerve of STZ-diabetic mice. 
GlcN is known to metabolize to GlcN-6-phosphate via hexokinase (Hex), but 
its metabolic sequelae is not well understood. In this study, we therefore ex-
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amined whether excessive GlcN-Hex flux influences on Schwann cell survival 
in vitro and peripheral nerve function in vivo.
Materials and methods: Schwann cell line (IMS32) maintained in DMEM 
supplemented with 10% FBS in 5% CO2 was stimulated with 10 mM GlcN. 
Western blot was conducted for the evaluation of apoptosis to identify 
cleaved caspase3 (CC3) and for the expression of modified glycosylation (O-
GlcNAC). Hex activation was sepraretely examined in the fractionated mito-
chondoria and cytosole of IMS32 exposed to GlcN. Specific siRNA for Hex I 
was applied to see the effects of the Hex I on GlcN-Hex pathway on Schwann 
cell survival. To see the effects of GlcN on Hex expression in the peripheral 
nerve in vivo, male C57Bl/6J mice, 12 weeks of age were administered (i.p.) 
with 2 g/kg GlcN and nerve conduction velocity was measured. A half of the 
animals were pretreated with inosine (100 mg/kg, i.p.), as an ATP donor, one 
hour prior to GlcN administration. Normal control mice were given saline 
alone to serve for comparison.
Results: In vitro experiment revealed that GlcN exposure elicited increased 
CC3 expression in Schwann cells. Concurrently, O-GlcNAc expression was 
increased with GlcN exposure, but it was not proportional to the extent of 
apoptosis. Hex I expression in mitochondria fraction was markedly increased 
after GlcN exposure irrespective of glucose concentration. Knock down of 
Hex I by siRNA suppressed the expression of GlcN-innduced CC3 activation 
and caused prolonged cell survival. Mice injected with GlcN exhibited en-
hanced Hex expression of mitochondrial fraction and delayed nerve conduc-
tion, which was prevented by pretreatment with inosine.
Conclusion: GlcN exposure induced Schwann cell death with Hex activa-
tion in vitro and nerve conduction delay in vivo. Inhibition of Hex activation 
by siRNA in vitro and inosine pretreatment significantly inhibited GlcN-
induced Schwann cell death or neuropathic changes. These findings suggest 
that GlcN-Hex activation may have a pathogenetic role in diabetic neuropa-
thy.
PS 098 Mechanisms and outcomes 
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Glycaemic variability as measured by continous glucose monitoring  
and diabetic cardiovascular autonomic neuropathy in patients with  
type 2 diabetes
J. Ji-Eun, O. Sewon, J. Sang-Man, K. Jae Hyeon;  
Endocrinology and Metabolism, Samsung Medical Center, Seoul,  
Republic of Korea.
Background and aims: It is still not clear whether glycemic variability con-
tributes to the development of diabetic autonomic neuropathy. We investi-
gated the association between glycemic variability determined by continuous 
glucose monitoring (CGM) and diabetic cardiovascular autonomic neuropa-
thy in the patients with type 2 diabetes.
Materials and methods: A total of 184 patients with type 2 diabetes with 
estimated glomerular filtration rate of >30ml/min/1.73m2 who wore a CGM 
device for 72 hours were enrolled. As parameters of glycemic variability, the 
standard deviation (SD) around the mean and the coefficient of variation 
(CV, SD/mean) were obtained from the CGM data. All subjects were inves-
tigated for five standard cardiovascular reflex tests according to the Ewing’s 
protocol. Diabetic cardiovascular autonomic neuropathy was defined as the 
presence of at least two abnormal tests or autonomic neuropathy points ≥2.
Results: Among the enrolled patients, 97 had diabetic cardiovascular au-
tonomic neuropathy (52.7%, neuropathy group). SD (49.76±19.28 vs 
46.05±21.24, P=0.22) and CV (28.63±8.24 vs 28.33±9.88, P=0.81) did not 
differ between neuropathy and control group. The hemoglobin A1c (HbA1c, 
%) was higher in neuropathy group ( 8.43±1.48 vs 7.95±1.32, P=0.02) than in 
the control group. The duration of diabetes was longer in neuropathy group 
than in control group (12.49±7.52 vs 6.72±6.72 year, P=0.048). In binary lo-
gistic regression analysis, CV and SD failed to contribute to the final model.
Conclusion: We failed to show an independent association between glycemic 
variability as measured by CGM and diabetic cardiovascular autonomic neu-
ropathy in the patients with type 2 diabetes.
1131
Effects of diabetic peripheral neuropathy on the use of vision during 
walking
J.C. Handsaker1, S.J. Brown1, C.N. Maganaris2,1, F. Bowling3,  
D.E. Marple-Horvat1, A.J.M. Boulton3, N.D. Reeves1;  
1Manchester Metropolitan University,  
2Liverpool John Moores University, 3University of Manchester, UK.
Background and aims: Due to a decrease in sensory feedback, patients with 
diabetic peripheral neuropathy (DPN) are expected to use vision as a way 
of detecting foot position during walking, restricting their ability to visually 
identify upcoming obstacles. By examining how people visually acquire (first 
look at) targets during walking, we can elucidate to what extent diabetes pa-
tients use their eyes to identify foot position, and plan subsequent stepping 
during walking.
Materials and methods: Twelve participants (4 with diabetic peripheral neu-
ropathy [DPN], 4 with non-neuropathic diabetes [D], and 4 healthy controls 
[C]) negotiated a stepping walkway, stepping on irregularly placed targets as 
accurately as possible whilst walking at a natural gait velocity. The timing 
of horizontal eye movements during stepping were measured using an eye-
tracking device, with respect to foot-target contact. Mean group differences 
were analysed using a one-way ANOVA (p<0.05).
Results: Patients with DPN visually acquired the targets significantly later 
(C: -0.63 ± 0.20; D: -0.41 ± 0.12; and PN: -0.41 ± 0.14s [p<0.05]) (Fig 1.), and 
remained looking at them for significantly longer after the foot had contacted 
the ground (C: 0.00 ± 0.08; D: 0.01 ± 0.08; and PN: 0.06 ± 0.14s [p<0.05]). 
Patients with DPN also spent significantly less time in total looking at targets 
than the control group (C: 0.62 ± 0.16; D: 0.42 ± 0.15; and DPN: 0.5 ± 0.21s 
[p<0.05]), but took significantly longer to look between targets (C: 0.1 ± 0.04; 
D: 0.11 ± 0.06; and DPN: 0.14 ± 0.11s [p<0.05]).
Conclusion: Patients with neuropathy appear to use vision as a method of 
detecting when foot placement occurs during stepping. Unlike healthy con-
trols, who look to the next target prior to foot-ground contact, patients with 
neuropathy remain looking at the target until after foot-ground contact, in 
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an attempt to increase stepping accuracy. Patients with neuropathy also take 
longer to look from one target to another, which may indicate the presence 
of motor neuropathy in the extra-occular muscles. The increased time to 
look between targets may therefore be an explanation for the later acquisi-
tion of the subsequent target. This visual gaze strategy may restrict the ability 
of patients with neuropathy to identify upcoming obstacles, increasing the 
chances of tripping and falling.
Supported by: EFSD
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Influence of cardiovascular autonomic neuropathy on the next fate  
of type 1 diabetic patients; 10 years follow up
S. Lacigova, J. Brozova, D. Cechurova, J. Tomesova, Z. Rusavy;  
Medical Dept.I., University Hospital, Pilsen, Czech Republic.
Background and aims: Cardiovascular autonomic neuropathy (CAN) is 
considered to impair morbidity and mortality of diabetic patients (DM). We 
did not believe in pessimistic results of some studies. Aim of our observation-
al retrospective study was to answer to these questions: 1. In what parameters 
differed DM with CAN (CAN+) and without CAN (CAN-) at baseline of 
observation? 2. Did the presence of CAN impair morbidity in next 10 years? 
3. Was there the higher mortality among CAN+? What were the reasons of 
mortality?
Materials and methods: During the years 2002-2004 we evaluated CAN in 
278 type 1DM (Ewing battery). CAN+ involved 111, CAN- involved 167 pa-
tients. In spite of positive test, majority of patients were asymptomatic. We 
have compared the control of DM, weight, presence of microangiopatic com-
plications (retinopathy, nephropathy, peripheral neuropathy, diabetic foot) 
and cardiovascular disease and other risk factors (hypertension, hyperlipo-
proteinemia and smoking) between groups (CAN+ vs CAN-) at baseline and 
10 years after. Median (interquartil range), Wilcoxon non paired test, contin-
gency table, mono- and multifactorial regression and multivariate Regression 
step-wise were used for statistical evaluation.
Results: 1. Group CAN+ was older (47 vs 33 years; p<0.001), with longer du-
ration of DM (20 vs 12 years; p<0.01), with worse metabolic control (HbA1c) 
(73 vs 68 mmol/mol; p<0.05), higher systolic (130 vs 120 mmHg; p<0.001) 
and diastolic (80 vs 70 mmHg; p<0.01) blood pressure and lower glomerular 
filtration rate (eGF) (1.16 vs 1.35 ml/s; p<0.001). Retinopathy (67.6 vs 21.6 
%; p<0.001), neuropathy (59.5 vs 18.6%; p<0.001), diabetic foot (6.3 vs 0%; 
p<0.01) and albuminuria (41.4 vs 11.4 %; p<0.001) were more frequent in 
CAN+ at baseline. Same trend was observed in cardiovascular disease (6.3 vs 
0.6%; p<0.01), hypertension (32.4 vs 6.6%; p<0.001) and hyperlipoproteine-
mia (29.7 vs 16.8 %; p<0.05). The ratio of smokers (19 vs 21.6 %) was similar 
in both groups. 2. During the follow up period there were more new cases of 
diabetic foot (8.2 vs 0.6%; p<0.01) and cardiovascular disease (24.7 vs 3.7%; 
p<0.001) in CAN+. The incidence of other complications and risk factors were 
similar in both groups: (retinopathy: 34 vs 35.9%; albuminuria 17.5 vs 9.2%; 
neuropathy 29.9 vs 21.5%; hypertension 35.1 vs 30.7%; hyperlipoproteinemia 
38.1 vs 29.5%; smoking 1.03 vs 0%). Group CAN+ gained less weight (3 vs 5 
kg; p<0.001) and the differences in systolic (0 vs 5 mmHg; p<0.05) and di-
astolic (0 vs 0 mmHg; p<0.05) blood pressure were smaller, therefore blood 
pressure in both group were same by the end of the study. The differences in 
HbA1c did not differ in both groups. 3. In follow up period deceased 18 pa-
tients in both groups (18/278; 6.5%), 14 of them from CAN+ (14/111; 12.6%) 
and 4 from CAN-(4/167; 2.4%) (p<0,001). The strongest parameter for mor-
tality was the presence of CAN (p<0.01) and systolic blood pressure at baseline 
(p<0.05). Influence of age and duration of DM were insignificant (multivariate 
regression step-wise model). The complications of DM (8x), cardiovascular 
disease (3x) and the other reasons (7x) were the causes of death.
Conclusion: In 1DM patients with CAN the incidence of cardiovascular dis-
ease was 7 times, of diabetic foot was 14 times and mortality rate was 5 times 
higher compared to 1DM without CAN. The incidence of the other complica-
tions was similar in both groups.
Supported by: Charles University Research Fund (project No. P36)
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Heart rate response to the exercise is impaired even in a mild degree  
of dysglycaemia
J. Tomono, H. Adachi;  
Gunma Prefectural Cardiovascular Center, Maebashi, Japan.
Background and aims: Impaired heart rate (HR) response to the exercise, 
chronotropic incompetence, is known to be one of the predictors of progno-
sis, and it is induced by myocardial ischemia and/or autonomic nervous dys-
function. Although diabetes mellitus is well known to induce the autonomic 
nervous dysfunction, relationship between chronotropic incompetence and 
the degree of dysglycaemia is not fully studied yet. We planned to investigate 
the relationship between them.
Materials and methods: Consecutive 68 angina pectoris patients with com-
plete revascularisation were enrolled. They performed cardiopulmonary ex-
ercise test (CPX) and 75g oral glucose tolerance test (OGTT) at the almost 
the same date. They were divided into two groups according to the result of 
OGTT (normal glucose tolerance (NGT) group (n=30) and impaired glucose 
tolerance (IGT) group (n=38)). Chronotropic incompetence was assessed as 
follows: HR difference between peak and rest (δHR), HR increase divided 
by work rate increase (δHR/δWR) andHR recovery 1 minute after exertion 
(HRR).
Results: All three parameters were smaller in IGT group than NGT 
group, δHR: 46.2±;3.2 vs. 57.0±;3.6 (p=0.029), δHR/δWR: 0.53±;0.032 vs. 
0.66±;0.037 (p=0.011), and HRR: 16.5±;1.5 vs. 21.7±;1.6 (p=0.023), respec-
tively.
Conclusion: This study clarified that chronotropic incompetence occurs 
even in the patients with mild dysglycaemia.
1134
Brain perfusion in painful diabetic neuropathy
M. Greig1, I.D. Wilkinson1, P. Shillo2, D. Selvarajah2, R. Gandhi3, S. Tesfaye3;  
1Academic Radiology, 2Diabetes, University of Sheffield,  
3Diabetes, Sheffield Teaching Hospitals, UK.
Background and aims: Diabetic neuropathy (DN) has been linked to ab-
normalities in structure and function of the brain on Magnetic Resonance 
(MR). This study sought to explore intracranial vascular perfusion in patients 
with type-1 diabetes, with and without painful DN (PDN) and those without 
diabetes (HV).
Materials and methods: Groups: PDN=7; T1DM without neuropathy (D-
NN)=8 & HV=7. MR images were obtained at 3T (Ingenia, Philips Health-
care) using a Dynamic Susceptibility Contrast, T2*-weighted technique (TR/
TE=1250/35; 72 dynamics) to assess the passage of a bolus of intravenous gad-
olinium-chelate passing through the cerebral vascular bed. Contrast perfu-
sion was determined (Nordic Neurolab ICE, Bergen, Norway) to yield the rBF 
(cerebral blood flow), rBV (volume) and mTT (mean transit time) in the SC 
(sensory cortex), Thalami (Thal) and parieto-occipital white matter (POWM).
Results: Statistically significant differences were observed (ANOVA) between 
PDN and D-NN group mean mTT as well as PDN and HV group mean mTT 
[ eg, SC-mTT: PDN mean=2.87,SD=0.35; D-NN mean=3.46,SD=0.51; HV 
mean=3.72,SD 0.73,p=0.004; Thal-mTT:PDPN mean=2.89, SD=0.48; D-NN 
mean=3.41,SD=0.55; HV mean=3.82, SD=0.63, p=0.004]. BV and BF did not 
show significant mean differences between the 3 groups.
Conclusion: These early results (from a large on-going study) suggest cere-
brovascular perfusion is altered within the brain parenchyma of subjects with 
PDN when compared to both diabetic and non-diabetic control groups. Mi-
crovascular dysfunction may have important implications in our understand-
ing of the brain’s involvement in DN, the search for functional neuropathic 
markers and indicators of future therapeutic intervention. Further work is 
warranted to further characterise this cerebrovascular involvement.
Supported by: EFSD/Novo Nordisk
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Insulin resistance associated interhemispheric coordination deficits in 
type 2 diabetes mellitus patients: a resting-state study
W. Xia, S. Wang, P. Wang, Y. Yang, R. Huang, R. Cai, H. Sun;  
Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Background and aims: Type 2 diabetes mellitus (T2DM) has an inextri-
cable link with mild cognitive impairment (MCI) and Alzheimer’s disease 
(AD). T2DM shares several same pathogenesis with AD as well as MCI, 
which might be mediated by insulin resistance. This study aims to investigate 
whether decreased interhemispheric coordination exists in T2DM patients 
using resting-state functional magnetic resonance imaging (rs-fMRI). If so, 
we further examine whether interhemispheric coordination deficits are as-
sociated with the insulin resistance among these patients.
Materials and methods: We compared the interhemispheric resting state 
functional connectivity of 32 T2DM patients and 30 age-, sex-, and educa-
tion-matched healthy controls using rs-fMRI, computed using a recently 
proposed measurement named ‘‘voxel-mirrored homotopic connectivity 
(VMHC)’’. Pearson’s correlation coefficients were measured to detect the rela-
tionship between rs-fMRI information and clinical data.
Results: Compared with the healthy controls, the patients showed significant 
decreases in VMHC in several brain regions within default mode network 
(DMN). Additionally, the VMHC values in the middle temporal gyrus (MTG) 
and superior frontal gyrus were found to be correlated inversely with the score 
of the Trail Making Test-B (r = -0.404, p = 0.027; r = -0.544, p = 0.002, respec-
tively) among the T2DM patients. Most importantly, log homeostasis model 
assessment-insulin resistance (HOMA-IR) had negative correlations with the 
VMHC values in the MTG among patients (r = -0. 528, p = 0.003).
Conclusion: Patients with T2DM suffer disturbed interhemispheric correla-
tion in several DMN regions, especially in the MTG, which is associated with 
insulin resistance. We suppose insulin resistance might play a not negligible 
role in the cognitive dysfunction in T2DM through damaging the MTG func-
tion.
Clinical Trial Registration Number: ChiCTR-ONRC-13003095
Supported by: NSFC
1136
Increased grey matter volume loss in diabetic neuropathic subjects with 
depression
S. Tesfaye1, R. Gandhi1, I.D. Wilkinson2, D. Selvarajah3;  
1Academic Department of Diabetes and Endocrinology, Sheffield Teaching 
Hospitals NHS Foundation Trust, 2Academic Department of Radiology, 
3Department of Human Metabolism, University of Sheffield, UK.
Background and aims: Using functional magnetic resonance imaging 
(fMRI), we have demonstrated increased neuronal activation within regions 
of the brain involved in emotional pain processing. We have also recently 
reported a significant volume loss in somatosensory cortex peripheral grey 
matter in patients with both painful and painless diabetic peripheral neu-
ropathy (DPN). As several studies have strongly linked chronic mood disor-
ders (depression and/or anxiety) that are very common in patients with DPN, 
with brain atrophy, we investigated the relationship between brain volumes 
and mood disorders in subjects with DPN.
Materials and methods: 24 subjects with type 1 diabetes [No-DPN (n=8), 
Painful DPN (8) and Painless DPN (8)] underwent detailed neurophysiologi-
cal assessments to quantify severity of DPN [NIS(LL)+7tests]. All subjects 
underwent volumetric (0.8x0.8x0.8mm3 resolution) brain MRI at 3T. Images 
were analysed using FSL (fMRIB, Oxford). Symptoms of depression were as-
sessed using the Hospital Anxiety and Depression Scale (HADS-D).
Results: There were no significant differences in age (p=0.69) and dura-
tion of diabetes (p=0.57) between groups. As expected subjects with pain-
ful [9.6(6.6)] and painless [10.2(7.3)] DPN had significantly greater Neu-
ropathy Composite Scores compared the No-DPN group [1.85(1.3); p=0.02]. 
Moreover, subjects with painful DPN had significantly greater depression 
(HADS-D; p<0.001) scores compared to the other study groups. Adjusted 
peripheral gray matter volume was statistically significantly lower in subjects 
with painless and painful DPN (mean 599.6 mL [SEM 9.8 mL] and 585.4 mL 
[10.0 mL], respectively) compared with those with No DPN (626.5 mL [5.7 
mL]) and HVs (639.9 mL [7.2 mL]; ANCOVA, P = 0.001). We also found 
a significant negative correlation between both, peripheral grey matter (ρ=-
0.43; p=0.04) and deep grey matter (ρ=-0.51; p=0.02) volumes with HADS-D 
scores after adjusting for known variables (age, microvascular disease status). 
There was no significant correlation between HADS-D score and other brain 
volumes (white matter and CSF).
Conclusion: We have for the first time demonstrated increased grey mat-
ter atrophy in DPN subjects with depressive symptoms. Although, previous 
studies have reported increased brain atrophy in subjects with depression in 
non diabetic people, this is the first study to demonstrate this association in 
DPN. Further studies are now required to examine if the brain atrophy relat-
ed to depression is localised to regions involved in emotional pain processing 
and the temporal relationship of mood disorders to the neuropathic process.
Supported by: JDRF
1137
Gender differences in impact of self-reported diabetes and neuropathy 
on quality of life in a large study on Romanian patients
C.I. Bondor1, E.J. Vinik2, A.I. Vinik2, B. Florea1, N.A. Găvan3, I.A. Vereşiu4;  
1Medical Informatics and Biostatistics, Iuliu Hatieganu University of 
Medicine and Pharmacy, Cluj-Napoca, Romania, 2Eastern Virginia Medical 
School, Norfolk, USA, 3Society for Diabetic Neuropathy, 4Diabetes, 
Nutrition and Metabolic Diseases, County Clinical Emergency Hospital, 
Cluj-Napoca, Romania.
Background and aims: Objective was to evaluate the gender differences be-
tween total and 5 subdomains of Norfolk Quality Of Life Diabetic Neuropa-
thy (QOL-DN) scores in self-reported diabetes with and without neuropathy 
(DN).
Materials and methods: In this cross-sectional survey, conducted between 
June and December 2012, 181 healthcare providers from 51 Romanian cities 
distributed the linguistically translated Romanian Norfolk QOL-DN ques-
tionnaire to their patients. Patients completed 35 questions related to their 
own health perception over the previous 4 weeks, resulting in 21,861 vali-
dated forms of 23,543 completed. Total QOL and each domain arithmetic 
means and standard errors (SEM) were computed.
Results: This is the largest study on gender differences in perception of QOL 
in patients with self-reported diabetes with and without neuropathy. Female 
patients reported higher scores than males on Total QOL (p<0.001) with 
greatest impact on AN, symptoms and ADLs in both patients with and with-
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out neuropathy. Most important, significantly more male patients (25.1%) 
than female (20.8%) reported DN complications - foot ulcers, gangrene and 
amputations (p<0.001), although all scores except SFN were significantly 
higher in women than in men. Both male and females had Total QOL and 
all 5 subdomains scores significant greater with DN and even greater with 
ulcers, gangrene or amputations (p<0.001).
Conclusion: Diabetes has a greater impact on QOL and all its domains in 
women than in men based on scores obtained with Norfolk QOL-DN ques-
tionnaire. Neuropathy and its complications of foot ulcers, gangrene and 
amputations greatly worsened QOL in both sexes and reduced but retained 
differences between the sexes.
Supported by: GmbH&Co.KG Germany, Romanian Rep. Office
PS 099 Diabetic foot: prevention and 
treatment
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A comparative study of E-Med scan and foot mate print technologies in 
diabetic neuropathy ascertainment, Dar es Salaam, Tanzania
Z.G. Abbas1,2, J.K. Lutale1, L.K. Archibald3;  
1Internal Medicine, Muhimbili University College Of Health Science, 
2Internal Medicine, Abbas Medical Centre, Dar es Salaam, United Republic 
of Tanzania, 3Internal Medicine, College of Medicine, University of Florida, 
Gainesville, USA.
Background and aims: In Africa, diabetic foot ulceration is often associated 
with peripheral neuropathy (PN) and substantial morbidity and mortality. 
Thus, new affordable technologies for PN screening have the potential to im-
prove patient outcomes across the African continent and other economically 
less-developed countries. We carried out this study to (i) evaluate two tech-
nologies_the foot E-med scan system (EMS) and the simple Foot Mate print 
(FMP)_in plantar pressure measurement; and (ii) correlate these measure-
ments with PN ascertained clinically.
Materials and methods: During Jan 2011 - Nov 2013 (study period), all pa-
tients attending a diabetes centre in Dar es Salaam, Tanzania, were evaluated 
clinically following informed consent. Pressure at various sites on each foot 
was measured with EMS technology and FMP with an ink pad (dark areas 
reflected high pressures.) PN was ascertained at standard anatomic sites with 
a thermal sensation machine for pain (warm, heat, cold), monofilament for 
protective sensation, and biothesiometer for vibration.
Results: Of 1407 patients enrolled during the study period, 801 (60%) were 
male and 747 (53%) had PN by clinical assessment. Median age =52 (range: 
11-90) years; median body mass index=29 (range: 14-59) kg/sq m). Patients 
with PN were significantly more likely than those without PN to be older (54 
vs. 50 years, p <0.01) or to have a longer diabetes duration (6 vs. 4 years, p 
<0.001). In addition, per EMS technology, patients with PN were more likely 
to have significantly higher plantar pressures at the big toe (p <0.0001), 3rd, 
4th, and 5th toes (p <0.0001), central hind foot (p <0.05), and mid hind foot 
(p=0.005) versus patients without PN. In contrast, FMP recorded high plan-
tar pressures for PN patients only at the 2nd (p <0.05) and 3rd (p=0.008) toes.
Conclusion: Pressure measurements were largely predictive of PN. While 
EMS was more sensitive than FMP in detecting high plantar pressures in pa-
tients with underlying PN confirmed by thermal sensation, biothesiometry, 
and monofilament testing across various anatomic areas of the foot, FMP was 
sensitive in predicting problems mainly in the toes rather than the hind foot. 
Despite these differences, both technologies have key major roles to play in 
the management of diabetic foot complications in Africa and other countries 
with limited resources.
1139
The Diabetes Modernisation Initiative (DMI) for Foot Health:  
“What does good look like?” Challenges in integrating foot care services 
across Southwark and Lambeth in London, UK
P.R.J. Vas1, M. Simmgen1, M. Ferdinand2, T. Patel2, M. Fisk3, L. Price3,  
J. Collins2, M.E. Edmonds1, C. Gayle1;  
1King‘s College Hospital, 2Guy‘s and St Thomas‘ NHS Foundation Trust, 
3GSTT Community Podiatry Service Lambeth and Southwark, London, UK.
Background and aims: The Diabetes Modernisation Initiative (DMI) in 
Southwark and Lambeth, two Boroughs in London, set out to bring together 
a working group of providers and commissioners to explore and develop 
further foot health improvements across care boundaries. The main areas of 
focus were to improve the number, quality and accuracy of foot assessments 
being completed in Primary Care practices. There also was a lack of informa-
tion as to whether patients were being seen in the most appropriate care set-
ting according to their risk classification.
Materials and methods: The working group in partnership with the South-
wark Clinical Commissioning Group (CCG) investigated the risk stratifica-
tion in primary care against actual patient activity in hospital and community 
settings in order to understand the scale of the discrepancies seen in report-
ing.
Results: From 2011/12 to 2012/13 the number of patients receiving a foot-
risk assessment in Primary Care in the Borough of Southwark increased by 
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13% (to 84.4% of patients on the Diabetes register). In 2012/13, 17% of pa-
tients were classified as moderate or high risk, which requires regular com-
munity podiatry input. However, the actual patient activity indicated that 
only 8% of such patients with diabetes were seen - a gap of over half. Based 
on population studies of prevalence of foot risk, it would have been expected 
that as much as 20-30% diabetes individuals would have a moderate or high 
classification score. A greater disparity between hospital activity and Primary 
Care was seen in active diabetes foot disease. Only 0.6% of patients were 
coded as active, while 4% of patients were actually being seen in the two local 
acute Trusts’ hospital foot clinics - a 6-fold difference.
Conclusion: The DMI found that only one in four patients identified to have 
moderate and high foot risk currently receives the desired foot follow-up. 
Furthermore, there was a substantial difference in active diabetes foot burden 
as perceived by Primary Care to that in fact seen at hospital clinics. Incorrect 
coding and risk stratification may have considerable impact on future com-
missioning of diabetes foot services as well as personnel. Improvements in 
coding can potentially lead to more efficient and responsive foot health ser-
vices. The challenge of non-integrated care for diabetes foot patients has been 
met by DMI by bringing together all healthcare providers and commissioners 
to devise a joint strategy across sectors. This includes a locally adapted traffic 
light risk screening tool, structured referral forms and standardised clinical 
letters, now in ubiquitous use across the host CCGs. Criteria for bi-direction-
al patient referral and discharge across community and hospital settings have 
now been implemented.
Supported by: DMI
1140
Barriers to inpatient diabetic foot examination
A.J. Welch, A.I. Eyre-Brook, E.J. Rogers, P. Verlekar, R.J.C. Guy;  
Diabetes, Hampshire Hospitals NHS Trust, Basingstoke, UK.
Background and aims: Despite NICE guidelines and Putting Feet First, only 
38% of patients with diabetes receive a foot assessment in England and Wales 
within 24 hours of admission (National Diabetes Inpatient Audit 2013). A lo-
cal audit has demonstrated an increase in foot examinations from 13 to 53% 
following education and introduction of a diabetic foot sticker in the acute 
medical admissions proforma. Our aim was to identify the major barriers to 
diabetic foot examination and to explain why compliance was so low.
Materials and methods: A self-administered questionnaire was designed to 
reflect knowledge, training, practice, confidence and barriers to diabetic foot 
examination. The survey was given to 110 doctors, 4 diabetic specialist nurses 
and 3 medical students involved in acute medical admissions.
Results: The response rate was 71%: 51% were doctors in training, 30% con-
sultants and 9% medical students/diabetic nurses. Although 96% thought 
foot examination important, only 56% would do this routinely. The other 
44% required a further clinical indication before they would perform an ex-
amination, such as a diabetic foot ulcer or sepsis. The greatest barriers to 
examination were: time constraints (86%), occlusive dressings (78%), for-
getting (69%), lack of equipment (64%), lack of training (56%) and patients 
being too ill (41%). Foot odour was a problem for 16% and foot phobia in 
11%. 69% admitted to examining less than half of their admissions and 94% 
examined less than half of patients‘ footwear. This was despite 60% highlight-
ing poor footwear as one of the greatest risk factors for ulceration. 31% of 
respondents have had no formal foot examination training, including 44% 
of all consultants. The preponderance (45%) of training was undertaken at 
medical school, the quality of which was only rated as good or excellent by 
39%. Little teaching was organised on the wards (18%), in hospital (14%) or 
online (6%). Confidence was expressed in diagnosing vascular disease (86%) 
and neuropathy (84%), but staff lacked confidence with acute Charcot joints 
(73%), neuro-ischaemic ulcers (52%), acute osteomyelitis (49%) and neuro-
pathic ulcers (47%). Staff thought the greatest risks for foot ulceration were: 
poor blood sugar control (80%), ill-fitting footwear (60%), peripheral neu-
ropathy (54%) and peripheral vascular disease (49%). Respondents grossly 
overestimated the number of patients presenting with a foot ulcer leading to 
a new diagnosis of type 2 diabetes (median 15%). However, the prediction of 
amputation rates in diabetic patients with an ulcer over a 20 year period was 
more accurate: median 20%.
Conclusion: Despite awareness that diabetic foot examination is important, 
there continues to be unwillingness to perform this crucial examination un-
less clinical indications are present. Lack of time, barrier dressings, forgetting, 
equipment shortages and poor training account for most incomplete exami-
nations. Staff lack confidence in their ability to diagnose acute Charcot joints 
and osteomyelitis and a significant number, especially consultants have had 
no formal training. Simple local interventions have the potential to signifi-
cantly increase compliance with foot examinations. Regular hospital-based 
teaching should be made more widely available with refresher courses for 
consultants. Increasing resources, improving access to equipment, encour-
agement to remove occlusive dressings and reminders in admission booklets 
are all fundamental to improving the foot care of diabetic patients admitted 
to hospital.
 
1141
Nonvisual foot examination for people with visual impairment
A.S. Williams1, B.D. Caldwell2, J.S. Kawalec2;  
1Nursing, Case Western Reserve University, Cleveland,  
2Kent State University College of Podiatric Medicine, Independence, USA.
Background and aims: Because people with both diabetes and visual im-
pairment have high risk for ulcers and amputation, prevention is a top pri-
ority. Usual care in diabetes self-management education is to teach visually 
impaired people to seek sighted assistance for regular foot examination, yet 
clinical experience suggests that this advice is seldom heeded. One possible 
solution is to teach use of the nonvisual senses for foot self-examination. The 
purpose of this pilot study was to compare the efficacy, acceptability, and fea-
sibility of nonvisual foot examination, using the senses of touch and smell, 
with usual care (examination of feet by a sighted person).
Materials and methods: Fifty-two visually impaired adults with type 2 dia-
betes received comprehensive diabetes self-management education, with the 
experimental and comparison groups receiving different foot examination 
instructions. The experimental group was taught nonvisual foot examina-
tion, i.e., use of their own hands for a systematic tactile inspection of feet for 
cuts, swelling, irregularities, or warmth, and use of the nose to detect unusual 
odors. The comparison group received usual care instructions for visually im-
paired persons, i.e., to have someone with good eyesight to check their feet. 
All kept large print or tactile diaries of how frequently foot examination was 
done at home and by whom; this was reported monthly to the research team 
in a phone call. All had baseline podiatric evaluations and follow-up evalua-
tions at 3 and 6 months, with extra visits if medically necessary. Participant-
reported foot symptoms and podiatrist-confirmed new foot problems were 
recorded at each visit following the baseline evaluation. Focus groups were 
held after the 6 month visit.
Results: Both the experimental and comparison Groups had their feet 
checked a mean of about 22 times per month, with no significant difference 
between groups(p = .69). However, people in the experimental group fol-
lowed the instructions they were given (i.e., checked their own feet) much 
more frequently (M = 1.03) than people in the comparison group did so (i.e., 
had someone else check their feet) (M = .56), F(1, 45) = 41.42, p < .001. This 
result is consistent with qualitative information gathered through the focus 
groups. Many in the experimental group reported checking their own feet 
frequently, as they were taught, with occasional backup from sighted people. 
In contrast, many in the comparison group reported being reluctant to fol-
low the instructions they had been given and ask for help checking their feet. 
They said they checked their own feet „as best they could“, using whatever 
vision they had or using self-invented tactile methods, and got help when 
it was not too embarrassing or difficult. At podiatrist visits, people in the 
experimental group reported a greater number of symptoms per visit (M = 
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1.61) than people in the comparison group (M = 1.13), F(2, 50) = 64.07, p 
< .001, indicating a greater effectiveness of their home foot check methods.
Conclusion: Visually impaired people in this study who were advised to 
ask someone with good eyesight to check their feet did not do so regularly. 
Many invented their own method of self-checking in whatever way they are 
able. These invented methods were not as effective for detecting symptoms of 
foot problems at home as systematic nonvisual foot examination. Systematic 
methods of nonvisual foot examination should be routinely taught to visually 
impaired people with diabetes.
Supported by: NIH R21 NR012513
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Relationship between gait alterations and microvascular chronic 
complications in type 2 diabetic patients
E. Iacopi1, R. Giannarelli1, A. Coppelli1, D. Martelli2, G. Lamola2,  
M. Venturi2, C. Chisari2, S. Del Prato1, A. Piaggesi3;  
1Department of Endocrinology and Metabolism,  
2Department of Neuro-Rehabilitation, 3Diabetic Foot Section -  
Department of Endocrinology and Metabolism, University of Pisa, Italy.
Background and aims: We evaluated gait alterations and their correla-
tions with microvascular chronic complications in type 2 diabetic patients 
(T2DM).
Materials and methods: Thirty-six T2DM (M/F: 27/9; age: 63±10 yrs; dia-
betes duration: 12±11 yrs; BMI: 29.2±5.6 Kgm2; HbA1c 8.1±0.9%) attending 
our outpatient clinic, were divided into 3 Groups: Group 1 (n=12) with no 
diabetic neuropathy (DN) and foot ulcerations (FU); Group 2 (n=10) with 
DN and no FU; Group 3 (n=15) with DN and non-infected, non-ischemic 
FU. We analyzed biomechanical alterations of lower limbs by motion analysis 
system (BTS Elite Clinic, BTS Bioengineering, Milan, Italy). Spatial-temporal 
and kinematics data were collected through photogrammetric infrared cam-
eras while kinetics data with two forces plates. Data were correlated with pa-
tients‘ microvascular chronic complications; in particular, all patients were 
examined with indirect and direct retinoscopy and two non-stereoscopic 45° 
retinal photographs for each eye. The presence and severity of retinopathy 
(DR) was determined according to the Eurodiab Study classification.
Results: Step Width (SW) was greater in Group 2 (240.9±47.5 mm) and 
Group 3 (271.6±41.7 mm, p<0.02 vs group 1); ankle range of motion (ROM) 
was significantly lower in Group 3 (Group 1: 26.6±5.6°, Group 2: 26.0±4.9°, 
Group 3: 23.6±4.7° (Group 3 p<0.05 vs Group 1 and 2); foot ROM was sig-
nificantly lower in Group 3 (Group 1: 37.2±6.6°, Group 2: 34.8±1.7°, Group 
3: 30.2±1.5° (Group 3 p<0.02 vs Group 1 and 2). There was no difference in 
vertical ground-reaction forces. When the whole population was considered, 
a positive correlation was apparent between DR presence and severity and 
SW (r=0.6; p< 0.05) and foot ROM (r=0.65; p< 0.05).
Conclusion: Our study demonstrated a positive correlation between biome-
chanical alterations and presence and severity of DR in T2DM, suggesting 
a possible contribution of the involvement of the microvascular bed in the 
pathogenesis of FU.
1143
Increased pulse pressure and reduced baroreflex gain precede diabetic 
foot complication by at least 10 years
M. Rorive, M. Tyberghein, M. Marchand, J.-C. Philips, A.J. Scheen;  
Division of Diabetes, Nutrition and Metabolic Disorders,  
University of Liège, Belgium.
Background and aims: This case-control retrospective study investigated 
whether abnormalities in arterial stiffness (estimated by increased pulse pres-
sure : PP) and cardiovascular autonomic neuropathy (evaluated by decreased 
baroreflex gain : BRG) may be present far before the occurrence of diabetic 
foot complications and thus potentially used as predictive markers.
Materials and methods: PP and BRG were derived from a continuous (us-
ing a Finapres® device) blood pressure (BP) and heart rate (HR) during a 
standardised squatting test (1 min standing - 1 min squatting - 1 min stand-
ing). Measurements were collected in 20 diabetic patients with future dia-
betic foot complication (selected in our diabetes foot clinic, around 9±4 years 
after initial haemodynamic assessment), in 20 patients without diabetic foot 
- matched for type (10 T1D/10 T2D) and duration of diabetes (mean : 24 
years), age (mean : 54 years), gender (15M/5F), BMI (mean : 28 kg/m²) and 
HbA1c (mean : 8,2%) - and in 20 nondiabetic well matched controls. PP 
was calculated by the difference between systolic BP (SBP) and diastolic BP 
(mmHg) during the whole 3 min test and during squatting position while 
BRG (msec/mmHg) was calculated by the slope of the relationship between 
RR intervals and SBP during the transient phase from squatting to standing.
Results: PP was higher in diabetic with (mean ± SD : 73±20, p<0.0001) 
and without future diabetic foot (68±17, p=0.001) than in controls (50±13 
mmHg). During squatting, diabetic patients with later diabetic foot had 
much greater PP increases (+17±12 mmHg) than diabetic patients without 
diabetic foot (+8±9, p=0.009) or controls (+7±7, p=0.003). During squatting, 
increases of PPxHR products and SBPxHR products were more than doubled 
(p<0.05) in patients with versus without later diabetic foot (Table). Baroreflex 
gain was significantly decreased in patients with later diabetic foot than in 
patients than in controls (1.11±0.91 versus 2.46±2.32; p=0.024), but not sig-
nificantly in patients free of diabetic foot (1.59±1.37; p=0.163).
Conclusion: Increased PP, mainly in squatting position, and decreased BRG 
were already present almost 10 years before the occurrence of a diabetic foot 
complication. These results are in favour of a contribution of arterial fitness 
and autonomic neuropathy in this complication. They also suggest that in-
creased PP and decreased BRG may be considered as initial markers of future 
diabetic foot complications and thus may help selecting patients who should 
be more particularly supervised and advised to avoid diabetic foot complica-
tions.
Supported by: NovoNordisk
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Microvascular dysfunction in diabetic Charcot neuroarthropathy
A. Araszkiewicz, J. Soska, K. Borucka, M. Olszewska, P. Niedzwiecki,  
D. Zozulinska-Ziolkiewicz, B. Wierusz-Wysocka;  
Department of Internal Medicine and Diabetology,  
Poznan University of Medical Sciences, Poland.
Background and aims: Charcot neuroarthropathy is a form of diabetic foot 
syndrome characterized by bone and joints deformation. The pathogenesis 
of Charcot foot is uncertain. The aim of this study was to assess factors as-
sociated with the occurrence of Charcot neuroarthropathy in patients with 
diabetes.
Materials and methods: It is a case-control study. We evaluated 40 diabetic 
patients (31 men) with Charcot neuroarthropathy (CN-DM), median age 59 
(IQR: 51-62), median disease duration 16 (9-24) years. The control group 
were 38 subjects with diabetes and without Charcot neuroarthropathy (DM), 
29 men, median age 60 (55-62), median diabetes duration 15 (10-21) years. 
We assessed metabolic control of diabetes, serum C-reactive protein concen-
tration (CRP) and cardiovascular autonomic neuropathy (ProsciCard III). 
We used AGE-Reader to measure skin autofluorescence (AF) associated with 
accumulation of advanced glycation end products that reflects long lasting 
metabolic control. Microvascular function was examined by laser Doppler 
flowmetry (PERIFLUX 5000) with thermal hyperemia and postocclusive re-
active hyperemia.
Results: CN-DM patients as compared to DM subjects had better HbA1c lev-
el [7.5 (6.6-8.2) vs 8.2 (7.1-9.5)%, p=0.01] and higher CRP concentration [4.8 
(2.3-11.0) vs 1.8 (0.6-4.1)mg/l, p<0.001]. The peak flow during thermal hy-
peremia (THmax) was lower in CN-DM subjects as compared to DM group 
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[163 (76-246) vs 254 (165-366)PU, p=0.001]. Additionally, we found nega-
tive correlation between THmax and CRP concentration (Rs=-0.33, p=0.03), 
TG concentration (Rs=-0.46, p=0.002) and skin AF (Rs=-0.32, p=0.04) and 
positive correlation between THmax and HDL cholesterol level (Rs=0.58, 
p<0.001). The cardiovascular autonomic neuropathy (CAN) prevalence was 
higher in CN-DM subjects [62 vs 35%, p=0.01].
Conclusion: Deterioration of microvascular function and autonomic system 
dysfunction might play a crucial role in the development of Charcot neu-
roarthropathy. Microvascular reactivity is related to long lasting metabolic 
control of diabetes and activation of inflammatory process.
Supported by: Grant of Diabetes Poland
1145
Endovascular revascularisation in type 2 diabetic patients with critical 
limb ischaemia: comparison of direct and indirect revascularisarion 
according to angiosome model
A. Coppelli1, E. Iacopi1, I. Bargellini2, A. Cicorelli2, A. Lunardi2,  
C. Mattaliano3, C. Goretti3, R. Cioni2, S. Del Prato1, A. Piaggesi3;  
1Department of Endocrinology and Metabolism, 2Department of Radiology, 
3Diabetic Foot Section - Department of Endocrinology and Metabolism, 
University of Pisa, Italy.
Background and aims: The angiosome model (AM) is commonly used to 
guide bypass and endovascular procedures in the lower limb. We evaluated 
whether direct or indirect revascularization, according to AM, may affect 
clinical outcomes in diabetic patients with critical limb ischemia (CLI) un-
dergoing percutaneous trans-luminal angioplasty (PTA).
Materials and methods: We retrospectively evaluated 137 type 2 diabetic pa-
tients (M/F: 93/44; age: 72.9±9.2 yrs; BMI: 27.7±8.2 kg/m2; diabetes duration: 
21.8±13.4 yrs; HbA1c 8.4±1.1%) consecutively admitted to our Department 
for CLI and foot lesions (FL) who underwent successfull lower limb PTA. 
Patients were divided in 2 groups: direct (92 pts, 67%) or indirect (45 pts, 
33%) depending on whether the flow to the artery directly feeding the site of 
ulceration, according to AM, was successfully aquired or not. Clinical out-
comes (ulcer healing rate, major amputation or death) were compared in the 
two groups 3 months post PTA.
Results: Healing rate was higher in direct vs indirect group (58% vs 30%, 
respectively, p<0.02). One major post-procedural amputation was necessary 
in the indirect group (2.2%) and none in the direct one. Mortality rate during 
the follow-up was 19% in direct vs 31% in indirect group (p=NS).
Conclusion: Our data confirm that direct revascularization of arteries sup-
plying the FL results in greater ulcer healing rate as compared to the indirect 
one. Thus, AM should be considered in diabetic patients with FL whenever 
possible.
1146
Perfusion scintigraphy as a method of stem cell therapy assessment  
in patients with critical limb ischaemia and diabetic foot
M. Dubský1, A. Jirkovská1, M. Buncová2, R. Bem1, V. Fejfarová1,  
A. Nemcová1, V. Wosková1, J. Skibová1;  
1Diabetes Centre, Institute for Clinical and Experimental Medicine, 
2Department of Nuclear Medicine, Institute for Clinical and Experimental 
Medicine, Prague, Czech Republic.
Background and aims: There is a lack of imaging methods for microcircula-
tion of the lower limbs in diabetic patients. Perfusion scintigraphy with Tech-
netium-99-methoxy-isobutyl-isonitrile (MIBI) is often clinically used for the 
assessment of myocardial function because of its fast uptake in mitochondrial 
membrane. The aim of our study was to assess perfusion scintigraphy as eligi-
ble imaging method for perfusion of calf muscles after stem cell therapy and 
to compare it with changes of transcutaneous oxygen pressure (TcPO2).
Materials and methods: Perfusion scintigraphy with 99mTc-MIBI was per-
formed before and 2 months after the autologous stem cell therapy in 19 
patients with no-option critical limb ischemia (mean age 63.3 ± 9.1 years, 
mean diabetes duration 24.2 ± 7.4 years). TcPO2 measurement was used as a 
standard method of non-invasive evaluation of limb ischemia. After applica-
tion of 4 MBq/kg of 99mTc-MIBI a whole-body scan and SPECT/CT was 
performed; next bolus of 8 MBq/kg of 99mTc-MIBI was applied after a stress 
test (60times flexion and extension in ankle joint). Scintigraphic parameters 
such as rest count (RC) and exercising count (EC) after stress test were set up. 
Ischemic ratio in rest (IRR) and after stress test (IRE) were defined as ratios 
of these parameters in treated to untreated (control) limb.
Results: We observed a significant improvement in IRR (from 0.44 to 0.49, 
p = 0.01) as well as in IRE (from 0.47 to 0.51, p = 0.03) after 2 months from 
cell treatment. The effect of stem cell therapy was confirmed by a significant 
increase of TcPO2 values from baseline 12.9 ± 9 to 37.2 ± 14.8 mm Hg after 
2 months (p = 0.0001).
Conclusion: Our study showed a significant improvement in scinthigraphic 
parameters after stem cell therapy in patients with ischemic diabetic foot 
which was in accordance with changes of TcPO2. Perfusion scintigraphy 
could be a promising technique to objectify the microcirculation of lower 
limbs.
Supported by: MZO 00023001
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A longitudinal cohort of people presenting with diabetic foot ulcers in 
northern England
N. Holman1, P.J. Chadwick2, J. McAdam2, S. Haycocks2, B. Young3;  
1Institute of Cardiovascular and Medical Sciences, University of Glasgow, 
2Podiatry Department, Salford Royal Foundation NHS Trust, 3Diabetes and 
Endocrinology, Salford Royal Foundation NHS Trust, UK.
Background and aims: It is known that people with diabetic foot ulcers have 
high morbidity and mortality but there is little contemporary data ‘real world’ 
data on this group of people outside specific research trials. This population 
based study examines the characteristics and outcomes of people with inci-
dent diabetic foot ulcers in a longitudinal cohort of people presenting with 
diabetic foot ulcers in Salford in the north of England.
Materials and methods: Since 2001 data on all people with an incident dia-
betic foot ulcer in Salford has been recorded in an electronic clinical system 
as part of routine clinical practice. This database has been linked with death 
registration records to identify all deaths up to June 2013. Regression models 
were created to examine factors associated with ulcer healing, ulcer recur-
rence and mortality.
Results: Between 2001 and 2012 there were 8028 incident cases of diabetic 
foot ulcers among 2937 people. There has been no change in age at pres-
entation (mean 68.6 years, median 70 years) or the proportion of patients 
that were male (59.4%). 2.4% of incident ulcers were deep enough to involve 
the bone, 24% were accompanied by cellulitis and 32.7% were in people 
with peripheral vascular disease. The proportion of people with a previously 
healed foot ulcer reduced from 67.2% in 2001 to 44.6% in 2012 (p<0.005). 
Median time to healing was 79 days (IQR 21-320 days). The proportion of 
ulcers that healed within 90 days declined from 61.1% in 2011 to 32.1% in 
2012 (p<0.005). Men (OR 0.868 95% CI 0.773-0.975) and older people (OR 
1.005 95% CI 1.001-1.009 per additional year) were less likely to heal within 
90 days. Having peripheral vascular disease (OR 0.750, 95% CI 0.660-0.853), 
cellulitis (OR 0.840, 95% CI 0.736-0.960), an ulcer to the bone (OR 0.461, 
95% CI 0.303-0.702) were significantly associated with a lower chance of the 
incident ulcer healing within 90 days whilst having a previously healed ul-
cer increased the chance of healing (OR 1.529, 95% CI 1.364-1.714). Of the 
people presenting with a foot ulcer in 2010 8.8% died within six months, 
15.5% died within one year and 24.6% had died after two years. Being male 
(OR 1.246, 95% CI 1.002-1.549), older (OR 1.064, 95% CI 1.054-1.075 per 
additional year), having peripheral vascular disease (OR 2.410, 95% CI 1.949-
2.978) or a rear-foot ulcer (OR 1.907, 95% CI 1.520-2.392) were associated 
with significantly higher mortality six months after presentation. These fac-
tors are also predictors of longer term mortality in this group.
Conclusion: The demographic characteristics of people presenting with inci-
dent diabetic foot ulcer have not changed since the turn of the century. Out-
comes remain very poor with the majority of ulcers unhealed at 90 days. One 
in four people presenting with foot ulcers died within two years; this short 
term mortality is very high especially in those with co-existent peripheral 
vascular disease which more than doubles the risk of dying.
1148
Identification of factors contributing to failure of ambulatory negative 
pressure wound therapy in patients with diabetic foot 
R. Bem, A. Jirkovska, M. Dubsky, V. Fejfarova, V. Woskova, A. Nemcova,  
L. Rezaninova, J. Skibova;  
Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, 
Czech Republic.
Background and aims: Previous studies showed that negative pressure 
wound therapy (NPWT) is an effective method for the treatment of patients 
with diabetic foot. Indication criteria of this treatment based on patient and 
wound characteristics are not clear verified. The aim of our study was to as-
sess the effect of ambulatory NPWT on diabetic foot healing and identify 
factors contributing to failure of this method.
Materials and methods: 148 patients with diabetic foot hospitalized in our 
Diabetes Department were treated by NPWT between May 2003 and Oc-
tober 2013. 60 patients continued with NPWT on ambulatory basis and 
were enrolled in the present study. The changes of dressing were done in our 
foot clinic 2-3 times per week. The median length of NPWT was 23 days 
(7-98). The success of NPWT was defined as a complete wound healing dur-
ing 6 months follow-up; the unsuccess as a premature termination of NPWT 
(worsening of the wound/no effect), non- healing, major amputation or intol-
erance of the treatment by patient during 6 month follow-up. In all patients, 
factors which could influence wound healing were evaluated: age, type of dia-
betes, duration of diabetes, diabetes control (HbA1c), presence of infection, 
ischemia, Charcot foot, renal failure and other comorbidities, but also local 
factors (wound localization, size, exposed bone etc.). Uni- and multivariate 
analyses were used to identification of factors contributing to failure of am-
bulatory NPWT.
Results: During follow-up period, 47/60 (78.3%) patients were completely 
healed after ambulatory NPWT, in 13/60 (21.7%) patients was not NPWT 
successful. In univariate analysis, the unsuccess of NPWT was influenced es-
pecially by poor diabetes control (HbA1c in unsuccess vs. success; 77.2±19 
vs. 62.5±18.6 mmol/mol; p=0.01). Potential factors of NPWT failure should 
be also exposed bone in the wound (76.9% of patients with unsuccess vs. 
46.8% with success; p=0.1) and haemodialysis (23.1% vs. 4.2%; p=0.1 resp.). 
There were no significant differences in other factors assessed in univariate 
analysis. Logistic regression showed that HbA1c (OR 1.05; 95% CI 1.01-1.09; 
p=0.01), haemodialysis (18; 1.6-208.3; p=0.02) and exposed bone (7.8; 1.3-
48.1; p=0.03) were significant factors for failure of ambulatory NPWT, other 
followed factors were not significant.
Conclusion: Ambulatory NPWT was effective in majority of patients, but 
poor diabetes control, haemodialysis or exposed bone in the wound may con-
tribute to the failure of this method. These results showed that patients with 
diabetic foot treated by ambulatory NPWT require precise follow-up focused 
on diabetes control and it is necessary to consider the indication in patients 
on haemodialysis and with exposed bone in the wound.
Supported by: Ministry of Health, Czech Republic: 00023001 IKEM
1149
Arterial stiffness influence outcome of chronic diabetic foot ulcers in 
patients with type 2 diabetes
D.-H. Cho, J.-O. Chung, D.-J. Chung, M.-Y. Chung;  
Department of Endocrinology and Metabolism, Chonnam National 
University Hospital, Gwangju, Republic of Korea.
Background and aims: Chronic diabetic foot ulcers are estimated to occur in 
15% of all patients with diabetes and precede 84% of all diabetes-related low-
er-leg amputations. The pathophysiology of chronic diabetic foot ulcers still 
incompletely understood, but both micro- and macroangiopathy strongly 
contribute to the development and delayed healing of diabetic wounds. Pulse 
wave velocity (PWV) is a method to estimate arterial stiffness and predicts 
cardiovascular morbidity and mortality. Several studies demonstrated that 
pulse wave velocity is a sensitive predicator for peripheral artery disease and 
cerebrovascular disease among diabetic patients. The objective of this study 
was to determine whether arterial stiffness index [brachial-ankle pulse wave 
velocity (baPWV)] can influence outcome of chronic diabetic foot ulcers in 
patients with type 2 diabetes.
Materials and methods: We recruited a total of 102 type 2 diabetic patients 
(63 men and 39 women) with chronic nonhealing diabetic foot ulcers with 
Wagner grade 1 or 2 ulcers that are ≥2 cm in largest diameter at diagnosis for 
more than 1-month duration. The age was 65.2±16.4 years, and the diabetes 
duration was 18.4±16.0 years. Anthropometric, clinical, and laboratory data 
were measured. All patients were seen bi-weekly for debridement, offload-
ing, and other treatments during the initial 8 weeks. The PWV was measured 
between the brachial and ankle regions (baPWV), and the baPWV was meas-
ured in all patients using a waveform analyzer.
Results: At 8 weeks, 49 of the 102 ulcers had completely healed. The patients 
were assigned into healed group (n = 49) or unhealed group (n = 53) accord-
ing to clinical outcome of ulcer healing at 8 weeks. There were not significant-
ly different in age, duration of diabetes, HbA1c, or initial wound size in diam-
eter of the ulcer between the healed and unhealed groups. The healing time 
of foot ulcers in healed group was 5.4±2.8 weeks (range 2.8-8.0). The baPWV 
was significantly (P<0.05) higher in the unhealed group (1773±279 cm/s) as 
compared with the healed group (1547±340 cm/s). ABI or TBI was not sig-
nificantly different between unhealed and healed group. Age (r = 0.463; p< 
0.01), duration of diabetes (r = 0.425; p< 0.05), ankle-brachial index (ABI) 
(r = -0.349; p< 0.05) and toe-brachial index (TBI) (r = -0.264; p< 0.05) were 
significantly correlated with baPWV. But BMI, lipid profiles, HbA1c, and sys-
tolic and diastolic BP were not correlated with baPWV. Univariate analysis 
revealed that baPWV was significantly correlated with healing rate of diabetic 
ulcers (r = 0.321, p < 0.05) and duration of diabetes (r = 0.412, p < 0.01).
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Conclusion: These findings indicate that baPWV is closely associated with 
the healing time of diabetic ulcers. We suggest that the measurement of sys-
temic arterial stiffness may help to identify ulcers at risk of poor healing in 
chronic diabetic foot ulcers in patients with type 2 diabetes.
1150
The association between Neuropad testing with foot ulceration in 
diabetes
N. Tentolouris1, N. Papanas2, G. Panagoulias1, D.S. Tesic3, Z. Kamenov4,  
C. Manes5, S. Bousboulas6, E. Jude7;  
11st Department of Propaedeutic and Internal Medicine, Athens University 
Medical School, Laiko General Hospital, 22nd Department of Internal 
Medicine, Democritus University of Thrace, Alexandroupolis, Greece, 
3Medical Faculty, University of Kragujevac, Serbia, 4Medical University, 
Sofia, Bulgaria, 5Diabetes Centre, General Hospital Papageorgiou, 
Thessaloniki, 63rd Department of Internal Medicine and Diabetes Centre, 
General Hospital of Nikaia Agios Panteleimon, Piraeus, Greece,  
7Diabetes Centre, Tameside General Hospital, UK.
Background and aims: Foot ulceration in patients with diabetes is a serious 
complication associated with increased morbidity, mortality and healthcare 
cost and is the main cause of amputation. The prevalence of foot ulcers is 
4% to 10%, and the annual population-based incidence is 1.0% to 4.1%. Pre-
vention of foot ulceration and consecutively amputation begins with identi-
fication of those at risk. Well-established risk factors for foot ulceration are 
previous foot ulceration and lower extremity amputation, long duration of 
diabetes, poor glycemic control, severity of diabetic neuropathy, foot deform-
ities and visual impairment. Cross-sectional data have shown that dryness of 
the skin of the feet assessed by either sympathetic skin response or Neuropad 
testing has been associated with foot ulceration in patients with diabetes. In 
addition, Neuropad testing has a high performance for the diagnosis of dia-
betic peripheral neuropathy and is proper for self- testing. The aim of the pre-
sent prospective multicenter study was to examine the association between 
Neuropad testing with foot ulceration in patients with diabetes.
Materials and methods: A total of 308 patients with diabetes (155 females 
and 153 males; 280 with type 2 diabetes; mean age 62.8 ± 11.3 years; mean 
diabetes duration 12.4 ± 9.7 years) with no history of foot ulceration were 
recruited in the study from the year 2005 until the year 2012. At baseline par-
ticipants were evaluated for neuropathy status using the neuropathy disability 
score (NDS). Patients with NDS 0-2 were considered as having no neuropa-
thy, those with NDS 3-5 as having mild neuropathy and those with NDS ≥6 as 
having severe neuropathy. In addition Neuropad testing was performed and 
the results were evaluated as normal or abnormal based on complete colour 
change of the test after 10 min of application.
Results: At baseline, 148 patients (48.1%) did not have neuropathy, 82 
(26.6%) had mild neuropathy and 78 (25.3%) had severe neuropathy. Neuro-
pad testing was normal in 128 (41.6%) and abnormal in 180 (58.4%) patients. 
The mean follow-up was 5.5 ± 2.5 years. During this time, 55 (17.9%) pa-
tients developed foot ulcers. At baseline, patients who developed foot ulcers 
were older (p=0.03) and had longer diabetes duration (p=0.01). After adjust-
ment for age, gender and duration of diabetes, abnormal Neuropad testing at 
baseline was associated with increased odds (OR, 95% confidence intervals) 
for foot ulceration [4.2 (1.8-9.8)]. Similarly, the adjusted OR of NDS≥6 vs. 
NDS<6 for foot ulceration was 8.5 (3.3-21.7). The OR for foot ulceration was 
not increased significantly (p=0.09) in those having mild neuropathy (NDS 
3-5) vs. those having no neuropathy.
Conclusion: These prospective demonstrate that abnormal Neuropad testing 
is associated with a 4-fold higher risk for foot ulceration. Neuropad testing 
can be included in the screening tests for the prevention of foot ulceration in 
patients with diabetes.
Supported by: TRIGOcare International, Germany
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Measurement of TcPO2, toe pressures and laser Doppler flow reveals 
hitherto undiagnosed subclinical ischaemia in patients with palpable 
pedal pulses and foot ulceration
C.A. Manu, V. Morris, P. Vas, M. Simmgen, M.E. Edmonds;  
Diabetic Foot Clinic, King‘s College Hospital, London, UK.
Background and aims: Patients presenting with a diabetic foot ulcer should 
be assessed and treated urgently as a “foot attack”. However, their clinical vas-
cular assessment is often limited to palpation of pulses and measurement of 
Ankle Brachial Pressure Index (ABPI). The aim of this study was to investi-
gate the contribution of a full assessment of the macro- and microcirculation 
in patients with foot ulceration.
Materials and methods: Consecutive patients with ulceration in one or both 
limbs underwent measurement of ABPI, Toe Blood Pressure Index (TBPI), 
TcpO2 in both feet, at supine and at 30
o elevation and simultaneously in fore-
arm, and forefoot laser Doppler flowmetry, in perfusion units (PU), at base-
line and with heat provocation. All measurements were carried out within 
35min. Results are reported as mean±SD.
Results: There were 53 limbs in 27 patients, age 57±9.8 yrs, 93% males, 86% 
with type 2 diabetes and 66% of limbs were ulcerated; 40 limbs had palpa-
ble pedal pulses (Group 1) and 13 limbs had a known diagnosis of ischemia 
(Group 2). Unexpectedly 58% of group 1 had evidence of ischemia (we called 
Group 1a) as denoted by a low TBPI of ≤ 0.7 (mean 0.5±0.1), compared 
with the remaining patients (Group 1b), with normal TBPI (mean 1.0±0.2) 
[p=0.001]. Doppler flow increment on heating was less in Group 1a, 12±9 to 
52 PU compared with Group 1b, 12±4 to 68 PU [p=0.03]. However, there was 
no significant difference between Group 1a and 1b as regards ABPI, 1.1±0.2 
vs 1.2±0.2 [p=0.053] nor TcpO2 at supine, 52±11 vs 55±8mmHg [p=0.55]. 
However, foot elevation identified 10% in group 1b with a ≥15mmHg drop in 
Tcpo2 despite their normal TBPI. As expected, in group 2 (known diagnosis 
of ischaemia), mean TBPI was 0.5±0.3, baseline TcpO2 39±20mmHg. There 
was no difference in proportion of ulcers across all groups, p=0.79.
Conclusion: We have identified a subgroup of patients with palpable pulses 
that have a low TBPI and a reduced heating response to Doppler flowmetry 
but a preserved tcpO2 at baseline. This subgroup is distinct both from pa-
tients with palpable pulses and normal TBPI who have a normal TcpO2 and 
heat response and also distinct from patients with known ischaemia in whom 
all these parameters are abnormal. This demonstrates that it is essential for all 
patients to have a thorough examination of both macro- and micro circula-
tion on presentation to the multidisciplinary team with a foot attack.
Clinical Trial Registration Number: KCH13-176
Supported by: King‘s College Charitable Trust
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Extent of disagreement and difference between tissue and swab samples 
from infected diabetic foot ulcers: the CODIFI Study
A. Nelson1, M. Backhose2, A. Wright-Hughes2, M. Bhogal2, S. Brown2,  
J. Nixon2, B. Lipsky3;  
1Healthcare, 2Medicine, University of Leeds, 3University of Oxford, UK.
Background and aims: A common complication of diabetic foot ulceration 
is a wound infection. Treatment with antibiotics is usually started immedi-
ately as spreading infection can lead to amputation. At the same time, how-
ever, a sample is usually taken for microbiologists to advice on the types of 
organisms in the wound, and what antibiotics they are sensitive to. Clinical 
practice guidelines state that tissue samples are the best way to collect sam-
ples of wound bacteria for the microbiological analysis, but wound swabs are 
commonly used. The CODIFI (concordance in diabetic foot infection) study 
set out to determine whether the results from wound swab and tissue samples 
taken from the same ulcer ‘agree’ with each other.
Materials and methods: Consenting patients with an infected diabetic foot 
ulcer had both swab and tissue samples taken from their ulcer for microbio-
logical analysis (plating and culture). Agreement was assessed between tech-
niques based upon the reported presence of ‘likely pathogens’. We reported 
overall prevalence, Kappa statistic, and McNemar’s test to investigate patterns 
of disagreement
Results: We recruited 401 patients from 25 centres (2011 - 2013). They had 
a median age of 63 years; 79% were male; 85.5% had type 2 diabetes; 27.5% 
presented with a recurrent ulcer; and 45.5% had a neuro-ischaemic ulcer, 
50.5% neuropathic ulceration, and 3.5% ischaemic ulceration. Swab and 
tissue reports were available for 395 patients. We found many ‘likely patho-
gens’ -the most prevalent were Gram Positive Cocci (70.4%), Gram Negative 
Bacilli (36.5%), Staphylococcus Aureus (35.7%), Anaerobic Cocci (20.5%), 
Coagulase-Negative Staphylococcus (12.2%), Gram Positive Bacilli (11.1%), 
Streptococcus (16.7%), Enterococcus (14.9%), Corynebacterium (9.4%), 
Pseudomonas (8.6%), and Methicillin-resistant S. Aureus (MRSA, 8.1%). 
With the exception of Staphylococcus Aureus, MRSA and Pseudomonas (for 
which identical discordance was observed), each isolate was reported in sig-
nificantly more tissue samples than the swab (p-value <0.05) by between 3.3% 
(Streptococcus) and 13.4% (Gram Positive Cocci).
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Conclusion: Overall, significantly more isolates are reported from tissue 
samples than swab samples in patients with infected diabetic foot ulcers. This 
has potential implications for choice of sampling technique in practice.
Clinical Trial Registration Number: ISTRCN 52608451
Supported by: NIHR HTA Programme
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Conservative management of neuropathic heel ulceration with calcaneal 
osteomyelitis and avulsion fracture in a cohort with diabetic foot disease
R. Fikri1, V. Bravis1, W.M. Gedroyc2, P. Rosenfeld3, R.A. Gibbs4,  
D.G. Samarasinghe5, N. Oliver1, J. Valabhji1;  
1Department of Endocrinology, Diabetes and Metabolism, 2Department of 
Radiology, 3Department of Orthopaedics, 4Department of Vascular Surgery, 
5Department of Microbiology, Imperial College Healthcare NHS Trust, 
London, UK.
Background and aims: The complex of neuropathic heel ulceration, calca-
neal osteomyelitis (OM) and calcaneal fracture in people with diabetes is rare 
and challenging to manage, especially when complicated by tendon avulsion. 
We describe 4 patients in whom a conservative non-operative approach re-
sulted in limb salvage.
Materials and methods: All patients were managed in the multidisciplinary 
diabetic foot clinic. Specialist input was provided by diabetologists, podia-
trists, radiologists, microbiologist, vascular surgeons, orthopaedic surgeons, 
neurologist and orthotists. Multidisciplinary management included, where 
appropriate, antibiotics, wound debridement, vascular intervention, vacuum 
pump therapy and heel offloading. Patients were closely monitored clinically 
and radiologically for wound healing, resolution of OM and preservation of 
ankle function.
Results: Four patients were included. Their demographics and management 
are summarised in table 1. Two subjects had multidrug resistant organisms 
identified. Resolution of complex heel ulceration with calcaneal fracture and 
tendon avulsion is ongoing with 9 (6-11) months of follow up to date and a 
similar duration of antibiotics (9 (8-9) months). Vascular surgical interven-
tion was required in 2 out of 4 subjects and adjunctive vacuum pump dress-
ings were used in all subjects. Ankle function was at least partially preserved 
in all subjects.
Conclusion: This is the first description of a cohort of patients with diabetes, 
heel ulceration and calcaneal OM complicated by an avulsion fracture man-
aged conservatively. Vacuum pump therapy was applied, not only to soft tis-
sue, but also to bone, with progressive wound healing. Despite tendon avul-
sion, 3 of 4 patients have preserved ankle function and there were no minor 
or major amputations. Conservative management so far has been successful 
despite the presence of multiple resistant organisms in 2 of the 4 subjects. 
This complex can occur following an ulcer or trauma, requires prolonged 
therapy and has serious physical, psychosocial and biomechanical implica-
tions. There is no consensus on conservative or surgical management and 
functional limb salvage is often unachievable resulting in a major amputa-
tion. Whilst this is a small case series, this challenging diabetes foot problem 
is too rare to examine by randomised controlled trial. These 4 cases, managed 
successfully by a highly skilled multidisciplinary team provide a template for 
management.
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The efficacy of removable offloading devices to heal plantar foot ulcers in 
diabetic patients
J.J. Van Netten1, J.G. Van Baal1, A. Kottink1, M. Hutten1, E. Manning1,  
M. Spraul2, S.A. Bus1,3;  
1Department of Surgery, Hospital Group Twente, Almelo, Netherlands, 
2Matias Spital, Rheine, Germany, 3Academic Medical Center, Amsterdam, 
Netherlands.
Background and aims: Adequate offloading is required for healing neuro-
pathic plantar foot ulcers in patients with diabetes. Guidelines recommend 
non-removable offloading as primary treatment for these ulcers. However, 
in clinical practice removable offloading devices are more commonly used, 
mainly for practical reasons. The aim of this study was to assess the efficacy of 
three commonly used removable offloading devices on success in healing of 
plantar neuropathic foot ulcers in diabetes.
Materials and methods: A total 60 diabetic patients (48 male, mean age 62.5 
years, 87% type 2) with a neuropathic non-infected, non-ischemic plantar foot 
ulcer were randomized to one of three treatment modalities: a bivalved total 
contact cast (BTCC), a Mabal Cast shoe (MABAL), or a forefoot offloading 
shoe (FOS). Patients were followed until healing or until 20 weeks, whichever 
came first. Primary outcomes were percentage healing in 12 and 20 weeks time.
Results: Foot ulcers were located at the hallux (n=24), first metatarsal head 
(n=21), other metatarsal heads (n=13) and toes (n=2). Forty-nine of the 60 
foot ulcers were classified as small (< 2 cm2), ), 11 as large (> 2 cm2). Healing 
rates within 12 and 20 weeks according to intention-to-treat were 60% and 
63% for BTCC, 60% and 83% for MABAL, and 70% and 80% for FOS (non-
significant between conditions, p=0.703 and p=0.305 for 12 and 20 weeks 
respectively). Per protocol healing rates were 57% and 69% for BTCC, 67% 
and 87% for MABAL, and 77% and 88% for FOS (non-significant between 
conditions, p=0.519 and p=0.374 for 12 and 20 weeks respectively).
Conclusion: Healing rates were not significantly different between the three 
removable devices, but the off-the-shelf FOS condition showed higher heal-
ing percentages than the two casting conditions at 12 weeks. Healing rates for 
the BTCC were substantially lower than previously found for non-removable 
total contact casts (~90% healing rates), while healing rates for the other two 
devices are comparable for those previously found for similar removable of-
floading devices. A lack of forced adherence is suggested to be an explanatory 
factor in lower healing rates found compared to non-removable offloading, 
which stresses the importance of continuous pressure relief in ulcer healing.
Supported by: Interreg III 2_EUR_II_2=60
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PS 101 Diabetic eye disease
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Ophthalmic biomarkers of diabetic neuropathy: does neural dysfunction 
precede vascular changes? 
M. Tavakoli, M. Ferdousi, I.N. Petropoulos, H. Fadavi, A. Marshall,  
A.J.M. Boulton, R.A. Malik;  
University of Manchester, UK.
Background and aims: To evaluate structural- functional changes in the 
neural level of retina and cornea in type 1 diabetic (T1DM) patients without 
clinical evidence of retinopathy.
Materials and methods: 30 T1DM patients (Age: 48±2 yrs; Duration diabe-
tes: 28±3 yrs, HbA1c: 7.6±0.5 %) with no evidence of retinopathy and 15 aged 
matched healthy controls underwent detailed neurological (including Neu-
ropathy Deficit Score (NDS)) and ophthalmic assessment including measure-
ments of global and sectorial retinal nerve fibre layer (RNFL) thickness using 
Spectral Domain OCT (SD-OCT) (SPECTRALIS, Heidelberg Engineering) 
and retinal ganglion layer function (Flicker-Defined-Form (FDF)) using Hei-
delberg High Edge Perimetry (HEP). Corneal nerve fibre length (CNFL) and 
density (CNFD) were assessed using a corneal confocal microscope (Heidel-
berg HRT III) and corneal sensitivity was quantified using non- contact cor-
neal aesthesiometer (NCCA).
Results: There was a significant reduction in the global and sectorial RNFL 
(P=0.01) in diabetic patients compared to controls which correlated with the 
severity of peripheral neuropathy measured by NDS) (r= -0.403, P=0.01). FDF 
(P=0.01), CNFD (P=0.01), CNFL (P=0.01) and corneal sensitivity (P=0.01) 
were significantly reduced in T1DM compared to control subjects and they 
were significantly correlated with NDS.A greater proportion of T1DM patients 
showed abnormal retinal structure (RNFL-61%) and function (FDF-52%) 
compared to corneal structure (CNFD-32%) and function (NCCA-20%).
Conclusion: Changes at the level of nerve fibre layers were observed in both 
the retina and cornea. However, the prevalence of abnormality was higher 
at the retina but the severity was more pronounced in the cornea especially 
in those patients without neuropathy. The results of this preliminary study 
suggest that structural changes in the cornea (Peripheral nerves) and in the 
retina (central nervous system) may occur in parallel and are correlated with 
functional changes.
Supported by: NIH R105991
1156
Early detection of neurodegenerative changes in diabetes: systematic 
review and meta-analysis
E.E.B. De Clerck1, J.S.A. Schouten1, T.T.J. Berendschot1, R.M.M. Nuijts1, 
H.J.M. Beckers1, M.T. Schram2, C.D.A. Stehouwer2, C.A.B. Webers1;  
1Ophthalmology, 2Internal Medicine and Cardiovascular Research Institute 
Maastricht (CARIM), Maastricht University Medical Centre, Netherlands.
Background and aims: The onset of diabetic neuropathy is difficult to detect 
by electrophysiology. The earliest damage occurs in the small nerve fibers. 
These fibers can be evaluated by thermal and pain perception, which have 
limited reproducibility, and by skin biopsy, which is invasive. A more reliable 
and feasible approach could be the imaging and quantification of neurode-
generative changes in the diabetic eye. Aims: To systematically assess ocu-
lar neurodegenerative changes in adults with type 1 or type 2 diabetes, their 
relationship with diabetic retinopathy and neuropathy, and whether these 
changes are already present in an early stage of diabetes.
Materials and methods: This meta-analysis was conducted according to the 
PRISMA statement and the Cochrane collaboration. The databases searched 
were MEDLINE, the Cochrane Controlled Trials Register and EMBASE 
(1968-2013). Language restrictions were English, French, German or Dutch. 
Only studies of neurodegenerative changes in the retina, the optic nerve head 
or the cornea in adults (>18 years) with type 1 or type 2 diabetes mellitus were 
included. One author reviewed studies for inclusion, quality and risk of bias. 
The second author checked the extracted data.
Results: 41 out of 4051 articles were included (3043 diabetic and 2021 non-
diabetic individuals). 35 neurodegenerative parameters were analyzed. Com-
pared with non-diabetic individuals, diabetic patients with any level of sever-
ity of diabetic retinopathy, had a mean reduction in thickness of at least 2 µm 
in 5 retinal layers: the mean ganglion cell/inner plexiform layer in the pe-
ripheral area and the inner plexiform layer, the ganglion cell layer, the mean 
outer nuclear layer/inner segments and the mean ganglion cell/inner plexi-
form layer thickness in the pericentral area of the macula. In the optic nerve 
head, the highest reduction was observed for the superior retinal nerve fiber 
layer thickness (superior RNFL: -7.98 µm, 95%CI -12.46 to -3.50). In the cor-
nea, the nerve branch density (NBD) and the nerve fiber density (NFD) were 
lower by 12.80/mm2 and 7.45/mm2, respectively (95% CI -14.56 to -11.04 and 
-9.88 to -5.01). In patients without diabetic retinopathy the pericentral outer 
nuclear layer and inner segment were reduced by 2.45 µm (95% CI -4.76 to 
-0.14). In the optic nerve head the superior and mean RNFL thickness were 
decreased by 3.24 and 2.37 µm respectively (95% CI -7.31 to 0.83 and -7.32 
to 2.59). In the cornea the NBD (-7.77/mm2 , 95% CI -12.20 to -3.34) and 
the NFD (-3.57/mm2, 95% CI -7.12 to -0.02) were lower. In patients with 
any severity of diabetic polyneuropathy, the NBD and the NFD of the cornea 
were decreased by 20.84/mm2 (95% CI -23.92 to -17.77) and 16.32/mm2 (95% 
CI -19.26 to -13.37). Ocular changes were already present in patients with-
out diabetic polyneuropathy (NBD: -9.99/mm2,95% CI -15.26 to -4.72; NFD: 
-7.80/mm2,95% CI -12.32 to -3.28).
Conclusion: This systematic review establishes a correlation between ocu-
lar neurodegenerative changes and diabetes. Structural changes are already 
present in diabetic individuals without diabetic retinopathy or neuropathy. 
Imaging and quantification of ocular neuronal tissues gives the opportunity 
to study diabetic neuronal changes and to early detect diabetic neuropathy.
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An evaluation of different methods of normalising fovea thickness 
measurements from optical coherence tomography instruments
K.M. Gooding1,2, A.C. Shore1,2, R. Ling3, E. Agardh4;  
1Diabetes and Vascular Medicine, University of Exeter Medical School, 
2NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS 
Foundation Trust, 3West of England Eye Unit, Royal Devon and Exeter 
NHS Foundation Trust, Exeter, UK, 4Department of Clinical Sciences, 
Ophthalmology, Lund University, Malmo, Sweden.
Background and aims: The assessment of macular thickness by optical co-
herence tomography (OCT) is routinely used in clinical practice. However, 
interpretation is hampered by the lack of a universal clinical scale, partly due 
to variations in the segmental algorithms between devices. For example the 
Stratus, Cirrus and Topcon OCTs all measure thickness to different depths: 
inner/outer photoreceptors interface, mid and inner limit of the retinal pig-
ment epithelium respectively; resulting in a systematic difference when com-
paring measurements between devices. Previous work have proposed the log-
arithmic transformation of normalised data, and then utilising step changes 
to define clinically significant changes. Using this approach fovea data has 
been normalised to fovea thickness as measured by Stratus (200µm) and mid-
range normal fovea thickness as measured by spectral domain (SD) OCTs 
(250µm) in healthy eyes. Utilising these normalisation values may still result 
in a systematic difference when comparing measurements from different de-
vices. Alternative approaches are to either customise the normalisation factor 
to each device or to normalise data to a ‘gold standard’ before log transforma-
tion. As part of the SUMMIT consortium this study aims to explore different 
normalisation procedures for combining data from different OCT devices.
Materials and methods: 43 individuals were recruited (11 controls, 32 with 
diabetes: 14, 15, 5 with no retinopathy, non- and proliferative retinopathy 
respectively). Macular thickness was assessed in all participants on both Cir-
rus and Topcon-1000 OCT devices (512x128 scanning protocol). Raw data 
comparisons demonstrated that, as expected, Topcon measurements were 
consistently lower than with the Cirrus in all quadrants (mean (SD) differ-
ence: 7.9(0.5)%, p<0.001 paired t-tests). Fovea data was log10 transformed 
following normalisation by expected normal fovea thickness by 1) Stratus 
(200µm); 2) mid-range SD-OCTs (250µm); 3) customised to device (based 
on literature: Cirrus: 270µm, Topcon: 230µm); 4) Topcon measurements nor-
malised to Cirrus based on raw data (8% increase). Transformed data was 
then examined using Bland-Altman plots and limits of agreement.
Results: Normalising Topcon fovea measurements to Cirrus measurements 
successfully eliminated the systematic difference between devices. The limits 
of agreement for this data before and after log transformation are -16 to 17µm 
and -0.025 to 0.027 respectively. Similar trends were observed in all macular 
regions. A systematic difference was observed with the other fovea normali-
sation approaches.
Conclusion: This study suggests that systematic differences in macular thick-
ness measured by different OCT devices may be eliminated; however, limits 
of agreement and methods of normalisation need to be considered.
Supported by: SUMMIT Consortium IMI-2008/115006
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Longitudinal association of retinopathy and glucose metabolism in a 
Japanese population
T. Nakagami1, K. Takahashi1, C. Suto2, A. Hirose1, Y. Uchigata1;  
1Diabetes Center, Tokyo Women‘s Medical University, Tokyo,  
2Department of Opthalomology, Saitama-ken Saiseikai Kurihashi Hospital, 
Kuki City, Japan.
Background and aims: The epidemiological data for diabetic retinopathy 
have been extensively analyzed, however, limited studies have assessed the 
development of retinopathy across different glucose levels ranging from 
normal glucose tolerance to diabetes. Some studies have reported that retin-
opathy increased the risk of vascular disease and incident diabetes. Here, we 
assess the 6-year incidence for retinopathy across different glucose categories 
and the association of retinal signs detected at baseline with development of 
diabetes in a Japanese population.
Materials and methods: Subjects were 3,580 among 5,200 health check-up 
examinees (2,353 men, mean age: 51±8 years old) who underwent the test of 
non-mydriatic 45° digital fundus photography. The retinal and glucose status 
were followed up for 6 years in 181 and 3,399 individuals, with and without 
retinopathy, respectively, at baseline (mean follow up: 5.7 years). Individuals 
were classified into five categories according to fasting plasma glucose (FPG)
(<90, 90-97, 98-125, ≥126 mg/dL, known diabetes) or HbA1c(<5.38, 5.38-
5.67, 5.68-6.49, ≥6.50%, known diabetes) at baseline, and the incidence of 
retinopathy was calculated in each category. Multivariable logistic regression 
analysis to examine the effects of the presence of retinopathy as well as FPG 
or HbA1c at baseline on incident diabetes was performed.
Results: 1) Of 3,194 non-diabetes and 287 diabetes without retinopathy at 
baseline, 1,926 were followed (follow-up rate: 55.3%). The incidence of retin-
opathy was 2.5% (48/1,926) during 6 years and increased with deteriorat-
ing glucose category evaluated by HbA1c (P=0.005): 1.5, 2.3, 3.0, 4.4, and 
6.6%, but not by FPG (p=0.08). The significant positive relationship between 
incident retinopathy and HbA1c category remained after adjusting for age 
(p=0.021). 2) The incidence of diabetes during 6 years was 4.4% (91/2,050) 
and 12.0% (10/83), respectively, among those with and without retinopathy at 
baseline. Multivariable logistic regression analysis showed that retinopathy at 
baseline as well as FPG or HbA1c, BMI, and SBP at baseline were significantly 
and independently associated with incident diabetes during 6 years. Adjusted 
odds ratios associated with the presence of retinopathy at baseline for inci-
dent diabetes during 6 years were 2.43 (95% Confidence Intervals: 1.05-5.65) 
and 2.95 (1.32-6.51) in the models including HbA1c and FPG at baseline, 
respectively, as independent variables.
Conclusion: The incidence of retinopathy during 6 years of follow-up was 
2.5% in a Japanese population, and it increased with deterioration of glu-
cose categories based on HbA1c. Non-diabetic individuals with retinopathy 
at baseline had a more than 2-fold higher risk of developing diabetes within 
6 years than those without retinopathy. Our result suggests the importance of 
retinal signs as a preclinical marker of diabetes risk in the future.
Supported by: Japan Diabetes Society
1159
Diabetic retinopathy prevalence in patients with type 2 diabetes not 
performing regular eye examination
N. Szyllo, M. Gilewska, M. Pawlowski, J. Loba, L. Czupryniak;  
Internal Medicine and Diabetology, Medical University of Lodz, Poland.
Background and aims: Regular eye examination is crucial in preventing 
diabetic retinopathy. As recommended, patients with type 2 diabetes should 
have an initial eye examination by an ophthalmologist at or shortly after dia-
betes diagnosis, and then have it performed on annual basis. However, a sig-
nificant number of patients do not comply with this recommendations and 
fail to perform regular eye examination. The aim of this study was to evaluate 
the frequency of retinal abnormalities in patients with type 2 diabetes who 
have not had eye exam performed for at least three years.
Materials and methods: The study group consisted of 674 patients with type 
2 diabetes for more than 5 years and had not their eyes examined for at least 
three years, which meant missing two annual eye exams. All patients under-
went eye fundus examination by an experienced ophthalmologist. Moreover, 
103 patients completed a questionnaire containing questions related to the 
reasons for not reporting for ophthalmologic examinations.
Results: The reasons for not reporting to the regular eye exams was the lack of 
awareness of eye examination importance (37%), lack of time (26%), lack of 
referral letter (21%). There were no differences between the treatment groups 
in the incidence of hypertension or smoking. 303 (45%) patients were treated 
with insulin only, while 212 (31.4%) were taking insulin and oral drugs.
Conclusion: Diabetic retinopathy was found in a significant number of the 
patients who failed to show up for their annual eye exam, with the duration 
of diabetes as the main risk factor. Regrettably, despite long duration of the 
disease a significant proportion of patients are not aware of the need for regu-
lar eye examination. This finding calls for more intensive education regarding 
eye complications in the wide range of type 2 diabetes patients.
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Validation of a simple stratification algorithm for progression to sight 
threatening diabetic retinopathy
S.J. Aldington, I.M. Stratton, P.H. Scanlon;  
Dept. Ophthalmology/Diabetic Eye Screening, Gloucestershire Hospitals 
NHS Foundation Trust, Gloucester, UK.
Background and aims: Diabetic retinopathy (DR) is a microvascular compli-
cation of diabetes and can lead to vision loss and blindness. Annual screening 
with 2-field digital retinal imaging after mydriasis is recommended by the 
UK National Screening Committee. This is becoming difficult to achieve be-
cause of resource limitations and increasing numbers of people with diabetes. 
We have previously published a risk stratification model based on the results 
of 2 consecutive screening episodes. We know that grading protocols differ 
between screening programmes and rates of DR are affected by duration of 
diabetes, ethnicity, deprivation and diabetic control, hence validation of the 
model is required in screening programmes to assess whether the stratifica-
tion tool could be used more widely. Here we aim to validate this stratification 
in independent samples.
Materials and methods: Data were obtained from 2 English screening pro-
grammes. Patients free of sight threatening DR (STDR) at each of two suc-
cessive screening episodes were categorised by the presence of DR in neither, 
one or both eyes at each screening. Using this risk categorisation the pro-
portion with progression to STDR in each of 9 groups was calculated using 
Kaplan Meier estimation.
Results: The programmes had 24,509 and 32,987 people respectively who 
had been screened at least three times with no STDR at either of the first 
two episodes. There were few non White Caucasian patients in the first pro-
gramme but 30% of those in the second programme were of African or Afro-
Caribbean ethnicity. In the first programme by 4 years from the second base-
line screening 9.5% of patients had been found to have STDR. In the highest 
risk group of 1838 people (7.5% of total) (those with mild NPDR in both eyes 
on each of two occasions) 44.0% had been found to have STDR by 4 years, 
in the middle risk group (n=1055, 4.3%) (those with mild NPDR in one eyes 
on each of two occasions) 11.3% had progressed and in the lowest risk group 
(n=15826 64.6%) (those with no DR in both eyes on each of two occasions) 
3.7% had progressed by 4 years. The c- statistic was 0.76. In the second pro-
gramme, by 4 years from the second baseline screening 12.1% of patients had 
been found to have STDR. In the highest risk group of 1669 people (6.5% of 
total) (those with mild NPDR in both eyes on each of two occasions) 54.0% 
had been found to have STDR by 4 years, in the middle risk group (n=1201, 
4.7%) (those with mild NPDR in one eyes on each of two occasions) 19.5% 
had progressed and in the lowest risk group (n=16570 64.5%) (those with no 
DR in both eyes on each of two occasions) 4.5% had progressed by 4 years. 
The c- statistic was 0.80.
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Conclusion: Within each of these two programmes the stratification enables 
categorisation of patients into those with very low of progression to STDR 
and those at high risk. This information could be used to inform decisions 
about screening intervals.
Supported by:  NIHR HTA
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Male sex, blood pressure and heart rate are associated with the risk of 
diabetic retinopathy in normoalbuminuric type 1 patients
M. Tomić1, T. Bulum1, K. Blaslov1, S. Ljubić1, S. Kaštelan2,  
L. Smirčić-Duvnjak1;  
1Vuk Vrhovac University Clinic Merkur Clinical Hospital,  
2Dubrava Clinical Hospital, Zagreb, Croatia.
Background and aims: The pathogenesis and the onset of diabetic retinopa-
thy (DR) are still insufficiently understood. It is presumed that retinopathy 
and nephropathy occur simultaneously and that the severity of retinopathy 
equals that of renal disease in diabetes. The aim of this study was to assess the 
prevalence of retinopathy in normoalbuminuric type 1 diabetic patients and 
evaluate the risk factors for its development and progression in these patients.
Materials and methods: A total of 223 normoalbuminuric type 1 diabetic 
patients (116 male / 107 female) with normal renal function (glomerular fil-
tration rate ≥60 ml/min/1.73m2) were included in this study and followed 
for 48 months. Basic and anthropometric parameters assessed were sex, 
age, diabetes duration and body mass index (BMI). Glycated haemoglobin 
(HbA1c), HDL and LDL cholesterol, triglycerides and serum creatinine were 
determined using routine laboratory methods. Glomerular filtration rate 
(GFR) was estimated using CKD-EPI formula. Urinary albumin excretion 
rate (UAE) was measured from at least two 24-hr urine samples and deter-
mined as the mean of 24-hr urine collections. Blood pressure was measured 
with a mercury sphygmomanometer and resting heart rate using a standard 
12-lead ECG, after a 10-minute resting period. Ophthalmologic examination 
included binocular indirect slit lamp fundoscopy and color fundus photogra-
phy after mydriasis of two fields (macular field, disc/nasal field) of both eyes 
according to the EURODIAB retinal photography methodology. Possible risk 
factors for the development and progression of DR were examined in back-
ward stepwise Cox‘s multiple regression analysis.
Results: Patients were 38.2 ± 10.3 years old with mean diabetes duration of 
17.2 ± 9.1 years. Mean/median values of BMI (24 (18 - 37) kg/m2), HDL cho-
lesterol (1.7 ± 0.4 mmol/L), triglycerides (1.02 ± 0.6 mmol/L), systolic (120 
(80 - 180) mmHg) and diastolic blood pressure (80 (60 - 110) mmHg), serum 
creatinine (70.1 ± 12.2 µmol/L), UAE (9.8 (1.3 - 29.0) mg/24h) and eGFR 
(106.2 ± 15.1 ml/min/1.73m2) were within normal range for diabetic patients, 
whereas HbA1c (7.0 ± 1.4 %) and LDL cholesterol (2.8 ± 0.8 mmol/L) were 
slightly elevated. At baseline, 156 (70%) patients had no retinopathy and 67 
(30%) had nonproliferative diabetic retinopathy (NPDR). After 48 months, 
24 patients (10.7%) developed NPDR or progressed to proliferative diabetic 
retinopathy (PDR). From the 156 patients with no retinopathy at the begin-
ning of the study 15 (9.6%) progressed to NPDR, while from the 67 patients 
with NPDR at the beginning of the study 9 (13.4%) progressed to PDR. Male 
sex (HR 2.9, CI 1.04-8.3, p=0.04), systolic blood pressure (HR 1.03, CI 1.01-
1.06, p=0.02), UAE (HR 1.14, CI 1.06-1.23, p=0.001) and resting heart rate 
(HR 1.03, CI 1.01-1.07, p=0.03) were significantly associated with the devel-
opment and progression of retinopathy.
Conclusion: The results of this study suggest that diabetic retinopathy may 
develop and progress in type 1 diabetic patients even without a coexisting 
renal disease. This points to the need for close monitoring of normoalbumi-
nuric type 1 diabetic patients aimed at early detecting, preventing or limiting 
the progression of retinopathy, especially in men with higher UAE, systolic 
blood pressure and higher resting heart rate.
1162
Incidence of severe diabetic retinopathy and all-cause mortality among 
migrants in Denmark
J. Oya, M.E. Jørgensen, B. Carstensen, G.S. Andersen;  
Clinical Epidemiology, Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Global migration has been increasing and it has been 
reported that migrants from non-European countries are usually diagnosed 
with diabetes more commonly and at younger age than European counter-
parts. Consequently, they may have higher rates of diabetic complications 
and death. Diabetic retinopathy (DR) is a common microvascular complica-
tion of diabetes and may progress to proliferative retinopathy and macular 
oedema if exposure of hyperglycemia and hypertension prolongs. Reports 
from UK and US showed that African and Asian migrants had higher preva-
lence of DR and especially sight-threatening retinopathy, than UK and US 
born people with diabetes. It has been considered that the difference probably 
reflects worse glucose and blood pressure control, lower frequency of eye ex-
amination and genetic background. However, longitudinal data on incidence 
of DR using nationwide data among migrants are lacking.
Materials and methods: Nationwide clinical data from the Danish Diabe-
tes Database for Adults (Dansk Voksen Diabetes Database) on >17 years 
old diabetes patients followed since 2005 was linked through the personal 
ID number with data from the National Patient Register for identification of 
retinopathy diagnoses, the Cause of Death Register for information on deaths 
and the Central Personal Register for information on country of origin. We 
classified patients according to country of origin into six groups: Denmark, 
other Europe, Sub Saharan Africa, Middle East (includes North Africa), Asia 
and America (includes Oceania). From 73,572 patients with complete infor-
mation, follow-up of 56,148 patients (mean age 58±15 years, duration of dia-
betes 8.6±9.3 years) and free from severe DR at baseline were analysed. We 
estimated event rates and hazard ratios (HR) for incidence of severe retinopa-
thy and all-cause mortality between geographical regions.
Results: At baseline, median age, duration of diabetes and systolic blood 
pressure were lower and median HbA1c was higher in migrants from Sub 
Saharan Africa, Middle East and Asia compared to diabetes patients of Dan-
ish origin. During 215,565 person-year of follow-up, 6,348 patients suffered 
an incident of severe DR and 2,400 patients died. Compared to Danish borns, 
migrants from Middle East and Asia had higher risk of severe retinopathy 
(HR, 1.15 [95% confidence interval (CI) 1.04-1.27] and 1.24 [1.03-1.49], 
respectively) after adjustment for age, sex, type of clinic, body mass index, 
smoking status, and diabetes type, duration and control. The associations re-
mained after further adjustment for blood pressure and lipids. Mortality rates 
were lower among those with other European, Sub Saharan, Middle Eastern, 
Asian or American origin compared to Danish borns after adjustment for age 
and sex (HR; 0.71, 0.26, 0.51, 0.55 and 0.52, all significant except America).
Conclusion: Migrants with diabetes from the Middle East and Asia showed 
higher risk of incidence of severe DR compared to Danish borns, but substan-
tially lower mortality rates.
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Topical administration of a GLP-1 agonist prevents retinal 
neurodegeneration in experimental diabetes
R. Simó1,2, P. Bogdanov1,2, L. Corraliza1,2, C. Solà1, C. Hernández1,2;  
1Diabetes and Metabolism Research Unit, Institut de Recerca Hospital 
Universitari Vall d‘Hebron, 2CIBERDEM, Barcelona, Spain. 
Background and aims: Retinal neurodegeneration is an early event in the 
pathogenesis of diabetic retinopathy (DR). Therefore, treatments aimed at 
preventing or arresting retinal neurodegeneration has been recently pro-
posed as a new strategy to reduce the incidence and progression of DR. There 
is evidence that glucagon-like peptide-1 (GLP-1) exerts a neuroprotective 
effect in the central nervous system but there is scarce information on this 
issue in the retina. The aim of the study was to explore the effectiveness of a 
GLP-1 analogue (liraglutide) administered topically (eye-drops) in prevent-
ing retinal neurodegeneration in db/db mice, an experimental model of type 
2 diabetes.
Materials and methods: For this purpose we evaluated a total of 24 diabetic 
mice (db/db) aged 8 weeks that were randomly assigned to daily oral treat-
ment with liraglutide (6 mg/ml) (n=12) or vehicle (n=12) for two weeks. 
Twelve non-diabetic mice (db/+) were used as control group. Retinal neuro-
degeneration was evaluated by measuring glial activation (immunofluores-
cence and Western blot) and apoptosis (TUNEL, cell count in ganglion cell 
layer). Functional abnormalities were assessed by electroretinography (ERG).
Results: We observed that diabetic mice presented significantly higher glial 
activation and apoptosis than age-matched non-diabetic mice. The diabetic 
mice treated with eye drops of GLP-1 analogue presented a significant de-
crease of both glial activation and rate of apoptosis than diabetic mice treated 
with vehicle. Furthermore, a significant improvement of ERG parameters was 
observed.
Conclusion: Topical administration of a GLP-1 analogue prevents retinal 
neurodegeneration induced by diabetes. Our findings open up a new phar-
macological strategy targeted to early stages of DR.
Supported by: SAF2012-35562 and PI13/00603
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Early-outgrowth bone marrow cells protect the retina of experimental 
model of type 2 diabetes by improving SIRT-1 signalling
D.A. Duarte1, K.C. Silva1, A. Papadimitriou1, M.A.B. Rosales1,  
E.B.M. Peixoto1, R.E. Gilbert2, J.B. Lopes de Faria1, J.M. Lopes de Faria1;  
1Faculty of Medicine, State University of Campinas, Brazil,  
2Keenan Research Centre of the Li Ka Shing Knowledge Institute,  
University of Toronto, Canada.
Background and aims: Cellular therapy has been studied in cardiovascu-
lar disease but has rarely been investigated in eye diseases. Sirtuins (SIRTs), 
a family of deacetylases, is thought to be sensitive to oxidative stress. This 
study hypothesized that cell therapy using early outgrowth cells (EOC) could 
protect the diabetic retina through antioxidant means, thus improving the 
SIRT1 pathway. This study investigated the possible therapeutic effects of 
cells derived from healthy (db/m) and diabetic (db/db) animals on diabetic 
retinopathy (DR.
Materials and methods: Mice aged 8-weeks and db/db were randomized to 
receive a unique intravenous injection of PBS or 0.5 × 105 db/m EOCs or 
0.5 × 105 db/db EOCs. Four weeks later, the animals were euthanized and 
the eyes enucleated. For in vitro study, an EOCs-conditioned medium (EOC-
CM) was generated from db/m and db/db EOCs cultures. The rat Müller cells 
(rMCs) were exposed for 24 h to normal (NG), high glucose (HG) combined, 
or with neither db/m nor db/db EOC-CMs.
Results: In diabetic rats, there was an increase of DR and oxidative damage 
markers accompanied by an increase in NOX4 expression leading to detri-
ment of SIRT1 protein. This was followed by lysine-310-p65-NFκB acetyla-
tion. The treatment with cells from db/m significantly reduced this damage, 
but the treatment with cells from db/db mice fully restored these alterations 
to normal levels. The rMCs exposed to HG displayed GFAP and VEGF ex-
pression upregulation accompanied by an increase in NOX4 expression, ROS 
levels and acetyl-lysine-310-p65-NFκB. Protein expression and activity of 
SIRT1 were markedly reduced in diabetic milieu conditions. The treatment 
with both EOC-CMs prevented all these abnormalities, but db/db EOC-
CM resulted in full restoration to NG conditions. The presence of EX-527, 
a SIRT1-specific blocker, or siRNA SIRT1 abolished the observed effects in 
both treatments.
Conclusion: This study demonstrates that the endocrine capacity of EOCs is 
effective in improving the retinal SIRT1 pathway, thus protecting the retina 
from diabetic milieu insult. This is one evidence that regenerative therapy for 
DR using EOCs or its released factors could be a promising tool for patients 
with diabetic eye disease.
Supported by: FAPESP and CNPq
1165
Attenuation of reactive gliosis in retinas by PARP-1 inhibitors treatment 
under diabetes in rats
M. Guzyk, A. Tykhomyrov, T. Kuchmerovska;  
Palladin Institute of Biochemistry, Kiev, Ukraine.
Background and aims: Diabetic retinopathy (DR) is a multifactorial disease, 
and persistent hyperglycemia appears to be a major contributor to its devel-
opment. Gliosis is a hallmark of retinas neurodegeneration. The exact mo-
lecular mechanisms which contribute to development of diabetes-induced 
retinas neuropathy are not completely understood. The study was aimed to 
estimate the Poly(ADP-ribose)ylation and reactive gliosis under DR and ef-
fect of Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors, 3-aminobenza-
mide (3-AB) and nicotinamide (NAm) on these processes.
Materials and methods: All studies were carried out after 10 weeks of diabe-
tes (streptozotocin, 70 mg/kg of body weight, i. p.) in male Wistar rats treated 
2 weeks with or without 3-AB (30 mg/kg/day, i. p.) and NAm (100 mg/kg/
day, i. p.). The proteins content was assessed by Western blot and immuno-
histochemically.
Results: The levels of glial fibrillary acidic protein (GFAP) were significantly 
increased in retinas at diabetes as result of glial reactivity. In addition, ex-
pression of immunoreactive products of GFAP degradation (lower molecular 
weight polypeptides, in the range from 47 to 37 kDa), another representa-
tive indicator of reactive gliosis, was observed. Marked reduction of GFAP 
levels was seen in retinas of diabetic rats treated with 3-AB or NAm, though 
content of retinas GFAP did not reached to the control. Noteworthy, 3-AB 
and NAm administration completely prevented increase in GFAP degrada-
tion. Increased GFAP immunoreactivity was observed in retinas sections of 
diabetic rats compared with control, which is in parallel with data obtained 
by Western blot. Immunohistochemically, supplementation of diabetic rats 
with PARP inhibitors counteracted glial activation in retinas. Intensity of glial 
response appeared to be correlated directly with PARP-1 activation. Western 
blot analysis demonstrated significant upregulation of PARP-1 expression by 
about 1.5 in diabetic retinas compared to nondiabetic group. At the same 
time PARP-1 fragmentation was exacerbated more than 2-fold in diabetic 
rats as compared to control. PARP-1 inhibitors administration to diabetic rats 
normalized PARP-1 expression in retinas. However, effect of NAm was more 
profound than 3-AB not only on protein expression but also on protection of 
PARP-1 from its fragmentation due to its antioxidant property and improv-
ing of proinsulin biosynthesis through increase of NAD level that is respon-
sible for the cellular ATP which is necerely for glycolysis and mitochondrial 
respiration. Poly(ADP-ribosyl)ated proteins (pADPs) were detected primar-
ily in range from 72 to 130 kDa of the retinas protein spectrum, with several 
minor bands at 17 to 55 kDa. Both 72 to 130 kDa and 26 to 37 kDa pADPs 
expression was increased in diabetic rats as compared to control and was es-
sentially prevented by 3-AB and NAm treatment.
Conclusion: Thus, PARP-1 inhibitors can be potential drugs for treatment 
of DR through improvement of PARP-1 fragmentation and modulation of 
reactive gliosis that maintain homeostasis and normal neuronal function in 
retinas under diabetes.
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p62 is not only a marker of autophagy but also a possible target against 
retinal Müller cells apoptosis under diabetic milieu conditions
C. Montemurro, V.H. de Oliveira Amancio, D. Andreazzi Duarte,  
A. Papadimitriou, J.B. Lopes de Faria, J. Mendoza Lopes de Faria;  
Faculty of Medical Sciences, University of Campinas (Unicamp), Renal 
Pathophysiology Laboratory, Investigation on Complications of Diabetes, 
Brazil.
Background and aims: Inhibition of autophagy, a catabolic process by which 
cells degrade intracellular components inside lysosomes, induces degenera-
tive changes in mammalian tissues that resemble those associated with aging, 
and was described to be altered in retinal cells under diabetic conditions. 
Apoptosis, or programmed cell death, appears to play an important role in 
the pathogenesis of diabetic complications. The aim of this study was to in-
vestigate the interaction between autophagy and apoptosis of retinal Muller 
cells under diabetic conditions in vitro.
Materials and methods: Rat Muller cells (rMCs) were cultured in normal 
glucose (NG; 5.5 mM), high glucose (HG; 30 mM) and under oxidative stress 
conditions (H2O2; 1 mM) for 24, 48, 72h, with and without N-Acetyl Cysteine 
(NAC), autophagosome formation inhibitor, 3 Methyladenine (3MA; 1mM) 
and PERK inhibitor I, GSK 2606414. The markers of autophagosome forma-
tion, Beclin1, and autophagosome-lysosome fusion, p62, were measured by 
Western blot (WB). Intracellular reactive oxygen species (ROS) were evaluat-
ed by 2´-7´ dichlorofluorescein (DCFH(2)) assay and apoptosis was assessed 
by TUNEL and extrinsic apoptotic pathway by caspase 8 activity.
Results: In rMCs, HG and H2O2 increased Beclin1 and p62 levels (p<0.05) 
as well as the rate of cellular apoptosis (p<0.05) in a time independent man-
ner, and increased activity of caspase 8 (p<0.05). Whereas 3MA decreased 
the expression of Beclin1 under HG, it increased further p62 levels, caspase 
8 activation and cellular apoptosis (p<0.05). The presence of GSK 2606414, 
an indirect inhibitor of phospho-eif2α, a endoplasmatic reticulum (ER) stress 
marker, decreased the activation of caspase 8 (p<0.05). NAC was able to pre-
vent the increase of intracellular ROS (p<0.05) and reversed the increments 
of Beclin1 and p62 expressions, caspase 8 activity and cellular apoptosis 
(p<0.05).
Conclusion: Cells exposed to diabetic conditions displayed an alteration of 
autophagic flux as demonstrated by increased levels of Beclin1 and p62. The 
increases in p62 levels suggest a defective clearance of autophagosome by 
lysosome fusion. The accumulation of p62 levels cause activation of caspase 
8 leading to retinal Muller apoptosis. The modulation of p62 levels could be a 
possible target to prevent retinal Muller cells apoptosis under diabetic condi-
tions.
Supported by: Fapesp
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The association between Bsm1/Apa1 polymorphisms in the vitamin 
D receptor gene and complications of type 2 diabetes in the Korean 
population
T. Oh1, H.-J. Jeon1, H.-J. Choi1, Y.-H. Lee2;  
1Internal Medicine, 2Biochemistry, Chungbuk National University, 
Cheongju, Republic of Korea.
Background and aims: Type 2 diabetes is one of the most common disease 
in with devastating complications. However, genetic susceptibility of diabetic 
complications has not been clarified. The vitamin D endocrine system is re-
lated with calcification and lipolysis, insulin secretion, and may be associated 
with many complicated disease including diabetes and cardiovascular dis-
ease. Recent studies reported that single nucleotide polymorphisms (SNP) of 
vitamin D receptor (VDR) gene were associated with diabetic complications.
Materials and methods: We evaluated the association of VDR SNPs (BsmI 
and ApaI) with diabetic complications in 537 type 2 diabetic patients. PCR-
restriction fragment length polymorphism was used to test the genotype and 
allele frequency of BsmI (rs1544410; BB, Bb, bb) and ApaI (rs7975232; AA, 
Aa, aa) polymorphisms.
Results: Patients with B allele (BB or Bb) was significantly associated with 
lower risk of severe retinopathy (severe nonproliferative diabetic retinopathy 
or proliferative retinopathy) (7.4%; 5/68) compared with patients without B 
allele (bb) (17.3%; 81/ 469) (Odds Ratio=2,63, P=0.037). This association was 
significant after adjusting for age, sex and BMI (P=0.044) in logistic regres-
sion analysis. In Kaplan-Meier survival analysis, there was a trend of lower 
risk of severe retinopathy among patients with B allele (BB or Bb) compared 
with patients without B allele (bb) (P=0.091). Regarding coronary artery dis-
ease, patients with B allele (BB or Bb) had significantly higher risk of devel-
oping myocardiac infarction compared with patients without B allele (bb) 
(P=0.049). No significant association was observed regarding ApaI SNP.
Conclusion: Our findings suggest that BsmI SNP in VDR gene is associated 
with lower risk of severe retinopathy and higher risk of coronary artery dis-
ease in type 2 diabetic patients. BsmI genotype could be used as a susceptibil-
ity marker to predict the risk of diabetes complications.
1168
Pro-angiogenic and anti-antiogenic microRNAs expression on 
endothelial progenitor cells from type 1 diabetic patients with and 
without diabetic retinopathy
N. García de la Torre1, R. Fernández1, R. Gómez1, A. Barabash1,  
M. Fuentes2, I. Runkle1, M. Roldán3, A.L. Calle1;  
1Endocrinology Department, 2Preventive Medicine Department, 
3Ophtalmology Department, Hospital Clínico San Carlos, Madrid, Spain.
Background and aims: Endothelial progenitor cells (EPCs) are recognized as 
a key cell responsible for healthy maintenance of the vasculature, including 
the retina. Recently, microRNAs (miRs) have emerged as critical regulators 
of signalling pathways in multiple cell types including endothelial cells. miR-
221 and miR-222 are highly expressed in vascular endothelial cells where 
they exert anti-proliferation, anti-migration and pro-apoptosis effects. miR-
126 has been identified as pro-angiogenic and increases colony formation, 
proliferation, and migration of EPCs. The expression of miRs in EPCs from 
patients with type 1 diabetes mellitus (DM1) and its relation with different 
stages of diabetic retinopathy (DR) has not been reported to date. In addi-
tion, there is evidence that triglyceride lowering drugs such us fenofibrate can 
reduce progression of DR, but the mechanisms implicated remain unknown. 
Therefore, the aim of the present study was to analyze the expression of miR-
222, miR-221, and miR-126 in circulating EPC from patients with DM1 with 
and without DR.
Materials and methods: Patients with DM1 without overt macrovascular 
disease, were recruited from January 2012 to December 2013. 33 DM1 pa-
tients with DR, 30 DM1 patients without DR, and 29 non-diabetic controls 
were included. Venous blood was collected for EPC colony culture and for 
flow cytometry analysis. Total RNA was extracted and purified and real-time 
qPCR was performed to analyse miRs expression after 7 days of EPC culture. 
Relative changes in miRs expression were analyzed with the 2 (delta delta 
c(T)) method. Non-parametric methods were used to compare differences 
between groups.
Results: There was no significant difference in age and gender distribution 
between patients and controls. Patients with RD were significantly older 
than those without DR (48.18 ± 10.33 vs 40.8 ± 11.104, p=0.009) and had 
longer duration of diabetes (34 [24-39] vs 17 [10.75-22.5] years, p<0.0001). 
Circulating EPC number was reduced in DM1 patients compared to controls 
(p=0.006) but was not significantly different in DM1 patients with and with-
out DR. miR-126 and miR-221 expression was significantly higher in DM1 
compared to controls (p=0.024 in both cases). In addition, miR-221 was sig-
nificantly higher in patients with DR than in those without DR (p=0.046). 
However, differences between non proliferative and proliferative DR were no 
significant (p=0.08).We did not find any relationship between miRs expres-
sion and duration of diabetes, HbA1c, fasting glucose, albumin excretion 
ratio, or total, HDL and LDL cholesterol. There was a positive correlation 
between miR-126 and miR-221 expression and triglyceride concentration 
(Rho 0.266, p=0.044 and Rho 0.413, p=0.01, respectively). We found, also, 
a positive correlation between circulating EPC number and total and LDL 
cholesterol concentrations (Rho 0.306, p=0.019 and Rho 0.321, p=0.013, re-
spectively).
Conclusion: Circulating EPC number is reduced in DM1 patients compared 
to controls. miR-221 expression is significantly higher in DM1 patients com-
pared to controls and in patients with DR than in those without DR. In addi-
tion there is a positive correlation between miR-221 expression and triglyc-
eride concentration.
Supported by: Instituto de Salud Carlos III
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Thiamine metabolism abnormalities contribute to the progression of 
diabetic nephropathy
K. Kankova1, K. Kuricova1, V. Dvorakova1, L. Pácal1, Z. Marcanova1,  
J. Svojanovsky2, J. Olsovsky2, J. Belobradkova3, J. Rehorova3;  
1Dept. of Pathophysiology, Masaryk University, 2Dept. of Internal Medicine, 
St. Anne University Hospital, 3Dept. of Gastroenterology, Faculty Hospital 
Brno-Bohunice, Brno, Czech Republic.
Background and aims: Pentose phosphate pathway (PPP) represents poten-
tially protective pathway in hyperglycaemia since it can process glycolytic 
intermediates and thus decrease production of reactive dicarbonyls (meth-
ylglyoxal) and reactive oxygen species in mitochondria. Transketolase (TKT) 
is the rate-limiting enzyme of non-oxidative branch of PPP whose activity 
depends on thiamine diphosphate (TDP) - an active form of thiamine (vit. 
B1) - as a cofactor. Thiamine supplementation was shown to prevent devel-
opment and progression of diabetic nephropathy (DN) in animal model of 
diabetes. Thiamine is delivered to the cell via specific thiamine transporters 
1 (encoded by SLC19A2) and 2 (SLC19A3) and phosphorylated by thiamine 
pyrophosphiokinase (TPK). We have previously shown that plasma levels of 
thiamine are dominantly influenced by GFR, however increasing plasma thi-
amine in subjects with decreased renal function are not paralleled by increase 
of intracellular TDP. The aim of the current study was to analyse relationship 
between plasma and erythrocyte parameters reflecting the thiamine status 
and progression of DN, cardiovascular morbidity and mortality. Additionally, 
since genetic variability in SLC19A2 and SLC19A3 loci may potentially affect 
activity of thiamine transport, common SNPs in those genes were detected 
and tested for their contribution to the progression of DN.
Materials and methods: Prospective observational cohort study comprised a 
total of 273 type 2 diabetics with variable stage of DN at baseline followed for 
a median of 39 [IQR 21 - 59] months. Following end-points were considered: 
(1) progression of DN by stage, (2) major cardiovascular event (MCVE, non-
fatal and fatal myocardial infarction or stroke, limb amputation, revasculari-
sation) and (3) all-cause mortality. Plasma and erythrocyte TDP was detected 
using HPLC. TKT activity was determined by kinetic method. Genotyping of 
6 SNPs (3 in the SLC19A2 locus (rs1983546, rs7522245, rs6656822) and 3 in 
the SLC19A3 locus (rs13025803, rs4973216, rs7567984)) was performed by 
RT-PCR. Time-to-event analysis was carried out to ascertain contribution of 
thiamine, TDP and SNPs to studied end-points.
Results: Cumulative incidence of DN progression was 22.9%, CVE 8.2%, and 
ACM 19.8%. Significant differences in DN progression and all-cause mortal-
ity were ascertained for plasma TDP tertile groups (both P<0.001) and for 
erythrocyte TKT activity for the latter end-point (P=0.01). In all cases the 
highest tertiles were associated with the worst survival rate while the low-
est tertile of erythrocyte TDP/plasma TDP was associated with the lowest 
survival rate (P=0.01). No significant effects were ascertained for any of the 
studied SNPs and the three end-points (all P>0.05).
Conclusion: Our results indicate that abnormalities of thiamine metabolism 
induced by diabetes, especially intracellular deficit of active TKT cofactor and 
impaired activity of TKT contribute to the progression of diabetes-associated 
morbidity or mortality. Elucidation of molecular mechanisms responsible for 
decreased intracellular availability of TDP is warranted.
Supported by: IGA MZČR NT/11405
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Defective mitochondrial turnover in experimental diabetic nephropathy
G.C. Higgins1,2, T.-V. Nguyen1, S.A. Penfold1, P.M. Robb1, G. Ramm3,  
K.E. White4, R.W. Bilous4, M.E. Cooper1,5, J.M. Forbes6, M.T. Coughlan1,5;  
1Diabetic Complications, Baker IDI Heart and Diabetes Institute, 
2Department of Biochemistry & Molecular Biology, Monash University, 
3Biochemistry & Molecular Biology, Monash University, Clayton, Australia, 
4EM Research Services, Faculty of Medical Sciences, Newcastle University, 
Newcastle, UK, 5Department of Medicine, Monash University, Melbourne, 
6Glycation & Diabetes, Mater Medical Research Institute, South Brisbane, 
Australia.
Background and aims: Diabetic nephropathy (DN) is the major cause of 
end stage renal disease in the Western world. Defects in mitochondrial bio-
energetics are evident in DN and are thought to initiate renal impairment. 
Accumulation of fragmented mitochondria are found in the renal cortex in 
experimental diabetes, suggesting that in tandem with a shift in dynamics, 
mitochondrial clearance mechanisms may be impaired. The process of mi-
tophagy is the selective targeting of damaged or dysfunctional mitochondria 
to autophagosomes for degradation through the autophagy pathway. Here, 
we aimed to determine if there was an impairment in mitophagy and changes 
in mitochondrial dynamics in the kidney in DN.
Materials and methods: Markers of mitophagy and mitochondrial dynamics 
were followed in the renal cortex from mice rendered diabetic with the beta 
cell toxin streptozotocin (STZ). Tissue from the renal cortex was studied by 
western immunoblot for changes in mitophagy and mitochondrial dynam-
ics changes, while mitochondrial bioenergetics were performed to measure 
mitochondrial function. Electron microscopy was also undertaken to follow 
changes in mitochondrial morphology, between control and diabetic popu-
lations. Human renal biopsies, taken from both type 1 and control patients 
(taken from kidney donor patients) were studied by electron microscopy 
for evidence of changes in mitochondrial morphology and autophagy/mi-
tophagy.
Results: Bioenergetics were impaired in mitochondria isolated from renal 
cortex, with a decline in ATP content, increased reactive oxygen species and 
depolarisation of the inner mitochondrial membrane. Increased recruitment 
of Drp-1 to mitochondria was observed in diabetes, with a 3-fold increase 
in Drp-1 translocating to mitochondria (n=6, P <0.05), indicating a shift 
towards mitochondrial fission. Electron microscopy imaging revealed mi-
tochondrial fragmentation in the proximal tubule epithelial cells (PTECs). 
Mitophagy impairment was seen with a decrease in autophagic flux (decline 
in LC3-II), with a 2-fold decrease (n=6, P<0.05) in renal cortical cell lysates, 
coupled with a decline in Parkin translocation to mitochondria (approximate 
2-fold decrease, n=6, P<0.05) and a approximate 10-fold decrease of p62 
within mitochondrial fractions (n=6, P<0.05). Importantly, these data corre-
late with findings from renal biopsies of patients with DN that show striking 
changes in morphology of mitochondria residing within PTECs manifesting 
as a greater percentage of fragmented mitochondria (3-fold increase, n=6, 
P<0.0001), indicative of a shift towards fission.
Conclusion: These data demonstrate that in chronic hyperglycaemia, mito-
chondria undergo fission, however, there is a defect in mitophagy, leading to 
reduced mitochondrial turnover and accumulation of dysfunctional mito-
chondria. A better understanding of the cellular and molecular events that 
govern mitophagy and dynamics in DN may lead to improved therapeutic 
strategies.
Supported by: JDRF
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Nrf2 overexpression inhibits mechanical stretch-induced fibronectin 
expression
L. Gnudi, A.A. Hayward, S. Duggan, K.L. Price, J. Pan, C. Dessapt,  
R.C.M. Siow, G.E. Mann;  
Cardiovascular Division, King‘s College London, London, UK.
Background and aims: Mesangial cells are a primary target for haemody-
namic perturbations in hypertensive glomerulopathies (e.g. diabetes). Oxida-
tive stress plays a central role in the pathogenesis of diabetic microvascular 
complications, and the transcription factor Nuclear factor (erythroid-derived 
2)-like 2 (Nrf2) has been proposed as a central player in the cellular anti-
oxidant response. The aim of this study was to evaluate, in cultured human 
mesangial cells (HMCs), the role of Nrf2 in the stretch-mediated antioxidant 
response and fibronectin secretion.
Materials and methods: HMCs were exposed to 10% average elongation (S) 
or static conditions (NS) up to 48h. Cellular superoxide was assessed with 
Cytochrome-C reduction assay, while mitochondrial superoxide was investi-
gated using MitoSOX Red. Protein and mRNA expression were assessed re-
spectively with western imunoblotting and real time PCR after normalisation 
against housekeeping genes. Fibronectin secretion was assessed by ELISA 
and normalised against cell number.
Results: S increased superoxide production (p=0.01), which was paralleled by 
an upregulation of the antioxidant enzyme heme oxygenase-1 (HO-1) both 
at the mRNA and protein level (p=0.01). The increase in superoxide was not 
accompanied by an increase in p22phox, p67phox or Nox4 mRNA expres-
sion, whilst mRNA expression of gamma-glutamate cysteine ligase catalytic 
subunit was upregulated (p=0.05), but not mRNA levels for NAD(P)H qui-
none oxidoreductase-1 or glutathione peroxidase. Stretch-mediated increase 
in superoxide production was significantly inhibited by the NADPH-oxidase 
inhibitors apocynin (10 mcM) and diphenyleneiodonium (100 mcM), and by 
the antioxidant rotenone (25nM), suggesting a mitochondrial origin of oxi-
dative stress in stretched cells. Inhibition of stretch-mediated superoxide pro-
duction was paralleled by absent stretch-induced HO-1 protein upregulation. 
Transfection of HMCs with dominant negative Nrf2 resulted in inhibition 
of stretch-induced HO-1 upregulation (p=0.05), but had no effect on basal 
and stretch-induced (24 and 48h) fibronectin secretion when compared to 
control (GFP-transfected) cells. Conversely overexpression of wild type Nrf2 
resulted in a significant HO-1 up regulation (p=0.01), which was paralleled 
by a reduction in both basal and stretch-induced fibronectin (p<0.01).
Conclusion: Mechanical stretch-mediated superoxide production in HMCs 
is paralleled by a upregulation of HO-1. Nrf2 plays a role in stretch-mediated 
HO-1 upregulation. Overexpression of Nrf2 (and parallel HO-1 upregula-
tion) is sufficient to prevent basal and stretch-induced fibronectin secretion 
in HMCs in vitro.
Supported by: EFSD, Diabetes UK
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Development of impaired renal function in pre-diabetic mice 
overexpressing SREBP-1c
K. Kaul1,2, T. Jelenik1,2, I. Rokitta1,2, J. Kotzka3,2, M. Roden1,4;  
1Institute of Clinical Diabetology, 2German Center for Diabetes Research, 
3Institute for Biochemistry and Pathobiochemistry,  
4Department of Endocrinology and Diabetology,  
Heinrich-Heine University, Düsseldorf, Germany.
Background and aims: Microalbuminuria associates with insulin resistance 
even in humans without overt type 2 diabetes. However, development of albu-
minuria and altered renal function remains unadequately understood in the 
context of insulin resistance. Here, we examined a specific model of insulin 
resistance with partial lipodystrophy and ectopic lipid deposition.Transgenic 
aP2-SREBP-1c mice overexpress sterol regulatory element binding protein 1c 
(SREBP-1c) in adipose tissue, and are hyperinsulinemic and insulin resistant 
based on hyperinsulinemic-euglycemic clamps, when compared to C57BL/6 
mice serving as controls.
Materials and methods: Urinary albumin-to-creatinine ratio was measured 
by ELISA. Kidneys from sacrificed mice were weighed and homogenized for 
assessing lipid peroxidation by thiobarbituric acid (TBARS).
Results: The aP2-SREBP-1c mice had 2.5-fold higher urinary albumin-to-
creatinine ratio than control mice (15.8±4.5 µg albumin/µg creatinine vs. 
6.2±0.8 µg albumin/µg creatinine, P<0.01, n=6). The transgenic mice showed 
higher kidney weight as compared to controls (394±13 mg vs. 299.9±13 mg, 
P<0.01, n=6) indicating renal hypertrophy. Similarly, kidney-to-body weight 
ratio was also higher in the transgenic mice (1.22±0.01% vs. 1.12±0.03%, 
P<0.01, n=6). In kidney homogenates of transgenic mice, TBARS were al-
most twice compared to controls (0.61±0.08 µmol/mg protein vs. 0.32±0.02 
µmol/mg protein, P<0.05, n=6).
Conclusion: In conclusion, insulin resistant but nondiabetic aP2-SREBP-1c 
transgenic mice display impaired renal function and increased lipid peroxi-
dation suggesting an oxidative stress response. The aP2-SREBP-1c transgenic 
mice may therefore serve as a novel rodent model of pre-diabetic kidney dis-
ease.
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Inactivation of Wnt pathway and interaction of GSK3ß with p53 
contribute to podocyte apoptosis in diabetes mellitus and are prevented 
by treatment with green tea
A. Papadimitriou, E. M.P. Prado, C. Montemurro, D. A.T. Teixeira,  
J. M. Lopes de Faria, J. B. Lopes de Faria;  
Renal Pathophysiology Laboratory, Investigation on Complications of 
Diabetes, Faculty of Medical Science, Campinas, Sao Paulo, Brazil.
Background and aims: In diabetes mellitus (DM) podocyte apoptosis con-
tributes to albuminuria and renal disease progression. Green tea (GT) re-
duced albuminuria in diabetic rats by an unknown mechanism. The mecha-
nism of podocyte apoptosis in DM is not well understood. Wnt pathway is a 
key signaling in integrating cell adhesion, motility, cell death and differentia-
tion in podocytes, and GSK3β plays a crucial role in this pathway. Activated 
GSK3β is known to promote p53-mediated increases in apoptotic signaling, 
by functional interaction GSK3β-p53 after camptothycin-DNA damage, in 
human neuroblastoma and lung carcinoma cells. The contribution of the in-
teraction GSK3ß-p53 leading to podocyte apoptosis under DM is not known. 
Aims of the present study were to assess the contribution of Wnt pathway, 
principally by the interaction of GSK3ß with p53 in podocyte apoptosis and 
the effects of GT in these abnormalities.
Materials and methods: For in vitro studies, immortalized mouse podocytes 
(iMPs) were cultured in normal glucose (NG; 5.5 mM) and high glucose 
(HG; 30 mM) with or without GSK3β blocker (BIO), p-LRP6 blocker (DKK-
1), siRNA for LRP6. We also tested if GT activates Wnt. Apoptosis was as-
sessed by caspase-3 activity and TUNEL. GSK3β-p53 interaction, and GSK3β 
and p-53 relations with Wnt components were done by immunoprecipitation 
(IP). In vitro filtration barrier integrity was done by albumin influx assay. 
For in vivo studies, diabetic 12 week-old spontaneously hypertensive rats 
(SHR) received or not daily GT treatment (1.7g/Kg body weight/day). After 
12 weeks of treatment, albuminuria was quantified by ELISA kit. Nephrin, 
Wnt pathway components (p-LRP6 and GSK3-β (p-Ser9) and p-p53 levels 
were measured by immunofluorescence and Western blot (WB). Podocyte 
foot processes were assessed by electron microscopy.
Results: In iMPs, HG inactivated Wnt by reducing p-LRP6 and WNT-1 
component expression (p<0.0001). Consequently, GSK3-β was activated 
(p=0.003) and GSK3β-p53 interaction led to rise in apoptosis and albumin 
permeability flux, all of which were ameliorated by GT. NG treatments with 
Wnt blockers, such as: BIO, DKK-1 and siRNA LRP-6 had the same effects as 
HG. In the rats, systolic blood pressure did not differ among the groups. Body 
weight was less and glycemia was greater in diabetic rats (treated or not with 
GT). In diabetic animals, rise in albuminuria (p=0.0083) was in parallel with 
reduction of nephrin (p=0.0002) and synaptopodin (p=0.038), and increased 
in podocyte foot process effacement and in p-p53 level (p=0.011). All these 
parameters were prevented by GT (p<0.0001; p=0.0016; p=0.003, respec-
tively). p-LRP6 and pGSK3β levels were reduced in diabetic rats (p=0.044 
and p=0.0002, respectively) and they were all reversed by GT (p=0.05 
and p=0.006, respectively). IPs showed a decrease in synaptopodin-LRP6 
(p=0.048) and synaptopodin-GSK3β (p=0.0008) interactions in diabetic 
animals, suggesting blockade of podocyte Wnt pathway, in vivo. GT reestab-
lished these interactions. (p=0.0004 and p<0.0001, respectively).
Conclusion: In summary, podocyte Wnt blockade leads to high GSK3β-p53 
interaction promoting podocyte apoptosis under diabetic conditions. Activa-
tion of Wnt pathway and inactivation of GSK3ß-p53 may be important strate-
gies to prevent podocyte apoptosis in diabetes mellitus.
Supported by: FAPESP
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Global toll-like receptor 4 knockout attenuates features of  
diabetic nephropathy
I. Jialal1, S. Devaraj2;  
1Internal Medicine, UC Davis Medical Center, Sacramento,  
2Pathology, Baylor College of Medicine, Houston, USA.
Background and aims: Type 1 Diabetes Mellitus (T1DM) is a pro-inflam-
matory state with increased Toll-like receptor (TLR) activity. Inflammation 
is crucial in diabetic vascular complications including diabetic nephropathy 
(DN). We tested the effect of a global deficiency of TLR4 on renal inflamma-
tion, fibrosis and podocytopathy.
Materials and methods: Streptozotocin (STZ) was used to induce diabetes in 
wildtype (WT) and TLR4-knockout (TLR4KO) mice. Control (C) and dia-
betic groups (STZ-WT and STZ-TLR4KO) mice were euthanized at 17 weeks 
and plasma and kidneys collected.
Results: Compared to C, the STZ-WT group had significantly increased 
macrophage and TLR4 immunostaining in the kidney, significant increases 
in MyD88, Interferon Regulatory Factor 3, Nuclear Factor Kappa B activity, 
Tumor Necrosis Factor Alpha, Interleukin 6, and MCP-1 protein levels; all 
these parameters were significantly decreased in the STZ-TLR4KO compared 
to STZ-WT mice. Compared to C, there were significant increases in fibro-
sis markers including Collagen 4,Laminin and Transforming Growth Factor 
Beta in STZ-WT which were significantly decreased in the STZ-TLR4KO 
versus the STZ-WT. Podocyte numbers and podocin protein were decreased 
in the STZ-WT versus C and these were increased in the STZ-TLR4KO mice.
Conclusion: In conclusion, a global genetic deficiency of TLR4 also amelio-
rates renal inflammation, fibrosis and podocytopathy and could be important 
in DN.
Supported by: JDRF
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Alkalinization attenuates diabetes-induced albuminuria and glomerular 
injury through reduced oxidative stress
T. Senmaru1, M. Fukui1, M. Tanaka1, H. Okada2,1, T. Fukuda1,  
K. Mitsuhashi1, N. Kitagawa1, T. Kimura1, Y. Hashimoto1, N. Nakanishi1,  
M. Yamazaki1, G. Hasegawa2,1, N. Nakamura1;  
1Department of Endocrinology and Metabolism, Kyoto Prefectural 
University of Medicine Graduate School of Medical Science,  
2Division of Metabolism, Nephrology and Rheumatology,  
Japanese Red Cross Kyoto Daini Hospital, Japan.
Background and aims: Patients with diabetes frequently have chronic meta-
bolic acidosis. Metabolic acidosis traditionally defined as a decrease in blood 
bicarbonate (HCO3-) concentration contributes to the progression of dia-
betic nephropathy, leading to end-stage renal failure. However, it is not well 
known whether alkalinization could prevent the progression of diabetic ne-
phropathy, and if so, its mechanism has not been elucidated. In this study, we 
investigated the effects of alkalinization by potassium-sodium citrate on the 
pathogenesis and progression of diabetic nephropathy.
Materials and methods: Diabetes was induced using streptozotocin in male 
C57BL/6 (WT) mice at 7 weeks of age. Diabetic mice were divided into two 
groups: alkalinization (Alkali+) and non-alkalinization (Alkali-). Alkali+ was 
allowed free access to water containing potassium-sodium citrate (0.2% po-
tassium citrate and sodium citrate hydrate) for 16 weeks.
Results: Blood HCO3- concentration is higher in Alkali+ than in Alkali- 
(25.1 ± 1.8 vs. 19.5 ± 1.5 mmol/L, p < 0.05). Urinary albumin excretion 
was decreased in Alkali+ compared to Alkali- (45.6 ± 7.1 vs. 99.8 ± 14.1 μg/
day, p < 0.05). Diabetic mice exhibited glomerular hypertrophy and mesan-
gial expansion as compared with WT mice. Histological and morphomet-
ric analysis of periodic acid-Schiff stained sections revealed that an increase 
of mesangial area was milder in Alkali+ than in Alkali- (26.2 ± 1.1 vs. 36.5 
± 1.0 %, p < 0.0001). In addition, the number of podocytes and the num-
ber of apoptosis cells was decreased in Alkali+ compared to Alkali-. On the 
other hand, alkalinization did not affect tubulointerstitial fibrosis (Sirius red 
stain). The degree of oxidative stress assessed by 4-hydroxynonena (4HNE) 
immunostaining in the glomerular area was decreased in Alkali+ compared 
to Alkali-. Similar to the degree of 4HNE expression, the mRNA expression 
of p67-phox was decreased in Alkali+ compared to Alkali-. Furthermore, 
the mRNA expression of TGF-β and vascular endothelial growth factor was 
down-regulated in Alkali+. It is conceivable that the decreased expression of 
these fibrogenic cytokine contributes to the prevention of advanced glomeru-
lar injury in Alkali+.
Conclusion: These results indicate that alkalinization attenuates diabetes-
induced albuminuria and glomerular injury. Reduction of oxidative stress 
may be mainly involved in these changes. Alkalinization could be a useful 
treatment for the progression of diabetic nephropathy.
1176
Zinc exerts anti-fibrotic action by inhibiting TGF-beta1-induced  
type I collagen and fibronectin in human renal proximal tubular cells
Y. Takiyama, M. Maeda, K.K. Atageldiyeva, T. Yanagimachi, J. Honjo,  
Y. Fujita, Y. Makino, M. Haneda;  
Department of Medicine, Asahikawa Medical University, Japan.
Background and aims: Hyperglycemia, chronic hypoxia and TGF-β1 con-
tribute to the development of diabetic nephropathy.The aim of this study is 
to investigate whether novel key factors contribute to the pathophysiological 
mechanism of diabetic nephropathy.
Materials and methods: We analyzed microarray data using Affymetrix 
GeneChip (Rat Gene 1.0 ST Array) with microdissected juxtamedullary 
proximal tubules in a rat model of type 2 diabetes, Zucker Diabetic Fatty 
(ZDF) rats. Then, we studied the regulation of the expression of the candidate 
using human renal proximal tubular epithelial cells (HRPTECs).
Results: A total of 27,342 transcripts were analyzed, among them, 47 
were upregulated (>2.0-fold) in the ZDF rat compared with the lean con-
trol rat. One of them which were upregulated in diabetic renal tubules was 
metallothionein(MT)-1. MT is a cysteine-rich protein with low molecular 
weight, and act as an antioxidant against the toxicity of metals, ischemia, and 
ROS. MT originally has a pivotal role in the regulation of the metabolism 
of zinc. Previous studies reported that diabetic patients showed decreased 
plasma level of zinc, and zinc might be involved in diabetic nephropathy. 
Therefore, to explore the interaction of MT and zinc in diabetic nephropathy, 
we next studied the regulation of MT expression, and the effects of zinc on 
MT expression. High glucose (25.5 mM) failed to affect MT-1 mRNA ex-
pression in HRPTECs, and insulin (100 nM) significantly enhanced MT-1 
mRNA levels. Hypoxia (1% O2) slightly increased MT-1 mRNA levels. 2.5 ng/
ml TGF-β1 significantly decreased MT-1 mRNA levels compared to that of 
the control (0.62 ±0.16 vs. control, p<0.05). This inhibitory effect of TGF-β1 
was not affected by the pretreatment of the inhibitors for ERK (PD98059) 
and JNK (SP600125) pathways, respectively. In contrast, the p38MAPK in-
hibitor (SB203580) apparently diminished the inhibitory effect of TGF-β1 
on MT-1 mRNA. Unexpectedly, TGF-β1 increased another isoform of MT, 
MT-2 mRNA (1.86 ± 0.49 vs. control, p<0.05), and the stimulatory effects 
of TGF-β1 on MT2 was inhibited by ERK inhibitor. On the other hand, zinc 
at 100 µM concentration remarkably increased MT-1 mRNA (17.3±7.83 
vs. control, p<0.05), and restored the inhibitory effect of TGF-β1 on MT-1 
mRNA in a dose-dependent manner (0~100 µM). Similarly, zinc augmented 
MT-2 expression in a dose-dependent manner, and 100µM zinc significantly 
increased MT-2 mRNA (7.00 ± 2.76 vs. control, p<0.05). TGF-β1 is known to 
be a profibrotic molecule which promotes renal fibrosis in diabetic nephropa-
thy. Accordingly, 2.5 ng/ml TGF-β1 significantly increased mRNA levels of 
type I collagen (7.07±1.48 vs. control, p<0.05) and fibronectin (3.00±0.88 
vs. control, p<0.05) in HRPTECs. Intriguingly, 75 µM zinc significantly sup-
pressed TGF-β1-induced type I collagen mRNA down to 61% (p<0.05), and 
50 µM zinc also decreased TGF-β1-induced fibronectin-1 mRNA down to 
65% (p<0.05) of those in TGF-β1 alone treatment, respectively.
Conclusion: In conclusion, the current study showed that MT may be dys-
regulated in diabetic nephropathy, and suggesting that zinc might have the 
potential therapeutic effects in diabetic nephropathy by anti-TGF-β1 action 
and via the induction of antioxidant MTs.
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Protective effects of adiponectin on uncoupling of glomerular  
VEGF-NO axis in type 2 diabetic rats
N. Huang1, F. Han2, J. Zhao1, N. Hou1, X. Liu1, X. Sun1;  
1Department of Endocrinology, 2Department of Pathology,  
Affiliated Hospital of Weifang Medical University, China.
Background and aims: The uncoupling of glomerular vascular endothelial 
growth factor (VEGF) - nitric oxide (NO) axis is an important mechanism 
of early diabetic nephropathy. We aimed to determine whether adiponectin 
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could reduce microalbuminuria and provide renal protective effects by im-
proving endothelial dysfunction and uncoupling of glomerular VEGF-NO 
axis in streptozotocin-induced type 2 diabetic rats.
Materials and methods: Wistar rats were randomly divided into a normal 
control (NC) group, a diabetic nephropathy (DN) group induced by high-fat 
feeding and streptozotocin, diabetic rats injected with adenovirus-expressed 
adiponectin AD-AdipoQ-IRES-EGFP (AD-AdipoQ, DA group), and diabet-
ic rats injected with AD-IRES-EGFP (AD-IRES, DI group). Blood and urine 
samples were collected. Endothelium-dependent vasodilatation (EDV) of the 
aorta was measured. Renal tissues were collected for CD34 immunohisto-
chemistry. Glomerular NO and VEGF levels were measured by the Griess 
reaction and western blot testing, respectively.
Results: STZ-injected rats in the DN group had severe hyperglycemia and 
high levels of insulin (P < 0.01). This was reduced by intravenous injections 
of AD-AdipoQ (glucose, 11.3 ± 5.5 mmol/L vs 21.2 ±3.3 mmol/L; insulin, 
16.70±2.40 uU/ml vs 20.91±2.78 uU/ml, P < 0.01). Serum hs-CRP and MDA 
levels increased and serum adiponectin levels decreased significantly in the 
DN group compared with the NC group (P < 0.01). Intravenous injections 
of AD-AdipoQ reduced serum hs-CRP and MDA levels and increased se-
rum adiponectin levels in diabetic rats (hs-CRP, 1.85±0.56 mg/L vs 3.13±0.38 
mg/L; MDA 2.44 ± 0.28 umol/L vs 4.80 ± 0.59 umol/L; adiponectin, 273.50 
± 21.20 ug/L vs 94.97 ± 25.12 ug/L, P < 0.01). Albumin-to-creatinine (ACR) 
was significantly higher in rats in the DN group than those of the NC group 
[180.35 (113.54-233.29) mg/g vs 13.15 (8.93-17.95) mg/g, P < 0.01]. Injec-
tions of AD-AdipoQ significantly reduced the ACR in diabetic rats. [72.0 
(46.18-99.41) mg/g vs 180.35 (113.54-233.29) mg/g, P < 0.01], indicating an 
improvement of early diabetic nephropathy. Severe EDV impairment was ob-
served in the DN group, which was improved by AD-AdipoQ. CD34 expres-
sion in the glomeruli was also enhanced in diabetic rats, indicating increased 
proliferation of glomerular endothelial cells [mean optical density (IOD/
area): 0.145 ± 0.015 vs 0.073 ± 0.007, P < 0.05]. However, treatment with 
AD-AdipoQ partly improved the increased proliferation of endothelial cells 
in glomeruli (IOD/area: 0.113 ± 0.012 vs 0.145 ± 0.015, P < 0.05). Diabetic 
rats showed increased glomerular VEGF levels and reduced NO levels (P < 
0.05). This uncoupling of the VEGF-NO axis was partially improved by AD-
AdipoQ (P < 0.05). There were no significant differences in these parameters 
between the DN and DI groups (P > 0.05).
Conclusion: Adiponectin reduces the degree of microalbuminuria and has 
renal-protective effects by improving endothelial dysfunction and uncou-
pling the glomerular VEGF-NO axis in early diabetic nephropathy.
Supported by: National Natural Science Foundation of China (Grant NO. 
81300688)
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Heat shock proteins role in the biochemical and molecular interplay 
leading to diabetic nephropathy
A.I. Serban1, L. Stanca1, O.I. Geicu1,2, F. Barbuceanu1, A. Dinischiotu2;  
1Preclinical Sciences, University of Agricultural Science and Veterinary 
Medicine, 2Biochemistry and Molecular Biology, University of Bucharest, 
Faculty of Biology, Bucharest, Romania.
Background and aims: Heat shock protein (Hsp) expression is correlated 
with oxidative stress, yet few studies focus on Hsp’s modulation in diabetes. 
The objective of this study was to highlight the link between Hsp levels and 
the biochemical changes leading to diabetic nephropathy, using the human 
embrionary kidney cells HEK293.
Materials and methods: Cells were treated for 12, 24 and 48 h with 200 μg/
ml glycated-bovine serum albumin (AGE-BSA) or BSA. Reduced glutathione 
(GSH), advanced glycation lipid products (ALEs) levels and enzyme activi-
ties were evaluated by spectrophotometric methods. Superoxide dismutase 
(SOD) was also assessed by zymography. The receptor for advanced glycation 
end products (RAGE), Hsp 27, 60 and 70 expressions were evaluated by west-
ern immunoblotting and real-time PCR.
Results: AGE-BSA induced a time dependent RAGE upregulation. Maximal 
increases of gene expression by 2.25 fold and protein expression by 2.01 fold 
were registered after 48 h. Increased expression of RAGE has been docu-
mented in chronic renal disease and diabetic complications. Probably the up-
regulated RAGE stimulated pro-inflammatory signaling and reactive oxygen 
species (ROS) production. Increased ROS contribute to GSH depletion by 70 
% after 48 h, which hinders the cellular antioxidative and anti-AGE activities. 
SOD activity upregulated with AGE-BSA exposure time and increased by 33 
% after 48 h. Zymogram analisys revealed a similar pattern. Cu/Zn-SOD had 
the most important contribution for the SOD activity after 12 h of exposure. 
Probably the initial superoxide anion source is not mitochondrial but cyto-
solic, although later, Mn-SOD increased, indicating mitochondrial damage. 
After 24 h and 48 h, ALEs arose by 1.75 and 2.29 fold, suggesting oxidative 
damage is amassed with time. Catalase activity increased over 200 % after 12 
h of AGE exposure and remained over 50 % higher than controls later on. 
This early increase denotes the presence of high hydrogen peroxide amounts, 
probably generated by NADPH oxidase rather than SOD activity. AGE ex-
posure boosted glutathione peroxidase activity by 50 % after 48 h. This en-
zyme could be involved in the detoxification of lipid hydroperoxides that are 
most abundant after 48 h. Glutathione reductase and glucose 6-phosphate 
dehydrogenase upregulated by 35 % after 48 h. These enzymes are sensitive 
to ROS, and probably their increase was supported by Hsp70 activity. Hsp 
70 gene and protein expressions augmented in a time dependent manner, 
increasing by 2.07 and 2.78 fold after 48 h. Hsp 70 expression seems a reliable 
indicator of the biochemical alterations described mainly by the increase of 
RAGE, ROS and ALE. Hsp 27 gene and protein expressions increased after 12 
h of treatment by 1.93 and 1.52 fold, but decrease to 0.45 and respectively 0.16 
fold after 48 h. Hsp 60 analysis revealed a similar profile. Hsp 27 and 60 de-
crease after 48 h suggests the possibility of pro-apoptotic pathways activation.
Conclusion: ROS induced by AGE - RAGE activation employ antioxida-
tive mechanisms, which are themselves susceptible to oxidative damage. Al-
though Hsps protective roles can improve some of the AGE-induced effects, 
therapeutic approaches based on Hsp overexpression must take great care not 
to target anti-apoptotic Hsps, because inhibiting AGE-promoted apoptosis 
could invoke cancerous transformation.
Supported by: CNCS-UEFISCDI, project number PN-II-RU-TE-2012-3-0034
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Lentiviral vector-mediated FoxO1 overexpression inhibits extracellular 
matrix protein secretion under high glucose conditions in mesangial 
cells
F. Guo, G. Qin, Q. Wang, Y. Zhou, L. Wu, X. Ma, F. Huang;  
Division of Endocrinology, The First Affiliated Hospital of Zhengzhou 
University, China.
Background and aims: The excessive accumulation of ECM proteins in the 
mesangium of glomerulus results in glomerulosclerosis and contributes to 
the genesis and development of diabetic nephropathy (DN). The bioactivity 
of Forkhead transcription factor O1 (FoxO1) is attenuated in renal cortex 
under high glucose conditions, which may be associated with the progres-
sion of DN. High glucose conditions also upregulate the expression level of 
ECM proteins by activating the transforming growth factor β (TGF-β)/Smad 
pathway in MCs. The study is designed to investigate whether FoxO1 is in-
volved in the redundant secretion of extracellular matrix (ECM) proteins in 
mesangial cells (MCs) under high glucose conditions.
Materials and methods: Constitutively active FoxO1 recombinant lentivi-
ral vectors (LV-CA-FoxO1) and GFP lentiviral vectors (LV-NC-GFP) were 
constructed. MCs were transfected with either LV-CA-FoxO1 or LV-NC-GFP 
cultured in high glucose medium (25 mmol/L), compared with untransfected 
cells cultured in high or normal glucose medium (5.6 mmol/L). Functional 
analysis was performed by real-time PCR, western blotting, immunofluores-
cence and flow cytometry to evaluate the expressions of FoxO1, ECM com-
ponents and TGF-β signaling pathways.
Results: High glucose conditions increased p-FoxO1 protein levels and the 
ratio of p-FoxO1/FoxO1, thereby attenuating bioactivity of endogenous 
FoxO1, which was accompanied by marked increases in the expression of 
ECM components, including FN and Col I. High glucose conditions also ac-
tivated TGF-β-mediated pathways by elevating the latent and mature protein 
levels of TGF-β1, in accordance with the increase of TGF-β1 mRNA levels. 
The expressions of TGF-βRI and TGF-βRII-as well as the expression and 
phosphorylation of Smad3-were both increased under high glucose condi-
tions, thereby promoting signal transduction of TGF-β-mediated pathways. 
Immunofluorescence analysis indicated that high glucose conditions in-
creased p-Smad3 staining in the nucleus, consistent with an overall increase 
in p-Smad3 expression. By contrast, FoxO1 expression markedly increased 
and the ratio of p-FoxO1/FoxO1 decreased after LV-CA-FoxO1 transfection, 
accompanied by reductions of FN and Col I mRNA levels. The mRNA level 
of TGF-β1 as well as its latent and mature protein levels both reduced with 
overexpression of transfected CA-FoxO1, while TGF-βRI and TGF-βRII lev-
els decreased simultaneously. Although mRNA and protein levels of Smad3 
remained unchanged after transfection, the phosphorylation of p-Smad3 was 
blocked and the ratio of p-Smad3/Smad3 declined to the level of which under 
normal glucose conditions. In addition, overexpression of CA-FoxO1 attenu-
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ated nuclear staining of p-Smad3, in concert with faintly observed immuno-
fluorescence in the cytoplasm, indicating lower basal expression of p-Smad 
levels and diminished transcriptional activity.
Conclusion: High glucose conditions increased the expression of fibronectin 
and collagen I by activating TGF-β/Smad3 pathway in mesangial cells, while 
lentiviral vector-mediated overexpression of constitutively active FoxO1 
blocked this effect by suppressing the activation and signaling of the TGF-β/
Smad3 pathway. FoxO1 may play a vital role in attenuating ECM protein 
secretion and alleviating the pathological changes associated with diabetic 
nephropathy.
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The experimental study of the effects of FoxO1 on the podocyte injury  
in diabetic rats
G. Qin, Y. Zhang, Q. Wang, Y. Zhou, X. Ma;  
The First Affiliated Hospital of Zhengzhou, China.
Background and aims: Diabetic nephropathy (DN) is the chief reason for 
end-stage renal disease (ESRD). The podocyte injury of DN is often char-
acterized by foot process fusion and effacement, podocytes getting smaller, 
negative charge becoming less, and podocytes detaching from glomerular 
basement membrane (GBM) and discharging in the urine. Nowadays, the 
importance of podocyte injury in pathogenesis of DN and the occurrence 
of proteinuria and glomerular sclerosis has been gradually acknowledged. 
We have previously demonstrated that the activity of forkhead transcription 
factor O1 (FoxO1) was decreased in the renal cortex of DN rats, and discov-
ered that compared with DN rats without treatment, the expression of FoxO1 
phosphorylation was reduced , the activity of FoxO1 was increased and the 
podocyte injury was improved in the renal cortex of DN rats with treatment. 
So it is inferred that the activity of FoxO1 may affect the podocyte injury in 
DN rats. Our study was performed to investigate the effects of FoxO1 on the 
podocyte injury in diabetic rats.
Materials and methods: Streptozotocin-induced diabetic rats were divided 
into three groups: diabetic rats (group d), rats transfected with empty lenti-
viral vectors (DM plus LV-empty-FoxO1 group, served as group a) and rats 
which were transfected with constitutively active FoxO1 recombinant len-
tiviral vectors (DM plus LV-CA-FoxO1 group, served as group b). The rats 
which received an injection of diluent buffer served as normal control (group 
c). 2,4,8 weeks after the infection, the levels of urine albumin, blood glucose, 
blood urea nitrogen and serum creatinine were measured. Real-time PCR 
and Western blotting were performed to measure the mRNA and protein ex-
pressions of FoxO1, podocalyxin, nephrin, desmin, COL4A3, COL4A5 and 
FoxO1 phosphorylation (p-FoxO1) level of renal cortex in rats. Moreover, 
light microscope and electron microscope were used to observe the structure 
changes of glomerulus and podocytes.
Results: Compared with group a and d, in group b, there was a significant 
increase in the mRNA and protein expressions of FoxO1,and a distinctly 
decrease in the levels of urine albumin, blood urea nitrogen and serum cre-
atinine of rats (except ones in two weeks) (all p<0.05, F values at the end of 
8 weeks were 44001.312, 1557.130, 126.153, 498.800, 186.960, respectively), 
the mRNA and protein expressions of podocalyxin and nephrin all increased 
(all p<0.05, F values of mRNA at the end of 8 weeks were 199.813, 116.899, 
respectively; F values of protein at the end of 8 weeks were 344.917, 353.486, 
respectively), the mRNA and protein expressions of COL4A3, COL4A5 and 
desmin all decreased (all p<0.05, F values of mRNA at the end of 8 weeks 
were 665.64, 784.015, 579.257, respectively; F values of protein at the end of 8 
weeks were 91.121, 122.954, 266.640, respectively), and pathological changes 
in kidney were also improved.
Conclusion: Upregulate the expression of FoxO1 by transfecting with con-
structed lentiviral vectors can definitely improve the podocyte injury in dia-
betic rats.
Supported by: Institute of Clinical Medical Research of Universities Henan
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Meta-analysis of genome-wide gene expression data from glomeruli in 
human kidney with diabetic nephropathy
K. Kodama1, K. Toda2, S. Yamada2, A.J. Butte1;  
1Stanford University, Stanford, USA,  
2Kitasato Institute Hospital, Kitasato University, Tokyo, Japan.
Background and aims: Genetic association studies have successfully re-
vealed a number of important genes associated with diabetic nephropathy 
(DN). However, these DN-associated genes do not fully elucidate the mecha-
nisms underlying the progression of the disease. In this report, we attempted 
to provide an additional catalog of functionally important candidate genes 
for DN by meta-analyzing genome-wide gene expression data from human 
glomeruli.
Materials and methods: We performed a gene-expression based genome-
wide association study (eGWAS; searching for genes repeatedly implicated 
in functional microarrays) using 67 DN case-control microarrays from glo-
meruli in human kidney biopsy samples.
Results: We identified 429 significantly up-regulated genes and 323 down-
regulated genes in DN glomeruli (Fig.1; P< 2.2 × 10-6). Pathway analysis high-
lighted the extracellular matrix (ECM) and receptor interaction, natural killer 
cell mediated cytotoxicity, and toll-like receptor signaling pathway (TLR1, 
TLR2 and MYD88) in up-regulated genes. Gene Ontology (GO) term analy-
sis revealed the enrichment of “regulation of epithelial cell proliferation” in 
down-regulated genes. We also found ERBB4 gene was significantly down-
regulated in patients with DN, together with the other related genes in Erbb 
signalling pathway, such as CDKN1B, SOS2, PLCG2 and CAMK2G.
Conclusion: Our studies have cataloged multiple gene-expression signatures 
that may play a role in the pathogenesis of DN or could serve as biomarkers.
Supported by: National Library of Medicine
1182
Genome-wide association study identifies novel variants associated with 
diabetic kidney disease in Chinese
R.C.W. Ma1, J.S.K. Ho1, Y. Wang1, C.H.T. Tam1, V.K.L. Lam1, G. Jiang1,  
H.M. Lee1, A.O.Y. Luk1, S.K.W. Tsui2, P.C.Y. Tong1, C.C. Chow1, M.C.Y. Ng3, 
C.C. Szeto1, W.Y. So1, J.C.N. Chan1;  
1Dept of Medicine and Therapeutics, Chinese University of Hong Kong, 
2School of Biomedical Sciences, Chinese University of Hong Kong, China, 
3Centre for Genomics and Personalized Medicine Research, Winston-Salem, 
USA.
Background and aims: Although several genetic variants have been identi-
fied to be associated with diabetic nephropathy, few genetic markers have 
been found to be able to predict development of kidney disease among sub-
jects with type 2 diabetes (T2D). In this study, we utilized prospective sam-
ples from the Hong Kong Diabetes Registry to identify genetic predictors of 
diabetic kidney disease (DKD).
Materials and methods: All subjects had T2D and were free of DKD at time 
of enrolment and DNA collection. We identified 200 subjects who developed 
incident diabetic kidney disease, defined as T2D with estimated glomerular 
filtration rate <60 ml/min per 1.73 m2, with other causes of renal impairment 
excluded, during the follow-up period. Two hundred individuals who were 
age, gender and disease-duration matched who did not develop DKD were 
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identified from the registry as controls. We performed genome-wide associa-
tion study using the Illumina 610Quad genotyping array. Validation was per-
formed by de novo genotyping using a MassARRAY platform on additional 
samples from the Registry.
Results: After quality control on the SNP data, we analyzed a total of 446,343 
SNPs. We identified 8 genomic regions which showed suggestive association 
with increased risk or protection against incident diabetic kidney disease 
(p<1 x 10-5). De novo genotyping in additional validation samples of 850 
incident DKD cases and 3064 controls free of DKD confirmed association 
of 2 novel variants with incident DKD. Cox regression analysis revealed that 
individuals who carry 1-2 risk variants at the two loci have increased risk of 
incident DKD with HR 1.502 (95% CI 1.25-1.81, p= 1.58 x 10-5).
Conclusion: We identified 2 novel variants associated with incident diabetic 
kidney disease in Chinese. Additional replication genotyping and targeted 
resequencing to identify the causal variants are currently underway.
Supported by: ITS/088/08, ITS/487/09FP, TS/130/11, T12-402/13N
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Glutathione peroxidase 1 (GPX1) variants, oxidative stress markers,  
and risk of kidney complications in patients with type 1 diabetes
K. Mohammedi1,2, N. Bellili-Muñoz1, F. Driss3, T. Patente4, S. Hadjadj5,6,  
F. Fumeron1,7, R. Roussel1,7, M. Corrêa-Giannella4, M. Marre1,7, G. Velho1;  
1INSERM, Research Unit 1138, 2AP - HP, Department of Diabetology, 
3INSERM, Research Unit 773, Paris, France, 4Laboratório de Endocrinologia 
Celular e Molecular (LIM-25), Faculdade de Medicina da USP, São Paulo, 
Brazil, 5INSERM, Research Unit 1082, Poitiers, 6Université de Poitiers,  
UFR de Médecine et Pharmacie, 7Univ Paris Diderot, Sorbonne Paris Cité, 
UFR de Médecine, France.
Background and aims: Glutathione peroxidase (GPX) is a class of antioxi-
dant enzymes that catalyzes the reduction of hydrogen peroxide to water. 
GPX1 is the most abondant isoform and is expressed in all kidney cells. 
Advanced oxidation protein products (AOPP) and 8-iso-prostaglandine 
(isoprostane) were identified as markers of oxidative stress in patients with 
kidney disease. We investigated associations of GPX1 genotypes and plasma 
concentrations of AOPP and isoprostane with kidney complications in type 
1 diabetic patients.
Materials and methods: Four SNPs in the GPX1 region were genotyped in 
SURGENE (n=340; 10-year follow-up), GENEDIAB (n=461) and GENESIS 
(n=498) cohorts of type 1 diabetic patients. Subsets of GENEDIAB (n=237) 
and GENESIS (n=393) participants were followed-up for 9 and 5 years, re-
spectively. Plasma concentration of AOPP (spectrophotometry assay) and 
isoprostane (ELISA) were measured at baseline in 436 GENEDIAB partici-
pants. Hazard ratios (HR) or odds ratios (OR) were estimated for incidence 
and prevalence of kidney complications. p≤0.02 was significant.
Results: In SURGENE, the minor T-allele of rs3448 was associated with the 
incidence of microalbuminuria (HR 1.97, 95% CI 1.23 - 1.33, p=0.004, n=76) 
and with the progression to a more severe stage of diabetic nephropathy (HR 
1.91, 95% CI 1.26 - 3.02, p=0.002, n=98). The variant was also associated with 
lower estimated GFR at baseline (78 ± 5 TT vs 93 ± 3 TC vs 87 ± 3 ml/min CC, 
ANCOVA, p=0.003) and with faster decline of eGFR during follow-up (-8.49 
± 2.74 TT+TC vs -5.09 ± 2.67 ml/min.year-1 CC, p=0.01; all SURGENE analy-
ses adjusted for sex, age, duration of diabetes, diabetic retinopathy stages, and 
use of ACE inhibitors). In pooled analyses of GENESIS/GENEDIAB cohorts, 
the same variant was associated with the prevalence at baseline (OR 2.79, 95% 
CI 1.16 - 6.20, p=0.01, n=82) and the incidence during follow-up of end stage 
renal disease (ESRD; HR 1.98, 95% CI, 1.38 - 2.92, p=0.0001; n=51, analyses 
adjusted for the above mentioned covariates plus cohort membership). As-
sociation with the incidence of ESRD was also observed for rs9818758 and 
rs1987628. Plasma AOPP and isoprostane concentrations at baseline were 
higher in participants who developed ESRD during follow-up as compared to 
those who did not. The risk T-allele of rs3448 was associated with higher plas-
ma AOPP (81 ± 5 TT+CT vs 64 ± 5 µmol/l CC, p=0.02) and isoprostane con-
centration (1.85 ± 0.08 TT+CT vs 1.57 ± 0.08 ng/ml CC, p=0.005; ANCOVA 
adjusted for sex, age, duration of diabetes, eGFR and use of ACE inhibitors).
Conclusion: The minor T-allele of rs3448 was associated with kidney com-
plications (incidence and progression of microalbuminuria, prevalence and 
incidence of ESRD, decline of eGFR) in patients with type 1 diabetes. The risk 
allele was associated with higher plasma concentration of markers of oxida-
tive stress. Our results are consistent with the implication of GPX1 in the 
mechanism of renal protection against oxidative stress in patients with type 
1 diabetes.
Supported by: ADRV, AJD
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Advanced glycation end products disrupt cholesterol feedback regulation 
in diabetic renal tubules
H. Sun1, Y. Yuan2, S. Wang2, H. Jin2, Y. Wang2, B. Yang2, Z. Sun2;  
1Medical School, Southeast University, 2Department of Endocrinology, 
Southeast University, Zhongda Hospital, Nanjing, China.
Background and aims: Advanced glycation end products (AGEs) cause dia-
betic renal tubules damage in various ways. The aim of this study is to inves-
tigate the lipid-mediated injuries caused by AGEs in HK-2 cells and the renal 
tubules of type 2 diabetic rats.
Materials and methods: For the in vitro study, human renal tubular epithelial 
cell line (HK-2) was respectively incubated with Nε-(carboxymethyl) lysine 
(CML,a member of the AGEs family) ,CML+anti-RAGE (receptor of AGEs), 
low density lipoprotein (LDL), LDL+CML, LDL+CML+ anti-RAGE for 24h. 
At in vivo level, animal model was developed by high fat/sucrose diet feed-
ing plus streptozotocin injection. Rats were divided into DM and DM+AG 
(Aminoguanidine, an inhibitor of AGEs) groups. The effects of cholesterol 
accumulation were examined by Oil Red O staining and a quantitative in-
tracellular cholesterol assay. Serum CML was determined by HPLC-MS ana-
lyzer, and renal CML was measured by immunohistochemical staining. The 
urine protein and neutrophil gelatinase-associated lipocalin (u-NGAL) were 
measured by ELISA. The gene transcription and protein translation were ana-
lyzed by quantitative RT-PCR and western blot respectively.
Results: 1. CML increased Oil Red O staining and intracellular cholesterol 
ester in the absence or presence of LDL in HK-2 cells. Anti-RAGE reduced 
the lipid droplets accumulation. A strong staining of Oil Red O was also 
found in the renal tubules of the diabetic group, but less staining in the AG 
treated group. 2. CML upregulated both mRNA and protein expression of 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR), LDL 
receptor(LDLr), sterol regulatory element binding protein-2 (SREBP-2), and 
SREBP cleavage-activating protein (SCAP), which were inhibited by anti-
RAGE. The overexpression of these molecules in the renal of the diabetic rats 
was also ameliorated by AG treatment 3. AG reduced serum and renal CML. 
4. The increased urine protein and u-NGAL were improved by AG.
Conclusion: For the in vitro study, we demonstrated CML increased lipid ac-
cumulation in HK-2 cells by disrupting the SCAP-mediated feedback regula-
tion of HMG-CoAR and LDLr. On in vivo level, we also found that reduce of 
CML improved the disrupted SCAP-mediated feedback regulation in the re-
nal tubules of type 2 diabetic rats. These data suggested that CML caused dia-
betic tubules injury might be via disturbing the intracellular feedback regula-
tion of cholesterol. Inhibition of CML-induced lipid accumulation might be 
a potential renoprotective role in the progression of diabetic tubules damage.
Supported by: Natural Science Foundation of China
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Inflammation and oxidative stress markers related to renal damage due 
to diabetes mellitus
A.A.F. Oliveira1, L.L. Bobadilla1, T.F. Oliveira1, M.H.G. Medeiros2,  
A.P.M. Loureiro1;  
1Department of Clinical and Toxicological Analysis,  
2Department of Biochemistry, University of São Paulo, Brazil.
Background and aims: Currently, strategies to monitor renal damage in the 
course of Diabetes mellitus (DM) are focused on diabetes markers and renal 
function. Assuming that oxidative stress and inflammation are implicated 
in the pathophysiology of Diabetic Nephropathy (DN), the aim here was to 
assess markers of inflammation and oxidative stress in the course of a long-
term model of DM and evaluate how different strategies of glycemic control 
would modulate these markers.
Materials and methods: An experimental model of streptozotocin-induced 
DM in male Wistar rats was employed here. After 12 weeks of diabetes induc-
tion, animals were treated with insulin alone or combined with metformin 
(100 mg/kg) or N-acetylcysteine (750 mg/kg) until a total period of 24 weeks. 
Non-diabetic or non-treated diabetic animals during 12 and 24 weeks served 
as control groups. Body weight and blood glucose were monitored weekly. 
HbA1c, urinary total protein and albumin, plasma IL-6 and TNF-α were as-
sessed after different periods of diabetes. The same cytokines were quantified 
in renal tissue after 12 or 24 weeks, beyond plasma and kidney malondialde-
hyde (MDA) by HPLC-DAD.
Results: As expected, diabetic animals showed higher glycemic levels, wa-
ter consumption and urine volume, and reduced weight gain compared 
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to non-diabetic. HbA1c was increased after 6, 12, 18 and 24 weeks of DM 
(p<0,0001). Renal function was significantly altered only from 12 weeks of 
DM, once diabetic animals presented higher proteinuria (p=0,027) and al-
buminuria (p<0,0001) compared to controls. At the end of 12 or 24 weeks, 
an enlarged kidney/body weight ratio was observed in non-treated diabetic 
groups (p<0,0001), indicating renal hypertrophy due to DM. All treat-
ment schemes reverted these alterations after 18 and 24 weeks. In respect 
to inflammation markers, higher levels of plasmatic IL-6 were found in dia-
betic rats after 6 (p=0,0015) and 12 weeks (p=0,0019), but not in 18 and 24 
weeks, showing this alteration is not persistent. NAC treatment had a pro-
inflammatory effect, once a 3 fold increase of plasmatic IL-6 was observed 
(p=0,0161). No significant alteration of kidney IL-6 and TNF-α or plasmatic 
TNF-α were detected. On the other hand, local and systemic oxidative stress 
(MDA quantitation) were found after 12 and 24 weeks of DM (p<0,0001). 
Insulin alone or combined with metformin recovered this change in plasma 
and kidney, but NAC led to increased MDA levels, showing a pro-oxidant ac-
tion (p<0,0001). Good Pearson or Spearman correlations were obtained be-
tween plasma MDA and glycaemia (r=0,7554, p=0,0003), HbA1c (r=0,5790, 
p=0,0149), proteinuria (r=0,7495, p=0,0020), relative kidney/body weight 
ratio (r=0,6690, p=0,0024) and kidney MDA (r=0,5885, p=0,0102).
Conclusion: Overall, therapeutic strategies employed here were capable to 
control changes related to DM, renal function and oxidative stress. NAC pre-
sented an unexpected pro-inflammatory and pro-oxidant effect. MDA can be 
considered a good oxidative stress biomarker related to renal damage in DM 
and could be used to improve therapeutic monitoring in DM.
Supported by: FAPESP, CNPq, CEPID Redoxoma, CAPES, PRP/USP
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Predominant role of glomerular podocytes in mediating the deleterious 
effects of CB2 deficiency in experimental diabetic nephropathy
F. Barutta, S. Grimaldi, P. Cavallo Perin, G. Gruden;  
Department of Medical Sciences, University of Turin, Italy.
Background and aims: Diabetic nephropathy (DN) is characterised by in-
creased glomerular permeability to proteins and excessive extracellular 
matrix accumulation in the mesangium, resulting eventually in glomerulo-
sclerosis and progressive renal impairment. A functionally active endocan-
nabinoid system is present within the kidney. The cannabinoid receptor of 
type 2 (CB2) is expressed by both inflammatory cells and podocytes. CB2 
receptor activation has beneficial effects in experimental DN, while CB2 dele-
tion worsens both functional and structural abnormalities of DN confirming 
a protective role of signalling through CB2. To investigate the relative contri-
butions of podocytes cells and monocytes to the phenotype of diabetic CB2-
/- mice, we have performed bone marrow (BM) transplantation experiments.
Materials and methods: Male CB2 knockout (CB2-/-) or wild type (CB2+/+) 
mice received bone marrow transplants at age 8 weeks. Twenty-four hours 
before transplantation, recipient CB2-/- and CB2+/+ mice underwent whole 
body irradiation with 8 Gy. Post-irradiated CB2-/- mice received a BM trans-
plant from CB2+/+ mice (KOCWT; n=15). Post-irradiated CB2+/+ mice received 
a BMT from CB2-/- mice (WTCKO; n=15). 4 weeks after BMT, diabetes was 
induced in all mice by intraperitoneal injection of streptozotocin (55 mg/
kg) in citrate buffer delivered in 5 consecutive days. Control mice were in-
jected with citrate buffer alone. 14 weeks after the induction of diabetes, mice 
were individually placed in metabolic cages for urine collections and blood 
samples taken for blood glucose and glycated haemoglobin measurements. 
Urinary albumin excretion was measured by enzyme-linked immunosorbent 
assay. Expression of the slit-diaphragm protein, podocin, was assessed by im-
munofluorescence. Fibronectin mRNA levels were quantitated by real-time 
PCR on total renal cortex.
Results: Diabetes was associated with reduced body weight and elevations 
in both plasma glucose and glycated haemoglobin levels. BMT did not affect 
metabolic/physiological parameters in either CB2+/+ or CB2-/- animals. Albu-
minuria was significantly (p<0.05) increased in the CB2+/+ diabetic animals 
[DM:234.0 (200.0-285.9) µg/18hrs, geometric mean (25th-75th percentile)] 
as compared to the controls [ND:68.1 (64.6-75.3)] and further enhanced by 
CB2 receptor deletion [DM CB2-/-:359.9 (227.9-519.4); p<0.05 DM CB2+/+ vs 
DM CB2-/-]. However, albuminuria was similar in diabetic CB2-/- and dia-
betic CB2-/- mice transplanted with bone marrow from CB2+/+ mice [DM-
KOCWT:376.8 (353.2-368.5)]. Moreover, in diabetic CB2+/+ animals, transplan-
tation of CB2-/- bone marrow did not affect the magnitude of albuminuria 
[DM-WTCKO:236.2 (211.5-257.4)]. In the diabetic mice the increase in al-
buminuria was paralleled a significant reduction in podocin and this effect 
was further exacerbated in diabetic mice lacking CB2 receptors. However, 
neither transplantation with BM from CB2+/+ mice in diabetic CB2-/- animals, 
nor transplantation with BM from CB2-/- mice into diabetic CB2+/+ animals 
altered podocin expression. Similarly, diabetes-induced upregulation of fi-
bronectin expression was further exacerbated in CB2-/- mice, but not altered 
by BMT. 
Conclusion: These findings demonstrate that in experimental diabetes the 
BM-derived cells do not play a major role in mediating the deleterious effects 
of CB2 deficiency and suggests a predominant role of podocytes.
Supported by: Compagnia di San Paolo
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Combinatorial therapy of cilostazol and probucol effectively reduces 
albuminuria through inhibition of proinflammatory pathways in 
podocytes
P. He, H. Kawamura, M. Takemoto, K. Kuno, M. Shoji, A. Hattori,  
M. Yamaga, K. Sakamoto, R. Ishibashi, T. Ishikawa, S. Onishi, Y. Maezawa, 
H. Tokuyama, K. Kobayashi, K. Yokote;  
Clinical Cell Biology and Medicine, Chiba University Graduate School of 
Medicine, Japan.
Background and aims: Long-lasting inflammation occurring in glomeruli 
has been proved to be involved in the development of chronic kidney dis-
ease such as diabetic nephropathy (DN). The aim of this study is to clarify 
the mechanism of renoprotective effect of combinatorial therapy of cilostazol 
(CSZ) and probucol (PBC), both of which exhibit anti-inflammatory proper-
ties.
Materials and methods: We employed lipopolysaccharide (LPS) induced 
acute renal inflammation model. In brief, after treatment with CSZ, PBC 
alone or in combination, mice were intraperitoneally injected with LPS. Af-
ter 24 h, urinary albumin levels were measured by ELISA and expression of 
MCP1 in glomeruli was analyzed by immunostaining. In vitro, we treated 
cultured podocytes with LPS in the presence or absence of CSZ, PBC in-
dividually or both and then estimated NF-κB activation by immunostain-
ing, MAPK phosphorylation by immunoblotting and reactive oxygen species 
(ROS) production by dihydroethidium staining. Also activation of NADPH 
oxidase (Nox) and components of Nox family were examined by lucigenin 
assay and real-time PCR, respectively.
Results: In mouse model, CSZ significantly reduced and PBC showed a ten-
dency to decrease LPS-induced albuminuria and the concurrent adminis-
tration showed a more potent effect. The MCP1 upregulation in glomeruli 
was suppressed by individual treatment of both drugs and more strongly by 
the combination. The MCP1 overexpressed by LPS was mainly produced 
in podocytes among the native cells of glomeruli. And the inhibitory effect 
of these drugs on MCP1 upregulation was shown in LPS-treated cultured 
podocytes similar to that in glomeruli. As for molecular mechanism, CSZ 
suppressed nuclear accumulation of NF-κB and phosphorylation of p44/42 
MAPK induced by LPS. Forskolin, an activator of adenylate cyclase, reduced 
p44/42 MAPK phosphorylation as well and a specific PKA inhibitor H89 re-
versed the inhibitory effect of CSZ, indicating CSZ suppresses p44/42 MAPK 
through cAMP-PKA activation. PBC also reduced LPS-induced nuclear ac-
cumulation of NF-κB, while it failed to suppress p44/42 MAPK phospho-
rylation. PBC is originally developed as an anti-oxidant and it completely 
suppressed ROS production in response to LPS in both mouse glomeluli and 
cultured podocytes. Also, another anti-oxidative agent, NAC inhibited MCP1 
upregulation and nuclear accumulation of NF-κB, indicating that ROS gen-
eration is prerequisite for NF-κB activation and following MCP1 induction. 
Further, PBC suppressed Nox activity and Nox4 expression, indicating PBC 
inhibits ROS generation through suppression of Nox4, which in turn lead to 
suppression of MCP1 upregulation induced by LPS.
Conclusion: We found the combination of CSZ and PBC had a strong pro-
tective effect on inflammatory renal dysfunction using LPS model. The com-
bined effect of these drugs was due to the fact that CSZ and PBC showed 
anti-inflammatory effects through inhibition of different pathway, p44/42 
MAPK and ROS, respectively. Although further investigations are needed, 
the combination therapy would hold promise for future refinement of treat-
ment of CKD.
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High-fat meals induce systemic cytokine release without evidence 
of endotoxaemia-mediated cytokine production from circulating 
monocytes or myeloid dendritic cells
C.L. Fogarty1, J.K. Nieminen2, L. Peräneva1, M.I. Lassenius1, C. Forsbloom1, 
P.-H. Groop1, O. Vaarala2, M. Lehto1, FinnDiane Study Group;  
1Folkhälsan Research Center,  
2National Institute for Health and Welfare, Helsinki, Finland.
Background and aims: Dietary fat is known to increase circulating levels 
of bacterial lipopolysaccharide (LPS) and proinflammatory cytokines in 
healthy subjects. Earlier studies have found increased intestinal permeability 
in patients with type 1 diabetes (T1D), suggesting that patients may display 
a more pronounced postprandial increase in circulating proinflammatory 
TLR4 agonists-LPS and triglycerides. While it has been long known that 
circulating inflammatory markers are predictors of progressive renal failure, 
we have recently shown that LPS activity levels are strongly associated with 
the components of the metabolic syndrome and the development of diabetic 
nephropathy in patients with T1D. Increased TLR4 responsiveness together 
with postprandially elevated circulating LPS and triglyceride levels may play 
a key role in the promotion and progression of inflammation, thereby in-
creasing the risk of developing diabetic complications. The aim of the present 
study was to investigate the acute effects of two sequential high-fat meals on 
circulating cytokines and the LPS responsiveness of innate immune cells in 
the context of T1D. We hypothesized that high-fat diet-induced endotoxemia 
would increase cytokine release from peripheral innate immune cells, which 
could in turn both induce systemic inflammation and modulate TLR4 re-
sponsiveness, particularly in patients with T1D.
Materials and methods: Eleven patients with T1D and eleven controls re-
ceived two fatty meals: breakfast (8:00, 65 g fat) and lunch (12:00, 42 g fat). 
The patients were studied as part of the Finnish Diabetic Nephropathy 
(FinnDiane) Study. Fasting (8:00) and postprandial (14:00) blood samples 
were taken and incubated with or without E. coli LPS. Cytokine levels in se-
rum, and cytokine responses in monocytes and mDCs were measured using 
flow cytometry
Results: At fasting, diabetic myeloid dendritic cells (mDCs) exhibited high-
er LPS-induced IL-6 and IL-1β production than controls. Postprandially, 
patients with T1D and controls showed significant increases in the serum 
concentrations of eight inflammatory cytokines (IL-6, TNF-α, IL-1β, IFN-α, 
IL-10, IFN-γ, IL-12, and MIP-1β) without concomitant increase in serum 
LPS activity. Serum cytokine production was similar in both groups. No post-
prandial change was seen in the IL-6, TNF-α, or IL-1β production of mDCs 
or monocytes.
Conclusion: Our results show that in whole blood, diabetic dendritic cells 
are hyperresponsive to in vitro LPS stimulation. Furthermore, in patients and 
controls alike, acute high-fat meals increase circulating cytokines but have 
no effect on serum LPS activity levels or cytokine production in circulating 
mDCs or monocytes. Our results suggest that postprandial increases in se-
rum cytokine levels are neither mediated by circulating endotoxins nor the 
activation of circulating innate immune cells. The production of high-fat 
meal induced inflammatory markers is conserved between patients and con-
trols and most likely regulated at the tissue level.
Supported by: Wilhelm and Else Stockmann Foundation (P.-H.G., M.L., C.F.)
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Effects of incretin on human mesangial cells loaded with apo E2 remnant 
lipoproteins and on nephropathy in diabetic patients
M. Eto, M. Saito;  
Clinical Medicine, Ohu University, Koriyama, Japan.
Background and aims: In JDCS (Japan) and UKPDS 74, hypertriglyceri-
demia was detected as one of the risk factors for diabetic nephropathy. In-
creased remnant lipoproteins underlie hypertriglyceridemia. We first found 
that apo E2 is a genetic factor for diabetic nephropathy, and that increase of 
plasma TG/remnant lipoproteins caused by apo E2 contributes to nephropa-
thy. Remnant lipoproteins are taken up by mesangial cells, and then cause 
renal damage. The frequency of apo E2 is approx.10% in Japan and western 
countries. Diabetic nephropathy is characterized by the accumulation of ex-
tracellular matrix protein in the glomerular mesangium. Incretin, which is 
widely used in T2DM patients, reduces plasma TG/remnant lipoproteins as 
well as glucose. There is little information about the effect of incretin on ne-
phropathy. In the present study we examined the effect of GLP-1 on TGF-β 
and type IV collagen expression in human mesangial cells (HMCs) loaded 
with apo E2 remnant lipoproteins, and examined whether sitagliptin which 
increases incretin is effective to improve nephropathy in T2DM patients with 
apo E2 allele.
Materials and methods: Remnant lipoproteins were isolated from plasma 
of a patient with T2DM and apo E2/2 genotype by ultracentrifugal method. 
HMCs loaded with remnant lipoproteins were incubated for 24 h with GLP-1 
at the concentration of 0, 50, 100 and 500 nmol/L. To evaluate the expres-
sion of TGF-β , type IV collagen and GLP-1 receptor mRNA in HMCs, RT-
PCR procedure was performed. T2DM with apo E3/3 (n=38 ) and apo E3/2 
genotype (n=7) were studied. Patients were treated with sitagliptin over 10 
months. HbA1c, plasma TG and remnant cholesterol were compared before 
and after sitagliptin therapy. Remnant cholesterol was determined as RLP-
cholesterol . Urinary albumin-to-creatinine ratio (ACR, normal range <30 
mg/g) was measured as a marker of nephropathy.
Results: Apo E2 remnant lipoproteins significantly stimulated the expres-
sion of TGF-β and type IV collagen mRNA in HMCs. GLP-1 significantly 
suppressed the expression of TGF-β and type IV collagen mRNA in HMCs 
loaded with remnant lipoproteins. GLP-1significantly stimulated the expres-
sion of GLP-1 receptor. In apoE3/3 patients, 10-month therapy with sitaglip-
tin significantly reduced HbA1c(6.6→6.0%), plasma TG (129→107mg/dl) and 
remnant cholesterol (5.5→3.9mg/dl), and ACR (57.4→34.1mg/g). In apo E3/2 
patients, it reduced HbA1c (6.8→6.0), plasma TG (173→119 ) and remnant 
cholesterol (8.0→5.0 ), and ACR (119.0→19.2 ). Reduction in HbA1c from 
baseline at 10 months was not significantly different between apo E3/3 and 
apo E3/2 patients, but reduction in plasma TG and remnant cholesterol, and 
ACR was significantly greater in apo E3/2 patients than in apo E3/3 patients.
Conclusion: GLP-1suppresses the expression of TGF-β and type IV colla-
gen in HMCs loaded with apo E2 remnant lipoproteins. Sitagliptin reduced 
plasma TG/remnant lipoproteins and ACR more greatly in apo E2 T2DM pa-
tients. It is suggested that incretin is effective to protect and improve diabetic 
nephropathy associated with apo E2 through its lowering effect of plasma 
TG/remnant lipoproteins and/or direct effect on mesangial cells.
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Performance of creatinine and cystatin C based CKD-EPI equations  
to estimate glomerular filtration rate in type 2 diabetes
A.A. Soares1, R. Boff1, J.D. Machado1, L.S. Rodrigues1, E.G. Camargo1,  
J.L. Camargo2, S.P. Silveiro1;  
1Universidade Federal do Rio Grande do Sul,  
2Hospital de Clínicas de Porto Alegre, Brazil.
Background and aims: Diabetes kidney disease (DKD) is the worldwide 
leading cause of end-stage renal disease. Current guidelines recommend 
annual screening with urinary albumin measurement and estimation of 
glomerular filtration rate (GFR) by equations. The aim of this study was to 
evaluate the accuracy of creatinine and cystatin C based Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) equations to estimate GFR in 
patients with type 2 diabetes (DM) as compared to healthy adults.
Materials and methods: Cross-sectional study included healthy adults 
and DM patients with GFR higher than 60 mL/min/1.73 m². GFR was es-
timated by CKD-EPI creatinine (CKDEPIcreat), CKD-EPI cystatin C (CK-
DEPIcystC), and CKD-EPI creatinine-cystatin C (CKDEPI-CC) equations 
in comparison with GFR measured by a reference method (51Cr-EDTA). 
Each group (DM vs healthy) was stratified according to ages above and be-
low 45 years and analyzed separately. Serum creatinine was measured by Jaffe 
traceable method (Advia 1800, Siemens Healthcare) and serum cystatin C 
was evaluated by immunoturbidimetric method (Dako, Cytomation). Ac-
curacy (percentage of estimated GFR within 30% [P30] of measured GFR), 
bias (mean difference between measured and estimated GFR), and precision 
(standard deviation of bias) were assessed. Agreement was evaluated accord-
ing to Bland & Altman analyses.
Results: One hundred healthy adult subjects and 84 DM patients, aged 38±14 
(18-86) and 59±19 (31-82) years, respectively, were evaluated. Measured 
51Cr-EDTA GFR was 112±19 (64-160) and 104±27 (60-184) mL/min1.73 
m², in healthy individuals and in DM patients, respectively. For the healthy 
group with less than 45 years of age, the measured 51Cr-EDTA GFR was 
117±19 and the CKDEPIcreat, CKDEPI-CC and CKDEPIcystC were 117±13, 
110±11 and 104±12 mL/min/1.73 m², respectively. Only CKDEPIcreat was 
in agreement with the reference method (P=0.894). In the DM group, the 
measured 51Cr-EDTA GFR (126±41 mL/min/1.73 m²) was different from 
all equations: CKDEPIcreat, CKDEPI-CC and CKDEPIcystC equations were, 
respectively 98±16, 95±16 and 93±18 mL/min/1.73 m². The Figure depicts 
the GFR mean values as well as the precision (SD) of the older individuals. In 
this set, the reference GFR method did not agree with any equation, in both 
groups. In healthy subjects older than 45 years, the accuracy (P30) was 94%, 
91% and 85% for CKDEPIcreat, CKDEPI-CC and CKDEPIcystC, respective-
ly. In DM patients older than 45 years, accuracy was 71%, 68% and 55% for 
CKDEPIcreat, CKDEPI-CC and CKDEPIcystC, respectively.
Conclusion: All CKD-EPI equations underestimated GFR in older adults, 
more markedly in type 2 DM patients. In younger subjects, the creatinine 
based equation presented the best performance.
Supported by: CNPq, FAPERGS and FIPE
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Albuminuria predicts progression to end-stage renal disease in diabetic 
patients
T. Babazono, H. Murata, A. Toyonaga, N. Yoshida, S. Takemura, M. Takagi, 
N. Yoshida, K. Toya, I. Nyumura, K. Hanai, N. Tanaka, Y. Uchigata;  
Tokyo Women‘s Medical University School of Medicine, Tokyo, Japan.
Background and aims: Albuminuria in diabetic patients has been repeatedly 
shown to be a crucial risk factor for renal outcomes; however, previous stud-
ies examining these associations were limited to short observational period 
or surrogate markers including decline in GFR. There are few large cohort 
studies that observed patients until reaching end-stage renal disease. We con-
ducted this study to clarify the association between albuminuria and hard 
renal endpoint in diabetic patients.
Materials and methods: This was a single-center historical cohort study 
consisting of adult Japanese diabetic patients who had both serum creatinine 
concentration and albuminuria data measured within 90 days at our hospital 
between 1995 and 2012, baseline estimated GFR (eGFR) ≥ 15 mL/min/1.73 
m2, and those who were observed at least 90 days. According to the baseline 
urinary albumin-to-creatinine ratio (ACR), patients were classified into the 
following 7 groups; <10, 10 to 29, 30-99, 100-299, 300-999, 1,000-2,999, and 
≥ 3,000mg/g (Table). The primary endpoint was decrease in eGFR < 15mL/
min/1.73 m2. Cumulative incidence of the primary endpoint was estimated 
by the Kaplan-Meier method and the statistical differences among groups 
were examined by the log-rank test. HRs and the corresponding 95% CIs 
for reaching the endpoint were calculated using the Cox proportional hazard 
model.
Results: A total of 20,884 patients, 8,547 women and 12,337 men, with the 
mean age of 55 ± 14 (SD) years (range; 20-93 years) were studied; number of 
patients with the ACR group was listed in Table. During the median follow-
up period of 5.6 years (up to 18.1 years), 1,033 patients reached the endpoint. 
Eighteen-year cumulative incidence of reaching the endpoint in each ACR 
group was summarized in the Table. Hazard ratio for patients in each ACR 
group after adjustment for gender, age and eGFR at baseline in reference to 
those with an ACR < 10 mg/g rose exponentially (Table, each p<0.001).
Conclusion: In this long-term large observational cohort study in Japanese 
diabetic patients, we found that stepwise rise in the risk of reaching ESRD 
according to increase in albuminuria. Higher levels of albuminuria, even 
within the normal rage, may be associated with increased risk of renal hard 
endpoint.
1192
Prevalence of albuminuria in subjects with impaired fasting glucose in 
Korean population
J. Won1, D.-J. Kim2, J. Kim1, J. Noh2, K. Ko1, B. Rhee1;  
1Department of Internal Medicine, Cardiovascular and Metabolic Disease 
Center, College of Medicine, Inje University, Seoul, 2Department of  
Internal Medicine, Cardiovascular and Metabolic Disease Center,  
College of Medicine, Inje University, Ilsan, Republic of Korea.
Background and aims: We tried to assess the prevalence of albuminuria 
across the fasting plasma glucose (FPG) level including normal fasting glu-
cose (NFG), impaired fasting glucose (IFG), and diabetes
Materials and methods: A total of 5,202 subjects who participated in the fifth 
Korea National Health and Nutrition Examination Survey (KNHANES V-2) 
were enrolled in this study. And, albumin-creatinine ratio was calculated.
Results: We divided subjects into five group according to fasting plasma glu-
cose level of < 5.0 (NGT1, n=1905), 5.0-5.5 (NGT2, n=1784), 5.6-6.0 (IFG1, 
n=727), 6.1-6.9 (IFG2, n=268), and ≥ 7.0 (or diabetes, n=518) mmol/l. 7.6 
percent (n=395). The prevalence of albuminuria in each group was 4.1, 6.0, 
7.6, 12.3, and 23.4%, respectively, in the five groups (P < 0.01 for the trend). 
The prevalence of albuminuria in IFG2 was significantly higher than in IFG1 
even after adjustment for age, sex, hypertension and obesity. In al multivari-
ate logistic regression, independent associations with albuminuria were age, 
hypertension, and increasing fasting glucose including IFG2 and diabetes.
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Conclusion: The current data suggest that prevalence of albuminuria may 
begin to increase in the higher range of IFG, independent of traditional risk 
factors.
1193
Arterial stiffness is more associated with albuminuria than decreased 
glomerular filtration rate in the development of type 2 diabetic 
nephropathy
Y. Nam1, S. Kim1, C. Lee2, S. Park1, J. Kim1, W. Kim1, Y. Jeon1, B. Kim1,  
I. Kim1, S. Son3;  
1Department of Internal Medicine, Pusan National University Hospital, 
2Department of Internal Medicine, Busan St. Mary’s Medical Center, 
3Department of Internal Medicine, Bongseng Memorial Hospital, Busan, 
Republic of Korea.
Background and aims: Arterial stiffness, a clinical atherosclerosis marker, 
was associated with the progression of chronic kidney disease (CKD) includ-
ing diabetic nephropathy. Each albuminuria and decline of glomerular func-
tion rate (GFR) are being recognized as complementary rather than obliga-
tory markers for diabetic nephropathy. The aim of study was to evaluate the 
association of arterial stiffness with albuminuria and/or GFR in the develop-
ment of type 2 diabetic nephropathy.
Materials and methods: This study was an analysis from participants of The 
Relationship between Cardiovascular disease and Brachial-ankle Pulse Wave 
Velocity in Patients with Type 2 Diabetes (REBOUND) Study, which was a 
prospective multi-center cohort study recruited from 8 general hospitals in 
Busan, Korea. Type 2 diabetic patients aged 30 years and more were recruited 
and measured brachial-ankle pulse wave velocity (baPWV) as noninvasive 
marker for arterial stiffness. The patients were categorized into 4 groups ac-
cording to albumin-to-creatinine ratio (ACR, normoalbuminuria and albu-
minuria) and eGFR (<, ≥ 60 mL/min/1.73 m2).
Results: A total of 2,613 patients were analyzed for this study. Maximal baP-
WV was significantly correlated with both ACR (r = 0.302, P <0.001) and 
eGFR (r = -0.218, P < 0.001) in univariate analysis with whole subjects. After 
adjusting for age, sex, several significant clinical variables and eGFR, baPWV 
remained significant association with ACR in multivariate analysis (r = 0.226, 
P < 0.001). In patients with eGFR ≥60 mL/min/1.73 m2 (n = 2,134), baPWV 
also showed positive correlations with ACR after adjusting in final model (r 
= 0.219, P < 0.001). However, baPWV lost significant correlation with eGFR 
after adjusting several significant clinical variables. In the patients with eGFR 
≥60 mL/min/1.73 m2, the increased level of baPWV remained significant as-
sociation with to being albuminuria after adjusting for several clinical factors 
in multivariate model. In the normoalbuminuric patients (n = 1,798), the in-
creased level of baPWV was not associated with decreased eGFR (<60 mL/
min/1.73 m2, normoalbuminuric CKD) in multivariate model.
Conclusion: The results of this study suggest that arterial stiffness is more 
associated with albuminuria than GFR in development of type 2 diabetic ne-
phropathy. Especially, arterial stiffness is not associated with normoalbumi-
nuric CKD in type 2 diabetic patients.
1194
Sex difference in coronary artery calcification score and its use as a 
predictor of progression of diabetic nephropathy
S. Fukushima1, A. Hagiwara1, T. Haruki1, J. Ogino1, K. Tajima1, C. Yoneda1, 
Y. Suzuki2, N. Hashimoto1;  
1Diabetes, Endocrine and metabolic Diseases, Yachiyo Medical Center, 
Tokyo Women’s Medical University, 2Diabetes and Metabolic Diseases, 
Asahi General Hospital, Chiba, Japan.
Background and aims: Cardiovascular disease (CVD) is a leading cause of 
death in type 2 diabetes mellitus (T2DM). The coronary artery calcification 
score (CACS) is believed to be one of the predictors of CVD. The progression 
of diabetic nephropathy (DN) leads to an increase in the risk of CVD and 
mortality. Moreover, it has been reported that progression of DN is strongly 
associated with macrovascular as well as microvascular complications. In this 
study, we assessed the relationship between progression of DN and CACS in 
T2DM patients at baseline and at 5-year follow-up.
Materials and methods: A total 103 T2DM patients (71 men, 65 ± 7 years 
old; 32 women, 67 ± 7 years old) of our medical center, who underwent 
multidetector CT scan and were assessed for DN each year, were studied. 
We excluded patients with a serum creatinine (Cr) over 1.0 mg/dl or those 
who had iodine sensitivity. Patients were divided into two group based on 
median CACS derived from the Agatston score. Low CACS were those < 116 
and < 65 for men and women, respectively, while high CACS were those ≥ 
116 and ≥ 65 for men and women, respectively. The main measured outcome 
was the progression of DN stage defined by Japan Diabetes Society, Ameri-
can Diabetes Association, or European Association for the Study of Diabetes. 
Kaplan-Meier method and Cox proportional hazard analysis were performed 
to examine whether the relationship between CACS and DN progression was 
different between the sexes.
Results: At baseline, the male group with high CACS at baseline had a signifi-
cantly higher albuminuria (283± 70 mg/g · Cr vs. 83 ± 39 mg/g · Cr, p = 0.016) 
and prevalence of diabetic retinopathy (DR, 53.1% vs. 21.9%, p =0.010) than 
the male group with low CACS. Other baseline parameters (age, duration of 
DM, BP, HbA1c, serum Cr, estimated GFR [eGFR], uric acid, lipid profile, 
white blood cell count, percentage of current smokers, use of statin, ACE 
inhibitor or angiotensin II receptor blocker) were not significantly different 
between the two groups. At baseline, the female group with high CACS were 
significantly older (70 ± 6 years vs. 64 ± 7 years, p = 0.036), had a lower level 
of eGFR (64.2 ± 10.6 ml/min/1.732 vs. 74.0 ± 11.7 ml/min/1.732, p = 0.019) 
and a higher level of Cr (0.70 ± 0.11 mg/dl vs. 0.63 ± 0.09 mg/dl, p = 0.041) 
compared with the female group with low CACS. Other parameters at base-
line were not significantly different. At the 5-year follow-up, 52.8% of men in 
the high CACS group demonstrated progression of DN compared with 22.9% 
in the low CACS group (p = 0.008). In male patients without DR, those in 
high CACS group also had significantly higher progression of DN than those 
in the low CACS group (60.0% vs. 20.0%, p = 0.007). Patients with DR in the 
high and low CACS groups did not have a significantly different rate of DN 
progression (47.1% vs. 14.3%, p = 0.145). In women, DN progression was 
not significantly different between the high and low CACS groups (25.0% vs. 
43.7%, p = 0.233) and the presence of DR had no effect on DN progression in 
the high and low CACS groups.
Conclusion: In men with T2DM, CACS is a good predictor of DN progres-
sion. DN progression was not related to the presence of DR, suggesting that 
the progression of nephropathy in men may be affected by atherosclerotic 
factors more than in women.
1195
Bimodal association of incidence and progression of diabetic 
nephropathy according to pack-years of smoking in type 1 diabetes
M. Feodoroff1,2, V. Harjutsalo1,3, C. Forsblom1,2, P.-H. Groop1,2, FinnDiane;  
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum 
Helsinki, 2Division of Nephrology, Department of Medicine, Helsinki 
University Central Hospital, 3National Institute for Health and Welfare, 
Diabetes Prevention Unit, Helsinki, Finland.
Background and aims: Our preliminary analyses of the relationship between 
dose of smoking as pack-years (py) and the initiation and progression of dia-
betic nephropathy (DN) based on the non-linear splines showed a bimodal 
distribution with the first peak at 10.5 pack-years and the second increase 
after 30 pack-years. This phenomenon was especially evident in women who 
progressed from normoalbuminuria to microalbuminuria.
Materials and methods: The study included 3,838 patients with type 1 diabe-
tes. At baseline, mean age was 37.7 (IQR 28.8-47.0) years, duration of diabetes 
21.4 (12.2-30.9) years, and 51% were males. Patients were followed for 6.3 
(4.1-9.1) years. All patients with progressive DN were analyzed together; any 
progression from normo- to micro-, micro- to macro- or macroalbuminuria 
to end-stage renal disease. First the potential non-linear relationship between 
pack-years and progression of DN was modeled by Generalized Additive 
Models (GAM). The data were further analysed by Kaplan-Meier method 
and finally by Cox regression models adjusted for age, HbA1c, systolic blood 
pressure (SBP) and triglycerides (TG) and providing hazard ratios (HR). 
Based on the bimodal distribution found by the GAM-analyses the data were 
divided into the groups 0-5, 5-8.5, 8.5-12.5 (±2 years around the first peak), 
12.5-30 and ≥30 pack-years (when risk started to increase again).
Results: There were a total of 438 progressors. Those who had smoked 8.5-
12.5 py had a more favorable profile for clinical risk factors than those who 
had smoked ≥30 py (such as TG, SBP, age, duration of diabetes), although the 
risk of progression of DN was similar. The 10-year progression risks for the 
groups (0-5, 5-8.5, 8.5-12.5, 12.5-30 and ≥30 py) were 14.3% (95% CI 12.6-
16.0), 22.6% (16.3-28.5), 34.7% (28.6-40.3), 25.8% (21.6-29.8) and 31.6% 
(24.7-37.8), respectively (Figure). HR was 2.2 (1.5-3.1) for those who had 
smoked 8.5-12.5 py, while it was 1.7 (1.1-2.7) for those who had smoked ≥30 
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py compared to those who had smoked 0-5 py. HR was 1.4 (0.9-2.1) and 1.3 
(0.9-1.8) for those who had smoked 5-8.5 and 12.5-30 py.
Conclusion: Increase in pack-years of smoking is associated with progression 
of DN, but the relationship is not linear but rather bimodal. We conclude that 
the first peak might indicate an increased risk of a subset for the patients who 
are genetically predisposed and the second due to harmful effects of smoking.
Supported by:  Academy of Finland, Wilhelm and Else Stockmann Foundation
1196
Reduction of microalbuminuria by calcium channel blockers in patients 
with type 2 diabetes mellitus and hypertension
Y.-C. Hwang1, S. Oh1, K.-H. Yoon2, B. Cha3, K.-W. Lee4, H. Jang5, K. Min6,  
C. Chung7, M.-K. Lee1;  
1Samsung Medical Center, Seoul, 2Seoul St. Mary‘s Hospital,  
3Yonsei University College of Medicine, Seoul, 4Ajou University School 
of Medicine, Gyeonggi-do, 5Seoul National University Bundang Hospital, 
Gyeonggi-do, 6Eulji General Hospital, Seoul,  
7Yonsei University Wonju College of Medicine, Republic of Korea.
Background and aims: It has been suggested that reno-protective effects are 
different among calcium channel blockers. The aim of this study was to com-
pare anti-albuminuric effect of different types of calcium channel blockers in 
patients with type 2 diabetes.
Materials and methods: A multicenter, randomized, open label, active-con-
trolled study was conducted in seven hospitals in Korea. Inclusion criteria 
were age ≥18 years, hypertension treated with angiotensin receptor blocker or 
angiotensin-converting enzyme inhibitor, type 2 diabetes with HbA1c ≤8%, 
and persistent microalbuminuria. A total of 74 patients were randomized 
into the cilnidipine 10mg group (n = 37) or the amlodipine 5mg group (n = 
37). Patients were assessed at baseline, 12 weeks and 24 weeks after treatment.
Results: Compared with cilnidipine group, amlodipine group showed greater 
diastolic blood pressure reduction at 24 weeks after treatment (P=0.03). In the 
cilnidipine group, urine albumin to creatinine ratio (ACR) was significantly 
reduced after 12 weeks (-53.0 ± 123.2 mg/g, P<0.01) and 24 weeks (-57.3 
± 106.9 mg/g, P<0.01) treatment. However, amlodipine group did not show 
any decrease in ACR after 12 weeks or 24 weeks treatment. Cilnidipine group 
showed significant reduction in ACR compared with amlodipine group after 
12 weeks (-84.7 ± 106.8 mg/g in cilnidipine group and -9.5 ± 79.2 mg/g in 
amlodipine group, P=0.02) and 24 weeks (-84.0 ± 111.7 mg/g in cilnidipine 
group and 14.6 ± 119.4 mg/g in amlodipine group, P<0.01) treatment, par-
ticularly in patients with long duration of diabetes more than 10 years.
Conclusion: Cilnidipine shows greater microalbuminuria reduction than 
amlodipine in rennin-angiotensin system blocker-treated hypertensive pa-
tients with long duration of type 2 diabetes.
Supported by: CKD PHARMA
1197
Adherence to medications improves risk reduction of end-stage renal 
disease in diabetes mellitus
P.-Y. Chang1, H.-Y. Chiou1, L.-N. Chien2, Y.-L. Li1, Y.-F. Lin3, C.-C. Wang1, 
W.-T. Chiu4;  
1School of Public Health, 2School of Health Care Administration,  
3Graduate Institute Clinical Medicine, 4Graduate Institute of Injury 
Prevention and Control, Taipei Medical University, Taiwan.
Background and aims: Diabetes is a prevalent chronic disease with signifi-
cant complications.Uncontrolled glycemic is an independent risk factor and 
results in accelerated progression to end-stage renal disease(ESRD).To our 
knowledge, there is no study discuss the association between antihypergly-
cemic medication adherence and subsequent ESRD among individuals with 
type 2 diabetes.The specific aims of this study was to examine the effect of 
better adherence to antihyperglycemic therapy on preventing the risk of 
ESRD among newly diagnosed diabetic patients.
Materials and methods: This study used a representative cohort of 1 mil-
lion people from National Health Insurance Research Database in Taiwan.
All subjects aged 20 years or older who have been diagnosed with diabetes 
mellitus(ICD-9code:250.xx) and received newly treated with antihypergly-
cemic agents were included.Newly treated patients were identified as those 
patients who had not taken any antihyperglycemic agents before the first 
date of being diagnosed with diabetes.Adherence was a medication pos-
session ratio(MPR) calculated by the sum of total days’ supply of medica-
tion dispensed divided by the number of days(365) for each year equal or 
greater than 80%.ESRD was defined as patients received dialysis claims 
continuously for three months.Time-dependent medication adherence for 
estimating the risk of ESRD was applied in the Cox proportional hazard re-
gression model.Covariates included age,gender,hypertension,ischemic heart 
disease,cerebrovascular disease,congestive heart failure,anemia,urinary tract 
infection,gout,chronic kidney disease,Charlson comorbidity index,use of 
statin,number of drugs therapy with hypertension,number of drugs therapy 
with diabetes and only use of metformin.All the analyses were performed us-
ing SAS version 9.3.The study was approved by the TMU-Joint Institutional 
Review Board.
Results: A total of 32,861 newly treated diabetes mellitus patients were en-
rolled and 327 cases developed ESRD during a mean follow-up of 4.9 years.
The mean age was 56.4±12.8 years, and male gender accounted for 53.6%.Af-
ter adjustment for potential confounders,patients who were nonadherent to 
diabetes medications were associated with the increased risk of ESRD[hazard 
ratio(HR)=1.56,95% confidence interval(CI):1.19-2.03].In addition,results 
indicated that patients with hypertension(HR=1.40,95%CI=[1.04-
1.87),cerebrovascular disease (HR=1.53,95%CI=1.05-2.24),chronic heart 
failure(HR=3.89,95%CI=2.49-6.05),anemia(HR=3.51,95%CI=2.06-
5.97),chronic kidney disease(HR=11.82,95%CI=8.61-16.22),monotherapy 
with hypertension (HR=1.52,95%CI=1.06-2.17),use two or more therapy 
with hypertension (HR=1.68,95%CI=1.09-2.59),and use two or more ther-
apy with diabetes(HR=1.56,95%CI=1.18-2.07)have higher risk of develop-
ing ESRD compared to their counterparts.However,patients only used met-
formin within the two year of diabetes diagnosis had lower risk of developing 
ESRD(HR=0.23,95% CI= 0.09-0.58).
Conclusion: This study showed nonadherence to antihyperglycemic medica-
tions are associated with increased the risk of ESRD among type 2 diabetes 
patients.
Clinical Trial Registration Number: 201204036
Supported by: Health Promotion Administration, Ministry of Health and Wel-
fare, Taiwan
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Effect of glycaemic and serum electrolyte variation on cardiac electrical 
activity during haemodialysis in people with insulin treated diabetes
N.H. Siddaramaiah1, D.K. Tez2, N.J. Linker3, M. Bilous1, S. Winship1,  
S.M. Marshall4, R.W. Bilous1;  
1Diabetes care, James Cook University Hospital,  
2Department of Renal Medicine, James Cook University Hospital, 
3Department of Cardiology, James Cook University Hospital, 
Middlesbrough, 4Institute of Cellular Medicine, Newcastle upon Tyne, UK.
Background and aims: One-year survival for diabetic patients on dialysis 
is 84.7% in the UK. Cardiovascular deaths account for 22%. Rapid electro-
lyte shifts, QT dispersion, left ventricular hypertrophy, myocardial structural 
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and functional abnormalities and sympathetic hyperactivity are potential 
causative factors. Hypoglycaemia has been linked to sudden death in insulin 
treated diabetes. To explore the relationships between; 1. glycaemic variation 
and heart rate, rhythm and QTc interval 4hrs before, during (3 to 4hrs) and 
4hrs after haemodialysis (HD) 2. changes in serum electrolyte levels during 
HD and heart rate, rhythm and QTc interval.
Materials and methods: In our ongoing study, we undertook week-long con-
tinuous glucose monitoring and Holter monitoring, for 1 to 3 weeks in insu-
lin deficient patients. Serum electrolytes and 12 lead ECGs were obtained at 
the beginning, middle and end of 3 HD sessions during the 1st study week. 10 
insulin deficient patients (7 female, mean age 50.6±9.8 yrs) were monitored, 
during 72 HD sessions.
Results: Mean glucose levels during HD were significantly lower than pre-
HD (8.4±3.6 vs11.2±4.5mmol/L, p<0.001) and post-HD period (8.3±3.5 vs 
12.3±4.7mmol/L, p<0.001) on paired samples. There were significant pe-
riods of hyperglycaemia (>13.0mmol/L) during pre-HD (68.3±93mins vs 
22.8±55mins, p<0.005) and also post-HD compared to HD period (89.5±82 
vs 19.9±48.6mins, p<0.001) on paired samples, with no significant difference 
between pre and post-HD levels. Hypoglycaemia (<3.5mmol/L) occurred 
more frequently during HD period, but was not statistically significant. Mean 
QTc interval was not significantly different between pre-HD and HD (420±20 
vs 424±19ms, p=0.2), but was significantly prolonged during post-HD com-
pared to pre-HD period (427±17 vs 420±20ms, p<0.05) on paired samples. 
Multiple short episodes of asymptomatic tachy- and brady-arrhythmias were 
noted in 6 out of 10 patients, including atrial tachycardia, non-sustained 
ventricular tachycardia, sinus bradycardia, ventricular bigeminy/trigeminy 
& junctional rhythm. Mean post-HD serum electrolytes were significantly 
lower than pre-HD levels (n=30): potassium (K+) 3.3±0.3 vs 4.4±0.8 mmol/L 
(p<0.001), magnesium (Mg2+) 0.78±0.07 vs 0.9±0.16mmol/L (p<0.001) cor-
rected calcium (Ca2+) 2.21±0.07 vs 2.27±0.14 mmol/L (p<0.05) A significant 
drop in K+ and Mg2+ levels occurred in both first and second half of HD ses-
sions. Ca2+ levels dropped significantly in first but not in second half of HD 
session. Post-HD QTc interval was significantly prolonged compared to pre-
HD ECG (500±56 vs 471±44 ms, p<0.005). The significant prolongation oc-
curred during second half of the HD session.
Conclusion: Glycaemic variation on HD days shows a ‘U’ shaped pattern 
with glucose levels being low during HD. There is significant prolongation 
of QTc interval during HD and subsequent period, which could be related 
to a drop in serum electrolyte levels. Potentially life threatening episodes of 
arrhythmias occur frequently in these patients. Larger study is required to 
understand the pathophysiological basis of these arrhythmias and their rela-
tion to glycaemia and electrolyte changes.
Supported by: Sanofi Northern Diabetes Fellowship 2013-2014
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Improving quality: chronic kidney disease in diabetes
N. Milne;  
Northenden Group Practice, Manchester, UK.
Background and aims: Implementation of a continuous audit tool to facili-
tate focused review and optimal medicines management of those persons 
with diabetes and chronic kidney disease (CKD) stage 3 and above within 
the primary care setting. A significant event review within a general practice 
highlighted that when there is a decline in renal function outside a patient‘s 
formal diabetes review, medication adjustment is not always undertaken. 
A need was identified for the development of an audit tool to facilitate the 
continuous and focused review of CKD stage 3 and above within the prac-
tice diabetes population which in addition, would also enhance appropriate 
medicines management and safe prescribing.
Materials and methods: An automated weekly search engine using the prac-
tice information technology system was established to identify and invite in 
patients within three population sub groups (estimated glomerular filtration 
rates (ml/min/1.73m²) 46-60, 31-45, and <30), who were failing to meet prac-
tice established protocol targets to include optimal medication.
Results: Within the practice diabetes population of 616 patients, the prev-
alence of CKD stage 3 and above was 22% which equated to 135 patients. 
During the first six months, eight patients (6%) required adjustment of their 
diabetes medication therapy and four patients (3%) required alternative 
medication to their non-steriodal anti-inflammatory drugs. This demon-
strated a move to enhanced medicines optimisation and safety. Other clinical 
interventions that are widely accepted as effective in delaying the onset or 
progression of CKD were also measured. Those patients without a recorded 
HbA1c fell from 8% to 3% and at the end of the six months all patients with 
a HbA1c over 54mmol/mol had a review plan. Those without a blood pres-
sure measurement fell from 3% to 2%. Patients who were not prescribed an 
angiotensin-converting enzyme inhibitor or angiotensin-II receptor antago-
nist where there was no contraindication, lowered from 6% to 1%. Those pa-
tients without a measurement of micro albuminuria rose from 12% to 13% 
thus highlighting an area for improvement. Three patients were identified as 
requiring referral to secondary care.
Conclusion: Against the background of an ever changing diabetes popula-
tion and newer therapies, this audit tool, in combination with focused review, 
is effective in reducing variation and in improving quality of patient care. In 
addition, it affords timely intervention to ensure appropriate and safe medi-
cines management within this complex patient population. It is hoped that 
the impacts will be increasingly evident over time, in terms of reduced patient 
mortality and morbidity.
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Is home blood pressure reporting in patients with type 2 diabetes 
reliable?
S. Majima1, M. Fukui1, S. Matsumoto1, E. Ushigome1, K. Matsushita1,  
H. Iwase1, T. Senmaru1, M. Hamaguchi1, M. Asano1, M. Yamazaki1,  
G. Hasegawa2,1, N. Nakamura1;  
1Department of Endocrinology and Metabolism, Kyoto Prefectural 
University of Medicine, Graduate School of Medical Science,  
2Division of Metabolism, Nephrology and Rheumatology, Japanese Red 
Cross Kyoto Daini Hospital, Japan.
Background and aims: Hypertension, as well as hyperglycemia, is well 
known as an important risk of cardiovascular and renal disease in patients 
with type 2 diabetes. Home blood pressure (HBP) monitoring is a valuable 
tool in the management of hypertension. To our knowledge no study has in-
vestigated the reliability of HBP measurements in patients with type 2 diabe-
tes. The aim of this study was to evaluate the reliability of HBP reporting and 
determine the factors that affected it in patients with type 2 diabetes.
Materials and methods: A cross-sectional study was conducted in 280 con-
secutive patients with type 2 diabetes recruited from the outpatient clinic at 
our university. Patients were requested to measure triplicate morning and 
evening HBP using a digital automatic BP monitor and to record these meas-
urements in a logbook over a 2-week period. The patients were not informed 
of the storage function of their BP monitor.
Results: Among a total of 280 patients, 155 (55.4%) were taking antihyper-
tensive medication. The concordance rate between the self-reported data in 
the logbook and the stored data in the monitor was 78.6%. Although 65 of the 
patients (23.2%) had 100% “concordant data” that were matched the stored 
data in the monitor and 144 (51.4%) had more than 90% concordant data, 44 
(15.7%) had 50% or less concordant data. The self-reported data were signifi-
cantly lower than the stored data (mean of morning systolic BP: 129.8 ± 15.8 
vs. 130.6 ± 16.2 mmHg, p < 0.0001). In addition, logbook BP was less variable 
than monitor BP (SD of morning systolic BP: 7.9 ± 3.2 vs. 9.8 ± 3.5 mmHg, 
p < 0.0001). The most frequent erroneous data (55.8%) were “selected data” 
that were randomly selected from multiple measurements in the monitor, the 
second most erroneous (23.3%) were “fictional data” that could not be found 
in the monitor, and the third most erroneous (11.6%) were “shifted data” that 
were stored in the monitor on another day but for the same time. The con-
cordance rate correlated significantly with HbA1c (r = -0.127, p = 0.0333), 
HDL cholesterol (r = 0.131, p = 0.0286), triglycerides (r = -0.121, p = 0.0429), 
mean of morning systolic monitor BP (r = -0.121, p = 0.0443), mean of even-
ing diastolic monitor BP (r = -0.127, p = 0.0386) and SD of morning systolic 
monitor BP (r = -0.129, p = 0.0310). Multiple regression analysis indicated 
that the independent explanatory variables concerning the concordance rate 
were HbA1c (β = -0.156, p = 0.0149) and current smoking (β = -0.165, p = 
0.0184). Urinary albumin excretion also correlated with the SD of morning 
systolic BP in the monitor, but not with that in the logbook.
Conclusion: Patients with type 2 diabetes sometimes report erroneous HBP, 
especially those with poor glycemic control or a smoking habit. As a result of 
this inaccurate reporting, HBP control obtained from logbooks may appear 
better than that obtained from a monitor. A device capable of automatically 
saving BP data may be helpful for obtaining accurate measurements of HBP 
that will assist in providing optimal treatment for hypertensive patients with 
type 2 diabetes.
1201
Predictive value of markers of vascular damage for renal outcome in  
type 2 diabetes and essential hypertension
R. Bruno1, A. Salvati2, K. Raimo2, M. Barzacchi2, E. Vitolo2, L. Ghiadoni2,  
A. Solini2;  
1Institute of Clinical Physiology, CNR Pisa, 2Dept of Clinical and 
Experimental Medicine, University of Pisa, Italy.
Background and aims: We have shown that renal vasodilating response to 
nitrates (dynamic renal resistive index, DRIN) is an early vascular alterations 
of type 2 diabetes (T2DM) and essential hypertension (EH) already present 
in normoalbuminuric individuals. In this study we prospectively evaluated 
whether this parameter and other markers of systemic vascular damage are 
able to predict microalbuminuria (MA) onset and renal function decline in 
these patients.
Materials and methods: We studied 65 individuals (27 T2DM and 38 EH) 
following them prospectively. Renal resistive index (RI), DRIN (% change 
in RI after glyceryl trinitrate, GTN 25 μg sl), endothelium-dependent (flow-
mediated-dilation - FMD) and independent (response to GTN) vasodilation 
in the brachial artery, carotid-femoral pulse wave velocity (PWV), and aug-
mentation index (AIx) were assessed. At the follow-up visit, MA onset was 
defined with urinary albumin-creatinine ratio (UACR)>30 mg/g; any reduc-
tion in estimated glomerular filtration rate (eGFR, CKD-EPI formula) was 
also considered as an endpoint.
Results: All patients were treatment-naïve at enrollment, whereas at the 
follow-up visit 62% were taking antihypertensive drugs and 37% were 
treated with anti-hyperglycemic agents. After a follow-up period of 4.1±0.6 
years, mean eGFR (CKD-EPI) decreased from 89.0±14.4 to 86.4±13.0 ml/
min1.73m2, whereas UACR increased from 5 (0-29) to 9 (0-407) mg/g. Ac-
cording to our definition, 19 individuals developed MA and 12 a reduction 
in eGFR. At enrollment, patients who would develop MA tended to be older 
(60.4±9.3 vs 53.8±10.4 years, p=0.07) and carrying more frequently diabe-
tes than their counterparts. Among vascular parameters, RI (0.63±0.04 vs 
0.59±0.06, p=0.04), DRIN (-6.4±8.9 vs -10.2±6.3 %, p= 0.09) and PWV (9.5 
±1.3 vs 7.9 ± 1.5 m/s, p= 0.003), were worse at baseline in those who would 
develop MA during follow-up. Conversely, AIx (24±11 vs 22±13 %, p=0.93), 
FMD (3.9±1.9 vs 5.6±3.9 %, p=0.27) and GTN (5.1±2.8 vs 5.6±3.4 %, p=0.85) 
were similar in the two groups. In T2DM patients there was a significant in-
crease (p<0.05) in RI (from 0.65±0.05 to 0.68±0.04) and PWV (from 8.7±2.1 
to 10.2±2.0 m/s) during follow-up, while both were unchanged in EH patients 
(RI from 0.56±0.03 to 0.59±0.06, PWV from 7.9±1.5 to 8.3±1.7 m/s). DRIN 
was not significantly modified during follow up. In T2DM, at enrollment 
DRIN (-2.2±7.0 vs -7.5±4.4%, p=0.03), but not RI (0.65±0.4 vs 0.65±0.05, 
p=0.63) or PWV (10.0±1.6 vs 8.3±2.4 m/s, p=0.14), was significantly worse in 
patients who would develop MA, whereas in the EH group RI (0.60±0.03 vs 
0.57±0.04, p=0.04) and PWV (8.7±0.7 vs 7.8±1.0 m/s, p=0.03), but not DRIN 
(-11.6±6.9% vs -12.9±7.6%, p=0.62), were altered in patients developing MA. 
At baseline, patient with reduction in eGFR where older and tended to have 
higher RI. Considering only T2DM patients, none of the explored vascular 
parameters were associated with reduction in eGFR.
Conclusion: These preliminary results suggest that some parameters of vas-
cular damage like RI, PWV and DRIN are able to predict MA onset in EH 
and in T2DM, respectively. These markers of vascular damage might be use-
ful in elucidating pathophysiology of renal damage and in predicting its de-
velopment during the course of these chronic diseases.
1202
Annual deterioration of renal function in hypertensive patients  
with diabetes vs without diabetes
J. Polonia1, M. Monte1, J. Silva2, S. Bertoquini1;  
1Medicina e Cintesis, Faculdade Medicina do Porto,  
2Unidade Hipertensao, Hospital Pedro Hispano, Matosinhos, Portugal.
Background and aims: Chronic renal disease (CKD) complicates hyperten-
sion and diabetes. Knowledge of the deterioration rate of CKD may antici-
pate adjustment of therapies with predominant renal elimination. We aim to 
evaluate the rate of annual deterioration of renal function in a large cohort 
of hypertensive patients either with diabetes(DM) and without it (non-DM) 
followed for 5 years in a reference out-patient hospital clinic of hypertension, 
and to relate it with BP and glycemic control.
Materials and methods: Out of a total of 1924 patients, 1023 patients (594 
non-DM and 429 DM, 53% female, ageing 62.1±10.2 years) were evaluated 
during the last 5 years for the annual evolution of renal function (MDRD) 
ambulatory 24-h blood pressure (ABP, SpaceLabs 90207) and metabolic pa-
rameters, corresponding to the analysis of 2378 patients-years.
Results: DM and non-DM did not differ for age (60.9 ± 10.1 v 62.8 ± 10.5 
years), mean 24h BP levels (134/86 ± 12/10 v 136/87 ± 11/11, nighttime 
123/74 ± 16/10 v 122/73 ± 15/10 mm Hg), albuminuria (145 ± 430 vs 130 
± 370 mg/24h) and body mass index (28±6 v 29±8 kg/m2). DM v non-DM 
showed a higher (qui square p &gt 0.01) prevalence of stage 3 CKD (24.2% v 
18.1%, GFR 30-59 mL/min/1.73m2), stage 4 (5.4% v 2.7%, GFR 15- 29) and 
stage 5 (0.8% v 0.5%, GFR 8.0 %). Each year net GFR was reduced by 3.3 ± 8.2 
in DM vs 2.4 ± 7.7 mL/min/1.73m2 in non-DM (p=0.12, ns). In multivariate 
analysis, age, nighttime BP, the use of double inhibition of renin angiotensin 
system and HbA1C &lt 8.0 % in DM were independent factors associated 
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with the deterioration of GFR. Also in average 16.2% of DM and 13.1% on 
non-DM moved each year towards the next and more severe stage of CKD 
(p=0.051). For initial GFR &gt90 mL/min/1.73m2, 24% of DM and 18% of 
non-DM showed a reduction per year &lt 10% of the previous GFR value 
(qui square, p=0.049).
Conclusion: A progressive deterioration of renal function for each next year 
is frequent in diabetics and non-diabetics with hypertension. Beyond ageing, 
renal deterioration may be particularly dependent on BP control particularly 
at nighttime, on certain therapies and on highly abnormal glucose control.
1203
A systematic review and meta-analysis of the effects of diuretics and 
beta-blockers on glycaemic control in diabetes mellitus
J.A. Hirst, A.J. Farmer, B.G. Feakins, J.K. Aronson, R.J. Stevens;  
Department of Primary Care Health Sciences, University of Oxford, UK.
Background and aims: Although there are reports that beta-adrenoceptor 
antagonists (beta-blockers) and diuretics can affect glycaemic control in peo-
ple with diabetes mellitus, there is little information on how blood glucose 
concentrations are likely to change and by how much.
Materials and methods: We systematically reviewed the published literature 
to identify randomised controlled trials (RCTs) in which glycaemic control 
was studied in people with diabetes mellitus taking either beta-blockers or 
diuretics. We pooled end-point data on HbA1c and fasting blood glucose 
(FBG) concentrations using inverse variance fixed effects meta-analysis.
Results: We retrieved 3864 papers and found 10 studies (15 comparisons in-
volving 1889 participants) of beta-blockers and 11 studies (12 comparisons 
involving 312 participants) of diuretics to include in the meta-analysis. One 
study included comparisons of both beta-blockers and diuretics, giving a to-
tal of 20 included trials. Beta-blockers increased fasting blood glucose con-
centrations by a mean of 0.64 mmol/l (95% CI 0.24 to 1.03) and HbA1c by 
0.75% (95% CI 0.30 to 1.20), corresponding to 8.2 mmol/mol (95% CI 3.3 to 
13.1) compared with placebo. Three trials (four comparisons) that studied 
the beta-blocker propranolol showed a larger increase in FBG concentra-
tions than three trials that used other beta-blockers (1.26 mmol/l, 95% CI 
0.62 to 1.89 compared with 0.25 mmol/l, 95% CI -0.25 to 0.76). Diuretics 
increased FBG by 0.96 mmol/l (95% CI 0.29 to 1.63) compared with placebo 
and HbA1c by 0.24% (95% CI -0.17 to 0.65), corresponding to 2.6 mmol/mol 
(95% CI -1.9 to 7.1) compared with placebo. The four trials (5 comparisons) 
that studied thiazide diuretics gave a larger increase in FBG levels than three 
trials that used non-thiazide diuretics (1.69 mmol/mol, 95% CI 0.69 to 2.69, 
and 0.36 mmol/mol, 95% CI -0.55 to 1.27 respectively), but when tested us-
ing meta-regression this difference was not significant (p=0.101). There were 
no significant differences in the numbers of hypoglycaemic events or other 
adverse events between beta-blockers and placebo in three trials.
Conclusion: In this synthesis of data we have quantified the effect of two 
commonly used types of antihypertensive medications on glycaemic control 
in diabetes. Both medication types increase fasting blood glucose and HbA1c 
concentrations in patients with diabetes by moderate but clinically significant 
amounts. Among beta-blockers, propranolol has the biggest effect, but there 
have been too few studies to allow a full analysis of other beta-blockers. These 
data will inform the monitoring and use of beta-blockers and diuretics in 
patients with diabetes.
Supported by: NIHR National School for Primary Care Research
 
1204
Renoprotective effect of ACE-I and ARB in combination with 
hydrochlorthiazide in hypertensive type 2 diabetic patients
N. Akbarova, N. Rakhimova, B.D. Babadjanov, B. Djanabaev, B. Ikramova;  
Public Center of Purulent Surgery and Diabetes Complications,  
Tashkent Medical Academy, Uzbekistan.
Background and aims: To compare the effects on albumin excretion rate(AER) 
of two combined preparations: ramipril/hydrochlorothiazide(Ram/htz) and 
valsartan/hydrochlorothiazide(Val/htz)
Materials and methods: This is a 12 months randomized parallel group 
study. 130patients with hypertension(140mmHg≤ SBP< 180mmHg and 
DBP< 110), controlled Type 2 diabetes and albuminuria ≥ 20and < 500μg/
min were randomized to Ram/htz(group1,n=61) or to Val/htz(group2, 
n=69). A dose up-titration from Ram2,5/htz12,5mg up to Ram5/htz25mg 
or from Val80/htz12,5mg up to Val160/htz12,5mg was allowed up toW12 to 
achieve blood pressure (BP) targets of SBP<140mmHg and DBP<90mmHg. 
The mean urinary albumin excretion was evaluated on overnight urine col-
lections All patients completed12 months of follow-up. Followings param-
eters were measured: blood pressure (BP), BMI and HBA1c
Results: 130 patients in 2 groups were similar in terms of sex, age(58,2 vs 
58.4), diabetes duration(10.8 vs 11.1), BMI, BP(systolic 156 vs 155.8 mmHg, 
diastolic 93.3 vs 92.8 mmHg), HBA1c(7.9 vs 8.0 %) cholesterol, creatinine 
and smoking habits. At the end of 1 year period: systolic BP 156 ± 11.2mmHg 
vs 142±12.5 for group 1 (p<0.01) and 155.8±11.1mmHg vs 143±14.2mmHg 
for group 2(p<0.01) and diastolic blood pressure 93.3±6mmHg vs 
84.5±9.2mmHg for group 1 (p<0.01) and 92.8±6.9mmHg vs 85.0±7.6mmHg 
for group 2 (p<0.01). Pre and post treatment AER were 75.3±25.5μg/min vs 
48.5±21μg/min (p<0.01) for group 1 and 76.1±26.1μg/min vs 49.0±23.4μg/
min (p<0.01) for group 2. The other parameters remained unchanged in both 
groups
Conclusion: Treatment with such combined preparations as ramipril/hydro-
chlorothiazide and valsartan/hydrochlorothiazide were equally effective in 
reducing AER as well as hypertension in hypertensive type 2diabetic patients
1205
Effect of weight loss on abnormal 24-h blood pressure patterns and 
endothelial function in hypertensive obese patients with and without 
type 2 diabetes
L. Flores1, M. Careaga1, I. Patrascioiu1, I. Nuñez2, L. Rodríguez1,  
E. Esmatjes3, J. Vidal1;  
1Endocrinology and Nutrition, Hospital Clinic, 2Diagnostic Imaging Center, 
Hospital Clinic, 3Diabetes Unit, Hospital Clinic, Barcelona, Spain.
Background and aims: Nocturnal hypertension [HT, night systolic blood 
pressure (SBP) > 120/70 mmHg), non-dipper status (nocturnal BP fall < 10% 
of daytime values), high pulse pressure (PP, difference between 24-h SBP and 
DBP readings) and endothelial dysfunction are associated with an increased 
risk of cardiovascular disease. Our aim was to compare the 1-year effect of 
significant weight loss on abnormal 24-h BP patterns (nocturnal HT, PP and 
non-dipper status) and endothelial function in severely obese hypertensive 
patients with and without type 2 diabetes mellitus (DM).
Materials and methods: Patients with documented HT undergoing bariat-
ric surgery (BS) were studied and evaluated before BS and 12 months post-
operatively. Antihypertensive treatment was withdrawn one week before each 
evaluation. Anthropometric data were collected, BP (24-h ambulatory BP 
measurement) was measured and endothelial function was determined by 
endothelial-dependent flow-mediated vasodilatation (FMD) of the brachial 
artery.
Results: Thirty-three patients [12 with DM and 21 patients without DM] 
were studied. DM remission was observed in 75% and HT remission was 
observed in 67 % and 86 % of patients with and without DM. The table below 
show the main results obtained.
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Conclusion: In patients with HT surgery-induced weight loss was associated 
with a sizeable decline in BP with a high HT remission range. After weight 
loss patients with DM maintain a high prevalence of abnormal 24-h BP pat-
terns and continue to have a high cardiovascular risk. In addition, endothelial 
function did not improve.
Supported by: (PI07/0124) from the Fondo de Investigación San
1206
Associations of visceral fat area and HOMA-R with both diabetes 
mellitus and hypertension in a health checkup programme: NingenDock
H. Hirose1,2, M. Takayama2, Y. Iwao2, H. Kawabe1, Y. Sugino2;  
1Health Center,  
2Center for Preventive Medicine, Keio University Hospital, Tokyo, Japan.
Background and aims: Although the visceral fat area (VFA) value and ho-
meostasis model assessment insulin resistance index (HOMA-R) in patients 
with metabolic syndrome (MetS) or type 2 diabetes mellitus (DM) are known 
to be higher, the relationship of VFA and HOMA-R with hypertension (HT) 
remains unclear. In the present study, we investigated the relationship of 
blood pressure status with VFA, subcutaneous fat area (SFA), HOMA-R, 
and insulin secretion capacity (HOMA-ß) in male subjects during an annual 
health check-up program.
Materials and methods: A total of 1737 Japanese male subjects, aged 45-74 
years, who underwent the whole body health check-up program ‚Ningen-
Dock‘ between August 2012 and October 2013 were enrolled in this study. 
Informed consent was obtained from each subject, and 9 subjects were ex-
cluded owing to predetermined exclusion criteria. The subjects were divided 
into 4 groups according to glucose tolerance status: normal glucose toler-
ance (NGT), preDM, DM, and DM with medication (DM+Tx), and blood 
pressure status: normotensive (NT), high normal (HN), HT, and HT with 
medication (HT+Tx). Both VFA and SFA were measured at the umbilical 
level using computed tomography.
Results: VFA (mean±SD) in the PreDM (n=425), DM (n=120), and DM+Tx 
(n=175) groups were significantly higher than that of the NGT (n=1008) 
group (117±43, 133±54, and 124±54 vs. 101±44cm², F=31.6 and P< 0.0001 
by ANOVA). Furthermore, the VFA of the HN (n=231), HT (n=202), and 
HT+Tx (n=517) groups were significantly higher than that of the NT (n=778) 
group (109±43, 118±46, and 128±49 vs. 95±42cm², F=58.8 and P< 0.0001). 
The HOMA-R (median [Q1-Q3] of the HN, HT, and HT+Tx groups were 
also significantly higher than that of NT group (1.4 [1.0-1.9], 1.5 [1.0-2.1] 
and 1.6 [1.1-2.7] vs. 1.2 [0.8-1.8], F=38.0 and P< 0.0001). Multiple logistic 
regression (MLR) analysis of DM as a dependent variable revealed that low 
HOMA-ß, high HOMA-R, age, VFA, and smoking were relevant. Moreover, 
MLR analysis of HT as a dependent variable revealed that age, VFA, alcohol 
consumption (more than 20g ethanol/day), BMI, and HOMA-R were rel-
evant (Table 1).
Conclusion: These results suggest that VFA and HOMA-R correlate with HT, 
as well as type 2 DM and MetS, in Japanese male subjects aged 45-74 years.
Supported by: MECSST, Japan, No.23500855
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Endoscopic, duodenal-jejunal bypass liner in obese patients with or 
without type 2 diabetes lowers incidence of metabolic syndrome and 
improves cardiovascular risk
R. Chilton1, D. Kim2, E.G.H. de Moura3, A. Liao4, J.-C. Tetreault4,  
E. Chiquette4, A. Escalona5;  
1University of Texas Health Science Center at San Antonio, San Antonio, 
2MetaCon, Inc, La Jolla, USA, 3University of Sao Paolo Medical School, 
Brazil, 4GI Dynamics, Lexington, USA, 5Catolica University, Santiago, Chile.
Background and aims: The endoscopically delivered duodenal-jejunal by-
pass liner (DJBL) exhibits robust metabolic effects in obese subjects with or 
without type 2 diabetes (T2D). Several clinical studies have been conducted 
in development of the DJBL. We report metabolic and cardiovascular (CV) 
effects of DJBL in obese subjects with or without T2D across 2 uncontrolled 
clinical studies.
Materials and methods: Forty subjects completed the intended 12 month 
treatment period (baseline mean ± SEM: age 44.5 ± 1.85 yr, BMI 45.2 ± 1.09 
kg/m2, A1C 8.6 ± 0.48% and 6.2 ± 0.26% in subjects with [n=13] and without 
[n=27] T2D, respectively, 77.5 % females). Most common co-morbid condi-
tions were hypertension (47.5%), GERD/Gastritis (12.5% each), and hyper-
lipidemia (10.0%).
Results: At baseline 35/40 ( 87.5%) subject had metabolic syndrome (as 
defined by ATPIII criteria) and, using the FraminghamBMI, Framingham 
Lipid, and UKPDS CV risk engine models, the 10-year CV risk was deter-
mined to be 11.9 ± 2.09%, 9.0 ± 1.52%, and 5.9 ± 0.93%, respectively. After 
12 months of intended implant time, the overall cohort lost 18.6 % in total 
body weight on average and 17.7 cm from the waist. Additionally, systolic BP 
dropped by -7.6 mmHg, LDL-cholesterol decreased by 0.6 mmol/L, and A1c 
reduction of 2.1 % in the diabetic subgroup. The improvement in CV risk fac-
tors translated to a 20-32% reduction in 10-year CV risk (see table) and a 37% 
decreased in subjects meeting the metabolic syndrome criteria, (20/40 sub-
jects (p<0.001). Analysis of concomitant medications during the 12 month 
period showed trends for dose reductions or discontinuation of glucose, BP, 
and lipid-lowering agents in 87% of subjects. Adverse events were mostly of 
gastrointestinal nature, mild or moderate in severity, and tended to diminish 
in frequency in the weeks after initial device implantation.
Conclusion: In 40 obese subjects with or without T2D who completed 12 
months of DJBL implantation, clinically meaningful improvements in preva-
lence of metabolic syndrome and 10-year CV risk level regardless of the 
model used. The device appears to be generally safe and well-tolerated. This 
non-surgical approach warrants further characterization as an important 
treatment option to improve CV risk in obese patients with or without T2D.
Clinical Trial Registration Number: NCT00791128; NCT00985491
Supported by: GI Dynamics sponsored clinical studies
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Multifactorial risk factor control in clinical practice and risk of 
cardiovascular disease in type 2 diabetes: report from the Swedish 
national diabetes register
K. Eeg-Olofsson1, S. Gudbjörnsdottir1,2, B. Eliasson1, B. Zethelius3,4,  
A.-M. Svensson2, J. Cederholm3;  
1University of Gothenburg, 2Centre of Registers in Region Västra Götaland, 
Göteborg, 3Uppsala University, 4Medical Products Agency, Uppsala, Sweden.
Background and aims: Cardiovascular complications are still the major 
cause of morbidity and mortality in patients with type 2 diabetes (T2D). To 
lower this risk, guidelines advocate multifactorial risk factor control with fo-
cus on glucose control, blood pressure (BP) and blood lipids levels. The aim 
of this observational study was to assess the effect of change in these risk fac-
tors on risk for cardiovascular disease (CVD) and mortality in T2D, also in a 
subgroup with albuminuria.
Materials and methods: 47,020 T2D patients from the Swedish National 
Diabetes Register, aged 30-70 years, were followed from baseline visits 2003-
2006 until 31 Dec 2009, mean follow-up 5.7 years. In all, mean age 60±8 years 
and diabetes duration 7±6 years. Reference group (n= 13,005) with stable val-
ues or increase in HbA1c, systolic BP (SBP) and the ratio non-HDL-to-HDL-
cholesterol (non-HDL:HDL) during the study period was compared with 
seven groups (n=3766 to n=6509) of decrease in either each or in combina-
tions of these risk factors. The reference group with stable or increasing risk 
factor values had mean HbA1c increasing from 52 to 57 mmol/mol, mean 
SBP increasing from 135 to 141 mmHg, and mean non-HDL:HDL increasing 
from 2.9 to 3.3. Groups with decrease in HbA1c showed decrease from mean 
60 to 52 mmol/mol, with decrease in SBP showed decrease from 146 to 130 
mmHg and with decrease in non-HDL:HDL had decrease from 3.3 to 2.5.
Results: Compared with reference group hazard ratios (HR) with 95% con-
fidence intervals at Cox regression for fatal/nonfatal CVD were 0.45 (0.40-
0.52) with decrease in HbA1c only, 0.31(0.27-0.36) with non-HDL:HDL, 0.27 
(0.23-0.31) with SBP, 0.25 (0.22-0.29)-0.36 (0.31-0.41) with decrease in two 
of three risk factors combined, and 0.24 (0.21-0.28) with all three risk factors 
decreasing, all p<0.001. Corresponding HR for total mortality were 0.36 with 
HbA1c decrease only, 0.23 with non-HDL:HDL, 0.27 with SBP, 0.23-0.36 
with decrease in two risk factors, and finally 0.29 with all three risk factors de-
creasing, p<0.001 after adjusting for clinical characteristics, CVD risk factors, 
treatments and a history of CVD.Similar results were found in a subgroup 
of 10,004 patients with albuminuria at baseline, HRs for fatal/nonfatal CVD 
0.27-0.49 with decrease in one, 0.26-0.36 with decease in two risk factors, and 
0.23 with all three risk factors decreasing, all p<0.001, while corresponding 
HR for total mortality were 0.22-0.31, 0.19-0.30, and 0.25, p<0.001.
Conclusion: Successful risk factor control in patients with T2D in clinical 
practice with reductions in HbA1c, blood pressure and blood lipids was as-
sociated with 55-76% lower risk for CVD and 36-77% lower risk for total 
mortality.
1209
Depressive symptoms predict incident stroke independent from 
low physical activity in older patients: the Japanese elderly diabetes 
intervention trial (J-EDIT)
A. Araki1, Y. Tamura1, Y. Chiba1, T. Shinozaki2, S. Iimuro2, Y. Ohashi2,  
H. Ito1, the Japanese Elderly Diabetes Intervention Trial Study Group;  
1Diabetes, Metabolism, and Endocrinology, Tokyo Metropolitan Geriatric 
Hospital, 2Biostatistics, School of Public Health, University of Tokyo, Japan.
Background and aims: Although recent remarkable advances in treatment 
of diabetes have been made, conventional risk factors cannot fully explain 
the increased risk of stroke in older patients with diabetes mellitus. Psycho-
logical factors and physical inactivity have been considered to be one of new 
potential risk factors for micro- and macrovascular complications in diabetes 
mellitus. Diabetes mellitus is more likely to have depressive symptoms, which 
lead to low physical activity. In contrast, physical inactivity is associated with 
depression. The aim of the study is to examine whether depressive symptoms 
predict incident stroke independent from conventional risk factors and low 
physical activity in a 5-year follow-up study of elderly patients with diabetes 
mellitus.
Materials and methods: The Japanese Elderly Diabetes Intervention Study 
(J-EDIT) is a randomized, controlled, multi-centre, prospective intervention 
trial using a total of 1173 older patients (aged≥65 years) with type 2 diabetes 
mellitus from 39 institutions. Nine hundred and seven patients were used 
for analysis after excluding 110 patients who were dropped out very early or 
had missing data about depressive symptoms at baseline. Mean age was 71.8 
years. Depressive symptoms were evaluated using a short form of the Geri-
atric Depression Scale (GDS-15, 15 items). Physical activities were assessed 
using the Baecke questionnaire. Cox regression analysis was performed to 
examine the independent association between depressive symptoms, conven-
tional risk factors, or physical activity, and incident stroke.
Results: During the 5-year of follow-up, 50 non-fatal and fatal strokes oc-
curred. The score of GDS-15 was 4.6 ± 3.0 at baseline. The prevalence of those 
who had GDS-15 ≥8 was 12.7%. The incidence of stroke in the patients who 
had the GDS-15 ≥8 was significantly higher than those who had the GDS-
15 <8 (P<0.001,log-rank test). Depressive symptoms (GDS-15 ≥8) predicted 
incident stroke after adjusting for age, sex, HbA1c, systolic blood pressures, 
non-HDL-C, and HDL-C(HR=3.2,95%CI:1.7-6.2). After adding physical ac-
tivity to the model, the association between depressive symptoms and inci-
dent stroke remained significant(HR=3.2,95%CI:1.6-6.3,p<0.001).
Conclusion: Depressive mood is one of independent predictors for stroke in 
older patients with diabetes mellitus.
Clinical Trial Registration Number: UMIN000000890
Supported by: Japan Foundation for Ageing and Health
1210
Fasting triglyceride is an independent cardiovascular risk factor in 
HbA1c less than 6.5%
Y.-P. Lin1, C.-Y. Wang2;  
1Department of Internal Medicine , Division of Endocrinology and 
Metabolism, Taipei Medical University Hospital,  
2Department of Internal Medicine, Division of Endocrinology and 
Metabolism, National Taiwan University Hospital, Taipei, Taiwan.
Background and aims: Although LDL is the primary target for lipid-lower-
ing therapy and non-HDL cholesterol is a secondary target in patients with 
elevated triglyceride (TG) levels, triglyceride rich lipoprotein (TGRLP) is still 
an early, reliable, and practical predictor for vascular inflammation. However, 
the independent relationship of triglycerides to the risk of future CVD events 
has long been controversial. More commonly identified are milder triglycer-
ide level elevations (ie, 100 to 500mg/dl) associated with environmental trig-
gers such as poor diet, lack of exercise, obesity, DM, and metabolic syndrome 
(MetS).The goal of our study tried to find whether TG less or more than 100 
mg/dl could be the predictive factor for cardiovascular inflammation.
Materials and methods: A total of 6883 subjects (TG < 100 mg/dl. N=3639, 
mean age 51.4 ±11.9;TG≧100 mg/dl, N=3244, mean age 52.6± 11.2; p < 
0.01), whose HbA1c was less than 6.5 %, without history of type 2 DM or 
documented cardiovascular diseases were enrolled in this retrospective case 
control cohort study. Levels of various lipid fractions and C-reactive protein 
(CRP) were measured.
Results: Data revealed as: (1) Total CHOL 198.2 ±32.3 mg/dl versus 208.9 
±34.4 mg/dl, in TG < 100 mg/dl & TG≧100 mg/dl (p< 0.01). (2) HDL-C 
54.9±12.6 mg/dl versus 46.6±10.1 mg/dl, in TG < 100 mg/dl & TG≧100 
mg/dl (p< 0.01). (3) LDL-C 111.4 ±28.6 mg/dl versus 124.8±30.7 mg/dl, in 
TG < 100 mg/dl & TG≧100 mg/dl (p< 0.01). (4) CRP 0.154 ±0.425 mg/dl 
versus 0.185±0.442 mg/dl, in TG < 100 mg/dl & TG≧100 mg/dl (p< 0.01). 
Linear regression for TG < 50 mg/dl, strong correlation with LDL-C, HDL-
C, total CHOL (p<0.01), but not for CRP (p=0.5637). On the other hand, 
strong correlation in linear regression was noted between TG≧100 mg/dl and 
HDL-C (p<0.01), total CHOL (p<0.01), CRP (p=0.0237), but not for LDL-C 
(p=0.0542). On the basis of CRP comparison, CRP is statistically correlated 
with subjects with TG ≧100 mg/dl, but not for subjects TG < 100 mg/dl.
Conclusion: Our results may suggest that healthy persons with HbA1c less 
than 6.5 % but fastingTG≧100 mg/dl could be the predictor for cardiovascu-
lar inflammation, independent from the level of LDL-C. An optimal triglyc-
eride cut point is intended to define one physiological parameter of cardio-
metabolic health in the future.
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Lipoprotein(a), type 2 diabetes and vascular risk in angiographied 
coronary patients
K.-M. Ebner1,2, A. Vonbank3, C.H. Saely3,2, D. Zanolin1,2, P. Rein3,  
H. Drexel3,4;  
1VIVIT Institute, Feldkirch, Austria, 2Private University of the Principality 
of Liechtenstein, Triesen, Liechtenstein,  
3Academic Teaching Hospital Feldkirch, Austria,  
4Drexel University College of Medicine, Philadelphia, USA.
Background and aims: Lipoprotein (a) [Lp(a)] especially in young individu-
als is an important cardiovascular risk factor. However, data on the long-term 
vascular risk conferred by Lp(a) in patients with type 2 diabetes (T2DM) are 
scarce.
Materials and methods: Lp(a) was measured in a cohort of 909 consecutive 
patients undergoing coronary angiography for the evaluation of established 
or suspected stable coronary artery disease; vascular events were recorded 
over 10 years.
Results: Median Lp(a) at baseline was significantly lower in patients with 
T2DM (n=260) than in subjects without T2DM (10 [interquartile range 1-34] 
vs. 16 [1-54] mg/dl; p=0.017). Prospectively, 27.8% of our patients suffered 
vascular events. Lp(a) proved to be a strong and independent predictor of 
vascular events in total population with a standardized adjusted hazard ra-
tio (HR) of 1.15 [1.03-1.27]; p=0.006) as well as in subjects without T2DM 
(HR 1.22 [1.10-1.36]; p<0.001) but not in patients with T2DM (HR 0.990 
[0.79-1.22]; p=0.888). An interaction term T2DM x Lp(a) was significant 
(p<0.001), indicating that Lp(a) was a significantly stronger predictor of vas-
cular events in subjects without T2DM than in patients with T2DM.
Conclusion: Lp(a) in patients with T2DM is low and is not associated with 
the incidence of vascular events. The power of Lp(a) as a predictor of cardio-
vascular events is significantly modulated by the presence T2DM.
1212
Impact of age on the cardiovascular event risk conferred by HbA1c in 
patients with established coronary artery disease
A. Vonbank1, C.H. Saely1,2, P. Rein1, D. Zanolin3,2, H. Drexel1,4;  
1Academic Teaching Hospital Feldkirch, Austria, 2Private University of 
the Principality of Liechtenstein, Triesen, Liechtenstein, 3VIVIT Institute, 
Feldkirch, Austria, 4Drexel University College of Medicine, Philadelphia, 
USA.
Background and aims: In the present study we tested the hypothesis that age 
modulates the impact of HbA1c on cardiovascular event risk in patients with 
established coronary artery disease (CAD).
Materials and methods: We prospectively recorded cardiovascular events 
over a mean follow-up period of 4.4±1.2 years in a large consecutive series of 
816 patients with angiographically proven CAD, including 376 subjects <65 
years and 440 subjects ≥65 years.
Results: During follow-up, the incidence of cardiovascular events was 9.3% 
among subjects <65 years and 24.8% among subjects ≥65 years (p<0.001). 
Among the younger patients, HbA1c strongly and significantly predicted 
cardiovascular events (HR 1.54 [1.06-2.23]; p=0.022), but not among in the 
older patients (HR 1.22 [0.94-1.59]; p=0.125). An interaction term age x 
HbA1c was statistically significant (p=0.007), indicating that HbA1c was a 
significantly stronger predictor of cardiovascular events among younger than 
among older CAD patients.
Conclusion: We conclude that HbA1c is a significantly stronger predictor of 
cardiovascular events in younger patients than in older patients with estab-
lished CAD.
1213
All-cause mortality in type 2 diabetes in New Zealand: development and 
validation of a risk model
P.L. Drury1, T.E. Robinson2, C.R. Elley2, T. Kenealy2;  
1Auckland Diabetes Centre, 2Department of General Practice & Primary 
Health Care, University of Auckland, New Zealand.
Background and aims: Type 2 diabetes is associated with a substantial increase 
in the risk of death. This study aimed to derive an up-to-date predictive risk 
model for all-cause mortality in type 2 diabetes in our multi-ethnic population.
Materials and methods: We used primary care data from a large national 
multi-ethnic cohort of patients with type 2 diabetes in New Zealand (the 
NZ Diabetes Cohort Study) and linked these with national death records to 
develop several predictive risk models for 5-year risk of mortality. We then 
validated these models using information from a separate cohort of patients 
with type 2 diabetes.
Results: 26,864 people, mean age 62 years, were included in the development 
cohort with a median follow up time of 9.1 years and 6333 deaths (24%). We 
developed three models initially using demographic information and then 
adding progressively more readily available clinical detail. The final model, 
which also included markers of renal disease (albuminuria and estimated 
GFR), proved to give best prediction of all-cause mortality with a C-statistic 
of 0.80 in the development cohort and 0.79 in the validation cohort (7,610 
people, follow-up 5 years, 759 deaths, 10%); it was well calibrated. In addition 
to the usual known risk factors including HbA1c, ethnicity was a major influ-
ence with hazard ratios of 1.37 for Maori, 0.79 for Pacific Peoples, 0.41 for 
East Asian and 0.55 for Indo-Asian compared with European (all p<0.001).
Conclusion: We have developed a model that provides an accurate assess-
ment of patients’ risk of death using information normally available in prima-
ry care. While our results are broadly similar to models previously published 
from smaller cohorts in other countries, they are superior to most and apply 
to a wide range of patients of multiple ethnicities and over recent years since 
2000. Reasons for the major influence of ethnicity, both adverse and protec-
tive, are as yet unclear.
Supported by: Auckland Medical Research Foundation
1214
Years of life lost attributable to type 2 diabetes in Germany
R. Brinks, A. Hoyer, T. Tamayo, B. Kowall, W. Rathmann;  
Biometry and Epidemiology, German Diabetes Center, Duesseldorf, 
Germany.
Background and aims: In Europe a decline in the diabetes-related mortality 
has been observed in recent years. However, in comparison to the general 
population, people with type 2 diabetes still had a reduced life expectancy. 
Years of life lost (YLL) is an important epidemiological measure to quantify 
the burden of a chronic disease in a population. YLL attributable to type 2 
diabetes has never been reported for Germany.
Materials and methods: We calculated the sex-specific YLL attributable to 
type 2 diabetes for a birth cohort in Germany (born 1955). The resulting YLL 
is a population average, independent from the individual life-time diabetes 
risk. The underlying incidence and mortality rates of known and unknown 
diabetes stem from the KORA S4/F4 survey, a cohort study with baseline ex-
aminations in 1999-2001 and follow-up period until 11/2009. Mortality rates 
of the general population (including a projection for future years) stem from 
the German Federal Statistical Office. Since KORA data have a restricted 
age range, we used data from the Danish diabetes register to expand the age 
range. Beside an analytical calculation of YLL based on a comparison of the 
areas under the survival curves, we additionally used a micro-simulation to 
assess statistical uncertainty. Calendar time trends in the incidence of diabe-
tes and mortality rates of persons with diabetes are not known for Germany 
and are assessed by scenarios. The scenarios assume a change of +/-1 and 
+/-2% per year for the incidence and a change of -2 and -1% in case of the 
mortality in the diabetic population.
Results: The results are shown in Table 1. In the base case, i.e. no an-
nual trends, the average YLL in the cohort is 5.7 and 2.4 years for 
men and women, respectively. Results from the simulation and 
the analytical calculation agree well within the confidence bounds. 
The uncertainty about trends in diabetes incidence and mortality in the dia-
betic population exceeds the statistical uncertainties in these estimates. In the 
male and female subgroup of the cohort, the range of YLL in the scenarios 
is 2.2-9.9 and 0.6-3.9 years, respectively. Independent from the scenario, it is 
striking how big the difference between men and women is. The reason lies 
in the different age courses of the prevalence in men and women. The preva-
lence in men is higher than in women until the age of about 80.
Conclusion: On population average, presence of type 2 diabetes was associ-
ated with a loss of 5.7 life years in men and of 2.4 years in women of the 1955 
birth cohort, respectively. The uncertainty about the trends in incidence and 
mortality leads to uncertainty in the estimated YLL. Due to the high numbers 
of persons born in Germany in 1955, the total YLL attributable to type 2 
diabetes sums up to more than 1.5 million years in the best case, 4.6 million 
years base case, and 7.5 million years in the worst case. These numbers refer 
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to the 1955 birth cohort alone. Therefore, despite improved diagnosis of dia-
betes and better medical treatment, type 2 diabetes is still associated with an 
enormous reduction of life-time.
1215
Predictors of ischaemic heart disease and cerebrovascular attack in late 
elderly diabetic individuals: lessons from 9.1 years study of 4014 diabetic 
patients
K. Ina1, T. Hayashi1, H. Nomura1, M. Takemoto2, K. Yokote2, A. Araki3,  
H. Sone4, H. Noto5, M. Noda5;  
1Department of Geriatrics, Nagoya University Graduate School of Medicine, 
2Division of Diabetes, Metabolism and Endocrinology, Department 
of Internal Medicin, Chiba University Graduate School of Medicine, 
3Division of Diabetes, Metabolism and Endocrinology, Tokyo Metropolitan 
Geriatric Hospital, 4Department of Internal Medicine, Endocrinology and 
Metabolism, Niigata University Graduate School of Medicine,  
5Department of Diabetes and Metabolic Medicine, National Center for 
Global Health and Medicine, Tokyo, Japan.
Background and aims: High LDL-cholesterol (LDL-C) and glucose levels are 
risk factors for ischemic heart disease (IHD) in middle-aged diabetic indi-
viduals; however, the risk among the elderly, especially late elderly older than 
75y.o., is not well known. The aim of this study was to identify factors that 
predict IHD and cerebrovascular attack (CVA) in the elderly and to investi-
gate their differences by age, especially legend effect.
Materials and methods: We performed a prospective cohort study (Japan 
Cholesterol and Diabetes Mellitus Study) with 9.1 years of follow-up. A to-
tal of 4,014 patients with type 2 diabetes and without previous IHD or CVA 
(1,936 women; age 67.4±9.5 years, median 70 years; <65 years old, n=1,261; 
65 to 74 years old, n=1,731; and ≥ 75 years old, n=1,016) were recruited on 
a consecutive outpatient basis from 40 hospitals throughout Japan. Lipids, 
glucose, and other factors related to IHD or CVA risk, such as blood pressure 
(BP), were investigated using the multivariate Cox hazard model.
Results: Two hundred eighteen cases of IHD and 138 CVAs (7.8 and 
5.7/1,000 people per year, respectively) occurred over 8.8 years. Systolic 
blood pressure on registration was correlated with IHD in all patients (haz-
ard ratio (HR):1.012, P<0.05). LDL-cholesterol (LDL-C) on registration was 
correlated with IHD in patients >75 years old (HR:1.014, P<0.01). In contrast, 
fasting plasma glucose, HDL-C and age were correlated with CVA in all sub-
jects (P<0.05) and HDL-C was correlated with CVA in all three generations 
(75 years old). Fasting plasma glucose and glycated hemoglobin(HbA1C) was 
correlated with CVA in patients of 65 to 74 years old. Age was correlated 
in patients >75 years old. Kaplan-Meier estimator curves showed same ten-
dency, however, laboratory data on registration (legend effect) and those just 
before events (IHD and CVA) affects differently.
Conclusion: IHD and CVA in late elderly diabetic patients were predicted 
by LDL-C or HDL-C. LDL-C, fasting blood glucose, HbA1C and SBP may 
have the effect for atherosclerotic events (IHD or CVA) as legend effect, age 
dependently. These age-dependent differences in risk are important for devel-
oping individualized strategies to prevent atherosclerotic disease.
Clinical Trial Registration Number: UMIN-CTR, UMIN00000516
Supported by: Japanese Ministry of Health, Welfare and Labor
PS 108 Predicting complications II
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Silent, advanced coronary artery disease in type 1 diabetes of forty years 
duration is prevalent and associated with glycaemic control
K. Sveen1, K. Dahl-Jørgensen2, W. Magyar3, M. Tuzcu4, M. Brekke5,  
K.F. Hanssen1;  
1Dept. endocrinology, Oslo University Hospital, 2Dept. of pediatrics, Oslo 
University Hospital, Norway, 3Imaging Core Laboratory, Cleveland Clinic, 
4Cleveland Clinic, USA, 5Oslo University Hospital, Norway.
Background and aims: The natural history and the pathophysiology of ath-
erosclerotic disease in type 1 diabetes is not known in detail. We therefore 
studied in detail the progression of atherosclerosis in a uniquely character-
ized cohort of type 1 diabetes with a long duration of the disease and defined 
factors associated with the progression of atheroscleosis in this population.
Materials and methods: The Oslo study cohort originally started in 1982. 
Fourty-five individuals with type 1 diabetes were randomized and included. 
In 1999 a subpopulation of 29 participants, not significantly different from 
the total group, without signs or symptoms of coronary heart disease were 
evaluated for coronary artery disease with exercise ECG, quantitative coro-
nary angiography (QCA) and intravascular ultrasound (IVUS). Twenty- six 
of these participants were enrolled for the same examination in 2009 (mean 
age 53 (7)). Twenty-three of these had technical adequate IVUS pullbacks for 
analysis. By QCA a vessel stenosis >50% of lumen diameter were classified 
as significant. By IVUS, an intimal thickness above 0.3mm was considered 
significant. % vessel area stenosis was defined as plaque area divided by vessel 
area x100.
Results: The QCA and IVUS results from 1999 and 2009 are reported in table 
1. A total of 3264 arterial segments in 63 vessels were evaluated with IVUS in 
this last follow-up. In 1999 ten of the patients had mild atherosclerotic disease 
(% vessel area stenosis <20) whereas all had progressed to moderate to severe 
atherosclerosis examined by IVUS (% vessel area stenosis >20%) in 2009. We 
observed that HbA1c and LDL cholesterol levels ten years before this last 
follow-up were associated with progression of % vessel area stenosis, β 0.1 
(0.01-0.2), p=.030 and β 0.12 (0.3-0.33),p= 0.0013, respectively.
Conclusion: Our data show no over-all progression of severe atherosclerosis 
evaluated by QCA. The plaque thickness was not significantly changed over 
ten years. However, the IVUS examinations revealed a progression of moder-
ate to advanced atherosclerosis over ten years in type 1 diabetes patients of 
forty years disease duration. This despite that many of the participants used 
statins for many years. One of the reasons for the discrepancy in QCA and 
IVUS may be that remodelling in the coronary vessels underestimates the ste-
nosis on QCA. Our data show the need to evaluate coronary atherosclerosis 
thoroughly in long term type 1 diabetes and reconfirm that LDL and blood 
glucose through many years may be main drivers of the process. Our findings 
are novel as there are no other studies with longitudinal data of the athero-
scleotic process evaluated by QCA and IVUS in long term type 1 diabetes 
with silent macrovascular disease.
Supported by: South-Eastern Norway Health authority, Oslo Diabetes research 
centre
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Impact of gender on the risk of coronary atherosclerosis and 
cardiovascular events conferred by HbA1c in subjects without known 
diabetes
A. Muendlein1, C.H. Saely2,3, A. Vonbank2, D. Zanolin1,3, P. Rein2,  
H. Drexel2,4;  
1VIVIT Institute, Feldkirch, Austria, 2Academic Teaching Hospital 
Feldkirch, Austria, 3Private University of the Principality of Liechtenstein, 
Triesen, Liechtenstein, 4Drexel University College of Medicine, Philadelphia, 
USA.
Background and aims: Diabetes confers a larger increase in the relative risk 
of cardiovascular events among women than among men. Whether gender 
also affects the association of HbA1c with coronary atherosclerosis and car-
diovascular events among subjects without known diabetes is unknown.
Materials and methods: We enrolled a large consecutive series of 1479 pa-
tients undergoing coronary angiography for the evaluation of established or 
suspected coronary artery disease (CAD), including 495 women and 984 
men who did not have previously known diabetes Significant CAD was diag-
nosed in the presence of significant coronary stenoses ≥50%. Prospectively, 
we recorded cardiovascular events over 4.4±1.2 years.
Results: Among women, 36.4%, 56.2%, and 7.4% and among men 44.2%, 
46.6%, and 9.1% had HbA1c values of <5.7% (normal according to ADA cri-
teria), 5.7-6.4% (at risk of diabetes according to ADA criteria), and ≥6.5% 
(diabetes according to ADA criteria), respectively. The prevalence of angio-
graphically diagnosed significant CAD in these HbA1c categories was 31.2%, 
38.2%, and 47.2% among women (ptrend = 0.041) and 63.2%, 65.3% and 
64.8% among men (ptrend = 0.589). An interaction term gender x HbA1c 
was statistically significant (p<0.001), indicating that the association of 
HbA1c with CAD was significantly stronger among women than among 
men. During follow-up, the incidence of cardiovascular events was 21.5% in 
women and 28.5% in men (p=0.002). Among women, HbA1c strongly and 
significantly predicted cardiovascular events (adjusted OR for a 1% increase 
in HbA1c (HR 2.08 [1.24-3.03]; p<0.001), but not among among men (HR 
1.12 [0.94-1.53]; p=0.145). An interaction term gender x HbA1c again was 
statistically significant (p=0.011), indicating that HbA1c was a significantly 
stronger predictor of cardiovascular events among women than among men.
Conclusion: We conclude that gender significantly modulates the risk of 
coronary atherosclerosis and cardiovascular events conferred by HbA1c in 
subjects without known diabetes.
1218
Diabetes is not a coronary artery disease risk equivalent among women
H. Drexel1,2, C.H. Saely1,3, A. Vonbank1, D. Zanolin4,3, P. Rein1;  
1Academic Teaching Hospital Feldkirch, Austria, 2Drexel University College 
of Medicine, Philadelphia, USA, 3Private University of the Principality of 
Liechtenstein, Triesen, Liechtenstein, 4VIVIT Institute, Feldkirch, Austria.
Background and aims: Diabetes per se is widely considered a coronary ar-
tery disease (CAD) risk equivalent, particularly among women. We aimed at 
investigating the contribution of baseline coronary atherosclerosis to the risk 
of diabetic women for future vascular events in a prospective cohort study on 
subjects who were characterized by coronary angiography at baseline.
Materials and methods: Vascular events were recorded over 10 years in 598 
consecutive women undergoing coronary angiography for the evaluation of 
established or suspected stable CAD.
Results: From our women, 271 had neither type 2 diabetes (T2DM) nor sig-
nificant CAD (i.e. coronary stenoses ≥50%) at the baseline angiography, 79 
had T2DM but not significant CAD, 152 did not have T2DM but had sig-
nificant CAD, and 96 had both T2DM and significant CAD. Non-diabetic 
women without significant CAD had an event rate of 12.5%. The event rate 
was similar in T2DM women without significant CAD (15.2%; p=0.749), 
but higher in non-diabetic women with significant CAD (32.9%; p<0.001). 
Women with both T2DM and significant CAD had the highest event rate 
(43.8%; p<0.001). Importantly, T2DM women without significant CAD had a 
significantly lower event rate than non-diabetic women with significant CAD 
(p=0.003).
Conclusion: We conclude that T2DM per se is not a CAD risk equivalent 
among women. Moderate-risk diabetic women without significant CAD and 
very high-risk diabetic women with significant CAD add up to a grand total 
of high-risk diabetic women. This is why diabetes seems to be a CAD risk 
equivalent in many epidemiological studies.
1219
Comparison of renal function markers for risk prediction in subjects 
with type 2 diabetes (ZODIAC-47)
A.E. Timmer1,2, I.J. Riphagen1,2, I. Drion1, A. Alkhalaf1, G.W.D. Landman1, 
K.H. Groenier1,2, G. Navis3, H.J.G. Bilo1,3, N. Kleefstra1,4, S.J.L. Bakker3;  
1Diabetes Centre, Isala Clinics, Zwolle, 2Departments of Internal Medicine 
and General Practice, UMCG, 3Department of Internal Medicine, UMCG, 
4Department of Internal Medicine, UMCG, Groningen, Netherlands.
Background and aims: Advanced chronic kidney disease, one of the compli-
cations in type 2 diabetes, is a well known predictor for cardiovascular (CV) 
disease and mortality. Since measurement of glomerular filtration rate (GFR) 
is complex, clinical laboratories currently report an estimated GFR based on 
serum creatinine (SCr) measurement. Cystatin C was suggested to more ac-
curately reflect kidney function and to improve risk prediction for the risk of 
death. However, it is not known whether other renal markers such as urea, 
uric acid and potassium improve risk prediction of CV and all-cause mortal-
ity. Our aim was to compare the predictive performance of these markers in 
type 2 diabetes.
Materials and methods: Patients with DM2 participating in the Zwolle Out-
patient Project Integrating Available Care (ZODIAC) study were included. 
Cox regression analyses were used to investigate the associations of the renal 
markers with CV and all-cause mortality. Our multivariable model consisted 
of CV risk factors including age, sex, BMI, smoking, systolic blood pressure, 
total cholesterol-to-HDL ratio, duration of diabetes, HbA1c, use of RAAS-in-
hibitors, history of CV diseases and log albumin-to-creatinine ratio. Harrell’s 
C statistics were used to compare the predictive performance of the markers.
Results: We included 1,185 patients (46% male, age 67 ± 12 years). Mean 
plasma concentrations of SCr, cystatin C, urea, uric acid and potassium were 
95 ± 21 µmol/L, 1.0 ± 0.3 mg/L, 6.7 ± 2.3 mmol/L, 0.33 ± 0.09 mmol/L and 
4.4 ± 0.4 mmol/L, respectively. After median follow-up for 5.5 [IQR 3.1-
10.1] years, 354 patients died (30%), with 149 deaths (13%) attributable to 
CV causes. Univariable associations of the markers (per SD increase) with 
CV and all-cause mortality are shown in Table 1. In univariable Cox regres-
sion analyses, all markers were significantly associated with CV and all-cause 
mortality, with the highest C statistics for cystatin C. If renal markers were 
added to multivariable models, all renal markers except potassium remained 
independent predictors for CV and all-cause mortality, but the added value in 
terms of increase in C-statistic was limited and insignificant for all markers.
Conclusion: In type 2 diabetes, we found that cystatin C was a better predic-
tor of CV and all-cause mortality than SCr, urea, uric acid and potassium. 
After adjustment for known CV risk factors, there was no added value in 
predictive performance for any of the studied markers.
Supported by: GSK, Gentian
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Impaired kidney function is a diabetes risk equivalent in patients with 
established coronary artery disease
H. Winkler1, C.H. Saely2,3, D. Zanolin1,3, A. Vonbank2, P. Rein2, H. Drexel2,4;  
1VIVIT Institute, Feldkirch, Austria, 2Academic Teaching Hospital, 
Feldkirch, Austria, 3Private University of the Principality of Liechtenstein, 
Triesen, Liechtenstein, 4Drexel University College of Medicine, Philadelphia, 
USA.
Background and aims: Type 2 diabetes (T2DM) is a paramount risk fac-
tor for cardiovascular disease, in particular among patients with established 
coronary artery disease (CAD). Similarly, chronic kidney disease (CKD) con-
fers a high risk of cardiovascular events. We aimed at investigating the single 
and joint effects of T2DM and of CKD on cardiovascular risk in patients with 
angiographically proven CAD.
Materials and methods: We prospectively recorded cardiovascular events 
over 10 years in a cohort of 1423 patients with angiographically proven CAD. 
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CKD was defined as an estimated glomerular filtration rate (eGFR) <60ml/
min/1.73m².
Results: The risk of cardiovascular events was significantly higher in T2DM 
patients (n=171) than in non-diabetic subjects (39.1% vs. 28.7%; p <0.001) 
and also was higher in patients with CKD (n=116) compared to those with 
an eGFR ≥60ml/min/1.73m² (47.2% vs. 28.7%; p <0.001). When both, T2DM 
and CKD were considered, 841 subjects had neither T2DM nor CKD, 336 
had T2DM but not CKD, 145 did not have diabetes but had CKD, and 101 
had both diabetes and CKD. When compared with the event rate among pa-
tients with neither T2DM nor CKD (26.3%), event rates were significantly 
higher in patients with T2DM who did not have CKD (34.8%; p=0.007) and 
in non-diabetic patients with CKD (42.8%; p=0.020) and were highest in pa-
tients with both, T2DM and CKD (53.5%; p <0.001). Further, patients with 
both, T2DM and CKD were at a significantly higher event risk than those 
with T2DM but no CKD (p=0.011) and those without T2DM but with CKD 
(p=0.048). Event rates were similar in patients with T2DM but not CKD and 
in non-diabetic patients with CKD (p=0.798).
Conclusion: We here report the novel findings that CKD and T2DM contrib-
ute synergistically to cardiovascular event risk and that CKD is a T2DM risk 
equivalent in patients with established coronary artery disease.
1221
Associations between BMI, HbA1c and mortality among people with 
screen-detected type 2 diabetes. ADDITION-Denmark
L. Grønbæk1, A. Sandbæk1, M.V. Skriver2;  
1Section for General Practice, 2Section for Health Promotion and Health 
Services, Department of Public Health, Aarhus, Denmark.
Background and aims: The associations between HbA1c, BMI, cardiovascu-
lar morbidity and all-cause mortality have earlier been investigated among 
people with type 2 diabetes, but not in the same study and previous results 
have been divergent. The obesity paradox implies greater survival among 
people with chronic diseases who are overweight or slightly obese compared 
to normal weight individuals. Considering this, we aim to examine whether 
BMI among people with screen-detected type 2 diabetes modify the asso-
ciations between 1) HbA1c and cardiovascular morbidity and 2) HbA1c and 
all-cause mortality.
Materials and methods: This is a cohort study including 1533 patients aged 
40-69 years with type 2 diabetes identified through the Danish arm of the 
Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-
detected Diabetes in Primary Care (ADDITION-DK). At baseline, HbA1c, 
BMI and cardiovascular risk factors were measured and information on 
medication, lifestyle and socioeconomic status were provided by means of 
a questionnaire. At follow-up, information on death or discharge from a 
Danish hospital were obtained from national registers. Information on BMI 
were available for 1489 patients. Five groups were formed according to BMI. 
Hazard ratios for the associations between baseline HbA1c, cardiovascular 
morbidity and all-cause mortality will be estimated in each group using Cox 
multivariate regression model. The results will be adjusted for sex, age, medi-
cation, lifestyle, socioeconomic status and comorbidity.
Results: Baseline characteristics are shown in table 1. Preliminary results 
indicate that among people with screen-detected type 2 diabetes those with 
BMI ≥35 tend to be younger than those with BMI <35. The percentage of 
current smokers and the consumption of alcohol seem to be higher among 
people with BMI <30 compared to people with BMI ≥30. Interestingly the 
proportions of people with HbA1c >7% appear to be equally distributed 
among the five BMI groups and likewise there are no immediate differences 
in systolic blood pressure and levels of cholesterol.
Conclusion: Full results and conclusions concerning the associations be-
tween HbA1c, cardiovascular morbidity and all-cause mortality will be pre-
sented at EASD Annual Meeting 2014. Our data indicate that a high BMI 
increases the risk of diabetes as individuals in the heaviest group tend to have 
developed diabetes at an younger age. Overall our full results will play a part 
in optimizing treatment strategies by clarifying the basis of rational treat-
ment. Importantly our results will also contribute to an overview of influen-
tial factors regarding prognosis for people with type 2 diabetes. Such identi-
fication may help general practitioners to direct attention to those with the 
poorest prognosis and consequently act at an earlier stage. This per se could 
reduce or delay complications to diabetes.
Clinical Trial Registration Number: NCT00237549
Supported by: National Health Service, Danish Council Strategic Research, 
Novo Nordisk DK
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Development of a prediction model for fatal and non-fatal  
coronary heart disease and cardiovascular disease in patients with  
newly-diagnosed type 2 diabetes mellitus
J.A. Piniés1, F. Gonzalez-Carril2, I. Irigoien3, J.M. Arteagoitia2,  
J.M. Altzibar2, J.L. Rodriguez-Murua2, L. Echevarriarteun2,  
Basque Country Sentinel Practice Network;  
1Endocrinology and Nutrition Department, Cruces University Hospital, 
Barakaldo, 2Department of Health. Basque Government, Epidemiology 
Unit, Public Health Service, Vitoria-Gasteiz, 3Department of Computation 
Science and Artificial Intelligence, University of the Basque Country (UPV-
EHU), Donostia, Spain.
Background and aims: To construct a model for predicting CHD, and car-
diovascular disease (CVD) risk in newly-diagnosed type 2 diabetic patients 
in a southern European region. External validation of two other cardiovascu-
lar risk models and internal validation of our developed model were assessed.
Materials and methods: A 10-year prospective population-based cohort 
study was performed with 777 newly-diagnosed type 2 diabetic patients 
older than 24 years in a Sentinel Practice Network. Cardiovascular risk fac-
tors, CVD events, and mortality were registered. The patients without CVD 
at baseline (659/777) who had data available for all variables (605/659) were 
included. Coefficients for the significant predictors of fatal/non-fatal CHD, 
and CVD were estimated using Cox models. Discrimination and calibration 
of the United Kingdom Prospective Diabetes Study risk engine (UKPDS-RE), 
the Framingham Risk Score-Regicor Study (FRS-RS), and the cardiovascular 
risk model we developed were assessed
Results: Beta coefficients, and standard error (SE) and HRs of risk factors 
in the best-fitting multivariable 5-year risk model for fatal/non-fatal CHD 
and CVD are shown in the table. The variable selection procedure identified 
baseline risk factors for fatal/non-fatal CHD, and CVD. Significant risk fac-
tors were age, non-HDL:HDL, and HbA1c for 5-yr risk prediction of CHD 
and the factors mentioned above, plus SBP and smoking, for 5-yr CVD risk 
prediction. In the CHD risk prediction equation, high SBP (TA≥ 140 mmHg) 
was an independent, significant stratified variable. All of the risk factors that 
were retained through the variable selection procedure were incorporated 
into the Bask Country risk engine (BASCORE). Therefore, the risk of fatal/
non-fatal CHD increased 24% for each 1% increase in HbA1c or 74% if the 
non-HDL:HDL was >5. The risk of fatal/non-fatal CVD increased 19% for 
each 1% increase in HbA1c, 2% for each mmHg of SBP or 19% for each 1 
unit of increase in non-HDL:HDL ; the risk was reduced by 64% if the patient 
was not a smoker. The UKPDS-RE and FRS-RS showed inadequate discrimi-
nation and calibration for predicting CHD risk. The internal discrimination 
and calibration of the developed model were acceptable for predicting fatal/
non-fatal 2-, and 5-, but not 10-year CHD and CVD risk
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Conclusion: This study is the first southern European validated population-
derived model for predicting 5-year fatal/non-fatal CHD and CVD risk in 
newly-diagnosed type 2 diabetic patients
1223
Single and joint effects of obesity and of the metabolic syndrome on 
cardiovascular event risk
C.H. Saely1,2, D. Zanolin3,2, A. Vonbank1, P. Rein1, H. Drexel1,4;  
1Academic Teaching Hospital Feldkirch, Austria, 2Private University  
of the Principality of Liechtenstein, Triesen, Liechtenstein,  
3VIVIT Institute, Feldkirch, Austria, 4Drexel University College of Medicine, 
Philadelphia, USA.
Background and aims: Obesity is a major risk factor for the metabolic syn-
drome (MetS), but some obese individuals do not have the MetS while others 
have the MetS but are non-obese. We prospectively investigated the single 
and joint effects of obesity and of the MetS on cardiovascular event risk.
Materials and methods: Cardiovascular events were prospectively recorded 
over 10 years in a large cohort of 1705 patients undergoing coronary angiog-
raphy for the evaluation of established or suspected stable coronary artery 
disease. Obesity was defined as a BMI ≥30kg/m²; presence of the MetS was 
defined according to the current harmonized consensus definition.
Results: From our patients, 827 were non-obese and did not have the MetS, 
443 were non-obese but had the MetS, 113 were obese but did not have the 
MetS, and 322 were obese and had MetS. Cardiovascular event risk was 34.1% 
in non-obese patients with the MetS. It was significantly higher in this pa-
tient group when compared to non-obese subjects without the MetS (25.3%; 
p<0.001), when compared to obese subjects without the MetS (22.1%; 
p=0.036), and even when compared to obese subjects with the MetS (25.2%; 
p=0.006).
Conclusion: We conclude that non-obese patients with the MetS face a par-
ticularly unfavourable cardiovascular prognosis.
PS 109 Predicting complications III
1224
Age, insulin requirements, waist circumference and triglycerides predict 
hypogonadism in type 1 diabetic patients
J.J. Chillarón1, M. Fernandez-Miró2, M. Albareda3, J.A. Flores-Le Roux1,  
C. Colom2, S. Fontserè1, J. Pedro-Botet1, L. Vila3, TEST-DM1 study group;  
1Hospital del Mar, 2Centre d´Atenció Integral Dos de Maig,  
3Hospital Sant Joan Despí-Moisés Broggi, Barcelona, Spain.
Background and aims: The prevalence of hypogonadotropic hypogonadism 
(HH) in patients with type 2 diabetes mellitus is higher than in the general 
population and leads to detrimental effects on metabolic control, lipid profile 
and body composition. Few studies have examined its role in type 1 diabetes 
mellitus (T1DM). Aims: To characterize patients with T1DM and HH and to 
evaluate risk factors for this condition.
Materials and methods: Cross-sectional study including T1DM men over 18 
years of age with a T1DM duration greater than six months, attended in the 
outpatient clinic of two hospitals between march-december 2013. A sample 
of fasting venous blood was taken to measure HbA1c, lipid profile, total tes-
tosterone, LH, FSH, SHBG and albumin. History of micro and macrovascular 
complications, hypertension, dyslipidemia and diabetes duration was gath-
ered. Clinical examination included weight, height, hip and waist circumfer-
ences and blood pressure. Metabolic syndrome was diagnosed according to 
the NCEP-ATP III criteria and the CUN-BAE equation was used to estimate 
the percentage of body fat. HH was defined as total testosterone less than 8 
nmol/L or a calculated free testosterone less than 225 pmol/L, with normal/
low levels of LH and FSH. Statistical analysis: Student’s t-test was performed 
to assess differences between two means. For non-normally distributed vari-
ables, Mann-Whitney U test was used. Either χ2 test or Fisher’s exact test 
was used to examine the degree of association of categorical variables. An 
experimental model to calculate HH risk was created (HH-Score) using the 
value of incremental odds for variables predisposing to HH (age, insulin 
requirements, waist circumference and triglycerides). HH Score = (1.060 x 
Age) + (1.084 x Waist circumference) + (14.00 x Insulin requirements) + Tri-
glycerides, where age is expressed in years, waist circumference in cm, insulin 
requirements in IU/kg/d and triglycerides in mg/dL.
Results: 157 patients with a mean age of 44.7 ± 13.1 years and a mean T1DM 
duration of 19.2 ± 12.7 years were included in the study. HbA1c levels were 
7.9 ± 1.3%. Fifteen patients had HH, representing a prevalence of 9.55% (95% 
CI: 5.0-14.1%).
HH patients presented more frequently hypertension (80.0% vs 47.2%, P 
<0.001) and peripheral neuropathy (33.3% vs 12.9%, P <0.05). No differences 
in other T1DM complications were detected. An HH-Score > 242.4 showed 
a 100% sensitivity and a 51.4% specificity for HH diagnosis. The positive and 
negative predictive values were 17.8% and 100%, respectively.
Conclusion: One in 10 patients with T1DM has HH. A simple formula, in-
cluding easy and available clinical parameters and trygliceride levels, can pre-
dict HH risk; an HH-Score < 242.4 excludes the diagnosis of HH in T1DM 
patients.
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Association between obstructive sleep apneas and complications  
of type 2 diabetes
C. Langrand1, J. Glerant2, F. Gormand3, J. Guerin4, P. Moulin1;  
1Endocrinology, Diabetology and Metabolic Diseases, Hôpital 
Cardiologique Louis Pradel, 2Pneumology, Hôpital Cardiologique Louis 
Pradel, Bron, 3Pneumology, Centre Hospitalier Lyon Sud, Pierre Benite, 
4Pneumology, Hôpital de la Croix Rousse, Lyon, France.
Background and aims: Obstructive sleep apneas are highly prevalent in 
diabetes subjects. Chronic intermittent hypoxia and sleep fragmentation in-
duced by sleep apnea increase sympathetic nervous system activity, oxidative 
stress and inflammation. These alterations are also involved in the develop-
ment of diabetes complications, more especially in microvascular complica-
tions. The aim of this study was to establish an association between obstruc-
tive sleep apnea severity and complications of type 2 diabetes.
Materials and methods: A retrospective observational study was set up in 
68 type 2 diabetic patients with obstructive sleep apnea syndrome (OSAS). 
Respiratory parameters of obstructive sleep apnea and occurrence of diabetes 
complications were reported between diagnosis of sleep apnea and a mean 
follow-up of 4 years.
Results: Participants were diabetic subjects with high cardiovascular risk. 
Most of them presented a severe OSAS (73%). Mean nocturnal oxygen 
saturation and time spent with oxygen saturation < 90% were significantly 
impaired in presence of microvascular complications compared to absence 
of microvascular complications (90% vs. 93% and 29% vs. 7% respectively, 
p<0,005). Using logistic regression analysis, occurrence of long-term mi-
crovascular complications was independently associated with hypoxemia 
indexes (OR=0,691[0,530-0,902] p=0,007), regardless of adherence to CPAP 
therapy, age, sex, BMI, HbA1C and diabetes duration. Diabetic nephropathy 
was predicted both by hypoxemia indexes and diabetes duration. No correla-
tion was found between apnea hypopnea index (AHI) and any diabetes com-
plications. Optimal adherence to CPAP therapy did not improve metabolic 
parameters or prevent microvascular complications. However, myocardial 
infarctions were more prevalent in subjects with weak adherence to CPAP 
therapy (+17% vs. +9%; p=0,03).
Conclusion: The independent association between hypoxemia indexes and 
microvascular complications suggests that chronic intermittent hypoxia in-
duced by sleep apneas could contribute to the progression of microvascu-
lar complications in type 2 diabetes. Theses findings support the need of a 
specific trial to test the hypothesis of an effect of CPAP therapy in order to 
prevent microvascular diabetic complications.
1226
Ectopic fat in the pancreas can predict diabetes complications in  
non-obese subjects
H.-S. Kwon, M.-K. Kim, S.-H. Lee, B.-Y. Cha;  
Department of Internal Medicine, The Catholic University of Korea, Seoul, 
Republic of Korea.
Background and aims: Evidence that pancreatic steatosis has a role in obe-
sity, metabolic syndrome and type 2 diabetes mellitus (DM) is emerging. 
However, data on the influence of pancreatic steatosis on DM complications 
are lacking.
Materials and methods: We examined 198 patients with type 2 DM. Pancre-
atic computed tomography (CT) attenuations were assessed using CT imag-
ing. Obesity was defined as BMI ≥ 25 kg/m2 according to the Asian-specific 
BMI cut-offs. We defined pancreatic steatosis as pancreatic attenuations be-
low median levels.
Results: The pancreatic attenuations was significantly correlated with age 
(r = −0.302, p < 0.001), visceral fat area (r = −0.194, p = 0.006) and vascu-
lar stiffness (r = −0.242, p = 0.001). In the non-obese group (BMI < 25 kg/
m2), pancreatic steatosis was associated with a higher prevalence of diabetic 
complications reflecting retinopathy, nephropathy, carotid artery plaque and 
vascular stiffness. In the non-obese group, patients with pancreatic steatosis, 
compared with those without, had an odds ratio (OR) of 5.6 (95% confidence 
intervals [CI] 1.4 - 22.7) for diabetic retinopathy, 3.5 (95% CI 1.3-9.4) for 
diabetic nephropathy and 3.1 (95% CI 1.2 - 8.1) for carotid artery plaque, 
after adjusting for age, gender and BMI. However, significant associations 
between pancreatic steatosis and diabetic complications were not found in 
the obese group.
Conclusion: Pancreatic steatosis is associated with increased diabetic com-
plications in non-obese subjects with type 2 DM. This finding highlights the 
importance of pancreatic fat deposits associated with the presence of diabetic 
complications, especially in non-obese subjects.
1227
Ketosis-prone diabetes is associated with less microvascular 
complications in sub-Saharan African patients
B. Baz1, J.-L. Nguewa1, S.P. Choukem2, E. Sobngwi3, M. Ait Djoudi1,  
P. Boudou4, J.-P. Riveline1, J.-F. Gautier1;  
1University Center for Diabetes and its Complications, Endocrinology and 
Diabetology Department, Lariboisiere Hospital, Paris, France, 2Department 
of Clinical Science, University of Buea, 3National Obesity Center, 
Endocrinology and Diabetology Department, Central Hospital of Yaounde, 
Cameroon, 4Hormonology Department, Saint Louis Hospital, Paris, France.
Background and aims: Ketosis-prone diabetes (KPD) is a heterogeneous 
syndrome characterized by ketoacidosis or unprovoked ketosis but do not 
necessarily have the typical phenotype of autoimmune type 1 diabetes. Data 
from longitudinally followed cohorts have shown that the clinical features 
of KPD are “intermediate” between type 1 and type 2 diabetes (T2D). Long-
term complications in KPD are not well studied. Our aim was to evaluate the 
prevalence of long-term microvascular complications in KPD patients com-
pared with T2D patients.
Materials and methods: Data from our KPD cohort register and medical 
files of T2D patients attending our department were restrospectively analysed 
and compared. Only patients of sub-Saharan African origin were included.
Results: A total of 80 patients (40 KPD vs 40 T2D) were evaluated. Both 
groups were matched on sex (female to male ratio 1:4) and diabetes dura-
tion (11.5±4.6 (SD) years). They had similar mean age (55.3±7.7 vs 56.5±8.9 
years) and mean BMI (28.6±5 vs 29.4±5 kg/m²). There was no significant 
difference between mean HbA1c (8.8±2.2 vs 8.4±1.2 % p=0.42). The number 
of patients with diabetic retinopathy (18 vs 27 patients) and nephropathy (8 
vs 19 patients) were higher in T2D (p<0.05). There was no significant differ-
ence between the two groups regarding the diabetic neuropathy prevalence.
Conclusion: Some long-term microvascular diabetes complications are less 
prevalent in KPD patients compared with T2D patients. The protecting fac-
tors and mechanisms remain to be revealed.
1228
Risk association of triglycerides variability with microvascular 
complications even in well-controlled type 2 diabetes
G. Bardini1, M. Innocenti1, C.M. Rotella1, E. Mannucci2, S. Giannini3;  
1Obesity Agency, 2Diabetology Agency,  
3Endocrinology Unit, University of Florence, Italy.
Background and aims: The risk of microvascular complications increases as 
the mean of glycated haemoglobin (HbA1c) levels increases. Recently, HbA1c 
variability seems to be an independent risk factor for diabetic microangiopa-
thy. Basic and clinical studies strongly showed that hyperlipidemia acceler-
ates the progression of microangiopathy. In particular, hypertriglyceridemia 
has an important role in the progression of diabetic kidney disease, while 
retinopathy (DR) is less clearly associated. Since no data are available, aim of 
this study was to examine the association between HbA1c and TG variability 
on the development of DR and nephropathy in type 2 diabetes (T2DM).
Materials and methods: Clinical and anthropometric data, HbA1c and lipid 
profile were serially recorded in each visit in 450 T2DM clinic outpatients 
(mean age 68.7 years, with 48.6% females) examined from 2007 to 2014. Pa-
tients who had a history of microangiopathy previous the baseline visit were 
excluded. HbA1c and TG variability, measured as the intrapersonal standard 
deviation (SD) of serially collected data, were compared in patients who did 
and did not develop DR or nephropathy. Retinopathy was assessed by dilated 
fundoscopy and diabetic nephropathy was defined based on micro-macroal-
buminuria. The association between TG variability and the development of 
nephropathy was determined by Cox regression analysis adjusted for age, sex, 
BMI, smoking, duration of diabetes, blood pressure, therapies.
Results: All subjects showed a mean HbA1c 7.2% and a mean duration of 
disease 13.8 years. Among patients studied, 88.0% were treated only with oral 
hypoglycemic drugs, 12.0% with insulin, 71.5% with statins and 68.0% as-
sumed renin-angiotensin system antagonists. Over a mean follow-up period 
of 6.8 years, 9.8% and 27.1% of patients developed retinopathy and nephropa-
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thy, respectively. Patients who progressed to retinopathy had higher mean 
HbA1c (7.4±0.8% vs 6.8±0.7%, p<0.001) and SD (0.63±0.3% vs 0.50±0.4%, 
p<0.05) than nonprogressors. Similarly, patients who developed nephropathy 
had higher mean HbA1c (7.1±0.8% vs 6.8±0.7%, p<0.05) and SD (0.60±0.4% 
vs 0.50±0.4%, p<0.05). Considering TG variability, no significant differences 
were observed between progressors and nonprogressors for retinopathy. In-
stead, patients who developed nephropathy had higher mean TG (170.2±65.0 
mg/dl vs 133.0±47.6 mg/dl, p<0.001) and TG-SD (52.1±30.0 mg/dl vs 
35.5±24.2 mg/dl, p=0.001) than nonprogressors. Cox analysis, adjusted for 
potential risk factors, showed that TG-SD was associated with nephropathy 
with HR of 2.2 (95% CI 1.2-4.3, p=0.014). Analyzing data from subjects with 
HbA1c-mean upper or below 7%, in patients with HbA1c>7%, as expected, 
the presence of hypertriglyceridemia (TG>150 mg/dl) increased the preva-
lence of nephropathy (from 31.6% to 43.0%, p<0.001). Of particular inter-
est, an increased prevalence of nephropathy was also observed in subjects at 
therapeutical target with HbA1c-mean<7% (from 17.4% to 31.0%, p<0.001). 
Instead, independently of HbA1c levels considered, the TG were not associ-
ated to significant differences in the prevalence of retinopathy (from 4.3% to 
4.8%, p=0.68).
Conclusion: The TG levels and their variability affect the development of 
diabetic nephropathy. This effect seems to be additive over HbA1c mean and 
variability even in patients at target for HbA1c levels.
1229
Low levels of serum insulin-like growth factor-I increase the risk of 
osteoporotic fracture and mortality in postmenopausal women with  
type 2 diabetes mellitus
H. Miyake, I. Kanazawa, T. Yamaguchi, T. Sugimoto;  
Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Japan.
Background and aims: Osteoporosis became a social problem in industri-
alized countries because osteoporotic fractures are associated with low mo-
bility and high mortality. Accumulating evidence has shown that the risk of 
osteoporotic fractures is increased in type 2 diabetes mellitus. Since the risk 
is independent of bone mineral density (BMD), the measurement of BMD, 
which is a gold standard to detect primary osteoporosis, is not useful for 
screening diabetes-related bone fragility. Therefore, it is an important issue to 
find evaluation tools to assess the risk of future osteoporotic fracture instead 
of BMD measurement in type 2 diabetes. Insulin-like growth factor-I (IGF-
I) is well-known to have anabolic effects on bone. In addition, serum IGF-I 
levels were reported to be associated with the presence of vertebral fracture. 
We previously showed that serum IGF-I levels was inversely associated with 
the prevalence and severity of vertebral fractures independent of BMD. We 
thus hypothesized that serum IGF-I was involved in the etiology of diabetes-
related bone fragility and its serum levels might be a clinically useful marker 
for assessing future fracture risk in type 2 diabetes mellitus. In this study, we 
examined the association between serum IGF-I levels and the incidence of 
fracture as well as mortality in postmenopausal women with type 2 diabetes 
mellitus.
Materials and methods: In this study, we recruited 197 postmenopausal 
women with type 2 diabetes mellitus whose serum IGF-I levels and BMD at 
lumbar spine (L-BMD) were previously measured from 1993 to 2009 at Shi-
mane university hospital. Medical doctors interviewed the history of the sub-
jects with special attention to osteoporotic fractures in 2013. Student’s t tests 
and multiple regression analyses were performed to examine the association 
of the incidence of osteoporotic fracture and death after IGF-I measurement 
with serum IGF-I levels.
Results: Of 197 subjects, 27 patients died, and 24 patients suffered from new 
osteoporotic fracture. Serum IGF-I levels were marginally lower in patients 
with osteoporotic non-vertebral fractures than in those without them (118 
± 38 ng/mL v.s 140 ± 53 ng/mL, p=0.054). Moreover, serum IGF-I levels 
were significantly lower in dead patients than in survivors (94 ± 50 ng/mL 
v.s 137 ± 52 ng/mL, p<0.001). Multiple logistic regression analysis adjusted 
for age, duration of diabetes, body mass index, HbA1c, serum creatinine, 
L-BMD showed that serum IGF-I levels were significantly and inversely as-
sociated with the incidence of osteoporotic non-vertebral fractures [odds 
ratio (OR)=0.49, 95%CI 0.24-0.99, p=0.049] as well as with all-cause death 
(OR=0.45, 95%CI 0.21-0.95, p=0.035).
Conclusion: The present study showed for the first time that serum IGF-I 
levels were associated with the incidence of osteoporotic non-vertebral frac-
tures and death in postmenopausal women with type 2 diabetes, suggesting 
that serum IGF-I could be clinically useful for assessing the risk of future 
osteoporotic fractures as well as mortality in postmenopausal women with 
type 2 diabetes mellitus.
Supported by: Japan osteoporosis society
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Metabolic and vascular characteristics of insulin resistance in Korean 
patients with type 2 diabetes
E. Lee1, Y. Choi2, S.-K. Kim3, B. Huh2, B.-W. Lee1, E. Kang1, B. Cha1, E. Lee1, 
H. Lee1, S. Lee2, K. Huh2;  
1Internal Medicine, Yonsei University College of Medicine,  
2Huh‘s Diabetes Center and 21th Century Diabetes and Vacular Research 
Institute, Seoul, 3Internal Medicine, CHA Bundang Medical Center,  
CHA University, Seongnam, Republic of Korea.
Background and aims: Insulin resistance (IR) is a paramount concern of 
type 2 diabetes and its associated disorders. To investigate the association 
of IR with metabolic and vascular disorders related to diabetes, we analyzed 
7,109 Korean type 2 diabetic patients according to IR.
Materials and methods: A total 7,109 patients with type 2 diabetes were re-
cruited through our Diabetes Center from January 2003 to June 2009. Insulin 
sensitivity was measured by a rate constant for plasma glucose disappearance 
(Kitt, %/min) using short insulin tolerance test. Subgroup analyses were per-
formed according to the tertiles of Kitt. Carotid atherosclerosis was defined 
as presence of isolated focal plaque or mean intima-media thickness (IMT) 
more than 1.0 mm.
Results: Mean age was 58.1 ± 10.1 years old, and 71.5% of diabetic patients 
had IR. Patients with the lowest tertile of Kitt (IR group) showed higher 
levels of metabolic parameters such as body mass index (BMI), visceral fat 
thickness, blood pressure, fasting blood glucose, HbA1c, total cholesterol, 
triglyceride and LDL cholesterol but lower HDL cholesterol compared to the 
patients with the highest tertile of Kitt (insulin-sensitive group). Mean and 
maximal IMT of carotid arteries was significantly higher in the patients with 
the lowest tertile of Kitt. As the value of Kitt was lower, the prevalence of 
metabolic and vascular disorders related to diabetes increased. In multiple 
regression analysis, IR was an independent risk factor for the metabolic and 
vascular disorders related to diabetes after adjusting for age, sex, duration of 
diabetes, BMI and HbA1c. Odds ratios for metabolic syndrome and carotid 
atherosclerosis in patients with the lowest tertile of Kitt were 3.108 (95% CI, 
2.721-3.549) and 1.232 (95% CI, 1.069-1.418), respectively.
Conclusion: IR is not only prevalent but also an important predictor for met-
abolic and vascular disorders in Korean patients with type 2 diabetes. Beyond 
reducing the HbA1c, management focusing on IR such as life-style modifi-
cation or using insulin-sensitizing agents should be evidently considered in 
patients with type 2 diabetes.
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Multi-morbidity in type 2 diabetes: systems biology analysis based on 
196,627 patients from a real-life multicentre analysis
J.M. Hermann1, D. Crowther2, C. Giegerich2, M. Hofer3, R. Beer4,  
R.W. Holl1, on behalf of the DPV initiative;  
1ZIBMT, University of Ulm, 2Sanofi-Aventis, Frankfurt, Germany,  
3First Department of Internal Medicine, General Hospital St. Pölten, Austria, 
4Department of Internal Medicine, Klinikum Hildesheim, Germany.
Background and aims: Patients with type 2 diabetes (T2D) often have vari-
ous chronic comorbid diseases. The aim was to investigate electronic medi-
cal record data to examine the incidence of multi-morbidity as well as the 
co-occurrence of T2D with the most prevalent diagnoses and to attempt to 
stratify metabolic syndrome.
Materials and methods: A cohort of 196,627 T2D patients from the Ger-
man/Austrian Prospective Diabetes Follow-up Registry (DPV) was analyzed. 
Data included gender, age, duration of diabetes and the additional diagnosis 
of the 20 most prevalent diseases. Proportional Venn diagrams were used to 
visualize patterns in the data. Subgroup analyses were compared with results 
from classical logistic regression models (SAS 9.4).
Results: The maximum number of comorbidities was 13. 95% of the patients 
had less than 6 diseases, 1.4% of the patients had no comorbidity. As ex-
pected, the most prevalent diseases were dyslipidemia (93.5%), hypertension 
(69.4%) and obesity (42.2%), matching the traditional components of meta-
bolic syndrome. The next most prevalent comorbidities were polyneuropathy 
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(12.9%) and retinopathy (10.1%). Female and male prevalence of all diseases 
except stroke, fatty liver and retinopathy differed significantly (all p<0.01). 
Prevalence of obesity and fatty liver decreased with increasing age, all other 
disease distributions increased or remained constant. Proportional Venn 
diagrams revealed that obesity and hypertension were mostly combined with 
dyslipidemia (94.4% and 94.7%, respectively). However, the proportions dif-
fered with age: young patients were more obese, older patients were more hy-
pertensive. The proportion of both obesity and hypertension increased with 
longer duration of diabetes. In contrast, duration of diabetes appeared to have 
little effect on the proportion of dyslipidemia. It is remarkable that a consid-
erable fraction of T2D patients was not obese, and that some patients seemed 
to be resistant to diabetes-induced hypertension. Based on Venn diagrams 
metabolic syndrome was stratified into four main groups. Prevalence of ad-
ditional comorbidities and their risk factors was different in these groups. For 
retinopathy, logistic regression models revealed duration of diabetes as risk 
factor in all 4 groups, whereas age was not significant in the ‘hypertension 
and dyslipidemia’ group. Both visualization and regression approach indi-
cated interactions between age and duration of diabetes.
Conclusion: We found a high prevalence of multi-morbidity in T2D patients, 
with dyslipidemia being almost omnipresent in all age groups. The concept 
of “metabolic syndrome” can be clearly visualized and stratified into 4 main 
types. The emergence of the additional comorbidities appears different in 
these groups.
Supported by: BMBF Competence net Diabetes mellitus, Sanofi-Aventis
PS 110 Biomarkers and 
complications I
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Alanine aminotransferase and mortality in patients with  
type 2 diabetes mellitus (ZODIAC-43)
P.E. Deetman1, A. Alkhalaf2, G.W.D. Landman3,4, K.H. Groenier3,5,  
G. Navis1, H.J.G. Bilo3, N. Kleefstra3, S.J.L. Bakker1;  
1Department of Medicine, University of Groningen, University Medical 
Center Groningen, 2Department of Gastroenterology, Isala Clinics, 
3Diabetes Centre, Isala Clinics, Zwolle, 4Department of Medicine, Gelre 
Hospital, Apeldoorn, 5Department of General Practice, University of 
Groningen, University Medical Center Groningen, Netherlands.
Background and aims: Combined data suggests the existence of a bimodal 
association of alanine aminotransferase (ALT) with mortality in the general 
population. Little is known about ALT as a predictor of mortality in patients 
with type 2 diabetes mellitus. We aimed to investigate the association of ALT 
with all-cause, cardiovascular, and non-cardiovascular mortality in patients 
with type 2 diabetes mellitus.
Materials and methods: A prospective cohort study was performed in pa-
tients with type 2 diabetes mellitus, treated in primary care, participating in 
the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) 
study. Cox regression analyses were performed to determine associations of 
log-transformed baseline ALT with all-cause, cardiovascular, and non-cardi-
ovascular mortality.
Results: In 1,187 patients with type 2 diabetes mellitus, mean age was 67±12 
years and 46% was male. Median (interquartile range) ALT levels were 11 
(8-16) U/l. ALT levels were above the upper limit of normal (45 U/L) in six-
teen (1.3%) patients. During median follow-up for 5.5 (3.1-10.1) years, 354 
(30%) patients died, with 149 (42%) attributable to cardiovascular causes. 
ALT was inversely associated with all-cause mortality (HR 0.75; 95%CI 0.61-
0.92; P=0.006). Furthermore, ALT was not associated with cardiovascular 
mortality (HR 0.94; 95% CI 0.68-1.29; P=0.68), but particularly with non-
cardiovascular mortality (HR 0.65; 95%CI 0.50-0.86; P=0.002). These asso-
ciations were independent of potential confounders including age, sex, body 
mass index, cholesterol/HDL ratio, smoking, systolic blood pressure, diabetes 
duration, serum creatinine, HbA1c, cardiovascular history, treatment with 
ACE inhibitors, and albumin to creatinine ratio. In addition, there appeared 
to be a bimodal association of ALT and all-cause mortality (P=0.013, Figure 
1), with a similar bimodal trend for non-cardiovascular mortality.
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Conclusion: In conclusion, our findings suggest that low levels of ALT are 
associated with a high risk of all-cause mortality, in particular of non-cardi-
ovascular mortality, in patients with type 2 diabetes mellitus with ALT levels 
largely within the normal range. 
Supported by: GlaxoSmithKline
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Serum PEDF levels in type 2 diabetes: correlations, predictive power for 
vascular events and increases by fenofibrate in the FIELD Study
A. Jenkins, A. Januszewski, D. Calandro, D. Sullivan, J.-X. Ma, J. Best,  
R. O‘Connell, S. Blankenburg, J. Simes, R. Scott, M. Whiting, P. Barter,  
M.-R. Taskinen, A. Keech, the FIELD Study;  
NHMRC Clinical Trials Centre, Sydney, Australia.
Background and aims: Pigment Epithelium Derived Factor (PEDF) is an en-
dogenous glycoprotein with potent anti-angiogenic, anti-inflammatory and 
anti-oxidant effects and links with lipoprotein metabolism. In the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) Study of Type 2 dia-
betes subjects we aimed to determine if baseline serum PEDF levels (i) are 
correlated with traditional and novel vascular risk factors; (ii) are associated 
with on-trial occurrence of microvascular and cardiovascular complications 
over 5-year follow-up; and (c) are changed by allocation to (up to one year of) 
200 mg daily comicronised fenofibrate.
Materials and methods: PEDF levels were quantified by ELISA (Merck Mil-
lipore, USA) with CVs<10% in sera from (n=8898) FIELD Study participants 
at baseline and after a 16 week run-in period, including 6 weeks of daily oral 
200 mg fenofibrate and in 1832 FIELD subjects after one year of allocation 
to fenofibrate or placebo. Risk factors evaluated included: BMI, lipid levels, 
HbA1c, renal dysfunction, insulin and HOMA-IR, leptin, inflammation 
(including sVCAM-1, sICAM, se-Selectin, IL-6, CRP and fibrinogen) and 
oxidative stress (OxLDL and myeloperoxidase (MPO)). Tertiles of PEDF at 
baseline were related to composite CVD (CVD death, MI, stroke or coronary 
or carotid revascularization) and microvascular (retinal laser, albuminuria, 
neuropathy or microvascular amputation) end-points with and without ad-
justment for covariates. Covariates were age, sex, diabetes duration, HbA1c, 
systolic BP, fasting triglycerides, LDL-C and HDL-C, smoking, and baseline 
glucose control treatment and (for CVD only) urinary albumin creatinine 
ratio. Statistical significance was taken at p<0.05.
Results: Baseline PEDF levels correlated (weakly (Spearman correlation r 
values 0.05-0.30, all p<0.0001) with: baseline HbA1c, blood pressure, tri-
glycerides, LDL-C and HDL-C (inverse), BMI and leptin, renal dysfunction 
(elevated plasma creatinine, cystatin C, lower calculated GFR and increased 
albuminuria), insulin levels and HOMA-IR, and with measures of inflamma-
tion (cell adhesion molecules, IL-6, CRP, fibrinogen) and MPO (p=0.002). 
On unadjusted analyses baseline PEDF tertiles were predictors of on-trial 
CVD (n=1199, HR up to 1.33, p<0.001) and microvascular events (n=3465, 
HR up to 1.47, p<0.001). With adjustment for all covariates (above) the rela-
tionship with subsequent CVD events was not statistically significant, whilst 
that with microvascular events was. In the active run-in period including 6 
weeks fenofibrate, PEDF levels increased 18 (95% CI 17-19) %from baseline 
levels. Over one year PEDF levels increased by 16.6 (14-1-19.0)% in the group 
allocated fenofibrate (n=917; p<0.0001) vs. a 3.4 (1.6-5.9)% increase in the 
placebo allocated group (n=915; p<0.006).
Conclusion: In Type 2 diabetes patients in the FIELD Study serum PEDF lev-
els correlated significantly, albeit weakly, with traditional and novel vascular 
risk factors, including renal dysfunction, adiposity, inflammation and oxida-
tive stress. Baseline PEDF levels predict on-trial microvascular and CVD and 
events. PEDF levels are significantly increased by fenofibrate. We suggest that 
some of fenofibrate’s clinical effects may be via effects on PEDF and PEDF 
may be a therapeutic target.
Clinical Trial Registration Number: 64783481
Supported by: NHMRC, Laboratoires Fournier / Solvay / Abbott
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Association of the alternative pathway of complement activation with 
incident cardiovascular diseases: the CODAM study
E. Hertle1,2, I.C.W. Arts1,3, C.J.H. van der Kallen1,2, E.J.M. Feskens4,  
C.G. Schalkwijk1,2, C.D.A. Stehouwer1,2, M.M.J. van Greevenbroek1,2;  
1CARIM School for Cardiovascular Diseases, Maastricht University Medical 
Centre, 2Dept. of Internal Medicine, Maastricht University Medical Centre, 
3Dept. of Epidemiology and School for Public Health and Primary Care 
(CAPHRI), Maastricht University Medical Centre,  
4Division of Human Nutrition, Section Nutrition and Epidemiology, 
Wageningen University, Netherlands.
Background and aims: The complement system has been implicated in the 
development of both type 2 diabetes (DM2) and cardiovascular diseases. 
Complement can be activated spontaneously via the alternative complement 
pathway, which functions also as potent amplifier of other routes of comple-
ment activation. We measured plasma properdin and factor D - a positive 
regulator and a protease, respectively, of the alternative pathway, and factor 
Bb - an alternative pathway activation marker, and investigated their associa-
tions with incident cardiovascular diseases in a diabetes-prone population.
Materials and methods: We conducted prospective analyses in the CODAM 
study (Cohort on Diabetes and Atherosclerosis Maastricht, baseline exami-
nation 1999-2001; follow-up examination 2006-2009). Cardiovascular events 
(CVE) included myocardial infarction (self-reported or identified with ECG-
examinations), self-reported stroke, self-reported cardiac angioplasty and/
or cardiac bypass. Cardiovascular disease (CVD) additionally included signs 
of ischaemia on an ECG and/or ankle-brachial index<0.9. We included 371 
individuals who were free of CVE at baseline (59% men, age 58.2±6.9 years, 
21% DM2). Participants with CVD at baseline (n=53) were additionally ex-
cluded in analyses of incident CVD. Associations between properdin, factor 
D and Bb at baseline and incident CVE and CVD were studied with logistic 
regression analyses adjusted for baseline age, sex, impaired glucose metabo-
lism, DM2, blood pressure, BMI, smoking, physical activity, renal function, 
and use of medication. We examined effect modification by prevalent DM2.
Results: After a mean follow-up time of 7.1±0.1 years, there were 48 incident 
CVE and 65 incident cases of CVD. Properdin was independently associ-
ated with CVE (per 1SD increase, OR=1.50, [95%CI: 1.10-2.06], P=0.011) 
but not CVD (OR=1.09, [0.81-1.46], P=0.58). Bb tended to be associated with 
CVD (per 1SD, OR =1.30, [0.98-1.71], P=0.065) but not with CVE (OR=1.06, 
[0.76-1.46], P=0.75). Factor D was in the whole population not associated 
with CVD (per 1SD, OR=1.32, [0.92-1.88], P=0.14) or CVE (OR=1.17, [0.80-
1.72], P=0.43), but effect modification by DM2 was observed in the asso-
ciation with CVD (Pfactor D*DM2=0.049). In stratified analyses, factor D was 
associated with CVD (OR=4.42, [1.29-15.16], P=0.018) only in participants 
with baseline DM2 (N=61, 19 cases).
Conclusion: In CODAM, higher levels of properdin were independently as-
sociated with CVE and higher levels of Bb tended to be associated with CVD. 
In participants with DM2, factor D was independently associated with CVD. 
This suggests that the alternative complement pathway may play a role in the 
development of cardiovascular diseases both in individuals with and without 
DM2.
Supported by: NHS2010B194
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 503
1 C
1235
Circulating resistin levels and mortality risk
A. Fontana1, S. Spadaro2, M. Copetti1, B. Spoto3, L. Salvemini4, P. Pizzini3,  
L. Frittitta2, F. Mallamaci3, S. Bacci5, F. Pellegrini1, V. Trischitta4,  
C. Menzaghi4;  
1Unit of Biostatistics, IRCCS, San Giovanni Rotondo,  
2Department of Clinical and Molecular Biomedicine, University of Catania, 
3Nephrology, Dialysis and Transplantation Unit, CNR-IBIM, Reggio 
Calabria, 4Research Unit of Diabetes and Endocrine Diseases, IRCCS,  
5Unit of Endocrinology, IRCCS, San Giovanni Rotondo, Italy.
Background and aims: Studies concerning the association between circulat-
ing resistin levels and mortality yielded mixed Results: some studies reported 
significant associations, while many others showed negative results. To ad-
dress this question, we analyzed data from European subjects with type 2 
diabetes and evidence of coronary artery disease (CAD), a prospective cohort 
followed over time for cardiovascular and all-cause mortality. To assess the 
consistency of the association between resistin and mortality risk, we also 
performed a meta-analysis of prospective studies.
Materials and methods: We investigated: i) the Gargano Heart Study (GHS) 
prospective design (n=359 diabetic patients; 81 and 58 incident cases of all-
cause and cardiovascular (CV) mortality, respectively); ii) meta-analized in 
a dose-risk fashion our present data from GHS study and all studies from 
MEDLINE and EMBASE until February 2014 reporting adjusted hazard ra-
tios (HR) of circulating resistin for all-cause or CV mortality.
Results: In GHS, the adjusted HRs per 10 ng/ml resistin increment were: 
1.45 (95% CI: 1.10-1.91) and 1.52 (95% CI: 1.09-2.12) for all-cause and CV 
mortalities, respectively. The dose-risk meta-analyses included 7 studies 
(n=3,699, 997 events) for all-cause mortality and 6 studies (n=4,187, 412 
events), for CV mortality. Pooled HRs per 10 ng/ml resistin increment were 
1.33 (95% CI: 1.03- 1.72, p=0.028, Q-test p for heterogeneity<0.001) and 1.16 
(95% CI: 0.95-1.43, p=0.147, Q-test p for heterogeneity=0.039) for all-cause 
and CV mortality, respectively. Due to the presence of between-studies het-
erogeneity, meta-regression analyses were performed. For all-cause mortal-
ity, study mean age (HR=1.08, 95%CI=1.01-1.14, p=0.017) explained 68.8% 
of heterogeneity resulting in a pooled HR per 10 ng/ml resistin increment 
equal to 1.33 (95% CI: 1.12-1.57, p=0.001). For CV mortality, study mean 
BMI (HR=1.07, 95%CI=1.02-1.11, p=0.004) explained the whole heteroge-
neity resulting in a pooled HR per 10 ng/ml resistin increment equal to 1.11 
(95% CI: 1.02-1.22, p=0.016).
Conclusion: Our results provide strong evidence for an association between 
higher circulating resistin levels and increased mortality risk.
Supported by: EFSD / Pfizer
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Prognostic value of plasma NT-proBNP levels in asymptomatic diabetic 
patients
I. Pham, E. Cosson, M. Nguyen, I. Banu, B. Chanu, P. Valensi;  
AP-HP, Jean Verdier hospital, Bondy, France.
Background and aims: Elevated plasma N-terminal (NT)-proBNP levels 
predict adverse cardiovascular events in the general population and in coro-
nary patients. We previously showed that NT-proBNP is also a marker of si-
lent coronary artery stenoses (CS) in diabetic patients without cardiac history 
or symptom. The aim of this study was to determine the prognostic value of 
plasma NT-proBNP levels independent from silent coronary disease and left 
ventricle hypertrophy (LVH).
Materials and methods: We included 323 diabetic patients (17 type 1, 306 
type 2; 185 men, 138 women) without history or sign of cardiac disease but 
with at least one additional risk factor including nephropathy in 41% of the 
patients. Silent myocardial ischaemia (SMI) was assessed using stress myo-
cardial scintigraphy and CS using coronary angiography in those with SMI. 
Left ventricular mass was evaluated reliably by echocardiography (ASE con-
vention) in 282 of them. LVH was defined as LV mass ≥106 (women) or 110 
g/m² (men). Plasma NT-proBNP was measured.
Results: SMI was detected in 108 patients, 39 of whom had CS, and LVH 
in 92 patients. The highest tertiles of NT-proBNP were associated with a 
higher prevalence of hypertension (p<0.0001), nephropathy (0.01), periph-
eral vascular disease (0.03), LVH (19.4, 35.1, 43.2% ; p<0.001) and CS (5.6, 
10.2, 20.4% ; p<0.001). At follow-up (4.6±2.6 years), 29 patients had a cardio-
vascular event (10 acute coronary syndrome, 4 cardiac death, 5 heart failure, 
4 stroke, 1 amputation, 5 revascularisations). CS and the highest NT-proBNP 
tertile (≥ 38 pg/ml) were significant predictors of events (p=0.01 and 0.002, 
respectively). In multivariate analysis including SMI or CS the highest tertile 
of NT-proBNP predicted the events independently from SMI (OR 2.9 [1.4-
6.0], p<0.005) and CS (OR 2.4 [1.1-5.2], p=0.02). In another model including 
also LVH the highest tertile of NT-proBNP was still an independent predictor 
(p<0.0001 and p=0.003, respectively).
Conclusion: This study suggests that in asymptomatic diabetic patients NT-
proBNP is a risk marker for cardio-vascular events independent from coro-
nary status and LVH.
1237
Comparison of predictive capabilities of MR-proANP and NT-proBNP 
for mortality (ZODIAC-42)
K.J.J. van Hateren1, G.W.D. Ladman1, I.J. Riphagen2, K.H. Groenier1,  
S.J.L. Bakker2, N. Kleefstra1, H.J.G. Bilo1;  
1Diabetes Centre, Zwolle, 2Department of Internal Medicine,  
University Medical Center Groningen, Netherlands.
Background and aims: The midregional fragment of pro-A-type natriuretic 
peptide (MR-proANP) has been suggested as an alternative for N-terminal 
pro-B-type natriuretic peptide (NT-proBNP), an established biomarker in 
heart failure. A previous head-to-head comparison in the general population 
between both peptides showed that MR-proANP was as efficient as NT-proB-
NP in predicting all-cause mortality and cardiovascular events. However, the 
association of MR-proANP with cardiovascular mortality was not independ-
ent from confounders. We aimed to compare the predictive capability of 
MR-proANP and NT-proBNP for all-cause and cardiovascular mortality in 
patients with type 2 diabetes mellitus (T2DM).
Materials and methods: Patients were selected from two cohorts (1998 and 
2001) of the prospective observational ZODIAC study (n=1688). For this 
study, 541 patients were excluded because plasma MR-proANP and/or plas-
ma NT-proBNP were not measured. A Cox proportional hazard model was 
used to investigate the relationship between the two natriuretic peptides and 
(cardiovascular) mortality. We used three models: a crude model, an age- and 
gender-adjusted model, and a model in which we additionally adjusted for 
smoking (yes or no), BMI, duration of diabetes, HbA1c, serum creatinine 
level, macrovascular complications (yes or no), albuminuria (yes or no) and 
total cholesterol-HDL ratio. Harrell’s C statistic was used to compare between 
models with MR-proANP and those with NT-proBNP.
Results: After a median follow-up period of 11 years, 552 (48%) patients died 
of which 239 patients (43%) died from cardiovascular causes. The median 
(interquartile range) values for plasma concentrations of MR-proANP and 
NT-proBNP were 74 pmol/L (48-120 pmol/L) and 11 pmol/L (4-27 pmol/L), 
respectively. The results of the Cox regression analyses are presented in table 
1. Increased plasma concentrations of both natriuretic peptides are indepen-
dently associated with all-cause and cardiovascular mortality. The Harrell’s 
C values of the models for all-cause mortality are similar for both peptides. 
For cardiovascular mortality, the Harrell’s C values of the models with NT-
proBNP are higher compared to the models with MR-proANP.
Conclusion: This study is the first study showing that MR-proANP is related 
to cardiovascular mortality after adjustment for cardiovascular risk factors. 
The predictive performance of both peptides is similar for all-cause mortality. 
Regarding cardiovascular mortality, NT-proBNP seems to perform slightly 
better.
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ProBNP strongly predicts future macrovascular events in angiographied 
coronary patients as well as in those without the metabolic syndrome
B. Patsch1, P. Rein2, C.H. Saely2,3, A. Vonbank2, D. Zanolin1,3, H. Drexel2,4;  
1VIVIT Institute, Feldkirch, Austria, 2Academic Teaching Hospital 
Feldkirch, Austria, 3Private University of the Principality of Liechtenstein, 
Triesen, Liechtenstein, 4Drexel University College of Medicine, Philadelphia, 
USA.
Background and aims: Pro-B-type natriuretic peptide (proBNP) is a prog-
nostic biomarker for patients with congestive heart failure as well as in other 
patient populations. The power of proBNP to predict cardiovascular end-
points in patients with the metabolic syndrome (MetS) is unclear and is ad-
dressed in the present study.
Materials and methods: We measured serum proBNP in 722 patients un-
dergoing coronary angiography for the evaluation of stable coronary artery 
disease (CAD). Significant CAD was diagnosed in the presence of coronary 
stenoses with lumen narrowing of ≥50%. Prospectively, we recorded vascular 
events over 3.2±1.2 years.
Results: ProBNP was significantly higher in patients with (n=386) than in 
subjects without significant CAD at baseline (711±1287 vs. 663±1565 pg/
ml; p=0.001). Prospectively, we recorded 121 cardiovascular events. The in-
cidence of vascular events significantly increased over tertiles of proBNP in 
patients with the MetS (10.7%, 18.5%, and 28.8% respectively; p=0.004) was 
well as in those without the MetS (10.4%, 11.5%, and 22.0%, respectively; 
p=0.011). Similarily, serum proBNP significantly predicted the incidence of 
major cardiovascular events after adjustment for age, gender, BMI, smoking, 
systolic and diastolic blood pressure, LDL cholesterol, HDL cholesterol and 
the eGFR both in subjects with the MetS (standardized adjusted HR 1.48 
[1.21-1.80]; p <0.001) and in those without the MetS (HR 1.21 [1.04-1.40]; 
p=0.011). These results were not attenuated after further adjustment for the 
angiographically determined baseline CAD state (HRs 1.50 [1.23-1.83]; p 
<0.001 and 1.26 [1.09-1.47]; p=0.003 in subjects with the MetS and in those 
without the MetS, respectively).
Conclusion: Serum proBNP predicts cardiovascular events independently 
of established cardiovascular risk factors and of the baseline coronary artery 
state both in patients with and in subjects without the MetS.
1239
Type 2 diabetes mellitus in patients with terminal stage heart failure
G. Dóka1, J. Mlynárová1, P. Křenek1, P. Musil1, J. Klimas1, E. Goncalvesová2, 
J. Kyselovič1;  
1Department of pharmacology and toxicology, Faculty of Pharmacy, 
Comenius University,  
2The National Institute of Cardiovascular Diseases, Bratislava, Slovakia.
Background and aims: Type 2 diabetes mellitus is a major independent risk 
factor for the development of heart failure. Prevalence of type 2 diabetes in 
patients with heart failure is higher than in general population. The cardio-
vascular disease mortality is higher in patient with diabetes and heart failure 
concurrently then in nondiabetics with failing heart. Based on these knowl-
edge, our interest was to compare diabetic and nondiabetic patients in termi-
nal stage heart failure and assess possible differences in routinely measured 
and recorded clinical parameters. On molecular level, we suspected deterio-
ration of gene expression of cardiac myosin heavy chain isoforms and regula-
tory microRNAs originating from these isoforms. Possible shift in expres-
sion of these main components of cardiac contractile apparatus may be the 
underlying source of increased cardiovascular mortality in diabetic patients.
Materials and methods: Cohort consisted of 42 patients (38 male, 4 female) 
with terminal stage heart failure. Inclusion criteria were: heart failure classi-
fied NYHA III - IV, patients were indicated for ortothopic heart transplanta-
tion, the recorded underlying cause of heart failure was dilated cardiomyopa-
thy or coronary artery disease (two most frequent causes). 16 of 42 patients 
was diagnosed type 2 diabetes previous to the heart transplantation. We test-
ed the differences in clinical parameter: age, blood pressure, body mass index, 
data from right heart catheterization, echocardiography, electrocardiography, 
blood biochemistry, anamnesis of co-morbidities, interventional procedures 
and complete pharmacotherapy. Expression of cardiac myosin heavy chain 
isoforms (MYH6, MYH7, MYH7B) and microRNAs originating from their 
intrones (miR-208a, miR-208b, miR-499 respectively) were analyzed in sam-
ples from left ventricular free wall of explanted hearts, using RT-qPCR.
Results: The most prominent difference between diabetic and nondiabetic 
patients was the expected difference in blood glucose (** p = 0.002; 8.7 ± 4.0 
vs. 5.8 ± 1.3 mmol/l respectively; mean ± SD). The only other detected dif-
ferences were the values of uric acid (** p = 0.006; 610.1 ± 207.3 vs. 450.8 ± 
136.1 μmol/l) and urea (*** p < 0.001; 11.1 ± 4.1 vs. 7.1 ± 2.8) contributing to 
altered metabolic state or perhaps resulting from modulated renal function. 
All other clinical parameter assessing heart function or blood biochemistry 
are indistinguishable between the two groups of patients. The same applies 
also for the indifference in gene expression of myosin heavy chain isoforms 
MYH6, MYH7, MYH7B and their innate microRNAs (miR-208a, -208b, 
-499).
Conclusion: In terminal stage of failing heart there is no clinical parameter, 
that would indicate even more deteriorate heart function in diabetic patients 
then it is all ready damaged in nondiabetic counterparts. The same is true 
also for gene expression of main motor proteins, cardiac myosin heavy chain 
isoforms and their innate regulatory microRNAs. Our results show that cur-
rently there is no indicator for deterioration of cardiac function in patient 
with diabetes in the terminal stage of heart failure.
Supported by: EFSD, VEGA1/0981/12
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Head to head comparison of inflammatory and metabolic biomarkers 
for the long-term prediction of new onset left ventricular diastolic 
dysfunction in type 2 diabetes patients
E. Fousteris1, A. Theodosis-Georgilas2, A. Destounis2, T. Mousiama2,  
A. Aggelidi1, S. Matsaggos3, P. Spiropoulou3, S. Foussas2, E. Boutati4,  
G. Dimitriadis4, S. Iraklianou1, A. Melidonis1;  
1Diabetes Center, Tzanio General Hospital of Piraeus,  
2Cardiology Department, Tzanio General Hospital of Piraeus,  
3Blood Bank Service, Tzanio General Hospital of Piraeus,  
42nd Department of Internal Medicine, Research Institute and Diabetes 
Center, Attikon University Hospital, Athens, Greece.
Background and aims: Left ventricular diastolic dysfunction in patients with 
diabetes is commonly used as an imaging finding of diabetic cardiomyopathy 
in the absence of other etiological factors. With this 48month prospective 
study we investigated the predictive value of the classic and novel biomark-
ers on the new onset left ventricular diastolic dysfunction in type 2 diabetes 
patients.
Materials and methods: We recruited 48 type 2 diabetes patients (45.83% 
males) of mean age 55.45±10.13 years with mean duration of diabetes 
2.81±2.50 years with normal both systolic and diastolic cardiac function. 
Exclusion criteria were systolic or diastolic cardiac impairment, coronary 
heart disease, arrhythmias or valvular diseases and history of other chronic 
inflammatory states (e.g. COPD or autoimmune diseases). All recruits were 
examined annually for 4 years for: BMI, FPG, HbA1c, eGFR, lipidemic pro-
file, aminotransferases, uric acid, BNP, hs-CRP, fibrinogen and the newer in-
flammatory biomarker soluble ST2. Complete echocardiograms at same time 
points revealed those that switched from normal to impaired diastolic func-
tion, according to the latest A.H.A./E.S.C. criteria.
Results: Left ventricular diastolic dysfunction (impaired relaxation pattern) 
was present at the 54.17% of our sample by the end of the study (switch-
ers). The remaining 45.83% preserved their normal cardiac function (non 
switchers) throughout the 48month observation period. Statistical signifi-
cant differences between switchers - non switchers were found only for: BMI 
(31.0±4.7 vs 27.5±5.0, p=0.024), FPG (148±35 vs 125±36, p=0.011), HDL-C 
(42±10 vs 52±19, p=0.041), triglycerides (139±35 vs 106±64, p=0.034), uric 
acid (6.3±1.4 vs 5.0±1.4, p=0.008) and hs-CRP (7.9±7.1 vs 2.8±3.2, p=0.011). 
No correlation was found with the rest of the study parameters. Mean se-
rum soluble ST2 for switchers was 11.5±3.4 ng/mL while for non switchers 
11.0±2.4 ng/mL (p=0.58). Multivariate regression analysis revealed hs-CRP 
and triglycerides as the only study parameters that can predict the new onset 
of left ventricular diastolic dysfunction in our type 2 diabetes population.
Conclusion: High sensitivity CRP along with triglycerides act as independ-
ent predictive biomarkers for the instatement of new onset left ventricular 
diastolic dysfunction in type 2 diabetes patients, pattern not proven for the 
soluble ST2, fibrinogen, BNP and other metabolic parameters.
Supported by: Hellenic National Diabetes Center
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Protective effect of telomere length in patients with type 2 diabetes 
mellitus
E.N. Dudinskaya1, N.V. Brailova1, I.D. Strazhesko1, O.N. Tkacheva1,  
S.A. Boytsov1, M.V. Shestakova2;  
1National Research Centre for Preventive Medicine,  
2National Research Center for Endocrinology, Moscow, Russian Federation.
Background and aims: Type 2 diabetes mellitus (T2DM) is the primary risk 
marker influencing risk of cardiovascular disease. It is known that telomere 
length (TL) shortening is a marker of cell aging and associated with increased 
arterial stiffness (AS) in patients with T2DM, despite the patient‘s age, lead-
ing to the vascular aging. The aim of the study was to compare the vascular 
and cellular aging in patients with and without T2DM.
Materials and methods: TL was assessed by quantitative polymerase chain 
reaction (PCR) in 98 patients with T2DM (mean age 61±2,6 years) and in 101 
healthy patients in mean age of 51±1,8 years. Intima media thickness (IMT) 
and plaque presence (PP) were determined by ultrasonography in both left 
and right carotid arteries. AS was appreciated by aortic pulse wave velocity 
(PWV) measuring by SphygmoCor (AtCor Medical).
Results: The median of telomere length (TLL) was 9,75. «Short» telomeres 
were considered if the telomere length was 9.75. All patients were divided 
into 4 groups by TL - “long” (T2DM+ (n=57) and T2DM- (n=49)) and 
“short” telomeres ((T2DM+ (n=41) and T2DM- (n=52)). Comparison of 
vascular aging parameters in patients with long telomeres showed that the 
state of vessels in T2DM were as similar as in healthy people - they had a 
lower arterial stiffness and other signs of vascular ageing : PWV 10,58±0,1 
(T2DM+) vs 10,5±0.5 m/s (T2DM- ), p=0,913; IMT 0,904±0,09 (T2DM+) 
vs 0,77±0,03 mm (T2DM-), p=0,1227; PP 0,886±0,4 (T2DM+) vs 0,782±0,2 
(T2DM-), p=0,979. In contrast in patients with «short» TL and DM PWV was 
significantly higher than in non-diabetic people (15,08±1.3 vs 10,7±0.5 m/s, 
p=0,0151), there were greater number of plaques (1.125±0,29 vs 0,789±0,22, 
p=,04); IMT was 0,87±0,1 (T2DM+) vs 0,78±0,1 mm (T2DM-), p=0,1814.
Conclusion: In patients with short TL and T2DM the severity of vascular 
disorders is higher than in healthy people. In contrast, in patients with long 
TL with T2DM there are no significant differences in the vascular struc-
ture as compared with healthy individuals. Despite the presence of T2DM 
signs of vascular aging are minimal in patients with long TL.Short TL may 
be regarded as non-hemodynamic components of rapid vascular ageing in 
patients with T2DM.
1242
Sleep apnoea syndrome and type 1 diabetes: impact on 
macroangiopathies
J.-P. Courrèges1, E. Ghanassia2, A. Iosup1, J.-F. Thuan1, P. Fisher2,  
H. Bonnaure1, N. Vigier-Simmore1;  
1Centre Hospitalier Général de Narbonne,  
2Clinique Sainte Marguerite, Sète, France.
Background and aims: Sleep Apnoea Syndrome (SAS) is an independent 
cardiovascular morbi-mortality factor that is undoubtedly enhanced when 
associated with T1D. The aim of this study is to assess prevalence and profile 
of macroangiopathies in this situation (T1D + SAS), more precisely blood 
pressure and potential conduction defects (QT interval).
Materials and methods: SAS was found in 28 patients (20.7%) from a 135 
T1D cohort consecutively enrolled with Apnoea Hypopnoea Index (AHI) 
)≥15/h confirmed with polysomnography. Among them, respectively 50% 
and 50% suffer from severe (AHI≥30/h) or moderate (AHI≥ 15 ≤29/h) SAS.
Results: Patients’ characteristics at enrolment were: age 64 ± 12.9 years, dia-
betes duration 27.1 ± 13.7 years, 75% of males, HbA1c 8.0 ± 1.0% (39.3% with 
HbA1c≤7.5%), weight: 75.2 ± 18.8kg, BMI : 26.5 ± 5.8 kg/m2 (50% lower than 
25kg/m2, 21.4% between 25 and 26.9kg/m2 et 28.6% higher than 27 kg/m²). 
Among them, 21 patients (75% of SAS T1D and 15.5% of all T1D) show at 
least one macroangiopathic damage (MA+): 8 coronaritis, 15 carotid damages, 
13 lower limb arteriopathy). MA+ patients were compared to MA- patients on 
HbA1c (8.0 vs 8.0%), BMI (27.2 vs 24.7 kg/m2), creatinemia (10.4 vs 8.2mg/l), 
total cholesterol (1.8 vs 2.1g/l), triglyceride level (1.4 vs 0.6g/l), neuropathy 
frequency (81 vs 57.1%), nicotine addiction frequency (14.3 vs 0%), Hypoxia 
(AHI : 30.4 vs 23.9/h ; 57.1 vs 28.6% of severe SAS and 42.9 vs 71.4% of moder-
ate SAS). We have also studied blood pressure (SBP : 126.5 ± 15.3 vs 126.4 ± 
15.5mmHg/DBP : 75.6 ± 7.7 vs 73.6 ± 10.3mmHg), Mean Arterial Pressure 
(MAP: 93.9 ± 9.2 vs 97.0 ± 3.0mmHg) and Pulse Pressure (PP: 50.9 ± 17.2 vs 
55.0 ± 13.8mmHg). The electrocardiogram of MA+ patients shows mean QT 
and QTC intervals of 401.2 ± 42.5 et 414.9 ± 22.4 mm/s while the one of a 22 
patients control group (C) with no SAS and no macroangiopathy shows mean 
QT and QTC intervals of 382.9 ± 22.5 et 398.8 ± 12.7 mm/s. There is a signifi-
cant difference in QTC intervals (p = 0.012). No heart rhythm disorder is ob-
served. SBP, DBP, MAP and PP have been compared too (SBP: 126.5 ± 15.3 vs 
124.7 ± 11.4 mmHg - NS; DBP : 75.6 ± 7.7 vs 72.5 ± 9.4 mmHg - NS; MAP : 93.9 
± 9.2 vs 89.8 ± 9.4 mmHg - NS; PP : 50.9 ± 17.2 vs 52.2 ± 7.7mmHg - NS). The 
median QTC interval stands respectively (MA+ vs C) at 409 vs 396 mm/s; the 
proportion of patients with QTC interval longer than 430 mm/s is 14.3 vs 0%.
Conclusion: The frequency of SAS in T1D patients is high and this popula-
tion often suffers from macroangiopathies. The study of T1D with SAS and 
macroangiopathy underlines a high frequency of associated neuropathy. The 
comparison between this group and a control group with no SAS and no 
macroangiopathy shows no difference in usual blood pressure characteristics. 
On the contrary, the study of QT (and particularly QTC) interval shows a 
significant lengthening. Referring to its potential implication in rhythm dam-
age, it has to be systematically assessed in this context.
1243
Presence of type 2 diabetes mellitus significantly modulates the power of 
thyroid stimulating hormone to predict cardiovascular mortality
E. Kinz1,2, A. Vonbank3, C.H. Saely3,2, D. Zanolin1,2, P. Rein3, H. Drexel3,4;  
1VIVIT Institute, Feldkirch, Austria,  
2Private University of the Principality of Liechtenstein, Triesen, 
Liechtenstein, 3Academic Teaching Hospital Feldkirch, Austria,  
4Drexel University College of Medicine, Philadelphia, USA.
Background and aims: Elevated thyroid stimulating hormone (TSH) is associ-
ated with an adverse cardiovascular risk profile, especially in patients with type 
2 diabetes (T2DM). We investigated the association between TSH and cardio-
vascular mortality in patients with T2DM as well as in non-diabetic subjects.
Materials and methods: We measured TSH in a high-risk cohort of 1741 
consecutive patients undergoing coronary angiography for the evaluation of 
established or suspected coronary artery disease (CAD). The incidence of 
vascular events was recorded over 10 years; T2DM was defined according to 
current ADA criteria.
Results: From our patients, 34% suffered vascular events. TSH proved to be 
a strong and independent predictor of cardiovascular mortality in subjects 
without T2DM (n=1220; standardized adjusted hazard ratio (HR) 1.11 [1.00-
1.24]; p=0.036), but not in patients with T2DM (n=521; HR 0.99 [0.87-1.14]; 
p=0.934). An interaction term TSH x T2DM was significant (p=0.039), indi-
cating that TSH was a significantly stronger predictor of vascular events in 
subjects without T2DM than in patients without T2DM.
Conclusion: From the data of this prospective cohort study we conclude that 
presence of T2DM significantly modulates the power of TSH to predict car-
diovascular mortality.
1244
Is it possible to improve the prediction of silent myocardial ischaemia in 
type 1 diabetes?
G. Llauradó1, A. Cano2, C. Hernández3, A. Rodríguez-Revuelto4,  
M. González-Sastre5, J. Puntí6, L. Albert2, R. Simó3, J. Vendrell1,  
J.M. González-Clemente2;  
1Endocrinology and Diabetes Unit, CIBERDEM. Hospital Universitari Joan 
XXIII de Tarragona. IISPV. Universitat Rovira i Virgili, 2Endocrinology 
and Nutrition Department, Hospital de Sabadell. Corporació Sanitària i 
Universitària Parc Taulí (UAB), 3Diabetes and Metabolism Research Unit. 
CIBERDEM. Institut de Recerca Hospital Universitari Vall d‘Hebron. 
Universitat Autònoma de Barcelona, 4Nuclear Medicine Department, UDIAT 
Centre Diagnòstic. Corporació Sanitària i Universitària Parc Taulí (UAB), 
Sabadell, 5Ophthalmology Department, 6Cardiology Department, Hospital 
de Sabadell. Corporació Sanitària i Universitària Parc Taulí (UAB), Spain.
Background and aims: Cardiovascular disease (CVD) is the major cause of 
mortality in type 1 diabetes (T1DM). Given the higher prevalence of silent 
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myocardial ischemia (SMI) in this population, the need to screen asymp-
tomatic T1DM patients assumes increasing importance. The aims of this 
study were: 1) to assess the prevalence of SMI in asymptomatic patients with 
T1DM, 2) to evaluate the clinical predictors associated with its presence, in-
cluding the evaluation of microvascular complications and the assessment of 
arterial stiffness (AS) (as a measurement of pre-clinic arteriosclerosis) and 
3) to evaluate the diagnostic value of the previous established criteria for its 
diagnosis (ADA 1998) and how to improve them.
Materials and methods: 80 patients with T1DM (without previous history 
of CVD) were screened for SMI by stress myocardial perfusion gated-SPECT 
(Single Photon Emission Computed Tomography). Data on traditional car-
diovascular risk factors and microvascular complications were also recorded. 
AS was assessed by aortic pulse wave velocity (aPWV - Sphygmocor®).
Results: The baseline characteristics of the patients included in the study are 
shown in Table 1. The prevalence of SMI was 12.5%. SMI was associated with 
the presence of hypertension (OR 4.5 (95%CI 1.1-18.9); p=0.041) and HbA1c 
value (OR 2.4 (95%CI 1.1-5.0); p=0.023.). The ADA criteria for the screening 
of SMI showed a good predictive value (OR 8.3 (95%IC 1.7-40.6); p=0.009. 
AUC 0.73 (0.54-0.91)). However, the addition of HbA1c value (AUC 0.87 
(0.75-0.99) vs. 0.73 (0.54-0.93); p=0.034) and the presence of diabetic retin-
opathy (AUC 0.86 (0.74-0.98) vs. 0.73 (0.54-0.92); p=0.057) improved the 
predictive value, thus resulting in the best model of SMI prediction (AUC 
0.91 (0.83-0.99) vs. 0.73 (0.54-0.92); p=0.026). aPWV did not add any signifi-
cant improvement for SMI identification (p=0.583).
Conclusion: The prevalence of SMI in patients with T1DM without previous 
CVD is 12.5%. Although The ADA criteria for the screening of SMI predicted 
its presence adequately, adding HbA1c and taking into account the presence 
of diabetic retinopathy significantly improve the prediction rate.
Supported by: BGLV 2012 (ACD); PI12/0095 (ISCIII); GLC - Rio Hortega 
(CM12/00044. ISCIII)
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Integrative analysis of biomarkers for cardiovascular complications 
through networks of metabolites and proteins
R.A. Momo1, F. Vitali2, F. Mulas3, V. Schnecke1, R. Bellazzi2;  
1Translational Science, AstraZeneca, Mölndal, Sweden, 2Dipartimento  
di Ingegneria Industriale e dell‘Informazione, 3Centro Interdipartimentale  
di Ingegneria Tissutale, Università degli Studi di Pavia, Italy.
Background and aims: The SUMMIT project (SUrrogate markers for Micro- 
and Macro-vascular hard endpoints for Innovative diabetes Tools), seeks to 
identify genetic and non-genetic biomarkers for prediction of disease pro-
gression and risk of vascular complications. A collection of samples from dif-
ferent cohorts have been provided by combining a variety of high-throughput 
techniques encompassing proteomics and metabolomics. Integrative bioin-
formatics methods that combine different data sources may provide deeper 
insights into the molecular interactions underlying complex diseases. Within 
this context, we constructed a network with proteins and metabolites as 
nodes whose analysis suggests the most relevant entities involved in the dis-
ease pathways.
Materials and methods: Starting from a list of SUMMIT-discovered bio-
markers, i.e., proteins and metabolites that have been shown to be associated 
with cardiovascular complications we obtained a disease-related network by 
combining evidences from different repositories. In detail, STRING, STITCH 
and MetaCore were used to initially build individual networks that were sub-
sequently merged into a combined network associating the discovered mark-
ers to other molecules known to interact with them. Topological analysis 
of this network has been used to identify enriched biological pathways and 
mechanisms, and to suggest a set of relevant nodes as candidates for pharma-
cological therapies.
Results: The network representation could elucidate molecules and interac-
tions involved in the disease and better define its global picture. While the 
different repositories can be used separately to build disease networks, merg-
ing these networks provided a better model of the whole disease context. The 
list of pathways identified as significantly enriched (p-value < 0.001) con-
tained those related to insulin resistance as well as others that have not previ-
ously been identified as potential targets for standard diabetes therapies. For 
example, the signaling by Insulin-like Growth Factor 1 Receptor (IGF1R) was 
amongst those identified. This receptor is a negative regulator of insulin sign-
aling and currently has not been taken into account for diabetes therapies. 
However, it has been shown that cardiac overexpression of IGF-1R in mice 
prevents diabetes-induced cardiac fibrosis and diastolic dysfunction.
Conclusion: We believe that higher integration across different systems biol-
ogy platforms eases interpretation of discoveries, supports validation of hy-
pothesis and ultimately speeds up the drug discovery process.
Supported by: IMI, European Commission’s FP7 (the SUMMIT consortium, 
IMI-2008/115006)
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Correlation of inflammatory markers and insulin resistance indexes with 
the short- and long-term outcome after an acute coronary syndrome in 
different glycaemic categories
A. Koutsovasilis1, A. Papazafiropoulou1, A. Sotiropoulos1, A. Melidonis2,  
S. Foussas3, T. Peppas1, E. Tamvakos1, S. Bousboulas1;  
13rd Internal Medicine Department & Diabetes Center, General Hospital 
of Nikaia-Piraeus, Athens, 21st Internal Medicine Department & Diabetes 
Center, 3Cardiology Department, Tzanio General Hospital of Piraeus, 
Greece.
Background and aims: The glucose metabolism disorder is frequent in pa-
tients who are admitted after an Acute Coronary Syndrome (ACS). The aim 
of this study is to examine the correlation of ACS outcome with insulin resist-
ance indexes and inflammatory markers in known diabetes patients, newly 
diagnosed diabetes patients, patients with impaired glucose tolerance (IGT) 
and normoglycaemic patients.
Materials and methods: 536 patients who were admitted at the Cardiology 
Department within a two-year period were included in the study. All patients 
underwent a clinical laboratory testing including insulin level in order to 
measure insulin-resistance indexes (HOMA- Homeostasis Model Assess-
ment and QUICKI- Quantative Insulin Sensitivity Check Index) and inflam-
matory markers (high-sensitivity C-reactive protein (hs-CRP), white blood 
cells count (WBC), fibrinogen and erythrocyte sedimentation rate (ESR)). All 
non diabetic patients went under an oral glucose tolerance test (OGTT) one 
month after discharge. Study’s end-points were death, a new ACS, arrhyth-
mias and acute pulmonary oedema of cardiological origin during hospitaliza-
tion and 12 months after the ACS.
Results: 199 (37,12%) patients were normoglycemic while 168 (31,34%) 
were known diabetics, 59 (11%) newly diagnosed diabetic patients and 
110 (20,52%) were IGT patients. There was a statistically significant corre-
lation of the hs-CRP with the outcome during hospitalization (HR=1.712, 
95%CI:1.193-2.458, p=0.004) for all patients. hs-CRP (HR=2.612, 
95%CI:1.474-4.628, p=0.001) and HOMA index (HR=1.967, 95%CI:1.184-
3.267, p=0.009) were significantly correlated with the appearance of a major 
cardiovascular event (MACE) during hospitalization for all patients but only 
hs-CRP was correlated with MACE for each group separately. Complications 
during the first 12 months after an ACS were significantly correlated only 
with the hs-CRP for all patient categories. hs-CRP, HOMA and QUICKI 
indexes were correlated with MACE in a multivariate analysis for known 
diabetes patients (HR=1.542, p=0.023, HR=1.482, p=0.039 and HR=0.810, 
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p=0.031 respectively), newly diagnosed diabetes patients (HR=2.401, 
p=0.035, HR=1.364, p=0.046, HR=0.832, p=0.041) and IGTs (HR=1.354, 
p=0.023, HR=1.269, p=0.047, HR=0.782, p=0.036) 12 months after the ACS. 
Association of hs-CRP (HR=2.012, p=0.008), HOMA (HR=2.438, p=0.002) 
and QUICKI (HR=0.503, p=0.010) with MACE was significant in an univari-
ate analysis while only hs-CRP (HR=1.477, p=0.032) remained significant in 
a multivariate analysis for normoglycaemic patients
Conclusion: hs-CRP is the inflammation marker which is correlated with the 
appearance of complications during hospitalization and 12 months after an 
ACS, while HOMA and QUICKI indexes are correlated with the appearance 
of major cardiovascular events during hospitalization as well as the 12-month 
follow-up period regardless of patient glycaemic profile. The combination of 
these indexes with hs-CR significantly improves the latter’s prognostic model 
in particular regarding major cardiovascular events.
1247
Both DHA/AA ratio and absolute DHA levels, but not EPA levels, 
constitute an independent risk factor for the severity of coronary 
atherosclerosis in type 2 diabetic patients
T. Nakamura, K. Murata, R. Kaneko, K. Ikeda;  
Omihachiman Medical Community Center, Omihachiman, Shiga, Japan.
Background and aims: The concentrations of dietary n-3 polyunsaturated 
fatty acids (PFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) modify the incidence of coronary heart disease (CHD). Espe-
cially, the effects of EPA on cardiovascular events have been clarified through 
recent large-scale intervention clinical studies. However, it is still unknown 
whether DHA may make a contribution to clinical efficacy associated with 
the risk of CHD. Thus, we investigate which n-3 PFA is more effective on the 
association of the severity of CHD in type 2 diabetic patients.
Materials and methods: 184 type 2 diabetic subjects were nominated as poor 
blood glucose control from April 2008 to September 2010 and aged 40 to 72 
years on this trial. We firstly calculated fasting plasma PFAs, LDL-cholesterol, 
HDL cholesterol and triglyceride (TG) levels. The subjects were asked about 
daily intake of different type of fish and n-3 PUFAs intake was calculated 
using computer food composition software. We excluded the subjects who 
reported the history of CHD or ECG abnormality consistent with ischemia 
at baseline survey. Then they had been followed for five years, focusing on 
the occurrence of major cardiovascular events or ECG abnormality for an 
observation period, which compromised nonfatal and fatal CHD diagnosed 
using percutaneous coronary intervention. CHD severity was assessed using 
the Gensini scoring system. Next, we divided them into 2 groups, who were 
in the presence of CHD (DM-PCI, N=56) and no episodes of CHD (DM, 
N=70) and 71 healthy volunteers were nominated (NGT). These values were 
analyzed using an ANOVA model, Pearson’s test and multivariate logistic re-
gression models analyses.
Results: The ratios of smokers and subjects with antihypertensive and/or li-
pid modifying treatment were not significant between DM-PCI and DM. The 
average of systolic blood pressure, age, BMI, the concentrations of HbA1c, 
LDL, HDL and TG were no different between two groups. On the contrary, 
the concentrations of FPG, HbA1c, LDL, TG and remnant like particle (RLP) 
were significantly lower in NGT than in DM-PCI and DM. Firstly, we inves-
tigated the relation between the basal plasma concentrations of both EPA and 
DHA and daily fish intake was the positive correlation in the diabetic sub-
jects (r=0.77 p<0.001, r=0.61 p<0.001, respectively). These data indicated the 
plasma concentrations of PFAs were considered to originate from fish intake. 
Both EPA/AA and DHA/AA levels in DM-PCI were significantly lower than 
those in NGT (EPA/AA; 0.31, 0.47 p<0.001, DHA/AA; 0.69, 0.85 p<0.001, 
respectively) but not significant compared to DM. Although the concentra-
tions of both EPA/AA and DHA/AA in DM-PCI were significantly negative 
correlation to Gensini score (r=0.44 p<0.001, r=0.50 p<0.001, respectively), 
there were no correlation between this score and non-HDL, LDL/HDL, RLP, 
HbA1c. In multivariate logistic regression model, only DHA/AA ratio in-
creased up to 3.08 (95% CI 1.76-5.89) with statistical value of p=0.01.
Conclusion: A negative correlation was noted between the severity of CHD 
and DHA/AA ratio in DM-PCI, as same as the absolute values for DHA. In 
addition, the lower levels of DHA/AA in DM-PCI may show us the evidence 
that PFAs, especially DHA intake, was inversely and independently associ-
ated the severity of CHD.
 
1248
Association of NLRP3 inflammasome activation and cardiovascular 
disease risk using Framingham score in patients with newly diagnosed 
type 2 diabetes mellitus
K. Joung, J. Lee, H. Kim, B. Ku;  
Internal Medicine, Endocrinology, Chungnam National University, Daejeon, 
Republic of Korea.
Background and aims: Chronic low-grade inflammation caused by activa-
tion of the innate immune system plays an essential role in the pathogenesis 
of type 2 diabetes and its major complications. Emerging evidence suggests 
that activation of the nucleotide binding and oligomerization domain-like 
receptor family pyrin domain-containing 3 (NLRP3) inflammasome leads to 
the maturation and secretion of interleukin (IL)-1β and is involved in the 
pathogenic mechanisms of obesity-induced inflammation, insulin resistance, 
and type 2 diabetes development. In our previous study, NLRP3 inflamma-
some activation is elevated in myeloid cells from drug-naïve, newly diag-
nosed type 2 diabetic patients and antidiabetic treatment with metformin 
contributes to modulation of inflammasome activation. These previous re-
ports prompted us to explore the association of cardiovascular risk and the 
inflammasome activation in type 2 Diabetes.
Materials and methods: We performed a sub-analysis to evaluate the associ-
ation of cardiovascular risk using the Framingham cardiovascular risk score 
with the NLRP3 inflammasome activation in 47 diabetic patients.
Results: Patients had a male-to-female ratio of 31:16, mean age of 51.9 ± 
11.8 years, a mean body mass index of 25.4 ± 3.0 kg/m2, a mean HbA1c of 
8.5 ± 2.3 %, a mean low density lipoprotein-cholesterol of 140 ± 37 mg/dl, 
and a mean baseline Framingham risk score of 7.3 ± 6.7 %. Framingham risk 
score was associated neither relative mRNA expression of NLRP3, apoptosis-
associated speck-like protein containing a CARD (ASC) nor production of 
proinflammatory cytokines regardless of stimulation with lipopolysaccharide 
(LPS) in monocyte-derived macrophages (MDMs) from the type 2 diabetic 
patients (Table 1). Also, Framingham score was not correlated with IL-1β se-
cretion in MDMs after stimulation with various danger molecules such as 
adenosine triphosphate, monosodium uric acid crystals, islet amyloid poly-
peptides, and free fatty acids. The type 2 diabetic patients with intermediate 
to high cardiovascular risk (Framingham risk score >10%) did not show the 
increase of either IL-1β or IL-18 in serum compared to the patients with low 
risk (Framingham risk score < 5%, 23.3±11.5 vs 21.3±16.7 pg/ml; P=0.651, 
34.6±14.3 vs 31.2±16.5 pg/ml; P=0.530).
Conclusion: In conclusion, the NLRP3 inflammasome activation was not as-
sociated the cardiovascular risk in the newly diagnosed type 2 diabetes.
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Soluble urokinase plasminogen activator receptor is elevated in  
diabetes and associated with diabetic complications in patients with  
type 1 diabetes
S. Theilade1, S. Lyngbaek2, T.W. Hansen1, J. Eugen-Olsen3, M. Fenger4,  
P. Rossing1,5, J. Jeppesen2,5;  
1520, Steno Diabetes Center, Gentofte, 2Department of Medicine, Glostrup 
Hospital, Glostrup, 3Clinical Research Centre, Hvidovre Hospital, 
4Department of Biochemistry, Hvidovre Hospital,  
5Aarhus University, Denmark.
Background and aims: Soluble urokinase plasminogen activator receptor 
(suPAR) is a marker of inflammation and endothelial dysfunction. We in-
vestigate associations between suPAR and diabetic complications in type 1 
diabetes.
Materials and methods: From 2009-2011, 667 type 1 diabetes patients and 
51 non-diabetic control subjects were included in a cross-sectional study at 
our center. suPAR was measured with ELISA (ViroGates, Denmark). Dia-
betic complications were cardiovascular disease (CVD) (previous myocar-
dial infarction, revascularisation, peripheral arterial disease and stroke), 
autonomic dysfunction (heart rate variability during deep breathing < 11 
beats per minute), albuminuria (urinary albumin excretion rate (UAER) ≥ 
30 mg/24-hours) or high arterial stiffness (pulse wave velocity ≥ 10 m/s). 
Adjusted analyses included gender, age, systolic blood pressure, estimated 
glomerular filtration rate, UAER, HbA1c, total-cholesterol, body mass index, 
C-reactive protein, antihypertensive treatment and smoking.
Results: suPAR was lower in controls vs. patients, controls vs. normoalbumi-
nuric patients (< 30 mg/24-hours), normoalbuminuric patients with short vs. 
long diabetes duration (> 10 years), and increased with degree of albuminuria 
(adjusted p < 0.001 for all). Furthermore, suPAR levels were higher in patients 
with vs. without CVD (n = 144 (21.3%)), autonomic dysfunction (n = 349 
(59.2%)), albuminuria (n = 357(53.1%)) and high arterial stiffness (n = 297 
(47.2%)) (adjusted p ≤ 0.024). Per 1 unit increase in ln-suPAR adjusted odds 
ratios were for CVD: 2.5 (1.1-5.7), autonomic dysfunction: 2.7 (1.2-6.2), al-
buminuria: 3.8 (1.3-10.9) and high arterial stiffness: (2.5 (1.1-6.1) (p ≤ 0.039).
Conclusion: suPAR is associated with type 1 diabetes, diabetes duration and 
complications independently of other risk factors. suPAR may be a novel risk 
marker in the management of diabetes.
Clinical Trial Registration Number: 2009-056; NCT01171248
PS 112 Clinical observations in 
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The role of glucagon in post-prandial hyperglycaemia for children  
5 years after onset of type 1 diabetes 
S. Fredheim1,2, M.L.M. Andersen1, S. Pørksen1, L.B. Nielsen1, C. Pipper3,  
L. Hansen1, J. Johannesen1,2, H.B. Mortensen1,2, J. Svensson1,2;  
1Pediatric Department, Herlev Hospital, 2Copenhagen University, 
3Department of Biostatistics, Copenhagen University, Denmark.
Background and aims: The role of glucagon on glycemic control in type 1 
diabetes is debated, and high glucose concentrations have previously been 
shown to increase glucagon release. We investigated stimulated glucagon and 
glucagon-like peptide-1 (GLP-1) levels in children during 12 to 60 months 
after onset of type 1 diabetes.
Materials and methods: The study cohort comprised 129 children (66 boys) 
mean (SD) age at onset; 10.04 (3.9) range 0.6-16.6 years with newly diagnosed 
type 1 diabetes. Liquid mixed-meal (Boost) stimulated levels of C-peptide, 
glucagon, glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide 
(GIP), blood glucose (measured 90 min post-ingestion of Boost drink), and 
HbA1c (DCCT), were analysed centrally 1, 3, 6, 12 and (N=40) 60 months 
(m) after diagnosis. Robust multivariate regression methods were used for 
statistical analyses. Results are listed as RR [95% CI] corresponding to a dou-
bling of the explanatory variable. Analyses were adjusted for age, sex, diabetes 
duration and stimulated C-peptide.
Results: During the 60 months, post-prandial glucagon levels were highly as-
sociated to the rise in stimulated GLP-1 (RR 1.33 [1.19; 1.48], p <0.0001) and 
stimulated blood glucose levels (1.36 [1.19; 1.56], p <0.0001). Post-prandial 
glucagon was negatively associated to stimulated C-peptide at 3 (RR0.94, 
[0.89; 0.99], p =0.019), 6 (RR 0.91 [0.87; 0.95], p < 0.0001) and 12 months 
((RR 0.94, [0.90; 0.99], p =0.021), when residual beta-cell function is present), 
but no association existed 60 months post-diagnosis. HbA1c associated sig-
nificantly to post-prandial glucagon levels (RR 1.03, [1.01; 1.05], p =0.003). 
A doubling of post-prandial glucagon levels corresponded to a 3% relative 
increase in HbA1c levels. Furthermore, HbA1c levels were negatively associ-
ated to stimulated C-peptide at 3 (p <0.0001), 6 (p <0.0001) and 12 months 
(p <0.0001), but not 60 months post-diagnosis.
Conclusion: Post-prandial glucagon levels were highly associated with 
worsening of glycaemic control and blood glucose levels during the first 60 
months after diagnosis. This suggests that elevated glucagon augmented hy-
perglycaemia (HbA1c) observed in the time period. The positive association 
with GLP-1 suggests that physiologic levels of GLP-1 levels are insufficient to 
constrain glucagon.
1251
Disease management and outcomes in European children, adolescents, 
and young adults with type 1 diabetes (T1D): the global TEENs study
M. Phillip1, L. Laffel2, C. Domenger3, V. Pilorget4, C. Candelas4, T. Danne5, 
C. Mazza6, B. Anderson7, R. Hanas8, S. Waldron9, R. Beck10, C. Mathieu11;  
1Schneider Children‘s Medical Center of Israel, Petah Tikva, Israel, 
2Joslin Diabetes Center, Boston, USA, 3Sanofi, Paris, 4Sanofi, Chilly 
Mazarin, France, 5Kinder und Jugendkrankenhaus “Auf der Bult”, 
Hannover, Germany, 6Hospital de Pediatría J P Garrahan, Buenos Aires, 
Argentina, 7Baylor College of Medicine, Houston, USA, 8Gothenburg 
University, Sweden, 9Hosted by West Midlands Strategic Clinical Network, 
Birmingham, UK, 10Jaeb Center for Health Research, Tampa, USA, 
11University Hospitals (UZ), Leuven, Belgium.
Background and aims: TEENs is the largest contemporary, international, 
cross-sectional study of young T1D patients (N=5,960), aiming to identify 
approaches to optimise glycaemic control and outcomes. Data from the Euro-
pean cohort (n=2,943; 49.4% of the global population) are reported.
Materials and methods: Of the 219 TEENs centres from 20 countries, 111 
centres from 11 European countries (Denmark, France, Germany, Hungary, 
Italy, Portugal, Romania, Russia, Slovenia, Spain and Sweden) participated. 
Data were collected by patient interview, medical record review, and patient/
parent survey from three age groups: children (8-12 years old [y/o]), adoles-
cents (13-18 y/o), and young adults (19-25 y/o). A1c was measured uniformly 
(reference range 4-6%) using A1cNow™ (Bayer). Target A1c levels were cat-
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egorised as <7.5% (58 mmol/mol) for patients ≤18 years of age (ISPAD) and 
<7% (53 mmol/mol) for patients 19-25 years of age (ADA). Patients aged 
13-18 and 19-25 y/o completed the Problem Areas In Diabetes (PAID) ques-
tionnaire; parents of youth aged 8-12 and 13-18 y/o completed the PAID 
parent-revised (PAID-PR) version. Scores on each survey range from 0 to 
100; higher scores indicate greater disease burden.
Results: Median (interquartile range) time since T1D diagnosis was 6.5 years 
(3.7-9.9). Overall mean (±SD) A1c was 8.1±1.6% (65±18 mmol/mol), with 
35% of patients attaining A1c targets. Treatment characteristics and diabe-
tes management methods by age group and A1c target attainment as well as 
treatment burden by age group are shown (Table).
Conclusion: In a sample of 8-25-year-olds with T1D from 11 European coun-
tries, A1c was suboptimal and approximately one third of patients achieved 
targets. In the TEENs study, European patients at target tended to receive 
more intensive management than those not at target, especially patients aged 
8-18. Parents/guardians reported a significantly higher perceived burden of 
care compared with adolescents. Thus, opportunities exist to improve A1c 
outcomes and reduce burden of disease for youth with T1D.
Supported by: Sanofi
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High and increasing prevalence of diabetic ketoacidosis at diagnosis of 
type 1 diabetes in children, Colorado, 1998-2012
A. Rewers, F. Dong, R. Slover, G. Klingensmith, M. Rewers;  
Pediatrics, University of Colorado, Aurora, USA.
Background and aims: Diabetic ketoacidosis (DKA) at the time of diagnosis 
of childhood diabetes is life-threatening and has a detrimental effect on the 
future course of the disease. Frequency of DKA reflects access to care and 
indicates the level of children’s health in a country. The aim of this study was 
to analyze time trends in DKA at diagnosis of childhood diabetes in Colorado 
during 1998-2012 and to explore modifiable risk factors.
Materials and methods: A prospective registry of children diagnosed with 
diabetes before 18 y of age during 1998-2012 and treated at the Barbara Da-
vis Center for Childhood Diabetes in Denver, CO. A total of 4989 children 
were registered, including 3544 diagnosed with type 1 diabetes and residing 
in Colorado at the time of diagnosis. The main outcome measure was preva-
lence of DKA at the time of diagnosis of diabetes.
Results: The prevalence of DKA increased significantly from 29.9% in 1998 
to 46.2% in 2012 (p<.001 for trend); the most rapid increase occurred be-
tween 2007 and 2012. DKA was most likely to occur at diagnosis among the 
youngest children and those of African-American ancestry. Family history 
of diabetes, especially type 1 diabetes among 1st degree relatives, was protec-
tive as was participation in research studies following children at high ge-
netic risk. Coverage by a private health insurance (OR=0.37; 0.29-0.49) or a 
government-provided one (OR=0.63; 0.51-0.81), was associated with a lower 
likelihood of DKA, compared to no insurance. The number of children cov-
ered by government-provided health insurance has doubled and their DKA 
rates continue to be high. In addition, DKA is rapidly increasing among chil-
dren with private health insurance.
Conclusion: The rapid and unabated increase in the prevalence of DKA at 
diagnosis of childhood type 1 diabetes suggests a major worsening in early 
recognition of diabetic symptoms and also in access to appropriate health 
care among Colorado children over the past 15 years. The frequency of DKA 
has increased to the levels rarely seen in developed countries.
1253
Diabetic ketoacidosis (DKA) in children with type 1 diabetes mellitus 
(T1DM): an Italian multicentre survey
S. Zucchini1, R. Bonfanti2, P. Buono3, F. Cardella4, V. Cauvin5, V. Cherubini6, 
G. D‘Annunzio7, A. Frongia8, D. Iafusco9, G. Maltoni1, I.P. Patera10,  
A. Scaramuzza11, S. Toni12, S. Tumini13, I. Rabbone14;  
1Dept of Woman Child and Adolescent Health, S.Orsola-Malpighi H., 
Bologna, 2Diabetes Research Institute, S.Raffaele H., Milan,  
3Dept of Pediatrics, University of Naples, 4Children H. G Di Cristina, 
Palermo, 5S.Chiara H., Trento, 6Dept of Women‘s and Children‘s Health, 
Salesi H., Ancona, 7Dept of Pediatrics, Gaslini H., Genoa, 8Dept of 
Pediatrics, Brotzu H., Cagliari, 9Dept of Pediatrics, 2nd University of Naples, 
10Endocrinology and Diabetology Unit, Bambino Gesù Children‘s H., Rome, 
11Dept of Pediatrics, Sacco H., Milan, 12Pediatric Diabetology Unit, Meyer 
Children‘s H., Florence, 13Dept of Pediatrics, University of Chieti, 1 
4Dept of Pediatrics, University of Turin, Italy.
Background and aims: Italian children with T1DM are usually followed by 
pediatric diabetologists. Since recent data on epidemiology and manage-
ment of primary diabetic ketoacidosis in children with T1DM are lacking a 
questionnaire was sent to the 77 centres belonging to the study group of dia-
betology of the Italian Society for Pediatric Diabetology and Endocrinology 
(ISPED) enquiring on epidemiology (2012-2013) and present management 
of DKA.
Materials and methods: From 1/1/2012 to 31/12/2013 a survey on DKA was 
conducted in all pediatric Centres belonging to the ISPED. Presence DKA 
was defined according to the IDF/ISPAD criteria. The following data were 
collected: treatment according IDF/ISPAD protocol yes or not, type of re-
hydrating solution used, bicarbonates use yes or not and amount of insulin 
infused.
Results: Data were returned from 68/77 Centres (87%) for a total of 14.493 
patients with T1D. We recorded 2453 children with T1DM onset, with DKA 
in 945 (38.5%) (severe in 10.3%). Considering only preschool children DKA 
was observed in 72% (severe in 16.6%). Cerebral oedema following DKA 
treatment was observed in 5 cases (0.5%). DKA treatment according ISPAD 
guidelines was adopted in 67% of the Centres, while 11% did not follow any 
specific guidelines. In the first 1-2 hours, rehydration was started with normal 
saline, at different rates: 5-10 ml/kg/h in 71%, 10-20 ml/kg/h in 16%, <5 ml/
kg/h in 4%. After the first hours, differences among Centres were observed 
regarding the type of solutions used: saline 0.9-0.45% in 75%, 5-10% glucose 
solution in 19%, irrespective of glycemic values. Potassium supplementation 
was performed at the rate of 20-40 mEq/l in 63% of Centres. Bicarbonates 
were never used in 17% of Centres, while in 68% were exceptionally used 
according to pH and clinical conditions. Insulin was infused starting form 
2nd-3rd hour at the rate of 0.05-0.1 U/kg/h in 63% of Centres, while others 
used infusion rate lowest as 0.025 U/kg/h.
Conclusion: Notwithstanding prevention campaign, DKA is still observed 
at clinical diabetes onset in Italian children. Despite international guidelines 
significant variability in DKA treatment still exists, underlying the need to 
share them among Centres. In Italy cerebral edema is a rare complication 
of DKA.
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Investigation of cerebrovascular changes in type 1 diabetic children and 
adolescents with transcranial Doppler ultrasound
A. Török1, R. Lovász2, A. Valikovics2, L. Barkai1;  
1Postgraduate Institute of Pediatrics, University of Debrecen, 2Department 
of Neurology, Borsod County Teaching Hospital, Miskolc, Hungary.
Background and aims: It is a well-known fact that diabetes (both type 1 and 
type 2) play a significant role in developing ischemic stroke in adults. Despite 
the fact that the prevalence of type 1 diabetes is rising among children and 
adolescents very few attention is paid to the cerebrovascular comlpication 
caused by this diseasae. Our aim was to measure the possible effect of dia-
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betes on the cerebrovascular system with a simple, non-invasive method the 
transcranial Doppler sonography.
Materials and methods: We performed transcranial Doppler sonography 
in 62 type 1 diabetic patients (older than 10 years of age, mean 14.59±2.46 
years) treated in our hospital and 46 (mean age 13.66±2.06) healthy children 
served as controls. We examined the middle cerebral arteries in both sides in 
lying position during rest by registering the velocities (peak systolic and end 
diastolic). Than we asked the children to stop their breathing as long as they 
can (but at least for 30 seconds) to increase the PCO2 which led to vasodila-
tation. After a short period of resting period came the decreasing of PCO2 
(causing vasoconstriction) by asking the children to take deep breaths for 30 
seconds. After collecting these data we calculated the pulsatility index ((sys-
tolic velocity-diastolic velocity)/mean velocity)and resistive index ((systolic 
velocity-diastolic veolcity)/systolic velocity) in all the 3 cases.
Results: The Kolmogorov-Smirnov test showed that all of the investigated 
variables showed normal distribution thus two-tailed t tests could be per-
formed to find statistical differences between diabetic patients and control 
group. After processing the data we can conclude that the diabetic group 
showed lower values in all investigated variables. The strongest difference 
(p=0.0214) could be found in the peak systolic velocities after hypervenitla-
tion (82.8 cm/s vs. 91.8 cm/s). An other significant (p=0.0401) difference was 
detected in the peak systolic velocities after hypoventilation (136.6 cm/s vs. 
146.5 cm/s), while all other findigs proved to be non-significant.
Conclusion: The fact that all measured velocities were lower among diabet-
ic children and adolescents suggests that some kind of pathophysiological 
changes must have been started among these patients and this harmful influ-
ence would proceed and would be responsible for the further well-known 
effects among adults. We assume that the first phase of this process affects the 
response for the ,,CO2 challenge”, that’s why the peak systolic velocities are 
influenced after both hypo- and hyperventilation. Besides raising the number 
of performing transcranial Doppler sonography we are working on inden-
tification of factors which can play a role forming the changes among our 
patients.
1255
40 year follow up of childhood onset diabetes reveals little long-term 
decline in the cumulative incidence of complications by diagnosis cohort 
except for renal failure
T. Orchard, T. Costacou, R.G. Miller;  
Department of Epidemiology, University of Pittsburgh, USA.
Background and aims: Despite dramatic improvements in life expectancy, 
morbidity rates in type 1 diabetes (T1D) still greatly exceed those of the gen-
eral population. To evaluate trends, by year of diagnosis, in the cumulative 
incidence of micro- and macro-vascular complications over 22 years of fol-
low-up, the prospective, observational, Pittsburgh Epidemiology of Diabetes 
Complications (EDC) study of childhood-onset T1D study was examined.
Materials and methods: Participants were categorized into five calendar 
year onset cohorts: 1950-59, 1960-64, 1965-69, 1970-74, and 1975-80. Renal 
failure (RF, self-report), hard coronary artery disease (CAD; MI, fatal CAD 
and revascularization), blindness (self-report) and amputations (self-report) 
were determined at 20, 25, 30, 35 and 40 years duration on the complete 
cohort (n=912). Proliferative retinopathy (PR; fundus photography), con-
firmed distal symmetric polyneuropathy (CDSP; clinical exam plus vibratron 
threshold), symptomatic autonomic neuropathy (SAN; 2+ symptoms and 
expiration/inspiration ratio <0.1), Lower Extremity Arterial Disease (LEAD; 
Ankle Brachial Index<0.9/amputation/intermittent claudication) and overt 
nephropathy (ON; albumin excretion rate>200 μg/min), were assessed at 20, 
25, 30, and 35 years’ duration on the subset of participants with a clinical 
examination (n=658).
Results: There was a marked decline in the cumulative incidence of RF across 
diagnosis cohorts at all durations (p<0.01-<0.001). An early decline in blind-
ness in those more recently diagnosed at 20 years duration (p<0.001) was 
no longer apparent at 30 or 40 years duration (p>0.6). CAD showed a small 
decline at 30 years across cohorts (p<0.03) which was less marked at 40 years 
(p=0.07). Amputations, PR, LEAD, ON, CDSP and SAN showed no diagno-
sis cohort declines except for CDSP at 20 years alone (p=0.04).
Conclusion: These data suggest that the cumulative incidences of T1D com-
plications are not declining universally although a strong decline in RF is ap-
parent which may represent better management of renal disease rather than 
prevention.
Supported by: NIH grants DK34818 and Rossi Memorial Fund
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Type 2 diabetes and associated complications in Western Australian 
children: a population based study (1990 - 2012)
A. Haynes1,2, R. Kalic1, J. Curran1, N. Paramalingam1,2, M.K. Bulsara3,  
M. Shah1, T.W. Jones1,2, E.A. Davis1,2;  
1Department of Endocrinology & Diabetes, Princess Margaret Hospital, 
Perth, 2Telethon Kids Institute, Perth, 3Institute of Health and Rehabilitation 
Research, Fremantle, Australia.
Background and aims: Data on childhood diabetes are available from the 
Western Australian Children’s Diabetes Database (WACDD), maintained by 
the only tertiary paediatric hospital in Western Australia servicing all chil-
dren diagnosed with diabetes throughout the State. This study aimed to de-
scribe the incidence of type 2 diabetes in Western Australian children and 
examine the prevalence of complications of diabetes.
Materials and methods: The study included children aged 0-16 years diag-
nosed with type 2 diabetes at our hospital, between 1990 to 2012, in a pop-
ulation-based sample. Incidence rates per 100,000 person-years at risk were 
calculated by Indigenous status and year of diagnosis. Mean (±SD) were es-
timated for age, BMI Z-score and HbA1C at diagnosis. Prevalence of micro-
albuminuria and hypertension were evaluated for patients at different time 
points for all available complications screening data.
Results: From 1990 to 2012, there were 135 (82 F:53 M) incident cases of type 
2 diabetes in children aged <17 years. Although Indigenous children make 
up ~6% of the general population, they were grossly over-represented, ac-
counting for 56% of cases. The mean incidence of type 2 diabetes was 0.6 per 
100,000 (95%CI: 0.5-0.8) in non-Indigenous children compared to 12.6 per 
100,000 (95%CI: 10.0-15.8) in Indigenous children. The mean age at diagno-
sis was 13.3(±2.0) years. At diagnosis, the mean BMI Z-score was 2.0(±0.6), 
with 12% of cases classified as being overweight and 61% obese. Mean HbA1c 
at diagnosis was 9.0%(±2.8%) compared to 7.7%(±2.5%) 3-12 months post-
diagnosis. Hypertension was observed in 15/75 (20%) of cases at the time of 
diagnosis and in 19% of cases 2 years post-diagnosis. Similarly, microalbumi-
nuria was detected in 11/61 (18%) of cases at the time of diagnosis and 23% 
of cases 2 years post-diagnosis.
Conclusion: In keeping with other populations, the incidence of childhood 
type 2 diabetes is increasing in Western Australia, the highest incidence be-
ing observed in Indigenous children. Despite their youth, complications of 
diabetes were already present in this cohort at diagnosis and their prevalence 
increased markedly even with short duration of disease. There is presently 
no screening program for children at increased risk of developing type 2 dia-
betes in Western Australia, and older adolescents with type 2 diabetes may 
not be ascertained by the paediatric service. Therefore, undiagnosed cases 
are likely to exist in the study population, and these data represent a likely 
underestimation.
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Glycaemic control and acute complications in children, adolescents, and 
young adults with type 1 diabetes (T1D): the global TEENs study
L. Laffel1, C. Domenger2, V. Pilorget3, C. Candelas3, T. Danne4, M. Phillip5, 
C. Mazza6, B. Anderson7, R. Hanas8, S. Waldron9, R. Beck10, C. Mathieu11;  
1Joslin Diabetes Center, Boston, USA, 2Sanofi, Paris, 3Sanofi, Chilly 
Mazarin, France, 4Kinder und Jugendkrankenhaus “Auf der Bult”, Hannover, 
Germany, 5Schneider Children‘s Medical Center of Israel, Petah Tikva, 
Israel, 6Hospital de Pediatría J P Garrahan, Buenos Aires, Argentina, 7Baylor 
College of Medicine, Houston, USA, 8Gothenburg University, Sweden, 
9Hosted by West Midlands Strategic Clinical Network, Birmingham, UK, 
10Jaeb Center for Health Research, Tampa, USA,  
11University Hospitals (UZ), Leuven, Belgium.
Background and aims: Optimal glycaemic control remains elusive for many 
young patients with T1D. The TEENs study is the largest contemporary, in-
ternational, observational study of young T1D patients (N=5,960), aiming to 
identify approaches to optimise glycaemic control and outcomes.
Materials and methods: 219 centres from 20 countries collected data by pa-
tient interview, medical record review, and patient/parent survey from three 
age groups (8-12-year-olds [y/o], n=1,724), adolescents (13-18 y/o, n=2,854), 
and young adults (19-25 y/o, n=1,382). A1c was measured uniformly (refer-
ence range 4-6%) using A1cNow™ (Bayer). Target A1c levels were categorised 
as <7.5% (58 mmol/mol) for patients ≤18 years of age (ISPAD) and <7% (53 
mmol/mol) for patients 19-25 years of age (ADA). Factors associated with 
attaining target A1c were identified by multivariate analysis.
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Results: Median (interquartile range) duration of T1D was 6.1 (3.3-9.6) 
years; mean (±SD) A1c was 8.5±1.8% (69±20 mmol/mol). A1c targets were 
achieved by 28% of patients (32% of 8-12 y/o, 29% of 13-18 y/o, and 19% 
of 19-25 y/o). Overall, 351 (5.9%) patients reported diabetic ketoacidosis 
(DKA) in the past 3 months, with the highest occurrence in 19-25 y/o (6.6% 
vs 5.6% in 8-12 y/o and 5.7% in 13-18 y/o). Severe hypoglycaemia leading to 
seizure or loss of consciousness was reported by 162 (2.7%) patients with the 
highest occurrence in 19-25 y/o (4.1% versus 2.5% in 8-12 y/o and 2.2% in 
13-18 y/o). Incidence of acute T1D complications by A1c goal attainment and 
age are shown (Table). In all age groups, occurrence of DKA rates was higher 
in those not at A1c target. Rates of microalbuminuria, retinopathy treatment, 
and neuropathy were highest in 19-25 y/o and in patients not at target. In 
multivariate analyses, presence of DKA (OR 0.53 [95% CI 0.39, 0.73]) and 
diabetic neuropathy symptoms (OR 0.47 [95% CI 0.34, 0.66]) were signifi-
cantly associated with not attaining A1c target (p<0.001).
Conclusion: In the TEENs study, occurrence of acute complications tended 
to be higher in patients not at target. Diabetes outcomes in these young T1D 
patients was suboptimal, with mean A1c above target for approximately two 
thirds of participants and many youth experienced acute complications, sup-
porting the need for further improvements.
Supported by: Sanofi
PS 113 Clinical observations  
in children and women
1258
Recent trends in type 1 diabetes incidence in children and adolescents in 
Germany
J. Rosenbauer1, A. Stahl-Pehe1, C. Baechle1, K. Castillo1, M. Grabert2,  
G. Giani1, R.W. Holl2, in cooperation with ESPED, DPV and the GCNDM;  
1Institute for Biometrics and Epidemiology, German Diabetes Centre, 
Duesseldorf, 2Institute for Epidemiology and Medical Biometry,  
Ulm University, Germany.
Background and aims: Recent data from Nordic European countries suggest 
that the increase in the incidence of childhood type 1 diabetes (T1D) may 
have levelled off or the trend may have even reversed in recent years. Aim 
of the present study was to estimate the recent time trend in T1D among 
children and adolescents 0-19 years of age in the German federal state North 
Rhine-Westphalia (NRW) between 2002 and 2012.
Materials and methods: The average risk population consisted of 3.08 mil-
lion children and adolescents. The NRW diabetes incidence register ascer-
tains newly diagnosed cases of T1D by means of three data sources: the 
prospective hospital-based active surveillance system ESPED, annual in-
quiries among medical practices, and the DPV database, a computer-based 
documentation system for quality control and scientific research in diabetes 
care. Completeness of ascertainment was estimated by the capture-recapture-
method. Point and interval estimates (95%CI) of incidence rates (per 100,000 
person-years) were based on Poisson distribution. Age- and/or sex-standard-
ized rates were estimated by the direct method using equal weights. Poisson 
regression analysis was applied to assess time trends adjusted for annual com-
pleteness of ascertainment.
Results: Between 2002 and 2012, a total of 8,274 children and adolescents 
(4,465 boys) aged 0-19 years with new-onset T1D were registered. Ascertain-
ment was estimated to be 98.7% (95%CI: 98.4%; 99.0%) complete. The overall 
incidence rate was 20.8 (20.3; 21.2). The incidence among boys (21.8 (21.2; 
22.5)) was higher than among girls (19.8 (19.1; 20.4), rel. risk 1.11 (1.07; 1.16), 
p<0.001), mainly owing to the male preponderance among the age groups 10-
14 (30.8 (29.4; 32.3) vs. 24.6 (23.3; 26.9)) and 15-19 years (11.4 (10.6; 12.3) 
vs. 8.3 (7.6; 9.1)). Age-specific estimates for age groups 0-4, 5-9, 10-14, and 
15-19 years were 17.7 (16.8; 18.5), 28.0 (26.9; 29.0), 27.7 (26.7; 28.7), and 
9.9 (9.3; 10.5), respectively (p<0.001). The annual incidence rates ranged be-
tween 17.6 in 2002 and 23.3 in 2012. The average relative annual increase 
was estimated as 2.1% (1.4%; 2.8%). Overall, there were no significant dif-
ferences in trends among boys and girls (annual increase: 2.3% (1.3%; 3.2%) 
vs. 1.9% (0.9%; 2.9%), p=0.592). Among boys, significant increasing trends 
were observed in the 0-4, 5-9 and 10-14 years age groups (2.3% (0.1%; 4.5%) 
vs. 2.9% (1.2%; 4.7%) vs. 2.3% (0.8%; 3.9%), p<0.05 each), but no change in 
adolescents (0.6% (-2.2%; 3.4%), p=0.529). Among girls, significant increas-
ing trends were observed in the 5-9 and 10-14 years age groups (3.7% (2.0%; 
5.4%) vs. 2.9% (1.1%; 4.7%), p<0.05 each), there was no change among 0-4 
year-olds (0.1% (-2.1%; 2.4%), p=0.909). The incidence among 15-19 year old 
girls tended to decrease (-2.6% (-5.3%; 0.1%), p=0.062).
Conclusion: The data suggest that T1D incidence in childhood and adoles-
cents is still increasing in Germany, unlike in Nordic European countries. 
However, age-specific trends are not uniform in both sexes. Based on the cur-
rent data, there are annually about 3,200-3,700 children and adolescents new-
ly diagnosed with T1D in Germany underlining the public health importance 
of the disease. Causes of the continuous rise and, in particular, the differential 
age-specific trends of T1D incidence between sexes have still to be identified.
Supported by: GMH, MISRT-NRW, GCNDM (01GI1109A, 01GI1106)
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Insulin pumps or injections in children with type 1 diabetes
R. Schiel, D. Burgard;  
Department of Diabetes and Metabolic Diseases, MEDIGREIF Inselklinik 
Heringsdorf GmbH, Ostseebad Heringsdorf, Germany.
Background and aims: During the last decades the percentage of children/
adolescents with type 1 diabetes and insulin pump treatment (continuous 
subcutaneous insulin infusion [CSII]) increased substantially. In Germany 
about 40% of the children younger than 6 years are currently treated with 
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CSII. It was the aim of the trial to analyse the quality of diabetes control and 
patients‘ ability for a sufficient diabetes self-management using CSII versus 
injection therapy.
Materials and methods: All children/adolescents (n=901, age 11.5±4.0, dia-
betes duration 4.0±3.6 years) with type 1 diabetes were enrolled in the trial, 
admitted to an in-patient rehabilitation during the period 04/2004-10/2010.
Results: At the time of hospital admission n=707 patients (78%) had an in-
jection therapy (IT), n=194 (22%) had a CSII. Quality of diabetes control 
(IT vs CSII: HbA1c 8.72±2.26 vs 8.35±1.71%, p=0.09), mean amplitude of 
daily blood glucose excursions (9.4±3.4 vs 9.8±3.2 mmol/l, p=0.22), inci-
dences of acute complications (hypo-/hyperglycaemia) were comparable. 
Children/Adolescents with CSII had a longer diabetes duration (5.3±3.7 vs 
3.6±3.5 years, p< 0.01), better postprandial blood glucose levels (10.0±3.0 vs 
12.2±3.3 mmol/l, p=0.03) and a higher frequency of blood-glucose self-tests 
(45.4±13.3 vs 38.2±11.5 self-tests/week, p< 0.01). Neither there were substan-
tial differences in the group of children younger than 6 years: CSII (n=34) 
vs IT (n=58) (HbA1c 7.44±0.82 vs 7.45±1.21%, p=0.99, mean amplitude of 
daily blood glucose excursions 10.5±3.4 vs 10.4±3.1 mmol/l, p=0.87, num-
ber of hypoglycaemia during the preceeding 4 weeks 15.4±11.1 vs 14.1±11.7, 
p=0.61). However, CSII offers children and adolescents more flexibility, more 
effective diabetes self-management and in adolescents a higher quality of life 
(p<0.01).
Conclusion: In children/adolescents CSII is an highly effective therapy. It of-
fers children and adolescents a good and to the injection therapy comparable 
quality of diabetes control (with even lower postprandial blood glucose lev-
els), but a significant better flexibility, more effective diabetes self-manage-
ment and additionally for adolescents a higher quality of life.
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The timing of transition from paediatric to adult care for  
childhood-onset type 1 diabetes in Japan: DERI mortality study
Y. Onda1, R. Nishimura1, A. Morimoto2, H. Sano1, K. Utsunomiya1,  
N. Tajima3;  
1Department of Internal Medicine Division of Diabetes and Endocrinology, 
The Jikei University School of Medicine, 2Department of Internal Medicine, 
Morimoto Hospital, 3The Jikei University School of medicine, Tokyo, Japan.
Background and aims: The timing for transition of patients with childhood-
onset type 1 diabetes (T1DM) from pediatric care (PC) to adult care (AC) 
has become a subject of much debate in recent years, which led to a posi-
tion statement being released by the ADA transition working group, and this 
topic is also being hotly debated in Japan, where not a few patients appear to 
continue to seek PC even after attaining adulthood. The aim of this study is 
to follow up patients with childhood-onset T1DM for a maximum duration 
of 40 years to see how they transitioned from PC to AC and to examine the 
factors that contributed to their transition.
Materials and methods: The study participants consisted of 1,299 patients 
(525 males/774 females) from two nationwide T1DM surveys in Japan who 
had been diagnosed as having T1DM at less than 15 years of age between 
1965 and 1979. Their attending physicians and affiliations were determined 
by questionnaire surveys conducted every 5 years. Patients were classified 
as having received either PC or AC when they were 15 years old. In addi-
tion, for those who sought PC at that time, the timing for transition from PC 
to AC as well as factors such as their age at diagnosis, sex, their physicians’ 
board certification status, and calendar year of diagnosis that contributed to 
their transition were assessed by Kaplan-Meier and Cox proportional hazard 
analyses as of 1 January 2010. All statistical analyses were performed by using 
SAS version 9.3.
Results: At the age of 15, 44.0% of the participants (n = 571) and 55.4% (n = 
720) consulted PC (PC group) and AC (AC group), respectively. Their mean 
age at diagnosis according to their attending physicians was 7.9 ± 3.7 vs. 8.6 
± 3.7 years, respectively (PC group vs. AC group; P < 0.0001). There were 
no significant sex differences between the PC and AC groups (PC, 46.7% vs. 
42.4%; AC, 53.1% vs.57.6%; P = 0.11). Of the 571 patients in the PC group, 
74.8% (n = 569), 58.1% (n = 562), 45.1% (n = 483), and 15.1% (n = 394) 
sought PC at 20, 30, 40, and 50 years of age, respectively. Cox proportional 
hazard analyses for patients with childhood-onset T1DM indicated that the 
more recent the calendar year of their diagnosis, the younger their age at di-
agnosis, and the more likely they were to continue to consult diabetes special-
ists, the significantly higher the risk of continuing to seek PC after attaining 
adulthood (hazard ratios, 1.03, 0.93, 1.80; P = 0.0046, < 0.0001, < 0.0001), 
while this risk was not significantly different between the sexes.
Conclusion: A majority of patients with childhood-onset T1DM sought AC 
at the age of 15 years in Japan. However, more than half of those who sought 
PC at the age of 15 continued to seek PC even after the age of 30 years, sug-
gesting that their transition from PC to AC was far from smooth. Further 
study is needed to identify the obstacles to their smooth transition to AC.
Supported by: COSTCO Japan Diabetes Foundation
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Predictor factors associated with higher risk of developing  
disordered eating behaviour in a group of female adolescents with  
type 1 diabetes mellitus
M. Marigliano, S. Zaffani, F. Tomasselli, M. Tommasi, A. Morandi,  
A. Sabbion, G. Contreas, C. Maffeis;  
Regional Center for Pediatric Diabetes, Clinical Nutrition & Obesity, 
Verona, Italy.
Background and aims: Patients with type 1 Diabetes Mellitus (T1DM) are at 
high risk for disordered eating behavior (DEB), due to an emphasis on nutri-
tion management in diabetes care . In particular females with T1DM may be 
principally vulnerable to develop DEBs due to factors related to the onset and 
management of the disease. Moreover DEBs can have negative effects on the 
management of T1DM. Because DEBs could be dangerous for people with 
T1DM, it is important to identify not only clinical and sub-clinical factors 
but also predictors of DEBs in adolescent females with T1DM. The aims of 
this study were: 1) to examine disordered eating attitudes and behaviors and 
body dissatisfaction in a sample of Italian adolescent and young adults with 
T1D; 2) to analyze what factors before and at the onset of T1DM could be 
associated with an increased risk of developing DEB.
Materials and methods: We enrolled 44 patients, adolescent females, aged 
12-20 years old, in therapy with multiple daily insulin injections (MDI), re-
cruited from our center. Inclusion criteria were: T1DM, duration of diabetes 
for at least 12 months, daily insulin dose of at least 0.5 U/Kg; age at the onset 
of T1DM 9-16 years, Caucasian race; no history of diabetes complications 
or autoimmune disorders. Patients with previously diagnosed eating disor-
ders were excluded. Anthropometrical characteristics (weight, height, BMI, 
BMI z-score) were collected before and at the onset. The bio-clinical data at 
the T1DM onset (age, HbA1c, blood pH, weight loss) and the family data 
(including mother’s and father’s BMI, socio-economic status) were also col-
lected. All patients completed the Eating Disorder Examination Question-
naire (EDE-Q); it asses the frequency of key behavior such as binge eating, 
objective or subjective episodes of overeating, self-induced vomiting, laxative 
and diuretics misuse, and the other feature of eating disorder. A patient with 
an EDE-Q score > 1SD from the mean was considered pathological and with 
a high risk of developing eating disorder.
Results: 44 patients completed the EDE-Q test, 6 of them reported a score > 
1SD (6/44, 13.2%) and were considered at risk of developing eating disorders. 
The logistic regression showed that, among all the anthropometric and meta-
bolic variables, the only one that could be considered a predictor of a high 
score at the EDE-Q test (> 1SD from the mean) was the BMI z-score before 
the onset of diabetes. The BMI z-score (index of overweight/obesity) before 
the onset of T1DM was then identified as an independent predictor of a posi-
tive EDE-Q test (p<0.05, OR=2.029, 95% CI 1.059-3.889).
Conclusion: The presence of overweight/obesity, represented by BMI z-
score, before the onset of T1DM could be considered an independent predic-
tor of an increased risk of developing eating disorders in the medium/long 
term. Therefore, the overweight/obese girls with T1DM and their families 
should be included in adequate prevention programs for the management of 
DEBs since the onset of diabetes and should be followed by a multidiscipli-
nary diabetes team with a peculiar attention to nutrition and psychological 
management.
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International comparison of quality of life in children and adolescents 
with type 1 diabetes
A. Lukács1, E. Kalyva2, M. Abdul-Rasoul3, L. Barkai1,4;  
1Faculty of Health Care, Department of Theoretical Health Sciences, 
University of Miskolc, Hungary, 2The International Faculty of the University 
of Sheffield, City College, Thessaloniki, Greece, 3Faculty of Medicine, Kuwait 
University, Kuwait, 4Postgraduate Institute of Pediatrics, Medical and Health 
Science Center, University of Debrecen, Miskolc, Hungary.
Background and aims: The ultimate goal of chronic patient care is to main-
tain or improve the quality of life. The patients’ quality of life may be affected 
the successful disease management in short- and long term. There is a lack 
of researches examining the quality of life in pediatric diabetic population 
across countries, because of the lack of appropriate validated age- and dis-
ease-specific quality of life instruments. Our research aimed to assess the 
diabetes-specific quality of life in children and adolescents with type 1 diabe-
tes from different geographically located countries using the child self- and 
parent proxy-reports. We looked for the relationship between the glycemic 
control and quality of life.
Materials and methods: A total of 416 youths with type 1 diabetes (212 boys 
and 204 girls) aged 8-18 years participated in the study (84 Greek, 135 Hun-
garian and 197 Kuwait participants). There were no significant differences 
among the study participants in gender, age and glycemic control. Diabetes-
specific quality of life was measured using the Pediatric Quality of Life™ 3.0 
Diabetes Module culturally adapted in every country. Glycemic control was 
expressed by HbA1c. Data were analysed with Chi-square test, paired t-test, 
one-way analysis of variance. The difference across countries was evaluated 
using Tukey post hoc test. SPSS 19.0 was used for statistical analysis.
Results: There were significant differences among countries both in self- (F(2, 
413)=13.17, p<0.001) and proxy-report (F(2, 413)=30.02, p<0.001). Greek 
youths (M=62.18, 95% CI [59.07, 65.29]) had significantly lower quality of 
life scores than the Hungarian (M=71.32, 95% CI [69.25, 73.40], p<0.001) 
and Kuwait youths (M=68.35, 95% [66.60, 70.10], p=0.001). These results 
were confirmed by the proxy reports. Parents of Greek youths (M=55.77, 
95% CI [52.91, 58.62]) reported significantly lower quality of life scores than 
parents of Hungarian (M=67.80, 95% CI [65.80, 69.79], p<0.001) and Ku-
wait youths (M=59.75, 95% CI [58.09, 61.40], p=0.031). Comparisons be-
tween quality of life of Hungarian and Kuwait youths we found statistically 
significant differences only in parents’ report (p<0.001). We found negative 
significant correlation between the glycemic control and quality of life for the 
overall sample (r(416)=- 0.212, p<0.001) and for each country (Gr: r(84)=-
0.384, p<0.001, Hu: r(135)=-0.207, p=0.016, Ku: r(197)=-0.207, p=0.004). 
It was the case in the parent proxy-report (Gr: r(84)=-0.387, p<0.001; Hu: 
r(135)=-0.170, p=0.049) except Kuwait (r(197)=-0.067, p=0.349).
Conclusion: Regardless the cultural and geographical differences, relation-
ship is found between glycemic control and diabetes-specific quality of life. 
Parents perceived their children’s quality of life worse than children them-
selves. Despite the similar clinical status of the study participants, the per-
ceived quality of life of diabetic youths differed across cultures. There is a 
challenge to find ways of improving the quality of life of youths and maintain 
throughout childhood and adolescence in every culture.
Supported by: Hungarian Diabetes Association
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Effect of aerobic exercise on HDL function in women with polycystic 
ovary syndrome: a randomised controlled trial
K. Distelmaier, A. Asante, A. Konopka, M. Shankarappa, M. Amols,  
K. Nair;  
Division of Endocrinology, Mayo Clinic, Rochester, USA.
Background and aims: Polycystic ovary syndrome (PCOS) is associated with 
increased cardiovascular risk. Insulin resistance and low levels of high-densi-
ty lipoprotein (HDL) cholesterol are considered as potential mechanism for 
the increased cardiovascular risk. Here we determined whether HDL func-
tion in PCOS women is different from healthy women who are more insulin 
sensitive. Since aerobic exercise (AE) enhances insulin sensitivity and is an 
effective treatment option in PCOS women we determined whether PCOS 
women improve their HDL concentrations and HDL function in response 
to 12 weeks of AE.
Materials and methods: HDL function, assessed by cholesterol efflux ca-
pacity, paraoxonase-1 (PON1) activity and total anti-oxidative capacity was 
compared between sedentary women with PCOS (n=25) and age- and sex-
matched non-PCOS, women (n=12). PCOS women were then randomized 
to a 12-week intervention of AE (n=12), or no treatment (n=13) to analyze 
the effect of AE on fasting serum insulin levels and glucose tolerance to a 
meal, and on HDL function. AE consisted of 5 supervised exercise sessions 
per week on a stationary bicycle to elicit heart rates corresponding to 65% of 
participants‘ pre-training VO2max. Participants in the control group main-
tained their regular sedentary behavior.
Results: The HDL of PCOS women exhibited impaired cholesterol efflux 
capacity compared to insulin-sensitive healthy women (15.9% ± 2.2 versus 
17.8% ± 2.4, p=0.034), whereas PON1 activity and total antioxidative func-
tion showed no differences. Although AE resulted in a significant increase 
in VO2 max (+4.53 ml/kgFFM/min ± 2.52, p=0.003), and improved glucose 
tolerance, no effect on HDL concentration and function was observed.
Conclusion: PCOS women have an impaired cholesterol efflux capacity, 
which cannot be normalized by a 12 week AE despite improvement in glu-
cose tolerance and endurance capacity.
Supported by: RO1 DK41973
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Association between bone metabolism and resting energy expenditure in 
postmenopausal women with type 2 diabetes
M. Ogata, R. Ide, N. Iwasaki, M. Takizawa, Y. Uchigata;  
Tokyo Women‘s Medical University, Diabetes Center, Tokyo, Japan.
Background and aims: Osteoporosis negatively affects quality of life in in-
dividuals with diabetes. While bone fractures occur more easily in patients 
with both type 1 diabetes (T1D) and T2D compared to non-diabetics, the 
pathology of osteoporosis is different between T1D and T2D. Although 
bone mineral density (BMD) is increased in patients with poorly controlled 
T2D, the bone quality is low. It is therefore important to determine criteria 
for osteoporosis other than BMD in patients with T2D. Recently, it has been 
reported that bone resorption suppression may prevent T2D, and BMD cor-
relates more strongly with basal metabolic rate than body mass index (BMI) 
in African Americans. These studies imply a direct association between bone 
metabolism and basal metabolic rate. The aim of this study was to examine 
the relationship between bone metabolism and resting energy expenditure 
(REE) in postmenopausal women with T2D.
Materials and methods: Postmenopausal Japanese women with T2D were 
recruited from the outpatient clinic at the Diabetes Center of our University. 
46 patients with over 1-year attendance, no other diseases except hyperten-
sion, dyslipidemia and overweight (BMI ≤30 kg/m2), no history of taking di-
etary supplements for previous 3 months, were included in this study. Fasting 
serum procollagen type 1 N-terminal propeptide (P1PN), Carboxy-terminal 
collagen crosslink’s-1 (CTX-1), intact parathyroid hormone, 25-hydroxyvi-
tamin D (25[OH]D), urine microalbumin, body composition and REE were 
evaluated. BMD was examined using dual-energy X-ray absorptiometry of 
the nondominant distal radius. Data are presented as mean ± standard devia-
tion.
Results: The mean REE of the patients (940 ± 156 kcal) was lower than the 
predicted value (1177 ± 98.3 kcal). The mean T-score was low with high 
variance (1.7 ± 1.6). 18 patients (39%) met the criterion for osteoporosis. 
Although 12 patients (26%) had a history of bone fractures, there was no 
difference in REE or BMD between the patients with or without the history 
of fractures. The respiratory quotient (0.87 ± 0.01) was positively correlated 
with serum 25(OH)D (21.5 ± 7.4 ng/mL). REE was positively correlated with 
BMI (24.5 ± 3.6 kg/m2), serum calcium (9.2 ± 0.3 mg/dL), HbA1c for the prior 
6 months (7.6% ± 1.1%), and the ratio of serum P1PN to CTX-1 (37.5 ± 11.7 
μg/L : 0.36 ± 0.1 ng/mL).
Conclusion: The present study shows that bone metabolism was significantly 
associated with REE (p<0.009). The basal metabolic rate interrelated with 
bone turnover in postmenopausal women with T2D. Declining bone turno-
ver related to low REE may result in decreased therapeutic efficacy of bone 
resorption suppression.
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Comparison of the effect of minodronic acid hydrate and bazedoxifene 
on biochemical markers of bone turnover in postmenopausal  
type 2 diabetes women with low bone mass
A. Miyoshi, H. Miyoshi, S. Nagai, T. Kondo, H. Nomoto, K. Yamamoto,  
T. Atsumi;  
Division of Rheumatology, Endocrinology and Nephrology, Hokkaido 
University, Sapporo, Japan.
Background and aims: Although patients with type 2 diabetes (T2D) are at 
significant risk for well-recognized diabetic complications, including mac-
rovascular disease, retinopathy, nephropathy, and neuropathy, it is also clear 
that T2D patients are at increased risk for fragility fractures. It is suggested 
abnormalities in not only bone material strength but also bone microarchi-
tecture (bone quality) are risk factors of bone fractures in T2D. It is reported 
that urinary pentosidine levels predict the future fracture independent of 
bone turnover and bone mineral density (BMD) without treatment for osteo-
porosis. Pentosidine is a surrogate marker of whole advanced glycation end 
products, which is characterized as non-enzymatic collagen cross-linking. 
Non-enzymatic cross-links reduce the mechanical and biological integrity of 
bone and so pentosidine is one of bone quality markers. It has been reported 
that selective estrogen receptor modulator (SERM) decreases urinary pento-
sidine and ameliorates bone quality in postmenopausal women with osteo-
porosis. However, effects of osteoporosis medication to bone quality have no 
proven in T2D with osteoporosis. Thus, we administered bisphosphonate or 
SERM to postmenopausal T2D women with low bone mass and evaluated the 
effects of bone turnover including bone quality markers.
Materials and methods: We measured femoral neck (FN) and lumbar spine 
(LS) BMD of postmenopausal women with T2D by dual-energy X-ray ab-
sorptiometry and 31 patients with a T score≦-2.0 at the FN or LS in this test 
were randomized 1:1 to receive minodronic acid hydrate (n=15) or bazedox-
ifene (n=16). Changes in born turnover and quality markers, BMD at the 
FN and LS, and common clinical data involved in T2D were assessed at 6 
month. This was a prospected observational study. Primary endpoint was set 
as the reduction of urinary pentosidine level. A total of 31 patients consented 
to participating in this study. On average, the patient group was aged 69 ± 7 
years and they had been living with T2D for the past 15.5 ± 10.7 years. Their 
HbA1c was 7.0 ± 0.7% and BMI was 24.0 ± 3.8.
Results: There was no difference in urinary pentosidine levels between the 
groups. No significant reduction was seen in both groups, which urinary 
pentosidine levels were very high and more than the level considered as a 
risk level of future fractures. In the other born turnover and quality markers, 
minodronic acid hydrate significantly decreased serum P1NP levels, urinary 
DPD and serum ucOC compared with bazedoxifene (-58.6% versus -19.1%, 
-30.1% versus 1.6%, -55.3% versus -29.1%, respectively). Significantly greater 
increases in BMD were observed with minodronic acid hydrate treatment at 
the FN or LS (6-mo treatment difference: 2.3%, FN; 2.4%, LS; p < 0.05) but no 
changes were observed with bazedoxifene therapy. Bazedoxifene significantly 
decreased serum non HDL-C levels compared with minodronic acid hydrate 
(-13.6 mg/dl versus 5.4 mg/dl; p < 0.05). Both treatments didn’t aggravate 
diabetes conditions.
Conclusion: Urinary pentosidine levels did not change in both treatments 
in this study. Minodronic acid hydrate showed significantly improvement in 
BMD and bone turnover markers compared with bazedoxifene therapy in 
also T2D patients. Bazedoxifene may ameliorate lipid metabolism in T2D 
women with osteoporosis.
Clinical Trial Registration Number: UMIN000008783
PS 114 Clinical observations  
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Clinical features and management of new-onset diabetes mellitus 
presenting with diabetic ketoacidosis in China: a multicentre,  
clinic-based study
X. Wu1, Y. Xu1, J. Bai2, J. Shaw3, China Initiative for Diabetes Excellence 
(CIDE) Collaborative Group;  
1Department of Endocrinology, First Affiliated Hospital of Nanjing  
Medical University, 2Department of Epidemiology & Biostatistics,  
Nanjing Medical University, China,  
3Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Background and aims: Diabetic ketoacidosis (DKA) is a serious acute com-
plication of diabetes, resulting from severe insulin deficiency and an excess of 
counter-regulatory hormones. Under certain circumstance, new-onset diabe-
tes patients may present with DKA, which is typical for type 1 diabetes mel-
litus (T1DM) or ketosis-prone diabetes in western countries. However, there 
is little information on hospitalization for this kind of diabetes patients in the 
Chinese population. The present study is to evaluate the clinical features and 
management of new-onset diabetes mellitus presenting with DKA in China.
Materials and methods: A retrospective cohort study of adult and adoles-
cents new-onset diabetes patients hospitalized with DKA between 2010 and 
2012 were carried out in fifteen tertiary hospitals around China. Clinical and 
laboratory data were collected. Patients were classified based on clinical fea-
tures. Groups were compared for differences in vital statistics and biochemi-
cal profiles at presentation.
Results: The study cohort comprised 255 new-onset diabetes patients pre-
senting with DKA: 115 patients (45.1%) with type 2 diabetes mellitus 
(T2DM), 98 patients (38.4%) with T1DM, 24 patients (9.4%) with atypical 
DM (ADM) and 18 patients (7.1%) with Fulminant T1DM. T1DM exceeded 
T2DM in the age group less than 40 years while T2DM predominated in the 
age group more than 40 years. Male patients were predominant in T1DM, 
T2DM and ADM group. The most common precipitating factors were un-
known reason (36.9%) and infection (29.0%). The typical symptoms included 
polyuria/polydipsia (72.9%), nausea/vomiting (67.1%), dehydration (27.1%), 
variable degree of confusion (26.7%) and abdominal pain (22.4%). More gas-
trointestinal symptoms and dehydration were found in T1DM due to severe 
ketoacidosis. The levels of blood glucose and HbA1c were 25.3±11.1mmol/L 
and 12.1±3.1% at admission. About 89.0%, 74.4% and 55.9% of patients were 
evaluated for HbA1c, beta-cell function and autoantibodies for classifica-
tion. The complications included electrolyte disturbance (71.4%), arrhythmia 
(19.6%), hyperosmotic state (14.5%), renal failure (6.7%), shock (3.1%), heart 
failure (0.8%) and cerebral edema (0.8%). During the first day after admis-
sion, total fluid supplement were 3550.4±1904.1ml. Low doses insulin infu-
sion lasted for 2.8±5.4 days. The disappearance of urine ketone body took 
3.3±2.7 days. Therapeutic regimen was markedly different within the four 
groups when they discharged from hospitals.
Conclusion: New-onset diabetes patients presenting with DKA occur in a 
spectrum of diabetes types in China, including T2DM, T1DM, ADM and 
Fulminant T1DM. Its clinical heterogeneity has significant implications for 
classification and management of diabetes.
 
1267
Effects of cardiovascular risk factors in urban community in patients 
with type 2 diabetes mellitus: a 48-months prospective trial
X.-L. Zhang1, S.-Y. Yuan1, G. Wan2, L.-X. Zhu1, H.-J. Fu1, M.-X. Yuan1,  
G.-R. Yang1, S.-F. Pan1, R.-R. Xie1, Y.-J. Lv3, Beijing Community Diabetes 
Study Group;  
1Department of Endocrinology, Beijing Tongren Hospital,  
Capital Medical University, 2Medical Records and Statistics Department, 
Beijing Ditan Hospital, Capital Medical University,  
3Cuigezhuang Community Health Service Cente, Beijing, China.
Background and aims: To assess whether prospective interventions have 
long-term effects on the risk of diabetes-related macrovascular complications 
in patients with type 2 diabetes mellitus in urban communities of Beijing.
Materials and methods: A total of 3,264 type 2 diabetic subjects (aged 20-80 
years) was recruited from 15 community health centers in Beijing in 2008. 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 515
1 C
The subjects were divided into three groups: DM group (n=930), HTN group 
(n=1397), and CVD group (n=937). By using Framingham risk score (FRS), 
the subjects in afore three groups are subdivided into risk categories of 20% 
(high Framingham risk strata). After 48 months, study participants were fol-
lowed-up to assess the long-term effects of the interventions.
Results: Subjects with CVD in diabetes were more prone to be older, have 
a longer duration of diabetes, higher systolic blood pressure and diastolic 
blood pressure than that of DM group (P<0.01, respectively). The mean NC 
at the baseline was significantly higher in HTN and CVD group than that in 
DM group (P<0.05). In the post-intervention, participants in CVD group or 
HTN group comparing the DM group, higher levels were detected on blood 
pressure, and lipid profiles (P<0.01, respectively). In 48-months of follow-
up, no significant increase of FRS could be demonstrated in low framingham 
risk strata and median framingham risk strata when compared with base-
line levels. In particular, a significant reduction of FRS was found in the high 
framingham risk strata at the end of follow-up. In COX multivariate analy-
ses, participants in the HTN group and CVD group had a higher incidence 
of events than those in the DM group (HR 2.561; 95% CI 1.043−6.289; HR 
4.678; 95% CI 1.937−11.298).
Conclusion: This study demonstrated for the first time the existing relation-
ship between NC and CVD in diabetic patients. Multi-factorial intervention 
of CVD risk factors in community for 48-months results in favorable changes 
in cardiovascular risk factors, and lowered the estimated 10-year risk for 
CVD events. Multi-factorial intervention of CVD risk factors in community 
is important to prevent the incidence of events in hypertension or CVD in 
Chinese diabetic patients.
ChiCTR-TRC-13003978
Supported by: BRIDGES Grant, CMDFC, Health Special funding for Capital 
Developing
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Cardiovascular risk factors outcomes in patients with newly-diagnosed 
type 2 diabetes. The Basque country 10-yr prospective diabetes study
J.M. Arteagoitia1, J.A. Piniés2, J.M. Altzibar1, F. Gonzalez-Carril1,  
I. Irigoien3, L. Echevarriarteun1, J.L. Rodriguez-Murua1,  
Basque Country Sentinel Practice Network;  
1Epidemiology Unit, Public Health Service, Department of Health, Basque 
Government, Vitoria-Gasteiz, 2Endocrinology and Nutrition Department, 
Cruces University Hospital, Osakidetza-Basque Country Health Service, 
Barakaldo (Bizkaia), 3Department of Computation Science and Artificial 
Intelligence, University of the Basque Country (UPV-EHU), Donostia, Spain.
Background and aims: To describe the cardiovascular risk factor outcomes 
in newly-diagnosed type 2 diabetes in the Basque Country Prospective Com-
plications and Mortality Study.
Materials and methods: A 10-year prospective population-based cohort 
study was performed with 777 newly-diagnosed type 2 diabetic patients older 
than 24 years in a Sentinel Practice Network. We recorded cardiovascular 
risk factors at baseline and during the 10-year follow up study. High blood 
pressure (systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood 
pressure (DBP) ≥ 80 mmHg), elevated LDL ≥2,58 mmol/l, low HDL <1,29 
mmol/l in women and <1,03 mmol/l in men, hypertriglyceridemia (triacyl-
glycerol ≥1,69 mmol/l), HbA1c ≥7% (≥53 mmol/mol), and albuminuria (al-
bumin/creatine ratio ≥ 3 mg/mmol) were recorded. Obesity (BMI ≥30 kg/
m2), and adiposity (% body fat) were calculated. The air displacement ple-
thysmography prediction equation was used to measure adiposity (obesity: 
above 25.1% and 35.1% in males and females, respectively). The patients were 
classified as sedentary if they rarely exercised and active if they performed 
three or more hours of exercise per week. With regard to smoking habits, the 
patients were classified as non-smokers, and smokers.
Results: Baseline characteristic of the patients are shown in table. At the end 
of the study, all cardiovascular risk factors outcomes were favorable, improv-
ing the percentage of patients at target for blood pressure from 87% to 78,3%, 
and LDL from 88,8% to 65%. However, the patients at HbA1c ≥ 7% increased 
from 29% to 35% in the cohort study. Sedentary life style and obesity did not 
change over time. Smoking habits decreased from 16,1% to 8,3%. Treatment 
with statins, blood pressure drugs and anti-hiperglycemic drugs increased in 
the follow-up study.
Conclusion: Cardiovascular risk factors prevalence and percentage of pa-
tients upper control target are very high. All risk factors except HbA1c, im-
proved or maintained in newly-diagnosed type 2 diabetic patients during 
10-yr. follow-up study.
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The relationship between coronary artery disease and peripheral artery 
disease in diabetes patients
S. Kawasaki1, H. Misawa1, Y. Tamura1, Y. Kondo2, S. Satoh2, O. Hasegawa3, 
Y. Terauchi4;  
1Department of Endocrinology and Metabolism, Shonan Fujisawa 
Tokushukai Hospital, Fujisawa, 2Department of Endocrinology and 
Metabolism, Chigasaki Municipal Hospital, 3Department of General 
Medicine, Yokohama City University Medical Center,  
4Department of Endocrinology and Metabolism, Yokohama City University 
Graduate School of Medicine, Japan.
Background and aims: In step with the aging of the population and the 
increasing number of diabetes patients, patients with peripheral artery dis-
ease (PAD) are increasing in number along with those with coronary artery 
disease (CAD). It is important for PAD to be detected early and managed 
because it has a poor prognosis and higher mortality rate than malignant 
disease. This study examined the associations of CAD and PAD in patients 
with type 2 diabetes mellitus (DM).
Materials and methods: Subjects were 1368 ambulatory patients with type 2 
diabetes (795 males, 573 females). They were classified into CAD+ and CAD-
groups, or into PAD+ and PAD- groups. Those with ischemic findings such 
as abnormal Q, ST depression and negative T on resting electrocardiogram 
or a past history of angina pectoris or myocardial infarction were categorized 
as CAD+, otherwise as CAD-; those with ankle-brachial index (ABI)≤0.99 or 
with a history of PAD were categorized as PAD+, otherwise as PAD-. They 
were further divided into two groups: one with diabetic retinopathy and the 
other without it. Diabetic nephropathy was treated as positive if urinary al-
bumin excretion was 30 mg/gCr or larger and as negative if it was less than 30 
mg/gCr. We compared risk factors between CAD which is representative of 
diabetic macrovascular disease and PAD.
Results: The characteristics of the 1368 patients with type 2 DM were as 
follows: age, 64.1±12.0 (SD) years; duration of DM, 11.4±10.0 years; BMI, 
24.5±8.0 kg/m2; blood pressure (BP), 135±19/76±13 mmHg; and hemo-
globin A1c, 7.9±2.0 %. Three hundred thirty-two patients had retinopathy, 
while 795 did not. Nephropathy afflicted 572 patients but did not afflict 720 
patients. The CAD+ group comprised 498 subjects (36.4%). After data cor-
rection, independent risk factors for CAD were age (OR1.03, 95%CI 1.01-
1.04, p<0.0005), nephropathy (OR1.53, 95%CI 1.12-2.09, p<0.01), retinopa-
thy (OR1.52, 95%CI 1.07-2.15, p<0.05) and smoking habit (OR1.58, 95%CI 
1.09-2.29, p<0.05). The PAD+ group comprised 227 subjects (16.6%). After 
data correction, age (OR1.05, 95%CI 1.03-1.07, p<0.0001), waist diameter 
(OR1.03, 95%CI 1.01-1.05, p<0.005), nephropathy (OR1.60, 95%CI 1.06-
2.42, p<0.05), retinopathy (OR2.61, 95%CI 1.67-4.08, p<0.0001), male gender 
(OR2.73, 95%CI 1.62-4.64, p<0.0005) and smoking habit (OR3.37, 95%CI 
1.98-5.85, p<0.0001) were independent risk factors for PAD. The cut-off value 
of the ROC curve for age was 75 years (sensitivity:0.39, specificity:0.82). PAD 
was found in 27% of the CAD+ group (p<0.0001), while CAD was found in 
59% of the PAD+ group (p<0.0001).
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Conclusion: About 30% of CAD patients had PAD while about 60% of PAD 
patients had CAD. Factors common to CAD and PAD were age, smoking 
habit, nephropathy and retinopathy. Especially PAD is considered clinically 
worthy of note in people over 75 years old. In our increasingly aging country, 
we consider it essential to educate the public as well as diabetes patients about 
the importance of early diagnosis of PAD which carries a poor prognosis.
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Outcome reduction with an initial glargine intervention and legacy 
effects (ORIGINALE)
Z. Punthakee1, J. Tyrwhitt1, J. Bosch1, G.R. Dagenais2, R. Díaz3, H. Jung1, 
A.P. Maggioni4, J. Pogue1, J. Probstfield5, A. Ramachandran6, M.C. Riddle7, 
L.E. Rydén8, S. Yusuf1, H.C. Gerstein1, ORIGIN Trial Investigators;  
1Medicine, Population Health Research Institute and McMaster University, 
Hamilton, 2Institut Universitaire de Cardiologie et de Pneumologie de 
Québec, Canada, 3Estudios Clínicos Latino América, Rosario, Argentina, 
4Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, 
Florence, Italy, 5University of Washington, Seattle, USA, 6India Diabetes 
Research Foundation, Chennai, India, 7Oregon Health and Science 
University, Portland, USA, 8Karolinska Institute, Stockholm, Sweden.
Background and aims: ORIGIN was a 2 x 2 factorial randomised trial as-
sessing cardiovascular and other effects of insulin glargine vs standard care 
and omega-3-fatty acids vs placebo among people with IFG, IGT or early 
type 2 diabetes and other cardiovascular risk factors. After a median 6.2-year 
follow-up, insulin glargine had a neutral effect on cardiovascular outcomes 
and cancers, and reduced the incidence of diabetes in people with IFG or 
IGT. Omega-3-fatty acids also had a neutral effect on cardiovascular out-
comes. ORIGIN participants who consented to the ORIGIN and Legacy 
Effects Study (ORIGINALE) were followed for more than 2 years after the 
trial finished to determine the longer term effect of therapy on cardiovascular 
outcomes and new diabetes.
Materials and methods: By the end of March 2014, consenting participants 
completed up to 2 study visits to ascertain anthropometrics, blood pres-
sure, creatinine, A1C, medication use and outcomes. Cumulative incidence, 
hazard ratios and odds ratios from the time of randomisation to the end of 
follow-up will be calculated for the ORIGIN trial outcomes. Participants will 
be analysed in the groups to which they were randomised.
Results: At the end of ORIGIN, 10,544 of the original 12,537 participants 
were alive and followed at 553 sites. 283 sites (comprising 6,497 participants) 
agreed to participate in ORIGINALE and obtained ethics approval. To date, 
at least 5721 participants from 274 sites have contributed data comprising ap-
proximately 96 new MIs, 63 new strokes, 194 new cardiovascular deaths and 
231 new cancer outcomes. Verification of events and data accuracy are ongo-
ing. Analyses comparing insulin glargine vs standard care, and omega-3-fatty 
acids vs placebo will be completed by August 2014.
Clinical Trial Registration Number: NCT00069784
Supported by: Sanofi-Aventis
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Effect of three insulin regimens on carotid intima-media thickness in 
patients with type 2 diabetes: the randomised Copenhagen Insulin and 
Metformin Therapy (CIMT) trial
L. Lundby-Christensen1,2, the CIMT trial group, Copenhagen university 
hospitals;  
1Steno Diabetes Center, Gentofte, 2Department of Paediatrics, Copenhagen 
University Hospital, Hvidovre, Denmark.
Background and aims: Post prandial hyperglycaemia may be associated with 
increased risk of cardiovascular disease in patients with type 2 diabetes. Insu-
lin analogue regimens targeting post prandial and/or fasting plasma glucose 
may therefore influence the risk of cardiovascular disease differently. Carotid 
intima-media thickness (IMT) is a frequently used risk marker for cardiovas-
cular disease. The aim of the Copenhagen Insulin and Metformin Therapy 
(CIMT) trial was to evaluate the effects of three insulin analogue regimens in 
combination with metformin or placebo. The metformin/placebo compari-
son has previously been reported. This abstract reports the insulin regimen 
comparisons.
Materials and methods: The CIMT trial is an investigator initiated, 3 x 2 
factorial, treat-to-target (HbA1c ≤ 7.0% (53 mmol/mol)), multicenter ran-
domised clinical trial. 412 participants with type 2 diabetes, HbA1c ≥7.5% 
(58 mmol/mol), receiving oral antidiabetic agents for at least one year and/or 
insulin for at least three months, were randomised 1:1:1 to 18 months open 
label treatment with one of three insulin regimens: insulin aspart biphasic 
one to three times daily (n=137) versus insulin aspart three times daily in 
combination with insulin detemir once daily (basal-bolus, n=138) versus in-
sulin detemir once daily (n=137). Primary outcome measure was change in 
mean carotid IMT. Other outcomes were change in HbA1c, weight,and insu-
lin dose, and risk of hypoglycaemia and serious adverse events. After multi-
ple imputations of missing data on the primary outcome, intention-to-treat 
analyses adjusting for baseline and stratification variables were performed.
Results: 90% (biphasic group), 80% (aspart+detemir group), and 72% (de-
temir group) of the participants completed the trial. Mean carotid IMT 
changed by −0.009 mm (95% confidence interval −0.022 to 0.004, P= 0.17) in 
the biphasic group, 0.000 mm (−0.013 to 0.013, P=0.99) in the aspart+detemir 
group, and −0.012 mm (−0.025 to 0.000, P=0.06) in the detemir group. These 
changes were not significantly different between the groups. HbA1c was sig-
nificantly more reduced (P<0.001) in the aspart biphasic group (−1.0% (−1.2 
to −0.8) (−11 mmol/mol (−13 to −9)) compared with the aspart+detemir 
(−0.4% (−0.6 to −0.3) (−4 mmol/mol (−7 to −3)) and the detemir (−0.3% 
(−0.4 to −0.1) (−3 mmol/mol (−4 to −1)) groups. Weight gain was signifi-
cantly higher (P<0.01) in the biphasic group (3.3kg (2.7 to 4.0)) and the 
aspart+detemir (3.2kg (2.6 to 3.9)) groups compared with the detemir group 
(1.9kg (1.3 to 2.6)). Total insulin dose at end-of-trial was significantly higher 
(P<0.001) in the detemir group (1.6 IU/kg/d (1.4 to 1.8)) compared with the 
biphasic (1.0 IU/kg/day (0.9 to 1.1) and aspart+detemir (1.1 IU/kg/day (1.0 
to 1.3)) groups. The number of participants with severe hypoglycaemia and 
other serious adverse events did not differ between the groups.
Conclusion: Despite major differences in HbA1c, weight gain and insulin 
dose, no significant differences on the progression of carotid IMT were found 
during 18 months treatment with three frequently used insulin analogue 
regimens targeting post prandial and/or fasting plasma glucose in patients 
with type 2 diabetes. Further long-term trials are needed examining whether 
different insulin regimens affect cardiovascular risk differently.
Clinical Trial Registration Number: NCT00657943
Supported by: Novo Nordisk 
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Glycaemic variability and glucose control in post-transplant diabetes 
mellitus after renal transplantation
J. Werzowa1, G. Pacini2, H. Brath3, M.D. Säemann1, A. Tura2;  
1Division of Nephrology and Dialysis, Medical University of Vienna, 
Austria, 2Metabolic Unit, ISIB-CNR, Padova, Italy,  
3Health Center South, WGKK, Vienna, Austria.
Background and aims: Post-transplant diabetes mellitus (PTDM) is a com-
mon and serious complication after renal transplantation leading to in-
creased cardiovascular morbidity and mortality. In patients with type 2 DM 
increased glycemic variability and poor glucose control have been associated 
with cardiovascular complications. We therefore aimed at determining gly-
cemic variability and glucose control in patients with PTDM in comparison 
to type 2 DM.
Materials and methods: We studied 10 non-diabetic transplanted subjects 
(TR_ND), 10 transplanted subjects with PTDM (TR_D), and 9 non-trans-
planted type 2 diabetic subjects (T2_D) using Continuous Glucose Moni-
toring (CGM). Subjects had similar age (60.4±2.9, 57.6±2.2, 56.2±2.5 years, 
P>0.26) and BMI (26.9±1.3, 28.9±1.3, 29.6±2.1 kg/m2, P>0.24). Subjects un-
derwent CGM for 2 to 8 days. The following indices were computed: (i) Basic 
indices: glucose mean and standard deviation (SD); (ii) Indices of glycemic 
variability: CONGAn equal to the SD of the difference between values ob-
tained 5 minutes apart; J-INDEX, equal to 0.001x(mean + SD)2; MAGE equal 
to the arithmetic mean of the glycaemic excursions greater than one SD; La-
bility Index equal to the mean of (Gn+1-Gn)
2/(hn+1-hn), where Gn is the n-th 
glucose value and hn is the time when that value was collected; (iii) Indices 
of glucose control quality: GRADE equal to 425x{log [log(Gn)]+0.16}
2; Hy-
perglycaemia index, equal to the weighted average of hyperglycaemic values, 
for glucose values higher than 140 mg/dl; Hypoglycaemia index, for glucose 
values below 80 mg/dl; IGC equal to the sum of Hyperglycaemia and Hypo-
glycaemia indices.
Results: Mean glucose in TR_D and T2_D was higher than in TR_ND 
(P<0.021), whereas SD was different only between TR_ND and T2_D 
(P<0.011). No difference in Mean and SD was found between TR_D and 
T2_D (P>0.3). Among the variability indices, main differences among groups 
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were shown by J-INDEX (lower in TR_ND than in TR_D and in T2_D, 
P<0.019) and by Lability Index (lower in TR_ND and in TR_D than in T2_D, 
P<0.029). Among the control quality indices, GRADE was found significant-
ly lower in TR_ND than in TR_D and in T2_D (P<0.034).
Conclusion: TR_D patients display worse glucose control than TR_ND, 
however, the degree of impairment parallels that of T2_D. Glycemic variabil-
ity expressed by Lability Index is significantly higher in T2_D compared to 
TR_ND but also to TR_D. These data underscore potential important patho-
physiological differences between type 2 DM and PTDM indicating that al-
though development of PTDM leads to increased glycemic variability, the 
degree of variability is significantly higher in type 2 DM and may thus play a 
less important role in PTDM.
Supported by: Novo Nordisk and Astellas Pharma
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The association between metformin use and change of serum creatinine 
after administration of contrast medium
S. Kim, J. Hahm, J. Jung, J. Jung;  
Gyeongsang National University School of Medicine, Jinju,  
Republic of Korea.
Background and aims: Metformin is widely used in the treatment of type 2 
diabetes mellitus. Because of a association between iodinated contrast me-
dium and the development of lactic acidosis in patients taking metformin, 
it usually restricted the use of metformin in situations considered to be high 
risk for the development of lactic acidosis. Several guidelines recommend 
stopping metformin before injection of contrast medium. Nevertheless, this 
has been controversial, because cases of lactic acidosis in patient taking met-
formin occurred in patient who had high risk factors for lactic acidosis. Thus, 
we evaluated the change of serum creatinine and total CO2 concentration in 
patients receiving metformin after administration of contrast medium.
Materials and methods: From January 2012 to August 2012, the patient’s 
records after administration of contrast medium for patients receiving met-
formin were retrospectively reviewed. Patients were excluded if 1)cancer with 
chemotheray or radiation therapy, 2)death after admission, 3)serum creati-
nine ≥ 3.0 mg/dL, or hemodialysis, 4) shock. Ninety patients were included 
in the final analysis. Serum creatinine is measured 1-3 days after adminis-
tration of contrast medium. We measure serum total CO2 content instead 
of measuring serum bicarbonate. The total CO2 content includes the serum 
bicarbonate as well as available forms of carbon dioxide (such as dissolved 
CO2 and carbonic acid). Generally, the serum bicarbonate comprises about 
95% of the total CO2 content, thus we can use this measurement as an ex-
cellent estimator of serum bicarbonate. We defined metabolic acidosis when 
total CO2 level is belowe 23 mEq/L. The Wilcoxon’s signed rank test was used 
to analyze the effects of contrast medium use on change in serum creatinine 
and total CO2 content level from baseline to 1-3 days after contrast medium.
Results: The mean subject age was 67.4 ± 10.5 years, and the mean A1C 
and metformin dosage of subjects were 7.3 ± 1.6 kg/m2 and 500(500-1000), 
respectively. Serum BUN level before and after administration of contrast 
medium were 17.2 ± 9.2 and 15.0 ± 7.9 mg/dL, respectively. Serum creati-
nine level before and after administration of contrast medium were 0.91 ± 
0.38 and 0.89 ± 0.36 mg/dL, respectively. There was no significant change 
of BUN or Cr level after administration of contrast medium (p > 0.05). The 
total CO2 level before and after administration of contrast medium were 24.3 
± 3.5 mEq/L and 27.7 ± 3.8 mEq/L, respectively. There was also no signifi-
cant change of CO2 level (p = 0.435). There was no significant relationship 
between increased creatinine and presence of metabolic acidosis (Table 1).
Conclusion: There is no significant increase or change of serum creatinine in 
patients with low risk of lactic acidosis after contrast media exposure. There-
fore, it imply that there is no evidence to stop metformin before administra-
tion of contrast medium in patients with normal renal function with low risk 
of lactic acidosis.
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Non-invasive predictor of non-alcoholic fatty liver disease in Japanese 
patients with type 2 diabetes mellitus
M. Miyasato1, Y. Murase-Mishiba1, M. Bessho1, M. Miyawaki1, H. Imbe1,  
C. Tsutsumi1, K. Tanimoto1, A. Imagawa2, J. Terasaki1, T. Hanafusa1;  
1First depertment of Internal Medicine, Osaka Medical College, 2Metabolic 
of Medicine, Graduate School of Medicine, Osaka University, Japan.
Background and aims: Individuals with type 2 diabetes mellitus (T2DM) 
have a higher risk of developing nonalcoholic fatty liver disease (NAFLD) 
than those without. The serum cytokeratin-18 fragment (CK-18) level has 
been suggested to be a biomarker of NAFLD, although its usefulness in pa-
tients with T2DM is unknown. The objective of the present study was to as-
sess the usefulness of the serum CK-18 level as a biomarker for NAFLD in 
T2DM patients.
Materials and methods: The study was divided into two parts. In the first 
cross-sectional study, a total of 200 patients with T2DM and 58 healthy con-
trol subjects were recruited. NAFLD was diagnosed using ultrasonography, 
and the T2DM patients and nondiabetic control subjects were subdivided 
into groups with or without NAFLD (DM/NAFLD, DM/nonNAFLD, non-
DM/NAFLD and nonDM/nonNAFLD, respectively). We used the scoring 
system, based on the criteria of hepatorenal echo contrast, vascular blur-
ring and liver brightness and deep attenuation, to evaluate the presence of 
NAFLD. The ultrasonography scores ranged from 0 to 6 points, and a diag-
nosis of NAFLD was made for scores of ≥2. In the subsequent longitudinal 
study, we evaluated the three-month change (Δ) in the CK-18 level and other 
parameters in 40 T2DM patients with NAFLD. Serum CK-18 levels were 
measured using ELISA.
Results: The median [IQR] level of serum CK18 was 158.4U/L [107.1-291.9] 
in the DM/NAFLD group, 96.1 U/L [74.1-142.6] in the DM/nonNAFLD 
group, 172.4 U/L [130.4-278.8] in the nonDM/NAFLD group and 120.4 
U/L [97.5-158.1] in the nonDM/nonNAFLD group. The serum CK18 val-
ues were significantly higher in the NAFLD group than in the nonNAFLD 
group among both diabetic (p<0.0001) and nondiabetic subjects (p=0.004). 
The median [IQR] level of CK18 was not significantly different between the 
patients with diabetes and the controls (139.9 U/L [84.0-223.6] vs 147.4 U/L 
[104.0-198.7], p=0.63). The CK-18 level was found to be an independent de-
terminant of NAFLD (Odds ratio 1.01, 95%CI 1.00-1.02, p=0.004) and was 
positively correlated with the ultrasonography score and AST and ALT levels 
in the T2DM patients. Positive correlations were also identified between the 
CK-18 and transaminase levels in the T2DM and NAFLD cohorts. Among 
the T2DM patients, the area under the ROC curve (AUROC) analysis in-
dicated that the CK-18 level was the best serum predictor of NAFLD (0.75, 
95%CI 0.67-0.81 compared with 0.73, 95%CI 0.65-0.79 for ALT, and 0.62, 
95%CI 0.54-0.70 for AST). The best cutoff point predicting NAFLD was 
180.93U/L, with a sensitivity of 44% and a specificity of 97%. ΔCK-18 was 
found to be significantly associated with ΔBMI in the T2DM patients with 
NAFLD.
Conclusion: The CK-18 level and the severity of NAFLD was positively cor-
related in the T2DM patients; thus, the CK-18 level is a potentially useful 
biomarker for assessing not only the severity but also the efficacy of treatment 
and the improvement in NAFLD in patients with T2DM.
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Unexpected prevalence of NAFLD among metabolically healthy patients 
with massive obesity
S. Chiheb1, N. Helmy2, B. Merioud1, C. Barrat2, M. Ziol3, C. Vons2,  
P. Valensi1;  
1Endocrinology Diabetology Nutrition, Jean Verdier Hospital,  
2Digestive and Metabolic Surgery, Jean Verdier Hospital,  
3Pathology, Jean Verdier Hospital, Bondy, France.
Background and aims: Metabolically healthy obese (MHO) is a phenotype 
referring to obese patients who are relatively insulin sensitive, normotensive 
and have favourable glucose and lipid profiles. However, clinical and bio-
logical parameters defining this group remain imprecise. In addition, data 
concerning the hepatic status of these patients and the presence or absence 
of non alcoholic liver disease (NAFLD) are scarce. It is widely agreed that 
NAFLD contributes to insulin resistance and poor metabolic prognosis. To 
evaluate the prevalence and the extent of NAFLD in MHO patients eligible 
for bariatric surgery
Materials and methods: In a prospective cohort of morbid obese patients 
undergoing bariatric surgery. Surgical liver biopsies were obtained from the 
left hepatic lobe at the beginning of different laparoscopic procedures, al-
lowing sufficient histological analysis. The study was approved by the ethical 
committee, and all included patients signed informed consent. Currently, 66 
patients were included (54 women), aged 36.4±9.6 years, body mass index 
44.8±5.3 kg/m². All patients were free of other liver disease (alcohol, viral...). 
Liver changes were classified by histological analysis into 2 Groups (accord-
ing to Bedossa and al 2012): normal liver, and NAFLD including simple stea-
tosis and steatohepatitis (NASH). All clinical and biological data were col-
lected: comorbidities, liver, lipid and glycemic profile, and HOMA-IR and 
fatty liver index (FLI) were calculated. MHO phenotype was defined as no or 
only one feature of the metabolic syndrome (IDF criteria)
Results: Of the 66 patients 22 had definite MHO status. Ten of them had 
histologically normal liver and 12 had NAFLD (9 steatosis and 3 NASH). In 
the metabolically unhealthy obese patients (44 MUO), 6 had histologically 
normal liver and 38 had NAFLD (25 steatosis, 13 NASH). Among MHO pa-
tients, those with NAFLD had higher BMI than patients with histologically 
normal liver (47.4±6.4 vs 41.6±3.8 kg/m², p=0.03) while ALAT, ASAT, GGT, 
fasting plasma glucose and insulin, FLI index, HOMA-IR were mostly nor-
mal and similar
Conclusion: The prevalence of liver lesions is high in massive obesity, even 
in metabolically healthy patients, with no simple predictive marker except a 
higher BMI
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Combination of empagliflozin and linagliptin shows promise in a rodent 
model of non-alcoholic fatty liver disease
T. Klein1, M. Kern2, N. Klöting3, R. Grempler1, E. Mayoux1, M. Mark1,  
M. Blüher2;  
1Boehringer Ingelheim, Biberach, 2Department of Medicine, 3IFB Obesity 
Diseases, Junior Research Group Animal Models, University of Leipzig, 
Germany.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH) are gaining increasing importance as the 
hepatic manifestations of metabolic syndrome and as primary causes for 
developing severe liver disease. Dipeptidyl peptidase (DPP)-4 and sodium-
dependent glucose cotransporter (SGLT)-2 inhibitors are established treat-
ments for type 2 diabetes (T2D). The DPP-4 inhibitor linagliptin (LINA) 
has been shown to improve hepatic steatosis and insulin sensitivity and re-
duce inflammation in preclinical models. The SGLT-2 inhibitor empagliflo-
zin (EMPA) has been shown to improve insulin sensitivity of the liver, and 
improve several inflammatory markers in tissue of diabetic animal models. 
Here we investigated the effects of the combination of EMPA and LINA 
(EMPA+LINA) on hepatic parameters in db/db mice.
Materials and methods: We determined the effects of 8 weeks’ treatment 
with EMPA (10 mg/kg/day) and LINA (3 mg/kg/day), alone or in combi-
nation, and vehicle on whole body insulin sensitivity in female db/db mice 
(n=15/group) using euglycaemic-hyperinsulinaemic clamps. Due to the 
mechanism of action of SGLT-2 inhibitors, euglycaemic-hyperinsulinaemic 
clamps were performed 4 days after the end of drug treatment. Liver triglyc-
eride content was determined and inflammatory markers (F4/80 and sup-
pressor of cytokine signaling [SOCS]-3) were detected using RT-PCR.
Results: Insulin-mediated suppression of hepatic glucose production 
(HGP) was significantly greater in the EMPA (13.1 mg/kg/min; p<0.05) and 
EMPA+LINA groups (11.8 mg/kg/min; p<0.05) compared with vehicle (26.3 
mg/kg/min). LINA monotherapy decreased HGP (21.8 mg/kg/min), al-
though statistical significance was not achieved. Tissue-specific labelled glu-
cose uptake in liver was higher with EMPA (822 dpm/g/ml; p<0.05), LINA 
(935 dpm/g/ml; p<0.05), and EMPA+LINA (1040 dpm/g/ml; p<0.01) com-
pared with vehicle (610 dpm/g/ml). The glucose disposal rate was improved 
in the EMPA (5.9 mg/kg/min; p<0.001), LINA (3.4 mg/kg/min; p<0.01), and 
EMPA+LINA groups (7.8 mg/kg/min; p<0.001) compared with vehicle (1.9 
mg/kg/min). Glucose uptake into muscle and adipose tissue was not affected 
by any treatment. Compared with vehicle (14.6%), triglyceride content was 
significantly lower with EMPA (9.1%; p<0.05), LINA (12.1%; p<0.01), and 
EMPA+LINA (5.7%; p<0.01) compared with vehicle. Levels of F4/80 and 
SOCS-3 mRNAs in the liver were reduced in the combination treatment 
compared with control.
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Conclusion: The combination of EMPA+LINA was superior to the respective 
monotherapies in improving insulin sensitivity of the liver and in reducing 
liver lipid content. These results suggest that the combination of both drugs 
may be a potential therapy for the most common liver diseases associated 
with T2D.
Supported by: Boehringer Ingelheim
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Mosapride citrate improves non-alcoholic steatohepatitis with increased 
faecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a 
rodent model
H. Okubo1, M. Yoneda2, H. Sakoda3, A. Kushiyama4, M. Fujishiro3,  
Y. Nakatsu1, T. Fukushima1, Y. Matsunaga1, H. Kamata1, M. Iwashita5,  
F. Nishimura5, A. Tomoichiro1;  
1Department of Medical Science, Graduate School of Medicine, 
2Department of Molecular and Internal Medicine, Graduate School of 
Biomedical and Health Sciences, University of Hiroshima, 3Department 
of Internal Medicine, Graduate School of Medicine, University of Tokyo, 
4Institute for Adult Disease, Asahi Life Foundation, Tokyo, 5Department of 
Dental Science for Health Promotion, University of Hiroshima, Japan.
Background and aims: Several lines of evidence have suggested a role of gut 
microbiota in the etiology of non-alcoholic steatohepatitis (NASH). Gastro-
intestinal motility may influence gut microbiota and NASH subjects report-
edly had a prolonged orocecal transit time coexistent with small intestinal 
bacterial overgrowth. Thus, we investigated effects of the gastroprokinetic 
agent mosapride citrate (MC) on gut microbiota and the development of 
NASH using methionine-choline deficient diet (MCDD)-induced NASH ro-
dent model.
Materials and methods: 6-week-old C57BL/6 mice were divided into three 
groups, given the normal chow diet (NCD), the MCDD or the MCDD con-
taining 10 mg/kg/day MC (MCDD plus MC) for 6 weeks.
Results: Gut microbiota analyses revealed that total numbers of bacteria 
were lower in the MCDD than in the NCD group, but similar to those in 
the MCDD plus MC group. Calculation of the relative abundance of each 
strain indicated lactic acid bacteria such as Bifidobacterium and Lactobacil-
lus in feces to be specifically decreased in the MCDD group. Interestingly, 
the reduction in lactic acid bacteria in the MCDD group was reversed in the 
MCDD plus MC group. Subsequently, HE staining of livers from the MCDD 
group revealed remarkable NASH development as evidenced by deformity 
of hepatocytes, large fat droplets and inflammatory cell infiltration, all of 
which were suppressed in the MCDD plus MC group. Serum ALT levels were 
also elevated in the MCDD group, but were normal in the MCDD plus MC 
group. Azan staining revealed marked collagen deposition and mRNA levels 
of fibrosis markers such as α-smooth muscle actin, tissue inhibitor of metal-
loproteinase 1 and transforming growth factor β were elevated in the MCDD 
group, while these abnormalities were significantly reversed in the MCDD 
plus MC group. Finally, the molecular mechanism underlying the resistance 
to NASH development conferred by MC treatment was investigated. The 
mRNA level of tumor necrosis factor α and the serum concentration of li-
popolysaccharide, a possible inducer of hepatic inflammation, were increased 
in the MCDD group, while these increases were suppressed in the MCDD 
plus MC group. Glucagon-like peptide-1 (GLP-1) reportedly attenuated the 
development of NASH. Plasma GLP-1 levels were lower in the MCDD than 
in the NCD group. Interestingly, plasma GLP-1 levels were increased in the 
MCDD plus MC group. To evaluate intestinal inflammation, immunostain-
ing employing the anti-NFκBp65 antibody was performed. Nuclear NFκBp65 
positive cells in the colon were increased in the MCDD group, while the 
numbers of these cells were reduced in the MCDD plus MC group.
Conclusion: MC showed a protective effect against the NASH development 
induced by MCDD, in which increased fecal lactic acid bacteria and plasma 
GLP-1 may be involved. Thus, MC may be effective for treating NASH.
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PDK2 deficiency reduces hepatic steatosis and insulin resistance in mice 
fed a high fat diet
S.-W. Kim1, K.-U. Lee2, M.-G. Choi3, K.-H. Bae1, Y.-H. Go1, I.-K. Lee1;  
1Department of Endocrine and Metabolism of Internal medicine, 
Kyungpook National University School of Medicine, Daegu, 2Department 
of Endocrine and Metabolism of Internal medicine, Asan Medical Center, 
Seoul, 3Department of Endocrine and Metabolism of Internal medicine, 
Hallym University Medical Center, Chuncheon, Republic of Korea.
Background and aims: Hepatic steatosis is rapidly evolving as a major medi-
cal problem in the world. It involves a variety of lipid abnormalities includ-
ing enhanced fatty acid influx from the adipose tissue, increased de novo 
lipogenesis,reduced fatty acid oxidation and ketogenesis. The pyruvate dehy-
drogenase kinases (PDKs) regulate pyruvate oxidation by controlling the ac-
tivity of the pyruvate dehydrogenase complex (PDC). We examined whether 
PDKs were increased in the liver of HFD-fed mice and how they regulate 
hepatic steatosis and insulin resistance.
Materials and methods: The physiological importance of regulation of PDC 
activity by PDK isoenzyme 2 was assessed by comparing PDK2 knockout 
(PDK2 KO) mice with wild type mice fed a high fat diet (HFD) and an isoca-
loric low fat diet (LFD).
Results: Body weight gain and hepatic steatosis were attenuated by PDK2 
deficiency in the HFD fed mice. Fasting blood glucose, serum insulin,and 
liver pyruvate, lactate, oxaloacetate, citrate, diacylglycerols, and triacylglyc-
erols were also reduced. Hepatic glucose production was also reduced and 
insulin sensitivity was increased in the HFD fed PDK2 KO mice. The hepatic 
enzyme capacity for fatty acid oxidation and ketogenesis was increased while 
the capacity for lipogenesis was decreased. In spite of this but consistent with 
greater PDC activity, the respiratory exchange ratio was higher in the PDK2 
knockout mice. Energy expenditure was increased without changes in physi-
cal activity. Increased hepatic insulin sensitivity and improved glucose toler-
ance correlated with reduced PKCε phosphorylation.
Conclusion: The findings support the case for PDK2 as a promising target for 
hepatic steatosis and insulin resistance.
Supported by: NRF-2012R1A2A1A03670452
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Pro- and antioxidant status in dependence on vitamin D3 availability in 
the development of diabetes-induced liver injury
D. Labudzynskyi, I. Shymanskyy, A. Mazanova, O. Lisakovskaya, M. Veliky; 
Laboratory of Medicine Biochemistry, Palladin Institute of Biochemistry of 
the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Background and aims: Diabetes is known to be associated with overpro-
duction of ROS and/or impaired antioxidant defence contributing to the 
onset and progression of diabetic complications on vessels, retina, kidneys, 
nerves and liver. Nevertheless, precise mechanism by which oxidative stress 
could facilitate and accelerate the development of hepatic lesions in diabetes 
is not fully clarified. Recent studies have shown that vitamin D3 is currently 
recognized as a potent immunomodulator and antioxidant affecting various 
inflammatory and autoimmune diseases. The present study was performed 
to determine the relationship between 25-hydroxyvitamin D3 (25(OH)D3) 
availability and pro-/antioxidant profile in liver of diabetic mice.
Materials and methods: Type 1 diabetes was induced in male C57BL/J6 mice 
(weighing 25.0 ± 1.5g) by i.p. injection of multiple low dose streptozotocin 
(40 mg/kg b.w.). Control and STZ-diabetic mice were treated with or without 
vitamin D3 (15 IU/mouse per os, for 8 weeks). Serum 25OHD3 was assessed 
by ELISA. The levels of phospho-NF-kB/p65, poly(ADP-ribose)polymerase 
1 (PARP-1), poly-ADP-ribosylated and nitrosylated proteins were measured 
by Western-blot analysis. Intracellular reactive oxygen and nitrogen species 
(ROS and RNS) production were detected by 2‘,7‘-dichlorofluorescin (DCF) 
and 4,5-diamino-fluorescein diacetate (DAF-DA) fluorescence respectively 
using flow cytometry. Hepatic pro-/antioxidant factors and enzymes activity 
in liver were measured spectrophotometrically.
Results: Serum level of 25OHD3, the main circulating metabolite of D3, was 
shown to be reduced to 23.8±1.9 in diabetes vs. 39.7±2.9 nmol/l in control, 
that reflects reliably vitamin D3 deficiency (p<0.05). As a strong evidence 
of diabetes-induced oxidative stress that may lead to liver lesions, increased 
hepatocytes ability to oxidize the fluorogenic substrate DCF and DAF was 
found. These changes were accompanied by a significant rise in the levels of 
protein nitrotyrosine, carbonyl groups and PAR by 42, 38, and 61% respec-
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tively vs. control, p<0.05. Diabetes also caused more than 1.67-fold increase 
in the level of 89 kDa apoptotic cleavage fragment of PARP. It was established 
diabetes-associated increase in the activities of key pro- and antioxidant en-
zymes in the liver: catalase (20%), SOD (7%), GPX (41%), xanthine oxidase 
(27%) DT-diaforase (54%) and NADPH-oxidase (39%). Alterations in pro-/
antioxidant status in diabetes were paralleled by 1.51- and 2.04-fold over-
expression of cytosolic and nuclear NF-kB/p65 respectively as compared to 
control (p<0.05), indicative of NF-kB-mediated signaling pathways contri-
bution to hepatic oxidative stress and inflammation. Vitamin D3 treatment 
completely restored blood serum 25OHD3 level, partially decreased PARP-1 
and NF-kB/p65 expression and counteracted diabetes-induced abnormalities 
of pro-/antioxidant profile in liver tissue. Normalized 25OHD3 availability 
strongly correlated with a significant decrease in ROS and RNS generation in 
hepatocytes as compared with diabetic mice.
Conclusion: The findings indicate that diabetes-associated vitamin D3 insuf-
ficiency can be related, at least in part, to increased prooxidant status of liver 
cells. Our data suggest a potential role of vitamin D3 treatment in the regula-
tion of impaired oxidative metabolism in diabetes.
1280
Liver-specific deletion of mitochondrial prohibitin-2 alters glucose 
homeostasis associated with liver damage
J. Martin-Levilain1, S. Supale1, C. Merkwirth2, D. Metzger3, P. Chambon3,  
T. Langer2, P. Maechler1;  
1Department of Cell Physiology and Metabolism, University of Geneva, 
Switzerland, 2Institute for Genetics, University of Cologne, Germany, 
3Institut de Génétique et de Biologie Moléculaire et Cellulaire,  
University of Strasbourg, Illkirch, France.
Background and aims: Regulation of mitochondrial dynamics and functions 
depends on various proteins. Recent studies highlighted the role of prohib-
itins which are highly conserved and ubiquitously expressed as two interde-
pendent isoforms (Phb1 and Phb2). Prohibitins are found in the inner mito-
chondrial membrane of mitochondria and form large ring complexes. Their 
dysfunctions are associated with aging, cancer, obesity and inflammation. 
Mice lacking liver Phb1 exhibit hepatic injury and hepatocellular carcinoma. 
Recently, it showed that Phb2 is essential to maintain beta-cell mitochondrial 
function and integrity, thereby controlling insulin secretion and beta-cell 
survival. The present study focused on the role of Phb2 in liver biology us-
ing transgenic mice with liver-specific and time-controlled deletion of Phb2 
(Hep-Phb2-/-).
Materials and methods: Conditional liver-specific (Alb-Cre-ERt/lox) dele-
tion of Phb2 was induced in 9-week old mice by sub-cutaneous implantation 
of one tamoxifen pellet per animal. After 3 weeks, mice were sacrificed, body 
and liver weights were measured and liver tissues analyzed by histology. The 
levels of hepatic transaminases (ALT and AST), bilirubin, cholesterol, triglyc-
erides and glucose were determined in blood and glycogen content was meas-
ured in liver. Pyruvate tolerance test was also performed. Expression of Phb2, 
Phb1 and proteins involved in glycogenesis/glycogenolysis/gluconeogenesis 
were assessed by Western Blot.
Results: Three weeks after Tamoxifen implantation, hepatic levels of Phb2 
protein were reduced by 90%. This deletion was associated with a 70-80% 
decrease of hepatic Phb1 protein. The body and liver weights of Hep-Phb2-/- 
were significantly lower compared to control (Phb2fl/fl) mice. Levels of AST 
(642±94 vs 90±19 IU/L, p<0.001), ALT (247±41 vs 33±3 IU/L, p<0.001) and 
bilirubin (45±13 vs 2±0.1 µM, p<0.05) were increased in Hep-Phb2-/- ani-
mals versus controls. Plasmatic levels of triglycerides (0.07±0.1 vs 1.1±0.1 
mM, p<0.05) and cholesterol (1.40±0.2 vs 1.9±0.07 mM, p<0.01) were lower 
in Hep-Phb2-/- mice compared to Phb2fl/fl mice. H&E staining showed pro-
nounced histologic damages in Hep-Phb2-/- such as bile duct hyperplasia, 
fibrosis and accumulation of lipid droplets. In fed conditions, blood glucose 
levels were lower (4.5±0.6 vs 7.8±0.8 mM, p<0.005) in Hep-Phb2-/- mice 
compared to Phb2fl/fl mice. Pyruvate tolerance test revealed impaired he-
patic glucose production in Hep-Phb2-/- mice. The hepatic glycogen content 
was reduced by 80% in Hep-Phb2-/- animals versus Phb2fl/fl mice. Accord-
ingly, marked reduction of expression of glucose-6-phosphatase (-25%), glu-
cokinase (-90%), glycogen phosphorylase (-75%) and glycogen synthetase 
(-50%) were observed in liver of Hep-Phb2-/- mice.
Conclusion: Hepatic deletion of Phb2 induced liver damage associated with 
impaired hepatic glycogen metabolism and hypoglycaemia. Liver Phb2 is re-
quired for the fine tuning of glycogenesis, glycogenolysis and gluconeogen-
esis, ultimately participating to glucose homeostasis.
Supported by: Swiss National Foundation
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Increased inflammatory and procoagulant state are responsible 
for vascular complications in diabetic patients with albuminuria 
accompanied by fatty liver
S. Ljubic1, M. Tomic1, A. Piljac1, D. Majic Milotic1, L. Smircic Duvnjak1,  
T. Bulum1, A. Jazbec2;  
1Merkur Clinical Hospital, Vuk Vrhovac University Clinic, Zagreb, 
2University of Zagreb, Croatia.
Background and aims: Vascular complications in diabetes are characterised 
by inflammation and a procoagulant state due to hyperglycaemia. The aim of 
this study was to compare the behaviour of inflammatory and other mark-
ers responsible for endothelial dysfunction and atherosclerosis related to ne-
phropathy and liver steatosis in type 2 diabetic patients.
Materials and methods: Markers of inflammation and coagulation, as well 
as other markers relevant for diabetes and metabolic syndrome, were tested 
in 594 patients according to the presence of non-alcoholic fatty liver disease 
(NAFLD) and the albumin excretion rate (AER) (normoalbuminuria<30 
mg/24h; albuminuria: 30-300 mg/24h). NAFLD was diagnosed by ultra-
sonography. Fatty liver index (FLI) (≤ 60; >60) was used as a predictor of liver 
steatosis (FLI = [e (0.953xloge (triglycerides [Tg]) + 0.139x body mass index [BMI] + 0.718xloge (gamma-glutamyl 
transpeptidase [GGT]) + 0.053xwaist-to-hip ratio [WHR] - 15.745) / 1 + e (0.953xloge [Tg] + 0.139xBMI + 0.718xloge 
[GGT] + 0.053xWC - 15.745)] x 100). AER was measured from three urine samples. Pe-
ripheral insulin sensitivity was measured using estimated glucose disposal 
rate (eGDR = 24.31 − [12.22 ×WHR] − [3.29 × hypertension] − [0.57 × gly-
cated haemoglobin (HbA1c)]). Patients were divided into quartiles according 
to FLI and AER (1st: FLI≤ 60 and AER<30, 2nd: FLI>60 and AER<30, 3rd: FLI≤ 
60 and AER:30-300 and 4th: FLI>60 and AER:30-300).
Results: Significant differences (p<0.05) were determined using analysis of 
variance in waste circumference (WC), postprandial blood glucose (BGPP), 
HbA1c, adiponectin (ApN), fibrinogen (FIB), white blood cell (WBC) count, 
AER, high density lipoprotein (HDL), Tg, alanine transaminase (ALT), fast-
ing C-peptide (FC) and eGDR among the groups according to the presence 
of NAFLD and albuminuria. Tested groups that differed were determined us-
ing Tukey post hoc test. Patients in the 4th quartile had significantly higher 
FIB, WBC, WC, BGPP, HbA1c, Tg, ALT, and fC-peptide, and lower ApN, 
HDL and eGDR values compared with the 1th quartile. Patients in the 2nd 
quartile had higher WC and lower eGDR compared with the 1st quartile. Af-
ter stepwise regression procedure for FIB as a dependent variable, the best 
model included (R2=0.479) high-sensitivity C-reactive protein (hs-CRP), sys-
tolic blood pressure (SBP), WHR, WBC and ApN. The best model for WBC 
(R2=0.310) included FLI and interleukin-6 (IL-6). FIB and WBC correlated 
significantly (p<0.05) with hs-CRP, IL-6, BGPP, HbA1c, AER, HDL, uric 
acid, FLI and eGDR; FIB additionaly correlated with fasting BG, and WBC 
with WC, ApN and Tg.
Conclusion: Increased FIB, WBC, Tg, ALT, BGPP and HbA1c, and de-
creased ApN, HDL and eGDR pointed to increased inflammatory and proco-
agulant state in the presence of albuminuria and NAFLD. Decreased eGDR 
reflected increased insulin resistance even in normoalbuminuric patients 
with NAFLD. Reported correlations among the tested variables unravelled 
the association between inflammation, procoagulant state and glycaemia as a 
culprit of vascular complications in the studied patients.
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Hepatic heat shock proteins in long term diabetic complications
M. Brune1,2, N.B. Nillegoda3, B. Bukau3, P.P. Nawroth1, S. Herzig2;  
1Department of Internal Medicine I and Clinical Chemistry, Heidelberg 
University Hospital, 2Molecular Metabolic Control, German Cancer 
Research Center, Heidelberg, 3Biogenesis & Quality Control of Proteins, 
Zentrum für Molekulare Biologie Heidelberg, Germany.
Background and aims: Current regimes for the treatment of Diabetes mel-
litus type 2 (DM2) can only postpone, but not prevent the development of 
long term diabetic complications. Therefore, the continuously earlier age of 
DM2 onset will dramatically increase the incidence and severity of diabetic 
complications in future years. The course of DM2 complications includes ac-
cumulation of damaged, misfolded and aggregated proteins, while protective 
heat shock proteins (HSP) are repressed. With this study we aim to identify 
HSP-regulated liver-to-periphery signalling pathways effecting the develop-
ment and progression of long term diabetic complications.
Materials and methods: Livers of Streptozotocin-induced type 1 diabetic 
mice, obesity-induced type 2 diabetic mice (db/db), mice fed a high-fat diet 
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and respective control mice were analyzed for expression of HSPs by qPCR 
and western blot. Hepatocyte-specific reconstitution of HSPs in db/db mice 
was achieved via adenoviral constructs for Hsp70, DNAJB1 and DNAJA2.
Results: In our models of diabetes, we observed downregulations of up to 
90% in the hepatic expression of central HSPs such as Hsp70. In contrast, 
non-diabetic mice on a high-fat diet showed no significant regulation of he-
patic HSP expression. In db/db mice, two weeks of hepatocyte-specific recon-
stitution of Hsp70 reduced both fasting glucose and HbA1c by approx. 25% 
(p<0.005) along with improved liver histopathology. Parameters of lipid me-
tabolism were not significantly affected. Since efficient recognition and pro-
cessing of damaged and aggregated proteins requires the cooperation of HSPs 
from different HSP families, we also analyzed the in vivo effects of simultane-
ous reconstitution of the cooperating HSPs Hsp70, DNAJB1 and DNAJA2 in 
db/db mice. This combined reconstitution improved fasting blood glucose 
from 444±91 mg/dl in control mice to 269±101 mg/dl in HSP-treated mice 
(-40%, p<0.005). As a measure of overall liver pathology, serum alanine ami-
no transferse (ALT) dropped from 325±112 IU/l to 108±50 IU/l (p<0.005). 
The response to acute glucose challenge showed a highly significant reduc-
tion of glucose tolerance (p<0.001 in two way ANOVA). Along with reduced 
serum insulin levels in HSP-treated mice, the improved glucose tolerance test 
was suggestive for a reduced insulin resistance and increased glucose uptake 
in periphery organs like muscle and adipose tissue. Importantly, only six days 
after reconstitution of cooperating HSPs, the thermal nociceptive responsive-
ness was significantly improved from 32.5±11 sec. in control mice to 24.5±8 
sec. in HSP-treated mice (p<0.01). Peripheral nerve histology revealed a sig-
nificant change in the number of infiltrating leukocytes, pointing towards im-
munological mechanisms that reduced the pre-existing diabetic neuropathy.
Conclusion: The hepatic reconstitution of HSPs cooperating in protein qual-
ity control resulted in a profound metabolic improvement in our in vivo mod-
el of DM2, affecting not only parameters of carbohydrate metabolism but 
also insulin resistance and the long term complication of diabetic neuropathy. 
Our data indicate that hepatic HSPs regulate systemic signalling pathways 
which direct the course of diabetes and its long term complications.
Supported by: Dietmar Hopp Stiftung
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Lipoprotein subclasses associate with hepatic glucose uptake, 
production, and genetic targets after bariatric surgery in morbidly  
obese patients
R.M. Badeau1, M.-J. Honka1, H. Immonen1, J.C. Hannukainen1,  
P. Soininen2, A.J. Kangas2, M. Ala-Korpela2, P. Nuutila1;  
1Turku Postron Emission Tomography Centre, Turku,  
2School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Background and aims: The cardiovascular complications arising from mor-
bidly obese individuals remains unsettled. If lifestyle modifications are not 
effective in reducing weight, these individuals have a high risk for insulin 
resistance and diabetes. Bariatric surgery is a potent treatment to rapidly 
remove weight. Although absolute very-low-density lipoprotein cholesterol 
(VLDL) serum levels are decreased and high-density lipoprotein (HDL) 
cholesterol concentrations are increased after bariatric surgery, their hetero-
geneity/subclass distributions remain unclear. These subclasses play a major 
role in the extent of atherosclerosis severity. This study’s objective was to map 
these subclasses in morbidly obese participants, both pre- and post-surgery, 
and to assess hepatic metabolic and genetic associations.
Materials and methods: Hepatic glucose uptake and production were as-
certained using 18F-fluorodeoxyglucose and positron emission tomogra-
phy from 23 morbidly obese (BMI > 39 kg/m2) participants, before and six 
months after surgery. Ten healthy lean controls were also recruited. Liver 
biopsies were taken from 23 participants before surgery. Targeted, real-time 
PCR analysis was conducted to assess gene levels in the morbidly obese, on 
lipoprotein assembly and catabolic genes: microsomal triglyceride transfer 
protein, apoB, apoE, ABCA1, apoAI, LDL receptor, CD36, hepatic lipase, and 
LCAT. Genes involved with liver triglyceride metabolism such as glucose ki-
nase regulatory protein, DGAT, etc. were also profiled. Lipoprotein subclass 
profiles, from serum, were analyzed by NMR spectroscopy. Principal compo-
nent analysis explained the 95 percent variation in the dataset. After a Bon-
ferroni correction, p-values less than 0.001041 were significant. Lipoprotein 
subclasses, which changed significantly, were compared to hepatic glucose 
uptake, production, and genetic profiles using Pearson correlations.
Results: After bariatric surgery, large, medium, and small VLDL-cholesterol 
concentrations were significantly reduced, while extra-large and large HDL 
cholesterol subclasses were significantly higher. Only after surgery, large 
and extra-large HDL correlated positively with hepatic glucose uptake rate 
(r=0.542; p=0.025 and r=0.510 and p=0.036, respectively) and these particles 
associated negatively with hepatic glucose production (r=-0.624, p=0.013 and 
r =-0.547 and p=0.035, respectively). Results from the liver genetic data are 
in process.
Conclusion: We showed that surgery induced, rapid weight loss caused sig-
nificant increases in antiatherogenic large HDL subclasses and that these 
were associated with hepatic glucose metabolism. In addition, this study used 
human liver samples, which are restricted based on ethical rationales. This 
pioneer study builds a framework for understanding hepatic lipoprotein me-
tabolism in morbid obesity, a condition preluding insulin resistance and type 
2 diabetes. With our novel findings, early prevention strategies can be in-
ducted. In summary, this report delivers an in-depth conceptualization about 
how liver and lipoprotein synergy dictates diabetes-induced cardiovascular 
risk factors.
Supported by: AOF
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 522 
1 C
PS 116 Vascular calcification
1284
Oestrogen-related receptor gamma mediates vascular calcification 
through up-regulation of BMP2
Y.-K. Choi1, J.-H. Kim1, M.-K. Kim2, G.-S. Jung1, K.-H. Bae1, M.-J. Kim3,  
E. Kim4, I.-K. Lee1, K.-G. Park1, M.-G. Choi5, K.-U. Lee6, E. Jung7;  
1Division of Endocrinology and Metabolism, Department of Internal 
Medicine, Kyungpook National University School of Medicine, 2Division 
of Endocrinology and Metabolism, Department of Internal Medicine, 
Keimyung University School of Medicine, 3Pooren Meerae Internal 
Medicine Clinic, 4Division of Endocrinology and Metabolism, Department 
of Internal Medicine, Daegu, 5Division of Endocrinology and Metabolism, 
Department of Internal Medicine, Hallym University Medical Cente, 
Chuncheon, 6Division of Endocrinology and Metabolism, Department of 
Internal Medicine, Asan Medical Center, Seoul, 7Division of Endocrinology 
and Metabolism, Department of Internal Medicine, Daegu Catholic 
University Medical Center, Republic of Korea.
Background and aims: Vascular calcification, which refers to ectopic miner-
alization in vascular smooth muscle cells, occurs frequently in many diseases 
such as chronic kidney disease, atherosclerosis, and diabetes. Estrogen re-
lated receptor (ERR)γ, a member of orphan nuclear receptor superfamily has 
diverse roles in regulating homeostatic and metabolic processes. However the 
role of ERRγ in vascular calcification has not yet been investigated. This study 
was undertaken to examine the role of ERRγ in vascular calcification.
Materials and methods: Rat aortic smooth muscle cells (RASMCs) were cul-
tured and vascular cell calcification was induced by treatment with inorganic 
phosphate and calcium. Next we investigated effects of adenovirus-mediated 
overexpression of ERRγ on phosphate-induced VSMC calcification and ex-
amined whether siRNA-mediated inhibition of endogenous expression of 
ERRγ or pharmacological inhibition of ERRγ with GSK5182 prevent phos-
phate-induced vascular calcification.
Results: Along with increased expression of bone morphogenic protein-
2(BMP2), Runx2 and Msx2, ERRγ expression was upregulated during phos-
phate - induced calcification. Von-kossa staining showed that adenovirus-
mediated overexpression of ERRγ (Ad-ERRγ) in RASMCs accelerated Pi-
induced calcification. Ad-ERRγ increased the expression of osteogenic gene 
including Runx2, OPN and Msx2 but decreased alpha-SMA. ERRγ induced 
BMP2 transcription through directly binding to its promoter region and 
increased BMP2 signaling including phosphorylation and nuclear localiza-
tion of smad1/5/8. Moreover, inhibition of ERRγ by both siRNA-mediated 
knockdown of endogenous ERRγ and a selective inverse agonist, GSK5182 
attenuated vascular calcification and osteogenic gene expression in vitro and 
in vivo.
Conclusion: This study demonstrated that ERRγ mediates vascular calcifi-
cation through up-regulation of BMP2 signaling. These results indicate that 
inhibition of ERRγ may be a potential therapeutic strategy for prevention of 
vascular calcification.
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Effects of high glucose on the OPG/RANK/RANKL/TRAIL system in the 
progression of vascular calcification in rat aortic vascular smooth muscle 
cells
Y. Kang, H. Choi, E. Sim, H. Lee, D. Yi, S. Son;  
Internal Medicine, Pusan National University School of Medicine, Yangsan, 
Republic of Korea.
Background and aims: Diabetes mellitus is frequently complicated by car-
diovascular disease, such as vascular calcification and accelerated athero-
sclerosis. Recently, it has been known that the OPG/RANK/RANKL/TRAIL 
system may play a major role in vascular calcification and atherosclerosis. 
However, the possible effects of long term high glucose stimulation at least 
4 weeks on the OPG/RANK/RANKL/TRAIL system in the progression of 
vascular calcification are less clear. We attempted to evaluate the effect of high 
glucose on the progression of vascular calcification in rat aortic smooth mus-
cle cells (RASMCs) and to detect the expression changes of OPG, RANK, 
RANKL, and TRAIL for 2 and 4 weeks. Furthermore, we used BMP-7, which 
has been known to attenuate vascular calcification, to detect the possible 
changes of OPG, RANK, RANKL, and TRAIL expressions on the calcifica-
tion of RASMCs.
Materials and methods: The primary cultured RASMCs were stimulated 
with normal glucose (5.5mmol/L glucose, NG) and high glucose (30 mmol/L 
glucose, HG) with calcification medium. The mRNA levels and the protein 
expressions of OPG, RANK, RANKL, and TRAIL were measured by reverse 
transcription polymerase chain reaction (RT-PCR) or Western blot.
Results: The intensity of calcium staining was increased in HG after 2 weeks 
and more increased and prominent after 4 weeks compared to NG. OPG 
mRNA and protein expressions were not different after 2 weeks, however, 
after 4 weeks, OPG expressions were significantly decreased in HG. Regard-
ing RANK, RANKL, and TRAIL expressions, there were no differences after 
2 or 4 weeks of stimulation. After 4 week of rhBMP-7 co-treatment, the den-
sities of calcium stains were attenuated and the total amount of calcium was 
also decreased. The mRNA and protein OPG expressions were maintained 
with BMP-7 after 4 weeks of stimulation. There were no differences in the 
expressions of RANK, RANKL, and TRAIL between with and without BMP-
7 co-treatment. There was no difference in Bax mRNA expression, an apop-
totic marker, between with and without BMP-7 co-treatment, however, ALP 
mRNA expression, a marker of mineralization, was decreased in the presence 
of BMP-7.
Conclusion: Chronic hyperglycemia may enhance vascular calcium depo-
sition and high glucose may increase OPG mRNA and protein expression 
with short-term stimulation, but decrease it with long-term stimulation. The 
expression of RANKL, RANK, and TRAIL were maintained with long term 
stimulation. As the OPG expression was decreased, the increased mineraliza-
tion activity may be more associated rather than apoptotic activity with the 
progression of long-term high glucose induced vascular calcification.
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The DPP-4 inhibitor linagliptin increases plasma fetuin-A concentrations 
in a rat model of uraemic calcification
C. Reichetzeder1,2, A. Pasch3, K. von Websky1,2, O. Tsuprykov1, T. Klein4,  
B. Hocher1;  
1University of Potsdam, 2Centre for Cardiovascular Research / Institute 
of Pharmacology, Charité, Berlin, Germany, 3Department of Nephrology, 
University of Bern, Switzerland, 4Boehringer Ingelheim, Germany.
Background and aims: Fetuin-A is a potent inhibitor of ectopic mineralisa-
tion. An increase in fetuin-A has beneficial effects in uraemic vascular calcifi-
cation, whereas fetuin-A deficiency is associated with soft tissue calcification 
in mice and humans. Biomarker data in diabetic and non-diabetic rodent 
models of chronic renal failure suggest that the dipeptidyl peptidase (DPP)-4 
inhibitor linagliptin may be able to influence the pathogenesis of vascular 
calcification. The aim of the present study was to investigate the effect of lina-
gliptin on uraemic vascular calcification in nephrectomised rats.
Materials and methods: 1,25-dihydroxyvitamin D3 (0.25 μg/kg/day) was 
used to induce uraemic vascular calcification in 5/6 nephrectomised rats 
(5/6NxVitD). Rats were allocated to 3 treatment groups: a) sham-operated 
rats treated with placebo (n=10); b) 5/6NxVitD rats treated with placebo 
(n=14); c) 5/6NxVitD rats treated with linagliptin (n=14). Rats were treated 
for 6 weeks. We analysed plasma factors known to be involved in uraemic 
vascular calcification such as cystatin C, fibroblast growth factor 23 (FGF23), 
magnesium, calcium, phosphate, and fetuin-A. Blood pressure was moni-
tored and at study end, animals were sacrificed; blood was taken and stored 
at -80°C for analysis.
Results: Blood pressure was similar in all groups. 5 of 14 animals died in the 
5/6NxVitD placebo group; 3 of 14 animals died in the 5/6NxVitD linaglip-
tin group (p>0.05). At study end, magnesium, FGF23, and cystatin C levels 
were unaffected by linagliptin in 5/6NxVitD rats. The change from baseline in 
phosphate levels was similar with linagliptin and placebo in 5/6NxVitD rats, 
whereas the change from baseline in calcium levels was less with linagliptin 
(-0.062 ± 0.255 mmol) than placebo (0.961 ± 0.439 mmol) in 5/6NxVitD rats 
(p<0.05). The change from baseline in fetuin-A levels was greater with lina-
gliptin (1.278 ± 0.125 g/l) than placebo (0.919 ± 0.072 g/l) in 5/6NxVitD rats 
(p<0.05).
Conclusion: The favorable change from baseline in plasma calcium after 6 
weeks of linagliptin treatment in an aggressive rat model of uraemic vascular 
calcification may be due to an increase in fetuin-A levels. Although further 
studies are required, linagliptin treatment may potentially offer a new thera-
peutic option to reduce uraemic vascular calcification in patients with ad-
vanced stages of renal failure.
Supported by: Boehringer Ingelheim
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Below-knee arterial calcification in type 2 diabetes: association with 
receptor activator of nuclear factor kappa B ligand, osteoprotegerin and 
neuropathy
O. Bourron1,2, C.E. Aubert1, S. Liabeuf3, P. Cluzel1, M. Komajda1,  
S. Jacqueminet1, Z. Massy3, A. Hartemann1,2;  
1Pierre et Marie Curie University Paris 06 - Assistance Publique Hôpitaux 
De Paris, 2CHU Pitié-Salpêtrière,  
3Picardie University - CHU Amiens, Paris, France.
Background and aims: Calcification of the arterial wall in diabetes con-
tributes to the arterial occlusive process at the below knee level. The 
osteoprotegerin(OPG)/RANKL system is suspected to be involved in the 
calcification process. The aim of the study was to investigate if there is a 
link between arterial calcification in type 2 diabetes and 1) the conventional 
cardio-vascular risk factors, 2) the serum RANKL and OPG levels and 3) 
neuropathy.
Materials and methods: We objectively scored, in a cross-sectional study, 
infra-popliteal vascular calcification using CT-scan in 198 patients with type 
2 diabetes, a high cardio-vascular risk and with glomerular filtration rate > 
30mL/mn. Colour duplex ultrasonography was performed to assess periph-
eral arterial occlusive disease, and mediacalcosis. Peripheral neuropathy was 
defined by a neuropathy disability score (NDS) > 6. RANKL and OPG were 
measured in serum by routine chemistry.
Results: Below knee arterial calcification was associated with arterial occlu-
sive disease. In multivariate logistic regression analysis, variables significantly 
and independently associated with the calcification score were age (OR=1.08; 
95% CI=1.04-1.13 ; p<0.0001), male gender (OR=3.53 ; 95% CI=1.54-8.08; 
p=0.003), previous CVD(OR=2.78 ; 95% CI=1.39-5.59 ; p=0.005) and NDS 
(per 1 point, OR=1.21 ; 95% CI=1.05-1.38 ; p=0.006). The association with Ln 
OPG, significantly associated with calcification score in univariate analysis 
(OR=3.14 ; 95% CI=1.05-9.40 ; p=0.045), was no longer significant in multi-
variate analysis. RANKL and OPG/RANKL were not significantly associated 
with the calcification score.
Conclusion: Below knee arterial calcification severity is clearly correlated 
with peripheral neuropathy severity and several usual cardio-vascular risk 
factors, but not with serum RANKL level.
Supported by: Lilly Company and the University of Lausanne
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Serum fetuin levels are associated with peripheral arterial disease in 
patients with type 2 diabetes mellitus
I. Eleftheriadou1, P. Grigoropoulou1, I. Mourouzis2, C. Liaskos1,  
A. Kokkinos1, D. Perrea3, K. Makrilakis1, N. Katsilambros1, N. Tentolouris1;  
1First Department of Propaedeutic and Internal Medicine, Athens University 
Medical School, Laiko General Hospital, 2Department of Pharmacology, 
Athens University Medical School, 3Laboratory of Experimental Surgery and 
Surgical Research, Athens University Medical School, Greece.
Background and aims: Fetuin is a hepatic glycoprotein that inhibits arte-
rial calcification and insulin action. Patients with type 2 diabetes mellitus 
(T2DM) have higher fetuin levels than non-diabetic individuals. However, 
increased fetuin levels have been associated with lower cardiovascular risk 
among non-diabetic individuals, while a trend towards the opposite direction 
has been demonstrated in patients with T2DM. Conflicting data exists re-
garding the association between fetuin and peripheral arterial disease (PAD) 
in diabetes. The purpose of this study was to determine the relationship of 
serum fetuin levels with PAD in patients with T2DM.
Materials and methods: A total of 71 patients (142 feet) with T2DM were 
recruited (mean age 67.7±8.9 years, mean diabetes duration 15.0±10.6 years, 
male/female 45/26). Serum fetuin levels were measured using ELISA. Diag-
nosis of PAD was based on the presence of either biphasic, monophasic or 
blunted waveforms at the pedal arteries, while ankle-brachial index (ABI) 
was also measured.
Results: Patients with PAD (n=35) had significantly lower serum fetuin lev-
els in comparison with those without PAD (510.0±108.5 vs 562.3±121.2 μg/
ml, p=0.008). Fetuin levels were significantly associated with ABI (r=0.236, 
p=0.006). Univariate logistic regression analysis showed that age (p=0.004), 
male gender (p=0.022), diabetes duration (p=0.001), dyslipidemia (p=0.002), 
arterial hypertension (p=0.008), smoking (p=0.052) and fetuin levels 
(p=0.010) were significantly associated with PAD. No significant associations 
were found with BMI and HbA1c. Multivariate logistic regression analysis, 
after adjustment for age and gender demonstrated that PAD was significantly 
associated with diabetes duration [odds ratio (OR): 1.06, 95% confidence in-
tervals (CI): 1.01-1.10, p=0.014], dyslipidemia (OR: 5.2, 95% CI: 1.85-14.57, 
p=0.002), arterial hypertension (OR: 7.0, 95% CI: 1.55-32.13, p=0.012), 
smoking (OR: 5.0, 95% CI: 1.27-19.55, p=0.022) and fetuin levels (OR: 0.99, 
95% CI: 0.989-0.997, p=0.001).
Conclusion: Serum fetuin levels are lower in patients with PAD and are as-
sociated with the presence of PAD irrespective of traditional cardiovascular 
risk factors.
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Relation of epicardial adipose tissue volume, microalbuminuria, thyroid 
hormones axis to coronary artery calcium in type 2 diabetic patients
M.M.M. Aboromia1, H.A. Elorabi2, K.M. Makbol2, Y.M. Eid2,  
S.A. Moharam3, A.M. Hamam3;  
1Internal Medicine, Diabetes Unit, Ain Shams University Hospitals,  
2Internal Medicine, Diabetes Unit, Ain Shams University Hospitals, 
3Cardiolgy, Military Medical Academy, Cairo, Egypt.
Background and aims: Cardiovascular disease (CVD) is the most signifi-
cant cause of mortality in type 2 diabetes mellitus(T2DM) patients. Visceral 
adipose tissue (VAT) may be important in sustaining the proinflamma-
tory background of cardiovascular disease. Epicardial adipose tissue(EAT), 
is a special VAT that surrounds the major branches of the coronary artery 
branches and myocardium. This close anatomical relationship between EAT 
and coronary arteries and myocardium further promotes local paracrine 
interactions between these tissues. Calcific deposits in coronary artery are 
in connection with coronary artery atheromatous plaque and is considered 
an indicator of atherosclerosis Microalbuminuria has long been recognized 
as an important biomarker that predicts micro and macrovascular compli-
cations and mortality in patients with T2DM.Complex interplay between 
thyroid function and insulin resistance has been implicated in diabetic dys-
lipidemia. Furthermore,triiodothyronine (T3) was found to be a key signal in 
myocardial cells.whether there is an association between EAT, albuminuria , 
thyroid hormones to coronary atherosclerosis and coronary artery calcium 
is a question to be further evaluated. Objective: to investigate the relation 
between EAT volume, thyroid hormones and microalbuminuria to coronary 
artery calcium in T2DM.
Materials and methods: Design: This study was conducted on 100 T2DM 
patients, they were further divided according to their calcium score into 4 
groups. Gr 1:T2DM with coronary artery calcium(CAC 0-10),Gr 2 :T2DM 
patients with CAC (11-100), Gr 3 : T2DM patients with CAC (101-400), Gr 4 
: T2DM patients with CAC >400, all patients were submitted to history tak-
ing, clinical and anthropometric evaluation, laboratory investigations (FBG,2 
h PP,lipid pfofile,HBA1C%,serum insulin, albumin creatinine ratio, TSH,free 
T3, free T4), HOMA-IR, coronary multislice CT.
Results: There was a high statistical significant difference between the 4 
groups as regards EAT volume ,being the highest( >200 cm3) among Gr 4 
,there was a high statistical significant difference between the 4 groups as 
regards HBA1C%, (10.23+1.49), Urinary albumin creatinine ratio(UACR) 
(109.87+52.31 )mg%, (P<0.001) being the highest among GR 4, there was a 
significant difference between the 4 groups as regards TSH levels (3.35+0.63) 
being the highest among Gr 4(P<0.05). Correlation between CAC and dif-
ferent studied parameters showed a high statistical significant(P<0.001) di-
rect correlation between CAC and Body mass index(r=0.396), total choles-
terol (r=0.267), non HDL (r=0.274),fasting blood glucose(FBG) (r = 0.363), 2 
hours Post prandial blood glucose(2H PPG) (r=0.354) HBA1C% ( r = 0.510), 
TSH ( r =0.293),UACR( r = 0.515), EAT ( r = 0.831), A statistical significant 
( P<0.05) direct correlation between CAC and age( r= 0.200), Serum triglyc-
erides ( r = 0.216) HOMA-IR ( r = 0.245).A statistical significant (P<0.05)
indirect correlations were found between CAC and HOMA-B( r = - 0.222) 
and free T3 ( r = - 0.229)
Conclusion: CAC score is strongly related to EAT volume, blood glucose 
control, insulin resistance, albuminuria and thyroid axis hormones.
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Metabolically unhealthy non-obese subjects are at higher risk of 
subclinical coronary artherosclerosis than metabolically healthy obese 
subjects in Korea
K.-U. Lee1,2, J. Jang1,2, C. Woo1, M. Lee1, C. Jung1, W. Lee1, E. Koh1,2,  
J.-Y. Park1, I.-K. Lee3, M. Choi4;  
1Department of Internal Medicine, Asan Medical Center, Seoul, 
2Metabolism Research Unit, Asan Institute for Life Sciences, Seoul, 
3Department of Internal Medicine, Kyungpook National University School 
of Medicine, Daegu, 4Department of Internal Medicine,  
College of Medicine, Chuncheon, Republic of Korea.
Background and aims: Metabolically healthy obesity (MHO) is an emerging 
phenotype with a cardiovascular disease (CVD) risk between healthy, normal 
weight and unhealthy, obese individuals. It is not yet established whether this 
phenotype has higher risk of CVD than nonobese subjects with metabolic 
abnormalities. In this study, we compared the degree of subclinical coronary 
atherosclerosis detected by coronary multidetector computed tomography 
(MDCT) in four groups defined by the state of metabolic health and obesity 
in an asymptomatic Korean population.
Materials and methods: We collected the data of 4,009 asymptomatic sub-
jects (mean age, 53.2 yr) who participated in a routine health screening ex-
amination at a medical center in Korea. Significant coronary artery stenosis 
(CAS) defined as >50% stenosis, and coronary artery calcium scores (CACS) 
were assessed by MDCT. Participants were stratified by BMI (cut-off value, 25 
mg/m2) and metabolically healthy state.
Results: MHO subjects (n = 589) had a significantly higher prevalence of 
subclinical coronary atherosclerotic burden (CAS and CACS > 0) compared 
with metabolically healthy non-obese (MHNO) subjects (n = 1367). Howev-
er, MHO subjects had a significantly lower prevalence of subclinical coronary 
atherosclerotic burden (CACS > 0) compared with metabolically unhealthy 
nonobese (MUNO) subjects (n = 853) as well as metabolically unhealthy 
obese (MUO) subjects (n = 1200). The prevalence of subclinical coronary 
stenosis in MUNO subjects was comparable to MUO subjects.
Conclusion: Our data show that MHO might not be a benign disease in 
terms of coronary atherosclerotic burden. However, MHO subjects had a 
significantly lower prevalence of subclinical coronary atherosclerotic burden 
compared with MUO subjects Thus, the presence of metabolic abnormalities 
may be more important than the presence of obesity in evaluating cardio-
vascular risk.
1291
Contributors to mortality in high risk diabetes patients
D.W. Bowden1, F.-C. Hsu2, B.I. Freedman3, J. Carr4, A.J. Cox5;  
1Center for Human Genomics, 2Biostatistical Sciences, 3Internal Medicine, 
Wake Forest University School of Medicine, Winston-Salem,  
4Radiology, Vanderbilt University School of Medicine, Nashville, USA, 
5Griffith Health Institute, Southport, Australia.
Background and aims: Individuals with type 2 diabetes (T2D) exhibit sub-
stantial differences in mortality risk. Coronary artery calcium (CAC) is a 
powerful, well documented, predictor of mortality. In this study we examined 
a set of individuals at high risk for death based on CAC>1000 (40% mortality 
in 7.5 years) and evaluated a range of clinical measures, including modifiable 
cardiovascular disease (CVD) risk factors, for insights into risk for mortality.
Materials and methods: All-cause mortality was determined in 371 Euro-
pean American individuals with T2D and CAC>1000 from a larger ongoing 
population based cohort study of CVD in people with T2D. After 8.2 ± 3.0 
(mean ± SD) years of follow-up differences in CVD risk factors, medication 
use, and other clinical measures were compared between living (n=218) and 
deceased (n=153) participants. Cox Proportional Hazards Regression models 
were used to quantify risk for mortality to appropriately account for time-to-
event effects.
Results: Mean age at basline was 65.5 years with mean duration of diabetes 
12.6 years. The subjects had a mean BMI of 32.0 and were 70.1% male. Death 
was confirmed through the US Social Security death index. Deceased par-
ticipants had a longer duration of T2D (p=0.02). Differences in cholesterol 
were nominal (HR 2.24 CI 1.09-4.60; p=0.03), but kidney function (HR 4.78 
CI 2.38-9.62; p<4x10-5) and CRP (HR 2.14 CI 1.33-3.43; p=0.002) were more 
strongly associated with mortality. Strikingly, measures of blood pressure, 
use of anti-hypertensive and hypoglycemic medications, and prior prevalent 
CVD were not significantly associated with risk. Use of cholesterol-lowering 
medication was strongly associated with survival (HR 1.68 CI 1.19-2.39; 
p=0.004). Additional measures of subclinical disease revealed that a vascular 
calcification score derived from three arterial beds (coronary, carotid and aor-
tic) was associated with the greatest risk for mortality (HR 2.31; p=3.43x10-7). 
In multivariable models elevated HbA1c, lipids, CRP and calcified plaque and 
lower kidney function were associated with a 1.1-1.5-fold increased risk for 
mortality (3.5x10-6 < p < 0.03), after adjustment for confounding factors.
Conclusion: Even in this high-risk group, a multi-bed assessment of vascular 
calcification and known CVD risk factors provide useful information for risk 
assessment. Importantly, even in a high risk T2D sample, patients have differ-
ential risks of death over a substantial time period and the use of cholesterol-
lowering medication appeared protective for mortality.
Supported by: USA NIH R01 HL092301
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A diagnostic dilemma: an investigation of non-invasive vascular 
assessment of the lower extremity in people with diabetes
V.H. Chuter1, P.E. Craike1, N.A. Johnson2, S.L. Casey1;  
1Health Sciences, University of Newcastle, Ourimbah,  
2Health Sciences, University of Sydney, Lidcombe, Australia.
Background and aims: Peripheral arterial disease (PAD) is estimated to af-
fect 21% of people over the age of 65. Non-invasive vascular assessment of 
the lower extremity using the ankle brachial index (ABI) is recommended 
to screen for the disease in those at risk of PAD including older people and 
people with diabetes. It is well known that the ABI loses clinical utility in 
the presence of diabetes and in older age due to the presence of medial arte-
rial calcification (MAC). The toe-brachial index (TBI) is recommended as 
an alternative to the ABI where elevated ABI values suggest incompressible 
arteries due to MAC. However there is some research to suggest the TBI may 
be more clinically effective in all people with diabetes due to the presence 
of co-existant PAD and MAC producing normal ABI values in the presence 
of significant arterial pathology. The aim of this study was to investigate the 
comparative diagnostic accuracy of the TBI and ABI for the presence of PAD 
in people with and without diabetes.
Materials and methods: Participants meeting current guidelines for lower 
extremity vascular screening including people with diabetes were recruited 
on a volunteer basis from two university podiatry teaching clinics. ABI and 
TBI measurements were performed on the right lower extremity of all par-
ticipants. Participants subsequently underwent colour duplex Ultrasound 
from the abdominal aorta to the distal ankle on the right side. This was used 
as the reference standard to calculate sensitivity, specificity and diagnostic 
accuracy of both the TBI and ABI for the presence of PAD. ROC analysis was 
performed to determine the clinical efficacy for diagnosis of PAD of each test.
Results: One hundred and sixty nine people were recruited to this study 
including 89 people with Type 2 diabetes and 100 males, with a mean age 
73.57 years (SD 7.31 years). The ABI has the highest specificity for PAD in 
both people with and without diabetes (specificity 93%, 95%CI 0.82 to 0.98 
and 95%, 95%CI 0.84 to 0.98 respectively). The TBI had greater sensitivity 
than the ABI in people with and without diabetes (sensitivity with diabetes 
TBI: 85%, 95%CI 0.72 to 0.92, ABI: 42%, 95%CI 0.30 to 0.57, sensitivity with-
out diabetes TBI: 89%, 95%CI 0.75 to 0.96, ABI: 61%, 95%CI 0.45 to 0.75). 
Overall, and, in the presence of diabetes, diagnostic accuracy was higher for 
the TBI (TBI: 78% and 88% respectively, ABI: 68% and 79% respectively). 
ROC analysis indicated the TBI had greater clinical efficacy for the diagno-
sis of PAD in people with diabetes and in the entire study population (ROC 
area:0.82 p=.0001, and 0.81 p=0.0001) than the ABI (ROC area:0.59, p=0.09, 
and 0.67,p=0.0001).
Conclusion: Our results demonstrated that the ABI had greater specificity 
for the presence of PAD than the TBI in people with and without diabetes. 
However, overall the TBI demonstrated greater diagnostic accuracy and may 
be more clinically effective than the ABI for diagnosing PAD in people with 
diabetes and those meeting current guidelines for PAD screening, particu-
larly if PAD is suspected. Further research needs to evaluate relationships 
between severity and location of PAD and the relative clinical utility of the 
TBI and ABI in people with diabetes.
Supported by: University of Newcastle ECR Grant, Ramaciotti Establishment 
Grant
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Caveolin-1 alpha expression is decreased in the aorta of rats with glucose 
intolerance induced by a low dose of streptozotocin
J. Srankova, L. Pivackova, G. Doka, B. Gajdacova, L. Mensikova,  
E. Malikova, K. Galkova, J. Klimas, P. Krenek;  
Department of Pharmacology and Toxicology, Faculty of Pharmacy 
Comenius University, Bratislava, Slovakia.
Background and aims: Caveolae are plasma membrane invaginations of en-
dothelial cells, which represent a predominant location of endothelial nitric 
oxide synthase (eNOS), important in regulation of endothelial function. Ca-
veolin-1 (cav-1) is the main component of caveolae, but the specific role of 
its isoforms α and β in regulation of eNOS activity in diabetes and glucose 
impaired tolerance is still not known.
Materials and methods: Impaired glucose tolerance was involved by strep-
tozotocin administration (STZ, 25 mg/kg/day, i.p. injections after every 24h, 
n=10). Control (CON, n=10) received the vehicle. After 8 weeks, oral glucose 
tolerance test (OGTT) was performed. At the end of experiment (10 weeks 
after STZ) we measured of vascular reactivity to acetylcholine. The expres-
sions of cav-1α, cav-1β, eNOS, hsp90, gp91phox and MnSOD were analyzed 
by Western blot in aorta samples. The expressions of both isoforms of cav-1 
in aorta were also determined at mRNA level by qRT-PCR.
Results: We observed normal fasting glucose in both groups (CON 6.15 ± 
0.27 mmol/l vs. STZ 6.65 ± 0.97 mmol/l), but STZ group had a significantly 
increased glycaemia 1h after oral administration of glucose in OGTT (CON 
8.06 ± 0.44 mmol/l vs. STZ 16.75 ± 2.58 mmol/l, P<0.05). A decreased en-
dothelium-dependent relaxation to acetylcholine was observed in STZ ani-
mals (pD2: CON 6.71 ± 0.16 vs. STZ 6.27 ± 0.08, P<0.01; Emax: CON 37.07% 
± 3.08 vs. STZ 29.67% ± 1.42, P<0.01), whereas endothelial-independent re-
laxation to nitroprusside was not changed. We found a decreased expression 
of eNOS in STZ group (CON 100 ± 12.85 vs. STZ 39.48 ± 7.14, P<0.05), 
while the expressions of hsp90 (CON 100 ± 17.36 vs. STZ 116.26 ± 11.48), gp-
91phox (CON 100 ± 17.09 vs. STZ 139.43 ± 21.53) and MnSOD (CON 100 ± 
11.21 vs. STZ 108.08 ± 14.34) were not altered. There were no changes in the 
expression of both isoforms of cav-1 at mRNA level (cav-1α: CON 1.00 ± 0.12 
vs. STZ 1.26 ± 0.2; cav-1β: CON 1.00 ± 0.21 vs. STZ 1.39 ± 0.18). However, we 
observed a significant downregulation of cav-1α (CON 100 ± 12.42 vs. STZ 
32.22 ± 12.06, P<0.01) and a trend of increased expression cav-1β at protein 
level in STZ group (CON 100 ± 23.86 vs. STZ 149.49 ± 13.86, P=0.07).
Conclusion: Our result showed an impaired glucose tolerance after low-dose 
streptozotocin, which was associated with dysfunction of endothelial-de-
pendent relaxation and decreased expression of eNOS. Endothelial dysfunc-
tion in STZ group probably is not related to expression of gp91phox and Mn-
SOD. It is possible, that decreased expression of cav-1α in STZ group could 
influence activity of eNOS and contribute to endothelial dysfunction.
Supported by: EFSD, VEGA1/0981/12
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Different expression of CYP enzymes generating vasoactive arachidonic 
acid metabolites in animal models of glucose intolerance and diabetes
L. Pivackova1, J. Srankova1, G. Doka1, B. Gajdacova1, L. Mensikova1,  
E. Malikova1, K. Galkova1, R. Sotnikova2, J. Klimas1, J. Navarova3, P. Krenek1; 
1Dept. of Pharmacology and Toxicology, Comenius University,  
2Dept. of Pharmacology and Toxicology, Slovak Academy of Sciences, 
3Slovak Academy of Sciences, Bratislava, Slovakia.
Background and aims: Epoxyeicosatrienoic acids (EETs) are synthetized by 
cytochrome P450 epoxygenases from arachidonic acid (AA). In additon to 
their cardioprotective, antiinflammatory and hypoglycaemic effects, there 
is strong evidence that EETs can act as endothelium-derived hyperpolariz-
ing factors in certain vascular beds and thus contribute to the regulation of 
vascular tone. An alternative route of AA metabolism by cytochrome P450 
omega-hydroxylases produces proinflammatory and vasoconstrictory hy-
droxyeicosatetraenoic acids (HETEs). EETs are degraded by soluble epoxide 
hydrolase to less active dihydroxyeicosatrienoic acids (DHETs). Our aim was 
to investigate the expression of these enzymes in 2 animal models reflecting 
different stages of glucose metabolism impairment accompanied by endothe-
lial dysfunction.
Materials and methods: In the first model, glucose intolerance (GI) was in-
duced in 12-13 weeks old male Wistar rats (n=6-7 for each group) by post-
prandial streptozotocin (STZ) injections (25 mg/kg/day, i.p.) on 3 consecutive 
days. To induce diabetes in the second model (D), rats received STZ (30 mg/
kg/day, i.p.) after overnight fasting for 3 consecutive days. Control groups (C) 
for each model received vehicle. 10 weeks after last dose, OGTT or prepran-
dial blood glucose measurements were performed and we analyzed mRNA 
expression of chosen epoxygenases (Cyp2j4, Cyp2c23), ω-hydroxylases 
(Cyp4a2, Cyp4a3) and soluble epoxide hydrolase (Ephx2) in thoracic aortae 
by RT-qPCR. Data were statistically analyzed by Student‘s t-test or Mann-
Whitney U test when appropriate and are represented as mean ± SEM.
Results: In the first model we observed impaired glucose tolerance (total glu-
cose AUC: 1835 ± 55 vs 3079 ± 415 mmol/l x 270min for C and GI group, 
respectively; p<0.01), but preprandial blood glucose levels remained un-
changed. In the second model, rats in diabetic group had significantly higher 
preprandial blood glucose (6.0 ± 0.2 vs 29.57 ± 0.4 mmol/l for C and D group, 
respectively; p<0.001). The only significant change of relative mRNA expres-
sion in GI model was an upregulation of Ephx2 (1.00 ± 0.16 vs 2.53 ± 0.27 
for C and GI group, respectively; p<0.05). On the contrary, the expression of 
Ephx2 in D model remained at control levels, but we observed an upregula-
tion of Cyp2j4 (1.00 ± 0.05 vs 3.16 ± 0.91 for C and D group, respectively; 
p<0.01) and Cyp4a3 (1.00 ± 0.24 vs 2.35 ± 0.6 for C and D group, respectively; 
p<0.05). The relative expression of Cyp2c23 and Cyp4a2 was unaltered in 
both models. Both models had an impaired relaxation of isolated aorta to 
acetylcholine.
Conclusion: Endothelial dysfunction was observed in both models, but the 
alterations in expression of enzymes regulating the CYP-dependent AA me-
tabolism suggest different pathogenic mechanisms. In the glucose intolerance 
model, increased Ephx2 expression could enhance EETs degradation and 
thus contribute to endothelial dysfunction. On the other hand, in diabetes 
model with hyperglycaemia,the balance between the production of vasodila-
tatory EETs and vasoconstrictory HETEs due to changes in expression of 
Cyp2j4 a Cyp4a. could be more important.
Supported by: EFSD, VEGA1/0981/12
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Association of endothelial progenitor cells with asymmetric 
dimethylarginine and cardiometabolic risk factors in prediabetes
A. Angelidi1, J. Protopsaltis1, T. Sergentanis2, A. Gritzapis3, S. Matsagos1,  
A. Misitzi3, E. Boutati4, G. Dimitriadis4, T. Economopoulos4, S. Raptis4,5,  
A. Melidonis1;  
1Diabetes Center, Tzanio General Hospital, Piraeus, 2Department of 
Epidemiology and Biostatistics, Athens University Medical School,  
3Locus Medicus SA, Athens, 42nd Department of Internal Medicine, 
Research Institute and Diabetes Center, Attikon University Hospital, 
Athens University Medical School, 5Hellenic National Center for Research, 
Prevention and Treatment of Diabetes Mellitus and its Complications, 
Athens, Greece.
Background and aims: It has been suggested that impaired endothelial 
function is present even in early states of diabetes. Endothelial Progenitor 
Cells (EPCs) take part in postnatal neovascularization and promote vascu-
lar homeostasis. EPCs have been considered as a potential biological marker 
of cardiovascular disease. Nitric oxide has been described as potential EPC 
mobilizing factor. Asymmetric dimethylarginine (ADMA) an endogenous 
inhibitor of nitric oxide synthase is a novel marker of endothelial dysfunc-
tion and atherosclerosis in humans. The aim of this study was to investigate 
the relation of EPC levels with several cardiovascular risk factors including 
ADMA among patients with prediabetes.
Materials and methods: 59 participants with newly diagnosed prediabetes 
and 32 controls were enrolled. Medical history, anthropometric and bio-
chemical parameters, including traditional cardiometabolic risk factors and 
high sensitivity C-reactive protein (hsCRP), were obtained. Homeostasis 
model assessment of insulin resistance (HOMA-IR) was estimated. ADMA 
concentrations were determined by ELISA method. Flow cytometry identi-
fied and quantified EPCs (CD34+ KDR+ cells). Univariate and stepwise mul-
tivariate ordinal logistic regression analyses were performed using STATA 
11.1 statistical software.
Results: EPCs and ADMA levels were higher in controls (p=0.027) and 
prediabetes (p=0.0001) group respectively. Univariate regression analyses 
performed separately for all estimated parameters in both groups. In con-
trol group EPC levels were significantly associated with: exercise (p=0.016), 
smoking (p=0.002), positive family history for diabetes (p=0.025), age 
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(p=0.004), c-peptide (p<0.0001) and ADMA (p=0.001). After stepwise 
multivariate ordinal logistic regression analysis EPC levels were signifi-
cantly associated with: age (OR=0.85, 95%Cl:0.77-0.94, p=0.001), exercise 
(OR=15.99, 95%Cl:2.43-105.17, p=0.004), smoking (OR=0.01, 95%Cl:0.001-
0.25, p=0.004), and family history of diabetes (OR=0.05, 95%Cl:0.01-0.36, 
p=0.003). Regarding prediabetes EPC levels were significantly associated 
with: BMI (p<0.0001), waist circumference (p=0.007), mean BP (p=0.016), 
c-peptide (p=0.010), hsCRP (p=0.041), statin intake (p=0.039) and ADMA 
(p=0.004). After stepwise multivariate ordinal logistic regression analysis 
EPC levels were significantly associated with BMI (OR=0.89, 95%Cl:0.82-
0.95, p=0.001) and ADMA (OR=0.64, 95%Cl:0.45-0.9, p=0.01).
Conclusion: The ADMA-induced impaired NO bioavailability may be cor-
related with the reduced EPC levels and the impaired endothelial function in 
prediabetes. The negative and independent association of BMI with EPCs in-
dicates a possible link between obesity and endothelial dysfunction in predia-
betes, and emphasizes the importance of lifestyle modification, and especially 
weight management, in subjects with glucose intolerance.
Supported by: Hellenic National Diabetes Center
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Endothelial progenitor cells show relation to asymmetric dimethyl-
arginine (ADMA) levels and HbA1c variability in young patients with 
type 1 without complications
K. Nagl1, G. Gericke2, E. Duffles2, M. Fritsch1, T. Hörtenhuber1,  
B. Rami-Merhar1, G.-H. Schernthaner2;  
1University Clinic for Pediatrics and Adolescent Medicine,  
2Internal Medicine II, Department for Angiology,  
Medical University Vienna, Austria.
Background and aims: Type 1 diabetes mellitus (T1D) leads to premature 
cardiovascular disease. Improvement or worsening of glycemic control re-
sults in indirect proportional changes in endothelial progenitor cells (EPC) in 
children with T1D. Circulating EPCs play an important role in maintaining 
endothelial function. Asymmetric dimethylarginine (ADMA) is a competi-
tive inhibitor of endothelial nitric oxide synthase (eNOS). ADMA is an inde-
pendent marker of endothelial dysfunction and is elevated in several diseases. 
ADMA levels in T1D are controversial. The aim of this study is to investigate 
the possible association of EPCs and ADMA in T1DM.
Materials and methods: In 63 patients (29 female, 34 male) with T1D and 
a median age of 18.3 years (16.2;21.2) circulating EPCs were enumerated 
by flow cytometry. Different subsets were measured and labeled according 
their antigen expression: CD34+, CD34+CD133+, CD34+CD133+CD309+, 
CD34+CD309+. Serum ADMA levels were measured by commercially avail-
able ELISA. HbA1c variability was calculated as the coefficient of variation 
(CV) from HbA1c values measured quarterly during one year before EPC 
enumeration and was available in 37 patients.
Results: There was no significant sex-dependent difference between male and 
female patients in age, diabetes duration (mean 11.4±3.3 years), body mass 
index (24.4±3.8 kg/m²) or glycemic control (mean HbA1c 7.7±1.4 %), nor 
was there a significant correlation between glycemic control and the vari-
ous EPC subsets. CD34+CD133+CD309+ positive EPC showed an inverse 
correlation with age (r: -0.274, p=0.034) and diabetes duration (r: -0.261, p 
= 0.044), but not with HbA1c. ADMA levels (mean 0.73±0.22 micromol/l) 
were neither associated with HbA1c nor with age or diabetes duration, but 
showed a positive correlation with several of the measured EPC subsets, such 
as CD34+ cells (r: 0.394, p=0.002), CD34+CD133+ positive cells (r: 0.378, p= 
0.03) and CD34+CD133+CD309+ positive EPC (r: 0.360, p=0.005). Mean 
HbA1c variability was 5.4±3.4% (CV). ADMA was negatively associated with 
HbA1c variability (r: -0.365; p=0.026). Multiple linear regression analysis 
revealed that only serum ADMA levels remained independently and signifi-
cantly (p=0.013) associated with CD34+CD133+CD309+ positive circulating 
EPC (beta = 0.411).
Conclusion: We show an independent and significant positive association 
of ADMA serum levels and circulating EPC in young patients with Type 1 
diabetes mellitus without cardiovascular complications. In vitro studies dem-
onstrated the role of ADMA as an endogenous inhibitor of mobilization, 
differentiation, and function of EPC. The paradoxical positive association of 
EPC counts and ADMA serum levels leads us to the assumption that due to 
oxidative stress and the consequently high ADMA levels EPC are mobilized 
to maintain endothelial integrity.
Supported by: Austrian National Bank - Jubiläumsfond
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The relationship between circulating irisin levels and endothelial 
function in obese patients
X. Sun1, N. Hou1, F. Han2, N. Huang1, J. Zhao1, X. Liu1;  
1Department of Endocrinology, 2Department of Pathology,  
Affiliated Hospital of Weifang Medical University, China.
Background and aims: Irisin is a novel hormone secreted by myocytes and 
could promote the browning of white adipose tissue. Some studies reported 
that circulating irisin levels were lower in both type 2 diabetes and obese pa-
tients compared with lean controls. Elevated NEFA levels from excess adipose 
tissue, which induce inflammation and oxidative stress, could account for en-
dothelial dysfunction in obesity. It is logical to consider that irisin could ame-
liorate NEFA-induced endothelial dysfunction by inducing white-to-brown 
adipose conversion. Thus, the aim of the study was to explore the relationship 
between circulating irisin levels and endothelial function in obese patients.
Materials and methods: A total of 41 non-hypertensive, non-diabetic, obese 
patients, and 40 age- and sex-matched normal volunteers were involved in 
this study. Clinical characteristics, blood biochemistry, circulating irisin, and 
adiponectin of the subjects were measured .Endothelium-dependent vaso-
dilation (EDV) and endothelial-independent vasodilation (EIV) in brachial 
artery were determined using high-resolution ultrasound.
Results: There were no significant differences in age, gender, blood pressure, 
total cholesterol, HDL, LDL, and fasting plasma glucose levels between two 
groups (P > 0.05). Obese patients had a higher (BMI 30.8 ± 3.8 kg/m2 vs 21.3 
± 1.8 kg/m2, P < 0.01) and larger waist circumference (WC 100.7 ± 10.47 
cm vs 74.3 ± 4.6 cm, P < 0.01). Plasma NEFA, serum triglyceride, fasting 
insulin, high-sensitivity C-reactive protein (hs-CRP), and malondialdehyde 
(MDA) levels in obese patients were significantly higher compared with nor-
mal subjects (NEFA, 763.4 ± 150.5 umol/L vs 404.6 ± 96.1 umol/L; insulin, 
18.7 ± 7.4 uU/ml vs 9.8+4 uU/ml; triglyceride, 1.51 ± 0.57 mmol/L vs 0.80 
± 0.24 mmol/L; hs-CRP, 2.28 ± 0.89 mg/L vs1.21 ± 0.32 mg/L; MDA, 4.91 ± 
1.02 umol/L vs 3.70 ± 0.43 umol/L, P < 0.01). However, serum irisin and adi-
ponectin levels were significantly lower in obese patients (irisin, 180.5 ± 22.4 
ng/ml vs 194.8 ± 19.9 ng/ml; adiponectin, 6.04 ±1.7 ug/ml vs 7.51± 1.64 ug/
ml, P < 0.05). Endothelial function was impaired in obese patients (maximum 
EDV: 8.95 ± 3.46% vs. 14.56 ± 3.90%, P 0.05). Bivariate correlation analysis 
revealed that circulating irisin was positively correlated with EDV(r=0.388, 
P < 0.01) and negatively correlated with BMI (r=-0.281, P < 0.05), WC (r=-
0.298, P < 0.01), NEFA (r=-0.289, P < 0.01), hs-CRP (r=-0.244, P < 0.05), and 
MDA (r=-0.258, P < 0.05). EDV was positively correlated with adiponectin 
(r= 0.381, P < 0.01) and negatively correlated with BMI (r=-0.510, P < 0.01), 
WC (r=-0.484, P < 0.01), triglycerides (r=-0.412, P < 0.01), NEFA (r=-0.535, 
P < 0.01), insulin (r=-0.279, P < 0.05), hs-CRP (r=-0.240, P < 0.05), and MDA 
(r=-0.396, P < 0.01). Multiple regression analysis was employed to study the 
association of EDV with BMI, irisin, adiponectin, NEFA, insulin, hs-CRP, 
and MDA. The model revealed that circulating irisin, adiponectin, NEFA, 
and BMI were independently associated with EDV after adjusting for covari-
ates (R2=0.412, F = 10.357,P =0.000)
Conclusion: Circulating irisin level was decreased in non-hypertensive, non-
diabetic, obese patients compared with normal subjects. Lower levels of irisin 
are independently associated with endothelial dysfunction. Therefore, irisin 
may be involved in the regulation of endothelial function in obesity.
Supported by: National Natural Science Foundation of China (Grants NO. 
81300688)
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Effects of vitamin D supplement on arterial stiffness in patients with  
type 2 diabetes mellitus and vitamin D deficiency
J.-H. Kim, J.-M. Lee, S.-A. Chang;  
Internal Medicine, The Catholic University of Korea, Seoul,  
Republic of Korea.
Background and aims: Vitamin D deficiency has been commonly detected 
in Korea and well known that deficiency is closely related with increasing 
risk of cardiovascular disease. Especially, the rate of Vitamin D deficiency is 
higher in patients with type 2 diabetes mellitus and low 25-hydroxyvitamin D 
[25(OH)D] level was significantly associated with increased arterial stiffness 
in these patients. Though there were several studies which were shown the 
effect of vitamin D supplement on vascular condition in vitamin D deficiency 
population, it is still controversy up to now. This study aimed to evaluate the 
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effect of vitamin D supplement on arterial stiffness in patients with type 2 
diabetes and vitamin D deficiency.
Materials and methods: This study was designed as a prospective, rand-
omized, open-label controlled trial. A total of 40 (20 men and 20 women) 
patients with type 2 diabetes and vitamin D deficiency, defined as serum 
25(OH)D levels < 20 ng/mL, were enrolled. A randomized-study group (10 
men and 10 women) was administered daily 1000IU vitamin D3 for 6 months, 
and control group had no interventional drug. After 6 month of intervention, 
authors estimated the pulse wave velocity and the aortic augmentation index 
as primary endpoints in both group, and statistically analyzed the variation.
Results: A mean age of patients was 56.2 years old, and mean level of 25(OH) 
D was 11.9 ng/mL. A 25(OH)D level of study group was significantly in-
creased for 6 months, which were 25.3 ng/mL in study group and 9.4 ng/mL 
in control group (P<0.001) . However, there were no significant changes in 
terms of pulse wave velosity (-0.11 ± 0.83 vs -0.10 ± 0.26 m/sec, P = 0.258) 
and aortic augmentation index (-0.9 ± 3.7 vs 0.3 ± 2.1%, P = 0.567). Though 
there is no significance, an aortic augmentation index level was tended to 
decrease in interventional group, compared to those of control group.
Conclusion: There were no significant changes of arterial stiffness measure-
ment when the patients with type 2 diabetes and vitamin D deficiency were 
supplemented daily vitamin D, however, vitamin D level was significantly 
increased. This study is shown that vitamin D supplement is not clinically 
effective for improving arterial stiffness in patients with type 2 diabetes and 
vitamin D deficiency.
1299
Influence of postprandial hyperglycaemia on arterial function in patients 
with type 2 diabetes with or without albuminuria
M. Saraheimo1,2, D. Gordin1,2, A. Soro-Paavonen1,2, C. Forsblom1,2,  
K. Paavonen1,3, B. Steckel-Hamann4, F. Vandenhende5, I. Pavo6, V. Koivisto7, 
P.-H. Groop1,2;  
1Folkhälsan Institute of Genetics, Biomedicum Helsinki,  
2Division of Nephrology, Helsinki University Central Hospital,  
3Division of Cardiology, Helsinki University Central Hospital, Finland,  
4Eli Lilly Export S.A., Vernier, Switzerland, 5ClinBAY, Genappe, Belgium,  
6Eli Lilly, Vienna, Austria, 7Eli Lilly, Helsinki, Finland.
Background and aims: To determine whether postprandial hyperglycemia 
affects arterial stiffness, and whether pulse wave velocity (PWV) is a surro-
gate for macrovascular complications in patients with type 2 diabetes with or 
without albuminuria.
Materials and methods: This was a single-center, open-label study of 3 
groups of males: patients with type 2 diabetes with albuminuria (N=22; 
mean±SD age 61±5 yrs, BMI 34±5 kg/m2, HbA1c 62±14 mmol/mol), patients 
with type 2 diabetes without albuminuria (N=24; age 64±5 yrs, BMI 32±6 
kg/m2, HbA1c 57±12 mmol/mol) and healthy controls (N=25; age 59±7 yrs, 
BMI 27±3kg/m2, HbA1c 36±3 mmol/mol). Patients were randomized to a 
2-period crossover study schedule, ingesting a mixed breakfast of 500 kcal 
with or without insulin lispro (to induce low or high postprandial glycemia). 
Healthy controls were studied for 1 period with an identical breakfast. Arte-
rial stiffness was assessed by calculating PWV and augmentation index (Alx) 
using applanation tonometry, and endothelial dysfunction was assessed using 
peripheral arterial tonometry (PAT), 30 min before breakfast and up to 240 
min post-meal. These parameters were analyzed using analysis of covariance. 
Blood concentrations of biomarkers of inflammation, endothelial dysfunc-
tion and oxidative stress, as well as glycated proteins, were also determined.
Results: In the diabetic patients, least square mean±SE glucose levels at 60 
min postprandial had increased by 5.3±0.3 mmol/L without lispro, and by 
3.3±0.3 mmol/L with lispro, from 6.8±0.2 mmol/L before breakfast. Before 
breakfast, compared with controls, aortic PWV was elevated in patients with 
albuminuria (mean±SD 11.0±4.0 m/s vs. 8.6±2.1 m/s, p=0.004), but not in pa-
tients without albuminuria (10.6±4.0 m/s, p=0.052). Similarly, before break-
fast, AIx was elevated in patients with albuminuria vs. controls (22.6±6.5% 
vs. 17.2±10.8%, p=0.031) but not in patients without albuminuria (21±6.3%, 
p=0.111). Adjusted for age and BMI, there were no significant differences 
pre-breakfast or postprandially in aortic PWV, Alx or PAT ratio, in patients 
vs. controls. Adjusted for age and BMI, brachial PWV was faster at 3 of 4 
postprandial time-points (60, 180, 240 min; p=0.003-0.046) in patients with 
albuminuria vs. controls, both under high and low postprandial glycemia. No 
changes were observed postprandially vs. pre-breakfast in the levels of asym-
metric dimethylarginine, endothelin-1, soluble vascular/intercellular cell 
adhesion molecule-1, superoxidase dismutase, soluble extracellular domain 
of the receptor for advanced glycation end-products, or C-reactive protein.
Conclusion: In patients with type 2 diabetes and albuminuria, indices sug-
gested that aortic stiffness was worse during fasting, relative to healthy con-
trols. Also in patients with type 2 diabetes and albuminuria, brachial stiff-
ness appeared to deteriorate when blood glucose increased postprandially by 
about 3-6 mmol/L.
Clinical Trial Registration Number: NCT01159938
Supported by: Eli Lilly & Co. Writing support by Trilogy Writing & Consulting.
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Endothelial glycocalyx is impaired in diabetic patients and first-degree 
relatives and is linked to abnormal aortic elastic properties  
and myocardial deformation
V.A. Lambadiari1, F. Kousathana1, I. Ikonomidis2, G. Pavlidis2,  
H. Triantafyllidi2, G. Matsaggouras1, M. Varoudi2, J. Lekakis2,  
G. Dimitriadis1;  
12nd Dept. of Internal Medicine, Research Institute and Diabetes Center, 
Attikon University Hospital, 22nd Cardiology Dept., University of Athens, 
Attikon Hospital, Athens, Greece.
Background and aims: The integrity of endothelial glycocalyx plays a vital 
role in vascular permeability, inflammation and elasticity. The association be-
tween damage of endothelial glycocalyx, impaired arterial elastic properties, 
and LV function in diabetics and first degree relatives has not been explored.
Materials and methods: In 40 untreated patients (age: 51±12 years) with 
newly diagnosed type II diabetes ,20 first degree relatives with normal oral 
glucose tolerance test and 25 controls of similar age and sex and no athero-
sclerotic risk factors we measured: a) carotid-femoral pulse wave velocity 
(PWVc m/sec-Complior SP ALAM), central systolic blood pressure (cSBP 
-mmHg),augmentation index (AI %), reflection time (RT-ms) and diastolic 
reflection area (DRA) of the aortic pulse wave, an index of coronary perfu-
sion (Arteriograph TensioMed) b) S’,E’ (m/sec) and E’/A’ of mitral annulus 
by Tissue Doppler c) LV longitudinal strain (GLS -%), systolic (LongSr-l/sec) 
and diastolic (LongSrE-l/sec) strain rate, using speckle tracking echocardi-
ography d) perfusion boundary region (PBR- micrometers) of the sublin-
gual arterial microvessels (ranged from 5-25 micrometers) using Sideview, 
Darkfield imaging (Microscan, Glycocheck). The PBR in microvessels is the 
cell-poor layer which results from the phase separation between the flowing 
red blood cells (RBC) and plasma.The PBR includes the most luminal part 
of glycocalyx that does allow cell penetration. Increased PBR is considered 
an accurate index of reduced endothelial glycocalyx thickness because of a 
deeper RBC penetration in the glycocalyx
Results: Compared to controls, diabetics and relatives had higher PBR 
(2.1±0.25 vs. 2.05±0.25 vs.1.89±0.1) AI (27±16 vs. 24±15 vs. 17±14) and 
DRA (44±12 vs. 49±13 vs. 68±27,) (p<0.05 for all comparisons). Diabetics 
and relatives had similar PBR, AI and DRA (p=ns).Compared to controls, di-
abetics had also higher PWV (10.9±2 vs. 8.9±2,), cSBP (137±19 vs. 116±17), 
reduced RT (118±26 vs. 151±14), GLS (-16±4 vs. -20±3), LongSr (-0.8±0.2 vs. 
-1.1±0.3), LongSrE (0.8±0.2 vs. 1.3±0.5,), S’ E’ and E’/A’ (p<0.05 for all com-
parisons). Reduced endothelial glucocalyx thickness as assessed by increased 
PBR was related with increased PWV (r=0.35), reduced RT (r=-0.42) and 
DRA (r=-0.36) in diabetics (p<0.05 for all associations). These associations 
were more prominent for PBR measured in the microvessels ranged from 
20-25 micrometers. Increased PWV were related with reduced S’ (r=-0.48), E’ 
(r=-0.63), E’/A’ (r=-0.63), GLS (r=0.48,) LongSr (r=0.35), LongsrE (r=-0.51) 
respectively (p<0.05 for all associations)
Conclusion: Endothelial glucocalyx is impaired in newly diagnosed diabetics 
and first degree relatives and is related to abnormal aortic elastic properties 
leading to impaired LV longitudinal deformation in diabetics.
Supported by: Research Grant Authority Athens Kapodistrian University
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Evaluation of a glyoxalase 1 mutant mouse
A. Shafie, M. Xue, P.J. Thornalley, N. Rabbani;  
WMS, CSRL, University of Warwick, Coventry, UK.
Background and aims: Glyoxalase 1 plays an important role in the metabo-
lism of reactive dicarbonyl metabolites, glyoxal and methylglyoxal, to less 
reactive products and prevention of dicarbonyl-derived advanced glycation 
endproduct formation. Glo1 deficient mice and transgenic mice overex-
pressing Glo1 provide valuable models to study control of change in extent 
of dicarbonyl glycation in mammalian systems. The aim of this study is to 
characterise the genotype and phenotype of the Lexicon Glo1 mutant mouse.
Materials and methods: The Glo1 mutant mice (+/- breeding pair), Glo1Lex 
were obtained from the European Mutant Mouse Archive, Heidelberg, Ger-
many. We maintain a colony of Glo1Lex heterozygotes and sibling wild type 
controls. The mice were produced by Lexicon Pharmaceuticals, Inc, USA. In 
a C57BL/6 genetic background, mutation was produced by retroviral inser-
tion of a DNA cassette between coding exons 1 and 2 (LEXKO-1493). Gen-
otyping Forty-four offspring were genotyped from ear punch samples. For 
PCR, the three pairs of primers were used to discriminate between wild-type: 
heterozygote and homozygote mutant mice. Phenotyping Nineteen mice, 12 
Glo1Lex (+/-) (6 male, 6 female) and 7 wild type control siblings (5 male, 2 
female) were sacrificed at 7 months old, tissues (brain, heart, liver, spleen, 
kidney, pancreas and skeletal muscle) collected and stored at -80°C until 
analysis. Aliquots of tissue were homogenised and Glo1 enzymatic activity 
was determined in cytosolic extracts by spectrophotometric assay, protein by 
Western blot and mRNA by RT-PCR. Protein advanced glycation endproduct 
(AGE) residues of liver were analysed in 10 Glo1Lex (+/-) (5 male, 5 female) 
and 10 wild type control siblings (5 male, 5 female) by LC-MS/MS and nor-
malized to the corresponding unmodified amino acid residue.
Results: In the genotyping of Glo1Lex mutant mice we found only Glo1Lex 
(+/-) heterozygote and wild type siblings. No homozygous Glo1Lex (-/-) 
mice have been born to date. No significant impairment in fertility was found 
for Glo1Lex (+/-) mice. The activity of Glo1 was not significantly different 
between wild-type controls and Glo1Lex (+/-) mice (P<0.05, Mann Whitney-
U). For brain, Glo1 activity (U/mg protein; median (lower - upper quartile)) 
was: wild type 1.77 (1.53 - 2.00), Glo1Lex (+/-) 2.05 (1.55 - 2.27). For heart, 
Glo1 activity was: wild type 0.95 (0.85 - 1.05), Glo1Lex (+/-) 0.98 (0.87 - 
1.04). Other tissues similarly gave no significant difference in Glo1 activity 
between wild-type controls and Glo1Lex (+/-). The expression of Glo1, as 
judged by protein and mRNA, in Glo1Lex mice was not significantly different 
from wild-type controls. AGE residue contents of liver were not significantly 
different between wild type controls and Glo1Lex (+/-) mice (P<0.05, Mann 
Whitney-U). MG-H1 residue content of liver was: wild type 0.330 (0.276 - 
0.417) mmol/mol arg and Glo1Lex (+/-) 0.309 (0.276 - 0.360) mmol/mol arg. 
G-H1 residue content of liver was: wild type 0.125 (0.105-0.152) mmol/mol 
arg and Glo1Lex (+/-) 0.140 (0.112- 0.166) mmol/mol arg. Other protein gly-
cation, oxidation and nitration adduct residue contents of liver were also not 
significantly different between wild type controls and Glo1Lex (+/-).
Conclusion: Glo1Lex mutant mouse appears embryonically lethal for ho-
mozygous inheritance; cf. mutant human GLO1 gene with no viable homozy-
gous offspring. It has compensatory increased Glo1 expression with normal 
fertility. The mutant mouse appears to have been incorrectly genotyped in 
preliminary characterisation by the originator.
Supported by: Taif University, Saudi Arabia
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Knockdown of glyoxalase 1 leads to collagen overproduction in human 
aortic endothelial cells
N. Klusmeier1, J. Tiemann1, B. Espelage1, Y. Mattern1, D. Hendig2,  
C. Knabbe2, D. Tschoepe1, B. Stratmann1;  
1Diabetes Center, 2Institute for Laboratory and Transfusion Medicine,  
Heart and Diabetes Center NRW, Bad Oeynhausen, Germany.
Background and aims: Chronic hyperglycaemia is an important predictor 
of diabetic complications and associated metabolic derangements are accom-
panied by accumulation of high glucose levels as well as rising methylglyoxal 
(MG) concentrations. MG is a highly reactive, cytotoxic carbonyl compound 
which is formed as a side product during glycolysis and other metabolic path-
ways. The main detoxification mechanism of MG is the glyoxalase system 
which consists of the enzymes glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2). 
The aim was to analyse the impact of MG on selected proteins in human 
aortic endothelial cells (HAECs) under hyperglycaemia.
Materials and methods: Detection of protein and mRNA expression levels 
were carried out by western blot and quantitative real time PCR (qRTPCR) 
analyses following siRNA mediated knockdown of Glo1 or direct stimulation 
experiments with exogenously added MG.
Results: Following Glo1 knockdown a significant accumulation of MG was 
detected by rising modifications of arginine in terms of arg-pyrimidine. Fur-
thermore, an elevated collagen-4 and collagen-5 synthesis was detected in 
combination with a reduced expression of the cross-linking enzymes PLOD2 
and LEPREL2. Levels of collagen-8 and collagen-18 remained unchanged 
in this experimental setting. In addition, an up-regulated expression of the 
proteoglycan metabolism associated enzymes xylosyltransferase 1 and 2 
(XT1, XT2) was verified. MMP-2, TIMP-2 and TIMP-4 were elevated non-
significantly. An decreased expression of Glo1 under hyperglycemia and MG 
stimulation (1µM) was clearly shown. MG stimulation significantly induced 
the expression of extracellular matrix components (collagen-4, -5, -8, -18), 
and the ECM-molecules TIMP-2, TIMP-4, MMP-2, TGF-ß under hyper-
glycaemia. Comparable to the knockdown experiments the expression of 
proteoglycan metabolism associated enzyme XT2 was significantly elevated. 
Comparable to the knockdown experiments MG stimulation led to an en-
hanced endothelial-mesenchymal transition measured by increased expres-
sion of ACTA-2 which is in close relation to the observed overall increase in 
extracellular matrix components production.
Conclusion: The results of this experimental research emphasize the effect 
of MG on composition and stability of the extracellular matrix. This may, at 
least partially, explain the molecular basis of the effect of hyperglycaemia on 
endothelial function seen in patients with diabetes mellitus.
1303
Methylglyoxal induced protein damage in diabetes is handled  
by the quality control system conserved from yeast to humans 
J. Tyedmers1, L. Schmidt1, T. Fleming1, E. Herpel2, S. Kaden3, H.-J. Gröne3, 
P.P. Nawroth1;  
1Innere Medizin I und Klinische Chemie, Universität Heidelberg, 
2Pathologisches Institut, Universitätsklinikum Heidelberg,  
3Zelluläre und Molekulare Pathologie, DKFZ, Heidelberg, Germany.
Background and aims: Increased concentrations of reactive metabolites 
such as methylglyoxal (MG) are thought to be involved in the development of 
late diabetic complications by causing intracellular protein damage through 
posttranslational protein modifications. We aim to reveal cellular mecha-
nisms and molecular pathways that are involved prevention and remission 
of protein damage by MG.
Materials and methods: We have established a yeast system to study protein 
damage and aggregate formation by increased intracellular concentrations of 
MG within physiological ranges. Results obtained in yeast were validated in 
endothelial cells in cell culture and tested in immunohistologic stains of tis-
sue samples from patients with diabetic complications.
Results: We found that yeast forms aggregates upon increased MG concen-
trations. A mass spectroscopy approach to identify potential targets of MG 
induced protein damage revealed several molecular chaperones and meta-
bolic enzymes. Aggregates are handled by the cellular protein quality control 
system. Induction of the heat shock response in general and Hsp70 in partic-
ular increased the tolerance towards increased MG levels. We next translated 
our findings to mammals by demonstrating that an intracellular increase of 
MG in mouse endothelial cells in cell culture also leads to the formation of 
aggregates which can be visualized with EM and are bound by Hsp70 chap-
erones. Pharmacological inhibition of Hsp70 rendered the cells more sensi-
tive towards MG. Finally, staining of kidney tissue from patients with severe 
diabetic complications revealed drastically increased levels of Hsp70 in the 
glomeruli.
Conclusion: The cellular protein quality control system including Hsp70 
handles MG induced protein damage from simple eukaryotes to mammals. 
It’s up-regulation renders cells more resistant towards MG induced cell dam-
age. These similarities between diverse species such as yeast and humans al-
low to exploit the high-throughput and large scale analysis tools available for 
simple eukaryotes such as yeast to better understand cellular responses to 
increased levels of reactive metabolites.
Supported by: DFG (BI-1281/3-1, NA 138/7-1, TY 93/1-1), DZD/BMBF, Di-
etmar Hopp Stiftung
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Nuclear RAGE, a regulator of DNA integrity in diabetic lung fibrosis
V. Kumar1, T. Fleming1, E. Schleicher2, H.-U. Häring2, P.P. Nawroth1;  
1Internal Medicine I and Clinical Chemistry, University of Heidelberg, 
2Department of Internal Medicine, University of Tübingen, Germany.
Background and aims: The receptor for advanced glycation endproducts 
(RAGE) is a member of the immunoglobulin super-family of cell receptors, 
whose activation has been suggested to contribute to various pathologies. Re-
cent studies have suggested that the localization of RAGE is not restricted 
to the cell-surface but also inside the nucleus interacting either directly or 
indirectly with DNA. However, the role that nuclear RAGE services in the 
nucleus remains unclear. In this study, we have investigated the ligand-inde-
pendent localization of RAGE to nucleus and its role as a DNA repair protein.
Materials and methods: Pulmonary fibroblasts were isolated from the lungs 
of RAGE-deficient (RAGE-/-) and aged-matched wild-type (C57BI/6; male) 
mice. RAGE and DNA repair proteins were detected by immunofluorescence. 
DNA damage was assessed by single-cell gel electrophoresis (COMET) as-
say. Micro-irradiation of cells was performed using a FluoView1000confo-
cal microscope, using 355nm laser. Laser settings were chosen to generate 
detectable double-strand breaks (DSBs) within the path of the laser, without 
induction of major cytotoxic effects
Results: Pulmonary phenotyping in RAGE-/- mice showed that these mice 
had a reduced lung volume as compared to aged-matched control, consist-
ent with a restrictive lung disease, such as fibrosis. This was confirmed by 
trichrome staining which showed that RAGE-/- mice had a greater accumula-
tion of collagen and other extracellular matrix. Analysis of the subcellular 
localization of RAGE within the lung showed that the majority of the pro-
tein was in the nucleus. The localization of RAGE to the nucleus was con-
firmed in vitro, using wild-type lung fibroblasts transient transfected with 
GFP-tagged RAGE. It was observed that RAGE-/- lung fibroblasts has a sig-
nificantly altered growth rate and morphology. Further analysis showed that 
RAGE-/- lung fibroblasts had significantly higher levels of DNA damage as 
compared to wild-type fibroblasts treated with and without bleomycin. The 
level of DNA damage could be increased in wild-type fibroblasts by transient 
transfection with a shRNA vector specific for RAGE. Conversely, transfection 
of the GFP-tagged RAGE into RAGE-/- lung fibroblasts could significantly 
reduce the level of DNA damage by ca.80%. This would suggest, that with-
in the context of the lung, nuclear RAGE is responsible for maintain DNA 
integrity. Following laser-induced DSBs, it was found that nuclear RAGE is 
phosphorylated by ATM, the main protein kinase sensor of DSBs, leading to 
its association with a variety of repair proteins, including MRN11, Rad50 and 
Nba1, which are involved in the formation of the MRN complex. It was sub-
sequently shown that post-translational modification of RAGE by methylgly-
oxal, a reactive metabolite elevated in diabetes, leads to loss of function with 
respect to DNA resectioning and binding, an effect which was not observed 
following oxidative modification.
Conclusion: Loss of nuclear RAGE in the lung may provide a new mecha-
nism for the development diabetic lung fibrosis; inactivation of nuclear 
RAGE by reactive metabolite driven post-translational modifications would 
prevent the correct formation and function of the MRN complex, leading to 
increased DNA damage via a reduced repair capacity, analogous to the mo-
lecular phenotype observed in the RAGE-/- mice.
Supported by: DFG (BI-1281/3-1 & NA 138 /7-1), DZD/BMBF, Dietmar Hopp 
Stiftung
 
1305
Soluble receptor for advance glycation end-products (sRAGE) relates to 
oxidative stress index in patients with diabetes
J. Škrha jr.1, J. Soupal1, M. Kalousova2, R. Mikova1, M. Prazny1, J. Škrha1;  
1Third Department of Medicine, First Faculty of Medicine,  
Charles University in Prague, General University Hospital,  
2Institute of Medical Biochemistry and Laboratory Diagnostics,  
First Faculty of Medicine, Charles University in Prague,  
General University Hospital, Czech Republic.
Background and aims: Oxidative stress is one of the most important factors 
in the development of vascular damage in patients with diabetes. Novel find-
ings support the idea of advanced glycation end-products involvement in the 
pathophysiology of diabetic angiopathy. The aim of our study was to evaluate 
relationship between oxidative stress and soluble receptor for advanced gly-
cation end-products (sRAGE) in patients with diabetes.
Materials and methods: Total 121 persons were included within the study 
- 45 patients with Type 1 diabetes (T1DM; aged 52 ± 15 yrs), 59 patients 
with Type 2 diabetes (T2DM; aged 65 ± 11 yrs) and 17 healthy controls (47 
± 15 yrs). Oxidative stress was measured by Free Radical Analytical System 
(FRAS4; H&D, Italy) and evaluated by two blood tests: reactive oxygen me-
tabolites test (d-ROMs) and by biological antioxidative potential test (BAP). 
Oxidative stress index (OSi) expressing the total oxidative status was calcu-
lated (OSi = d-ROMs/BAP). In all patients routine biochemical parameters, 
glycated hemoglobin (expressed in mmol/mol acc. EFCC), sRAGE, cell adhe-
sion molecules (VCAM, ICAM), von Willebrand factor, (micro)albuminuria 
(expressed as albumin/creatinine ratio UACR), and anthropometrical data 
were measured.
Results: Oxidative stress index was similar between groups (T1DM: 0.25 
[0.13 - 0.47], T2DM: 0.25 [0.13 - 0.42], controls 0.24 [0.18 - 0.34]; NS) and 
also sRAGE did not differ significantly (T1DM: 1352 ± 514, T2DM: 1179 ± 
814, controls: 1177 ± 564 ng/l, NS). Significantly lower d-ROMs were ob-
served in patients with T1DM and T2DM without albuminuria (UACR<2.5 
g/mol creatinine) as compared to patients with albuminuria (368 ± 105 vs. 
432 ± 134 U; p=0.009). Significant positive relationship of OSi and sRAGE 
was found both in T1DM (r=0.39; p<0.01) and T2DM (r=0.33; p<0.02), 
and similarly of OSi and VCAM (T1DM: r=0.47, p<0.005; T2DM: r=0.35, 
p<0.05).
Conclusion: This is the first study describing significant relationship between 
oxidative stress expressed by oxidative stress index and sRAGE concentration 
in patients with diabetes. Similar relationship was observed between OSi and 
marker of vascular activation - adhesion molecule VCAM. Oxidative stress, 
apart from direct effect, likely participate in the development of endothelial 
activation also by other mechanisms - e.g. RAGE activation. Though, more 
studies will be necessary for better understanding of these processes.
Supported by: PRVOUK-P25/LF1/2
1306
One-compartment kinetic model predicts dicarbonyl modification 
influence half-life and functionality of HDL in high risk CVD group
N. Rabbani1, L. Godfrey1, N. Yamada-Fowler1, J. Smith2, P.J. Thornalley1;  
1Clinical Sciences Research Institute, University of Warwick,  
2Bruker UK Ltd, Coventry, UK.
Background and aims: Decreased plasma concentration and anti-atherogen-
ic properties of high density lipoprotein cholesterol (HDL-C) is implicated in 
increased CVD risk. The cause is unknown and under intense investigation. 
The extent of modification of HDL by methylglyoxal, a reactive dicarbonyl 
metabolite, in patients with diabetes and related functional effects is also un-
known. Dicarbonyl modification of HDL may be linked to the reported 20% 
and 37% decrease in half-life of HDL in type 2 diabetes and renal failure. The 
aim of this study was to: (i) to construct a one-compartment model of HDL 
influx and clearance from plasma in human subjects, and (ii) from the effect 
of minimal modification of HDL by methylglyoxal on HDL plasma clearance, 
predict how dicarbonyl glycation influences plasma HDL concentration in 
patients with diabetes, renal failure and the ageing population.
Materials and methods: The extent of dicarbonyl glycation of HDL - modi-
fication by methylglyoxal and related metabolites glyoxal and 3-deoxyglu-
cosone - was assessed by quantitation of dicarbonyl-derived AGEs in HDL 
protein. We constructed a one-compartment model of HDL release into and 
clearance from plasma assuming that dicarbonyl-modified HDL is preferen-
tially cleared. We measured the change in clearance of HDL when modified 
minimally by methylglyoxal in rats. The mathematical model of HDL influx 
and clearance from plasma in human subjects was defined by published es-
timates of values of apolipoprotein (ApoA1) synthesis (14 mg kg-1day-1) and 
HDL half-life (4.47 days), and validated experimentally by measurement of 
plasma HDL and methylglyoxal-modified HDL in human subjects. HDL 
kinetics were computed for 2 - 4 fold increase in dicarbonyl concentration 
typical of old-age, diabetes and renal failure using the COPASI programme.
Results: Dicarbonyl-modified HDL accounted for ca. 2.6% HDL in healthy 
people. Experimental studies in rats showed that clearance of HDL from 
plasma increased 2-fold when modified minimally by methylglyoxal. Input 
of a 2 - 4 fold increase in plasma dicarbonyl concentration into the one com-
partment model of plasma HDL predicted a 2 - 6% decrease in plasma total 
HDL. ApoA1 concentration correlates strongly with HDL-C (r = 0.83) and 
so this translates to a predicted ca. 3 - 9% increased risk of CVD. The model 
also predicted a greater decrease in functional HDL (4.5 - 12.5%). Suggested 
validity of the model came from experimental confirmation of the predicted 
negative association of plasma HDL-C to the level of methylglyoxal modified 
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HDL in healthy people. From the correlation coefficient, r = - 0.42, P<0.05 (n 
= 22, Pearson), glycation of HDL by methylglyoxal accounts for 18% of the 
variation in HDL-C.
Conclusion: The kinetic model predicted dicarbonyl modification contrib-
utes significantly to decreased half-life and dysfunction of HDL, and through 
this to increased CVD risk in high risk populations such as elderly and pa-
tients with type 2 diabetes and renal failure. Therapeutic interventions to 
counter dicarbonyl glycation of HDL may decrease risk of CVD.
Supported by: BHF
1307
Protection from diabetes-induced atherosclerosis and renal disease 
by octyl-D-carnosine: evidence for a role of AGEs in hyperglycaemic 
memory 
S. Menini, C. Iacobini, C. Ricci, C. Blasetti Fantauzzi, G. Pugliese;  
Department of Clinical and Molecular Medicine, La Sapienza University, 
Rome, Italy.
Background and aims: The advanced glycation end-products (AGEs) are 
involved in the pathogenesis of vascular and renal complications of diabetes 
and are considered as a putative mechanism for “hyperglycaemic memory”. 
Octyl-D-carnosine (ODC) was shown to attenuate AGE formation as well 
as vascular and renal injury induced by high fat diet in ApoE null mice. This 
study was aimed at verifying the protective effect of ODC in atherosclerosis 
and renal disease induced by experimental diabetes and the role of AGEs in 
“hyperglycemic memory”.
Materials and methods: To this end, ApoE null mice were rendered diabetic 
by multiple injections of streptozotocin and divided in 4 groups: untreated 
(DIAB) or treated with ODC for 20 weeks (ODC-Extended) or for first 11 
weeks only, starting immediately after diabetes induction (ODC-Early) or at 
week 9 (ODC-Late). Non-diabetic ApoE null mice served as controls. Meta-
bolic parameters were assessed using standard methods. Aortic and renal 
lesions were evaluated by morphometry. Protein and gene expression of rel-
evant disease markers were assessed by immunohistochemistry and RT-PCR, 
respectively.
Results: Treatment ODC-Extended was effective in reducing the size of ather-
osclerotic lesions (48,496±5,501 vs. 90,545±4,267 μm2), and plaque content of 
macrophages (11.9±3.2 vs. 39.9±3.3 % lesion area, and 1.46±0.36 vs. 3.4±0.69 
UA), MCP-1 (1.74±0.58 vs. 3.61±0.63 UA), RAGE (10.4±1.6 vs. 37.3±3.3 % 
lesion area, and 1.12±0.31 vs. 2.41±0.44 UA), Nε-carboxymethyllysine (CML, 
16.6±3.1 vs. 64.0±6.2 % lesion area), nitrothyrosine (11.4±2.7 vs. 37.1±4.5% 
lesion area), and apoptotic cells (24.8±4.4 vs. 88.8±6.8 n/mm2). Conversely, 
plaque content of collagen (42.3±3.3 vs. 26.4±2.5 % lesion area) and smooth 
muscle cells (13.4±2.1 vs. 4.9±1.1% lesion area) was increased, as compared 
with DIAB. ODC treatment for 11 weeks afforded partial protection from 
atherosclerotic lesions, which however was significantly higher in ODC-
Early than in ODC-Late for most of the above parameters. In fact, ODC-
Early plaques were smaller as compared with ODC-Late plaques and showed 
reduced content of CML, which was associated with less inflammation and 
oxidative stress markers, smaller necrotic cores, increased deposition of col-
lagen and thicker fibrous caps. In addition to quantitative differences, also 
qualitative differences were observed. In particular, immunohistochemistry 
staining for CML, macrophage, apoptosis and oxidative stress markers was 
restricted to the luminal side of the ODC-Early plaques, at variance with what 
observed in plaques from ODC-Late and untreated DIAB mice, which cov-
ered the entire depth of the atherosclerotic intima. Also renal disease was 
attenuated in ODC-Extended than in DIAB and partial protection was ob-
served in mice treated for 11 weeks, with no significant difference between 
ODC-Early and ODC-Late.
Conclusion: These data show that therapy with ODC protects from vascular 
and renal disease induced by experimental diabetes and early treatment is 
more effective than late treatment on atheroslerosis, thus suggesting that in-
hibition of AGE formation and accumulation within early plaques might slow 
down post-treatment atherosclerosis progression and favour development of 
more stable lesions. This is consistent with the hypothesis that AGEs could 
represent the underlying mechanism responsible for the „hyperglycaemic 
memory“.
Supported by: EFSD / Sanofi
PS 119 Metabolism and 
complications
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Glucagon-like peptide-1 reduces intestinal lipoprotein production by 
peripheral pathways and central melanocortin-4 receptor signalling
S.L. Farr, C. Baker, M. Naples, J. Taher, K. Adeli;  
Molecular Structure and Function, The Hospital for Sick Children, Toronto, 
Canada.
Background and aims: The intestinal overproduction of chylomicron parti-
cles is a common feature of insulin resistance and the metabolic syndrome, 
resulting in postprandial dyslipidemia and heightened levels of atherogenic 
particle remnants. Recently, the anti-diabetic hormone glucagon-like pep-
tide-1 (GLP-1) has gained attention not only as an insulin secretagogue, but 
also as a modulator of intestinal lipoprotein metabolism in the periphery. 
GLP-1 can additionally be produced within the brain to regulate neuronal 
activity in regions like the arcuate nucleus of the hypothalamus, and through 
sympathetic pathways GLP-1 has been shown to modulate peripheral lipid 
metabolism. Here we investigated the involvement of both peripheral and 
central GLP-1 in regulating intestinal chylomicron production.
Materials and methods: Healthy hamsters received an oral gavage of olive 
oil followed by an acute intraperitoneal (IP) or intracerebroventricular (ICV) 
injection of the GLP-1 receptor (GLP-1R) agonist exendin-4 (5nmol/kg and 
250ng, respectively) or vehicle. The postprandial production of triglyceride 
(TG)-rich lipoproteins (TRL) was then assessed over 6h by measuring levels 
of TRL-TG and -apolipoprotein B48 (apoB48). This study was repeated with 
3µg ICV MK-0626, an inhibitor of endogenous GLP-1 degradation, in the 
presence of absence of the GLP-1R antagonist exendin9-39. To character-
ize the central pathways of GLP-1 action, the effects of ICV exendin-4 on 
TRL production were assessed during ICV melanocortin-4 receptor (MC4R) 
antagonism and in the presence or absence of α and β adrenergic receptor 
blockers given intravenously.
Results: Both IP and ICV exendin-4 treatment induced prolonged reductions 
in the rate of TRL-TG accumulation (IP 72% p<0.05 and ICV 56.5% p<0.01). 
A similar trend was seen in apoB48 accumulation. The effects of central ex-
endin-4 were mirrored by ICV administration of MK-0626 and negated by 
ICV pre-treatment with the GLP-1R antagonist exendin9-39. This indicates 
that GLP-1 produced in the brain can act on central GLP-1Rs to modulate 
chylomicron production in the periphery. In accordance with satiety stud-
ies supporting the notion that central GLP-1 may signal through the MC4R 
system, central MC4R antagonism prevented ICV exendin-4 from lowering 
TRL-TG levels. An infusion of adrenergic receptor antagonists also prevented 
the reduction in TRL-TG levels seen with exendin-4 treatment alone, sug-
gesting that the GLP-1-sensitive brain-gut axis modulating chylomicron 
production is likely via sympathetic pathways. Finally, to study the interplay 
between central and peripheral pathways of GLP-1R signaling, exendin-4 
was given IP while exendin9-39 was given ICV and vice-versa. IP exendin-4 
maintained its ability to diminish TRL-TG levels during central antagonism; 
however, IP exendin9-39 prevented the action of ICV exendin-4. This sug-
gests that central stimulation may potentiate peripheral GLP-1Rs, and that 
peripheral GLP-1Rs can act independently of central signaling to modulate 
intestinal lipoprotein metabolism.
Conclusion: Our results demonstrate an important role for central GLP-1R 
signaling in modulating chylomicron production, which has critical implica-
tions for diabetic dyslipidemia. In line with previous studies showing that ex-
endin-4 activates neurons in the arcuate nucleus, this brain-gut axis appears 
to involve MC4Rs and sympathetic outflow to the periphery.
Supported by: CIHR, OGS, Merck & Co., Inc
 
Diabetologia (2014) 57:[Suppl1]S1–S564 
S 531
1 C
1309
Serum paroxonase-1 activity is more closely related to HDL particle 
concentration and large HDL particles than to HDL cholesterol in  
type 2 diabetic and non-diabetic subjects
R.P.F. Dullaart1, J.D. Otvos2, R.W. James3;  
1Endocrinology, University Medical Center, Groningen, Netherlands, 
2LipoScience Inc., Raleigh, USA, 3Internal Medicine, Division of 
Endocrinology, Diabetology, Hypertension and Nutrition, University 
Hospital Geneva, Switzerland.
Background and aims: We determined relationships of the anti-oxidative 
enzyme, paraoxonase-1 (PON-1), with high density lipoprotein (HDL) sub-
fractions, and tested whether these relationships are stronger than those with 
HDL cholesterol and apolipoprotein A-I (apoA-I) in subjects with and with-
out type 2 diabetes mellitus (T2DM).
Materials and methods: Serum PON-1 (arylesterase activity) and HDL sub-
fractions (nuclear magnetic resonance spectroscopy) were determined in 67 
T2DM patients and in 56 non-diabetic subjects.
Results: PON-1 activity, HDL cholesterol and apoA-I were decreased in 
T2DM (all p<0.05). The HDL particle concentration was unaltered, but large 
HDL particles, medium HDL particles and HDL particle size were decreased, 
whereas small HDL particles were increased in T2DM (all p<0.05). PON-1 
was more closely related to HDL cholesterol than to apoA-I (p=0.001). In 
turn, the positive relationship of PON-1 with the HDL particle concentration 
and with large HDL particles was stronger than that with HDL cholesterol 
(both p<0.01). The inverse relationship of PON-1 with T2DM was only mod-
estly attenuated by HDL cholesterol or HDL particle characteristics. Multi-
variable linear regression analyses demonstrating relationships of serum par-
aoxonase-1 activity with mutually adjusted high density lipoprotein (HDL) 
variables and apolipoprotein A-I (apoA-I) in 63 subjects with Type 2 diabetes 
mellitus (T2DM) and in 56 non-diabetic subjects. HDL variables are given 
in standard deviation scores (Z-scores). Independent statistical determined 
as assessed by subsequent backward elimination are shown in bold print. 
β: standardized regression coefficient. Model 1: HDL cholesterol + apoA-I; 
model 2: HDL cholesterol + HDL particle concentration; model 3: HDL cho-
lesterol + large HDL particles.
Conclusion: PON-1 activity is more closely related to the HDL particle con-
centration or large HDL particles than to HDL cholesterol. Impaired PON-1 
activity in T2DM is not to a considerable extent explained by altered HDL 
subfraction levels.
Supported by: DDRF (grant 2001.00.012); Cost ActionBM0904
1310
HDL and blood glucose correlations in patients with familial 
hypercholesterolaemia
M. Walus-Miarka1, B. Idzior-Walus1, M. Małecki1, P. Miarka2,  
E. Wozniakiewicz1;  
1Metabolic Diseases, CMUJ, 2Nephrology, CMUJ, Krakow, Poland.
Background and aims: Familial hypercholesterolemia is characterized by 
markedly increased LDL-cholesterol concentration due to mutation in LDL-
receptor, apo B 100 and PCSK9 genes and, in consequence, premature coro-
nary artery disease. Typically HDL-C and trigliceryde concentrations are 
within normal limits. Accumulating data suggest that cholesterol homeosta-
sis is a major regulator of beta cell function. Intra-cellular cholesterol accu-
mulation leads to islet dysfunction and impaired insulin secretion. There is 
also evidence suggesting that the different lipoprotein classes have varying 
effects on beta cell apoptosis and proliferation. The aim of our study was to 
assess blood glucose correlates in patients with familial hypercholesterolemia 
(FH), familial combined hyperlipidemia (FCH) and healthy controls (C).
Materials and methods: Material included patients from outpatient lipid 
clinic, referred for treatment of resistant hyperlipidemia. Familial hypercho-
lesterolemia was diagnosed according to Simon Broome register criteria. In 
each patient standardized questionnaire, anthropometric examinations and 
lab test were performed. Serum lipids and glucose were examined in fasting 
state by enzymatic methods, using Roche reagents.
Results: We examined 241 patients with FH, 124 patients with FCH and 45 
controls. Mean age and BMI values in FH, FCH and C groups were as fol-
lows: 41.1 +/-18.4, 41.8+/-15.0 and 32.5+/-15 years; 24.7+/-5, 26+/-4.4 and 
22.4+/-4.4 kg/m2. Mean values of serum concentrations of LDL-cholesterol 
in FH, FCH and controls were 4.6+/-1.6, 3.5+/-0.7 and 2.5+/-0.6, while of 
HDL-cholesterol; 1.6+/-2.2, 1.5+/-0.4, and 1.5+/-0.5 mmol/l respectively. In 
FH patients serum glucose concentration significantly correlated with age 
and obesity parameters (BMI and waist circumference) and blood pressure 
values. We also found significant correlation between serum glucose and 
creatinine (r=0.15, p=0.02), GGTP (r=0.13, p<0.05) and a strong negative 
correlation with HDL-cholesterol (r=-0.26, p<0.001). In FCH group apart 
from correlation with age, obesity indices, blood pressure and creatinine, 
significant association between glucose and serum triglyceride, insulin resist-
ance syndrome component, was found (r=0.18, p<0.05). In healthy persons 
only significant positive correlations between serum glucose and CRP and 
negative with serum creatinine were observed. Multiple regression analysis 
with serum glucose as dependent variable revealed that in FH patients serum 
HDL-C concentration (p=0.0009) and waist/hip ratio (p=0.014) were signifi-
cant associates. In statin treated FH patients serum glucose concentrations 
were associated with the same variables as in the whole group of patients 
with exception of lack of correlation with HDL-C, similarly like in healthy 
controls, and the presence of negative correlation between LDL-C (r=-0.18, 
p<0.05). In FH patients not taking statins only the negative correlation be-
tween HDL-C and serum glucose was observed.
Conclusion: The results of the study suggest that HDL-C and WHR are sig-
nificant correlates of blood glucose levels in FH patients, while HDL-C is 
associated with blood glucose levels only in patients not treated with statin. 
These results might be of importance in development of carbohydrate me-
tabolism disturbances in statin treated FH patients.
Supported by: K/PMI/000004
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Diet induced fat storage in the ApoE knockout rat: a novel animal model
S. Skovsø1, I. Rune1,2, X.A. Wolf2, B. Rolin2;  
1University of Copenhagen, 2Translational Pharmacology,  
Novo Nordisk A/S, Måløv, Denmark.
Background and aims: Apolipoprotein E (ApoE) is highly expressed in adi-
pose tissue and plays a pivotal role in lipoprotein and triglyceride metabolism 
in adipocytes. The role of ApoE in site-specific fat storage remains poorly 
understood. The contribution of ApoE in adipocyte triglyceride accumula-
tion has previously been described in ApoE knockout mice, but not in ApoE-
deficient rats. Moreover, the effect of dietary gluten as a potential accelerator 
of site specific fat accumulation has not been thoroughly examined. Fat dis-
tribution and cardiovascular risk are highly associated. Thus, we investigated 
site specific fat storage in rats with systemic knockout of the ApoE gene, fed 
either a cholesterol enriched Western Diet or a normal Low Fat diet in com-
bination with or without gluten.
Materials and methods: ApoE knockout rats were fed either: 1) a Western 
Diet (WD) high in cholesterol, fat and sucrose; 2) a WD with gluten (WD+G); 
3) a Low Fat diet (LF); or 4) LF and gluten (LF+G) from 10 days of age. At 
20 weeks of age body weight, whole body fat, visceral fat and subcutaneous 
fat were measured. Fat distribution was measured by MRI and CT scanning
Results: We compared rats fed either WD or LF diets in combination with 
or without gluten at 20 weeks of age. The greatest differences were observed 
between rats fed WD+G diet or LF+G diet. When compared to LF+G fed 
rats, WD+G fed rats had significantly higher body weight (352±14 g versus 
293±11 g; p<0.001), whole body fat/body weight ratios (0.26± 0.081 versus 
0.17±0.010; p<0.001), visceral fat (13.4±0.9 g versus 7.1±0.7 g; p<0.01), and 
subcutaneous fat (5.1±0.3 g versus 2.5±0.4 g; p<0.001). No significant dif-
ferences were observed between LF and WD, between WD and WD+G or 
between LF and LF+G for any of the above mentioned parameters. However, 
the visceral fat was significantly increased in WD+G fed rats, when compared 
to WD fed rats (13.4±0.9 g versus 10.8±0.7 g; p<0.05). Finally, the liver den-
sity, an inverse measure of liver fat, was observed to be significantly lower in 
the WD+G fed rats, when compared to the WD rats (-46.1±3.6 Hounsfield 
Units (HU) versus -19.9±5.1 HU, p<0.01) at week 20.
Conclusion: Our data suggest that WD in combination with gluten, but not 
alone, increases deposition of fat in the visceral compartment rather than the 
subcutaneous compartment in ApoE knock out rats when the different diets 
are introduced from 10 days of age. The differences observed in body weight, 
whole fat and the site of fat deposition between the group fed WD combined 
with gluten and the group fed LF diet combined with gluten also suggest that 
it is the interaction between gluten and the cholesterol-enriched WD, rather 
than gluten per se, that promotes the early signs of the metabolic syndrome.
Supported by: The LIFEPHARM Centre
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The synergistic effect of two mtDNA point mutations in complexes 
of the respiratory chain promote age-dependent hyperglycaemia and 
mitochondrial ROS production
S. Schröder, J. Niemann, F. Koch, C. Johne, M. Tiedge, S. Baltrusch;  
Institute of Medical Biochemistry and Molecularbiology, Rostock, Germany.
Background and aims: Mutations in complexes of the respiratory chain, 
which are encoded in the mitochondrial genome (mtDNA), can mediate an 
increase in production of reactive oxygen species (ROS). Thus, mtDNA mu-
tations are proposed to evoke mitochondrial dysfunction and to contribute 
to the pathogenesis of type 2 diabetes mellitus. In this study we investigated 
ROS production and the expression of antioxidative enzymes in liver and 
muscle from conplastic mice carrying a mtDNA point mutation in the cy-
tochrome c oxidase (complex IV) or a combined mutation in the cytochrome 
c oxidase (complex IV) and the NADH dehydrogenase (complex I).
Materials and methods: Blood glucose was measured in the conplastic 
mouse strains C57BL/6NTac-mtBPL/1J (NADH dehydrogenase mutation 
und cytochrome c oxidase mutation, mtBPL), C57BL/6NTac-mtNOD/LtJ 
(cytochrome c oxidase mutation, mtNOD) and C57BL/6NTac-mtAKR/J 
(control; mtAKR). For analysis of mitochondrial ROS production MitoSox 
was injected in living animals. Thereafter mice were killed and tissues were 
analyzed for accumulated ROS by fluorescence microscopy. Gene expression 
of the antioxidative enzymes catalase, SOD1, SOD2 was investigated by quan-
titative PCR analyses.
Results: At the age of 6 months mtBPL mice (7.5 mmol/l) showed signifi-
cantly higher blood glucose levels compared to mtNOD mice (6.1 mmol/l) 
and mtAKR control mice (6.2 mmol/l). In liver and muscle of mtNOD and 
mtAKR mice an age-dependent increase in ROS was observed between 
month 3 and 12. In contrast, mtBPL mice showed a significant 20-fold peak 
increase in ROS at the age of 6 months, which normalized at the age of 12 
month. At this time point the ROS level in muscle and live was comparable 
to mtAKR control mice. In dependence of age mtNOD mice showed a com-
parable or higher expression of antioxidative enzymes than mtAKR control 
mice, whereas in mtBPL mice the expression of all antioxidative enzymes and 
in particular the expression of catalase was significantly reduced.
Conclusion: The coincidence of mtDNA point mutations in the cytochrome 
c oxidase and NADH dehydrogenase resulted in higher blood glucose levels 
in 6 month old mtBPL mice. At this age mtBPL mice showed a significant 
increase of ROS production in liver and muscle. Thus, mtDNA mutations 
confer high ROS production in liver during adolescence with inadequate 
adaptation of the antioxidative system. This scenario could be a pathogenic 
trigger for insulin resistance with progressive ageing and contribute to the 
development of type 2 diabetes mellitus.
1313
Streptozotocin-induced diabetes does not affect mitochondrial structure 
and function
N. Volk1, T.H. Fleming1, A.S. Hidmark1, E.-M. de Villiers2, P.P. Nawroth1;  
1Department of Medicine I and Clinical Chemistry, University of 
Heidelberg, 2Division for the Characterization of Tumorviruses,  
Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Background and aims: A central mechanism underlying the development 
and progression of late diabetic complications is increased production of 
reactive oxygen species (ROS). Mitochondria, and specifically the electron 
transport chain (ETC), are considered to be the main source for intracellular 
ROS. During hyperglycemia, ROS production is increased leading to chang-
es in the function of mitochondria including decreased activity of the ETC 
complexes, reduced ATP production, as well as changes in morphology. Un-
published data from our research group have shown discrepancies between 
hyperglycemic conditions and elevated ROS levels. To estimate whether mi-
tochondria dysfunction is associated with diabetes, the structure and func-
tional properties of mitochondria were studied in the organs of streptozo-
tocin-induced diabetic mice, using high-through put screening assays.
Materials and methods: Diabetes was induced in healthy, wild-type mice 
(C57BI/6; male), by low-dose streptozotocin treatment. After four months, 
the hearts, kidneys, and livers from control and diabetic mice were collected, 
and mitochondria isolated by differential centrifugation. Purity of the iso-
lated mitochondria was determined by electron microscopy (EM) and FACS. 
Morphology of the mitochondria within the tissue was also assessed by EM. 
The abundance of ETC complexes was analyzed by western blot (WB) and 
the activity of the complexes was tested using specific activity assays. Total 
oxygen consumption, ATP, and ROS production were analyzed during state 
3 and state 4 respiration.
Results: After four months of diabetes, both blood glucose (158.8 ± 4.1 mg/
dl vs 467.8 ± 75.7 mg/dl, P-value = 0.0002) and HbA1c (2.9 ± 0.1 % vs 9.5 ± 
0.4 %, P-value < 0.0001) were significantly increased in the diabetic group, 
and body weight was significantly decreased (36.1 ± 1.2 mg vs 23.8 ± 2.0 
mg, P-value < 0.0001). The mitochondria fraction isolated from the organs of 
each group had a purity of more than 95 %. No gross morphological changes 
between control and diabetic groups were observed in either the isolated mi-
tochondria or within the tissue. No differences were observed with respect to 
the abundance of the ETC complexes, ATP, and ROS production. However, 
during state 3 respiration, both heart- and liver-derived mitochondria from 
diabetic mice showed increased oxygen consumption. During state 4 respira-
tion, oxygen consumption was increased in liver-derived mitochondria from 
diabetic mice. No changes could be observed at either state 3 or 4 for kidney-
derived mitochondria.
Conclusion: This study describes a methodology not only for the isolation of 
high purity mitochondria from tissue, but also high-through put screening of 
mitochondrial function. Utilizing this methodology, it was found that at four 
months of streptozotocin-induced diabetes, there were little or no changes in 
the structure and function of mitochondria. Additional studies are required 
to determine whether mitochondria dysfunction is observed at later stages of 
diabetes and is associated with increased ROS production.
1314
Pyruvate kinase isoenzyme M2 shows increased expression in diabetes
S. Vittas, S. Kopf, N. Volk, A. Hidmark, D. Oikonomou, T.H. Fleming,  
P.P. Nawroth;  
Department of Medicine I and Clinical Chemistry, University of Heidelberg, 
Germany.
Background and aims: Pyruvate kinase (PK) catalyzes the conversion of 
phosphoenolpyruvate (PEP) to pyruvate, generating ATP as the last step of 
glycolysis. PK is expressed in 3 different isoforms named M1, M2 and LR. 
PKM1 and PKM2 show different activity levels, with PKM2 being highly 
expressed in cancer where enables cells to use aerobic glycolysis instead of 
oxidative phosphorylation. mRNA expression of the different isoforms (M1-
M2) was investigated using specific primers and siRNAs in control and dia-
betic material from mouse and human in order to investigate whether PKM 
isoforms show differential expression in diabetes and how this balance affects 
late diabetic complications.
Materials and methods: Hearts, kidneys, sciatic nerves (SN) and dorsal root 
ganglia (DRG) derived from 3-6 months control and diabetic mice and hu-
man peripheral blood mononuclear cells (pBMCs) derived from healthy aged 
matched control and type 2 diabetic individuals were used for RNA extrac-
tion, cDNA preparation and subsequent real-time PCR using specific prim-
ers for the different PKM isoforms (M1-M2). Additionally, in vitro experi-
ments were performed by the use of siRNA specific for either both or M2 PK 
isoform in order to measure metabolic dysfunction with respect to glycolysis 
and the electron transport chain.
Results: PKM isoforms show differential expression in diabetic tissues and 
cells in compare to the respective controls. PK M1/M2 ratio is significantly 
decreased in hearts, kidneys, SN and DRG derived from diabetic mice in 
compare to age matched control mice. The same ratio is also decreased in 
human pBMCs derived from diabetic individuals in compare to control ones 
with a positive correlation being found between the levels of PKM2 isoform 
and the neuropathy symptom score (NSS) in the diabetic group.
Conclusion: PK as the last enzyme of glycolysis plays an important role in 
cell metabolism. This study reveals a differential expression of the two major 
PK isoforms (M1-M2) in diabetes. The increased PKM2 expression in dia-
betic tissue can be correlated with the ability of cells to use aerobic glycolysis 
instead of oxidative phosphorylation. These findings reveal new aspects in 
development of late diabetic complications, thereby providing new opportu-
nities for therapeutic interventions.
Supported by: DFG (BI-1281/3-1 & NA 138 /7-1), DZD/BMBF, Dietmar Hopp 
Stiftung
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Treatment with divalent copper chelation reverses defective myocellular 
copper transport in the heart of diabetic rat
S. Zhang1, H. Liu1, G. Amarsingh1, C.C.H. Cheung1, S. Hogl1,  
U. Narayanan1, L. Zhang1, S. McHarg2, J. Xu1, D. Gong1, J. Kennedy3,  
B. Barry3, Y. Choong1, A.R.J. Phillips1, G.J.S. Cooper1,2;  
1School of Biological Sciences, University of Auckland, New Zealand, 
2Institute of Human Development, University of Manchester, UK,  
3National Isotope Centre, GNS Science, Wellington, New Zealand.
Background and aims: Heart disease is the leading cause of death in diabetic 
patients, and defective copper metabolism could play important roles in the 
pathogenesis of diabetic cardiomyopathy. This study was to determine how 
myocardial copper status and myocellular copper chaperon proteins become 
impaired by diabetes, and how they respond to treatment with the Cu(II)-
selective chelator triethylenetetramine (TETA).
Materials and methods: Experiments were performed using streptozo-
tocin (STZ)-induced diabetic rats with and without TETA treatment. Car-
diac function were analysed in isolated, ex-vivo perfused working hearts and 
myocardial copper content measured using particle-induced x-ray emission 
spectroscopy coupled with Rutherford backscattering spectrometry. The ex-
pression (mRNA and proteins) and/or activity of key protein components 
involved in copper binding and transport were analysed using combination 
of RT-qPCR, western blotting, immunofluorescence staining and enzyme ac-
tivity assays.
Results: Left-ventricular (LV) copper levels and LV function were markedly 
deficient (~50%, p<0.01) in rats following 16-weeks’ diabetes in STZ-rats, 
but both were unexpectedly normalized after 8-weeks’ treatment with TETA. 
Localized myocardial copper deficiency was accompanied by decreased 
expression (~40-50%, p<0.05) and increased polymerization of the copper-
responsive transition-metal-binding metallothionein proteins (MT1/MT2), 
consistent with impaired anti-oxidant defences and elevated susceptibility to 
pro-oxidant stress. Levels of the high-affinity copper transporter-1 (CTR1) 
were depressed (~30%, p<0.01) in diabetes, consistent with impaired mem-
brane copper uptake, and were not modified by TETA which, contrastingly, 
renormalized myocardial copper and increased levels (~1.5 fold, p<0.05) and 
cell-membrane localization of the low-affinity copper transporter-2 (CTR2). 
Diabetes also lowered indexes (~30%, p<0.01) of intracellular copper deliv-
ery via the copper chaperone for superoxide dismutase (CCS) to its target 
cuproenzyme, superoxide dismutase-1 (SOD1): this pathway was restored 
by TETA treatment, which normalized SOD1 activity with consequent bol-
stering of anti-oxidant defences. Furthermore, diabetes depressed levels 
(~20%, p<0.01) of additional intracellular copper-transporting proteins, in-
cluding antioxidant-protein-1 (ATOX1) and Cu(II)-transporting-ATPase-2 
(ATP7B), whereas TETA elevated copper-transporting-ATPase-1(ATP7A) 
(~20%, p<0.01).
Conclusion: Myocardial copper deficiency and defective cellular copper 
transport/trafficking are revealed as key molecular defects underlying LV 
impairment in diabetes, and TETA-mediated restoration of copper regula-
tion provides a potential new class of therapeutic molecules for diabetic heart 
disease.
Supported by: Endocore Research Associates, HRC, NERF, MPPT and Lottery 
Health of NZ
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Exendin-4 counteracts palmitate-induced autophagy in human cardiac 
progenitor cells by inhibiting p38 MAPK phosphorylation and de novo 
production of ceramide
A. Leonardini, R. D‘Oria, M. Incalza, C. Caccioppoli, V. Andrulli Buccheri, 
M.R. Orlando, A. Natalicchio, S. Perrini, L. Laviola, F. Giorgino;  
Endocrinology & Metabolic Diseases, University of Bari, Italy.
Background and aims: Increased autophagy of cardiomyocytes has been 
proposed as a mechanism of myocardial damage and dysfunction. Glucagon-
like peptide-1 (GLP-1) and GLP-1 analogs exert protective effects on cardiac 
cells. In this study, the effects of exendin-4 (Ex-4) on lipotoxicity-induced 
autophagy were investigated in human cardiac progenitor cells (hCPC).
Materials and methods: hCPCs were isolated from right auricle biopsies of 
patients undergoing elective heart surgery and exposed to palmitate (0.25 
mM up to 16 h). Autophagy was evidenced by monodansyl cadaverine and 
autophagolysosome labeling, and by immunoblotting of microtubule-associ-
ated protein 1 light chain 3 (LC3)-II and beclin1. p38 expression and phos-
phorylation was detected by immunoblotting. The expression of ceramide 
synthase 5 (CerS5) was studied by RT-PCR and immunoblotting. Intracel-
lular ceramide content was evidenced by immunofluorescence.
Results: Palmitate induced an increased autophagy in hCPC, evidenced by 
monodansyl cadaverine and autophagolysosome labeling, and confirmed 
by increased levels of microtubule-associated protein 1 light chain 3 (LC3)-
II and beclin1, respectively (p<0.05). Palmitate also stimulated p38 MAPK 
phosphorylation (p<0.05), and pretreatment with the p38 MAPK inhibi-
tors SB203580 and SB202190 significantly inhibited palmitate-induced au-
tophagy. In palmitate-exposed hCPC, intracellular ceramide content, evalu-
ated by immunofluorescence, was concomitantly augmented, in parallel with 
increased expression of ceramide synthase 5 (CerS5), a critical enzyme in 
ceramide generation. Co-incubation of hCPCs with fumonisin-B1, a specific 
CerS5 inhibitor, partially prevented palmitate-induced autophagy. However, 
the inhibition of CerS5 with a specific siRNA did not prevent p38 MAPK 
phosphorylation induced by palmitate. When hCPC were pretreated with 
Ex-4, the palmitate-induced increase in LC3-II and beclin1 and p38 MAPK 
phosphorylation were abrogated (p<0.05), and so was the increase in CerS5 
and ceramide levels (p<0.05).
Conclusion: Palmitate-induced hCPC autophagy is mediated both by p38 
MAPK activation and de novo ceramide synthesis in parallel, and the GLP-1 
analog Ex-4 can counteract these responses. GLP-1 mimetics may thus pro-
tect the myocardium from lipotoxic damage in type 2 diabetic and/or obese 
subjects with elevated free fatty acid levels.
Supported by: Eli-Lilly Foundation
1317
Cardiac immuno-inflammatory response to dietary sodium restriction 
in rats with insulin resistance and hypertension
B. Jover, C. Guzman, A.-D. Lajoix, C. Rugale, C. Desmetz;  
EA7288, University, Montpellier, France.
Background and aims: Controversial influence of dietary sodium restriction 
was reported in rats with insulin resistance. We have recently observed that 
low sodium (LS) diet prevents renal damages in rats fed high fructose. In the 
present study, we aimed at verify whether LS diet may also prevent fructose-
induced modifications in the heart, even in presence of a moderate arterial 
hypertension. In addition, the involvement of the immuno-inflammatory 
response in the beneficial effect of a low sodium diet was assessed in cardiac 
tissue.
Materials and methods: At the age of 8 weeks, Sprague-Dawley rats received 
three different regimens for 8 weeks. Low sodium (LS, <0.01% NaCl) or 
normal sodium (NS, 0.65% NaCl) diets were proposed to rats made insulin 
resistant with high fructose consumption (60%, n=20) and hypertensive by 
chronic infusion of Angiotensin II (AngII, 200 ng.kg-1.min-1, sc, n=20). Af-
ter 4 weeks of the fructose diet, AngII was infused or not during an additional 
4-week period on fructose. A regular rat chow with NS content was given to 
control rats. Tail-cuff pressure (TCP) was measured before and after AngII. 
Heart weight index (HWI, mg HW / g BW) as well as the cardiomyocytes 
size (histology) were determined at the end of study. Insulin resistance was 
determined through the use of an insulin tolerance test (ITT, 0.6 UI/kg, ip). 
Cardiac expression of various genes was assessed by real-time PCR (qPCR). 
Presence of monocytes/macrophages was evidenced by immunostaining and 
expression of CD68. Transcription factor, NF-kBp65, and the presence of 
CD4+ and CD8+ T cells or B cells (CD20) were evaluated by qPCR.
Results: As expected, AngII induced a clear rise in TCP in rats fed NS fruc-
tose diet (40±5% from basal value of 139±2 mmHg, P<0.01). TCP rose to a 
lesser extent (20±4%, P<0.05) in rats fed LS fructose diet. The response to 
ITT was similar in NS and LS rats fed high fructose and infused with AngII. 
When compared to standard rats, fructose induced a cardiac hypertrophy 
with a HWI of 2.80±0.05 vs 2.44±0.07 mg/g, P<0.05. HWI was lower in rats 
fed the LS- than the NS-fructose diet (~ 8% vs 15%). HWI further increased 
in AngII-infused rats on both diets (HWI of 3.01±0.28 in NS and 2.89±0.07 
mg/g in LS); yet the rise was less marked in LS- than NS-fed rats (~ 9 vs 23% 
compared to control group). The rise in cardiomyocytes size was prevented 
by the LS diet. In the heart, macrophages infiltration (CD68 staining and 
expression) during fructose feeding was reduced by the LS diet in absence 
(9.5±0.8.10-2 vs 7.1±0.5.10-2, P<0.05) and in presence of AngII (10.6±1.5.10-
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2 vs 5.6±0.4.10-2, P<0.01). Similarly, expression of CD4 and CD8 in cardiac 
tissue was lower in LS-fed rats with or without AngII infusion. No significant 
changes were detected for CD20. Expression of NF-kBp65 was reduced in 
rats fed the low sodium diet in absence or presence of AngII infusion.
Conclusion: Reduction of sodium consumption has a beneficial effect on car-
diac morphology in insulin resistance alone or associated with a clear arterial 
hypertension. This beneficial effect is not related to improvement of insulin 
resistance. Beside a reduction in the level of hypertension, sodium depriva-
tion seems to act through the blunting of local cardiac inflammation response 
and the reduction of immune cells (not B cells) infiltration in the heart.
Supported by: SFHTA
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HDL and signals of endothelial inflammation in type 2 diabetes mellitus
R.F.H. Lemmers1, S. Shagiwal2, A.J.M. Verhoeven2, M. van Hoek2,  
A.G. Lieverse1, E.J.G. Sijbrands2, M.T. Mulder2, W.A. Dik3;  
1Internal Medicine, Máxima Medical Center, Eindhoven, 2Internal Medicine, 
3Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
Background and aims: In type 2 diabetes (T2D), structural as well as com-
positional changes of HDL have been observed. HDL usually attenuates in-
flammation, but can under certain conditions become pro-inflammatory. We 
hypothesized that pro-inflammatory HDL contributes to vascular complica-
tions in T2D. In an ongoing study, we compare the effects of HDL from T2D 
patients on endothelial signals of different human endothelial cells. Here, we 
report our preliminary results with retinal endothelial cells (REC).
Materials and methods: Anti-inflammatory properties of HDL isolated with 
iodixanol Gradient centrifugation were measured as TNF-α induced cytokine 
production and adhesion molecule expression by human retinal endothelial 
cells (REC). IL-6 and IL-8 production were measured with ELISA and vascu-
lar cell adhesion molecule-1 (VCAM1) expression with fluorescence-activat-
ed cell sorting (FACS) using fluorescent antibodies. HDL was isolated from 
T2D patients with both micro- and macrovascular complications (HDLT2D+C, 
n=3), T2D patients without complications (HDLT2D, n=3) and healthy con-
trol subjects (HDLHealthy, n=3).
Results: Pre-incubation of REC with HDL did not alter basal IL-6 and IL-8 
production or VCAM1 expression. TNF-α increased IL-6 production from 
31.6ng/ml (SD 5.7, n=3)) to 75.0ng/ml (SD 12.2, n=3). After pre-incuba-
tion with HDL, TNF-α-induced IL-6 production decreased significantly 
(p<0.0001) to 42.7ng/ml (SD 7.7, n=9). TNF-α increased IL-8 production 
from 245.1ng/ml (SD 10.8; n3) to 3618.1ng/ml (SD 728.1; n=3). When pre-
incubated with HDL, TNF-α stimulated IL-8 production decreased signifi-
cantly (p<0.0001) to 2676.1ng/ml (SD 474.0; n=9). The median fluorescent 
intensity (MFI) of VCAM1-expression on REC was 604.0 units (range 594.2-
642.1; n=3) and increased to 7612.8 (range 7331.0-7894.6; n=2) after TNF-α 
stimulation. Pre-incubation with HDL decreased TNF-α-induced VCAM1 
expression significantly (p<0.0001) to 3414.1 units (range 2203.9-4246.2; 
n=9). The groups were too small for subgroup analyses and comparisons.
Conclusion: We were able to observe inhibitory effects of HDL on TNF-α 
induced VCAM-1 expression and IL-6 and IL-8 production by Retinal En-
dothelial Cells. Our ongoing recruitment and testing will increase the power 
of the study and enable comparisons between the subgroups.
1319
Soluble dipeptidyl peptidase 4 induces inflammation and proliferation of 
human vascular smooth muscle cells via protease-activated receptor 2
N. Wronkowitz1, S.W. Görgens1, T. Romacho1, L.A. Villalobos2,  
C.F. Sánchez-Ferrer2, C. Peiró2, H. Sell1, J. Eckel1;  
1Paul-Langerhans Group for Integrative Physiology, German Diabetes 
Center, Düsseldorf, Germany, 2Department of Pharmacology and 
Therapeutics, Universidad Autónoma de Madrid, Spain.
Background and aims: Dipeptidyl peptidase 4 (DPP4) is a ubiquitously ex-
pressed cell-surface protease and a novel adipokine, as shown by us. Due to 
DPP4-mediated degradation of the incretin hormone glucagon-like peptide 
(GLP)-1, inhibition of DPP4 is now widely used as a therapeutic approach 
for type 2 diabetes mellitus treatment. In addition, DPP4 inhibitors display 
beneficial cardiovascular effects that are not only GLP-1 mediated. However, 
nothing is known about direct cellular effects of soluble DPP4 (sDPP4), the 
circulating form of this enzyme. Previously, we showed that sDPP4 directly 
induces inflammation and proliferation in human vascular smooth muscle 
cells (hVSMC). The aim of the present study was to identify a responsible 
receptor for the sDPP4-induced effects in hVSMC.
Materials and methods: Primary hVSMC from three distinct donors were 
exposed to protease-activated receptor 2 (PAR2) specific siRNA or the antag-
onist GB83. Cells were then treated with sDPP4 for 6 and 24h and the impact 
of PAR2 on the sDPP4-induced effects was investigated. The sDPP4-induced 
signaling pathways were assessed by Western blot analysis. To analyze the 
expression of different cytokines mRNA were measured by real-time PCR. 
Effects on proliferation were detected by ELISA.
Results: Bioinformatic analysis and signaling signature induced by sDPP4 
suggest that sDPP4 might be an agonist for PAR2. Indeed, we found a po-
tential PAR2 binding site in the cystein-rich region of DPP4 responsible for 
partner binding. When we aligned the potential PAR2 binding site with the 
sequence of the crystallized DPP4, we could locate it on the surface of DPP4. 
Interestingly, PAR2 protein level was significantly higher in hVSMC com-
pared to endothelial cell, adipocytes or skeletal muscle cells. After silencing 
of PAR2, the sDPP4-induced ERK activation (2.5-fold) as well as the pro-
liferation (1.7-fold) was totally abolished. Additionally, the same effect was 
observed by the PAR2 antagonist GB83. In accordance to that the sDPP4-
induced NF-κB activation (1.5-fold) as well as the upregulation of the pro-in-
flammatory cytokines IL-6 and IL-8 (2-fold and 1.9-fold, respectively) could 
completely be prevented by PAR2 silencing.
Conclusion: In conclusion, in this study we characterized a novel sDPP4-
induced signaling cascade in hVSMC. sDPP4 directly and markedly activates 
the MAPK- and NF-κB signaling pathway in a PAR2 dependent manner 
leading to pro-atherogenic changes in hVSMC like increased proliferation 
and inflammation. Considering the increased circulating levels of sDPP4 in 
obesity and the upregulation of PAR2 in atherosclerotic lesions, our proposed 
sDPP4-PAR2 interaction might play an important role in linking obesity to 
cardiovascular disease.
1320
Inflammatory stimulation transforms glucose into a deleterious agent in 
human vascular smooth muscle cells
C.F. Sanchez-Ferrer1, C. Peiro1, T. Romacho1, V. Azcutia1, L. Villalobos1,  
E. Fernandez2, J.P. Bolanos2, S. Moncada3;  
1Farmacologia, Universidad Autonoma de Madrid,  
2Instituto de Biologia Funcional y Genetica, Salamanca, Spain,  
3Wolfson Institute for Biomedical Research, London, UK.
Background and aims: Although hyperglycemia is recognized as an inde-
pendent risk factor for cardiovascular diseases, the links between glucose me-
tabolism and the development of atherosclerosis still require elucidation. We 
have previously shown that normal vascular cells, which have the capacity to 
regulate the entry of glucose, are not damaged by high glucose concentration 
unless they are primed with an inflammatory stimulus such as interleukin 
(IL)1β.
Materials and methods: In cultured human vascular smooth muscle cells 
(VSMC) submitted to normal or high glucose (5.5 or 22 mmol/L), inflam-
mation (1 to 10 ng/mL IL1β), and/or infection with the glucose transporter 
GLUT1, the following parameters were analysed: (1) glucose uptake and con-
sumption, as well as lactate production; (2) characterization of GLUT1 by 
flow cytometry, RT-PCR, and immunofluorescence; (3) determination of in-
flammatory parameters, such as the expression of inducible nitric oxide syn-
thase (iNOS) and the activity of nuclear factor-κB (NF-κB); (4) NADPH oxi-
dase activity; (5) expression of glucose-6-phosphate dehydrogenase (G6PD) 
and activity of the pentose phosphate pathway (PPP) and; (6) determination 
of total and reduced glutathione.
Results: In VSMC submitted to high glucose, we show that excess glucose 
uptake and utilization only occurs in the presence of IL1β. However, we dem-
onstrate that the simple entry of glucose is not enough to be deleterious in 
these cells since over-expression of GLUT1 or increased glucose uptake fol-
lowing inhibition of mitochondrial oxidative phosphorylation with sodium 
azide are not sufficient to trigger inflammatory mechanisms. Our results in-
dicate that, besides allowing glucose entry, IL1β enhances G6PD expression 
and activates the PPP in VSMC, thus permitting some of the excess glucose 
to be metabolized by this route. Such activation provides additional substrate 
for the enzyme NADPH oxidase and results in increased generation of free 
radicals. These are necessary intermediates for the inflammatory response 
since they are required for the activation of iNOS and NF-κB. The higher the 
concentration of glucose the more the PPP pathway is activated, giving rise 
to an increased inflammatory condition which cannot be counterbalanced by 
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the simultaneous regeneration of reduced glutathione that occurs following 
activation of the PPP.
Conclusion: A pro-inflammatory stimulus such as IL1β transforms excess 
glucose into a deleterious agent in VSMC by causing an increase in glucose 
uptake and its subsequent diversion into the PPP. This action ultimately 
promotes the pro-oxidant conditions required for the exaggeration of pro-
inflammatory pathways. Interestingly, all these pathways were blunted by 
the blockade of IL1 receptors with anakinra. These findings can improve our 
understanding of the mechanisms for the development of diabetic vascular 
complications and suggest the combination of anti-inflammatory strategies 
together with glycaemic control for a more efficient prevention of such dis-
eases.
Supported by: SAF2011-24648; SAF2011.28011
1321
Nitric oxide hyperproduction and markers of DNA damage in the early 
phase of diabetic nephropathy in rat streptozotocin diabetes mellitus 
model
J. Sokolovska1, E. Rostoka1, O. Sugoka2, S. Isajevs3, L. Baumane1,  
J. Sharipova1, I. Kalvinsh1, N. Sjakste1;  
1Latvian Institute of Organic synthesis, Riga, 2University of Latvia,  
Institute of Biology, Salaspils, 3University of Latvia, Riga, Latvia.
Background and aims: Reactive oxygen species (ROS) production due to 
intracellular hyperglycaemia is an important factor that initiates inflamma-
tory pathways leading to diabetic nephropathy. NO hyperproduction in the 
kidney might lead to nitrosative stress with resulting DNA damage. However, 
data on NO, nitric oxide synthases (NOS) in the diabetic nephropathy are 
contradictory. Other enzymes like xantine oxidoreductase (XOR) might be 
involved. The aim of this work was to study changes and mechanisms of NO 
production in the kidneys of rats with streptozotocin (STZ) diabetes mellitus 
model, along with expression of poly ADP ribose polymerase (PARP) and 
histone gamma H2AX as markers of DNA damage. In order to modify NO 
production, we have used 1,4-dihydropyridine (1,4-DHP) class compounds, 
synthesized in the Latvian Institute of Organic Synthesis.
Materials and methods: Diabetes mellitus in rats was induced by streptozo-
tocin (STZ) 50 mg/kg, i.v. Production of NO in kidneys was monitored by 
means of ESP spectroscopy of Fe-DETC-NO complex. Different inhibitors of 
NO synthesis (GdCl3, aminoguanidine, 1400W, allopurinole) have been ap-
plied. 1,4-DHP class drugs have been administered 0,5 mg/kg for 3 days per 
os. Kidney iNOS, eNOS, XOR, PARP and H2AX mRNA and protein expres-
sion were detected by qRT-PCR and immunohistochemistry correspond-
ingly, 12 days after diabetes mellitus induction and after 3 days of treatment 
with DHP class drugs.
Results: NO production increase in kidneys was stable and potent (from 2.64 
± 0.97 to 15.04 ± 2.04 ng/g tissue). Application of non-selective NOS inhibi-
tor aminoguanidine and XOR inhibitor allopurinol resulted in a significant 
decrease of NO hyperproduction. Further, 1,4-DHP class compounds etafto-
ron, cerebrocrast and fenoftoron significantly decreased NO production. 
iNOS and XOR protein expression was upregulated in STZ rat kidney and 
decreased under etaftaron treatment (iNOS: control 11 ± 4 cells/mm2, STZ: 
29 ± 15 cells/mm2 , STZ+etaftoron; 13 ± 6 cells/mm2 p<0.05) and (XOR: 
control 8± 2 cells/mm2, STZ 27 ± 7 cells/mm2.; STZ+etaftoron 9 ± 3 cells/
mm2, p<0,05.). In kidneys of STZ rats, PARP expression was significantly 
elevated, and normalized by 1,4-DHP drug AV153. H2AX expression also 
significantly increased in kidneys of diabetic rats, AV153 did not affect this 
parameter.
Conclusion: We report increased NO production in kidneys of STZ diabetic 
rats, along with increased markers of DNA damage, after short duration of se-
vere hyperglycaemia. 1,4-DHP class compounds could normalize increased 
NO production, iNOS, XOR and PARP hyperexpression in STZ rat kidneys. 
NO production in the kidney might become a therapeutic target to decrease 
oxidative stress and progression of diabetic nephropathy.
Supported by: ESF 1DP/1.1.1.2./13/APIA /VIAA/002 , 1DP/1.1.2.1.2./09/IPIA/
VIAA/004
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Early intervention with GLP-1 analogue prevents memory impairment 
and tau hyperphosphorylation in diabetic db/db mice
Y. Yang, S. Shao;  
Department of Endocrinology, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan, China.
Background and aims: Recent studies have shown that type 2 diabetes mel-
litus (T2D) is a risk factor for Alzheimer’s disease (AD), and hyperphospho-
rylated tau protein is a pathophysiological change in hippocampus on the 
early set of AD, which is called AD associated tau change. Insulin resistance 
is often associated with T2D and can induce defective insulin signaling in the 
central nervous system. Glucagon like peptide-1 (GLP-1) stimulates insulin 
secretion and has been employed in the treatment of T2D. Unlike insulin, 
GLP-1 and its analogs could cross the brain blood barrier freely. In this study, 
we investigated the potential effects on AD associated tau protein with treat-
ment with a GLP-1 analog in db/db mice.
Materials and methods: A total of 80 male db/db mice at the age of 2-2.5 
weeks were randomly divided into three groups: GLP-1-treated, insulin-
treated and control-treated groups. After being acclimatized and received 
daily subcutaneous saline injections for 1 week, all mice received daily subcu-
taneous injection of GLP-1 analog, insulin or, as a control, saline right before 
the dark cycle each day. Five to seven mice from each group were sacrificed 
every two weeks. Blood, cerebrospinal fluid (CSF) and brain tissues were 
collected at the second, forth, sixth and eighth weeks separately after GLP-
1analog or insulin administration for analyses.
Results: We found that GLP-1 analog promoted more beneficial effects on 
learn memory in db/db mice compared with insulin treatment. The drug re-
duced hyperphsphorylated tau protein by activating insulin signaling path-
way in the hippocampus. On the contrary, insulin peripheral administration 
had no effects on AD associated tau protein changes. Neither GLP-1 analog 
nor insulin could stimulate neuronal degeneration.
Conclusion: In summary, our data indicate that early GLP-1 analog interven-
tion improves cognition in db/db mice, an effect likely driven by increasing 
the activity of insulin signaling pathway in the T2D brain, which leads to the 
reduction of AD associated tau hyperphosphorylation.
Supported by: NSFC (81100581 and 81100582)
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Effect of hyperglycaemia on the expression of aquaporins in diabetic  
rat testis
A. Kannan, C. Prahalathan;  
Biochemistry, Bharathidasan University, Tiruchirappalli, India.
Background and aims: Diabetes mellitus (DM) is one of the greatest public 
health threats in modern societies. DM is a well-recognized cause of male 
sexual dysfunction and impairments of male fertility. Sustained hypergly-
cemic and hypoinsulinemic states is considered as a major cause of sexual; 
ejaculatory and erectile dysfunction in human population. Water and solute 
movement across the epithelium of the male reproductive tract is respon-
sible for balancing the luminal environment for spermatogenesis and plays 
a pivotal role for establishment of male fertility. Aquaporins (AQPs) are a 
family of integral membrane proteins allowing the transcellular transport, 
maintaining water homeostasis and is strongly associated with female and 
male reproductive systems. In the testis, AQPs play an indirect role in main-
taining spermatogenesis, while in the efferent ducts and epididymis; provide 
environment for the transport and maturation of sperm. The main aim of this 
study is to determine the effect of hyperglycemia on expression of AQPs in 
testis of diabetic rats.
Materials and methods: Experimental animals were handled according to 
the University and institutional legislation, regulated by the Committee for 
the Purpose of Control and Supervision of Experiments on Animals (CPC-
SEA), Ministry of Social Justice and Empowerment, Government of India 
(BDU/IAEC/2011/28/29.03.2011). Experimental diabetes in rats was in-
duced by a single intraperitoneal injection of streptozotocin (65 mg/kg body 
weight). Plasma glucose was measured using glucometer. The mRNA expres-
sions of AQPs (1, 7, 8, 9 & 11) in testis from control and diabetic rats were 
examined by RT-PCR after a time interval of 4weeks. All statistical analysis 
was carried out using GraphPad Prism4 software. All data were presented in 
mean (±) standard deviations (SD).
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Results: Plasma glucose was significantly higher in diabetic groups than in 
controls (P < 0.05). The RT-PCR detection of the aquaporins (1, 7, 8, 9 &11) 
considered in this study is illustrated in Fig. 1. The level of expression of AQP 
1 in diabetic testis was similar to that of control groups. The levels of expres-
sion of AQPs 7, 8, 9 and 11 in diabetic testis were significantly higher com-
pared to controls (P < 0.05).
Conclusion: In summary, this work describes the expression of AQPs 7, 8, 
9, & 11 in testis of diabetic rats were altered compared to controls. Altera-
tion of AQPs expression leads to disruption of water homeostasis and affects 
spermatogenesis. Recent, studies shows that AQPs 7, 8 & 11 plays an im-
portant role in spermatogenesis and physiological sperm volume regulation. 
AQP9 plays a specific role in the transport of water and non-charged solutes 
in Leydig cells. Furthermore, altered expression and regulation of AQPs have 
already been demonstrated to be the cause of several disorders of the male 
reproductive system. The full enlightenment of these molecular interactions 
and mechanisms may point towards possible therapeutic targets to counter-
act diabetes induced male subfertility/infertility.
PS 121 Animal models of 
complications II
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Decreased use of experimental animals through optimisation of 
experimental design for efficacy studies
R. Stoop, A.M. van den Hoek, R. Hanemaaijer, S. van Buuren,  
A.-M. Zuurmond;  
Metabolic Health Research, Netherlands Organization for Applied Scientific 
Research (TNO), Leiden, Netherlands.
Background and aims: Well-designed studies provide the maximum of in-
formation from the minimal number of experimental animals. Aim of this 
study was to explore whether asymmetric experimental designs can reduce 
number of animals needed without affecting statistical power of the study.
Materials and methods: Data from several efficacy studies in bleomycin-
induced lung fibrosis in mice were combined to make tentative estimates of 
the expected outcomes for newly planned studies. Classically, these types of 
studies comprise a PBS control group, a bleomycin-induced (bleo) group, 
and several treatment groups with the same number of animals in all groups. 
Instead of comparing all groups to each other using ANOVA and post-hoc 
testing, k + 1 planned comparisons were defined in advance: bleo versus PBS 
control, and bleo versus k treatments (in total k + 1 comparisons). Since the 
bleo group appears in both the comparison with the PBS control and the 
treatment group, changing the size of this group will have most effect on the 
statistical power. Since the direction of the effects was anticipated, only one-
sided t-tests were used. For fixed type I error, statistical power of the Student 
t-test was calculated for all combinations of group sizes of 2-30 animals. The 
optimal asymmetric design achieves the desired statistical power for each 
planned comparison with the minimum of animals needed.
Results: We calculated that the best asymmetric designs required about 20-
25% fewer animals than the best symmetric design.
Conclusion: This demonstrates that substantial reduction of animal use is 
possible by smarter choices on group size without loss of power. To aid re-
searchers to optimize their experimental design, we developed a freely availa-
ble sample size calculator (available at www.tno.nl/3R) to compare symmetric 
and asymmetric designs.
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Twice-daily hyperglycaemic spikes accelerate atherosclerotic lesion 
formation in C57BL/6 mice
Y. Shuto, A. Asai, M. Nagao, M. Kawahara, H. Sugihara, S. Oikawa;  
Endocrinology, Diabetes and Metabolism, Nippon Medical School, Tokyo, 
Japan.
Background and aims: Increasing epidemiological evidence indicates that 
postprandial hyperglycemia in individuals with impaired glucose tolerance 
(IGT) is a risk factor for atherosclerotic cardiovascular disease. A number 
of studies have demonstrated the possible roles of acute glucose fluctuations, 
a hallmark of IGT, in atherogenesis in cell culture models; e.g., intermittent 
high glucose exposure-induced oxidative stress, inflammatory response, and 
subsequent proatherogenic changes in vascular endothelial cells, smooth 
muscle cells, and macrophages. However, there is little convincing experi-
mental evidence that repetitive glucose fluctuations can actually result in 
accelerated atherosclerosis in vivo. Hence, the in vivo mechanism underly-
ing IGT-induced atherogenesis is not yet fully understood. In this study, we 
demonstrated the effect of long-term repetitive hyperglycemic spikes on ath-
erosclerotic lesion formation in mice.
Materials and methods: Female C57BL/6 mice were fed an atherogenic diet 
(AD; 1.25% w/w cholesterol, 0.5% w/w sodium cholate, 36% energy fat) from 
8 to 28 weeks of age. During the 20-week AD feeding period, the mice re-
ceived 20% glucose solution (50 mg glucose/mouse) (G) or distilled water 
(W) twice daily by oral gavage (6 days a week). The post-challenge blood 
glucose changes were monitored on a day in the week 2, 11, and 20. OGTT 
and insulin tolerance test were performed in the week 19 and 20, respec-
tively. After the AD feeding, serial frozen sections (10 µm thickness, spanned 
450 µm) of aortic sinus were prepared and the atherosclerotic lesion size was 
quantitated from the oil red O-stained area (mean of 9 sections, each sepa-
rated by 50 µm). Gene expression levels in the thoracic aorta and the plasma 
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lipid profiles were also analyzed. Data are expressed as mean±SEM (n=8). 
Differences between G and W were assessed by Student’s t test.
Results: Blood glucose levels in G increased by ~5 mmol/l above W at 20 min 
after the glucose ingestions and returned to similar levels to W within 60 min. 
There are no significant differences in body weight, plasma lipid profiles (to-
tal cholesterol, HDL-cholesterol, non-HDL-cholesterol, triacylglycerols, and 
NEFA), and blood glucose levels in OGTT and insulin tolerance test between 
G and W. Aortic sinus atherosclerotic lesion size in G was 3.8-fold greater 
than that of W (22.2±5.7 vs 5.8±1.8 ×103 µm2, p=0.025). Gene expression 
levels of an adhesion molecule Icam-1 (1.26-fold, p=0.036) and a macrophage 
marker Cd68 (1.27-fold, p=0.036) in thoracic aorta were significantly higher 
in G relative to those in W.
Conclusion: These results demonstrate that repetitive hyperglycemic spikes 
can accelerate atherosclerotic lesion formation in vivo independent of basal 
blood glucose levels, insulin resistance, or plasma lipid profiles, possibly via 
proatherogenic changes in arterial wall. The repetitive glucose ingestion in 
mice on AD would be a simple and useful method for studying the patho-
genesis, prevention, and treatment of IGT-induced atherosclerotic vascular 
disorders.
1326
Cardiac magnetic resonance imaging evaluation after experimental 
myocardial infarction in streptozotocine induced diabetic rats with high 
glycaemic variability
M. Joubert1, J. Hardouin1, K. Blanchart2, S. Allouche3, A. Manrique3;  
1Endocrinology Unit, 2Cardiology Unit, University Hospital of Caen, 
3EA4650, Caen, France.
Background and aims: During acute myocardial infarction (MI) in type 2 
diabetic (T2D) patients, both hyperglycemia and hypoglycemia (at admis-
sion and/or during the hospital stay) are associated with poor outcome. In 
addition, the impact of glycemic variability in these patients is also discussed: 
several in vitro and in vivo studies have suggested a deleterious effect of gly-
cemic variability on endothelial function through an increase in oxidative 
stress. However, there is actually no data concerning the direct impact of this 
glucose metric on MI morbidity. We address here this question in a rodent 
diabetic model.
Materials and methods: Twenty-six adult male Wistar rats (315 ± 41 g), 
synchronized to a reverse 12 hours dark-light cycle were divided in three 
groups : control (C) (n=7), sham (S) (n=5) and diabetes (D) (n=14). Rats 
from group D received 70 mg/kg of intraperitoneal (IP) streptozotocin 
(STZ). Rats from group C and S received vehicle only 70 mg/Kg IP. Group 
D was divided in two subgroups : diabetes hyperglycemia (Dh) (n=6) and 
diabetes variability (Dv) (n=8). Glargine was introduced 48 hours after STZ 
injection : 5 UI/kg/j subcutaneously (SC) at 9:00 AM for Dh rats and 15 UI/
kg/j SC at 9:00 AM for Dv rats. Blood glucose monitoring was performed 
to confirm that glycemia was maintained above 250 mg/dl in Dh sub-group 
and presented swings below 150 and above 250 mg/dl in Dv sub-group. 
After 4 weeks, all rats (except in group S) were subjected to ischemia (30 
min of transient coronary artery ligation) followed by reperfusion. Cardiac 
magnetic resonance imaging (CMR) was performed 1 and 3 weeks (w1 and 
w3) after surgery to assess left ventricular function [end-diastolic volume 
(EDV), end-systolic volume (ESV), ejection fraction (LVEF), wall motion 
score (WMS)] and myocardial edema.
Results: Mean blood glucose was 140±24, 130±28 and 265±88 mg/dl in 
group C, S and D (global p<0.001). Glycemic standard deviation, a glycemic 
variability index, was higher in Dv compared to Dh group (205 vs. 94 mg/
dl; p=0.021). LVEF (%) at w1/w3 was 47.5±11.5/46.5±7.7; 59.5±8.5/55.7±3.7 
and 51.1±9.3/47.4±10.7% for group C, S and D, respectively (ns). Likewise, 
no inter or intra group difference was found for ESV and EDV. However, 
WMS was increased (indicating abnormal wall motion) after ischemia in 
group C and D vs S at w1/w3 (1.40±0.20/1.35±0.20 and 1.56±0.15/1.50±0.27 
vs 1±0; p<0.0001). Myocardial edema decreased in infarct zone between 
w1 and w3 in group C (20.3±5.0 vs 14.5±3.2; p<0.001) but not in group 
D (20.4±5.9 vs 21.2±6.3; ns). In subgroup analysis, myocardial edema also 
decreased in infarct zone between w1 and w3 in group Dh (20.6±5.7 vs 
18.6±4.1; p<0.05) but not in group Dv (20.3±6.0 vs 22.4±6.8; ns). In the re-
mote territory, myocardial edema decreased in group Dh but increased in 
group Dv between w1 and w3 (Dh: 19.3±5.5 vs. 16.7±4.1; Dv: 17.7±4.8 vs. 
18.9±6.1; all p<0.05).
Conclusion: Myocardial edema, reflecting myocardial injuries, does not 
improve over time in diabetic rats compared to control animals after an ex-
perimental MI. This effect is due to the sole subgroup with high glycemic 
variability. Furthermore, in this particular subgroup, prolonged edema was 
also observed in the remote territory. These results suggest that glycemic vari-
ability might be more deleterious than persistent hyperglycemia after MI.
1327
Cardioprotective effect of decorin in type 2 diabetes
F. Chen1, J. Tang2, D. Wang2;  
1Department of Endocrinology, 2Department of Internal Medicine and 
Institute of Hypertension, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science, Wuhan, Hubei, China.
Background and aims: Cardiomyopathy in diabetes is the leading cause of 
increased mortality in diabetes patients. In the present studies, we investi-
gated the effect of decorin (DCN) gene therapy on left ventricular function, 
cardiac inflammation and fibrosis in high-fat diet (HFD) and streptozotocin 
(STZ)-induced type 2 diabetes.
Materials and methods: Type 2 diabetes was induced in male Wistar rats 
by HFD (60% of calories as fat) and injection of low-dose STZ, (20 mg/kg, 
intravenously). Diabetic rats were divided into (n=6 for each group) the con-
trol group, the GFP-treated group ) and the DCN-treated group, received 
intravenous injection of saline solution, recombinant adeno-associated viral 
(rAAV)-GFP and rAAV-DCN, respectively. We investigated cardiac inflam-
mation, fibrosis, left ventricular (LV) function at 6 months after gene delivery.
Results: rAAV-DCN Treatment attenuated diabetic cardiomyopathy with 
improved LV function, cardiac inflammation and fibrosis compared with 
control animals. These protective effects were associated with increased ex-
pression of PKC-α and Hsp70, decreased activation state of IGF-IR, pERK, 
TGF-β1 and α-SMA and NF-κB pathways.
Conclusion: Our results show that rAAV-mediated DCN therapy may be 
beneficial in the treatment of diabetic Cardiomyopathy.
Supported by: NSFC (No.30871068)
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Hyperglycaemia does not affect restenosis development after 
percutaneous transluminal angioplasty in a diabetic rabbit model
J.X. Zhou1, L. Zhang2, W.Z. Zhang1, L. Liao1, J.J. Dong3;  
1Department of Endocrinology, 2Department of Sonography,  
Affiliated Qianfoshan Hospital of Shandong University, 3Department of 
Endocrinology, Qilu Hospital of Shandong University, Jinan, China.
Background and aims: It is clear that hyperglycemia aggravates the develop-
ment of atherosclerosis. However, whether hyperglycemia promotes preva-
lence of restenosis remains unknown. In the studies, we investigated the ef-
fect of hyperglycemia on restenosis.
Materials and methods: Restenosis was evaluated in two sets of diabetic 
rabbits models: (1) diabetic restenosis (DR) versus non-diabetic restenosis 
(NDR); and (2) diabetic atherosclerosis (DA) versus non-diabetic atheroscle-
rosis (NDA).
Results: Our study showed no difference in restenosis rates between the 
diabetic and the non-diabetic rabbits (92.33±5.46% versus 89.17±7.14%, P > 
0.05). However, the prevalence of stenosis was significantly increased in the 
DA group compared with NDA group (72.37±24.55% versus 35.54±40.97%, 
P < 0.05). Similarly, intima-media thickness and cell proliferation were re-
markably higher in the DA group than that of the NDA group, while no dif-
ference was found between the DR and NDR groups.
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Conclusion: Our results provide evidence that hyperglycemia is an inde-
pendent rist factor for atherosclerosis, but it does not promote restenosis, and 
different mechanisms are involved in the development of atherosclerosis and 
restenosis.
Supported by: NSFC, CMAF
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Effect of glucose level on the size of myocardial infarction in pigs
S.S. Diemar1,2, A.-S. Sejling1,3, K.K. Iversen1, T. Engstrøm4, J.L. Honge5,  
N. Tønder1, N. Vejlstrup4, K. Ekström1,2, U. Pedersen-Bjergaard1,2,  
M. Dalsgaard1, B. Thorsteinsson1,2;  
1Department of Cardiology, Nephrology and Endocrinology, Nordsjællands 
Hospital, Hillerød, 2Faculty of Health Sciences, University of Copenhagen, 
3Faculty of Health Sciences, University of Southern Denmark,  
Odense, 4Department of Cardiology, Rigshospitalet, Copenhagen,  
5Department of Cardiothoracic and Vascular Surgery,  
Aarhus University Hospital, Skejby, Denmark.
Background and aims: Patients with diabetes and acute myocardial infarc-
tion (MI) have a two- to five-fold increased in-hospital mortality compared 
with non-diabetic patients. Concomitant hypoglycaemia or hyperglycaemia 
is suggested to worsen the acute prognosis of MI. Mortality after MI is associ-
ated with necrotic damage to the myocardium. Consequently, minimising the 
necrotic area is warranted. Our aim was to investigate the effect of the acute 
plasma glucose level on the size of MI in a closed-chest pig model.
Materials and methods: 38 non-diabetic Danish/Landrace female pigs were 
randomised to three different plasma glucose levels: hypoglycaemia (2.1 ± 1.0 
mmol/l; 15 pigs (mean±SD)): normoglycaemia (5.8 ± 1.6 mmol/l; 12 pigs) 
and hyperglycaemia (21.5 ± 2.9 mmol/l; 11 pigs). After 30 minutes of steady 
state with plasma glucose levels within target (1.8-2.2 mmol/l, 5-7 mmol/l, 
22-23 mmol/l, respectively) MI was induced. Using a closed-chest model a 
balloon catheter was inserted via the internal carotid artery to the left ante-
rior descending coronary artery and inflated for 30 minutes. Afterwards the 
heart was reperfused while the plasma glucose level remained in target for 2 
hours. Following sternum split an in-vivo staining with Evans Blue was per-
formed. The heart was subsequently taken out and in-vitro stained with TTC 
to delineate the necrotic tissue from the viable tissue (area at risk (AAR)).
Results: Twenty-five (66%) pigs developed ventricular fibrillation (VF) dur-
ing the reperfusion period. Of these 7 pigs died. There was no difference in 
incidence of VF (p=1.0) or death (p=0.22) between the glycaemic groups. No 
significant differences in infarction size, AAR or infarction/AAR ratio were 
detectable between the groups.
Conclusion: In a closed-chest pig model the acute glucose level did neither 
affect cardiac morbidity or mortality nor the size of the myocardial infarction.
Supported by: Research Foundation of Nordsjællands Hospital, Hillerød, Den-
mark
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Dipeptidyl peptidase-4 inhibition in a rat model of ischaemia-
reperfusion injury may accelerate tubular regeneration but does not 
improve glomerular filtration rate
B. Hocher1, C. Reichetzeder1, K. von Websky1, O. Tsuprykov1, T. Klein2;  
1University of Potsdam, 2Boehringer Ingelheim, Biberach, Germany.
Background and aims: Dipeptidyl peptidase (DPP)-4 inhibitors have been 
shown to have protective effects on ischaemia-reperfusion injury (IRI) of the 
heart and lung. As the DPP-4 enzyme and its substrates are also expressed in 
the kidney, we studied the effects of the DPP-4 inhibitors linagliptin, vilda-
gliptin, and sitagliptin on the outcome of IR-induced acute kidney injury in 
uninephrectomised rats.
Materials and methods: Male Wistar rats obtained from Charles River (Ger-
many) weighing 150-170 g were subjected to uninephrectomy. Two weeks 
later, the remaining kidney was exposed to IRI by clamping the renal artery 
for 30 min; sham surgery was performed without clamping. The rats (n=10-
14 per group) received DPP-4 inhibitor treatment once-daily with either 
linagliptin (1.5 mg/kg/day), vildagliptin (8 mg/kg/day), sitagliptin (30 mg/
kg/day), or vehicle via gavage on the 3 consecutive days prior to IRI. An ad-
ditional group was treated with sitagliptin until study end in order to inhibit 
DPP-4 activity during the entire experiment. This group was treated initially 
with sitagliptin 30 mg/kg/day; after induction of IRI, the dose was adjusted 
to 15 mg/kg/day because of renal failure. Levels of plasma cystatin C (a bio-
marker of glomerular filtration rate) and clusterin (a biomarker of tubular 
regeneration) were measured at 0, 24, 48, 72, and 168 hours after IRI or sham 
operation.
Results: Levels of active GLP-1 increased 3-4 fold in all DPP-4 inhibitor 
treatment groups versus the placebo group, up to 24 hours after clamping 
(p<0.05 for all comparisons). Levels of plasma cystatin C peaked 48 hours 
after clamping and increased from 1454 ± 320 ng/ml in the sham-operated 
group to 1728 ± 323 ng/ml in the placebo-treated group with IRI (p=0.059). 
This increase was unaffected by treatment with either linagliptin, vildaglip-
tin, or sitagliptin. Similarly, the area under the curve for plasma cystatin C 
(0 to 168 hours after IRI) was comparable across all treatment groups. At 
study end, levels of plasma clusterin were lowest in the placebo-treated group 
(97.14 ± 15.71 µg/ml) and significantly higher in all treatment groups (lina-
gliptin: 116.53 ± 25.28 µg/ml; vildagliptin: 111.28 ± 17.78 µg/ml; sitagliptin: 
113.53 ± 16.45 µg/ml; extended sitagliptin treatment: 114.99 ± 16.00 µg/ml; 
p<0.05 for all comparisons).
Conclusion: In rats with acute IRI of the kidney, DPP-4 inhibition does not 
alter the glomerular filtration rate but may enhance tubular regeneration. 
These findings were observed when DPP-4 activity was inhibited prior to IRI 
and for one week following IRI.
Supported by: Boehringer Ingelheim
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Morphometric characteristics of the air-blood barrier in experimental 
diabetes mellitus
O. Pivovarova1, E. Rozova2, B. Mankovsky3;  
1State Establishment „Lugansk State Medical University, Lugansk, 
2Bogomoletz Institute of Physiology, Kyiv, 3P.L. Shupyk National Medical 
Academy of Post-Graduate Education, Kyiv, Ukraine.
Background and aims: Respiratory diseases contribute significatntly to mor-
tality and morbidity in patients with diabetes mellitus. However, the mecha-
nisms underlying the lung damage in diabetic patients are not fully under-
stood. The air-blood barrier (ABB) performs an important role in function-
ing of the respiratory system but his structure in diabetes was not studied in 
detail. Therefore, the aim of this study was to investigate specific histological 
features of the ABB in the streptozotocin (STZ)-induced diabetes.
Materials and methods: The study was performed on 47 STZ-induced diabet-
ic and 43 control male Wistar rats. Diabetes was induced by single intraperito-
neal injection of STZ (SIGMA, USA) 60 mg/kg in 0.1 M citrate buffer, pH 4.5. 
The tissue for the further evaluation was collected after 18 weeks of diabetes. 
The diabetic rats were not treated with insulin. The morphometric assessment 
was performed using the electron microscope PEM-125K and the data were 
analyzed using the software Image Tool Version 3 (USА). The thickness of 
arithmetic average (τ) and harmonic average (τh) were calculated.
Results: We found the significant increase of thicknesses of τ and τh of ABB 
in STZ-induced diabetic rats compared to control group - τ were 302,7 ± 11,4 
nm and 163,4 ± 6,8 nm, τh were - 289,5 ± 12,5 nm and 155,6 ± 5,4 nm, re-
spectively, in diabetic and control animals, p<0,01. These changes could indi-
cate the hyperhydration. Also, τ and τh of epithelial layer of ABB in the STZ-
induced diabetic rats were significantly elevated (98,6 ± 2,2 nm and 91,5 ± 1,7 
nm, respectively), compared to controls (71,6 ± 3,5 nm and 65.1 ± 2,1 nm), 
p<0,05. The values of τ, τh of the interstitium of ABB in the STZ-induced 
diabetic rats were significantly higher than in non-diabetic animals - 92,4 ± 
4,3 nm, 97,6 ± 5,2 nm in diabetes and 49,2 ± 3,1 nm and 46,1 ± 3,3 nm, in 
controls, respectively, p<0,001. In the STZ-induced diabetic rats, τ and τh of 
endothelium of ABB were 118,8 ± 7,1 nm and 121,7 ± 4,2 nm, whereas in the 
controls there were 63,9 ± 3,3 nm and 50,1 ± 3,2 nm respectively, p<0,001.
Conclusion: We found the significant thickening of all layers of the ABB, 
including epithelial, which may underlie the development of intraalveolar 
edema in the STZ-induced diabetic rats. Permeability changes caused by hy-
perhydration of ABB can lead to the disturbance of the oxygen transport and 
the development of hypoxia in diabetic rats.
1332
Adipose tissue mitochondrial dysfunction triggers a lipodystrophic 
syndrome with insulin resistance, hepatosteatosis and cardiovascular 
complications
C. Vernochet1, F. Damilano1, A. Mourier2, O. Bezy1, M.A. Mori1, G. Smith1, 
A. Rosenzweig3, N.-G. Larsson2, R.C. Kahn1;  
1Joslin Diabetes Center, 2Department of Mitochondrial Biology, Max Planck 
Institute for Biology of Ageing, 3Cardiovascular Division of the Beth Israel 
Deaconess Medical Center and Harvard Medical School, Boston, USA.
Background and aims: Mitochondrial dysfunction in adipose tissue occurs 
in obesity, type 2 diabetes and some forms of lipodystrophy, but whether this 
dysfunction contributes to or is the result of these disorders is unknown.
Materials and methods: To investigate the physiological consequences of 
severe mitochondrial impairment in adipose tissue, we generated mice defi-
cient for the mitochondrial transcription factor TFAM in adipocytes by using 
mice carrying Adiponectin-Cre and TFAM floxed alleles.
Results: These Adipo-TFAM KO mice had a 75-81% reduction of TFAM 
in subcutaneous and intra-abdominal white adipose tissue (WAT) and in-
terscapular brown adipose tissue (BAT), and this resulted in decreased ex-
pression and enzymatic activity of proteins in complexes I, III, and IV of the 
electron transport chain (ETC). This mitochondrial dysfunction led to adipo-
cyte death and inflammation in WAT and a “whitening” of BAT. As a result, 
Adipo-TFAM KO mice were resistant to weight gain, but exhibited insulin 
resistance, on both normal chow and high fat diets.
Conclusion: These lipodystrophic mice also developed hypertension, cardiac 
hypertrophy and cardiac dysfunction. Thus, isolated mitochondrial dysfunc-
tion in adipose tissue can lead a syndrome of lipodystrophy with metabolic 
syndrome and cardiovascular complications
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